[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$feYjZjumP6sgrKt5egK91wau2iA__90ekLkSkMNeukD0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":38,"phaseBuckets":83,"rows":90},"GlaxoSmithKline",[4],3599,false,139,882,6392809,173,363,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Pulmonary Disease, Chronic Obstructive",251,{"name":18,"count":19},"Asthma",241,{"name":21,"count":22},"Influenza",147,{"name":24,"count":25},"Hepatitis B",125,{"name":27,"count":28},"Diabetes Mellitus, Type 2",110,{"name":30,"count":31},"Diphtheria",87,{"name":33,"count":34},"Tetanus",86,{"name":36,"count":37},"Cancer",68,[39,44,49,54,58,62,66,69,74,78],{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT04732871","Immunogenicity, Safety, Reactogenicity and Persistence of an Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above","2022-06-06","RSVPreF3 OA investigational vaccine",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT04162210","Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom\u002FDex) in Participants With Relapsed\u002FRefractory Multiple Myeloma (RRMM)","2022-09-12","Belantamab mafodotin",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT04179032","Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)","2023-01-16","Belimumab",{"nctId":55,"briefTitle":56,"date":57,"intervention":48},"NCT04246047","Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed\u002FRefractory Multiple Myeloma","2023-10-02",{"nctId":59,"briefTitle":60,"date":61,"intervention":48},"NCT04484623","Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed\u002FRefractory Multiple Myeloma","2024-01-29",{"nctId":63,"briefTitle":64,"date":65,"intervention":48},"NCT06868654","China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed\u002FRefractory Multiple Myeloma","2024-04-03",{"nctId":67,"briefTitle":68,"date":65,"intervention":48},"NCT06868667","Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed\u002FRefractory Multiple Myeloma",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT03843359","A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors","2024-04-04","GSK3745417",{"nctId":75,"briefTitle":76,"date":77,"intervention":48},"NCT06956170","All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed\u002FRefractory Multiple Myeloma","2024-05-27",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT04915755","Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease","2024-06-28","Niraparib",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,420,627,693,973,1009,1034,1060,1078,1323,1458,1522,1633,1788,1826,1860,1908,1989,2023,2076,2129,2159,2189,2219,2249,2453,2490,2520,2546,2600,2654,2687,2709,2731,2894,3004,3130,3272,3350,3409,3449,3495,3525,3569,3604,3656,3688,3724,3746,3771,3789,3807,3825,3843,3861,3879,3897,3915,3933,3951,3969,3987,4013,4031,4108,4205,4235,4293,4323,4355,4398,4451,4505,4551,4582,4604,4626,4660,4896,4945,5006,5063,5108,5145,5224,5258,5306,5336,5373,5395,5417,5439,5463,5481,5504,5529,5552,5570,5592,5617,5642,5672,5690,5708,5726,5744,5762,5780,5802,5820,5846,5864,5891,5909,5927,5955,5973,5991,6009,6027,6045,6063,6081,6099,6117,6135,6153,6171,6189,6207,6225,6243,6261,6279,6297,6357,6409,6439,6470,6602,6653,6683,6709,6735,6766,6788,6836,6863,6887,6905,6923,6941,6963,6981,7012,7030,7048,7066,7084,7102,7120,7147,7165,7183,7201,7219,7237,7262,7280,7305,7333,7351,7369,7418,7717,7996,8176,8353,8504,8635,8773,8904,9015,9140,9250,9369,9476,9583,9663,9742,9827,9919,9988,10064,10133,10199,10262,10317,10373,10422,10470,10525,10597,10644,10699,10741,10771,10820,10871,10918,10962,11005,11049,11082,11125,11157,11188,11222,11255,11295,11329,11363,11395,11427,11453,11493,11530,11562,11605,11631,11670,11696,11731,11779,11805,11838,11878,11924,11967,12006,12051,12094,12121,12155,12187,12214,12242,12276,12305,12333,12358,12386,12422,12452,12480,12502,12534,12566,12588,12610,12632,12660,12689,12711,12739,12761,12783,12818,12844,12879,12904,12926,12948,12982,13004,13036,13070,13101,13131,13153,13190,13212,13234,13256,13278,13299,13323,13341,13365,13383,13401,13427,13445,13463,13485,13503,13524,13548,13566,13589,13607,13625,13649,13667,13689,13713,13731,13749,13774,13792,13818,13836,13858,13876,13894,13917,13941,13965,13983,14006,14029,14047,14065,14088,14106,14127,14150,14174,14192,14213,14236,14259,14284,14302,14326,14350,14374,14397,14415,14436,14462,14480,14501,14525,14548,14566,14591,14609,14634,14657,14675,14701,14719,14737,14755,14777,14795,14813,14834,14852,14870,14892,14910,14928,14946,14970,14988,15009,15027,15049,15067,15093,15111,15129,15154,15178,15196,15220,15242,15264,15289,15307,15329,15350,15372,15390,15408,15426,15444,15462,15480,15498,15520,15538,15559,15582,15605,15628,15653,15671,15689,15707,15731,15752,15773,15796,15814,15837,15861,15885,15903,15921,15939,15957,15975,15993,16011,16029,16047,16065,16083,16109,16127,16151,16169,16187,16205,16223,16241,16263,16287,16305,16329,16347,16369,16391,16417,16435,16453,16471,16495,16513,16531,16549,16567,16585,16603,16621,16649,16667,16685,16703,16721,16739,16757,16775,16798,16816,16840,16858,16876,16894,16918,16936,16954,16980,16998,17016,17039,17057,17078,17099,17117,17141,17165,17188,17214,17232,17258,17276,17300,17321,17342,17363,17385,17403,17425,17449,17473,17491,17509,17533,17551,17569,17587,17605,17623,17641,17659,17683,17701,17719,17742,17766,17784,17802,17824,17842,17973,18113,18232,18344,18450,18544,18660,18759,18859,18972,19067,19150,19232,19290,19363,19439,19485,19561,19629,19692,19768,19817,19898,19964,20012,20074,20115,20158,20196,20234,20308,20358,20396,20455,20511,20562,20610,20661,20709,20755,20789,20829,20868,20916,20969,21012,21070,21121,21155,21208,21259,21299,21329,21366,21420,21462,21499,21546,21576,21621,21674,21715,21765,21812,21847,21886,21916,21965,22011,22046,22098,22146,22197,22227,22264,22304,22348,22385,22418,22453,22492,22530,22565,22602,22646,22685,22722,22755,22781,22812,22838,22868,22907,22948,22979,23015,23068,23094,23120,23158,23190,23231,23271,23300,23326,23360,23397,23440,23480,23523,23556,23592,23618,23647,23685,23721,23757,23790,23825,23851,23878,23906,23932,23966,23998,24024,24057,24092,24132,24167,24215,24251,24291,24326,24367,24401,24434,24467,24489,24521,24543,24565,24597,24619,24641,24671,24703,24732,24754,24776,24798,24834,24856,24883,24917,24948,24970,24992,25019,25047,25069,25094,25116,25150,25181,25211,25238,25269,25291,25321,25343,25365,25387,25409,25431,25465,25502,25524,25546,25568,25590,25615,25637,25678,25707,25735,25764,25796,25818,25840,25871,25903,25925,25947,25979,26001,26026,26052,26077,26102,26135,26166,26193,26215,26242,26264,26295,26321,26352,26374,26402,26424,26446,26483,26505,26527,26549,26576,26598,26630,26665,26699,26721,26743,26774,26796,26822,26853,26875,26897,26919,26954,26982,27008,27035,27071,27101,27133,27155,27180,27208,27237,27287,27309,27342,27360,27381,27399,27417,27435,27453,27474,27492,27513,27535,27553,27571,27594,27612,27633,27651,27672,27694,27712,27734,27757,27775,27793,27811,27829,27847,27865,27883,27901,27919,27937,27959,27977,28000,28025,28043,28061,28079,28097,28115,28133,28151,28169,28187,28205,28223,28247,28265,28283,28301,28319,28337,28355,28378,28396,28419,28437,28459,28480,28504,28522,28540,28558,28576,28594,28612,28630,28648,28666,28691,28709,28735,28753,28771,28789,28807,28825,28843,28861,28879,28902,28927,28945,28963,28981,28999,29023,29041,29066,29084,29107,29125,29143,29164,29185,29206,29224,29248,29266,29288,29306,29324,29342,29360,29383,29401,29425,29443,29461,29479,29497,29520,29538,29563,29581,29599,29622,29645,29663,29686,29704,29726,29744,29767,29792,29810,29828,29846,29864,29885,29906,29928,29946,29969,29987,30005,30027,30052,30070,30088,30106,30124,30148,30174,30192,30210,30233,30257,30283,30301,30325,30343,30361,30379,30397,30415,30433,30451,30474,30492,30514,30532,30550,30568,30586,30604,30628,30646,30664,30682,30700,30724,30746,30764,30782,30803,30821,30839,30863,30881,30899,30917,30935,30959,30977,31003,31021,31039,31057,31084,31102,31120,31138,31156,31174,31192,31213,31236,31254,31272,31290,31308,31332,31350,31373,31391,31409,31427,31445,31467,31485,31503,31521,31539,31557,31580,31598,31616,31640,31658,31676,31694,31718,31736,31759,31777,31795,31817,31835,31853,31875,31899,31917,31939,31957,31981,31999,32023,32041,32059,32077,32095,32113,32131,32149,32167,32191,32214,32232,32250,32268,32290,32312,32330,32354,32375,32393,32411,32429,32447,32468,32493,32511,32529,32552,32570,32595,32613,32635,32653,32671,32689,32713,32738,32756,32774,32796,32814,32832,32850,32868,32886,32907,32932,32950,32971,32994,33012,33030,33048,33066,33084,33102,33120,33138,33156,33181,33199,33217,33235,33253,33271,33294,33312,33330,33348,33366,33387,33405,33427,33445,33467,33485,33503,33521,33539,33560,33583,33601,33619,33637,33655,33680,33698,33716,33739,33757,33775,33797,33821,33839,33861,33886,33904,33922,33945,33963,33981,33999,34020,34038,34056,34074,34092,34110,34128,34146,34164,34187,34205,34223,34241,34259,34286,34304,34322,34340,34358,34376,34394,34412,34433,34451,34469,34487,34510,34528,34550,34568,34593,34611,34632,34655,34673,34697,34715,34733,34751,34769,34792,34810,34828,34846,34864,34882,34900,34918,34941,34963,34981,35003,35021,35039,35057,35075,35093,35119,35137,35155,35178,35196,35221,35239,35261,35283,35304,35322,35347,35365,35387,35411,35429,35447,35465,35483,35501,35519,35537,35555,35576,35594,35612,35636,35654,35672,35696,35714,35732,35754,35777,35795,35813,35831,35855,35873,35891,35917,35935,35960,35982,36000,36021,36044,36062,36080,36098,36121,36143,36161,36179,36197,36218,36241,36259,36282,36303,36330,36348,36370,36394,36412,36430,36448,36466,36487,36510,36528,36546,36564,36586,36607,36631,36649,36673,36691,36715,36733,36757,36775,36793,36811,36829,36847,36865,36883,36901,36919,36937,36955,36973,36991,37009,37027,37050,37068,37086,37104,37126,37144,37167,37185,37203,37221,37243,37261,37283,37301,37325,37343,37366,37384,37406,37431,37449,37467,37485,37503,37521,37539,37557,37579,37597,37615,37633,37655,37673,37691,37709,37734,37752,37775,37793,37811,37829,37847,37868,37886,37904,37925,37948,37966,37984,38002,38026,38049,38072,38096,38118,38136,38154,38172,38190,38208,38226,38252,38270,38294,38312,38330,38352,38382,38400,38418,38436,38454,38472,38490,38508,38529,38550,38568,38586,38604,38622,38640,38658,38676,38698,38722,38740,38761,38779,38797,38815,38836,38941,39026,39109,39183,39252,39315,39396,39460,39530,39574,39612,39666,39726,39779,39832,39883,39948,40009,40068,40125,40178,40222,40274,40321,40375,40419,40477,40521,40570,40618,40656,40701,40752,40796,40838,40881,40928,40965,41010,41047,41095,41148,41196,41231,41261,41308,41353,41403,41447,41476,41513,41550,41587,41619,41657,41696,41735,41761,41792,41824,41850,41884,41917,41951,41992,42018,42052,42089,42115,42147,42182,42216,42259,42290,42324,42352,42378,42421,42459,42496,42522,42560,42597,42623,42657,42693,42724,42763,42793,42849,42879,42903,42925,42947,42979,43012,43037,43062,43091,43113,43146,43168,43190,43220,43242,43273,43303,43333,43355,43377,43399,43421,43445,43472,43501,43529,43559,43584,43615,43644,43666,43696,43722,43744,43774,43799,43827,43849,43871,43901,43923,43956,43984,44012,44041,44069,44095,44120,44145,44171,44193,44223,44250,44272,44294,44316,44345,44376,44408,44440,44473,44495,44517,44547,44569,44603,44625,44647,44678,44700,44727,44756,44791,44813,44842,44875,44897,44919,44947,44978,45000,45022,45059,45081,45103,45134,45156,45184,45214,45236,45258,45280,45302,45324,45353,45375,45400,45422,45460,45482,45504,45540,45569,45591,45609,45634,45652,45673,45691,45709,45731,45749,45767,45785,45803,45821,45845,45863,45881,45899,45917,45938,45963,45981,45999,46023,46045,46063,46086,46110,46128,46146,46164,46182,46203,46226,46244,46262,46280,46298,46316,46334,46356,46374,46398,46416,46434,46460,46478,46496,46514,46532,46554,46576,46602,46620,46638,46656,46677,46701,46719,46737,46755,46773,46795,46813,46831,46849,46875,46893,46911,46929,46956,46974,46992,47019,47037,47055,47073,47098,47126,47144,47162,47180,47198,47216,47234,47257,47275,47293,47311,47329,47347,47368,47386,47404,47427,47445,47470,47488,47506,47524,47542,47564,47582,47606,47624,47642,47660,47678,47700,47718,47736,47754,47772,47790,47812,47830,47854,47872,47895,47913,47937,47955,47977,47995,48013,48031,48054,48081,48099,48117,48135,48153,48186,48204,48222,48240,48258,48276,48294,48312,48330,48348,48366,48384,48405,48423,48441,48463,48484,48508,48526,48544,48574,48592,48610,48628,48646,48664,48685,48706,48728,48746,48771,48789,48812,48834,48852,48870,48898,48916,48934,48952,48976,48994,49012,49030,49048,49074,49092,49110,49128,49146,49170,49188,49206,49227,49249,49273,49291,49309,49327,49345,49366,49390,49408,49426,49450,49468,49486,49511,49529,49547,49565,49583,49605,49623,49641,49659,49677,49700,49721,49747,49765,49783,49805,49823,49841,49859,49877,49900,49918,49939,49957,49980,50007,50025,50043,50061,50079,50097,50115,50133,50156,50178,50196,50218,50236,50261,50279,50297,50315,50333,50351,50373,50391,50413,50431,50449,50471,50497,50515,50533,50551,50569,50587,50605,50623,50641,50669,50687,50705,50723,50747,50765,50787,50805,50835,50853,50871,50889,50907,50925,50943,50961,50979,51004,51022,51040,51058,51079,51100,51118,51141,51163,51184,51207,51233,51251,51269,51287,51308,51329,51347,51365,51383,51408,51426,51444,51473,51491,51509,51527,51545,51563,51581,51599,51620,51638,51656,51674,51697,51719,51737,51755,51773,51791,51813,51831,51859,51877,51895,51913,51931,51949,51972,51990,52013,52031,52054,52072,52090,52111,52135,52153,52171,52189,52211,52234,52252,52270,52291,52309,52330,52348,52371,52389,52407,52425,52443,52467,52485,52503,52521,52539,52557,52578,52606,52624,52642,52660,52683,52701,52722,52746,52764,52786,52807,52829,52852,52870,52893,52911,52934,52952,52970,53012,53030,53048,53066,53084,53102,53120,53138,53156,53174,53192,53210,53228,53246,53264,53282,53300,53318,53336,53360,53382,53404,53428,53446,53467,53491,53509,53527,53545,53563,53586,53607,53631,53649,53667,53692,53710,53732,53750,53768,53786,53807,53830,53848,53866,53884,53902,53920,53938,53960,53978,53996,54017,54039,54061,54079,54101,54133,54151,54169,54187,54205,54223,54241,54259,54277,54295,54313,54331,54349,54367,54388,54406,54428,54454,54472,54490,54508,54526,54552,54570,54588,54606,54631,54649,54667,54685,54703,54725,54743,54761,54779,54797,54815,54833,54860,54878,54896,54914,54932,54950,54968,54989,55014,55032,55050,55073,55091,55109,55127,55145,55163,55181,55203,55226,55244,55262,55280,55302,55323,55347,55365,55383,55401,55419,55444,55462,55480,55504,55522,55540,55563,55586,55604,55629,55647,55665,55683,55704,55725,55750,55768,55786,55804,55822,55840,55864,55889,55907,55931,55949,55967,55997,56015,56033,56051,56069,56087,56105,56123,56141,56162,56184,56202,56220,56242,56260,56285,56303,56321,56344,56365,56387,56405,56423,56441,56462,56484,56511,56529,56547,56565,56583,56601,56619,56637,56655,56673,56691,56717,56735,56753,56771,56794,56812,56830,56848,56870,56888,56906,56924,56942,56960,56981,56999,57022,57045,57063,57081,57109,57127,57145,57163,57181,57205,57223,57245,57269,57287,57305,57323,57341,57363,57381,57399,57417,57435,57453,57471,57494,57512,57540,57558,57576,57594,57617,57635,57658,57680,57704,57722,57743,57761,57782,57804,57826,57844,57867,57885,57903,57921,57939,57968,57986,58004,58022,58040,58058,58076,58099,58117,58142,58160,58178,58200,58221,58243,58268,58286,58304,58322,58340,58358,58376,58394,58412,58430,58455,58473,58491,58512,58530,58554,58572,58590,58608,58626,58648,58666,58684,58702,58720,58738,58759,58781,58799,58817,58835,58853,58871,58889,58911,58932,58950,58975,58993,59011,59029,59052,59070,59097,59115,59133,59151,59169,59191,59216,59234,59256,59274,59296,59314,59404,59467,59515,59566,59613,59647,59694,59724,59767,59803,59839,59882,59920,59946,59982,60013,60053,60088,60117,60157,60185,60222,60248,60284,60310,60344,60382,60414,60451,60473,60503,60534,60561,60590,60620,60647,60669,60698,60720,60747,60772,60807,60829,60851,60873,60902,60930,60962,60992,61017,61044,61076,61098,61120,61146,61171,61193,61221,61248,61275,61305,61327,61357,61379,61404,61426,61453,61475,61499,61521,61553,61575,61604,61635,61657,61679,61701,61734,61759,61781,61809,61840,61867,61889,61911,61933,61957,61987,62009,62040,62062,62086,62108,62137,62159,62189,62221,62243,62272,62294,62326,62348,62370,62399,62427,62456,62481,62514,62536,62558,62589,62612,62635,62658,62690,62708,62726,62744,62762,62780,62798,62816,62834,62852,62870,62888,62906,62929,62947,62965,62983,63005,63030,63048,63066,63088,63112,63130,63151,63175,63193,63211,63234,63252,63270,63294,63312,63330,63360,63378,63396,63414,63432,63450,63468,63486,63504,63528,63546,63568,63590,63612,63630,63648,63666,63689,63707,63725,63747,63765,63788,63806,63824,63842,63860,63878,63900,63923,63941,63965,63983,64008,64026,64044,64066,64084,64102,64124,64148,64178,64196,64214,64232,64250,64268,64286,64304,64322,64340,64358,64379,64402,64420,64442,64460,64478,64500,64518,64539,64562,64580,64602,64624,64648,64666,64684,64702,64725,64743,64761,64784,64802,64820,64841,64859,64877,64899,64917,64935,64957,64975,64993,65016,65034,65056,65077,65095,65118,65136,65157,65179,65202,65225,65247,65265,65287,65310,65328,65350,65372,65393,65414,65435,65456,65478,65502,65520,65538,65556,65577,65598,65621,65639,65665,65683,65701,65719,65737,65758,65782,65800,65824,65842,65860,65882,65900,65923,65941,65964,65989,66007,66025,66043,66061,66083,66107,66125,66146,66167,66189,66215,66233,66251,66276,66294,66312,66330,66348,66370,66395,66413,66431,66449,66470,66492,66510,66528,66546,66564,66585,66608,66626,66644,66666,66692,66710,66728,66749,66774,66792,66810,66833,66851,66869,66887,66905,66923,66941,66959,66977,66995,67016,67038,67059,67080,67104,67122,67145,67167,67185,67206,67228,67246,67264,67282,67306,67324,67342,67360,67378,67402,67423,67441,67465,67483,67501,67523,67547,67565,67587,67605,67623,67641,67659,67677,67699,67717,67740,67758,67783,67801,67819,67842,67864,67891,67909,67927,67945,67963,67985,68003,68026,68044,68065,68088,68106,68129,68147,68165,68183,68201,68222,68244,68265,68283,68301,68322,68347,68365,68383,68401,68426,68444,68462,68483,68501,68528,68546,68564,68582,68600,68618,68636,68659,68677,68695,68713,68731,68749,68767,68785,68807,68825,68846,68870,68888,68906,68924,68942,68960,68978,68996,69018,69040,69064,69082,69104,69122,69140,69164,69182,69200,69218,69242,69260,69278,69300,69318,69340,69362,69380,69398,69421,69445,69463,69481,69504,69528,69546,69570,69591,69614,69632,69656,69674,69697,69715,69733,69751,69773,69791,69809,69832,69850,69868,69886,69907,69931,69949,69976,69994,70012,70030,70048,70069,70093,70111,70129,70151,70174,70192,70218,70236,70254,70272,70294,70315,70340,70358,70379,70402,70420,70438,70456,70474,70492,70510,70528,70546,70564,70582,70603,70621,70646,70664,70682,70700,70718,70736,70754,70772,70795,70813,70837,70855,70873,70891,70913,70931,70949,70971,70992,71010,71031,71053,71071,71089,71111,71129,71154,71172,71190,71208,71236,71254,71272,71290,71308,71326,71347,71369,71387,71405,71423,71447,71465,71483,71504,71526,71544,71562,71585,71603,71621,71643,71661,71686,71704,71722,71740,71763,71781,71802,71832,71850,71868,71886,71904,71922,71940,71958,71976,71997,72015,72033,72051,72069,72094,72112,72134,72158,72176,72198,72216,72237,72260,72283,72314,72332,72350,72368,72386,72404,72422,72440,72458,72476,72502,72520,72538,72556,72579,72602,72624,72645,72667,72685,72703,72728,72752,72770,72788,72813,72831,72849,72872,72896,72914,72940,72958,72976,72994,73012,73034,73052,73070,73088,73106,73124,73142,73160,73178,73200,73218,73236,73259,73277,73295,73313,73331,73349,73367,73385,73408,73426,73448,73466,73484,73502,73526,73544,73562,73580,73603,73621,73639,73661,73679,73700,73727,73745,73763,73781,73799,73817,73843,73861,73879,73897,73915,73933,73951,73969,73993,74017,74035,74053,74075,74098,74116,74137,74159,74177,74199,74217,74235,74253,74271,74289,74307,74330,74348,74371,74389,74407,74425,74443,74464,74486,74508,74526,74544,74562,74580,74598,74616,74634,74652,74670,74688,74712,74730,74748,74766,74784,74805,74827,74851,74869,74887,74916,74934,74952,74970,74988,75006,75024,75042,75066,75084,75107,75125,75143,75164,75189,75207,75225,75248,75271,75289,75307,75325,75343,75361,75384,75405,75423,75441,75459,75477,75495,75517,75540,75558,75576,75598,75622,75640,75664,75682,75707,75725,75743,75761,75784,75802,75825,75847,75865,75883,75907,75925,75943,75961,75979,76001,76023,76046,76064,76082,76105,76123,76145,76163,76181,76203,76225,76248,76271,76289,76314,76332,76350,76368,76391,76413,76436,76457,76479,76500,76526,76544,76562,76580,76603,76621,76639,76657,76675,76696,76717,76739,76773,76791,76809,76827,76845,76863,76881,76899,76917,76935,76953,76971,76989,77007,77029,77047,77068,77091,77109,77130,77152,77170,77193,77211,77229,77247,77268,77296,77314,77332,77350,77368,77386,77404,77422,77440,77458,77476,77499,77517,77535,77553,77577,77595,77613,77638,77656,77677,77695,77713,77731,77756,77774,77792,77810,77831,77849,77872,77890,77911,77934,77952,77978,77996,78014,78032,78055,78077,78095,78120,78138,78156,78174,78192,78213,78231,78249,78267,78289,78313,78331,78349,78367,78385,78403,78426,78444,78462,78480,78498,78523,78541,78559,78577,78598,78621,78639,78657,78675,78693,78714,78736,78754,78772,78797,78815,78839,78857,78875,78902,78920,78938,78956,78974,78992,79013,79031,79049,79067,79085,79106,79134,79152,79170,79188,79206,79224,79246,79267,79285,79303,79321,79345,79368,79386,79408,79426,79444,79462,79480,79498,79516,79534,79552,79570,79588,79612,79630,79648,79666,79690,79708,79730,79756,79774,79792,79815,79836,79857,79880,79902,79920,79938,79960,79978,80000,80022,80044,80066,80089,80107,80131,80149,80174,80192,80215,80238,80261,80279,80302,80323,80346,80371,80389,80407,80425,80443,80464,80486,80509,80527,80550,80571,80594,80612,80630,80648,80669,80692,80714,80736,80760,80778,80796,80814,80835,80853,80871,80889,80912,80930,80948,80970,80988,81006,81024,81042,81060,81078,81099,81123,81141,81159,81188,81206,81224,81242,81260,81278,81296,81314,81336,81354,81375,81397,81415,81438,81456,81479,81501,81519,81543,81561,81579,81607,81625,81643,81661,81679,81697,81715,81900,82098,82257,82401,82577,82743,82851,82970,83080,83194,83304,83383,83454,83540,83601,83670,83750,83809,83887,83962,84042,84118,84181,84252,84301,84343,84385,84431,84473,84515,84567,84609,84660,84699,84733,84780,84820,84850,84885,84925,84971,84997,85033,85071,85099,85128,85167,85199,85237,85274,85311,85340,85368,85396,85426,85457,85489,85514,85543,85571,85599,85626,85653,85680,85710,85735,85767,85796,85818,85840,85862,85886,85918,85944,85971,86001,86023,86064,86091,86120,86142,86173,86204,86226,86256,86278,86301,86325,86343,86366,86384,86407,86425,86447,86472,86490,86512,86530,86552,86573,86591,86609,86627,86645,86663,86681,86704,86722,86745,86763,86784,86806,86824,86846,86870,86888,86906,86928,86948,86970,86988,87009,87031,87052,87074,87097,87115,87137,87155,87177,87199,87217,87238,87256,87274,87295,87320,87338,87356,87374,87392,87415,87438,87459,87477,87495,87519,87537,87555,87573,87599,87617,87635,87653,87671,87689,87707,87730,87748,87766,87791,87809,87827,87848,87869,87890,87913,87935,87953,87971,87989,88012,88034,88052,88075,88097,88120,88138,88160,88178,88199,88220,88241,88265,88287,88308,88326,88344,88362,88383,88401,88422,88444,88462,88485,88508,88526,88544,88566,88584,88605,88623,88641,88659,88681,88707,88725,88743,88761,88785,88803,88824,88846,88864,88885,88907,88930,88948,88971,88992,89014,89036,89054,89078,89096,89117,89139,89164,89182,89200,89218,89236,89261,89279,89297,89315,89341,89363,89386,89407,89428,89451,89475,89493,89511,89533,89554,89576,89594,89618,89636,89654,89672,89690,89708,89729,89751,89773,89791,89812,89834,89857,89875,89893,89911,89929,89947,89970,89988,90014,90032,90050,90068,90086,90104,90122,90143,90167,90185,90203],{"intervention":92,"totalTrials":93,"cells":94},"Dostarlimab",26,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":182,"PHASE3":362,"PHASE4":405,"NA":418},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":181,"soonestReadout":72},[100,109,122,142,152,171],{"nctId":70,"briefTitle":71,"status":101,"phases":102,"primaryCompletion":72,"completion":103,"start":104,"enrollment":105,"conditions":106,"interventions":108},"ACTIVE_NOT_RECRUITING",[85],"2026-03-31","2019-03-12",97,[107],"Neoplasms",[73,92],{"nctId":110,"briefTitle":111,"status":101,"phases":112,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":117},"NCT05277051","First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors",[85],"2027-08-31","2022-03-22",152,[107],[118,92,119,120,121],"Remzistotug","Belrestotug","Nelistotug","GSK5764227",{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":132},"NCT06551142","A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)","RECRUITING",[85],"2028-10-16","2029-06-08","2024-09-30",845,[107],[133,134,135,136,137,138,139,140,141,92],"Ris-Rez","Cisplatin","Carboplatin","Atezolizumab","Pembrolizumab","Durvalumab","Cetuximab","Bevacizumab","Tarlatamab",{"nctId":143,"briefTitle":144,"status":145,"phases":146,"primaryCompletion":147,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":151},"NCT04544995","Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)","TERMINATED",[85],"2025-04-23","2020-10-06",47,[107],[82,92,82],{"nctId":153,"briefTitle":154,"status":155,"phases":156,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":160,"interventions":161},"NCT02723955","Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)","COMPLETED",[85],"2023-07-05","2016-06-23",829,[107],[162,163,137,164,165,166,167,168,92,169,170],"feladilimab","GSK3174998","Docetaxel","Pemetrexed","Paclitaxel plus Carboplatin","Gemcitabine plus Carboplatin","Fluorouracil (5-FU) plus carboplatin or cisplatin","Cobolimab","Bintrafusp alfa",{"nctId":172,"briefTitle":173,"status":101,"phases":174,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":179},"NCT04446351","Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors",[85],"2026-12-31","2020-06-25",107,[107],[180,92,169,119],"GSK6097608",4,{"trials":183,"activeCount":361,"soonestReadout":273},[184,194,206,217,228,238,249,259,269,285,296,307,317,338,349],{"nctId":185,"briefTitle":186,"status":145,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":181,"conditions":190,"interventions":192},"NCT06655818","Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM",[85,86],"2024-02-14","2021-03-09",[191],"Relapsed\u002FRefractory Multiple Myeloma",[193,92],"Belantamab Mafodotin",{"nctId":195,"briefTitle":196,"status":125,"phases":197,"primaryCompletion":198,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":204},"NCT06567782","A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)\u002FMicrosatellite Stable (MSS) Colon Cancer",[86],"2026-11-23","2028-10-26","2025-02-18",120,[203],"Neoplasms, Colon",[92,205],"CAPEOX",{"nctId":207,"briefTitle":208,"status":101,"phases":209,"primaryCompletion":210,"completion":113,"start":211,"enrollment":212,"conditions":213,"interventions":215},"NCT06317311","A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer",[86],"2026-07-15","2024-05-07",41,[214],"Carcinoma",[92,135,216],"Paclitaxel",{"nctId":218,"briefTitle":219,"status":101,"phases":220,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":227},"NCT05723562","A Study of Dostarlimab in Untreated dMMR\u002FMSI-H Locally Advanced Rectal Cancer",[86],"2026-11-02","2029-10-11","2023-04-03",154,[226],"Neoplasms, Rectal",[92],{"nctId":229,"briefTitle":230,"status":155,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":236},"NCT06926673","Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3",[86],"2024-05-02","2021-12-23",62,[107],[92,237,120],"Belrestotug.",{"nctId":239,"briefTitle":240,"status":155,"phases":241,"primaryCompletion":232,"completion":232,"start":242,"enrollment":243,"conditions":244,"interventions":245},"NCT03739710","Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)",[86],"2019-01-24",175,[107],[164,246,247,248,92,180],"Feladilimab","Ipilimumab","GSK4428859A",{"nctId":250,"briefTitle":251,"status":125,"phases":252,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":258},"NCT07108270","A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)",[86],"2030-03-31","2025-11-27",30,[257],"Neoplasms, Endometrial",[92,135,216],{"nctId":260,"briefTitle":261,"status":101,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT05565378","A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced\u002FMetastatic Non-Small-Cell Lung Cancer",[86],"2027-02-26","2022-10-14",351,[267],"Lung Cancer, Non-Small Cell",[137,92,119,120],{"nctId":270,"briefTitle":271,"status":101,"phases":272,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":277,"interventions":279},"NCT04126200","Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed\u002FRefractory Multiple Myeloma (RRMM)",[85,86],"2025-04-17","2027-03-11","2019-10-07",208,[278],"Multiple Myeloma",[48,163,246,280,92,281,282,283,284],"Nirogacestat","Isatuximab","Lenalidomide","Dexamethasone","Pomalidomide",{"nctId":286,"briefTitle":287,"status":145,"phases":288,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":294},"NCT04581824","Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)",[86],"2022-08-04","2024-09-10","2020-11-19",243,[267],[92,137,295],"Chemotherapy",{"nctId":297,"briefTitle":298,"status":101,"phases":299,"primaryCompletion":300,"completion":301,"start":302,"enrollment":303,"conditions":304,"interventions":306},"NCT06062420","A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent\u002FMetastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202",[86],"2026-09-01","2027-12-31","2023-11-14",316,[305],"Neoplasms, Head and Neck",[92,119,120,118],{"nctId":308,"briefTitle":309,"status":101,"phases":310,"primaryCompletion":311,"completion":312,"start":313,"enrollment":314,"conditions":315,"interventions":316},"NCT06640049","A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China",[86],"2027-10-24","2031-04-15","2024-10-17",23,[226],[92],{"nctId":318,"briefTitle":319,"status":101,"phases":320,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":337},"NCT06521567","A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer",[85,86],"2026-10-13","2025-03-06",83,[325,326,327,328,329,330,331,332,333,334,335,336],"Melanoma","Hodgkin Lymphoma","High and Low Grade Glioma","Glioblastoma Multiforme (GBM)","Diffuse Intrinsic Pontine Glioma (DIPG)","Ependymoma","Osteosarcoma","Hepatic Tumors","Hepatoblastoma","Hepatocellular Carcinoma (HCC)","Fibrolamellar Carcinoma","Rhabdomyosarcoma",[169,92],{"nctId":339,"briefTitle":340,"status":125,"phases":341,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":346,"interventions":347},"NCT06405230","Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)",[85,86],"2028-08-07","2029-10-10","2025-12-30",40,[267],[137,92,348],"Pemetrexed+",{"nctId":350,"briefTitle":351,"status":125,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":359},"NCT06796907","A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors",[85,86],"2027-06-21","2028-10-10","2025-03-04",305,[358],"Tumours, Gynecological",[360,92,140],"Mo-Rez",11,{"trials":363,"activeCount":181,"soonestReadout":387},[364,373,383,393],{"nctId":365,"briefTitle":366,"status":101,"phases":367,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":371,"interventions":372},"NCT06472076","A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)",[87],"2027-02-02","2024-06-10",88,[267],[92,119,137],{"nctId":374,"briefTitle":375,"status":125,"phases":376,"primaryCompletion":377,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":382},"NCT06256588","A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma",[87],"2028-06-30","2029-10-26","2024-03-21",864,[305],[92],{"nctId":384,"briefTitle":385,"status":101,"phases":386,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":392},"NCT04655976","Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy",[87],"2025-06-05","2027-03-30","2020-12-08",758,[267],[169,92,164],{"nctId":394,"briefTitle":395,"status":125,"phases":396,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":403},"NCT05855200","Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR\u002FMSI-H Resectable Colon Cancer",[87],"2029-03-19","2031-03-27","2023-08-01",892,[402,203],"Colonic Neoplasms",[92,205,404],"FOLFOX",{"trials":406,"activeCount":417,"soonestReadout":412},[407],{"nctId":408,"briefTitle":409,"status":410,"phases":411,"primaryCompletion":412,"completion":412,"start":413,"enrollment":414,"conditions":415,"interventions":416},"NCT06897527","A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)","NOT_YET_RECRUITING",[88],"2027-01-13","2025-07-15",100,[257],[92],1,{"trials":419,"activeCount":97},[],{"intervention":53,"totalTrials":421,"cells":422},19,{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":457,"PHASE3":518,"PHASE4":594,"NA":616},{"trials":424,"activeCount":97},[],{"trials":426,"activeCount":417,"soonestReadout":442},[427,438,448],{"nctId":428,"briefTitle":429,"status":155,"phases":430,"primaryCompletion":431,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":436},"NCT05917288","A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus",[85],"2024-10-30","2023-07-07",16,[435],"Systemic Lupus Erythematosus",[53,437],"Standard of care",{"nctId":439,"briefTitle":440,"status":125,"phases":441,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":445,"interventions":446},"NCT06576271","A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants",[85],"2028-01-11","2024-09-02",142,[435],[447,53],"GSK4527363",{"nctId":449,"briefTitle":450,"status":155,"phases":451,"primaryCompletion":452,"completion":452,"start":453,"enrollment":454,"conditions":455,"interventions":456},"NCT02880852","Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus",[85],"2017-09-08","2017-01-23",20,[435],[53],{"trials":458,"activeCount":417,"soonestReadout":52},[459,466,478,488,497,508],{"nctId":50,"briefTitle":51,"status":101,"phases":460,"primaryCompletion":52,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":465},[86],"2027-04-26","2019-11-28",25,[435],[53],{"nctId":467,"briefTitle":468,"status":155,"phases":469,"primaryCompletion":470,"completion":471,"start":472,"enrollment":473,"conditions":474,"interventions":476},"NCT01610492","A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy",[86],"2014-09-24","2016-09-14","2012-07-01",14,[475],"Glomerulonephritis, Membranous",[477],"belimumab",{"nctId":479,"briefTitle":480,"status":155,"phases":481,"primaryCompletion":482,"completion":483,"start":484,"enrollment":345,"conditions":485,"interventions":487},"NCT01480596","The Evaluation of Belimumab in Myasthenia Gravis (MG)",[86],"2015-08","2015-10","2013-04",[486],"Myasthaenia Gravis",[53],{"nctId":489,"briefTitle":490,"status":155,"phases":491,"primaryCompletion":492,"completion":492,"start":493,"enrollment":255,"conditions":494,"interventions":496},"NCT01536379","A Study of Belimumab in the Prevention of Kidney Transplant Rejection",[86],"2016-02","2013-09",[495],"Transplantation, Organ",[53],{"nctId":498,"briefTitle":499,"status":500,"phases":501,"primaryCompletion":502,"completion":502,"start":503,"enrollment":97,"conditions":504,"interventions":506},"NCT01440361","A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.","WITHDRAWN",[86],"2015-04","2013-03",[505],"Purpura, Thrombocytopaenic, Idiopathic",[53,507],"Normal saline placebo",{"nctId":509,"briefTitle":510,"status":155,"phases":511,"primaryCompletion":512,"completion":512,"start":513,"enrollment":34,"conditions":514,"interventions":516},"NCT02631538","Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome",[86],"2020-06-23","2016-02-17",[515],"Sjogren's Syndrome",[53,517],"Rituximab",{"trials":519,"activeCount":593,"soonestReadout":566},[520,529,541,549,562,573,583],{"nctId":521,"briefTitle":522,"status":155,"phases":523,"primaryCompletion":524,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":528},"NCT02119156","Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients",[87],"2018-12-14","2014-05-13",80,[435],[53],{"nctId":530,"briefTitle":531,"status":125,"phases":532,"primaryCompletion":533,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":540},"NCT05878717","A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease",[86,87],"2029-05-17","2029-07-12","2023-09-13",300,[538,539],"Systemic Sclerosis Associated Interstitial Lung Disease","Scleroderma, Systemic",[53],{"nctId":542,"briefTitle":543,"status":155,"phases":544,"primaryCompletion":545,"completion":545,"start":546,"enrollment":444,"conditions":547,"interventions":548},"NCT01597622","BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115",[87],"2018-09-13","2012-06-11",[435],[53],{"nctId":550,"briefTitle":551,"status":155,"phases":552,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":557,"interventions":558},"NCT03312907","A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE",[87],"2020-05-29","2021-07-07","2018-03-01",292,[435],[53,517,559,560,560,561],"Rituximab-placebo","Standard therapy","Steroid Taper",{"nctId":563,"briefTitle":564,"status":125,"phases":565,"primaryCompletion":566,"completion":567,"start":568,"enrollment":569,"conditions":570,"interventions":572},"NCT06572384","A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease",[87],"2028-10-18","2028-12-13","2024-09-11",440,[571],"Lung Diseases, Interstitial",[53],{"nctId":574,"briefTitle":575,"status":125,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":582},"NCT06716606","A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)",[87],"2029-12-27","2024-12-12",514,[581],"Connective Tissue Diseases",[53],{"nctId":584,"briefTitle":585,"status":155,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":590,"conditions":591,"interventions":592},"NCT01345253","GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia",[87],"2015-09-15","2018-09-21","2011-05-23",709,[435],[53],3,{"trials":595,"activeCount":417,"soonestReadout":600},[596,606],{"nctId":597,"briefTitle":598,"status":125,"phases":599,"primaryCompletion":600,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":605},"NCT06411249","A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)",[88],"2027-05-31","2029-05-29","2024-06-06",350,[435],[53],{"nctId":607,"briefTitle":608,"status":155,"phases":609,"primaryCompletion":610,"completion":611,"start":612,"enrollment":613,"conditions":614,"interventions":615},"NCT04908865","Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)",[88],"2024-05-23","2024-08-13","2021-10-21",67,[435],[53,560],{"trials":617,"activeCount":97},[618],{"nctId":619,"briefTitle":620,"status":155,"phases":621,"primaryCompletion":622,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":626},"NCT01532310","Belimumab (BENLYSTA®) Pregnancy Registry",[],"2022-11-11","2012-07-16",77,[435],[477],{"intervention":82,"totalTrials":628,"cells":629},6,{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":638,"PHASE3":661,"PHASE4":680,"NA":691},{"trials":631,"activeCount":97},[],{"trials":633,"activeCount":97},[634],{"nctId":143,"briefTitle":144,"status":145,"phases":635,"primaryCompletion":147,"completion":147,"start":148,"enrollment":149,"conditions":636,"interventions":637},[85],[107],[82,92,82],{"trials":639,"activeCount":660,"soonestReadout":654},[640,650],{"nctId":641,"briefTitle":642,"status":125,"phases":643,"primaryCompletion":644,"completion":644,"start":645,"enrollment":255,"conditions":646,"interventions":649},"NCT04641247","A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline\u002FTESARO-sponsored Niraparib Study",[86],"2026-11-13","2021-04-16",[647,648],"Ovarian Neoplasms","Breast Neoplasms",[82],{"nctId":651,"briefTitle":652,"status":101,"phases":653,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":658},"NCT06077877","A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors",[85,86],"2026-06-30","2023-10-24",42,[107],[659,82],"GSK4524101",2,{"trials":662,"activeCount":417,"soonestReadout":81},[663,670],{"nctId":79,"briefTitle":80,"status":101,"phases":664,"primaryCompletion":81,"completion":665,"start":666,"enrollment":345,"conditions":667,"interventions":669},[87],"2025-12-31","2021-06-28",[668],"Neoplasms, Breast",[82],{"nctId":671,"briefTitle":672,"status":155,"phases":673,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":679},"NCT04475939","Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced\u002FMetastatic Non-Small Cell Lung Cancer",[87],"2025-02-26","2026-03-23","2020-10-26",666,[267],[82,137],{"trials":681,"activeCount":417,"soonestReadout":686},[682],{"nctId":683,"briefTitle":684,"status":410,"phases":685,"primaryCompletion":686,"completion":687,"start":688,"enrollment":613,"conditions":689,"interventions":690},"NCT06887933","A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer",[88],"2026-03-20","2026-07-08","2025-04-22",[647],[82],{"trials":692,"activeCount":97},[],{"intervention":694,"totalTrials":695,"cells":696},"Mepolizumab",28,{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":753,"PHASE4":943,"NA":964},{"trials":698,"activeCount":97},[],{"trials":700,"activeCount":97},[],{"trials":702,"activeCount":97},[703,713,724,733,744],{"nctId":704,"briefTitle":705,"status":155,"phases":706,"primaryCompletion":707,"completion":708,"start":709,"enrollment":710,"conditions":711,"interventions":712},"NCT02377427","Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children",[86],"2016-12-07","2018-01-31","2015-08-25",36,[18],[694],{"nctId":714,"briefTitle":715,"status":155,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":722},"NCT00358449","Intravenous Mepolizumab In Children With Eosinophilic Esophagitis",[86],"2008-11-25","2006-09-11",84,[721],"Oesophagitis, Eosinophilic",[723],"mepolizumab",{"nctId":725,"briefTitle":726,"status":155,"phases":727,"primaryCompletion":728,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":732},"NCT01366521","Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils",[86],"2012-03","2011-02",70,[18],[694],{"nctId":734,"briefTitle":735,"status":155,"phases":736,"primaryCompletion":737,"completion":737,"start":738,"enrollment":739,"conditions":740,"interventions":742},"NCT01362244","Mepolizumab in Nasal Polyposis",[86],"2014-12-05","2009-05-12",109,[741],"Nasal Polyps",[694,743],"Run In Medication",{"nctId":745,"briefTitle":746,"status":155,"phases":747,"primaryCompletion":748,"completion":748,"start":749,"enrollment":750,"conditions":751,"interventions":752},"NCT00274703","An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients",[86],"2007-03","2005-12",10,[721],[723],{"trials":754,"activeCount":417,"soonestReadout":778},[755,764,774,786,797,806,815,823,833,843,853,862,871,880,889,898,907,916,925,934],{"nctId":756,"briefTitle":757,"status":155,"phases":758,"primaryCompletion":759,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":763},"NCT03099096","Study of Mepolizumab Autoinjector in Asthmatics",[87],"2017-11-30","2017-05-04",159,[18],[694],{"nctId":765,"briefTitle":766,"status":155,"phases":767,"primaryCompletion":768,"completion":768,"start":769,"enrollment":770,"conditions":771,"interventions":772},"NCT03085797","Effect of Mepolizumab in Severe Bilateral Nasal Polyps",[87],"2019-12-11","2017-05-25",414,[741],[694,773],"Mometasone furoate",{"nctId":775,"briefTitle":776,"status":101,"phases":777,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":784},"NCT05263934","Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)",[87],"2026-09-29","2026-10-27","2022-07-14",163,[783],"Eosinophilic Granulomatosis With Polyangiitis",[785,694],"Depemokimab",{"nctId":787,"briefTitle":788,"status":155,"phases":789,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":793,"interventions":794},"NCT04718389","A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype",[87],"2025-09-14","2021-01-26",1717,[18],[795,694,796,437],"GSK3511294","Benralizumab",{"nctId":798,"briefTitle":799,"status":155,"phases":800,"primaryCompletion":801,"completion":801,"start":802,"enrollment":803,"conditions":804,"interventions":805},"NCT04607005","Efficacy and Safety of Mepolizumab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)\u002F Eosinophilic Chronic Rhinosinusitis (ECRS)",[87],"2023-04-12","2021-04-22",169,[741],[694,437],{"nctId":807,"briefTitle":808,"status":155,"phases":809,"primaryCompletion":810,"completion":810,"start":811,"enrollment":812,"conditions":813,"interventions":814},"NCT02105961","Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)",[87],"2017-01-16","2014-04-24",674,[15],[694],{"nctId":816,"briefTitle":817,"status":155,"phases":818,"primaryCompletion":819,"completion":819,"start":780,"enrollment":433,"conditions":820,"interventions":822},"NCT04965636","Study in Pediatrics With HypEREosinophilic Syndrome (SPHERE)",[87],"2025-10-28",[821],"Hypereosinophilic Syndrome",[694],{"nctId":824,"briefTitle":825,"status":155,"phases":826,"primaryCompletion":827,"completion":827,"start":828,"enrollment":829,"conditions":830,"interventions":831},"NCT01691508","Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma",[87],"2013-12","2012-10",135,[18],[694,832],"OCS",{"nctId":834,"briefTitle":835,"status":155,"phases":836,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":841},"NCT02281318","Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control",[87],"2016-06-10","2014-12-11",556,[18],[694,842],"SOC",{"nctId":844,"briefTitle":845,"status":155,"phases":846,"primaryCompletion":847,"completion":847,"start":848,"enrollment":849,"conditions":850,"interventions":852},"NCT02020889","A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis",[87],"2016-09-05","2014-02-05",136,[851],"Churg-Strauss Syndrome",[694],{"nctId":854,"briefTitle":855,"status":155,"phases":856,"primaryCompletion":857,"completion":857,"start":858,"enrollment":859,"conditions":860,"interventions":861},"NCT01842607","A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects",[87],"2015-03-13","2013-05-27",651,[18],[694],{"nctId":863,"briefTitle":864,"status":145,"phases":865,"primaryCompletion":866,"completion":866,"start":867,"enrollment":868,"conditions":869,"interventions":870},"NCT00097370","Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome",[87],"2010-09-29","2004-09-30",78,[821],[723],{"nctId":872,"briefTitle":873,"status":155,"phases":874,"primaryCompletion":875,"completion":875,"start":876,"enrollment":877,"conditions":878,"interventions":879},"NCT01691859","MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects",[87],"2017-05-31","2012-09-28",347,[18],[694],{"nctId":881,"briefTitle":882,"status":155,"phases":883,"primaryCompletion":884,"completion":884,"start":885,"enrollment":886,"conditions":887,"interventions":888},"NCT02105948","Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients",[87],"2017-01-17","2014-04-15",837,[15],[694],{"nctId":890,"briefTitle":891,"status":155,"phases":892,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":896,"interventions":897},"NCT04133909","Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level",[87],"2024-08-08","2019-10-30",806,[15],[694],{"nctId":899,"briefTitle":900,"status":155,"phases":901,"primaryCompletion":902,"completion":902,"start":903,"enrollment":904,"conditions":905,"interventions":906},"NCT03021304","Study of Mepolizumab Safety Syringe in Asthmatics",[87],"2017-08-08","2017-02-01",56,[18],[694],{"nctId":908,"briefTitle":909,"status":155,"phases":910,"primaryCompletion":911,"completion":911,"start":912,"enrollment":414,"conditions":913,"interventions":914},"NCT03298061","Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921",[87],"2023-02-16","2015-04-14",[851,783],[694,915],"Prednisolone",{"nctId":917,"briefTitle":918,"status":155,"phases":919,"primaryCompletion":920,"completion":920,"start":921,"enrollment":34,"conditions":922,"interventions":924},"NCT00086658","Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)",[87],"2006-05-01","2004-03-23",[923,821],"Hypereosinophilia",[723],{"nctId":926,"briefTitle":927,"status":155,"phases":928,"primaryCompletion":929,"completion":929,"start":930,"enrollment":931,"conditions":932,"interventions":933},"NCT03306043","A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622",[87],"2019-12-30","2017-11-13",102,[821],[694],{"nctId":935,"briefTitle":936,"status":155,"phases":937,"primaryCompletion":938,"completion":938,"start":939,"enrollment":940,"conditions":941,"interventions":942},"NCT02135692","A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects",[87],"2017-10-05","2014-05-29",339,[18],[694,842],{"trials":944,"activeCount":417,"soonestReadout":949},[945,955],{"nctId":946,"briefTitle":947,"status":101,"phases":948,"primaryCompletion":949,"completion":950,"start":951,"enrollment":952,"conditions":953,"interventions":954},"NCT06041386","REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study",[88],"2025-01-31","2028-06-14","2024-03-20",336,[18],[694],{"nctId":956,"briefTitle":957,"status":155,"phases":958,"primaryCompletion":959,"completion":959,"start":960,"enrollment":414,"conditions":961,"interventions":962},"NCT04276233","Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma",[88],"2023-10-28","2021-06-29",[18],[694,963],"Salbutamol",{"trials":965,"activeCount":97},[966],{"nctId":967,"briefTitle":968,"status":969,"phases":970,"conditions":971,"interventions":972},"NCT00244686","This Record Contains Information About the Mepolizumab Compassionate Use (CU) Product Activities: 104317: CU and Long-Term Access Study of Mepolizumab in HES. 201956:A Long-term Access Programme for Subjects With Severe Asthma 112562: Expanded Access for Patients With Hypereosinophilic","NO_LONGER_AVAILABLE",[],[821],[694],{"intervention":974,"totalTrials":660,"cells":975},"rMenB+OMV NZ",{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":982,"PHASE4":994,"NA":1007},{"trials":977,"activeCount":97},[],{"trials":979,"activeCount":97},[],{"trials":981,"activeCount":97},[],{"trials":983,"activeCount":97},[984],{"nctId":985,"briefTitle":986,"status":155,"phases":987,"primaryCompletion":988,"completion":988,"start":989,"enrollment":990,"conditions":991,"interventions":993},"NCT02446743","Combined Study - Phase 3b MenB Long Term Persistence in Adolescents",[87],"2016-09-23","2015-11-17",531,[992],"Infections, Meningococcal",[974],{"trials":995,"activeCount":417,"soonestReadout":1000},[996],{"nctId":997,"briefTitle":998,"status":101,"phases":999,"primaryCompletion":1000,"completion":1001,"start":1002,"enrollment":1003,"conditions":1004,"interventions":1006},"NCT06113198","A Study on the Immune Response and Safety of a Vaccine Against N. Meningitidis Serogroup B Infection in Healthy Infants From 2 Months of Age",[88],"2026-09-07","2027-02-08","2023-11-10",50,[1005],"Meningitis, Meningococcal",[974],{"trials":1008,"activeCount":97},[],{"intervention":1010,"totalTrials":417,"cells":1011},"Recombinant zoster vaccine",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1018,"PHASE4":1020,"NA":1032},{"trials":1013,"activeCount":97},[],{"trials":1015,"activeCount":97},[],{"trials":1017,"activeCount":97},[],{"trials":1019,"activeCount":97},[],{"trials":1021,"activeCount":417,"soonestReadout":1026},[1022],{"nctId":1023,"briefTitle":1024,"status":125,"phases":1025,"primaryCompletion":1026,"completion":1027,"start":103,"enrollment":1028,"conditions":1029,"interventions":1031},"NCT07502560","A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland",[88],"2030-04-01","2037-03-31",33609,[1030],"Herpes Zoster",[1010],{"trials":1033,"activeCount":97},[],{"intervention":1035,"totalTrials":417,"cells":1036},"Fluticasone furoate\u002Fumeclidinium bromide\u002Fvilanterol trifenatate",{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1043,"PHASE4":1045,"NA":1058},{"trials":1038,"activeCount":97},[],{"trials":1040,"activeCount":97},[],{"trials":1042,"activeCount":97},[],{"trials":1044,"activeCount":97},[],{"trials":1046,"activeCount":417,"soonestReadout":1051},[1047],{"nctId":1048,"briefTitle":1049,"status":101,"phases":1050,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":1054,"conditions":1055,"interventions":1056},"NCT06372496","Pragmatic Open - Label Randomized Clinical Trial of FF\u002FUMEC\u002FVI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma",[88],"2025-07-28","2027-03-31","2024-04-16",1366,[18],[1035,1057],"Inhaled corticosteroids\u002Flong-acting beta-2 agonists",{"trials":1059,"activeCount":97},[],{"intervention":1057,"totalTrials":417,"cells":1061},{"EARLY_PHASE1":1062,"PHASE1":1064,"PHASE2":1066,"PHASE3":1068,"PHASE4":1070,"NA":1076},{"trials":1063,"activeCount":97},[],{"trials":1065,"activeCount":97},[],{"trials":1067,"activeCount":97},[],{"trials":1069,"activeCount":97},[],{"trials":1071,"activeCount":417,"soonestReadout":1051},[1072],{"nctId":1048,"briefTitle":1049,"status":101,"phases":1073,"primaryCompletion":1051,"completion":1052,"start":1053,"enrollment":1054,"conditions":1074,"interventions":1075},[88],[18],[1035,1057],{"trials":1077,"activeCount":97},[],{"intervention":48,"totalTrials":1079,"cells":1080},29,{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1137,"PHASE3":1259,"PHASE4":1319,"NA":1321},{"trials":1082,"activeCount":97},[],{"trials":1084,"activeCount":593,"soonestReadout":1106},[1085,1094,1102,1110,1120,1128],{"nctId":1086,"briefTitle":1087,"status":410,"phases":1088,"primaryCompletion":1089,"completion":1089,"start":1090,"enrollment":454,"conditions":1091,"interventions":1092},"NCT07609706","A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment",[85],"2031-08-22","2026-10-23",[278],[48,1093,283],"Bortezomib",{"nctId":1095,"briefTitle":1096,"status":155,"phases":1097,"primaryCompletion":1098,"completion":1098,"start":1099,"enrollment":628,"conditions":1100,"interventions":1101},"NCT04177823","A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed\u002FRefractory Multiple Myeloma (RRMM)",[85],"2021-12-30","2019-12-09",[278],[48],{"nctId":1103,"briefTitle":1104,"status":101,"phases":1105,"primaryCompletion":1106,"completion":665,"start":1107,"enrollment":710,"conditions":1108,"interventions":1109},"NCT04398745","A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function",[85],"2025-04-21","2020-10-09",[278],[48],{"nctId":1111,"briefTitle":1112,"status":155,"phases":1113,"primaryCompletion":1114,"completion":1115,"start":1116,"enrollment":1117,"conditions":1118,"interventions":1119},"NCT03828292","An Open-label, Dose Escalation Study in Japanese Participants With Relapsed\u002FRefractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments",[85],"2023-04-06","2024-09-05","2019-03-14",15,[278],[48,1093,283,284],{"nctId":1121,"briefTitle":1122,"status":500,"phases":1123,"primaryCompletion":1124,"completion":1124,"start":1125,"enrollment":97,"conditions":1126,"interventions":1127},"NCT04398680","A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function",[85],"2025-11-04","2021-04-20",[278],[48],{"nctId":1129,"briefTitle":1130,"status":101,"phases":1131,"primaryCompletion":1132,"completion":175,"start":1133,"enrollment":1134,"conditions":1135,"interventions":1136},"NCT04091126","Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma",[85],"2025-06-02","2019-12-18",118,[278],[48,1093,282,283],{"trials":1138,"activeCount":750,"soonestReadout":273},[1139,1143,1153,1160,1168,1177,1181,1190,1200,1207,1217,1224,1232,1242,1252],{"nctId":185,"briefTitle":186,"status":145,"phases":1140,"primaryCompletion":188,"completion":188,"start":189,"enrollment":181,"conditions":1141,"interventions":1142},[85,86],[191],[193,92],{"nctId":1144,"briefTitle":1145,"status":155,"phases":1146,"primaryCompletion":1147,"completion":1148,"start":1149,"enrollment":1150,"conditions":1151,"interventions":1152},"NCT03544281","To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed\u002FRefractory Multiple Myeloma (RRMM)",[85,86],"2023-02-28","2024-02-28","2018-09-20",153,[278],[48,282,283,1093],{"nctId":1154,"briefTitle":1155,"status":101,"phases":1156,"primaryCompletion":273,"completion":274,"start":1157,"enrollment":473,"conditions":1158,"interventions":1159},"NCT07150104","Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM",[85,86],"2022-08-31",[278],[48,280,284,283],{"nctId":1161,"briefTitle":1162,"status":145,"phases":1163,"primaryCompletion":1164,"completion":1164,"start":275,"enrollment":1165,"conditions":1166,"interventions":1167},"NCT06160609","Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM",[85,86],"2023-01-09",9,[191],[193,163],{"nctId":1169,"briefTitle":1170,"status":155,"phases":1171,"primaryCompletion":1172,"completion":1173,"start":1116,"enrollment":212,"conditions":1174,"interventions":1175},"NCT03848845","Study Evaluating Safety, Tolerability and Clinical Activity of GSK2857916 in Combination With Pembrolizumab in Subjects With Relapsed\u002FRefractory Multiple Myeloma (RRMM)",[85,86],"2021-10-18","2023-06-14",[278],[1176,137],"belantamab mafodotin",{"nctId":270,"briefTitle":271,"status":101,"phases":1178,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":1179,"interventions":1180},[85,86],[278],[48,163,246,280,92,281,282,283,284],{"nctId":1182,"briefTitle":1183,"status":410,"phases":1184,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":201,"conditions":1188,"interventions":1189},"NCT07614360","Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed\u002FRefractory Multiple Myeloma",[86],"2029-02-28","2031-02-11","2026-08-03",[278],[48,283,1093],{"nctId":1191,"briefTitle":1192,"status":125,"phases":1193,"primaryCompletion":1194,"completion":1194,"start":1195,"enrollment":1196,"conditions":1197,"interventions":1198},"NCT07227311","A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)",[86],"2030-08-30","2026-04-15",200,[278],[48,283,284,1093,1199],"Carfilzomib",{"nctId":1201,"briefTitle":1202,"status":101,"phases":1203,"primaryCompletion":273,"completion":274,"start":1204,"enrollment":255,"conditions":1205,"interventions":1206},"NCT07217184","Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM",[85,86],"2021-07-29",[278],[48,281],{"nctId":1208,"briefTitle":1209,"status":155,"phases":1210,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":1215,"interventions":1216},"NCT05064358","Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma",[86],"2024-08-19","2026-02-10","2022-03-03",177,[278],[48],{"nctId":1218,"briefTitle":1219,"status":101,"phases":1220,"primaryCompletion":273,"completion":274,"start":1221,"enrollment":454,"conditions":1222,"interventions":1223},"NCT07150091","Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM",[85,86],"2022-07-19",[278],[48,280,282,283],{"nctId":1225,"briefTitle":1226,"status":101,"phases":1227,"primaryCompletion":273,"completion":274,"start":1228,"enrollment":1229,"conditions":1230,"interventions":1231},"NCT07084896","Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM",[85,86],"2020-06-08",106,[278],[48,280],{"nctId":1233,"briefTitle":1234,"status":410,"phases":1235,"primaryCompletion":1236,"completion":1236,"start":686,"enrollment":1237,"conditions":1238,"interventions":1240},"NCT07224672","A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis",[86],"2032-12-13",60,[1239],"Amyloidosis",[48,1241,1093,283],"Cyclophosphamide",{"nctId":1243,"briefTitle":1244,"status":125,"phases":1245,"primaryCompletion":1246,"completion":1246,"start":1173,"enrollment":115,"conditions":1247,"interventions":1248},"NCT05714839","A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments",[85,86],"2029-12-03",[278],[1249,48,1250,1251],"Unconjugated belantamab antibody","Unconjugated belantamab antibody and belantamab mafodotin","Unconjugated belantamab antibody in combination with pomalidomide-dexamethasone backbone, with or without belantamab mafodotin",{"nctId":1253,"briefTitle":1254,"status":101,"phases":1255,"primaryCompletion":273,"completion":274,"start":1256,"enrollment":463,"conditions":1257,"interventions":1258},"NCT07217119","Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM",[85,86],"2019-11-26",[278],[48,246],{"trials":1260,"activeCount":1318,"soonestReadout":47},[1261,1268,1275,1282,1290,1296,1301,1311],{"nctId":63,"briefTitle":64,"status":101,"phases":1262,"primaryCompletion":65,"completion":377,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1266},[87],"2021-07-28",72,[278],[48,1267,1093,283],"Daratumumab",{"nctId":59,"briefTitle":60,"status":101,"phases":1269,"primaryCompletion":61,"completion":1270,"start":1271,"enrollment":1272,"conditions":1273,"interventions":1274},[87],"2029-10-25","2020-10-01",302,[278],[48,284,283,1093],{"nctId":75,"briefTitle":76,"status":101,"phases":1276,"primaryCompletion":77,"completion":1277,"start":1278,"enrollment":1279,"conditions":1280,"interventions":1281},[87],"2029-11-30","2022-02-10",21,[278],[48,284,283,1093],{"nctId":1283,"briefTitle":1284,"status":145,"phases":1285,"primaryCompletion":1286,"completion":1286,"start":1287,"enrollment":433,"conditions":1288,"interventions":1289},"NCT04549363","Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin",[87],"2022-11-21","2020-12-21",[278],[48],{"nctId":55,"briefTitle":56,"status":101,"phases":1291,"primaryCompletion":57,"completion":377,"start":1292,"enrollment":1293,"conditions":1294,"interventions":1295},[87],"2020-05-07",494,[278],[48,1267,1093,283],{"nctId":67,"briefTitle":68,"status":101,"phases":1297,"primaryCompletion":65,"completion":377,"start":1263,"enrollment":1298,"conditions":1299,"interventions":1300},[87],24,[278],[48,1267,1093,283],{"nctId":1302,"briefTitle":1303,"status":125,"phases":1304,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":1308,"interventions":1310},"NCT06679101","A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)",[87],"2031-04-28","2024-12-16",520,[278,1309],"Newly Diagnosed Multiple Myeloma",[48,282,283,1267],{"nctId":45,"briefTitle":46,"status":101,"phases":1312,"primaryCompletion":47,"completion":274,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1316},[87],"2020-04-02",325,[278],[48,1317],"Pom\u002Fdex",7,{"trials":1320,"activeCount":97},[],{"trials":1322,"activeCount":97},[],{"intervention":283,"totalTrials":1279,"cells":1324},{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1354,"PHASE3":1408,"PHASE4":1454,"NA":1456},{"trials":1326,"activeCount":97},[],{"trials":1328,"activeCount":660,"soonestReadout":1132},[1329,1342,1346,1350],{"nctId":1330,"briefTitle":1331,"status":155,"phases":1332,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":1336,"interventions":1338},"NCT00437229","A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults",[85],"2007-05-15","2007-02-19",37,[1337],"Nausea and Vomiting, Chemotherapy-Induced",[1339,1340,1341],"Casopitant (GW679769) Oral","dexamethasone","ondansetron",{"nctId":1086,"briefTitle":1087,"status":410,"phases":1343,"primaryCompletion":1089,"completion":1089,"start":1090,"enrollment":454,"conditions":1344,"interventions":1345},[85],[278],[48,1093,283],{"nctId":1111,"briefTitle":1112,"status":155,"phases":1347,"primaryCompletion":1114,"completion":1115,"start":1116,"enrollment":1117,"conditions":1348,"interventions":1349},[85],[278],[48,1093,283,284],{"nctId":1129,"briefTitle":1130,"status":101,"phases":1351,"primaryCompletion":1132,"completion":175,"start":1133,"enrollment":1134,"conditions":1352,"interventions":1353},[85],[278],[48,1093,282,283],{"trials":1355,"activeCount":628,"soonestReadout":273},[1356,1368,1372,1376,1388,1392,1396,1400,1404],{"nctId":1357,"briefTitle":1358,"status":155,"phases":1359,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1362,"conditions":1363,"interventions":1365},"NCT00104403","Study Of Prevention of Chemo-Induced Nausea and Vomiting Caused By Moderately Emetogenic Chemotherapy",[86],"2006-01","2004-12",722,[1337,1364],"Chemotherapy-Induced Nausea and Vomiting",[1366,283,1367],"GW679769","Ondansetron Hydrochloride",{"nctId":1144,"briefTitle":1145,"status":155,"phases":1369,"primaryCompletion":1147,"completion":1148,"start":1149,"enrollment":1150,"conditions":1370,"interventions":1371},[85,86],[278],[48,282,283,1093],{"nctId":1154,"briefTitle":1155,"status":101,"phases":1373,"primaryCompletion":273,"completion":274,"start":1157,"enrollment":473,"conditions":1374,"interventions":1375},[85,86],[278],[48,280,284,283],{"nctId":1377,"briefTitle":1378,"status":155,"phases":1379,"start":1380,"enrollment":1381,"conditions":1382,"interventions":1385},"NCT00169572","Study for The Prevention Of Nausea in Cancer Patients Receiving Highly Emetogenic Cisplatin Based Chemotherapy",[86],"2005-02",492,[1383,1384],"Nausea and Vomiting","Chemotherapy-Induced",[1386,1387,1366,283],"Aprepitant","Ondansetron",{"nctId":270,"briefTitle":271,"status":101,"phases":1389,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":1390,"interventions":1391},[85,86],[278],[48,163,246,280,92,281,282,283,284],{"nctId":1182,"briefTitle":1183,"status":410,"phases":1393,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":201,"conditions":1394,"interventions":1395},[86],[278],[48,283,1093],{"nctId":1191,"briefTitle":1192,"status":125,"phases":1397,"primaryCompletion":1194,"completion":1194,"start":1195,"enrollment":1196,"conditions":1398,"interventions":1399},[86],[278],[48,283,284,1093,1199],{"nctId":1218,"briefTitle":1219,"status":101,"phases":1401,"primaryCompletion":273,"completion":274,"start":1221,"enrollment":454,"conditions":1402,"interventions":1403},[85,86],[278],[48,280,282,283],{"nctId":1233,"briefTitle":1234,"status":410,"phases":1405,"primaryCompletion":1236,"completion":1236,"start":686,"enrollment":1237,"conditions":1406,"interventions":1407},[86],[1239],[48,1241,1093,283],{"trials":1409,"activeCount":628,"soonestReadout":57},[1410,1420,1424,1434,1438,1442,1446,1450],{"nctId":1411,"briefTitle":1412,"status":155,"phases":1413,"primaryCompletion":1414,"completion":1414,"start":1415,"enrollment":1416,"conditions":1417,"interventions":1418},"NCT00601172","A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.",[87],"2009-04-13","2008-03-10",710,[1337],[1419,283,1387],"Casopitant",{"nctId":63,"briefTitle":64,"status":101,"phases":1421,"primaryCompletion":65,"completion":377,"start":1263,"enrollment":1264,"conditions":1422,"interventions":1423},[87],[278],[48,1267,1093,283],{"nctId":1425,"briefTitle":1426,"status":500,"phases":1427,"primaryCompletion":1428,"completion":1428,"start":1429,"enrollment":97,"conditions":1430,"interventions":1432},"NCT00891761","A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy",[87],"2010-07","2009-09",[36,1364,1383,1431],"Solid Tumor Cancer",[283,283,1433,1433,1387],"IV casopitant",{"nctId":59,"briefTitle":60,"status":101,"phases":1435,"primaryCompletion":61,"completion":1270,"start":1271,"enrollment":1272,"conditions":1436,"interventions":1437},[87],[278],[48,284,283,1093],{"nctId":75,"briefTitle":76,"status":101,"phases":1439,"primaryCompletion":77,"completion":1277,"start":1278,"enrollment":1279,"conditions":1440,"interventions":1441},[87],[278],[48,284,283,1093],{"nctId":55,"briefTitle":56,"status":101,"phases":1443,"primaryCompletion":57,"completion":377,"start":1292,"enrollment":1293,"conditions":1444,"interventions":1445},[87],[278],[48,1267,1093,283],{"nctId":67,"briefTitle":68,"status":101,"phases":1447,"primaryCompletion":65,"completion":377,"start":1263,"enrollment":1298,"conditions":1448,"interventions":1449},[87],[278],[48,1267,1093,283],{"nctId":1302,"briefTitle":1303,"status":125,"phases":1451,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":1452,"interventions":1453},[87],[278,1309],[48,282,283,1267],{"trials":1455,"activeCount":97},[],{"trials":1457,"activeCount":97},[],{"intervention":1093,"totalTrials":1459,"cells":1460},12,{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1477,"PHASE3":1495,"PHASE4":1518,"NA":1520},{"trials":1462,"activeCount":97},[],{"trials":1464,"activeCount":660,"soonestReadout":1132},[1465,1469,1473],{"nctId":1086,"briefTitle":1087,"status":410,"phases":1466,"primaryCompletion":1089,"completion":1089,"start":1090,"enrollment":454,"conditions":1467,"interventions":1468},[85],[278],[48,1093,283],{"nctId":1111,"briefTitle":1112,"status":155,"phases":1470,"primaryCompletion":1114,"completion":1115,"start":1116,"enrollment":1117,"conditions":1471,"interventions":1472},[85],[278],[48,1093,283,284],{"nctId":1129,"briefTitle":1130,"status":101,"phases":1474,"primaryCompletion":1132,"completion":175,"start":1133,"enrollment":1134,"conditions":1475,"interventions":1476},[85],[278],[48,1093,282,283],{"trials":1478,"activeCount":593,"soonestReadout":1185},[1479,1483,1487,1491],{"nctId":1144,"briefTitle":1145,"status":155,"phases":1480,"primaryCompletion":1147,"completion":1148,"start":1149,"enrollment":1150,"conditions":1481,"interventions":1482},[85,86],[278],[48,282,283,1093],{"nctId":1182,"briefTitle":1183,"status":410,"phases":1484,"primaryCompletion":1185,"completion":1186,"start":1187,"enrollment":201,"conditions":1485,"interventions":1486},[86],[278],[48,283,1093],{"nctId":1191,"briefTitle":1192,"status":125,"phases":1488,"primaryCompletion":1194,"completion":1194,"start":1195,"enrollment":1196,"conditions":1489,"interventions":1490},[86],[278],[48,283,284,1093,1199],{"nctId":1233,"briefTitle":1234,"status":410,"phases":1492,"primaryCompletion":1236,"completion":1236,"start":686,"enrollment":1237,"conditions":1493,"interventions":1494},[86],[1239],[48,1241,1093,283],{"trials":1496,"activeCount":1517,"soonestReadout":57},[1497,1501,1505,1509,1513],{"nctId":63,"briefTitle":64,"status":101,"phases":1498,"primaryCompletion":65,"completion":377,"start":1263,"enrollment":1264,"conditions":1499,"interventions":1500},[87],[278],[48,1267,1093,283],{"nctId":59,"briefTitle":60,"status":101,"phases":1502,"primaryCompletion":61,"completion":1270,"start":1271,"enrollment":1272,"conditions":1503,"interventions":1504},[87],[278],[48,284,283,1093],{"nctId":75,"briefTitle":76,"status":101,"phases":1506,"primaryCompletion":77,"completion":1277,"start":1278,"enrollment":1279,"conditions":1507,"interventions":1508},[87],[278],[48,284,283,1093],{"nctId":55,"briefTitle":56,"status":101,"phases":1510,"primaryCompletion":57,"completion":377,"start":1292,"enrollment":1293,"conditions":1511,"interventions":1512},[87],[278],[48,1267,1093,283],{"nctId":67,"briefTitle":68,"status":101,"phases":1514,"primaryCompletion":65,"completion":377,"start":1263,"enrollment":1298,"conditions":1515,"interventions":1516},[87],[278],[48,1267,1093,283],5,{"trials":1519,"activeCount":97},[],{"trials":1521,"activeCount":97},[],{"intervention":785,"totalTrials":361,"cells":1523},{"EARLY_PHASE1":1524,"PHASE1":1526,"PHASE2":1545,"PHASE3":1547,"PHASE4":1629,"NA":1631},{"trials":1525,"activeCount":97},[],{"trials":1527,"activeCount":97},[1528,1537],{"nctId":1529,"briefTitle":1530,"status":155,"phases":1531,"primaryCompletion":1532,"completion":1532,"start":1533,"enrollment":1534,"conditions":1535,"interventions":1536},"NCT05602025","A Study to Compare the Pharmacokinetics (PK) of Depemokimab When Delivered With a Safety Syringe Device (SSD) or an Autoinjector in Healthy Adult Participants",[85],"2023-10-23","2022-12-13",140,[18],[785],{"nctId":1538,"briefTitle":1539,"status":155,"phases":1540,"primaryCompletion":1541,"completion":1541,"start":1542,"enrollment":454,"conditions":1543,"interventions":1544},"NCT05140200","Study of GSK3511294 in Healthy Chinese Participants",[85],"2022-12-23","2021-12-10",[18],[785],{"trials":1546,"activeCount":97},[],{"trials":1548,"activeCount":1318,"soonestReadout":778},[1549,1553,1563,1572,1582,1592,1601,1611,1620],{"nctId":775,"briefTitle":776,"status":101,"phases":1550,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":1551,"interventions":1552},[87],[783],[785,694],{"nctId":1554,"briefTitle":1555,"status":155,"phases":1556,"primaryCompletion":1557,"completion":1558,"start":1559,"enrollment":1560,"conditions":1561,"interventions":1562},"NCT05281523","Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)",[87],"2024-07-12","2024-08-06","2022-04-18",264,[741],[785],{"nctId":1564,"briefTitle":1565,"status":125,"phases":1566,"primaryCompletion":1567,"completion":1567,"start":1568,"enrollment":1569,"conditions":1570,"interventions":1571},"NCT06959095","Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)",[87],"2029-08-20","2025-06-20",981,[15],[785],{"nctId":1573,"briefTitle":1574,"status":125,"phases":1575,"primaryCompletion":1576,"completion":1577,"start":1578,"enrollment":1579,"conditions":1580,"interventions":1581},"NCT06979323","Depemokimab Asthma Imaging and Bronchoscopy Sub-Study",[87],"2027-12-08","2028-02-11","2025-06-03",150,[18],[785],{"nctId":1583,"briefTitle":1584,"status":155,"phases":1585,"primaryCompletion":1586,"completion":1587,"start":1588,"enrollment":1589,"conditions":1590,"interventions":1591},"NCT05274750","Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps",[87],"2024-07-30","2024-08-27","2022-04-22",276,[741],[785],{"nctId":1593,"briefTitle":1594,"status":125,"phases":1595,"primaryCompletion":1596,"completion":1596,"start":1597,"enrollment":1598,"conditions":1599,"interventions":1600},"NCT05334368","Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial",[87],"2028-12-19","2022-09-06",123,[821],[785],{"nctId":1602,"briefTitle":1603,"status":125,"phases":1604,"primaryCompletion":1605,"completion":1606,"start":1607,"enrollment":1608,"conditions":1609,"interventions":1610},"NCT07177339","eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation",[87],"2029-11-02","2029-12-14","2025-10-20",1196,[15],[785],{"nctId":1612,"briefTitle":1613,"status":410,"phases":1614,"primaryCompletion":1615,"completion":1615,"start":1616,"enrollment":1617,"conditions":1618,"interventions":1619},"NCT07456033","A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma",[87],"2030-07-01","2026-03-06",456,[18],[785],{"nctId":1621,"briefTitle":1622,"status":125,"phases":1623,"primaryCompletion":1624,"completion":1624,"start":1625,"enrollment":1626,"conditions":1627,"interventions":1628},"NCT06961214","Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)",[87],"2029-08-21","2025-06-23",960,[15],[785],{"trials":1630,"activeCount":97},[],{"trials":1632,"activeCount":97},[],{"intervention":137,"totalTrials":1634,"cells":1635},18,{"EARLY_PHASE1":1636,"PHASE1":1638,"PHASE2":1691,"PHASE3":1740,"PHASE4":1784,"NA":1786},{"trials":1637,"activeCount":97},[],{"trials":1639,"activeCount":417,"soonestReadout":127},[1640,1652,1656,1666,1675,1679],{"nctId":1641,"briefTitle":1642,"status":145,"phases":1643,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":628,"conditions":1647,"interventions":1648},"NCT03168438","Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma",[85],"2020-07-13","2020-11-05","2017-08-18",[107],[1649,1650,1651,1241,137],"Letetresgene autoleucel","Letetresgene autoleucel with pembrolizumab","Fludarabine",{"nctId":123,"briefTitle":124,"status":125,"phases":1653,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":1654,"interventions":1655},[85],[107],[133,134,135,136,137,138,139,140,141,92],{"nctId":1657,"briefTitle":1658,"status":155,"phases":1659,"primaryCompletion":1660,"completion":1660,"start":1661,"enrollment":1662,"conditions":1663,"interventions":1664},"NCT02783300","An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma",[85],"2023-08-30","2016-08-30",297,[107],[1665,137],"GSK3326595",{"nctId":1667,"briefTitle":1668,"status":155,"phases":1669,"primaryCompletion":1670,"completion":1670,"start":1671,"enrollment":1672,"conditions":1673,"interventions":1674},"NCT02528357","GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1)",[85],"2020-04-29","2015-09-11",141,[107],[163,137],{"nctId":153,"briefTitle":154,"status":155,"phases":1676,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":1677,"interventions":1678},[85],[107],[162,163,137,164,165,166,167,168,92,169,170],{"nctId":1680,"briefTitle":1681,"status":155,"phases":1682,"primaryCompletion":1683,"completion":1684,"start":1685,"enrollment":1686,"conditions":1687,"interventions":1688},"NCT03447314","Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors",[85],"2020-07-01","2022-03-11","2018-03-26",54,[107],[1689,163,1690,137],"GSK1795091","GSK3359609",{"trials":1692,"activeCount":660,"soonestReadout":263},[1693,1702,1706,1710,1714,1725,1729],{"nctId":1694,"briefTitle":1695,"status":500,"phases":1696,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":97,"conditions":1699,"interventions":1700},"NCT03697824","Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and\u002For LAGE-1a",[86],"2022-07-18","2019-02-25",[107],[1701,137,1651,1241],"GSK3377794",{"nctId":1169,"briefTitle":1170,"status":155,"phases":1703,"primaryCompletion":1172,"completion":1173,"start":1116,"enrollment":212,"conditions":1704,"interventions":1705},[85,86],[278],[1176,137],{"nctId":260,"briefTitle":261,"status":101,"phases":1707,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":1708,"interventions":1709},[86],[267],[137,92,119,120],{"nctId":286,"briefTitle":287,"status":145,"phases":1711,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":1712,"interventions":1713},[86],[267],[92,137,295],{"nctId":1715,"briefTitle":1716,"status":145,"phases":1717,"primaryCompletion":1718,"completion":1718,"start":1719,"enrollment":1720,"conditions":1721,"interventions":1723},"NCT03681951","First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors",[86],"2019-08-13","2018-11-16",8,[1722],"Neoplasms, Pancreatic",[1724,137],"GSK3145095",{"nctId":339,"briefTitle":340,"status":125,"phases":1726,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":1727,"interventions":1728},[85,86],[267],[137,92,348],{"nctId":1730,"briefTitle":1731,"status":145,"phases":1732,"primaryCompletion":1733,"completion":1734,"start":1735,"enrollment":1736,"conditions":1737,"interventions":1738},"NCT03709706","Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)\u002F LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab",[85,86],"2022-06-27","2022-11-04","2018-12-31",34,[107],[1739,137],"Lete-cel",{"trials":1741,"activeCount":660,"soonestReadout":368},[1742,1746,1759,1763,1775],{"nctId":365,"briefTitle":366,"status":101,"phases":1743,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":1744,"interventions":1745},[87],[267],[92,119,137],{"nctId":1747,"briefTitle":1748,"status":410,"phases":1749,"primaryCompletion":1750,"completion":1750,"start":1751,"enrollment":1752,"conditions":1753,"interventions":1754},"NCT07286266","A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)",[87],"2030-08-21","2026-06-24",450,[647],[1755,216,1756,1757,1758,137,140],"Mocertatug rezetecan","Pegylated liposomal doxorubicin","Topotecan","Gemcitabine",{"nctId":671,"briefTitle":672,"status":155,"phases":1760,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":1761,"interventions":1762},[87],[267],[82,137],{"nctId":1764,"briefTitle":1765,"status":145,"phases":1766,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":1770,"conditions":1771,"interventions":1772},"NCT04428333","Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",[87],"2021-04-27","2023-09-19","2020-08-12",117,[305],[246,137,1773,1774],"Platinum based chemotherapy","Fluorouracil",{"nctId":1776,"briefTitle":1777,"status":145,"phases":1778,"primaryCompletion":1767,"completion":1779,"start":1780,"enrollment":1781,"conditions":1782,"interventions":1783},"NCT04128696","Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",[87],"2023-06-20","2019-11-21",315,[305],[162,137],{"trials":1785,"activeCount":97},[],{"trials":1787,"activeCount":97},[],{"intervention":284,"totalTrials":628,"cells":1789},{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1798,"PHASE3":1812,"PHASE4":1822,"NA":1824},{"trials":1791,"activeCount":97},[],{"trials":1793,"activeCount":97},[1794],{"nctId":1111,"briefTitle":1112,"status":155,"phases":1795,"primaryCompletion":1114,"completion":1115,"start":1116,"enrollment":1117,"conditions":1796,"interventions":1797},[85],[278],[48,1093,283,284],{"trials":1799,"activeCount":593,"soonestReadout":273},[1800,1804,1808],{"nctId":1154,"briefTitle":1155,"status":101,"phases":1801,"primaryCompletion":273,"completion":274,"start":1157,"enrollment":473,"conditions":1802,"interventions":1803},[85,86],[278],[48,280,284,283],{"nctId":270,"briefTitle":271,"status":101,"phases":1805,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":1806,"interventions":1807},[85,86],[278],[48,163,246,280,92,281,282,283,284],{"nctId":1191,"briefTitle":1192,"status":125,"phases":1809,"primaryCompletion":1194,"completion":1194,"start":1195,"enrollment":1196,"conditions":1810,"interventions":1811},[86],[278],[48,283,284,1093,1199],{"trials":1813,"activeCount":660,"soonestReadout":61},[1814,1818],{"nctId":59,"briefTitle":60,"status":101,"phases":1815,"primaryCompletion":61,"completion":1270,"start":1271,"enrollment":1272,"conditions":1816,"interventions":1817},[87],[278],[48,284,283,1093],{"nctId":75,"briefTitle":76,"status":101,"phases":1819,"primaryCompletion":77,"completion":1277,"start":1278,"enrollment":1279,"conditions":1820,"interventions":1821},[87],[278],[48,284,283,1093],{"trials":1823,"activeCount":97},[],{"trials":1825,"activeCount":97},[],{"intervention":119,"totalTrials":1517,"cells":1827},{"EARLY_PHASE1":1828,"PHASE1":1830,"PHASE2":1840,"PHASE3":1850,"PHASE4":1856,"NA":1858},{"trials":1829,"activeCount":97},[],{"trials":1831,"activeCount":660,"soonestReadout":175},[1832,1836],{"nctId":110,"briefTitle":111,"status":101,"phases":1833,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":1834,"interventions":1835},[85],[107],[118,92,119,120,121],{"nctId":172,"briefTitle":173,"status":101,"phases":1837,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":1838,"interventions":1839},[85],[107],[180,92,169,119],{"trials":1841,"activeCount":660,"soonestReadout":300},[1842,1846],{"nctId":260,"briefTitle":261,"status":101,"phases":1843,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":1844,"interventions":1845},[86],[267],[137,92,119,120],{"nctId":297,"briefTitle":298,"status":101,"phases":1847,"primaryCompletion":300,"completion":301,"start":302,"enrollment":303,"conditions":1848,"interventions":1849},[86],[305],[92,119,120,118],{"trials":1851,"activeCount":417,"soonestReadout":368},[1852],{"nctId":365,"briefTitle":366,"status":101,"phases":1853,"primaryCompletion":368,"completion":368,"start":369,"enrollment":370,"conditions":1854,"interventions":1855},[87],[267],[92,119,137],{"trials":1857,"activeCount":97},[],{"trials":1859,"activeCount":97},[],{"intervention":140,"totalTrials":1517,"cells":1861},{"EARLY_PHASE1":1862,"PHASE1":1864,"PHASE2":1892,"PHASE3":1898,"PHASE4":1904,"NA":1906},{"trials":1863,"activeCount":97},[],{"trials":1865,"activeCount":660,"soonestReadout":1885},[1866,1870,1881],{"nctId":123,"briefTitle":124,"status":125,"phases":1867,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":1868,"interventions":1869},[85],[107],[133,134,135,136,137,138,139,140,141,92],{"nctId":1871,"briefTitle":1872,"status":155,"phases":1873,"primaryCompletion":1874,"completion":1874,"start":1875,"enrollment":361,"conditions":1876,"interventions":1878},"NCT00992121","An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma",[85],"2013-11-01","2009-11-18",[1877],"Carcinoma, Renal Cell",[140,1879,1880],"Pazopanib 2 week","Pazopanib 3 week",{"nctId":1882,"briefTitle":1883,"status":125,"phases":1884,"primaryCompletion":1885,"completion":1886,"start":1887,"enrollment":719,"conditions":1888,"interventions":1889},"NCT07277270","A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors",[85],"2026-07-13","2028-09-29","2025-12-03",[107],[121,140,1774,1890,1891],"leucovorin","Enzalutamide",{"trials":1893,"activeCount":417,"soonestReadout":353},[1894],{"nctId":350,"briefTitle":351,"status":125,"phases":1895,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":1896,"interventions":1897},[85,86],[358],[360,92,140],{"trials":1899,"activeCount":417,"soonestReadout":1750},[1900],{"nctId":1747,"briefTitle":1748,"status":410,"phases":1901,"primaryCompletion":1750,"completion":1750,"start":1751,"enrollment":1752,"conditions":1902,"interventions":1903},[87],[647],[1755,216,1756,1757,1758,137,140],{"trials":1905,"activeCount":97},[],{"trials":1907,"activeCount":97},[],{"intervention":1909,"totalTrials":1517,"cells":1910},"Hepatitis A vaccine",{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1935,"PHASE4":1985,"NA":1987},{"trials":1912,"activeCount":97},[],{"trials":1914,"activeCount":97},[],{"trials":1916,"activeCount":97},[1917],{"nctId":1918,"briefTitle":1919,"status":155,"phases":1920,"primaryCompletion":1921,"completion":1922,"start":1923,"enrollment":1924,"conditions":1925,"interventions":1927},"NCT05084508","A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age",[86],"2024-02-09","2024-06-13","2022-02-03",800,[1926],"Chickenpox",[1928,1929,1930,1931,1932,1933,1909,1934],"Investigational varicella vaccine low potency","Investigational varicella vaccine medium potency","Investigational varicella vaccine high potency","Licensed varicella vaccine Lot 1","Licensed varicella vaccine Lot 2","Measles, mumps, and rubella vaccine","13-valent pneumococcal conjugate vaccine",{"trials":1936,"activeCount":181,"soonestReadout":1972},[1937,1953,1968,1977],{"nctId":1938,"briefTitle":1939,"status":125,"phases":1940,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1944,"conditions":1945,"interventions":1946},"NCT06806137","A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age",[87],"2026-12-14","2027-05-03","2025-05-15",600,[1926],[1947,1948,1949,1909,1950,1951,1952],"Investigational varicella vaccine","Marketed varicella vaccine","MMR vaccine","PCV (pneumococcal conjugate vaccine) 13","PCV 20","Vaxneuvance",{"nctId":1954,"briefTitle":1955,"status":125,"phases":1956,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":1960,"conditions":1961,"interventions":1962},"NCT06740630","A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age",[87],"2026-12-25","2027-05-17","2025-01-10",1840,[1926],[1963,1964,1965,1966,1967,1949,1909,1950,1951,1952],"Investigational varicella vaccine_Lot 1","Investigational varicella vaccine_Lot 2","Investigational varicella vaccine_Lot 3","Marketed varicella vaccine_Lot 1","Marketed varicella vaccine_Lot 2",{"nctId":1969,"briefTitle":1970,"status":125,"phases":1971,"primaryCompletion":1972,"completion":368,"start":273,"enrollment":1973,"conditions":1974,"interventions":1975},"NCT06855160","A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age",[87],"2026-09-10",911,[1926],[1976,1948,1949,1909,1950,1951,1952],"Candidate varicella vaccine",{"nctId":1978,"briefTitle":1979,"status":125,"phases":1980,"primaryCompletion":198,"completion":198,"start":1981,"enrollment":1982,"conditions":1983,"interventions":1984},"NCT06693895","A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age",[87],"2024-11-26",750,[1926],[1947,1948,1933,1909,1950,1951,1952],{"trials":1986,"activeCount":97},[],{"trials":1988,"activeCount":97},[],{"intervention":282,"totalTrials":1517,"cells":1990},{"EARLY_PHASE1":1991,"PHASE1":1993,"PHASE2":1999,"PHASE3":2013,"PHASE4":2019,"NA":2021},{"trials":1992,"activeCount":97},[],{"trials":1994,"activeCount":417,"soonestReadout":1132},[1995],{"nctId":1129,"briefTitle":1130,"status":101,"phases":1996,"primaryCompletion":1132,"completion":175,"start":1133,"enrollment":1134,"conditions":1997,"interventions":1998},[85],[278],[48,1093,282,283],{"trials":2000,"activeCount":660,"soonestReadout":273},[2001,2005,2009],{"nctId":1144,"briefTitle":1145,"status":155,"phases":2002,"primaryCompletion":1147,"completion":1148,"start":1149,"enrollment":1150,"conditions":2003,"interventions":2004},[85,86],[278],[48,282,283,1093],{"nctId":270,"briefTitle":271,"status":101,"phases":2006,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":2007,"interventions":2008},[85,86],[278],[48,163,246,280,92,281,282,283,284],{"nctId":1218,"briefTitle":1219,"status":101,"phases":2010,"primaryCompletion":273,"completion":274,"start":1221,"enrollment":454,"conditions":2011,"interventions":2012},[85,86],[278],[48,280,282,283],{"trials":2014,"activeCount":417,"soonestReadout":1305},[2015],{"nctId":1302,"briefTitle":1303,"status":125,"phases":2016,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":2017,"interventions":2018},[87],[278,1309],[48,282,283,1267],{"trials":2020,"activeCount":97},[],{"trials":2022,"activeCount":97},[],{"intervention":2024,"totalTrials":181,"cells":2025},"Efimosfermin alfa",{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2048,"PHASE3":2050,"PHASE4":2072,"NA":2074},{"trials":2027,"activeCount":97},[],{"trials":2029,"activeCount":660,"soonestReadout":2034},[2030,2039],{"nctId":2031,"briefTitle":2032,"status":125,"phases":2033,"primaryCompletion":2034,"completion":2034,"start":2035,"enrollment":255,"conditions":2036,"interventions":2038},"NCT07335198","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Efimosfermin Alfa Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and White\u002FEuropean Ancestry",[85],"2026-08-17","2026-03-05",[2037],"Non-alcoholic Fatty Liver Disease",[2024],{"nctId":2040,"briefTitle":2041,"status":125,"phases":2042,"primaryCompletion":2043,"completion":2043,"start":2044,"enrollment":2045,"conditions":2046,"interventions":2047},"NCT07358546","A Study of Efimosfermin Alfa in Adults With Hepatic Impairment",[85],"2027-10-13","2026-03-13",32,[2037],[2024],{"trials":2049,"activeCount":97},[],{"trials":2051,"activeCount":660,"soonestReadout":2056},[2052,2062],{"nctId":2053,"briefTitle":2054,"status":125,"phases":2055,"primaryCompletion":2056,"completion":2056,"start":2057,"enrollment":2058,"conditions":2059,"interventions":2060},"NCT07221188","A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH",[87],"2028-03-24","2025-12-12",1250,[2037],[2061],"Efimosfermin Alfa",{"nctId":2063,"briefTitle":2064,"status":125,"phases":2065,"primaryCompletion":2066,"completion":2067,"start":2068,"enrollment":2069,"conditions":2070,"interventions":2071},"NCT07221227","A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH",[87],"2028-03-29","2031-12-12","2025-10-24",1200,[2037],[2024,2024],{"trials":2073,"activeCount":97},[],{"trials":2075,"activeCount":97},[],{"intervention":133,"totalTrials":181,"cells":2077},{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2086,"PHASE3":2112,"PHASE4":2125,"NA":2127},{"trials":2079,"activeCount":97},[],{"trials":2081,"activeCount":417,"soonestReadout":127},[2082],{"nctId":123,"briefTitle":124,"status":125,"phases":2083,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":2084,"interventions":2085},[85],[107],[133,134,135,136,137,138,139,140,141,92],{"trials":2087,"activeCount":660,"soonestReadout":2104},[2088,2100],{"nctId":2089,"briefTitle":2090,"status":410,"phases":2091,"primaryCompletion":2092,"completion":2093,"start":2094,"enrollment":2095,"conditions":2096,"interventions":2098},"NCT07602855","A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)",[85,86],"2029-07-05","2030-01-04","2026-09-08",184,[2097],"Solid Tumors",[133,2099],"Ivonescimab",{"nctId":2101,"briefTitle":2102,"status":410,"phases":2103,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":2107,"conditions":2108,"interventions":2110},"NCT07602777","A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcoma-202)",[85,86],"2027-12-10","2029-12-17","2026-07-14",113,[2109],"Sarcoma",[133,2111],"G-CSF",{"trials":2113,"activeCount":417,"soonestReadout":2118},[2114],{"nctId":2115,"briefTitle":2116,"status":125,"phases":2117,"primaryCompletion":2118,"completion":2119,"start":2120,"enrollment":2121,"conditions":2122,"interventions":2124},"NCT07099898","A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)",[87],"2027-11-05","2029-09-28","2025-08-11",420,[2123],"Neoplasms, Lung",[133,1757],{"trials":2126,"activeCount":97},[],{"trials":2128,"activeCount":97},[],{"intervention":1267,"totalTrials":181,"cells":2130},{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2137,"PHASE4":2155,"NA":2157},{"trials":2132,"activeCount":97},[],{"trials":2134,"activeCount":97},[],{"trials":2136,"activeCount":97},[],{"trials":2138,"activeCount":181,"soonestReadout":57},[2139,2143,2147,2151],{"nctId":63,"briefTitle":64,"status":101,"phases":2140,"primaryCompletion":65,"completion":377,"start":1263,"enrollment":1264,"conditions":2141,"interventions":2142},[87],[278],[48,1267,1093,283],{"nctId":55,"briefTitle":56,"status":101,"phases":2144,"primaryCompletion":57,"completion":377,"start":1292,"enrollment":1293,"conditions":2145,"interventions":2146},[87],[278],[48,1267,1093,283],{"nctId":67,"briefTitle":68,"status":101,"phases":2148,"primaryCompletion":65,"completion":377,"start":1263,"enrollment":1298,"conditions":2149,"interventions":2150},[87],[278],[48,1267,1093,283],{"nctId":1302,"briefTitle":1303,"status":125,"phases":2152,"primaryCompletion":1305,"completion":1305,"start":1306,"enrollment":1307,"conditions":2153,"interventions":2154},[87],[278,1309],[48,282,283,1267],{"trials":2156,"activeCount":97},[],{"trials":2158,"activeCount":97},[],{"intervention":1950,"totalTrials":181,"cells":2160},{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2167,"PHASE4":2185,"NA":2187},{"trials":2162,"activeCount":97},[],{"trials":2164,"activeCount":97},[],{"trials":2166,"activeCount":97},[],{"trials":2168,"activeCount":181,"soonestReadout":1972},[2169,2173,2177,2181],{"nctId":1938,"briefTitle":1939,"status":125,"phases":2170,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1944,"conditions":2171,"interventions":2172},[87],[1926],[1947,1948,1949,1909,1950,1951,1952],{"nctId":1954,"briefTitle":1955,"status":125,"phases":2174,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":1960,"conditions":2175,"interventions":2176},[87],[1926],[1963,1964,1965,1966,1967,1949,1909,1950,1951,1952],{"nctId":1969,"briefTitle":1970,"status":125,"phases":2178,"primaryCompletion":1972,"completion":368,"start":273,"enrollment":1973,"conditions":2179,"interventions":2180},[87],[1926],[1976,1948,1949,1909,1950,1951,1952],{"nctId":1978,"briefTitle":1979,"status":125,"phases":2182,"primaryCompletion":198,"completion":198,"start":1981,"enrollment":1982,"conditions":2183,"interventions":2184},[87],[1926],[1947,1948,1933,1909,1950,1951,1952],{"trials":2186,"activeCount":97},[],{"trials":2188,"activeCount":97},[],{"intervention":1951,"totalTrials":181,"cells":2190},{"EARLY_PHASE1":2191,"PHASE1":2193,"PHASE2":2195,"PHASE3":2197,"PHASE4":2215,"NA":2217},{"trials":2192,"activeCount":97},[],{"trials":2194,"activeCount":97},[],{"trials":2196,"activeCount":97},[],{"trials":2198,"activeCount":181,"soonestReadout":1972},[2199,2203,2207,2211],{"nctId":1938,"briefTitle":1939,"status":125,"phases":2200,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1944,"conditions":2201,"interventions":2202},[87],[1926],[1947,1948,1949,1909,1950,1951,1952],{"nctId":1954,"briefTitle":1955,"status":125,"phases":2204,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":1960,"conditions":2205,"interventions":2206},[87],[1926],[1963,1964,1965,1966,1967,1949,1909,1950,1951,1952],{"nctId":1969,"briefTitle":1970,"status":125,"phases":2208,"primaryCompletion":1972,"completion":368,"start":273,"enrollment":1973,"conditions":2209,"interventions":2210},[87],[1926],[1976,1948,1949,1909,1950,1951,1952],{"nctId":1978,"briefTitle":1979,"status":125,"phases":2212,"primaryCompletion":198,"completion":198,"start":1981,"enrollment":1982,"conditions":2213,"interventions":2214},[87],[1926],[1947,1948,1933,1909,1950,1951,1952],{"trials":2216,"activeCount":97},[],{"trials":2218,"activeCount":97},[],{"intervention":1952,"totalTrials":181,"cells":2220},{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2227,"PHASE4":2245,"NA":2247},{"trials":2222,"activeCount":97},[],{"trials":2224,"activeCount":97},[],{"trials":2226,"activeCount":97},[],{"trials":2228,"activeCount":181,"soonestReadout":1972},[2229,2233,2237,2241],{"nctId":1938,"briefTitle":1939,"status":125,"phases":2230,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1944,"conditions":2231,"interventions":2232},[87],[1926],[1947,1948,1949,1909,1950,1951,1952],{"nctId":1954,"briefTitle":1955,"status":125,"phases":2234,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":1960,"conditions":2235,"interventions":2236},[87],[1926],[1963,1964,1965,1966,1967,1949,1909,1950,1951,1952],{"nctId":1969,"briefTitle":1970,"status":125,"phases":2238,"primaryCompletion":1972,"completion":368,"start":273,"enrollment":1973,"conditions":2239,"interventions":2240},[87],[1926],[1976,1948,1949,1909,1950,1951,1952],{"nctId":1978,"briefTitle":1979,"status":125,"phases":2242,"primaryCompletion":198,"completion":198,"start":1981,"enrollment":1982,"conditions":2243,"interventions":2244},[87],[1926],[1947,1948,1933,1909,1950,1951,1952],{"trials":2246,"activeCount":97},[],{"trials":2248,"activeCount":97},[],{"intervention":216,"totalTrials":454,"cells":2250},{"EARLY_PHASE1":2251,"PHASE1":2253,"PHASE2":2289,"PHASE3":2398,"PHASE4":2433,"NA":2435},{"trials":2252,"activeCount":97},[],{"trials":2254,"activeCount":97},[2255,2265,2276],{"nctId":2256,"briefTitle":2257,"status":155,"phases":2258,"primaryCompletion":2259,"completion":2259,"start":2260,"enrollment":255,"conditions":2261,"interventions":2262},"NCT00866528","Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer",[85],"2012-10-25","2009-07-09",[267],[2263,2264],"pazopanib","paclitaxel",{"nctId":2266,"briefTitle":2267,"status":155,"phases":2268,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":34,"conditions":2271,"interventions":2272},"NCT00388076","Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)",[85],"2009-07-21","2006-04-28",[668],[2273,2274,2264,2275],"Pazopanib","Lapatinib","carboplatin",{"nctId":2277,"briefTitle":2278,"status":155,"phases":2279,"primaryCompletion":2280,"completion":2280,"start":2281,"enrollment":2282,"conditions":2283,"interventions":2284},"NCT01868022","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",[85],"2017-10-24","2013-10-09",65,[107],[2285,2264,2275,2286,2287,2288],"GSK3052230","docetaxel","pemetrexed","cisplatin",{"trials":2290,"activeCount":660,"soonestReadout":210},[2291,2305,2315,2331,2340,2347,2351,2365,2369,2378,2388],{"nctId":2292,"briefTitle":2293,"status":155,"phases":2294,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":2297,"conditions":2298,"interventions":2299},"NCT00429299","Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer",[86],"2012-06","2006-08",121,[668],[2300,2301,2264,2302,2303,2304],"lapatinib","trastuzumab","fluorouracil","epidoxorubicin","cyclophosphamide",{"nctId":2306,"briefTitle":2307,"status":155,"phases":2308,"primaryCompletion":2309,"completion":2310,"start":2311,"enrollment":93,"conditions":2312,"interventions":2313},"NCT03693612","GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors",[85,86],"2021-06-25","2021-09-16","2018-11-26",[107],[162,2314,164,216,139],"Tremelimumab",{"nctId":2316,"briefTitle":2317,"status":145,"phases":2318,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":2322,"interventions":2323},"NCT01220128","Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer",[86],"2014-11-14","2011-04-11",66,[668],[2324,2325,2326,2327,1241,164,2328,2329,216,2330],"GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A","Aromatase inhibitor","5-Fluorouracil","Carboplatin AUC","Doxorubicin","Epirubicin","Trastuzumab",{"nctId":2332,"briefTitle":2333,"status":155,"phases":2334,"primaryCompletion":2335,"completion":482,"start":2336,"enrollment":414,"conditions":2337,"interventions":2338},"NCT00524303","Lapatinib +\u002F- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.",[86],"2010-10","2007-08",[668],[2330,216,2339,2274],"FEC75",{"nctId":2341,"briefTitle":2342,"status":500,"phases":2343,"primaryCompletion":2344,"completion":2344,"start":2344,"enrollment":97,"conditions":2345,"interventions":2346},"NCT01205217","Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer",[86],"2010-12",[668],[2274,2330,2329,1241,216],{"nctId":207,"briefTitle":208,"status":101,"phases":2348,"primaryCompletion":210,"completion":113,"start":211,"enrollment":212,"conditions":2349,"interventions":2350},[86],[214],[92,135,216],{"nctId":2352,"briefTitle":2353,"status":155,"phases":2354,"primaryCompletion":2355,"completion":2355,"start":2356,"enrollment":1459,"conditions":2357,"interventions":2364},"NCT00561795","Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors",[86],"2008-04","2007-09",[2358,2359,2360,2361,2362,2363,36],"Primary Peritoneal Carcinoma","Tumor","Epithelial Ovarian Cancer","Uterine Disease","Cervix Diseases","Neoplasms, Ovarian",[2263,2275,2264],{"nctId":250,"briefTitle":251,"status":125,"phases":2366,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":2367,"interventions":2368},[86],[257],[92,135,216],{"nctId":2370,"briefTitle":2371,"status":155,"phases":2372,"primaryCompletion":2373,"completion":2373,"start":2374,"enrollment":2375,"conditions":2376,"interventions":2377},"NCT00111787","Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer",[86],"2006-11-01","2005-04-11",49,[668],[2274,216],{"nctId":2379,"briefTitle":2380,"status":155,"phases":2381,"primaryCompletion":2382,"completion":827,"start":2383,"enrollment":2384,"conditions":2385,"interventions":2386},"NCT00356811","Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer",[86],"2008-03","2006-05",57,[668],[2387,216],"Lapatinib oral",{"nctId":2389,"briefTitle":2390,"status":500,"phases":2391,"primaryCompletion":2392,"completion":2393,"start":2394,"enrollment":97,"conditions":2395,"interventions":2396},"NCT01137994","A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer",[86],"2016-12","2018-03","2011-10",[668],[2274,2330,164,216,2397],"Vinorelbine",{"trials":2399,"activeCount":660,"soonestReadout":2414},[2400,2410,2419,2423],{"nctId":2401,"briefTitle":2402,"status":155,"phases":2403,"primaryCompletion":2404,"completion":728,"start":2405,"enrollment":2406,"conditions":2407,"interventions":2408},"NCT00075270","Paclitaxel With \u002F Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer",[87],"2006-10","2004-01",580,[668],[216,2409],"GW572016",{"nctId":2411,"briefTitle":2412,"status":410,"phases":2413,"primaryCompletion":2414,"completion":2415,"start":2416,"enrollment":1944,"conditions":2417,"interventions":2418},"NCT07286331","A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)",[87],"2028-02-29","2029-05-30","2026-06-09",[257],[1755,216,2328],{"nctId":1747,"briefTitle":1748,"status":410,"phases":2420,"primaryCompletion":1750,"completion":1750,"start":1751,"enrollment":1752,"conditions":2421,"interventions":2422},[87],[647],[1755,216,1756,1757,1758,137,140],{"nctId":2424,"briefTitle":2425,"status":155,"phases":2426,"primaryCompletion":2427,"completion":828,"start":2428,"enrollment":2429,"conditions":2430,"interventions":2432},"NCT00486954","Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer",[87],"2012-01","2007-07",273,[2431],"Neoplasms, Gastrointestinal Tract",[2274,216],{"trials":2434,"activeCount":97},[],{"trials":2436,"activeCount":97},[2437,2447],{"nctId":2438,"briefTitle":2439,"status":155,"phases":2440,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":417,"conditions":2443,"interventions":2445},"NCT01160185","Meta-analysis of Efficacy of Topotecan",[],"2009-07","2009-06",[2444],"Cervical Intraepithelial Neoplasia",[2264,2288,2446],"topotecan",{"nctId":2448,"briefTitle":2449,"status":155,"phases":2450,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":417,"conditions":2451,"interventions":2452},"NCT01345279","Indirect Comparison Topotecan Cervical Carcinoma",[],[2444],[2288,2446,2264],{"intervention":1949,"totalTrials":181,"cells":2454},{"EARLY_PHASE1":2455,"PHASE1":2457,"PHASE2":2459,"PHASE3":2461,"PHASE4":2475,"NA":2488},{"trials":2456,"activeCount":97},[],{"trials":2458,"activeCount":97},[],{"trials":2460,"activeCount":97},[],{"trials":2462,"activeCount":593,"soonestReadout":1972},[2463,2467,2471],{"nctId":1938,"briefTitle":1939,"status":125,"phases":2464,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1944,"conditions":2465,"interventions":2466},[87],[1926],[1947,1948,1949,1909,1950,1951,1952],{"nctId":1954,"briefTitle":1955,"status":125,"phases":2468,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":1960,"conditions":2469,"interventions":2470},[87],[1926],[1963,1964,1965,1966,1967,1949,1909,1950,1951,1952],{"nctId":1969,"briefTitle":1970,"status":125,"phases":2472,"primaryCompletion":1972,"completion":368,"start":273,"enrollment":1973,"conditions":2473,"interventions":2474},[87],[1926],[1976,1948,1949,1909,1950,1951,1952],{"trials":2476,"activeCount":97},[2477],{"nctId":2478,"briefTitle":2479,"status":155,"phases":2480,"primaryCompletion":2481,"completion":2481,"start":2482,"enrollment":1579,"conditions":2483,"interventions":2487},"NCT00388440","Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.",[88],"2001-04","2000-11",[2484,2485,2486],"Rubella","Mumps","Measles",[1949],{"trials":2489,"activeCount":97},[],{"intervention":169,"totalTrials":181,"cells":2491},{"EARLY_PHASE1":2492,"PHASE1":2494,"PHASE2":2504,"PHASE3":2510,"PHASE4":2516,"NA":2518},{"trials":2493,"activeCount":97},[],{"trials":2495,"activeCount":417,"soonestReadout":175},[2496,2500],{"nctId":153,"briefTitle":154,"status":155,"phases":2497,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":2498,"interventions":2499},[85],[107],[162,163,137,164,165,166,167,168,92,169,170],{"nctId":172,"briefTitle":173,"status":101,"phases":2501,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":2502,"interventions":2503},[85],[107],[180,92,169,119],{"trials":2505,"activeCount":417,"soonestReadout":321},[2506],{"nctId":318,"briefTitle":319,"status":101,"phases":2507,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":2508,"interventions":2509},[85,86],[325,326,327,328,329,330,331,332,333,334,335,336],[169,92],{"trials":2511,"activeCount":417,"soonestReadout":387},[2512],{"nctId":384,"briefTitle":385,"status":101,"phases":2513,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":2514,"interventions":2515},[87],[267],[169,92,164],{"trials":2517,"activeCount":97},[],{"trials":2519,"activeCount":97},[],{"intervention":1948,"totalTrials":593,"cells":2521},{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2542,"NA":2544},{"trials":2523,"activeCount":97},[],{"trials":2525,"activeCount":97},[],{"trials":2527,"activeCount":97},[],{"trials":2529,"activeCount":593,"soonestReadout":1972},[2530,2534,2538],{"nctId":1938,"briefTitle":1939,"status":125,"phases":2531,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1944,"conditions":2532,"interventions":2533},[87],[1926],[1947,1948,1949,1909,1950,1951,1952],{"nctId":1969,"briefTitle":1970,"status":125,"phases":2535,"primaryCompletion":1972,"completion":368,"start":273,"enrollment":1973,"conditions":2536,"interventions":2537},[87],[1926],[1976,1948,1949,1909,1950,1951,1952],{"nctId":1978,"briefTitle":1979,"status":125,"phases":2539,"primaryCompletion":198,"completion":198,"start":1981,"enrollment":1982,"conditions":2540,"interventions":2541},[87],[1926],[1947,1948,1933,1909,1950,1951,1952],{"trials":2543,"activeCount":97},[],{"trials":2545,"activeCount":97},[],{"intervention":2547,"totalTrials":181,"cells":2548},"Momelotinib",{"EARLY_PHASE1":2549,"PHASE1":2551,"PHASE2":2553,"PHASE3":2576,"PHASE4":2589,"NA":2591},{"trials":2550,"activeCount":97},[],{"trials":2552,"activeCount":97},[],{"trials":2554,"activeCount":660,"soonestReadout":2559},[2555,2567],{"nctId":2556,"briefTitle":2557,"status":125,"phases":2558,"primaryCompletion":2559,"completion":2560,"start":2561,"enrollment":37,"conditions":2562,"interventions":2565},"NCT06517875","Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis",[86],"2027-03-19","2028-03-17","2025-02-28",[2563,2564],"Primary Myelofibrosis","Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis",[2547,2566],"Luspatercept",{"nctId":2568,"briefTitle":2569,"status":125,"phases":2570,"primaryCompletion":2571,"completion":2572,"start":387,"enrollment":526,"conditions":2573,"interventions":2575},"NCT06847867","A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome",[86],"2027-07-14","2027-12-29",[2574],"Myelodysplastic Syndromes",[2547],{"trials":2577,"activeCount":417,"soonestReadout":2582},[2578],{"nctId":2579,"briefTitle":2580,"status":410,"phases":2581,"primaryCompletion":2582,"completion":2583,"start":2584,"enrollment":849,"conditions":2585,"interventions":2587},"NCT07569081","A Study Evaluating the Efficacy and Safety of Momelotinib in Participants With Vacuoles, E1-enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome",[86,87],"2028-12-06","2031-06-04","2026-08-05",[2586],"VEXAS Syndrome",[2547,2588],"Glucocorticoids",{"trials":2590,"activeCount":97},[],{"trials":2592,"activeCount":97},[2593],{"nctId":2594,"briefTitle":2595,"status":969,"phases":2596,"conditions":2597,"interventions":2599},"NCT05582083","Managed Access Program for Momelotinib in Myelofibrosis",[],[2598,2563],"Myelofibrosis",[2547],{"intervention":2601,"totalTrials":181,"cells":2602},"RSVPreF3 OA vaccine",{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2609,"PHASE4":2650,"NA":2652},{"trials":2604,"activeCount":97},[],{"trials":2606,"activeCount":97},[],{"trials":2608,"activeCount":97},[],{"trials":2610,"activeCount":660,"soonestReadout":2645},[2611,2622,2631,2641],{"nctId":2612,"briefTitle":2613,"status":155,"phases":2614,"primaryCompletion":2615,"completion":2616,"start":2617,"enrollment":2618,"conditions":2619,"interventions":2621},"NCT04886596","Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above",[87],"2022-04-11","2024-05-31","2021-05-25",26675,[2620],"Respiratory Syncytial Virus Infections",[2601],{"nctId":2623,"briefTitle":2624,"status":101,"phases":2625,"primaryCompletion":2626,"completion":2626,"start":2627,"enrollment":2628,"conditions":2629,"interventions":2630},"NCT06534892","An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study",[87],"2026-09-30","2024-08-01",10212,[2620],[2601],{"nctId":2632,"briefTitle":2633,"status":155,"phases":2634,"primaryCompletion":2635,"completion":2636,"start":264,"enrollment":2637,"conditions":2638,"interventions":2639},"NCT05568797","A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above",[87],"2023-02-17","2023-07-17",1045,[2620],[2601,2640],"FLU vaccine",{"nctId":2642,"briefTitle":2643,"status":125,"phases":2644,"primaryCompletion":2645,"completion":2646,"start":2647,"enrollment":1982,"conditions":2648,"interventions":2649},"NCT07220109","A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease",[87],"2026-09-25","2027-03-12","2025-10-29",[2620],[2601],{"trials":2651,"activeCount":97},[],{"trials":2653,"activeCount":97},[],{"intervention":205,"totalTrials":593,"cells":2655},{"EARLY_PHASE1":2656,"PHASE1":2658,"PHASE2":2671,"PHASE3":2677,"PHASE4":2683,"NA":2685},{"trials":2657,"activeCount":97},[],{"trials":2659,"activeCount":97},[2660],{"nctId":2661,"briefTitle":2662,"status":155,"phases":2663,"primaryCompletion":2664,"completion":2664,"start":2665,"enrollment":1003,"conditions":2666,"interventions":2668},"NCT00387387","Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin)",[85],"2009-08-14","2006-10-20",[2667],"Neoplasms, Colorectal",[2273,2669,2670],"FOLFOX 6","CapeOx",{"trials":2672,"activeCount":417,"soonestReadout":198},[2673],{"nctId":195,"briefTitle":196,"status":125,"phases":2674,"primaryCompletion":198,"completion":199,"start":200,"enrollment":201,"conditions":2675,"interventions":2676},[86],[203],[92,205],{"trials":2678,"activeCount":417,"soonestReadout":397},[2679],{"nctId":394,"briefTitle":395,"status":125,"phases":2680,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":2681,"interventions":2682},[87],[402,203],[92,205,404],{"trials":2684,"activeCount":97},[],{"trials":2686,"activeCount":97},[],{"intervention":1755,"totalTrials":660,"cells":2688},{"EARLY_PHASE1":2689,"PHASE1":2691,"PHASE2":2693,"PHASE3":2695,"PHASE4":2705,"NA":2707},{"trials":2690,"activeCount":97},[],{"trials":2692,"activeCount":97},[],{"trials":2694,"activeCount":97},[],{"trials":2696,"activeCount":660,"soonestReadout":2414},[2697,2701],{"nctId":2411,"briefTitle":2412,"status":410,"phases":2698,"primaryCompletion":2414,"completion":2415,"start":2416,"enrollment":1944,"conditions":2699,"interventions":2700},[87],[257],[1755,216,2328],{"nctId":1747,"briefTitle":1748,"status":410,"phases":2702,"primaryCompletion":1750,"completion":1750,"start":1751,"enrollment":1752,"conditions":2703,"interventions":2704},[87],[647],[1755,216,1756,1757,1758,137,140],{"trials":2706,"activeCount":97},[],{"trials":2708,"activeCount":97},[],{"intervention":1947,"totalTrials":660,"cells":2710},{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2715,"PHASE3":2717,"PHASE4":2727,"NA":2729},{"trials":2712,"activeCount":97},[],{"trials":2714,"activeCount":97},[],{"trials":2716,"activeCount":97},[],{"trials":2718,"activeCount":660,"soonestReadout":198},[2719,2723],{"nctId":1938,"briefTitle":1939,"status":125,"phases":2720,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1944,"conditions":2721,"interventions":2722},[87],[1926],[1947,1948,1949,1909,1950,1951,1952],{"nctId":1978,"briefTitle":1979,"status":125,"phases":2724,"primaryCompletion":198,"completion":198,"start":1981,"enrollment":1982,"conditions":2725,"interventions":2726},[87],[1926],[1947,1948,1933,1909,1950,1951,1952],{"trials":2728,"activeCount":97},[],{"trials":2730,"activeCount":97},[],{"intervention":2446,"totalTrials":421,"cells":2732},{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2788,"PHASE3":2849,"PHASE4":2874,"NA":2876},{"trials":2734,"activeCount":97},[],{"trials":2736,"activeCount":97},[2737,2745,2753,2763,2771,2780],{"nctId":2738,"briefTitle":2739,"status":155,"phases":2740,"primaryCompletion":2741,"completion":2741,"start":2742,"enrollment":1117,"conditions":2743,"interventions":2744},"NCT00361803","Topotecan Pharmacokinetic Characterization Study",[85],"2007-08-09","2006-09-12",[36],[2446],{"nctId":2746,"briefTitle":2747,"status":145,"phases":2748,"primaryCompletion":2749,"completion":2749,"start":2750,"enrollment":93,"conditions":2751,"interventions":2752},"NCT00158886","Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer",[85],"2006-08-11","2001-11-08",[1877],[1757],{"nctId":2754,"briefTitle":2755,"status":155,"phases":2756,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":2760,"interventions":2762},"NCT00483860","A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function",[85],"2012-02-06","2007-06-20",59,[2761],"Solid Tumours",[1757],{"nctId":2764,"briefTitle":2765,"status":155,"phases":2766,"primaryCompletion":2767,"completion":2767,"start":2768,"enrollment":37,"conditions":2769,"interventions":2770},"NCT00732420","Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors",[85],"2013-06-12","2008-09-24",[2761],[2446,2263],{"nctId":2772,"briefTitle":2773,"status":155,"phases":2774,"primaryCompletion":2775,"completion":2775,"start":2776,"enrollment":417,"conditions":2777,"interventions":2779},"NCT00046111","A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors",[85],"2004-04","2001-09",[2778,1431],"Lung Cancer, Small Cell",[2446],{"nctId":2781,"briefTitle":2782,"status":155,"phases":2783,"primaryCompletion":2784,"completion":2784,"start":2785,"enrollment":177,"conditions":2786,"interventions":2787},"NCT00259935","A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors",[85],"2007-07-05","2004-10-04",[2778],[2446],{"trials":2789,"activeCount":97},[2790,2800,2809,2819,2830,2840],{"nctId":2791,"briefTitle":2792,"status":155,"phases":2793,"primaryCompletion":2794,"completion":2795,"start":2796,"enrollment":2797,"conditions":2798,"interventions":2799},"NCT00316186","First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin",[86],"2009-03","2009-05","2005-06",33,[2778],[2446,2275],{"nctId":2801,"briefTitle":2802,"status":155,"phases":2803,"primaryCompletion":2804,"completion":2804,"start":2805,"enrollment":730,"conditions":2806,"interventions":2808},"NCT00267488","Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer",[86],"2007-12","2005-10",[257,2807],"Endometrial Cancer",[2446],{"nctId":2810,"briefTitle":2811,"status":155,"phases":2812,"primaryCompletion":2813,"completion":2794,"start":2814,"enrollment":624,"conditions":2815,"interventions":2817},"NCT00316173","Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer",[86],"2009-01","2005-03",[2816,2363],"Ovarian Cancer",[2446,2818],"CARBOPLATIN",{"nctId":2820,"briefTitle":2821,"status":155,"phases":2822,"primaryCompletion":2823,"start":2824,"enrollment":2825,"conditions":2826,"interventions":2829},"NCT00061308","Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer",[86],"2004-09","2002-12",75,[2827,2816,2363,2828],"Peritoneal Cancer","Fallopian Tube Cancer",[1757,1758],{"nctId":2831,"briefTitle":2832,"status":145,"phases":2833,"primaryCompletion":2813,"completion":2834,"start":2835,"enrollment":2836,"conditions":2837,"interventions":2838},"NCT00437073","Brain Metastases In ErbB2-Positive Breast Cancer",[86],"2010-02","2007-05",22,[668],[2839,2446,2300],"capecitabine",{"nctId":2841,"briefTitle":2842,"status":155,"phases":2843,"primaryCompletion":2844,"start":2845,"enrollment":1237,"conditions":2846,"interventions":2848},"NCT00043862","The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)",[86],"2005-11","2002-08",[2778,2847],"Small Cell Lung Cancer",[2446],{"trials":2850,"activeCount":660,"soonestReadout":2118},[2851,2860,2864,2870],{"nctId":2852,"briefTitle":2853,"status":155,"phases":2854,"primaryCompletion":2775,"start":2855,"enrollment":2856,"conditions":2857,"interventions":2859},"NCT00049998","Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer",[87],"2001-10",760,[2858],"Non-Small-Cell Lung Cancer",[2446],{"nctId":1747,"briefTitle":1748,"status":410,"phases":2861,"primaryCompletion":1750,"completion":1750,"start":1751,"enrollment":1752,"conditions":2862,"interventions":2863},[87],[647],[1755,216,1756,1757,1758,137,140],{"nctId":2865,"briefTitle":2866,"status":155,"phases":2867,"start":2482,"enrollment":1672,"conditions":2868,"interventions":2869},"NCT00276276","Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer",[87],[2778],[2446],{"nctId":2115,"briefTitle":2116,"status":125,"phases":2871,"primaryCompletion":2118,"completion":2119,"start":2120,"enrollment":2121,"conditions":2872,"interventions":2873},[87],[2123],[133,1757],{"trials":2875,"activeCount":97},[],{"trials":2877,"activeCount":97},[2878,2886,2890],{"nctId":2879,"briefTitle":2880,"status":155,"phases":2881,"primaryCompletion":2882,"completion":2882,"start":2335,"enrollment":2883,"conditions":2884,"interventions":2885},"NCT01037023","Regulatory Hycamtin(Oral) PMS",[],"2014-11",92,[2778],[1757],{"nctId":2438,"briefTitle":2439,"status":155,"phases":2887,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":417,"conditions":2888,"interventions":2889},[],[2444],[2264,2288,2446],{"nctId":2448,"briefTitle":2449,"status":155,"phases":2891,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":417,"conditions":2892,"interventions":2893},[],[2444],[2288,2446,2264],{"intervention":2895,"totalTrials":750,"cells":2896},"FF\u002FUMEC\u002FVI",{"EARLY_PHASE1":2897,"PHASE1":2899,"PHASE2":2901,"PHASE3":2903,"PHASE4":2943,"NA":3002},{"trials":2898,"activeCount":97},[],{"trials":2900,"activeCount":97},[],{"trials":2902,"activeCount":97},[],{"trials":2904,"activeCount":417,"soonestReadout":2939},[2905,2917,2925,2935],{"nctId":2906,"briefTitle":2907,"status":155,"phases":2908,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":2912,"interventions":2913},"NCT02729051","Comparative Study of Fluticasone Furoate(FF)\u002FUmeclidinium Bromide (UMEC)\u002F Vilanterol (VI) Closed Therapy Versus FF\u002FVI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2017-05-23","2016-06-29",1055,[15],[2895,2914,2915,2916],"FF\u002FVI","UMEC","Albuterol\u002Fsalbutamol",{"nctId":2918,"briefTitle":2919,"status":155,"phases":2920,"primaryCompletion":2921,"completion":2921,"start":1204,"enrollment":2922,"conditions":2923,"interventions":2924},"NCT04937387","Efficacy and Safety of Fluticasone Furoate\u002FUmeclidinium\u002FVilanterol (FF\u002FUMEC\u002FVI) in Chinese Participants With Inadequately Controlled Asthma",[87],"2024-08-05",359,[18],[2914,2895],{"nctId":2926,"briefTitle":2927,"status":500,"phases":2928,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":97,"conditions":2931,"interventions":2932},"NCT03376932","Effectiveness of Fluticasone Furoate\u002F Umeclidinium\u002F Vilanterol (FF\u002FUMEC\u002FVI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate\u002F Salmeterol (FP\u002FSAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma",[87],"2021-02-03","2019-01-18",[18],[2895,2933,2934,2916],"FP\u002FSAL","Tiotropium",{"nctId":2936,"briefTitle":2937,"status":125,"phases":2938,"primaryCompletion":2939,"completion":2939,"start":2940,"enrollment":556,"conditions":2941,"interventions":2942},"NCT05757102","A Study to Compare the Efficacy, Safety and Tolerability of FF\u002FUMEC\u002FVI With FF\u002FVI in 12-17-year-olds With Asthma",[87],"2027-01-15","2023-04-25",[18],[2895,2914],{"trials":2944,"activeCount":97},[2945,2954,2962,2970,2981,2989],{"nctId":2946,"briefTitle":2947,"status":155,"phases":2948,"primaryCompletion":2949,"completion":2949,"start":2950,"enrollment":2951,"conditions":2952,"interventions":2953},"NCT04923347","A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)\u002FUmeclidinium(UMEC)\u002FVilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)",[88],"2024-03-14","2023-06-06",229,[15],[2895],{"nctId":2955,"briefTitle":2956,"status":155,"phases":2957,"primaryCompletion":2958,"completion":2958,"start":264,"enrollment":2959,"conditions":2960,"interventions":2961},"NCT05535972","To Evaluate Real-World Effectiveness of Fluticasone Furoate\u002FUmeclidinium Bromide\u002FVilanterol (FF\u002FUMEC\u002FVI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD",[88],"2023-09-25",463,[15],[2895],{"nctId":2963,"briefTitle":2964,"status":155,"phases":2965,"primaryCompletion":2966,"completion":2966,"start":2967,"enrollment":1924,"conditions":2968,"interventions":2969},"NCT03474081","A Comparative Study Between Fluticasone Furoate\u002FUmeclidinium\u002FVilanterol (FF\u002FUMEC\u002FVI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[88],"2019-07-17","2018-03-29",[15],[2895,2934,2916],{"nctId":2971,"briefTitle":2972,"status":155,"phases":2973,"primaryCompletion":1116,"completion":1116,"start":2974,"enrollment":2975,"conditions":2976,"interventions":2977},"NCT03478683","A Randomized Study, Comparing Fluticasone Furoate\u002FUmeclidinium\u002FVilanterol (FF\u002FUMEC\u002FVI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide\u002FFormoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[88],"2018-06-25",729,[15],[2978,2979,2895,2980],"budesonide\u002Fformoterol","albuterol\u002Fsalbutamol","tiotropium",{"nctId":2982,"briefTitle":2983,"status":155,"phases":2984,"primaryCompletion":2985,"completion":2985,"start":2974,"enrollment":2986,"conditions":2987,"interventions":2988},"NCT03478696","A Randomized Study, Comparing Fluticasone Furoate\u002FUmeclidinium\u002FVilanterol (FF\u002FUMEC \u002FVI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide\u002FFormoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[88],"2019-03-18",732,[15],[2978,2979,2895,2980],{"nctId":2990,"briefTitle":2991,"status":155,"phases":2992,"primaryCompletion":2993,"completion":2993,"start":2994,"enrollment":2995,"conditions":2996,"interventions":2997},"NCT03467425","INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design",[88],"2019-10-10","2018-04-11",3109,[15],[2895,2998,2999,3000,3001],"Inhaled Corticosteroid","LAMA","LABA","COPD rescue medications",{"trials":3003,"activeCount":97},[],{"intervention":164,"totalTrials":433,"cells":3005},{"EARLY_PHASE1":3006,"PHASE1":3008,"PHASE2":3064,"PHASE3":3120,"PHASE4":3126,"NA":3128},{"trials":3007,"activeCount":97},[],{"trials":3009,"activeCount":97},[3010,3019,3028,3032,3040,3050,3054],{"nctId":3011,"briefTitle":3012,"status":155,"phases":3013,"primaryCompletion":3014,"completion":3014,"start":3015,"enrollment":1459,"conditions":3016,"interventions":3017},"NCT00440128","The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer",[85],"2008-07-17","2007-05-04",[1337],[164,3018],"Casopitant\u002FDocetaxel",{"nctId":3020,"briefTitle":3021,"status":155,"phases":3022,"primaryCompletion":3023,"completion":3023,"start":3024,"enrollment":3025,"conditions":3026,"interventions":3027},"NCT00148902","Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)",[85],"2006-01-21","2003-04-28",52,[668],[2300,2286],{"nctId":2277,"briefTitle":2278,"status":155,"phases":3029,"primaryCompletion":2280,"completion":2280,"start":2281,"enrollment":2282,"conditions":3030,"interventions":3031},[85],[107],[2285,2264,2275,2286,2287,2288],{"nctId":3033,"briefTitle":3034,"status":155,"phases":3035,"start":3036,"enrollment":255,"conditions":3037,"interventions":3038},"NCT00169520","SB-715992 In Combination With Docetaxel In Patients With Solid Tumors",[85],"2004-06",[1431],[2286,3039],"SB-715992",{"nctId":3041,"briefTitle":3042,"status":500,"phases":3043,"primaryCompletion":3044,"completion":3044,"start":3045,"enrollment":97,"conditions":3046,"interventions":3047},"NCT01938456","Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer",[85],"2014-07","2013-10",[267],[3048,164,3049],"Trametinib","Filgrastim",{"nctId":153,"briefTitle":154,"status":155,"phases":3051,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":3052,"interventions":3053},[85],[107],[162,163,137,164,165,166,167,168,92,169,170],{"nctId":3055,"briefTitle":3056,"status":155,"phases":3057,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":803,"conditions":3060,"interventions":3061},"NCT01192165","Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel",[85],"2013-10-07","2010-09-14",[36],[3048,164,3062,165,135,3063,134],"Erlotinib","nab-Paclitaxel",{"trials":3065,"activeCount":97},[3066,3070,3074,3084,3092,3096,3106,3116],{"nctId":2306,"briefTitle":2307,"status":155,"phases":3067,"primaryCompletion":2309,"completion":2310,"start":2311,"enrollment":93,"conditions":3068,"interventions":3069},[85,86],[107],[162,2314,164,216,139],{"nctId":2316,"briefTitle":2317,"status":145,"phases":3071,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":3072,"interventions":3073},[86],[668],[2324,2325,2326,2327,1241,164,2328,2329,216,2330],{"nctId":3075,"briefTitle":3076,"status":145,"phases":3077,"primaryCompletion":1429,"completion":3078,"start":3079,"enrollment":1165,"conditions":3080,"interventions":3082},"NCT00479856","Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer",[86],"2010-03","2007-11",[3081,668],"Relapsed Breast Cancer",[2274,3083,164,3063],"Capecitabine",{"nctId":3085,"briefTitle":3086,"status":155,"phases":3087,"primaryCompletion":3088,"completion":3088,"start":242,"enrollment":3089,"conditions":3090,"interventions":3091},"NCT05553808","Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 1",[86],"2021-09-23",105,[107],[164,246],{"nctId":239,"briefTitle":240,"status":155,"phases":3093,"primaryCompletion":232,"completion":232,"start":242,"enrollment":243,"conditions":3094,"interventions":3095},[86],[107],[164,246,247,248,92,180],{"nctId":3097,"briefTitle":3098,"status":155,"phases":3099,"primaryCompletion":3100,"completion":3100,"start":3101,"enrollment":3102,"conditions":3103,"interventions":3104},"NCT00065182","Comparison of IV Topotecan\u002FDocetaxel to Docetaxel Alone in Second-Line Stage IIIB\u002FIV Non-Small Cell Lung Cancer",[86],"2007-08-30","2003-08-14",399,[267,2858],[3105,164],"Topotecan\u002FDocetaxel combination",{"nctId":3107,"briefTitle":3108,"status":155,"phases":3109,"primaryCompletion":3110,"completion":493,"start":3111,"enrollment":3112,"conditions":3113,"interventions":3114},"NCT01362296","An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer",[86],"2012-09","2011-09",134,[267],[3115,2286],"GSK1120212",{"nctId":2389,"briefTitle":2390,"status":500,"phases":3117,"primaryCompletion":2392,"completion":2393,"start":2394,"enrollment":97,"conditions":3118,"interventions":3119},[86],[668],[2274,2330,164,216,2397],{"trials":3121,"activeCount":417,"soonestReadout":387},[3122],{"nctId":384,"briefTitle":385,"status":101,"phases":3123,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":3124,"interventions":3125},[87],[267],[169,92,164],{"trials":3127,"activeCount":97},[],{"trials":3129,"activeCount":97},[],{"intervention":43,"totalTrials":3131,"cells":3132},13,{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3160,"PHASE4":3268,"NA":3270},{"trials":3134,"activeCount":97},[],{"trials":3136,"activeCount":97},[],{"trials":3138,"activeCount":97},[3139,3150],{"nctId":3140,"briefTitle":3141,"status":155,"phases":3142,"primaryCompletion":3143,"completion":3144,"start":3145,"enrollment":3146,"conditions":3147,"interventions":3148},"NCT05921903","A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above",[86],"2024-06-25","2025-05-16","2023-07-28",386,[2620],[3149],"RSVPreF3 OA Investigational Vaccine",{"nctId":3151,"briefTitle":3152,"status":155,"phases":3153,"primaryCompletion":3154,"completion":3155,"start":3156,"enrollment":3157,"conditions":3158,"interventions":3159},"NCT04657198","Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 OA Investigational Vaccine in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study",[86],"2021-06-03","2021-10-25","2020-12-09",126,[2620],[43],{"trials":3161,"activeCount":417,"soonestReadout":42},[3162,3173,3183,3193,3203,3214,3223,3234,3243,3253,3260],{"nctId":3163,"briefTitle":3164,"status":155,"phases":3165,"primaryCompletion":3166,"completion":3167,"start":3145,"enrollment":3168,"conditions":3169,"interventions":3171},"NCT05966090","A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults",[87],"2024-02-19","2024-07-29",530,[3170,2620],"Respiratory Syncytial Viruses",[43,3172],"HZ\u002Fsu vaccine",{"nctId":3174,"briefTitle":3175,"status":155,"phases":3176,"primaryCompletion":3177,"completion":211,"start":3178,"enrollment":3179,"conditions":3180,"interventions":3181},"NCT05879107","Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults",[87],"2023-12-06","2023-05-26",1113,[2620],[43,3182],"PCV20",{"nctId":3184,"briefTitle":3185,"status":155,"phases":3186,"primaryCompletion":3187,"completion":3188,"start":3189,"enrollment":3190,"conditions":3191,"interventions":3192},"NCT05059301","A Study of 3 Lots of an Investigational Vaccine Against Respiratory Syncytial Virus (RSV) in Adults Aged 60 Years and Above",[87],"2022-01-24","2022-06-30","2021-10-01",770,[2620],[43],{"nctId":3194,"briefTitle":3195,"status":155,"phases":3196,"primaryCompletion":3197,"completion":3198,"start":1767,"enrollment":3199,"conditions":3200,"interventions":3201},"NCT04841577","A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 60 Years and Above",[87],"2021-09-22","2022-02-08",976,[2620],[43,3202],"FLU-QIV",{"nctId":3204,"briefTitle":3205,"status":155,"phases":3206,"primaryCompletion":3207,"completion":3208,"start":3209,"enrollment":3210,"conditions":3211,"interventions":3212},"NCT05559476","A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above",[87],"2023-03-07","2023-08-15","2022-10-20",1029,[2620],[43,3213],"FLU HD vaccine",{"nctId":3215,"briefTitle":3216,"status":155,"phases":3217,"primaryCompletion":3218,"completion":3219,"start":2921,"enrollment":3220,"conditions":3221,"interventions":3222},"NCT06551181","A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older",[87],"2025-04-24","2025-09-15",2620,[2620],[43],{"nctId":3224,"briefTitle":3225,"status":155,"phases":3226,"primaryCompletion":3227,"completion":3228,"start":3229,"enrollment":3230,"conditions":3231,"interventions":3232},"NCT06374394","A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above",[87],"2024-11-01","2025-03-31","2024-04-29",841,[2620],[43,3233],"COVID-19 mRNA vaccine",{"nctId":3235,"briefTitle":3236,"status":155,"phases":3237,"primaryCompletion":1578,"completion":3238,"start":3239,"enrollment":3240,"conditions":3241,"interventions":3242},"NCT06614725","A Study in India on the Immune Response and Safety of a Respiratory Syncytial Virus (RSV) Older Adults (OA) Vaccine When Given to Older Adults 60 Years of Age and Above and Adults 50-59 Years of Age at Increased Risk (AIR) of Respiratory Syncytial Virus Lower Respiratory Tract Disease (RSV-LRTD)",[87],"2025-11-14","2024-10-01",751,[2620],[43],{"nctId":3244,"briefTitle":3245,"status":155,"phases":3246,"primaryCompletion":3247,"completion":3248,"start":3249,"enrollment":3250,"conditions":3251,"interventions":3252},"NCT05590403","A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 50-59 Years of Age, Including Adults at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease, Compared to Older Adults 60 Years of Age and Above",[87],"2023-03-13","2024-02-12","2022-10-28",1544,[2620],[43],{"nctId":40,"briefTitle":41,"status":101,"phases":3254,"primaryCompletion":42,"completion":3255,"start":3256,"enrollment":3257,"conditions":3258,"interventions":3259},[87],"2027-02-19","2021-02-15",1720,[2620],[43],{"nctId":3261,"briefTitle":3262,"status":155,"phases":3263,"primaryCompletion":3167,"completion":3264,"start":3229,"enrollment":3265,"conditions":3266,"interventions":3267},"NCT06389487","A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus (RSV) Given to Adults 18 to 49 Years of Age at Increased Risk for Respiratory Syncytial Virus Disease, Compared to Older Adults 60 Years of Age and Above",[87],"2025-03-18",1459,[2620],[43],{"trials":3269,"activeCount":97},[],{"trials":3271,"activeCount":97},[],{"intervention":3273,"totalTrials":628,"cells":3274},"Tafenoquine",{"EARLY_PHASE1":3275,"PHASE1":3277,"PHASE2":3302,"PHASE3":3313,"PHASE4":3346,"NA":3348},{"trials":3276,"activeCount":97},[],{"trials":3278,"activeCount":97},[3279,3291],{"nctId":3280,"briefTitle":3281,"status":155,"phases":3282,"primaryCompletion":3283,"completion":3283,"start":3284,"enrollment":3285,"conditions":3286,"interventions":3288},"NCT01205178","G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine)",[85],"2013-04-01","2009-07-02",192,[3287],"Malaria",[3289,3290,3273],"Chloroquine","Primaquine",{"nctId":3292,"briefTitle":3293,"status":155,"phases":3294,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":201,"conditions":3297,"interventions":3299},"NCT02184637","A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate",[85],"2015-04-08","2014-07-31",[3298],"Malaria, Vivax",[3273,3300,3301],"Dihydroartemisinin + Piperaquine tetraphosphate","Artemether + Lumefantrine",{"trials":3303,"activeCount":97},[3304],{"nctId":3305,"briefTitle":3306,"status":155,"phases":3307,"primaryCompletion":3308,"completion":3309,"start":3310,"enrollment":1237,"conditions":3311,"interventions":3312},"NCT02563496","A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria",[86],"2019-12-15","2020-02-17","2017-02-06",[3298],[3273,3289],{"trials":3314,"activeCount":417,"soonestReadout":3319},[3315,3323,3336],{"nctId":3316,"briefTitle":3317,"status":125,"phases":3318,"primaryCompletion":3319,"completion":3319,"start":3320,"enrollment":536,"conditions":3321,"interventions":3322},"NCT06666491","An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older",[87],"2026-05-25","2024-11-13",[3298],[3273,3290,3289],{"nctId":3324,"briefTitle":3325,"status":155,"phases":3326,"primaryCompletion":3327,"completion":3327,"start":3328,"enrollment":1579,"conditions":3329,"interventions":3330},"NCT02802501","Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria",[87],"2019-08-19","2018-04-08",[3298],[3273,3331,3290,3332,3333,3334,3335],"Matched-Placebo for Tafenoquine","Matched-Placebo for Primaquine","Dihydroartemisinin-piperaquine","ACT plus PQ","PQ",{"nctId":3337,"briefTitle":3338,"status":155,"phases":3339,"primaryCompletion":3340,"completion":3340,"start":3341,"enrollment":16,"conditions":3342,"interventions":3343},"NCT02216123","Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria",[87],"2016-11-04","2015-04-30",[3298],[3273,3344,3289,3290,3345],"Tafenoquine Placebo","Primaquine Placebo",{"trials":3347,"activeCount":97},[],{"trials":3349,"activeCount":97},[],{"intervention":1758,"totalTrials":628,"cells":3351},{"EARLY_PHASE1":3352,"PHASE1":3354,"PHASE2":3383,"PHASE3":3399,"PHASE4":3405,"NA":3407},{"trials":3353,"activeCount":97},[],{"trials":3355,"activeCount":97},[3356,3364,3373],{"nctId":3357,"briefTitle":3358,"status":155,"phases":3359,"primaryCompletion":3360,"completion":3360,"start":3361,"enrollment":421,"conditions":3362,"interventions":3363},"NCT01324258","Trial of GSK1120212 and GSK1120212 in Combination With GEM in Japanese Subjects With Solid Tumors",[85],"2013-07-08","2011-01-24",[2761],[3115,1758],{"nctId":3365,"briefTitle":3366,"status":155,"phases":3367,"primaryCompletion":3368,"completion":3369,"start":3370,"enrollment":2836,"conditions":3371,"interventions":3372},"NCT00678977","A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors",[85],"2010-03-30","2011-06-30","2008-04-03",[267],[2273,1758,134],{"nctId":3374,"briefTitle":3375,"status":155,"phases":3376,"primaryCompletion":3377,"completion":3377,"start":3378,"enrollment":3379,"conditions":3380,"interventions":3382},"NCT01428427","Combination Study of GSK1120212 With Gemcitabine in Subjects With Solid Tumors",[85],"2011-07-18","2009-08-12",31,[3381],"Leukaemia, Myelocytic, Acute",[3115,1758],{"trials":3384,"activeCount":97},[3385,3395],{"nctId":3386,"briefTitle":3387,"status":155,"phases":3388,"primaryCompletion":3389,"completion":3390,"start":3391,"enrollment":3392,"conditions":3393,"interventions":3394},"NCT01231581","Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer",[86],"2012-04","2013-02","2010-08",160,[36],[3115,1758],{"nctId":2820,"briefTitle":2821,"status":155,"phases":3396,"primaryCompletion":2823,"start":2824,"enrollment":2825,"conditions":3397,"interventions":3398},[86],[2827,2816,2363,2828],[1757,1758],{"trials":3400,"activeCount":417,"soonestReadout":1750},[3401],{"nctId":1747,"briefTitle":1748,"status":410,"phases":3402,"primaryCompletion":1750,"completion":1750,"start":1751,"enrollment":1752,"conditions":3403,"interventions":3404},[87],[647],[1755,216,1756,1757,1758,137,140],{"trials":3406,"activeCount":97},[],{"trials":3408,"activeCount":97},[],{"intervention":3289,"totalTrials":1517,"cells":3410},{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3419,"PHASE3":3435,"PHASE4":3445,"NA":3447},{"trials":3412,"activeCount":97},[],{"trials":3414,"activeCount":97},[3415],{"nctId":3280,"briefTitle":3281,"status":155,"phases":3416,"primaryCompletion":3283,"completion":3283,"start":3284,"enrollment":3285,"conditions":3417,"interventions":3418},[85],[3287],[3289,3290,3273],{"trials":3420,"activeCount":97},[3421,3431],{"nctId":3422,"briefTitle":3423,"status":155,"phases":3424,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":695,"conditions":3427,"interventions":3429},"NCT00972725","Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose",[86],"2010-10-04","2009-12-01",[3428],"AIDS",[3430,3289],"GSK Biologicals' HIV vaccine",{"nctId":3305,"briefTitle":3306,"status":155,"phases":3432,"primaryCompletion":3308,"completion":3309,"start":3310,"enrollment":1237,"conditions":3433,"interventions":3434},[86],[3298],[3273,3289],{"trials":3436,"activeCount":417,"soonestReadout":3319},[3437,3441],{"nctId":3316,"briefTitle":3317,"status":125,"phases":3438,"primaryCompletion":3319,"completion":3319,"start":3320,"enrollment":536,"conditions":3439,"interventions":3440},[87],[3298],[3273,3290,3289],{"nctId":3337,"briefTitle":3338,"status":155,"phases":3442,"primaryCompletion":3340,"completion":3340,"start":3341,"enrollment":16,"conditions":3443,"interventions":3444},[87],[3298],[3273,3344,3289,3290,3345],{"trials":3446,"activeCount":97},[],{"trials":3448,"activeCount":97},[],{"intervention":2914,"totalTrials":1517,"cells":3450},{"EARLY_PHASE1":3451,"PHASE1":3453,"PHASE2":3455,"PHASE3":3468,"PHASE4":3491,"NA":3493},{"trials":3452,"activeCount":97},[],{"trials":3454,"activeCount":97},[],{"trials":3456,"activeCount":97},[3457],{"nctId":3458,"briefTitle":3459,"status":155,"phases":3460,"primaryCompletion":3461,"completion":3461,"start":3462,"enrollment":3463,"conditions":3464,"interventions":3465},"NCT01573624","Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma",[86],"2013-02-04","2012-04-03",421,[18],[3466,3466,3466,3466,3466,3467,2914],"FF\u002FGSK573719","FF",{"trials":3469,"activeCount":417,"soonestReadout":2939},[3470,3474,3478,3487],{"nctId":2906,"briefTitle":2907,"status":155,"phases":3471,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":3472,"interventions":3473},[87],[15],[2895,2914,2915,2916],{"nctId":2918,"briefTitle":2919,"status":155,"phases":3475,"primaryCompletion":2921,"completion":2921,"start":1204,"enrollment":2922,"conditions":3476,"interventions":3477},[87],[18],[2914,2895],{"nctId":3479,"briefTitle":3480,"status":155,"phases":3481,"primaryCompletion":3482,"completion":3482,"start":3483,"enrollment":3484,"conditions":3485,"interventions":3486},"NCT01551758","A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)\u002FVilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)",[87],"2015-11-24","2012-03-13",2802,[15],[2914],{"nctId":2936,"briefTitle":2937,"status":125,"phases":3488,"primaryCompletion":2939,"completion":2939,"start":2940,"enrollment":556,"conditions":3489,"interventions":3490},[87],[18],[2895,2914],{"trials":3492,"activeCount":97},[],{"trials":3494,"activeCount":97},[],{"intervention":3290,"totalTrials":181,"cells":3496},{"EARLY_PHASE1":3497,"PHASE1":3499,"PHASE2":3505,"PHASE3":3507,"PHASE4":3521,"NA":3523},{"trials":3498,"activeCount":97},[],{"trials":3500,"activeCount":97},[3501],{"nctId":3280,"briefTitle":3281,"status":155,"phases":3502,"primaryCompletion":3283,"completion":3283,"start":3284,"enrollment":3285,"conditions":3503,"interventions":3504},[85],[3287],[3289,3290,3273],{"trials":3506,"activeCount":97},[],{"trials":3508,"activeCount":417,"soonestReadout":3319},[3509,3513,3517],{"nctId":3316,"briefTitle":3317,"status":125,"phases":3510,"primaryCompletion":3319,"completion":3319,"start":3320,"enrollment":536,"conditions":3511,"interventions":3512},[87],[3298],[3273,3290,3289],{"nctId":3324,"briefTitle":3325,"status":155,"phases":3514,"primaryCompletion":3327,"completion":3327,"start":3328,"enrollment":1579,"conditions":3515,"interventions":3516},[87],[3298],[3273,3331,3290,3332,3333,3334,3335],{"nctId":3337,"briefTitle":3338,"status":155,"phases":3518,"primaryCompletion":3340,"completion":3340,"start":3341,"enrollment":16,"conditions":3519,"interventions":3520},[87],[3298],[3273,3344,3289,3290,3345],{"trials":3522,"activeCount":97},[],{"trials":3524,"activeCount":97},[],{"intervention":2328,"totalTrials":181,"cells":3526},{"EARLY_PHASE1":3527,"PHASE1":3529,"PHASE2":3540,"PHASE3":3559,"PHASE4":3565,"NA":3567},{"trials":3528,"activeCount":97},[],{"trials":3530,"activeCount":97},[3531],{"nctId":3532,"briefTitle":3533,"status":155,"phases":3534,"primaryCompletion":546,"completion":3535,"start":3536,"enrollment":3537,"conditions":3538,"interventions":3539},"NCT00722293","A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors",[85],"2014-02-25","2008-07-08",111,[668],[2328,2273,2329],{"trials":3541,"activeCount":97},[3542,3546],{"nctId":2316,"briefTitle":2317,"status":145,"phases":3543,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":3544,"interventions":3545},[86],[668],[2324,2325,2326,2327,1241,164,2328,2329,216,2330],{"nctId":3547,"briefTitle":3548,"status":155,"phases":3549,"primaryCompletion":3550,"completion":3551,"start":3552,"enrollment":2759,"conditions":3553,"interventions":3555},"NCT00494780","Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients",[86],"2009-04","2010-09","2007-06",[3554],"Lymphoma, Follicular",[3556,1241,2328,3557,3558],"Ofatumumab","Vincristine","Prednisolone, Prednisone or equivalent",{"trials":3560,"activeCount":417,"soonestReadout":2414},[3561],{"nctId":2411,"briefTitle":2412,"status":410,"phases":3562,"primaryCompletion":2414,"completion":2415,"start":2416,"enrollment":1944,"conditions":3563,"interventions":3564},[87],[257],[1755,216,2328],{"trials":3566,"activeCount":97},[],{"trials":3568,"activeCount":97},[],{"intervention":3172,"totalTrials":593,"cells":3570},{"EARLY_PHASE1":3571,"PHASE1":3573,"PHASE2":3575,"PHASE3":3577,"PHASE4":3600,"NA":3602},{"trials":3572,"activeCount":97},[],{"trials":3574,"activeCount":97},[],{"trials":3576,"activeCount":97},[],{"trials":3578,"activeCount":417,"soonestReadout":3595},[3579,3583,3591],{"nctId":3163,"briefTitle":3164,"status":155,"phases":3580,"primaryCompletion":3166,"completion":3167,"start":3145,"enrollment":3168,"conditions":3581,"interventions":3582},[87],[3170,2620],[43,3172],{"nctId":3584,"briefTitle":3585,"status":155,"phases":3586,"primaryCompletion":3587,"completion":3588,"start":1099,"enrollment":37,"conditions":3589,"interventions":3590},"NCT04176939","A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response",[87],"2022-08-12","2024-06-27",[1030],[3172],{"nctId":3592,"briefTitle":3593,"status":101,"phases":3594,"primaryCompletion":3595,"completion":3595,"start":3596,"enrollment":3597,"conditions":3598,"interventions":3599},"NCT05371080","A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults",[87],"2027-08-23","2022-08-10",3038,[1030],[3172],{"trials":3601,"activeCount":97},[],{"trials":3603,"activeCount":97},[],{"intervention":3605,"totalTrials":593,"cells":3606},"DTPa",{"EARLY_PHASE1":3607,"PHASE1":3609,"PHASE2":3611,"PHASE3":3613,"PHASE4":3652,"NA":3654},{"trials":3608,"activeCount":97},[],{"trials":3610,"activeCount":97},[],{"trials":3612,"activeCount":97},[],{"trials":3614,"activeCount":417,"soonestReadout":3644},[3615,3628,3640],{"nctId":3616,"briefTitle":3617,"status":155,"phases":3618,"primaryCompletion":3619,"completion":3620,"start":3621,"enrollment":3622,"conditions":3623,"interventions":3625},"NCT00290342","Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants",[87],"2007-01-01","2007-01-23","2006-01-01",458,[33,3624,30],"Acellular Pertussis",[3626,3605,3627],"DTPa-IPV","IMOVAX Polio®",{"nctId":3629,"briefTitle":3630,"status":155,"phases":3631,"primaryCompletion":3632,"completion":3633,"start":3634,"enrollment":3635,"conditions":3636,"interventions":3638},"NCT01027845","Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A in Healthy Japanese Children",[87],"2010-08-13","2011-09-17","2009-12-08",360,[3637],"Infections, Streptococcal",[3639,3605],"Pneumococcal vaccine GSK1024850A",{"nctId":3641,"briefTitle":3642,"status":410,"phases":3643,"primaryCompletion":3644,"completion":3645,"start":3646,"enrollment":3647,"conditions":3648,"interventions":3650},"NCT07596199","A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women",[87],"2026-12-11","2027-01-20","2026-06-29",95,[3649],"Diphtheria-Tetanus-acellular Pertussis Vaccines",[3651],"dTpa",{"trials":3653,"activeCount":97},[],{"trials":3655,"activeCount":97},[],{"intervention":3657,"totalTrials":660,"cells":3658},"dTpa vaccine",{"EARLY_PHASE1":3659,"PHASE1":3661,"PHASE2":3663,"PHASE3":3665,"PHASE4":3684,"NA":3686},{"trials":3660,"activeCount":97},[],{"trials":3662,"activeCount":97},[],{"trials":3664,"activeCount":97},[],{"trials":3666,"activeCount":417,"soonestReadout":3671},[3667,3675],{"nctId":3668,"briefTitle":3669,"status":410,"phases":3670,"primaryCompletion":3671,"completion":3671,"start":3646,"enrollment":3672,"conditions":3673,"interventions":3674},"NCT07596173","A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to \u003C13 Years",[87],"2026-10-14",85,[3649],[3657],{"nctId":3676,"briefTitle":3677,"status":155,"phases":3678,"primaryCompletion":3679,"completion":3679,"start":3680,"enrollment":1165,"conditions":3681,"interventions":3682},"NCT05169905","A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age",[87],"2022-08-03","2022-02-02",[2620],[3683,3657],"RSV MAT vaccine",{"trials":3685,"activeCount":97},[],{"trials":3687,"activeCount":97},[],{"intervention":3689,"totalTrials":660,"cells":3690},"MMRV",{"EARLY_PHASE1":3691,"PHASE1":3693,"PHASE2":3695,"PHASE3":3697,"PHASE4":3720,"NA":3722},{"trials":3692,"activeCount":97},[],{"trials":3694,"activeCount":97},[],{"trials":3696,"activeCount":97},[],{"trials":3698,"activeCount":417,"soonestReadout":3703},[3699,3710],{"nctId":3700,"briefTitle":3701,"status":410,"phases":3702,"primaryCompletion":3703,"completion":3704,"start":3705,"enrollment":3706,"conditions":3707,"interventions":3708},"NCT07406360","A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age",[87],"2028-01-31","2028-06-22","2026-04-13",1209,[2486],[3709,3689],"MMRVNS",{"nctId":3711,"briefTitle":3712,"status":155,"phases":3713,"primaryCompletion":1361,"completion":1361,"start":3714,"enrollment":3715,"conditions":3716,"interventions":3718},"NCT00406211","Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine",[87],"2004-07",398,[2484,3717,2485,2486],"Varicella",[3689,3719,3717],"MMR",{"trials":3721,"activeCount":97},[],{"trials":3723,"activeCount":97},[],{"intervention":1933,"totalTrials":660,"cells":3725},{"EARLY_PHASE1":3726,"PHASE1":3728,"PHASE2":3730,"PHASE3":3736,"PHASE4":3742,"NA":3744},{"trials":3727,"activeCount":97},[],{"trials":3729,"activeCount":97},[],{"trials":3731,"activeCount":97},[3732],{"nctId":1918,"briefTitle":1919,"status":155,"phases":3733,"primaryCompletion":1921,"completion":1922,"start":1923,"enrollment":1924,"conditions":3734,"interventions":3735},[86],[1926],[1928,1929,1930,1931,1932,1933,1909,1934],{"trials":3737,"activeCount":417,"soonestReadout":198},[3738],{"nctId":1978,"briefTitle":1979,"status":125,"phases":3739,"primaryCompletion":198,"completion":198,"start":1981,"enrollment":1982,"conditions":3740,"interventions":3741},[87],[1926],[1947,1948,1933,1909,1950,1951,1952],{"trials":3743,"activeCount":97},[],{"trials":3745,"activeCount":97},[],{"intervention":3747,"totalTrials":417,"cells":3748},"IDRX-42",{"EARLY_PHASE1":3749,"PHASE1":3751,"PHASE2":3753,"PHASE3":3755,"PHASE4":3767,"NA":3769},{"trials":3750,"activeCount":97},[],{"trials":3752,"activeCount":97},[],{"trials":3754,"activeCount":97},[],{"trials":3756,"activeCount":417,"soonestReadout":3761},[3757],{"nctId":3758,"briefTitle":3759,"status":125,"phases":3760,"primaryCompletion":3761,"completion":3762,"start":1887,"enrollment":1752,"conditions":3763,"interventions":3765},"NCT07218926","A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy",[87],"2028-05-30","2030-11-29",[3764],"Gastrointestinal Neoplasms",[3747,3766],"Sunitinib",{"trials":3768,"activeCount":97},[],{"trials":3770,"activeCount":97},[],{"intervention":3766,"totalTrials":417,"cells":3772},{"EARLY_PHASE1":3773,"PHASE1":3775,"PHASE2":3777,"PHASE3":3779,"PHASE4":3785,"NA":3787},{"trials":3774,"activeCount":97},[],{"trials":3776,"activeCount":97},[],{"trials":3778,"activeCount":97},[],{"trials":3780,"activeCount":417,"soonestReadout":3761},[3781],{"nctId":3758,"briefTitle":3759,"status":125,"phases":3782,"primaryCompletion":3761,"completion":3762,"start":1887,"enrollment":1752,"conditions":3783,"interventions":3784},[87],[3764],[3747,3766],{"trials":3786,"activeCount":97},[],{"trials":3788,"activeCount":97},[],{"intervention":1756,"totalTrials":417,"cells":3790},{"EARLY_PHASE1":3791,"PHASE1":3793,"PHASE2":3795,"PHASE3":3797,"PHASE4":3803,"NA":3805},{"trials":3792,"activeCount":97},[],{"trials":3794,"activeCount":97},[],{"trials":3796,"activeCount":97},[],{"trials":3798,"activeCount":417,"soonestReadout":1750},[3799],{"nctId":1747,"briefTitle":1748,"status":410,"phases":3800,"primaryCompletion":1750,"completion":1750,"start":1751,"enrollment":1752,"conditions":3801,"interventions":3802},[87],[647],[1755,216,1756,1757,1758,137,140],{"trials":3804,"activeCount":97},[],{"trials":3806,"activeCount":97},[],{"intervention":3709,"totalTrials":417,"cells":3808},{"EARLY_PHASE1":3809,"PHASE1":3811,"PHASE2":3813,"PHASE3":3815,"PHASE4":3821,"NA":3823},{"trials":3810,"activeCount":97},[],{"trials":3812,"activeCount":97},[],{"trials":3814,"activeCount":97},[],{"trials":3816,"activeCount":417,"soonestReadout":3703},[3817],{"nctId":3700,"briefTitle":3701,"status":410,"phases":3818,"primaryCompletion":3703,"completion":3704,"start":3705,"enrollment":3706,"conditions":3819,"interventions":3820},[87],[2486],[3709,3689],{"trials":3822,"activeCount":97},[],{"trials":3824,"activeCount":97},[],{"intervention":1963,"totalTrials":417,"cells":3826},{"EARLY_PHASE1":3827,"PHASE1":3829,"PHASE2":3831,"PHASE3":3833,"PHASE4":3839,"NA":3841},{"trials":3828,"activeCount":97},[],{"trials":3830,"activeCount":97},[],{"trials":3832,"activeCount":97},[],{"trials":3834,"activeCount":417,"soonestReadout":1957},[3835],{"nctId":1954,"briefTitle":1955,"status":125,"phases":3836,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":1960,"conditions":3837,"interventions":3838},[87],[1926],[1963,1964,1965,1966,1967,1949,1909,1950,1951,1952],{"trials":3840,"activeCount":97},[],{"trials":3842,"activeCount":97},[],{"intervention":1964,"totalTrials":417,"cells":3844},{"EARLY_PHASE1":3845,"PHASE1":3847,"PHASE2":3849,"PHASE3":3851,"PHASE4":3857,"NA":3859},{"trials":3846,"activeCount":97},[],{"trials":3848,"activeCount":97},[],{"trials":3850,"activeCount":97},[],{"trials":3852,"activeCount":417,"soonestReadout":1957},[3853],{"nctId":1954,"briefTitle":1955,"status":125,"phases":3854,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":1960,"conditions":3855,"interventions":3856},[87],[1926],[1963,1964,1965,1966,1967,1949,1909,1950,1951,1952],{"trials":3858,"activeCount":97},[],{"trials":3860,"activeCount":97},[],{"intervention":1965,"totalTrials":417,"cells":3862},{"EARLY_PHASE1":3863,"PHASE1":3865,"PHASE2":3867,"PHASE3":3869,"PHASE4":3875,"NA":3877},{"trials":3864,"activeCount":97},[],{"trials":3866,"activeCount":97},[],{"trials":3868,"activeCount":97},[],{"trials":3870,"activeCount":417,"soonestReadout":1957},[3871],{"nctId":1954,"briefTitle":1955,"status":125,"phases":3872,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":1960,"conditions":3873,"interventions":3874},[87],[1926],[1963,1964,1965,1966,1967,1949,1909,1950,1951,1952],{"trials":3876,"activeCount":97},[],{"trials":3878,"activeCount":97},[],{"intervention":1966,"totalTrials":417,"cells":3880},{"EARLY_PHASE1":3881,"PHASE1":3883,"PHASE2":3885,"PHASE3":3887,"PHASE4":3893,"NA":3895},{"trials":3882,"activeCount":97},[],{"trials":3884,"activeCount":97},[],{"trials":3886,"activeCount":97},[],{"trials":3888,"activeCount":417,"soonestReadout":1957},[3889],{"nctId":1954,"briefTitle":1955,"status":125,"phases":3890,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":1960,"conditions":3891,"interventions":3892},[87],[1926],[1963,1964,1965,1966,1967,1949,1909,1950,1951,1952],{"trials":3894,"activeCount":97},[],{"trials":3896,"activeCount":97},[],{"intervention":1967,"totalTrials":417,"cells":3898},{"EARLY_PHASE1":3899,"PHASE1":3901,"PHASE2":3903,"PHASE3":3905,"PHASE4":3911,"NA":3913},{"trials":3900,"activeCount":97},[],{"trials":3902,"activeCount":97},[],{"trials":3904,"activeCount":97},[],{"trials":3906,"activeCount":417,"soonestReadout":1957},[3907],{"nctId":1954,"briefTitle":1955,"status":125,"phases":3908,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":1960,"conditions":3909,"interventions":3910},[87],[1926],[1963,1964,1965,1966,1967,1949,1909,1950,1951,1952],{"trials":3912,"activeCount":97},[],{"trials":3914,"activeCount":97},[],{"intervention":1976,"totalTrials":417,"cells":3916},{"EARLY_PHASE1":3917,"PHASE1":3919,"PHASE2":3921,"PHASE3":3923,"PHASE4":3929,"NA":3931},{"trials":3918,"activeCount":97},[],{"trials":3920,"activeCount":97},[],{"trials":3922,"activeCount":97},[],{"trials":3924,"activeCount":417,"soonestReadout":1972},[3925],{"nctId":1969,"briefTitle":1970,"status":125,"phases":3926,"primaryCompletion":1972,"completion":368,"start":273,"enrollment":1973,"conditions":3927,"interventions":3928},[87],[1926],[1976,1948,1949,1909,1950,1951,1952],{"trials":3930,"activeCount":97},[],{"trials":3932,"activeCount":97},[],{"intervention":404,"totalTrials":417,"cells":3934},{"EARLY_PHASE1":3935,"PHASE1":3937,"PHASE2":3939,"PHASE3":3941,"PHASE4":3947,"NA":3949},{"trials":3936,"activeCount":97},[],{"trials":3938,"activeCount":97},[],{"trials":3940,"activeCount":97},[],{"trials":3942,"activeCount":417,"soonestReadout":397},[3943],{"nctId":394,"briefTitle":395,"status":125,"phases":3944,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":3945,"interventions":3946},[87],[402,203],[92,205,404],{"trials":3948,"activeCount":97},[],{"trials":3950,"activeCount":97},[],{"intervention":2588,"totalTrials":417,"cells":3952},{"EARLY_PHASE1":3953,"PHASE1":3955,"PHASE2":3957,"PHASE3":3959,"PHASE4":3965,"NA":3967},{"trials":3954,"activeCount":97},[],{"trials":3956,"activeCount":97},[],{"trials":3958,"activeCount":97},[],{"trials":3960,"activeCount":417,"soonestReadout":2582},[3961],{"nctId":2579,"briefTitle":2580,"status":410,"phases":3962,"primaryCompletion":2582,"completion":2583,"start":2584,"enrollment":849,"conditions":3963,"interventions":3964},[86,87],[2586],[2547,2588],{"trials":3966,"activeCount":97},[],{"trials":3968,"activeCount":97},[],{"intervention":1317,"totalTrials":417,"cells":3970},{"EARLY_PHASE1":3971,"PHASE1":3973,"PHASE2":3975,"PHASE3":3977,"PHASE4":3983,"NA":3985},{"trials":3972,"activeCount":97},[],{"trials":3974,"activeCount":97},[],{"trials":3976,"activeCount":97},[],{"trials":3978,"activeCount":417,"soonestReadout":47},[3979],{"nctId":45,"briefTitle":46,"status":101,"phases":3980,"primaryCompletion":47,"completion":274,"start":1313,"enrollment":1314,"conditions":3981,"interventions":3982},[87],[278],[48,1317],{"trials":3984,"activeCount":97},[],{"trials":3986,"activeCount":97},[],{"intervention":3988,"totalTrials":417,"cells":3989},"Velzatinib",{"EARLY_PHASE1":3990,"PHASE1":3992,"PHASE2":3994,"PHASE3":3996,"PHASE4":4009,"NA":4011},{"trials":3991,"activeCount":97},[],{"trials":3993,"activeCount":97},[],{"trials":3995,"activeCount":97},[],{"trials":3997,"activeCount":417,"soonestReadout":4002},[3998],{"nctId":3999,"briefTitle":4000,"status":410,"phases":4001,"primaryCompletion":4002,"completion":4003,"start":4004,"enrollment":1924,"conditions":4005,"interventions":4007},"NCT07585266","A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and\u002For Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)",[87],"2032-08-30","2032-09-28","2026-06-15",[4006],"Gastrointestinal Stromal Neoplasms",[3988,4008],"Imatinib",{"trials":4010,"activeCount":97},[],{"trials":4012,"activeCount":97},[],{"intervention":4008,"totalTrials":417,"cells":4014},{"EARLY_PHASE1":4015,"PHASE1":4017,"PHASE2":4019,"PHASE3":4021,"PHASE4":4027,"NA":4029},{"trials":4016,"activeCount":97},[],{"trials":4018,"activeCount":97},[],{"trials":4020,"activeCount":97},[],{"trials":4022,"activeCount":417,"soonestReadout":4002},[4023],{"nctId":3999,"briefTitle":4000,"status":410,"phases":4024,"primaryCompletion":4002,"completion":4003,"start":4004,"enrollment":1924,"conditions":4025,"interventions":4026},[87],[4006],[3988,4008],{"trials":4028,"activeCount":97},[],{"trials":4030,"activeCount":97},[],{"intervention":4032,"totalTrials":1318,"cells":4033},"Linerixibat",{"EARLY_PHASE1":4034,"PHASE1":4036,"PHASE2":4075,"PHASE3":4077,"PHASE4":4097,"NA":4099},{"trials":4035,"activeCount":97},[],{"trials":4037,"activeCount":97},[4038,4048,4057,4064],{"nctId":4039,"briefTitle":4040,"status":155,"phases":4041,"primaryCompletion":4042,"completion":4042,"start":4043,"enrollment":314,"conditions":4044,"interventions":4046},"NCT05435170","Food Effect Study of Linerixibat Tablets in Healthy Adult Participants",[85],"2022-10-10","2022-08-11",[4045],"Pruritus",[4047],"linerixibat",{"nctId":4049,"briefTitle":4050,"status":155,"phases":4051,"primaryCompletion":4052,"completion":4052,"start":4053,"enrollment":3025,"conditions":4054,"interventions":4055},"NCT05133830","Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants",[85],"2022-05-31","2021-11-23",[4045],[4056,4032],"Obeticholic acid",{"nctId":4058,"briefTitle":4059,"status":155,"phases":4060,"primaryCompletion":4061,"completion":4061,"start":1221,"enrollment":1720,"conditions":4062,"interventions":4063},"NCT05393076","Phase I Study of Linerixibat in Adults With Moderate Hepatic Impairment and Healthy Controls",[85],"2022-12-06",[4045],[4032],{"nctId":4065,"briefTitle":4066,"status":155,"phases":4067,"primaryCompletion":4068,"completion":4068,"start":4069,"enrollment":628,"conditions":4070,"interventions":4072},"NCT03992014","Pharmacokinetics (PKs) and Metabolism of Radiolabelled Linerixibat",[85],"2019-08-26","2019-07-08",[4071],"Cholestasis",[4032,4073,4074],"[14C]-linerixibat intravenous","Linerixibat oral solution",{"trials":4076,"activeCount":97},[],{"trials":4078,"activeCount":417,"soonestReadout":2626},[4079,4089],{"nctId":4080,"briefTitle":4081,"status":155,"phases":4082,"primaryCompletion":4083,"completion":4084,"start":4085,"enrollment":4086,"conditions":4087,"interventions":4088},"NCT04950127","Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)",[87],"2024-10-28","2024-12-20","2021-08-27",238,[4045],[4032],{"nctId":4090,"briefTitle":4091,"status":101,"phases":4092,"primaryCompletion":2626,"completion":2626,"start":4093,"enrollment":4094,"conditions":4095,"interventions":4096},"NCT04167358","Linerixibat Long-term Safety, and Tolerability Study",[87],"2020-07-14",242,[4071],[4032],{"trials":4098,"activeCount":97},[],{"trials":4100,"activeCount":97},[4101],{"nctId":4102,"briefTitle":4103,"status":4104,"phases":4105,"conditions":4106,"interventions":4107},"NCT05448170","Linerixibat Compassionate Use for Cholestatic Pruritus Adult Patients With Primary Biliary Cholangitis (PBC)","AVAILABLE",[],[4045],[4032],{"intervention":4109,"totalTrials":1165,"cells":4110},"Bepirovirsen",{"EARLY_PHASE1":4111,"PHASE1":4113,"PHASE2":4141,"PHASE3":4181,"PHASE4":4201,"NA":4203},{"trials":4112,"activeCount":97},[],{"trials":4114,"activeCount":417,"soonestReadout":4128},[4115,4124,4133],{"nctId":4116,"briefTitle":4117,"status":155,"phases":4118,"primaryCompletion":4119,"completion":4119,"start":4120,"enrollment":4121,"conditions":4122,"interventions":4123},"NCT06422767","Study to Evaluate the Effect of Bepirovirsen on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers",[85],"2025-04-28","2024-07-18",46,[24],[4109],{"nctId":4125,"briefTitle":4126,"status":101,"phases":4127,"primaryCompletion":4128,"completion":4129,"start":4130,"enrollment":2045,"conditions":4131,"interventions":4132},"NCT07168356","A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease",[85],"2026-03-03","2026-08-18","2025-09-26",[24],[4109],{"nctId":4134,"briefTitle":4135,"status":155,"phases":4136,"primaryCompletion":4137,"completion":4137,"start":4138,"enrollment":3392,"conditions":4139,"interventions":4140},"NCT06058390","A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult Participants",[85],"2024-05-03","2023-10-04",[24],[4109],{"trials":4142,"activeCount":593,"soonestReadout":4147},[4143,4151,4162,4170],{"nctId":4144,"briefTitle":4145,"status":101,"phases":4146,"primaryCompletion":4147,"completion":4147,"start":4148,"enrollment":1150,"conditions":4149,"interventions":4150},"NCT06497504","Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)",[86],"2027-04-22","2024-09-17",[24],[4109],{"nctId":4152,"briefTitle":4153,"status":145,"phases":4154,"primaryCompletion":4155,"completion":4156,"start":4157,"enrollment":4158,"conditions":4159,"interventions":4160},"NCT05330455","Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection",[85,86],"2025-05-19","2026-04-08","2022-04-14",74,[24],[4161,4109],"GSK3965193",{"nctId":4163,"briefTitle":4164,"status":125,"phases":4165,"primaryCompletion":4166,"completion":4166,"start":4167,"enrollment":1752,"conditions":4168,"interventions":4169},"NCT04954859","Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)",[86],"2029-02-08","2021-12-14",[24],[4109],{"nctId":4171,"briefTitle":4172,"status":101,"phases":4173,"primaryCompletion":600,"completion":600,"start":4174,"enrollment":4175,"conditions":4176,"interventions":4178},"NCT06537414","A Study of Sequential Therapy With Daplusiran\u002FTomligisiran (DAP\u002FTOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)",[86],"2024-11-11",283,[4177,24],"Chronic Hepatitis B Virus Infection",[4179,4180,4109],"Daplusiran\u002FTomligisiran Dose Level 1","Daplusiran\u002FTomligisiran Dose Level 2",{"trials":4182,"activeCount":97},[4183,4193],{"nctId":4184,"briefTitle":4185,"status":155,"phases":4186,"primaryCompletion":4187,"completion":1195,"start":4188,"enrollment":1569,"conditions":4189,"interventions":4192},"NCT05630807","Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)",[87],"2025-11-11","2022-12-07",[4190,4191],"Chronic Hepatitis B","Hepatitis B, Chronic",[4109],{"nctId":4194,"briefTitle":4195,"status":155,"phases":4196,"primaryCompletion":4197,"completion":3705,"start":4061,"enrollment":4198,"conditions":4199,"interventions":4200},"NCT05630820","Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)",[87],"2025-11-03",857,[4190,4191],[4109],{"trials":4202,"activeCount":97},[],{"trials":4204,"activeCount":97},[],{"intervention":280,"totalTrials":181,"cells":4206},{"EARLY_PHASE1":4207,"PHASE1":4209,"PHASE2":4211,"PHASE3":4229,"PHASE4":4231,"NA":4233},{"trials":4208,"activeCount":97},[],{"trials":4210,"activeCount":97},[],{"trials":4212,"activeCount":181,"soonestReadout":273},[4213,4217,4221,4225],{"nctId":1154,"briefTitle":1155,"status":101,"phases":4214,"primaryCompletion":273,"completion":274,"start":1157,"enrollment":473,"conditions":4215,"interventions":4216},[85,86],[278],[48,280,284,283],{"nctId":270,"briefTitle":271,"status":101,"phases":4218,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":4219,"interventions":4220},[85,86],[278],[48,163,246,280,92,281,282,283,284],{"nctId":1218,"briefTitle":1219,"status":101,"phases":4222,"primaryCompletion":273,"completion":274,"start":1221,"enrollment":454,"conditions":4223,"interventions":4224},[85,86],[278],[48,280,282,283],{"nctId":1225,"briefTitle":1226,"status":101,"phases":4226,"primaryCompletion":273,"completion":274,"start":1228,"enrollment":1229,"conditions":4227,"interventions":4228},[85,86],[278],[48,280],{"trials":4230,"activeCount":97},[],{"trials":4232,"activeCount":97},[],{"trials":4234,"activeCount":97},[],{"intervention":2275,"totalTrials":750,"cells":4236},{"EARLY_PHASE1":4237,"PHASE1":4239,"PHASE2":4265,"PHASE3":4287,"PHASE4":4289,"NA":4291},{"trials":4238,"activeCount":97},[],{"trials":4240,"activeCount":417,"soonestReadout":127},[4241,4245,4249,4253,4261],{"nctId":123,"briefTitle":124,"status":125,"phases":4242,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":4243,"interventions":4244},[85],[107],[133,134,135,136,137,138,139,140,141,92],{"nctId":2266,"briefTitle":2267,"status":155,"phases":4246,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":34,"conditions":4247,"interventions":4248},[85],[668],[2273,2274,2264,2275],{"nctId":2277,"briefTitle":2278,"status":155,"phases":4250,"primaryCompletion":2280,"completion":2280,"start":2281,"enrollment":2282,"conditions":4251,"interventions":4252},[85],[107],[2285,2264,2275,2286,2287,2288],{"nctId":4254,"briefTitle":4255,"status":155,"phases":4256,"primaryCompletion":4257,"completion":4257,"start":4258,"enrollment":255,"conditions":4259,"interventions":4260},"NCT00136578","Ispinesib In Combination With Carboplatin In Patients With Solid Tumors",[85],"2006-10-25","2004-10-20",[2761],[3039,2275],{"nctId":3055,"briefTitle":3056,"status":155,"phases":4262,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":803,"conditions":4263,"interventions":4264},[85],[36],[3048,164,3062,165,135,3063,134],{"trials":4266,"activeCount":660,"soonestReadout":210},[4267,4271,4275,4279,4283],{"nctId":2791,"briefTitle":2792,"status":155,"phases":4268,"primaryCompletion":2794,"completion":2795,"start":2796,"enrollment":2797,"conditions":4269,"interventions":4270},[86],[2778],[2446,2275],{"nctId":207,"briefTitle":208,"status":101,"phases":4272,"primaryCompletion":210,"completion":113,"start":211,"enrollment":212,"conditions":4273,"interventions":4274},[86],[214],[92,135,216],{"nctId":2810,"briefTitle":2811,"status":155,"phases":4276,"primaryCompletion":2813,"completion":2794,"start":2814,"enrollment":624,"conditions":4277,"interventions":4278},[86],[2816,2363],[2446,2818],{"nctId":2352,"briefTitle":2353,"status":155,"phases":4280,"primaryCompletion":2355,"completion":2355,"start":2356,"enrollment":1459,"conditions":4281,"interventions":4282},[86],[2358,2359,2360,2361,2362,2363,36],[2263,2275,2264],{"nctId":250,"briefTitle":251,"status":125,"phases":4284,"primaryCompletion":253,"completion":253,"start":254,"enrollment":255,"conditions":4285,"interventions":4286},[86],[257],[92,135,216],{"trials":4288,"activeCount":97},[],{"trials":4290,"activeCount":97},[],{"trials":4292,"activeCount":97},[],{"intervention":120,"totalTrials":181,"cells":4294},{"EARLY_PHASE1":4295,"PHASE1":4297,"PHASE2":4303,"PHASE3":4317,"PHASE4":4319,"NA":4321},{"trials":4296,"activeCount":97},[],{"trials":4298,"activeCount":417,"soonestReadout":113},[4299],{"nctId":110,"briefTitle":111,"status":101,"phases":4300,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":4301,"interventions":4302},[85],[107],[118,92,119,120,121],{"trials":4304,"activeCount":660,"soonestReadout":300},[4305,4309,4313],{"nctId":229,"briefTitle":230,"status":155,"phases":4306,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":4307,"interventions":4308},[86],[107],[92,237,120],{"nctId":260,"briefTitle":261,"status":101,"phases":4310,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":4311,"interventions":4312},[86],[267],[137,92,119,120],{"nctId":297,"briefTitle":298,"status":101,"phases":4314,"primaryCompletion":300,"completion":301,"start":302,"enrollment":303,"conditions":4315,"interventions":4316},[86],[305],[92,119,120,118],{"trials":4318,"activeCount":97},[],{"trials":4320,"activeCount":97},[],{"trials":4322,"activeCount":97},[],{"intervention":121,"totalTrials":593,"cells":4324},{"EARLY_PHASE1":4325,"PHASE1":4327,"PHASE2":4337,"PHASE3":4349,"PHASE4":4351,"NA":4353},{"trials":4326,"activeCount":97},[],{"trials":4328,"activeCount":660,"soonestReadout":1885},[4329,4333],{"nctId":110,"briefTitle":111,"status":101,"phases":4330,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":4331,"interventions":4332},[85],[107],[118,92,119,120,121],{"nctId":1882,"briefTitle":1883,"status":125,"phases":4334,"primaryCompletion":1885,"completion":1886,"start":1887,"enrollment":719,"conditions":4335,"interventions":4336},[85],[107],[121,140,1774,1890,1891],{"trials":4338,"activeCount":417,"soonestReadout":4343},[4339],{"nctId":4340,"briefTitle":4341,"status":125,"phases":4342,"primaryCompletion":4343,"completion":4344,"start":4345,"enrollment":4346,"conditions":4347,"interventions":4348},"NCT06885034","A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed",[85,86],"2027-11-11","2028-06-23","2025-06-11",320,[3764],[121],{"trials":4350,"activeCount":97},[],{"trials":4352,"activeCount":97},[],{"trials":4354,"activeCount":97},[],{"intervention":4356,"totalTrials":593,"cells":4357},"GSK3862995B",{"EARLY_PHASE1":4358,"PHASE1":4360,"PHASE2":4380,"PHASE3":4392,"PHASE4":4394,"NA":4396},{"trials":4359,"activeCount":97},[],{"trials":4361,"activeCount":660,"soonestReadout":4366},[4362,4371],{"nctId":4363,"briefTitle":4364,"status":410,"phases":4365,"primaryCompletion":4366,"completion":4367,"start":4368,"enrollment":255,"conditions":4369,"interventions":4370},"NCT06979518","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry",[85],"2025-11-25","2026-04-27","2025-05-20",[15],[4356],{"nctId":4372,"briefTitle":4373,"status":101,"phases":4374,"primaryCompletion":4375,"completion":4375,"start":4376,"enrollment":4377,"conditions":4378,"interventions":4379},"NCT06154837","A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease",[85],"2026-12-17","2023-11-27",127,[15],[4356],{"trials":4381,"activeCount":417,"soonestReadout":4386},[4382],{"nctId":4383,"briefTitle":4384,"status":410,"phases":4385,"primaryCompletion":4386,"completion":4387,"start":4130,"enrollment":4388,"conditions":4389,"interventions":4391},"NCT07201051","A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis",[86],"2027-03-15","2027-11-08",400,[4390],"Bronchiectasis",[4356],{"trials":4393,"activeCount":97},[],{"trials":4395,"activeCount":97},[],{"trials":4397,"activeCount":97},[],{"intervention":246,"totalTrials":1165,"cells":4399},{"EARLY_PHASE1":4400,"PHASE1":4402,"PHASE2":4408,"PHASE3":4437,"PHASE4":4447,"NA":4449},{"trials":4401,"activeCount":97},[],{"trials":4403,"activeCount":97},[4404],{"nctId":153,"briefTitle":154,"status":155,"phases":4405,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":4406,"interventions":4407},[85],[107],[162,163,137,164,165,166,167,168,92,169,170],{"trials":4409,"activeCount":660,"soonestReadout":273},[4410,4414,4421,4425,4429,4433],{"nctId":2306,"briefTitle":2307,"status":155,"phases":4411,"primaryCompletion":2309,"completion":2310,"start":2311,"enrollment":93,"conditions":4412,"interventions":4413},[85,86],[107],[162,2314,164,216,139],{"nctId":4415,"briefTitle":4416,"status":145,"phases":4417,"primaryCompletion":3088,"completion":3088,"start":4418,"enrollment":1720,"conditions":4419,"interventions":4420},"NCT06790303","Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2",[86],"2021-03-04",[107],[246,247],{"nctId":3085,"briefTitle":3086,"status":155,"phases":4422,"primaryCompletion":3088,"completion":3088,"start":242,"enrollment":3089,"conditions":4423,"interventions":4424},[86],[107],[164,246],{"nctId":239,"briefTitle":240,"status":155,"phases":4426,"primaryCompletion":232,"completion":232,"start":242,"enrollment":243,"conditions":4427,"interventions":4428},[86],[107],[164,246,247,248,92,180],{"nctId":270,"briefTitle":271,"status":101,"phases":4430,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":4431,"interventions":4432},[85,86],[278],[48,163,246,280,92,281,282,283,284],{"nctId":1253,"briefTitle":1254,"status":101,"phases":4434,"primaryCompletion":273,"completion":274,"start":1256,"enrollment":463,"conditions":4435,"interventions":4436},[85,86],[278],[48,246],{"trials":4438,"activeCount":97},[4439,4443],{"nctId":1764,"briefTitle":1765,"status":145,"phases":4440,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":1770,"conditions":4441,"interventions":4442},[87],[305],[246,137,1773,1774],{"nctId":1776,"briefTitle":1777,"status":145,"phases":4444,"primaryCompletion":1767,"completion":1779,"start":1780,"enrollment":1781,"conditions":4445,"interventions":4446},[87],[305],[162,137],{"trials":4448,"activeCount":97},[],{"trials":4450,"activeCount":97},[],{"intervention":4452,"totalTrials":593,"cells":4453},"TYPHIBEV",{"EARLY_PHASE1":4454,"PHASE1":4456,"PHASE2":4458,"PHASE3":4499,"PHASE4":4501,"NA":4503},{"trials":4455,"activeCount":97},[],{"trials":4457,"activeCount":97},[],{"trials":4459,"activeCount":660,"soonestReadout":4477},[4460,4473,4488],{"nctId":4461,"briefTitle":4462,"status":410,"phases":4463,"primaryCompletion":4464,"completion":4464,"start":4465,"enrollment":4466,"conditions":4467,"interventions":4469},"NCT07320716","Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children",[86],"2028-10-31","2026-01-02",528,[4468],"Diarrhoea",[4470,4471,4472,4452],"AltSonflex1-2-3","Menveo","Infanrix hexa",{"nctId":4474,"briefTitle":4475,"status":125,"phases":4476,"primaryCompletion":4477,"completion":4477,"start":4478,"enrollment":4479,"conditions":4480,"interventions":4482},"NCT07286370","A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants",[86],"2028-04-27","2026-04-01",537,[4481],"Salmonella Infections",[4483,4484,4452,4485,4486,4487],"Low dose of iNTS-TCV","Full dose of iNTS-TCV","Prevenar 13","Nimenrix","Saline",{"nctId":4489,"briefTitle":4490,"status":155,"phases":4491,"primaryCompletion":4492,"completion":4492,"start":3320,"enrollment":1196,"conditions":4493,"interventions":4494},"NCT06663436","A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants",[86],"2025-10-21",[4468],[4495,4496,4497,4452,4472,4498],"altSonflex1-2-3 Dose A","altSonflex1-2-3 Dose B","altSonflex1-2-3 Dose C","MR-VAC",{"trials":4500,"activeCount":97},[],{"trials":4502,"activeCount":97},[],{"trials":4504,"activeCount":97},[],{"intervention":4506,"totalTrials":593,"cells":4507},"GSK4532990",{"EARLY_PHASE1":4508,"PHASE1":4510,"PHASE2":4512,"PHASE3":4545,"PHASE4":4547,"NA":4549},{"trials":4509,"activeCount":97},[],{"trials":4511,"activeCount":97},[],{"trials":4513,"activeCount":660,"soonestReadout":4518},[4514,4525,4536],{"nctId":4515,"briefTitle":4516,"status":101,"phases":4517,"primaryCompletion":4518,"completion":4519,"start":4520,"enrollment":4521,"conditions":4522,"interventions":4524},"NCT05583344","Phase 2b Study of GSK4532990 in Adults With NASH",[86],"2026-01-31","2027-04-05","2023-01-02",284,[4523,2037],"Nonalcoholic Fatty Liver Disease",[4506],{"nctId":4526,"briefTitle":4527,"status":125,"phases":4528,"primaryCompletion":4529,"completion":4530,"start":4531,"enrollment":4532,"conditions":4533,"interventions":4535},"NCT06613698","A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease",[86],"2027-08-02","2028-03-07","2024-09-27",393,[4534],"Liver Diseases, Alcoholic",[4506],{"nctId":4537,"briefTitle":4538,"status":155,"phases":4539,"primaryCompletion":4540,"completion":4540,"start":4541,"enrollment":4542,"conditions":4543,"interventions":4544},"NCT06104319","Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH",[86],"2025-09-23","2024-01-22",61,[2037],[4506],{"trials":4546,"activeCount":97},[],{"trials":4548,"activeCount":97},[],{"trials":4550,"activeCount":97},[],{"intervention":4552,"totalTrials":660,"cells":4553},"GSK5926371",{"EARLY_PHASE1":4554,"PHASE1":4556,"PHASE2":4565,"PHASE3":4576,"PHASE4":4578,"NA":4580},{"trials":4555,"activeCount":97},[],{"trials":4557,"activeCount":417,"soonestReadout":4562},[4558],{"nctId":4559,"briefTitle":4560,"status":125,"phases":4561,"primaryCompletion":4562,"completion":4562,"start":1212,"enrollment":1686,"conditions":4563,"interventions":4564},"NCT07371468","A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)",[85],"2028-03-15",[435],[4552],{"trials":4566,"activeCount":417,"soonestReadout":4571},[4567],{"nctId":4568,"briefTitle":4569,"status":410,"phases":4570,"primaryCompletion":4571,"completion":4571,"start":4572,"enrollment":2375,"conditions":4573,"interventions":4575},"NCT07607925","A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL",[85,86],"2029-09-24","2026-06-12",[4574],"Lymphoma, Non-Hodgkin",[4552],{"trials":4577,"activeCount":97},[],{"trials":4579,"activeCount":97},[],{"trials":4581,"activeCount":97},[],{"intervention":118,"totalTrials":660,"cells":4583},{"EARLY_PHASE1":4584,"PHASE1":4586,"PHASE2":4592,"PHASE3":4598,"PHASE4":4600,"NA":4602},{"trials":4585,"activeCount":97},[],{"trials":4587,"activeCount":417,"soonestReadout":113},[4588],{"nctId":110,"briefTitle":111,"status":101,"phases":4589,"primaryCompletion":113,"completion":113,"start":114,"enrollment":115,"conditions":4590,"interventions":4591},[85],[107],[118,92,119,120,121],{"trials":4593,"activeCount":417,"soonestReadout":300},[4594],{"nctId":297,"briefTitle":298,"status":101,"phases":4595,"primaryCompletion":300,"completion":301,"start":302,"enrollment":303,"conditions":4596,"interventions":4597},[86],[305],[92,119,120,118],{"trials":4599,"activeCount":97},[],{"trials":4601,"activeCount":97},[],{"trials":4603,"activeCount":97},[],{"intervention":281,"totalTrials":660,"cells":4605},{"EARLY_PHASE1":4606,"PHASE1":4608,"PHASE2":4610,"PHASE3":4620,"PHASE4":4622,"NA":4624},{"trials":4607,"activeCount":97},[],{"trials":4609,"activeCount":97},[],{"trials":4611,"activeCount":660,"soonestReadout":273},[4612,4616],{"nctId":270,"briefTitle":271,"status":101,"phases":4613,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":4614,"interventions":4615},[85,86],[278],[48,163,246,280,92,281,282,283,284],{"nctId":1201,"briefTitle":1202,"status":101,"phases":4617,"primaryCompletion":273,"completion":274,"start":1204,"enrollment":255,"conditions":4618,"interventions":4619},[85,86],[278],[48,281],{"trials":4621,"activeCount":97},[],{"trials":4623,"activeCount":97},[],{"trials":4625,"activeCount":97},[],{"intervention":4627,"totalTrials":660,"cells":4628},"GSK4527226",{"EARLY_PHASE1":4629,"PHASE1":4631,"PHASE2":4633,"PHASE3":4654,"PHASE4":4656,"NA":4658},{"trials":4630,"activeCount":97},[],{"trials":4632,"activeCount":97},[],{"trials":4634,"activeCount":660,"soonestReadout":2626},[4635,4646],{"nctId":4636,"briefTitle":4637,"status":125,"phases":4638,"primaryCompletion":4639,"completion":4640,"start":4641,"enrollment":4642,"conditions":4643,"interventions":4645},"NCT07105709","Open-label Extension Study in Participants With Early Alzheimer's Disease",[86],"2028-09-15","2028-12-08","2025-08-14",220,[4644],"Alzheimer's Disease",[4627],{"nctId":4647,"briefTitle":4648,"status":101,"phases":4649,"primaryCompletion":2626,"completion":198,"start":4650,"enrollment":4651,"conditions":4652,"interventions":4653},"NCT06079190","Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease",[86],"2023-10-20",367,[4644],[4627],{"trials":4655,"activeCount":97},[],{"trials":4657,"activeCount":97},[],{"trials":4659,"activeCount":97},[],{"intervention":4472,"totalTrials":1279,"cells":4661},{"EARLY_PHASE1":4662,"PHASE1":4664,"PHASE2":4666,"PHASE3":4731,"PHASE4":4861,"NA":4894},{"trials":4663,"activeCount":97},[],{"trials":4665,"activeCount":97},[],{"trials":4667,"activeCount":417,"soonestReadout":4464},[4668,4672,4685,4695,4708,4717,4727],{"nctId":4461,"briefTitle":4462,"status":410,"phases":4669,"primaryCompletion":4464,"completion":4464,"start":4465,"enrollment":4466,"conditions":4670,"interventions":4671},[86],[4468],[4470,4471,4472,4452],{"nctId":4673,"briefTitle":4674,"status":155,"phases":4675,"primaryCompletion":4676,"completion":4677,"start":4678,"enrollment":4679,"conditions":4680,"interventions":4681},"NCT01204658","Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV\u002FHib in Healthy Infants",[86],"2011-11-03","2012-10-01","2010-09-27",576,[3637],[4682,4682,4683,4485,4684],"Pneumococcal vaccine GSK 2189242A","Synflorix","Infanrix Hexa",{"nctId":4686,"briefTitle":4687,"status":155,"phases":4688,"primaryCompletion":4689,"completion":4690,"start":4691,"enrollment":781,"conditions":4692,"interventions":4693},"NCT00513409","Assess Reacto- and Immunogenicity of Pneumococcal Conjugate Vaccine When Given as Booster or a 2 Dose Catch up Schedule",[86],"2008-02-20","2008-08-28","2007-08-22",[3637],[4683,4684,4694],"Havrix",{"nctId":4696,"briefTitle":4697,"status":145,"phases":4698,"primaryCompletion":4699,"completion":4699,"start":4700,"enrollment":433,"conditions":4701,"interventions":4705},"NCT00871741","Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.",[86],"2009-06-25","2009-04-01",[33,4702,4703,4704,30,3624,24],"Poliomyelitis","Neisseria Meningitidis","Haemophilus Influenzae Type b",[4706,4472,4707],"GSK2202083A vaccine","Menjugate",{"nctId":4709,"briefTitle":4710,"status":155,"phases":4711,"primaryCompletion":4712,"completion":4712,"start":4713,"enrollment":4714,"conditions":4715,"interventions":4716},"NCT00627458","Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV\u002FHib Vaccine",[86],"2008-08-18","2008-02-01",403,[3624,30,4702,4704,33,24],[4684],{"nctId":4718,"briefTitle":4719,"status":155,"phases":4720,"primaryCompletion":4721,"completion":4721,"start":4722,"enrollment":4723,"conditions":4724,"interventions":4725},"NCT01453998","Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV\u002FHib Vaccine (GSK217744)",[86],"2012-11-12","2011-10-14",657,[3624,24,4704,33,30,4702],[4472,4485,4726],"GSK217744",{"nctId":4489,"briefTitle":4490,"status":155,"phases":4728,"primaryCompletion":4492,"completion":4492,"start":3320,"enrollment":1196,"conditions":4729,"interventions":4730},[86],[4468],[4495,4496,4497,4452,4472,4498],{"trials":4732,"activeCount":97},[4733,4752,4764,4774,4785,4795,4812,4822,4831,4839,4850],{"nctId":4734,"briefTitle":4735,"status":155,"phases":4736,"primaryCompletion":4737,"completion":4738,"start":4739,"enrollment":4740,"conditions":4741,"interventions":4743},"NCT00463437","Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines",[87],"2008-01-21","2008-06-14","2007-04-25",1437,[24,3624,33,4702,30,4742],"Streptococcus Pneumoniae Vaccines",[4744,4745,4472,4746,4747,4748,4749,4750,4751],"Pneumococcal conjugate vaccine GSK1024850A","Prevenar","Infanrix IPV Hib","Infanrix penta","Infanrix IPV","Meningitec","NeisVac-C","Menitorix",{"nctId":4753,"briefTitle":4754,"status":155,"phases":4755,"completion":4756,"start":4757,"enrollment":4388,"conditions":4758,"interventions":4760},"NCT00370318","Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines",[87],"2007-04","2006-09",[4759],"Infections, Rotavirus",[4761,4684,4762,4763],"10 valent pneumococcal conjugate vaccine","Rotarix","Paracetamol",{"nctId":4765,"briefTitle":4766,"status":155,"phases":4767,"primaryCompletion":4768,"completion":4769,"start":4770,"enrollment":4771,"conditions":4772,"interventions":4773},"NCT00533507","Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of Age",[87],"2008-06-01","2008-06-06","2007-09-18",230,[4759],[4683,4472,4762],{"nctId":4775,"briefTitle":4776,"status":155,"phases":4777,"primaryCompletion":4778,"completion":4778,"start":4779,"enrollment":4780,"conditions":4781,"interventions":4782},"NCT00624819","Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine",[87],"2008-06-02","2008-03-03",524,[3637,4742],[4783,4745,4472,4694,4784],"GSK1024805A","Varilrix",{"nctId":4786,"briefTitle":4787,"status":155,"phases":4788,"primaryCompletion":4789,"completion":4790,"start":4791,"enrollment":4792,"conditions":4793,"interventions":4794},"NCT00390910","Study to Evaluate the Safety and Immunogenicity of a 10-valent Pneumococcal Conjugate Vaccine in Preterm Infants",[87],"2007-07-02","2008-05-02","2006-10-01",286,[3637],[4744,4472],{"nctId":4796,"briefTitle":4797,"status":155,"phases":4798,"primaryCompletion":4799,"completion":4800,"start":4801,"enrollment":4802,"conditions":4803,"interventions":4804},"NCT02096263","Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants",[87],"2015-02-06","2015-11-13","2014-04-16",585,[4702,30,4704,33,3624,24],[4472,4805,4806,4807,4808,4809,4810,4811,4762],"Pediarix","ActHIB","Pentacel","Engerix-B","Infanrix","Hiberix","Prevnar13",{"nctId":4813,"briefTitle":4814,"status":155,"phases":4815,"primaryCompletion":4816,"completion":4816,"start":4817,"enrollment":4818,"conditions":4819,"interventions":4820},"NCT00808444","Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age",[87],"2009-11-02","2009-01-05",466,[3637],[4744,4472,4821,4762],"Infanrix-IPV\u002FHib",{"nctId":4823,"briefTitle":4824,"status":155,"phases":4825,"primaryCompletion":4826,"completion":4827,"start":4828,"enrollment":2069,"conditions":4829,"interventions":4830},"NCT00370396","Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine.",[87],"2007-06-04","2007-11-06","2006-09-25",[3637],[4683,4745,4472],{"nctId":4832,"briefTitle":4833,"status":155,"phases":4834,"primaryCompletion":4835,"completion":4835,"start":4836,"enrollment":4771,"conditions":4837,"interventions":4838},"NCT00489554","Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of Age",[87],"2008-03-31","2007-07-03",[3637,4742],[4683,4472,4762],{"nctId":4840,"briefTitle":4841,"status":155,"phases":4842,"primaryCompletion":4843,"completion":4843,"start":4844,"enrollment":590,"conditions":4845,"interventions":4846},"NCT00327184","Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine",[87],"2006-11","2006-04",[4703,4704],[4847,4848,4472,4849],"Haemophilus influenzae type b- and meningococcal serogroup C","Infanrix Penta","Neis-Vac-C",{"nctId":4851,"briefTitle":4852,"status":155,"phases":4853,"primaryCompletion":4854,"completion":4855,"start":4856,"enrollment":4857,"conditions":4858,"interventions":4859},"NCT00466947","COMPAS (Clinical Otitis Media & Pneumonia Study): Pneumonia & Acute Otitis Media (AOM ) Efficacy Study of the Pneumococcal Conjugate Vaccine",[87],"2010-08-31","2011-07-28","2007-06-28",23802,[3637],[4744,4694,4808,4472,4860],"GSK Biologicals' DTPa-IPV\u002FHib vaccine",{"trials":4862,"activeCount":97},[4863,4873,4885],{"nctId":4864,"briefTitle":4865,"status":155,"phases":4866,"primaryCompletion":4867,"completion":4867,"start":4868,"enrollment":4869,"conditions":4870,"interventions":4872},"NCT02422264","Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery",[88],"2018-03-07","2016-01-22",601,[3624,33,4702,30,4871],"Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines",[4472,4811],{"nctId":4874,"briefTitle":4875,"status":155,"phases":4876,"primaryCompletion":4877,"completion":4878,"start":4879,"enrollment":4880,"conditions":4881,"interventions":4882},"NCT01235949","Primary and Booster Vaccination Study With Pneumococcal Vaccine GSK1024850A and Prophylactic Antipyretic Treatment",[88],"2012-03-28","2012-12-08","2010-11-12",850,[3637],[4883,4472,4821,4884,4763],"GSK1024850A","Ibuprofen",{"nctId":4886,"briefTitle":4887,"status":155,"phases":4888,"primaryCompletion":4889,"completion":4889,"start":4890,"enrollment":4891,"conditions":4892,"interventions":4893},"NCT02853929","Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery",[88],"2019-03-19","2016-09-19",551,[30,24,3624,4704,33,4702,4871],[4472],{"trials":4895,"activeCount":97},[],{"intervention":4897,"totalTrials":593,"cells":4898},"MenACWY",{"EARLY_PHASE1":4899,"PHASE1":4901,"PHASE2":4903,"PHASE3":4930,"PHASE4":4932,"NA":4943},{"trials":4900,"activeCount":97},[],{"trials":4902,"activeCount":97},[],{"trials":4904,"activeCount":417,"soonestReadout":2626},[4905,4916],{"nctId":4906,"briefTitle":4907,"status":155,"phases":4908,"primaryCompletion":4909,"completion":4910,"start":4911,"enrollment":4912,"conditions":4913,"interventions":4914},"NCT03433482","A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age",[86],"2019-07-26","2019-12-17","2018-08-30",1707,[1005],[4915,4897],"MenACWY liquid",{"nctId":4917,"briefTitle":4918,"status":101,"phases":4919,"primaryCompletion":2626,"completion":2626,"start":4920,"enrollment":4921,"conditions":4922,"interventions":4923},"NCT06213506","A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants",[86],"2024-01-15",215,[4481],[4924,4925,4926,4897,4927,4928,4929],"iNTS-GMMA Dose C","iNTS-GMMA Dose B","iNTS-GMMA Dose A","DTPa-HBV-IPV+Hib","Measles and Rubella vaccine","Yellow Fever vaccine",{"trials":4931,"activeCount":97},[],{"trials":4933,"activeCount":97},[4934],{"nctId":4935,"briefTitle":4936,"status":155,"phases":4937,"primaryCompletion":4938,"completion":4938,"start":4939,"enrollment":4940,"conditions":4941,"interventions":4942},"NCT02446691","Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations",[88],"2017-12-28","2015-07-13",128,[992],[4897],{"trials":4944,"activeCount":97},[],{"intervention":4485,"totalTrials":628,"cells":4946},{"EARLY_PHASE1":4947,"PHASE1":4949,"PHASE2":4951,"PHASE3":4965,"PHASE4":5002,"NA":5004},{"trials":4948,"activeCount":97},[],{"trials":4950,"activeCount":97},[],{"trials":4952,"activeCount":417,"soonestReadout":4477},[4953,4957,4961],{"nctId":4673,"briefTitle":4674,"status":155,"phases":4954,"primaryCompletion":4676,"completion":4677,"start":4678,"enrollment":4679,"conditions":4955,"interventions":4956},[86],[3637],[4682,4682,4683,4485,4684],{"nctId":4718,"briefTitle":4719,"status":155,"phases":4958,"primaryCompletion":4721,"completion":4721,"start":4722,"enrollment":4723,"conditions":4959,"interventions":4960},[86],[3624,24,4704,33,30,4702],[4472,4485,4726],{"nctId":4474,"briefTitle":4475,"status":125,"phases":4962,"primaryCompletion":4477,"completion":4477,"start":4478,"enrollment":4479,"conditions":4963,"interventions":4964},[86],[4481],[4483,4484,4452,4485,4486,4487],{"trials":4966,"activeCount":97},[4967,4980,4990],{"nctId":4968,"briefTitle":4969,"status":155,"phases":4970,"primaryCompletion":4971,"completion":4972,"start":4973,"enrollment":4974,"conditions":4975,"interventions":4976},"NCT01439360","An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children",[87],"2014-10-31","2014-12-31","2011-10-01",12046,[21],[4977,4978,4485,4979,4784],"Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A","Havrix Junior","Varivax\u002FProVarivax",{"nctId":4981,"briefTitle":4982,"status":155,"phases":4983,"primaryCompletion":4984,"completion":4985,"start":4986,"enrollment":4987,"conditions":4988,"interventions":4989},"NCT01641133","Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™",[87],"2013-07-15","2014-05-07","2012-09-04",457,[3637,4742],[4683,4683,4683,4485,4485],{"nctId":4991,"briefTitle":4992,"status":155,"phases":4993,"primaryCompletion":4994,"completion":4995,"start":4996,"enrollment":4997,"conditions":4998,"interventions":5001},"NCT03207750","This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine",[87],"2018-10-09","2019-03-01","2017-09-14",1280,[4999,5000],"Rotavirus Infection","Rotavirus Vaccines",[4762,4805,4810,4485],{"trials":5003,"activeCount":97},[],{"trials":5005,"activeCount":97},[],{"intervention":4486,"totalTrials":1517,"cells":5007},{"EARLY_PHASE1":5008,"PHASE1":5010,"PHASE2":5012,"PHASE3":5026,"PHASE4":5059,"NA":5061},{"trials":5009,"activeCount":97},[],{"trials":5011,"activeCount":97},[],{"trials":5013,"activeCount":417,"soonestReadout":4477},[5014,5022],{"nctId":5015,"briefTitle":5016,"status":155,"phases":5017,"primaryCompletion":484,"completion":3045,"start":5018,"enrollment":5019,"conditions":5020,"interventions":5021},"NCT00715910","The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents\u002FAdults",[86],"2008-07",818,[992],[4486],{"nctId":4474,"briefTitle":4475,"status":125,"phases":5023,"primaryCompletion":4477,"completion":4477,"start":4478,"enrollment":4479,"conditions":5024,"interventions":5025},[86],[4481],[4483,4484,4452,4485,4486,4487],{"trials":5027,"activeCount":97},[5028,5038,5049],{"nctId":5029,"briefTitle":5030,"status":155,"phases":5031,"primaryCompletion":5032,"completion":5032,"start":5033,"enrollment":5034,"conditions":5035,"interventions":5036},"NCT00465816","Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612",[87],"2008-04-28","2007-04-11",611,[992],[4486,5037],"Twinrix",{"nctId":5039,"briefTitle":5040,"status":155,"phases":5041,"primaryCompletion":5042,"completion":5043,"start":4770,"enrollment":5044,"conditions":5045,"interventions":5047},"NCT00514904","Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects",[87],"2008-09-03","2009-01-06",1504,[992,5046],"Meningococcal Vaccines",[4486,5048],"Mencevax",{"nctId":5050,"briefTitle":5051,"status":155,"phases":5052,"primaryCompletion":5053,"completion":5054,"start":5055,"enrollment":5056,"conditions":5057,"interventions":5058},"NCT01266993","Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children",[87],"2014-03-31","2014-05-17","2011-01-03",271,[992,5046],[4486,4707],{"trials":5060,"activeCount":97},[],{"trials":5062,"activeCount":97},[],{"intervention":5064,"totalTrials":593,"cells":5065},"MenABCWY vaccine",{"EARLY_PHASE1":5066,"PHASE1":5068,"PHASE2":5070,"PHASE3":5091,"PHASE4":5104,"NA":5106},{"trials":5067,"activeCount":97},[],{"trials":5069,"activeCount":97},[],{"trials":5071,"activeCount":417,"soonestReadout":5086},[5072,5082],{"nctId":5073,"briefTitle":5074,"status":155,"phases":5075,"primaryCompletion":5076,"completion":5076,"start":5077,"enrollment":1307,"conditions":5078,"interventions":5079},"NCT03587207","Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years",[86],"2018-12-19","2018-07-09",[1005],[5064,5080,5081],"rMenB+OMV NZ (Bexsero) vaccine","MenACWY (Menveo) vaccine",{"nctId":5083,"briefTitle":5084,"status":101,"phases":5085,"primaryCompletion":5086,"completion":5086,"start":5087,"enrollment":5088,"conditions":5089,"interventions":5090},"NCT05087056","Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents",[86],"2027-03-10","2021-11-18",312,[1005],[5064],{"trials":5092,"activeCount":97},[5093],{"nctId":5094,"briefTitle":5095,"status":155,"phases":5096,"primaryCompletion":5097,"completion":5098,"start":5099,"enrollment":2058,"conditions":5100,"interventions":5101},"NCT04707391","Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine",[87],"2023-05-03","2023-09-29","2021-01-25",[1005],[5064,5102,5103],"MenACWY vaccine","MenB vaccine",{"trials":5105,"activeCount":97},[],{"trials":5107,"activeCount":97},[],{"intervention":5109,"totalTrials":660,"cells":5110},"Yellow fever vaccine",{"EARLY_PHASE1":5111,"PHASE1":5113,"PHASE2":5115,"PHASE3":5121,"PHASE4":5141,"NA":5143},{"trials":5112,"activeCount":97},[],{"trials":5114,"activeCount":97},[],{"trials":5116,"activeCount":417,"soonestReadout":2626},[5117],{"nctId":4917,"briefTitle":4918,"status":101,"phases":5118,"primaryCompletion":2626,"completion":2626,"start":4920,"enrollment":4921,"conditions":5119,"interventions":5120},[86],[4481],[4924,4925,4926,4897,4927,4928,4929],{"trials":5122,"activeCount":97},[5123],{"nctId":5124,"briefTitle":5125,"status":155,"phases":5126,"primaryCompletion":5127,"completion":5128,"start":5129,"enrollment":5130,"conditions":5131,"interventions":5133},"NCT01345240","Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049)",[87],"2013-01-09","2017-02-09","2011-11-17",705,[3287,5132],"Malaria Vaccines",[5134,5135,5136,5137,5138,5139,5140,5109],"GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049","Engerix-B™ vaccine","Infanrix\u002FHib™ vaccine","Polio Sabin™ vaccine","Rotarix™ vaccine","Synflorix™ vaccine","Measles vaccine",{"trials":5142,"activeCount":97},[],{"trials":5144,"activeCount":97},[],{"intervention":1241,"totalTrials":361,"cells":5146},{"EARLY_PHASE1":5147,"PHASE1":5149,"PHASE2":5173,"PHASE3":5218,"PHASE4":5220,"NA":5222},{"trials":5148,"activeCount":97},[],{"trials":5150,"activeCount":97},[5151,5155,5164],{"nctId":1641,"briefTitle":1642,"status":145,"phases":5152,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":628,"conditions":5153,"interventions":5154},[85],[107],[1649,1650,1651,1241,137],{"nctId":5156,"briefTitle":5157,"status":155,"phases":5158,"primaryCompletion":5159,"completion":5159,"start":5160,"enrollment":750,"conditions":5161,"interventions":5162},"NCT02588612","Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)",[85],"2020-08-10","2016-02-01",[107],[5163,1241,1651],"letetresgene autoleucel",{"nctId":5165,"briefTitle":5166,"status":155,"phases":5167,"primaryCompletion":5168,"completion":5168,"start":5169,"enrollment":1003,"conditions":5170,"interventions":5171},"NCT01343043","A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma",[85],"2019-06-18","2012-09-27",[107],[5172,1651,1241],"NY-ESO-1(c259)T Cells",{"trials":5174,"activeCount":417,"soonestReadout":1236},[5175,5179,5183,5187,5191,5202,5210,5214],{"nctId":2292,"briefTitle":2293,"status":155,"phases":5176,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":2297,"conditions":5177,"interventions":5178},[86],[668],[2300,2301,2264,2302,2303,2304],{"nctId":1694,"briefTitle":1695,"status":500,"phases":5180,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":97,"conditions":5181,"interventions":5182},[86],[107],[1701,137,1651,1241],{"nctId":2316,"briefTitle":2317,"status":145,"phases":5184,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":5185,"interventions":5186},[86],[668],[2324,2325,2326,2327,1241,164,2328,2329,216,2330],{"nctId":2341,"briefTitle":2342,"status":500,"phases":5188,"primaryCompletion":2344,"completion":2344,"start":2344,"enrollment":97,"conditions":5189,"interventions":5190},[86],[668],[2274,2330,2329,1241,216],{"nctId":5192,"briefTitle":5193,"status":155,"phases":5194,"primaryCompletion":2794,"completion":5195,"start":5196,"enrollment":4542,"conditions":5197,"interventions":5199},"NCT00410163","Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients",[86],"2013-05","2007-01",[5198],"Leukaemia, Lymphocytic, Chronic",[5200,5201,1651,1241],"Ofatumumab 500mg","Ofatumumab 1000mg",{"nctId":5203,"briefTitle":5204,"status":155,"phases":5205,"primaryCompletion":5206,"completion":114,"start":5207,"enrollment":314,"conditions":5208,"interventions":5209},"NCT02992743","Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid\u002F Round Cell Liposarcoma",[86],"2021-11-01","2016-12-06",[107],[5163,1241,1651],{"nctId":3547,"briefTitle":3548,"status":155,"phases":5211,"primaryCompletion":3550,"completion":3551,"start":3552,"enrollment":2759,"conditions":5212,"interventions":5213},[86],[3554],[3556,1241,2328,3557,3558],{"nctId":1233,"briefTitle":1234,"status":410,"phases":5215,"primaryCompletion":1236,"completion":1236,"start":686,"enrollment":1237,"conditions":5216,"interventions":5217},[86],[1239],[48,1241,1093,283],{"trials":5219,"activeCount":97},[],{"trials":5221,"activeCount":97},[],{"trials":5223,"activeCount":97},[],{"intervention":163,"totalTrials":1517,"cells":5225},{"EARLY_PHASE1":5226,"PHASE1":5228,"PHASE2":5242,"PHASE3":5252,"PHASE4":5254,"NA":5256},{"trials":5227,"activeCount":97},[],{"trials":5229,"activeCount":97},[5230,5234,5238],{"nctId":1667,"briefTitle":1668,"status":155,"phases":5231,"primaryCompletion":1670,"completion":1670,"start":1671,"enrollment":1672,"conditions":5232,"interventions":5233},[85],[107],[163,137],{"nctId":153,"briefTitle":154,"status":155,"phases":5235,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":5236,"interventions":5237},[85],[107],[162,163,137,164,165,166,167,168,92,169,170],{"nctId":1680,"briefTitle":1681,"status":155,"phases":5239,"primaryCompletion":1683,"completion":1684,"start":1685,"enrollment":1686,"conditions":5240,"interventions":5241},[85],[107],[1689,163,1690,137],{"trials":5243,"activeCount":417,"soonestReadout":273},[5244,5248],{"nctId":1161,"briefTitle":1162,"status":145,"phases":5245,"primaryCompletion":1164,"completion":1164,"start":275,"enrollment":1165,"conditions":5246,"interventions":5247},[85,86],[191],[193,163],{"nctId":270,"briefTitle":271,"status":101,"phases":5249,"primaryCompletion":273,"completion":274,"start":275,"enrollment":276,"conditions":5250,"interventions":5251},[85,86],[278],[48,163,246,280,92,281,282,283,284],{"trials":5253,"activeCount":97},[],{"trials":5255,"activeCount":97},[],{"trials":5257,"activeCount":97},[],{"intervention":4487,"totalTrials":181,"cells":5259},{"EARLY_PHASE1":5260,"PHASE1":5262,"PHASE2":5294,"PHASE3":5300,"PHASE4":5302,"NA":5304},{"trials":5261,"activeCount":97},[],{"trials":5263,"activeCount":97},[5264,5274,5284],{"nctId":5265,"briefTitle":5266,"status":155,"phases":5267,"primaryCompletion":5268,"completion":5268,"start":5269,"enrollment":2836,"conditions":5270,"interventions":5272},"NCT01449838","Phase I Study of Colistin Methanesulfonate Sodium",[85],"2010-12-09","2010-10-23",[5271],"Infections, Pseudomonas",[5273,4487],"Colistimethate sodium",{"nctId":5275,"briefTitle":5276,"status":145,"phases":5277,"primaryCompletion":5278,"completion":5278,"start":2974,"enrollment":149,"conditions":5279,"interventions":5281},"NCT03511105","Effects of GSK2798745 on Alveolar Barrier Disruption in a Segmental Lipopolysaccharide (LPS) Challenge Model",[85],"2018-12-18",[5280],"Healthy Volunteers",[5282,5283,4487],"GSK2798745","Lipoplysaccharide from Escherichia Coli",{"nctId":5285,"briefTitle":5286,"status":155,"phases":5287,"primaryCompletion":5288,"completion":5288,"start":5289,"enrollment":593,"conditions":5290,"interventions":5292},"NCT01640990","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers",[85],"2011-12-09","2011-11-22",[5291],"Lung Injury, Acute",[4487,5293,5293],"GW328267X",{"trials":5295,"activeCount":417,"soonestReadout":4477},[5296],{"nctId":4474,"briefTitle":4475,"status":125,"phases":5297,"primaryCompletion":4477,"completion":4477,"start":4478,"enrollment":4479,"conditions":5298,"interventions":5299},[86],[4481],[4483,4484,4452,4485,4486,4487],{"trials":5301,"activeCount":97},[],{"trials":5303,"activeCount":97},[],{"trials":5305,"activeCount":97},[],{"intervention":4471,"totalTrials":660,"cells":5307},{"EARLY_PHASE1":5308,"PHASE1":5310,"PHASE2":5312,"PHASE3":5330,"PHASE4":5332,"NA":5334},{"trials":5309,"activeCount":97},[],{"trials":5311,"activeCount":97},[],{"trials":5313,"activeCount":417,"soonestReadout":4464},[5314,5318],{"nctId":4461,"briefTitle":4462,"status":410,"phases":5315,"primaryCompletion":4464,"completion":4464,"start":4465,"enrollment":4466,"conditions":5316,"interventions":5317},[86],[4468],[4470,4471,4472,4452],{"nctId":5319,"briefTitle":5320,"status":155,"phases":5321,"primaryCompletion":5322,"completion":5322,"start":5323,"enrollment":4158,"conditions":5324,"interventions":5326},"NCT02676895","A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults",[86],"2017-03-10","2016-08-08",[5325],"Shigella Sonnei Infection",[5327,5328,4471,5329],"GVGH S. sonnei (1790GAHB) vaccine 25 μg","GVGH S. sonnei (1790GAHB) vaccine 100 μg","Boostrix",{"trials":5331,"activeCount":97},[],{"trials":5333,"activeCount":97},[],{"trials":5335,"activeCount":97},[],{"intervention":5337,"totalTrials":660,"cells":5338},"Flu mRNA",{"EARLY_PHASE1":5339,"PHASE1":5341,"PHASE2":5343,"PHASE3":5367,"PHASE4":5369,"NA":5371},{"trials":5340,"activeCount":97},[],{"trials":5342,"activeCount":97},[],{"trials":5344,"activeCount":417,"soonestReadout":5349},[5345,5358],{"nctId":5346,"briefTitle":5347,"status":101,"phases":5348,"primaryCompletion":5349,"completion":5349,"start":5350,"enrollment":5351,"conditions":5352,"interventions":5354},"NCT07204964","A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above",[86],"2026-07-31","2025-10-07",971,[5353],"Influenza, Human",[5337,5337,5337,5355,5356,5357],"Comparator 1","Comparator 2","Comparator 3",{"nctId":5359,"briefTitle":5360,"status":155,"phases":5361,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":5364,"conditions":5365,"interventions":5366},"NCT07121192","A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older",[86],"2026-05-11","2025-08-25",776,[5353],[5337,5337,5355,5356,5357],{"trials":5368,"activeCount":97},[],{"trials":5370,"activeCount":97},[],{"trials":5372,"activeCount":97},[],{"intervention":5355,"totalTrials":660,"cells":5374},{"EARLY_PHASE1":5375,"PHASE1":5377,"PHASE2":5379,"PHASE3":5389,"PHASE4":5391,"NA":5393},{"trials":5376,"activeCount":97},[],{"trials":5378,"activeCount":97},[],{"trials":5380,"activeCount":417,"soonestReadout":5349},[5381,5385],{"nctId":5346,"briefTitle":5347,"status":101,"phases":5382,"primaryCompletion":5349,"completion":5349,"start":5350,"enrollment":5351,"conditions":5383,"interventions":5384},[86],[5353],[5337,5337,5337,5355,5356,5357],{"nctId":5359,"briefTitle":5360,"status":155,"phases":5386,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":5364,"conditions":5387,"interventions":5388},[86],[5353],[5337,5337,5355,5356,5357],{"trials":5390,"activeCount":97},[],{"trials":5392,"activeCount":97},[],{"trials":5394,"activeCount":97},[],{"intervention":5356,"totalTrials":660,"cells":5396},{"EARLY_PHASE1":5397,"PHASE1":5399,"PHASE2":5401,"PHASE3":5411,"PHASE4":5413,"NA":5415},{"trials":5398,"activeCount":97},[],{"trials":5400,"activeCount":97},[],{"trials":5402,"activeCount":417,"soonestReadout":5349},[5403,5407],{"nctId":5346,"briefTitle":5347,"status":101,"phases":5404,"primaryCompletion":5349,"completion":5349,"start":5350,"enrollment":5351,"conditions":5405,"interventions":5406},[86],[5353],[5337,5337,5337,5355,5356,5357],{"nctId":5359,"briefTitle":5360,"status":155,"phases":5408,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":5364,"conditions":5409,"interventions":5410},[86],[5353],[5337,5337,5355,5356,5357],{"trials":5412,"activeCount":97},[],{"trials":5414,"activeCount":97},[],{"trials":5416,"activeCount":97},[],{"intervention":5357,"totalTrials":660,"cells":5418},{"EARLY_PHASE1":5419,"PHASE1":5421,"PHASE2":5423,"PHASE3":5433,"PHASE4":5435,"NA":5437},{"trials":5420,"activeCount":97},[],{"trials":5422,"activeCount":97},[],{"trials":5424,"activeCount":417,"soonestReadout":5349},[5425,5429],{"nctId":5346,"briefTitle":5347,"status":101,"phases":5426,"primaryCompletion":5349,"completion":5349,"start":5350,"enrollment":5351,"conditions":5427,"interventions":5428},[86],[5353],[5337,5337,5337,5355,5356,5357],{"nctId":5359,"briefTitle":5360,"status":155,"phases":5430,"primaryCompletion":5362,"completion":5362,"start":5363,"enrollment":5364,"conditions":5431,"interventions":5432},[86],[5353],[5337,5337,5355,5356,5357],{"trials":5434,"activeCount":97},[],{"trials":5436,"activeCount":97},[],{"trials":5438,"activeCount":97},[],{"intervention":5440,"totalTrials":417,"cells":5441},"Adjuvanted RSVPreF3 vaccine",{"EARLY_PHASE1":5442,"PHASE1":5444,"PHASE2":5446,"PHASE3":5457,"PHASE4":5459,"NA":5461},{"trials":5443,"activeCount":97},[],{"trials":5445,"activeCount":97},[],{"trials":5447,"activeCount":417,"soonestReadout":5452},[5448],{"nctId":5449,"briefTitle":5450,"status":125,"phases":5451,"primaryCompletion":5452,"completion":5453,"start":5454,"enrollment":2095,"conditions":5455,"interventions":5456},"NCT07092865","A Study Evaluating Persistence of the Immune Response of the Adjuvanted Respiratory Syncytial Virus (RSV) Vaccine and the Safety and Immune Response Following Revaccination in Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant",[86],"2027-01-12","2027-07-16","2025-08-06",[2620],[5440],{"trials":5458,"activeCount":97},[],{"trials":5460,"activeCount":97},[],{"trials":5462,"activeCount":97},[],{"intervention":4470,"totalTrials":417,"cells":5464},{"EARLY_PHASE1":5465,"PHASE1":5467,"PHASE2":5469,"PHASE3":5475,"PHASE4":5477,"NA":5479},{"trials":5466,"activeCount":97},[],{"trials":5468,"activeCount":97},[],{"trials":5470,"activeCount":417,"soonestReadout":4464},[5471],{"nctId":4461,"briefTitle":4462,"status":410,"phases":5472,"primaryCompletion":4464,"completion":4464,"start":4465,"enrollment":4466,"conditions":5473,"interventions":5474},[86],[4468],[4470,4471,4472,4452],{"trials":5476,"activeCount":97},[],{"trials":5478,"activeCount":97},[],{"trials":5480,"activeCount":97},[],{"intervention":5482,"totalTrials":417,"cells":5483},"PED-HZ\u002Fsu",{"EARLY_PHASE1":5484,"PHASE1":5486,"PHASE2":5488,"PHASE3":5498,"PHASE4":5500,"NA":5502},{"trials":5485,"activeCount":97},[],{"trials":5487,"activeCount":97},[],{"trials":5489,"activeCount":417,"soonestReadout":5494},[5490],{"nctId":5491,"briefTitle":5492,"status":125,"phases":5493,"primaryCompletion":5494,"completion":1052,"start":5495,"enrollment":2095,"conditions":5496,"interventions":5497},"NCT04006808","A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant",[85,86],"2026-05-01","2019-10-25",[1030],[5482],{"trials":5499,"activeCount":97},[],{"trials":5501,"activeCount":97},[],{"trials":5503,"activeCount":97},[],{"intervention":5505,"totalTrials":417,"cells":5506},"GSK5784283",{"EARLY_PHASE1":5507,"PHASE1":5509,"PHASE2":5511,"PHASE3":5523,"PHASE4":5525,"NA":5527},{"trials":5508,"activeCount":97},[],{"trials":5510,"activeCount":97},[],{"trials":5512,"activeCount":417,"soonestReadout":5517},[5513],{"nctId":5514,"briefTitle":5515,"status":101,"phases":5516,"primaryCompletion":5517,"completion":5518,"start":5519,"enrollment":5520,"conditions":5521,"interventions":5522},"NCT06748053","A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma",[86],"2026-07-17","2027-09-09","2025-02-10",307,[18],[5505],{"trials":5524,"activeCount":97},[],{"trials":5526,"activeCount":97},[],{"trials":5528,"activeCount":97},[],{"intervention":5530,"totalTrials":417,"cells":5531},"GSK5460025",{"EARLY_PHASE1":5532,"PHASE1":5534,"PHASE2":5536,"PHASE3":5546,"PHASE4":5548,"NA":5550},{"trials":5533,"activeCount":97},[],{"trials":5535,"activeCount":97},[],{"trials":5537,"activeCount":417,"soonestReadout":5542},[5538],{"nctId":5539,"briefTitle":5540,"status":125,"phases":5541,"primaryCompletion":5542,"completion":5543,"start":1607,"enrollment":149,"conditions":5544,"interventions":5545},"NCT07213609","A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors",[85,86],"2028-09-28","2028-10-27",[2667,107],[5530],{"trials":5547,"activeCount":97},[],{"trials":5549,"activeCount":97},[],{"trials":5551,"activeCount":97},[],{"intervention":2099,"totalTrials":417,"cells":5553},{"EARLY_PHASE1":5554,"PHASE1":5556,"PHASE2":5558,"PHASE3":5564,"PHASE4":5566,"NA":5568},{"trials":5555,"activeCount":97},[],{"trials":5557,"activeCount":97},[],{"trials":5559,"activeCount":417,"soonestReadout":2092},[5560],{"nctId":2089,"briefTitle":2090,"status":410,"phases":5561,"primaryCompletion":2092,"completion":2093,"start":2094,"enrollment":2095,"conditions":5562,"interventions":5563},[85,86],[2097],[133,2099],{"trials":5565,"activeCount":97},[],{"trials":5567,"activeCount":97},[],{"trials":5569,"activeCount":97},[],{"intervention":5571,"totalTrials":417,"cells":5572},"RTS,S\u002FAS01E vaccine",{"EARLY_PHASE1":5573,"PHASE1":5575,"PHASE2":5577,"PHASE3":5586,"PHASE4":5588,"NA":5590},{"trials":5574,"activeCount":97},[],{"trials":5576,"activeCount":97},[],{"trials":5578,"activeCount":417,"soonestReadout":5583},[5579],{"nctId":5580,"briefTitle":5581,"status":125,"phases":5582,"primaryCompletion":5583,"completion":5583,"start":5454,"enrollment":4086,"conditions":5584,"interventions":5585},"NCT07036159","A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Months",[86],"2027-04-23",[3287],[5571],{"trials":5587,"activeCount":97},[],{"trials":5589,"activeCount":97},[],{"trials":5591,"activeCount":97},[],{"intervention":5593,"totalTrials":417,"cells":5594},"Camlipixant",{"EARLY_PHASE1":5595,"PHASE1":5597,"PHASE2":5599,"PHASE3":5611,"PHASE4":5613,"NA":5615},{"trials":5596,"activeCount":97},[],{"trials":5598,"activeCount":97},[],{"trials":5600,"activeCount":417,"soonestReadout":5605},[5601],{"nctId":5602,"briefTitle":5603,"status":410,"phases":5604,"primaryCompletion":5605,"completion":5606,"start":5607,"enrollment":2121,"conditions":5608,"interventions":5610},"NCT07519395","A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)",[86],"2027-03-05","2027-07-09","2026-04-06",[5609],"Irritable Bowel Syndrome",[5593],{"trials":5612,"activeCount":97},[],{"trials":5614,"activeCount":97},[],{"trials":5616,"activeCount":97},[],{"intervention":5618,"totalTrials":417,"cells":5619},"GSK5458514",{"EARLY_PHASE1":5620,"PHASE1":5622,"PHASE2":5624,"PHASE3":5636,"PHASE4":5638,"NA":5640},{"trials":5621,"activeCount":97},[],{"trials":5623,"activeCount":97},[],{"trials":5625,"activeCount":417,"soonestReadout":5630},[5626],{"nctId":5627,"briefTitle":5628,"status":125,"phases":5629,"primaryCompletion":5630,"completion":5631,"start":5632,"enrollment":3672,"conditions":5633,"interventions":5635},"NCT06990880","A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer",[85,86],"2027-10-26","2028-08-09","2025-06-12",[5634],"Neoplasms, Prostate",[5618],{"trials":5637,"activeCount":97},[],{"trials":5639,"activeCount":97},[],{"trials":5641,"activeCount":97},[],{"intervention":5643,"totalTrials":417,"cells":5644},"Candidate UTI vaccine low dose formulation 1",{"EARLY_PHASE1":5645,"PHASE1":5647,"PHASE2":5649,"PHASE3":5666,"PHASE4":5668,"NA":5670},{"trials":5646,"activeCount":97},[],{"trials":5648,"activeCount":97},[],{"trials":5650,"activeCount":417,"soonestReadout":600},[5651],{"nctId":5652,"briefTitle":5653,"status":125,"phases":5654,"primaryCompletion":600,"completion":600,"start":5655,"enrollment":5656,"conditions":5657,"interventions":5659},"NCT06702449","A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age",[85,86],"2024-11-19",448,[5658],"Urinary Tract Infections",[5643,5660,5661,5662,5663,5664,5665],"Candidate UTI vaccine low dose formulation 2","Candidate UTI vaccine medium dose formulation 1","Candidate UTI vaccine medium dose formulation 2","Candidate UTI vaccine high dose formulation 1","Candidate UTI vaccine high dose formulation 2","Candidate UTI vaccine HTD formulation 2",{"trials":5667,"activeCount":97},[],{"trials":5669,"activeCount":97},[],{"trials":5671,"activeCount":97},[],{"intervention":5660,"totalTrials":417,"cells":5673},{"EARLY_PHASE1":5674,"PHASE1":5676,"PHASE2":5678,"PHASE3":5684,"PHASE4":5686,"NA":5688},{"trials":5675,"activeCount":97},[],{"trials":5677,"activeCount":97},[],{"trials":5679,"activeCount":417,"soonestReadout":600},[5680],{"nctId":5652,"briefTitle":5653,"status":125,"phases":5681,"primaryCompletion":600,"completion":600,"start":5655,"enrollment":5656,"conditions":5682,"interventions":5683},[85,86],[5658],[5643,5660,5661,5662,5663,5664,5665],{"trials":5685,"activeCount":97},[],{"trials":5687,"activeCount":97},[],{"trials":5689,"activeCount":97},[],{"intervention":5661,"totalTrials":417,"cells":5691},{"EARLY_PHASE1":5692,"PHASE1":5694,"PHASE2":5696,"PHASE3":5702,"PHASE4":5704,"NA":5706},{"trials":5693,"activeCount":97},[],{"trials":5695,"activeCount":97},[],{"trials":5697,"activeCount":417,"soonestReadout":600},[5698],{"nctId":5652,"briefTitle":5653,"status":125,"phases":5699,"primaryCompletion":600,"completion":600,"start":5655,"enrollment":5656,"conditions":5700,"interventions":5701},[85,86],[5658],[5643,5660,5661,5662,5663,5664,5665],{"trials":5703,"activeCount":97},[],{"trials":5705,"activeCount":97},[],{"trials":5707,"activeCount":97},[],{"intervention":5662,"totalTrials":417,"cells":5709},{"EARLY_PHASE1":5710,"PHASE1":5712,"PHASE2":5714,"PHASE3":5720,"PHASE4":5722,"NA":5724},{"trials":5711,"activeCount":97},[],{"trials":5713,"activeCount":97},[],{"trials":5715,"activeCount":417,"soonestReadout":600},[5716],{"nctId":5652,"briefTitle":5653,"status":125,"phases":5717,"primaryCompletion":600,"completion":600,"start":5655,"enrollment":5656,"conditions":5718,"interventions":5719},[85,86],[5658],[5643,5660,5661,5662,5663,5664,5665],{"trials":5721,"activeCount":97},[],{"trials":5723,"activeCount":97},[],{"trials":5725,"activeCount":97},[],{"intervention":5663,"totalTrials":417,"cells":5727},{"EARLY_PHASE1":5728,"PHASE1":5730,"PHASE2":5732,"PHASE3":5738,"PHASE4":5740,"NA":5742},{"trials":5729,"activeCount":97},[],{"trials":5731,"activeCount":97},[],{"trials":5733,"activeCount":417,"soonestReadout":600},[5734],{"nctId":5652,"briefTitle":5653,"status":125,"phases":5735,"primaryCompletion":600,"completion":600,"start":5655,"enrollment":5656,"conditions":5736,"interventions":5737},[85,86],[5658],[5643,5660,5661,5662,5663,5664,5665],{"trials":5739,"activeCount":97},[],{"trials":5741,"activeCount":97},[],{"trials":5743,"activeCount":97},[],{"intervention":5664,"totalTrials":417,"cells":5745},{"EARLY_PHASE1":5746,"PHASE1":5748,"PHASE2":5750,"PHASE3":5756,"PHASE4":5758,"NA":5760},{"trials":5747,"activeCount":97},[],{"trials":5749,"activeCount":97},[],{"trials":5751,"activeCount":417,"soonestReadout":600},[5752],{"nctId":5652,"briefTitle":5653,"status":125,"phases":5753,"primaryCompletion":600,"completion":600,"start":5655,"enrollment":5656,"conditions":5754,"interventions":5755},[85,86],[5658],[5643,5660,5661,5662,5663,5664,5665],{"trials":5757,"activeCount":97},[],{"trials":5759,"activeCount":97},[],{"trials":5761,"activeCount":97},[],{"intervention":5665,"totalTrials":417,"cells":5763},{"EARLY_PHASE1":5764,"PHASE1":5766,"PHASE2":5768,"PHASE3":5774,"PHASE4":5776,"NA":5778},{"trials":5765,"activeCount":97},[],{"trials":5767,"activeCount":97},[],{"trials":5769,"activeCount":417,"soonestReadout":600},[5770],{"nctId":5652,"briefTitle":5653,"status":125,"phases":5771,"primaryCompletion":600,"completion":600,"start":5655,"enrollment":5656,"conditions":5772,"interventions":5773},[85,86],[5658],[5643,5660,5661,5662,5663,5664,5665],{"trials":5775,"activeCount":97},[],{"trials":5777,"activeCount":97},[],{"trials":5779,"activeCount":97},[],{"intervention":5781,"totalTrials":417,"cells":5782},"GSK5471713",{"EARLY_PHASE1":5783,"PHASE1":5785,"PHASE2":5787,"PHASE3":5796,"PHASE4":5798,"NA":5800},{"trials":5784,"activeCount":97},[],{"trials":5786,"activeCount":97},[],{"trials":5788,"activeCount":417,"soonestReadout":2056},[5789],{"nctId":5790,"briefTitle":5791,"status":125,"phases":5792,"primaryCompletion":2056,"completion":5793,"start":1212,"enrollment":1686,"conditions":5794,"interventions":5795},"NCT07332455","First-Time-in-Human Study of GSK5471713 in Adults With mCRPC",[85,86],"2030-03-26",[5634],[5781],{"trials":5797,"activeCount":97},[],{"trials":5799,"activeCount":97},[],{"trials":5801,"activeCount":97},[],{"intervention":659,"totalTrials":417,"cells":5803},{"EARLY_PHASE1":5804,"PHASE1":5806,"PHASE2":5808,"PHASE3":5814,"PHASE4":5816,"NA":5818},{"trials":5805,"activeCount":97},[],{"trials":5807,"activeCount":97},[],{"trials":5809,"activeCount":417,"soonestReadout":654},[5810],{"nctId":651,"briefTitle":652,"status":101,"phases":5811,"primaryCompletion":654,"completion":654,"start":655,"enrollment":656,"conditions":5812,"interventions":5813},[85,86],[107],[659,82],{"trials":5815,"activeCount":97},[],{"trials":5817,"activeCount":97},[],{"trials":5819,"activeCount":97},[],{"intervention":5821,"totalTrials":417,"cells":5822},"MMB",{"EARLY_PHASE1":5823,"PHASE1":5825,"PHASE2":5827,"PHASE3":5840,"PHASE4":5842,"NA":5844},{"trials":5824,"activeCount":97},[],{"trials":5826,"activeCount":97},[],{"trials":5828,"activeCount":417,"soonestReadout":3644},[5829],{"nctId":5830,"briefTitle":5831,"status":101,"phases":5832,"primaryCompletion":3644,"completion":3644,"start":5833,"enrollment":5834,"conditions":5835,"interventions":5839},"NCT03441113","Extended Access of Momelotinib in Adults With Myelofibrosis",[86],"2018-05-03",237,[107,5836,5837,5838,2563],"Post-polycythemia Vera Myelofibrosis (Post-PV MF)","Primary Myelofibrosis (PMF)","Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)",[5821],{"trials":5841,"activeCount":97},[],{"trials":5843,"activeCount":97},[],{"trials":5845,"activeCount":97},[],{"intervention":2566,"totalTrials":417,"cells":5847},{"EARLY_PHASE1":5848,"PHASE1":5850,"PHASE2":5852,"PHASE3":5858,"PHASE4":5860,"NA":5862},{"trials":5849,"activeCount":97},[],{"trials":5851,"activeCount":97},[],{"trials":5853,"activeCount":417,"soonestReadout":2559},[5854],{"nctId":2556,"briefTitle":2557,"status":125,"phases":5855,"primaryCompletion":2559,"completion":2560,"start":2561,"enrollment":37,"conditions":5856,"interventions":5857},[86],[2563,2564],[2547,2566],{"trials":5859,"activeCount":97},[],{"trials":5861,"activeCount":97},[],{"trials":5863,"activeCount":97},[],{"intervention":5865,"totalTrials":417,"cells":5866},"GSK4418959",{"EARLY_PHASE1":5867,"PHASE1":5869,"PHASE2":5871,"PHASE3":5885,"PHASE4":5887,"NA":5889},{"trials":5868,"activeCount":97},[],{"trials":5870,"activeCount":97},[],{"trials":5872,"activeCount":417,"soonestReadout":5877},[5873],{"nctId":5874,"briefTitle":5875,"status":101,"phases":5876,"primaryCompletion":5877,"completion":5877,"start":5878,"enrollment":473,"conditions":5879,"interventions":5883},"NCT06710847","A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors",[85,86],"2026-06-22","2024-12-13",[2667,5880,5881,5882,2807],"Solid Tumor","Colon Cancer","Rectal Cancer",[5865,5884],"PD-1 inhibitor",{"trials":5886,"activeCount":97},[],{"trials":5888,"activeCount":97},[],{"trials":5890,"activeCount":97},[],{"intervention":5884,"totalTrials":417,"cells":5892},{"EARLY_PHASE1":5893,"PHASE1":5895,"PHASE2":5897,"PHASE3":5903,"PHASE4":5905,"NA":5907},{"trials":5894,"activeCount":97},[],{"trials":5896,"activeCount":97},[],{"trials":5898,"activeCount":417,"soonestReadout":5877},[5899],{"nctId":5874,"briefTitle":5875,"status":101,"phases":5900,"primaryCompletion":5877,"completion":5877,"start":5878,"enrollment":473,"conditions":5901,"interventions":5902},[85,86],[2667,5880,5881,5882,2807],[5865,5884],{"trials":5904,"activeCount":97},[],{"trials":5906,"activeCount":97},[],{"trials":5908,"activeCount":97},[],{"intervention":1199,"totalTrials":417,"cells":5910},{"EARLY_PHASE1":5911,"PHASE1":5913,"PHASE2":5915,"PHASE3":5921,"PHASE4":5923,"NA":5925},{"trials":5912,"activeCount":97},[],{"trials":5914,"activeCount":97},[],{"trials":5916,"activeCount":417,"soonestReadout":1194},[5917],{"nctId":1191,"briefTitle":1192,"status":125,"phases":5918,"primaryCompletion":1194,"completion":1194,"start":1195,"enrollment":1196,"conditions":5919,"interventions":5920},[86],[278],[48,283,284,1093,1199],{"trials":5922,"activeCount":97},[],{"trials":5924,"activeCount":97},[],{"trials":5926,"activeCount":97},[],{"intervention":5928,"totalTrials":417,"cells":5929},"GSK3772701 600 mg",{"EARLY_PHASE1":5930,"PHASE1":5932,"PHASE2":5934,"PHASE3":5949,"PHASE4":5951,"NA":5953},{"trials":5931,"activeCount":97},[],{"trials":5933,"activeCount":97},[],{"trials":5935,"activeCount":417,"soonestReadout":5940},[5936],{"nctId":5937,"briefTitle":5938,"status":410,"phases":5939,"primaryCompletion":5940,"completion":5940,"start":5941,"enrollment":730,"conditions":5942,"interventions":5944},"NCT07545681","A Phase 2A Study of a Novel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. Falciparum Malaria",[86],"2027-07-22","2026-04-20",[5943],"Malaria, Falciparum",[5928,5945,5946,5947,5948],"GSK3772701 900 mg","GSK3772701 150 mg","GSK3772701 400 mg","GSK3772701 50 mg",{"trials":5950,"activeCount":97},[],{"trials":5952,"activeCount":97},[],{"trials":5954,"activeCount":97},[],{"intervention":5945,"totalTrials":417,"cells":5956},{"EARLY_PHASE1":5957,"PHASE1":5959,"PHASE2":5961,"PHASE3":5967,"PHASE4":5969,"NA":5971},{"trials":5958,"activeCount":97},[],{"trials":5960,"activeCount":97},[],{"trials":5962,"activeCount":417,"soonestReadout":5940},[5963],{"nctId":5937,"briefTitle":5938,"status":410,"phases":5964,"primaryCompletion":5940,"completion":5940,"start":5941,"enrollment":730,"conditions":5965,"interventions":5966},[86],[5943],[5928,5945,5946,5947,5948],{"trials":5968,"activeCount":97},[],{"trials":5970,"activeCount":97},[],{"trials":5972,"activeCount":97},[],{"intervention":5946,"totalTrials":417,"cells":5974},{"EARLY_PHASE1":5975,"PHASE1":5977,"PHASE2":5979,"PHASE3":5985,"PHASE4":5987,"NA":5989},{"trials":5976,"activeCount":97},[],{"trials":5978,"activeCount":97},[],{"trials":5980,"activeCount":417,"soonestReadout":5940},[5981],{"nctId":5937,"briefTitle":5938,"status":410,"phases":5982,"primaryCompletion":5940,"completion":5940,"start":5941,"enrollment":730,"conditions":5983,"interventions":5984},[86],[5943],[5928,5945,5946,5947,5948],{"trials":5986,"activeCount":97},[],{"trials":5988,"activeCount":97},[],{"trials":5990,"activeCount":97},[],{"intervention":5947,"totalTrials":417,"cells":5992},{"EARLY_PHASE1":5993,"PHASE1":5995,"PHASE2":5997,"PHASE3":6003,"PHASE4":6005,"NA":6007},{"trials":5994,"activeCount":97},[],{"trials":5996,"activeCount":97},[],{"trials":5998,"activeCount":417,"soonestReadout":5940},[5999],{"nctId":5937,"briefTitle":5938,"status":410,"phases":6000,"primaryCompletion":5940,"completion":5940,"start":5941,"enrollment":730,"conditions":6001,"interventions":6002},[86],[5943],[5928,5945,5946,5947,5948],{"trials":6004,"activeCount":97},[],{"trials":6006,"activeCount":97},[],{"trials":6008,"activeCount":97},[],{"intervention":5948,"totalTrials":417,"cells":6010},{"EARLY_PHASE1":6011,"PHASE1":6013,"PHASE2":6015,"PHASE3":6021,"PHASE4":6023,"NA":6025},{"trials":6012,"activeCount":97},[],{"trials":6014,"activeCount":97},[],{"trials":6016,"activeCount":417,"soonestReadout":5940},[6017],{"nctId":5937,"briefTitle":5938,"status":410,"phases":6018,"primaryCompletion":5940,"completion":5940,"start":5941,"enrollment":730,"conditions":6019,"interventions":6020},[86],[5943],[5928,5945,5946,5947,5948],{"trials":6022,"activeCount":97},[],{"trials":6024,"activeCount":97},[],{"trials":6026,"activeCount":97},[],{"intervention":348,"totalTrials":417,"cells":6028},{"EARLY_PHASE1":6029,"PHASE1":6031,"PHASE2":6033,"PHASE3":6039,"PHASE4":6041,"NA":6043},{"trials":6030,"activeCount":97},[],{"trials":6032,"activeCount":97},[],{"trials":6034,"activeCount":417,"soonestReadout":342},[6035],{"nctId":339,"briefTitle":340,"status":125,"phases":6036,"primaryCompletion":342,"completion":343,"start":344,"enrollment":345,"conditions":6037,"interventions":6038},[85,86],[267],[137,92,348],{"trials":6040,"activeCount":97},[],{"trials":6042,"activeCount":97},[],{"trials":6044,"activeCount":97},[],{"intervention":4924,"totalTrials":417,"cells":6046},{"EARLY_PHASE1":6047,"PHASE1":6049,"PHASE2":6051,"PHASE3":6057,"PHASE4":6059,"NA":6061},{"trials":6048,"activeCount":97},[],{"trials":6050,"activeCount":97},[],{"trials":6052,"activeCount":417,"soonestReadout":2626},[6053],{"nctId":4917,"briefTitle":4918,"status":101,"phases":6054,"primaryCompletion":2626,"completion":2626,"start":4920,"enrollment":4921,"conditions":6055,"interventions":6056},[86],[4481],[4924,4925,4926,4897,4927,4928,4929],{"trials":6058,"activeCount":97},[],{"trials":6060,"activeCount":97},[],{"trials":6062,"activeCount":97},[],{"intervention":4925,"totalTrials":417,"cells":6064},{"EARLY_PHASE1":6065,"PHASE1":6067,"PHASE2":6069,"PHASE3":6075,"PHASE4":6077,"NA":6079},{"trials":6066,"activeCount":97},[],{"trials":6068,"activeCount":97},[],{"trials":6070,"activeCount":417,"soonestReadout":2626},[6071],{"nctId":4917,"briefTitle":4918,"status":101,"phases":6072,"primaryCompletion":2626,"completion":2626,"start":4920,"enrollment":4921,"conditions":6073,"interventions":6074},[86],[4481],[4924,4925,4926,4897,4927,4928,4929],{"trials":6076,"activeCount":97},[],{"trials":6078,"activeCount":97},[],{"trials":6080,"activeCount":97},[],{"intervention":4926,"totalTrials":417,"cells":6082},{"EARLY_PHASE1":6083,"PHASE1":6085,"PHASE2":6087,"PHASE3":6093,"PHASE4":6095,"NA":6097},{"trials":6084,"activeCount":97},[],{"trials":6086,"activeCount":97},[],{"trials":6088,"activeCount":417,"soonestReadout":2626},[6089],{"nctId":4917,"briefTitle":4918,"status":101,"phases":6090,"primaryCompletion":2626,"completion":2626,"start":4920,"enrollment":4921,"conditions":6091,"interventions":6092},[86],[4481],[4924,4925,4926,4897,4927,4928,4929],{"trials":6094,"activeCount":97},[],{"trials":6096,"activeCount":97},[],{"trials":6098,"activeCount":97},[],{"intervention":4927,"totalTrials":417,"cells":6100},{"EARLY_PHASE1":6101,"PHASE1":6103,"PHASE2":6105,"PHASE3":6111,"PHASE4":6113,"NA":6115},{"trials":6102,"activeCount":97},[],{"trials":6104,"activeCount":97},[],{"trials":6106,"activeCount":417,"soonestReadout":2626},[6107],{"nctId":4917,"briefTitle":4918,"status":101,"phases":6108,"primaryCompletion":2626,"completion":2626,"start":4920,"enrollment":4921,"conditions":6109,"interventions":6110},[86],[4481],[4924,4925,4926,4897,4927,4928,4929],{"trials":6112,"activeCount":97},[],{"trials":6114,"activeCount":97},[],{"trials":6116,"activeCount":97},[],{"intervention":4928,"totalTrials":417,"cells":6118},{"EARLY_PHASE1":6119,"PHASE1":6121,"PHASE2":6123,"PHASE3":6129,"PHASE4":6131,"NA":6133},{"trials":6120,"activeCount":97},[],{"trials":6122,"activeCount":97},[],{"trials":6124,"activeCount":417,"soonestReadout":2626},[6125],{"nctId":4917,"briefTitle":4918,"status":101,"phases":6126,"primaryCompletion":2626,"completion":2626,"start":4920,"enrollment":4921,"conditions":6127,"interventions":6128},[86],[4481],[4924,4925,4926,4897,4927,4928,4929],{"trials":6130,"activeCount":97},[],{"trials":6132,"activeCount":97},[],{"trials":6134,"activeCount":97},[],{"intervention":2111,"totalTrials":417,"cells":6136},{"EARLY_PHASE1":6137,"PHASE1":6139,"PHASE2":6141,"PHASE3":6147,"PHASE4":6149,"NA":6151},{"trials":6138,"activeCount":97},[],{"trials":6140,"activeCount":97},[],{"trials":6142,"activeCount":417,"soonestReadout":2104},[6143],{"nctId":2101,"briefTitle":2102,"status":410,"phases":6144,"primaryCompletion":2104,"completion":2105,"start":2106,"enrollment":2107,"conditions":6145,"interventions":6146},[85,86],[2109],[133,2111],{"trials":6148,"activeCount":97},[],{"trials":6150,"activeCount":97},[],{"trials":6152,"activeCount":97},[],{"intervention":4483,"totalTrials":417,"cells":6154},{"EARLY_PHASE1":6155,"PHASE1":6157,"PHASE2":6159,"PHASE3":6165,"PHASE4":6167,"NA":6169},{"trials":6156,"activeCount":97},[],{"trials":6158,"activeCount":97},[],{"trials":6160,"activeCount":417,"soonestReadout":4477},[6161],{"nctId":4474,"briefTitle":4475,"status":125,"phases":6162,"primaryCompletion":4477,"completion":4477,"start":4478,"enrollment":4479,"conditions":6163,"interventions":6164},[86],[4481],[4483,4484,4452,4485,4486,4487],{"trials":6166,"activeCount":97},[],{"trials":6168,"activeCount":97},[],{"trials":6170,"activeCount":97},[],{"intervention":4484,"totalTrials":417,"cells":6172},{"EARLY_PHASE1":6173,"PHASE1":6175,"PHASE2":6177,"PHASE3":6183,"PHASE4":6185,"NA":6187},{"trials":6174,"activeCount":97},[],{"trials":6176,"activeCount":97},[],{"trials":6178,"activeCount":417,"soonestReadout":4477},[6179],{"nctId":4474,"briefTitle":4475,"status":125,"phases":6180,"primaryCompletion":4477,"completion":4477,"start":4478,"enrollment":4479,"conditions":6181,"interventions":6182},[86],[4481],[4483,4484,4452,4485,4486,4487],{"trials":6184,"activeCount":97},[],{"trials":6186,"activeCount":97},[],{"trials":6188,"activeCount":97},[],{"intervention":4179,"totalTrials":417,"cells":6190},{"EARLY_PHASE1":6191,"PHASE1":6193,"PHASE2":6195,"PHASE3":6201,"PHASE4":6203,"NA":6205},{"trials":6192,"activeCount":97},[],{"trials":6194,"activeCount":97},[],{"trials":6196,"activeCount":417,"soonestReadout":600},[6197],{"nctId":4171,"briefTitle":4172,"status":101,"phases":6198,"primaryCompletion":600,"completion":600,"start":4174,"enrollment":4175,"conditions":6199,"interventions":6200},[86],[4177,24],[4179,4180,4109],{"trials":6202,"activeCount":97},[],{"trials":6204,"activeCount":97},[],{"trials":6206,"activeCount":97},[],{"intervention":4180,"totalTrials":417,"cells":6208},{"EARLY_PHASE1":6209,"PHASE1":6211,"PHASE2":6213,"PHASE3":6219,"PHASE4":6221,"NA":6223},{"trials":6210,"activeCount":97},[],{"trials":6212,"activeCount":97},[],{"trials":6214,"activeCount":417,"soonestReadout":600},[6215],{"nctId":4171,"briefTitle":4172,"status":101,"phases":6216,"primaryCompletion":600,"completion":600,"start":4174,"enrollment":4175,"conditions":6217,"interventions":6218},[86],[4177,24],[4179,4180,4109],{"trials":6220,"activeCount":97},[],{"trials":6222,"activeCount":97},[],{"trials":6224,"activeCount":97},[],{"intervention":1249,"totalTrials":417,"cells":6226},{"EARLY_PHASE1":6227,"PHASE1":6229,"PHASE2":6231,"PHASE3":6237,"PHASE4":6239,"NA":6241},{"trials":6228,"activeCount":97},[],{"trials":6230,"activeCount":97},[],{"trials":6232,"activeCount":417,"soonestReadout":1246},[6233],{"nctId":1243,"briefTitle":1244,"status":125,"phases":6234,"primaryCompletion":1246,"completion":1246,"start":1173,"enrollment":115,"conditions":6235,"interventions":6236},[85,86],[278],[1249,48,1250,1251],{"trials":6238,"activeCount":97},[],{"trials":6240,"activeCount":97},[],{"trials":6242,"activeCount":97},[],{"intervention":1250,"totalTrials":417,"cells":6244},{"EARLY_PHASE1":6245,"PHASE1":6247,"PHASE2":6249,"PHASE3":6255,"PHASE4":6257,"NA":6259},{"trials":6246,"activeCount":97},[],{"trials":6248,"activeCount":97},[],{"trials":6250,"activeCount":417,"soonestReadout":1246},[6251],{"nctId":1243,"briefTitle":1244,"status":125,"phases":6252,"primaryCompletion":1246,"completion":1246,"start":1173,"enrollment":115,"conditions":6253,"interventions":6254},[85,86],[278],[1249,48,1250,1251],{"trials":6256,"activeCount":97},[],{"trials":6258,"activeCount":97},[],{"trials":6260,"activeCount":97},[],{"intervention":1251,"totalTrials":417,"cells":6262},{"EARLY_PHASE1":6263,"PHASE1":6265,"PHASE2":6267,"PHASE3":6273,"PHASE4":6275,"NA":6277},{"trials":6264,"activeCount":97},[],{"trials":6266,"activeCount":97},[],{"trials":6268,"activeCount":417,"soonestReadout":1246},[6269],{"nctId":1243,"briefTitle":1244,"status":125,"phases":6270,"primaryCompletion":1246,"completion":1246,"start":1173,"enrollment":115,"conditions":6271,"interventions":6272},[85,86],[278],[1249,48,1250,1251],{"trials":6274,"activeCount":97},[],{"trials":6276,"activeCount":97},[],{"trials":6278,"activeCount":97},[],{"intervention":360,"totalTrials":417,"cells":6280},{"EARLY_PHASE1":6281,"PHASE1":6283,"PHASE2":6285,"PHASE3":6291,"PHASE4":6293,"NA":6295},{"trials":6282,"activeCount":97},[],{"trials":6284,"activeCount":97},[],{"trials":6286,"activeCount":417,"soonestReadout":353},[6287],{"nctId":350,"briefTitle":351,"status":125,"phases":6288,"primaryCompletion":353,"completion":354,"start":355,"enrollment":356,"conditions":6289,"interventions":6290},[85,86],[358],[360,92,140],{"trials":6292,"activeCount":97},[],{"trials":6294,"activeCount":97},[],{"trials":6296,"activeCount":97},[],{"intervention":6298,"totalTrials":1517,"cells":6299},"Zanamivir",{"EARLY_PHASE1":6300,"PHASE1":6302,"PHASE2":6321,"PHASE3":6331,"PHASE4":6343,"NA":6345},{"trials":6301,"activeCount":97},[],{"trials":6303,"activeCount":97},[6304,6312],{"nctId":6305,"briefTitle":6306,"status":155,"phases":6307,"primaryCompletion":6308,"completion":6308,"start":6309,"enrollment":1298,"conditions":6310,"interventions":6311},"NCT02377401","Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults",[85],"2015-06-19","2015-04-28",[5353],[6298],{"nctId":6313,"briefTitle":6314,"status":155,"phases":6315,"primaryCompletion":6316,"completion":6316,"start":6317,"enrollment":1634,"conditions":6318,"interventions":6320},"NCT00989404","Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir\u002FPlacebo Via Devices Administered Twice Daily for 5 Days",[85],"2009-12-07","2009-10-12",[6319],"Influenza A Virus, H1N1 Subtype",[6298,6298,6298],{"trials":6322,"activeCount":417,"soonestReadout":6327},[6323],{"nctId":6324,"briefTitle":6325,"status":125,"phases":6326,"primaryCompletion":6327,"completion":6327,"start":1286,"enrollment":1459,"conditions":6328,"interventions":6330},"NCT04494412","An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection",[86],"2026-04-30",[5353,6329],"Arthralgia",[6298],{"trials":6332,"activeCount":97},[6333],{"nctId":6334,"briefTitle":6335,"status":155,"phases":6336,"primaryCompletion":6337,"completion":6337,"start":6338,"enrollment":6339,"conditions":6340,"interventions":6341},"NCT01231620","A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza",[87],"2015-03-18","2011-01-15",626,[5353],[6298,6342],"Oseltamivir",{"trials":6344,"activeCount":97},[],{"trials":6346,"activeCount":97},[6347],{"nctId":6348,"briefTitle":6349,"status":155,"phases":6350,"primaryCompletion":6351,"completion":6352,"start":6351,"enrollment":6353,"conditions":6354,"interventions":6355},"NCT01199744","Relenza® Sentinel Site Monitoring Program in Japan",[],"2009-11","2010-04",1575,[5353],[6356],"zanamivir",{"intervention":3182,"totalTrials":1517,"cells":6358},{"EARLY_PHASE1":6359,"PHASE1":6361,"PHASE2":6397,"PHASE3":6399,"PHASE4":6405,"NA":6407},{"trials":6360,"activeCount":97},[],{"trials":6362,"activeCount":181,"soonestReadout":2416},[6363,6374,6382,6390],{"nctId":6364,"briefTitle":6365,"status":410,"phases":6366,"primaryCompletion":6367,"completion":6367,"start":6368,"enrollment":6369,"conditions":6370,"interventions":6372},"NCT07406334","A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose",[85],"2027-02-22","2026-05-15",45,[6371],"Pneumonia, Bacterial",[6373,3182],"Pn-MAPS30plus",{"nctId":6375,"briefTitle":6376,"status":101,"phases":6377,"primaryCompletion":6378,"completion":6378,"start":6379,"enrollment":2297,"conditions":6380,"interventions":6381},"NCT07428759","Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years",[85],"2026-12-09","2026-03-10",[6371],[6373,3182],{"nctId":6383,"briefTitle":6384,"status":410,"phases":6385,"primaryCompletion":6386,"completion":6386,"start":6387,"enrollment":1237,"conditions":6388,"interventions":6389},"NCT07406347","A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age",[85],"2028-04-03","2026-07-10",[6371],[6373,3182],{"nctId":6391,"briefTitle":6392,"status":101,"phases":6393,"primaryCompletion":2416,"completion":2416,"start":6394,"enrollment":4377,"conditions":6395,"interventions":6396},"NCT07105722","A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age",[85],"2025-08-12",[6371],[6373,3182],{"trials":6398,"activeCount":97},[],{"trials":6400,"activeCount":97},[6401],{"nctId":3174,"briefTitle":3175,"status":155,"phases":6402,"primaryCompletion":3177,"completion":211,"start":3178,"enrollment":3179,"conditions":6403,"interventions":6404},[87],[2620],[43,3182],{"trials":6406,"activeCount":97},[],{"trials":6408,"activeCount":97},[],{"intervention":6373,"totalTrials":181,"cells":6410},{"EARLY_PHASE1":6411,"PHASE1":6413,"PHASE2":6431,"PHASE3":6433,"PHASE4":6435,"NA":6437},{"trials":6412,"activeCount":97},[],{"trials":6414,"activeCount":181,"soonestReadout":2416},[6415,6419,6423,6427],{"nctId":6364,"briefTitle":6365,"status":410,"phases":6416,"primaryCompletion":6367,"completion":6367,"start":6368,"enrollment":6369,"conditions":6417,"interventions":6418},[85],[6371],[6373,3182],{"nctId":6375,"briefTitle":6376,"status":101,"phases":6420,"primaryCompletion":6378,"completion":6378,"start":6379,"enrollment":2297,"conditions":6421,"interventions":6422},[85],[6371],[6373,3182],{"nctId":6383,"briefTitle":6384,"status":410,"phases":6424,"primaryCompletion":6386,"completion":6386,"start":6387,"enrollment":1237,"conditions":6425,"interventions":6426},[85],[6371],[6373,3182],{"nctId":6391,"briefTitle":6392,"status":101,"phases":6428,"primaryCompletion":2416,"completion":2416,"start":6394,"enrollment":4377,"conditions":6429,"interventions":6430},[85],[6371],[6373,3182],{"trials":6432,"activeCount":97},[],{"trials":6434,"activeCount":97},[],{"trials":6436,"activeCount":97},[],{"trials":6438,"activeCount":97},[],{"intervention":6440,"totalTrials":660,"cells":6441},"GSK4771261",{"EARLY_PHASE1":6442,"PHASE1":6444,"PHASE2":6462,"PHASE3":6464,"PHASE4":6466,"NA":6468},{"trials":6443,"activeCount":97},[],{"trials":6445,"activeCount":660,"soonestReadout":6458},[6446,6454],{"nctId":6447,"briefTitle":6448,"status":410,"phases":6449,"primaryCompletion":6450,"completion":6450,"start":6368,"enrollment":255,"conditions":6451,"interventions":6453},"NCT07600450","A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive",[85],"2026-09-22",[6452],"Kidney Disease",[6440],{"nctId":6455,"briefTitle":6456,"status":125,"phases":6457,"primaryCompletion":6458,"completion":6458,"start":6459,"enrollment":719,"conditions":6460,"interventions":6461},"NCT06734234","A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease",[85],"2026-09-04","2024-12-11",[6452],[6440],{"trials":6463,"activeCount":97},[],{"trials":6465,"activeCount":97},[],{"trials":6467,"activeCount":97},[],{"trials":6469,"activeCount":97},[],{"intervention":6471,"totalTrials":3131,"cells":6472},"Gepotidacin",{"EARLY_PHASE1":6473,"PHASE1":6475,"PHASE2":6538,"PHASE3":6548,"PHASE4":6598,"NA":6600},{"trials":6474,"activeCount":97},[],{"trials":6476,"activeCount":417,"soonestReadout":3595},[6477,6490,6497,6508,6515,6523,6531],{"nctId":6478,"briefTitle":6479,"status":155,"phases":6480,"primaryCompletion":1287,"completion":1287,"start":6481,"enrollment":6482,"conditions":6483,"interventions":6485},"NCT04493931","Drug-drug Interaction Study of Gepotidacin",[85],"2020-08-14",64,[6484],"Infections, Bacterial",[6471,6486,6487,6488,6489],"Cimetidine","Rifampicin","Midazolam","Digoxin",{"nctId":6491,"briefTitle":6492,"status":410,"phases":6493,"primaryCompletion":3595,"completion":3595,"start":6494,"enrollment":454,"conditions":6495,"interventions":6496},"NCT07371429","A Study in Pediatric Participants Aged ≥2 to \u003C12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics",[85],"2026-04-29",[5658],[6471,842],{"nctId":6498,"briefTitle":6499,"status":155,"phases":6500,"primaryCompletion":6501,"completion":6501,"start":6502,"enrollment":6503,"conditions":6504,"interventions":6505},"NCT02853435","To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.",[85],"2017-10-17","2016-08-04",48,[6484],[6506,6507,6471],"Gepotidacin RC","Gepotidacin HSWG",{"nctId":6509,"briefTitle":6510,"status":155,"phases":6511,"primaryCompletion":1588,"completion":1588,"start":6512,"enrollment":1298,"conditions":6513,"interventions":6514},"NCT05271799","A Study to Evaluate Pharmacokinetic, Safety, Tolerability and Relative Bioavailability of Gepotidacin in Healthy Adult Male and Female Participants",[85],"2022-03-01",[5280],[6471],{"nctId":6516,"briefTitle":6517,"status":155,"phases":6518,"primaryCompletion":6519,"completion":6519,"start":6520,"enrollment":1736,"conditions":6521,"interventions":6522},"NCT04079790","Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects",[85],"2019-11-25","2019-09-04",[6484],[6471],{"nctId":6524,"briefTitle":6525,"status":155,"phases":6526,"primaryCompletion":6527,"completion":6527,"start":6528,"enrollment":463,"conditions":6529,"interventions":6530},"NCT03562117","Pharmacokinetics (PK) Study of Gepotidacin (GSK2140944) in Adult Subjects With Varying Degrees of Hepatic Impairment and in Matched Control Subjects With Normal Hepatic Function",[85],"2018-12-26","2018-06-14",[6484],[6471],{"nctId":6532,"briefTitle":6533,"status":155,"phases":6534,"primaryCompletion":6535,"completion":6535,"start":2910,"enrollment":2045,"conditions":6536,"interventions":6537},"NCT02729038","Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function",[85],"2017-06-20",[6484],[6471],{"trials":6539,"activeCount":97},[6540],{"nctId":6541,"briefTitle":6542,"status":155,"phases":6543,"primaryCompletion":6544,"completion":6544,"start":6545,"enrollment":2836,"conditions":6546,"interventions":6547},"NCT03568942","Pharmacokinetic Study of Oral Gepotidacin (GSK2140944) in Subjects With Uncomplicated Urinary Tract Infection (Acute Cystitis)",[86],"2019-01-07","2018-07-23",[6484],[6471],{"trials":6549,"activeCount":97},[6550,6558,6570,6580,6589],{"nctId":6551,"briefTitle":6552,"status":155,"phases":6553,"primaryCompletion":6554,"completion":6554,"start":6555,"enrollment":105,"conditions":6556,"interventions":6557},"NCT06597344","A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)",[87],"2025-03-10","2024-10-02",[5658],[6471],{"nctId":6559,"briefTitle":6560,"status":155,"phases":6561,"primaryCompletion":6562,"completion":6562,"start":6563,"enrollment":6564,"conditions":6565,"interventions":6567},"NCT04010539","A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea",[87],"2023-10-10","2019-10-21",628,[6566],"Gonorrhea",[6471,6568,6569],"Ceftriaxone","Azithromycin",{"nctId":6571,"briefTitle":6572,"status":155,"phases":6573,"primaryCompletion":6574,"completion":6574,"start":6575,"enrollment":6576,"conditions":6577,"interventions":6578},"NCT05630833","A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)",[87],"2024-02-02","2023-01-11",380,[5658],[6471,6579],"Nitrofurantoin",{"nctId":6581,"briefTitle":6582,"status":155,"phases":6583,"primaryCompletion":6584,"completion":6584,"start":6585,"enrollment":6586,"conditions":6587,"interventions":6588},"NCT04020341","A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)",[87],"2022-11-30","2019-10-17",1531,[5658],[6471,6579],{"nctId":6590,"briefTitle":6591,"status":155,"phases":6592,"primaryCompletion":6593,"completion":6593,"start":6594,"enrollment":6595,"conditions":6596,"interventions":6597},"NCT04187144","Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)",[87],"2022-12-01","2020-04-23",1606,[5658],[6471,6579],{"trials":6599,"activeCount":97},[],{"trials":6601,"activeCount":97},[],{"intervention":6603,"totalTrials":181,"cells":6604},"Salbutamol HFA-152a",{"EARLY_PHASE1":6605,"PHASE1":6607,"PHASE2":6637,"PHASE3":6639,"PHASE4":6649,"NA":6651},{"trials":6606,"activeCount":97},[],{"trials":6608,"activeCount":417,"soonestReadout":6631},[6609,6620,6627],{"nctId":6610,"briefTitle":6611,"status":155,"phases":6612,"primaryCompletion":6613,"completion":6614,"start":6615,"enrollment":1237,"conditions":6616,"interventions":6618},"NCT06433908","A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive",[85],"2024-10-18","2024-10-22","2024-06-04",[18,6617],"Healthy Participants",[6603,6619],"Salbutamol HFA-134a",{"nctId":6621,"briefTitle":6622,"status":155,"phases":6623,"primaryCompletion":6624,"completion":6624,"start":223,"enrollment":695,"conditions":6625,"interventions":6626},"NCT05791565","Green (Sustainable) VENTOLIN - Pharmacokinetics (PK) Study in Healthy Participants",[85],"2023-05-21",[18],[6603,6619],{"nctId":6628,"briefTitle":6629,"status":125,"phases":6630,"primaryCompletion":6631,"completion":6632,"start":6633,"enrollment":719,"conditions":6634,"interventions":6636},"NCT06433921","A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive",[85],"2026-10-30","2026-11-06","2024-08-14",[18,6635],"Mild Asthma",[6603,6619],{"trials":6638,"activeCount":97},[],{"trials":6640,"activeCount":97},[6641],{"nctId":6642,"briefTitle":6643,"status":155,"phases":6644,"primaryCompletion":6645,"completion":6645,"start":2616,"enrollment":6646,"conditions":6647,"interventions":6648},"NCT06261957","A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma",[87],"2025-09-02",477,[18],[6619,6603],{"trials":6650,"activeCount":97},[],{"trials":6652,"activeCount":97},[],{"intervention":6619,"totalTrials":181,"cells":6654},{"EARLY_PHASE1":6655,"PHASE1":6657,"PHASE2":6671,"PHASE3":6673,"PHASE4":6679,"NA":6681},{"trials":6656,"activeCount":97},[],{"trials":6658,"activeCount":417,"soonestReadout":6631},[6659,6663,6667],{"nctId":6610,"briefTitle":6611,"status":155,"phases":6660,"primaryCompletion":6613,"completion":6614,"start":6615,"enrollment":1237,"conditions":6661,"interventions":6662},[85],[18,6617],[6603,6619],{"nctId":6621,"briefTitle":6622,"status":155,"phases":6664,"primaryCompletion":6624,"completion":6624,"start":223,"enrollment":695,"conditions":6665,"interventions":6666},[85],[18],[6603,6619],{"nctId":6628,"briefTitle":6629,"status":125,"phases":6668,"primaryCompletion":6631,"completion":6632,"start":6633,"enrollment":719,"conditions":6669,"interventions":6670},[85],[18,6635],[6603,6619],{"trials":6672,"activeCount":97},[],{"trials":6674,"activeCount":97},[6675],{"nctId":6642,"briefTitle":6643,"status":155,"phases":6676,"primaryCompletion":6645,"completion":6645,"start":2616,"enrollment":6646,"conditions":6677,"interventions":6678},[87],[18],[6619,6603],{"trials":6680,"activeCount":97},[],{"trials":6682,"activeCount":97},[],{"intervention":1774,"totalTrials":593,"cells":6684},{"EARLY_PHASE1":6685,"PHASE1":6687,"PHASE2":6693,"PHASE3":6699,"PHASE4":6705,"NA":6707},{"trials":6686,"activeCount":97},[],{"trials":6688,"activeCount":417,"soonestReadout":1885},[6689],{"nctId":1882,"briefTitle":1883,"status":125,"phases":6690,"primaryCompletion":1885,"completion":1886,"start":1887,"enrollment":719,"conditions":6691,"interventions":6692},[85],[107],[121,140,1774,1890,1891],{"trials":6694,"activeCount":97},[6695],{"nctId":2292,"briefTitle":2293,"status":155,"phases":6696,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":2297,"conditions":6697,"interventions":6698},[86],[668],[2300,2301,2264,2302,2303,2304],{"trials":6700,"activeCount":97},[6701],{"nctId":1764,"briefTitle":1765,"status":145,"phases":6702,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":1770,"conditions":6703,"interventions":6704},[87],[305],[246,137,1773,1774],{"trials":6706,"activeCount":97},[],{"trials":6708,"activeCount":97},[],{"intervention":842,"totalTrials":593,"cells":6710},{"EARLY_PHASE1":6711,"PHASE1":6713,"PHASE2":6719,"PHASE3":6721,"PHASE4":6731,"NA":6733},{"trials":6712,"activeCount":97},[],{"trials":6714,"activeCount":417,"soonestReadout":3595},[6715],{"nctId":6491,"briefTitle":6492,"status":410,"phases":6716,"primaryCompletion":3595,"completion":3595,"start":6494,"enrollment":454,"conditions":6717,"interventions":6718},[85],[5658],[6471,842],{"trials":6720,"activeCount":97},[],{"trials":6722,"activeCount":97},[6723,6727],{"nctId":834,"briefTitle":835,"status":155,"phases":6724,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":6725,"interventions":6726},[87],[18],[694,842],{"nctId":935,"briefTitle":936,"status":155,"phases":6728,"primaryCompletion":938,"completion":938,"start":939,"enrollment":940,"conditions":6729,"interventions":6730},[87],[18],[694,842],{"trials":6732,"activeCount":97},[],{"trials":6734,"activeCount":97},[],{"intervention":139,"totalTrials":593,"cells":6736},{"EARLY_PHASE1":6737,"PHASE1":6739,"PHASE2":6754,"PHASE3":6760,"PHASE4":6762,"NA":6764},{"trials":6738,"activeCount":97},[],{"trials":6740,"activeCount":417,"soonestReadout":127},[6741,6745],{"nctId":123,"briefTitle":124,"status":125,"phases":6742,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":6743,"interventions":6744},[85],[107],[133,134,135,136,137,138,139,140,141,92],{"nctId":6746,"briefTitle":6747,"status":155,"phases":6748,"primaryCompletion":6749,"completion":6749,"start":6750,"enrollment":463,"conditions":6751,"interventions":6752},"NCT00540943","Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer",[85],"2010-05-03","2007-07-13",[2667],[2273,139,6753],"Irinotecan",{"trials":6755,"activeCount":97},[6756],{"nctId":2306,"briefTitle":2307,"status":155,"phases":6757,"primaryCompletion":2309,"completion":2310,"start":2311,"enrollment":93,"conditions":6758,"interventions":6759},[85,86],[107],[162,2314,164,216,139],{"trials":6761,"activeCount":97},[],{"trials":6763,"activeCount":97},[],{"trials":6765,"activeCount":97},[],{"intervention":180,"totalTrials":660,"cells":6767},{"EARLY_PHASE1":6768,"PHASE1":6770,"PHASE2":6776,"PHASE3":6782,"PHASE4":6784,"NA":6786},{"trials":6769,"activeCount":97},[],{"trials":6771,"activeCount":417,"soonestReadout":175},[6772],{"nctId":172,"briefTitle":173,"status":101,"phases":6773,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":6774,"interventions":6775},[85],[107],[180,92,169,119],{"trials":6777,"activeCount":97},[6778],{"nctId":239,"briefTitle":240,"status":155,"phases":6779,"primaryCompletion":232,"completion":232,"start":242,"enrollment":243,"conditions":6780,"interventions":6781},[86],[107],[164,246,247,248,92,180],{"trials":6783,"activeCount":97},[],{"trials":6785,"activeCount":97},[],{"trials":6787,"activeCount":97},[],{"intervention":1891,"totalTrials":181,"cells":6789},{"EARLY_PHASE1":6790,"PHASE1":6792,"PHASE2":6828,"PHASE3":6830,"PHASE4":6832,"NA":6834},{"trials":6791,"activeCount":97},[],{"trials":6793,"activeCount":417,"soonestReadout":1885},[6794,6803,6807,6820],{"nctId":6795,"briefTitle":6796,"status":155,"phases":6797,"primaryCompletion":6798,"completion":6798,"start":6799,"enrollment":1335,"conditions":6800,"interventions":6801},"NCT02215096","Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer",[85],"2019-10-03","2014-11-13",[107],[6802,1891],"GSK2636771",{"nctId":1882,"briefTitle":1883,"status":125,"phases":6804,"primaryCompletion":1885,"completion":1886,"start":1887,"enrollment":719,"conditions":6805,"interventions":6806},[85],[107],[121,140,1774,1890,1891],{"nctId":6808,"briefTitle":6809,"status":145,"phases":6810,"primaryCompletion":6811,"completion":6812,"start":6813,"enrollment":6814,"conditions":6815,"interventions":6816},"NCT03150056","Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer",[85],"2020-07-31","2021-06-22","2017-07-18",73,[2761],[6817,6818,1891,6819],"GSK525762","Abiraterone","Prednisone",{"nctId":6821,"briefTitle":6822,"status":500,"phases":6823,"primaryCompletion":6824,"completion":6824,"start":483,"enrollment":97,"conditions":6825,"interventions":6826},"NCT02380313","Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone",[85],"2017-05",[36],[6827,1891,6818,6819],"Afuresertib",{"trials":6829,"activeCount":97},[],{"trials":6831,"activeCount":97},[],{"trials":6833,"activeCount":97},[],{"trials":6835,"activeCount":97},[],{"intervention":73,"totalTrials":660,"cells":6837},{"EARLY_PHASE1":6838,"PHASE1":6840,"PHASE2":6855,"PHASE3":6857,"PHASE4":6859,"NA":6861},{"trials":6839,"activeCount":97},[],{"trials":6841,"activeCount":417,"soonestReadout":72},[6842,6846],{"nctId":70,"briefTitle":71,"status":101,"phases":6843,"primaryCompletion":72,"completion":103,"start":104,"enrollment":105,"conditions":6844,"interventions":6845},[85],[107],[73,92],{"nctId":6847,"briefTitle":6848,"status":145,"phases":6849,"primaryCompletion":6850,"completion":6850,"start":6851,"enrollment":1634,"conditions":6852,"interventions":6854},"NCT05424380","A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS",[85],"2024-03-04","2022-09-20",[6853],"Leukemia, Myeloid, Acute",[73],{"trials":6856,"activeCount":97},[],{"trials":6858,"activeCount":97},[],{"trials":6860,"activeCount":97},[],{"trials":6862,"activeCount":97},[],{"intervention":6864,"totalTrials":417,"cells":6865},"GSK4024484C",{"EARLY_PHASE1":6866,"PHASE1":6868,"PHASE2":6879,"PHASE3":6881,"PHASE4":6883,"NA":6885},{"trials":6867,"activeCount":97},[],{"trials":6869,"activeCount":417,"soonestReadout":6874},[6870],{"nctId":6871,"briefTitle":6872,"status":125,"phases":6873,"primaryCompletion":6874,"completion":6874,"start":6875,"enrollment":6876,"conditions":6877,"interventions":6878},"NCT06171113","A Study to Investigate the Safety of GSK4024484 in Healthy Adult Participants",[85],"2026-08-07","2023-12-11",156,[5943],[6864],{"trials":6880,"activeCount":97},[],{"trials":6882,"activeCount":97},[],{"trials":6884,"activeCount":97},[],{"trials":6886,"activeCount":97},[],{"intervention":136,"totalTrials":417,"cells":6888},{"EARLY_PHASE1":6889,"PHASE1":6891,"PHASE2":6897,"PHASE3":6899,"PHASE4":6901,"NA":6903},{"trials":6890,"activeCount":97},[],{"trials":6892,"activeCount":417,"soonestReadout":127},[6893],{"nctId":123,"briefTitle":124,"status":125,"phases":6894,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":6895,"interventions":6896},[85],[107],[133,134,135,136,137,138,139,140,141,92],{"trials":6898,"activeCount":97},[],{"trials":6900,"activeCount":97},[],{"trials":6902,"activeCount":97},[],{"trials":6904,"activeCount":97},[],{"intervention":138,"totalTrials":417,"cells":6906},{"EARLY_PHASE1":6907,"PHASE1":6909,"PHASE2":6915,"PHASE3":6917,"PHASE4":6919,"NA":6921},{"trials":6908,"activeCount":97},[],{"trials":6910,"activeCount":417,"soonestReadout":127},[6911],{"nctId":123,"briefTitle":124,"status":125,"phases":6912,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":6913,"interventions":6914},[85],[107],[133,134,135,136,137,138,139,140,141,92],{"trials":6916,"activeCount":97},[],{"trials":6918,"activeCount":97},[],{"trials":6920,"activeCount":97},[],{"trials":6922,"activeCount":97},[],{"intervention":141,"totalTrials":417,"cells":6924},{"EARLY_PHASE1":6925,"PHASE1":6927,"PHASE2":6933,"PHASE3":6935,"PHASE4":6937,"NA":6939},{"trials":6926,"activeCount":97},[],{"trials":6928,"activeCount":417,"soonestReadout":127},[6929],{"nctId":123,"briefTitle":124,"status":125,"phases":6930,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":6931,"interventions":6932},[85],[107],[133,134,135,136,137,138,139,140,141,92],{"trials":6934,"activeCount":97},[],{"trials":6936,"activeCount":97},[],{"trials":6938,"activeCount":97},[],{"trials":6940,"activeCount":97},[],{"intervention":6942,"totalTrials":417,"cells":6943},"GSK5533524",{"EARLY_PHASE1":6944,"PHASE1":6946,"PHASE2":6955,"PHASE3":6957,"PHASE4":6959,"NA":6961},{"trials":6945,"activeCount":97},[],{"trials":6947,"activeCount":417,"soonestReadout":6952},[6948],{"nctId":6949,"briefTitle":6950,"status":125,"phases":6951,"primaryCompletion":6952,"completion":6952,"start":675,"enrollment":105,"conditions":6953,"interventions":6954},"NCT07438782","First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors",[85],"2029-02-06",[107],[6942],{"trials":6956,"activeCount":97},[],{"trials":6958,"activeCount":97},[],{"trials":6960,"activeCount":97},[],{"trials":6962,"activeCount":97},[],{"intervention":1890,"totalTrials":417,"cells":6964},{"EARLY_PHASE1":6965,"PHASE1":6967,"PHASE2":6973,"PHASE3":6975,"PHASE4":6977,"NA":6979},{"trials":6966,"activeCount":97},[],{"trials":6968,"activeCount":417,"soonestReadout":1885},[6969],{"nctId":1882,"briefTitle":1883,"status":125,"phases":6970,"primaryCompletion":1885,"completion":1886,"start":1887,"enrollment":719,"conditions":6971,"interventions":6972},[85],[107],[121,140,1774,1890,1891],{"trials":6974,"activeCount":97},[],{"trials":6976,"activeCount":97},[],{"trials":6978,"activeCount":97},[],{"trials":6980,"activeCount":97},[],{"intervention":6982,"totalTrials":417,"cells":6983},"Low dose Strep A Alum",{"EARLY_PHASE1":6984,"PHASE1":6986,"PHASE2":7004,"PHASE3":7006,"PHASE4":7008,"NA":7010},{"trials":6985,"activeCount":97},[],{"trials":6987,"activeCount":417,"soonestReadout":6992},[6988],{"nctId":6989,"briefTitle":6990,"status":125,"phases":6991,"primaryCompletion":6992,"completion":6992,"start":6993,"enrollment":6994,"conditions":6995,"interventions":6997},"NCT07085702","A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults",[85],"2026-11-30","2025-07-31",108,[6996],"Streptococcal Infections",[6982,6998,6999,7000,7001,7002,7003],"Medium dose Strep A Alum","High dose Strep A Alum","Low dose Strep A AS37","Medium dose Strep A AS37","High dose Strep A AS37","Strep A Alum Placebo",{"trials":7005,"activeCount":97},[],{"trials":7007,"activeCount":97},[],{"trials":7009,"activeCount":97},[],{"trials":7011,"activeCount":97},[],{"intervention":6998,"totalTrials":417,"cells":7013},{"EARLY_PHASE1":7014,"PHASE1":7016,"PHASE2":7022,"PHASE3":7024,"PHASE4":7026,"NA":7028},{"trials":7015,"activeCount":97},[],{"trials":7017,"activeCount":417,"soonestReadout":6992},[7018],{"nctId":6989,"briefTitle":6990,"status":125,"phases":7019,"primaryCompletion":6992,"completion":6992,"start":6993,"enrollment":6994,"conditions":7020,"interventions":7021},[85],[6996],[6982,6998,6999,7000,7001,7002,7003],{"trials":7023,"activeCount":97},[],{"trials":7025,"activeCount":97},[],{"trials":7027,"activeCount":97},[],{"trials":7029,"activeCount":97},[],{"intervention":6999,"totalTrials":417,"cells":7031},{"EARLY_PHASE1":7032,"PHASE1":7034,"PHASE2":7040,"PHASE3":7042,"PHASE4":7044,"NA":7046},{"trials":7033,"activeCount":97},[],{"trials":7035,"activeCount":417,"soonestReadout":6992},[7036],{"nctId":6989,"briefTitle":6990,"status":125,"phases":7037,"primaryCompletion":6992,"completion":6992,"start":6993,"enrollment":6994,"conditions":7038,"interventions":7039},[85],[6996],[6982,6998,6999,7000,7001,7002,7003],{"trials":7041,"activeCount":97},[],{"trials":7043,"activeCount":97},[],{"trials":7045,"activeCount":97},[],{"trials":7047,"activeCount":97},[],{"intervention":7000,"totalTrials":417,"cells":7049},{"EARLY_PHASE1":7050,"PHASE1":7052,"PHASE2":7058,"PHASE3":7060,"PHASE4":7062,"NA":7064},{"trials":7051,"activeCount":97},[],{"trials":7053,"activeCount":417,"soonestReadout":6992},[7054],{"nctId":6989,"briefTitle":6990,"status":125,"phases":7055,"primaryCompletion":6992,"completion":6992,"start":6993,"enrollment":6994,"conditions":7056,"interventions":7057},[85],[6996],[6982,6998,6999,7000,7001,7002,7003],{"trials":7059,"activeCount":97},[],{"trials":7061,"activeCount":97},[],{"trials":7063,"activeCount":97},[],{"trials":7065,"activeCount":97},[],{"intervention":7001,"totalTrials":417,"cells":7067},{"EARLY_PHASE1":7068,"PHASE1":7070,"PHASE2":7076,"PHASE3":7078,"PHASE4":7080,"NA":7082},{"trials":7069,"activeCount":97},[],{"trials":7071,"activeCount":417,"soonestReadout":6992},[7072],{"nctId":6989,"briefTitle":6990,"status":125,"phases":7073,"primaryCompletion":6992,"completion":6992,"start":6993,"enrollment":6994,"conditions":7074,"interventions":7075},[85],[6996],[6982,6998,6999,7000,7001,7002,7003],{"trials":7077,"activeCount":97},[],{"trials":7079,"activeCount":97},[],{"trials":7081,"activeCount":97},[],{"trials":7083,"activeCount":97},[],{"intervention":7002,"totalTrials":417,"cells":7085},{"EARLY_PHASE1":7086,"PHASE1":7088,"PHASE2":7094,"PHASE3":7096,"PHASE4":7098,"NA":7100},{"trials":7087,"activeCount":97},[],{"trials":7089,"activeCount":417,"soonestReadout":6992},[7090],{"nctId":6989,"briefTitle":6990,"status":125,"phases":7091,"primaryCompletion":6992,"completion":6992,"start":6993,"enrollment":6994,"conditions":7092,"interventions":7093},[85],[6996],[6982,6998,6999,7000,7001,7002,7003],{"trials":7095,"activeCount":97},[],{"trials":7097,"activeCount":97},[],{"trials":7099,"activeCount":97},[],{"trials":7101,"activeCount":97},[],{"intervention":7003,"totalTrials":417,"cells":7103},{"EARLY_PHASE1":7104,"PHASE1":7106,"PHASE2":7112,"PHASE3":7114,"PHASE4":7116,"NA":7118},{"trials":7105,"activeCount":97},[],{"trials":7107,"activeCount":417,"soonestReadout":6992},[7108],{"nctId":6989,"briefTitle":6990,"status":125,"phases":7109,"primaryCompletion":6992,"completion":6992,"start":6993,"enrollment":6994,"conditions":7110,"interventions":7111},[85],[6996],[6982,6998,6999,7000,7001,7002,7003],{"trials":7113,"activeCount":97},[],{"trials":7115,"activeCount":97},[],{"trials":7117,"activeCount":97},[],{"trials":7119,"activeCount":97},[],{"intervention":7121,"totalTrials":417,"cells":7122},"Investigational RSV vaccine 1",{"EARLY_PHASE1":7123,"PHASE1":7125,"PHASE2":7139,"PHASE3":7141,"PHASE4":7143,"NA":7145},{"trials":7124,"activeCount":97},[],{"trials":7126,"activeCount":417,"soonestReadout":3705},[7127],{"nctId":7128,"briefTitle":7129,"status":101,"phases":7130,"primaryCompletion":3705,"completion":3705,"start":129,"enrollment":7131,"conditions":7132,"interventions":7133},"NCT06573281","A Study on the Safety and Immune Response to an mRNA-based RSV Investigational Vaccine in Healthy Adults Aged 18-45 Years",[85],213,[2620],[7121,7134,7135,7136,7137,7138],"Investigational RSV vaccine 2","Investigational RSV vaccine 3","Investigational RSV vaccine 4","Investigational RSV vaccine 5","Investigational RSV vaccine 6",{"trials":7140,"activeCount":97},[],{"trials":7142,"activeCount":97},[],{"trials":7144,"activeCount":97},[],{"trials":7146,"activeCount":97},[],{"intervention":7134,"totalTrials":417,"cells":7148},{"EARLY_PHASE1":7149,"PHASE1":7151,"PHASE2":7157,"PHASE3":7159,"PHASE4":7161,"NA":7163},{"trials":7150,"activeCount":97},[],{"trials":7152,"activeCount":417,"soonestReadout":3705},[7153],{"nctId":7128,"briefTitle":7129,"status":101,"phases":7154,"primaryCompletion":3705,"completion":3705,"start":129,"enrollment":7131,"conditions":7155,"interventions":7156},[85],[2620],[7121,7134,7135,7136,7137,7138],{"trials":7158,"activeCount":97},[],{"trials":7160,"activeCount":97},[],{"trials":7162,"activeCount":97},[],{"trials":7164,"activeCount":97},[],{"intervention":7135,"totalTrials":417,"cells":7166},{"EARLY_PHASE1":7167,"PHASE1":7169,"PHASE2":7175,"PHASE3":7177,"PHASE4":7179,"NA":7181},{"trials":7168,"activeCount":97},[],{"trials":7170,"activeCount":417,"soonestReadout":3705},[7171],{"nctId":7128,"briefTitle":7129,"status":101,"phases":7172,"primaryCompletion":3705,"completion":3705,"start":129,"enrollment":7131,"conditions":7173,"interventions":7174},[85],[2620],[7121,7134,7135,7136,7137,7138],{"trials":7176,"activeCount":97},[],{"trials":7178,"activeCount":97},[],{"trials":7180,"activeCount":97},[],{"trials":7182,"activeCount":97},[],{"intervention":7136,"totalTrials":417,"cells":7184},{"EARLY_PHASE1":7185,"PHASE1":7187,"PHASE2":7193,"PHASE3":7195,"PHASE4":7197,"NA":7199},{"trials":7186,"activeCount":97},[],{"trials":7188,"activeCount":417,"soonestReadout":3705},[7189],{"nctId":7128,"briefTitle":7129,"status":101,"phases":7190,"primaryCompletion":3705,"completion":3705,"start":129,"enrollment":7131,"conditions":7191,"interventions":7192},[85],[2620],[7121,7134,7135,7136,7137,7138],{"trials":7194,"activeCount":97},[],{"trials":7196,"activeCount":97},[],{"trials":7198,"activeCount":97},[],{"trials":7200,"activeCount":97},[],{"intervention":7137,"totalTrials":417,"cells":7202},{"EARLY_PHASE1":7203,"PHASE1":7205,"PHASE2":7211,"PHASE3":7213,"PHASE4":7215,"NA":7217},{"trials":7204,"activeCount":97},[],{"trials":7206,"activeCount":417,"soonestReadout":3705},[7207],{"nctId":7128,"briefTitle":7129,"status":101,"phases":7208,"primaryCompletion":3705,"completion":3705,"start":129,"enrollment":7131,"conditions":7209,"interventions":7210},[85],[2620],[7121,7134,7135,7136,7137,7138],{"trials":7212,"activeCount":97},[],{"trials":7214,"activeCount":97},[],{"trials":7216,"activeCount":97},[],{"trials":7218,"activeCount":97},[],{"intervention":7138,"totalTrials":417,"cells":7220},{"EARLY_PHASE1":7221,"PHASE1":7223,"PHASE2":7229,"PHASE3":7231,"PHASE4":7233,"NA":7235},{"trials":7222,"activeCount":97},[],{"trials":7224,"activeCount":417,"soonestReadout":3705},[7225],{"nctId":7128,"briefTitle":7129,"status":101,"phases":7226,"primaryCompletion":3705,"completion":3705,"start":129,"enrollment":7131,"conditions":7227,"interventions":7228},[85],[2620],[7121,7134,7135,7136,7137,7138],{"trials":7230,"activeCount":97},[],{"trials":7232,"activeCount":97},[],{"trials":7234,"activeCount":97},[],{"trials":7236,"activeCount":97},[],{"intervention":7238,"totalTrials":417,"cells":7239},"GSK5733584",{"EARLY_PHASE1":7240,"PHASE1":7242,"PHASE2":7254,"PHASE3":7256,"PHASE4":7258,"NA":7260},{"trials":7241,"activeCount":97},[],{"trials":7243,"activeCount":417,"soonestReadout":7248},[7244],{"nctId":7245,"briefTitle":7246,"status":125,"phases":7247,"primaryCompletion":7248,"completion":7249,"start":7250,"enrollment":7251,"conditions":7252,"interventions":7253},"NCT06431594","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors",[85],"2027-09-22","2029-12-31","2024-07-02",675,[2097,107],[7238],{"trials":7255,"activeCount":97},[],{"trials":7257,"activeCount":97},[],{"trials":7259,"activeCount":97},[],{"trials":7261,"activeCount":97},[],{"intervention":447,"totalTrials":417,"cells":7263},{"EARLY_PHASE1":7264,"PHASE1":7266,"PHASE2":7272,"PHASE3":7274,"PHASE4":7276,"NA":7278},{"trials":7265,"activeCount":97},[],{"trials":7267,"activeCount":417,"soonestReadout":442},[7268],{"nctId":439,"briefTitle":440,"status":125,"phases":7269,"primaryCompletion":442,"completion":442,"start":443,"enrollment":444,"conditions":7270,"interventions":7271},[85],[435],[447,53],{"trials":7273,"activeCount":97},[],{"trials":7275,"activeCount":97},[],{"trials":7277,"activeCount":97},[],{"trials":7279,"activeCount":97},[],{"intervention":7281,"totalTrials":417,"cells":7282},"GSK4528287",{"EARLY_PHASE1":7283,"PHASE1":7285,"PHASE2":7297,"PHASE3":7299,"PHASE4":7301,"NA":7303},{"trials":7284,"activeCount":97},[],{"trials":7286,"activeCount":417,"soonestReadout":7291},[7287],{"nctId":7288,"briefTitle":7289,"status":101,"phases":7290,"primaryCompletion":7291,"completion":7292,"start":7293,"enrollment":6503,"conditions":7294,"interventions":7296},"NCT06681181","A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants",[85],"2026-04-23","2027-02-25","2024-11-18",[7295],"Colitis, Ulcerative",[7281],{"trials":7298,"activeCount":97},[],{"trials":7300,"activeCount":97},[],{"trials":7302,"activeCount":97},[],{"trials":7304,"activeCount":97},[],{"intervention":7306,"totalTrials":417,"cells":7307},"Investigational mRNA Seasonal Flu\u002FCOVID-19 Combination (Flu\u002FCOVm) Vaccine",{"EARLY_PHASE1":7308,"PHASE1":7310,"PHASE2":7325,"PHASE3":7327,"PHASE4":7329,"NA":7331},{"trials":7309,"activeCount":97},[],{"trials":7311,"activeCount":417,"soonestReadout":7316},[7312],{"nctId":7313,"briefTitle":7314,"status":125,"phases":7315,"primaryCompletion":7316,"completion":7317,"start":7318,"enrollment":7319,"conditions":7320,"interventions":7322},"NCT07464314","A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu\u002FCOVID-19 Combination Vaccine in Adults",[85],"2026-12-03","2027-06-03","2026-03-09",225,[7321],"Influenza, Human+COVID-19",[7306,7323,7324],"Licensed Seasonal Influenza Vaccine","Licensed COVID-19 Vaccine",{"trials":7326,"activeCount":97},[],{"trials":7328,"activeCount":97},[],{"trials":7330,"activeCount":97},[],{"trials":7332,"activeCount":97},[],{"intervention":7323,"totalTrials":417,"cells":7334},{"EARLY_PHASE1":7335,"PHASE1":7337,"PHASE2":7343,"PHASE3":7345,"PHASE4":7347,"NA":7349},{"trials":7336,"activeCount":97},[],{"trials":7338,"activeCount":417,"soonestReadout":7316},[7339],{"nctId":7313,"briefTitle":7314,"status":125,"phases":7340,"primaryCompletion":7316,"completion":7317,"start":7318,"enrollment":7319,"conditions":7341,"interventions":7342},[85],[7321],[7306,7323,7324],{"trials":7344,"activeCount":97},[],{"trials":7346,"activeCount":97},[],{"trials":7348,"activeCount":97},[],{"trials":7350,"activeCount":97},[],{"intervention":7324,"totalTrials":417,"cells":7352},{"EARLY_PHASE1":7353,"PHASE1":7355,"PHASE2":7361,"PHASE3":7363,"PHASE4":7365,"NA":7367},{"trials":7354,"activeCount":97},[],{"trials":7356,"activeCount":417,"soonestReadout":7316},[7357],{"nctId":7313,"briefTitle":7314,"status":125,"phases":7358,"primaryCompletion":7316,"completion":7317,"start":7318,"enrollment":7319,"conditions":7359,"interventions":7360},[85],[7321],[7306,7323,7324],{"trials":7362,"activeCount":97},[],{"trials":7364,"activeCount":97},[],{"trials":7366,"activeCount":97},[],{"trials":7368,"activeCount":97},[],{"intervention":134,"totalTrials":1318,"cells":7370},{"EARLY_PHASE1":7371,"PHASE1":7373,"PHASE2":7402,"PHASE3":7404,"PHASE4":7406,"NA":7408},{"trials":7372,"activeCount":97},[],{"trials":7374,"activeCount":417,"soonestReadout":127},[7375,7379,7383,7387,7398],{"nctId":123,"briefTitle":124,"status":125,"phases":7376,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":7377,"interventions":7378},[85],[107],[133,134,135,136,137,138,139,140,141,92],{"nctId":3365,"briefTitle":3366,"status":155,"phases":7380,"primaryCompletion":3368,"completion":3369,"start":3370,"enrollment":2836,"conditions":7381,"interventions":7382},[85],[267],[2273,1758,134],{"nctId":2277,"briefTitle":2278,"status":155,"phases":7384,"primaryCompletion":2280,"completion":2280,"start":2281,"enrollment":2282,"conditions":7385,"interventions":7386},[85],[107],[2285,2264,2275,2286,2287,2288],{"nctId":7388,"briefTitle":7389,"status":145,"phases":7390,"primaryCompletion":7391,"completion":7392,"start":7393,"enrollment":7394,"conditions":7395,"interventions":7396},"NCT00455572","Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer",[85],"2013-08-04","2013-08-08","2007-05-11",71,[267],[7397,134,2397],"Immunotherapeutic GSK1572932A",{"nctId":3055,"briefTitle":3056,"status":155,"phases":7399,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":803,"conditions":7400,"interventions":7401},[85],[36],[3048,164,3062,165,135,3063,134],{"trials":7403,"activeCount":97},[],{"trials":7405,"activeCount":97},[],{"trials":7407,"activeCount":97},[],{"trials":7409,"activeCount":97},[7410,7414],{"nctId":2438,"briefTitle":2439,"status":155,"phases":7411,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":417,"conditions":7412,"interventions":7413},[],[2444],[2264,2288,2446],{"nctId":2448,"briefTitle":2449,"status":155,"phases":7415,"primaryCompletion":2441,"completion":2441,"start":2442,"enrollment":417,"conditions":7416,"interventions":7417},[],[2444],[2288,2446,2264],{"intervention":2300,"totalTrials":345,"cells":7419},{"EARLY_PHASE1":7420,"PHASE1":7422,"PHASE2":7535,"PHASE3":7667,"PHASE4":7705,"NA":7715},{"trials":7421,"activeCount":97},[],{"trials":7423,"activeCount":97},[7424,7432,7441,7450,7459,7468,7476,7485,7489,7493,7501,7510,7518,7526],{"nctId":7425,"briefTitle":7426,"status":155,"phases":7427,"primaryCompletion":7428,"completion":7428,"start":7429,"enrollment":1298,"conditions":7430,"interventions":7431},"NCT00258050","To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients",[85],"2007-02-08","2005-11-21",[668],[6488,2274],{"nctId":7433,"briefTitle":7434,"status":155,"phases":7435,"primaryCompletion":7436,"completion":7436,"start":7437,"enrollment":7438,"conditions":7439,"interventions":7440},"NCT00650910","Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w\u002F ErbB2 Positive Breast Cancer",[85],"2009-07-10","2008-04-23",17,[668],[2300,6489],{"nctId":7442,"briefTitle":7443,"status":155,"phases":7444,"primaryCompletion":7445,"completion":7445,"start":7446,"enrollment":750,"conditions":7447,"interventions":7448},"NCT01290354","Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer",[85],"2013-03-18","2011-09-12",[36],[2274,7449],"[11C] lapatinib",{"nctId":7451,"briefTitle":7452,"status":155,"phases":7453,"primaryCompletion":7454,"completion":7454,"start":7455,"enrollment":2825,"conditions":7456,"interventions":7457},"NCT00158782","Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients",[85],"2007-08-21","2004-09-28",[1877],[7458,2300],"GW786034",{"nctId":7460,"briefTitle":7461,"status":155,"phases":7462,"primaryCompletion":7463,"completion":7464,"start":7465,"enrollment":255,"conditions":7466,"interventions":7467},"NCT00516672","Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors",[85],"2010-08-30","2015-10-14","2007-09-10",[1877],[2263,2274],{"nctId":7469,"briefTitle":7470,"status":155,"phases":7471,"primaryCompletion":7472,"completion":7472,"start":7473,"enrollment":1634,"conditions":7474,"interventions":7475},"NCT00528281","A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase",[85],"2009-05-27","2007-09-20",[267],[2274,165],{"nctId":7477,"briefTitle":7478,"status":155,"phases":7479,"primaryCompletion":7480,"completion":7480,"start":7481,"enrollment":1459,"conditions":7482,"interventions":7483},"NCT00536809","Phase I\u002FII Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer",[85],"2008-10-31","2007-09-26",[2667],[2300,7484,2839],"oxaliplatin",{"nctId":2266,"briefTitle":2267,"status":155,"phases":7486,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":34,"conditions":7487,"interventions":7488},[85],[668],[2273,2274,2264,2275],{"nctId":3020,"briefTitle":3021,"status":155,"phases":7490,"primaryCompletion":3023,"completion":3023,"start":3024,"enrollment":3025,"conditions":7491,"interventions":7492},[85],[668],[2300,2286],{"nctId":7494,"briefTitle":7495,"status":155,"phases":7496,"primaryCompletion":7497,"completion":7497,"start":7498,"enrollment":695,"conditions":7499,"interventions":7500},"NCT00359190","Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer",[85],"2008-01-09","2004-06-29",[668],[2300],{"nctId":7502,"briefTitle":7503,"status":155,"phases":7504,"primaryCompletion":7505,"completion":7505,"start":7506,"enrollment":1459,"conditions":7507,"interventions":7508},"NCT00849329","A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer",[85],"2009-11-24","2009-03-10",[668],[2300,7509],"lapatinib plus esomeprazole",{"nctId":7511,"briefTitle":7512,"status":155,"phases":7513,"primaryCompletion":7514,"completion":7514,"start":7515,"enrollment":1298,"conditions":7516,"interventions":7517},"NCT00821054","A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients",[85],"2011-03-22","2009-03-06",[668],[2274],{"nctId":7519,"briefTitle":7520,"status":500,"phases":7521,"primaryCompletion":7522,"completion":7522,"start":2355,"enrollment":97,"conditions":7523,"interventions":7525},"NCT00513253","A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib",[85],"2008-05",[7524],"Healthy Subjects",[2300],{"nctId":7527,"briefTitle":7528,"status":155,"phases":7529,"primaryCompletion":7530,"completion":7530,"start":7531,"enrollment":7532,"conditions":7533,"interventions":7534},"NCT00996762","A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib",[85],"2012-09-18","2009-11-12",158,[668],[2300],{"trials":7536,"activeCount":97},[7537,7541,7550,7557,7561,7565,7569,7577,7586,7594,7602,7609,7617,7626,7630,7639,7643,7650,7654,7663],{"nctId":2292,"briefTitle":2293,"status":155,"phases":7538,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":2297,"conditions":7539,"interventions":7540},[86],[668],[2300,2301,2264,2302,2303,2304],{"nctId":7542,"briefTitle":7543,"status":145,"phases":7544,"primaryCompletion":7545,"completion":7545,"start":7546,"enrollment":314,"conditions":7547,"interventions":7548},"NCT00820924","Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells",[86],"2011-07","2008-06",[668],[7549],"LAPATINIB",{"nctId":7551,"briefTitle":7552,"status":155,"phases":7553,"primaryCompletion":2382,"completion":2382,"start":3036,"enrollment":7554,"conditions":7555,"interventions":7556},"NCT00089999","Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer",[86],138,[668],[2274],{"nctId":2332,"briefTitle":2333,"status":155,"phases":7558,"primaryCompletion":2335,"completion":482,"start":2336,"enrollment":414,"conditions":7559,"interventions":7560},[86],[668],[2330,216,2339,2274],{"nctId":3075,"briefTitle":3076,"status":145,"phases":7562,"primaryCompletion":1429,"completion":3078,"start":3079,"enrollment":1165,"conditions":7563,"interventions":7564},[86],[3081,668],[2274,3083,164,3063],{"nctId":2341,"briefTitle":2342,"status":500,"phases":7566,"primaryCompletion":2344,"completion":2344,"start":2344,"enrollment":97,"conditions":7567,"interventions":7568},[86],[668],[2274,2330,2329,1241,216],{"nctId":7570,"briefTitle":7571,"status":155,"phases":7572,"primaryCompletion":2344,"completion":2344,"start":3552,"enrollment":7573,"conditions":7574,"interventions":7576},"NCT00477464","Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer",[86],51,[7575,668],"Metastatic Breast Cancer",[2274,2839],{"nctId":7578,"briefTitle":7579,"status":155,"phases":7580,"primaryCompletion":7581,"completion":7581,"start":7582,"enrollment":526,"conditions":7583,"interventions":7585},"NCT00044343","GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And\u002FOr Oxaliplatin",[86],"2003-10","2002-09",[7584],"Colorectal Cancer",[2300],{"nctId":7587,"briefTitle":7588,"status":155,"phases":7589,"primaryCompletion":7590,"completion":7591,"start":2804,"enrollment":781,"conditions":7592,"interventions":7593},"NCT00558103","Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer",[86],"2011-05","2011-12",[668],[2300,2273],{"nctId":7595,"briefTitle":7596,"status":155,"phases":7597,"primaryCompletion":7598,"completion":7598,"start":4756,"enrollment":2883,"conditions":7599,"interventions":7600},"NCT00422903","Letrozole In Combination With Lapatinib In Neoadjuvant Treatment Of Early Breast Cancer",[86],"2011-04",[668],[2300,7601],"letrozole",{"nctId":7603,"briefTitle":7604,"status":155,"phases":7605,"primaryCompletion":4700,"completion":4700,"start":7606,"enrollment":234,"conditions":7607,"interventions":7608},"NCT00320411","GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer",[86],"2005-11-28",[668],[2300],{"nctId":7610,"briefTitle":7611,"status":155,"phases":7612,"primaryCompletion":2804,"completion":2804,"start":7613,"enrollment":177,"conditions":7614,"interventions":7616},"NCT00371566","A Study Of Lapatinib Versus Placebo Followed By Chemoradiation In Patients With Locally Advanced Head And Neck Cancer",[86],"2006-03",[7615],"Squamous Cell Carcinoma of Head and Neck",[2387],{"nctId":7618,"briefTitle":7619,"status":155,"phases":7620,"primaryCompletion":5018,"completion":7545,"start":4843,"enrollment":7621,"conditions":7622,"interventions":7625},"NCT00430781","Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer",[86],228,[7623,7624],"Neoplasms, Uterine Cervix","Metastatic Cervical Cancer",[2263,2300],{"nctId":2831,"briefTitle":2832,"status":145,"phases":7627,"primaryCompletion":2813,"completion":2834,"start":2835,"enrollment":2836,"conditions":7628,"interventions":7629},[86],[668],[2839,2446,2300],{"nctId":7631,"briefTitle":7632,"status":155,"phases":7633,"primaryCompletion":2442,"completion":7634,"start":4843,"enrollment":613,"conditions":7635,"interventions":7636},"NCT00387127","Lapatinib Versus Placebo Given Concurrently With Cisplatin And Radiotherapy In Patients With Unresected Head And Neck Cancer",[86],"2014-01",[305],[2387,7637,7638],"radiotherapy","cisplatin chemotherapy",{"nctId":2370,"briefTitle":2371,"status":155,"phases":7640,"primaryCompletion":2373,"completion":2373,"start":2374,"enrollment":2375,"conditions":7641,"interventions":7642},[86],[668],[2274,216],{"nctId":7644,"briefTitle":7645,"status":155,"phases":7646,"primaryCompletion":2356,"completion":7647,"start":2814,"enrollment":3157,"conditions":7648,"interventions":7649},"NCT00105950","Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer",[86],"2010-05",[668],[2300],{"nctId":2379,"briefTitle":2380,"status":155,"phases":7651,"primaryCompletion":2382,"completion":827,"start":2383,"enrollment":2384,"conditions":7652,"interventions":7653},[86],[668],[2387,216],{"nctId":7655,"briefTitle":7656,"status":155,"phases":7657,"primaryCompletion":7658,"completion":7658,"start":7659,"enrollment":2825,"conditions":7660,"interventions":7662},"NCT00350727","Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma",[86],"2009-12","2006-12",[7661],"Glioma",[2263,2300],{"nctId":2389,"briefTitle":2390,"status":500,"phases":7664,"primaryCompletion":2392,"completion":2393,"start":2394,"enrollment":97,"conditions":7665,"interventions":7666},[86],[668],[2274,2330,164,216,2397],{"trials":7668,"activeCount":97},[7669,7678,7686,7690,7697],{"nctId":7670,"briefTitle":7671,"status":155,"phases":7672,"primaryCompletion":4844,"completion":2834,"start":7673,"enrollment":7674,"conditions":7675,"interventions":7677},"NCT00078572","Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer",[87],"2004-03",408,[7676],"Breast Cancer",[2839,2300],{"nctId":7679,"briefTitle":7680,"status":155,"phases":7681,"primaryCompletion":3111,"completion":7682,"start":2296,"enrollment":7683,"conditions":7684,"interventions":7685},"NCT00374322","Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer",[87],"2013-07",3166,[668],[2300],{"nctId":2424,"briefTitle":2425,"status":155,"phases":7687,"primaryCompletion":2427,"completion":828,"start":2428,"enrollment":2429,"conditions":7688,"interventions":7689},[87],[2431],[2274,216],{"nctId":7691,"briefTitle":7692,"status":155,"phases":7693,"primaryCompletion":3552,"completion":2335,"start":2844,"enrollment":7694,"conditions":7695,"interventions":7696},"NCT00320385","Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer",[87],296,[668],[2274,2330],{"nctId":7698,"briefTitle":7699,"status":155,"phases":7700,"primaryCompletion":503,"completion":7701,"start":7659,"enrollment":7702,"conditions":7703,"interventions":7704},"NCT00424255","Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery",[87],"2013-11",688,[305],[2274],{"trials":7706,"activeCount":97},[7707],{"nctId":7708,"briefTitle":7709,"status":155,"phases":7710,"primaryCompletion":7711,"completion":7711,"start":7591,"enrollment":7712,"conditions":7713,"interventions":7714},"NCT01328054","A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval",[88],"2015-03",58,[36],[2300],{"trials":7716,"activeCount":97},[],{"intervention":7718,"totalTrials":695,"cells":7719},"Engerix™-B",{"EARLY_PHASE1":7720,"PHASE1":7722,"PHASE2":7733,"PHASE3":7802,"PHASE4":7939,"NA":7994},{"trials":7721,"activeCount":97},[],{"trials":7723,"activeCount":97},[7724],{"nctId":7725,"briefTitle":7726,"status":155,"phases":7727,"primaryCompletion":7728,"completion":7728,"start":7729,"enrollment":255,"conditions":7730,"interventions":7731},"NCT00699231","Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients",[85],"1992-12","1992-02",[24],[7732,7718],"HBV-MPL vaccine 208129",{"trials":7734,"activeCount":97},[7735,7745,7754,7762,7772,7781,7794],{"nctId":7736,"briefTitle":7737,"status":155,"phases":7738,"primaryCompletion":7739,"start":7740,"enrollment":1196,"conditions":7741,"interventions":7742},"NCT00697775","Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents",[86],"1999-05","1998-03",[24],[7743,7744,7718],"HBV-MPL vaccine Formulation A","HBV-MPL vaccine Formulation B",{"nctId":7746,"briefTitle":7747,"status":155,"phases":7748,"primaryCompletion":7749,"start":7750,"enrollment":3392,"conditions":7751,"interventions":7752},"NCT00698906","Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y",[86],"1998-02","1997-06",[24],[7753,7718],"HBV-MPL vaccine",{"nctId":7755,"briefTitle":7756,"status":155,"phases":7757,"primaryCompletion":7758,"start":7759,"enrollment":1196,"conditions":7760,"interventions":7761},"NCT00697853","Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults",[86],"1999-07","1998-11",[24],[7718,7732],{"nctId":7763,"briefTitle":7764,"status":155,"phases":7765,"primaryCompletion":7766,"completion":7767,"start":7768,"enrollment":7769,"conditions":7770,"interventions":7771},"NCT00697229","Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules",[86],"1996-05","1998-12","1992-09",99,[24],[7718,7753],{"nctId":7773,"briefTitle":7774,"status":155,"phases":7775,"primaryCompletion":7776,"completion":7776,"start":7777,"enrollment":1237,"conditions":7778,"interventions":7779},"NCT00697125","Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants",[86],"1994-07","1993-06",[24],[7718,7753,7780],"Hepatitis B vaccine, experimental formulation",{"nctId":7782,"briefTitle":7783,"status":155,"phases":7784,"primaryCompletion":2835,"completion":2835,"start":7785,"enrollment":7786,"conditions":7787,"interventions":7788},"NCT00323622","Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine",[86],"2005-04",1737,[3287],[7789,7718,7790,7791,7792,7793],"GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049","Hiberix®","Prevnar™","sulfadoxine-pyrimethamine","amodiaquine",{"nctId":7795,"briefTitle":7796,"status":155,"phases":7797,"primaryCompletion":7798,"start":7799,"enrollment":781,"conditions":7800,"interventions":7801},"NCT00698555","Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y",[86],"1998-05","1997-03",[24],[7753,7718],{"trials":7803,"activeCount":97},[7804,7814,7820,7833,7843,7852,7861,7877,7885,7895,7905,7914,7923,7929],{"nctId":7805,"briefTitle":7806,"status":155,"phases":7807,"primaryCompletion":7808,"completion":7808,"start":7809,"enrollment":7810,"conditions":7811,"interventions":7812},"NCT00697242","Comparison of Immuno, Reacto and Safety of Recombinant Hepatitis B Vaccine With or Without MPL in Healthy Older Adults",[87],"1995-11","1994-01",362,[24],[7718,7813],"Recombinant HBsAg with different concentrations of Aluminium Salts and\u002For MPL",{"nctId":7815,"briefTitle":7816,"status":155,"phases":7817,"primaryCompletion":7739,"start":7750,"enrollment":6576,"conditions":7818,"interventions":7819},"NCT00696891","Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults",[87],[24],[7753,7718],{"nctId":7821,"briefTitle":7822,"status":155,"phases":7823,"primaryCompletion":2373,"completion":7824,"start":7825,"enrollment":7826,"conditions":7827,"interventions":7828},"NCT00158756","Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants",[87],"2006-11-23","2005-09-12",308,[24],[7829,7830,7831,7832,7718],"Tritanrix™-HepB","Rotarix™","Zilbrix™","Triple Antigen™",{"nctId":7834,"briefTitle":7835,"status":155,"phases":7836,"primaryCompletion":7837,"completion":7838,"start":7839,"enrollment":7840,"conditions":7841,"interventions":7842},"NCT00698061","Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y",[87],"2000-09","2001-05","1999-11",145,[24],[7732,7718],{"nctId":7844,"briefTitle":7845,"status":155,"phases":7846,"primaryCompletion":7847,"start":7848,"enrollment":7849,"conditions":7850,"interventions":7851},"NCT00697866","Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control",[87],"2001-02","2000-08",951,[24],[7732,7718],{"nctId":7853,"briefTitle":7854,"status":155,"phases":7855,"primaryCompletion":7856,"completion":7856,"start":7857,"enrollment":1237,"conditions":7858,"interventions":7859},"NCT00698087","Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B",[87],"1996-02","1995-01",[24],[7860,7718],"MPL-Adjuvanted recombinant hepatitis B vaccine",{"nctId":7862,"briefTitle":7863,"status":155,"phases":7864,"primaryCompletion":7865,"completion":7866,"start":7867,"enrollment":7868,"conditions":7869,"interventions":7870},"NCT01000974","Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants",[87],"2011-11-18","2013-07-17","2010-06-18",4003,[4704],[7871,7872,7873,7874,7875,7830,7718,7876],"GSK Biologicals' Haemophilus influenzae type b vaccine","ActHIB™","Pentacel™","Pediarix™","Prevnar 13™","Infanrix™",{"nctId":7878,"briefTitle":7879,"status":155,"phases":7880,"primaryCompletion":7881,"start":7799,"enrollment":7882,"conditions":7883,"interventions":7884},"NCT00697216","Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).",[87],"1999-03",340,[24],[7732,7718],{"nctId":7886,"briefTitle":7887,"status":155,"phases":7888,"primaryCompletion":7889,"completion":7889,"start":7890,"enrollment":7891,"conditions":7892,"interventions":7893},"NCT00697931","Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders",[87],"1998-06","1997-05",116,[24],[7894,7718],"Recombinant MPL- adjuvanted hepatitis B vaccine",{"nctId":7896,"briefTitle":7897,"status":155,"phases":7898,"primaryCompletion":7899,"completion":7899,"start":7900,"enrollment":1579,"conditions":7901,"interventions":7902},"NCT00697840","Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B",[87],"1996-01","1995-06",[24],[7718,7903,7904],"HBV-MPL 208129","Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation",{"nctId":7906,"briefTitle":7907,"status":155,"phases":7908,"primaryCompletion":7909,"start":7910,"enrollment":7911,"conditions":7912,"interventions":7913},"NCT00697554","Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age",[87],"2002-05","2000-01",93,[24],[7732,7718],{"nctId":7915,"briefTitle":7916,"status":155,"phases":7917,"primaryCompletion":7918,"start":7919,"enrollment":7920,"conditions":7921,"interventions":7922},"NCT00696917","Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y",[87],"2000-02","1999-04",1303,[24],[7732,7718],{"nctId":7924,"briefTitle":7925,"status":155,"phases":7926,"primaryCompletion":7910,"completion":7910,"start":7919,"enrollment":4771,"conditions":7927,"interventions":7928},"NCT00697749","Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype",[87],[24],[7732,7718],{"nctId":7930,"briefTitle":7931,"status":155,"phases":7932,"primaryCompletion":7933,"completion":7933,"start":7934,"enrollment":7935,"conditions":7936,"interventions":7937},"NCT00697970","Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine",[87],"1995-04","1993-11",321,[24],[7938,7718],"HBsAg formulated with different concentrations of MPL and Aluminium Salts",{"trials":7940,"activeCount":97},[7941,7950,7958,7972,7979,7985],{"nctId":7942,"briefTitle":7943,"status":155,"phases":7944,"primaryCompletion":7945,"completion":7945,"start":7946,"enrollment":7947,"conditions":7948,"interventions":7949},"NCT00524576","Challenge Dose of Hepatitis B Vaccine in Subjects Who Previously Received Engerix™-B Vaccine",[88],"2008-05-14","2007-11-28",144,[24],[7718],{"nctId":7951,"briefTitle":7952,"status":155,"phases":7953,"primaryCompletion":7954,"completion":7954,"start":4756,"enrollment":7955,"conditions":7956,"interventions":7957},"NCT00456625","Immune Response to Hepatitis B Vaccine Challenge Dose in Subjects Who Received a Primary Neonatal Hepatitis B Vaccine.",[88],"2008-01",76,[24],[7718],{"nctId":7959,"briefTitle":7960,"status":155,"phases":7961,"primaryCompletion":7962,"completion":7962,"start":7963,"enrollment":7964,"conditions":7965,"interventions":7967},"NCT00289731","Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc",[88],"2004-12-21","2003-11-24",596,[24,7966],"Hepatitis A",[7968,7718,7969,7970,7971],"TWINRIX™","HAVRIX™","HB VAX PRO™","Vaqta™",{"nctId":7973,"briefTitle":7974,"status":155,"phases":7975,"primaryCompletion":7976,"completion":7976,"start":2355,"enrollment":1079,"conditions":7977,"interventions":7978},"NCT00657657","Safety and Immunogenicity of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine",[88],"2008-08",[24],[7718],{"nctId":7980,"briefTitle":7981,"status":155,"phases":7982,"primaryCompletion":3079,"completion":3079,"start":7581,"enrollment":739,"conditions":7983,"interventions":7984},"NCT00240500","Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B of Newborns From HBeAg+ & HBsAg+ Mothers",[88],[24],[7718],{"nctId":7986,"briefTitle":7987,"status":155,"phases":7988,"primaryCompletion":7989,"completion":7989,"start":7990,"enrollment":7991,"conditions":7992,"interventions":7993},"NCT01138098","Evaluation of Antibody Persistence and Immune Memory Against the Hepatitis B Antigen in Previously Vaccinated Children",[88],"2010-11-26","2010-06-07",185,[24],[7718],{"trials":7995,"activeCount":97},[],{"intervention":7997,"totalTrials":421,"cells":7998},"albiglutide",{"EARLY_PHASE1":7999,"PHASE1":8001,"PHASE2":8031,"PHASE3":8053,"PHASE4":8155,"NA":8174},{"trials":8000,"activeCount":97},[],{"trials":8002,"activeCount":97},[8003,8012,8023],{"nctId":8004,"briefTitle":8005,"status":155,"phases":8006,"primaryCompletion":8007,"completion":8007,"start":8008,"enrollment":433,"conditions":8009,"interventions":8010},"NCT01077505","An Evaluation of the Pharmacokinetics of an Oral Contraceptive (Brevicon) When Co-administered With Albiglutide .",[85],"2010-11-24","2010-03-15",[27],[7997,8011],"Oral contraceptive",{"nctId":8013,"briefTitle":8014,"status":155,"phases":8015,"primaryCompletion":8016,"completion":8016,"start":8017,"enrollment":8018,"conditions":8019,"interventions":8020},"NCT01406262","Albiglutide Thorough ECG Study in Healthy Volunteers",[85],"2011-12-29","2011-07-06",94,[27],[8021,8022],"Albiglutide","Moxifloxacin",{"nctId":8024,"briefTitle":8025,"status":155,"phases":8026,"primaryCompletion":8027,"completion":8027,"start":8028,"enrollment":2825,"conditions":8029,"interventions":8030},"NCT00938158","A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.",[85],"2011-04-12","2009-08-05",[27],[7997],{"trials":8032,"activeCount":97},[8033,8041,8047],{"nctId":8034,"briefTitle":8035,"status":155,"phases":8036,"primaryCompletion":8037,"completion":8037,"start":7591,"enrollment":8038,"conditions":8039,"interventions":8040},"NCT01475734","Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes",[86],"2012-07",44,[27],[7997],{"nctId":8042,"briefTitle":8043,"status":155,"phases":8044,"primaryCompletion":828,"completion":828,"start":7545,"enrollment":4175,"conditions":8045,"interventions":8046},"NCT01357889","Pharmacokinetics\u002FPharmacodynamics of Albiglutide",[86],[27],[7997,7997],{"nctId":8048,"briefTitle":8049,"status":155,"phases":8050,"primaryCompletion":7590,"completion":7590,"start":6352,"enrollment":4921,"conditions":8051,"interventions":8052},"NCT01098461","Dose Ranging Study of Albiglutide in Japanese Subjects",[86],[27],[7997],{"trials":8054,"activeCount":97},[8055,8070,8077,8085,8094,8102,8112,8121,8131,8140,8147],{"nctId":8056,"briefTitle":8057,"status":155,"phases":8058,"primaryCompletion":8059,"completion":8059,"start":8060,"enrollment":8061,"conditions":8062,"interventions":8064},"NCT01777282","A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus",[87],"2015-01-27","2013-02-23",374,[8063],"Diabetes Mellitus",[8021,8065,8066,8067,8068,8069],"Sulfonylurea","Biguanide","Glinide","Thiazolidinedione","Alpha-glucosidase inhibitor",{"nctId":8071,"briefTitle":8072,"status":155,"phases":8073,"primaryCompletion":3111,"completion":3111,"start":7647,"enrollment":3230,"conditions":8074,"interventions":8075},"NCT01128894","A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.",[87],[27],[7997,8076],"liraglutide",{"nctId":8078,"briefTitle":8079,"status":500,"phases":8080,"primaryCompletion":8081,"completion":8081,"start":8082,"enrollment":97,"conditions":8083,"interventions":8084},"NCT03015519","A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus",[87],"2020-04-20","2017-08-14",[27],[8021],{"nctId":8086,"briefTitle":8087,"status":155,"phases":8088,"primaryCompletion":8089,"completion":8089,"start":7647,"enrollment":8090,"conditions":8091,"interventions":8092},"NCT01098539","A Study of the Efficacy and Safety of Albiglutide in Subjects With Type 2 Diabetes With Renal Impairment.",[87],"2012-11",507,[27],[7997,8093],"sitagliptin",{"nctId":8095,"briefTitle":8096,"status":500,"phases":8097,"primaryCompletion":8098,"completion":8098,"start":482,"enrollment":97,"conditions":8099,"interventions":8100},"NCT02229240","Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus",[87],"2015-12",[27],[8021,8101],"Matching albiglutide placebo",{"nctId":8103,"briefTitle":8104,"status":155,"phases":8105,"primaryCompletion":8106,"completion":8106,"start":8107,"enrollment":8108,"conditions":8109,"interventions":8110},"NCT02229227","Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus",[87],"2017-07-24","2014-11-21",814,[27],[8021,8111],"Insulin Glargine and Insulin Lispro",{"nctId":8113,"briefTitle":8114,"status":155,"phases":8115,"primaryCompletion":2427,"completion":5195,"start":8116,"enrollment":8117,"conditions":8118,"interventions":8119},"NCT00838916","A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes",[87],"2009-02",779,[27],[7997,8120],"insulin glargine",{"nctId":8122,"briefTitle":8123,"status":155,"phases":8124,"primaryCompletion":2427,"completion":484,"start":8116,"enrollment":8125,"conditions":8126,"interventions":8127},"NCT00839527","A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes",[87],685,[27],[7997,8128,8129,8130],"metformin","glimepiride","pioglitazone",{"nctId":8132,"briefTitle":8133,"status":155,"phases":8134,"primaryCompletion":8135,"completion":3390,"start":2813,"enrollment":8136,"conditions":8137,"interventions":8138},"NCT00849017","Safety and Efficacy Study of Albiglutide in Type 2 Diabetes",[87],"2011-11",309,[27],[7997,8139],"albiglutide uptitration",{"nctId":8141,"briefTitle":8142,"status":155,"phases":8143,"primaryCompletion":2427,"completion":484,"start":8116,"enrollment":8144,"conditions":8145,"interventions":8146},"NCT00838903","Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes",[87],1049,[27],[7997,8093,8129,8128],{"nctId":8148,"briefTitle":8149,"status":155,"phases":8150,"primaryCompletion":8135,"completion":8151,"start":2813,"enrollment":8152,"conditions":8153,"interventions":8154},"NCT00849056","Safety and Efficacy of Albiglutide in Type 2 Diabetes",[87],"2013-01",310,[27],[7997],{"trials":8156,"activeCount":97},[8157,8166],{"nctId":8158,"briefTitle":8159,"status":145,"phases":8160,"primaryCompletion":8161,"completion":8161,"start":8162,"enrollment":181,"conditions":8163,"interventions":8164},"NCT02793154","An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects",[88],"2017-03-16","2016-09-26",[27],[8165,8021],"Exenatide",{"nctId":8167,"briefTitle":8168,"status":145,"phases":8169,"primaryCompletion":8170,"completion":8170,"start":8171,"enrollment":1720,"conditions":8172,"interventions":8173},"NCT02750930","Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects",[88],"2017-03-21","2016-10-07",[27],[8021],{"trials":8175,"activeCount":97},[],{"intervention":8177,"totalTrials":7438,"cells":8178},"Fluarix™",{"EARLY_PHASE1":8179,"PHASE1":8181,"PHASE2":8183,"PHASE3":8279,"PHASE4":8321,"NA":8351},{"trials":8180,"activeCount":97},[],{"trials":8182,"activeCount":97},[],{"trials":8184,"activeCount":97},[8185,8194,8203,8213,8221,8231,8240,8249,8259,8269],{"nctId":8186,"briefTitle":8187,"status":155,"phases":8188,"primaryCompletion":8189,"completion":8189,"start":8190,"enrollment":7554,"conditions":8191,"interventions":8192},"NCT00502593","Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children",[86],"2009-12-04","2007-07-23",[21],[8193,8177],"Pandemic Influenza Vaccine",{"nctId":8195,"briefTitle":8196,"status":155,"phases":8197,"primaryCompletion":2373,"completion":8198,"start":8199,"enrollment":1579,"conditions":8200,"interventions":8201},"NCT00363077","Study to Evaluate the Immunogenicity and the Safety of an Adjuvanted Influenza Vaccine Candidate",[86],"2006-11-17","2006-10-02",[21],[8202,8177],"GSK1247446A Group",{"nctId":8204,"briefTitle":8205,"status":155,"phases":8206,"primaryCompletion":8207,"completion":8208,"start":8209,"enrollment":37,"conditions":8210,"interventions":8211},"NCT00538473","Evaluate Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults",[86],"2007-12-01","2007-12-12","2007-10-23",[21],[8212,8177],"GSK Biologicals' influenza vaccine GSK576389A",{"nctId":8214,"briefTitle":8215,"status":155,"phases":8216,"primaryCompletion":8208,"completion":8208,"start":8217,"enrollment":292,"conditions":8218,"interventions":8219},"NCT00545025","Revaccination With Influenza Vaccine GSK1247446A",[86],"2007-10-15",[21,5353],[8220,8177],"Influenza Vaccine GSK1247446A",{"nctId":8222,"briefTitle":8223,"status":155,"phases":8224,"primaryCompletion":8225,"completion":8225,"start":8226,"enrollment":8227,"conditions":8228,"interventions":8229},"NCT00985790","Immunogenicity and Safety Study of a GlaxoSmithKline Biologicals' Candidate Influenza Vaccine in Healthy Children",[86],"2010-05-21","2009-10-08",599,[21],[8230,8177],"Influenza vaccine GSK2321138A",{"nctId":8232,"briefTitle":8233,"status":155,"phases":8234,"primaryCompletion":8235,"completion":7946,"start":8217,"enrollment":8236,"conditions":8237,"interventions":8238},"NCT00538213","Evaluation of Safety and Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults",[86],"2007-11-01",133,[21],[8177,8239],"GSK Bio's Influenza Vaccine GSK576389A",{"nctId":8241,"briefTitle":8242,"status":155,"phases":8243,"primaryCompletion":2373,"completion":8244,"start":8245,"enrollment":536,"conditions":8246,"interventions":8247},"NCT00374842","Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate",[86],"2006-11-30","2006-10-03",[21],[8177,8248],"GSK1247446A",{"nctId":8250,"briefTitle":8251,"status":155,"phases":8252,"primaryCompletion":8253,"completion":8253,"start":8254,"enrollment":8255,"conditions":8256,"interventions":8257},"NCT00540228","Study to Evaluate an Influenza Vaccine Candidate",[86],"2008-05-08","2007-10-05",1006,[21],[8258,8177],"Influenza Vaccine GSK1247446A - 4 different formulations",{"nctId":8260,"briefTitle":8261,"status":145,"phases":8262,"primaryCompletion":7514,"completion":7514,"start":8263,"enrollment":181,"conditions":8264,"interventions":8266},"NCT01195779","Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children",[86],"2010-09-30",[21,8265],"Influenza Vaccines",[8267,8268,8177],"GSK Bio's influenza vaccine GSK2584786A, different formulations","GSK Bio's influenza vaccine GSK2321138A",{"nctId":8270,"briefTitle":8271,"status":155,"phases":8272,"primaryCompletion":8273,"completion":8273,"start":8274,"enrollment":8275,"conditions":8276,"interventions":8277},"NCT00968890","Immunogenicity and Safety of Vaccine GSK2340272A (H1N1) and GSK Biologicals Fluarix™ Vaccine When Co-administered in Elderly",[86],"2010-09-23","2009-09-12",168,[21],[8278,8177],"Pandemrix",{"trials":8280,"activeCount":97},[8281,8293,8301,8312],{"nctId":8282,"briefTitle":8283,"status":155,"phases":8284,"primaryCompletion":8285,"completion":8286,"start":8287,"enrollment":8288,"conditions":8289,"interventions":8290},"NCT00453986","Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults",[87],"2007-11-30","2008-05-21","2007-04-09",1352,[992],[8291,8292,8177],"Meningococcal vaccine GSK134612","Mencevax™ACWY",{"nctId":8294,"briefTitle":8295,"status":155,"phases":8296,"primaryCompletion":8297,"completion":8297,"start":8298,"enrollment":201,"conditions":8299,"interventions":8300},"NCT00706563","A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix™ \u002F Influsplit SSW® 2008\u002F2009 in Adults",[87],"2008-07-30","2008-07-07",[21],[8177],{"nctId":8302,"briefTitle":8303,"status":155,"phases":8304,"primaryCompletion":8305,"completion":8306,"start":8307,"enrollment":8308,"conditions":8309,"interventions":8310},"NCT00383123","Study Comparing the Immune Response and Safety of Fluarix and Fluzone Influenza Vaccines in Children",[87],"2007-10-01","2007-10-19","2006-11-02",3327,[21],[8177,8311],"Fluzone",{"nctId":8313,"briefTitle":8314,"status":155,"phases":8315,"primaryCompletion":8316,"completion":8317,"start":8318,"enrollment":7840,"conditions":8319,"interventions":8320},"NCT00971425","Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)",[87],"2009-11-16","2010-10-08","2009-09-08",[21],[8278,8177],{"trials":8322,"activeCount":97},[8323,8331,8341],{"nctId":8324,"briefTitle":8325,"status":155,"phases":8326,"primaryCompletion":2758,"completion":2758,"start":8327,"enrollment":8328,"conditions":8329,"interventions":8330},"NCT00377611","Study on the Incidence of Influenza and Its Complications, in Subjects Aged 50 Years and Over Vaccinated With Fluarix™",[88],"2006-10-05",3054,[21],[8177],{"nctId":8332,"briefTitle":8333,"status":155,"phases":8334,"primaryCompletion":8335,"completion":8335,"start":8336,"enrollment":8337,"conditions":8338,"interventions":8339},"NCT01730378","Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old",[88],"2013-12-17","2012-12-05",131,[21],[8340,8177],"Prepandrix™",{"nctId":8342,"briefTitle":8343,"status":155,"phases":8344,"primaryCompletion":8345,"completion":8345,"start":8346,"enrollment":8347,"conditions":8348,"interventions":8349},"NCT01196026","Immunogenicity and Safety Study of Fluarix™ Vaccine in Children Who Have Previously Been Vaccinated With Pandemrix™",[88],"2011-05-26","2010-09-15",162,[21],[8177,8350],"Havrix™ Junior",{"trials":8352,"activeCount":97},[],{"intervention":8354,"totalTrials":1117,"cells":8355},"fluticasone propionate\u002Fsalmeterol",{"EARLY_PHASE1":8356,"PHASE1":8358,"PHASE2":8368,"PHASE3":8389,"PHASE4":8420,"NA":8502},{"trials":8357,"activeCount":97},[],{"trials":8359,"activeCount":97},[8360],{"nctId":8361,"briefTitle":8362,"status":155,"phases":8363,"primaryCompletion":8364,"completion":8364,"start":8365,"enrollment":1459,"conditions":8366,"interventions":8367},"NCT00364442","Repeat Dose Study of Fluticasone Propionate\u002FSalmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics",[85],"2005-04-13","2005-01-28",[18],[8354],{"trials":8369,"activeCount":97},[8370,8382],{"nctId":8371,"briefTitle":8372,"status":155,"phases":8373,"primaryCompletion":8374,"completion":8375,"start":4996,"enrollment":8376,"conditions":8377,"interventions":8378},"NCT03207243","Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma",[86],"2019-02-15","2019-05-15",165,[18],[8379,8380,8381],"GSK3772847","Fluticasone propionate\u002Fsalmeterol","Fluticasone propionate",{"nctId":8383,"briefTitle":8384,"status":155,"phases":8385,"primaryCompletion":8386,"completion":8386,"start":2814,"enrollment":454,"conditions":8387,"interventions":8388},"NCT00369993","Spacer Comparison In Adult Asthmatics",[86],"2005-05",[18],[8354],{"trials":8390,"activeCount":97},[8391,8402,8410],{"nctId":8392,"briefTitle":8393,"status":155,"phases":8394,"primaryCompletion":8395,"completion":8396,"start":8397,"enrollment":8398,"conditions":8399,"interventions":8400},"NCT01817764","A Study to Compare the Efficacy and Safety of Umeclidinium\u002FVilanterol and Fluticasone Propionate\u002FSalmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2013-10-01","2013-10-25","2013-03-01",707,[15],[8401,8380],"Umeclidinium\u002Fvilanterol",{"nctId":8403,"briefTitle":8404,"status":155,"phases":8405,"primaryCompletion":7954,"completion":7954,"start":8406,"enrollment":265,"conditions":8407,"interventions":8408},"NCT00441441","A 12-Week Study To Assess The Safety Of Fluticasone Propionate\u002FSalmeterol 100\u002F50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma",[87],"2007-02",[18],[8409,8354],"fluticasone propionate",{"nctId":8411,"briefTitle":8412,"status":155,"phases":8413,"primaryCompletion":8395,"completion":3058,"start":8414,"enrollment":8415,"conditions":8416,"interventions":8417},"NCT01822899","A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide\u002FVilanterol Compared With Fluticasone Propionate\u002FSalmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2013-04-04",717,[15],[8418,8419],"Umeclidinium bromide\u002FVilanterol","Fluticasone propionate\u002FSalmeterol",{"trials":8421,"activeCount":97},[8422,8433,8442,8455,8464,8474,8483,8489,8496],{"nctId":8423,"briefTitle":8424,"status":155,"phases":8425,"primaryCompletion":8426,"completion":8426,"start":8427,"enrollment":8428,"conditions":8429,"interventions":8430},"NCT00296491","Study Of Allergic Rhinitis In Patients Who Also Have Asthma",[88],"2007-10","2005-09",725,[18],[8354,8431,8409,8432],"montelukast","ADVAIR DISKUS",{"nctId":8434,"briefTitle":8435,"status":155,"phases":8436,"primaryCompletion":7701,"completion":7701,"start":3390,"enrollment":8437,"conditions":8438,"interventions":8439},"NCT01751113","A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects",[88],53,[15],[8354,8440,8441],"tiotropium bromide","fluticasone propionate\u002Fsalmeterol plus tiotropium bromide",{"nctId":8443,"briefTitle":8444,"status":155,"phases":8445,"primaryCompletion":8446,"completion":8447,"start":8448,"enrollment":8449,"conditions":8450,"interventions":8453},"NCT00118716","A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise",[88],"2006-04-01","2006-04-23","2003-12-23",248,[8451,8452],"Bronchospasm","Activity\u002FExercise Induced Bronchospasm",[8380,8454],"Fluticasone Propionate",{"nctId":8456,"briefTitle":8457,"status":155,"phases":8458,"primaryCompletion":8459,"completion":8459,"start":8460,"enrollment":8461,"conditions":8462,"interventions":8463},"NCT00353873","Seretide Versus Flixotide In Asthmatic Children Not Controlled By Inhaled Corticosteroids",[88],"2006-10-26","2005-11-18",506,[18],[8381,8380],{"nctId":8465,"briefTitle":8466,"status":155,"phases":8467,"primaryCompletion":7658,"completion":7658,"start":8468,"enrollment":8469,"conditions":8470,"interventions":8471},"NCT00784550","A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250\u002F50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).",[88],"2008-12",342,[15],[8472,8473],"Tiotropium Bromide","Fluticasone Propionate\u002FSalmeterol",{"nctId":8475,"briefTitle":8476,"status":155,"phases":8477,"primaryCompletion":5196,"completion":5196,"start":8478,"enrollment":8479,"conditions":8480,"interventions":8481},"NCT00102882","Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate\u002FSalmeterol Or Salmeterol Xinafoate",[88],"2004-10",547,[18],[8354,8482],"salmeterol xinafoate",{"nctId":8484,"briefTitle":8485,"status":155,"phases":8486,"primaryCompletion":2428,"completion":2428,"start":8427,"enrollment":1944,"conditions":8487,"interventions":8488},"NCT00296530","Study Of Patients With Allergic Rhinitis And Asthma",[88],[18],[8354,8409,8431],{"nctId":8490,"briefTitle":8444,"status":155,"phases":8491,"primaryCompletion":749,"completion":749,"start":8492,"enrollment":8493,"conditions":8494,"interventions":8495},"NCT00118690",[88],"2003-12",227,[8451,8452],[8380],{"nctId":8497,"briefTitle":8498,"status":145,"phases":8499,"primaryCompletion":5018,"completion":5018,"start":8426,"enrollment":433,"conditions":8500,"interventions":8501},"NCT00503009","Study Of RV-39 In Patients Who Also Have Asthma",[88],[18],[8354,8409],{"trials":8503,"activeCount":97},[],{"intervention":2916,"totalTrials":473,"cells":8505},{"EARLY_PHASE1":8506,"PHASE1":8508,"PHASE2":8510,"PHASE3":8533,"PHASE4":8599,"NA":8633},{"trials":8507,"activeCount":97},[],{"trials":8509,"activeCount":97},[],{"trials":8511,"activeCount":97},[8512,8523],{"nctId":8513,"briefTitle":8514,"status":500,"phases":8515,"primaryCompletion":8516,"completion":8516,"start":8517,"enrollment":97,"conditions":8518,"interventions":8519},"NCT03707678","A Safety and Efficacy Study of Intranasal GSK2245035 in Adults With Allergic Asthma",[86],"2019-12-23","2019-01-21",[18],[8520,8521,8522],"GSK2245035","FP-DPI","Albuterol\u002FSalbutamol",{"nctId":8524,"briefTitle":8525,"status":155,"phases":8526,"primaryCompletion":8527,"completion":8527,"start":8528,"enrollment":8529,"conditions":8530,"interventions":8531},"NCT03012061","Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma",[86],"2018-05-30","2017-01-25",425,[18],[2915,8532,2916],"Fluticasone Furoate",{"trials":8534,"activeCount":97},[8535,8546,8550,8557,8569,8579,8595],{"nctId":8536,"briefTitle":8537,"status":500,"phases":8538,"primaryCompletion":8539,"completion":8539,"start":8540,"enrollment":97,"conditions":8541,"interventions":8542},"NCT02731846","A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2016-11","2016-06",[15],[8543,8544,8545,8522],"Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg","Fluticasone furoate 100 mcg + Vilanterol 25 mcg","Umeclidinium 62.5 mcg",{"nctId":2906,"briefTitle":2907,"status":155,"phases":8547,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":8548,"interventions":8549},[87],[15],[2895,2914,2915,2916],{"nctId":8551,"briefTitle":8552,"status":155,"phases":8553,"primaryCompletion":828,"completion":828,"start":3111,"enrollment":4086,"conditions":8554,"interventions":8555},"NCT01431950","Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents",[87],[18],[8556,2979],"fluticasone furoate",{"nctId":8558,"briefTitle":8559,"status":155,"phases":8560,"primaryCompletion":8561,"completion":8562,"start":8563,"enrollment":8564,"conditions":8565,"interventions":8566},"NCT02345161","A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate\u002F Umeclidinium\u002F Vilanterol Trifenatate (FF\u002FUMEC\u002FVI) With Budesonide\u002FFormoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2016-04-01","2016-04-07","2015-01-23",1811,[15],[8567,8568,2916],"Triple FF\u002FUMEC\u002FVI","Budesonide\u002FFormoterol",{"nctId":8570,"briefTitle":8571,"status":155,"phases":8572,"primaryCompletion":8573,"completion":8574,"start":8575,"enrollment":3537,"conditions":8576,"interventions":8577},"NCT02483975","Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma",[87],"2016-06-20","2016-06-21","2015-10-09",[18],[3467,8578,8522],"Montelukast",{"nctId":8580,"briefTitle":8581,"status":155,"phases":8582,"primaryCompletion":8583,"completion":8583,"start":8584,"enrollment":8585,"conditions":8586,"interventions":8587},"NCT02924688","A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF\u002FUMEC\u002FVI) With the FDC of FF\u002FVI in Subjects With Inadequately Controlled Asthma",[87],"2019-02-22","2016-10-13",2436,[18],[8588,8589,8590,8591,8592,8593,8594,2916],"FF\u002FUMEC\u002FVI (100\u002F31.25\u002F25) mcg","FF\u002FUMEC\u002FVI (100\u002F62.5\u002F25) mcg","FF\u002FUMEC\u002FVI (200\u002F31.25\u002F25) mcg","FF\u002FUMEC\u002FVI (200\u002F62.5\u002F25) mcg","FF\u002FVI (100\u002F25) mcg","FF\u002FVI (200\u002F25) mcg","Fluticasone\u002Fsalmeterol",{"nctId":2926,"briefTitle":2927,"status":500,"phases":8596,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":97,"conditions":8597,"interventions":8598},[87],[18],[2895,2933,2934,2916],{"trials":8600,"activeCount":97},[8601,8605,8609,8613,8624],{"nctId":2963,"briefTitle":2964,"status":155,"phases":8602,"primaryCompletion":2966,"completion":2966,"start":2967,"enrollment":1924,"conditions":8603,"interventions":8604},[88],[15],[2895,2934,2916],{"nctId":2971,"briefTitle":2972,"status":155,"phases":8606,"primaryCompletion":1116,"completion":1116,"start":2974,"enrollment":2975,"conditions":8607,"interventions":8608},[88],[15],[2978,2979,2895,2980],{"nctId":2982,"briefTitle":2983,"status":155,"phases":8610,"primaryCompletion":2985,"completion":2985,"start":2974,"enrollment":2986,"conditions":8611,"interventions":8612},[88],[15],[2978,2979,2895,2980],{"nctId":8614,"briefTitle":8615,"status":155,"phases":8616,"primaryCompletion":8617,"completion":8617,"start":8618,"enrollment":8619,"conditions":8620,"interventions":8621},"NCT02799784","An Efficacy Study of Umeclidinium\u002FVilanterol With Tiotropium\u002FOlodaterol in COPD Patients",[88],"2017-04-27","2016-07-14",236,[15],[8622,8623,2916],"UMEC\u002FVI","TIO\u002FOLO",{"nctId":8625,"briefTitle":8626,"status":155,"phases":8627,"primaryCompletion":4677,"completion":8628,"start":8629,"enrollment":904,"conditions":8630,"interventions":8631},"NCT01691482","A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol\u002FSalbutamol and Ipratropium",[88],"2012-10-22","2012-07-23",[15],[2916,8632],"Ipratropium",{"trials":8634,"activeCount":97},[],{"intervention":4694,"totalTrials":473,"cells":8636},{"EARLY_PHASE1":8637,"PHASE1":8639,"PHASE2":8641,"PHASE3":8659,"PHASE4":8726,"NA":8771},{"trials":8638,"activeCount":97},[],{"trials":8640,"activeCount":97},[],{"trials":8642,"activeCount":97},[8643,8655],{"nctId":8644,"briefTitle":8645,"status":155,"phases":8646,"primaryCompletion":8647,"completion":8648,"start":8649,"enrollment":8650,"conditions":8651,"interventions":8652},"NCT02212457","Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents",[86],"2015-05-22","2016-03-03","2014-08-21",1063,[992],[8653,4694,8654],"Bexsero","MenABCWY",{"nctId":4686,"briefTitle":4687,"status":155,"phases":8656,"primaryCompletion":4689,"completion":4690,"start":4691,"enrollment":781,"conditions":8657,"interventions":8658},[86],[3637],[4683,4684,4694],{"trials":8660,"activeCount":97},[8661,8677,8687,8691,8701,8712,8716],{"nctId":8662,"briefTitle":8663,"status":155,"phases":8664,"primaryCompletion":8665,"completion":8666,"start":8667,"enrollment":8668,"conditions":8669,"interventions":8672},"NCT02184572","Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",[87],"2015-08-14","2015-12-22","2014-08-25",1742,[8670,8671],"Measles; Mumps; Rubella","Measles-Mumps-Rubella Vaccine",[8673,8674,8675,4694,8676],"Priorix","M-M-R II","Varivax","Prevnar 13",{"nctId":8678,"briefTitle":8679,"status":155,"phases":8680,"primaryCompletion":8681,"completion":8682,"start":8683,"enrollment":8684,"conditions":8685,"interventions":8686},"NCT01702428","Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age",[87],"2014-11-25","2015-04-16","2012-11-09",5016,[2484,2486,2485],[8673,8674,8675,4694,8676],{"nctId":4775,"briefTitle":4776,"status":155,"phases":8688,"primaryCompletion":4778,"completion":4778,"start":4779,"enrollment":4780,"conditions":8689,"interventions":8690},[87],[3637,4742],[4783,4745,4472,4694,4784],{"nctId":8692,"briefTitle":8693,"status":155,"phases":8694,"primaryCompletion":8695,"completion":8696,"start":8697,"enrollment":8698,"conditions":8699,"interventions":8700},"NCT01681992","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life",[87],"2015-02-03","2015-08-18","2012-10-10",4538,[2486,2485,2484,8671],[8673,8674,8675,4694,8676],{"nctId":8702,"briefTitle":8703,"status":155,"phases":8704,"primaryCompletion":8705,"completion":8705,"start":8706,"enrollment":8707,"conditions":8708,"interventions":8710},"NCT00224484","Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old",[87],"2007-07-24","2004-04-07",5960,[8709],"Herpes Simplex",[8711,4694],"GSK208141",{"nctId":4851,"briefTitle":4852,"status":155,"phases":8713,"primaryCompletion":4854,"completion":4855,"start":4856,"enrollment":4857,"conditions":8714,"interventions":8715},[87],[3637],[4744,4694,4808,4472,4860],{"nctId":8717,"briefTitle":8718,"status":500,"phases":8719,"primaryCompletion":482,"completion":8720,"start":8721,"enrollment":97,"conditions":8722,"interventions":8724},"NCT02082639","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years",[87],"2015-11","2015-02",[8723],"Infections, Papillomavirus",[8725,4694],"Cervarix™",{"trials":8727,"activeCount":97},[8728,8736,8746,8757,8763],{"nctId":8729,"briefTitle":8730,"status":155,"phases":8731,"primaryCompletion":8732,"completion":8732,"start":8733,"enrollment":8038,"conditions":8734,"interventions":8735},"NCT01000324","Antibody Persistence & Immune Memory in Healthy Adults Previously Vaccinated With Twinrix Adult",[88],"2014-07-25","2009-11-06",[7966,24],[4808,4694],{"nctId":8737,"briefTitle":8738,"status":155,"phases":8739,"primaryCompletion":8740,"completion":8740,"start":8741,"enrollment":8461,"conditions":8742,"interventions":8743},"NCT00684671","Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination",[88],"2008-11-03","2008-05-26",[7966,24],[5037,4808,4694,8744,8745],"HBVAXPRO","Vaqta",{"nctId":8747,"briefTitle":8748,"status":145,"phases":8749,"completion":2405,"start":8750,"enrollment":8751,"conditions":8752,"interventions":8753},"NCT00544271","Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.",[88],"2003-05",720,[3624,33,30],[8754,8755,8756],"INFANRIX","BOOSTRIX","HAVRIX",{"nctId":8758,"briefTitle":8759,"status":155,"phases":8760,"primaryCompletion":7546,"completion":7546,"start":7954,"enrollment":7131,"conditions":8761,"interventions":8762},"NCT00603252","Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults",[88],[24,7966],[5037,4808,4694,8744,8745],{"nctId":8764,"briefTitle":8765,"status":155,"phases":8766,"primaryCompletion":8767,"completion":8767,"start":8768,"enrollment":1003,"conditions":8769,"interventions":8770},"NCT01037114","Long-term Persistence Study in Healthy Adults Previously Vaccinated With Twinrix Adult",[88],"2014-02-28","2010-01-27",[7966,24],[4808,4694],{"trials":8772,"activeCount":97},[],{"intervention":3556,"totalTrials":473,"cells":8774},{"EARLY_PHASE1":8775,"PHASE1":8777,"PHASE2":8808,"PHASE3":8865,"PHASE4":8894,"NA":8902},{"trials":8776,"activeCount":97},[],{"trials":8778,"activeCount":97},[8779,8791,8799],{"nctId":8780,"briefTitle":8781,"status":155,"phases":8782,"primaryCompletion":8783,"completion":8784,"start":8785,"enrollment":8786,"conditions":8787,"interventions":8789},"NCT00686868","Study to Evaluate SC Route of Administration of Ofatumumab in RA Patients",[85],"2011-03-11","2011-05-02","2008-06-13",35,[8788],"Arthritis, Rheumatoid",[8790],"ofatumumab",{"nctId":8792,"briefTitle":8793,"status":155,"phases":8794,"primaryCompletion":1875,"completion":1875,"start":8795,"enrollment":628,"conditions":8796,"interventions":8798},"NCT00742144","Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia",[85],"2008-09-19",[8797],"Leukaemia, Lymphocytic, Chronic and Lymphoma, Follicular",[8790],{"nctId":8800,"briefTitle":8801,"status":155,"phases":8802,"primaryCompletion":8803,"completion":8804,"start":8805,"enrollment":1459,"conditions":8806,"interventions":8807},"NCT01110031","Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects",[85],"2012-04-12","2012-06-26","2010-05-13",[5198],[3556],{"trials":8809,"activeCount":97},[8810,8820,8830,8834,8840,8848,8856],{"nctId":8811,"briefTitle":8812,"status":145,"phases":8813,"primaryCompletion":8814,"completion":8815,"start":8816,"enrollment":8817,"conditions":8818,"interventions":8819},"NCT00655824","Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403",[86],"2011-05-25","2013-03-19","2008-01-01",124,[8788],[8790],{"nctId":8821,"briefTitle":8822,"status":155,"phases":8823,"primaryCompletion":8824,"completion":8825,"start":8826,"enrollment":1335,"conditions":8827,"interventions":8829},"NCT00811733","A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia",[86],"2011-06-01","2014-02-01","2009-03-01",[8828],"Waldenstrom Macroglobulinaemia",[3556],{"nctId":3547,"briefTitle":3548,"status":155,"phases":8831,"primaryCompletion":3550,"completion":3551,"start":3552,"enrollment":2759,"conditions":8832,"interventions":8833},[86],[3554],[3556,1241,2328,3557,3558],{"nctId":8835,"briefTitle":8836,"status":155,"phases":8837,"primaryCompletion":3550,"completion":493,"start":2835,"enrollment":7891,"conditions":8838,"interventions":8839},"NCT00394836","HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab",[86],[3554],[3556,3556],{"nctId":8841,"briefTitle":8842,"status":155,"phases":8843,"primaryCompletion":2882,"completion":2882,"start":3389,"enrollment":750,"conditions":8844,"interventions":8845},"NCT01563055","A Phase I\u002FII, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia",[86],[5198],[8846,8847],"chlorambucil,","ofatumumab (GSK1841157)",{"nctId":8849,"briefTitle":8850,"status":155,"phases":8851,"primaryCompletion":7522,"completion":2295,"start":8852,"enrollment":8853,"conditions":8854,"interventions":8855},"NCT00349349","HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab",[86],"2006-06",223,[5198],[8790],{"nctId":8857,"briefTitle":8858,"status":155,"phases":8859,"primaryCompletion":7647,"completion":8860,"start":2804,"enrollment":8861,"conditions":8862,"interventions":8864},"NCT00622388","Ofatumumab in Patients With Relapsed\u002FProgressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse\u002FProgression After Transplant",[86],"2014-08",81,[8863],"Lymphoma, Large-Cell, Diffuse",[3556],{"trials":8866,"activeCount":97},[8867,8879,8886],{"nctId":8868,"briefTitle":8869,"status":145,"phases":8870,"primaryCompletion":8871,"completion":8871,"start":8872,"enrollment":417,"conditions":8873,"interventions":8875},"NCT02613910","Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris",[87],"2016-03-23","2015-12-23",[8874],"Pemphigus",[3556,8876,8877,8878],"Acetaminophen\u002Fparacetamol","Antihistamine","Prednisone\u002FPrednisolone",{"nctId":8880,"briefTitle":8881,"status":145,"phases":8882,"primaryCompletion":8883,"completion":7682,"start":7954,"enrollment":803,"conditions":8884,"interventions":8885},"NCT00603525","Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist Therapy",[87],"2011-03",[8788],[3556],{"nctId":8887,"briefTitle":8888,"status":145,"phases":8889,"primaryCompletion":8890,"completion":4984,"start":8816,"enrollment":8891,"conditions":8892,"interventions":8893},"NCT00611455","Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX Therapy",[87],"2009-06-08",265,[8788],[8790],{"trials":8895,"activeCount":97},[8896],{"nctId":8897,"briefTitle":8898,"status":155,"phases":8899,"primaryCompletion":3111,"completion":5195,"start":2813,"enrollment":1079,"conditions":8900,"interventions":8901},"NCT00802737","Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)",[88],[5198],[3556],{"trials":8903,"activeCount":97},[],{"intervention":4808,"totalTrials":3131,"cells":8905},{"EARLY_PHASE1":8906,"PHASE1":8908,"PHASE2":8922,"PHASE3":8939,"PHASE4":8976,"NA":9013},{"trials":8907,"activeCount":97},[],{"trials":8909,"activeCount":97},[8910],{"nctId":8911,"briefTitle":8912,"status":155,"phases":8913,"primaryCompletion":8914,"completion":8915,"start":8916,"enrollment":345,"conditions":8917,"interventions":8920},"NCT00814489","Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults",[85],"2009-05-04","2010-06-10","2009-01-08",[8918,8919],"Streptococcus Pneumoniae","Haemophilus Influenzae",[8921,4808],"GSK2231395A",{"trials":8923,"activeCount":97},[8924],{"nctId":8925,"briefTitle":8926,"status":155,"phases":8927,"primaryCompletion":8928,"completion":8929,"start":8930,"enrollment":8931,"conditions":8932,"interventions":8933},"NCT01231503","Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants",[86],"2014-04-30","2014-12-23","2011-01-13",480,[3287],[8934,4808,8935,8936,8937,8938],"GSK Biological's Investigational Malaria Vaccine 257049","Tritanrix HepB Hib","BCG","OPV","Rouvax",{"trials":8940,"activeCount":97},[8941,8949,8953,8959,8972],{"nctId":8942,"briefTitle":8943,"status":155,"phases":8944,"completion":2405,"start":8945,"enrollment":201,"conditions":8946,"interventions":8947},"NCT00383591","Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- \u002FHaemodialysis Patients Aged ≥15 Years",[87],"2002-03",[24],[8948,4808],"Hepatitis B adjuvanted vaccine",{"nctId":4796,"briefTitle":4797,"status":155,"phases":8950,"primaryCompletion":4799,"completion":4800,"start":4801,"enrollment":4802,"conditions":8951,"interventions":8952},[87],[4702,30,4704,33,3624,24],[4472,4805,4806,4807,4808,4809,4810,4811,4762],{"nctId":8954,"briefTitle":8943,"status":155,"phases":8955,"start":8956,"enrollment":1672,"conditions":8957,"interventions":8958},"NCT00383383",[87],"1999-12",[24],[8948,4808],{"nctId":8960,"briefTitle":8961,"status":155,"phases":8962,"primaryCompletion":8963,"completion":3551,"start":2383,"enrollment":4771,"conditions":8964,"interventions":8965},"NCT00322335","Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC",[87],"2006-07",[4704,4703],[8966,8967,8968,4808,8969,8970,8971],"Haemophilus influenzae type b- and meningococcal","Infanrix™ penta","Infanrix™ hexa","NeisVac-C™","Infanrix™ IPV\u002FHIB","Meningitec™",{"nctId":4851,"briefTitle":4852,"status":155,"phases":8973,"primaryCompletion":4854,"completion":4855,"start":4856,"enrollment":4857,"conditions":8974,"interventions":8975},[87],[3637],[4744,4694,4808,4472,4860],{"trials":8977,"activeCount":97},[8978,8987,8991,9001,9005,9009],{"nctId":8979,"briefTitle":8980,"status":155,"phases":8981,"primaryCompletion":8982,"completion":8982,"start":8983,"enrollment":1229,"conditions":8984,"interventions":8986},"NCT02901951","Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B",[88],"2017-05-01","2016-10-11",[8985],"Hepatitis B Vaccine",[4808],{"nctId":8729,"briefTitle":8730,"status":155,"phases":8988,"primaryCompletion":8732,"completion":8732,"start":8733,"enrollment":8038,"conditions":8989,"interventions":8990},[88],[7966,24],[4808,4694],{"nctId":8992,"briefTitle":8993,"status":155,"phases":8994,"primaryCompletion":8995,"completion":8995,"start":8996,"enrollment":8997,"conditions":8998,"interventions":8999},"NCT00534638","Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents",[88],"2014-12-17","2007-10-04",34412,[8723],[9000,4808],"Cervarix",{"nctId":8737,"briefTitle":8738,"status":155,"phases":9002,"primaryCompletion":8740,"completion":8740,"start":8741,"enrollment":8461,"conditions":9003,"interventions":9004},[88],[7966,24],[5037,4808,4694,8744,8745],{"nctId":8758,"briefTitle":8759,"status":155,"phases":9006,"primaryCompletion":7546,"completion":7546,"start":7954,"enrollment":7131,"conditions":9007,"interventions":9008},[88],[24,7966],[5037,4808,4694,8744,8745],{"nctId":8764,"briefTitle":8765,"status":155,"phases":9010,"primaryCompletion":8767,"completion":8767,"start":8768,"enrollment":1003,"conditions":9011,"interventions":9012},[88],[7966,24],[4808,4694],{"trials":9014,"activeCount":97},[],{"intervention":9016,"totalTrials":3131,"cells":9017},"Metformin",{"EARLY_PHASE1":9018,"PHASE1":9020,"PHASE2":9039,"PHASE3":9070,"PHASE4":9110,"NA":9138},{"trials":9019,"activeCount":97},[],{"trials":9021,"activeCount":97},[9022,9031],{"nctId":9023,"briefTitle":9024,"status":155,"phases":9025,"primaryCompletion":9026,"completion":9026,"start":9027,"enrollment":1003,"conditions":9028,"interventions":9029},"NCT00519480","A Study To Assess The Safety And Tolerability Of GSK189075 When Given With A Total Daily Dose Of >\u002F 2000mg of Metformin",[85],"2008-04-01","2007-09-11",[27],[9030,9016],"GSK189075",{"nctId":9032,"briefTitle":9033,"status":155,"phases":9034,"primaryCompletion":2404,"completion":2404,"start":2296,"enrollment":3131,"conditions":9035,"interventions":9037},"NCT00376038","Drug Interactions From Simultaneous Administration Of Metformin And GSK189075 To Subjects With Type 2 Diabetes",[85],[9036,27],"Type 2 Diabetes Mellitus",[9038,8128],"GSK189075 oral",{"trials":9040,"activeCount":97},[9041,9052,9062],{"nctId":9042,"briefTitle":9043,"status":155,"phases":9044,"primaryCompletion":9045,"completion":9045,"start":9046,"enrollment":8437,"conditions":9047,"interventions":9049},"NCT01725126","To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes",[86],"2013-09-12","2013-02-10",[9048],"Obesity",[9050,9016,9051],"GSK2890457","Liraglutide",{"nctId":9053,"briefTitle":9054,"status":155,"phases":9055,"primaryCompletion":9056,"completion":9056,"start":9057,"enrollment":730,"conditions":9058,"interventions":9059},"NCT02202161","A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients",[86],"2015-01-30","2014-08-27",[27],[9060,9061,9016],"GSK2330672","Sitagliptin",{"nctId":9063,"briefTitle":9064,"status":155,"phases":9065,"primaryCompletion":1874,"completion":9066,"start":9067,"enrollment":433,"conditions":9068,"interventions":9069},"NCT01929863","Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin",[86],"2013-11-21","2013-08-01",[27],[9060,9016],{"trials":9071,"activeCount":97},[9072,9083,9095,9102,9106],{"nctId":9073,"briefTitle":9074,"status":155,"phases":9075,"start":9076,"enrollment":9077,"conditions":9078,"interventions":9080},"NCT00359112","AVANDAMET Versus Metformin And Sulphonylurea In People With Poorly Controlled Type 2 Diabetes",[87],"2004-02",544,[9079],"Non-Insulin-Dependent Diabetes Mellitus",[8128,9081,9082],"sulphonylurea","Avandamet",{"nctId":9084,"briefTitle":9085,"status":155,"phases":9086,"primaryCompletion":9087,"completion":9088,"start":9089,"enrollment":9090,"conditions":9091,"interventions":9092},"NCT00279045","Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide\u002FGlibenclamide",[87],"2006-06-01","2006-06-19","2000-01-03",4426,[27],[9093,9094,8128],"Rosiglitazone","glyburide",{"nctId":9096,"briefTitle":9097,"status":155,"phases":9098,"primaryCompletion":8468,"completion":8468,"start":2481,"enrollment":9099,"conditions":9100,"interventions":9101},"NCT00379769","RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes",[87],4447,[27],[9093,8065,9016],{"nctId":8122,"briefTitle":8123,"status":155,"phases":9103,"primaryCompletion":2427,"completion":484,"start":8116,"enrollment":8125,"conditions":9104,"interventions":9105},[87],[27],[7997,8128,8129,8130],{"nctId":8141,"briefTitle":8142,"status":155,"phases":9107,"primaryCompletion":2427,"completion":484,"start":8116,"enrollment":8144,"conditions":9108,"interventions":9109},[87],[27],[7997,8093,8129,8128],{"trials":9111,"activeCount":97},[9112,9121,9129],{"nctId":9113,"briefTitle":9114,"status":155,"phases":9115,"primaryCompletion":9116,"completion":9116,"start":9117,"enrollment":9118,"conditions":9119,"interventions":9120},"NCT00679939","Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health",[88],"2010-09-16","2008-04-21",226,[27],[9093,9016],{"nctId":9122,"briefTitle":9123,"status":155,"phases":9124,"primaryCompletion":9125,"completion":9125,"start":9126,"enrollment":463,"conditions":9127,"interventions":9128},"NCT01842620","OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.",[88],"2013-05-04","2013-03-13",[27],[9016],{"nctId":9130,"briefTitle":9131,"status":155,"phases":9132,"primaryCompletion":9133,"completion":9133,"start":8478,"enrollment":719,"conditions":9134,"interventions":9135},"NCT00367055","Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes",[88],"2008-10",[9036],[9136,9016,9137],"rosiglitazone-metformin","metformin+ gliclazide",{"trials":9139,"activeCount":97},[],{"intervention":4763,"totalTrials":1459,"cells":9141},{"EARLY_PHASE1":9142,"PHASE1":9144,"PHASE2":9176,"PHASE3":9186,"PHASE4":9201,"NA":9248},{"trials":9143,"activeCount":97},[],{"trials":9145,"activeCount":97},[9146,9155,9167],{"nctId":9147,"briefTitle":9148,"status":155,"phases":9149,"primaryCompletion":6352,"completion":6352,"start":6352,"enrollment":255,"conditions":9150,"interventions":9154},"NCT01767428","Pharmacokinetic Study to Compare Two Formulations of Paracetamol",[85],[9151,9152,9153],"Fever","Headache Disorders","Pain",[4763],{"nctId":9156,"briefTitle":9157,"status":155,"phases":9158,"primaryCompletion":9159,"completion":9159,"start":8468,"enrollment":473,"conditions":9160,"interventions":9162},"NCT01568749","A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations",[85],"2009-08",[9161],"Analgesia",[4763,9163,9164,9165,9166],"Paracetamol formulation 1","Paracetamol Formulation 2","Paracetamol formulation 3","Paracetamol formulation 4",{"nctId":9168,"briefTitle":9169,"status":155,"phases":9170,"primaryCompletion":6351,"completion":6351,"start":6351,"enrollment":1634,"conditions":9171,"interventions":9172},"NCT01476215","A Pharmacokinetic Study Investigating the Rate and Extent of Paracetamol Absorption of Three Experimental Sustained Release Pediatric Suspensions",[85],[7524],[9173,9174,9175,4763],"Paracetamol fast dissolution suspension","Paracetamol medium dissolution suspension","Paracetamol slow dissolution suspension",{"trials":9177,"activeCount":97},[9178],{"nctId":9179,"briefTitle":9180,"status":155,"phases":9181,"primaryCompletion":2344,"completion":2344,"start":2335,"enrollment":1196,"conditions":9182,"interventions":9184},"NCT01277081","Effect of Paracetamol on the Common Cold",[86],[9183],"Common Cold",[9185,4763],"Paracetamol hot drink",{"trials":9187,"activeCount":97},[9188,9192],{"nctId":4753,"briefTitle":4754,"status":155,"phases":9189,"completion":4756,"start":4757,"enrollment":4388,"conditions":9190,"interventions":9191},[87],[4759],[4761,4684,4762,4763],{"nctId":9193,"briefTitle":9194,"status":155,"phases":9195,"primaryCompletion":8089,"completion":8089,"start":8135,"enrollment":9196,"conditions":9197,"interventions":9198},"NCT01686646","Effects of Two Doses of a Common Cold Treatment on Alertness",[87],240,[9183],[9199,9200],"paracetamol + caffeine","paracetamol",{"trials":9202,"activeCount":97},[9203,9212,9220,9229,9237,9241],{"nctId":9204,"briefTitle":9205,"status":155,"phases":9206,"primaryCompletion":9207,"completion":9207,"start":9208,"enrollment":3379,"conditions":9209,"interventions":9211},"NCT01105936","Assess the Blood-Oxygen-Level-Dependent (BOLD) Signal Changes in the Brain by Paracetamol as Measured by Functional Magnetic Resonance Imaging (fMRI) in Subjects With Osteoarthritis (OA)",[88],"2011-08-01","2010-09-01",[9210],"Osteoarthritis, Knee",[4763],{"nctId":9213,"briefTitle":9214,"status":145,"phases":9215,"primaryCompletion":3310,"completion":3310,"start":9216,"enrollment":1279,"conditions":9217,"interventions":9218},"NCT02974114","Exploratory Study to Investigate Cognition Function and Mobility in Individuals With Pain",[88],"2016-10-31",[9153],[9219,4763],"Paracetamol and caffeine",{"nctId":9221,"briefTitle":9222,"status":155,"phases":9223,"primaryCompletion":9224,"completion":9224,"start":7590,"enrollment":463,"conditions":9225,"interventions":9226},"NCT01332578","A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies",[88],"2011-06",[21,9183],[4763,9227,9228],"Phenylephrine","Ascorbic Acid",{"nctId":9230,"briefTitle":9231,"status":155,"phases":9232,"primaryCompletion":8037,"completion":8037,"start":9233,"enrollment":695,"conditions":9234,"interventions":9236},"NCT01822665","Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics",[88],"2012-02",[9235],"Gastrointestinal Mucosal Damage",[4884,4763],{"nctId":4874,"briefTitle":4875,"status":155,"phases":9238,"primaryCompletion":4877,"completion":4878,"start":4879,"enrollment":4880,"conditions":9239,"interventions":9240},[88],[3637],[4883,4472,4821,4884,4763],{"nctId":9242,"briefTitle":9243,"status":155,"phases":9244,"primaryCompletion":7598,"completion":7598,"start":729,"enrollment":1264,"conditions":9245,"interventions":9246},"NCT01466348","Effects of a Common Cold Treatment on Cognitive Function",[88],[9183],[9247,4763],"Paracetamol and Caffeine",{"trials":9249,"activeCount":97},[],{"intervention":6488,"totalTrials":361,"cells":9251},{"EARLY_PHASE1":9252,"PHASE1":9254,"PHASE2":9348,"PHASE3":9350,"PHASE4":9352,"NA":9367},{"trials":9253,"activeCount":97},[],{"trials":9255,"activeCount":97},[9256,9260,9264,9274,9285,9295,9303,9312,9328,9338],{"nctId":7425,"briefTitle":7426,"status":155,"phases":9257,"primaryCompletion":7428,"completion":7428,"start":7429,"enrollment":1298,"conditions":9258,"interventions":9259},[85],[668],[6488,2274],{"nctId":6478,"briefTitle":6479,"status":155,"phases":9261,"primaryCompletion":1287,"completion":1287,"start":6481,"enrollment":6482,"conditions":9262,"interventions":9263},[85],[6484],[6471,6486,6487,6488,6489],{"nctId":9265,"briefTitle":9266,"status":155,"phases":9267,"primaryCompletion":9268,"completion":9268,"start":9269,"enrollment":314,"conditions":9270,"interventions":9271},"NCT00615212","Effect of GSK376501 on CYP450 Activity in Healthy Adult Subjects",[85],"2008-02-15","2008-01-02",[27],[9272,6488,9093,9273],"GSK376501","Flurbiprofen",{"nctId":9275,"briefTitle":9276,"status":155,"phases":9277,"primaryCompletion":9278,"completion":9279,"start":9280,"enrollment":9281,"conditions":9282,"interventions":9283},"NCT00880321","A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors",[85],"2011-03-25","2012-03-20","2009-06-04",170,[36],[9284,9284,6488],"GSK2118436",{"nctId":9286,"briefTitle":9287,"status":155,"phases":9288,"primaryCompletion":9289,"completion":9289,"start":9290,"enrollment":710,"conditions":9291,"interventions":9293},"NCT00511654","28-day Repeat Dose and Drug Interaction Study With Orvepitant (GW823296)",[85],"2008-01-11","2007-06-12",[9292],"Depressive Disorder",[9294,6488],"GW823296",{"nctId":9296,"briefTitle":9297,"status":155,"phases":9298,"start":7659,"enrollment":463,"conditions":9299,"interventions":9300},"NCT00423761","An Investigation To Determine The Potential Interaction Effect Between GW876008 And Midazolam.",[85],[7524],[9301,9302],"midazolam","GW876008",{"nctId":9304,"briefTitle":9305,"status":155,"phases":9306,"primaryCompletion":9045,"completion":9045,"start":9307,"enrollment":93,"conditions":9308,"interventions":9310},"NCT01873339","Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects",[85],"2013-06-19",[9309],"Atherosclerosis",[9311,6488],"Darapladib",{"nctId":9313,"briefTitle":9314,"status":155,"phases":9315,"primaryCompletion":9316,"completion":9316,"start":9317,"enrollment":31,"conditions":9318,"interventions":9320},"NCT00964106","Validation Study of Multiple Probe Compounds for Drug Interaction Evaluation",[85],"2011-08-29","2009-08-26",[9319],"Drug Interactions",[9321,9093,9273,9322,9323,6488,9324,9325,9326,9327,9093],"Caffeine","Omeprazole","Dextromethorphan","Rosuvastatin","Ketoconazole","Fluconazole","Rifampin",{"nctId":9329,"briefTitle":9330,"status":155,"phases":9331,"primaryCompletion":611,"completion":9332,"start":9333,"enrollment":9334,"conditions":9335,"interventions":9336},"NCT05760261","Drug Interaction Assessment of GSK3882347 in Healthy Participants Aged 18 to 65 Years",[85],"2024-08-20","2023-04-11",27,[5658],[6488,9337],"GSK3882347",{"nctId":9339,"briefTitle":9340,"status":155,"phases":9341,"primaryCompletion":6351,"completion":6351,"start":2442,"enrollment":1298,"conditions":9342,"interventions":9344},"NCT00920088","Drug Interaction Study of Darunavir\u002FRitonavir and Lopinavir\u002FRitonavir on GSK2248761 PK and CYP450 Probe Drugs",[85],[7524,9343],"Infection, Human Immunodeficiency Virus",[9345,9346,6488,9323,9273,9347],"darunavir\u002Fritonavir","lopinavir\u002Fritonavir","GSK2248761",{"trials":9349,"activeCount":97},[],{"trials":9351,"activeCount":97},[],{"trials":9353,"activeCount":97},[9354],{"nctId":9355,"briefTitle":9356,"status":155,"phases":9357,"start":2823,"enrollment":9358,"conditions":9359,"interventions":9361},"NCT00158873","Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects",[88],224,[9360],"Sedation",[9301,9362,9363,9364,9365,9366],"lorazepam","fentanyl","morphine","remifentanil","propofol",{"trials":9368,"activeCount":97},[],{"intervention":9370,"totalTrials":361,"cells":9371},"Salmeterol",{"EARLY_PHASE1":9372,"PHASE1":9374,"PHASE2":9386,"PHASE3":9404,"PHASE4":9418,"NA":9474},{"trials":9373,"activeCount":97},[],{"trials":9375,"activeCount":97},[9376],{"nctId":9377,"briefTitle":9378,"status":155,"phases":9379,"primaryCompletion":9380,"completion":9380,"start":9381,"enrollment":9382,"conditions":9383,"interventions":9384},"NCT00364273","GSK159802 In Healthy Male Subjects And Asthmatics",[85],"2006-07-06","2005-08-24",43,[15],[9385,9370],"GSK159802",{"trials":9387,"activeCount":97},[9388,9396],{"nctId":9389,"briefTitle":9390,"status":155,"phases":9391,"primaryCompletion":3111,"completion":3111,"start":2344,"enrollment":9392,"conditions":9393,"interventions":9394},"NCT01319019","A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[86],437,[15],[9395,9370],"GSK961081",{"nctId":9397,"briefTitle":9398,"status":155,"phases":9399,"primaryCompletion":2835,"completion":2835,"start":2404,"enrollment":1237,"conditions":9400,"interventions":9401},"NCT00422604","Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[86],[15],[9402,2980,9403],"salmeterol","GSK233705",{"trials":9405,"activeCount":97},[9406],{"nctId":9407,"briefTitle":9408,"status":155,"phases":9409,"primaryCompletion":9410,"completion":9410,"start":9411,"enrollment":9412,"conditions":9413,"interventions":9414},"NCT02446418","A Study to Compare the Efficacy of Fluticasone Furoate\u002FVilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)\u002FLong Acting Beta Agonists (LABA) in Persistent Asthma",[87],"2017-07-20","2015-07-09",423,[18],[8532,9415,8381,9370,9416,9417],"Vilanterol","Budesonide","Formoterol Fumarate",{"trials":9419,"activeCount":97},[9420,9427,9435,9441,9448,9458,9467],{"nctId":9421,"briefTitle":9422,"status":155,"phases":9423,"start":2405,"enrollment":624,"conditions":9424,"interventions":9425},"NCT00327353","Influence Of Different Airflow Resistances On Drug Effect Of 50μg Salmeterol And 6 μg Formoterol",[88],[18],[9426,9370],"formoterol",{"nctId":9428,"briefTitle":9429,"status":155,"phases":9430,"primaryCompletion":3552,"completion":3552,"start":1361,"enrollment":9431,"conditions":9432,"interventions":9433},"NCT00115492","Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations",[88],797,[15],[9434,9370],"Fluticasone Propionate\u002FSalmeterol Combination Product",{"nctId":9436,"briefTitle":9437,"status":155,"phases":9438,"primaryCompletion":8089,"completion":8089,"start":8037,"enrollment":2045,"conditions":9439,"interventions":9440},"NCT01536587","Effects of Salmeterol on Autonomic Nervous System",[88],[15],[9370],{"nctId":9442,"briefTitle":9443,"status":145,"phases":9444,"primaryCompletion":2428,"completion":2428,"start":7659,"enrollment":9445,"conditions":9446,"interventions":9447},"NCT00346749","ADVAIR DISKUS® (Fluticasone Propionate\u002FSalmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.",[88],180,[15],[9370,9434],{"nctId":9449,"briefTitle":9450,"status":155,"phases":9451,"primaryCompletion":9452,"completion":9452,"start":9453,"enrollment":9454,"conditions":9455,"interventions":9456},"NCT00984659","Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease",[88],"2010-07-01","2009-10-29",366,[15],[9457,9370],"Fluticasone propionate\u002Fsalmeterol combination product",{"nctId":9459,"briefTitle":9460,"status":155,"phases":9461,"primaryCompletion":1380,"completion":1380,"start":9462,"enrollment":4651,"conditions":9463,"interventions":9465},"NCT00950794","Study of Salmeterol (SN408D) for Adult Asthma",[88],"2003-09",[18,9464],"Bronchial Asthma",[9370,9466],"Hokunalin (tulobuterol) tape",{"nctId":9468,"briefTitle":9469,"status":155,"phases":9470,"primaryCompletion":7659,"completion":7659,"start":8478,"enrollment":9471,"conditions":9472,"interventions":9473},"NCT00144911","ADVAIR® DISKUS® Inhaler (Fluticasone Propionate\u002FSalmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.",[88],740,[15],[9370,9434],{"trials":9475,"activeCount":97},[],{"intervention":9415,"totalTrials":361,"cells":9477},{"EARLY_PHASE1":9478,"PHASE1":9480,"PHASE2":9492,"PHASE3":9511,"PHASE4":9572,"NA":9581},{"trials":9479,"activeCount":97},[],{"trials":9481,"activeCount":97},[9482],{"nctId":9483,"briefTitle":9484,"status":155,"phases":9485,"primaryCompletion":9486,"completion":9486,"start":9487,"enrollment":433,"conditions":9488,"interventions":9489},"NCT00625196","Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects",[85],"2008-05-06","2008-02-27",[18],[9490,9491,9415],"Fluticasone foroate\u002F vilanterol","Fluticasone foroate",{"trials":9493,"activeCount":97},[9494,9503],{"nctId":9495,"briefTitle":9496,"status":155,"phases":9497,"primaryCompletion":9498,"completion":9498,"start":9499,"enrollment":695,"conditions":9500,"interventions":9501},"NCT02712047","A Phase IIA FF\u002FVI Study to Measure FeNO in Asthmatic Patients.",[86],"2017-02-21","2016-04-29",[18],[9502,9415],"Fluticasone furoate",{"nctId":9504,"briefTitle":9505,"status":155,"phases":9506,"primaryCompletion":9507,"completion":9507,"start":3389,"enrollment":2959,"conditions":9508,"interventions":9509},"NCT01573767","Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children",[86],"2014-04",[18],[9510,9415],"Fluticasone propionate 100mcg",{"trials":9512,"activeCount":97},[9513,9522,9533,9537,9547,9557,9563],{"nctId":9514,"briefTitle":9515,"status":155,"phases":9516,"primaryCompletion":9207,"completion":9517,"start":9208,"enrollment":9518,"conditions":9519,"interventions":9520},"NCT01181895","Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma",[87],"2011-08-26",348,[18],[9415,9521],"Salmeterol Inhalation Powder",{"nctId":9523,"briefTitle":9524,"status":155,"phases":9525,"primaryCompletion":9526,"completion":9526,"start":9527,"enrollment":9528,"conditions":9529,"interventions":9530},"NCT02164513","A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF\u002FUMEC\u002FVI With the FDC of FF\u002FVI and UMEC\u002FVI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2017-07-17","2014-06-30",10355,[15],[8556,9531,9532],"vilanterol","umeclidinium bromide",{"nctId":9407,"briefTitle":9408,"status":155,"phases":9534,"primaryCompletion":9410,"completion":9410,"start":9411,"enrollment":9412,"conditions":9535,"interventions":9536},[87],[18],[8532,9415,8381,9370,9416,9417],{"nctId":9538,"briefTitle":9539,"status":155,"phases":9540,"primaryCompletion":9541,"completion":9541,"start":9542,"enrollment":9543,"conditions":9544,"interventions":9545},"NCT02105974","Study Evaluating the Efficacy and Safety of Fluticasone Furoate\u002FVilanterol Inhalation Powder (FF\u002FVI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2015-07-08","2014-04-07",1621,[15],[9546,9415],"Fluticasone Furoate\u002FVilanterol",{"nctId":9548,"briefTitle":9549,"status":155,"phases":9550,"primaryCompletion":9551,"completion":9551,"start":9552,"enrollment":9553,"conditions":9554,"interventions":9555},"NCT01313676","Study to Evaluate the Effect of Fluticasone Furoate\u002FVilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease",[87],"2015-07-15","2011-01-25",16568,[15],[9556,8556,9531],"fluticasone furoate\u002Fvilanterol",{"nctId":9558,"briefTitle":9559,"status":155,"phases":9560,"primaryCompletion":3044,"completion":8860,"start":8089,"enrollment":6369,"conditions":9561,"interventions":9562},"NCT01691885","RELOVAIR® Lung Deflation Study",[87],[15],[8532,9415],{"nctId":9564,"briefTitle":9565,"status":155,"phases":9566,"primaryCompletion":9567,"completion":9567,"start":9568,"enrollment":9569,"conditions":9570,"interventions":9571},"NCT01336608","A 24-week Arterial Stiffness Study With Fluticasone Furoate\u002FVilanterol in COPD",[87],"2014-11-04","2011-03-04",446,[15],[9546,9415],{"trials":9573,"activeCount":97},[9574],{"nctId":9575,"briefTitle":9576,"status":155,"phases":9577,"primaryCompletion":1685,"completion":1685,"start":9578,"enrollment":4175,"conditions":9579,"interventions":9580},"NCT01957150","Study Evaluating the Effect of Fluticasone Furoate\u002F Vilanterol (FF\u002FVI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).",[88],"2014-01-28",[15],[9546,9415],{"trials":9582,"activeCount":97},[],{"intervention":9546,"totalTrials":750,"cells":9584},{"EARLY_PHASE1":9585,"PHASE1":9587,"PHASE2":9604,"PHASE3":9612,"PHASE4":9647,"NA":9661},{"trials":9586,"activeCount":97},[],{"trials":9588,"activeCount":97},[9589,9597],{"nctId":9590,"briefTitle":9591,"status":155,"phases":9592,"primaryCompletion":9593,"completion":9593,"start":9594,"enrollment":255,"conditions":9595,"interventions":9596},"NCT01485445","Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF\u002FVilanterol Combination",[85],"2012-03-12","2011-12-21",[18],[8532,9546],{"nctId":9598,"briefTitle":9599,"status":155,"phases":9600,"primaryCompletion":9601,"completion":9601,"start":8336,"enrollment":433,"conditions":9602,"interventions":9603},"NCT01711463","Relovair PD PK in Chinese Healthy Subjects",[85],"2013-06-04",[18],[9546],{"trials":9605,"activeCount":97},[9606],{"nctId":9607,"briefTitle":9608,"status":155,"phases":9609,"primaryCompletion":2295,"completion":2295,"start":2394,"enrollment":93,"conditions":9610,"interventions":9611},"NCT01453023","Inhaled Fluticasone Furoate\u002FVilanterol Safety and Tolerability, PK and PD Study",[86],[18],[8532,9546],{"trials":9613,"activeCount":97},[9614,9621,9635,9639,9643],{"nctId":9615,"briefTitle":9616,"status":155,"phases":9617,"primaryCompletion":3110,"completion":3110,"start":7598,"enrollment":9618,"conditions":9619,"interventions":9620},"NCT01376245","A 24-week Study of Fluticasone Furoate\u002FVilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD",[87],646,[15],[9556],{"nctId":9622,"briefTitle":9623,"status":155,"phases":9624,"primaryCompletion":9625,"completion":9625,"start":9626,"enrollment":9627,"conditions":9628,"interventions":9629},"NCT02094937","A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects",[87],"2015-08-28","2014-03-27",430,[18],[9546,9630,9631,9632,9633,9634],"Fluticasone Furoate 100 mcg","Fluticasone Propionate 250 mcg","Fluticasone Propionate 100 mcg","Fluticasone Furoate Placebo","Fluticasone Propionate Placebo",{"nctId":9538,"briefTitle":9539,"status":155,"phases":9636,"primaryCompletion":9541,"completion":9541,"start":9542,"enrollment":9543,"conditions":9637,"interventions":9638},[87],[15],[9546,9415],{"nctId":9548,"briefTitle":9549,"status":155,"phases":9640,"primaryCompletion":9551,"completion":9551,"start":9552,"enrollment":9553,"conditions":9641,"interventions":9642},[87],[15],[9556,8556,9531],{"nctId":9564,"briefTitle":9565,"status":155,"phases":9644,"primaryCompletion":9567,"completion":9567,"start":9568,"enrollment":9569,"conditions":9645,"interventions":9646},[87],[15],[9546,9415],{"trials":9648,"activeCount":97},[9649,9657],{"nctId":9650,"briefTitle":9651,"status":500,"phases":9652,"primaryCompletion":9653,"completion":9653,"start":4867,"enrollment":97,"conditions":9654,"interventions":9655},"NCT03363191","The Efficacy of Fluticasone Furoate\u002FVilanterol Versus (vs) Fluticasone Furoate on Asthma",[88],"2019-05-29",[18],[9546,8532,9656],"Salbutamol\u002FAlbuterol",{"nctId":9575,"briefTitle":9576,"status":155,"phases":9658,"primaryCompletion":1685,"completion":1685,"start":9578,"enrollment":4175,"conditions":9659,"interventions":9660},[88],[15],[9546,9415],{"trials":9662,"activeCount":97},[],{"intervention":9664,"totalTrials":1165,"cells":9665},"Nicotine",{"EARLY_PHASE1":9666,"PHASE1":9668,"PHASE2":9700,"PHASE3":9715,"PHASE4":9731,"NA":9740},{"trials":9667,"activeCount":97},[],{"trials":9669,"activeCount":97},[9670,9678,9686,9693],{"nctId":9671,"briefTitle":9672,"status":155,"phases":9673,"primaryCompletion":728,"completion":728,"start":728,"enrollment":345,"conditions":9674,"interventions":9676},"NCT01702519","A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers",[85],[9675],"Smoking",[9677],"nicotine",{"nctId":9679,"briefTitle":9680,"status":155,"phases":9681,"primaryCompletion":9682,"completion":9682,"start":7545,"enrollment":1003,"conditions":9683,"interventions":9685},"NCT01536704","Nicotine Lozenge Bioequivalence Study",[85],"2011-08",[9684],"Smoking Cessation",[9664,9664],{"nctId":9687,"briefTitle":9688,"status":155,"phases":9689,"primaryCompletion":2813,"completion":2813,"start":2356,"enrollment":1196,"conditions":9690,"interventions":9692},"NCT00682461","Oral Tolerability Of Two Nicotine Dosage Forms",[85],[9691],"Healthy Volunteer Smokers",[9664,9664],{"nctId":9694,"briefTitle":9695,"status":155,"phases":9696,"primaryCompletion":9697,"completion":9697,"start":5195,"enrollment":719,"conditions":9698,"interventions":9699},"NCT01847443","Comparison of Pharmacokinetic Profiles of Two Nicotine Gum Formulations",[85],"2013-06",[9684],[9664,9664],{"trials":9701,"activeCount":97},[9702,9709],{"nctId":9703,"briefTitle":9704,"status":155,"phases":9705,"primaryCompletion":9706,"completion":9706,"start":2295,"enrollment":345,"conditions":9707,"interventions":9708},"NCT01669122","Pharmacokinetic Study of 4 mg Nicotine Lozenge.",[86],"2012-08",[9684],[9677],{"nctId":9710,"briefTitle":9711,"status":155,"phases":9712,"primaryCompletion":2427,"completion":2427,"start":8135,"enrollment":201,"conditions":9713,"interventions":9714},"NCT01476202","Provoked Craving Relief Study by NRT",[86],[9684],[9677],{"trials":9716,"activeCount":97},[9717,9724],{"nctId":9718,"briefTitle":9719,"status":155,"phases":9720,"primaryCompletion":8883,"completion":8883,"start":2795,"enrollment":9721,"conditions":9722,"interventions":9723},"NCT00985985","Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation",[87],723,[9675],[9664],{"nctId":9725,"briefTitle":9726,"status":155,"phases":9727,"primaryCompletion":9728,"completion":9728,"start":3110,"enrollment":4346,"conditions":9729,"interventions":9730},"NCT01702532","Nicotine Mouth Film for Craving Relief.",[87],"2012-12",[9684],[9664],{"trials":9732,"activeCount":97},[9733],{"nctId":9734,"briefTitle":9735,"status":155,"phases":9736,"primaryCompletion":9737,"completion":9737,"start":2356,"enrollment":314,"conditions":9738,"interventions":9739},"NCT00657020","Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdrawal Symptoms",[88],"2008-02",[9675],[9664],{"trials":9741,"activeCount":97},[],{"intervention":9743,"totalTrials":1720,"cells":9744},"FluarixTM",{"EARLY_PHASE1":9745,"PHASE1":9747,"PHASE2":9749,"PHASE3":9770,"PHASE4":9806,"NA":9825},{"trials":9746,"activeCount":97},[],{"trials":9748,"activeCount":97},[],{"trials":9750,"activeCount":97},[9751,9761],{"nctId":9752,"briefTitle":8251,"status":155,"phases":9753,"primaryCompletion":9754,"completion":9755,"start":9756,"enrollment":9757,"conditions":9758,"interventions":9759},"NCT00321373",[86],"2006-07-01","2006-07-18","2006-05-11",1220,[21],[9760,9743],"Candidate Influenza Vaccine GSK1247446A - 2 different formulations",{"nctId":9762,"briefTitle":9763,"status":155,"phases":9764,"primaryCompletion":9765,"completion":9766,"start":2665,"enrollment":9767,"conditions":9768,"interventions":9769},"NCT00385840","Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate",[86],"2007-02-01","2007-02-05",678,[21],[8220,9743],{"trials":9771,"activeCount":97},[9772,9781,9788,9798],{"nctId":9773,"briefTitle":9774,"status":155,"phases":9775,"primaryCompletion":9776,"completion":9776,"start":3425,"enrollment":9777,"conditions":9778,"interventions":9779},"NCT01196988","Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children",[87],"2011-06-15",3027,[21],[8230,9743,9780],"Influenza vaccine GSK2604409A",{"nctId":9782,"briefTitle":9783,"status":500,"phases":9784,"primaryCompletion":7545,"completion":7545,"start":7647,"enrollment":97,"conditions":9785,"interventions":9786},"NCT00866580","A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine",[87],[21],[9787,9743],"GSK's candidate influenza vaccine 1562902A",{"nctId":9789,"briefTitle":9790,"status":155,"phases":9791,"primaryCompletion":9792,"completion":9792,"start":9793,"enrollment":9794,"conditions":9795,"interventions":9796},"NCT00992784","Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People",[87],"2010-05-27","2009-10-15",370,[21],[9797,9743],"GSK investigational vaccine 2186877A",{"nctId":9799,"briefTitle":9800,"status":155,"phases":9801,"primaryCompletion":9802,"completion":9802,"start":3425,"enrollment":9803,"conditions":9804,"interventions":9805},"NCT01204671","Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)",[87],"2011-06-06",4659,[21],[8230,9743,9780],{"trials":9807,"activeCount":97},[9808,9816],{"nctId":9809,"briefTitle":9810,"status":155,"phases":9811,"primaryCompletion":9812,"completion":9812,"start":3425,"enrollment":624,"conditions":9813,"interventions":9814},"NCT01190215","Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM",[88],"2011-07-07",[21],[9743,9815],"HavrixTM Junior",{"nctId":9817,"briefTitle":9818,"status":155,"phases":9819,"primaryCompletion":8207,"completion":9820,"start":9821,"enrollment":9822,"conditions":9823,"interventions":9824},"NCT00750360","Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age.",[88],"2007-12-28","2003-10-03",883,[21],[9743],{"trials":9826,"activeCount":97},[],{"intervention":9828,"totalTrials":1318,"cells":9829},"Saline placebo",{"EARLY_PHASE1":9830,"PHASE1":9832,"PHASE2":9871,"PHASE3":9895,"PHASE4":9908,"NA":9917},{"trials":9831,"activeCount":97},[],{"trials":9833,"activeCount":97},[9834,9848,9858],{"nctId":9835,"briefTitle":9836,"status":155,"phases":9837,"primaryCompletion":1263,"completion":9838,"start":1718,"enrollment":3392,"conditions":9839,"interventions":9841},"NCT04062669","A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults",[85],"2022-07-01",[9840],"Virus Diseases",[9842,9843,9844,9845,9846,9847],"Low dose formulation of RG SAM","Medium dose formulation of RG SAM","Lower dose formulation of RG SAM","Lowest dose formulation of RG SAM","Saline Placebo","RabAvert",{"nctId":9849,"briefTitle":9850,"status":155,"phases":9851,"primaryCompletion":9852,"completion":9852,"start":9853,"enrollment":6503,"conditions":9854,"interventions":9856},"NCT01657526","Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine",[85],"2013-11-25","2012-08-08",[9855],"Respiratory Disorders",[9857,9857,9828],"GSK Biologicals' Non-Typeable H. influenzae",{"nctId":9859,"briefTitle":9860,"status":155,"phases":9861,"primaryCompletion":9862,"completion":9862,"start":9863,"enrollment":370,"conditions":9864,"interventions":9866},"NCT01160172","A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults",[85],"2012-08-23","2010-07-19",[9865],"Infections, Staphylococcal",[9867,9868,9869,9870,9828],"Staphylococcal investigational vaccine GSK2392103A","Staphylococcal investigational vaccine GSK2392105A","Staphylococcal investigational vaccine GSK2392106A","Staphylococcal investigational vaccine GSK2392019A",{"trials":9872,"activeCount":97},[9873,9885],{"nctId":9874,"briefTitle":9875,"status":155,"phases":9876,"primaryCompletion":9877,"completion":9878,"start":9879,"enrollment":9880,"conditions":9881,"interventions":9882},"NCT00985088","Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older",[86],"2009-11-09","2010-12-16","2009-10-11",1343,[21],[9883,9884,9828],"GSK2340274A","GSK2340273A",{"nctId":9886,"briefTitle":9887,"status":155,"phases":9888,"primaryCompletion":9889,"completion":9890,"start":9891,"enrollment":5034,"conditions":9892,"interventions":9893},"NCT00985673","Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults",[86],"2009-12-28","2010-12-29","2009-10-01",[21],[9883,9884,9894,9828],"Seasonal trivalent influenza vaccine",{"trials":9896,"activeCount":97},[9897],{"nctId":9898,"briefTitle":9899,"status":155,"phases":9900,"primaryCompletion":9901,"completion":9902,"start":9903,"enrollment":9904,"conditions":9905,"interventions":9906},"NCT01310413","Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to \u003C 18 Years of Age",[87],"2011-07-21","2014-01-26","2011-03-07",842,[21,8265],[9907,9828],"Influenza A (H5N1) Virus monovalent vaccine",{"trials":9909,"activeCount":97},[9910],{"nctId":9911,"briefTitle":9912,"status":155,"phases":9913,"primaryCompletion":8082,"completion":2280,"start":7464,"enrollment":7702,"conditions":9914,"interventions":9915},"NCT02377349","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women",[88],[3649],[9916,9828],"Boostrix™",{"trials":9918,"activeCount":97},[],{"intervention":9920,"totalTrials":1318,"cells":9921},"Havrix™",{"EARLY_PHASE1":9922,"PHASE1":9924,"PHASE2":9926,"PHASE3":9928,"PHASE4":9967,"NA":9986},{"trials":9923,"activeCount":97},[],{"trials":9925,"activeCount":97},[],{"trials":9927,"activeCount":97},[],{"trials":9929,"activeCount":97},[9930,9939,9948,9958],{"nctId":9931,"briefTitle":9932,"status":155,"phases":9933,"primaryCompletion":9934,"completion":9934,"start":5268,"enrollment":9935,"conditions":9936,"interventions":9937},"NCT01218308","A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children",[87],"2012-01-09",5220,[21],[9938,9920],"FluLaval® Quadrivalent",{"nctId":9940,"briefTitle":9941,"status":155,"phases":9942,"primaryCompletion":2813,"completion":2813,"start":2805,"enrollment":9943,"conditions":9944,"interventions":9946},"NCT00316706","Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16\u002F18 Vaccine",[87],1245,[2444,9945],"Papillomavirus Infection",[9947,9920],"GSK Biologicals' HPV-16\u002F18 Vaccine",{"nctId":9949,"briefTitle":9950,"status":155,"phases":9951,"primaryCompletion":9952,"completion":9953,"start":4855,"enrollment":1307,"conditions":9954,"interventions":9955},"NCT01379937","A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children",[87],"2012-08-02","2012-10-05",[21],[9956,9957,9920,8350],"Influenza vaccine GSK1562902A Formulation 1","Influenza vaccine GSK1562902A Formulation 2",{"nctId":9959,"briefTitle":9960,"status":155,"phases":9961,"primaryCompletion":9962,"completion":9962,"start":9963,"enrollment":9964,"conditions":9965,"interventions":9966},"NCT00197236","Immunogenicity and Safety of Havrix™ Co-Administered With a Diphtheria, Tetanus and Pertussis and a Haemophilus b Vaccine in Children Aged 15 Months",[87],"2007-12-03","2003-11-11",468,[7966],[9920,7876,7872],{"trials":9968,"activeCount":97},[9969,9973,9980],{"nctId":7959,"briefTitle":7960,"status":155,"phases":9970,"primaryCompletion":7962,"completion":7962,"start":7963,"enrollment":7964,"conditions":9971,"interventions":9972},[88],[24,7966],[7968,7718,7969,7970,7971],{"nctId":9974,"briefTitle":9975,"status":155,"phases":9976,"primaryCompletion":8397,"completion":8397,"start":9977,"enrollment":829,"conditions":9978,"interventions":9979},"NCT00291876","Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule",[88],"2004-01-01",[7966],[9920],{"nctId":9981,"briefTitle":9982,"status":155,"phases":9983,"primaryCompletion":8397,"completion":8397,"start":9977,"enrollment":868,"conditions":9984,"interventions":9985},"NCT00289757","Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine, Injected According to 0, 6-month Schedule",[88],[7966],[9920],{"trials":9987,"activeCount":97},[],{"intervention":9916,"totalTrials":1318,"cells":9989},{"EARLY_PHASE1":9990,"PHASE1":9992,"PHASE2":9994,"PHASE3":9996,"PHASE4":10028,"NA":10062},{"trials":9991,"activeCount":97},[],{"trials":9993,"activeCount":97},[],{"trials":9995,"activeCount":97},[],{"trials":9997,"activeCount":97},[9998,10009,10020],{"nctId":9999,"briefTitle":10000,"status":155,"phases":10001,"primaryCompletion":10002,"completion":10002,"start":10003,"enrollment":895,"conditions":10004,"interventions":10005},"NCT01277705","Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®",[87],"2002-04","2002-01",[33,30,3624],[10006,9916,10007,10008],"GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine","GSK Biologicals' IPV vaccine","Revaxis®",{"nctId":10010,"briefTitle":10011,"status":155,"phases":10012,"primaryCompletion":10013,"completion":10014,"start":10015,"enrollment":10016,"conditions":10017,"interventions":10018},"NCT00346073","Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years",[87],"2007-03-01","2007-03-07","2006-07-13",2337,[3624,30,33],[9916,10019],"ADACEL®",{"nctId":10021,"briefTitle":10022,"status":155,"phases":10023,"primaryCompletion":10024,"completion":10024,"start":10025,"enrollment":1272,"conditions":10026,"interventions":10027},"NCT01988857","Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children",[87],"2014-05-10","2014-02-22",[30,33,3624],[9916],{"trials":10029,"activeCount":97},[10030,10034,10043,10052],{"nctId":9911,"briefTitle":9912,"status":155,"phases":10031,"primaryCompletion":8082,"completion":2280,"start":7464,"enrollment":7702,"conditions":10032,"interventions":10033},[88],[3649],[9916,9828],{"nctId":10035,"briefTitle":10036,"status":155,"phases":10037,"primaryCompletion":10038,"completion":10038,"start":10039,"enrollment":9445,"conditions":10040,"interventions":10041},"NCT01147900","Evaluation of Boostrix™10 Years After Previous Booster Vaccination",[88],"2012-05-08","2010-06-15",[3624,33,30],[9916,10042],"Boostrix™-US formulation",{"nctId":10044,"briefTitle":10045,"status":155,"phases":10046,"primaryCompletion":10047,"completion":10047,"start":10048,"enrollment":10049,"conditions":10050,"interventions":10051},"NCT00548171","Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058",[88],"2008-04-30","2007-11-05",203,[3624,33,30,3649],[9916],{"nctId":10053,"briefTitle":10054,"status":155,"phases":10055,"primaryCompletion":2823,"completion":2823,"start":10056,"enrollment":10057,"conditions":10058,"interventions":10059},"NCT01294605","Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)",[88],"2003-04",460,[3624,33,30],[9916,10060,10061,10061],"GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine","Ditanrix™ Adult, TedivaxTM",{"trials":10063,"activeCount":97},[],{"intervention":10065,"totalTrials":628,"cells":10066},"DTPa-HBV-IPV\u002FHib",{"EARLY_PHASE1":10067,"PHASE1":10069,"PHASE2":10071,"PHASE3":10091,"PHASE4":10118,"NA":10131},{"trials":10068,"activeCount":97},[],{"trials":10070,"activeCount":97},[],{"trials":10072,"activeCount":97},[10073,10079],{"nctId":10074,"briefTitle":10075,"status":155,"phases":10076,"primaryCompletion":4844,"completion":7659,"start":3714,"enrollment":2297,"conditions":10077,"interventions":10078},"NCT00289796","Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV\u002FHib Vaccine",[86],[24],[10065],{"nctId":10080,"briefTitle":10081,"status":155,"phases":10082,"primaryCompletion":10083,"completion":10083,"start":10084,"enrollment":5088,"conditions":10085,"interventions":10088},"NCT01457495","Immunogenicity and Safety of DTPa-HBV-IPV\u002FHib Compared to DTPa-IPV\u002FHib and HBV Administered Concomitantly",[86],"1999-09","1998-09",[24,30,10086,4702,10087,33],"Haemophilus Influenzae Type b (Hib)","Pertussis",[10065,10089,10090],"DTPa-IPV\u002FHib","HBV",{"trials":10092,"activeCount":97},[10093,10102,10112],{"nctId":10094,"briefTitle":10095,"status":155,"phases":10096,"primaryCompletion":9765,"completion":9765,"start":10097,"enrollment":10098,"conditions":10099,"interventions":10100},"NCT00325143","Safety of DTPa-IPV\u002FHib & DTPa-HBV-IPV\u002FHib, Followed by DTPa-IPV\u002FHib Vaccine in Infants Who Received Hepatitis B Vaccine",[87],"2003-12-01",702,[4704,30,33,4702,3624],[10065,10101],"DTPa-IPV\u002FHib vaccine",{"nctId":10103,"briefTitle":10104,"status":155,"phases":10105,"primaryCompletion":10106,"completion":10106,"start":10107,"enrollment":569,"conditions":10108,"interventions":10109},"NCT01457508","Immunogenicity and Reactogenicity of DTPa-HBV-IPV\u002FHib, Compared to DTPa-HBV-IPV and Hib Administered Separately",[87],"2000-03","1999-01",[24,30,10086,4702,10087,33],[10065,10110,10111],"DTPa-HBV-IPV","Hib",{"nctId":10113,"briefTitle":10114,"status":155,"phases":10115,"primaryCompletion":2481,"completion":2481,"start":7918,"enrollment":526,"conditions":10116,"interventions":10117},"NCT01457560","Immunogenicity and Reactogenicity of DTPa-HBV-IPV\u002FHib Vaccine Followed by the Same Vaccine and Oral Polio Vaccine",[87],[24,3624,4704,30,33,4702],[10065,8937],{"trials":10119,"activeCount":97},[10120],{"nctId":10121,"briefTitle":10122,"status":155,"phases":10123,"primaryCompletion":10124,"completion":10124,"start":10125,"enrollment":10126,"conditions":10127,"interventions":10128},"NCT04535037","A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV\u002FHib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers",[88],"2022-07-25","2021-05-26",500,[30],[10065,10129,10130],"DTaP5-HBV-IPV-Hib","Pneumococcal 13-valent conjugate vaccine",{"trials":10132,"activeCount":97},[],{"intervention":10134,"totalTrials":1517,"cells":10135},"Cetirizine",{"EARLY_PHASE1":10136,"PHASE1":10138,"PHASE2":10160,"PHASE3":10172,"PHASE4":10184,"NA":10197},{"trials":10137,"activeCount":97},[],{"trials":10139,"activeCount":97},[10140,10150],{"nctId":10141,"briefTitle":10142,"status":155,"phases":10143,"primaryCompletion":10144,"completion":10144,"start":10145,"enrollment":454,"conditions":10146,"interventions":10148},"NCT01622283","Pharmacokinetic Study of Levocetirizine Oral Solution",[85],"2012-06-10","2012-05-02",[10147],"Rhinitis, Allergic, Perennial and Seasonal",[10149,10134],"Levocetirizine",{"nctId":10151,"briefTitle":10152,"status":155,"phases":10153,"primaryCompletion":10047,"completion":10047,"start":10154,"enrollment":454,"conditions":10155,"interventions":10157},"NCT02447393","Phase 1 Study of Levocetirizine",[85],"2008-03-18",[10156],"Dermatitis",[10158,10159],"levocetirizine","cetirizine",{"trials":10161,"activeCount":97},[10162],{"nctId":10163,"briefTitle":10164,"status":155,"phases":10165,"primaryCompletion":10166,"completion":10166,"start":10167,"enrollment":1686,"conditions":10168,"interventions":10170},"NCT00851344","Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo",[86],"2008-11","2008-09",[10169],"Rhinitis, Allergic, Seasonal",[10171,10171,10171,10134],"GSK835726",{"trials":10173,"activeCount":97},[10174],{"nctId":10175,"briefTitle":10176,"status":155,"phases":10177,"primaryCompletion":10178,"completion":10178,"start":10179,"enrollment":10180,"conditions":10181,"interventions":10183},"NCT00490204","Cetirizine Placebo Controlled Study For Perennial Allergic Rhinitis",[87],"2007-10-03","2007-07-27",239,[10182],"Rhinitis, Allergic, Perennial",[10134],{"trials":10185,"activeCount":97},[10186],{"nctId":10187,"briefTitle":10188,"status":155,"phases":10189,"primaryCompletion":8395,"completion":10190,"start":9067,"enrollment":10191,"conditions":10192,"interventions":10193},"NCT01916226","A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis",[88],"2013-10-17",682,[10147],[10194,10195,10134,10196],"FPNS","FPNS Placebo","Cetirizine Placebo",{"trials":10198,"activeCount":97},[],{"intervention":10200,"totalTrials":1517,"cells":10201},"Mencevax ACWY",{"EARLY_PHASE1":10202,"PHASE1":10204,"PHASE2":10206,"PHASE3":10218,"PHASE4":10242,"NA":10260},{"trials":10203,"activeCount":97},[],{"trials":10205,"activeCount":97},[],{"trials":10207,"activeCount":97},[10208],{"nctId":10209,"briefTitle":10210,"status":155,"phases":10211,"primaryCompletion":9737,"completion":9737,"start":10212,"enrollment":10213,"conditions":10214,"interventions":10215},"NCT00126984","Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine",[86],"2005-07",508,[992],[10216,10217,4749,10200],"Conjugated meningococcal ACWY-TT","DTPa\u002FHib containing vaccine",{"trials":10219,"activeCount":97},[10220,10232],{"nctId":10221,"briefTitle":10222,"status":155,"phases":10223,"primaryCompletion":8447,"completion":8447,"start":10224,"enrollment":10225,"conditions":10226,"interventions":10229},"NCT00136604","Response to GSK Biologicals' Tritanrix-HepB\u002FHib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m",[87],"2006-01-22",617,[10227,4704,24,30,33,10228],"Whole Cell Pertussis","Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin",[10230,10200,10231,4749],"Tritanrix-HepB\u002FHib-MenAC","Tritanrix-HepB\u002FHiberix",{"nctId":10233,"briefTitle":10234,"status":155,"phases":10235,"primaryCompletion":10236,"completion":10236,"start":10237,"enrollment":10238,"conditions":10239,"interventions":10240},"NCT01154088","Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds",[87],"2010-12-30","2010-08-27",1170,[992],[10200,10241],"GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]",{"trials":10243,"activeCount":97},[10244,10253],{"nctId":10245,"briefTitle":10246,"status":155,"phases":10247,"primaryCompletion":4791,"completion":10248,"start":10249,"enrollment":10250,"conditions":10251,"interventions":10252},"NCT00290329","Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years",[88],"2006-10-17","2006-01-14",249,[992],[10200],{"nctId":10254,"briefTitle":10255,"status":155,"phases":10256,"completion":2844,"start":2796,"enrollment":10257,"conditions":10258,"interventions":10259},"NCT00227422","Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs",[88],324,[992],[10200],{"trials":10261,"activeCount":97},[],{"intervention":10263,"totalTrials":1517,"cells":10264},"DTPa-HBV-IPV\u002FHib vaccine",{"EARLY_PHASE1":10265,"PHASE1":10267,"PHASE2":10269,"PHASE3":10281,"PHASE4":10305,"NA":10315},{"trials":10266,"activeCount":97},[],{"trials":10268,"activeCount":97},[],{"trials":10270,"activeCount":97},[10271],{"nctId":10272,"briefTitle":10273,"status":155,"phases":10274,"primaryCompletion":10275,"completion":10276,"start":10277,"enrollment":10278,"conditions":10279,"interventions":10280},"NCT00196976","Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old",[86],"2006-03-01","2006-03-03","2005-03-24",461,[992],[10216,10101,10263,8971,8292],{"trials":10282,"activeCount":97},[10283,10292,10299],{"nctId":10284,"briefTitle":10285,"status":155,"phases":10286,"primaryCompletion":10287,"completion":10287,"start":10288,"enrollment":1534,"conditions":10289,"interventions":10290},"NCT00880477","Immunogenicity and Safety of Primary and Booster Vaccination With DTPa-HBV-IPV\u002FHib Vaccine",[87],"2002-11","2001-01",[24],[10263,10101,10291],"EngerixTM-B",{"nctId":10293,"briefTitle":10294,"status":155,"phases":10295,"completion":5196,"start":4844,"enrollment":10296,"conditions":10297,"interventions":10298},"NCT00320463","Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV\u002FHib Vaccine Given in Healthy Infants",[87],415,[30,24,4702,33,3624],[10263],{"nctId":10300,"briefTitle":10301,"status":155,"phases":10302,"completion":2296,"start":749,"enrollment":9358,"conditions":10303,"interventions":10304},"NCT00316147","Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV\u002FHib Vaccine in Indian Infants at 2 Diff Vaccination Schedules",[87],[30,3624,33,4704,24,4702],[10263],{"trials":10306,"activeCount":97},[10307],{"nctId":10308,"briefTitle":10309,"status":155,"phases":10310,"primaryCompletion":8386,"completion":8386,"start":7581,"enrollment":1293,"conditions":10311,"interventions":10312},"NCT01457547","Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course",[88],[24,4702,30,3624,33,4704],[10313,10314],"DTPa-HBV-IPV\u002FHib Vaccine","DTPa-HBV-IPV-Hib vaccine",{"trials":10316,"activeCount":97},[],{"intervention":8968,"totalTrials":1517,"cells":10318},{"EARLY_PHASE1":10319,"PHASE1":10321,"PHASE2":10323,"PHASE3":10325,"PHASE4":10353,"NA":10371},{"trials":10320,"activeCount":97},[],{"trials":10322,"activeCount":97},[],{"trials":10324,"activeCount":97},[],{"trials":10326,"activeCount":97},[10327,10336,10349],{"nctId":10328,"briefTitle":10329,"status":155,"phases":10330,"primaryCompletion":8741,"completion":10331,"start":10332,"enrollment":10333,"conditions":10334,"interventions":10335},"NCT00508261","Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine",[87],"2008-10-27","2007-08-01",793,[992],[8291,8968,8971],{"nctId":10337,"briefTitle":10338,"status":155,"phases":10339,"primaryCompletion":10340,"completion":10341,"start":9452,"enrollment":10342,"conditions":10343,"interventions":10344},"NCT01144663","Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV\u002FHib Vaccines",[87],"2012-06-22","2013-09-10",2095,[992,5046],[10345,10346,10347,8968,10348],"Nimenrix™","Menjugate®","NeisVac-CTM","Synflorix™",{"nctId":8960,"briefTitle":8961,"status":155,"phases":10350,"primaryCompletion":8963,"completion":3551,"start":2383,"enrollment":4771,"conditions":10351,"interventions":10352},[87],[4704,4703],[8966,8967,8968,4808,8969,8970,8971],{"trials":10354,"activeCount":97},[10355,10363],{"nctId":10356,"briefTitle":10357,"status":155,"phases":10358,"primaryCompletion":10359,"completion":10359,"start":10360,"enrollment":4175,"conditions":10361,"interventions":10362},"NCT00611559","Study of a New Formulation of DTPa-HBV-IPV\u002FHib Vaccine Administered as a Booster Dose to 18-23 Months Old Children",[88],"2008-06-25","2008-02-14",[4702,3624,33,30,24],[8967,8968],{"nctId":10364,"briefTitle":10365,"status":155,"phases":10366,"primaryCompletion":10367,"completion":10367,"start":10368,"enrollment":9358,"conditions":10369,"interventions":10370},"NCT00753649","Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants",[88],"2013-03-12","2008-09-23",[24,33,4702,30,4704,3624],[8968],{"trials":10372,"activeCount":97},[],{"intervention":4884,"totalTrials":1517,"cells":10374},{"EARLY_PHASE1":10375,"PHASE1":10377,"PHASE2":10398,"PHASE3":10400,"PHASE4":10410,"NA":10420},{"trials":10376,"activeCount":97},[],{"trials":10378,"activeCount":97},[10379,10391],{"nctId":10380,"briefTitle":10381,"status":155,"phases":10382,"primaryCompletion":10383,"completion":10383,"start":10384,"enrollment":2045,"conditions":10385,"interventions":10387},"NCT00411190","Study To Determine The Effects Of Doses Of Relacatib On The Metabolism Of Acetaminophen, Ibuprofen And Atorvastatin",[85],"2006-12-15","2006-10-19",[10386],"Osteoarthritis",[10388,10389,4884,10390],"Relacatib","Acetaminophen","Atorvastatin",{"nctId":10392,"briefTitle":10393,"status":155,"phases":10394,"start":10395,"enrollment":710,"conditions":10396,"interventions":10397},"NCT00372801","Effectiveness Of Single Doses Of Ibuprofen In Patients With Osteoarthritis Of The Knee",[85],"2005-08",[10386],[4884],{"trials":10399,"activeCount":97},[],{"trials":10401,"activeCount":97},[10402],{"nctId":10403,"briefTitle":10404,"status":145,"phases":10405,"primaryCompletion":10406,"completion":10406,"start":3283,"enrollment":10407,"conditions":10408,"interventions":10409},"NCT01842633","Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache",[87],"2015-03-31",365,[9153],[9247,4884],{"trials":10411,"activeCount":97},[10412,10416],{"nctId":9230,"briefTitle":9231,"status":155,"phases":10413,"primaryCompletion":8037,"completion":8037,"start":9233,"enrollment":695,"conditions":10414,"interventions":10415},[88],[9235],[4884,4763],{"nctId":4874,"briefTitle":4875,"status":155,"phases":10417,"primaryCompletion":4877,"completion":4878,"start":4879,"enrollment":4880,"conditions":10418,"interventions":10419},[88],[3637],[4883,4472,4821,4884,4763],{"trials":10421,"activeCount":97},[],{"intervention":8130,"totalTrials":1517,"cells":10423},{"EARLY_PHASE1":10424,"PHASE1":10426,"PHASE2":10434,"PHASE3":10451,"PHASE4":10457,"NA":10468},{"trials":10425,"activeCount":97},[],{"trials":10427,"activeCount":97},[10428],{"nctId":10429,"briefTitle":10430,"status":155,"phases":10431,"start":1360,"enrollment":2045,"conditions":10432,"interventions":10433},"NCT00269061","Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin",[85],[9079],[8130],{"trials":10435,"activeCount":97},[10436,10443],{"nctId":10437,"briefTitle":10438,"status":155,"phases":10439,"primaryCompletion":10360,"completion":10360,"start":3620,"enrollment":10440,"conditions":10441,"interventions":10442},"NCT00500331","Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)",[86],334,[27],[9030,8130],{"nctId":10444,"briefTitle":10445,"status":155,"phases":10446,"primaryCompletion":4756,"completion":4756,"start":8427,"enrollment":5656,"conditions":10447,"interventions":10448},"NCT00196989","Study In People With Type 2 Diabetes",[86],[27],[10449,10450],"Pioglitazone","GW677954",{"trials":10452,"activeCount":97},[10453],{"nctId":8122,"briefTitle":8123,"status":155,"phases":10454,"primaryCompletion":2427,"completion":484,"start":8116,"enrollment":8125,"conditions":10455,"interventions":10456},[87],[27],[7997,8128,8129,8130],{"trials":10458,"activeCount":97},[10459],{"nctId":10460,"briefTitle":10461,"status":145,"phases":10462,"primaryCompletion":10463,"completion":10463,"start":2795,"enrollment":10464,"conditions":10465,"interventions":10466},"NCT00879970","Thiazolidinedione Intervention With Vitamin D Evaluation",[88],"2010-11",1332,[27],[8130,10467],"rosiglitazone",{"trials":10469,"activeCount":97},[],{"intervention":10471,"totalTrials":1517,"cells":10472},"Engerix™-B Kinder",{"EARLY_PHASE1":10473,"PHASE1":10475,"PHASE2":10477,"PHASE3":10479,"PHASE4":10481,"NA":10523},{"trials":10474,"activeCount":97},[],{"trials":10476,"activeCount":97},[],{"trials":10478,"activeCount":97},[],{"trials":10480,"activeCount":97},[],{"trials":10482,"activeCount":97},[10483,10492,10500,10508,10514],{"nctId":10484,"briefTitle":10485,"status":155,"phases":10486,"primaryCompletion":10487,"completion":10487,"start":10488,"enrollment":10489,"conditions":10490,"interventions":10491},"NCT02052661","This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa",[88],"2014-09-23","2014-02-18",301,[24],[10471],{"nctId":10493,"briefTitle":10494,"status":155,"phases":10495,"primaryCompletion":10496,"completion":10496,"start":6317,"enrollment":10497,"conditions":10498,"interventions":10499},"NCT00984139","Persistence of Immunity Against Hepatitis B in 12-13 Year Old Adolescents After Infant Hepatitis B Vaccination",[88],"2010-04-07",306,[24],[10471],{"nctId":10501,"briefTitle":10502,"status":155,"phases":10503,"primaryCompletion":10504,"completion":10504,"start":10505,"enrollment":10489,"conditions":10506,"interventions":10507},"NCT00519649","Long-term Persistence of Immunity Against Hepatitis B in 7-8 Years Old Children After Hepatitis B Vaccination.",[88],"2007-12-31","2007-08-31",[8985],[10471],{"nctId":10509,"briefTitle":10510,"status":155,"phases":10511,"primaryCompletion":2835,"completion":2835,"start":7659,"enrollment":10489,"conditions":10512,"interventions":10513},"NCT00411697","Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B Vaccine Challenge",[88],[24],[10471],{"nctId":10515,"briefTitle":10516,"status":155,"phases":10517,"primaryCompletion":10518,"completion":10518,"start":10519,"enrollment":10520,"conditions":10521,"interventions":10522},"NCT01847430","Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder",[88],"2014-02-21","2013-07-19",303,[24],[10471],{"trials":10524,"activeCount":97},[],{"intervention":10526,"totalTrials":1517,"cells":10527},"Havrix®",{"EARLY_PHASE1":10528,"PHASE1":10530,"PHASE2":10532,"PHASE3":10560,"PHASE4":10585,"NA":10595},{"trials":10529,"activeCount":97},[],{"trials":10531,"activeCount":97},[],{"trials":10533,"activeCount":97},[10534,10548],{"nctId":10535,"briefTitle":10536,"status":155,"phases":10537,"primaryCompletion":10538,"completion":10539,"start":10540,"enrollment":10541,"conditions":10542,"interventions":10543},"NCT00861744","Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age",[86],"2010-07-21","2012-06-18","2009-06-03",1259,[2484,2485,2486,8671],[10544,10545,10546,10526,10547],"GSK Biological's investigational vaccine 209762","M-M-R® II","Varivax®","Prevnar®",{"nctId":10549,"briefTitle":10550,"status":155,"phases":10551,"primaryCompletion":10552,"completion":10553,"start":10554,"enrollment":10555,"conditions":10556,"interventions":10557},"NCT00578175","Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age",[86],"2009-02-24","2009-03-17","2007-11-20",1851,[3717,2484,2485,2486],[10558,10559,10526,10547],"Priorix-Tetra™","ProQuad®",{"trials":10561,"activeCount":97},[10562,10574],{"nctId":10563,"briefTitle":10564,"status":155,"phases":10565,"primaryCompletion":10566,"completion":10566,"start":8825,"enrollment":1944,"conditions":10567,"interventions":10568},"NCT01978093","Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age",[87],"2016-03-18",[4703,4704],[10569,10570,10571,10572,10573,10526],"Hib-MenCY-TT","Pediarix®","Rotarix®","Prevnar 13®","PedvaxHIB®",{"nctId":10575,"briefTitle":10576,"status":155,"phases":10577,"primaryCompletion":10578,"completion":10578,"start":10579,"enrollment":10580,"conditions":10581,"interventions":10582},"NCT00197015","Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles\u002FMumps\u002FRubella & a Varicella Vaccine in Children",[87],"2009-06-09","2003-10-06",1474,[7966],[10526,10583,10584],"M-M-R®II","VARIVAX®",{"trials":10586,"activeCount":97},[10587],{"nctId":10588,"briefTitle":10589,"status":500,"phases":10590,"primaryCompletion":10591,"completion":10591,"start":10592,"enrollment":97,"conditions":10593,"interventions":10594},"NCT03183492","Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel",[88],"2019-01-28","2018-05-07",[7966],[10526],{"trials":10596,"activeCount":97},[],{"intervention":4821,"totalTrials":1517,"cells":10598},{"EARLY_PHASE1":10599,"PHASE1":10601,"PHASE2":10603,"PHASE3":10605,"PHASE4":10636,"NA":10642},{"trials":10600,"activeCount":97},[],{"trials":10602,"activeCount":97},[],{"trials":10604,"activeCount":97},[],{"trials":10606,"activeCount":97},[10607,10616,10624,10628],{"nctId":10608,"briefTitle":10609,"status":155,"phases":10610,"primaryCompletion":2280,"completion":10611,"start":10612,"enrollment":10613,"conditions":10614,"interventions":10615},"NCT02858440","A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV\u002FHib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia",[87],"2018-11-13","2016-09-13",235,[30,33,10087,24,4704],[4821],{"nctId":10617,"briefTitle":10618,"status":500,"phases":10619,"primaryCompletion":10620,"completion":10620,"start":10621,"enrollment":97,"conditions":10622,"interventions":10623},"NCT03128489","Evaluation of Immunogenicity and Safety of DTPa-IPV\u002FHib Conjugate Vaccine (Infanrix™-IPV\u002FHib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants",[87],"2018-08-01","2017-12-01",[30,3624,4704,33,4702],[4821],{"nctId":4813,"briefTitle":4814,"status":155,"phases":10625,"primaryCompletion":4816,"completion":4816,"start":4817,"enrollment":4818,"conditions":10626,"interventions":10627},[87],[3637],[4744,4472,4821,4762],{"nctId":10629,"briefTitle":10630,"status":155,"phases":10631,"primaryCompletion":10632,"completion":10632,"start":10633,"enrollment":4086,"conditions":10634,"interventions":10635},"NCT01119625","Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose",[87],"2011-02-17","2010-07-12",[3637],[3639,4821],{"trials":10637,"activeCount":97},[10638],{"nctId":4874,"briefTitle":4875,"status":155,"phases":10639,"primaryCompletion":4877,"completion":4878,"start":4879,"enrollment":4880,"conditions":10640,"interventions":10641},[88],[3637],[4883,4472,4821,4884,4763],{"trials":10643,"activeCount":97},[],{"intervention":10645,"totalTrials":181,"cells":10646},"abacavir\u002Flamivudine",{"EARLY_PHASE1":10647,"PHASE1":10649,"PHASE2":10651,"PHASE3":10653,"PHASE4":10688,"NA":10697},{"trials":10648,"activeCount":97},[],{"trials":10650,"activeCount":97},[],{"trials":10652,"activeCount":97},[],{"trials":10654,"activeCount":97},[10655,10666,10681],{"nctId":10656,"briefTitle":10657,"status":155,"phases":10658,"primaryCompletion":8478,"completion":8478,"start":10659,"enrollment":10660,"conditions":10661,"interventions":10663},"NCT00053638","A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy",[87],"2003-02",345,[10662],"HIV Infection",[10664,10665,10645],"efavirenz","tenofovir",{"nctId":10667,"briefTitle":10668,"status":155,"phases":10669,"start":10670,"enrollment":10671,"conditions":10672,"interventions":10673},"NCT00085943","KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks",[87],"2004-05",866,[10662,9343],[10674,10675,10676,10677,10678,10679,10680],"LEXIVA","Ritonavir","KALETRA","EPIVIR","Ziagen","Abacavir\u002FLamivudine","Fosamprenavir",{"nctId":10682,"briefTitle":10683,"status":155,"phases":10684,"primaryCompletion":2805,"completion":2805,"start":3714,"enrollment":10685,"conditions":10686,"interventions":10687},"NCT00094367","A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)",[87],900,[10662],[10679],{"trials":10689,"activeCount":97},[10690],{"nctId":10691,"briefTitle":10692,"status":155,"phases":10693,"primaryCompletion":2355,"completion":2355,"start":10212,"enrollment":7702,"conditions":10694,"interventions":10695},"NCT00244712","Abacavir\u002FLamivudine Versus Emtricitabine\u002FTenofovir Both In Combination With Lopinavir\u002FRitonavir For The Treatment Of HIV",[88],[10662],[10696,10645],"emtricitabine\u002Ftenofovir",{"trials":10698,"activeCount":97},[],{"intervention":10700,"totalTrials":181,"cells":10701},"Hepatitis B vaccine",{"EARLY_PHASE1":10702,"PHASE1":10704,"PHASE2":10706,"PHASE3":10708,"PHASE4":10710,"NA":10739},{"trials":10703,"activeCount":97},[],{"trials":10705,"activeCount":97},[],{"trials":10707,"activeCount":97},[],{"trials":10709,"activeCount":97},[],{"trials":10711,"activeCount":97},[10712,10719,10726,10732],{"nctId":10713,"briefTitle":10714,"status":155,"phases":10715,"primaryCompletion":749,"completion":749,"start":2814,"enrollment":10716,"conditions":10717,"interventions":10718},"NCT00197158","Comparison of Monodose and Multidose Presentations of GSK Biologicals' Hepatitis B Vaccine in Terms of Immune Response",[88],280,[24],[10700],{"nctId":10720,"briefTitle":10721,"status":155,"phases":10722,"completion":4843,"start":8852,"enrollment":536,"conditions":10723,"interventions":10724},"NCT00335881","Persistence of the Immune Response to Hepatitis B in 4-6 Years Old Children Previously Vaccinated With DTPa-HBV-IPV\u002FHib",[88],[24],[10725],"hepatitis B vaccine",{"nctId":10727,"briefTitle":10728,"status":155,"phases":10729,"completion":7659,"start":8963,"enrollment":603,"conditions":10730,"interventions":10731},"NCT00356564","Persistence of the Immune Response to Hepatitis B in 7-9 Years Old Children Previously Vaccinated With DTPa-HBV-IPV\u002FHib",[88],[24],[10725],{"nctId":10733,"briefTitle":10734,"status":155,"phases":10735,"completion":2296,"start":2383,"enrollment":10736,"conditions":10737,"interventions":10738},"NCT00329576","Evaluate Immune Response Approximately 5 to 6 Years After Receiving Different Formulations of GSK Bio Hep B Vaccine",[88],632,[24],[10700],{"trials":10740,"activeCount":97},[],{"intervention":9434,"totalTrials":181,"cells":10742},{"EARLY_PHASE1":10743,"PHASE1":10745,"PHASE2":10747,"PHASE3":10749,"PHASE4":10751,"NA":10769},{"trials":10744,"activeCount":97},[],{"trials":10746,"activeCount":97},[],{"trials":10748,"activeCount":97},[],{"trials":10750,"activeCount":97},[],{"trials":10752,"activeCount":97},[10753,10757,10761,10765],{"nctId":9428,"briefTitle":9429,"status":155,"phases":10754,"primaryCompletion":3552,"completion":3552,"start":1361,"enrollment":9431,"conditions":10755,"interventions":10756},[88],[15],[9434,9370],{"nctId":9442,"briefTitle":9443,"status":145,"phases":10758,"primaryCompletion":2428,"completion":2428,"start":7659,"enrollment":9445,"conditions":10759,"interventions":10760},[88],[15],[9370,9434],{"nctId":9449,"briefTitle":9450,"status":155,"phases":10762,"primaryCompletion":9452,"completion":9452,"start":9453,"enrollment":9454,"conditions":10763,"interventions":10764},[88],[15],[9457,9370],{"nctId":9468,"briefTitle":9469,"status":155,"phases":10766,"primaryCompletion":7659,"completion":7659,"start":8478,"enrollment":9471,"conditions":10767,"interventions":10768},[88],[15],[9370,9434],{"trials":10770,"activeCount":97},[],{"intervention":10772,"totalTrials":181,"cells":10773},"salmeterol 50mcg",{"EARLY_PHASE1":10774,"PHASE1":10776,"PHASE2":10778,"PHASE3":10806,"PHASE4":10808,"NA":10818},{"trials":10775,"activeCount":97},[],{"trials":10777,"activeCount":97},[],{"trials":10779,"activeCount":97},[10780,10788,10799],{"nctId":10781,"briefTitle":10782,"status":155,"phases":10783,"primaryCompletion":5196,"completion":5196,"start":4844,"enrollment":1686,"conditions":10784,"interventions":10785},"NCT00358488","Study Investigating Repeat Doses Of A New Medication (GSK159797) In Asthmatic Patients",[86],[15],[10786,10787,10772],"GSK159797","salbutamol",{"nctId":10789,"briefTitle":10790,"status":155,"phases":10791,"primaryCompletion":10792,"completion":10792,"start":10793,"enrollment":10794,"conditions":10795,"interventions":10796},"NCT00347139","Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients",[86],"2007-01-10","2006-05-23",55,[15],[10797,10798],"GW642444","Salmeterol 50mcg",{"nctId":10800,"briefTitle":10801,"status":155,"phases":10802,"primaryCompletion":2796,"completion":2796,"start":10803,"enrollment":695,"conditions":10804,"interventions":10805},"NCT00354874","Investigation Of A New Medication (GW642444) In Asthmatic Patients",[86],"2005-01",[18],[10797,10772],{"trials":10807,"activeCount":97},[],{"trials":10809,"activeCount":97},[10810],{"nctId":10811,"briefTitle":10812,"status":155,"phases":10813,"primaryCompletion":8406,"completion":8406,"start":7613,"enrollment":781,"conditions":10814,"interventions":10815},"NCT00358358","Chronic Obstructive Pulmonary Disease Endpoints Study",[88],[15],[10816,10817,10798],"Fluticasone Propionate\u002FSalmeterol 500\u002F50mcg combination","Fluticasone Propionate 500mcg",{"trials":10819,"activeCount":97},[],{"intervention":10821,"totalTrials":181,"cells":10822},"Tenofovir disoproxil fumarate",{"EARLY_PHASE1":10823,"PHASE1":10825,"PHASE2":10827,"PHASE3":10829,"PHASE4":10842,"NA":10869},{"trials":10824,"activeCount":97},[],{"trials":10826,"activeCount":97},[],{"trials":10828,"activeCount":97},[],{"trials":10830,"activeCount":97},[10831],{"nctId":10832,"briefTitle":10833,"status":155,"phases":10834,"primaryCompletion":10835,"completion":5207,"start":10836,"enrollment":10837,"conditions":10838,"interventions":10839},"NCT01300234","Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) 300mg in Chinese Subjects With Chronic Hepatitis B (CHB)",[87],"2012-10-17","2011-03-30",512,[24],[10840,10841],"Tenofovir disoproxil fumarate (TDF)","Adefovir dipivoxil (ADV)",{"trials":10843,"activeCount":97},[10844,10853,10862],{"nctId":10845,"briefTitle":10846,"status":155,"phases":10847,"primaryCompletion":10848,"completion":10848,"start":10849,"enrollment":10850,"conditions":10851,"interventions":10852},"NCT02224456","Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis",[88],"2020-12-04","2015-03-25",197,[4191],[10821],{"nctId":10854,"briefTitle":10855,"status":155,"phases":10856,"primaryCompletion":10857,"completion":6519,"start":10858,"enrollment":2825,"conditions":10859,"interventions":10860},"NCT03258710","A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B",[88],"2018-12-28","2017-10-02",[4191],[10861],"Tenofovir Disoproxil Fumarate",{"nctId":10863,"briefTitle":10864,"status":155,"phases":10865,"primaryCompletion":10866,"completion":10866,"start":6337,"enrollment":7131,"conditions":10867,"interventions":10868},"NCT02195518","Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study",[88],"2018-08-14",[4191],[10821],{"trials":10870,"activeCount":97},[],{"intervention":10872,"totalTrials":181,"cells":10873},"Paroxetine CR",{"EARLY_PHASE1":10874,"PHASE1":10876,"PHASE2":10878,"PHASE3":10880,"PHASE4":10899,"NA":10916},{"trials":10875,"activeCount":97},[],{"trials":10877,"activeCount":97},[],{"trials":10879,"activeCount":97},[],{"trials":10881,"activeCount":97},[10882,10892],{"nctId":10883,"briefTitle":10884,"status":155,"phases":10885,"primaryCompletion":10803,"completion":10803,"start":10886,"enrollment":10887,"conditions":10888,"interventions":10891},"NCT00067444","Depression Study In Elderly Patients",[87],"2003-06",560,[10889,10890],"Depressive Disorder, Major","Major Depressive Disorder (MDD)",[10872],{"nctId":10893,"briefTitle":10894,"status":155,"phases":10895,"start":7659,"enrollment":7810,"conditions":10896,"interventions":10897},"NCT00368303","A Local Register Study For Major Depression Of Paroxetine Controlled Release",[87],[10889,10890],[10872,10898],"Paroxetine IR",{"trials":10900,"activeCount":97},[10901,10908],{"nctId":10902,"briefTitle":10903,"status":500,"phases":10904,"primaryCompletion":10905,"completion":10905,"start":7634,"enrollment":97,"conditions":10906,"interventions":10907},"NCT01916200","Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients",[88],"2014-09",[9292],[10872],{"nctId":10909,"briefTitle":10910,"status":155,"phases":10911,"primaryCompletion":9462,"completion":9462,"start":7582,"enrollment":9618,"conditions":10912,"interventions":10914},"NCT00049972","Major Depressive Disorder Study In Adults",[88],[10913],"Major Depressive Disorder",[10915],"paroxetine CR",{"trials":10917,"activeCount":97},[],{"intervention":10919,"totalTrials":593,"cells":10920},"Combivir",{"EARLY_PHASE1":10921,"PHASE1":10923,"PHASE2":10934,"PHASE3":10936,"PHASE4":10949,"NA":10960},{"trials":10922,"activeCount":97},[],{"trials":10924,"activeCount":97},[10925],{"nctId":10926,"briefTitle":10927,"status":155,"phases":10928,"primaryCompletion":2427,"completion":2427,"start":8135,"enrollment":656,"conditions":10929,"interventions":10931},"NCT01597648","A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™",[85],[10930],"Infection, Human Immunodeficiency Virus I",[10932,10919,10933],"Maraviroc","GSK2838510",{"trials":10935,"activeCount":97},[],{"trials":10937,"activeCount":97},[10938],{"nctId":10939,"briefTitle":10940,"status":155,"phases":10941,"primaryCompletion":8750,"completion":8750,"start":10003,"enrollment":1237,"conditions":10942,"interventions":10944},"NCT00043888","Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR",[87],[10943],"HIV Infections",[10945,10946,10947,10948],"fosamprenavir","COMBIVIR","ritonavir","TRIZIVIR",{"trials":10950,"activeCount":97},[10951],{"nctId":10952,"briefTitle":10953,"status":155,"phases":10954,"primaryCompletion":10275,"completion":10275,"start":10955,"conditions":10956,"interventions":10957},"NCT00082394","A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV",[88],"2004-04-26",[10930,10662],[10958,10959,10919],"Trizivir","atazanavir",{"trials":10961,"activeCount":97},[],{"intervention":10963,"totalTrials":593,"cells":10964},"Rabipur",{"EARLY_PHASE1":10965,"PHASE1":10967,"PHASE2":10969,"PHASE3":10981,"PHASE4":10993,"NA":11003},{"trials":10966,"activeCount":97},[],{"trials":10968,"activeCount":97},[],{"trials":10970,"activeCount":97},[10971],{"nctId":10972,"briefTitle":10973,"status":155,"phases":10974,"primaryCompletion":10975,"completion":10976,"start":10977,"enrollment":10978,"conditions":10979,"interventions":10980},"NCT00360230","Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children",[86],"2007-08-25","2008-05-30","2006-08-30",540,[3287],[7789,10963],{"trials":10982,"activeCount":97},[10983],{"nctId":10984,"briefTitle":10985,"status":155,"phases":10986,"primaryCompletion":1541,"completion":1541,"start":10987,"enrollment":10988,"conditions":10989,"interventions":10991},"NCT02545517","A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre\u002FExposure Prophylaxis.",[87],"2015-10-05",459,[9840,10990],"Rabies",[10963,10992],"Purified Chick-Embryo Cell Rabies Vaccine",{"trials":10994,"activeCount":97},[10995],{"nctId":10996,"briefTitle":10997,"status":500,"phases":10998,"primaryCompletion":10999,"completion":10999,"start":11000,"enrollment":97,"conditions":11001,"interventions":11002},"NCT03192371","A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children",[88],"2019-05-12","2018-02-15",[9840],[10963],{"trials":11004,"activeCount":97},[],{"intervention":11006,"totalTrials":593,"cells":11007},"Eltrombopag olamine",{"EARLY_PHASE1":11008,"PHASE1":11010,"PHASE2":11023,"PHASE3":11035,"PHASE4":11037,"NA":11047},{"trials":11009,"activeCount":97},[],{"trials":11011,"activeCount":97},[11012],{"nctId":11013,"briefTitle":11014,"status":155,"phases":11015,"primaryCompletion":8804,"completion":11016,"start":11017,"enrollment":11018,"conditions":11019,"interventions":11021},"NCT00903422","Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML\u002FMDS)",[85],"2013-12-05","2009-05-14",98,[11020],"Myelodysplastic Syndrome",[11022],"eltrombopag olamine",{"trials":11024,"activeCount":97},[11025],{"nctId":11026,"briefTitle":11027,"status":155,"phases":11028,"primaryCompletion":11029,"completion":7711,"start":11030,"enrollment":11031,"conditions":11032,"interventions":11034},"NCT01147809","Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag",[86],"2015-01","2010-06",130,[11033],"Thrombocytopaenia",[11006],{"trials":11036,"activeCount":97},[],{"trials":11038,"activeCount":97},[11039],{"nctId":11040,"briefTitle":11041,"status":155,"phases":11042,"primaryCompletion":11043,"completion":11043,"start":7647,"enrollment":11044,"conditions":11045,"interventions":11046},"NCT01098487","A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)",[88],"2014-05",167,[505],[11006],{"trials":11048,"activeCount":97},[],{"intervention":8967,"totalTrials":593,"cells":11050},{"EARLY_PHASE1":11051,"PHASE1":11053,"PHASE2":11055,"PHASE3":11057,"PHASE4":11074,"NA":11080},{"trials":11052,"activeCount":97},[],{"trials":11054,"activeCount":97},[],{"trials":11056,"activeCount":97},[],{"trials":11058,"activeCount":97},[11059,11070],{"nctId":11060,"briefTitle":11061,"status":155,"phases":11062,"primaryCompletion":11063,"completion":11063,"start":8207,"enrollment":11064,"conditions":11065,"interventions":11066},"NCT00586612","Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants",[87],"2008-12-30",313,[4704,4703],[11067,8967,11068,11069],"Menitorix™","Prevenar™","Infanrix™ IPV",{"nctId":8960,"briefTitle":8961,"status":155,"phases":11071,"primaryCompletion":8963,"completion":3551,"start":2383,"enrollment":4771,"conditions":11072,"interventions":11073},[87],[4704,4703],[8966,8967,8968,4808,8969,8970,8971],{"trials":11075,"activeCount":97},[11076],{"nctId":10356,"briefTitle":10357,"status":155,"phases":11077,"primaryCompletion":10359,"completion":10359,"start":10360,"enrollment":4175,"conditions":11078,"interventions":11079},[88],[4702,3624,33,30,24],[8967,8968],{"trials":11081,"activeCount":97},[],{"intervention":11083,"totalTrials":593,"cells":11084},"rosiglitazone\u002Fmetformin",{"EARLY_PHASE1":11085,"PHASE1":11087,"PHASE2":11089,"PHASE3":11091,"PHASE4":11112,"NA":11123},{"trials":11086,"activeCount":97},[],{"trials":11088,"activeCount":97},[],{"trials":11090,"activeCount":97},[],{"trials":11092,"activeCount":97},[11093,11102],{"nctId":11094,"briefTitle":11095,"status":155,"phases":11096,"primaryCompletion":11097,"completion":11097,"start":7581,"enrollment":11098,"conditions":11099,"interventions":11100},"NCT00069836","Study Of AVANDAMET® With Or Without Insulin In Type II Diabetes Mellitus Patients. AVANDAMET® is a Registered Trademark of the GSK Group of Companies.",[87],"2004-11",272,[27],[11101],"Rosiglitazone\u002Fmetformin",{"nctId":11103,"briefTitle":11104,"status":155,"phases":11105,"primaryCompletion":11106,"completion":11107,"start":11108,"enrollment":11109,"conditions":11110,"interventions":11111},"NCT00067951","A Study To Evaluate The Safety And Efficacy Of An Investigational Diabetes Drug In Poorly Controlled Type II Diabetics",[87],"2004-11-01","2004-11-30","2003-10-17",190,[27],[11083],{"trials":11113,"activeCount":97},[11114],{"nctId":11115,"briefTitle":11116,"status":155,"phases":11117,"primaryCompletion":11118,"completion":11119,"start":11120,"enrollment":1944,"conditions":11121,"interventions":11122},"NCT00241605","AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus",[88],"2005-12-01","2005-12-16","2003-06-25",[27],[11083],{"trials":11124,"activeCount":97},[],{"intervention":10948,"totalTrials":593,"cells":11126},{"EARLY_PHASE1":11127,"PHASE1":11129,"PHASE2":11131,"PHASE3":11133,"PHASE4":11139,"NA":11155},{"trials":11128,"activeCount":97},[],{"trials":11130,"activeCount":97},[],{"trials":11132,"activeCount":97},[],{"trials":11134,"activeCount":97},[11135],{"nctId":10939,"briefTitle":10940,"status":155,"phases":11136,"primaryCompletion":8750,"completion":8750,"start":10003,"enrollment":1237,"conditions":11137,"interventions":11138},[87],[10943],[10945,10946,10947,10948],{"trials":11140,"activeCount":97},[11141,11145],{"nctId":10952,"briefTitle":10953,"status":155,"phases":11142,"primaryCompletion":10275,"completion":10275,"start":10955,"conditions":11143,"interventions":11144},[88],[10930,10662],[10958,10959,10919],{"nctId":11146,"briefTitle":11147,"status":155,"phases":11148,"primaryCompletion":8208,"completion":11149,"start":11150,"enrollment":115,"conditions":11151,"interventions":11152},"NCT00449436","Study To Evaluate Long Term Maintenance With TRIZIVIR After Boosted Protease Inhibitor (PI) Or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) In HIV-1 Infected Adults",[88],"2007-12-13","2005-01-10",[10943],[10948,11153,11154],"Non-nucleoside reverse transcriptase inhibitor","Boosted Protease Inhibitor",{"trials":11156,"activeCount":97},[],{"intervention":4811,"totalTrials":593,"cells":11158},{"EARLY_PHASE1":11159,"PHASE1":11161,"PHASE2":11163,"PHASE3":11165,"PHASE4":11180,"NA":11186},{"trials":11160,"activeCount":97},[],{"trials":11162,"activeCount":97},[],{"trials":11164,"activeCount":97},[],{"trials":11166,"activeCount":97},[11167,11176],{"nctId":11168,"briefTitle":11169,"status":155,"phases":11170,"primaryCompletion":11171,"completion":11171,"start":11172,"enrollment":1608,"conditions":11173,"interventions":11174},"NCT03621670","Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants",[87],"2024-12-27","2018-07-27",[992],[8653,4811,4805,4810,4762,8674,8675,11175],"Prevnar 20",{"nctId":4796,"briefTitle":4797,"status":155,"phases":11177,"primaryCompletion":4799,"completion":4800,"start":4801,"enrollment":4802,"conditions":11178,"interventions":11179},[87],[4702,30,4704,33,3624,24],[4472,4805,4806,4807,4808,4809,4810,4811,4762],{"trials":11181,"activeCount":97},[11182],{"nctId":4864,"briefTitle":4865,"status":155,"phases":11183,"primaryCompletion":4867,"completion":4867,"start":4868,"enrollment":4869,"conditions":11184,"interventions":11185},[88],[3624,33,4702,30,4871],[4472,4811],{"trials":11187,"activeCount":97},[],{"intervention":11189,"totalTrials":593,"cells":11190},"Measles, Mumps, Rubella and Chickenpox",{"EARLY_PHASE1":11191,"PHASE1":11193,"PHASE2":11195,"PHASE3":11197,"PHASE4":11211,"NA":11220},{"trials":11192,"activeCount":97},[],{"trials":11194,"activeCount":97},[],{"trials":11196,"activeCount":97},[],{"trials":11198,"activeCount":97},[11199,11206],{"nctId":11200,"briefTitle":11201,"status":155,"phases":11202,"completion":2844,"start":8386,"enrollment":11203,"conditions":11204,"interventions":11205},"NCT00127023","Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases",[87],944,[2485,3717,2484,2486],[11189],{"nctId":11207,"briefTitle":11201,"status":155,"phases":11208,"completion":8852,"start":2844,"conditions":11209,"interventions":11210},"NCT00127010",[87],[2486,2484,2485,3717],[11189],{"trials":11212,"activeCount":97},[11213],{"nctId":11214,"briefTitle":11215,"status":155,"phases":11216,"primaryCompletion":2844,"completion":2844,"start":8386,"enrollment":11217,"conditions":11218,"interventions":11219},"NCT00126997","Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases",[88],1439,[2485,2484,2486,3717],[11189],{"trials":11221,"activeCount":97},[],{"intervention":10291,"totalTrials":593,"cells":11223},{"EARLY_PHASE1":11224,"PHASE1":11226,"PHASE2":11228,"PHASE3":11239,"PHASE4":11245,"NA":11253},{"trials":11225,"activeCount":97},[],{"trials":11227,"activeCount":97},[],{"trials":11229,"activeCount":97},[11230],{"nctId":11231,"briefTitle":11232,"status":155,"phases":11233,"primaryCompletion":11234,"completion":10612,"start":11235,"enrollment":8861,"conditions":11236,"interventions":11237},"NCT01777295","Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System",[86],"2016-05-17","2013-02-25",[24],[11238,10291],"Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.",{"trials":11240,"activeCount":97},[11241],{"nctId":10284,"briefTitle":10285,"status":155,"phases":11242,"primaryCompletion":10287,"completion":10287,"start":10288,"enrollment":1534,"conditions":11243,"interventions":11244},[87],[24],[10263,10101,10291],{"trials":11246,"activeCount":97},[11247],{"nctId":11248,"briefTitle":11249,"status":155,"phases":11250,"primaryCompletion":11030,"completion":11030,"start":10166,"enrollment":2375,"conditions":11251,"interventions":11252},"NCT00774995","Immune Response of Healthy Subjects Who Received Neonatal Vaccination Course With Engerix™-B Vaccine.",[88],[24],[10291],{"trials":11254,"activeCount":97},[],{"intervention":11256,"totalTrials":593,"cells":11257},"Rotarix ™",{"EARLY_PHASE1":11258,"PHASE1":11260,"PHASE2":11278,"PHASE3":11280,"PHASE4":11282,"NA":11293},{"trials":11259,"activeCount":97},[],{"trials":11261,"activeCount":97},[11262,11270],{"nctId":11263,"briefTitle":11264,"status":155,"phases":11265,"primaryCompletion":11266,"completion":11266,"start":11267,"enrollment":1003,"conditions":11268,"interventions":11269},"NCT01086436","Study to Evaluate the Safety of Rotarix™ in Chinese Children",[85],"2010-04-16","2010-03-13",[4759],[11256],{"nctId":11271,"briefTitle":11272,"status":155,"phases":11273,"primaryCompletion":11274,"completion":11274,"start":11275,"enrollment":3025,"conditions":11276,"interventions":11277},"NCT01162590","Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese Adults",[85],"2010-03-31","2010-03-01",[4759],[11256],{"trials":11279,"activeCount":97},[],{"trials":11281,"activeCount":97},[],{"trials":11283,"activeCount":97},[11284],{"nctId":11285,"briefTitle":11286,"status":155,"phases":11287,"primaryCompletion":11288,"completion":11288,"start":11289,"enrollment":11290,"conditions":11291,"interventions":11292},"NCT00969228","Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants",[88],"2010-07-23","2009-08-25",684,[4759,5000],[11256],{"trials":11294,"activeCount":97},[],{"intervention":9656,"totalTrials":593,"cells":11296},{"EARLY_PHASE1":11297,"PHASE1":11299,"PHASE2":11309,"PHASE3":11319,"PHASE4":11321,"NA":11327},{"trials":11298,"activeCount":97},[],{"trials":11300,"activeCount":97},[11301],{"nctId":11302,"briefTitle":11303,"status":155,"phases":11304,"primaryCompletion":11305,"completion":11305,"start":6501,"enrollment":1003,"conditions":11306,"interventions":11307},"NCT03287310","First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma",[85],"2019-07-31",[18],[795,11308],"Salbutamol\u002Falbuterol",{"trials":11310,"activeCount":97},[11311],{"nctId":11312,"briefTitle":11313,"status":155,"phases":11314,"primaryCompletion":3390,"completion":3390,"start":11315,"enrollment":603,"conditions":11316,"interventions":11317},"NCT01641692","A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma",[86],"2012-05",[18],[11318,9656],"GSK573719 Active treatment or Placebo",{"trials":11320,"activeCount":97},[],{"trials":11322,"activeCount":97},[11323],{"nctId":9650,"briefTitle":9651,"status":500,"phases":11324,"primaryCompletion":9653,"completion":9653,"start":4867,"enrollment":97,"conditions":11325,"interventions":11326},[88],[18],[9546,8532,9656],{"trials":11328,"activeCount":97},[],{"intervention":9362,"totalTrials":593,"cells":11330},{"EARLY_PHASE1":11331,"PHASE1":11333,"PHASE2":11351,"PHASE3":11353,"PHASE4":11355,"NA":11361},{"trials":11332,"activeCount":97},[],{"trials":11334,"activeCount":97},[11335,11341],{"nctId":11336,"briefTitle":11337,"status":155,"phases":11338,"primaryCompletion":2804,"completion":2804,"start":748,"enrollment":93,"conditions":11339,"interventions":11340},"NCT00424697","A Study to Investigate the Effects of GW876008 on Brain Activation During Emotional Processing in Healthy Subjects.",[85],[7524],[9362,9302],{"nctId":11342,"briefTitle":11343,"status":145,"phases":11344,"primaryCompletion":10212,"completion":10212,"start":10212,"enrollment":10794,"conditions":11345,"interventions":11347},"NCT00364429","SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia",[85],[11346],"Schizophrenia",[11348,11349,11350],"[123]I-CNS 1261","Lorazepam","Risperidone",{"trials":11352,"activeCount":97},[],{"trials":11354,"activeCount":97},[],{"trials":11356,"activeCount":97},[11357],{"nctId":9355,"briefTitle":9356,"status":155,"phases":11358,"start":2823,"enrollment":9358,"conditions":11359,"interventions":11360},[88],[9360],[9301,9362,9363,9364,9365,9366],{"trials":11362,"activeCount":97},[],{"intervention":10194,"totalTrials":593,"cells":11364},{"EARLY_PHASE1":11365,"PHASE1":11367,"PHASE2":11369,"PHASE3":11371,"PHASE4":11373,"NA":11393},{"trials":11366,"activeCount":97},[],{"trials":11368,"activeCount":97},[],{"trials":11370,"activeCount":97},[],{"trials":11372,"activeCount":97},[],{"trials":11374,"activeCount":97},[11375,11383,11389],{"nctId":11376,"briefTitle":11377,"status":155,"phases":11378,"primaryCompletion":3079,"completion":3079,"start":2336,"enrollment":11379,"conditions":11380,"interventions":11381},"NCT00539006","Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS",[88],377,[10182],[10194,11382],"FFNS",{"nctId":11384,"briefTitle":11385,"status":155,"phases":11386,"primaryCompletion":3079,"completion":3079,"start":2336,"enrollment":3635,"conditions":11387,"interventions":11388},"NCT00519636","Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS",[88],[10182],[10194,11382],{"nctId":10187,"briefTitle":10188,"status":155,"phases":11390,"primaryCompletion":8395,"completion":10190,"start":9067,"enrollment":10191,"conditions":11391,"interventions":11392},[88],[10147],[10194,10195,10134,10196],{"trials":11394,"activeCount":97},[],{"intervention":11382,"totalTrials":593,"cells":11396},{"EARLY_PHASE1":11397,"PHASE1":11399,"PHASE2":11401,"PHASE3":11403,"PHASE4":11405,"NA":11425},{"trials":11398,"activeCount":97},[],{"trials":11400,"activeCount":97},[],{"trials":11402,"activeCount":97},[],{"trials":11404,"activeCount":97},[],{"trials":11406,"activeCount":97},[11407,11411,11415],{"nctId":11376,"briefTitle":11377,"status":155,"phases":11408,"primaryCompletion":3079,"completion":3079,"start":2336,"enrollment":11379,"conditions":11409,"interventions":11410},[88],[10182],[10194,11382],{"nctId":11384,"briefTitle":11385,"status":155,"phases":11412,"primaryCompletion":3079,"completion":3079,"start":2336,"enrollment":3635,"conditions":11413,"interventions":11414},[88],[10182],[10194,11382],{"nctId":11416,"briefTitle":11417,"status":155,"phases":11418,"primaryCompletion":11419,"completion":11419,"start":11420,"enrollment":11421,"conditions":11422,"interventions":11424},"NCT02424539","A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)",[88],"2017-10-25","2015-09-30",358,[10147,11423],"Rhinitis, Allergic",[11382],{"trials":11426,"activeCount":97},[],{"intervention":9247,"totalTrials":593,"cells":11428},{"EARLY_PHASE1":11429,"PHASE1":11431,"PHASE2":11433,"PHASE3":11435,"PHASE4":11441,"NA":11451},{"trials":11430,"activeCount":97},[],{"trials":11432,"activeCount":97},[],{"trials":11434,"activeCount":97},[],{"trials":11436,"activeCount":97},[11437],{"nctId":10403,"briefTitle":10404,"status":145,"phases":11438,"primaryCompletion":10406,"completion":10406,"start":3283,"enrollment":10407,"conditions":11439,"interventions":11440},[87],[9153],[9247,4884],{"trials":11442,"activeCount":97},[11443,11447],{"nctId":9213,"briefTitle":9214,"status":145,"phases":11444,"primaryCompletion":3310,"completion":3310,"start":9216,"enrollment":1279,"conditions":11445,"interventions":11446},[88],[9153],[9219,4763],{"nctId":9242,"briefTitle":9243,"status":155,"phases":11448,"primaryCompletion":7598,"completion":7598,"start":729,"enrollment":1264,"conditions":11449,"interventions":11450},[88],[9183],[9247,4763],{"trials":11452,"activeCount":97},[],{"intervention":10572,"totalTrials":593,"cells":11454},{"EARLY_PHASE1":11455,"PHASE1":11457,"PHASE2":11459,"PHASE3":11471,"PHASE4":11477,"NA":11491},{"trials":11456,"activeCount":97},[],{"trials":11458,"activeCount":97},[],{"trials":11460,"activeCount":97},[11461],{"nctId":11462,"briefTitle":11463,"status":155,"phases":11464,"primaryCompletion":11465,"completion":11465,"start":11466,"enrollment":11467,"conditions":11468,"interventions":11469},"NCT01545375","Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children",[86],"2016-07-26","2012-05-21",1806,[3637],[11470,10572,10573],"Pneumococcal vaccine GSK2189242A",{"trials":11472,"activeCount":97},[11473],{"nctId":10563,"briefTitle":10564,"status":155,"phases":11474,"primaryCompletion":10566,"completion":10566,"start":8825,"enrollment":1944,"conditions":11475,"interventions":11476},[87],[4703,4704],[10569,10570,10571,10572,10573,10526],{"trials":11478,"activeCount":97},[11479],{"nctId":11480,"briefTitle":11481,"status":155,"phases":11482,"primaryCompletion":11483,"completion":11483,"start":11484,"enrollment":2922,"conditions":11485,"interventions":11487},"NCT02072525","A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays",[88],"2015-06-02","2014-04-01",[11486],"Meningococcal",[11488,11489,11490,10572],"Menveo®","Boostrix®","Pneumovax 23®",{"trials":11492,"activeCount":97},[],{"intervention":11494,"totalTrials":593,"cells":11495},"alosetron",{"EARLY_PHASE1":11496,"PHASE1":11498,"PHASE2":11500,"PHASE3":11502,"PHASE4":11520,"NA":11528},{"trials":11497,"activeCount":97},[],{"trials":11499,"activeCount":97},[],{"trials":11501,"activeCount":97},[],{"trials":11503,"activeCount":97},[11504,11513],{"nctId":11505,"briefTitle":11506,"status":155,"phases":11507,"primaryCompletion":749,"completion":749,"start":10886,"enrollment":11508,"conditions":11509,"interventions":11512},"NCT00067457","Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy",[87],700,[11510,11511],"Irritable Colon","Irritable Bowel Syndrome (IBS)",[11494],{"nctId":11514,"briefTitle":11515,"status":155,"phases":11516,"primaryCompletion":10803,"completion":10803,"start":10886,"enrollment":10098,"conditions":11517,"interventions":11518},"NCT00067561","Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy",[87],[11510,11511],[11519],"Alosetron",{"trials":11521,"activeCount":97},[11522],{"nctId":11523,"briefTitle":11524,"status":155,"phases":11525,"primaryCompletion":2804,"completion":2804,"start":7659,"enrollment":2375,"conditions":11526,"interventions":11527},"NCT00370032","Study to Assess the Effect Of Alosetron On Mucosal Blood Flow",[88],[11510],[11494],{"trials":11529,"activeCount":97},[],{"intervention":8165,"totalTrials":593,"cells":11531},{"EARLY_PHASE1":11532,"PHASE1":11534,"PHASE2":11550,"PHASE3":11552,"PHASE4":11554,"NA":11560},{"trials":11533,"activeCount":97},[],{"trials":11535,"activeCount":97},[11536,11543],{"nctId":11537,"briefTitle":11538,"status":155,"phases":11539,"primaryCompletion":1874,"completion":1874,"start":11540,"enrollment":750,"conditions":11541,"interventions":11542},"NCT01857895","Feasibility Study of Exenatide by Continuous Subcutaneous Infusion",[85],"2013-05-16",[9048],[8165],{"nctId":11544,"briefTitle":11545,"status":155,"phases":11546,"start":2805,"enrollment":255,"conditions":11547,"interventions":11548},"NCT00259896","In-patient Study in Patients With Type 2 Diabetes Mellitus",[85],[9036,27],[11549],"exenatide",{"trials":11551,"activeCount":97},[],{"trials":11553,"activeCount":97},[],{"trials":11555,"activeCount":97},[11556],{"nctId":8158,"briefTitle":8159,"status":145,"phases":11557,"primaryCompletion":8161,"completion":8161,"start":8162,"enrollment":181,"conditions":11558,"interventions":11559},[88],[27],[8165,8021],{"trials":11561,"activeCount":97},[],{"intervention":11563,"totalTrials":593,"cells":11564},"FP 100mcg",{"EARLY_PHASE1":11565,"PHASE1":11567,"PHASE2":11569,"PHASE3":11571,"PHASE4":11582,"NA":11603},{"trials":11566,"activeCount":97},[],{"trials":11568,"activeCount":97},[],{"trials":11570,"activeCount":97},[],{"trials":11572,"activeCount":97},[11573],{"nctId":11574,"briefTitle":11575,"status":155,"phases":11576,"primaryCompletion":2405,"completion":2405,"start":11577,"enrollment":11578,"conditions":11579,"interventions":11580},"NCT00920959","Advair Pediatric Once-Daily",[87],"2001-11",908,[18],[11563,11581],"FSC 100\u002F50mcg",{"trials":11583,"activeCount":97},[11584,11595],{"nctId":11585,"briefTitle":11586,"status":155,"phases":11587,"primaryCompletion":8478,"completion":8478,"start":10659,"enrollment":11588,"conditions":11589,"interventions":11590},"NCT00920543","GSK BHR Study (Sont)",[88],464,[18],[11563,11591,11592,11581,11593,11594],"FP 500mcg","FP 250mcg","FSC 250\u002F50mcg","FSC 500\u002F50mcg",{"nctId":11596,"briefTitle":11597,"status":155,"phases":11598,"primaryCompletion":8478,"completion":8478,"start":11599,"enrollment":9569,"conditions":11600,"interventions":11601},"NCT01324362","GSK BHR Study (Sont - Second Study)",[88],"2003-01",[18],[11563,11592,11591,11581,11593,11602],"FSC500\u002F50mcg",{"trials":11604,"activeCount":97},[],{"intervention":11581,"totalTrials":593,"cells":11606},{"EARLY_PHASE1":11607,"PHASE1":11609,"PHASE2":11611,"PHASE3":11613,"PHASE4":11619,"NA":11629},{"trials":11608,"activeCount":97},[],{"trials":11610,"activeCount":97},[],{"trials":11612,"activeCount":97},[],{"trials":11614,"activeCount":97},[11615],{"nctId":11574,"briefTitle":11575,"status":155,"phases":11616,"primaryCompletion":2405,"completion":2405,"start":11577,"enrollment":11578,"conditions":11617,"interventions":11618},[87],[18],[11563,11581],{"trials":11620,"activeCount":97},[11621,11625],{"nctId":11585,"briefTitle":11586,"status":155,"phases":11622,"primaryCompletion":8478,"completion":8478,"start":10659,"enrollment":11588,"conditions":11623,"interventions":11624},[88],[18],[11563,11591,11592,11581,11593,11594],{"nctId":11596,"briefTitle":11597,"status":155,"phases":11626,"primaryCompletion":8478,"completion":8478,"start":11599,"enrollment":9569,"conditions":11627,"interventions":11628},[88],[18],[11563,11592,11591,11581,11593,11602],{"trials":11630,"activeCount":97},[],{"intervention":8622,"totalTrials":593,"cells":11632},{"EARLY_PHASE1":11633,"PHASE1":11635,"PHASE2":11637,"PHASE3":11639,"PHASE4":11662,"NA":11668},{"trials":11634,"activeCount":97},[],{"trials":11636,"activeCount":97},[],{"trials":11638,"activeCount":97},[],{"trials":11640,"activeCount":97},[11641,11652],{"nctId":11642,"briefTitle":11643,"status":155,"phases":11644,"primaryCompletion":11645,"completion":11645,"start":11646,"enrollment":11647,"conditions":11648,"interventions":11649},"NCT02257385","Comparative Study of Umeclidinium\u002FVilanterol (UMEC\u002FVI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium",[87],"2015-05-04","2014-10-15",967,[15],[8622,2934,11650,11651],"Indacaterol","Albuterol\u002Fsalbutamol Metered Dose Inhaler",{"nctId":11653,"briefTitle":11654,"status":155,"phases":11655,"primaryCompletion":11656,"completion":11657,"start":11658,"enrollment":11659,"conditions":11660,"interventions":11661},"NCT02152605","A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium\u002FVilanterol (UMEC\u002FVI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2015-03-01","2015-03-05","2014-09-01",498,[15],[8622],{"trials":11663,"activeCount":97},[11664],{"nctId":8614,"briefTitle":8615,"status":155,"phases":11665,"primaryCompletion":8617,"completion":8617,"start":8618,"enrollment":8619,"conditions":11666,"interventions":11667},[88],[15],[8622,8623,2916],{"trials":11669,"activeCount":97},[],{"intervention":5037,"totalTrials":593,"cells":11671},{"EARLY_PHASE1":11672,"PHASE1":11674,"PHASE2":11676,"PHASE3":11678,"PHASE4":11684,"NA":11694},{"trials":11673,"activeCount":97},[],{"trials":11675,"activeCount":97},[],{"trials":11677,"activeCount":97},[],{"trials":11679,"activeCount":97},[11680],{"nctId":5029,"briefTitle":5030,"status":155,"phases":11681,"primaryCompletion":5032,"completion":5032,"start":5033,"enrollment":5034,"conditions":11682,"interventions":11683},[87],[992],[4486,5037],{"trials":11685,"activeCount":97},[11686,11690],{"nctId":8737,"briefTitle":8738,"status":155,"phases":11687,"primaryCompletion":8740,"completion":8740,"start":8741,"enrollment":8461,"conditions":11688,"interventions":11689},[88],[7966,24],[5037,4808,4694,8744,8745],{"nctId":8758,"briefTitle":8759,"status":155,"phases":11691,"primaryCompletion":7546,"completion":7546,"start":7954,"enrollment":7131,"conditions":11692,"interventions":11693},[88],[24,7966],[5037,4808,4694,8744,8745],{"trials":11695,"activeCount":97},[],{"intervention":8632,"totalTrials":593,"cells":11697},{"EARLY_PHASE1":11698,"PHASE1":11700,"PHASE2":11719,"PHASE3":11721,"PHASE4":11723,"NA":11729},{"trials":11699,"activeCount":97},[],{"trials":11701,"activeCount":97},[11702,11710],{"nctId":11703,"briefTitle":11704,"status":155,"phases":11705,"primaryCompletion":11706,"completion":11706,"start":11707,"enrollment":361,"conditions":11708,"interventions":11709},"NCT02207452","Helium-3 MRI Imaging Study in COPD",[85],"2011-07-04","2010-08-05",[15],[963,8632],{"nctId":11711,"briefTitle":11712,"status":155,"phases":11713,"primaryCompletion":11714,"completion":11714,"start":11715,"enrollment":1634,"conditions":11716,"interventions":11717},"NCT00549120","Optimising the Propranolol Block Model",[85],"2007-10-26","2007-08-15",[15],[11718,963,8632],"Propranolol",{"trials":11720,"activeCount":97},[],{"trials":11722,"activeCount":97},[],{"trials":11724,"activeCount":97},[11725],{"nctId":8625,"briefTitle":8626,"status":155,"phases":11726,"primaryCompletion":4677,"completion":8628,"start":8629,"enrollment":904,"conditions":11727,"interventions":11728},[88],[15],[2916,8632],{"trials":11730,"activeCount":97},[],{"intervention":11732,"totalTrials":593,"cells":11733},"tiotropium bromide 18mcg",{"EARLY_PHASE1":11734,"PHASE1":11736,"PHASE2":11738,"PHASE3":11740,"PHASE4":11753,"NA":11777},{"trials":11735,"activeCount":97},[],{"trials":11737,"activeCount":97},[],{"trials":11739,"activeCount":97},[],{"trials":11741,"activeCount":97},[11742],{"nctId":11743,"briefTitle":11744,"status":155,"phases":11745,"primaryCompletion":11746,"completion":11747,"start":11748,"enrollment":11749,"conditions":11750,"interventions":11751},"NCT01627327","Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate\u002FVilanterol (FF\u002FVI) Inhalation Powder 100\u002F25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease",[87],"2012-12-01","2012-12-21","2012-04-01",623,[15],[11752,11732],"fluticasone furoate\u002Fvilanterol 100\u002F25mcg",{"trials":11754,"activeCount":97},[11755,11765],{"nctId":11756,"briefTitle":11757,"status":155,"phases":11758,"primaryCompletion":11759,"completion":11759,"start":10886,"enrollment":11760,"conditions":11761,"interventions":11762},"NCT00361959","SERETIDE 50\u002F500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease",[88],"2006-02",1270,[15],[11763,11764],"Tiotropium bromide 18mcg","Fluticasone propionate\u002F salmeterol combination 50\u002F500mcg",{"nctId":11766,"briefTitle":11767,"status":155,"phases":11768,"primaryCompletion":11769,"completion":11769,"start":3390,"enrollment":11770,"conditions":11771,"interventions":11772},"NCT01762800","Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50\u002F250mcg Twice Daily Alone or ADOAIR 50\u002F250mcg Plus Tiotropium Bromide 18mcg",[88],"2015-09",407,[15],[11773,11774,11732,11775,11776],"fluticasone propionate\u002Fsalmeterol 50\u002F250mcg","fluticasone propionate\u002Fsalmeterol placebo","tiotropium bromide placebo","fluticasone propionate\u002Fsalmeterol 50\u002F250mcg and tiotropium 18mcg",{"trials":11778,"activeCount":97},[],{"intervention":2978,"totalTrials":593,"cells":11780},{"EARLY_PHASE1":11781,"PHASE1":11783,"PHASE2":11785,"PHASE3":11787,"PHASE4":11793,"NA":11803},{"trials":11782,"activeCount":97},[],{"trials":11784,"activeCount":97},[],{"trials":11786,"activeCount":97},[],{"trials":11788,"activeCount":97},[11789],{"nctId":8558,"briefTitle":8559,"status":155,"phases":11790,"primaryCompletion":8561,"completion":8562,"start":8563,"enrollment":8564,"conditions":11791,"interventions":11792},[87],[15],[8567,8568,2916],{"trials":11794,"activeCount":97},[11795,11799],{"nctId":2971,"briefTitle":2972,"status":155,"phases":11796,"primaryCompletion":1116,"completion":1116,"start":2974,"enrollment":2975,"conditions":11797,"interventions":11798},[88],[15],[2978,2979,2895,2980],{"nctId":2982,"briefTitle":2983,"status":155,"phases":11800,"primaryCompletion":2985,"completion":2985,"start":2974,"enrollment":2986,"conditions":11801,"interventions":11802},[88],[15],[2978,2979,2895,2980],{"trials":11804,"activeCount":97},[],{"intervention":560,"totalTrials":593,"cells":11806},{"EARLY_PHASE1":11807,"PHASE1":11809,"PHASE2":11811,"PHASE3":11813,"PHASE4":11830,"NA":11836},{"trials":11808,"activeCount":97},[],{"trials":11810,"activeCount":97},[],{"trials":11812,"activeCount":97},[],{"trials":11814,"activeCount":97},[11815,11819],{"nctId":550,"briefTitle":551,"status":155,"phases":11816,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":11817,"interventions":11818},[87],[435],[53,517,559,560,560,561],{"nctId":11820,"briefTitle":11821,"status":155,"phases":11822,"primaryCompletion":11823,"completion":11823,"start":11824,"enrollment":11825,"conditions":11826,"interventions":11828},"NCT02145468","A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)",[87],"2015-12-14","2014-06-03",3503,[11827],"Acute Coronary Syndrome",[11829,560],"Losmapimod 7.5 mg twice daily",{"trials":11831,"activeCount":97},[11832],{"nctId":607,"briefTitle":608,"status":155,"phases":11833,"primaryCompletion":610,"completion":611,"start":612,"enrollment":613,"conditions":11834,"interventions":11835},[88],[435],[53,560],{"trials":11837,"activeCount":97},[],{"intervention":11839,"totalTrials":593,"cells":11840},"FP",{"EARLY_PHASE1":11841,"PHASE1":11843,"PHASE2":11845,"PHASE3":11865,"PHASE4":11867,"NA":11876},{"trials":11842,"activeCount":97},[],{"trials":11844,"activeCount":97},[],{"trials":11846,"activeCount":97},[11847,11856],{"nctId":11848,"briefTitle":11849,"status":155,"phases":11850,"primaryCompletion":9812,"completion":9812,"start":11851,"enrollment":730,"conditions":11852,"interventions":11854},"NCT01424397","Intranasal SB-705498 in Allergic Rhinitis (AR) Patients",[86],"2011-04-14",[11853],"Rhinitis",[11855,11839],"SB-705498",{"nctId":11857,"briefTitle":11858,"status":155,"phases":11859,"primaryCompletion":11860,"completion":11860,"start":11861,"enrollment":1298,"conditions":11862,"interventions":11863},"NCT00857857","A Study to Evaluate the Effect of GW870086X on Allergen Challenge in Mild Asthmatics",[86],"2009-11-03","2009-02-16",[18],[11864,11839],"GW870086X",{"trials":11866,"activeCount":97},[],{"trials":11868,"activeCount":97},[11869],{"nctId":11870,"briefTitle":11871,"status":155,"phases":11872,"primaryCompletion":5018,"completion":5018,"start":2336,"enrollment":314,"conditions":11873,"interventions":11874},"NCT00517634","Study Of Fluticasone Propionate\u002FSalmeterol In Asthmatic Subjects",[88],[18],[11839,11875],"SFC",{"trials":11877,"activeCount":97},[],{"intervention":11879,"totalTrials":593,"cells":11880},"rMenB+OMV NZ vaccine",{"EARLY_PHASE1":11881,"PHASE1":11883,"PHASE2":11885,"PHASE3":11887,"PHASE4":11911,"NA":11922},{"trials":11882,"activeCount":97},[],{"trials":11884,"activeCount":97},[],{"trials":11886,"activeCount":97},[],{"trials":11888,"activeCount":97},[11889,11899],{"nctId":11890,"briefTitle":11891,"status":155,"phases":11892,"primaryCompletion":11893,"completion":11894,"start":11895,"enrollment":5088,"conditions":11896,"interventions":11898},"NCT06995430","A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)",[87],"2025-12-08","2025-12-15","2025-07-07",[11897],"Meningitis",[11879],{"nctId":11900,"briefTitle":11901,"status":155,"phases":11902,"primaryCompletion":11903,"completion":11903,"start":6481,"enrollment":11904,"conditions":11905,"interventions":11906},"NCT04502693","Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults",[87],"2022-09-13",3657,[992],[11879,11907,11908,11909,11910],"Meningococcal Groups A, C, W and Y Conjugate Vaccine","MenABCWY-1","MenABCWY-2","MenABCWY-3",{"trials":11912,"activeCount":97},[11913],{"nctId":11914,"briefTitle":11915,"status":155,"phases":11916,"primaryCompletion":11917,"completion":11917,"start":11918,"enrollment":11919,"conditions":11920,"interventions":11921},"NCT03493919","A Sourcing Study to Collect Human Blood Samples From Healthy Adults",[88],"2022-05-27","2018-03-08",1021,[1005],[11879,11907],{"trials":11923,"activeCount":97},[],{"intervention":11925,"totalTrials":593,"cells":11926},"Boostrix TM",{"EARLY_PHASE1":11927,"PHASE1":11929,"PHASE2":11931,"PHASE3":11933,"PHASE4":11947,"NA":11965},{"trials":11928,"activeCount":97},[],{"trials":11930,"activeCount":97},[],{"trials":11932,"activeCount":97},[],{"trials":11934,"activeCount":97},[11935],{"nctId":11936,"briefTitle":11937,"status":155,"phases":11938,"primaryCompletion":11939,"completion":11940,"start":11941,"enrollment":11942,"conditions":11943,"interventions":11944},"NCT00369824","Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects",[87],"2007-11-22","2008-02-13","2006-09-26",1330,[8723],[11945,11946,11925],"Different formulations of GSK Biologicals' HPV vaccine","Menactra TM",{"trials":11948,"activeCount":97},[11949,11956],{"nctId":11950,"briefTitle":11951,"status":155,"phases":11952,"primaryCompletion":10047,"completion":10047,"start":8816,"enrollment":11953,"conditions":11954,"interventions":11955},"NCT00610168","Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.",[88],82,[3624,33,30],[11925],{"nctId":11957,"briefTitle":11958,"status":155,"phases":11959,"primaryCompletion":11960,"completion":11960,"start":11961,"enrollment":11962,"conditions":11963,"interventions":11964},"NCT01362322","Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents",[88],"2012-09-03","2011-07-01",671,[30,33,3624],[11925,11925],{"trials":11966,"activeCount":97},[],{"intervention":11968,"totalTrials":593,"cells":11969},"Paracetamol 1000 mg",{"EARLY_PHASE1":11970,"PHASE1":11972,"PHASE2":11982,"PHASE3":11984,"PHASE4":11986,"NA":12004},{"trials":11971,"activeCount":97},[],{"trials":11973,"activeCount":97},[11974],{"nctId":11975,"briefTitle":11976,"status":155,"phases":11977,"primaryCompletion":2335,"completion":2335,"start":7647,"enrollment":473,"conditions":11978,"interventions":11979},"NCT01551797","A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol Formulations.",[85],[9153],[11980,11968,11981],"Paracetamol 500 mg","Paracetamol 750 mg",{"trials":11983,"activeCount":97},[],{"trials":11985,"activeCount":97},[],{"trials":11987,"activeCount":97},[11988,11996],{"nctId":11989,"briefTitle":11990,"status":155,"phases":11991,"primaryCompletion":3078,"completion":3078,"start":11992,"enrollment":536,"conditions":11993,"interventions":11995},"NCT01082081","Post-operative Dental Pain Study Comparing Analgesic Efficacy",[88],"2009-10",[11994],"Post-surgical Dental Pain",[11968,11980],{"nctId":11997,"briefTitle":11998,"status":155,"phases":11999,"primaryCompletion":3078,"completion":3078,"start":6351,"enrollment":12000,"conditions":12001,"interventions":12002},"NCT01075243","Post-operative Dental Pain Study Comparing Two Different Dosage of Analgesic Efficacy",[88],401,[11994],[11968,12003],"Paracetamol 650 mg",{"trials":12005,"activeCount":97},[],{"intervention":12007,"totalTrials":593,"cells":12008},"Sodium fluoride toothpaste",{"EARLY_PHASE1":12009,"PHASE1":12011,"PHASE2":12013,"PHASE3":12015,"PHASE4":12035,"NA":12049},{"trials":12010,"activeCount":97},[],{"trials":12012,"activeCount":97},[],{"trials":12014,"activeCount":97},[],{"trials":12016,"activeCount":97},[12017,12028],{"nctId":12018,"briefTitle":12019,"status":155,"phases":12020,"primaryCompletion":2794,"completion":2794,"start":10166,"enrollment":2282,"conditions":12021,"interventions":12023},"NCT01005966","In Situ Caries Model of Fluoride Toothpastes",[87],[12022],"Caries",[12024,12025,12026,12027],"Sodium Fluoride Toothpaste","Amine Fluoride Toothpaste","Sodium monofluorophosphate\u002FSodium Fluoride Toothpaste","675 ppmf toothpaste",{"nctId":12029,"briefTitle":12030,"status":155,"phases":12031,"primaryCompletion":2355,"completion":2355,"start":3079,"enrollment":1237,"conditions":12032,"interventions":12034},"NCT00708123","In Situ Caries of Fluoride Toothpastes",[87],[7524,12033,12022],"Partial Denture Wearers",[12007],{"trials":12036,"activeCount":97},[12037],{"nctId":12038,"briefTitle":12039,"status":155,"phases":12040,"primaryCompletion":12041,"completion":12042,"start":12043,"enrollment":12044,"conditions":12045,"interventions":12047},"NCT02319668","Antimicrobial Agent for Reducing Bacteria in Aerosols and Oral Cavity",[88],"2015-06-01","2016-02-29","2015-02-01",38,[12046],"Dental Prophylaxis and Implant Surgery",[12048,12007],"0.2% w\u002Fv Chlorhexidine digluconate",{"trials":12050,"activeCount":97},[],{"intervention":12052,"totalTrials":593,"cells":12053},"Umeclidinium",{"EARLY_PHASE1":12054,"PHASE1":12056,"PHASE2":12058,"PHASE3":12070,"PHASE4":12081,"NA":12092},{"trials":12055,"activeCount":97},[],{"trials":12057,"activeCount":97},[],{"trials":12059,"activeCount":97},[12060],{"nctId":12061,"briefTitle":12062,"status":155,"phases":12063,"primaryCompletion":12064,"completion":12064,"start":12065,"enrollment":695,"conditions":12066,"interventions":12068},"NCT02563899","Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis",[86],"2016-02-25","2015-11-23",[12067],"Hyperhidrosis",[12052,12069],"Vehicle",{"trials":12071,"activeCount":97},[12072],{"nctId":12073,"briefTitle":12074,"status":155,"phases":12075,"primaryCompletion":12076,"completion":12077,"start":11658,"enrollment":12078,"conditions":12079,"interventions":12080},"NCT02207829","A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease",[87],"2015-05-25","2015-06-15",1017,[15],[12052,2934],{"trials":12082,"activeCount":97},[12083],{"nctId":12084,"briefTitle":12085,"status":155,"phases":12086,"primaryCompletion":11483,"completion":11483,"start":12087,"enrollment":12088,"conditions":12089,"interventions":12090},"NCT02236611","A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[88],"2014-09-26",1036,[15],[12052,12091],"Glycopyrronium",{"trials":12093,"activeCount":97},[],{"intervention":10664,"totalTrials":660,"cells":12095},{"EARLY_PHASE1":12096,"PHASE1":12098,"PHASE2":12100,"PHASE3":12102,"PHASE4":12108,"NA":12119},{"trials":12097,"activeCount":97},[],{"trials":12099,"activeCount":97},[],{"trials":12101,"activeCount":97},[],{"trials":12103,"activeCount":97},[12104],{"nctId":10656,"briefTitle":10657,"status":155,"phases":12105,"primaryCompletion":8478,"completion":8478,"start":10659,"enrollment":10660,"conditions":12106,"interventions":12107},[87],[10662],[10664,10665,10645],{"trials":12109,"activeCount":97},[12110],{"nctId":12111,"briefTitle":12112,"status":12113,"phases":12114,"start":7847,"enrollment":4388,"conditions":12115,"interventions":12116},"NCT00011895","Safety and Effectiveness of TRIZIVIR (Abacavir\u002FLamivudine\u002FZidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs","UNKNOWN",[88],[10943],[12117,12118],"Abacavir sulfate, Lamivudine and Zidovudine","Efavirenz",{"trials":12120,"activeCount":97},[],{"intervention":12122,"totalTrials":660,"cells":12123},"Alendronate",{"EARLY_PHASE1":12124,"PHASE1":12126,"PHASE2":12128,"PHASE3":12142,"PHASE4":12144,"NA":12153},{"trials":12125,"activeCount":97},[],{"trials":12127,"activeCount":97},[],{"trials":12129,"activeCount":97},[12130],{"nctId":12131,"briefTitle":12132,"status":145,"phases":12133,"primaryCompletion":12134,"completion":12134,"start":12135,"enrollment":12136,"conditions":12137,"interventions":12139},"NCT00471237","A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis.",[86],"2008-12-26","2007-05-14",564,[12138],"Osteoporosis",[12140,12141,12122],"Ronacaleret","Teriparatide",{"trials":12143,"activeCount":97},[],{"trials":12145,"activeCount":97},[12146],{"nctId":12147,"briefTitle":12148,"status":155,"phases":12149,"primaryCompletion":7659,"completion":7659,"start":7785,"enrollment":536,"conditions":12150,"interventions":12151},"NCT00327990","Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate",[88],[12138],[12152,12122],"Ibandronate",{"trials":12154,"activeCount":97},[],{"intervention":12156,"totalTrials":660,"cells":12157},"Seretide",{"EARLY_PHASE1":12158,"PHASE1":12160,"PHASE2":12162,"PHASE3":12172,"PHASE4":12174,"NA":12185},{"trials":12159,"activeCount":97},[],{"trials":12161,"activeCount":97},[],{"trials":12163,"activeCount":97},[12164],{"nctId":12165,"briefTitle":12166,"status":155,"phases":12167,"primaryCompletion":12168,"completion":12168,"start":10360,"enrollment":10497,"conditions":12169,"interventions":12170},"NCT00642148","A 12 Week Study To Assess Efficacy And Safety Of GW856553 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[86],"2009-07-27",[15],[12171,12156],"GW856553",{"trials":12173,"activeCount":97},[],{"trials":12175,"activeCount":97},[12176],{"nctId":12177,"briefTitle":12178,"status":155,"phases":12179,"primaryCompletion":12180,"completion":12180,"start":12181,"enrollment":414,"conditions":12182,"interventions":12183},"NCT00455923","SERETIDE Vs FLIXOTIDE In Mild Persistent Asthma (GINAII)",[88],"2007-07-31","2005-05-03",[18],[12156,12184],"Flixotide",{"trials":12186,"activeCount":97},[],{"intervention":12188,"totalTrials":660,"cells":12189},"Propofol",{"EARLY_PHASE1":12190,"PHASE1":12192,"PHASE2":12194,"PHASE3":12196,"PHASE4":12206,"NA":12212},{"trials":12191,"activeCount":97},[],{"trials":12193,"activeCount":97},[],{"trials":12195,"activeCount":97},[],{"trials":12197,"activeCount":97},[12198],{"nctId":12199,"briefTitle":12200,"status":145,"phases":12201,"primaryCompletion":7976,"completion":10167,"start":3079,"enrollment":12202,"conditions":12203,"interventions":12204},"NCT00436345","Pharmacoeconomic Consequences Of Analgesia in the Intensive Care Unit (ICU)",[87],39,[9161],[12205,12188],"Remifentanil",{"trials":12207,"activeCount":97},[12208],{"nctId":9355,"briefTitle":9356,"status":155,"phases":12209,"start":2823,"enrollment":9358,"conditions":12210,"interventions":12211},[88],[9360],[9301,9362,9363,9364,9365,9366],{"trials":12213,"activeCount":97},[],{"intervention":12215,"totalTrials":660,"cells":12216},"Abacavir",{"EARLY_PHASE1":12217,"PHASE1":12219,"PHASE2":12228,"PHASE3":12230,"PHASE4":12232,"NA":12240},{"trials":12218,"activeCount":97},[],{"trials":12220,"activeCount":97},[12221],{"nctId":12222,"briefTitle":12223,"status":155,"phases":12224,"start":8427,"enrollment":255,"conditions":12225,"interventions":12226},"NCT00320307","Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In HIV Infected Subjects",[85],[10662],[12227],"abacavir",{"trials":12229,"activeCount":97},[],{"trials":12231,"activeCount":97},[],{"trials":12233,"activeCount":97},[12234],{"nctId":12235,"briefTitle":12236,"status":155,"phases":12237,"start":4844,"enrollment":11467,"conditions":12238,"interventions":12239},"NCT00340080","Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir Hypersensitivity",[88],[10662],[12215],{"trials":12241,"activeCount":97},[],{"intervention":12243,"totalTrials":660,"cells":12244},"Dutasteride plus tamsulosin",{"EARLY_PHASE1":12245,"PHASE1":12247,"PHASE2":12249,"PHASE3":12251,"PHASE4":12253,"NA":12274},{"trials":12246,"activeCount":97},[],{"trials":12248,"activeCount":97},[],{"trials":12250,"activeCount":97},[],{"trials":12252,"activeCount":97},[],{"trials":12254,"activeCount":97},[12255,12265],{"nctId":12256,"briefTitle":12257,"status":155,"phases":12258,"primaryCompletion":12259,"completion":12259,"start":12260,"enrollment":12261,"conditions":12262,"interventions":12264},"NCT01777269","Prospective Sexual Function Study for BPH Subjects",[88],"2016-04-05","2013-02-18",489,[12263],"Prostatic Hyperplasia",[12243],{"nctId":12266,"briefTitle":12267,"status":155,"phases":12268,"primaryCompletion":10190,"completion":10190,"start":12269,"enrollment":12270,"conditions":12271,"interventions":12272},"NCT01294592","Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement",[88],"2010-12-22",742,[12263],[12243,12273],"tamsulosin",{"trials":12275,"activeCount":97},[],{"intervention":12277,"totalTrials":660,"cells":12278},"Antara",{"EARLY_PHASE1":12279,"PHASE1":12281,"PHASE2":12283,"PHASE3":12285,"PHASE4":12287,"NA":12303},{"trials":12280,"activeCount":97},[],{"trials":12282,"activeCount":97},[],{"trials":12284,"activeCount":97},[],{"trials":12286,"activeCount":97},[],{"trials":12288,"activeCount":97},[12289,12297],{"nctId":12290,"briefTitle":12291,"status":155,"phases":12292,"primaryCompletion":8406,"completion":748,"start":2805,"enrollment":11044,"conditions":12293,"interventions":12295},"NCT00246636","Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension",[88],[12294],"Hypertriglyceridemia",[12296,12277],"Antara (fenofibrate) + Lovaza",{"nctId":12298,"briefTitle":12299,"status":155,"phases":12300,"primaryCompletion":7522,"completion":7522,"start":7613,"enrollment":7911,"conditions":12301,"interventions":12302},"NCT00891293","A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™",[88],[12294],[12277],{"trials":12304,"activeCount":97},[],{"intervention":4883,"totalTrials":660,"cells":12306},{"EARLY_PHASE1":12307,"PHASE1":12309,"PHASE2":12311,"PHASE3":12313,"PHASE4":12325,"NA":12331},{"trials":12308,"activeCount":97},[],{"trials":12310,"activeCount":97},[],{"trials":12312,"activeCount":97},[],{"trials":12314,"activeCount":97},[12315],{"nctId":12316,"briefTitle":12317,"status":155,"phases":12318,"primaryCompletion":12319,"completion":12320,"start":8824,"enrollment":536,"conditions":12321,"interventions":12322},"NCT01175083","Immunization of Children Between 8 Weeks and 2 Years of Age With GSK Pneumococcal Vaccine GSK1024850A",[87],"2013-01-17","2013-05-23",[3637],[4883,12323,12324],"Tritanrix-HepB\u002FHib","Polio Sabin",{"trials":12326,"activeCount":97},[12327],{"nctId":4874,"briefTitle":4875,"status":155,"phases":12328,"primaryCompletion":4877,"completion":4878,"start":4879,"enrollment":4880,"conditions":12329,"interventions":12330},[88],[3637],[4883,4472,4821,4884,4763],{"trials":12332,"activeCount":97},[],{"intervention":8432,"totalTrials":660,"cells":12334},{"EARLY_PHASE1":12335,"PHASE1":12337,"PHASE2":12339,"PHASE3":12341,"PHASE4":12343,"NA":12356},{"trials":12336,"activeCount":97},[],{"trials":12338,"activeCount":97},[],{"trials":12340,"activeCount":97},[],{"trials":12342,"activeCount":97},[],{"trials":12344,"activeCount":97},[12345,12349],{"nctId":8423,"briefTitle":8424,"status":155,"phases":12346,"primaryCompletion":8426,"completion":8426,"start":8427,"enrollment":8428,"conditions":12347,"interventions":12348},[88],[18],[8354,8431,8409,8432],{"nctId":12350,"briefTitle":12351,"status":155,"phases":12352,"completion":8406,"start":2404,"enrollment":695,"conditions":12353,"interventions":12354},"NCT00400608","A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS",[88],[18],[12355,8432],"ADVAIR HFA",{"trials":12357,"activeCount":97},[],{"intervention":9631,"totalTrials":660,"cells":12359},{"EARLY_PHASE1":12360,"PHASE1":12362,"PHASE2":12364,"PHASE3":12366,"PHASE4":12372,"NA":12384},{"trials":12361,"activeCount":97},[],{"trials":12363,"activeCount":97},[],{"trials":12365,"activeCount":97},[],{"trials":12367,"activeCount":97},[12368],{"nctId":9622,"briefTitle":9623,"status":155,"phases":12369,"primaryCompletion":9625,"completion":9625,"start":9626,"enrollment":9627,"conditions":12370,"interventions":12371},[87],[18],[9546,9630,9631,9632,9633,9634],{"trials":12373,"activeCount":97},[12374],{"nctId":12375,"briefTitle":12376,"status":155,"phases":12377,"primaryCompletion":12378,"completion":12378,"start":12379,"enrollment":2825,"conditions":12380,"interventions":12381},"NCT02730351","Crossover Study Comparing Fluticasone Furoate (FF)\u002FVilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)",[88],"2017-02-03","2016-05-25",[18],[12382,12383],"Fluticasone furoate\u002F Vilanterol 100 mcg\u002F25 mcg","Fluticasone propionate 250 mcg",{"trials":12385,"activeCount":97},[],{"intervention":12387,"totalTrials":660,"cells":12388},"GSK Biologicals' HPV vaccine 580299",{"EARLY_PHASE1":12389,"PHASE1":12391,"PHASE2":12393,"PHASE3":12395,"PHASE4":12406,"NA":12420},{"trials":12390,"activeCount":97},[],{"trials":12392,"activeCount":97},[],{"trials":12394,"activeCount":97},[],{"trials":12396,"activeCount":97},[12397],{"nctId":12398,"briefTitle":12399,"status":155,"phases":12400,"primaryCompletion":12401,"completion":6799,"start":12402,"enrollment":12403,"conditions":12404,"interventions":12405},"NCT01381575","Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls",[87],"2012-06-28","2011-06-29",1447,[8723],[12387],{"trials":12407,"activeCount":97},[12408],{"nctId":12409,"briefTitle":12410,"status":155,"phases":12411,"primaryCompletion":12412,"completion":12413,"start":12414,"enrollment":12415,"conditions":12416,"interventions":12418},"NCT01031069","Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females",[88],"2016-01-13","2017-04-19","2010-10-26",873,[8723,12417],"Papillomavirus Vaccines",[12387,12419],"Merck's Human Papillomavirus Quadrivalent",{"trials":12421,"activeCount":97},[],{"intervention":12423,"totalTrials":660,"cells":12424},"Sotrovimab",{"EARLY_PHASE1":12425,"PHASE1":12427,"PHASE2":12429,"PHASE3":12439,"PHASE4":12441,"NA":12450},{"trials":12426,"activeCount":97},[],{"trials":12428,"activeCount":97},[],{"trials":12430,"activeCount":97},[12431],{"nctId":12432,"briefTitle":12433,"status":145,"phases":12434,"primaryCompletion":1173,"completion":1173,"start":12435,"enrollment":1720,"conditions":12436,"interventions":12438},"NCT05124210","Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19",[86],"2021-12-16",[12437],"COVID-19",[12423],{"trials":12440,"activeCount":97},[],{"trials":12442,"activeCount":97},[12443],{"nctId":12444,"briefTitle":12445,"status":155,"phases":12446,"primaryCompletion":2636,"completion":2636,"start":9838,"enrollment":12447,"conditions":12448,"interventions":12449},"NCT05305651","Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19",[88],217,[12437],[12423],{"trials":12451,"activeCount":97},[],{"intervention":4751,"totalTrials":660,"cells":12453},{"EARLY_PHASE1":12454,"PHASE1":12456,"PHASE2":12458,"PHASE3":12460,"PHASE4":12466,"NA":12478},{"trials":12455,"activeCount":97},[],{"trials":12457,"activeCount":97},[],{"trials":12459,"activeCount":97},[],{"trials":12461,"activeCount":97},[12462],{"nctId":4734,"briefTitle":4735,"status":155,"phases":12463,"primaryCompletion":4737,"completion":4738,"start":4739,"enrollment":4740,"conditions":12464,"interventions":12465},[87],[24,3624,33,4702,30,4742],[4744,4745,4472,4746,4747,4748,4749,4750,4751],{"trials":12467,"activeCount":97},[12468],{"nctId":12469,"briefTitle":12470,"status":155,"phases":12471,"primaryCompletion":12472,"completion":12472,"start":12473,"enrollment":12474,"conditions":12475,"interventions":12477},"NCT00454987","Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine",[88],"2007-10-12","2007-05-16",288,[4704,4703,12476],"Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine",[4751,4748],{"trials":12479,"activeCount":97},[],{"intervention":4748,"totalTrials":660,"cells":12481},{"EARLY_PHASE1":12482,"PHASE1":12484,"PHASE2":12486,"PHASE3":12488,"PHASE4":12494,"NA":12500},{"trials":12483,"activeCount":97},[],{"trials":12485,"activeCount":97},[],{"trials":12487,"activeCount":97},[],{"trials":12489,"activeCount":97},[12490],{"nctId":4734,"briefTitle":4735,"status":155,"phases":12491,"primaryCompletion":4737,"completion":4738,"start":4739,"enrollment":4740,"conditions":12492,"interventions":12493},[87],[24,3624,33,4702,30,4742],[4744,4745,4472,4746,4747,4748,4749,4750,4751],{"trials":12495,"activeCount":97},[12496],{"nctId":12469,"briefTitle":12470,"status":155,"phases":12497,"primaryCompletion":12472,"completion":12472,"start":12473,"enrollment":12474,"conditions":12498,"interventions":12499},[88],[4704,4703,12476],[4751,4748],{"trials":12501,"activeCount":97},[],{"intervention":12503,"totalTrials":660,"cells":12504},"ezogabine\u002Fretigabine",{"EARLY_PHASE1":12505,"PHASE1":12507,"PHASE2":12509,"PHASE3":12520,"PHASE4":12522,"NA":12532},{"trials":12506,"activeCount":97},[],{"trials":12508,"activeCount":97},[],{"trials":12510,"activeCount":97},[12511],{"nctId":12512,"briefTitle":12513,"status":145,"phases":12514,"primaryCompletion":12515,"completion":12515,"start":12516,"enrollment":1517,"conditions":12517,"interventions":12519},"NCT01494584","Study in Pediatric Subjects With Epilepsy",[86],"2013-04-29","2012-07-25",[12518],"Epilepsy",[12503],{"trials":12521,"activeCount":97},[],{"trials":12523,"activeCount":97},[12524],{"nctId":12525,"briefTitle":12526,"status":145,"phases":12527,"primaryCompletion":12528,"completion":12528,"start":12529,"enrollment":750,"conditions":12530,"interventions":12531},"NCT01607346","An Open Label Study to Evaluate the Effects of Ezogabine\u002FRetigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures",[88],"2016-11-16","2013-03-27",[12518],[12503],{"trials":12533,"activeCount":97},[],{"intervention":12535,"totalTrials":660,"cells":12536},"Indomethacin",{"EARLY_PHASE1":12537,"PHASE1":12539,"PHASE2":12550,"PHASE3":12552,"PHASE4":12554,"NA":12564},{"trials":12538,"activeCount":97},[],{"trials":12540,"activeCount":97},[12541],{"nctId":12542,"briefTitle":12543,"status":500,"phases":12544,"primaryCompletion":12545,"completion":12545,"start":12546,"enrollment":97,"conditions":12547,"interventions":12548},"NCT05999708","A First Time in Human Study to Evaluate the Safety and Tolerability of GSK4381406 in Healthy Participants",[85],"2024-12-05","2023-10-31",[7295],[12549,12535],"GSK4381406",{"trials":12551,"activeCount":97},[],{"trials":12553,"activeCount":97},[],{"trials":12555,"activeCount":97},[12556],{"nctId":12557,"briefTitle":12558,"status":155,"phases":12559,"primaryCompletion":10905,"completion":10905,"start":3045,"enrollment":12560,"conditions":12561,"interventions":12563},"NCT01957215","Efficacy of Topical Indomethacin Patch Over Placebo in Ankle Sprain Pain Relief",[88],270,[12562],"Ankle Sprain",[12535],{"trials":12565,"activeCount":97},[],{"intervention":11591,"totalTrials":660,"cells":12567},{"EARLY_PHASE1":12568,"PHASE1":12570,"PHASE2":12572,"PHASE3":12574,"PHASE4":12576,"NA":12586},{"trials":12569,"activeCount":97},[],{"trials":12571,"activeCount":97},[],{"trials":12573,"activeCount":97},[],{"trials":12575,"activeCount":97},[],{"trials":12577,"activeCount":97},[12578,12582],{"nctId":11585,"briefTitle":11586,"status":155,"phases":12579,"primaryCompletion":8478,"completion":8478,"start":10659,"enrollment":11588,"conditions":12580,"interventions":12581},[88],[18],[11563,11591,11592,11581,11593,11594],{"nctId":11596,"briefTitle":11597,"status":155,"phases":12583,"primaryCompletion":8478,"completion":8478,"start":11599,"enrollment":9569,"conditions":12584,"interventions":12585},[88],[18],[11563,11592,11591,11581,11593,11602],{"trials":12587,"activeCount":97},[],{"intervention":11592,"totalTrials":660,"cells":12589},{"EARLY_PHASE1":12590,"PHASE1":12592,"PHASE2":12594,"PHASE3":12596,"PHASE4":12598,"NA":12608},{"trials":12591,"activeCount":97},[],{"trials":12593,"activeCount":97},[],{"trials":12595,"activeCount":97},[],{"trials":12597,"activeCount":97},[],{"trials":12599,"activeCount":97},[12600,12604],{"nctId":11585,"briefTitle":11586,"status":155,"phases":12601,"primaryCompletion":8478,"completion":8478,"start":10659,"enrollment":11588,"conditions":12602,"interventions":12603},[88],[18],[11563,11591,11592,11581,11593,11594],{"nctId":11596,"briefTitle":11597,"status":155,"phases":12605,"primaryCompletion":8478,"completion":8478,"start":11599,"enrollment":9569,"conditions":12606,"interventions":12607},[88],[18],[11563,11592,11591,11581,11593,11602],{"trials":12609,"activeCount":97},[],{"intervention":11593,"totalTrials":660,"cells":12611},{"EARLY_PHASE1":12612,"PHASE1":12614,"PHASE2":12616,"PHASE3":12618,"PHASE4":12620,"NA":12630},{"trials":12613,"activeCount":97},[],{"trials":12615,"activeCount":97},[],{"trials":12617,"activeCount":97},[],{"trials":12619,"activeCount":97},[],{"trials":12621,"activeCount":97},[12622,12626],{"nctId":11585,"briefTitle":11586,"status":155,"phases":12623,"primaryCompletion":8478,"completion":8478,"start":10659,"enrollment":11588,"conditions":12624,"interventions":12625},[88],[18],[11563,11591,11592,11581,11593,11594],{"nctId":11596,"briefTitle":11597,"status":155,"phases":12627,"primaryCompletion":8478,"completion":8478,"start":11599,"enrollment":9569,"conditions":12628,"interventions":12629},[88],[18],[11563,11592,11591,11581,11593,11602],{"trials":12631,"activeCount":97},[],{"intervention":11651,"totalTrials":660,"cells":12633},{"EARLY_PHASE1":12634,"PHASE1":12636,"PHASE2":12638,"PHASE3":12640,"PHASE4":12646,"NA":12658},{"trials":12635,"activeCount":97},[],{"trials":12637,"activeCount":97},[],{"trials":12639,"activeCount":97},[],{"trials":12641,"activeCount":97},[12642],{"nctId":11642,"briefTitle":11643,"status":155,"phases":12643,"primaryCompletion":11645,"completion":11645,"start":11646,"enrollment":11647,"conditions":12644,"interventions":12645},[87],[15],[8622,2934,11650,11651],{"trials":12647,"activeCount":97},[12648],{"nctId":12649,"briefTitle":12650,"status":155,"phases":12651,"primaryCompletion":12652,"completion":12652,"start":12653,"enrollment":8619,"conditions":12654,"interventions":12655},"NCT02257372","A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[88],"2015-03-24","2014-09-30",[15],[12656,12657,11651],"UMEC DPI","ICS\u002FLABA medication",{"trials":12659,"activeCount":97},[],{"intervention":12661,"totalTrials":660,"cells":12662},"Fluticasone Propionate\u002Fsalmeterol xinofoate 250\u002F50 mcg BID",{"EARLY_PHASE1":12663,"PHASE1":12665,"PHASE2":12667,"PHASE3":12669,"PHASE4":12671,"NA":12687},{"trials":12664,"activeCount":97},[],{"trials":12666,"activeCount":97},[],{"trials":12668,"activeCount":97},[],{"trials":12670,"activeCount":97},[],{"trials":12672,"activeCount":97},[12673,12680],{"nctId":12674,"briefTitle":12675,"status":155,"phases":12676,"primaryCompletion":3550,"completion":3550,"start":2835,"enrollment":6564,"conditions":12677,"interventions":12678},"NCT00452348","A 12-Month Study Comparing Fluticasone Propionate\u002FSalmeterol (ADVAIR) DISKUS Combination Product 250\u002F50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma",[88],[18],[12661,12679],"Fluticasone propionate 250 mcg BID",{"nctId":12681,"briefTitle":12682,"status":155,"phases":12683,"primaryCompletion":2795,"completion":2795,"start":2835,"enrollment":12684,"conditions":12685,"interventions":12686},"NCT00452699","A 12-Month Study Comparing Fluticasone Propionate\u002FSalmeterol (ADVAIR) DISKUS Combination Product 250\u002F50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma",[88],621,[18],[12661,12679],{"trials":12688,"activeCount":97},[],{"intervention":12679,"totalTrials":660,"cells":12690},{"EARLY_PHASE1":12691,"PHASE1":12693,"PHASE2":12695,"PHASE3":12697,"PHASE4":12699,"NA":12709},{"trials":12692,"activeCount":97},[],{"trials":12694,"activeCount":97},[],{"trials":12696,"activeCount":97},[],{"trials":12698,"activeCount":97},[],{"trials":12700,"activeCount":97},[12701,12705],{"nctId":12674,"briefTitle":12675,"status":155,"phases":12702,"primaryCompletion":3550,"completion":3550,"start":2835,"enrollment":6564,"conditions":12703,"interventions":12704},[88],[18],[12661,12679],{"nctId":12681,"briefTitle":12682,"status":155,"phases":12706,"primaryCompletion":2795,"completion":2795,"start":2835,"enrollment":12684,"conditions":12707,"interventions":12708},[88],[18],[12661,12679],{"trials":12710,"activeCount":97},[],{"intervention":12712,"totalTrials":660,"cells":12713},"Retapamulin Ointment, 1%",{"EARLY_PHASE1":12714,"PHASE1":12716,"PHASE2":12718,"PHASE3":12720,"PHASE4":12729,"NA":12737},{"trials":12715,"activeCount":97},[],{"trials":12717,"activeCount":97},[],{"trials":12719,"activeCount":97},[],{"trials":12721,"activeCount":97},[12722],{"nctId":12723,"briefTitle":12724,"status":155,"phases":12725,"primaryCompletion":11992,"completion":11992,"start":7522,"enrollment":10213,"conditions":12726,"interventions":12728},"NCT00684177","Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)",[87],[12727],"Skin Infections, Bacterial",[12712],{"trials":12730,"activeCount":97},[12731],{"nctId":12732,"briefTitle":12733,"status":155,"phases":12734,"primaryCompletion":7976,"completion":7976,"start":2356,"enrollment":1237,"conditions":12735,"interventions":12736},"NCT00555061","Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.",[88],[12727],[12712],{"trials":12738,"activeCount":97},[],{"intervention":8744,"totalTrials":660,"cells":12740},{"EARLY_PHASE1":12741,"PHASE1":12743,"PHASE2":12745,"PHASE3":12747,"PHASE4":12749,"NA":12759},{"trials":12742,"activeCount":97},[],{"trials":12744,"activeCount":97},[],{"trials":12746,"activeCount":97},[],{"trials":12748,"activeCount":97},[],{"trials":12750,"activeCount":97},[12751,12755],{"nctId":8737,"briefTitle":8738,"status":155,"phases":12752,"primaryCompletion":8740,"completion":8740,"start":8741,"enrollment":8461,"conditions":12753,"interventions":12754},[88],[7966,24],[5037,4808,4694,8744,8745],{"nctId":8758,"briefTitle":8759,"status":155,"phases":12756,"primaryCompletion":7546,"completion":7546,"start":7954,"enrollment":7131,"conditions":12757,"interventions":12758},[88],[24,7966],[5037,4808,4694,8744,8745],{"trials":12760,"activeCount":97},[],{"intervention":8745,"totalTrials":660,"cells":12762},{"EARLY_PHASE1":12763,"PHASE1":12765,"PHASE2":12767,"PHASE3":12769,"PHASE4":12771,"NA":12781},{"trials":12764,"activeCount":97},[],{"trials":12766,"activeCount":97},[],{"trials":12768,"activeCount":97},[],{"trials":12770,"activeCount":97},[],{"trials":12772,"activeCount":97},[12773,12777],{"nctId":8737,"briefTitle":8738,"status":155,"phases":12774,"primaryCompletion":8740,"completion":8740,"start":8741,"enrollment":8461,"conditions":12775,"interventions":12776},[88],[7966,24],[5037,4808,4694,8744,8745],{"nctId":8758,"briefTitle":8759,"status":155,"phases":12778,"primaryCompletion":7546,"completion":7546,"start":7954,"enrollment":7131,"conditions":12779,"interventions":12780},[88],[24,7966],[5037,4808,4694,8744,8745],{"trials":12782,"activeCount":97},[],{"intervention":12784,"totalTrials":660,"cells":12785},"MenACWY-CRM",{"EARLY_PHASE1":12786,"PHASE1":12788,"PHASE2":12790,"PHASE3":12792,"PHASE4":12805,"NA":12816},{"trials":12787,"activeCount":97},[],{"trials":12789,"activeCount":97},[],{"trials":12791,"activeCount":97},[],{"trials":12793,"activeCount":97},[12794],{"nctId":12795,"briefTitle":12796,"status":155,"phases":12797,"primaryCompletion":12798,"completion":12799,"start":12800,"enrollment":12801,"conditions":12802,"interventions":12804},"NCT01682876","Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.",[87],"2013-07-02","2014-05-30","2012-10-07",715,[12803,992],"Meningococcal Disease",[12784],{"trials":12806,"activeCount":97},[12807],{"nctId":12808,"briefTitle":12809,"status":155,"phases":12810,"primaryCompletion":12811,"completion":12811,"start":12812,"enrollment":12813,"conditions":12814,"interventions":12815},"NCT01766206","Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea",[88],"2018-01-22","2013-03-15",3948,[12803],[12784],{"trials":12817,"activeCount":97},[],{"intervention":12819,"totalTrials":660,"cells":12820},"Twinrix™",{"EARLY_PHASE1":12821,"PHASE1":12823,"PHASE2":12825,"PHASE3":12827,"PHASE4":12836,"NA":12842},{"trials":12822,"activeCount":97},[],{"trials":12824,"activeCount":97},[],{"trials":12826,"activeCount":97},[],{"trials":12828,"activeCount":97},[12829],{"nctId":12830,"briefTitle":12831,"status":155,"phases":12832,"primaryCompletion":12833,"completion":12833,"start":11106,"enrollment":1003,"conditions":12834,"interventions":12835},"NCT00289770","Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults",[87],"2004-12-20",[24,7966],[12819],{"trials":12837,"activeCount":97},[12838],{"nctId":7959,"briefTitle":7960,"status":155,"phases":12839,"primaryCompletion":7962,"completion":7962,"start":7963,"enrollment":7964,"conditions":12840,"interventions":12841},[88],[24,7966],[7968,7718,7969,7970,7971],{"trials":12843,"activeCount":97},[],{"intervention":12845,"totalTrials":660,"cells":12846},"Albiglutide 50 mg",{"EARLY_PHASE1":12847,"PHASE1":12849,"PHASE2":12851,"PHASE3":12853,"PHASE4":12855,"NA":12877},{"trials":12848,"activeCount":97},[],{"trials":12850,"activeCount":97},[],{"trials":12852,"activeCount":97},[],{"trials":12854,"activeCount":97},[],{"trials":12856,"activeCount":97},[12857,12868],{"nctId":12858,"briefTitle":12859,"status":155,"phases":12860,"primaryCompletion":12861,"completion":12862,"start":12863,"enrollment":12864,"conditions":12865,"interventions":12866},"NCT02465515","Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus",[88],"2018-02-20","2018-03-14","2015-07-01",9463,[8063],[12867,12845],"Albiglutide 30 mg",{"nctId":12869,"briefTitle":12870,"status":155,"phases":12871,"primaryCompletion":12872,"completion":12872,"start":12873,"enrollment":454,"conditions":12874,"interventions":12875},"NCT02496221","A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects",[88],"2015-10-13","2015-06-11",[27],[12845,12876],"CCK",{"trials":12878,"activeCount":97},[],{"intervention":8482,"totalTrials":660,"cells":12880},{"EARLY_PHASE1":12881,"PHASE1":12883,"PHASE2":12885,"PHASE3":12887,"PHASE4":12896,"NA":12902},{"trials":12882,"activeCount":97},[],{"trials":12884,"activeCount":97},[],{"trials":12886,"activeCount":97},[],{"trials":12888,"activeCount":97},[12889],{"nctId":12890,"briefTitle":12891,"status":155,"phases":12892,"primaryCompletion":10395,"completion":10395,"start":1380,"enrollment":1579,"conditions":12893,"interventions":12894},"NCT00269126","Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)",[87],[15],[12895,8482],"fluticasone propionate\u002Fsalmeterol combination DISKUS",{"trials":12897,"activeCount":97},[12898],{"nctId":8475,"briefTitle":8476,"status":155,"phases":12899,"primaryCompletion":5196,"completion":5196,"start":8478,"enrollment":8479,"conditions":12900,"interventions":12901},[88],[18],[8354,8482],{"trials":12903,"activeCount":97},[],{"intervention":11907,"totalTrials":660,"cells":12905},{"EARLY_PHASE1":12906,"PHASE1":12908,"PHASE2":12910,"PHASE3":12912,"PHASE4":12918,"NA":12924},{"trials":12907,"activeCount":97},[],{"trials":12909,"activeCount":97},[],{"trials":12911,"activeCount":97},[],{"trials":12913,"activeCount":97},[12914],{"nctId":11900,"briefTitle":11901,"status":155,"phases":12915,"primaryCompletion":11903,"completion":11903,"start":6481,"enrollment":11904,"conditions":12916,"interventions":12917},[87],[992],[11879,11907,11908,11909,11910],{"trials":12919,"activeCount":97},[12920],{"nctId":11914,"briefTitle":11915,"status":155,"phases":12921,"primaryCompletion":11917,"completion":11917,"start":11918,"enrollment":11919,"conditions":12922,"interventions":12923},[88],[1005],[11879,11907],{"trials":12925,"activeCount":97},[],{"intervention":8350,"totalTrials":660,"cells":12927},{"EARLY_PHASE1":12928,"PHASE1":12930,"PHASE2":12932,"PHASE3":12934,"PHASE4":12940,"NA":12946},{"trials":12929,"activeCount":97},[],{"trials":12931,"activeCount":97},[],{"trials":12933,"activeCount":97},[],{"trials":12935,"activeCount":97},[12936],{"nctId":9949,"briefTitle":9950,"status":155,"phases":12937,"primaryCompletion":9952,"completion":9953,"start":4855,"enrollment":1307,"conditions":12938,"interventions":12939},[87],[21],[9956,9957,9920,8350],{"trials":12941,"activeCount":97},[12942],{"nctId":8342,"briefTitle":8343,"status":155,"phases":12943,"primaryCompletion":8345,"completion":8345,"start":8346,"enrollment":8347,"conditions":12944,"interventions":12945},[88],[21],[8177,8350],{"trials":12947,"activeCount":97},[],{"intervention":12949,"totalTrials":660,"cells":12950},"Idiazole 20mg DR tabs",{"EARLY_PHASE1":12951,"PHASE1":12953,"PHASE2":12955,"PHASE3":12957,"PHASE4":12959,"NA":12980},{"trials":12952,"activeCount":97},[],{"trials":12954,"activeCount":97},[],{"trials":12956,"activeCount":97},[],{"trials":12958,"activeCount":97},[],{"trials":12960,"activeCount":97},[12961,12971],{"nctId":12962,"briefTitle":12963,"status":155,"phases":12964,"primaryCompletion":12965,"completion":12965,"start":12966,"enrollment":1237,"conditions":12967,"interventions":12969},"NCT02446483","A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults",[88],"2014-03-26","2014-03-19",[12968],"Gastrointestinal Diseases",[12949,12970],"PARIET 20 mg DR tabs",{"nctId":12972,"briefTitle":12973,"status":155,"phases":12974,"primaryCompletion":12975,"completion":12975,"start":12976,"enrollment":730,"conditions":12977,"interventions":12978},"NCT02605395","Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions",[88],"2014-03-30","2014-03-22",[12968],[12979,12970],"IDIAZOLE 20mg DR tabs",{"trials":12981,"activeCount":97},[],{"intervention":12970,"totalTrials":660,"cells":12983},{"EARLY_PHASE1":12984,"PHASE1":12986,"PHASE2":12988,"PHASE3":12990,"PHASE4":12992,"NA":13002},{"trials":12985,"activeCount":97},[],{"trials":12987,"activeCount":97},[],{"trials":12989,"activeCount":97},[],{"trials":12991,"activeCount":97},[],{"trials":12993,"activeCount":97},[12994,12998],{"nctId":12962,"briefTitle":12963,"status":155,"phases":12995,"primaryCompletion":12965,"completion":12965,"start":12966,"enrollment":1237,"conditions":12996,"interventions":12997},[88],[12968],[12949,12970],{"nctId":12972,"briefTitle":12973,"status":155,"phases":12999,"primaryCompletion":12975,"completion":12975,"start":12976,"enrollment":730,"conditions":13000,"interventions":13001},[88],[12968],[12979,12970],{"trials":13003,"activeCount":97},[],{"intervention":13005,"totalTrials":660,"cells":13006},"metoprolol",{"EARLY_PHASE1":13007,"PHASE1":13009,"PHASE2":13011,"PHASE3":13013,"PHASE4":13015,"NA":13034},{"trials":13008,"activeCount":97},[],{"trials":13010,"activeCount":97},[],{"trials":13012,"activeCount":97},[],{"trials":13014,"activeCount":97},[],{"trials":13016,"activeCount":97},[13017,13027],{"nctId":13018,"briefTitle":13019,"status":155,"phases":13020,"primaryCompletion":2775,"completion":2775,"start":13021,"enrollment":13022,"conditions":13023,"interventions":13025},"NCT00060918","Glycemic Control Of Carvedilol Versus Metoprolol In Patients With Type II Diabetes Mellitus And Hypertension",[88],"2001-06",1210,[13024],"Hypertension",[13026,13005],"carvedilol",{"nctId":13028,"briefTitle":13029,"status":155,"phases":13030,"primaryCompletion":2775,"completion":2775,"start":13021,"enrollment":13031,"conditions":13032,"interventions":13033},"NCT00060931","Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension",[88],501,[13024],[13026,13005],{"trials":13035,"activeCount":97},[],{"intervention":13037,"totalTrials":660,"cells":13038},"Hydrochlorothiazide",{"EARLY_PHASE1":13039,"PHASE1":13041,"PHASE2":13051,"PHASE3":13053,"PHASE4":13055,"NA":13068},{"trials":13040,"activeCount":97},[],{"trials":13042,"activeCount":97},[13043],{"nctId":13044,"briefTitle":13045,"status":155,"phases":13046,"primaryCompletion":7522,"completion":7522,"start":2382,"enrollment":6503,"conditions":13047,"interventions":13048},"NCT00671424","A Study To Compare Effects Of GSK189075 In Combination With Either Furosemide Or Hydrochlorothiazide",[85],[9036,27],[13037,13049,13050],"Remogliflozin etabonate","Furosemide",{"trials":13052,"activeCount":97},[],{"trials":13054,"activeCount":97},[],{"trials":13056,"activeCount":97},[13057],{"nctId":13058,"briefTitle":13059,"status":155,"phases":13060,"completion":2405,"start":13061,"enrollment":13062,"conditions":13063,"interventions":13064},"NCT00306696","Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.",[88],"2002-10",388,[8063],[9093,13065,13066,13067],"spironolactone","hydrochlorothiazide","frusemide",{"trials":13069,"activeCount":97},[],{"intervention":13071,"totalTrials":660,"cells":13072},"Dutasteride\u002FTamsulosin",{"EARLY_PHASE1":13073,"PHASE1":13075,"PHASE2":13085,"PHASE3":13087,"PHASE4":13089,"NA":13099},{"trials":13074,"activeCount":97},[],{"trials":13076,"activeCount":97},[13077],{"nctId":13078,"briefTitle":13079,"status":155,"phases":13080,"primaryCompletion":8336,"completion":8336,"start":9862,"enrollment":8786,"conditions":13081,"interventions":13082},"NCT01657851","Bioequivalence - Duodart Against Avodart & Omnic",[85],[12263],[13083,13084,12273],"dutasteride\u002Ftamsulosin","dutasteride",{"trials":13086,"activeCount":97},[],{"trials":13088,"activeCount":97},[],{"trials":13090,"activeCount":97},[13091],{"nctId":13092,"briefTitle":13093,"status":145,"phases":13094,"primaryCompletion":13095,"completion":13095,"start":13096,"enrollment":2759,"conditions":13097,"interventions":13098},"NCT01673490","Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia",[88],"2015-03-20","2012-06-29",[12263],[13071],{"trials":13100,"activeCount":97},[],{"intervention":13102,"totalTrials":660,"cells":13103},"NaF",{"EARLY_PHASE1":13104,"PHASE1":13106,"PHASE2":13108,"PHASE3":13110,"PHASE4":13119,"NA":13129},{"trials":13105,"activeCount":97},[],{"trials":13107,"activeCount":97},[],{"trials":13109,"activeCount":97},[],{"trials":13111,"activeCount":97},[13112],{"nctId":13113,"briefTitle":13114,"status":155,"phases":13115,"primaryCompletion":5018,"completion":5018,"start":2355,"enrollment":2384,"conditions":13116,"interventions":13117},"NCT00708097","In Situ Caries Efficacy of Fluoride Toothpastes",[87],[12022],[13102,13118],"NaMFP",{"trials":13120,"activeCount":97},[13121],{"nctId":13122,"briefTitle":13123,"status":155,"phases":13124,"primaryCompletion":3078,"completion":3078,"start":6351,"enrollment":323,"conditions":13125,"interventions":13127},"NCT01128946","Enamel Remineralization Potential of Dentifrices in Situ",[88],[13126],"Dental Caries",[13102,13128,13118],"SnF",{"trials":13130,"activeCount":97},[],{"intervention":13118,"totalTrials":660,"cells":13132},{"EARLY_PHASE1":13133,"PHASE1":13135,"PHASE2":13137,"PHASE3":13139,"PHASE4":13145,"NA":13151},{"trials":13134,"activeCount":97},[],{"trials":13136,"activeCount":97},[],{"trials":13138,"activeCount":97},[],{"trials":13140,"activeCount":97},[13141],{"nctId":13113,"briefTitle":13114,"status":155,"phases":13142,"primaryCompletion":5018,"completion":5018,"start":2355,"enrollment":2384,"conditions":13143,"interventions":13144},[87],[12022],[13102,13118],{"trials":13146,"activeCount":97},[13147],{"nctId":13122,"briefTitle":13123,"status":155,"phases":13148,"primaryCompletion":3078,"completion":3078,"start":6351,"enrollment":323,"conditions":13149,"interventions":13150},[88],[13126],[13102,13128,13118],{"trials":13152,"activeCount":97},[],{"intervention":13154,"totalTrials":660,"cells":13155},"ADVAIR 100\u002F50mcg",{"EARLY_PHASE1":13156,"PHASE1":13158,"PHASE2":13160,"PHASE3":13162,"PHASE4":13164,"NA":13188},{"trials":13157,"activeCount":97},[],{"trials":13159,"activeCount":97},[],{"trials":13161,"activeCount":97},[],{"trials":13163,"activeCount":97},[],{"trials":13165,"activeCount":97},[13166,13179],{"nctId":13167,"briefTitle":13168,"status":155,"phases":13169,"primaryCompletion":13170,"completion":13170,"start":7865,"enrollment":13171,"conditions":13172,"interventions":13173},"NCT01475721","SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate\u002FSalmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.",[88],"2015-06-23",11751,[18],[13154,13174,13175,13176,13177,13178],"ADVAIR 250\u002F50mcg","ADVAIR 500\u002F50mcg","FLOVENT 100mcg","FLOVENT 250mcg","FLOVENT 500mcg",{"nctId":13180,"briefTitle":13181,"status":155,"phases":13182,"primaryCompletion":13183,"completion":13184,"start":5129,"enrollment":13185,"conditions":13186,"interventions":13187},"NCT01462344","6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old",[88],"2015-11-01","2015-11-03",6250,[18],[13154,13174,13176,13177],{"trials":13189,"activeCount":97},[],{"intervention":13174,"totalTrials":660,"cells":13191},{"EARLY_PHASE1":13192,"PHASE1":13194,"PHASE2":13196,"PHASE3":13198,"PHASE4":13200,"NA":13210},{"trials":13193,"activeCount":97},[],{"trials":13195,"activeCount":97},[],{"trials":13197,"activeCount":97},[],{"trials":13199,"activeCount":97},[],{"trials":13201,"activeCount":97},[13202,13206],{"nctId":13167,"briefTitle":13168,"status":155,"phases":13203,"primaryCompletion":13170,"completion":13170,"start":7865,"enrollment":13171,"conditions":13204,"interventions":13205},[88],[18],[13154,13174,13175,13176,13177,13178],{"nctId":13180,"briefTitle":13181,"status":155,"phases":13207,"primaryCompletion":13183,"completion":13184,"start":5129,"enrollment":13185,"conditions":13208,"interventions":13209},[88],[18],[13154,13174,13176,13177],{"trials":13211,"activeCount":97},[],{"intervention":13176,"totalTrials":660,"cells":13213},{"EARLY_PHASE1":13214,"PHASE1":13216,"PHASE2":13218,"PHASE3":13220,"PHASE4":13222,"NA":13232},{"trials":13215,"activeCount":97},[],{"trials":13217,"activeCount":97},[],{"trials":13219,"activeCount":97},[],{"trials":13221,"activeCount":97},[],{"trials":13223,"activeCount":97},[13224,13228],{"nctId":13167,"briefTitle":13168,"status":155,"phases":13225,"primaryCompletion":13170,"completion":13170,"start":7865,"enrollment":13171,"conditions":13226,"interventions":13227},[88],[18],[13154,13174,13175,13176,13177,13178],{"nctId":13180,"briefTitle":13181,"status":155,"phases":13229,"primaryCompletion":13183,"completion":13184,"start":5129,"enrollment":13185,"conditions":13230,"interventions":13231},[88],[18],[13154,13174,13176,13177],{"trials":13233,"activeCount":97},[],{"intervention":13177,"totalTrials":660,"cells":13235},{"EARLY_PHASE1":13236,"PHASE1":13238,"PHASE2":13240,"PHASE3":13242,"PHASE4":13244,"NA":13254},{"trials":13237,"activeCount":97},[],{"trials":13239,"activeCount":97},[],{"trials":13241,"activeCount":97},[],{"trials":13243,"activeCount":97},[],{"trials":13245,"activeCount":97},[13246,13250],{"nctId":13167,"briefTitle":13168,"status":155,"phases":13247,"primaryCompletion":13170,"completion":13170,"start":7865,"enrollment":13171,"conditions":13248,"interventions":13249},[88],[18],[13154,13174,13175,13176,13177,13178],{"nctId":13180,"briefTitle":13181,"status":155,"phases":13251,"primaryCompletion":13183,"completion":13184,"start":5129,"enrollment":13185,"conditions":13252,"interventions":13253},[88],[18],[13154,13174,13176,13177],{"trials":13255,"activeCount":97},[],{"intervention":12273,"totalTrials":660,"cells":13257},{"EARLY_PHASE1":13258,"PHASE1":13260,"PHASE2":13266,"PHASE3":13268,"PHASE4":13270,"NA":13276},{"trials":13259,"activeCount":97},[],{"trials":13261,"activeCount":97},[13262],{"nctId":13078,"briefTitle":13079,"status":155,"phases":13263,"primaryCompletion":8336,"completion":8336,"start":9862,"enrollment":8786,"conditions":13264,"interventions":13265},[85],[12263],[13083,13084,12273],{"trials":13267,"activeCount":97},[],{"trials":13269,"activeCount":97},[],{"trials":13271,"activeCount":97},[13272],{"nctId":12266,"briefTitle":12267,"status":155,"phases":13273,"primaryCompletion":10190,"completion":10190,"start":12269,"enrollment":12270,"conditions":13274,"interventions":13275},[88],[12263],[12243,12273],{"trials":13277,"activeCount":97},[],{"intervention":13279,"totalTrials":417,"cells":13280},"FLIXOTIDE Diskus 500 mcg",{"EARLY_PHASE1":13281,"PHASE1":13283,"PHASE2":13285,"PHASE3":13287,"PHASE4":13289,"NA":13297},{"trials":13282,"activeCount":97},[],{"trials":13284,"activeCount":97},[],{"trials":13286,"activeCount":97},[],{"trials":13288,"activeCount":97},[],{"trials":13290,"activeCount":97},[13291],{"nctId":13292,"briefTitle":13293,"status":155,"phases":13294,"primaryCompletion":10670,"completion":10670,"start":10287,"enrollment":473,"conditions":13295,"interventions":13296},"NCT00453778","A Study To Investigate The Effect Of Inhaled Fluticasone Propionate On The Bronchial Responsiveness To Leukotriene D4 In Asthmatics Patients",[88],[18,6635],[13279],{"trials":13298,"activeCount":97},[],{"intervention":13300,"totalTrials":417,"cells":13301},"UMEC\u002FVI DPI",{"EARLY_PHASE1":13302,"PHASE1":13304,"PHASE2":13306,"PHASE3":13308,"PHASE4":13310,"NA":13321},{"trials":13303,"activeCount":97},[],{"trials":13305,"activeCount":97},[],{"trials":13307,"activeCount":97},[],{"trials":13309,"activeCount":97},[],{"trials":13311,"activeCount":97},[13312],{"nctId":13313,"briefTitle":13314,"status":155,"phases":13315,"primaryCompletion":13316,"completion":13316,"start":8563,"enrollment":13317,"conditions":13318,"interventions":13319},"NCT02275052","A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)",[88],"2016-06-02",198,[15],[13300,13320],"Albuterol\u002Fsalbutamol MDI",{"trials":13322,"activeCount":97},[],{"intervention":13320,"totalTrials":417,"cells":13324},{"EARLY_PHASE1":13325,"PHASE1":13327,"PHASE2":13329,"PHASE3":13331,"PHASE4":13333,"NA":13339},{"trials":13326,"activeCount":97},[],{"trials":13328,"activeCount":97},[],{"trials":13330,"activeCount":97},[],{"trials":13332,"activeCount":97},[],{"trials":13334,"activeCount":97},[13335],{"nctId":13313,"briefTitle":13314,"status":155,"phases":13336,"primaryCompletion":13316,"completion":13316,"start":8563,"enrollment":13317,"conditions":13337,"interventions":13338},[88],[15],[13300,13320],{"trials":13340,"activeCount":97},[],{"intervention":13342,"totalTrials":417,"cells":13343},"fluticasone propionate\u002Fsalmeterol inhalation powder DISKUS 250\u002F50",{"EARLY_PHASE1":13344,"PHASE1":13346,"PHASE2":13348,"PHASE3":13350,"PHASE4":13352,"NA":13363},{"trials":13345,"activeCount":97},[],{"trials":13347,"activeCount":97},[],{"trials":13349,"activeCount":97},[],{"trials":13351,"activeCount":97},[],{"trials":13353,"activeCount":97},[13354],{"nctId":13355,"briefTitle":13356,"status":155,"phases":13357,"primaryCompletion":13358,"completion":8784,"start":9863,"enrollment":13359,"conditions":13360,"interventions":13361},"NCT01124422","Fluticasone Propionate\u002FSalmeterol Combination 250\u002F50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease",[88],"2011-05-01",255,[15],[13342,13362],"tiotropium bromide inhalation powder HandiHaler",{"trials":13364,"activeCount":97},[],{"intervention":13362,"totalTrials":417,"cells":13366},{"EARLY_PHASE1":13367,"PHASE1":13369,"PHASE2":13371,"PHASE3":13373,"PHASE4":13375,"NA":13381},{"trials":13368,"activeCount":97},[],{"trials":13370,"activeCount":97},[],{"trials":13372,"activeCount":97},[],{"trials":13374,"activeCount":97},[],{"trials":13376,"activeCount":97},[13377],{"nctId":13355,"briefTitle":13356,"status":155,"phases":13378,"primaryCompletion":13358,"completion":8784,"start":9863,"enrollment":13359,"conditions":13379,"interventions":13380},[88],[15],[13342,13362],{"trials":13382,"activeCount":97},[],{"intervention":12296,"totalTrials":417,"cells":13384},{"EARLY_PHASE1":13385,"PHASE1":13387,"PHASE2":13389,"PHASE3":13391,"PHASE4":13393,"NA":13399},{"trials":13386,"activeCount":97},[],{"trials":13388,"activeCount":97},[],{"trials":13390,"activeCount":97},[],{"trials":13392,"activeCount":97},[],{"trials":13394,"activeCount":97},[13395],{"nctId":12290,"briefTitle":12291,"status":155,"phases":13396,"primaryCompletion":8406,"completion":748,"start":2805,"enrollment":11044,"conditions":13397,"interventions":13398},[88],[12294],[12296,12277],{"trials":13400,"activeCount":97},[],{"intervention":13402,"totalTrials":417,"cells":13403},"3% Benzoyl Peroxide",{"EARLY_PHASE1":13404,"PHASE1":13406,"PHASE2":13408,"PHASE3":13410,"PHASE4":13412,"NA":13425},{"trials":13405,"activeCount":97},[],{"trials":13407,"activeCount":97},[],{"trials":13409,"activeCount":97},[],{"trials":13411,"activeCount":97},[],{"trials":13413,"activeCount":97},[13414],{"nctId":13415,"briefTitle":13416,"status":155,"phases":13417,"primaryCompletion":11043,"completion":11043,"start":13418,"enrollment":13419,"conditions":13420,"interventions":13422},"NCT02052752","A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions",[88],"2014-02",90,[13421],"Skin Diseases",[13402,13423,13424],"3% Benzoyl Peroxide Placebo","Neutrogena Rapid Clear®",{"trials":13426,"activeCount":97},[],{"intervention":13423,"totalTrials":417,"cells":13428},{"EARLY_PHASE1":13429,"PHASE1":13431,"PHASE2":13433,"PHASE3":13435,"PHASE4":13437,"NA":13443},{"trials":13430,"activeCount":97},[],{"trials":13432,"activeCount":97},[],{"trials":13434,"activeCount":97},[],{"trials":13436,"activeCount":97},[],{"trials":13438,"activeCount":97},[13439],{"nctId":13415,"briefTitle":13416,"status":155,"phases":13440,"primaryCompletion":11043,"completion":11043,"start":13418,"enrollment":13419,"conditions":13441,"interventions":13442},[88],[13421],[13402,13423,13424],{"trials":13444,"activeCount":97},[],{"intervention":13424,"totalTrials":417,"cells":13446},{"EARLY_PHASE1":13447,"PHASE1":13449,"PHASE2":13451,"PHASE3":13453,"PHASE4":13455,"NA":13461},{"trials":13448,"activeCount":97},[],{"trials":13450,"activeCount":97},[],{"trials":13452,"activeCount":97},[],{"trials":13454,"activeCount":97},[],{"trials":13456,"activeCount":97},[13457],{"nctId":13415,"briefTitle":13416,"status":155,"phases":13458,"primaryCompletion":11043,"completion":11043,"start":13418,"enrollment":13419,"conditions":13459,"interventions":13460},[88],[13421],[13402,13423,13424],{"trials":13462,"activeCount":97},[],{"intervention":13464,"totalTrials":417,"cells":13465},"Encepur Adults",{"EARLY_PHASE1":13466,"PHASE1":13468,"PHASE2":13470,"PHASE3":13472,"PHASE4":13474,"NA":13483},{"trials":13467,"activeCount":97},[],{"trials":13469,"activeCount":97},[],{"trials":13471,"activeCount":97},[],{"trials":13473,"activeCount":97},[],{"trials":13475,"activeCount":97},[13476],{"nctId":13477,"briefTitle":13478,"status":155,"phases":13479,"primaryCompletion":3155,"completion":3155,"start":938,"enrollment":13480,"conditions":13481,"interventions":13482},"NCT03294135","The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine",[88],194,[9840],[13464],{"trials":13484,"activeCount":97},[],{"intervention":12419,"totalTrials":417,"cells":13486},{"EARLY_PHASE1":13487,"PHASE1":13489,"PHASE2":13491,"PHASE3":13493,"PHASE4":13495,"NA":13501},{"trials":13488,"activeCount":97},[],{"trials":13490,"activeCount":97},[],{"trials":13492,"activeCount":97},[],{"trials":13494,"activeCount":97},[],{"trials":13496,"activeCount":97},[13497],{"nctId":12409,"briefTitle":12410,"status":155,"phases":13498,"primaryCompletion":12412,"completion":12413,"start":12414,"enrollment":12415,"conditions":13499,"interventions":13500},[88],[8723,12417],[12387,12419],{"trials":13502,"activeCount":97},[],{"intervention":13504,"totalTrials":417,"cells":13505},"Test",{"EARLY_PHASE1":13506,"PHASE1":13508,"PHASE2":13510,"PHASE3":13512,"PHASE4":13514,"NA":13522},{"trials":13507,"activeCount":97},[],{"trials":13509,"activeCount":97},[],{"trials":13511,"activeCount":97},[],{"trials":13513,"activeCount":97},[],{"trials":13515,"activeCount":97},[13516],{"nctId":13517,"briefTitle":13518,"status":155,"phases":13519,"primaryCompletion":8721,"completion":8721,"start":11029,"enrollment":8437,"conditions":13520,"interventions":13521},"NCT02246166","The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.",[88],[9183],[13504],{"trials":13523,"activeCount":97},[],{"intervention":13525,"totalTrials":417,"cells":13526},"ACT guided Routine Treatment",{"EARLY_PHASE1":13527,"PHASE1":13529,"PHASE2":13531,"PHASE3":13533,"PHASE4":13535,"NA":13546},{"trials":13528,"activeCount":97},[],{"trials":13530,"activeCount":97},[],{"trials":13532,"activeCount":97},[],{"trials":13534,"activeCount":97},[],{"trials":13536,"activeCount":97},[13537],{"nctId":13538,"briefTitle":13539,"status":155,"phases":13540,"primaryCompletion":13541,"completion":13541,"start":13542,"enrollment":3168,"conditions":13543,"interventions":13544},"NCT02868281","Asthma Control Test Guided Treatment in Chinese Subjects",[88],"2019-08-09","2016-08-26",[18],[13525,13545],"Routine Treatment",{"trials":13547,"activeCount":97},[],{"intervention":13545,"totalTrials":417,"cells":13549},{"EARLY_PHASE1":13550,"PHASE1":13552,"PHASE2":13554,"PHASE3":13556,"PHASE4":13558,"NA":13564},{"trials":13551,"activeCount":97},[],{"trials":13553,"activeCount":97},[],{"trials":13555,"activeCount":97},[],{"trials":13557,"activeCount":97},[],{"trials":13559,"activeCount":97},[13560],{"nctId":13538,"briefTitle":13539,"status":155,"phases":13561,"primaryCompletion":13541,"completion":13541,"start":13542,"enrollment":3168,"conditions":13562,"interventions":13563},[88],[18],[13525,13545],{"trials":13565,"activeCount":97},[],{"intervention":13567,"totalTrials":417,"cells":13568},"IODEX® balm",{"EARLY_PHASE1":13569,"PHASE1":13571,"PHASE2":13573,"PHASE3":13575,"PHASE4":13577,"NA":13587},{"trials":13570,"activeCount":97},[],{"trials":13572,"activeCount":97},[],{"trials":13574,"activeCount":97},[],{"trials":13576,"activeCount":97},[],{"trials":13578,"activeCount":97},[13579],{"nctId":13580,"briefTitle":13581,"status":155,"phases":13582,"primaryCompletion":13583,"completion":13584,"start":13583,"enrollment":1117,"conditions":13585,"interventions":13586},"NCT02424565","Effect of Topical Application of Iodex® Balm on Local Surface Temperature",[88],"2015-05","2015-06",[9153],[13567],{"trials":13588,"activeCount":97},[],{"intervention":9363,"totalTrials":417,"cells":13590},{"EARLY_PHASE1":13591,"PHASE1":13593,"PHASE2":13595,"PHASE3":13597,"PHASE4":13599,"NA":13605},{"trials":13592,"activeCount":97},[],{"trials":13594,"activeCount":97},[],{"trials":13596,"activeCount":97},[],{"trials":13598,"activeCount":97},[],{"trials":13600,"activeCount":97},[13601],{"nctId":9355,"briefTitle":9356,"status":155,"phases":13602,"start":2823,"enrollment":9358,"conditions":13603,"interventions":13604},[88],[9360],[9301,9362,9363,9364,9365,9366],{"trials":13606,"activeCount":97},[],{"intervention":9364,"totalTrials":417,"cells":13608},{"EARLY_PHASE1":13609,"PHASE1":13611,"PHASE2":13613,"PHASE3":13615,"PHASE4":13617,"NA":13623},{"trials":13610,"activeCount":97},[],{"trials":13612,"activeCount":97},[],{"trials":13614,"activeCount":97},[],{"trials":13616,"activeCount":97},[],{"trials":13618,"activeCount":97},[13619],{"nctId":9355,"briefTitle":9356,"status":155,"phases":13620,"start":2823,"enrollment":9358,"conditions":13621,"interventions":13622},[88],[9360],[9301,9362,9363,9364,9365,9366],{"trials":13624,"activeCount":97},[],{"intervention":13626,"totalTrials":417,"cells":13627},"Ezogabine\u002FRetigabine IR",{"EARLY_PHASE1":13628,"PHASE1":13630,"PHASE2":13632,"PHASE3":13634,"PHASE4":13636,"NA":13647},{"trials":13629,"activeCount":97},[],{"trials":13631,"activeCount":97},[],{"trials":13633,"activeCount":97},[],{"trials":13635,"activeCount":97},[],{"trials":13637,"activeCount":97},[13638],{"nctId":13639,"briefTitle":13640,"status":145,"phases":13641,"primaryCompletion":13642,"completion":13642,"start":13643,"enrollment":628,"conditions":13644,"interventions":13646},"NCT01721317","Dose-Optimization, Adjunctive Treatment Study of Ezogabine\u002FRetigabine Immediate Release in Partial-onset Seizures",[88],"2013-06-20","2012-12-19",[13645],"Seizures",[13626],{"trials":13648,"activeCount":97},[],{"intervention":8441,"totalTrials":417,"cells":13650},{"EARLY_PHASE1":13651,"PHASE1":13653,"PHASE2":13655,"PHASE3":13657,"PHASE4":13659,"NA":13665},{"trials":13652,"activeCount":97},[],{"trials":13654,"activeCount":97},[],{"trials":13656,"activeCount":97},[],{"trials":13658,"activeCount":97},[],{"trials":13660,"activeCount":97},[13661],{"nctId":8434,"briefTitle":8435,"status":155,"phases":13662,"primaryCompletion":7701,"completion":7701,"start":3390,"enrollment":8437,"conditions":13663,"interventions":13664},[88],[15],[8354,8440,8441],{"trials":13666,"activeCount":97},[],{"intervention":13668,"totalTrials":417,"cells":13669},"fluticasone furoate, fexofenadine",{"EARLY_PHASE1":13670,"PHASE1":13672,"PHASE2":13674,"PHASE3":13676,"PHASE4":13678,"NA":13687},{"trials":13671,"activeCount":97},[],{"trials":13673,"activeCount":97},[],{"trials":13675,"activeCount":97},[],{"trials":13677,"activeCount":97},[],{"trials":13679,"activeCount":97},[13680],{"nctId":13681,"briefTitle":13682,"status":155,"phases":13683,"primaryCompletion":3079,"completion":3079,"start":2336,"enrollment":13684,"conditions":13685,"interventions":13686},"NCT00502775","Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine",[88],680,[10169],[13668],{"trials":13688,"activeCount":97},[],{"intervention":13690,"totalTrials":417,"cells":13691},"Mepolizumab 100mg SC",{"EARLY_PHASE1":13692,"PHASE1":13694,"PHASE2":13696,"PHASE3":13698,"PHASE4":13700,"NA":13711},{"trials":13693,"activeCount":97},[],{"trials":13695,"activeCount":97},[],{"trials":13697,"activeCount":97},[],{"trials":13699,"activeCount":97},[],{"trials":13701,"activeCount":97},[13702],{"nctId":13703,"briefTitle":13704,"status":155,"phases":13705,"primaryCompletion":875,"completion":875,"start":13706,"enrollment":7840,"conditions":13707,"interventions":13708},"NCT02654145","Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients",[88],"2016-03-17",[18],[13690,13709,13710],"Albuterol\u002Fsalbutamol MDIs","Omalizumab",{"trials":13712,"activeCount":97},[],{"intervention":13709,"totalTrials":417,"cells":13714},{"EARLY_PHASE1":13715,"PHASE1":13717,"PHASE2":13719,"PHASE3":13721,"PHASE4":13723,"NA":13729},{"trials":13716,"activeCount":97},[],{"trials":13718,"activeCount":97},[],{"trials":13720,"activeCount":97},[],{"trials":13722,"activeCount":97},[],{"trials":13724,"activeCount":97},[13725],{"nctId":13703,"briefTitle":13704,"status":155,"phases":13726,"primaryCompletion":875,"completion":875,"start":13706,"enrollment":7840,"conditions":13727,"interventions":13728},[88],[18],[13690,13709,13710],{"trials":13730,"activeCount":97},[],{"intervention":13710,"totalTrials":417,"cells":13732},{"EARLY_PHASE1":13733,"PHASE1":13735,"PHASE2":13737,"PHASE3":13739,"PHASE4":13741,"NA":13747},{"trials":13734,"activeCount":97},[],{"trials":13736,"activeCount":97},[],{"trials":13738,"activeCount":97},[],{"trials":13740,"activeCount":97},[],{"trials":13742,"activeCount":97},[13743],{"nctId":13703,"briefTitle":13704,"status":155,"phases":13744,"primaryCompletion":875,"completion":875,"start":13706,"enrollment":7840,"conditions":13745,"interventions":13746},[88],[18],[13690,13709,13710],{"trials":13748,"activeCount":97},[],{"intervention":13750,"totalTrials":417,"cells":13751},"salmeterol\u002Ffluticasone propionate 50\u002F250 µg + 3 training sessions of compliance enhancement training",{"EARLY_PHASE1":13752,"PHASE1":13754,"PHASE2":13756,"PHASE3":13758,"PHASE4":13760,"NA":13772},{"trials":13753,"activeCount":97},[],{"trials":13755,"activeCount":97},[],{"trials":13757,"activeCount":97},[],{"trials":13759,"activeCount":97},[],{"trials":13761,"activeCount":97},[13762],{"nctId":13763,"briefTitle":13764,"status":155,"phases":13765,"primaryCompletion":13766,"completion":13766,"start":13767,"enrollment":13768,"conditions":13769,"interventions":13770},"NCT00351143","A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control",[88],"2007-06-13","2005-07-26",274,[18],[13750,13771],"salmeterol\u002Ffluticasone propionate 50\u002F250 µg",{"trials":13773,"activeCount":97},[],{"intervention":13771,"totalTrials":417,"cells":13775},{"EARLY_PHASE1":13776,"PHASE1":13778,"PHASE2":13780,"PHASE3":13782,"PHASE4":13784,"NA":13790},{"trials":13777,"activeCount":97},[],{"trials":13779,"activeCount":97},[],{"trials":13781,"activeCount":97},[],{"trials":13783,"activeCount":97},[],{"trials":13785,"activeCount":97},[13786],{"nctId":13763,"briefTitle":13764,"status":155,"phases":13787,"primaryCompletion":13766,"completion":13766,"start":13767,"enrollment":13768,"conditions":13788,"interventions":13789},[88],[18],[13750,13771],{"trials":13791,"activeCount":97},[],{"intervention":13793,"totalTrials":417,"cells":13794},"Amoxicillin\u002Fclavulanate",{"EARLY_PHASE1":13795,"PHASE1":13797,"PHASE2":13799,"PHASE3":13801,"PHASE4":13803,"NA":13816},{"trials":13796,"activeCount":97},[],{"trials":13798,"activeCount":97},[],{"trials":13800,"activeCount":97},[],{"trials":13802,"activeCount":97},[],{"trials":13804,"activeCount":97},[13805],{"nctId":13806,"briefTitle":13807,"status":155,"phases":13808,"primaryCompletion":13809,"completion":13809,"start":13810,"enrollment":13811,"conditions":13812,"interventions":13814},"NCT02141217","AUGMENTIN™ in Dental Infections",[88],"2013-12-28","2013-03-21",472,[13813],"Focal Infection, Dental",[13793,13815],"Clindamycin",{"trials":13817,"activeCount":97},[],{"intervention":13815,"totalTrials":417,"cells":13819},{"EARLY_PHASE1":13820,"PHASE1":13822,"PHASE2":13824,"PHASE3":13826,"PHASE4":13828,"NA":13834},{"trials":13821,"activeCount":97},[],{"trials":13823,"activeCount":97},[],{"trials":13825,"activeCount":97},[],{"trials":13827,"activeCount":97},[],{"trials":13829,"activeCount":97},[13830],{"nctId":13806,"briefTitle":13807,"status":155,"phases":13831,"primaryCompletion":13809,"completion":13809,"start":13810,"enrollment":13811,"conditions":13832,"interventions":13833},[88],[13813],[13793,13815],{"trials":13835,"activeCount":97},[],{"intervention":13837,"totalTrials":417,"cells":13838},"Metformin Small Pack",{"EARLY_PHASE1":13839,"PHASE1":13841,"PHASE2":13843,"PHASE3":13845,"PHASE4":13847,"NA":13856},{"trials":13840,"activeCount":97},[],{"trials":13842,"activeCount":97},[],{"trials":13844,"activeCount":97},[],{"trials":13846,"activeCount":97},[],{"trials":13848,"activeCount":97},[13849],{"nctId":13850,"briefTitle":13851,"status":145,"phases":13852,"primaryCompletion":13418,"completion":13418,"start":5195,"enrollment":3379,"conditions":13853,"interventions":13854},"NCT01817777","An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Treatment in Subjects With Type II Diabetes",[88],[27],[13837,13855],"Metformin Large Pack",{"trials":13857,"activeCount":97},[],{"intervention":13855,"totalTrials":417,"cells":13859},{"EARLY_PHASE1":13860,"PHASE1":13862,"PHASE2":13864,"PHASE3":13866,"PHASE4":13868,"NA":13874},{"trials":13861,"activeCount":97},[],{"trials":13863,"activeCount":97},[],{"trials":13865,"activeCount":97},[],{"trials":13867,"activeCount":97},[],{"trials":13869,"activeCount":97},[13870],{"nctId":13850,"briefTitle":13851,"status":145,"phases":13871,"primaryCompletion":13418,"completion":13418,"start":5195,"enrollment":3379,"conditions":13872,"interventions":13873},[88],[27],[13837,13855],{"trials":13875,"activeCount":97},[],{"intervention":11594,"totalTrials":417,"cells":13877},{"EARLY_PHASE1":13878,"PHASE1":13880,"PHASE2":13882,"PHASE3":13884,"PHASE4":13886,"NA":13892},{"trials":13879,"activeCount":97},[],{"trials":13881,"activeCount":97},[],{"trials":13883,"activeCount":97},[],{"trials":13885,"activeCount":97},[],{"trials":13887,"activeCount":97},[13888],{"nctId":11585,"briefTitle":11586,"status":155,"phases":13889,"primaryCompletion":8478,"completion":8478,"start":10659,"enrollment":11588,"conditions":13890,"interventions":13891},[88],[18],[11563,11591,11592,11581,11593,11594],{"trials":13893,"activeCount":97},[],{"intervention":13895,"totalTrials":417,"cells":13896},"vehicle placebo nasal spray",{"EARLY_PHASE1":13897,"PHASE1":13899,"PHASE2":13901,"PHASE3":13903,"PHASE4":13905,"NA":13915},{"trials":13898,"activeCount":97},[],{"trials":13900,"activeCount":97},[],{"trials":13902,"activeCount":97},[],{"trials":13904,"activeCount":97},[],{"trials":13906,"activeCount":97},[13907],{"nctId":13908,"briefTitle":13909,"status":155,"phases":13910,"primaryCompletion":729,"completion":729,"start":7546,"enrollment":13911,"conditions":13912,"interventions":13913},"NCT00682643","A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis",[88],550,[10182],[13914,13895],"fluticasone furoate nasal spray",{"trials":13916,"activeCount":97},[],{"intervention":13918,"totalTrials":417,"cells":13919},"valacyclovir hydrochloride",{"EARLY_PHASE1":13920,"PHASE1":13922,"PHASE2":13924,"PHASE3":13926,"PHASE4":13928,"NA":13939},{"trials":13921,"activeCount":97},[],{"trials":13923,"activeCount":97},[],{"trials":13925,"activeCount":97},[],{"trials":13927,"activeCount":97},[],{"trials":13929,"activeCount":97},[13930],{"nctId":13931,"briefTitle":13932,"status":145,"phases":13933,"primaryCompletion":13934,"completion":13934,"start":13935,"enrollment":1318,"conditions":13936,"interventions":13938},"NCT00079911","A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons",[88],"2004-10-15","2004-03-12",[13937],"Herpes Genitalis",[13918],{"trials":13940,"activeCount":97},[],{"intervention":13942,"totalTrials":417,"cells":13943},"FF nasal spray",{"EARLY_PHASE1":13944,"PHASE1":13946,"PHASE2":13948,"PHASE3":13950,"PHASE4":13952,"NA":13963},{"trials":13945,"activeCount":97},[],{"trials":13947,"activeCount":97},[],{"trials":13949,"activeCount":97},[],{"trials":13951,"activeCount":97},[],{"trials":13953,"activeCount":97},[13954],{"nctId":13955,"briefTitle":13956,"status":155,"phases":13957,"primaryCompletion":13958,"completion":13958,"start":13959,"enrollment":536,"conditions":13960,"interventions":13961},"NCT02397915","Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays",[88],"2015-06-08","2015-03-26",[10147],[13942,13962],"MF nasal spray",{"trials":13964,"activeCount":97},[],{"intervention":13962,"totalTrials":417,"cells":13966},{"EARLY_PHASE1":13967,"PHASE1":13969,"PHASE2":13971,"PHASE3":13973,"PHASE4":13975,"NA":13981},{"trials":13968,"activeCount":97},[],{"trials":13970,"activeCount":97},[],{"trials":13972,"activeCount":97},[],{"trials":13974,"activeCount":97},[],{"trials":13976,"activeCount":97},[13977],{"nctId":13955,"briefTitle":13956,"status":155,"phases":13978,"primaryCompletion":13958,"completion":13958,"start":13959,"enrollment":536,"conditions":13979,"interventions":13980},[88],[10147],[13942,13962],{"trials":13982,"activeCount":97},[],{"intervention":13984,"totalTrials":417,"cells":13985},"salmeterol xinafoate\u002Ffluticasone propionate",{"EARLY_PHASE1":13986,"PHASE1":13988,"PHASE2":13990,"PHASE3":13992,"PHASE4":13994,"NA":14004},{"trials":13987,"activeCount":97},[],{"trials":13989,"activeCount":97},[],{"trials":13991,"activeCount":97},[],{"trials":13993,"activeCount":97},[],{"trials":13995,"activeCount":97},[13996],{"nctId":13997,"briefTitle":13998,"status":145,"phases":13999,"completion":14000,"start":14001,"enrollment":13684,"conditions":14002,"interventions":14003},"NCT00273026","Study In Asthma Control",[88],"2006-03-28","2004-11-08",[18],[13984],{"trials":14005,"activeCount":97},[],{"intervention":14007,"totalTrials":417,"cells":14008},"Engerix-B Kinder",{"EARLY_PHASE1":14009,"PHASE1":14011,"PHASE2":14013,"PHASE3":14015,"PHASE4":14017,"NA":14027},{"trials":14010,"activeCount":97},[],{"trials":14012,"activeCount":97},[],{"trials":14014,"activeCount":97},[],{"trials":14016,"activeCount":97},[],{"trials":14018,"activeCount":97},[14019],{"nctId":14020,"briefTitle":14021,"status":155,"phases":14022,"primaryCompletion":14023,"completion":14023,"start":14024,"enrollment":1272,"conditions":14025,"interventions":14026},"NCT02798952","A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy",[88],"2017-07-05","2016-08-23",[24],[14007],{"trials":14028,"activeCount":97},[],{"intervention":9426,"totalTrials":417,"cells":14030},{"EARLY_PHASE1":14031,"PHASE1":14033,"PHASE2":14035,"PHASE3":14037,"PHASE4":14039,"NA":14045},{"trials":14032,"activeCount":97},[],{"trials":14034,"activeCount":97},[],{"trials":14036,"activeCount":97},[],{"trials":14038,"activeCount":97},[],{"trials":14040,"activeCount":97},[14041],{"nctId":9421,"briefTitle":9422,"status":155,"phases":14042,"start":2405,"enrollment":624,"conditions":14043,"interventions":14044},[88],[18],[9426,9370],{"trials":14046,"activeCount":97},[],{"intervention":12117,"totalTrials":417,"cells":14048},{"EARLY_PHASE1":14049,"PHASE1":14051,"PHASE2":14053,"PHASE3":14055,"PHASE4":14057,"NA":14063},{"trials":14050,"activeCount":97},[],{"trials":14052,"activeCount":97},[],{"trials":14054,"activeCount":97},[],{"trials":14056,"activeCount":97},[],{"trials":14058,"activeCount":97},[14059],{"nctId":12111,"briefTitle":12112,"status":12113,"phases":14060,"start":7847,"enrollment":4388,"conditions":14061,"interventions":14062},[88],[10943],[12117,12118],{"trials":14064,"activeCount":97},[],{"intervention":14066,"totalTrials":417,"cells":14067},"Salmeterol \u002F Fluticasone (50\u002F500 µg) BID fixed combination",{"EARLY_PHASE1":14068,"PHASE1":14070,"PHASE2":14072,"PHASE3":14074,"PHASE4":14076,"NA":14086},{"trials":14069,"activeCount":97},[],{"trials":14071,"activeCount":97},[],{"trials":14073,"activeCount":97},[],{"trials":14075,"activeCount":97},[],{"trials":14077,"activeCount":97},[14078],{"nctId":14079,"briefTitle":14080,"status":155,"phases":14081,"primaryCompletion":2441,"completion":2441,"start":3079,"enrollment":14082,"conditions":14083,"interventions":14084},"NCT00527826","Influence Of Salmeterol Xinafoate\u002FFluticasone Propionate (50\u002F500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV",[88],214,[15],[14066,14085],"Salmeterol \u002F Fluticasone (50\u002F500 µg) BID separate Inhalers",{"trials":14087,"activeCount":97},[],{"intervention":14085,"totalTrials":417,"cells":14089},{"EARLY_PHASE1":14090,"PHASE1":14092,"PHASE2":14094,"PHASE3":14096,"PHASE4":14098,"NA":14104},{"trials":14091,"activeCount":97},[],{"trials":14093,"activeCount":97},[],{"trials":14095,"activeCount":97},[],{"trials":14097,"activeCount":97},[],{"trials":14099,"activeCount":97},[14100],{"nctId":14079,"briefTitle":14080,"status":155,"phases":14101,"primaryCompletion":2441,"completion":2441,"start":3079,"enrollment":14082,"conditions":14102,"interventions":14103},[88],[15],[14066,14085],{"trials":14105,"activeCount":97},[],{"intervention":14107,"totalTrials":417,"cells":14108},"Salmeterol\u002Ffluticasone propionate or formoterol\u002Fbudesonide",{"EARLY_PHASE1":14109,"PHASE1":14111,"PHASE2":14113,"PHASE3":14115,"PHASE4":14117,"NA":14125},{"trials":14110,"activeCount":97},[],{"trials":14112,"activeCount":97},[],{"trials":14114,"activeCount":97},[],{"trials":14116,"activeCount":97},[],{"trials":14118,"activeCount":97},[14119],{"nctId":14120,"briefTitle":14121,"status":155,"phases":14122,"primaryCompletion":3714,"completion":3714,"start":10287,"enrollment":11508,"conditions":14123,"interventions":14124},"NCT00479739","CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.",[88],[18],[14107],{"trials":14126,"activeCount":97},[],{"intervention":14128,"totalTrials":417,"cells":14129},"Adefor dipivoxil",{"EARLY_PHASE1":14130,"PHASE1":14132,"PHASE2":14134,"PHASE3":14136,"PHASE4":14138,"NA":14148},{"trials":14131,"activeCount":97},[],{"trials":14133,"activeCount":97},[],{"trials":14135,"activeCount":97},[],{"trials":14137,"activeCount":97},[],{"trials":14139,"activeCount":97},[14140],{"nctId":14141,"briefTitle":14142,"status":155,"phases":14143,"primaryCompletion":2270,"completion":2270,"start":14144,"enrollment":14145,"conditions":14146,"interventions":14147},"NCT01205165","An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB)",[88],"2004-12-17",104,[4191],[14128],{"trials":14149,"activeCount":97},[],{"intervention":14151,"totalTrials":417,"cells":14152},"sumatriptan and naproxen sodium combination",{"EARLY_PHASE1":14153,"PHASE1":14155,"PHASE2":14157,"PHASE3":14159,"PHASE4":14161,"NA":14172},{"trials":14154,"activeCount":97},[],{"trials":14156,"activeCount":97},[],{"trials":14158,"activeCount":97},[],{"trials":14160,"activeCount":97},[],{"trials":14162,"activeCount":97},[14163],{"nctId":14164,"briefTitle":14165,"status":155,"phases":14166,"primaryCompletion":6351,"completion":6351,"start":10166,"enrollment":11770,"conditions":14167,"interventions":14169},"NCT00792636","A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period",[88],[14168],"Migraine Disorders",[14151,14170,14171],"sumatriptan","naproxen sodium",{"trials":14173,"activeCount":97},[],{"intervention":14171,"totalTrials":417,"cells":14175},{"EARLY_PHASE1":14176,"PHASE1":14178,"PHASE2":14180,"PHASE3":14182,"PHASE4":14184,"NA":14190},{"trials":14177,"activeCount":97},[],{"trials":14179,"activeCount":97},[],{"trials":14181,"activeCount":97},[],{"trials":14183,"activeCount":97},[],{"trials":14185,"activeCount":97},[14186],{"nctId":14164,"briefTitle":14165,"status":155,"phases":14187,"primaryCompletion":6351,"completion":6351,"start":10166,"enrollment":11770,"conditions":14188,"interventions":14189},[88],[14168],[14151,14170,14171],{"trials":14191,"activeCount":97},[],{"intervention":14193,"totalTrials":417,"cells":14194},"adefovir dipivoxil 10mg",{"EARLY_PHASE1":14195,"PHASE1":14197,"PHASE2":14199,"PHASE3":14201,"PHASE4":14203,"NA":14211},{"trials":14196,"activeCount":97},[],{"trials":14198,"activeCount":97},[],{"trials":14200,"activeCount":97},[],{"trials":14202,"activeCount":97},[],{"trials":14204,"activeCount":97},[14205],{"nctId":14206,"briefTitle":14207,"status":155,"phases":14208,"primaryCompletion":2355,"completion":2355,"start":8963,"enrollment":526,"conditions":14209,"interventions":14210},"NCT00403585","Study of Adefovir Dipivoxil for Korean Patients With Chronic Hepatitis B(CHB) Who Have Completed ADF 103814",[88],[4191,4190],[14193],{"trials":14212,"activeCount":97},[],{"intervention":14214,"totalTrials":417,"cells":14215},"Engerix-B™ Kinder",{"EARLY_PHASE1":14216,"PHASE1":14218,"PHASE2":14220,"PHASE3":14222,"PHASE4":14224,"NA":14234},{"trials":14217,"activeCount":97},[],{"trials":14219,"activeCount":97},[],{"trials":14221,"activeCount":97},[],{"trials":14223,"activeCount":97},[],{"trials":14225,"activeCount":97},[14226],{"nctId":14227,"briefTitle":14228,"status":155,"phases":14229,"primaryCompletion":14230,"completion":14230,"start":14231,"enrollment":536,"conditions":14232,"interventions":14233},"NCT01333813","Hepatitis B Antibody Persistence and Immune Response to Hepatitis B Vaccine Challenge in Previously Vaccinated Children",[88],"2011-09-28","2011-04-26",[24],[14214],{"trials":14235,"activeCount":97},[],{"intervention":14237,"totalTrials":417,"cells":14238},"ropinirole CR-RLS",{"EARLY_PHASE1":14239,"PHASE1":14241,"PHASE2":14243,"PHASE3":14245,"PHASE4":14247,"NA":14257},{"trials":14240,"activeCount":97},[],{"trials":14242,"activeCount":97},[],{"trials":14244,"activeCount":97},[],{"trials":14246,"activeCount":97},[],{"trials":14248,"activeCount":97},[14249],{"nctId":14250,"briefTitle":14251,"status":155,"phases":14252,"primaryCompletion":3552,"completion":3552,"start":2404,"enrollment":12202,"conditions":14253,"interventions":14256},"NCT00373542","12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome",[88],[14254,14255],"Restless Legs Syndrome (RLS)","Restless Legs Syndrome",[14237],{"trials":14258,"activeCount":97},[],{"intervention":14260,"totalTrials":417,"cells":14261},"FLOLAN injection with currently marketed diluent",{"EARLY_PHASE1":14262,"PHASE1":14264,"PHASE2":14266,"PHASE3":14268,"PHASE4":14270,"NA":14282},{"trials":14263,"activeCount":97},[],{"trials":14265,"activeCount":97},[],{"trials":14267,"activeCount":97},[],{"trials":14269,"activeCount":97},[],{"trials":14271,"activeCount":97},[14272],{"nctId":14273,"briefTitle":14274,"status":155,"phases":14275,"primaryCompletion":14276,"completion":14276,"start":14277,"enrollment":750,"conditions":14278,"interventions":14280},"NCT02705807","Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects",[88],"2016-07","2016-05",[14279],"Cardiovascular Disease",[14260,14281],"FLOLAN injection with reformulated diluent",{"trials":14283,"activeCount":97},[],{"intervention":14281,"totalTrials":417,"cells":14285},{"EARLY_PHASE1":14286,"PHASE1":14288,"PHASE2":14290,"PHASE3":14292,"PHASE4":14294,"NA":14300},{"trials":14287,"activeCount":97},[],{"trials":14289,"activeCount":97},[],{"trials":14291,"activeCount":97},[],{"trials":14293,"activeCount":97},[],{"trials":14295,"activeCount":97},[14296],{"nctId":14273,"briefTitle":14274,"status":155,"phases":14297,"primaryCompletion":14276,"completion":14276,"start":14277,"enrollment":750,"conditions":14298,"interventions":14299},[88],[14279],[14260,14281],{"trials":14301,"activeCount":97},[],{"intervention":14303,"totalTrials":417,"cells":14304},"Short Acting Beta 2 Agonist",{"EARLY_PHASE1":14305,"PHASE1":14307,"PHASE2":14309,"PHASE3":14311,"PHASE4":14313,"NA":14324},{"trials":14306,"activeCount":97},[],{"trials":14308,"activeCount":97},[],{"trials":14310,"activeCount":97},[],{"trials":14312,"activeCount":97},[],{"trials":14314,"activeCount":97},[14315],{"nctId":14316,"briefTitle":14317,"status":155,"phases":14318,"primaryCompletion":14319,"completion":14320,"start":14321,"enrollment":6646,"conditions":14322,"interventions":14323},"NCT02889809","Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year",[88],"2021-04-09","2021-06-04","2017-07-10",[18],[9502,8578,14303],{"trials":14325,"activeCount":97},[],{"intervention":14327,"totalTrials":417,"cells":14328},"RZV",{"EARLY_PHASE1":14329,"PHASE1":14331,"PHASE2":14333,"PHASE3":14335,"PHASE4":14337,"NA":14348},{"trials":14330,"activeCount":97},[],{"trials":14332,"activeCount":97},[],{"trials":14334,"activeCount":97},[],{"trials":14336,"activeCount":97},[],{"trials":14338,"activeCount":97},[14339],{"nctId":14340,"briefTitle":14341,"status":155,"phases":14342,"primaryCompletion":14343,"completion":14343,"start":14344,"enrollment":14345,"conditions":14346,"interventions":14347},"NCT04869982","Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years",[88],"2023-04-20","2021-05-14",6138,[1030],[14327],{"trials":14349,"activeCount":97},[],{"intervention":14351,"totalTrials":417,"cells":14352},"amoxicillin\u002Fclavulanate potassium 1gm",{"EARLY_PHASE1":14353,"PHASE1":14355,"PHASE2":14357,"PHASE3":14359,"PHASE4":14361,"NA":14372},{"trials":14354,"activeCount":97},[],{"trials":14356,"activeCount":97},[],{"trials":14358,"activeCount":97},[],{"trials":14360,"activeCount":97},[],{"trials":14362,"activeCount":97},[14363],{"nctId":14364,"briefTitle":14365,"status":155,"phases":14366,"primaryCompletion":2814,"completion":2814,"start":1361,"enrollment":14367,"conditions":14368,"interventions":14371},"NCT00343135","AUGMENTIN 1gm In Skin And Soft Tissue Infection",[88],195,[14369,14370],"Skin Diseases, Infectious","Infection, Soft Tissue",[14351],{"trials":14373,"activeCount":97},[],{"intervention":14375,"totalTrials":417,"cells":14376},"Fluticasone Propionate\u002FSalmeterol DISKUS 250\u002F50mcg",{"EARLY_PHASE1":14377,"PHASE1":14379,"PHASE2":14381,"PHASE3":14383,"PHASE4":14385,"NA":14395},{"trials":14378,"activeCount":97},[],{"trials":14380,"activeCount":97},[],{"trials":14382,"activeCount":97},[],{"trials":14384,"activeCount":97},[],{"trials":14386,"activeCount":97},[14387],{"nctId":14388,"briefTitle":14389,"status":155,"phases":14390,"primaryCompletion":8116,"completion":8116,"start":2382,"enrollment":14391,"conditions":14392,"interventions":14393},"NCT00633217","Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)",[88],247,[15],[14375,14394],"Fluticasone Propionate\u002FSalmeterol Hydrofluoroalkane 134a MDI 230\u002F42mcg",{"trials":14396,"activeCount":97},[],{"intervention":14394,"totalTrials":417,"cells":14398},{"EARLY_PHASE1":14399,"PHASE1":14401,"PHASE2":14403,"PHASE3":14405,"PHASE4":14407,"NA":14413},{"trials":14400,"activeCount":97},[],{"trials":14402,"activeCount":97},[],{"trials":14404,"activeCount":97},[],{"trials":14406,"activeCount":97},[],{"trials":14408,"activeCount":97},[14409],{"nctId":14388,"briefTitle":14389,"status":155,"phases":14410,"primaryCompletion":8116,"completion":8116,"start":2382,"enrollment":14391,"conditions":14411,"interventions":14412},[88],[15],[14375,14394],{"trials":14414,"activeCount":97},[],{"intervention":14416,"totalTrials":417,"cells":14417},"Avamys aqueous nasal spray 110mcg",{"EARLY_PHASE1":14418,"PHASE1":14420,"PHASE2":14422,"PHASE3":14424,"PHASE4":14426,"NA":14434},{"trials":14419,"activeCount":97},[],{"trials":14421,"activeCount":97},[],{"trials":14423,"activeCount":97},[],{"trials":14425,"activeCount":97},[],{"trials":14427,"activeCount":97},[14428],{"nctId":14429,"briefTitle":14430,"status":155,"phases":14431,"primaryCompletion":2834,"completion":2834,"start":9159,"enrollment":1237,"conditions":14432,"interventions":14433},"NCT01270958","A Phase-IV, Open-label Study to Evaluate Safety\u002FTolerability of Once-daily AVAMYS (TM) Aqueous Nasal Spray 110mcg Among Vietnamese Adult Patients With Established Perennial Allergic Rhinitis",[88],[10182],[14416],{"trials":14435,"activeCount":97},[],{"intervention":14437,"totalTrials":417,"cells":14438},"Lacidipine 4 or 6 mg",{"EARLY_PHASE1":14439,"PHASE1":14441,"PHASE2":14443,"PHASE3":14445,"PHASE4":14447,"NA":14460},{"trials":14440,"activeCount":97},[],{"trials":14442,"activeCount":97},[],{"trials":14444,"activeCount":97},[],{"trials":14446,"activeCount":97},[],{"trials":14448,"activeCount":97},[14449],{"nctId":14450,"briefTitle":14451,"status":155,"phases":14452,"primaryCompletion":14453,"completion":14453,"start":14454,"enrollment":730,"conditions":14455,"interventions":14458},"NCT00338338","The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients",[88],"2007-09-14","2005-11-07",[14456,13024,14457],"Uncomplicated Hypertension","Essential",[14437,14459],"Amlodipine 5 or 10 mg",{"trials":14461,"activeCount":97},[],{"intervention":14459,"totalTrials":417,"cells":14463},{"EARLY_PHASE1":14464,"PHASE1":14466,"PHASE2":14468,"PHASE3":14470,"PHASE4":14472,"NA":14478},{"trials":14465,"activeCount":97},[],{"trials":14467,"activeCount":97},[],{"trials":14469,"activeCount":97},[],{"trials":14471,"activeCount":97},[],{"trials":14473,"activeCount":97},[14474],{"nctId":14450,"briefTitle":14451,"status":155,"phases":14475,"primaryCompletion":14453,"completion":14453,"start":14454,"enrollment":730,"conditions":14476,"interventions":14477},[88],[14456,13024,14457],[14437,14459],{"trials":14479,"activeCount":97},[],{"intervention":14481,"totalTrials":417,"cells":14482},"Boostrix-Polio",{"EARLY_PHASE1":14483,"PHASE1":14485,"PHASE2":14487,"PHASE3":14489,"PHASE4":14491,"NA":14499},{"trials":14484,"activeCount":97},[],{"trials":14486,"activeCount":97},[],{"trials":14488,"activeCount":97},[],{"trials":14490,"activeCount":97},[],{"trials":14492,"activeCount":97},[14493],{"nctId":14494,"briefTitle":14495,"status":155,"phases":14496,"primaryCompletion":3536,"completion":3536,"start":4713,"enrollment":10296,"conditions":14497,"interventions":14498},"NCT00635128","Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine",[88],[4702,30,33,3624],[14481],{"trials":14500,"activeCount":97},[],{"intervention":14502,"totalTrials":417,"cells":14503},"valacyclovir",{"EARLY_PHASE1":14504,"PHASE1":14506,"PHASE2":14508,"PHASE3":14510,"PHASE4":14512,"NA":14523},{"trials":14505,"activeCount":97},[],{"trials":14507,"activeCount":97},[],{"trials":14509,"activeCount":97},[],{"trials":14511,"activeCount":97},[],{"trials":14513,"activeCount":97},[14514],{"nctId":14515,"briefTitle":14516,"status":155,"phases":14517,"primaryCompletion":14518,"completion":14518,"start":14519,"enrollment":730,"conditions":14520,"interventions":14522},"NCT00306293","VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2",[88],"2006-11-27","2006-02-20",[14521],"Herpes Labialis",[14502],{"trials":14524,"activeCount":97},[],{"intervention":14526,"totalTrials":417,"cells":14527},"Engerix™ -B",{"EARLY_PHASE1":14528,"PHASE1":14530,"PHASE2":14532,"PHASE3":14534,"PHASE4":14536,"NA":14546},{"trials":14529,"activeCount":97},[],{"trials":14531,"activeCount":97},[],{"trials":14533,"activeCount":97},[],{"trials":14535,"activeCount":97},[],{"trials":14537,"activeCount":97},[14538],{"nctId":14539,"briefTitle":14540,"status":155,"phases":14541,"primaryCompletion":3078,"completion":3078,"start":7581,"enrollment":14542,"conditions":14543,"interventions":14544},"NCT00240526","LT F-up Study 16-20 Yrs After Vaccine Dose of Hepatitis B With\u002FWithout HBIg in Newborns to HBeAg+ Mothers",[88],79,[24],[14526,14545],"Hepatitis B immunoglobulin",{"trials":14547,"activeCount":97},[],{"intervention":14545,"totalTrials":417,"cells":14549},{"EARLY_PHASE1":14550,"PHASE1":14552,"PHASE2":14554,"PHASE3":14556,"PHASE4":14558,"NA":14564},{"trials":14551,"activeCount":97},[],{"trials":14553,"activeCount":97},[],{"trials":14555,"activeCount":97},[],{"trials":14557,"activeCount":97},[],{"trials":14559,"activeCount":97},[14560],{"nctId":14539,"briefTitle":14540,"status":155,"phases":14561,"primaryCompletion":3078,"completion":3078,"start":7581,"enrollment":14542,"conditions":14562,"interventions":14563},[88],[24],[14526,14545],{"trials":14565,"activeCount":97},[],{"intervention":14567,"totalTrials":417,"cells":14568},"Salmeterol 50 mcg BID",{"EARLY_PHASE1":14569,"PHASE1":14571,"PHASE2":14573,"PHASE3":14575,"PHASE4":14577,"NA":14589},{"trials":14570,"activeCount":97},[],{"trials":14572,"activeCount":97},[],{"trials":14574,"activeCount":97},[],{"trials":14576,"activeCount":97},[],{"trials":14578,"activeCount":97},[14579],{"nctId":14580,"briefTitle":14581,"status":155,"phases":14582,"primaryCompletion":14583,"completion":14583,"start":14584,"enrollment":14585,"conditions":14586,"interventions":14587},"NCT00355342","Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.",[88],"2007-09-06","2004-04-28",186,[15],[14567,14588],"Fluticasone Propionate\u002FSalmeterol 250\u002F50 mcg BID",{"trials":14590,"activeCount":97},[],{"intervention":14588,"totalTrials":417,"cells":14592},{"EARLY_PHASE1":14593,"PHASE1":14595,"PHASE2":14597,"PHASE3":14599,"PHASE4":14601,"NA":14607},{"trials":14594,"activeCount":97},[],{"trials":14596,"activeCount":97},[],{"trials":14598,"activeCount":97},[],{"trials":14600,"activeCount":97},[],{"trials":14602,"activeCount":97},[14603],{"nctId":14580,"briefTitle":14581,"status":155,"phases":14604,"primaryCompletion":14583,"completion":14583,"start":14584,"enrollment":14585,"conditions":14605,"interventions":14606},[88],[15],[14567,14588],{"trials":14608,"activeCount":97},[],{"intervention":14610,"totalTrials":417,"cells":14611},"LEVITRA",{"EARLY_PHASE1":14612,"PHASE1":14614,"PHASE2":14616,"PHASE3":14618,"PHASE4":14620,"NA":14632},{"trials":14613,"activeCount":97},[],{"trials":14615,"activeCount":97},[],{"trials":14617,"activeCount":97},[],{"trials":14619,"activeCount":97},[],{"trials":14621,"activeCount":97},[14622],{"nctId":14623,"briefTitle":14624,"status":155,"phases":14625,"primaryCompletion":14626,"completion":14626,"start":14627,"enrollment":14628,"conditions":14629,"interventions":14631},"NCT00379756","A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia",[88],"2007-05-17","2006-05-22",395,[14630],"Erectile Dysfunction",[14610],{"trials":14633,"activeCount":97},[],{"intervention":14635,"totalTrials":417,"cells":14636},"Inhaled corticosteroids\u002Flong-acting beta2-adrenergic\u002Flong-acting muscarinic receptor antagonists",{"EARLY_PHASE1":14637,"PHASE1":14639,"PHASE2":14641,"PHASE3":14643,"PHASE4":14645,"NA":14655},{"trials":14638,"activeCount":97},[],{"trials":14640,"activeCount":97},[],{"trials":14642,"activeCount":97},[],{"trials":14644,"activeCount":97},[],{"trials":14646,"activeCount":97},[14647],{"nctId":14648,"briefTitle":14649,"status":500,"phases":14650,"primaryCompletion":6584,"completion":6584,"start":14651,"enrollment":97,"conditions":14652,"interventions":14653},"NCT03949842","Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study",[88],"2019-06-27",[15],[14635,14654],"Fluticasone furoate\u002Fumeclidinium\u002Fvilanterol",{"trials":14656,"activeCount":97},[],{"intervention":14654,"totalTrials":417,"cells":14658},{"EARLY_PHASE1":14659,"PHASE1":14661,"PHASE2":14663,"PHASE3":14665,"PHASE4":14667,"NA":14673},{"trials":14660,"activeCount":97},[],{"trials":14662,"activeCount":97},[],{"trials":14664,"activeCount":97},[],{"trials":14666,"activeCount":97},[],{"trials":14668,"activeCount":97},[14669],{"nctId":14648,"briefTitle":14649,"status":500,"phases":14670,"primaryCompletion":6584,"completion":6584,"start":14651,"enrollment":97,"conditions":14671,"interventions":14672},[88],[15],[14635,14654],{"trials":14674,"activeCount":97},[],{"intervention":14676,"totalTrials":417,"cells":14677},"Augmentin (ES)-600",{"EARLY_PHASE1":14678,"PHASE1":14680,"PHASE2":14682,"PHASE3":14684,"PHASE4":14686,"NA":14699},{"trials":14679,"activeCount":97},[],{"trials":14681,"activeCount":97},[],{"trials":14683,"activeCount":97},[],{"trials":14685,"activeCount":97},[],{"trials":14687,"activeCount":97},[14688],{"nctId":14689,"briefTitle":14690,"status":155,"phases":14691,"primaryCompletion":14692,"completion":14692,"start":14693,"enrollment":8152,"conditions":14694,"interventions":14698},"NCT04600752","Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India",[88],"2022-11-12","2022-05-07",[14695,14696,14697],"Otitis Media","Infections, Respiratory Tract","Respiratory Tract Infections",[14676],{"trials":14700,"activeCount":97},[],{"intervention":8340,"totalTrials":417,"cells":14702},{"EARLY_PHASE1":14703,"PHASE1":14705,"PHASE2":14707,"PHASE3":14709,"PHASE4":14711,"NA":14717},{"trials":14704,"activeCount":97},[],{"trials":14706,"activeCount":97},[],{"trials":14708,"activeCount":97},[],{"trials":14710,"activeCount":97},[],{"trials":14712,"activeCount":97},[14713],{"nctId":8332,"briefTitle":8333,"status":155,"phases":14714,"primaryCompletion":8335,"completion":8335,"start":8336,"enrollment":8337,"conditions":14715,"interventions":14716},[88],[21],[8340,8177],{"trials":14718,"activeCount":97},[],{"intervention":12867,"totalTrials":417,"cells":14720},{"EARLY_PHASE1":14721,"PHASE1":14723,"PHASE2":14725,"PHASE3":14727,"PHASE4":14729,"NA":14735},{"trials":14722,"activeCount":97},[],{"trials":14724,"activeCount":97},[],{"trials":14726,"activeCount":97},[],{"trials":14728,"activeCount":97},[],{"trials":14730,"activeCount":97},[14731],{"nctId":12858,"briefTitle":12859,"status":155,"phases":14732,"primaryCompletion":12861,"completion":12862,"start":12863,"enrollment":12864,"conditions":14733,"interventions":14734},[88],[8063],[12867,12845],{"trials":14736,"activeCount":97},[],{"intervention":9815,"totalTrials":417,"cells":14738},{"EARLY_PHASE1":14739,"PHASE1":14741,"PHASE2":14743,"PHASE3":14745,"PHASE4":14747,"NA":14753},{"trials":14740,"activeCount":97},[],{"trials":14742,"activeCount":97},[],{"trials":14744,"activeCount":97},[],{"trials":14746,"activeCount":97},[],{"trials":14748,"activeCount":97},[14749],{"nctId":9809,"briefTitle":9810,"status":155,"phases":14750,"primaryCompletion":9812,"completion":9812,"start":3425,"enrollment":624,"conditions":14751,"interventions":14752},[88],[21],[9743,9815],{"trials":14754,"activeCount":97},[],{"intervention":14756,"totalTrials":417,"cells":14757},"Salmeterol\u002F fluticasone propionate",{"EARLY_PHASE1":14758,"PHASE1":14760,"PHASE2":14762,"PHASE3":14764,"PHASE4":14766,"NA":14775},{"trials":14759,"activeCount":97},[],{"trials":14761,"activeCount":97},[],{"trials":14763,"activeCount":97},[],{"trials":14765,"activeCount":97},[],{"trials":14767,"activeCount":97},[14768],{"nctId":14769,"briefTitle":14770,"status":155,"phases":14771,"primaryCompletion":8427,"completion":8427,"start":2405,"enrollment":14772,"conditions":14773,"interventions":14774},"NCT00480649","Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol\u002FFluticasone Propionate) Study In Asthma.(SUCCESS)",[88],424,[18],[14756],{"trials":14776,"activeCount":97},[],{"intervention":9227,"totalTrials":417,"cells":14778},{"EARLY_PHASE1":14779,"PHASE1":14781,"PHASE2":14783,"PHASE3":14785,"PHASE4":14787,"NA":14793},{"trials":14780,"activeCount":97},[],{"trials":14782,"activeCount":97},[],{"trials":14784,"activeCount":97},[],{"trials":14786,"activeCount":97},[],{"trials":14788,"activeCount":97},[14789],{"nctId":9221,"briefTitle":9222,"status":155,"phases":14790,"primaryCompletion":9224,"completion":9224,"start":7590,"enrollment":463,"conditions":14791,"interventions":14792},[88],[21,9183],[4763,9227,9228],{"trials":14794,"activeCount":97},[],{"intervention":9228,"totalTrials":417,"cells":14796},{"EARLY_PHASE1":14797,"PHASE1":14799,"PHASE2":14801,"PHASE3":14803,"PHASE4":14805,"NA":14811},{"trials":14798,"activeCount":97},[],{"trials":14800,"activeCount":97},[],{"trials":14802,"activeCount":97},[],{"trials":14804,"activeCount":97},[],{"trials":14806,"activeCount":97},[14807],{"nctId":9221,"briefTitle":9222,"status":155,"phases":14808,"primaryCompletion":9224,"completion":9224,"start":7590,"enrollment":463,"conditions":14809,"interventions":14810},[88],[21,9183],[4763,9227,9228],{"trials":14812,"activeCount":97},[],{"intervention":14814,"totalTrials":417,"cells":14815},"Lamivudine \u002F Abacavir Sulfate",{"EARLY_PHASE1":14816,"PHASE1":14818,"PHASE2":14820,"PHASE3":14822,"PHASE4":14824,"NA":14832},{"trials":14817,"activeCount":97},[],{"trials":14819,"activeCount":97},[],{"trials":14821,"activeCount":97},[],{"trials":14823,"activeCount":97},[],{"trials":14825,"activeCount":97},[14826],{"nctId":14827,"briefTitle":14828,"status":155,"phases":14829,"start":8963,"enrollment":1720,"conditions":14830,"interventions":14831},"NCT00337922","Pharmacokinetic Study Of EPZICOM Tablet",[88],[10662],[14814],{"trials":14833,"activeCount":97},[],{"intervention":10042,"totalTrials":417,"cells":14835},{"EARLY_PHASE1":14836,"PHASE1":14838,"PHASE2":14840,"PHASE3":14842,"PHASE4":14844,"NA":14850},{"trials":14837,"activeCount":97},[],{"trials":14839,"activeCount":97},[],{"trials":14841,"activeCount":97},[],{"trials":14843,"activeCount":97},[],{"trials":14845,"activeCount":97},[14846],{"nctId":10035,"briefTitle":10036,"status":155,"phases":14847,"primaryCompletion":10038,"completion":10038,"start":10039,"enrollment":9445,"conditions":14848,"interventions":14849},[88],[3624,33,30],[9916,10042],{"trials":14851,"activeCount":97},[],{"intervention":12876,"totalTrials":417,"cells":14853},{"EARLY_PHASE1":14854,"PHASE1":14856,"PHASE2":14858,"PHASE3":14860,"PHASE4":14862,"NA":14868},{"trials":14855,"activeCount":97},[],{"trials":14857,"activeCount":97},[],{"trials":14859,"activeCount":97},[],{"trials":14861,"activeCount":97},[],{"trials":14863,"activeCount":97},[14864],{"nctId":12869,"briefTitle":12870,"status":155,"phases":14865,"primaryCompletion":12872,"completion":12872,"start":12873,"enrollment":454,"conditions":14866,"interventions":14867},[88],[27],[12845,12876],{"trials":14869,"activeCount":97},[],{"intervention":14871,"totalTrials":417,"cells":14872},"Fluarix vaccine",{"EARLY_PHASE1":14873,"PHASE1":14875,"PHASE2":14877,"PHASE3":14879,"PHASE4":14881,"NA":14890},{"trials":14874,"activeCount":97},[],{"trials":14876,"activeCount":97},[],{"trials":14878,"activeCount":97},[],{"trials":14880,"activeCount":97},[],{"trials":14882,"activeCount":97},[14883],{"nctId":14884,"briefTitle":14885,"status":155,"phases":14886,"primaryCompletion":3552,"completion":3552,"start":4757,"enrollment":14887,"conditions":14888,"interventions":14889},"NCT00363870","A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults",[88],7632,[21],[14871],{"trials":14891,"activeCount":97},[],{"intervention":7970,"totalTrials":417,"cells":14893},{"EARLY_PHASE1":14894,"PHASE1":14896,"PHASE2":14898,"PHASE3":14900,"PHASE4":14902,"NA":14908},{"trials":14895,"activeCount":97},[],{"trials":14897,"activeCount":97},[],{"trials":14899,"activeCount":97},[],{"trials":14901,"activeCount":97},[],{"trials":14903,"activeCount":97},[14904],{"nctId":7959,"briefTitle":7960,"status":155,"phases":14905,"primaryCompletion":7962,"completion":7962,"start":7963,"enrollment":7964,"conditions":14906,"interventions":14907},[88],[24,7966],[7968,7718,7969,7970,7971],{"trials":14909,"activeCount":97},[],{"intervention":7971,"totalTrials":417,"cells":14911},{"EARLY_PHASE1":14912,"PHASE1":14914,"PHASE2":14916,"PHASE3":14918,"PHASE4":14920,"NA":14926},{"trials":14913,"activeCount":97},[],{"trials":14915,"activeCount":97},[],{"trials":14917,"activeCount":97},[],{"trials":14919,"activeCount":97},[],{"trials":14921,"activeCount":97},[14922],{"nctId":7959,"briefTitle":7960,"status":155,"phases":14923,"primaryCompletion":7962,"completion":7962,"start":7963,"enrollment":7964,"conditions":14924,"interventions":14925},[88],[24,7966],[7968,7718,7969,7970,7971],{"trials":14927,"activeCount":97},[],{"intervention":10959,"totalTrials":417,"cells":14929},{"EARLY_PHASE1":14930,"PHASE1":14932,"PHASE2":14934,"PHASE3":14936,"PHASE4":14938,"NA":14944},{"trials":14931,"activeCount":97},[],{"trials":14933,"activeCount":97},[],{"trials":14935,"activeCount":97},[],{"trials":14937,"activeCount":97},[],{"trials":14939,"activeCount":97},[14940],{"nctId":10952,"briefTitle":10953,"status":155,"phases":14941,"primaryCompletion":10275,"completion":10275,"start":10955,"conditions":14942,"interventions":14943},[88],[10930,10662],[10958,10959,10919],{"trials":14945,"activeCount":97},[],{"intervention":14947,"totalTrials":417,"cells":14948},"Cefadroxil tablets manufactured by GSK",{"EARLY_PHASE1":14949,"PHASE1":14951,"PHASE2":14953,"PHASE3":14955,"PHASE4":14957,"NA":14968},{"trials":14950,"activeCount":97},[],{"trials":14952,"activeCount":97},[],{"trials":14954,"activeCount":97},[],{"trials":14956,"activeCount":97},[],{"trials":14958,"activeCount":97},[14959],{"nctId":14960,"briefTitle":14961,"status":155,"phases":14962,"primaryCompletion":14963,"completion":14963,"start":5053,"enrollment":1298,"conditions":14964,"interventions":14966},"NCT02446496","A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects",[88],"2014-04-08",[14965],"Infections, Urinary Tract",[14947,14967],"Cefadroxil tablets manufactured by NP",{"trials":14969,"activeCount":97},[],{"intervention":14967,"totalTrials":417,"cells":14971},{"EARLY_PHASE1":14972,"PHASE1":14974,"PHASE2":14976,"PHASE3":14978,"PHASE4":14980,"NA":14986},{"trials":14973,"activeCount":97},[],{"trials":14975,"activeCount":97},[],{"trials":14977,"activeCount":97},[],{"trials":14979,"activeCount":97},[],{"trials":14981,"activeCount":97},[14982],{"nctId":14960,"briefTitle":14961,"status":155,"phases":14983,"primaryCompletion":14963,"completion":14963,"start":5053,"enrollment":1298,"conditions":14984,"interventions":14985},[88],[14965],[14947,14967],{"trials":14987,"activeCount":97},[],{"intervention":14989,"totalTrials":417,"cells":14990},"ADOAIR250",{"EARLY_PHASE1":14991,"PHASE1":14993,"PHASE2":14995,"PHASE3":14997,"PHASE4":14999,"NA":15007},{"trials":14992,"activeCount":97},[],{"trials":14994,"activeCount":97},[],{"trials":14996,"activeCount":97},[],{"trials":14998,"activeCount":97},[],{"trials":15000,"activeCount":97},[15001],{"nctId":15002,"briefTitle":15003,"status":155,"phases":15004,"primaryCompletion":7682,"completion":7682,"start":11315,"enrollment":904,"conditions":15005,"interventions":15006},"NCT01607398","ADOAIR250 Anti-inflammatory Effects in Japanese Subjects With Chronic Obstructive Pulmonary Disease",[88],[15],[14989],{"trials":15008,"activeCount":97},[],{"intervention":11764,"totalTrials":417,"cells":15010},{"EARLY_PHASE1":15011,"PHASE1":15013,"PHASE2":15015,"PHASE3":15017,"PHASE4":15019,"NA":15025},{"trials":15012,"activeCount":97},[],{"trials":15014,"activeCount":97},[],{"trials":15016,"activeCount":97},[],{"trials":15018,"activeCount":97},[],{"trials":15020,"activeCount":97},[15021],{"nctId":11756,"briefTitle":11757,"status":155,"phases":15022,"primaryCompletion":11759,"completion":11759,"start":10886,"enrollment":11760,"conditions":15023,"interventions":15024},[88],[15],[11763,11764],{"trials":15026,"activeCount":97},[],{"intervention":15028,"totalTrials":417,"cells":15029},"Lacidipine",{"EARLY_PHASE1":15030,"PHASE1":15032,"PHASE2":15034,"PHASE3":15036,"PHASE4":15038,"NA":15047},{"trials":15031,"activeCount":97},[],{"trials":15033,"activeCount":97},[],{"trials":15035,"activeCount":97},[],{"trials":15037,"activeCount":97},[],{"trials":15039,"activeCount":97},[15040],{"nctId":15041,"briefTitle":15042,"status":155,"phases":15043,"primaryCompletion":2383,"completion":2383,"start":11097,"conditions":15044,"interventions":15046},"NCT00328965","Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea",[88],[27,15045],"Essential Hypertension",[15028],{"trials":15048,"activeCount":97},[],{"intervention":10696,"totalTrials":417,"cells":15050},{"EARLY_PHASE1":15051,"PHASE1":15053,"PHASE2":15055,"PHASE3":15057,"PHASE4":15059,"NA":15065},{"trials":15052,"activeCount":97},[],{"trials":15054,"activeCount":97},[],{"trials":15056,"activeCount":97},[],{"trials":15058,"activeCount":97},[],{"trials":15060,"activeCount":97},[15061],{"nctId":10691,"briefTitle":10692,"status":155,"phases":15062,"primaryCompletion":2355,"completion":2355,"start":10212,"enrollment":7702,"conditions":15063,"interventions":15064},[88],[10662],[10696,10645],{"trials":15066,"activeCount":97},[],{"intervention":15068,"totalTrials":417,"cells":15069},"Duac® fixed dose combination gel",{"EARLY_PHASE1":15070,"PHASE1":15072,"PHASE2":15074,"PHASE3":15076,"PHASE4":15078,"NA":15091},{"trials":15071,"activeCount":97},[],{"trials":15073,"activeCount":97},[],{"trials":15075,"activeCount":97},[],{"trials":15077,"activeCount":97},[],{"trials":15079,"activeCount":97},[15080],{"nctId":15081,"briefTitle":15082,"status":155,"phases":15083,"primaryCompletion":15084,"completion":513,"start":15085,"enrollment":603,"conditions":15086,"interventions":15088},"NCT02557399","DUAC® Early Onset Efficacy Study in Japanese Subjects",[88],"2015-12-17","2015-10-07",[15087],"Acne Vulgaris",[15068,15089,15090],"ADA 0.1% gel","CLDM 1% gel",{"trials":15092,"activeCount":97},[],{"intervention":15089,"totalTrials":417,"cells":15094},{"EARLY_PHASE1":15095,"PHASE1":15097,"PHASE2":15099,"PHASE3":15101,"PHASE4":15103,"NA":15109},{"trials":15096,"activeCount":97},[],{"trials":15098,"activeCount":97},[],{"trials":15100,"activeCount":97},[],{"trials":15102,"activeCount":97},[],{"trials":15104,"activeCount":97},[15105],{"nctId":15081,"briefTitle":15082,"status":155,"phases":15106,"primaryCompletion":15084,"completion":513,"start":15085,"enrollment":603,"conditions":15107,"interventions":15108},[88],[15087],[15068,15089,15090],{"trials":15110,"activeCount":97},[],{"intervention":15090,"totalTrials":417,"cells":15112},{"EARLY_PHASE1":15113,"PHASE1":15115,"PHASE2":15117,"PHASE3":15119,"PHASE4":15121,"NA":15127},{"trials":15114,"activeCount":97},[],{"trials":15116,"activeCount":97},[],{"trials":15118,"activeCount":97},[],{"trials":15120,"activeCount":97},[],{"trials":15122,"activeCount":97},[15123],{"nctId":15081,"briefTitle":15082,"status":155,"phases":15124,"primaryCompletion":15084,"completion":513,"start":15085,"enrollment":603,"conditions":15125,"interventions":15126},[88],[15087],[15068,15089,15090],{"trials":15128,"activeCount":97},[],{"intervention":15130,"totalTrials":417,"cells":15131},"GSK Biologicals' combined DTPa-IPV\u002FHib vaccine",{"EARLY_PHASE1":15132,"PHASE1":15134,"PHASE2":15136,"PHASE3":15138,"PHASE4":15140,"NA":15152},{"trials":15133,"activeCount":97},[],{"trials":15135,"activeCount":97},[],{"trials":15137,"activeCount":97},[],{"trials":15139,"activeCount":97},[],{"trials":15141,"activeCount":97},[15142],{"nctId":15143,"briefTitle":15144,"status":155,"phases":15145,"primaryCompletion":15146,"completion":15146,"start":15147,"enrollment":15148,"conditions":15149,"interventions":15151},"NCT00325156","Assess the Safety & Reactogenicity of DTPa-IPV\u002FHib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants",[88],"2007-08-23","2004-11-02",2590,[30,33,4702,3624,4704,15150],"Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines",[15130],{"trials":15153,"activeCount":97},[],{"intervention":15155,"totalTrials":417,"cells":15156},"Sensodyne Repair and Protect",{"EARLY_PHASE1":15157,"PHASE1":15159,"PHASE2":15161,"PHASE3":15163,"PHASE4":15165,"NA":15176},{"trials":15158,"activeCount":97},[],{"trials":15160,"activeCount":97},[],{"trials":15162,"activeCount":97},[],{"trials":15164,"activeCount":97},[],{"trials":15166,"activeCount":97},[15167],{"nctId":15168,"briefTitle":15169,"status":155,"phases":15170,"primaryCompletion":15171,"completion":15171,"start":275,"enrollment":11031,"conditions":15172,"interventions":15174},"NCT04050722","A Clinical Study Investigating the Efficacy of a Stannous Fluoride Dentifrice in Improving Gingival Health After Twice Daily Use for 3 Weeks",[88],"2019-11-13",[15173],"Gingivitis",[15155,15175],"Colgate Cavity Protection",{"trials":15177,"activeCount":97},[],{"intervention":15175,"totalTrials":417,"cells":15179},{"EARLY_PHASE1":15180,"PHASE1":15182,"PHASE2":15184,"PHASE3":15186,"PHASE4":15188,"NA":15194},{"trials":15181,"activeCount":97},[],{"trials":15183,"activeCount":97},[],{"trials":15185,"activeCount":97},[],{"trials":15187,"activeCount":97},[],{"trials":15189,"activeCount":97},[15190],{"nctId":15168,"briefTitle":15169,"status":155,"phases":15191,"primaryCompletion":15171,"completion":15171,"start":275,"enrollment":11031,"conditions":15192,"interventions":15193},[88],[15173],[15155,15175],{"trials":15195,"activeCount":97},[],{"intervention":15197,"totalTrials":417,"cells":15198},"BoostrixTM Polio",{"EARLY_PHASE1":15199,"PHASE1":15201,"PHASE2":15203,"PHASE3":15205,"PHASE4":15207,"NA":15218},{"trials":15200,"activeCount":97},[],{"trials":15202,"activeCount":97},[],{"trials":15204,"activeCount":97},[],{"trials":15206,"activeCount":97},[],{"trials":15208,"activeCount":97},[15209],{"nctId":15210,"briefTitle":15211,"status":155,"phases":15212,"primaryCompletion":15213,"completion":15213,"start":15214,"enrollment":15215,"conditions":15216,"interventions":15217},"NCT01323959","Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults",[88],"2012-03-01","2011-04-01",212,[3624,4702,30,33],[15197],{"trials":15219,"activeCount":97},[],{"intervention":15221,"totalTrials":417,"cells":15222},"Marketed Denture Adhesive",{"EARLY_PHASE1":15223,"PHASE1":15225,"PHASE2":15227,"PHASE3":15229,"PHASE4":15231,"NA":15240},{"trials":15224,"activeCount":97},[],{"trials":15226,"activeCount":97},[],{"trials":15228,"activeCount":97},[],{"trials":15230,"activeCount":97},[],{"trials":15232,"activeCount":97},[15233],{"nctId":15234,"briefTitle":15235,"status":155,"phases":15236,"primaryCompletion":242,"completion":242,"start":6544,"enrollment":2375,"conditions":15237,"interventions":15239},"NCT03709810","A Study to Investigate Food Occlusion Efficacy of a Denture Adhesive in Denture Wearers",[88],[15238],"Denture Retention",[15221],{"trials":15241,"activeCount":97},[],{"intervention":15243,"totalTrials":417,"cells":15244},"Sufentanil",{"EARLY_PHASE1":15245,"PHASE1":15247,"PHASE2":15249,"PHASE3":15251,"PHASE4":15253,"NA":15262},{"trials":15246,"activeCount":97},[],{"trials":15248,"activeCount":97},[],{"trials":15250,"activeCount":97},[],{"trials":15252,"activeCount":97},[],{"trials":15254,"activeCount":97},[15255],{"nctId":15256,"briefTitle":15257,"status":145,"phases":15258,"start":5196,"enrollment":15259,"conditions":15260,"interventions":15261},"NCT00421720","A Study Comparing Two Analgesia\u002FSedation Regimens, Remifentanil\u002FPropofol Versus Sufentanil\u002FPropofol In Mechanically Ventilated Intensive Care Patients Requiring Analgesia And Sedation.",[88],164,[9161,9360],[15243,12205],{"trials":15263,"activeCount":97},[],{"intervention":15265,"totalTrials":417,"cells":15266},"Salmeterol\u002FFluticasone 50\u002F250 mcg",{"EARLY_PHASE1":15267,"PHASE1":15269,"PHASE2":15271,"PHASE3":15273,"PHASE4":15275,"NA":15287},{"trials":15268,"activeCount":97},[],{"trials":15270,"activeCount":97},[],{"trials":15272,"activeCount":97},[],{"trials":15274,"activeCount":97},[],{"trials":15276,"activeCount":97},[15277],{"nctId":15278,"briefTitle":15279,"status":155,"phases":15280,"primaryCompletion":15281,"completion":14453,"start":15282,"enrollment":15283,"conditions":15284,"interventions":15285},"NCT00363480","Results Of Patient Rated Asthma Control Test In Comparison To Diary Card Data",[88],"2007-09-01","2006-05-17",221,[18],[15265,15286],"Salbutamol 100 mcg",{"trials":15288,"activeCount":97},[],{"intervention":15286,"totalTrials":417,"cells":15290},{"EARLY_PHASE1":15291,"PHASE1":15293,"PHASE2":15295,"PHASE3":15297,"PHASE4":15299,"NA":15305},{"trials":15292,"activeCount":97},[],{"trials":15294,"activeCount":97},[],{"trials":15296,"activeCount":97},[],{"trials":15298,"activeCount":97},[],{"trials":15300,"activeCount":97},[15301],{"nctId":15278,"briefTitle":15279,"status":155,"phases":15302,"primaryCompletion":15281,"completion":14453,"start":15282,"enrollment":15283,"conditions":15303,"interventions":15304},[88],[18],[15265,15286],{"trials":15306,"activeCount":97},[],{"intervention":15308,"totalTrials":417,"cells":15309},"Chlorhexidine digluconate",{"EARLY_PHASE1":15310,"PHASE1":15312,"PHASE2":15314,"PHASE3":15316,"PHASE4":15318,"NA":15327},{"trials":15311,"activeCount":97},[],{"trials":15313,"activeCount":97},[],{"trials":15315,"activeCount":97},[],{"trials":15317,"activeCount":97},[],{"trials":15319,"activeCount":97},[15320],{"nctId":15321,"briefTitle":15322,"status":155,"phases":15323,"primaryCompletion":7701,"completion":7701,"start":493,"enrollment":3392,"conditions":15324,"interventions":15326},"NCT01962493","An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Tooth Staining",[88],[15325],"Oral Hygiene",[15308],{"trials":15328,"activeCount":97},[],{"intervention":15330,"totalTrials":417,"cells":15331},"Valaciclovir Hydrochloride",{"EARLY_PHASE1":15332,"PHASE1":15334,"PHASE2":15336,"PHASE3":15338,"PHASE4":15340,"NA":15348},{"trials":15333,"activeCount":97},[],{"trials":15335,"activeCount":97},[],{"trials":15337,"activeCount":97},[],{"trials":15339,"activeCount":97},[],{"trials":15341,"activeCount":97},[15342],{"nctId":15343,"briefTitle":15344,"status":155,"phases":15345,"primaryCompletion":10395,"completion":10395,"start":10212,"enrollment":1634,"conditions":15346,"interventions":15347},"NCT00343278","Pharmacokinetic Study Of Valaciclovir Hydrochloride Tablets",[88],[9840],[15330],{"trials":15349,"activeCount":97},[],{"intervention":15351,"totalTrials":417,"cells":15352},"FLOVENT™ DISKUS™ 100 mcg BID",{"EARLY_PHASE1":15353,"PHASE1":15355,"PHASE2":15357,"PHASE3":15359,"PHASE4":15361,"NA":15370},{"trials":15354,"activeCount":97},[],{"trials":15356,"activeCount":97},[],{"trials":15358,"activeCount":97},[],{"trials":15360,"activeCount":97},[],{"trials":15362,"activeCount":97},[15363],{"nctId":15364,"briefTitle":15365,"status":155,"phases":15366,"primaryCompletion":2344,"completion":2344,"start":3391,"enrollment":940,"conditions":15367,"interventions":15368},"NCT01192178","Fall Epidemic Viral Pediatric Study",[88],[18],[15351,15369],"ADVAIR™ DISKUS™ 100\u002F50 mcg BID",{"trials":15371,"activeCount":97},[],{"intervention":15369,"totalTrials":417,"cells":15373},{"EARLY_PHASE1":15374,"PHASE1":15376,"PHASE2":15378,"PHASE3":15380,"PHASE4":15382,"NA":15388},{"trials":15375,"activeCount":97},[],{"trials":15377,"activeCount":97},[],{"trials":15379,"activeCount":97},[],{"trials":15381,"activeCount":97},[],{"trials":15383,"activeCount":97},[15384],{"nctId":15364,"briefTitle":15365,"status":155,"phases":15385,"primaryCompletion":2344,"completion":2344,"start":3391,"enrollment":940,"conditions":15386,"interventions":15387},[88],[18],[15351,15369],{"trials":15389,"activeCount":97},[],{"intervention":11488,"totalTrials":417,"cells":15391},{"EARLY_PHASE1":15392,"PHASE1":15394,"PHASE2":15396,"PHASE3":15398,"PHASE4":15400,"NA":15406},{"trials":15393,"activeCount":97},[],{"trials":15395,"activeCount":97},[],{"trials":15397,"activeCount":97},[],{"trials":15399,"activeCount":97},[],{"trials":15401,"activeCount":97},[15402],{"nctId":11480,"briefTitle":11481,"status":155,"phases":15403,"primaryCompletion":11483,"completion":11483,"start":11484,"enrollment":2922,"conditions":15404,"interventions":15405},[88],[11486],[11488,11489,11490,10572],{"trials":15407,"activeCount":97},[],{"intervention":11490,"totalTrials":417,"cells":15409},{"EARLY_PHASE1":15410,"PHASE1":15412,"PHASE2":15414,"PHASE3":15416,"PHASE4":15418,"NA":15424},{"trials":15411,"activeCount":97},[],{"trials":15413,"activeCount":97},[],{"trials":15415,"activeCount":97},[],{"trials":15417,"activeCount":97},[],{"trials":15419,"activeCount":97},[15420],{"nctId":11480,"briefTitle":11481,"status":155,"phases":15421,"primaryCompletion":11483,"completion":11483,"start":11484,"enrollment":2922,"conditions":15422,"interventions":15423},[88],[11486],[11488,11489,11490,10572],{"trials":15425,"activeCount":97},[],{"intervention":2998,"totalTrials":417,"cells":15427},{"EARLY_PHASE1":15428,"PHASE1":15430,"PHASE2":15432,"PHASE3":15434,"PHASE4":15436,"NA":15442},{"trials":15429,"activeCount":97},[],{"trials":15431,"activeCount":97},[],{"trials":15433,"activeCount":97},[],{"trials":15435,"activeCount":97},[],{"trials":15437,"activeCount":97},[15438],{"nctId":2990,"briefTitle":2991,"status":155,"phases":15439,"primaryCompletion":2993,"completion":2993,"start":2994,"enrollment":2995,"conditions":15440,"interventions":15441},[88],[15],[2895,2998,2999,3000,3001],{"trials":15443,"activeCount":97},[],{"intervention":2999,"totalTrials":417,"cells":15445},{"EARLY_PHASE1":15446,"PHASE1":15448,"PHASE2":15450,"PHASE3":15452,"PHASE4":15454,"NA":15460},{"trials":15447,"activeCount":97},[],{"trials":15449,"activeCount":97},[],{"trials":15451,"activeCount":97},[],{"trials":15453,"activeCount":97},[],{"trials":15455,"activeCount":97},[15456],{"nctId":2990,"briefTitle":2991,"status":155,"phases":15457,"primaryCompletion":2993,"completion":2993,"start":2994,"enrollment":2995,"conditions":15458,"interventions":15459},[88],[15],[2895,2998,2999,3000,3001],{"trials":15461,"activeCount":97},[],{"intervention":3000,"totalTrials":417,"cells":15463},{"EARLY_PHASE1":15464,"PHASE1":15466,"PHASE2":15468,"PHASE3":15470,"PHASE4":15472,"NA":15478},{"trials":15465,"activeCount":97},[],{"trials":15467,"activeCount":97},[],{"trials":15469,"activeCount":97},[],{"trials":15471,"activeCount":97},[],{"trials":15473,"activeCount":97},[15474],{"nctId":2990,"briefTitle":2991,"status":155,"phases":15475,"primaryCompletion":2993,"completion":2993,"start":2994,"enrollment":2995,"conditions":15476,"interventions":15477},[88],[15],[2895,2998,2999,3000,3001],{"trials":15479,"activeCount":97},[],{"intervention":3001,"totalTrials":417,"cells":15481},{"EARLY_PHASE1":15482,"PHASE1":15484,"PHASE2":15486,"PHASE3":15488,"PHASE4":15490,"NA":15496},{"trials":15483,"activeCount":97},[],{"trials":15485,"activeCount":97},[],{"trials":15487,"activeCount":97},[],{"trials":15489,"activeCount":97},[],{"trials":15491,"activeCount":97},[15492],{"nctId":2990,"briefTitle":2991,"status":155,"phases":15493,"primaryCompletion":2993,"completion":2993,"start":2994,"enrollment":2995,"conditions":15494,"interventions":15495},[88],[15],[2895,2998,2999,3000,3001],{"trials":15497,"activeCount":97},[],{"intervention":15499,"totalTrials":417,"cells":15500},"Bupropion Hydrochloride Extended-release",{"EARLY_PHASE1":15501,"PHASE1":15503,"PHASE2":15505,"PHASE3":15507,"PHASE4":15509,"NA":15518},{"trials":15502,"activeCount":97},[],{"trials":15504,"activeCount":97},[],{"trials":15506,"activeCount":97},[],{"trials":15508,"activeCount":97},[],{"trials":15510,"activeCount":97},[15511],{"nctId":15512,"briefTitle":15513,"status":155,"phases":15514,"primaryCompletion":8386,"completion":8386,"start":2823,"enrollment":877,"conditions":15515,"interventions":15516},"NCT00316160","Sexual Functioning Study With Antidepressants",[88],[10889,10890],[15499,15517],"Extended-release Venlafaxine",{"trials":15519,"activeCount":97},[],{"intervention":15517,"totalTrials":417,"cells":15521},{"EARLY_PHASE1":15522,"PHASE1":15524,"PHASE2":15526,"PHASE3":15528,"PHASE4":15530,"NA":15536},{"trials":15523,"activeCount":97},[],{"trials":15525,"activeCount":97},[],{"trials":15527,"activeCount":97},[],{"trials":15529,"activeCount":97},[],{"trials":15531,"activeCount":97},[15532],{"nctId":15512,"briefTitle":15513,"status":155,"phases":15533,"primaryCompletion":8386,"completion":8386,"start":2823,"enrollment":877,"conditions":15534,"interventions":15535},[88],[10889,10890],[15499,15517],{"trials":15537,"activeCount":97},[],{"intervention":15539,"totalTrials":417,"cells":15540},"ADVAIR DISKUS™ 250\u002F50mcg",{"EARLY_PHASE1":15541,"PHASE1":15543,"PHASE2":15545,"PHASE3":15547,"PHASE4":15549,"NA":15557},{"trials":15542,"activeCount":97},[],{"trials":15544,"activeCount":97},[],{"trials":15546,"activeCount":97},[],{"trials":15548,"activeCount":97},[],{"trials":15550,"activeCount":97},[15551],{"nctId":15552,"briefTitle":15553,"status":155,"phases":15554,"primaryCompletion":3078,"completion":3078,"start":2794,"enrollment":10250,"conditions":15555,"interventions":15556},"NCT00857766","A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250\u002F50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[88],[15],[15539],{"trials":15558,"activeCount":97},[],{"intervention":15560,"totalTrials":417,"cells":15561},"Haemophilus Influenza type b vaccine",{"EARLY_PHASE1":15562,"PHASE1":15564,"PHASE2":15566,"PHASE3":15568,"PHASE4":15570,"NA":15580},{"trials":15563,"activeCount":97},[],{"trials":15565,"activeCount":97},[],{"trials":15567,"activeCount":97},[],{"trials":15569,"activeCount":97},[],{"trials":15571,"activeCount":97},[15572],{"nctId":15573,"briefTitle":15574,"status":155,"phases":15575,"primaryCompletion":10212,"completion":10212,"start":10803,"enrollment":15576,"conditions":15577,"interventions":15579},"NCT00158795","Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine",[88],454,[15578],"Haemophilus Influenzae Type b Disease",[15560],{"trials":15581,"activeCount":97},[],{"intervention":15583,"totalTrials":417,"cells":15584},"Arepanrix™",{"EARLY_PHASE1":15585,"PHASE1":15587,"PHASE2":15589,"PHASE3":15591,"PHASE4":15593,"NA":15603},{"trials":15586,"activeCount":97},[],{"trials":15588,"activeCount":97},[],{"trials":15590,"activeCount":97},[],{"trials":15592,"activeCount":97},[],{"trials":15594,"activeCount":97},[15595],{"nctId":15596,"briefTitle":15597,"status":155,"phases":15598,"primaryCompletion":15599,"completion":5268,"start":15600,"enrollment":1003,"conditions":15601,"interventions":15602},"NCT01114620","Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older",[88],"2010-11-05","2010-05-17",[21],[15583],{"trials":15604,"activeCount":97},[],{"intervention":15606,"totalTrials":417,"cells":15607},"Fluticasone furoate and fexofenadine",{"EARLY_PHASE1":15608,"PHASE1":15610,"PHASE2":15612,"PHASE3":15614,"PHASE4":15616,"NA":15626},{"trials":15609,"activeCount":97},[],{"trials":15611,"activeCount":97},[],{"trials":15613,"activeCount":97},[],{"trials":15615,"activeCount":97},[],{"trials":15617,"activeCount":97},[15618],{"nctId":15619,"briefTitle":13682,"status":155,"phases":15620,"primaryCompletion":9765,"completion":15621,"start":15622,"enrollment":15623,"conditions":15624,"interventions":15625},"NCT00435461",[88],"2007-02-28","2006-12-20",1000,[10169],[15606],{"trials":15627,"activeCount":97},[],{"intervention":15629,"totalTrials":417,"cells":15630},"NEUMOTEROL 400 (BFF 400\u002F12 mcg) single capsule inhaler",{"EARLY_PHASE1":15631,"PHASE1":15633,"PHASE2":15635,"PHASE3":15637,"PHASE4":15639,"NA":15651},{"trials":15632,"activeCount":97},[],{"trials":15634,"activeCount":97},[],{"trials":15636,"activeCount":97},[],{"trials":15638,"activeCount":97},[],{"trials":15640,"activeCount":97},[15641],{"nctId":15642,"briefTitle":15643,"status":155,"phases":15644,"primaryCompletion":15645,"completion":15645,"start":2319,"enrollment":10180,"conditions":15646,"interventions":15647},"NCT02233803","A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma",[88],"2015-12-11",[18],[15629,15648,15649,15650],"SYMBICORT forte (BFF 320\u002F9mcg) TURBUHALER inhaler","NEUMOTEX 400","Salbutamol 100 mcg pMDI",{"trials":15652,"activeCount":97},[],{"intervention":15648,"totalTrials":417,"cells":15654},{"EARLY_PHASE1":15655,"PHASE1":15657,"PHASE2":15659,"PHASE3":15661,"PHASE4":15663,"NA":15669},{"trials":15656,"activeCount":97},[],{"trials":15658,"activeCount":97},[],{"trials":15660,"activeCount":97},[],{"trials":15662,"activeCount":97},[],{"trials":15664,"activeCount":97},[15665],{"nctId":15642,"briefTitle":15643,"status":155,"phases":15666,"primaryCompletion":15645,"completion":15645,"start":2319,"enrollment":10180,"conditions":15667,"interventions":15668},[88],[18],[15629,15648,15649,15650],{"trials":15670,"activeCount":97},[],{"intervention":15649,"totalTrials":417,"cells":15672},{"EARLY_PHASE1":15673,"PHASE1":15675,"PHASE2":15677,"PHASE3":15679,"PHASE4":15681,"NA":15687},{"trials":15674,"activeCount":97},[],{"trials":15676,"activeCount":97},[],{"trials":15678,"activeCount":97},[],{"trials":15680,"activeCount":97},[],{"trials":15682,"activeCount":97},[15683],{"nctId":15642,"briefTitle":15643,"status":155,"phases":15684,"primaryCompletion":15645,"completion":15645,"start":2319,"enrollment":10180,"conditions":15685,"interventions":15686},[88],[18],[15629,15648,15649,15650],{"trials":15688,"activeCount":97},[],{"intervention":15650,"totalTrials":417,"cells":15690},{"EARLY_PHASE1":15691,"PHASE1":15693,"PHASE2":15695,"PHASE3":15697,"PHASE4":15699,"NA":15705},{"trials":15692,"activeCount":97},[],{"trials":15694,"activeCount":97},[],{"trials":15696,"activeCount":97},[],{"trials":15698,"activeCount":97},[],{"trials":15700,"activeCount":97},[15701],{"nctId":15642,"briefTitle":15643,"status":155,"phases":15702,"primaryCompletion":15645,"completion":15645,"start":2319,"enrollment":10180,"conditions":15703,"interventions":15704},[88],[18],[15629,15648,15649,15650],{"trials":15706,"activeCount":97},[],{"intervention":15708,"totalTrials":417,"cells":15709},"Engerix™-B vaccine",{"EARLY_PHASE1":15710,"PHASE1":15712,"PHASE2":15714,"PHASE3":15716,"PHASE4":15718,"NA":15729},{"trials":15711,"activeCount":97},[],{"trials":15713,"activeCount":97},[],{"trials":15715,"activeCount":97},[],{"trials":15717,"activeCount":97},[],{"trials":15719,"activeCount":97},[15720],{"nctId":15721,"briefTitle":15722,"status":155,"phases":15723,"primaryCompletion":15724,"completion":15724,"start":15725,"enrollment":15726,"conditions":15727,"interventions":15728},"NCT01627340","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus",[88],"2013-12-18","2012-07-24",667,[24],[15708],{"trials":15730,"activeCount":97},[],{"intervention":15732,"totalTrials":417,"cells":15733},"Salmeterol xinafoate\u002Ffluticasone propionate combination",{"EARLY_PHASE1":15734,"PHASE1":15736,"PHASE2":15738,"PHASE3":15740,"PHASE4":15742,"NA":15750},{"trials":15735,"activeCount":97},[],{"trials":15737,"activeCount":97},[],{"trials":15739,"activeCount":97},[],{"trials":15741,"activeCount":97},[],{"trials":15743,"activeCount":97},[15744],{"nctId":15745,"briefTitle":15746,"status":155,"phases":15747,"primaryCompletion":2804,"completion":2804,"start":748,"enrollment":8861,"conditions":15748,"interventions":15749},"NCT00461500","SERETIDE 100\u002F50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults",[88],[18],[15732,8381],{"trials":15751,"activeCount":97},[],{"intervention":15753,"totalTrials":417,"cells":15754},"RELVAR\u002FBREO",{"EARLY_PHASE1":15755,"PHASE1":15757,"PHASE2":15759,"PHASE3":15761,"PHASE4":15763,"NA":15771},{"trials":15756,"activeCount":97},[],{"trials":15758,"activeCount":97},[],{"trials":15760,"activeCount":97},[],{"trials":15762,"activeCount":97},[],{"trials":15764,"activeCount":97},[15765],{"nctId":15766,"briefTitle":15767,"status":155,"phases":15768,"primaryCompletion":242,"completion":242,"start":708,"enrollment":9392,"conditions":15769,"interventions":15770},"NCT03380429","A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects",[88],[18],[15753,963],{"trials":15772,"activeCount":97},[],{"intervention":15774,"totalTrials":417,"cells":15775},"fluticasone propionate\u002Fsalmeterol powder",{"EARLY_PHASE1":15776,"PHASE1":15778,"PHASE2":15780,"PHASE3":15782,"PHASE4":15784,"NA":15794},{"trials":15777,"activeCount":97},[],{"trials":15779,"activeCount":97},[],{"trials":15781,"activeCount":97},[],{"trials":15783,"activeCount":97},[],{"trials":15785,"activeCount":97},[15786],{"nctId":15787,"briefTitle":15788,"status":155,"phases":15789,"primaryCompletion":4756,"completion":4756,"start":11097,"enrollment":15790,"conditions":15791,"interventions":15792},"NCT00102765","Study Of Asthma In Patients Of African Descent",[88],479,[18],[15774,15793],"fluticasone propionate powder",{"trials":15795,"activeCount":97},[],{"intervention":15793,"totalTrials":417,"cells":15797},{"EARLY_PHASE1":15798,"PHASE1":15800,"PHASE2":15802,"PHASE3":15804,"PHASE4":15806,"NA":15812},{"trials":15799,"activeCount":97},[],{"trials":15801,"activeCount":97},[],{"trials":15803,"activeCount":97},[],{"trials":15805,"activeCount":97},[],{"trials":15807,"activeCount":97},[15808],{"nctId":15787,"briefTitle":15788,"status":155,"phases":15809,"primaryCompletion":4756,"completion":4756,"start":11097,"enrollment":15790,"conditions":15810,"interventions":15811},[88],[18],[15774,15793],{"trials":15813,"activeCount":97},[],{"intervention":15815,"totalTrials":417,"cells":15816},"Lamotrigine tablets 25\u002F100 mg",{"EARLY_PHASE1":15817,"PHASE1":15819,"PHASE2":15821,"PHASE3":15823,"PHASE4":15825,"NA":15835},{"trials":15818,"activeCount":97},[],{"trials":15820,"activeCount":97},[],{"trials":15822,"activeCount":97},[],{"trials":15824,"activeCount":97},[],{"trials":15826,"activeCount":97},[15827],{"nctId":15828,"briefTitle":15829,"status":155,"phases":15830,"primaryCompletion":15831,"completion":15831,"start":15832,"enrollment":2797,"conditions":15833,"interventions":15834},"NCT02100644","Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study",[88],"2015-05-11","2014-04-12",[12518],[15815],{"trials":15836,"activeCount":97},[],{"intervention":15838,"totalTrials":417,"cells":15839},"HPV (Types 16, 18) Vaccine, Adsorbed",{"EARLY_PHASE1":15840,"PHASE1":15842,"PHASE2":15844,"PHASE3":15846,"PHASE4":15848,"NA":15859},{"trials":15841,"activeCount":97},[],{"trials":15843,"activeCount":97},[],{"trials":15845,"activeCount":97},[],{"trials":15847,"activeCount":97},[],{"trials":15849,"activeCount":97},[15850],{"nctId":15851,"briefTitle":15852,"status":155,"phases":15853,"primaryCompletion":15854,"completion":15854,"start":15855,"enrollment":15856,"conditions":15857,"interventions":15858},"NCT03629886","Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study",[88],"2020-02-28","2018-08-22",6051,[2444],[15838],{"trials":15860,"activeCount":97},[],{"intervention":15862,"totalTrials":417,"cells":15863},"ROP",{"EARLY_PHASE1":15864,"PHASE1":15866,"PHASE2":15868,"PHASE3":15870,"PHASE4":15872,"NA":15883},{"trials":15865,"activeCount":97},[],{"trials":15867,"activeCount":97},[],{"trials":15869,"activeCount":97},[],{"trials":15871,"activeCount":97},[],{"trials":15873,"activeCount":97},[15874],{"nctId":15875,"briefTitle":15876,"status":155,"phases":15877,"primaryCompletion":7658,"completion":7658,"start":3552,"enrollment":1598,"conditions":15878,"interventions":15881},"NCT00485069","REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study",[88],[15879,15880],"Parkinson Disease","Parkinson's Disease",[15862,15882],"ROP+L-Dopa",{"trials":15884,"activeCount":97},[],{"intervention":15882,"totalTrials":417,"cells":15886},{"EARLY_PHASE1":15887,"PHASE1":15889,"PHASE2":15891,"PHASE3":15893,"PHASE4":15895,"NA":15901},{"trials":15888,"activeCount":97},[],{"trials":15890,"activeCount":97},[],{"trials":15892,"activeCount":97},[],{"trials":15894,"activeCount":97},[],{"trials":15896,"activeCount":97},[15897],{"nctId":15875,"briefTitle":15876,"status":155,"phases":15898,"primaryCompletion":7658,"completion":7658,"start":3552,"enrollment":1598,"conditions":15899,"interventions":15900},[88],[15879,15880],[15862,15882],{"trials":15902,"activeCount":97},[],{"intervention":12656,"totalTrials":417,"cells":15904},{"EARLY_PHASE1":15905,"PHASE1":15907,"PHASE2":15909,"PHASE3":15911,"PHASE4":15913,"NA":15919},{"trials":15906,"activeCount":97},[],{"trials":15908,"activeCount":97},[],{"trials":15910,"activeCount":97},[],{"trials":15912,"activeCount":97},[],{"trials":15914,"activeCount":97},[15915],{"nctId":12649,"briefTitle":12650,"status":155,"phases":15916,"primaryCompletion":12652,"completion":12652,"start":12653,"enrollment":8619,"conditions":15917,"interventions":15918},[88],[15],[12656,12657,11651],{"trials":15920,"activeCount":97},[],{"intervention":12657,"totalTrials":417,"cells":15922},{"EARLY_PHASE1":15923,"PHASE1":15925,"PHASE2":15927,"PHASE3":15929,"PHASE4":15931,"NA":15937},{"trials":15924,"activeCount":97},[],{"trials":15926,"activeCount":97},[],{"trials":15928,"activeCount":97},[],{"trials":15930,"activeCount":97},[],{"trials":15932,"activeCount":97},[15933],{"nctId":12649,"briefTitle":12650,"status":155,"phases":15934,"primaryCompletion":12652,"completion":12652,"start":12653,"enrollment":8619,"conditions":15935,"interventions":15936},[88],[15],[12656,12657,11651],{"trials":15938,"activeCount":97},[],{"intervention":10060,"totalTrials":417,"cells":15940},{"EARLY_PHASE1":15941,"PHASE1":15943,"PHASE2":15945,"PHASE3":15947,"PHASE4":15949,"NA":15955},{"trials":15942,"activeCount":97},[],{"trials":15944,"activeCount":97},[],{"trials":15946,"activeCount":97},[],{"trials":15948,"activeCount":97},[],{"trials":15950,"activeCount":97},[15951],{"nctId":10053,"briefTitle":10054,"status":155,"phases":15952,"primaryCompletion":2823,"completion":2823,"start":10056,"enrollment":10057,"conditions":15953,"interventions":15954},[88],[3624,33,30],[9916,10060,10061,10061],{"trials":15956,"activeCount":97},[],{"intervention":10061,"totalTrials":417,"cells":15958},{"EARLY_PHASE1":15959,"PHASE1":15961,"PHASE2":15963,"PHASE3":15965,"PHASE4":15967,"NA":15973},{"trials":15960,"activeCount":97},[],{"trials":15962,"activeCount":97},[],{"trials":15964,"activeCount":97},[],{"trials":15966,"activeCount":97},[],{"trials":15968,"activeCount":97},[15969],{"nctId":10053,"briefTitle":10054,"status":155,"phases":15970,"primaryCompletion":2823,"completion":2823,"start":10056,"enrollment":10057,"conditions":15971,"interventions":15972},[88],[3624,33,30],[9916,10060,10061,10061],{"trials":15974,"activeCount":97},[],{"intervention":10195,"totalTrials":417,"cells":15976},{"EARLY_PHASE1":15977,"PHASE1":15979,"PHASE2":15981,"PHASE3":15983,"PHASE4":15985,"NA":15991},{"trials":15978,"activeCount":97},[],{"trials":15980,"activeCount":97},[],{"trials":15982,"activeCount":97},[],{"trials":15984,"activeCount":97},[],{"trials":15986,"activeCount":97},[15987],{"nctId":10187,"briefTitle":10188,"status":155,"phases":15988,"primaryCompletion":8395,"completion":10190,"start":9067,"enrollment":10191,"conditions":15989,"interventions":15990},[88],[10147],[10194,10195,10134,10196],{"trials":15992,"activeCount":97},[],{"intervention":10196,"totalTrials":417,"cells":15994},{"EARLY_PHASE1":15995,"PHASE1":15997,"PHASE2":15999,"PHASE3":16001,"PHASE4":16003,"NA":16009},{"trials":15996,"activeCount":97},[],{"trials":15998,"activeCount":97},[],{"trials":16000,"activeCount":97},[],{"trials":16002,"activeCount":97},[],{"trials":16004,"activeCount":97},[16005],{"nctId":10187,"briefTitle":10188,"status":155,"phases":16006,"primaryCompletion":8395,"completion":10190,"start":9067,"enrollment":10191,"conditions":16007,"interventions":16008},[88],[10147],[10194,10195,10134,10196],{"trials":16010,"activeCount":97},[],{"intervention":9466,"totalTrials":417,"cells":16012},{"EARLY_PHASE1":16013,"PHASE1":16015,"PHASE2":16017,"PHASE3":16019,"PHASE4":16021,"NA":16027},{"trials":16014,"activeCount":97},[],{"trials":16016,"activeCount":97},[],{"trials":16018,"activeCount":97},[],{"trials":16020,"activeCount":97},[],{"trials":16022,"activeCount":97},[16023],{"nctId":9459,"briefTitle":9460,"status":155,"phases":16024,"primaryCompletion":1380,"completion":1380,"start":9462,"enrollment":4651,"conditions":16025,"interventions":16026},[88],[18,9464],[9370,9466],{"trials":16028,"activeCount":97},[],{"intervention":10816,"totalTrials":417,"cells":16030},{"EARLY_PHASE1":16031,"PHASE1":16033,"PHASE2":16035,"PHASE3":16037,"PHASE4":16039,"NA":16045},{"trials":16032,"activeCount":97},[],{"trials":16034,"activeCount":97},[],{"trials":16036,"activeCount":97},[],{"trials":16038,"activeCount":97},[],{"trials":16040,"activeCount":97},[16041],{"nctId":10811,"briefTitle":10812,"status":155,"phases":16042,"primaryCompletion":8406,"completion":8406,"start":7613,"enrollment":781,"conditions":16043,"interventions":16044},[88],[15],[10816,10817,10798],{"trials":16046,"activeCount":97},[],{"intervention":10817,"totalTrials":417,"cells":16048},{"EARLY_PHASE1":16049,"PHASE1":16051,"PHASE2":16053,"PHASE3":16055,"PHASE4":16057,"NA":16063},{"trials":16050,"activeCount":97},[],{"trials":16052,"activeCount":97},[],{"trials":16054,"activeCount":97},[],{"trials":16056,"activeCount":97},[],{"trials":16058,"activeCount":97},[16059],{"nctId":10811,"briefTitle":10812,"status":155,"phases":16060,"primaryCompletion":8406,"completion":8406,"start":7613,"enrollment":781,"conditions":16061,"interventions":16062},[88],[15],[10816,10817,10798],{"trials":16064,"activeCount":97},[],{"intervention":12048,"totalTrials":417,"cells":16066},{"EARLY_PHASE1":16067,"PHASE1":16069,"PHASE2":16071,"PHASE3":16073,"PHASE4":16075,"NA":16081},{"trials":16068,"activeCount":97},[],{"trials":16070,"activeCount":97},[],{"trials":16072,"activeCount":97},[],{"trials":16074,"activeCount":97},[],{"trials":16076,"activeCount":97},[16077],{"nctId":12038,"briefTitle":12039,"status":155,"phases":16078,"primaryCompletion":12041,"completion":12042,"start":12043,"enrollment":12044,"conditions":16079,"interventions":16080},[88],[12046],[12048,12007],{"trials":16082,"activeCount":97},[],{"intervention":16084,"totalTrials":417,"cells":16085},"Topical Spray",{"EARLY_PHASE1":16086,"PHASE1":16088,"PHASE2":16090,"PHASE3":16092,"PHASE4":16094,"NA":16107},{"trials":16087,"activeCount":97},[],{"trials":16089,"activeCount":97},[],{"trials":16091,"activeCount":97},[],{"trials":16093,"activeCount":97},[],{"trials":16095,"activeCount":97},[16096],{"nctId":16097,"briefTitle":16098,"status":500,"phases":16099,"primaryCompletion":16100,"completion":16101,"start":16102,"enrollment":97,"conditions":16103,"interventions":16105},"NCT02400320","Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol",[88],"2016-06-01","2016-06-30","2016-03-01",[16104],"Skin Irritation",[16084,16106],"Topical Gel",{"trials":16108,"activeCount":97},[],{"intervention":16106,"totalTrials":417,"cells":16110},{"EARLY_PHASE1":16111,"PHASE1":16113,"PHASE2":16115,"PHASE3":16117,"PHASE4":16119,"NA":16125},{"trials":16112,"activeCount":97},[],{"trials":16114,"activeCount":97},[],{"trials":16116,"activeCount":97},[],{"trials":16118,"activeCount":97},[],{"trials":16120,"activeCount":97},[16121],{"nctId":16097,"briefTitle":16098,"status":500,"phases":16122,"primaryCompletion":16100,"completion":16101,"start":16102,"enrollment":97,"conditions":16123,"interventions":16124},[88],[16104],[16084,16106],{"trials":16126,"activeCount":97},[],{"intervention":16128,"totalTrials":417,"cells":16129},"Squarekids",{"EARLY_PHASE1":16130,"PHASE1":16132,"PHASE2":16134,"PHASE3":16136,"PHASE4":16138,"NA":16149},{"trials":16131,"activeCount":97},[],{"trials":16133,"activeCount":97},[],{"trials":16135,"activeCount":97},[],{"trials":16137,"activeCount":97},[],{"trials":16139,"activeCount":97},[16140],{"nctId":16141,"briefTitle":16142,"status":155,"phases":16143,"primaryCompletion":16144,"completion":16144,"start":16145,"enrollment":556,"conditions":16146,"interventions":16148},"NCT02907216","Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants",[88],"2017-05-29","2016-09-16",[16147],"Rotavirus",[16128,4762],{"trials":16150,"activeCount":97},[],{"intervention":12184,"totalTrials":417,"cells":16152},{"EARLY_PHASE1":16153,"PHASE1":16155,"PHASE2":16157,"PHASE3":16159,"PHASE4":16161,"NA":16167},{"trials":16154,"activeCount":97},[],{"trials":16156,"activeCount":97},[],{"trials":16158,"activeCount":97},[],{"trials":16160,"activeCount":97},[],{"trials":16162,"activeCount":97},[16163],{"nctId":12177,"briefTitle":12178,"status":155,"phases":16164,"primaryCompletion":12180,"completion":12180,"start":12181,"enrollment":414,"conditions":16165,"interventions":16166},[88],[18],[12156,12184],{"trials":16168,"activeCount":97},[],{"intervention":11153,"totalTrials":417,"cells":16170},{"EARLY_PHASE1":16171,"PHASE1":16173,"PHASE2":16175,"PHASE3":16177,"PHASE4":16179,"NA":16185},{"trials":16172,"activeCount":97},[],{"trials":16174,"activeCount":97},[],{"trials":16176,"activeCount":97},[],{"trials":16178,"activeCount":97},[],{"trials":16180,"activeCount":97},[16181],{"nctId":11146,"briefTitle":11147,"status":155,"phases":16182,"primaryCompletion":8208,"completion":11149,"start":11150,"enrollment":115,"conditions":16183,"interventions":16184},[88],[10943],[10948,11153,11154],{"trials":16186,"activeCount":97},[],{"intervention":11154,"totalTrials":417,"cells":16188},{"EARLY_PHASE1":16189,"PHASE1":16191,"PHASE2":16193,"PHASE3":16195,"PHASE4":16197,"NA":16203},{"trials":16190,"activeCount":97},[],{"trials":16192,"activeCount":97},[],{"trials":16194,"activeCount":97},[],{"trials":16196,"activeCount":97},[],{"trials":16198,"activeCount":97},[16199],{"nctId":11146,"briefTitle":11147,"status":155,"phases":16200,"primaryCompletion":8208,"completion":11149,"start":11150,"enrollment":115,"conditions":16201,"interventions":16202},[88],[10943],[10948,11153,11154],{"trials":16204,"activeCount":97},[],{"intervention":10314,"totalTrials":417,"cells":16206},{"EARLY_PHASE1":16207,"PHASE1":16209,"PHASE2":16211,"PHASE3":16213,"PHASE4":16215,"NA":16221},{"trials":16208,"activeCount":97},[],{"trials":16210,"activeCount":97},[],{"trials":16212,"activeCount":97},[],{"trials":16214,"activeCount":97},[],{"trials":16216,"activeCount":97},[16217],{"nctId":10308,"briefTitle":10309,"status":155,"phases":16218,"primaryCompletion":8386,"completion":8386,"start":7581,"enrollment":1293,"conditions":16219,"interventions":16220},[88],[24,4702,30,3624,33,4704],[10313,10314],{"trials":16222,"activeCount":97},[],{"intervention":12091,"totalTrials":417,"cells":16224},{"EARLY_PHASE1":16225,"PHASE1":16227,"PHASE2":16229,"PHASE3":16231,"PHASE4":16233,"NA":16239},{"trials":16226,"activeCount":97},[],{"trials":16228,"activeCount":97},[],{"trials":16230,"activeCount":97},[],{"trials":16232,"activeCount":97},[],{"trials":16234,"activeCount":97},[16235],{"nctId":12084,"briefTitle":12085,"status":155,"phases":16236,"primaryCompletion":11483,"completion":11483,"start":12087,"enrollment":12088,"conditions":16237,"interventions":16238},[88],[15],[12052,12091],{"trials":16240,"activeCount":97},[],{"intervention":16242,"totalTrials":417,"cells":16243},"Levothyroxine",{"EARLY_PHASE1":16244,"PHASE1":16246,"PHASE2":16248,"PHASE3":16250,"PHASE4":16252,"NA":16261},{"trials":16245,"activeCount":97},[],{"trials":16247,"activeCount":97},[],{"trials":16249,"activeCount":97},[],{"trials":16251,"activeCount":97},[],{"trials":16253,"activeCount":97},[16254],{"nctId":16255,"briefTitle":16256,"status":155,"phases":16257,"primaryCompletion":3389,"completion":3389,"start":2427,"enrollment":93,"conditions":16258,"interventions":16260},"NCT01536678","Bioequivalence of Two Levothyroxine Tablet Formulations in Healthy Indian Volunteers",[88],[16259],"Hypothyroidism",[16242,16242],{"trials":16262,"activeCount":97},[],{"intervention":16264,"totalTrials":417,"cells":16265},"ADVAIR DISKUS 250\u002F50 mg BID",{"EARLY_PHASE1":16266,"PHASE1":16268,"PHASE2":16270,"PHASE3":16272,"PHASE4":16274,"NA":16285},{"trials":16267,"activeCount":97},[],{"trials":16269,"activeCount":97},[],{"trials":16271,"activeCount":97},[],{"trials":16273,"activeCount":97},[],{"trials":16275,"activeCount":97},[16276],{"nctId":16277,"briefTitle":16278,"status":155,"phases":16279,"primaryCompletion":11748,"completion":10038,"start":16280,"enrollment":16281,"conditions":16282,"interventions":16283},"NCT01110200","Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study",[88],"2010-04-30",639,[15],[16264,16284],"SEREVENT 50 mcg BID",{"trials":16286,"activeCount":97},[],{"intervention":16284,"totalTrials":417,"cells":16288},{"EARLY_PHASE1":16289,"PHASE1":16291,"PHASE2":16293,"PHASE3":16295,"PHASE4":16297,"NA":16303},{"trials":16290,"activeCount":97},[],{"trials":16292,"activeCount":97},[],{"trials":16294,"activeCount":97},[],{"trials":16296,"activeCount":97},[],{"trials":16298,"activeCount":97},[16299],{"nctId":16277,"briefTitle":16278,"status":155,"phases":16300,"primaryCompletion":11748,"completion":10038,"start":16280,"enrollment":16281,"conditions":16301,"interventions":16302},[88],[15],[16264,16284],{"trials":16304,"activeCount":97},[],{"intervention":16306,"totalTrials":417,"cells":16307},"Sodium fluoride \u002F silica and carbopol, 0.5g",{"EARLY_PHASE1":16308,"PHASE1":16310,"PHASE2":16312,"PHASE3":16314,"PHASE4":16316,"NA":16327},{"trials":16309,"activeCount":97},[],{"trials":16311,"activeCount":97},[],{"trials":16313,"activeCount":97},[],{"trials":16315,"activeCount":97},[],{"trials":16317,"activeCount":97},[16318],{"nctId":16319,"briefTitle":16320,"status":155,"phases":16321,"primaryCompletion":16322,"completion":16322,"start":16323,"enrollment":2282,"conditions":16324,"interventions":16325},"NCT01563172","Effect of Dentifrice Usage Regime on Delivery and Efficacy of Fluoride",[88],"2009-06-01","2009-01-01",[13126],[16306,16326,16326],"Sodium fluoride \u002F silica and carbopol, 1.5g",{"trials":16328,"activeCount":97},[],{"intervention":16326,"totalTrials":417,"cells":16330},{"EARLY_PHASE1":16331,"PHASE1":16333,"PHASE2":16335,"PHASE3":16337,"PHASE4":16339,"NA":16345},{"trials":16332,"activeCount":97},[],{"trials":16334,"activeCount":97},[],{"trials":16336,"activeCount":97},[],{"trials":16338,"activeCount":97},[],{"trials":16340,"activeCount":97},[16341],{"nctId":16319,"briefTitle":16320,"status":155,"phases":16342,"primaryCompletion":16322,"completion":16322,"start":16323,"enrollment":2282,"conditions":16343,"interventions":16344},[88],[13126],[16306,16326,16326],{"trials":16346,"activeCount":97},[],{"intervention":16348,"totalTrials":417,"cells":16349},"ropinirole monotherapy",{"EARLY_PHASE1":16350,"PHASE1":16352,"PHASE2":16354,"PHASE3":16356,"PHASE4":16358,"NA":16367},{"trials":16351,"activeCount":97},[],{"trials":16353,"activeCount":97},[],{"trials":16355,"activeCount":97},[],{"trials":16357,"activeCount":97},[],{"trials":16359,"activeCount":97},[16360],{"nctId":16361,"briefTitle":16362,"status":155,"phases":16363,"primaryCompletion":8928,"completion":8928,"start":16364,"enrollment":14585,"conditions":16365,"interventions":16366},"NCT01485172","A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease",[88],"2012-01-31",[15879],[16348],{"trials":16368,"activeCount":97},[],{"intervention":16370,"totalTrials":417,"cells":16371},"Influsplit SSW® 2005\u002F2006",{"EARLY_PHASE1":16372,"PHASE1":16374,"PHASE2":16376,"PHASE3":16378,"PHASE4":16380,"NA":16389},{"trials":16373,"activeCount":97},[],{"trials":16375,"activeCount":97},[],{"trials":16377,"activeCount":97},[],{"trials":16379,"activeCount":97},[],{"trials":16381,"activeCount":97},[16382],{"nctId":16383,"briefTitle":16384,"status":155,"phases":16385,"primaryCompletion":14000,"completion":14000,"start":16386,"enrollment":9196,"conditions":16387,"interventions":16388},"NCT00372255","Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005\u002F2006 in Children Aged 6 - 13 Years",[88],"2005-11-17",[21],[16370],{"trials":16390,"activeCount":97},[],{"intervention":16392,"totalTrials":417,"cells":16393},"Albiglutide 50mg",{"EARLY_PHASE1":16394,"PHASE1":16396,"PHASE2":16398,"PHASE3":16400,"PHASE4":16402,"NA":16415},{"trials":16395,"activeCount":97},[],{"trials":16397,"activeCount":97},[],{"trials":16399,"activeCount":97},[],{"trials":16401,"activeCount":97},[],{"trials":16403,"activeCount":97},[16404],{"nctId":16405,"briefTitle":16406,"status":145,"phases":16407,"primaryCompletion":16408,"completion":16409,"start":16410,"enrollment":1517,"conditions":16411,"interventions":16412},"NCT02802514","A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects",[88],"2017-08-10","2017-09-07","2016-09-20",[8063],[16392,16413,16414],"Exenatide 10microgram","Exenatide placebo",{"trials":16416,"activeCount":97},[],{"intervention":16413,"totalTrials":417,"cells":16418},{"EARLY_PHASE1":16419,"PHASE1":16421,"PHASE2":16423,"PHASE3":16425,"PHASE4":16427,"NA":16433},{"trials":16420,"activeCount":97},[],{"trials":16422,"activeCount":97},[],{"trials":16424,"activeCount":97},[],{"trials":16426,"activeCount":97},[],{"trials":16428,"activeCount":97},[16429],{"nctId":16405,"briefTitle":16406,"status":145,"phases":16430,"primaryCompletion":16408,"completion":16409,"start":16410,"enrollment":1517,"conditions":16431,"interventions":16432},[88],[8063],[16392,16413,16414],{"trials":16434,"activeCount":97},[],{"intervention":16414,"totalTrials":417,"cells":16436},{"EARLY_PHASE1":16437,"PHASE1":16439,"PHASE2":16441,"PHASE3":16443,"PHASE4":16445,"NA":16451},{"trials":16438,"activeCount":97},[],{"trials":16440,"activeCount":97},[],{"trials":16442,"activeCount":97},[],{"trials":16444,"activeCount":97},[],{"trials":16446,"activeCount":97},[16447],{"nctId":16405,"briefTitle":16406,"status":145,"phases":16448,"primaryCompletion":16408,"completion":16409,"start":16410,"enrollment":1517,"conditions":16449,"interventions":16450},[88],[8063],[16392,16413,16414],{"trials":16452,"activeCount":97},[],{"intervention":11875,"totalTrials":417,"cells":16454},{"EARLY_PHASE1":16455,"PHASE1":16457,"PHASE2":16459,"PHASE3":16461,"PHASE4":16463,"NA":16469},{"trials":16456,"activeCount":97},[],{"trials":16458,"activeCount":97},[],{"trials":16460,"activeCount":97},[],{"trials":16462,"activeCount":97},[],{"trials":16464,"activeCount":97},[16465],{"nctId":11870,"briefTitle":11871,"status":155,"phases":16466,"primaryCompletion":5018,"completion":5018,"start":2336,"enrollment":314,"conditions":16467,"interventions":16468},[88],[18],[11839,11875],{"trials":16470,"activeCount":97},[],{"intervention":16472,"totalTrials":417,"cells":16473},"paroxetine 10mg",{"EARLY_PHASE1":16474,"PHASE1":16476,"PHASE2":16478,"PHASE3":16480,"PHASE4":16482,"NA":16493},{"trials":16475,"activeCount":97},[],{"trials":16477,"activeCount":97},[],{"trials":16479,"activeCount":97},[],{"trials":16481,"activeCount":97},[],{"trials":16483,"activeCount":97},[16484],{"nctId":16485,"briefTitle":16486,"status":145,"phases":16487,"primaryCompletion":729,"completion":729,"start":2794,"enrollment":904,"conditions":16488,"interventions":16489},"NCT00812812","Paxil Japanese Post Marketing Paediatric Study in Depression (Double-blind, Placebo Controlled Study)",[88],[9292],[16472,16490,16491,16492],"paroxetine 20mg","matched placebo to paroxetine 10mg","matched placebo to paroxetine 20mg",{"trials":16494,"activeCount":97},[],{"intervention":16490,"totalTrials":417,"cells":16496},{"EARLY_PHASE1":16497,"PHASE1":16499,"PHASE2":16501,"PHASE3":16503,"PHASE4":16505,"NA":16511},{"trials":16498,"activeCount":97},[],{"trials":16500,"activeCount":97},[],{"trials":16502,"activeCount":97},[],{"trials":16504,"activeCount":97},[],{"trials":16506,"activeCount":97},[16507],{"nctId":16485,"briefTitle":16486,"status":145,"phases":16508,"primaryCompletion":729,"completion":729,"start":2794,"enrollment":904,"conditions":16509,"interventions":16510},[88],[9292],[16472,16490,16491,16492],{"trials":16512,"activeCount":97},[],{"intervention":16491,"totalTrials":417,"cells":16514},{"EARLY_PHASE1":16515,"PHASE1":16517,"PHASE2":16519,"PHASE3":16521,"PHASE4":16523,"NA":16529},{"trials":16516,"activeCount":97},[],{"trials":16518,"activeCount":97},[],{"trials":16520,"activeCount":97},[],{"trials":16522,"activeCount":97},[],{"trials":16524,"activeCount":97},[16525],{"nctId":16485,"briefTitle":16486,"status":145,"phases":16526,"primaryCompletion":729,"completion":729,"start":2794,"enrollment":904,"conditions":16527,"interventions":16528},[88],[9292],[16472,16490,16491,16492],{"trials":16530,"activeCount":97},[],{"intervention":16492,"totalTrials":417,"cells":16532},{"EARLY_PHASE1":16533,"PHASE1":16535,"PHASE2":16537,"PHASE3":16539,"PHASE4":16541,"NA":16547},{"trials":16534,"activeCount":97},[],{"trials":16536,"activeCount":97},[],{"trials":16538,"activeCount":97},[],{"trials":16540,"activeCount":97},[],{"trials":16542,"activeCount":97},[16543],{"nctId":16485,"briefTitle":16486,"status":145,"phases":16544,"primaryCompletion":729,"completion":729,"start":2794,"enrollment":904,"conditions":16545,"interventions":16546},[88],[9292],[16472,16490,16491,16492],{"trials":16548,"activeCount":97},[],{"intervention":11773,"totalTrials":417,"cells":16550},{"EARLY_PHASE1":16551,"PHASE1":16553,"PHASE2":16555,"PHASE3":16557,"PHASE4":16559,"NA":16565},{"trials":16552,"activeCount":97},[],{"trials":16554,"activeCount":97},[],{"trials":16556,"activeCount":97},[],{"trials":16558,"activeCount":97},[],{"trials":16560,"activeCount":97},[16561],{"nctId":11766,"briefTitle":11767,"status":155,"phases":16562,"primaryCompletion":11769,"completion":11769,"start":3390,"enrollment":11770,"conditions":16563,"interventions":16564},[88],[15],[11773,11774,11732,11775,11776],{"trials":16566,"activeCount":97},[],{"intervention":11774,"totalTrials":417,"cells":16568},{"EARLY_PHASE1":16569,"PHASE1":16571,"PHASE2":16573,"PHASE3":16575,"PHASE4":16577,"NA":16583},{"trials":16570,"activeCount":97},[],{"trials":16572,"activeCount":97},[],{"trials":16574,"activeCount":97},[],{"trials":16576,"activeCount":97},[],{"trials":16578,"activeCount":97},[16579],{"nctId":11766,"briefTitle":11767,"status":155,"phases":16580,"primaryCompletion":11769,"completion":11769,"start":3390,"enrollment":11770,"conditions":16581,"interventions":16582},[88],[15],[11773,11774,11732,11775,11776],{"trials":16584,"activeCount":97},[],{"intervention":11775,"totalTrials":417,"cells":16586},{"EARLY_PHASE1":16587,"PHASE1":16589,"PHASE2":16591,"PHASE3":16593,"PHASE4":16595,"NA":16601},{"trials":16588,"activeCount":97},[],{"trials":16590,"activeCount":97},[],{"trials":16592,"activeCount":97},[],{"trials":16594,"activeCount":97},[],{"trials":16596,"activeCount":97},[16597],{"nctId":11766,"briefTitle":11767,"status":155,"phases":16598,"primaryCompletion":11769,"completion":11769,"start":3390,"enrollment":11770,"conditions":16599,"interventions":16600},[88],[15],[11773,11774,11732,11775,11776],{"trials":16602,"activeCount":97},[],{"intervention":11776,"totalTrials":417,"cells":16604},{"EARLY_PHASE1":16605,"PHASE1":16607,"PHASE2":16609,"PHASE3":16611,"PHASE4":16613,"NA":16619},{"trials":16606,"activeCount":97},[],{"trials":16608,"activeCount":97},[],{"trials":16610,"activeCount":97},[],{"trials":16612,"activeCount":97},[],{"trials":16614,"activeCount":97},[16615],{"nctId":11766,"briefTitle":11767,"status":155,"phases":16616,"primaryCompletion":11769,"completion":11769,"start":3390,"enrollment":11770,"conditions":16617,"interventions":16618},[88],[15],[11773,11774,11732,11775,11776],{"trials":16620,"activeCount":97},[],{"intervention":16622,"totalTrials":417,"cells":16623},"Avandamet 6 mg\u002F1500 mg",{"EARLY_PHASE1":16624,"PHASE1":16626,"PHASE2":16628,"PHASE3":16630,"PHASE4":16632,"NA":16647},{"trials":16625,"activeCount":97},[],{"trials":16627,"activeCount":97},[],{"trials":16629,"activeCount":97},[],{"trials":16631,"activeCount":97},[],{"trials":16633,"activeCount":97},[16634],{"nctId":16635,"briefTitle":16636,"status":155,"phases":16637,"primaryCompletion":1429,"completion":1429,"start":2404,"enrollment":7702,"conditions":16638,"interventions":16639},"NCT00386100","A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin",[88],[27],[16622,16640,16641,16642,16643,16644,16645,16646],"Avandamet 4 mg\u002F1000 mg","Avandamet 2 mg\u002F500 mg","Avandamet 8 mg\u002F 2000 mg","Metformin 500 mg","Metformin 1000 mg","Metformin 1500 mg","Metformin 2000 mg",{"trials":16648,"activeCount":97},[],{"intervention":16640,"totalTrials":417,"cells":16650},{"EARLY_PHASE1":16651,"PHASE1":16653,"PHASE2":16655,"PHASE3":16657,"PHASE4":16659,"NA":16665},{"trials":16652,"activeCount":97},[],{"trials":16654,"activeCount":97},[],{"trials":16656,"activeCount":97},[],{"trials":16658,"activeCount":97},[],{"trials":16660,"activeCount":97},[16661],{"nctId":16635,"briefTitle":16636,"status":155,"phases":16662,"primaryCompletion":1429,"completion":1429,"start":2404,"enrollment":7702,"conditions":16663,"interventions":16664},[88],[27],[16622,16640,16641,16642,16643,16644,16645,16646],{"trials":16666,"activeCount":97},[],{"intervention":16641,"totalTrials":417,"cells":16668},{"EARLY_PHASE1":16669,"PHASE1":16671,"PHASE2":16673,"PHASE3":16675,"PHASE4":16677,"NA":16683},{"trials":16670,"activeCount":97},[],{"trials":16672,"activeCount":97},[],{"trials":16674,"activeCount":97},[],{"trials":16676,"activeCount":97},[],{"trials":16678,"activeCount":97},[16679],{"nctId":16635,"briefTitle":16636,"status":155,"phases":16680,"primaryCompletion":1429,"completion":1429,"start":2404,"enrollment":7702,"conditions":16681,"interventions":16682},[88],[27],[16622,16640,16641,16642,16643,16644,16645,16646],{"trials":16684,"activeCount":97},[],{"intervention":16642,"totalTrials":417,"cells":16686},{"EARLY_PHASE1":16687,"PHASE1":16689,"PHASE2":16691,"PHASE3":16693,"PHASE4":16695,"NA":16701},{"trials":16688,"activeCount":97},[],{"trials":16690,"activeCount":97},[],{"trials":16692,"activeCount":97},[],{"trials":16694,"activeCount":97},[],{"trials":16696,"activeCount":97},[16697],{"nctId":16635,"briefTitle":16636,"status":155,"phases":16698,"primaryCompletion":1429,"completion":1429,"start":2404,"enrollment":7702,"conditions":16699,"interventions":16700},[88],[27],[16622,16640,16641,16642,16643,16644,16645,16646],{"trials":16702,"activeCount":97},[],{"intervention":16643,"totalTrials":417,"cells":16704},{"EARLY_PHASE1":16705,"PHASE1":16707,"PHASE2":16709,"PHASE3":16711,"PHASE4":16713,"NA":16719},{"trials":16706,"activeCount":97},[],{"trials":16708,"activeCount":97},[],{"trials":16710,"activeCount":97},[],{"trials":16712,"activeCount":97},[],{"trials":16714,"activeCount":97},[16715],{"nctId":16635,"briefTitle":16636,"status":155,"phases":16716,"primaryCompletion":1429,"completion":1429,"start":2404,"enrollment":7702,"conditions":16717,"interventions":16718},[88],[27],[16622,16640,16641,16642,16643,16644,16645,16646],{"trials":16720,"activeCount":97},[],{"intervention":16644,"totalTrials":417,"cells":16722},{"EARLY_PHASE1":16723,"PHASE1":16725,"PHASE2":16727,"PHASE3":16729,"PHASE4":16731,"NA":16737},{"trials":16724,"activeCount":97},[],{"trials":16726,"activeCount":97},[],{"trials":16728,"activeCount":97},[],{"trials":16730,"activeCount":97},[],{"trials":16732,"activeCount":97},[16733],{"nctId":16635,"briefTitle":16636,"status":155,"phases":16734,"primaryCompletion":1429,"completion":1429,"start":2404,"enrollment":7702,"conditions":16735,"interventions":16736},[88],[27],[16622,16640,16641,16642,16643,16644,16645,16646],{"trials":16738,"activeCount":97},[],{"intervention":16645,"totalTrials":417,"cells":16740},{"EARLY_PHASE1":16741,"PHASE1":16743,"PHASE2":16745,"PHASE3":16747,"PHASE4":16749,"NA":16755},{"trials":16742,"activeCount":97},[],{"trials":16744,"activeCount":97},[],{"trials":16746,"activeCount":97},[],{"trials":16748,"activeCount":97},[],{"trials":16750,"activeCount":97},[16751],{"nctId":16635,"briefTitle":16636,"status":155,"phases":16752,"primaryCompletion":1429,"completion":1429,"start":2404,"enrollment":7702,"conditions":16753,"interventions":16754},[88],[27],[16622,16640,16641,16642,16643,16644,16645,16646],{"trials":16756,"activeCount":97},[],{"intervention":16646,"totalTrials":417,"cells":16758},{"EARLY_PHASE1":16759,"PHASE1":16761,"PHASE2":16763,"PHASE3":16765,"PHASE4":16767,"NA":16773},{"trials":16760,"activeCount":97},[],{"trials":16762,"activeCount":97},[],{"trials":16764,"activeCount":97},[],{"trials":16766,"activeCount":97},[],{"trials":16768,"activeCount":97},[16769],{"nctId":16635,"briefTitle":16636,"status":155,"phases":16770,"primaryCompletion":1429,"completion":1429,"start":2404,"enrollment":7702,"conditions":16771,"interventions":16772},[88],[27],[16622,16640,16641,16642,16643,16644,16645,16646],{"trials":16774,"activeCount":97},[],{"intervention":16776,"totalTrials":417,"cells":16777},"Abacavir\u002Flamivudine and efavirenz",{"EARLY_PHASE1":16778,"PHASE1":16780,"PHASE2":16782,"PHASE3":16784,"PHASE4":16786,"NA":16796},{"trials":16779,"activeCount":97},[],{"trials":16781,"activeCount":97},[],{"trials":16783,"activeCount":97},[],{"trials":16785,"activeCount":97},[],{"trials":16787,"activeCount":97},[16788],{"nctId":16789,"briefTitle":16790,"status":155,"phases":16791,"primaryCompletion":7658,"completion":7658,"start":3552,"enrollment":16792,"conditions":16793,"interventions":16794},"NCT00549198","KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects",[88],392,[10930,10662],[16776,16795],"Tenofovir\u002FEmtricitabine and efavirenz",{"trials":16797,"activeCount":97},[],{"intervention":16795,"totalTrials":417,"cells":16799},{"EARLY_PHASE1":16800,"PHASE1":16802,"PHASE2":16804,"PHASE3":16806,"PHASE4":16808,"NA":16814},{"trials":16801,"activeCount":97},[],{"trials":16803,"activeCount":97},[],{"trials":16805,"activeCount":97},[],{"trials":16807,"activeCount":97},[],{"trials":16809,"activeCount":97},[16810],{"nctId":16789,"briefTitle":16790,"status":155,"phases":16811,"primaryCompletion":7658,"completion":7658,"start":3552,"enrollment":16792,"conditions":16812,"interventions":16813},[88],[10930,10662],[16776,16795],{"trials":16815,"activeCount":97},[],{"intervention":16817,"totalTrials":417,"cells":16818},"Poliorix TM",{"EARLY_PHASE1":16819,"PHASE1":16821,"PHASE2":16823,"PHASE3":16825,"PHASE4":16827,"NA":16838},{"trials":16820,"activeCount":97},[],{"trials":16822,"activeCount":97},[],{"trials":16824,"activeCount":97},[],{"trials":16826,"activeCount":97},[],{"trials":16828,"activeCount":97},[16829],{"nctId":16830,"briefTitle":16831,"status":155,"phases":16832,"primaryCompletion":16833,"completion":16833,"start":16834,"enrollment":4388,"conditions":16835,"interventions":16836},"NCT01094171","Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia",[88],"2012-10-27","2010-12-03",[4702],[16817,16837],"Infanrix TM",{"trials":16839,"activeCount":97},[],{"intervention":16837,"totalTrials":417,"cells":16841},{"EARLY_PHASE1":16842,"PHASE1":16844,"PHASE2":16846,"PHASE3":16848,"PHASE4":16850,"NA":16856},{"trials":16843,"activeCount":97},[],{"trials":16845,"activeCount":97},[],{"trials":16847,"activeCount":97},[],{"trials":16849,"activeCount":97},[],{"trials":16851,"activeCount":97},[16852],{"nctId":16830,"briefTitle":16831,"status":155,"phases":16853,"primaryCompletion":16833,"completion":16833,"start":16834,"enrollment":4388,"conditions":16854,"interventions":16855},[88],[4702],[16817,16837],{"trials":16857,"activeCount":97},[],{"intervention":13175,"totalTrials":417,"cells":16859},{"EARLY_PHASE1":16860,"PHASE1":16862,"PHASE2":16864,"PHASE3":16866,"PHASE4":16868,"NA":16874},{"trials":16861,"activeCount":97},[],{"trials":16863,"activeCount":97},[],{"trials":16865,"activeCount":97},[],{"trials":16867,"activeCount":97},[],{"trials":16869,"activeCount":97},[16870],{"nctId":13167,"briefTitle":13168,"status":155,"phases":16871,"primaryCompletion":13170,"completion":13170,"start":7865,"enrollment":13171,"conditions":16872,"interventions":16873},[88],[18],[13154,13174,13175,13176,13177,13178],{"trials":16875,"activeCount":97},[],{"intervention":13178,"totalTrials":417,"cells":16877},{"EARLY_PHASE1":16878,"PHASE1":16880,"PHASE2":16882,"PHASE3":16884,"PHASE4":16886,"NA":16892},{"trials":16879,"activeCount":97},[],{"trials":16881,"activeCount":97},[],{"trials":16883,"activeCount":97},[],{"trials":16885,"activeCount":97},[],{"trials":16887,"activeCount":97},[16888],{"nctId":13167,"briefTitle":13168,"status":155,"phases":16889,"primaryCompletion":13170,"completion":13170,"start":7865,"enrollment":13171,"conditions":16890,"interventions":16891},[88],[18],[13154,13174,13175,13176,13177,13178],{"trials":16893,"activeCount":97},[],{"intervention":16895,"totalTrials":417,"cells":16896},"FP\u002F SLM HFA MDI 50\u002F25 mcg",{"EARLY_PHASE1":16897,"PHASE1":16899,"PHASE2":16901,"PHASE3":16903,"PHASE4":16905,"NA":16916},{"trials":16898,"activeCount":97},[],{"trials":16900,"activeCount":97},[],{"trials":16902,"activeCount":97},[],{"trials":16904,"activeCount":97},[],{"trials":16906,"activeCount":97},[16907],{"nctId":16908,"briefTitle":16909,"status":155,"phases":16910,"primaryCompletion":16100,"completion":16911,"start":16912,"enrollment":536,"conditions":16913,"interventions":16914},"NCT02113436","Efficacy and Safety of Fluticasone Propionate(FP)\u002F Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma",[88],"2016-10-01","2014-05-01",[18],[16895,16915],"FP HFA MDI 50 mcg",{"trials":16917,"activeCount":97},[],{"intervention":16915,"totalTrials":417,"cells":16919},{"EARLY_PHASE1":16920,"PHASE1":16922,"PHASE2":16924,"PHASE3":16926,"PHASE4":16928,"NA":16934},{"trials":16921,"activeCount":97},[],{"trials":16923,"activeCount":97},[],{"trials":16925,"activeCount":97},[],{"trials":16927,"activeCount":97},[],{"trials":16929,"activeCount":97},[16930],{"nctId":16908,"briefTitle":16909,"status":155,"phases":16931,"primaryCompletion":16100,"completion":16911,"start":16912,"enrollment":536,"conditions":16932,"interventions":16933},[88],[18],[16895,16915],{"trials":16935,"activeCount":97},[],{"intervention":8623,"totalTrials":417,"cells":16937},{"EARLY_PHASE1":16938,"PHASE1":16940,"PHASE2":16942,"PHASE3":16944,"PHASE4":16946,"NA":16952},{"trials":16939,"activeCount":97},[],{"trials":16941,"activeCount":97},[],{"trials":16943,"activeCount":97},[],{"trials":16945,"activeCount":97},[],{"trials":16947,"activeCount":97},[16948],{"nctId":8614,"briefTitle":8615,"status":155,"phases":16949,"primaryCompletion":8617,"completion":8617,"start":8618,"enrollment":8619,"conditions":16950,"interventions":16951},[88],[15],[8622,8623,2916],{"trials":16953,"activeCount":97},[],{"intervention":16955,"totalTrials":417,"cells":16956},"UMEC\u002FVI 62.5\u002F25 mcg via ELLIPTA",{"EARLY_PHASE1":16957,"PHASE1":16959,"PHASE2":16961,"PHASE3":16963,"PHASE4":16965,"NA":16978},{"trials":16958,"activeCount":97},[],{"trials":16960,"activeCount":97},[],{"trials":16962,"activeCount":97},[],{"trials":16964,"activeCount":97},[],{"trials":16966,"activeCount":97},[16967],{"nctId":16968,"briefTitle":16969,"status":155,"phases":16970,"primaryCompletion":16971,"completion":16971,"start":16972,"enrollment":16973,"conditions":16974,"interventions":16975},"NCT03034915","A 24-week Study to Compare Umeclidinium\u002FVilanterol (UMEC\u002FVI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[88],"2018-06-18","2017-06-16",2696,[15],[16955,16976,16977],"UMEC 62.5 mcg via ELLIPTA","Salmeterol 50 mcg via DISKUS",{"trials":16979,"activeCount":97},[],{"intervention":16976,"totalTrials":417,"cells":16981},{"EARLY_PHASE1":16982,"PHASE1":16984,"PHASE2":16986,"PHASE3":16988,"PHASE4":16990,"NA":16996},{"trials":16983,"activeCount":97},[],{"trials":16985,"activeCount":97},[],{"trials":16987,"activeCount":97},[],{"trials":16989,"activeCount":97},[],{"trials":16991,"activeCount":97},[16992],{"nctId":16968,"briefTitle":16969,"status":155,"phases":16993,"primaryCompletion":16971,"completion":16971,"start":16972,"enrollment":16973,"conditions":16994,"interventions":16995},[88],[15],[16955,16976,16977],{"trials":16997,"activeCount":97},[],{"intervention":16977,"totalTrials":417,"cells":16999},{"EARLY_PHASE1":17000,"PHASE1":17002,"PHASE2":17004,"PHASE3":17006,"PHASE4":17008,"NA":17014},{"trials":17001,"activeCount":97},[],{"trials":17003,"activeCount":97},[],{"trials":17005,"activeCount":97},[],{"trials":17007,"activeCount":97},[],{"trials":17009,"activeCount":97},[17010],{"nctId":16968,"briefTitle":16969,"status":155,"phases":17011,"primaryCompletion":16971,"completion":16971,"start":16972,"enrollment":16973,"conditions":17012,"interventions":17013},[88],[15],[16955,16976,16977],{"trials":17015,"activeCount":97},[],{"intervention":17017,"totalTrials":417,"cells":17018},"Salmeterol\u002F fluticasone propionate Diskus® inhaler 50\u002F100 mcg",{"EARLY_PHASE1":17019,"PHASE1":17021,"PHASE2":17023,"PHASE3":17025,"PHASE4":17027,"NA":17037},{"trials":17020,"activeCount":97},[],{"trials":17022,"activeCount":97},[],{"trials":17024,"activeCount":97},[],{"trials":17026,"activeCount":97},[],{"trials":17028,"activeCount":97},[17029],{"nctId":17030,"briefTitle":17031,"status":155,"phases":17032,"primaryCompletion":9133,"completion":9133,"start":2796,"enrollment":17033,"conditions":17034,"interventions":17035},"NCT00197106","Treatment Of Symptomatic Asthma In Children",[88],176,[18],[17017,17036],"fluticasone propionate 2 x 100 mcg",{"trials":17038,"activeCount":97},[],{"intervention":17036,"totalTrials":417,"cells":17040},{"EARLY_PHASE1":17041,"PHASE1":17043,"PHASE2":17045,"PHASE3":17047,"PHASE4":17049,"NA":17055},{"trials":17042,"activeCount":97},[],{"trials":17044,"activeCount":97},[],{"trials":17046,"activeCount":97},[],{"trials":17048,"activeCount":97},[],{"trials":17050,"activeCount":97},[17051],{"nctId":17030,"briefTitle":17031,"status":155,"phases":17052,"primaryCompletion":9133,"completion":9133,"start":2796,"enrollment":17033,"conditions":17053,"interventions":17054},[88],[18],[17017,17036],{"trials":17056,"activeCount":97},[],{"intervention":17058,"totalTrials":417,"cells":17059},"titration",{"EARLY_PHASE1":17060,"PHASE1":17062,"PHASE2":17064,"PHASE3":17066,"PHASE4":17068,"NA":17076},{"trials":17061,"activeCount":97},[],{"trials":17063,"activeCount":97},[],{"trials":17065,"activeCount":97},[],{"trials":17067,"activeCount":97},[],{"trials":17069,"activeCount":97},[17070],{"nctId":17071,"briefTitle":17072,"status":155,"phases":17073,"primaryCompletion":11759,"completion":11759,"start":8492,"enrollment":414,"conditions":17074,"interventions":17075},"NCT01045590","Glibenclamide (Dose to be Titrated From Starting Dose of 5mg om) Plus Rosiglitazone 4mg om (Increased to 8mg om After 6 Months) and vs Glibenclamide (Dose to be Titrated With Starting Dose of 5mg om) Plus Placebo, Administered to Patients With Type 2 Diabetes Mellitus",[88],[27],[17058,17058],{"trials":17077,"activeCount":97},[],{"intervention":17079,"totalTrials":417,"cells":17080},"Salmeterol\u002Ffluticasone propionate combination",{"EARLY_PHASE1":17081,"PHASE1":17083,"PHASE2":17085,"PHASE3":17087,"PHASE4":17089,"NA":17097},{"trials":17082,"activeCount":97},[],{"trials":17084,"activeCount":97},[],{"trials":17086,"activeCount":97},[],{"trials":17088,"activeCount":97},[],{"trials":17090,"activeCount":97},[17091],{"nctId":17092,"briefTitle":17093,"status":155,"phases":17094,"primaryCompletion":2428,"completion":2428,"start":2844,"enrollment":1579,"conditions":17095,"interventions":17096},"NCT00291382","Airway Hyper-responsiveness Study In Asthma Using Salmeterol\u002FFluticasone Propionate Combination Product",[88],[18],[17079],{"trials":17098,"activeCount":97},[],{"intervention":12355,"totalTrials":417,"cells":17100},{"EARLY_PHASE1":17101,"PHASE1":17103,"PHASE2":17105,"PHASE3":17107,"PHASE4":17109,"NA":17115},{"trials":17102,"activeCount":97},[],{"trials":17104,"activeCount":97},[],{"trials":17106,"activeCount":97},[],{"trials":17108,"activeCount":97},[],{"trials":17110,"activeCount":97},[17111],{"nctId":12350,"briefTitle":12351,"status":155,"phases":17112,"completion":8406,"start":2404,"enrollment":695,"conditions":17113,"interventions":17114},[88],[18],[12355,8432],{"trials":17116,"activeCount":97},[],{"intervention":17118,"totalTrials":417,"cells":17119},"Additional challenge dose",{"EARLY_PHASE1":17120,"PHASE1":17122,"PHASE2":17124,"PHASE3":17126,"PHASE4":17128,"NA":17139},{"trials":17121,"activeCount":97},[],{"trials":17123,"activeCount":97},[],{"trials":17125,"activeCount":97},[],{"trials":17127,"activeCount":97},[],{"trials":17129,"activeCount":97},[17130],{"nctId":17131,"briefTitle":17132,"status":155,"phases":17133,"primaryCompletion":17134,"completion":17134,"start":17135,"enrollment":17136,"conditions":17137,"interventions":17138},"NCT00875485","Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™",[88],"2014-07-01","2009-05-01",210,[24,7966],[17118],{"trials":17140,"activeCount":97},[],{"intervention":17142,"totalTrials":417,"cells":17143},"ropinirole\u002FL-dopa",{"EARLY_PHASE1":17144,"PHASE1":17146,"PHASE2":17148,"PHASE3":17150,"PHASE4":17152,"NA":17163},{"trials":17145,"activeCount":97},[],{"trials":17147,"activeCount":97},[],{"trials":17149,"activeCount":97},[],{"trials":17151,"activeCount":97},[],{"trials":17153,"activeCount":97},[17154],{"nctId":17155,"briefTitle":17156,"status":155,"phases":17157,"primaryCompletion":17158,"completion":17158,"start":17159,"enrollment":17160,"conditions":17161,"interventions":17162},"NCT01494532","A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease",[88],"2014-11-18","2012-04-02",352,[15879],[17142],{"trials":17164,"activeCount":97},[],{"intervention":17166,"totalTrials":417,"cells":17167},"Fluviral",{"EARLY_PHASE1":17168,"PHASE1":17170,"PHASE2":17172,"PHASE3":17174,"PHASE4":17176,"NA":17186},{"trials":17169,"activeCount":97},[],{"trials":17171,"activeCount":97},[],{"trials":17173,"activeCount":97},[],{"trials":17175,"activeCount":97},[],{"trials":17177,"activeCount":97},[17178],{"nctId":17179,"briefTitle":17180,"status":155,"phases":17181,"primaryCompletion":17182,"completion":17182,"start":17183,"enrollment":15623,"conditions":17184,"interventions":17185},"NCT00586469","A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk",[88],"2008-01-14","2007-12-14",[8265],[17166],{"trials":17187,"activeCount":97},[],{"intervention":17189,"totalTrials":417,"cells":17190},"current marketed FLOLAN",{"EARLY_PHASE1":17191,"PHASE1":17193,"PHASE2":17195,"PHASE3":17197,"PHASE4":17199,"NA":17212},{"trials":17192,"activeCount":97},[],{"trials":17194,"activeCount":97},[],{"trials":17196,"activeCount":97},[],{"trials":17198,"activeCount":97},[],{"trials":17200,"activeCount":97},[17201],{"nctId":17202,"briefTitle":17203,"status":155,"phases":17204,"primaryCompletion":17205,"completion":17206,"start":17207,"enrollment":433,"conditions":17208,"interventions":17210},"NCT01462565","Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)",[88],"2012-05-16","2012-11-08","2011-11-01",[17209],"Hypertension, Pulmonary",[17189,17211],"new thermo stable formulation of epoprostenol sodium",{"trials":17213,"activeCount":97},[],{"intervention":17211,"totalTrials":417,"cells":17215},{"EARLY_PHASE1":17216,"PHASE1":17218,"PHASE2":17220,"PHASE3":17222,"PHASE4":17224,"NA":17230},{"trials":17217,"activeCount":97},[],{"trials":17219,"activeCount":97},[],{"trials":17221,"activeCount":97},[],{"trials":17223,"activeCount":97},[],{"trials":17225,"activeCount":97},[17226],{"nctId":17202,"briefTitle":17203,"status":155,"phases":17227,"primaryCompletion":17205,"completion":17206,"start":17207,"enrollment":433,"conditions":17228,"interventions":17229},[88],[17209],[17189,17211],{"trials":17231,"activeCount":97},[],{"intervention":17233,"totalTrials":417,"cells":17234},"Beta-blockers including Carvedilol",{"EARLY_PHASE1":17235,"PHASE1":17237,"PHASE2":17239,"PHASE3":17241,"PHASE4":17243,"NA":17256},{"trials":17236,"activeCount":97},[],{"trials":17238,"activeCount":97},[],{"trials":17240,"activeCount":97},[],{"trials":17242,"activeCount":97},[],{"trials":17244,"activeCount":97},[17245],{"nctId":17246,"briefTitle":17247,"status":155,"phases":17248,"completion":17249,"start":17250,"enrollment":17251,"conditions":17252,"interventions":17254},"NCT00344513","Organized Program To Initiate Lifesaving Treatment In Hospitalized Patients With Heart Failure (OPTIMIZE-HF)",[88],"2005-06-30","2002-12-16",50000,[17253],"Heart Failure, Congestive",[17233,17255],"ACE inhibitors",{"trials":17257,"activeCount":97},[],{"intervention":17255,"totalTrials":417,"cells":17259},{"EARLY_PHASE1":17260,"PHASE1":17262,"PHASE2":17264,"PHASE3":17266,"PHASE4":17268,"NA":17274},{"trials":17261,"activeCount":97},[],{"trials":17263,"activeCount":97},[],{"trials":17265,"activeCount":97},[],{"trials":17267,"activeCount":97},[],{"trials":17269,"activeCount":97},[17270],{"nctId":17246,"briefTitle":17247,"status":155,"phases":17271,"completion":17249,"start":17250,"enrollment":17251,"conditions":17272,"interventions":17273},[88],[17253],[17233,17255],{"trials":17275,"activeCount":97},[],{"intervention":17277,"totalTrials":417,"cells":17278},"Fluarix Tetra Vaccine",{"EARLY_PHASE1":17279,"PHASE1":17281,"PHASE2":17283,"PHASE3":17285,"PHASE4":17287,"NA":17298},{"trials":17280,"activeCount":97},[],{"trials":17282,"activeCount":97},[],{"trials":17284,"activeCount":97},[],{"trials":17286,"activeCount":97},[],{"trials":17288,"activeCount":97},[17289],{"nctId":17290,"briefTitle":17291,"status":155,"phases":17292,"primaryCompletion":17293,"completion":17293,"start":17294,"enrollment":17295,"conditions":17296,"interventions":17297},"NCT05648357","A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India",[88],"2024-02-26","2023-12-14",250,[5353],[17277],{"trials":17299,"activeCount":97},[],{"intervention":17301,"totalTrials":417,"cells":17302},"FLIXOTIDE and SERETIDE",{"EARLY_PHASE1":17303,"PHASE1":17305,"PHASE2":17307,"PHASE3":17309,"PHASE4":17311,"NA":17319},{"trials":17304,"activeCount":97},[],{"trials":17306,"activeCount":97},[],{"trials":17308,"activeCount":97},[],{"trials":17310,"activeCount":97},[],{"trials":17312,"activeCount":97},[17313],{"nctId":17314,"briefTitle":17315,"status":500,"phases":17316,"primaryCompletion":2804,"completion":2804,"start":2804,"enrollment":97,"conditions":17317,"interventions":17318},"NCT00456313","No Resistance After Long Term Treatment SERETIDE",[88],[18],[17301],{"trials":17320,"activeCount":97},[],{"intervention":17322,"totalTrials":417,"cells":17323},"bicalutamide",{"EARLY_PHASE1":17324,"PHASE1":17326,"PHASE2":17328,"PHASE3":17330,"PHASE4":17332,"NA":17340},{"trials":17325,"activeCount":97},[],{"trials":17327,"activeCount":97},[],{"trials":17329,"activeCount":97},[],{"trials":17331,"activeCount":97},[],{"trials":17333,"activeCount":97},[17334],{"nctId":17335,"briefTitle":17336,"status":155,"phases":17337,"primaryCompletion":3390,"completion":3390,"start":2835,"enrollment":4377,"conditions":17338,"interventions":17339},"NCT00470834","Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy",[88],[5634],[13084,17322],{"trials":17341,"activeCount":97},[],{"intervention":17343,"totalTrials":417,"cells":17344},"Salmeterol\u002Ffluticasone propionate and fluticasone propionate",{"EARLY_PHASE1":17345,"PHASE1":17347,"PHASE2":17349,"PHASE3":17351,"PHASE4":17353,"NA":17361},{"trials":17346,"activeCount":97},[],{"trials":17348,"activeCount":97},[],{"trials":17350,"activeCount":97},[],{"trials":17352,"activeCount":97},[],{"trials":17354,"activeCount":97},[17355],{"nctId":17356,"briefTitle":17357,"status":155,"phases":17358,"primaryCompletion":2775,"completion":2775,"start":2824,"enrollment":6503,"conditions":17359,"interventions":17360},"NCT00370591","Study Of Airway Physiology In Adults. SERETIDE DISKUS® Inhaler and FLIXOTIDE® Inhaler Are Trademarks of GSK Croup of Companies.",[88],[18],[17343],{"trials":17362,"activeCount":97},[],{"intervention":17364,"totalTrials":417,"cells":17365},"Chlorhexidine Digluconate Mouthwash with Alcohol",{"EARLY_PHASE1":17366,"PHASE1":17368,"PHASE2":17370,"PHASE3":17372,"PHASE4":17374,"NA":17383},{"trials":17367,"activeCount":97},[],{"trials":17369,"activeCount":97},[],{"trials":17371,"activeCount":97},[],{"trials":17373,"activeCount":97},[],{"trials":17375,"activeCount":97},[17376],{"nctId":17377,"briefTitle":17378,"status":155,"phases":17379,"primaryCompletion":503,"completion":503,"start":828,"enrollment":10257,"conditions":17380,"interventions":17381},"NCT01751178","An Efficacy Study of Chlorhexidine Mouthwashes",[88],[15173],[17364,17382],"Chlorhexidine Digluconate Mouthwash without Alcohol",{"trials":17384,"activeCount":97},[],{"intervention":17382,"totalTrials":417,"cells":17386},{"EARLY_PHASE1":17387,"PHASE1":17389,"PHASE2":17391,"PHASE3":17393,"PHASE4":17395,"NA":17401},{"trials":17388,"activeCount":97},[],{"trials":17390,"activeCount":97},[],{"trials":17392,"activeCount":97},[],{"trials":17394,"activeCount":97},[],{"trials":17396,"activeCount":97},[17397],{"nctId":17377,"briefTitle":17378,"status":155,"phases":17398,"primaryCompletion":503,"completion":503,"start":828,"enrollment":10257,"conditions":17399,"interventions":17400},[88],[15173],[17364,17382],{"trials":17402,"activeCount":97},[],{"intervention":17404,"totalTrials":417,"cells":17405},"Fluticasone\u002FSalmeterol HFA",{"EARLY_PHASE1":17406,"PHASE1":17408,"PHASE2":17410,"PHASE3":17412,"PHASE4":17414,"NA":17423},{"trials":17407,"activeCount":97},[],{"trials":17409,"activeCount":97},[],{"trials":17411,"activeCount":97},[],{"trials":17413,"activeCount":97},[],{"trials":17415,"activeCount":97},[17416],{"nctId":17417,"briefTitle":17418,"status":155,"phases":17419,"primaryCompletion":2336,"completion":2336,"start":5196,"enrollment":17420,"conditions":17421,"interventions":17422},"NCT00404261","Evaluation Of Patient Satisfaction Of Metered Dose Inhaler (MDI) With Counter In Asthmatics And Chronic Obstructive Pulmonary Disease Patients (COPD).",[88],132,[18],[17404],{"trials":17424,"activeCount":97},[],{"intervention":17426,"totalTrials":417,"cells":17427},"Belimumab 10 mg\u002Fkg plus standard therapy",{"EARLY_PHASE1":17428,"PHASE1":17430,"PHASE2":17432,"PHASE3":17434,"PHASE4":17436,"NA":17447},{"trials":17429,"activeCount":97},[],{"trials":17431,"activeCount":97},[],{"trials":17433,"activeCount":97},[],{"trials":17435,"activeCount":97},[],{"trials":17437,"activeCount":97},[17438],{"nctId":17439,"briefTitle":17440,"status":155,"phases":17441,"primaryCompletion":17442,"completion":3596,"start":17443,"enrollment":17444,"conditions":17445,"interventions":17446},"NCT01705977","Belimumab Assessment of Safety in SLE",[88],"2018-07-30","2012-11-27",4019,[435],[17426],{"trials":17448,"activeCount":97},[],{"intervention":17450,"totalTrials":417,"cells":17451},"Menactra™",{"EARLY_PHASE1":17452,"PHASE1":17454,"PHASE2":17456,"PHASE3":17458,"PHASE4":17460,"NA":17471},{"trials":17453,"activeCount":97},[],{"trials":17455,"activeCount":97},[],{"trials":17457,"activeCount":97},[],{"trials":17459,"activeCount":97},[],{"trials":17461,"activeCount":97},[17462],{"nctId":17463,"briefTitle":17464,"status":155,"phases":17465,"primaryCompletion":17466,"completion":17466,"start":17467,"enrollment":17468,"conditions":17469,"interventions":17470},"NCT00282295","US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease",[88],"2006-08-08","2006-01-25",1344,[3624,33,30],[11489,17450],{"trials":17472,"activeCount":97},[],{"intervention":9136,"totalTrials":417,"cells":17474},{"EARLY_PHASE1":17475,"PHASE1":17477,"PHASE2":17479,"PHASE3":17481,"PHASE4":17483,"NA":17489},{"trials":17476,"activeCount":97},[],{"trials":17478,"activeCount":97},[],{"trials":17480,"activeCount":97},[],{"trials":17482,"activeCount":97},[],{"trials":17484,"activeCount":97},[17485],{"nctId":9130,"briefTitle":9131,"status":155,"phases":17486,"primaryCompletion":9133,"completion":9133,"start":8478,"enrollment":719,"conditions":17487,"interventions":17488},[88],[9036],[9136,9016,9137],{"trials":17490,"activeCount":97},[],{"intervention":9137,"totalTrials":417,"cells":17492},{"EARLY_PHASE1":17493,"PHASE1":17495,"PHASE2":17497,"PHASE3":17499,"PHASE4":17501,"NA":17507},{"trials":17494,"activeCount":97},[],{"trials":17496,"activeCount":97},[],{"trials":17498,"activeCount":97},[],{"trials":17500,"activeCount":97},[],{"trials":17502,"activeCount":97},[17503],{"nctId":9130,"briefTitle":9131,"status":155,"phases":17504,"primaryCompletion":9133,"completion":9133,"start":8478,"enrollment":719,"conditions":17505,"interventions":17506},[88],[9036],[9136,9016,9137],{"trials":17508,"activeCount":97},[],{"intervention":17510,"totalTrials":417,"cells":17511},"Clindamycin + BPO",{"EARLY_PHASE1":17512,"PHASE1":17514,"PHASE2":17516,"PHASE3":17518,"PHASE4":17520,"NA":17531},{"trials":17513,"activeCount":97},[],{"trials":17515,"activeCount":97},[],{"trials":17517,"activeCount":97},[],{"trials":17519,"activeCount":97},[],{"trials":17521,"activeCount":97},[17522],{"nctId":17523,"briefTitle":17524,"status":155,"phases":17525,"primaryCompletion":17526,"completion":17526,"start":10518,"enrollment":17527,"conditions":17528,"interventions":17529},"NCT02058628","Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris",[88],"2014-09-08",222,[15087],[17510,17530],"Azelaic acid",{"trials":17532,"activeCount":97},[],{"intervention":17530,"totalTrials":417,"cells":17534},{"EARLY_PHASE1":17535,"PHASE1":17537,"PHASE2":17539,"PHASE3":17541,"PHASE4":17543,"NA":17549},{"trials":17536,"activeCount":97},[],{"trials":17538,"activeCount":97},[],{"trials":17540,"activeCount":97},[],{"trials":17542,"activeCount":97},[],{"trials":17544,"activeCount":97},[17545],{"nctId":17523,"briefTitle":17524,"status":155,"phases":17546,"primaryCompletion":17526,"completion":17526,"start":10518,"enrollment":17527,"conditions":17547,"interventions":17548},[88],[15087],[17510,17530],{"trials":17550,"activeCount":97},[],{"intervention":13128,"totalTrials":417,"cells":17552},{"EARLY_PHASE1":17553,"PHASE1":17555,"PHASE2":17557,"PHASE3":17559,"PHASE4":17561,"NA":17567},{"trials":17554,"activeCount":97},[],{"trials":17556,"activeCount":97},[],{"trials":17558,"activeCount":97},[],{"trials":17560,"activeCount":97},[],{"trials":17562,"activeCount":97},[17563],{"nctId":13122,"briefTitle":13123,"status":155,"phases":17564,"primaryCompletion":3078,"completion":3078,"start":6351,"enrollment":323,"conditions":17565,"interventions":17566},[88],[13126],[13102,13128,13118],{"trials":17568,"activeCount":97},[],{"intervention":11602,"totalTrials":417,"cells":17570},{"EARLY_PHASE1":17571,"PHASE1":17573,"PHASE2":17575,"PHASE3":17577,"PHASE4":17579,"NA":17585},{"trials":17572,"activeCount":97},[],{"trials":17574,"activeCount":97},[],{"trials":17576,"activeCount":97},[],{"trials":17578,"activeCount":97},[],{"trials":17580,"activeCount":97},[17581],{"nctId":11596,"briefTitle":11597,"status":155,"phases":17582,"primaryCompletion":8478,"completion":8478,"start":11599,"enrollment":9569,"conditions":17583,"interventions":17584},[88],[18],[11563,11592,11591,11581,11593,11602],{"trials":17586,"activeCount":97},[],{"intervention":13065,"totalTrials":417,"cells":17588},{"EARLY_PHASE1":17589,"PHASE1":17591,"PHASE2":17593,"PHASE3":17595,"PHASE4":17597,"NA":17603},{"trials":17590,"activeCount":97},[],{"trials":17592,"activeCount":97},[],{"trials":17594,"activeCount":97},[],{"trials":17596,"activeCount":97},[],{"trials":17598,"activeCount":97},[17599],{"nctId":13058,"briefTitle":13059,"status":155,"phases":17600,"completion":2405,"start":13061,"enrollment":13062,"conditions":17601,"interventions":17602},[88],[8063],[9093,13065,13066,13067],{"trials":17604,"activeCount":97},[],{"intervention":13067,"totalTrials":417,"cells":17606},{"EARLY_PHASE1":17607,"PHASE1":17609,"PHASE2":17611,"PHASE3":17613,"PHASE4":17615,"NA":17621},{"trials":17608,"activeCount":97},[],{"trials":17610,"activeCount":97},[],{"trials":17612,"activeCount":97},[],{"trials":17614,"activeCount":97},[],{"trials":17616,"activeCount":97},[17617],{"nctId":13058,"briefTitle":13059,"status":155,"phases":17618,"completion":2405,"start":13061,"enrollment":13062,"conditions":17619,"interventions":17620},[88],[8063],[9093,13065,13066,13067],{"trials":17622,"activeCount":97},[],{"intervention":10129,"totalTrials":417,"cells":17624},{"EARLY_PHASE1":17625,"PHASE1":17627,"PHASE2":17629,"PHASE3":17631,"PHASE4":17633,"NA":17639},{"trials":17626,"activeCount":97},[],{"trials":17628,"activeCount":97},[],{"trials":17630,"activeCount":97},[],{"trials":17632,"activeCount":97},[],{"trials":17634,"activeCount":97},[17635],{"nctId":10121,"briefTitle":10122,"status":155,"phases":17636,"primaryCompletion":10124,"completion":10124,"start":10125,"enrollment":10126,"conditions":17637,"interventions":17638},[88],[30],[10065,10129,10130],{"trials":17640,"activeCount":97},[],{"intervention":10130,"totalTrials":417,"cells":17642},{"EARLY_PHASE1":17643,"PHASE1":17645,"PHASE2":17647,"PHASE3":17649,"PHASE4":17651,"NA":17657},{"trials":17644,"activeCount":97},[],{"trials":17646,"activeCount":97},[],{"trials":17648,"activeCount":97},[],{"trials":17650,"activeCount":97},[],{"trials":17652,"activeCount":97},[17653],{"nctId":10121,"briefTitle":10122,"status":155,"phases":17654,"primaryCompletion":10124,"completion":10124,"start":10125,"enrollment":10126,"conditions":17655,"interventions":17656},[88],[30],[10065,10129,10130],{"trials":17658,"activeCount":97},[],{"intervention":17660,"totalTrials":417,"cells":17661},"Salmeterol\u002Ffluticasone",{"EARLY_PHASE1":17662,"PHASE1":17664,"PHASE2":17666,"PHASE3":17668,"PHASE4":17670,"NA":17681},{"trials":17663,"activeCount":97},[],{"trials":17665,"activeCount":97},[],{"trials":17667,"activeCount":97},[],{"trials":17669,"activeCount":97},[],{"trials":17671,"activeCount":97},[17672],{"nctId":17673,"briefTitle":17674,"status":155,"phases":17675,"primaryCompletion":17676,"completion":17676,"start":17677,"enrollment":17678,"conditions":17679,"interventions":17680},"NCT00315744","Viapaed Study In Children And Adolescents With Asthma",[88],"2007-04-12","2004-11-04",285,[18],[17660,8381,963],{"trials":17682,"activeCount":97},[],{"intervention":12003,"totalTrials":417,"cells":17684},{"EARLY_PHASE1":17685,"PHASE1":17687,"PHASE2":17689,"PHASE3":17691,"PHASE4":17693,"NA":17699},{"trials":17686,"activeCount":97},[],{"trials":17688,"activeCount":97},[],{"trials":17690,"activeCount":97},[],{"trials":17692,"activeCount":97},[],{"trials":17694,"activeCount":97},[17695],{"nctId":11997,"briefTitle":11998,"status":155,"phases":17696,"primaryCompletion":3078,"completion":3078,"start":6351,"enrollment":12000,"conditions":17697,"interventions":17698},[88],[11994],[11968,12003],{"trials":17700,"activeCount":97},[],{"intervention":12382,"totalTrials":417,"cells":17702},{"EARLY_PHASE1":17703,"PHASE1":17705,"PHASE2":17707,"PHASE3":17709,"PHASE4":17711,"NA":17717},{"trials":17704,"activeCount":97},[],{"trials":17706,"activeCount":97},[],{"trials":17708,"activeCount":97},[],{"trials":17710,"activeCount":97},[],{"trials":17712,"activeCount":97},[17713],{"nctId":12375,"briefTitle":12376,"status":155,"phases":17714,"primaryCompletion":12378,"completion":12378,"start":12379,"enrollment":2825,"conditions":17715,"interventions":17716},[88],[18],[12382,12383],{"trials":17718,"activeCount":97},[],{"intervention":17720,"totalTrials":417,"cells":17721},"Rotarix TM",{"EARLY_PHASE1":17722,"PHASE1":17724,"PHASE2":17726,"PHASE3":17728,"PHASE4":17730,"NA":17740},{"trials":17723,"activeCount":97},[],{"trials":17725,"activeCount":97},[],{"trials":17727,"activeCount":97},[],{"trials":17729,"activeCount":97},[],{"trials":17731,"activeCount":97},[17732],{"nctId":17733,"briefTitle":17734,"status":155,"phases":17735,"primaryCompletion":17736,"completion":17736,"start":17737,"enrollment":1117,"conditions":17738,"interventions":17739},"NCT01198769","Immunogenicity and Safety Study of Rotarix TM in Taiwanese Infants Who Received Hepatitis B Immunoglobulin After Birth.",[88],"2011-04-18","2010-11-11",[4759],[17720],{"trials":17741,"activeCount":97},[],{"intervention":17743,"totalTrials":417,"cells":17744},"fondaparinux background and standard dose UFH",{"EARLY_PHASE1":17745,"PHASE1":17747,"PHASE2":17749,"PHASE3":17751,"PHASE4":17753,"NA":17764},{"trials":17746,"activeCount":97},[],{"trials":17748,"activeCount":97},[],{"trials":17750,"activeCount":97},[],{"trials":17752,"activeCount":97},[],{"trials":17754,"activeCount":97},[17755],{"nctId":17756,"briefTitle":17757,"status":155,"phases":17758,"primaryCompletion":7647,"completion":7647,"start":8116,"enrollment":17759,"conditions":17760,"interventions":17761},"NCT00790907","Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS)",[88],3235,[11827],[17743,17762,17763],"Fondaparinux background and low dose heparin","Open label fondaparinux",{"trials":17765,"activeCount":97},[],{"intervention":17762,"totalTrials":417,"cells":17767},{"EARLY_PHASE1":17768,"PHASE1":17770,"PHASE2":17772,"PHASE3":17774,"PHASE4":17776,"NA":17782},{"trials":17769,"activeCount":97},[],{"trials":17771,"activeCount":97},[],{"trials":17773,"activeCount":97},[],{"trials":17775,"activeCount":97},[],{"trials":17777,"activeCount":97},[17778],{"nctId":17756,"briefTitle":17757,"status":155,"phases":17779,"primaryCompletion":7647,"completion":7647,"start":8116,"enrollment":17759,"conditions":17780,"interventions":17781},[88],[11827],[17743,17762,17763],{"trials":17783,"activeCount":97},[],{"intervention":17763,"totalTrials":417,"cells":17785},{"EARLY_PHASE1":17786,"PHASE1":17788,"PHASE2":17790,"PHASE3":17792,"PHASE4":17794,"NA":17800},{"trials":17787,"activeCount":97},[],{"trials":17789,"activeCount":97},[],{"trials":17791,"activeCount":97},[],{"trials":17793,"activeCount":97},[],{"trials":17795,"activeCount":97},[17796],{"nctId":17756,"briefTitle":17757,"status":155,"phases":17797,"primaryCompletion":7647,"completion":7647,"start":8116,"enrollment":17759,"conditions":17798,"interventions":17799},[88],[11827],[17743,17762,17763],{"trials":17801,"activeCount":97},[],{"intervention":17803,"totalTrials":417,"cells":17804},"rosiglitazone-metformin fixed dose combination",{"EARLY_PHASE1":17805,"PHASE1":17807,"PHASE2":17809,"PHASE3":17811,"PHASE4":17813,"NA":17822},{"trials":17806,"activeCount":97},[],{"trials":17808,"activeCount":97},[],{"trials":17810,"activeCount":97},[],{"trials":17812,"activeCount":97},[],{"trials":17814,"activeCount":97},[17815],{"nctId":17816,"briefTitle":17817,"status":155,"phases":17818,"primaryCompletion":8426,"completion":8426,"start":2844,"enrollment":314,"conditions":17819,"interventions":17820},"NCT00318656","24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes",[88],[9079],[17803,17821],"metformin + glimepiride",{"trials":17823,"activeCount":97},[],{"intervention":17821,"totalTrials":417,"cells":17825},{"EARLY_PHASE1":17826,"PHASE1":17828,"PHASE2":17830,"PHASE3":17832,"PHASE4":17834,"NA":17840},{"trials":17827,"activeCount":97},[],{"trials":17829,"activeCount":97},[],{"trials":17831,"activeCount":97},[],{"trials":17833,"activeCount":97},[],{"trials":17835,"activeCount":97},[17836],{"nctId":17816,"briefTitle":17817,"status":155,"phases":17837,"primaryCompletion":8426,"completion":8426,"start":2844,"enrollment":314,"conditions":17838,"interventions":17839},[88],[9079],[17803,17821],{"trials":17841,"activeCount":97},[],{"intervention":17843,"totalTrials":433,"cells":17844},"GW685698X",{"EARLY_PHASE1":17845,"PHASE1":17847,"PHASE2":17879,"PHASE3":17911,"PHASE4":17969,"NA":17971},{"trials":17846,"activeCount":97},[],{"trials":17848,"activeCount":97},[17849,17857,17864,17871],{"nctId":17850,"briefTitle":17851,"status":155,"phases":17852,"primaryCompletion":8287,"completion":8287,"start":17853,"enrollment":454,"conditions":17854,"interventions":17855},"NCT00444509","Single Dose GW685698X Magnesium Stearate Study In Asthmatic Patients.",[85],"2007-02-17",[18],[17843,17856],"GW685698X containing magnesium stearate",{"nctId":17858,"briefTitle":17859,"status":155,"phases":17860,"primaryCompletion":17861,"completion":17861,"start":2768,"enrollment":6503,"conditions":17862,"interventions":17863},"NCT00972673","A Study of GW685698X in Healthy Japanese Male Subjects",[85],"2008-12-19",[18],[17843],{"nctId":17865,"briefTitle":17866,"status":155,"phases":17867,"primaryCompletion":4739,"completion":4739,"start":17868,"enrollment":710,"conditions":17869,"interventions":17870},"NCT00522678","Repeat Dose GW685698X With Magnesium Stearate, Excipient Bridging Study, In Healthy Volunteers",[85],"2007-02-15",[18],[17843],{"nctId":17872,"briefTitle":17873,"status":155,"phases":17874,"primaryCompletion":17875,"completion":17875,"start":17876,"enrollment":454,"conditions":17877,"interventions":17878},"NCT00419237","Investigating The Pharmacokinetics Of An Inhaled Dose Of A New Corticosteroid In Patients With Impaired Liver Function",[85],"2005-04-15","2005-01-13",[18],[17843],{"trials":17880,"activeCount":97},[17881,17890,17898,17904],{"nctId":17882,"briefTitle":17883,"status":155,"phases":17884,"primaryCompletion":17885,"completion":17886,"start":8207,"enrollment":17887,"conditions":17888,"interventions":17889},"NCT00603746","A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.",[86],"2008-09-01","2008-09-20",627,[18],[17843],{"nctId":17891,"briefTitle":17892,"status":155,"phases":17893,"primaryCompletion":17894,"completion":17895,"start":8207,"enrollment":8227,"conditions":17896,"interventions":17897},"NCT00603382","A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.",[86],"2008-10-01","2008-10-02",[18],[17843],{"nctId":17899,"briefTitle":17900,"status":155,"phases":17901,"primaryCompletion":2794,"completion":2794,"start":9133,"enrollment":11109,"conditions":17902,"interventions":17903},"NCT00766090","Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma",[86],[18],[17843],{"nctId":17905,"briefTitle":17906,"status":155,"phases":17907,"primaryCompletion":10166,"completion":10166,"start":2804,"enrollment":17908,"conditions":17909,"interventions":17910},"NCT00603278","A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.",[86],622,[18],[17843],{"trials":17912,"activeCount":97},[17913,17919,17926,17932,17938,17944,17955,17962],{"nctId":17914,"briefTitle":17915,"status":155,"phases":17916,"primaryCompletion":10395,"completion":10395,"start":8386,"enrollment":12474,"conditions":17917,"interventions":17918},"NCT00225823","Study In Adults And Adolescents With Seasonal Allergic Rhinitis.",[87],[10169],[17843],{"nctId":17920,"briefTitle":17921,"status":155,"phases":17922,"primaryCompletion":2844,"completion":2844,"start":1380,"enrollment":17923,"conditions":17924,"interventions":17925},"NCT00108914","Perennial Allergic Rhinitis Study In Pediatric Subjects",[87],558,[10182],[17843],{"nctId":17927,"briefTitle":17928,"status":155,"phases":17929,"primaryCompletion":2844,"completion":2844,"start":7785,"enrollment":904,"conditions":17930,"interventions":17931},"NCT00109486","Safety Study To Assess Growth In Children With Seasonal Allergic And\u002FOr Perennial Allergic Rhinitis Treated With GW685698X Aqueous Nasal Spray Or Placebo Nasal Spray",[87],[10147],[17843],{"nctId":17933,"briefTitle":17934,"status":155,"phases":17935,"completion":2844,"start":2814,"enrollment":4679,"conditions":17936,"interventions":17937},"NCT00107757","Seasonal Allergic Rhinitis In Pediatric Subjects",[87],[10182],[17843],{"nctId":17939,"briefTitle":17940,"status":155,"phases":17941,"primaryCompletion":8386,"completion":8386,"start":10803,"enrollment":12474,"conditions":17942,"interventions":17943},"NCT00103454","A Study To Evaluate The Efficacy And Safety Of A Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR).",[87],[10182],[17843],{"nctId":17945,"briefTitle":17946,"status":155,"phases":17947,"primaryCompletion":17948,"completion":17949,"start":17950,"enrollment":603,"conditions":17951,"interventions":17954},"NCT00118703","Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis",[87],"2006-02-01","2006-02-09","2005-07-01",[17952,17953],"Vasomotor Rhinitis","Rhinitis, Vasomotor",[17843],{"nctId":17956,"briefTitle":17957,"status":155,"phases":17958,"primaryCompletion":17949,"completion":17949,"start":17959,"enrollment":17160,"conditions":17960,"interventions":17961},"NCT00117325","Study Of Adults And Adolescents With Vasomotor Rhinitis",[87],"2005-07-11",[17953],[17843],{"nctId":17963,"briefTitle":17964,"status":155,"phases":17965,"primaryCompletion":8406,"completion":8406,"start":8427,"enrollment":25,"conditions":17966,"interventions":17967},"NCT00224523","Long Term Safety Of GW685698X Via Nasal Biopsy",[87],[10182],[17843,17968],"mometasone furoate",{"trials":17970,"activeCount":97},[],{"trials":17972,"activeCount":97},[],{"intervention":17974,"totalTrials":1117,"cells":17975},"GSK1278863",{"EARLY_PHASE1":17976,"PHASE1":17978,"PHASE2":18025,"PHASE3":18099,"PHASE4":18109,"NA":18111},{"trials":17977,"activeCount":97},[],{"trials":17979,"activeCount":97},[17980,17989,17998,18008,18016],{"nctId":17981,"briefTitle":17982,"status":155,"phases":17983,"primaryCompletion":17984,"completion":17984,"start":17985,"enrollment":93,"conditions":17986,"interventions":17988},"NCT02231190","GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage",[85],"2015-06-12","2015-01-15",[17987],"Tendon Injuries",[17974],{"nctId":17990,"briefTitle":17991,"status":155,"phases":17992,"primaryCompletion":17993,"completion":17993,"start":17994,"enrollment":1720,"conditions":17995,"interventions":17997},"NCT02243306","Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis",[85],"2017-05-10","2014-10-24",[17996],"Anaemia",[17974],{"nctId":17999,"briefTitle":18000,"status":155,"phases":18001,"primaryCompletion":18002,"completion":18002,"start":18003,"enrollment":314,"conditions":18004,"interventions":18005},"NCT01376232","Study to Assess the Pharmacokinetics of GSK1278863A Coadministered With a High Fat Meal or an Inhibitor of CYP2C8 (Gemfibrozil)",[85],"2010-12-20","2010-11-08",[17996],[17974,18006,18007],"GSK1278863 + food","Gemfibrozil",{"nctId":18009,"briefTitle":18010,"status":155,"phases":18011,"primaryCompletion":18012,"completion":18012,"start":18013,"enrollment":2375,"conditions":18014,"interventions":18015},"NCT01673555","Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers",[85],"2012-11-19","2012-05-15",[17996],[17974],{"nctId":18017,"briefTitle":18018,"status":155,"phases":18019,"primaryCompletion":18020,"completion":18020,"start":18021,"enrollment":2282,"conditions":18022,"interventions":18024},"NCT01831804","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863",[85],"2017-02-10","2013-06-17",[18023],"Wound Healing",[17974],{"trials":18026,"activeCount":97},[18027,18036,18045,18052,18060,18067,18075,18082,18091],{"nctId":18028,"briefTitle":18029,"status":155,"phases":18030,"primaryCompletion":18031,"completion":18031,"start":18032,"enrollment":2384,"conditions":18033,"interventions":18035},"NCT01920594","Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair",[86],"2014-10-08","2013-10-31",[18034],"Surgical Procedures",[17974],{"nctId":18037,"briefTitle":18038,"status":155,"phases":18039,"primaryCompletion":18040,"completion":12077,"start":18032,"enrollment":18041,"conditions":18042,"interventions":18043},"NCT01977573","A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)",[86],"2015-05-01",252,[17996],[17974,18044],"rhEPO",{"nctId":18046,"briefTitle":18047,"status":155,"phases":18048,"primaryCompletion":12043,"completion":4799,"start":1874,"enrollment":18049,"conditions":18050,"interventions":18051},"NCT01977482","Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia",[86],216,[17996],[17974,18044],{"nctId":18053,"briefTitle":18054,"status":155,"phases":18055,"primaryCompletion":17207,"completion":17207,"start":18056,"enrollment":4121,"conditions":18057,"interventions":18059},"NCT02135848","3 Month PHI PAD PoM Study",[86],"2010-10-15",[18058],"Vascular Disease, Peripheral",[17974],{"nctId":18061,"briefTitle":18062,"status":155,"phases":18063,"primaryCompletion":858,"completion":858,"start":18064,"enrollment":526,"conditions":18065,"interventions":18066},"NCT01587924","4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease",[86],"2012-05-23",[17996],[17974,18044],{"nctId":18068,"briefTitle":18069,"status":155,"phases":18070,"primaryCompletion":18071,"completion":18071,"start":18072,"enrollment":105,"conditions":18073,"interventions":18074},"NCT02019719","Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease",[86],"2014-08-06","2013-11-05",[17996],[17974],{"nctId":18076,"briefTitle":18077,"status":155,"phases":18078,"primaryCompletion":8528,"completion":8528,"start":513,"enrollment":18079,"conditions":18080,"interventions":18081},"NCT02689206","Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent",[86],103,[17996],[17974],{"nctId":18083,"briefTitle":18084,"status":145,"phases":18085,"primaryCompletion":16102,"completion":18086,"start":18087,"enrollment":1117,"conditions":18088,"interventions":18090},"NCT02075463","Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia",[86],"2016-03-16","2014-06-01",[18089],"Anemia",[17974],{"nctId":18092,"briefTitle":18093,"status":155,"phases":18094,"primaryCompletion":18095,"completion":18095,"start":18096,"enrollment":1264,"conditions":18097,"interventions":18098},"NCT01587898","4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis",[86],"2013-05-07","2012-05-17",[17996],[17974],{"trials":18100,"activeCount":97},[18101],{"nctId":18102,"briefTitle":18103,"status":155,"phases":18104,"primaryCompletion":18105,"completion":6501,"start":5323,"enrollment":695,"conditions":18106,"interventions":18107},"NCT02829320","Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents",[87],"2017-05-16",[17996],[17974,18108],"Iron",{"trials":18110,"activeCount":97},[],{"trials":18112,"activeCount":97},[],{"intervention":3115,"totalTrials":1117,"cells":18114},{"EARLY_PHASE1":18115,"PHASE1":18117,"PHASE2":18186,"PHASE3":18217,"PHASE4":18228,"NA":18230},{"trials":18116,"activeCount":97},[],{"trials":18118,"activeCount":97},[18119,18128,18138,18142,18151,18160,18168,18175,18179],{"nctId":18120,"briefTitle":18121,"status":155,"phases":18122,"primaryCompletion":18123,"completion":18123,"start":18124,"enrollment":9196,"conditions":18125,"interventions":18126},"NCT01138085","Safety, Pharmacokinetics (PK) of AKT and MEK Combination",[85],"2014-11-19","2010-05-04",[36],[3115,18127],"GSK2141795",{"nctId":18129,"briefTitle":18130,"status":155,"phases":18131,"primaryCompletion":18132,"completion":18133,"start":18134,"enrollment":18135,"conditions":18136,"interventions":18137},"NCT00687622","Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma",[85],"2011-06-07","2011-11-08","2008-07-28",206,[2761],[3115],{"nctId":3357,"briefTitle":3358,"status":155,"phases":18139,"primaryCompletion":3360,"completion":3360,"start":3361,"enrollment":421,"conditions":18140,"interventions":18141},[85],[2761],[3115,1758],{"nctId":18143,"briefTitle":18144,"status":155,"phases":18145,"primaryCompletion":10367,"completion":10367,"start":18146,"enrollment":18147,"conditions":18148,"interventions":18149},"NCT01476137","A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers",[85],"2011-10-26",335,[36],[3115,18150],"GSK2110183",{"nctId":18152,"briefTitle":18153,"status":155,"phases":18154,"primaryCompletion":18155,"completion":18155,"start":18156,"enrollment":628,"conditions":18157,"interventions":18158},"NCT01416337","Absolute Bioavialability of GSK1120212",[85],"2011-12-17","2011-06-20",[36],[3115,18159],"GSK1120212B",{"nctId":18161,"briefTitle":18162,"status":155,"phases":18163,"primaryCompletion":18164,"completion":18164,"start":18165,"enrollment":1237,"conditions":18166,"interventions":18167},"NCT01658553","A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212",[85],"2014-04-05","2012-09-19",[36],[3115],{"nctId":18169,"briefTitle":18170,"status":155,"phases":18171,"primaryCompletion":18172,"completion":18172,"start":8784,"enrollment":345,"conditions":18173,"interventions":18174},"NCT01371487","GSK1120212 Food-effect Study",[85],"2011-09-30",[36],[3115],{"nctId":3374,"briefTitle":3375,"status":155,"phases":18176,"primaryCompletion":3377,"completion":3377,"start":3378,"enrollment":3379,"conditions":18177,"interventions":18178},[85],[3381],[3115,1758],{"nctId":18180,"briefTitle":18181,"status":155,"phases":18182,"primaryCompletion":3377,"completion":3377,"start":18183,"enrollment":628,"conditions":18184,"interventions":18185},"NCT01387204","Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212",[85],"2011-02-15",[36],[3115],{"trials":18187,"activeCount":97},[18188,18194,18198,18204,18213],{"nctId":18189,"briefTitle":18190,"status":155,"phases":18191,"primaryCompletion":7545,"completion":8151,"start":6351,"enrollment":105,"conditions":18192,"interventions":18193},"NCT01037127","Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor",[86],[36],[3115],{"nctId":3386,"briefTitle":3387,"status":155,"phases":18195,"primaryCompletion":3389,"completion":3390,"start":3391,"enrollment":3392,"conditions":18196,"interventions":18197},[86],[36],[3115,1758],{"nctId":18199,"briefTitle":18200,"status":155,"phases":18201,"primaryCompletion":484,"completion":484,"start":7590,"enrollment":105,"conditions":18202,"interventions":18203},"NCT00920140","Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias",[86],[36],[3115,3115],{"nctId":18205,"briefTitle":18206,"status":500,"phases":18207,"primaryCompletion":9682,"completion":11315,"start":10463,"enrollment":97,"conditions":18208,"interventions":18212},"NCT01328106","Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma",[86],[18209,18210,36,18211],"GNA11 Mutation-positive Metastatic Melanoma","GNAQ Mutation-positive Metastatic Melanoma","Metastatic Uveal Melanoma",[3115],{"nctId":3107,"briefTitle":3108,"status":155,"phases":18214,"primaryCompletion":3110,"completion":493,"start":3111,"enrollment":3112,"conditions":18215,"interventions":18216},[86],[267],[3115,2286],{"trials":18218,"activeCount":97},[18219],{"nctId":18220,"briefTitle":18221,"status":155,"phases":18222,"primaryCompletion":18146,"completion":18223,"start":18224,"enrollment":18225,"conditions":18226,"interventions":18227},"NCT01245062","GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E\u002FK Mutation-positive Melanoma",[87],"2016-12-16","2010-11-22",322,[325],[3115,295],{"trials":18229,"activeCount":97},[],{"trials":18231,"activeCount":97},[],{"intervention":8291,"totalTrials":1459,"cells":18233},{"EARLY_PHASE1":18234,"PHASE1":18236,"PHASE2":18238,"PHASE3":18266,"PHASE4":18340,"NA":18342},{"trials":18235,"activeCount":97},[],{"trials":18237,"activeCount":97},[],{"trials":18239,"activeCount":97},[18240,18250,18259],{"nctId":18241,"briefTitle":18242,"status":155,"phases":18243,"primaryCompletion":18244,"completion":18245,"start":18246,"enrollment":18247,"conditions":18248,"interventions":18249},"NCT00718666","The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers",[86],"2013-11-13","2014-03-28","2008-10-20",387,[992],[8291],{"nctId":18251,"briefTitle":18252,"status":155,"phases":18253,"primaryCompletion":18254,"completion":18255,"start":2784,"enrollment":18256,"conditions":18257,"interventions":18258},"NCT00471081","Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.",[86],"2008-10-23","2008-11-26",385,[992],[8291],{"nctId":18260,"briefTitle":18261,"status":155,"phases":18262,"primaryCompletion":17861,"completion":17861,"start":18263,"enrollment":5056,"conditions":18264,"interventions":18265},"NCT00661557","Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects",[86],"2008-05-19",[992],[8291],{"trials":18267,"activeCount":97},[18268,18276,18284,18294,18298,18302,18313,18323,18332],{"nctId":18269,"briefTitle":18270,"status":155,"phases":18271,"primaryCompletion":18272,"completion":18273,"start":11289,"enrollment":8469,"conditions":18274,"interventions":18275},"NCT00955682","Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612",[87],"2009-12-16","2012-09-10",[992],[8291,8971],{"nctId":18277,"briefTitle":18278,"status":155,"phases":18279,"primaryCompletion":18280,"completion":4816,"start":18281,"enrollment":12,"conditions":18282,"interventions":18283},"NCT00758264","Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration",[87],"2009-06-02","2008-10-30",[992],[8291,3639],{"nctId":18285,"briefTitle":18286,"status":155,"phases":18287,"primaryCompletion":18288,"completion":18289,"start":18290,"enrollment":15623,"conditions":18291,"interventions":18292},"NCT00474266","Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children",[87],"2008-02-26","2008-03-26","2007-06-05",[992],[8291,18293,4749],"Priorix-Tetra",{"nctId":10328,"briefTitle":10329,"status":155,"phases":18295,"primaryCompletion":8741,"completion":10331,"start":10332,"enrollment":10333,"conditions":18296,"interventions":18297},[87],[992],[8291,8968,8971],{"nctId":8282,"briefTitle":8283,"status":155,"phases":18299,"primaryCompletion":8285,"completion":8286,"start":8287,"enrollment":8288,"conditions":18300,"interventions":18301},[87],[992],[8291,8292,8177],{"nctId":18303,"briefTitle":18304,"status":155,"phases":18305,"primaryCompletion":18306,"completion":18307,"start":18308,"enrollment":18309,"conditions":18310,"interventions":18311},"NCT00464815","Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects",[87],"2008-04-16","2008-09-10","2007-05-02",1025,[992],[8291,18312],"Mencevax™ ACWY",{"nctId":18314,"briefTitle":18315,"status":155,"phases":18316,"primaryCompletion":18317,"completion":18317,"start":18318,"enrollment":18319,"conditions":18320,"interventions":18321},"NCT01755689","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults",[87],"2014-04-29","2013-01-11",1300,[992],[8291,18322,11489],"Cervarix®",{"nctId":18324,"briefTitle":18325,"status":155,"phases":18326,"primaryCompletion":18327,"completion":18327,"start":18328,"enrollment":18329,"conditions":18330,"interventions":18331},"NCT01767376","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age",[87],"2014-01-16","2013-01-10",692,[992],[8291,11489],{"nctId":18333,"briefTitle":18334,"status":155,"phases":18335,"primaryCompletion":18336,"completion":18337,"start":18273,"enrollment":34,"conditions":18338,"interventions":18339},"NCT01641042","Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects",[87],"2014-10-10","2015-03-03",[992],[8291],{"trials":18341,"activeCount":97},[],{"trials":18343,"activeCount":97},[],{"intervention":18345,"totalTrials":1459,"cells":18346},"GSK573719",{"EARLY_PHASE1":18347,"PHASE1":18349,"PHASE2":18392,"PHASE3":18421,"PHASE4":18446,"NA":18448},{"trials":18348,"activeCount":97},[],{"trials":18350,"activeCount":97},[18351,18359,18365,18375,18383],{"nctId":18352,"briefTitle":18353,"status":155,"phases":18354,"primaryCompletion":18355,"completion":18355,"start":18356,"enrollment":750,"conditions":18357,"interventions":18358},"NCT01110018","GSK573719 IV Enabling Study",[85],"2010-06-09","2010-04-28",[15],[18345,18345],{"nctId":18360,"briefTitle":18361,"status":155,"phases":18362,"primaryCompletion":4770,"completion":4770,"start":12135,"enrollment":710,"conditions":18363,"interventions":18364},"NCT00475436","A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers",[85],[15],[18345],{"nctId":18366,"briefTitle":18367,"status":155,"phases":18368,"primaryCompletion":18369,"completion":18369,"start":18370,"enrollment":414,"conditions":18371,"interventions":18372},"NCT01521377","QTc Study GSK573719+GW642444",[85],"2012-06-05","2011-12-19",[15],[8022,18373,18345,18374],"GSK573719\u002FVilanterol 125\u002F25mcg","GSK573719\u002FVilanterol 500\u002F100mcg",{"nctId":18376,"briefTitle":18377,"status":155,"phases":18378,"primaryCompletion":18379,"completion":18379,"start":18380,"enrollment":433,"conditions":18381,"interventions":18382},"NCT00976144","Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects",[85],"2009-09-22","2009-07-29",[15],[18345],{"nctId":18384,"briefTitle":18385,"status":155,"phases":18386,"primaryCompletion":18387,"completion":18387,"start":18388,"enrollment":2045,"conditions":18389,"interventions":18390},"NCT01128634","Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects",[85],"2010-04-26","2010-03-04",[15],[18345,18391],"GW573719\u002FGW573719",{"trials":18393,"activeCount":97},[18394,18400,18407,18414],{"nctId":18395,"briefTitle":18396,"status":155,"phases":18397,"primaryCompletion":9159,"completion":9159,"start":9133,"enrollment":1335,"conditions":18398,"interventions":18399},"NCT00732472","A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days",[86],[15],[18345],{"nctId":18401,"briefTitle":18402,"status":155,"phases":18403,"primaryCompletion":4973,"completion":18404,"start":11961,"enrollment":781,"conditions":18405,"interventions":18406},"NCT01372410","A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[86],"2011-10-27",[15],[18345,18345,18345,18345,18345,18345,2934],{"nctId":18408,"briefTitle":18409,"status":155,"phases":18410,"primaryCompletion":4827,"completion":4827,"start":18411,"enrollment":1298,"conditions":18412,"interventions":18413},"NCT00515502","Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease",[86],"2007-06-21",[15],[18345,2934],{"nctId":18415,"briefTitle":18416,"status":500,"phases":18417,"primaryCompletion":3110,"completion":503,"start":3110,"enrollment":97,"conditions":18418,"interventions":18419},"NCT01653483","Aura Adolescent PK Study GSK2829332",[86],[18],[18345,18420],"GSK573719matched-placebo",{"trials":18422,"activeCount":97},[18423,18431,18437],{"nctId":18424,"briefTitle":18425,"status":155,"phases":18426,"primaryCompletion":18427,"completion":18428,"start":11961,"enrollment":18135,"conditions":18429,"interventions":18430},"NCT01387230","Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD",[87],"2012-02-01","2012-02-13",[15],[18345,18345],{"nctId":18432,"briefTitle":18433,"status":155,"phases":18434,"primaryCompletion":827,"completion":827,"start":9706,"enrollment":8337,"conditions":18435,"interventions":18436},"NCT01702363","Long-term Safety Study for GSK573719 in Japanese",[87],[15],[18345],{"nctId":18438,"briefTitle":18439,"status":155,"phases":18440,"primaryCompletion":3389,"completion":3389,"start":8883,"enrollment":18441,"conditions":18442,"interventions":18443},"NCT01316913","24-week Trial Comparing GSK573719\u002FGW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease",[87],872,[15],[18444,18445,18345,8440],"GSK573719\u002FGW642444 125\u002F25","GSK573719\u002FGW642444 62.5\u002F25",{"trials":18447,"activeCount":97},[],{"trials":18449,"activeCount":97},[],{"intervention":10797,"totalTrials":361,"cells":18451},{"EARLY_PHASE1":18452,"PHASE1":18454,"PHASE2":18504,"PHASE3":18529,"PHASE4":18540,"NA":18542},{"trials":18453,"activeCount":97},[],{"trials":18455,"activeCount":97},[18456,18464,18473,18481,18489,18497],{"nctId":18457,"briefTitle":18458,"status":155,"phases":18459,"primaryCompletion":18460,"completion":18460,"start":15600,"enrollment":433,"conditions":18461,"interventions":18462},"NCT01299558","Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects",[85],"2010-07-15",[18],[18463,8556,10797],"fluticasone furoate\u002F\u002FGW642444",{"nctId":18465,"briefTitle":18466,"status":155,"phases":18467,"primaryCompletion":18468,"completion":18468,"start":18469,"enrollment":1298,"conditions":18470,"interventions":18471},"NCT00702910","A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients",[85],"2008-10-04","2008-04-27",[15],[10797,18472],"Magnesium Stearate",{"nctId":18474,"briefTitle":18475,"status":155,"phases":18476,"primaryCompletion":18477,"completion":18477,"start":18478,"enrollment":1165,"conditions":18479,"interventions":18480},"NCT00711126","A Study To Investigate Safety, Blood Levels And Effects Of Giving GW642444, By Mouth, By Inhalation & By Injection",[85],"2008-12-17","2008-10-21",[15],[10797,10797,10797,10797,10797,10797],{"nctId":18482,"briefTitle":18483,"status":155,"phases":18484,"primaryCompletion":8298,"completion":8298,"start":18485,"enrollment":433,"conditions":18486,"interventions":18487},"NCT00671216","A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.",[85],"2008-05-20",[15],[9403,10797,18488],"GSK233705 and GW642444",{"nctId":18490,"briefTitle":18491,"status":155,"phases":18492,"primaryCompletion":18493,"completion":18493,"start":18494,"enrollment":433,"conditions":18495,"interventions":18496},"NCT00783003","A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects",[85],"2009-02-06","2008-11-10",[15],[18488,10797,9403],{"nctId":18498,"briefTitle":18499,"status":155,"phases":18500,"primaryCompletion":18501,"completion":18501,"start":17886,"enrollment":2045,"conditions":18502,"interventions":18503},"NCT00964249","Phase I Study of GW642444M in Healthy Japanese Male Subjects",[85],"2008-12-01",[15],[10797],{"trials":18505,"activeCount":97},[18506,18510,18514,18520],{"nctId":10789,"briefTitle":10790,"status":155,"phases":18507,"primaryCompletion":10792,"completion":10792,"start":10793,"enrollment":10794,"conditions":18508,"interventions":18509},[86],[15],[10797,10798],{"nctId":10800,"briefTitle":10801,"status":155,"phases":18511,"primaryCompletion":2796,"completion":2796,"start":10803,"enrollment":695,"conditions":18512,"interventions":18513},[86],[18],[10797,10772],{"nctId":18515,"briefTitle":18516,"status":155,"phases":18517,"primaryCompletion":7598,"completion":7598,"start":3391,"enrollment":695,"conditions":18518,"interventions":18519},"NCT01453296","Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects",[86],[18],[10797],{"nctId":18521,"briefTitle":18522,"status":155,"phases":18523,"primaryCompletion":18524,"completion":18525,"start":18526,"enrollment":37,"conditions":18527,"interventions":18528},"NCT00372112","A Study To Assess The Safety And Tolerability Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[86],"2007-05-01","2007-05-10","2006-11-03",[15],[10797],{"trials":18530,"activeCount":97},[18531],{"nctId":18532,"briefTitle":18533,"status":155,"phases":18534,"primaryCompletion":11748,"completion":18535,"start":18536,"enrollment":18537,"conditions":18538,"interventions":18539},"NCT01316900","24-week Trial Comparing GSK573719\u002FGW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease",[87],"2012-04-24","2011-03-01",846,[15],[18444,18445,10797,8440],{"trials":18541,"activeCount":97},[],{"trials":18543,"activeCount":97},[],{"intervention":18545,"totalTrials":361,"cells":18546},"Daprodustat",{"EARLY_PHASE1":18547,"PHASE1":18549,"PHASE2":18567,"PHASE3":18598,"PHASE4":18656,"NA":18658},{"trials":18548,"activeCount":97},[],{"trials":18550,"activeCount":97},[18551,18558],{"nctId":18552,"briefTitle":18553,"status":155,"phases":18554,"primaryCompletion":18555,"completion":18555,"start":8106,"enrollment":1335,"conditions":18556,"interventions":18557},"NCT03223337","Daprodustat Hepatic Impairment Study",[85],"2018-08-20",[17996],[18545],{"nctId":18559,"briefTitle":18560,"status":155,"phases":18561,"primaryCompletion":18562,"completion":18562,"start":18563,"enrollment":18564,"conditions":18565,"interventions":18566},"NCT04640311","Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants",[85],"2021-05-18","2020-12-18",259,[17996],[18545],{"trials":18568,"activeCount":97},[18569,18578,18589],{"nctId":18570,"briefTitle":18571,"status":155,"phases":18572,"primaryCompletion":18573,"completion":18573,"start":18574,"enrollment":3089,"conditions":18575,"interventions":18576},"NCT03029247","Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)",[86],"2020-07-09","2017-07-27",[17996],[18545,18577],"Epoetin alfa",{"nctId":18579,"briefTitle":18580,"status":145,"phases":18581,"primaryCompletion":9653,"completion":9653,"start":18582,"enrollment":628,"conditions":18583,"interventions":18584},"NCT03446612","Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)",[86],"2019-01-10",[17996],[18545,18585,18586,18587,18588],"Darbepoetin alfa","Acetylcholine","Sodium nitroprusside","L-N-monomethyl arginine acetate",{"nctId":18590,"briefTitle":18591,"status":155,"phases":18592,"primaryCompletion":18593,"completion":18593,"start":18594,"enrollment":1117,"conditions":18595,"interventions":18596},"NCT03457701","Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)",[86],"2022-07-05","2019-07-30",[17996],[18545,18044,18597,18597],"Ferrous sulfate containing the stable iron isotope",{"trials":18599,"activeCount":97},[18600,18608,18618,18627,18637,18647],{"nctId":18601,"briefTitle":18602,"status":155,"phases":18603,"primaryCompletion":6613,"completion":18604,"start":18605,"enrollment":181,"conditions":18606,"interventions":18607},"NCT05682326","Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)",[87],"2025-03-17","2023-09-06",[17996],[18545],{"nctId":18609,"briefTitle":18610,"status":155,"phases":18611,"primaryCompletion":18612,"completion":18612,"start":18613,"enrollment":11770,"conditions":18614,"interventions":18615},"NCT03400033","Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)",[87],"2020-06-19","2018-09-05",[17996],[18545,18616,18617],"Epoetin alfa vials","Saline vials or bags",{"nctId":18619,"briefTitle":18620,"status":155,"phases":18621,"primaryCompletion":18622,"completion":18622,"start":18623,"enrollment":5088,"conditions":18624,"interventions":18625},"NCT03029208","Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)",[87],"2020-09-24","2017-05-11",[17996],[18545,18585,18626],"Iron therapy",{"nctId":18628,"briefTitle":18629,"status":155,"phases":18630,"primaryCompletion":18631,"completion":18631,"start":18632,"enrollment":18633,"conditions":18634,"interventions":18635},"NCT02876835","Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)",[87],"2021-04-19","2016-09-27",3872,[17996],[18545,18585,18636],"Iron Therapy",{"nctId":18638,"briefTitle":18639,"status":155,"phases":18640,"primaryCompletion":18641,"completion":18641,"start":18642,"enrollment":18643,"conditions":18644,"interventions":18646},"NCT02879305","Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)",[87],"2020-11-09","2016-09-28",2964,[17996,18645],"Aspergillosis, Allergic Bronchopulmonary",[18545,18044,18626],{"nctId":18648,"briefTitle":18649,"status":155,"phases":18650,"primaryCompletion":18651,"completion":18651,"start":18652,"enrollment":18653,"conditions":18654,"interventions":18655},"NCT03409107","Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)",[87],"2020-10-07","2018-03-05",614,[17996],[18545,18626],{"trials":18657,"activeCount":97},[],{"trials":18659,"activeCount":97},[],{"intervention":3467,"totalTrials":361,"cells":18661},{"EARLY_PHASE1":18662,"PHASE1":18664,"PHASE2":18705,"PHASE3":18727,"PHASE4":18755,"NA":18757},{"trials":18663,"activeCount":97},[],{"trials":18665,"activeCount":97},[18666,18677,18685,18695],{"nctId":18667,"briefTitle":18668,"status":155,"phases":18669,"primaryCompletion":18670,"completion":18670,"start":18671,"enrollment":6503,"conditions":18672,"interventions":18673},"NCT02666287","GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)",[85],"2016-06-03","2016-01-27",[15],[18674,18675,3467,3467,18676],"BAT\u002FFF","BAT","FF\u002FVilanterol",{"nctId":18678,"briefTitle":18679,"status":155,"phases":18680,"primaryCompletion":8539,"completion":8539,"start":18681,"enrollment":433,"conditions":18682,"interventions":18683},"NCT02837380","A Phase I Pharmacokinetic Study of Fluticasone Furoate \u002FUmeclidinium Bromide\u002FVilanterol (100\u002F62.5\u002F25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects",[85],"2016-09",[15],[3467,18684],"VI\u002FUMEC",{"nctId":18686,"briefTitle":18687,"status":155,"phases":18688,"primaryCompletion":18689,"completion":18689,"start":18690,"enrollment":8038,"conditions":18691,"interventions":18692},"NCT01691547","A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects",[85],"2013-03-08","2012-12-17",[15],[18693,2915,18694,3467],"UMEC \u002FVI","VI",{"nctId":18696,"briefTitle":18697,"status":155,"phases":18698,"primaryCompletion":18699,"completion":18699,"start":18700,"enrollment":255,"conditions":18701,"interventions":18702},"NCT01962467","A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine",[85],"2014-02-27","2013-10-11",[10147],[18703,3467,18704],"FF\u002FLEV FDC","LEV",{"trials":18706,"activeCount":97},[18707,18715,18719],{"nctId":18708,"briefTitle":18709,"status":155,"phases":18710,"primaryCompletion":12863,"completion":18711,"start":17134,"enrollment":18712,"conditions":18713,"interventions":18714},"NCT02164539","Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component",[86],"2015-07-18",338,[15],[3467,2915,18694],{"nctId":3458,"briefTitle":3459,"status":155,"phases":18716,"primaryCompletion":3461,"completion":3461,"start":3462,"enrollment":3463,"conditions":18717,"interventions":18718},[86],[18],[3466,3466,3466,3466,3466,3467,2914],{"nctId":18720,"briefTitle":18721,"status":155,"phases":18722,"primaryCompletion":13418,"completion":13418,"start":3045,"enrollment":7394,"conditions":18723,"interventions":18724},"NCT01957202","A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)\u002FLevocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)",[86],[10147],[18725,3467,18726],"FF\u002Flevocabastine","levocabastine",{"trials":18728,"activeCount":97},[18729,18736,18744,18751],{"nctId":18730,"briefTitle":18731,"status":155,"phases":18732,"primaryCompletion":9507,"completion":9507,"start":3045,"enrollment":18733,"conditions":18734,"interventions":18735},"NCT02119286","Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)\u002FVilanterol (VI), With Placebo Plus FF\u002FVI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2",[87],620,[15],[3467,18694,2915],{"nctId":18737,"briefTitle":18738,"status":155,"phases":18739,"primaryCompletion":9754,"completion":18740,"start":18741,"enrollment":10489,"conditions":18742,"interventions":18743},"NCT00289198","Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)",[87],"2006-07-04","2006-02-07",[10182],[3467],{"nctId":18745,"briefTitle":18746,"status":155,"phases":18747,"primaryCompletion":11484,"completion":11484,"start":8395,"enrollment":18748,"conditions":18749,"interventions":18750},"NCT01957163","Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)\u002FVilanterol (VI), With Placebo Plus FF\u002FVI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],619,[15],[3467,18694,2915],{"nctId":8570,"briefTitle":8571,"status":155,"phases":18752,"primaryCompletion":8573,"completion":8574,"start":8575,"enrollment":3537,"conditions":18753,"interventions":18754},[87],[18],[3467,8578,8522],{"trials":18756,"activeCount":97},[],{"trials":18758,"activeCount":97},[],{"intervention":3639,"totalTrials":361,"cells":18760},{"EARLY_PHASE1":18761,"PHASE1":18763,"PHASE2":18765,"PHASE3":18777,"PHASE4":18855,"NA":18857},{"trials":18762,"activeCount":97},[],{"trials":18764,"activeCount":97},[],{"trials":18766,"activeCount":97},[18767],{"nctId":18768,"briefTitle":18769,"status":155,"phases":18770,"primaryCompletion":18771,"completion":18772,"start":7505,"enrollment":18773,"conditions":18774,"interventions":18775},"NCT00985751","Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination",[86],"2010-10-12","2011-03-02",257,[3637],[11470,11470,18776,18776,3639],"Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A",{"trials":18778,"activeCount":97},[18779,18783,18792,18801,18812,18820,18830,18839,18843,18847],{"nctId":18277,"briefTitle":18278,"status":155,"phases":18780,"primaryCompletion":18280,"completion":4816,"start":18281,"enrollment":12,"conditions":18781,"interventions":18782},[87],[992],[8291,3639],{"nctId":18784,"briefTitle":18785,"status":155,"phases":18786,"primaryCompletion":18787,"completion":18788,"start":12873,"enrollment":4346,"conditions":18789,"interventions":18790},"NCT02447432","A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants",[87],"2016-01-23","2016-05-22",[3637],[3639,3639,18791],"DTPw-HBV\u002FHib",{"nctId":18793,"briefTitle":18794,"status":155,"phases":18795,"primaryCompletion":18796,"completion":18796,"start":18797,"enrollment":18798,"conditions":18799,"interventions":18800},"NCT01030822","Booster and Catch-up Vaccination With Vaccine GSK1024850A",[87],"2011-08-19","2010-04-02",282,[3637],[3639,3639],{"nctId":18802,"briefTitle":18803,"status":155,"phases":18804,"primaryCompletion":18805,"completion":18806,"start":18807,"enrollment":12261,"conditions":18808,"interventions":18809},"NCT00829010","Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.",[87],"2011-06-13","2012-06-27","2009-02-17",[3637],[3639,12323,18810,4762,18811],"measles","Local OPV",{"nctId":18813,"briefTitle":18814,"status":155,"phases":18815,"primaryCompletion":9116,"completion":18816,"start":18817,"enrollment":4818,"conditions":18818,"interventions":18819},"NCT00950833","Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed Children",[87],"2010-10-27","2009-08-10",[3637],[3639],{"nctId":18821,"briefTitle":18822,"status":155,"phases":18823,"primaryCompletion":18824,"completion":18824,"start":18825,"enrollment":18826,"conditions":18827,"interventions":18828},"NCT00680914","Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™",[87],"2009-05-08","2008-06-10",503,[3637],[3639,4745,18829],"GSK Biologicals' Hiberix™",{"nctId":18831,"briefTitle":18832,"status":155,"phases":18833,"primaryCompletion":18834,"completion":18835,"start":7531,"enrollment":18836,"conditions":18837,"interventions":18838},"NCT00985465","Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Mali",[87],"2010-06-26","2010-07-26",218,[3637],[3639],{"nctId":3629,"briefTitle":3630,"status":155,"phases":18840,"primaryCompletion":3632,"completion":3633,"start":3634,"enrollment":3635,"conditions":18841,"interventions":18842},[87],[3637],[3639,3605],{"nctId":10629,"briefTitle":10630,"status":155,"phases":18844,"primaryCompletion":10632,"completion":10632,"start":10633,"enrollment":4086,"conditions":18845,"interventions":18846},[87],[3637],[3639,4821],{"nctId":18848,"briefTitle":18849,"status":155,"phases":18850,"primaryCompletion":18851,"completion":18851,"start":3425,"enrollment":3089,"conditions":18852,"interventions":18853},"NCT01153893","Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria",[87],"2011-02-16",[3637],[3639,18854],"InfanrixTM",{"trials":18856,"activeCount":97},[],{"trials":18858,"activeCount":97},[],{"intervention":18860,"totalTrials":361,"cells":18861},"Herpes Zoster Vaccine GSK1437173A",{"EARLY_PHASE1":18862,"PHASE1":18864,"PHASE2":18866,"PHASE3":18886,"PHASE4":18968,"NA":18970},{"trials":18863,"activeCount":97},[],{"trials":18865,"activeCount":97},[],{"trials":18867,"activeCount":97},[18868,18876],{"nctId":18869,"briefTitle":18870,"status":155,"phases":18871,"primaryCompletion":18872,"completion":18873,"start":8263,"enrollment":1598,"conditions":18874,"interventions":18875},"NCT01165203","Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects",[86],"2012-07-06","2013-05-14",[1030],[18860],{"nctId":18877,"briefTitle":18878,"status":155,"phases":18879,"primaryCompletion":18880,"completion":18880,"start":18881,"enrollment":18882,"conditions":18883,"interventions":18884},"NCT00802464","Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years",[86],"2010-07-02","2009-01-12",410,[1030],[18885],"Herpes zoster vaccine GSK1437173A",{"trials":18887,"activeCount":97},[18888,18896,18906,18914,18923,18931,18941,18952,18960],{"nctId":18889,"briefTitle":18890,"status":155,"phases":18891,"primaryCompletion":18892,"completion":18892,"start":18086,"enrollment":18893,"conditions":18894,"interventions":18895},"NCT02690207","Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ\u002Fsu) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.",[87],"2019-03-15",8687,[1030],[18860],{"nctId":18897,"briefTitle":18898,"status":155,"phases":18899,"primaryCompletion":18900,"completion":18901,"start":18902,"enrollment":8891,"conditions":18903,"interventions":18904},"NCT02058589","Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ\u002Fsu) Vaccine in Adults 18 Years of Age or Older With Renal Transplant",[87],"2016-05-11","2017-04-13","2014-03-20",[1030],[18905],"Herpes Zoster vaccine GSK1437173A",{"nctId":18907,"briefTitle":18908,"status":155,"phases":18909,"primaryCompletion":18910,"completion":18911,"start":18021,"enrollment":1237,"conditions":18912,"interventions":18913},"NCT01777321","Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ\u002Fsu) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years",[87],"2013-10-10","2014-11-11",[1030],[18885],{"nctId":18915,"briefTitle":18916,"status":155,"phases":18917,"primaryCompletion":18918,"completion":18919,"start":18920,"enrollment":730,"conditions":18921,"interventions":18922},"NCT02735915","Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ\u002Fsu) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older",[87],"2017-08-28","2018-10-08","2016-04-11",[1030],[18860],{"nctId":18924,"briefTitle":18925,"status":155,"phases":18926,"primaryCompletion":18927,"completion":3295,"start":10367,"enrollment":18928,"conditions":18929,"interventions":18930},"NCT01751165","Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older",[87],"2014-05-22",354,[1030],[18885],{"nctId":18932,"briefTitle":18933,"status":155,"phases":18934,"primaryCompletion":18935,"completion":18936,"start":18937,"enrollment":18938,"conditions":18939,"interventions":18940},"NCT01165177","Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older",[87],"2014-05-09","2015-07-27","2010-08-02",16165,[1030],[18860],{"nctId":18942,"briefTitle":18943,"status":155,"phases":18944,"primaryCompletion":18945,"completion":18946,"start":18947,"enrollment":18948,"conditions":18949,"interventions":18951},"NCT02723773","A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ\u002Fsu) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults",[87],"2023-06-28","2024-01-30","2016-04-16",7539,[1030,18950],"Herpes Zoster Vaccine",[18860],{"nctId":18953,"briefTitle":18954,"status":155,"phases":18955,"primaryCompletion":3340,"completion":903,"start":18956,"enrollment":18957,"conditions":18958,"interventions":18959},"NCT01610414","Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A",[87],"2012-07-13",1877,[1030],[18905],{"nctId":18961,"briefTitle":18962,"status":155,"phases":18963,"primaryCompletion":18964,"completion":18964,"start":18937,"enrollment":18965,"conditions":18966,"interventions":18967},"NCT01165229","Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older",[87],"2015-07-24",14819,[1030,18950],[18860],{"trials":18969,"activeCount":97},[],{"trials":18971,"activeCount":97},[],{"intervention":915,"totalTrials":750,"cells":18973},{"EARLY_PHASE1":18974,"PHASE1":18976,"PHASE2":19031,"PHASE3":19049,"PHASE4":19063,"NA":19065},{"trials":18975,"activeCount":97},[],{"trials":18977,"activeCount":97},[18978,18989,18996,19008,19016,19024],{"nctId":18979,"briefTitle":18980,"status":155,"phases":18981,"primaryCompletion":18982,"completion":18982,"start":18983,"enrollment":345,"conditions":18984,"interventions":18986},"NCT01762787","Phase I Methodology Study to Validate the Cantharidin Blister Model in Healthy Volunteers",[85],"2011-01-14","2010-08-17",[18985],"Inflammation",[18987,18988,915],"Cantharidin solution","Aspirin",{"nctId":18990,"briefTitle":18991,"status":145,"phases":18992,"primaryCompletion":9802,"completion":9802,"start":18993,"enrollment":149,"conditions":18994,"interventions":18995},"NCT00327197","Assessment Of Disease Pathology And Key Therapeutic Targets In Severe Asthma",[85],"2005-08-02",[18],[915],{"nctId":18997,"briefTitle":18998,"status":155,"phases":18999,"primaryCompletion":19000,"completion":19000,"start":19001,"enrollment":454,"conditions":19002,"interventions":19003},"NCT00920660","Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy Volunteers",[85],"2009-06-12","2009-04-06",[15],[19004,915,19005,19006,19007],"0.25g SRT2104","0.5g SRT2104","1g SRT2104","2g SRT2104",{"nctId":19009,"briefTitle":19010,"status":155,"phases":19011,"primaryCompletion":1360,"completion":1360,"start":3036,"enrollment":1165,"conditions":19012,"interventions":19014},"NCT00384306","Effects Of Oral Prednisolone On Bone Metabolism In Patients With Chronic Obstructive Pulmonary Disease",[85],[19013],"Chronic Obstructive Pulmonary Disease",[19015],"prednisolone",{"nctId":19017,"briefTitle":19018,"status":155,"phases":19019,"completion":19020,"start":19021,"enrollment":13419,"conditions":19022,"interventions":19023},"NCT00379730","Prednisolone Novel Endpoint Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[85],"2007-05-03","2006-03-21",[15],[915],{"nctId":19025,"briefTitle":19026,"status":155,"phases":19027,"primaryCompletion":4844,"completion":4844,"start":2796,"enrollment":454,"conditions":19028,"interventions":19029},"NCT00380133","Study of SB681323 and Prednisolone on Biomarkers in COPD (Chronic Obstructive Pulmonary Disease) Patients",[85],[15],[19030,915],"SB681323",{"trials":19032,"activeCount":97},[19033,19042],{"nctId":19034,"briefTitle":19035,"status":155,"phases":19036,"primaryCompletion":19037,"completion":19037,"start":19038,"enrollment":624,"conditions":19039,"interventions":19040},"NCT00134693","A Single Dose Of Compound SB-681323 Compared To Prednisolone On A Protein That Is an Indicator For Rheumatoid Arthritis",[86],"2006-08-03","2005-06-21",[8788],[915,19041],"SB-681323",{"nctId":19043,"briefTitle":19044,"status":155,"phases":19045,"primaryCompletion":2804,"completion":2804,"start":1360,"enrollment":6503,"conditions":19046,"interventions":19047},"NCT00379990","A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.",[86],[8788],[19048,915],"GW274150",{"trials":19050,"activeCount":97},[19051,19059],{"nctId":19052,"briefTitle":19053,"status":155,"phases":19054,"primaryCompletion":3551,"completion":3551,"start":3078,"enrollment":7991,"conditions":19055,"interventions":19056},"NCT01086410","Safety Study of the Effects of Inhaled Fluticasone Furoate\u002FGW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis",[87],[18],[19057,19057,19058],"Fluticasone Furoate\u002FGW642444 Inhalation Powder","Prednisolone Oral",{"nctId":908,"briefTitle":909,"status":155,"phases":19060,"primaryCompletion":911,"completion":911,"start":912,"enrollment":414,"conditions":19061,"interventions":19062},[87],[851,783],[694,915],{"trials":19064,"activeCount":97},[],{"trials":19066,"activeCount":97},[],{"intervention":4744,"totalTrials":1165,"cells":19068},{"EARLY_PHASE1":19069,"PHASE1":19071,"PHASE2":19073,"PHASE3":19075,"PHASE4":19146,"NA":19148},{"trials":19070,"activeCount":97},[],{"trials":19072,"activeCount":97},[],{"trials":19074,"activeCount":97},[],{"trials":19076,"activeCount":97},[19077,19081,19089,19101,19116,19124,19134,19138,19142],{"nctId":4734,"briefTitle":4735,"status":155,"phases":19078,"primaryCompletion":4737,"completion":4738,"start":4739,"enrollment":4740,"conditions":19079,"interventions":19080},[87],[24,3624,33,4702,30,4742],[4744,4745,4472,4746,4747,4748,4749,4750,4751],{"nctId":19082,"briefTitle":19083,"status":155,"phases":19084,"primaryCompletion":3284,"completion":3284,"start":19085,"enrollment":19086,"conditions":19087,"interventions":19088},"NCT00792909","Vaccination Course in Primed Children and Age-matched Unprimed Children With Pneumococcal Vaccine GSK1024850A",[87],"2008-12-02",172,[3637],[4744,4744],{"nctId":19090,"briefTitle":19091,"status":155,"phases":19092,"primaryCompletion":19093,"completion":19094,"start":19095,"enrollment":895,"conditions":19096,"interventions":19097},"NCT00344318","Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine",[87],"2007-04-27","2007-10-17","2006-08-07",[3637],[4744,4745,19098,4810,19099,19100],"Tritanrix-HepB","Polio Sabin.","Poliorix.",{"nctId":19102,"briefTitle":19103,"status":155,"phases":19104,"primaryCompletion":19105,"completion":19105,"start":11017,"enrollment":19106,"conditions":19107,"interventions":19108},"NCT00891176","Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines",[87],"2012-11-21",582,[4703,4704],[19109,4744,19110,19111,10347,19112,19113,19114,19115],"MenitorixTM","PrevenarTM","MeningitecTM","InfanrixTM hexa","InfanrixTM penta","InfanrixTM IPV\u002FHib","InfanrixTM IPV",{"nctId":19117,"briefTitle":19118,"status":155,"phases":19119,"primaryCompletion":19120,"completion":19120,"start":19121,"enrollment":3635,"conditions":19122,"interventions":19123},"NCT00814710","Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age",[87],"2009-11-13","2009-03-07",[3637,8918],[4744,12323,4810,19098],{"nctId":19125,"briefTitle":19126,"status":155,"phases":19127,"primaryCompletion":16364,"completion":19128,"start":8914,"enrollment":19129,"conditions":19130,"interventions":19131},"NCT00861380","Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease",[87],"2013-10-05",41188,[3637,8918],[4744,19132,19133],"GSK Biologicals' Engerix TM vaccine","GSK Biologicals' Havrix TM vaccine",{"nctId":4786,"briefTitle":4787,"status":155,"phases":19135,"primaryCompletion":4789,"completion":4790,"start":4791,"enrollment":4792,"conditions":19136,"interventions":19137},[87],[3637],[4744,4472],{"nctId":4813,"briefTitle":4814,"status":155,"phases":19139,"primaryCompletion":4816,"completion":4816,"start":4817,"enrollment":4818,"conditions":19140,"interventions":19141},[87],[3637],[4744,4472,4821,4762],{"nctId":4851,"briefTitle":4852,"status":155,"phases":19143,"primaryCompletion":4854,"completion":4855,"start":4856,"enrollment":4857,"conditions":19144,"interventions":19145},[87],[3637],[4744,4694,4808,4472,4860],{"trials":19147,"activeCount":97},[],{"trials":19149,"activeCount":97},[],{"intervention":19151,"totalTrials":1720,"cells":19152},"Infanrix hexa™",{"EARLY_PHASE1":19153,"PHASE1":19155,"PHASE2":19157,"PHASE3":19212,"PHASE4":19228,"NA":19230},{"trials":19154,"activeCount":97},[],{"trials":19156,"activeCount":97},[],{"trials":19158,"activeCount":97},[19159,19171,19180,19188,19197,19205],{"nctId":19160,"briefTitle":19161,"status":155,"phases":19162,"primaryCompletion":19163,"completion":19164,"start":19165,"enrollment":19166,"conditions":19167,"interventions":19168},"NCT01616459","Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants",[86],"2013-04-25","2014-01-22","2012-07-11",953,[3637],[19169,19170,10348,7875,19151],"Pneumococcal conjugate vaccine GSK2830929A","Pneumococcal conjugate vaccine GSK2830930A",{"nctId":19172,"briefTitle":19173,"status":155,"phases":19174,"primaryCompletion":8768,"completion":8768,"start":19175,"enrollment":3463,"conditions":19176,"interventions":19178},"NCT00970307","Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age",[86],"2009-08-13",[33,30,4704,4702,3624,24,19177],"Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b-Neisseria Meni",[4706,19179,19151,10346],"10-valent pneumococcal vaccine",{"nctId":19181,"briefTitle":19182,"status":155,"phases":19183,"primaryCompletion":19184,"completion":19184,"start":15600,"enrollment":8931,"conditions":19185,"interventions":19186},"NCT01090453","Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants",[86],"2011-10-11",[33,24,4704,4702,3624,30,4703],[4706,19187,19151,10346,7830],"Prevenar 13®",{"nctId":19189,"briefTitle":19190,"status":155,"phases":19191,"primaryCompletion":16834,"completion":16834,"start":19192,"enrollment":19193,"conditions":19194,"interventions":19195},"NCT01171989","Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose",[86],"2010-08-18",391,[33,30,4704,24,4702,3624,19177],[4706,19151,19196,8969,10348],"Menjugate™",{"nctId":19198,"briefTitle":19199,"status":155,"phases":19200,"primaryCompletion":19201,"completion":19201,"start":5268,"enrollment":19202,"conditions":19203,"interventions":19204},"NCT01248884","Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV\u002FHib Vaccine (GSK217744)",[86],"2012-01-05",721,[33,4702,24,4704,3624,30],[19151,19187,4726],{"nctId":19206,"briefTitle":19207,"status":500,"phases":19208,"primaryCompletion":9706,"completion":9706,"start":6352,"enrollment":97,"conditions":19209,"interventions":19210},"NCT01110044","Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine",[86],[4759],[19211,19151,10348,7830],"251154 vaccine",{"trials":19213,"activeCount":97},[19214,19221],{"nctId":19215,"briefTitle":19216,"status":155,"phases":19217,"primaryCompletion":19218,"completion":19218,"start":10632,"enrollment":536,"conditions":19219,"interventions":19220},"NCT01153841","Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam",[87],"2011-07-26",[3637,4742],[10348,19151],{"nctId":19222,"briefTitle":19223,"status":155,"phases":19224,"primaryCompletion":11235,"completion":11235,"start":19225,"enrollment":9358,"conditions":19226,"interventions":19227},"NCT01353703","Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV\u002FHib) Vaccine",[87],"2012-04-16",[4702,33,3624,4704,30,24,4871],[19151],{"trials":19229,"activeCount":97},[],{"trials":19231,"activeCount":97},[],{"intervention":4683,"totalTrials":1720,"cells":19233},{"EARLY_PHASE1":19234,"PHASE1":19236,"PHASE2":19238,"PHASE3":19248,"PHASE4":19286,"NA":19288},{"trials":19235,"activeCount":97},[],{"trials":19237,"activeCount":97},[],{"trials":19239,"activeCount":97},[19240,19244],{"nctId":4673,"briefTitle":4674,"status":155,"phases":19241,"primaryCompletion":4676,"completion":4677,"start":4678,"enrollment":4679,"conditions":19242,"interventions":19243},[86],[3637],[4682,4682,4683,4485,4684],{"nctId":4686,"briefTitle":4687,"status":155,"phases":19245,"primaryCompletion":4689,"completion":4690,"start":4691,"enrollment":781,"conditions":19246,"interventions":19247},[86],[3637],[4683,4684,4694],{"trials":19249,"activeCount":97},[19250,19259,19263,19274,19278,19282],{"nctId":19251,"briefTitle":19252,"status":155,"phases":19253,"primaryCompletion":19254,"completion":19254,"start":19255,"enrollment":1944,"conditions":19256,"interventions":19257},"NCT00345358","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine",[87],"2007-11-15","2006-09-18",[3637],[4683,19258],"Infanrix IPV\u002FHib",{"nctId":4981,"briefTitle":4982,"status":155,"phases":19260,"primaryCompletion":4984,"completion":4985,"start":4986,"enrollment":4987,"conditions":19261,"interventions":19262},[87],[3637,4742],[4683,4683,4683,4485,4485],{"nctId":19264,"briefTitle":19265,"status":155,"phases":19266,"primaryCompletion":19267,"completion":19268,"start":19269,"enrollment":19270,"conditions":19271,"interventions":19272},"NCT00547248","Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines",[87],"2008-05-10","2008-10-07","2007-10-22",756,[3637],[4683,19098,4810,12324,19273,4745],"Poliorix",{"nctId":4765,"briefTitle":4766,"status":155,"phases":19275,"primaryCompletion":4768,"completion":4769,"start":4770,"enrollment":4771,"conditions":19276,"interventions":19277},[87],[4759],[4683,4472,4762],{"nctId":4823,"briefTitle":4824,"status":155,"phases":19279,"primaryCompletion":4826,"completion":4827,"start":4828,"enrollment":2069,"conditions":19280,"interventions":19281},[87],[3637],[4683,4745,4472],{"nctId":4832,"briefTitle":4833,"status":155,"phases":19283,"primaryCompletion":4835,"completion":4835,"start":4836,"enrollment":4771,"conditions":19284,"interventions":19285},[87],[3637,4742],[4683,4472,4762],{"trials":19287,"activeCount":97},[],{"trials":19289,"activeCount":97},[],{"intervention":10675,"totalTrials":1720,"cells":19291},{"EARLY_PHASE1":19292,"PHASE1":19294,"PHASE2":19338,"PHASE3":19340,"PHASE4":19359,"NA":19361},{"trials":19293,"activeCount":97},[],{"trials":19295,"activeCount":97},[19296,19306,19313,19322,19331],{"nctId":19297,"briefTitle":19298,"status":155,"phases":19299,"primaryCompletion":2442,"completion":2442,"start":3550,"enrollment":1298,"conditions":19300,"interventions":19302},"NCT00883935","GSK1349572 Drug Interaction Study With Atazanavir\u002FRitonavir and Atazanavir",[85],[19301],"Healthy Volunteer",[19303,19304,19305,10675],"GSK1349572","Atazanavir 300 mg","Atazanavir 400 mg",{"nctId":19307,"briefTitle":19308,"status":155,"phases":19309,"primaryCompletion":9066,"completion":9066,"start":12260,"enrollment":7438,"conditions":19310,"interventions":19311},"NCT01802918","Single Dose Escalation Study of GSK2838232 in Healthy Subjects",[85],[9343],[19312,10675],"GSK2838232",{"nctId":19314,"briefTitle":19315,"status":145,"phases":19316,"primaryCompletion":19317,"completion":19317,"start":19318,"enrollment":454,"conditions":19319,"interventions":19320},"NCT02289482","A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects",[85],"2015-03-10","2014-11-17",[9343],[19321,19321,10675],"GSK2838232 PIB",{"nctId":19323,"briefTitle":19324,"status":155,"phases":19325,"primaryCompletion":2392,"completion":2392,"start":19326,"enrollment":234,"conditions":19327,"interventions":19328},"NCT02795754","Single and Repeated Dose Escalation Study of GSK2838232",[85],"2016-03",[9343],[19321,19329,19330,10675],"GSK2838232 IR1","GSK2838232 IR2",{"nctId":19332,"briefTitle":19333,"status":145,"phases":19334,"primaryCompletion":19335,"completion":19335,"start":17158,"enrollment":1298,"conditions":19336,"interventions":19337},"NCT02289495","A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects",[85],"2015-06-27",[9343],[19312,10675],{"trials":19339,"activeCount":97},[],{"trials":19341,"activeCount":97},[19342,19346,19355],{"nctId":10939,"briefTitle":10940,"status":155,"phases":19343,"primaryCompletion":8750,"completion":8750,"start":10003,"enrollment":1237,"conditions":19344,"interventions":19345},[87],[10943],[10945,10946,10947,10948],{"nctId":19347,"briefTitle":19348,"status":12113,"phases":19349,"start":7838,"enrollment":19350,"conditions":19351,"interventions":19352},"NCT00025727","Comparison of Two Dosing Regimens of GW433908\u002FRitonavir Versus Lopinavir\u002FRitonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure",[87],330,[10943],[19353,10675,19354],"Lopinavir\u002FRitonavir","GW433908",{"nctId":10667,"briefTitle":10668,"status":155,"phases":19356,"start":10670,"enrollment":10671,"conditions":19357,"interventions":19358},[87],[10662,9343],[10674,10675,10676,10677,10678,10679,10680],{"trials":19360,"activeCount":97},[],{"trials":19362,"activeCount":97},[],{"intervention":8674,"totalTrials":1720,"cells":19364},{"EARLY_PHASE1":19365,"PHASE1":19367,"PHASE2":19369,"PHASE3":19371,"PHASE4":19435,"NA":19437},{"trials":19366,"activeCount":97},[],{"trials":19368,"activeCount":97},[],{"trials":19370,"activeCount":97},[],{"trials":19372,"activeCount":97},[19373,19377,19387,19391,19404,19417,19421,19431],{"nctId":11168,"briefTitle":11169,"status":155,"phases":19374,"primaryCompletion":11171,"completion":11171,"start":11172,"enrollment":1608,"conditions":19375,"interventions":19376},[87],[992],[8653,4811,4805,4810,4762,8674,8675,11175],{"nctId":19378,"briefTitle":19379,"status":155,"phases":19380,"primaryCompletion":10167,"completion":10166,"start":2428,"enrollment":19381,"conditions":19382,"interventions":19383},"NCT00345683","Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.",[87],4021,[4704,4703],[19384,19385,19386,8674,8675],"GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined","PedvaxHIB","Prevnar",{"nctId":8662,"briefTitle":8663,"status":155,"phases":19388,"primaryCompletion":8665,"completion":8666,"start":8667,"enrollment":8668,"conditions":19389,"interventions":19390},[87],[8670,8671],[8673,8674,8675,4694,8676],{"nctId":19392,"briefTitle":19393,"status":155,"phases":19394,"primaryCompletion":19395,"completion":19396,"start":19397,"enrollment":19398,"conditions":19399,"interventions":19401},"NCT01621802","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age",[87],"2015-07-06","2015-11-09","2012-06-21",4011,[19400],"Measles-Mumps-Rubella",[8673,8674,19402,19403],"Kinrix","ProQuad",{"nctId":19405,"briefTitle":19406,"status":155,"phases":19407,"primaryCompletion":2373,"completion":19408,"start":19409,"enrollment":19410,"conditions":19411,"interventions":19412},"NCT00148941","Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccines",[87],"2006-12-04","2005-01-06",4209,[33,3624,30],[19413,19414,19415,4809,19416,8674],"SB213503 lot 1","SB213503 lot 2","SB213503 lot 3","IPOL",{"nctId":8678,"briefTitle":8679,"status":155,"phases":19418,"primaryCompletion":8681,"completion":8682,"start":8683,"enrollment":8684,"conditions":19419,"interventions":19420},[87],[2484,2486,2485],[8673,8674,8675,4694,8676],{"nctId":19422,"briefTitle":19423,"status":155,"phases":19424,"primaryCompletion":19425,"completion":18288,"start":19426,"enrollment":19427,"conditions":19428,"interventions":19429},"NCT00289783","Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine",[87],"2007-08-27","2006-02-22",4441,[4704,4703],[19430,4806,19385,4805,19386,8674,8675],"GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine",{"nctId":8692,"briefTitle":8693,"status":155,"phases":19432,"primaryCompletion":8695,"completion":8696,"start":8697,"enrollment":8698,"conditions":19433,"interventions":19434},[87],[2486,2485,2484,8671],[8673,8674,8675,4694,8676],{"trials":19436,"activeCount":97},[],{"trials":19438,"activeCount":97},[],{"intervention":7732,"totalTrials":1720,"cells":19440},{"EARLY_PHASE1":19441,"PHASE1":19443,"PHASE2":19449,"PHASE3":19455,"PHASE4":19481,"NA":19483},{"trials":19442,"activeCount":97},[],{"trials":19444,"activeCount":97},[19445],{"nctId":7725,"briefTitle":7726,"status":155,"phases":19446,"primaryCompletion":7728,"completion":7728,"start":7729,"enrollment":255,"conditions":19447,"interventions":19448},[85],[24],[7732,7718],{"trials":19450,"activeCount":97},[19451],{"nctId":7755,"briefTitle":7756,"status":155,"phases":19452,"primaryCompletion":7758,"start":7759,"enrollment":1196,"conditions":19453,"interventions":19454},[86],[24],[7718,7732],{"trials":19456,"activeCount":97},[19457,19461,19465,19469,19473,19477],{"nctId":7834,"briefTitle":7835,"status":155,"phases":19458,"primaryCompletion":7837,"completion":7838,"start":7839,"enrollment":7840,"conditions":19459,"interventions":19460},[87],[24],[7732,7718],{"nctId":7844,"briefTitle":7845,"status":155,"phases":19462,"primaryCompletion":7847,"start":7848,"enrollment":7849,"conditions":19463,"interventions":19464},[87],[24],[7732,7718],{"nctId":7878,"briefTitle":7879,"status":155,"phases":19466,"primaryCompletion":7881,"start":7799,"enrollment":7882,"conditions":19467,"interventions":19468},[87],[24],[7732,7718],{"nctId":7906,"briefTitle":7907,"status":155,"phases":19470,"primaryCompletion":7909,"start":7910,"enrollment":7911,"conditions":19471,"interventions":19472},[87],[24],[7732,7718],{"nctId":7915,"briefTitle":7916,"status":155,"phases":19474,"primaryCompletion":7918,"start":7919,"enrollment":7920,"conditions":19475,"interventions":19476},[87],[24],[7732,7718],{"nctId":7924,"briefTitle":7925,"status":155,"phases":19478,"primaryCompletion":7910,"completion":7910,"start":7919,"enrollment":4771,"conditions":19479,"interventions":19480},[87],[24],[7732,7718],{"trials":19482,"activeCount":97},[],{"trials":19484,"activeCount":97},[],{"intervention":19486,"totalTrials":1318,"cells":19487},"Otelixizumab",{"EARLY_PHASE1":19488,"PHASE1":19490,"PHASE2":19507,"PHASE3":19547,"PHASE4":19557,"NA":19559},{"trials":19489,"activeCount":97},[],{"trials":19491,"activeCount":97},[19492,19501],{"nctId":19493,"briefTitle":19494,"status":155,"phases":19495,"primaryCompletion":9207,"completion":19496,"start":19497,"enrollment":2797,"conditions":19498,"interventions":19500},"NCT00946257","Subcutaneous Administration of Otelixizumab to T1DM Patients",[85],"2013-06-25","2009-07-08",[19499],"Diabetes Mellitus, Type 1",[19486],{"nctId":19502,"briefTitle":19503,"status":145,"phases":19504,"primaryCompletion":8815,"completion":8815,"start":18356,"enrollment":1459,"conditions":19505,"interventions":19506},"NCT01077531","Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis",[85],[8788],[19486],{"trials":19508,"activeCount":97},[19509,19517,19525,19533],{"nctId":19510,"briefTitle":19511,"status":145,"phases":19512,"primaryCompletion":19513,"completion":19513,"start":18224,"enrollment":417,"conditions":19514,"interventions":19515},"NCT01222078","Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus",[86],"2011-05-19",[19499],[19516],"otelixizumab",{"nctId":19518,"briefTitle":19519,"status":155,"phases":19520,"primaryCompletion":19521,"completion":19521,"start":19522,"enrollment":255,"conditions":19523,"interventions":19524},"NCT02000817","Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients",[85,86],"2018-09-27","2014-03-12",[19499],[19486],{"nctId":19526,"briefTitle":19527,"status":145,"phases":19528,"primaryCompletion":19529,"completion":19529,"start":19530,"enrollment":370,"conditions":19531,"interventions":19532},"NCT00451321","TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)",[86],"2011-12-01","2006-07-31",[19499],[19486],{"nctId":19534,"briefTitle":19535,"status":145,"phases":19536,"primaryCompletion":19537,"completion":19537,"start":19538,"enrollment":660,"conditions":19539,"interventions":19541},"NCT01114503","A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease",[86],"2012-08-29","2010-07-07",[19540],"Graves Ophthalmopathy",[19542,19543,19544,19545,19486,19546],"Otelixizumab - low dose","Otelixizumab - medium low dose","Otelixizumab - medium high dose","Otelixizumab - high dose","Methylprednisolone",{"trials":19548,"activeCount":97},[19549],{"nctId":19550,"briefTitle":19551,"status":155,"phases":19552,"primaryCompletion":19553,"completion":19553,"start":15600,"enrollment":19554,"conditions":19555,"interventions":19556},"NCT01123083","Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2",[87],"2012-03-09",179,[19499],[19486],{"trials":19558,"activeCount":97},[],{"trials":19560,"activeCount":97},[],{"intervention":19562,"totalTrials":1318,"cells":19563},"GSK1358820",{"EARLY_PHASE1":19564,"PHASE1":19566,"PHASE2":19568,"PHASE3":19570,"PHASE4":19625,"NA":19627},{"trials":19565,"activeCount":97},[],{"trials":19567,"activeCount":97},[],{"trials":19569,"activeCount":97},[],{"trials":19571,"activeCount":97},[19572,19580,19591,19598,19605,19613,19619],{"nctId":19573,"briefTitle":19574,"status":155,"phases":19575,"primaryCompletion":7682,"completion":19576,"start":11315,"enrollment":212,"conditions":19577,"interventions":19579},"NCT01584843","Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus",[87],"2014-06",[19578],"Strabismus",[19562],{"nctId":19581,"briefTitle":19582,"status":155,"phases":19583,"primaryCompletion":19584,"completion":19585,"start":19586,"enrollment":17295,"conditions":19587,"interventions":19589},"NCT02820844","Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder",[87],"2018-03-06","2018-11-12","2016-08-10",[19588],"Urinary Bladder, Overactive",[19562,19590],"Antibiotic therapy",{"nctId":19592,"briefTitle":19593,"status":155,"phases":19594,"primaryCompletion":9224,"completion":9224,"start":6352,"enrollment":9281,"conditions":19595,"interventions":19597},"NCT01153815","A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity",[87],[19596],"Cerebrovascular Accident",[19562],{"nctId":19599,"briefTitle":19600,"status":155,"phases":19601,"primaryCompletion":8468,"completion":8468,"start":2835,"enrollment":201,"conditions":19602,"interventions":19604},"NCT00460655","Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity",[87],[19603,19596],"Post-Stroke Spasticity",[19562],{"nctId":19606,"briefTitle":19607,"status":155,"phases":19608,"primaryCompletion":19609,"completion":19610,"start":8983,"enrollment":1279,"conditions":19611,"interventions":19612},"NCT02849418","Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity",[87],"2018-03-02","2018-12-20",[19588],[19562],{"nctId":19614,"briefTitle":19615,"status":155,"phases":19616,"primaryCompletion":8468,"completion":8468,"start":2835,"enrollment":739,"conditions":19617,"interventions":19618},"NCT00460564","Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity",[87],[19603,19596],[19562],{"nctId":19620,"briefTitle":19621,"status":155,"phases":19622,"primaryCompletion":9682,"completion":9682,"start":6352,"enrollment":115,"conditions":19623,"interventions":19624},"NCT01128738","GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis",[87],[12067],[19562],{"trials":19626,"activeCount":97},[],{"trials":19628,"activeCount":97},[],{"intervention":9284,"totalTrials":1318,"cells":19630},{"EARLY_PHASE1":19631,"PHASE1":19633,"PHASE2":19662,"PHASE3":19678,"PHASE4":19688,"NA":19690},{"trials":19632,"activeCount":97},[],{"trials":19634,"activeCount":97},[19635,19643,19650,19654],{"nctId":19636,"briefTitle":19637,"status":155,"phases":19638,"primaryCompletion":19639,"completion":19639,"start":19640,"enrollment":181,"conditions":19641,"interventions":19642},"NCT01262963","An Absorption, Distribution, Metabolism and Excretion (ADME) Study of Single Oral Dose [14C] GSK2118436 in Subjects With BRAF Mutant Solid Tumors",[85],"2011-04-08","2011-01-26",[36],[9284],{"nctId":19644,"briefTitle":19645,"status":155,"phases":19646,"primaryCompletion":7446,"completion":7446,"start":19647,"enrollment":628,"conditions":19648,"interventions":19649},"NCT01340833","Determination of the Absolute Bioavailability of GSK2118436 Following a Single Oral Dose Co-Administered With an Intravenous Radiolabelled Microtracer of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",[85],"2011-06-08",[36],[9284],{"nctId":9275,"briefTitle":9276,"status":155,"phases":19651,"primaryCompletion":9278,"completion":9279,"start":9280,"enrollment":9281,"conditions":19652,"interventions":19653},[85],[36],[9284,9284,6488],{"nctId":19655,"briefTitle":19656,"status":155,"phases":19657,"primaryCompletion":19658,"completion":8682,"start":19659,"enrollment":1459,"conditions":19660,"interventions":19661},"NCT01582997","A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of of GSK2118436 in Japanese Subjects With BRAF Mutation Positive Solid Tumors",[85],"2014-08-01","2012-05-11",[36],[9284],{"trials":19663,"activeCount":97},[19664,19671],{"nctId":19665,"briefTitle":19666,"status":155,"phases":19667,"primaryCompletion":11961,"completion":16100,"start":19668,"enrollment":2883,"conditions":19669,"interventions":19670},"NCT01153763","A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma",[86],"2010-08-09",[325],[9284],{"nctId":19672,"briefTitle":19673,"status":155,"phases":19674,"primaryCompletion":8135,"completion":8089,"start":729,"enrollment":19086,"conditions":19675,"interventions":19677},"NCT01266967","A Study of GSK2118436 in BRAF Mutant Metastatic Melanoma to the Brain",[86],[19676],"Melanoma and Brain Metastases",[9284],{"trials":19679,"activeCount":97},[19680],{"nctId":19681,"briefTitle":19682,"status":155,"phases":19683,"primaryCompletion":18370,"completion":16145,"start":19684,"enrollment":16,"conditions":19685,"interventions":19686},"NCT01227889","A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma",[87],"2010-12-23",[36],[9284,19687],"Dacarbazine",{"trials":19689,"activeCount":97},[],{"trials":19691,"activeCount":97},[],{"intervention":19693,"totalTrials":1318,"cells":19694},"Simvastatin",{"EARLY_PHASE1":19695,"PHASE1":19697,"PHASE2":19751,"PHASE3":19753,"PHASE4":19764,"NA":19766},{"trials":19696,"activeCount":97},[],{"trials":19698,"activeCount":97},[19699,19709,19719,19726,19735,19741],{"nctId":19700,"briefTitle":19701,"status":155,"phases":19702,"primaryCompletion":19703,"completion":19703,"start":19704,"enrollment":1335,"conditions":19705,"interventions":19706},"NCT01953835","A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184",[85],"2014-03-10","2013-10-04",[435],[19707,19693,9324,19708],"GSK2586184 standard formulation","GSK2586184 new formulation",{"nctId":19710,"briefTitle":19711,"status":155,"phases":19712,"primaryCompletion":19713,"completion":19713,"start":19714,"enrollment":710,"conditions":19715,"interventions":19717},"NCT00495729","15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.",[85],"2007-08-04","2007-04-18",[19716],"Sleep Initiation and Maintenance Disorders",[19718,19693],"SB-649868",{"nctId":19720,"briefTitle":19721,"status":155,"phases":19722,"primaryCompletion":14583,"completion":14583,"start":4826,"enrollment":710,"conditions":19723,"interventions":19724},"NCT00504439","A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects",[85],[15],[19725,19693],"SB-656933-AAA",{"nctId":19727,"briefTitle":19728,"status":155,"phases":19729,"primaryCompletion":19730,"completion":19730,"start":19731,"enrollment":695,"conditions":19732,"interventions":19733},"NCT01101568","A Study to Investigate the Interaction of GSK1292263 With Rosuvastatin and Simvastatin in Healthy Subjects",[85],"2010-06-24","2010-04-14",[27],[19693,9324,19734],"GSK1292263",{"nctId":19736,"briefTitle":19737,"status":155,"phases":19738,"primaryCompletion":3391,"completion":3391,"start":11030,"enrollment":473,"conditions":19739,"interventions":19740},"NCT01138072","A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.",[85],[9343],[9347,19693,10390,9324],{"nctId":19742,"briefTitle":19743,"status":155,"phases":19744,"primaryCompletion":19745,"completion":19745,"start":19746,"enrollment":255,"conditions":19747,"interventions":19749},"NCT01299597","A Single-centre Open Label Study to Investigate the Effect of Repeat Doses of SB-649868 on the Pharmacokinetics of Simvastatin and Atorvastatin in Healthy Male Volunteers.",[85],"2010-02-26","2010-01-18",[19748],"Sleep Disorders",[10390,19693,19750],"SB649868",{"trials":19752,"activeCount":97},[],{"trials":19754,"activeCount":97},[19755],{"nctId":19756,"briefTitle":19757,"status":155,"phases":19758,"primaryCompletion":9087,"completion":9087,"start":19759,"enrollment":19760,"conditions":19761,"interventions":19762},"NCT00246701","Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects",[87],"2005-11-01",256,[12294],[19693,19763],"Simvastatin + Lovaza",{"trials":19765,"activeCount":97},[],{"trials":19767,"activeCount":97},[],{"intervention":4810,"totalTrials":1318,"cells":19769},{"EARLY_PHASE1":19770,"PHASE1":19772,"PHASE2":19774,"PHASE3":19776,"PHASE4":19813,"NA":19815},{"trials":19771,"activeCount":97},[],{"trials":19773,"activeCount":97},[],{"trials":19775,"activeCount":97},[],{"trials":19777,"activeCount":97},[19778,19782,19793,19797,19801,19805,19809],{"nctId":11168,"briefTitle":11169,"status":155,"phases":19779,"primaryCompletion":11171,"completion":11171,"start":11172,"enrollment":1608,"conditions":19780,"interventions":19781},[87],[992],[8653,4811,4805,4810,4762,8674,8675,11175],{"nctId":19783,"briefTitle":19784,"status":155,"phases":19785,"primaryCompletion":19786,"completion":19787,"start":19788,"enrollment":19789,"conditions":19790,"interventions":19791},"NCT00412854","Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa\u002FHib Vaccine vs Separate Administration of DTPa and Hib.",[87],"2007-06-01","2007-06-25","2007-01-03",660,[33,30,3624],[19792,4809,4810],"Infanrix™\u002FHib",{"nctId":19090,"briefTitle":19091,"status":155,"phases":19794,"primaryCompletion":19093,"completion":19094,"start":19095,"enrollment":895,"conditions":19795,"interventions":19796},[87],[3637],[4744,4745,19098,4810,19099,19100],{"nctId":19264,"briefTitle":19265,"status":155,"phases":19798,"primaryCompletion":19267,"completion":19268,"start":19269,"enrollment":19270,"conditions":19799,"interventions":19800},[87],[3637],[4683,19098,4810,12324,19273,4745],{"nctId":19117,"briefTitle":19118,"status":155,"phases":19802,"primaryCompletion":19120,"completion":19120,"start":19121,"enrollment":3635,"conditions":19803,"interventions":19804},[87],[3637,8918],[4744,12323,4810,19098],{"nctId":4796,"briefTitle":4797,"status":155,"phases":19806,"primaryCompletion":4799,"completion":4800,"start":4801,"enrollment":4802,"conditions":19807,"interventions":19808},[87],[4702,30,4704,33,3624,24],[4472,4805,4806,4807,4808,4809,4810,4811,4762],{"nctId":4991,"briefTitle":4992,"status":155,"phases":19810,"primaryCompletion":4994,"completion":4995,"start":4996,"enrollment":4997,"conditions":19811,"interventions":19812},[87],[4999,5000],[4762,4805,4810,4485],{"trials":19814,"activeCount":97},[],{"trials":19816,"activeCount":97},[],{"intervention":19818,"totalTrials":1318,"cells":19819},"Hiberix™",{"EARLY_PHASE1":19820,"PHASE1":19822,"PHASE2":19824,"PHASE3":19837,"PHASE4":19894,"NA":19896},{"trials":19821,"activeCount":97},[],{"trials":19823,"activeCount":97},[],{"trials":19825,"activeCount":97},[19826],{"nctId":19827,"briefTitle":19828,"status":155,"phases":19829,"primaryCompletion":2405,"completion":19830,"start":19831,"enrollment":3285,"conditions":19832,"interventions":19833},"NCT01061541","Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB\u002FHib2.5 Compared to GSK Vaccine Tritanrix™-HepB\u002FHiberix™",[86],"2004-08","2003-08",[4704],[19834,19835,7829,19818,19836],"Tritanrix™-HepB low thio \u002F","Hib 2.5","Unconjugated Hib vaccine",{"trials":19838,"activeCount":97},[19839,19848,19856,19869,19878,19886],{"nctId":19840,"briefTitle":19841,"status":155,"phases":19842,"primaryCompletion":19843,"completion":19843,"start":19844,"enrollment":19845,"conditions":19846,"interventions":19847},"NCT00696423","Immunogenicity and Safety of GSK Biologicals' Infanrix\u002FHib in Children",[87],"2008-07-26","2008-06-07",467,[3624,30,33],[7876,19818],{"nctId":19849,"briefTitle":19850,"status":155,"phases":19851,"primaryCompletion":19852,"completion":19852,"start":17948,"enrollment":7694,"conditions":19853,"interventions":19854},"NCT00291343","Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study",[87],"2007-03-15",[992],[19855,19818,18312],"Tritanrix™- HepB",{"nctId":19857,"briefTitle":19858,"status":155,"phases":19859,"primaryCompletion":10275,"completion":19860,"start":19861,"enrollment":19862,"conditions":19863,"interventions":19864},"NCT00169442","Immune Memory of DTPw-HBV\u002FHib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants",[87],"2006-03-10","2005-02-10",745,[10227,30,24,33,4704],[19865,19866,19818,19867,19868],"Tritanrix™-HepB\u002FHiberix™ Kft.","Tritanrix™-HepB\u002FHiberix™","Polyribosil-Ribitol-Phosphate (PRP) vaccine","Tritanrix™-HepB Kft",{"nctId":19870,"briefTitle":19871,"status":155,"phases":19872,"primaryCompletion":8235,"completion":4827,"start":9087,"enrollment":19873,"conditions":19874,"interventions":19875},"NCT00326118","Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.",[87],433,[4704,4703],[19876,19877,19818,8971],"Haemophilus influenzae type b and meningococcal serogroup C","Priorix™",{"nctId":19879,"briefTitle":19880,"status":155,"phases":19881,"primaryCompletion":18524,"completion":14626,"start":19882,"enrollment":8275,"conditions":19883,"interventions":19884},"NCT00317109","Study to Asses DTPw-HBV\u002FHib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects",[87],"2006-04-19",[992],[19855,19818,19885],"Mencevax™ ACW",{"nctId":19887,"briefTitle":19888,"status":155,"phases":19889,"primaryCompletion":19890,"completion":19890,"start":9568,"enrollment":15576,"conditions":19891,"interventions":19892},"NCT01309646","Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine",[87],"2012-02-24",[4702,33,3624,30,4704],[19893,11069,19818,10348,7830],"Infanrix™-IPV+Hib",{"trials":19895,"activeCount":97},[],{"trials":19897,"activeCount":97},[],{"intervention":8725,"totalTrials":1318,"cells":19899},{"EARLY_PHASE1":19900,"PHASE1":19902,"PHASE2":19904,"PHASE3":19913,"PHASE4":19960,"NA":19962},{"trials":19901,"activeCount":97},[],{"trials":19903,"activeCount":97},[],{"trials":19905,"activeCount":97},[19906],{"nctId":19907,"briefTitle":19908,"status":155,"phases":19909,"primaryCompletion":19910,"completion":3426,"start":17182,"enrollment":7891,"conditions":19911,"interventions":19912},"NCT00546078","Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America",[86],"2008-12-22",[8723],[8725],{"trials":19914,"activeCount":97},[19915,19925,19933,19940,19949,19956],{"nctId":19916,"briefTitle":19917,"status":155,"phases":19918,"primaryCompletion":18526,"completion":19919,"start":19920,"enrollment":19921,"conditions":19922,"interventions":19923},"NCT00122681","Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16\u002F18",[87],"2009-11-26","2004-05-06",18729,[8723],[8725,19924],"Havrix™-based investigational formulation",{"nctId":19926,"briefTitle":19927,"status":155,"phases":19928,"primaryCompletion":10013,"completion":10013,"start":19929,"enrollment":19930,"conditions":19931,"interventions":19932},"NCT00250276","Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation.",[87],"2005-10-28",798,[8723,12417],[8725],{"nctId":19934,"briefTitle":19935,"status":155,"phases":19936,"primaryCompletion":8852,"completion":2813,"start":8852,"enrollment":3190,"conditions":19937,"interventions":19939},"NCT00337818","Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women",[87],[19938,2444],"Papillomavirus Type 16\u002F18 Infection",[8725],{"nctId":19941,"briefTitle":19942,"status":155,"phases":19943,"primaryCompletion":18501,"completion":19944,"start":19945,"enrollment":8108,"conditions":19946,"interventions":19947},"NCT00578227","Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects",[87],"2009-04-28","2007-12-15",[8723],[8725,19948],"Twinrix ™ Paediatric",{"nctId":19950,"briefTitle":19951,"status":155,"phases":19952,"primaryCompletion":19953,"completion":19953,"start":4789,"enrollment":414,"conditions":19954,"interventions":19955},"NCT00492544","Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age",[87],"2008-03-28",[8723],[8725],{"nctId":8717,"briefTitle":8718,"status":500,"phases":19957,"primaryCompletion":482,"completion":8720,"start":8721,"enrollment":97,"conditions":19958,"interventions":19959},[87],[8723],[8725,4694],{"trials":19961,"activeCount":97},[],{"trials":19963,"activeCount":97},[],{"intervention":4745,"totalTrials":1318,"cells":19965},{"EARLY_PHASE1":19966,"PHASE1":19968,"PHASE2":19970,"PHASE3":19982,"PHASE4":20008,"NA":20010},{"trials":19967,"activeCount":97},[],{"trials":19969,"activeCount":97},[],{"trials":19971,"activeCount":97},[19972],{"nctId":19973,"briefTitle":19974,"status":145,"phases":19975,"primaryCompletion":19976,"completion":19976,"start":19977,"enrollment":1720,"conditions":19978,"interventions":19979},"NCT01003418","Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children",[86],"2010-11-25","2009-11-17",[21],[19980,19981,4745],"GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine","Infanrix™-IPV\u002FHib",{"trials":19983,"activeCount":97},[19984,19988,19992,19996,20000,20004],{"nctId":4734,"briefTitle":4735,"status":155,"phases":19985,"primaryCompletion":4737,"completion":4738,"start":4739,"enrollment":4740,"conditions":19986,"interventions":19987},[87],[24,3624,33,4702,30,4742],[4744,4745,4472,4746,4747,4748,4749,4750,4751],{"nctId":19090,"briefTitle":19091,"status":155,"phases":19989,"primaryCompletion":19093,"completion":19094,"start":19095,"enrollment":895,"conditions":19990,"interventions":19991},[87],[3637],[4744,4745,19098,4810,19099,19100],{"nctId":19264,"briefTitle":19265,"status":155,"phases":19993,"primaryCompletion":19267,"completion":19268,"start":19269,"enrollment":19270,"conditions":19994,"interventions":19995},[87],[3637],[4683,19098,4810,12324,19273,4745],{"nctId":18821,"briefTitle":18822,"status":155,"phases":19997,"primaryCompletion":18824,"completion":18824,"start":18825,"enrollment":18826,"conditions":19998,"interventions":19999},[87],[3637],[3639,4745,18829],{"nctId":4775,"briefTitle":4776,"status":155,"phases":20001,"primaryCompletion":4778,"completion":4778,"start":4779,"enrollment":4780,"conditions":20002,"interventions":20003},[87],[3637,4742],[4783,4745,4472,4694,4784],{"nctId":4823,"briefTitle":4824,"status":155,"phases":20005,"primaryCompletion":4826,"completion":4827,"start":4828,"enrollment":2069,"conditions":20006,"interventions":20007},[87],[3637],[4683,4745,4472],{"trials":20009,"activeCount":97},[],{"trials":20011,"activeCount":97},[],{"intervention":20013,"totalTrials":1318,"cells":20014},"Pneumococcal",{"EARLY_PHASE1":20015,"PHASE1":20017,"PHASE2":20019,"PHASE3":20040,"PHASE4":20070,"NA":20072},{"trials":20016,"activeCount":97},[],{"trials":20018,"activeCount":97},[],{"trials":20020,"activeCount":97},[20021,20028,20034],{"nctId":20022,"briefTitle":20023,"status":155,"phases":20024,"completion":7613,"start":2844,"enrollment":20025,"conditions":20026,"interventions":20027},"NCT00307567","Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488",[86],689,[3624,33,24,30,4704,4702],[20013],{"nctId":20029,"briefTitle":20030,"status":155,"phases":20031,"completion":2404,"start":4844,"enrollment":9196,"conditions":20032,"interventions":20033},"NCT00338351","Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.",[86],[7966],[20013],{"nctId":20035,"briefTitle":20036,"status":155,"phases":20037,"primaryCompletion":8386,"completion":8386,"start":8478,"enrollment":20025,"conditions":20038,"interventions":20039},"NCT00169481","A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine",[86],[6996],[20013],{"trials":20041,"activeCount":97},[20042,20048,20055,20063],{"nctId":20043,"briefTitle":20030,"status":155,"phases":20044,"primaryCompletion":2428,"completion":2336,"start":8852,"enrollment":20045,"conditions":20046,"interventions":20047},"NCT00334334",[87],1572,[3637],[20013],{"nctId":20049,"briefTitle":20050,"status":155,"phases":20051,"completion":8852,"start":2844,"enrollment":20052,"conditions":20053,"interventions":20054},"NCT00307554","A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study",[87],1600,[3637],[20013],{"nctId":20056,"briefTitle":20057,"status":155,"phases":20058,"primaryCompletion":20059,"completion":20059,"start":20060,"enrollment":201,"conditions":20061,"interventions":20062},"NCT00307541","Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine",[87],"2006-04-07","2005-10-27",[3637,4742],[20013],{"nctId":20064,"briefTitle":20065,"status":155,"phases":20066,"primaryCompletion":7785,"completion":7785,"start":2814,"enrollment":414,"conditions":20067,"interventions":20069},"NCT00169507","Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)",[87],[20068],"Prophylaxis Pneumococcal Vaccine",[20013],{"trials":20071,"activeCount":97},[],{"trials":20073,"activeCount":97},[],{"intervention":2839,"totalTrials":628,"cells":20075},{"EARLY_PHASE1":20076,"PHASE1":20078,"PHASE2":20091,"PHASE3":20105,"PHASE4":20111,"NA":20113},{"trials":20077,"activeCount":97},[],{"trials":20079,"activeCount":97},[20080,20084],{"nctId":7477,"briefTitle":7478,"status":155,"phases":20081,"primaryCompletion":7480,"completion":7480,"start":7481,"enrollment":1459,"conditions":20082,"interventions":20083},[85],[2667],[2300,7484,2839],{"nctId":20085,"briefTitle":20086,"status":155,"phases":20087,"start":11097,"enrollment":255,"conditions":20088,"interventions":20089},"NCT00119171","Ispinesib In Combination With Capecitabine In Patients With Solid Tumors",[85],[1431],[20090,3083],"Ispinesib",{"trials":20092,"activeCount":97},[20093,20097,20101],{"nctId":3075,"briefTitle":3076,"status":145,"phases":20094,"primaryCompletion":1429,"completion":3078,"start":3079,"enrollment":1165,"conditions":20095,"interventions":20096},[86],[3081,668],[2274,3083,164,3063],{"nctId":7570,"briefTitle":7571,"status":155,"phases":20098,"primaryCompletion":2344,"completion":2344,"start":3552,"enrollment":7573,"conditions":20099,"interventions":20100},[86],[7575,668],[2274,2839],{"nctId":2831,"briefTitle":2832,"status":145,"phases":20102,"primaryCompletion":2813,"completion":2834,"start":2835,"enrollment":2836,"conditions":20103,"interventions":20104},[86],[668],[2839,2446,2300],{"trials":20106,"activeCount":97},[20107],{"nctId":7670,"briefTitle":7671,"status":155,"phases":20108,"primaryCompletion":4844,"completion":2834,"start":7673,"enrollment":7674,"conditions":20109,"interventions":20110},[87],[7676],[2839,2300],{"trials":20112,"activeCount":97},[],{"trials":20114,"activeCount":97},[],{"intervention":8971,"totalTrials":628,"cells":20116},{"EARLY_PHASE1":20117,"PHASE1":20119,"PHASE2":20121,"PHASE3":20136,"PHASE4":20154,"NA":20156},{"trials":20118,"activeCount":97},[],{"trials":20120,"activeCount":97},[],{"trials":20122,"activeCount":97},[20123,20127],{"nctId":10272,"briefTitle":10273,"status":155,"phases":20124,"primaryCompletion":10275,"completion":10276,"start":10277,"enrollment":10278,"conditions":20125,"interventions":20126},[86],[992],[10216,10101,10263,8971,8292],{"nctId":20128,"briefTitle":20129,"status":155,"phases":20130,"primaryCompletion":9962,"completion":9962,"start":20131,"enrollment":20132,"conditions":20133,"interventions":20134},"NCT00427908","Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612",[86],"2007-02-07",613,[992],[20135,18312,8971],"GSK Biolgicals' meningococcal vaccine 134612",{"trials":20137,"activeCount":97},[20138,20142,20146,20150],{"nctId":18269,"briefTitle":18270,"status":155,"phases":20139,"primaryCompletion":18272,"completion":18273,"start":11289,"enrollment":8469,"conditions":20140,"interventions":20141},[87],[992],[8291,8971],{"nctId":10328,"briefTitle":10329,"status":155,"phases":20143,"primaryCompletion":8741,"completion":10331,"start":10332,"enrollment":10333,"conditions":20144,"interventions":20145},[87],[992],[8291,8968,8971],{"nctId":19870,"briefTitle":19871,"status":155,"phases":20147,"primaryCompletion":8235,"completion":4827,"start":9087,"enrollment":19873,"conditions":20148,"interventions":20149},[87],[4704,4703],[19876,19877,19818,8971],{"nctId":8960,"briefTitle":8961,"status":155,"phases":20151,"primaryCompletion":8963,"completion":3551,"start":2383,"enrollment":4771,"conditions":20152,"interventions":20153},[87],[4704,4703],[8966,8967,8968,4808,8969,8970,8971],{"trials":20155,"activeCount":97},[],{"trials":20157,"activeCount":97},[],{"intervention":2330,"totalTrials":628,"cells":20159},{"EARLY_PHASE1":20160,"PHASE1":20162,"PHASE2":20164,"PHASE3":20186,"PHASE4":20192,"NA":20194},{"trials":20161,"activeCount":97},[],{"trials":20163,"activeCount":97},[],{"trials":20165,"activeCount":97},[20166,20170,20174,20178,20182],{"nctId":2292,"briefTitle":2293,"status":155,"phases":20167,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":2297,"conditions":20168,"interventions":20169},[86],[668],[2300,2301,2264,2302,2303,2304],{"nctId":2316,"briefTitle":2317,"status":145,"phases":20171,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":20172,"interventions":20173},[86],[668],[2324,2325,2326,2327,1241,164,2328,2329,216,2330],{"nctId":2332,"briefTitle":2333,"status":155,"phases":20175,"primaryCompletion":2335,"completion":482,"start":2336,"enrollment":414,"conditions":20176,"interventions":20177},[86],[668],[2330,216,2339,2274],{"nctId":2341,"briefTitle":2342,"status":500,"phases":20179,"primaryCompletion":2344,"completion":2344,"start":2344,"enrollment":97,"conditions":20180,"interventions":20181},[86],[668],[2274,2330,2329,1241,216],{"nctId":2389,"briefTitle":2390,"status":500,"phases":20183,"primaryCompletion":2392,"completion":2393,"start":2394,"enrollment":97,"conditions":20184,"interventions":20185},[86],[668],[2274,2330,164,216,2397],{"trials":20187,"activeCount":97},[20188],{"nctId":7691,"briefTitle":7692,"status":155,"phases":20189,"primaryCompletion":3552,"completion":2335,"start":2844,"enrollment":7694,"conditions":20190,"interventions":20191},[87],[668],[2274,2330],{"trials":20193,"activeCount":97},[],{"trials":20195,"activeCount":97},[],{"intervention":8675,"totalTrials":628,"cells":20197},{"EARLY_PHASE1":20198,"PHASE1":20200,"PHASE2":20202,"PHASE3":20204,"PHASE4":20230,"NA":20232},{"trials":20199,"activeCount":97},[],{"trials":20201,"activeCount":97},[],{"trials":20203,"activeCount":97},[],{"trials":20205,"activeCount":97},[20206,20210,20214,20218,20222,20226],{"nctId":11168,"briefTitle":11169,"status":155,"phases":20207,"primaryCompletion":11171,"completion":11171,"start":11172,"enrollment":1608,"conditions":20208,"interventions":20209},[87],[992],[8653,4811,4805,4810,4762,8674,8675,11175],{"nctId":19378,"briefTitle":19379,"status":155,"phases":20211,"primaryCompletion":10167,"completion":10166,"start":2428,"enrollment":19381,"conditions":20212,"interventions":20213},[87],[4704,4703],[19384,19385,19386,8674,8675],{"nctId":8662,"briefTitle":8663,"status":155,"phases":20215,"primaryCompletion":8665,"completion":8666,"start":8667,"enrollment":8668,"conditions":20216,"interventions":20217},[87],[8670,8671],[8673,8674,8675,4694,8676],{"nctId":8678,"briefTitle":8679,"status":155,"phases":20219,"primaryCompletion":8681,"completion":8682,"start":8683,"enrollment":8684,"conditions":20220,"interventions":20221},[87],[2484,2486,2485],[8673,8674,8675,4694,8676],{"nctId":19422,"briefTitle":19423,"status":155,"phases":20223,"primaryCompletion":19425,"completion":18288,"start":19426,"enrollment":19427,"conditions":20224,"interventions":20225},[87],[4704,4703],[19430,4806,19385,4805,19386,8674,8675],{"nctId":8692,"briefTitle":8693,"status":155,"phases":20227,"primaryCompletion":8695,"completion":8696,"start":8697,"enrollment":8698,"conditions":20228,"interventions":20229},[87],[2486,2485,2484,8671],[8673,8674,8675,4694,8676],{"trials":20231,"activeCount":97},[],{"trials":20233,"activeCount":97},[],{"intervention":20235,"totalTrials":628,"cells":20236},"GSK3196165",{"EARLY_PHASE1":20237,"PHASE1":20239,"PHASE2":20241,"PHASE3":20270,"PHASE4":20304,"NA":20306},{"trials":20238,"activeCount":97},[],{"trials":20240,"activeCount":97},[],{"trials":20242,"activeCount":97},[20243,20253,20260],{"nctId":20244,"briefTitle":20245,"status":155,"phases":20246,"primaryCompletion":20247,"completion":20247,"start":20248,"enrollment":12202,"conditions":20249,"interventions":20250},"NCT02799472","Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis",[86],"2017-10-30","2016-06-15",[8788],[20235,20251,20252],"MTX","Folic (or folinic) acid",{"nctId":20254,"briefTitle":20255,"status":155,"phases":20256,"primaryCompletion":20257,"completion":20257,"start":13706,"enrollment":8038,"conditions":20258,"interventions":20259},"NCT02683785","A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis",[86],"2017-11-29",[10386],[20235],{"nctId":20261,"briefTitle":20262,"status":155,"phases":20263,"primaryCompletion":20264,"completion":20265,"start":20266,"enrollment":17527,"conditions":20267,"interventions":20268},"NCT02504671","Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis",[86],"2017-12-22","2017-12-29","2015-07-23",[8788],[20235,20251,20269],"Folic acid",{"trials":20271,"activeCount":97},[20272,20283,20294],{"nctId":20273,"briefTitle":20274,"status":145,"phases":20275,"primaryCompletion":20276,"completion":20277,"start":20278,"enrollment":20279,"conditions":20280,"interventions":20281},"NCT03970837","Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)\u002FBiologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)",[87],"2021-10-29","2023-01-18","2019-06-05",1764,[8788],[20235,20282],"Tofacitinib",{"nctId":20284,"briefTitle":20285,"status":155,"phases":20286,"primaryCompletion":20287,"completion":20288,"start":20289,"enrollment":13911,"conditions":20290,"interventions":20291},"NCT04134728","Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and\u002For Janus Kinase (JAK) Inhibitors",[87],"2021-09-15","2022-02-01","2019-10-31",[8788],[20235,20292,20293],"Sarilumab","csDMARDs",{"nctId":20295,"briefTitle":20296,"status":155,"phases":20297,"primaryCompletion":20287,"completion":20298,"start":20299,"enrollment":20300,"conditions":20301,"interventions":20302},"NCT03980483","Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate",[87],"2022-08-16","2019-05-16",1537,[8788],[20235,20303],"Tofacitinib 5 mg",{"trials":20305,"activeCount":97},[],{"trials":20307,"activeCount":97},[],{"intervention":1387,"totalTrials":628,"cells":20309},{"EARLY_PHASE1":20310,"PHASE1":20312,"PHASE2":20326,"PHASE3":20332,"PHASE4":20354,"NA":20356},{"trials":20311,"activeCount":97},[],{"trials":20313,"activeCount":97},[20314,20318],{"nctId":1330,"briefTitle":1331,"status":155,"phases":20315,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":20316,"interventions":20317},[85],[1337],[1339,1340,1341],{"nctId":20319,"briefTitle":20320,"status":155,"phases":20321,"primaryCompletion":18370,"completion":18370,"start":20322,"enrollment":1237,"conditions":20323,"interventions":20324},"NCT01449188","To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects",[85],"2011-08-16",[1337],[1341,20325],"moxifloxacin",{"trials":20327,"activeCount":97},[20328],{"nctId":1377,"briefTitle":1378,"status":155,"phases":20329,"start":1380,"enrollment":1381,"conditions":20330,"interventions":20331},[86],[1383,1384],[1386,1387,1366,283],{"trials":20333,"activeCount":97},[20334,20338,20342],{"nctId":1411,"briefTitle":1412,"status":155,"phases":20335,"primaryCompletion":1414,"completion":1414,"start":1415,"enrollment":1416,"conditions":20336,"interventions":20337},[87],[1337],[1419,283,1387],{"nctId":1425,"briefTitle":1426,"status":500,"phases":20339,"primaryCompletion":1428,"completion":1428,"start":1429,"enrollment":97,"conditions":20340,"interventions":20341},[87],[36,1364,1383,1431],[283,283,1433,1433,1387],{"nctId":20343,"briefTitle":20344,"status":155,"phases":20345,"primaryCompletion":8426,"completion":11992,"start":8963,"enrollment":1960,"conditions":20346,"interventions":20349},"NCT00366834","Intravenous And Oral Casopitant (GW679769) For The Prevention Of Chemotherapy Induced Nausea And Vomiting",[87],[20347,20348,1337],"Vomiting","Nausea",[20350,20351,20352,20353],"Casopitant (GW679769) oral","Casopitant (GW679769) intravenous","Dexamethasone intravenous","Ondansetron oral",{"trials":20355,"activeCount":97},[],{"trials":20357,"activeCount":97},[],{"intervention":2915,"totalTrials":628,"cells":20359},{"EARLY_PHASE1":20360,"PHASE1":20362,"PHASE2":20368,"PHASE3":20378,"PHASE4":20392,"NA":20394},{"trials":20361,"activeCount":97},[],{"trials":20363,"activeCount":97},[20364],{"nctId":18686,"briefTitle":18687,"status":155,"phases":20365,"primaryCompletion":18689,"completion":18689,"start":18690,"enrollment":8038,"conditions":20366,"interventions":20367},[85],[15],[18693,2915,18694,3467],{"trials":20369,"activeCount":97},[20370,20374],{"nctId":18708,"briefTitle":18709,"status":155,"phases":20371,"primaryCompletion":12863,"completion":18711,"start":17134,"enrollment":18712,"conditions":20372,"interventions":20373},[86],[15],[3467,2915,18694],{"nctId":8524,"briefTitle":8525,"status":155,"phases":20375,"primaryCompletion":8527,"completion":8527,"start":8528,"enrollment":8529,"conditions":20376,"interventions":20377},[86],[18],[2915,8532,2916],{"trials":20379,"activeCount":97},[20380,20384,20388],{"nctId":2906,"briefTitle":2907,"status":155,"phases":20381,"primaryCompletion":2909,"completion":2909,"start":2910,"enrollment":2911,"conditions":20382,"interventions":20383},[87],[15],[2895,2914,2915,2916],{"nctId":18730,"briefTitle":18731,"status":155,"phases":20385,"primaryCompletion":9507,"completion":9507,"start":3045,"enrollment":18733,"conditions":20386,"interventions":20387},[87],[15],[3467,18694,2915],{"nctId":18745,"briefTitle":18746,"status":155,"phases":20389,"primaryCompletion":11484,"completion":11484,"start":8395,"enrollment":18748,"conditions":20390,"interventions":20391},[87],[15],[3467,18694,2915],{"trials":20393,"activeCount":97},[],{"trials":20395,"activeCount":97},[],{"intervention":20397,"totalTrials":628,"cells":20398},"GSK investigational vaccine GSK2340272A",{"EARLY_PHASE1":20399,"PHASE1":20401,"PHASE2":20403,"PHASE3":20413,"PHASE4":20451,"NA":20453},{"trials":20400,"activeCount":97},[],{"trials":20402,"activeCount":97},[],{"trials":20404,"activeCount":97},[20405],{"nctId":20406,"briefTitle":20407,"status":155,"phases":20408,"primaryCompletion":7463,"completion":7463,"start":20409,"enrollment":11031,"conditions":20410,"interventions":20411},"NCT00951041","Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults",[86],"2009-08-11",[21],[20397,20412],"GSK investigational vaccine GSK2340269A",{"trials":20414,"activeCount":97},[20415,20421,20428,20435,20443],{"nctId":20416,"briefTitle":20417,"status":155,"phases":20418,"primaryCompletion":8273,"completion":8273,"start":8318,"enrollment":9196,"conditions":20419,"interventions":20420},"NCT00968526","Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults",[87],[21],[20397],{"nctId":20422,"briefTitle":20423,"status":155,"phases":20424,"primaryCompletion":16280,"completion":16280,"start":20425,"enrollment":5088,"conditions":20426,"interventions":20427},"NCT00975884","Study to Evaluate Immunogenicity & Safety of an Investigational Influenza Vaccine in Adults",[87],"2009-09-14",[21],[20397],{"nctId":20429,"briefTitle":20430,"status":155,"phases":20431,"primaryCompletion":20432,"completion":20432,"start":8318,"enrollment":11031,"conditions":20433,"interventions":20434},"NCT00968539","Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults",[87],"2010-09-28",[21],[20397,20412],{"nctId":20436,"briefTitle":20437,"status":155,"phases":20438,"primaryCompletion":20439,"completion":20439,"start":20440,"enrollment":536,"conditions":20441,"interventions":20442},"NCT00992511","Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes",[87],"2010-11-09","2009-10-14",[21],[20397,20397,20397,20397],{"nctId":20444,"briefTitle":20445,"status":155,"phases":20446,"primaryCompletion":18224,"completion":18224,"start":20447,"enrollment":20448,"conditions":20449,"interventions":20450},"NCT00972517","Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children",[87],"2009-09-29",245,[21],[20397],{"trials":20452,"activeCount":97},[],{"trials":20454,"activeCount":97},[],{"intervention":20456,"totalTrials":628,"cells":20457},"Tositumomab and Iodine I 131 Tositumomab",{"EARLY_PHASE1":20458,"PHASE1":20460,"PHASE2":20462,"PHASE3":20499,"PHASE4":20507,"NA":20509},{"trials":20459,"activeCount":97},[],{"trials":20461,"activeCount":97},[],{"trials":20463,"activeCount":97},[20464,20471,20478,20485,20492],{"nctId":20465,"briefTitle":20466,"status":155,"phases":20467,"primaryCompletion":8750,"completion":9697,"start":20468,"enrollment":2045,"conditions":20469,"interventions":20470},"NCT00938041","Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody",[86],"1998-04",[4574],[20456],{"nctId":20472,"briefTitle":20473,"status":155,"phases":20474,"primaryCompletion":2405,"completion":10167,"start":20475,"enrollment":1237,"conditions":20476,"interventions":20477},"NCT00989664","Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma",[86],"1996-11",[4574],[20456],{"nctId":20479,"briefTitle":20480,"status":155,"phases":20481,"primaryCompletion":7598,"completion":7598,"start":7889,"enrollment":212,"conditions":20482,"interventions":20483},"NCT00950755","Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology",[86],[4574],[20484],"tositumomab and Iodine I 131 tositumomab",{"nctId":20486,"briefTitle":20487,"status":155,"phases":20488,"primaryCompletion":7658,"completion":3391,"start":20489,"enrollment":12044,"conditions":20490,"interventions":20491},"NCT00933335","Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab",[86],"1998-08",[4574],[20456],{"nctId":20493,"briefTitle":20494,"status":155,"phases":20495,"primaryCompletion":7881,"completion":2394,"start":20496,"enrollment":624,"conditions":20497,"interventions":20498},"NCT00996996","Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma",[86],"1996-06",[4574],[20456],{"trials":20500,"activeCount":97},[20501],{"nctId":20502,"briefTitle":20503,"status":155,"phases":20504,"primaryCompletion":1429,"completion":9697,"start":8478,"enrollment":473,"conditions":20505,"interventions":20506},"NCT00268983","Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma",[87],[4574],[20456,517],{"trials":20508,"activeCount":97},[],{"trials":20510,"activeCount":97},[],{"intervention":9061,"totalTrials":628,"cells":20512},{"EARLY_PHASE1":20513,"PHASE1":20515,"PHASE2":20526,"PHASE3":20548,"PHASE4":20558,"NA":20560},{"trials":20514,"activeCount":97},[],{"trials":20516,"activeCount":97},[20517],{"nctId":20518,"briefTitle":20519,"status":155,"phases":20520,"primaryCompletion":20521,"completion":20521,"start":20522,"enrollment":1264,"conditions":20523,"interventions":20524},"NCT00976261","A 2-Part Trial in Subjects With Type 2 Diabetes and in Healthy Subjects to Evaluate GSK1614235, a New Glucose Lowering Drug to Treat Type 2 Diabetes",[85],"2010-09-05","2009-10-17",[27],[20525,9061],"GSK1614235",{"trials":20527,"activeCount":97},[20528,20532,20540],{"nctId":9053,"briefTitle":9054,"status":155,"phases":20529,"primaryCompletion":9056,"completion":9056,"start":9057,"enrollment":730,"conditions":20530,"interventions":20531},[86],[27],[9060,9061,9016],{"nctId":20533,"briefTitle":20534,"status":155,"phases":20535,"primaryCompletion":20536,"completion":20536,"start":20537,"enrollment":414,"conditions":20538,"interventions":20539},"NCT01119846","A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics",[86],"2010-03-19","2009-06-05",[27],[19734,9061],{"nctId":20541,"briefTitle":20542,"status":155,"phases":20543,"primaryCompletion":20544,"completion":20544,"start":20545,"enrollment":2321,"conditions":20546,"interventions":20547},"NCT01128621","A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263",[86],"2010-04-12","2009-11-23",[27],[19734,9061],{"trials":20549,"activeCount":97},[20550,20554],{"nctId":8086,"briefTitle":8087,"status":155,"phases":20551,"primaryCompletion":8089,"completion":8089,"start":7647,"enrollment":8090,"conditions":20552,"interventions":20553},[87],[27],[7997,8093],{"nctId":8141,"briefTitle":8142,"status":155,"phases":20555,"primaryCompletion":2427,"completion":484,"start":8116,"enrollment":8144,"conditions":20556,"interventions":20557},[87],[27],[7997,8093,8129,8128],{"trials":20559,"activeCount":97},[],{"trials":20561,"activeCount":97},[],{"intervention":20563,"totalTrials":1517,"cells":20564},"GW685698X Aqueous Nasal Spray",{"EARLY_PHASE1":20565,"PHASE1":20567,"PHASE2":20569,"PHASE3":20571,"PHASE4":20606,"NA":20608},{"trials":20566,"activeCount":97},[],{"trials":20568,"activeCount":97},[],{"trials":20570,"activeCount":97},[],{"trials":20572,"activeCount":97},[20573,20579,20586,20592,20600],{"nctId":20574,"briefTitle":20575,"status":155,"phases":20576,"primaryCompletion":2805,"completion":2805,"start":10395,"enrollment":12474,"conditions":20577,"interventions":20578},"NCT00197262","Once-Daily Investigational Nasal Spray In Adults And Adolescents With Seasonal Allergic Rhinitis (SAR)",[87],[10169],[20563],{"nctId":20580,"briefTitle":20581,"status":155,"phases":20582,"primaryCompletion":10212,"completion":10212,"start":1380,"enrollment":13419,"conditions":20583,"interventions":20584},"NCT00116883","A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics",[87],[10182],[20585],"GW685698X aqueous nasal spray",{"nctId":20587,"briefTitle":20588,"status":155,"phases":20589,"primaryCompletion":8386,"completion":8386,"start":10803,"enrollment":13419,"conditions":20590,"interventions":20591},"NCT00116818","A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults",[87],[10182],[20585],{"nctId":20593,"briefTitle":20594,"status":155,"phases":20595,"primaryCompletion":20596,"completion":8364,"start":20597,"enrollment":12044,"conditions":20598,"interventions":20599},"NCT00363740","Study of GW685698X In Patients With Seasonal Allergic Rhinitis",[87],"2005-04-01","2005-02-19",[10169],[20563],{"nctId":20601,"briefTitle":20602,"status":155,"phases":20603,"primaryCompletion":10395,"completion":10395,"start":7785,"enrollment":6576,"conditions":20604,"interventions":20605},"NCT00118729","Study In Adolescent And Adult Subjects 12 Years Of Age And Older With Seasonal Allergic Rhinitis To Assess Onset of Action",[87],[10169],[20563],{"trials":20607,"activeCount":97},[],{"trials":20609,"activeCount":97},[],{"intervention":20611,"totalTrials":1517,"cells":20612},"Extended-release Bupropion Hydrochloride",{"EARLY_PHASE1":20613,"PHASE1":20615,"PHASE2":20625,"PHASE3":20627,"PHASE4":20657,"NA":20659},{"trials":20614,"activeCount":97},[],{"trials":20616,"activeCount":97},[20617],{"nctId":20618,"briefTitle":20619,"status":155,"phases":20620,"primaryCompletion":20621,"completion":20621,"start":20622,"enrollment":17295,"conditions":20623,"interventions":20624},"NCT00069459","Seasonal Affective Depression (SAD) Study",[85],"2004-06-03","2003-09-23",[9292],[20611],{"trials":20626,"activeCount":97},[],{"trials":20628,"activeCount":97},[20629,20635,20642,20650],{"nctId":20630,"briefTitle":20631,"status":155,"phases":20632,"primaryCompletion":3036,"completion":3036,"start":11599,"enrollment":8529,"conditions":20633,"interventions":20634},"NCT00051272","Effects Of Antidepressants On Sexual Functioning In Adults",[87],[10890],[20611],{"nctId":20636,"briefTitle":20637,"status":155,"phases":20638,"primaryCompletion":3036,"completion":3036,"start":11599,"enrollment":2121,"conditions":20639,"interventions":20640},"NCT00051259","Effects of Antidepressants on Sexual Functioning",[87],[10890],[20641],"Extended-Release Bupropion Hydrochloride",{"nctId":20643,"briefTitle":20644,"status":155,"phases":20645,"primaryCompletion":10886,"completion":10886,"start":7582,"enrollment":536,"conditions":20646,"interventions":20648},"NCT00046241","Prevention of Seasonal Affective Disorder",[87],[20647],"Seasonal Affective Disorder",[20649],"Extended-release bupropion hydrochloride",{"nctId":20651,"briefTitle":20652,"status":155,"phases":20653,"primaryCompletion":10886,"completion":10886,"start":13061,"enrollment":8347,"conditions":20654,"interventions":20656},"NCT00048360","Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults",[87],[20655],"Attention Deficit Disorder",[20649],{"trials":20658,"activeCount":97},[],{"trials":20660,"activeCount":97},[],{"intervention":2409,"totalTrials":1517,"cells":20662},{"EARLY_PHASE1":20663,"PHASE1":20665,"PHASE2":20684,"PHASE3":20699,"PHASE4":20705,"NA":20707},{"trials":20664,"activeCount":97},[],{"trials":20666,"activeCount":97},[20667,20676],{"nctId":20668,"briefTitle":20669,"status":155,"phases":20670,"primaryCompletion":20671,"completion":20671,"start":20672,"enrollment":3379,"conditions":20673,"interventions":20674},"NCT00169533","Rollover Study Of Lapatinib In Cancer Patients",[85],"2009-05-05","2004-08-19",[668],[20675],"GW572016 oral",{"nctId":20677,"briefTitle":20678,"status":155,"phases":20679,"primaryCompletion":20680,"completion":20680,"start":20681,"enrollment":361,"conditions":20682,"interventions":20683},"NCT00371488","GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer",[85],"2007-12-10","2006-04-06",[668],[20675],{"trials":20685,"activeCount":97},[20686,20693],{"nctId":20687,"briefTitle":20688,"status":155,"phases":20689,"primaryCompletion":1380,"completion":1380,"start":20690,"enrollment":1196,"conditions":20691,"interventions":20692},"NCT00062686","GW572016 For Treatment Of Refractory Metastatic Breast Cancer",[86],"2003-11",[668],[2409],{"nctId":20694,"briefTitle":20695,"status":145,"phases":20696,"primaryCompletion":5018,"completion":5018,"start":20690,"enrollment":8337,"conditions":20697,"interventions":20698},"NCT00073008","A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer",[86],[267],[2409],{"trials":20700,"activeCount":97},[20701],{"nctId":2401,"briefTitle":2402,"status":155,"phases":20702,"primaryCompletion":2404,"completion":728,"start":2405,"enrollment":2406,"conditions":20703,"interventions":20704},[87],[668],[216,2409],{"trials":20706,"activeCount":97},[],{"trials":20708,"activeCount":97},[],{"intervention":795,"totalTrials":1517,"cells":20710},{"EARLY_PHASE1":20711,"PHASE1":20713,"PHASE2":20719,"PHASE3":20721,"PHASE4":20751,"NA":20753},{"trials":20712,"activeCount":97},[],{"trials":20714,"activeCount":97},[20715],{"nctId":11302,"briefTitle":11303,"status":155,"phases":20716,"primaryCompletion":11305,"completion":11305,"start":6501,"enrollment":1003,"conditions":20717,"interventions":20718},[85],[18],[795,11308],{"trials":20720,"activeCount":97},[],{"trials":20722,"activeCount":97},[20723,20730,20738,20742],{"nctId":20724,"briefTitle":20725,"status":155,"phases":20726,"primaryCompletion":4155,"completion":4155,"start":6512,"enrollment":20727,"conditions":20728,"interventions":20729},"NCT05243680","An Open-Label Extension Study of GSK3511294 (Depemokimab) in Participants Who Were Previously Enrolled in 206713 (NCT04719832) or 213744 (NCT04718103)",[87],641,[18],[795],{"nctId":20731,"briefTitle":20732,"status":155,"phases":20733,"primaryCompletion":20734,"completion":20734,"start":20735,"enrollment":14628,"conditions":20736,"interventions":20737},"NCT04719832","Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype",[87],"2023-11-21","2021-03-17",[18],[795],{"nctId":787,"briefTitle":788,"status":155,"phases":20739,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":20740,"interventions":20741},[87],[18],[795,694,796,437],{"nctId":20743,"briefTitle":20744,"status":155,"phases":20745,"primaryCompletion":20746,"completion":20746,"start":20747,"enrollment":20748,"conditions":20749,"interventions":20750},"NCT04718103","A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype",[87],"2024-04-11","2021-02-04",397,[18],[795],{"trials":20752,"activeCount":97},[],{"trials":20754,"activeCount":97},[],{"intervention":7753,"totalTrials":1517,"cells":20756},{"EARLY_PHASE1":20757,"PHASE1":20759,"PHASE2":20761,"PHASE3":20779,"PHASE4":20785,"NA":20787},{"trials":20758,"activeCount":97},[],{"trials":20760,"activeCount":97},[],{"trials":20762,"activeCount":97},[20763,20767,20771,20775],{"nctId":7746,"briefTitle":7747,"status":155,"phases":20764,"primaryCompletion":7749,"start":7750,"enrollment":3392,"conditions":20765,"interventions":20766},[86],[24],[7753,7718],{"nctId":7763,"briefTitle":7764,"status":155,"phases":20768,"primaryCompletion":7766,"completion":7767,"start":7768,"enrollment":7769,"conditions":20769,"interventions":20770},[86],[24],[7718,7753],{"nctId":7773,"briefTitle":7774,"status":155,"phases":20772,"primaryCompletion":7776,"completion":7776,"start":7777,"enrollment":1237,"conditions":20773,"interventions":20774},[86],[24],[7718,7753,7780],{"nctId":7795,"briefTitle":7796,"status":155,"phases":20776,"primaryCompletion":7798,"start":7799,"enrollment":781,"conditions":20777,"interventions":20778},[86],[24],[7753,7718],{"trials":20780,"activeCount":97},[20781],{"nctId":7815,"briefTitle":7816,"status":155,"phases":20782,"primaryCompletion":7739,"start":7750,"enrollment":6576,"conditions":20783,"interventions":20784},[87],[24],[7753,7718],{"trials":20786,"activeCount":97},[],{"trials":20788,"activeCount":97},[],{"intervention":8673,"totalTrials":1517,"cells":20790},{"EARLY_PHASE1":20791,"PHASE1":20793,"PHASE2":20795,"PHASE3":20797,"PHASE4":20825,"NA":20827},{"trials":20792,"activeCount":97},[],{"trials":20794,"activeCount":97},[],{"trials":20796,"activeCount":97},[],{"trials":20798,"activeCount":97},[20799,20803,20807,20817,20821],{"nctId":8662,"briefTitle":8663,"status":155,"phases":20800,"primaryCompletion":8665,"completion":8666,"start":8667,"enrollment":8668,"conditions":20801,"interventions":20802},[87],[8670,8671],[8673,8674,8675,4694,8676],{"nctId":19392,"briefTitle":19393,"status":155,"phases":20804,"primaryCompletion":19395,"completion":19396,"start":19397,"enrollment":19398,"conditions":20805,"interventions":20806},[87],[19400],[8673,8674,19402,19403],{"nctId":20808,"briefTitle":20809,"status":155,"phases":20810,"primaryCompletion":20811,"completion":20812,"start":20813,"enrollment":20814,"conditions":20815,"interventions":20816},"NCT01627561","Safety and Immunogenicity of GSK Biologicals' HPV-16\u002F18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old",[87],"2014-04-23","2016-10-06","2012-10-15",148,[8723],[9000,8673,4809],{"nctId":8678,"briefTitle":8679,"status":155,"phases":20818,"primaryCompletion":8681,"completion":8682,"start":8683,"enrollment":8684,"conditions":20819,"interventions":20820},[87],[2484,2486,2485],[8673,8674,8675,4694,8676],{"nctId":8692,"briefTitle":8693,"status":155,"phases":20822,"primaryCompletion":8695,"completion":8696,"start":8697,"enrollment":8698,"conditions":20823,"interventions":20824},[87],[2486,2485,2484,8671],[8673,8674,8675,4694,8676],{"trials":20826,"activeCount":97},[],{"trials":20828,"activeCount":97},[],{"intervention":4749,"totalTrials":1517,"cells":20830},{"EARLY_PHASE1":20831,"PHASE1":20833,"PHASE2":20835,"PHASE3":20841,"PHASE4":20864,"NA":20866},{"trials":20832,"activeCount":97},[],{"trials":20834,"activeCount":97},[],{"trials":20836,"activeCount":97},[20837],{"nctId":10209,"briefTitle":10210,"status":155,"phases":20838,"primaryCompletion":9737,"completion":9737,"start":10212,"enrollment":10213,"conditions":20839,"interventions":20840},[86],[992],[10216,10217,4749,10200],{"trials":20842,"activeCount":97},[20843,20847,20851,20855],{"nctId":18285,"briefTitle":18286,"status":155,"phases":20844,"primaryCompletion":18288,"completion":18289,"start":18290,"enrollment":15623,"conditions":20845,"interventions":20846},[87],[992],[8291,18293,4749],{"nctId":4734,"briefTitle":4735,"status":155,"phases":20848,"primaryCompletion":4737,"completion":4738,"start":4739,"enrollment":4740,"conditions":20849,"interventions":20850},[87],[24,3624,33,4702,30,4742],[4744,4745,4472,4746,4747,4748,4749,4750,4751],{"nctId":10221,"briefTitle":10222,"status":155,"phases":20852,"primaryCompletion":8447,"completion":8447,"start":10224,"enrollment":10225,"conditions":20853,"interventions":20854},[87],[10227,4704,24,30,33,10228],[10230,10200,10231,4749],{"nctId":20856,"briefTitle":20857,"status":155,"phases":20858,"primaryCompletion":20859,"completion":5053,"start":2757,"enrollment":20860,"conditions":20861,"interventions":20862},"NCT01506193","Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children",[87],"2014-02-17",716,[2484,3717,2486,2485],[20863,4749],"PriorixTetra™",{"trials":20865,"activeCount":97},[],{"trials":20867,"activeCount":97},[],{"intervention":437,"totalTrials":1517,"cells":20869},{"EARLY_PHASE1":20870,"PHASE1":20872,"PHASE2":20878,"PHASE3":20902,"PHASE4":20912,"NA":20914},{"trials":20871,"activeCount":97},[],{"trials":20873,"activeCount":97},[20874],{"nctId":428,"briefTitle":429,"status":155,"phases":20875,"primaryCompletion":431,"completion":431,"start":432,"enrollment":433,"conditions":20876,"interventions":20877},[85],[435],[53,437],{"trials":20879,"activeCount":97},[20880,20892],{"nctId":20881,"briefTitle":20882,"status":155,"phases":20883,"primaryCompletion":20884,"completion":20885,"start":20886,"enrollment":20887,"conditions":20888,"interventions":20890},"NCT04376684","Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease",[86],"2021-07-15","2021-08-16","2020-05-28",1156,[20889],"Severe Acute Respiratory Syndrome",[20891,437],"Otilimab",{"nctId":20893,"briefTitle":20894,"status":155,"phases":20895,"primaryCompletion":20896,"completion":20896,"start":20897,"enrollment":18653,"conditions":20898,"interventions":20899},"NCT03034967","Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)",[86],"2018-10-05","2017-04-25",[15],[20900,437,20901],"Danirixin","Rescue medication",{"trials":20903,"activeCount":97},[20904,20908],{"nctId":787,"briefTitle":788,"status":155,"phases":20905,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":20906,"interventions":20907},[87],[18],[795,694,796,437],{"nctId":798,"briefTitle":799,"status":155,"phases":20909,"primaryCompletion":801,"completion":801,"start":802,"enrollment":803,"conditions":20910,"interventions":20911},[87],[741],[694,437],{"trials":20913,"activeCount":97},[],{"trials":20915,"activeCount":97},[],{"intervention":20917,"totalTrials":1517,"cells":20918},"GW406381",{"EARLY_PHASE1":20919,"PHASE1":20921,"PHASE2":20939,"PHASE3":20941,"PHASE4":20965,"NA":20967},{"trials":20920,"activeCount":97},[],{"trials":20922,"activeCount":97},[20923,20932],{"nctId":20924,"briefTitle":20925,"status":155,"phases":20926,"start":9462,"enrollment":345,"conditions":20927,"interventions":20931},"NCT00279032","GW406381 In Patients With Peripheral Nerve Injury",[85],[20928,20929,9153,20930],"Hyperalgesia","Neurodynia","Trauma",[20917],{"nctId":20933,"briefTitle":20934,"status":155,"phases":20935,"primaryCompletion":11941,"completion":11941,"start":20936,"enrollment":1298,"conditions":20937,"interventions":20938},"NCT00373243","A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment",[85],"2005-10-19",[9153],[20917],{"trials":20940,"activeCount":97},[],{"trials":20942,"activeCount":97},[20943,20951,20958],{"nctId":20944,"briefTitle":20945,"status":155,"phases":20946,"primaryCompletion":7785,"completion":7785,"start":1361,"enrollment":536,"conditions":20947,"interventions":20950},"NCT00114049","Dental Pain (Following Third Molar Tooth Extraction) Study",[87],[20948,20949],"Dental Pain","Surgery, Dental",[20917],{"nctId":20952,"briefTitle":20953,"status":155,"phases":20954,"primaryCompletion":4757,"completion":4757,"start":2796,"enrollment":20955,"conditions":20956,"interventions":20957},"NCT00113308","COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis",[87],2208,[8788],[20917],{"nctId":20959,"briefTitle":20960,"status":155,"phases":20961,"primaryCompletion":2356,"completion":2356,"start":8386,"enrollment":20962,"conditions":20963,"interventions":20964},"NCT00120900","Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee",[87],1340,[9210],[20917],{"trials":20966,"activeCount":97},[],{"trials":20968,"activeCount":97},[],{"intervention":18312,"totalTrials":1517,"cells":20970},{"EARLY_PHASE1":20971,"PHASE1":20973,"PHASE2":20975,"PHASE3":20998,"PHASE4":21008,"NA":21010},{"trials":20972,"activeCount":97},[],{"trials":20974,"activeCount":97},[],{"trials":20976,"activeCount":97},[20977,20984,20994],{"nctId":20978,"briefTitle":20979,"status":155,"phases":20980,"primaryCompletion":2795,"completion":2795,"start":8406,"enrollment":4121,"conditions":20981,"interventions":20982},"NCT00390143","Study in Adolescents\u002FAdults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612",[86],[992],[20983,18312],"Meningococcal vaccine 134612",{"nctId":20985,"briefTitle":20986,"status":155,"phases":20987,"primaryCompletion":20988,"completion":20989,"start":20990,"enrollment":10126,"conditions":20991,"interventions":20992},"NCT00356369","Study in Adolescents\u002FAdults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine",[86],"2007-09-07","2008-02-28","2006-12-23",[992],[20993,18312],"meningococcal ACWY",{"nctId":20128,"briefTitle":20129,"status":155,"phases":20995,"primaryCompletion":9962,"completion":9962,"start":20131,"enrollment":20132,"conditions":20996,"interventions":20997},[86],[992],[20135,18312,8971],{"trials":20999,"activeCount":97},[21000,21004],{"nctId":19849,"briefTitle":19850,"status":155,"phases":21001,"primaryCompletion":19852,"completion":19852,"start":17948,"enrollment":7694,"conditions":21002,"interventions":21003},[87],[992],[19855,19818,18312],{"nctId":18303,"briefTitle":18304,"status":155,"phases":21005,"primaryCompletion":18306,"completion":18307,"start":18308,"enrollment":18309,"conditions":21006,"interventions":21007},[87],[992],[8291,18312],{"trials":21009,"activeCount":97},[],{"trials":21011,"activeCount":97},[],{"intervention":21013,"totalTrials":1517,"cells":21014},"lisinopril",{"EARLY_PHASE1":21015,"PHASE1":21017,"PHASE2":21036,"PHASE3":21038,"PHASE4":21066,"NA":21068},{"trials":21016,"activeCount":97},[],{"trials":21018,"activeCount":97},[21019,21029],{"nctId":21020,"briefTitle":21021,"status":155,"phases":21022,"primaryCompletion":21023,"completion":21023,"start":21024,"enrollment":234,"conditions":21025,"interventions":21026},"NCT00508365","Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives",[85],"2008-06-03","2007-09-25",[13024],[21027,21028],"Carvedilol CR","Lisinopril",{"nctId":21030,"briefTitle":21031,"status":155,"phases":21032,"primaryCompletion":2804,"completion":2804,"start":2356,"enrollment":10794,"conditions":21033,"interventions":21034},"NCT00552708","A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.",[85],[13024],[21035,21028],"COREG CR",{"trials":21037,"activeCount":97},[],{"trials":21039,"activeCount":97},[21040,21048,21058],{"nctId":21041,"briefTitle":21042,"status":155,"phases":21043,"primaryCompletion":2355,"completion":2355,"start":8963,"enrollment":21044,"conditions":21045,"interventions":21046},"NCT00347360","The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial",[87],654,[13024],[21013,21047],"carvedilol controlled release formulation",{"nctId":21049,"briefTitle":21050,"status":155,"phases":21051,"primaryCompletion":7976,"completion":7976,"start":10803,"enrollment":21052,"conditions":21053,"interventions":21055},"NCT00108082","The CLEVER Study - Coreg And Left Ventricular Mass Regression",[87],287,[21054],"Hypertrophy, Left Ventricular",[21056,21057,21013],"carvedilol MR","atenolol",{"nctId":21059,"briefTitle":21060,"status":145,"phases":21061,"primaryCompletion":2383,"completion":2383,"start":10212,"enrollment":9757,"conditions":21062,"interventions":21064},"NCT00123903","COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria",[87],[21063],"Heart Failure, Congestive and Microalbuminuria",[21065,21056,21013],"metoprolol xl",{"trials":21067,"activeCount":97},[],{"trials":21069,"activeCount":97},[],{"intervention":21071,"totalTrials":1517,"cells":21072},"DTPw-HBV\u002FHib-MenAC conjugate vaccine",{"EARLY_PHASE1":21073,"PHASE1":21075,"PHASE2":21077,"PHASE3":21095,"PHASE4":21117,"NA":21119},{"trials":21074,"activeCount":97},[],{"trials":21076,"activeCount":97},[],{"trials":21078,"activeCount":97},[21079,21088],{"nctId":21080,"briefTitle":21081,"status":155,"phases":21082,"start":10287,"enrollment":21083,"conditions":21084,"interventions":21087},"NCT00291967","Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to Infants",[86],525,[30,33,10087,24,21085,21086],"Hib Diseases","Neisseria Meningitidis Serogroups A & C Diseases",[21071],{"nctId":21089,"briefTitle":21090,"status":155,"phases":21091,"completion":2775,"start":21092,"enrollment":1752,"conditions":21093,"interventions":21094},"NCT00317174","A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.",[86],"2003-07",[4704,33,10227,24,30],[21071],{"trials":21096,"activeCount":97},[21097,21104,21110],{"nctId":21098,"briefTitle":21099,"status":155,"phases":21100,"primaryCompletion":2814,"completion":2814,"start":10670,"enrollment":21101,"conditions":21102,"interventions":21103},"NCT00290303","Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB\u002FHib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB\u002FHiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy Infants",[87],996,[4704,30,10227,24,33],[21071],{"nctId":21105,"briefTitle":21106,"status":155,"phases":21107,"primaryCompletion":7785,"completion":7785,"start":19830,"enrollment":15623,"conditions":21108,"interventions":21109},"NCT00317161","Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.",[87],[30,24,4704,10227,33],[21071],{"nctId":21111,"briefTitle":21112,"status":155,"phases":21113,"primaryCompletion":10212,"completion":10212,"start":8478,"enrollment":3285,"conditions":21114,"interventions":21116},"NCT00317122","Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB\u002FHib-MenAC vs Tritanrix™-HepB\u002FHiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth",[87],[21115],"Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis",[21071],{"trials":21118,"activeCount":97},[],{"trials":21120,"activeCount":97},[],{"intervention":18044,"totalTrials":1517,"cells":21122},{"EARLY_PHASE1":21123,"PHASE1":21125,"PHASE2":21127,"PHASE3":21145,"PHASE4":21151,"NA":21153},{"trials":21124,"activeCount":97},[],{"trials":21126,"activeCount":97},[],{"trials":21128,"activeCount":97},[21129,21133,21137,21141],{"nctId":18037,"briefTitle":18038,"status":155,"phases":21130,"primaryCompletion":18040,"completion":12077,"start":18032,"enrollment":18041,"conditions":21131,"interventions":21132},[86],[17996],[17974,18044],{"nctId":18046,"briefTitle":18047,"status":155,"phases":21134,"primaryCompletion":12043,"completion":4799,"start":1874,"enrollment":18049,"conditions":21135,"interventions":21136},[86],[17996],[17974,18044],{"nctId":18061,"briefTitle":18062,"status":155,"phases":21138,"primaryCompletion":858,"completion":858,"start":18064,"enrollment":526,"conditions":21139,"interventions":21140},[86],[17996],[17974,18044],{"nctId":18590,"briefTitle":18591,"status":155,"phases":21142,"primaryCompletion":18593,"completion":18593,"start":18594,"enrollment":1117,"conditions":21143,"interventions":21144},[86],[17996],[18545,18044,18597,18597],{"trials":21146,"activeCount":97},[21147],{"nctId":18638,"briefTitle":18639,"status":155,"phases":21148,"primaryCompletion":18641,"completion":18641,"start":18642,"enrollment":18643,"conditions":21149,"interventions":21150},[87],[17996,18645],[18545,18044,18626],{"trials":21152,"activeCount":97},[],{"trials":21154,"activeCount":97},[],{"intervention":21156,"totalTrials":1517,"cells":21157},"Fluviral®",{"EARLY_PHASE1":21158,"PHASE1":21160,"PHASE2":21162,"PHASE3":21164,"PHASE4":21204,"NA":21206},{"trials":21159,"activeCount":97},[],{"trials":21161,"activeCount":97},[],{"trials":21163,"activeCount":97},[],{"trials":21165,"activeCount":97},[21166,21174,21182,21190,21196],{"nctId":21167,"briefTitle":21168,"status":155,"phases":21169,"primaryCompletion":21170,"completion":21170,"start":21171,"enrollment":28,"conditions":21172,"interventions":21173},"NCT00718120","Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years",[87],"2008-08-09","2008-07-18",[8265],[21156],{"nctId":21175,"briefTitle":21176,"status":155,"phases":21177,"primaryCompletion":21178,"completion":21178,"start":21179,"enrollment":2107,"conditions":21180,"interventions":21181},"NCT01626820","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012\u002F2013 Season) in Adults",[87],"2012-08-10","2012-07-19",[21],[21156],{"nctId":21183,"briefTitle":21184,"status":155,"phases":21185,"primaryCompletion":21186,"completion":21186,"start":21187,"enrollment":201,"conditions":21188,"interventions":21189},"NCT01153685","Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years",[87],"2010-07-31","2010-07-09",[21],[21156],{"nctId":21191,"briefTitle":21192,"status":155,"phases":21193,"completion":2336,"start":2428,"enrollment":28,"conditions":21194,"interventions":21195},"NCT00505453","A Phase III, Open-Label, Single-Dose Study to Evaluate the Safety and Immunogenicity of Fluviral® Vaccine",[87],[21],[21156],{"nctId":21197,"briefTitle":21198,"status":155,"phases":21199,"primaryCompletion":21200,"completion":21200,"start":21201,"enrollment":28,"conditions":21202,"interventions":21203},"NCT00929331","Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years",[87],"2009-08-01","2009-07-11",[5353],[21156],{"trials":21205,"activeCount":97},[],{"trials":21207,"activeCount":97},[],{"intervention":16147,"totalTrials":1517,"cells":21209},{"EARLY_PHASE1":21210,"PHASE1":21212,"PHASE2":21214,"PHASE3":21230,"PHASE4":21255,"NA":21257},{"trials":21211,"activeCount":97},[],{"trials":21213,"activeCount":97},[],{"trials":21215,"activeCount":97},[21216,21224],{"nctId":21217,"briefTitle":21218,"status":155,"phases":21219,"primaryCompletion":21220,"start":11577,"enrollment":1752,"conditions":21221,"interventions":21223},"NCT00346892","To Evaluate 2 Doses of GSK Biologicals' Oral Live Attenuated Human HRV Vaccine Co-administered With Either OPV or IPV",[86],"2003-03",[21222],"Rotavirus Infections",[16147],{"nctId":21225,"briefTitle":21226,"status":155,"phases":21227,"completion":1360,"start":2796,"enrollment":536,"conditions":21228,"interventions":21229},"NCT00139334","A Study to Test 2 Doses of the HRV Vaccine Given With or Without OPV in Healthy Infants in Bangladesh",[86],[4759],[16147],{"trials":21231,"activeCount":97},[21232,21239,21246],{"nctId":21233,"briefTitle":21234,"status":155,"phases":21235,"primaryCompletion":2428,"completion":2428,"start":8492,"enrollment":21236,"conditions":21237,"interventions":21238},"NCT00197210","A Study to Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants",[87],10708,[4759],[16147],{"nctId":21240,"briefTitle":21241,"status":155,"phases":21242,"primaryCompletion":2296,"completion":2296,"start":2823,"enrollment":21243,"conditions":21244,"interventions":21245},"NCT00140686","To Test 2 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants in Co-administration With Specific Childhood Vaccines",[87],3994,[4759],[16147],{"nctId":21247,"briefTitle":21248,"status":155,"phases":21249,"completion":21250,"start":21251,"enrollment":21252,"conditions":21253,"interventions":21254},"NCT00140673","A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.",[87],"2005-10-20","2003-08-05",63227,[4759],[16147],{"trials":21256,"activeCount":97},[],{"trials":21258,"activeCount":97},[],{"intervention":9883,"totalTrials":181,"cells":21260},{"EARLY_PHASE1":21261,"PHASE1":21263,"PHASE2":21265,"PHASE3":21284,"PHASE4":21295,"NA":21297},{"trials":21262,"activeCount":97},[],{"trials":21264,"activeCount":97},[],{"trials":21266,"activeCount":97},[21267,21271,21280],{"nctId":9874,"briefTitle":9875,"status":155,"phases":21268,"primaryCompletion":9877,"completion":9878,"start":9879,"enrollment":9880,"conditions":21269,"interventions":21270},[86],[21],[9883,9884,9828],{"nctId":21272,"briefTitle":21273,"status":155,"phases":21274,"primaryCompletion":21275,"completion":21275,"start":21276,"enrollment":21277,"conditions":21278,"interventions":21279},"NCT00976820","Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age",[86],"2011-03-21","2009-10-20",323,[21],[9883,9884],{"nctId":9886,"briefTitle":9887,"status":155,"phases":21281,"primaryCompletion":9889,"completion":9890,"start":9891,"enrollment":5034,"conditions":21282,"interventions":21283},[86],[21],[9883,9884,9894,9828],{"trials":21285,"activeCount":97},[21286],{"nctId":21287,"briefTitle":21288,"status":155,"phases":21289,"primaryCompletion":21290,"completion":21291,"start":9877,"enrollment":21292,"conditions":21293,"interventions":21294},"NCT00979602","Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older",[87],"2011-01-10","2011-02-01",4048,[21],[9883,9884],{"trials":21296,"activeCount":97},[],{"trials":21298,"activeCount":97},[],{"intervention":9884,"totalTrials":181,"cells":21300},{"EARLY_PHASE1":21301,"PHASE1":21303,"PHASE2":21305,"PHASE3":21319,"PHASE4":21325,"NA":21327},{"trials":21302,"activeCount":97},[],{"trials":21304,"activeCount":97},[],{"trials":21306,"activeCount":97},[21307,21311,21315],{"nctId":9874,"briefTitle":9875,"status":155,"phases":21308,"primaryCompletion":9877,"completion":9878,"start":9879,"enrollment":9880,"conditions":21309,"interventions":21310},[86],[21],[9883,9884,9828],{"nctId":21272,"briefTitle":21273,"status":155,"phases":21312,"primaryCompletion":21275,"completion":21275,"start":21276,"enrollment":21277,"conditions":21313,"interventions":21314},[86],[21],[9883,9884],{"nctId":9886,"briefTitle":9887,"status":155,"phases":21316,"primaryCompletion":9889,"completion":9890,"start":9891,"enrollment":5034,"conditions":21317,"interventions":21318},[86],[21],[9883,9884,9894,9828],{"trials":21320,"activeCount":97},[21321],{"nctId":21287,"briefTitle":21288,"status":155,"phases":21322,"primaryCompletion":21290,"completion":21291,"start":9877,"enrollment":21292,"conditions":21323,"interventions":21324},[87],[21],[9883,9884],{"trials":21326,"activeCount":97},[],{"trials":21328,"activeCount":97},[],{"intervention":8676,"totalTrials":181,"cells":21330},{"EARLY_PHASE1":21331,"PHASE1":21333,"PHASE2":21335,"PHASE3":21348,"PHASE4":21362,"NA":21364},{"trials":21332,"activeCount":97},[],{"trials":21334,"activeCount":97},[],{"trials":21336,"activeCount":97},[21337],{"nctId":21338,"briefTitle":21339,"status":155,"phases":21340,"primaryCompletion":21341,"completion":21341,"start":21342,"enrollment":13062,"conditions":21343,"interventions":21346},"NCT05412030","A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants",[86],"2025-09-18","2022-06-16",[6371,21344,21345],"Pneumococcal Infections","Pneumonia, Pneumococcal",[21347,8676,11175],"AFX3772",{"trials":21349,"activeCount":97},[21350,21354,21358],{"nctId":8662,"briefTitle":8663,"status":155,"phases":21351,"primaryCompletion":8665,"completion":8666,"start":8667,"enrollment":8668,"conditions":21352,"interventions":21353},[87],[8670,8671],[8673,8674,8675,4694,8676],{"nctId":8678,"briefTitle":8679,"status":155,"phases":21355,"primaryCompletion":8681,"completion":8682,"start":8683,"enrollment":8684,"conditions":21356,"interventions":21357},[87],[2484,2486,2485],[8673,8674,8675,4694,8676],{"nctId":8692,"briefTitle":8693,"status":155,"phases":21359,"primaryCompletion":8695,"completion":8696,"start":8697,"enrollment":8698,"conditions":21360,"interventions":21361},[87],[2486,2485,2484,8671],[8673,8674,8675,4694,8676],{"trials":21363,"activeCount":97},[],{"trials":21365,"activeCount":97},[],{"intervention":21367,"totalTrials":181,"cells":21368},"Poliorix™",{"EARLY_PHASE1":21369,"PHASE1":21371,"PHASE2":21373,"PHASE3":21385,"PHASE4":21416,"NA":21418},{"trials":21370,"activeCount":97},[],{"trials":21372,"activeCount":97},[],{"trials":21374,"activeCount":97},[21375],{"nctId":21376,"briefTitle":21377,"status":155,"phases":21378,"primaryCompletion":21379,"completion":21379,"start":8805,"enrollment":5088,"conditions":21380,"interventions":21382},"NCT01106092","Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers",[86],"2010-09-02",[4704,33,24,10227,30,21381],"Poliomyelitis Vaccines",[21383,21384,21367],"GSK2036874A vaccine","Zilbrix™\u002FHib vaccine",{"trials":21386,"activeCount":97},[21387,21397,21407],{"nctId":21388,"briefTitle":21389,"status":155,"phases":21390,"primaryCompletion":21391,"completion":21391,"start":11275,"enrollment":21392,"conditions":21393,"interventions":21394},"NCT01086423","Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine",[87],"2010-11-19",985,[33,4702,3624,30,4704],[21395,21396,21367],"Infanrix-IPV\u002FHib™","Infanrix Hib™",{"nctId":21398,"briefTitle":21399,"status":155,"phases":21400,"primaryCompletion":21401,"completion":21401,"start":21402,"enrollment":21403,"conditions":21404,"interventions":21405},"NCT01021293","Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine",[87],"2010-07-05","2009-11-28",1101,[4702,21381],[21367,21406],"Oral Poliovirus vaccine",{"nctId":21408,"briefTitle":21409,"status":155,"phases":21410,"primaryCompletion":21411,"completion":21411,"start":4973,"enrollment":21412,"conditions":21413,"interventions":21414},"NCT01449812","Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa\u002FHib (Infanrix+Hib™) Vaccine",[87],"2012-01-16",831,[3624,33,30,4704],[21415,21367],"Infanrix+Hib™",{"trials":21417,"activeCount":97},[],{"trials":21419,"activeCount":97},[],{"intervention":19386,"totalTrials":181,"cells":21421},{"EARLY_PHASE1":21422,"PHASE1":21424,"PHASE2":21426,"PHASE3":21448,"PHASE4":21458,"NA":21460},{"trials":21423,"activeCount":97},[],{"trials":21425,"activeCount":97},[],{"trials":21427,"activeCount":97},[21428,21437],{"nctId":21429,"briefTitle":21430,"status":155,"phases":21431,"primaryCompletion":7582,"completion":7582,"start":2482,"enrollment":21432,"conditions":21433,"interventions":21434},"NCT00729001","Study of Two Doses of GSK Biologicals' Live Attenuated HRV Vaccine (Two Different Formulations) in Healthy Infants.",[86],529,[4759],[21435,19386,19416,4809,21436,4807],"Human Rotavirus Vaccine - two different formulations","OmniHIB",{"nctId":21438,"briefTitle":21439,"status":155,"phases":21440,"primaryCompletion":21441,"completion":21442,"start":21443,"enrollment":19270,"conditions":21444,"interventions":21445},"NCT00129129","Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine",[86],"2005-09-15","2006-03-29","2004-08-01",[4704,4703],[21446,4806,4805,19386,21447],"GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine","Menomune",{"trials":21449,"activeCount":97},[21450,21454],{"nctId":19378,"briefTitle":19379,"status":155,"phases":21451,"primaryCompletion":10167,"completion":10166,"start":2428,"enrollment":19381,"conditions":21452,"interventions":21453},[87],[4704,4703],[19384,19385,19386,8674,8675],{"nctId":19422,"briefTitle":19423,"status":155,"phases":21455,"primaryCompletion":19425,"completion":18288,"start":19426,"enrollment":19427,"conditions":21456,"interventions":21457},[87],[4704,4703],[19430,4806,19385,4805,19386,8674,8675],{"trials":21459,"activeCount":97},[],{"trials":21461,"activeCount":97},[],{"intervention":7876,"totalTrials":181,"cells":21463},{"EARLY_PHASE1":21464,"PHASE1":21466,"PHASE2":21468,"PHASE3":21470,"PHASE4":21495,"NA":21497},{"trials":21465,"activeCount":97},[],{"trials":21467,"activeCount":97},[],{"trials":21469,"activeCount":97},[],{"trials":21471,"activeCount":97},[21472,21476,21480,21484],{"nctId":19840,"briefTitle":19841,"status":155,"phases":21473,"primaryCompletion":19843,"completion":19843,"start":19844,"enrollment":19845,"conditions":21474,"interventions":21475},[87],[3624,30,33],[7876,19818],{"nctId":7862,"briefTitle":7863,"status":155,"phases":21477,"primaryCompletion":7865,"completion":7866,"start":7867,"enrollment":7868,"conditions":21478,"interventions":21479},[87],[4704],[7871,7872,7873,7874,7875,7830,7718,7876],{"nctId":9959,"briefTitle":9960,"status":155,"phases":21481,"primaryCompletion":9962,"completion":9962,"start":9963,"enrollment":9964,"conditions":21482,"interventions":21483},[87],[7966],[9920,7876,7872],{"nctId":21485,"briefTitle":21486,"status":155,"phases":21487,"primaryCompletion":21488,"completion":21488,"start":21489,"enrollment":21490,"conditions":21491,"interventions":21492},"NCT01171963","Study to Assess the Efficacy, Immunogenicity and Safety of Liquid Human Rotavirus Vaccine, in Healthy Chinese Infants",[87],"2012-05-12","2010-08-29",3340,[4759],[21493,7876,21494],"GSK Biologicals' liquid human rotavirus vaccine 444563","Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine",{"trials":21496,"activeCount":97},[],{"trials":21498,"activeCount":97},[],{"intervention":21500,"totalTrials":181,"cells":21501},"Rosiglitazone XR",{"EARLY_PHASE1":21502,"PHASE1":21504,"PHASE2":21514,"PHASE3":21524,"PHASE4":21542,"NA":21544},{"trials":21503,"activeCount":97},[],{"trials":21505,"activeCount":97},[21506],{"nctId":21507,"briefTitle":21508,"status":155,"phases":21509,"primaryCompletion":21510,"completion":21510,"start":21511,"enrollment":1237,"conditions":21512,"interventions":21513},"NCT00733785","PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy Volunteers",[85],"2008-11-28","2008-08-13",[4644],[21500],{"trials":21515,"activeCount":97},[21516],{"nctId":21517,"briefTitle":21518,"status":155,"phases":21519,"primaryCompletion":7659,"completion":7659,"start":11097,"enrollment":21520,"conditions":21521,"interventions":21522},"NCT00379600","The Anti-Inflammatory And Metabolic Effects Of Rosiglitazone In Subjects With Rheumatoid Arthritis",[86],96,[8788],[21523],"rosiglitazone XR",{"trials":21525,"activeCount":97},[21526,21534],{"nctId":21527,"briefTitle":21528,"status":145,"phases":21529,"primaryCompletion":16322,"completion":16322,"start":21530,"enrollment":21531,"conditions":21532,"interventions":21533},"NCT00490568","Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers",[87],"2007-08-08",1461,[4644],[21500],{"nctId":21535,"briefTitle":21536,"status":145,"phases":21537,"primaryCompletion":21538,"completion":21538,"start":8305,"enrollment":21539,"conditions":21540,"interventions":21541},"NCT00550420","Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers",[87],"2009-02-12",331,[4644],[21500],{"trials":21543,"activeCount":97},[],{"trials":21545,"activeCount":97},[],{"intervention":18694,"totalTrials":181,"cells":21547},{"EARLY_PHASE1":21548,"PHASE1":21550,"PHASE2":21556,"PHASE3":21562,"PHASE4":21572,"NA":21574},{"trials":21549,"activeCount":97},[],{"trials":21551,"activeCount":97},[21552],{"nctId":18686,"briefTitle":18687,"status":155,"phases":21553,"primaryCompletion":18689,"completion":18689,"start":18690,"enrollment":8038,"conditions":21554,"interventions":21555},[85],[15],[18693,2915,18694,3467],{"trials":21557,"activeCount":97},[21558],{"nctId":18708,"briefTitle":18709,"status":155,"phases":21559,"primaryCompletion":12863,"completion":18711,"start":17134,"enrollment":18712,"conditions":21560,"interventions":21561},[86],[15],[3467,2915,18694],{"trials":21563,"activeCount":97},[21564,21568],{"nctId":18730,"briefTitle":18731,"status":155,"phases":21565,"primaryCompletion":9507,"completion":9507,"start":3045,"enrollment":18733,"conditions":21566,"interventions":21567},[87],[15],[3467,18694,2915],{"nctId":18745,"briefTitle":18746,"status":155,"phases":21569,"primaryCompletion":11484,"completion":11484,"start":8395,"enrollment":18748,"conditions":21570,"interventions":21571},[87],[15],[3467,18694,2915],{"trials":21573,"activeCount":97},[],{"trials":21575,"activeCount":97},[],{"intervention":1419,"totalTrials":181,"cells":21577},{"EARLY_PHASE1":21578,"PHASE1":21580,"PHASE2":21600,"PHASE3":21602,"PHASE4":21617,"NA":21619},{"trials":21579,"activeCount":97},[],{"trials":21581,"activeCount":97},[21582,21592],{"nctId":21583,"briefTitle":21584,"status":155,"phases":21585,"primaryCompletion":21586,"completion":21586,"start":8190,"enrollment":433,"conditions":21587,"interventions":21588},"NCT00511823","The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects",[85],"2007-09-21",[1337],[21589,21590,21591,10467],"casopitant","dolasetron","granisetron",{"nctId":21593,"briefTitle":21594,"status":155,"phases":21595,"primaryCompletion":21596,"completion":21596,"start":21597,"enrollment":1634,"conditions":21598,"interventions":21599},"NCT00358813","Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment",[85],"2008-08-22","2006-09-08",[20347],[1419],{"trials":21601,"activeCount":97},[],{"trials":21603,"activeCount":97},[21604,21608],{"nctId":1411,"briefTitle":1412,"status":155,"phases":21605,"primaryCompletion":1414,"completion":1414,"start":1415,"enrollment":1416,"conditions":21606,"interventions":21607},[87],[1337],[1419,283,1387],{"nctId":21609,"briefTitle":21610,"status":155,"phases":21611,"primaryCompletion":8963,"completion":8963,"start":7613,"enrollment":21612,"conditions":21613,"interventions":21616},"NCT00334152","Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women",[87],515,[21614,21615],"Nausea and Vomiting, Postoperative","Postoperative Nausea and Vomiting",[21589],{"trials":21618,"activeCount":97},[],{"trials":21620,"activeCount":97},[],{"intervention":21622,"totalTrials":181,"cells":21623},"Herpes Zoster vaccine GSK 1437173A",{"EARLY_PHASE1":21624,"PHASE1":21626,"PHASE2":21636,"PHASE3":21638,"PHASE4":21670,"NA":21672},{"trials":21625,"activeCount":97},[],{"trials":21627,"activeCount":97},[21628],{"nctId":21629,"briefTitle":21630,"status":155,"phases":21631,"primaryCompletion":21632,"completion":19976,"start":18388,"enrollment":454,"conditions":21633,"interventions":21634},"NCT01086449","Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults",[85],"2010-06-25",[1030],[21635],"Herpes Zoster Vaccine GSK 1437173A",{"trials":21637,"activeCount":97},[],{"trials":21639,"activeCount":97},[21640,21650,21659],{"nctId":21641,"briefTitle":21642,"status":155,"phases":21643,"primaryCompletion":21644,"completion":21645,"start":21646,"enrollment":21647,"conditions":21648,"interventions":21649},"NCT02052596","Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ\u002Fsu) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older",[87],"2015-06-16","2016-04-21","2014-02-07",935,[1030],[21622,5329],{"nctId":21651,"briefTitle":21652,"status":155,"phases":21653,"primaryCompletion":21654,"completion":13095,"start":21655,"enrollment":159,"conditions":21656,"interventions":21657},"NCT01954251","Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older",[87],"2014-06-02","2013-10-03",[1030],[21622,21658],"GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A",{"nctId":21660,"briefTitle":21661,"status":155,"phases":21662,"primaryCompletion":21663,"completion":21664,"start":21665,"enrollment":21666,"conditions":21667,"interventions":21668},"NCT02045836","Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older",[87],"2015-07-02","2016-06-17","2014-03-05",865,[1030,18950],[21622,21669],"Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™",{"trials":21671,"activeCount":97},[],{"trials":21673,"activeCount":97},[],{"intervention":21675,"totalTrials":181,"cells":21676},"Cetirizine Dry Syrup",{"EARLY_PHASE1":21677,"PHASE1":21679,"PHASE2":21681,"PHASE3":21683,"PHASE4":21711,"NA":21713},{"trials":21678,"activeCount":97},[],{"trials":21680,"activeCount":97},[],{"trials":21682,"activeCount":97},[],{"trials":21684,"activeCount":97},[21685,21693,21699,21705],{"nctId":21686,"briefTitle":21687,"status":155,"phases":21688,"start":10395,"enrollment":21689,"conditions":21690,"interventions":21692},"NCT00257569","Study Of Atopic Dermatitis In Pediatrics",[87],278,[21691],"Dermatitis, Atopic",[21675],{"nctId":21694,"briefTitle":21695,"status":155,"phases":21696,"start":10395,"enrollment":1237,"conditions":21697,"interventions":21698},"NCT00257582","Study Of Cutaneous Disease Accompanied With Pruritus In Pediatrics",[87],[4045],[21675],{"nctId":21700,"briefTitle":21701,"status":155,"phases":21702,"start":10212,"enrollment":4792,"conditions":21703,"interventions":21704},"NCT00253058","Study Of Perennial Allergic Rhinitis In Pediatrics",[87],[10182],[21675],{"nctId":21706,"briefTitle":21707,"status":155,"phases":21708,"start":10395,"enrollment":255,"conditions":21709,"interventions":21710},"NCT00257595","Perennial Allergic Rhinitis In Pediatric Subjects",[87],[10182],[21675],{"trials":21712,"activeCount":97},[],{"trials":21714,"activeCount":97},[],{"intervention":21716,"totalTrials":181,"cells":21717},"Twinrix™ Adult",{"EARLY_PHASE1":21718,"PHASE1":21720,"PHASE2":21722,"PHASE3":21724,"PHASE4":21761,"NA":21763},{"trials":21719,"activeCount":97},[],{"trials":21721,"activeCount":97},[],{"trials":21723,"activeCount":97},[],{"trials":21725,"activeCount":97},[21726,21735,21743,21750],{"nctId":21727,"briefTitle":21728,"status":155,"phases":21729,"primaryCompletion":21730,"completion":21730,"start":21731,"enrollment":1589,"conditions":21732,"interventions":21733},"NCT00197184","Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared",[87],"2004-03-10","2003-11-01",[24,7966],[21716,21734],"Twinrix™ Junior",{"nctId":21736,"briefTitle":21737,"status":155,"phases":21738,"primaryCompletion":21739,"completion":21739,"start":11106,"enrollment":7573,"conditions":21740,"interventions":21741},"NCT00289718","Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule",[87],"2005-03-02",[24,7966],[21742],"Twinrix™ adult",{"nctId":21744,"briefTitle":21745,"status":155,"phases":21746,"primaryCompletion":3036,"completion":3036,"start":10670,"enrollment":21747,"conditions":21748,"interventions":21749},"NCT00197119","Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A\u002FB Vaccine Compared in Subjects Aged 12-15 Years",[87],244,[24,7966],[21716,21734],{"nctId":21751,"briefTitle":21752,"status":155,"phases":21753,"primaryCompletion":21754,"completion":21754,"start":21755,"enrollment":21756,"conditions":21757,"interventions":21758},"NCT00289744","Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule",[87],"2009-04-15","2004-02-16",178,[24,7966],[21759,21760],"TWINRIX™ ADULT","Engerix TM",{"trials":21762,"activeCount":97},[],{"trials":21764,"activeCount":97},[],{"intervention":21766,"totalTrials":181,"cells":21767},"GSK1605786A",{"EARLY_PHASE1":21768,"PHASE1":21770,"PHASE2":21772,"PHASE3":21774,"PHASE4":21808,"NA":21810},{"trials":21769,"activeCount":97},[],{"trials":21771,"activeCount":97},[],{"trials":21773,"activeCount":97},[],{"trials":21775,"activeCount":97},[21776,21784,21792,21800],{"nctId":21777,"briefTitle":21778,"status":145,"phases":21779,"primaryCompletion":10190,"completion":10190,"start":21780,"enrollment":13359,"conditions":21781,"interventions":21783},"NCT01536418","An Active Treatment Study to Induce Clinical Response and\u002For Remission With GSK1605786A in Subjects With Crohn's Disease",[87],"2011-11-11",[21782],"Crohn's Disease",[21766,21766],{"nctId":21785,"briefTitle":21786,"status":145,"phases":21787,"primaryCompletion":21788,"completion":21789,"start":15214,"enrollment":3102,"conditions":21790,"interventions":21791},"NCT01318993","Open-Label Extension Study of GSK1605786A",[87],"2013-09-01","2013-10-29",[21782],[21766],{"nctId":21793,"briefTitle":21794,"status":155,"phases":21795,"primaryCompletion":21796,"completion":21796,"start":18002,"enrollment":21797,"conditions":21798,"interventions":21799},"NCT01277666","A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease",[87],"2013-07-11",608,[21782],[21766,21766],{"nctId":21801,"briefTitle":21802,"status":145,"phases":21803,"primaryCompletion":21804,"completion":21804,"start":21805,"enrollment":2951,"conditions":21806,"interventions":21807},"NCT01316939","GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease",[87],"2013-10-23","2011-05-09",[21782],[21766,21766],{"trials":21809,"activeCount":97},[],{"trials":21811,"activeCount":97},[],{"intervention":6579,"totalTrials":181,"cells":21813},{"EARLY_PHASE1":21814,"PHASE1":21816,"PHASE2":21827,"PHASE3":21829,"PHASE4":21843,"NA":21845},{"trials":21815,"activeCount":97},[],{"trials":21817,"activeCount":97},[21818],{"nctId":21819,"briefTitle":21820,"status":155,"phases":21821,"primaryCompletion":21822,"completion":21822,"start":21823,"enrollment":1534,"conditions":21824,"interventions":21826},"NCT05138822","Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections",[85],"2024-12-03","2022-05-18",[21825,5658],"Uncomplicated Urinary Tract Infections",[9337,6579],{"trials":21828,"activeCount":97},[],{"trials":21830,"activeCount":97},[21831,21835,21839],{"nctId":6571,"briefTitle":6572,"status":155,"phases":21832,"primaryCompletion":6574,"completion":6574,"start":6575,"enrollment":6576,"conditions":21833,"interventions":21834},[87],[5658],[6471,6579],{"nctId":6581,"briefTitle":6582,"status":155,"phases":21836,"primaryCompletion":6584,"completion":6584,"start":6585,"enrollment":6586,"conditions":21837,"interventions":21838},[87],[5658],[6471,6579],{"nctId":6590,"briefTitle":6591,"status":155,"phases":21840,"primaryCompletion":6593,"completion":6593,"start":6594,"enrollment":6595,"conditions":21841,"interventions":21842},[87],[5658],[6471,6579],{"trials":21844,"activeCount":97},[],{"trials":21846,"activeCount":97},[],{"intervention":18585,"totalTrials":181,"cells":21848},{"EARLY_PHASE1":21849,"PHASE1":21851,"PHASE2":21853,"PHASE3":21859,"PHASE4":21882,"NA":21884},{"trials":21850,"activeCount":97},[],{"trials":21852,"activeCount":97},[],{"trials":21854,"activeCount":97},[21855],{"nctId":18579,"briefTitle":18580,"status":145,"phases":21856,"primaryCompletion":9653,"completion":9653,"start":18582,"enrollment":628,"conditions":21857,"interventions":21858},[86],[17996],[18545,18585,18586,18587,18588],{"trials":21860,"activeCount":97},[21861,21865,21878],{"nctId":18619,"briefTitle":18620,"status":155,"phases":21862,"primaryCompletion":18622,"completion":18622,"start":18623,"enrollment":5088,"conditions":21863,"interventions":21864},[87],[17996],[18545,18585,18626],{"nctId":21866,"briefTitle":21867,"status":155,"phases":21868,"primaryCompletion":21869,"completion":21869,"start":21870,"enrollment":5056,"conditions":21871,"interventions":21872},"NCT02969655","A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)",[87],"2018-07-02","2016-11-21",[17996],[21873,21874,21875,21876,18585,21877],"Daprodustat small","Daprodustat small placebo","Daprodustat large","Daprodustat large placebo","Darbepoetin alfa placebo",{"nctId":18628,"briefTitle":18629,"status":155,"phases":21879,"primaryCompletion":18631,"completion":18631,"start":18632,"enrollment":18633,"conditions":21880,"interventions":21881},[87],[17996],[18545,18585,18636],{"trials":21883,"activeCount":97},[],{"trials":21885,"activeCount":97},[],{"intervention":18626,"totalTrials":181,"cells":21887},{"EARLY_PHASE1":21888,"PHASE1":21890,"PHASE2":21892,"PHASE3":21894,"PHASE4":21912,"NA":21914},{"trials":21889,"activeCount":97},[],{"trials":21891,"activeCount":97},[],{"trials":21893,"activeCount":97},[],{"trials":21895,"activeCount":97},[21896,21900,21904,21908],{"nctId":18619,"briefTitle":18620,"status":155,"phases":21897,"primaryCompletion":18622,"completion":18622,"start":18623,"enrollment":5088,"conditions":21898,"interventions":21899},[87],[17996],[18545,18585,18626],{"nctId":18628,"briefTitle":18629,"status":155,"phases":21901,"primaryCompletion":18631,"completion":18631,"start":18632,"enrollment":18633,"conditions":21902,"interventions":21903},[87],[17996],[18545,18585,18636],{"nctId":18638,"briefTitle":18639,"status":155,"phases":21905,"primaryCompletion":18641,"completion":18641,"start":18642,"enrollment":18643,"conditions":21906,"interventions":21907},[87],[17996,18645],[18545,18044,18626],{"nctId":18648,"briefTitle":18649,"status":155,"phases":21909,"primaryCompletion":18651,"completion":18651,"start":18652,"enrollment":18653,"conditions":21910,"interventions":21911},[87],[17996],[18545,18626],{"trials":21913,"activeCount":97},[],{"trials":21915,"activeCount":97},[],{"intervention":21917,"totalTrials":181,"cells":21918},"GSK580299",{"EARLY_PHASE1":21919,"PHASE1":21921,"PHASE2":21931,"PHASE3":21933,"PHASE4":21961,"NA":21963},{"trials":21920,"activeCount":97},[],{"trials":21922,"activeCount":97},[21923],{"nctId":21924,"briefTitle":21925,"status":155,"phases":21926,"primaryCompletion":21927,"completion":21927,"start":21928,"enrollment":255,"conditions":21929,"interventions":21930},"NCT00549900","A Single Centre Study to Evaluate the Safety and Immunogenicity of the Human Papillomavirus Vaccine (GSK-580299) in Chinese Females",[85],"2008-07-12","2007-12-02",[8723],[21917],{"trials":21932,"activeCount":97},[],{"trials":21934,"activeCount":97},[21935,21943,21951],{"nctId":21936,"briefTitle":21937,"status":155,"phases":21938,"primaryCompletion":21939,"completion":21939,"start":3361,"enrollment":21940,"conditions":21941,"interventions":21942},"NCT01249365","The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study",[87],"2017-01-10",199,[8723],[21917],{"nctId":21944,"briefTitle":21945,"status":155,"phases":21946,"primaryCompletion":21947,"completion":21947,"start":15214,"enrollment":21948,"conditions":21949,"interventions":21950},"NCT01190189","Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study",[87],"2017-11-23",137,[8723],[21917],{"nctId":21952,"briefTitle":21953,"status":155,"phases":21954,"primaryCompletion":21955,"completion":21956,"start":10632,"enrollment":21957,"conditions":21958,"interventions":21959},"NCT01277042","Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)",[87],"2011-09-26","2012-02-28",1212,[8723],[21917,21960],"Engerix-BTM",{"trials":21962,"activeCount":97},[],{"trials":21964,"activeCount":97},[],{"intervention":21966,"totalTrials":181,"cells":21967},"Retigabine",{"EARLY_PHASE1":21968,"PHASE1":21970,"PHASE2":21980,"PHASE3":21982,"PHASE4":22007,"NA":22009},{"trials":21969,"activeCount":97},[],{"trials":21971,"activeCount":97},[21972],{"nctId":21973,"briefTitle":21974,"status":500,"phases":21975,"primaryCompletion":21976,"completion":21976,"start":8697,"enrollment":97,"conditions":21977,"interventions":21979},"NCT01691872","Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects",[85],"2012-10-18",[21978],"Epilepsy, Partial",[21966],{"trials":21981,"activeCount":97},[],{"trials":21983,"activeCount":97},[21984,21994,22001],{"nctId":21985,"briefTitle":21986,"status":145,"phases":21987,"primaryCompletion":21988,"completion":21989,"start":21990,"enrollment":21991,"conditions":21992,"interventions":21993},"NCT00310388","Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097",[87],"2017-04-18","2018-05-24","2006-07-05",376,[12518],[21966],{"nctId":21995,"briefTitle":21996,"status":155,"phases":21997,"primaryCompletion":2355,"completion":2355,"start":749,"enrollment":21998,"conditions":21999,"interventions":22000},"NCT00235755","Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy",[87],539,[13645],[21966,21966],{"nctId":22002,"briefTitle":22003,"status":155,"phases":22004,"primaryCompletion":7954,"completion":7954,"start":8427,"enrollment":10497,"conditions":22005,"interventions":22006},"NCT00232596","Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy",[87],[13645],[21966],{"trials":22008,"activeCount":97},[],{"trials":22010,"activeCount":97},[],{"intervention":4806,"totalTrials":181,"cells":22012},{"EARLY_PHASE1":22013,"PHASE1":22015,"PHASE2":22017,"PHASE3":22023,"PHASE4":22042,"NA":22044},{"trials":22014,"activeCount":97},[],{"trials":22016,"activeCount":97},[],{"trials":22018,"activeCount":97},[22019],{"nctId":21438,"briefTitle":21439,"status":155,"phases":22020,"primaryCompletion":21441,"completion":21442,"start":21443,"enrollment":19270,"conditions":22021,"interventions":22022},[86],[4704,4703],[21446,4806,4805,19386,21447],{"trials":22024,"activeCount":97},[22025,22034,22038],{"nctId":22026,"briefTitle":22027,"status":155,"phases":22028,"primaryCompletion":8426,"completion":2382,"start":4757,"enrollment":22029,"conditions":22030,"interventions":22031},"NCT00345579","Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age",[87],4432,[4704,4703],[22032,4806,22033],"GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014","Pediarix\u002FInfanrix Penta",{"nctId":19422,"briefTitle":19423,"status":155,"phases":22035,"primaryCompletion":19425,"completion":18288,"start":19426,"enrollment":19427,"conditions":22036,"interventions":22037},[87],[4704,4703],[19430,4806,19385,4805,19386,8674,8675],{"nctId":4796,"briefTitle":4797,"status":155,"phases":22039,"primaryCompletion":4799,"completion":4800,"start":4801,"enrollment":4802,"conditions":22040,"interventions":22041},[87],[4702,30,4704,33,3624,24],[4472,4805,4806,4807,4808,4809,4810,4811,4762],{"trials":22043,"activeCount":97},[],{"trials":22045,"activeCount":97},[],{"intervention":22047,"totalTrials":181,"cells":22048},"GSK2894512 1% Cream",{"EARLY_PHASE1":22049,"PHASE1":22051,"PHASE2":22064,"PHASE3":22084,"PHASE4":22094,"NA":22096},{"trials":22050,"activeCount":97},[],{"trials":22052,"activeCount":97},[22053],{"nctId":22054,"briefTitle":22055,"status":500,"phases":22056,"primaryCompletion":22057,"completion":22057,"start":22058,"enrollment":97,"conditions":22059,"interventions":22061},"NCT03201978","A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects",[85],"2018-05-15","2017-12-14",[22060],"Psoriasis",[22062,22063],"GSK2894512 1% CREAM","GSK2894512 MATCHING VEHICLE CREAM",{"trials":22065,"activeCount":97},[22066,22075],{"nctId":22067,"briefTitle":22068,"status":155,"phases":22069,"primaryCompletion":16911,"completion":22070,"start":12065,"enrollment":8493,"conditions":22071,"interventions":22072},"NCT02564042","A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis",[86],"2016-10-05",[22060],[22047,22073,22074],"GSK2894512 0.5% Cream","Vehicle cream",{"nctId":22076,"briefTitle":22077,"status":155,"phases":22078,"primaryCompletion":22079,"completion":22080,"start":22081,"enrollment":14391,"conditions":22082,"interventions":22083},"NCT02564055","A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)",[86],"2017-01-01","2017-01-12","2015-12-01",[21691],[22047,22073,22074],{"trials":22085,"activeCount":97},[22086],{"nctId":22087,"briefTitle":22088,"status":500,"phases":22089,"primaryCompletion":22090,"completion":22090,"start":12811,"enrollment":97,"conditions":22091,"interventions":22092},"NCT03202004","GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis",[87],"2018-09-28",[22060],[22093,22074],"GSK2894512 1% cream",{"trials":22095,"activeCount":97},[],{"trials":22097,"activeCount":97},[],{"intervention":22099,"totalTrials":181,"cells":22100},"Fluticasone furoate\u002FVilanterol Inhalation Powder",{"EARLY_PHASE1":22101,"PHASE1":22103,"PHASE2":22105,"PHASE3":22107,"PHASE4":22142,"NA":22144},{"trials":22102,"activeCount":97},[],{"trials":22104,"activeCount":97},[],{"trials":22106,"activeCount":97},[],{"trials":22108,"activeCount":97},[22109,22119,22127,22136],{"nctId":22110,"briefTitle":22111,"status":155,"phases":22112,"primaryCompletion":4973,"completion":22113,"start":22114,"enrollment":22115,"conditions":22116,"interventions":22117},"NCT01165138","Study HZA106827: Efficacy\u002FSafety Study of Fluticasone Furoate\u002FVilanterol (GW642444) in Adult and Adolescent Asthmatics",[87],"2011-10-19","2010-08-20",612,[18],[22099,22118],"Fluticasone Furoate Inhalation Powder",{"nctId":22120,"briefTitle":22121,"status":155,"phases":22122,"primaryCompletion":7545,"completion":7545,"start":11030,"enrollment":22123,"conditions":22124,"interventions":22125},"NCT01147848","HZA113091 Efficacy and Safety of Fluticasone Furoate\u002FVilanterol (GW642444) in Adults and Adolescents",[87],810,[18],[22099,22126],"Fluticasone propionate\u002Fsalmeterol Inhalation Powder",{"nctId":22128,"briefTitle":22129,"status":155,"phases":22130,"primaryCompletion":2394,"completion":2394,"start":11030,"enrollment":22131,"conditions":22132,"interventions":22133},"NCT01134042","Study HZA106829: Efficacy\u002FSafety Study of Fluticasone Furoate\u002FVilanterol (GW642444) in Adult and Adolescent Asthmatics",[87],587,[18],[22134,22118,22135],"Fluticasone Furoate\u002FVilanterol Inhalation Powder","Fluticasone Propionate Inhalation Powder",{"nctId":22137,"briefTitle":22138,"status":500,"phases":22139,"primaryCompletion":9706,"completion":9706,"start":2427,"enrollment":97,"conditions":22140,"interventions":22141},"NCT01435902","A Study of a New Asthma Medicine in Asthmatics Whose Asthma Worsens With Exercise",[87],[18],[22134,22135],{"trials":22143,"activeCount":97},[],{"trials":22145,"activeCount":97},[],{"intervention":22147,"totalTrials":181,"cells":22148},"FF\u002FGW642444 Inhalation Powder",{"EARLY_PHASE1":22149,"PHASE1":22151,"PHASE2":22153,"PHASE3":22155,"PHASE4":22193,"NA":22195},{"trials":22150,"activeCount":97},[],{"trials":22152,"activeCount":97},[],{"trials":22154,"activeCount":97},[],{"trials":22156,"activeCount":97},[22157,22167,22176,22184],{"nctId":22158,"briefTitle":22159,"status":155,"phases":22160,"primaryCompletion":4973,"completion":22161,"start":22162,"enrollment":22163,"conditions":22164,"interventions":22165},"NCT01009463","A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)\u002FGW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2011-10-31","2009-09-25",1626,[15],[22147,22166],"GW642444 Inhalation Powder",{"nctId":22168,"briefTitle":22169,"status":155,"phases":22170,"primaryCompletion":21291,"completion":11851,"start":22171,"enrollment":22172,"conditions":22173,"interventions":22174},"NCT01053988","A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)\u002FGW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2009-10-05",1031,[15],[22147,22175,22166],"FF Inhalation Powder",{"nctId":22177,"briefTitle":22178,"status":155,"phases":22179,"primaryCompletion":4973,"completion":22180,"start":22162,"enrollment":22181,"conditions":22182,"interventions":22183},"NCT01017952","A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)\u002FGW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2011-10-17",1635,[15],[22147,22166],{"nctId":22185,"briefTitle":22186,"status":155,"phases":22187,"primaryCompletion":21291,"completion":22188,"start":22189,"enrollment":22190,"conditions":22191,"interventions":22192},"NCT01054885","Efficacy and Safety Study of Fluticasone Furoate (FF)\u002FGW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2011-02-08","2009-10-19",1226,[15],[22175,22147,22166],{"trials":22194,"activeCount":97},[],{"trials":22196,"activeCount":97},[],{"intervention":22166,"totalTrials":181,"cells":22198},{"EARLY_PHASE1":22199,"PHASE1":22201,"PHASE2":22203,"PHASE3":22205,"PHASE4":22223,"NA":22225},{"trials":22200,"activeCount":97},[],{"trials":22202,"activeCount":97},[],{"trials":22204,"activeCount":97},[],{"trials":22206,"activeCount":97},[22207,22211,22215,22219],{"nctId":22158,"briefTitle":22159,"status":155,"phases":22208,"primaryCompletion":4973,"completion":22161,"start":22162,"enrollment":22163,"conditions":22209,"interventions":22210},[87],[15],[22147,22166],{"nctId":22168,"briefTitle":22169,"status":155,"phases":22212,"primaryCompletion":21291,"completion":11851,"start":22171,"enrollment":22172,"conditions":22213,"interventions":22214},[87],[15],[22147,22175,22166],{"nctId":22177,"briefTitle":22178,"status":155,"phases":22216,"primaryCompletion":4973,"completion":22180,"start":22162,"enrollment":22181,"conditions":22217,"interventions":22218},[87],[15],[22147,22166],{"nctId":22185,"briefTitle":22186,"status":155,"phases":22220,"primaryCompletion":21291,"completion":22188,"start":22189,"enrollment":22190,"conditions":22221,"interventions":22222},[87],[15],[22175,22147,22166],{"trials":22224,"activeCount":97},[],{"trials":22226,"activeCount":97},[],{"intervention":22074,"totalTrials":181,"cells":22228},{"EARLY_PHASE1":22229,"PHASE1":22231,"PHASE2":22244,"PHASE3":22254,"PHASE4":22260,"NA":22262},{"trials":22230,"activeCount":97},[],{"trials":22232,"activeCount":97},[22233],{"nctId":22234,"briefTitle":22235,"status":155,"phases":22236,"primaryCompletion":22237,"completion":22237,"start":22238,"enrollment":93,"conditions":22239,"interventions":22240},"NCT02637206","Skin Irritation Study of GSK2894512 Cream",[85],"2015-12-02","2015-10-27",[21691],[22241,22242,22243],"GSK2894512 Cream","Vehicle Cream","Empty Patch",{"trials":22245,"activeCount":97},[22246,22250],{"nctId":22067,"briefTitle":22068,"status":155,"phases":22247,"primaryCompletion":16911,"completion":22070,"start":12065,"enrollment":8493,"conditions":22248,"interventions":22249},[86],[22060],[22047,22073,22074],{"nctId":22076,"briefTitle":22077,"status":155,"phases":22251,"primaryCompletion":22079,"completion":22080,"start":22081,"enrollment":14391,"conditions":22252,"interventions":22253},[86],[21691],[22047,22073,22074],{"trials":22255,"activeCount":97},[22256],{"nctId":22087,"briefTitle":22088,"status":500,"phases":22257,"primaryCompletion":22090,"completion":22090,"start":12811,"enrollment":97,"conditions":22258,"interventions":22259},[87],[22060],[22093,22074],{"trials":22261,"activeCount":97},[],{"trials":22263,"activeCount":97},[],{"intervention":22265,"totalTrials":181,"cells":22266},"sumatriptan succinate\u002Fnaproxen sodium",{"EARLY_PHASE1":22267,"PHASE1":22269,"PHASE2":22271,"PHASE3":22273,"PHASE4":22300,"NA":22302},{"trials":22268,"activeCount":97},[],{"trials":22270,"activeCount":97},[],{"trials":22272,"activeCount":97},[],{"trials":22274,"activeCount":97},[22275,22282,22288,22294],{"nctId":22276,"briefTitle":22277,"status":155,"phases":22278,"primaryCompletion":4843,"completion":4843,"start":2383,"enrollment":265,"conditions":22279,"interventions":22281},"NCT00329355","Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)",[87],[22280,14168],"Migraine",[22265],{"nctId":22283,"briefTitle":22284,"status":155,"phases":22285,"primaryCompletion":4843,"completion":4843,"start":2383,"enrollment":4346,"conditions":22286,"interventions":22287},"NCT00329459","Treximet (Sumatriptan\u002FNaproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea",[87],[14168],[22265],{"nctId":22289,"briefTitle":22290,"status":155,"phases":22291,"primaryCompletion":8852,"completion":8852,"start":2805,"enrollment":9618,"conditions":22292,"interventions":22293},"NCT00240630","Treximet (Sumatriptan\u002FNaproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks",[87],[14168,22280],[22265],{"nctId":22295,"briefTitle":22296,"status":155,"phases":22297,"primaryCompletion":8852,"completion":8852,"start":2805,"enrollment":11749,"conditions":22298,"interventions":22299},"NCT00240617","Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks",[87],[14168],[22265],{"trials":22301,"activeCount":97},[],{"trials":22303,"activeCount":97},[],{"intervention":22305,"totalTrials":181,"cells":22306},"lamictal",{"EARLY_PHASE1":22307,"PHASE1":22309,"PHASE2":22311,"PHASE3":22313,"PHASE4":22344,"NA":22346},{"trials":22308,"activeCount":97},[],{"trials":22310,"activeCount":97},[],{"trials":22312,"activeCount":97},[],{"trials":22314,"activeCount":97},[22315,22323,22330,22337],{"nctId":22316,"briefTitle":22317,"status":155,"phases":22318,"primaryCompletion":22319,"completion":22319,"start":5018,"enrollment":10489,"conditions":22320,"interventions":22322},"NCT00723450","Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients",[87],"2013-08",[22321],"Bipolar Disorder",[22305],{"nctId":22324,"briefTitle":22325,"status":155,"phases":22326,"primaryCompletion":13418,"completion":8720,"start":3111,"enrollment":454,"conditions":22327,"interventions":22328},"NCT01431976","Clinical Study of Lamotrigine to Treat Newly Diagnosed Typical Absence Seizure in Children and Adolescents",[87],[12518],[22329],"Lamictal",{"nctId":22331,"briefTitle":22332,"status":155,"phases":22333,"primaryCompletion":503,"completion":22334,"start":3111,"enrollment":730,"conditions":22335,"interventions":22336},"NCT01431963","Clinical Study of Lamotrigine to Treat Newly Diagnosed Epilepsy",[87],"2014-10",[12518],[22329],{"nctId":22338,"briefTitle":22339,"status":155,"phases":22340,"primaryCompletion":8826,"completion":22341,"start":19095,"enrollment":931,"conditions":22342,"interventions":22343},"NCT00395694","Clinical Evaluation of BW430C in Epilepsy",[87],"2009-03-26",[12518],[22305],{"trials":22345,"activeCount":97},[],{"trials":22347,"activeCount":97},[],{"intervention":8966,"totalTrials":181,"cells":22349},{"EARLY_PHASE1":22350,"PHASE1":22352,"PHASE2":22354,"PHASE3":22356,"PHASE4":22381,"NA":22383},{"trials":22351,"activeCount":97},[],{"trials":22353,"activeCount":97},[],{"trials":22355,"activeCount":97},[],{"trials":22357,"activeCount":97},[22358,22365,22371,22375],{"nctId":22359,"briefTitle":22360,"status":155,"phases":22361,"primaryCompletion":8963,"completion":8963,"start":1380,"enrollment":22362,"conditions":22363,"interventions":22364},"NCT00258700","Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine",[87],478,[4704,4703],[8966],{"nctId":22366,"briefTitle":22367,"status":155,"phases":22368,"primaryCompletion":2814,"completion":2814,"start":11097,"enrollment":9964,"conditions":22369,"interventions":22370},"NCT00323050","Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects",[87],[4703,4704],[8966],{"nctId":8960,"briefTitle":8961,"status":155,"phases":22372,"primaryCompletion":8963,"completion":3551,"start":2383,"enrollment":4771,"conditions":22373,"interventions":22374},[87],[4704,4703],[8966,8967,8968,4808,8969,8970,8971],{"nctId":22376,"briefTitle":22377,"status":155,"phases":22378,"primaryCompletion":2814,"completion":8427,"start":2814,"enrollment":1662,"conditions":22379,"interventions":22380},"NCT00263653","Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197",[87],[4704,4703],[8966],{"trials":22382,"activeCount":97},[],{"trials":22384,"activeCount":97},[],{"intervention":517,"totalTrials":181,"cells":22386},{"EARLY_PHASE1":22387,"PHASE1":22389,"PHASE2":22398,"PHASE3":22404,"PHASE4":22414,"NA":22416},{"trials":22388,"activeCount":97},[],{"trials":22390,"activeCount":97},[22391],{"nctId":22392,"briefTitle":22393,"status":155,"phases":22394,"primaryCompletion":18388,"completion":18388,"start":12180,"enrollment":1298,"conditions":22395,"interventions":22396},"NCT00500058","A Phase I, Dose-Escalation Study to Assess the Safety and Biological Activity of Recombinant Human Interleukin-18",[85],[4574],[22397,517],"SB-485232",{"trials":22399,"activeCount":97},[22400],{"nctId":509,"briefTitle":510,"status":155,"phases":22401,"primaryCompletion":512,"completion":512,"start":513,"enrollment":34,"conditions":22402,"interventions":22403},[86],[515],[53,517],{"trials":22405,"activeCount":97},[22406,22410],{"nctId":550,"briefTitle":551,"status":155,"phases":22407,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":22408,"interventions":22409},[87],[435],[53,517,559,560,560,561],{"nctId":20502,"briefTitle":20503,"status":155,"phases":22411,"primaryCompletion":1429,"completion":9697,"start":8478,"enrollment":473,"conditions":22412,"interventions":22413},[87],[4574],[20456,517],{"trials":22415,"activeCount":97},[],{"trials":22417,"activeCount":97},[],{"intervention":22419,"totalTrials":593,"cells":22420},"GSK1325760A",{"EARLY_PHASE1":22421,"PHASE1":22423,"PHASE2":22431,"PHASE3":22439,"PHASE4":22449,"NA":22451},{"trials":22422,"activeCount":97},[],{"trials":22424,"activeCount":97},[22425],{"nctId":22426,"briefTitle":22427,"status":155,"phases":22428,"primaryCompletion":8406,"completion":8406,"start":5196,"enrollment":2045,"conditions":22429,"interventions":22430},"NCT00424034","A Study of GSK1325760A in Healthy Japanese Subjects",[85],[7524],[22419],{"trials":22432,"activeCount":97},[22433],{"nctId":22434,"briefTitle":22435,"status":155,"phases":22436,"primaryCompletion":2813,"completion":2813,"start":2336,"enrollment":463,"conditions":22437,"interventions":22438},"NCT00540436","Evaluate the Efficacy, Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension",[86],[17209],[22419],{"trials":22440,"activeCount":97},[22441],{"nctId":22442,"briefTitle":22443,"status":155,"phases":22444,"primaryCompletion":22445,"completion":22445,"start":9737,"enrollment":1279,"conditions":22446,"interventions":22448},"NCT00554619","A Study to Evaluate GSK1325760A - a Long-Term Extension Study",[87],"2011-01",[22447,17209],"Pulmonary Arterial Hypertension",[22419],{"trials":22450,"activeCount":97},[],{"trials":22452,"activeCount":97},[],{"intervention":22454,"totalTrials":593,"cells":22455},"Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted",{"EARLY_PHASE1":22456,"PHASE1":22458,"PHASE2":22460,"PHASE3":22476,"PHASE4":22488,"NA":22490},{"trials":22457,"activeCount":97},[],{"trials":22459,"activeCount":97},[],{"trials":22461,"activeCount":97},[22462,22468],{"nctId":22463,"briefTitle":22464,"status":155,"phases":22465,"primaryCompletion":19121,"completion":19121,"start":17885,"enrollment":414,"conditions":22466,"interventions":22467},"NCT00742885","Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine",[86],[21],[22454],{"nctId":22469,"briefTitle":22470,"status":155,"phases":22471,"primaryCompletion":22472,"completion":876,"start":22473,"enrollment":868,"conditions":22474,"interventions":22475},"NCT01416571","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults",[86],"2011-11-29","2011-08-12",[21],[22454],{"trials":22477,"activeCount":97},[22478],{"nctId":22479,"briefTitle":22480,"status":155,"phases":22481,"primaryCompletion":22482,"completion":22483,"start":22484,"enrollment":22485,"conditions":22486,"interventions":22487},"NCT00616928","Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years",[87],"2008-10-15","2009-03-19","2008-01-23",4561,[21],[22454],{"trials":22489,"activeCount":97},[],{"trials":22491,"activeCount":97},[],{"intervention":5103,"totalTrials":593,"cells":22493},{"EARLY_PHASE1":22494,"PHASE1":22496,"PHASE2":22498,"PHASE3":22520,"PHASE4":22526,"NA":22528},{"trials":22495,"activeCount":97},[],{"trials":22497,"activeCount":97},[],{"trials":22499,"activeCount":97},[22500,22512],{"nctId":22501,"briefTitle":22502,"status":155,"phases":22503,"primaryCompletion":3228,"completion":3228,"start":22504,"enrollment":22505,"conditions":22506,"interventions":22507},"NCT05082285","A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants",[86],"2021-11-29",724,[992],[22508,22509,22510,5103,22511],"MenABCWY-2Gen low dose vaccine","MenABCWY-2Gen high dose vaccine","MenABCWY-1Gen vaccine","MenACWY-TT vaccine",{"nctId":22513,"briefTitle":22514,"status":155,"phases":22515,"primaryCompletion":6574,"completion":6574,"start":22516,"enrollment":22517,"conditions":22518,"interventions":22519},"NCT04886154","A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults",[85,86],"2021-06-14",1440,[992],[22508,22509,5103,5102],{"trials":22521,"activeCount":97},[22522],{"nctId":5094,"briefTitle":5095,"status":155,"phases":22523,"primaryCompletion":5097,"completion":5098,"start":5099,"enrollment":2058,"conditions":22524,"interventions":22525},[87],[1005],[5064,5102,5103],{"trials":22527,"activeCount":97},[],{"trials":22529,"activeCount":97},[],{"intervention":9938,"totalTrials":593,"cells":22531},{"EARLY_PHASE1":22532,"PHASE1":22534,"PHASE2":22536,"PHASE3":22546,"PHASE4":22561,"NA":22563},{"trials":22533,"activeCount":97},[],{"trials":22535,"activeCount":97},[],{"trials":22537,"activeCount":97},[22538],{"nctId":22539,"briefTitle":22540,"status":155,"phases":22541,"primaryCompletion":18699,"completion":22542,"start":21804,"enrollment":303,"conditions":22543,"interventions":22544},"NCT01974895","Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age",[86],"2014-07-03",[21],[9938,22545],"Fluzone®",{"trials":22547,"activeCount":97},[22548,22552],{"nctId":9931,"briefTitle":9932,"status":155,"phases":22549,"primaryCompletion":9934,"completion":9934,"start":5268,"enrollment":9935,"conditions":22550,"interventions":22551},[87],[21],[9938,9920],{"nctId":22553,"briefTitle":22554,"status":155,"phases":22555,"primaryCompletion":22556,"completion":22556,"start":18172,"enrollment":22557,"conditions":22558,"interventions":22559},"NCT01440387","A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older",[87],"2011-10-22",112,[21],[22560],"FLULAVAL® QUADRIVALENT",{"trials":22562,"activeCount":97},[],{"trials":22564,"activeCount":97},[],{"intervention":11068,"totalTrials":593,"cells":22566},{"EARLY_PHASE1":22567,"PHASE1":22569,"PHASE2":22571,"PHASE3":22582,"PHASE4":22598,"NA":22600},{"trials":22568,"activeCount":97},[],{"trials":22570,"activeCount":97},[],{"trials":22572,"activeCount":97},[22573],{"nctId":22574,"briefTitle":22575,"status":155,"phases":22576,"primaryCompletion":11274,"completion":5268,"start":22577,"enrollment":4521,"conditions":22578,"interventions":22579},"NCT00871338","Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants",[86],"2009-06-24",[4703,4704],[22580,11068,11067,22581,19196],"GSK2197870A","Pediacel™",{"trials":22583,"activeCount":97},[22584,22588],{"nctId":11060,"briefTitle":11061,"status":155,"phases":22585,"primaryCompletion":11063,"completion":11063,"start":8207,"enrollment":11064,"conditions":22586,"interventions":22587},[87],[4704,4703],[11067,8967,11068,11069],{"nctId":22589,"briefTitle":22590,"status":155,"phases":22591,"primaryCompletion":738,"completion":22592,"start":9026,"enrollment":22593,"conditions":22594,"interventions":22595},"NCT00652951","Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV\u002FHib",[87],"2010-12-01",780,[3637],[22596,22597,22581,11068],"GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A","Infanrix™ hexa.",{"trials":22599,"activeCount":97},[],{"trials":22601,"activeCount":97},[],{"intervention":22603,"totalTrials":593,"cells":22604},"Dutasteride 0.5mg",{"EARLY_PHASE1":22605,"PHASE1":22607,"PHASE2":22609,"PHASE3":22611,"PHASE4":22642,"NA":22644},{"trials":22606,"activeCount":97},[],{"trials":22608,"activeCount":97},[],{"trials":22610,"activeCount":97},[],{"trials":22612,"activeCount":97},[22613,22622,22630],{"nctId":22614,"briefTitle":22615,"status":155,"phases":22616,"primaryCompletion":2794,"completion":2794,"start":8426,"enrollment":22617,"conditions":22618,"interventions":22620},"NCT00527605","Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)",[87],253,[22619,12263],"Benign Prostatic Hyperplasia",[22603,22621],"Dutasteride matched placebo",{"nctId":22623,"briefTitle":22624,"status":155,"phases":22625,"primaryCompletion":4737,"completion":4737,"start":10383,"enrollment":1150,"conditions":22626,"interventions":22628},"NCT00441116","A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia",[87],[22627],"Alopecia",[22629],"Dutasteride 0.5mg oral",{"nctId":22631,"briefTitle":22632,"status":155,"phases":22633,"primaryCompletion":22634,"completion":22634,"start":22635,"enrollment":22636,"conditions":22637,"interventions":22638},"NCT02058368","Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia",[87],"2017-03-03","2014-02-10",607,[12263],[22603,22639,22640,22641],"Dutasteride placebo","Tamsulosin 0.2mg","Disintegrating placebo tamsulosin",{"trials":22643,"activeCount":97},[],{"trials":22645,"activeCount":97},[],{"intervention":22647,"totalTrials":593,"cells":22648},"GSK2585823",{"EARLY_PHASE1":22649,"PHASE1":22651,"PHASE2":22669,"PHASE3":22671,"PHASE4":22681,"NA":22683},{"trials":22650,"activeCount":97},[],{"trials":22652,"activeCount":97},[22653,22660],{"nctId":22654,"briefTitle":22655,"status":155,"phases":22656,"primaryCompletion":22657,"completion":22657,"start":21956,"enrollment":1459,"conditions":22658,"interventions":22659},"NCT01527123","A Study to Evaluate the Pharmacokinetics of Benzoic Acid and Hippuric Acid After Topical Administration of GSK2585823 in Japanese Subjects With Acne Vulgaris",[85],"2012-06-01",[15087],[22647],{"nctId":22661,"briefTitle":22662,"status":155,"phases":22663,"primaryCompletion":18183,"completion":18183,"start":22664,"enrollment":454,"conditions":22665,"interventions":22666},"NCT01428466","Japanese Phase 1 Study of GSK2585823",[85],"2010-11-18",[15087],[22647,22667,22668],"Benzoyl peroxide 3%","Benzoyl peroxide 5%",{"trials":22670,"activeCount":97},[],{"trials":22672,"activeCount":97},[22673],{"nctId":22674,"briefTitle":22675,"status":155,"phases":22676,"primaryCompletion":9952,"completion":9952,"start":22677,"enrollment":1924,"conditions":22678,"interventions":22679},"NCT01445301","Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects",[87],"2011-09-27",[15087],[22647,22680],"CLDM 1% gel twice daily",{"trials":22682,"activeCount":97},[],{"trials":22684,"activeCount":97},[],{"intervention":22686,"totalTrials":593,"cells":22687},"chlorproguanil-dapsone-artesunate",{"EARLY_PHASE1":22688,"PHASE1":22690,"PHASE2":22692,"PHASE3":22701,"PHASE4":22718,"NA":22720},{"trials":22689,"activeCount":97},[],{"trials":22691,"activeCount":97},[],{"trials":22693,"activeCount":97},[22694],{"nctId":22695,"briefTitle":22696,"status":155,"phases":22697,"primaryCompletion":1380,"completion":1380,"start":10886,"enrollment":201,"conditions":22698,"interventions":22699},"NCT00519467","Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria",[86],[3287],[22700],"Chlorproguanil-dapsone-artesunate",{"trials":22702,"activeCount":97},[22703,22710],{"nctId":22704,"briefTitle":22705,"status":155,"phases":22706,"primaryCompletion":2835,"completion":2835,"start":4844,"enrollment":10685,"conditions":22707,"interventions":22708},"NCT00371735","Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria",[87],[5943],[22686,22709],"chlorproguanil-dapsone",{"nctId":22711,"briefTitle":22712,"status":155,"phases":22713,"primaryCompletion":2336,"completion":2336,"start":8852,"enrollment":22714,"conditions":22715,"interventions":22716},"NCT00344006","Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria",[87],1395,[5943],[22686,22717],"artemether-lumefantrine",{"trials":22719,"activeCount":97},[],{"trials":22721,"activeCount":97},[],{"intervention":8653,"totalTrials":593,"cells":22723},{"EARLY_PHASE1":22724,"PHASE1":22726,"PHASE2":22739,"PHASE3":22745,"PHASE4":22751,"NA":22753},{"trials":22725,"activeCount":97},[],{"trials":22727,"activeCount":97},[22728],{"nctId":22729,"briefTitle":22730,"status":155,"phases":22731,"primaryCompletion":22732,"completion":22733,"start":20266,"enrollment":6814,"conditions":22734,"interventions":22736},"NCT02491463","A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults",[85],"2016-04-08","2017-01-26",[22735],"Respiratory Synctial Virus Infections",[22737,22738,8653],"GSK3389245A_LD GROUP","GSK3389245A_HD GROUP",{"trials":22740,"activeCount":97},[22741],{"nctId":8644,"briefTitle":8645,"status":155,"phases":22742,"primaryCompletion":8647,"completion":8648,"start":8649,"enrollment":8650,"conditions":22743,"interventions":22744},[86],[992],[8653,4694,8654],{"trials":22746,"activeCount":97},[22747],{"nctId":11168,"briefTitle":11169,"status":155,"phases":22748,"primaryCompletion":11171,"completion":11171,"start":11172,"enrollment":1608,"conditions":22749,"interventions":22750},[87],[992],[8653,4811,4805,4810,4762,8674,8675,11175],{"trials":22752,"activeCount":97},[],{"trials":22754,"activeCount":97},[],{"intervention":12323,"totalTrials":593,"cells":22756},{"EARLY_PHASE1":22757,"PHASE1":22759,"PHASE2":22761,"PHASE3":22763,"PHASE4":22777,"NA":22779},{"trials":22758,"activeCount":97},[],{"trials":22760,"activeCount":97},[],{"trials":22762,"activeCount":97},[],{"trials":22764,"activeCount":97},[22765,22769,22773],{"nctId":12316,"briefTitle":12317,"status":155,"phases":22766,"primaryCompletion":12319,"completion":12320,"start":8824,"enrollment":536,"conditions":22767,"interventions":22768},[87],[3637],[4883,12323,12324],{"nctId":19117,"briefTitle":19118,"status":155,"phases":22770,"primaryCompletion":19120,"completion":19120,"start":19121,"enrollment":3635,"conditions":22771,"interventions":22772},[87],[3637,8918],[4744,12323,4810,19098],{"nctId":18802,"briefTitle":18803,"status":155,"phases":22774,"primaryCompletion":18805,"completion":18806,"start":18807,"enrollment":12261,"conditions":22775,"interventions":22776},[87],[3637],[3639,12323,18810,4762,18811],{"trials":22778,"activeCount":97},[],{"trials":22780,"activeCount":97},[],{"intervention":12324,"totalTrials":593,"cells":22782},{"EARLY_PHASE1":22783,"PHASE1":22785,"PHASE2":22787,"PHASE3":22798,"PHASE4":22808,"NA":22810},{"trials":22784,"activeCount":97},[],{"trials":22786,"activeCount":97},[],{"trials":22788,"activeCount":97},[22789],{"nctId":22790,"briefTitle":22791,"status":155,"phases":22792,"primaryCompletion":22793,"completion":11940,"start":22794,"enrollment":414,"conditions":22795,"interventions":22796},"NCT00263666","A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South Africa",[86],"2008-02-07","2005-03-16",[4759],[4762,22797,12324],"Tritanrix-HB+Hib",{"trials":22799,"activeCount":97},[22800,22804],{"nctId":12316,"briefTitle":12317,"status":155,"phases":22801,"primaryCompletion":12319,"completion":12320,"start":8824,"enrollment":536,"conditions":22802,"interventions":22803},[87],[3637],[4883,12323,12324],{"nctId":19264,"briefTitle":19265,"status":155,"phases":22805,"primaryCompletion":19267,"completion":19268,"start":19269,"enrollment":19270,"conditions":22806,"interventions":22807},[87],[3637],[4683,19098,4810,12324,19273,4745],{"trials":22809,"activeCount":97},[],{"trials":22811,"activeCount":97},[],{"intervention":10101,"totalTrials":593,"cells":22813},{"EARLY_PHASE1":22814,"PHASE1":22816,"PHASE2":22818,"PHASE3":22824,"PHASE4":22834,"NA":22836},{"trials":22815,"activeCount":97},[],{"trials":22817,"activeCount":97},[],{"trials":22819,"activeCount":97},[22820],{"nctId":10272,"briefTitle":10273,"status":155,"phases":22821,"primaryCompletion":10275,"completion":10276,"start":10277,"enrollment":10278,"conditions":22822,"interventions":22823},[86],[992],[10216,10101,10263,8971,8292],{"trials":22825,"activeCount":97},[22826,22830],{"nctId":10284,"briefTitle":10285,"status":155,"phases":22827,"primaryCompletion":10287,"completion":10287,"start":10288,"enrollment":1534,"conditions":22828,"interventions":22829},[87],[24],[10263,10101,10291],{"nctId":10094,"briefTitle":10095,"status":155,"phases":22831,"primaryCompletion":9765,"completion":9765,"start":10097,"enrollment":10098,"conditions":22832,"interventions":22833},[87],[4704,30,33,4702,3624],[10065,10101],{"trials":22835,"activeCount":97},[],{"trials":22837,"activeCount":97},[],{"intervention":20350,"totalTrials":593,"cells":22839},{"EARLY_PHASE1":22840,"PHASE1":22842,"PHASE2":22856,"PHASE3":22858,"PHASE4":22864,"NA":22866},{"trials":22841,"activeCount":97},[],{"trials":22843,"activeCount":97},[22844,22848],{"nctId":1330,"briefTitle":1331,"status":155,"phases":22845,"primaryCompletion":1333,"completion":1333,"start":1334,"enrollment":1335,"conditions":22846,"interventions":22847},[85],[1337],[1339,1340,1341],{"nctId":22849,"briefTitle":22850,"status":155,"phases":22851,"primaryCompletion":22852,"completion":22852,"start":2373,"enrollment":105,"conditions":22853,"interventions":22854},"NCT00404274","A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers",[85],"2007-03-18",[1337],[20350,22855],"Warfarin oral",{"trials":22857,"activeCount":97},[],{"trials":22859,"activeCount":97},[22860],{"nctId":20343,"briefTitle":20344,"status":155,"phases":22861,"primaryCompletion":8426,"completion":11992,"start":8963,"enrollment":1960,"conditions":22862,"interventions":22863},[87],[20347,20348,1337],[20350,20351,20352,20353],{"trials":22865,"activeCount":97},[],{"trials":22867,"activeCount":97},[],{"intervention":9630,"totalTrials":593,"cells":22869},{"EARLY_PHASE1":22870,"PHASE1":22872,"PHASE2":22884,"PHASE3":22886,"PHASE4":22903,"NA":22905},{"trials":22871,"activeCount":97},[],{"trials":22873,"activeCount":97},[22874],{"nctId":22875,"briefTitle":22876,"status":155,"phases":22877,"primaryCompletion":19976,"completion":19976,"start":3425,"enrollment":1298,"conditions":22878,"interventions":22879},"NCT01213849","Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF\u002FVI Via an Inhaler",[85],[18],[22880,22881,22882,22883],"Fluticasone furoate 50 mcg","Fluticasone furoate 100 mcg","Fluticasone furoate 200 mcg","Vilanterol 25 mcg",{"trials":22885,"activeCount":97},[],{"trials":22887,"activeCount":97},[22888,22892],{"nctId":9622,"briefTitle":9623,"status":155,"phases":22889,"primaryCompletion":9625,"completion":9625,"start":9626,"enrollment":9627,"conditions":22890,"interventions":22891},[87],[18],[9546,9630,9631,9632,9633,9634],{"nctId":22893,"briefTitle":22894,"status":155,"phases":22895,"primaryCompletion":8395,"completion":22896,"start":22897,"enrollment":22898,"conditions":22899,"interventions":22900},"NCT01686633","An Efficacy and Safety Study of Fluticasone Furoate\u002FVilanterol (FF\u002FVI) 200\u002F25 Microgram (mcg) , FF\u002FVI 100\u002F25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.",[87],"2013-10-15","2012-09-20",1040,[18],[22901,22902,9630],"Fluticasone Furoate\u002F Vilanterol 200\u002F25 mcg","Fluticasone Furoate\u002F Vilanterol 100\u002F25 mcg",{"trials":22904,"activeCount":97},[],{"trials":22906,"activeCount":97},[],{"intervention":22908,"totalTrials":593,"cells":22909},"Retosiban",{"EARLY_PHASE1":22910,"PHASE1":22912,"PHASE2":22924,"PHASE3":22926,"PHASE4":22944,"NA":22946},{"trials":22911,"activeCount":97},[],{"trials":22913,"activeCount":97},[22914],{"nctId":22915,"briefTitle":22916,"status":155,"phases":22917,"primaryCompletion":22918,"completion":22918,"start":22919,"enrollment":1634,"conditions":22920,"interventions":22922},"NCT01867996","A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)",[85],"2013-09-26","2013-06-11",[22921],"Obstetric Labour, Premature",[22908,22923],"EFZ 600 mg",{"trials":22925,"activeCount":97},[],{"trials":22927,"activeCount":97},[22928,22937],{"nctId":22929,"briefTitle":22930,"status":145,"phases":22931,"primaryCompletion":22932,"completion":22932,"start":22933,"enrollment":105,"conditions":22934,"interventions":22935},"NCT02292771","A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour",[87],"2017-08-25","2015-03-16",[22921],[22908,22936],"Atosiban",{"nctId":22938,"briefTitle":22939,"status":155,"phases":22940,"primaryCompletion":22941,"completion":22941,"start":12041,"enrollment":11018,"conditions":22942,"interventions":22943},"NCT02292784","Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies",[87],"2019-09-02",[22921],[22908,22936],{"trials":22945,"activeCount":97},[],{"trials":22947,"activeCount":97},[],{"intervention":4707,"totalTrials":593,"cells":22949},{"EARLY_PHASE1":22950,"PHASE1":22952,"PHASE2":22954,"PHASE3":22960,"PHASE4":22975,"NA":22977},{"trials":22951,"activeCount":97},[],{"trials":22953,"activeCount":97},[],{"trials":22955,"activeCount":97},[22956],{"nctId":4696,"briefTitle":4697,"status":145,"phases":22957,"primaryCompletion":4699,"completion":4699,"start":4700,"enrollment":433,"conditions":22958,"interventions":22959},[86],[33,4702,4703,4704,30,3624,24],[4706,4472,4707],{"trials":22961,"activeCount":97},[22962,22971],{"nctId":22963,"briefTitle":22964,"status":155,"phases":22965,"primaryCompletion":22966,"completion":8916,"start":22967,"enrollment":770,"conditions":22968,"interventions":22969},"NCT00674583","Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children",[87],"2008-09-02","2008-05-09",[992],[22970,4707],"GSK Biologicals' meningococcal vaccine GSK134612",{"nctId":5050,"briefTitle":5051,"status":155,"phases":22972,"primaryCompletion":5053,"completion":5054,"start":5055,"enrollment":5056,"conditions":22973,"interventions":22974},[87],[992,5046],[4486,4707],{"trials":22976,"activeCount":97},[],{"trials":22978,"activeCount":97},[],{"intervention":20891,"totalTrials":593,"cells":22980},{"EARLY_PHASE1":22981,"PHASE1":22983,"PHASE2":22993,"PHASE3":22999,"PHASE4":23011,"NA":23013},{"trials":22982,"activeCount":97},[],{"trials":22984,"activeCount":97},[22985],{"nctId":22986,"briefTitle":22987,"status":500,"phases":22988,"primaryCompletion":22989,"completion":22989,"start":22990,"enrollment":97,"conditions":22991,"interventions":22992},"NCT05304130","A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of Otilimab",[85],"2023-05-04","2023-02-08",[8788],[20891],{"trials":22994,"activeCount":97},[22995],{"nctId":20881,"briefTitle":20882,"status":155,"phases":22996,"primaryCompletion":20884,"completion":20885,"start":20886,"enrollment":20887,"conditions":22997,"interventions":22998},[86],[20889],[20891,437],{"trials":23000,"activeCount":97},[23001],{"nctId":23002,"briefTitle":23003,"status":145,"phases":23004,"primaryCompletion":23005,"completion":23005,"start":23006,"enrollment":23007,"conditions":23008,"interventions":23009},"NCT04333147","Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)",[87],"2023-02-24","2020-05-12",2916,[8788],[20891,23010],"csDMARD",{"trials":23012,"activeCount":97},[],{"trials":23014,"activeCount":97},[],{"intervention":23016,"totalTrials":593,"cells":23017},"ActHIB®",{"EARLY_PHASE1":23018,"PHASE1":23020,"PHASE2":23022,"PHASE3":23050,"PHASE4":23064,"NA":23066},{"trials":23019,"activeCount":97},[],{"trials":23021,"activeCount":97},[],{"trials":23023,"activeCount":97},[23024,23037],{"nctId":23025,"briefTitle":23026,"status":155,"phases":23027,"primaryCompletion":23028,"completion":23029,"start":2374,"enrollment":23030,"conditions":23031,"interventions":23032},"NCT00134719","Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines",[86],"2006-07-24","2007-02-21",1104,[4703,4704],[23033,23034,23035,23016,23036,10583,10546,10573],"MenHibrix","Infanrix® Penta","Prevenar®","Meningitec®",{"nctId":23038,"briefTitle":23039,"status":155,"phases":23040,"primaryCompletion":23041,"completion":23042,"start":23043,"enrollment":23044,"conditions":23045,"interventions":23046},"NCT00127855","Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccine",[86],"2004-02-01","2004-02-12","2003-03-01",409,[4704,4703],[23047,23036,23016,23034,23035,23048,23049],"Hib-MenCY-TT vaccine","Mencevax® ACWY","PRP",{"trials":23051,"activeCount":97},[23052],{"nctId":23053,"briefTitle":23054,"status":155,"phases":23055,"primaryCompletion":23056,"completion":23057,"start":11940,"enrollment":23058,"conditions":23059,"interventions":23060},"NCT00614614","Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014",[87],"2009-07-31","2009-09-17",1558,[992],[23061,23062,23063,23016,10570],"GSK Biologicals' Meningococcal vaccine GSK134612","GSK Biologicals' Hib-meningococcal vaccine GSK 792014","Infanrix®",{"trials":23065,"activeCount":97},[],{"trials":23067,"activeCount":97},[],{"intervention":10546,"totalTrials":593,"cells":23069},{"EARLY_PHASE1":23070,"PHASE1":23072,"PHASE2":23074,"PHASE3":23084,"PHASE4":23090,"NA":23092},{"trials":23071,"activeCount":97},[],{"trials":23073,"activeCount":97},[],{"trials":23075,"activeCount":97},[23076,23080],{"nctId":23025,"briefTitle":23026,"status":155,"phases":23077,"primaryCompletion":23028,"completion":23029,"start":2374,"enrollment":23030,"conditions":23078,"interventions":23079},[86],[4703,4704],[23033,23034,23035,23016,23036,10583,10546,10573],{"nctId":10535,"briefTitle":10536,"status":155,"phases":23081,"primaryCompletion":10538,"completion":10539,"start":10540,"enrollment":10541,"conditions":23082,"interventions":23083},[86],[2484,2485,2486,8671],[10544,10545,10546,10526,10547],{"trials":23085,"activeCount":97},[23086],{"nctId":10575,"briefTitle":10576,"status":155,"phases":23087,"primaryCompletion":10578,"completion":10578,"start":10579,"enrollment":10580,"conditions":23088,"interventions":23089},[87],[7966],[10526,10583,10584],{"trials":23091,"activeCount":97},[],{"trials":23093,"activeCount":97},[],{"intervention":10573,"totalTrials":593,"cells":23095},{"EARLY_PHASE1":23096,"PHASE1":23098,"PHASE2":23100,"PHASE3":23110,"PHASE4":23116,"NA":23118},{"trials":23097,"activeCount":97},[],{"trials":23099,"activeCount":97},[],{"trials":23101,"activeCount":97},[23102,23106],{"nctId":23025,"briefTitle":23026,"status":155,"phases":23103,"primaryCompletion":23028,"completion":23029,"start":2374,"enrollment":23030,"conditions":23104,"interventions":23105},[86],[4703,4704],[23033,23034,23035,23016,23036,10583,10546,10573],{"nctId":11462,"briefTitle":11463,"status":155,"phases":23107,"primaryCompletion":11465,"completion":11465,"start":11466,"enrollment":11467,"conditions":23108,"interventions":23109},[86],[3637],[11470,10572,10573],{"trials":23111,"activeCount":97},[23112],{"nctId":10563,"briefTitle":10564,"status":155,"phases":23113,"primaryCompletion":10566,"completion":10566,"start":8825,"enrollment":1944,"conditions":23114,"interventions":23115},[87],[4703,4704],[10569,10570,10571,10572,10573,10526],{"trials":23117,"activeCount":97},[],{"trials":23119,"activeCount":97},[],{"intervention":19877,"totalTrials":593,"cells":23121},{"EARLY_PHASE1":23122,"PHASE1":23124,"PHASE2":23126,"PHASE3":23128,"PHASE4":23154,"NA":23156},{"trials":23123,"activeCount":97},[],{"trials":23125,"activeCount":97},[],{"trials":23127,"activeCount":97},[],{"trials":23129,"activeCount":97},[23130,23142,23150],{"nctId":23131,"briefTitle":23132,"status":155,"phases":23133,"primaryCompletion":23134,"completion":23134,"start":23135,"enrollment":23136,"conditions":23137,"interventions":23139},"NCT00226499","Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox",[87],"2006-10-12","2005-09-01",5803,[3717,23138],"Chickenpox Vaccines",[23140,19877,23141],"Priorix-tetra™","Varilrix™",{"nctId":23143,"briefTitle":23144,"status":155,"phases":23145,"primaryCompletion":23146,"completion":23146,"start":9877,"enrollment":1752,"conditions":23147,"interventions":23148},"NCT00969436","Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM",[87],"2011-02-21",[3717,2484,2485,2486],[23149,19877,23141],"GSK Biological's investigational MMRV vaccine 208136",{"nctId":19870,"briefTitle":19871,"status":155,"phases":23151,"primaryCompletion":8235,"completion":4827,"start":9087,"enrollment":19873,"conditions":23152,"interventions":23153},[87],[4704,4703],[19876,19877,19818,8971],{"trials":23155,"activeCount":97},[],{"trials":23157,"activeCount":97},[],{"intervention":23141,"totalTrials":593,"cells":23159},{"EARLY_PHASE1":23160,"PHASE1":23162,"PHASE2":23164,"PHASE3":23166,"PHASE4":23186,"NA":23188},{"trials":23161,"activeCount":97},[],{"trials":23163,"activeCount":97},[],{"trials":23165,"activeCount":97},[],{"trials":23167,"activeCount":97},[23168,23172,23176],{"nctId":23131,"briefTitle":23132,"status":155,"phases":23169,"primaryCompletion":23134,"completion":23134,"start":23135,"enrollment":23136,"conditions":23170,"interventions":23171},[87],[3717,23138],[23140,19877,23141],{"nctId":23143,"briefTitle":23144,"status":155,"phases":23173,"primaryCompletion":23146,"completion":23146,"start":9877,"enrollment":1752,"conditions":23174,"interventions":23175},[87],[3717,2484,2485,2486],[23149,19877,23141],{"nctId":23177,"briefTitle":23178,"status":155,"phases":23179,"primaryCompletion":23180,"completion":23180,"start":4800,"enrollment":23181,"conditions":23182,"interventions":23184},"NCT02570126","A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.",[87],"2016-10-25",1236,[23183,1926],"Chicken-pox Illness (Varicella Virus Disease)",[23185,23141],"Varilrix HSA-free",{"trials":23187,"activeCount":97},[],{"trials":23189,"activeCount":97},[],{"intervention":23191,"totalTrials":593,"cells":23192},"Herpes Zoster vaccine",{"EARLY_PHASE1":23193,"PHASE1":23195,"PHASE2":23197,"PHASE3":23199,"PHASE4":23227,"NA":23229},{"trials":23194,"activeCount":97},[],{"trials":23196,"activeCount":97},[],{"trials":23198,"activeCount":97},[],{"trials":23200,"activeCount":97},[23201,23208,23217],{"nctId":23202,"briefTitle":23203,"status":155,"phases":23204,"primaryCompletion":22635,"completion":8681,"start":23205,"enrollment":21520,"conditions":23206,"interventions":23207},"NCT01827839","Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ\u002Fsu) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster",[87],"2013-06-10",[1030],[23191],{"nctId":23209,"briefTitle":23210,"status":155,"phases":23211,"primaryCompletion":23212,"completion":23213,"start":23214,"enrollment":859,"conditions":23215,"interventions":23216},"NCT02075515","Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age",[87],"2015-04-29","2016-04-25","2014-08-13",[1030,18950],[23191],{"nctId":23218,"briefTitle":23219,"status":155,"phases":23220,"primaryCompletion":23221,"completion":23222,"start":8397,"enrollment":23223,"conditions":23224,"interventions":23225},"NCT01767467","Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ\u002Fsu) Vaccine in Adults Aged 18 Years and Older With Blood Cancers",[87],"2016-01-07","2017-01-06",568,[1030],[23226],"Herpes zoster vaccine",{"trials":23228,"activeCount":97},[],{"trials":23230,"activeCount":97},[],{"intervention":7791,"totalTrials":593,"cells":23232},{"EARLY_PHASE1":23233,"PHASE1":23235,"PHASE2":23237,"PHASE3":23255,"PHASE4":23267,"NA":23269},{"trials":23234,"activeCount":97},[],{"trials":23236,"activeCount":97},[],{"trials":23238,"activeCount":97},[23239,23251],{"nctId":23240,"briefTitle":23241,"status":155,"phases":23242,"primaryCompletion":23243,"completion":23244,"start":19538,"enrollment":10489,"conditions":23245,"interventions":23247},"NCT01098474","Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Healthy Infants",[86],"2011-04-30","2012-03-16",[23246],"Tuberculosis",[23248,23249,7791,23250,19196],"GSK's investigational vaccine 692342","Tritanrix™ HB+Hib","Polio Sabin™",{"nctId":7782,"briefTitle":7783,"status":155,"phases":23252,"primaryCompletion":2835,"completion":2835,"start":7785,"enrollment":7786,"conditions":23253,"interventions":23254},[86],[3287],[7789,7718,7790,7791,7792,7793],{"trials":23256,"activeCount":97},[23257],{"nctId":23258,"briefTitle":23259,"status":155,"phases":23260,"primaryCompletion":23261,"completion":23261,"start":23262,"enrollment":23263,"conditions":23264,"interventions":23265},"NCT00197002","Immune Response & Safety of a Hepatitis A Vaccine Given Together With a Pneumococcal Vaccine in Healthy Children 15 m of Age",[87],"2006-01-16","2003-09-11",521,[7966],[23266,7791],"GSK Biologicals 2-dose inactivated hepatitis A vaccine",{"trials":23268,"activeCount":97},[],{"trials":23270,"activeCount":97},[],{"intervention":4784,"totalTrials":593,"cells":23272},{"EARLY_PHASE1":23273,"PHASE1":23275,"PHASE2":23277,"PHASE3":23286,"PHASE4":23296,"NA":23298},{"trials":23274,"activeCount":97},[],{"trials":23276,"activeCount":97},[],{"trials":23278,"activeCount":97},[23279],{"nctId":23280,"briefTitle":23281,"status":155,"phases":23282,"primaryCompletion":10154,"completion":23283,"start":8235,"enrollment":21747,"conditions":23284,"interventions":23285},"NCT00568334","Study of Two Formulations of GSK Biologicals' Varicella Vaccine",[86],"2008-04-29",[3717],[4784],{"trials":23287,"activeCount":97},[23288,23292],{"nctId":4968,"briefTitle":4969,"status":155,"phases":23289,"primaryCompletion":4971,"completion":4972,"start":4973,"enrollment":4974,"conditions":23290,"interventions":23291},[87],[21],[4977,4978,4485,4979,4784],{"nctId":4775,"briefTitle":4776,"status":155,"phases":23293,"primaryCompletion":4778,"completion":4778,"start":4779,"enrollment":4780,"conditions":23294,"interventions":23295},[87],[3637,4742],[4783,4745,4472,4694,4784],{"trials":23297,"activeCount":97},[],{"trials":23299,"activeCount":97},[],{"intervention":8230,"totalTrials":593,"cells":23301},{"EARLY_PHASE1":23302,"PHASE1":23304,"PHASE2":23306,"PHASE3":23312,"PHASE4":23322,"NA":23324},{"trials":23303,"activeCount":97},[],{"trials":23305,"activeCount":97},[],{"trials":23307,"activeCount":97},[23308],{"nctId":8222,"briefTitle":8223,"status":155,"phases":23309,"primaryCompletion":8225,"completion":8225,"start":8226,"enrollment":8227,"conditions":23310,"interventions":23311},[86],[21],[8230,8177],{"trials":23313,"activeCount":97},[23314,23318],{"nctId":9773,"briefTitle":9774,"status":155,"phases":23315,"primaryCompletion":9776,"completion":9776,"start":3425,"enrollment":9777,"conditions":23316,"interventions":23317},[87],[21],[8230,9743,9780],{"nctId":9799,"briefTitle":9800,"status":155,"phases":23319,"primaryCompletion":9802,"completion":9802,"start":3425,"enrollment":9803,"conditions":23320,"interventions":23321},[87],[21],[8230,9743,9780],{"trials":23323,"activeCount":97},[],{"trials":23325,"activeCount":97},[],{"intervention":23327,"totalTrials":593,"cells":23328},"HPV-16\u002F18 L1\u002FAS04",{"EARLY_PHASE1":23329,"PHASE1":23331,"PHASE2":23333,"PHASE3":23335,"PHASE4":23356,"NA":23358},{"trials":23330,"activeCount":97},[],{"trials":23332,"activeCount":97},[],{"trials":23334,"activeCount":97},[],{"trials":23336,"activeCount":97},[23337,23344,23350],{"nctId":23338,"briefTitle":23339,"status":155,"phases":23340,"primaryCompletion":7613,"completion":7613,"start":3036,"enrollment":23341,"conditions":23342,"interventions":23343},"NCT00196924","Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16\u002F18.",[87],2067,[8723],[23327],{"nctId":23345,"briefTitle":23346,"status":155,"phases":23347,"completion":2296,"start":2844,"enrollment":536,"conditions":23348,"interventions":23349},"NCT00290277","Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years",[87],[8723],[23327],{"nctId":23351,"briefTitle":23352,"status":155,"phases":23353,"primaryCompletion":10212,"completion":10212,"start":2823,"enrollment":3190,"conditions":23354,"interventions":23355},"NCT00169494","Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16\u002F18",[87],[8723],[23327],{"trials":23357,"activeCount":97},[],{"trials":23359,"activeCount":97},[],{"intervention":23361,"totalTrials":593,"cells":23362},"denosumab",{"EARLY_PHASE1":23363,"PHASE1":23365,"PHASE2":23367,"PHASE3":23369,"PHASE4":23393,"NA":23395},{"trials":23364,"activeCount":97},[],{"trials":23366,"activeCount":97},[],{"trials":23368,"activeCount":97},[],{"trials":23370,"activeCount":97},[23371,23378,23386],{"nctId":23372,"briefTitle":23373,"status":155,"phases":23374,"primaryCompletion":3390,"completion":3390,"start":2427,"enrollment":17295,"conditions":23375,"interventions":23377},"NCT01495000","A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab",[87],[23376],"Osteoporosis, Postmenopausal",[23361],{"nctId":23379,"briefTitle":23380,"status":155,"phases":23381,"primaryCompletion":482,"completion":482,"start":7634,"enrollment":23382,"conditions":23383,"interventions":23384},"NCT02014467","Denosumab China Phase III Study",[87],486,[23376],[23385],"Denosumab",{"nctId":23387,"briefTitle":23388,"status":155,"phases":23389,"primaryCompletion":9728,"completion":9697,"start":8135,"enrollment":829,"conditions":23390,"interventions":23391},"NCT01457950","A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab",[87],[23376],[23361,23392],"open-label denosumab",{"trials":23394,"activeCount":97},[],{"trials":23396,"activeCount":97},[],{"intervention":23398,"totalTrials":593,"cells":23399},"Ropinirole immediate release",{"EARLY_PHASE1":23400,"PHASE1":23402,"PHASE2":23412,"PHASE3":23423,"PHASE4":23436,"NA":23438},{"trials":23401,"activeCount":97},[],{"trials":23403,"activeCount":97},[23404],{"nctId":23405,"briefTitle":23406,"status":155,"phases":23407,"primaryCompletion":20989,"completion":20989,"start":23408,"enrollment":1165,"conditions":23409,"interventions":23410},"NCT00140712","Ropinirole Tablets In Young Patients With Restless Legs Syndrome",[85],"2005-06-10",[14255],[23411],"Ropinirole Immediate Release",{"trials":23413,"activeCount":97},[23414],{"nctId":23415,"briefTitle":23416,"status":145,"phases":23417,"primaryCompletion":23418,"completion":23419,"start":23420,"enrollment":1736,"conditions":23421,"interventions":23422},"NCT00996944","Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)",[86],"2010-06-01","2010-06-29","2009-11-30",[14255],[23398],{"trials":23424,"activeCount":97},[23425],{"nctId":23426,"briefTitle":23427,"status":155,"phases":23428,"primaryCompletion":23429,"completion":23429,"start":23430,"enrollment":23431,"conditions":23432,"interventions":23433},"NCT00331149","A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's",[87],"2007-08-29","2006-06-20",343,[15879],[23434,23435],"Ropinirole prolonged release","ropinirole immediate release",{"trials":23437,"activeCount":97},[],{"trials":23439,"activeCount":97},[],{"intervention":12069,"totalTrials":593,"cells":23441},{"EARLY_PHASE1":23442,"PHASE1":23444,"PHASE2":23459,"PHASE3":23465,"PHASE4":23476,"NA":23478},{"trials":23443,"activeCount":97},[],{"trials":23445,"activeCount":97},[23446],{"nctId":23447,"briefTitle":23448,"status":155,"phases":23449,"primaryCompletion":23450,"completion":23450,"start":23451,"enrollment":1117,"conditions":23452,"interventions":23453},"NCT02548052","Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis",[85],"2016-02-19","2015-10-22",[22060],[23454,23455,23456,23457,12069,23458],"GSK2981278 0.03%","GSK2981278 0.1%","GSK2981278 0.8%","GSK2981278 4%","Betamethasone valerate 0.1%",{"trials":23460,"activeCount":97},[23461],{"nctId":12061,"briefTitle":12062,"status":155,"phases":23462,"primaryCompletion":12064,"completion":12064,"start":12065,"enrollment":695,"conditions":23463,"interventions":23464},[86],[12067],[12052,12069],{"trials":23466,"activeCount":97},[23467],{"nctId":23468,"briefTitle":23469,"status":155,"phases":23470,"primaryCompletion":16323,"completion":23471,"start":20989,"enrollment":9196,"conditions":23472,"interventions":23474},"NCT01567995","Randomised, Double-blind, Placebo-controlled Study of Topical Clobetasone Butyrate 0.05% Cream in Subjects With Eczema for Two Weeks to Evaluate the Efficacy and Safety",[87],"2009-02-10",[23473],"Eczema",[23475,12069],"Clobetasone Butyrate 0.05% Cream",{"trials":23477,"activeCount":97},[],{"trials":23479,"activeCount":97},[],{"intervention":23481,"totalTrials":593,"cells":23482},"Sirukumab",{"EARLY_PHASE1":23483,"PHASE1":23485,"PHASE2":23487,"PHASE3":23496,"PHASE4":23519,"NA":23521},{"trials":23484,"activeCount":97},[],{"trials":23486,"activeCount":97},[],{"trials":23488,"activeCount":97},[23489],{"nctId":23490,"briefTitle":23491,"status":500,"phases":23492,"primaryCompletion":23493,"completion":23493,"start":988,"enrollment":97,"conditions":23494,"interventions":23495},"NCT02794519","A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma",[86],"2016-10-04",[18],[23481,20901],{"trials":23497,"activeCount":97},[23498,23508],{"nctId":23499,"briefTitle":23500,"status":145,"phases":23501,"primaryCompletion":23502,"completion":23502,"start":23503,"enrollment":23504,"conditions":23505,"interventions":23507},"NCT02531633","Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis",[87],"2018-03-21","2015-10-16",161,[23506],"Giant Cell Arteritis",[23481,6819],{"nctId":23509,"briefTitle":23510,"status":500,"phases":23511,"primaryCompletion":23512,"completion":23513,"start":23514,"enrollment":97,"conditions":23515,"interventions":23517},"NCT02899026","Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica",[87],"2020-08-26","2021-08-26","2018-03-15",[23516],"Polymyalgia Rheumatica",[23481,23518],"Prednisone \u002FPrednisone placebo",{"trials":23520,"activeCount":97},[],{"trials":23522,"activeCount":97},[],{"intervention":23524,"totalTrials":593,"cells":23525},"MeMuRu-OKA",{"EARLY_PHASE1":23526,"PHASE1":23528,"PHASE2":23530,"PHASE3":23544,"PHASE4":23552,"NA":23554},{"trials":23527,"activeCount":97},[],{"trials":23529,"activeCount":97},[],{"trials":23531,"activeCount":97},[23532,23539],{"nctId":23533,"briefTitle":23534,"status":155,"phases":23535,"primaryCompletion":4843,"completion":4843,"start":7613,"enrollment":9569,"conditions":23536,"interventions":23537},"NCT00353288","Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™",[86],[3717,2484,2486,2485],[23524,23538],"MMR, Varicella vacc",{"nctId":23540,"briefTitle":23534,"status":155,"phases":23541,"completion":4843,"start":4844,"enrollment":4388,"conditions":23542,"interventions":23543},"NCT00352898",[86],[2485,2484,2486,3717],[23524,23538],{"trials":23545,"activeCount":97},[23546],{"nctId":23547,"briefTitle":23548,"status":155,"phases":23549,"completion":7659,"start":7613,"enrollment":19350,"conditions":23550,"interventions":23551},"NCT00351923","Immunogenicity\u002FSafety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes",[87],[2486,2485,2484,3717],[23524],{"trials":23553,"activeCount":97},[],{"trials":23555,"activeCount":97},[],{"intervention":23557,"totalTrials":593,"cells":23558},"Ropinirole XL",{"EARLY_PHASE1":23559,"PHASE1":23561,"PHASE2":23571,"PHASE3":23573,"PHASE4":23588,"NA":23590},{"trials":23560,"activeCount":97},[],{"trials":23562,"activeCount":97},[23563],{"nctId":23564,"briefTitle":23565,"status":155,"phases":23566,"primaryCompletion":23567,"completion":23567,"start":23568,"enrollment":1003,"conditions":23569,"interventions":23570},"NCT01371682","A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda",[85],"2009-12-02","2009-09-18",[15879],[23557],{"trials":23572,"activeCount":97},[],{"trials":23574,"activeCount":97},[23575,23582],{"nctId":23576,"briefTitle":23577,"status":155,"phases":23578,"primaryCompletion":3078,"completion":3078,"start":9076,"enrollment":23579,"conditions":23580,"interventions":23581},"NCT00632736","An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease",[87],419,[15879,15880],[23557],{"nctId":23583,"briefTitle":23584,"status":155,"phases":23585,"primaryCompletion":2794,"completion":2794,"start":7909,"enrollment":7955,"conditions":23586,"interventions":23587},"NCT00650104","Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164",[87],[15879],[23557],{"trials":23589,"activeCount":97},[],{"trials":23591,"activeCount":97},[],{"intervention":10346,"totalTrials":593,"cells":23593},{"EARLY_PHASE1":23594,"PHASE1":23596,"PHASE2":23598,"PHASE3":23608,"PHASE4":23614,"NA":23616},{"trials":23595,"activeCount":97},[],{"trials":23597,"activeCount":97},[],{"trials":23599,"activeCount":97},[23600,23604],{"nctId":19172,"briefTitle":19173,"status":155,"phases":23601,"primaryCompletion":8768,"completion":8768,"start":19175,"enrollment":3463,"conditions":23602,"interventions":23603},[86],[33,30,4704,4702,3624,24,19177],[4706,19179,19151,10346],{"nctId":19181,"briefTitle":19182,"status":155,"phases":23605,"primaryCompletion":19184,"completion":19184,"start":15600,"enrollment":8931,"conditions":23606,"interventions":23607},[86],[33,24,4704,4702,3624,30,4703],[4706,19187,19151,10346,7830],{"trials":23609,"activeCount":97},[23610],{"nctId":10337,"briefTitle":10338,"status":155,"phases":23611,"primaryCompletion":10340,"completion":10341,"start":9452,"enrollment":10342,"conditions":23612,"interventions":23613},[87],[992,5046],[10345,10346,10347,8968,10348],{"trials":23615,"activeCount":97},[],{"trials":23617,"activeCount":97},[],{"intervention":8129,"totalTrials":593,"cells":23619},{"EARLY_PHASE1":23620,"PHASE1":23622,"PHASE2":23624,"PHASE3":23626,"PHASE4":23643,"NA":23645},{"trials":23621,"activeCount":97},[],{"trials":23623,"activeCount":97},[],{"trials":23625,"activeCount":97},[],{"trials":23627,"activeCount":97},[23628,23635,23639],{"nctId":23629,"briefTitle":23630,"status":145,"phases":23631,"primaryCompletion":2335,"completion":2335,"start":6352,"enrollment":34,"conditions":23632,"interventions":23633},"NCT01453049","An Efficacy and Safety Study of Fixed-dose Rosiglitazone\u002FGlimepiride to Treat Chinese Type 2 Diabetes Patients",[87],[27],[23634,8129],"rosiglitazone\u002Fglimepiride fix dose combination",{"nctId":8122,"briefTitle":8123,"status":155,"phases":23636,"primaryCompletion":2427,"completion":484,"start":8116,"enrollment":8125,"conditions":23637,"interventions":23638},[87],[27],[7997,8128,8129,8130],{"nctId":8141,"briefTitle":8142,"status":155,"phases":23640,"primaryCompletion":2427,"completion":484,"start":8116,"enrollment":8144,"conditions":23641,"interventions":23642},[87],[27],[7997,8093,8129,8128],{"trials":23644,"activeCount":97},[],{"trials":23646,"activeCount":97},[],{"intervention":23648,"totalTrials":593,"cells":23649},"Darapladib 160 mg",{"EARLY_PHASE1":23650,"PHASE1":23652,"PHASE2":23670,"PHASE3":23672,"PHASE4":23681,"NA":23683},{"trials":23651,"activeCount":97},[],{"trials":23653,"activeCount":97},[23654,23662],{"nctId":23655,"briefTitle":23656,"status":155,"phases":23657,"primaryCompletion":23658,"completion":23658,"start":23659,"enrollment":433,"conditions":23660,"interventions":23661},"NCT01711723","A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment",[85],"2013-03-25","2012-10-29",[9309],[23648],{"nctId":23663,"briefTitle":23664,"status":155,"phases":23665,"primaryCompletion":23666,"completion":23666,"start":18690,"enrollment":1634,"conditions":23667,"interventions":23668},"NCT01751074","To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers",[85],"2013-03-14",[9309],[23669,23648],"Rosuvastatin 10 mg",{"trials":23671,"activeCount":97},[],{"trials":23673,"activeCount":97},[23674],{"nctId":23675,"briefTitle":23676,"status":155,"phases":23677,"primaryCompletion":11484,"completion":811,"start":3426,"enrollment":23678,"conditions":23679,"interventions":23680},"NCT01000727","The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial",[87],13026,[11827],[23648],{"trials":23682,"activeCount":97},[],{"trials":23684,"activeCount":97},[],{"intervention":23686,"totalTrials":593,"cells":23687},"Retigabine IR",{"EARLY_PHASE1":23688,"PHASE1":23690,"PHASE2":23692,"PHASE3":23694,"PHASE4":23717,"NA":23719},{"trials":23689,"activeCount":97},[],{"trials":23691,"activeCount":97},[],{"trials":23693,"activeCount":97},[],{"trials":23695,"activeCount":97},[23696,23702,23711],{"nctId":23697,"briefTitle":23698,"status":155,"phases":23699,"primaryCompletion":9728,"completion":9728,"start":1428,"enrollment":10049,"conditions":23700,"interventions":23701},"NCT01227902","Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures",[87],[12518],[23686],{"nctId":23703,"briefTitle":23704,"status":155,"phases":23705,"primaryCompletion":23706,"completion":23707,"start":23708,"enrollment":255,"conditions":23709,"interventions":23710},"NCT01777139","A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures",[87],"2016-12-14","2017-09-13","2013-04-11",[12518],[23686],{"nctId":23712,"briefTitle":23713,"status":155,"phases":23714,"primaryCompletion":23706,"completion":23707,"start":23146,"enrollment":11018,"conditions":23715,"interventions":23716},"NCT01336621","Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)",[87],[12518],[23686],{"trials":23718,"activeCount":97},[],{"trials":23720,"activeCount":97},[],{"intervention":22545,"totalTrials":593,"cells":23722},{"EARLY_PHASE1":23723,"PHASE1":23725,"PHASE2":23727,"PHASE3":23733,"PHASE4":23753,"NA":23755},{"trials":23724,"activeCount":97},[],{"trials":23726,"activeCount":97},[],{"trials":23728,"activeCount":97},[23729],{"nctId":22539,"briefTitle":22540,"status":155,"phases":23730,"primaryCompletion":18699,"completion":22542,"start":21804,"enrollment":303,"conditions":23731,"interventions":23732},[86],[21],[9938,22545],{"trials":23734,"activeCount":97},[23735,23742],{"nctId":23736,"briefTitle":23737,"status":155,"phases":23738,"primaryCompletion":8386,"completion":8386,"start":10803,"enrollment":15623,"conditions":23739,"interventions":23740},"NCT01389479","Study to Evaluate the Safety, Tolerance and Immunogenicity of Fluviral™ in Healthy Adults",[87],[21],[23741,22545],"Fluviral™",{"nctId":23743,"briefTitle":23744,"status":155,"phases":23745,"primaryCompletion":23746,"completion":23747,"start":23748,"enrollment":23749,"conditions":23750,"interventions":23751},"NCT00980005","Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children",[87],"2010-03-02","2010-06-17","2009-10-13",2116,[21],[23752,22545],"GSK investigational vaccine GSK1557482A",{"trials":23754,"activeCount":97},[],{"trials":23756,"activeCount":97},[],{"intervention":19353,"totalTrials":593,"cells":23758},{"EARLY_PHASE1":23759,"PHASE1":23761,"PHASE2":23778,"PHASE3":23780,"PHASE4":23786,"NA":23788},{"trials":23760,"activeCount":97},[],{"trials":23762,"activeCount":97},[23763,23774],{"nctId":23764,"briefTitle":23765,"status":155,"phases":23766,"primaryCompletion":23767,"completion":23767,"start":23768,"enrollment":345,"conditions":23769,"interventions":23771},"NCT00833378","Drug Interaction Study Between Eltrombopag and Lopinavir\u002FRitonavir in Healthy Adult Subjects.",[85],"2009-03-11","2009-01-19",[23770],"Hepatitis C",[23772,19353,23773],"Eltrombopag","Eltrombopag and Lopinavir\u002FRitonavir",{"nctId":9339,"briefTitle":9340,"status":155,"phases":23775,"primaryCompletion":6351,"completion":6351,"start":2442,"enrollment":1298,"conditions":23776,"interventions":23777},[85],[7524,9343],[9345,9346,6488,9323,9273,9347],{"trials":23779,"activeCount":97},[],{"trials":23781,"activeCount":97},[23782],{"nctId":19347,"briefTitle":19348,"status":12113,"phases":23783,"start":7838,"enrollment":19350,"conditions":23784,"interventions":23785},[87],[10943],[19353,10675,19354],{"trials":23787,"activeCount":97},[],{"trials":23789,"activeCount":97},[],{"intervention":23791,"totalTrials":593,"cells":23792},"GW685698\u002FGW642444",{"EARLY_PHASE1":23793,"PHASE1":23795,"PHASE2":23797,"PHASE3":23805,"PHASE4":23821,"NA":23823},{"trials":23794,"activeCount":97},[],{"trials":23796,"activeCount":97},[],{"trials":23798,"activeCount":97},[23799],{"nctId":23800,"briefTitle":23801,"status":155,"phases":23802,"primaryCompletion":8116,"completion":8116,"start":7976,"enrollment":1237,"conditions":23803,"interventions":23804},"NCT00731822","A Study To Assess Single Dosage Strength Of GW685698\u002FGW642444 Chronic Obstructive Pulmonary Disease (COPD)",[86],[15],[23791],{"trials":23806,"activeCount":97},[23807,23814],{"nctId":23808,"briefTitle":23809,"status":155,"phases":23810,"primaryCompletion":3390,"completion":3390,"start":2427,"enrollment":11064,"conditions":23811,"interventions":23812},"NCT01498653","Evaluating the Efficacy and Safety of Fluticasone Furoate\u002FVilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry",[87],[18],[23791,23813],"CCI18781",{"nctId":23815,"briefTitle":23816,"status":155,"phases":23817,"primaryCompletion":7682,"completion":7682,"start":2427,"enrollment":23818,"conditions":23819,"interventions":23820},"NCT01498679","Evaluating the Efficacy and Safety of Fluticasone Furoate\u002FVilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.",[87],311,[18],[23791],{"trials":23822,"activeCount":97},[],{"trials":23824,"activeCount":97},[],{"intervention":6819,"totalTrials":593,"cells":23826},{"EARLY_PHASE1":23827,"PHASE1":23829,"PHASE2":23839,"PHASE3":23841,"PHASE4":23847,"NA":23849},{"trials":23828,"activeCount":97},[],{"trials":23830,"activeCount":97},[23831,23835],{"nctId":6808,"briefTitle":6809,"status":145,"phases":23832,"primaryCompletion":6811,"completion":6812,"start":6813,"enrollment":6814,"conditions":23833,"interventions":23834},[85],[2761],[6817,6818,1891,6819],{"nctId":6821,"briefTitle":6822,"status":500,"phases":23836,"primaryCompletion":6824,"completion":6824,"start":483,"enrollment":97,"conditions":23837,"interventions":23838},[85],[36],[6827,1891,6818,6819],{"trials":23840,"activeCount":97},[],{"trials":23842,"activeCount":97},[23843],{"nctId":23499,"briefTitle":23500,"status":145,"phases":23844,"primaryCompletion":23502,"completion":23502,"start":23503,"enrollment":23504,"conditions":23845,"interventions":23846},[87],[23506],[23481,6819],{"trials":23848,"activeCount":97},[],{"trials":23850,"activeCount":97},[],{"intervention":8948,"totalTrials":593,"cells":23852},{"EARLY_PHASE1":23853,"PHASE1":23855,"PHASE2":23857,"PHASE3":23859,"PHASE4":23874,"NA":23876},{"trials":23854,"activeCount":97},[],{"trials":23856,"activeCount":97},[],{"trials":23858,"activeCount":97},[],{"trials":23860,"activeCount":97},[23861,23866,23870],{"nctId":23862,"briefTitle":8943,"status":155,"phases":23863,"primaryCompletion":2482,"completion":2482,"start":8956,"enrollment":8376,"conditions":23864,"interventions":23865},"NCT00383227",[87],[24],[8948],{"nctId":8942,"briefTitle":8943,"status":155,"phases":23867,"completion":2405,"start":8945,"enrollment":201,"conditions":23868,"interventions":23869},[87],[24],[8948,4808],{"nctId":8954,"briefTitle":8943,"status":155,"phases":23871,"start":8956,"enrollment":1672,"conditions":23872,"interventions":23873},[87],[24],[8948,4808],{"trials":23875,"activeCount":97},[],{"trials":23877,"activeCount":97},[],{"intervention":22118,"totalTrials":593,"cells":23879},{"EARLY_PHASE1":23880,"PHASE1":23882,"PHASE2":23884,"PHASE3":23886,"PHASE4":23902,"NA":23904},{"trials":23881,"activeCount":97},[],{"trials":23883,"activeCount":97},[],{"trials":23885,"activeCount":97},[],{"trials":23887,"activeCount":97},[23888,23892,23896],{"nctId":22110,"briefTitle":22111,"status":155,"phases":23889,"primaryCompletion":4973,"completion":22113,"start":22114,"enrollment":22115,"conditions":23890,"interventions":23891},[87],[18],[22099,22118],{"nctId":22128,"briefTitle":22129,"status":155,"phases":23893,"primaryCompletion":2394,"completion":2394,"start":11030,"enrollment":22131,"conditions":23894,"interventions":23895},[87],[18],[22134,22118,22135],{"nctId":23897,"briefTitle":23898,"status":155,"phases":23899,"primaryCompletion":2427,"completion":2427,"start":1428,"enrollment":292,"conditions":23900,"interventions":23901},"NCT01244984","A Long-term Safety Study of Fluticasone Furoate (FF)\u002FGW642444 and FF in Japanese Subjects With Asthma",[87],[18],[19057,22118],{"trials":23903,"activeCount":97},[],{"trials":23905,"activeCount":97},[],{"intervention":19098,"totalTrials":593,"cells":23907},{"EARLY_PHASE1":23908,"PHASE1":23910,"PHASE2":23912,"PHASE3":23914,"PHASE4":23928,"NA":23930},{"trials":23909,"activeCount":97},[],{"trials":23911,"activeCount":97},[],{"trials":23913,"activeCount":97},[],{"trials":23915,"activeCount":97},[23916,23920,23924],{"nctId":19090,"briefTitle":19091,"status":155,"phases":23917,"primaryCompletion":19093,"completion":19094,"start":19095,"enrollment":895,"conditions":23918,"interventions":23919},[87],[3637],[4744,4745,19098,4810,19099,19100],{"nctId":19264,"briefTitle":19265,"status":155,"phases":23921,"primaryCompletion":19267,"completion":19268,"start":19269,"enrollment":19270,"conditions":23922,"interventions":23923},[87],[3637],[4683,19098,4810,12324,19273,4745],{"nctId":19117,"briefTitle":19118,"status":155,"phases":23925,"primaryCompletion":19120,"completion":19120,"start":19121,"enrollment":3635,"conditions":23926,"interventions":23927},[87],[3637,8918],[4744,12323,4810,19098],{"trials":23929,"activeCount":97},[],{"trials":23931,"activeCount":97},[],{"intervention":23933,"totalTrials":593,"cells":23934},"GW873140",{"EARLY_PHASE1":23935,"PHASE1":23937,"PHASE2":23939,"PHASE3":23941,"PHASE4":23962,"NA":23964},{"trials":23936,"activeCount":97},[],{"trials":23938,"activeCount":97},[],{"trials":23940,"activeCount":97},[],{"trials":23942,"activeCount":97},[23943,23949,23955],{"nctId":23944,"briefTitle":23945,"status":145,"phases":23946,"primaryCompletion":2805,"completion":2805,"start":2796,"enrollment":97,"conditions":23947,"interventions":23948},"NCT00123890","Screening Protocol To Determine Eligibility For Studies Of The Chemokine Coreceptor 5 (CCR5) Antagonist GW873140",[87],[10662],[23933],{"nctId":23950,"briefTitle":23951,"status":145,"phases":23952,"primaryCompletion":2805,"completion":2805,"start":10212,"enrollment":1634,"conditions":23953,"interventions":23954},"NCT00197197","Study Of Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5\u002FX4-Tropic Treatment-Experienced HIV-Infected Subjects",[87],[10662],[23933],{"nctId":23956,"briefTitle":23957,"status":145,"phases":23958,"primaryCompletion":8426,"completion":8426,"start":10212,"enrollment":23959,"conditions":23960,"interventions":23961},"NCT00297076","Chemokine Coreceptor 5 (CCR5) Antagonist GW873140 In R5-Tropic Treatment-Experienced HIV-Infected Subjects",[87],406,[10662],[23933],{"trials":23963,"activeCount":97},[],{"trials":23965,"activeCount":97},[],{"intervention":18444,"totalTrials":593,"cells":23967},{"EARLY_PHASE1":23968,"PHASE1":23970,"PHASE2":23972,"PHASE3":23974,"PHASE4":23994,"NA":23996},{"trials":23969,"activeCount":97},[],{"trials":23971,"activeCount":97},[],{"trials":23973,"activeCount":97},[],{"trials":23975,"activeCount":97},[23976,23986,23990],{"nctId":23977,"briefTitle":23978,"status":155,"phases":23979,"primaryCompletion":472,"completion":623,"start":23980,"enrollment":5520,"conditions":23981,"interventions":23982},"NCT01323660","An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719\u002FGW642444.Study B",[87],"2011-03-16",[15],[18444,18445,23983,23984,23985],"GSK573719 125","GSK573719 62.5","GW642444 25",{"nctId":18532,"briefTitle":18533,"status":155,"phases":23987,"primaryCompletion":11748,"completion":18535,"start":18536,"enrollment":18537,"conditions":23988,"interventions":23989},[87],[15],[18444,18445,10797,8440],{"nctId":18438,"briefTitle":18439,"status":155,"phases":23991,"primaryCompletion":3389,"completion":3389,"start":8883,"enrollment":18441,"conditions":23992,"interventions":23993},[87],[15],[18444,18445,18345,8440],{"trials":23995,"activeCount":97},[],{"trials":23997,"activeCount":97},[],{"intervention":18445,"totalTrials":593,"cells":23999},{"EARLY_PHASE1":24000,"PHASE1":24002,"PHASE2":24004,"PHASE3":24006,"PHASE4":24020,"NA":24022},{"trials":24001,"activeCount":97},[],{"trials":24003,"activeCount":97},[],{"trials":24005,"activeCount":97},[],{"trials":24007,"activeCount":97},[24008,24012,24016],{"nctId":23977,"briefTitle":23978,"status":155,"phases":24009,"primaryCompletion":472,"completion":623,"start":23980,"enrollment":5520,"conditions":24010,"interventions":24011},[87],[15],[18444,18445,23983,23984,23985],{"nctId":18532,"briefTitle":18533,"status":155,"phases":24013,"primaryCompletion":11748,"completion":18535,"start":18536,"enrollment":18537,"conditions":24014,"interventions":24015},[87],[15],[18444,18445,10797,8440],{"nctId":18438,"briefTitle":18439,"status":155,"phases":24017,"primaryCompletion":3389,"completion":3389,"start":8883,"enrollment":18441,"conditions":24018,"interventions":24019},[87],[15],[18444,18445,18345,8440],{"trials":24021,"activeCount":97},[],{"trials":24023,"activeCount":97},[],{"intervention":19981,"totalTrials":593,"cells":24025},{"EARLY_PHASE1":24026,"PHASE1":24028,"PHASE2":24030,"PHASE3":24036,"PHASE4":24053,"NA":24055},{"trials":24027,"activeCount":97},[],{"trials":24029,"activeCount":97},[],{"trials":24031,"activeCount":97},[24032],{"nctId":19973,"briefTitle":19974,"status":145,"phases":24033,"primaryCompletion":19976,"completion":19976,"start":19977,"enrollment":1720,"conditions":24034,"interventions":24035},[86],[21],[19980,19981,4745],{"trials":24037,"activeCount":97},[24038,24047],{"nctId":24039,"briefTitle":24040,"status":155,"phases":24041,"primaryCompletion":18494,"completion":24042,"start":24043,"enrollment":20448,"conditions":24044,"interventions":24045},"NCT00609492","Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.",[87],"2009-03-30","2008-01-03",[3637,4742],[24046,19981],"GSK Biologicals´ Pneumococcal Conjugate Vaccine",{"nctId":24048,"briefTitle":24049,"status":155,"phases":24050,"primaryCompletion":20544,"completion":20544,"start":3426,"enrollment":1003,"conditions":24051,"interventions":24052},"NCT00964028","Safety Study of GSK Biologicals' DTPa-IPV\u002FHib (Infanrix™-IPV\u002FHib)",[87],[4704,3624,30,33,4702],[19981],{"trials":24054,"activeCount":97},[],{"trials":24056,"activeCount":97},[],{"intervention":24058,"totalTrials":593,"cells":24059},"Live attenuated human rotavirus vaccine",{"EARLY_PHASE1":24060,"PHASE1":24062,"PHASE2":24064,"PHASE3":24066,"PHASE4":24088,"NA":24090},{"trials":24061,"activeCount":97},[],{"trials":24063,"activeCount":97},[],{"trials":24065,"activeCount":97},[],{"trials":24067,"activeCount":97},[24068,24075,24081],{"nctId":24069,"briefTitle":24070,"status":155,"phases":24071,"primaryCompletion":749,"completion":749,"start":2814,"enrollment":1752,"conditions":24072,"interventions":24074},"NCT00169455","Assess the Immunogenicity of the Human Rotavirus (HRV) Vaccine After Reconstitution Without Buffering Agent; & Evaluate the Immunogenicity, Reactogenicity & Safety of the Vaccine After Storage for 7 d at 37°C Following 2 Doses in Healthy Infants",[87],[24073],"Rotavirus Gastroenteritis",[24058],{"nctId":24076,"briefTitle":24077,"status":155,"phases":24078,"completion":2383,"start":10212,"enrollment":1579,"conditions":24079,"interventions":24080},"NCT00134732","Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis",[87],[4759],[24058],{"nctId":24082,"briefTitle":24083,"status":155,"phases":24084,"completion":21597,"start":24085,"enrollment":3635,"conditions":24086,"interventions":24087},"NCT00289172","Assess the Immunogenicity & Safety of 2 Doses of Oral Live Attenuated Human Rota(HRV)Vaccine in Healthy Infants in India",[87],"2006-02-10",[4759],[24058],{"trials":24089,"activeCount":97},[],{"trials":24091,"activeCount":97},[],{"intervention":24093,"totalTrials":593,"cells":24094},"CervarixTM",{"EARLY_PHASE1":24095,"PHASE1":24097,"PHASE2":24099,"PHASE3":24110,"PHASE4":24128,"NA":24130},{"trials":24096,"activeCount":97},[],{"trials":24098,"activeCount":97},[],{"trials":24100,"activeCount":97},[24101],{"nctId":24102,"briefTitle":24103,"status":155,"phases":24104,"primaryCompletion":24105,"completion":24105,"start":2742,"enrollment":24106,"conditions":24107,"interventions":24108},"NCT00359619","Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine",[86],"2007-01-30",383,[8723,12417],[24093,24109],"HPV investigational vaccine GSK568893A, different formulations",{"trials":24111,"activeCount":97},[24112,24120],{"nctId":24113,"briefTitle":24114,"status":155,"phases":24115,"primaryCompletion":24116,"completion":24116,"start":24117,"enrollment":15259,"conditions":24118,"interventions":24119},"NCT01418937","Safety Evaluation of a Human Papillomavirus (HPV) Vaccine in Healthy Female Control Subjects From the GSK HPV 023 Study",[87],"2015-01-09","2012-05-29",[8723],[24093],{"nctId":24121,"briefTitle":24122,"status":155,"phases":24123,"primaryCompletion":24124,"completion":24124,"start":24125,"enrollment":1982,"conditions":24126,"interventions":24127},"NCT00996125","Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects",[87],"2010-12-08","2009-10-24",[8723],[24093],{"trials":24129,"activeCount":97},[],{"trials":24131,"activeCount":97},[],{"intervention":24133,"totalTrials":593,"cells":24134},"2-dose oral live attenuated G1P[8] human rotavirus vaccine",{"EARLY_PHASE1":24135,"PHASE1":24137,"PHASE2":24139,"PHASE3":24141,"PHASE4":24163,"NA":24165},{"trials":24136,"activeCount":97},[],{"trials":24138,"activeCount":97},[],{"trials":24140,"activeCount":97},[],{"trials":24142,"activeCount":97},[24143,24150,24157],{"nctId":24144,"briefTitle":24145,"status":155,"phases":24146,"primaryCompletion":8406,"completion":3552,"start":8852,"enrollment":24147,"conditions":24148,"interventions":24149},"NCT00334607","Study of 2 Doses of HRV Vaccine Given Concomitantly or Separately With Routine Vaccinations in Healthy Infants in USA",[87],484,[4759],[24133],{"nctId":24151,"briefTitle":24152,"status":155,"phases":24153,"primaryCompletion":748,"completion":748,"start":8492,"enrollment":24154,"conditions":24155,"interventions":24156},"NCT00139347","Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants",[87],6360,[4759],[24133],{"nctId":24158,"briefTitle":24159,"status":155,"phases":24160,"primaryCompletion":4756,"completion":2336,"start":4843,"enrollment":2069,"conditions":24161,"interventions":24162},"NCT00382772","A Study in Infants to Test Two Preparations (Freeze-dried or Liquid) of the Rotavirus Vaccine (HRV Vaccine).",[87],[4759],[24133],{"trials":24164,"activeCount":97},[],{"trials":24166,"activeCount":97},[],{"intervention":24168,"totalTrials":593,"cells":24169},"Meningococcal vaccine GSK 134612",{"EARLY_PHASE1":24170,"PHASE1":24172,"PHASE2":24174,"PHASE3":24187,"PHASE4":24211,"NA":24213},{"trials":24171,"activeCount":97},[],{"trials":24173,"activeCount":97},[],{"trials":24175,"activeCount":97},[24176],{"nctId":24177,"briefTitle":24178,"status":155,"phases":24179,"primaryCompletion":24180,"completion":24181,"start":24182,"enrollment":24183,"conditions":24184,"interventions":24185},"NCT01165242","Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents\u002FAdults",[86],"2011-02-25","2011-07-29","2010-08-19",1013,[992],[24168,24186],"Menactra®",{"trials":24188,"activeCount":97},[24189,24198],{"nctId":24190,"briefTitle":24191,"status":155,"phases":24192,"primaryCompletion":24181,"completion":24193,"start":24194,"enrollment":4388,"conditions":24195,"interventions":24196},"NCT01235975","Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years",[87],"2011-08-03","2010-11-30",[992],[24168,24197],"MencevaxACWY TM",{"nctId":24199,"briefTitle":24200,"status":155,"phases":24201,"primaryCompletion":24202,"completion":24203,"start":24204,"enrollment":24205,"conditions":24206,"interventions":24208},"NCT01340898","Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers",[87],"2014-08-04","2015-10-19","2012-01-27",753,[24207],"Meningococcal Infection",[24168,24209,24210],"SynflorixTM","Infanrix-IPV\u002FHiberixTM",{"trials":24212,"activeCount":97},[],{"trials":24214,"activeCount":97},[],{"intervention":24216,"totalTrials":593,"cells":24217},"Combination Product",{"EARLY_PHASE1":24218,"PHASE1":24220,"PHASE2":24222,"PHASE3":24224,"PHASE4":24247,"NA":24249},{"trials":24219,"activeCount":97},[],{"trials":24221,"activeCount":97},[],{"trials":24223,"activeCount":97},[],{"trials":24225,"activeCount":97},[24226,24232,24241],{"nctId":24227,"briefTitle":24228,"status":155,"phases":24229,"primaryCompletion":8426,"completion":8426,"start":4843,"enrollment":11,"conditions":24230,"interventions":24231},"NCT00383162","A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)",[87],[14168],[24216],{"nctId":24233,"briefTitle":24234,"status":155,"phases":24235,"primaryCompletion":24236,"completion":24236,"start":24237,"enrollment":454,"conditions":24238,"interventions":24239},"NCT00385008","TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine",[87],"2006-11-24","2006-09-13",[14168],[24216,24240],"RELPAX(eletriptan) 40mg",{"nctId":24242,"briefTitle":24243,"status":155,"phases":24244,"primaryCompletion":3079,"completion":3079,"start":7659,"enrollment":803,"conditions":24245,"interventions":24246},"NCT00382993","A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)",[87],[14168],[24216],{"trials":24248,"activeCount":97},[],{"trials":24250,"activeCount":97},[],{"intervention":24252,"totalTrials":593,"cells":24253},"RSV MAT",{"EARLY_PHASE1":24254,"PHASE1":24256,"PHASE2":24258,"PHASE3":24260,"PHASE4":24287,"NA":24289},{"trials":24255,"activeCount":97},[],{"trials":24257,"activeCount":97},[],{"trials":24259,"activeCount":97},[],{"trials":24261,"activeCount":97},[24262,24270,24278],{"nctId":24263,"briefTitle":24264,"status":145,"phases":24265,"primaryCompletion":1173,"completion":1173,"start":24266,"enrollment":24267,"conditions":24268,"interventions":24269},"NCT04605159","A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers",[87],"2020-11-20",11194,[2620],[24252],{"nctId":24271,"briefTitle":24272,"status":500,"phases":24273,"primaryCompletion":24274,"completion":24275,"start":1684,"enrollment":97,"conditions":24276,"interventions":24277},"NCT05229068","A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy",[87],"2023-11-06","2024-10-24",[2620],[24252],{"nctId":24279,"briefTitle":24280,"status":145,"phases":24281,"primaryCompletion":24282,"completion":24282,"start":24283,"enrollment":24284,"conditions":24285,"interventions":24286},"NCT04980391","A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers",[87],"2023-05-30","2021-08-03",384,[2620],[24252],{"trials":24288,"activeCount":97},[],{"trials":24290,"activeCount":97},[],{"intervention":11486,"totalTrials":593,"cells":24292},{"EARLY_PHASE1":24293,"PHASE1":24295,"PHASE2":24297,"PHASE3":24311,"PHASE4":24322,"NA":24324},{"trials":24294,"activeCount":97},[],{"trials":24296,"activeCount":97},[],{"trials":24298,"activeCount":97},[24299,24305],{"nctId":24300,"briefTitle":24301,"status":155,"phases":24302,"primaryCompletion":7581,"completion":7581,"start":9462,"enrollment":1003,"conditions":24303,"interventions":24304},"NCT00196950","Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years",[86],[992],[11486],{"nctId":24306,"briefTitle":24307,"status":155,"phases":24308,"primaryCompletion":10212,"completion":10212,"start":2814,"enrollment":25,"conditions":24309,"interventions":24310},"NCT00196963","Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs",[86],[992],[11486],{"trials":24312,"activeCount":97},[24313],{"nctId":24314,"briefTitle":24315,"status":155,"phases":24316,"primaryCompletion":9526,"completion":24317,"start":24318,"enrollment":24319,"conditions":24320,"interventions":24321},"NCT02986854","Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination",[87],"2017-12-07","2016-12-08",704,[992],[11486],{"trials":24323,"activeCount":97},[],{"trials":24325,"activeCount":97},[],{"intervention":24327,"totalTrials":593,"cells":24328},"Cervarix TM",{"EARLY_PHASE1":24329,"PHASE1":24331,"PHASE2":24343,"PHASE3":24345,"PHASE4":24363,"NA":24365},{"trials":24330,"activeCount":97},[],{"trials":24332,"activeCount":97},[24333],{"nctId":24334,"briefTitle":24335,"status":155,"phases":24336,"primaryCompletion":24337,"completion":24338,"start":24339,"enrollment":10978,"conditions":24340,"interventions":24341},"NCT00478621","Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)",[85],"2008-06-30","2008-10-13","2007-05-25",[8723],[24342,24327],"GSK Biologicals' HPV vaccine",{"trials":24344,"activeCount":97},[],{"trials":24346,"activeCount":97},[24347,24353],{"nctId":24348,"briefTitle":24349,"status":155,"phases":24350,"primaryCompletion":7954,"completion":7954,"start":4756,"enrollment":414,"conditions":24351,"interventions":24352},"NCT00456807","Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >\u002F= 26 Years",[87],[8723],[24327],{"nctId":24354,"briefTitle":24355,"status":155,"phases":24356,"primaryCompletion":24357,"completion":24358,"start":24359,"enrollment":24360,"conditions":24361,"interventions":24362},"NCT00552279","Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age",[87],"2009-02-26","2009-07-20","2007-11-12",805,[8723],[24327,24327],{"trials":24364,"activeCount":97},[],{"trials":24366,"activeCount":97},[],{"intervention":24368,"totalTrials":593,"cells":24369},"Ropinirole Extended Release",{"EARLY_PHASE1":24370,"PHASE1":24372,"PHASE2":24374,"PHASE3":24376,"PHASE4":24397,"NA":24399},{"trials":24371,"activeCount":97},[],{"trials":24373,"activeCount":97},[],{"trials":24375,"activeCount":97},[],{"trials":24377,"activeCount":97},[24378,24384,24391],{"nctId":24379,"briefTitle":24380,"status":155,"phases":24381,"completion":1360,"start":2796,"enrollment":6576,"conditions":24382,"interventions":24383},"NCT00197080","Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome",[87],[14255],[24368],{"nctId":24385,"briefTitle":24386,"status":155,"phases":24387,"primaryCompletion":7659,"completion":7659,"start":11759,"enrollment":23223,"conditions":24388,"interventions":24389},"NCT00314860","RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole",[87],[14255,14254],[24390],"ropinirole Extended Release",{"nctId":24392,"briefTitle":24393,"status":155,"phases":24394,"primaryCompletion":8426,"completion":8426,"start":2805,"enrollment":1752,"conditions":24395,"interventions":24396},"NCT00355641","Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome",[87],[14255],[24368],{"trials":24398,"activeCount":97},[],{"trials":24400,"activeCount":97},[],{"intervention":24402,"totalTrials":660,"cells":24403},"fluticasone propionate inhalation solution",{"EARLY_PHASE1":24404,"PHASE1":24406,"PHASE2":24408,"PHASE3":24410,"PHASE4":24430,"NA":24432},{"trials":24405,"activeCount":97},[],{"trials":24407,"activeCount":97},[],{"trials":24409,"activeCount":97},[],{"trials":24411,"activeCount":97},[24412,24422],{"nctId":24413,"briefTitle":24414,"status":155,"phases":24415,"primaryCompletion":24416,"completion":24417,"start":4721,"enrollment":24418,"conditions":24419,"interventions":24420},"NCT01687296","Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma",[87],"2013-06-01","2013-06-21",261,[18],[24402,24421,10787],"oral prednisone",{"nctId":24423,"briefTitle":24424,"status":155,"phases":24425,"primaryCompletion":24426,"completion":24426,"start":5169,"enrollment":303,"conditions":24427,"interventions":24428},"NCT01687283","Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma",[87],"2013-11-07",[18],[24402,24429],"budesonide suspension",{"trials":24431,"activeCount":97},[],{"trials":24433,"activeCount":97},[],{"intervention":24435,"totalTrials":660,"cells":24436},"PriorixTM",{"EARLY_PHASE1":24437,"PHASE1":24439,"PHASE2":24441,"PHASE3":24443,"PHASE4":24463,"NA":24465},{"trials":24438,"activeCount":97},[],{"trials":24440,"activeCount":97},[],{"trials":24442,"activeCount":97},[],{"trials":24444,"activeCount":97},[24445,24454],{"nctId":24446,"briefTitle":24447,"status":155,"phases":24448,"primaryCompletion":24449,"completion":17159,"start":15214,"enrollment":18247,"conditions":24450,"interventions":24451},"NCT01245049","Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children",[87],"2012-03-27",[3624,4702,33,30],[24452,24453,24435],"Boostrix PolioTM","RepevaxTM",{"nctId":24455,"briefTitle":24456,"status":155,"phases":24457,"primaryCompletion":9792,"completion":9792,"start":17894,"enrollment":24458,"conditions":24459,"interventions":24460},"NCT00751348","Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136",[87],475,[2486,3717,2485,2484],[24435,24461,24462],"VarilrixTM","Priorix-Tetra®",{"trials":24464,"activeCount":97},[],{"trials":24466,"activeCount":97},[],{"intervention":11175,"totalTrials":660,"cells":24468},{"EARLY_PHASE1":24469,"PHASE1":24471,"PHASE2":24473,"PHASE3":24479,"PHASE4":24485,"NA":24487},{"trials":24470,"activeCount":97},[],{"trials":24472,"activeCount":97},[],{"trials":24474,"activeCount":97},[24475],{"nctId":21338,"briefTitle":21339,"status":155,"phases":24476,"primaryCompletion":21341,"completion":21341,"start":21342,"enrollment":13062,"conditions":24477,"interventions":24478},[86],[6371,21344,21345],[21347,8676,11175],{"trials":24480,"activeCount":97},[24481],{"nctId":11168,"briefTitle":11169,"status":155,"phases":24482,"primaryCompletion":11171,"completion":11171,"start":11172,"enrollment":1608,"conditions":24483,"interventions":24484},[87],[992],[8653,4811,4805,4810,4762,8674,8675,11175],{"trials":24486,"activeCount":97},[],{"trials":24488,"activeCount":97},[],{"intervention":24490,"totalTrials":660,"cells":24491},"PoliorixTM",{"EARLY_PHASE1":24492,"PHASE1":24494,"PHASE2":24496,"PHASE3":24498,"PHASE4":24517,"NA":24519},{"trials":24493,"activeCount":97},[],{"trials":24495,"activeCount":97},[],{"trials":24497,"activeCount":97},[],{"trials":24499,"activeCount":97},[24500,24510],{"nctId":24501,"briefTitle":24502,"status":155,"phases":24503,"primaryCompletion":24504,"completion":24504,"start":24505,"enrollment":24506,"conditions":24507,"interventions":24508},"NCT01323647","Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers",[87],"2011-09-19","2011-04-25",957,[4702],[24490,24509],"Infanrix+Hib",{"nctId":24511,"briefTitle":24512,"status":155,"phases":24513,"primaryCompletion":24514,"completion":24514,"start":16322,"enrollment":93,"conditions":24515,"interventions":24516},"NCT00920439","Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers",[87],"2009-08-03",[4702],[24490],{"trials":24518,"activeCount":97},[],{"trials":24520,"activeCount":97},[],{"intervention":11067,"totalTrials":660,"cells":24522},{"EARLY_PHASE1":24523,"PHASE1":24525,"PHASE2":24527,"PHASE3":24533,"PHASE4":24539,"NA":24541},{"trials":24524,"activeCount":97},[],{"trials":24526,"activeCount":97},[],{"trials":24528,"activeCount":97},[24529],{"nctId":22574,"briefTitle":22575,"status":155,"phases":24530,"primaryCompletion":11274,"completion":5268,"start":22577,"enrollment":4521,"conditions":24531,"interventions":24532},[86],[4703,4704],[22580,11068,11067,22581,19196],{"trials":24534,"activeCount":97},[24535],{"nctId":11060,"briefTitle":11061,"status":155,"phases":24536,"primaryCompletion":11063,"completion":11063,"start":8207,"enrollment":11064,"conditions":24537,"interventions":24538},[87],[4704,4703],[11067,8967,11068,11069],{"trials":24540,"activeCount":97},[],{"trials":24542,"activeCount":97},[],{"intervention":11069,"totalTrials":660,"cells":24544},{"EARLY_PHASE1":24545,"PHASE1":24547,"PHASE2":24549,"PHASE3":24551,"PHASE4":24561,"NA":24563},{"trials":24546,"activeCount":97},[],{"trials":24548,"activeCount":97},[],{"trials":24550,"activeCount":97},[],{"trials":24552,"activeCount":97},[24553,24557],{"nctId":11060,"briefTitle":11061,"status":155,"phases":24554,"primaryCompletion":11063,"completion":11063,"start":8207,"enrollment":11064,"conditions":24555,"interventions":24556},[87],[4704,4703],[11067,8967,11068,11069],{"nctId":19887,"briefTitle":19888,"status":155,"phases":24558,"primaryCompletion":19890,"completion":19890,"start":9568,"enrollment":15576,"conditions":24559,"interventions":24560},[87],[4702,33,3624,30,4704],[19893,11069,19818,10348,7830],{"trials":24562,"activeCount":97},[],{"trials":24564,"activeCount":97},[],{"intervention":24566,"totalTrials":660,"cells":24567},"Umeclidinium bromide 62.5mcg",{"EARLY_PHASE1":24568,"PHASE1":24570,"PHASE2":24572,"PHASE3":24574,"PHASE4":24593,"NA":24595},{"trials":24569,"activeCount":97},[],{"trials":24571,"activeCount":97},[],{"trials":24573,"activeCount":97},[],{"trials":24575,"activeCount":97},[24576,24587],{"nctId":24577,"briefTitle":24578,"status":155,"phases":24579,"primaryCompletion":24580,"completion":24581,"start":24582,"enrollment":10225,"conditions":24583,"interventions":24584},"NCT01772134","Efficacy and Safety of the Addition of Fluticanse Propionate\u002FSalmeterol (250\u002F50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks",[87],"2013-07-01","2013-07-22","2013-01-01",[15],[24566,24585,24586],"Umeclidinium bromide 125mcg","Fluticasone propionate 250mcg\u002FSalmeterol 50mcg",{"nctId":24588,"briefTitle":24589,"status":155,"phases":24590,"primaryCompletion":22319,"completion":22319,"start":8151,"enrollment":21797,"conditions":24591,"interventions":24592},"NCT01772147","Efficacy and Safety of the Addition of Fluticasone Propionate\u002FSalmeterol (250\u002F50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.",[87],[15],[24566,24585,24586],{"trials":24594,"activeCount":97},[],{"trials":24596,"activeCount":97},[],{"intervention":24585,"totalTrials":660,"cells":24598},{"EARLY_PHASE1":24599,"PHASE1":24601,"PHASE2":24603,"PHASE3":24605,"PHASE4":24615,"NA":24617},{"trials":24600,"activeCount":97},[],{"trials":24602,"activeCount":97},[],{"trials":24604,"activeCount":97},[],{"trials":24606,"activeCount":97},[24607,24611],{"nctId":24577,"briefTitle":24578,"status":155,"phases":24608,"primaryCompletion":24580,"completion":24581,"start":24582,"enrollment":10225,"conditions":24609,"interventions":24610},[87],[15],[24566,24585,24586],{"nctId":24588,"briefTitle":24589,"status":155,"phases":24612,"primaryCompletion":22319,"completion":22319,"start":8151,"enrollment":21797,"conditions":24613,"interventions":24614},[87],[15],[24566,24585,24586],{"trials":24616,"activeCount":97},[],{"trials":24618,"activeCount":97},[],{"intervention":24586,"totalTrials":660,"cells":24620},{"EARLY_PHASE1":24621,"PHASE1":24623,"PHASE2":24625,"PHASE3":24627,"PHASE4":24637,"NA":24639},{"trials":24622,"activeCount":97},[],{"trials":24624,"activeCount":97},[],{"trials":24626,"activeCount":97},[],{"trials":24628,"activeCount":97},[24629,24633],{"nctId":24577,"briefTitle":24578,"status":155,"phases":24630,"primaryCompletion":24580,"completion":24581,"start":24582,"enrollment":10225,"conditions":24631,"interventions":24632},[87],[15],[24566,24585,24586],{"nctId":24588,"briefTitle":24589,"status":155,"phases":24634,"primaryCompletion":22319,"completion":22319,"start":8151,"enrollment":21797,"conditions":24635,"interventions":24636},[87],[15],[24566,24585,24586],{"trials":24638,"activeCount":97},[],{"trials":24640,"activeCount":97},[],{"intervention":24642,"totalTrials":660,"cells":24643},"Fluarix™\u002FInflusplit SSW®",{"EARLY_PHASE1":24644,"PHASE1":24646,"PHASE2":24648,"PHASE3":24650,"PHASE4":24667,"NA":24669},{"trials":24645,"activeCount":97},[],{"trials":24647,"activeCount":97},[],{"trials":24649,"activeCount":97},[],{"trials":24651,"activeCount":97},[24652,24660],{"nctId":24653,"briefTitle":24654,"status":155,"phases":24655,"primaryCompletion":24656,"completion":24656,"start":23747,"enrollment":24657,"conditions":24658,"interventions":24659},"NCT01144299","A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults",[87],"2010-07-10",114,[21],[24642],{"nctId":24661,"briefTitle":24662,"status":155,"phases":24663,"primaryCompletion":19497,"completion":19497,"start":24664,"enrollment":1134,"conditions":24665,"interventions":24666},"NCT00920374","A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM \u002F Influsplit SSW® 2009\u002F2010 in Adults",[87],"2009-06-16",[21],[24642],{"trials":24668,"activeCount":97},[],{"trials":24670,"activeCount":97},[],{"intervention":24672,"totalTrials":660,"cells":24673},"ReQuip PR",{"EARLY_PHASE1":24674,"PHASE1":24676,"PHASE2":24678,"PHASE3":24680,"PHASE4":24699,"NA":24701},{"trials":24675,"activeCount":97},[],{"trials":24677,"activeCount":97},[],{"trials":24679,"activeCount":97},[],{"trials":24681,"activeCount":97},[24682,24691],{"nctId":24683,"briefTitle":24684,"status":155,"phases":24685,"primaryCompletion":24686,"completion":24687,"start":24688,"enrollment":877,"conditions":24689,"interventions":24690},"NCT01154166","A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa",[87],"2011-09-01","2011-09-29","2010-02-15",[15879],[24672],{"nctId":24692,"briefTitle":24693,"status":155,"phases":24694,"primaryCompletion":15213,"completion":4877,"start":21379,"enrollment":24695,"conditions":24696,"interventions":24697},"NCT01536574","Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528",[87],295,[15879],[24698],"Requip PR",{"trials":24700,"activeCount":97},[],{"trials":24702,"activeCount":97},[],{"intervention":24704,"totalTrials":660,"cells":24705},"Pneumococcal vaccine",{"EARLY_PHASE1":24706,"PHASE1":24708,"PHASE2":24710,"PHASE3":24720,"PHASE4":24728,"NA":24730},{"trials":24707,"activeCount":97},[],{"trials":24709,"activeCount":97},[],{"trials":24711,"activeCount":97},[24712],{"nctId":24713,"briefTitle":24714,"status":155,"phases":24715,"start":8852,"enrollment":750,"conditions":24716,"interventions":24718},"NCT00327522","Safety and Immune Response Study of an Investigational Pneumococcal Vaccine.",[86],[24717],"Prophylactic Pneumococcal Diseases",[24719],"pneumococcal vaccine",{"trials":24721,"activeCount":97},[24722],{"nctId":24723,"briefTitle":24724,"status":155,"phases":24725,"completion":7659,"start":2296,"enrollment":201,"conditions":24726,"interventions":24727},"NCT00333450","Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.",[87],[3637],[24704],{"trials":24729,"activeCount":97},[],{"trials":24731,"activeCount":97},[],{"intervention":10945,"totalTrials":660,"cells":24733},{"EARLY_PHASE1":24734,"PHASE1":24736,"PHASE2":24738,"PHASE3":24740,"PHASE4":24750,"NA":24752},{"trials":24735,"activeCount":97},[],{"trials":24737,"activeCount":97},[],{"trials":24739,"activeCount":97},[],{"trials":24741,"activeCount":97},[24742,24746],{"nctId":10939,"briefTitle":10940,"status":155,"phases":24743,"primaryCompletion":8750,"completion":8750,"start":10003,"enrollment":1237,"conditions":24744,"interventions":24745},[87],[10943],[10945,10946,10947,10948],{"nctId":10667,"briefTitle":10668,"status":155,"phases":24747,"start":10670,"enrollment":10671,"conditions":24748,"interventions":24749},[87],[10662,9343],[10674,10675,10676,10677,10678,10679,10680],{"trials":24751,"activeCount":97},[],{"trials":24753,"activeCount":97},[],{"intervention":19385,"totalTrials":660,"cells":24755},{"EARLY_PHASE1":24756,"PHASE1":24758,"PHASE2":24760,"PHASE3":24762,"PHASE4":24772,"NA":24774},{"trials":24757,"activeCount":97},[],{"trials":24759,"activeCount":97},[],{"trials":24761,"activeCount":97},[],{"trials":24763,"activeCount":97},[24764,24768],{"nctId":19378,"briefTitle":19379,"status":155,"phases":24765,"primaryCompletion":10167,"completion":10166,"start":2428,"enrollment":19381,"conditions":24766,"interventions":24767},[87],[4704,4703],[19384,19385,19386,8674,8675],{"nctId":19422,"briefTitle":19423,"status":155,"phases":24769,"primaryCompletion":19425,"completion":18288,"start":19426,"enrollment":19427,"conditions":24770,"interventions":24771},[87],[4704,4703],[19430,4806,19385,4805,19386,8674,8675],{"trials":24773,"activeCount":97},[],{"trials":24775,"activeCount":97},[],{"intervention":8065,"totalTrials":660,"cells":24777},{"EARLY_PHASE1":24778,"PHASE1":24780,"PHASE2":24782,"PHASE3":24784,"PHASE4":24794,"NA":24796},{"trials":24779,"activeCount":97},[],{"trials":24781,"activeCount":97},[],{"trials":24783,"activeCount":97},[],{"trials":24785,"activeCount":97},[24786,24790],{"nctId":8056,"briefTitle":8057,"status":155,"phases":24787,"primaryCompletion":8059,"completion":8059,"start":8060,"enrollment":8061,"conditions":24788,"interventions":24789},[87],[8063],[8021,8065,8066,8067,8068,8069],{"nctId":9096,"briefTitle":9097,"status":155,"phases":24791,"primaryCompletion":8468,"completion":8468,"start":2481,"enrollment":9099,"conditions":24792,"interventions":24793},[87],[27],[9093,8065,9016],{"trials":24795,"activeCount":97},[],{"trials":24797,"activeCount":97},[],{"intervention":24799,"totalTrials":660,"cells":24800},"GW642444 25mcg",{"EARLY_PHASE1":24801,"PHASE1":24803,"PHASE2":24805,"PHASE3":24818,"PHASE4":24830,"NA":24832},{"trials":24802,"activeCount":97},[],{"trials":24804,"activeCount":97},[],{"trials":24806,"activeCount":97},[24807],{"nctId":24808,"briefTitle":24809,"status":155,"phases":24810,"primaryCompletion":9133,"completion":9133,"start":9737,"enrollment":24811,"conditions":24812,"interventions":24813},"NCT00606684","A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[86],602,[15],[24814,24815,24816,24799,24817],"GW642444 6.25","GW642444 3mcg","GW642444 12.5mcg","GW642444 50mcg",{"trials":24819,"activeCount":97},[24820],{"nctId":24821,"briefTitle":24822,"status":155,"phases":24823,"primaryCompletion":15213,"completion":24824,"start":18536,"enrollment":24825,"conditions":24826,"interventions":24827},"NCT01313637","A 24-week Evaluation of GSK573719\u002FVilanterol (125\u002F25mcg) and Components in COPD",[87],"2012-04-19",1493,[15],[24828,24829,24799],"GSK573719\u002FGW642444 125\u002F25mcg","GSK573719 125mcg",{"trials":24831,"activeCount":97},[],{"trials":24833,"activeCount":97},[],{"intervention":7829,"totalTrials":660,"cells":24835},{"EARLY_PHASE1":24836,"PHASE1":24838,"PHASE2":24840,"PHASE3":24846,"PHASE4":24852,"NA":24854},{"trials":24837,"activeCount":97},[],{"trials":24839,"activeCount":97},[],{"trials":24841,"activeCount":97},[24842],{"nctId":19827,"briefTitle":19828,"status":155,"phases":24843,"primaryCompletion":2405,"completion":19830,"start":19831,"enrollment":3285,"conditions":24844,"interventions":24845},[86],[4704],[19834,19835,7829,19818,19836],{"trials":24847,"activeCount":97},[24848],{"nctId":7821,"briefTitle":7822,"status":155,"phases":24849,"primaryCompletion":2373,"completion":7824,"start":7825,"enrollment":7826,"conditions":24850,"interventions":24851},[87],[24],[7829,7830,7831,7832,7718],{"trials":24853,"activeCount":97},[],{"trials":24855,"activeCount":97},[],{"intervention":18293,"totalTrials":660,"cells":24857},{"EARLY_PHASE1":24858,"PHASE1":24860,"PHASE2":24862,"PHASE3":24873,"PHASE4":24879,"NA":24881},{"trials":24859,"activeCount":97},[],{"trials":24861,"activeCount":97},[],{"trials":24863,"activeCount":97},[24864],{"nctId":24865,"briefTitle":24866,"status":155,"phases":24867,"primaryCompletion":24868,"completion":24869,"start":10540,"enrollment":13031,"conditions":24870,"interventions":24871},"NCT00892775","Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds",[86],"2010-09-17","2010-12-13",[2486,3717,2485,2484],[18293,24872],"GSK Biologicals' 208136, new formulation",{"trials":24874,"activeCount":97},[24875],{"nctId":18285,"briefTitle":18286,"status":155,"phases":24876,"primaryCompletion":18288,"completion":18289,"start":18290,"enrollment":15623,"conditions":24877,"interventions":24878},[87],[992],[8291,18293,4749],{"trials":24880,"activeCount":97},[],{"trials":24882,"activeCount":97},[],{"intervention":24884,"totalTrials":660,"cells":24885},"GSK Biologicals' Synflorix™",{"EARLY_PHASE1":24886,"PHASE1":24888,"PHASE2":24890,"PHASE3":24892,"PHASE4":24913,"NA":24915},{"trials":24887,"activeCount":97},[],{"trials":24889,"activeCount":97},[],{"trials":24891,"activeCount":97},[],{"trials":24893,"activeCount":97},[24894,24904],{"nctId":24895,"briefTitle":24896,"status":155,"phases":24897,"primaryCompletion":9877,"completion":24898,"start":24899,"enrollment":10407,"conditions":24900,"interventions":24901},"NCT00678301","Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™",[87],"2009-12-10","2008-06-18",[3637],[24884,24902,24903],"GSK Biologicals' Polio Sabin™","GSK Biologicals' Zilbrix™ Hib",{"nctId":24905,"briefTitle":24906,"status":155,"phases":24907,"primaryCompletion":24908,"completion":24908,"start":24909,"enrollment":1752,"conditions":24910,"interventions":24911},"NCT00911144","Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine",[87],"2010-01-11","2009-06-11",[3637],[24884,24912,18829],"Wyeth-Lederle's Prevenar™",{"trials":24914,"activeCount":97},[],{"trials":24916,"activeCount":97},[],{"intervention":23985,"totalTrials":660,"cells":24918},{"EARLY_PHASE1":24919,"PHASE1":24921,"PHASE2":24923,"PHASE3":24925,"PHASE4":24944,"NA":24946},{"trials":24920,"activeCount":97},[],{"trials":24922,"activeCount":97},[],{"trials":24924,"activeCount":97},[],{"trials":24926,"activeCount":97},[24927,24940],{"nctId":24928,"briefTitle":24929,"status":155,"phases":24930,"primaryCompletion":22657,"completion":24931,"start":18536,"enrollment":24932,"conditions":24933,"interventions":24934},"NCT01328444","An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719\u002FGW642444. Study A",[87],"2012-06-14",349,[15],[24935,24936,24937,24938,23985,24939],"GSK 573719 +GW642444 125\u002F25","GSK573719 + GW642444 62.5\u002F25","GSK 573719 125","GSK 573719 62.5","Plb",{"nctId":23977,"briefTitle":23978,"status":155,"phases":24941,"primaryCompletion":472,"completion":623,"start":23980,"enrollment":5520,"conditions":24942,"interventions":24943},[87],[15],[18444,18445,23983,23984,23985],{"trials":24945,"activeCount":97},[],{"trials":24947,"activeCount":97},[],{"intervention":22936,"totalTrials":660,"cells":24949},{"EARLY_PHASE1":24950,"PHASE1":24952,"PHASE2":24954,"PHASE3":24956,"PHASE4":24966,"NA":24968},{"trials":24951,"activeCount":97},[],{"trials":24953,"activeCount":97},[],{"trials":24955,"activeCount":97},[],{"trials":24957,"activeCount":97},[24958,24962],{"nctId":22929,"briefTitle":22930,"status":145,"phases":24959,"primaryCompletion":22932,"completion":22932,"start":22933,"enrollment":105,"conditions":24960,"interventions":24961},[87],[22921],[22908,22936],{"nctId":22938,"briefTitle":22939,"status":155,"phases":24963,"primaryCompletion":22941,"completion":22941,"start":12041,"enrollment":11018,"conditions":24964,"interventions":24965},[87],[22921],[22908,22936],{"trials":24967,"activeCount":97},[],{"trials":24969,"activeCount":97},[],{"intervention":22970,"totalTrials":660,"cells":24971},{"EARLY_PHASE1":24972,"PHASE1":24974,"PHASE2":24976,"PHASE3":24978,"PHASE4":24988,"NA":24990},{"trials":24973,"activeCount":97},[],{"trials":24975,"activeCount":97},[],{"trials":24977,"activeCount":97},[],{"trials":24979,"activeCount":97},[24980,24984],{"nctId":22963,"briefTitle":22964,"status":155,"phases":24981,"primaryCompletion":22966,"completion":8916,"start":22967,"enrollment":770,"conditions":24982,"interventions":24983},[87],[992],[22970,4707],{"nctId":23053,"briefTitle":23054,"status":155,"phases":24985,"primaryCompletion":23056,"completion":23057,"start":11940,"enrollment":23058,"conditions":24986,"interventions":24987},[87],[992],[23061,23062,23063,23016,10570],{"trials":24989,"activeCount":97},[],{"trials":24991,"activeCount":97},[],{"intervention":24993,"totalTrials":660,"cells":24994},"Umeclidinium bromide",{"EARLY_PHASE1":24995,"PHASE1":24997,"PHASE2":24999,"PHASE3":25001,"PHASE4":25015,"NA":25017},{"trials":24996,"activeCount":97},[],{"trials":24998,"activeCount":97},[],{"trials":25000,"activeCount":97},[],{"trials":25002,"activeCount":97},[25003,25011],{"nctId":25004,"briefTitle":25005,"status":155,"phases":25006,"primaryCompletion":25007,"completion":25007,"start":25008,"enrollment":7826,"conditions":25009,"interventions":25010},"NCT02184611","A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)",[87],"2017-11-08","2016-05-09",[15],[24993],{"nctId":9523,"briefTitle":9524,"status":155,"phases":25012,"primaryCompletion":9526,"completion":9526,"start":9527,"enrollment":9528,"conditions":25013,"interventions":25014},[87],[15],[8556,9531,9532],{"trials":25016,"activeCount":97},[],{"trials":25018,"activeCount":97},[],{"intervention":24829,"totalTrials":660,"cells":25020},{"EARLY_PHASE1":25021,"PHASE1":25023,"PHASE2":25025,"PHASE3":25037,"PHASE4":25043,"NA":25045},{"trials":25022,"activeCount":97},[],{"trials":25024,"activeCount":97},[],{"trials":25026,"activeCount":97},[25027],{"nctId":25028,"briefTitle":25029,"status":155,"phases":25030,"primaryCompletion":25031,"completion":25031,"start":25032,"enrollment":17678,"conditions":25033,"interventions":25034},"NCT01030965","28-day Repeat Dose Study of GSK573719",[86],"2010-07-04","2009-12-15",[15],[24829,25035,25036],"GSK573719 250mcg","GSK573719 500mcg",{"trials":25038,"activeCount":97},[25039],{"nctId":24821,"briefTitle":24822,"status":155,"phases":25040,"primaryCompletion":15213,"completion":24824,"start":18536,"enrollment":24825,"conditions":25041,"interventions":25042},[87],[15],[24828,24829,24799],{"trials":25044,"activeCount":97},[],{"trials":25046,"activeCount":97},[],{"intervention":9051,"totalTrials":660,"cells":25048},{"EARLY_PHASE1":25049,"PHASE1":25051,"PHASE2":25053,"PHASE3":25059,"PHASE4":25065,"NA":25067},{"trials":25050,"activeCount":97},[],{"trials":25052,"activeCount":97},[],{"trials":25054,"activeCount":97},[25055],{"nctId":9042,"briefTitle":9043,"status":155,"phases":25056,"primaryCompletion":9045,"completion":9045,"start":9046,"enrollment":8437,"conditions":25057,"interventions":25058},[86],[9048],[9050,9016,9051],{"trials":25060,"activeCount":97},[25061],{"nctId":8071,"briefTitle":8072,"status":155,"phases":25062,"primaryCompletion":3111,"completion":3111,"start":7647,"enrollment":3230,"conditions":25063,"interventions":25064},[87],[27],[7997,8076],{"trials":25066,"activeCount":97},[],{"trials":25068,"activeCount":97},[],{"intervention":23033,"totalTrials":660,"cells":25070},{"EARLY_PHASE1":25071,"PHASE1":25073,"PHASE2":25075,"PHASE3":25081,"PHASE4":25090,"NA":25092},{"trials":25072,"activeCount":97},[],{"trials":25074,"activeCount":97},[],{"trials":25076,"activeCount":97},[25077],{"nctId":23025,"briefTitle":23026,"status":155,"phases":25078,"primaryCompletion":23028,"completion":23029,"start":2374,"enrollment":23030,"conditions":25079,"interventions":25080},[86],[4703,4704],[23033,23034,23035,23016,23036,10583,10546,10573],{"trials":25082,"activeCount":97},[25083],{"nctId":25084,"briefTitle":25085,"status":155,"phases":25086,"primaryCompletion":3079,"completion":7590,"start":4757,"enrollment":12560,"conditions":25087,"interventions":25088},"NCT00359983","Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB",[87],[4703,4704],[23033,25089],"Hib conjugate vaccine",{"trials":25091,"activeCount":97},[],{"trials":25093,"activeCount":97},[],{"intervention":10583,"totalTrials":660,"cells":25095},{"EARLY_PHASE1":25096,"PHASE1":25098,"PHASE2":25100,"PHASE3":25106,"PHASE4":25112,"NA":25114},{"trials":25097,"activeCount":97},[],{"trials":25099,"activeCount":97},[],{"trials":25101,"activeCount":97},[25102],{"nctId":23025,"briefTitle":23026,"status":155,"phases":25103,"primaryCompletion":23028,"completion":23029,"start":2374,"enrollment":23030,"conditions":25104,"interventions":25105},[86],[4703,4704],[23033,23034,23035,23016,23036,10583,10546,10573],{"trials":25107,"activeCount":97},[25108],{"nctId":10575,"briefTitle":10576,"status":155,"phases":25109,"primaryCompletion":10578,"completion":10578,"start":10579,"enrollment":10580,"conditions":25110,"interventions":25111},[87],[7966],[10526,10583,10584],{"trials":25113,"activeCount":97},[],{"trials":25115,"activeCount":97},[],{"intervention":25117,"totalTrials":660,"cells":25118},"HZ\u002Fsu",{"EARLY_PHASE1":25119,"PHASE1":25121,"PHASE2":25123,"PHASE3":25125,"PHASE4":25146,"NA":25148},{"trials":25120,"activeCount":97},[],{"trials":25122,"activeCount":97},[],{"trials":25124,"activeCount":97},[],{"trials":25126,"activeCount":97},[25127,25138],{"nctId":25128,"briefTitle":25129,"status":155,"phases":25130,"primaryCompletion":25131,"completion":1157,"start":25132,"enrollment":25133,"conditions":25134,"interventions":25135},"NCT05047770","A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine",[87],"2022-08-29","2021-10-07",2013,[1030],[25117,25136,25137],"Flu D-QIV","mRNA-1273",{"nctId":25139,"briefTitle":25140,"status":155,"phases":25141,"primaryCompletion":25142,"completion":25143,"start":3680,"enrollment":12474,"conditions":25144,"interventions":25145},"NCT05219253","A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India",[87],"2022-10-11","2022-12-12",[1030],[25117],{"trials":25147,"activeCount":97},[],{"trials":25149,"activeCount":97},[],{"intervention":25151,"totalTrials":660,"cells":25152},"Paracetamol marketed formulation",{"EARLY_PHASE1":25153,"PHASE1":25155,"PHASE2":25165,"PHASE3":25167,"PHASE4":25177,"NA":25179},{"trials":25154,"activeCount":97},[],{"trials":25156,"activeCount":97},[25157],{"nctId":25158,"briefTitle":25159,"status":155,"phases":25160,"primaryCompletion":9159,"completion":9159,"start":2441,"enrollment":255,"conditions":25161,"interventions":25163},"NCT01476176","A Pharmacokinetic Study of an Experimental Paracetamol Formulation",[85],[25162],"Headache, Tension-Type",[25164,25151],"Experimental paracetamol",{"trials":25166,"activeCount":97},[],{"trials":25168,"activeCount":97},[25169],{"nctId":25170,"briefTitle":25171,"status":145,"phases":25172,"primaryCompletion":3078,"completion":3078,"start":2441,"enrollment":2321,"conditions":25173,"interventions":25174},"NCT01755702","Paracetamol With Caffeine to Treat Episodic Tension Type Headache",[86,87],[25162],[25175,25176,25151],"Experimental paracetamol + caffeine formulation","ibuprofen marketed formulation",{"trials":25178,"activeCount":97},[],{"trials":25180,"activeCount":97},[],{"intervention":25182,"totalTrials":660,"cells":25183},"rosiglitazone maleate",{"EARLY_PHASE1":25184,"PHASE1":25186,"PHASE2":25195,"PHASE3":25197,"PHASE4":25207,"NA":25209},{"trials":25185,"activeCount":97},[],{"trials":25187,"activeCount":97},[25188],{"nctId":25189,"briefTitle":25190,"status":155,"phases":25191,"primaryCompletion":25192,"completion":25192,"start":12180,"enrollment":710,"conditions":25193,"interventions":25194},"NCT00551564","Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate",[85],"2008-09-08",[27],[25182],{"trials":25196,"activeCount":97},[],{"trials":25198,"activeCount":97},[25199],{"nctId":25200,"briefTitle":25201,"status":155,"phases":25202,"primaryCompletion":7976,"completion":7976,"start":10803,"enrollment":25203,"conditions":25204,"interventions":25205},"NCT00116831","Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes",[87],672,[9309],[25206,25182],"Glipizide",{"trials":25208,"activeCount":97},[],{"trials":25210,"activeCount":97},[],{"intervention":25212,"totalTrials":660,"cells":25213},"Fluticasone furoate 50mcg",{"EARLY_PHASE1":25214,"PHASE1":25216,"PHASE2":25218,"PHASE3":25220,"PHASE4":25234,"NA":25236},{"trials":25215,"activeCount":97},[],{"trials":25217,"activeCount":97},[],{"trials":25219,"activeCount":97},[],{"trials":25221,"activeCount":97},[25222,25228],{"nctId":25223,"briefTitle":25224,"status":155,"phases":25225,"primaryCompletion":2295,"completion":9706,"start":3111,"enrollment":8449,"conditions":25226,"interventions":25227},"NCT01436071","Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma",[87],[18],[25212],{"nctId":25229,"briefTitle":25230,"status":155,"phases":25231,"primaryCompletion":3110,"completion":3110,"start":3111,"enrollment":265,"conditions":25232,"interventions":25233},"NCT01436110","Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate and Fluticasone Propionate in People With Asthma",[87],[18],[25212,9510],{"trials":25235,"activeCount":97},[],{"trials":25237,"activeCount":97},[],{"intervention":25239,"totalTrials":660,"cells":25240},"GSK Biologicals Herpes Zoster subunit",{"EARLY_PHASE1":25241,"PHASE1":25243,"PHASE2":25245,"PHASE3":25247,"PHASE4":25265,"NA":25267},{"trials":25242,"activeCount":97},[],{"trials":25244,"activeCount":97},[],{"trials":25246,"activeCount":97},[],{"trials":25248,"activeCount":97},[25249,25257],{"nctId":25250,"briefTitle":25251,"status":155,"phases":25252,"primaryCompletion":25253,"completion":21989,"start":810,"enrollment":25254,"conditions":25255,"interventions":25256},"NCT02979639","Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ\u002Fsu) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age",[87],"2017-04-12",404,[1030],[25239],{"nctId":25258,"briefTitle":25259,"status":155,"phases":25260,"primaryCompletion":1661,"completion":25261,"start":25262,"enrollment":9627,"conditions":25263,"interventions":25264},"NCT02581410","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ\u002Fsu) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier",[87],"2017-08-01","2015-12-15",[1030],[25239],{"trials":25266,"activeCount":97},[],{"trials":25268,"activeCount":97},[],{"intervention":7875,"totalTrials":660,"cells":25270},{"EARLY_PHASE1":25271,"PHASE1":25273,"PHASE2":25275,"PHASE3":25281,"PHASE4":25287,"NA":25289},{"trials":25272,"activeCount":97},[],{"trials":25274,"activeCount":97},[],{"trials":25276,"activeCount":97},[25277],{"nctId":19160,"briefTitle":19161,"status":155,"phases":25278,"primaryCompletion":19163,"completion":19164,"start":19165,"enrollment":19166,"conditions":25279,"interventions":25280},[86],[3637],[19169,19170,10348,7875,19151],{"trials":25282,"activeCount":97},[25283],{"nctId":7862,"briefTitle":7863,"status":155,"phases":25284,"primaryCompletion":7865,"completion":7866,"start":7867,"enrollment":7868,"conditions":25285,"interventions":25286},[87],[4704],[7871,7872,7873,7874,7875,7830,7718,7876],{"trials":25288,"activeCount":97},[],{"trials":25290,"activeCount":97},[],{"intervention":25292,"totalTrials":660,"cells":25293},"IV Casopitant",{"EARLY_PHASE1":25294,"PHASE1":25296,"PHASE2":25298,"PHASE3":25300,"PHASE4":25317,"NA":25319},{"trials":25295,"activeCount":97},[],{"trials":25297,"activeCount":97},[],{"trials":25299,"activeCount":97},[],{"trials":25301,"activeCount":97},[25302,25313],{"nctId":25303,"briefTitle":25304,"status":155,"phases":25305,"primaryCompletion":25306,"completion":25306,"start":25307,"enrollment":22123,"conditions":25308,"interventions":25309},"NCT00431236","A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy",[87],"2007-10-09","2006-11-06",[1337],[25310,25292,25311,25312],"Oral Casopitant","IV ondansetron hydrochloride","Oral dexamethasone",{"nctId":1425,"briefTitle":1426,"status":500,"phases":25314,"primaryCompletion":1428,"completion":1428,"start":1429,"enrollment":97,"conditions":25315,"interventions":25316},[87],[36,1364,1383,1431],[283,283,1433,1433,1387],{"trials":25318,"activeCount":97},[],{"trials":25320,"activeCount":97},[],{"intervention":8292,"totalTrials":660,"cells":25322},{"EARLY_PHASE1":25323,"PHASE1":25325,"PHASE2":25327,"PHASE3":25333,"PHASE4":25339,"NA":25341},{"trials":25324,"activeCount":97},[],{"trials":25326,"activeCount":97},[],{"trials":25328,"activeCount":97},[25329],{"nctId":10272,"briefTitle":10273,"status":155,"phases":25330,"primaryCompletion":10275,"completion":10276,"start":10277,"enrollment":10278,"conditions":25331,"interventions":25332},[86],[992],[10216,10101,10263,8971,8292],{"trials":25334,"activeCount":97},[25335],{"nctId":8282,"briefTitle":8283,"status":155,"phases":25336,"primaryCompletion":8285,"completion":8286,"start":8287,"enrollment":8288,"conditions":25337,"interventions":25338},[87],[992],[8291,8292,8177],{"trials":25340,"activeCount":97},[],{"trials":25342,"activeCount":97},[],{"intervention":9780,"totalTrials":660,"cells":25344},{"EARLY_PHASE1":25345,"PHASE1":25347,"PHASE2":25349,"PHASE3":25351,"PHASE4":25361,"NA":25363},{"trials":25346,"activeCount":97},[],{"trials":25348,"activeCount":97},[],{"trials":25350,"activeCount":97},[],{"trials":25352,"activeCount":97},[25353,25357],{"nctId":9773,"briefTitle":9774,"status":155,"phases":25354,"primaryCompletion":9776,"completion":9776,"start":3425,"enrollment":9777,"conditions":25355,"interventions":25356},[87],[21],[8230,9743,9780],{"nctId":9799,"briefTitle":9800,"status":155,"phases":25358,"primaryCompletion":9802,"completion":9802,"start":3425,"enrollment":9803,"conditions":25359,"interventions":25360},[87],[21],[8230,9743,9780],{"trials":25362,"activeCount":97},[],{"trials":25364,"activeCount":97},[],{"intervention":4747,"totalTrials":660,"cells":25366},{"EARLY_PHASE1":25367,"PHASE1":25369,"PHASE2":25371,"PHASE3":25373,"PHASE4":25383,"NA":25385},{"trials":25368,"activeCount":97},[],{"trials":25370,"activeCount":97},[],{"trials":25372,"activeCount":97},[],{"trials":25374,"activeCount":97},[25375,25379],{"nctId":4734,"briefTitle":4735,"status":155,"phases":25376,"primaryCompletion":4737,"completion":4738,"start":4739,"enrollment":4740,"conditions":25377,"interventions":25378},[87],[24,3624,33,4702,30,4742],[4744,4745,4472,4746,4747,4748,4749,4750,4751],{"nctId":4840,"briefTitle":4841,"status":155,"phases":25380,"primaryCompletion":4843,"completion":4843,"start":4844,"enrollment":590,"conditions":25381,"interventions":25382},[87],[4703,4704],[4847,4848,4472,4849],{"trials":25384,"activeCount":97},[],{"trials":25386,"activeCount":97},[],{"intervention":21734,"totalTrials":660,"cells":25388},{"EARLY_PHASE1":25389,"PHASE1":25391,"PHASE2":25393,"PHASE3":25395,"PHASE4":25405,"NA":25407},{"trials":25390,"activeCount":97},[],{"trials":25392,"activeCount":97},[],{"trials":25394,"activeCount":97},[],{"trials":25396,"activeCount":97},[25397,25401],{"nctId":21727,"briefTitle":21728,"status":155,"phases":25398,"primaryCompletion":21730,"completion":21730,"start":21731,"enrollment":1589,"conditions":25399,"interventions":25400},[87],[24,7966],[21716,21734],{"nctId":21744,"briefTitle":21745,"status":155,"phases":25402,"primaryCompletion":3036,"completion":3036,"start":10670,"enrollment":21747,"conditions":25403,"interventions":25404},[87],[24,7966],[21716,21734],{"trials":25406,"activeCount":97},[],{"trials":25408,"activeCount":97},[],{"intervention":19855,"totalTrials":660,"cells":25410},{"EARLY_PHASE1":25411,"PHASE1":25413,"PHASE2":25415,"PHASE3":25417,"PHASE4":25427,"NA":25429},{"trials":25412,"activeCount":97},[],{"trials":25414,"activeCount":97},[],{"trials":25416,"activeCount":97},[],{"trials":25418,"activeCount":97},[25419,25423],{"nctId":19849,"briefTitle":19850,"status":155,"phases":25420,"primaryCompletion":19852,"completion":19852,"start":17948,"enrollment":7694,"conditions":25421,"interventions":25422},[87],[992],[19855,19818,18312],{"nctId":19879,"briefTitle":19880,"status":155,"phases":25424,"primaryCompletion":18524,"completion":14626,"start":19882,"enrollment":8275,"conditions":25425,"interventions":25426},[87],[992],[19855,19818,19885],{"trials":25428,"activeCount":97},[],{"trials":25430,"activeCount":97},[],{"intervention":25432,"totalTrials":660,"cells":25433},"Infanrix hexa.",{"EARLY_PHASE1":25434,"PHASE1":25436,"PHASE2":25438,"PHASE3":25440,"PHASE4":25461,"NA":25463},{"trials":25435,"activeCount":97},[],{"trials":25437,"activeCount":97},[],{"trials":25439,"activeCount":97},[],{"trials":25441,"activeCount":97},[25442,25452],{"nctId":25443,"briefTitle":25444,"status":155,"phases":25445,"primaryCompletion":25446,"completion":18807,"start":4789,"enrollment":1982,"conditions":25447,"interventions":25448},"NCT00496015","Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A",[87],"2008-03-25",[3637],[25449,25432,25450,25451],"Pneumococcal conjugate vaccine GSK1024850A.","Meningococcal vaccine GSK134612.","Paracetamol.",{"nctId":25453,"briefTitle":25454,"status":155,"phases":25455,"primaryCompletion":3619,"completion":25456,"start":3621,"enrollment":265,"conditions":25457,"interventions":25458},"NCT00307034","Safety & Immunogenicity Study of 10-Valent Pneumococcal Conjugate Vaccine When Administered as a 2-Dose Schedule",[87],"2007-01-25",[3637],[25459,25432,25460],"GSK Biologicals' 10-valent pneumococcal conjugate vaccine.","Infanrix-IPV\u002FHib.",{"trials":25462,"activeCount":97},[],{"trials":25464,"activeCount":97},[],{"intervention":25466,"totalTrials":660,"cells":25467},"Malaria Vaccine 257049",{"EARLY_PHASE1":25468,"PHASE1":25470,"PHASE2":25472,"PHASE3":25474,"PHASE4":25498,"NA":25500},{"trials":25469,"activeCount":97},[],{"trials":25471,"activeCount":97},[],{"trials":25473,"activeCount":97},[],{"trials":25475,"activeCount":97},[25476,25489],{"nctId":25477,"briefTitle":25478,"status":155,"phases":25479,"primaryCompletion":25480,"completion":25480,"start":25481,"enrollment":25482,"conditions":25483,"interventions":25484},"NCT02207816","An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa",[87],"2017-01-31","2014-09-18",3084,[3287],[25466,25485,25486,25487,25488],"Meningococcal C Conjugate Vaccine","Cell-culture rabies vaccine","TritanrixHepB\u002FHib","Polio Sabin Oral Polio Vaccine",{"nctId":25490,"briefTitle":25491,"status":155,"phases":25492,"primaryCompletion":18536,"completion":25493,"start":25494,"enrollment":25495,"conditions":25496,"interventions":25497},"NCT00866619","Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa",[87],"2014-01-31","2009-03-27",15459,[3287],[25466,25485,25486,25487,25488],{"trials":25499,"activeCount":97},[],{"trials":25501,"activeCount":97},[],{"intervention":25485,"totalTrials":660,"cells":25503},{"EARLY_PHASE1":25504,"PHASE1":25506,"PHASE2":25508,"PHASE3":25510,"PHASE4":25520,"NA":25522},{"trials":25505,"activeCount":97},[],{"trials":25507,"activeCount":97},[],{"trials":25509,"activeCount":97},[],{"trials":25511,"activeCount":97},[25512,25516],{"nctId":25477,"briefTitle":25478,"status":155,"phases":25513,"primaryCompletion":25480,"completion":25480,"start":25481,"enrollment":25482,"conditions":25514,"interventions":25515},[87],[3287],[25466,25485,25486,25487,25488],{"nctId":25490,"briefTitle":25491,"status":155,"phases":25517,"primaryCompletion":18536,"completion":25493,"start":25494,"enrollment":25495,"conditions":25518,"interventions":25519},[87],[3287],[25466,25485,25486,25487,25488],{"trials":25521,"activeCount":97},[],{"trials":25523,"activeCount":97},[],{"intervention":25486,"totalTrials":660,"cells":25525},{"EARLY_PHASE1":25526,"PHASE1":25528,"PHASE2":25530,"PHASE3":25532,"PHASE4":25542,"NA":25544},{"trials":25527,"activeCount":97},[],{"trials":25529,"activeCount":97},[],{"trials":25531,"activeCount":97},[],{"trials":25533,"activeCount":97},[25534,25538],{"nctId":25477,"briefTitle":25478,"status":155,"phases":25535,"primaryCompletion":25480,"completion":25480,"start":25481,"enrollment":25482,"conditions":25536,"interventions":25537},[87],[3287],[25466,25485,25486,25487,25488],{"nctId":25490,"briefTitle":25491,"status":155,"phases":25539,"primaryCompletion":18536,"completion":25493,"start":25494,"enrollment":25495,"conditions":25540,"interventions":25541},[87],[3287],[25466,25485,25486,25487,25488],{"trials":25543,"activeCount":97},[],{"trials":25545,"activeCount":97},[],{"intervention":25487,"totalTrials":660,"cells":25547},{"EARLY_PHASE1":25548,"PHASE1":25550,"PHASE2":25552,"PHASE3":25554,"PHASE4":25564,"NA":25566},{"trials":25549,"activeCount":97},[],{"trials":25551,"activeCount":97},[],{"trials":25553,"activeCount":97},[],{"trials":25555,"activeCount":97},[25556,25560],{"nctId":25477,"briefTitle":25478,"status":155,"phases":25557,"primaryCompletion":25480,"completion":25480,"start":25481,"enrollment":25482,"conditions":25558,"interventions":25559},[87],[3287],[25466,25485,25486,25487,25488],{"nctId":25490,"briefTitle":25491,"status":155,"phases":25561,"primaryCompletion":18536,"completion":25493,"start":25494,"enrollment":25495,"conditions":25562,"interventions":25563},[87],[3287],[25466,25485,25486,25487,25488],{"trials":25565,"activeCount":97},[],{"trials":25567,"activeCount":97},[],{"intervention":25488,"totalTrials":660,"cells":25569},{"EARLY_PHASE1":25570,"PHASE1":25572,"PHASE2":25574,"PHASE3":25576,"PHASE4":25586,"NA":25588},{"trials":25571,"activeCount":97},[],{"trials":25573,"activeCount":97},[],{"trials":25575,"activeCount":97},[],{"trials":25577,"activeCount":97},[25578,25582],{"nctId":25477,"briefTitle":25478,"status":155,"phases":25579,"primaryCompletion":25480,"completion":25480,"start":25481,"enrollment":25482,"conditions":25580,"interventions":25581},[87],[3287],[25466,25485,25486,25487,25488],{"nctId":25490,"briefTitle":25491,"status":155,"phases":25583,"primaryCompletion":18536,"completion":25493,"start":25494,"enrollment":25495,"conditions":25584,"interventions":25585},[87],[3287],[25466,25485,25486,25487,25488],{"trials":25587,"activeCount":97},[],{"trials":25589,"activeCount":97},[],{"intervention":12895,"totalTrials":660,"cells":25591},{"EARLY_PHASE1":25592,"PHASE1":25594,"PHASE2":25596,"PHASE3":25598,"PHASE4":25611,"NA":25613},{"trials":25593,"activeCount":97},[],{"trials":25595,"activeCount":97},[],{"trials":25597,"activeCount":97},[],{"trials":25599,"activeCount":97},[25600,25607],{"nctId":25601,"briefTitle":25602,"status":155,"phases":25603,"primaryCompletion":4791,"completion":4257,"start":8365,"enrollment":25604,"conditions":25605,"interventions":25606},"NCT00269087","GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)",[87],122,[15],[12895],{"nctId":12890,"briefTitle":12891,"status":155,"phases":25608,"primaryCompletion":10395,"completion":10395,"start":1380,"enrollment":1579,"conditions":25609,"interventions":25610},[87],[15],[12895,8482],{"trials":25612,"activeCount":97},[],{"trials":25614,"activeCount":97},[],{"intervention":10570,"totalTrials":660,"cells":25616},{"EARLY_PHASE1":25617,"PHASE1":25619,"PHASE2":25621,"PHASE3":25623,"PHASE4":25633,"NA":25635},{"trials":25618,"activeCount":97},[],{"trials":25620,"activeCount":97},[],{"trials":25622,"activeCount":97},[],{"trials":25624,"activeCount":97},[25625,25629],{"nctId":23053,"briefTitle":23054,"status":155,"phases":25626,"primaryCompletion":23056,"completion":23057,"start":11940,"enrollment":23058,"conditions":25627,"interventions":25628},[87],[992],[23061,23062,23063,23016,10570],{"nctId":10563,"briefTitle":10564,"status":155,"phases":25630,"primaryCompletion":10566,"completion":10566,"start":8825,"enrollment":1944,"conditions":25631,"interventions":25632},[87],[4703,4704],[10569,10570,10571,10572,10573,10526],{"trials":25634,"activeCount":97},[],{"trials":25636,"activeCount":97},[],{"intervention":25638,"totalTrials":660,"cells":25639},"Fluarix Quadrivalent",{"EARLY_PHASE1":25640,"PHASE1":25642,"PHASE2":25661,"PHASE3":25663,"PHASE4":25674,"NA":25676},{"trials":25641,"activeCount":97},[],{"trials":25643,"activeCount":97},[25644],{"nctId":25645,"briefTitle":25646,"status":155,"phases":25647,"primaryCompletion":25648,"completion":25648,"start":452,"enrollment":25649,"conditions":25650,"interventions":25651},"NCT03275389","A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years",[85],"2020-03-26",470,[5353],[25652,25653,25654,25655,25656,25657,25658,25659,25660,25638],"D-SUIV cH8\u002F1N1+AS03","D-SUIV cH5\u002F1N1+AS03","D-SUIV cH11\u002F1N1+AS03","D-SUIV cH8\u002F1N1+AS01","D-SUIV cH5\u002F1N1+AS01","D-SUIV cH11\u002F1N1+AS01","D-SUIV cH8\u002F1N1","D-SUIV cH5\u002F1N1","D-SUIV cH11\u002F1N1",{"trials":25662,"activeCount":97},[],{"trials":25664,"activeCount":97},[25665],{"nctId":25666,"briefTitle":25667,"status":155,"phases":25668,"primaryCompletion":25669,"completion":25670,"start":25671,"enrollment":25649,"conditions":25672,"interventions":25673},"NCT01702454","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345",[87],"2013-05-06","2013-06-05","2012-10-06",[21],[25638],{"trials":25675,"activeCount":97},[],{"trials":25677,"activeCount":97},[],{"intervention":25679,"totalTrials":660,"cells":25680},"Influenza vaccine",{"EARLY_PHASE1":25681,"PHASE1":25683,"PHASE2":25685,"PHASE3":25687,"PHASE4":25703,"NA":25705},{"trials":25682,"activeCount":97},[],{"trials":25684,"activeCount":97},[],{"trials":25686,"activeCount":97},[],{"trials":25688,"activeCount":97},[25689,25696],{"nctId":25690,"briefTitle":25691,"status":155,"phases":25692,"primaryCompletion":2805,"completion":2383,"start":8427,"enrollment":25693,"conditions":25694,"interventions":25695},"NCT00197223","Post-marketing Study to Evaluate the Efficacy of Influenza Vaccine",[87],6213,[21],[25679],{"nctId":25697,"briefTitle":25698,"status":155,"phases":25699,"completion":4843,"start":4757,"enrollment":19789,"conditions":25700,"interventions":25701},"NCT00380211","Safety and Immunogenicity of FluLaval™ TR and Fluarix® (Influenza Vaccines) in Young and Older Adults",[87],[21],[25679,25702],"Fluarix",{"trials":25704,"activeCount":97},[],{"trials":25706,"activeCount":97},[],{"intervention":25708,"totalTrials":660,"cells":25709},"HPV-16\u002F18 L1 VLP AS04",{"EARLY_PHASE1":25710,"PHASE1":25712,"PHASE2":25714,"PHASE3":25716,"PHASE4":25731,"NA":25733},{"trials":25711,"activeCount":97},[],{"trials":25713,"activeCount":97},[],{"trials":25715,"activeCount":97},[],{"trials":25717,"activeCount":97},[25718,25724],{"nctId":25719,"briefTitle":25720,"status":155,"phases":25721,"primaryCompletion":3552,"completion":3552,"start":7613,"enrollment":536,"conditions":25722,"interventions":25723},"NCT00306241","A Study to Evaluate the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years",[87],[8723],[25708],{"nctId":25725,"briefTitle":25726,"status":155,"phases":25727,"primaryCompletion":25728,"completion":25728,"start":4828,"enrollment":5056,"conditions":25729,"interventions":25730},"NCT00345878","Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years",[87],"2007-12-21",[8723],[25708],{"trials":25732,"activeCount":97},[],{"trials":25734,"activeCount":97},[],{"intervention":25736,"totalTrials":660,"cells":25737},"Ambrisentan 5 mg",{"EARLY_PHASE1":25738,"PHASE1":25740,"PHASE2":25742,"PHASE3":25744,"PHASE4":25760,"NA":25762},{"trials":25739,"activeCount":97},[],{"trials":25741,"activeCount":97},[],{"trials":25743,"activeCount":97},[],{"trials":25745,"activeCount":97},[25746,25752],{"nctId":25747,"briefTitle":25748,"status":145,"phases":25749,"primaryCompletion":7711,"completion":7711,"start":493,"enrollment":2797,"conditions":25750,"interventions":25751},"NCT01884675","Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.",[87],[13024],[25736],{"nctId":25753,"briefTitle":25754,"status":145,"phases":25755,"primaryCompletion":25756,"completion":25756,"start":25757,"enrollment":421,"conditions":25758,"interventions":25759},"NCT01894022","A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)",[87],"2015-11-18","2014-01-23",[13024],[25736],{"trials":25761,"activeCount":97},[],{"trials":25763,"activeCount":97},[],{"intervention":25765,"totalTrials":660,"cells":25766},"Iodine I 131 Tositumomab",{"EARLY_PHASE1":25767,"PHASE1":25769,"PHASE2":25771,"PHASE3":25780,"PHASE4":25792,"NA":25794},{"trials":25768,"activeCount":97},[],{"trials":25770,"activeCount":97},[],{"trials":25772,"activeCount":97},[25773],{"nctId":25774,"briefTitle":25775,"status":155,"phases":25776,"completion":4756,"start":10056,"enrollment":1459,"conditions":25777,"interventions":25779},"NCT00062894","Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab",[85,86],[25778],"Non-Hodgkin's Lymphoma",[25765],{"trials":25781,"activeCount":97},[25782],{"nctId":25783,"briefTitle":25784,"status":500,"phases":25785,"primaryCompletion":25786,"completion":25786,"start":8427,"enrollment":97,"conditions":25787,"interventions":25790},"NCT00319332","A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen",[87],"2021-02",[25788,25789,3554,4574],"Lymphoma, Small Cleaved-Cell, Follicular","Lymphoma, Large-Cell, Follicular",[25791,25765],"Ibritumomab Tiuxetan",{"trials":25793,"activeCount":97},[],{"trials":25795,"activeCount":97},[],{"intervention":19416,"totalTrials":660,"cells":25797},{"EARLY_PHASE1":25798,"PHASE1":25800,"PHASE2":25802,"PHASE3":25808,"PHASE4":25814,"NA":25816},{"trials":25799,"activeCount":97},[],{"trials":25801,"activeCount":97},[],{"trials":25803,"activeCount":97},[25804],{"nctId":21429,"briefTitle":21430,"status":155,"phases":25805,"primaryCompletion":7582,"completion":7582,"start":2482,"enrollment":21432,"conditions":25806,"interventions":25807},[86],[4759],[21435,19386,19416,4809,21436,4807],{"trials":25809,"activeCount":97},[25810],{"nctId":19405,"briefTitle":19406,"status":155,"phases":25811,"primaryCompletion":2373,"completion":19408,"start":19409,"enrollment":19410,"conditions":25812,"interventions":25813},[87],[33,3624,30],[19413,19414,19415,4809,19416,8674],{"trials":25815,"activeCount":97},[],{"trials":25817,"activeCount":97},[],{"intervention":4807,"totalTrials":660,"cells":25819},{"EARLY_PHASE1":25820,"PHASE1":25822,"PHASE2":25824,"PHASE3":25830,"PHASE4":25836,"NA":25838},{"trials":25821,"activeCount":97},[],{"trials":25823,"activeCount":97},[],{"trials":25825,"activeCount":97},[25826],{"nctId":21429,"briefTitle":21430,"status":155,"phases":25827,"primaryCompletion":7582,"completion":7582,"start":2482,"enrollment":21432,"conditions":25828,"interventions":25829},[86],[4759],[21435,19386,19416,4809,21436,4807],{"trials":25831,"activeCount":97},[25832],{"nctId":4796,"briefTitle":4797,"status":155,"phases":25833,"primaryCompletion":4799,"completion":4800,"start":4801,"enrollment":4802,"conditions":25834,"interventions":25835},[87],[4702,30,4704,33,3624,24],[4472,4805,4806,4807,4808,4809,4810,4811,4762],{"trials":25837,"activeCount":97},[],{"trials":25839,"activeCount":97},[],{"intervention":25841,"totalTrials":660,"cells":25842},"GSK2402968",{"EARLY_PHASE1":25843,"PHASE1":25845,"PHASE2":25847,"PHASE3":25857,"PHASE4":25867,"NA":25869},{"trials":25844,"activeCount":97},[],{"trials":25846,"activeCount":97},[],{"trials":25848,"activeCount":97},[25849],{"nctId":25850,"briefTitle":25851,"status":155,"phases":25852,"primaryCompletion":728,"completion":3110,"start":3551,"enrollment":8437,"conditions":25853,"interventions":25855},"NCT01153932","Phase II Doubleblind Exploratory Study of GSK2402968 in Ambulant Subjects With Duchenne Muscular Dystrophy",[86],[25854],"Muscular Dystrophies",[25841,25856],"matched placebo",{"trials":25858,"activeCount":97},[25859],{"nctId":25860,"briefTitle":25861,"status":145,"phases":25862,"primaryCompletion":25863,"completion":25863,"start":3111,"enrollment":25864,"conditions":25865,"interventions":25866},"NCT01480245","Open Label Study of GSK2402968 in Subjects With Duchenne Muscular Dystrophy",[87],"2014-03",233,[25854],[25841],{"trials":25868,"activeCount":97},[],{"trials":25870,"activeCount":97},[],{"intervention":25872,"totalTrials":660,"cells":25873},"Tritanrix-HepB\u002FMeningitec conjugate vaccine",{"EARLY_PHASE1":25874,"PHASE1":25876,"PHASE2":25878,"PHASE3":25880,"PHASE4":25899,"NA":25901},{"trials":25875,"activeCount":97},[],{"trials":25877,"activeCount":97},[],{"trials":25879,"activeCount":97},[],{"trials":25881,"activeCount":97},[25882,25891],{"nctId":25883,"briefTitle":25884,"status":155,"phases":25885,"primaryCompletion":25886,"completion":25886,"start":25887,"enrollment":10126,"conditions":25888,"interventions":25889},"NCT00317187","Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.",[87],"2005-01-16","2004-06-08",[24,30,10227,33,4704],[25872,25890],"Tritanrix\u002FHiberix vaccine",{"nctId":25892,"briefTitle":25893,"status":155,"phases":25894,"primaryCompletion":25895,"completion":25895,"start":25896,"enrollment":10126,"conditions":25897,"interventions":25898},"NCT00317135","Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.",[87],"2004-10-23","2003-12-11",[30,24,10227,4704,33],[25872,25890],{"trials":25900,"activeCount":97},[],{"trials":25902,"activeCount":97},[],{"intervention":25890,"totalTrials":660,"cells":25904},{"EARLY_PHASE1":25905,"PHASE1":25907,"PHASE2":25909,"PHASE3":25911,"PHASE4":25921,"NA":25923},{"trials":25906,"activeCount":97},[],{"trials":25908,"activeCount":97},[],{"trials":25910,"activeCount":97},[],{"trials":25912,"activeCount":97},[25913,25917],{"nctId":25883,"briefTitle":25884,"status":155,"phases":25914,"primaryCompletion":25886,"completion":25886,"start":25887,"enrollment":10126,"conditions":25915,"interventions":25916},[87],[24,30,10227,33,4704],[25872,25890],{"nctId":25892,"briefTitle":25893,"status":155,"phases":25918,"primaryCompletion":25895,"completion":25895,"start":25896,"enrollment":10126,"conditions":25919,"interventions":25920},[87],[30,24,10227,4704,33],[25872,25890],{"trials":25922,"activeCount":97},[],{"trials":25924,"activeCount":97},[],{"intervention":19057,"totalTrials":660,"cells":25926},{"EARLY_PHASE1":25927,"PHASE1":25929,"PHASE2":25931,"PHASE3":25933,"PHASE4":25943,"NA":25945},{"trials":25928,"activeCount":97},[],{"trials":25930,"activeCount":97},[],{"trials":25932,"activeCount":97},[],{"trials":25934,"activeCount":97},[25935,25939],{"nctId":19052,"briefTitle":19053,"status":155,"phases":25936,"primaryCompletion":3551,"completion":3551,"start":3078,"enrollment":7991,"conditions":25937,"interventions":25938},[87],[18],[19057,19057,19058],{"nctId":23897,"briefTitle":23898,"status":155,"phases":25940,"primaryCompletion":2427,"completion":2427,"start":1428,"enrollment":292,"conditions":25941,"interventions":25942},[87],[18],[19057,22118],{"trials":25944,"activeCount":97},[],{"trials":25946,"activeCount":97},[],{"intervention":25948,"totalTrials":660,"cells":25949},"Quadrivalent seasonal influenza vaccine GSK2282512A",{"EARLY_PHASE1":25950,"PHASE1":25952,"PHASE2":25954,"PHASE3":25956,"PHASE4":25975,"NA":25977},{"trials":25951,"activeCount":97},[],{"trials":25953,"activeCount":97},[],{"trials":25955,"activeCount":97},[],{"trials":25957,"activeCount":97},[25958,25967],{"nctId":25959,"briefTitle":25960,"status":155,"phases":25961,"primaryCompletion":11961,"completion":11961,"start":25962,"enrollment":2995,"conditions":25963,"interventions":25964},"NCT01198756","A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children",[87],"2010-10-01",[21],[25948,25965,25966,25948],"Fluarix™ VB","Fluarix™ YB",{"nctId":25968,"briefTitle":24654,"status":155,"phases":25969,"primaryCompletion":9552,"completion":25970,"start":25962,"enrollment":4912,"conditions":25971,"interventions":25972},"NCT01196975",[87],"2011-06-24",[21],[25948,25973,25974],"FluLavalTM-VB","FluLavalTM-YB",{"trials":25976,"activeCount":97},[],{"trials":25978,"activeCount":97},[],{"intervention":7872,"totalTrials":660,"cells":25980},{"EARLY_PHASE1":25981,"PHASE1":25983,"PHASE2":25985,"PHASE3":25987,"PHASE4":25997,"NA":25999},{"trials":25982,"activeCount":97},[],{"trials":25984,"activeCount":97},[],{"trials":25986,"activeCount":97},[],{"trials":25988,"activeCount":97},[25989,25993],{"nctId":7862,"briefTitle":7863,"status":155,"phases":25990,"primaryCompletion":7865,"completion":7866,"start":7867,"enrollment":7868,"conditions":25991,"interventions":25992},[87],[4704],[7871,7872,7873,7874,7875,7830,7718,7876],{"nctId":9959,"briefTitle":9960,"status":155,"phases":25994,"primaryCompletion":9962,"completion":9962,"start":9963,"enrollment":9964,"conditions":25995,"interventions":25996},[87],[7966],[9920,7876,7872],{"trials":25998,"activeCount":97},[],{"trials":26000,"activeCount":97},[],{"intervention":19866,"totalTrials":660,"cells":26002},{"EARLY_PHASE1":26003,"PHASE1":26005,"PHASE2":26007,"PHASE3":26009,"PHASE4":26022,"NA":26024},{"trials":26004,"activeCount":97},[],{"trials":26006,"activeCount":97},[],{"trials":26008,"activeCount":97},[],{"trials":26010,"activeCount":97},[26011,26018],{"nctId":26012,"briefTitle":26013,"status":155,"phases":26014,"primaryCompletion":2404,"completion":2404,"start":8852,"enrollment":20814,"conditions":26015,"interventions":26016},"NCT00332566","Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV\u002FHib Kft Compared to DTPw-HBV\u002FHib",[87],[24,10227,33,4704,30],[26017,19866],"DTPw-HBV\u002FHib Kft vaccine GSK323527A",{"nctId":19857,"briefTitle":19858,"status":155,"phases":26019,"primaryCompletion":10275,"completion":19860,"start":19861,"enrollment":19862,"conditions":26020,"interventions":26021},[87],[10227,30,24,33,4704],[19865,19866,19818,19867,19868],{"trials":26023,"activeCount":97},[],{"trials":26025,"activeCount":97},[],{"intervention":23741,"totalTrials":660,"cells":26027},{"EARLY_PHASE1":26028,"PHASE1":26030,"PHASE2":26032,"PHASE3":26034,"PHASE4":26048,"NA":26050},{"trials":26029,"activeCount":97},[],{"trials":26031,"activeCount":97},[],{"trials":26033,"activeCount":97},[],{"trials":26035,"activeCount":97},[26036,26040],{"nctId":23736,"briefTitle":23737,"status":155,"phases":26037,"primaryCompletion":8386,"completion":8386,"start":10803,"enrollment":15623,"conditions":26038,"interventions":26039},[87],[21],[23741,22545],{"nctId":26041,"briefTitle":26042,"status":155,"phases":26043,"primaryCompletion":26044,"completion":26044,"start":26045,"enrollment":2297,"conditions":26046,"interventions":26047},"NCT01878825","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older",[87],"2013-08-09","2013-07-18",[21],[23741],{"trials":26049,"activeCount":97},[],{"trials":26051,"activeCount":97},[],{"intervention":19273,"totalTrials":660,"cells":26053},{"EARLY_PHASE1":26054,"PHASE1":26056,"PHASE2":26065,"PHASE3":26067,"PHASE4":26073,"NA":26075},{"trials":26055,"activeCount":97},[],{"trials":26057,"activeCount":97},[26058],{"nctId":26059,"briefTitle":26060,"status":155,"phases":26061,"primaryCompletion":19120,"completion":19120,"start":26062,"enrollment":463,"conditions":26063,"interventions":26064},"NCT00937404","Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants",[85],"2009-08-04",[4702],[19273],{"trials":26066,"activeCount":97},[],{"trials":26068,"activeCount":97},[26069],{"nctId":19264,"briefTitle":19265,"status":155,"phases":26070,"primaryCompletion":19267,"completion":19268,"start":19269,"enrollment":19270,"conditions":26071,"interventions":26072},[87],[3637],[4683,19098,4810,12324,19273,4745],{"trials":26074,"activeCount":97},[],{"trials":26076,"activeCount":97},[],{"intervention":6569,"totalTrials":660,"cells":26078},{"EARLY_PHASE1":26079,"PHASE1":26081,"PHASE2":26090,"PHASE3":26092,"PHASE4":26098,"NA":26100},{"trials":26080,"activeCount":97},[],{"trials":26082,"activeCount":97},[26083],{"nctId":26084,"briefTitle":26085,"status":155,"phases":26086,"primaryCompletion":26087,"completion":26087,"start":9280,"enrollment":8038,"conditions":26088,"interventions":26089},"NCT01026064","Cantharidin-induced Skin Blister for Testing Anti-inflammatory Effects of Macrolides",[85],"2009-11-27",[18985],[6569],{"trials":26091,"activeCount":97},[],{"trials":26093,"activeCount":97},[26094],{"nctId":6559,"briefTitle":6560,"status":155,"phases":26095,"primaryCompletion":6562,"completion":6562,"start":6563,"enrollment":6564,"conditions":26096,"interventions":26097},[87],[6566],[6471,6568,6569],{"trials":26099,"activeCount":97},[],{"trials":26101,"activeCount":97},[],{"intervention":26103,"totalTrials":660,"cells":26104},"Albiglutide liquid auto-injector",{"EARLY_PHASE1":26105,"PHASE1":26107,"PHASE2":26118,"PHASE3":26120,"PHASE4":26131,"NA":26133},{"trials":26106,"activeCount":97},[],{"trials":26108,"activeCount":97},[26109],{"nctId":26110,"briefTitle":26111,"status":155,"phases":26112,"primaryCompletion":26113,"completion":26113,"start":492,"enrollment":2759,"conditions":26114,"interventions":26115},"NCT02660736","Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects",[85],"2016-08",[27],[26116,26117],"Albiglutide Liquid Auto-injector","Albiglutide Lyophilized DCC Pen Injector",{"trials":26119,"activeCount":97},[],{"trials":26121,"activeCount":97},[26122],{"nctId":26123,"briefTitle":26124,"status":155,"phases":26125,"primaryCompletion":26126,"completion":26127,"start":18086,"enrollment":7826,"conditions":26128,"interventions":26129},"NCT02683746","Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus",[87],"2017-04-03","2017-05-15",[27],[26130,26103],"Lyophilized albiglutide DCC pen injector",{"trials":26132,"activeCount":97},[],{"trials":26134,"activeCount":97},[],{"intervention":26136,"totalTrials":660,"cells":26137},"Fluticasone Furoate\u002FGW642444",{"EARLY_PHASE1":26138,"PHASE1":26140,"PHASE2":26142,"PHASE3":26144,"PHASE4":26162,"NA":26164},{"trials":26139,"activeCount":97},[],{"trials":26141,"activeCount":97},[],{"trials":26143,"activeCount":97},[],{"trials":26145,"activeCount":97},[26146,26155],{"nctId":26147,"briefTitle":26148,"status":155,"phases":26149,"primaryCompletion":24686,"completion":26150,"start":26151,"enrollment":26152,"conditions":26153,"interventions":26154},"NCT01086384","Asthma Exacerbation Study",[87],"2011-09-15","2010-02-22",2020,[18],[26136,9502],{"nctId":26156,"briefTitle":26157,"status":155,"phases":26158,"primaryCompletion":13358,"completion":26159,"start":22189,"enrollment":18826,"conditions":26160,"interventions":26161},"NCT01018186","Fluticasone Furoate\u002FGW642444 Inhalation Powder Long-Term Safety Study",[87],"2011-05-12",[18],[26136,8381],{"trials":26163,"activeCount":97},[],{"trials":26165,"activeCount":97},[],{"intervention":6342,"totalTrials":660,"cells":26167},{"EARLY_PHASE1":26168,"PHASE1":26170,"PHASE2":26181,"PHASE3":26183,"PHASE4":26189,"NA":26191},{"trials":26169,"activeCount":97},[],{"trials":26171,"activeCount":97},[26172],{"nctId":26173,"briefTitle":26174,"status":155,"phases":26175,"primaryCompletion":26176,"completion":26176,"start":18002,"enrollment":695,"conditions":26177,"interventions":26178},"NCT01258530","A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers",[85],"2011-02-03",[5353],[26179,26180],"over-encapsulated oseltamivir","oseltamivir",{"trials":26182,"activeCount":97},[],{"trials":26184,"activeCount":97},[26185],{"nctId":6334,"briefTitle":6335,"status":155,"phases":26186,"primaryCompletion":6337,"completion":6337,"start":6338,"enrollment":6339,"conditions":26187,"interventions":26188},[87],[5353],[6298,6342],{"trials":26190,"activeCount":97},[],{"trials":26192,"activeCount":97},[],{"intervention":9510,"totalTrials":660,"cells":26194},{"EARLY_PHASE1":26195,"PHASE1":26197,"PHASE2":26199,"PHASE3":26205,"PHASE4":26211,"NA":26213},{"trials":26196,"activeCount":97},[],{"trials":26198,"activeCount":97},[],{"trials":26200,"activeCount":97},[26201],{"nctId":9504,"briefTitle":9505,"status":155,"phases":26202,"primaryCompletion":9507,"completion":9507,"start":3389,"enrollment":2959,"conditions":26203,"interventions":26204},[86],[18],[9510,9415],{"trials":26206,"activeCount":97},[26207],{"nctId":25229,"briefTitle":25230,"status":155,"phases":26208,"primaryCompletion":3110,"completion":3110,"start":3111,"enrollment":265,"conditions":26209,"interventions":26210},[87],[18],[25212,9510],{"trials":26212,"activeCount":97},[],{"trials":26214,"activeCount":97},[],{"intervention":10230,"totalTrials":660,"cells":26216},{"EARLY_PHASE1":26217,"PHASE1":26219,"PHASE2":26221,"PHASE3":26223,"PHASE4":26238,"NA":26240},{"trials":26218,"activeCount":97},[],{"trials":26220,"activeCount":97},[],{"trials":26222,"activeCount":97},[],{"trials":26224,"activeCount":97},[26225,26229],{"nctId":10221,"briefTitle":10222,"status":155,"phases":26226,"primaryCompletion":8447,"completion":8447,"start":10224,"enrollment":10225,"conditions":26227,"interventions":26228},[87],[10227,4704,24,30,33,10228],[10230,10200,10231,4749],{"nctId":26230,"briefTitle":26231,"status":155,"phases":26232,"primaryCompletion":26233,"completion":26233,"start":26234,"enrollment":19930,"conditions":26235,"interventions":26236},"NCT00228917","Safety Study of Tritanrix-HepB\u002FHib-MenAC, Tritanrix-HepB\u002FHiberix, and Mencevax ACWY Vaccines in Children",[87],"2006-01-20","2005-06-16",[10227,33,24,30,4704,10228],[10230,10231,26237],"Mencevax-ACWY",{"trials":26239,"activeCount":97},[],{"trials":26241,"activeCount":97},[],{"intervention":10231,"totalTrials":660,"cells":26243},{"EARLY_PHASE1":26244,"PHASE1":26246,"PHASE2":26248,"PHASE3":26250,"PHASE4":26260,"NA":26262},{"trials":26245,"activeCount":97},[],{"trials":26247,"activeCount":97},[],{"trials":26249,"activeCount":97},[],{"trials":26251,"activeCount":97},[26252,26256],{"nctId":10221,"briefTitle":10222,"status":155,"phases":26253,"primaryCompletion":8447,"completion":8447,"start":10224,"enrollment":10225,"conditions":26254,"interventions":26255},[87],[10227,4704,24,30,33,10228],[10230,10200,10231,4749],{"nctId":26230,"briefTitle":26231,"status":155,"phases":26257,"primaryCompletion":26233,"completion":26233,"start":26234,"enrollment":19930,"conditions":26258,"interventions":26259},[87],[10227,33,24,30,4704,10228],[10230,10231,26237],{"trials":26261,"activeCount":97},[],{"trials":26263,"activeCount":97},[],{"intervention":26265,"totalTrials":660,"cells":26266},"vehicle gel",{"EARLY_PHASE1":26267,"PHASE1":26269,"PHASE2":26280,"PHASE3":26282,"PHASE4":26291,"NA":26293},{"trials":26268,"activeCount":97},[],{"trials":26270,"activeCount":97},[26271],{"nctId":26272,"briefTitle":26273,"status":155,"phases":26274,"primaryCompletion":26275,"completion":26275,"start":26276,"enrollment":6482,"conditions":26277,"interventions":26278},"NCT01915758","W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers",[85],"2009-02-20","2008-11-21",[15087],[26279,26265],"clindamycin1%\u002Ftretinoin 0.025% gel",{"trials":26281,"activeCount":97},[],{"trials":26283,"activeCount":97},[26284],{"nctId":26285,"briefTitle":26286,"status":155,"phases":26287,"primaryCompletion":3389,"completion":3389,"start":7545,"enrollment":3635,"conditions":26288,"interventions":26289},"NCT01400932","Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects",[87],[15087],[26290,26265],"GI148512",{"trials":26292,"activeCount":97},[],{"trials":26294,"activeCount":97},[],{"intervention":19687,"totalTrials":660,"cells":26296},{"EARLY_PHASE1":26297,"PHASE1":26299,"PHASE2":26301,"PHASE3":26311,"PHASE4":26317,"NA":26319},{"trials":26298,"activeCount":97},[],{"trials":26300,"activeCount":97},[],{"trials":26302,"activeCount":97},[26303],{"nctId":26304,"briefTitle":26305,"status":145,"phases":26306,"primaryCompletion":19318,"completion":19318,"start":26307,"enrollment":6503,"conditions":26308,"interventions":26309},"NCT00849875","A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients",[86],"2009-05-26",[325],[26310,19687],"Immunotherapeutic GSK2132231A",{"trials":26312,"activeCount":97},[26313],{"nctId":19681,"briefTitle":19682,"status":155,"phases":26314,"primaryCompletion":18370,"completion":16145,"start":19684,"enrollment":16,"conditions":26315,"interventions":26316},[87],[36],[9284,19687],{"trials":26318,"activeCount":97},[],{"trials":26320,"activeCount":97},[],{"intervention":26322,"totalTrials":660,"cells":26323},"Nadroparin",{"EARLY_PHASE1":26324,"PHASE1":26326,"PHASE2":26328,"PHASE3":26330,"PHASE4":26348,"NA":26350},{"trials":26325,"activeCount":97},[],{"trials":26327,"activeCount":97},[],{"trials":26329,"activeCount":97},[],{"trials":26331,"activeCount":97},[26332,26342],{"nctId":26333,"briefTitle":26334,"status":155,"phases":26335,"primaryCompletion":26336,"completion":11030,"start":8468,"enrollment":26337,"conditions":26338,"interventions":26340},"NCT00843492","A Study to Evaluate the Efficacy and Safety of Fondaparinux for the Prevention of Venous Blood Clots in Patients With a Plaster Cast or Other Type of Immobilization for a Below-knee Injury Not Needing Surgery",[87],"2010-01",1351,[26339],"Thrombosis, Venous",[26341,26322],"Fondaparinux sodium",{"nctId":26343,"briefTitle":26344,"status":155,"phases":26345,"primaryCompletion":2441,"completion":2441,"start":2383,"enrollment":18826,"conditions":26346,"interventions":26347},"NCT00312013","Effects Of Nadroparin In Patients With Lung, Pancreas Or Prostate Cancer",[87],[26339],[26322],{"trials":26349,"activeCount":97},[],{"trials":26351,"activeCount":97},[],{"intervention":10347,"totalTrials":660,"cells":26353},{"EARLY_PHASE1":26354,"PHASE1":26356,"PHASE2":26358,"PHASE3":26360,"PHASE4":26370,"NA":26372},{"trials":26355,"activeCount":97},[],{"trials":26357,"activeCount":97},[],{"trials":26359,"activeCount":97},[],{"trials":26361,"activeCount":97},[26362,26366],{"nctId":19102,"briefTitle":19103,"status":155,"phases":26363,"primaryCompletion":19105,"completion":19105,"start":11017,"enrollment":19106,"conditions":26364,"interventions":26365},[87],[4703,4704],[19109,4744,19110,19111,10347,19112,19113,19114,19115],{"nctId":10337,"briefTitle":10338,"status":155,"phases":26367,"primaryCompletion":10340,"completion":10341,"start":9452,"enrollment":10342,"conditions":26368,"interventions":26369},[87],[992,5046],[10345,10346,10347,8968,10348],{"trials":26371,"activeCount":97},[],{"trials":26373,"activeCount":97},[],{"intervention":8934,"totalTrials":660,"cells":26375},{"EARLY_PHASE1":26376,"PHASE1":26378,"PHASE2":26380,"PHASE3":26386,"PHASE4":26398,"NA":26400},{"trials":26377,"activeCount":97},[],{"trials":26379,"activeCount":97},[],{"trials":26381,"activeCount":97},[26382],{"nctId":8925,"briefTitle":8926,"status":155,"phases":26383,"primaryCompletion":8928,"completion":8929,"start":8930,"enrollment":8931,"conditions":26384,"interventions":26385},[86],[3287],[8934,4808,8935,8936,8937,8938],{"trials":26387,"activeCount":97},[26388],{"nctId":26389,"briefTitle":26390,"status":155,"phases":26391,"primaryCompletion":26392,"completion":26392,"start":26393,"enrollment":1196,"conditions":26394,"interventions":26395},"NCT01148459","Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children",[87],"2013-05-24","2010-07-30",[3287],[8934,26396,26397],"Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);","Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).",{"trials":26399,"activeCount":97},[],{"trials":26401,"activeCount":97},[],{"intervention":8937,"totalTrials":660,"cells":26403},{"EARLY_PHASE1":26404,"PHASE1":26406,"PHASE2":26408,"PHASE3":26414,"PHASE4":26420,"NA":26422},{"trials":26405,"activeCount":97},[],{"trials":26407,"activeCount":97},[],{"trials":26409,"activeCount":97},[26410],{"nctId":8925,"briefTitle":8926,"status":155,"phases":26411,"primaryCompletion":8928,"completion":8929,"start":8930,"enrollment":8931,"conditions":26412,"interventions":26413},[86],[3287],[8934,4808,8935,8936,8937,8938],{"trials":26415,"activeCount":97},[26416],{"nctId":10113,"briefTitle":10114,"status":155,"phases":26417,"primaryCompletion":2481,"completion":2481,"start":7918,"enrollment":526,"conditions":26418,"interventions":26419},[87],[24,3624,4704,30,33,4702],[10065,8937],{"trials":26421,"activeCount":97},[],{"trials":26423,"activeCount":97},[],{"intervention":20412,"totalTrials":660,"cells":26425},{"EARLY_PHASE1":26426,"PHASE1":26428,"PHASE2":26430,"PHASE3":26436,"PHASE4":26442,"NA":26444},{"trials":26427,"activeCount":97},[],{"trials":26429,"activeCount":97},[],{"trials":26431,"activeCount":97},[26432],{"nctId":20406,"briefTitle":20407,"status":155,"phases":26433,"primaryCompletion":7463,"completion":7463,"start":20409,"enrollment":11031,"conditions":26434,"interventions":26435},[86],[21],[20397,20412],{"trials":26437,"activeCount":97},[26438],{"nctId":20429,"briefTitle":20430,"status":155,"phases":26439,"primaryCompletion":20432,"completion":20432,"start":8318,"enrollment":11031,"conditions":26440,"interventions":26441},[87],[21],[20397,20412],{"trials":26443,"activeCount":97},[],{"trials":26445,"activeCount":97},[],{"intervention":26447,"totalTrials":660,"cells":26448},"GSK Biologicals' investigational vaccine GSK2340274A",{"EARLY_PHASE1":26449,"PHASE1":26451,"PHASE2":26465,"PHASE3":26467,"PHASE4":26479,"NA":26481},{"trials":26450,"activeCount":97},[],{"trials":26452,"activeCount":97},[26453],{"nctId":26454,"briefTitle":26455,"status":155,"phases":26456,"primaryCompletion":26457,"completion":26458,"start":26459,"enrollment":23263,"conditions":26460,"interventions":26461},"NCT01236040","Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old",[85],"2011-09-06","2012-08-20","2010-11-29",[21],[26462,26463,26447,26464],"GSK Biologicals' investigational vaccine GSK2590066A","GSK Biologicals' investigational vaccine GSK2592984A","GSK Biologicals' investigational vaccine GSK2340273A",{"trials":26466,"activeCount":97},[],{"trials":26468,"activeCount":97},[26469],{"nctId":26470,"briefTitle":26471,"status":155,"phases":26472,"primaryCompletion":26473,"completion":26474,"start":26475,"enrollment":26476,"conditions":26477,"interventions":26478},"NCT01051661","Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age",[87],"2011-08-31","2011-09-09","2010-02-12",6154,[21],[26447,26464],{"trials":26480,"activeCount":97},[],{"trials":26482,"activeCount":97},[],{"intervention":26464,"totalTrials":660,"cells":26484},{"EARLY_PHASE1":26485,"PHASE1":26487,"PHASE2":26493,"PHASE3":26495,"PHASE4":26501,"NA":26503},{"trials":26486,"activeCount":97},[],{"trials":26488,"activeCount":97},[26489],{"nctId":26454,"briefTitle":26455,"status":155,"phases":26490,"primaryCompletion":26457,"completion":26458,"start":26459,"enrollment":23263,"conditions":26491,"interventions":26492},[85],[21],[26462,26463,26447,26464],{"trials":26494,"activeCount":97},[],{"trials":26496,"activeCount":97},[26497],{"nctId":26470,"briefTitle":26471,"status":155,"phases":26498,"primaryCompletion":26473,"completion":26474,"start":26475,"enrollment":26476,"conditions":26499,"interventions":26500},[87],[21],[26447,26464],{"trials":26502,"activeCount":97},[],{"trials":26504,"activeCount":97},[],{"intervention":22175,"totalTrials":660,"cells":26506},{"EARLY_PHASE1":26507,"PHASE1":26509,"PHASE2":26511,"PHASE3":26513,"PHASE4":26523,"NA":26525},{"trials":26508,"activeCount":97},[],{"trials":26510,"activeCount":97},[],{"trials":26512,"activeCount":97},[],{"trials":26514,"activeCount":97},[26515,26519],{"nctId":22168,"briefTitle":22169,"status":155,"phases":26516,"primaryCompletion":21291,"completion":11851,"start":22171,"enrollment":22172,"conditions":26517,"interventions":26518},[87],[15],[22147,22175,22166],{"nctId":22185,"briefTitle":22186,"status":155,"phases":26520,"primaryCompletion":21291,"completion":22188,"start":22189,"enrollment":22190,"conditions":26521,"interventions":26522},[87],[15],[22175,22147,22166],{"trials":26524,"activeCount":97},[],{"trials":26526,"activeCount":97},[],{"intervention":21056,"totalTrials":660,"cells":26528},{"EARLY_PHASE1":26529,"PHASE1":26531,"PHASE2":26533,"PHASE3":26535,"PHASE4":26545,"NA":26547},{"trials":26530,"activeCount":97},[],{"trials":26532,"activeCount":97},[],{"trials":26534,"activeCount":97},[],{"trials":26536,"activeCount":97},[26537,26541],{"nctId":21049,"briefTitle":21050,"status":155,"phases":26538,"primaryCompletion":7976,"completion":7976,"start":10803,"enrollment":21052,"conditions":26539,"interventions":26540},[87],[21054],[21056,21057,21013],{"nctId":21059,"briefTitle":21060,"status":145,"phases":26542,"primaryCompletion":2383,"completion":2383,"start":10212,"enrollment":9757,"conditions":26543,"interventions":26544},[87],[21063],[21065,21056,21013],{"trials":26546,"activeCount":97},[],{"trials":26548,"activeCount":97},[],{"intervention":19132,"totalTrials":660,"cells":26550},{"EARLY_PHASE1":26551,"PHASE1":26553,"PHASE2":26555,"PHASE3":26557,"PHASE4":26572,"NA":26574},{"trials":26552,"activeCount":97},[],{"trials":26554,"activeCount":97},[],{"trials":26556,"activeCount":97},[],{"trials":26558,"activeCount":97},[26559,26568],{"nctId":26560,"briefTitle":26561,"status":155,"phases":26562,"primaryCompletion":16364,"completion":16364,"start":26563,"enrollment":26564,"conditions":26565,"interventions":26566},"NCT00839254","Impact on Carriage, Acute Otitis Media, Immuno & Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A",[87],"2009-02-18",6181,[3637,8918],[26567,19132,19133],"Pneumococcal conjugate vaccine Synflorix",{"nctId":19125,"briefTitle":19126,"status":155,"phases":26569,"primaryCompletion":16364,"completion":19128,"start":8914,"enrollment":19129,"conditions":26570,"interventions":26571},[87],[3637,8918],[4744,19132,19133],{"trials":26573,"activeCount":97},[],{"trials":26575,"activeCount":97},[],{"intervention":19133,"totalTrials":660,"cells":26577},{"EARLY_PHASE1":26578,"PHASE1":26580,"PHASE2":26582,"PHASE3":26584,"PHASE4":26594,"NA":26596},{"trials":26579,"activeCount":97},[],{"trials":26581,"activeCount":97},[],{"trials":26583,"activeCount":97},[],{"trials":26585,"activeCount":97},[26586,26590],{"nctId":26560,"briefTitle":26561,"status":155,"phases":26587,"primaryCompletion":16364,"completion":16364,"start":26563,"enrollment":26564,"conditions":26588,"interventions":26589},[87],[3637,8918],[26567,19132,19133],{"nctId":19125,"briefTitle":19126,"status":155,"phases":26591,"primaryCompletion":16364,"completion":19128,"start":8914,"enrollment":19129,"conditions":26592,"interventions":26593},[87],[3637,8918],[4744,19132,19133],{"trials":26595,"activeCount":97},[],{"trials":26597,"activeCount":97},[],{"intervention":26599,"totalTrials":660,"cells":26600},"HPV-16\u002F18 VLP\u002FAS04 vaccine",{"EARLY_PHASE1":26601,"PHASE1":26603,"PHASE2":26605,"PHASE3":26607,"PHASE4":26626,"NA":26628},{"trials":26602,"activeCount":97},[],{"trials":26604,"activeCount":97},[],{"trials":26606,"activeCount":97},[],{"trials":26608,"activeCount":97},[26609,26617],{"nctId":26610,"briefTitle":26611,"status":155,"phases":26612,"primaryCompletion":26613,"completion":26613,"start":26614,"enrollment":7319,"conditions":26615,"interventions":26616},"NCT00485732","A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16\u002F18 L1 VLP AS04 Vaccine\u002FCervarix TM Vaccine in Healthy Females Aged 15-25 Years",[87],"2008-03-30","2007-06-11",[8723],[26599],{"nctId":26618,"briefTitle":26619,"status":155,"phases":26620,"primaryCompletion":8207,"completion":26621,"start":26622,"enrollment":18928,"conditions":26623,"interventions":26624},"NCT00344032","Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women",[87],"2007-12-04","2006-07-28",[8723],[26625],"HPV-16\u002F18 VLP\u002FAS04 Vaccine",{"trials":26627,"activeCount":97},[],{"trials":26629,"activeCount":97},[],{"intervention":26631,"totalTrials":660,"cells":26632},"3% menthol",{"EARLY_PHASE1":26633,"PHASE1":26635,"PHASE2":26648,"PHASE3":26650,"PHASE4":26661,"NA":26663},{"trials":26634,"activeCount":97},[],{"trials":26636,"activeCount":97},[26637],{"nctId":26638,"briefTitle":26639,"status":155,"phases":26640,"primaryCompletion":17134,"completion":17134,"start":18087,"enrollment":710,"conditions":26641,"interventions":26642},"NCT02169154","A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel",[85],[9153],[26643,26644,26645,26646,26647],"1% Diclofenac Sodium","3% Menthol","0.09% Menthol","0.2% Sodium Lauryl Sulfate","0.9% Saline",{"trials":26649,"activeCount":97},[],{"trials":26651,"activeCount":97},[26652],{"nctId":26653,"briefTitle":26654,"status":155,"phases":26655,"primaryCompletion":11656,"completion":26656,"start":1874,"enrollment":18256,"conditions":26657,"interventions":26658},"NCT02100670","A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain",[87],"2015-03-22",[9153],[26659,26660,26631],"1% diclofenac sodium plus 3% menthol","1% diclofenac sodium plus 0.09% menthol",{"trials":26662,"activeCount":97},[],{"trials":26664,"activeCount":97},[],{"intervention":26666,"totalTrials":660,"cells":26667},"Umeclidinium\u002FVilanterol 62.5\u002F25 mcg",{"EARLY_PHASE1":26668,"PHASE1":26670,"PHASE2":26672,"PHASE3":26674,"PHASE4":26695,"NA":26697},{"trials":26669,"activeCount":97},[],{"trials":26671,"activeCount":97},[],{"trials":26673,"activeCount":97},[],{"trials":26675,"activeCount":97},[26676,26686],{"nctId":26677,"briefTitle":26678,"status":155,"phases":26679,"primaryCompletion":26680,"completion":26680,"start":26681,"enrollment":26682,"conditions":26683,"interventions":26684},"NCT01899742","The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium\u002FVilanterol 62.5\u002F25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium",[87],"2015-07-22","2014-09-15",497,[15],[26666,26685],"Tiotropium 18 mcg",{"nctId":26687,"briefTitle":26688,"status":155,"phases":26689,"primaryCompletion":26690,"completion":26690,"start":26691,"enrollment":26692,"conditions":26693,"interventions":26694},"NCT01777334","The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium\u002FVilanterol 62.5\u002F25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD",[87],"2013-09-24","2013-01-23",905,[15],[26666,26685],{"trials":26696,"activeCount":97},[],{"trials":26698,"activeCount":97},[],{"intervention":26685,"totalTrials":660,"cells":26700},{"EARLY_PHASE1":26701,"PHASE1":26703,"PHASE2":26705,"PHASE3":26707,"PHASE4":26717,"NA":26719},{"trials":26702,"activeCount":97},[],{"trials":26704,"activeCount":97},[],{"trials":26706,"activeCount":97},[],{"trials":26708,"activeCount":97},[26709,26713],{"nctId":26677,"briefTitle":26678,"status":155,"phases":26710,"primaryCompletion":26680,"completion":26680,"start":26681,"enrollment":26682,"conditions":26711,"interventions":26712},[87],[15],[26666,26685],{"nctId":26687,"briefTitle":26688,"status":155,"phases":26714,"primaryCompletion":26690,"completion":26690,"start":26691,"enrollment":26692,"conditions":26715,"interventions":26716},[87],[15],[26666,26685],{"trials":26718,"activeCount":97},[],{"trials":26720,"activeCount":97},[],{"intervention":5102,"totalTrials":660,"cells":26722},{"EARLY_PHASE1":26723,"PHASE1":26725,"PHASE2":26727,"PHASE3":26733,"PHASE4":26739,"NA":26741},{"trials":26724,"activeCount":97},[],{"trials":26726,"activeCount":97},[],{"trials":26728,"activeCount":97},[26729],{"nctId":22513,"briefTitle":22514,"status":155,"phases":26730,"primaryCompletion":6574,"completion":6574,"start":22516,"enrollment":22517,"conditions":26731,"interventions":26732},[85,86],[992],[22508,22509,5103,5102],{"trials":26734,"activeCount":97},[26735],{"nctId":5094,"briefTitle":5095,"status":155,"phases":26736,"primaryCompletion":5097,"completion":5098,"start":5099,"enrollment":2058,"conditions":26737,"interventions":26738},[87],[1005],[5064,5102,5103],{"trials":26740,"activeCount":97},[],{"trials":26742,"activeCount":97},[],{"intervention":26744,"totalTrials":660,"cells":26745},"Paroxetine hydrochloride hydrate",{"EARLY_PHASE1":26746,"PHASE1":26748,"PHASE2":26750,"PHASE3":26752,"PHASE4":26770,"NA":26772},{"trials":26747,"activeCount":97},[],{"trials":26749,"activeCount":97},[],{"trials":26751,"activeCount":97},[],{"trials":26753,"activeCount":97},[26754,26762],{"nctId":26755,"briefTitle":26756,"status":155,"phases":26757,"primaryCompletion":4843,"completion":4843,"start":749,"enrollment":26758,"conditions":26759,"interventions":26761},"NCT00318669","Social Anxiety Disorder Study Of Paroxetine",[87],390,[26760],"Social Phobia",[26744],{"nctId":26763,"briefTitle":26764,"status":155,"phases":26765,"primaryCompletion":2844,"completion":2844,"start":2805,"enrollment":1003,"conditions":26766,"interventions":26767},"NCT00264654","Long-term Study Of Paroxetine in Women and Men",[87],[26760],[26768,26769],"BRL29060A","paroxetine hydrochloride hydrate",{"trials":26771,"activeCount":97},[],{"trials":26773,"activeCount":97},[],{"intervention":22581,"totalTrials":660,"cells":26775},{"EARLY_PHASE1":26776,"PHASE1":26778,"PHASE2":26780,"PHASE3":26786,"PHASE4":26792,"NA":26794},{"trials":26777,"activeCount":97},[],{"trials":26779,"activeCount":97},[],{"trials":26781,"activeCount":97},[26782],{"nctId":22574,"briefTitle":22575,"status":155,"phases":26783,"primaryCompletion":11274,"completion":5268,"start":22577,"enrollment":4521,"conditions":26784,"interventions":26785},[86],[4703,4704],[22580,11068,11067,22581,19196],{"trials":26787,"activeCount":97},[26788],{"nctId":22589,"briefTitle":22590,"status":155,"phases":26789,"primaryCompletion":738,"completion":22592,"start":9026,"enrollment":22593,"conditions":26790,"interventions":26791},[87],[3637],[22596,22597,22581,11068],{"trials":26793,"activeCount":97},[],{"trials":26795,"activeCount":97},[],{"intervention":9907,"totalTrials":660,"cells":26797},{"EARLY_PHASE1":26798,"PHASE1":26800,"PHASE2":26802,"PHASE3":26812,"PHASE4":26818,"NA":26820},{"trials":26799,"activeCount":97},[],{"trials":26801,"activeCount":97},[],{"trials":26803,"activeCount":97},[26804],{"nctId":26805,"briefTitle":26806,"status":155,"phases":26807,"primaryCompletion":21511,"completion":8916,"start":26808,"enrollment":5088,"conditions":26809,"interventions":26810},"NCT00695669","A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64",[86],"2008-06-05",[21],[26811],"Influenza A (H5N1) Virus Monovalent Vaccine",{"trials":26813,"activeCount":97},[26814],{"nctId":9898,"briefTitle":9899,"status":155,"phases":26815,"primaryCompletion":9901,"completion":9902,"start":9903,"enrollment":9904,"conditions":26816,"interventions":26817},[87],[21,8265],[9907,9828],{"trials":26819,"activeCount":97},[],{"trials":26821,"activeCount":97},[],{"intervention":26823,"totalTrials":660,"cells":26824},"OFATUMUMAB + DHAP",{"EARLY_PHASE1":26825,"PHASE1":26827,"PHASE2":26829,"PHASE3":26839,"PHASE4":26849,"NA":26851},{"trials":26826,"activeCount":97},[],{"trials":26828,"activeCount":97},[],{"trials":26830,"activeCount":97},[26831],{"nctId":26832,"briefTitle":26833,"status":155,"phases":26834,"primaryCompletion":7545,"completion":3111,"start":2795,"enrollment":4542,"conditions":26835,"interventions":26836},"NCT00823719","Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed\u002F Refractory Diffuse Large B Cell Lymphoma (DLBCL)",[86],[8863],[26837,26838],"ofatumumab + ICE","ofatumumab + DHAP",{"trials":26840,"activeCount":97},[26841],{"nctId":26842,"briefTitle":26843,"status":155,"phases":26844,"primaryCompletion":13418,"completion":2882,"start":3078,"enrollment":26845,"conditions":26846,"interventions":26847},"NCT01014208","Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma",[87],447,[8863],[26823,26848],"RITUXIMAB + DHAP",{"trials":26850,"activeCount":97},[],{"trials":26852,"activeCount":97},[],{"intervention":22135,"totalTrials":660,"cells":26854},{"EARLY_PHASE1":26855,"PHASE1":26857,"PHASE2":26859,"PHASE3":26861,"PHASE4":26871,"NA":26873},{"trials":26856,"activeCount":97},[],{"trials":26858,"activeCount":97},[],{"trials":26860,"activeCount":97},[],{"trials":26862,"activeCount":97},[26863,26867],{"nctId":22128,"briefTitle":22129,"status":155,"phases":26864,"primaryCompletion":2394,"completion":2394,"start":11030,"enrollment":22131,"conditions":26865,"interventions":26866},[87],[18],[22134,22118,22135],{"nctId":22137,"briefTitle":22138,"status":500,"phases":26868,"primaryCompletion":9706,"completion":9706,"start":2427,"enrollment":97,"conditions":26869,"interventions":26870},[87],[18],[22134,22135],{"trials":26872,"activeCount":97},[],{"trials":26874,"activeCount":97},[],{"intervention":8969,"totalTrials":660,"cells":26876},{"EARLY_PHASE1":26877,"PHASE1":26879,"PHASE2":26881,"PHASE3":26887,"PHASE4":26893,"NA":26895},{"trials":26878,"activeCount":97},[],{"trials":26880,"activeCount":97},[],{"trials":26882,"activeCount":97},[26883],{"nctId":19189,"briefTitle":19190,"status":155,"phases":26884,"primaryCompletion":16834,"completion":16834,"start":19192,"enrollment":19193,"conditions":26885,"interventions":26886},[86],[33,30,4704,24,4702,3624,19177],[4706,19151,19196,8969,10348],{"trials":26888,"activeCount":97},[26889],{"nctId":8960,"briefTitle":8961,"status":155,"phases":26890,"primaryCompletion":8963,"completion":3551,"start":2383,"enrollment":4771,"conditions":26891,"interventions":26892},[87],[4704,4703],[8966,8967,8968,4808,8969,8970,8971],{"trials":26894,"activeCount":97},[],{"trials":26896,"activeCount":97},[],{"intervention":18829,"totalTrials":660,"cells":26898},{"EARLY_PHASE1":26899,"PHASE1":26901,"PHASE2":26903,"PHASE3":26905,"PHASE4":26915,"NA":26917},{"trials":26900,"activeCount":97},[],{"trials":26902,"activeCount":97},[],{"trials":26904,"activeCount":97},[],{"trials":26906,"activeCount":97},[26907,26911],{"nctId":18821,"briefTitle":18822,"status":155,"phases":26908,"primaryCompletion":18824,"completion":18824,"start":18825,"enrollment":18826,"conditions":26909,"interventions":26910},[87],[3637],[3639,4745,18829],{"nctId":24905,"briefTitle":24906,"status":155,"phases":26912,"primaryCompletion":24908,"completion":24908,"start":24909,"enrollment":1752,"conditions":26913,"interventions":26914},[87],[3637],[24884,24912,18829],{"trials":26916,"activeCount":97},[],{"trials":26918,"activeCount":97},[],{"intervention":26920,"totalTrials":660,"cells":26921},"Fluarix TM",{"EARLY_PHASE1":26922,"PHASE1":26924,"PHASE2":26926,"PHASE3":26938,"PHASE4":26950,"NA":26952},{"trials":26923,"activeCount":97},[],{"trials":26925,"activeCount":97},[],{"trials":26927,"activeCount":97},[26928],{"nctId":26929,"briefTitle":26930,"status":155,"phases":26931,"primaryCompletion":9754,"completion":26932,"start":26933,"enrollment":26934,"conditions":26935,"interventions":26936},"NCT00321763","Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate",[86],"2006-07-07","2006-04-27",3124,[21],[26937,26920],"Candidate Influenza Vaccine GSK1247446A - 3 different formulations",{"trials":26939,"activeCount":97},[26940],{"nctId":26941,"briefTitle":26942,"status":155,"phases":26943,"primaryCompletion":7867,"completion":26944,"start":26945,"enrollment":26946,"conditions":26947,"interventions":26948},"NCT00753272","Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older",[87],"2011-01-05","2008-09-15",43695,[21],[26949,26920],"GSK Bio's influenza vaccine GSK2186877A",{"trials":26951,"activeCount":97},[],{"trials":26953,"activeCount":97},[],{"intervention":26955,"totalTrials":660,"cells":26956},"SB-275833 ointment, 1%",{"EARLY_PHASE1":26957,"PHASE1":26959,"PHASE2":26961,"PHASE3":26963,"PHASE4":26978,"NA":26980},{"trials":26958,"activeCount":97},[],{"trials":26960,"activeCount":97},[],{"trials":26962,"activeCount":97},[],{"trials":26964,"activeCount":97},[26965,26972],{"nctId":26966,"briefTitle":26967,"status":155,"phases":26968,"completion":1360,"start":7785,"enrollment":17136,"conditions":26969,"interventions":26971},"NCT00133848","Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment",[87],[26970],"Impetigo",[26955],{"nctId":26973,"briefTitle":26974,"status":155,"phases":26975,"primaryCompletion":8427,"completion":8427,"start":7785,"enrollment":1307,"conditions":26976,"interventions":26977},"NCT00133874","Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo",[87],[12727],[26955],{"trials":26979,"activeCount":97},[],{"trials":26981,"activeCount":97},[],{"intervention":8311,"totalTrials":660,"cells":26983},{"EARLY_PHASE1":26984,"PHASE1":26986,"PHASE2":26988,"PHASE3":26990,"PHASE4":27004,"NA":27006},{"trials":26985,"activeCount":97},[],{"trials":26987,"activeCount":97},[],{"trials":26989,"activeCount":97},[],{"trials":26991,"activeCount":97},[26992,27000],{"nctId":26993,"briefTitle":26994,"status":155,"phases":26995,"primaryCompletion":26996,"completion":16322,"start":17894,"enrollment":26997,"conditions":26998,"interventions":26999},"NCT00764790","Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children",[87],"2009-03-05",3317,[21],[25702,8311],{"nctId":8302,"briefTitle":8303,"status":155,"phases":27001,"primaryCompletion":8305,"completion":8306,"start":8307,"enrollment":8308,"conditions":27002,"interventions":27003},[87],[21],[8177,8311],{"trials":27005,"activeCount":97},[],{"trials":27007,"activeCount":97},[],{"intervention":26949,"totalTrials":660,"cells":27009},{"EARLY_PHASE1":27010,"PHASE1":27012,"PHASE2":27014,"PHASE3":27016,"PHASE4":27031,"NA":27033},{"trials":27011,"activeCount":97},[],{"trials":27013,"activeCount":97},[],{"trials":27015,"activeCount":97},[],{"trials":27017,"activeCount":97},[27018,27027],{"nctId":27019,"briefTitle":27020,"status":155,"phases":27021,"primaryCompletion":27022,"completion":27022,"start":27023,"enrollment":27024,"conditions":27025,"interventions":27026},"NCT00760617","Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older",[87],"2009-05-15","2008-10-06",526,[21],[26949,25702],{"nctId":26941,"briefTitle":26942,"status":155,"phases":27028,"primaryCompletion":7867,"completion":26944,"start":26945,"enrollment":26946,"conditions":27029,"interventions":27030},[87],[21],[26949,26920],{"trials":27032,"activeCount":97},[],{"trials":27034,"activeCount":97},[],{"intervention":27036,"totalTrials":660,"cells":27037},"Salbutamol as needed",{"EARLY_PHASE1":27038,"PHASE1":27040,"PHASE2":27042,"PHASE3":27044,"PHASE4":27067,"NA":27069},{"trials":27039,"activeCount":97},[],{"trials":27041,"activeCount":97},[],{"trials":27043,"activeCount":97},[],{"trials":27045,"activeCount":97},[27046,27055],{"nctId":27047,"briefTitle":27048,"status":155,"phases":27049,"primaryCompletion":18021,"completion":18021,"start":20813,"enrollment":27050,"conditions":27051,"interventions":27052},"NCT01706328","A Study to Assess the Efficacy of Fluticasone Furoate\u002FVilanterol (FF\u002FVI) Inhalation Powder 100\u002F25 mcg Once Daily Compared With Fluticasone Propionate\u002FSalmeterol Inhalation Powder 250\u002F50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],828,[15],[27053,27054,27036],"FF\u002FVI 100\u002F25 Inhalation Powder NDPI","Fluticasone Propionate\u002FSalmeterol 250\u002F50 Inhalation Powder ACCUHALER\u002FDISKUS",{"nctId":27056,"briefTitle":27057,"status":155,"phases":27058,"primaryCompletion":27059,"completion":27060,"start":27061,"enrollment":10837,"conditions":27062,"interventions":27063},"NCT01323621","Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) \u002FGW642444 (Vilanterol) (VI) Inhalation Powder 100\u002F25mcg Once Daily Compared With Fluticasone Propionate\u002FSalmeterol Inhalation Powder 250\u002F50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2012-01-01","2012-01-24","2011-03-18",[15],[27064,27065,27066,27036],"Fluticasone Furoate 100mcg\u002F GW642444 (vilanterol) 25mcg","Fluticasone Propionate 250mcg \u002F salmeterol 50mcg","Double-dummy placebo",{"trials":27068,"activeCount":97},[],{"trials":27070,"activeCount":97},[],{"intervention":27072,"totalTrials":660,"cells":27073},"Pandemic influenza vaccine GSK2340272A",{"EARLY_PHASE1":27074,"PHASE1":27076,"PHASE2":27078,"PHASE3":27088,"PHASE4":27097,"NA":27099},{"trials":27075,"activeCount":97},[],{"trials":27077,"activeCount":97},[],{"trials":27079,"activeCount":97},[27080],{"nctId":27081,"briefTitle":27082,"status":155,"phases":27083,"primaryCompletion":8007,"completion":8007,"start":27084,"enrollment":27085,"conditions":27086,"interventions":27087},"NCT00971321","Safety, Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)",[86],"2009-09-10",157,[21],[27072],{"trials":27089,"activeCount":97},[27090],{"nctId":27091,"briefTitle":27092,"status":155,"phases":27093,"primaryCompletion":27094,"completion":27094,"start":27084,"enrollment":17136,"conditions":27095,"interventions":27096},"NCT00964158","Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)",[87],"2010-11-27",[21],[27072],{"trials":27098,"activeCount":97},[],{"trials":27100,"activeCount":97},[],{"intervention":22639,"totalTrials":660,"cells":27102},{"EARLY_PHASE1":27103,"PHASE1":27105,"PHASE2":27107,"PHASE3":27109,"PHASE4":27129,"NA":27131},{"trials":27104,"activeCount":97},[],{"trials":27106,"activeCount":97},[],{"trials":27108,"activeCount":97},[],{"trials":27110,"activeCount":97},[27111,27115],{"nctId":22631,"briefTitle":22632,"status":155,"phases":27112,"primaryCompletion":22634,"completion":22634,"start":22635,"enrollment":22636,"conditions":27113,"interventions":27114},[87],[12263],[22603,22639,22640,22641],{"nctId":27116,"briefTitle":27117,"status":155,"phases":27118,"primaryCompletion":18427,"completion":21956,"start":27119,"enrollment":27120,"conditions":27121,"interventions":27123},"NCT01231607","Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia",[87],"2010-10-28",917,[27122],"Androgenetic Alopecia",[27124,27125,27126,27127,27128,22639],"1mg Finasteride active","0.02mg dutasteride","0.1mg dutasteride","0.5mg dutasteride","Finasteride placebo",{"trials":27130,"activeCount":97},[],{"trials":27132,"activeCount":97},[],{"intervention":295,"totalTrials":660,"cells":27134},{"EARLY_PHASE1":27135,"PHASE1":27137,"PHASE2":27139,"PHASE3":27145,"PHASE4":27151,"NA":27153},{"trials":27136,"activeCount":97},[],{"trials":27138,"activeCount":97},[],{"trials":27140,"activeCount":97},[27141],{"nctId":286,"briefTitle":287,"status":145,"phases":27142,"primaryCompletion":289,"completion":290,"start":291,"enrollment":292,"conditions":27143,"interventions":27144},[86],[267],[92,137,295],{"trials":27146,"activeCount":97},[27147],{"nctId":18220,"briefTitle":18221,"status":155,"phases":27148,"primaryCompletion":18146,"completion":18223,"start":18224,"enrollment":18225,"conditions":27149,"interventions":27150},[87],[325],[3115,295],{"trials":27152,"activeCount":97},[],{"trials":27154,"activeCount":97},[],{"intervention":24461,"totalTrials":660,"cells":27156},{"EARLY_PHASE1":27157,"PHASE1":27159,"PHASE2":27161,"PHASE3":27170,"PHASE4":27176,"NA":27178},{"trials":27158,"activeCount":97},[],{"trials":27160,"activeCount":97},[],{"trials":27162,"activeCount":97},[27163],{"nctId":27164,"briefTitle":27165,"status":155,"phases":27166,"primaryCompletion":7465,"completion":7465,"start":27167,"enrollment":6369,"conditions":27168,"interventions":27169},"NCT00792623","Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).",[86],"2003-09-08",[3717],[24461],{"trials":27171,"activeCount":97},[27172],{"nctId":24455,"briefTitle":24456,"status":155,"phases":27173,"primaryCompletion":9792,"completion":9792,"start":17894,"enrollment":24458,"conditions":27174,"interventions":27175},[87],[2486,3717,2485,2484],[24435,24461,24462],{"trials":27177,"activeCount":97},[],{"trials":27179,"activeCount":97},[],{"intervention":27181,"totalTrials":660,"cells":27182},"MR-Vac",{"EARLY_PHASE1":27183,"PHASE1":27185,"PHASE2":27187,"PHASE3":27193,"PHASE4":27204,"NA":27206},{"trials":27184,"activeCount":97},[],{"trials":27186,"activeCount":97},[],{"trials":27188,"activeCount":97},[27189],{"nctId":4489,"briefTitle":4490,"status":155,"phases":27190,"primaryCompletion":4492,"completion":4492,"start":3320,"enrollment":1196,"conditions":27191,"interventions":27192},[86],[4468],[4495,4496,4497,4452,4472,4498],{"trials":27194,"activeCount":97},[27195],{"nctId":27196,"briefTitle":27197,"status":155,"phases":27198,"primaryCompletion":12862,"completion":18651,"start":17993,"enrollment":27199,"conditions":27200,"interventions":27201},"NCT02699099","Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.",[87],699,[3287,5132],[27202,27181,27203],"Candidate Plasmodium falciparum malaria vaccine","Stamaril",{"trials":27205,"activeCount":97},[],{"trials":27207,"activeCount":97},[],{"intervention":27209,"totalTrials":660,"cells":27210},"GSK548470 300 mg",{"EARLY_PHASE1":27211,"PHASE1":27213,"PHASE2":27215,"PHASE3":27217,"PHASE4":27233,"NA":27235},{"trials":27212,"activeCount":97},[],{"trials":27214,"activeCount":97},[],{"trials":27216,"activeCount":97},[],{"trials":27218,"activeCount":97},[27219,27227],{"nctId":27220,"briefTitle":27221,"status":155,"phases":27222,"primaryCompletion":8151,"completion":2882,"start":8135,"enrollment":27223,"conditions":27224,"interventions":27225},"NCT01480284","Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B Untreated With Nucleic Acid Analogue",[87],166,[4191],[27209,27226],"ETV 0.5 mg",{"nctId":27228,"briefTitle":27229,"status":155,"phases":27230,"primaryCompletion":9697,"completion":22334,"start":7591,"enrollment":1736,"conditions":27231,"interventions":27232},"NCT01475851","Phase 3 Study of GSK548470 in Patients With Compensated Chronic Hepatitis B With Poor Response to Other Drugs",[87],[4191],[27209],{"trials":27234,"activeCount":97},[],{"trials":27236,"activeCount":97},[],{"intervention":27238,"totalTrials":660,"cells":27239},"10mg Atorvastatin",{"EARLY_PHASE1":27240,"PHASE1":27242,"PHASE2":27244,"PHASE3":27261,"PHASE4":27283,"NA":27285},{"trials":27241,"activeCount":97},[],{"trials":27243,"activeCount":97},[],{"trials":27245,"activeCount":97},[27246],{"nctId":27247,"briefTitle":27248,"status":155,"phases":27249,"primaryCompletion":12402,"completion":12402,"start":3059,"enrollment":21052,"conditions":27250,"interventions":27253},"NCT01218204","A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin",[86],[27251,27252],"Dyslipidaemias","Dyslipidemias",[27254,27255,27256,27257,27258,27259,27260],"10mg atorvastatin","80mg atorvastatin","GSK1292263 Placebo","100mg GSK1292263","300mg GSK1292263","800mg GSK1292263","10mg ezetimibe",{"trials":27262,"activeCount":97},[27263],{"nctId":27264,"briefTitle":27265,"status":155,"phases":27266,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":27268,"interventions":27269},"NCT01495013","A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus",[87],427,[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],"1mg Glimepiride\u002F10mg Atorvastatin FDC","2mg Glimepiride\u002F10mg Atorvastatin FDC","3mg Glimepiride\u002F10mg Atorvastatin FDC","4mg Glimepiride\u002F10mg Atorvastatin FDC","1mg Glimepiride\u002F20mg Atorvastatin FDC","2mg Glimepiride\u002F20mg Atorvastatin FDC","3mg Glimepiride\u002F20mg Atorvastatin FDC","4mg Glimepiride\u002F20mg Atorvastatin FDC","1mg Glimepiride","2mg Glimepiride","3mg Glimepiride","4mg Glimepiride","20mg Atorvastatin",{"trials":27284,"activeCount":97},[],{"trials":27286,"activeCount":97},[],{"intervention":8278,"totalTrials":660,"cells":27288},{"EARLY_PHASE1":27289,"PHASE1":27291,"PHASE2":27293,"PHASE3":27299,"PHASE4":27305,"NA":27307},{"trials":27290,"activeCount":97},[],{"trials":27292,"activeCount":97},[],{"trials":27294,"activeCount":97},[27295],{"nctId":8270,"briefTitle":8271,"status":155,"phases":27296,"primaryCompletion":8273,"completion":8273,"start":8274,"enrollment":8275,"conditions":27297,"interventions":27298},[86],[21],[8278,8177],{"trials":27300,"activeCount":97},[27301],{"nctId":8313,"briefTitle":8314,"status":155,"phases":27302,"primaryCompletion":8316,"completion":8317,"start":8318,"enrollment":7840,"conditions":27303,"interventions":27304},[87],[21],[8278,8177],{"trials":27306,"activeCount":97},[],{"trials":27308,"activeCount":97},[],{"intervention":27310,"totalTrials":660,"cells":27311},"Influenza A",{"EARLY_PHASE1":27312,"PHASE1":27314,"PHASE2":27316,"PHASE3":27328,"PHASE4":27338,"NA":27340},{"trials":27313,"activeCount":97},[],{"trials":27315,"activeCount":97},[],{"trials":27317,"activeCount":97},[27318],{"nctId":27319,"briefTitle":27320,"status":155,"phases":27321,"primaryCompletion":27322,"completion":27323,"start":27324,"enrollment":3230,"conditions":27325,"interventions":27326},"NCT00719043","Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years",[86],"2010-04-22","2011-02-18","2008-07-11",[21],[27327,27310],"A\u002Fturkey H5N1 vaccine",{"trials":27329,"activeCount":97},[27330],{"nctId":27331,"briefTitle":27332,"status":155,"phases":27333,"primaryCompletion":9626,"completion":27334,"start":27335,"enrollment":1003,"conditions":27336,"interventions":27337},"NCT01788228","Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure",[87],"2015-02-25","2013-03-22",[21,8265],[27310],{"trials":27339,"activeCount":97},[],{"trials":27341,"activeCount":97},[],{"intervention":7813,"totalTrials":417,"cells":27343},{"EARLY_PHASE1":27344,"PHASE1":27346,"PHASE2":27348,"PHASE3":27350,"PHASE4":27356,"NA":27358},{"trials":27345,"activeCount":97},[],{"trials":27347,"activeCount":97},[],{"trials":27349,"activeCount":97},[],{"trials":27351,"activeCount":97},[27352],{"nctId":7805,"briefTitle":7806,"status":155,"phases":27353,"primaryCompletion":7808,"completion":7808,"start":7809,"enrollment":7810,"conditions":27354,"interventions":27355},[87],[24],[7718,7813],{"trials":27357,"activeCount":97},[],{"trials":27359,"activeCount":97},[],{"intervention":27361,"totalTrials":417,"cells":27362},"albuterol sulfate inhalation aerosol",{"EARLY_PHASE1":27363,"PHASE1":27365,"PHASE2":27367,"PHASE3":27369,"PHASE4":27377,"NA":27379},{"trials":27364,"activeCount":97},[],{"trials":27366,"activeCount":97},[],{"trials":27368,"activeCount":97},[],{"trials":27370,"activeCount":97},[27371],{"nctId":27372,"briefTitle":27373,"status":155,"phases":27374,"primaryCompletion":11759,"completion":11759,"start":2823,"enrollment":526,"conditions":27375,"interventions":27376},"NCT00144846","Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children",[87],[18],[27361],{"trials":27378,"activeCount":97},[],{"trials":27380,"activeCount":97},[],{"intervention":10665,"totalTrials":417,"cells":27382},{"EARLY_PHASE1":27383,"PHASE1":27385,"PHASE2":27387,"PHASE3":27389,"PHASE4":27395,"NA":27397},{"trials":27384,"activeCount":97},[],{"trials":27386,"activeCount":97},[],{"trials":27388,"activeCount":97},[],{"trials":27390,"activeCount":97},[27391],{"nctId":10656,"briefTitle":10657,"status":155,"phases":27392,"primaryCompletion":8478,"completion":8478,"start":10659,"enrollment":10660,"conditions":27393,"interventions":27394},[87],[10662],[10664,10665,10645],{"trials":27396,"activeCount":97},[],{"trials":27398,"activeCount":97},[],{"intervention":24421,"totalTrials":417,"cells":27400},{"EARLY_PHASE1":27401,"PHASE1":27403,"PHASE2":27405,"PHASE3":27407,"PHASE4":27413,"NA":27415},{"trials":27402,"activeCount":97},[],{"trials":27404,"activeCount":97},[],{"trials":27406,"activeCount":97},[],{"trials":27408,"activeCount":97},[27409],{"nctId":24413,"briefTitle":24414,"status":155,"phases":27410,"primaryCompletion":24416,"completion":24417,"start":4721,"enrollment":24418,"conditions":27411,"interventions":27412},[87],[18],[24402,24421,10787],{"trials":27414,"activeCount":97},[],{"trials":27416,"activeCount":97},[],{"intervention":24452,"totalTrials":417,"cells":27418},{"EARLY_PHASE1":27419,"PHASE1":27421,"PHASE2":27423,"PHASE3":27425,"PHASE4":27431,"NA":27433},{"trials":27420,"activeCount":97},[],{"trials":27422,"activeCount":97},[],{"trials":27424,"activeCount":97},[],{"trials":27426,"activeCount":97},[27427],{"nctId":24446,"briefTitle":24447,"status":155,"phases":27428,"primaryCompletion":24449,"completion":17159,"start":15214,"enrollment":18247,"conditions":27429,"interventions":27430},[87],[3624,4702,33,30],[24452,24453,24435],{"trials":27432,"activeCount":97},[],{"trials":27434,"activeCount":97},[],{"intervention":24453,"totalTrials":417,"cells":27436},{"EARLY_PHASE1":27437,"PHASE1":27439,"PHASE2":27441,"PHASE3":27443,"PHASE4":27449,"NA":27451},{"trials":27438,"activeCount":97},[],{"trials":27440,"activeCount":97},[],{"trials":27442,"activeCount":97},[],{"trials":27444,"activeCount":97},[27445],{"nctId":24446,"briefTitle":24447,"status":155,"phases":27446,"primaryCompletion":24449,"completion":17159,"start":15214,"enrollment":18247,"conditions":27447,"interventions":27448},[87],[3624,4702,33,30],[24452,24453,24435],{"trials":27450,"activeCount":97},[],{"trials":27452,"activeCount":97},[],{"intervention":27454,"totalTrials":417,"cells":27455},"valaciclovir HCl granules",{"EARLY_PHASE1":27456,"PHASE1":27458,"PHASE2":27460,"PHASE3":27462,"PHASE4":27470,"NA":27472},{"trials":27457,"activeCount":97},[],{"trials":27459,"activeCount":97},[],{"trials":27461,"activeCount":97},[],{"trials":27463,"activeCount":97},[27464],{"nctId":27465,"briefTitle":27466,"status":155,"phases":27467,"primaryCompletion":10395,"completion":10395,"start":2814,"enrollment":9382,"conditions":27468,"interventions":27469},"NCT00169416","Evaluation Of Valaciclovir In Patients With Chickenpox",[87],[3717],[27454],{"trials":27471,"activeCount":97},[],{"trials":27473,"activeCount":97},[],{"intervention":19258,"totalTrials":417,"cells":27475},{"EARLY_PHASE1":27476,"PHASE1":27478,"PHASE2":27480,"PHASE3":27482,"PHASE4":27488,"NA":27490},{"trials":27477,"activeCount":97},[],{"trials":27479,"activeCount":97},[],{"trials":27481,"activeCount":97},[],{"trials":27483,"activeCount":97},[27484],{"nctId":19251,"briefTitle":19252,"status":155,"phases":27485,"primaryCompletion":19254,"completion":19254,"start":19255,"enrollment":1944,"conditions":27486,"interventions":27487},[87],[3637],[4683,19258],{"trials":27489,"activeCount":97},[],{"trials":27491,"activeCount":97},[],{"intervention":27493,"totalTrials":417,"cells":27494},"denagliptin",{"EARLY_PHASE1":27495,"PHASE1":27497,"PHASE2":27499,"PHASE3":27501,"PHASE4":27509,"NA":27511},{"trials":27496,"activeCount":97},[],{"trials":27498,"activeCount":97},[],{"trials":27500,"activeCount":97},[],{"trials":27502,"activeCount":97},[27503],{"nctId":27504,"briefTitle":27505,"status":500,"phases":27506,"primaryCompletion":8426,"completion":8426,"start":2383,"enrollment":97,"conditions":27507,"interventions":27508},"NCT00387972","Study Of Denagliptin In Subjects With Type 2 Diabetes Mellitus (T2DM)",[86,87],[9036],[27493],{"trials":27510,"activeCount":97},[],{"trials":27512,"activeCount":97},[],{"intervention":27514,"totalTrials":417,"cells":27515},"PandemrixTM",{"EARLY_PHASE1":27516,"PHASE1":27518,"PHASE2":27520,"PHASE3":27522,"PHASE4":27531,"NA":27533},{"trials":27517,"activeCount":97},[],{"trials":27519,"activeCount":97},[],{"trials":27521,"activeCount":97},[],{"trials":27523,"activeCount":97},[27524],{"nctId":27525,"briefTitle":27526,"status":145,"phases":27527,"primaryCompletion":729,"completion":729,"start":3391,"enrollment":1318,"conditions":27528,"interventions":27529},"NCT01160237","Study to Evaluate the Immune Response and the Safety of Fluarix TM\u002F Influsplit SSW® 2010\u002F2011 or Pandemrix TM",[87],[21],[27514,27530],"FluarixTM\u002F Influsplit SSW® 2010\u002F2011",{"trials":27532,"activeCount":97},[],{"trials":27534,"activeCount":97},[],{"intervention":27530,"totalTrials":417,"cells":27536},{"EARLY_PHASE1":27537,"PHASE1":27539,"PHASE2":27541,"PHASE3":27543,"PHASE4":27549,"NA":27551},{"trials":27538,"activeCount":97},[],{"trials":27540,"activeCount":97},[],{"trials":27542,"activeCount":97},[],{"trials":27544,"activeCount":97},[27545],{"nctId":27525,"briefTitle":27526,"status":145,"phases":27546,"primaryCompletion":729,"completion":729,"start":3391,"enrollment":1318,"conditions":27547,"interventions":27548},[87],[21],[27514,27530],{"trials":27550,"activeCount":97},[],{"trials":27552,"activeCount":97},[],{"intervention":24509,"totalTrials":417,"cells":27554},{"EARLY_PHASE1":27555,"PHASE1":27557,"PHASE2":27559,"PHASE3":27561,"PHASE4":27567,"NA":27569},{"trials":27556,"activeCount":97},[],{"trials":27558,"activeCount":97},[],{"trials":27560,"activeCount":97},[],{"trials":27562,"activeCount":97},[27563],{"nctId":24501,"briefTitle":24502,"status":155,"phases":27564,"primaryCompletion":24504,"completion":24504,"start":24505,"enrollment":24506,"conditions":27565,"interventions":27566},[87],[4702],[24490,24509],{"trials":27568,"activeCount":97},[],{"trials":27570,"activeCount":97},[],{"intervention":27572,"totalTrials":417,"cells":27573},"Beclomethasone dipropionate",{"EARLY_PHASE1":27574,"PHASE1":27576,"PHASE2":27578,"PHASE3":27580,"PHASE4":27590,"NA":27592},{"trials":27575,"activeCount":97},[],{"trials":27577,"activeCount":97},[],{"trials":27579,"activeCount":97},[],{"trials":27581,"activeCount":97},[27582],{"nctId":27583,"briefTitle":27584,"status":155,"phases":27585,"primaryCompletion":27586,"completion":27586,"start":920,"enrollment":105,"conditions":27587,"interventions":27588},"NCT00346775","Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)",[87],"2006-06-29",[10182],[27572,27589],"Flunisolide",{"trials":27591,"activeCount":97},[],{"trials":27593,"activeCount":97},[],{"intervention":27589,"totalTrials":417,"cells":27595},{"EARLY_PHASE1":27596,"PHASE1":27598,"PHASE2":27600,"PHASE3":27602,"PHASE4":27608,"NA":27610},{"trials":27597,"activeCount":97},[],{"trials":27599,"activeCount":97},[],{"trials":27601,"activeCount":97},[],{"trials":27603,"activeCount":97},[27604],{"nctId":27583,"briefTitle":27584,"status":155,"phases":27605,"primaryCompletion":27586,"completion":27586,"start":920,"enrollment":105,"conditions":27606,"interventions":27607},[87],[10182],[27572,27589],{"trials":27609,"activeCount":97},[],{"trials":27611,"activeCount":97},[],{"intervention":27613,"totalTrials":417,"cells":27614},"Sumatriptan Succinate",{"EARLY_PHASE1":27615,"PHASE1":27617,"PHASE2":27619,"PHASE3":27621,"PHASE4":27629,"NA":27631},{"trials":27616,"activeCount":97},[],{"trials":27618,"activeCount":97},[],{"trials":27620,"activeCount":97},[],{"trials":27622,"activeCount":97},[27623],{"nctId":27624,"briefTitle":27625,"status":155,"phases":27626,"primaryCompletion":19095,"completion":19095,"start":23430,"enrollment":2825,"conditions":27627,"interventions":27628},"NCT00356603","Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan",[87],[14168],[27613],{"trials":27630,"activeCount":97},[],{"trials":27632,"activeCount":97},[],{"intervention":22621,"totalTrials":417,"cells":27634},{"EARLY_PHASE1":27635,"PHASE1":27637,"PHASE2":27639,"PHASE3":27641,"PHASE4":27647,"NA":27649},{"trials":27636,"activeCount":97},[],{"trials":27638,"activeCount":97},[],{"trials":27640,"activeCount":97},[],{"trials":27642,"activeCount":97},[27643],{"nctId":22614,"briefTitle":22615,"status":155,"phases":27644,"primaryCompletion":2794,"completion":2794,"start":8426,"enrollment":22617,"conditions":27645,"interventions":27646},[87],[22619,12263],[22603,22621],{"trials":27648,"activeCount":97},[],{"trials":27650,"activeCount":97},[],{"intervention":27652,"totalTrials":417,"cells":27653},"cilomilast",{"EARLY_PHASE1":27654,"PHASE1":27656,"PHASE2":27658,"PHASE3":27660,"PHASE4":27668,"NA":27670},{"trials":27655,"activeCount":97},[],{"trials":27657,"activeCount":97},[],{"trials":27659,"activeCount":97},[],{"trials":27661,"activeCount":97},[27662],{"nctId":27663,"briefTitle":27664,"status":155,"phases":27665,"primaryCompletion":5196,"completion":5196,"start":11097,"enrollment":1944,"conditions":27666,"interventions":27667},"NCT00103922","Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)",[87],[15],[27652],{"trials":27669,"activeCount":97},[],{"trials":27671,"activeCount":97},[],{"intervention":27673,"totalTrials":417,"cells":27674},"Fondaparinux 2.5mg or placebo",{"EARLY_PHASE1":27675,"PHASE1":27677,"PHASE2":27679,"PHASE3":27681,"PHASE4":27690,"NA":27692},{"trials":27676,"activeCount":97},[],{"trials":27678,"activeCount":97},[],{"trials":27680,"activeCount":97},[],{"trials":27682,"activeCount":97},[27683],{"nctId":27684,"briefTitle":27685,"status":155,"phases":27686,"primaryCompletion":2441,"completion":2441,"start":748,"enrollment":27687,"conditions":27688,"interventions":27689},"NCT00443053","Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)",[87],3002,[26339],[27673],{"trials":27691,"activeCount":97},[],{"trials":27693,"activeCount":97},[],{"intervention":22709,"totalTrials":417,"cells":27695},{"EARLY_PHASE1":27696,"PHASE1":27698,"PHASE2":27700,"PHASE3":27702,"PHASE4":27708,"NA":27710},{"trials":27697,"activeCount":97},[],{"trials":27699,"activeCount":97},[],{"trials":27701,"activeCount":97},[],{"trials":27703,"activeCount":97},[27704],{"nctId":22704,"briefTitle":22705,"status":155,"phases":27705,"primaryCompletion":2835,"completion":2835,"start":4844,"enrollment":10685,"conditions":27706,"interventions":27707},[87],[5943],[22686,22709],{"trials":27709,"activeCount":97},[],{"trials":27711,"activeCount":97},[],{"intervention":27713,"totalTrials":417,"cells":27714},"GSK Biological's HPV vaccine GSK580299",{"EARLY_PHASE1":27715,"PHASE1":27717,"PHASE2":27719,"PHASE3":27721,"PHASE4":27730,"NA":27732},{"trials":27716,"activeCount":97},[],{"trials":27718,"activeCount":97},[],{"trials":27720,"activeCount":97},[],{"trials":27722,"activeCount":97},[27723],{"nctId":27724,"briefTitle":27725,"status":155,"phases":27726,"primaryCompletion":9952,"completion":9952,"start":16323,"enrollment":27727,"conditions":27728,"interventions":27729},"NCT00799825","Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299\u002F008 Subjects From Canada or the US",[87],346,[8723],[27713],{"trials":27731,"activeCount":97},[],{"trials":27733,"activeCount":97},[],{"intervention":27735,"totalTrials":417,"cells":27736},"Dutasteride 0.5 mg",{"EARLY_PHASE1":27737,"PHASE1":27739,"PHASE2":27741,"PHASE3":27743,"PHASE4":27753,"NA":27755},{"trials":27738,"activeCount":97},[],{"trials":27740,"activeCount":97},[],{"trials":27742,"activeCount":97},[],{"trials":27744,"activeCount":97},[27745],{"nctId":27746,"briefTitle":27747,"status":155,"phases":27748,"primaryCompletion":27749,"completion":27749,"start":27750,"enrollment":201,"conditions":27751,"interventions":27752},"NCT01831791","A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia",[87],"2014-07-19","2013-04-14",[22627],[27735],{"trials":27754,"activeCount":97},[],{"trials":27756,"activeCount":97},[],{"intervention":19384,"totalTrials":417,"cells":27758},{"EARLY_PHASE1":27759,"PHASE1":27761,"PHASE2":27763,"PHASE3":27765,"PHASE4":27771,"NA":27773},{"trials":27760,"activeCount":97},[],{"trials":27762,"activeCount":97},[],{"trials":27764,"activeCount":97},[],{"trials":27766,"activeCount":97},[27767],{"nctId":19378,"briefTitle":19379,"status":155,"phases":27768,"primaryCompletion":10167,"completion":10166,"start":2428,"enrollment":19381,"conditions":27769,"interventions":27770},[87],[4704,4703],[19384,19385,19386,8674,8675],{"trials":27772,"activeCount":97},[],{"trials":27774,"activeCount":97},[],{"intervention":21395,"totalTrials":417,"cells":27776},{"EARLY_PHASE1":27777,"PHASE1":27779,"PHASE2":27781,"PHASE3":27783,"PHASE4":27789,"NA":27791},{"trials":27778,"activeCount":97},[],{"trials":27780,"activeCount":97},[],{"trials":27782,"activeCount":97},[],{"trials":27784,"activeCount":97},[27785],{"nctId":21388,"briefTitle":21389,"status":155,"phases":27786,"primaryCompletion":21391,"completion":21391,"start":11275,"enrollment":21392,"conditions":27787,"interventions":27788},[87],[33,4702,3624,30,4704],[21395,21396,21367],{"trials":27790,"activeCount":97},[],{"trials":27792,"activeCount":97},[],{"intervention":21396,"totalTrials":417,"cells":27794},{"EARLY_PHASE1":27795,"PHASE1":27797,"PHASE2":27799,"PHASE3":27801,"PHASE4":27807,"NA":27809},{"trials":27796,"activeCount":97},[],{"trials":27798,"activeCount":97},[],{"trials":27800,"activeCount":97},[],{"trials":27802,"activeCount":97},[27803],{"nctId":21388,"briefTitle":21389,"status":155,"phases":27804,"primaryCompletion":21391,"completion":21391,"start":11275,"enrollment":21392,"conditions":27805,"interventions":27806},[87],[33,4702,3624,30,4704],[21395,21396,21367],{"trials":27808,"activeCount":97},[],{"trials":27810,"activeCount":97},[],{"intervention":8066,"totalTrials":417,"cells":27812},{"EARLY_PHASE1":27813,"PHASE1":27815,"PHASE2":27817,"PHASE3":27819,"PHASE4":27825,"NA":27827},{"trials":27814,"activeCount":97},[],{"trials":27816,"activeCount":97},[],{"trials":27818,"activeCount":97},[],{"trials":27820,"activeCount":97},[27821],{"nctId":8056,"briefTitle":8057,"status":155,"phases":27822,"primaryCompletion":8059,"completion":8059,"start":8060,"enrollment":8061,"conditions":27823,"interventions":27824},[87],[8063],[8021,8065,8066,8067,8068,8069],{"trials":27826,"activeCount":97},[],{"trials":27828,"activeCount":97},[],{"intervention":8067,"totalTrials":417,"cells":27830},{"EARLY_PHASE1":27831,"PHASE1":27833,"PHASE2":27835,"PHASE3":27837,"PHASE4":27843,"NA":27845},{"trials":27832,"activeCount":97},[],{"trials":27834,"activeCount":97},[],{"trials":27836,"activeCount":97},[],{"trials":27838,"activeCount":97},[27839],{"nctId":8056,"briefTitle":8057,"status":155,"phases":27840,"primaryCompletion":8059,"completion":8059,"start":8060,"enrollment":8061,"conditions":27841,"interventions":27842},[87],[8063],[8021,8065,8066,8067,8068,8069],{"trials":27844,"activeCount":97},[],{"trials":27846,"activeCount":97},[],{"intervention":8068,"totalTrials":417,"cells":27848},{"EARLY_PHASE1":27849,"PHASE1":27851,"PHASE2":27853,"PHASE3":27855,"PHASE4":27861,"NA":27863},{"trials":27850,"activeCount":97},[],{"trials":27852,"activeCount":97},[],{"trials":27854,"activeCount":97},[],{"trials":27856,"activeCount":97},[27857],{"nctId":8056,"briefTitle":8057,"status":155,"phases":27858,"primaryCompletion":8059,"completion":8059,"start":8060,"enrollment":8061,"conditions":27859,"interventions":27860},[87],[8063],[8021,8065,8066,8067,8068,8069],{"trials":27862,"activeCount":97},[],{"trials":27864,"activeCount":97},[],{"intervention":8069,"totalTrials":417,"cells":27866},{"EARLY_PHASE1":27867,"PHASE1":27869,"PHASE2":27871,"PHASE3":27873,"PHASE4":27879,"NA":27881},{"trials":27868,"activeCount":97},[],{"trials":27870,"activeCount":97},[],{"trials":27872,"activeCount":97},[],{"trials":27874,"activeCount":97},[27875],{"nctId":8056,"briefTitle":8057,"status":155,"phases":27876,"primaryCompletion":8059,"completion":8059,"start":8060,"enrollment":8061,"conditions":27877,"interventions":27878},[87],[8063],[8021,8065,8066,8067,8068,8069],{"trials":27880,"activeCount":97},[],{"trials":27882,"activeCount":97},[],{"intervention":8543,"totalTrials":417,"cells":27884},{"EARLY_PHASE1":27885,"PHASE1":27887,"PHASE2":27889,"PHASE3":27891,"PHASE4":27897,"NA":27899},{"trials":27886,"activeCount":97},[],{"trials":27888,"activeCount":97},[],{"trials":27890,"activeCount":97},[],{"trials":27892,"activeCount":97},[27893],{"nctId":8536,"briefTitle":8537,"status":500,"phases":27894,"primaryCompletion":8539,"completion":8539,"start":8540,"enrollment":97,"conditions":27895,"interventions":27896},[87],[15],[8543,8544,8545,8522],{"trials":27898,"activeCount":97},[],{"trials":27900,"activeCount":97},[],{"intervention":8544,"totalTrials":417,"cells":27902},{"EARLY_PHASE1":27903,"PHASE1":27905,"PHASE2":27907,"PHASE3":27909,"PHASE4":27915,"NA":27917},{"trials":27904,"activeCount":97},[],{"trials":27906,"activeCount":97},[],{"trials":27908,"activeCount":97},[],{"trials":27910,"activeCount":97},[27911],{"nctId":8536,"briefTitle":8537,"status":500,"phases":27912,"primaryCompletion":8539,"completion":8539,"start":8540,"enrollment":97,"conditions":27913,"interventions":27914},[87],[15],[8543,8544,8545,8522],{"trials":27916,"activeCount":97},[],{"trials":27918,"activeCount":97},[],{"intervention":8545,"totalTrials":417,"cells":27920},{"EARLY_PHASE1":27921,"PHASE1":27923,"PHASE2":27925,"PHASE3":27927,"PHASE4":27933,"NA":27935},{"trials":27922,"activeCount":97},[],{"trials":27924,"activeCount":97},[],{"trials":27926,"activeCount":97},[],{"trials":27928,"activeCount":97},[27929],{"nctId":8536,"briefTitle":8537,"status":500,"phases":27930,"primaryCompletion":8539,"completion":8539,"start":8540,"enrollment":97,"conditions":27931,"interventions":27932},[87],[15],[8543,8544,8545,8522],{"trials":27934,"activeCount":97},[],{"trials":27936,"activeCount":97},[],{"intervention":27938,"totalTrials":417,"cells":27939},"Fluticasone Furoate 100mcg\u002FVilanterol 25mcg",{"EARLY_PHASE1":27940,"PHASE1":27942,"PHASE2":27944,"PHASE3":27946,"PHASE4":27955,"NA":27957},{"trials":27941,"activeCount":97},[],{"trials":27943,"activeCount":97},[],{"trials":27945,"activeCount":97},[],{"trials":27947,"activeCount":97},[27948],{"nctId":27949,"briefTitle":27950,"status":155,"phases":27951,"primaryCompletion":4973,"completion":22113,"start":21291,"enrollment":4466,"conditions":27952,"interventions":27953},"NCT01342913","A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate\u002FVilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)\u002F25mcg Vilanterol (VI)) Compared With Salmeterol\u002FFluticasone Propionate Inhalation Powder (50mcg Salmeterol\u002F500mcg Fluticasone Propionate (FP))",[87],[15],[27938,27954],"Fluticaosne Propionate 500mcg\u002FSalmeterol 50mcg",{"trials":27956,"activeCount":97},[],{"trials":27958,"activeCount":97},[],{"intervention":27954,"totalTrials":417,"cells":27960},{"EARLY_PHASE1":27961,"PHASE1":27963,"PHASE2":27965,"PHASE3":27967,"PHASE4":27973,"NA":27975},{"trials":27962,"activeCount":97},[],{"trials":27964,"activeCount":97},[],{"trials":27966,"activeCount":97},[],{"trials":27968,"activeCount":97},[27969],{"nctId":27949,"briefTitle":27950,"status":155,"phases":27970,"primaryCompletion":4973,"completion":22113,"start":21291,"enrollment":4466,"conditions":27971,"interventions":27972},[87],[15],[27938,27954],{"trials":27974,"activeCount":97},[],{"trials":27976,"activeCount":97},[],{"intervention":27978,"totalTrials":417,"cells":27979},"GSK1572932A Antigen-Specific Cancer Immunotherapeutic",{"EARLY_PHASE1":27980,"PHASE1":27982,"PHASE2":27984,"PHASE3":27986,"PHASE4":27996,"NA":27998},{"trials":27981,"activeCount":97},[],{"trials":27983,"activeCount":97},[],{"trials":27985,"activeCount":97},[],{"trials":27987,"activeCount":97},[27988],{"nctId":27989,"briefTitle":27990,"status":145,"phases":27991,"primaryCompletion":27992,"completion":10487,"start":8996,"enrollment":27993,"conditions":27994,"interventions":27995},"NCT00480025","GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer",[87],"2013-12-06",2278,[267],[27978],{"trials":27997,"activeCount":97},[],{"trials":27999,"activeCount":97},[],{"intervention":28001,"totalTrials":417,"cells":28002},"125\u002F25 mcg once-daily GSK573719\u002FGW642444",{"EARLY_PHASE1":28003,"PHASE1":28005,"PHASE2":28007,"PHASE3":28009,"PHASE4":28021,"NA":28023},{"trials":28004,"activeCount":97},[],{"trials":28006,"activeCount":97},[],{"trials":28008,"activeCount":97},[],{"trials":28010,"activeCount":97},[28011],{"nctId":28012,"briefTitle":28013,"status":155,"phases":28014,"primaryCompletion":472,"completion":28015,"start":28016,"enrollment":28017,"conditions":28018,"interventions":28019},"NCT01316887","A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719\u002FGW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2012-07-21","2011-01-01",563,[15],[28001,28020],"125mcg once-daily GSK573719",{"trials":28022,"activeCount":97},[],{"trials":28024,"activeCount":97},[],{"intervention":28020,"totalTrials":417,"cells":28026},{"EARLY_PHASE1":28027,"PHASE1":28029,"PHASE2":28031,"PHASE3":28033,"PHASE4":28039,"NA":28041},{"trials":28028,"activeCount":97},[],{"trials":28030,"activeCount":97},[],{"trials":28032,"activeCount":97},[],{"trials":28034,"activeCount":97},[28035],{"nctId":28012,"briefTitle":28013,"status":155,"phases":28036,"primaryCompletion":472,"completion":28015,"start":28016,"enrollment":28017,"conditions":28037,"interventions":28038},[87],[15],[28001,28020],{"trials":28040,"activeCount":97},[],{"trials":28042,"activeCount":97},[],{"intervention":18616,"totalTrials":417,"cells":28044},{"EARLY_PHASE1":28045,"PHASE1":28047,"PHASE2":28049,"PHASE3":28051,"PHASE4":28057,"NA":28059},{"trials":28046,"activeCount":97},[],{"trials":28048,"activeCount":97},[],{"trials":28050,"activeCount":97},[],{"trials":28052,"activeCount":97},[28053],{"nctId":18609,"briefTitle":18610,"status":155,"phases":28054,"primaryCompletion":18612,"completion":18612,"start":18613,"enrollment":11770,"conditions":28055,"interventions":28056},[87],[17996],[18545,18616,18617],{"trials":28058,"activeCount":97},[],{"trials":28060,"activeCount":97},[],{"intervention":18617,"totalTrials":417,"cells":28062},{"EARLY_PHASE1":28063,"PHASE1":28065,"PHASE2":28067,"PHASE3":28069,"PHASE4":28075,"NA":28077},{"trials":28064,"activeCount":97},[],{"trials":28066,"activeCount":97},[],{"trials":28068,"activeCount":97},[],{"trials":28070,"activeCount":97},[28071],{"nctId":18609,"briefTitle":18610,"status":155,"phases":28072,"primaryCompletion":18612,"completion":18612,"start":18613,"enrollment":11770,"conditions":28073,"interventions":28074},[87],[17996],[18545,18616,18617],{"trials":28076,"activeCount":97},[],{"trials":28078,"activeCount":97},[],{"intervention":7831,"totalTrials":417,"cells":28080},{"EARLY_PHASE1":28081,"PHASE1":28083,"PHASE2":28085,"PHASE3":28087,"PHASE4":28093,"NA":28095},{"trials":28082,"activeCount":97},[],{"trials":28084,"activeCount":97},[],{"trials":28086,"activeCount":97},[],{"trials":28088,"activeCount":97},[28089],{"nctId":7821,"briefTitle":7822,"status":155,"phases":28090,"primaryCompletion":2373,"completion":7824,"start":7825,"enrollment":7826,"conditions":28091,"interventions":28092},[87],[24],[7829,7830,7831,7832,7718],{"trials":28094,"activeCount":97},[],{"trials":28096,"activeCount":97},[],{"intervention":7832,"totalTrials":417,"cells":28098},{"EARLY_PHASE1":28099,"PHASE1":28101,"PHASE2":28103,"PHASE3":28105,"PHASE4":28111,"NA":28113},{"trials":28100,"activeCount":97},[],{"trials":28102,"activeCount":97},[],{"trials":28104,"activeCount":97},[],{"trials":28106,"activeCount":97},[28107],{"nctId":7821,"briefTitle":7822,"status":155,"phases":28108,"primaryCompletion":2373,"completion":7824,"start":7825,"enrollment":7826,"conditions":28109,"interventions":28110},[87],[24],[7829,7830,7831,7832,7718],{"trials":28112,"activeCount":97},[],{"trials":28114,"activeCount":97},[],{"intervention":20282,"totalTrials":417,"cells":28116},{"EARLY_PHASE1":28117,"PHASE1":28119,"PHASE2":28121,"PHASE3":28123,"PHASE4":28129,"NA":28131},{"trials":28118,"activeCount":97},[],{"trials":28120,"activeCount":97},[],{"trials":28122,"activeCount":97},[],{"trials":28124,"activeCount":97},[28125],{"nctId":20273,"briefTitle":20274,"status":145,"phases":28126,"primaryCompletion":20276,"completion":20277,"start":20278,"enrollment":20279,"conditions":28127,"interventions":28128},[87],[8788],[20235,20282],{"trials":28130,"activeCount":97},[],{"trials":28132,"activeCount":97},[],{"intervention":9632,"totalTrials":417,"cells":28134},{"EARLY_PHASE1":28135,"PHASE1":28137,"PHASE2":28139,"PHASE3":28141,"PHASE4":28147,"NA":28149},{"trials":28136,"activeCount":97},[],{"trials":28138,"activeCount":97},[],{"trials":28140,"activeCount":97},[],{"trials":28142,"activeCount":97},[28143],{"nctId":9622,"briefTitle":9623,"status":155,"phases":28144,"primaryCompletion":9625,"completion":9625,"start":9626,"enrollment":9627,"conditions":28145,"interventions":28146},[87],[18],[9546,9630,9631,9632,9633,9634],{"trials":28148,"activeCount":97},[],{"trials":28150,"activeCount":97},[],{"intervention":9633,"totalTrials":417,"cells":28152},{"EARLY_PHASE1":28153,"PHASE1":28155,"PHASE2":28157,"PHASE3":28159,"PHASE4":28165,"NA":28167},{"trials":28154,"activeCount":97},[],{"trials":28156,"activeCount":97},[],{"trials":28158,"activeCount":97},[],{"trials":28160,"activeCount":97},[28161],{"nctId":9622,"briefTitle":9623,"status":155,"phases":28162,"primaryCompletion":9625,"completion":9625,"start":9626,"enrollment":9627,"conditions":28163,"interventions":28164},[87],[18],[9546,9630,9631,9632,9633,9634],{"trials":28166,"activeCount":97},[],{"trials":28168,"activeCount":97},[],{"intervention":9634,"totalTrials":417,"cells":28170},{"EARLY_PHASE1":28171,"PHASE1":28173,"PHASE2":28175,"PHASE3":28177,"PHASE4":28183,"NA":28185},{"trials":28172,"activeCount":97},[],{"trials":28174,"activeCount":97},[],{"trials":28176,"activeCount":97},[],{"trials":28178,"activeCount":97},[28179],{"nctId":9622,"briefTitle":9623,"status":155,"phases":28180,"primaryCompletion":9625,"completion":9625,"start":9626,"enrollment":9627,"conditions":28181,"interventions":28182},[87],[18],[9546,9630,9631,9632,9633,9634],{"trials":28184,"activeCount":97},[],{"trials":28186,"activeCount":97},[],{"intervention":24902,"totalTrials":417,"cells":28188},{"EARLY_PHASE1":28189,"PHASE1":28191,"PHASE2":28193,"PHASE3":28195,"PHASE4":28201,"NA":28203},{"trials":28190,"activeCount":97},[],{"trials":28192,"activeCount":97},[],{"trials":28194,"activeCount":97},[],{"trials":28196,"activeCount":97},[28197],{"nctId":24895,"briefTitle":24896,"status":155,"phases":28198,"primaryCompletion":9877,"completion":24898,"start":24899,"enrollment":10407,"conditions":28199,"interventions":28200},[87],[3637],[24884,24902,24903],{"trials":28202,"activeCount":97},[],{"trials":28204,"activeCount":97},[],{"intervention":24903,"totalTrials":417,"cells":28206},{"EARLY_PHASE1":28207,"PHASE1":28209,"PHASE2":28211,"PHASE3":28213,"PHASE4":28219,"NA":28221},{"trials":28208,"activeCount":97},[],{"trials":28210,"activeCount":97},[],{"trials":28212,"activeCount":97},[],{"trials":28214,"activeCount":97},[28215],{"nctId":24895,"briefTitle":24896,"status":155,"phases":28216,"primaryCompletion":9877,"completion":24898,"start":24899,"enrollment":10407,"conditions":28217,"interventions":28218},[87],[3637],[24884,24902,24903],{"trials":28220,"activeCount":97},[],{"trials":28222,"activeCount":97},[],{"intervention":28224,"totalTrials":417,"cells":28225},"HRV PCV-free",{"EARLY_PHASE1":28226,"PHASE1":28228,"PHASE2":28230,"PHASE3":28232,"PHASE4":28243,"NA":28245},{"trials":28227,"activeCount":97},[],{"trials":28229,"activeCount":97},[],{"trials":28231,"activeCount":97},[],{"trials":28233,"activeCount":97},[28234],{"nctId":28235,"briefTitle":28236,"status":155,"phases":28237,"primaryCompletion":6614,"completion":6614,"start":28238,"enrollment":4388,"conditions":28239,"interventions":28241},"NCT06331156","A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants",[87],"2024-03-22",[28240],"Gastroenteritis",[28224,28242],"IPV",{"trials":28244,"activeCount":97},[],{"trials":28246,"activeCount":97},[],{"intervention":28242,"totalTrials":417,"cells":28248},{"EARLY_PHASE1":28249,"PHASE1":28251,"PHASE2":28253,"PHASE3":28255,"PHASE4":28261,"NA":28263},{"trials":28250,"activeCount":97},[],{"trials":28252,"activeCount":97},[],{"trials":28254,"activeCount":97},[],{"trials":28256,"activeCount":97},[28257],{"nctId":28235,"briefTitle":28236,"status":155,"phases":28258,"primaryCompletion":6614,"completion":6614,"start":28238,"enrollment":4388,"conditions":28259,"interventions":28260},[87],[28240],[28224,28242],{"trials":28262,"activeCount":97},[],{"trials":28264,"activeCount":97},[],{"intervention":24935,"totalTrials":417,"cells":28266},{"EARLY_PHASE1":28267,"PHASE1":28269,"PHASE2":28271,"PHASE3":28273,"PHASE4":28279,"NA":28281},{"trials":28268,"activeCount":97},[],{"trials":28270,"activeCount":97},[],{"trials":28272,"activeCount":97},[],{"trials":28274,"activeCount":97},[28275],{"nctId":24928,"briefTitle":24929,"status":155,"phases":28276,"primaryCompletion":22657,"completion":24931,"start":18536,"enrollment":24932,"conditions":28277,"interventions":28278},[87],[15],[24935,24936,24937,24938,23985,24939],{"trials":28280,"activeCount":97},[],{"trials":28282,"activeCount":97},[],{"intervention":24936,"totalTrials":417,"cells":28284},{"EARLY_PHASE1":28285,"PHASE1":28287,"PHASE2":28289,"PHASE3":28291,"PHASE4":28297,"NA":28299},{"trials":28286,"activeCount":97},[],{"trials":28288,"activeCount":97},[],{"trials":28290,"activeCount":97},[],{"trials":28292,"activeCount":97},[28293],{"nctId":24928,"briefTitle":24929,"status":155,"phases":28294,"primaryCompletion":22657,"completion":24931,"start":18536,"enrollment":24932,"conditions":28295,"interventions":28296},[87],[15],[24935,24936,24937,24938,23985,24939],{"trials":28298,"activeCount":97},[],{"trials":28300,"activeCount":97},[],{"intervention":24937,"totalTrials":417,"cells":28302},{"EARLY_PHASE1":28303,"PHASE1":28305,"PHASE2":28307,"PHASE3":28309,"PHASE4":28315,"NA":28317},{"trials":28304,"activeCount":97},[],{"trials":28306,"activeCount":97},[],{"trials":28308,"activeCount":97},[],{"trials":28310,"activeCount":97},[28311],{"nctId":24928,"briefTitle":24929,"status":155,"phases":28312,"primaryCompletion":22657,"completion":24931,"start":18536,"enrollment":24932,"conditions":28313,"interventions":28314},[87],[15],[24935,24936,24937,24938,23985,24939],{"trials":28316,"activeCount":97},[],{"trials":28318,"activeCount":97},[],{"intervention":24938,"totalTrials":417,"cells":28320},{"EARLY_PHASE1":28321,"PHASE1":28323,"PHASE2":28325,"PHASE3":28327,"PHASE4":28333,"NA":28335},{"trials":28322,"activeCount":97},[],{"trials":28324,"activeCount":97},[],{"trials":28326,"activeCount":97},[],{"trials":28328,"activeCount":97},[28329],{"nctId":24928,"briefTitle":24929,"status":155,"phases":28330,"primaryCompletion":22657,"completion":24931,"start":18536,"enrollment":24932,"conditions":28331,"interventions":28332},[87],[15],[24935,24936,24937,24938,23985,24939],{"trials":28334,"activeCount":97},[],{"trials":28336,"activeCount":97},[],{"intervention":24939,"totalTrials":417,"cells":28338},{"EARLY_PHASE1":28339,"PHASE1":28341,"PHASE2":28343,"PHASE3":28345,"PHASE4":28351,"NA":28353},{"trials":28340,"activeCount":97},[],{"trials":28342,"activeCount":97},[],{"trials":28344,"activeCount":97},[],{"trials":28346,"activeCount":97},[28347],{"nctId":24928,"briefTitle":24929,"status":155,"phases":28348,"primaryCompletion":22657,"completion":24931,"start":18536,"enrollment":24932,"conditions":28349,"interventions":28350},[87],[15],[24935,24936,24937,24938,23985,24939],{"trials":28352,"activeCount":97},[],{"trials":28354,"activeCount":97},[],{"intervention":28356,"totalTrials":417,"cells":28357},"omega-3-acid ethyl esters",{"EARLY_PHASE1":28358,"PHASE1":28360,"PHASE2":28362,"PHASE3":28364,"PHASE4":28374,"NA":28376},{"trials":28359,"activeCount":97},[],{"trials":28361,"activeCount":97},[],{"trials":28363,"activeCount":97},[],{"trials":28365,"activeCount":97},[28366],{"nctId":28367,"briefTitle":28368,"status":155,"phases":28369,"primaryCompletion":26336,"completion":26336,"start":4843,"enrollment":28370,"conditions":28371,"interventions":28373},"NCT00402363","Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation",[87],663,[28372],"Fibrillation, Atrial",[28356],{"trials":28375,"activeCount":97},[],{"trials":28377,"activeCount":97},[],{"intervention":3202,"totalTrials":417,"cells":28379},{"EARLY_PHASE1":28380,"PHASE1":28382,"PHASE2":28384,"PHASE3":28386,"PHASE4":28392,"NA":28394},{"trials":28381,"activeCount":97},[],{"trials":28383,"activeCount":97},[],{"trials":28385,"activeCount":97},[],{"trials":28387,"activeCount":97},[28388],{"nctId":3194,"briefTitle":3195,"status":155,"phases":28389,"primaryCompletion":3197,"completion":3198,"start":1767,"enrollment":3199,"conditions":28390,"interventions":28391},[87],[2620],[43,3202],{"trials":28393,"activeCount":97},[],{"trials":28395,"activeCount":97},[],{"intervention":28397,"totalTrials":417,"cells":28398},"fosamprenavir\u002Fritonavir",{"EARLY_PHASE1":28399,"PHASE1":28401,"PHASE2":28403,"PHASE3":28405,"PHASE4":28415,"NA":28417},{"trials":28400,"activeCount":97},[],{"trials":28402,"activeCount":97},[],{"trials":28404,"activeCount":97},[],{"trials":28406,"activeCount":97},[28407],{"nctId":28408,"briefTitle":28409,"status":145,"phases":28410,"start":2814,"enrollment":1579,"conditions":28411,"interventions":28413},"NCT00144833","Open Label Study of 908\u002FRTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects",[87],[28412],"HIV-1",[28397,28397,28414],"fosamprenavir\u002Flopinavir\u002Fritonavir",{"trials":28416,"activeCount":97},[],{"trials":28418,"activeCount":97},[],{"intervention":28414,"totalTrials":417,"cells":28420},{"EARLY_PHASE1":28421,"PHASE1":28423,"PHASE2":28425,"PHASE3":28427,"PHASE4":28433,"NA":28435},{"trials":28422,"activeCount":97},[],{"trials":28424,"activeCount":97},[],{"trials":28426,"activeCount":97},[],{"trials":28428,"activeCount":97},[28429],{"nctId":28408,"briefTitle":28409,"status":145,"phases":28430,"start":2814,"enrollment":1579,"conditions":28431,"interventions":28432},[87],[28412],[28397,28397,28414],{"trials":28434,"activeCount":97},[],{"trials":28436,"activeCount":97},[],{"intervention":28438,"totalTrials":417,"cells":28439},"Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin",{"EARLY_PHASE1":28440,"PHASE1":28442,"PHASE2":28444,"PHASE3":28446,"PHASE4":28455,"NA":28457},{"trials":28441,"activeCount":97},[],{"trials":28443,"activeCount":97},[],{"trials":28445,"activeCount":97},[],{"trials":28447,"activeCount":97},[28448],{"nctId":28449,"briefTitle":28450,"status":155,"phases":28451,"primaryCompletion":8426,"completion":8426,"start":8406,"enrollment":20448,"conditions":28452,"interventions":28453},"NCT00435045","Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia",[87],[12294],[28438,28454],"atorvastatin",{"trials":28456,"activeCount":97},[],{"trials":28458,"activeCount":97},[],{"intervention":28460,"totalTrials":417,"cells":28461},"lamotrigine extended-release",{"EARLY_PHASE1":28462,"PHASE1":28464,"PHASE2":28466,"PHASE3":28468,"PHASE4":28476,"NA":28478},{"trials":28463,"activeCount":97},[],{"trials":28465,"activeCount":97},[],{"trials":28467,"activeCount":97},[],{"trials":28469,"activeCount":97},[28470],{"nctId":28471,"briefTitle":28472,"status":155,"phases":28473,"primaryCompletion":8852,"completion":8852,"start":2805,"enrollment":6369,"conditions":28474,"interventions":28475},"NCT00264615","Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa",[87],[12518],[28460],{"trials":28477,"activeCount":97},[],{"trials":28479,"activeCount":97},[],{"intervention":28481,"totalTrials":417,"cells":28482},"Herpes simplex candidate vaccine- adjuvanted GSK 208141",{"EARLY_PHASE1":28483,"PHASE1":28485,"PHASE2":28487,"PHASE3":28489,"PHASE4":28500,"NA":28502},{"trials":28484,"activeCount":97},[],{"trials":28486,"activeCount":97},[],{"trials":28488,"activeCount":97},[],{"trials":28490,"activeCount":97},[28491],{"nctId":28492,"briefTitle":28493,"status":155,"phases":28494,"primaryCompletion":7919,"completion":7919,"start":28495,"enrollment":28496,"conditions":28497,"interventions":28499},"NCT00698568","Safety Evaluation of Herpes Simplex Candidate Vaccine (gD2t) With Adjuvant in HSV Seropositive \u002F Seronegative Subjects",[87],"1996-10",7460,[28498],"Prophylaxis for Herpes Simplex",[28481],{"trials":28501,"activeCount":97},[],{"trials":28503,"activeCount":97},[],{"intervention":8876,"totalTrials":417,"cells":28505},{"EARLY_PHASE1":28506,"PHASE1":28508,"PHASE2":28510,"PHASE3":28512,"PHASE4":28518,"NA":28520},{"trials":28507,"activeCount":97},[],{"trials":28509,"activeCount":97},[],{"trials":28511,"activeCount":97},[],{"trials":28513,"activeCount":97},[28514],{"nctId":8868,"briefTitle":8869,"status":145,"phases":28515,"primaryCompletion":8871,"completion":8871,"start":8872,"enrollment":417,"conditions":28516,"interventions":28517},[87],[8874],[3556,8876,8877,8878],{"trials":28519,"activeCount":97},[],{"trials":28521,"activeCount":97},[],{"intervention":8877,"totalTrials":417,"cells":28523},{"EARLY_PHASE1":28524,"PHASE1":28526,"PHASE2":28528,"PHASE3":28530,"PHASE4":28536,"NA":28538},{"trials":28525,"activeCount":97},[],{"trials":28527,"activeCount":97},[],{"trials":28529,"activeCount":97},[],{"trials":28531,"activeCount":97},[28532],{"nctId":8868,"briefTitle":8869,"status":145,"phases":28533,"primaryCompletion":8871,"completion":8871,"start":8872,"enrollment":417,"conditions":28534,"interventions":28535},[87],[8874],[3556,8876,8877,8878],{"trials":28537,"activeCount":97},[],{"trials":28539,"activeCount":97},[],{"intervention":8878,"totalTrials":417,"cells":28541},{"EARLY_PHASE1":28542,"PHASE1":28544,"PHASE2":28546,"PHASE3":28548,"PHASE4":28554,"NA":28556},{"trials":28543,"activeCount":97},[],{"trials":28545,"activeCount":97},[],{"trials":28547,"activeCount":97},[],{"trials":28549,"activeCount":97},[28550],{"nctId":8868,"briefTitle":8869,"status":145,"phases":28551,"primaryCompletion":8871,"completion":8871,"start":8872,"enrollment":417,"conditions":28552,"interventions":28553},[87],[8874],[3556,8876,8877,8878],{"trials":28555,"activeCount":97},[],{"trials":28557,"activeCount":97},[],{"intervention":22680,"totalTrials":417,"cells":28559},{"EARLY_PHASE1":28560,"PHASE1":28562,"PHASE2":28564,"PHASE3":28566,"PHASE4":28572,"NA":28574},{"trials":28561,"activeCount":97},[],{"trials":28563,"activeCount":97},[],{"trials":28565,"activeCount":97},[],{"trials":28567,"activeCount":97},[28568],{"nctId":22674,"briefTitle":22675,"status":155,"phases":28569,"primaryCompletion":9952,"completion":9952,"start":22677,"enrollment":1924,"conditions":28570,"interventions":28571},[87],[15087],[22647,22680],{"trials":28573,"activeCount":97},[],{"trials":28575,"activeCount":97},[],{"intervention":8401,"totalTrials":417,"cells":28577},{"EARLY_PHASE1":28578,"PHASE1":28580,"PHASE2":28582,"PHASE3":28584,"PHASE4":28590,"NA":28592},{"trials":28579,"activeCount":97},[],{"trials":28581,"activeCount":97},[],{"trials":28583,"activeCount":97},[],{"trials":28585,"activeCount":97},[28586],{"nctId":8392,"briefTitle":8393,"status":155,"phases":28587,"primaryCompletion":8395,"completion":8396,"start":8397,"enrollment":8398,"conditions":28588,"interventions":28589},[87],[15],[8401,8380],{"trials":28591,"activeCount":97},[],{"trials":28593,"activeCount":97},[],{"intervention":25136,"totalTrials":417,"cells":28595},{"EARLY_PHASE1":28596,"PHASE1":28598,"PHASE2":28600,"PHASE3":28602,"PHASE4":28608,"NA":28610},{"trials":28597,"activeCount":97},[],{"trials":28599,"activeCount":97},[],{"trials":28601,"activeCount":97},[],{"trials":28603,"activeCount":97},[28604],{"nctId":25128,"briefTitle":25129,"status":155,"phases":28605,"primaryCompletion":25131,"completion":1157,"start":25132,"enrollment":25133,"conditions":28606,"interventions":28607},[87],[1030],[25117,25136,25137],{"trials":28609,"activeCount":97},[],{"trials":28611,"activeCount":97},[],{"intervention":25137,"totalTrials":417,"cells":28613},{"EARLY_PHASE1":28614,"PHASE1":28616,"PHASE2":28618,"PHASE3":28620,"PHASE4":28626,"NA":28628},{"trials":28615,"activeCount":97},[],{"trials":28617,"activeCount":97},[],{"trials":28619,"activeCount":97},[],{"trials":28621,"activeCount":97},[28622],{"nctId":25128,"briefTitle":25129,"status":155,"phases":28623,"primaryCompletion":25131,"completion":1157,"start":25132,"enrollment":25133,"conditions":28624,"interventions":28625},[87],[1030],[25117,25136,25137],{"trials":28627,"activeCount":97},[],{"trials":28629,"activeCount":97},[],{"intervention":10992,"totalTrials":417,"cells":28631},{"EARLY_PHASE1":28632,"PHASE1":28634,"PHASE2":28636,"PHASE3":28638,"PHASE4":28644,"NA":28646},{"trials":28633,"activeCount":97},[],{"trials":28635,"activeCount":97},[],{"trials":28637,"activeCount":97},[],{"trials":28639,"activeCount":97},[28640],{"nctId":10984,"briefTitle":10985,"status":155,"phases":28641,"primaryCompletion":1541,"completion":1541,"start":10987,"enrollment":10988,"conditions":28642,"interventions":28643},[87],[9840,10990],[10963,10992],{"trials":28645,"activeCount":97},[],{"trials":28647,"activeCount":97},[],{"intervention":19590,"totalTrials":417,"cells":28649},{"EARLY_PHASE1":28650,"PHASE1":28652,"PHASE2":28654,"PHASE3":28656,"PHASE4":28662,"NA":28664},{"trials":28651,"activeCount":97},[],{"trials":28653,"activeCount":97},[],{"trials":28655,"activeCount":97},[],{"trials":28657,"activeCount":97},[28658],{"nctId":19581,"briefTitle":19582,"status":155,"phases":28659,"primaryCompletion":19584,"completion":19585,"start":19586,"enrollment":17295,"conditions":28660,"interventions":28661},[87],[19588],[19562,19590],{"trials":28663,"activeCount":97},[],{"trials":28665,"activeCount":97},[],{"intervention":28667,"totalTrials":417,"cells":28668},"H5N1 adjuvanted split virus vaccine",{"EARLY_PHASE1":28669,"PHASE1":28671,"PHASE2":28673,"PHASE3":28675,"PHASE4":28687,"NA":28689},{"trials":28670,"activeCount":97},[],{"trials":28672,"activeCount":97},[],{"trials":28674,"activeCount":97},[],{"trials":28676,"activeCount":97},[28677],{"nctId":28678,"briefTitle":28679,"status":155,"phases":28680,"primaryCompletion":28681,"completion":18825,"start":28682,"enrollment":28683,"conditions":28684,"interventions":28685},"NCT00449670","Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults",[87],"2007-07-12","2007-03-24",1206,[21,8265],[28667,28686,28667],"H5N1 non-adjuvanted split virus vaccine",{"trials":28688,"activeCount":97},[],{"trials":28690,"activeCount":97},[],{"intervention":28686,"totalTrials":417,"cells":28692},{"EARLY_PHASE1":28693,"PHASE1":28695,"PHASE2":28697,"PHASE3":28699,"PHASE4":28705,"NA":28707},{"trials":28694,"activeCount":97},[],{"trials":28696,"activeCount":97},[],{"trials":28698,"activeCount":97},[],{"trials":28700,"activeCount":97},[28701],{"nctId":28678,"briefTitle":28679,"status":155,"phases":28702,"primaryCompletion":28681,"completion":18825,"start":28682,"enrollment":28683,"conditions":28703,"interventions":28704},[87],[21,8265],[28667,28686,28667],{"trials":28706,"activeCount":97},[],{"trials":28708,"activeCount":97},[],{"intervention":28710,"totalTrials":417,"cells":28711},"HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum\u002F3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine",{"EARLY_PHASE1":28712,"PHASE1":28714,"PHASE2":28716,"PHASE3":28718,"PHASE4":28731,"NA":28733},{"trials":28713,"activeCount":97},[],{"trials":28715,"activeCount":97},[],{"trials":28717,"activeCount":97},[],{"trials":28719,"activeCount":97},[28720],{"nctId":28721,"briefTitle":28722,"status":155,"phases":28723,"primaryCompletion":28724,"completion":28724,"start":28725,"enrollment":28726,"conditions":28727,"interventions":28729},"NCT00057330","HerpeVac Trial for Young Women",[87],"2009-08-22","2003-01-14",8323,[28728],"Herpes Simplex Infection",[28710,28730],"Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine",{"trials":28732,"activeCount":97},[],{"trials":28734,"activeCount":97},[],{"intervention":28730,"totalTrials":417,"cells":28736},{"EARLY_PHASE1":28737,"PHASE1":28739,"PHASE2":28741,"PHASE3":28743,"PHASE4":28749,"NA":28751},{"trials":28738,"activeCount":97},[],{"trials":28740,"activeCount":97},[],{"trials":28742,"activeCount":97},[],{"trials":28744,"activeCount":97},[28745],{"nctId":28721,"briefTitle":28722,"status":155,"phases":28746,"primaryCompletion":28724,"completion":28724,"start":28725,"enrollment":28726,"conditions":28747,"interventions":28748},[87],[28728],[28710,28730],{"trials":28750,"activeCount":97},[],{"trials":28752,"activeCount":97},[],{"intervention":19924,"totalTrials":417,"cells":28754},{"EARLY_PHASE1":28755,"PHASE1":28757,"PHASE2":28759,"PHASE3":28761,"PHASE4":28767,"NA":28769},{"trials":28756,"activeCount":97},[],{"trials":28758,"activeCount":97},[],{"trials":28760,"activeCount":97},[],{"trials":28762,"activeCount":97},[28763],{"nctId":19916,"briefTitle":19917,"status":155,"phases":28764,"primaryCompletion":18526,"completion":19919,"start":19920,"enrollment":19921,"conditions":28765,"interventions":28766},[87],[8723],[8725,19924],{"trials":28768,"activeCount":97},[],{"trials":28770,"activeCount":97},[],{"intervention":20292,"totalTrials":417,"cells":28772},{"EARLY_PHASE1":28773,"PHASE1":28775,"PHASE2":28777,"PHASE3":28779,"PHASE4":28785,"NA":28787},{"trials":28774,"activeCount":97},[],{"trials":28776,"activeCount":97},[],{"trials":28778,"activeCount":97},[],{"trials":28780,"activeCount":97},[28781],{"nctId":20284,"briefTitle":20285,"status":155,"phases":28782,"primaryCompletion":20287,"completion":20288,"start":20289,"enrollment":13911,"conditions":28783,"interventions":28784},[87],[8788],[20235,20292,20293],{"trials":28786,"activeCount":97},[],{"trials":28788,"activeCount":97},[],{"intervention":20293,"totalTrials":417,"cells":28790},{"EARLY_PHASE1":28791,"PHASE1":28793,"PHASE2":28795,"PHASE3":28797,"PHASE4":28803,"NA":28805},{"trials":28792,"activeCount":97},[],{"trials":28794,"activeCount":97},[],{"trials":28796,"activeCount":97},[],{"trials":28798,"activeCount":97},[28799],{"nctId":20284,"briefTitle":20285,"status":155,"phases":28800,"primaryCompletion":20287,"completion":20288,"start":20289,"enrollment":13911,"conditions":28801,"interventions":28802},[87],[8788],[20235,20292,20293],{"trials":28804,"activeCount":97},[],{"trials":28806,"activeCount":97},[],{"intervention":23149,"totalTrials":417,"cells":28808},{"EARLY_PHASE1":28809,"PHASE1":28811,"PHASE2":28813,"PHASE3":28815,"PHASE4":28821,"NA":28823},{"trials":28810,"activeCount":97},[],{"trials":28812,"activeCount":97},[],{"trials":28814,"activeCount":97},[],{"trials":28816,"activeCount":97},[28817],{"nctId":23143,"briefTitle":23144,"status":155,"phases":28818,"primaryCompletion":23146,"completion":23146,"start":9877,"enrollment":1752,"conditions":28819,"interventions":28820},[87],[3717,2484,2485,2486],[23149,19877,23141],{"trials":28822,"activeCount":97},[],{"trials":28824,"activeCount":97},[],{"intervention":25310,"totalTrials":417,"cells":28826},{"EARLY_PHASE1":28827,"PHASE1":28829,"PHASE2":28831,"PHASE3":28833,"PHASE4":28839,"NA":28841},{"trials":28828,"activeCount":97},[],{"trials":28830,"activeCount":97},[],{"trials":28832,"activeCount":97},[],{"trials":28834,"activeCount":97},[28835],{"nctId":25303,"briefTitle":25304,"status":155,"phases":28836,"primaryCompletion":25306,"completion":25306,"start":25307,"enrollment":22123,"conditions":28837,"interventions":28838},[87],[1337],[25310,25292,25311,25312],{"trials":28840,"activeCount":97},[],{"trials":28842,"activeCount":97},[],{"intervention":25311,"totalTrials":417,"cells":28844},{"EARLY_PHASE1":28845,"PHASE1":28847,"PHASE2":28849,"PHASE3":28851,"PHASE4":28857,"NA":28859},{"trials":28846,"activeCount":97},[],{"trials":28848,"activeCount":97},[],{"trials":28850,"activeCount":97},[],{"trials":28852,"activeCount":97},[28853],{"nctId":25303,"briefTitle":25304,"status":155,"phases":28854,"primaryCompletion":25306,"completion":25306,"start":25307,"enrollment":22123,"conditions":28855,"interventions":28856},[87],[1337],[25310,25292,25311,25312],{"trials":28858,"activeCount":97},[],{"trials":28860,"activeCount":97},[],{"intervention":25312,"totalTrials":417,"cells":28862},{"EARLY_PHASE1":28863,"PHASE1":28865,"PHASE2":28867,"PHASE3":28869,"PHASE4":28875,"NA":28877},{"trials":28864,"activeCount":97},[],{"trials":28866,"activeCount":97},[],{"trials":28868,"activeCount":97},[],{"trials":28870,"activeCount":97},[28871],{"nctId":25303,"briefTitle":25304,"status":155,"phases":28872,"primaryCompletion":25306,"completion":25306,"start":25307,"enrollment":22123,"conditions":28873,"interventions":28874},[87],[1337],[25310,25292,25311,25312],{"trials":28876,"activeCount":97},[],{"trials":28878,"activeCount":97},[],{"intervention":28880,"totalTrials":417,"cells":28881},"no added fluoride in a silica base",{"EARLY_PHASE1":28882,"PHASE1":28884,"PHASE2":28886,"PHASE3":28888,"PHASE4":28898,"NA":28900},{"trials":28883,"activeCount":97},[],{"trials":28885,"activeCount":97},[],{"trials":28887,"activeCount":97},[],{"trials":28889,"activeCount":97},[28890],{"nctId":28891,"briefTitle":28892,"status":155,"phases":28893,"primaryCompletion":11315,"completion":11315,"start":728,"enrollment":1264,"conditions":28894,"interventions":28896},"NCT01641237","Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions",[87],[28895],"Enamel Erosion",[28897,28880],"sodium fluoride",{"trials":28899,"activeCount":97},[],{"trials":28901,"activeCount":97},[],{"intervention":28903,"totalTrials":417,"cells":28904},"Subjects received 3 doses of GSK Biologicals' HPV vaccine",{"EARLY_PHASE1":28905,"PHASE1":28907,"PHASE2":28909,"PHASE3":28911,"PHASE4":28923,"NA":28925},{"trials":28906,"activeCount":97},[],{"trials":28908,"activeCount":97},[],{"trials":28910,"activeCount":97},[],{"trials":28912,"activeCount":97},[28913],{"nctId":28914,"briefTitle":28915,"status":155,"phases":28916,"primaryCompletion":28917,"completion":28918,"start":28919,"enrollment":115,"conditions":28920,"interventions":28921},"NCT00637195","Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)",[87],"2008-06-20","2009-06-18","2008-03-11",[8723,12417],[28903,28922],"Engerix™",{"trials":28924,"activeCount":97},[],{"trials":28926,"activeCount":97},[],{"intervention":28922,"totalTrials":417,"cells":28928},{"EARLY_PHASE1":28929,"PHASE1":28931,"PHASE2":28933,"PHASE3":28935,"PHASE4":28941,"NA":28943},{"trials":28930,"activeCount":97},[],{"trials":28932,"activeCount":97},[],{"trials":28934,"activeCount":97},[],{"trials":28936,"activeCount":97},[28937],{"nctId":28914,"briefTitle":28915,"status":155,"phases":28938,"primaryCompletion":28917,"completion":28918,"start":28919,"enrollment":115,"conditions":28939,"interventions":28940},[87],[8723,12417],[28903,28922],{"trials":28942,"activeCount":97},[],{"trials":28944,"activeCount":97},[],{"intervention":4977,"totalTrials":417,"cells":28946},{"EARLY_PHASE1":28947,"PHASE1":28949,"PHASE2":28951,"PHASE3":28953,"PHASE4":28959,"NA":28961},{"trials":28948,"activeCount":97},[],{"trials":28950,"activeCount":97},[],{"trials":28952,"activeCount":97},[],{"trials":28954,"activeCount":97},[28955],{"nctId":4968,"briefTitle":4969,"status":155,"phases":28956,"primaryCompletion":4971,"completion":4972,"start":4973,"enrollment":4974,"conditions":28957,"interventions":28958},[87],[21],[4977,4978,4485,4979,4784],{"trials":28960,"activeCount":97},[],{"trials":28962,"activeCount":97},[],{"intervention":4978,"totalTrials":417,"cells":28964},{"EARLY_PHASE1":28965,"PHASE1":28967,"PHASE2":28969,"PHASE3":28971,"PHASE4":28977,"NA":28979},{"trials":28966,"activeCount":97},[],{"trials":28968,"activeCount":97},[],{"trials":28970,"activeCount":97},[],{"trials":28972,"activeCount":97},[28973],{"nctId":4968,"briefTitle":4969,"status":155,"phases":28974,"primaryCompletion":4971,"completion":4972,"start":4973,"enrollment":4974,"conditions":28975,"interventions":28976},[87],[21],[4977,4978,4485,4979,4784],{"trials":28978,"activeCount":97},[],{"trials":28980,"activeCount":97},[],{"intervention":4979,"totalTrials":417,"cells":28982},{"EARLY_PHASE1":28983,"PHASE1":28985,"PHASE2":28987,"PHASE3":28989,"PHASE4":28995,"NA":28997},{"trials":28984,"activeCount":97},[],{"trials":28986,"activeCount":97},[],{"trials":28988,"activeCount":97},[],{"trials":28990,"activeCount":97},[28991],{"nctId":4968,"briefTitle":4969,"status":155,"phases":28992,"primaryCompletion":4971,"completion":4972,"start":4973,"enrollment":4974,"conditions":28993,"interventions":28994},[87],[21],[4977,4978,4485,4979,4784],{"trials":28996,"activeCount":97},[],{"trials":28998,"activeCount":97},[],{"intervention":29000,"totalTrials":417,"cells":29001},"Abciximab",{"EARLY_PHASE1":29002,"PHASE1":29004,"PHASE2":29006,"PHASE3":29008,"PHASE4":29019,"NA":29021},{"trials":29003,"activeCount":97},[],{"trials":29005,"activeCount":97},[],{"trials":29007,"activeCount":97},[],{"trials":29009,"activeCount":97},[29010],{"nctId":29011,"briefTitle":29012,"status":155,"phases":29013,"primaryCompletion":2804,"completion":2804,"start":2404,"enrollment":29014,"conditions":29015,"interventions":29017},"NCT00426751","Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)",[87],429,[29016],"Infarction, Myocardial",[29000,29018],"Eptifibatide",{"trials":29020,"activeCount":97},[],{"trials":29022,"activeCount":97},[],{"intervention":29018,"totalTrials":417,"cells":29024},{"EARLY_PHASE1":29025,"PHASE1":29027,"PHASE2":29029,"PHASE3":29031,"PHASE4":29037,"NA":29039},{"trials":29026,"activeCount":97},[],{"trials":29028,"activeCount":97},[],{"trials":29030,"activeCount":97},[],{"trials":29032,"activeCount":97},[29033],{"nctId":29011,"briefTitle":29012,"status":155,"phases":29034,"primaryCompletion":2804,"completion":2804,"start":2404,"enrollment":29014,"conditions":29035,"interventions":29036},[87],[29016],[29000,29018],{"trials":29038,"activeCount":97},[],{"trials":29040,"activeCount":97},[],{"intervention":29042,"totalTrials":417,"cells":29043},"Boostrix ® Polio",{"EARLY_PHASE1":29044,"PHASE1":29046,"PHASE2":29048,"PHASE3":29050,"PHASE4":29062,"NA":29064},{"trials":29045,"activeCount":97},[],{"trials":29047,"activeCount":97},[],{"trials":29049,"activeCount":97},[],{"trials":29051,"activeCount":97},[29052],{"nctId":29053,"briefTitle":29054,"status":155,"phases":29055,"primaryCompletion":29056,"completion":29057,"start":29058,"enrollment":3240,"conditions":29059,"interventions":29060},"NCT00426361","Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects",[87],"2008-03-17","2008-07-25","2007-02-13",[8723],[29042,29061],"GSK Biologicals' HPV-16\u002F18 L1 AS04 vaccine",{"trials":29063,"activeCount":97},[],{"trials":29065,"activeCount":97},[],{"intervention":29061,"totalTrials":417,"cells":29067},{"EARLY_PHASE1":29068,"PHASE1":29070,"PHASE2":29072,"PHASE3":29074,"PHASE4":29080,"NA":29082},{"trials":29069,"activeCount":97},[],{"trials":29071,"activeCount":97},[],{"trials":29073,"activeCount":97},[],{"trials":29075,"activeCount":97},[29076],{"nctId":29053,"briefTitle":29054,"status":155,"phases":29077,"primaryCompletion":29056,"completion":29057,"start":29058,"enrollment":3240,"conditions":29078,"interventions":29079},[87],[8723],[29042,29061],{"trials":29081,"activeCount":97},[],{"trials":29083,"activeCount":97},[],{"intervention":29085,"totalTrials":417,"cells":29086},"ropinirole controlled-release (REQUIP CR) for RLS",{"EARLY_PHASE1":29087,"PHASE1":29089,"PHASE2":29091,"PHASE3":29093,"PHASE4":29103,"NA":29105},{"trials":29088,"activeCount":97},[],{"trials":29090,"activeCount":97},[],{"trials":29092,"activeCount":97},[],{"trials":29094,"activeCount":97},[29095],{"nctId":29096,"briefTitle":29097,"status":155,"phases":29098,"primaryCompletion":1360,"completion":1360,"start":8492,"enrollment":29099,"conditions":29100,"interventions":29102},"NCT00363727","Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's",[87],209,[15880,15879,29101],"Dyskinesias",[29085],{"trials":29104,"activeCount":97},[],{"trials":29106,"activeCount":97},[],{"intervention":4746,"totalTrials":417,"cells":29108},{"EARLY_PHASE1":29109,"PHASE1":29111,"PHASE2":29113,"PHASE3":29115,"PHASE4":29121,"NA":29123},{"trials":29110,"activeCount":97},[],{"trials":29112,"activeCount":97},[],{"trials":29114,"activeCount":97},[],{"trials":29116,"activeCount":97},[29117],{"nctId":4734,"briefTitle":4735,"status":155,"phases":29118,"primaryCompletion":4737,"completion":4738,"start":4739,"enrollment":4740,"conditions":29119,"interventions":29120},[87],[24,3624,33,4702,30,4742],[4744,4745,4472,4746,4747,4748,4749,4750,4751],{"trials":29122,"activeCount":97},[],{"trials":29124,"activeCount":97},[],{"intervention":4750,"totalTrials":417,"cells":29126},{"EARLY_PHASE1":29127,"PHASE1":29129,"PHASE2":29131,"PHASE3":29133,"PHASE4":29139,"NA":29141},{"trials":29128,"activeCount":97},[],{"trials":29130,"activeCount":97},[],{"trials":29132,"activeCount":97},[],{"trials":29134,"activeCount":97},[29135],{"nctId":4734,"briefTitle":4735,"status":155,"phases":29136,"primaryCompletion":4737,"completion":4738,"start":4739,"enrollment":4740,"conditions":29137,"interventions":29138},[87],[24,3624,33,4702,30,4742],[4744,4745,4472,4746,4747,4748,4749,4750,4751],{"trials":29140,"activeCount":97},[],{"trials":29142,"activeCount":97},[],{"intervention":29144,"totalTrials":417,"cells":29145},"diphtheria, tetanus, pertussis & Hib vaccine",{"EARLY_PHASE1":29146,"PHASE1":29148,"PHASE2":29150,"PHASE3":29152,"PHASE4":29160,"NA":29162},{"trials":29147,"activeCount":97},[],{"trials":29149,"activeCount":97},[],{"trials":29151,"activeCount":97},[],{"trials":29153,"activeCount":97},[29154],{"nctId":29155,"briefTitle":29156,"status":155,"phases":29157,"completion":7659,"start":4757,"enrollment":255,"conditions":29158,"interventions":29159},"NCT00379977","Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa\u002FHib Vaccine When Given at 3, 4 and 5 Months of Age",[87],[33,4704,3624,30],[29144],{"trials":29161,"activeCount":97},[],{"trials":29163,"activeCount":97},[],{"intervention":29165,"totalTrials":417,"cells":29166},"GW815SF Salmeterol\u002FFluticasone propionate",{"EARLY_PHASE1":29167,"PHASE1":29169,"PHASE2":29171,"PHASE3":29173,"PHASE4":29181,"NA":29183},{"trials":29168,"activeCount":97},[],{"trials":29170,"activeCount":97},[],{"trials":29172,"activeCount":97},[],{"trials":29174,"activeCount":97},[29175],{"nctId":29176,"briefTitle":29177,"status":155,"phases":29178,"primaryCompletion":3079,"completion":3079,"start":748,"enrollment":345,"conditions":29179,"interventions":29180},"NCT00449046","Clinical Assessment Of GW815SF Salmeterol\u002FFluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-",[87],[9464],[29165],{"trials":29182,"activeCount":97},[],{"trials":29184,"activeCount":97},[],{"intervention":21,"totalTrials":417,"cells":29186},{"EARLY_PHASE1":29187,"PHASE1":29189,"PHASE2":29191,"PHASE3":29193,"PHASE4":29202,"NA":29204},{"trials":29188,"activeCount":97},[],{"trials":29190,"activeCount":97},[],{"trials":29192,"activeCount":97},[],{"trials":29194,"activeCount":97},[29195],{"nctId":29196,"briefTitle":29197,"status":155,"phases":29198,"primaryCompletion":2383,"completion":8852,"start":2805,"enrollment":29199,"conditions":29200,"interventions":29201},"NCT00197288","Study Comparing the Immune Response of Fluarix and Fluzone Influenza Vaccines",[87],1847,[21],[21],{"trials":29203,"activeCount":97},[],{"trials":29205,"activeCount":97},[],{"intervention":9521,"totalTrials":417,"cells":29207},{"EARLY_PHASE1":29208,"PHASE1":29210,"PHASE2":29212,"PHASE3":29214,"PHASE4":29220,"NA":29222},{"trials":29209,"activeCount":97},[],{"trials":29211,"activeCount":97},[],{"trials":29213,"activeCount":97},[],{"trials":29215,"activeCount":97},[29216],{"nctId":9514,"briefTitle":9515,"status":155,"phases":29217,"primaryCompletion":9207,"completion":9517,"start":9208,"enrollment":9518,"conditions":29218,"interventions":29219},[87],[18],[9415,9521],{"trials":29221,"activeCount":97},[],{"trials":29223,"activeCount":97},[],{"intervention":29225,"totalTrials":417,"cells":29226},"Meningococcal group B Vaccine, rMenB+OMV NZ",{"EARLY_PHASE1":29227,"PHASE1":29229,"PHASE2":29231,"PHASE3":29233,"PHASE4":29244,"NA":29246},{"trials":29228,"activeCount":97},[],{"trials":29230,"activeCount":97},[],{"trials":29232,"activeCount":97},[],{"trials":29234,"activeCount":97},[29235],{"nctId":29236,"briefTitle":29237,"status":155,"phases":29238,"primaryCompletion":29239,"completion":29239,"start":29240,"enrollment":1982,"conditions":29241,"interventions":29242},"NCT02106390","Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants",[87],"2016-10-14","2014-06-05",[992],[29225,29243],"Meningococcal ACWY Conjugate Vaccine, MenACWY",{"trials":29245,"activeCount":97},[],{"trials":29247,"activeCount":97},[],{"intervention":29243,"totalTrials":417,"cells":29249},{"EARLY_PHASE1":29250,"PHASE1":29252,"PHASE2":29254,"PHASE3":29256,"PHASE4":29262,"NA":29264},{"trials":29251,"activeCount":97},[],{"trials":29253,"activeCount":97},[],{"trials":29255,"activeCount":97},[],{"trials":29257,"activeCount":97},[29258],{"nctId":29236,"briefTitle":29237,"status":155,"phases":29259,"primaryCompletion":29239,"completion":29239,"start":29240,"enrollment":1982,"conditions":29260,"interventions":29261},[87],[992],[29225,29243],{"trials":29263,"activeCount":97},[],{"trials":29265,"activeCount":97},[],{"intervention":29267,"totalTrials":417,"cells":29268},"Fluticasone Furoate (FF)\u002FGW642444 Inhalation Powder",{"EARLY_PHASE1":29269,"PHASE1":29271,"PHASE2":29273,"PHASE3":29275,"PHASE4":29284,"NA":29286},{"trials":29270,"activeCount":97},[],{"trials":29272,"activeCount":97},[],{"trials":29274,"activeCount":97},[],{"trials":29276,"activeCount":97},[29277],{"nctId":29278,"briefTitle":29279,"status":155,"phases":29280,"primaryCompletion":9452,"completion":9452,"start":29281,"enrollment":1686,"conditions":29282,"interventions":29283},"NCT01072149","A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)\u002FGW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo",[87],"2010-01-01",[15],[29267],{"trials":29285,"activeCount":97},[],{"trials":29287,"activeCount":97},[],{"intervention":25449,"totalTrials":417,"cells":29289},{"EARLY_PHASE1":29290,"PHASE1":29292,"PHASE2":29294,"PHASE3":29296,"PHASE4":29302,"NA":29304},{"trials":29291,"activeCount":97},[],{"trials":29293,"activeCount":97},[],{"trials":29295,"activeCount":97},[],{"trials":29297,"activeCount":97},[29298],{"nctId":25443,"briefTitle":25444,"status":155,"phases":29299,"primaryCompletion":25446,"completion":18807,"start":4789,"enrollment":1982,"conditions":29300,"interventions":29301},[87],[3637],[25449,25432,25450,25451],{"trials":29303,"activeCount":97},[],{"trials":29305,"activeCount":97},[],{"intervention":25450,"totalTrials":417,"cells":29307},{"EARLY_PHASE1":29308,"PHASE1":29310,"PHASE2":29312,"PHASE3":29314,"PHASE4":29320,"NA":29322},{"trials":29309,"activeCount":97},[],{"trials":29311,"activeCount":97},[],{"trials":29313,"activeCount":97},[],{"trials":29315,"activeCount":97},[29316],{"nctId":25443,"briefTitle":25444,"status":155,"phases":29317,"primaryCompletion":25446,"completion":18807,"start":4789,"enrollment":1982,"conditions":29318,"interventions":29319},[87],[3637],[25449,25432,25450,25451],{"trials":29321,"activeCount":97},[],{"trials":29323,"activeCount":97},[],{"intervention":25451,"totalTrials":417,"cells":29325},{"EARLY_PHASE1":29326,"PHASE1":29328,"PHASE2":29330,"PHASE3":29332,"PHASE4":29338,"NA":29340},{"trials":29327,"activeCount":97},[],{"trials":29329,"activeCount":97},[],{"trials":29331,"activeCount":97},[],{"trials":29333,"activeCount":97},[29334],{"nctId":25443,"briefTitle":25444,"status":155,"phases":29335,"primaryCompletion":25446,"completion":18807,"start":4789,"enrollment":1982,"conditions":29336,"interventions":29337},[87],[3637],[25449,25432,25450,25451],{"trials":29339,"activeCount":97},[],{"trials":29341,"activeCount":97},[],{"intervention":21406,"totalTrials":417,"cells":29343},{"EARLY_PHASE1":29344,"PHASE1":29346,"PHASE2":29348,"PHASE3":29350,"PHASE4":29356,"NA":29358},{"trials":29345,"activeCount":97},[],{"trials":29347,"activeCount":97},[],{"trials":29349,"activeCount":97},[],{"trials":29351,"activeCount":97},[29352],{"nctId":21398,"briefTitle":21399,"status":155,"phases":29353,"primaryCompletion":21401,"completion":21401,"start":21402,"enrollment":21403,"conditions":29354,"interventions":29355},[87],[4702,21381],[21367,21406],{"trials":29357,"activeCount":97},[],{"trials":29359,"activeCount":97},[],{"intervention":29361,"totalTrials":417,"cells":29362},"Combination Tablet of Treximet",{"EARLY_PHASE1":29363,"PHASE1":29365,"PHASE2":29367,"PHASE3":29369,"PHASE4":29379,"NA":29381},{"trials":29364,"activeCount":97},[],{"trials":29366,"activeCount":97},[],{"trials":29368,"activeCount":97},[],{"trials":29370,"activeCount":97},[29371],{"nctId":29372,"briefTitle":29373,"status":155,"phases":29374,"primaryCompletion":21200,"completion":29375,"start":6750,"enrollment":29376,"conditions":29377,"interventions":29378},"NCT00488514","Long-Term Safety of Treximet (Sumatriptan\u002FNaproxen Sodium) for Migraine in Adolescents",[87],"2009-08-20",656,[14168],[29361],{"trials":29380,"activeCount":97},[],{"trials":29382,"activeCount":97},[],{"intervention":22717,"totalTrials":417,"cells":29384},{"EARLY_PHASE1":29385,"PHASE1":29387,"PHASE2":29389,"PHASE3":29391,"PHASE4":29397,"NA":29399},{"trials":29386,"activeCount":97},[],{"trials":29388,"activeCount":97},[],{"trials":29390,"activeCount":97},[],{"trials":29392,"activeCount":97},[29393],{"nctId":22711,"briefTitle":22712,"status":155,"phases":29394,"primaryCompletion":2336,"completion":2336,"start":8852,"enrollment":22714,"conditions":29395,"interventions":29396},[87],[5943],[22686,22717],{"trials":29398,"activeCount":97},[],{"trials":29400,"activeCount":97},[],{"intervention":29402,"totalTrials":417,"cells":29403},"Mepolizumab 300 mg",{"EARLY_PHASE1":29404,"PHASE1":29406,"PHASE2":29408,"PHASE3":29410,"PHASE4":29421,"NA":29423},{"trials":29405,"activeCount":97},[],{"trials":29407,"activeCount":97},[],{"trials":29409,"activeCount":97},[],{"trials":29411,"activeCount":97},[29412],{"nctId":29413,"briefTitle":29414,"status":155,"phases":29415,"primaryCompletion":29416,"completion":29416,"start":29417,"enrollment":6994,"conditions":29418,"interventions":29419},"NCT02836496","Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)",[87],"2019-08-08","2017-03-07",[821],[29402,29420],"Active OCS",{"trials":29422,"activeCount":97},[],{"trials":29424,"activeCount":97},[],{"intervention":29420,"totalTrials":417,"cells":29426},{"EARLY_PHASE1":29427,"PHASE1":29429,"PHASE2":29431,"PHASE3":29433,"PHASE4":29439,"NA":29441},{"trials":29428,"activeCount":97},[],{"trials":29430,"activeCount":97},[],{"trials":29432,"activeCount":97},[],{"trials":29434,"activeCount":97},[29435],{"nctId":29413,"briefTitle":29414,"status":155,"phases":29436,"primaryCompletion":29416,"completion":29416,"start":29417,"enrollment":6994,"conditions":29437,"interventions":29438},[87],[821],[29402,29420],{"trials":29440,"activeCount":97},[],{"trials":29442,"activeCount":97},[],{"intervention":796,"totalTrials":417,"cells":29444},{"EARLY_PHASE1":29445,"PHASE1":29447,"PHASE2":29449,"PHASE3":29451,"PHASE4":29457,"NA":29459},{"trials":29446,"activeCount":97},[],{"trials":29448,"activeCount":97},[],{"trials":29450,"activeCount":97},[],{"trials":29452,"activeCount":97},[29453],{"nctId":787,"briefTitle":788,"status":155,"phases":29454,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":29455,"interventions":29456},[87],[18],[795,694,796,437],{"trials":29458,"activeCount":97},[],{"trials":29460,"activeCount":97},[],{"intervention":18108,"totalTrials":417,"cells":29462},{"EARLY_PHASE1":29463,"PHASE1":29465,"PHASE2":29467,"PHASE3":29469,"PHASE4":29475,"NA":29477},{"trials":29464,"activeCount":97},[],{"trials":29466,"activeCount":97},[],{"trials":29468,"activeCount":97},[],{"trials":29470,"activeCount":97},[29471],{"nctId":18102,"briefTitle":18103,"status":155,"phases":29472,"primaryCompletion":18105,"completion":6501,"start":5323,"enrollment":695,"conditions":29473,"interventions":29474},[87],[17996],[17974,18108],{"trials":29476,"activeCount":97},[],{"trials":29478,"activeCount":97},[],{"intervention":23475,"totalTrials":417,"cells":29480},{"EARLY_PHASE1":29481,"PHASE1":29483,"PHASE2":29485,"PHASE3":29487,"PHASE4":29493,"NA":29495},{"trials":29482,"activeCount":97},[],{"trials":29484,"activeCount":97},[],{"trials":29486,"activeCount":97},[],{"trials":29488,"activeCount":97},[29489],{"nctId":23468,"briefTitle":23469,"status":155,"phases":29490,"primaryCompletion":16323,"completion":23471,"start":20989,"enrollment":9196,"conditions":29491,"interventions":29492},[87],[23473],[23475,12069],{"trials":29494,"activeCount":97},[],{"trials":29496,"activeCount":97},[],{"intervention":29498,"totalTrials":417,"cells":29499},"Mepolizumab 100 milligrams",{"EARLY_PHASE1":29500,"PHASE1":29502,"PHASE2":29504,"PHASE3":29506,"PHASE4":29516,"NA":29518},{"trials":29501,"activeCount":97},[],{"trials":29503,"activeCount":97},[],{"trials":29505,"activeCount":97},[],{"trials":29507,"activeCount":97},[29508],{"nctId":29509,"briefTitle":29510,"status":155,"phases":29511,"primaryCompletion":29512,"completion":29512,"start":29513,"enrollment":536,"conditions":29514,"interventions":29515},"NCT03562195","A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma",[87],"2022-09-07","2018-08-29",[18],[29498,963],{"trials":29517,"activeCount":97},[],{"trials":29519,"activeCount":97},[],{"intervention":7860,"totalTrials":417,"cells":29521},{"EARLY_PHASE1":29522,"PHASE1":29524,"PHASE2":29526,"PHASE3":29528,"PHASE4":29534,"NA":29536},{"trials":29523,"activeCount":97},[],{"trials":29525,"activeCount":97},[],{"trials":29527,"activeCount":97},[],{"trials":29529,"activeCount":97},[29530],{"nctId":7853,"briefTitle":7854,"status":155,"phases":29531,"primaryCompletion":7856,"completion":7856,"start":7857,"enrollment":1237,"conditions":29532,"interventions":29533},[87],[24],[7860,7718],{"trials":29535,"activeCount":97},[],{"trials":29537,"activeCount":97},[],{"intervention":29539,"totalTrials":417,"cells":29540},"62.5\u002F25mcg",{"EARLY_PHASE1":29541,"PHASE1":29543,"PHASE2":29545,"PHASE3":29547,"PHASE4":29559,"NA":29561},{"trials":29542,"activeCount":97},[],{"trials":29544,"activeCount":97},[],{"trials":29546,"activeCount":97},[],{"trials":29548,"activeCount":97},[29549],{"nctId":29550,"briefTitle":29551,"status":155,"phases":29552,"primaryCompletion":11748,"completion":29553,"start":18536,"enrollment":29554,"conditions":29555,"interventions":29556},"NCT01313650","A 24-week Evaluation of GSK573719\u002FVilanterol (62.5\u002F25mcg) and Components in COPD",[87],"2012-04-05",1538,[15],[29539,29557,29558],"62.5mcg","25mcg",{"trials":29560,"activeCount":97},[],{"trials":29562,"activeCount":97},[],{"intervention":29557,"totalTrials":417,"cells":29564},{"EARLY_PHASE1":29565,"PHASE1":29567,"PHASE2":29569,"PHASE3":29571,"PHASE4":29577,"NA":29579},{"trials":29566,"activeCount":97},[],{"trials":29568,"activeCount":97},[],{"trials":29570,"activeCount":97},[],{"trials":29572,"activeCount":97},[29573],{"nctId":29550,"briefTitle":29551,"status":155,"phases":29574,"primaryCompletion":11748,"completion":29553,"start":18536,"enrollment":29554,"conditions":29575,"interventions":29576},[87],[15],[29539,29557,29558],{"trials":29578,"activeCount":97},[],{"trials":29580,"activeCount":97},[],{"intervention":29558,"totalTrials":417,"cells":29582},{"EARLY_PHASE1":29583,"PHASE1":29585,"PHASE2":29587,"PHASE3":29589,"PHASE4":29595,"NA":29597},{"trials":29584,"activeCount":97},[],{"trials":29586,"activeCount":97},[],{"trials":29588,"activeCount":97},[],{"trials":29590,"activeCount":97},[29591],{"nctId":29550,"briefTitle":29551,"status":155,"phases":29592,"primaryCompletion":11748,"completion":29553,"start":18536,"enrollment":29554,"conditions":29593,"interventions":29594},[87],[15],[29539,29557,29558],{"trials":29596,"activeCount":97},[],{"trials":29598,"activeCount":97},[],{"intervention":29600,"totalTrials":417,"cells":29601},"Study vaccines: IH+Hib-MenC\u002FNVC; Control: IH+Meningitec",{"EARLY_PHASE1":29602,"PHASE1":29604,"PHASE2":29606,"PHASE3":29608,"PHASE4":29618,"NA":29620},{"trials":29603,"activeCount":97},[],{"trials":29605,"activeCount":97},[],{"trials":29607,"activeCount":97},[],{"trials":29609,"activeCount":97},[29610],{"nctId":29611,"briefTitle":29612,"status":155,"phases":29613,"completion":29614,"start":29615,"enrollment":8931,"conditions":29616,"interventions":29617},"NCT00352963","Immunogenicity & Safety Study of Combined\u002FSeparate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).",[87],"2004-07-16","2003-09-30",[4702,33,3624,24,30],[29600],{"trials":29619,"activeCount":97},[],{"trials":29621,"activeCount":97},[],{"intervention":29623,"totalTrials":417,"cells":29624},"Fluticasone Furoate\u002FGW642444 Inhalation Powder 100\u002F25mcg",{"EARLY_PHASE1":29625,"PHASE1":29627,"PHASE2":29629,"PHASE3":29631,"PHASE4":29641,"NA":29643},{"trials":29626,"activeCount":97},[],{"trials":29628,"activeCount":97},[],{"trials":29630,"activeCount":97},[],{"trials":29632,"activeCount":97},[29633],{"nctId":29634,"briefTitle":29635,"status":155,"phases":29636,"primaryCompletion":2427,"completion":2427,"start":3391,"enrollment":29637,"conditions":29638,"interventions":29639},"NCT01192191","A Long-term Safety Study of Fluticasone Furoate (FF)\u002FGW642444 in Japanese Subjects With COPD",[87],187,[15],[29623,29640],"Fluticasone Furoate\u002FGW642444 Inhalation Powder 200\u002F25mcg",{"trials":29642,"activeCount":97},[],{"trials":29644,"activeCount":97},[],{"intervention":29640,"totalTrials":417,"cells":29646},{"EARLY_PHASE1":29647,"PHASE1":29649,"PHASE2":29651,"PHASE3":29653,"PHASE4":29659,"NA":29661},{"trials":29648,"activeCount":97},[],{"trials":29650,"activeCount":97},[],{"trials":29652,"activeCount":97},[],{"trials":29654,"activeCount":97},[29655],{"nctId":29634,"briefTitle":29635,"status":155,"phases":29656,"primaryCompletion":2427,"completion":2427,"start":3391,"enrollment":29637,"conditions":29657,"interventions":29658},[87],[15],[29623,29640],{"trials":29660,"activeCount":97},[],{"trials":29662,"activeCount":97},[],{"intervention":29664,"totalTrials":417,"cells":29665},"sumatriptan succinate \u002F naproxen sodium",{"EARLY_PHASE1":29666,"PHASE1":29668,"PHASE2":29670,"PHASE3":29672,"PHASE4":29682,"NA":29684},{"trials":29667,"activeCount":97},[],{"trials":29669,"activeCount":97},[],{"trials":29671,"activeCount":97},[],{"trials":29673,"activeCount":97},[29674],{"nctId":29675,"briefTitle":29676,"status":155,"phases":29677,"primaryCompletion":9737,"completion":9737,"start":4757,"enrollment":29678,"conditions":29679,"interventions":29681},"NCT00387881","TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)",[87],679,[29680],"Migraine, Without Aura",[29664],{"trials":29683,"activeCount":97},[],{"trials":29685,"activeCount":97},[],{"intervention":20303,"totalTrials":417,"cells":29687},{"EARLY_PHASE1":29688,"PHASE1":29690,"PHASE2":29692,"PHASE3":29694,"PHASE4":29700,"NA":29702},{"trials":29689,"activeCount":97},[],{"trials":29691,"activeCount":97},[],{"trials":29693,"activeCount":97},[],{"trials":29695,"activeCount":97},[29696],{"nctId":20295,"briefTitle":20296,"status":155,"phases":29697,"primaryCompletion":20287,"completion":20298,"start":20299,"enrollment":20300,"conditions":29698,"interventions":29699},[87],[8788],[20235,20303],{"trials":29701,"activeCount":97},[],{"trials":29703,"activeCount":97},[],{"intervention":29705,"totalTrials":417,"cells":29706},"Thiomersal free trivalent influenza split vaccine 2003\u002F2004",{"EARLY_PHASE1":29707,"PHASE1":29709,"PHASE2":29711,"PHASE3":29713,"PHASE4":29722,"NA":29724},{"trials":29708,"activeCount":97},[],{"trials":29710,"activeCount":97},[],{"trials":29712,"activeCount":97},[],{"trials":29714,"activeCount":97},[29715],{"nctId":29716,"briefTitle":29717,"status":155,"phases":29718,"primaryCompletion":19830,"completion":19830,"start":7581,"enrollment":27085,"conditions":29719,"interventions":29720},"NCT00731393","Immuno & Reacto of TF Trivalent Influenza Split Vaccine 2003\u002F04 or of Std Formulation Influsplit SSW®\u002FFluarix™ 2003\u002F04",[87],[21],[29705,29721],"GlaxoSmithKline Biologicals' Influsplit SSW®\u002FFluarix™ 2003\u002F2004",{"trials":29723,"activeCount":97},[],{"trials":29725,"activeCount":97},[],{"intervention":29721,"totalTrials":417,"cells":29727},{"EARLY_PHASE1":29728,"PHASE1":29730,"PHASE2":29732,"PHASE3":29734,"PHASE4":29740,"NA":29742},{"trials":29729,"activeCount":97},[],{"trials":29731,"activeCount":97},[],{"trials":29733,"activeCount":97},[],{"trials":29735,"activeCount":97},[29736],{"nctId":29716,"briefTitle":29717,"status":155,"phases":29737,"primaryCompletion":19830,"completion":19830,"start":7581,"enrollment":27085,"conditions":29738,"interventions":29739},[87],[21],[29705,29721],{"trials":29741,"activeCount":97},[],{"trials":29743,"activeCount":97},[],{"intervention":29745,"totalTrials":417,"cells":29746},"GSK2402968 6mg\u002Fkg\u002Fweek",{"EARLY_PHASE1":29747,"PHASE1":29749,"PHASE2":29751,"PHASE3":29753,"PHASE4":29763,"NA":29765},{"trials":29748,"activeCount":97},[],{"trials":29750,"activeCount":97},[],{"trials":29752,"activeCount":97},[],{"trials":29754,"activeCount":97},[29755],{"nctId":29756,"briefTitle":29757,"status":155,"phases":29758,"primaryCompletion":29759,"completion":29759,"start":29760,"enrollment":14585,"conditions":29761,"interventions":29762},"NCT01254019","A Clinical Study to Assess the Efficacy and Safety of GSK2402968 in Subjects With Duchenne Muscular Dystrophy",[87],"2013-06-28","2010-12-02",[25854],[29745],{"trials":29764,"activeCount":97},[],{"trials":29766,"activeCount":97},[],{"intervention":29768,"totalTrials":417,"cells":29769},"FF\u002FVI via ELLIPTA DPI",{"EARLY_PHASE1":29770,"PHASE1":29772,"PHASE2":29774,"PHASE3":29776,"PHASE4":29788,"NA":29790},{"trials":29771,"activeCount":97},[],{"trials":29773,"activeCount":97},[],{"trials":29775,"activeCount":97},[],{"trials":29777,"activeCount":97},[29778],{"nctId":29779,"briefTitle":29780,"status":155,"phases":29781,"primaryCompletion":29782,"completion":29782,"start":29783,"enrollment":29784,"conditions":29785,"interventions":29786},"NCT03248128","Safety and Efficacy Study of Fluticasone Furoate\u002FVilanterol (FF\u002FVI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma",[87],"2022-03-21","2017-10-20",906,[18],[29768,29787],"FF via ELLIPTA DPI",{"trials":29789,"activeCount":97},[],{"trials":29791,"activeCount":97},[],{"intervention":29787,"totalTrials":417,"cells":29793},{"EARLY_PHASE1":29794,"PHASE1":29796,"PHASE2":29798,"PHASE3":29800,"PHASE4":29806,"NA":29808},{"trials":29795,"activeCount":97},[],{"trials":29797,"activeCount":97},[],{"trials":29799,"activeCount":97},[],{"trials":29801,"activeCount":97},[29802],{"nctId":29779,"briefTitle":29780,"status":155,"phases":29803,"primaryCompletion":29782,"completion":29782,"start":29783,"enrollment":29784,"conditions":29804,"interventions":29805},[87],[18],[29768,29787],{"trials":29807,"activeCount":97},[],{"trials":29809,"activeCount":97},[],{"intervention":19763,"totalTrials":417,"cells":29811},{"EARLY_PHASE1":29812,"PHASE1":29814,"PHASE2":29816,"PHASE3":29818,"PHASE4":29824,"NA":29826},{"trials":29813,"activeCount":97},[],{"trials":29815,"activeCount":97},[],{"trials":29817,"activeCount":97},[],{"trials":29819,"activeCount":97},[29820],{"nctId":19756,"briefTitle":19757,"status":155,"phases":29821,"primaryCompletion":9087,"completion":9087,"start":19759,"enrollment":19760,"conditions":29822,"interventions":29823},[87],[12294],[19693,19763],{"trials":29825,"activeCount":97},[],{"trials":29827,"activeCount":97},[],{"intervention":23062,"totalTrials":417,"cells":29829},{"EARLY_PHASE1":29830,"PHASE1":29832,"PHASE2":29834,"PHASE3":29836,"PHASE4":29842,"NA":29844},{"trials":29831,"activeCount":97},[],{"trials":29833,"activeCount":97},[],{"trials":29835,"activeCount":97},[],{"trials":29837,"activeCount":97},[29838],{"nctId":23053,"briefTitle":23054,"status":155,"phases":29839,"primaryCompletion":23056,"completion":23057,"start":11940,"enrollment":23058,"conditions":29840,"interventions":29841},[87],[992],[23061,23062,23063,23016,10570],{"trials":29843,"activeCount":97},[],{"trials":29845,"activeCount":97},[],{"intervention":23063,"totalTrials":417,"cells":29847},{"EARLY_PHASE1":29848,"PHASE1":29850,"PHASE2":29852,"PHASE3":29854,"PHASE4":29860,"NA":29862},{"trials":29849,"activeCount":97},[],{"trials":29851,"activeCount":97},[],{"trials":29853,"activeCount":97},[],{"trials":29855,"activeCount":97},[29856],{"nctId":23053,"briefTitle":23054,"status":155,"phases":29857,"primaryCompletion":23056,"completion":23057,"start":11940,"enrollment":23058,"conditions":29858,"interventions":29859},[87],[992],[23061,23062,23063,23016,10570],{"trials":29861,"activeCount":97},[],{"trials":29863,"activeCount":97},[],{"intervention":29865,"totalTrials":417,"cells":29866},"Influsplit SSW®",{"EARLY_PHASE1":29867,"PHASE1":29869,"PHASE2":29871,"PHASE3":29873,"PHASE4":29881,"NA":29883},{"trials":29868,"activeCount":97},[],{"trials":29870,"activeCount":97},[],{"trials":29872,"activeCount":97},[],{"trials":29874,"activeCount":97},[29875],{"nctId":29876,"briefTitle":29877,"status":155,"phases":29878,"primaryCompletion":10395,"completion":10395,"start":10212,"enrollment":201,"conditions":29879,"interventions":29880},"NCT00306943","Annual Study for Fluarix Registration",[87],[21],[29865],{"trials":29882,"activeCount":97},[],{"trials":29884,"activeCount":97},[],{"intervention":29886,"totalTrials":417,"cells":29887},"Fluarix™\u002FInflusplit SSW® 2007\u002F2008",{"EARLY_PHASE1":29888,"PHASE1":29890,"PHASE2":29892,"PHASE3":29894,"PHASE4":29902,"NA":29904},{"trials":29889,"activeCount":97},[],{"trials":29891,"activeCount":97},[],{"trials":29893,"activeCount":97},[],{"trials":29895,"activeCount":97},[29896],{"nctId":29897,"briefTitle":29898,"status":155,"phases":29899,"completion":2428,"start":3552,"enrollment":201,"conditions":29900,"interventions":29901},"NCT00476307","Immunogenicity and Reactogenicity of Fluarix™ (Influsplit SSW®) 2007\u002F2008 in People 18 Years Old or Above",[87],[21],[29886],{"trials":29903,"activeCount":97},[],{"trials":29905,"activeCount":97},[],{"intervention":29907,"totalTrials":417,"cells":29908},"Combined Hepatitis A and B vaccine",{"EARLY_PHASE1":29909,"PHASE1":29911,"PHASE2":29913,"PHASE3":29915,"PHASE4":29924,"NA":29926},{"trials":29910,"activeCount":97},[],{"trials":29912,"activeCount":97},[],{"trials":29914,"activeCount":97},[],{"trials":29916,"activeCount":97},[29917],{"nctId":29918,"briefTitle":29919,"status":155,"phases":29920,"primaryCompletion":8492,"completion":8492,"start":9462,"enrollment":29921,"conditions":29922,"interventions":29923},"NCT00197171","Long Term F\u002FU Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine",[87],143,[24,7966],[29907],{"trials":29925,"activeCount":97},[],{"trials":29927,"activeCount":97},[],{"intervention":11650,"totalTrials":417,"cells":29929},{"EARLY_PHASE1":29930,"PHASE1":29932,"PHASE2":29934,"PHASE3":29936,"PHASE4":29942,"NA":29944},{"trials":29931,"activeCount":97},[],{"trials":29933,"activeCount":97},[],{"trials":29935,"activeCount":97},[],{"trials":29937,"activeCount":97},[29938],{"nctId":11642,"briefTitle":11643,"status":155,"phases":29939,"primaryCompletion":11645,"completion":11645,"start":11646,"enrollment":11647,"conditions":29940,"interventions":29941},[87],[15],[8622,2934,11650,11651],{"trials":29943,"activeCount":97},[],{"trials":29945,"activeCount":97},[],{"intervention":29947,"totalTrials":417,"cells":29948},"Detox-B adjuvant",{"EARLY_PHASE1":29949,"PHASE1":29951,"PHASE2":29953,"PHASE3":29955,"PHASE4":29965,"NA":29967},{"trials":29950,"activeCount":97},[],{"trials":29952,"activeCount":97},[],{"trials":29954,"activeCount":97},[],{"trials":29956,"activeCount":97},[29957],{"nctId":29958,"briefTitle":29959,"status":12113,"phases":29960,"start":7899,"enrollment":536,"conditions":29961,"interventions":29963},"NCT00002767","Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma",[87],[29962],"Melanoma (Skin)",[29947,29964],"recombinant interferon alfa",{"trials":29966,"activeCount":97},[],{"trials":29968,"activeCount":97},[],{"intervention":29964,"totalTrials":417,"cells":29970},{"EARLY_PHASE1":29971,"PHASE1":29973,"PHASE2":29975,"PHASE3":29977,"PHASE4":29983,"NA":29985},{"trials":29972,"activeCount":97},[],{"trials":29974,"activeCount":97},[],{"trials":29976,"activeCount":97},[],{"trials":29978,"activeCount":97},[29979],{"nctId":29958,"briefTitle":29959,"status":12113,"phases":29980,"start":7899,"enrollment":536,"conditions":29981,"interventions":29982},[87],[29962],[29947,29964],{"trials":29984,"activeCount":97},[],{"trials":29986,"activeCount":97},[],{"intervention":18791,"totalTrials":417,"cells":29988},{"EARLY_PHASE1":29989,"PHASE1":29991,"PHASE2":29993,"PHASE3":29995,"PHASE4":30001,"NA":30003},{"trials":29990,"activeCount":97},[],{"trials":29992,"activeCount":97},[],{"trials":29994,"activeCount":97},[],{"trials":29996,"activeCount":97},[29997],{"nctId":18784,"briefTitle":18785,"status":155,"phases":29998,"primaryCompletion":18787,"completion":18788,"start":12873,"enrollment":4346,"conditions":29999,"interventions":30000},[87],[3637],[3639,3639,18791],{"trials":30002,"activeCount":97},[],{"trials":30004,"activeCount":97},[],{"intervention":30006,"totalTrials":417,"cells":30007},"Fluarix Tetra",{"EARLY_PHASE1":30008,"PHASE1":30010,"PHASE2":30012,"PHASE3":30014,"PHASE4":30023,"NA":30025},{"trials":30009,"activeCount":97},[],{"trials":30011,"activeCount":97},[],{"trials":30013,"activeCount":97},[],{"trials":30015,"activeCount":97},[30016],{"nctId":30017,"briefTitle":30018,"status":155,"phases":30019,"primaryCompletion":30020,"completion":30020,"start":23212,"enrollment":2297,"conditions":30021,"interventions":30022},"NCT02369341","Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above",[87],"2015-06-03",[21],[30006],{"trials":30024,"activeCount":97},[],{"trials":30026,"activeCount":97},[],{"intervention":30028,"totalTrials":417,"cells":30029},"323U66 SR 150 mg",{"EARLY_PHASE1":30030,"PHASE1":30032,"PHASE2":30034,"PHASE3":30036,"PHASE4":30048,"NA":30050},{"trials":30031,"activeCount":97},[],{"trials":30033,"activeCount":97},[],{"trials":30035,"activeCount":97},[],{"trials":30037,"activeCount":97},[30038],{"nctId":30039,"briefTitle":30040,"status":155,"phases":30041,"primaryCompletion":30042,"completion":30043,"start":23747,"enrollment":30044,"conditions":30045,"interventions":30046},"NCT01138007","A Fixed Dose Study of 323U66 SR in the Treatment of Major Depressive Disorder (MDD)",[87],"2012-08-01","2012-08-07",572,[10889],[30028,30047],"323U66 SR 150 mg placebo",{"trials":30049,"activeCount":97},[],{"trials":30051,"activeCount":97},[],{"intervention":30047,"totalTrials":417,"cells":30053},{"EARLY_PHASE1":30054,"PHASE1":30056,"PHASE2":30058,"PHASE3":30060,"PHASE4":30066,"NA":30068},{"trials":30055,"activeCount":97},[],{"trials":30057,"activeCount":97},[],{"trials":30059,"activeCount":97},[],{"trials":30061,"activeCount":97},[30062],{"nctId":30039,"briefTitle":30040,"status":155,"phases":30063,"primaryCompletion":30042,"completion":30043,"start":23747,"enrollment":30044,"conditions":30064,"interventions":30065},[87],[10889],[30028,30047],{"trials":30067,"activeCount":97},[],{"trials":30069,"activeCount":97},[],{"intervention":25175,"totalTrials":417,"cells":30071},{"EARLY_PHASE1":30072,"PHASE1":30074,"PHASE2":30076,"PHASE3":30078,"PHASE4":30084,"NA":30086},{"trials":30073,"activeCount":97},[],{"trials":30075,"activeCount":97},[],{"trials":30077,"activeCount":97},[],{"trials":30079,"activeCount":97},[30080],{"nctId":25170,"briefTitle":25171,"status":145,"phases":30081,"primaryCompletion":3078,"completion":3078,"start":2441,"enrollment":2321,"conditions":30082,"interventions":30083},[86,87],[25162],[25175,25176,25151],{"trials":30085,"activeCount":97},[],{"trials":30087,"activeCount":97},[],{"intervention":25176,"totalTrials":417,"cells":30089},{"EARLY_PHASE1":30090,"PHASE1":30092,"PHASE2":30094,"PHASE3":30096,"PHASE4":30102,"NA":30104},{"trials":30091,"activeCount":97},[],{"trials":30093,"activeCount":97},[],{"trials":30095,"activeCount":97},[],{"trials":30097,"activeCount":97},[30098],{"nctId":25170,"briefTitle":25171,"status":145,"phases":30099,"primaryCompletion":3078,"completion":3078,"start":2441,"enrollment":2321,"conditions":30100,"interventions":30101},[86,87],[25162],[25175,25176,25151],{"trials":30103,"activeCount":97},[],{"trials":30105,"activeCount":97},[],{"intervention":19403,"totalTrials":417,"cells":30107},{"EARLY_PHASE1":30108,"PHASE1":30110,"PHASE2":30112,"PHASE3":30114,"PHASE4":30120,"NA":30122},{"trials":30109,"activeCount":97},[],{"trials":30111,"activeCount":97},[],{"trials":30113,"activeCount":97},[],{"trials":30115,"activeCount":97},[30116],{"nctId":19392,"briefTitle":19393,"status":155,"phases":30117,"primaryCompletion":19395,"completion":19396,"start":19397,"enrollment":19398,"conditions":30118,"interventions":30119},[87],[19400],[8673,8674,19402,19403],{"trials":30121,"activeCount":97},[],{"trials":30123,"activeCount":97},[],{"intervention":30125,"totalTrials":417,"cells":30126},"Herpes Zoster subunit",{"EARLY_PHASE1":30127,"PHASE1":30129,"PHASE2":30131,"PHASE3":30133,"PHASE4":30144,"NA":30146},{"trials":30128,"activeCount":97},[],{"trials":30130,"activeCount":97},[],{"trials":30132,"activeCount":97},[],{"trials":30134,"activeCount":97},[30135],{"nctId":30136,"briefTitle":30137,"status":155,"phases":30138,"primaryCompletion":30139,"completion":30139,"start":30140,"enrollment":30141,"conditions":30142,"interventions":30143},"NCT04091451","Safety and Immunogenicity Study of GlaxoSmithKline's Herpes Zoster Subunit Vaccine (HZ\u002Fsu) When Given on a Two-dose Schedule to Adults at Least 50 Years of Age (YOA) With a Prior Episode of Herpes Zoster",[87],"2024-02-15","2019-09-17",1430,[1030],[30125],{"trials":30145,"activeCount":97},[],{"trials":30147,"activeCount":97},[],{"intervention":30149,"totalTrials":417,"cells":30150},"Fluticasone Furoate\u002FVilanterol 100\u002F25 mcg via ELLIPTA inhaler",{"EARLY_PHASE1":30151,"PHASE1":30153,"PHASE2":30155,"PHASE3":30157,"PHASE4":30170,"NA":30172},{"trials":30152,"activeCount":97},[],{"trials":30154,"activeCount":97},[],{"trials":30156,"activeCount":97},[],{"trials":30158,"activeCount":97},[30159],{"nctId":30160,"briefTitle":30161,"status":155,"phases":30162,"primaryCompletion":30163,"completion":30164,"start":11656,"enrollment":30165,"conditions":30166,"interventions":30167},"NCT02301975","An Efficacy and Safety Study of Fluticasone Furoate\u002FVilanterol 100\u002F25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate\u002FSalmeterol 250\u002F50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",[87],"2016-11-01","2016-11-25",1526,[18],[30149,30168,30169],"Fluticasone Propionate\u002FSalmeterol 250\u002F50 mcg via ACCUHALER\u002FDISKUS inhaler","Fluticasone Propionate 250 mcg via ACCUHALER\u002FDISKUS inhaler",{"trials":30171,"activeCount":97},[],{"trials":30173,"activeCount":97},[],{"intervention":30168,"totalTrials":417,"cells":30175},{"EARLY_PHASE1":30176,"PHASE1":30178,"PHASE2":30180,"PHASE3":30182,"PHASE4":30188,"NA":30190},{"trials":30177,"activeCount":97},[],{"trials":30179,"activeCount":97},[],{"trials":30181,"activeCount":97},[],{"trials":30183,"activeCount":97},[30184],{"nctId":30160,"briefTitle":30161,"status":155,"phases":30185,"primaryCompletion":30163,"completion":30164,"start":11656,"enrollment":30165,"conditions":30186,"interventions":30187},[87],[18],[30149,30168,30169],{"trials":30189,"activeCount":97},[],{"trials":30191,"activeCount":97},[],{"intervention":30169,"totalTrials":417,"cells":30193},{"EARLY_PHASE1":30194,"PHASE1":30196,"PHASE2":30198,"PHASE3":30200,"PHASE4":30206,"NA":30208},{"trials":30195,"activeCount":97},[],{"trials":30197,"activeCount":97},[],{"trials":30199,"activeCount":97},[],{"trials":30201,"activeCount":97},[30202],{"nctId":30160,"briefTitle":30161,"status":155,"phases":30203,"primaryCompletion":30163,"completion":30164,"start":11656,"enrollment":30165,"conditions":30204,"interventions":30205},[87],[18],[30149,30168,30169],{"trials":30207,"activeCount":97},[],{"trials":30209,"activeCount":97},[],{"intervention":30211,"totalTrials":417,"cells":30212},"Amoxicillin-Potassium Clavulanate Combination",{"EARLY_PHASE1":30213,"PHASE1":30215,"PHASE2":30217,"PHASE3":30219,"PHASE4":30229,"NA":30231},{"trials":30214,"activeCount":97},[],{"trials":30216,"activeCount":97},[],{"trials":30218,"activeCount":97},[],{"trials":30220,"activeCount":97},[30221],{"nctId":30222,"briefTitle":30223,"status":155,"phases":30224,"primaryCompletion":24426,"completion":24426,"start":30225,"enrollment":9334,"conditions":30226,"interventions":30228},"NCT01934231","Study to Assess the Efficacy and Safety of Potassium Clavulanate\u002FAmoxicillin in Children With Acute Bacterial Rhinosinusitis",[87],"2013-08-30",[30227],"Sinusitis, Acute",[30211],{"trials":30230,"activeCount":97},[],{"trials":30232,"activeCount":97},[],{"intervention":30234,"totalTrials":417,"cells":30235},"Simvastatin + Lovaza®",{"EARLY_PHASE1":30236,"PHASE1":30238,"PHASE2":30240,"PHASE3":30242,"PHASE4":30253,"NA":30255},{"trials":30237,"activeCount":97},[],{"trials":30239,"activeCount":97},[],{"trials":30241,"activeCount":97},[],{"trials":30243,"activeCount":97},[30244],{"nctId":30245,"briefTitle":30246,"status":155,"phases":30247,"primaryCompletion":30248,"completion":30248,"start":30249,"enrollment":30250,"conditions":30251,"interventions":30252},"NCT00903409","Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects",[87],"2008-06-27","2005-11-15",188,[12294],[30234],{"trials":30254,"activeCount":97},[],{"trials":30256,"activeCount":97},[],{"intervention":30258,"totalTrials":417,"cells":30259},"GSK's liquid oral live attenuated HRV",{"EARLY_PHASE1":30260,"PHASE1":30262,"PHASE2":30264,"PHASE3":30266,"PHASE4":30279,"NA":30281},{"trials":30261,"activeCount":97},[],{"trials":30263,"activeCount":97},[],{"trials":30265,"activeCount":97},[],{"trials":30267,"activeCount":97},[30268],{"nctId":30269,"briefTitle":30270,"status":155,"phases":30271,"primaryCompletion":30272,"completion":30273,"start":30274,"enrollment":30275,"conditions":30276,"interventions":30277},"NCT06025695","Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks",[87],"2024-05-28","2024-10-23","2023-09-01",2000,[28240],[30258,30278],"PCV-free liquid formulation of GSK's oral live attenuated HRV",{"trials":30280,"activeCount":97},[],{"trials":30282,"activeCount":97},[],{"intervention":30278,"totalTrials":417,"cells":30284},{"EARLY_PHASE1":30285,"PHASE1":30287,"PHASE2":30289,"PHASE3":30291,"PHASE4":30297,"NA":30299},{"trials":30286,"activeCount":97},[],{"trials":30288,"activeCount":97},[],{"trials":30290,"activeCount":97},[],{"trials":30292,"activeCount":97},[30293],{"nctId":30269,"briefTitle":30270,"status":155,"phases":30294,"primaryCompletion":30272,"completion":30273,"start":30274,"enrollment":30275,"conditions":30295,"interventions":30296},[87],[28240],[30258,30278],{"trials":30298,"activeCount":97},[],{"trials":30300,"activeCount":97},[],{"intervention":30302,"totalTrials":417,"cells":30303},"Priorix®",{"EARLY_PHASE1":30304,"PHASE1":30306,"PHASE2":30308,"PHASE3":30310,"PHASE4":30321,"NA":30323},{"trials":30305,"activeCount":97},[],{"trials":30307,"activeCount":97},[],{"trials":30309,"activeCount":97},[],{"trials":30311,"activeCount":97},[30312],{"nctId":30313,"briefTitle":30314,"status":155,"phases":30315,"primaryCompletion":30316,"completion":30317,"start":17134,"enrollment":21101,"conditions":30318,"interventions":30319},"NCT02058563","Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older",[87],"2015-05-24","2015-09-17",[2484,2485,2486],[30302,30320],"Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine",{"trials":30322,"activeCount":97},[],{"trials":30324,"activeCount":97},[],{"intervention":30320,"totalTrials":417,"cells":30326},{"EARLY_PHASE1":30327,"PHASE1":30329,"PHASE2":30331,"PHASE3":30333,"PHASE4":30339,"NA":30341},{"trials":30328,"activeCount":97},[],{"trials":30330,"activeCount":97},[],{"trials":30332,"activeCount":97},[],{"trials":30334,"activeCount":97},[30335],{"nctId":30313,"briefTitle":30314,"status":155,"phases":30336,"primaryCompletion":30316,"completion":30317,"start":17134,"enrollment":21101,"conditions":30337,"interventions":30338},[87],[2484,2485,2486],[30302,30320],{"trials":30340,"activeCount":97},[],{"trials":30342,"activeCount":97},[],{"intervention":23634,"totalTrials":417,"cells":30344},{"EARLY_PHASE1":30345,"PHASE1":30347,"PHASE2":30349,"PHASE3":30351,"PHASE4":30357,"NA":30359},{"trials":30346,"activeCount":97},[],{"trials":30348,"activeCount":97},[],{"trials":30350,"activeCount":97},[],{"trials":30352,"activeCount":97},[30353],{"nctId":23629,"briefTitle":23630,"status":145,"phases":30354,"primaryCompletion":2335,"completion":2335,"start":6352,"enrollment":34,"conditions":30355,"interventions":30356},[87],[27],[23634,8129],{"trials":30358,"activeCount":97},[],{"trials":30360,"activeCount":97},[],{"intervention":21873,"totalTrials":417,"cells":30362},{"EARLY_PHASE1":30363,"PHASE1":30365,"PHASE2":30367,"PHASE3":30369,"PHASE4":30375,"NA":30377},{"trials":30364,"activeCount":97},[],{"trials":30366,"activeCount":97},[],{"trials":30368,"activeCount":97},[],{"trials":30370,"activeCount":97},[30371],{"nctId":21866,"briefTitle":21867,"status":155,"phases":30372,"primaryCompletion":21869,"completion":21869,"start":21870,"enrollment":5056,"conditions":30373,"interventions":30374},[87],[17996],[21873,21874,21875,21876,18585,21877],{"trials":30376,"activeCount":97},[],{"trials":30378,"activeCount":97},[],{"intervention":21874,"totalTrials":417,"cells":30380},{"EARLY_PHASE1":30381,"PHASE1":30383,"PHASE2":30385,"PHASE3":30387,"PHASE4":30393,"NA":30395},{"trials":30382,"activeCount":97},[],{"trials":30384,"activeCount":97},[],{"trials":30386,"activeCount":97},[],{"trials":30388,"activeCount":97},[30389],{"nctId":21866,"briefTitle":21867,"status":155,"phases":30390,"primaryCompletion":21869,"completion":21869,"start":21870,"enrollment":5056,"conditions":30391,"interventions":30392},[87],[17996],[21873,21874,21875,21876,18585,21877],{"trials":30394,"activeCount":97},[],{"trials":30396,"activeCount":97},[],{"intervention":21875,"totalTrials":417,"cells":30398},{"EARLY_PHASE1":30399,"PHASE1":30401,"PHASE2":30403,"PHASE3":30405,"PHASE4":30411,"NA":30413},{"trials":30400,"activeCount":97},[],{"trials":30402,"activeCount":97},[],{"trials":30404,"activeCount":97},[],{"trials":30406,"activeCount":97},[30407],{"nctId":21866,"briefTitle":21867,"status":155,"phases":30408,"primaryCompletion":21869,"completion":21869,"start":21870,"enrollment":5056,"conditions":30409,"interventions":30410},[87],[17996],[21873,21874,21875,21876,18585,21877],{"trials":30412,"activeCount":97},[],{"trials":30414,"activeCount":97},[],{"intervention":21876,"totalTrials":417,"cells":30416},{"EARLY_PHASE1":30417,"PHASE1":30419,"PHASE2":30421,"PHASE3":30423,"PHASE4":30429,"NA":30431},{"trials":30418,"activeCount":97},[],{"trials":30420,"activeCount":97},[],{"trials":30422,"activeCount":97},[],{"trials":30424,"activeCount":97},[30425],{"nctId":21866,"briefTitle":21867,"status":155,"phases":30426,"primaryCompletion":21869,"completion":21869,"start":21870,"enrollment":5056,"conditions":30427,"interventions":30428},[87],[17996],[21873,21874,21875,21876,18585,21877],{"trials":30430,"activeCount":97},[],{"trials":30432,"activeCount":97},[],{"intervention":21877,"totalTrials":417,"cells":30434},{"EARLY_PHASE1":30435,"PHASE1":30437,"PHASE2":30439,"PHASE3":30441,"PHASE4":30447,"NA":30449},{"trials":30436,"activeCount":97},[],{"trials":30438,"activeCount":97},[],{"trials":30440,"activeCount":97},[],{"trials":30442,"activeCount":97},[30443],{"nctId":21866,"briefTitle":21867,"status":155,"phases":30444,"primaryCompletion":21869,"completion":21869,"start":21870,"enrollment":5056,"conditions":30445,"interventions":30446},[87],[17996],[21873,21874,21875,21876,18585,21877],{"trials":30448,"activeCount":97},[],{"trials":30450,"activeCount":97},[],{"intervention":30452,"totalTrials":417,"cells":30453},"GSK Biologicals' influenza vaccine GSK2186877A",{"EARLY_PHASE1":30454,"PHASE1":30456,"PHASE2":30458,"PHASE3":30460,"PHASE4":30470,"NA":30472},{"trials":30455,"activeCount":97},[],{"trials":30457,"activeCount":97},[],{"trials":30459,"activeCount":97},[],{"trials":30461,"activeCount":97},[30462],{"nctId":30463,"briefTitle":30464,"status":155,"phases":30465,"primaryCompletion":8189,"completion":8189,"start":30466,"enrollment":3285,"conditions":30467,"interventions":30468},"NCT00765076","Clinical Study of the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in People Aged 65 Years or Older",[87],"2008-10-16",[21],[30452,30469],"GSK Biologicals' Fluarix",{"trials":30471,"activeCount":97},[],{"trials":30473,"activeCount":97},[],{"intervention":30469,"totalTrials":417,"cells":30475},{"EARLY_PHASE1":30476,"PHASE1":30478,"PHASE2":30480,"PHASE3":30482,"PHASE4":30488,"NA":30490},{"trials":30477,"activeCount":97},[],{"trials":30479,"activeCount":97},[],{"trials":30481,"activeCount":97},[],{"trials":30483,"activeCount":97},[30484],{"nctId":30463,"briefTitle":30464,"status":155,"phases":30485,"primaryCompletion":8189,"completion":8189,"start":30466,"enrollment":3285,"conditions":30486,"interventions":30487},[87],[21],[30452,30469],{"trials":30489,"activeCount":97},[],{"trials":30491,"activeCount":97},[],{"intervention":30493,"totalTrials":417,"cells":30494},"lamotrigine, 300 mg\u002Fday",{"EARLY_PHASE1":30495,"PHASE1":30497,"PHASE2":30499,"PHASE3":30501,"PHASE4":30510,"NA":30512},{"trials":30496,"activeCount":97},[],{"trials":30498,"activeCount":97},[],{"trials":30500,"activeCount":97},[],{"trials":30502,"activeCount":97},[30503],{"nctId":30504,"briefTitle":30505,"status":155,"phases":30506,"primaryCompletion":10166,"completion":10166,"start":2383,"enrollment":9118,"conditions":30507,"interventions":30508},"NCT00355082","Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy",[87],[21978],[30493,30509],"lamotrigine, 250 mg\u002Fday",{"trials":30511,"activeCount":97},[],{"trials":30513,"activeCount":97},[],{"intervention":30509,"totalTrials":417,"cells":30515},{"EARLY_PHASE1":30516,"PHASE1":30518,"PHASE2":30520,"PHASE3":30522,"PHASE4":30528,"NA":30530},{"trials":30517,"activeCount":97},[],{"trials":30519,"activeCount":97},[],{"trials":30521,"activeCount":97},[],{"trials":30523,"activeCount":97},[30524],{"nctId":30504,"briefTitle":30505,"status":155,"phases":30525,"primaryCompletion":10166,"completion":10166,"start":2383,"enrollment":9118,"conditions":30526,"interventions":30527},[87],[21978],[30493,30509],{"trials":30529,"activeCount":97},[],{"trials":30531,"activeCount":97},[],{"intervention":22032,"totalTrials":417,"cells":30533},{"EARLY_PHASE1":30534,"PHASE1":30536,"PHASE2":30538,"PHASE3":30540,"PHASE4":30546,"NA":30548},{"trials":30535,"activeCount":97},[],{"trials":30537,"activeCount":97},[],{"trials":30539,"activeCount":97},[],{"trials":30541,"activeCount":97},[30542],{"nctId":22026,"briefTitle":22027,"status":155,"phases":30543,"primaryCompletion":8426,"completion":2382,"start":4757,"enrollment":22029,"conditions":30544,"interventions":30545},[87],[4704,4703],[22032,4806,22033],{"trials":30547,"activeCount":97},[],{"trials":30549,"activeCount":97},[],{"intervention":22033,"totalTrials":417,"cells":30551},{"EARLY_PHASE1":30552,"PHASE1":30554,"PHASE2":30556,"PHASE3":30558,"PHASE4":30564,"NA":30566},{"trials":30553,"activeCount":97},[],{"trials":30555,"activeCount":97},[],{"trials":30557,"activeCount":97},[],{"trials":30559,"activeCount":97},[30560],{"nctId":22026,"briefTitle":22027,"status":155,"phases":30561,"primaryCompletion":8426,"completion":2382,"start":4757,"enrollment":22029,"conditions":30562,"interventions":30563},[87],[4704,4703],[22032,4806,22033],{"trials":30565,"activeCount":97},[],{"trials":30567,"activeCount":97},[],{"intervention":25965,"totalTrials":417,"cells":30569},{"EARLY_PHASE1":30570,"PHASE1":30572,"PHASE2":30574,"PHASE3":30576,"PHASE4":30582,"NA":30584},{"trials":30571,"activeCount":97},[],{"trials":30573,"activeCount":97},[],{"trials":30575,"activeCount":97},[],{"trials":30577,"activeCount":97},[30578],{"nctId":25959,"briefTitle":25960,"status":155,"phases":30579,"primaryCompletion":11961,"completion":11961,"start":25962,"enrollment":2995,"conditions":30580,"interventions":30581},[87],[21],[25948,25965,25966,25948],{"trials":30583,"activeCount":97},[],{"trials":30585,"activeCount":97},[],{"intervention":25966,"totalTrials":417,"cells":30587},{"EARLY_PHASE1":30588,"PHASE1":30590,"PHASE2":30592,"PHASE3":30594,"PHASE4":30600,"NA":30602},{"trials":30589,"activeCount":97},[],{"trials":30591,"activeCount":97},[],{"trials":30593,"activeCount":97},[],{"trials":30595,"activeCount":97},[30596],{"nctId":25959,"briefTitle":25960,"status":155,"phases":30597,"primaryCompletion":11961,"completion":11961,"start":25962,"enrollment":2995,"conditions":30598,"interventions":30599},[87],[21],[25948,25965,25966,25948],{"trials":30601,"activeCount":97},[],{"trials":30603,"activeCount":97},[],{"intervention":30605,"totalTrials":417,"cells":30606},"TREXIMET®",{"EARLY_PHASE1":30607,"PHASE1":30609,"PHASE2":30611,"PHASE3":30613,"PHASE4":30624,"NA":30626},{"trials":30608,"activeCount":97},[],{"trials":30610,"activeCount":97},[],{"trials":30612,"activeCount":97},[],{"trials":30614,"activeCount":97},[30615],{"nctId":30616,"briefTitle":30617,"status":155,"phases":30618,"primaryCompletion":9159,"completion":9159,"start":9737,"enrollment":30619,"conditions":30620,"interventions":30622},"NCT00573170","TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults",[87],375,[14168,30621],"Migraine, Acute",[30605,30623],"Butalbital-containing Combination Medications",{"trials":30625,"activeCount":97},[],{"trials":30627,"activeCount":97},[],{"intervention":30623,"totalTrials":417,"cells":30629},{"EARLY_PHASE1":30630,"PHASE1":30632,"PHASE2":30634,"PHASE3":30636,"PHASE4":30642,"NA":30644},{"trials":30631,"activeCount":97},[],{"trials":30633,"activeCount":97},[],{"trials":30635,"activeCount":97},[],{"trials":30637,"activeCount":97},[30638],{"nctId":30616,"briefTitle":30617,"status":155,"phases":30639,"primaryCompletion":9159,"completion":9159,"start":9737,"enrollment":30619,"conditions":30640,"interventions":30641},[87],[14168,30621],[30605,30623],{"trials":30643,"activeCount":97},[],{"trials":30645,"activeCount":97},[],{"intervention":7871,"totalTrials":417,"cells":30647},{"EARLY_PHASE1":30648,"PHASE1":30650,"PHASE2":30652,"PHASE3":30654,"PHASE4":30660,"NA":30662},{"trials":30649,"activeCount":97},[],{"trials":30651,"activeCount":97},[],{"trials":30653,"activeCount":97},[],{"trials":30655,"activeCount":97},[30656],{"nctId":7862,"briefTitle":7863,"status":155,"phases":30657,"primaryCompletion":7865,"completion":7866,"start":7867,"enrollment":7868,"conditions":30658,"interventions":30659},[87],[4704],[7871,7872,7873,7874,7875,7830,7718,7876],{"trials":30661,"activeCount":97},[],{"trials":30663,"activeCount":97},[],{"intervention":7873,"totalTrials":417,"cells":30665},{"EARLY_PHASE1":30666,"PHASE1":30668,"PHASE2":30670,"PHASE3":30672,"PHASE4":30678,"NA":30680},{"trials":30667,"activeCount":97},[],{"trials":30669,"activeCount":97},[],{"trials":30671,"activeCount":97},[],{"trials":30673,"activeCount":97},[30674],{"nctId":7862,"briefTitle":7863,"status":155,"phases":30675,"primaryCompletion":7865,"completion":7866,"start":7867,"enrollment":7868,"conditions":30676,"interventions":30677},[87],[4704],[7871,7872,7873,7874,7875,7830,7718,7876],{"trials":30679,"activeCount":97},[],{"trials":30681,"activeCount":97},[],{"intervention":7874,"totalTrials":417,"cells":30683},{"EARLY_PHASE1":30684,"PHASE1":30686,"PHASE2":30688,"PHASE3":30690,"PHASE4":30696,"NA":30698},{"trials":30685,"activeCount":97},[],{"trials":30687,"activeCount":97},[],{"trials":30689,"activeCount":97},[],{"trials":30691,"activeCount":97},[30692],{"nctId":7862,"briefTitle":7863,"status":155,"phases":30693,"primaryCompletion":7865,"completion":7866,"start":7867,"enrollment":7868,"conditions":30694,"interventions":30695},[87],[4704],[7871,7872,7873,7874,7875,7830,7718,7876],{"trials":30697,"activeCount":97},[],{"trials":30699,"activeCount":97},[],{"intervention":30701,"totalTrials":417,"cells":30702},"sodium chloride",{"EARLY_PHASE1":30703,"PHASE1":30705,"PHASE2":30707,"PHASE3":30709,"PHASE4":30720,"NA":30722},{"trials":30704,"activeCount":97},[],{"trials":30706,"activeCount":97},[],{"trials":30708,"activeCount":97},[],{"trials":30710,"activeCount":97},[30711],{"nctId":30712,"briefTitle":30713,"status":155,"phases":30714,"primaryCompletion":30715,"completion":30715,"start":2373,"enrollment":19760,"conditions":30716,"interventions":30718},"NCT00408785","A Study Of BOTOX For The Treatment Of Glabellar Lines",[87],"2007-05-09",[30717],"Glabellar Lines",[30719,30701],"Botulinum Toxin Type A",{"trials":30721,"activeCount":97},[],{"trials":30723,"activeCount":97},[],{"intervention":30725,"totalTrials":417,"cells":30726},"Salmeterol 50mcg\u002F Fluticasone Propionate 500mcg",{"EARLY_PHASE1":30727,"PHASE1":30729,"PHASE2":30731,"PHASE3":30733,"PHASE4":30742,"NA":30744},{"trials":30728,"activeCount":97},[],{"trials":30730,"activeCount":97},[],{"trials":30732,"activeCount":97},[],{"trials":30734,"activeCount":97},[30735],{"nctId":30736,"briefTitle":30737,"status":155,"phases":30738,"primaryCompletion":2844,"completion":2844,"start":7837,"enrollment":30739,"conditions":30740,"interventions":30741},"NCT00268216","Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],6228,[15],[30725],{"trials":30743,"activeCount":97},[],{"trials":30745,"activeCount":97},[],{"intervention":26017,"totalTrials":417,"cells":30747},{"EARLY_PHASE1":30748,"PHASE1":30750,"PHASE2":30752,"PHASE3":30754,"PHASE4":30760,"NA":30762},{"trials":30749,"activeCount":97},[],{"trials":30751,"activeCount":97},[],{"trials":30753,"activeCount":97},[],{"trials":30755,"activeCount":97},[30756],{"nctId":26012,"briefTitle":26013,"status":155,"phases":30757,"primaryCompletion":2404,"completion":2404,"start":8852,"enrollment":20814,"conditions":30758,"interventions":30759},[87],[24,10227,33,4704,30],[26017,19866],{"trials":30761,"activeCount":97},[],{"trials":30763,"activeCount":97},[],{"intervention":23813,"totalTrials":417,"cells":30765},{"EARLY_PHASE1":30766,"PHASE1":30768,"PHASE2":30770,"PHASE3":30772,"PHASE4":30778,"NA":30780},{"trials":30767,"activeCount":97},[],{"trials":30769,"activeCount":97},[],{"trials":30771,"activeCount":97},[],{"trials":30773,"activeCount":97},[30774],{"nctId":23808,"briefTitle":23809,"status":155,"phases":30775,"primaryCompletion":3390,"completion":3390,"start":2427,"enrollment":11064,"conditions":30776,"interventions":30777},[87],[18],[23791,23813],{"trials":30779,"activeCount":97},[],{"trials":30781,"activeCount":97},[],{"intervention":30783,"totalTrials":417,"cells":30784},"Salmeterol\u002Ffluticasone propionate 50\u002F500mcg Diskus",{"EARLY_PHASE1":30785,"PHASE1":30787,"PHASE2":30789,"PHASE3":30791,"PHASE4":30799,"NA":30801},{"trials":30786,"activeCount":97},[],{"trials":30788,"activeCount":97},[],{"trials":30790,"activeCount":97},[],{"trials":30792,"activeCount":97},[30793],{"nctId":30794,"briefTitle":30795,"status":155,"phases":30796,"completion":8492,"start":13061,"enrollment":11031,"conditions":30797,"interventions":30798},"NCT00268177","Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease",[87],[15],[30783],{"trials":30800,"activeCount":97},[],{"trials":30802,"activeCount":97},[],{"intervention":20351,"totalTrials":417,"cells":30804},{"EARLY_PHASE1":30805,"PHASE1":30807,"PHASE2":30809,"PHASE3":30811,"PHASE4":30817,"NA":30819},{"trials":30806,"activeCount":97},[],{"trials":30808,"activeCount":97},[],{"trials":30810,"activeCount":97},[],{"trials":30812,"activeCount":97},[30813],{"nctId":20343,"briefTitle":20344,"status":155,"phases":30814,"primaryCompletion":8426,"completion":11992,"start":8963,"enrollment":1960,"conditions":30815,"interventions":30816},[87],[20347,20348,1337],[20350,20351,20352,20353],{"trials":30818,"activeCount":97},[],{"trials":30820,"activeCount":97},[],{"intervention":20352,"totalTrials":417,"cells":30822},{"EARLY_PHASE1":30823,"PHASE1":30825,"PHASE2":30827,"PHASE3":30829,"PHASE4":30835,"NA":30837},{"trials":30824,"activeCount":97},[],{"trials":30826,"activeCount":97},[],{"trials":30828,"activeCount":97},[],{"trials":30830,"activeCount":97},[30831],{"nctId":20343,"briefTitle":20344,"status":155,"phases":30832,"primaryCompletion":8426,"completion":11992,"start":8963,"enrollment":1960,"conditions":30833,"interventions":30834},[87],[20347,20348,1337],[20350,20351,20352,20353],{"trials":30836,"activeCount":97},[],{"trials":30838,"activeCount":97},[],{"intervention":30840,"totalTrials":417,"cells":30841},"RSVPreF3",{"EARLY_PHASE1":30842,"PHASE1":30844,"PHASE2":30846,"PHASE3":30848,"PHASE4":30859,"NA":30861},{"trials":30843,"activeCount":97},[],{"trials":30845,"activeCount":97},[],{"trials":30847,"activeCount":97},[],{"trials":30849,"activeCount":97},[30850],{"nctId":30851,"briefTitle":30852,"status":155,"phases":30853,"primaryCompletion":42,"completion":42,"start":30854,"enrollment":30855,"conditions":30856,"interventions":30857},"NCT05045144","A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.",[87],"2021-10-26",1586,[2620],[30840,30858],"Flu Quadrivalent influenza vaccine",{"trials":30860,"activeCount":97},[],{"trials":30862,"activeCount":97},[],{"intervention":30858,"totalTrials":417,"cells":30864},{"EARLY_PHASE1":30865,"PHASE1":30867,"PHASE2":30869,"PHASE3":30871,"PHASE4":30877,"NA":30879},{"trials":30866,"activeCount":97},[],{"trials":30868,"activeCount":97},[],{"trials":30870,"activeCount":97},[],{"trials":30872,"activeCount":97},[30873],{"nctId":30851,"briefTitle":30852,"status":155,"phases":30874,"primaryCompletion":42,"completion":42,"start":30854,"enrollment":30855,"conditions":30875,"interventions":30876},[87],[2620],[30840,30858],{"trials":30878,"activeCount":97},[],{"trials":30880,"activeCount":97},[],{"intervention":7894,"totalTrials":417,"cells":30882},{"EARLY_PHASE1":30883,"PHASE1":30885,"PHASE2":30887,"PHASE3":30889,"PHASE4":30895,"NA":30897},{"trials":30884,"activeCount":97},[],{"trials":30886,"activeCount":97},[],{"trials":30888,"activeCount":97},[],{"trials":30890,"activeCount":97},[30891],{"nctId":7886,"briefTitle":7887,"status":155,"phases":30892,"primaryCompletion":7889,"completion":7889,"start":7890,"enrollment":7891,"conditions":30893,"interventions":30894},[87],[24],[7894,7718],{"trials":30896,"activeCount":97},[],{"trials":30898,"activeCount":97},[],{"intervention":6568,"totalTrials":417,"cells":30900},{"EARLY_PHASE1":30901,"PHASE1":30903,"PHASE2":30905,"PHASE3":30907,"PHASE4":30913,"NA":30915},{"trials":30902,"activeCount":97},[],{"trials":30904,"activeCount":97},[],{"trials":30906,"activeCount":97},[],{"trials":30908,"activeCount":97},[30909],{"nctId":6559,"briefTitle":6560,"status":155,"phases":30910,"primaryCompletion":6562,"completion":6562,"start":6563,"enrollment":6564,"conditions":30911,"interventions":30912},[87],[6566],[6471,6568,6569],{"trials":30914,"activeCount":97},[],{"trials":30916,"activeCount":97},[],{"intervention":5048,"totalTrials":417,"cells":30918},{"EARLY_PHASE1":30919,"PHASE1":30921,"PHASE2":30923,"PHASE3":30925,"PHASE4":30931,"NA":30933},{"trials":30920,"activeCount":97},[],{"trials":30922,"activeCount":97},[],{"trials":30924,"activeCount":97},[],{"trials":30926,"activeCount":97},[30927],{"nctId":5039,"briefTitle":5040,"status":155,"phases":30928,"primaryCompletion":5042,"completion":5043,"start":4770,"enrollment":5044,"conditions":30929,"interventions":30930},[87],[992,5046],[4486,5048],{"trials":30932,"activeCount":97},[],{"trials":30934,"activeCount":97},[],{"intervention":30936,"totalTrials":417,"cells":30937},"Retigabine 900mg\u002Fday",{"EARLY_PHASE1":30938,"PHASE1":30940,"PHASE2":30942,"PHASE3":30944,"PHASE4":30955,"NA":30957},{"trials":30939,"activeCount":97},[],{"trials":30941,"activeCount":97},[],{"trials":30943,"activeCount":97},[],{"trials":30945,"activeCount":97},[30946],{"nctId":30947,"briefTitle":30948,"status":145,"phases":30949,"primaryCompletion":30950,"completion":30951,"start":19537,"enrollment":7955,"conditions":30952,"interventions":30953},"NCT01648101","Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg\u002FDay and 600 mg\u002FDay) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures",[87],"2013-12-01","2013-12-23",[12518],[30936,30954],"Retigabine 600mg\u002Fday",{"trials":30956,"activeCount":97},[],{"trials":30958,"activeCount":97},[],{"intervention":30954,"totalTrials":417,"cells":30960},{"EARLY_PHASE1":30961,"PHASE1":30963,"PHASE2":30965,"PHASE3":30967,"PHASE4":30973,"NA":30975},{"trials":30962,"activeCount":97},[],{"trials":30964,"activeCount":97},[],{"trials":30966,"activeCount":97},[],{"trials":30968,"activeCount":97},[30969],{"nctId":30947,"briefTitle":30948,"status":145,"phases":30970,"primaryCompletion":30950,"completion":30951,"start":19537,"enrollment":7955,"conditions":30971,"interventions":30972},[87],[12518],[30936,30954],{"trials":30974,"activeCount":97},[],{"trials":30976,"activeCount":97},[],{"intervention":30978,"totalTrials":417,"cells":30979},"1 to 4 mg tablets of GSK1278863",{"EARLY_PHASE1":30980,"PHASE1":30982,"PHASE2":30984,"PHASE3":30986,"PHASE4":30999,"NA":31001},{"trials":30981,"activeCount":97},[],{"trials":30983,"activeCount":97},[],{"trials":30985,"activeCount":97},[],{"trials":30987,"activeCount":97},[30988],{"nctId":30989,"briefTitle":30990,"status":155,"phases":30991,"primaryCompletion":30992,"completion":30992,"start":30993,"enrollment":30994,"conditions":30995,"interventions":30996},"NCT02791763","Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia",[87],"2018-10-26","2016-06-06",355,[17996],[30978,30997,30998],"6 mg GSK1278863","Epoetin beta pegol",{"trials":31000,"activeCount":97},[],{"trials":31002,"activeCount":97},[],{"intervention":30997,"totalTrials":417,"cells":31004},{"EARLY_PHASE1":31005,"PHASE1":31007,"PHASE2":31009,"PHASE3":31011,"PHASE4":31017,"NA":31019},{"trials":31006,"activeCount":97},[],{"trials":31008,"activeCount":97},[],{"trials":31010,"activeCount":97},[],{"trials":31012,"activeCount":97},[31013],{"nctId":30989,"briefTitle":30990,"status":155,"phases":31014,"primaryCompletion":30992,"completion":30992,"start":30993,"enrollment":30994,"conditions":31015,"interventions":31016},[87],[17996],[30978,30997,30998],{"trials":31018,"activeCount":97},[],{"trials":31020,"activeCount":97},[],{"intervention":30998,"totalTrials":417,"cells":31022},{"EARLY_PHASE1":31023,"PHASE1":31025,"PHASE2":31027,"PHASE3":31029,"PHASE4":31035,"NA":31037},{"trials":31024,"activeCount":97},[],{"trials":31026,"activeCount":97},[],{"trials":31028,"activeCount":97},[],{"trials":31030,"activeCount":97},[31031],{"nctId":30989,"briefTitle":30990,"status":155,"phases":31032,"primaryCompletion":30992,"completion":30992,"start":30993,"enrollment":30994,"conditions":31033,"interventions":31034},[87],[17996],[30978,30997,30998],{"trials":31036,"activeCount":97},[],{"trials":31038,"activeCount":97},[],{"intervention":9947,"totalTrials":417,"cells":31040},{"EARLY_PHASE1":31041,"PHASE1":31043,"PHASE2":31045,"PHASE3":31047,"PHASE4":31053,"NA":31055},{"trials":31042,"activeCount":97},[],{"trials":31044,"activeCount":97},[],{"trials":31046,"activeCount":97},[],{"trials":31048,"activeCount":97},[31049],{"nctId":9940,"briefTitle":9941,"status":155,"phases":31050,"primaryCompletion":2813,"completion":2813,"start":2805,"enrollment":9943,"conditions":31051,"interventions":31052},[87],[2444,9945],[9947,9920],{"trials":31054,"activeCount":97},[],{"trials":31056,"activeCount":97},[],{"intervention":31058,"totalTrials":417,"cells":31059},"Mepolizumab IV",{"EARLY_PHASE1":31060,"PHASE1":31062,"PHASE2":31064,"PHASE3":31066,"PHASE4":31080,"NA":31082},{"trials":31061,"activeCount":97},[],{"trials":31063,"activeCount":97},[],{"trials":31065,"activeCount":97},[],{"trials":31067,"activeCount":97},[31068],{"nctId":31069,"briefTitle":31070,"status":155,"phases":31071,"primaryCompletion":31072,"completion":31073,"start":31074,"enrollment":2406,"conditions":31075,"interventions":31076},"NCT01691521","Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma",[87],"2014-01-01","2014-01-18","2012-10-08",[18],[31058,31077,31078,31079],"Mepolizumab SC","IV Placebo","SC Placebo",{"trials":31081,"activeCount":97},[],{"trials":31083,"activeCount":97},[],{"intervention":31077,"totalTrials":417,"cells":31085},{"EARLY_PHASE1":31086,"PHASE1":31088,"PHASE2":31090,"PHASE3":31092,"PHASE4":31098,"NA":31100},{"trials":31087,"activeCount":97},[],{"trials":31089,"activeCount":97},[],{"trials":31091,"activeCount":97},[],{"trials":31093,"activeCount":97},[31094],{"nctId":31069,"briefTitle":31070,"status":155,"phases":31095,"primaryCompletion":31072,"completion":31073,"start":31074,"enrollment":2406,"conditions":31096,"interventions":31097},[87],[18],[31058,31077,31078,31079],{"trials":31099,"activeCount":97},[],{"trials":31101,"activeCount":97},[],{"intervention":31078,"totalTrials":417,"cells":31103},{"EARLY_PHASE1":31104,"PHASE1":31106,"PHASE2":31108,"PHASE3":31110,"PHASE4":31116,"NA":31118},{"trials":31105,"activeCount":97},[],{"trials":31107,"activeCount":97},[],{"trials":31109,"activeCount":97},[],{"trials":31111,"activeCount":97},[31112],{"nctId":31069,"briefTitle":31070,"status":155,"phases":31113,"primaryCompletion":31072,"completion":31073,"start":31074,"enrollment":2406,"conditions":31114,"interventions":31115},[87],[18],[31058,31077,31078,31079],{"trials":31117,"activeCount":97},[],{"trials":31119,"activeCount":97},[],{"intervention":31079,"totalTrials":417,"cells":31121},{"EARLY_PHASE1":31122,"PHASE1":31124,"PHASE2":31126,"PHASE3":31128,"PHASE4":31134,"NA":31136},{"trials":31123,"activeCount":97},[],{"trials":31125,"activeCount":97},[],{"trials":31127,"activeCount":97},[],{"trials":31129,"activeCount":97},[31130],{"nctId":31069,"briefTitle":31070,"status":155,"phases":31131,"primaryCompletion":31072,"completion":31073,"start":31074,"enrollment":2406,"conditions":31132,"interventions":31133},[87],[18],[31058,31077,31078,31079],{"trials":31135,"activeCount":97},[],{"trials":31137,"activeCount":97},[],{"intervention":19354,"totalTrials":417,"cells":31139},{"EARLY_PHASE1":31140,"PHASE1":31142,"PHASE2":31144,"PHASE3":31146,"PHASE4":31152,"NA":31154},{"trials":31141,"activeCount":97},[],{"trials":31143,"activeCount":97},[],{"trials":31145,"activeCount":97},[],{"trials":31147,"activeCount":97},[31148],{"nctId":19347,"briefTitle":19348,"status":12113,"phases":31149,"start":7838,"enrollment":19350,"conditions":31150,"interventions":31151},[87],[10943],[19353,10675,19354],{"trials":31153,"activeCount":97},[],{"trials":31155,"activeCount":97},[],{"intervention":19792,"totalTrials":417,"cells":31157},{"EARLY_PHASE1":31158,"PHASE1":31160,"PHASE2":31162,"PHASE3":31164,"PHASE4":31170,"NA":31172},{"trials":31159,"activeCount":97},[],{"trials":31161,"activeCount":97},[],{"trials":31163,"activeCount":97},[],{"trials":31165,"activeCount":97},[31166],{"nctId":19783,"briefTitle":19784,"status":155,"phases":31167,"primaryCompletion":19786,"completion":19787,"start":19788,"enrollment":19789,"conditions":31168,"interventions":31169},[87],[33,30,3624],[19792,4809,4810],{"trials":31171,"activeCount":97},[],{"trials":31173,"activeCount":97},[],{"intervention":26130,"totalTrials":417,"cells":31175},{"EARLY_PHASE1":31176,"PHASE1":31178,"PHASE2":31180,"PHASE3":31182,"PHASE4":31188,"NA":31190},{"trials":31177,"activeCount":97},[],{"trials":31179,"activeCount":97},[],{"trials":31181,"activeCount":97},[],{"trials":31183,"activeCount":97},[31184],{"nctId":26123,"briefTitle":26124,"status":155,"phases":31185,"primaryCompletion":26126,"completion":26127,"start":18086,"enrollment":7826,"conditions":31186,"interventions":31187},[87],[27],[26130,26103],{"trials":31189,"activeCount":97},[],{"trials":31191,"activeCount":97},[],{"intervention":31193,"totalTrials":417,"cells":31194},"Infanrix-Hexa",{"EARLY_PHASE1":31195,"PHASE1":31197,"PHASE2":31199,"PHASE3":31201,"PHASE4":31209,"NA":31211},{"trials":31196,"activeCount":97},[],{"trials":31198,"activeCount":97},[],{"trials":31200,"activeCount":97},[],{"trials":31202,"activeCount":97},[31203],{"nctId":31204,"briefTitle":31205,"status":155,"phases":31206,"primaryCompletion":7582,"completion":7582,"start":2776,"enrollment":1579,"conditions":31207,"interventions":31208},"NCT00366366","To Evaluate Immunogenicity & Safety of GSK Bio's DTPa-HBV-IPV\u002FHib (Mixed Vaccine) and DTPa-IPV\u002FHib + HBV Vaccines",[87],[24],[31193],{"trials":31210,"activeCount":97},[],{"trials":31212,"activeCount":97},[],{"intervention":31214,"totalTrials":417,"cells":31215},"albiglutide + insulin glargine",{"EARLY_PHASE1":31216,"PHASE1":31218,"PHASE2":31220,"PHASE3":31222,"PHASE4":31232,"NA":31234},{"trials":31217,"activeCount":97},[],{"trials":31219,"activeCount":97},[],{"trials":31221,"activeCount":97},[],{"trials":31223,"activeCount":97},[31224],{"nctId":31225,"briefTitle":31226,"status":155,"phases":31227,"primaryCompletion":2394,"completion":11315,"start":1429,"enrollment":31228,"conditions":31229,"interventions":31230},"NCT00976391","A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine",[87],586,[27],[31214,31231],"insulin glargine + preprandial lispro insulin",{"trials":31233,"activeCount":97},[],{"trials":31235,"activeCount":97},[],{"intervention":31231,"totalTrials":417,"cells":31237},{"EARLY_PHASE1":31238,"PHASE1":31240,"PHASE2":31242,"PHASE3":31244,"PHASE4":31250,"NA":31252},{"trials":31239,"activeCount":97},[],{"trials":31241,"activeCount":97},[],{"trials":31243,"activeCount":97},[],{"trials":31245,"activeCount":97},[31246],{"nctId":31225,"briefTitle":31226,"status":155,"phases":31247,"primaryCompletion":2394,"completion":11315,"start":1429,"enrollment":31228,"conditions":31248,"interventions":31249},[87],[27],[31214,31231],{"trials":31251,"activeCount":97},[],{"trials":31253,"activeCount":97},[],{"intervention":9417,"totalTrials":417,"cells":31255},{"EARLY_PHASE1":31256,"PHASE1":31258,"PHASE2":31260,"PHASE3":31262,"PHASE4":31268,"NA":31270},{"trials":31257,"activeCount":97},[],{"trials":31259,"activeCount":97},[],{"trials":31261,"activeCount":97},[],{"trials":31263,"activeCount":97},[31264],{"nctId":9407,"briefTitle":9408,"status":155,"phases":31265,"primaryCompletion":9410,"completion":9410,"start":9411,"enrollment":9412,"conditions":31266,"interventions":31267},[87],[18],[8532,9415,8381,9370,9416,9417],{"trials":31269,"activeCount":97},[],{"trials":31271,"activeCount":97},[],{"intervention":9081,"totalTrials":417,"cells":31273},{"EARLY_PHASE1":31274,"PHASE1":31276,"PHASE2":31278,"PHASE3":31280,"PHASE4":31286,"NA":31288},{"trials":31275,"activeCount":97},[],{"trials":31277,"activeCount":97},[],{"trials":31279,"activeCount":97},[],{"trials":31281,"activeCount":97},[31282],{"nctId":9073,"briefTitle":9074,"status":155,"phases":31283,"start":9076,"enrollment":9077,"conditions":31284,"interventions":31285},[87],[9079],[8128,9081,9082],{"trials":31287,"activeCount":97},[],{"trials":31289,"activeCount":97},[],{"intervention":9082,"totalTrials":417,"cells":31291},{"EARLY_PHASE1":31292,"PHASE1":31294,"PHASE2":31296,"PHASE3":31298,"PHASE4":31304,"NA":31306},{"trials":31293,"activeCount":97},[],{"trials":31295,"activeCount":97},[],{"trials":31297,"activeCount":97},[],{"trials":31299,"activeCount":97},[31300],{"nctId":9073,"briefTitle":9074,"status":155,"phases":31301,"start":9076,"enrollment":9077,"conditions":31302,"interventions":31303},[87],[9079],[8128,9081,9082],{"trials":31305,"activeCount":97},[],{"trials":31307,"activeCount":97},[],{"intervention":31309,"totalTrials":417,"cells":31310},"GSK Biologicals' candidate Plasmodium falciparum malaria vaccine",{"EARLY_PHASE1":31311,"PHASE1":31313,"PHASE2":31315,"PHASE3":31317,"PHASE4":31328,"NA":31330},{"trials":31312,"activeCount":97},[],{"trials":31314,"activeCount":97},[],{"trials":31316,"activeCount":97},[],{"trials":31318,"activeCount":97},[31319],{"nctId":31320,"briefTitle":31321,"status":155,"phases":31322,"primaryCompletion":5289,"completion":31323,"start":31324,"enrollment":31325,"conditions":31326,"interventions":31327},"NCT01323972","Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children",[87],"2012-05-04","2011-05-16",327,[3287],[31309],{"trials":31329,"activeCount":97},[],{"trials":31331,"activeCount":97},[],{"intervention":8101,"totalTrials":417,"cells":31333},{"EARLY_PHASE1":31334,"PHASE1":31336,"PHASE2":31338,"PHASE3":31340,"PHASE4":31346,"NA":31348},{"trials":31335,"activeCount":97},[],{"trials":31337,"activeCount":97},[],{"trials":31339,"activeCount":97},[],{"trials":31341,"activeCount":97},[31342],{"nctId":8095,"briefTitle":8096,"status":500,"phases":31343,"primaryCompletion":8098,"completion":8098,"start":482,"enrollment":97,"conditions":31344,"interventions":31345},[87],[27],[8021,8101],{"trials":31347,"activeCount":97},[],{"trials":31349,"activeCount":97},[],{"intervention":31351,"totalTrials":417,"cells":31352},"Meningococcal conjugate vaccine GSK134612",{"EARLY_PHASE1":31353,"PHASE1":31355,"PHASE2":31357,"PHASE3":31359,"PHASE4":31369,"NA":31371},{"trials":31354,"activeCount":97},[],{"trials":31356,"activeCount":97},[],{"trials":31358,"activeCount":97},[],{"trials":31360,"activeCount":97},[31361],{"nctId":31362,"briefTitle":31363,"status":155,"phases":31364,"primaryCompletion":22542,"completion":31365,"start":31366,"enrollment":6876,"conditions":31367,"interventions":31368},"NCT01777308","Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination",[87],"2016-04-20","2013-05-03",[992],[31351],{"trials":31370,"activeCount":97},[],{"trials":31372,"activeCount":97},[],{"intervention":3213,"totalTrials":417,"cells":31374},{"EARLY_PHASE1":31375,"PHASE1":31377,"PHASE2":31379,"PHASE3":31381,"PHASE4":31387,"NA":31389},{"trials":31376,"activeCount":97},[],{"trials":31378,"activeCount":97},[],{"trials":31380,"activeCount":97},[],{"trials":31382,"activeCount":97},[31383],{"nctId":3204,"briefTitle":3205,"status":155,"phases":31384,"primaryCompletion":3207,"completion":3208,"start":3209,"enrollment":3210,"conditions":31385,"interventions":31386},[87],[2620],[43,3213],{"trials":31388,"activeCount":97},[],{"trials":31390,"activeCount":97},[],{"intervention":19865,"totalTrials":417,"cells":31392},{"EARLY_PHASE1":31393,"PHASE1":31395,"PHASE2":31397,"PHASE3":31399,"PHASE4":31405,"NA":31407},{"trials":31394,"activeCount":97},[],{"trials":31396,"activeCount":97},[],{"trials":31398,"activeCount":97},[],{"trials":31400,"activeCount":97},[31401],{"nctId":19857,"briefTitle":19858,"status":155,"phases":31402,"primaryCompletion":10275,"completion":19860,"start":19861,"enrollment":19862,"conditions":31403,"interventions":31404},[87],[10227,30,24,33,4704],[19865,19866,19818,19867,19868],{"trials":31406,"activeCount":97},[],{"trials":31408,"activeCount":97},[],{"intervention":19867,"totalTrials":417,"cells":31410},{"EARLY_PHASE1":31411,"PHASE1":31413,"PHASE2":31415,"PHASE3":31417,"PHASE4":31423,"NA":31425},{"trials":31412,"activeCount":97},[],{"trials":31414,"activeCount":97},[],{"trials":31416,"activeCount":97},[],{"trials":31418,"activeCount":97},[31419],{"nctId":19857,"briefTitle":19858,"status":155,"phases":31420,"primaryCompletion":10275,"completion":19860,"start":19861,"enrollment":19862,"conditions":31421,"interventions":31422},[87],[10227,30,24,33,4704],[19865,19866,19818,19867,19868],{"trials":31424,"activeCount":97},[],{"trials":31426,"activeCount":97},[],{"intervention":19868,"totalTrials":417,"cells":31428},{"EARLY_PHASE1":31429,"PHASE1":31431,"PHASE2":31433,"PHASE3":31435,"PHASE4":31441,"NA":31443},{"trials":31430,"activeCount":97},[],{"trials":31432,"activeCount":97},[],{"trials":31434,"activeCount":97},[],{"trials":31436,"activeCount":97},[31437],{"nctId":19857,"briefTitle":19858,"status":155,"phases":31438,"primaryCompletion":10275,"completion":19860,"start":19861,"enrollment":19862,"conditions":31439,"interventions":31440},[87],[10227,30,24,33,4704],[19865,19866,19818,19867,19868],{"trials":31442,"activeCount":97},[],{"trials":31444,"activeCount":97},[],{"intervention":31446,"totalTrials":417,"cells":31447},"Intravenous (IV) zanamivir",{"EARLY_PHASE1":31448,"PHASE1":31450,"PHASE2":31452,"PHASE3":31454,"PHASE4":31463,"NA":31465},{"trials":31449,"activeCount":97},[],{"trials":31451,"activeCount":97},[],{"trials":31453,"activeCount":97},[],{"trials":31455,"activeCount":97},[31456],{"nctId":31457,"briefTitle":31458,"status":155,"phases":31459,"primaryCompletion":8397,"completion":31460,"start":27059,"enrollment":1279,"conditions":31461,"interventions":31462},"NCT01527110","A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection",[87],"2013-03-29",[5353],[31446],{"trials":31464,"activeCount":97},[],{"trials":31466,"activeCount":97},[],{"intervention":4761,"totalTrials":417,"cells":31468},{"EARLY_PHASE1":31469,"PHASE1":31471,"PHASE2":31473,"PHASE3":31475,"PHASE4":31481,"NA":31483},{"trials":31470,"activeCount":97},[],{"trials":31472,"activeCount":97},[],{"trials":31474,"activeCount":97},[],{"trials":31476,"activeCount":97},[31477],{"nctId":4753,"briefTitle":4754,"status":155,"phases":31478,"completion":4756,"start":4757,"enrollment":4388,"conditions":31479,"interventions":31480},[87],[4759],[4761,4684,4762,4763],{"trials":31482,"activeCount":97},[],{"trials":31484,"activeCount":97},[],{"intervention":19099,"totalTrials":417,"cells":31486},{"EARLY_PHASE1":31487,"PHASE1":31489,"PHASE2":31491,"PHASE3":31493,"PHASE4":31499,"NA":31501},{"trials":31488,"activeCount":97},[],{"trials":31490,"activeCount":97},[],{"trials":31492,"activeCount":97},[],{"trials":31494,"activeCount":97},[31495],{"nctId":19090,"briefTitle":19091,"status":155,"phases":31496,"primaryCompletion":19093,"completion":19094,"start":19095,"enrollment":895,"conditions":31497,"interventions":31498},[87],[3637],[4744,4745,19098,4810,19099,19100],{"trials":31500,"activeCount":97},[],{"trials":31502,"activeCount":97},[],{"intervention":19100,"totalTrials":417,"cells":31504},{"EARLY_PHASE1":31505,"PHASE1":31507,"PHASE2":31509,"PHASE3":31511,"PHASE4":31517,"NA":31519},{"trials":31506,"activeCount":97},[],{"trials":31508,"activeCount":97},[],{"trials":31510,"activeCount":97},[],{"trials":31512,"activeCount":97},[31513],{"nctId":19090,"briefTitle":19091,"status":155,"phases":31514,"primaryCompletion":19093,"completion":19094,"start":19095,"enrollment":895,"conditions":31515,"interventions":31516},[87],[3637],[4744,4745,19098,4810,19099,19100],{"trials":31518,"activeCount":97},[],{"trials":31520,"activeCount":97},[],{"intervention":23983,"totalTrials":417,"cells":31522},{"EARLY_PHASE1":31523,"PHASE1":31525,"PHASE2":31527,"PHASE3":31529,"PHASE4":31535,"NA":31537},{"trials":31524,"activeCount":97},[],{"trials":31526,"activeCount":97},[],{"trials":31528,"activeCount":97},[],{"trials":31530,"activeCount":97},[31531],{"nctId":23977,"briefTitle":23978,"status":155,"phases":31532,"primaryCompletion":472,"completion":623,"start":23980,"enrollment":5520,"conditions":31533,"interventions":31534},[87],[15],[18444,18445,23983,23984,23985],{"trials":31536,"activeCount":97},[],{"trials":31538,"activeCount":97},[],{"intervention":23984,"totalTrials":417,"cells":31540},{"EARLY_PHASE1":31541,"PHASE1":31543,"PHASE2":31545,"PHASE3":31547,"PHASE4":31553,"NA":31555},{"trials":31542,"activeCount":97},[],{"trials":31544,"activeCount":97},[],{"trials":31546,"activeCount":97},[],{"trials":31548,"activeCount":97},[31549],{"nctId":23977,"briefTitle":23978,"status":155,"phases":31550,"primaryCompletion":472,"completion":623,"start":23980,"enrollment":5520,"conditions":31551,"interventions":31552},[87],[15],[18444,18445,23983,23984,23985],{"trials":31554,"activeCount":97},[],{"trials":31556,"activeCount":97},[],{"intervention":31558,"totalTrials":417,"cells":31559},"Fluarix®",{"EARLY_PHASE1":31560,"PHASE1":31562,"PHASE2":31564,"PHASE3":31566,"PHASE4":31576,"NA":31578},{"trials":31561,"activeCount":97},[],{"trials":31563,"activeCount":97},[],{"trials":31565,"activeCount":97},[],{"trials":31567,"activeCount":97},[31568],{"nctId":31569,"briefTitle":31570,"status":155,"phases":31571,"primaryCompletion":15621,"completion":15621,"start":31572,"enrollment":31573,"conditions":31574,"interventions":31575},"NCT00385255","Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults",[87],"2006-10-23",1726,[3624,30,33],[31558,11489],{"trials":31577,"activeCount":97},[],{"trials":31579,"activeCount":97},[],{"intervention":832,"totalTrials":417,"cells":31581},{"EARLY_PHASE1":31582,"PHASE1":31584,"PHASE2":31586,"PHASE3":31588,"PHASE4":31594,"NA":31596},{"trials":31583,"activeCount":97},[],{"trials":31585,"activeCount":97},[],{"trials":31587,"activeCount":97},[],{"trials":31589,"activeCount":97},[31590],{"nctId":824,"briefTitle":825,"status":155,"phases":31591,"primaryCompletion":827,"completion":827,"start":828,"enrollment":829,"conditions":31592,"interventions":31593},[87],[18],[694,832],{"trials":31595,"activeCount":97},[],{"trials":31597,"activeCount":97},[],{"intervention":21047,"totalTrials":417,"cells":31599},{"EARLY_PHASE1":31600,"PHASE1":31602,"PHASE2":31604,"PHASE3":31606,"PHASE4":31612,"NA":31614},{"trials":31601,"activeCount":97},[],{"trials":31603,"activeCount":97},[],{"trials":31605,"activeCount":97},[],{"trials":31607,"activeCount":97},[31608],{"nctId":21041,"briefTitle":21042,"status":155,"phases":31609,"primaryCompletion":2355,"completion":2355,"start":8963,"enrollment":21044,"conditions":31610,"interventions":31611},[87],[13024],[21013,21047],{"trials":31613,"activeCount":97},[],{"trials":31615,"activeCount":97},[],{"intervention":31617,"totalTrials":417,"cells":31618},"GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine",{"EARLY_PHASE1":31619,"PHASE1":31621,"PHASE2":31623,"PHASE3":31625,"PHASE4":31636,"NA":31638},{"trials":31620,"activeCount":97},[],{"trials":31622,"activeCount":97},[],{"trials":31624,"activeCount":97},[],{"trials":31626,"activeCount":97},[31627],{"nctId":31628,"briefTitle":31629,"status":155,"phases":31630,"primaryCompletion":7749,"completion":7749,"start":31631,"enrollment":13911,"conditions":31632,"interventions":31633},"NCT01267058","Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults",[87],"1997-09",[30,10087,33],[31617,31634,31635],"GSK Biologicals' acellular pertussis vaccine","Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine",{"trials":31637,"activeCount":97},[],{"trials":31639,"activeCount":97},[],{"intervention":31634,"totalTrials":417,"cells":31641},{"EARLY_PHASE1":31642,"PHASE1":31644,"PHASE2":31646,"PHASE3":31648,"PHASE4":31654,"NA":31656},{"trials":31643,"activeCount":97},[],{"trials":31645,"activeCount":97},[],{"trials":31647,"activeCount":97},[],{"trials":31649,"activeCount":97},[31650],{"nctId":31628,"briefTitle":31629,"status":155,"phases":31651,"primaryCompletion":7749,"completion":7749,"start":31631,"enrollment":13911,"conditions":31652,"interventions":31653},[87],[30,10087,33],[31617,31634,31635],{"trials":31655,"activeCount":97},[],{"trials":31657,"activeCount":97},[],{"intervention":31635,"totalTrials":417,"cells":31659},{"EARLY_PHASE1":31660,"PHASE1":31662,"PHASE2":31664,"PHASE3":31666,"PHASE4":31672,"NA":31674},{"trials":31661,"activeCount":97},[],{"trials":31663,"activeCount":97},[],{"trials":31665,"activeCount":97},[],{"trials":31667,"activeCount":97},[31668],{"nctId":31628,"briefTitle":31629,"status":155,"phases":31669,"primaryCompletion":7749,"completion":7749,"start":31631,"enrollment":13911,"conditions":31670,"interventions":31671},[87],[30,10087,33],[31617,31634,31635],{"trials":31673,"activeCount":97},[],{"trials":31675,"activeCount":97},[],{"intervention":24046,"totalTrials":417,"cells":31677},{"EARLY_PHASE1":31678,"PHASE1":31680,"PHASE2":31682,"PHASE3":31684,"PHASE4":31690,"NA":31692},{"trials":31679,"activeCount":97},[],{"trials":31681,"activeCount":97},[],{"trials":31683,"activeCount":97},[],{"trials":31685,"activeCount":97},[31686],{"nctId":24039,"briefTitle":24040,"status":155,"phases":31687,"primaryCompletion":18494,"completion":24042,"start":24043,"enrollment":20448,"conditions":31688,"interventions":31689},[87],[3637,4742],[24046,19981],{"trials":31691,"activeCount":97},[],{"trials":31693,"activeCount":97},[],{"intervention":31695,"totalTrials":417,"cells":31696},"Lyophilized mepolizumab",{"EARLY_PHASE1":31697,"PHASE1":31699,"PHASE2":31701,"PHASE3":31703,"PHASE4":31714,"NA":31716},{"trials":31698,"activeCount":97},[],{"trials":31700,"activeCount":97},[],{"trials":31702,"activeCount":97},[],{"trials":31704,"activeCount":97},[31705],{"nctId":31706,"briefTitle":31707,"status":155,"phases":31708,"primaryCompletion":31709,"completion":31709,"start":23222,"enrollment":31710,"conditions":31711,"interventions":31712},"NCT03014674","A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug",[87],"2017-08-11",246,[18],[31695,31713],"Liquid mepolizumab",{"trials":31715,"activeCount":97},[],{"trials":31717,"activeCount":97},[],{"intervention":31713,"totalTrials":417,"cells":31719},{"EARLY_PHASE1":31720,"PHASE1":31722,"PHASE2":31724,"PHASE3":31726,"PHASE4":31732,"NA":31734},{"trials":31721,"activeCount":97},[],{"trials":31723,"activeCount":97},[],{"trials":31725,"activeCount":97},[],{"trials":31727,"activeCount":97},[31728],{"nctId":31706,"briefTitle":31707,"status":155,"phases":31729,"primaryCompletion":31709,"completion":31709,"start":23222,"enrollment":31710,"conditions":31730,"interventions":31731},[87],[18],[31695,31713],{"trials":31733,"activeCount":97},[],{"trials":31735,"activeCount":97},[],{"intervention":31737,"totalTrials":417,"cells":31738},"dutasteride 0.5mg once daily for 4 years",{"EARLY_PHASE1":31739,"PHASE1":31741,"PHASE2":31743,"PHASE3":31745,"PHASE4":31755,"NA":31757},{"trials":31740,"activeCount":97},[],{"trials":31742,"activeCount":97},[],{"trials":31744,"activeCount":97},[],{"trials":31746,"activeCount":97},[31747],{"nctId":31748,"briefTitle":31749,"status":155,"phases":31750,"primaryCompletion":3550,"completion":3550,"start":20690,"enrollment":31751,"conditions":31752,"interventions":31753},"NCT00090103","Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment",[87],4844,[12263],[31737,31754],"tamsulosin 0.4mg once daily for 4 years",{"trials":31756,"activeCount":97},[],{"trials":31758,"activeCount":97},[],{"intervention":31754,"totalTrials":417,"cells":31760},{"EARLY_PHASE1":31761,"PHASE1":31763,"PHASE2":31765,"PHASE3":31767,"PHASE4":31773,"NA":31775},{"trials":31762,"activeCount":97},[],{"trials":31764,"activeCount":97},[],{"trials":31766,"activeCount":97},[],{"trials":31768,"activeCount":97},[31769],{"nctId":31748,"briefTitle":31749,"status":155,"phases":31770,"primaryCompletion":3550,"completion":3550,"start":20690,"enrollment":31751,"conditions":31771,"interventions":31772},[87],[12263],[31737,31754],{"trials":31774,"activeCount":97},[],{"trials":31776,"activeCount":97},[],{"intervention":11752,"totalTrials":417,"cells":31778},{"EARLY_PHASE1":31779,"PHASE1":31781,"PHASE2":31783,"PHASE3":31785,"PHASE4":31791,"NA":31793},{"trials":31780,"activeCount":97},[],{"trials":31782,"activeCount":97},[],{"trials":31784,"activeCount":97},[],{"trials":31786,"activeCount":97},[31787],{"nctId":11743,"briefTitle":11744,"status":155,"phases":31788,"primaryCompletion":11746,"completion":11747,"start":11748,"enrollment":11749,"conditions":31789,"interventions":31790},[87],[15],[11752,11732],{"trials":31792,"activeCount":97},[],{"trials":31794,"activeCount":97},[],{"intervention":31796,"totalTrials":417,"cells":31797},"Adacel",{"EARLY_PHASE1":31798,"PHASE1":31800,"PHASE2":31802,"PHASE3":31804,"PHASE4":31813,"NA":31815},{"trials":31799,"activeCount":97},[],{"trials":31801,"activeCount":97},[],{"trials":31803,"activeCount":97},[],{"trials":31805,"activeCount":97},[31806],{"nctId":31807,"briefTitle":31808,"status":155,"phases":31809,"primaryCompletion":24686,"completion":16102,"start":19786,"enrollment":31810,"conditions":31811,"interventions":31812},"NCT00489970","Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9",[87],1954,[3624,33,30],[5329,31796],{"trials":31814,"activeCount":97},[],{"trials":31816,"activeCount":97},[],{"intervention":25089,"totalTrials":417,"cells":31818},{"EARLY_PHASE1":31819,"PHASE1":31821,"PHASE2":31823,"PHASE3":31825,"PHASE4":31831,"NA":31833},{"trials":31820,"activeCount":97},[],{"trials":31822,"activeCount":97},[],{"trials":31824,"activeCount":97},[],{"trials":31826,"activeCount":97},[31827],{"nctId":25084,"briefTitle":25085,"status":155,"phases":31828,"primaryCompletion":3079,"completion":7590,"start":4757,"enrollment":12560,"conditions":31829,"interventions":31830},[87],[4703,4704],[23033,25089],{"trials":31832,"activeCount":97},[],{"trials":31834,"activeCount":97},[],{"intervention":25206,"totalTrials":417,"cells":31836},{"EARLY_PHASE1":31837,"PHASE1":31839,"PHASE2":31841,"PHASE3":31843,"PHASE4":31849,"NA":31851},{"trials":31838,"activeCount":97},[],{"trials":31840,"activeCount":97},[],{"trials":31842,"activeCount":97},[],{"trials":31844,"activeCount":97},[31845],{"nctId":25200,"briefTitle":25201,"status":155,"phases":31846,"primaryCompletion":7976,"completion":7976,"start":10803,"enrollment":25203,"conditions":31847,"interventions":31848},[87],[9309],[25206,25182],{"trials":31850,"activeCount":97},[],{"trials":31852,"activeCount":97},[],{"intervention":31854,"totalTrials":417,"cells":31855},"Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C",{"EARLY_PHASE1":31856,"PHASE1":31858,"PHASE2":31860,"PHASE3":31862,"PHASE4":31871,"NA":31873},{"trials":31857,"activeCount":97},[],{"trials":31859,"activeCount":97},[],{"trials":31861,"activeCount":97},[],{"trials":31863,"activeCount":97},[31864],{"nctId":31865,"briefTitle":31866,"status":500,"phases":31867,"primaryCompletion":31868,"completion":31868,"start":903,"enrollment":97,"conditions":31869,"interventions":31870},"NCT02730364","An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu",[87],"2017-04-01",[14696],[31854],{"trials":31872,"activeCount":97},[],{"trials":31874,"activeCount":97},[],{"intervention":31876,"totalTrials":417,"cells":31877},"RSVPreF3 vaccine",{"EARLY_PHASE1":31878,"PHASE1":31880,"PHASE2":31882,"PHASE3":31884,"PHASE4":31895,"NA":31897},{"trials":31879,"activeCount":97},[],{"trials":31881,"activeCount":97},[],{"trials":31883,"activeCount":97},[],{"trials":31885,"activeCount":97},[31886],{"nctId":31887,"briefTitle":31888,"status":155,"phases":31889,"primaryCompletion":31890,"completion":31890,"start":31891,"enrollment":31892,"conditions":31893,"interventions":31894},"NCT05705440","A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination\u002FControl",[87],"2025-01-15","2023-02-07",3855,[2620],[31876],{"trials":31896,"activeCount":97},[],{"trials":31898,"activeCount":97},[],{"intervention":23518,"totalTrials":417,"cells":31900},{"EARLY_PHASE1":31901,"PHASE1":31903,"PHASE2":31905,"PHASE3":31907,"PHASE4":31913,"NA":31915},{"trials":31902,"activeCount":97},[],{"trials":31904,"activeCount":97},[],{"trials":31906,"activeCount":97},[],{"trials":31908,"activeCount":97},[31909],{"nctId":23509,"briefTitle":23510,"status":500,"phases":31910,"primaryCompletion":23512,"completion":23513,"start":23514,"enrollment":97,"conditions":31911,"interventions":31912},[87],[23516],[23481,23518],{"trials":31914,"activeCount":97},[],{"trials":31916,"activeCount":97},[],{"intervention":31918,"totalTrials":417,"cells":31919},"Pediarix TM, Infanrix penta TM",{"EARLY_PHASE1":31920,"PHASE1":31922,"PHASE2":31924,"PHASE3":31926,"PHASE4":31935,"NA":31937},{"trials":31921,"activeCount":97},[],{"trials":31923,"activeCount":97},[],{"trials":31925,"activeCount":97},[],{"trials":31927,"activeCount":97},[31928],{"nctId":31929,"briefTitle":31930,"status":155,"phases":31931,"primaryCompletion":7838,"completion":7838,"start":7837,"enrollment":1237,"conditions":31932,"interventions":31933},"NCT00879827","Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants",[87],[30,4702,24,33,3624],[31918,31934],"Hiberix TM",{"trials":31936,"activeCount":97},[],{"trials":31938,"activeCount":97},[],{"intervention":31934,"totalTrials":417,"cells":31940},{"EARLY_PHASE1":31941,"PHASE1":31943,"PHASE2":31945,"PHASE3":31947,"PHASE4":31953,"NA":31955},{"trials":31942,"activeCount":97},[],{"trials":31944,"activeCount":97},[],{"trials":31946,"activeCount":97},[],{"trials":31948,"activeCount":97},[31949],{"nctId":31929,"briefTitle":31930,"status":155,"phases":31950,"primaryCompletion":7838,"completion":7838,"start":7837,"enrollment":1237,"conditions":31951,"interventions":31952},[87],[30,4702,24,33,3624],[31918,31934],{"trials":31954,"activeCount":97},[],{"trials":31956,"activeCount":97},[],{"intervention":31958,"totalTrials":417,"cells":31959},"UMEC\u002FVI Inhalation Powder 62.5\u002F25 mcg via NDPI",{"EARLY_PHASE1":31960,"PHASE1":31962,"PHASE2":31964,"PHASE3":31966,"PHASE4":31977,"NA":31979},{"trials":31961,"activeCount":97},[],{"trials":31963,"activeCount":97},[],{"trials":31965,"activeCount":97},[],{"trials":31967,"activeCount":97},[31968],{"nctId":31969,"briefTitle":31970,"status":155,"phases":31971,"primaryCompletion":31072,"completion":31972,"start":31973,"enrollment":11508,"conditions":31974,"interventions":31975},"NCT01879410","A Study to Compare the Efficacy and Safety of Umeclidinium\u002FVilanterol With Fluticasone Propionate\u002FSalmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2014-01-09","2013-06-13",[15],[31958,31976],"FSC Inhalation Powder 250\u002F50 mcg via ACCUHALER\u002FDISKUS",{"trials":31978,"activeCount":97},[],{"trials":31980,"activeCount":97},[],{"intervention":31976,"totalTrials":417,"cells":31982},{"EARLY_PHASE1":31983,"PHASE1":31985,"PHASE2":31987,"PHASE3":31989,"PHASE4":31995,"NA":31997},{"trials":31984,"activeCount":97},[],{"trials":31986,"activeCount":97},[],{"trials":31988,"activeCount":97},[],{"trials":31990,"activeCount":97},[31991],{"nctId":31969,"briefTitle":31970,"status":155,"phases":31992,"primaryCompletion":31072,"completion":31972,"start":31973,"enrollment":11508,"conditions":31993,"interventions":31994},[87],[15],[31958,31976],{"trials":31996,"activeCount":97},[],{"trials":31998,"activeCount":97},[],{"intervention":32000,"totalTrials":417,"cells":32001},"Diclofenac diethylamine 2.32% gel",{"EARLY_PHASE1":32002,"PHASE1":32004,"PHASE2":32006,"PHASE3":32008,"PHASE4":32019,"NA":32021},{"trials":32003,"activeCount":97},[],{"trials":32005,"activeCount":97},[],{"trials":32007,"activeCount":97},[],{"trials":32009,"activeCount":97},[32010],{"nctId":32011,"briefTitle":32012,"status":155,"phases":32013,"primaryCompletion":32014,"completion":32014,"start":32015,"enrollment":11064,"conditions":32016,"interventions":32017},"NCT04052620","Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study",[87],"2020-11-12","2019-10-24",[9153],[32000,32018],"Diclofenac diethylamine 1.16% gel",{"trials":32020,"activeCount":97},[],{"trials":32022,"activeCount":97},[],{"intervention":32018,"totalTrials":417,"cells":32024},{"EARLY_PHASE1":32025,"PHASE1":32027,"PHASE2":32029,"PHASE3":32031,"PHASE4":32037,"NA":32039},{"trials":32026,"activeCount":97},[],{"trials":32028,"activeCount":97},[],{"trials":32030,"activeCount":97},[],{"trials":32032,"activeCount":97},[32033],{"nctId":32011,"briefTitle":32012,"status":155,"phases":32034,"primaryCompletion":32014,"completion":32014,"start":32015,"enrollment":11064,"conditions":32035,"interventions":32036},[87],[9153],[32000,32018],{"trials":32038,"activeCount":97},[],{"trials":32040,"activeCount":97},[],{"intervention":19109,"totalTrials":417,"cells":32042},{"EARLY_PHASE1":32043,"PHASE1":32045,"PHASE2":32047,"PHASE3":32049,"PHASE4":32055,"NA":32057},{"trials":32044,"activeCount":97},[],{"trials":32046,"activeCount":97},[],{"trials":32048,"activeCount":97},[],{"trials":32050,"activeCount":97},[32051],{"nctId":19102,"briefTitle":19103,"status":155,"phases":32052,"primaryCompletion":19105,"completion":19105,"start":11017,"enrollment":19106,"conditions":32053,"interventions":32054},[87],[4703,4704],[19109,4744,19110,19111,10347,19112,19113,19114,19115],{"trials":32056,"activeCount":97},[],{"trials":32058,"activeCount":97},[],{"intervention":19110,"totalTrials":417,"cells":32060},{"EARLY_PHASE1":32061,"PHASE1":32063,"PHASE2":32065,"PHASE3":32067,"PHASE4":32073,"NA":32075},{"trials":32062,"activeCount":97},[],{"trials":32064,"activeCount":97},[],{"trials":32066,"activeCount":97},[],{"trials":32068,"activeCount":97},[32069],{"nctId":19102,"briefTitle":19103,"status":155,"phases":32070,"primaryCompletion":19105,"completion":19105,"start":11017,"enrollment":19106,"conditions":32071,"interventions":32072},[87],[4703,4704],[19109,4744,19110,19111,10347,19112,19113,19114,19115],{"trials":32074,"activeCount":97},[],{"trials":32076,"activeCount":97},[],{"intervention":19111,"totalTrials":417,"cells":32078},{"EARLY_PHASE1":32079,"PHASE1":32081,"PHASE2":32083,"PHASE3":32085,"PHASE4":32091,"NA":32093},{"trials":32080,"activeCount":97},[],{"trials":32082,"activeCount":97},[],{"trials":32084,"activeCount":97},[],{"trials":32086,"activeCount":97},[32087],{"nctId":19102,"briefTitle":19103,"status":155,"phases":32088,"primaryCompletion":19105,"completion":19105,"start":11017,"enrollment":19106,"conditions":32089,"interventions":32090},[87],[4703,4704],[19109,4744,19110,19111,10347,19112,19113,19114,19115],{"trials":32092,"activeCount":97},[],{"trials":32094,"activeCount":97},[],{"intervention":19112,"totalTrials":417,"cells":32096},{"EARLY_PHASE1":32097,"PHASE1":32099,"PHASE2":32101,"PHASE3":32103,"PHASE4":32109,"NA":32111},{"trials":32098,"activeCount":97},[],{"trials":32100,"activeCount":97},[],{"trials":32102,"activeCount":97},[],{"trials":32104,"activeCount":97},[32105],{"nctId":19102,"briefTitle":19103,"status":155,"phases":32106,"primaryCompletion":19105,"completion":19105,"start":11017,"enrollment":19106,"conditions":32107,"interventions":32108},[87],[4703,4704],[19109,4744,19110,19111,10347,19112,19113,19114,19115],{"trials":32110,"activeCount":97},[],{"trials":32112,"activeCount":97},[],{"intervention":19113,"totalTrials":417,"cells":32114},{"EARLY_PHASE1":32115,"PHASE1":32117,"PHASE2":32119,"PHASE3":32121,"PHASE4":32127,"NA":32129},{"trials":32116,"activeCount":97},[],{"trials":32118,"activeCount":97},[],{"trials":32120,"activeCount":97},[],{"trials":32122,"activeCount":97},[32123],{"nctId":19102,"briefTitle":19103,"status":155,"phases":32124,"primaryCompletion":19105,"completion":19105,"start":11017,"enrollment":19106,"conditions":32125,"interventions":32126},[87],[4703,4704],[19109,4744,19110,19111,10347,19112,19113,19114,19115],{"trials":32128,"activeCount":97},[],{"trials":32130,"activeCount":97},[],{"intervention":19114,"totalTrials":417,"cells":32132},{"EARLY_PHASE1":32133,"PHASE1":32135,"PHASE2":32137,"PHASE3":32139,"PHASE4":32145,"NA":32147},{"trials":32134,"activeCount":97},[],{"trials":32136,"activeCount":97},[],{"trials":32138,"activeCount":97},[],{"trials":32140,"activeCount":97},[32141],{"nctId":19102,"briefTitle":19103,"status":155,"phases":32142,"primaryCompletion":19105,"completion":19105,"start":11017,"enrollment":19106,"conditions":32143,"interventions":32144},[87],[4703,4704],[19109,4744,19110,19111,10347,19112,19113,19114,19115],{"trials":32146,"activeCount":97},[],{"trials":32148,"activeCount":97},[],{"intervention":19115,"totalTrials":417,"cells":32150},{"EARLY_PHASE1":32151,"PHASE1":32153,"PHASE2":32155,"PHASE3":32157,"PHASE4":32163,"NA":32165},{"trials":32152,"activeCount":97},[],{"trials":32154,"activeCount":97},[],{"trials":32156,"activeCount":97},[],{"trials":32158,"activeCount":97},[32159],{"nctId":19102,"briefTitle":19103,"status":155,"phases":32160,"primaryCompletion":19105,"completion":19105,"start":11017,"enrollment":19106,"conditions":32161,"interventions":32162},[87],[4703,4704],[19109,4744,19110,19111,10347,19112,19113,19114,19115],{"trials":32164,"activeCount":97},[],{"trials":32166,"activeCount":97},[],{"intervention":32168,"totalTrials":417,"cells":32169},"GSK 1437173A",{"EARLY_PHASE1":32170,"PHASE1":32172,"PHASE2":32174,"PHASE3":32176,"PHASE4":32187,"NA":32189},{"trials":32171,"activeCount":97},[],{"trials":32173,"activeCount":97},[],{"trials":32175,"activeCount":97},[],{"trials":32177,"activeCount":97},[32178],{"nctId":32179,"briefTitle":32180,"status":155,"phases":32181,"primaryCompletion":32182,"completion":32183,"start":32184,"enrollment":5834,"conditions":32185,"interventions":32186},"NCT01798056","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ\u002Fsu) Vaccine in Adults With Solid Tumours Receiving Chemotherapy",[87],"2015-06-18","2016-05-20","2013-03-06",[1030,18950],[32168],{"trials":32188,"activeCount":97},[],{"trials":32190,"activeCount":97},[],{"intervention":32192,"totalTrials":417,"cells":32193},"tadalafil",{"EARLY_PHASE1":32194,"PHASE1":32196,"PHASE2":32198,"PHASE3":32200,"PHASE4":32210,"NA":32212},{"trials":32195,"activeCount":97},[],{"trials":32197,"activeCount":97},[],{"trials":32199,"activeCount":97},[],{"trials":32201,"activeCount":97},[32202],{"nctId":32203,"briefTitle":32204,"status":155,"phases":32205,"primaryCompletion":3296,"completion":3296,"start":25962,"enrollment":32206,"conditions":32207,"interventions":32208},"NCT01178073","A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)",[87],610,[17209],[32209,32192],"ambrisentan",{"trials":32211,"activeCount":97},[],{"trials":32213,"activeCount":97},[],{"intervention":19413,"totalTrials":417,"cells":32215},{"EARLY_PHASE1":32216,"PHASE1":32218,"PHASE2":32220,"PHASE3":32222,"PHASE4":32228,"NA":32230},{"trials":32217,"activeCount":97},[],{"trials":32219,"activeCount":97},[],{"trials":32221,"activeCount":97},[],{"trials":32223,"activeCount":97},[32224],{"nctId":19405,"briefTitle":19406,"status":155,"phases":32225,"primaryCompletion":2373,"completion":19408,"start":19409,"enrollment":19410,"conditions":32226,"interventions":32227},[87],[33,3624,30],[19413,19414,19415,4809,19416,8674],{"trials":32229,"activeCount":97},[],{"trials":32231,"activeCount":97},[],{"intervention":19414,"totalTrials":417,"cells":32233},{"EARLY_PHASE1":32234,"PHASE1":32236,"PHASE2":32238,"PHASE3":32240,"PHASE4":32246,"NA":32248},{"trials":32235,"activeCount":97},[],{"trials":32237,"activeCount":97},[],{"trials":32239,"activeCount":97},[],{"trials":32241,"activeCount":97},[32242],{"nctId":19405,"briefTitle":19406,"status":155,"phases":32243,"primaryCompletion":2373,"completion":19408,"start":19409,"enrollment":19410,"conditions":32244,"interventions":32245},[87],[33,3624,30],[19413,19414,19415,4809,19416,8674],{"trials":32247,"activeCount":97},[],{"trials":32249,"activeCount":97},[],{"intervention":19415,"totalTrials":417,"cells":32251},{"EARLY_PHASE1":32252,"PHASE1":32254,"PHASE2":32256,"PHASE3":32258,"PHASE4":32264,"NA":32266},{"trials":32253,"activeCount":97},[],{"trials":32255,"activeCount":97},[],{"trials":32257,"activeCount":97},[],{"trials":32259,"activeCount":97},[32260],{"nctId":19405,"briefTitle":19406,"status":155,"phases":32261,"primaryCompletion":2373,"completion":19408,"start":19409,"enrollment":19410,"conditions":32262,"interventions":32263},[87],[33,3624,30],[19413,19414,19415,4809,19416,8674],{"trials":32265,"activeCount":97},[],{"trials":32267,"activeCount":97},[],{"intervention":32269,"totalTrials":417,"cells":32270},"otelixizumab infusion plus physician determined standard of care",{"EARLY_PHASE1":32271,"PHASE1":32273,"PHASE2":32275,"PHASE3":32277,"PHASE4":32286,"NA":32288},{"trials":32272,"activeCount":97},[],{"trials":32274,"activeCount":97},[],{"trials":32276,"activeCount":97},[],{"trials":32278,"activeCount":97},[32279],{"nctId":32280,"briefTitle":32281,"status":155,"phases":32282,"primaryCompletion":16364,"completion":16364,"start":32283,"enrollment":11098,"conditions":32284,"interventions":32285},"NCT00678886","Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1",[87],"2008-07-29",[19499],[32269],{"trials":32287,"activeCount":97},[],{"trials":32289,"activeCount":97},[],{"intervention":32291,"totalTrials":417,"cells":32292},"Decavac™",{"EARLY_PHASE1":32293,"PHASE1":32295,"PHASE2":32297,"PHASE3":32299,"PHASE4":32308,"NA":32310},{"trials":32294,"activeCount":97},[],{"trials":32296,"activeCount":97},[],{"trials":32298,"activeCount":97},[],{"trials":32300,"activeCount":97},[32301],{"nctId":32302,"briefTitle":32303,"status":155,"phases":32304,"primaryCompletion":32305,"completion":9793,"start":18807,"enrollment":10464,"conditions":32306,"interventions":32307},"NCT00835237","Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.",[87],"2009-07-23",[33,3624,30,3649],[11489,32291],{"trials":32309,"activeCount":97},[],{"trials":32311,"activeCount":97},[],{"intervention":20863,"totalTrials":417,"cells":32313},{"EARLY_PHASE1":32314,"PHASE1":32316,"PHASE2":32318,"PHASE3":32320,"PHASE4":32326,"NA":32328},{"trials":32315,"activeCount":97},[],{"trials":32317,"activeCount":97},[],{"trials":32319,"activeCount":97},[],{"trials":32321,"activeCount":97},[32322],{"nctId":20856,"briefTitle":20857,"status":155,"phases":32323,"primaryCompletion":20859,"completion":5053,"start":2757,"enrollment":20860,"conditions":32324,"interventions":32325},[87],[2484,3717,2486,2485],[20863,4749],{"trials":32327,"activeCount":97},[],{"trials":32329,"activeCount":97},[],{"intervention":32331,"totalTrials":417,"cells":32332},"HRV PCV-free liquid vaccine",{"EARLY_PHASE1":32333,"PHASE1":32335,"PHASE2":32337,"PHASE3":32339,"PHASE4":32350,"NA":32352},{"trials":32334,"activeCount":97},[],{"trials":32336,"activeCount":97},[],{"trials":32338,"activeCount":97},[],{"trials":32340,"activeCount":97},[32341],{"nctId":32342,"briefTitle":32343,"status":155,"phases":32344,"primaryCompletion":32345,"completion":2311,"start":32346,"enrollment":32347,"conditions":32348,"interventions":32349},"NCT02914184","Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks",[87],"2018-06-27","2016-10-27",1612,[4759,5000],[32331,4762],{"trials":32351,"activeCount":97},[],{"trials":32353,"activeCount":97},[],{"intervention":32355,"totalTrials":417,"cells":32356},"Acetylcystine",{"EARLY_PHASE1":32357,"PHASE1":32359,"PHASE2":32361,"PHASE3":32363,"PHASE4":32371,"NA":32373},{"trials":32358,"activeCount":97},[],{"trials":32360,"activeCount":97},[],{"trials":32362,"activeCount":97},[],{"trials":32364,"activeCount":97},[32365],{"nctId":32366,"briefTitle":32367,"status":155,"phases":32368,"primaryCompletion":19326,"completion":19326,"start":492,"enrollment":7712,"conditions":32369,"interventions":32370},"NCT02822287","Warming Sensation and Tolerability Study of Acetylcysteine 2% Oral Solution for Productive Cough",[87],[9183],[32355],{"trials":32372,"activeCount":97},[],{"trials":32374,"activeCount":97},[],{"intervention":10674,"totalTrials":417,"cells":32376},{"EARLY_PHASE1":32377,"PHASE1":32379,"PHASE2":32381,"PHASE3":32383,"PHASE4":32389,"NA":32391},{"trials":32378,"activeCount":97},[],{"trials":32380,"activeCount":97},[],{"trials":32382,"activeCount":97},[],{"trials":32384,"activeCount":97},[32385],{"nctId":10667,"briefTitle":10668,"status":155,"phases":32386,"start":10670,"enrollment":10671,"conditions":32387,"interventions":32388},[87],[10662,9343],[10674,10675,10676,10677,10678,10679,10680],{"trials":32390,"activeCount":97},[],{"trials":32392,"activeCount":97},[],{"intervention":10676,"totalTrials":417,"cells":32394},{"EARLY_PHASE1":32395,"PHASE1":32397,"PHASE2":32399,"PHASE3":32401,"PHASE4":32407,"NA":32409},{"trials":32396,"activeCount":97},[],{"trials":32398,"activeCount":97},[],{"trials":32400,"activeCount":97},[],{"trials":32402,"activeCount":97},[32403],{"nctId":10667,"briefTitle":10668,"status":155,"phases":32404,"start":10670,"enrollment":10671,"conditions":32405,"interventions":32406},[87],[10662,9343],[10674,10675,10676,10677,10678,10679,10680],{"trials":32408,"activeCount":97},[],{"trials":32410,"activeCount":97},[],{"intervention":10677,"totalTrials":417,"cells":32412},{"EARLY_PHASE1":32413,"PHASE1":32415,"PHASE2":32417,"PHASE3":32419,"PHASE4":32425,"NA":32427},{"trials":32414,"activeCount":97},[],{"trials":32416,"activeCount":97},[],{"trials":32418,"activeCount":97},[],{"trials":32420,"activeCount":97},[32421],{"nctId":10667,"briefTitle":10668,"status":155,"phases":32422,"start":10670,"enrollment":10671,"conditions":32423,"interventions":32424},[87],[10662,9343],[10674,10675,10676,10677,10678,10679,10680],{"trials":32426,"activeCount":97},[],{"trials":32428,"activeCount":97},[],{"intervention":10678,"totalTrials":417,"cells":32430},{"EARLY_PHASE1":32431,"PHASE1":32433,"PHASE2":32435,"PHASE3":32437,"PHASE4":32443,"NA":32445},{"trials":32432,"activeCount":97},[],{"trials":32434,"activeCount":97},[],{"trials":32436,"activeCount":97},[],{"trials":32438,"activeCount":97},[32439],{"nctId":10667,"briefTitle":10668,"status":155,"phases":32440,"start":10670,"enrollment":10671,"conditions":32441,"interventions":32442},[87],[10662,9343],[10674,10675,10676,10677,10678,10679,10680],{"trials":32444,"activeCount":97},[],{"trials":32446,"activeCount":97},[],{"intervention":32448,"totalTrials":417,"cells":32449},"GSK pandemic vaccine GSK2340272A",{"EARLY_PHASE1":32450,"PHASE1":32452,"PHASE2":32454,"PHASE3":32456,"PHASE4":32464,"NA":32466},{"trials":32451,"activeCount":97},[],{"trials":32453,"activeCount":97},[],{"trials":32455,"activeCount":97},[],{"trials":32457,"activeCount":97},[32458],{"nctId":32459,"briefTitle":32460,"status":145,"phases":32461,"primaryCompletion":18982,"completion":18982,"start":3426,"enrollment":1237,"conditions":32462,"interventions":32463},"NCT01014091","Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children",[87],[21],[32448],{"trials":32465,"activeCount":97},[],{"trials":32467,"activeCount":97},[],{"intervention":32469,"totalTrials":417,"cells":32470},"GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine",{"EARLY_PHASE1":32471,"PHASE1":32473,"PHASE2":32475,"PHASE3":32477,"PHASE4":32489,"NA":32491},{"trials":32472,"activeCount":97},[],{"trials":32474,"activeCount":97},[],{"trials":32476,"activeCount":97},[],{"trials":32478,"activeCount":97},[32479],{"nctId":32480,"briefTitle":32481,"status":155,"phases":32482,"primaryCompletion":7767,"completion":7767,"start":32483,"enrollment":7891,"conditions":32484,"interventions":32486},"NCT01262924","Study of Reduced-antigen-content Acellular Pertussis Vaccine and Diphtheria-Tetanus-Acellular Pertussis Vaccine",[87],"1997-10",[32485],"Diphteria, Tetanus and Pertussis",[32469,32487,32488],"GSK Biologicals' reduced-antigen-content acellular pertussis vaccine","Tedivax-Adult™\u002F Td-Rix™",{"trials":32490,"activeCount":97},[],{"trials":32492,"activeCount":97},[],{"intervention":32487,"totalTrials":417,"cells":32494},{"EARLY_PHASE1":32495,"PHASE1":32497,"PHASE2":32499,"PHASE3":32501,"PHASE4":32507,"NA":32509},{"trials":32496,"activeCount":97},[],{"trials":32498,"activeCount":97},[],{"trials":32500,"activeCount":97},[],{"trials":32502,"activeCount":97},[32503],{"nctId":32480,"briefTitle":32481,"status":155,"phases":32504,"primaryCompletion":7767,"completion":7767,"start":32483,"enrollment":7891,"conditions":32505,"interventions":32506},[87],[32485],[32469,32487,32488],{"trials":32508,"activeCount":97},[],{"trials":32510,"activeCount":97},[],{"intervention":32488,"totalTrials":417,"cells":32512},{"EARLY_PHASE1":32513,"PHASE1":32515,"PHASE2":32517,"PHASE3":32519,"PHASE4":32525,"NA":32527},{"trials":32514,"activeCount":97},[],{"trials":32516,"activeCount":97},[],{"trials":32518,"activeCount":97},[],{"trials":32520,"activeCount":97},[32521],{"nctId":32480,"briefTitle":32481,"status":155,"phases":32522,"primaryCompletion":7767,"completion":7767,"start":32483,"enrollment":7891,"conditions":32523,"interventions":32524},[87],[32485],[32469,32487,32488],{"trials":32526,"activeCount":97},[],{"trials":32528,"activeCount":97},[],{"intervention":32530,"totalTrials":417,"cells":32531},"GSK573719\u002FVI 62.5\u002F25",{"EARLY_PHASE1":32532,"PHASE1":32534,"PHASE2":32536,"PHASE3":32538,"PHASE4":32548,"NA":32550},{"trials":32533,"activeCount":97},[],{"trials":32535,"activeCount":97},[],{"trials":32537,"activeCount":97},[],{"trials":32539,"activeCount":97},[32540],{"nctId":32541,"briefTitle":32542,"status":155,"phases":32543,"primaryCompletion":3045,"completion":3045,"start":8037,"enrollment":32544,"conditions":32545,"interventions":32546},"NCT01636713","A 24-week Study to Evaluate the Efficacy and Safety of GSK573719\u002FGW642444 125\u002F25 mcg and 62.5\u002F25mcg Inhalation Powder Compared With Placebo in Subjects With COPD",[87],581,[15],[32530,32547],"GSK573719\u002FVI 125\u002F25",{"trials":32549,"activeCount":97},[],{"trials":32551,"activeCount":97},[],{"intervention":32547,"totalTrials":417,"cells":32553},{"EARLY_PHASE1":32554,"PHASE1":32556,"PHASE2":32558,"PHASE3":32560,"PHASE4":32566,"NA":32568},{"trials":32555,"activeCount":97},[],{"trials":32557,"activeCount":97},[],{"trials":32559,"activeCount":97},[],{"trials":32561,"activeCount":97},[32562],{"nctId":32541,"briefTitle":32542,"status":155,"phases":32563,"primaryCompletion":3045,"completion":3045,"start":8037,"enrollment":32544,"conditions":32564,"interventions":32565},[87],[15],[32530,32547],{"trials":32567,"activeCount":97},[],{"trials":32569,"activeCount":97},[],{"intervention":32571,"totalTrials":417,"cells":32572},"Influsplit™ Tetra",{"EARLY_PHASE1":32573,"PHASE1":32575,"PHASE2":32577,"PHASE3":32579,"PHASE4":32591,"NA":32593},{"trials":32574,"activeCount":97},[],{"trials":32576,"activeCount":97},[],{"trials":32578,"activeCount":97},[],{"trials":32580,"activeCount":97},[32581],{"nctId":32582,"briefTitle":32583,"status":155,"phases":32584,"primaryCompletion":32585,"completion":11645,"start":32586,"enrollment":32587,"conditions":32588,"interventions":32589},"NCT02218697","Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older",[87],"2015-01-14","2014-10-01",357,[21],[32571,32590],"Pneumovax™ 23",{"trials":32592,"activeCount":97},[],{"trials":32594,"activeCount":97},[],{"intervention":32590,"totalTrials":417,"cells":32596},{"EARLY_PHASE1":32597,"PHASE1":32599,"PHASE2":32601,"PHASE3":32603,"PHASE4":32609,"NA":32611},{"trials":32598,"activeCount":97},[],{"trials":32600,"activeCount":97},[],{"trials":32602,"activeCount":97},[],{"trials":32604,"activeCount":97},[32605],{"nctId":32582,"briefTitle":32583,"status":155,"phases":32606,"primaryCompletion":32585,"completion":11645,"start":32586,"enrollment":32587,"conditions":32607,"interventions":32608},[87],[21],[32571,32590],{"trials":32610,"activeCount":97},[],{"trials":32612,"activeCount":97},[],{"intervention":32614,"totalTrials":417,"cells":32615},"bupropion XL",{"EARLY_PHASE1":32616,"PHASE1":32618,"PHASE2":32620,"PHASE3":32622,"PHASE4":32631,"NA":32633},{"trials":32617,"activeCount":97},[],{"trials":32619,"activeCount":97},[],{"trials":32621,"activeCount":97},[],{"trials":32623,"activeCount":97},[32624],{"nctId":32625,"briefTitle":32626,"status":155,"phases":32627,"primaryCompletion":2805,"completion":2805,"start":3036,"enrollment":32628,"conditions":32629,"interventions":32630},"NCT00093288","Major Depressive Disorder In The Elderly",[87],364,[10889],[32614],{"trials":32632,"activeCount":97},[],{"trials":32634,"activeCount":97},[],{"intervention":8111,"totalTrials":417,"cells":32636},{"EARLY_PHASE1":32637,"PHASE1":32639,"PHASE2":32641,"PHASE3":32643,"PHASE4":32649,"NA":32651},{"trials":32638,"activeCount":97},[],{"trials":32640,"activeCount":97},[],{"trials":32642,"activeCount":97},[],{"trials":32644,"activeCount":97},[32645],{"nctId":8103,"briefTitle":8104,"status":155,"phases":32646,"primaryCompletion":8106,"completion":8106,"start":8107,"enrollment":8108,"conditions":32647,"interventions":32648},[87],[27],[8021,8111],{"trials":32650,"activeCount":97},[],{"trials":32652,"activeCount":97},[],{"intervention":21057,"totalTrials":417,"cells":32654},{"EARLY_PHASE1":32655,"PHASE1":32657,"PHASE2":32659,"PHASE3":32661,"PHASE4":32667,"NA":32669},{"trials":32656,"activeCount":97},[],{"trials":32658,"activeCount":97},[],{"trials":32660,"activeCount":97},[],{"trials":32662,"activeCount":97},[32663],{"nctId":21049,"briefTitle":21050,"status":155,"phases":32664,"primaryCompletion":7976,"completion":7976,"start":10803,"enrollment":21052,"conditions":32665,"interventions":32666},[87],[21054],[21056,21057,21013],{"trials":32668,"activeCount":97},[],{"trials":32670,"activeCount":97},[],{"intervention":26567,"totalTrials":417,"cells":32672},{"EARLY_PHASE1":32673,"PHASE1":32675,"PHASE2":32677,"PHASE3":32679,"PHASE4":32685,"NA":32687},{"trials":32674,"activeCount":97},[],{"trials":32676,"activeCount":97},[],{"trials":32678,"activeCount":97},[],{"trials":32680,"activeCount":97},[32681],{"nctId":26560,"briefTitle":26561,"status":155,"phases":32682,"primaryCompletion":16364,"completion":16364,"start":26563,"enrollment":26564,"conditions":32683,"interventions":32684},[87],[3637,8918],[26567,19132,19133],{"trials":32686,"activeCount":97},[],{"trials":32688,"activeCount":97},[],{"intervention":32690,"totalTrials":417,"cells":32691},"Ezogabine: USAN Retigabine",{"EARLY_PHASE1":32692,"PHASE1":32694,"PHASE2":32696,"PHASE3":32698,"PHASE4":32709,"NA":32711},{"trials":32693,"activeCount":97},[],{"trials":32695,"activeCount":97},[],{"trials":32697,"activeCount":97},[],{"trials":32699,"activeCount":97},[32700],{"nctId":32701,"briefTitle":32702,"status":155,"phases":32703,"primaryCompletion":32704,"completion":32705,"start":920,"enrollment":32706,"conditions":32707,"interventions":32708},"NCT00310375","Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial",[87],"2016-11-30","2017-03-15",181,[12518],[32690],{"trials":32710,"activeCount":97},[],{"trials":32712,"activeCount":97},[],{"intervention":32714,"totalTrials":417,"cells":32715},"0.254% w\u002Fw sodium fluoride and 5% KNO3",{"EARLY_PHASE1":32716,"PHASE1":32718,"PHASE2":32720,"PHASE3":32722,"PHASE4":32734,"NA":32736},{"trials":32717,"activeCount":97},[],{"trials":32719,"activeCount":97},[],{"trials":32721,"activeCount":97},[],{"trials":32723,"activeCount":97},[32724],{"nctId":32725,"briefTitle":32726,"status":155,"phases":32727,"primaryCompletion":32728,"completion":32728,"start":930,"enrollment":234,"conditions":32729,"interventions":32731},"NCT03296072","In Situ Erosion Study to Investigate the Effectiveness of an Experimental Toothpaste",[87],"2018-01-16",[32730],"Tooth Erosion",[32714,32732,32733],"0.454% w\u002Fw stannous fluoride","5% KNO3",{"trials":32735,"activeCount":97},[],{"trials":32737,"activeCount":97},[],{"intervention":32732,"totalTrials":417,"cells":32739},{"EARLY_PHASE1":32740,"PHASE1":32742,"PHASE2":32744,"PHASE3":32746,"PHASE4":32752,"NA":32754},{"trials":32741,"activeCount":97},[],{"trials":32743,"activeCount":97},[],{"trials":32745,"activeCount":97},[],{"trials":32747,"activeCount":97},[32748],{"nctId":32725,"briefTitle":32726,"status":155,"phases":32749,"primaryCompletion":32728,"completion":32728,"start":930,"enrollment":234,"conditions":32750,"interventions":32751},[87],[32730],[32714,32732,32733],{"trials":32753,"activeCount":97},[],{"trials":32755,"activeCount":97},[],{"intervention":32733,"totalTrials":417,"cells":32757},{"EARLY_PHASE1":32758,"PHASE1":32760,"PHASE2":32762,"PHASE3":32764,"PHASE4":32770,"NA":32772},{"trials":32759,"activeCount":97},[],{"trials":32761,"activeCount":97},[],{"trials":32763,"activeCount":97},[],{"trials":32765,"activeCount":97},[32766],{"nctId":32725,"briefTitle":32726,"status":155,"phases":32767,"primaryCompletion":32728,"completion":32728,"start":930,"enrollment":234,"conditions":32768,"interventions":32769},[87],[32730],[32714,32732,32733],{"trials":32771,"activeCount":97},[],{"trials":32773,"activeCount":97},[],{"intervention":32775,"totalTrials":417,"cells":32776},"Extended-release bupropion",{"EARLY_PHASE1":32777,"PHASE1":32779,"PHASE2":32781,"PHASE3":32783,"PHASE4":32792,"NA":32794},{"trials":32778,"activeCount":97},[],{"trials":32780,"activeCount":97},[],{"trials":32782,"activeCount":97},[],{"trials":32784,"activeCount":97},[32785],{"nctId":32786,"briefTitle":32787,"status":155,"phases":32788,"primaryCompletion":8386,"completion":8386,"start":10886,"enrollment":32789,"conditions":32790,"interventions":32791},"NCT00064467","Lethargic Depression Study",[87],268,[12518,10890],[32775],{"trials":32793,"activeCount":97},[],{"trials":32795,"activeCount":97},[],{"intervention":26659,"totalTrials":417,"cells":32797},{"EARLY_PHASE1":32798,"PHASE1":32800,"PHASE2":32802,"PHASE3":32804,"PHASE4":32810,"NA":32812},{"trials":32799,"activeCount":97},[],{"trials":32801,"activeCount":97},[],{"trials":32803,"activeCount":97},[],{"trials":32805,"activeCount":97},[32806],{"nctId":26653,"briefTitle":26654,"status":155,"phases":32807,"primaryCompletion":11656,"completion":26656,"start":1874,"enrollment":18256,"conditions":32808,"interventions":32809},[87],[9153],[26659,26660,26631],{"trials":32811,"activeCount":97},[],{"trials":32813,"activeCount":97},[],{"intervention":26660,"totalTrials":417,"cells":32815},{"EARLY_PHASE1":32816,"PHASE1":32818,"PHASE2":32820,"PHASE3":32822,"PHASE4":32828,"NA":32830},{"trials":32817,"activeCount":97},[],{"trials":32819,"activeCount":97},[],{"trials":32821,"activeCount":97},[],{"trials":32823,"activeCount":97},[32824],{"nctId":26653,"briefTitle":26654,"status":155,"phases":32825,"primaryCompletion":11656,"completion":26656,"start":1874,"enrollment":18256,"conditions":32826,"interventions":32827},[87],[9153],[26659,26660,26631],{"trials":32829,"activeCount":97},[],{"trials":32831,"activeCount":97},[],{"intervention":9956,"totalTrials":417,"cells":32833},{"EARLY_PHASE1":32834,"PHASE1":32836,"PHASE2":32838,"PHASE3":32840,"PHASE4":32846,"NA":32848},{"trials":32835,"activeCount":97},[],{"trials":32837,"activeCount":97},[],{"trials":32839,"activeCount":97},[],{"trials":32841,"activeCount":97},[32842],{"nctId":9949,"briefTitle":9950,"status":155,"phases":32843,"primaryCompletion":9952,"completion":9953,"start":4855,"enrollment":1307,"conditions":32844,"interventions":32845},[87],[21],[9956,9957,9920,8350],{"trials":32847,"activeCount":97},[],{"trials":32849,"activeCount":97},[],{"intervention":9957,"totalTrials":417,"cells":32851},{"EARLY_PHASE1":32852,"PHASE1":32854,"PHASE2":32856,"PHASE3":32858,"PHASE4":32864,"NA":32866},{"trials":32853,"activeCount":97},[],{"trials":32855,"activeCount":97},[],{"trials":32857,"activeCount":97},[],{"trials":32859,"activeCount":97},[32860],{"nctId":9949,"briefTitle":9950,"status":155,"phases":32861,"primaryCompletion":9952,"completion":9953,"start":4855,"enrollment":1307,"conditions":32862,"interventions":32863},[87],[21],[9956,9957,9920,8350],{"trials":32865,"activeCount":97},[],{"trials":32867,"activeCount":97},[],{"intervention":9094,"totalTrials":417,"cells":32869},{"EARLY_PHASE1":32870,"PHASE1":32872,"PHASE2":32874,"PHASE3":32876,"PHASE4":32882,"NA":32884},{"trials":32871,"activeCount":97},[],{"trials":32873,"activeCount":97},[],{"trials":32875,"activeCount":97},[],{"trials":32877,"activeCount":97},[32878],{"nctId":9084,"briefTitle":9085,"status":155,"phases":32879,"primaryCompletion":9087,"completion":9088,"start":9089,"enrollment":9090,"conditions":32880,"interventions":32881},[87],[27],[9093,9094,8128],{"trials":32883,"activeCount":97},[],{"trials":32885,"activeCount":97},[],{"intervention":32887,"totalTrials":417,"cells":32888},"10 valent pneumococcal conjugate",{"EARLY_PHASE1":32889,"PHASE1":32891,"PHASE2":32893,"PHASE3":32895,"PHASE4":32903,"NA":32905},{"trials":32890,"activeCount":97},[],{"trials":32892,"activeCount":97},[],{"trials":32894,"activeCount":97},[],{"trials":32896,"activeCount":97},[32897],{"nctId":32898,"briefTitle":32899,"status":155,"phases":32900,"completion":748,"start":2404,"enrollment":26758,"conditions":32901,"interventions":32902},"NCT00370227","Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine",[87],[3637],[32887],{"trials":32904,"activeCount":97},[],{"trials":32906,"activeCount":97},[],{"intervention":32908,"totalTrials":417,"cells":32909},"Ropinirole CR 2mg",{"EARLY_PHASE1":32910,"PHASE1":32912,"PHASE2":32914,"PHASE3":32916,"PHASE4":32928,"NA":32930},{"trials":32911,"activeCount":97},[],{"trials":32913,"activeCount":97},[],{"trials":32915,"activeCount":97},[],{"trials":32917,"activeCount":97},[32918],{"nctId":32919,"briefTitle":32920,"status":145,"phases":32921,"primaryCompletion":32922,"completion":32923,"start":32924,"enrollment":8861,"conditions":32925,"interventions":32926},"NCT01929317","A Study to Evaluate the Efficacy of 18 to 24mg\u002FDay Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.",[87],"2014-09-16","2015-06-09","2013-08-28",[15879],[32908,32927],"Ropinirole CR 8mg",{"trials":32929,"activeCount":97},[],{"trials":32931,"activeCount":97},[],{"intervention":32927,"totalTrials":417,"cells":32933},{"EARLY_PHASE1":32934,"PHASE1":32936,"PHASE2":32938,"PHASE3":32940,"PHASE4":32946,"NA":32948},{"trials":32935,"activeCount":97},[],{"trials":32937,"activeCount":97},[],{"trials":32939,"activeCount":97},[],{"trials":32941,"activeCount":97},[32942],{"nctId":32919,"briefTitle":32920,"status":145,"phases":32943,"primaryCompletion":32922,"completion":32923,"start":32924,"enrollment":8861,"conditions":32944,"interventions":32945},[87],[15879],[32908,32927],{"trials":32947,"activeCount":97},[],{"trials":32949,"activeCount":97},[],{"intervention":32951,"totalTrials":417,"cells":32952},"GSK573719\u002FGW642444 Inhalation Powder",{"EARLY_PHASE1":32953,"PHASE1":32955,"PHASE2":32957,"PHASE3":32959,"PHASE4":32967,"NA":32969},{"trials":32954,"activeCount":97},[],{"trials":32956,"activeCount":97},[],{"trials":32958,"activeCount":97},[],{"trials":32960,"activeCount":97},[32961],{"nctId":32962,"briefTitle":32963,"status":155,"phases":32964,"primaryCompletion":9728,"completion":9728,"start":9682,"enrollment":8337,"conditions":32965,"interventions":32966},"NCT01376388","Long-term Safety Study for GSK573719\u002FGW642444 in Japanese",[87],[15],[32951],{"trials":32968,"activeCount":97},[],{"trials":32970,"activeCount":97},[],{"intervention":32972,"totalTrials":417,"cells":32973},"Pneumococcal conjugate vaccine GSK 1024850A",{"EARLY_PHASE1":32974,"PHASE1":32976,"PHASE2":32978,"PHASE3":32980,"PHASE4":32990,"NA":32992},{"trials":32975,"activeCount":97},[],{"trials":32977,"activeCount":97},[],{"trials":32979,"activeCount":97},[],{"trials":32981,"activeCount":97},[32982],{"nctId":32983,"briefTitle":32984,"status":155,"phases":32985,"primaryCompletion":22171,"completion":22171,"start":32986,"enrollment":3025,"conditions":32987,"interventions":32988},"NCT00907777","Vaccination With GSK 1024850A in Children Primed With GSK 1024850A & Boosted With Pneumovax 23™",[87],"2009-06-23",[3637,8918],[32972,32989],"Pneumococcal conjugate vaccine Prevenar™",{"trials":32991,"activeCount":97},[],{"trials":32993,"activeCount":97},[],{"intervention":32989,"totalTrials":417,"cells":32995},{"EARLY_PHASE1":32996,"PHASE1":32998,"PHASE2":33000,"PHASE3":33002,"PHASE4":33008,"NA":33010},{"trials":32997,"activeCount":97},[],{"trials":32999,"activeCount":97},[],{"trials":33001,"activeCount":97},[],{"trials":33003,"activeCount":97},[33004],{"nctId":32983,"briefTitle":32984,"status":155,"phases":33005,"primaryCompletion":22171,"completion":22171,"start":32986,"enrollment":3025,"conditions":33006,"interventions":33007},[87],[3637,8918],[32972,32989],{"trials":33009,"activeCount":97},[],{"trials":33011,"activeCount":97},[],{"intervention":10006,"totalTrials":417,"cells":33013},{"EARLY_PHASE1":33014,"PHASE1":33016,"PHASE2":33018,"PHASE3":33020,"PHASE4":33026,"NA":33028},{"trials":33015,"activeCount":97},[],{"trials":33017,"activeCount":97},[],{"trials":33019,"activeCount":97},[],{"trials":33021,"activeCount":97},[33022],{"nctId":9999,"briefTitle":10000,"status":155,"phases":33023,"primaryCompletion":10002,"completion":10002,"start":10003,"enrollment":895,"conditions":33024,"interventions":33025},[87],[33,30,3624],[10006,9916,10007,10008],{"trials":33027,"activeCount":97},[],{"trials":33029,"activeCount":97},[],{"intervention":10007,"totalTrials":417,"cells":33031},{"EARLY_PHASE1":33032,"PHASE1":33034,"PHASE2":33036,"PHASE3":33038,"PHASE4":33044,"NA":33046},{"trials":33033,"activeCount":97},[],{"trials":33035,"activeCount":97},[],{"trials":33037,"activeCount":97},[],{"trials":33039,"activeCount":97},[33040],{"nctId":9999,"briefTitle":10000,"status":155,"phases":33041,"primaryCompletion":10002,"completion":10002,"start":10003,"enrollment":895,"conditions":33042,"interventions":33043},[87],[33,30,3624],[10006,9916,10007,10008],{"trials":33045,"activeCount":97},[],{"trials":33047,"activeCount":97},[],{"intervention":10008,"totalTrials":417,"cells":33049},{"EARLY_PHASE1":33050,"PHASE1":33052,"PHASE2":33054,"PHASE3":33056,"PHASE4":33062,"NA":33064},{"trials":33051,"activeCount":97},[],{"trials":33053,"activeCount":97},[],{"trials":33055,"activeCount":97},[],{"trials":33057,"activeCount":97},[33058],{"nctId":9999,"briefTitle":10000,"status":155,"phases":33059,"primaryCompletion":10002,"completion":10002,"start":10003,"enrollment":895,"conditions":33060,"interventions":33061},[87],[33,30,3624],[10006,9916,10007,10008],{"trials":33063,"activeCount":97},[],{"trials":33065,"activeCount":97},[],{"intervention":1773,"totalTrials":417,"cells":33067},{"EARLY_PHASE1":33068,"PHASE1":33070,"PHASE2":33072,"PHASE3":33074,"PHASE4":33080,"NA":33082},{"trials":33069,"activeCount":97},[],{"trials":33071,"activeCount":97},[],{"trials":33073,"activeCount":97},[],{"trials":33075,"activeCount":97},[33076],{"nctId":1764,"briefTitle":1765,"status":145,"phases":33077,"primaryCompletion":1767,"completion":1768,"start":1769,"enrollment":1770,"conditions":33078,"interventions":33079},[87],[305],[246,137,1773,1774],{"trials":33081,"activeCount":97},[],{"trials":33083,"activeCount":97},[],{"intervention":18810,"totalTrials":417,"cells":33085},{"EARLY_PHASE1":33086,"PHASE1":33088,"PHASE2":33090,"PHASE3":33092,"PHASE4":33098,"NA":33100},{"trials":33087,"activeCount":97},[],{"trials":33089,"activeCount":97},[],{"trials":33091,"activeCount":97},[],{"trials":33093,"activeCount":97},[33094],{"nctId":18802,"briefTitle":18803,"status":155,"phases":33095,"primaryCompletion":18805,"completion":18806,"start":18807,"enrollment":12261,"conditions":33096,"interventions":33097},[87],[3637],[3639,12323,18810,4762,18811],{"trials":33099,"activeCount":97},[],{"trials":33101,"activeCount":97},[],{"intervention":18811,"totalTrials":417,"cells":33103},{"EARLY_PHASE1":33104,"PHASE1":33106,"PHASE2":33108,"PHASE3":33110,"PHASE4":33116,"NA":33118},{"trials":33105,"activeCount":97},[],{"trials":33107,"activeCount":97},[],{"trials":33109,"activeCount":97},[],{"trials":33111,"activeCount":97},[33112],{"nctId":18802,"briefTitle":18803,"status":155,"phases":33113,"primaryCompletion":18805,"completion":18806,"start":18807,"enrollment":12261,"conditions":33114,"interventions":33115},[87],[3637],[3639,12323,18810,4762,18811],{"trials":33117,"activeCount":97},[],{"trials":33119,"activeCount":97},[],{"intervention":23266,"totalTrials":417,"cells":33121},{"EARLY_PHASE1":33122,"PHASE1":33124,"PHASE2":33126,"PHASE3":33128,"PHASE4":33134,"NA":33136},{"trials":33123,"activeCount":97},[],{"trials":33125,"activeCount":97},[],{"trials":33127,"activeCount":97},[],{"trials":33129,"activeCount":97},[33130],{"nctId":23258,"briefTitle":23259,"status":155,"phases":33131,"primaryCompletion":23261,"completion":23261,"start":23262,"enrollment":23263,"conditions":33132,"interventions":33133},[87],[7966],[23266,7791],{"trials":33135,"activeCount":97},[],{"trials":33137,"activeCount":97},[],{"intervention":24197,"totalTrials":417,"cells":33139},{"EARLY_PHASE1":33140,"PHASE1":33142,"PHASE2":33144,"PHASE3":33146,"PHASE4":33152,"NA":33154},{"trials":33141,"activeCount":97},[],{"trials":33143,"activeCount":97},[],{"trials":33145,"activeCount":97},[],{"trials":33147,"activeCount":97},[33148],{"nctId":24190,"briefTitle":24191,"status":155,"phases":33149,"primaryCompletion":24181,"completion":24193,"start":24194,"enrollment":4388,"conditions":33150,"interventions":33151},[87],[992],[24168,24197],{"trials":33153,"activeCount":97},[],{"trials":33155,"activeCount":97},[],{"intervention":33157,"totalTrials":417,"cells":33158},"GSK Biologicals'Kinrix®",{"EARLY_PHASE1":33159,"PHASE1":33161,"PHASE2":33163,"PHASE3":33165,"PHASE4":33177,"NA":33179},{"trials":33160,"activeCount":97},[],{"trials":33162,"activeCount":97},[],{"trials":33164,"activeCount":97},[],{"trials":33166,"activeCount":97},[33167],{"nctId":33168,"briefTitle":33169,"status":155,"phases":33170,"primaryCompletion":33171,"completion":10039,"start":33172,"enrollment":22362,"conditions":33173,"interventions":33174},"NCT00871117","Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Years",[87],"2010-01-15","2009-03-31",[33,3624,30],[33157,33175,33176],"Merck and Company's MMRII","Merck and Company's Varivax",{"trials":33178,"activeCount":97},[],{"trials":33180,"activeCount":97},[],{"intervention":33175,"totalTrials":417,"cells":33182},{"EARLY_PHASE1":33183,"PHASE1":33185,"PHASE2":33187,"PHASE3":33189,"PHASE4":33195,"NA":33197},{"trials":33184,"activeCount":97},[],{"trials":33186,"activeCount":97},[],{"trials":33188,"activeCount":97},[],{"trials":33190,"activeCount":97},[33191],{"nctId":33168,"briefTitle":33169,"status":155,"phases":33192,"primaryCompletion":33171,"completion":10039,"start":33172,"enrollment":22362,"conditions":33193,"interventions":33194},[87],[33,3624,30],[33157,33175,33176],{"trials":33196,"activeCount":97},[],{"trials":33198,"activeCount":97},[],{"intervention":33176,"totalTrials":417,"cells":33200},{"EARLY_PHASE1":33201,"PHASE1":33203,"PHASE2":33205,"PHASE3":33207,"PHASE4":33213,"NA":33215},{"trials":33202,"activeCount":97},[],{"trials":33204,"activeCount":97},[],{"trials":33206,"activeCount":97},[],{"trials":33208,"activeCount":97},[33209],{"nctId":33168,"briefTitle":33169,"status":155,"phases":33210,"primaryCompletion":33171,"completion":10039,"start":33172,"enrollment":22362,"conditions":33211,"interventions":33212},[87],[33,3624,30],[33157,33175,33176],{"trials":33214,"activeCount":97},[],{"trials":33216,"activeCount":97},[],{"intervention":10110,"totalTrials":417,"cells":33218},{"EARLY_PHASE1":33219,"PHASE1":33221,"PHASE2":33223,"PHASE3":33225,"PHASE4":33231,"NA":33233},{"trials":33220,"activeCount":97},[],{"trials":33222,"activeCount":97},[],{"trials":33224,"activeCount":97},[],{"trials":33226,"activeCount":97},[33227],{"nctId":10103,"briefTitle":10104,"status":155,"phases":33228,"primaryCompletion":10106,"completion":10106,"start":10107,"enrollment":569,"conditions":33229,"interventions":33230},[87],[24,30,10086,4702,10087,33],[10065,10110,10111],{"trials":33232,"activeCount":97},[],{"trials":33234,"activeCount":97},[],{"intervention":10111,"totalTrials":417,"cells":33236},{"EARLY_PHASE1":33237,"PHASE1":33239,"PHASE2":33241,"PHASE3":33243,"PHASE4":33249,"NA":33251},{"trials":33238,"activeCount":97},[],{"trials":33240,"activeCount":97},[],{"trials":33242,"activeCount":97},[],{"trials":33244,"activeCount":97},[33245],{"nctId":10103,"briefTitle":10104,"status":155,"phases":33246,"primaryCompletion":10106,"completion":10106,"start":10107,"enrollment":569,"conditions":33247,"interventions":33248},[87],[24,30,10086,4702,10087,33],[10065,10110,10111],{"trials":33250,"activeCount":97},[],{"trials":33252,"activeCount":97},[],{"intervention":23010,"totalTrials":417,"cells":33254},{"EARLY_PHASE1":33255,"PHASE1":33257,"PHASE2":33259,"PHASE3":33261,"PHASE4":33267,"NA":33269},{"trials":33256,"activeCount":97},[],{"trials":33258,"activeCount":97},[],{"trials":33260,"activeCount":97},[],{"trials":33262,"activeCount":97},[33263],{"nctId":23002,"briefTitle":23003,"status":145,"phases":33264,"primaryCompletion":23005,"completion":23005,"start":23006,"enrollment":23007,"conditions":33265,"interventions":33266},[87],[8788],[20891,23010],{"trials":33268,"activeCount":97},[],{"trials":33270,"activeCount":97},[],{"intervention":33272,"totalTrials":417,"cells":33273},"undecavalent pneumococcal-protein D conjugate vaccine",{"EARLY_PHASE1":33274,"PHASE1":33276,"PHASE2":33278,"PHASE3":33280,"PHASE4":33290,"NA":33292},{"trials":33275,"activeCount":97},[],{"trials":33277,"activeCount":97},[],{"trials":33279,"activeCount":97},[],{"trials":33281,"activeCount":97},[33282],{"nctId":33283,"briefTitle":33284,"status":145,"phases":33285,"primaryCompletion":3036,"completion":3036,"start":33286,"enrollment":33287,"conditions":33288,"interventions":33289},"NCT00119743","A Efficacy Against Otitis Media in Children With 11 Valent Pneumococcal Vaccine",[87],"2000-10",5000,[7966],[33272],{"trials":33291,"activeCount":97},[],{"trials":33293,"activeCount":97},[],{"intervention":22126,"totalTrials":417,"cells":33295},{"EARLY_PHASE1":33296,"PHASE1":33298,"PHASE2":33300,"PHASE3":33302,"PHASE4":33308,"NA":33310},{"trials":33297,"activeCount":97},[],{"trials":33299,"activeCount":97},[],{"trials":33301,"activeCount":97},[],{"trials":33303,"activeCount":97},[33304],{"nctId":22120,"briefTitle":22121,"status":155,"phases":33305,"primaryCompletion":7545,"completion":7545,"start":11030,"enrollment":22123,"conditions":33306,"interventions":33307},[87],[18],[22099,22126],{"trials":33309,"activeCount":97},[],{"trials":33311,"activeCount":97},[],{"intervention":21065,"totalTrials":417,"cells":33313},{"EARLY_PHASE1":33314,"PHASE1":33316,"PHASE2":33318,"PHASE3":33320,"PHASE4":33326,"NA":33328},{"trials":33315,"activeCount":97},[],{"trials":33317,"activeCount":97},[],{"trials":33319,"activeCount":97},[],{"trials":33321,"activeCount":97},[33322],{"nctId":21059,"briefTitle":21060,"status":145,"phases":33323,"primaryCompletion":2383,"completion":2383,"start":10212,"enrollment":9757,"conditions":33324,"interventions":33325},[87],[21063],[21065,21056,21013],{"trials":33327,"activeCount":97},[],{"trials":33329,"activeCount":97},[],{"intervention":7903,"totalTrials":417,"cells":33331},{"EARLY_PHASE1":33332,"PHASE1":33334,"PHASE2":33336,"PHASE3":33338,"PHASE4":33344,"NA":33346},{"trials":33333,"activeCount":97},[],{"trials":33335,"activeCount":97},[],{"trials":33337,"activeCount":97},[],{"trials":33339,"activeCount":97},[33340],{"nctId":7896,"briefTitle":7897,"status":155,"phases":33341,"primaryCompletion":7899,"completion":7899,"start":7900,"enrollment":1579,"conditions":33342,"interventions":33343},[87],[24],[7718,7903,7904],{"trials":33345,"activeCount":97},[],{"trials":33347,"activeCount":97},[],{"intervention":7904,"totalTrials":417,"cells":33349},{"EARLY_PHASE1":33350,"PHASE1":33352,"PHASE2":33354,"PHASE3":33356,"PHASE4":33362,"NA":33364},{"trials":33351,"activeCount":97},[],{"trials":33353,"activeCount":97},[],{"trials":33355,"activeCount":97},[],{"trials":33357,"activeCount":97},[33358],{"nctId":7896,"briefTitle":7897,"status":155,"phases":33359,"primaryCompletion":7899,"completion":7899,"start":7900,"enrollment":1579,"conditions":33360,"interventions":33361},[87],[24],[7718,7903,7904],{"trials":33363,"activeCount":97},[],{"trials":33365,"activeCount":97},[],{"intervention":33367,"totalTrials":417,"cells":33368},"Chinese DT vaccine",{"EARLY_PHASE1":33369,"PHASE1":33371,"PHASE2":33373,"PHASE3":33375,"PHASE4":33383,"NA":33385},{"trials":33370,"activeCount":97},[],{"trials":33372,"activeCount":97},[],{"trials":33374,"activeCount":97},[],{"trials":33376,"activeCount":97},[33377],{"nctId":33378,"briefTitle":33379,"status":155,"phases":33380,"completion":2835,"start":748,"enrollment":19789,"conditions":33381,"interventions":33382},"NCT00452686","Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine",[87],[30,3624,33],[5329,33367],{"trials":33384,"activeCount":97},[],{"trials":33386,"activeCount":97},[],{"intervention":19948,"totalTrials":417,"cells":33388},{"EARLY_PHASE1":33389,"PHASE1":33391,"PHASE2":33393,"PHASE3":33395,"PHASE4":33401,"NA":33403},{"trials":33390,"activeCount":97},[],{"trials":33392,"activeCount":97},[],{"trials":33394,"activeCount":97},[],{"trials":33396,"activeCount":97},[33397],{"nctId":19941,"briefTitle":19942,"status":155,"phases":33398,"primaryCompletion":18501,"completion":19944,"start":19945,"enrollment":8108,"conditions":33399,"interventions":33400},[87],[8723],[8725,19948],{"trials":33402,"activeCount":97},[],{"trials":33404,"activeCount":97},[],{"intervention":33406,"totalTrials":417,"cells":33407},"Pandemic influenza vaccine GSK1562902A",{"EARLY_PHASE1":33408,"PHASE1":33410,"PHASE2":33412,"PHASE3":33414,"PHASE4":33423,"NA":33425},{"trials":33409,"activeCount":97},[],{"trials":33411,"activeCount":97},[],{"trials":33413,"activeCount":97},[],{"trials":33415,"activeCount":97},[33416],{"nctId":33417,"briefTitle":33418,"status":155,"phases":33419,"primaryCompletion":19647,"completion":19647,"start":33420,"enrollment":130,"conditions":33421,"interventions":33422},"NCT00652743","Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules",[87],"2008-03-23",[21],[33406],{"trials":33424,"activeCount":97},[],{"trials":33426,"activeCount":97},[],{"intervention":26848,"totalTrials":417,"cells":33428},{"EARLY_PHASE1":33429,"PHASE1":33431,"PHASE2":33433,"PHASE3":33435,"PHASE4":33441,"NA":33443},{"trials":33430,"activeCount":97},[],{"trials":33432,"activeCount":97},[],{"trials":33434,"activeCount":97},[],{"trials":33436,"activeCount":97},[33437],{"nctId":26842,"briefTitle":26843,"status":155,"phases":33438,"primaryCompletion":13418,"completion":2882,"start":3078,"enrollment":26845,"conditions":33439,"interventions":33440},[87],[8863],[26823,26848],{"trials":33442,"activeCount":97},[],{"trials":33444,"activeCount":97},[],{"intervention":33446,"totalTrials":417,"cells":33447},"Paracetamol 1000 mg SR",{"EARLY_PHASE1":33448,"PHASE1":33450,"PHASE2":33452,"PHASE3":33454,"PHASE4":33463,"NA":33465},{"trials":33449,"activeCount":97},[],{"trials":33451,"activeCount":97},[],{"trials":33453,"activeCount":97},[],{"trials":33455,"activeCount":97},[33456],{"nctId":33457,"briefTitle":33458,"status":155,"phases":33459,"primaryCompletion":492,"completion":492,"start":11029,"enrollment":1626,"conditions":33460,"interventions":33461},"NCT02311881","A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis",[87],[9153],[33446,33462],"Paracetamol 665 mg SR",{"trials":33464,"activeCount":97},[],{"trials":33466,"activeCount":97},[],{"intervention":33462,"totalTrials":417,"cells":33468},{"EARLY_PHASE1":33469,"PHASE1":33471,"PHASE2":33473,"PHASE3":33475,"PHASE4":33481,"NA":33483},{"trials":33470,"activeCount":97},[],{"trials":33472,"activeCount":97},[],{"trials":33474,"activeCount":97},[],{"trials":33476,"activeCount":97},[33477],{"nctId":33457,"briefTitle":33458,"status":155,"phases":33478,"primaryCompletion":492,"completion":492,"start":11029,"enrollment":1626,"conditions":33479,"interventions":33480},[87],[9153],[33446,33462],{"trials":33482,"activeCount":97},[],{"trials":33484,"activeCount":97},[],{"intervention":21415,"totalTrials":417,"cells":33486},{"EARLY_PHASE1":33487,"PHASE1":33489,"PHASE2":33491,"PHASE3":33493,"PHASE4":33499,"NA":33501},{"trials":33488,"activeCount":97},[],{"trials":33490,"activeCount":97},[],{"trials":33492,"activeCount":97},[],{"trials":33494,"activeCount":97},[33495],{"nctId":21408,"briefTitle":21409,"status":155,"phases":33496,"primaryCompletion":21411,"completion":21411,"start":4973,"enrollment":21412,"conditions":33497,"interventions":33498},[87],[3624,33,30,4704],[21415,21367],{"trials":33500,"activeCount":97},[],{"trials":33502,"activeCount":97},[],{"intervention":22596,"totalTrials":417,"cells":33504},{"EARLY_PHASE1":33505,"PHASE1":33507,"PHASE2":33509,"PHASE3":33511,"PHASE4":33517,"NA":33519},{"trials":33506,"activeCount":97},[],{"trials":33508,"activeCount":97},[],{"trials":33510,"activeCount":97},[],{"trials":33512,"activeCount":97},[33513],{"nctId":22589,"briefTitle":22590,"status":155,"phases":33514,"primaryCompletion":738,"completion":22592,"start":9026,"enrollment":22593,"conditions":33515,"interventions":33516},[87],[3637],[22596,22597,22581,11068],{"trials":33518,"activeCount":97},[],{"trials":33520,"activeCount":97},[],{"intervention":22597,"totalTrials":417,"cells":33522},{"EARLY_PHASE1":33523,"PHASE1":33525,"PHASE2":33527,"PHASE3":33529,"PHASE4":33535,"NA":33537},{"trials":33524,"activeCount":97},[],{"trials":33526,"activeCount":97},[],{"trials":33528,"activeCount":97},[],{"trials":33530,"activeCount":97},[33531],{"nctId":22589,"briefTitle":22590,"status":155,"phases":33532,"primaryCompletion":738,"completion":22592,"start":9026,"enrollment":22593,"conditions":33533,"interventions":33534},[87],[3637],[22596,22597,22581,11068],{"trials":33536,"activeCount":97},[],{"trials":33538,"activeCount":97},[],{"intervention":33540,"totalTrials":417,"cells":33541},"LAMICTAL extended-release",{"EARLY_PHASE1":33542,"PHASE1":33544,"PHASE2":33546,"PHASE3":33548,"PHASE4":33556,"NA":33558},{"trials":33543,"activeCount":97},[],{"trials":33545,"activeCount":97},[],{"trials":33547,"activeCount":97},[],{"trials":33549,"activeCount":97},[33550],{"nctId":33551,"briefTitle":33552,"status":155,"phases":33553,"primaryCompletion":2428,"completion":2428,"start":8478,"enrollment":21747,"conditions":33554,"interventions":33555},"NCT00113165","Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Partial Seizures",[87],[12518,21978],[33540],{"trials":33557,"activeCount":97},[],{"trials":33559,"activeCount":97},[],{"intervention":33561,"totalTrials":417,"cells":33562},"Albiglutide 30 mg weekly",{"EARLY_PHASE1":33563,"PHASE1":33565,"PHASE2":33567,"PHASE3":33569,"PHASE4":33579,"NA":33581},{"trials":33564,"activeCount":97},[],{"trials":33566,"activeCount":97},[],{"trials":33568,"activeCount":97},[],{"trials":33570,"activeCount":97},[33571],{"nctId":33572,"briefTitle":33573,"status":155,"phases":33574,"primaryCompletion":19576,"completion":8721,"start":3390,"enrollment":1293,"conditions":33575,"interventions":33576},"NCT01733758","A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)",[87],[27],[33561,33577,33578],"Albiglutide 50 mg weekly","Liraglutide 0.9 mg daily",{"trials":33580,"activeCount":97},[],{"trials":33582,"activeCount":97},[],{"intervention":33577,"totalTrials":417,"cells":33584},{"EARLY_PHASE1":33585,"PHASE1":33587,"PHASE2":33589,"PHASE3":33591,"PHASE4":33597,"NA":33599},{"trials":33586,"activeCount":97},[],{"trials":33588,"activeCount":97},[],{"trials":33590,"activeCount":97},[],{"trials":33592,"activeCount":97},[33593],{"nctId":33572,"briefTitle":33573,"status":155,"phases":33594,"primaryCompletion":19576,"completion":8721,"start":3390,"enrollment":1293,"conditions":33595,"interventions":33596},[87],[27],[33561,33577,33578],{"trials":33598,"activeCount":97},[],{"trials":33600,"activeCount":97},[],{"intervention":33578,"totalTrials":417,"cells":33602},{"EARLY_PHASE1":33603,"PHASE1":33605,"PHASE2":33607,"PHASE3":33609,"PHASE4":33615,"NA":33617},{"trials":33604,"activeCount":97},[],{"trials":33606,"activeCount":97},[],{"trials":33608,"activeCount":97},[],{"trials":33610,"activeCount":97},[33611],{"nctId":33572,"briefTitle":33573,"status":155,"phases":33612,"primaryCompletion":19576,"completion":8721,"start":3390,"enrollment":1293,"conditions":33613,"interventions":33614},[87],[27],[33561,33577,33578],{"trials":33616,"activeCount":97},[],{"trials":33618,"activeCount":97},[],{"intervention":3233,"totalTrials":417,"cells":33620},{"EARLY_PHASE1":33621,"PHASE1":33623,"PHASE2":33625,"PHASE3":33627,"PHASE4":33633,"NA":33635},{"trials":33622,"activeCount":97},[],{"trials":33624,"activeCount":97},[],{"trials":33626,"activeCount":97},[],{"trials":33628,"activeCount":97},[33629],{"nctId":3224,"briefTitle":3225,"status":155,"phases":33630,"primaryCompletion":3227,"completion":3228,"start":3229,"enrollment":3230,"conditions":33631,"interventions":33632},[87],[2620],[43,3233],{"trials":33634,"activeCount":97},[],{"trials":33636,"activeCount":97},[],{"intervention":9199,"totalTrials":417,"cells":33638},{"EARLY_PHASE1":33639,"PHASE1":33641,"PHASE2":33643,"PHASE3":33645,"PHASE4":33651,"NA":33653},{"trials":33640,"activeCount":97},[],{"trials":33642,"activeCount":97},[],{"trials":33644,"activeCount":97},[],{"trials":33646,"activeCount":97},[33647],{"nctId":9193,"briefTitle":9194,"status":155,"phases":33648,"primaryCompletion":8089,"completion":8089,"start":8135,"enrollment":9196,"conditions":33649,"interventions":33650},[87],[9183],[9199,9200],{"trials":33652,"activeCount":97},[],{"trials":33654,"activeCount":97},[],{"intervention":33656,"totalTrials":417,"cells":33657},"SB-497115-GR 12.5mg",{"EARLY_PHASE1":33658,"PHASE1":33660,"PHASE2":33662,"PHASE3":33664,"PHASE4":33676,"NA":33678},{"trials":33659,"activeCount":97},[],{"trials":33661,"activeCount":97},[],{"trials":33663,"activeCount":97},[],{"trials":33665,"activeCount":97},[33666],{"nctId":33667,"briefTitle":33668,"status":155,"phases":33669,"primaryCompletion":8468,"completion":8468,"start":2356,"enrollment":314,"conditions":33670,"interventions":33673},"NCT00540423","Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)",[87],[33671,33672],"Chronic Idiopathic Thrombocytopenic Purpura","Purpura, Thrombocytopenic, Idiopathic",[33656,33674,33675],"SB-497115-GR 25mg","SB-497115-GR 50 mg",{"trials":33677,"activeCount":97},[],{"trials":33679,"activeCount":97},[],{"intervention":33674,"totalTrials":417,"cells":33681},{"EARLY_PHASE1":33682,"PHASE1":33684,"PHASE2":33686,"PHASE3":33688,"PHASE4":33694,"NA":33696},{"trials":33683,"activeCount":97},[],{"trials":33685,"activeCount":97},[],{"trials":33687,"activeCount":97},[],{"trials":33689,"activeCount":97},[33690],{"nctId":33667,"briefTitle":33668,"status":155,"phases":33691,"primaryCompletion":8468,"completion":8468,"start":2356,"enrollment":314,"conditions":33692,"interventions":33693},[87],[33671,33672],[33656,33674,33675],{"trials":33695,"activeCount":97},[],{"trials":33697,"activeCount":97},[],{"intervention":33675,"totalTrials":417,"cells":33699},{"EARLY_PHASE1":33700,"PHASE1":33702,"PHASE2":33704,"PHASE3":33706,"PHASE4":33712,"NA":33714},{"trials":33701,"activeCount":97},[],{"trials":33703,"activeCount":97},[],{"trials":33705,"activeCount":97},[],{"trials":33707,"activeCount":97},[33708],{"nctId":33667,"briefTitle":33668,"status":155,"phases":33709,"primaryCompletion":8468,"completion":8468,"start":2356,"enrollment":314,"conditions":33710,"interventions":33711},[87],[33671,33672],[33656,33674,33675],{"trials":33713,"activeCount":97},[],{"trials":33715,"activeCount":97},[],{"intervention":33717,"totalTrials":417,"cells":33718},"Zilbrix-Hib",{"EARLY_PHASE1":33719,"PHASE1":33721,"PHASE2":33723,"PHASE3":33725,"PHASE4":33735,"NA":33737},{"trials":33720,"activeCount":97},[],{"trials":33722,"activeCount":97},[],{"trials":33724,"activeCount":97},[],{"trials":33726,"activeCount":97},[33727],{"nctId":33728,"briefTitle":33729,"status":155,"phases":33730,"primaryCompletion":33731,"completion":33731,"start":19786,"enrollment":536,"conditions":33732,"interventions":33733},"NCT00473668","Non-inferiority of GSK Biologicals' DTPw-HBV\u002FHib Compared to Two Formulations of GSK Biologicals' DTPw-HBV\u002FHib",[87],"2008-01-30",[10227,4704,33,30,24],[33717,33734],"Tritanrix™-HepB\u002F Hiberix™",{"trials":33736,"activeCount":97},[],{"trials":33738,"activeCount":97},[],{"intervention":33734,"totalTrials":417,"cells":33740},{"EARLY_PHASE1":33741,"PHASE1":33743,"PHASE2":33745,"PHASE3":33747,"PHASE4":33753,"NA":33755},{"trials":33742,"activeCount":97},[],{"trials":33744,"activeCount":97},[],{"trials":33746,"activeCount":97},[],{"trials":33748,"activeCount":97},[33749],{"nctId":33728,"briefTitle":33729,"status":155,"phases":33750,"primaryCompletion":33731,"completion":33731,"start":19786,"enrollment":536,"conditions":33751,"interventions":33752},[87],[10227,4704,33,30,24],[33717,33734],{"trials":33754,"activeCount":97},[],{"trials":33756,"activeCount":97},[],{"intervention":24240,"totalTrials":417,"cells":33758},{"EARLY_PHASE1":33759,"PHASE1":33761,"PHASE2":33763,"PHASE3":33765,"PHASE4":33771,"NA":33773},{"trials":33760,"activeCount":97},[],{"trials":33762,"activeCount":97},[],{"trials":33764,"activeCount":97},[],{"trials":33766,"activeCount":97},[33767],{"nctId":24233,"briefTitle":24234,"status":155,"phases":33768,"primaryCompletion":24236,"completion":24236,"start":24237,"enrollment":454,"conditions":33769,"interventions":33770},[87],[14168],[24216,24240],{"trials":33772,"activeCount":97},[],{"trials":33774,"activeCount":97},[],{"intervention":33776,"totalTrials":417,"cells":33777},"Fluarix\u002FInflusplit Tetra®",{"EARLY_PHASE1":33778,"PHASE1":33780,"PHASE2":33782,"PHASE3":33784,"PHASE4":33793,"NA":33795},{"trials":33779,"activeCount":97},[],{"trials":33781,"activeCount":97},[],{"trials":33783,"activeCount":97},[],{"trials":33785,"activeCount":97},[33786],{"nctId":33787,"briefTitle":33788,"status":155,"phases":33789,"primaryCompletion":33790,"completion":33790,"start":21796,"enrollment":1770,"conditions":33791,"interventions":33792},"NCT01878812","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix\u002FInflusplit Tetra® (2013\u002F2014 Season), in Adults 18 Years of Age and Older",[87],"2013-08-05",[21],[33776],{"trials":33794,"activeCount":97},[],{"trials":33796,"activeCount":97},[],{"intervention":33798,"totalTrials":417,"cells":33799},"Bexsero®",{"EARLY_PHASE1":33800,"PHASE1":33802,"PHASE2":33804,"PHASE3":33806,"PHASE4":33817,"NA":33819},{"trials":33801,"activeCount":97},[],{"trials":33803,"activeCount":97},[],{"trials":33805,"activeCount":97},[],{"trials":33807,"activeCount":97},[33808],{"nctId":33809,"briefTitle":33810,"status":155,"phases":33811,"primaryCompletion":33812,"completion":21664,"start":33813,"enrollment":7319,"conditions":33814,"interventions":33815},"NCT02173704","Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.",[87],"2015-12-25","2014-09-11",[12803,992],[33798,33816],"Routine vaccines",{"trials":33818,"activeCount":97},[],{"trials":33820,"activeCount":97},[],{"intervention":33816,"totalTrials":417,"cells":33822},{"EARLY_PHASE1":33823,"PHASE1":33825,"PHASE2":33827,"PHASE3":33829,"PHASE4":33835,"NA":33837},{"trials":33824,"activeCount":97},[],{"trials":33826,"activeCount":97},[],{"trials":33828,"activeCount":97},[],{"trials":33830,"activeCount":97},[33831],{"nctId":33809,"briefTitle":33810,"status":155,"phases":33832,"primaryCompletion":33812,"completion":21664,"start":33813,"enrollment":7319,"conditions":33833,"interventions":33834},[87],[12803,992],[33798,33816],{"trials":33836,"activeCount":97},[],{"trials":33838,"activeCount":97},[],{"intervention":33840,"totalTrials":417,"cells":33841},"Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix",{"EARLY_PHASE1":33842,"PHASE1":33844,"PHASE2":33846,"PHASE3":33848,"PHASE4":33857,"NA":33859},{"trials":33843,"activeCount":97},[],{"trials":33845,"activeCount":97},[],{"trials":33847,"activeCount":97},[],{"trials":33849,"activeCount":97},[33850],{"nctId":33851,"briefTitle":33852,"status":155,"phases":33853,"primaryCompletion":10886,"completion":2844,"start":7909,"enrollment":33854,"conditions":33855,"interventions":33856},"NCT00197249","Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity",[87],1034,[7966],[33840],{"trials":33858,"activeCount":97},[],{"trials":33860,"activeCount":97},[],{"intervention":33862,"totalTrials":417,"cells":33863},"HRV Liquid",{"EARLY_PHASE1":33864,"PHASE1":33866,"PHASE2":33868,"PHASE3":33870,"PHASE4":33882,"NA":33884},{"trials":33865,"activeCount":97},[],{"trials":33867,"activeCount":97},[],{"trials":33869,"activeCount":97},[],{"trials":33871,"activeCount":97},[33872],{"nctId":33873,"briefTitle":33874,"status":155,"phases":33875,"primaryCompletion":33876,"completion":33876,"start":33877,"enrollment":33878,"conditions":33879,"interventions":33880},"NCT02141204","Immunogenicity, Reactogenicity and Safety Study of Two Different Formulations of GSK Biologicals' Human Rotavirus Vaccine, Rotarix, in Healthy Infants",[87],"2019-12-28","2019-02-20",451,[16147],[33862,33881],"HRV Lyophilized",{"trials":33883,"activeCount":97},[],{"trials":33885,"activeCount":97},[],{"intervention":33881,"totalTrials":417,"cells":33887},{"EARLY_PHASE1":33888,"PHASE1":33890,"PHASE2":33892,"PHASE3":33894,"PHASE4":33900,"NA":33902},{"trials":33889,"activeCount":97},[],{"trials":33891,"activeCount":97},[],{"trials":33893,"activeCount":97},[],{"trials":33895,"activeCount":97},[33896],{"nctId":33873,"briefTitle":33874,"status":155,"phases":33897,"primaryCompletion":33876,"completion":33876,"start":33877,"enrollment":33878,"conditions":33898,"interventions":33899},[87],[16147],[33862,33881],{"trials":33901,"activeCount":97},[],{"trials":33903,"activeCount":97},[],{"intervention":8120,"totalTrials":417,"cells":33905},{"EARLY_PHASE1":33906,"PHASE1":33908,"PHASE2":33910,"PHASE3":33912,"PHASE4":33918,"NA":33920},{"trials":33907,"activeCount":97},[],{"trials":33909,"activeCount":97},[],{"trials":33911,"activeCount":97},[],{"trials":33913,"activeCount":97},[33914],{"nctId":8113,"briefTitle":8114,"status":155,"phases":33915,"primaryCompletion":2427,"completion":5195,"start":8116,"enrollment":8117,"conditions":33916,"interventions":33917},[87],[27],[7997,8120],{"trials":33919,"activeCount":97},[],{"trials":33921,"activeCount":97},[],{"intervention":33923,"totalTrials":417,"cells":33924},"FluLaval™ Quadrivalent",{"EARLY_PHASE1":33925,"PHASE1":33927,"PHASE2":33929,"PHASE3":33931,"PHASE4":33941,"NA":33943},{"trials":33926,"activeCount":97},[],{"trials":33928,"activeCount":97},[],{"trials":33930,"activeCount":97},[],{"trials":33932,"activeCount":97},[33933],{"nctId":33934,"briefTitle":33935,"status":155,"phases":33936,"primaryCompletion":22933,"completion":13170,"start":32586,"enrollment":33937,"conditions":33938,"interventions":33939},"NCT02242643","Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age",[87],2432,[21],[33923,33940],"Fluzone® Quadrivalent",{"trials":33942,"activeCount":97},[],{"trials":33944,"activeCount":97},[],{"intervention":33940,"totalTrials":417,"cells":33946},{"EARLY_PHASE1":33947,"PHASE1":33949,"PHASE2":33951,"PHASE3":33953,"PHASE4":33959,"NA":33961},{"trials":33948,"activeCount":97},[],{"trials":33950,"activeCount":97},[],{"trials":33952,"activeCount":97},[],{"trials":33954,"activeCount":97},[33955],{"nctId":33934,"briefTitle":33935,"status":155,"phases":33956,"primaryCompletion":22933,"completion":13170,"start":32586,"enrollment":33937,"conditions":33957,"interventions":33958},[87],[21],[33923,33940],{"trials":33960,"activeCount":97},[],{"trials":33962,"activeCount":97},[],{"intervention":3626,"totalTrials":417,"cells":33964},{"EARLY_PHASE1":33965,"PHASE1":33967,"PHASE2":33969,"PHASE3":33971,"PHASE4":33977,"NA":33979},{"trials":33966,"activeCount":97},[],{"trials":33968,"activeCount":97},[],{"trials":33970,"activeCount":97},[],{"trials":33972,"activeCount":97},[33973],{"nctId":3616,"briefTitle":3617,"status":155,"phases":33974,"primaryCompletion":3619,"completion":3620,"start":3621,"enrollment":3622,"conditions":33975,"interventions":33976},[87],[33,3624,30],[3626,3605,3627],{"trials":33978,"activeCount":97},[],{"trials":33980,"activeCount":97},[],{"intervention":3627,"totalTrials":417,"cells":33982},{"EARLY_PHASE1":33983,"PHASE1":33985,"PHASE2":33987,"PHASE3":33989,"PHASE4":33995,"NA":33997},{"trials":33984,"activeCount":97},[],{"trials":33986,"activeCount":97},[],{"trials":33988,"activeCount":97},[],{"trials":33990,"activeCount":97},[33991],{"nctId":3616,"briefTitle":3617,"status":155,"phases":33992,"primaryCompletion":3619,"completion":3620,"start":3621,"enrollment":3622,"conditions":33993,"interventions":33994},[87],[33,3624,30],[3626,3605,3627],{"trials":33996,"activeCount":97},[],{"trials":33998,"activeCount":97},[],{"intervention":34000,"totalTrials":417,"cells":34001},"Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine",{"EARLY_PHASE1":34002,"PHASE1":34004,"PHASE2":34006,"PHASE3":34008,"PHASE4":34016,"NA":34018},{"trials":34003,"activeCount":97},[],{"trials":34005,"activeCount":97},[],{"trials":34007,"activeCount":97},[],{"trials":34009,"activeCount":97},[34010],{"nctId":34011,"briefTitle":34012,"status":145,"phases":34013,"completion":4843,"start":7613,"enrollment":12474,"conditions":34014,"interventions":34015},"NCT00316680","Immuno & Safety Study With 2 Formulations of DTPw-HBV\u002FHIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age.",[87],[4704,30,33,24,10227],[34000],{"trials":34017,"activeCount":97},[],{"trials":34019,"activeCount":97},[],{"intervention":26237,"totalTrials":417,"cells":34021},{"EARLY_PHASE1":34022,"PHASE1":34024,"PHASE2":34026,"PHASE3":34028,"PHASE4":34034,"NA":34036},{"trials":34023,"activeCount":97},[],{"trials":34025,"activeCount":97},[],{"trials":34027,"activeCount":97},[],{"trials":34029,"activeCount":97},[34030],{"nctId":26230,"briefTitle":26231,"status":155,"phases":34031,"primaryCompletion":26233,"completion":26233,"start":26234,"enrollment":19930,"conditions":34032,"interventions":34033},[87],[10227,33,24,30,4704,10228],[10230,10231,26237],{"trials":34035,"activeCount":97},[],{"trials":34037,"activeCount":97},[],{"intervention":5134,"totalTrials":417,"cells":34039},{"EARLY_PHASE1":34040,"PHASE1":34042,"PHASE2":34044,"PHASE3":34046,"PHASE4":34052,"NA":34054},{"trials":34041,"activeCount":97},[],{"trials":34043,"activeCount":97},[],{"trials":34045,"activeCount":97},[],{"trials":34047,"activeCount":97},[34048],{"nctId":5124,"briefTitle":5125,"status":155,"phases":34049,"primaryCompletion":5127,"completion":5128,"start":5129,"enrollment":5130,"conditions":34050,"interventions":34051},[87],[3287,5132],[5134,5135,5136,5137,5138,5139,5140,5109],{"trials":34053,"activeCount":97},[],{"trials":34055,"activeCount":97},[],{"intervention":5135,"totalTrials":417,"cells":34057},{"EARLY_PHASE1":34058,"PHASE1":34060,"PHASE2":34062,"PHASE3":34064,"PHASE4":34070,"NA":34072},{"trials":34059,"activeCount":97},[],{"trials":34061,"activeCount":97},[],{"trials":34063,"activeCount":97},[],{"trials":34065,"activeCount":97},[34066],{"nctId":5124,"briefTitle":5125,"status":155,"phases":34067,"primaryCompletion":5127,"completion":5128,"start":5129,"enrollment":5130,"conditions":34068,"interventions":34069},[87],[3287,5132],[5134,5135,5136,5137,5138,5139,5140,5109],{"trials":34071,"activeCount":97},[],{"trials":34073,"activeCount":97},[],{"intervention":5136,"totalTrials":417,"cells":34075},{"EARLY_PHASE1":34076,"PHASE1":34078,"PHASE2":34080,"PHASE3":34082,"PHASE4":34088,"NA":34090},{"trials":34077,"activeCount":97},[],{"trials":34079,"activeCount":97},[],{"trials":34081,"activeCount":97},[],{"trials":34083,"activeCount":97},[34084],{"nctId":5124,"briefTitle":5125,"status":155,"phases":34085,"primaryCompletion":5127,"completion":5128,"start":5129,"enrollment":5130,"conditions":34086,"interventions":34087},[87],[3287,5132],[5134,5135,5136,5137,5138,5139,5140,5109],{"trials":34089,"activeCount":97},[],{"trials":34091,"activeCount":97},[],{"intervention":5137,"totalTrials":417,"cells":34093},{"EARLY_PHASE1":34094,"PHASE1":34096,"PHASE2":34098,"PHASE3":34100,"PHASE4":34106,"NA":34108},{"trials":34095,"activeCount":97},[],{"trials":34097,"activeCount":97},[],{"trials":34099,"activeCount":97},[],{"trials":34101,"activeCount":97},[34102],{"nctId":5124,"briefTitle":5125,"status":155,"phases":34103,"primaryCompletion":5127,"completion":5128,"start":5129,"enrollment":5130,"conditions":34104,"interventions":34105},[87],[3287,5132],[5134,5135,5136,5137,5138,5139,5140,5109],{"trials":34107,"activeCount":97},[],{"trials":34109,"activeCount":97},[],{"intervention":5138,"totalTrials":417,"cells":34111},{"EARLY_PHASE1":34112,"PHASE1":34114,"PHASE2":34116,"PHASE3":34118,"PHASE4":34124,"NA":34126},{"trials":34113,"activeCount":97},[],{"trials":34115,"activeCount":97},[],{"trials":34117,"activeCount":97},[],{"trials":34119,"activeCount":97},[34120],{"nctId":5124,"briefTitle":5125,"status":155,"phases":34121,"primaryCompletion":5127,"completion":5128,"start":5129,"enrollment":5130,"conditions":34122,"interventions":34123},[87],[3287,5132],[5134,5135,5136,5137,5138,5139,5140,5109],{"trials":34125,"activeCount":97},[],{"trials":34127,"activeCount":97},[],{"intervention":5139,"totalTrials":417,"cells":34129},{"EARLY_PHASE1":34130,"PHASE1":34132,"PHASE2":34134,"PHASE3":34136,"PHASE4":34142,"NA":34144},{"trials":34131,"activeCount":97},[],{"trials":34133,"activeCount":97},[],{"trials":34135,"activeCount":97},[],{"trials":34137,"activeCount":97},[34138],{"nctId":5124,"briefTitle":5125,"status":155,"phases":34139,"primaryCompletion":5127,"completion":5128,"start":5129,"enrollment":5130,"conditions":34140,"interventions":34141},[87],[3287,5132],[5134,5135,5136,5137,5138,5139,5140,5109],{"trials":34143,"activeCount":97},[],{"trials":34145,"activeCount":97},[],{"intervention":5140,"totalTrials":417,"cells":34147},{"EARLY_PHASE1":34148,"PHASE1":34150,"PHASE2":34152,"PHASE3":34154,"PHASE4":34160,"NA":34162},{"trials":34149,"activeCount":97},[],{"trials":34151,"activeCount":97},[],{"trials":34153,"activeCount":97},[],{"trials":34155,"activeCount":97},[34156],{"nctId":5124,"briefTitle":5125,"status":155,"phases":34157,"primaryCompletion":5127,"completion":5128,"start":5129,"enrollment":5130,"conditions":34158,"interventions":34159},[87],[3287,5132],[5134,5135,5136,5137,5138,5139,5140,5109],{"trials":34161,"activeCount":97},[],{"trials":34163,"activeCount":97},[],{"intervention":34165,"totalTrials":417,"cells":34166},"Influenza vaccine GSK2186877A",{"EARLY_PHASE1":34167,"PHASE1":34169,"PHASE2":34171,"PHASE3":34173,"PHASE4":34183,"NA":34185},{"trials":34168,"activeCount":97},[],{"trials":34170,"activeCount":97},[],{"trials":34172,"activeCount":97},[],{"trials":34174,"activeCount":97},[34175],{"nctId":34176,"briefTitle":34177,"status":155,"phases":34178,"primaryCompletion":25032,"completion":25032,"start":34179,"enrollment":5351,"conditions":34180,"interventions":34181},"NCT00772889","Evaluation of the Safety and Immunogenicity of the Influenza Vaccine GSK2186877A in the Elderly",[87],"2008-10-09",[21],[34165,34182],"GSK Biologicals' Fluarix™",{"trials":34184,"activeCount":97},[],{"trials":34186,"activeCount":97},[],{"intervention":34182,"totalTrials":417,"cells":34188},{"EARLY_PHASE1":34189,"PHASE1":34191,"PHASE2":34193,"PHASE3":34195,"PHASE4":34201,"NA":34203},{"trials":34190,"activeCount":97},[],{"trials":34192,"activeCount":97},[],{"trials":34194,"activeCount":97},[],{"trials":34196,"activeCount":97},[34197],{"nctId":34176,"briefTitle":34177,"status":155,"phases":34198,"primaryCompletion":25032,"completion":25032,"start":34179,"enrollment":5351,"conditions":34199,"interventions":34200},[87],[21],[34165,34182],{"trials":34202,"activeCount":97},[],{"trials":34204,"activeCount":97},[],{"intervention":19430,"totalTrials":417,"cells":34206},{"EARLY_PHASE1":34207,"PHASE1":34209,"PHASE2":34211,"PHASE3":34213,"PHASE4":34219,"NA":34221},{"trials":34208,"activeCount":97},[],{"trials":34210,"activeCount":97},[],{"trials":34212,"activeCount":97},[],{"trials":34214,"activeCount":97},[34215],{"nctId":19422,"briefTitle":19423,"status":155,"phases":34216,"primaryCompletion":19425,"completion":18288,"start":19426,"enrollment":19427,"conditions":34217,"interventions":34218},[87],[4704,4703],[19430,4806,19385,4805,19386,8674,8675],{"trials":34220,"activeCount":97},[],{"trials":34222,"activeCount":97},[],{"intervention":27053,"totalTrials":417,"cells":34224},{"EARLY_PHASE1":34225,"PHASE1":34227,"PHASE2":34229,"PHASE3":34231,"PHASE4":34237,"NA":34239},{"trials":34226,"activeCount":97},[],{"trials":34228,"activeCount":97},[],{"trials":34230,"activeCount":97},[],{"trials":34232,"activeCount":97},[34233],{"nctId":27047,"briefTitle":27048,"status":155,"phases":34234,"primaryCompletion":18021,"completion":18021,"start":20813,"enrollment":27050,"conditions":34235,"interventions":34236},[87],[15],[27053,27054,27036],{"trials":34238,"activeCount":97},[],{"trials":34240,"activeCount":97},[],{"intervention":27054,"totalTrials":417,"cells":34242},{"EARLY_PHASE1":34243,"PHASE1":34245,"PHASE2":34247,"PHASE3":34249,"PHASE4":34255,"NA":34257},{"trials":34244,"activeCount":97},[],{"trials":34246,"activeCount":97},[],{"trials":34248,"activeCount":97},[],{"trials":34250,"activeCount":97},[34251],{"nctId":27047,"briefTitle":27048,"status":155,"phases":34252,"primaryCompletion":18021,"completion":18021,"start":20813,"enrollment":27050,"conditions":34253,"interventions":34254},[87],[15],[27053,27054,27036],{"trials":34256,"activeCount":97},[],{"trials":34258,"activeCount":97},[],{"intervention":34260,"totalTrials":417,"cells":34261},"paroxetine IR 10mg",{"EARLY_PHASE1":34262,"PHASE1":34264,"PHASE2":34266,"PHASE3":34268,"PHASE4":34282,"NA":34284},{"trials":34263,"activeCount":97},[],{"trials":34265,"activeCount":97},[],{"trials":34267,"activeCount":97},[],{"trials":34269,"activeCount":97},[34270],{"nctId":34271,"briefTitle":34272,"status":155,"phases":34273,"primaryCompletion":2834,"completion":2834,"start":3550,"enrollment":34274,"conditions":34275,"interventions":34276},"NCT00866294","Controlled-release Paroxetine in Major Depressive Disorder (Double-blind, Placebo-controlled Study)",[87],416,[9292],[34260,34277,34278,34279,34280,34281],"paroxetine IR 20mg","matched placebo to paroxetine IR 10mg or 20mg","Paroxetine CR 12.5mg","Paroxetine CR 25mg","matched placebo to paroxetine CR 12.5mg or 25mg",{"trials":34283,"activeCount":97},[],{"trials":34285,"activeCount":97},[],{"intervention":34277,"totalTrials":417,"cells":34287},{"EARLY_PHASE1":34288,"PHASE1":34290,"PHASE2":34292,"PHASE3":34294,"PHASE4":34300,"NA":34302},{"trials":34289,"activeCount":97},[],{"trials":34291,"activeCount":97},[],{"trials":34293,"activeCount":97},[],{"trials":34295,"activeCount":97},[34296],{"nctId":34271,"briefTitle":34272,"status":155,"phases":34297,"primaryCompletion":2834,"completion":2834,"start":3550,"enrollment":34274,"conditions":34298,"interventions":34299},[87],[9292],[34260,34277,34278,34279,34280,34281],{"trials":34301,"activeCount":97},[],{"trials":34303,"activeCount":97},[],{"intervention":34278,"totalTrials":417,"cells":34305},{"EARLY_PHASE1":34306,"PHASE1":34308,"PHASE2":34310,"PHASE3":34312,"PHASE4":34318,"NA":34320},{"trials":34307,"activeCount":97},[],{"trials":34309,"activeCount":97},[],{"trials":34311,"activeCount":97},[],{"trials":34313,"activeCount":97},[34314],{"nctId":34271,"briefTitle":34272,"status":155,"phases":34315,"primaryCompletion":2834,"completion":2834,"start":3550,"enrollment":34274,"conditions":34316,"interventions":34317},[87],[9292],[34260,34277,34278,34279,34280,34281],{"trials":34319,"activeCount":97},[],{"trials":34321,"activeCount":97},[],{"intervention":34279,"totalTrials":417,"cells":34323},{"EARLY_PHASE1":34324,"PHASE1":34326,"PHASE2":34328,"PHASE3":34330,"PHASE4":34336,"NA":34338},{"trials":34325,"activeCount":97},[],{"trials":34327,"activeCount":97},[],{"trials":34329,"activeCount":97},[],{"trials":34331,"activeCount":97},[34332],{"nctId":34271,"briefTitle":34272,"status":155,"phases":34333,"primaryCompletion":2834,"completion":2834,"start":3550,"enrollment":34274,"conditions":34334,"interventions":34335},[87],[9292],[34260,34277,34278,34279,34280,34281],{"trials":34337,"activeCount":97},[],{"trials":34339,"activeCount":97},[],{"intervention":34280,"totalTrials":417,"cells":34341},{"EARLY_PHASE1":34342,"PHASE1":34344,"PHASE2":34346,"PHASE3":34348,"PHASE4":34354,"NA":34356},{"trials":34343,"activeCount":97},[],{"trials":34345,"activeCount":97},[],{"trials":34347,"activeCount":97},[],{"trials":34349,"activeCount":97},[34350],{"nctId":34271,"briefTitle":34272,"status":155,"phases":34351,"primaryCompletion":2834,"completion":2834,"start":3550,"enrollment":34274,"conditions":34352,"interventions":34353},[87],[9292],[34260,34277,34278,34279,34280,34281],{"trials":34355,"activeCount":97},[],{"trials":34357,"activeCount":97},[],{"intervention":34281,"totalTrials":417,"cells":34359},{"EARLY_PHASE1":34360,"PHASE1":34362,"PHASE2":34364,"PHASE3":34366,"PHASE4":34372,"NA":34374},{"trials":34361,"activeCount":97},[],{"trials":34363,"activeCount":97},[],{"trials":34365,"activeCount":97},[],{"trials":34367,"activeCount":97},[34368],{"nctId":34271,"briefTitle":34272,"status":155,"phases":34369,"primaryCompletion":2834,"completion":2834,"start":3550,"enrollment":34274,"conditions":34370,"interventions":34371},[87],[9292],[34260,34277,34278,34279,34280,34281],{"trials":34373,"activeCount":97},[],{"trials":34375,"activeCount":97},[],{"intervention":21658,"totalTrials":417,"cells":34377},{"EARLY_PHASE1":34378,"PHASE1":34380,"PHASE2":34382,"PHASE3":34384,"PHASE4":34390,"NA":34392},{"trials":34379,"activeCount":97},[],{"trials":34381,"activeCount":97},[],{"trials":34383,"activeCount":97},[],{"trials":34385,"activeCount":97},[34386],{"nctId":21651,"briefTitle":21652,"status":155,"phases":34387,"primaryCompletion":21654,"completion":13095,"start":21655,"enrollment":159,"conditions":34388,"interventions":34389},[87],[1030],[21622,21658],{"trials":34391,"activeCount":97},[],{"trials":34393,"activeCount":97},[],{"intervention":4783,"totalTrials":417,"cells":34395},{"EARLY_PHASE1":34396,"PHASE1":34398,"PHASE2":34400,"PHASE3":34402,"PHASE4":34408,"NA":34410},{"trials":34397,"activeCount":97},[],{"trials":34399,"activeCount":97},[],{"trials":34401,"activeCount":97},[],{"trials":34403,"activeCount":97},[34404],{"nctId":4775,"briefTitle":4776,"status":155,"phases":34405,"primaryCompletion":4778,"completion":4778,"start":4779,"enrollment":4780,"conditions":34406,"interventions":34407},[87],[3637,4742],[4783,4745,4472,4694,4784],{"trials":34409,"activeCount":97},[],{"trials":34411,"activeCount":97},[],{"intervention":34413,"totalTrials":417,"cells":34414},"Retosiban IV",{"EARLY_PHASE1":34415,"PHASE1":34417,"PHASE2":34419,"PHASE3":34421,"PHASE4":34429,"NA":34431},{"trials":34416,"activeCount":97},[],{"trials":34418,"activeCount":97},[],{"trials":34420,"activeCount":97},[],{"trials":34422,"activeCount":97},[34423],{"nctId":34424,"briefTitle":34425,"status":145,"phases":34426,"primaryCompletion":8106,"completion":8106,"start":12042,"enrollment":463,"conditions":34427,"interventions":34428},"NCT02377466","A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor",[87],[22921],[34413],{"trials":34430,"activeCount":97},[],{"trials":34432,"activeCount":97},[],{"intervention":8567,"totalTrials":417,"cells":34434},{"EARLY_PHASE1":34435,"PHASE1":34437,"PHASE2":34439,"PHASE3":34441,"PHASE4":34447,"NA":34449},{"trials":34436,"activeCount":97},[],{"trials":34438,"activeCount":97},[],{"trials":34440,"activeCount":97},[],{"trials":34442,"activeCount":97},[34443],{"nctId":8558,"briefTitle":8559,"status":155,"phases":34444,"primaryCompletion":8561,"completion":8562,"start":8563,"enrollment":8564,"conditions":34445,"interventions":34446},[87],[15],[8567,8568,2916],{"trials":34448,"activeCount":97},[],{"trials":34450,"activeCount":97},[],{"intervention":26396,"totalTrials":417,"cells":34452},{"EARLY_PHASE1":34453,"PHASE1":34455,"PHASE2":34457,"PHASE3":34459,"PHASE4":34465,"NA":34467},{"trials":34454,"activeCount":97},[],{"trials":34456,"activeCount":97},[],{"trials":34458,"activeCount":97},[],{"trials":34460,"activeCount":97},[34461],{"nctId":26389,"briefTitle":26390,"status":155,"phases":34462,"primaryCompletion":26392,"completion":26392,"start":26393,"enrollment":1196,"conditions":34463,"interventions":34464},[87],[3287],[8934,26396,26397],{"trials":34466,"activeCount":97},[],{"trials":34468,"activeCount":97},[],{"intervention":26397,"totalTrials":417,"cells":34470},{"EARLY_PHASE1":34471,"PHASE1":34473,"PHASE2":34475,"PHASE3":34477,"PHASE4":34483,"NA":34485},{"trials":34472,"activeCount":97},[],{"trials":34474,"activeCount":97},[],{"trials":34476,"activeCount":97},[],{"trials":34478,"activeCount":97},[34479],{"nctId":26389,"briefTitle":26390,"status":155,"phases":34480,"primaryCompletion":26392,"completion":26392,"start":26393,"enrollment":1196,"conditions":34481,"interventions":34482},[87],[3287],[8934,26396,26397],{"trials":34484,"activeCount":97},[],{"trials":34486,"activeCount":97},[],{"intervention":34488,"totalTrials":417,"cells":34489},"fluticasone propionate\u002Fsalmeterol 250\u002F50 DISKUS combination product",{"EARLY_PHASE1":34490,"PHASE1":34492,"PHASE2":34494,"PHASE3":34496,"PHASE4":34506,"NA":34508},{"trials":34491,"activeCount":97},[],{"trials":34493,"activeCount":97},[],{"trials":34495,"activeCount":97},[],{"trials":34497,"activeCount":97},[34498],{"nctId":34499,"briefTitle":34500,"status":155,"phases":34501,"primaryCompletion":4844,"completion":4844,"start":20690,"enrollment":34502,"conditions":34503,"interventions":34504},"NCT00549146","Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease",[87],290,[15],[34488,34505],"fluticasone propionate DISKUS 500mcg",{"trials":34507,"activeCount":97},[],{"trials":34509,"activeCount":97},[],{"intervention":34505,"totalTrials":417,"cells":34511},{"EARLY_PHASE1":34512,"PHASE1":34514,"PHASE2":34516,"PHASE3":34518,"PHASE4":34524,"NA":34526},{"trials":34513,"activeCount":97},[],{"trials":34515,"activeCount":97},[],{"trials":34517,"activeCount":97},[],{"trials":34519,"activeCount":97},[34520],{"nctId":34499,"briefTitle":34500,"status":155,"phases":34521,"primaryCompletion":4844,"completion":4844,"start":20690,"enrollment":34502,"conditions":34522,"interventions":34523},[87],[15],[34488,34505],{"trials":34525,"activeCount":97},[],{"trials":34527,"activeCount":97},[],{"intervention":34529,"totalTrials":417,"cells":34530},"topotecan\u002Fcisplatin",{"EARLY_PHASE1":34531,"PHASE1":34533,"PHASE2":34535,"PHASE3":34537,"PHASE4":34546,"NA":34548},{"trials":34532,"activeCount":97},[],{"trials":34534,"activeCount":97},[],{"trials":34536,"activeCount":97},[],{"trials":34538,"activeCount":97},[34539],{"nctId":34540,"briefTitle":34541,"status":155,"phases":34542,"primaryCompletion":2405,"start":2481,"enrollment":2856,"conditions":34543,"interventions":34544},"NCT00043927","Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults",[87],[2847],[34529,34545],"etoposide\u002Fcisplatin",{"trials":34547,"activeCount":97},[],{"trials":34549,"activeCount":97},[],{"intervention":34545,"totalTrials":417,"cells":34551},{"EARLY_PHASE1":34552,"PHASE1":34554,"PHASE2":34556,"PHASE3":34558,"PHASE4":34564,"NA":34566},{"trials":34553,"activeCount":97},[],{"trials":34555,"activeCount":97},[],{"trials":34557,"activeCount":97},[],{"trials":34559,"activeCount":97},[34560],{"nctId":34540,"briefTitle":34541,"status":155,"phases":34561,"primaryCompletion":2405,"start":2481,"enrollment":2856,"conditions":34562,"interventions":34563},[87],[2847],[34529,34545],{"trials":34565,"activeCount":97},[],{"trials":34567,"activeCount":97},[],{"intervention":34569,"totalTrials":417,"cells":34570},"Influsplit Tetra™ vaccine produced by investigational process",{"EARLY_PHASE1":34571,"PHASE1":34573,"PHASE2":34575,"PHASE3":34577,"PHASE4":34589,"NA":34591},{"trials":34572,"activeCount":97},[],{"trials":34574,"activeCount":97},[],{"trials":34576,"activeCount":97},[],{"trials":34578,"activeCount":97},[34579],{"nctId":34580,"briefTitle":34581,"status":155,"phases":34582,"primaryCompletion":34583,"completion":34583,"start":34584,"enrollment":34585,"conditions":34586,"interventions":34587},"NCT02207413","A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children",[87],"2015-04-18","2014-08-18",1886,[21],[34569,34588],"Influsplit Tetra™ vaccine produced by licensed process",{"trials":34590,"activeCount":97},[],{"trials":34592,"activeCount":97},[],{"intervention":34588,"totalTrials":417,"cells":34594},{"EARLY_PHASE1":34595,"PHASE1":34597,"PHASE2":34599,"PHASE3":34601,"PHASE4":34607,"NA":34609},{"trials":34596,"activeCount":97},[],{"trials":34598,"activeCount":97},[],{"trials":34600,"activeCount":97},[],{"trials":34602,"activeCount":97},[34603],{"nctId":34580,"briefTitle":34581,"status":155,"phases":34604,"primaryCompletion":34583,"completion":34583,"start":34584,"enrollment":34585,"conditions":34605,"interventions":34606},[87],[21],[34569,34588],{"trials":34608,"activeCount":97},[],{"trials":34610,"activeCount":97},[],{"intervention":34612,"totalTrials":417,"cells":34613},"BW430C",{"EARLY_PHASE1":34614,"PHASE1":34616,"PHASE2":34618,"PHASE3":34620,"PHASE4":34628,"NA":34630},{"trials":34615,"activeCount":97},[],{"trials":34617,"activeCount":97},[],{"trials":34619,"activeCount":97},[],{"trials":34621,"activeCount":97},[34622],{"nctId":34623,"briefTitle":34624,"status":155,"phases":34625,"primaryCompletion":2335,"completion":2335,"start":7522,"enrollment":2883,"conditions":34626,"interventions":34627},"NCT00566020","A Clinical Evaluation Of BW430C (Lamotrigine) In Bipolar I Disorder- Long-term Extension Of Study SCA104779 (NCT00550407) -",[87],[22321],[34612],{"trials":34629,"activeCount":97},[],{"trials":34631,"activeCount":97},[],{"intervention":34633,"totalTrials":417,"cells":34634},"Duac™Once Daily Gel",{"EARLY_PHASE1":34635,"PHASE1":34637,"PHASE2":34639,"PHASE3":34641,"PHASE4":34651,"NA":34653},{"trials":34636,"activeCount":97},[],{"trials":34638,"activeCount":97},[],{"trials":34640,"activeCount":97},[],{"trials":34642,"activeCount":97},[34643],{"nctId":34644,"briefTitle":34645,"status":155,"phases":34646,"primaryCompletion":9507,"completion":9507,"start":484,"enrollment":34647,"conditions":34648,"interventions":34649},"NCT01915732","A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris",[87],1018,[15087],[34633,34650],"1% clindamycin phosphate gel",{"trials":34652,"activeCount":97},[],{"trials":34654,"activeCount":97},[],{"intervention":34650,"totalTrials":417,"cells":34656},{"EARLY_PHASE1":34657,"PHASE1":34659,"PHASE2":34661,"PHASE3":34663,"PHASE4":34669,"NA":34671},{"trials":34658,"activeCount":97},[],{"trials":34660,"activeCount":97},[],{"trials":34662,"activeCount":97},[],{"trials":34664,"activeCount":97},[34665],{"nctId":34644,"briefTitle":34645,"status":155,"phases":34666,"primaryCompletion":9507,"completion":9507,"start":484,"enrollment":34647,"conditions":34667,"interventions":34668},[87],[15087],[34633,34650],{"trials":34670,"activeCount":97},[],{"trials":34672,"activeCount":97},[],{"intervention":34674,"totalTrials":417,"cells":34675},"GSK investigational FluNG vaccine GSK2186877A, aged lot",{"EARLY_PHASE1":34676,"PHASE1":34678,"PHASE2":34680,"PHASE3":34682,"PHASE4":34693,"NA":34695},{"trials":34677,"activeCount":97},[],{"trials":34679,"activeCount":97},[],{"trials":34681,"activeCount":97},[],{"trials":34683,"activeCount":97},[34684],{"nctId":34685,"briefTitle":34686,"status":155,"phases":34687,"primaryCompletion":22171,"completion":22171,"start":34688,"enrollment":34689,"conditions":34690,"interventions":34691},"NCT00938392","Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly",[87],"2009-07-30",726,[21],[34674,34692],"GSK investigational FluNG vaccine GSK2186877A, fresh lot",{"trials":34694,"activeCount":97},[],{"trials":34696,"activeCount":97},[],{"intervention":34692,"totalTrials":417,"cells":34698},{"EARLY_PHASE1":34699,"PHASE1":34701,"PHASE2":34703,"PHASE3":34705,"PHASE4":34711,"NA":34713},{"trials":34700,"activeCount":97},[],{"trials":34702,"activeCount":97},[],{"trials":34704,"activeCount":97},[],{"trials":34706,"activeCount":97},[34707],{"nctId":34685,"briefTitle":34686,"status":155,"phases":34708,"primaryCompletion":22171,"completion":22171,"start":34688,"enrollment":34689,"conditions":34709,"interventions":34710},[87],[21],[34674,34692],{"trials":34712,"activeCount":97},[],{"trials":34714,"activeCount":97},[],{"intervention":24912,"totalTrials":417,"cells":34716},{"EARLY_PHASE1":34717,"PHASE1":34719,"PHASE2":34721,"PHASE3":34723,"PHASE4":34729,"NA":34731},{"trials":34718,"activeCount":97},[],{"trials":34720,"activeCount":97},[],{"trials":34722,"activeCount":97},[],{"trials":34724,"activeCount":97},[34725],{"nctId":24905,"briefTitle":24906,"status":155,"phases":34726,"primaryCompletion":24908,"completion":24908,"start":24909,"enrollment":1752,"conditions":34727,"interventions":34728},[87],[3637],[24884,24912,18829],{"trials":34730,"activeCount":97},[],{"trials":34732,"activeCount":97},[],{"intervention":25459,"totalTrials":417,"cells":34734},{"EARLY_PHASE1":34735,"PHASE1":34737,"PHASE2":34739,"PHASE3":34741,"PHASE4":34747,"NA":34749},{"trials":34736,"activeCount":97},[],{"trials":34738,"activeCount":97},[],{"trials":34740,"activeCount":97},[],{"trials":34742,"activeCount":97},[34743],{"nctId":25453,"briefTitle":25454,"status":155,"phases":34744,"primaryCompletion":3619,"completion":25456,"start":3621,"enrollment":265,"conditions":34745,"interventions":34746},[87],[3637],[25459,25432,25460],{"trials":34748,"activeCount":97},[],{"trials":34750,"activeCount":97},[],{"intervention":25460,"totalTrials":417,"cells":34752},{"EARLY_PHASE1":34753,"PHASE1":34755,"PHASE2":34757,"PHASE3":34759,"PHASE4":34765,"NA":34767},{"trials":34754,"activeCount":97},[],{"trials":34756,"activeCount":97},[],{"trials":34758,"activeCount":97},[],{"trials":34760,"activeCount":97},[34761],{"nctId":25453,"briefTitle":25454,"status":155,"phases":34762,"primaryCompletion":3619,"completion":25456,"start":3621,"enrollment":265,"conditions":34763,"interventions":34764},[87],[3637],[25459,25432,25460],{"trials":34766,"activeCount":97},[],{"trials":34768,"activeCount":97},[],{"intervention":34770,"totalTrials":417,"cells":34771},"AAAA",{"EARLY_PHASE1":34772,"PHASE1":34774,"PHASE2":34776,"PHASE3":34778,"PHASE4":34788,"NA":34790},{"trials":34773,"activeCount":97},[],{"trials":34775,"activeCount":97},[],{"trials":34777,"activeCount":97},[],{"trials":34779,"activeCount":97},[34780],{"nctId":34781,"briefTitle":34782,"status":155,"phases":34783,"primaryCompletion":2382,"completion":2382,"start":2824,"enrollment":8931,"conditions":34784,"interventions":34785},"NCT00857675","A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B",[87],[4190],[34770,34786,34787],"AAPA","PAAA",{"trials":34789,"activeCount":97},[],{"trials":34791,"activeCount":97},[],{"intervention":34786,"totalTrials":417,"cells":34793},{"EARLY_PHASE1":34794,"PHASE1":34796,"PHASE2":34798,"PHASE3":34800,"PHASE4":34806,"NA":34808},{"trials":34795,"activeCount":97},[],{"trials":34797,"activeCount":97},[],{"trials":34799,"activeCount":97},[],{"trials":34801,"activeCount":97},[34802],{"nctId":34781,"briefTitle":34782,"status":155,"phases":34803,"primaryCompletion":2382,"completion":2382,"start":2824,"enrollment":8931,"conditions":34804,"interventions":34805},[87],[4190],[34770,34786,34787],{"trials":34807,"activeCount":97},[],{"trials":34809,"activeCount":97},[],{"intervention":34787,"totalTrials":417,"cells":34811},{"EARLY_PHASE1":34812,"PHASE1":34814,"PHASE2":34816,"PHASE3":34818,"PHASE4":34824,"NA":34826},{"trials":34813,"activeCount":97},[],{"trials":34815,"activeCount":97},[],{"trials":34817,"activeCount":97},[],{"trials":34819,"activeCount":97},[34820],{"nctId":34781,"briefTitle":34782,"status":155,"phases":34821,"primaryCompletion":2382,"completion":2382,"start":2824,"enrollment":8931,"conditions":34822,"interventions":34823},[87],[4190],[34770,34786,34787],{"trials":34825,"activeCount":97},[],{"trials":34827,"activeCount":97},[],{"intervention":3331,"totalTrials":417,"cells":34829},{"EARLY_PHASE1":34830,"PHASE1":34832,"PHASE2":34834,"PHASE3":34836,"PHASE4":34842,"NA":34844},{"trials":34831,"activeCount":97},[],{"trials":34833,"activeCount":97},[],{"trials":34835,"activeCount":97},[],{"trials":34837,"activeCount":97},[34838],{"nctId":3324,"briefTitle":3325,"status":155,"phases":34839,"primaryCompletion":3327,"completion":3327,"start":3328,"enrollment":1579,"conditions":34840,"interventions":34841},[87],[3298],[3273,3331,3290,3332,3333,3334,3335],{"trials":34843,"activeCount":97},[],{"trials":34845,"activeCount":97},[],{"intervention":3332,"totalTrials":417,"cells":34847},{"EARLY_PHASE1":34848,"PHASE1":34850,"PHASE2":34852,"PHASE3":34854,"PHASE4":34860,"NA":34862},{"trials":34849,"activeCount":97},[],{"trials":34851,"activeCount":97},[],{"trials":34853,"activeCount":97},[],{"trials":34855,"activeCount":97},[34856],{"nctId":3324,"briefTitle":3325,"status":155,"phases":34857,"primaryCompletion":3327,"completion":3327,"start":3328,"enrollment":1579,"conditions":34858,"interventions":34859},[87],[3298],[3273,3331,3290,3332,3333,3334,3335],{"trials":34861,"activeCount":97},[],{"trials":34863,"activeCount":97},[],{"intervention":3333,"totalTrials":417,"cells":34865},{"EARLY_PHASE1":34866,"PHASE1":34868,"PHASE2":34870,"PHASE3":34872,"PHASE4":34878,"NA":34880},{"trials":34867,"activeCount":97},[],{"trials":34869,"activeCount":97},[],{"trials":34871,"activeCount":97},[],{"trials":34873,"activeCount":97},[34874],{"nctId":3324,"briefTitle":3325,"status":155,"phases":34875,"primaryCompletion":3327,"completion":3327,"start":3328,"enrollment":1579,"conditions":34876,"interventions":34877},[87],[3298],[3273,3331,3290,3332,3333,3334,3335],{"trials":34879,"activeCount":97},[],{"trials":34881,"activeCount":97},[],{"intervention":3334,"totalTrials":417,"cells":34883},{"EARLY_PHASE1":34884,"PHASE1":34886,"PHASE2":34888,"PHASE3":34890,"PHASE4":34896,"NA":34898},{"trials":34885,"activeCount":97},[],{"trials":34887,"activeCount":97},[],{"trials":34889,"activeCount":97},[],{"trials":34891,"activeCount":97},[34892],{"nctId":3324,"briefTitle":3325,"status":155,"phases":34893,"primaryCompletion":3327,"completion":3327,"start":3328,"enrollment":1579,"conditions":34894,"interventions":34895},[87],[3298],[3273,3331,3290,3332,3333,3334,3335],{"trials":34897,"activeCount":97},[],{"trials":34899,"activeCount":97},[],{"intervention":3335,"totalTrials":417,"cells":34901},{"EARLY_PHASE1":34902,"PHASE1":34904,"PHASE2":34906,"PHASE3":34908,"PHASE4":34914,"NA":34916},{"trials":34903,"activeCount":97},[],{"trials":34905,"activeCount":97},[],{"trials":34907,"activeCount":97},[],{"trials":34909,"activeCount":97},[34910],{"nctId":3324,"briefTitle":3325,"status":155,"phases":34911,"primaryCompletion":3327,"completion":3327,"start":3328,"enrollment":1579,"conditions":34912,"interventions":34913},[87],[3298],[3273,3331,3290,3332,3333,3334,3335],{"trials":34915,"activeCount":97},[],{"trials":34917,"activeCount":97},[],{"intervention":34919,"totalTrials":417,"cells":34920},"Short Acting Beta Agonist",{"EARLY_PHASE1":34921,"PHASE1":34923,"PHASE2":34925,"PHASE3":34927,"PHASE4":34937,"NA":34939},{"trials":34922,"activeCount":97},[],{"trials":34924,"activeCount":97},[],{"trials":34926,"activeCount":97},[],{"trials":34928,"activeCount":97},[34929],{"nctId":34930,"briefTitle":34931,"status":155,"phases":34932,"primaryCompletion":13583,"completion":13583,"start":34933,"enrollment":34934,"conditions":34935,"interventions":34936},"NCT02293265","Cross-sectional Study for Identification and Description of Severe Asthma Patients",[87],"2014-12",767,[18],[34919],{"trials":34938,"activeCount":97},[],{"trials":34940,"activeCount":97},[],{"intervention":34942,"totalTrials":417,"cells":34943},"ropinirole PR\u002FXR",{"EARLY_PHASE1":34944,"PHASE1":34946,"PHASE2":34948,"PHASE3":34950,"PHASE4":34959,"NA":34961},{"trials":34945,"activeCount":97},[],{"trials":34947,"activeCount":97},[],{"trials":34949,"activeCount":97},[],{"trials":34951,"activeCount":97},[34952],{"nctId":34953,"briefTitle":34954,"status":155,"phases":34955,"primaryCompletion":2344,"completion":2344,"start":2794,"enrollment":1272,"conditions":34956,"interventions":34957},"NCT00823836","Clinical Evaluation of Ropinirole Prolonged Release\u002FExtended Release (PR\u002FXR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease",[87],[15879],[34942,34958],"ropinirole IR",{"trials":34960,"activeCount":97},[],{"trials":34962,"activeCount":97},[],{"intervention":34958,"totalTrials":417,"cells":34964},{"EARLY_PHASE1":34965,"PHASE1":34967,"PHASE2":34969,"PHASE3":34971,"PHASE4":34977,"NA":34979},{"trials":34966,"activeCount":97},[],{"trials":34968,"activeCount":97},[],{"trials":34970,"activeCount":97},[],{"trials":34972,"activeCount":97},[34973],{"nctId":34953,"briefTitle":34954,"status":155,"phases":34974,"primaryCompletion":2344,"completion":2344,"start":2794,"enrollment":1272,"conditions":34975,"interventions":34976},[87],[15879],[34942,34958],{"trials":34978,"activeCount":97},[],{"trials":34980,"activeCount":97},[],{"intervention":34982,"totalTrials":417,"cells":34983},"GSK580299, GSK Biological's HPV vaccine",{"EARLY_PHASE1":34984,"PHASE1":34986,"PHASE2":34988,"PHASE3":34990,"PHASE4":34999,"NA":35001},{"trials":34985,"activeCount":97},[],{"trials":34987,"activeCount":97},[],{"trials":34989,"activeCount":97},[],{"trials":34991,"activeCount":97},[34992],{"nctId":34993,"briefTitle":34994,"status":155,"phases":34995,"primaryCompletion":9728,"completion":9728,"start":3550,"enrollment":34996,"conditions":34997,"interventions":34998},"NCT00849381","Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299\u002F008 Subjects From Brazil, Taiwan or Thailand",[87],1239,[8723],[34982],{"trials":35000,"activeCount":97},[],{"trials":35002,"activeCount":97},[],{"intervention":3683,"totalTrials":417,"cells":35004},{"EARLY_PHASE1":35005,"PHASE1":35007,"PHASE2":35009,"PHASE3":35011,"PHASE4":35017,"NA":35019},{"trials":35006,"activeCount":97},[],{"trials":35008,"activeCount":97},[],{"trials":35010,"activeCount":97},[],{"trials":35012,"activeCount":97},[35013],{"nctId":3676,"briefTitle":3677,"status":155,"phases":35014,"primaryCompletion":3679,"completion":3679,"start":3680,"enrollment":1165,"conditions":35015,"interventions":35016},[87],[2620],[3683,3657],{"trials":35018,"activeCount":97},[],{"trials":35020,"activeCount":97},[],{"intervention":24828,"totalTrials":417,"cells":35022},{"EARLY_PHASE1":35023,"PHASE1":35025,"PHASE2":35027,"PHASE3":35029,"PHASE4":35035,"NA":35037},{"trials":35024,"activeCount":97},[],{"trials":35026,"activeCount":97},[],{"trials":35028,"activeCount":97},[],{"trials":35030,"activeCount":97},[35031],{"nctId":24821,"briefTitle":24822,"status":155,"phases":35032,"primaryCompletion":15213,"completion":24824,"start":18536,"enrollment":24825,"conditions":35033,"interventions":35034},[87],[15],[24828,24829,24799],{"trials":35036,"activeCount":97},[],{"trials":35038,"activeCount":97},[],{"intervention":12025,"totalTrials":417,"cells":35040},{"EARLY_PHASE1":35041,"PHASE1":35043,"PHASE2":35045,"PHASE3":35047,"PHASE4":35053,"NA":35055},{"trials":35042,"activeCount":97},[],{"trials":35044,"activeCount":97},[],{"trials":35046,"activeCount":97},[],{"trials":35048,"activeCount":97},[35049],{"nctId":12018,"briefTitle":12019,"status":155,"phases":35050,"primaryCompletion":2794,"completion":2794,"start":10166,"enrollment":2282,"conditions":35051,"interventions":35052},[87],[12022],[12024,12025,12026,12027],{"trials":35054,"activeCount":97},[],{"trials":35056,"activeCount":97},[],{"intervention":12026,"totalTrials":417,"cells":35058},{"EARLY_PHASE1":35059,"PHASE1":35061,"PHASE2":35063,"PHASE3":35065,"PHASE4":35071,"NA":35073},{"trials":35060,"activeCount":97},[],{"trials":35062,"activeCount":97},[],{"trials":35064,"activeCount":97},[],{"trials":35066,"activeCount":97},[35067],{"nctId":12018,"briefTitle":12019,"status":155,"phases":35068,"primaryCompletion":2794,"completion":2794,"start":10166,"enrollment":2282,"conditions":35069,"interventions":35070},[87],[12022],[12024,12025,12026,12027],{"trials":35072,"activeCount":97},[],{"trials":35074,"activeCount":97},[],{"intervention":12027,"totalTrials":417,"cells":35076},{"EARLY_PHASE1":35077,"PHASE1":35079,"PHASE2":35081,"PHASE3":35083,"PHASE4":35089,"NA":35091},{"trials":35078,"activeCount":97},[],{"trials":35080,"activeCount":97},[],{"trials":35082,"activeCount":97},[],{"trials":35084,"activeCount":97},[35085],{"nctId":12018,"briefTitle":12019,"status":155,"phases":35086,"primaryCompletion":2794,"completion":2794,"start":10166,"enrollment":2282,"conditions":35087,"interventions":35088},[87],[12022],[12024,12025,12026,12027],{"trials":35090,"activeCount":97},[],{"trials":35092,"activeCount":97},[],{"intervention":35094,"totalTrials":417,"cells":35095},"GSK Biologicals HPV 16\u002F18 vaccine 580299",{"EARLY_PHASE1":35096,"PHASE1":35098,"PHASE2":35100,"PHASE3":35102,"PHASE4":35115,"NA":35117},{"trials":35097,"activeCount":97},[],{"trials":35099,"activeCount":97},[],{"trials":35101,"activeCount":97},[],{"trials":35103,"activeCount":97},[35104],{"nctId":35105,"briefTitle":35106,"status":155,"phases":35107,"primaryCompletion":35108,"completion":35109,"start":35110,"enrollment":35111,"conditions":35112,"interventions":35113},"NCT00423046","Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age",[87],"2008-03-07","2012-05-14","2007-01-24",1106,[8723,12417],[35094,35114],"Gardasil ®",{"trials":35116,"activeCount":97},[],{"trials":35118,"activeCount":97},[],{"intervention":35114,"totalTrials":417,"cells":35120},{"EARLY_PHASE1":35121,"PHASE1":35123,"PHASE2":35125,"PHASE3":35127,"PHASE4":35133,"NA":35135},{"trials":35122,"activeCount":97},[],{"trials":35124,"activeCount":97},[],{"trials":35126,"activeCount":97},[],{"trials":35128,"activeCount":97},[35129],{"nctId":35105,"briefTitle":35106,"status":155,"phases":35130,"primaryCompletion":35108,"completion":35109,"start":35110,"enrollment":35111,"conditions":35131,"interventions":35132},[87],[8723,12417],[35094,35114],{"trials":35134,"activeCount":97},[],{"trials":35136,"activeCount":97},[],{"intervention":9787,"totalTrials":417,"cells":35138},{"EARLY_PHASE1":35139,"PHASE1":35141,"PHASE2":35143,"PHASE3":35145,"PHASE4":35151,"NA":35153},{"trials":35140,"activeCount":97},[],{"trials":35142,"activeCount":97},[],{"trials":35144,"activeCount":97},[],{"trials":35146,"activeCount":97},[35147],{"nctId":9782,"briefTitle":9783,"status":500,"phases":35148,"primaryCompletion":7545,"completion":7545,"start":7647,"enrollment":97,"conditions":35149,"interventions":35150},[87],[21],[9787,9743],{"trials":35152,"activeCount":97},[],{"trials":35154,"activeCount":97},[],{"intervention":35156,"totalTrials":417,"cells":35157},"Influenza vaccine GSK2340272A",{"EARLY_PHASE1":35158,"PHASE1":35160,"PHASE2":35162,"PHASE3":35164,"PHASE4":35174,"NA":35176},{"trials":35159,"activeCount":97},[],{"trials":35161,"activeCount":97},[],{"trials":35163,"activeCount":97},[],{"trials":35165,"activeCount":97},[35166],{"nctId":35167,"briefTitle":35168,"status":155,"phases":35169,"primaryCompletion":9877,"completion":35170,"start":6317,"enrollment":952,"conditions":35171,"interventions":35172},"NCT00979407","Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)",[87],"2010-11-04",[21],[35156,35173],"Influenza vaccine GSK2340274A",{"trials":35175,"activeCount":97},[],{"trials":35177,"activeCount":97},[],{"intervention":35173,"totalTrials":417,"cells":35179},{"EARLY_PHASE1":35180,"PHASE1":35182,"PHASE2":35184,"PHASE3":35186,"PHASE4":35192,"NA":35194},{"trials":35181,"activeCount":97},[],{"trials":35183,"activeCount":97},[],{"trials":35185,"activeCount":97},[],{"trials":35187,"activeCount":97},[35188],{"nctId":35167,"briefTitle":35168,"status":155,"phases":35189,"primaryCompletion":9877,"completion":35170,"start":6317,"enrollment":952,"conditions":35190,"interventions":35191},[87],[21],[35156,35173],{"trials":35193,"activeCount":97},[],{"trials":35195,"activeCount":97},[],{"intervention":35197,"totalTrials":417,"cells":35198},"Denosumab 70 mg\u002FmL",{"EARLY_PHASE1":35199,"PHASE1":35201,"PHASE2":35203,"PHASE3":35205,"PHASE4":35217,"NA":35219},{"trials":35200,"activeCount":97},[],{"trials":35202,"activeCount":97},[],{"trials":35204,"activeCount":97},[],{"trials":35206,"activeCount":97},[35207],{"nctId":35208,"briefTitle":35209,"status":155,"phases":35210,"primaryCompletion":8721,"completion":35211,"start":22319,"enrollment":35212,"conditions":35213,"interventions":35215},"NCT01920568","A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors",[87],"2016-04",487,[35214],"Fractures, Bone",[35197,35216],"Zoledronic acid 4 mg",{"trials":35218,"activeCount":97},[],{"trials":35220,"activeCount":97},[],{"intervention":35216,"totalTrials":417,"cells":35222},{"EARLY_PHASE1":35223,"PHASE1":35225,"PHASE2":35227,"PHASE3":35229,"PHASE4":35235,"NA":35237},{"trials":35224,"activeCount":97},[],{"trials":35226,"activeCount":97},[],{"trials":35228,"activeCount":97},[],{"trials":35230,"activeCount":97},[35231],{"nctId":35208,"briefTitle":35209,"status":155,"phases":35232,"primaryCompletion":8721,"completion":35211,"start":22319,"enrollment":35212,"conditions":35233,"interventions":35234},[87],[35214],[35197,35216],{"trials":35236,"activeCount":97},[],{"trials":35238,"activeCount":97},[],{"intervention":35240,"totalTrials":417,"cells":35241},"Levofloxacin oral",{"EARLY_PHASE1":35242,"PHASE1":35244,"PHASE2":35246,"PHASE3":35248,"PHASE4":35257,"NA":35259},{"trials":35243,"activeCount":97},[],{"trials":35245,"activeCount":97},[],{"trials":35247,"activeCount":97},[],{"trials":35249,"activeCount":97},[35250],{"nctId":35251,"briefTitle":35252,"status":155,"phases":35253,"primaryCompletion":4756,"completion":4756,"start":2814,"enrollment":9196,"conditions":35254,"interventions":35256},"NCT00169585","Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)",[87],[12263,35255],"Prostatitis",[35240],{"trials":35258,"activeCount":97},[],{"trials":35260,"activeCount":97},[],{"intervention":35262,"totalTrials":417,"cells":35263},"323U66",{"EARLY_PHASE1":35264,"PHASE1":35266,"PHASE2":35268,"PHASE3":35270,"PHASE4":35279,"NA":35281},{"trials":35265,"activeCount":97},[],{"trials":35267,"activeCount":97},[],{"trials":35269,"activeCount":97},[],{"trials":35271,"activeCount":97},[35272],{"nctId":35273,"briefTitle":35274,"status":155,"phases":35275,"primaryCompletion":19953,"completion":19953,"start":35276,"enrollment":1314,"conditions":35277,"interventions":35278},"NCT00296517","Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors",[87],"2006-01-19",[9292],[35262],{"trials":35280,"activeCount":97},[],{"trials":35282,"activeCount":97},[],{"intervention":35284,"totalTrials":417,"cells":35285},"GSK 2132231A",{"EARLY_PHASE1":35286,"PHASE1":35288,"PHASE2":35290,"PHASE3":35292,"PHASE4":35300,"NA":35302},{"trials":35287,"activeCount":97},[],{"trials":35289,"activeCount":97},[],{"trials":35291,"activeCount":97},[],{"trials":35293,"activeCount":97},[35294],{"nctId":35295,"briefTitle":35296,"status":145,"phases":35297,"primaryCompletion":18671,"completion":18671,"start":18501,"enrollment":26337,"conditions":35298,"interventions":35299},"NCT00796445","A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor",[87],[325],[35284],{"trials":35301,"activeCount":97},[],{"trials":35303,"activeCount":97},[],{"intervention":24429,"totalTrials":417,"cells":35305},{"EARLY_PHASE1":35306,"PHASE1":35308,"PHASE2":35310,"PHASE3":35312,"PHASE4":35318,"NA":35320},{"trials":35307,"activeCount":97},[],{"trials":35309,"activeCount":97},[],{"trials":35311,"activeCount":97},[],{"trials":35313,"activeCount":97},[35314],{"nctId":24423,"briefTitle":24424,"status":155,"phases":35315,"primaryCompletion":24426,"completion":24426,"start":5169,"enrollment":303,"conditions":35316,"interventions":35317},[87],[18],[24402,24429],{"trials":35319,"activeCount":97},[],{"trials":35321,"activeCount":97},[],{"intervention":35323,"totalTrials":417,"cells":35324},"ARIXTRA",{"EARLY_PHASE1":35325,"PHASE1":35327,"PHASE2":35329,"PHASE3":35331,"PHASE4":35343,"NA":35345},{"trials":35326,"activeCount":97},[],{"trials":35328,"activeCount":97},[],{"trials":35330,"activeCount":97},[],{"trials":35332,"activeCount":97},[35333],{"nctId":35334,"briefTitle":35335,"status":155,"phases":35336,"start":10670,"enrollment":9196,"conditions":35337,"interventions":35341},"NCT00328939","ARIXTRA Local Study For Registration In China.",[87],[35338,35339,35340],"Thromboembolism","Knee Replacement","Hip Replacement",[35323,35342],"Enoxaparine",{"trials":35344,"activeCount":97},[],{"trials":35346,"activeCount":97},[],{"intervention":35342,"totalTrials":417,"cells":35348},{"EARLY_PHASE1":35349,"PHASE1":35351,"PHASE2":35353,"PHASE3":35355,"PHASE4":35361,"NA":35363},{"trials":35350,"activeCount":97},[],{"trials":35352,"activeCount":97},[],{"trials":35354,"activeCount":97},[],{"trials":35356,"activeCount":97},[35357],{"nctId":35334,"briefTitle":35335,"status":155,"phases":35358,"start":10670,"enrollment":9196,"conditions":35359,"interventions":35360},[87],[35338,35339,35340],[35323,35342],{"trials":35362,"activeCount":97},[],{"trials":35364,"activeCount":97},[],{"intervention":35366,"totalTrials":417,"cells":35367},"Fluarix\u002FInflusplit SSW®",{"EARLY_PHASE1":35368,"PHASE1":35370,"PHASE2":35372,"PHASE3":35374,"PHASE4":35383,"NA":35385},{"trials":35369,"activeCount":97},[],{"trials":35371,"activeCount":97},[],{"trials":35373,"activeCount":97},[],{"trials":35375,"activeCount":97},[35376],{"nctId":35377,"briefTitle":35378,"status":155,"phases":35379,"primaryCompletion":35380,"completion":35380,"start":24580,"enrollment":201,"conditions":35381,"interventions":35382},"NCT01884519","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®\u002FInflusplit SSW® (2013\u002F2014 Season), in Adults 18 Years of Age and Older",[87],"2013-08-02",[21],[35366],{"trials":35384,"activeCount":97},[],{"trials":35386,"activeCount":97},[],{"intervention":35388,"totalTrials":417,"cells":35389},"GSK523338",{"EARLY_PHASE1":35390,"PHASE1":35392,"PHASE2":35394,"PHASE3":35396,"PHASE4":35407,"NA":35409},{"trials":35391,"activeCount":97},[],{"trials":35393,"activeCount":97},[],{"trials":35395,"activeCount":97},[],{"trials":35397,"activeCount":97},[35398],{"nctId":35399,"briefTitle":35400,"status":155,"phases":35401,"primaryCompletion":35402,"completion":35402,"start":35403,"enrollment":35404,"conditions":35405,"interventions":35406},"NCT00256867","A Study In Patients With Type 2 Diabetes Mellitus",[87],"2006-10-31","2005-08-18",369,[27],[35388],{"trials":35408,"activeCount":97},[],{"trials":35410,"activeCount":97},[],{"intervention":10569,"totalTrials":417,"cells":35412},{"EARLY_PHASE1":35413,"PHASE1":35415,"PHASE2":35417,"PHASE3":35419,"PHASE4":35425,"NA":35427},{"trials":35414,"activeCount":97},[],{"trials":35416,"activeCount":97},[],{"trials":35418,"activeCount":97},[],{"trials":35420,"activeCount":97},[35421],{"nctId":10563,"briefTitle":10564,"status":155,"phases":35422,"primaryCompletion":10566,"completion":10566,"start":8825,"enrollment":1944,"conditions":35423,"interventions":35424},[87],[4703,4704],[10569,10570,10571,10572,10573,10526],{"trials":35426,"activeCount":97},[],{"trials":35428,"activeCount":97},[],{"intervention":10571,"totalTrials":417,"cells":35430},{"EARLY_PHASE1":35431,"PHASE1":35433,"PHASE2":35435,"PHASE3":35437,"PHASE4":35443,"NA":35445},{"trials":35432,"activeCount":97},[],{"trials":35434,"activeCount":97},[],{"trials":35436,"activeCount":97},[],{"trials":35438,"activeCount":97},[35439],{"nctId":10563,"briefTitle":10564,"status":155,"phases":35440,"primaryCompletion":10566,"completion":10566,"start":8825,"enrollment":1944,"conditions":35441,"interventions":35442},[87],[4703,4704],[10569,10570,10571,10572,10573,10526],{"trials":35444,"activeCount":97},[],{"trials":35446,"activeCount":97},[],{"intervention":19876,"totalTrials":417,"cells":35448},{"EARLY_PHASE1":35449,"PHASE1":35451,"PHASE2":35453,"PHASE3":35455,"PHASE4":35461,"NA":35463},{"trials":35450,"activeCount":97},[],{"trials":35452,"activeCount":97},[],{"trials":35454,"activeCount":97},[],{"trials":35456,"activeCount":97},[35457],{"nctId":19870,"briefTitle":19871,"status":155,"phases":35458,"primaryCompletion":8235,"completion":4827,"start":9087,"enrollment":19873,"conditions":35459,"interventions":35460},[87],[4704,4703],[19876,19877,19818,8971],{"trials":35462,"activeCount":97},[],{"trials":35464,"activeCount":97},[],{"intervention":22640,"totalTrials":417,"cells":35466},{"EARLY_PHASE1":35467,"PHASE1":35469,"PHASE2":35471,"PHASE3":35473,"PHASE4":35479,"NA":35481},{"trials":35468,"activeCount":97},[],{"trials":35470,"activeCount":97},[],{"trials":35472,"activeCount":97},[],{"trials":35474,"activeCount":97},[35475],{"nctId":22631,"briefTitle":22632,"status":155,"phases":35476,"primaryCompletion":22634,"completion":22634,"start":22635,"enrollment":22636,"conditions":35477,"interventions":35478},[87],[12263],[22603,22639,22640,22641],{"trials":35480,"activeCount":97},[],{"trials":35482,"activeCount":97},[],{"intervention":22641,"totalTrials":417,"cells":35484},{"EARLY_PHASE1":35485,"PHASE1":35487,"PHASE2":35489,"PHASE3":35491,"PHASE4":35497,"NA":35499},{"trials":35486,"activeCount":97},[],{"trials":35488,"activeCount":97},[],{"trials":35490,"activeCount":97},[],{"trials":35492,"activeCount":97},[35493],{"nctId":22631,"briefTitle":22632,"status":155,"phases":35494,"primaryCompletion":22634,"completion":22634,"start":22635,"enrollment":22636,"conditions":35495,"interventions":35496},[87],[12263],[22603,22639,22640,22641],{"trials":35498,"activeCount":97},[],{"trials":35500,"activeCount":97},[],{"intervention":10241,"totalTrials":417,"cells":35502},{"EARLY_PHASE1":35503,"PHASE1":35505,"PHASE2":35507,"PHASE3":35509,"PHASE4":35515,"NA":35517},{"trials":35504,"activeCount":97},[],{"trials":35506,"activeCount":97},[],{"trials":35508,"activeCount":97},[],{"trials":35510,"activeCount":97},[35511],{"nctId":10233,"briefTitle":10234,"status":155,"phases":35512,"primaryCompletion":10236,"completion":10236,"start":10237,"enrollment":10238,"conditions":35513,"interventions":35514},[87],[992],[10200,10241],{"trials":35516,"activeCount":97},[],{"trials":35518,"activeCount":97},[],{"intervention":11945,"totalTrials":417,"cells":35520},{"EARLY_PHASE1":35521,"PHASE1":35523,"PHASE2":35525,"PHASE3":35527,"PHASE4":35533,"NA":35535},{"trials":35522,"activeCount":97},[],{"trials":35524,"activeCount":97},[],{"trials":35526,"activeCount":97},[],{"trials":35528,"activeCount":97},[35529],{"nctId":11936,"briefTitle":11937,"status":155,"phases":35530,"primaryCompletion":11939,"completion":11940,"start":11941,"enrollment":11942,"conditions":35531,"interventions":35532},[87],[8723],[11945,11946,11925],{"trials":35534,"activeCount":97},[],{"trials":35536,"activeCount":97},[],{"intervention":11946,"totalTrials":417,"cells":35538},{"EARLY_PHASE1":35539,"PHASE1":35541,"PHASE2":35543,"PHASE3":35545,"PHASE4":35551,"NA":35553},{"trials":35540,"activeCount":97},[],{"trials":35542,"activeCount":97},[],{"trials":35544,"activeCount":97},[],{"trials":35546,"activeCount":97},[35547],{"nctId":11936,"briefTitle":11937,"status":155,"phases":35548,"primaryCompletion":11939,"completion":11940,"start":11941,"enrollment":11942,"conditions":35549,"interventions":35550},[87],[8723],[11945,11946,11925],{"trials":35552,"activeCount":97},[],{"trials":35554,"activeCount":97},[],{"intervention":35556,"totalTrials":417,"cells":35557},"Investigational Seasonal Affective Disorder (SAD) Drug",{"EARLY_PHASE1":35558,"PHASE1":35560,"PHASE2":35562,"PHASE3":35564,"PHASE4":35572,"NA":35574},{"trials":35559,"activeCount":97},[],{"trials":35561,"activeCount":97},[],{"trials":35563,"activeCount":97},[],{"trials":35565,"activeCount":97},[35566],{"nctId":35567,"briefTitle":20644,"status":155,"phases":35568,"primaryCompletion":10886,"completion":10886,"start":7582,"conditions":35569,"interventions":35571},"NCT00046449",[87],[35570],"Seasonal Affective Disorder (SAD)",[35556],{"trials":35573,"activeCount":97},[],{"trials":35575,"activeCount":97},[],{"intervention":3719,"totalTrials":417,"cells":35577},{"EARLY_PHASE1":35578,"PHASE1":35580,"PHASE2":35582,"PHASE3":35584,"PHASE4":35590,"NA":35592},{"trials":35579,"activeCount":97},[],{"trials":35581,"activeCount":97},[],{"trials":35583,"activeCount":97},[],{"trials":35585,"activeCount":97},[35586],{"nctId":3711,"briefTitle":3712,"status":155,"phases":35587,"primaryCompletion":1361,"completion":1361,"start":3714,"enrollment":3715,"conditions":35588,"interventions":35589},[87],[2484,3717,2485,2486],[3689,3719,3717],{"trials":35591,"activeCount":97},[],{"trials":35593,"activeCount":97},[],{"intervention":3717,"totalTrials":417,"cells":35595},{"EARLY_PHASE1":35596,"PHASE1":35598,"PHASE2":35600,"PHASE3":35602,"PHASE4":35608,"NA":35610},{"trials":35597,"activeCount":97},[],{"trials":35599,"activeCount":97},[],{"trials":35601,"activeCount":97},[],{"trials":35603,"activeCount":97},[35604],{"nctId":3711,"briefTitle":3712,"status":155,"phases":35605,"primaryCompletion":1361,"completion":1361,"start":3714,"enrollment":3715,"conditions":35606,"interventions":35607},[87],[2484,3717,2485,2486],[3689,3719,3717],{"trials":35609,"activeCount":97},[],{"trials":35611,"activeCount":97},[],{"intervention":35613,"totalTrials":417,"cells":35614},"Experimental Denture Adhesive",{"EARLY_PHASE1":35615,"PHASE1":35617,"PHASE2":35619,"PHASE3":35621,"PHASE4":35632,"NA":35634},{"trials":35616,"activeCount":97},[],{"trials":35618,"activeCount":97},[],{"trials":35620,"activeCount":97},[],{"trials":35622,"activeCount":97},[35623],{"nctId":35624,"briefTitle":35625,"status":155,"phases":35626,"primaryCompletion":35627,"completion":35627,"start":35628,"enrollment":35629,"conditions":35630,"interventions":35631},"NCT03807700","To Evaluate Oral Health and Quality of Life Associated With Use of a Denture Adhesive",[87],"2019-05-04","2019-02-04",119,[15238],[35613],{"trials":35633,"activeCount":97},[],{"trials":35635,"activeCount":97},[],{"intervention":9797,"totalTrials":417,"cells":35637},{"EARLY_PHASE1":35638,"PHASE1":35640,"PHASE2":35642,"PHASE3":35644,"PHASE4":35650,"NA":35652},{"trials":35639,"activeCount":97},[],{"trials":35641,"activeCount":97},[],{"trials":35643,"activeCount":97},[],{"trials":35645,"activeCount":97},[35646],{"nctId":9789,"briefTitle":9790,"status":155,"phases":35647,"primaryCompletion":9792,"completion":9792,"start":9793,"enrollment":9794,"conditions":35648,"interventions":35649},[87],[21],[9797,9743],{"trials":35651,"activeCount":97},[],{"trials":35653,"activeCount":97},[],{"intervention":25791,"totalTrials":417,"cells":35655},{"EARLY_PHASE1":35656,"PHASE1":35658,"PHASE2":35660,"PHASE3":35662,"PHASE4":35668,"NA":35670},{"trials":35657,"activeCount":97},[],{"trials":35659,"activeCount":97},[],{"trials":35661,"activeCount":97},[],{"trials":35663,"activeCount":97},[35664],{"nctId":25783,"briefTitle":25784,"status":500,"phases":35665,"primaryCompletion":25786,"completion":25786,"start":8427,"enrollment":97,"conditions":35666,"interventions":35667},[87],[25788,25789,3554,4574],[25791,25765],{"trials":35669,"activeCount":97},[],{"trials":35671,"activeCount":97},[],{"intervention":35673,"totalTrials":417,"cells":35674},"Meningococcal Group B Vaccine",{"EARLY_PHASE1":35675,"PHASE1":35677,"PHASE2":35679,"PHASE3":35681,"PHASE4":35692,"NA":35694},{"trials":35676,"activeCount":97},[],{"trials":35678,"activeCount":97},[],{"trials":35680,"activeCount":97},[],{"trials":35682,"activeCount":97},[35683],{"nctId":35684,"briefTitle":35685,"status":155,"phases":35686,"primaryCompletion":20734,"completion":20734,"start":35687,"enrollment":35688,"conditions":35689,"interventions":35690},"NCT04318548","Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age",[87],"2020-08-25",945,[992],[35673,35691],"Meningococcal MenACWY Conjugate Vaccine",{"trials":35693,"activeCount":97},[],{"trials":35695,"activeCount":97},[],{"intervention":35691,"totalTrials":417,"cells":35697},{"EARLY_PHASE1":35698,"PHASE1":35700,"PHASE2":35702,"PHASE3":35704,"PHASE4":35710,"NA":35712},{"trials":35699,"activeCount":97},[],{"trials":35701,"activeCount":97},[],{"trials":35703,"activeCount":97},[],{"trials":35705,"activeCount":97},[35706],{"nctId":35684,"briefTitle":35685,"status":155,"phases":35707,"primaryCompletion":20734,"completion":20734,"start":35687,"enrollment":35688,"conditions":35708,"interventions":35709},[87],[992],[35673,35691],{"trials":35711,"activeCount":97},[],{"trials":35713,"activeCount":97},[],{"intervention":19885,"totalTrials":417,"cells":35715},{"EARLY_PHASE1":35716,"PHASE1":35718,"PHASE2":35720,"PHASE3":35722,"PHASE4":35728,"NA":35730},{"trials":35717,"activeCount":97},[],{"trials":35719,"activeCount":97},[],{"trials":35721,"activeCount":97},[],{"trials":35723,"activeCount":97},[35724],{"nctId":19879,"briefTitle":19880,"status":155,"phases":35725,"primaryCompletion":18524,"completion":14626,"start":19882,"enrollment":8275,"conditions":35726,"interventions":35727},[87],[992],[19855,19818,19885],{"trials":35729,"activeCount":97},[],{"trials":35731,"activeCount":97},[],{"intervention":35733,"totalTrials":417,"cells":35734},"Drisapersen",{"EARLY_PHASE1":35735,"PHASE1":35737,"PHASE2":35739,"PHASE3":35741,"PHASE4":35750,"NA":35752},{"trials":35736,"activeCount":97},[],{"trials":35738,"activeCount":97},[],{"trials":35740,"activeCount":97},[],{"trials":35742,"activeCount":97},[35743],{"nctId":35744,"briefTitle":35745,"status":500,"phases":35746,"primaryCompletion":7634,"completion":35747,"start":7634,"enrollment":97,"conditions":35748,"interventions":35749},"NCT01890798","Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol",[87],"2015-07",[25854],[35733],{"trials":35751,"activeCount":97},[],{"trials":35753,"activeCount":97},[],{"intervention":35755,"totalTrials":417,"cells":35756},"ferrous ascorbate",{"EARLY_PHASE1":35757,"PHASE1":35759,"PHASE2":35761,"PHASE3":35763,"PHASE4":35773,"NA":35775},{"trials":35758,"activeCount":97},[],{"trials":35760,"activeCount":97},[],{"trials":35762,"activeCount":97},[],{"trials":35764,"activeCount":97},[35765],{"nctId":35766,"briefTitle":35767,"status":155,"phases":35768,"primaryCompletion":27323,"completion":27323,"start":35769,"enrollment":5056,"conditions":35770,"interventions":35772},"NCT01160198","A Study to Demonstrate the Efficacy and Tolerability of Ferrous Bisglycinate Chelate in Iron Deficiency Anaemia and to Compare These With Those of Ferrous Ascorbate.",[87],"2010-10-13",[35771],"Haematopoiesis",[35755],{"trials":35774,"activeCount":97},[],{"trials":35776,"activeCount":97},[],{"intervention":27064,"totalTrials":417,"cells":35778},{"EARLY_PHASE1":35779,"PHASE1":35781,"PHASE2":35783,"PHASE3":35785,"PHASE4":35791,"NA":35793},{"trials":35780,"activeCount":97},[],{"trials":35782,"activeCount":97},[],{"trials":35784,"activeCount":97},[],{"trials":35786,"activeCount":97},[35787],{"nctId":27056,"briefTitle":27057,"status":155,"phases":35788,"primaryCompletion":27059,"completion":27060,"start":27061,"enrollment":10837,"conditions":35789,"interventions":35790},[87],[15],[27064,27065,27066,27036],{"trials":35792,"activeCount":97},[],{"trials":35794,"activeCount":97},[],{"intervention":27065,"totalTrials":417,"cells":35796},{"EARLY_PHASE1":35797,"PHASE1":35799,"PHASE2":35801,"PHASE3":35803,"PHASE4":35809,"NA":35811},{"trials":35798,"activeCount":97},[],{"trials":35800,"activeCount":97},[],{"trials":35802,"activeCount":97},[],{"trials":35804,"activeCount":97},[35805],{"nctId":27056,"briefTitle":27057,"status":155,"phases":35806,"primaryCompletion":27059,"completion":27060,"start":27061,"enrollment":10837,"conditions":35807,"interventions":35808},[87],[15],[27064,27065,27066,27036],{"trials":35810,"activeCount":97},[],{"trials":35812,"activeCount":97},[],{"intervention":27066,"totalTrials":417,"cells":35814},{"EARLY_PHASE1":35815,"PHASE1":35817,"PHASE2":35819,"PHASE3":35821,"PHASE4":35827,"NA":35829},{"trials":35816,"activeCount":97},[],{"trials":35818,"activeCount":97},[],{"trials":35820,"activeCount":97},[],{"trials":35822,"activeCount":97},[35823],{"nctId":27056,"briefTitle":27057,"status":155,"phases":35824,"primaryCompletion":27059,"completion":27060,"start":27061,"enrollment":10837,"conditions":35825,"interventions":35826},[87],[15],[27064,27065,27066,27036],{"trials":35828,"activeCount":97},[],{"trials":35830,"activeCount":97},[],{"intervention":35832,"totalTrials":417,"cells":35833},"Herpes simplex candidate vaccine- adjuvanted GSK208141",{"EARLY_PHASE1":35834,"PHASE1":35836,"PHASE2":35838,"PHASE3":35840,"PHASE4":35851,"NA":35853},{"trials":35835,"activeCount":97},[],{"trials":35837,"activeCount":97},[],{"trials":35839,"activeCount":97},[],{"trials":35841,"activeCount":97},[35842],{"nctId":35843,"briefTitle":35844,"status":155,"phases":35845,"primaryCompletion":35846,"completion":35846,"start":35847,"enrollment":35848,"conditions":35849,"interventions":35850},"NCT00699764","Safety of a Herpes Simplex Candidate Vaccine (gD2t) With MPL and Its Efficacy to Prevent Genital Herpes Disease",[87],"1999-10","1996-03",2491,[8709],[35832],{"trials":35852,"activeCount":97},[],{"trials":35854,"activeCount":97},[],{"intervention":559,"totalTrials":417,"cells":35856},{"EARLY_PHASE1":35857,"PHASE1":35859,"PHASE2":35861,"PHASE3":35863,"PHASE4":35869,"NA":35871},{"trials":35858,"activeCount":97},[],{"trials":35860,"activeCount":97},[],{"trials":35862,"activeCount":97},[],{"trials":35864,"activeCount":97},[35865],{"nctId":550,"briefTitle":551,"status":155,"phases":35866,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":35867,"interventions":35868},[87],[435],[53,517,559,560,560,561],{"trials":35870,"activeCount":97},[],{"trials":35872,"activeCount":97},[],{"intervention":561,"totalTrials":417,"cells":35874},{"EARLY_PHASE1":35875,"PHASE1":35877,"PHASE2":35879,"PHASE3":35881,"PHASE4":35887,"NA":35889},{"trials":35876,"activeCount":97},[],{"trials":35878,"activeCount":97},[],{"trials":35880,"activeCount":97},[],{"trials":35882,"activeCount":97},[35883],{"nctId":550,"briefTitle":551,"status":155,"phases":35884,"primaryCompletion":553,"completion":554,"start":555,"enrollment":556,"conditions":35885,"interventions":35886},[87],[435],[53,517,559,560,560,561],{"trials":35888,"activeCount":97},[],{"trials":35890,"activeCount":97},[],{"intervention":35892,"totalTrials":417,"cells":35893},"HZ\u002Fsu vaccine GSK1437173A",{"EARLY_PHASE1":35894,"PHASE1":35896,"PHASE2":35898,"PHASE3":35900,"PHASE4":35913,"NA":35915},{"trials":35895,"activeCount":97},[],{"trials":35897,"activeCount":97},[],{"trials":35899,"activeCount":97},[],{"trials":35901,"activeCount":97},[35902],{"nctId":35903,"briefTitle":35904,"status":155,"phases":35905,"primaryCompletion":35906,"completion":35907,"start":35908,"enrollment":35909,"conditions":35910,"interventions":35911},"NCT03439657","Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older",[87],"2019-05-06","2020-03-03","2018-04-12",913,[1030],[35892,35912],"Prevenar13",{"trials":35914,"activeCount":97},[],{"trials":35916,"activeCount":97},[],{"intervention":35912,"totalTrials":417,"cells":35918},{"EARLY_PHASE1":35919,"PHASE1":35921,"PHASE2":35923,"PHASE3":35925,"PHASE4":35931,"NA":35933},{"trials":35920,"activeCount":97},[],{"trials":35922,"activeCount":97},[],{"trials":35924,"activeCount":97},[],{"trials":35926,"activeCount":97},[35927],{"nctId":35903,"briefTitle":35904,"status":155,"phases":35928,"primaryCompletion":35906,"completion":35907,"start":35908,"enrollment":35909,"conditions":35929,"interventions":35930},[87],[1030],[35892,35912],{"trials":35932,"activeCount":97},[],{"trials":35934,"activeCount":97},[],{"intervention":35936,"totalTrials":417,"cells":35937},"rosiglitazone maleate\u002Fmetformin hydrochloride",{"EARLY_PHASE1":35938,"PHASE1":35940,"PHASE2":35942,"PHASE3":35944,"PHASE4":35956,"NA":35958},{"trials":35939,"activeCount":97},[],{"trials":35941,"activeCount":97},[],{"trials":35943,"activeCount":97},[],{"trials":35945,"activeCount":97},[35946],{"nctId":35947,"briefTitle":35948,"status":155,"phases":35949,"primaryCompletion":35950,"completion":35951,"start":35952,"enrollment":35953,"conditions":35954,"interventions":35955},"NCT00499707","Efficacy and Safety Study of Rosiglitazone\u002FMetformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects",[87],"2004-12-01","2004-12-16","2003-10-08",453,[27],[35936],{"trials":35957,"activeCount":97},[],{"trials":35959,"activeCount":97},[],{"intervention":35961,"totalTrials":417,"cells":35962},"LAM group",{"EARLY_PHASE1":35963,"PHASE1":35965,"PHASE2":35967,"PHASE3":35969,"PHASE4":35978,"NA":35980},{"trials":35964,"activeCount":97},[],{"trials":35966,"activeCount":97},[],{"trials":35968,"activeCount":97},[],{"trials":35970,"activeCount":97},[35971],{"nctId":35972,"briefTitle":35973,"status":155,"phases":35974,"primaryCompletion":7954,"completion":7954,"start":1360,"enrollment":3089,"conditions":35975,"interventions":35976},"NCT00316719","Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients",[87],[4190],[35961,35977],"ADV group",{"trials":35979,"activeCount":97},[],{"trials":35981,"activeCount":97},[],{"intervention":35977,"totalTrials":417,"cells":35983},{"EARLY_PHASE1":35984,"PHASE1":35986,"PHASE2":35988,"PHASE3":35990,"PHASE4":35996,"NA":35998},{"trials":35985,"activeCount":97},[],{"trials":35987,"activeCount":97},[],{"trials":35989,"activeCount":97},[],{"trials":35991,"activeCount":97},[35992],{"nctId":35972,"briefTitle":35973,"status":155,"phases":35993,"primaryCompletion":7954,"completion":7954,"start":1360,"enrollment":3089,"conditions":35994,"interventions":35995},[87],[4190],[35961,35977],{"trials":35997,"activeCount":97},[],{"trials":35999,"activeCount":97},[],{"intervention":36001,"totalTrials":417,"cells":36002},"HYCAMTIN, oral",{"EARLY_PHASE1":36003,"PHASE1":36005,"PHASE2":36007,"PHASE3":36009,"PHASE4":36017,"NA":36019},{"trials":36004,"activeCount":97},[],{"trials":36006,"activeCount":97},[],{"trials":36008,"activeCount":97},[],{"trials":36010,"activeCount":97},[36011],{"nctId":36012,"briefTitle":36013,"status":155,"phases":36014,"primaryCompletion":8037,"completion":493,"start":7659,"enrollment":13811,"conditions":36015,"interventions":36016},"NCT00390806","Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer",[87],[267],[36001],{"trials":36018,"activeCount":97},[],{"trials":36020,"activeCount":97},[],{"intervention":36022,"totalTrials":417,"cells":36023},"GSK Biologicals Influenza Vaccine GSK576389A",{"EARLY_PHASE1":36024,"PHASE1":36026,"PHASE2":36028,"PHASE3":36030,"PHASE4":36040,"NA":36042},{"trials":36025,"activeCount":97},[],{"trials":36027,"activeCount":97},[],{"trials":36029,"activeCount":97},[],{"trials":36031,"activeCount":97},[36032],{"nctId":36033,"briefTitle":36034,"status":155,"phases":36035,"primaryCompletion":25728,"completion":36036,"start":8217,"enrollment":36037,"conditions":36038,"interventions":36039},"NCT00529516","Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults",[87],"2008-06-04",1252,[21],[25702,36022],{"trials":36041,"activeCount":97},[],{"trials":36043,"activeCount":97},[],{"intervention":24209,"totalTrials":417,"cells":36045},{"EARLY_PHASE1":36046,"PHASE1":36048,"PHASE2":36050,"PHASE3":36052,"PHASE4":36058,"NA":36060},{"trials":36047,"activeCount":97},[],{"trials":36049,"activeCount":97},[],{"trials":36051,"activeCount":97},[],{"trials":36053,"activeCount":97},[36054],{"nctId":24199,"briefTitle":24200,"status":155,"phases":36055,"primaryCompletion":24202,"completion":24203,"start":24204,"enrollment":24205,"conditions":36056,"interventions":36057},[87],[24207],[24168,24209,24210],{"trials":36059,"activeCount":97},[],{"trials":36061,"activeCount":97},[],{"intervention":24210,"totalTrials":417,"cells":36063},{"EARLY_PHASE1":36064,"PHASE1":36066,"PHASE2":36068,"PHASE3":36070,"PHASE4":36076,"NA":36078},{"trials":36065,"activeCount":97},[],{"trials":36067,"activeCount":97},[],{"trials":36069,"activeCount":97},[],{"trials":36071,"activeCount":97},[36072],{"nctId":24199,"briefTitle":24200,"status":155,"phases":36073,"primaryCompletion":24202,"completion":24203,"start":24204,"enrollment":24205,"conditions":36074,"interventions":36075},[87],[24207],[24168,24209,24210],{"trials":36077,"activeCount":97},[],{"trials":36079,"activeCount":97},[],{"intervention":10345,"totalTrials":417,"cells":36081},{"EARLY_PHASE1":36082,"PHASE1":36084,"PHASE2":36086,"PHASE3":36088,"PHASE4":36094,"NA":36096},{"trials":36083,"activeCount":97},[],{"trials":36085,"activeCount":97},[],{"trials":36087,"activeCount":97},[],{"trials":36089,"activeCount":97},[36090],{"nctId":10337,"briefTitle":10338,"status":155,"phases":36091,"primaryCompletion":10340,"completion":10341,"start":9452,"enrollment":10342,"conditions":36092,"interventions":36093},[87],[992,5046],[10345,10346,10347,8968,10348],{"trials":36095,"activeCount":97},[],{"trials":36097,"activeCount":97},[],{"intervention":36099,"totalTrials":417,"cells":36100},"VACV",{"EARLY_PHASE1":36101,"PHASE1":36103,"PHASE2":36105,"PHASE3":36107,"PHASE4":36117,"NA":36119},{"trials":36102,"activeCount":97},[],{"trials":36104,"activeCount":97},[],{"trials":36106,"activeCount":97},[],{"trials":36108,"activeCount":97},[36109],{"nctId":36110,"briefTitle":36111,"status":155,"phases":36112,"primaryCompletion":36113,"completion":26392,"start":36114,"enrollment":345,"conditions":36115,"interventions":36116},"NCT01602562","Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients",[87],"2013-05-01","2012-05-07",[8709],[36099],{"trials":36118,"activeCount":97},[],{"trials":36120,"activeCount":97},[],{"intervention":36122,"totalTrials":417,"cells":36123},"Sumatriptan and Naproxen Sodium",{"EARLY_PHASE1":36124,"PHASE1":36126,"PHASE2":36128,"PHASE3":36130,"PHASE4":36139,"NA":36141},{"trials":36125,"activeCount":97},[],{"trials":36127,"activeCount":97},[],{"trials":36129,"activeCount":97},[],{"trials":36131,"activeCount":97},[36132],{"nctId":36133,"briefTitle":36134,"status":155,"phases":36135,"primaryCompletion":7647,"completion":11030,"start":8468,"enrollment":36136,"conditions":36137,"interventions":36138},"NCT00843024","Migraine Study in Adolescent Patients",[87],589,[14168],[36122],{"trials":36140,"activeCount":97},[],{"trials":36142,"activeCount":97},[],{"intervention":11829,"totalTrials":417,"cells":36144},{"EARLY_PHASE1":36145,"PHASE1":36147,"PHASE2":36149,"PHASE3":36151,"PHASE4":36157,"NA":36159},{"trials":36146,"activeCount":97},[],{"trials":36148,"activeCount":97},[],{"trials":36150,"activeCount":97},[],{"trials":36152,"activeCount":97},[36153],{"nctId":11820,"briefTitle":11821,"status":155,"phases":36154,"primaryCompletion":11823,"completion":11823,"start":11824,"enrollment":11825,"conditions":36155,"interventions":36156},[87],[11827],[11829,560],{"trials":36158,"activeCount":97},[],{"trials":36160,"activeCount":97},[],{"intervention":10019,"totalTrials":417,"cells":36162},{"EARLY_PHASE1":36163,"PHASE1":36165,"PHASE2":36167,"PHASE3":36169,"PHASE4":36175,"NA":36177},{"trials":36164,"activeCount":97},[],{"trials":36166,"activeCount":97},[],{"trials":36168,"activeCount":97},[],{"trials":36170,"activeCount":97},[36171],{"nctId":10010,"briefTitle":10011,"status":155,"phases":36172,"primaryCompletion":10013,"completion":10014,"start":10015,"enrollment":10016,"conditions":36173,"interventions":36174},[87],[3624,30,33],[9916,10019],{"trials":36176,"activeCount":97},[],{"trials":36178,"activeCount":97},[],{"intervention":23185,"totalTrials":417,"cells":36180},{"EARLY_PHASE1":36181,"PHASE1":36183,"PHASE2":36185,"PHASE3":36187,"PHASE4":36193,"NA":36195},{"trials":36182,"activeCount":97},[],{"trials":36184,"activeCount":97},[],{"trials":36186,"activeCount":97},[],{"trials":36188,"activeCount":97},[36189],{"nctId":23177,"briefTitle":23178,"status":155,"phases":36190,"primaryCompletion":23180,"completion":23180,"start":4800,"enrollment":23181,"conditions":36191,"interventions":36192},[87],[23183,1926],[23185,23141],{"trials":36194,"activeCount":97},[],{"trials":36196,"activeCount":97},[],{"intervention":36198,"totalTrials":417,"cells":36199},"Paracetamol, phenylephrine HCl, and vitamin C",{"EARLY_PHASE1":36200,"PHASE1":36202,"PHASE2":36204,"PHASE3":36206,"PHASE4":36214,"NA":36216},{"trials":36201,"activeCount":97},[],{"trials":36203,"activeCount":97},[],{"trials":36205,"activeCount":97},[],{"trials":36207,"activeCount":97},[36208],{"nctId":36209,"briefTitle":36210,"status":500,"phases":36211,"primaryCompletion":31868,"completion":31868,"start":903,"enrollment":97,"conditions":36212,"interventions":36213},"NCT02678234","An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu",[87],[14696],[36198],{"trials":36215,"activeCount":97},[],{"trials":36217,"activeCount":97},[],{"intervention":36219,"totalTrials":417,"cells":36220},"GSK1562902A",{"EARLY_PHASE1":36221,"PHASE1":36223,"PHASE2":36225,"PHASE3":36227,"PHASE4":36237,"NA":36239},{"trials":36222,"activeCount":97},[],{"trials":36224,"activeCount":97},[],{"trials":36226,"activeCount":97},[],{"trials":36228,"activeCount":97},[36229],{"nctId":36230,"briefTitle":36231,"status":155,"phases":36232,"primaryCompletion":36233,"completion":36233,"start":36234,"enrollment":4346,"conditions":36235,"interventions":36236},"NCT00812981","A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.",[87],"2009-06-07","2008-11-15",[21],[36219,36219],{"trials":36238,"activeCount":97},[],{"trials":36240,"activeCount":97},[],{"intervention":23434,"totalTrials":417,"cells":36242},{"EARLY_PHASE1":36243,"PHASE1":36245,"PHASE2":36247,"PHASE3":36249,"PHASE4":36255,"NA":36257},{"trials":36244,"activeCount":97},[],{"trials":36246,"activeCount":97},[],{"trials":36248,"activeCount":97},[],{"trials":36250,"activeCount":97},[36251],{"nctId":23426,"briefTitle":23427,"status":155,"phases":36252,"primaryCompletion":23429,"completion":23429,"start":23430,"enrollment":23431,"conditions":36253,"interventions":36254},[87],[15879],[23434,23435],{"trials":36256,"activeCount":97},[],{"trials":36258,"activeCount":97},[],{"intervention":36260,"totalTrials":417,"cells":36261},"GW685698",{"EARLY_PHASE1":36262,"PHASE1":36264,"PHASE2":36266,"PHASE3":36268,"PHASE4":36278,"NA":36280},{"trials":36263,"activeCount":97},[],{"trials":36265,"activeCount":97},[],{"trials":36267,"activeCount":97},[],{"trials":36269,"activeCount":97},[36270],{"nctId":36271,"briefTitle":36272,"status":155,"phases":36273,"primaryCompletion":36274,"completion":36275,"start":19038,"enrollment":2282,"conditions":36276,"interventions":36277},"NCT00358475","Study Of Perennial Allergic Rhinitis",[87],"2005-10-01","2005-10-12",[10169],[36260],{"trials":36279,"activeCount":97},[],{"trials":36281,"activeCount":97},[],{"intervention":36283,"totalTrials":417,"cells":36284},"Prophylaxis: Diphtheria, tetanus and pertussis",{"EARLY_PHASE1":36285,"PHASE1":36287,"PHASE2":36289,"PHASE3":36291,"PHASE4":36299,"NA":36301},{"trials":36286,"activeCount":97},[],{"trials":36288,"activeCount":97},[],{"trials":36290,"activeCount":97},[],{"trials":36292,"activeCount":97},[36293],{"nctId":36294,"briefTitle":36295,"status":155,"phases":36296,"primaryCompletion":10670,"completion":8478,"start":20690,"enrollment":7935,"conditions":36297,"interventions":36298},"NCT00263679","Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.",[87],[3624,30,33],[36283],{"trials":36300,"activeCount":97},[],{"trials":36302,"activeCount":97},[],{"intervention":36304,"totalTrials":417,"cells":36305},"human papillomavirus 16\u002F18 L1 virus-like particle\u002FAS04 vaccine",{"EARLY_PHASE1":36306,"PHASE1":36308,"PHASE2":36310,"PHASE3":36312,"PHASE4":36326,"NA":36328},{"trials":36307,"activeCount":97},[],{"trials":36309,"activeCount":97},[],{"trials":36311,"activeCount":97},[],{"trials":36313,"activeCount":97},[36314],{"nctId":36315,"briefTitle":36316,"status":155,"phases":36317,"primaryCompletion":36318,"completion":36318,"start":36319,"enrollment":36320,"conditions":36321,"interventions":36324},"NCT00128661","Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants",[87],"2010-12-31","2004-06-30",7466,[36322,36323],"Cervical Cancer","Precancerous Condition",[36304,36325],"hepatitis A inactivated virus vaccine",{"trials":36327,"activeCount":97},[],{"trials":36329,"activeCount":97},[],{"intervention":36325,"totalTrials":417,"cells":36331},{"EARLY_PHASE1":36332,"PHASE1":36334,"PHASE2":36336,"PHASE3":36338,"PHASE4":36344,"NA":36346},{"trials":36333,"activeCount":97},[],{"trials":36335,"activeCount":97},[],{"trials":36337,"activeCount":97},[],{"trials":36339,"activeCount":97},[36340],{"nctId":36315,"briefTitle":36316,"status":155,"phases":36341,"primaryCompletion":36318,"completion":36318,"start":36319,"enrollment":36320,"conditions":36342,"interventions":36343},[87],[36322,36323],[36304,36325],{"trials":36345,"activeCount":97},[],{"trials":36347,"activeCount":97},[],{"intervention":36349,"totalTrials":417,"cells":36350},"Combined diphtheria, tetanus, acellular pertussis vaccine",{"EARLY_PHASE1":36351,"PHASE1":36353,"PHASE2":36355,"PHASE3":36357,"PHASE4":36366,"NA":36368},{"trials":36352,"activeCount":97},[],{"trials":36354,"activeCount":97},[],{"trials":36356,"activeCount":97},[],{"trials":36358,"activeCount":97},[36359],{"nctId":36360,"briefTitle":36361,"status":155,"phases":36362,"primaryCompletion":2775,"completion":2775,"start":10287,"enrollment":36363,"conditions":36364,"interventions":36365},"NCT00109330","A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine",[87],4116,[30,33,3624],[36349],{"trials":36367,"activeCount":97},[],{"trials":36369,"activeCount":97},[],{"intervention":36371,"totalTrials":417,"cells":36372},"fondaparinux - UFH not indicated",{"EARLY_PHASE1":36373,"PHASE1":36375,"PHASE2":36377,"PHASE3":36379,"PHASE4":36390,"NA":36392},{"trials":36374,"activeCount":97},[],{"trials":36376,"activeCount":97},[],{"trials":36378,"activeCount":97},[],{"trials":36380,"activeCount":97},[36381],{"nctId":36382,"briefTitle":36383,"status":155,"phases":36384,"primaryCompletion":11759,"completion":11759,"start":19831,"enrollment":36385,"conditions":36386,"interventions":36387},"NCT00064428","OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction",[87],12092,[35338],[36371,36388,36389],"Fondaparinux - UFH indicated","Control - UFH",{"trials":36391,"activeCount":97},[],{"trials":36393,"activeCount":97},[],{"intervention":36388,"totalTrials":417,"cells":36395},{"EARLY_PHASE1":36396,"PHASE1":36398,"PHASE2":36400,"PHASE3":36402,"PHASE4":36408,"NA":36410},{"trials":36397,"activeCount":97},[],{"trials":36399,"activeCount":97},[],{"trials":36401,"activeCount":97},[],{"trials":36403,"activeCount":97},[36404],{"nctId":36382,"briefTitle":36383,"status":155,"phases":36405,"primaryCompletion":11759,"completion":11759,"start":19831,"enrollment":36385,"conditions":36406,"interventions":36407},[87],[35338],[36371,36388,36389],{"trials":36409,"activeCount":97},[],{"trials":36411,"activeCount":97},[],{"intervention":36389,"totalTrials":417,"cells":36413},{"EARLY_PHASE1":36414,"PHASE1":36416,"PHASE2":36418,"PHASE3":36420,"PHASE4":36426,"NA":36428},{"trials":36415,"activeCount":97},[],{"trials":36417,"activeCount":97},[],{"trials":36419,"activeCount":97},[],{"trials":36421,"activeCount":97},[36422],{"nctId":36382,"briefTitle":36383,"status":155,"phases":36423,"primaryCompletion":11759,"completion":11759,"start":19831,"enrollment":36385,"conditions":36424,"interventions":36425},[87],[35338],[36371,36388,36389],{"trials":36427,"activeCount":97},[],{"trials":36429,"activeCount":97},[],{"intervention":19893,"totalTrials":417,"cells":36431},{"EARLY_PHASE1":36432,"PHASE1":36434,"PHASE2":36436,"PHASE3":36438,"PHASE4":36444,"NA":36446},{"trials":36433,"activeCount":97},[],{"trials":36435,"activeCount":97},[],{"trials":36437,"activeCount":97},[],{"trials":36439,"activeCount":97},[36440],{"nctId":19887,"briefTitle":19888,"status":155,"phases":36441,"primaryCompletion":19890,"completion":19890,"start":9568,"enrollment":15576,"conditions":36442,"interventions":36443},[87],[4702,33,3624,30,4704],[19893,11069,19818,10348,7830],{"trials":36445,"activeCount":97},[],{"trials":36447,"activeCount":97},[],{"intervention":21960,"totalTrials":417,"cells":36449},{"EARLY_PHASE1":36450,"PHASE1":36452,"PHASE2":36454,"PHASE3":36456,"PHASE4":36462,"NA":36464},{"trials":36451,"activeCount":97},[],{"trials":36453,"activeCount":97},[],{"trials":36455,"activeCount":97},[],{"trials":36457,"activeCount":97},[36458],{"nctId":21952,"briefTitle":21953,"status":155,"phases":36459,"primaryCompletion":21955,"completion":21956,"start":10632,"enrollment":21957,"conditions":36460,"interventions":36461},[87],[8723],[21917,21960],{"trials":36463,"activeCount":97},[],{"trials":36465,"activeCount":97},[],{"intervention":36467,"totalTrials":417,"cells":36468},"Salmeterol\u002FFluticasone propionate Inhalation Powder",{"EARLY_PHASE1":36469,"PHASE1":36471,"PHASE2":36473,"PHASE3":36475,"PHASE4":36483,"NA":36485},{"trials":36470,"activeCount":97},[],{"trials":36472,"activeCount":97},[],{"trials":36474,"activeCount":97},[],{"trials":36476,"activeCount":97},[36477],{"nctId":36478,"briefTitle":36479,"status":155,"phases":36480,"primaryCompletion":4756,"completion":4756,"start":2805,"enrollment":27024,"conditions":36481,"interventions":36482},"NCT00328718","Pediatric ADVAIR DISKUS Versus Oral Montelukast Chewable Tablets",[87],[18],[8431,36467],{"trials":36484,"activeCount":97},[],{"trials":36486,"activeCount":97},[],{"intervention":36488,"totalTrials":417,"cells":36489},"Half-boosted Fosamprenavir",{"EARLY_PHASE1":36490,"PHASE1":36492,"PHASE2":36494,"PHASE3":36496,"PHASE4":36506,"NA":36508},{"trials":36491,"activeCount":97},[],{"trials":36493,"activeCount":97},[],{"trials":36495,"activeCount":97},[],{"trials":36497,"activeCount":97},[36498],{"nctId":36499,"briefTitle":36500,"status":155,"phases":36501,"primaryCompletion":7546,"completion":7546,"start":2383,"enrollment":36502,"conditions":36503,"interventions":36504},"NCT00363142","A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects",[87],211,[10662,9343],[36488,36505],"Full Boosted Fosamprenavir",{"trials":36507,"activeCount":97},[],{"trials":36509,"activeCount":97},[],{"intervention":36505,"totalTrials":417,"cells":36511},{"EARLY_PHASE1":36512,"PHASE1":36514,"PHASE2":36516,"PHASE3":36518,"PHASE4":36524,"NA":36526},{"trials":36513,"activeCount":97},[],{"trials":36515,"activeCount":97},[],{"trials":36517,"activeCount":97},[],{"trials":36519,"activeCount":97},[36520],{"nctId":36499,"briefTitle":36500,"status":155,"phases":36521,"primaryCompletion":7546,"completion":7546,"start":2383,"enrollment":36502,"conditions":36522,"interventions":36523},[87],[10662,9343],[36488,36505],{"trials":36525,"activeCount":97},[],{"trials":36527,"activeCount":97},[],{"intervention":27202,"totalTrials":417,"cells":36529},{"EARLY_PHASE1":36530,"PHASE1":36532,"PHASE2":36534,"PHASE3":36536,"PHASE4":36542,"NA":36544},{"trials":36531,"activeCount":97},[],{"trials":36533,"activeCount":97},[],{"trials":36535,"activeCount":97},[],{"trials":36537,"activeCount":97},[36538],{"nctId":27196,"briefTitle":27197,"status":155,"phases":36539,"primaryCompletion":12862,"completion":18651,"start":17993,"enrollment":27199,"conditions":36540,"interventions":36541},[87],[3287,5132],[27202,27181,27203],{"trials":36543,"activeCount":97},[],{"trials":36545,"activeCount":97},[],{"intervention":27203,"totalTrials":417,"cells":36547},{"EARLY_PHASE1":36548,"PHASE1":36550,"PHASE2":36552,"PHASE3":36554,"PHASE4":36560,"NA":36562},{"trials":36549,"activeCount":97},[],{"trials":36551,"activeCount":97},[],{"trials":36553,"activeCount":97},[],{"trials":36555,"activeCount":97},[36556],{"nctId":27196,"briefTitle":27197,"status":155,"phases":36557,"primaryCompletion":12862,"completion":18651,"start":17993,"enrollment":27199,"conditions":36558,"interventions":36559},[87],[3287,5132],[27202,27181,27203],{"trials":36561,"activeCount":97},[],{"trials":36563,"activeCount":97},[],{"intervention":36565,"totalTrials":417,"cells":36566},"GSK576428",{"EARLY_PHASE1":36567,"PHASE1":36569,"PHASE2":36571,"PHASE3":36573,"PHASE4":36582,"NA":36584},{"trials":36568,"activeCount":97},[],{"trials":36570,"activeCount":97},[],{"trials":36572,"activeCount":97},[],{"trials":36574,"activeCount":97},[36575],{"nctId":36576,"briefTitle":36577,"status":155,"phases":36578,"completion":8406,"start":2383,"enrollment":4377,"conditions":36579,"interventions":36581},"NCT00333021","Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients",[87],[36580],"Venous Thromboembolism",[26341,36565],{"trials":36583,"activeCount":97},[],{"trials":36585,"activeCount":97},[],{"intervention":36587,"totalTrials":417,"cells":36588},"Human rotavirus liquid vaccine",{"EARLY_PHASE1":36589,"PHASE1":36591,"PHASE2":36593,"PHASE3":36595,"PHASE4":36603,"NA":36605},{"trials":36590,"activeCount":97},[],{"trials":36592,"activeCount":97},[],{"trials":36594,"activeCount":97},[],{"trials":36596,"activeCount":97},[36597],{"nctId":36598,"briefTitle":36599,"status":155,"phases":36600,"completion":748,"start":4757,"enrollment":30619,"conditions":36601,"interventions":36602},"NCT00345956","To Evaluate Immunogenicity, Reactogenicity & Safety of 2 Doses of GSK Bio HRV Liquid Vaccine Given to Infants (Vietnam)",[87],[4759],[36587],{"trials":36604,"activeCount":97},[],{"trials":36606,"activeCount":97},[],{"intervention":36608,"totalTrials":417,"cells":36609},"GSK2340272A",{"EARLY_PHASE1":36610,"PHASE1":36612,"PHASE2":36614,"PHASE3":36616,"PHASE4":36627,"NA":36629},{"trials":36611,"activeCount":97},[],{"trials":36613,"activeCount":97},[],{"trials":36615,"activeCount":97},[],{"trials":36617,"activeCount":97},[36618],{"nctId":36619,"briefTitle":36620,"status":155,"phases":36621,"primaryCompletion":36622,"completion":12414,"start":36623,"enrollment":8337,"conditions":36624,"interventions":36625},"NCT00989287","Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults",[87],"2009-10-09","2009-10-07",[21],[36608,36626],"GSK2340269A",{"trials":36628,"activeCount":97},[],{"trials":36630,"activeCount":97},[],{"intervention":36626,"totalTrials":417,"cells":36632},{"EARLY_PHASE1":36633,"PHASE1":36635,"PHASE2":36637,"PHASE3":36639,"PHASE4":36645,"NA":36647},{"trials":36634,"activeCount":97},[],{"trials":36636,"activeCount":97},[],{"trials":36638,"activeCount":97},[],{"trials":36640,"activeCount":97},[36641],{"nctId":36619,"briefTitle":36620,"status":155,"phases":36642,"primaryCompletion":36622,"completion":12414,"start":36623,"enrollment":8337,"conditions":36643,"interventions":36644},[87],[21],[36608,36626],{"trials":36646,"activeCount":97},[],{"trials":36648,"activeCount":97},[],{"intervention":36650,"totalTrials":417,"cells":36651},"Quadrivalent influenza GSK2282512A vaccine",{"EARLY_PHASE1":36652,"PHASE1":36654,"PHASE2":36656,"PHASE3":36658,"PHASE4":36669,"NA":36671},{"trials":36653,"activeCount":97},[],{"trials":36655,"activeCount":97},[],{"trials":36657,"activeCount":97},[],{"trials":36659,"activeCount":97},[36660],{"nctId":36661,"briefTitle":36662,"status":155,"phases":36663,"primaryCompletion":36664,"completion":9307,"start":36665,"enrollment":36666,"conditions":36667,"interventions":36668},"NCT01711736","Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age",[87],"2013-02-21","2012-11-01",606,[21],[36650,25702],{"trials":36670,"activeCount":97},[],{"trials":36672,"activeCount":97},[],{"intervention":27226,"totalTrials":417,"cells":36674},{"EARLY_PHASE1":36675,"PHASE1":36677,"PHASE2":36679,"PHASE3":36681,"PHASE4":36687,"NA":36689},{"trials":36676,"activeCount":97},[],{"trials":36678,"activeCount":97},[],{"trials":36680,"activeCount":97},[],{"trials":36682,"activeCount":97},[36683],{"nctId":27220,"briefTitle":27221,"status":155,"phases":36684,"primaryCompletion":8151,"completion":2882,"start":8135,"enrollment":27223,"conditions":36685,"interventions":36686},[87],[4191],[27209,27226],{"trials":36688,"activeCount":97},[],{"trials":36690,"activeCount":97},[],{"intervention":36692,"totalTrials":417,"cells":36693},"fluticasone furoate + vilanterol",{"EARLY_PHASE1":36694,"PHASE1":36696,"PHASE2":36698,"PHASE3":36700,"PHASE4":36711,"NA":36713},{"trials":36695,"activeCount":97},[],{"trials":36697,"activeCount":97},[],{"trials":36699,"activeCount":97},[],{"trials":36701,"activeCount":97},[36702],{"nctId":36703,"briefTitle":36704,"status":155,"phases":36705,"primaryCompletion":36706,"completion":18223,"start":36665,"enrollment":36707,"conditions":36708,"interventions":36709},"NCT01706198","An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)\u002FVilanterol (VI, GW642444) With Standard Treatment in Asthma",[87],"2016-12-01",4233,[18],[36692,36710],"inhaled corticosteroid with or without a long acting beta2-agonist",{"trials":36712,"activeCount":97},[],{"trials":36714,"activeCount":97},[],{"intervention":36710,"totalTrials":417,"cells":36716},{"EARLY_PHASE1":36717,"PHASE1":36719,"PHASE2":36721,"PHASE3":36723,"PHASE4":36729,"NA":36731},{"trials":36718,"activeCount":97},[],{"trials":36720,"activeCount":97},[],{"trials":36722,"activeCount":97},[],{"trials":36724,"activeCount":97},[36725],{"nctId":36703,"briefTitle":36704,"status":155,"phases":36726,"primaryCompletion":36706,"completion":18223,"start":36665,"enrollment":36707,"conditions":36727,"interventions":36728},[87],[18],[36692,36710],{"trials":36730,"activeCount":97},[],{"trials":36732,"activeCount":97},[],{"intervention":36734,"totalTrials":417,"cells":36735},"PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine",{"EARLY_PHASE1":36736,"PHASE1":36738,"PHASE2":36740,"PHASE3":36742,"PHASE4":36753,"NA":36755},{"trials":36737,"activeCount":97},[],{"trials":36739,"activeCount":97},[],{"trials":36741,"activeCount":97},[],{"trials":36743,"activeCount":97},[36744],{"nctId":36745,"briefTitle":36746,"status":155,"phases":36747,"primaryCompletion":36748,"completion":36748,"start":36749,"enrollment":26337,"conditions":36750,"interventions":36751},"NCT03954743","Safety Study of 2 Formulations of GSK's Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks",[87],"2020-11-30","2019-07-19",[4759],[36734,36752],"Lyophilized formulation of GSK's oral live attenuated HRV vaccine",{"trials":36754,"activeCount":97},[],{"trials":36756,"activeCount":97},[],{"intervention":36752,"totalTrials":417,"cells":36758},{"EARLY_PHASE1":36759,"PHASE1":36761,"PHASE2":36763,"PHASE3":36765,"PHASE4":36771,"NA":36773},{"trials":36760,"activeCount":97},[],{"trials":36762,"activeCount":97},[],{"trials":36764,"activeCount":97},[],{"trials":36766,"activeCount":97},[36767],{"nctId":36745,"briefTitle":36746,"status":155,"phases":36768,"primaryCompletion":36748,"completion":36748,"start":36749,"enrollment":26337,"conditions":36769,"interventions":36770},[87],[4759],[36734,36752],{"trials":36772,"activeCount":97},[],{"trials":36774,"activeCount":97},[],{"intervention":8139,"totalTrials":417,"cells":36776},{"EARLY_PHASE1":36777,"PHASE1":36779,"PHASE2":36781,"PHASE3":36783,"PHASE4":36789,"NA":36791},{"trials":36778,"activeCount":97},[],{"trials":36780,"activeCount":97},[],{"trials":36782,"activeCount":97},[],{"trials":36784,"activeCount":97},[36785],{"nctId":8132,"briefTitle":8133,"status":155,"phases":36786,"primaryCompletion":8135,"completion":3390,"start":2813,"enrollment":8136,"conditions":36787,"interventions":36788},[87],[27],[7997,8139],{"trials":36790,"activeCount":97},[],{"trials":36792,"activeCount":97},[],{"intervention":27270,"totalTrials":417,"cells":36794},{"EARLY_PHASE1":36795,"PHASE1":36797,"PHASE2":36799,"PHASE3":36801,"PHASE4":36807,"NA":36809},{"trials":36796,"activeCount":97},[],{"trials":36798,"activeCount":97},[],{"trials":36800,"activeCount":97},[],{"trials":36802,"activeCount":97},[36803],{"nctId":27264,"briefTitle":27265,"status":155,"phases":36804,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":36805,"interventions":36806},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":36808,"activeCount":97},[],{"trials":36810,"activeCount":97},[],{"intervention":27271,"totalTrials":417,"cells":36812},{"EARLY_PHASE1":36813,"PHASE1":36815,"PHASE2":36817,"PHASE3":36819,"PHASE4":36825,"NA":36827},{"trials":36814,"activeCount":97},[],{"trials":36816,"activeCount":97},[],{"trials":36818,"activeCount":97},[],{"trials":36820,"activeCount":97},[36821],{"nctId":27264,"briefTitle":27265,"status":155,"phases":36822,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":36823,"interventions":36824},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":36826,"activeCount":97},[],{"trials":36828,"activeCount":97},[],{"intervention":27272,"totalTrials":417,"cells":36830},{"EARLY_PHASE1":36831,"PHASE1":36833,"PHASE2":36835,"PHASE3":36837,"PHASE4":36843,"NA":36845},{"trials":36832,"activeCount":97},[],{"trials":36834,"activeCount":97},[],{"trials":36836,"activeCount":97},[],{"trials":36838,"activeCount":97},[36839],{"nctId":27264,"briefTitle":27265,"status":155,"phases":36840,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":36841,"interventions":36842},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":36844,"activeCount":97},[],{"trials":36846,"activeCount":97},[],{"intervention":27273,"totalTrials":417,"cells":36848},{"EARLY_PHASE1":36849,"PHASE1":36851,"PHASE2":36853,"PHASE3":36855,"PHASE4":36861,"NA":36863},{"trials":36850,"activeCount":97},[],{"trials":36852,"activeCount":97},[],{"trials":36854,"activeCount":97},[],{"trials":36856,"activeCount":97},[36857],{"nctId":27264,"briefTitle":27265,"status":155,"phases":36858,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":36859,"interventions":36860},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":36862,"activeCount":97},[],{"trials":36864,"activeCount":97},[],{"intervention":27274,"totalTrials":417,"cells":36866},{"EARLY_PHASE1":36867,"PHASE1":36869,"PHASE2":36871,"PHASE3":36873,"PHASE4":36879,"NA":36881},{"trials":36868,"activeCount":97},[],{"trials":36870,"activeCount":97},[],{"trials":36872,"activeCount":97},[],{"trials":36874,"activeCount":97},[36875],{"nctId":27264,"briefTitle":27265,"status":155,"phases":36876,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":36877,"interventions":36878},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":36880,"activeCount":97},[],{"trials":36882,"activeCount":97},[],{"intervention":27275,"totalTrials":417,"cells":36884},{"EARLY_PHASE1":36885,"PHASE1":36887,"PHASE2":36889,"PHASE3":36891,"PHASE4":36897,"NA":36899},{"trials":36886,"activeCount":97},[],{"trials":36888,"activeCount":97},[],{"trials":36890,"activeCount":97},[],{"trials":36892,"activeCount":97},[36893],{"nctId":27264,"briefTitle":27265,"status":155,"phases":36894,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":36895,"interventions":36896},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":36898,"activeCount":97},[],{"trials":36900,"activeCount":97},[],{"intervention":27276,"totalTrials":417,"cells":36902},{"EARLY_PHASE1":36903,"PHASE1":36905,"PHASE2":36907,"PHASE3":36909,"PHASE4":36915,"NA":36917},{"trials":36904,"activeCount":97},[],{"trials":36906,"activeCount":97},[],{"trials":36908,"activeCount":97},[],{"trials":36910,"activeCount":97},[36911],{"nctId":27264,"briefTitle":27265,"status":155,"phases":36912,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":36913,"interventions":36914},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":36916,"activeCount":97},[],{"trials":36918,"activeCount":97},[],{"intervention":27277,"totalTrials":417,"cells":36920},{"EARLY_PHASE1":36921,"PHASE1":36923,"PHASE2":36925,"PHASE3":36927,"PHASE4":36933,"NA":36935},{"trials":36922,"activeCount":97},[],{"trials":36924,"activeCount":97},[],{"trials":36926,"activeCount":97},[],{"trials":36928,"activeCount":97},[36929],{"nctId":27264,"briefTitle":27265,"status":155,"phases":36930,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":36931,"interventions":36932},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":36934,"activeCount":97},[],{"trials":36936,"activeCount":97},[],{"intervention":27278,"totalTrials":417,"cells":36938},{"EARLY_PHASE1":36939,"PHASE1":36941,"PHASE2":36943,"PHASE3":36945,"PHASE4":36951,"NA":36953},{"trials":36940,"activeCount":97},[],{"trials":36942,"activeCount":97},[],{"trials":36944,"activeCount":97},[],{"trials":36946,"activeCount":97},[36947],{"nctId":27264,"briefTitle":27265,"status":155,"phases":36948,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":36949,"interventions":36950},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":36952,"activeCount":97},[],{"trials":36954,"activeCount":97},[],{"intervention":27279,"totalTrials":417,"cells":36956},{"EARLY_PHASE1":36957,"PHASE1":36959,"PHASE2":36961,"PHASE3":36963,"PHASE4":36969,"NA":36971},{"trials":36958,"activeCount":97},[],{"trials":36960,"activeCount":97},[],{"trials":36962,"activeCount":97},[],{"trials":36964,"activeCount":97},[36965],{"nctId":27264,"briefTitle":27265,"status":155,"phases":36966,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":36967,"interventions":36968},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":36970,"activeCount":97},[],{"trials":36972,"activeCount":97},[],{"intervention":27280,"totalTrials":417,"cells":36974},{"EARLY_PHASE1":36975,"PHASE1":36977,"PHASE2":36979,"PHASE3":36981,"PHASE4":36987,"NA":36989},{"trials":36976,"activeCount":97},[],{"trials":36978,"activeCount":97},[],{"trials":36980,"activeCount":97},[],{"trials":36982,"activeCount":97},[36983],{"nctId":27264,"briefTitle":27265,"status":155,"phases":36984,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":36985,"interventions":36986},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":36988,"activeCount":97},[],{"trials":36990,"activeCount":97},[],{"intervention":27281,"totalTrials":417,"cells":36992},{"EARLY_PHASE1":36993,"PHASE1":36995,"PHASE2":36997,"PHASE3":36999,"PHASE4":37005,"NA":37007},{"trials":36994,"activeCount":97},[],{"trials":36996,"activeCount":97},[],{"trials":36998,"activeCount":97},[],{"trials":37000,"activeCount":97},[37001],{"nctId":27264,"briefTitle":27265,"status":155,"phases":37002,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":37003,"interventions":37004},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":37006,"activeCount":97},[],{"trials":37008,"activeCount":97},[],{"intervention":27282,"totalTrials":417,"cells":37010},{"EARLY_PHASE1":37011,"PHASE1":37013,"PHASE2":37015,"PHASE3":37017,"PHASE4":37023,"NA":37025},{"trials":37012,"activeCount":97},[],{"trials":37014,"activeCount":97},[],{"trials":37016,"activeCount":97},[],{"trials":37018,"activeCount":97},[37019],{"nctId":27264,"briefTitle":27265,"status":155,"phases":37020,"primaryCompletion":484,"completion":493,"start":7591,"enrollment":27267,"conditions":37021,"interventions":37022},[87],[27],[27270,27271,27272,27273,27274,27275,27276,27277,27278,27279,27280,27281,27238,27282],{"trials":37024,"activeCount":97},[],{"trials":37026,"activeCount":97},[],{"intervention":37028,"totalTrials":417,"cells":37029},"Infanrix-IPV+Hib™",{"EARLY_PHASE1":37030,"PHASE1":37032,"PHASE2":37034,"PHASE3":37036,"PHASE4":37046,"NA":37048},{"trials":37031,"activeCount":97},[],{"trials":37033,"activeCount":97},[],{"trials":37035,"activeCount":97},[],{"trials":37037,"activeCount":97},[37038],{"nctId":37039,"briefTitle":37040,"status":155,"phases":37041,"primaryCompletion":37042,"completion":37042,"start":4878,"enrollment":7935,"conditions":37043,"interventions":37045},"NCT01577732","Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers",[87],"2013-04-09",[3624,4704,33,4702,30,37044],"Diphtheria-Tetanus-aPertussis-Poliomyelitis-Haemophilus Influenzae Type b Vaccines",[37028],{"trials":37047,"activeCount":97},[],{"trials":37049,"activeCount":97},[],{"intervention":8970,"totalTrials":417,"cells":37051},{"EARLY_PHASE1":37052,"PHASE1":37054,"PHASE2":37056,"PHASE3":37058,"PHASE4":37064,"NA":37066},{"trials":37053,"activeCount":97},[],{"trials":37055,"activeCount":97},[],{"trials":37057,"activeCount":97},[],{"trials":37059,"activeCount":97},[37060],{"nctId":8960,"briefTitle":8961,"status":155,"phases":37061,"primaryCompletion":8963,"completion":3551,"start":2383,"enrollment":4771,"conditions":37062,"interventions":37063},[87],[4704,4703],[8966,8967,8968,4808,8969,8970,8971],{"trials":37065,"activeCount":97},[],{"trials":37067,"activeCount":97},[],{"intervention":8711,"totalTrials":417,"cells":37069},{"EARLY_PHASE1":37070,"PHASE1":37072,"PHASE2":37074,"PHASE3":37076,"PHASE4":37082,"NA":37084},{"trials":37071,"activeCount":97},[],{"trials":37073,"activeCount":97},[],{"trials":37075,"activeCount":97},[],{"trials":37077,"activeCount":97},[37078],{"nctId":8702,"briefTitle":8703,"status":155,"phases":37079,"primaryCompletion":8705,"completion":8705,"start":8706,"enrollment":8707,"conditions":37080,"interventions":37081},[87],[8709],[8711,4694],{"trials":37083,"activeCount":97},[],{"trials":37085,"activeCount":97},[],{"intervention":23752,"totalTrials":417,"cells":37087},{"EARLY_PHASE1":37088,"PHASE1":37090,"PHASE2":37092,"PHASE3":37094,"PHASE4":37100,"NA":37102},{"trials":37089,"activeCount":97},[],{"trials":37091,"activeCount":97},[],{"trials":37093,"activeCount":97},[],{"trials":37095,"activeCount":97},[37096],{"nctId":23743,"briefTitle":23744,"status":155,"phases":37097,"primaryCompletion":23746,"completion":23747,"start":23748,"enrollment":23749,"conditions":37098,"interventions":37099},[87],[21],[23752,22545],{"trials":37101,"activeCount":97},[],{"trials":37103,"activeCount":97},[],{"intervention":37105,"totalTrials":417,"cells":37106},"Thiomersal free trivalent influenza split vaccine 2002\u002F2003",{"EARLY_PHASE1":37107,"PHASE1":37109,"PHASE2":37111,"PHASE3":37113,"PHASE4":37122,"NA":37124},{"trials":37108,"activeCount":97},[],{"trials":37110,"activeCount":97},[],{"trials":37112,"activeCount":97},[],{"trials":37114,"activeCount":97},[37115],{"nctId":37116,"briefTitle":37117,"status":155,"phases":37118,"primaryCompletion":10056,"start":7582,"enrollment":10180,"conditions":37119,"interventions":37120},"NCT00731029","Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002\u002F03 v\u002Fs Std Formulation of Influsplit SSW® 2002\u002F03",[87],[21],[37105,37121],"GlaxoSmithKline Biologicals' Influsplit SSW®\u002FFluarix™ 2002\u002F2003",{"trials":37123,"activeCount":97},[],{"trials":37125,"activeCount":97},[],{"intervention":37121,"totalTrials":417,"cells":37127},{"EARLY_PHASE1":37128,"PHASE1":37130,"PHASE2":37132,"PHASE3":37134,"PHASE4":37140,"NA":37142},{"trials":37129,"activeCount":97},[],{"trials":37131,"activeCount":97},[],{"trials":37133,"activeCount":97},[],{"trials":37135,"activeCount":97},[37136],{"nctId":37116,"briefTitle":37117,"status":155,"phases":37137,"primaryCompletion":10056,"start":7582,"enrollment":10180,"conditions":37138,"interventions":37139},[87],[21],[37105,37121],{"trials":37141,"activeCount":97},[],{"trials":37143,"activeCount":97},[],{"intervention":37145,"totalTrials":417,"cells":37146},"Carvedilol Phosphate modified release formulation",{"EARLY_PHASE1":37147,"PHASE1":37149,"PHASE2":37151,"PHASE3":37153,"PHASE4":37163,"NA":37165},{"trials":37148,"activeCount":97},[],{"trials":37150,"activeCount":97},[],{"trials":37152,"activeCount":97},[],{"trials":37154,"activeCount":97},[37155],{"nctId":37156,"briefTitle":37157,"status":155,"phases":37158,"primaryCompletion":8207,"completion":9820,"start":37159,"enrollment":579,"conditions":37160,"interventions":37161},"NCT00273052","COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension",[87],"2006-01-05",[13024],[37145,37162],"metoprolol succinate",{"trials":37164,"activeCount":97},[],{"trials":37166,"activeCount":97},[],{"intervention":37162,"totalTrials":417,"cells":37168},{"EARLY_PHASE1":37169,"PHASE1":37171,"PHASE2":37173,"PHASE3":37175,"PHASE4":37181,"NA":37183},{"trials":37170,"activeCount":97},[],{"trials":37172,"activeCount":97},[],{"trials":37174,"activeCount":97},[],{"trials":37176,"activeCount":97},[37177],{"nctId":37156,"briefTitle":37157,"status":155,"phases":37178,"primaryCompletion":8207,"completion":9820,"start":37159,"enrollment":579,"conditions":37179,"interventions":37180},[87],[13024],[37145,37162],{"trials":37182,"activeCount":97},[],{"trials":37184,"activeCount":97},[],{"intervention":4847,"totalTrials":417,"cells":37186},{"EARLY_PHASE1":37187,"PHASE1":37189,"PHASE2":37191,"PHASE3":37193,"PHASE4":37199,"NA":37201},{"trials":37188,"activeCount":97},[],{"trials":37190,"activeCount":97},[],{"trials":37192,"activeCount":97},[],{"trials":37194,"activeCount":97},[37195],{"nctId":4840,"briefTitle":4841,"status":155,"phases":37196,"primaryCompletion":4843,"completion":4843,"start":4844,"enrollment":590,"conditions":37197,"interventions":37198},[87],[4703,4704],[4847,4848,4472,4849],{"trials":37200,"activeCount":97},[],{"trials":37202,"activeCount":97},[],{"intervention":4849,"totalTrials":417,"cells":37204},{"EARLY_PHASE1":37205,"PHASE1":37207,"PHASE2":37209,"PHASE3":37211,"PHASE4":37217,"NA":37219},{"trials":37206,"activeCount":97},[],{"trials":37208,"activeCount":97},[],{"trials":37210,"activeCount":97},[],{"trials":37212,"activeCount":97},[37213],{"nctId":4840,"briefTitle":4841,"status":155,"phases":37214,"primaryCompletion":4843,"completion":4843,"start":4844,"enrollment":590,"conditions":37215,"interventions":37216},[87],[4703,4704],[4847,4848,4472,4849],{"trials":37218,"activeCount":97},[],{"trials":37220,"activeCount":97},[],{"intervention":37222,"totalTrials":417,"cells":37223},"carvedilol controlled release\u002Flisinopril",{"EARLY_PHASE1":37224,"PHASE1":37226,"PHASE2":37228,"PHASE3":37230,"PHASE4":37239,"NA":37241},{"trials":37225,"activeCount":97},[],{"trials":37227,"activeCount":97},[],{"trials":37229,"activeCount":97},[],{"trials":37231,"activeCount":97},[37232],{"nctId":37233,"briefTitle":37234,"status":155,"phases":37235,"primaryCompletion":7976,"completion":7976,"start":2382,"enrollment":9518,"conditions":37236,"interventions":37237},"NCT00624065","Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure",[87],[13024],[37222,37238],"lisinopril + placebo",{"trials":37240,"activeCount":97},[],{"trials":37242,"activeCount":97},[],{"intervention":37238,"totalTrials":417,"cells":37244},{"EARLY_PHASE1":37245,"PHASE1":37247,"PHASE2":37249,"PHASE3":37251,"PHASE4":37257,"NA":37259},{"trials":37246,"activeCount":97},[],{"trials":37248,"activeCount":97},[],{"trials":37250,"activeCount":97},[],{"trials":37252,"activeCount":97},[37253],{"nctId":37233,"briefTitle":37234,"status":155,"phases":37254,"primaryCompletion":7976,"completion":7976,"start":2382,"enrollment":9518,"conditions":37255,"interventions":37256},[87],[13024],[37222,37238],{"trials":37258,"activeCount":97},[],{"trials":37260,"activeCount":97},[],{"intervention":37262,"totalTrials":417,"cells":37263},"Intravenous topotecan\u002Fcisplatin",{"EARLY_PHASE1":37264,"PHASE1":37266,"PHASE2":37268,"PHASE3":37270,"PHASE4":37279,"NA":37281},{"trials":37265,"activeCount":97},[],{"trials":37267,"activeCount":97},[],{"trials":37269,"activeCount":97},[],{"trials":37271,"activeCount":97},[37272],{"nctId":37273,"briefTitle":37274,"status":155,"phases":37275,"primaryCompletion":8406,"completion":8406,"start":2845,"enrollment":11508,"conditions":37276,"interventions":37277},"NCT00320359","Topotecan Plus Cisplatin Versus Etoposide Plus Cisplatin In 1st Line Extensive Disease Small Cell Lung Cancer",[87],[2778],[37262,37278],"Intravenous etoposide\u002Fcisplatin",{"trials":37280,"activeCount":97},[],{"trials":37282,"activeCount":97},[],{"intervention":37278,"totalTrials":417,"cells":37284},{"EARLY_PHASE1":37285,"PHASE1":37287,"PHASE2":37289,"PHASE3":37291,"PHASE4":37297,"NA":37299},{"trials":37286,"activeCount":97},[],{"trials":37288,"activeCount":97},[],{"trials":37290,"activeCount":97},[],{"trials":37292,"activeCount":97},[37293],{"nctId":37273,"briefTitle":37274,"status":155,"phases":37294,"primaryCompletion":8406,"completion":8406,"start":2845,"enrollment":11508,"conditions":37295,"interventions":37296},[87],[2778],[37262,37278],{"trials":37298,"activeCount":97},[],{"trials":37300,"activeCount":97},[],{"intervention":37302,"totalTrials":417,"cells":37303},"Lyophilized formulation of HRV vaccine",{"EARLY_PHASE1":37304,"PHASE1":37306,"PHASE2":37308,"PHASE3":37310,"PHASE4":37321,"NA":37323},{"trials":37305,"activeCount":97},[],{"trials":37307,"activeCount":97},[],{"trials":37309,"activeCount":97},[],{"trials":37311,"activeCount":97},[37312],{"nctId":37313,"briefTitle":37314,"status":155,"phases":37315,"primaryCompletion":17676,"completion":17676,"start":37316,"enrollment":37317,"conditions":37318,"interventions":37319},"NCT00363545","To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)",[87],"2006-09-01",1274,[4759],[37302,37320],"Liquid formulation of HRV vaccine",{"trials":37322,"activeCount":97},[],{"trials":37324,"activeCount":97},[],{"intervention":37320,"totalTrials":417,"cells":37326},{"EARLY_PHASE1":37327,"PHASE1":37329,"PHASE2":37331,"PHASE3":37333,"PHASE4":37339,"NA":37341},{"trials":37328,"activeCount":97},[],{"trials":37330,"activeCount":97},[],{"trials":37332,"activeCount":97},[],{"trials":37334,"activeCount":97},[37335],{"nctId":37313,"briefTitle":37314,"status":155,"phases":37336,"primaryCompletion":17676,"completion":17676,"start":37316,"enrollment":37317,"conditions":37337,"interventions":37338},[87],[4759],[37302,37320],{"trials":37340,"activeCount":97},[],{"trials":37342,"activeCount":97},[],{"intervention":37344,"totalTrials":417,"cells":37345},"Sumatriptan 25 mg",{"EARLY_PHASE1":37346,"PHASE1":37348,"PHASE2":37350,"PHASE3":37352,"PHASE4":37362,"NA":37364},{"trials":37347,"activeCount":97},[],{"trials":37349,"activeCount":97},[],{"trials":37351,"activeCount":97},[],{"trials":37353,"activeCount":97},[37354],{"nctId":37355,"briefTitle":37356,"status":155,"phases":37357,"primaryCompletion":22592,"completion":16834,"start":37358,"enrollment":21756,"conditions":37359,"interventions":37360},"NCT00963937","Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents",[87],"2009-09-28",[14168],[37344,37361],"Sumatriptan 50 mg",{"trials":37363,"activeCount":97},[],{"trials":37365,"activeCount":97},[],{"intervention":37361,"totalTrials":417,"cells":37367},{"EARLY_PHASE1":37368,"PHASE1":37370,"PHASE2":37372,"PHASE3":37374,"PHASE4":37380,"NA":37382},{"trials":37369,"activeCount":97},[],{"trials":37371,"activeCount":97},[],{"trials":37373,"activeCount":97},[],{"trials":37375,"activeCount":97},[37376],{"nctId":37355,"briefTitle":37356,"status":155,"phases":37377,"primaryCompletion":22592,"completion":16834,"start":37358,"enrollment":21756,"conditions":37378,"interventions":37379},[87],[14168],[37344,37361],{"trials":37381,"activeCount":97},[],{"trials":37383,"activeCount":97},[],{"intervention":37385,"totalTrials":417,"cells":37386},"Avandia",{"EARLY_PHASE1":37387,"PHASE1":37389,"PHASE2":37391,"PHASE3":37393,"PHASE4":37402,"NA":37404},{"trials":37388,"activeCount":97},[],{"trials":37390,"activeCount":97},[],{"trials":37392,"activeCount":97},[],{"trials":37394,"activeCount":97},[37395],{"nctId":37396,"briefTitle":37397,"status":155,"phases":37398,"primaryCompletion":19831,"completion":19831,"start":13061,"enrollment":1634,"conditions":37399,"interventions":37401},"NCT00197132","Study In Patients With Insulin Resistance",[87],[37400],"Insulin Resistance",[37385],{"trials":37403,"activeCount":97},[],{"trials":37405,"activeCount":97},[],{"intervention":37407,"totalTrials":417,"cells":37408},"Escitalopram",{"EARLY_PHASE1":37409,"PHASE1":37411,"PHASE2":37413,"PHASE3":37415,"PHASE4":37427,"NA":37429},{"trials":37410,"activeCount":97},[],{"trials":37412,"activeCount":97},[],{"trials":37414,"activeCount":97},[],{"trials":37416,"activeCount":97},[37417],{"nctId":37418,"briefTitle":37419,"status":155,"phases":37420,"primaryCompletion":37421,"completion":23180,"start":37422,"enrollment":37423,"conditions":37424,"interventions":37425},"NCT02191397","Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder",[87],"2016-10-10","2015-02-10",534,[10889],[37426,37407],"Bupropion",{"trials":37428,"activeCount":97},[],{"trials":37430,"activeCount":97},[],{"intervention":8588,"totalTrials":417,"cells":37432},{"EARLY_PHASE1":37433,"PHASE1":37435,"PHASE2":37437,"PHASE3":37439,"PHASE4":37445,"NA":37447},{"trials":37434,"activeCount":97},[],{"trials":37436,"activeCount":97},[],{"trials":37438,"activeCount":97},[],{"trials":37440,"activeCount":97},[37441],{"nctId":8580,"briefTitle":8581,"status":155,"phases":37442,"primaryCompletion":8583,"completion":8583,"start":8584,"enrollment":8585,"conditions":37443,"interventions":37444},[87],[18],[8588,8589,8590,8591,8592,8593,8594,2916],{"trials":37446,"activeCount":97},[],{"trials":37448,"activeCount":97},[],{"intervention":8589,"totalTrials":417,"cells":37450},{"EARLY_PHASE1":37451,"PHASE1":37453,"PHASE2":37455,"PHASE3":37457,"PHASE4":37463,"NA":37465},{"trials":37452,"activeCount":97},[],{"trials":37454,"activeCount":97},[],{"trials":37456,"activeCount":97},[],{"trials":37458,"activeCount":97},[37459],{"nctId":8580,"briefTitle":8581,"status":155,"phases":37460,"primaryCompletion":8583,"completion":8583,"start":8584,"enrollment":8585,"conditions":37461,"interventions":37462},[87],[18],[8588,8589,8590,8591,8592,8593,8594,2916],{"trials":37464,"activeCount":97},[],{"trials":37466,"activeCount":97},[],{"intervention":8590,"totalTrials":417,"cells":37468},{"EARLY_PHASE1":37469,"PHASE1":37471,"PHASE2":37473,"PHASE3":37475,"PHASE4":37481,"NA":37483},{"trials":37470,"activeCount":97},[],{"trials":37472,"activeCount":97},[],{"trials":37474,"activeCount":97},[],{"trials":37476,"activeCount":97},[37477],{"nctId":8580,"briefTitle":8581,"status":155,"phases":37478,"primaryCompletion":8583,"completion":8583,"start":8584,"enrollment":8585,"conditions":37479,"interventions":37480},[87],[18],[8588,8589,8590,8591,8592,8593,8594,2916],{"trials":37482,"activeCount":97},[],{"trials":37484,"activeCount":97},[],{"intervention":8591,"totalTrials":417,"cells":37486},{"EARLY_PHASE1":37487,"PHASE1":37489,"PHASE2":37491,"PHASE3":37493,"PHASE4":37499,"NA":37501},{"trials":37488,"activeCount":97},[],{"trials":37490,"activeCount":97},[],{"trials":37492,"activeCount":97},[],{"trials":37494,"activeCount":97},[37495],{"nctId":8580,"briefTitle":8581,"status":155,"phases":37496,"primaryCompletion":8583,"completion":8583,"start":8584,"enrollment":8585,"conditions":37497,"interventions":37498},[87],[18],[8588,8589,8590,8591,8592,8593,8594,2916],{"trials":37500,"activeCount":97},[],{"trials":37502,"activeCount":97},[],{"intervention":8592,"totalTrials":417,"cells":37504},{"EARLY_PHASE1":37505,"PHASE1":37507,"PHASE2":37509,"PHASE3":37511,"PHASE4":37517,"NA":37519},{"trials":37506,"activeCount":97},[],{"trials":37508,"activeCount":97},[],{"trials":37510,"activeCount":97},[],{"trials":37512,"activeCount":97},[37513],{"nctId":8580,"briefTitle":8581,"status":155,"phases":37514,"primaryCompletion":8583,"completion":8583,"start":8584,"enrollment":8585,"conditions":37515,"interventions":37516},[87],[18],[8588,8589,8590,8591,8592,8593,8594,2916],{"trials":37518,"activeCount":97},[],{"trials":37520,"activeCount":97},[],{"intervention":8593,"totalTrials":417,"cells":37522},{"EARLY_PHASE1":37523,"PHASE1":37525,"PHASE2":37527,"PHASE3":37529,"PHASE4":37535,"NA":37537},{"trials":37524,"activeCount":97},[],{"trials":37526,"activeCount":97},[],{"trials":37528,"activeCount":97},[],{"trials":37530,"activeCount":97},[37531],{"nctId":8580,"briefTitle":8581,"status":155,"phases":37532,"primaryCompletion":8583,"completion":8583,"start":8584,"enrollment":8585,"conditions":37533,"interventions":37534},[87],[18],[8588,8589,8590,8591,8592,8593,8594,2916],{"trials":37536,"activeCount":97},[],{"trials":37538,"activeCount":97},[],{"intervention":8594,"totalTrials":417,"cells":37540},{"EARLY_PHASE1":37541,"PHASE1":37543,"PHASE2":37545,"PHASE3":37547,"PHASE4":37553,"NA":37555},{"trials":37542,"activeCount":97},[],{"trials":37544,"activeCount":97},[],{"trials":37546,"activeCount":97},[],{"trials":37548,"activeCount":97},[37549],{"nctId":8580,"briefTitle":8581,"status":155,"phases":37550,"primaryCompletion":8583,"completion":8583,"start":8584,"enrollment":8585,"conditions":37551,"interventions":37552},[87],[18],[8588,8589,8590,8591,8592,8593,8594,2916],{"trials":37554,"activeCount":97},[],{"trials":37556,"activeCount":97},[],{"intervention":37558,"totalTrials":417,"cells":37559},"GSK1755165; placebo; zopiclone",{"EARLY_PHASE1":37560,"PHASE1":37562,"PHASE2":37564,"PHASE3":37566,"PHASE4":37575,"NA":37577},{"trials":37561,"activeCount":97},[],{"trials":37563,"activeCount":97},[],{"trials":37565,"activeCount":97},[],{"trials":37567,"activeCount":97},[37568],{"nctId":37569,"briefTitle":37570,"status":155,"phases":37571,"primaryCompletion":9133,"completion":9133,"start":5018,"enrollment":37572,"conditions":37573,"interventions":37574},"NCT00699608","An Evaluation of Potential Next-day Residual Effects of Eszopiclone in Healthy Volunteers.",[87],91,[7524,19716],[37558],{"trials":37576,"activeCount":97},[],{"trials":37578,"activeCount":97},[],{"intervention":10898,"totalTrials":417,"cells":37580},{"EARLY_PHASE1":37581,"PHASE1":37583,"PHASE2":37585,"PHASE3":37587,"PHASE4":37593,"NA":37595},{"trials":37582,"activeCount":97},[],{"trials":37584,"activeCount":97},[],{"trials":37586,"activeCount":97},[],{"trials":37588,"activeCount":97},[37589],{"nctId":10893,"briefTitle":10894,"status":155,"phases":37590,"start":7659,"enrollment":7810,"conditions":37591,"interventions":37592},[87],[10889,10890],[10872,10898],{"trials":37594,"activeCount":97},[],{"trials":37596,"activeCount":97},[],{"intervention":3344,"totalTrials":417,"cells":37598},{"EARLY_PHASE1":37599,"PHASE1":37601,"PHASE2":37603,"PHASE3":37605,"PHASE4":37611,"NA":37613},{"trials":37600,"activeCount":97},[],{"trials":37602,"activeCount":97},[],{"trials":37604,"activeCount":97},[],{"trials":37606,"activeCount":97},[37607],{"nctId":3337,"briefTitle":3338,"status":155,"phases":37608,"primaryCompletion":3340,"completion":3340,"start":3341,"enrollment":16,"conditions":37609,"interventions":37610},[87],[3298],[3273,3344,3289,3290,3345],{"trials":37612,"activeCount":97},[],{"trials":37614,"activeCount":97},[],{"intervention":3345,"totalTrials":417,"cells":37616},{"EARLY_PHASE1":37617,"PHASE1":37619,"PHASE2":37621,"PHASE3":37623,"PHASE4":37629,"NA":37631},{"trials":37618,"activeCount":97},[],{"trials":37620,"activeCount":97},[],{"trials":37622,"activeCount":97},[],{"trials":37624,"activeCount":97},[37625],{"nctId":3337,"briefTitle":3338,"status":155,"phases":37626,"primaryCompletion":3340,"completion":3340,"start":3341,"enrollment":16,"conditions":37627,"interventions":37628},[87],[3298],[3273,3344,3289,3290,3345],{"trials":37630,"activeCount":97},[],{"trials":37632,"activeCount":97},[],{"intervention":37634,"totalTrials":417,"cells":37635},"GW815SF HFA MDI",{"EARLY_PHASE1":37636,"PHASE1":37638,"PHASE2":37640,"PHASE3":37642,"PHASE4":37651,"NA":37653},{"trials":37637,"activeCount":97},[],{"trials":37639,"activeCount":97},[],{"trials":37641,"activeCount":97},[],{"trials":37643,"activeCount":97},[37644],{"nctId":37645,"briefTitle":37646,"status":155,"phases":37647,"primaryCompletion":7954,"completion":7954,"start":4756,"enrollment":7573,"conditions":37648,"interventions":37649},"NCT00448435","Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma",[87],[9464],[37634,37650],"salmeterol and fluticasone propionate",{"trials":37652,"activeCount":97},[],{"trials":37654,"activeCount":97},[],{"intervention":37650,"totalTrials":417,"cells":37656},{"EARLY_PHASE1":37657,"PHASE1":37659,"PHASE2":37661,"PHASE3":37663,"PHASE4":37669,"NA":37671},{"trials":37658,"activeCount":97},[],{"trials":37660,"activeCount":97},[],{"trials":37662,"activeCount":97},[],{"trials":37664,"activeCount":97},[37665],{"nctId":37645,"briefTitle":37646,"status":155,"phases":37666,"primaryCompletion":7954,"completion":7954,"start":4756,"enrollment":7573,"conditions":37667,"interventions":37668},[87],[9464],[37634,37650],{"trials":37670,"activeCount":97},[],{"trials":37672,"activeCount":97},[],{"intervention":7938,"totalTrials":417,"cells":37674},{"EARLY_PHASE1":37675,"PHASE1":37677,"PHASE2":37679,"PHASE3":37681,"PHASE4":37687,"NA":37689},{"trials":37676,"activeCount":97},[],{"trials":37678,"activeCount":97},[],{"trials":37680,"activeCount":97},[],{"trials":37682,"activeCount":97},[37683],{"nctId":7930,"briefTitle":7931,"status":155,"phases":37684,"primaryCompletion":7933,"completion":7933,"start":7934,"enrollment":7935,"conditions":37685,"interventions":37686},[87],[24],[7938,7718],{"trials":37688,"activeCount":97},[],{"trials":37690,"activeCount":97},[],{"intervention":23392,"totalTrials":417,"cells":37692},{"EARLY_PHASE1":37693,"PHASE1":37695,"PHASE2":37697,"PHASE3":37699,"PHASE4":37705,"NA":37707},{"trials":37694,"activeCount":97},[],{"trials":37696,"activeCount":97},[],{"trials":37698,"activeCount":97},[],{"trials":37700,"activeCount":97},[37701],{"nctId":23387,"briefTitle":23388,"status":155,"phases":37702,"primaryCompletion":9728,"completion":9697,"start":8135,"enrollment":829,"conditions":37703,"interventions":37704},[87],[23376],[23361,23392],{"trials":37706,"activeCount":97},[],{"trials":37708,"activeCount":97},[],{"intervention":37710,"totalTrials":417,"cells":37711},"Engerix™-B (thiomersal-free) 20µg",{"EARLY_PHASE1":37712,"PHASE1":37714,"PHASE2":37716,"PHASE3":37718,"PHASE4":37730,"NA":37732},{"trials":37713,"activeCount":97},[],{"trials":37715,"activeCount":97},[],{"trials":37717,"activeCount":97},[],{"trials":37719,"activeCount":97},[37720],{"nctId":37721,"briefTitle":37722,"status":155,"phases":37723,"primaryCompletion":37724,"completion":37724,"start":37725,"enrollment":37726,"conditions":37727,"interventions":37728},"NCT00343915","Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs",[87],"2008-01-10","2004-04-21",267,[24],[37710,37729],"10 μg Engerix™-B",{"trials":37731,"activeCount":97},[],{"trials":37733,"activeCount":97},[],{"intervention":37729,"totalTrials":417,"cells":37735},{"EARLY_PHASE1":37736,"PHASE1":37738,"PHASE2":37740,"PHASE3":37742,"PHASE4":37748,"NA":37750},{"trials":37737,"activeCount":97},[],{"trials":37739,"activeCount":97},[],{"trials":37741,"activeCount":97},[],{"trials":37743,"activeCount":97},[37744],{"nctId":37721,"briefTitle":37722,"status":155,"phases":37745,"primaryCompletion":37724,"completion":37724,"start":37725,"enrollment":37726,"conditions":37746,"interventions":37747},[87],[24],[37710,37729],{"trials":37749,"activeCount":97},[],{"trials":37751,"activeCount":97},[],{"intervention":37753,"totalTrials":417,"cells":37754},"Lamivudine plus Polyethylene glyco-interferon alfa-2b",{"EARLY_PHASE1":37755,"PHASE1":37757,"PHASE2":37759,"PHASE3":37761,"PHASE4":37771,"NA":37773},{"trials":37756,"activeCount":97},[],{"trials":37758,"activeCount":97},[],{"trials":37760,"activeCount":97},[],{"trials":37762,"activeCount":97},[37763],{"nctId":37764,"briefTitle":37765,"status":155,"phases":37766,"start":37767,"enrollment":3392,"conditions":37768,"interventions":37769},"NCT00140725","Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)",[87],"2000-04",[4190],[37753,37770],"Lamivudine",{"trials":37772,"activeCount":97},[],{"trials":37774,"activeCount":97},[],{"intervention":24462,"totalTrials":417,"cells":37776},{"EARLY_PHASE1":37777,"PHASE1":37779,"PHASE2":37781,"PHASE3":37783,"PHASE4":37789,"NA":37791},{"trials":37778,"activeCount":97},[],{"trials":37780,"activeCount":97},[],{"trials":37782,"activeCount":97},[],{"trials":37784,"activeCount":97},[37785],{"nctId":24455,"briefTitle":24456,"status":155,"phases":37786,"primaryCompletion":9792,"completion":9792,"start":17894,"enrollment":24458,"conditions":37787,"interventions":37788},[87],[2486,3717,2485,2484],[24435,24461,24462],{"trials":37790,"activeCount":97},[],{"trials":37792,"activeCount":97},[],{"intervention":11908,"totalTrials":417,"cells":37794},{"EARLY_PHASE1":37795,"PHASE1":37797,"PHASE2":37799,"PHASE3":37801,"PHASE4":37807,"NA":37809},{"trials":37796,"activeCount":97},[],{"trials":37798,"activeCount":97},[],{"trials":37800,"activeCount":97},[],{"trials":37802,"activeCount":97},[37803],{"nctId":11900,"briefTitle":11901,"status":155,"phases":37804,"primaryCompletion":11903,"completion":11903,"start":6481,"enrollment":11904,"conditions":37805,"interventions":37806},[87],[992],[11879,11907,11908,11909,11910],{"trials":37808,"activeCount":97},[],{"trials":37810,"activeCount":97},[],{"intervention":11909,"totalTrials":417,"cells":37812},{"EARLY_PHASE1":37813,"PHASE1":37815,"PHASE2":37817,"PHASE3":37819,"PHASE4":37825,"NA":37827},{"trials":37814,"activeCount":97},[],{"trials":37816,"activeCount":97},[],{"trials":37818,"activeCount":97},[],{"trials":37820,"activeCount":97},[37821],{"nctId":11900,"briefTitle":11901,"status":155,"phases":37822,"primaryCompletion":11903,"completion":11903,"start":6481,"enrollment":11904,"conditions":37823,"interventions":37824},[87],[992],[11879,11907,11908,11909,11910],{"trials":37826,"activeCount":97},[],{"trials":37828,"activeCount":97},[],{"intervention":11910,"totalTrials":417,"cells":37830},{"EARLY_PHASE1":37831,"PHASE1":37833,"PHASE2":37835,"PHASE3":37837,"PHASE4":37843,"NA":37845},{"trials":37832,"activeCount":97},[],{"trials":37834,"activeCount":97},[],{"trials":37836,"activeCount":97},[],{"trials":37838,"activeCount":97},[37839],{"nctId":11900,"briefTitle":11901,"status":155,"phases":37840,"primaryCompletion":11903,"completion":11903,"start":6481,"enrollment":11904,"conditions":37841,"interventions":37842},[87],[992],[11879,11907,11908,11909,11910],{"trials":37844,"activeCount":97},[],{"trials":37846,"activeCount":97},[],{"intervention":37848,"totalTrials":417,"cells":37849},"Antiviral therapy",{"EARLY_PHASE1":37850,"PHASE1":37852,"PHASE2":37854,"PHASE3":37856,"PHASE4":37864,"NA":37866},{"trials":37851,"activeCount":97},[],{"trials":37853,"activeCount":97},[],{"trials":37855,"activeCount":97},[],{"trials":37857,"activeCount":97},[37858],{"nctId":37859,"briefTitle":37860,"status":155,"phases":37861,"primaryCompletion":3390,"completion":3390,"start":1429,"enrollment":9334,"conditions":37862,"interventions":37863},"NCT00996216","Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390",[87],[23770],[23772,37848],{"trials":37865,"activeCount":97},[],{"trials":37867,"activeCount":97},[],{"intervention":21760,"totalTrials":417,"cells":37869},{"EARLY_PHASE1":37870,"PHASE1":37872,"PHASE2":37874,"PHASE3":37876,"PHASE4":37882,"NA":37884},{"trials":37871,"activeCount":97},[],{"trials":37873,"activeCount":97},[],{"trials":37875,"activeCount":97},[],{"trials":37877,"activeCount":97},[37878],{"nctId":21751,"briefTitle":21752,"status":155,"phases":37879,"primaryCompletion":21754,"completion":21754,"start":21755,"enrollment":21756,"conditions":37880,"interventions":37881},[87],[24,7966],[21759,21760],{"trials":37883,"activeCount":97},[],{"trials":37885,"activeCount":97},[],{"intervention":2933,"totalTrials":417,"cells":37887},{"EARLY_PHASE1":37888,"PHASE1":37890,"PHASE2":37892,"PHASE3":37894,"PHASE4":37900,"NA":37902},{"trials":37889,"activeCount":97},[],{"trials":37891,"activeCount":97},[],{"trials":37893,"activeCount":97},[],{"trials":37895,"activeCount":97},[37896],{"nctId":2926,"briefTitle":2927,"status":500,"phases":37897,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":97,"conditions":37898,"interventions":37899},[87],[18],[2895,2933,2934,2916],{"trials":37901,"activeCount":97},[],{"trials":37903,"activeCount":97},[],{"intervention":37905,"totalTrials":417,"cells":37906},"Hib-MenAC mixed with Tritanrix™-HepB",{"EARLY_PHASE1":37907,"PHASE1":37909,"PHASE2":37911,"PHASE3":37913,"PHASE4":37921,"NA":37923},{"trials":37908,"activeCount":97},[],{"trials":37910,"activeCount":97},[],{"trials":37912,"activeCount":97},[],{"trials":37914,"activeCount":97},[37915],{"nctId":37916,"briefTitle":37917,"status":155,"phases":37918,"completion":4843,"start":11759,"enrollment":1924,"conditions":37919,"interventions":37920},"NCT00197275","Lot-to-lot Consistency of Tritanrix™-HepB\u002FHib-MenAC & Its Non-inferiority vs Tritanrix™-HepB\u002FHiberix™ in Infants",[87],[33,24,4704,10227,30],[37905],{"trials":37922,"activeCount":97},[],{"trials":37924,"activeCount":97},[],{"intervention":37926,"totalTrials":417,"cells":37927},"Boostrix Polio™ 711866",{"EARLY_PHASE1":37928,"PHASE1":37930,"PHASE2":37932,"PHASE3":37934,"PHASE4":37944,"NA":37946},{"trials":37929,"activeCount":97},[],{"trials":37931,"activeCount":97},[],{"trials":37933,"activeCount":97},[],{"trials":37935,"activeCount":97},[37936],{"nctId":37937,"briefTitle":37938,"status":155,"phases":37939,"primaryCompletion":1875,"completion":1875,"start":4700,"enrollment":10520,"conditions":37940,"interventions":37941},"NCT00871000","Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.",[87],[3624,33,30,4702],[37926,37942,37943],"Priorix Tetra TM 208136","Tetravac TM",{"trials":37945,"activeCount":97},[],{"trials":37947,"activeCount":97},[],{"intervention":37942,"totalTrials":417,"cells":37949},{"EARLY_PHASE1":37950,"PHASE1":37952,"PHASE2":37954,"PHASE3":37956,"PHASE4":37962,"NA":37964},{"trials":37951,"activeCount":97},[],{"trials":37953,"activeCount":97},[],{"trials":37955,"activeCount":97},[],{"trials":37957,"activeCount":97},[37958],{"nctId":37937,"briefTitle":37938,"status":155,"phases":37959,"primaryCompletion":1875,"completion":1875,"start":4700,"enrollment":10520,"conditions":37960,"interventions":37961},[87],[3624,33,30,4702],[37926,37942,37943],{"trials":37963,"activeCount":97},[],{"trials":37965,"activeCount":97},[],{"intervention":37943,"totalTrials":417,"cells":37967},{"EARLY_PHASE1":37968,"PHASE1":37970,"PHASE2":37972,"PHASE3":37974,"PHASE4":37980,"NA":37982},{"trials":37969,"activeCount":97},[],{"trials":37971,"activeCount":97},[],{"trials":37973,"activeCount":97},[],{"trials":37975,"activeCount":97},[37976],{"nctId":37937,"briefTitle":37938,"status":155,"phases":37977,"primaryCompletion":1875,"completion":1875,"start":4700,"enrollment":10520,"conditions":37978,"interventions":37979},[87],[3624,33,30,4702],[37926,37942,37943],{"trials":37981,"activeCount":97},[],{"trials":37983,"activeCount":97},[],{"intervention":2640,"totalTrials":417,"cells":37985},{"EARLY_PHASE1":37986,"PHASE1":37988,"PHASE2":37990,"PHASE3":37992,"PHASE4":37998,"NA":38000},{"trials":37987,"activeCount":97},[],{"trials":37989,"activeCount":97},[],{"trials":37991,"activeCount":97},[],{"trials":37993,"activeCount":97},[37994],{"nctId":2632,"briefTitle":2633,"status":155,"phases":37995,"primaryCompletion":2635,"completion":2636,"start":264,"enrollment":2637,"conditions":37996,"interventions":37997},[87],[2620],[2601,2640],{"trials":37999,"activeCount":97},[],{"trials":38001,"activeCount":97},[],{"intervention":38003,"totalTrials":417,"cells":38004},"Botulinum toxin A",{"EARLY_PHASE1":38005,"PHASE1":38007,"PHASE2":38009,"PHASE3":38011,"PHASE4":38022,"NA":38024},{"trials":38006,"activeCount":97},[],{"trials":38008,"activeCount":97},[],{"trials":38010,"activeCount":97},[],{"trials":38012,"activeCount":97},[38013],{"nctId":38014,"briefTitle":38015,"status":155,"phases":38016,"primaryCompletion":38017,"completion":18582,"start":38018,"enrollment":8817,"conditions":38019,"interventions":38021},"NCT03261167","A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity",[87],"2018-03-20","2017-08-02",[38020],"Spasticity, Post-Stroke",[38003],{"trials":38023,"activeCount":97},[],{"trials":38025,"activeCount":97},[],{"intervention":38027,"totalTrials":417,"cells":38028},"Gardasil",{"EARLY_PHASE1":38029,"PHASE1":38031,"PHASE2":38033,"PHASE3":38035,"PHASE4":38045,"NA":38047},{"trials":38030,"activeCount":97},[],{"trials":38032,"activeCount":97},[],{"trials":38034,"activeCount":97},[],{"trials":38036,"activeCount":97},[38037],{"nctId":38038,"briefTitle":38039,"status":155,"phases":38040,"primaryCompletion":22238,"completion":22238,"start":38041,"enrollment":38042,"conditions":38043,"interventions":38044},"NCT01462357","Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Human Papillomavirus (HPV) Vaccine (GSK-580299) and Merck's Gardasil Vaccine When Administered According to Alternative 2-dose Schedules in 9-14 Year Old Females",[87],"2011-11-21",1079,[8723],[9000,38027],{"trials":38046,"activeCount":97},[],{"trials":38048,"activeCount":97},[],{"intervention":38050,"totalTrials":417,"cells":38051},"Fluarix\u002FInflusplit SSW 2012-2013",{"EARLY_PHASE1":38052,"PHASE1":38054,"PHASE2":38056,"PHASE3":38058,"PHASE4":38068,"NA":38070},{"trials":38053,"activeCount":97},[],{"trials":38055,"activeCount":97},[],{"trials":38057,"activeCount":97},[],{"trials":38059,"activeCount":97},[38060],{"nctId":38061,"briefTitle":38062,"status":155,"phases":38063,"primaryCompletion":38064,"completion":38064,"start":38065,"enrollment":35629,"conditions":38066,"interventions":38067},"NCT01607112","A Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix\u002FInflusplit SSW 2012\u002F2013 in People Aged 18 Years and Above",[87],"2012-07-31","2012-07-10",[21],[38050],{"trials":38069,"activeCount":97},[],{"trials":38071,"activeCount":97},[],{"intervention":38073,"totalTrials":417,"cells":38074},"HPV GSK 580299 vaccine",{"EARLY_PHASE1":38075,"PHASE1":38077,"PHASE2":38079,"PHASE3":38081,"PHASE4":38092,"NA":38094},{"trials":38076,"activeCount":97},[],{"trials":38078,"activeCount":97},[],{"trials":38080,"activeCount":97},[],{"trials":38082,"activeCount":97},[38083],{"nctId":38084,"briefTitle":38085,"status":155,"phases":38086,"primaryCompletion":26457,"completion":38087,"start":38088,"enrollment":38089,"conditions":38090,"interventions":38091},"NCT00779766","Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects",[87],"2016-02-28","2008-10-22",6081,[8723],[38073],{"trials":38093,"activeCount":97},[],{"trials":38095,"activeCount":97},[],{"intervention":38097,"totalTrials":417,"cells":38098},"Mepolizumab 100mg",{"EARLY_PHASE1":38099,"PHASE1":38101,"PHASE2":38103,"PHASE3":38105,"PHASE4":38114,"NA":38116},{"trials":38100,"activeCount":97},[],{"trials":38102,"activeCount":97},[],{"trials":38104,"activeCount":97},[],{"trials":38106,"activeCount":97},[38107],{"nctId":38108,"briefTitle":38109,"status":155,"phases":38110,"primaryCompletion":38111,"completion":38111,"start":23221,"enrollment":10497,"conditions":38112,"interventions":38113},"NCT02555371","Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients",[87],"2019-07-24",[18],[38097],{"trials":38115,"activeCount":97},[],{"trials":38117,"activeCount":97},[],{"intervention":18854,"totalTrials":417,"cells":38119},{"EARLY_PHASE1":38120,"PHASE1":38122,"PHASE2":38124,"PHASE3":38126,"PHASE4":38132,"NA":38134},{"trials":38121,"activeCount":97},[],{"trials":38123,"activeCount":97},[],{"trials":38125,"activeCount":97},[],{"trials":38127,"activeCount":97},[38128],{"nctId":18848,"briefTitle":18849,"status":155,"phases":38129,"primaryCompletion":18851,"completion":18851,"start":3425,"enrollment":3089,"conditions":38130,"interventions":38131},[87],[3637],[3639,18854],{"trials":38133,"activeCount":97},[],{"trials":38135,"activeCount":97},[],{"intervention":21493,"totalTrials":417,"cells":38137},{"EARLY_PHASE1":38138,"PHASE1":38140,"PHASE2":38142,"PHASE3":38144,"PHASE4":38150,"NA":38152},{"trials":38139,"activeCount":97},[],{"trials":38141,"activeCount":97},[],{"trials":38143,"activeCount":97},[],{"trials":38145,"activeCount":97},[38146],{"nctId":21485,"briefTitle":21486,"status":155,"phases":38147,"primaryCompletion":21488,"completion":21488,"start":21489,"enrollment":21490,"conditions":38148,"interventions":38149},[87],[4759],[21493,7876,21494],{"trials":38151,"activeCount":97},[],{"trials":38153,"activeCount":97},[],{"intervention":21494,"totalTrials":417,"cells":38155},{"EARLY_PHASE1":38156,"PHASE1":38158,"PHASE2":38160,"PHASE3":38162,"PHASE4":38168,"NA":38170},{"trials":38157,"activeCount":97},[],{"trials":38159,"activeCount":97},[],{"trials":38161,"activeCount":97},[],{"trials":38163,"activeCount":97},[38164],{"nctId":21485,"briefTitle":21486,"status":155,"phases":38165,"primaryCompletion":21488,"completion":21488,"start":21489,"enrollment":21490,"conditions":38166,"interventions":38167},[87],[4759],[21493,7876,21494],{"trials":38169,"activeCount":97},[],{"trials":38171,"activeCount":97},[],{"intervention":4860,"totalTrials":417,"cells":38173},{"EARLY_PHASE1":38174,"PHASE1":38176,"PHASE2":38178,"PHASE3":38180,"PHASE4":38186,"NA":38188},{"trials":38175,"activeCount":97},[],{"trials":38177,"activeCount":97},[],{"trials":38179,"activeCount":97},[],{"trials":38181,"activeCount":97},[38182],{"nctId":4851,"briefTitle":4852,"status":155,"phases":38183,"primaryCompletion":4854,"completion":4855,"start":4856,"enrollment":4857,"conditions":38184,"interventions":38185},[87],[3637],[4744,4694,4808,4472,4860],{"trials":38187,"activeCount":97},[],{"trials":38189,"activeCount":97},[],{"intervention":22901,"totalTrials":417,"cells":38191},{"EARLY_PHASE1":38192,"PHASE1":38194,"PHASE2":38196,"PHASE3":38198,"PHASE4":38204,"NA":38206},{"trials":38193,"activeCount":97},[],{"trials":38195,"activeCount":97},[],{"trials":38197,"activeCount":97},[],{"trials":38199,"activeCount":97},[38200],{"nctId":22893,"briefTitle":22894,"status":155,"phases":38201,"primaryCompletion":8395,"completion":22896,"start":22897,"enrollment":22898,"conditions":38202,"interventions":38203},[87],[18],[22901,22902,9630],{"trials":38205,"activeCount":97},[],{"trials":38207,"activeCount":97},[],{"intervention":22902,"totalTrials":417,"cells":38209},{"EARLY_PHASE1":38210,"PHASE1":38212,"PHASE2":38214,"PHASE3":38216,"PHASE4":38222,"NA":38224},{"trials":38211,"activeCount":97},[],{"trials":38213,"activeCount":97},[],{"trials":38215,"activeCount":97},[],{"trials":38217,"activeCount":97},[38218],{"nctId":22893,"briefTitle":22894,"status":155,"phases":38219,"primaryCompletion":8395,"completion":22896,"start":22897,"enrollment":22898,"conditions":38220,"interventions":38221},[87],[18],[22901,22902,9630],{"trials":38223,"activeCount":97},[],{"trials":38225,"activeCount":97},[],{"intervention":38227,"totalTrials":417,"cells":38228},"HPV Vaccine (GSK580299) Cervarix TM",{"EARLY_PHASE1":38229,"PHASE1":38231,"PHASE2":38233,"PHASE3":38235,"PHASE4":38248,"NA":38250},{"trials":38230,"activeCount":97},[],{"trials":38232,"activeCount":97},[],{"trials":38234,"activeCount":97},[],{"trials":38236,"activeCount":97},[38237],{"nctId":38238,"briefTitle":38239,"status":155,"phases":38240,"primaryCompletion":38241,"completion":38242,"start":38243,"enrollment":38244,"conditions":38245,"interventions":38246},"NCT00652938","Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects",[87],"2009-08-28","2010-01-08","2008-04-09",744,[8723],[38227,38247],"Engerix B",{"trials":38249,"activeCount":97},[],{"trials":38251,"activeCount":97},[],{"intervention":38247,"totalTrials":417,"cells":38253},{"EARLY_PHASE1":38254,"PHASE1":38256,"PHASE2":38258,"PHASE3":38260,"PHASE4":38266,"NA":38268},{"trials":38255,"activeCount":97},[],{"trials":38257,"activeCount":97},[],{"trials":38259,"activeCount":97},[],{"trials":38261,"activeCount":97},[38262],{"nctId":38238,"briefTitle":38239,"status":155,"phases":38263,"primaryCompletion":38241,"completion":38242,"start":38243,"enrollment":38244,"conditions":38264,"interventions":38265},[87],[8723],[38227,38247],{"trials":38267,"activeCount":97},[],{"trials":38269,"activeCount":97},[],{"intervention":38271,"totalTrials":417,"cells":38272},"Fluticasone Furoate 100mcg \u002F GW642444 (vilanterol) 25mcg",{"EARLY_PHASE1":38273,"PHASE1":38275,"PHASE2":38277,"PHASE3":38279,"PHASE4":38290,"NA":38292},{"trials":38274,"activeCount":97},[],{"trials":38276,"activeCount":97},[],{"trials":38278,"activeCount":97},[],{"trials":38280,"activeCount":97},[38281],{"nctId":38282,"briefTitle":38283,"status":155,"phases":38284,"primaryCompletion":38285,"completion":38285,"start":27061,"enrollment":38286,"conditions":38287,"interventions":38288},"NCT01323634","Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) \u002FGW642444 (Vilanterol) (VI) Inhalation Powder 100\u002F25mcg Once Daily Compared With Fluticasone Propionate\u002FSalmeterol Inhalation Powder 250\u002F50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease",[87],"2011-12-14",519,[15],[38271,38289],"Fluticasone Propionate 250mcg\u002F salmeterol 50mcg",{"trials":38291,"activeCount":97},[],{"trials":38293,"activeCount":97},[],{"intervention":38289,"totalTrials":417,"cells":38295},{"EARLY_PHASE1":38296,"PHASE1":38298,"PHASE2":38300,"PHASE3":38302,"PHASE4":38308,"NA":38310},{"trials":38297,"activeCount":97},[],{"trials":38299,"activeCount":97},[],{"trials":38301,"activeCount":97},[],{"trials":38303,"activeCount":97},[38304],{"nctId":38282,"briefTitle":38283,"status":155,"phases":38305,"primaryCompletion":38285,"completion":38285,"start":27061,"enrollment":38286,"conditions":38306,"interventions":38307},[87],[15],[38271,38289],{"trials":38309,"activeCount":97},[],{"trials":38311,"activeCount":97},[],{"intervention":8418,"totalTrials":417,"cells":38313},{"EARLY_PHASE1":38314,"PHASE1":38316,"PHASE2":38318,"PHASE3":38320,"PHASE4":38326,"NA":38328},{"trials":38315,"activeCount":97},[],{"trials":38317,"activeCount":97},[],{"trials":38319,"activeCount":97},[],{"trials":38321,"activeCount":97},[38322],{"nctId":8411,"briefTitle":8412,"status":155,"phases":38323,"primaryCompletion":8395,"completion":3058,"start":8414,"enrollment":8415,"conditions":38324,"interventions":38325},[87],[15],[8418,8419],{"trials":38327,"activeCount":97},[],{"trials":38329,"activeCount":97},[],{"intervention":38331,"totalTrials":417,"cells":38332},"lamotrigine (LAMICTAL) extended-release",{"EARLY_PHASE1":38333,"PHASE1":38335,"PHASE2":38337,"PHASE3":38339,"PHASE4":38348,"NA":38350},{"trials":38334,"activeCount":97},[],{"trials":38336,"activeCount":97},[],{"trials":38338,"activeCount":97},[],{"trials":38340,"activeCount":97},[38341],{"nctId":38342,"briefTitle":38343,"status":155,"phases":38344,"primaryCompletion":5018,"completion":5018,"start":1361,"enrollment":1150,"conditions":38345,"interventions":38347},"NCT00104416","Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures",[87],[38346],"Epilepsy, Tonic-Clonic",[38331],{"trials":38349,"activeCount":97},[],{"trials":38351,"activeCount":97},[],{"intervention":38353,"totalTrials":417,"cells":38354},"Ropinirole IR 1 mg",{"EARLY_PHASE1":38355,"PHASE1":38357,"PHASE2":38359,"PHASE3":38361,"PHASE4":38378,"NA":38380},{"trials":38356,"activeCount":97},[],{"trials":38358,"activeCount":97},[],{"trials":38360,"activeCount":97},[],{"trials":38362,"activeCount":97},[38363],{"nctId":38364,"briefTitle":38365,"status":155,"phases":38366,"primaryCompletion":38367,"completion":38367,"start":38368,"enrollment":829,"conditions":38369,"interventions":38370},"NCT00256854","Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)",[87],"2006-09-21","2005-11-14",[14255,14254],[38353,38371,38372,38373,38374,38375,38376,38377],"Ropinirole IR 2 mg","Ropinirole IR 1 mg Placebo","Ropinirole IR 2 mg Placebo","Ropinirole CR 2 mg","Ropinirole CR 3 mg","Ropinirole CR 2 mg Placebo","Ropinirole CR 3 mg Placebo",{"trials":38379,"activeCount":97},[],{"trials":38381,"activeCount":97},[],{"intervention":38371,"totalTrials":417,"cells":38383},{"EARLY_PHASE1":38384,"PHASE1":38386,"PHASE2":38388,"PHASE3":38390,"PHASE4":38396,"NA":38398},{"trials":38385,"activeCount":97},[],{"trials":38387,"activeCount":97},[],{"trials":38389,"activeCount":97},[],{"trials":38391,"activeCount":97},[38392],{"nctId":38364,"briefTitle":38365,"status":155,"phases":38393,"primaryCompletion":38367,"completion":38367,"start":38368,"enrollment":829,"conditions":38394,"interventions":38395},[87],[14255,14254],[38353,38371,38372,38373,38374,38375,38376,38377],{"trials":38397,"activeCount":97},[],{"trials":38399,"activeCount":97},[],{"intervention":38372,"totalTrials":417,"cells":38401},{"EARLY_PHASE1":38402,"PHASE1":38404,"PHASE2":38406,"PHASE3":38408,"PHASE4":38414,"NA":38416},{"trials":38403,"activeCount":97},[],{"trials":38405,"activeCount":97},[],{"trials":38407,"activeCount":97},[],{"trials":38409,"activeCount":97},[38410],{"nctId":38364,"briefTitle":38365,"status":155,"phases":38411,"primaryCompletion":38367,"completion":38367,"start":38368,"enrollment":829,"conditions":38412,"interventions":38413},[87],[14255,14254],[38353,38371,38372,38373,38374,38375,38376,38377],{"trials":38415,"activeCount":97},[],{"trials":38417,"activeCount":97},[],{"intervention":38373,"totalTrials":417,"cells":38419},{"EARLY_PHASE1":38420,"PHASE1":38422,"PHASE2":38424,"PHASE3":38426,"PHASE4":38432,"NA":38434},{"trials":38421,"activeCount":97},[],{"trials":38423,"activeCount":97},[],{"trials":38425,"activeCount":97},[],{"trials":38427,"activeCount":97},[38428],{"nctId":38364,"briefTitle":38365,"status":155,"phases":38429,"primaryCompletion":38367,"completion":38367,"start":38368,"enrollment":829,"conditions":38430,"interventions":38431},[87],[14255,14254],[38353,38371,38372,38373,38374,38375,38376,38377],{"trials":38433,"activeCount":97},[],{"trials":38435,"activeCount":97},[],{"intervention":38374,"totalTrials":417,"cells":38437},{"EARLY_PHASE1":38438,"PHASE1":38440,"PHASE2":38442,"PHASE3":38444,"PHASE4":38450,"NA":38452},{"trials":38439,"activeCount":97},[],{"trials":38441,"activeCount":97},[],{"trials":38443,"activeCount":97},[],{"trials":38445,"activeCount":97},[38446],{"nctId":38364,"briefTitle":38365,"status":155,"phases":38447,"primaryCompletion":38367,"completion":38367,"start":38368,"enrollment":829,"conditions":38448,"interventions":38449},[87],[14255,14254],[38353,38371,38372,38373,38374,38375,38376,38377],{"trials":38451,"activeCount":97},[],{"trials":38453,"activeCount":97},[],{"intervention":38375,"totalTrials":417,"cells":38455},{"EARLY_PHASE1":38456,"PHASE1":38458,"PHASE2":38460,"PHASE3":38462,"PHASE4":38468,"NA":38470},{"trials":38457,"activeCount":97},[],{"trials":38459,"activeCount":97},[],{"trials":38461,"activeCount":97},[],{"trials":38463,"activeCount":97},[38464],{"nctId":38364,"briefTitle":38365,"status":155,"phases":38465,"primaryCompletion":38367,"completion":38367,"start":38368,"enrollment":829,"conditions":38466,"interventions":38467},[87],[14255,14254],[38353,38371,38372,38373,38374,38375,38376,38377],{"trials":38469,"activeCount":97},[],{"trials":38471,"activeCount":97},[],{"intervention":38376,"totalTrials":417,"cells":38473},{"EARLY_PHASE1":38474,"PHASE1":38476,"PHASE2":38478,"PHASE3":38480,"PHASE4":38486,"NA":38488},{"trials":38475,"activeCount":97},[],{"trials":38477,"activeCount":97},[],{"trials":38479,"activeCount":97},[],{"trials":38481,"activeCount":97},[38482],{"nctId":38364,"briefTitle":38365,"status":155,"phases":38483,"primaryCompletion":38367,"completion":38367,"start":38368,"enrollment":829,"conditions":38484,"interventions":38485},[87],[14255,14254],[38353,38371,38372,38373,38374,38375,38376,38377],{"trials":38487,"activeCount":97},[],{"trials":38489,"activeCount":97},[],{"intervention":38377,"totalTrials":417,"cells":38491},{"EARLY_PHASE1":38492,"PHASE1":38494,"PHASE2":38496,"PHASE3":38498,"PHASE4":38504,"NA":38506},{"trials":38493,"activeCount":97},[],{"trials":38495,"activeCount":97},[],{"trials":38497,"activeCount":97},[],{"trials":38499,"activeCount":97},[38500],{"nctId":38364,"briefTitle":38365,"status":155,"phases":38501,"primaryCompletion":38367,"completion":38367,"start":38368,"enrollment":829,"conditions":38502,"interventions":38503},[87],[14255,14254],[38353,38371,38372,38373,38374,38375,38376,38377],{"trials":38505,"activeCount":97},[],{"trials":38507,"activeCount":97},[],{"intervention":38509,"totalTrials":417,"cells":38510},"GSK208141 vaccine",{"EARLY_PHASE1":38511,"PHASE1":38513,"PHASE2":38515,"PHASE3":38517,"PHASE4":38525,"NA":38527},{"trials":38512,"activeCount":97},[],{"trials":38514,"activeCount":97},[],{"trials":38516,"activeCount":97},[],{"trials":38518,"activeCount":97},[38519],{"nctId":38520,"briefTitle":38521,"status":155,"phases":38522,"primaryCompletion":8427,"completion":1360,"start":8492,"enrollment":11962,"conditions":38523,"interventions":38524},"NCT00224471","Study to Compare Safety and Immunogenicity of Commercial Scale Consistency Lots of Herpes Simplex Vaccine",[87],[8709],[38509],{"trials":38526,"activeCount":97},[],{"trials":38528,"activeCount":97},[],{"intervention":38530,"totalTrials":417,"cells":38531},"Salmeterol\u002FFluticasone propionate combination product",{"EARLY_PHASE1":38532,"PHASE1":38534,"PHASE2":38536,"PHASE3":38538,"PHASE4":38546,"NA":38548},{"trials":38533,"activeCount":97},[],{"trials":38535,"activeCount":97},[],{"trials":38537,"activeCount":97},[],{"trials":38539,"activeCount":97},[38540],{"nctId":38541,"briefTitle":38542,"status":155,"phases":38543,"start":7839,"enrollment":1196,"conditions":38544,"interventions":38545},"NCT00158834","Pediatric Asthma Study Using Stepwise Treatment With Two Food And Drug Administration Approved Asthma Medications",[87],[18],[38530,8381],{"trials":38547,"activeCount":97},[],{"trials":38549,"activeCount":97},[],{"intervention":26290,"totalTrials":417,"cells":38551},{"EARLY_PHASE1":38552,"PHASE1":38554,"PHASE2":38556,"PHASE3":38558,"PHASE4":38564,"NA":38566},{"trials":38553,"activeCount":97},[],{"trials":38555,"activeCount":97},[],{"trials":38557,"activeCount":97},[],{"trials":38559,"activeCount":97},[38560],{"nctId":26285,"briefTitle":26286,"status":155,"phases":38561,"primaryCompletion":3389,"completion":3389,"start":7545,"enrollment":3635,"conditions":38562,"interventions":38563},[87],[15087],[26290,26265],{"trials":38565,"activeCount":97},[],{"trials":38567,"activeCount":97},[],{"intervention":27124,"totalTrials":417,"cells":38569},{"EARLY_PHASE1":38570,"PHASE1":38572,"PHASE2":38574,"PHASE3":38576,"PHASE4":38582,"NA":38584},{"trials":38571,"activeCount":97},[],{"trials":38573,"activeCount":97},[],{"trials":38575,"activeCount":97},[],{"trials":38577,"activeCount":97},[38578],{"nctId":27116,"briefTitle":27117,"status":155,"phases":38579,"primaryCompletion":18427,"completion":21956,"start":27119,"enrollment":27120,"conditions":38580,"interventions":38581},[87],[27122],[27124,27125,27126,27127,27128,22639],{"trials":38583,"activeCount":97},[],{"trials":38585,"activeCount":97},[],{"intervention":27125,"totalTrials":417,"cells":38587},{"EARLY_PHASE1":38588,"PHASE1":38590,"PHASE2":38592,"PHASE3":38594,"PHASE4":38600,"NA":38602},{"trials":38589,"activeCount":97},[],{"trials":38591,"activeCount":97},[],{"trials":38593,"activeCount":97},[],{"trials":38595,"activeCount":97},[38596],{"nctId":27116,"briefTitle":27117,"status":155,"phases":38597,"primaryCompletion":18427,"completion":21956,"start":27119,"enrollment":27120,"conditions":38598,"interventions":38599},[87],[27122],[27124,27125,27126,27127,27128,22639],{"trials":38601,"activeCount":97},[],{"trials":38603,"activeCount":97},[],{"intervention":27126,"totalTrials":417,"cells":38605},{"EARLY_PHASE1":38606,"PHASE1":38608,"PHASE2":38610,"PHASE3":38612,"PHASE4":38618,"NA":38620},{"trials":38607,"activeCount":97},[],{"trials":38609,"activeCount":97},[],{"trials":38611,"activeCount":97},[],{"trials":38613,"activeCount":97},[38614],{"nctId":27116,"briefTitle":27117,"status":155,"phases":38615,"primaryCompletion":18427,"completion":21956,"start":27119,"enrollment":27120,"conditions":38616,"interventions":38617},[87],[27122],[27124,27125,27126,27127,27128,22639],{"trials":38619,"activeCount":97},[],{"trials":38621,"activeCount":97},[],{"intervention":27127,"totalTrials":417,"cells":38623},{"EARLY_PHASE1":38624,"PHASE1":38626,"PHASE2":38628,"PHASE3":38630,"PHASE4":38636,"NA":38638},{"trials":38625,"activeCount":97},[],{"trials":38627,"activeCount":97},[],{"trials":38629,"activeCount":97},[],{"trials":38631,"activeCount":97},[38632],{"nctId":27116,"briefTitle":27117,"status":155,"phases":38633,"primaryCompletion":18427,"completion":21956,"start":27119,"enrollment":27120,"conditions":38634,"interventions":38635},[87],[27122],[27124,27125,27126,27127,27128,22639],{"trials":38637,"activeCount":97},[],{"trials":38639,"activeCount":97},[],{"intervention":27128,"totalTrials":417,"cells":38641},{"EARLY_PHASE1":38642,"PHASE1":38644,"PHASE2":38646,"PHASE3":38648,"PHASE4":38654,"NA":38656},{"trials":38643,"activeCount":97},[],{"trials":38645,"activeCount":97},[],{"trials":38647,"activeCount":97},[],{"trials":38649,"activeCount":97},[38650],{"nctId":27116,"briefTitle":27117,"status":155,"phases":38651,"primaryCompletion":18427,"completion":21956,"start":27119,"enrollment":27120,"conditions":38652,"interventions":38653},[87],[27122],[27124,27125,27126,27127,27128,22639],{"trials":38655,"activeCount":97},[],{"trials":38657,"activeCount":97},[],{"intervention":21669,"totalTrials":417,"cells":38659},{"EARLY_PHASE1":38660,"PHASE1":38662,"PHASE2":38664,"PHASE3":38666,"PHASE4":38672,"NA":38674},{"trials":38661,"activeCount":97},[],{"trials":38663,"activeCount":97},[],{"trials":38665,"activeCount":97},[],{"trials":38667,"activeCount":97},[38668],{"nctId":21660,"briefTitle":21661,"status":155,"phases":38669,"primaryCompletion":21663,"completion":21664,"start":21665,"enrollment":21666,"conditions":38670,"interventions":38671},[87],[1030,18950],[21622,21669],{"trials":38673,"activeCount":97},[],{"trials":38675,"activeCount":97},[],{"intervention":38677,"totalTrials":417,"cells":38678},"Adjuvanted pandemic influenza candidate vaccine",{"EARLY_PHASE1":38679,"PHASE1":38681,"PHASE2":38683,"PHASE3":38685,"PHASE4":38694,"NA":38696},{"trials":38680,"activeCount":97},[],{"trials":38682,"activeCount":97},[],{"trials":38684,"activeCount":97},[],{"trials":38686,"activeCount":97},[38687],{"nctId":38688,"briefTitle":38689,"status":155,"phases":38690,"primaryCompletion":3619,"completion":12180,"start":920,"enrollment":38691,"conditions":38692,"interventions":38693},"NCT00319098","Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above",[87],5075,[21],[38677,25702],{"trials":38695,"activeCount":97},[],{"trials":38697,"activeCount":97},[],{"intervention":38699,"totalTrials":417,"cells":38700},"FF\u002FUMEC\u002FVI 100\u002F62.5\u002F25 mcg",{"EARLY_PHASE1":38701,"PHASE1":38703,"PHASE2":38705,"PHASE3":38707,"PHASE4":38718,"NA":38720},{"trials":38702,"activeCount":97},[],{"trials":38704,"activeCount":97},[],{"trials":38706,"activeCount":97},[],{"trials":38708,"activeCount":97},[38709],{"nctId":38710,"briefTitle":38711,"status":155,"phases":38712,"primaryCompletion":38713,"completion":38713,"start":38714,"enrollment":3537,"conditions":38715,"interventions":38716},"NCT03184987","A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate\u002FUmeclidinium Bromide\u002FVilanterol Trifenatate in Japanese Subjects With Asthma",[87],"2019-06-25","2017-06-22",[18],[38699,38717,963],"FF\u002FUMEC\u002FVI 200\u002F62.5\u002F25 mcg",{"trials":38719,"activeCount":97},[],{"trials":38721,"activeCount":97},[],{"intervention":38717,"totalTrials":417,"cells":38723},{"EARLY_PHASE1":38724,"PHASE1":38726,"PHASE2":38728,"PHASE3":38730,"PHASE4":38736,"NA":38738},{"trials":38725,"activeCount":97},[],{"trials":38727,"activeCount":97},[],{"trials":38729,"activeCount":97},[],{"trials":38731,"activeCount":97},[38732],{"nctId":38710,"briefTitle":38711,"status":155,"phases":38733,"primaryCompletion":38713,"completion":38713,"start":38714,"enrollment":3537,"conditions":38734,"interventions":38735},[87],[18],[38699,38717,963],{"trials":38737,"activeCount":97},[],{"trials":38739,"activeCount":97},[],{"intervention":38741,"totalTrials":417,"cells":38742},"Rosiglitazone 4 mg",{"EARLY_PHASE1":38743,"PHASE1":38745,"PHASE2":38747,"PHASE3":38749,"PHASE4":38757,"NA":38759},{"trials":38744,"activeCount":97},[],{"trials":38746,"activeCount":97},[],{"trials":38748,"activeCount":97},[],{"trials":38750,"activeCount":97},[38751],{"nctId":38752,"briefTitle":38753,"status":155,"phases":38754,"start":2805,"enrollment":19760,"conditions":38755,"interventions":38756},"NCT00349427","A Study Of Rosiglitazone Plus Insulin To Treat Type 2 Diabetes Mellitus Patients",[87],[9036,27],[38741],{"trials":38758,"activeCount":97},[],{"trials":38760,"activeCount":97},[],{"intervention":26768,"totalTrials":417,"cells":38762},{"EARLY_PHASE1":38763,"PHASE1":38765,"PHASE2":38767,"PHASE3":38769,"PHASE4":38775,"NA":38777},{"trials":38764,"activeCount":97},[],{"trials":38766,"activeCount":97},[],{"trials":38768,"activeCount":97},[],{"trials":38770,"activeCount":97},[38771],{"nctId":26763,"briefTitle":26764,"status":155,"phases":38772,"primaryCompletion":2844,"completion":2844,"start":2805,"enrollment":1003,"conditions":38773,"interventions":38774},[87],[26760],[26768,26769],{"trials":38776,"activeCount":97},[],{"trials":38778,"activeCount":97},[],{"intervention":25973,"totalTrials":417,"cells":38780},{"EARLY_PHASE1":38781,"PHASE1":38783,"PHASE2":38785,"PHASE3":38787,"PHASE4":38793,"NA":38795},{"trials":38782,"activeCount":97},[],{"trials":38784,"activeCount":97},[],{"trials":38786,"activeCount":97},[],{"trials":38788,"activeCount":97},[38789],{"nctId":25968,"briefTitle":24654,"status":155,"phases":38790,"primaryCompletion":9552,"completion":25970,"start":25962,"enrollment":4912,"conditions":38791,"interventions":38792},[87],[21],[25948,25973,25974],{"trials":38794,"activeCount":97},[],{"trials":38796,"activeCount":97},[],{"intervention":25974,"totalTrials":417,"cells":38798},{"EARLY_PHASE1":38799,"PHASE1":38801,"PHASE2":38803,"PHASE3":38805,"PHASE4":38811,"NA":38813},{"trials":38800,"activeCount":97},[],{"trials":38802,"activeCount":97},[],{"trials":38804,"activeCount":97},[],{"trials":38806,"activeCount":97},[38807],{"nctId":25968,"briefTitle":24654,"status":155,"phases":38808,"primaryCompletion":9552,"completion":25970,"start":25962,"enrollment":4912,"conditions":38809,"interventions":38810},[87],[21],[25948,25973,25974],{"trials":38812,"activeCount":97},[],{"trials":38814,"activeCount":97},[],{"intervention":38816,"totalTrials":417,"cells":38817},"fluticasone propionate\u002Fsalmeterol 250\u002F50mcg combination, salmeterol 50mcg",{"EARLY_PHASE1":38818,"PHASE1":38820,"PHASE2":38822,"PHASE3":38824,"PHASE4":38832,"NA":38834},{"trials":38819,"activeCount":97},[],{"trials":38821,"activeCount":97},[],{"trials":38823,"activeCount":97},[],{"trials":38825,"activeCount":97},[38826],{"nctId":38827,"briefTitle":38828,"status":500,"phases":38829,"start":4843,"enrollment":97,"conditions":38830,"interventions":38831},"NCT00411372","Shortness Of Breath Questionnaire Validation Study",[87],[15],[38816],{"trials":38833,"activeCount":97},[],{"trials":38835,"activeCount":97},[],{"intervention":9030,"totalTrials":473,"cells":38837},{"EARLY_PHASE1":38838,"PHASE1":38840,"PHASE2":38908,"PHASE3":38935,"PHASE4":38937,"NA":38939},{"trials":38839,"activeCount":97},[],{"trials":38841,"activeCount":97},[38842,38846,38850,38857,38863,38869,38877,38888,38894,38901],{"nctId":9023,"briefTitle":9024,"status":155,"phases":38843,"primaryCompletion":9026,"completion":9026,"start":9027,"enrollment":1003,"conditions":38844,"interventions":38845},[85],[27],[9030,9016],{"nctId":9032,"briefTitle":9033,"status":155,"phases":38847,"primaryCompletion":2404,"completion":2404,"start":2296,"enrollment":3131,"conditions":38848,"interventions":38849},[85],[9036,27],[9038,8128],{"nctId":38851,"briefTitle":38852,"status":155,"phases":38853,"start":8406,"enrollment":2836,"conditions":38854,"interventions":38855},"NCT00501397","A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers",[85],[9036,27],[38856,9030],"ketoconazole",{"nctId":38858,"briefTitle":38859,"status":155,"phases":38860,"primaryCompletion":9737,"completion":9737,"start":2356,"enrollment":868,"conditions":38861,"interventions":38862},"NCT00532610","A Study to Compare the Effect on Heart Rhythm of 3 Days of GSK189075, Placebo, or Moxifloxacin in Healthy Adults",[85],[9036,27],[9030],{"nctId":38864,"briefTitle":38865,"status":155,"phases":38866,"start":3079,"enrollment":710,"conditions":38867,"interventions":38868},"NCT00559884","A Study to Compare the Safety and Drug Levels in Blood When Using Various Forms of GSK189075 Given to Healthy Subjects",[85],[9036,27],[9030],{"nctId":38870,"briefTitle":38871,"status":155,"phases":38872,"primaryCompletion":38873,"completion":38873,"start":38874,"enrollment":9334,"conditions":38875,"interventions":38876},"NCT00625859","A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects",[85],"2008-04-10","2008-01-16",[27],[9030,37426],{"nctId":38878,"briefTitle":38879,"status":155,"phases":38880,"primaryCompletion":38881,"completion":38881,"start":38882,"enrollment":9334,"conditions":38883,"interventions":38884},"NCT00494767","Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs",[85],"2007-06-07","2006-09-29",[27,9048],[38885,9030,38886,38887],"GW869682","GSK189075-Placebo","GW869682-Placebo",{"nctId":38889,"briefTitle":38890,"status":155,"phases":38891,"start":4756,"enrollment":1459,"conditions":38892,"interventions":38893},"NCT00501930","A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers",[85],[9036,27],[9030],{"nctId":38895,"briefTitle":38896,"status":155,"phases":38897,"primaryCompletion":2382,"completion":2382,"start":2428,"enrollment":1079,"conditions":38898,"interventions":38900},"NCT00501462","A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function",[85],[9036,27,38899],"Renal Insufficiency",[9030],{"nctId":38902,"briefTitle":38903,"status":155,"phases":38904,"primaryCompletion":7954,"completion":2355,"start":4756,"enrollment":2836,"conditions":38905,"interventions":38906},"NCT00504816","A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers",[85],[9036,27],[9030,38907],"Brevicon",{"trials":38909,"activeCount":97},[38910,38917,38921,38928],{"nctId":38911,"briefTitle":38912,"status":155,"phases":38913,"primaryCompletion":26808,"completion":26808,"start":38914,"enrollment":17295,"conditions":38915,"interventions":38916},"NCT00495469","Dose-Ranging Study In Subjects With Type 2 Diabetes Mellitus Who Are Treatment-Naive",[86],"2007-08-17",[27],[9030],{"nctId":10437,"briefTitle":10438,"status":155,"phases":38918,"primaryCompletion":10360,"completion":10360,"start":3620,"enrollment":10440,"conditions":38919,"interventions":38920},[86],[27],[9030,8130],{"nctId":38922,"briefTitle":38923,"status":155,"phases":38924,"primaryCompletion":38925,"completion":38925,"start":4835,"enrollment":750,"conditions":38926,"interventions":38927},"NCT00575159","A Study to Assess the Safety of Single Doses of GSK189075 in Subjects With Type 1 Diabetes Mellitus",[86],"2008-12-18",[19499],[9030],{"nctId":38929,"briefTitle":38930,"status":155,"phases":38931,"primaryCompletion":2383,"completion":2383,"start":1360,"enrollment":6369,"conditions":38932,"interventions":38933},"NCT00291356","GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients",[86],[27,9079],[9038,38934],"GW869682 oral",{"trials":38936,"activeCount":97},[],{"trials":38938,"activeCount":97},[],{"trials":38940,"activeCount":97},[],{"intervention":12171,"totalTrials":361,"cells":38942},{"EARLY_PHASE1":38943,"PHASE1":38945,"PHASE2":38969,"PHASE3":39020,"PHASE4":39022,"NA":39024},{"trials":38944,"activeCount":97},[],{"trials":38946,"activeCount":97},[38947,38955,38961],{"nctId":38948,"briefTitle":38949,"status":155,"phases":38950,"primaryCompletion":8426,"completion":8426,"start":2336,"enrollment":710,"conditions":38951,"interventions":38954},"NCT00517543","A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability",[85],[38952,38953,9309],"Chronic Obstructive Pulmonary Disease (COPD)","Rheumatoid Arthritis",[12171],{"nctId":38956,"briefTitle":38957,"status":155,"phases":38958,"primaryCompletion":2804,"completion":2804,"start":8426,"enrollment":8038,"conditions":38959,"interventions":38960},"NCT00549653","A Study Investigating Blood Concentrations Of Rosuvastatin When Co-administered With GW856553 In Healthy Men",[85],[9309,14279],[12171],{"nctId":38962,"briefTitle":38963,"status":155,"phases":38964,"primaryCompletion":38965,"completion":38965,"start":38966,"enrollment":628,"conditions":38967,"interventions":38968},"NCT00599612","To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]GW856553 in Healthy Adult Males",[85],"2008-02-18","2008-01-17",[15],[12171],{"trials":38970,"activeCount":97},[38971,38975,38982,38988,38994,39000,39007,39013],{"nctId":12165,"briefTitle":12166,"status":155,"phases":38972,"primaryCompletion":12168,"completion":12168,"start":10360,"enrollment":10497,"conditions":38973,"interventions":38974},[86],[15],[12171,12156],{"nctId":38976,"briefTitle":38977,"status":155,"phases":38978,"primaryCompletion":1428,"completion":1428,"start":9159,"enrollment":8275,"conditions":38979,"interventions":38981},"NCT00969059","Study in Neuropathic Pain Patients With Peripheral Nerve Injury",[86],[38980],"Pain, Neuropathic",[12171],{"nctId":38983,"briefTitle":38984,"status":155,"phases":38985,"primaryCompletion":4843,"completion":4843,"start":2844,"enrollment":7573,"conditions":38986,"interventions":38987},"NCT00256919","Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)",[86],[8788],[12171],{"nctId":38989,"briefTitle":38990,"status":155,"phases":38991,"primaryCompletion":19538,"completion":19538,"start":22162,"enrollment":4940,"conditions":38992,"interventions":38993},"NCT00976560","Clinical Study to Test a New Drug to Treat Major Depression",[86],[10889],[12171],{"nctId":38995,"briefTitle":38996,"status":155,"phases":38997,"primaryCompletion":7954,"completion":7954,"start":2404,"enrollment":2384,"conditions":38998,"interventions":38999},"NCT00393146","A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis",[86],[8788],[12171],{"nctId":39001,"briefTitle":39002,"status":155,"phases":39003,"primaryCompletion":39004,"completion":39004,"start":8226,"enrollment":27024,"conditions":39005,"interventions":39006},"NCT00910962","A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation",[86],"2012-03-06",[11827],[12171,12171],{"nctId":39008,"briefTitle":39009,"status":155,"phases":39010,"start":2296,"enrollment":255,"conditions":39011,"interventions":39012},"NCT00392587","A Study To Investigate The Effects Of GW856553 On Patients With COPD (Chronic Obstructive Pulmonary Disease)",[86],[15,38952],[12171],{"nctId":39014,"briefTitle":39015,"status":155,"phases":39016,"primaryCompletion":2355,"completion":2355,"start":2428,"enrollment":2321,"conditions":39017,"interventions":39019},"NCT00474864","Study To Evaluate The Effects Of GW856553 On Endothelial Function\u002FVascular Compliance In Subjects With Dyslipidaemia.",[86],[7524,27251,39018],"Dyslipidaemia",[12171],{"trials":39021,"activeCount":97},[],{"trials":39023,"activeCount":97},[],{"trials":39025,"activeCount":97},[],{"intervention":39027,"totalTrials":750,"cells":39028},"GSK256066",{"EARLY_PHASE1":39029,"PHASE1":39031,"PHASE2":39040,"PHASE3":39103,"PHASE4":39105,"NA":39107},{"trials":39030,"activeCount":97},[],{"trials":39032,"activeCount":97},[39033],{"nctId":39034,"briefTitle":39035,"status":155,"phases":39036,"primaryCompletion":7437,"completion":7437,"start":39037,"enrollment":1335,"conditions":39038,"interventions":39039},"NCT00515268","Endotoxin Challenge Study For Healthy Men and Women",[85],"2007-09-27",[15],[39027],{"trials":39041,"activeCount":97},[39042,39048,39054,39061,39068,39074,39081,39089,39097],{"nctId":39043,"briefTitle":39044,"status":155,"phases":39045,"start":8852,"enrollment":1298,"conditions":39046,"interventions":39047},"NCT00445510","This Study Will Examine the Effects of GSK256066 to Protect Mild Steroid-naive Asthmatics Against an Antigen Challenge",[86],[18],[39027],{"nctId":39049,"briefTitle":39050,"status":155,"phases":39051,"completion":3552,"start":4757,"enrollment":361,"conditions":39052,"interventions":39053},"NCT00380354","Study To Evaluate GSK256066 In Subjects With Mild Bronchial Asthma",[86],[18,6635],[39027],{"nctId":39055,"briefTitle":39056,"status":155,"phases":39057,"primaryCompletion":2383,"completion":2383,"start":7613,"enrollment":8038,"conditions":39058,"interventions":39060},"NCT00377728","Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber",[86],[10169,39059],"Seasonal Allergic Rhinitis",[39027],{"nctId":39062,"briefTitle":39063,"status":155,"phases":39064,"primaryCompletion":39065,"completion":39065,"start":8996,"enrollment":14145,"conditions":39066,"interventions":39067},"NCT00549679","Study To Evaluate Safety And Tolerability Of GSK256066 In Chronic Obstructive Pulmonary Disease (COPD) Patients",[86],"2008-12-15",[15],[39027],{"nctId":39069,"briefTitle":39070,"status":155,"phases":39071,"start":5196,"enrollment":6369,"conditions":39072,"interventions":39073},"NCT00430157","Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber",[86],[10169,39059],[39027],{"nctId":39075,"briefTitle":39076,"status":155,"phases":39077,"primaryCompletion":12473,"completion":12473,"start":39078,"enrollment":2045,"conditions":39079,"interventions":39080},"NCT00464568","A 5-way Treatment Period Trial of Single Doses of Intranasal GSK256066 in Patients With Rhinitis",[86],"2007-03-28",[10169],[39027],{"nctId":39082,"briefTitle":39083,"status":155,"phases":39084,"primaryCompletion":7522,"completion":7522,"start":9737,"enrollment":730,"conditions":39085,"interventions":39087},"NCT00612118","A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis",[86],[39086,10169],"Allergic Rhinitis",[39027,39088],"azelastine hydrochloride",{"nctId":39090,"briefTitle":39091,"status":155,"phases":39092,"primaryCompletion":39093,"completion":39093,"start":39094,"enrollment":868,"conditions":39095,"interventions":39096},"NCT00549744","Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing",[86],"2008-08-27","2007-11-16",[18],[39027],{"nctId":39098,"briefTitle":39099,"status":155,"phases":39100,"primaryCompletion":7522,"completion":7522,"start":7954,"enrollment":10794,"conditions":39101,"interventions":39102},"NCT00612820","A Phase II Study Evaluating Intranasal GSK256066 and Fluticasone Propionate in Subjects With Seasonal Allergic Rhinitis (SAR)",[86],[10169],[39027,8409],{"trials":39104,"activeCount":97},[],{"trials":39106,"activeCount":97},[],{"trials":39108,"activeCount":97},[],{"intervention":39110,"totalTrials":1720,"cells":39111},"GSK598809",{"EARLY_PHASE1":39112,"PHASE1":39114,"PHASE2":39168,"PHASE3":39177,"PHASE4":39179,"NA":39181},{"trials":39113,"activeCount":97},[],{"trials":39115,"activeCount":97},[39116,39125,39133,39140,39148,39155,39162],{"nctId":39117,"briefTitle":39118,"status":155,"phases":39119,"primaryCompletion":39120,"completion":39120,"start":39121,"enrollment":1634,"conditions":39122,"interventions":39124},"NCT00728052","A Human Volunteer Study Investigating Single Oral Doses of GSK598809 in Otherwise Healthy Smokers",[85],"2008-08-19","2008-06-09",[39123],"Substance Dependence",[39110],{"nctId":39126,"briefTitle":39127,"status":155,"phases":39128,"primaryCompletion":39129,"completion":39129,"start":39130,"enrollment":1079,"conditions":39131,"interventions":39132},"NCT00605241","A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward",[85],"2009-03-20","2008-02-25",[39123],[39110],{"nctId":39134,"briefTitle":39135,"status":500,"phases":39136,"primaryCompletion":2441,"completion":2441,"start":2795,"enrollment":97,"conditions":39137,"interventions":39139},"NCT00908206","Effects of GSK598809 on Brain Activation in Abstinent Alcoholics",[85],[39123,39138],"Alcohol Dependence",[39110],{"nctId":39141,"briefTitle":39142,"status":155,"phases":39143,"primaryCompletion":39144,"completion":39144,"start":39145,"enrollment":454,"conditions":39146,"interventions":39147},"NCT00887367","EtOH Interaction Study",[85],"2008-12-03","2008-09-29",[39123],[39110],{"nctId":39149,"briefTitle":39150,"status":155,"phases":39151,"primaryCompletion":18387,"completion":18387,"start":38925,"enrollment":1298,"conditions":39152,"interventions":39153},"NCT01039454","Effects of the D3 Antagonist GSK598809 on Food Reward and Reinforcement",[85],[39123],[39110,39154],"GSK598809 Placebo",{"nctId":39156,"briefTitle":39157,"status":155,"phases":39158,"primaryCompletion":2758,"completion":2758,"start":39159,"enrollment":1459,"conditions":39160,"interventions":39161},"NCT00437840","A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809",[85],"2007-03-20",[39123],[39110],{"nctId":39163,"briefTitle":39164,"status":155,"phases":39165,"primaryCompletion":21596,"completion":21596,"start":10013,"enrollment":14145,"conditions":39166,"interventions":39167},"NCT00437632","Study To Investigate If Repeat Doses Of GSK598809 Are Safe And Well Tolerated And To Evaluate Blood Levels Of GSK598809",[85],[39123],[39110,9321],{"trials":39169,"activeCount":97},[39170],{"nctId":39171,"briefTitle":39172,"status":500,"phases":39173,"primaryCompletion":8468,"completion":8468,"start":8468,"enrollment":97,"conditions":39174,"interventions":39175},"NCT00793468","Relapse Prevention Study in Newly Abstinent Smokers",[86],[39123],[39110,39176],"Nicotine Replacement Transdermal Patch",{"trials":39178,"activeCount":97},[],{"trials":39180,"activeCount":97},[],{"trials":39182,"activeCount":97},[],{"intervention":9302,"totalTrials":1720,"cells":39184},{"EARLY_PHASE1":39185,"PHASE1":39187,"PHASE2":39220,"PHASE3":39246,"PHASE4":39248,"NA":39250},{"trials":39186,"activeCount":97},[],{"trials":39188,"activeCount":97},[39189,39195,39204,39208,39216],{"nctId":39190,"briefTitle":39191,"status":155,"phases":39192,"start":4843,"enrollment":93,"conditions":39193,"interventions":39194},"NCT00429728","A Study To Investigate The Metabolism Of GW876008 In Smokers Compared To Non-Smokers.",[85],[7524],[9302],{"nctId":39196,"briefTitle":39197,"status":155,"phases":39198,"primaryCompletion":37724,"completion":37724,"start":39199,"enrollment":8786,"conditions":39200,"interventions":39201},"NCT00555139","A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder",[85],"2007-03-27",[26760],[39202,9302,39203],"GSK561679","alprazolam",{"nctId":11336,"briefTitle":11337,"status":155,"phases":39205,"primaryCompletion":2804,"completion":2804,"start":748,"enrollment":93,"conditions":39206,"interventions":39207},[85],[7524],[9362,9302],{"nctId":39209,"briefTitle":39210,"status":145,"phases":39211,"primaryCompletion":19269,"completion":19269,"start":39212,"enrollment":181,"conditions":39213,"interventions":39214},"NCT00508911","A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills",[85],"2007-06-08",[26760],[9302,39215],"COC",{"nctId":9296,"briefTitle":9297,"status":155,"phases":39217,"start":7659,"enrollment":463,"conditions":39218,"interventions":39219},[85],[7524],[9301,9302],{"trials":39221,"activeCount":97},[39222,39229,39239],{"nctId":39223,"briefTitle":39224,"status":155,"phases":39225,"primaryCompletion":10359,"completion":10359,"start":39226,"enrollment":8236,"conditions":39227,"interventions":39228},"NCT00421707","Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome",[86],"2006-10-14",[11511],[9302],{"nctId":39230,"briefTitle":39231,"status":155,"phases":39232,"primaryCompletion":39233,"completion":39233,"start":39234,"enrollment":39235,"conditions":39236,"interventions":39237},"NCT00397722","Treatment Of Patients With Social Anxiety Disorder",[86],"2007-09-05","2006-11-09",299,[26760],[9302,39238],"paroxetine",{"nctId":39240,"briefTitle":39241,"status":155,"phases":39242,"primaryCompletion":8217,"completion":8217,"start":39243,"enrollment":750,"conditions":39244,"interventions":39245},"NCT00385099","Effects Of GW876008 On The Bowel In Patients With Irritable Bowel Syndrome",[86],"2006-12-08",[11510],[9302],{"trials":39247,"activeCount":97},[],{"trials":39249,"activeCount":97},[],{"trials":39251,"activeCount":97},[],{"intervention":11855,"totalTrials":1720,"cells":39253},{"EARLY_PHASE1":39254,"PHASE1":39256,"PHASE2":39272,"PHASE3":39309,"PHASE4":39311,"NA":39313},{"trials":39255,"activeCount":97},[],{"trials":39257,"activeCount":97},[39258,39265],{"nctId":39259,"briefTitle":39260,"status":155,"phases":39261,"primaryCompletion":8826,"completion":33172,"start":39262,"enrollment":6369,"conditions":39263,"interventions":39264},"NCT00731250","A Study To Assess The Effect Of SB-705498 In A Capsaicin Challenge Model",[85],"2008-07-22",[11853],[11855],{"nctId":39266,"briefTitle":39267,"status":155,"phases":39268,"primaryCompletion":39269,"completion":39269,"start":18494,"enrollment":8038,"conditions":39270,"interventions":39271},"NCT00907933","Intranasal SB-705498 in Healthy Volunteers",[85],"2009-02-11",[11853],[11855,11855,11855,11855,11855,11855,11855],{"trials":39273,"activeCount":97},[39274,39281,39287,39291,39297,39303],{"nctId":39275,"briefTitle":39276,"status":145,"phases":39277,"primaryCompletion":15281,"completion":15281,"start":39278,"enrollment":417,"conditions":39279,"interventions":39280},"NCT00461682","Sb-705498 Rectal Pain Study",[86],"2007-01-26",[11510],[11855],{"nctId":39282,"briefTitle":39283,"status":155,"phases":39284,"primaryCompletion":6352,"completion":7647,"start":7658,"enrollment":345,"conditions":39285,"interventions":39286},"NCT01439308","Intranasal SB-705498 in Non-allergic Rhinitis Patients",[86],[11853],[11855],{"nctId":11848,"briefTitle":11849,"status":155,"phases":39288,"primaryCompletion":9812,"completion":9812,"start":11851,"enrollment":730,"conditions":39289,"interventions":39290},[86],[11853],[11855,11839],{"nctId":39292,"briefTitle":39293,"status":155,"phases":39294,"primaryCompletion":15214,"completion":17736,"start":22592,"enrollment":345,"conditions":39295,"interventions":39296},"NCT01424514","SB705498 Proof of Concept Chamber Challenge in Subjects With Non Allergic Rhinitis",[86],[11853],[11855],{"nctId":39298,"briefTitle":39299,"status":155,"phases":39300,"start":1360,"enrollment":730,"conditions":39301,"interventions":39302},"NCT00269022","Use Of SB-705498 In The Acute Treatment Of Migraine",[86],[30621],[11855],{"nctId":39304,"briefTitle":39305,"status":155,"phases":39306,"primaryCompletion":7591,"completion":2427,"start":7598,"enrollment":1279,"conditions":39307,"interventions":39308},"NCT01476098","A Study to Investigate the Effect of SB-705498 on Chronic Cough",[86],[11853],[11855],{"trials":39310,"activeCount":97},[],{"trials":39312,"activeCount":97},[],{"trials":39314,"activeCount":97},[],{"intervention":39316,"totalTrials":1720,"cells":39317},"GSK2140944",{"EARLY_PHASE1":39318,"PHASE1":39320,"PHASE2":39370,"PHASE3":39390,"PHASE4":39392,"NA":39394},{"trials":39319,"activeCount":97},[],{"trials":39321,"activeCount":97},[39322,39331,39338,39345,39353,39363],{"nctId":39323,"briefTitle":39324,"status":155,"phases":39325,"primaryCompletion":39326,"completion":39326,"start":39327,"enrollment":628,"conditions":39328,"interventions":39329},"NCT02000765","A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects",[85],"2013-11-30","2013-11-08",[14696],[39330,39316],"GSK2140944 for",{"nctId":39332,"briefTitle":39333,"status":155,"phases":39334,"primaryCompletion":39335,"completion":39335,"start":21955,"enrollment":6503,"conditions":39336,"interventions":39337},"NCT02202187","A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers",[85],"2012-02-15",[14696],[39316],{"nctId":39339,"briefTitle":39340,"status":155,"phases":39341,"primaryCompletion":39342,"completion":39342,"start":10835,"enrollment":1264,"conditions":39343,"interventions":39344},"NCT01706315","This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects",[85],"2013-12-13",[14696],[39316],{"nctId":39346,"briefTitle":39347,"status":155,"phases":39348,"primaryCompletion":39349,"completion":39349,"start":39350,"enrollment":2836,"conditions":39351,"interventions":39352},"NCT01934205","To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944",[85],"2013-12-21","2013-09-25",[6484],[39316,39316],{"nctId":39354,"briefTitle":39355,"status":155,"phases":39356,"primaryCompletion":39357,"completion":39357,"start":39358,"enrollment":10794,"conditions":39359,"interventions":39360},"NCT02257398","Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers",[85],"2015-03-02","2014-10-06",[14696],[39316,39361,8022,39362],"GSK2140944 placebo","Moxifloxacin placebo",{"nctId":39364,"briefTitle":39365,"status":155,"phases":39366,"primaryCompletion":8649,"completion":8649,"start":9578,"enrollment":4121,"conditions":39367,"interventions":39368},"NCT02045849","Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects",[85],[6484],[39316,39316,39369],"Itraconazole",{"trials":39371,"activeCount":97},[39372,39381],{"nctId":39373,"briefTitle":39374,"status":155,"phases":39375,"primaryCompletion":39376,"completion":39377,"start":39378,"enrollment":1229,"conditions":39379,"interventions":39380},"NCT02294682","A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae",[86],"2016-07-01","2016-07-27","2015-04-15",[6566],[39316],{"nctId":39382,"briefTitle":39383,"status":155,"phases":39384,"primaryCompletion":39385,"completion":39385,"start":39386,"enrollment":3157,"conditions":39387,"interventions":39388},"NCT02045797","Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections",[86],"2015-06-29","2014-03-24",[6484],[39389,39316],"GSK2140944 Lyophile",{"trials":39391,"activeCount":97},[],{"trials":39393,"activeCount":97},[],{"trials":39395,"activeCount":97},[],{"intervention":9403,"totalTrials":1720,"cells":39397},{"EARLY_PHASE1":39398,"PHASE1":39400,"PHASE2":39440,"PHASE3":39454,"PHASE4":39456,"NA":39458},{"trials":39399,"activeCount":97},[],{"trials":39401,"activeCount":97},[39402,39410,39417,39424,39428,39432],{"nctId":39403,"briefTitle":39404,"status":155,"phases":39405,"primaryCompletion":39406,"completion":39406,"start":39407,"enrollment":3379,"conditions":39408,"interventions":39409},"NCT00279019","Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease",[85],"2006-06-13","2005-12-12",[15],[9403,2934],{"nctId":39411,"briefTitle":39412,"status":155,"phases":39413,"primaryCompletion":39414,"completion":39414,"start":17886,"enrollment":695,"conditions":39415,"interventions":39416},"NCT00964405","Phase I Study of GSK233705 in Healthy Japanese Male Subjects",[85],"2008-12-20",[15],[9403],{"nctId":39418,"briefTitle":39419,"status":155,"phases":39420,"primaryCompletion":12473,"completion":12473,"start":39421,"enrollment":1459,"conditions":39422,"interventions":39423},"NCT00453687","A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK233705 In Healthy Volunteers.",[85],"2007-03-09",[15],[9403],{"nctId":18482,"briefTitle":18483,"status":155,"phases":39425,"primaryCompletion":8298,"completion":8298,"start":18485,"enrollment":433,"conditions":39426,"interventions":39427},[85],[15],[9403,10797,18488],{"nctId":18490,"briefTitle":18491,"status":155,"phases":39429,"primaryCompletion":18493,"completion":18493,"start":18494,"enrollment":433,"conditions":39430,"interventions":39431},[85],[15],[18488,10797,9403],{"nctId":39433,"briefTitle":39434,"status":155,"phases":39435,"primaryCompletion":39436,"completion":39437,"start":4826,"enrollment":1165,"conditions":39438,"interventions":39439},"NCT00500461","Study To Examine Safety, Tolerability And Pharmacokinetics Of Intravenous Doses And Oral Dose Of GSK233705",[85],"2007-07-01","2007-07-25",[15],[9403],{"trials":39441,"activeCount":97},[39442,39450],{"nctId":39443,"briefTitle":39444,"status":155,"phases":39445,"completion":39446,"start":39447,"enrollment":6369,"conditions":39448,"interventions":39449},"NCT00376714","Safety And Tolerability Study In Patients With Chronic Obstructive Pulmonary Disease",[86],"2007-04-03","2006-08-16",[15],[9403],{"nctId":9397,"briefTitle":9398,"status":155,"phases":39451,"primaryCompletion":2835,"completion":2835,"start":2404,"enrollment":1237,"conditions":39452,"interventions":39453},[86],[15],[9402,2980,9403],{"trials":39455,"activeCount":97},[],{"trials":39457,"activeCount":97},[],{"trials":39459,"activeCount":97},[],{"intervention":39461,"totalTrials":1318,"cells":39462},"GSK1070806",{"EARLY_PHASE1":39463,"PHASE1":39465,"PHASE2":39490,"PHASE3":39524,"PHASE4":39526,"NA":39528},{"trials":39464,"activeCount":97},[],{"trials":39466,"activeCount":97},[39467,39475,39483],{"nctId":39468,"briefTitle":39469,"status":155,"phases":39470,"primaryCompletion":39471,"completion":39472,"start":1734,"enrollment":12044,"conditions":39473,"interventions":39474},"NCT05590338","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive",[85],"2023-07-12","2023-12-28",[21691],[39461],{"nctId":39476,"briefTitle":39477,"status":155,"phases":39478,"primaryCompletion":19165,"completion":19165,"start":39479,"enrollment":868,"conditions":39480,"interventions":39482},"NCT01035645","First Time in Human Study of Intravenous Interleukin-18 Antibody",[85],"2010-01-05",[39481],"Inflammatory Bowel Diseases",[39461],{"nctId":39484,"briefTitle":39485,"status":155,"phases":39486,"primaryCompletion":39487,"completion":3247,"start":5087,"enrollment":1736,"conditions":39488,"interventions":39489},"NCT04975438","Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis",[85],"2022-12-19",[21691],[39461],{"trials":39491,"activeCount":97},[39492,39498,39506,39516],{"nctId":39493,"briefTitle":39494,"status":155,"phases":39495,"primaryCompletion":493,"completion":7634,"start":9706,"enrollment":1335,"conditions":39496,"interventions":39497},"NCT01648153","Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM",[86],[8063],[39461,39461],{"nctId":39499,"briefTitle":39500,"status":145,"phases":39501,"primaryCompletion":39502,"completion":39502,"start":39503,"enrollment":23504,"conditions":39504,"interventions":39505},"NCT05999799","A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis",[86],"2025-07-23","2023-11-16",[21691],[39461],{"nctId":39507,"briefTitle":39508,"status":145,"phases":39509,"primaryCompletion":39510,"completion":19584,"start":39511,"enrollment":1318,"conditions":39512,"interventions":39514},"NCT02723786","Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation",[86],"2017-03-31","2016-08-27",[39513],"Kidney Transplantation (Status Post)",[39461,39515],"1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids",{"nctId":39517,"briefTitle":39518,"status":145,"phases":39519,"primaryCompletion":39520,"completion":39520,"start":39521,"enrollment":14542,"conditions":39522,"interventions":39523},"NCT06447506","Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.",[86],"2025-07-29","2024-06-05",[21691],[39461],{"trials":39525,"activeCount":97},[],{"trials":39527,"activeCount":97},[],{"trials":39529,"activeCount":97},[],{"intervention":2287,"totalTrials":628,"cells":39531},{"EARLY_PHASE1":39532,"PHASE1":39534,"PHASE2":39560,"PHASE3":39568,"PHASE4":39570,"NA":39572},{"trials":39533,"activeCount":97},[],{"trials":39535,"activeCount":97},[39536,39544,39548,39552,39556],{"nctId":39537,"briefTitle":39538,"status":155,"phases":39539,"primaryCompletion":39540,"completion":39540,"start":19254,"enrollment":7712,"conditions":39541,"interventions":39542},"NCT00619424","A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors",[85],"2009-09-04",[267],[2263,39543,2287],"erlotinib",{"nctId":7469,"briefTitle":7470,"status":155,"phases":39545,"primaryCompletion":7472,"completion":7472,"start":7473,"enrollment":1634,"conditions":39546,"interventions":39547},[85],[267],[2274,165],{"nctId":2277,"briefTitle":2278,"status":155,"phases":39549,"primaryCompletion":2280,"completion":2280,"start":2281,"enrollment":2282,"conditions":39550,"interventions":39551},[85],[107],[2285,2264,2275,2286,2287,2288],{"nctId":153,"briefTitle":154,"status":155,"phases":39553,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":39554,"interventions":39555},[85],[107],[162,163,137,164,165,166,167,168,92,169,170],{"nctId":3055,"briefTitle":3056,"status":155,"phases":39557,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":803,"conditions":39558,"interventions":39559},[85],[36],[3048,164,3062,165,135,3063,134],{"trials":39561,"activeCount":97},[39562],{"nctId":39563,"briefTitle":39564,"status":145,"phases":39565,"primaryCompletion":8037,"completion":8037,"start":729,"enrollment":454,"conditions":39566,"interventions":39567},"NCT01313663","A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population",[86],[2778],[2263,2287],{"trials":39569,"activeCount":97},[],{"trials":39571,"activeCount":97},[],{"trials":39573,"activeCount":97},[],{"intervention":1651,"totalTrials":628,"cells":39575},{"EARLY_PHASE1":39576,"PHASE1":39578,"PHASE2":39592,"PHASE3":39606,"PHASE4":39608,"NA":39610},{"trials":39577,"activeCount":97},[],{"trials":39579,"activeCount":97},[39580,39584,39588],{"nctId":1641,"briefTitle":1642,"status":145,"phases":39581,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":628,"conditions":39582,"interventions":39583},[85],[107],[1649,1650,1651,1241,137],{"nctId":5156,"briefTitle":5157,"status":155,"phases":39585,"primaryCompletion":5159,"completion":5159,"start":5160,"enrollment":750,"conditions":39586,"interventions":39587},[85],[107],[5163,1241,1651],{"nctId":5165,"briefTitle":5166,"status":155,"phases":39589,"primaryCompletion":5168,"completion":5168,"start":5169,"enrollment":1003,"conditions":39590,"interventions":39591},[85],[107],[5172,1651,1241],{"trials":39593,"activeCount":97},[39594,39598,39602],{"nctId":1694,"briefTitle":1695,"status":500,"phases":39595,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":97,"conditions":39596,"interventions":39597},[86],[107],[1701,137,1651,1241],{"nctId":5192,"briefTitle":5193,"status":155,"phases":39599,"primaryCompletion":2794,"completion":5195,"start":5196,"enrollment":4542,"conditions":39600,"interventions":39601},[86],[5198],[5200,5201,1651,1241],{"nctId":5203,"briefTitle":5204,"status":155,"phases":39603,"primaryCompletion":5206,"completion":114,"start":5207,"enrollment":314,"conditions":39604,"interventions":39605},[86],[107],[5163,1241,1651],{"trials":39607,"activeCount":97},[],{"trials":39609,"activeCount":97},[],{"trials":39611,"activeCount":97},[],{"intervention":39613,"totalTrials":628,"cells":39614},"GSK962040",{"EARLY_PHASE1":39615,"PHASE1":39617,"PHASE2":39638,"PHASE3":39660,"PHASE4":39662,"NA":39664},{"trials":39616,"activeCount":97},[],{"trials":39618,"activeCount":97},[39619,39626,39632],{"nctId":39620,"briefTitle":39621,"status":155,"phases":39622,"primaryCompletion":24358,"completion":24358,"start":10368,"enrollment":3379,"conditions":39623,"interventions":39625},"NCT00733551","Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK962040 Administered to Healthy Adult Subjects.",[85],[39624],"Gastroparesis",[39613],{"nctId":39627,"briefTitle":39628,"status":155,"phases":39629,"primaryCompletion":23420,"completion":23420,"start":23568,"enrollment":628,"conditions":39630,"interventions":39631},"NCT01039974","GSK962040 Drug-drug Interaction Study With Ketoconazole",[85],[39624],[39613,9325],{"nctId":39633,"briefTitle":39634,"status":155,"phases":39635,"primaryCompletion":30248,"completion":30248,"start":7465,"enrollment":6503,"conditions":39636,"interventions":39637},"NCT00562848","A Study to Evaluate Safety, Side Effects, Muscle Activity and Speed of Gastric Emptying of GSK962040",[85],[39624],[39613],{"trials":39639,"activeCount":97},[39640,39648,39654],{"nctId":39641,"briefTitle":39642,"status":155,"phases":39643,"primaryCompletion":39644,"completion":39644,"start":39645,"enrollment":14542,"conditions":39646,"interventions":39647},"NCT01262898","Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis",[86],"2013-02-26","2011-05-03",[39624],[39613,39613,39613],{"nctId":39649,"briefTitle":39650,"status":155,"phases":39651,"primaryCompletion":7545,"completion":7545,"start":7658,"enrollment":1736,"conditions":39652,"interventions":39653},"NCT01039805","Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance",[86],[39624],[39613,39613],{"nctId":39655,"briefTitle":39656,"status":155,"phases":39657,"primaryCompletion":11043,"completion":11043,"start":8037,"enrollment":7712,"conditions":39658,"interventions":39659},"NCT01602549","A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying",[86],[39624],[39613],{"trials":39661,"activeCount":97},[],{"trials":39663,"activeCount":97},[],{"trials":39665,"activeCount":97},[],{"intervention":39667,"totalTrials":628,"cells":39668},"GSK2315698",{"EARLY_PHASE1":39669,"PHASE1":39671,"PHASE2":39711,"PHASE3":39720,"PHASE4":39722,"NA":39724},{"trials":39670,"activeCount":97},[],{"trials":39672,"activeCount":97},[39673,39681,39689,39695,39704],{"nctId":39674,"briefTitle":39675,"status":155,"phases":39676,"primaryCompletion":39677,"completion":39677,"start":39678,"enrollment":7438,"conditions":39679,"interventions":39680},"NCT01406314","SAP Depleter Dose Assessment Study in Patients",[85],"2012-11-14","2011-10-13",[1239],[39667],{"nctId":39682,"briefTitle":39683,"status":155,"phases":39684,"primaryCompletion":8666,"completion":8666,"start":39685,"enrollment":463,"conditions":39686,"interventions":39687},"NCT01777243","A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis",[85],"2013-05-13",[1239],[39688,39667],"GSK2398852",{"nctId":39690,"briefTitle":39691,"status":155,"phases":39692,"primaryCompletion":2392,"completion":2392,"start":8539,"enrollment":1634,"conditions":39693,"interventions":39694},"NCT02953808","Phase 1 Study of GSK2315698 in Healthy Japanese Subjects",[85],[1239],[39667],{"nctId":39696,"briefTitle":39697,"status":145,"phases":39698,"primaryCompletion":39699,"completion":39699,"start":39700,"enrollment":660,"conditions":39701,"interventions":39702},"NCT03417830","Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging",[85],"2018-07-20","2018-04-06",[1239],[39667,39688,39703],"89Zr-GSK2398852",{"nctId":39705,"briefTitle":39706,"status":155,"phases":39707,"primaryCompletion":3369,"completion":3369,"start":39708,"enrollment":1279,"conditions":39709,"interventions":39710},"NCT01323985","SAP Depleter Dose Escalation Study in Healthy Volunteers",[85],"2011-01-06",[1239],[39667,39667],{"trials":39712,"activeCount":97},[39713],{"nctId":39714,"briefTitle":39715,"status":145,"phases":39716,"primaryCompletion":39717,"completion":39717,"start":14321,"enrollment":1318,"conditions":39718,"interventions":39719},"NCT03044353","Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698",[86],"2019-01-03",[1239],[39667,39688],{"trials":39721,"activeCount":97},[],{"trials":39723,"activeCount":97},[],{"trials":39725,"activeCount":97},[],{"intervention":39727,"totalTrials":628,"cells":39728},"SB-751689",{"EARLY_PHASE1":39729,"PHASE1":39731,"PHASE2":39764,"PHASE3":39773,"PHASE4":39775,"NA":39777},{"trials":39730,"activeCount":97},[],{"trials":39732,"activeCount":97},[39733,39739,39745,39752,39758],{"nctId":39734,"briefTitle":39735,"status":155,"phases":39736,"primaryCompletion":2428,"completion":2428,"start":4756,"enrollment":628,"conditions":39737,"interventions":39738},"NCT00499928","A Study To Investigate The Metabolism And Excretion Of 14C SB-751689 Given To Healthy Males And Postmenopausal Women",[85],[12138],[39727],{"nctId":39740,"briefTitle":39741,"status":155,"phases":39742,"primaryCompletion":2336,"completion":2336,"start":2428,"enrollment":3131,"conditions":39743,"interventions":39744},"NCT00508534","A Study To Evaluate The Effects Of Repeat Dosing Of Esomeprazole On The Pharmacokinetics Of SB-751689 In Healthy People",[85],[12138],[39727],{"nctId":39746,"briefTitle":39747,"status":155,"phases":39748,"primaryCompletion":2336,"completion":2336,"start":4756,"enrollment":1117,"conditions":39749,"interventions":39750},"NCT00468689","Evaluation Of SB-751689 Administered At Supratherapeutic Dose Levels In Healthy Adult Subjects.",[85],[12138],[39751,9325],"SB-751689 oral",{"nctId":39753,"briefTitle":39754,"status":155,"phases":39755,"start":2404,"enrollment":710,"conditions":39756,"interventions":39757},"NCT00388596","A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.",[85],[12138],[39727],{"nctId":39759,"briefTitle":39760,"status":155,"phases":39761,"start":4756,"enrollment":463,"conditions":39762,"interventions":39763},"NCT00540878","A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women",[85],[12138],[39751],{"trials":39765,"activeCount":97},[39766],{"nctId":39767,"briefTitle":39768,"status":145,"phases":39769,"primaryCompletion":18255,"completion":18255,"start":7473,"enrollment":34,"conditions":39770,"interventions":39772},"NCT00548496","A Phase IIa Study Of Men And Post-Menopausal Women With A Fractured Distal Radius",[86],[39771],"Fracture Healing",[39727],{"trials":39774,"activeCount":97},[],{"trials":39776,"activeCount":97},[],{"trials":39778,"activeCount":97},[],{"intervention":9060,"totalTrials":628,"cells":39780},{"EARLY_PHASE1":39781,"PHASE1":39783,"PHASE2":39800,"PHASE3":39826,"PHASE4":39828,"NA":39830},{"trials":39782,"activeCount":97},[],{"trials":39784,"activeCount":97},[39785,39792],{"nctId":39786,"briefTitle":39787,"status":155,"phases":39788,"primaryCompletion":6519,"completion":6519,"start":39789,"enrollment":421,"conditions":39790,"interventions":39791},"NCT04053023","Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Subjects",[85],"2019-08-27",[4071],[9060,4056],{"nctId":39793,"briefTitle":39794,"status":155,"phases":39795,"primaryCompletion":39796,"completion":39796,"start":39797,"enrollment":904,"conditions":39798,"interventions":39799},"NCT01607385","A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.",[85],"2012-12-03","2012-05-18",[27],[9060,20525],{"trials":39801,"activeCount":97},[39802,39806,39810,39818],{"nctId":9053,"briefTitle":9054,"status":155,"phases":39803,"primaryCompletion":9056,"completion":9056,"start":9057,"enrollment":730,"conditions":39804,"interventions":39805},[86],[27],[9060,9061,9016],{"nctId":9063,"briefTitle":9064,"status":155,"phases":39807,"primaryCompletion":1874,"completion":9066,"start":9067,"enrollment":433,"conditions":39808,"interventions":39809},[86],[27],[9060,9016],{"nctId":39811,"briefTitle":39812,"status":155,"phases":39813,"primaryCompletion":39814,"completion":39814,"start":39815,"enrollment":22,"conditions":39816,"interventions":39817},"NCT02966834","Dose Response Study of GSK2330672 for the Treatment of Pruritus in Participants With Primary Biliary Cholangitis",[86],"2020-04-15","2017-01-11",[4071],[9060],{"nctId":39819,"briefTitle":39820,"status":155,"phases":39821,"primaryCompletion":15085,"completion":15085,"start":19703,"enrollment":2836,"conditions":39822,"interventions":39824},"NCT01899703","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus",[86],[39823],"Cholestasis, Intrahepatic",[9060,39825],"Ursodeoxycholic acid",{"trials":39827,"activeCount":97},[],{"trials":39829,"activeCount":97},[],{"trials":39831,"activeCount":97},[],{"intervention":7458,"totalTrials":628,"cells":39833},{"EARLY_PHASE1":39834,"PHASE1":39836,"PHASE2":39857,"PHASE3":39877,"PHASE4":39879,"NA":39881},{"trials":39835,"activeCount":97},[],{"trials":39837,"activeCount":97},[39838,39842,39850],{"nctId":7451,"briefTitle":7452,"status":155,"phases":39839,"primaryCompletion":7454,"completion":7454,"start":7455,"enrollment":2825,"conditions":39840,"interventions":39841},[85],[1877],[7458,2300],{"nctId":39843,"briefTitle":39844,"status":155,"phases":39845,"primaryCompletion":9792,"completion":9792,"start":39846,"enrollment":1264,"conditions":39847,"interventions":39849},"NCT01051700","A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans",[85],"2010-01-12",[39848],"Macular Degeneration",[7458],{"nctId":39851,"briefTitle":39852,"status":155,"phases":39853,"primaryCompletion":4689,"completion":4689,"start":26622,"enrollment":1298,"conditions":39854,"interventions":39855},"NCT00401583","A Study To Test The Effect Of GW786034 (Pazopanib) On P450 Enzymes",[85],[1877],[7458,39856],"Probe drugs",{"trials":39858,"activeCount":97},[39859,39865,39871],{"nctId":39860,"briefTitle":39861,"status":155,"phases":39862,"primaryCompletion":2382,"completion":493,"start":2805,"enrollment":7319,"conditions":39863,"interventions":39864},"NCT00244764","GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma",[86],[1877],[7458],{"nctId":39866,"briefTitle":39867,"status":155,"phases":39868,"primaryCompletion":2355,"completion":2335,"start":7613,"enrollment":8786,"conditions":39869,"interventions":39870},"NCT00281632","A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer",[86],[2827,2816,2363,2828],[7458],{"nctId":39872,"briefTitle":39873,"status":155,"phases":39874,"completion":749,"start":10803,"enrollment":414,"conditions":39875,"interventions":39876},"NCT00256880","Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma",[86],[1877],[7458],{"trials":39878,"activeCount":97},[],{"trials":39880,"activeCount":97},[],{"trials":39882,"activeCount":97},[],{"intervention":39884,"totalTrials":628,"cells":39885},"GSK2982772",{"EARLY_PHASE1":39886,"PHASE1":39888,"PHASE2":39925,"PHASE3":39942,"PHASE4":39944,"NA":39946},{"trials":39887,"activeCount":97},[],{"trials":39889,"activeCount":97},[39890,39899,39908,39916],{"nctId":39891,"briefTitle":39892,"status":155,"phases":39893,"primaryCompletion":588,"completion":39894,"start":39895,"enrollment":3131,"conditions":39896,"interventions":39898},"NCT03590613","Phase I Study of GSK2982772 in Japanese Healthy Male Participants",[85],"2018-09-26","2018-07-19",[39897],"Autoimmune Diseases",[39884],{"nctId":39900,"briefTitle":39901,"status":155,"phases":39902,"primaryCompletion":39903,"completion":39904,"start":39905,"enrollment":1079,"conditions":39906,"interventions":39907},"NCT04316585","A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants",[85],"2021-09-13","2021-10-12","2020-09-28",[22060],[39884],{"nctId":39909,"briefTitle":39910,"status":155,"phases":39911,"primaryCompletion":39912,"completion":39912,"start":39913,"enrollment":234,"conditions":39914,"interventions":39915},"NCT03305419","A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects",[85],"2018-10-15","2017-10-11",[39897],[39884],{"nctId":39917,"briefTitle":39918,"status":155,"phases":39919,"primaryCompletion":39920,"completion":39920,"start":39921,"enrollment":14542,"conditions":39922,"interventions":39923},"NCT02302404","A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects",[85],"2016-03-05","2015-01-06",[39481],[39924,39884],"GSK2982772 solution",{"trials":39926,"activeCount":97},[39927,39934],{"nctId":39928,"briefTitle":39929,"status":155,"phases":39930,"primaryCompletion":39931,"completion":39931,"start":1661,"enrollment":2282,"conditions":39932,"interventions":39933},"NCT02776033","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis",[86],"2018-01-04",[22060],[39884],{"nctId":39935,"briefTitle":39936,"status":155,"phases":39937,"primaryCompletion":39938,"completion":39938,"start":39939,"enrollment":710,"conditions":39940,"interventions":39941},"NCT02903966","GSK2982772 Study in Subjects With Ulcerative Colitis",[86],"2019-06-17","2016-11-15",[7295],[39884],{"trials":39943,"activeCount":97},[],{"trials":39945,"activeCount":97},[],{"trials":39947,"activeCount":97},[],{"intervention":39949,"totalTrials":628,"cells":39950},"GSK239512",{"EARLY_PHASE1":39951,"PHASE1":39953,"PHASE2":39979,"PHASE3":40003,"PHASE4":40005,"NA":40007},{"trials":39952,"activeCount":97},[],{"trials":39954,"activeCount":97},[39955,39964,39971],{"nctId":39956,"briefTitle":39957,"status":155,"phases":39958,"primaryCompletion":39959,"completion":39959,"start":39960,"enrollment":2836,"conditions":39961,"interventions":39963},"NCT01802931","GSK239512 DDI Study",[85],"2013-04-15","2013-01-07",[39962],"Multiple Sclerosis",[39949,38856],{"nctId":39965,"briefTitle":39966,"status":155,"phases":39967,"primaryCompletion":24664,"completion":24664,"start":39968,"enrollment":695,"conditions":39969,"interventions":39970},"NCT00675090","Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's Disease",[85],"2008-02-21",[4644],[39949],{"nctId":39972,"briefTitle":39973,"status":155,"phases":39974,"primaryCompletion":2382,"completion":2382,"start":748,"enrollment":1517,"conditions":39975,"interventions":39978},"NCT00474513","An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.",[85],[39976,39977],"Mild Cognitive Impairment","Dementia",[39949],{"trials":39980,"activeCount":97},[39981,39989,39996],{"nctId":39982,"briefTitle":39983,"status":155,"phases":39984,"primaryCompletion":39985,"completion":39985,"start":4816,"enrollment":39986,"conditions":39987,"interventions":39988},"NCT01009255","Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's Disease",[86],"2010-11-10",196,[4644],[39949],{"nctId":39990,"briefTitle":39991,"status":155,"phases":39992,"primaryCompletion":10905,"completion":10905,"start":3390,"enrollment":8337,"conditions":39993,"interventions":39995},"NCT01772199","Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis",[86],[39994],"Multiple Sclerosis, Relapsing-Remitting",[39949],{"nctId":39997,"briefTitle":39998,"status":155,"phases":39999,"primaryCompletion":40000,"completion":40000,"start":3426,"enrollment":1003,"conditions":40001,"interventions":40002},"NCT01009060","Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia",[86],"2011-08-10",[11346],[39949],{"trials":40004,"activeCount":97},[],{"trials":40006,"activeCount":97},[],{"trials":40008,"activeCount":97},[],{"intervention":40010,"totalTrials":628,"cells":40011},"GSK1325756",{"EARLY_PHASE1":40012,"PHASE1":40014,"PHASE2":40053,"PHASE3":40062,"PHASE4":40064,"NA":40066},{"trials":40013,"activeCount":97},[],{"trials":40015,"activeCount":97},[40016,40024,40030,40037,40046],{"nctId":40017,"briefTitle":40018,"status":155,"phases":40019,"primaryCompletion":40020,"completion":40020,"start":19731,"enrollment":2045,"conditions":40021,"interventions":40023},"NCT01209104","Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors",[85],"2010-05-24",[40022],"Nutritional Status",[40010,40010],{"nctId":40025,"briefTitle":40026,"status":155,"phases":40027,"primaryCompletion":23746,"completion":23746,"start":9793,"enrollment":7712,"conditions":40028,"interventions":40029},"NCT01209052","First Time in Human Study With GSK1325756",[85],[15],[40010],{"nctId":40031,"briefTitle":40032,"status":155,"phases":40033,"primaryCompletion":18370,"completion":18370,"start":40034,"enrollment":454,"conditions":40035,"interventions":40036},"NCT01453478","A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is Reduced",[85],"2011-10-12",[15],[40010],{"nctId":40038,"briefTitle":40039,"status":155,"phases":40040,"primaryCompletion":40041,"completion":40041,"start":40042,"enrollment":1298,"conditions":40043,"interventions":40044},"NCT02169583","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects",[85],"2014-08-28","2014-06-12",[14696],[40045,40010],"GSK1325756 Solution",{"nctId":40047,"briefTitle":40048,"status":155,"phases":40049,"primaryCompletion":40050,"completion":40050,"start":15599,"enrollment":345,"conditions":40051,"interventions":40052},"NCT01267006","Blood Levels and Effects of GSK1325756 in Healthy Adult Volunteers Aged 40 to 80 Years Old",[85],"2011-01-27",[15],[40010],{"trials":40054,"activeCount":97},[40055],{"nctId":40056,"briefTitle":40057,"status":155,"phases":40058,"primaryCompletion":23213,"completion":23213,"start":12041,"enrollment":6369,"conditions":40059,"interventions":40060},"NCT02469298","Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza",[86],[9840],[40010,40061],"Oseltamivir Phosphate",{"trials":40063,"activeCount":97},[],{"trials":40065,"activeCount":97},[],{"trials":40067,"activeCount":97},[],{"intervention":40069,"totalTrials":1517,"cells":40070},"Losmapimod",{"EARLY_PHASE1":40071,"PHASE1":40073,"PHASE2":40095,"PHASE3":40119,"PHASE4":40121,"NA":40123},{"trials":40072,"activeCount":97},[],{"trials":40074,"activeCount":97},[40075,40084],{"nctId":40076,"briefTitle":40077,"status":155,"phases":40078,"primaryCompletion":40079,"completion":40079,"start":18328,"enrollment":904,"conditions":40080,"interventions":40081},"NCT01756495","A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin",[85],"2013-04-23",[11827],[40069,8022,40082,40083],"Losmapimod matched Placebo","Moxifloxacin Placebo",{"nctId":40085,"briefTitle":40086,"status":155,"phases":40087,"primaryCompletion":40088,"completion":40088,"start":40089,"enrollment":433,"conditions":40090,"interventions":40091},"NCT01039961","PK Study of IV Formulation of GW856553",[85],"2010-04-15","2010-02-02",[14279],[40092,40093,40094],"losmapimod 1 mg","losmapimod","losmapimod 15 mg",{"trials":40096,"activeCount":97},[40097,40104,40112],{"nctId":40098,"briefTitle":40099,"status":155,"phases":40100,"primaryCompletion":12042,"completion":18900,"start":17134,"enrollment":7438,"conditions":40101,"interventions":40103},"NCT02000440","A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)",[86],[40102],"Glomerulosclerosis, Focal Segmental",[40069],{"nctId":40105,"briefTitle":40106,"status":155,"phases":40107,"primaryCompletion":16101,"completion":16101,"start":40108,"enrollment":2095,"conditions":40109,"interventions":40110},"NCT02299375","Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)",[86],"2014-12-09",[15],[40069,40111],"Salbutamol MDI",{"nctId":40113,"briefTitle":40114,"status":155,"phases":40115,"primaryCompletion":9594,"completion":9594,"start":35170,"enrollment":40116,"conditions":40117,"interventions":40118},"NCT01218126","Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD).",[86],604,[15],[40093],{"trials":40120,"activeCount":97},[],{"trials":40122,"activeCount":97},[],{"trials":40124,"activeCount":97},[],{"intervention":40126,"totalTrials":1517,"cells":40127},"SRT2104",{"EARLY_PHASE1":40128,"PHASE1":40130,"PHASE2":40162,"PHASE3":40172,"PHASE4":40174,"NA":40176},{"trials":40129,"activeCount":97},[],{"trials":40131,"activeCount":97},[40132,40139,40148,40156],{"nctId":40133,"briefTitle":40134,"status":155,"phases":40135,"primaryCompletion":738,"completion":738,"start":40136,"enrollment":750,"conditions":40137,"interventions":40138},"NCT00933062","Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers",[85],"2009-03-23",[27],[40126],{"nctId":40140,"briefTitle":40141,"status":155,"phases":40142,"primaryCompletion":40143,"completion":40143,"start":40144,"enrollment":212,"conditions":40145,"interventions":40147},"NCT01014117","Effect of SRT2104 on Endotoxin-induced Inflammation",[85],"2010-05-10","2009-12-09",[40146],"Sepsis",[40126],{"nctId":40149,"briefTitle":40150,"status":155,"phases":40151,"primaryCompletion":40152,"completion":40152,"start":9891,"enrollment":1298,"conditions":40153,"interventions":40155},"NCT00964340","A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral SRT2104 Capsules Administered to Healthy Elderly Subjects for 28 Days",[85],"2010-04-27",[40154],"Atrophy, Muscular",[40126],{"nctId":40157,"briefTitle":40158,"status":500,"phases":40159,"primaryCompletion":729,"completion":729,"start":22445,"enrollment":97,"conditions":40160,"interventions":40161},"NCT01039909","A Clinical Study to Assess the Effects of SRT2104 Upon Immobilization-Induced Skeletal Muscle Atrophy in Healthy Human Volunteers",[85],[19301,40154],[40126],{"trials":40163,"activeCount":97},[40164],{"nctId":40165,"briefTitle":40166,"status":155,"phases":40167,"primaryCompletion":40168,"completion":40168,"start":40169,"enrollment":34,"conditions":40170,"interventions":40171},"NCT01018017","A Clinical Study to Assess the Safety, Tolerability, and Activity of Oral SRT2104 Capsules Administered for 28 Days to Subjects With Type 2 Diabetes Mellitus",[86],"2010-12-25","2010-03-03",[27],[40126],{"trials":40173,"activeCount":97},[],{"trials":40175,"activeCount":97},[],{"trials":40177,"activeCount":97},[],{"intervention":19041,"totalTrials":1517,"cells":40179},{"EARLY_PHASE1":40180,"PHASE1":40182,"PHASE2":40197,"PHASE3":40216,"PHASE4":40218,"NA":40220},{"trials":40181,"activeCount":97},[],{"trials":40183,"activeCount":97},[40184,40190],{"nctId":40185,"briefTitle":40186,"status":155,"phases":40187,"start":2404,"enrollment":433,"conditions":40188,"interventions":40189},"NCT00439881","A Study To Look At The Safety Of SB-681323 In Healthy Adult Subjects After Intravenous Administration Of A Single Dose",[85],[8788,18985],[19041],{"nctId":40191,"briefTitle":40192,"status":155,"phases":40193,"primaryCompletion":749,"completion":749,"start":8386,"enrollment":1634,"conditions":40194,"interventions":40195},"NCT00419809","SB-681323-Methotrexate Interaction Study",[85],[8788],[40196],"SB-681323 oral",{"trials":40198,"activeCount":97},[40199,40206,40212],{"nctId":40200,"briefTitle":40201,"status":155,"phases":40202,"start":7613,"enrollment":526,"conditions":40203,"interventions":40205},"NCT00291902","A Pharmacokinetic Study Of SB-681323 In Subjects With Coronary Heart Disease Undergoing Percutaneous Intervention",[86],[40204],"Coronary Heart Disease",[19041],{"nctId":40207,"briefTitle":40208,"status":155,"phases":40209,"primaryCompletion":2404,"completion":2404,"start":2844,"enrollment":868,"conditions":40210,"interventions":40211},"NCT00320450","SB-681323 In Subjects With Rheumatoid Arthritis",[86],[8788],[19041],{"nctId":19034,"briefTitle":19035,"status":155,"phases":40213,"primaryCompletion":19037,"completion":19037,"start":19038,"enrollment":624,"conditions":40214,"interventions":40215},[86],[8788],[915,19041],{"trials":40217,"activeCount":97},[],{"trials":40219,"activeCount":97},[],{"trials":40221,"activeCount":97},[],{"intervention":40223,"totalTrials":1517,"cells":40224},"GSK1363089",{"EARLY_PHASE1":40225,"PHASE1":40227,"PHASE2":40252,"PHASE3":40268,"PHASE4":40270,"NA":40272},{"trials":40226,"activeCount":97},[],{"trials":40228,"activeCount":97},[40229,40237,40244],{"nctId":40230,"briefTitle":40231,"status":155,"phases":40232,"primaryCompletion":40233,"completion":9877,"start":40234,"enrollment":1335,"conditions":40235,"interventions":40236},"NCT00743067","A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors",[85],"2009-05-02","2006-08-09",[2761],[40223],{"nctId":40238,"briefTitle":40239,"status":155,"phases":40240,"primaryCompletion":22577,"completion":22577,"start":40241,"enrollment":1459,"conditions":40242,"interventions":40243},"NCT00742261","A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors",[85],"2008-08-11",[2761],[40223],{"nctId":40245,"briefTitle":40246,"status":155,"phases":40247,"primaryCompletion":40248,"completion":9316,"start":40249,"enrollment":345,"conditions":40250,"interventions":40251},"NCT00742131","A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors",[85],"2008-05-13","2005-03-17",[2761],[40223],{"trials":40253,"activeCount":97},[40254,40260],{"nctId":40255,"briefTitle":40256,"status":155,"phases":40257,"primaryCompletion":40233,"completion":40233,"start":19425,"enrollment":473,"conditions":40258,"interventions":40259},"NCT00725764","Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck",[86],[305],[40223],{"nctId":40261,"briefTitle":40262,"status":155,"phases":40263,"primaryCompletion":40264,"completion":23420,"start":40265,"enrollment":4158,"conditions":40266,"interventions":40267},"NCT00725712","Study of GSK1363089 in Metastatic Gastric Cancer",[86],"2009-11-01","2007-03-31",[2431],[40223],{"trials":40269,"activeCount":97},[],{"trials":40271,"activeCount":97},[],{"trials":40273,"activeCount":97},[],{"intervention":19718,"totalTrials":1517,"cells":40275},{"EARLY_PHASE1":40276,"PHASE1":40278,"PHASE2":40307,"PHASE3":40315,"PHASE4":40317,"NA":40319},{"trials":40277,"activeCount":97},[],{"trials":40279,"activeCount":97},[40280,40284,40291,40299],{"nctId":19710,"briefTitle":19711,"status":155,"phases":40281,"primaryCompletion":19713,"completion":19713,"start":19714,"enrollment":710,"conditions":40282,"interventions":40283},[85],[19716],[19718,19693],{"nctId":40285,"briefTitle":40286,"status":500,"phases":40287,"primaryCompletion":8426,"completion":8426,"start":8426,"enrollment":97,"conditions":40288,"interventions":40290},"NCT00534872","A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female Population",[85],[40289],"Insomnia",[19718],{"nctId":40292,"briefTitle":40293,"status":155,"phases":40294,"primaryCompletion":4836,"completion":4836,"start":40295,"enrollment":3025,"conditions":40296,"interventions":40297},"NCT00440323","Disturbed Sleep Model Study.",[85],"2007-01-05",[19716],[19718,40298],"Zolpidem",{"nctId":40300,"briefTitle":40301,"status":155,"phases":40302,"primaryCompletion":40303,"completion":40303,"start":40304,"enrollment":1264,"conditions":40305,"interventions":40306},"NCT01030939","Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers",[85],"2010-01-06","2009-08-27",[19748],[19718],{"trials":40308,"activeCount":97},[40309],{"nctId":40310,"briefTitle":40311,"status":155,"phases":40312,"primaryCompletion":2835,"completion":2835,"start":7659,"enrollment":6503,"conditions":40313,"interventions":40314},"NCT00426816","To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia",[86],[19716],[19718],{"trials":40316,"activeCount":97},[],{"trials":40318,"activeCount":97},[],{"trials":40320,"activeCount":97},[],{"intervention":5282,"totalTrials":1517,"cells":40322},{"EARLY_PHASE1":40323,"PHASE1":40325,"PHASE2":40339,"PHASE3":40369,"PHASE4":40371,"NA":40373},{"trials":40324,"activeCount":97},[],{"trials":40326,"activeCount":97},[40327,40335],{"nctId":40328,"briefTitle":40329,"status":145,"phases":40330,"primaryCompletion":2615,"completion":2615,"start":40331,"enrollment":433,"conditions":40332,"interventions":40334},"NCT04292912","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema",[85],"2020-09-07",[40333],"Macular Edema",[5282],{"nctId":5275,"briefTitle":5276,"status":145,"phases":40336,"primaryCompletion":5278,"completion":5278,"start":2974,"enrollment":149,"conditions":40337,"interventions":40338},[85],[5280],[5282,5283,4487],{"trials":40340,"activeCount":97},[40341,40349,40358],{"nctId":40342,"briefTitle":40343,"status":145,"phases":40344,"primaryCompletion":18919,"completion":18919,"start":40345,"enrollment":7438,"conditions":40346,"interventions":40348},"NCT03372603","A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough",[85,86],"2018-04-05",[40347],"Cough",[5282],{"nctId":40350,"briefTitle":40351,"status":155,"phases":40352,"primaryCompletion":40353,"completion":40353,"start":40354,"enrollment":361,"conditions":40355,"interventions":40357},"NCT02497937","A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure",[86],"2017-08-21","2016-04-13",[40356],"Heart Failure",[5282],{"nctId":40359,"briefTitle":40360,"status":155,"phases":40361,"primaryCompletion":40362,"completion":40362,"start":40363,"enrollment":4542,"conditions":40364,"interventions":40366},"NCT02119260","A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients",[86],"2016-12-25","2014-06-09",[40365],"Oedema, Pulmonary",[40367,40368,5282],"GSK2798745 solution","GSK2798745 suspension",{"trials":40370,"activeCount":97},[],{"trials":40372,"activeCount":97},[],{"trials":40374,"activeCount":97},[],{"intervention":19048,"totalTrials":1517,"cells":40376},{"EARLY_PHASE1":40377,"PHASE1":40379,"PHASE2":40389,"PHASE3":40413,"PHASE4":40415,"NA":40417},{"trials":40378,"activeCount":97},[],{"trials":40380,"activeCount":97},[40381],{"nctId":40382,"briefTitle":40383,"status":155,"phases":40384,"primaryCompletion":19929,"completion":19929,"start":40385,"enrollment":695,"conditions":40386,"interventions":40387},"NCT00273013","Study With GW274150 In Patients With Mild Asthma",[85],"2004-11-15",[18],[19048,40388],"Singulair",{"trials":40390,"activeCount":97},[40391,40397,40403,40409],{"nctId":40392,"briefTitle":40393,"status":155,"phases":40394,"start":749,"enrollment":3157,"conditions":40395,"interventions":40396},"NCT00319137","An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine",[86],[14168,22280],[19048],{"nctId":40398,"briefTitle":40399,"status":155,"phases":40400,"primaryCompletion":8427,"completion":8427,"start":10395,"enrollment":628,"conditions":40401,"interventions":40402},"NCT00370435","Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA)",[86],[8788],[19048],{"nctId":40404,"briefTitle":40405,"status":155,"phases":40406,"primaryCompletion":2356,"completion":2356,"start":2805,"enrollment":9627,"conditions":40407,"interventions":40408},"NCT00242866","Use Of GW274150 In The Prophylactic Treatment Of Migraine",[86],[14168],[19048],{"nctId":19043,"briefTitle":19044,"status":155,"phases":40410,"primaryCompletion":2804,"completion":2804,"start":1360,"enrollment":6503,"conditions":40411,"interventions":40412},[86],[8788],[19048,915],{"trials":40414,"activeCount":97},[],{"trials":40416,"activeCount":97},[],{"trials":40418,"activeCount":97},[],{"intervention":40420,"totalTrials":1517,"cells":40421},"GSK3228836",{"EARLY_PHASE1":40422,"PHASE1":40424,"PHASE2":40434,"PHASE3":40471,"PHASE4":40473,"NA":40475},{"trials":40423,"activeCount":97},[],{"trials":40425,"activeCount":97},[40426],{"nctId":40427,"briefTitle":40428,"status":155,"phases":40429,"primaryCompletion":40430,"completion":40430,"start":40431,"enrollment":1298,"conditions":40432,"interventions":40433},"NCT04971928","Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment",[85],"2022-05-12","2021-09-07",[24],[40420],{"trials":40435,"activeCount":97},[40436,40444,40453,40463],{"nctId":40437,"briefTitle":40438,"status":155,"phases":40439,"primaryCompletion":40440,"completion":40440,"start":148,"enrollment":1459,"conditions":40441,"interventions":40442},"NCT04544956","A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B",[86],"2023-11-30",[24],[40420,40443],"Nucleos(t)ide therapy",{"nctId":40445,"briefTitle":40446,"status":155,"phases":40447,"primaryCompletion":2635,"completion":2635,"start":40448,"enrollment":6994,"conditions":40449,"interventions":40450},"NCT04676724","Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)",[86],"2021-01-28",[24],[40420,40451,40452],"PegIFN","NA therapy",{"nctId":40454,"briefTitle":40455,"status":155,"phases":40456,"primaryCompletion":40457,"completion":40457,"start":114,"enrollment":40458,"conditions":40459,"interventions":40460},"NCT05276297","A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy",[86],"2025-08-05",174,[4191],[40420,40461,40462],"GSK3528869A","Control",{"nctId":40464,"briefTitle":40465,"status":155,"phases":40466,"primaryCompletion":40467,"completion":40467,"start":40468,"enrollment":4987,"conditions":40469,"interventions":40470},"NCT04449029","A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)",[86],"2022-03-18","2020-07-27",[24],[40420,40443],{"trials":40472,"activeCount":97},[],{"trials":40474,"activeCount":97},[],{"trials":40476,"activeCount":97},[],{"intervention":11864,"totalTrials":1517,"cells":40478},{"EARLY_PHASE1":40479,"PHASE1":40481,"PHASE2":40503,"PHASE3":40515,"PHASE4":40517,"NA":40519},{"trials":40480,"activeCount":97},[],{"trials":40482,"activeCount":97},[40483,40490,40496],{"nctId":40484,"briefTitle":40485,"status":155,"phases":40486,"primaryCompletion":15599,"completion":15599,"start":40487,"enrollment":1459,"conditions":40488,"interventions":40489},"NCT01160003","A Blinded, Dose Ascending Study to Assess the Pharmacokinetics, Safety and Tollerability of Repeat Inhaled Doses of Nebulised GW870086X in Healthy Adult Male Volunteers.",[85],"2010-07-29",[18],[11864],{"nctId":40491,"briefTitle":40492,"status":155,"phases":40493,"primaryCompletion":7954,"completion":7954,"start":2356,"enrollment":710,"conditions":40494,"interventions":40495},"NCT00549497","A Randomized Study Evaluating Steroid Hormone Levels, Safety And Tolerability Of GW870086X In Healthy Volunteers",[85],[18],[11864],{"nctId":40497,"briefTitle":40498,"status":155,"phases":40499,"primaryCompletion":10383,"completion":10383,"start":40500,"enrollment":454,"conditions":40501,"interventions":40502},"NCT00483899","Examine the Effect of Repeat Inhaled Doses of GW870086X on Lung Function in Mild Asthmatic Male Subjects",[85],"2005-10-07",[18],[11864],{"trials":40504,"activeCount":97},[40505,40509],{"nctId":11857,"briefTitle":11858,"status":155,"phases":40506,"primaryCompletion":11860,"completion":11860,"start":11861,"enrollment":1298,"conditions":40507,"interventions":40508},[86],[18],[11864,11839],{"nctId":40510,"briefTitle":40511,"status":155,"phases":40512,"primaryCompletion":7658,"completion":7658,"start":2441,"enrollment":1335,"conditions":40513,"interventions":40514},"NCT00945932","A Study to Evaluate the Effect of Repeat Doses of GW870086X in Mild to Moderate Asthmatics",[86],[18],[11864],{"trials":40516,"activeCount":97},[],{"trials":40518,"activeCount":97},[],{"trials":40520,"activeCount":97},[],{"intervention":20900,"totalTrials":1517,"cells":40522},{"EARLY_PHASE1":40523,"PHASE1":40525,"PHASE2":40542,"PHASE3":40564,"PHASE4":40566,"NA":40568},{"trials":40524,"activeCount":97},[],{"trials":40526,"activeCount":97},[40527,40535],{"nctId":40528,"briefTitle":40529,"status":155,"phases":40530,"primaryCompletion":21663,"completion":21663,"start":40531,"enrollment":345,"conditions":40532,"interventions":40534},"NCT02201303","Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression",[85],"2014-01-13",[40533],"Infections, Respiratory Syncytial Virus",[20900],{"nctId":40536,"briefTitle":40537,"status":155,"phases":40538,"primaryCompletion":40539,"completion":40539,"start":4867,"enrollment":345,"conditions":40540,"interventions":40541},"NCT03457727","GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects",[85],"2018-07-25",[15],[20900,9322],{"trials":40543,"activeCount":97},[40544,40552,40560],{"nctId":40545,"briefTitle":40546,"status":155,"phases":40547,"primaryCompletion":40548,"completion":40548,"start":40549,"enrollment":931,"conditions":40550,"interventions":40551},"NCT02130193","Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations",[86],"2016-08-29","2014-02-13",[15],[20900],{"nctId":40553,"briefTitle":40554,"status":145,"phases":40555,"primaryCompletion":18919,"completion":18919,"start":40556,"enrollment":421,"conditions":40557,"interventions":40558},"NCT03250689","Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)",[86],"2017-11-15",[15],[20900,20901,40559],"Inhaled COPD maintenance medication",{"nctId":20893,"briefTitle":20894,"status":155,"phases":40561,"primaryCompletion":20896,"completion":20896,"start":20897,"enrollment":18653,"conditions":40562,"interventions":40563},[86],[15],[20900,437,20901],{"trials":40565,"activeCount":97},[],{"trials":40567,"activeCount":97},[],{"trials":40569,"activeCount":97},[],{"intervention":40571,"totalTrials":1517,"cells":40572},"GW642444M",{"EARLY_PHASE1":40573,"PHASE1":40575,"PHASE2":40585,"PHASE3":40612,"PHASE4":40614,"NA":40616},{"trials":40574,"activeCount":97},[],{"trials":40576,"activeCount":97},[40577],{"nctId":40578,"briefTitle":40579,"status":155,"phases":40580,"primaryCompletion":19713,"completion":19713,"start":40581,"enrollment":454,"conditions":40582,"interventions":40583},"NCT00463697","A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In Asthmatic Patients",[85],"2007-04-02",[15],[40584,40571],"GW642444H",{"trials":40586,"activeCount":97},[40587,40593,40599,40605],{"nctId":40588,"briefTitle":40589,"status":155,"phases":40590,"primaryCompletion":5196,"completion":5196,"start":2296,"enrollment":473,"conditions":40591,"interventions":40592},"NCT00381667","Study to Assess GW642444 in Asthma Patients",[86],[15],[40571,40584],{"nctId":40594,"briefTitle":40595,"status":155,"phases":40596,"primaryCompletion":3079,"completion":3079,"start":2336,"enrollment":454,"conditions":40597,"interventions":40598},"NCT00519376","A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.",[86],[15],[40571,40584],{"nctId":40600,"briefTitle":40601,"status":155,"phases":40602,"primaryCompletion":10167,"completion":10167,"start":2804,"enrollment":18653,"conditions":40603,"interventions":40604},"NCT00600171","Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.",[86],[18],[40571],{"nctId":40606,"briefTitle":40607,"status":155,"phases":40608,"primaryCompletion":7590,"completion":7590,"start":7647,"enrollment":9334,"conditions":40609,"interventions":40610},"NCT01128595","Randomised Study Comparing the Effects of Inhaled FF\u002FGW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response",[86],[18],[40611,40571,8532],"FF\u002FGW642444M",{"trials":40613,"activeCount":97},[],{"trials":40615,"activeCount":97},[],{"trials":40617,"activeCount":97},[],{"intervention":22397,"totalTrials":181,"cells":40619},{"EARLY_PHASE1":40620,"PHASE1":40622,"PHASE2":40641,"PHASE3":40650,"PHASE4":40652,"NA":40654},{"trials":40621,"activeCount":97},[],{"trials":40623,"activeCount":97},[40624,40630,40637],{"nctId":40625,"briefTitle":40626,"status":155,"phases":40627,"start":11599,"enrollment":463,"conditions":40628,"interventions":40629},"NCT00085878","Dose-Escalation Study Of SB-485232 Administered As Daily Subcutaneous Injections In Adults With Solid Tumors",[85],[1431],[22397],{"nctId":40631,"briefTitle":40632,"status":155,"phases":40633,"start":2775,"enrollment":1459,"conditions":40634,"interventions":40636},"NCT00085904","Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas",[85],[1431,40635],"Lymphoma",[22397],{"nctId":22392,"briefTitle":22393,"status":155,"phases":40638,"primaryCompletion":18388,"completion":18388,"start":12180,"enrollment":1298,"conditions":40639,"interventions":40640},[85],[4574],[22397,517],{"trials":40642,"activeCount":97},[40643],{"nctId":40644,"briefTitle":40645,"status":155,"phases":40646,"primaryCompletion":40647,"completion":40647,"start":40385,"enrollment":6482,"conditions":40648,"interventions":40649},"NCT00107718","Anti-Tumor Activity Of SB-485232 In Patients With Previously Untreated Metastatic Melanoma",[86],"2006-05-19",[325],[22397],{"trials":40651,"activeCount":97},[],{"trials":40653,"activeCount":97},[],{"trials":40655,"activeCount":97},[],{"intervention":40657,"totalTrials":181,"cells":40658},"GSK2269557",{"EARLY_PHASE1":40659,"PHASE1":40661,"PHASE2":40678,"PHASE3":40695,"PHASE4":40697,"NA":40699},{"trials":40660,"activeCount":97},[],{"trials":40662,"activeCount":97},[40663,40670],{"nctId":40664,"briefTitle":40665,"status":155,"phases":40666,"primaryCompletion":40667,"completion":40667,"start":5127,"enrollment":6369,"conditions":40668,"interventions":40669},"NCT01762878","A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects",[85],"2013-10-21",[15],[40657],{"nctId":40671,"briefTitle":40672,"status":155,"phases":40673,"primaryCompletion":40674,"completion":40674,"start":40675,"enrollment":4542,"conditions":40676,"interventions":40677},"NCT01462617","Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557",[85],"2012-03-26","2011-07-24",[18],[40657],{"trials":40679,"activeCount":97},[40680,40689],{"nctId":40681,"briefTitle":40682,"status":155,"phases":40683,"primaryCompletion":40684,"completion":40685,"start":40686,"enrollment":8038,"conditions":40687,"interventions":40688},"NCT02522299","A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation",[86],"2018-06-15","2018-06-22","2015-11-04",[15],[40657],{"nctId":40690,"briefTitle":40691,"status":155,"phases":40692,"primaryCompletion":23450,"completion":23213,"start":10406,"enrollment":3157,"conditions":40693,"interventions":40694},"NCT02294734","An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease",[86],[15],[40657],{"trials":40696,"activeCount":97},[],{"trials":40698,"activeCount":97},[],{"trials":40700,"activeCount":97},[],{"intervention":40702,"totalTrials":181,"cells":40703},"GSK1322322",{"EARLY_PHASE1":40704,"PHASE1":40706,"PHASE2":40734,"PHASE3":40746,"PHASE4":40748,"NA":40750},{"trials":40705,"activeCount":97},[],{"trials":40707,"activeCount":97},[40708,40715,40724],{"nctId":40709,"briefTitle":40710,"status":155,"phases":40711,"primaryCompletion":2260,"completion":2260,"start":40712,"enrollment":454,"conditions":40713,"interventions":40714},"NCT00924911","Relative Bioavailability Study in Healthy Subjects",[85],"2009-04-27",[6484],[40702,40702],{"nctId":40716,"briefTitle":40717,"status":500,"phases":40718,"primaryCompletion":7711,"completion":7711,"start":8860,"enrollment":97,"conditions":40719,"interventions":40720},"NCT01953809","A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women",[85],[6484],[40702,40721,40722,40723],"EE\u002FNE","GSK1322322 Placebo","EE\u002FNE Placebo",{"nctId":40725,"briefTitle":40726,"status":155,"phases":40727,"primaryCompletion":11315,"completion":11315,"start":728,"enrollment":1298,"conditions":40728,"interventions":40729},"NCT01648179","A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects",[85],[6484],[40730,40731,40732,40733],"GSK1322322 (mesylate salt) Powder for","GSK1322322 (freebase)","GSK1322322 (mesylate salt) Powder for Oral Solution","GSK1322322 (freebase) tablets FED",{"trials":40735,"activeCount":97},[40736],{"nctId":40737,"briefTitle":40738,"status":155,"phases":40739,"primaryCompletion":40740,"completion":40740,"start":18983,"enrollment":719,"conditions":40741,"interventions":40742},"NCT01209078","GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection",[86],"2011-01-18",[12727],[40702,40743,40744,40745],"Linezolid","GSK1322322 placebo","Linezolid placebo",{"trials":40747,"activeCount":97},[],{"trials":40749,"activeCount":97},[],{"trials":40751,"activeCount":97},[],{"intervention":40753,"totalTrials":181,"cells":40754},"Talnetant",{"EARLY_PHASE1":40755,"PHASE1":40757,"PHASE2":40759,"PHASE3":40790,"PHASE4":40792,"NA":40794},{"trials":40756,"activeCount":97},[],{"trials":40758,"activeCount":97},[],{"trials":40760,"activeCount":97},[40761,40767,40774,40782],{"nctId":40762,"briefTitle":40763,"status":155,"phases":40764,"primaryCompletion":2805,"completion":2805,"start":1361,"enrollment":18798,"conditions":40765,"interventions":40766},"NCT00103727","Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia",[86],[11346],[40753],{"nctId":40768,"briefTitle":40769,"status":155,"phases":40770,"primaryCompletion":2805,"completion":2805,"start":1361,"enrollment":40771,"conditions":40772,"interventions":40773},"NCT00300963","Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients",[86],275,[11346],[40753],{"nctId":40775,"briefTitle":40776,"status":155,"phases":40777,"primaryCompletion":10212,"completion":10212,"start":8478,"enrollment":40778,"conditions":40779,"interventions":40780},"NCT00101985","Eight-Weeks Of Treatment With Talnetant In Subjects With Irritable Bowel Syndrome (IBS)",[86],741,[11510],[40781],"talnetant",{"nctId":40783,"briefTitle":40784,"status":155,"phases":40785,"primaryCompletion":10056,"completion":10056,"start":13061,"enrollment":40786,"conditions":40787,"interventions":40788},"NCT00049946","Schizophrenia Study In Adults",[86],231,[11346],[40781,40789],"risperidone",{"trials":40791,"activeCount":97},[],{"trials":40793,"activeCount":97},[],{"trials":40795,"activeCount":97},[],{"intervention":40797,"totalTrials":181,"cells":40798},"SB-480848",{"EARLY_PHASE1":40799,"PHASE1":40801,"PHASE2":40815,"PHASE3":40832,"PHASE4":40834,"NA":40836},{"trials":40800,"activeCount":97},[],{"trials":40802,"activeCount":97},[40803,40809],{"nctId":40804,"briefTitle":40805,"status":155,"phases":40806,"primaryCompletion":9133,"completion":9133,"start":7522,"enrollment":660,"conditions":40807,"interventions":40808},"NCT00704431","A Study With Darapladib to Collect Tolerability Information",[85],[9309],[40797],{"nctId":40810,"briefTitle":40811,"status":155,"phases":40812,"primaryCompletion":2382,"completion":2382,"start":7954,"enrollment":1634,"conditions":40813,"interventions":40814},"NCT00622830","Phase I Study of SB-480848(Darapladib) -Repeat Dose Study in Healthy Japanese Male Subjects-",[85],[9309],[40797],{"trials":40816,"activeCount":97},[40817,40824],{"nctId":40818,"briefTitle":40819,"status":155,"phases":40820,"primaryCompletion":4757,"completion":4757,"start":2844,"enrollment":40821,"conditions":40822,"interventions":40823},"NCT00269048","SB-480848 In Subjects With Coronary Heart Disease",[86],969,[9309],[40797],{"nctId":40825,"briefTitle":40826,"status":155,"phases":40827,"primaryCompletion":40828,"completion":40828,"start":40829,"enrollment":952,"conditions":40830,"interventions":40831},"NCT00268996","Integrated Biomarker And Imaging Study - 2",[86],"2007-08-28","2005-11-10",[9309],[40797],{"trials":40833,"activeCount":97},[],{"trials":40835,"activeCount":97},[],{"trials":40837,"activeCount":97},[],{"intervention":40839,"totalTrials":181,"cells":40840},"SB-742457",{"EARLY_PHASE1":40841,"PHASE1":40843,"PHASE2":40851,"PHASE3":40875,"PHASE4":40877,"NA":40879},{"trials":40842,"activeCount":97},[],{"trials":40844,"activeCount":97},[40845],{"nctId":40846,"briefTitle":40847,"status":155,"phases":40848,"start":2336,"enrollment":1459,"conditions":40849,"interventions":40850},"NCT00551772","A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.",[85],[4644],[40839],{"trials":40852,"activeCount":97},[40853,40859,40868],{"nctId":40854,"briefTitle":40855,"status":155,"phases":40856,"start":8427,"enrollment":6576,"conditions":40857,"interventions":40858},"NCT00224497","A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's Disease",[86],[4644],[40839],{"nctId":40860,"briefTitle":40861,"status":155,"phases":40862,"primaryCompletion":11275,"completion":40863,"start":40864,"enrollment":4679,"conditions":40865,"interventions":40866},"NCT00708552","Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's Disease",[86],"2010-03-09","2008-07-04",[4644],[40839,40867],"Donepezil",{"nctId":40869,"briefTitle":40870,"status":155,"phases":40871,"start":2383,"enrollment":1196,"conditions":40872,"interventions":40873},"NCT00348192","SB-742457 And Donepezil In Alzheimer's Disease",[86],[4644],[40839,40874],"donepezil",{"trials":40876,"activeCount":97},[],{"trials":40878,"activeCount":97},[],{"trials":40880,"activeCount":97},[],{"intervention":40882,"totalTrials":181,"cells":40883},"GSK2330811",{"EARLY_PHASE1":40884,"PHASE1":40886,"PHASE2":40902,"PHASE3":40922,"PHASE4":40924,"NA":40926},{"trials":40885,"activeCount":97},[],{"trials":40887,"activeCount":97},[40888,40895],{"nctId":40889,"briefTitle":40890,"status":155,"phases":40891,"primaryCompletion":20886,"completion":20886,"start":40892,"enrollment":1165,"conditions":40893,"interventions":40894},"NCT04138043","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of GSK2330811 in Healthy Japanese Participants",[85],"2019-12-05",[5280],[40882],{"nctId":40896,"briefTitle":40897,"status":155,"phases":40898,"primaryCompletion":18920,"completion":18920,"start":40899,"enrollment":212,"conditions":40900,"interventions":40901},"NCT02386436","A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects",[85],"2015-04-21",[539],[40882],{"trials":40903,"activeCount":97},[40904,40912],{"nctId":40905,"briefTitle":40906,"status":155,"phases":40907,"primaryCompletion":40908,"completion":40908,"start":40909,"enrollment":8786,"conditions":40910,"interventions":40911},"NCT03041025","Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis",[86],"2020-07-07","2017-06-05",[539],[40882],{"nctId":40913,"briefTitle":40914,"status":500,"phases":40915,"primaryCompletion":40916,"completion":40917,"start":40918,"enrollment":97,"conditions":40919,"interventions":40921},"NCT04151225","Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease",[86],"2024-04-22","2025-05-26","2021-04-05",[40920,21782],"Crohns Disease",[40882],{"trials":40923,"activeCount":97},[],{"trials":40925,"activeCount":97},[],{"trials":40927,"activeCount":97},[],{"intervention":20090,"totalTrials":181,"cells":40929},{"EARLY_PHASE1":40930,"PHASE1":40932,"PHASE2":40938,"PHASE3":40959,"PHASE4":40961,"NA":40963},{"trials":40931,"activeCount":97},[],{"trials":40933,"activeCount":97},[40934],{"nctId":20085,"briefTitle":20086,"status":155,"phases":40935,"start":11097,"enrollment":255,"conditions":40936,"interventions":40937},[85],[1431],[20090,3083],{"trials":40939,"activeCount":97},[40940,40947,40953],{"nctId":40941,"briefTitle":40942,"status":155,"phases":40943,"primaryCompletion":40944,"completion":40944,"start":36319,"enrollment":1003,"conditions":40945,"interventions":40946},"NCT00089973","Study Of Ispinesib In Subjects With Breast Cancer",[86],"2006-08-25",[668],[20090],{"nctId":40948,"briefTitle":40949,"status":155,"phases":40950,"primaryCompletion":2805,"completion":2805,"start":8492,"enrollment":730,"conditions":40951,"interventions":40952},"NCT00085813","Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer",[86],[2858],[20090],{"nctId":40954,"briefTitle":40955,"status":155,"phases":40956,"primaryCompletion":2835,"completion":2835,"start":1361,"enrollment":8786,"conditions":40957,"interventions":40958},"NCT00097409","Ispinesib In Subjects With Platinum-Taxane-Refractory Or Resistant Relapsed Ovarian Cancer",[86],[2816],[20090],{"trials":40960,"activeCount":97},[],{"trials":40962,"activeCount":97},[],{"trials":40964,"activeCount":97},[],{"intervention":40966,"totalTrials":181,"cells":40967},"orvepitant",{"EARLY_PHASE1":40968,"PHASE1":40970,"PHASE2":40979,"PHASE3":41004,"PHASE4":41006,"NA":41008},{"trials":40969,"activeCount":97},[],{"trials":40971,"activeCount":97},[40972],{"nctId":40973,"briefTitle":40974,"status":155,"phases":40975,"primaryCompletion":18254,"completion":18254,"start":4690,"enrollment":473,"conditions":40976,"interventions":40977},"NCT00843011","Food and Relative Bioavailability Study",[85],[9292],[40978],"Orvepitant",{"trials":40980,"activeCount":97},[40981,40989,40997],{"nctId":40982,"briefTitle":40983,"status":145,"phases":40984,"primaryCompletion":23418,"completion":40985,"start":8826,"enrollment":40986,"conditions":40987,"interventions":40988},"NCT00880399","A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed Dose Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder",[86],"2010-06-16",328,[10889],[40966],{"nctId":40990,"briefTitle":40991,"status":155,"phases":40992,"primaryCompletion":40993,"completion":40993,"start":4816,"enrollment":17420,"conditions":40994,"interventions":40996},"NCT01000493","Orvepitant (GW823296) in Adult Post Traumatic Stress Disorder",[86],"2010-06-28",[40995],"Post-Traumatic Stress Disorder",[40966],{"nctId":40998,"briefTitle":40999,"status":145,"phases":41000,"primaryCompletion":41001,"completion":41001,"start":23767,"enrollment":23431,"conditions":41002,"interventions":41003},"NCT00880048","A Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Orvepitant in Subjects With Major Depressive Disorder",[86],"2010-06-21",[9292],[40966],{"trials":41005,"activeCount":97},[],{"trials":41007,"activeCount":97},[],{"trials":41009,"activeCount":97},[],{"intervention":11470,"totalTrials":181,"cells":41011},{"EARLY_PHASE1":41012,"PHASE1":41014,"PHASE2":41024,"PHASE3":41041,"PHASE4":41043,"NA":41045},{"trials":41013,"activeCount":97},[],{"trials":41015,"activeCount":97},[41016],{"nctId":41017,"briefTitle":41018,"status":155,"phases":41019,"primaryCompletion":41020,"completion":41020,"start":24337,"enrollment":27085,"conditions":41021,"interventions":41022},"NCT00707798","Evaluation of Pneumococcal Vaccine Formulations in Young Adults",[85],"2009-01-15",[3637],[11470,41023],"Pneumo 23™",{"trials":41025,"activeCount":97},[41026,41030,41037],{"nctId":11462,"briefTitle":11463,"status":155,"phases":41027,"primaryCompletion":11465,"completion":11465,"start":11466,"enrollment":11467,"conditions":41028,"interventions":41029},[86],[3637],[11470,10572,10573],{"nctId":41031,"briefTitle":41032,"status":155,"phases":41033,"primaryCompletion":8028,"completion":8028,"start":41034,"enrollment":9382,"conditions":41035,"interventions":41036},"NCT00896064","Evaluation of a Booster Dose of Pneumococcal Vaccine Formulations in Young Adults",[86],"2009-05-18",[3637],[11470,11470],{"nctId":18768,"briefTitle":18769,"status":155,"phases":41038,"primaryCompletion":18771,"completion":18772,"start":7505,"enrollment":18773,"conditions":41039,"interventions":41040},[86],[3637],[11470,11470,18776,18776,3639],{"trials":41042,"activeCount":97},[],{"trials":41044,"activeCount":97},[],{"trials":41046,"activeCount":97},[],{"intervention":41048,"totalTrials":181,"cells":41049},"Epelsiban",{"EARLY_PHASE1":41050,"PHASE1":41052,"PHASE2":41079,"PHASE3":41089,"PHASE4":41091,"NA":41093},{"trials":41051,"activeCount":97},[],{"trials":41053,"activeCount":97},[41054,41063,41070],{"nctId":41055,"briefTitle":41056,"status":155,"phases":41057,"primaryCompletion":41058,"completion":41058,"start":41059,"enrollment":1459,"conditions":41060,"interventions":41062},"NCT02257359","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers",[85],"2015-01-29","2014-12-18",[41061],"Embryo Transfer",[41048],{"nctId":41064,"briefTitle":41065,"status":155,"phases":41066,"primaryCompletion":41067,"completion":41067,"start":9411,"enrollment":3379,"conditions":41068,"interventions":41069},"NCT02703181","Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers",[85],"2015-09-10",[41061],[41048],{"nctId":41071,"briefTitle":41072,"status":145,"phases":41073,"primaryCompletion":41074,"completion":41074,"start":40041,"enrollment":2797,"conditions":41075,"interventions":41076},"NCT02213029","A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban",[85],"2016-02-07",[41061],[41048,41077,41078],"Oxytocin","Ortho-Cylcen (21)®",{"trials":41080,"activeCount":97},[41081],{"nctId":41082,"briefTitle":41083,"status":500,"phases":41084,"primaryCompletion":41085,"completion":41085,"start":14276,"enrollment":97,"conditions":41086,"interventions":41088},"NCT02794467","Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis",[86],"2016-10",[41087],"Adenomyosis",[41048],{"trials":41090,"activeCount":97},[],{"trials":41092,"activeCount":97},[],{"trials":41094,"activeCount":97},[],{"intervention":41096,"totalTrials":181,"cells":41097},"GSK3036656",{"EARLY_PHASE1":41098,"PHASE1":41100,"PHASE2":41119,"PHASE3":41142,"PHASE4":41144,"NA":41146},{"trials":41099,"activeCount":97},[],{"trials":41101,"activeCount":97},[41102,41110],{"nctId":41103,"briefTitle":41104,"status":155,"phases":41105,"primaryCompletion":41106,"completion":41106,"start":41107,"enrollment":255,"conditions":41108,"interventions":41109},"NCT03075410","First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects",[85],"2017-08-04","2017-04-02",[23246],[41096],{"nctId":41111,"briefTitle":41112,"status":155,"phases":41113,"primaryCompletion":41114,"completion":41114,"start":41115,"enrollment":454,"conditions":41116,"interventions":41117},"NCT06354257","A Study to Investigate the Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With GSK3036656 in Female Participants of Non-childbearing Potential Aged 18 to 65 Years of Age",[85],"2024-07-01","2024-04-05",[23246],[41118,41096],"Microgynon",{"trials":41120,"activeCount":97},[41121,41130],{"nctId":41122,"briefTitle":41123,"status":155,"phases":41124,"primaryCompletion":41125,"completion":4167,"start":41126,"enrollment":7955,"conditions":41127,"interventions":41128},"NCT03557281","An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis",[86],"2021-12-03","2019-03-22",[23246],[41096,41129],"Rifafour e-275",{"nctId":41131,"briefTitle":41132,"status":155,"phases":41133,"primaryCompletion":41134,"completion":41134,"start":41135,"enrollment":4377,"conditions":41136,"interventions":41137},"NCT05382312","Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis",[86],"2025-05-27","2022-07-26",[23246],[41096,41138,41139,41140,41141],"Bedaquiline","Delamanid","RIFAFOUR e-275","BTZ-043",{"trials":41143,"activeCount":97},[],{"trials":41145,"activeCount":97},[],{"trials":41147,"activeCount":97},[],{"intervention":41149,"totalTrials":181,"cells":41150},"GSK3858279",{"EARLY_PHASE1":41151,"PHASE1":41153,"PHASE2":41171,"PHASE3":41190,"PHASE4":41192,"NA":41194},{"trials":41152,"activeCount":97},[],{"trials":41154,"activeCount":97},[41155,41162],{"nctId":41156,"briefTitle":41157,"status":145,"phases":41158,"primaryCompletion":2310,"completion":2310,"start":41159,"enrollment":1279,"conditions":41160,"interventions":41161},"NCT04114656","Effects of Intravenous GSK3858279 on a Battery of Evoked Pain Tests in Healthy Volunteers",[85],"2019-10-15",[9153],[41149],{"nctId":41163,"briefTitle":41164,"status":155,"phases":41165,"primaryCompletion":41166,"completion":41167,"start":41168,"enrollment":2797,"conditions":41169,"interventions":41170},"NCT05174013","Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants",[85],"2023-02-10","2023-04-17","2022-02-14",[9153],[41149],{"trials":41172,"activeCount":97},[41173,41182],{"nctId":41174,"briefTitle":41175,"status":145,"phases":41176,"primaryCompletion":41177,"completion":41178,"start":41179,"enrollment":22,"conditions":41180,"interventions":41181},"NCT05838755","A Study to Evaluate Efficacy and Safety of GSK3858279 in Diabetic Peripheral Neuropathic Pain",[86],"2024-10-14","2025-02-17","2023-09-20",[9153],[41149],{"nctId":41183,"briefTitle":41184,"status":145,"phases":41185,"primaryCompletion":41186,"completion":21822,"start":535,"enrollment":41187,"conditions":41188,"interventions":41189},"NCT05838742","A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain",[86],"2024-08-12",314,[9153,9210],[41149],{"trials":41191,"activeCount":97},[],{"trials":41193,"activeCount":97},[],{"trials":41195,"activeCount":97},[],{"intervention":20901,"totalTrials":181,"cells":41197},{"EARLY_PHASE1":41198,"PHASE1":41200,"PHASE2":41202,"PHASE3":41225,"PHASE4":41227,"NA":41229},{"trials":41199,"activeCount":97},[],{"trials":41201,"activeCount":97},[],{"trials":41203,"activeCount":97},[41204,41208,41217,41221],{"nctId":23490,"briefTitle":23491,"status":500,"phases":41205,"primaryCompletion":23493,"completion":23493,"start":988,"enrollment":97,"conditions":41206,"interventions":41207},[86],[18],[23481,20901],{"nctId":41209,"briefTitle":41210,"status":145,"phases":41211,"primaryCompletion":41212,"completion":41212,"start":41213,"enrollment":1686,"conditions":41214,"interventions":41215},"NCT03170232","A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)",[86],"2018-11-15","2017-10-16",[15],[41216,20901],"Danirixin 35 mg",{"nctId":40553,"briefTitle":40554,"status":145,"phases":41218,"primaryCompletion":18919,"completion":18919,"start":40556,"enrollment":421,"conditions":41219,"interventions":41220},[86],[15],[20900,20901,40559],{"nctId":20893,"briefTitle":20894,"status":155,"phases":41222,"primaryCompletion":20896,"completion":20896,"start":20897,"enrollment":18653,"conditions":41223,"interventions":41224},[86],[15],[20900,437,20901],{"trials":41226,"activeCount":97},[],{"trials":41228,"activeCount":97},[],{"trials":41230,"activeCount":97},[],{"intervention":4706,"totalTrials":181,"cells":41232},{"EARLY_PHASE1":41233,"PHASE1":41235,"PHASE2":41237,"PHASE3":41255,"PHASE4":41257,"NA":41259},{"trials":41234,"activeCount":97},[],{"trials":41236,"activeCount":97},[],{"trials":41238,"activeCount":97},[41239,41243,41247,41251],{"nctId":19172,"briefTitle":19173,"status":155,"phases":41240,"primaryCompletion":8768,"completion":8768,"start":19175,"enrollment":3463,"conditions":41241,"interventions":41242},[86],[33,30,4704,4702,3624,24,19177],[4706,19179,19151,10346],{"nctId":19181,"briefTitle":19182,"status":155,"phases":41244,"primaryCompletion":19184,"completion":19184,"start":15600,"enrollment":8931,"conditions":41245,"interventions":41246},[86],[33,24,4704,4702,3624,30,4703],[4706,19187,19151,10346,7830],{"nctId":4696,"briefTitle":4697,"status":145,"phases":41248,"primaryCompletion":4699,"completion":4699,"start":4700,"enrollment":433,"conditions":41249,"interventions":41250},[86],[33,4702,4703,4704,30,3624,24],[4706,4472,4707],{"nctId":19189,"briefTitle":19190,"status":155,"phases":41252,"primaryCompletion":16834,"completion":16834,"start":19192,"enrollment":19193,"conditions":41253,"interventions":41254},[86],[33,30,4704,24,4702,3624,19177],[4706,19151,19196,8969,10348],{"trials":41256,"activeCount":97},[],{"trials":41258,"activeCount":97},[],{"trials":41260,"activeCount":97},[],{"intervention":41262,"totalTrials":181,"cells":41263},"GSK2251052",{"EARLY_PHASE1":41264,"PHASE1":41266,"PHASE2":41292,"PHASE3":41302,"PHASE4":41304,"NA":41306},{"trials":41265,"activeCount":97},[],{"trials":41267,"activeCount":97},[41268,41276,41285],{"nctId":41269,"briefTitle":41270,"status":155,"phases":41271,"primaryCompletion":41272,"completion":41272,"start":41273,"enrollment":719,"conditions":41274,"interventions":41275},"NCT01262885","A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects",[85],"2011-08-25","2010-10-07",[6484],[41262],{"nctId":41277,"briefTitle":41278,"status":145,"phases":41279,"primaryCompletion":41280,"completion":41280,"start":41281,"enrollment":1298,"conditions":41282,"interventions":41284},"NCT01702350","A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study",[85],"2011-12-08","2011-10-21",[41283],"Community-acquired Infection",[41262],{"nctId":41286,"briefTitle":41287,"status":155,"phases":41288,"primaryCompletion":23980,"completion":23980,"start":41289,"enrollment":463,"conditions":41290,"interventions":41291},"NCT01267968","An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects",[85],"2011-01-11",[41283],[41262],{"trials":41293,"activeCount":97},[41294],{"nctId":41295,"briefTitle":41296,"status":145,"phases":41297,"primaryCompletion":39004,"completion":39004,"start":41298,"enrollment":454,"conditions":41299,"interventions":41300},"NCT01381549","GSK2251052 in Complicated Urinary Tract Infection",[86],"2011-06-28",[14965],[41262,41301],"imipenem-cilastatin",{"trials":41303,"activeCount":97},[],{"trials":41305,"activeCount":97},[],{"trials":41307,"activeCount":97},[],{"intervention":6817,"totalTrials":181,"cells":41309},{"EARLY_PHASE1":41310,"PHASE1":41312,"PHASE2":41337,"PHASE3":41347,"PHASE4":41349,"NA":41351},{"trials":41311,"activeCount":97},[],{"trials":41313,"activeCount":97},[41314,41318,41328],{"nctId":6808,"briefTitle":6809,"status":145,"phases":41315,"primaryCompletion":6811,"completion":6812,"start":6813,"enrollment":6814,"conditions":41316,"interventions":41317},[85],[2761],[6817,6818,1891,6819],{"nctId":41319,"briefTitle":41320,"status":145,"phases":41321,"primaryCompletion":41322,"completion":41323,"start":41324,"enrollment":8817,"conditions":41325,"interventions":41326},"NCT02964507","Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)\u002FHuman Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer",[85],"2020-09-29","2021-07-19","2019-09-26",[107],[6817,41327],"Fulvestrant",{"nctId":41329,"briefTitle":41330,"status":155,"phases":41331,"primaryCompletion":41332,"completion":41333,"start":4877,"enrollment":39986,"conditions":41334,"interventions":41336},"NCT01587703","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",[85],"2018-04-13","2019-07-29",[41335],"Carcinoma, Midline",[6817],{"trials":41338,"activeCount":97},[41339],{"nctId":41340,"briefTitle":41341,"status":155,"phases":41342,"primaryCompletion":41343,"completion":41343,"start":41344,"enrollment":3537,"conditions":41345,"interventions":41346},"NCT01943851","A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies",[86],"2020-04-30","2014-05-14",[107],[6817],{"trials":41348,"activeCount":97},[],{"trials":41350,"activeCount":97},[],{"trials":41352,"activeCount":97},[],{"intervention":41354,"totalTrials":181,"cells":41355},"GSK2190915 100mg",{"EARLY_PHASE1":41356,"PHASE1":41358,"PHASE2":41378,"PHASE3":41397,"PHASE4":41399,"NA":41401},{"trials":41357,"activeCount":97},[],{"trials":41359,"activeCount":97},[41360,41370],{"nctId":41361,"briefTitle":41362,"status":500,"phases":41363,"primaryCompletion":34933,"completion":34933,"start":3551,"enrollment":97,"conditions":41364,"interventions":41365},"NCT01721135","A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.",[85],[18],[41354,41366,41367,41368,41369],"GSK2190915 200mg","moxifloxacin 400mg","moxifloxacin placebo","GSK2190915 placebo",{"nctId":41371,"briefTitle":41372,"status":155,"phases":41373,"primaryCompletion":41374,"completion":41374,"start":39708,"enrollment":695,"conditions":41375,"interventions":41376},"NCT01411111","A Repeat Dose Study to Investigate the Interaction of GSK2190915 on the Pharmacokinetics of Rosuvastatin",[85],"2011-02-23",[18],[23669,41377,41354],"GSK2190915 30mg",{"trials":41379,"activeCount":97},[41380,41386],{"nctId":41381,"briefTitle":41382,"status":155,"phases":41383,"primaryCompletion":11315,"completion":11315,"start":9224,"enrollment":473,"conditions":41384,"interventions":41385},"NCT01471665","GSK2190915 Neutrophilic Asthma Study",[86],[18],[41354],{"nctId":41387,"briefTitle":41388,"status":155,"phases":41389,"primaryCompletion":41390,"completion":41390,"start":40993,"enrollment":11508,"conditions":41391,"interventions":41392},"NCT01147744","Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily",[86],"2011-10-06",[18],[41393,41354,41394,41395,41377,41396],"Fluticasone Propionate 100mcg via ACCUHALER\u002FDISKUS","GSK2190915 10mg","GSK2190915 300mg","Montelukast 10mg",{"trials":41398,"activeCount":97},[],{"trials":41400,"activeCount":97},[],{"trials":41402,"activeCount":97},[],{"intervention":41404,"totalTrials":181,"cells":41405},"GSK372475",{"EARLY_PHASE1":41406,"PHASE1":41408,"PHASE2":41423,"PHASE3":41441,"PHASE4":41443,"NA":41445},{"trials":41407,"activeCount":97},[],{"trials":41409,"activeCount":97},[41410,41417],{"nctId":41411,"briefTitle":41412,"status":155,"phases":41413,"primaryCompletion":41414,"completion":41414,"start":18134,"enrollment":2321,"conditions":41415,"interventions":41416},"NCT00728208","GSK372475 PK Study in Healthy Volunteers",[85],"2008-12-29",[9292],[41404],{"nctId":41418,"briefTitle":41419,"status":155,"phases":41420,"start":2428,"enrollment":2321,"conditions":41421,"interventions":41422},"NCT00488098","GSK372475 Bioequivalence Study",[85],[7524,9292],[41404],{"trials":41424,"activeCount":97},[41425,41433],{"nctId":41426,"briefTitle":41427,"status":155,"phases":41428,"primaryCompletion":4768,"completion":22482,"start":41429,"enrollment":1381,"conditions":41430,"interventions":41431},"NCT00420641","MDD POC Study GSK372475 Subjects Depressive Disease",[86],"2006-12-19",[9292],[41404,41432],"Paroxetine",{"nctId":41434,"briefTitle":41435,"status":155,"phases":41436,"primaryCompletion":8468,"completion":8468,"start":4756,"enrollment":41437,"conditions":41438,"interventions":41439},"NCT00448058","A Study Of New Medicine (GSK 372475) For The Treatment Of Depression",[86],396,[9292],[41404,41440],"venlafaxine",{"trials":41442,"activeCount":97},[],{"trials":41444,"activeCount":97},[],{"trials":41446,"activeCount":97},[],{"intervention":7789,"totalTrials":593,"cells":41448},{"EARLY_PHASE1":41449,"PHASE1":41451,"PHASE2":41453,"PHASE3":41470,"PHASE4":41472,"NA":41474},{"trials":41450,"activeCount":97},[],{"trials":41452,"activeCount":97},[],{"trials":41454,"activeCount":97},[41455,41459,41466],{"nctId":10972,"briefTitle":10973,"status":155,"phases":41456,"primaryCompletion":10975,"completion":10976,"start":10977,"enrollment":10978,"conditions":41457,"interventions":41458},[86],[3287],[7789,10963],{"nctId":41460,"briefTitle":41461,"status":155,"phases":41462,"primaryCompletion":41463,"completion":4691,"start":20059,"enrollment":9445,"conditions":41464,"interventions":41465},"NCT00307021","Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children",[86],"2006-09-15",[3287],[7789],{"nctId":7782,"briefTitle":7783,"status":155,"phases":41467,"primaryCompletion":2835,"completion":2835,"start":7785,"enrollment":7786,"conditions":41468,"interventions":41469},[86],[3287],[7789,7718,7790,7791,7792,7793],{"trials":41471,"activeCount":97},[],{"trials":41473,"activeCount":97},[],{"trials":41475,"activeCount":97},[],{"intervention":41477,"totalTrials":593,"cells":41478},"GSK706769",{"EARLY_PHASE1":41479,"PHASE1":41481,"PHASE2":41497,"PHASE3":41507,"PHASE4":41509,"NA":41511},{"trials":41480,"activeCount":97},[],{"trials":41482,"activeCount":97},[41483,41489],{"nctId":41484,"briefTitle":41485,"status":145,"phases":41486,"primaryCompletion":9737,"completion":9737,"start":2356,"enrollment":1736,"conditions":41487,"interventions":41488},"NCT00539201","GSK706769 A First Time in Human Study For Males and Females",[85],[7524],[41477],{"nctId":41490,"briefTitle":41491,"status":155,"phases":41492,"primaryCompletion":41493,"completion":41493,"start":41494,"enrollment":345,"conditions":41495,"interventions":41496},"NCT00711386","GSK706769 Repeat Dose Study",[85],"2008-09-12","2008-05-16",[9343],[41477],{"trials":41498,"activeCount":97},[41499],{"nctId":41500,"briefTitle":41501,"status":500,"phases":41502,"primaryCompletion":41503,"completion":41503,"start":41504,"enrollment":97,"conditions":41505,"interventions":41506},"NCT00979771","A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients",[86],"2011-04-28","2010-02-01",[8788],[41477],{"trials":41508,"activeCount":97},[],{"trials":41510,"activeCount":97},[],{"trials":41512,"activeCount":97},[],{"intervention":41514,"totalTrials":593,"cells":41515},"GW597599",{"EARLY_PHASE1":41516,"PHASE1":41518,"PHASE2":41520,"PHASE3":41544,"PHASE4":41546,"NA":41548},{"trials":41517,"activeCount":97},[],{"trials":41519,"activeCount":97},[],{"trials":41521,"activeCount":97},[41522,41529,41535],{"nctId":41523,"briefTitle":41524,"status":155,"phases":41525,"primaryCompletion":8963,"completion":8963,"start":1361,"enrollment":41526,"conditions":41527,"interventions":41528},"NCT00600990","Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients",[86],624,[21615,21614],[41514],{"nctId":41530,"briefTitle":41531,"status":155,"phases":41532,"primaryCompletion":1429,"completion":1429,"start":2795,"enrollment":23504,"conditions":41533,"interventions":41534},"NCT00992160","Vestipitant 28-day Tolerance Study",[86],[19748],[41514],{"nctId":41536,"briefTitle":41537,"status":155,"phases":41538,"primaryCompletion":41539,"completion":41539,"start":41540,"enrollment":7573,"conditions":41541,"interventions":41542},"NCT00606697","A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia",[86],"2008-05-07","2007-12-19",[19716],[41543,41514],"GR205171",{"trials":41545,"activeCount":97},[],{"trials":41547,"activeCount":97},[],{"trials":41549,"activeCount":97},[],{"intervention":41551,"totalTrials":593,"cells":41552},"GSK1605786",{"EARLY_PHASE1":41553,"PHASE1":41555,"PHASE2":41573,"PHASE3":41581,"PHASE4":41583,"NA":41585},{"trials":41554,"activeCount":97},[],{"trials":41556,"activeCount":97},[41557,41566],{"nctId":41558,"briefTitle":41559,"status":155,"phases":41560,"primaryCompletion":41561,"completion":41561,"start":41562,"enrollment":255,"conditions":41563,"interventions":41564},"NCT01611805","Japanese Phase I of GSK1605786",[85],"2010-10-06","2010-07-22",[21782],[41551,41565],"GSK1605786 Placebo",{"nctId":41567,"briefTitle":41568,"status":155,"phases":41569,"primaryCompletion":41570,"completion":19496,"start":858,"enrollment":1279,"conditions":41571,"interventions":41572},"NCT01827631","Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects",[85],"2013-06-14",[21782],[41551],{"trials":41574,"activeCount":97},[41575],{"nctId":41576,"briefTitle":41577,"status":500,"phases":41578,"primaryCompletion":3390,"completion":34933,"start":3390,"enrollment":97,"conditions":41579,"interventions":41580},"NCT01658605","A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis",[86],[7295],[41551],{"trials":41582,"activeCount":97},[],{"trials":41584,"activeCount":97},[],{"trials":41586,"activeCount":97},[],{"intervention":12140,"totalTrials":593,"cells":41588},{"EARLY_PHASE1":41589,"PHASE1":41591,"PHASE2":41607,"PHASE3":41613,"PHASE4":41615,"NA":41617},{"trials":41590,"activeCount":97},[],{"trials":41592,"activeCount":97},[41593,41599],{"nctId":41594,"briefTitle":41595,"status":155,"phases":41596,"start":9737,"enrollment":2045,"conditions":41597,"interventions":41598},"NCT00651534","To Estimate Relative Bioavailability of 5 Formulations of Ronacaleret Given to Healthy Postmenopausal Females",[85],[12138],[12140],{"nctId":41600,"briefTitle":41601,"status":155,"phases":41602,"primaryCompletion":41603,"completion":41603,"start":18404,"enrollment":12202,"conditions":41604,"interventions":41606},"NCT01466335","An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers",[85],"2012-03-05",[41605],"Bone Marrow Transplantation",[12140],{"trials":41608,"activeCount":97},[41609],{"nctId":12131,"briefTitle":12132,"status":145,"phases":41610,"primaryCompletion":12134,"completion":12134,"start":12135,"enrollment":12136,"conditions":41611,"interventions":41612},[86],[12138],[12140,12141,12122],{"trials":41614,"activeCount":97},[],{"trials":41616,"activeCount":97},[],{"trials":41618,"activeCount":97},[],{"intervention":41620,"totalTrials":593,"cells":41621},"GSK933776",{"EARLY_PHASE1":41622,"PHASE1":41624,"PHASE2":41641,"PHASE3":41651,"PHASE4":41653,"NA":41655},{"trials":41623,"activeCount":97},[],{"trials":41625,"activeCount":97},[41626,41634],{"nctId":41627,"briefTitle":41628,"status":155,"phases":41629,"primaryCompletion":41630,"completion":41630,"start":41631,"enrollment":1003,"conditions":41632,"interventions":41633},"NCT00459550","A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease",[85],"2011-05-30","2007-03-12",[4644],[41620],{"nctId":41635,"briefTitle":41636,"status":155,"phases":41637,"primaryCompletion":41280,"completion":41280,"start":41638,"enrollment":421,"conditions":41639,"interventions":41640},"NCT01424436","Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient",[85],"2010-05-19",[4644],[41620,41620,41620],{"trials":41642,"activeCount":97},[41643],{"nctId":41644,"briefTitle":41645,"status":155,"phases":41646,"primaryCompletion":8561,"completion":8561,"start":8824,"enrollment":41647,"conditions":41648,"interventions":41650},"NCT01342926","Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration",[86],191,[41649],"Atrophy, Geographic",[41620],{"trials":41652,"activeCount":97},[],{"trials":41654,"activeCount":97},[],{"trials":41656,"activeCount":97},[],{"intervention":41658,"totalTrials":593,"cells":41659},"GSK2879552",{"EARLY_PHASE1":41660,"PHASE1":41662,"PHASE2":41680,"PHASE3":41690,"PHASE4":41692,"NA":41694},{"trials":41661,"activeCount":97},[],{"trials":41663,"activeCount":97},[41664,41672],{"nctId":41665,"briefTitle":41666,"status":145,"phases":41667,"primaryCompletion":41668,"completion":41668,"start":9057,"enrollment":212,"conditions":41669,"interventions":41670},"NCT02177812","A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)",[85],"2017-12-08",[3381],[41658,41671],"ATRA",{"nctId":41673,"briefTitle":41674,"status":145,"phases":41675,"primaryCompletion":21988,"completion":21988,"start":41676,"enrollment":1079,"conditions":41677,"interventions":41679},"NCT02034123","Investigation of GSK2879552 in Subjects With Relapsed\u002FRefractory Small Cell Lung Carcinoma",[85],"2014-02-04",[41678],"Carcinoma, Small Cell",[41658],{"trials":41681,"activeCount":97},[41682],{"nctId":41683,"briefTitle":41684,"status":145,"phases":41685,"primaryCompletion":708,"completion":708,"start":41686,"enrollment":1318,"conditions":41687,"interventions":41688},"NCT02929498","Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)",[85,86],"2017-07-31",[11020,2574],[41658,41689],"Azacitidine",{"trials":41691,"activeCount":97},[],{"trials":41693,"activeCount":97},[],{"trials":41695,"activeCount":97},[],{"intervention":41697,"totalTrials":593,"cells":41698},"GSK's candidate Mycobacterium tuberculosis vaccine 692342",{"EARLY_PHASE1":41699,"PHASE1":41701,"PHASE2":41710,"PHASE3":41729,"PHASE4":41731,"NA":41733},{"trials":41700,"activeCount":97},[],{"trials":41702,"activeCount":97},[41703],{"nctId":41704,"briefTitle":41705,"status":155,"phases":41706,"primaryCompletion":1361,"start":2405,"enrollment":1459,"conditions":41707,"interventions":41709},"NCT00730795","Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults",[85],[41708],"Tuberculosis (TB)",[41697],{"trials":41711,"activeCount":97},[41712,41720],{"nctId":41713,"briefTitle":41714,"status":155,"phases":41715,"primaryCompletion":7472,"completion":7472,"start":24337,"enrollment":1335,"conditions":41716,"interventions":41717},"NCT00707967","Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.",[86],[23246],[41697,41718,41719],"Control vaccine with the adjuvant system.","Control vaccine with physiological saline",{"nctId":41721,"briefTitle":41722,"status":155,"phases":41723,"primaryCompletion":3426,"completion":3426,"start":41724,"enrollment":28,"conditions":41725,"interventions":41726},"NCT00397943","Safety and Immunogenicity of 2 Formulations of Tuberculosis Vaccine GSK692342 Given at 0,1 Months to Healthy Adults",[86],"2006-11-15",[23246],[41697,41727,41728,41718],"Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system","Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline",{"trials":41730,"activeCount":97},[],{"trials":41732,"activeCount":97},[],{"trials":41734,"activeCount":97},[],{"intervention":5163,"totalTrials":593,"cells":41736},{"EARLY_PHASE1":41737,"PHASE1":41739,"PHASE2":41749,"PHASE3":41755,"PHASE4":41757,"NA":41759},{"trials":41738,"activeCount":97},[],{"trials":41740,"activeCount":97},[41741,41745],{"nctId":1641,"briefTitle":1642,"status":145,"phases":41742,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":628,"conditions":41743,"interventions":41744},[85],[107],[1649,1650,1651,1241,137],{"nctId":5156,"briefTitle":5157,"status":155,"phases":41746,"primaryCompletion":5159,"completion":5159,"start":5160,"enrollment":750,"conditions":41747,"interventions":41748},[85],[107],[5163,1241,1651],{"trials":41750,"activeCount":97},[41751],{"nctId":5203,"briefTitle":5204,"status":155,"phases":41752,"primaryCompletion":5206,"completion":114,"start":5207,"enrollment":314,"conditions":41753,"interventions":41754},[86],[107],[5163,1241,1651],{"trials":41756,"activeCount":97},[],{"trials":41758,"activeCount":97},[],{"trials":41760,"activeCount":97},[],{"intervention":247,"totalTrials":593,"cells":41762},{"EARLY_PHASE1":41763,"PHASE1":41765,"PHASE2":41776,"PHASE3":41786,"PHASE4":41788,"NA":41790},{"trials":41764,"activeCount":97},[],{"trials":41766,"activeCount":97},[41767],{"nctId":41768,"briefTitle":41769,"status":155,"phases":41770,"primaryCompletion":41771,"completion":41771,"start":41772,"enrollment":12044,"conditions":41773,"interventions":41774},"NCT01767454","Study of Dabrafenib +\u002F- Trametinib in Combination With Ipilimumab for V600E\u002FK Mutation Positive Metastatic or Unresectable Melanoma",[85],"2015-09-04","2013-02-12",[2761],[41775,3048,247],"Dabrafenib",{"trials":41777,"activeCount":97},[41778,41782],{"nctId":4415,"briefTitle":4416,"status":145,"phases":41779,"primaryCompletion":3088,"completion":3088,"start":4418,"enrollment":1720,"conditions":41780,"interventions":41781},[86],[107],[246,247],{"nctId":239,"briefTitle":240,"status":155,"phases":41783,"primaryCompletion":232,"completion":232,"start":242,"enrollment":243,"conditions":41784,"interventions":41785},[86],[107],[164,246,247,248,92,180],{"trials":41787,"activeCount":97},[],{"trials":41789,"activeCount":97},[],{"trials":41791,"activeCount":97},[],{"intervention":9395,"totalTrials":593,"cells":41793},{"EARLY_PHASE1":41794,"PHASE1":41796,"PHASE2":41806,"PHASE3":41818,"PHASE4":41820,"NA":41822},{"trials":41795,"activeCount":97},[],{"trials":41797,"activeCount":97},[41798],{"nctId":41799,"briefTitle":41800,"status":155,"phases":41801,"primaryCompletion":41802,"completion":41802,"start":41803,"enrollment":6503,"conditions":41804,"interventions":41805},"NCT02064504","Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination",[85],"2014-05-20","2014-02-19",[15],[9395,9502],{"trials":41807,"activeCount":97},[41808,41812],{"nctId":9389,"briefTitle":9390,"status":155,"phases":41809,"primaryCompletion":3111,"completion":3111,"start":2344,"enrollment":9392,"conditions":41810,"interventions":41811},[86],[15],[9395,9370],{"nctId":41813,"briefTitle":41814,"status":155,"phases":41815,"primaryCompletion":7522,"completion":7522,"start":3552,"enrollment":11953,"conditions":41816,"interventions":41817},"NCT00478738","A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients",[86],[15],[9395],{"trials":41819,"activeCount":97},[],{"trials":41821,"activeCount":97},[],{"trials":41823,"activeCount":97},[],{"intervention":2329,"totalTrials":593,"cells":41825},{"EARLY_PHASE1":41826,"PHASE1":41828,"PHASE2":41834,"PHASE3":41844,"PHASE4":41846,"NA":41848},{"trials":41827,"activeCount":97},[],{"trials":41829,"activeCount":97},[41830],{"nctId":3532,"briefTitle":3533,"status":155,"phases":41831,"primaryCompletion":546,"completion":3535,"start":3536,"enrollment":3537,"conditions":41832,"interventions":41833},[85],[668],[2328,2273,2329],{"trials":41835,"activeCount":97},[41836,41840],{"nctId":2316,"briefTitle":2317,"status":145,"phases":41837,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":41838,"interventions":41839},[86],[668],[2324,2325,2326,2327,1241,164,2328,2329,216,2330],{"nctId":2341,"briefTitle":2342,"status":500,"phases":41841,"primaryCompletion":2344,"completion":2344,"start":2344,"enrollment":97,"conditions":41842,"interventions":41843},[86],[668],[2274,2330,2329,1241,216],{"trials":41845,"activeCount":97},[],{"trials":41847,"activeCount":97},[],{"trials":41849,"activeCount":97},[],{"intervention":39202,"totalTrials":593,"cells":41851},{"EARLY_PHASE1":41852,"PHASE1":41854,"PHASE2":41870,"PHASE3":41878,"PHASE4":41880,"NA":41882},{"trials":41853,"activeCount":97},[],{"trials":41855,"activeCount":97},[41856,41860],{"nctId":39196,"briefTitle":39197,"status":155,"phases":41857,"primaryCompletion":37724,"completion":37724,"start":39199,"enrollment":8786,"conditions":41858,"interventions":41859},[85],[26760],[39202,9302,39203],{"nctId":41861,"briefTitle":41862,"status":155,"phases":41863,"primaryCompletion":41864,"completion":41864,"start":41865,"enrollment":454,"conditions":41866,"interventions":41868},"NCT00426608","To Investigate Effects GSK561679 on Part of the Body's System That Controls the Balance of Many of the Hormones.",[85],"2007-01-08","2006-10-06",[41867],"Depressive Disorder and Anxiety Disorders",[41869,39203,39202],"metyrapone",{"trials":41871,"activeCount":97},[41872],{"nctId":41873,"briefTitle":41874,"status":155,"phases":41875,"primaryCompletion":7867,"completion":7867,"start":17895,"enrollment":1579,"conditions":41876,"interventions":41877},"NCT00733980","A Study of the Effects of a New Antidepressant Treatment (GSK561679) in Females With Major Depressive Disorder",[86],[10889],[39202],{"trials":41879,"activeCount":97},[],{"trials":41881,"activeCount":97},[],{"trials":41883,"activeCount":97},[],{"intervention":26310,"totalTrials":593,"cells":41885},{"EARLY_PHASE1":41886,"PHASE1":41888,"PHASE2":41890,"PHASE3":41911,"PHASE4":41913,"NA":41915},{"trials":41887,"activeCount":97},[],{"trials":41889,"activeCount":97},[],{"trials":41891,"activeCount":97},[41892,41899,41903],{"nctId":41893,"briefTitle":41894,"status":155,"phases":41895,"primaryCompletion":18806,"completion":41896,"start":2664,"enrollment":25,"conditions":41897,"interventions":41898},"NCT00942162","A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma",[86],"2015-04-01",[325],[26310],{"nctId":26304,"briefTitle":26305,"status":145,"phases":41900,"primaryCompletion":19318,"completion":19318,"start":26307,"enrollment":6503,"conditions":41901,"interventions":41902},[86],[325],[26310,19687],{"nctId":41904,"briefTitle":41905,"status":155,"phases":41906,"primaryCompletion":41907,"completion":41907,"start":41908,"enrollment":1298,"conditions":41909,"interventions":41910},"NCT00896480","Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma",[86],"2014-11-03","2009-05-19",[325],[26310],{"trials":41912,"activeCount":97},[],{"trials":41914,"activeCount":97},[],{"trials":41916,"activeCount":97},[],{"intervention":23248,"totalTrials":593,"cells":41918},{"EARLY_PHASE1":41919,"PHASE1":41921,"PHASE2":41923,"PHASE3":41945,"PHASE4":41947,"NA":41949},{"trials":41920,"activeCount":97},[],{"trials":41922,"activeCount":97},[],{"trials":41924,"activeCount":97},[41925,41929,41939],{"nctId":23240,"briefTitle":23241,"status":155,"phases":41926,"primaryCompletion":23243,"completion":23244,"start":19538,"enrollment":10489,"conditions":41927,"interventions":41928},[86],[23246],[23248,23249,7791,23250,19196],{"nctId":41930,"briefTitle":41931,"status":155,"phases":41932,"primaryCompletion":41933,"completion":41934,"start":41935,"enrollment":9196,"conditions":41936,"interventions":41937},"NCT01262976","Safety and Immunogenicity Study of a Candidate Tuberculosis Vaccine in Human Immunodeficiency Virus (HIV)-Positive Adults",[86],"2012-07-17","2015-06-04","2011-01-17",[23246],[23248,41938],"Physiological saline",{"nctId":41940,"briefTitle":41941,"status":155,"phases":41942,"primaryCompletion":8263,"completion":8263,"start":3634,"enrollment":1237,"conditions":41943,"interventions":41944},"NCT00950612","Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Healthy HIV Negative Adolescents",[86],[23246],[23248],{"trials":41946,"activeCount":97},[],{"trials":41948,"activeCount":97},[],{"trials":41950,"activeCount":97},[],{"intervention":23250,"totalTrials":593,"cells":41952},{"EARLY_PHASE1":41953,"PHASE1":41955,"PHASE2":41957,"PHASE3":41986,"PHASE4":41988,"NA":41990},{"trials":41954,"activeCount":97},[],{"trials":41956,"activeCount":97},[],{"trials":41958,"activeCount":97},[41959,41963,41975],{"nctId":23240,"briefTitle":23241,"status":155,"phases":41960,"primaryCompletion":23243,"completion":23244,"start":19538,"enrollment":10489,"conditions":41961,"interventions":41962},[86],[23246],[23248,23249,7791,23250,19196],{"nctId":41964,"briefTitle":41965,"status":155,"phases":41966,"primaryCompletion":7445,"completion":7445,"start":41967,"enrollment":41968,"conditions":41969,"interventions":41970},"NCT01262872","Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants",[86],"2011-02-09",1320,[3637],[4682,4682,10348,41971,41972,23250,41973,41974],"Prevnar13™","Tritanrix™-HepB\u002FHib","M-Vac™","Stamaril™",{"nctId":41976,"briefTitle":41977,"status":155,"phases":41978,"primaryCompletion":26945,"completion":36623,"start":41979,"enrollment":41980,"conditions":41981,"interventions":41982},"NCT00436007","Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen",[86],"2007-04-30",511,[3287],[41983,41984,41985,41974,23250],"GSK 257049","Tritanrix™ HepB\u002FHib","Rouvax™",{"trials":41987,"activeCount":97},[],{"trials":41989,"activeCount":97},[],{"trials":41991,"activeCount":97},[],{"intervention":19196,"totalTrials":593,"cells":41993},{"EARLY_PHASE1":41994,"PHASE1":41996,"PHASE2":41998,"PHASE3":42012,"PHASE4":42014,"NA":42016},{"trials":41995,"activeCount":97},[],{"trials":41997,"activeCount":97},[],{"trials":41999,"activeCount":97},[42000,42004,42008],{"nctId":23240,"briefTitle":23241,"status":155,"phases":42001,"primaryCompletion":23243,"completion":23244,"start":19538,"enrollment":10489,"conditions":42002,"interventions":42003},[86],[23246],[23248,23249,7791,23250,19196],{"nctId":22574,"briefTitle":22575,"status":155,"phases":42005,"primaryCompletion":11274,"completion":5268,"start":22577,"enrollment":4521,"conditions":42006,"interventions":42007},[86],[4703,4704],[22580,11068,11067,22581,19196],{"nctId":19189,"briefTitle":19190,"status":155,"phases":42009,"primaryCompletion":16834,"completion":16834,"start":19192,"enrollment":19193,"conditions":42010,"interventions":42011},[86],[33,30,4704,24,4702,3624,19177],[4706,19151,19196,8969,10348],{"trials":42013,"activeCount":97},[],{"trials":42015,"activeCount":97},[],{"trials":42017,"activeCount":97},[],{"intervention":42019,"totalTrials":593,"cells":42020},"GW842166",{"EARLY_PHASE1":42021,"PHASE1":42023,"PHASE2":42025,"PHASE3":42046,"PHASE4":42048,"NA":42050},{"trials":42022,"activeCount":97},[],{"trials":42024,"activeCount":97},[],{"trials":42026,"activeCount":97},[42027,42033,42039],{"nctId":42028,"briefTitle":42029,"status":155,"phases":42030,"start":4756,"enrollment":7826,"conditions":42031,"interventions":42032},"NCT00447486","A Study of GW842166 in Adults With Osteoarthritis Pain",[86],[9210],[42019],{"nctId":42034,"briefTitle":42035,"status":155,"phases":42036,"start":2404,"enrollment":22557,"conditions":42037,"interventions":42038},"NCT00444769","Dental Pain 3rd Molar Tooth Extraction GW842166",[86],[9153],[42019],{"nctId":42040,"briefTitle":42041,"status":155,"phases":42042,"primaryCompletion":25306,"completion":25306,"start":42043,"enrollment":417,"conditions":42044,"interventions":42045},"NCT00479427","A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthritis",[86],"2007-07-06",[10386],[42019],{"trials":42047,"activeCount":97},[],{"trials":42049,"activeCount":97},[],{"trials":42051,"activeCount":97},[],{"intervention":42053,"totalTrials":593,"cells":42054},"Foretinib",{"EARLY_PHASE1":42055,"PHASE1":42057,"PHASE2":42067,"PHASE3":42083,"PHASE4":42085,"NA":42087},{"trials":42056,"activeCount":97},[],{"trials":42058,"activeCount":97},[42059],{"nctId":42060,"briefTitle":42061,"status":155,"phases":42062,"primaryCompletion":42063,"completion":12652,"start":3378,"enrollment":6369,"conditions":42064,"interventions":42066},"NCT00920192","Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer",[85],"2012-03-07",[42065],"Carcinoma, Hepatocellular",[42053],{"trials":42068,"activeCount":97},[42069,42075],{"nctId":42070,"briefTitle":42071,"status":500,"phases":42072,"primaryCompletion":9507,"completion":2392,"start":9507,"enrollment":97,"conditions":42073,"interventions":42074},"NCT02034097","A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer",[86],[36],[42053,3062],{"nctId":42076,"briefTitle":42077,"status":155,"phases":42078,"primaryCompletion":19192,"completion":19192,"start":42079,"enrollment":4158,"conditions":42080,"interventions":42081},"NCT00726323","A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)",[86],"2006-06-30",[1877],[42082],"foretinib",{"trials":42084,"activeCount":97},[],{"trials":42086,"activeCount":97},[],{"trials":42088,"activeCount":97},[],{"intervention":3062,"totalTrials":593,"cells":42090},{"EARLY_PHASE1":42091,"PHASE1":42093,"PHASE2":42103,"PHASE3":42109,"PHASE4":42111,"NA":42113},{"trials":42092,"activeCount":97},[],{"trials":42094,"activeCount":97},[42095,42099],{"nctId":39537,"briefTitle":39538,"status":155,"phases":42096,"primaryCompletion":39540,"completion":39540,"start":19254,"enrollment":7712,"conditions":42097,"interventions":42098},[85],[267],[2263,39543,2287],{"nctId":3055,"briefTitle":3056,"status":155,"phases":42100,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":803,"conditions":42101,"interventions":42102},[85],[36],[3048,164,3062,165,135,3063,134],{"trials":42104,"activeCount":97},[42105],{"nctId":42070,"briefTitle":42071,"status":500,"phases":42106,"primaryCompletion":9507,"completion":2392,"start":9507,"enrollment":97,"conditions":42107,"interventions":42108},[86],[36],[42053,3062],{"trials":42110,"activeCount":97},[],{"trials":42112,"activeCount":97},[],{"trials":42114,"activeCount":97},[],{"intervention":8520,"totalTrials":593,"cells":42116},{"EARLY_PHASE1":42117,"PHASE1":42119,"PHASE2":42121,"PHASE3":42141,"PHASE4":42143,"NA":42145},{"trials":42118,"activeCount":97},[],{"trials":42120,"activeCount":97},[],{"trials":42122,"activeCount":97},[42123,42127,42134],{"nctId":8513,"briefTitle":8514,"status":500,"phases":42124,"primaryCompletion":8516,"completion":8516,"start":8517,"enrollment":97,"conditions":42125,"interventions":42126},[86],[18],[8520,8521,8522],{"nctId":42128,"briefTitle":42129,"status":155,"phases":42130,"primaryCompletion":493,"completion":493,"start":3389,"enrollment":1634,"conditions":42131,"interventions":42133},"NCT01607372","A Study to Investigate the Safety and Pharmacodynamics of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies",[86],[42132],"Asthma and Rhinitis",[8520],{"nctId":42135,"briefTitle":42136,"status":155,"phases":42137,"primaryCompletion":8860,"completion":8860,"start":503,"enrollment":656,"conditions":42138,"interventions":42140},"NCT01788813","To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies",[86],[42139],"Mild Asthma and Allergic Rhinitis",[8520],{"trials":42142,"activeCount":97},[],{"trials":42144,"activeCount":97},[],{"trials":42146,"activeCount":97},[],{"intervention":42148,"totalTrials":593,"cells":42149},"GW273225",{"EARLY_PHASE1":42150,"PHASE1":42152,"PHASE2":42168,"PHASE3":42176,"PHASE4":42178,"NA":42180},{"trials":42151,"activeCount":97},[],{"trials":42153,"activeCount":97},[42154,42162],{"nctId":42155,"briefTitle":42156,"status":155,"phases":42157,"primaryCompletion":42158,"completion":42158,"start":42159,"enrollment":473,"conditions":42160,"interventions":42161},"NCT00501865","Study to Assess the Effect of Food on the Concentration of GW273225 in the Body of Healthy Male and Female Volunteers",[85],"2007-10-11","2007-08-06",[22321],[42148],{"nctId":42163,"briefTitle":42164,"status":145,"phases":42165,"primaryCompletion":39094,"completion":39094,"start":10014,"enrollment":1459,"conditions":42166,"interventions":42167},"NCT00483535","Oral Contraceptive Interaction Study for GW273225",[85],[22321],[42148,39215],{"trials":42169,"activeCount":97},[42170],{"nctId":42171,"briefTitle":42172,"status":500,"phases":42173,"primaryCompletion":2382,"completion":2382,"start":8963,"enrollment":97,"conditions":42174,"interventions":42175},"NCT00567424","GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures",[86],[12518],[42148],{"trials":42177,"activeCount":97},[],{"trials":42179,"activeCount":97},[],{"trials":42181,"activeCount":97},[],{"intervention":42183,"totalTrials":593,"cells":42184},"Radafaxine",{"EARLY_PHASE1":42185,"PHASE1":42187,"PHASE2":42189,"PHASE3":42210,"PHASE4":42212,"NA":42214},{"trials":42186,"activeCount":97},[],{"trials":42188,"activeCount":97},[],{"trials":42190,"activeCount":97},[42191,42197,42203],{"nctId":42192,"briefTitle":42193,"status":155,"phases":42194,"primaryCompletion":2775,"completion":2775,"start":21220,"enrollment":10407,"conditions":42195,"interventions":42196},"NCT00057226","An 8 Week Study Of Adults Diagnosed With Major Depressive Disorder",[86],[10889],[42183],{"nctId":42198,"briefTitle":42199,"status":155,"phases":42200,"primaryCompletion":4756,"completion":4756,"start":21220,"enrollment":4651,"conditions":42201,"interventions":42202},"NCT00057213","An 8 Week Study Of Depression In Adults Diagnosed With Major Depressive Disorder",[86],[10889],[42183],{"nctId":42204,"briefTitle":42205,"status":155,"phases":42206,"primaryCompletion":10670,"completion":10670,"start":21220,"enrollment":42207,"conditions":42208,"interventions":42209},"NCT00057239","An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder",[86],546,[10890],[42183],{"trials":42211,"activeCount":97},[],{"trials":42213,"activeCount":97},[],{"trials":42215,"activeCount":97},[],{"intervention":42217,"totalTrials":593,"cells":42218},"RTS,S\u002FAS01E",{"EARLY_PHASE1":42219,"PHASE1":42221,"PHASE2":42223,"PHASE3":42253,"PHASE4":42255,"NA":42257},{"trials":42220,"activeCount":97},[],{"trials":42222,"activeCount":97},[],{"trials":42224,"activeCount":97},[42225,42233,42242],{"nctId":42226,"briefTitle":42227,"status":155,"phases":42228,"primaryCompletion":42229,"completion":41324,"start":42230,"enrollment":4542,"conditions":42231,"interventions":42232},"NCT03824236","A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults",[86],"2019-04-30","2019-02-05",[3287],[42217],{"nctId":42234,"briefTitle":42235,"status":155,"phases":42236,"primaryCompletion":5077,"completion":42237,"start":42238,"enrollment":224,"conditions":42239,"interventions":42240},"NCT03162614","Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults",[86],"2018-09-24","2017-05-24",[3287],[42217,42241],"RTS,S\u002FAS01B",{"nctId":42243,"briefTitle":42244,"status":155,"phases":42245,"primaryCompletion":42246,"completion":42247,"start":42248,"enrollment":42249,"conditions":42250,"interventions":42251},"NCT03276962","Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age",[86],"2019-11-04","2022-11-14","2017-09-28",1500,[3287],[42217,42217,42252],"Rabies vaccine",{"trials":42254,"activeCount":97},[],{"trials":42256,"activeCount":97},[],{"trials":42258,"activeCount":97},[],{"intervention":19312,"totalTrials":593,"cells":42260},{"EARLY_PHASE1":42261,"PHASE1":42263,"PHASE2":42273,"PHASE3":42284,"PHASE4":42286,"NA":42288},{"trials":42262,"activeCount":97},[],{"trials":42264,"activeCount":97},[42265,42269],{"nctId":19307,"briefTitle":19308,"status":155,"phases":42266,"primaryCompletion":9066,"completion":9066,"start":12260,"enrollment":7438,"conditions":42267,"interventions":42268},[85],[9343],[19312,10675],{"nctId":19332,"briefTitle":19333,"status":145,"phases":42270,"primaryCompletion":19335,"completion":19335,"start":17158,"enrollment":1298,"conditions":42271,"interventions":42272},[85],[9343],[19312,10675],{"trials":42274,"activeCount":97},[42275],{"nctId":42276,"briefTitle":42277,"status":155,"phases":42278,"primaryCompletion":42279,"completion":42279,"start":42280,"enrollment":2797,"conditions":42281,"interventions":42282},"NCT03045861","Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults",[86],"2018-04-23","2017-03-17",[9343,10943],[19312,42283],"Cobicistat",{"trials":42285,"activeCount":97},[],{"trials":42287,"activeCount":97},[],{"trials":42289,"activeCount":97},[],{"intervention":42291,"totalTrials":593,"cells":42292},"Solabegron",{"EARLY_PHASE1":42293,"PHASE1":42295,"PHASE2":42310,"PHASE3":42318,"PHASE4":42320,"NA":42322},{"trials":42294,"activeCount":97},[],{"trials":42296,"activeCount":97},[42297,42304],{"nctId":42298,"briefTitle":42299,"status":155,"phases":42300,"primaryCompletion":2336,"completion":2336,"start":5196,"enrollment":1634,"conditions":42301,"interventions":42303},"NCT00427596","A Two-Part Study to Determine: Best Medication Formulation and Food Effect",[85],[42302],"Overactive Bladder",[42291],{"nctId":42305,"briefTitle":42306,"status":155,"phases":42307,"start":2404,"enrollment":710,"conditions":42308,"interventions":42309},"NCT00401479","A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers",[85],[11511],[42291],{"trials":42311,"activeCount":97},[42312],{"nctId":42313,"briefTitle":42314,"status":155,"phases":42315,"start":2383,"enrollment":9196,"conditions":42316,"interventions":42317},"NCT00343486","Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms",[86],[42302],[42291],{"trials":42319,"activeCount":97},[],{"trials":42321,"activeCount":97},[],{"trials":42323,"activeCount":97},[],{"intervention":38885,"totalTrials":593,"cells":42325},{"EARLY_PHASE1":42326,"PHASE1":42328,"PHASE2":42334,"PHASE3":42346,"PHASE4":42348,"NA":42350},{"trials":42327,"activeCount":97},[],{"trials":42329,"activeCount":97},[42330],{"nctId":38878,"briefTitle":38879,"status":155,"phases":42331,"primaryCompletion":38881,"completion":38881,"start":38882,"enrollment":9334,"conditions":42332,"interventions":42333},[85],[27,9048],[38885,9030,38886,38887],{"trials":42335,"activeCount":97},[42336,42342],{"nctId":42337,"briefTitle":42338,"status":155,"phases":42339,"primaryCompletion":4757,"completion":4757,"start":1360,"enrollment":849,"conditions":42340,"interventions":42341},"NCT00297180","Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks",[86],[9048],[38885],{"nctId":38929,"briefTitle":38930,"status":155,"phases":42343,"primaryCompletion":2383,"completion":2383,"start":1360,"enrollment":6369,"conditions":42344,"interventions":42345},[86],[27,9079],[9038,38934],{"trials":42347,"activeCount":97},[],{"trials":42349,"activeCount":97},[],{"trials":42351,"activeCount":97},[],{"intervention":39688,"totalTrials":593,"cells":42353},{"EARLY_PHASE1":42354,"PHASE1":42356,"PHASE2":42366,"PHASE3":42372,"PHASE4":42374,"NA":42376},{"trials":42355,"activeCount":97},[],{"trials":42357,"activeCount":97},[42358,42362],{"nctId":39682,"briefTitle":39683,"status":155,"phases":42359,"primaryCompletion":8666,"completion":8666,"start":39685,"enrollment":463,"conditions":42360,"interventions":42361},[85],[1239],[39688,39667],{"nctId":39696,"briefTitle":39697,"status":145,"phases":42363,"primaryCompletion":39699,"completion":39699,"start":39700,"enrollment":660,"conditions":42364,"interventions":42365},[85],[1239],[39667,39688,39703],{"trials":42367,"activeCount":97},[42368],{"nctId":39714,"briefTitle":39715,"status":145,"phases":42369,"primaryCompletion":39717,"completion":39717,"start":14321,"enrollment":1318,"conditions":42370,"interventions":42371},[86],[1239],[39667,39688],{"trials":42373,"activeCount":97},[],{"trials":42375,"activeCount":97},[],{"trials":42377,"activeCount":97},[],{"intervention":42379,"totalTrials":593,"cells":42380},"GSK3915393",{"EARLY_PHASE1":42381,"PHASE1":42383,"PHASE2":42406,"PHASE3":42415,"PHASE4":42417,"NA":42419},{"trials":42382,"activeCount":97},[],{"trials":42384,"activeCount":97},[42385,42396],{"nctId":42386,"briefTitle":42387,"status":155,"phases":42388,"primaryCompletion":42389,"completion":42389,"start":42390,"enrollment":1003,"conditions":42391,"interventions":42393},"NCT06625489","A Study to Evaluate the Safety, Tolerability and Blood Levels of GSK3915393 Administered to Healthy Participants of Chinese, Japanese and European Ancestry and to Assess Effects of GSK3915393 on Nintedanib",[85],"2024-11-25","2024-10-07",[42392],"Idiopathic Pulmonary Fibrosis",[42394,42395,42379],"Part A: Placebo","Nintedanib",{"nctId":42397,"briefTitle":42398,"status":155,"phases":42399,"primaryCompletion":960,"completion":960,"start":42400,"enrollment":2282,"conditions":42401,"interventions":42404},"NCT04604795","Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK3915393 in Healthy Participants and to Evaluate the Interaction Between GSK3915393 and Grapefruit Juice and Itraconazole",[85],"2020-11-04",[42402,42403],"Celiac Disease","Coeliac Disease",[42379,42405,39369],"GSK3915393 Solution for",{"trials":42407,"activeCount":97},[42408],{"nctId":42409,"briefTitle":42410,"status":145,"phases":42411,"primaryCompletion":42412,"completion":42412,"start":72,"enrollment":7532,"conditions":42413,"interventions":42414},"NCT06317285","A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)",[86],"2025-10-01",[42392],[42379],{"trials":42416,"activeCount":97},[],{"trials":42418,"activeCount":97},[],{"trials":42420,"activeCount":97},[],{"intervention":42422,"totalTrials":593,"cells":42423},"Warfarin",{"EARLY_PHASE1":42424,"PHASE1":42426,"PHASE2":42440,"PHASE3":42453,"PHASE4":42455,"NA":42457},{"trials":42425,"activeCount":97},[],{"trials":42427,"activeCount":97},[42428,42432],{"nctId":22849,"briefTitle":22850,"status":155,"phases":42429,"primaryCompletion":22852,"completion":22852,"start":2373,"enrollment":105,"conditions":42430,"interventions":42431},[85],[1337],[20350,22855],{"nctId":42433,"briefTitle":42434,"status":155,"phases":42435,"primaryCompletion":39677,"completion":39677,"start":11960,"enrollment":6503,"conditions":42436,"interventions":42437},"NCT01340846","A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors",[85],[36],[42422,9325,18007,42438,42439],"GSK2118436 150mg","GSK2118436 75mg",{"trials":42441,"activeCount":97},[42442],{"nctId":42443,"briefTitle":42444,"status":155,"phases":42445,"primaryCompletion":4757,"completion":4757,"start":8427,"enrollment":42446,"conditions":42447,"interventions":42450},"NCT00244725","Odiparcil For The Prevention Of Venous Thromboembolism",[86],961,[42448,28372,36580,42449],"Deep Vein Thrombosis","Pulmonary Embolism",[42451,42422,42452],"Odiparcil","Coumadin",{"trials":42454,"activeCount":97},[],{"trials":42456,"activeCount":97},[],{"trials":42458,"activeCount":97},[],{"intervention":42460,"totalTrials":593,"cells":42461},"GSK2881078",{"EARLY_PHASE1":42462,"PHASE1":42464,"PHASE2":42480,"PHASE3":42490,"PHASE4":42492,"NA":42494},{"trials":42463,"activeCount":97},[],{"trials":42465,"activeCount":97},[42466,42474],{"nctId":42467,"briefTitle":42468,"status":155,"phases":42469,"primaryCompletion":13959,"completion":13959,"start":42470,"enrollment":7769,"conditions":42471,"interventions":42473},"NCT02045940","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses",[85],"2014-01-20",[42472],"Cachexia",[42460],{"nctId":42475,"briefTitle":42476,"status":155,"phases":42477,"primaryCompletion":2392,"completion":2392,"start":11769,"enrollment":6994,"conditions":42478,"interventions":42479},"NCT02567773","Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078",[85],[42472],[42460,39369],{"trials":42481,"activeCount":97},[42482],{"nctId":42483,"briefTitle":42484,"status":155,"phases":42485,"primaryCompletion":42486,"completion":42486,"start":42487,"enrollment":105,"conditions":42488,"interventions":42489},"NCT03359473","Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)",[86],"2019-11-19","2018-02-28",[42472],[42460],{"trials":42491,"activeCount":97},[],{"trials":42493,"activeCount":97},[],{"trials":42495,"activeCount":97},[],{"intervention":19734,"totalTrials":593,"cells":42497},{"EARLY_PHASE1":42498,"PHASE1":42500,"PHASE2":42506,"PHASE3":42516,"PHASE4":42518,"NA":42520},{"trials":42499,"activeCount":97},[],{"trials":42501,"activeCount":97},[42502],{"nctId":19727,"briefTitle":19728,"status":155,"phases":42503,"primaryCompletion":19730,"completion":19730,"start":19731,"enrollment":695,"conditions":42504,"interventions":42505},[85],[27],[19693,9324,19734],{"trials":42507,"activeCount":97},[42508,42512],{"nctId":20533,"briefTitle":20534,"status":155,"phases":42509,"primaryCompletion":20536,"completion":20536,"start":20537,"enrollment":414,"conditions":42510,"interventions":42511},[86],[27],[19734,9061],{"nctId":20541,"briefTitle":20542,"status":155,"phases":42513,"primaryCompletion":20544,"completion":20544,"start":20545,"enrollment":2321,"conditions":42514,"interventions":42515},[86],[27],[19734,9061],{"trials":42517,"activeCount":97},[],{"trials":42519,"activeCount":97},[],{"trials":42521,"activeCount":97},[],{"intervention":42523,"totalTrials":593,"cells":42524},"GSK256073",{"EARLY_PHASE1":42525,"PHASE1":42527,"PHASE2":42543,"PHASE3":42554,"PHASE4":42556,"NA":42558},{"trials":42526,"activeCount":97},[],{"trials":42528,"activeCount":97},[42529,42536],{"nctId":42530,"briefTitle":42531,"status":155,"phases":42532,"primaryCompletion":39093,"completion":39093,"start":42533,"enrollment":255,"conditions":42534,"interventions":42535},"NCT00808093","Repeat Dose Food Effect Study of GSK256073F in Healthy Adult Subjects",[85],"2008-05-12",[27251],[42523],{"nctId":42537,"briefTitle":42538,"status":155,"phases":42539,"primaryCompletion":42540,"completion":42540,"start":9452,"enrollment":12202,"conditions":42541,"interventions":42542},"NCT01147861","A Phase 1 Study to Evaluate the Effect of GSK256073, an HM74A Receptor Agonist, on Glucose and NEFA Levels in Type 2 Diabetics",[85],"2010-09-07",[27],[42523,42523,42523,42523],{"trials":42544,"activeCount":97},[42545],{"nctId":42546,"briefTitle":42547,"status":155,"phases":42548,"primaryCompletion":42549,"completion":42549,"start":42550,"enrollment":526,"conditions":42551,"interventions":42552},"NCT00903617","Study to Test GSK256073 in Patients With Dyslipidemia",[86],"2010-02-16","2009-06-15",[27251,27252],[42523,42523,42523,42553,42523,42523],"Niaspan",{"trials":42555,"activeCount":97},[],{"trials":42557,"activeCount":97},[],{"trials":42559,"activeCount":97},[],{"intervention":42561,"totalTrials":593,"cells":42562},"pazopanib eye drops",{"EARLY_PHASE1":42563,"PHASE1":42565,"PHASE2":42575,"PHASE3":42591,"PHASE4":42593,"NA":42595},{"trials":42564,"activeCount":97},[],{"trials":42566,"activeCount":97},[42567],{"nctId":42568,"briefTitle":42569,"status":155,"phases":42570,"primaryCompletion":19267,"completion":19267,"start":42571,"enrollment":1298,"conditions":42572,"interventions":42573},"NCT00659555","Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops",[85],"2008-04-04",[39848],[42561,42574],"Ketoconozole",{"trials":42576,"activeCount":97},[42577,42583],{"nctId":42578,"briefTitle":42579,"status":145,"phases":42580,"primaryCompletion":19225,"completion":19225,"start":9812,"enrollment":421,"conditions":42581,"interventions":42582},"NCT01362348","12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)",[86],[39848],[42561],{"nctId":42584,"briefTitle":42585,"status":155,"phases":42586,"primaryCompletion":4677,"completion":4677,"start":23418,"enrollment":42587,"conditions":42588,"interventions":42589},"NCT01134055","Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration",[86],510,[39848],[42561,42590],"ranibizumab intravitreal",{"trials":42592,"activeCount":97},[],{"trials":42594,"activeCount":97},[],{"trials":42596,"activeCount":97},[],{"intervention":40584,"totalTrials":593,"cells":42598},{"EARLY_PHASE1":42599,"PHASE1":42601,"PHASE2":42607,"PHASE3":42617,"PHASE4":42619,"NA":42621},{"trials":42600,"activeCount":97},[],{"trials":42602,"activeCount":97},[42603],{"nctId":40578,"briefTitle":40579,"status":155,"phases":42604,"primaryCompletion":19713,"completion":19713,"start":40581,"enrollment":454,"conditions":42605,"interventions":42606},[85],[15],[40584,40571],{"trials":42608,"activeCount":97},[42609,42613],{"nctId":40588,"briefTitle":40589,"status":155,"phases":42610,"primaryCompletion":5196,"completion":5196,"start":2296,"enrollment":473,"conditions":42611,"interventions":42612},[86],[15],[40571,40584],{"nctId":40594,"briefTitle":40595,"status":155,"phases":42614,"primaryCompletion":3079,"completion":3079,"start":2336,"enrollment":454,"conditions":42615,"interventions":42616},[86],[15],[40571,40584],{"trials":42618,"activeCount":97},[],{"trials":42620,"activeCount":97},[],{"trials":42622,"activeCount":97},[],{"intervention":42624,"totalTrials":593,"cells":42625},"GSK2190915",{"EARLY_PHASE1":42626,"PHASE1":42628,"PHASE2":42636,"PHASE3":42651,"PHASE4":42653,"NA":42655},{"trials":42627,"activeCount":97},[],{"trials":42629,"activeCount":97},[42630],{"nctId":42631,"briefTitle":42632,"status":155,"phases":42633,"primaryCompletion":6317,"completion":6317,"start":2664,"enrollment":1459,"conditions":42634,"interventions":42635},"NCT00955383","GSK2190915 Safety and Pharmacokinetic Study in Healthy Japanese Subjects",[85],[18],[42624],{"trials":42637,"activeCount":97},[42638,42645],{"nctId":42639,"briefTitle":42640,"status":155,"phases":42641,"primaryCompletion":16322,"completion":42642,"start":18501,"enrollment":149,"conditions":42643,"interventions":42644},"NCT00812929","A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise",[86],"2009-07-15",[18],[42624],{"nctId":42646,"briefTitle":42647,"status":155,"phases":42648,"primaryCompletion":2441,"completion":2441,"start":8468,"enrollment":7438,"conditions":42649,"interventions":42650},"NCT00812773","Study to Evaluate GSK2190915 in Subjects With Mild Asthma",[86],[18],[42624],{"trials":42652,"activeCount":97},[],{"trials":42654,"activeCount":97},[],{"trials":42656,"activeCount":97},[],{"intervention":42658,"totalTrials":593,"cells":42659},"SB497115",{"EARLY_PHASE1":42660,"PHASE1":42662,"PHASE2":42664,"PHASE3":42687,"PHASE4":42689,"NA":42691},{"trials":42661,"activeCount":97},[],{"trials":42663,"activeCount":97},[],{"trials":42665,"activeCount":97},[42666,42673,42679],{"nctId":42667,"briefTitle":42668,"status":155,"phases":42669,"primaryCompletion":8406,"completion":8406,"start":1380,"enrollment":42670,"conditions":42671,"interventions":42672},"NCT00102726","SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy",[86],183,[11033],[42658],{"nctId":42674,"briefTitle":42675,"status":155,"phases":42676,"primaryCompletion":5196,"completion":5196,"start":1380,"enrollment":7769,"conditions":42677,"interventions":42678},"NCT00102739","SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)",[86],[505],[42658],{"nctId":42680,"briefTitle":42681,"status":155,"phases":42682,"primaryCompletion":2404,"completion":4843,"start":7785,"enrollment":2825,"conditions":42683,"interventions":42686},"NCT00110799","SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C",[86],[42684,23770,42685],"Hepatitis C, Chronic","Thrombocytopenia",[42658],{"trials":42688,"activeCount":97},[],{"trials":42690,"activeCount":97},[],{"trials":42692,"activeCount":97},[],{"intervention":40867,"totalTrials":593,"cells":42694},{"EARLY_PHASE1":42695,"PHASE1":42697,"PHASE2":42708,"PHASE3":42718,"PHASE4":42720,"NA":42722},{"trials":42696,"activeCount":97},[],{"trials":42698,"activeCount":97},[42699],{"nctId":42700,"briefTitle":42701,"status":155,"phases":42702,"primaryCompletion":42703,"completion":42703,"start":19184,"enrollment":6503,"conditions":42704,"interventions":42705},"NCT01485185","Gabapentin and Donepezil Combination on Experimental Human Pain Models",[85],"2012-07-03",[38980],[42706,40867,42707],"Gabapentin lower dose","Gabapentin higher dose",{"trials":42709,"activeCount":97},[42710,42714],{"nctId":40860,"briefTitle":40861,"status":155,"phases":42711,"primaryCompletion":11275,"completion":40863,"start":40864,"enrollment":4679,"conditions":42712,"interventions":42713},[86],[4644],[40839,40867],{"nctId":40869,"briefTitle":40870,"status":155,"phases":42715,"start":2383,"enrollment":1196,"conditions":42716,"interventions":42717},[86],[4644],[40839,40874],{"trials":42719,"activeCount":97},[],{"trials":42721,"activeCount":97},[],{"trials":42723,"activeCount":97},[],{"intervention":42725,"totalTrials":593,"cells":42726},"GSK1521498",{"EARLY_PHASE1":42727,"PHASE1":42729,"PHASE2":42749,"PHASE3":42757,"PHASE4":42759,"NA":42761},{"trials":42728,"activeCount":97},[],{"trials":42730,"activeCount":97},[42731,42741],{"nctId":42732,"briefTitle":42733,"status":155,"phases":42734,"primaryCompletion":42735,"completion":42735,"start":42736,"enrollment":904,"conditions":42737,"interventions":42739},"NCT01738867","To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers",[85],"2014-05-27","2012-12-12",[42738],"Alcoholism",[42725,42740],"Naltrexone",{"nctId":42742,"briefTitle":42743,"status":155,"phases":42744,"primaryCompletion":42745,"completion":42745,"start":42746,"enrollment":417,"conditions":42747,"interventions":42748},"NCT01366573","GSK1521498 Alcohol Interaction Study",[85],"2011-09-16","2011-05-13",[42738],[42725],{"trials":42750,"activeCount":97},[42751],{"nctId":42752,"briefTitle":42753,"status":155,"phases":42754,"primaryCompletion":7590,"completion":7590,"start":3551,"enrollment":1237,"conditions":42755,"interventions":42756},"NCT01195792","A 35 Day Study to Investigate the Effects of GSK1521498 on Bodyweight in Obese Subjects With Over-Eating Behaviours.",[86],[9048],[42725],{"trials":42758,"activeCount":97},[],{"trials":42760,"activeCount":97},[],{"trials":42762,"activeCount":97},[],{"intervention":19030,"totalTrials":593,"cells":42764},{"EARLY_PHASE1":42765,"PHASE1":42767,"PHASE2":42773,"PHASE3":42787,"PHASE4":42789,"NA":42791},{"trials":42766,"activeCount":97},[],{"trials":42768,"activeCount":97},[42769],{"nctId":19025,"briefTitle":19026,"status":155,"phases":42770,"primaryCompletion":4844,"completion":4844,"start":2796,"enrollment":454,"conditions":42771,"interventions":42772},[85],[15],[19030,915],{"trials":42774,"activeCount":97},[42775,42781],{"nctId":42776,"briefTitle":42777,"status":155,"phases":42778,"start":10212,"enrollment":11953,"conditions":42779,"interventions":42780},"NCT00144859","Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease (COPD)",[86],[15,38952],[19030],{"nctId":42782,"briefTitle":42783,"status":155,"phases":42784,"primaryCompletion":40241,"completion":40241,"start":10977,"enrollment":1003,"conditions":42785,"interventions":42786},"NCT00390845","P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain",[86],[38980],[19030],{"trials":42788,"activeCount":97},[],{"trials":42790,"activeCount":97},[],{"trials":42792,"activeCount":97},[],{"intervention":42794,"totalTrials":593,"cells":42795},"Sanofi Pasteur's Typhoid Vi polysaccharide vaccine",{"EARLY_PHASE1":42796,"PHASE1":42798,"PHASE2":42827,"PHASE3":42843,"PHASE4":42845,"NA":42847},{"trials":42797,"activeCount":97},[],{"trials":42799,"activeCount":97},[42800,42814],{"nctId":42801,"briefTitle":42802,"status":155,"phases":42803,"primaryCompletion":3177,"completion":42804,"start":42805,"enrollment":105,"conditions":42806,"interventions":42808},"NCT05613205","Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults",[85],"2024-04-02","2022-11-28",[42807],"Typhoid Fever",[42809,42810,42811,42812,42794,42813],"TYP04A Low Dose without Alum investigational vaccine","TYP04B Full Dose without Alum investigational vaccine","TYP03A Low Dose with Alum investigational vaccine","TYP03B Full Dose with Alum investigational vaccine","GSK's Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine",{"nctId":42815,"briefTitle":42816,"status":155,"phases":42817,"primaryCompletion":42818,"completion":42818,"start":42819,"enrollment":4891,"conditions":42820,"interventions":42821},"NCT05073003","A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants",[85],"2025-06-24","2021-10-06",[4468],[42822,4497,4496,4495,42823,42824,42825,42794,42826],"altSonflex Placebo","GSK's Meningococcal A, C, Y and W-135 conjugate vaccine","GSK's Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine","GSK's Diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b vaccine","Serum Institute of India's Measles and rubella vaccine",{"trials":42828,"activeCount":97},[42829],{"nctId":42830,"briefTitle":42831,"status":155,"phases":42832,"primaryCompletion":443,"completion":42833,"start":11903,"enrollment":42834,"conditions":42835,"interventions":42836},"NCT05480800","A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever",[85,86],"2025-01-07",155,[4481],[42837,42838,42839,42840,42841,42842,42823,42824,42794],"Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose","Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose","Typhoid conjugate vaccine (TCV) low dose","Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) full dose","Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) full dose","Typhoid conjugate vaccine (TCV) full dose",{"trials":42844,"activeCount":97},[],{"trials":42846,"activeCount":97},[],{"trials":42848,"activeCount":97},[],{"intervention":11350,"totalTrials":593,"cells":42850},{"EARLY_PHASE1":42851,"PHASE1":42853,"PHASE2":42867,"PHASE3":42873,"PHASE4":42875,"NA":42877},{"trials":42852,"activeCount":97},[],{"trials":42854,"activeCount":97},[42855,42863],{"nctId":42856,"briefTitle":42857,"status":155,"phases":42858,"primaryCompletion":42859,"completion":42859,"start":19038,"enrollment":3647,"conditions":42860,"interventions":42861},"NCT00269035","SPECT Study With SB-773812 In Schizophrenic Patients",[85],"2007-05-26",[11346],[42862,11350],"SB773812",{"nctId":11342,"briefTitle":11343,"status":145,"phases":42864,"primaryCompletion":10212,"completion":10212,"start":10212,"enrollment":10794,"conditions":42865,"interventions":42866},[85],[11346],[11348,11349,11350],{"trials":42868,"activeCount":97},[42869],{"nctId":40783,"briefTitle":40784,"status":155,"phases":42870,"primaryCompletion":10056,"completion":10056,"start":13061,"enrollment":40786,"conditions":42871,"interventions":42872},[86],[11346],[40781,40789],{"trials":42874,"activeCount":97},[],{"trials":42876,"activeCount":97},[],{"trials":42878,"activeCount":97},[],{"intervention":18676,"totalTrials":660,"cells":42880},{"EARLY_PHASE1":42881,"PHASE1":42883,"PHASE2":42889,"PHASE3":42897,"PHASE4":42899,"NA":42901},{"trials":42882,"activeCount":97},[],{"trials":42884,"activeCount":97},[42885],{"nctId":18667,"briefTitle":18668,"status":155,"phases":42886,"primaryCompletion":18670,"completion":18670,"start":18671,"enrollment":6503,"conditions":42887,"interventions":42888},[85],[15],[18674,18675,3467,3467,18676],{"trials":42890,"activeCount":97},[42891],{"nctId":42892,"briefTitle":42893,"status":155,"phases":42894,"primaryCompletion":2335,"completion":2335,"start":26336,"enrollment":3025,"conditions":42895,"interventions":42896},"NCT01128569","Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)\u002FVilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response",[86],[18],[8532,18676],{"trials":42898,"activeCount":97},[],{"trials":42900,"activeCount":97},[],{"trials":42902,"activeCount":97},[],{"intervention":22508,"totalTrials":660,"cells":42904},{"EARLY_PHASE1":42905,"PHASE1":42907,"PHASE2":42909,"PHASE3":42919,"PHASE4":42921,"NA":42923},{"trials":42906,"activeCount":97},[],{"trials":42908,"activeCount":97},[],{"trials":42910,"activeCount":97},[42911,42915],{"nctId":22501,"briefTitle":22502,"status":155,"phases":42912,"primaryCompletion":3228,"completion":3228,"start":22504,"enrollment":22505,"conditions":42913,"interventions":42914},[86],[992],[22508,22509,22510,5103,22511],{"nctId":22513,"briefTitle":22514,"status":155,"phases":42916,"primaryCompletion":6574,"completion":6574,"start":22516,"enrollment":22517,"conditions":42917,"interventions":42918},[85,86],[992],[22508,22509,5103,5102],{"trials":42920,"activeCount":97},[],{"trials":42922,"activeCount":97},[],{"trials":42924,"activeCount":97},[],{"intervention":22509,"totalTrials":660,"cells":42926},{"EARLY_PHASE1":42927,"PHASE1":42929,"PHASE2":42931,"PHASE3":42941,"PHASE4":42943,"NA":42945},{"trials":42928,"activeCount":97},[],{"trials":42930,"activeCount":97},[],{"trials":42932,"activeCount":97},[42933,42937],{"nctId":22501,"briefTitle":22502,"status":155,"phases":42934,"primaryCompletion":3228,"completion":3228,"start":22504,"enrollment":22505,"conditions":42935,"interventions":42936},[86],[992],[22508,22509,22510,5103,22511],{"nctId":22513,"briefTitle":22514,"status":155,"phases":42938,"primaryCompletion":6574,"completion":6574,"start":22516,"enrollment":22517,"conditions":42939,"interventions":42940},[85,86],[992],[22508,22509,5103,5102],{"trials":42942,"activeCount":97},[],{"trials":42944,"activeCount":97},[],{"trials":42946,"activeCount":97},[],{"intervention":42948,"totalTrials":660,"cells":42949},"GSK962040 50 mg",{"EARLY_PHASE1":42950,"PHASE1":42952,"PHASE2":42954,"PHASE3":42973,"PHASE4":42975,"NA":42977},{"trials":42951,"activeCount":97},[],{"trials":42953,"activeCount":97},[],{"trials":42955,"activeCount":97},[42956,42965],{"nctId":42957,"briefTitle":42958,"status":145,"phases":42959,"primaryCompletion":42960,"completion":42960,"start":42961,"enrollment":37572,"conditions":42962,"interventions":42963},"NCT01934192","Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study",[86],"2016-07-08","2014-04-04",[39624],[42948,42964],"Metoclopramide 10 mg",{"nctId":42966,"briefTitle":42967,"status":155,"phases":42968,"primaryCompletion":10463,"completion":10463,"start":2442,"enrollment":361,"conditions":42969,"interventions":42970},"NCT00861809","The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis",[86],[39624],[42971,42948,42972],"GSK962040 25 mg","GSK962040 1250 mg",{"trials":42974,"activeCount":97},[],{"trials":42976,"activeCount":97},[],{"trials":42978,"activeCount":97},[],{"intervention":42980,"totalTrials":660,"cells":42981},"GSK189254",{"EARLY_PHASE1":42982,"PHASE1":42984,"PHASE2":42996,"PHASE3":43006,"PHASE4":43008,"NA":43010},{"trials":42983,"activeCount":97},[],{"trials":42985,"activeCount":97},[42986],{"nctId":42987,"briefTitle":42988,"status":155,"phases":42989,"primaryCompletion":42990,"completion":42990,"start":8199,"enrollment":345,"conditions":42991,"interventions":42992},"NCT00387413","A Study Of GSK189254 And Duloxetine In The Electrical Hyperalgesia Model Of Healthy Volunteers",[85],"2007-05-31",[20928],[42993,42980,42994,42995],"Duloxetine","GSK189254 Placebo","Duloxetine Placebo",{"trials":42997,"activeCount":97},[42998],{"nctId":42999,"briefTitle":43000,"status":145,"phases":43001,"primaryCompletion":7954,"completion":7954,"start":4843,"enrollment":43002,"conditions":43003,"interventions":43005},"NCT00366080","Effectiveness Of The Drug GSK189254 In Treating Patients With Narcolepsy",[86],69,[43004],"Narcolepsy",[42980],{"trials":43007,"activeCount":97},[],{"trials":43009,"activeCount":97},[],{"trials":43011,"activeCount":97},[],{"intervention":42451,"totalTrials":660,"cells":43013},{"EARLY_PHASE1":43014,"PHASE1":43016,"PHASE2":43025,"PHASE3":43031,"PHASE4":43033,"NA":43035},{"trials":43015,"activeCount":97},[],{"trials":43017,"activeCount":97},[43018],{"nctId":43019,"briefTitle":43020,"status":145,"phases":43021,"start":2404,"enrollment":1686,"conditions":43022,"interventions":43024},"NCT00437242","Odiparcil QT Definitive Study",[85],[28372,43023],"Atrial Fibrillation",[42451],{"trials":43026,"activeCount":97},[43027],{"nctId":42443,"briefTitle":42444,"status":155,"phases":43028,"primaryCompletion":4757,"completion":4757,"start":8427,"enrollment":42446,"conditions":43029,"interventions":43030},[86],[42448,28372,36580,42449],[42451,42422,42452],{"trials":43032,"activeCount":97},[],{"trials":43034,"activeCount":97},[],{"trials":43036,"activeCount":97},[],{"intervention":8193,"totalTrials":660,"cells":43038},{"EARLY_PHASE1":43039,"PHASE1":43041,"PHASE2":43043,"PHASE3":43056,"PHASE4":43058,"NA":43060},{"trials":43040,"activeCount":97},[],{"trials":43042,"activeCount":97},[],{"trials":43044,"activeCount":97},[43045,43049],{"nctId":8186,"briefTitle":8187,"status":155,"phases":43046,"primaryCompletion":8189,"completion":8189,"start":8190,"enrollment":7554,"conditions":43047,"interventions":43048},[86],[21],[8193,8177],{"nctId":43050,"briefTitle":43051,"status":155,"phases":43052,"primaryCompletion":20425,"completion":20425,"start":8198,"enrollment":9392,"conditions":43053,"interventions":43054},"NCT00397215","Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age",[86],[21],[43055,25702],"Pandemic influenza vaccine",{"trials":43057,"activeCount":97},[],{"trials":43059,"activeCount":97},[],{"trials":43061,"activeCount":97},[],{"intervention":43063,"totalTrials":660,"cells":43064},"SERETIDE Rotacaps",{"EARLY_PHASE1":43065,"PHASE1":43067,"PHASE2":43076,"PHASE3":43085,"PHASE4":43087,"NA":43089},{"trials":43066,"activeCount":97},[],{"trials":43068,"activeCount":97},[43069],{"nctId":43070,"briefTitle":43071,"status":155,"phases":43072,"primaryCompletion":4986,"completion":4986,"start":21411,"enrollment":710,"conditions":43073,"interventions":43074},"NCT01540708","A Single Centre Study in Healthy Volunteers to Optimise the Rotacap Formulation and ROTAHALER Device for Delivery of Fluticasone Propionate\u002FSalmeterol",[85],[18],[43063,43075],"SERETIDE Diskus",{"trials":43077,"activeCount":97},[43078],{"nctId":43079,"briefTitle":43080,"status":155,"phases":43081,"primaryCompletion":19647,"completion":19647,"start":43082,"enrollment":1237,"conditions":43083,"interventions":43084},"NCT01494610","Pharmacokinetic and Pharmacodynamic (PK and PD) Study of Fluticasone Propionate and Salmeterol Combination Product Delivered in a Capsule-based Inhaler and in a Multi-dose Dry Powder Inhaler in Moderate Asthma Patients and Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients.",[85,86],"2010-10-25",[18],[43063,43075],{"trials":43086,"activeCount":97},[],{"trials":43088,"activeCount":97},[],{"trials":43090,"activeCount":97},[],{"intervention":43075,"totalTrials":660,"cells":43092},{"EARLY_PHASE1":43093,"PHASE1":43095,"PHASE2":43101,"PHASE3":43107,"PHASE4":43109,"NA":43111},{"trials":43094,"activeCount":97},[],{"trials":43096,"activeCount":97},[43097],{"nctId":43070,"briefTitle":43071,"status":155,"phases":43098,"primaryCompletion":4986,"completion":4986,"start":21411,"enrollment":710,"conditions":43099,"interventions":43100},[85],[18],[43063,43075],{"trials":43102,"activeCount":97},[43103],{"nctId":43079,"briefTitle":43080,"status":155,"phases":43104,"primaryCompletion":19647,"completion":19647,"start":43082,"enrollment":1237,"conditions":43105,"interventions":43106},[85,86],[18],[43063,43075],{"trials":43108,"activeCount":97},[],{"trials":43110,"activeCount":97},[],{"trials":43112,"activeCount":97},[],{"intervention":43114,"totalTrials":660,"cells":43115},"RSV vaccine GSK3003895A",{"EARLY_PHASE1":43116,"PHASE1":43118,"PHASE2":43132,"PHASE3":43140,"PHASE4":43142,"NA":43144},{"trials":43117,"activeCount":97},[],{"trials":43119,"activeCount":97},[43120],{"nctId":43121,"briefTitle":43122,"status":155,"phases":43123,"primaryCompletion":43124,"completion":22933,"start":24581,"enrollment":4940,"conditions":43125,"interventions":43126},"NCT01905215","Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines",[85],"2014-04-09",[40533],[43127,43128,43114,43129,43130,43131],"RSV vaccine GSK3003892A","RSV vaccine GSK3003893A","RSV vaccine GSK3003896A","RSV vaccine GSK3003898A","RSV vaccine GSK3003899A",{"trials":43133,"activeCount":97},[43134],{"nctId":43135,"briefTitle":43136,"status":155,"phases":43137,"primaryCompletion":21663,"completion":8574,"start":13095,"enrollment":8090,"conditions":43138,"interventions":43139},"NCT02360475","Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women",[86],[2620],[43114,43130,43131,5329],{"trials":43141,"activeCount":97},[],{"trials":43143,"activeCount":97},[],{"trials":43145,"activeCount":97},[],{"intervention":43130,"totalTrials":660,"cells":43147},{"EARLY_PHASE1":43148,"PHASE1":43150,"PHASE2":43156,"PHASE3":43162,"PHASE4":43164,"NA":43166},{"trials":43149,"activeCount":97},[],{"trials":43151,"activeCount":97},[43152],{"nctId":43121,"briefTitle":43122,"status":155,"phases":43153,"primaryCompletion":43124,"completion":22933,"start":24581,"enrollment":4940,"conditions":43154,"interventions":43155},[85],[40533],[43127,43128,43114,43129,43130,43131],{"trials":43157,"activeCount":97},[43158],{"nctId":43135,"briefTitle":43136,"status":155,"phases":43159,"primaryCompletion":21663,"completion":8574,"start":13095,"enrollment":8090,"conditions":43160,"interventions":43161},[86],[2620],[43114,43130,43131,5329],{"trials":43163,"activeCount":97},[],{"trials":43165,"activeCount":97},[],{"trials":43167,"activeCount":97},[],{"intervention":43131,"totalTrials":660,"cells":43169},{"EARLY_PHASE1":43170,"PHASE1":43172,"PHASE2":43178,"PHASE3":43184,"PHASE4":43186,"NA":43188},{"trials":43171,"activeCount":97},[],{"trials":43173,"activeCount":97},[43174],{"nctId":43121,"briefTitle":43122,"status":155,"phases":43175,"primaryCompletion":43124,"completion":22933,"start":24581,"enrollment":4940,"conditions":43176,"interventions":43177},[85],[40533],[43127,43128,43114,43129,43130,43131],{"trials":43179,"activeCount":97},[43180],{"nctId":43135,"briefTitle":43136,"status":155,"phases":43181,"primaryCompletion":21663,"completion":8574,"start":13095,"enrollment":8090,"conditions":43182,"interventions":43183},[86],[2620],[43114,43130,43131,5329],{"trials":43185,"activeCount":97},[],{"trials":43187,"activeCount":97},[],{"trials":43189,"activeCount":97},[],{"intervention":43191,"totalTrials":660,"cells":43192},"Sodium monoflurophosphate",{"EARLY_PHASE1":43193,"PHASE1":43195,"PHASE2":43197,"PHASE3":43214,"PHASE4":43216,"NA":43218},{"trials":43194,"activeCount":97},[],{"trials":43196,"activeCount":97},[],{"trials":43198,"activeCount":97},[43199,43207],{"nctId":43200,"briefTitle":43201,"status":155,"phases":43202,"primaryCompletion":11992,"completion":11992,"start":9159,"enrollment":710,"conditions":43203,"interventions":43204},"NCT01128972","Evaluation of a Test Mouthwash and Dentifrice Regimen in an In-situ Model of Dental Erosion",[86],[32730],[43205,43191,43206],"Sodium fluoride","Sterile water",{"nctId":43208,"briefTitle":43209,"status":155,"phases":43210,"primaryCompletion":9697,"completion":9697,"start":11315,"enrollment":414,"conditions":43211,"interventions":43212},"NCT01657877","Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice",[86],[12022],[43213,43191],"Calcium sodium phosphosilicate",{"trials":43215,"activeCount":97},[],{"trials":43217,"activeCount":97},[],{"trials":43219,"activeCount":97},[],{"intervention":41718,"totalTrials":660,"cells":43221},{"EARLY_PHASE1":43222,"PHASE1":43224,"PHASE2":43226,"PHASE3":43236,"PHASE4":43238,"NA":43240},{"trials":43223,"activeCount":97},[],{"trials":43225,"activeCount":97},[],{"trials":43227,"activeCount":97},[43228,43232],{"nctId":41713,"briefTitle":41714,"status":155,"phases":43229,"primaryCompletion":7472,"completion":7472,"start":24337,"enrollment":1335,"conditions":43230,"interventions":43231},[86],[23246],[41697,41718,41719],{"nctId":41721,"briefTitle":41722,"status":155,"phases":43233,"primaryCompletion":3426,"completion":3426,"start":41724,"enrollment":28,"conditions":43234,"interventions":43235},[86],[23246],[41697,41727,41728,41718],{"trials":43237,"activeCount":97},[],{"trials":43239,"activeCount":97},[],{"trials":43241,"activeCount":97},[],{"intervention":43243,"totalTrials":660,"cells":43244},"GSK Biologicals' investigational TB vaccine GSK 692342",{"EARLY_PHASE1":43245,"PHASE1":43247,"PHASE2":43249,"PHASE3":43267,"PHASE4":43269,"NA":43271},{"trials":43246,"activeCount":97},[],{"trials":43248,"activeCount":97},[],{"trials":43250,"activeCount":97},[43251,43259],{"nctId":43252,"briefTitle":43253,"status":145,"phases":43254,"primaryCompletion":11484,"completion":43255,"start":43256,"enrollment":444,"conditions":43257,"interventions":43258},"NCT01424501","Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in Adults With TB Disease",[86],"2014-04-10","2011-11-14",[23246],[43243],{"nctId":43260,"briefTitle":43261,"status":155,"phases":43262,"primaryCompletion":43263,"completion":26392,"start":43264,"enrollment":454,"conditions":43265,"interventions":43266},"NCT01669096","Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342",[86],"2012-12-06","2012-08-21",[23246],[43243],{"trials":43268,"activeCount":97},[],{"trials":43270,"activeCount":97},[],{"trials":43272,"activeCount":97},[],{"intervention":43274,"totalTrials":660,"cells":43275},"GSK3389404",{"EARLY_PHASE1":43276,"PHASE1":43278,"PHASE2":43287,"PHASE3":43297,"PHASE4":43299,"NA":43301},{"trials":43277,"activeCount":97},[],{"trials":43279,"activeCount":97},[43280],{"nctId":43281,"briefTitle":43282,"status":155,"phases":43283,"primaryCompletion":43284,"completion":43284,"start":15084,"enrollment":904,"conditions":43285,"interventions":43286},"NCT02647281","First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects",[85],"2017-01-03",[24],[43274],{"trials":43288,"activeCount":97},[43289],{"nctId":43290,"briefTitle":43291,"status":155,"phases":43292,"primaryCompletion":10591,"completion":43293,"start":43294,"enrollment":868,"conditions":43295,"interventions":43296},"NCT03020745","A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects",[86],"2019-11-06","2017-02-14",[24],[43274],{"trials":43298,"activeCount":97},[],{"trials":43300,"activeCount":97},[],{"trials":43302,"activeCount":97},[],{"intervention":43304,"totalTrials":660,"cells":43305},"HRV vaccine",{"EARLY_PHASE1":43306,"PHASE1":43308,"PHASE2":43310,"PHASE3":43327,"PHASE4":43329,"NA":43331},{"trials":43307,"activeCount":97},[],{"trials":43309,"activeCount":97},[],{"trials":43311,"activeCount":97},[43312,43318],{"nctId":43313,"briefTitle":43314,"status":155,"phases":43315,"primaryCompletion":2823,"completion":2823,"start":9462,"enrollment":13811,"conditions":43316,"interventions":43317},"NCT00383903","Evaluate Safety & Immunogenicity of 2 or 3 Doses of GSK HRV Vaccine in Healthy Infants in South Africa",[86],[4759],[43304],{"nctId":43319,"briefTitle":43320,"status":155,"phases":43321,"primaryCompletion":43322,"completion":43322,"start":43323,"enrollment":43324,"conditions":43325,"interventions":43326},"NCT00385320","Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 Months",[86],"2003-04-30","2001-05-31",2640,[4759],[43304],{"trials":43328,"activeCount":97},[],{"trials":43330,"activeCount":97},[],{"trials":43332,"activeCount":97},[],{"intervention":23034,"totalTrials":660,"cells":43334},{"EARLY_PHASE1":43335,"PHASE1":43337,"PHASE2":43339,"PHASE3":43349,"PHASE4":43351,"NA":43353},{"trials":43336,"activeCount":97},[],{"trials":43338,"activeCount":97},[],{"trials":43340,"activeCount":97},[43341,43345],{"nctId":23025,"briefTitle":23026,"status":155,"phases":43342,"primaryCompletion":23028,"completion":23029,"start":2374,"enrollment":23030,"conditions":43343,"interventions":43344},[86],[4703,4704],[23033,23034,23035,23016,23036,10583,10546,10573],{"nctId":23038,"briefTitle":23039,"status":155,"phases":43346,"primaryCompletion":23041,"completion":23042,"start":23043,"enrollment":23044,"conditions":43347,"interventions":43348},[86],[4704,4703],[23047,23036,23016,23034,23035,23048,23049],{"trials":43350,"activeCount":97},[],{"trials":43352,"activeCount":97},[],{"trials":43354,"activeCount":97},[],{"intervention":23035,"totalTrials":660,"cells":43356},{"EARLY_PHASE1":43357,"PHASE1":43359,"PHASE2":43361,"PHASE3":43371,"PHASE4":43373,"NA":43375},{"trials":43358,"activeCount":97},[],{"trials":43360,"activeCount":97},[],{"trials":43362,"activeCount":97},[43363,43367],{"nctId":23025,"briefTitle":23026,"status":155,"phases":43364,"primaryCompletion":23028,"completion":23029,"start":2374,"enrollment":23030,"conditions":43365,"interventions":43366},[86],[4703,4704],[23033,23034,23035,23016,23036,10583,10546,10573],{"nctId":23038,"briefTitle":23039,"status":155,"phases":43368,"primaryCompletion":23041,"completion":23042,"start":23043,"enrollment":23044,"conditions":43369,"interventions":43370},[86],[4704,4703],[23047,23036,23016,23034,23035,23048,23049],{"trials":43372,"activeCount":97},[],{"trials":43374,"activeCount":97},[],{"trials":43376,"activeCount":97},[],{"intervention":23036,"totalTrials":660,"cells":43378},{"EARLY_PHASE1":43379,"PHASE1":43381,"PHASE2":43383,"PHASE3":43393,"PHASE4":43395,"NA":43397},{"trials":43380,"activeCount":97},[],{"trials":43382,"activeCount":97},[],{"trials":43384,"activeCount":97},[43385,43389],{"nctId":23025,"briefTitle":23026,"status":155,"phases":43386,"primaryCompletion":23028,"completion":23029,"start":2374,"enrollment":23030,"conditions":43387,"interventions":43388},[86],[4703,4704],[23033,23034,23035,23016,23036,10583,10546,10573],{"nctId":23038,"briefTitle":23039,"status":155,"phases":43390,"primaryCompletion":23041,"completion":23042,"start":23043,"enrollment":23044,"conditions":43391,"interventions":43392},[86],[4704,4703],[23047,23036,23016,23034,23035,23048,23049],{"trials":43394,"activeCount":97},[],{"trials":43396,"activeCount":97},[],{"trials":43398,"activeCount":97},[],{"intervention":4682,"totalTrials":660,"cells":43400},{"EARLY_PHASE1":43401,"PHASE1":43403,"PHASE2":43405,"PHASE3":43415,"PHASE4":43417,"NA":43419},{"trials":43402,"activeCount":97},[],{"trials":43404,"activeCount":97},[],{"trials":43406,"activeCount":97},[43407,43411],{"nctId":4673,"briefTitle":4674,"status":155,"phases":43408,"primaryCompletion":4676,"completion":4677,"start":4678,"enrollment":4679,"conditions":43409,"interventions":43410},[86],[3637],[4682,4682,4683,4485,4684],{"nctId":41964,"briefTitle":41965,"status":155,"phases":43412,"primaryCompletion":7445,"completion":7445,"start":41967,"enrollment":41968,"conditions":43413,"interventions":43414},[86],[3637],[4682,4682,10348,41971,41972,23250,41973,41974],{"trials":43416,"activeCount":97},[],{"trials":43418,"activeCount":97},[],{"trials":43420,"activeCount":97},[],{"intervention":10786,"totalTrials":660,"cells":43422},{"EARLY_PHASE1":43423,"PHASE1":43425,"PHASE2":43427,"PHASE3":43439,"PHASE4":43441,"NA":43443},{"trials":43424,"activeCount":97},[],{"trials":43426,"activeCount":97},[],{"trials":43428,"activeCount":97},[43429,43435],{"nctId":43430,"briefTitle":43431,"status":155,"phases":43432,"completion":1361,"start":2823,"enrollment":454,"conditions":43433,"interventions":43434},"NCT00354666","Single Doses GSK159797 On Patient Safety And Lung Function In Patients With Mild To Moderate Asthma",[86],[15],[10786],{"nctId":10781,"briefTitle":10782,"status":155,"phases":43436,"primaryCompletion":5196,"completion":5196,"start":4844,"enrollment":1686,"conditions":43437,"interventions":43438},[86],[15],[10786,10787,10772],{"trials":43440,"activeCount":97},[],{"trials":43442,"activeCount":97},[],{"trials":43444,"activeCount":97},[],{"intervention":20983,"totalTrials":660,"cells":43446},{"EARLY_PHASE1":43447,"PHASE1":43449,"PHASE2":43451,"PHASE3":43466,"PHASE4":43468,"NA":43470},{"trials":43448,"activeCount":97},[],{"trials":43450,"activeCount":97},[],{"trials":43452,"activeCount":97},[43453,43457],{"nctId":20978,"briefTitle":20979,"status":155,"phases":43454,"primaryCompletion":2795,"completion":2795,"start":8406,"enrollment":4121,"conditions":43455,"interventions":43456},[86],[992],[20983,18312],{"nctId":43458,"briefTitle":43459,"status":155,"phases":43460,"primaryCompletion":43461,"completion":43462,"start":43463,"enrollment":12415,"conditions":43464,"interventions":43465},"NCT00454909","Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent\u002FAdults Aged 10-25 Years.",[86],"2007-10-31","2008-04-11","2007-04-23",[992],[20983,24186],{"trials":43467,"activeCount":97},[],{"trials":43469,"activeCount":97},[],{"trials":43471,"activeCount":97},[],{"intervention":43473,"totalTrials":660,"cells":43474},"10mg Ezetimibe",{"EARLY_PHASE1":43475,"PHASE1":43477,"PHASE2":43489,"PHASE3":43495,"PHASE4":43497,"NA":43499},{"trials":43476,"activeCount":97},[],{"trials":43478,"activeCount":97},[43479],{"nctId":43480,"briefTitle":43481,"status":155,"phases":43482,"primaryCompletion":43483,"completion":43483,"start":43484,"enrollment":3025,"conditions":43485,"interventions":43487},"NCT01597700","Acotral® Versus Zetia® Ezetimibe Bioequivalance Study.",[85],"2012-01-30","2012-01-13",[43486],"Hypercholesterolaemia",[43473,43488],"10 mg Ezetimibe - wash out period",{"trials":43490,"activeCount":97},[43491],{"nctId":27247,"briefTitle":27248,"status":155,"phases":43492,"primaryCompletion":12402,"completion":12402,"start":3059,"enrollment":21052,"conditions":43493,"interventions":43494},[86],[27251,27252],[27254,27255,27256,27257,27258,27259,27260],{"trials":43496,"activeCount":97},[],{"trials":43498,"activeCount":97},[],{"trials":43500,"activeCount":97},[],{"intervention":43502,"totalTrials":660,"cells":43503},"GSK1004723",{"EARLY_PHASE1":43504,"PHASE1":43506,"PHASE2":43515,"PHASE3":43523,"PHASE4":43525,"NA":43527},{"trials":43505,"activeCount":97},[],{"trials":43507,"activeCount":97},[43508],{"nctId":43509,"briefTitle":43510,"status":155,"phases":43511,"primaryCompletion":8741,"completion":8741,"start":43512,"enrollment":421,"conditions":43513,"interventions":43514},"NCT00694993","Single and Repeat Dose First Time in Human Study for an Intranasal H1\u002FH3 Dual Antagonist in Healthy Male Subjects",[85],"2007-12-17",[10169],[43502],{"trials":43516,"activeCount":97},[43517],{"nctId":43518,"briefTitle":43519,"status":155,"phases":43520,"primaryCompletion":7976,"completion":7976,"start":7546,"enrollment":1686,"conditions":43521,"interventions":43522},"NCT00824356","Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo",[86],[39086],[43502,43502],{"trials":43524,"activeCount":97},[],{"trials":43526,"activeCount":97},[],{"trials":43528,"activeCount":97},[],{"intervention":43530,"totalTrials":660,"cells":43531},"Insulin",{"EARLY_PHASE1":43532,"PHASE1":43534,"PHASE2":43536,"PHASE3":43553,"PHASE4":43555,"NA":43557},{"trials":43533,"activeCount":97},[],{"trials":43535,"activeCount":97},[],{"trials":43537,"activeCount":97},[43538,43545],{"nctId":43539,"briefTitle":43540,"status":145,"phases":43541,"primaryCompletion":4843,"completion":4843,"start":4757,"enrollment":417,"conditions":43542,"interventions":43543},"NCT00437164","A Study To Assess GW677954 Used In Combination With Insulin In Subjects Who Have Type 2 Diabetes Mellitus",[86],[9036,27],[43530,43544],"Oral GW677954",{"nctId":43546,"briefTitle":43547,"status":155,"phases":43548,"primaryCompletion":43549,"completion":43549,"start":18336,"enrollment":613,"conditions":43550,"interventions":43551},"NCT02284009","Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus",[86],"2017-10-18",[19499],[43552,43530],"Albiglutide weekly",{"trials":43554,"activeCount":97},[],{"trials":43556,"activeCount":97},[],{"trials":43558,"activeCount":97},[],{"intervention":40743,"totalTrials":660,"cells":43560},{"EARLY_PHASE1":43561,"PHASE1":43563,"PHASE2":43572,"PHASE3":43578,"PHASE4":43580,"NA":43582},{"trials":43562,"activeCount":97},[],{"trials":43564,"activeCount":97},[43565],{"nctId":43566,"briefTitle":43567,"status":500,"phases":43568,"primaryCompletion":3391,"completion":3391,"start":6351,"enrollment":97,"conditions":43569,"interventions":43570},"NCT01039610","A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.",[85],[6484],[43571,40743,8022],"GSK945237",{"trials":43573,"activeCount":97},[43574],{"nctId":40737,"briefTitle":40738,"status":155,"phases":43575,"primaryCompletion":40740,"completion":40740,"start":18983,"enrollment":719,"conditions":43576,"interventions":43577},[86],[12727],[40702,40743,40744,40745],{"trials":43579,"activeCount":97},[],{"trials":43581,"activeCount":97},[],{"trials":43583,"activeCount":97},[],{"intervention":43585,"totalTrials":660,"cells":43586},"GSK2336805",{"EARLY_PHASE1":43587,"PHASE1":43589,"PHASE2":43598,"PHASE3":43609,"PHASE4":43611,"NA":43613},{"trials":43588,"activeCount":97},[],{"trials":43590,"activeCount":97},[43591],{"nctId":43592,"briefTitle":43593,"status":155,"phases":43594,"primaryCompletion":18902,"completion":18902,"start":43595,"enrollment":3379,"conditions":43596,"interventions":43597},"NCT01827657","Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects",[85],"2013-05-28",[23770],[43585],{"trials":43599,"activeCount":97},[43600],{"nctId":43601,"briefTitle":43602,"status":155,"phases":43603,"primaryCompletion":43604,"completion":43604,"start":9812,"enrollment":433,"conditions":43605,"interventions":43606},"NCT01439373","Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects",[86],"2011-12-05",[42684],[43585,43607,43608],"Pegylated interferon alfa-2a","Ribavirin",{"trials":43610,"activeCount":97},[],{"trials":43612,"activeCount":97},[],{"trials":43614,"activeCount":97},[],{"intervention":43608,"totalTrials":660,"cells":43616},{"EARLY_PHASE1":43617,"PHASE1":43619,"PHASE2":43621,"PHASE3":43638,"PHASE4":43640,"NA":43642},{"trials":43618,"activeCount":97},[],{"trials":43620,"activeCount":97},[],{"trials":43622,"activeCount":97},[43623,43627],{"nctId":43601,"briefTitle":43602,"status":155,"phases":43624,"primaryCompletion":43604,"completion":43604,"start":9812,"enrollment":433,"conditions":43625,"interventions":43626},[86],[42684],[43585,43607,43608],{"nctId":43628,"briefTitle":43629,"status":155,"phases":43630,"primaryCompletion":17134,"completion":43631,"start":30042,"enrollment":4792,"conditions":43632,"interventions":43633},"NCT01648140","Dose Ranging of GSK2336805 in Combination Therapy",[86],"2014-07-16",[42684],[43634,43635,43636,43608,43637],"GSK2336805 40 mg","GSK2336805 60 mg","Pegylated interferon alpha-2a","Telaprevir",{"trials":43639,"activeCount":97},[],{"trials":43641,"activeCount":97},[],{"trials":43643,"activeCount":97},[],{"intervention":41129,"totalTrials":660,"cells":43645},{"EARLY_PHASE1":43646,"PHASE1":43648,"PHASE2":43650,"PHASE3":43660,"PHASE4":43662,"NA":43664},{"trials":43647,"activeCount":97},[],{"trials":43649,"activeCount":97},[],{"trials":43651,"activeCount":97},[43652,43656],{"nctId":41122,"briefTitle":41123,"status":155,"phases":43653,"primaryCompletion":41125,"completion":4167,"start":41126,"enrollment":7955,"conditions":43654,"interventions":43655},[86],[23246],[41096,41129],{"nctId":41131,"briefTitle":41132,"status":155,"phases":43657,"primaryCompletion":41134,"completion":41134,"start":41135,"enrollment":4377,"conditions":43658,"interventions":43659},[86],[23246],[41096,41138,41139,41140,41141],{"trials":43661,"activeCount":97},[],{"trials":43663,"activeCount":97},[],{"trials":43665,"activeCount":97},[],{"intervention":43667,"totalTrials":660,"cells":43668},"NTHi Mcat investigational vaccine",{"EARLY_PHASE1":43669,"PHASE1":43671,"PHASE2":43673,"PHASE3":43690,"PHASE4":43692,"NA":43694},{"trials":43670,"activeCount":97},[],{"trials":43672,"activeCount":97},[],{"trials":43674,"activeCount":97},[43675,43682],{"nctId":43676,"briefTitle":43677,"status":155,"phases":43678,"primaryCompletion":25648,"completion":25648,"start":43679,"enrollment":36666,"conditions":43680,"interventions":43681},"NCT03281876","A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.",[86],"2017-11-27",[9855],[43667],{"nctId":43683,"briefTitle":43684,"status":155,"phases":43685,"primaryCompletion":43686,"completion":43687,"start":38017,"enrollment":1196,"conditions":43688,"interventions":43689},"NCT03443427","A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine",[86],"2019-12-31","2020-09-23",[9855],[43667],{"trials":43691,"activeCount":97},[],{"trials":43693,"activeCount":97},[],{"trials":43695,"activeCount":97},[],{"intervention":43637,"totalTrials":660,"cells":43697},{"EARLY_PHASE1":43698,"PHASE1":43700,"PHASE2":43710,"PHASE3":43716,"PHASE4":43718,"NA":43720},{"trials":43699,"activeCount":97},[],{"trials":43701,"activeCount":97},[43702],{"nctId":43703,"briefTitle":43704,"status":155,"phases":43705,"primaryCompletion":43706,"completion":43706,"start":30042,"enrollment":904,"conditions":43707,"interventions":43708},"NCT01657552","Eltrombopag\u002FBoceprevir and Eltrombopag\u002FTelaprevir Drug-Drug Interaction Study In Healthy Adult Subjects",[85],"2012-10-26",[11033],[23772,43709,43637],"Boceprevir",{"trials":43711,"activeCount":97},[43712],{"nctId":43628,"briefTitle":43629,"status":155,"phases":43713,"primaryCompletion":17134,"completion":43631,"start":30042,"enrollment":4792,"conditions":43714,"interventions":43715},[86],[42684],[43634,43635,43636,43608,43637],{"trials":43717,"activeCount":97},[],{"trials":43719,"activeCount":97},[],{"trials":43721,"activeCount":97},[],{"intervention":3063,"totalTrials":660,"cells":43723},{"EARLY_PHASE1":43724,"PHASE1":43726,"PHASE2":43732,"PHASE3":43738,"PHASE4":43740,"NA":43742},{"trials":43725,"activeCount":97},[],{"trials":43727,"activeCount":97},[43728],{"nctId":3055,"briefTitle":3056,"status":155,"phases":43729,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":803,"conditions":43730,"interventions":43731},[85],[36],[3048,164,3062,165,135,3063,134],{"trials":43733,"activeCount":97},[43734],{"nctId":3075,"briefTitle":3076,"status":145,"phases":43735,"primaryCompletion":1429,"completion":3078,"start":3079,"enrollment":1165,"conditions":43736,"interventions":43737},[86],[3081,668],[2274,3083,164,3063],{"trials":43739,"activeCount":97},[],{"trials":43741,"activeCount":97},[],{"trials":43743,"activeCount":97},[],{"intervention":43745,"totalTrials":660,"cells":43746},"GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A",{"EARLY_PHASE1":43747,"PHASE1":43749,"PHASE2":43760,"PHASE3":43768,"PHASE4":43770,"NA":43772},{"trials":43748,"activeCount":97},[],{"trials":43750,"activeCount":97},[43751],{"nctId":43752,"briefTitle":43753,"status":155,"phases":43754,"primaryCompletion":18982,"completion":41281,"start":43755,"enrollment":8236,"conditions":43756,"interventions":43757},"NCT01059617","Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults",[85],"2010-02-09",[21],[43758,43745,43759],"GSK Biologicals' FluLaval®","GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A",{"trials":43761,"activeCount":97},[43762],{"nctId":43763,"briefTitle":43764,"status":500,"phases":43765,"primaryCompletion":2335,"completion":2335,"start":6352,"enrollment":97,"conditions":43766,"interventions":43767},"NCT01008956","Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults",[86],[21],[43745],{"trials":43769,"activeCount":97},[],{"trials":43771,"activeCount":97},[],{"trials":43773,"activeCount":97},[],{"intervention":10450,"totalTrials":660,"cells":43775},{"EARLY_PHASE1":43776,"PHASE1":43778,"PHASE2":43780,"PHASE3":43793,"PHASE4":43795,"NA":43797},{"trials":43777,"activeCount":97},[],{"trials":43779,"activeCount":97},[],{"trials":43781,"activeCount":97},[43782,43786],{"nctId":10444,"briefTitle":10445,"status":155,"phases":43783,"primaryCompletion":4756,"completion":4756,"start":8427,"enrollment":5656,"conditions":43784,"interventions":43785},[86],[27],[10449,10450],{"nctId":43787,"briefTitle":43788,"status":155,"phases":43789,"completion":3552,"start":749,"enrollment":34502,"conditions":43790,"interventions":43792},"NCT00264667","Study In Patients With Dyslipidaemia",[86],[43791],"Metabolic Syndrome X",[10450],{"trials":43794,"activeCount":97},[],{"trials":43796,"activeCount":97},[],{"trials":43798,"activeCount":97},[],{"intervention":43800,"totalTrials":660,"cells":43801},"MenC-TT",{"EARLY_PHASE1":43802,"PHASE1":43804,"PHASE2":43806,"PHASE3":43821,"PHASE4":43823,"NA":43825},{"trials":43803,"activeCount":97},[],{"trials":43805,"activeCount":97},[],{"trials":43807,"activeCount":97},[43808,43815],{"nctId":43809,"briefTitle":43810,"status":155,"phases":43811,"primaryCompletion":21092,"completion":21092,"start":11599,"enrollment":10126,"conditions":43812,"interventions":43813},"NCT00135564","Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers",[86],[992],[43800,43814],"Hib-MenC-TT",{"nctId":43816,"briefTitle":43817,"status":155,"phases":43818,"primaryCompletion":11599,"completion":11599,"start":8945,"enrollment":10126,"conditions":43819,"interventions":43820},"NCT00135486","Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants",[86],[992],[43800,43814],{"trials":43822,"activeCount":97},[],{"trials":43824,"activeCount":97},[],{"trials":43826,"activeCount":97},[],{"intervention":43814,"totalTrials":660,"cells":43828},{"EARLY_PHASE1":43829,"PHASE1":43831,"PHASE2":43833,"PHASE3":43843,"PHASE4":43845,"NA":43847},{"trials":43830,"activeCount":97},[],{"trials":43832,"activeCount":97},[],{"trials":43834,"activeCount":97},[43835,43839],{"nctId":43809,"briefTitle":43810,"status":155,"phases":43836,"primaryCompletion":21092,"completion":21092,"start":11599,"enrollment":10126,"conditions":43837,"interventions":43838},[86],[992],[43800,43814],{"nctId":43816,"briefTitle":43817,"status":155,"phases":43840,"primaryCompletion":11599,"completion":11599,"start":8945,"enrollment":10126,"conditions":43841,"interventions":43842},[86],[992],[43800,43814],{"trials":43844,"activeCount":97},[],{"trials":43846,"activeCount":97},[],{"trials":43848,"activeCount":97},[],{"intervention":20251,"totalTrials":660,"cells":43850},{"EARLY_PHASE1":43851,"PHASE1":43853,"PHASE2":43855,"PHASE3":43865,"PHASE4":43867,"NA":43869},{"trials":43852,"activeCount":97},[],{"trials":43854,"activeCount":97},[],{"trials":43856,"activeCount":97},[43857,43861],{"nctId":20244,"briefTitle":20245,"status":155,"phases":43858,"primaryCompletion":20247,"completion":20247,"start":20248,"enrollment":12202,"conditions":43859,"interventions":43860},[86],[8788],[20235,20251,20252],{"nctId":20261,"briefTitle":20262,"status":155,"phases":43862,"primaryCompletion":20264,"completion":20265,"start":20266,"enrollment":17527,"conditions":43863,"interventions":43864},[86],[8788],[20235,20251,20269],{"trials":43866,"activeCount":97},[],{"trials":43868,"activeCount":97},[],{"trials":43870,"activeCount":97},[],{"intervention":43872,"totalTrials":660,"cells":43873},"MEDI-517 HPV-16\u002F18 VLP AS04 vaccine",{"EARLY_PHASE1":43874,"PHASE1":43876,"PHASE2":43878,"PHASE3":43895,"PHASE4":43897,"NA":43899},{"trials":43875,"activeCount":97},[],{"trials":43877,"activeCount":97},[],{"trials":43879,"activeCount":97},[43880,43887],{"nctId":43881,"briefTitle":43882,"status":155,"phases":43883,"primaryCompletion":2823,"completion":2823,"start":35846,"enrollment":17136,"conditions":43884,"interventions":43885},"NCT00693966","Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females",[86],[8723],[43872,43872,43872,43886],"MEDI-517 HPV-16\u002F18 VLP with Al",{"nctId":43888,"briefTitle":43889,"status":155,"phases":43890,"primaryCompletion":10803,"completion":10803,"start":33286,"enrollment":1237,"conditions":43891,"interventions":43892},"NCT00693615","Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females",[86],[8723],[43872,43893,43894],"MEDI-517 HPV-16\u002F18 VLP vaccine with Al(OH)3","MEDI-517 HPV-16\u002F18 VLP vaccine without adjuvant",{"trials":43896,"activeCount":97},[],{"trials":43898,"activeCount":97},[],{"trials":43900,"activeCount":97},[],{"intervention":40443,"totalTrials":660,"cells":43902},{"EARLY_PHASE1":43903,"PHASE1":43905,"PHASE2":43907,"PHASE3":43917,"PHASE4":43919,"NA":43921},{"trials":43904,"activeCount":97},[],{"trials":43906,"activeCount":97},[],{"trials":43908,"activeCount":97},[43909,43913],{"nctId":40437,"briefTitle":40438,"status":155,"phases":43910,"primaryCompletion":40440,"completion":40440,"start":148,"enrollment":1459,"conditions":43911,"interventions":43912},[86],[24],[40420,40443],{"nctId":40464,"briefTitle":40465,"status":155,"phases":43914,"primaryCompletion":40467,"completion":40467,"start":40468,"enrollment":4987,"conditions":43915,"interventions":43916},[86],[24],[40420,40443],{"trials":43918,"activeCount":97},[],{"trials":43920,"activeCount":97},[],{"trials":43922,"activeCount":97},[],{"intervention":43924,"totalTrials":660,"cells":43925},"Pneumovax 23™",{"EARLY_PHASE1":43926,"PHASE1":43928,"PHASE2":43930,"PHASE3":43950,"PHASE4":43952,"NA":43954},{"trials":43927,"activeCount":97},[],{"trials":43929,"activeCount":97},[],{"trials":43931,"activeCount":97},[43932,43943],{"nctId":43933,"briefTitle":43934,"status":155,"phases":43935,"primaryCompletion":43936,"completion":43936,"start":43937,"enrollment":43938,"conditions":43939,"interventions":43941},"NCT00307528","Safety and Efficacy Study of Investigational Pneumococcal Vaccine in Elderly Population",[86],"2005-03-30","2004-01-20",146,[43940],"Prophylaxis Invasive Pneumococcal Diseases and Pneumonia",[43942,43924],"Pneumococcal vaccine GSK513026",{"nctId":43944,"briefTitle":43945,"status":155,"phases":43946,"primaryCompletion":1380,"completion":1380,"start":7581,"enrollment":43947,"conditions":43948,"interventions":43949},"NCT00307008","Study to Evaluate the Response Rate to the Licensed Pneumovax 23™ in Elderly Population.",[86],1198,[4742],[43924],{"trials":43951,"activeCount":97},[],{"trials":43953,"activeCount":97},[],{"trials":43955,"activeCount":97},[],{"intervention":43957,"totalTrials":660,"cells":43958},"GSK221149A",{"EARLY_PHASE1":43959,"PHASE1":43961,"PHASE2":43970,"PHASE3":43978,"PHASE4":43980,"NA":43982},{"trials":43960,"activeCount":97},[],{"trials":43962,"activeCount":97},[43963],{"nctId":43964,"briefTitle":43965,"status":155,"phases":43966,"start":2404,"enrollment":628,"conditions":43967,"interventions":43969},"NCT00457925","Absorption, Distribution, Metabolism And Excretion Study For GSK221149A",[85],[22921,43968],"Premature Labor",[43957],{"trials":43971,"activeCount":97},[43972],{"nctId":43973,"briefTitle":43974,"status":155,"phases":43975,"primaryCompletion":9812,"completion":9812,"start":12472,"enrollment":7911,"conditions":43976,"interventions":43977},"NCT00404768","The Safety, Tolerability And Metabolism Of GSK221149A, In Pregnant Women (30-36 Weeks), In Pre-Term Labor",[86],[22921],[43957],{"trials":43979,"activeCount":97},[],{"trials":43981,"activeCount":97},[],{"trials":43983,"activeCount":97},[],{"intervention":43985,"totalTrials":660,"cells":43986},"HuMax-CD20",{"EARLY_PHASE1":43987,"PHASE1":43989,"PHASE2":43991,"PHASE3":44006,"PHASE4":44008,"NA":44010},{"trials":43988,"activeCount":97},[],{"trials":43990,"activeCount":97},[],{"trials":43992,"activeCount":97},[43993,44000],{"nctId":43994,"briefTitle":43995,"status":500,"phases":43996,"primaryCompletion":5196,"completion":5196,"start":8478,"enrollment":97,"conditions":43997,"interventions":43999},"NCT00093314","HuMax-CD20 in Chronic Lymphocytic Leukemia",[85,86],[43998],"Chronic Lymphocytic Leukemia",[43985],{"nctId":44001,"briefTitle":44002,"status":500,"phases":44003,"primaryCompletion":10803,"completion":10803,"start":2823,"enrollment":97,"conditions":44004,"interventions":44005},"NCT00092274","Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma",[85,86],[3554],[43985],{"trials":44007,"activeCount":97},[],{"trials":44009,"activeCount":97},[],{"trials":44011,"activeCount":97},[],{"intervention":4,"totalTrials":660,"cells":44013},{"EARLY_PHASE1":44014,"PHASE1":44016,"PHASE2":44018,"PHASE3":44035,"PHASE4":44037,"NA":44039},{"trials":44015,"activeCount":97},[],{"trials":44017,"activeCount":97},[],{"trials":44019,"activeCount":97},[44020,44028],{"nctId":44021,"briefTitle":44022,"status":155,"phases":44023,"primaryCompletion":44024,"completion":44024,"start":9551,"enrollment":44025,"conditions":44026,"interventions":44027},"NCT02485301","A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults",[86],"2016-12-23",3024,[9840],[4],{"nctId":44029,"briefTitle":44030,"status":155,"phases":44031,"primaryCompletion":26127,"completion":26127,"start":19396,"enrollment":1944,"conditions":44032,"interventions":44033},"NCT02548078","A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children",[86],[9840],[4,44034],"Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine",{"trials":44036,"activeCount":97},[],{"trials":44038,"activeCount":97},[],{"trials":44040,"activeCount":97},[],{"intervention":44042,"totalTrials":660,"cells":44043},"Rilapladib",{"EARLY_PHASE1":44044,"PHASE1":44046,"PHASE2":44054,"PHASE3":44063,"PHASE4":44065,"NA":44067},{"trials":44045,"activeCount":97},[],{"trials":44047,"activeCount":97},[44048],{"nctId":44049,"briefTitle":44050,"status":155,"phases":44051,"primaryCompletion":4756,"completion":4756,"start":2404,"enrollment":7712,"conditions":44052,"interventions":44053},"NCT00387257","Effect Of Rilapladib (SB-659032) On Platelet Aggregation",[85],[7524,9309],[44042],{"trials":44055,"activeCount":97},[44056],{"nctId":44057,"briefTitle":44058,"status":155,"phases":44059,"primaryCompletion":7647,"completion":7647,"start":10166,"enrollment":323,"conditions":44060,"interventions":44061},"NCT00695305","An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks",[86],[9309],[44062],"rilapladib",{"trials":44064,"activeCount":97},[],{"trials":44066,"activeCount":97},[],{"trials":44068,"activeCount":97},[],{"intervention":10171,"totalTrials":660,"cells":44070},{"EARLY_PHASE1":44071,"PHASE1":44073,"PHASE2":44083,"PHASE3":44089,"PHASE4":44091,"NA":44093},{"trials":44072,"activeCount":97},[],{"trials":44074,"activeCount":97},[44075],{"nctId":44076,"briefTitle":44077,"status":155,"phases":44078,"primaryCompletion":44079,"completion":44079,"start":44080,"enrollment":1079,"conditions":44081,"interventions":44082},"NCT00605852","Investigation Of a New Oral Anti-Histamine in Healthy Male Subjects",[85],"2008-05-03","2007-10-29",[10169],[10171],{"trials":44084,"activeCount":97},[44085],{"nctId":10163,"briefTitle":10164,"status":155,"phases":44086,"primaryCompletion":10166,"completion":10166,"start":10167,"enrollment":1686,"conditions":44087,"interventions":44088},[86],[10169],[10171,10171,10171,10134],{"trials":44090,"activeCount":97},[],{"trials":44092,"activeCount":97},[],{"trials":44094,"activeCount":97},[],{"intervention":18150,"totalTrials":660,"cells":44096},{"EARLY_PHASE1":44097,"PHASE1":44099,"PHASE2":44105,"PHASE3":44114,"PHASE4":44116,"NA":44118},{"trials":44098,"activeCount":97},[],{"trials":44100,"activeCount":97},[44101],{"nctId":18143,"briefTitle":18144,"status":155,"phases":44102,"primaryCompletion":10367,"completion":10367,"start":18146,"enrollment":18147,"conditions":44103,"interventions":44104},[85],[36],[3115,18150],{"trials":44106,"activeCount":97},[44107],{"nctId":44108,"briefTitle":44109,"status":155,"phases":44110,"primaryCompletion":7701,"completion":7701,"start":8135,"enrollment":7438,"conditions":44111,"interventions":44113},"NCT01395004","A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis",[86],[44112],"Langerhans Cell Histiocytosis",[18150],{"trials":44115,"activeCount":97},[],{"trials":44117,"activeCount":97},[],{"trials":44119,"activeCount":97},[],{"intervention":44121,"totalTrials":660,"cells":44122},"Levocabastine",{"EARLY_PHASE1":44123,"PHASE1":44125,"PHASE2":44127,"PHASE3":44139,"PHASE4":44141,"NA":44143},{"trials":44124,"activeCount":97},[],{"trials":44126,"activeCount":97},[],{"trials":44128,"activeCount":97},[44129,44135],{"nctId":44130,"briefTitle":44131,"status":155,"phases":44132,"primaryCompletion":41676,"completion":41676,"start":8395,"enrollment":868,"conditions":44133,"interventions":44134},"NCT01949051","A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis",[86],[10147],[44121],{"nctId":18720,"briefTitle":18721,"status":155,"phases":44136,"primaryCompletion":13418,"completion":13418,"start":3045,"enrollment":7394,"conditions":44137,"interventions":44138},[86],[10147],[18725,3467,18726],{"trials":44140,"activeCount":97},[],{"trials":44142,"activeCount":97},[],{"trials":44144,"activeCount":97},[],{"intervention":25856,"totalTrials":660,"cells":44146},{"EARLY_PHASE1":44147,"PHASE1":44149,"PHASE2":44159,"PHASE3":44165,"PHASE4":44167,"NA":44169},{"trials":44148,"activeCount":97},[],{"trials":44150,"activeCount":97},[44151],{"nctId":44152,"briefTitle":44153,"status":155,"phases":44154,"primaryCompletion":8539,"completion":8539,"start":8540,"enrollment":4121,"conditions":44155,"interventions":44156},"NCT02798991","A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects",[85],[5609],[44157,44158],"GSK3179106","Matched Placebo",{"trials":44160,"activeCount":97},[44161],{"nctId":25850,"briefTitle":25851,"status":155,"phases":44162,"primaryCompletion":728,"completion":3110,"start":3551,"enrollment":8437,"conditions":44163,"interventions":44164},[86],[25854],[25841,25856],{"trials":44166,"activeCount":97},[],{"trials":44168,"activeCount":97},[],{"trials":44170,"activeCount":97},[],{"intervention":8220,"totalTrials":660,"cells":44172},{"EARLY_PHASE1":44173,"PHASE1":44175,"PHASE2":44177,"PHASE3":44187,"PHASE4":44189,"NA":44191},{"trials":44174,"activeCount":97},[],{"trials":44176,"activeCount":97},[],{"trials":44178,"activeCount":97},[44179,44183],{"nctId":8214,"briefTitle":8215,"status":155,"phases":44180,"primaryCompletion":8208,"completion":8208,"start":8217,"enrollment":292,"conditions":44181,"interventions":44182},[86],[21,5353],[8220,8177],{"nctId":9762,"briefTitle":9763,"status":155,"phases":44184,"primaryCompletion":9765,"completion":9766,"start":2665,"enrollment":9767,"conditions":44185,"interventions":44186},[86],[21],[8220,9743],{"trials":44188,"activeCount":97},[],{"trials":44190,"activeCount":97},[],{"trials":44192,"activeCount":97},[],{"intervention":44194,"totalTrials":660,"cells":44195},"vestipitant",{"EARLY_PHASE1":44196,"PHASE1":44198,"PHASE2":44200,"PHASE3":44217,"PHASE4":44219,"NA":44221},{"trials":44197,"activeCount":97},[],{"trials":44199,"activeCount":97},[],{"trials":44201,"activeCount":97},[44202,44208],{"nctId":44203,"briefTitle":44204,"status":155,"phases":44205,"primaryCompletion":2844,"completion":2844,"start":11097,"enrollment":1264,"conditions":44206,"interventions":44207},"NCT00343707","PET (Positron Emission Tomography)\u002FPublic Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients",[86],[41867],[44194,39238],{"nctId":44209,"briefTitle":44210,"status":155,"phases":44211,"primaryCompletion":9159,"completion":9159,"start":7659,"enrollment":93,"conditions":44212,"interventions":44214},"NCT00394056","Vestipitant Or Vestipitant\u002FParoxetine Combination In Subjects With Tinnitus And Hearing Loss.",[86],[44213],"Tinnitus",[44215,44216],"Vestipitant","Vestipitant + Paroxetine",{"trials":44218,"activeCount":97},[],{"trials":44220,"activeCount":97},[],{"trials":44222,"activeCount":97},[],{"intervention":8379,"totalTrials":660,"cells":44224},{"EARLY_PHASE1":44225,"PHASE1":44227,"PHASE2":44229,"PHASE3":44244,"PHASE4":44246,"NA":44248},{"trials":44226,"activeCount":97},[],{"trials":44228,"activeCount":97},[],{"trials":44230,"activeCount":97},[44231,44235],{"nctId":8371,"briefTitle":8372,"status":155,"phases":44232,"primaryCompletion":8374,"completion":8375,"start":4996,"enrollment":8376,"conditions":44233,"interventions":44234},[86],[18],[8379,8380,8381],{"nctId":44236,"briefTitle":44237,"status":145,"phases":44238,"primaryCompletion":44239,"completion":44240,"start":44241,"enrollment":7438,"conditions":44242,"interventions":44243},"NCT03393806","Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)",[86],"2019-10-09","2020-01-06","2018-04-18",[18],[8379],{"trials":44245,"activeCount":97},[],{"trials":44247,"activeCount":97},[],{"trials":44249,"activeCount":97},[],{"intervention":19187,"totalTrials":660,"cells":44251},{"EARLY_PHASE1":44252,"PHASE1":44254,"PHASE2":44256,"PHASE3":44266,"PHASE4":44268,"NA":44270},{"trials":44253,"activeCount":97},[],{"trials":44255,"activeCount":97},[],{"trials":44257,"activeCount":97},[44258,44262],{"nctId":19181,"briefTitle":19182,"status":155,"phases":44259,"primaryCompletion":19184,"completion":19184,"start":15600,"enrollment":8931,"conditions":44260,"interventions":44261},[86],[33,24,4704,4702,3624,30,4703],[4706,19187,19151,10346,7830],{"nctId":19198,"briefTitle":19199,"status":155,"phases":44263,"primaryCompletion":19201,"completion":19201,"start":5268,"enrollment":19202,"conditions":44264,"interventions":44265},[86],[33,4702,24,4704,3624,30],[19151,19187,4726],{"trials":44267,"activeCount":97},[],{"trials":44269,"activeCount":97},[],{"trials":44271,"activeCount":97},[],{"intervention":24186,"totalTrials":660,"cells":44273},{"EARLY_PHASE1":44274,"PHASE1":44276,"PHASE2":44278,"PHASE3":44288,"PHASE4":44290,"NA":44292},{"trials":44275,"activeCount":97},[],{"trials":44277,"activeCount":97},[],{"trials":44279,"activeCount":97},[44280,44284],{"nctId":43458,"briefTitle":43459,"status":155,"phases":44281,"primaryCompletion":43461,"completion":43462,"start":43463,"enrollment":12415,"conditions":44282,"interventions":44283},[86],[992],[20983,24186],{"nctId":24177,"briefTitle":24178,"status":155,"phases":44285,"primaryCompletion":24180,"completion":24181,"start":24182,"enrollment":24183,"conditions":44286,"interventions":44287},[86],[992],[24168,24186],{"trials":44289,"activeCount":97},[],{"trials":44291,"activeCount":97},[],{"trials":44293,"activeCount":97},[],{"intervention":10547,"totalTrials":660,"cells":44295},{"EARLY_PHASE1":44296,"PHASE1":44298,"PHASE2":44300,"PHASE3":44310,"PHASE4":44312,"NA":44314},{"trials":44297,"activeCount":97},[],{"trials":44299,"activeCount":97},[],{"trials":44301,"activeCount":97},[44302,44306],{"nctId":10535,"briefTitle":10536,"status":155,"phases":44303,"primaryCompletion":10538,"completion":10539,"start":10540,"enrollment":10541,"conditions":44304,"interventions":44305},[86],[2484,2485,2486,8671],[10544,10545,10546,10526,10547],{"nctId":10549,"briefTitle":10550,"status":155,"phases":44307,"primaryCompletion":10552,"completion":10553,"start":10554,"enrollment":10555,"conditions":44308,"interventions":44309},[86],[3717,2484,2485,2486],[10558,10559,10526,10547],{"trials":44311,"activeCount":97},[],{"trials":44313,"activeCount":97},[],{"trials":44315,"activeCount":97},[],{"intervention":44317,"totalTrials":660,"cells":44318},"GSK1399686",{"EARLY_PHASE1":44319,"PHASE1":44321,"PHASE2":44330,"PHASE3":44339,"PHASE4":44341,"NA":44343},{"trials":44320,"activeCount":97},[],{"trials":44322,"activeCount":97},[44323],{"nctId":44324,"briefTitle":44325,"status":155,"phases":44326,"primaryCompletion":7472,"completion":7472,"start":44327,"enrollment":31,"conditions":44328,"interventions":44329},"NCT00721812","A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686",[85],"2008-09-25",[39481],[44317],{"trials":44331,"activeCount":97},[44332],{"nctId":44333,"briefTitle":44334,"status":155,"phases":44335,"primaryCompletion":18328,"completion":18328,"start":44336,"enrollment":201,"conditions":44337,"interventions":44338},"NCT01036022","Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis",[86],"2009-09-15",[7295],[44317],{"trials":44340,"activeCount":97},[],{"trials":44342,"activeCount":97},[],{"trials":44344,"activeCount":97},[],{"intervention":44346,"totalTrials":660,"cells":44347},"GSK2586881",{"EARLY_PHASE1":44348,"PHASE1":44350,"PHASE2":44360,"PHASE3":44370,"PHASE4":44372,"NA":44374},{"trials":44349,"activeCount":97},[],{"trials":44351,"activeCount":97},[44352],{"nctId":44353,"briefTitle":44354,"status":145,"phases":44355,"primaryCompletion":44356,"completion":44356,"start":44357,"enrollment":7438,"conditions":44358,"interventions":44359},"NCT03000686","Study of GSK2586881 on Acute Hypoxia and Exercise",[85],"2019-01-04","2017-05-17",[5280],[44346],{"trials":44361,"activeCount":97},[44362],{"nctId":44363,"briefTitle":44364,"status":155,"phases":44365,"primaryCompletion":44366,"completion":44366,"start":44367,"enrollment":314,"conditions":44368,"interventions":44369},"NCT03177603","A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)",[86],"2019-05-07","2018-02-21",[17209],[44346],{"trials":44371,"activeCount":97},[],{"trials":44373,"activeCount":97},[],{"trials":44375,"activeCount":97},[],{"intervention":44377,"totalTrials":660,"cells":44378},"Investigational H7N1 vaccine GSK2789869A",{"EARLY_PHASE1":44379,"PHASE1":44381,"PHASE2":44392,"PHASE3":44402,"PHASE4":44404,"NA":44406},{"trials":44380,"activeCount":97},[],{"trials":44382,"activeCount":97},[44383],{"nctId":44384,"briefTitle":44385,"status":155,"phases":44386,"primaryCompletion":1874,"completion":44387,"start":44388,"enrollment":27267,"conditions":44389,"interventions":44390},"NCT01934127","Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age",[85],"2014-10-20","2013-08-26",[21],[44377,44391],"Investigational H7N1 vaccine GSK2789868A",{"trials":44393,"activeCount":97},[44394],{"nctId":44395,"briefTitle":44396,"status":155,"phases":44397,"primaryCompletion":44398,"completion":44399,"start":39350,"enrollment":12,"conditions":44400,"interventions":44401},"NCT01949090","Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older",[86],"2013-12-04","2014-10-23",[21],[44377],{"trials":44403,"activeCount":97},[],{"trials":44405,"activeCount":97},[],{"trials":44407,"activeCount":97},[],{"intervention":44409,"totalTrials":660,"cells":44410},"Nemiralisib",{"EARLY_PHASE1":44411,"PHASE1":44413,"PHASE2":44423,"PHASE3":44434,"PHASE4":44436,"NA":44438},{"trials":44412,"activeCount":97},[],{"trials":44414,"activeCount":97},[44415],{"nctId":44416,"briefTitle":44417,"status":155,"phases":44418,"primaryCompletion":44419,"completion":44419,"start":44420,"enrollment":454,"conditions":44421,"interventions":44422},"NCT03398421","A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib",[85],"2018-03-12","2018-01-17",[15],[44409,39369],{"trials":44424,"activeCount":97},[44425],{"nctId":44426,"briefTitle":44427,"status":155,"phases":44428,"primaryCompletion":44429,"completion":44429,"start":44430,"enrollment":1517,"conditions":44431,"interventions":44433},"NCT02593539","Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled Nemiralisib in Patients With APDS\u002FPASLI",[86],"2020-06-04","2016-07-22",[44432],"Activated PI3K-delta Syndrome",[44409],{"trials":44435,"activeCount":97},[],{"trials":44437,"activeCount":97},[],{"trials":44439,"activeCount":97},[],{"intervention":44441,"totalTrials":660,"cells":44442},"RTS,S\u002FAS02D",{"EARLY_PHASE1":44443,"PHASE1":44445,"PHASE2":44447,"PHASE3":44467,"PHASE4":44469,"NA":44471},{"trials":44444,"activeCount":97},[],{"trials":44446,"activeCount":97},[],{"trials":44448,"activeCount":97},[44449,44459],{"nctId":44450,"briefTitle":44451,"status":155,"phases":44452,"primaryCompletion":44453,"completion":44453,"start":44454,"enrollment":14082,"conditions":44455,"interventions":44456},"NCT00197028","Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region",[86],"2007-12-27","2005-08-23",[3287],[44441,44457,44458],"TETRActHib™","Engerix-B®",{"nctId":44460,"briefTitle":44461,"status":155,"phases":44462,"primaryCompletion":44463,"completion":41020,"start":44464,"enrollment":7882,"conditions":44465,"interventions":44466},"NCT00289185","Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants",[86],"2008-02-11","2006-09-27",[3287,5132],[44441,44458,44457],{"trials":44468,"activeCount":97},[],{"trials":44470,"activeCount":97},[],{"trials":44472,"activeCount":97},[],{"intervention":44457,"totalTrials":660,"cells":44474},{"EARLY_PHASE1":44475,"PHASE1":44477,"PHASE2":44479,"PHASE3":44489,"PHASE4":44491,"NA":44493},{"trials":44476,"activeCount":97},[],{"trials":44478,"activeCount":97},[],{"trials":44480,"activeCount":97},[44481,44485],{"nctId":44450,"briefTitle":44451,"status":155,"phases":44482,"primaryCompletion":44453,"completion":44453,"start":44454,"enrollment":14082,"conditions":44483,"interventions":44484},[86],[3287],[44441,44457,44458],{"nctId":44460,"briefTitle":44461,"status":155,"phases":44486,"primaryCompletion":44463,"completion":41020,"start":44464,"enrollment":7882,"conditions":44487,"interventions":44488},[86],[3287,5132],[44441,44458,44457],{"trials":44490,"activeCount":97},[],{"trials":44492,"activeCount":97},[],{"trials":44494,"activeCount":97},[],{"intervention":44458,"totalTrials":660,"cells":44496},{"EARLY_PHASE1":44497,"PHASE1":44499,"PHASE2":44501,"PHASE3":44511,"PHASE4":44513,"NA":44515},{"trials":44498,"activeCount":97},[],{"trials":44500,"activeCount":97},[],{"trials":44502,"activeCount":97},[44503,44507],{"nctId":44450,"briefTitle":44451,"status":155,"phases":44504,"primaryCompletion":44453,"completion":44453,"start":44454,"enrollment":14082,"conditions":44505,"interventions":44506},[86],[3287],[44441,44457,44458],{"nctId":44460,"briefTitle":44461,"status":155,"phases":44508,"primaryCompletion":44463,"completion":41020,"start":44464,"enrollment":7882,"conditions":44509,"interventions":44510},[86],[3287,5132],[44441,44458,44457],{"trials":44512,"activeCount":97},[],{"trials":44514,"activeCount":97},[],{"trials":44516,"activeCount":97},[],{"intervention":44518,"totalTrials":660,"cells":44519},"SB-656933",{"EARLY_PHASE1":44520,"PHASE1":44522,"PHASE2":44531,"PHASE3":44541,"PHASE4":44543,"NA":44545},{"trials":44521,"activeCount":97},[],{"trials":44523,"activeCount":97},[44524],{"nctId":44525,"briefTitle":44526,"status":155,"phases":44527,"primaryCompletion":44528,"completion":44528,"start":18289,"enrollment":3131,"conditions":44529,"interventions":44530},"NCT00615576","Repeat Dose Study in Male Healthy Volunteer Smokers",[85],"2008-07-24",[15],[44518],{"trials":44532,"activeCount":97},[44533],{"nctId":44534,"briefTitle":44535,"status":145,"phases":44536,"primaryCompletion":44537,"completion":44537,"start":44538,"enrollment":593,"conditions":44539,"interventions":44540},"NCT00748410","Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis",[86],"2009-12-12","2009-01-22",[7295],[44518],{"trials":44542,"activeCount":97},[],{"trials":44544,"activeCount":97},[],{"trials":44546,"activeCount":97},[],{"intervention":10216,"totalTrials":660,"cells":44548},{"EARLY_PHASE1":44549,"PHASE1":44551,"PHASE2":44553,"PHASE3":44563,"PHASE4":44565,"NA":44567},{"trials":44550,"activeCount":97},[],{"trials":44552,"activeCount":97},[],{"trials":44554,"activeCount":97},[44555,44559],{"nctId":10272,"briefTitle":10273,"status":155,"phases":44556,"primaryCompletion":10275,"completion":10276,"start":10277,"enrollment":10278,"conditions":44557,"interventions":44558},[86],[992],[10216,10101,10263,8971,8292],{"nctId":10209,"briefTitle":10210,"status":155,"phases":44560,"primaryCompletion":9737,"completion":9737,"start":10212,"enrollment":10213,"conditions":44561,"interventions":44562},[86],[992],[10216,10217,4749,10200],{"trials":44564,"activeCount":97},[],{"trials":44566,"activeCount":97},[],{"trials":44568,"activeCount":97},[],{"intervention":44570,"totalTrials":660,"cells":44571},"5% calcium sodium phosphosilicate\u002F sodium monofluorophosphate dentifrice",{"EARLY_PHASE1":44572,"PHASE1":44574,"PHASE2":44576,"PHASE3":44597,"PHASE4":44599,"NA":44601},{"trials":44573,"activeCount":97},[],{"trials":44575,"activeCount":97},[],{"trials":44577,"activeCount":97},[44578,44588],{"nctId":44579,"briefTitle":44580,"status":155,"phases":44581,"primaryCompletion":8089,"completion":8089,"start":9706,"enrollment":1534,"conditions":44582,"interventions":44584},"NCT01691560","Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity",[86],[44583],"Dentine Hypersensitivity",[44570,44585,44586,44587],"0% calcium sodium phosphosilicate\u002Fsodium monofluorophosphate dentifrice","Sodium monofluorophosphate dentifrice","Sodium fluoride dentifrice",{"nctId":44589,"briefTitle":44590,"status":155,"phases":44591,"primaryCompletion":5195,"completion":5195,"start":8151,"enrollment":1534,"conditions":44592,"interventions":44594},"NCT01831817","Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity",[86],[44593],"Dentinal Hypersensitivity",[44570,44595,44586,44596],"0% calcium sodium phosphosilicate\u002F sodium monofluorophosphate dentifrice","Sodium Fluoride dentifrice",{"trials":44598,"activeCount":97},[],{"trials":44600,"activeCount":97},[],{"trials":44602,"activeCount":97},[],{"intervention":44586,"totalTrials":660,"cells":44604},{"EARLY_PHASE1":44605,"PHASE1":44607,"PHASE2":44609,"PHASE3":44619,"PHASE4":44621,"NA":44623},{"trials":44606,"activeCount":97},[],{"trials":44608,"activeCount":97},[],{"trials":44610,"activeCount":97},[44611,44615],{"nctId":44579,"briefTitle":44580,"status":155,"phases":44612,"primaryCompletion":8089,"completion":8089,"start":9706,"enrollment":1534,"conditions":44613,"interventions":44614},[86],[44583],[44570,44585,44586,44587],{"nctId":44589,"briefTitle":44590,"status":155,"phases":44616,"primaryCompletion":5195,"completion":5195,"start":8151,"enrollment":1534,"conditions":44617,"interventions":44618},[86],[44593],[44570,44595,44586,44596],{"trials":44620,"activeCount":97},[],{"trials":44622,"activeCount":97},[],{"trials":44624,"activeCount":97},[],{"intervention":44587,"totalTrials":660,"cells":44626},{"EARLY_PHASE1":44627,"PHASE1":44629,"PHASE2":44631,"PHASE3":44641,"PHASE4":44643,"NA":44645},{"trials":44628,"activeCount":97},[],{"trials":44630,"activeCount":97},[],{"trials":44632,"activeCount":97},[44633,44637],{"nctId":44579,"briefTitle":44580,"status":155,"phases":44634,"primaryCompletion":8089,"completion":8089,"start":9706,"enrollment":1534,"conditions":44635,"interventions":44636},[86],[44583],[44570,44585,44586,44587],{"nctId":44589,"briefTitle":44590,"status":155,"phases":44638,"primaryCompletion":5195,"completion":5195,"start":8151,"enrollment":1534,"conditions":44639,"interventions":44640},[86],[44593],[44570,44595,44586,44596],{"trials":44642,"activeCount":97},[],{"trials":44644,"activeCount":97},[],{"trials":44646,"activeCount":97},[],{"intervention":44648,"totalTrials":660,"cells":44649},"GSK525762 Besylate",{"EARLY_PHASE1":44650,"PHASE1":44652,"PHASE2":44663,"PHASE3":44672,"PHASE4":44674,"NA":44676},{"trials":44651,"activeCount":97},[],{"trials":44653,"activeCount":97},[44654],{"nctId":44655,"briefTitle":44656,"status":155,"phases":44657,"primaryCompletion":23222,"completion":23222,"start":44658,"enrollment":1079,"conditions":44659,"interventions":44660},"NCT02706535","A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential",[85],"2016-05-05",[9319,107],[44648,44661,44662],"Itraconazole 200 mg","Rifampicin 300 mg",{"trials":44664,"activeCount":97},[44665],{"nctId":44666,"briefTitle":44667,"status":500,"phases":44668,"primaryCompletion":44669,"completion":44669,"start":43679,"enrollment":97,"conditions":44670,"interventions":44671},"NCT03266159","A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors",[86],"2020-08-19",[2761],[44648,3048],{"trials":44673,"activeCount":97},[],{"trials":44675,"activeCount":97},[],{"trials":44677,"activeCount":97},[],{"intervention":41974,"totalTrials":660,"cells":44679},{"EARLY_PHASE1":44680,"PHASE1":44682,"PHASE2":44684,"PHASE3":44694,"PHASE4":44696,"NA":44698},{"trials":44681,"activeCount":97},[],{"trials":44683,"activeCount":97},[],{"trials":44685,"activeCount":97},[44686,44690],{"nctId":41964,"briefTitle":41965,"status":155,"phases":44687,"primaryCompletion":7445,"completion":7445,"start":41967,"enrollment":41968,"conditions":44688,"interventions":44689},[86],[3637],[4682,4682,10348,41971,41972,23250,41973,41974],{"nctId":41976,"briefTitle":41977,"status":155,"phases":44691,"primaryCompletion":26945,"completion":36623,"start":41979,"enrollment":41980,"conditions":44692,"interventions":44693},[86],[3287],[41983,41984,41985,41974,23250],{"trials":44695,"activeCount":97},[],{"trials":44697,"activeCount":97},[],{"trials":44699,"activeCount":97},[],{"intervention":1665,"totalTrials":660,"cells":44701},{"EARLY_PHASE1":44702,"PHASE1":44704,"PHASE2":44710,"PHASE3":44721,"PHASE4":44723,"NA":44725},{"trials":44703,"activeCount":97},[],{"trials":44705,"activeCount":97},[44706],{"nctId":1657,"briefTitle":1658,"status":155,"phases":44707,"primaryCompletion":1660,"completion":1660,"start":1661,"enrollment":1662,"conditions":44708,"interventions":44709},[85],[107],[1665,137],{"trials":44711,"activeCount":97},[44712],{"nctId":44713,"briefTitle":44714,"status":145,"phases":44715,"primaryCompletion":44716,"completion":44716,"start":44717,"enrollment":255,"conditions":44718,"interventions":44719},"NCT03614728","Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)",[85,86],"2022-01-11","2018-10-16",[107],[1665,44720],"5-Azacitidine",{"trials":44722,"activeCount":97},[],{"trials":44724,"activeCount":97},[],{"trials":44726,"activeCount":97},[],{"intervention":44728,"totalTrials":660,"cells":44729},"GSK716155 subcutaneous injections",{"EARLY_PHASE1":44730,"PHASE1":44732,"PHASE2":44742,"PHASE3":44750,"PHASE4":44752,"NA":44754},{"trials":44731,"activeCount":97},[],{"trials":44733,"activeCount":97},[44734],{"nctId":44735,"briefTitle":44736,"status":155,"phases":44737,"primaryCompletion":39159,"completion":39159,"start":44738,"enrollment":44739,"conditions":44740,"interventions":44741},"NCT00394030","Injection Site Study In Patients With Type 2 Diabetes Mellitus (T2DM) And Healthy Volunteers",[85],"2006-10-16",63,[27],[44728],{"trials":44743,"activeCount":97},[44744],{"nctId":44745,"briefTitle":44746,"status":155,"phases":44747,"primaryCompletion":4757,"completion":4757,"start":11759,"enrollment":1237,"conditions":44748,"interventions":44749},"NCT00354536","In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus",[86],[27],[44728],{"trials":44751,"activeCount":97},[],{"trials":44753,"activeCount":97},[],{"trials":44755,"activeCount":97},[],{"intervention":44757,"totalTrials":660,"cells":44758},"Methotrexate",{"EARLY_PHASE1":44759,"PHASE1":44761,"PHASE2":44763,"PHASE3":44785,"PHASE4":44787,"NA":44789},{"trials":44760,"activeCount":97},[],{"trials":44762,"activeCount":97},[],{"trials":44764,"activeCount":97},[44765,44774],{"nctId":44766,"briefTitle":44767,"status":500,"phases":44768,"primaryCompletion":44769,"completion":44769,"start":44770,"enrollment":97,"conditions":44771,"interventions":44772},"NCT03239600","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)",[86],"2017-10-12","2017-09-19",[39897],[44773,44757],"GSK2618960 2 mg\u002Fkg",{"nctId":44775,"briefTitle":44776,"status":155,"phases":44777,"primaryCompletion":44778,"completion":44778,"start":44779,"enrollment":1117,"conditions":44780,"interventions":44781},"NCT03028467","Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis",[85,86],"2017-12-20","2017-01-24",[8788],[44782,44783,44784,44757,20269],"GSK3196165 Dose 1","GSK3196165 Dose 2","GSK3196165 Dose 3",{"trials":44786,"activeCount":97},[],{"trials":44788,"activeCount":97},[],{"trials":44790,"activeCount":97},[],{"intervention":40722,"totalTrials":660,"cells":44792},{"EARLY_PHASE1":44793,"PHASE1":44795,"PHASE2":44801,"PHASE3":44807,"PHASE4":44809,"NA":44811},{"trials":44794,"activeCount":97},[],{"trials":44796,"activeCount":97},[44797],{"nctId":40716,"briefTitle":40717,"status":500,"phases":44798,"primaryCompletion":7711,"completion":7711,"start":8860,"enrollment":97,"conditions":44799,"interventions":44800},[85],[6484],[40702,40721,40722,40723],{"trials":44802,"activeCount":97},[44803],{"nctId":40737,"briefTitle":40738,"status":155,"phases":44804,"primaryCompletion":40740,"completion":40740,"start":18983,"enrollment":719,"conditions":44805,"interventions":44806},[86],[12727],[40702,40743,40744,40745],{"trials":44808,"activeCount":97},[],{"trials":44810,"activeCount":97},[],{"trials":44812,"activeCount":97},[],{"intervention":23047,"totalTrials":660,"cells":44814},{"EARLY_PHASE1":44815,"PHASE1":44817,"PHASE2":44819,"PHASE3":44836,"PHASE4":44838,"NA":44840},{"trials":44816,"activeCount":97},[],{"trials":44818,"activeCount":97},[],{"trials":44820,"activeCount":97},[44821,44825],{"nctId":23038,"briefTitle":23039,"status":155,"phases":44822,"primaryCompletion":23041,"completion":23042,"start":23043,"enrollment":23044,"conditions":44823,"interventions":44824},[86],[4704,4703],[23047,23036,23016,23034,23035,23048,23049],{"nctId":44826,"briefTitle":44827,"status":155,"phases":44828,"primaryCompletion":10097,"completion":44829,"start":23043,"enrollment":13062,"conditions":44830,"interventions":44831},"NCT00129116","3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococcal Serogroup C Conjugate Vaccine, Each Administered at 2,3,4 Mths of Age",[86],"2003-12-16",[4704,4703],[23047,44832,44833,44834,44835],"Hib-MenC-TT vaccine","Menjugate ®","Infanrix penta ®","Infanrix hexa ®",{"trials":44837,"activeCount":97},[],{"trials":44839,"activeCount":97},[],{"trials":44841,"activeCount":97},[],{"intervention":44843,"totalTrials":660,"cells":44844},"Carbomer 980",{"EARLY_PHASE1":44845,"PHASE1":44847,"PHASE2":44858,"PHASE3":44869,"PHASE4":44871,"NA":44873},{"trials":44846,"activeCount":97},[],{"trials":44848,"activeCount":97},[44849],{"nctId":44850,"briefTitle":44851,"status":155,"phases":44852,"primaryCompletion":44853,"completion":44854,"start":44855,"enrollment":255,"conditions":44856,"interventions":44857},"NCT02832362","Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants",[85],"2016-07-10","2016-07-18","2016-06-11",[9183],[44843],{"trials":44859,"activeCount":97},[44860],{"nctId":44861,"briefTitle":44862,"status":155,"phases":44863,"primaryCompletion":44864,"completion":44864,"start":44865,"enrollment":44866,"conditions":44867,"interventions":44868},"NCT03005067","To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold",[86],"2017-06-07","2016-12-29",171,[9183],[44843],{"trials":44870,"activeCount":97},[],{"trials":44872,"activeCount":97},[],{"trials":44874,"activeCount":97},[],{"intervention":23538,"totalTrials":660,"cells":44876},{"EARLY_PHASE1":44877,"PHASE1":44879,"PHASE2":44881,"PHASE3":44891,"PHASE4":44893,"NA":44895},{"trials":44878,"activeCount":97},[],{"trials":44880,"activeCount":97},[],{"trials":44882,"activeCount":97},[44883,44887],{"nctId":23533,"briefTitle":23534,"status":155,"phases":44884,"primaryCompletion":4843,"completion":4843,"start":7613,"enrollment":9569,"conditions":44885,"interventions":44886},[86],[3717,2484,2486,2485],[23524,23538],{"nctId":23540,"briefTitle":23534,"status":155,"phases":44888,"completion":4843,"start":4844,"enrollment":4388,"conditions":44889,"interventions":44890},[86],[2485,2484,2486,3717],[23524,23538],{"trials":44892,"activeCount":97},[],{"trials":44894,"activeCount":97},[],{"trials":44896,"activeCount":97},[],{"intervention":22073,"totalTrials":660,"cells":44898},{"EARLY_PHASE1":44899,"PHASE1":44901,"PHASE2":44903,"PHASE3":44913,"PHASE4":44915,"NA":44917},{"trials":44900,"activeCount":97},[],{"trials":44902,"activeCount":97},[],{"trials":44904,"activeCount":97},[44905,44909],{"nctId":22067,"briefTitle":22068,"status":155,"phases":44906,"primaryCompletion":16911,"completion":22070,"start":12065,"enrollment":8493,"conditions":44907,"interventions":44908},[86],[22060],[22047,22073,22074],{"nctId":22076,"briefTitle":22077,"status":155,"phases":44910,"primaryCompletion":22079,"completion":22080,"start":22081,"enrollment":14391,"conditions":44911,"interventions":44912},[86],[21691],[22047,22073,22074],{"trials":44914,"activeCount":97},[],{"trials":44916,"activeCount":97},[],{"trials":44918,"activeCount":97},[],{"intervention":44920,"totalTrials":660,"cells":44921},"GSK716155",{"EARLY_PHASE1":44922,"PHASE1":44924,"PHASE2":44933,"PHASE3":44941,"PHASE4":44943,"NA":44945},{"trials":44923,"activeCount":97},[],{"trials":44925,"activeCount":97},[44926],{"nctId":44927,"briefTitle":44928,"status":155,"phases":44929,"primaryCompletion":42571,"completion":42571,"start":44930,"enrollment":1736,"conditions":44931,"interventions":44932},"NCT00537719","Scintigraphy Study to Assess Gastric Emptying in Healthy Subjects Given GSK716155 or Placebo.",[85],"2007-12-07",[27],[44920],{"trials":44934,"activeCount":97},[44935],{"nctId":44936,"briefTitle":44937,"status":155,"phases":44938,"primaryCompletion":7530,"completion":7530,"start":8346,"enrollment":11953,"conditions":44939,"interventions":44940},"NCT01357850","A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II\u002FIII Congestive Heart Failure",[86],[17253],[44920],{"trials":44942,"activeCount":97},[],{"trials":44944,"activeCount":97},[],{"trials":44946,"activeCount":97},[],{"intervention":44948,"totalTrials":660,"cells":44949},"Nanomilled testosterone",{"EARLY_PHASE1":44950,"PHASE1":44952,"PHASE2":44964,"PHASE3":44972,"PHASE4":44974,"NA":44976},{"trials":44951,"activeCount":97},[],{"trials":44953,"activeCount":97},[44954],{"nctId":44955,"briefTitle":44956,"status":155,"phases":44957,"start":2404,"enrollment":1237,"conditions":44958,"interventions":44961},"NCT00400335","Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride",[85],[44959,44960],"Hypogonadism","Hypogonadism, Male",[44948,44962,44963],"commercially available dutasteride","Nanomilled dutasteride",{"trials":44965,"activeCount":97},[44966],{"nctId":44967,"briefTitle":44968,"status":155,"phases":44969,"primaryCompletion":8426,"completion":8426,"start":2404,"enrollment":9382,"conditions":44970,"interventions":44971},"NCT00398580","28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men",[86],[44959,44960],[44948,44963,44962],{"trials":44973,"activeCount":97},[],{"trials":44975,"activeCount":97},[],{"trials":44977,"activeCount":97},[],{"intervention":44963,"totalTrials":660,"cells":44979},{"EARLY_PHASE1":44980,"PHASE1":44982,"PHASE2":44988,"PHASE3":44994,"PHASE4":44996,"NA":44998},{"trials":44981,"activeCount":97},[],{"trials":44983,"activeCount":97},[44984],{"nctId":44955,"briefTitle":44956,"status":155,"phases":44985,"start":2404,"enrollment":1237,"conditions":44986,"interventions":44987},[85],[44959,44960],[44948,44962,44963],{"trials":44989,"activeCount":97},[44990],{"nctId":44967,"briefTitle":44968,"status":155,"phases":44991,"primaryCompletion":8426,"completion":8426,"start":2404,"enrollment":9382,"conditions":44992,"interventions":44993},[86],[44959,44960],[44948,44963,44962],{"trials":44995,"activeCount":97},[],{"trials":44997,"activeCount":97},[],{"trials":44999,"activeCount":97},[],{"intervention":44962,"totalTrials":660,"cells":45001},{"EARLY_PHASE1":45002,"PHASE1":45004,"PHASE2":45010,"PHASE3":45016,"PHASE4":45018,"NA":45020},{"trials":45003,"activeCount":97},[],{"trials":45005,"activeCount":97},[45006],{"nctId":44955,"briefTitle":44956,"status":155,"phases":45007,"start":2404,"enrollment":1237,"conditions":45008,"interventions":45009},[85],[44959,44960],[44948,44962,44963],{"trials":45011,"activeCount":97},[45012],{"nctId":44967,"briefTitle":44968,"status":155,"phases":45013,"primaryCompletion":8426,"completion":8426,"start":2404,"enrollment":9382,"conditions":45014,"interventions":45015},[86],[44959,44960],[44948,44963,44962],{"trials":45017,"activeCount":97},[],{"trials":45019,"activeCount":97},[],{"trials":45021,"activeCount":97},[],{"intervention":45023,"totalTrials":660,"cells":45024},"RSV vaccine (GSK3003891A) formulation 1",{"EARLY_PHASE1":45025,"PHASE1":45027,"PHASE2":45029,"PHASE3":45053,"PHASE4":45055,"NA":45057},{"trials":45026,"activeCount":97},[],{"trials":45028,"activeCount":97},[],{"trials":45030,"activeCount":97},[45031,45041],{"nctId":45032,"briefTitle":45033,"status":500,"phases":45034,"primaryCompletion":45035,"completion":45035,"start":45036,"enrollment":97,"conditions":45037,"interventions":45038},"NCT03191383","A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers",[86],"2017-07-14","2017-07-11",[2620],[45023,45039,45040],"RSV vaccine (GSK3003891A) formulation 2","RSV vaccine (GSK3003891A) formulation 3",{"nctId":45042,"briefTitle":45043,"status":155,"phases":45044,"primaryCompletion":45045,"completion":45046,"start":45047,"enrollment":23959,"conditions":45048,"interventions":45049},"NCT02956837","A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women",[86],"2017-08-30","2018-02-05","2016-11-10",[2620],[45050,45051,45052],"RSV Vaccine (GSK3003891A) formulation 1","RSV Vaccine (GSK3003891A) formulation 2","RSV Vaccine (GSK3003891A) formulation 3",{"trials":45054,"activeCount":97},[],{"trials":45056,"activeCount":97},[],{"trials":45058,"activeCount":97},[],{"intervention":45039,"totalTrials":660,"cells":45060},{"EARLY_PHASE1":45061,"PHASE1":45063,"PHASE2":45065,"PHASE3":45075,"PHASE4":45077,"NA":45079},{"trials":45062,"activeCount":97},[],{"trials":45064,"activeCount":97},[],{"trials":45066,"activeCount":97},[45067,45071],{"nctId":45032,"briefTitle":45033,"status":500,"phases":45068,"primaryCompletion":45035,"completion":45035,"start":45036,"enrollment":97,"conditions":45069,"interventions":45070},[86],[2620],[45023,45039,45040],{"nctId":45042,"briefTitle":45043,"status":155,"phases":45072,"primaryCompletion":45045,"completion":45046,"start":45047,"enrollment":23959,"conditions":45073,"interventions":45074},[86],[2620],[45050,45051,45052],{"trials":45076,"activeCount":97},[],{"trials":45078,"activeCount":97},[],{"trials":45080,"activeCount":97},[],{"intervention":45040,"totalTrials":660,"cells":45082},{"EARLY_PHASE1":45083,"PHASE1":45085,"PHASE2":45087,"PHASE3":45097,"PHASE4":45099,"NA":45101},{"trials":45084,"activeCount":97},[],{"trials":45086,"activeCount":97},[],{"trials":45088,"activeCount":97},[45089,45093],{"nctId":45032,"briefTitle":45033,"status":500,"phases":45090,"primaryCompletion":45035,"completion":45035,"start":45036,"enrollment":97,"conditions":45091,"interventions":45092},[86],[2620],[45023,45039,45040],{"nctId":45042,"briefTitle":45043,"status":155,"phases":45094,"primaryCompletion":45045,"completion":45046,"start":45047,"enrollment":23959,"conditions":45095,"interventions":45096},[86],[2620],[45050,45051,45052],{"trials":45098,"activeCount":97},[],{"trials":45100,"activeCount":97},[],{"trials":45102,"activeCount":97},[],{"intervention":45104,"totalTrials":660,"cells":45105},"GW870086 0.2%",{"EARLY_PHASE1":45106,"PHASE1":45108,"PHASE2":45118,"PHASE3":45128,"PHASE4":45130,"NA":45132},{"trials":45107,"activeCount":97},[],{"trials":45109,"activeCount":97},[45110],{"nctId":45111,"briefTitle":45112,"status":155,"phases":45113,"primaryCompletion":9812,"completion":9812,"start":11851,"enrollment":454,"conditions":45114,"interventions":45115},"NCT01381445","A Study Assessing GW870086's Potential to Cause Skin Thinning",[85],[21691],[45104,45116,45117],"GW870086 2%","Clobetasol Propionate",{"trials":45119,"activeCount":97},[45120],{"nctId":45121,"briefTitle":45122,"status":155,"phases":45123,"primaryCompletion":18536,"completion":11851,"start":22592,"enrollment":463,"conditions":45124,"interventions":45125},"NCT01299610","A Study to Test the Effect of 2 Different Doses of Topical GW870086X on Atopic Dermatitis Also Including a Postive Control and a Placebo",[86],[21691],[45126,45104,45127],"GW870086 2.0%","FP 0.05%",{"trials":45129,"activeCount":97},[],{"trials":45131,"activeCount":97},[],{"trials":45133,"activeCount":97},[],{"intervention":20269,"totalTrials":660,"cells":45135},{"EARLY_PHASE1":45136,"PHASE1":45138,"PHASE2":45140,"PHASE3":45150,"PHASE4":45152,"NA":45154},{"trials":45137,"activeCount":97},[],{"trials":45139,"activeCount":97},[],{"trials":45141,"activeCount":97},[45142,45146],{"nctId":44775,"briefTitle":44776,"status":155,"phases":45143,"primaryCompletion":44778,"completion":44778,"start":44779,"enrollment":1117,"conditions":45144,"interventions":45145},[85,86],[8788],[44782,44783,44784,44757,20269],{"nctId":20261,"briefTitle":20262,"status":155,"phases":45147,"primaryCompletion":20264,"completion":20265,"start":20266,"enrollment":17527,"conditions":45148,"interventions":45149},[86],[8788],[20235,20251,20269],{"trials":45151,"activeCount":97},[],{"trials":45153,"activeCount":97},[],{"trials":45155,"activeCount":97},[],{"intervention":45157,"totalTrials":660,"cells":45158},"SB656933",{"EARLY_PHASE1":45159,"PHASE1":45161,"PHASE2":45170,"PHASE3":45178,"PHASE4":45180,"NA":45182},{"trials":45160,"activeCount":97},[],{"trials":45162,"activeCount":97},[45163],{"nctId":45164,"briefTitle":45165,"status":155,"phases":45166,"primaryCompletion":8468,"completion":8468,"start":9737,"enrollment":1165,"conditions":45167,"interventions":45169},"NCT00605761","SD Cystic Fibrosis Study",[85],[45168],"Cystic Fibrosis",[45157,45157],{"trials":45171,"activeCount":97},[45172],{"nctId":45173,"briefTitle":45174,"status":155,"phases":45175,"primaryCompletion":9890,"completion":9890,"start":37358,"enrollment":43938,"conditions":45176,"interventions":45177},"NCT00903201","28 Day Repeat Dose in Cystic Fibrosis Patients",[86],[45168],[45157,45157],{"trials":45179,"activeCount":97},[],{"trials":45181,"activeCount":97},[],{"trials":45183,"activeCount":97},[],{"intervention":45185,"totalTrials":660,"cells":45186},"GSK557296",{"EARLY_PHASE1":45187,"PHASE1":45189,"PHASE2":45198,"PHASE3":45208,"PHASE4":45210,"NA":45212},{"trials":45188,"activeCount":97},[],{"trials":45190,"activeCount":97},[45191],{"nctId":45192,"briefTitle":45193,"status":155,"phases":45194,"start":8426,"enrollment":656,"conditions":45195,"interventions":45197},"NCT00549211","A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.",[85],[22921,45196],"Premature Ejaculation",[45185],{"trials":45199,"activeCount":97},[45200],{"nctId":45201,"briefTitle":45202,"status":155,"phases":45203,"primaryCompletion":45204,"completion":45204,"start":45205,"enrollment":624,"conditions":45206,"interventions":45207},"NCT01021553","A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation",[86],"2011-05-05","2009-12-23",[45196],[45185,45185],{"trials":45209,"activeCount":97},[],{"trials":45211,"activeCount":97},[],{"trials":45213,"activeCount":97},[],{"intervention":4497,"totalTrials":660,"cells":45215},{"EARLY_PHASE1":45216,"PHASE1":45218,"PHASE2":45224,"PHASE3":45230,"PHASE4":45232,"NA":45234},{"trials":45217,"activeCount":97},[],{"trials":45219,"activeCount":97},[45220],{"nctId":42815,"briefTitle":42816,"status":155,"phases":45221,"primaryCompletion":42818,"completion":42818,"start":42819,"enrollment":4891,"conditions":45222,"interventions":45223},[85],[4468],[42822,4497,4496,4495,42823,42824,42825,42794,42826],{"trials":45225,"activeCount":97},[45226],{"nctId":4489,"briefTitle":4490,"status":155,"phases":45227,"primaryCompletion":4492,"completion":4492,"start":3320,"enrollment":1196,"conditions":45228,"interventions":45229},[86],[4468],[4495,4496,4497,4452,4472,4498],{"trials":45231,"activeCount":97},[],{"trials":45233,"activeCount":97},[],{"trials":45235,"activeCount":97},[],{"intervention":4496,"totalTrials":660,"cells":45237},{"EARLY_PHASE1":45238,"PHASE1":45240,"PHASE2":45246,"PHASE3":45252,"PHASE4":45254,"NA":45256},{"trials":45239,"activeCount":97},[],{"trials":45241,"activeCount":97},[45242],{"nctId":42815,"briefTitle":42816,"status":155,"phases":45243,"primaryCompletion":42818,"completion":42818,"start":42819,"enrollment":4891,"conditions":45244,"interventions":45245},[85],[4468],[42822,4497,4496,4495,42823,42824,42825,42794,42826],{"trials":45247,"activeCount":97},[45248],{"nctId":4489,"briefTitle":4490,"status":155,"phases":45249,"primaryCompletion":4492,"completion":4492,"start":3320,"enrollment":1196,"conditions":45250,"interventions":45251},[86],[4468],[4495,4496,4497,4452,4472,4498],{"trials":45253,"activeCount":97},[],{"trials":45255,"activeCount":97},[],{"trials":45257,"activeCount":97},[],{"intervention":4495,"totalTrials":660,"cells":45259},{"EARLY_PHASE1":45260,"PHASE1":45262,"PHASE2":45268,"PHASE3":45274,"PHASE4":45276,"NA":45278},{"trials":45261,"activeCount":97},[],{"trials":45263,"activeCount":97},[45264],{"nctId":42815,"briefTitle":42816,"status":155,"phases":45265,"primaryCompletion":42818,"completion":42818,"start":42819,"enrollment":4891,"conditions":45266,"interventions":45267},[85],[4468],[42822,4497,4496,4495,42823,42824,42825,42794,42826],{"trials":45269,"activeCount":97},[45270],{"nctId":4489,"briefTitle":4490,"status":155,"phases":45271,"primaryCompletion":4492,"completion":4492,"start":3320,"enrollment":1196,"conditions":45272,"interventions":45273},[86],[4468],[4495,4496,4497,4452,4472,4498],{"trials":45275,"activeCount":97},[],{"trials":45277,"activeCount":97},[],{"trials":45279,"activeCount":97},[],{"intervention":42823,"totalTrials":660,"cells":45281},{"EARLY_PHASE1":45282,"PHASE1":45284,"PHASE2":45290,"PHASE3":45296,"PHASE4":45298,"NA":45300},{"trials":45283,"activeCount":97},[],{"trials":45285,"activeCount":97},[45286],{"nctId":42815,"briefTitle":42816,"status":155,"phases":45287,"primaryCompletion":42818,"completion":42818,"start":42819,"enrollment":4891,"conditions":45288,"interventions":45289},[85],[4468],[42822,4497,4496,4495,42823,42824,42825,42794,42826],{"trials":45291,"activeCount":97},[45292],{"nctId":42830,"briefTitle":42831,"status":155,"phases":45293,"primaryCompletion":443,"completion":42833,"start":11903,"enrollment":42834,"conditions":45294,"interventions":45295},[85,86],[4481],[42837,42838,42839,42840,42841,42842,42823,42824,42794],{"trials":45297,"activeCount":97},[],{"trials":45299,"activeCount":97},[],{"trials":45301,"activeCount":97},[],{"intervention":42824,"totalTrials":660,"cells":45303},{"EARLY_PHASE1":45304,"PHASE1":45306,"PHASE2":45312,"PHASE3":45318,"PHASE4":45320,"NA":45322},{"trials":45305,"activeCount":97},[],{"trials":45307,"activeCount":97},[45308],{"nctId":42815,"briefTitle":42816,"status":155,"phases":45309,"primaryCompletion":42818,"completion":42818,"start":42819,"enrollment":4891,"conditions":45310,"interventions":45311},[85],[4468],[42822,4497,4496,4495,42823,42824,42825,42794,42826],{"trials":45313,"activeCount":97},[45314],{"nctId":42830,"briefTitle":42831,"status":155,"phases":45315,"primaryCompletion":443,"completion":42833,"start":11903,"enrollment":42834,"conditions":45316,"interventions":45317},[85,86],[4481],[42837,42838,42839,42840,42841,42842,42823,42824,42794],{"trials":45319,"activeCount":97},[],{"trials":45321,"activeCount":97},[],{"trials":45323,"activeCount":97},[],{"intervention":45325,"totalTrials":660,"cells":45326},"adjuvanted influenza vaccine",{"EARLY_PHASE1":45327,"PHASE1":45329,"PHASE2":45331,"PHASE3":45347,"PHASE4":45349,"NA":45351},{"trials":45328,"activeCount":97},[],{"trials":45330,"activeCount":97},[],{"trials":45332,"activeCount":97},[45333,45341],{"nctId":45334,"briefTitle":45335,"status":155,"phases":45336,"completion":24105,"start":45337,"enrollment":45338,"conditions":45339,"interventions":45340},"NCT00377585","Demonstrate the Superiority of the Immune Response of Adjuvanted Influenza Vaccine Induced in an Adult Population",[86],"2006-09-22",3350,[21],[25702,45325],{"nctId":45342,"briefTitle":45343,"status":155,"phases":45344,"completion":7659,"start":2404,"enrollment":1196,"conditions":45345,"interventions":45346},"NCT00386698","Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly Adults",[86],[21],[25702,45325],{"trials":45348,"activeCount":97},[],{"trials":45350,"activeCount":97},[],{"trials":45352,"activeCount":97},[],{"intervention":4726,"totalTrials":660,"cells":45354},{"EARLY_PHASE1":45355,"PHASE1":45357,"PHASE2":45359,"PHASE3":45369,"PHASE4":45371,"NA":45373},{"trials":45356,"activeCount":97},[],{"trials":45358,"activeCount":97},[],{"trials":45360,"activeCount":97},[45361,45365],{"nctId":19198,"briefTitle":19199,"status":155,"phases":45362,"primaryCompletion":19201,"completion":19201,"start":5268,"enrollment":19202,"conditions":45363,"interventions":45364},[86],[33,4702,24,4704,3624,30],[19151,19187,4726],{"nctId":4718,"briefTitle":4719,"status":155,"phases":45366,"primaryCompletion":4721,"completion":4721,"start":4722,"enrollment":4723,"conditions":45367,"interventions":45368},[86],[3624,24,4704,33,30,4702],[4472,4485,4726],{"trials":45370,"activeCount":97},[],{"trials":45372,"activeCount":97},[],{"trials":45374,"activeCount":97},[],{"intervention":8846,"totalTrials":660,"cells":45376},{"EARLY_PHASE1":45377,"PHASE1":45379,"PHASE2":45381,"PHASE3":45394,"PHASE4":45396,"NA":45398},{"trials":45378,"activeCount":97},[],{"trials":45380,"activeCount":97},[],{"trials":45382,"activeCount":97},[45383,45390],{"nctId":45384,"briefTitle":45385,"status":155,"phases":45386,"primaryCompletion":2882,"completion":2882,"start":484,"enrollment":1517,"conditions":45387,"interventions":45389},"NCT01808326","A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia",[86],[45388],"Leukaemia, Lymphoblastic",[8846],{"nctId":8841,"briefTitle":8842,"status":155,"phases":45391,"primaryCompletion":2882,"completion":2882,"start":3389,"enrollment":750,"conditions":45392,"interventions":45393},[86],[5198],[8846,8847],{"trials":45395,"activeCount":97},[],{"trials":45397,"activeCount":97},[],{"trials":45399,"activeCount":97},[],{"intervention":41377,"totalTrials":660,"cells":45401},{"EARLY_PHASE1":45402,"PHASE1":45404,"PHASE2":45410,"PHASE3":45416,"PHASE4":45418,"NA":45420},{"trials":45403,"activeCount":97},[],{"trials":45405,"activeCount":97},[45406],{"nctId":41371,"briefTitle":41372,"status":155,"phases":45407,"primaryCompletion":41374,"completion":41374,"start":39708,"enrollment":695,"conditions":45408,"interventions":45409},[85],[18],[23669,41377,41354],{"trials":45411,"activeCount":97},[45412],{"nctId":41387,"briefTitle":41388,"status":155,"phases":45413,"primaryCompletion":41390,"completion":41390,"start":40993,"enrollment":11508,"conditions":45414,"interventions":45415},[86],[18],[41393,41354,41394,41395,41377,41396],{"trials":45417,"activeCount":97},[],{"trials":45419,"activeCount":97},[],{"trials":45421,"activeCount":97},[],{"intervention":45423,"totalTrials":660,"cells":45424},"Tafenoquine 300mg",{"EARLY_PHASE1":45425,"PHASE1":45427,"PHASE2":45439,"PHASE3":45454,"PHASE4":45456,"NA":45458},{"trials":45426,"activeCount":97},[],{"trials":45428,"activeCount":97},[45429],{"nctId":45430,"briefTitle":45431,"status":155,"phases":45432,"primaryCompletion":45433,"completion":45433,"start":19218,"enrollment":45434,"conditions":45435,"interventions":45436},"NCT01928914","Tafenoquine Thorough QTc Study in Healthy Subjects",[85],"2012-06-04",260,[3298],[45423,45437,45438,20325],"Tafenoquine 600mg","Tafenoquine 1200mg",{"trials":45440,"activeCount":97},[45441],{"nctId":45442,"briefTitle":45443,"status":155,"phases":45444,"primaryCompletion":45445,"completion":45445,"start":811,"enrollment":45446,"conditions":45447,"interventions":45448},"NCT01376167","Ph 2B\u002F3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse",[86],"2016-11-18",851,[3298],[45449,45450,45451,45452,45423,45437,45453,45449,45450,45423,45453],"Chloroquine 600mg","Chloroquine 300mg","Tafenoquine 50mg","Tafenoquine 100mg","Primaquine 15mg",{"trials":45455,"activeCount":97},[],{"trials":45457,"activeCount":97},[],{"trials":45459,"activeCount":97},[],{"intervention":45437,"totalTrials":660,"cells":45461},{"EARLY_PHASE1":45462,"PHASE1":45464,"PHASE2":45470,"PHASE3":45476,"PHASE4":45478,"NA":45480},{"trials":45463,"activeCount":97},[],{"trials":45465,"activeCount":97},[45466],{"nctId":45430,"briefTitle":45431,"status":155,"phases":45467,"primaryCompletion":45433,"completion":45433,"start":19218,"enrollment":45434,"conditions":45468,"interventions":45469},[85],[3298],[45423,45437,45438,20325],{"trials":45471,"activeCount":97},[45472],{"nctId":45442,"briefTitle":45443,"status":155,"phases":45473,"primaryCompletion":45445,"completion":45445,"start":811,"enrollment":45446,"conditions":45474,"interventions":45475},[86],[3298],[45449,45450,45451,45452,45423,45437,45453,45449,45450,45423,45453],{"trials":45477,"activeCount":97},[],{"trials":45479,"activeCount":97},[],{"trials":45481,"activeCount":97},[],{"intervention":2397,"totalTrials":660,"cells":45483},{"EARLY_PHASE1":45484,"PHASE1":45486,"PHASE2":45492,"PHASE3":45498,"PHASE4":45500,"NA":45502},{"trials":45485,"activeCount":97},[],{"trials":45487,"activeCount":97},[45488],{"nctId":7388,"briefTitle":7389,"status":145,"phases":45489,"primaryCompletion":7391,"completion":7392,"start":7393,"enrollment":7394,"conditions":45490,"interventions":45491},[85],[267],[7397,134,2397],{"trials":45493,"activeCount":97},[45494],{"nctId":2389,"briefTitle":2390,"status":500,"phases":45495,"primaryCompletion":2392,"completion":2393,"start":2394,"enrollment":97,"conditions":45496,"interventions":45497},[86],[668],[2274,2330,164,216,2397],{"trials":45499,"activeCount":97},[],{"trials":45501,"activeCount":97},[],{"trials":45503,"activeCount":97},[],{"intervention":45505,"totalTrials":660,"cells":45506},"GBS Trivalent Vaccine",{"EARLY_PHASE1":45507,"PHASE1":45509,"PHASE2":45511,"PHASE3":45534,"PHASE4":45536,"NA":45538},{"trials":45508,"activeCount":97},[],{"trials":45510,"activeCount":97},[],{"trials":45512,"activeCount":97},[45513,45523],{"nctId":45514,"briefTitle":45515,"status":155,"phases":45516,"primaryCompletion":45517,"completion":45517,"start":45518,"enrollment":526,"conditions":45519,"interventions":45522},"NCT02690181","Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.",[86],"2016-11-02","2016-03-29",[45520,45521],"Bacterial Infection Due to Streptococcus, Group B","Streptococcus Agalactiae",[45505],{"nctId":45524,"briefTitle":45525,"status":155,"phases":45526,"primaryCompletion":45527,"completion":45528,"start":45529,"enrollment":2825,"conditions":45530,"interventions":45532},"NCT02046148","Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women",[86],"2015-12-30","2016-03-26","2014-03-18",[45531,45521],"GBS Disease",[45533],"GBS trivalent vaccine",{"trials":45535,"activeCount":97},[],{"trials":45537,"activeCount":97},[],{"trials":45539,"activeCount":97},[],{"intervention":45541,"totalTrials":660,"cells":45542},"GSK2339345",{"EARLY_PHASE1":45543,"PHASE1":45545,"PHASE2":45555,"PHASE3":45563,"PHASE4":45565,"NA":45567},{"trials":45544,"activeCount":97},[],{"trials":45546,"activeCount":97},[45547],{"nctId":45548,"briefTitle":45549,"status":155,"phases":45550,"primaryCompletion":45551,"completion":45551,"start":22180,"enrollment":3379,"conditions":45552,"interventions":45553},"NCT01494636","The Safety, Tolerability, PK and PD of GSK2339345 in Healthy Subjects",[85],"2012-03-15",[40347],[45541,45541,45554],"Lidocaine",{"trials":45556,"activeCount":97},[45557],{"nctId":45558,"briefTitle":45559,"status":155,"phases":45560,"primaryCompletion":22334,"completion":22334,"start":7701,"enrollment":433,"conditions":45561,"interventions":45562},"NCT01899768","GSK2339345 Hypertussive Challenge Study",[86],[40347],[45541],{"trials":45564,"activeCount":97},[],{"trials":45566,"activeCount":97},[],{"trials":45568,"activeCount":97},[],{"intervention":45570,"totalTrials":417,"cells":45571},"GSK2269557 100 MCG",{"EARLY_PHASE1":45572,"PHASE1":45574,"PHASE2":45576,"PHASE3":45585,"PHASE4":45587,"NA":45589},{"trials":45573,"activeCount":97},[],{"trials":45575,"activeCount":97},[],{"trials":45577,"activeCount":97},[45578],{"nctId":45579,"briefTitle":45580,"status":155,"phases":45581,"primaryCompletion":8696,"completion":8696,"start":3296,"enrollment":6482,"conditions":45582,"interventions":45583},"NCT02130635","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients",[86],[15],[45570,45584],"GSK2269557 500 MCG",{"trials":45586,"activeCount":97},[],{"trials":45588,"activeCount":97},[],{"trials":45590,"activeCount":97},[],{"intervention":45584,"totalTrials":417,"cells":45592},{"EARLY_PHASE1":45593,"PHASE1":45595,"PHASE2":45597,"PHASE3":45603,"PHASE4":45605,"NA":45607},{"trials":45594,"activeCount":97},[],{"trials":45596,"activeCount":97},[],{"trials":45598,"activeCount":97},[45599],{"nctId":45579,"briefTitle":45580,"status":155,"phases":45600,"primaryCompletion":8696,"completion":8696,"start":3296,"enrollment":6482,"conditions":45601,"interventions":45602},[86],[15],[45570,45584],{"trials":45604,"activeCount":97},[],{"trials":45606,"activeCount":97},[],{"trials":45608,"activeCount":97},[],{"intervention":45610,"totalTrials":417,"cells":45611},"GBS Vaccine",{"EARLY_PHASE1":45612,"PHASE1":45614,"PHASE2":45616,"PHASE3":45628,"PHASE4":45630,"NA":45632},{"trials":45613,"activeCount":97},[],{"trials":45615,"activeCount":97},[],{"trials":45617,"activeCount":97},[45618],{"nctId":45619,"briefTitle":45620,"status":155,"phases":45621,"primaryCompletion":45622,"completion":45623,"start":45624,"enrollment":45625,"conditions":45626,"interventions":45627},"NCT02270944","Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine",[86],"2015-04-23","2015-09-22","2014-11-20",1053,[3637,6996],[45610,45610],{"trials":45629,"activeCount":97},[],{"trials":45631,"activeCount":97},[],{"trials":45633,"activeCount":97},[],{"intervention":2303,"totalTrials":417,"cells":45635},{"EARLY_PHASE1":45636,"PHASE1":45638,"PHASE2":45640,"PHASE3":45646,"PHASE4":45648,"NA":45650},{"trials":45637,"activeCount":97},[],{"trials":45639,"activeCount":97},[],{"trials":45641,"activeCount":97},[45642],{"nctId":2292,"briefTitle":2293,"status":155,"phases":45643,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":2297,"conditions":45644,"interventions":45645},[86],[668],[2300,2301,2264,2302,2303,2304],{"trials":45647,"activeCount":97},[],{"trials":45649,"activeCount":97},[],{"trials":45651,"activeCount":97},[],{"intervention":45653,"totalTrials":417,"cells":45654},"cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.",{"EARLY_PHASE1":45655,"PHASE1":45657,"PHASE2":45659,"PHASE3":45667,"PHASE4":45669,"NA":45671},{"trials":45656,"activeCount":97},[],{"trials":45658,"activeCount":97},[],{"trials":45660,"activeCount":97},[45661],{"nctId":45662,"briefTitle":45663,"status":155,"phases":45664,"primaryCompletion":9233,"completion":9233,"start":7918,"enrollment":255,"conditions":45665,"interventions":45666},"NCT01663714","Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.",[86],[4574],[45653],{"trials":45668,"activeCount":97},[],{"trials":45670,"activeCount":97},[],{"trials":45672,"activeCount":97},[],{"intervention":22510,"totalTrials":417,"cells":45674},{"EARLY_PHASE1":45675,"PHASE1":45677,"PHASE2":45679,"PHASE3":45685,"PHASE4":45687,"NA":45689},{"trials":45676,"activeCount":97},[],{"trials":45678,"activeCount":97},[],{"trials":45680,"activeCount":97},[45681],{"nctId":22501,"briefTitle":22502,"status":155,"phases":45682,"primaryCompletion":3228,"completion":3228,"start":22504,"enrollment":22505,"conditions":45683,"interventions":45684},[86],[992],[22508,22509,22510,5103,22511],{"trials":45686,"activeCount":97},[],{"trials":45688,"activeCount":97},[],{"trials":45690,"activeCount":97},[],{"intervention":22511,"totalTrials":417,"cells":45692},{"EARLY_PHASE1":45693,"PHASE1":45695,"PHASE2":45697,"PHASE3":45703,"PHASE4":45705,"NA":45707},{"trials":45694,"activeCount":97},[],{"trials":45696,"activeCount":97},[],{"trials":45698,"activeCount":97},[45699],{"nctId":22501,"briefTitle":22502,"status":155,"phases":45700,"primaryCompletion":3228,"completion":3228,"start":22504,"enrollment":22505,"conditions":45701,"interventions":45702},[86],[992],[22508,22509,22510,5103,22511],{"trials":45704,"activeCount":97},[],{"trials":45706,"activeCount":97},[],{"trials":45708,"activeCount":97},[],{"intervention":45710,"totalTrials":417,"cells":45711},"Firategrast 150 mg",{"EARLY_PHASE1":45712,"PHASE1":45714,"PHASE2":45716,"PHASE3":45725,"PHASE4":45727,"NA":45729},{"trials":45713,"activeCount":97},[],{"trials":45715,"activeCount":97},[],{"trials":45717,"activeCount":97},[45718],{"nctId":45719,"briefTitle":45720,"status":155,"phases":45721,"primaryCompletion":9159,"completion":3391,"start":7659,"enrollment":23431,"conditions":45722,"interventions":45723},"NCT00395317","Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)",[86],[39962],[45710,45724],"Firategrast 300 mg",{"trials":45726,"activeCount":97},[],{"trials":45728,"activeCount":97},[],{"trials":45730,"activeCount":97},[],{"intervention":45724,"totalTrials":417,"cells":45732},{"EARLY_PHASE1":45733,"PHASE1":45735,"PHASE2":45737,"PHASE3":45743,"PHASE4":45745,"NA":45747},{"trials":45734,"activeCount":97},[],{"trials":45736,"activeCount":97},[],{"trials":45738,"activeCount":97},[45739],{"nctId":45719,"briefTitle":45720,"status":155,"phases":45740,"primaryCompletion":9159,"completion":3391,"start":7659,"enrollment":23431,"conditions":45741,"interventions":45742},[86],[39962],[45710,45724],{"trials":45744,"activeCount":97},[],{"trials":45746,"activeCount":97},[],{"trials":45748,"activeCount":97},[],{"intervention":5080,"totalTrials":417,"cells":45750},{"EARLY_PHASE1":45751,"PHASE1":45753,"PHASE2":45755,"PHASE3":45761,"PHASE4":45763,"NA":45765},{"trials":45752,"activeCount":97},[],{"trials":45754,"activeCount":97},[],{"trials":45756,"activeCount":97},[45757],{"nctId":5073,"briefTitle":5074,"status":155,"phases":45758,"primaryCompletion":5076,"completion":5076,"start":5077,"enrollment":1307,"conditions":45759,"interventions":45760},[86],[1005],[5064,5080,5081],{"trials":45762,"activeCount":97},[],{"trials":45764,"activeCount":97},[],{"trials":45766,"activeCount":97},[],{"intervention":5081,"totalTrials":417,"cells":45768},{"EARLY_PHASE1":45769,"PHASE1":45771,"PHASE2":45773,"PHASE3":45779,"PHASE4":45781,"NA":45783},{"trials":45770,"activeCount":97},[],{"trials":45772,"activeCount":97},[],{"trials":45774,"activeCount":97},[45775],{"nctId":5073,"briefTitle":5074,"status":155,"phases":45776,"primaryCompletion":5076,"completion":5076,"start":5077,"enrollment":1307,"conditions":45777,"interventions":45778},[86],[1005],[5064,5080,5081],{"trials":45780,"activeCount":97},[],{"trials":45782,"activeCount":97},[],{"trials":45784,"activeCount":97},[],{"intervention":21347,"totalTrials":417,"cells":45786},{"EARLY_PHASE1":45787,"PHASE1":45789,"PHASE2":45791,"PHASE3":45797,"PHASE4":45799,"NA":45801},{"trials":45788,"activeCount":97},[],{"trials":45790,"activeCount":97},[],{"trials":45792,"activeCount":97},[45793],{"nctId":21338,"briefTitle":21339,"status":155,"phases":45794,"primaryCompletion":21341,"completion":21341,"start":21342,"enrollment":13062,"conditions":45795,"interventions":45796},[86],[6371,21344,21345],[21347,8676,11175],{"trials":45798,"activeCount":97},[],{"trials":45800,"activeCount":97},[],{"trials":45802,"activeCount":97},[],{"intervention":2314,"totalTrials":417,"cells":45804},{"EARLY_PHASE1":45805,"PHASE1":45807,"PHASE2":45809,"PHASE3":45815,"PHASE4":45817,"NA":45819},{"trials":45806,"activeCount":97},[],{"trials":45808,"activeCount":97},[],{"trials":45810,"activeCount":97},[45811],{"nctId":2306,"briefTitle":2307,"status":155,"phases":45812,"primaryCompletion":2309,"completion":2310,"start":2311,"enrollment":93,"conditions":45813,"interventions":45814},[85,86],[107],[162,2314,164,216,139],{"trials":45816,"activeCount":97},[],{"trials":45818,"activeCount":97},[],{"trials":45820,"activeCount":97},[],{"intervention":45822,"totalTrials":417,"cells":45823},"Part 1; Cohort 1",{"EARLY_PHASE1":45824,"PHASE1":45826,"PHASE2":45828,"PHASE3":45839,"PHASE4":45841,"NA":45843},{"trials":45825,"activeCount":97},[],{"trials":45827,"activeCount":97},[],{"trials":45829,"activeCount":97},[45830],{"nctId":45831,"briefTitle":45832,"status":500,"phases":45833,"primaryCompletion":8135,"completion":8135,"start":8135,"enrollment":97,"conditions":45834,"interventions":45835},"NCT01445587","A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma",[86],[36],[45822,45836,45837,45838],"Part 1; Cohort 2","Part 2; Stage 1","Part 2, Stage 2",{"trials":45840,"activeCount":97},[],{"trials":45842,"activeCount":97},[],{"trials":45844,"activeCount":97},[],{"intervention":45836,"totalTrials":417,"cells":45846},{"EARLY_PHASE1":45847,"PHASE1":45849,"PHASE2":45851,"PHASE3":45857,"PHASE4":45859,"NA":45861},{"trials":45848,"activeCount":97},[],{"trials":45850,"activeCount":97},[],{"trials":45852,"activeCount":97},[45853],{"nctId":45831,"briefTitle":45832,"status":500,"phases":45854,"primaryCompletion":8135,"completion":8135,"start":8135,"enrollment":97,"conditions":45855,"interventions":45856},[86],[36],[45822,45836,45837,45838],{"trials":45858,"activeCount":97},[],{"trials":45860,"activeCount":97},[],{"trials":45862,"activeCount":97},[],{"intervention":45837,"totalTrials":417,"cells":45864},{"EARLY_PHASE1":45865,"PHASE1":45867,"PHASE2":45869,"PHASE3":45875,"PHASE4":45877,"NA":45879},{"trials":45866,"activeCount":97},[],{"trials":45868,"activeCount":97},[],{"trials":45870,"activeCount":97},[45871],{"nctId":45831,"briefTitle":45832,"status":500,"phases":45872,"primaryCompletion":8135,"completion":8135,"start":8135,"enrollment":97,"conditions":45873,"interventions":45874},[86],[36],[45822,45836,45837,45838],{"trials":45876,"activeCount":97},[],{"trials":45878,"activeCount":97},[],{"trials":45880,"activeCount":97},[],{"intervention":45838,"totalTrials":417,"cells":45882},{"EARLY_PHASE1":45883,"PHASE1":45885,"PHASE2":45887,"PHASE3":45893,"PHASE4":45895,"NA":45897},{"trials":45884,"activeCount":97},[],{"trials":45886,"activeCount":97},[],{"trials":45888,"activeCount":97},[45889],{"nctId":45831,"briefTitle":45832,"status":500,"phases":45890,"primaryCompletion":8135,"completion":8135,"start":8135,"enrollment":97,"conditions":45891,"interventions":45892},[86],[36],[45822,45836,45837,45838],{"trials":45894,"activeCount":97},[],{"trials":45896,"activeCount":97},[],{"trials":45898,"activeCount":97},[],{"intervention":42964,"totalTrials":417,"cells":45900},{"EARLY_PHASE1":45901,"PHASE1":45903,"PHASE2":45905,"PHASE3":45911,"PHASE4":45913,"NA":45915},{"trials":45902,"activeCount":97},[],{"trials":45904,"activeCount":97},[],{"trials":45906,"activeCount":97},[45907],{"nctId":42957,"briefTitle":42958,"status":145,"phases":45908,"primaryCompletion":42960,"completion":42960,"start":42961,"enrollment":37572,"conditions":45909,"interventions":45910},[86],[39624],[42948,42964],{"trials":45912,"activeCount":97},[],{"trials":45914,"activeCount":97},[],{"trials":45916,"activeCount":97},[],{"intervention":45918,"totalTrials":417,"cells":45919},"Investigational Cancer Drug",{"EARLY_PHASE1":45920,"PHASE1":45922,"PHASE2":45924,"PHASE3":45932,"PHASE4":45934,"NA":45936},{"trials":45921,"activeCount":97},[],{"trials":45923,"activeCount":97},[],{"trials":45925,"activeCount":97},[45926],{"nctId":45927,"briefTitle":45928,"status":155,"phases":45929,"primaryCompletion":2796,"completion":2796,"start":13061,"conditions":45930,"interventions":45931},"NCT00051103","Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.",[86],[7575,668],[45918],{"trials":45933,"activeCount":97},[],{"trials":45935,"activeCount":97},[],{"trials":45937,"activeCount":97},[],{"intervention":45939,"totalTrials":417,"cells":45940},"Intravenous GR270773- Phospholipid Emulsion",{"EARLY_PHASE1":45941,"PHASE1":45943,"PHASE2":45945,"PHASE3":45957,"PHASE4":45959,"NA":45961},{"trials":45942,"activeCount":97},[],{"trials":45944,"activeCount":97},[],{"trials":45946,"activeCount":97},[45947],{"nctId":45948,"briefTitle":45949,"status":155,"phases":45950,"primaryCompletion":45951,"completion":45952,"start":45953,"enrollment":45954,"conditions":45955,"interventions":45956},"NCT00089986","GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults",[86],"2007-04-01","2007-04-15","2004-09-01",1415,[40146],[45939],{"trials":45958,"activeCount":97},[],{"trials":45960,"activeCount":97},[],{"trials":45962,"activeCount":97},[],{"intervention":21383,"totalTrials":417,"cells":45964},{"EARLY_PHASE1":45965,"PHASE1":45967,"PHASE2":45969,"PHASE3":45975,"PHASE4":45977,"NA":45979},{"trials":45966,"activeCount":97},[],{"trials":45968,"activeCount":97},[],{"trials":45970,"activeCount":97},[45971],{"nctId":21376,"briefTitle":21377,"status":155,"phases":45972,"primaryCompletion":21379,"completion":21379,"start":8805,"enrollment":5088,"conditions":45973,"interventions":45974},[86],[4704,33,24,10227,30,21381],[21383,21384,21367],{"trials":45976,"activeCount":97},[],{"trials":45978,"activeCount":97},[],{"trials":45980,"activeCount":97},[],{"intervention":21384,"totalTrials":417,"cells":45982},{"EARLY_PHASE1":45983,"PHASE1":45985,"PHASE2":45987,"PHASE3":45993,"PHASE4":45995,"NA":45997},{"trials":45984,"activeCount":97},[],{"trials":45986,"activeCount":97},[],{"trials":45988,"activeCount":97},[45989],{"nctId":21376,"briefTitle":21377,"status":155,"phases":45990,"primaryCompletion":21379,"completion":21379,"start":8805,"enrollment":5088,"conditions":45991,"interventions":45992},[86],[4704,33,24,10227,30,21381],[21383,21384,21367],{"trials":45994,"activeCount":97},[],{"trials":45996,"activeCount":97},[],{"trials":45998,"activeCount":97},[],{"intervention":46000,"totalTrials":417,"cells":46001},"GSK2245035 Nasal Spray Solution",{"EARLY_PHASE1":46002,"PHASE1":46004,"PHASE2":46006,"PHASE3":46017,"PHASE4":46019,"NA":46021},{"trials":46003,"activeCount":97},[],{"trials":46005,"activeCount":97},[],{"trials":46007,"activeCount":97},[46008],{"nctId":46009,"briefTitle":46010,"status":155,"phases":46011,"primaryCompletion":46012,"completion":46013,"start":46014,"enrollment":710,"conditions":46015,"interventions":46016},"NCT02833974","Effect of the GSK2245035 on the Allergen-induced Asthmatic Response",[86],"2018-02-14","2018-05-04","2016-12-05",[18],[46000],{"trials":46018,"activeCount":97},[],{"trials":46020,"activeCount":97},[],{"trials":46022,"activeCount":97},[],{"intervention":46024,"totalTrials":417,"cells":46025},"SB-480848 40 mg",{"EARLY_PHASE1":46026,"PHASE1":46028,"PHASE2":46030,"PHASE3":46039,"PHASE4":46041,"NA":46043},{"trials":46027,"activeCount":97},[],{"trials":46029,"activeCount":97},[],{"trials":46031,"activeCount":97},[46032],{"nctId":46033,"briefTitle":46034,"status":155,"phases":46035,"primaryCompletion":21092,"completion":21092,"start":11599,"enrollment":18079,"conditions":46036,"interventions":46037},"NCT01916720","Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy",[86],[9309],[46024,46038],"SB-480848 80 mg",{"trials":46040,"activeCount":97},[],{"trials":46042,"activeCount":97},[],{"trials":46044,"activeCount":97},[],{"intervention":46038,"totalTrials":417,"cells":46046},{"EARLY_PHASE1":46047,"PHASE1":46049,"PHASE2":46051,"PHASE3":46057,"PHASE4":46059,"NA":46061},{"trials":46048,"activeCount":97},[],{"trials":46050,"activeCount":97},[],{"trials":46052,"activeCount":97},[46053],{"nctId":46033,"briefTitle":46034,"status":155,"phases":46054,"primaryCompletion":21092,"completion":21092,"start":11599,"enrollment":18079,"conditions":46055,"interventions":46056},[86],[9309],[46024,46038],{"trials":46058,"activeCount":97},[],{"trials":46060,"activeCount":97},[],{"trials":46062,"activeCount":97},[],{"intervention":46064,"totalTrials":417,"cells":46065},"Pazopanib 800 mg",{"EARLY_PHASE1":46066,"PHASE1":46068,"PHASE2":46070,"PHASE3":46080,"PHASE4":46082,"NA":46084},{"trials":46067,"activeCount":97},[],{"trials":46069,"activeCount":97},[],{"trials":46071,"activeCount":97},[46072],{"nctId":46073,"briefTitle":46074,"status":500,"phases":46075,"primaryCompletion":46076,"completion":46076,"start":13584,"enrollment":97,"conditions":46077,"interventions":46079},"NCT02367651","Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma",[86],"2018-05",[46078],"Sarcoma, Soft Tissue",[46064],{"trials":46081,"activeCount":97},[],{"trials":46083,"activeCount":97},[],{"trials":46085,"activeCount":97},[],{"intervention":46087,"totalTrials":417,"cells":46088},"Danirixin 15 mg FBE",{"EARLY_PHASE1":46089,"PHASE1":46091,"PHASE2":46093,"PHASE3":46104,"PHASE4":46106,"NA":46108},{"trials":46090,"activeCount":97},[],{"trials":46092,"activeCount":97},[],{"trials":46094,"activeCount":97},[46095],{"nctId":46096,"briefTitle":46097,"status":145,"phases":46098,"primaryCompletion":42238,"completion":42238,"start":46099,"enrollment":750,"conditions":46100,"interventions":46101},"NCT02927431","Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza",[86],"2017-01-19",[9840],[46087,46102,46103],"Danirixin 50 mg FBE","Oseltamivir 75 mg",{"trials":46105,"activeCount":97},[],{"trials":46107,"activeCount":97},[],{"trials":46109,"activeCount":97},[],{"intervention":46102,"totalTrials":417,"cells":46111},{"EARLY_PHASE1":46112,"PHASE1":46114,"PHASE2":46116,"PHASE3":46122,"PHASE4":46124,"NA":46126},{"trials":46113,"activeCount":97},[],{"trials":46115,"activeCount":97},[],{"trials":46117,"activeCount":97},[46118],{"nctId":46096,"briefTitle":46097,"status":145,"phases":46119,"primaryCompletion":42238,"completion":42238,"start":46099,"enrollment":750,"conditions":46120,"interventions":46121},[86],[9840],[46087,46102,46103],{"trials":46123,"activeCount":97},[],{"trials":46125,"activeCount":97},[],{"trials":46127,"activeCount":97},[],{"intervention":46103,"totalTrials":417,"cells":46129},{"EARLY_PHASE1":46130,"PHASE1":46132,"PHASE2":46134,"PHASE3":46140,"PHASE4":46142,"NA":46144},{"trials":46131,"activeCount":97},[],{"trials":46133,"activeCount":97},[],{"trials":46135,"activeCount":97},[46136],{"nctId":46096,"briefTitle":46097,"status":145,"phases":46137,"primaryCompletion":42238,"completion":42238,"start":46099,"enrollment":750,"conditions":46138,"interventions":46139},[86],[9840],[46087,46102,46103],{"trials":46141,"activeCount":97},[],{"trials":46143,"activeCount":97},[],{"trials":46145,"activeCount":97},[],{"intervention":4915,"totalTrials":417,"cells":46147},{"EARLY_PHASE1":46148,"PHASE1":46150,"PHASE2":46152,"PHASE3":46158,"PHASE4":46160,"NA":46162},{"trials":46149,"activeCount":97},[],{"trials":46151,"activeCount":97},[],{"trials":46153,"activeCount":97},[46154],{"nctId":4906,"briefTitle":4907,"status":155,"phases":46155,"primaryCompletion":4909,"completion":4910,"start":4911,"enrollment":4912,"conditions":46156,"interventions":46157},[86],[1005],[4915,4897],{"trials":46159,"activeCount":97},[],{"trials":46161,"activeCount":97},[],{"trials":46163,"activeCount":97},[],{"intervention":1701,"totalTrials":417,"cells":46165},{"EARLY_PHASE1":46166,"PHASE1":46168,"PHASE2":46170,"PHASE3":46176,"PHASE4":46178,"NA":46180},{"trials":46167,"activeCount":97},[],{"trials":46169,"activeCount":97},[],{"trials":46171,"activeCount":97},[46172],{"nctId":1694,"briefTitle":1695,"status":500,"phases":46173,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":97,"conditions":46174,"interventions":46175},[86],[107],[1701,137,1651,1241],{"trials":46177,"activeCount":97},[],{"trials":46179,"activeCount":97},[],{"trials":46181,"activeCount":97},[],{"intervention":46183,"totalTrials":417,"cells":46184},"Rosiglitazone XR (extended release) oral",{"EARLY_PHASE1":46185,"PHASE1":46187,"PHASE2":46189,"PHASE3":46197,"PHASE4":46199,"NA":46201},{"trials":46186,"activeCount":97},[],{"trials":46188,"activeCount":97},[],{"trials":46190,"activeCount":97},[46191],{"nctId":46192,"briefTitle":46193,"status":145,"phases":46194,"primaryCompletion":2428,"completion":2428,"start":1361,"enrollment":1459,"conditions":46195,"interventions":46196},"NCT00334568","Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers Disease",[86],[4644],[46183],{"trials":46198,"activeCount":97},[],{"trials":46200,"activeCount":97},[],{"trials":46202,"activeCount":97},[],{"intervention":46204,"totalTrials":417,"cells":46205},"Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine",{"EARLY_PHASE1":46206,"PHASE1":46208,"PHASE2":46210,"PHASE3":46220,"PHASE4":46222,"NA":46224},{"trials":46207,"activeCount":97},[],{"trials":46209,"activeCount":97},[],{"trials":46211,"activeCount":97},[46212],{"nctId":46213,"briefTitle":46214,"status":155,"phases":46215,"primaryCompletion":46216,"completion":42703,"start":40000,"enrollment":613,"conditions":46217,"interventions":46218},"NCT01366534","Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults",[86],"2012-02-27",[3287],[46204,46219,46219],"GSK Biologicals' malaria vaccine 257049",{"trials":46221,"activeCount":97},[],{"trials":46223,"activeCount":97},[],{"trials":46225,"activeCount":97},[],{"intervention":46219,"totalTrials":417,"cells":46227},{"EARLY_PHASE1":46228,"PHASE1":46230,"PHASE2":46232,"PHASE3":46238,"PHASE4":46240,"NA":46242},{"trials":46229,"activeCount":97},[],{"trials":46231,"activeCount":97},[],{"trials":46233,"activeCount":97},[46234],{"nctId":46213,"briefTitle":46214,"status":155,"phases":46235,"primaryCompletion":46216,"completion":42703,"start":40000,"enrollment":613,"conditions":46236,"interventions":46237},[86],[3287],[46204,46219,46219],{"trials":46239,"activeCount":97},[],{"trials":46241,"activeCount":97},[],{"trials":46243,"activeCount":97},[],{"intervention":24814,"totalTrials":417,"cells":46245},{"EARLY_PHASE1":46246,"PHASE1":46248,"PHASE2":46250,"PHASE3":46256,"PHASE4":46258,"NA":46260},{"trials":46247,"activeCount":97},[],{"trials":46249,"activeCount":97},[],{"trials":46251,"activeCount":97},[46252],{"nctId":24808,"briefTitle":24809,"status":155,"phases":46253,"primaryCompletion":9133,"completion":9133,"start":9737,"enrollment":24811,"conditions":46254,"interventions":46255},[86],[15],[24814,24815,24816,24799,24817],{"trials":46257,"activeCount":97},[],{"trials":46259,"activeCount":97},[],{"trials":46261,"activeCount":97},[],{"intervention":24815,"totalTrials":417,"cells":46263},{"EARLY_PHASE1":46264,"PHASE1":46266,"PHASE2":46268,"PHASE3":46274,"PHASE4":46276,"NA":46278},{"trials":46265,"activeCount":97},[],{"trials":46267,"activeCount":97},[],{"trials":46269,"activeCount":97},[46270],{"nctId":24808,"briefTitle":24809,"status":155,"phases":46271,"primaryCompletion":9133,"completion":9133,"start":9737,"enrollment":24811,"conditions":46272,"interventions":46273},[86],[15],[24814,24815,24816,24799,24817],{"trials":46275,"activeCount":97},[],{"trials":46277,"activeCount":97},[],{"trials":46279,"activeCount":97},[],{"intervention":24816,"totalTrials":417,"cells":46281},{"EARLY_PHASE1":46282,"PHASE1":46284,"PHASE2":46286,"PHASE3":46292,"PHASE4":46294,"NA":46296},{"trials":46283,"activeCount":97},[],{"trials":46285,"activeCount":97},[],{"trials":46287,"activeCount":97},[46288],{"nctId":24808,"briefTitle":24809,"status":155,"phases":46289,"primaryCompletion":9133,"completion":9133,"start":9737,"enrollment":24811,"conditions":46290,"interventions":46291},[86],[15],[24814,24815,24816,24799,24817],{"trials":46293,"activeCount":97},[],{"trials":46295,"activeCount":97},[],{"trials":46297,"activeCount":97},[],{"intervention":24817,"totalTrials":417,"cells":46299},{"EARLY_PHASE1":46300,"PHASE1":46302,"PHASE2":46304,"PHASE3":46310,"PHASE4":46312,"NA":46314},{"trials":46301,"activeCount":97},[],{"trials":46303,"activeCount":97},[],{"trials":46305,"activeCount":97},[46306],{"nctId":24808,"briefTitle":24809,"status":155,"phases":46307,"primaryCompletion":9133,"completion":9133,"start":9737,"enrollment":24811,"conditions":46308,"interventions":46309},[86],[15],[24814,24815,24816,24799,24817],{"trials":46311,"activeCount":97},[],{"trials":46313,"activeCount":97},[],{"trials":46315,"activeCount":97},[],{"intervention":12141,"totalTrials":417,"cells":46317},{"EARLY_PHASE1":46318,"PHASE1":46320,"PHASE2":46322,"PHASE3":46328,"PHASE4":46330,"NA":46332},{"trials":46319,"activeCount":97},[],{"trials":46321,"activeCount":97},[],{"trials":46323,"activeCount":97},[46324],{"nctId":12131,"briefTitle":12132,"status":145,"phases":46325,"primaryCompletion":12134,"completion":12134,"start":12135,"enrollment":12136,"conditions":46326,"interventions":46327},[86],[12138],[12140,12141,12122],{"trials":46329,"activeCount":97},[],{"trials":46331,"activeCount":97},[],{"trials":46333,"activeCount":97},[],{"intervention":46335,"totalTrials":417,"cells":46336},"oral nicotine",{"EARLY_PHASE1":46337,"PHASE1":46339,"PHASE2":46341,"PHASE3":46350,"PHASE4":46352,"NA":46354},{"trials":46338,"activeCount":97},[],{"trials":46340,"activeCount":97},[],{"trials":46342,"activeCount":97},[46343],{"nctId":46344,"briefTitle":46345,"status":155,"phases":46346,"primaryCompletion":7591,"completion":7591,"start":3111,"enrollment":21277,"conditions":46347,"interventions":46349},"NCT01506908","Provoked Craving Assessment",[86],[46348,9675],"Smoking Dependence",[46335],{"trials":46351,"activeCount":97},[],{"trials":46353,"activeCount":97},[],{"trials":46355,"activeCount":97},[],{"intervention":8202,"totalTrials":417,"cells":46357},{"EARLY_PHASE1":46358,"PHASE1":46360,"PHASE2":46362,"PHASE3":46368,"PHASE4":46370,"NA":46372},{"trials":46359,"activeCount":97},[],{"trials":46361,"activeCount":97},[],{"trials":46363,"activeCount":97},[46364],{"nctId":8195,"briefTitle":8196,"status":155,"phases":46365,"primaryCompletion":2373,"completion":8198,"start":8199,"enrollment":1579,"conditions":46366,"interventions":46367},[86],[21],[8202,8177],{"trials":46369,"activeCount":97},[],{"trials":46371,"activeCount":97},[],{"trials":46373,"activeCount":97},[],{"intervention":46375,"totalTrials":417,"cells":46376},"Cervarix vaccine",{"EARLY_PHASE1":46377,"PHASE1":46379,"PHASE2":46381,"PHASE3":46392,"PHASE4":46394,"NA":46396},{"trials":46378,"activeCount":97},[],{"trials":46380,"activeCount":97},[],{"trials":46382,"activeCount":97},[46383],{"nctId":46384,"briefTitle":46385,"status":155,"phases":46386,"primaryCompletion":19786,"completion":46387,"start":46388,"enrollment":12560,"conditions":46389,"interventions":46390},"NCT00309166","Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.",[86],"2007-06-19","2006-04-05",[8723],[46375,46391],"Engerix-B vaccine",{"trials":46393,"activeCount":97},[],{"trials":46395,"activeCount":97},[],{"trials":46397,"activeCount":97},[],{"intervention":46391,"totalTrials":417,"cells":46399},{"EARLY_PHASE1":46400,"PHASE1":46402,"PHASE2":46404,"PHASE3":46410,"PHASE4":46412,"NA":46414},{"trials":46401,"activeCount":97},[],{"trials":46403,"activeCount":97},[],{"trials":46405,"activeCount":97},[46406],{"nctId":46384,"briefTitle":46385,"status":155,"phases":46407,"primaryCompletion":19786,"completion":46387,"start":46388,"enrollment":12560,"conditions":46408,"interventions":46409},[86],[8723],[46375,46391],{"trials":46411,"activeCount":97},[],{"trials":46413,"activeCount":97},[],{"trials":46415,"activeCount":97},[],{"intervention":43206,"totalTrials":417,"cells":46417},{"EARLY_PHASE1":46418,"PHASE1":46420,"PHASE2":46422,"PHASE3":46428,"PHASE4":46430,"NA":46432},{"trials":46419,"activeCount":97},[],{"trials":46421,"activeCount":97},[],{"trials":46423,"activeCount":97},[46424],{"nctId":43200,"briefTitle":43201,"status":155,"phases":46425,"primaryCompletion":11992,"completion":11992,"start":9159,"enrollment":710,"conditions":46426,"interventions":46427},[86],[32730],[43205,43191,43206],{"trials":46429,"activeCount":97},[],{"trials":46431,"activeCount":97},[],{"trials":46433,"activeCount":97},[],{"intervention":46435,"totalTrials":417,"cells":46436},"Herpes Zoster vaccine GSK1437173A Low Dose",{"EARLY_PHASE1":46437,"PHASE1":46439,"PHASE2":46441,"PHASE3":46454,"PHASE4":46456,"NA":46458},{"trials":46438,"activeCount":97},[],{"trials":46440,"activeCount":97},[],{"trials":46442,"activeCount":97},[46443],{"nctId":46444,"briefTitle":46445,"status":155,"phases":46446,"primaryCompletion":8996,"completion":46447,"start":46448,"enrollment":12801,"conditions":46449,"interventions":46450},"NCT00434577","Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects",[86],"2010-07-14","2007-02-14",[1030],[46435,46451,46452,46453],"Herpes Zoster vaccine GSK1437173A Medium Dose","Herpes Zoster vaccine GSK1437173A High Dose","Herpes Zoster vaccine GSK1437173A Modified",{"trials":46455,"activeCount":97},[],{"trials":46457,"activeCount":97},[],{"trials":46459,"activeCount":97},[],{"intervention":46451,"totalTrials":417,"cells":46461},{"EARLY_PHASE1":46462,"PHASE1":46464,"PHASE2":46466,"PHASE3":46472,"PHASE4":46474,"NA":46476},{"trials":46463,"activeCount":97},[],{"trials":46465,"activeCount":97},[],{"trials":46467,"activeCount":97},[46468],{"nctId":46444,"briefTitle":46445,"status":155,"phases":46469,"primaryCompletion":8996,"completion":46447,"start":46448,"enrollment":12801,"conditions":46470,"interventions":46471},[86],[1030],[46435,46451,46452,46453],{"trials":46473,"activeCount":97},[],{"trials":46475,"activeCount":97},[],{"trials":46477,"activeCount":97},[],{"intervention":46452,"totalTrials":417,"cells":46479},{"EARLY_PHASE1":46480,"PHASE1":46482,"PHASE2":46484,"PHASE3":46490,"PHASE4":46492,"NA":46494},{"trials":46481,"activeCount":97},[],{"trials":46483,"activeCount":97},[],{"trials":46485,"activeCount":97},[46486],{"nctId":46444,"briefTitle":46445,"status":155,"phases":46487,"primaryCompletion":8996,"completion":46447,"start":46448,"enrollment":12801,"conditions":46488,"interventions":46489},[86],[1030],[46435,46451,46452,46453],{"trials":46491,"activeCount":97},[],{"trials":46493,"activeCount":97},[],{"trials":46495,"activeCount":97},[],{"intervention":46453,"totalTrials":417,"cells":46497},{"EARLY_PHASE1":46498,"PHASE1":46500,"PHASE2":46502,"PHASE3":46508,"PHASE4":46510,"NA":46512},{"trials":46499,"activeCount":97},[],{"trials":46501,"activeCount":97},[],{"trials":46503,"activeCount":97},[46504],{"nctId":46444,"briefTitle":46445,"status":155,"phases":46505,"primaryCompletion":8996,"completion":46447,"start":46448,"enrollment":12801,"conditions":46506,"interventions":46507},[86],[1030],[46435,46451,46452,46453],{"trials":46509,"activeCount":97},[],{"trials":46511,"activeCount":97},[],{"trials":46513,"activeCount":97},[],{"intervention":41719,"totalTrials":417,"cells":46515},{"EARLY_PHASE1":46516,"PHASE1":46518,"PHASE2":46520,"PHASE3":46526,"PHASE4":46528,"NA":46530},{"trials":46517,"activeCount":97},[],{"trials":46519,"activeCount":97},[],{"trials":46521,"activeCount":97},[46522],{"nctId":41713,"briefTitle":41714,"status":155,"phases":46523,"primaryCompletion":7472,"completion":7472,"start":24337,"enrollment":1335,"conditions":46524,"interventions":46525},[86],[23246],[41697,41718,41719],{"trials":46527,"activeCount":97},[],{"trials":46529,"activeCount":97},[],{"trials":46531,"activeCount":97},[],{"intervention":46533,"totalTrials":417,"cells":46534},"Mepolizumab 100 mg",{"EARLY_PHASE1":46535,"PHASE1":46537,"PHASE2":46539,"PHASE3":46548,"PHASE4":46550,"NA":46552},{"trials":46536,"activeCount":97},[],{"trials":46538,"activeCount":97},[],{"trials":46540,"activeCount":97},[46541],{"nctId":46542,"briefTitle":46543,"status":145,"phases":46544,"primaryCompletion":46545,"completion":46545,"start":8170,"enrollment":1736,"conditions":46546,"interventions":46547},"NCT03055195","Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis",[86],"2017-12-06",[21691],[46533],{"trials":46549,"activeCount":97},[],{"trials":46551,"activeCount":97},[],{"trials":46553,"activeCount":97},[],{"intervention":46555,"totalTrials":417,"cells":46556},"Meningococcal serogroup B vaccine",{"EARLY_PHASE1":46557,"PHASE1":46559,"PHASE2":46561,"PHASE3":46570,"PHASE4":46572,"NA":46574},{"trials":46558,"activeCount":97},[],{"trials":46560,"activeCount":97},[],{"trials":46562,"activeCount":97},[46563],{"nctId":46564,"briefTitle":46565,"status":155,"phases":46566,"primaryCompletion":10886,"completion":10886,"start":46567,"enrollment":22362,"conditions":46568,"interventions":46569},"NCT00137917","Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs",[86],"2002-07",[992],[46555],{"trials":46571,"activeCount":97},[],{"trials":46573,"activeCount":97},[],{"trials":46575,"activeCount":97},[],{"intervention":46577,"totalTrials":417,"cells":46578},"SB-681323 Intravenous 3mg",{"EARLY_PHASE1":46579,"PHASE1":46581,"PHASE2":46583,"PHASE3":46596,"PHASE4":46598,"NA":46600},{"trials":46580,"activeCount":97},[],{"trials":46582,"activeCount":97},[],{"trials":46584,"activeCount":97},[46585],{"nctId":46586,"briefTitle":46587,"status":155,"phases":46588,"primaryCompletion":46589,"completion":46589,"start":46590,"enrollment":624,"conditions":46591,"interventions":46592},"NCT00996840","SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS",[86],"2013-02-09","2009-10-16",[5291],[46577,46593,46594,46595],"SB-681323 Intravenous 7.5 mg","SB-681323 Intravenous 7.5mg","SB-681323 Intravenous 10mg",{"trials":46597,"activeCount":97},[],{"trials":46599,"activeCount":97},[],{"trials":46601,"activeCount":97},[],{"intervention":46593,"totalTrials":417,"cells":46603},{"EARLY_PHASE1":46604,"PHASE1":46606,"PHASE2":46608,"PHASE3":46614,"PHASE4":46616,"NA":46618},{"trials":46605,"activeCount":97},[],{"trials":46607,"activeCount":97},[],{"trials":46609,"activeCount":97},[46610],{"nctId":46586,"briefTitle":46587,"status":155,"phases":46611,"primaryCompletion":46589,"completion":46589,"start":46590,"enrollment":624,"conditions":46612,"interventions":46613},[86],[5291],[46577,46593,46594,46595],{"trials":46615,"activeCount":97},[],{"trials":46617,"activeCount":97},[],{"trials":46619,"activeCount":97},[],{"intervention":46594,"totalTrials":417,"cells":46621},{"EARLY_PHASE1":46622,"PHASE1":46624,"PHASE2":46626,"PHASE3":46632,"PHASE4":46634,"NA":46636},{"trials":46623,"activeCount":97},[],{"trials":46625,"activeCount":97},[],{"trials":46627,"activeCount":97},[46628],{"nctId":46586,"briefTitle":46587,"status":155,"phases":46629,"primaryCompletion":46589,"completion":46589,"start":46590,"enrollment":624,"conditions":46630,"interventions":46631},[86],[5291],[46577,46593,46594,46595],{"trials":46633,"activeCount":97},[],{"trials":46635,"activeCount":97},[],{"trials":46637,"activeCount":97},[],{"intervention":46595,"totalTrials":417,"cells":46639},{"EARLY_PHASE1":46640,"PHASE1":46642,"PHASE2":46644,"PHASE3":46650,"PHASE4":46652,"NA":46654},{"trials":46641,"activeCount":97},[],{"trials":46643,"activeCount":97},[],{"trials":46645,"activeCount":97},[46646],{"nctId":46586,"briefTitle":46587,"status":155,"phases":46647,"primaryCompletion":46589,"completion":46589,"start":46590,"enrollment":624,"conditions":46648,"interventions":46649},[86],[5291],[46577,46593,46594,46595],{"trials":46651,"activeCount":97},[],{"trials":46653,"activeCount":97},[],{"trials":46655,"activeCount":97},[],{"intervention":46657,"totalTrials":417,"cells":46658},"Oral lapatinib tablets or placebo",{"EARLY_PHASE1":46659,"PHASE1":46661,"PHASE2":46663,"PHASE3":46671,"PHASE4":46673,"NA":46675},{"trials":46660,"activeCount":97},[],{"trials":46662,"activeCount":97},[],{"trials":46664,"activeCount":97},[46665],{"nctId":46666,"briefTitle":46667,"status":145,"phases":46668,"primaryCompletion":2795,"completion":1429,"start":2835,"enrollment":2045,"conditions":46669,"interventions":46670},"NCT00447226","Randomized Discontinuation Study of Lapatinib Versus Placebo in Subjects With Documented Tumor Progression After Chemotherapy, or Where no Approved Therapy Exists",[86],[36],[46657],{"trials":46672,"activeCount":97},[],{"trials":46674,"activeCount":97},[],{"trials":46676,"activeCount":97},[],{"intervention":46678,"totalTrials":417,"cells":46679},"Ambrisentan - low dose",{"EARLY_PHASE1":46680,"PHASE1":46682,"PHASE2":46684,"PHASE3":46695,"PHASE4":46697,"NA":46699},{"trials":46681,"activeCount":97},[],{"trials":46683,"activeCount":97},[],{"trials":46685,"activeCount":97},[46686],{"nctId":46687,"briefTitle":46688,"status":145,"phases":46689,"primaryCompletion":46690,"completion":46690,"start":46691,"enrollment":212,"conditions":46692,"interventions":46693},"NCT01332331","Efficacy and Safety of Ambrisentan in Children 8-18yrs",[86],"2013-11-12","2011-01-04",[17209],[46678,46694],"Ambrisentan - high dose",{"trials":46696,"activeCount":97},[],{"trials":46698,"activeCount":97},[],{"trials":46700,"activeCount":97},[],{"intervention":46694,"totalTrials":417,"cells":46702},{"EARLY_PHASE1":46703,"PHASE1":46705,"PHASE2":46707,"PHASE3":46713,"PHASE4":46715,"NA":46717},{"trials":46704,"activeCount":97},[],{"trials":46706,"activeCount":97},[],{"trials":46708,"activeCount":97},[46709],{"nctId":46687,"briefTitle":46688,"status":145,"phases":46710,"primaryCompletion":46690,"completion":46690,"start":46691,"enrollment":212,"conditions":46711,"interventions":46712},[86],[17209],[46678,46694],{"trials":46714,"activeCount":97},[],{"trials":46716,"activeCount":97},[],{"trials":46718,"activeCount":97},[],{"intervention":25035,"totalTrials":417,"cells":46720},{"EARLY_PHASE1":46721,"PHASE1":46723,"PHASE2":46725,"PHASE3":46731,"PHASE4":46733,"NA":46735},{"trials":46722,"activeCount":97},[],{"trials":46724,"activeCount":97},[],{"trials":46726,"activeCount":97},[46727],{"nctId":25028,"briefTitle":25029,"status":155,"phases":46728,"primaryCompletion":25031,"completion":25031,"start":25032,"enrollment":17678,"conditions":46729,"interventions":46730},[86],[15],[24829,25035,25036],{"trials":46732,"activeCount":97},[],{"trials":46734,"activeCount":97},[],{"trials":46736,"activeCount":97},[],{"intervention":25036,"totalTrials":417,"cells":46738},{"EARLY_PHASE1":46739,"PHASE1":46741,"PHASE2":46743,"PHASE3":46749,"PHASE4":46751,"NA":46753},{"trials":46740,"activeCount":97},[],{"trials":46742,"activeCount":97},[],{"trials":46744,"activeCount":97},[46745],{"nctId":25028,"briefTitle":25029,"status":155,"phases":46746,"primaryCompletion":25031,"completion":25031,"start":25032,"enrollment":17678,"conditions":46747,"interventions":46748},[86],[15],[24829,25035,25036],{"trials":46750,"activeCount":97},[],{"trials":46752,"activeCount":97},[],{"trials":46754,"activeCount":97},[],{"intervention":9050,"totalTrials":417,"cells":46756},{"EARLY_PHASE1":46757,"PHASE1":46759,"PHASE2":46761,"PHASE3":46767,"PHASE4":46769,"NA":46771},{"trials":46758,"activeCount":97},[],{"trials":46760,"activeCount":97},[],{"trials":46762,"activeCount":97},[46763],{"nctId":9042,"briefTitle":9043,"status":155,"phases":46764,"primaryCompletion":9045,"completion":9045,"start":9046,"enrollment":8437,"conditions":46765,"interventions":46766},[86],[9048],[9050,9016,9051],{"trials":46768,"activeCount":97},[],{"trials":46770,"activeCount":97},[],{"trials":46772,"activeCount":97},[],{"intervention":46774,"totalTrials":417,"cells":46775},"287615 containing HBsAg with adjuvants",{"EARLY_PHASE1":46776,"PHASE1":46778,"PHASE2":46780,"PHASE3":46789,"PHASE4":46791,"NA":46793},{"trials":46777,"activeCount":97},[],{"trials":46779,"activeCount":97},[],{"trials":46781,"activeCount":97},[46782],{"nctId":46783,"briefTitle":46784,"status":155,"phases":46785,"start":10106,"enrollment":1196,"conditions":46786,"interventions":46788},"NCT00508833","Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615)",[85,86],[46787],"Hepatitis B Disease",[46774],{"trials":46790,"activeCount":97},[],{"trials":46792,"activeCount":97},[],{"trials":46794,"activeCount":97},[],{"intervention":11318,"totalTrials":417,"cells":46796},{"EARLY_PHASE1":46797,"PHASE1":46799,"PHASE2":46801,"PHASE3":46807,"PHASE4":46809,"NA":46811},{"trials":46798,"activeCount":97},[],{"trials":46800,"activeCount":97},[],{"trials":46802,"activeCount":97},[46803],{"nctId":11312,"briefTitle":11313,"status":155,"phases":46804,"primaryCompletion":3390,"completion":3390,"start":11315,"enrollment":603,"conditions":46805,"interventions":46806},[86],[18],[11318,9656],{"trials":46808,"activeCount":97},[],{"trials":46810,"activeCount":97},[],{"trials":46812,"activeCount":97},[],{"intervention":9760,"totalTrials":417,"cells":46814},{"EARLY_PHASE1":46815,"PHASE1":46817,"PHASE2":46819,"PHASE3":46825,"PHASE4":46827,"NA":46829},{"trials":46816,"activeCount":97},[],{"trials":46818,"activeCount":97},[],{"trials":46820,"activeCount":97},[46821],{"nctId":9752,"briefTitle":8251,"status":155,"phases":46822,"primaryCompletion":9754,"completion":9755,"start":9756,"enrollment":9757,"conditions":46823,"interventions":46824},[86],[21],[9760,9743],{"trials":46826,"activeCount":97},[],{"trials":46828,"activeCount":97},[],{"trials":46830,"activeCount":97},[],{"intervention":1367,"totalTrials":417,"cells":46832},{"EARLY_PHASE1":46833,"PHASE1":46835,"PHASE2":46837,"PHASE3":46843,"PHASE4":46845,"NA":46847},{"trials":46834,"activeCount":97},[],{"trials":46836,"activeCount":97},[],{"trials":46838,"activeCount":97},[46839],{"nctId":1357,"briefTitle":1358,"status":155,"phases":46840,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1362,"conditions":46841,"interventions":46842},[86],[1337,1364],[1366,283,1367],{"trials":46844,"activeCount":97},[],{"trials":46846,"activeCount":97},[],{"trials":46848,"activeCount":97},[],{"intervention":46850,"totalTrials":417,"cells":46851},"Fluarix-AS25",{"EARLY_PHASE1":46852,"PHASE1":46854,"PHASE2":46856,"PHASE3":46869,"PHASE4":46871,"NA":46873},{"trials":46853,"activeCount":97},[],{"trials":46855,"activeCount":97},[],{"trials":46857,"activeCount":97},[46858],{"nctId":46859,"briefTitle":46860,"status":155,"phases":46861,"primaryCompletion":46862,"completion":46862,"start":46863,"enrollment":8529,"conditions":46864,"interventions":46865},"NCT00318149","Safety Study of Four Candidate Influenza Vaccines to Prevent Influenza Disease in the Elderly Population",[86],"2006-05-14","2005-10-10",[21],[25702,46850,46866,46867,46868],"Fluarix-AS50","Fluarix-AS01B","Fluarix-AS01E",{"trials":46870,"activeCount":97},[],{"trials":46872,"activeCount":97},[],{"trials":46874,"activeCount":97},[],{"intervention":46866,"totalTrials":417,"cells":46876},{"EARLY_PHASE1":46877,"PHASE1":46879,"PHASE2":46881,"PHASE3":46887,"PHASE4":46889,"NA":46891},{"trials":46878,"activeCount":97},[],{"trials":46880,"activeCount":97},[],{"trials":46882,"activeCount":97},[46883],{"nctId":46859,"briefTitle":46860,"status":155,"phases":46884,"primaryCompletion":46862,"completion":46862,"start":46863,"enrollment":8529,"conditions":46885,"interventions":46886},[86],[21],[25702,46850,46866,46867,46868],{"trials":46888,"activeCount":97},[],{"trials":46890,"activeCount":97},[],{"trials":46892,"activeCount":97},[],{"intervention":46867,"totalTrials":417,"cells":46894},{"EARLY_PHASE1":46895,"PHASE1":46897,"PHASE2":46899,"PHASE3":46905,"PHASE4":46907,"NA":46909},{"trials":46896,"activeCount":97},[],{"trials":46898,"activeCount":97},[],{"trials":46900,"activeCount":97},[46901],{"nctId":46859,"briefTitle":46860,"status":155,"phases":46902,"primaryCompletion":46862,"completion":46862,"start":46863,"enrollment":8529,"conditions":46903,"interventions":46904},[86],[21],[25702,46850,46866,46867,46868],{"trials":46906,"activeCount":97},[],{"trials":46908,"activeCount":97},[],{"trials":46910,"activeCount":97},[],{"intervention":46868,"totalTrials":417,"cells":46912},{"EARLY_PHASE1":46913,"PHASE1":46915,"PHASE2":46917,"PHASE3":46923,"PHASE4":46925,"NA":46927},{"trials":46914,"activeCount":97},[],{"trials":46916,"activeCount":97},[],{"trials":46918,"activeCount":97},[46919],{"nctId":46859,"briefTitle":46860,"status":155,"phases":46920,"primaryCompletion":46862,"completion":46862,"start":46863,"enrollment":8529,"conditions":46921,"interventions":46922},[86],[21],[25702,46850,46866,46867,46868],{"trials":46924,"activeCount":97},[],{"trials":46926,"activeCount":97},[],{"trials":46928,"activeCount":97},[],{"intervention":46930,"totalTrials":417,"cells":46931},"Other: Placebo",{"EARLY_PHASE1":46932,"PHASE1":46934,"PHASE2":46936,"PHASE3":46950,"PHASE4":46952,"NA":46954},{"trials":46933,"activeCount":97},[],{"trials":46935,"activeCount":97},[],{"trials":46937,"activeCount":97},[46938],{"nctId":46939,"briefTitle":46940,"status":155,"phases":46941,"primaryCompletion":46942,"completion":46942,"start":46943,"enrollment":46944,"conditions":46945,"interventions":46947},"NCT00604825","Treatment Of Hot Flashes\u002FFlushes In Postmenopausal Women (WARM Study)",[86],"2008-07-23","2007-07-17",356,[46946],"Menopausal and Female Climacteric States",[46930,46948,46949],"GSK232802","PREMARIN",{"trials":46951,"activeCount":97},[],{"trials":46953,"activeCount":97},[],{"trials":46955,"activeCount":97},[],{"intervention":46948,"totalTrials":417,"cells":46957},{"EARLY_PHASE1":46958,"PHASE1":46960,"PHASE2":46962,"PHASE3":46968,"PHASE4":46970,"NA":46972},{"trials":46959,"activeCount":97},[],{"trials":46961,"activeCount":97},[],{"trials":46963,"activeCount":97},[46964],{"nctId":46939,"briefTitle":46940,"status":155,"phases":46965,"primaryCompletion":46942,"completion":46942,"start":46943,"enrollment":46944,"conditions":46966,"interventions":46967},[86],[46946],[46930,46948,46949],{"trials":46969,"activeCount":97},[],{"trials":46971,"activeCount":97},[],{"trials":46973,"activeCount":97},[],{"intervention":46949,"totalTrials":417,"cells":46975},{"EARLY_PHASE1":46976,"PHASE1":46978,"PHASE2":46980,"PHASE3":46986,"PHASE4":46988,"NA":46990},{"trials":46977,"activeCount":97},[],{"trials":46979,"activeCount":97},[],{"trials":46981,"activeCount":97},[46982],{"nctId":46939,"briefTitle":46940,"status":155,"phases":46983,"primaryCompletion":46942,"completion":46942,"start":46943,"enrollment":46944,"conditions":46984,"interventions":46985},[86],[46946],[46930,46948,46949],{"trials":46987,"activeCount":97},[],{"trials":46989,"activeCount":97},[],{"trials":46991,"activeCount":97},[],{"intervention":46993,"totalTrials":417,"cells":46994},"Sa-5Ag half dose non-adjuvanted",{"EARLY_PHASE1":46995,"PHASE1":46997,"PHASE2":46999,"PHASE3":47013,"PHASE4":47015,"NA":47017},{"trials":46996,"activeCount":97},[],{"trials":46998,"activeCount":97},[],{"trials":47000,"activeCount":97},[47001],{"nctId":47002,"briefTitle":47003,"status":155,"phases":47004,"primaryCompletion":47005,"completion":47005,"start":47006,"enrollment":9118,"conditions":47007,"interventions":47009},"NCT04420221","Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)",[86],"2024-03-12","2022-11-16",[47008],"Infections, Soft Tissue",[46993,47010,47011,47012],"Sa-5Ag full dose non-adjuvanted","Sa-5Ag half dose adjuvanted","Sa-5Ag full dose adjuvanted",{"trials":47014,"activeCount":97},[],{"trials":47016,"activeCount":97},[],{"trials":47018,"activeCount":97},[],{"intervention":47010,"totalTrials":417,"cells":47020},{"EARLY_PHASE1":47021,"PHASE1":47023,"PHASE2":47025,"PHASE3":47031,"PHASE4":47033,"NA":47035},{"trials":47022,"activeCount":97},[],{"trials":47024,"activeCount":97},[],{"trials":47026,"activeCount":97},[47027],{"nctId":47002,"briefTitle":47003,"status":155,"phases":47028,"primaryCompletion":47005,"completion":47005,"start":47006,"enrollment":9118,"conditions":47029,"interventions":47030},[86],[47008],[46993,47010,47011,47012],{"trials":47032,"activeCount":97},[],{"trials":47034,"activeCount":97},[],{"trials":47036,"activeCount":97},[],{"intervention":47011,"totalTrials":417,"cells":47038},{"EARLY_PHASE1":47039,"PHASE1":47041,"PHASE2":47043,"PHASE3":47049,"PHASE4":47051,"NA":47053},{"trials":47040,"activeCount":97},[],{"trials":47042,"activeCount":97},[],{"trials":47044,"activeCount":97},[47045],{"nctId":47002,"briefTitle":47003,"status":155,"phases":47046,"primaryCompletion":47005,"completion":47005,"start":47006,"enrollment":9118,"conditions":47047,"interventions":47048},[86],[47008],[46993,47010,47011,47012],{"trials":47050,"activeCount":97},[],{"trials":47052,"activeCount":97},[],{"trials":47054,"activeCount":97},[],{"intervention":47012,"totalTrials":417,"cells":47056},{"EARLY_PHASE1":47057,"PHASE1":47059,"PHASE2":47061,"PHASE3":47067,"PHASE4":47069,"NA":47071},{"trials":47058,"activeCount":97},[],{"trials":47060,"activeCount":97},[],{"trials":47062,"activeCount":97},[47063],{"nctId":47002,"briefTitle":47003,"status":155,"phases":47064,"primaryCompletion":47005,"completion":47005,"start":47006,"enrollment":9118,"conditions":47065,"interventions":47066},[86],[47008],[46993,47010,47011,47012],{"trials":47068,"activeCount":97},[],{"trials":47070,"activeCount":97},[],{"trials":47072,"activeCount":97},[],{"intervention":47074,"totalTrials":417,"cells":47075},"MenABCWY+OMV vaccine",{"EARLY_PHASE1":47076,"PHASE1":47078,"PHASE2":47080,"PHASE3":47092,"PHASE4":47094,"NA":47096},{"trials":47077,"activeCount":97},[],{"trials":47079,"activeCount":97},[],{"trials":47081,"activeCount":97},[47082],{"nctId":47083,"briefTitle":47084,"status":155,"phases":47085,"primaryCompletion":47086,"completion":47087,"start":47088,"enrollment":47089,"conditions":47090,"interventions":47091},"NCT02451514","A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)",[86],"2015-11-14","2015-12-10","2015-06-30",129,[12803,992],[47074],{"trials":47093,"activeCount":97},[],{"trials":47095,"activeCount":97},[],{"trials":47097,"activeCount":97},[],{"intervention":47099,"totalTrials":417,"cells":47100},"SB218352_15",{"EARLY_PHASE1":47101,"PHASE1":47103,"PHASE2":47105,"PHASE3":47120,"PHASE4":47122,"NA":47124},{"trials":47102,"activeCount":97},[],{"trials":47104,"activeCount":97},[],{"trials":47106,"activeCount":97},[47107],{"nctId":47108,"briefTitle":47109,"status":155,"phases":47110,"primaryCompletion":18740,"completion":18740,"start":47111,"enrollment":18256,"conditions":47112,"interventions":47113},"NCT00306995","Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population",[86],"2005-05-11",[21,8265],[47099,47114,47115,47116,47117,47118,47119],"SB218352_8","SB218352_4","SB218352_2","SB218352_8AL","SB218352_4AL","SB218352_2AL",{"trials":47121,"activeCount":97},[],{"trials":47123,"activeCount":97},[],{"trials":47125,"activeCount":97},[],{"intervention":47114,"totalTrials":417,"cells":47127},{"EARLY_PHASE1":47128,"PHASE1":47130,"PHASE2":47132,"PHASE3":47138,"PHASE4":47140,"NA":47142},{"trials":47129,"activeCount":97},[],{"trials":47131,"activeCount":97},[],{"trials":47133,"activeCount":97},[47134],{"nctId":47108,"briefTitle":47109,"status":155,"phases":47135,"primaryCompletion":18740,"completion":18740,"start":47111,"enrollment":18256,"conditions":47136,"interventions":47137},[86],[21,8265],[47099,47114,47115,47116,47117,47118,47119],{"trials":47139,"activeCount":97},[],{"trials":47141,"activeCount":97},[],{"trials":47143,"activeCount":97},[],{"intervention":47115,"totalTrials":417,"cells":47145},{"EARLY_PHASE1":47146,"PHASE1":47148,"PHASE2":47150,"PHASE3":47156,"PHASE4":47158,"NA":47160},{"trials":47147,"activeCount":97},[],{"trials":47149,"activeCount":97},[],{"trials":47151,"activeCount":97},[47152],{"nctId":47108,"briefTitle":47109,"status":155,"phases":47153,"primaryCompletion":18740,"completion":18740,"start":47111,"enrollment":18256,"conditions":47154,"interventions":47155},[86],[21,8265],[47099,47114,47115,47116,47117,47118,47119],{"trials":47157,"activeCount":97},[],{"trials":47159,"activeCount":97},[],{"trials":47161,"activeCount":97},[],{"intervention":47116,"totalTrials":417,"cells":47163},{"EARLY_PHASE1":47164,"PHASE1":47166,"PHASE2":47168,"PHASE3":47174,"PHASE4":47176,"NA":47178},{"trials":47165,"activeCount":97},[],{"trials":47167,"activeCount":97},[],{"trials":47169,"activeCount":97},[47170],{"nctId":47108,"briefTitle":47109,"status":155,"phases":47171,"primaryCompletion":18740,"completion":18740,"start":47111,"enrollment":18256,"conditions":47172,"interventions":47173},[86],[21,8265],[47099,47114,47115,47116,47117,47118,47119],{"trials":47175,"activeCount":97},[],{"trials":47177,"activeCount":97},[],{"trials":47179,"activeCount":97},[],{"intervention":47117,"totalTrials":417,"cells":47181},{"EARLY_PHASE1":47182,"PHASE1":47184,"PHASE2":47186,"PHASE3":47192,"PHASE4":47194,"NA":47196},{"trials":47183,"activeCount":97},[],{"trials":47185,"activeCount":97},[],{"trials":47187,"activeCount":97},[47188],{"nctId":47108,"briefTitle":47109,"status":155,"phases":47189,"primaryCompletion":18740,"completion":18740,"start":47111,"enrollment":18256,"conditions":47190,"interventions":47191},[86],[21,8265],[47099,47114,47115,47116,47117,47118,47119],{"trials":47193,"activeCount":97},[],{"trials":47195,"activeCount":97},[],{"trials":47197,"activeCount":97},[],{"intervention":47118,"totalTrials":417,"cells":47199},{"EARLY_PHASE1":47200,"PHASE1":47202,"PHASE2":47204,"PHASE3":47210,"PHASE4":47212,"NA":47214},{"trials":47201,"activeCount":97},[],{"trials":47203,"activeCount":97},[],{"trials":47205,"activeCount":97},[47206],{"nctId":47108,"briefTitle":47109,"status":155,"phases":47207,"primaryCompletion":18740,"completion":18740,"start":47111,"enrollment":18256,"conditions":47208,"interventions":47209},[86],[21,8265],[47099,47114,47115,47116,47117,47118,47119],{"trials":47211,"activeCount":97},[],{"trials":47213,"activeCount":97},[],{"trials":47215,"activeCount":97},[],{"intervention":47119,"totalTrials":417,"cells":47217},{"EARLY_PHASE1":47218,"PHASE1":47220,"PHASE2":47222,"PHASE3":47228,"PHASE4":47230,"NA":47232},{"trials":47219,"activeCount":97},[],{"trials":47221,"activeCount":97},[],{"trials":47223,"activeCount":97},[47224],{"nctId":47108,"briefTitle":47109,"status":155,"phases":47225,"primaryCompletion":18740,"completion":18740,"start":47111,"enrollment":18256,"conditions":47226,"interventions":47227},[86],[21,8265],[47099,47114,47115,47116,47117,47118,47119],{"trials":47229,"activeCount":97},[],{"trials":47231,"activeCount":97},[],{"trials":47233,"activeCount":97},[],{"intervention":47235,"totalTrials":417,"cells":47236},"GSK2831781 - Double Blind Phase",{"EARLY_PHASE1":47237,"PHASE1":47239,"PHASE2":47241,"PHASE3":47251,"PHASE4":47253,"NA":47255},{"trials":47238,"activeCount":97},[],{"trials":47240,"activeCount":97},[],{"trials":47242,"activeCount":97},[47243],{"nctId":47244,"briefTitle":47245,"status":145,"phases":47246,"primaryCompletion":47247,"completion":47247,"start":35906,"enrollment":14145,"conditions":47248,"interventions":47249},"NCT03893565","Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis",[86],"2021-05-17",[7295],[47235,47250],"GSK2831781 - Open Label phase",{"trials":47252,"activeCount":97},[],{"trials":47254,"activeCount":97},[],{"trials":47256,"activeCount":97},[],{"intervention":47250,"totalTrials":417,"cells":47258},{"EARLY_PHASE1":47259,"PHASE1":47261,"PHASE2":47263,"PHASE3":47269,"PHASE4":47271,"NA":47273},{"trials":47260,"activeCount":97},[],{"trials":47262,"activeCount":97},[],{"trials":47264,"activeCount":97},[47265],{"nctId":47244,"briefTitle":47245,"status":145,"phases":47266,"primaryCompletion":47247,"completion":47247,"start":35906,"enrollment":14145,"conditions":47267,"interventions":47268},[86],[7295],[47235,47250],{"trials":47270,"activeCount":97},[],{"trials":47272,"activeCount":97},[],{"trials":47274,"activeCount":97},[],{"intervention":2324,"totalTrials":417,"cells":47276},{"EARLY_PHASE1":47277,"PHASE1":47279,"PHASE2":47281,"PHASE3":47287,"PHASE4":47289,"NA":47291},{"trials":47278,"activeCount":97},[],{"trials":47280,"activeCount":97},[],{"trials":47282,"activeCount":97},[47283],{"nctId":2316,"briefTitle":2317,"status":145,"phases":47284,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":47285,"interventions":47286},[86],[668],[2324,2325,2326,2327,1241,164,2328,2329,216,2330],{"trials":47288,"activeCount":97},[],{"trials":47290,"activeCount":97},[],{"trials":47292,"activeCount":97},[],{"intervention":2325,"totalTrials":417,"cells":47294},{"EARLY_PHASE1":47295,"PHASE1":47297,"PHASE2":47299,"PHASE3":47305,"PHASE4":47307,"NA":47309},{"trials":47296,"activeCount":97},[],{"trials":47298,"activeCount":97},[],{"trials":47300,"activeCount":97},[47301],{"nctId":2316,"briefTitle":2317,"status":145,"phases":47302,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":47303,"interventions":47304},[86],[668],[2324,2325,2326,2327,1241,164,2328,2329,216,2330],{"trials":47306,"activeCount":97},[],{"trials":47308,"activeCount":97},[],{"trials":47310,"activeCount":97},[],{"intervention":2326,"totalTrials":417,"cells":47312},{"EARLY_PHASE1":47313,"PHASE1":47315,"PHASE2":47317,"PHASE3":47323,"PHASE4":47325,"NA":47327},{"trials":47314,"activeCount":97},[],{"trials":47316,"activeCount":97},[],{"trials":47318,"activeCount":97},[47319],{"nctId":2316,"briefTitle":2317,"status":145,"phases":47320,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":47321,"interventions":47322},[86],[668],[2324,2325,2326,2327,1241,164,2328,2329,216,2330],{"trials":47324,"activeCount":97},[],{"trials":47326,"activeCount":97},[],{"trials":47328,"activeCount":97},[],{"intervention":2327,"totalTrials":417,"cells":47330},{"EARLY_PHASE1":47331,"PHASE1":47333,"PHASE2":47335,"PHASE3":47341,"PHASE4":47343,"NA":47345},{"trials":47332,"activeCount":97},[],{"trials":47334,"activeCount":97},[],{"trials":47336,"activeCount":97},[47337],{"nctId":2316,"briefTitle":2317,"status":145,"phases":47338,"primaryCompletion":2319,"completion":2319,"start":2320,"enrollment":2321,"conditions":47339,"interventions":47340},[86],[668],[2324,2325,2326,2327,1241,164,2328,2329,216,2330],{"trials":47342,"activeCount":97},[],{"trials":47344,"activeCount":97},[],{"trials":47346,"activeCount":97},[],{"intervention":47348,"totalTrials":417,"cells":47349},"GSK233705B",{"EARLY_PHASE1":47350,"PHASE1":47352,"PHASE2":47354,"PHASE3":47362,"PHASE4":47364,"NA":47366},{"trials":47351,"activeCount":97},[],{"trials":47353,"activeCount":97},[],{"trials":47355,"activeCount":97},[47356],{"nctId":47357,"briefTitle":47358,"status":155,"phases":47359,"primaryCompletion":42158,"completion":42158,"start":39078,"enrollment":314,"conditions":47360,"interventions":47361},"NCT00453479","A Dose Ascending, Study To Examine The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of GSK233705B.",[86],[15],[47348],{"trials":47363,"activeCount":97},[],{"trials":47365,"activeCount":97},[],{"trials":47367,"activeCount":97},[],{"intervention":19169,"totalTrials":417,"cells":47369},{"EARLY_PHASE1":47370,"PHASE1":47372,"PHASE2":47374,"PHASE3":47380,"PHASE4":47382,"NA":47384},{"trials":47371,"activeCount":97},[],{"trials":47373,"activeCount":97},[],{"trials":47375,"activeCount":97},[47376],{"nctId":19160,"briefTitle":19161,"status":155,"phases":47377,"primaryCompletion":19163,"completion":19164,"start":19165,"enrollment":19166,"conditions":47378,"interventions":47379},[86],[3637],[19169,19170,10348,7875,19151],{"trials":47381,"activeCount":97},[],{"trials":47383,"activeCount":97},[],{"trials":47385,"activeCount":97},[],{"intervention":19170,"totalTrials":417,"cells":47387},{"EARLY_PHASE1":47388,"PHASE1":47390,"PHASE2":47392,"PHASE3":47398,"PHASE4":47400,"NA":47402},{"trials":47389,"activeCount":97},[],{"trials":47391,"activeCount":97},[],{"trials":47393,"activeCount":97},[47394],{"nctId":19160,"briefTitle":19161,"status":155,"phases":47395,"primaryCompletion":19163,"completion":19164,"start":19165,"enrollment":19166,"conditions":47396,"interventions":47397},[86],[3637],[19169,19170,10348,7875,19151],{"trials":47399,"activeCount":97},[],{"trials":47401,"activeCount":97},[],{"trials":47403,"activeCount":97},[],{"intervention":47405,"totalTrials":417,"cells":47406},"Meningococcal ABCWY Vaccine",{"EARLY_PHASE1":47407,"PHASE1":47409,"PHASE2":47411,"PHASE3":47421,"PHASE4":47423,"NA":47425},{"trials":47408,"activeCount":97},[],{"trials":47410,"activeCount":97},[],{"trials":47412,"activeCount":97},[47413],{"nctId":47414,"briefTitle":47415,"status":155,"phases":47416,"primaryCompletion":47417,"completion":47417,"start":39939,"enrollment":40116,"conditions":47418,"interventions":47419},"NCT02946385","Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents",[86],"2018-02-13",[992],[47405,47420],"Meningococcal B Recombinant vaccine",{"trials":47422,"activeCount":97},[],{"trials":47424,"activeCount":97},[],{"trials":47426,"activeCount":97},[],{"intervention":47420,"totalTrials":417,"cells":47428},{"EARLY_PHASE1":47429,"PHASE1":47431,"PHASE2":47433,"PHASE3":47439,"PHASE4":47441,"NA":47443},{"trials":47430,"activeCount":97},[],{"trials":47432,"activeCount":97},[],{"trials":47434,"activeCount":97},[47435],{"nctId":47414,"briefTitle":47415,"status":155,"phases":47436,"primaryCompletion":47417,"completion":47417,"start":39939,"enrollment":40116,"conditions":47437,"interventions":47438},[86],[992],[47405,47420],{"trials":47440,"activeCount":97},[],{"trials":47442,"activeCount":97},[],{"trials":47444,"activeCount":97},[],{"intervention":47446,"totalTrials":417,"cells":47447},"GSK2190915A 5mg",{"EARLY_PHASE1":47448,"PHASE1":47450,"PHASE2":47452,"PHASE3":47464,"PHASE4":47466,"NA":47468},{"trials":47449,"activeCount":97},[],{"trials":47451,"activeCount":97},[],{"trials":47453,"activeCount":97},[47454],{"nctId":47455,"briefTitle":47456,"status":500,"phases":47457,"primaryCompletion":7590,"completion":7590,"start":10463,"enrollment":97,"conditions":47458,"interventions":47459},"NCT01286844","GSK2190915 Pediatric Study",[86],[18],[47446,47460,47461,47462,47463],"GSK2190915A 10mg","GSK2190915A 25mg","GSK2190915A 50mg","GSK2190915A 100mg",{"trials":47465,"activeCount":97},[],{"trials":47467,"activeCount":97},[],{"trials":47469,"activeCount":97},[],{"intervention":47460,"totalTrials":417,"cells":47471},{"EARLY_PHASE1":47472,"PHASE1":47474,"PHASE2":47476,"PHASE3":47482,"PHASE4":47484,"NA":47486},{"trials":47473,"activeCount":97},[],{"trials":47475,"activeCount":97},[],{"trials":47477,"activeCount":97},[47478],{"nctId":47455,"briefTitle":47456,"status":500,"phases":47479,"primaryCompletion":7590,"completion":7590,"start":10463,"enrollment":97,"conditions":47480,"interventions":47481},[86],[18],[47446,47460,47461,47462,47463],{"trials":47483,"activeCount":97},[],{"trials":47485,"activeCount":97},[],{"trials":47487,"activeCount":97},[],{"intervention":47461,"totalTrials":417,"cells":47489},{"EARLY_PHASE1":47490,"PHASE1":47492,"PHASE2":47494,"PHASE3":47500,"PHASE4":47502,"NA":47504},{"trials":47491,"activeCount":97},[],{"trials":47493,"activeCount":97},[],{"trials":47495,"activeCount":97},[47496],{"nctId":47455,"briefTitle":47456,"status":500,"phases":47497,"primaryCompletion":7590,"completion":7590,"start":10463,"enrollment":97,"conditions":47498,"interventions":47499},[86],[18],[47446,47460,47461,47462,47463],{"trials":47501,"activeCount":97},[],{"trials":47503,"activeCount":97},[],{"trials":47505,"activeCount":97},[],{"intervention":47462,"totalTrials":417,"cells":47507},{"EARLY_PHASE1":47508,"PHASE1":47510,"PHASE2":47512,"PHASE3":47518,"PHASE4":47520,"NA":47522},{"trials":47509,"activeCount":97},[],{"trials":47511,"activeCount":97},[],{"trials":47513,"activeCount":97},[47514],{"nctId":47455,"briefTitle":47456,"status":500,"phases":47515,"primaryCompletion":7590,"completion":7590,"start":10463,"enrollment":97,"conditions":47516,"interventions":47517},[86],[18],[47446,47460,47461,47462,47463],{"trials":47519,"activeCount":97},[],{"trials":47521,"activeCount":97},[],{"trials":47523,"activeCount":97},[],{"intervention":47463,"totalTrials":417,"cells":47525},{"EARLY_PHASE1":47526,"PHASE1":47528,"PHASE2":47530,"PHASE3":47536,"PHASE4":47538,"NA":47540},{"trials":47527,"activeCount":97},[],{"trials":47529,"activeCount":97},[],{"trials":47531,"activeCount":97},[47532],{"nctId":47455,"briefTitle":47456,"status":500,"phases":47533,"primaryCompletion":7590,"completion":7590,"start":10463,"enrollment":97,"conditions":47534,"interventions":47535},[86],[18],[47446,47460,47461,47462,47463],{"trials":47537,"activeCount":97},[],{"trials":47539,"activeCount":97},[],{"trials":47541,"activeCount":97},[],{"intervention":47543,"totalTrials":417,"cells":47544},"SB-773812",{"EARLY_PHASE1":47545,"PHASE1":47547,"PHASE2":47549,"PHASE3":47558,"PHASE4":47560,"NA":47562},{"trials":47546,"activeCount":97},[],{"trials":47548,"activeCount":97},[],{"trials":47550,"activeCount":97},[47551],{"nctId":47552,"briefTitle":47553,"status":155,"phases":47554,"completion":2336,"start":8427,"enrollment":18712,"conditions":47555,"interventions":47556},"NCT00259870","SB-773812 Administered In Adults With Schizophrenia",[86],[11346],[47543,47557],"Olanzapine",{"trials":47559,"activeCount":97},[],{"trials":47561,"activeCount":97},[],{"trials":47563,"activeCount":97},[],{"intervention":47557,"totalTrials":417,"cells":47565},{"EARLY_PHASE1":47566,"PHASE1":47568,"PHASE2":47570,"PHASE3":47576,"PHASE4":47578,"NA":47580},{"trials":47567,"activeCount":97},[],{"trials":47569,"activeCount":97},[],{"trials":47571,"activeCount":97},[47572],{"nctId":47552,"briefTitle":47553,"status":155,"phases":47573,"completion":2336,"start":8427,"enrollment":18712,"conditions":47574,"interventions":47575},[86],[11346],[47543,47557],{"trials":47577,"activeCount":97},[],{"trials":47579,"activeCount":97},[],{"trials":47581,"activeCount":97},[],{"intervention":47583,"totalTrials":417,"cells":47584},"HPV-16\u002F18 vaccine",{"EARLY_PHASE1":47585,"PHASE1":47587,"PHASE2":47589,"PHASE3":47600,"PHASE4":47602,"NA":47604},{"trials":47586,"activeCount":97},[],{"trials":47588,"activeCount":97},[],{"trials":47590,"activeCount":97},[47591],{"nctId":47592,"briefTitle":47593,"status":155,"phases":47594,"primaryCompletion":23471,"completion":23471,"start":47595,"enrollment":47596,"conditions":47597,"interventions":47598},"NCT00316693","Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16\u002F18 Vaccine",[86],"2006-04-26",1046,[8723],[47583,47599],"Aimmugen™",{"trials":47601,"activeCount":97},[],{"trials":47603,"activeCount":97},[],{"trials":47605,"activeCount":97},[],{"intervention":47599,"totalTrials":417,"cells":47607},{"EARLY_PHASE1":47608,"PHASE1":47610,"PHASE2":47612,"PHASE3":47618,"PHASE4":47620,"NA":47622},{"trials":47609,"activeCount":97},[],{"trials":47611,"activeCount":97},[],{"trials":47613,"activeCount":97},[47614],{"nctId":47592,"briefTitle":47593,"status":155,"phases":47615,"primaryCompletion":23471,"completion":23471,"start":47595,"enrollment":47596,"conditions":47616,"interventions":47617},[86],[8723],[47583,47599],{"trials":47619,"activeCount":97},[],{"trials":47621,"activeCount":97},[],{"trials":47623,"activeCount":97},[],{"intervention":43544,"totalTrials":417,"cells":47625},{"EARLY_PHASE1":47626,"PHASE1":47628,"PHASE2":47630,"PHASE3":47636,"PHASE4":47638,"NA":47640},{"trials":47627,"activeCount":97},[],{"trials":47629,"activeCount":97},[],{"trials":47631,"activeCount":97},[47632],{"nctId":43539,"briefTitle":43540,"status":145,"phases":47633,"primaryCompletion":4843,"completion":4843,"start":4757,"enrollment":417,"conditions":47634,"interventions":47635},[86],[9036,27],[43530,43544],{"trials":47637,"activeCount":97},[],{"trials":47639,"activeCount":97},[],{"trials":47641,"activeCount":97},[],{"intervention":23249,"totalTrials":417,"cells":47643},{"EARLY_PHASE1":47644,"PHASE1":47646,"PHASE2":47648,"PHASE3":47654,"PHASE4":47656,"NA":47658},{"trials":47645,"activeCount":97},[],{"trials":47647,"activeCount":97},[],{"trials":47649,"activeCount":97},[47650],{"nctId":23240,"briefTitle":23241,"status":155,"phases":47651,"primaryCompletion":23243,"completion":23244,"start":19538,"enrollment":10489,"conditions":47652,"interventions":47653},[86],[23246],[23248,23249,7791,23250,19196],{"trials":47655,"activeCount":97},[],{"trials":47657,"activeCount":97},[],{"trials":47659,"activeCount":97},[],{"intervention":2339,"totalTrials":417,"cells":47661},{"EARLY_PHASE1":47662,"PHASE1":47664,"PHASE2":47666,"PHASE3":47672,"PHASE4":47674,"NA":47676},{"trials":47663,"activeCount":97},[],{"trials":47665,"activeCount":97},[],{"trials":47667,"activeCount":97},[47668],{"nctId":2332,"briefTitle":2333,"status":155,"phases":47669,"primaryCompletion":2335,"completion":482,"start":2336,"enrollment":414,"conditions":47670,"interventions":47671},[86],[668],[2330,216,2339,2274],{"trials":47673,"activeCount":97},[],{"trials":47675,"activeCount":97},[],{"trials":47677,"activeCount":97},[],{"intervention":47679,"totalTrials":417,"cells":47680},"Nicotine lower dose",{"EARLY_PHASE1":47681,"PHASE1":47683,"PHASE2":47685,"PHASE3":47694,"PHASE4":47696,"NA":47698},{"trials":47682,"activeCount":97},[],{"trials":47684,"activeCount":97},[],{"trials":47686,"activeCount":97},[47687],{"nctId":47688,"briefTitle":47689,"status":155,"phases":47690,"primaryCompletion":2344,"completion":2344,"start":3551,"enrollment":29637,"conditions":47691,"interventions":47692},"NCT01466361","Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving",[86],[9675,9684],[47679,47693],"Nicotine higher dose",{"trials":47695,"activeCount":97},[],{"trials":47697,"activeCount":97},[],{"trials":47699,"activeCount":97},[],{"intervention":47693,"totalTrials":417,"cells":47701},{"EARLY_PHASE1":47702,"PHASE1":47704,"PHASE2":47706,"PHASE3":47712,"PHASE4":47714,"NA":47716},{"trials":47703,"activeCount":97},[],{"trials":47705,"activeCount":97},[],{"trials":47707,"activeCount":97},[47708],{"nctId":47688,"briefTitle":47689,"status":155,"phases":47709,"primaryCompletion":2344,"completion":2344,"start":3551,"enrollment":29637,"conditions":47710,"interventions":47711},[86],[9675,9684],[47679,47693],{"trials":47713,"activeCount":97},[],{"trials":47715,"activeCount":97},[],{"trials":47717,"activeCount":97},[],{"intervention":43607,"totalTrials":417,"cells":47719},{"EARLY_PHASE1":47720,"PHASE1":47722,"PHASE2":47724,"PHASE3":47730,"PHASE4":47732,"NA":47734},{"trials":47721,"activeCount":97},[],{"trials":47723,"activeCount":97},[],{"trials":47725,"activeCount":97},[47726],{"nctId":43601,"briefTitle":43602,"status":155,"phases":47727,"primaryCompletion":43604,"completion":43604,"start":9812,"enrollment":433,"conditions":47728,"interventions":47729},[86],[42684],[43585,43607,43608],{"trials":47731,"activeCount":97},[],{"trials":47733,"activeCount":97},[],{"trials":47735,"activeCount":97},[],{"intervention":19834,"totalTrials":417,"cells":47737},{"EARLY_PHASE1":47738,"PHASE1":47740,"PHASE2":47742,"PHASE3":47748,"PHASE4":47750,"NA":47752},{"trials":47739,"activeCount":97},[],{"trials":47741,"activeCount":97},[],{"trials":47743,"activeCount":97},[47744],{"nctId":19827,"briefTitle":19828,"status":155,"phases":47745,"primaryCompletion":2405,"completion":19830,"start":19831,"enrollment":3285,"conditions":47746,"interventions":47747},[86],[4704],[19834,19835,7829,19818,19836],{"trials":47749,"activeCount":97},[],{"trials":47751,"activeCount":97},[],{"trials":47753,"activeCount":97},[],{"intervention":19835,"totalTrials":417,"cells":47755},{"EARLY_PHASE1":47756,"PHASE1":47758,"PHASE2":47760,"PHASE3":47766,"PHASE4":47768,"NA":47770},{"trials":47757,"activeCount":97},[],{"trials":47759,"activeCount":97},[],{"trials":47761,"activeCount":97},[47762],{"nctId":19827,"briefTitle":19828,"status":155,"phases":47763,"primaryCompletion":2405,"completion":19830,"start":19831,"enrollment":3285,"conditions":47764,"interventions":47765},[86],[4704],[19834,19835,7829,19818,19836],{"trials":47767,"activeCount":97},[],{"trials":47769,"activeCount":97},[],{"trials":47771,"activeCount":97},[],{"intervention":19836,"totalTrials":417,"cells":47773},{"EARLY_PHASE1":47774,"PHASE1":47776,"PHASE2":47778,"PHASE3":47784,"PHASE4":47786,"NA":47788},{"trials":47775,"activeCount":97},[],{"trials":47777,"activeCount":97},[],{"trials":47779,"activeCount":97},[47780],{"nctId":19827,"briefTitle":19828,"status":155,"phases":47781,"primaryCompletion":2405,"completion":19830,"start":19831,"enrollment":3285,"conditions":47782,"interventions":47783},[86],[4704],[19834,19835,7829,19818,19836],{"trials":47785,"activeCount":97},[],{"trials":47787,"activeCount":97},[],{"trials":47789,"activeCount":97},[],{"intervention":47791,"totalTrials":417,"cells":47792},"GW766944",{"EARLY_PHASE1":47793,"PHASE1":47795,"PHASE2":47797,"PHASE3":47806,"PHASE4":47808,"NA":47810},{"trials":47794,"activeCount":97},[],{"trials":47796,"activeCount":97},[],{"trials":47798,"activeCount":97},[47799],{"nctId":47800,"briefTitle":47801,"status":155,"phases":47802,"primaryCompletion":9316,"completion":9316,"start":47803,"enrollment":1237,"conditions":47804,"interventions":47805},"NCT01160224","Oral GW766944 (Oral CCR3 Antagonist)",[86],"2010-09-08",[18],[47791],{"trials":47807,"activeCount":97},[],{"trials":47809,"activeCount":97},[],{"trials":47811,"activeCount":97},[],{"intervention":8654,"totalTrials":417,"cells":47813},{"EARLY_PHASE1":47814,"PHASE1":47816,"PHASE2":47818,"PHASE3":47824,"PHASE4":47826,"NA":47828},{"trials":47815,"activeCount":97},[],{"trials":47817,"activeCount":97},[],{"trials":47819,"activeCount":97},[47820],{"nctId":8644,"briefTitle":8645,"status":155,"phases":47821,"primaryCompletion":8647,"completion":8648,"start":8649,"enrollment":8650,"conditions":47822,"interventions":47823},[86],[992],[8653,4694,8654],{"trials":47825,"activeCount":97},[],{"trials":47827,"activeCount":97},[],{"trials":47829,"activeCount":97},[],{"intervention":47831,"totalTrials":417,"cells":47832},"GSK2402968 3mg\u002Fkg\u002Fweek",{"EARLY_PHASE1":47833,"PHASE1":47835,"PHASE2":47837,"PHASE3":47848,"PHASE4":47850,"NA":47852},{"trials":47834,"activeCount":97},[],{"trials":47836,"activeCount":97},[],{"trials":47838,"activeCount":97},[47839],{"nctId":47840,"briefTitle":47841,"status":155,"phases":47842,"primaryCompletion":47843,"completion":47844,"start":18146,"enrollment":7573,"conditions":47845,"interventions":47846},"NCT01462292","A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)",[86],"2013-05-21","2013-11-04",[25854],[47831,47847],"GSK2402968 6 mg\u002Fkg\u002Fweek",{"trials":47849,"activeCount":97},[],{"trials":47851,"activeCount":97},[],{"trials":47853,"activeCount":97},[],{"intervention":47847,"totalTrials":417,"cells":47855},{"EARLY_PHASE1":47856,"PHASE1":47858,"PHASE2":47860,"PHASE3":47866,"PHASE4":47868,"NA":47870},{"trials":47857,"activeCount":97},[],{"trials":47859,"activeCount":97},[],{"trials":47861,"activeCount":97},[47862],{"nctId":47840,"briefTitle":47841,"status":155,"phases":47863,"primaryCompletion":47843,"completion":47844,"start":18146,"enrollment":7573,"conditions":47864,"interventions":47865},[86],[25854],[47831,47847],{"trials":47867,"activeCount":97},[],{"trials":47869,"activeCount":97},[],{"trials":47871,"activeCount":97},[],{"intervention":47873,"totalTrials":417,"cells":47874},"eltrombopag 12.5 milligrams (mg)",{"EARLY_PHASE1":47875,"PHASE1":47877,"PHASE2":47879,"PHASE3":47889,"PHASE4":47891,"NA":47893},{"trials":47876,"activeCount":97},[],{"trials":47878,"activeCount":97},[],{"trials":47880,"activeCount":97},[47881],{"nctId":47882,"briefTitle":47883,"status":155,"phases":47884,"primaryCompletion":9159,"completion":9159,"start":2813,"enrollment":12044,"conditions":47885,"interventions":47887},"NCT00861601","Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease",[86],[47886],"Liver Diseases",[47873,47888],"eltrombopag 25 mg",{"trials":47890,"activeCount":97},[],{"trials":47892,"activeCount":97},[],{"trials":47894,"activeCount":97},[],{"intervention":47888,"totalTrials":417,"cells":47896},{"EARLY_PHASE1":47897,"PHASE1":47899,"PHASE2":47901,"PHASE3":47907,"PHASE4":47909,"NA":47911},{"trials":47898,"activeCount":97},[],{"trials":47900,"activeCount":97},[],{"trials":47902,"activeCount":97},[47903],{"nctId":47882,"briefTitle":47883,"status":155,"phases":47904,"primaryCompletion":9159,"completion":9159,"start":2813,"enrollment":12044,"conditions":47905,"interventions":47906},[86],[47886],[47873,47888],{"trials":47908,"activeCount":97},[],{"trials":47910,"activeCount":97},[],{"trials":47912,"activeCount":97},[],{"intervention":47914,"totalTrials":417,"cells":47915},"Belantamab mafodotin frozen liquid",{"EARLY_PHASE1":47916,"PHASE1":47918,"PHASE2":47920,"PHASE3":47931,"PHASE4":47933,"NA":47935},{"trials":47917,"activeCount":97},[],{"trials":47919,"activeCount":97},[],{"trials":47921,"activeCount":97},[47922],{"nctId":47923,"briefTitle":47924,"status":155,"phases":47925,"primaryCompletion":47926,"completion":47927,"start":16971,"enrollment":15283,"conditions":47928,"interventions":47929},"NCT03525678","A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody",[86],"2019-06-21","2024-09-12",[278],[47914,47930],"Belantamab mafodotin lyophilized powder",{"trials":47932,"activeCount":97},[],{"trials":47934,"activeCount":97},[],{"trials":47936,"activeCount":97},[],{"intervention":47930,"totalTrials":417,"cells":47938},{"EARLY_PHASE1":47939,"PHASE1":47941,"PHASE2":47943,"PHASE3":47949,"PHASE4":47951,"NA":47953},{"trials":47940,"activeCount":97},[],{"trials":47942,"activeCount":97},[],{"trials":47944,"activeCount":97},[47945],{"nctId":47923,"briefTitle":47924,"status":155,"phases":47946,"primaryCompletion":47926,"completion":47927,"start":16971,"enrollment":15283,"conditions":47947,"interventions":47948},[86],[278],[47914,47930],{"trials":47950,"activeCount":97},[],{"trials":47952,"activeCount":97},[],{"trials":47954,"activeCount":97},[],{"intervention":47956,"totalTrials":417,"cells":47957},"Albiglutide (GSK716155) or exenatide",{"EARLY_PHASE1":47958,"PHASE1":47960,"PHASE2":47962,"PHASE3":47971,"PHASE4":47973,"NA":47975},{"trials":47959,"activeCount":97},[],{"trials":47961,"activeCount":97},[],{"trials":47963,"activeCount":97},[47964],{"nctId":47965,"briefTitle":47966,"status":155,"phases":47967,"primaryCompletion":7522,"completion":7522,"start":4756,"enrollment":47968,"conditions":47969,"interventions":47970},"NCT00518115","Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only",[86],361,[27],[47956],{"trials":47972,"activeCount":97},[],{"trials":47974,"activeCount":97},[],{"trials":47976,"activeCount":97},[],{"intervention":43634,"totalTrials":417,"cells":47978},{"EARLY_PHASE1":47979,"PHASE1":47981,"PHASE2":47983,"PHASE3":47989,"PHASE4":47991,"NA":47993},{"trials":47980,"activeCount":97},[],{"trials":47982,"activeCount":97},[],{"trials":47984,"activeCount":97},[47985],{"nctId":43628,"briefTitle":43629,"status":155,"phases":47986,"primaryCompletion":17134,"completion":43631,"start":30042,"enrollment":4792,"conditions":47987,"interventions":47988},[86],[42684],[43634,43635,43636,43608,43637],{"trials":47990,"activeCount":97},[],{"trials":47992,"activeCount":97},[],{"trials":47994,"activeCount":97},[],{"intervention":43635,"totalTrials":417,"cells":47996},{"EARLY_PHASE1":47997,"PHASE1":47999,"PHASE2":48001,"PHASE3":48007,"PHASE4":48009,"NA":48011},{"trials":47998,"activeCount":97},[],{"trials":48000,"activeCount":97},[],{"trials":48002,"activeCount":97},[48003],{"nctId":43628,"briefTitle":43629,"status":155,"phases":48004,"primaryCompletion":17134,"completion":43631,"start":30042,"enrollment":4792,"conditions":48005,"interventions":48006},[86],[42684],[43634,43635,43636,43608,43637],{"trials":48008,"activeCount":97},[],{"trials":48010,"activeCount":97},[],{"trials":48012,"activeCount":97},[],{"intervention":43636,"totalTrials":417,"cells":48014},{"EARLY_PHASE1":48015,"PHASE1":48017,"PHASE2":48019,"PHASE3":48025,"PHASE4":48027,"NA":48029},{"trials":48016,"activeCount":97},[],{"trials":48018,"activeCount":97},[],{"trials":48020,"activeCount":97},[48021],{"nctId":43628,"briefTitle":43629,"status":155,"phases":48022,"primaryCompletion":17134,"completion":43631,"start":30042,"enrollment":4792,"conditions":48023,"interventions":48024},[86],[42684],[43634,43635,43636,43608,43637],{"trials":48026,"activeCount":97},[],{"trials":48028,"activeCount":97},[],{"trials":48030,"activeCount":97},[],{"intervention":48032,"totalTrials":417,"cells":48033},"GSK249320 100\u002Fmg",{"EARLY_PHASE1":48034,"PHASE1":48036,"PHASE2":48038,"PHASE3":48048,"PHASE4":48050,"NA":48052},{"trials":48035,"activeCount":97},[],{"trials":48037,"activeCount":97},[],{"trials":48039,"activeCount":97},[48040],{"nctId":48041,"briefTitle":48042,"status":145,"phases":48043,"primaryCompletion":48044,"completion":48044,"start":48045,"enrollment":3112,"conditions":48046,"interventions":48047},"NCT01808261","Proof of Concept (POC) in Patients With Ischaemic Stroke",[86],"2014-07-28","2013-05-18",[19596],[48032],{"trials":48049,"activeCount":97},[],{"trials":48051,"activeCount":97},[],{"trials":48053,"activeCount":97},[],{"intervention":48055,"totalTrials":417,"cells":48056},"FLU-Q-PAN H7N9 Formulation 1",{"EARLY_PHASE1":48057,"PHASE1":48059,"PHASE2":48061,"PHASE3":48075,"PHASE4":48077,"NA":48079},{"trials":48058,"activeCount":97},[],{"trials":48060,"activeCount":97},[],{"trials":48062,"activeCount":97},[48063],{"nctId":48064,"briefTitle":48065,"status":155,"phases":48066,"primaryCompletion":47,"completion":47,"start":48067,"enrollment":48068,"conditions":48069,"interventions":48070},"NCT04789577","A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older",[86],"2021-03-16",833,[5353],[48055,48071,48072,48073,48074],"FLU-Q-PAN H7N9 Formulation 2","FLU-Q-PAN H7N9 Formulation 3","AS03B","AS03A",{"trials":48076,"activeCount":97},[],{"trials":48078,"activeCount":97},[],{"trials":48080,"activeCount":97},[],{"intervention":48071,"totalTrials":417,"cells":48082},{"EARLY_PHASE1":48083,"PHASE1":48085,"PHASE2":48087,"PHASE3":48093,"PHASE4":48095,"NA":48097},{"trials":48084,"activeCount":97},[],{"trials":48086,"activeCount":97},[],{"trials":48088,"activeCount":97},[48089],{"nctId":48064,"briefTitle":48065,"status":155,"phases":48090,"primaryCompletion":47,"completion":47,"start":48067,"enrollment":48068,"conditions":48091,"interventions":48092},[86],[5353],[48055,48071,48072,48073,48074],{"trials":48094,"activeCount":97},[],{"trials":48096,"activeCount":97},[],{"trials":48098,"activeCount":97},[],{"intervention":48072,"totalTrials":417,"cells":48100},{"EARLY_PHASE1":48101,"PHASE1":48103,"PHASE2":48105,"PHASE3":48111,"PHASE4":48113,"NA":48115},{"trials":48102,"activeCount":97},[],{"trials":48104,"activeCount":97},[],{"trials":48106,"activeCount":97},[48107],{"nctId":48064,"briefTitle":48065,"status":155,"phases":48108,"primaryCompletion":47,"completion":47,"start":48067,"enrollment":48068,"conditions":48109,"interventions":48110},[86],[5353],[48055,48071,48072,48073,48074],{"trials":48112,"activeCount":97},[],{"trials":48114,"activeCount":97},[],{"trials":48116,"activeCount":97},[],{"intervention":48073,"totalTrials":417,"cells":48118},{"EARLY_PHASE1":48119,"PHASE1":48121,"PHASE2":48123,"PHASE3":48129,"PHASE4":48131,"NA":48133},{"trials":48120,"activeCount":97},[],{"trials":48122,"activeCount":97},[],{"trials":48124,"activeCount":97},[48125],{"nctId":48064,"briefTitle":48065,"status":155,"phases":48126,"primaryCompletion":47,"completion":47,"start":48067,"enrollment":48068,"conditions":48127,"interventions":48128},[86],[5353],[48055,48071,48072,48073,48074],{"trials":48130,"activeCount":97},[],{"trials":48132,"activeCount":97},[],{"trials":48134,"activeCount":97},[],{"intervention":48074,"totalTrials":417,"cells":48136},{"EARLY_PHASE1":48137,"PHASE1":48139,"PHASE2":48141,"PHASE3":48147,"PHASE4":48149,"NA":48151},{"trials":48138,"activeCount":97},[],{"trials":48140,"activeCount":97},[],{"trials":48142,"activeCount":97},[48143],{"nctId":48064,"briefTitle":48065,"status":155,"phases":48144,"primaryCompletion":47,"completion":47,"start":48067,"enrollment":48068,"conditions":48145,"interventions":48146},[86],[5353],[48055,48071,48072,48073,48074],{"trials":48148,"activeCount":97},[],{"trials":48150,"activeCount":97},[],{"trials":48152,"activeCount":97},[],{"intervention":48154,"totalTrials":417,"cells":48155},"Non-adjuvanted HSV formulation 1",{"EARLY_PHASE1":48156,"PHASE1":48158,"PHASE2":48160,"PHASE3":48180,"PHASE4":48182,"NA":48184},{"trials":48157,"activeCount":97},[],{"trials":48159,"activeCount":97},[],{"trials":48161,"activeCount":97},[48162],{"nctId":48163,"briefTitle":48164,"status":155,"phases":48165,"primaryCompletion":5632,"completion":5632,"start":48166,"enrollment":48167,"conditions":48168,"interventions":48169},"NCT05298254","A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes",[85,86],"2022-03-07",505,[8709],[48154,48170,48171,48172,48173,48174,48175,48176,48177,48178,48179],"Non-adjuvanted HSV formulation 2","Non-adjuvanted HSV formulation 3","HSV formulation 1 with adjuvant 1","HSV formulation 2 with adjuvant 1","HSV formulation 3 with adjuvant 1","HSV formulation 1 with adjuvant 2","HSV formulation 2 with adjuvant 2","HSV formulation 3 with adjuvant 2","HSVTI_F1","HSVTI_F2",{"trials":48181,"activeCount":97},[],{"trials":48183,"activeCount":97},[],{"trials":48185,"activeCount":97},[],{"intervention":48170,"totalTrials":417,"cells":48187},{"EARLY_PHASE1":48188,"PHASE1":48190,"PHASE2":48192,"PHASE3":48198,"PHASE4":48200,"NA":48202},{"trials":48189,"activeCount":97},[],{"trials":48191,"activeCount":97},[],{"trials":48193,"activeCount":97},[48194],{"nctId":48163,"briefTitle":48164,"status":155,"phases":48195,"primaryCompletion":5632,"completion":5632,"start":48166,"enrollment":48167,"conditions":48196,"interventions":48197},[85,86],[8709],[48154,48170,48171,48172,48173,48174,48175,48176,48177,48178,48179],{"trials":48199,"activeCount":97},[],{"trials":48201,"activeCount":97},[],{"trials":48203,"activeCount":97},[],{"intervention":48171,"totalTrials":417,"cells":48205},{"EARLY_PHASE1":48206,"PHASE1":48208,"PHASE2":48210,"PHASE3":48216,"PHASE4":48218,"NA":48220},{"trials":48207,"activeCount":97},[],{"trials":48209,"activeCount":97},[],{"trials":48211,"activeCount":97},[48212],{"nctId":48163,"briefTitle":48164,"status":155,"phases":48213,"primaryCompletion":5632,"completion":5632,"start":48166,"enrollment":48167,"conditions":48214,"interventions":48215},[85,86],[8709],[48154,48170,48171,48172,48173,48174,48175,48176,48177,48178,48179],{"trials":48217,"activeCount":97},[],{"trials":48219,"activeCount":97},[],{"trials":48221,"activeCount":97},[],{"intervention":48172,"totalTrials":417,"cells":48223},{"EARLY_PHASE1":48224,"PHASE1":48226,"PHASE2":48228,"PHASE3":48234,"PHASE4":48236,"NA":48238},{"trials":48225,"activeCount":97},[],{"trials":48227,"activeCount":97},[],{"trials":48229,"activeCount":97},[48230],{"nctId":48163,"briefTitle":48164,"status":155,"phases":48231,"primaryCompletion":5632,"completion":5632,"start":48166,"enrollment":48167,"conditions":48232,"interventions":48233},[85,86],[8709],[48154,48170,48171,48172,48173,48174,48175,48176,48177,48178,48179],{"trials":48235,"activeCount":97},[],{"trials":48237,"activeCount":97},[],{"trials":48239,"activeCount":97},[],{"intervention":48173,"totalTrials":417,"cells":48241},{"EARLY_PHASE1":48242,"PHASE1":48244,"PHASE2":48246,"PHASE3":48252,"PHASE4":48254,"NA":48256},{"trials":48243,"activeCount":97},[],{"trials":48245,"activeCount":97},[],{"trials":48247,"activeCount":97},[48248],{"nctId":48163,"briefTitle":48164,"status":155,"phases":48249,"primaryCompletion":5632,"completion":5632,"start":48166,"enrollment":48167,"conditions":48250,"interventions":48251},[85,86],[8709],[48154,48170,48171,48172,48173,48174,48175,48176,48177,48178,48179],{"trials":48253,"activeCount":97},[],{"trials":48255,"activeCount":97},[],{"trials":48257,"activeCount":97},[],{"intervention":48174,"totalTrials":417,"cells":48259},{"EARLY_PHASE1":48260,"PHASE1":48262,"PHASE2":48264,"PHASE3":48270,"PHASE4":48272,"NA":48274},{"trials":48261,"activeCount":97},[],{"trials":48263,"activeCount":97},[],{"trials":48265,"activeCount":97},[48266],{"nctId":48163,"briefTitle":48164,"status":155,"phases":48267,"primaryCompletion":5632,"completion":5632,"start":48166,"enrollment":48167,"conditions":48268,"interventions":48269},[85,86],[8709],[48154,48170,48171,48172,48173,48174,48175,48176,48177,48178,48179],{"trials":48271,"activeCount":97},[],{"trials":48273,"activeCount":97},[],{"trials":48275,"activeCount":97},[],{"intervention":48175,"totalTrials":417,"cells":48277},{"EARLY_PHASE1":48278,"PHASE1":48280,"PHASE2":48282,"PHASE3":48288,"PHASE4":48290,"NA":48292},{"trials":48279,"activeCount":97},[],{"trials":48281,"activeCount":97},[],{"trials":48283,"activeCount":97},[48284],{"nctId":48163,"briefTitle":48164,"status":155,"phases":48285,"primaryCompletion":5632,"completion":5632,"start":48166,"enrollment":48167,"conditions":48286,"interventions":48287},[85,86],[8709],[48154,48170,48171,48172,48173,48174,48175,48176,48177,48178,48179],{"trials":48289,"activeCount":97},[],{"trials":48291,"activeCount":97},[],{"trials":48293,"activeCount":97},[],{"intervention":48176,"totalTrials":417,"cells":48295},{"EARLY_PHASE1":48296,"PHASE1":48298,"PHASE2":48300,"PHASE3":48306,"PHASE4":48308,"NA":48310},{"trials":48297,"activeCount":97},[],{"trials":48299,"activeCount":97},[],{"trials":48301,"activeCount":97},[48302],{"nctId":48163,"briefTitle":48164,"status":155,"phases":48303,"primaryCompletion":5632,"completion":5632,"start":48166,"enrollment":48167,"conditions":48304,"interventions":48305},[85,86],[8709],[48154,48170,48171,48172,48173,48174,48175,48176,48177,48178,48179],{"trials":48307,"activeCount":97},[],{"trials":48309,"activeCount":97},[],{"trials":48311,"activeCount":97},[],{"intervention":48177,"totalTrials":417,"cells":48313},{"EARLY_PHASE1":48314,"PHASE1":48316,"PHASE2":48318,"PHASE3":48324,"PHASE4":48326,"NA":48328},{"trials":48315,"activeCount":97},[],{"trials":48317,"activeCount":97},[],{"trials":48319,"activeCount":97},[48320],{"nctId":48163,"briefTitle":48164,"status":155,"phases":48321,"primaryCompletion":5632,"completion":5632,"start":48166,"enrollment":48167,"conditions":48322,"interventions":48323},[85,86],[8709],[48154,48170,48171,48172,48173,48174,48175,48176,48177,48178,48179],{"trials":48325,"activeCount":97},[],{"trials":48327,"activeCount":97},[],{"trials":48329,"activeCount":97},[],{"intervention":48178,"totalTrials":417,"cells":48331},{"EARLY_PHASE1":48332,"PHASE1":48334,"PHASE2":48336,"PHASE3":48342,"PHASE4":48344,"NA":48346},{"trials":48333,"activeCount":97},[],{"trials":48335,"activeCount":97},[],{"trials":48337,"activeCount":97},[48338],{"nctId":48163,"briefTitle":48164,"status":155,"phases":48339,"primaryCompletion":5632,"completion":5632,"start":48166,"enrollment":48167,"conditions":48340,"interventions":48341},[85,86],[8709],[48154,48170,48171,48172,48173,48174,48175,48176,48177,48178,48179],{"trials":48343,"activeCount":97},[],{"trials":48345,"activeCount":97},[],{"trials":48347,"activeCount":97},[],{"intervention":48179,"totalTrials":417,"cells":48349},{"EARLY_PHASE1":48350,"PHASE1":48352,"PHASE2":48354,"PHASE3":48360,"PHASE4":48362,"NA":48364},{"trials":48351,"activeCount":97},[],{"trials":48353,"activeCount":97},[],{"trials":48355,"activeCount":97},[48356],{"nctId":48163,"briefTitle":48164,"status":155,"phases":48357,"primaryCompletion":5632,"completion":5632,"start":48166,"enrollment":48167,"conditions":48358,"interventions":48359},[85,86],[8709],[48154,48170,48171,48172,48173,48174,48175,48176,48177,48178,48179],{"trials":48361,"activeCount":97},[],{"trials":48363,"activeCount":97},[],{"trials":48365,"activeCount":97},[],{"intervention":20252,"totalTrials":417,"cells":48367},{"EARLY_PHASE1":48368,"PHASE1":48370,"PHASE2":48372,"PHASE3":48378,"PHASE4":48380,"NA":48382},{"trials":48369,"activeCount":97},[],{"trials":48371,"activeCount":97},[],{"trials":48373,"activeCount":97},[48374],{"nctId":20244,"briefTitle":20245,"status":155,"phases":48375,"primaryCompletion":20247,"completion":20247,"start":20248,"enrollment":12202,"conditions":48376,"interventions":48377},[86],[8788],[20235,20251,20252],{"trials":48379,"activeCount":97},[],{"trials":48381,"activeCount":97},[],{"trials":48383,"activeCount":97},[],{"intervention":48385,"totalTrials":417,"cells":48386},"Mtb72F\u002FAS02A",{"EARLY_PHASE1":48387,"PHASE1":48389,"PHASE2":48391,"PHASE3":48399,"PHASE4":48401,"NA":48403},{"trials":48388,"activeCount":97},[],{"trials":48390,"activeCount":97},[],{"trials":48392,"activeCount":97},[48393],{"nctId":48394,"briefTitle":48395,"status":155,"phases":48396,"primaryCompletion":2383,"completion":2383,"start":10212,"enrollment":12044,"conditions":48397,"interventions":48398},"NCT00146744","Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F\u002FAS02A in Healthy PPD-positive Adults",[86],[41708],[48385],{"trials":48400,"activeCount":97},[],{"trials":48402,"activeCount":97},[],{"trials":48404,"activeCount":97},[],{"intervention":43886,"totalTrials":417,"cells":48406},{"EARLY_PHASE1":48407,"PHASE1":48409,"PHASE2":48411,"PHASE3":48417,"PHASE4":48419,"NA":48421},{"trials":48408,"activeCount":97},[],{"trials":48410,"activeCount":97},[],{"trials":48412,"activeCount":97},[48413],{"nctId":43881,"briefTitle":43882,"status":155,"phases":48414,"primaryCompletion":2823,"completion":2823,"start":35846,"enrollment":17136,"conditions":48415,"interventions":48416},[86],[8723],[43872,43872,43872,43886],{"trials":48418,"activeCount":97},[],{"trials":48420,"activeCount":97},[],{"trials":48422,"activeCount":97},[],{"intervention":43942,"totalTrials":417,"cells":48424},{"EARLY_PHASE1":48425,"PHASE1":48427,"PHASE2":48429,"PHASE3":48435,"PHASE4":48437,"NA":48439},{"trials":48426,"activeCount":97},[],{"trials":48428,"activeCount":97},[],{"trials":48430,"activeCount":97},[48431],{"nctId":43933,"briefTitle":43934,"status":155,"phases":48432,"primaryCompletion":43936,"completion":43936,"start":43937,"enrollment":43938,"conditions":48433,"interventions":48434},[86],[43940],[43942,43924],{"trials":48436,"activeCount":97},[],{"trials":48438,"activeCount":97},[],{"trials":48440,"activeCount":97},[],{"intervention":48442,"totalTrials":417,"cells":48443},"vinorelbine tartrate",{"EARLY_PHASE1":48444,"PHASE1":48446,"PHASE2":48448,"PHASE3":48457,"PHASE4":48459,"NA":48461},{"trials":48445,"activeCount":97},[],{"trials":48447,"activeCount":97},[],{"trials":48449,"activeCount":97},[48450],{"nctId":48451,"briefTitle":48452,"status":155,"phases":48453,"completion":3552,"start":37767,"conditions":48454,"interventions":48456},"NCT00005865","Vinorelbine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",[86],[48455],"Lung Cancer",[48442],{"trials":48458,"activeCount":97},[],{"trials":48460,"activeCount":97},[],{"trials":48462,"activeCount":97},[],{"intervention":48464,"totalTrials":417,"cells":48465},"firategrast",{"EARLY_PHASE1":48466,"PHASE1":48468,"PHASE2":48470,"PHASE3":48478,"PHASE4":48480,"NA":48482},{"trials":48467,"activeCount":97},[],{"trials":48469,"activeCount":97},[],{"trials":48471,"activeCount":97},[48472],{"nctId":48473,"briefTitle":48474,"status":155,"phases":48475,"primaryCompletion":2795,"completion":2834,"start":2428,"enrollment":4121,"conditions":48476,"interventions":48477},"NCT00469378","Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple Sclerosis",[86],[39962],[48464],{"trials":48479,"activeCount":97},[],{"trials":48481,"activeCount":97},[],{"trials":48483,"activeCount":97},[],{"intervention":48485,"totalTrials":417,"cells":48486},"100 micrograms Fluticasone propionate",{"EARLY_PHASE1":48487,"PHASE1":48489,"PHASE2":48491,"PHASE3":48502,"PHASE4":48504,"NA":48506},{"trials":48488,"activeCount":97},[],{"trials":48490,"activeCount":97},[],{"trials":48492,"activeCount":97},[48493],{"nctId":48494,"briefTitle":48495,"status":155,"phases":48496,"primaryCompletion":11746,"completion":42736,"start":48497,"enrollment":710,"conditions":48498,"interventions":48499},"NCT01400906","Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.",[86],"2011-07-20",[18],[48485,48500,48501],"500 micrograms Fluticasone propionate","lactose powder",{"trials":48503,"activeCount":97},[],{"trials":48505,"activeCount":97},[],{"trials":48507,"activeCount":97},[],{"intervention":48500,"totalTrials":417,"cells":48509},{"EARLY_PHASE1":48510,"PHASE1":48512,"PHASE2":48514,"PHASE3":48520,"PHASE4":48522,"NA":48524},{"trials":48511,"activeCount":97},[],{"trials":48513,"activeCount":97},[],{"trials":48515,"activeCount":97},[48516],{"nctId":48494,"briefTitle":48495,"status":155,"phases":48517,"primaryCompletion":11746,"completion":42736,"start":48497,"enrollment":710,"conditions":48518,"interventions":48519},[86],[18],[48485,48500,48501],{"trials":48521,"activeCount":97},[],{"trials":48523,"activeCount":97},[],{"trials":48525,"activeCount":97},[],{"intervention":48501,"totalTrials":417,"cells":48527},{"EARLY_PHASE1":48528,"PHASE1":48530,"PHASE2":48532,"PHASE3":48538,"PHASE4":48540,"NA":48542},{"trials":48529,"activeCount":97},[],{"trials":48531,"activeCount":97},[],{"trials":48533,"activeCount":97},[48534],{"nctId":48494,"briefTitle":48495,"status":155,"phases":48535,"primaryCompletion":11746,"completion":42736,"start":48497,"enrollment":710,"conditions":48536,"interventions":48537},[86],[18],[48485,48500,48501],{"trials":48539,"activeCount":97},[],{"trials":48541,"activeCount":97},[],{"trials":48543,"activeCount":97},[],{"intervention":48545,"totalTrials":417,"cells":48546},"RSV (GSK3389245A) lower dose formulation vaccine",{"EARLY_PHASE1":48547,"PHASE1":48549,"PHASE2":48551,"PHASE3":48568,"PHASE4":48570,"NA":48572},{"trials":48548,"activeCount":97},[],{"trials":48550,"activeCount":97},[],{"trials":48552,"activeCount":97},[48553],{"nctId":48554,"briefTitle":48555,"status":155,"phases":48556,"primaryCompletion":48557,"completion":48558,"start":48559,"enrollment":48560,"conditions":48561,"interventions":48562},"NCT03636906","Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV",[85,86],"2020-01-16","2021-07-22","2019-04-08",201,[2620],[48545,48563,48564,48565,48566,48567],"RSV (GSK3389245A) higher dose formulation vaccine","GSK's multicomponent meningococcal B vaccine","Pfizer's meningococcal group A, C, W-135 and Y conjugate vaccine","GSK's pneumococcal polysaccharide conjugate vaccine","GSK's meningococcal group A, C, W-135 and Y conjugate vaccine",{"trials":48569,"activeCount":97},[],{"trials":48571,"activeCount":97},[],{"trials":48573,"activeCount":97},[],{"intervention":48563,"totalTrials":417,"cells":48575},{"EARLY_PHASE1":48576,"PHASE1":48578,"PHASE2":48580,"PHASE3":48586,"PHASE4":48588,"NA":48590},{"trials":48577,"activeCount":97},[],{"trials":48579,"activeCount":97},[],{"trials":48581,"activeCount":97},[48582],{"nctId":48554,"briefTitle":48555,"status":155,"phases":48583,"primaryCompletion":48557,"completion":48558,"start":48559,"enrollment":48560,"conditions":48584,"interventions":48585},[85,86],[2620],[48545,48563,48564,48565,48566,48567],{"trials":48587,"activeCount":97},[],{"trials":48589,"activeCount":97},[],{"trials":48591,"activeCount":97},[],{"intervention":48564,"totalTrials":417,"cells":48593},{"EARLY_PHASE1":48594,"PHASE1":48596,"PHASE2":48598,"PHASE3":48604,"PHASE4":48606,"NA":48608},{"trials":48595,"activeCount":97},[],{"trials":48597,"activeCount":97},[],{"trials":48599,"activeCount":97},[48600],{"nctId":48554,"briefTitle":48555,"status":155,"phases":48601,"primaryCompletion":48557,"completion":48558,"start":48559,"enrollment":48560,"conditions":48602,"interventions":48603},[85,86],[2620],[48545,48563,48564,48565,48566,48567],{"trials":48605,"activeCount":97},[],{"trials":48607,"activeCount":97},[],{"trials":48609,"activeCount":97},[],{"intervention":48565,"totalTrials":417,"cells":48611},{"EARLY_PHASE1":48612,"PHASE1":48614,"PHASE2":48616,"PHASE3":48622,"PHASE4":48624,"NA":48626},{"trials":48613,"activeCount":97},[],{"trials":48615,"activeCount":97},[],{"trials":48617,"activeCount":97},[48618],{"nctId":48554,"briefTitle":48555,"status":155,"phases":48619,"primaryCompletion":48557,"completion":48558,"start":48559,"enrollment":48560,"conditions":48620,"interventions":48621},[85,86],[2620],[48545,48563,48564,48565,48566,48567],{"trials":48623,"activeCount":97},[],{"trials":48625,"activeCount":97},[],{"trials":48627,"activeCount":97},[],{"intervention":48566,"totalTrials":417,"cells":48629},{"EARLY_PHASE1":48630,"PHASE1":48632,"PHASE2":48634,"PHASE3":48640,"PHASE4":48642,"NA":48644},{"trials":48631,"activeCount":97},[],{"trials":48633,"activeCount":97},[],{"trials":48635,"activeCount":97},[48636],{"nctId":48554,"briefTitle":48555,"status":155,"phases":48637,"primaryCompletion":48557,"completion":48558,"start":48559,"enrollment":48560,"conditions":48638,"interventions":48639},[85,86],[2620],[48545,48563,48564,48565,48566,48567],{"trials":48641,"activeCount":97},[],{"trials":48643,"activeCount":97},[],{"trials":48645,"activeCount":97},[],{"intervention":48567,"totalTrials":417,"cells":48647},{"EARLY_PHASE1":48648,"PHASE1":48650,"PHASE2":48652,"PHASE3":48658,"PHASE4":48660,"NA":48662},{"trials":48649,"activeCount":97},[],{"trials":48651,"activeCount":97},[],{"trials":48653,"activeCount":97},[48654],{"nctId":48554,"briefTitle":48555,"status":155,"phases":48655,"primaryCompletion":48557,"completion":48558,"start":48559,"enrollment":48560,"conditions":48656,"interventions":48657},[85,86],[2620],[48545,48563,48564,48565,48566,48567],{"trials":48659,"activeCount":97},[],{"trials":48661,"activeCount":97},[],{"trials":48663,"activeCount":97},[],{"intervention":48665,"totalTrials":417,"cells":48666},"1278863A",{"EARLY_PHASE1":48667,"PHASE1":48669,"PHASE2":48671,"PHASE3":48679,"PHASE4":48681,"NA":48683},{"trials":48668,"activeCount":97},[],{"trials":48670,"activeCount":97},[],{"trials":48672,"activeCount":97},[48673],{"nctId":48674,"briefTitle":48675,"status":155,"phases":48676,"primaryCompletion":729,"completion":729,"start":3078,"enrollment":177,"conditions":48677,"interventions":48678},"NCT01047397","Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia",[86],[6452],[48665],{"trials":48680,"activeCount":97},[],{"trials":48682,"activeCount":97},[],{"trials":48684,"activeCount":97},[],{"intervention":48686,"totalTrials":417,"cells":48687},"GW427353",{"EARLY_PHASE1":48688,"PHASE1":48690,"PHASE2":48692,"PHASE3":48700,"PHASE4":48702,"NA":48704},{"trials":48689,"activeCount":97},[],{"trials":48691,"activeCount":97},[],{"trials":48693,"activeCount":97},[48694],{"nctId":48695,"briefTitle":48696,"status":155,"phases":48697,"start":2296,"enrollment":414,"conditions":48698,"interventions":48699},"NCT00394186","A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)",[86],[11511],[48686],{"trials":48701,"activeCount":97},[],{"trials":48703,"activeCount":97},[],{"trials":48705,"activeCount":97},[],{"intervention":48707,"totalTrials":417,"cells":48708},"FF(100mcg)\u002FVilanterol(25mcg) AM",{"EARLY_PHASE1":48709,"PHASE1":48711,"PHASE2":48713,"PHASE3":48722,"PHASE4":48724,"NA":48726},{"trials":48710,"activeCount":97},[],{"trials":48712,"activeCount":97},[],{"trials":48714,"activeCount":97},[48715],{"nctId":48716,"briefTitle":48717,"status":155,"phases":48718,"primaryCompletion":3111,"completion":3111,"start":2335,"enrollment":93,"conditions":48719,"interventions":48720},"NCT01287065","A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate\u002FVilanterol Inhalation Powder in the Morning or Evening on Lung Function",[86],[18],[48707,48721],"FF(100mcg)\u002FVilanterol(25mcg) PM",{"trials":48723,"activeCount":97},[],{"trials":48725,"activeCount":97},[],{"trials":48727,"activeCount":97},[],{"intervention":48721,"totalTrials":417,"cells":48729},{"EARLY_PHASE1":48730,"PHASE1":48732,"PHASE2":48734,"PHASE3":48740,"PHASE4":48742,"NA":48744},{"trials":48731,"activeCount":97},[],{"trials":48733,"activeCount":97},[],{"trials":48735,"activeCount":97},[48736],{"nctId":48716,"briefTitle":48717,"status":155,"phases":48737,"primaryCompletion":3111,"completion":3111,"start":2335,"enrollment":93,"conditions":48738,"interventions":48739},[86],[18],[48707,48721],{"trials":48741,"activeCount":97},[],{"trials":48743,"activeCount":97},[],{"trials":48745,"activeCount":97},[],{"intervention":48747,"totalTrials":417,"cells":48748},"GI262570 0.5 mg",{"EARLY_PHASE1":48749,"PHASE1":48751,"PHASE2":48753,"PHASE3":48765,"PHASE4":48767,"NA":48769},{"trials":48750,"activeCount":97},[],{"trials":48752,"activeCount":97},[],{"trials":48754,"activeCount":97},[48755],{"nctId":48756,"briefTitle":48757,"status":155,"phases":48758,"primaryCompletion":48759,"completion":48759,"start":48760,"enrollment":8891,"conditions":48761,"interventions":48763},"NCT00244751","Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects",[86],"2008-03-13","2005-11-02",[48762],"Cirrhosis, Liver",[48747,48764],"GI262570 1.0 mg",{"trials":48766,"activeCount":97},[],{"trials":48768,"activeCount":97},[],{"trials":48770,"activeCount":97},[],{"intervention":48764,"totalTrials":417,"cells":48772},{"EARLY_PHASE1":48773,"PHASE1":48775,"PHASE2":48777,"PHASE3":48783,"PHASE4":48785,"NA":48787},{"trials":48774,"activeCount":97},[],{"trials":48776,"activeCount":97},[],{"trials":48778,"activeCount":97},[48779],{"nctId":48756,"briefTitle":48757,"status":155,"phases":48780,"primaryCompletion":48759,"completion":48759,"start":48760,"enrollment":8891,"conditions":48781,"interventions":48782},[86],[48762],[48747,48764],{"trials":48784,"activeCount":97},[],{"trials":48786,"activeCount":97},[],{"trials":48788,"activeCount":97},[],{"intervention":48790,"totalTrials":417,"cells":48791},"GSK2190195 100mg",{"EARLY_PHASE1":48792,"PHASE1":48794,"PHASE2":48796,"PHASE3":48806,"PHASE4":48808,"NA":48810},{"trials":48793,"activeCount":97},[],{"trials":48795,"activeCount":97},[],{"trials":48797,"activeCount":97},[48798],{"nctId":48799,"briefTitle":48800,"status":145,"phases":48801,"primaryCompletion":48802,"completion":48802,"start":48803,"enrollment":1318,"conditions":48804,"interventions":48805},"NCT00850642","GSK2190915 Moderate to Severe Asthma Study",[86],"2010-06-02","2009-06-26",[18],[48790],{"trials":48807,"activeCount":97},[],{"trials":48809,"activeCount":97},[],{"trials":48811,"activeCount":97},[],{"intervention":48813,"totalTrials":417,"cells":48814},"Thiomersal-free FluAS25 adjuvanted vaccine",{"EARLY_PHASE1":48815,"PHASE1":48817,"PHASE2":48819,"PHASE3":48828,"PHASE4":48830,"NA":48832},{"trials":48816,"activeCount":97},[],{"trials":48818,"activeCount":97},[],{"trials":48820,"activeCount":97},[48821],{"nctId":48822,"briefTitle":48823,"status":155,"phases":48824,"primaryCompletion":43462,"completion":43462,"start":4779,"enrollment":8751,"conditions":48825,"interventions":48826},"NCT00633074","Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations",[86],[21],[48813,48827],"Thiomersal reduced FluAS25 adjuvanted vaccine",{"trials":48829,"activeCount":97},[],{"trials":48831,"activeCount":97},[],{"trials":48833,"activeCount":97},[],{"intervention":48827,"totalTrials":417,"cells":48835},{"EARLY_PHASE1":48836,"PHASE1":48838,"PHASE2":48840,"PHASE3":48846,"PHASE4":48848,"NA":48850},{"trials":48837,"activeCount":97},[],{"trials":48839,"activeCount":97},[],{"trials":48841,"activeCount":97},[48842],{"nctId":48822,"briefTitle":48823,"status":155,"phases":48843,"primaryCompletion":43462,"completion":43462,"start":4779,"enrollment":8751,"conditions":48844,"interventions":48845},[86],[21],[48813,48827],{"trials":48847,"activeCount":97},[],{"trials":48849,"activeCount":97},[],{"trials":48851,"activeCount":97},[],{"intervention":41938,"totalTrials":417,"cells":48853},{"EARLY_PHASE1":48854,"PHASE1":48856,"PHASE2":48858,"PHASE3":48864,"PHASE4":48866,"NA":48868},{"trials":48855,"activeCount":97},[],{"trials":48857,"activeCount":97},[],{"trials":48859,"activeCount":97},[48860],{"nctId":41930,"briefTitle":41931,"status":155,"phases":48861,"primaryCompletion":41933,"completion":41934,"start":41935,"enrollment":9196,"conditions":48862,"interventions":48863},[86],[23246],[23248,41938],{"trials":48865,"activeCount":97},[],{"trials":48867,"activeCount":97},[],{"trials":48869,"activeCount":97},[],{"intervention":48871,"totalTrials":417,"cells":48872},"FLU Q-PAN H5N8 375_B",{"EARLY_PHASE1":48873,"PHASE1":48875,"PHASE2":48877,"PHASE3":48892,"PHASE4":48894,"NA":48896},{"trials":48874,"activeCount":97},[],{"trials":48876,"activeCount":97},[],{"trials":48878,"activeCount":97},[48879],{"nctId":48880,"briefTitle":48881,"status":155,"phases":48882,"primaryCompletion":48883,"completion":48884,"start":48885,"enrollment":48886,"conditions":48887,"interventions":48888},"NCT05975840","Safety and Immunogenicity of Different Formulations of Monovalent Influenza A\u002FAstrakhan\u002F3212\u002F2020 Like (H5N8) Virus Vaccine With AS03 Adjuvant System in Medically Stable Adults",[85,86],"2024-05-21","2024-09-19","2023-08-03",518,[5353],[48871,48889,48890,48891],"FLU Q-PAN H5N8 375_A","FLU Q-PAN H5N8 750_B","FLU Q-PAN H5N8 750_A",{"trials":48893,"activeCount":97},[],{"trials":48895,"activeCount":97},[],{"trials":48897,"activeCount":97},[],{"intervention":48889,"totalTrials":417,"cells":48899},{"EARLY_PHASE1":48900,"PHASE1":48902,"PHASE2":48904,"PHASE3":48910,"PHASE4":48912,"NA":48914},{"trials":48901,"activeCount":97},[],{"trials":48903,"activeCount":97},[],{"trials":48905,"activeCount":97},[48906],{"nctId":48880,"briefTitle":48881,"status":155,"phases":48907,"primaryCompletion":48883,"completion":48884,"start":48885,"enrollment":48886,"conditions":48908,"interventions":48909},[85,86],[5353],[48871,48889,48890,48891],{"trials":48911,"activeCount":97},[],{"trials":48913,"activeCount":97},[],{"trials":48915,"activeCount":97},[],{"intervention":48890,"totalTrials":417,"cells":48917},{"EARLY_PHASE1":48918,"PHASE1":48920,"PHASE2":48922,"PHASE3":48928,"PHASE4":48930,"NA":48932},{"trials":48919,"activeCount":97},[],{"trials":48921,"activeCount":97},[],{"trials":48923,"activeCount":97},[48924],{"nctId":48880,"briefTitle":48881,"status":155,"phases":48925,"primaryCompletion":48883,"completion":48884,"start":48885,"enrollment":48886,"conditions":48926,"interventions":48927},[85,86],[5353],[48871,48889,48890,48891],{"trials":48929,"activeCount":97},[],{"trials":48931,"activeCount":97},[],{"trials":48933,"activeCount":97},[],{"intervention":48891,"totalTrials":417,"cells":48935},{"EARLY_PHASE1":48936,"PHASE1":48938,"PHASE2":48940,"PHASE3":48946,"PHASE4":48948,"NA":48950},{"trials":48937,"activeCount":97},[],{"trials":48939,"activeCount":97},[],{"trials":48941,"activeCount":97},[48942],{"nctId":48880,"briefTitle":48881,"status":155,"phases":48943,"primaryCompletion":48883,"completion":48884,"start":48885,"enrollment":48886,"conditions":48944,"interventions":48945},[85,86],[5353],[48871,48889,48890,48891],{"trials":48947,"activeCount":97},[],{"trials":48949,"activeCount":97},[],{"trials":48951,"activeCount":97},[],{"intervention":48953,"totalTrials":417,"cells":48954},"GSK Biologicals' GSK2340274A",{"EARLY_PHASE1":48955,"PHASE1":48957,"PHASE2":48959,"PHASE3":48970,"PHASE4":48972,"NA":48974},{"trials":48956,"activeCount":97},[],{"trials":48958,"activeCount":97},[],{"trials":48960,"activeCount":97},[48961],{"nctId":48962,"briefTitle":48963,"status":155,"phases":48964,"primaryCompletion":48965,"completion":48966,"start":9452,"enrollment":29099,"conditions":48967,"interventions":48968},"NCT01161160","Safety and Immune Response of Candidate H1N1 Influenza Vaccines GSK2340274A and GSK234072A in Children 3 to Less Than 10 Years Old",[86],"2010-08-23","2011-01-31",[21],[48953,48969],"GSK Biologicals' - GSK2340272A",{"trials":48971,"activeCount":97},[],{"trials":48973,"activeCount":97},[],{"trials":48975,"activeCount":97},[],{"intervention":48969,"totalTrials":417,"cells":48977},{"EARLY_PHASE1":48978,"PHASE1":48980,"PHASE2":48982,"PHASE3":48988,"PHASE4":48990,"NA":48992},{"trials":48979,"activeCount":97},[],{"trials":48981,"activeCount":97},[],{"trials":48983,"activeCount":97},[48984],{"nctId":48962,"briefTitle":48963,"status":155,"phases":48985,"primaryCompletion":48965,"completion":48966,"start":9452,"enrollment":29099,"conditions":48986,"interventions":48987},[86],[21],[48953,48969],{"trials":48989,"activeCount":97},[],{"trials":48991,"activeCount":97},[],{"trials":48993,"activeCount":97},[],{"intervention":7743,"totalTrials":417,"cells":48995},{"EARLY_PHASE1":48996,"PHASE1":48998,"PHASE2":49000,"PHASE3":49006,"PHASE4":49008,"NA":49010},{"trials":48997,"activeCount":97},[],{"trials":48999,"activeCount":97},[],{"trials":49001,"activeCount":97},[49002],{"nctId":7736,"briefTitle":7737,"status":155,"phases":49003,"primaryCompletion":7739,"start":7740,"enrollment":1196,"conditions":49004,"interventions":49005},[86],[24],[7743,7744,7718],{"trials":49007,"activeCount":97},[],{"trials":49009,"activeCount":97},[],{"trials":49011,"activeCount":97},[],{"intervention":7744,"totalTrials":417,"cells":49013},{"EARLY_PHASE1":49014,"PHASE1":49016,"PHASE2":49018,"PHASE3":49024,"PHASE4":49026,"NA":49028},{"trials":49015,"activeCount":97},[],{"trials":49017,"activeCount":97},[],{"trials":49019,"activeCount":97},[49020],{"nctId":7736,"briefTitle":7737,"status":155,"phases":49021,"primaryCompletion":7739,"start":7740,"enrollment":1196,"conditions":49022,"interventions":49023},[86],[24],[7743,7744,7718],{"trials":49025,"activeCount":97},[],{"trials":49027,"activeCount":97},[],{"trials":49029,"activeCount":97},[],{"intervention":8521,"totalTrials":417,"cells":49031},{"EARLY_PHASE1":49032,"PHASE1":49034,"PHASE2":49036,"PHASE3":49042,"PHASE4":49044,"NA":49046},{"trials":49033,"activeCount":97},[],{"trials":49035,"activeCount":97},[],{"trials":49037,"activeCount":97},[49038],{"nctId":8513,"briefTitle":8514,"status":500,"phases":49039,"primaryCompletion":8516,"completion":8516,"start":8517,"enrollment":97,"conditions":49040,"interventions":49041},[86],[18],[8520,8521,8522],{"trials":49043,"activeCount":97},[],{"trials":49045,"activeCount":97},[],{"trials":49047,"activeCount":97},[],{"intervention":49049,"totalTrials":417,"cells":49050},"GSK Bio's influenza vaccine GSK576389A [NH 2006\u002F07 season]",{"EARLY_PHASE1":49051,"PHASE1":49053,"PHASE2":49055,"PHASE3":49068,"PHASE4":49070,"NA":49072},{"trials":49052,"activeCount":97},[],{"trials":49054,"activeCount":97},[],{"trials":49056,"activeCount":97},[49057],{"nctId":49058,"briefTitle":49059,"status":155,"phases":49060,"primaryCompletion":8235,"completion":49061,"start":7473,"enrollment":49062,"conditions":49063,"interventions":49064},"NCT00532298","Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over",[86],"2007-11-02",1596,[21],[49049,49065,49066,49067],"GSK Bio's influenza vaccine GSK576389A [NH 2007\u002F08 season]","Fluarix [NH 2006\u002F07 season]","Fluarix [NH 2007\u002F08 season]",{"trials":49069,"activeCount":97},[],{"trials":49071,"activeCount":97},[],{"trials":49073,"activeCount":97},[],{"intervention":49065,"totalTrials":417,"cells":49075},{"EARLY_PHASE1":49076,"PHASE1":49078,"PHASE2":49080,"PHASE3":49086,"PHASE4":49088,"NA":49090},{"trials":49077,"activeCount":97},[],{"trials":49079,"activeCount":97},[],{"trials":49081,"activeCount":97},[49082],{"nctId":49058,"briefTitle":49059,"status":155,"phases":49083,"primaryCompletion":8235,"completion":49061,"start":7473,"enrollment":49062,"conditions":49084,"interventions":49085},[86],[21],[49049,49065,49066,49067],{"trials":49087,"activeCount":97},[],{"trials":49089,"activeCount":97},[],{"trials":49091,"activeCount":97},[],{"intervention":49066,"totalTrials":417,"cells":49093},{"EARLY_PHASE1":49094,"PHASE1":49096,"PHASE2":49098,"PHASE3":49104,"PHASE4":49106,"NA":49108},{"trials":49095,"activeCount":97},[],{"trials":49097,"activeCount":97},[],{"trials":49099,"activeCount":97},[49100],{"nctId":49058,"briefTitle":49059,"status":155,"phases":49101,"primaryCompletion":8235,"completion":49061,"start":7473,"enrollment":49062,"conditions":49102,"interventions":49103},[86],[21],[49049,49065,49066,49067],{"trials":49105,"activeCount":97},[],{"trials":49107,"activeCount":97},[],{"trials":49109,"activeCount":97},[],{"intervention":49067,"totalTrials":417,"cells":49111},{"EARLY_PHASE1":49112,"PHASE1":49114,"PHASE2":49116,"PHASE3":49122,"PHASE4":49124,"NA":49126},{"trials":49113,"activeCount":97},[],{"trials":49115,"activeCount":97},[],{"trials":49117,"activeCount":97},[49118],{"nctId":49058,"briefTitle":49059,"status":155,"phases":49119,"primaryCompletion":8235,"completion":49061,"start":7473,"enrollment":49062,"conditions":49120,"interventions":49121},[86],[21],[49049,49065,49066,49067],{"trials":49123,"activeCount":97},[],{"trials":49125,"activeCount":97},[],{"trials":49127,"activeCount":97},[],{"intervention":18577,"totalTrials":417,"cells":49129},{"EARLY_PHASE1":49130,"PHASE1":49132,"PHASE2":49134,"PHASE3":49140,"PHASE4":49142,"NA":49144},{"trials":49131,"activeCount":97},[],{"trials":49133,"activeCount":97},[],{"trials":49135,"activeCount":97},[49136],{"nctId":18570,"briefTitle":18571,"status":155,"phases":49137,"primaryCompletion":18573,"completion":18573,"start":18574,"enrollment":3089,"conditions":49138,"interventions":49139},[86],[17996],[18545,18577],{"trials":49141,"activeCount":97},[],{"trials":49143,"activeCount":97},[],{"trials":49145,"activeCount":97},[],{"intervention":49147,"totalTrials":417,"cells":49148},"Mepolizumab 750",{"EARLY_PHASE1":49149,"PHASE1":49151,"PHASE2":49153,"PHASE3":49164,"PHASE4":49166,"NA":49168},{"trials":49150,"activeCount":97},[],{"trials":49152,"activeCount":97},[],{"trials":49154,"activeCount":97},[49155],{"nctId":49156,"briefTitle":49157,"status":155,"phases":49158,"primaryCompletion":49159,"completion":49159,"start":40264,"enrollment":12684,"conditions":49160,"interventions":49161},"NCT01000506","Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma",[86],"2012-03-23",[18],[49147,49162,49163],"Mepolizumab 250","Mepolizumab 75",{"trials":49165,"activeCount":97},[],{"trials":49167,"activeCount":97},[],{"trials":49169,"activeCount":97},[],{"intervention":49162,"totalTrials":417,"cells":49171},{"EARLY_PHASE1":49172,"PHASE1":49174,"PHASE2":49176,"PHASE3":49182,"PHASE4":49184,"NA":49186},{"trials":49173,"activeCount":97},[],{"trials":49175,"activeCount":97},[],{"trials":49177,"activeCount":97},[49178],{"nctId":49156,"briefTitle":49157,"status":155,"phases":49179,"primaryCompletion":49159,"completion":49159,"start":40264,"enrollment":12684,"conditions":49180,"interventions":49181},[86],[18],[49147,49162,49163],{"trials":49183,"activeCount":97},[],{"trials":49185,"activeCount":97},[],{"trials":49187,"activeCount":97},[],{"intervention":49163,"totalTrials":417,"cells":49189},{"EARLY_PHASE1":49190,"PHASE1":49192,"PHASE2":49194,"PHASE3":49200,"PHASE4":49202,"NA":49204},{"trials":49191,"activeCount":97},[],{"trials":49193,"activeCount":97},[],{"trials":49195,"activeCount":97},[49196],{"nctId":49156,"briefTitle":49157,"status":155,"phases":49197,"primaryCompletion":49159,"completion":49159,"start":40264,"enrollment":12684,"conditions":49198,"interventions":49199},[86],[18],[49147,49162,49163],{"trials":49201,"activeCount":97},[],{"trials":49203,"activeCount":97},[],{"trials":49205,"activeCount":97},[],{"intervention":49207,"totalTrials":417,"cells":49208},"250mg rilapladib",{"EARLY_PHASE1":49209,"PHASE1":49211,"PHASE2":49213,"PHASE3":49221,"PHASE4":49223,"NA":49225},{"trials":49210,"activeCount":97},[],{"trials":49212,"activeCount":97},[],{"trials":49214,"activeCount":97},[49215],{"nctId":49216,"briefTitle":49217,"status":155,"phases":49218,"primaryCompletion":3461,"completion":12260,"start":4973,"enrollment":8817,"conditions":49219,"interventions":49220},"NCT01428453","A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease",[86],[4644],[49207],{"trials":49222,"activeCount":97},[],{"trials":49224,"activeCount":97},[],{"trials":49226,"activeCount":97},[],{"intervention":49228,"totalTrials":417,"cells":49229},"LOSMAPIMOD 7.5 MG",{"EARLY_PHASE1":49230,"PHASE1":49232,"PHASE2":49234,"PHASE3":49243,"PHASE4":49245,"NA":49247},{"trials":49231,"activeCount":97},[],{"trials":49233,"activeCount":97},[],{"trials":49235,"activeCount":97},[49236],{"nctId":49237,"briefTitle":49238,"status":155,"phases":49239,"primaryCompletion":49240,"completion":49240,"start":4778,"enrollment":7769,"conditions":49241,"interventions":49242},"NCT00633022","A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET\u002FCT Imaging",[86],"2009-12-03",[9309],[49228],{"trials":49244,"activeCount":97},[],{"trials":49246,"activeCount":97},[],{"trials":49248,"activeCount":97},[],{"intervention":49250,"totalTrials":417,"cells":49251},"GSK257049 Dosage 1",{"EARLY_PHASE1":49252,"PHASE1":49254,"PHASE2":49256,"PHASE3":49267,"PHASE4":49269,"NA":49271},{"trials":49253,"activeCount":97},[],{"trials":49255,"activeCount":97},[],{"trials":49257,"activeCount":97},[49258],{"nctId":49259,"briefTitle":49260,"status":155,"phases":49261,"primaryCompletion":39386,"completion":49262,"start":49263,"enrollment":6482,"conditions":49264,"interventions":49265},"NCT01857869","Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults",[86],"2014-12-16","2013-05-20",[3287],[49250,49266],"GSK257049 Dosage 2",{"trials":49268,"activeCount":97},[],{"trials":49270,"activeCount":97},[],{"trials":49272,"activeCount":97},[],{"intervention":49266,"totalTrials":417,"cells":49274},{"EARLY_PHASE1":49275,"PHASE1":49277,"PHASE2":49279,"PHASE3":49285,"PHASE4":49287,"NA":49289},{"trials":49276,"activeCount":97},[],{"trials":49278,"activeCount":97},[],{"trials":49280,"activeCount":97},[49281],{"nctId":49259,"briefTitle":49260,"status":155,"phases":49282,"primaryCompletion":39386,"completion":49262,"start":49263,"enrollment":6482,"conditions":49283,"interventions":49284},[86],[3287],[49250,49266],{"trials":49286,"activeCount":97},[],{"trials":49288,"activeCount":97},[],{"trials":49290,"activeCount":97},[],{"intervention":8212,"totalTrials":417,"cells":49292},{"EARLY_PHASE1":49293,"PHASE1":49295,"PHASE2":49297,"PHASE3":49303,"PHASE4":49305,"NA":49307},{"trials":49294,"activeCount":97},[],{"trials":49296,"activeCount":97},[],{"trials":49298,"activeCount":97},[49299],{"nctId":8204,"briefTitle":8205,"status":155,"phases":49300,"primaryCompletion":8207,"completion":8208,"start":8209,"enrollment":37,"conditions":49301,"interventions":49302},[86],[21],[8212,8177],{"trials":49304,"activeCount":97},[],{"trials":49306,"activeCount":97},[],{"trials":49308,"activeCount":97},[],{"intervention":21435,"totalTrials":417,"cells":49310},{"EARLY_PHASE1":49311,"PHASE1":49313,"PHASE2":49315,"PHASE3":49321,"PHASE4":49323,"NA":49325},{"trials":49312,"activeCount":97},[],{"trials":49314,"activeCount":97},[],{"trials":49316,"activeCount":97},[49317],{"nctId":21429,"briefTitle":21430,"status":155,"phases":49318,"primaryCompletion":7582,"completion":7582,"start":2482,"enrollment":21432,"conditions":49319,"interventions":49320},[86],[4759],[21435,19386,19416,4809,21436,4807],{"trials":49322,"activeCount":97},[],{"trials":49324,"activeCount":97},[],{"trials":49326,"activeCount":97},[],{"intervention":21436,"totalTrials":417,"cells":49328},{"EARLY_PHASE1":49329,"PHASE1":49331,"PHASE2":49333,"PHASE3":49339,"PHASE4":49341,"NA":49343},{"trials":49330,"activeCount":97},[],{"trials":49332,"activeCount":97},[],{"trials":49334,"activeCount":97},[49335],{"nctId":21429,"briefTitle":21430,"status":155,"phases":49336,"primaryCompletion":7582,"completion":7582,"start":2482,"enrollment":21432,"conditions":49337,"interventions":49338},[86],[4759],[21435,19386,19416,4809,21436,4807],{"trials":49340,"activeCount":97},[],{"trials":49342,"activeCount":97},[],{"trials":49344,"activeCount":97},[],{"intervention":49346,"totalTrials":417,"cells":49347},"GSK Biologicals' Pandemic influenza",{"EARLY_PHASE1":49348,"PHASE1":49350,"PHASE2":49352,"PHASE3":49360,"PHASE4":49362,"NA":49364},{"trials":49349,"activeCount":97},[],{"trials":49351,"activeCount":97},[],{"trials":49353,"activeCount":97},[49354],{"nctId":49355,"briefTitle":49356,"status":155,"phases":49357,"primaryCompletion":15600,"completion":15600,"start":9891,"enrollment":1237,"conditions":49358,"interventions":49359},"NCT01001169","Safety and Immunogenocity Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Japanese Children",[86],[21],[49346],{"trials":49361,"activeCount":97},[],{"trials":49363,"activeCount":97},[],{"trials":49365,"activeCount":97},[],{"intervention":49367,"totalTrials":417,"cells":49368},"GSK2981278 ointment",{"EARLY_PHASE1":49369,"PHASE1":49371,"PHASE2":49373,"PHASE3":49384,"PHASE4":49386,"NA":49388},{"trials":49370,"activeCount":97},[],{"trials":49372,"activeCount":97},[],{"trials":49374,"activeCount":97},[49375],{"nctId":49376,"briefTitle":49377,"status":155,"phases":49378,"primaryCompletion":49379,"completion":49379,"start":49380,"enrollment":1720,"conditions":49381,"interventions":49382},"NCT03004846","A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis",[85,86],"2017-05-05","2017-02-13",[22060],[49367,49383],"Vehicle ointment",{"trials":49385,"activeCount":97},[],{"trials":49387,"activeCount":97},[],{"trials":49389,"activeCount":97},[],{"intervention":49383,"totalTrials":417,"cells":49391},{"EARLY_PHASE1":49392,"PHASE1":49394,"PHASE2":49396,"PHASE3":49402,"PHASE4":49404,"NA":49406},{"trials":49393,"activeCount":97},[],{"trials":49395,"activeCount":97},[],{"trials":49397,"activeCount":97},[49398],{"nctId":49376,"briefTitle":49377,"status":155,"phases":49399,"primaryCompletion":49379,"completion":49379,"start":49380,"enrollment":1720,"conditions":49400,"interventions":49401},[85,86],[22060],[49367,49383],{"trials":49403,"activeCount":97},[],{"trials":49405,"activeCount":97},[],{"trials":49407,"activeCount":97},[],{"intervention":42283,"totalTrials":417,"cells":49409},{"EARLY_PHASE1":49410,"PHASE1":49412,"PHASE2":49414,"PHASE3":49420,"PHASE4":49422,"NA":49424},{"trials":49411,"activeCount":97},[],{"trials":49413,"activeCount":97},[],{"trials":49415,"activeCount":97},[49416],{"nctId":42276,"briefTitle":42277,"status":155,"phases":49417,"primaryCompletion":42279,"completion":42279,"start":42280,"enrollment":2797,"conditions":49418,"interventions":49419},[86],[9343,10943],[19312,42283],{"trials":49421,"activeCount":97},[],{"trials":49423,"activeCount":97},[],{"trials":49425,"activeCount":97},[],{"intervention":49427,"totalTrials":417,"cells":49428},"doxorubicin + cyclophosphamide",{"EARLY_PHASE1":49429,"PHASE1":49431,"PHASE2":49433,"PHASE3":49444,"PHASE4":49446,"NA":49448},{"trials":49430,"activeCount":97},[],{"trials":49432,"activeCount":97},[],{"trials":49434,"activeCount":97},[49435],{"nctId":49436,"briefTitle":49437,"status":155,"phases":49438,"primaryCompletion":7591,"completion":484,"start":2441,"enrollment":49439,"conditions":49440,"interventions":49441},"NCT00849472","Treatment With Pazopanib for Neoadjuvant Breast Cancer",[86],101,[668],[49427,49442,49443],"paclitaxel + pazopanib","pazopanib monotherapy",{"trials":49445,"activeCount":97},[],{"trials":49447,"activeCount":97},[],{"trials":49449,"activeCount":97},[],{"intervention":49442,"totalTrials":417,"cells":49451},{"EARLY_PHASE1":49452,"PHASE1":49454,"PHASE2":49456,"PHASE3":49462,"PHASE4":49464,"NA":49466},{"trials":49453,"activeCount":97},[],{"trials":49455,"activeCount":97},[],{"trials":49457,"activeCount":97},[49458],{"nctId":49436,"briefTitle":49437,"status":155,"phases":49459,"primaryCompletion":7591,"completion":484,"start":2441,"enrollment":49439,"conditions":49460,"interventions":49461},[86],[668],[49427,49442,49443],{"trials":49463,"activeCount":97},[],{"trials":49465,"activeCount":97},[],{"trials":49467,"activeCount":97},[],{"intervention":49443,"totalTrials":417,"cells":49469},{"EARLY_PHASE1":49470,"PHASE1":49472,"PHASE2":49474,"PHASE3":49480,"PHASE4":49482,"NA":49484},{"trials":49471,"activeCount":97},[],{"trials":49473,"activeCount":97},[],{"trials":49475,"activeCount":97},[49476],{"nctId":49436,"briefTitle":49437,"status":155,"phases":49477,"primaryCompletion":7591,"completion":484,"start":2441,"enrollment":49439,"conditions":49478,"interventions":49479},[86],[668],[49427,49442,49443],{"trials":49481,"activeCount":97},[],{"trials":49483,"activeCount":97},[],{"trials":49485,"activeCount":97},[],{"intervention":49487,"totalTrials":417,"cells":49488},"GSK233705 12.5mcg",{"EARLY_PHASE1":49489,"PHASE1":49491,"PHASE2":49493,"PHASE3":49505,"PHASE4":49507,"NA":49509},{"trials":49490,"activeCount":97},[],{"trials":49492,"activeCount":97},[],{"trials":49494,"activeCount":97},[49495],{"nctId":49496,"briefTitle":49497,"status":155,"phases":49498,"primaryCompletion":19910,"completion":19910,"start":41494,"enrollment":4679,"conditions":49499,"interventions":49500},"NCT00676052","Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)",[86],[15],[49487,49501,49502,49503,49504],"GSK233705 25mcg","GSK233705 50mcg","GSK233705 100mcg","GSK233705 200mcg",{"trials":49506,"activeCount":97},[],{"trials":49508,"activeCount":97},[],{"trials":49510,"activeCount":97},[],{"intervention":49501,"totalTrials":417,"cells":49512},{"EARLY_PHASE1":49513,"PHASE1":49515,"PHASE2":49517,"PHASE3":49523,"PHASE4":49525,"NA":49527},{"trials":49514,"activeCount":97},[],{"trials":49516,"activeCount":97},[],{"trials":49518,"activeCount":97},[49519],{"nctId":49496,"briefTitle":49497,"status":155,"phases":49520,"primaryCompletion":19910,"completion":19910,"start":41494,"enrollment":4679,"conditions":49521,"interventions":49522},[86],[15],[49487,49501,49502,49503,49504],{"trials":49524,"activeCount":97},[],{"trials":49526,"activeCount":97},[],{"trials":49528,"activeCount":97},[],{"intervention":49502,"totalTrials":417,"cells":49530},{"EARLY_PHASE1":49531,"PHASE1":49533,"PHASE2":49535,"PHASE3":49541,"PHASE4":49543,"NA":49545},{"trials":49532,"activeCount":97},[],{"trials":49534,"activeCount":97},[],{"trials":49536,"activeCount":97},[49537],{"nctId":49496,"briefTitle":49497,"status":155,"phases":49538,"primaryCompletion":19910,"completion":19910,"start":41494,"enrollment":4679,"conditions":49539,"interventions":49540},[86],[15],[49487,49501,49502,49503,49504],{"trials":49542,"activeCount":97},[],{"trials":49544,"activeCount":97},[],{"trials":49546,"activeCount":97},[],{"intervention":49503,"totalTrials":417,"cells":49548},{"EARLY_PHASE1":49549,"PHASE1":49551,"PHASE2":49553,"PHASE3":49559,"PHASE4":49561,"NA":49563},{"trials":49550,"activeCount":97},[],{"trials":49552,"activeCount":97},[],{"trials":49554,"activeCount":97},[49555],{"nctId":49496,"briefTitle":49497,"status":155,"phases":49556,"primaryCompletion":19910,"completion":19910,"start":41494,"enrollment":4679,"conditions":49557,"interventions":49558},[86],[15],[49487,49501,49502,49503,49504],{"trials":49560,"activeCount":97},[],{"trials":49562,"activeCount":97},[],{"trials":49564,"activeCount":97},[],{"intervention":49504,"totalTrials":417,"cells":49566},{"EARLY_PHASE1":49567,"PHASE1":49569,"PHASE2":49571,"PHASE3":49577,"PHASE4":49579,"NA":49581},{"trials":49568,"activeCount":97},[],{"trials":49570,"activeCount":97},[],{"trials":49572,"activeCount":97},[49573],{"nctId":49496,"briefTitle":49497,"status":155,"phases":49574,"primaryCompletion":19910,"completion":19910,"start":41494,"enrollment":4679,"conditions":49575,"interventions":49576},[86],[15],[49487,49501,49502,49503,49504],{"trials":49578,"activeCount":97},[],{"trials":49580,"activeCount":97},[],{"trials":49582,"activeCount":97},[],{"intervention":49584,"totalTrials":417,"cells":49585},"GW685698X 200mcg,GW685698X 200mcg and 400mcg",{"EARLY_PHASE1":49586,"PHASE1":49588,"PHASE2":49590,"PHASE3":49599,"PHASE4":49601,"NA":49603},{"trials":49587,"activeCount":97},[],{"trials":49589,"activeCount":97},[],{"trials":49591,"activeCount":97},[49592],{"nctId":49593,"briefTitle":49594,"status":155,"phases":49595,"primaryCompletion":10332,"completion":3100,"start":41724,"enrollment":49596,"conditions":49597,"interventions":49598},"NCT00398645","A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.",[86],648,[18],[49584],{"trials":49600,"activeCount":97},[],{"trials":49602,"activeCount":97},[],{"trials":49604,"activeCount":97},[],{"intervention":41138,"totalTrials":417,"cells":49606},{"EARLY_PHASE1":49607,"PHASE1":49609,"PHASE2":49611,"PHASE3":49617,"PHASE4":49619,"NA":49621},{"trials":49608,"activeCount":97},[],{"trials":49610,"activeCount":97},[],{"trials":49612,"activeCount":97},[49613],{"nctId":41131,"briefTitle":41132,"status":155,"phases":49614,"primaryCompletion":41134,"completion":41134,"start":41135,"enrollment":4377,"conditions":49615,"interventions":49616},[86],[23246],[41096,41138,41139,41140,41141],{"trials":49618,"activeCount":97},[],{"trials":49620,"activeCount":97},[],{"trials":49622,"activeCount":97},[],{"intervention":41139,"totalTrials":417,"cells":49624},{"EARLY_PHASE1":49625,"PHASE1":49627,"PHASE2":49629,"PHASE3":49635,"PHASE4":49637,"NA":49639},{"trials":49626,"activeCount":97},[],{"trials":49628,"activeCount":97},[],{"trials":49630,"activeCount":97},[49631],{"nctId":41131,"briefTitle":41132,"status":155,"phases":49632,"primaryCompletion":41134,"completion":41134,"start":41135,"enrollment":4377,"conditions":49633,"interventions":49634},[86],[23246],[41096,41138,41139,41140,41141],{"trials":49636,"activeCount":97},[],{"trials":49638,"activeCount":97},[],{"trials":49640,"activeCount":97},[],{"intervention":41141,"totalTrials":417,"cells":49642},{"EARLY_PHASE1":49643,"PHASE1":49645,"PHASE2":49647,"PHASE3":49653,"PHASE4":49655,"NA":49657},{"trials":49644,"activeCount":97},[],{"trials":49646,"activeCount":97},[],{"trials":49648,"activeCount":97},[49649],{"nctId":41131,"briefTitle":41132,"status":155,"phases":49650,"primaryCompletion":41134,"completion":41134,"start":41135,"enrollment":4377,"conditions":49651,"interventions":49652},[86],[23246],[41096,41138,41139,41140,41141],{"trials":49654,"activeCount":97},[],{"trials":49656,"activeCount":97},[],{"trials":49658,"activeCount":97},[],{"intervention":19179,"totalTrials":417,"cells":49660},{"EARLY_PHASE1":49661,"PHASE1":49663,"PHASE2":49665,"PHASE3":49671,"PHASE4":49673,"NA":49675},{"trials":49662,"activeCount":97},[],{"trials":49664,"activeCount":97},[],{"trials":49666,"activeCount":97},[49667],{"nctId":19172,"briefTitle":19173,"status":155,"phases":49668,"primaryCompletion":8768,"completion":8768,"start":19175,"enrollment":3463,"conditions":49669,"interventions":49670},[86],[33,30,4704,4702,3624,24,19177],[4706,19179,19151,10346],{"trials":49672,"activeCount":97},[],{"trials":49674,"activeCount":97},[],{"trials":49676,"activeCount":97},[],{"intervention":49678,"totalTrials":417,"cells":49679},"GlaxoSmithKline Biologicals' influenza vaccine GSK576389A",{"EARLY_PHASE1":49680,"PHASE1":49682,"PHASE2":49684,"PHASE3":49694,"PHASE4":49696,"NA":49698},{"trials":49681,"activeCount":97},[],{"trials":49683,"activeCount":97},[],{"trials":49685,"activeCount":97},[49686],{"nctId":49687,"briefTitle":49688,"status":155,"phases":49689,"primaryCompletion":18825,"completion":18825,"start":49690,"enrollment":49691,"conditions":49692,"interventions":49693},"NCT00540592","Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A",[86],"2007-10-08",2007,[21],[49678,25702],{"trials":49695,"activeCount":97},[],{"trials":49697,"activeCount":97},[],{"trials":49699,"activeCount":97},[],{"intervention":49701,"totalTrials":417,"cells":49702},"Naproxen",{"EARLY_PHASE1":49703,"PHASE1":49705,"PHASE2":49707,"PHASE3":49715,"PHASE4":49717,"NA":49719},{"trials":49704,"activeCount":97},[],{"trials":49706,"activeCount":97},[],{"trials":49708,"activeCount":97},[49709],{"nctId":49710,"briefTitle":49711,"status":155,"phases":49712,"primaryCompletion":2813,"completion":2794,"start":10167,"enrollment":8437,"conditions":49713,"interventions":49714},"NCT01231490","Acute Osteoarthritis Experimental Model Study.",[86],[10386],[49701],{"trials":49716,"activeCount":97},[],{"trials":49718,"activeCount":97},[],{"trials":49720,"activeCount":97},[],{"intervention":49722,"totalTrials":417,"cells":49723},"Ofatumumab 3mg",{"EARLY_PHASE1":49724,"PHASE1":49726,"PHASE2":49728,"PHASE3":49741,"PHASE4":49743,"NA":49745},{"trials":49725,"activeCount":97},[],{"trials":49727,"activeCount":97},[],{"trials":49729,"activeCount":97},[49730],{"nctId":49731,"briefTitle":49732,"status":155,"phases":49733,"primaryCompletion":49734,"completion":49735,"start":17207,"enrollment":49736,"conditions":49737,"interventions":49738},"NCT01457924","Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis",[86],"2013-08-23","2015-06-10",232,[39962],[49722,49739,49740],"Ofatumumab 30mg","Ofatumumab 60mg",{"trials":49742,"activeCount":97},[],{"trials":49744,"activeCount":97},[],{"trials":49746,"activeCount":97},[],{"intervention":49739,"totalTrials":417,"cells":49748},{"EARLY_PHASE1":49749,"PHASE1":49751,"PHASE2":49753,"PHASE3":49759,"PHASE4":49761,"NA":49763},{"trials":49750,"activeCount":97},[],{"trials":49752,"activeCount":97},[],{"trials":49754,"activeCount":97},[49755],{"nctId":49731,"briefTitle":49732,"status":155,"phases":49756,"primaryCompletion":49734,"completion":49735,"start":17207,"enrollment":49736,"conditions":49757,"interventions":49758},[86],[39962],[49722,49739,49740],{"trials":49760,"activeCount":97},[],{"trials":49762,"activeCount":97},[],{"trials":49764,"activeCount":97},[],{"intervention":49740,"totalTrials":417,"cells":49766},{"EARLY_PHASE1":49767,"PHASE1":49769,"PHASE2":49771,"PHASE3":49777,"PHASE4":49779,"NA":49781},{"trials":49768,"activeCount":97},[],{"trials":49770,"activeCount":97},[],{"trials":49772,"activeCount":97},[49773],{"nctId":49731,"briefTitle":49732,"status":155,"phases":49774,"primaryCompletion":49734,"completion":49735,"start":17207,"enrollment":49736,"conditions":49775,"interventions":49776},[86],[39962],[49722,49739,49740],{"trials":49778,"activeCount":97},[],{"trials":49780,"activeCount":97},[],{"trials":49782,"activeCount":97},[],{"intervention":49784,"totalTrials":417,"cells":49785},"Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose",{"EARLY_PHASE1":49786,"PHASE1":49788,"PHASE2":49790,"PHASE3":49799,"PHASE4":49801,"NA":49803},{"trials":49787,"activeCount":97},[],{"trials":49789,"activeCount":97},[],{"trials":49791,"activeCount":97},[49792],{"nctId":49793,"briefTitle":49794,"status":155,"phases":49795,"primaryCompletion":6317,"completion":6317,"start":10332,"enrollment":603,"conditions":49796,"interventions":49797},"NCT00506350","Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults",[86],[21],[49784,49798],"Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses",{"trials":49800,"activeCount":97},[],{"trials":49802,"activeCount":97},[],{"trials":49804,"activeCount":97},[],{"intervention":49798,"totalTrials":417,"cells":49806},{"EARLY_PHASE1":49807,"PHASE1":49809,"PHASE2":49811,"PHASE3":49817,"PHASE4":49819,"NA":49821},{"trials":49808,"activeCount":97},[],{"trials":49810,"activeCount":97},[],{"trials":49812,"activeCount":97},[49813],{"nctId":49793,"briefTitle":49794,"status":155,"phases":49814,"primaryCompletion":6317,"completion":6317,"start":10332,"enrollment":603,"conditions":49815,"interventions":49816},[86],[21],[49784,49798],{"trials":49818,"activeCount":97},[],{"trials":49820,"activeCount":97},[],{"trials":49822,"activeCount":97},[],{"intervention":18586,"totalTrials":417,"cells":49824},{"EARLY_PHASE1":49825,"PHASE1":49827,"PHASE2":49829,"PHASE3":49835,"PHASE4":49837,"NA":49839},{"trials":49826,"activeCount":97},[],{"trials":49828,"activeCount":97},[],{"trials":49830,"activeCount":97},[49831],{"nctId":18579,"briefTitle":18580,"status":145,"phases":49832,"primaryCompletion":9653,"completion":9653,"start":18582,"enrollment":628,"conditions":49833,"interventions":49834},[86],[17996],[18545,18585,18586,18587,18588],{"trials":49836,"activeCount":97},[],{"trials":49838,"activeCount":97},[],{"trials":49840,"activeCount":97},[],{"intervention":18587,"totalTrials":417,"cells":49842},{"EARLY_PHASE1":49843,"PHASE1":49845,"PHASE2":49847,"PHASE3":49853,"PHASE4":49855,"NA":49857},{"trials":49844,"activeCount":97},[],{"trials":49846,"activeCount":97},[],{"trials":49848,"activeCount":97},[49849],{"nctId":18579,"briefTitle":18580,"status":145,"phases":49850,"primaryCompletion":9653,"completion":9653,"start":18582,"enrollment":628,"conditions":49851,"interventions":49852},[86],[17996],[18545,18585,18586,18587,18588],{"trials":49854,"activeCount":97},[],{"trials":49856,"activeCount":97},[],{"trials":49858,"activeCount":97},[],{"intervention":18588,"totalTrials":417,"cells":49860},{"EARLY_PHASE1":49861,"PHASE1":49863,"PHASE2":49865,"PHASE3":49871,"PHASE4":49873,"NA":49875},{"trials":49862,"activeCount":97},[],{"trials":49864,"activeCount":97},[],{"trials":49866,"activeCount":97},[49867],{"nctId":18579,"briefTitle":18580,"status":145,"phases":49868,"primaryCompletion":9653,"completion":9653,"start":18582,"enrollment":628,"conditions":49869,"interventions":49870},[86],[17996],[18545,18585,18586,18587,18588],{"trials":49872,"activeCount":97},[],{"trials":49874,"activeCount":97},[],{"trials":49876,"activeCount":97},[],{"intervention":49878,"totalTrials":417,"cells":49879},"FFNS 110 mcg QD",{"EARLY_PHASE1":49880,"PHASE1":49882,"PHASE2":49884,"PHASE3":49894,"PHASE4":49896,"NA":49898},{"trials":49881,"activeCount":97},[],{"trials":49883,"activeCount":97},[],{"trials":49885,"activeCount":97},[49886],{"nctId":49887,"briefTitle":49888,"status":155,"phases":49889,"primaryCompletion":9452,"completion":49890,"start":40303,"enrollment":40778,"conditions":49891,"interventions":49892},"NCT01018030","Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis",[86],"2010-07-16",[30227],[49878,49893],"FFNS 110 mcg BID",{"trials":49895,"activeCount":97},[],{"trials":49897,"activeCount":97},[],{"trials":49899,"activeCount":97},[],{"intervention":49893,"totalTrials":417,"cells":49901},{"EARLY_PHASE1":49902,"PHASE1":49904,"PHASE2":49906,"PHASE3":49912,"PHASE4":49914,"NA":49916},{"trials":49903,"activeCount":97},[],{"trials":49905,"activeCount":97},[],{"trials":49907,"activeCount":97},[49908],{"nctId":49887,"briefTitle":49888,"status":155,"phases":49909,"primaryCompletion":9452,"completion":49890,"start":40303,"enrollment":40778,"conditions":49910,"interventions":49911},[86],[30227],[49878,49893],{"trials":49913,"activeCount":97},[],{"trials":49915,"activeCount":97},[],{"trials":49917,"activeCount":97},[],{"intervention":49919,"totalTrials":417,"cells":49920},"lapatinib and Vinorelbine",{"EARLY_PHASE1":49921,"PHASE1":49923,"PHASE2":49925,"PHASE3":49933,"PHASE4":49935,"NA":49937},{"trials":49922,"activeCount":97},[],{"trials":49924,"activeCount":97},[],{"trials":49926,"activeCount":97},[49927],{"nctId":49928,"briefTitle":49929,"status":155,"phases":49930,"primaryCompletion":728,"completion":728,"start":3550,"enrollment":1079,"conditions":49931,"interventions":49932},"NCT01128543","Lapatinib in Combination With Vinorelbine",[86],[36],[49919],{"trials":49934,"activeCount":97},[],{"trials":49936,"activeCount":97},[],{"trials":49938,"activeCount":97},[],{"intervention":4161,"totalTrials":417,"cells":49940},{"EARLY_PHASE1":49941,"PHASE1":49943,"PHASE2":49945,"PHASE3":49951,"PHASE4":49953,"NA":49955},{"trials":49942,"activeCount":97},[],{"trials":49944,"activeCount":97},[],{"trials":49946,"activeCount":97},[49947],{"nctId":4152,"briefTitle":4153,"status":145,"phases":49948,"primaryCompletion":4155,"completion":4156,"start":4157,"enrollment":4158,"conditions":49949,"interventions":49950},[85,86],[24],[4161,4109],{"trials":49952,"activeCount":97},[],{"trials":49954,"activeCount":97},[],{"trials":49956,"activeCount":97},[],{"intervention":49958,"totalTrials":417,"cells":49959},"GR68755 (Alosetron hydrochloride) 1 mg",{"EARLY_PHASE1":49960,"PHASE1":49962,"PHASE2":49964,"PHASE3":49974,"PHASE4":49976,"NA":49978},{"trials":49961,"activeCount":97},[],{"trials":49963,"activeCount":97},[],{"trials":49965,"activeCount":97},[49966],{"nctId":49967,"briefTitle":49968,"status":155,"phases":49969,"primaryCompletion":49970,"completion":49970,"start":49971,"enrollment":2045,"conditions":49972,"interventions":49973},"NCT01855711","Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)",[86],"2005-05-10","2003-09-18",[11510],[49958],{"trials":49975,"activeCount":97},[],{"trials":49977,"activeCount":97},[],{"trials":49979,"activeCount":97},[],{"intervention":49981,"totalTrials":417,"cells":49982},"GSK Biologicals' AS01B adjuvant",{"EARLY_PHASE1":49983,"PHASE1":49985,"PHASE2":49987,"PHASE3":50001,"PHASE4":50003,"NA":50005},{"trials":49984,"activeCount":97},[],{"trials":49986,"activeCount":97},[],{"trials":49988,"activeCount":97},[49989],{"nctId":49990,"briefTitle":49991,"status":155,"phases":49992,"primaryCompletion":49993,"completion":49993,"start":3370,"enrollment":9445,"conditions":49994,"interventions":49995},"NCT00621322","Safety and Immunogenicity Study of GSK Biologicals Tuberculosis Vaccines (692342) to Healthy Adults",[86],"2009-04-03",[23246],[49981,49996,49997,49998,49999,50000],"GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 1","GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 2","GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 3","GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 1","GSK Biologicals' Candidate Tuberculosis Vaccine (692342) - Formulation 4 - Dosage 2",{"trials":50002,"activeCount":97},[],{"trials":50004,"activeCount":97},[],{"trials":50006,"activeCount":97},[],{"intervention":49996,"totalTrials":417,"cells":50008},{"EARLY_PHASE1":50009,"PHASE1":50011,"PHASE2":50013,"PHASE3":50019,"PHASE4":50021,"NA":50023},{"trials":50010,"activeCount":97},[],{"trials":50012,"activeCount":97},[],{"trials":50014,"activeCount":97},[50015],{"nctId":49990,"briefTitle":49991,"status":155,"phases":50016,"primaryCompletion":49993,"completion":49993,"start":3370,"enrollment":9445,"conditions":50017,"interventions":50018},[86],[23246],[49981,49996,49997,49998,49999,50000],{"trials":50020,"activeCount":97},[],{"trials":50022,"activeCount":97},[],{"trials":50024,"activeCount":97},[],{"intervention":49997,"totalTrials":417,"cells":50026},{"EARLY_PHASE1":50027,"PHASE1":50029,"PHASE2":50031,"PHASE3":50037,"PHASE4":50039,"NA":50041},{"trials":50028,"activeCount":97},[],{"trials":50030,"activeCount":97},[],{"trials":50032,"activeCount":97},[50033],{"nctId":49990,"briefTitle":49991,"status":155,"phases":50034,"primaryCompletion":49993,"completion":49993,"start":3370,"enrollment":9445,"conditions":50035,"interventions":50036},[86],[23246],[49981,49996,49997,49998,49999,50000],{"trials":50038,"activeCount":97},[],{"trials":50040,"activeCount":97},[],{"trials":50042,"activeCount":97},[],{"intervention":49998,"totalTrials":417,"cells":50044},{"EARLY_PHASE1":50045,"PHASE1":50047,"PHASE2":50049,"PHASE3":50055,"PHASE4":50057,"NA":50059},{"trials":50046,"activeCount":97},[],{"trials":50048,"activeCount":97},[],{"trials":50050,"activeCount":97},[50051],{"nctId":49990,"briefTitle":49991,"status":155,"phases":50052,"primaryCompletion":49993,"completion":49993,"start":3370,"enrollment":9445,"conditions":50053,"interventions":50054},[86],[23246],[49981,49996,49997,49998,49999,50000],{"trials":50056,"activeCount":97},[],{"trials":50058,"activeCount":97},[],{"trials":50060,"activeCount":97},[],{"intervention":49999,"totalTrials":417,"cells":50062},{"EARLY_PHASE1":50063,"PHASE1":50065,"PHASE2":50067,"PHASE3":50073,"PHASE4":50075,"NA":50077},{"trials":50064,"activeCount":97},[],{"trials":50066,"activeCount":97},[],{"trials":50068,"activeCount":97},[50069],{"nctId":49990,"briefTitle":49991,"status":155,"phases":50070,"primaryCompletion":49993,"completion":49993,"start":3370,"enrollment":9445,"conditions":50071,"interventions":50072},[86],[23246],[49981,49996,49997,49998,49999,50000],{"trials":50074,"activeCount":97},[],{"trials":50076,"activeCount":97},[],{"trials":50078,"activeCount":97},[],{"intervention":50000,"totalTrials":417,"cells":50080},{"EARLY_PHASE1":50081,"PHASE1":50083,"PHASE2":50085,"PHASE3":50091,"PHASE4":50093,"NA":50095},{"trials":50082,"activeCount":97},[],{"trials":50084,"activeCount":97},[],{"trials":50086,"activeCount":97},[50087],{"nctId":49990,"briefTitle":49991,"status":155,"phases":50088,"primaryCompletion":49993,"completion":49993,"start":3370,"enrollment":9445,"conditions":50089,"interventions":50090},[86],[23246],[49981,49996,49997,49998,49999,50000],{"trials":50092,"activeCount":97},[],{"trials":50094,"activeCount":97},[],{"trials":50096,"activeCount":97},[],{"intervention":10544,"totalTrials":417,"cells":50098},{"EARLY_PHASE1":50099,"PHASE1":50101,"PHASE2":50103,"PHASE3":50109,"PHASE4":50111,"NA":50113},{"trials":50100,"activeCount":97},[],{"trials":50102,"activeCount":97},[],{"trials":50104,"activeCount":97},[50105],{"nctId":10535,"briefTitle":10536,"status":155,"phases":50106,"primaryCompletion":10538,"completion":10539,"start":10540,"enrollment":10541,"conditions":50107,"interventions":50108},[86],[2484,2485,2486,8671],[10544,10545,10546,10526,10547],{"trials":50110,"activeCount":97},[],{"trials":50112,"activeCount":97},[],{"trials":50114,"activeCount":97},[],{"intervention":10545,"totalTrials":417,"cells":50116},{"EARLY_PHASE1":50117,"PHASE1":50119,"PHASE2":50121,"PHASE3":50127,"PHASE4":50129,"NA":50131},{"trials":50118,"activeCount":97},[],{"trials":50120,"activeCount":97},[],{"trials":50122,"activeCount":97},[50123],{"nctId":10535,"briefTitle":10536,"status":155,"phases":50124,"primaryCompletion":10538,"completion":10539,"start":10540,"enrollment":10541,"conditions":50125,"interventions":50126},[86],[2484,2485,2486,8671],[10544,10545,10546,10526,10547],{"trials":50128,"activeCount":97},[],{"trials":50130,"activeCount":97},[],{"trials":50132,"activeCount":97},[],{"intervention":50134,"totalTrials":417,"cells":50135},"Avodart",{"EARLY_PHASE1":50136,"PHASE1":50138,"PHASE2":50140,"PHASE3":50150,"PHASE4":50152,"NA":50154},{"trials":50137,"activeCount":97},[],{"trials":50139,"activeCount":97},[],{"trials":50141,"activeCount":97},[50142],{"nctId":50143,"briefTitle":50144,"status":155,"phases":50145,"primaryCompletion":2344,"completion":8883,"start":3079,"enrollment":50146,"conditions":50147,"interventions":50149},"NCT00558363","ARTS - AVODART After Radical Therapy For Prostate Cancer Study",[86],294,[5634,50148],"Prostate Cancer After a Radical Treatment",[50134],{"trials":50151,"activeCount":97},[],{"trials":50153,"activeCount":97},[],{"trials":50155,"activeCount":97},[],{"intervention":50157,"totalTrials":417,"cells":50158},"Pandemic influenza vaccine (GSK1119711A)-formulation 1",{"EARLY_PHASE1":50159,"PHASE1":50161,"PHASE2":50163,"PHASE3":50172,"PHASE4":50174,"NA":50176},{"trials":50160,"activeCount":97},[],{"trials":50162,"activeCount":97},[],{"trials":50164,"activeCount":97},[50165],{"nctId":50166,"briefTitle":50167,"status":155,"phases":50168,"primaryCompletion":18246,"completion":18246,"start":9766,"enrollment":10837,"conditions":50169,"interventions":50170},"NCT00430521","Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)",[86],[21,8265],[50157,50171],"Pandemic influenza vaccine (GSK1119711A)-formulation 2",{"trials":50173,"activeCount":97},[],{"trials":50175,"activeCount":97},[],{"trials":50177,"activeCount":97},[],{"intervention":50171,"totalTrials":417,"cells":50179},{"EARLY_PHASE1":50180,"PHASE1":50182,"PHASE2":50184,"PHASE3":50190,"PHASE4":50192,"NA":50194},{"trials":50181,"activeCount":97},[],{"trials":50183,"activeCount":97},[],{"trials":50185,"activeCount":97},[50186],{"nctId":50166,"briefTitle":50167,"status":155,"phases":50187,"primaryCompletion":18246,"completion":18246,"start":9766,"enrollment":10837,"conditions":50188,"interventions":50189},[86],[21,8265],[50157,50171],{"trials":50191,"activeCount":97},[],{"trials":50193,"activeCount":97},[],{"trials":50195,"activeCount":97},[],{"intervention":50197,"totalTrials":417,"cells":50198},"GW493838",{"EARLY_PHASE1":50199,"PHASE1":50201,"PHASE2":50203,"PHASE3":50212,"PHASE4":50214,"NA":50216},{"trials":50200,"activeCount":97},[],{"trials":50202,"activeCount":97},[],{"trials":50204,"activeCount":97},[50205],{"nctId":50206,"briefTitle":50207,"status":155,"phases":50208,"primaryCompletion":10886,"completion":10886,"start":10287,"enrollment":2107,"conditions":50209,"interventions":50211},"NCT00376454","The Study of GW493838, an Adenosine A1 Agonist, in Peripheral Neuropathic Pain",[86],[50210],"Neuropathic Pain",[50197],{"trials":50213,"activeCount":97},[],{"trials":50215,"activeCount":97},[],{"trials":50217,"activeCount":97},[],{"intervention":237,"totalTrials":417,"cells":50219},{"EARLY_PHASE1":50220,"PHASE1":50222,"PHASE2":50224,"PHASE3":50230,"PHASE4":50232,"NA":50234},{"trials":50221,"activeCount":97},[],{"trials":50223,"activeCount":97},[],{"trials":50225,"activeCount":97},[50226],{"nctId":229,"briefTitle":230,"status":155,"phases":50227,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":50228,"interventions":50229},[86],[107],[92,237,120],{"trials":50231,"activeCount":97},[],{"trials":50233,"activeCount":97},[],{"trials":50235,"activeCount":97},[],{"intervention":50237,"totalTrials":417,"cells":50238},"GSK2586184 50 mg",{"EARLY_PHASE1":50239,"PHASE1":50241,"PHASE2":50243,"PHASE3":50255,"PHASE4":50257,"NA":50259},{"trials":50240,"activeCount":97},[],{"trials":50242,"activeCount":97},[],{"trials":50244,"activeCount":97},[50245],{"nctId":50246,"briefTitle":50247,"status":145,"phases":50248,"primaryCompletion":50249,"completion":5053,"start":8397,"enrollment":7573,"conditions":50250,"interventions":50251},"NCT01777256","An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184",[86],"2014-03-01",[435],[50237,50252,50253,50254],"GSK2586184 100 mg","GSK2586184 200 mg","GSK2586184 400 mg",{"trials":50256,"activeCount":97},[],{"trials":50258,"activeCount":97},[],{"trials":50260,"activeCount":97},[],{"intervention":50252,"totalTrials":417,"cells":50262},{"EARLY_PHASE1":50263,"PHASE1":50265,"PHASE2":50267,"PHASE3":50273,"PHASE4":50275,"NA":50277},{"trials":50264,"activeCount":97},[],{"trials":50266,"activeCount":97},[],{"trials":50268,"activeCount":97},[50269],{"nctId":50246,"briefTitle":50247,"status":145,"phases":50270,"primaryCompletion":50249,"completion":5053,"start":8397,"enrollment":7573,"conditions":50271,"interventions":50272},[86],[435],[50237,50252,50253,50254],{"trials":50274,"activeCount":97},[],{"trials":50276,"activeCount":97},[],{"trials":50278,"activeCount":97},[],{"intervention":50253,"totalTrials":417,"cells":50280},{"EARLY_PHASE1":50281,"PHASE1":50283,"PHASE2":50285,"PHASE3":50291,"PHASE4":50293,"NA":50295},{"trials":50282,"activeCount":97},[],{"trials":50284,"activeCount":97},[],{"trials":50286,"activeCount":97},[50287],{"nctId":50246,"briefTitle":50247,"status":145,"phases":50288,"primaryCompletion":50249,"completion":5053,"start":8397,"enrollment":7573,"conditions":50289,"interventions":50290},[86],[435],[50237,50252,50253,50254],{"trials":50292,"activeCount":97},[],{"trials":50294,"activeCount":97},[],{"trials":50296,"activeCount":97},[],{"intervention":50254,"totalTrials":417,"cells":50298},{"EARLY_PHASE1":50299,"PHASE1":50301,"PHASE2":50303,"PHASE3":50309,"PHASE4":50311,"NA":50313},{"trials":50300,"activeCount":97},[],{"trials":50302,"activeCount":97},[],{"trials":50304,"activeCount":97},[50305],{"nctId":50246,"briefTitle":50247,"status":145,"phases":50306,"primaryCompletion":50249,"completion":5053,"start":8397,"enrollment":7573,"conditions":50307,"interventions":50308},[86],[435],[50237,50252,50253,50254],{"trials":50310,"activeCount":97},[],{"trials":50312,"activeCount":97},[],{"trials":50314,"activeCount":97},[],{"intervention":248,"totalTrials":417,"cells":50316},{"EARLY_PHASE1":50317,"PHASE1":50319,"PHASE2":50321,"PHASE3":50327,"PHASE4":50329,"NA":50331},{"trials":50318,"activeCount":97},[],{"trials":50320,"activeCount":97},[],{"trials":50322,"activeCount":97},[50323],{"nctId":239,"briefTitle":240,"status":155,"phases":50324,"primaryCompletion":232,"completion":232,"start":242,"enrollment":243,"conditions":50325,"interventions":50326},[86],[107],[164,246,247,248,92,180],{"trials":50328,"activeCount":97},[],{"trials":50330,"activeCount":97},[],{"trials":50332,"activeCount":97},[],{"intervention":41216,"totalTrials":417,"cells":50334},{"EARLY_PHASE1":50335,"PHASE1":50337,"PHASE2":50339,"PHASE3":50345,"PHASE4":50347,"NA":50349},{"trials":50336,"activeCount":97},[],{"trials":50338,"activeCount":97},[],{"trials":50340,"activeCount":97},[50341],{"nctId":41209,"briefTitle":41210,"status":145,"phases":50342,"primaryCompletion":41212,"completion":41212,"start":41213,"enrollment":1686,"conditions":50343,"interventions":50344},[86],[15],[41216,20901],{"trials":50346,"activeCount":97},[],{"trials":50348,"activeCount":97},[],{"trials":50350,"activeCount":97},[],{"intervention":50352,"totalTrials":417,"cells":50353},"Oral Hycamtin",{"EARLY_PHASE1":50354,"PHASE1":50356,"PHASE2":50358,"PHASE3":50367,"PHASE4":50369,"NA":50371},{"trials":50355,"activeCount":97},[],{"trials":50357,"activeCount":97},[],{"trials":50359,"activeCount":97},[50360],{"nctId":50361,"briefTitle":50362,"status":155,"phases":50363,"primaryCompletion":7647,"completion":7647,"start":5018,"enrollment":1003,"conditions":50364,"interventions":50366},"NCT00698516","Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer",[86],[50365,2778],"Recurrent Small-cell Lung Cancer (SCLC)",[50352],{"trials":50368,"activeCount":97},[],{"trials":50370,"activeCount":97},[],{"trials":50372,"activeCount":97},[],{"intervention":3430,"totalTrials":417,"cells":50374},{"EARLY_PHASE1":50375,"PHASE1":50377,"PHASE2":50379,"PHASE3":50385,"PHASE4":50387,"NA":50389},{"trials":50376,"activeCount":97},[],{"trials":50378,"activeCount":97},[],{"trials":50380,"activeCount":97},[50381],{"nctId":3422,"briefTitle":3423,"status":155,"phases":50382,"primaryCompletion":3425,"completion":3425,"start":3426,"enrollment":695,"conditions":50383,"interventions":50384},[86],[3428],[3430,3289],{"trials":50386,"activeCount":97},[],{"trials":50388,"activeCount":97},[],{"trials":50390,"activeCount":97},[],{"intervention":50392,"totalTrials":417,"cells":50393},"GS856553",{"EARLY_PHASE1":50394,"PHASE1":50396,"PHASE2":50398,"PHASE3":50407,"PHASE4":50409,"NA":50411},{"trials":50395,"activeCount":97},[],{"trials":50397,"activeCount":97},[],{"trials":50399,"activeCount":97},[50400],{"nctId":50401,"briefTitle":50402,"status":155,"phases":50403,"primaryCompletion":48965,"completion":48965,"start":50404,"enrollment":444,"conditions":50405,"interventions":50406},"NCT01110057","Efficacy Study in Lumbosacral Radiculopathy",[86],"2010-01-07",[38980],[50392],{"trials":50408,"activeCount":97},[],{"trials":50410,"activeCount":97},[],{"trials":50412,"activeCount":97},[],{"intervention":5327,"totalTrials":417,"cells":50414},{"EARLY_PHASE1":50415,"PHASE1":50417,"PHASE2":50419,"PHASE3":50425,"PHASE4":50427,"NA":50429},{"trials":50416,"activeCount":97},[],{"trials":50418,"activeCount":97},[],{"trials":50420,"activeCount":97},[50421],{"nctId":5319,"briefTitle":5320,"status":155,"phases":50422,"primaryCompletion":5322,"completion":5322,"start":5323,"enrollment":4158,"conditions":50423,"interventions":50424},[86],[5325],[5327,5328,4471,5329],{"trials":50426,"activeCount":97},[],{"trials":50428,"activeCount":97},[],{"trials":50430,"activeCount":97},[],{"intervention":5328,"totalTrials":417,"cells":50432},{"EARLY_PHASE1":50433,"PHASE1":50435,"PHASE2":50437,"PHASE3":50443,"PHASE4":50445,"NA":50447},{"trials":50434,"activeCount":97},[],{"trials":50436,"activeCount":97},[],{"trials":50438,"activeCount":97},[50439],{"nctId":5319,"briefTitle":5320,"status":155,"phases":50440,"primaryCompletion":5322,"completion":5322,"start":5323,"enrollment":4158,"conditions":50441,"interventions":50442},[86],[5325],[5327,5328,4471,5329],{"trials":50444,"activeCount":97},[],{"trials":50446,"activeCount":97},[],{"trials":50448,"activeCount":97},[],{"intervention":50450,"totalTrials":417,"cells":50451},"Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody",{"EARLY_PHASE1":50452,"PHASE1":50454,"PHASE2":50456,"PHASE3":50465,"PHASE4":50467,"NA":50469},{"trials":50453,"activeCount":97},[],{"trials":50455,"activeCount":97},[],{"trials":50457,"activeCount":97},[50458],{"nctId":50459,"briefTitle":50460,"status":155,"phases":50461,"primaryCompletion":2481,"completion":9159,"start":50462,"enrollment":9382,"conditions":50463,"interventions":50464},"NCT00996593","Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab",[86],"1998-07",[4574],[50450],{"trials":50466,"activeCount":97},[],{"trials":50468,"activeCount":97},[],{"trials":50470,"activeCount":97},[],{"intervention":50472,"totalTrials":417,"cells":50473},"GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E",{"EARLY_PHASE1":50474,"PHASE1":50476,"PHASE2":50478,"PHASE3":50491,"PHASE4":50493,"NA":50495},{"trials":50475,"activeCount":97},[],{"trials":50477,"activeCount":97},[],{"trials":50479,"activeCount":97},[50480],{"nctId":50481,"briefTitle":50482,"status":155,"phases":50483,"primaryCompletion":50484,"completion":50485,"start":50486,"enrollment":50487,"conditions":50488,"interventions":50489},"NCT03894969","Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine",[86],"2020-08-31","2021-08-13","2019-04-23",541,[9855],[50472,50490],"Shingrix GSK's lyophilized formulation of the herpes zoster",{"trials":50492,"activeCount":97},[],{"trials":50494,"activeCount":97},[],{"trials":50496,"activeCount":97},[],{"intervention":50490,"totalTrials":417,"cells":50498},{"EARLY_PHASE1":50499,"PHASE1":50501,"PHASE2":50503,"PHASE3":50509,"PHASE4":50511,"NA":50513},{"trials":50500,"activeCount":97},[],{"trials":50502,"activeCount":97},[],{"trials":50504,"activeCount":97},[50505],{"nctId":50481,"briefTitle":50482,"status":155,"phases":50506,"primaryCompletion":50484,"completion":50485,"start":50486,"enrollment":50487,"conditions":50507,"interventions":50508},[86],[9855],[50472,50490],{"trials":50510,"activeCount":97},[],{"trials":50512,"activeCount":97},[],{"trials":50514,"activeCount":97},[],{"intervention":40451,"totalTrials":417,"cells":50516},{"EARLY_PHASE1":50517,"PHASE1":50519,"PHASE2":50521,"PHASE3":50527,"PHASE4":50529,"NA":50531},{"trials":50518,"activeCount":97},[],{"trials":50520,"activeCount":97},[],{"trials":50522,"activeCount":97},[50523],{"nctId":40445,"briefTitle":40446,"status":155,"phases":50524,"primaryCompletion":2635,"completion":2635,"start":40448,"enrollment":6994,"conditions":50525,"interventions":50526},[86],[24],[40420,40451,40452],{"trials":50528,"activeCount":97},[],{"trials":50530,"activeCount":97},[],{"trials":50532,"activeCount":97},[],{"intervention":40452,"totalTrials":417,"cells":50534},{"EARLY_PHASE1":50535,"PHASE1":50537,"PHASE2":50539,"PHASE3":50545,"PHASE4":50547,"NA":50549},{"trials":50536,"activeCount":97},[],{"trials":50538,"activeCount":97},[],{"trials":50540,"activeCount":97},[50541],{"nctId":40445,"briefTitle":40446,"status":155,"phases":50542,"primaryCompletion":2635,"completion":2635,"start":40448,"enrollment":6994,"conditions":50543,"interventions":50544},[86],[24],[40420,40451,40452],{"trials":50546,"activeCount":97},[],{"trials":50548,"activeCount":97},[],{"trials":50550,"activeCount":97},[],{"intervention":19542,"totalTrials":417,"cells":50552},{"EARLY_PHASE1":50553,"PHASE1":50555,"PHASE2":50557,"PHASE3":50563,"PHASE4":50565,"NA":50567},{"trials":50554,"activeCount":97},[],{"trials":50556,"activeCount":97},[],{"trials":50558,"activeCount":97},[50559],{"nctId":19534,"briefTitle":19535,"status":145,"phases":50560,"primaryCompletion":19537,"completion":19537,"start":19538,"enrollment":660,"conditions":50561,"interventions":50562},[86],[19540],[19542,19543,19544,19545,19486,19546],{"trials":50564,"activeCount":97},[],{"trials":50566,"activeCount":97},[],{"trials":50568,"activeCount":97},[],{"intervention":19543,"totalTrials":417,"cells":50570},{"EARLY_PHASE1":50571,"PHASE1":50573,"PHASE2":50575,"PHASE3":50581,"PHASE4":50583,"NA":50585},{"trials":50572,"activeCount":97},[],{"trials":50574,"activeCount":97},[],{"trials":50576,"activeCount":97},[50577],{"nctId":19534,"briefTitle":19535,"status":145,"phases":50578,"primaryCompletion":19537,"completion":19537,"start":19538,"enrollment":660,"conditions":50579,"interventions":50580},[86],[19540],[19542,19543,19544,19545,19486,19546],{"trials":50582,"activeCount":97},[],{"trials":50584,"activeCount":97},[],{"trials":50586,"activeCount":97},[],{"intervention":19544,"totalTrials":417,"cells":50588},{"EARLY_PHASE1":50589,"PHASE1":50591,"PHASE2":50593,"PHASE3":50599,"PHASE4":50601,"NA":50603},{"trials":50590,"activeCount":97},[],{"trials":50592,"activeCount":97},[],{"trials":50594,"activeCount":97},[50595],{"nctId":19534,"briefTitle":19535,"status":145,"phases":50596,"primaryCompletion":19537,"completion":19537,"start":19538,"enrollment":660,"conditions":50597,"interventions":50598},[86],[19540],[19542,19543,19544,19545,19486,19546],{"trials":50600,"activeCount":97},[],{"trials":50602,"activeCount":97},[],{"trials":50604,"activeCount":97},[],{"intervention":19545,"totalTrials":417,"cells":50606},{"EARLY_PHASE1":50607,"PHASE1":50609,"PHASE2":50611,"PHASE3":50617,"PHASE4":50619,"NA":50621},{"trials":50608,"activeCount":97},[],{"trials":50610,"activeCount":97},[],{"trials":50612,"activeCount":97},[50613],{"nctId":19534,"briefTitle":19535,"status":145,"phases":50614,"primaryCompletion":19537,"completion":19537,"start":19538,"enrollment":660,"conditions":50615,"interventions":50616},[86],[19540],[19542,19543,19544,19545,19486,19546],{"trials":50618,"activeCount":97},[],{"trials":50620,"activeCount":97},[],{"trials":50622,"activeCount":97},[],{"intervention":19546,"totalTrials":417,"cells":50624},{"EARLY_PHASE1":50625,"PHASE1":50627,"PHASE2":50629,"PHASE3":50635,"PHASE4":50637,"NA":50639},{"trials":50626,"activeCount":97},[],{"trials":50628,"activeCount":97},[],{"trials":50630,"activeCount":97},[50631],{"nctId":19534,"briefTitle":19535,"status":145,"phases":50632,"primaryCompletion":19537,"completion":19537,"start":19538,"enrollment":660,"conditions":50633,"interventions":50634},[86],[19540],[19542,19543,19544,19545,19486,19546],{"trials":50636,"activeCount":97},[],{"trials":50638,"activeCount":97},[],{"trials":50640,"activeCount":97},[],{"intervention":50642,"totalTrials":417,"cells":50643},"RSVPreF3 formulation 3",{"EARLY_PHASE1":50644,"PHASE1":50646,"PHASE2":50648,"PHASE3":50663,"PHASE4":50665,"NA":50667},{"trials":50645,"activeCount":97},[],{"trials":50647,"activeCount":97},[],{"trials":50649,"activeCount":97},[50650],{"nctId":50651,"briefTitle":50652,"status":155,"phases":50653,"primaryCompletion":50654,"completion":50655,"start":50656,"enrollment":50657,"conditions":50658,"interventions":50659},"NCT04138056","A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women",[86],"2020-02-25","2021-11-22","2019-11-05",509,[2620],[50642,50660,50661,50662],"RSVPreF3 formulation 2","Boostrix-ex-US","Boostrix-US",{"trials":50664,"activeCount":97},[],{"trials":50666,"activeCount":97},[],{"trials":50668,"activeCount":97},[],{"intervention":50660,"totalTrials":417,"cells":50670},{"EARLY_PHASE1":50671,"PHASE1":50673,"PHASE2":50675,"PHASE3":50681,"PHASE4":50683,"NA":50685},{"trials":50672,"activeCount":97},[],{"trials":50674,"activeCount":97},[],{"trials":50676,"activeCount":97},[50677],{"nctId":50651,"briefTitle":50652,"status":155,"phases":50678,"primaryCompletion":50654,"completion":50655,"start":50656,"enrollment":50657,"conditions":50679,"interventions":50680},[86],[2620],[50642,50660,50661,50662],{"trials":50682,"activeCount":97},[],{"trials":50684,"activeCount":97},[],{"trials":50686,"activeCount":97},[],{"intervention":50661,"totalTrials":417,"cells":50688},{"EARLY_PHASE1":50689,"PHASE1":50691,"PHASE2":50693,"PHASE3":50699,"PHASE4":50701,"NA":50703},{"trials":50690,"activeCount":97},[],{"trials":50692,"activeCount":97},[],{"trials":50694,"activeCount":97},[50695],{"nctId":50651,"briefTitle":50652,"status":155,"phases":50696,"primaryCompletion":50654,"completion":50655,"start":50656,"enrollment":50657,"conditions":50697,"interventions":50698},[86],[2620],[50642,50660,50661,50662],{"trials":50700,"activeCount":97},[],{"trials":50702,"activeCount":97},[],{"trials":50704,"activeCount":97},[],{"intervention":50662,"totalTrials":417,"cells":50706},{"EARLY_PHASE1":50707,"PHASE1":50709,"PHASE2":50711,"PHASE3":50717,"PHASE4":50719,"NA":50721},{"trials":50708,"activeCount":97},[],{"trials":50710,"activeCount":97},[],{"trials":50712,"activeCount":97},[50713],{"nctId":50651,"briefTitle":50652,"status":155,"phases":50714,"primaryCompletion":50654,"completion":50655,"start":50656,"enrollment":50657,"conditions":50715,"interventions":50716},[86],[2620],[50642,50660,50661,50662],{"trials":50718,"activeCount":97},[],{"trials":50720,"activeCount":97},[],{"trials":50722,"activeCount":97},[],{"intervention":50724,"totalTrials":417,"cells":50725},"IONIS-HBVRx",{"EARLY_PHASE1":50726,"PHASE1":50728,"PHASE2":50730,"PHASE3":50741,"PHASE4":50743,"NA":50745},{"trials":50727,"activeCount":97},[],{"trials":50729,"activeCount":97},[],{"trials":50731,"activeCount":97},[50732],{"nctId":50733,"briefTitle":50734,"status":155,"phases":50735,"primaryCompletion":1133,"completion":50736,"start":50737,"enrollment":3379,"conditions":50738,"interventions":50740},"NCT02981602","Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection",[86],"2019-12-26","2017-02-24",[24,50739],"Chronic Hepatitis B Atypical",[50724],{"trials":50742,"activeCount":97},[],{"trials":50744,"activeCount":97},[],{"trials":50746,"activeCount":97},[],{"intervention":44034,"totalTrials":417,"cells":50748},{"EARLY_PHASE1":50749,"PHASE1":50751,"PHASE2":50753,"PHASE3":50759,"PHASE4":50761,"NA":50763},{"trials":50750,"activeCount":97},[],{"trials":50752,"activeCount":97},[],{"trials":50754,"activeCount":97},[50755],{"nctId":44029,"briefTitle":44030,"status":155,"phases":50756,"primaryCompletion":26127,"completion":26127,"start":19396,"enrollment":1944,"conditions":50757,"interventions":50758},[86],[9840],[4,44034],{"trials":50760,"activeCount":97},[],{"trials":50762,"activeCount":97},[],{"trials":50764,"activeCount":97},[],{"intervention":50766,"totalTrials":417,"cells":50767},"Fluarix and adjuvanted influenza vaccine",{"EARLY_PHASE1":50768,"PHASE1":50770,"PHASE2":50772,"PHASE3":50781,"PHASE4":50783,"NA":50785},{"trials":50769,"activeCount":97},[],{"trials":50771,"activeCount":97},[],{"trials":50773,"activeCount":97},[50774],{"nctId":50775,"briefTitle":50776,"status":155,"phases":50777,"primaryCompletion":50778,"completion":50778,"start":44738,"enrollment":4158,"conditions":50779,"interventions":50780},"NCT00386113","Study to Evaluate Reactogenicity and Immunogenicity of Revaccination With Adjuvanted Influenza Vaccine in Elderly",[86],"2006-11-14",[21],[50766],{"trials":50782,"activeCount":97},[],{"trials":50784,"activeCount":97},[],{"trials":50786,"activeCount":97},[],{"intervention":7601,"totalTrials":417,"cells":50788},{"EARLY_PHASE1":50789,"PHASE1":50791,"PHASE2":50793,"PHASE3":50799,"PHASE4":50801,"NA":50803},{"trials":50790,"activeCount":97},[],{"trials":50792,"activeCount":97},[],{"trials":50794,"activeCount":97},[50795],{"nctId":7595,"briefTitle":7596,"status":155,"phases":50796,"primaryCompletion":7598,"completion":7598,"start":4756,"enrollment":2883,"conditions":50797,"interventions":50798},[86],[668],[2300,7601],{"trials":50800,"activeCount":97},[],{"trials":50802,"activeCount":97},[],{"trials":50804,"activeCount":97},[],{"intervention":50806,"totalTrials":417,"cells":50807},"RSV Vaccine (GSK3844766A) unadjuvanted low dose",{"EARLY_PHASE1":50808,"PHASE1":50810,"PHASE2":50812,"PHASE3":50829,"PHASE4":50831,"NA":50833},{"trials":50809,"activeCount":97},[],{"trials":50811,"activeCount":97},[],{"trials":50813,"activeCount":97},[50814],{"nctId":50815,"briefTitle":50816,"status":155,"phases":50817,"primaryCompletion":50818,"completion":36748,"start":8517,"enrollment":45625,"conditions":50819,"interventions":50820},"NCT03814590","A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older Adults",[85,86],"2019-12-12",[2620],[50806,50821,50822,50823,50824,50825,50826,50827,50828],"RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E","RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B","RSV Vaccine (GSK3844766A) unadjuvanted medium dose","RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E","RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B","RSV Vaccine (GSK3844766A) unadjuvanted high dose","RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E","RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B",{"trials":50830,"activeCount":97},[],{"trials":50832,"activeCount":97},[],{"trials":50834,"activeCount":97},[],{"intervention":50821,"totalTrials":417,"cells":50836},{"EARLY_PHASE1":50837,"PHASE1":50839,"PHASE2":50841,"PHASE3":50847,"PHASE4":50849,"NA":50851},{"trials":50838,"activeCount":97},[],{"trials":50840,"activeCount":97},[],{"trials":50842,"activeCount":97},[50843],{"nctId":50815,"briefTitle":50816,"status":155,"phases":50844,"primaryCompletion":50818,"completion":36748,"start":8517,"enrollment":45625,"conditions":50845,"interventions":50846},[85,86],[2620],[50806,50821,50822,50823,50824,50825,50826,50827,50828],{"trials":50848,"activeCount":97},[],{"trials":50850,"activeCount":97},[],{"trials":50852,"activeCount":97},[],{"intervention":50822,"totalTrials":417,"cells":50854},{"EARLY_PHASE1":50855,"PHASE1":50857,"PHASE2":50859,"PHASE3":50865,"PHASE4":50867,"NA":50869},{"trials":50856,"activeCount":97},[],{"trials":50858,"activeCount":97},[],{"trials":50860,"activeCount":97},[50861],{"nctId":50815,"briefTitle":50816,"status":155,"phases":50862,"primaryCompletion":50818,"completion":36748,"start":8517,"enrollment":45625,"conditions":50863,"interventions":50864},[85,86],[2620],[50806,50821,50822,50823,50824,50825,50826,50827,50828],{"trials":50866,"activeCount":97},[],{"trials":50868,"activeCount":97},[],{"trials":50870,"activeCount":97},[],{"intervention":50823,"totalTrials":417,"cells":50872},{"EARLY_PHASE1":50873,"PHASE1":50875,"PHASE2":50877,"PHASE3":50883,"PHASE4":50885,"NA":50887},{"trials":50874,"activeCount":97},[],{"trials":50876,"activeCount":97},[],{"trials":50878,"activeCount":97},[50879],{"nctId":50815,"briefTitle":50816,"status":155,"phases":50880,"primaryCompletion":50818,"completion":36748,"start":8517,"enrollment":45625,"conditions":50881,"interventions":50882},[85,86],[2620],[50806,50821,50822,50823,50824,50825,50826,50827,50828],{"trials":50884,"activeCount":97},[],{"trials":50886,"activeCount":97},[],{"trials":50888,"activeCount":97},[],{"intervention":50824,"totalTrials":417,"cells":50890},{"EARLY_PHASE1":50891,"PHASE1":50893,"PHASE2":50895,"PHASE3":50901,"PHASE4":50903,"NA":50905},{"trials":50892,"activeCount":97},[],{"trials":50894,"activeCount":97},[],{"trials":50896,"activeCount":97},[50897],{"nctId":50815,"briefTitle":50816,"status":155,"phases":50898,"primaryCompletion":50818,"completion":36748,"start":8517,"enrollment":45625,"conditions":50899,"interventions":50900},[85,86],[2620],[50806,50821,50822,50823,50824,50825,50826,50827,50828],{"trials":50902,"activeCount":97},[],{"trials":50904,"activeCount":97},[],{"trials":50906,"activeCount":97},[],{"intervention":50825,"totalTrials":417,"cells":50908},{"EARLY_PHASE1":50909,"PHASE1":50911,"PHASE2":50913,"PHASE3":50919,"PHASE4":50921,"NA":50923},{"trials":50910,"activeCount":97},[],{"trials":50912,"activeCount":97},[],{"trials":50914,"activeCount":97},[50915],{"nctId":50815,"briefTitle":50816,"status":155,"phases":50916,"primaryCompletion":50818,"completion":36748,"start":8517,"enrollment":45625,"conditions":50917,"interventions":50918},[85,86],[2620],[50806,50821,50822,50823,50824,50825,50826,50827,50828],{"trials":50920,"activeCount":97},[],{"trials":50922,"activeCount":97},[],{"trials":50924,"activeCount":97},[],{"intervention":50826,"totalTrials":417,"cells":50926},{"EARLY_PHASE1":50927,"PHASE1":50929,"PHASE2":50931,"PHASE3":50937,"PHASE4":50939,"NA":50941},{"trials":50928,"activeCount":97},[],{"trials":50930,"activeCount":97},[],{"trials":50932,"activeCount":97},[50933],{"nctId":50815,"briefTitle":50816,"status":155,"phases":50934,"primaryCompletion":50818,"completion":36748,"start":8517,"enrollment":45625,"conditions":50935,"interventions":50936},[85,86],[2620],[50806,50821,50822,50823,50824,50825,50826,50827,50828],{"trials":50938,"activeCount":97},[],{"trials":50940,"activeCount":97},[],{"trials":50942,"activeCount":97},[],{"intervention":50827,"totalTrials":417,"cells":50944},{"EARLY_PHASE1":50945,"PHASE1":50947,"PHASE2":50949,"PHASE3":50955,"PHASE4":50957,"NA":50959},{"trials":50946,"activeCount":97},[],{"trials":50948,"activeCount":97},[],{"trials":50950,"activeCount":97},[50951],{"nctId":50815,"briefTitle":50816,"status":155,"phases":50952,"primaryCompletion":50818,"completion":36748,"start":8517,"enrollment":45625,"conditions":50953,"interventions":50954},[85,86],[2620],[50806,50821,50822,50823,50824,50825,50826,50827,50828],{"trials":50956,"activeCount":97},[],{"trials":50958,"activeCount":97},[],{"trials":50960,"activeCount":97},[],{"intervention":50828,"totalTrials":417,"cells":50962},{"EARLY_PHASE1":50963,"PHASE1":50965,"PHASE2":50967,"PHASE3":50973,"PHASE4":50975,"NA":50977},{"trials":50964,"activeCount":97},[],{"trials":50966,"activeCount":97},[],{"trials":50968,"activeCount":97},[50969],{"nctId":50815,"briefTitle":50816,"status":155,"phases":50970,"primaryCompletion":50818,"completion":36748,"start":8517,"enrollment":45625,"conditions":50971,"interventions":50972},[85,86],[2620],[50806,50821,50822,50823,50824,50825,50826,50827,50828],{"trials":50974,"activeCount":97},[],{"trials":50976,"activeCount":97},[],{"trials":50978,"activeCount":97},[],{"intervention":50980,"totalTrials":417,"cells":50981},"Dose 1 GSK2586881",{"EARLY_PHASE1":50982,"PHASE1":50984,"PHASE2":50986,"PHASE3":50998,"PHASE4":51000,"NA":51002},{"trials":50983,"activeCount":97},[],{"trials":50985,"activeCount":97},[],{"trials":50987,"activeCount":97},[50988],{"nctId":50989,"briefTitle":50990,"status":155,"phases":50991,"primaryCompletion":32586,"completion":39358,"start":50992,"enrollment":8038,"conditions":50993,"interventions":50994},"NCT01597635","The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury",[86],"2012-09-01",[5291],[50980,50995,50996,50997],"Dose 2 GSK2586881","Dose 3 GSK2586881","Dose 4 GSK2586881",{"trials":50999,"activeCount":97},[],{"trials":51001,"activeCount":97},[],{"trials":51003,"activeCount":97},[],{"intervention":50995,"totalTrials":417,"cells":51005},{"EARLY_PHASE1":51006,"PHASE1":51008,"PHASE2":51010,"PHASE3":51016,"PHASE4":51018,"NA":51020},{"trials":51007,"activeCount":97},[],{"trials":51009,"activeCount":97},[],{"trials":51011,"activeCount":97},[51012],{"nctId":50989,"briefTitle":50990,"status":155,"phases":51013,"primaryCompletion":32586,"completion":39358,"start":50992,"enrollment":8038,"conditions":51014,"interventions":51015},[86],[5291],[50980,50995,50996,50997],{"trials":51017,"activeCount":97},[],{"trials":51019,"activeCount":97},[],{"trials":51021,"activeCount":97},[],{"intervention":50996,"totalTrials":417,"cells":51023},{"EARLY_PHASE1":51024,"PHASE1":51026,"PHASE2":51028,"PHASE3":51034,"PHASE4":51036,"NA":51038},{"trials":51025,"activeCount":97},[],{"trials":51027,"activeCount":97},[],{"trials":51029,"activeCount":97},[51030],{"nctId":50989,"briefTitle":50990,"status":155,"phases":51031,"primaryCompletion":32586,"completion":39358,"start":50992,"enrollment":8038,"conditions":51032,"interventions":51033},[86],[5291],[50980,50995,50996,50997],{"trials":51035,"activeCount":97},[],{"trials":51037,"activeCount":97},[],{"trials":51039,"activeCount":97},[],{"intervention":50997,"totalTrials":417,"cells":51041},{"EARLY_PHASE1":51042,"PHASE1":51044,"PHASE2":51046,"PHASE3":51052,"PHASE4":51054,"NA":51056},{"trials":51043,"activeCount":97},[],{"trials":51045,"activeCount":97},[],{"trials":51047,"activeCount":97},[51048],{"nctId":50989,"briefTitle":50990,"status":155,"phases":51049,"primaryCompletion":32586,"completion":39358,"start":50992,"enrollment":8038,"conditions":51050,"interventions":51051},[86],[5291],[50980,50995,50996,50997],{"trials":51053,"activeCount":97},[],{"trials":51055,"activeCount":97},[],{"trials":51057,"activeCount":97},[],{"intervention":51059,"totalTrials":417,"cells":51060},"Belimumab 10 mg",{"EARLY_PHASE1":51061,"PHASE1":51063,"PHASE2":51065,"PHASE3":51073,"PHASE4":51075,"NA":51077},{"trials":51062,"activeCount":97},[],{"trials":51064,"activeCount":97},[],{"trials":51066,"activeCount":97},[51067],{"nctId":51068,"briefTitle":51069,"status":500,"phases":51070,"primaryCompletion":7634,"completion":7634,"start":484,"enrollment":97,"conditions":51071,"interventions":51072},"NCT01762852","Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy",[86],[475],[51059],{"trials":51074,"activeCount":97},[],{"trials":51076,"activeCount":97},[],{"trials":51078,"activeCount":97},[],{"intervention":51080,"totalTrials":417,"cells":51081},"Infanrix hexa Vaccine",{"EARLY_PHASE1":51082,"PHASE1":51084,"PHASE2":51086,"PHASE3":51094,"PHASE4":51096,"NA":51098},{"trials":51083,"activeCount":97},[],{"trials":51085,"activeCount":97},[],{"trials":51087,"activeCount":97},[51088],{"nctId":51089,"briefTitle":51090,"status":155,"phases":51091,"primaryCompletion":2835,"completion":2835,"start":2404,"enrollment":1752,"conditions":51092,"interventions":51093},"NCT00376779","Immunogenicity and Safety of a DTPa-HBV-IPV\u002FHib Vaccine Given at 2, 3 and 4 Months of Age",[86],[3624,33,30,24,4702,4704],[51080],{"trials":51095,"activeCount":97},[],{"trials":51097,"activeCount":97},[],{"trials":51099,"activeCount":97},[],{"intervention":44585,"totalTrials":417,"cells":51101},{"EARLY_PHASE1":51102,"PHASE1":51104,"PHASE2":51106,"PHASE3":51112,"PHASE4":51114,"NA":51116},{"trials":51103,"activeCount":97},[],{"trials":51105,"activeCount":97},[],{"trials":51107,"activeCount":97},[51108],{"nctId":44579,"briefTitle":44580,"status":155,"phases":51109,"primaryCompletion":8089,"completion":8089,"start":9706,"enrollment":1534,"conditions":51110,"interventions":51111},[86],[44583],[44570,44585,44586,44587],{"trials":51113,"activeCount":97},[],{"trials":51115,"activeCount":97},[],{"trials":51117,"activeCount":97},[],{"intervention":51119,"totalTrials":417,"cells":51120},"GSK2269557 DPI",{"EARLY_PHASE1":51121,"PHASE1":51123,"PHASE2":51125,"PHASE3":51135,"PHASE4":51137,"NA":51139},{"trials":51122,"activeCount":97},[],{"trials":51124,"activeCount":97},[],{"trials":51126,"activeCount":97},[51127],{"nctId":51128,"briefTitle":51129,"status":155,"phases":51130,"primaryCompletion":51131,"completion":18642,"start":51132,"enrollment":1003,"conditions":51133,"interventions":51134},"NCT02567708","A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma",[86],"2016-09-21","2015-10-01",[15],[51119],{"trials":51136,"activeCount":97},[],{"trials":51138,"activeCount":97},[],{"trials":51140,"activeCount":97},[],{"intervention":51142,"totalTrials":417,"cells":51143},"GSK249320",{"EARLY_PHASE1":51144,"PHASE1":51146,"PHASE2":51148,"PHASE3":51157,"PHASE4":51159,"NA":51161},{"trials":51145,"activeCount":97},[],{"trials":51147,"activeCount":97},[],{"trials":51149,"activeCount":97},[51150],{"nctId":51151,"briefTitle":51152,"status":155,"phases":51153,"primaryCompletion":48966,"completion":48966,"start":19497,"enrollment":656,"conditions":51154,"interventions":51156},"NCT00833989","Safety Escalating Repeat IV, in Stroke Patients",[86],[51155],"Ischaemic Attack, Transient",[51142],{"trials":51158,"activeCount":97},[],{"trials":51160,"activeCount":97},[],{"trials":51162,"activeCount":97},[],{"intervention":51164,"totalTrials":417,"cells":51165},"Sodium bicarbonate plus sodium fluoride",{"EARLY_PHASE1":51166,"PHASE1":51168,"PHASE2":51170,"PHASE3":51178,"PHASE4":51180,"NA":51182},{"trials":51167,"activeCount":97},[],{"trials":51169,"activeCount":97},[],{"trials":51171,"activeCount":97},[51172],{"nctId":51173,"briefTitle":51174,"status":155,"phases":51175,"primaryCompletion":8721,"completion":7711,"start":8860,"enrollment":14391,"conditions":51176,"interventions":51177},"NCT02207907","To Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste",[86],[15325],[51164,43205],{"trials":51179,"activeCount":97},[],{"trials":51181,"activeCount":97},[],{"trials":51183,"activeCount":97},[],{"intervention":51185,"totalTrials":417,"cells":51186},"GSK Biologicals' Candidate Tuberculosis",{"EARLY_PHASE1":51187,"PHASE1":51189,"PHASE2":51191,"PHASE3":51201,"PHASE4":51203,"NA":51205},{"trials":51188,"activeCount":97},[],{"trials":51190,"activeCount":97},[],{"trials":51192,"activeCount":97},[51193],{"nctId":51194,"briefTitle":51195,"status":155,"phases":51196,"primaryCompletion":17861,"completion":17861,"start":51197,"enrollment":6369,"conditions":51198,"interventions":51200},"NCT00600782","Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region",[86],"2008-02-05",[41708,51199],"Tuberculosis Vaccines",[51185],{"trials":51202,"activeCount":97},[],{"trials":51204,"activeCount":97},[],{"trials":51206,"activeCount":97},[],{"intervention":51208,"totalTrials":417,"cells":51209},"Engerix-B™",{"EARLY_PHASE1":51210,"PHASE1":51212,"PHASE2":51214,"PHASE3":51227,"PHASE4":51229,"NA":51231},{"trials":51211,"activeCount":97},[],{"trials":51213,"activeCount":97},[],{"trials":51215,"activeCount":97},[51216],{"nctId":51217,"briefTitle":51218,"status":155,"phases":51219,"primaryCompletion":866,"completion":51220,"start":39065,"enrollment":51221,"conditions":51222,"interventions":51223},"NCT00805389","Study to Compare the Efficacy of GSK Biologicals' Adjuvants in Combination With the Antigen of the Hepatitis B Vaccine",[86],"2011-07-14",713,[24],[51208,51224,51225,51226],"Fendrix™","GSK Biologicals' Hepatitis B vaccines","HBsAg",{"trials":51228,"activeCount":97},[],{"trials":51230,"activeCount":97},[],{"trials":51232,"activeCount":97},[],{"intervention":51224,"totalTrials":417,"cells":51234},{"EARLY_PHASE1":51235,"PHASE1":51237,"PHASE2":51239,"PHASE3":51245,"PHASE4":51247,"NA":51249},{"trials":51236,"activeCount":97},[],{"trials":51238,"activeCount":97},[],{"trials":51240,"activeCount":97},[51241],{"nctId":51217,"briefTitle":51218,"status":155,"phases":51242,"primaryCompletion":866,"completion":51220,"start":39065,"enrollment":51221,"conditions":51243,"interventions":51244},[86],[24],[51208,51224,51225,51226],{"trials":51246,"activeCount":97},[],{"trials":51248,"activeCount":97},[],{"trials":51250,"activeCount":97},[],{"intervention":51225,"totalTrials":417,"cells":51252},{"EARLY_PHASE1":51253,"PHASE1":51255,"PHASE2":51257,"PHASE3":51263,"PHASE4":51265,"NA":51267},{"trials":51254,"activeCount":97},[],{"trials":51256,"activeCount":97},[],{"trials":51258,"activeCount":97},[51259],{"nctId":51217,"briefTitle":51218,"status":155,"phases":51260,"primaryCompletion":866,"completion":51220,"start":39065,"enrollment":51221,"conditions":51261,"interventions":51262},[86],[24],[51208,51224,51225,51226],{"trials":51264,"activeCount":97},[],{"trials":51266,"activeCount":97},[],{"trials":51268,"activeCount":97},[],{"intervention":51226,"totalTrials":417,"cells":51270},{"EARLY_PHASE1":51271,"PHASE1":51273,"PHASE2":51275,"PHASE3":51281,"PHASE4":51283,"NA":51285},{"trials":51272,"activeCount":97},[],{"trials":51274,"activeCount":97},[],{"trials":51276,"activeCount":97},[51277],{"nctId":51217,"briefTitle":51218,"status":155,"phases":51278,"primaryCompletion":866,"completion":51220,"start":39065,"enrollment":51221,"conditions":51279,"interventions":51280},[86],[24],[51208,51224,51225,51226],{"trials":51282,"activeCount":97},[],{"trials":51284,"activeCount":97},[],{"trials":51286,"activeCount":97},[],{"intervention":51288,"totalTrials":417,"cells":51289},"0.12% chlorhexidine mouthrinse",{"EARLY_PHASE1":51290,"PHASE1":51292,"PHASE2":51294,"PHASE3":51302,"PHASE4":51304,"NA":51306},{"trials":51291,"activeCount":97},[],{"trials":51293,"activeCount":97},[],{"trials":51295,"activeCount":97},[51296],{"nctId":51297,"briefTitle":51298,"status":155,"phases":51299,"primaryCompletion":7647,"completion":7647,"start":6352,"enrollment":314,"conditions":51300,"interventions":51301},"NCT01122862","Effect of a Commercial Cosmetic Mouth Rinse on Plaque Re-growth",[86],[7524],[51288],{"trials":51303,"activeCount":97},[],{"trials":51305,"activeCount":97},[],{"trials":51307,"activeCount":97},[],{"intervention":51309,"totalTrials":417,"cells":51310},"Meningococcal Vaccine",{"EARLY_PHASE1":51311,"PHASE1":51313,"PHASE2":51315,"PHASE3":51323,"PHASE4":51325,"NA":51327},{"trials":51312,"activeCount":97},[],{"trials":51314,"activeCount":97},[],{"trials":51316,"activeCount":97},[51317],{"nctId":51318,"briefTitle":51319,"status":155,"phases":51320,"completion":2805,"start":10395,"enrollment":25,"conditions":51321,"interventions":51322},"NCT00126945","Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs",[86],[992],[51309],{"trials":51324,"activeCount":97},[],{"trials":51326,"activeCount":97},[],{"trials":51328,"activeCount":97},[],{"intervention":41971,"totalTrials":417,"cells":51330},{"EARLY_PHASE1":51331,"PHASE1":51333,"PHASE2":51335,"PHASE3":51341,"PHASE4":51343,"NA":51345},{"trials":51332,"activeCount":97},[],{"trials":51334,"activeCount":97},[],{"trials":51336,"activeCount":97},[51337],{"nctId":41964,"briefTitle":41965,"status":155,"phases":51338,"primaryCompletion":7445,"completion":7445,"start":41967,"enrollment":41968,"conditions":51339,"interventions":51340},[86],[3637],[4682,4682,10348,41971,41972,23250,41973,41974],{"trials":51342,"activeCount":97},[],{"trials":51344,"activeCount":97},[],{"trials":51346,"activeCount":97},[],{"intervention":41972,"totalTrials":417,"cells":51348},{"EARLY_PHASE1":51349,"PHASE1":51351,"PHASE2":51353,"PHASE3":51359,"PHASE4":51361,"NA":51363},{"trials":51350,"activeCount":97},[],{"trials":51352,"activeCount":97},[],{"trials":51354,"activeCount":97},[51355],{"nctId":41964,"briefTitle":41965,"status":155,"phases":51356,"primaryCompletion":7445,"completion":7445,"start":41967,"enrollment":41968,"conditions":51357,"interventions":51358},[86],[3637],[4682,4682,10348,41971,41972,23250,41973,41974],{"trials":51360,"activeCount":97},[],{"trials":51362,"activeCount":97},[],{"trials":51364,"activeCount":97},[],{"intervention":41973,"totalTrials":417,"cells":51366},{"EARLY_PHASE1":51367,"PHASE1":51369,"PHASE2":51371,"PHASE3":51377,"PHASE4":51379,"NA":51381},{"trials":51368,"activeCount":97},[],{"trials":51370,"activeCount":97},[],{"trials":51372,"activeCount":97},[51373],{"nctId":41964,"briefTitle":41965,"status":155,"phases":51374,"primaryCompletion":7445,"completion":7445,"start":41967,"enrollment":41968,"conditions":51375,"interventions":51376},[86],[3637],[4682,4682,10348,41971,41972,23250,41973,41974],{"trials":51378,"activeCount":97},[],{"trials":51380,"activeCount":97},[],{"trials":51382,"activeCount":97},[],{"intervention":51384,"totalTrials":417,"cells":51385},"ASP3772",{"EARLY_PHASE1":51386,"PHASE1":51388,"PHASE2":51390,"PHASE3":51402,"PHASE4":51404,"NA":51406},{"trials":51387,"activeCount":97},[],{"trials":51389,"activeCount":97},[],{"trials":51391,"activeCount":97},[51392],{"nctId":51393,"briefTitle":51394,"status":155,"phases":51395,"primaryCompletion":39905,"completion":39905,"start":242,"enrollment":51396,"conditions":51397,"interventions":51399},"NCT03803202","A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine",[85,86],630,[6371,5280,51398],"Pneumococcal Disease",[51384,51400,51401],"PCV13","PPSV23",{"trials":51403,"activeCount":97},[],{"trials":51405,"activeCount":97},[],{"trials":51407,"activeCount":97},[],{"intervention":51400,"totalTrials":417,"cells":51409},{"EARLY_PHASE1":51410,"PHASE1":51412,"PHASE2":51414,"PHASE3":51420,"PHASE4":51422,"NA":51424},{"trials":51411,"activeCount":97},[],{"trials":51413,"activeCount":97},[],{"trials":51415,"activeCount":97},[51416],{"nctId":51393,"briefTitle":51394,"status":155,"phases":51417,"primaryCompletion":39905,"completion":39905,"start":242,"enrollment":51396,"conditions":51418,"interventions":51419},[85,86],[6371,5280,51398],[51384,51400,51401],{"trials":51421,"activeCount":97},[],{"trials":51423,"activeCount":97},[],{"trials":51425,"activeCount":97},[],{"intervention":51401,"totalTrials":417,"cells":51427},{"EARLY_PHASE1":51428,"PHASE1":51430,"PHASE2":51432,"PHASE3":51438,"PHASE4":51440,"NA":51442},{"trials":51429,"activeCount":97},[],{"trials":51431,"activeCount":97},[],{"trials":51433,"activeCount":97},[51434],{"nctId":51393,"briefTitle":51394,"status":155,"phases":51435,"primaryCompletion":39905,"completion":39905,"start":242,"enrollment":51396,"conditions":51436,"interventions":51437},[85,86],[6371,5280,51398],[51384,51400,51401],{"trials":51439,"activeCount":97},[],{"trials":51441,"activeCount":97},[],{"trials":51443,"activeCount":97},[],{"intervention":51445,"totalTrials":417,"cells":51446},"Nemiralisib ELLIPTA 50 µg",{"EARLY_PHASE1":51447,"PHASE1":51449,"PHASE2":51451,"PHASE3":51467,"PHASE4":51469,"NA":51471},{"trials":51448,"activeCount":97},[],{"trials":51450,"activeCount":97},[],{"trials":51452,"activeCount":97},[51453],{"nctId":51454,"briefTitle":51455,"status":145,"phases":51456,"primaryCompletion":18582,"completion":18582,"start":51457,"enrollment":51458,"conditions":51459,"interventions":51460},"NCT03345407","Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)",[86],"2017-11-28",943,[15],[51445,51461,51462,51463,51464,51465,51466],"Nemiralisib ELLIPTA 100 µg","Nemiralisib ELLIPTA 250 µg","Nemiralisib ELLIPTA 500 µg","Nemiralisib ELLIPTA 750 µg","Albuterol (Salbutamol) MDI or nebules","Standard of care therapy",{"trials":51468,"activeCount":97},[],{"trials":51470,"activeCount":97},[],{"trials":51472,"activeCount":97},[],{"intervention":51461,"totalTrials":417,"cells":51474},{"EARLY_PHASE1":51475,"PHASE1":51477,"PHASE2":51479,"PHASE3":51485,"PHASE4":51487,"NA":51489},{"trials":51476,"activeCount":97},[],{"trials":51478,"activeCount":97},[],{"trials":51480,"activeCount":97},[51481],{"nctId":51454,"briefTitle":51455,"status":145,"phases":51482,"primaryCompletion":18582,"completion":18582,"start":51457,"enrollment":51458,"conditions":51483,"interventions":51484},[86],[15],[51445,51461,51462,51463,51464,51465,51466],{"trials":51486,"activeCount":97},[],{"trials":51488,"activeCount":97},[],{"trials":51490,"activeCount":97},[],{"intervention":51462,"totalTrials":417,"cells":51492},{"EARLY_PHASE1":51493,"PHASE1":51495,"PHASE2":51497,"PHASE3":51503,"PHASE4":51505,"NA":51507},{"trials":51494,"activeCount":97},[],{"trials":51496,"activeCount":97},[],{"trials":51498,"activeCount":97},[51499],{"nctId":51454,"briefTitle":51455,"status":145,"phases":51500,"primaryCompletion":18582,"completion":18582,"start":51457,"enrollment":51458,"conditions":51501,"interventions":51502},[86],[15],[51445,51461,51462,51463,51464,51465,51466],{"trials":51504,"activeCount":97},[],{"trials":51506,"activeCount":97},[],{"trials":51508,"activeCount":97},[],{"intervention":51463,"totalTrials":417,"cells":51510},{"EARLY_PHASE1":51511,"PHASE1":51513,"PHASE2":51515,"PHASE3":51521,"PHASE4":51523,"NA":51525},{"trials":51512,"activeCount":97},[],{"trials":51514,"activeCount":97},[],{"trials":51516,"activeCount":97},[51517],{"nctId":51454,"briefTitle":51455,"status":145,"phases":51518,"primaryCompletion":18582,"completion":18582,"start":51457,"enrollment":51458,"conditions":51519,"interventions":51520},[86],[15],[51445,51461,51462,51463,51464,51465,51466],{"trials":51522,"activeCount":97},[],{"trials":51524,"activeCount":97},[],{"trials":51526,"activeCount":97},[],{"intervention":51464,"totalTrials":417,"cells":51528},{"EARLY_PHASE1":51529,"PHASE1":51531,"PHASE2":51533,"PHASE3":51539,"PHASE4":51541,"NA":51543},{"trials":51530,"activeCount":97},[],{"trials":51532,"activeCount":97},[],{"trials":51534,"activeCount":97},[51535],{"nctId":51454,"briefTitle":51455,"status":145,"phases":51536,"primaryCompletion":18582,"completion":18582,"start":51457,"enrollment":51458,"conditions":51537,"interventions":51538},[86],[15],[51445,51461,51462,51463,51464,51465,51466],{"trials":51540,"activeCount":97},[],{"trials":51542,"activeCount":97},[],{"trials":51544,"activeCount":97},[],{"intervention":51465,"totalTrials":417,"cells":51546},{"EARLY_PHASE1":51547,"PHASE1":51549,"PHASE2":51551,"PHASE3":51557,"PHASE4":51559,"NA":51561},{"trials":51548,"activeCount":97},[],{"trials":51550,"activeCount":97},[],{"trials":51552,"activeCount":97},[51553],{"nctId":51454,"briefTitle":51455,"status":145,"phases":51554,"primaryCompletion":18582,"completion":18582,"start":51457,"enrollment":51458,"conditions":51555,"interventions":51556},[86],[15],[51445,51461,51462,51463,51464,51465,51466],{"trials":51558,"activeCount":97},[],{"trials":51560,"activeCount":97},[],{"trials":51562,"activeCount":97},[],{"intervention":51466,"totalTrials":417,"cells":51564},{"EARLY_PHASE1":51565,"PHASE1":51567,"PHASE2":51569,"PHASE3":51575,"PHASE4":51577,"NA":51579},{"trials":51566,"activeCount":97},[],{"trials":51568,"activeCount":97},[],{"trials":51570,"activeCount":97},[51571],{"nctId":51454,"briefTitle":51455,"status":145,"phases":51572,"primaryCompletion":18582,"completion":18582,"start":51457,"enrollment":51458,"conditions":51573,"interventions":51574},[86],[15],[51445,51461,51462,51463,51464,51465,51466],{"trials":51576,"activeCount":97},[],{"trials":51578,"activeCount":97},[],{"trials":51580,"activeCount":97},[],{"intervention":44773,"totalTrials":417,"cells":51582},{"EARLY_PHASE1":51583,"PHASE1":51585,"PHASE2":51587,"PHASE3":51593,"PHASE4":51595,"NA":51597},{"trials":51584,"activeCount":97},[],{"trials":51586,"activeCount":97},[],{"trials":51588,"activeCount":97},[51589],{"nctId":44766,"briefTitle":44767,"status":500,"phases":51590,"primaryCompletion":44769,"completion":44769,"start":44770,"enrollment":97,"conditions":51591,"interventions":51592},[86],[39897],[44773,44757],{"trials":51594,"activeCount":97},[],{"trials":51596,"activeCount":97},[],{"trials":51598,"activeCount":97},[],{"intervention":51600,"totalTrials":417,"cells":51601},"GW876008 and GSK561679",{"EARLY_PHASE1":51602,"PHASE1":51604,"PHASE2":51606,"PHASE3":51614,"PHASE4":51616,"NA":51618},{"trials":51603,"activeCount":97},[],{"trials":51605,"activeCount":97},[],{"trials":51607,"activeCount":97},[51608],{"nctId":51609,"briefTitle":51610,"status":500,"phases":51611,"primaryCompletion":8089,"start":2336,"enrollment":97,"conditions":51612,"interventions":51613},"NCT00511563","A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679",[86],[5609],[51600],{"trials":51615,"activeCount":97},[],{"trials":51617,"activeCount":97},[],{"trials":51619,"activeCount":97},[],{"intervention":23048,"totalTrials":417,"cells":51621},{"EARLY_PHASE1":51622,"PHASE1":51624,"PHASE2":51626,"PHASE3":51632,"PHASE4":51634,"NA":51636},{"trials":51623,"activeCount":97},[],{"trials":51625,"activeCount":97},[],{"trials":51627,"activeCount":97},[51628],{"nctId":23038,"briefTitle":23039,"status":155,"phases":51629,"primaryCompletion":23041,"completion":23042,"start":23043,"enrollment":23044,"conditions":51630,"interventions":51631},[86],[4704,4703],[23047,23036,23016,23034,23035,23048,23049],{"trials":51633,"activeCount":97},[],{"trials":51635,"activeCount":97},[],{"trials":51637,"activeCount":97},[],{"intervention":23049,"totalTrials":417,"cells":51639},{"EARLY_PHASE1":51640,"PHASE1":51642,"PHASE2":51644,"PHASE3":51650,"PHASE4":51652,"NA":51654},{"trials":51641,"activeCount":97},[],{"trials":51643,"activeCount":97},[],{"trials":51645,"activeCount":97},[51646],{"nctId":23038,"briefTitle":23039,"status":155,"phases":51647,"primaryCompletion":23041,"completion":23042,"start":23043,"enrollment":23044,"conditions":51648,"interventions":51649},[86],[4704,4703],[23047,23036,23016,23034,23035,23048,23049],{"trials":51651,"activeCount":97},[],{"trials":51653,"activeCount":97},[],{"trials":51655,"activeCount":97},[],{"intervention":42553,"totalTrials":417,"cells":51657},{"EARLY_PHASE1":51658,"PHASE1":51660,"PHASE2":51662,"PHASE3":51668,"PHASE4":51670,"NA":51672},{"trials":51659,"activeCount":97},[],{"trials":51661,"activeCount":97},[],{"trials":51663,"activeCount":97},[51664],{"nctId":42546,"briefTitle":42547,"status":155,"phases":51665,"primaryCompletion":42549,"completion":42549,"start":42550,"enrollment":526,"conditions":51666,"interventions":51667},[86],[27251,27252],[42523,42523,42523,42553,42523,42523],{"trials":51669,"activeCount":97},[],{"trials":51671,"activeCount":97},[],{"trials":51673,"activeCount":97},[],{"intervention":51675,"totalTrials":417,"cells":51676},"Augmentin ES",{"EARLY_PHASE1":51677,"PHASE1":51679,"PHASE2":51681,"PHASE3":51691,"PHASE4":51693,"NA":51695},{"trials":51678,"activeCount":97},[],{"trials":51680,"activeCount":97},[],{"trials":51682,"activeCount":97},[51683],{"nctId":51684,"briefTitle":51685,"status":500,"phases":51686,"primaryCompletion":51687,"completion":51687,"start":51688,"enrollment":97,"conditions":51689,"interventions":51690},"NCT05340257","A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS",[86],"2024-07-08","2023-10-14",[6484],[51675],{"trials":51692,"activeCount":97},[],{"trials":51694,"activeCount":97},[],{"trials":51696,"activeCount":97},[],{"intervention":51698,"totalTrials":417,"cells":51699},"Iodine I 131 Tositumomab Therapeutic Regimen",{"EARLY_PHASE1":51700,"PHASE1":51702,"PHASE2":51704,"PHASE3":51713,"PHASE4":51715,"NA":51717},{"trials":51701,"activeCount":97},[],{"trials":51703,"activeCount":97},[],{"trials":51705,"activeCount":97},[51706],{"nctId":51707,"briefTitle":51708,"status":155,"phases":51709,"primaryCompletion":10106,"completion":3390,"start":10084,"enrollment":51710,"conditions":51711,"interventions":51712},"NCT00268203","Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma",[86],765,[4574],[51698],{"trials":51714,"activeCount":97},[],{"trials":51716,"activeCount":97},[],{"trials":51718,"activeCount":97},[],{"intervention":8935,"totalTrials":417,"cells":51720},{"EARLY_PHASE1":51721,"PHASE1":51723,"PHASE2":51725,"PHASE3":51731,"PHASE4":51733,"NA":51735},{"trials":51722,"activeCount":97},[],{"trials":51724,"activeCount":97},[],{"trials":51726,"activeCount":97},[51727],{"nctId":8925,"briefTitle":8926,"status":155,"phases":51728,"primaryCompletion":8928,"completion":8929,"start":8930,"enrollment":8931,"conditions":51729,"interventions":51730},[86],[3287],[8934,4808,8935,8936,8937,8938],{"trials":51732,"activeCount":97},[],{"trials":51734,"activeCount":97},[],{"trials":51736,"activeCount":97},[],{"intervention":8936,"totalTrials":417,"cells":51738},{"EARLY_PHASE1":51739,"PHASE1":51741,"PHASE2":51743,"PHASE3":51749,"PHASE4":51751,"NA":51753},{"trials":51740,"activeCount":97},[],{"trials":51742,"activeCount":97},[],{"trials":51744,"activeCount":97},[51745],{"nctId":8925,"briefTitle":8926,"status":155,"phases":51746,"primaryCompletion":8928,"completion":8929,"start":8930,"enrollment":8931,"conditions":51747,"interventions":51748},[86],[3287],[8934,4808,8935,8936,8937,8938],{"trials":51750,"activeCount":97},[],{"trials":51752,"activeCount":97},[],{"trials":51754,"activeCount":97},[],{"intervention":8938,"totalTrials":417,"cells":51756},{"EARLY_PHASE1":51757,"PHASE1":51759,"PHASE2":51761,"PHASE3":51767,"PHASE4":51769,"NA":51771},{"trials":51758,"activeCount":97},[],{"trials":51760,"activeCount":97},[],{"trials":51762,"activeCount":97},[51763],{"nctId":8925,"briefTitle":8926,"status":155,"phases":51764,"primaryCompletion":8928,"completion":8929,"start":8930,"enrollment":8931,"conditions":51765,"interventions":51766},[86],[3287],[8934,4808,8935,8936,8937,8938],{"trials":51768,"activeCount":97},[],{"trials":51770,"activeCount":97},[],{"trials":51772,"activeCount":97},[],{"intervention":11238,"totalTrials":417,"cells":51774},{"EARLY_PHASE1":51775,"PHASE1":51777,"PHASE2":51779,"PHASE3":51785,"PHASE4":51787,"NA":51789},{"trials":51776,"activeCount":97},[],{"trials":51778,"activeCount":97},[],{"trials":51780,"activeCount":97},[51781],{"nctId":11231,"briefTitle":11232,"status":155,"phases":51782,"primaryCompletion":11234,"completion":10612,"start":11235,"enrollment":8861,"conditions":51783,"interventions":51784},[86],[24],[11238,10291],{"trials":51786,"activeCount":97},[],{"trials":51788,"activeCount":97},[],{"trials":51790,"activeCount":97},[],{"intervention":51792,"totalTrials":417,"cells":51793},"SB424323",{"EARLY_PHASE1":51794,"PHASE1":51796,"PHASE2":51798,"PHASE3":51807,"PHASE4":51809,"NA":51811},{"trials":51795,"activeCount":97},[],{"trials":51797,"activeCount":97},[],{"trials":51799,"activeCount":97},[51800],{"nctId":51801,"briefTitle":51802,"status":155,"phases":51803,"primaryCompletion":7659,"completion":7659,"start":2844,"enrollment":51804,"conditions":51805,"interventions":51806},"NCT00240643","Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke",[86],640,[28372,43023],[51792],{"trials":51808,"activeCount":97},[],{"trials":51810,"activeCount":97},[],{"trials":51812,"activeCount":97},[],{"intervention":7780,"totalTrials":417,"cells":51814},{"EARLY_PHASE1":51815,"PHASE1":51817,"PHASE2":51819,"PHASE3":51825,"PHASE4":51827,"NA":51829},{"trials":51816,"activeCount":97},[],{"trials":51818,"activeCount":97},[],{"trials":51820,"activeCount":97},[51821],{"nctId":7773,"briefTitle":7774,"status":155,"phases":51822,"primaryCompletion":7776,"completion":7776,"start":7777,"enrollment":1237,"conditions":51823,"interventions":51824},[86],[24],[7718,7753,7780],{"trials":51826,"activeCount":97},[],{"trials":51828,"activeCount":97},[],{"trials":51830,"activeCount":97},[],{"intervention":51832,"totalTrials":417,"cells":51833},"GSK256073 1mg",{"EARLY_PHASE1":51834,"PHASE1":51836,"PHASE2":51838,"PHASE3":51853,"PHASE4":51855,"NA":51857},{"trials":51835,"activeCount":97},[],{"trials":51837,"activeCount":97},[],{"trials":51839,"activeCount":97},[51840],{"nctId":51841,"briefTitle":51842,"status":155,"phases":51843,"primaryCompletion":51844,"completion":51845,"start":51846,"enrollment":2883,"conditions":51847,"interventions":51848},"NCT01376323","A Study of GSK256073 in Subjects With Type 2 Diabetes Mellitus Who Are Being Treated With Metformin",[86],"2012-09-16","2012-09-17","2011-07-13",[27],[51832,51849,51850,51851,51852],"GSK256073 5mg","GSK256073 10mg","GSK256073 25mg","Sitagliptin 100mg",{"trials":51854,"activeCount":97},[],{"trials":51856,"activeCount":97},[],{"trials":51858,"activeCount":97},[],{"intervention":51849,"totalTrials":417,"cells":51860},{"EARLY_PHASE1":51861,"PHASE1":51863,"PHASE2":51865,"PHASE3":51871,"PHASE4":51873,"NA":51875},{"trials":51862,"activeCount":97},[],{"trials":51864,"activeCount":97},[],{"trials":51866,"activeCount":97},[51867],{"nctId":51841,"briefTitle":51842,"status":155,"phases":51868,"primaryCompletion":51844,"completion":51845,"start":51846,"enrollment":2883,"conditions":51869,"interventions":51870},[86],[27],[51832,51849,51850,51851,51852],{"trials":51872,"activeCount":97},[],{"trials":51874,"activeCount":97},[],{"trials":51876,"activeCount":97},[],{"intervention":51850,"totalTrials":417,"cells":51878},{"EARLY_PHASE1":51879,"PHASE1":51881,"PHASE2":51883,"PHASE3":51889,"PHASE4":51891,"NA":51893},{"trials":51880,"activeCount":97},[],{"trials":51882,"activeCount":97},[],{"trials":51884,"activeCount":97},[51885],{"nctId":51841,"briefTitle":51842,"status":155,"phases":51886,"primaryCompletion":51844,"completion":51845,"start":51846,"enrollment":2883,"conditions":51887,"interventions":51888},[86],[27],[51832,51849,51850,51851,51852],{"trials":51890,"activeCount":97},[],{"trials":51892,"activeCount":97},[],{"trials":51894,"activeCount":97},[],{"intervention":51851,"totalTrials":417,"cells":51896},{"EARLY_PHASE1":51897,"PHASE1":51899,"PHASE2":51901,"PHASE3":51907,"PHASE4":51909,"NA":51911},{"trials":51898,"activeCount":97},[],{"trials":51900,"activeCount":97},[],{"trials":51902,"activeCount":97},[51903],{"nctId":51841,"briefTitle":51842,"status":155,"phases":51904,"primaryCompletion":51844,"completion":51845,"start":51846,"enrollment":2883,"conditions":51905,"interventions":51906},[86],[27],[51832,51849,51850,51851,51852],{"trials":51908,"activeCount":97},[],{"trials":51910,"activeCount":97},[],{"trials":51912,"activeCount":97},[],{"intervention":51852,"totalTrials":417,"cells":51914},{"EARLY_PHASE1":51915,"PHASE1":51917,"PHASE2":51919,"PHASE3":51925,"PHASE4":51927,"NA":51929},{"trials":51916,"activeCount":97},[],{"trials":51918,"activeCount":97},[],{"trials":51920,"activeCount":97},[51921],{"nctId":51841,"briefTitle":51842,"status":155,"phases":51922,"primaryCompletion":51844,"completion":51845,"start":51846,"enrollment":2883,"conditions":51923,"interventions":51924},[86],[27],[51832,51849,51850,51851,51852],{"trials":51926,"activeCount":97},[],{"trials":51928,"activeCount":97},[],{"trials":51930,"activeCount":97},[],{"intervention":3105,"totalTrials":417,"cells":51932},{"EARLY_PHASE1":51933,"PHASE1":51935,"PHASE2":51937,"PHASE3":51943,"PHASE4":51945,"NA":51947},{"trials":51934,"activeCount":97},[],{"trials":51936,"activeCount":97},[],{"trials":51938,"activeCount":97},[51939],{"nctId":3097,"briefTitle":3098,"status":155,"phases":51940,"primaryCompletion":3100,"completion":3100,"start":3101,"enrollment":3102,"conditions":51941,"interventions":51942},[86],[267,2858],[3105,164],{"trials":51944,"activeCount":97},[],{"trials":51946,"activeCount":97},[],{"trials":51948,"activeCount":97},[],{"intervention":51950,"totalTrials":417,"cells":51951},"sitamaquine",{"EARLY_PHASE1":51952,"PHASE1":51954,"PHASE2":51956,"PHASE3":51966,"PHASE4":51968,"NA":51970},{"trials":51953,"activeCount":97},[],{"trials":51955,"activeCount":97},[],{"trials":51957,"activeCount":97},[51958],{"nctId":51959,"briefTitle":51960,"status":155,"phases":51961,"primaryCompletion":14453,"completion":14453,"start":51962,"enrollment":4542,"conditions":51963,"interventions":51965},"NCT00381394","A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis.",[86],"2006-08-04",[51964],"Leishmaniasis, Visceral",[51950],{"trials":51967,"activeCount":97},[],{"trials":51969,"activeCount":97},[],{"trials":51971,"activeCount":97},[],{"intervention":39515,"totalTrials":417,"cells":51973},{"EARLY_PHASE1":51974,"PHASE1":51976,"PHASE2":51978,"PHASE3":51984,"PHASE4":51986,"NA":51988},{"trials":51975,"activeCount":97},[],{"trials":51977,"activeCount":97},[],{"trials":51979,"activeCount":97},[51980],{"nctId":39507,"briefTitle":39508,"status":145,"phases":51981,"primaryCompletion":39510,"completion":19584,"start":39511,"enrollment":1318,"conditions":51982,"interventions":51983},[86],[39513],[39461,39515],{"trials":51985,"activeCount":97},[],{"trials":51987,"activeCount":97},[],{"trials":51989,"activeCount":97},[],{"intervention":51991,"totalTrials":417,"cells":51992},"NTHi-10-AS01E",{"EARLY_PHASE1":51993,"PHASE1":51995,"PHASE2":51997,"PHASE3":52007,"PHASE4":52009,"NA":52011},{"trials":51994,"activeCount":97},[],{"trials":51996,"activeCount":97},[],{"trials":51998,"activeCount":97},[51999],{"nctId":52000,"briefTitle":52001,"status":155,"phases":52002,"primaryCompletion":12413,"completion":12413,"start":52003,"enrollment":7840,"conditions":52004,"interventions":52005},"NCT02075541","A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.",[86],"2014-07-08",[9855],[51991,52006],"NaCl Placebo",{"trials":52008,"activeCount":97},[],{"trials":52010,"activeCount":97},[],{"trials":52012,"activeCount":97},[],{"intervention":52006,"totalTrials":417,"cells":52014},{"EARLY_PHASE1":52015,"PHASE1":52017,"PHASE2":52019,"PHASE3":52025,"PHASE4":52027,"NA":52029},{"trials":52016,"activeCount":97},[],{"trials":52018,"activeCount":97},[],{"trials":52020,"activeCount":97},[52021],{"nctId":52000,"briefTitle":52001,"status":155,"phases":52022,"primaryCompletion":12413,"completion":12413,"start":52003,"enrollment":7840,"conditions":52023,"interventions":52024},[86],[9855],[51991,52006],{"trials":52026,"activeCount":97},[],{"trials":52028,"activeCount":97},[],{"trials":52030,"activeCount":97},[],{"intervention":52032,"totalTrials":417,"cells":52033},"GI198745 0.05mg",{"EARLY_PHASE1":52034,"PHASE1":52036,"PHASE2":52038,"PHASE3":52048,"PHASE4":52050,"NA":52052},{"trials":52035,"activeCount":97},[],{"trials":52037,"activeCount":97},[],{"trials":52039,"activeCount":97},[52040],{"nctId":52041,"briefTitle":52042,"status":155,"phases":52043,"primaryCompletion":1380,"completion":1380,"start":19831,"enrollment":2297,"conditions":52044,"interventions":52045},"NCT00969072","Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia",[86],[22619,12263],[52032,52046,52047],"GI198745 0.5mg","GI198745 2.5mg",{"trials":52049,"activeCount":97},[],{"trials":52051,"activeCount":97},[],{"trials":52053,"activeCount":97},[],{"intervention":52046,"totalTrials":417,"cells":52055},{"EARLY_PHASE1":52056,"PHASE1":52058,"PHASE2":52060,"PHASE3":52066,"PHASE4":52068,"NA":52070},{"trials":52057,"activeCount":97},[],{"trials":52059,"activeCount":97},[],{"trials":52061,"activeCount":97},[52062],{"nctId":52041,"briefTitle":52042,"status":155,"phases":52063,"primaryCompletion":1380,"completion":1380,"start":19831,"enrollment":2297,"conditions":52064,"interventions":52065},[86],[22619,12263],[52032,52046,52047],{"trials":52067,"activeCount":97},[],{"trials":52069,"activeCount":97},[],{"trials":52071,"activeCount":97},[],{"intervention":52047,"totalTrials":417,"cells":52073},{"EARLY_PHASE1":52074,"PHASE1":52076,"PHASE2":52078,"PHASE3":52084,"PHASE4":52086,"NA":52088},{"trials":52075,"activeCount":97},[],{"trials":52077,"activeCount":97},[],{"trials":52079,"activeCount":97},[52080],{"nctId":52041,"briefTitle":52042,"status":155,"phases":52081,"primaryCompletion":1380,"completion":1380,"start":19831,"enrollment":2297,"conditions":52082,"interventions":52083},[86],[22619,12263],[52032,52046,52047],{"trials":52085,"activeCount":97},[],{"trials":52087,"activeCount":97},[],{"trials":52089,"activeCount":97},[],{"intervention":52091,"totalTrials":417,"cells":52092},"Autologous Genetically modified T cells",{"EARLY_PHASE1":52093,"PHASE1":52095,"PHASE2":52097,"PHASE3":52105,"PHASE4":52107,"NA":52109},{"trials":52094,"activeCount":97},[],{"trials":52096,"activeCount":97},[],{"trials":52098,"activeCount":97},[52099],{"nctId":52100,"briefTitle":52101,"status":155,"phases":52102,"primaryCompletion":22932,"completion":4069,"start":42746,"enrollment":463,"conditions":52103,"interventions":52104},"NCT01352286","Redirected Auto T Cells for Advanced Myeloma",[86],[278],[52091],{"trials":52106,"activeCount":97},[],{"trials":52108,"activeCount":97},[],{"trials":52110,"activeCount":97},[],{"intervention":52112,"totalTrials":417,"cells":52113},"Dose 4 QD",{"EARLY_PHASE1":52114,"PHASE1":52116,"PHASE2":52118,"PHASE3":52129,"PHASE4":52131,"NA":52133},{"trials":52115,"activeCount":97},[],{"trials":52117,"activeCount":97},[],{"trials":52119,"activeCount":97},[52120],{"nctId":52121,"briefTitle":52122,"status":155,"phases":52123,"primaryCompletion":26336,"completion":26336,"start":1429,"enrollment":2825,"conditions":52124,"interventions":52125},"NCT00980200","Efficacy and Safety Study in Subjects With Asthma",[86],[18],[52112,52126,52127,52128],"Dose 3 QD","Dose 2 QD","Dose 1 BD",{"trials":52130,"activeCount":97},[],{"trials":52132,"activeCount":97},[],{"trials":52134,"activeCount":97},[],{"intervention":52126,"totalTrials":417,"cells":52136},{"EARLY_PHASE1":52137,"PHASE1":52139,"PHASE2":52141,"PHASE3":52147,"PHASE4":52149,"NA":52151},{"trials":52138,"activeCount":97},[],{"trials":52140,"activeCount":97},[],{"trials":52142,"activeCount":97},[52143],{"nctId":52121,"briefTitle":52122,"status":155,"phases":52144,"primaryCompletion":26336,"completion":26336,"start":1429,"enrollment":2825,"conditions":52145,"interventions":52146},[86],[18],[52112,52126,52127,52128],{"trials":52148,"activeCount":97},[],{"trials":52150,"activeCount":97},[],{"trials":52152,"activeCount":97},[],{"intervention":52127,"totalTrials":417,"cells":52154},{"EARLY_PHASE1":52155,"PHASE1":52157,"PHASE2":52159,"PHASE3":52165,"PHASE4":52167,"NA":52169},{"trials":52156,"activeCount":97},[],{"trials":52158,"activeCount":97},[],{"trials":52160,"activeCount":97},[52161],{"nctId":52121,"briefTitle":52122,"status":155,"phases":52162,"primaryCompletion":26336,"completion":26336,"start":1429,"enrollment":2825,"conditions":52163,"interventions":52164},[86],[18],[52112,52126,52127,52128],{"trials":52166,"activeCount":97},[],{"trials":52168,"activeCount":97},[],{"trials":52170,"activeCount":97},[],{"intervention":52128,"totalTrials":417,"cells":52172},{"EARLY_PHASE1":52173,"PHASE1":52175,"PHASE2":52177,"PHASE3":52183,"PHASE4":52185,"NA":52187},{"trials":52174,"activeCount":97},[],{"trials":52176,"activeCount":97},[],{"trials":52178,"activeCount":97},[52179],{"nctId":52121,"briefTitle":52122,"status":155,"phases":52180,"primaryCompletion":26336,"completion":26336,"start":1429,"enrollment":2825,"conditions":52181,"interventions":52182},[86],[18],[52112,52126,52127,52128],{"trials":52184,"activeCount":97},[],{"trials":52186,"activeCount":97},[],{"trials":52188,"activeCount":97},[],{"intervention":52190,"totalTrials":417,"cells":52191},"GSK233705\u002FGW642444",{"EARLY_PHASE1":52192,"PHASE1":52194,"PHASE2":52196,"PHASE3":52205,"PHASE4":52207,"NA":52209},{"trials":52193,"activeCount":97},[],{"trials":52195,"activeCount":97},[],{"trials":52197,"activeCount":97},[52198],{"nctId":52199,"briefTitle":52200,"status":155,"phases":52201,"primaryCompletion":21538,"completion":21538,"start":52202,"enrollment":4542,"conditions":52203,"interventions":52204},"NCT00749411","Safety and Tolerability of Repeat Dosing of GSK233705\u002FGW642444 in COPD",[86],"2008-11-13",[15],[52190],{"trials":52206,"activeCount":97},[],{"trials":52208,"activeCount":97},[],{"trials":52210,"activeCount":97},[],{"intervention":52212,"totalTrials":417,"cells":52213},"Ofatumumab 100",{"EARLY_PHASE1":52214,"PHASE1":52216,"PHASE2":52218,"PHASE3":52228,"PHASE4":52230,"NA":52232},{"trials":52215,"activeCount":97},[],{"trials":52217,"activeCount":97},[],{"trials":52219,"activeCount":97},[52220],{"nctId":52221,"briefTitle":52222,"status":155,"phases":52223,"primaryCompletion":7647,"completion":2394,"start":7522,"enrollment":12044,"conditions":52224,"interventions":52225},"NCT00640328","Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients",[86],[39962],[52212,52226,52227],"Ofatumumab 300","Ofatumumab 700",{"trials":52229,"activeCount":97},[],{"trials":52231,"activeCount":97},[],{"trials":52233,"activeCount":97},[],{"intervention":52226,"totalTrials":417,"cells":52235},{"EARLY_PHASE1":52236,"PHASE1":52238,"PHASE2":52240,"PHASE3":52246,"PHASE4":52248,"NA":52250},{"trials":52237,"activeCount":97},[],{"trials":52239,"activeCount":97},[],{"trials":52241,"activeCount":97},[52242],{"nctId":52221,"briefTitle":52222,"status":155,"phases":52243,"primaryCompletion":7647,"completion":2394,"start":7522,"enrollment":12044,"conditions":52244,"interventions":52245},[86],[39962],[52212,52226,52227],{"trials":52247,"activeCount":97},[],{"trials":52249,"activeCount":97},[],{"trials":52251,"activeCount":97},[],{"intervention":52227,"totalTrials":417,"cells":52253},{"EARLY_PHASE1":52254,"PHASE1":52256,"PHASE2":52258,"PHASE3":52264,"PHASE4":52266,"NA":52268},{"trials":52255,"activeCount":97},[],{"trials":52257,"activeCount":97},[],{"trials":52259,"activeCount":97},[52260],{"nctId":52221,"briefTitle":52222,"status":155,"phases":52261,"primaryCompletion":7647,"completion":2394,"start":7522,"enrollment":12044,"conditions":52262,"interventions":52263},[86],[39962],[52212,52226,52227],{"trials":52265,"activeCount":97},[],{"trials":52267,"activeCount":97},[],{"trials":52269,"activeCount":97},[],{"intervention":52271,"totalTrials":417,"cells":52272},"GSK influenza virus H5N1 vaccine 1557484A",{"EARLY_PHASE1":52273,"PHASE1":52275,"PHASE2":52277,"PHASE3":52285,"PHASE4":52287,"NA":52289},{"trials":52274,"activeCount":97},[],{"trials":52276,"activeCount":97},[],{"trials":52278,"activeCount":97},[52279],{"nctId":52280,"briefTitle":52281,"status":500,"phases":52282,"primaryCompletion":3390,"completion":3390,"start":22445,"enrollment":97,"conditions":52283,"interventions":52284},"NCT01045564","Safety and Immunogenicity of Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure",[86],[21],[52271],{"trials":52286,"activeCount":97},[],{"trials":52288,"activeCount":97},[],{"trials":52290,"activeCount":97},[],{"intervention":43552,"totalTrials":417,"cells":52292},{"EARLY_PHASE1":52293,"PHASE1":52295,"PHASE2":52297,"PHASE3":52303,"PHASE4":52305,"NA":52307},{"trials":52294,"activeCount":97},[],{"trials":52296,"activeCount":97},[],{"trials":52298,"activeCount":97},[52299],{"nctId":43546,"briefTitle":43547,"status":155,"phases":52300,"primaryCompletion":43549,"completion":43549,"start":18336,"enrollment":613,"conditions":52301,"interventions":52302},[86],[19499],[43552,43530],{"trials":52304,"activeCount":97},[],{"trials":52306,"activeCount":97},[],{"trials":52308,"activeCount":97},[],{"intervention":52310,"totalTrials":417,"cells":52311},"SB-207266",{"EARLY_PHASE1":52312,"PHASE1":52314,"PHASE2":52316,"PHASE3":52324,"PHASE4":52326,"NA":52328},{"trials":52313,"activeCount":97},[],{"trials":52315,"activeCount":97},[],{"trials":52317,"activeCount":97},[52318],{"nctId":52319,"briefTitle":52320,"status":155,"phases":52321,"primaryCompletion":8492,"completion":8492,"start":11577,"enrollment":1307,"conditions":52322,"interventions":52323},"NCT00041496","Prevention Of Recurrence Of Atrial Fibrillation",[86],[28372],[52310],{"trials":52325,"activeCount":97},[],{"trials":52327,"activeCount":97},[],{"trials":52329,"activeCount":97},[],{"intervention":20993,"totalTrials":417,"cells":52331},{"EARLY_PHASE1":52332,"PHASE1":52334,"PHASE2":52336,"PHASE3":52342,"PHASE4":52344,"NA":52346},{"trials":52333,"activeCount":97},[],{"trials":52335,"activeCount":97},[],{"trials":52337,"activeCount":97},[52338],{"nctId":20985,"briefTitle":20986,"status":155,"phases":52339,"primaryCompletion":20988,"completion":20989,"start":20990,"enrollment":10126,"conditions":52340,"interventions":52341},[86],[992],[20993,18312],{"trials":52343,"activeCount":97},[],{"trials":52345,"activeCount":97},[],{"trials":52347,"activeCount":97},[],{"intervention":52349,"totalTrials":417,"cells":52350},"Dabrafenib 150 mg",{"EARLY_PHASE1":52351,"PHASE1":52353,"PHASE2":52355,"PHASE3":52365,"PHASE4":52367,"NA":52369},{"trials":52352,"activeCount":97},[],{"trials":52354,"activeCount":97},[],{"trials":52356,"activeCount":97},[52357],{"nctId":52358,"briefTitle":52359,"status":145,"phases":52360,"primaryCompletion":52361,"completion":52361,"start":14963,"enrollment":628,"conditions":52362,"interventions":52363},"NCT01978236","Dabrafenib\u002FTrametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",[86],"2017-04-26",[19676],[52349,52364],"Trametinib 2.0 mg",{"trials":52366,"activeCount":97},[],{"trials":52368,"activeCount":97},[],{"trials":52370,"activeCount":97},[],{"intervention":52364,"totalTrials":417,"cells":52372},{"EARLY_PHASE1":52373,"PHASE1":52375,"PHASE2":52377,"PHASE3":52383,"PHASE4":52385,"NA":52387},{"trials":52374,"activeCount":97},[],{"trials":52376,"activeCount":97},[],{"trials":52378,"activeCount":97},[52379],{"nctId":52358,"briefTitle":52359,"status":145,"phases":52380,"primaryCompletion":52361,"completion":52361,"start":14963,"enrollment":628,"conditions":52381,"interventions":52382},[86],[19676],[52349,52364],{"trials":52384,"activeCount":97},[],{"trials":52386,"activeCount":97},[],{"trials":52388,"activeCount":97},[],{"intervention":44782,"totalTrials":417,"cells":52390},{"EARLY_PHASE1":52391,"PHASE1":52393,"PHASE2":52395,"PHASE3":52401,"PHASE4":52403,"NA":52405},{"trials":52392,"activeCount":97},[],{"trials":52394,"activeCount":97},[],{"trials":52396,"activeCount":97},[52397],{"nctId":44775,"briefTitle":44776,"status":155,"phases":52398,"primaryCompletion":44778,"completion":44778,"start":44779,"enrollment":1117,"conditions":52399,"interventions":52400},[85,86],[8788],[44782,44783,44784,44757,20269],{"trials":52402,"activeCount":97},[],{"trials":52404,"activeCount":97},[],{"trials":52406,"activeCount":97},[],{"intervention":44783,"totalTrials":417,"cells":52408},{"EARLY_PHASE1":52409,"PHASE1":52411,"PHASE2":52413,"PHASE3":52419,"PHASE4":52421,"NA":52423},{"trials":52410,"activeCount":97},[],{"trials":52412,"activeCount":97},[],{"trials":52414,"activeCount":97},[52415],{"nctId":44775,"briefTitle":44776,"status":155,"phases":52416,"primaryCompletion":44778,"completion":44778,"start":44779,"enrollment":1117,"conditions":52417,"interventions":52418},[85,86],[8788],[44782,44783,44784,44757,20269],{"trials":52420,"activeCount":97},[],{"trials":52422,"activeCount":97},[],{"trials":52424,"activeCount":97},[],{"intervention":44784,"totalTrials":417,"cells":52426},{"EARLY_PHASE1":52427,"PHASE1":52429,"PHASE2":52431,"PHASE3":52437,"PHASE4":52439,"NA":52441},{"trials":52428,"activeCount":97},[],{"trials":52430,"activeCount":97},[],{"trials":52432,"activeCount":97},[52433],{"nctId":44775,"briefTitle":44776,"status":155,"phases":52434,"primaryCompletion":44778,"completion":44778,"start":44779,"enrollment":1117,"conditions":52435,"interventions":52436},[85,86],[8788],[44782,44783,44784,44757,20269],{"trials":52438,"activeCount":97},[],{"trials":52440,"activeCount":97},[],{"trials":52442,"activeCount":97},[],{"intervention":52444,"totalTrials":417,"cells":52445},"FP 100",{"EARLY_PHASE1":52446,"PHASE1":52448,"PHASE2":52450,"PHASE3":52461,"PHASE4":52463,"NA":52465},{"trials":52447,"activeCount":97},[],{"trials":52449,"activeCount":97},[],{"trials":52451,"activeCount":97},[52452],{"nctId":52453,"briefTitle":52454,"status":155,"phases":52455,"primaryCompletion":2394,"completion":2394,"start":3551,"enrollment":8347,"conditions":52456,"interventions":52457},"NCT01156792","Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age",[86],[18],[52444,52458,52459,8431,52460],"GSK2190915 100","GSK2190915 300","FP\u002FSAL 100\u002F50",{"trials":52462,"activeCount":97},[],{"trials":52464,"activeCount":97},[],{"trials":52466,"activeCount":97},[],{"intervention":52458,"totalTrials":417,"cells":52468},{"EARLY_PHASE1":52469,"PHASE1":52471,"PHASE2":52473,"PHASE3":52479,"PHASE4":52481,"NA":52483},{"trials":52470,"activeCount":97},[],{"trials":52472,"activeCount":97},[],{"trials":52474,"activeCount":97},[52475],{"nctId":52453,"briefTitle":52454,"status":155,"phases":52476,"primaryCompletion":2394,"completion":2394,"start":3551,"enrollment":8347,"conditions":52477,"interventions":52478},[86],[18],[52444,52458,52459,8431,52460],{"trials":52480,"activeCount":97},[],{"trials":52482,"activeCount":97},[],{"trials":52484,"activeCount":97},[],{"intervention":52459,"totalTrials":417,"cells":52486},{"EARLY_PHASE1":52487,"PHASE1":52489,"PHASE2":52491,"PHASE3":52497,"PHASE4":52499,"NA":52501},{"trials":52488,"activeCount":97},[],{"trials":52490,"activeCount":97},[],{"trials":52492,"activeCount":97},[52493],{"nctId":52453,"briefTitle":52454,"status":155,"phases":52494,"primaryCompletion":2394,"completion":2394,"start":3551,"enrollment":8347,"conditions":52495,"interventions":52496},[86],[18],[52444,52458,52459,8431,52460],{"trials":52498,"activeCount":97},[],{"trials":52500,"activeCount":97},[],{"trials":52502,"activeCount":97},[],{"intervention":52460,"totalTrials":417,"cells":52504},{"EARLY_PHASE1":52505,"PHASE1":52507,"PHASE2":52509,"PHASE3":52515,"PHASE4":52517,"NA":52519},{"trials":52506,"activeCount":97},[],{"trials":52508,"activeCount":97},[],{"trials":52510,"activeCount":97},[52511],{"nctId":52453,"briefTitle":52454,"status":155,"phases":52512,"primaryCompletion":2394,"completion":2394,"start":3551,"enrollment":8347,"conditions":52513,"interventions":52514},[86],[18],[52444,52458,52459,8431,52460],{"trials":52516,"activeCount":97},[],{"trials":52518,"activeCount":97},[],{"trials":52520,"activeCount":97},[],{"intervention":39088,"totalTrials":417,"cells":52522},{"EARLY_PHASE1":52523,"PHASE1":52525,"PHASE2":52527,"PHASE3":52533,"PHASE4":52535,"NA":52537},{"trials":52524,"activeCount":97},[],{"trials":52526,"activeCount":97},[],{"trials":52528,"activeCount":97},[52529],{"nctId":39082,"briefTitle":39083,"status":155,"phases":52530,"primaryCompletion":7522,"completion":7522,"start":9737,"enrollment":730,"conditions":52531,"interventions":52532},[86],[39086,10169],[39027,39088],{"trials":52534,"activeCount":97},[],{"trials":52536,"activeCount":97},[],{"trials":52538,"activeCount":97},[],{"intervention":44216,"totalTrials":417,"cells":52540},{"EARLY_PHASE1":52541,"PHASE1":52543,"PHASE2":52545,"PHASE3":52551,"PHASE4":52553,"NA":52555},{"trials":52542,"activeCount":97},[],{"trials":52544,"activeCount":97},[],{"trials":52546,"activeCount":97},[52547],{"nctId":44209,"briefTitle":44210,"status":155,"phases":52548,"primaryCompletion":9159,"completion":9159,"start":7659,"enrollment":93,"conditions":52549,"interventions":52550},[86],[44213],[44215,44216],{"trials":52552,"activeCount":97},[],{"trials":52554,"activeCount":97},[],{"trials":52556,"activeCount":97},[],{"intervention":52558,"totalTrials":417,"cells":52559},"Lapatinib and Capecitabine",{"EARLY_PHASE1":52560,"PHASE1":52562,"PHASE2":52564,"PHASE3":52572,"PHASE4":52574,"NA":52576},{"trials":52561,"activeCount":97},[],{"trials":52563,"activeCount":97},[],{"trials":52565,"activeCount":97},[52566],{"nctId":52567,"briefTitle":52568,"status":155,"phases":52569,"primaryCompletion":7598,"completion":11029,"start":2382,"enrollment":37,"conditions":52570,"interventions":52571},"NCT00526669","Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib",[86],[2431],[52558],{"trials":52573,"activeCount":97},[],{"trials":52575,"activeCount":97},[],{"trials":52577,"activeCount":97},[],{"intervention":52579,"totalTrials":417,"cells":52580},"HPV9 High formulation",{"EARLY_PHASE1":52581,"PHASE1":52583,"PHASE2":52585,"PHASE3":52600,"PHASE4":52602,"NA":52604},{"trials":52582,"activeCount":97},[],{"trials":52584,"activeCount":97},[],{"trials":52586,"activeCount":97},[52587],{"nctId":52588,"briefTitle":52589,"status":155,"phases":52590,"primaryCompletion":52591,"completion":52592,"start":52593,"enrollment":52594,"conditions":52595,"interventions":52596},"NCT05496231","A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age",[85,86],"2024-02-23","2024-02-25","2022-08-22",1080,[2444],[52579,52597,52598,52599],"HPV9 Medium formulation","HPV9 Low formulation","Gardasil 9",{"trials":52601,"activeCount":97},[],{"trials":52603,"activeCount":97},[],{"trials":52605,"activeCount":97},[],{"intervention":52597,"totalTrials":417,"cells":52607},{"EARLY_PHASE1":52608,"PHASE1":52610,"PHASE2":52612,"PHASE3":52618,"PHASE4":52620,"NA":52622},{"trials":52609,"activeCount":97},[],{"trials":52611,"activeCount":97},[],{"trials":52613,"activeCount":97},[52614],{"nctId":52588,"briefTitle":52589,"status":155,"phases":52615,"primaryCompletion":52591,"completion":52592,"start":52593,"enrollment":52594,"conditions":52616,"interventions":52617},[85,86],[2444],[52579,52597,52598,52599],{"trials":52619,"activeCount":97},[],{"trials":52621,"activeCount":97},[],{"trials":52623,"activeCount":97},[],{"intervention":52598,"totalTrials":417,"cells":52625},{"EARLY_PHASE1":52626,"PHASE1":52628,"PHASE2":52630,"PHASE3":52636,"PHASE4":52638,"NA":52640},{"trials":52627,"activeCount":97},[],{"trials":52629,"activeCount":97},[],{"trials":52631,"activeCount":97},[52632],{"nctId":52588,"briefTitle":52589,"status":155,"phases":52633,"primaryCompletion":52591,"completion":52592,"start":52593,"enrollment":52594,"conditions":52634,"interventions":52635},[85,86],[2444],[52579,52597,52598,52599],{"trials":52637,"activeCount":97},[],{"trials":52639,"activeCount":97},[],{"trials":52641,"activeCount":97},[],{"intervention":52599,"totalTrials":417,"cells":52643},{"EARLY_PHASE1":52644,"PHASE1":52646,"PHASE2":52648,"PHASE3":52654,"PHASE4":52656,"NA":52658},{"trials":52645,"activeCount":97},[],{"trials":52647,"activeCount":97},[],{"trials":52649,"activeCount":97},[52650],{"nctId":52588,"briefTitle":52589,"status":155,"phases":52651,"primaryCompletion":52591,"completion":52592,"start":52593,"enrollment":52594,"conditions":52652,"interventions":52653},[85,86],[2444],[52579,52597,52598,52599],{"trials":52655,"activeCount":97},[],{"trials":52657,"activeCount":97},[],{"trials":52659,"activeCount":97},[],{"intervention":52661,"totalTrials":417,"cells":52662},"Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib",{"EARLY_PHASE1":52663,"PHASE1":52665,"PHASE2":52667,"PHASE3":52677,"PHASE4":52679,"NA":52681},{"trials":52664,"activeCount":97},[],{"trials":52666,"activeCount":97},[],{"trials":52668,"activeCount":97},[52669],{"nctId":52670,"briefTitle":52671,"status":155,"phases":52672,"primaryCompletion":7785,"completion":7785,"start":10803,"enrollment":243,"conditions":52673,"interventions":52676},"NCT00158808","Immune Memory Foll Pry Vaccination With DTPw-HBV\u002FHib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths",[86],[52674,24,10087,52675,33],"Hib Disease","Prophylaxis of Diphtheria",[52661],{"trials":52678,"activeCount":97},[],{"trials":52680,"activeCount":97},[],{"trials":52682,"activeCount":97},[],{"intervention":19980,"totalTrials":417,"cells":52684},{"EARLY_PHASE1":52685,"PHASE1":52687,"PHASE2":52689,"PHASE3":52695,"PHASE4":52697,"NA":52699},{"trials":52686,"activeCount":97},[],{"trials":52688,"activeCount":97},[],{"trials":52690,"activeCount":97},[52691],{"nctId":19973,"briefTitle":19974,"status":145,"phases":52692,"primaryCompletion":19976,"completion":19976,"start":19977,"enrollment":1720,"conditions":52693,"interventions":52694},[86],[21],[19980,19981,4745],{"trials":52696,"activeCount":97},[],{"trials":52698,"activeCount":97},[],{"trials":52700,"activeCount":97},[],{"intervention":52702,"totalTrials":417,"cells":52703},"ropinirole controlled release (CR)-RLS",{"EARLY_PHASE1":52704,"PHASE1":52706,"PHASE2":52708,"PHASE3":52716,"PHASE4":52718,"NA":52720},{"trials":52705,"activeCount":97},[],{"trials":52707,"activeCount":97},[],{"trials":52709,"activeCount":97},[52710],{"nctId":52711,"briefTitle":52712,"status":155,"phases":52713,"primaryCompletion":4713,"completion":4713,"start":15146,"enrollment":8786,"conditions":52714,"interventions":52715},"NCT00530790","Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome",[86],[14255],[52702],{"trials":52717,"activeCount":97},[],{"trials":52719,"activeCount":97},[],{"trials":52721,"activeCount":97},[],{"intervention":52723,"totalTrials":417,"cells":52724},"Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant",{"EARLY_PHASE1":52725,"PHASE1":52727,"PHASE2":52729,"PHASE3":52740,"PHASE4":52742,"NA":52744},{"trials":52726,"activeCount":97},[],{"trials":52728,"activeCount":97},[],{"trials":52730,"activeCount":97},[52731],{"nctId":52732,"briefTitle":52733,"status":155,"phases":52734,"primaryCompletion":52735,"completion":52735,"start":7768,"enrollment":526,"conditions":52736,"interventions":52738},"NCT00697567","Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With\u002FWithout Adjuvant",[86],"1997-12",[52737],"Prophylaxis Herpes Simplex",[52723,52739],"Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant",{"trials":52741,"activeCount":97},[],{"trials":52743,"activeCount":97},[],{"trials":52745,"activeCount":97},[],{"intervention":52739,"totalTrials":417,"cells":52747},{"EARLY_PHASE1":52748,"PHASE1":52750,"PHASE2":52752,"PHASE3":52758,"PHASE4":52760,"NA":52762},{"trials":52749,"activeCount":97},[],{"trials":52751,"activeCount":97},[],{"trials":52753,"activeCount":97},[52754],{"nctId":52732,"briefTitle":52733,"status":155,"phases":52755,"primaryCompletion":52735,"completion":52735,"start":7768,"enrollment":526,"conditions":52756,"interventions":52757},[86],[52737],[52723,52739],{"trials":52759,"activeCount":97},[],{"trials":52761,"activeCount":97},[],{"trials":52763,"activeCount":97},[],{"intervention":52765,"totalTrials":417,"cells":52766},"GSK573179",{"EARLY_PHASE1":52767,"PHASE1":52769,"PHASE2":52771,"PHASE3":52780,"PHASE4":52782,"NA":52784},{"trials":52768,"activeCount":97},[],{"trials":52770,"activeCount":97},[],{"trials":52772,"activeCount":97},[52773],{"nctId":52774,"briefTitle":52775,"status":155,"phases":52776,"primaryCompletion":11275,"completion":8008,"start":52777,"enrollment":17033,"conditions":52778,"interventions":52779},"NCT00950807","GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease",[86],"2009-09-01",[15],[2934,52765],{"trials":52781,"activeCount":97},[],{"trials":52783,"activeCount":97},[],{"trials":52785,"activeCount":97},[],{"intervention":52787,"totalTrials":417,"cells":52788},"Live attenuated rotavirus vaccine",{"EARLY_PHASE1":52789,"PHASE1":52791,"PHASE2":52793,"PHASE3":52801,"PHASE4":52803,"NA":52805},{"trials":52790,"activeCount":97},[],{"trials":52792,"activeCount":97},[],{"trials":52794,"activeCount":97},[52795],{"nctId":52796,"briefTitle":52797,"status":155,"phases":52798,"completion":2844,"start":10395,"enrollment":17295,"conditions":52799,"interventions":52800},"NCT00137930","Study of Immunogenicity & Safety of 2 Different Formulations of Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis",[86],[4759],[52787],{"trials":52802,"activeCount":97},[],{"trials":52804,"activeCount":97},[],{"trials":52806,"activeCount":97},[],{"intervention":52808,"totalTrials":417,"cells":52809},"Camicinal",{"EARLY_PHASE1":52810,"PHASE1":52812,"PHASE2":52814,"PHASE3":52823,"PHASE4":52825,"NA":52827},{"trials":52811,"activeCount":97},[],{"trials":52813,"activeCount":97},[],{"trials":52815,"activeCount":97},[52816],{"nctId":52817,"briefTitle":52818,"status":155,"phases":52819,"primaryCompletion":52820,"completion":52820,"start":9057,"enrollment":24657,"conditions":52821,"interventions":52822},"NCT02210000","A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis",[86],"2015-08-24",[39624],[52808],{"trials":52824,"activeCount":97},[],{"trials":52826,"activeCount":97},[],{"trials":52828,"activeCount":97},[],{"intervention":52830,"totalTrials":417,"cells":52831},"500mcg\u002F25mcg once daily",{"EARLY_PHASE1":52832,"PHASE1":52834,"PHASE2":52836,"PHASE3":52846,"PHASE4":52848,"NA":52850},{"trials":52833,"activeCount":97},[],{"trials":52835,"activeCount":97},[],{"trials":52837,"activeCount":97},[52838],{"nctId":52839,"briefTitle":52840,"status":155,"phases":52841,"primaryCompletion":52842,"completion":52843,"start":29281,"enrollment":7573,"conditions":52844,"interventions":52845},"NCT01039675","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Combination of GSK573719 and GW642444 in Subjects With COPD",[86],"2010-04-01","2010-04-20",[15],[52830],{"trials":52847,"activeCount":97},[],{"trials":52849,"activeCount":97},[],{"trials":52851,"activeCount":97},[],{"intervention":22580,"totalTrials":417,"cells":52853},{"EARLY_PHASE1":52854,"PHASE1":52856,"PHASE2":52858,"PHASE3":52864,"PHASE4":52866,"NA":52868},{"trials":52855,"activeCount":97},[],{"trials":52857,"activeCount":97},[],{"trials":52859,"activeCount":97},[52860],{"nctId":22574,"briefTitle":22575,"status":155,"phases":52861,"primaryCompletion":11274,"completion":5268,"start":22577,"enrollment":4521,"conditions":52862,"interventions":52863},[86],[4703,4704],[22580,11068,11067,22581,19196],{"trials":52865,"activeCount":97},[],{"trials":52867,"activeCount":97},[],{"trials":52869,"activeCount":97},[],{"intervention":52871,"totalTrials":417,"cells":52872},"GSK Biologicals' Influenza investigational vaccine GSK2340274A",{"EARLY_PHASE1":52873,"PHASE1":52875,"PHASE2":52877,"PHASE3":52887,"PHASE4":52889,"NA":52891},{"trials":52874,"activeCount":97},[],{"trials":52876,"activeCount":97},[],{"trials":52878,"activeCount":97},[52879],{"nctId":52880,"briefTitle":52881,"status":155,"phases":52882,"primaryCompletion":4678,"completion":52883,"start":41504,"enrollment":8152,"conditions":52884,"interventions":52885},"NCT01035749","Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years",[86],"2011-05-10",[21],[52871,52886],"GSK Biologicals' Influenza investigational vaccine GSK2340273A",{"trials":52888,"activeCount":97},[],{"trials":52890,"activeCount":97},[],{"trials":52892,"activeCount":97},[],{"intervention":52886,"totalTrials":417,"cells":52894},{"EARLY_PHASE1":52895,"PHASE1":52897,"PHASE2":52899,"PHASE3":52905,"PHASE4":52907,"NA":52909},{"trials":52896,"activeCount":97},[],{"trials":52898,"activeCount":97},[],{"trials":52900,"activeCount":97},[52901],{"nctId":52880,"briefTitle":52881,"status":155,"phases":52902,"primaryCompletion":4678,"completion":52883,"start":41504,"enrollment":8152,"conditions":52903,"interventions":52904},[86],[21],[52871,52886],{"trials":52906,"activeCount":97},[],{"trials":52908,"activeCount":97},[],{"trials":52910,"activeCount":97},[],{"intervention":52912,"totalTrials":417,"cells":52913},"GSK835726 10mg",{"EARLY_PHASE1":52914,"PHASE1":52916,"PHASE2":52918,"PHASE3":52928,"PHASE4":52930,"NA":52932},{"trials":52915,"activeCount":97},[],{"trials":52917,"activeCount":97},[],{"trials":52919,"activeCount":97},[52920],{"nctId":52921,"briefTitle":52922,"status":155,"phases":52923,"primaryCompletion":21200,"completion":2664,"start":16322,"enrollment":1686,"conditions":52924,"interventions":52925},"NCT00972504","723\u002F726 Proof of Concept Study in Allergen Challenge Chamber in Hannover",[86],[10169],[52912,52926,52927],"GSK1004723 1000mcg","Cetirizine 10mg",{"trials":52929,"activeCount":97},[],{"trials":52931,"activeCount":97},[],{"trials":52933,"activeCount":97},[],{"intervention":52926,"totalTrials":417,"cells":52935},{"EARLY_PHASE1":52936,"PHASE1":52938,"PHASE2":52940,"PHASE3":52946,"PHASE4":52948,"NA":52950},{"trials":52937,"activeCount":97},[],{"trials":52939,"activeCount":97},[],{"trials":52941,"activeCount":97},[52942],{"nctId":52921,"briefTitle":52922,"status":155,"phases":52943,"primaryCompletion":21200,"completion":2664,"start":16322,"enrollment":1686,"conditions":52944,"interventions":52945},[86],[10169],[52912,52926,52927],{"trials":52947,"activeCount":97},[],{"trials":52949,"activeCount":97},[],{"trials":52951,"activeCount":97},[],{"intervention":52927,"totalTrials":417,"cells":52953},{"EARLY_PHASE1":52954,"PHASE1":52956,"PHASE2":52958,"PHASE3":52964,"PHASE4":52966,"NA":52968},{"trials":52955,"activeCount":97},[],{"trials":52957,"activeCount":97},[],{"trials":52959,"activeCount":97},[52960],{"nctId":52921,"briefTitle":52922,"status":155,"phases":52961,"primaryCompletion":21200,"completion":2664,"start":16322,"enrollment":1686,"conditions":52962,"interventions":52963},[86],[10169],[52912,52926,52927],{"trials":52965,"activeCount":97},[],{"trials":52967,"activeCount":97},[],{"trials":52969,"activeCount":97},[],{"intervention":52971,"totalTrials":417,"cells":52972},"F2C22C\u002FDL001Z",{"EARLY_PHASE1":52973,"PHASE1":52975,"PHASE2":52977,"PHASE3":53006,"PHASE4":53008,"NA":53010},{"trials":52974,"activeCount":97},[],{"trials":52976,"activeCount":97},[],{"trials":52978,"activeCount":97},[52979],{"nctId":52980,"briefTitle":52981,"status":155,"phases":52982,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":52986,"interventions":52987},"NCT05823974","A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults",[85,86],"2024-12-18","2023-04-27",1275,[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],"F2B22A\u002FDL001Z","F2B22B\u002FDL001Z","F2B22C\u002FDL001Z","F2B22D\u002FDL001Z","F2B22E\u002FDL001Z","F2F22A\u002FDL001Z","F2F22B\u002FDL001Z","F2F22C\u002FDL001Z","F2F22D\u002FDL001Z","F2F22E\u002FDL001Z","Control 1","F2F23D\u002FDL001Z-NH","F2F23A\u002FDL001Z-NH","F2F23B\u002FDL001Z-NH","Control 2","F2F23C\u002FDL001Z-NH","Control 3","F2F22F\u002FDL001Z",{"trials":53007,"activeCount":97},[],{"trials":53009,"activeCount":97},[],{"trials":53011,"activeCount":97},[],{"intervention":52988,"totalTrials":417,"cells":53013},{"EARLY_PHASE1":53014,"PHASE1":53016,"PHASE2":53018,"PHASE3":53024,"PHASE4":53026,"NA":53028},{"trials":53015,"activeCount":97},[],{"trials":53017,"activeCount":97},[],{"trials":53019,"activeCount":97},[53020],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53021,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53022,"interventions":53023},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53025,"activeCount":97},[],{"trials":53027,"activeCount":97},[],{"trials":53029,"activeCount":97},[],{"intervention":52989,"totalTrials":417,"cells":53031},{"EARLY_PHASE1":53032,"PHASE1":53034,"PHASE2":53036,"PHASE3":53042,"PHASE4":53044,"NA":53046},{"trials":53033,"activeCount":97},[],{"trials":53035,"activeCount":97},[],{"trials":53037,"activeCount":97},[53038],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53039,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53040,"interventions":53041},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53043,"activeCount":97},[],{"trials":53045,"activeCount":97},[],{"trials":53047,"activeCount":97},[],{"intervention":52990,"totalTrials":417,"cells":53049},{"EARLY_PHASE1":53050,"PHASE1":53052,"PHASE2":53054,"PHASE3":53060,"PHASE4":53062,"NA":53064},{"trials":53051,"activeCount":97},[],{"trials":53053,"activeCount":97},[],{"trials":53055,"activeCount":97},[53056],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53057,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53058,"interventions":53059},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53061,"activeCount":97},[],{"trials":53063,"activeCount":97},[],{"trials":53065,"activeCount":97},[],{"intervention":52991,"totalTrials":417,"cells":53067},{"EARLY_PHASE1":53068,"PHASE1":53070,"PHASE2":53072,"PHASE3":53078,"PHASE4":53080,"NA":53082},{"trials":53069,"activeCount":97},[],{"trials":53071,"activeCount":97},[],{"trials":53073,"activeCount":97},[53074],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53075,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53076,"interventions":53077},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53079,"activeCount":97},[],{"trials":53081,"activeCount":97},[],{"trials":53083,"activeCount":97},[],{"intervention":52992,"totalTrials":417,"cells":53085},{"EARLY_PHASE1":53086,"PHASE1":53088,"PHASE2":53090,"PHASE3":53096,"PHASE4":53098,"NA":53100},{"trials":53087,"activeCount":97},[],{"trials":53089,"activeCount":97},[],{"trials":53091,"activeCount":97},[53092],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53093,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53094,"interventions":53095},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53097,"activeCount":97},[],{"trials":53099,"activeCount":97},[],{"trials":53101,"activeCount":97},[],{"intervention":52993,"totalTrials":417,"cells":53103},{"EARLY_PHASE1":53104,"PHASE1":53106,"PHASE2":53108,"PHASE3":53114,"PHASE4":53116,"NA":53118},{"trials":53105,"activeCount":97},[],{"trials":53107,"activeCount":97},[],{"trials":53109,"activeCount":97},[53110],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53111,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53112,"interventions":53113},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53115,"activeCount":97},[],{"trials":53117,"activeCount":97},[],{"trials":53119,"activeCount":97},[],{"intervention":52994,"totalTrials":417,"cells":53121},{"EARLY_PHASE1":53122,"PHASE1":53124,"PHASE2":53126,"PHASE3":53132,"PHASE4":53134,"NA":53136},{"trials":53123,"activeCount":97},[],{"trials":53125,"activeCount":97},[],{"trials":53127,"activeCount":97},[53128],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53129,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53130,"interventions":53131},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53133,"activeCount":97},[],{"trials":53135,"activeCount":97},[],{"trials":53137,"activeCount":97},[],{"intervention":52995,"totalTrials":417,"cells":53139},{"EARLY_PHASE1":53140,"PHASE1":53142,"PHASE2":53144,"PHASE3":53150,"PHASE4":53152,"NA":53154},{"trials":53141,"activeCount":97},[],{"trials":53143,"activeCount":97},[],{"trials":53145,"activeCount":97},[53146],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53147,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53148,"interventions":53149},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53151,"activeCount":97},[],{"trials":53153,"activeCount":97},[],{"trials":53155,"activeCount":97},[],{"intervention":52996,"totalTrials":417,"cells":53157},{"EARLY_PHASE1":53158,"PHASE1":53160,"PHASE2":53162,"PHASE3":53168,"PHASE4":53170,"NA":53172},{"trials":53159,"activeCount":97},[],{"trials":53161,"activeCount":97},[],{"trials":53163,"activeCount":97},[53164],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53165,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53166,"interventions":53167},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53169,"activeCount":97},[],{"trials":53171,"activeCount":97},[],{"trials":53173,"activeCount":97},[],{"intervention":52997,"totalTrials":417,"cells":53175},{"EARLY_PHASE1":53176,"PHASE1":53178,"PHASE2":53180,"PHASE3":53186,"PHASE4":53188,"NA":53190},{"trials":53177,"activeCount":97},[],{"trials":53179,"activeCount":97},[],{"trials":53181,"activeCount":97},[53182],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53183,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53184,"interventions":53185},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53187,"activeCount":97},[],{"trials":53189,"activeCount":97},[],{"trials":53191,"activeCount":97},[],{"intervention":52998,"totalTrials":417,"cells":53193},{"EARLY_PHASE1":53194,"PHASE1":53196,"PHASE2":53198,"PHASE3":53204,"PHASE4":53206,"NA":53208},{"trials":53195,"activeCount":97},[],{"trials":53197,"activeCount":97},[],{"trials":53199,"activeCount":97},[53200],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53201,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53202,"interventions":53203},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53205,"activeCount":97},[],{"trials":53207,"activeCount":97},[],{"trials":53209,"activeCount":97},[],{"intervention":52999,"totalTrials":417,"cells":53211},{"EARLY_PHASE1":53212,"PHASE1":53214,"PHASE2":53216,"PHASE3":53222,"PHASE4":53224,"NA":53226},{"trials":53213,"activeCount":97},[],{"trials":53215,"activeCount":97},[],{"trials":53217,"activeCount":97},[53218],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53219,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53220,"interventions":53221},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53223,"activeCount":97},[],{"trials":53225,"activeCount":97},[],{"trials":53227,"activeCount":97},[],{"intervention":53000,"totalTrials":417,"cells":53229},{"EARLY_PHASE1":53230,"PHASE1":53232,"PHASE2":53234,"PHASE3":53240,"PHASE4":53242,"NA":53244},{"trials":53231,"activeCount":97},[],{"trials":53233,"activeCount":97},[],{"trials":53235,"activeCount":97},[53236],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53237,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53238,"interventions":53239},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53241,"activeCount":97},[],{"trials":53243,"activeCount":97},[],{"trials":53245,"activeCount":97},[],{"intervention":53001,"totalTrials":417,"cells":53247},{"EARLY_PHASE1":53248,"PHASE1":53250,"PHASE2":53252,"PHASE3":53258,"PHASE4":53260,"NA":53262},{"trials":53249,"activeCount":97},[],{"trials":53251,"activeCount":97},[],{"trials":53253,"activeCount":97},[53254],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53255,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53256,"interventions":53257},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53259,"activeCount":97},[],{"trials":53261,"activeCount":97},[],{"trials":53263,"activeCount":97},[],{"intervention":53002,"totalTrials":417,"cells":53265},{"EARLY_PHASE1":53266,"PHASE1":53268,"PHASE2":53270,"PHASE3":53276,"PHASE4":53278,"NA":53280},{"trials":53267,"activeCount":97},[],{"trials":53269,"activeCount":97},[],{"trials":53271,"activeCount":97},[53272],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53273,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53274,"interventions":53275},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53277,"activeCount":97},[],{"trials":53279,"activeCount":97},[],{"trials":53281,"activeCount":97},[],{"intervention":53003,"totalTrials":417,"cells":53283},{"EARLY_PHASE1":53284,"PHASE1":53286,"PHASE2":53288,"PHASE3":53294,"PHASE4":53296,"NA":53298},{"trials":53285,"activeCount":97},[],{"trials":53287,"activeCount":97},[],{"trials":53289,"activeCount":97},[53290],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53291,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53292,"interventions":53293},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53295,"activeCount":97},[],{"trials":53297,"activeCount":97},[],{"trials":53299,"activeCount":97},[],{"intervention":53004,"totalTrials":417,"cells":53301},{"EARLY_PHASE1":53302,"PHASE1":53304,"PHASE2":53306,"PHASE3":53312,"PHASE4":53314,"NA":53316},{"trials":53303,"activeCount":97},[],{"trials":53305,"activeCount":97},[],{"trials":53307,"activeCount":97},[53308],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53309,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53310,"interventions":53311},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53313,"activeCount":97},[],{"trials":53315,"activeCount":97},[],{"trials":53317,"activeCount":97},[],{"intervention":53005,"totalTrials":417,"cells":53319},{"EARLY_PHASE1":53320,"PHASE1":53322,"PHASE2":53324,"PHASE3":53330,"PHASE4":53332,"NA":53334},{"trials":53321,"activeCount":97},[],{"trials":53323,"activeCount":97},[],{"trials":53325,"activeCount":97},[53326],{"nctId":52980,"briefTitle":52981,"status":155,"phases":53327,"primaryCompletion":7250,"completion":52983,"start":52984,"enrollment":52985,"conditions":53328,"interventions":53329},[85,86],[5353],[52971,52988,52989,52990,52991,52992,52993,52994,52995,52996,52997,52998,52999,53000,53001,53002,53003,53004,53005],{"trials":53331,"activeCount":97},[],{"trials":53333,"activeCount":97},[],{"trials":53335,"activeCount":97},[],{"intervention":53337,"totalTrials":417,"cells":53338},"GSK 249553 vaccine",{"EARLY_PHASE1":53339,"PHASE1":53341,"PHASE2":53343,"PHASE3":53354,"PHASE4":53356,"NA":53358},{"trials":53340,"activeCount":97},[],{"trials":53342,"activeCount":97},[],{"trials":53344,"activeCount":97},[53345],{"nctId":53346,"briefTitle":53347,"status":155,"phases":53348,"primaryCompletion":53349,"completion":53349,"start":53350,"enrollment":53351,"conditions":53352,"interventions":53353},"NCT00290355","Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery",[86],"2011-07-19","2002-05-28",182,[267],[53337],{"trials":53355,"activeCount":97},[],{"trials":53357,"activeCount":97},[],{"trials":53359,"activeCount":97},[],{"intervention":53361,"totalTrials":417,"cells":53362},"Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A",{"EARLY_PHASE1":53363,"PHASE1":53365,"PHASE2":53367,"PHASE3":53376,"PHASE4":53378,"NA":53380},{"trials":53364,"activeCount":97},[],{"trials":53366,"activeCount":97},[],{"trials":53368,"activeCount":97},[53369],{"nctId":53370,"briefTitle":53371,"status":155,"phases":53372,"primaryCompletion":53373,"completion":53373,"start":2767,"enrollment":21948,"conditions":53374,"interventions":53375},"NCT01853878","A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor",[86],"2016-08-24",[267],[53361],{"trials":53377,"activeCount":97},[],{"trials":53379,"activeCount":97},[],{"trials":53381,"activeCount":97},[],{"intervention":53383,"totalTrials":417,"cells":53384},"fenofibrate",{"EARLY_PHASE1":53385,"PHASE1":53387,"PHASE2":53389,"PHASE3":53398,"PHASE4":53400,"NA":53402},{"trials":53386,"activeCount":97},[],{"trials":53388,"activeCount":97},[],{"trials":53390,"activeCount":97},[53391],{"nctId":53392,"briefTitle":53393,"status":155,"phases":53394,"primaryCompletion":7785,"completion":7785,"start":20690,"enrollment":17295,"conditions":53395,"interventions":53396},"NCT00169559","Dyslipidemia Study Investigating The Increase In \"Good Cholesterol\"",[86],[27251],[53397,53383],"GW590735",{"trials":53399,"activeCount":97},[],{"trials":53401,"activeCount":97},[],{"trials":53403,"activeCount":97},[],{"intervention":53405,"totalTrials":417,"cells":53406},"Drug: GSK2251052",{"EARLY_PHASE1":53407,"PHASE1":53409,"PHASE2":53411,"PHASE3":53422,"PHASE4":53424,"NA":53426},{"trials":53408,"activeCount":97},[],{"trials":53410,"activeCount":97},[],{"trials":53412,"activeCount":97},[53413],{"nctId":53414,"briefTitle":53415,"status":145,"phases":53416,"primaryCompletion":41603,"completion":41603,"start":53417,"enrollment":1117,"conditions":53418,"interventions":53420},"NCT01381562","GSK2251052 in the Treatment of Complicated Intra-abdominal Infections",[86],"2011-10-03",[53419],"Infections, Intestinal",[53405,53421],"Meropenem",{"trials":53423,"activeCount":97},[],{"trials":53425,"activeCount":97},[],{"trials":53427,"activeCount":97},[],{"intervention":53421,"totalTrials":417,"cells":53429},{"EARLY_PHASE1":53430,"PHASE1":53432,"PHASE2":53434,"PHASE3":53440,"PHASE4":53442,"NA":53444},{"trials":53431,"activeCount":97},[],{"trials":53433,"activeCount":97},[],{"trials":53435,"activeCount":97},[53436],{"nctId":53414,"briefTitle":53415,"status":145,"phases":53437,"primaryCompletion":41603,"completion":41603,"start":53417,"enrollment":1117,"conditions":53438,"interventions":53439},[86],[53419],[53405,53421],{"trials":53441,"activeCount":97},[],{"trials":53443,"activeCount":97},[],{"trials":53445,"activeCount":97},[],{"intervention":53447,"totalTrials":417,"cells":53448},"GSK3152314A",{"EARLY_PHASE1":53449,"PHASE1":53451,"PHASE2":53453,"PHASE3":53461,"PHASE4":53463,"NA":53465},{"trials":53450,"activeCount":97},[],{"trials":53452,"activeCount":97},[],{"trials":53454,"activeCount":97},[53455],{"nctId":53456,"briefTitle":53457,"status":155,"phases":53458,"primaryCompletion":2344,"completion":2344,"start":2355,"enrollment":829,"conditions":53459,"interventions":53460},"NCT00674635","Phase II Study Evaluating the Safety and Efficacy of GSK315234A in Patients With Rheumatoid Arthritis",[86],[8788],[53447],{"trials":53462,"activeCount":97},[],{"trials":53464,"activeCount":97},[],{"trials":53466,"activeCount":97},[],{"intervention":53468,"totalTrials":417,"cells":53469},"NaF\u002F KNO3\u002Fisopentane Dentifrice",{"EARLY_PHASE1":53470,"PHASE1":53472,"PHASE2":53474,"PHASE3":53485,"PHASE4":53487,"NA":53489},{"trials":53471,"activeCount":97},[],{"trials":53473,"activeCount":97},[],{"trials":53475,"activeCount":97},[53476],{"nctId":53477,"briefTitle":53478,"status":155,"phases":53479,"primaryCompletion":7954,"completion":7954,"start":2356,"enrollment":454,"conditions":53480,"interventions":53482},"NCT00752089","Experimental Dentifrice Remineralization\u002FFluoride Uptake in an in Situ Model",[86],[53481],"Dental Erosion",[53468,53483,53484],"NaF\u002FKNO3 Dentifrice","NaF Dentifrice",{"trials":53486,"activeCount":97},[],{"trials":53488,"activeCount":97},[],{"trials":53490,"activeCount":97},[],{"intervention":53483,"totalTrials":417,"cells":53492},{"EARLY_PHASE1":53493,"PHASE1":53495,"PHASE2":53497,"PHASE3":53503,"PHASE4":53505,"NA":53507},{"trials":53494,"activeCount":97},[],{"trials":53496,"activeCount":97},[],{"trials":53498,"activeCount":97},[53499],{"nctId":53477,"briefTitle":53478,"status":155,"phases":53500,"primaryCompletion":7954,"completion":7954,"start":2356,"enrollment":454,"conditions":53501,"interventions":53502},[86],[53481],[53468,53483,53484],{"trials":53504,"activeCount":97},[],{"trials":53506,"activeCount":97},[],{"trials":53508,"activeCount":97},[],{"intervention":53484,"totalTrials":417,"cells":53510},{"EARLY_PHASE1":53511,"PHASE1":53513,"PHASE2":53515,"PHASE3":53521,"PHASE4":53523,"NA":53525},{"trials":53512,"activeCount":97},[],{"trials":53514,"activeCount":97},[],{"trials":53516,"activeCount":97},[53517],{"nctId":53477,"briefTitle":53478,"status":155,"phases":53518,"primaryCompletion":7954,"completion":7954,"start":2356,"enrollment":454,"conditions":53519,"interventions":53520},[86],[53481],[53468,53483,53484],{"trials":53522,"activeCount":97},[],{"trials":53524,"activeCount":97},[],{"trials":53526,"activeCount":97},[],{"intervention":40559,"totalTrials":417,"cells":53528},{"EARLY_PHASE1":53529,"PHASE1":53531,"PHASE2":53533,"PHASE3":53539,"PHASE4":53541,"NA":53543},{"trials":53530,"activeCount":97},[],{"trials":53532,"activeCount":97},[],{"trials":53534,"activeCount":97},[53535],{"nctId":40553,"briefTitle":40554,"status":145,"phases":53536,"primaryCompletion":18919,"completion":18919,"start":40556,"enrollment":421,"conditions":53537,"interventions":53538},[86],[15],[20900,20901,40559],{"trials":53540,"activeCount":97},[],{"trials":53542,"activeCount":97},[],{"trials":53544,"activeCount":97},[],{"intervention":40111,"totalTrials":417,"cells":53546},{"EARLY_PHASE1":53547,"PHASE1":53549,"PHASE2":53551,"PHASE3":53557,"PHASE4":53559,"NA":53561},{"trials":53548,"activeCount":97},[],{"trials":53550,"activeCount":97},[],{"trials":53552,"activeCount":97},[53553],{"nctId":40105,"briefTitle":40106,"status":155,"phases":53554,"primaryCompletion":16101,"completion":16101,"start":40108,"enrollment":2095,"conditions":53555,"interventions":53556},[86],[15],[40069,40111],{"trials":53558,"activeCount":97},[],{"trials":53560,"activeCount":97},[],{"trials":53562,"activeCount":97},[],{"intervention":53564,"totalTrials":417,"cells":53565},"GSK2862277",{"EARLY_PHASE1":53566,"PHASE1":53568,"PHASE2":53570,"PHASE3":53580,"PHASE4":53582,"NA":53584},{"trials":53567,"activeCount":97},[],{"trials":53569,"activeCount":97},[],{"trials":53571,"activeCount":97},[53572],{"nctId":53573,"briefTitle":53574,"status":145,"phases":53575,"primaryCompletion":53576,"completion":53576,"start":6309,"enrollment":8786,"conditions":53577,"interventions":53579},"NCT02221037","Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery",[86],"2017-06-28",[53578],"Lung Injury, Acute and Respiratory Distress Syndrome, Adult",[53564],{"trials":53581,"activeCount":97},[],{"trials":53583,"activeCount":97},[],{"trials":53585,"activeCount":97},[],{"intervention":53587,"totalTrials":417,"cells":53588},"GW813893",{"EARLY_PHASE1":53589,"PHASE1":53591,"PHASE2":53593,"PHASE3":53601,"PHASE4":53603,"NA":53605},{"trials":53590,"activeCount":97},[],{"trials":53592,"activeCount":97},[],{"trials":53594,"activeCount":97},[53595],{"nctId":53596,"briefTitle":53597,"status":500,"phases":53598,"start":8406,"enrollment":97,"conditions":53599,"interventions":53600},"NCT00541320","Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)",[86],[36580],[53587],{"trials":53602,"activeCount":97},[],{"trials":53604,"activeCount":97},[],{"trials":53606,"activeCount":97},[],{"intervention":53608,"totalTrials":417,"cells":53609},"GW823093C A",{"EARLY_PHASE1":53610,"PHASE1":53612,"PHASE2":53614,"PHASE3":53625,"PHASE4":53627,"NA":53629},{"trials":53611,"activeCount":97},[],{"trials":53613,"activeCount":97},[],{"trials":53615,"activeCount":97},[53616],{"nctId":53617,"briefTitle":53618,"status":145,"phases":53619,"primaryCompletion":2373,"completion":53620,"start":8446,"enrollment":761,"conditions":53621,"interventions":53622},"NCT00370942","GW823093C For The Treatment Of Type 2 Diabetes Mellitus",[86],"2006-11-25",[27],[53608,53623,53624],"GW823093C B","GW823093C C",{"trials":53626,"activeCount":97},[],{"trials":53628,"activeCount":97},[],{"trials":53630,"activeCount":97},[],{"intervention":53623,"totalTrials":417,"cells":53632},{"EARLY_PHASE1":53633,"PHASE1":53635,"PHASE2":53637,"PHASE3":53643,"PHASE4":53645,"NA":53647},{"trials":53634,"activeCount":97},[],{"trials":53636,"activeCount":97},[],{"trials":53638,"activeCount":97},[53639],{"nctId":53617,"briefTitle":53618,"status":145,"phases":53640,"primaryCompletion":2373,"completion":53620,"start":8446,"enrollment":761,"conditions":53641,"interventions":53642},[86],[27],[53608,53623,53624],{"trials":53644,"activeCount":97},[],{"trials":53646,"activeCount":97},[],{"trials":53648,"activeCount":97},[],{"intervention":53624,"totalTrials":417,"cells":53650},{"EARLY_PHASE1":53651,"PHASE1":53653,"PHASE2":53655,"PHASE3":53661,"PHASE4":53663,"NA":53665},{"trials":53652,"activeCount":97},[],{"trials":53654,"activeCount":97},[],{"trials":53656,"activeCount":97},[53657],{"nctId":53617,"briefTitle":53618,"status":145,"phases":53658,"primaryCompletion":2373,"completion":53620,"start":8446,"enrollment":761,"conditions":53659,"interventions":53660},[86],[27],[53608,53623,53624],{"trials":53662,"activeCount":97},[],{"trials":53664,"activeCount":97},[],{"trials":53666,"activeCount":97},[],{"intervention":53668,"totalTrials":417,"cells":53669},"Ozanezumab",{"EARLY_PHASE1":53670,"PHASE1":53672,"PHASE2":53674,"PHASE3":53686,"PHASE4":53688,"NA":53690},{"trials":53671,"activeCount":97},[],{"trials":53673,"activeCount":97},[],{"trials":53675,"activeCount":97},[53676],{"nctId":53677,"briefTitle":53678,"status":155,"phases":53679,"primaryCompletion":53680,"completion":53680,"start":53681,"enrollment":53682,"conditions":53683,"interventions":53685},"NCT01753076","Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis",[86],"2015-01-22","2012-12-20",304,[53684],"Amyotrophic Lateral Sclerosis",[53668],{"trials":53687,"activeCount":97},[],{"trials":53689,"activeCount":97},[],{"trials":53691,"activeCount":97},[],{"intervention":20135,"totalTrials":417,"cells":53693},{"EARLY_PHASE1":53694,"PHASE1":53696,"PHASE2":53698,"PHASE3":53704,"PHASE4":53706,"NA":53708},{"trials":53695,"activeCount":97},[],{"trials":53697,"activeCount":97},[],{"trials":53699,"activeCount":97},[53700],{"nctId":20128,"briefTitle":20129,"status":155,"phases":53701,"primaryCompletion":9962,"completion":9962,"start":20131,"enrollment":20132,"conditions":53702,"interventions":53703},[86],[992],[20135,18312,8971],{"trials":53705,"activeCount":97},[],{"trials":53707,"activeCount":97},[],{"trials":53709,"activeCount":97},[],{"intervention":53711,"totalTrials":417,"cells":53712},"Part A",{"EARLY_PHASE1":53713,"PHASE1":53715,"PHASE2":53717,"PHASE3":53726,"PHASE4":53728,"NA":53730},{"trials":53714,"activeCount":97},[],{"trials":53716,"activeCount":97},[],{"trials":53718,"activeCount":97},[53719],{"nctId":53720,"briefTitle":53721,"status":155,"phases":53722,"primaryCompletion":2356,"completion":2356,"start":1380,"enrollment":48560,"conditions":53723,"interventions":53724},"NCT00291928","HuMax-CD20 in Active Rheumatoid Arthritis, Phase I\u002FII",[86],[8788],[53711,53725],"Part B",{"trials":53727,"activeCount":97},[],{"trials":53729,"activeCount":97},[],{"trials":53731,"activeCount":97},[],{"intervention":53725,"totalTrials":417,"cells":53733},{"EARLY_PHASE1":53734,"PHASE1":53736,"PHASE2":53738,"PHASE3":53744,"PHASE4":53746,"NA":53748},{"trials":53735,"activeCount":97},[],{"trials":53737,"activeCount":97},[],{"trials":53739,"activeCount":97},[53740],{"nctId":53720,"briefTitle":53721,"status":155,"phases":53741,"primaryCompletion":2356,"completion":2356,"start":1380,"enrollment":48560,"conditions":53742,"interventions":53743},[86],[8788],[53711,53725],{"trials":53745,"activeCount":97},[],{"trials":53747,"activeCount":97},[],{"trials":53749,"activeCount":97},[],{"intervention":1386,"totalTrials":417,"cells":53751},{"EARLY_PHASE1":53752,"PHASE1":53754,"PHASE2":53756,"PHASE3":53762,"PHASE4":53764,"NA":53766},{"trials":53753,"activeCount":97},[],{"trials":53755,"activeCount":97},[],{"trials":53757,"activeCount":97},[53758],{"nctId":1377,"briefTitle":1378,"status":155,"phases":53759,"start":1380,"enrollment":1381,"conditions":53760,"interventions":53761},[86],[1383,1384],[1386,1387,1366,283],{"trials":53763,"activeCount":97},[],{"trials":53765,"activeCount":97},[],{"trials":53767,"activeCount":97},[],{"intervention":26837,"totalTrials":417,"cells":53769},{"EARLY_PHASE1":53770,"PHASE1":53772,"PHASE2":53774,"PHASE3":53780,"PHASE4":53782,"NA":53784},{"trials":53771,"activeCount":97},[],{"trials":53773,"activeCount":97},[],{"trials":53775,"activeCount":97},[53776],{"nctId":26832,"briefTitle":26833,"status":155,"phases":53777,"primaryCompletion":7545,"completion":3111,"start":2795,"enrollment":4542,"conditions":53778,"interventions":53779},[86],[8863],[26837,26838],{"trials":53781,"activeCount":97},[],{"trials":53783,"activeCount":97},[],{"trials":53785,"activeCount":97},[],{"intervention":53787,"totalTrials":417,"cells":53788},"Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3",{"EARLY_PHASE1":53789,"PHASE1":53791,"PHASE2":53793,"PHASE3":53801,"PHASE4":53803,"NA":53805},{"trials":53790,"activeCount":97},[],{"trials":53792,"activeCount":97},[],{"trials":53794,"activeCount":97},[53795],{"nctId":53796,"briefTitle":53797,"status":155,"phases":53798,"primaryCompletion":2823,"completion":2823,"start":10287,"enrollment":12000,"conditions":53799,"interventions":53800},"NCT00263692","Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety",[86],[30,3624,33],[53787],{"trials":53802,"activeCount":97},[],{"trials":53804,"activeCount":97},[],{"trials":53806,"activeCount":97},[],{"intervention":53808,"totalTrials":417,"cells":53809},"LGD-4665",{"EARLY_PHASE1":53810,"PHASE1":53812,"PHASE2":53814,"PHASE3":53824,"PHASE4":53826,"NA":53828},{"trials":53811,"activeCount":97},[],{"trials":53813,"activeCount":97},[],{"trials":53815,"activeCount":97},[53816],{"nctId":53817,"briefTitle":53818,"status":155,"phases":53819,"primaryCompletion":17135,"completion":27022,"start":53820,"enrollment":314,"conditions":53821,"interventions":53823},"NCT00621894","Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation",[86],"2008-03-15",[53822],"Immune Thrombocytopenic Purpura",[53808],{"trials":53825,"activeCount":97},[],{"trials":53827,"activeCount":97},[],{"trials":53829,"activeCount":97},[],{"intervention":24109,"totalTrials":417,"cells":53831},{"EARLY_PHASE1":53832,"PHASE1":53834,"PHASE2":53836,"PHASE3":53842,"PHASE4":53844,"NA":53846},{"trials":53833,"activeCount":97},[],{"trials":53835,"activeCount":97},[],{"trials":53837,"activeCount":97},[53838],{"nctId":24102,"briefTitle":24103,"status":155,"phases":53839,"primaryCompletion":24105,"completion":24105,"start":2742,"enrollment":24106,"conditions":53840,"interventions":53841},[86],[8723,12417],[24093,24109],{"trials":53843,"activeCount":97},[],{"trials":53845,"activeCount":97},[],{"trials":53847,"activeCount":97},[],{"intervention":5200,"totalTrials":417,"cells":53849},{"EARLY_PHASE1":53850,"PHASE1":53852,"PHASE2":53854,"PHASE3":53860,"PHASE4":53862,"NA":53864},{"trials":53851,"activeCount":97},[],{"trials":53853,"activeCount":97},[],{"trials":53855,"activeCount":97},[53856],{"nctId":5192,"briefTitle":5193,"status":155,"phases":53857,"primaryCompletion":2794,"completion":5195,"start":5196,"enrollment":4542,"conditions":53858,"interventions":53859},[86],[5198],[5200,5201,1651,1241],{"trials":53861,"activeCount":97},[],{"trials":53863,"activeCount":97},[],{"trials":53865,"activeCount":97},[],{"intervention":5201,"totalTrials":417,"cells":53867},{"EARLY_PHASE1":53868,"PHASE1":53870,"PHASE2":53872,"PHASE3":53878,"PHASE4":53880,"NA":53882},{"trials":53869,"activeCount":97},[],{"trials":53871,"activeCount":97},[],{"trials":53873,"activeCount":97},[53874],{"nctId":5192,"briefTitle":5193,"status":155,"phases":53875,"primaryCompletion":2794,"completion":5195,"start":5196,"enrollment":4542,"conditions":53876,"interventions":53877},[86],[5198],[5200,5201,1651,1241],{"trials":53879,"activeCount":97},[],{"trials":53881,"activeCount":97},[],{"trials":53883,"activeCount":97},[],{"intervention":26937,"totalTrials":417,"cells":53885},{"EARLY_PHASE1":53886,"PHASE1":53888,"PHASE2":53890,"PHASE3":53896,"PHASE4":53898,"NA":53900},{"trials":53887,"activeCount":97},[],{"trials":53889,"activeCount":97},[],{"trials":53891,"activeCount":97},[53892],{"nctId":26929,"briefTitle":26930,"status":155,"phases":53893,"primaryCompletion":9754,"completion":26932,"start":26933,"enrollment":26934,"conditions":53894,"interventions":53895},[86],[21],[26937,26920],{"trials":53897,"activeCount":97},[],{"trials":53899,"activeCount":97},[],{"trials":53901,"activeCount":97},[],{"intervention":3466,"totalTrials":417,"cells":53903},{"EARLY_PHASE1":53904,"PHASE1":53906,"PHASE2":53908,"PHASE3":53914,"PHASE4":53916,"NA":53918},{"trials":53905,"activeCount":97},[],{"trials":53907,"activeCount":97},[],{"trials":53909,"activeCount":97},[53910],{"nctId":3458,"briefTitle":3459,"status":155,"phases":53911,"primaryCompletion":3461,"completion":3461,"start":3462,"enrollment":3463,"conditions":53912,"interventions":53913},[86],[18],[3466,3466,3466,3466,3466,3467,2914],{"trials":53915,"activeCount":97},[],{"trials":53917,"activeCount":97},[],{"trials":53919,"activeCount":97},[],{"intervention":42452,"totalTrials":417,"cells":53921},{"EARLY_PHASE1":53922,"PHASE1":53924,"PHASE2":53926,"PHASE3":53932,"PHASE4":53934,"NA":53936},{"trials":53923,"activeCount":97},[],{"trials":53925,"activeCount":97},[],{"trials":53927,"activeCount":97},[53928],{"nctId":42443,"briefTitle":42444,"status":155,"phases":53929,"primaryCompletion":4757,"completion":4757,"start":8427,"enrollment":42446,"conditions":53930,"interventions":53931},[86],[42448,28372,36580,42449],[42451,42422,42452],{"trials":53933,"activeCount":97},[],{"trials":53935,"activeCount":97},[],{"trials":53937,"activeCount":97},[],{"intervention":53939,"totalTrials":417,"cells":53940},"zanamivir aqueous solution",{"EARLY_PHASE1":53941,"PHASE1":53943,"PHASE2":53945,"PHASE3":53954,"PHASE4":53956,"NA":53958},{"trials":53942,"activeCount":97},[],{"trials":53944,"activeCount":97},[],{"trials":53946,"activeCount":97},[53947],{"nctId":53948,"briefTitle":53949,"status":155,"phases":53950,"primaryCompletion":8721,"completion":8721,"start":6351,"enrollment":53951,"conditions":53952,"interventions":53953},"NCT01014988","Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital",[86],202,[5353],[53939],{"trials":53955,"activeCount":97},[],{"trials":53957,"activeCount":97},[],{"trials":53959,"activeCount":97},[],{"intervention":3557,"totalTrials":417,"cells":53961},{"EARLY_PHASE1":53962,"PHASE1":53964,"PHASE2":53966,"PHASE3":53972,"PHASE4":53974,"NA":53976},{"trials":53963,"activeCount":97},[],{"trials":53965,"activeCount":97},[],{"trials":53967,"activeCount":97},[53968],{"nctId":3547,"briefTitle":3548,"status":155,"phases":53969,"primaryCompletion":3550,"completion":3551,"start":3552,"enrollment":2759,"conditions":53970,"interventions":53971},[86],[3554],[3556,1241,2328,3557,3558],{"trials":53973,"activeCount":97},[],{"trials":53975,"activeCount":97},[],{"trials":53977,"activeCount":97},[],{"intervention":3558,"totalTrials":417,"cells":53979},{"EARLY_PHASE1":53980,"PHASE1":53982,"PHASE2":53984,"PHASE3":53990,"PHASE4":53992,"NA":53994},{"trials":53981,"activeCount":97},[],{"trials":53983,"activeCount":97},[],{"trials":53985,"activeCount":97},[53986],{"nctId":3547,"briefTitle":3548,"status":155,"phases":53987,"primaryCompletion":3550,"completion":3551,"start":3552,"enrollment":2759,"conditions":53988,"interventions":53989},[86],[3554],[3556,1241,2328,3557,3558],{"trials":53991,"activeCount":97},[],{"trials":53993,"activeCount":97},[],{"trials":53995,"activeCount":97},[],{"intervention":53997,"totalTrials":417,"cells":53998},"ofatumumab 100 mg, 1000 mg \u002F vial",{"EARLY_PHASE1":53999,"PHASE1":54001,"PHASE2":54003,"PHASE3":54011,"PHASE4":54013,"NA":54015},{"trials":54000,"activeCount":97},[],{"trials":54002,"activeCount":97},[],{"trials":54004,"activeCount":97},[54005],{"nctId":54006,"briefTitle":54007,"status":155,"phases":54008,"primaryCompletion":15214,"completion":15214,"start":52777,"enrollment":750,"conditions":54009,"interventions":54010},"NCT01077622","A Phase I\u002FII, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia",[86],[5198],[53997],{"trials":54012,"activeCount":97},[],{"trials":54014,"activeCount":97},[],{"trials":54016,"activeCount":97},[],{"intervention":54018,"totalTrials":417,"cells":54019},"exemestane and pazopanib",{"EARLY_PHASE1":54020,"PHASE1":54022,"PHASE2":54024,"PHASE3":54033,"PHASE4":54035,"NA":54037},{"trials":54021,"activeCount":97},[],{"trials":54023,"activeCount":97},[],{"trials":54025,"activeCount":97},[54026],{"nctId":54027,"briefTitle":54028,"status":500,"phases":54029,"primaryCompletion":8089,"completion":8089,"start":2355,"enrollment":97,"conditions":54030,"interventions":54032},"NCT00615524","Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer",[86],[54031],"Hormone-receptor Positive Breast Cancer",[54018],{"trials":54034,"activeCount":97},[],{"trials":54036,"activeCount":97},[],{"trials":54038,"activeCount":97},[],{"intervention":54040,"totalTrials":417,"cells":54041},"GSK A\u002Fturkey H5N1 Influenza vaccine",{"EARLY_PHASE1":54042,"PHASE1":54044,"PHASE2":54046,"PHASE3":54055,"PHASE4":54057,"NA":54059},{"trials":54043,"activeCount":97},[],{"trials":54045,"activeCount":97},[],{"trials":54047,"activeCount":97},[54048],{"nctId":54049,"briefTitle":54050,"status":155,"phases":54051,"primaryCompletion":26307,"completion":8189,"start":30466,"enrollment":54052,"conditions":54053,"interventions":54054},"NCT00771615","Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years",[86],469,[21],[54040],{"trials":54056,"activeCount":97},[],{"trials":54058,"activeCount":97},[],{"trials":54060,"activeCount":97},[],{"intervention":43213,"totalTrials":417,"cells":54062},{"EARLY_PHASE1":54063,"PHASE1":54065,"PHASE2":54067,"PHASE3":54073,"PHASE4":54075,"NA":54077},{"trials":54064,"activeCount":97},[],{"trials":54066,"activeCount":97},[],{"trials":54068,"activeCount":97},[54069],{"nctId":43208,"briefTitle":43209,"status":155,"phases":54070,"primaryCompletion":9697,"completion":9697,"start":11315,"enrollment":414,"conditions":54071,"interventions":54072},[86],[12022],[43213,43191],{"trials":54074,"activeCount":97},[],{"trials":54076,"activeCount":97},[],{"trials":54078,"activeCount":97},[],{"intervention":54080,"totalTrials":417,"cells":54081},"GSK Biologicals' investigational vaccine GSK1562902A",{"EARLY_PHASE1":54082,"PHASE1":54084,"PHASE2":54086,"PHASE3":54095,"PHASE4":54097,"NA":54099},{"trials":54083,"activeCount":97},[],{"trials":54085,"activeCount":97},[],{"trials":54087,"activeCount":97},[54088],{"nctId":54089,"briefTitle":54090,"status":155,"phases":54091,"primaryCompletion":10340,"completion":54092,"start":17736,"enrollment":2107,"conditions":54093,"interventions":54094},"NCT01323946","Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children",[86],"2012-11-02",[21],[54080],{"trials":54096,"activeCount":97},[],{"trials":54098,"activeCount":97},[],{"trials":54100,"activeCount":97},[],{"intervention":54102,"totalTrials":417,"cells":54103},"F2G22B\u002FDL001Z",{"EARLY_PHASE1":54104,"PHASE1":54106,"PHASE2":54108,"PHASE3":54127,"PHASE4":54129,"NA":54131},{"trials":54105,"activeCount":97},[],{"trials":54107,"activeCount":97},[],{"trials":54109,"activeCount":97},[54110],{"nctId":54111,"briefTitle":54112,"status":155,"phases":54113,"primaryCompletion":11171,"completion":54114,"start":610,"enrollment":130,"conditions":54115,"interventions":54116},"NCT06431607","A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults",[86],"2025-06-04",[5353],[54102,54117,54118,54119,54120,54121,54122,54123,54124,54125,54126],"F2H23D\u002FDL001Z-NH","F2H23B\u002FDL001Z-NH","F2H23H\u002FDL001Z","FDQ23A-NH","GSK5800544A","Flu D-TIV","F2H23A\u002FDL001Z-NH","F2H23G\u002FDL001Z","Fluzone HD Quadrivalent","Fluzone HD",{"trials":54128,"activeCount":97},[],{"trials":54130,"activeCount":97},[],{"trials":54132,"activeCount":97},[],{"intervention":54117,"totalTrials":417,"cells":54134},{"EARLY_PHASE1":54135,"PHASE1":54137,"PHASE2":54139,"PHASE3":54145,"PHASE4":54147,"NA":54149},{"trials":54136,"activeCount":97},[],{"trials":54138,"activeCount":97},[],{"trials":54140,"activeCount":97},[54141],{"nctId":54111,"briefTitle":54112,"status":155,"phases":54142,"primaryCompletion":11171,"completion":54114,"start":610,"enrollment":130,"conditions":54143,"interventions":54144},[86],[5353],[54102,54117,54118,54119,54120,54121,54122,54123,54124,54125,54126],{"trials":54146,"activeCount":97},[],{"trials":54148,"activeCount":97},[],{"trials":54150,"activeCount":97},[],{"intervention":54118,"totalTrials":417,"cells":54152},{"EARLY_PHASE1":54153,"PHASE1":54155,"PHASE2":54157,"PHASE3":54163,"PHASE4":54165,"NA":54167},{"trials":54154,"activeCount":97},[],{"trials":54156,"activeCount":97},[],{"trials":54158,"activeCount":97},[54159],{"nctId":54111,"briefTitle":54112,"status":155,"phases":54160,"primaryCompletion":11171,"completion":54114,"start":610,"enrollment":130,"conditions":54161,"interventions":54162},[86],[5353],[54102,54117,54118,54119,54120,54121,54122,54123,54124,54125,54126],{"trials":54164,"activeCount":97},[],{"trials":54166,"activeCount":97},[],{"trials":54168,"activeCount":97},[],{"intervention":54119,"totalTrials":417,"cells":54170},{"EARLY_PHASE1":54171,"PHASE1":54173,"PHASE2":54175,"PHASE3":54181,"PHASE4":54183,"NA":54185},{"trials":54172,"activeCount":97},[],{"trials":54174,"activeCount":97},[],{"trials":54176,"activeCount":97},[54177],{"nctId":54111,"briefTitle":54112,"status":155,"phases":54178,"primaryCompletion":11171,"completion":54114,"start":610,"enrollment":130,"conditions":54179,"interventions":54180},[86],[5353],[54102,54117,54118,54119,54120,54121,54122,54123,54124,54125,54126],{"trials":54182,"activeCount":97},[],{"trials":54184,"activeCount":97},[],{"trials":54186,"activeCount":97},[],{"intervention":54120,"totalTrials":417,"cells":54188},{"EARLY_PHASE1":54189,"PHASE1":54191,"PHASE2":54193,"PHASE3":54199,"PHASE4":54201,"NA":54203},{"trials":54190,"activeCount":97},[],{"trials":54192,"activeCount":97},[],{"trials":54194,"activeCount":97},[54195],{"nctId":54111,"briefTitle":54112,"status":155,"phases":54196,"primaryCompletion":11171,"completion":54114,"start":610,"enrollment":130,"conditions":54197,"interventions":54198},[86],[5353],[54102,54117,54118,54119,54120,54121,54122,54123,54124,54125,54126],{"trials":54200,"activeCount":97},[],{"trials":54202,"activeCount":97},[],{"trials":54204,"activeCount":97},[],{"intervention":54121,"totalTrials":417,"cells":54206},{"EARLY_PHASE1":54207,"PHASE1":54209,"PHASE2":54211,"PHASE3":54217,"PHASE4":54219,"NA":54221},{"trials":54208,"activeCount":97},[],{"trials":54210,"activeCount":97},[],{"trials":54212,"activeCount":97},[54213],{"nctId":54111,"briefTitle":54112,"status":155,"phases":54214,"primaryCompletion":11171,"completion":54114,"start":610,"enrollment":130,"conditions":54215,"interventions":54216},[86],[5353],[54102,54117,54118,54119,54120,54121,54122,54123,54124,54125,54126],{"trials":54218,"activeCount":97},[],{"trials":54220,"activeCount":97},[],{"trials":54222,"activeCount":97},[],{"intervention":54122,"totalTrials":417,"cells":54224},{"EARLY_PHASE1":54225,"PHASE1":54227,"PHASE2":54229,"PHASE3":54235,"PHASE4":54237,"NA":54239},{"trials":54226,"activeCount":97},[],{"trials":54228,"activeCount":97},[],{"trials":54230,"activeCount":97},[54231],{"nctId":54111,"briefTitle":54112,"status":155,"phases":54232,"primaryCompletion":11171,"completion":54114,"start":610,"enrollment":130,"conditions":54233,"interventions":54234},[86],[5353],[54102,54117,54118,54119,54120,54121,54122,54123,54124,54125,54126],{"trials":54236,"activeCount":97},[],{"trials":54238,"activeCount":97},[],{"trials":54240,"activeCount":97},[],{"intervention":54123,"totalTrials":417,"cells":54242},{"EARLY_PHASE1":54243,"PHASE1":54245,"PHASE2":54247,"PHASE3":54253,"PHASE4":54255,"NA":54257},{"trials":54244,"activeCount":97},[],{"trials":54246,"activeCount":97},[],{"trials":54248,"activeCount":97},[54249],{"nctId":54111,"briefTitle":54112,"status":155,"phases":54250,"primaryCompletion":11171,"completion":54114,"start":610,"enrollment":130,"conditions":54251,"interventions":54252},[86],[5353],[54102,54117,54118,54119,54120,54121,54122,54123,54124,54125,54126],{"trials":54254,"activeCount":97},[],{"trials":54256,"activeCount":97},[],{"trials":54258,"activeCount":97},[],{"intervention":54124,"totalTrials":417,"cells":54260},{"EARLY_PHASE1":54261,"PHASE1":54263,"PHASE2":54265,"PHASE3":54271,"PHASE4":54273,"NA":54275},{"trials":54262,"activeCount":97},[],{"trials":54264,"activeCount":97},[],{"trials":54266,"activeCount":97},[54267],{"nctId":54111,"briefTitle":54112,"status":155,"phases":54268,"primaryCompletion":11171,"completion":54114,"start":610,"enrollment":130,"conditions":54269,"interventions":54270},[86],[5353],[54102,54117,54118,54119,54120,54121,54122,54123,54124,54125,54126],{"trials":54272,"activeCount":97},[],{"trials":54274,"activeCount":97},[],{"trials":54276,"activeCount":97},[],{"intervention":54125,"totalTrials":417,"cells":54278},{"EARLY_PHASE1":54279,"PHASE1":54281,"PHASE2":54283,"PHASE3":54289,"PHASE4":54291,"NA":54293},{"trials":54280,"activeCount":97},[],{"trials":54282,"activeCount":97},[],{"trials":54284,"activeCount":97},[54285],{"nctId":54111,"briefTitle":54112,"status":155,"phases":54286,"primaryCompletion":11171,"completion":54114,"start":610,"enrollment":130,"conditions":54287,"interventions":54288},[86],[5353],[54102,54117,54118,54119,54120,54121,54122,54123,54124,54125,54126],{"trials":54290,"activeCount":97},[],{"trials":54292,"activeCount":97},[],{"trials":54294,"activeCount":97},[],{"intervention":54126,"totalTrials":417,"cells":54296},{"EARLY_PHASE1":54297,"PHASE1":54299,"PHASE2":54301,"PHASE3":54307,"PHASE4":54309,"NA":54311},{"trials":54298,"activeCount":97},[],{"trials":54300,"activeCount":97},[],{"trials":54302,"activeCount":97},[54303],{"nctId":54111,"briefTitle":54112,"status":155,"phases":54304,"primaryCompletion":11171,"completion":54114,"start":610,"enrollment":130,"conditions":54305,"interventions":54306},[86],[5353],[54102,54117,54118,54119,54120,54121,54122,54123,54124,54125,54126],{"trials":54308,"activeCount":97},[],{"trials":54310,"activeCount":97},[],{"trials":54312,"activeCount":97},[],{"intervention":21446,"totalTrials":417,"cells":54314},{"EARLY_PHASE1":54315,"PHASE1":54317,"PHASE2":54319,"PHASE3":54325,"PHASE4":54327,"NA":54329},{"trials":54316,"activeCount":97},[],{"trials":54318,"activeCount":97},[],{"trials":54320,"activeCount":97},[54321],{"nctId":21438,"briefTitle":21439,"status":155,"phases":54322,"primaryCompletion":21441,"completion":21442,"start":21443,"enrollment":19270,"conditions":54323,"interventions":54324},[86],[4704,4703],[21446,4806,4805,19386,21447],{"trials":54326,"activeCount":97},[],{"trials":54328,"activeCount":97},[],{"trials":54330,"activeCount":97},[],{"intervention":21447,"totalTrials":417,"cells":54332},{"EARLY_PHASE1":54333,"PHASE1":54335,"PHASE2":54337,"PHASE3":54343,"PHASE4":54345,"NA":54347},{"trials":54334,"activeCount":97},[],{"trials":54336,"activeCount":97},[],{"trials":54338,"activeCount":97},[54339],{"nctId":21438,"briefTitle":21439,"status":155,"phases":54340,"primaryCompletion":21441,"completion":21442,"start":21443,"enrollment":19270,"conditions":54341,"interventions":54342},[86],[4704,4703],[21446,4806,4805,19386,21447],{"trials":54344,"activeCount":97},[],{"trials":54346,"activeCount":97},[],{"trials":54348,"activeCount":97},[],{"intervention":18597,"totalTrials":417,"cells":54350},{"EARLY_PHASE1":54351,"PHASE1":54353,"PHASE2":54355,"PHASE3":54361,"PHASE4":54363,"NA":54365},{"trials":54352,"activeCount":97},[],{"trials":54354,"activeCount":97},[],{"trials":54356,"activeCount":97},[54357],{"nctId":18590,"briefTitle":18591,"status":155,"phases":54358,"primaryCompletion":18593,"completion":18593,"start":18594,"enrollment":1117,"conditions":54359,"interventions":54360},[86],[17996],[18545,18044,18597,18597],{"trials":54362,"activeCount":97},[],{"trials":54364,"activeCount":97},[],{"trials":54366,"activeCount":97},[],{"intervention":54368,"totalTrials":417,"cells":54369},"Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed\u002FRefractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma",{"EARLY_PHASE1":54370,"PHASE1":54372,"PHASE2":54374,"PHASE3":54382,"PHASE4":54384,"NA":54386},{"trials":54371,"activeCount":97},[],{"trials":54373,"activeCount":97},[],{"trials":54375,"activeCount":97},[54376],{"nctId":54377,"briefTitle":54378,"status":155,"phases":54379,"primaryCompletion":2481,"completion":6352,"start":10084,"enrollment":868,"conditions":54380,"interventions":54381},"NCT01573000","A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed\u002FRefractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)",[86],[4574],[54368],{"trials":54383,"activeCount":97},[],{"trials":54385,"activeCount":97},[],{"trials":54387,"activeCount":97},[],{"intervention":40745,"totalTrials":417,"cells":54389},{"EARLY_PHASE1":54390,"PHASE1":54392,"PHASE2":54394,"PHASE3":54400,"PHASE4":54402,"NA":54404},{"trials":54391,"activeCount":97},[],{"trials":54393,"activeCount":97},[],{"trials":54395,"activeCount":97},[54396],{"nctId":40737,"briefTitle":40738,"status":155,"phases":54397,"primaryCompletion":40740,"completion":40740,"start":18983,"enrollment":719,"conditions":54398,"interventions":54399},[86],[12727],[40702,40743,40744,40745],{"trials":54401,"activeCount":97},[],{"trials":54403,"activeCount":97},[],{"trials":54405,"activeCount":97},[],{"intervention":54407,"totalTrials":417,"cells":54408},"GW842470X cream",{"EARLY_PHASE1":54409,"PHASE1":54411,"PHASE2":54413,"PHASE3":54422,"PHASE4":54424,"NA":54426},{"trials":54410,"activeCount":97},[],{"trials":54412,"activeCount":97},[],{"trials":54414,"activeCount":97},[54415],{"nctId":54416,"briefTitle":54417,"status":155,"phases":54418,"start":7613,"enrollment":11109,"conditions":54419,"interventions":54421},"NCT00354510","Topical GW842470X In Adults Patients With Moderate Atopic Dermatitis",[86],[54420,21691],"Atopic Dermatitis",[54407],{"trials":54423,"activeCount":97},[],{"trials":54425,"activeCount":97},[],{"trials":54427,"activeCount":97},[],{"intervention":54429,"totalTrials":417,"cells":54430},"CV0701 mRNA COVID-19 Vaccine",{"EARLY_PHASE1":54431,"PHASE1":54433,"PHASE2":54435,"PHASE3":54448,"PHASE4":54450,"NA":54452},{"trials":54432,"activeCount":97},[],{"trials":54434,"activeCount":97},[],{"trials":54436,"activeCount":97},[54437],{"nctId":54438,"briefTitle":54439,"status":155,"phases":54440,"primaryCompletion":54441,"completion":54441,"start":399,"enrollment":18329,"conditions":54442,"interventions":54444},"NCT05960097","A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults",[86],"2024-08-30",[54443,12437],"SARS-CoV-2",[54429,54429,54429,54445,54446,54447],"CV0601 mRNA COVID-19 Vaccine","Control vaccine","CV0801 mRNA COVID-19 Vaccine",{"trials":54449,"activeCount":97},[],{"trials":54451,"activeCount":97},[],{"trials":54453,"activeCount":97},[],{"intervention":54445,"totalTrials":417,"cells":54455},{"EARLY_PHASE1":54456,"PHASE1":54458,"PHASE2":54460,"PHASE3":54466,"PHASE4":54468,"NA":54470},{"trials":54457,"activeCount":97},[],{"trials":54459,"activeCount":97},[],{"trials":54461,"activeCount":97},[54462],{"nctId":54438,"briefTitle":54439,"status":155,"phases":54463,"primaryCompletion":54441,"completion":54441,"start":399,"enrollment":18329,"conditions":54464,"interventions":54465},[86],[54443,12437],[54429,54429,54429,54445,54446,54447],{"trials":54467,"activeCount":97},[],{"trials":54469,"activeCount":97},[],{"trials":54471,"activeCount":97},[],{"intervention":54446,"totalTrials":417,"cells":54473},{"EARLY_PHASE1":54474,"PHASE1":54476,"PHASE2":54478,"PHASE3":54484,"PHASE4":54486,"NA":54488},{"trials":54475,"activeCount":97},[],{"trials":54477,"activeCount":97},[],{"trials":54479,"activeCount":97},[54480],{"nctId":54438,"briefTitle":54439,"status":155,"phases":54481,"primaryCompletion":54441,"completion":54441,"start":399,"enrollment":18329,"conditions":54482,"interventions":54483},[86],[54443,12437],[54429,54429,54429,54445,54446,54447],{"trials":54485,"activeCount":97},[],{"trials":54487,"activeCount":97},[],{"trials":54489,"activeCount":97},[],{"intervention":54447,"totalTrials":417,"cells":54491},{"EARLY_PHASE1":54492,"PHASE1":54494,"PHASE2":54496,"PHASE3":54502,"PHASE4":54504,"NA":54506},{"trials":54493,"activeCount":97},[],{"trials":54495,"activeCount":97},[],{"trials":54497,"activeCount":97},[54498],{"nctId":54438,"briefTitle":54439,"status":155,"phases":54499,"primaryCompletion":54441,"completion":54441,"start":399,"enrollment":18329,"conditions":54500,"interventions":54501},[86],[54443,12437],[54429,54429,54429,54445,54446,54447],{"trials":54503,"activeCount":97},[],{"trials":54505,"activeCount":97},[],{"trials":54507,"activeCount":97},[],{"intervention":44595,"totalTrials":417,"cells":54509},{"EARLY_PHASE1":54510,"PHASE1":54512,"PHASE2":54514,"PHASE3":54520,"PHASE4":54522,"NA":54524},{"trials":54511,"activeCount":97},[],{"trials":54513,"activeCount":97},[],{"trials":54515,"activeCount":97},[54516],{"nctId":44589,"briefTitle":44590,"status":155,"phases":54517,"primaryCompletion":5195,"completion":5195,"start":8151,"enrollment":1534,"conditions":54518,"interventions":54519},[86],[44593],[44570,44595,44586,44596],{"trials":54521,"activeCount":97},[],{"trials":54523,"activeCount":97},[],{"trials":54525,"activeCount":97},[],{"intervention":54527,"totalTrials":417,"cells":54528},"SB480848 40mg EC",{"EARLY_PHASE1":54529,"PHASE1":54531,"PHASE2":54533,"PHASE3":54546,"PHASE4":54548,"NA":54550},{"trials":54530,"activeCount":97},[],{"trials":54532,"activeCount":97},[],{"trials":54534,"activeCount":97},[54535],{"nctId":54536,"briefTitle":54537,"status":155,"phases":54538,"primaryCompletion":54539,"completion":54539,"start":54540,"enrollment":177,"conditions":54541,"interventions":54542},"NCT00734032","A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients",[86],"2009-01-16","2008-08-26",[9309],[54527,54543,54544,54545],"SB480848 80mg EC","SB480848 160mg EC","SB480848 Placebo",{"trials":54547,"activeCount":97},[],{"trials":54549,"activeCount":97},[],{"trials":54551,"activeCount":97},[],{"intervention":54543,"totalTrials":417,"cells":54553},{"EARLY_PHASE1":54554,"PHASE1":54556,"PHASE2":54558,"PHASE3":54564,"PHASE4":54566,"NA":54568},{"trials":54555,"activeCount":97},[],{"trials":54557,"activeCount":97},[],{"trials":54559,"activeCount":97},[54560],{"nctId":54536,"briefTitle":54537,"status":155,"phases":54561,"primaryCompletion":54539,"completion":54539,"start":54540,"enrollment":177,"conditions":54562,"interventions":54563},[86],[9309],[54527,54543,54544,54545],{"trials":54565,"activeCount":97},[],{"trials":54567,"activeCount":97},[],{"trials":54569,"activeCount":97},[],{"intervention":54544,"totalTrials":417,"cells":54571},{"EARLY_PHASE1":54572,"PHASE1":54574,"PHASE2":54576,"PHASE3":54582,"PHASE4":54584,"NA":54586},{"trials":54573,"activeCount":97},[],{"trials":54575,"activeCount":97},[],{"trials":54577,"activeCount":97},[54578],{"nctId":54536,"briefTitle":54537,"status":155,"phases":54579,"primaryCompletion":54539,"completion":54539,"start":54540,"enrollment":177,"conditions":54580,"interventions":54581},[86],[9309],[54527,54543,54544,54545],{"trials":54583,"activeCount":97},[],{"trials":54585,"activeCount":97},[],{"trials":54587,"activeCount":97},[],{"intervention":54545,"totalTrials":417,"cells":54589},{"EARLY_PHASE1":54590,"PHASE1":54592,"PHASE2":54594,"PHASE3":54600,"PHASE4":54602,"NA":54604},{"trials":54591,"activeCount":97},[],{"trials":54593,"activeCount":97},[],{"trials":54595,"activeCount":97},[54596],{"nctId":54536,"briefTitle":54537,"status":155,"phases":54597,"primaryCompletion":54539,"completion":54539,"start":54540,"enrollment":177,"conditions":54598,"interventions":54599},[86],[9309],[54527,54543,54544,54545],{"trials":54601,"activeCount":97},[],{"trials":54603,"activeCount":97},[],{"trials":54605,"activeCount":97},[],{"intervention":54607,"totalTrials":417,"cells":54608},"pazopanib (GW786034) 400 mg",{"EARLY_PHASE1":54609,"PHASE1":54611,"PHASE2":54613,"PHASE3":54625,"PHASE4":54627,"NA":54629},{"trials":54610,"activeCount":97},[],{"trials":54612,"activeCount":97},[],{"trials":54614,"activeCount":97},[54615],{"nctId":54616,"briefTitle":54617,"status":155,"phases":54618,"primaryCompletion":7976,"completion":7711,"start":8963,"enrollment":54619,"conditions":54620,"interventions":54621},"NCT00347919","Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer",[86],189,[668],[54607,54622,54623,54624],"lapatinib (GW572016) 1500 mg","lapatinib (GW572016) 1000 mg","pazopanib (GW786034) 800 mg",{"trials":54626,"activeCount":97},[],{"trials":54628,"activeCount":97},[],{"trials":54630,"activeCount":97},[],{"intervention":54622,"totalTrials":417,"cells":54632},{"EARLY_PHASE1":54633,"PHASE1":54635,"PHASE2":54637,"PHASE3":54643,"PHASE4":54645,"NA":54647},{"trials":54634,"activeCount":97},[],{"trials":54636,"activeCount":97},[],{"trials":54638,"activeCount":97},[54639],{"nctId":54616,"briefTitle":54617,"status":155,"phases":54640,"primaryCompletion":7976,"completion":7711,"start":8963,"enrollment":54619,"conditions":54641,"interventions":54642},[86],[668],[54607,54622,54623,54624],{"trials":54644,"activeCount":97},[],{"trials":54646,"activeCount":97},[],{"trials":54648,"activeCount":97},[],{"intervention":54623,"totalTrials":417,"cells":54650},{"EARLY_PHASE1":54651,"PHASE1":54653,"PHASE2":54655,"PHASE3":54661,"PHASE4":54663,"NA":54665},{"trials":54652,"activeCount":97},[],{"trials":54654,"activeCount":97},[],{"trials":54656,"activeCount":97},[54657],{"nctId":54616,"briefTitle":54617,"status":155,"phases":54658,"primaryCompletion":7976,"completion":7711,"start":8963,"enrollment":54619,"conditions":54659,"interventions":54660},[86],[668],[54607,54622,54623,54624],{"trials":54662,"activeCount":97},[],{"trials":54664,"activeCount":97},[],{"trials":54666,"activeCount":97},[],{"intervention":54624,"totalTrials":417,"cells":54668},{"EARLY_PHASE1":54669,"PHASE1":54671,"PHASE2":54673,"PHASE3":54679,"PHASE4":54681,"NA":54683},{"trials":54670,"activeCount":97},[],{"trials":54672,"activeCount":97},[],{"trials":54674,"activeCount":97},[54675],{"nctId":54616,"briefTitle":54617,"status":155,"phases":54676,"primaryCompletion":7976,"completion":7711,"start":8963,"enrollment":54619,"conditions":54677,"interventions":54678},[86],[668],[54607,54622,54623,54624],{"trials":54680,"activeCount":97},[],{"trials":54682,"activeCount":97},[],{"trials":54684,"activeCount":97},[],{"intervention":40061,"totalTrials":417,"cells":54686},{"EARLY_PHASE1":54687,"PHASE1":54689,"PHASE2":54691,"PHASE3":54697,"PHASE4":54699,"NA":54701},{"trials":54688,"activeCount":97},[],{"trials":54690,"activeCount":97},[],{"trials":54692,"activeCount":97},[54693],{"nctId":40056,"briefTitle":40057,"status":155,"phases":54694,"primaryCompletion":23213,"completion":23213,"start":12041,"enrollment":6369,"conditions":54695,"interventions":54696},[86],[9840],[40010,40061],{"trials":54698,"activeCount":97},[],{"trials":54700,"activeCount":97},[],{"trials":54702,"activeCount":97},[],{"intervention":54704,"totalTrials":417,"cells":54705},"HIV vaccine 732461",{"EARLY_PHASE1":54706,"PHASE1":54708,"PHASE2":54710,"PHASE3":54719,"PHASE4":54721,"NA":54723},{"trials":54707,"activeCount":97},[],{"trials":54709,"activeCount":97},[],{"trials":54711,"activeCount":97},[54712],{"nctId":54713,"briefTitle":54714,"status":155,"phases":54715,"primaryCompletion":8785,"completion":8785,"start":54716,"enrollment":9445,"conditions":54717,"interventions":54718},"NCT00434512","Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers",[86],"2007-02-20",[3428,10943],[54704],{"trials":54720,"activeCount":97},[],{"trials":54722,"activeCount":97},[],{"trials":54724,"activeCount":97},[],{"intervention":10089,"totalTrials":417,"cells":54726},{"EARLY_PHASE1":54727,"PHASE1":54729,"PHASE2":54731,"PHASE3":54737,"PHASE4":54739,"NA":54741},{"trials":54728,"activeCount":97},[],{"trials":54730,"activeCount":97},[],{"trials":54732,"activeCount":97},[54733],{"nctId":10080,"briefTitle":10081,"status":155,"phases":54734,"primaryCompletion":10083,"completion":10083,"start":10084,"enrollment":5088,"conditions":54735,"interventions":54736},[86],[24,30,10086,4702,10087,33],[10065,10089,10090],{"trials":54738,"activeCount":97},[],{"trials":54740,"activeCount":97},[],{"trials":54742,"activeCount":97},[],{"intervention":10090,"totalTrials":417,"cells":54744},{"EARLY_PHASE1":54745,"PHASE1":54747,"PHASE2":54749,"PHASE3":54755,"PHASE4":54757,"NA":54759},{"trials":54746,"activeCount":97},[],{"trials":54748,"activeCount":97},[],{"trials":54750,"activeCount":97},[54751],{"nctId":10080,"briefTitle":10081,"status":155,"phases":54752,"primaryCompletion":10083,"completion":10083,"start":10084,"enrollment":5088,"conditions":54753,"interventions":54754},[86],[24,30,10086,4702,10087,33],[10065,10089,10090],{"trials":54756,"activeCount":97},[],{"trials":54758,"activeCount":97},[],{"trials":54760,"activeCount":97},[],{"intervention":7790,"totalTrials":417,"cells":54762},{"EARLY_PHASE1":54763,"PHASE1":54765,"PHASE2":54767,"PHASE3":54773,"PHASE4":54775,"NA":54777},{"trials":54764,"activeCount":97},[],{"trials":54766,"activeCount":97},[],{"trials":54768,"activeCount":97},[54769],{"nctId":7782,"briefTitle":7783,"status":155,"phases":54770,"primaryCompletion":2835,"completion":2835,"start":7785,"enrollment":7786,"conditions":54771,"interventions":54772},[86],[3287],[7789,7718,7790,7791,7792,7793],{"trials":54774,"activeCount":97},[],{"trials":54776,"activeCount":97},[],{"trials":54778,"activeCount":97},[],{"intervention":7792,"totalTrials":417,"cells":54780},{"EARLY_PHASE1":54781,"PHASE1":54783,"PHASE2":54785,"PHASE3":54791,"PHASE4":54793,"NA":54795},{"trials":54782,"activeCount":97},[],{"trials":54784,"activeCount":97},[],{"trials":54786,"activeCount":97},[54787],{"nctId":7782,"briefTitle":7783,"status":155,"phases":54788,"primaryCompletion":2835,"completion":2835,"start":7785,"enrollment":7786,"conditions":54789,"interventions":54790},[86],[3287],[7789,7718,7790,7791,7792,7793],{"trials":54792,"activeCount":97},[],{"trials":54794,"activeCount":97},[],{"trials":54796,"activeCount":97},[],{"intervention":7793,"totalTrials":417,"cells":54798},{"EARLY_PHASE1":54799,"PHASE1":54801,"PHASE2":54803,"PHASE3":54809,"PHASE4":54811,"NA":54813},{"trials":54800,"activeCount":97},[],{"trials":54802,"activeCount":97},[],{"trials":54804,"activeCount":97},[54805],{"nctId":7782,"briefTitle":7783,"status":155,"phases":54806,"primaryCompletion":2835,"completion":2835,"start":7785,"enrollment":7786,"conditions":54807,"interventions":54808},[86],[3287],[7789,7718,7790,7791,7792,7793],{"trials":54810,"activeCount":97},[],{"trials":54812,"activeCount":97},[],{"trials":54814,"activeCount":97},[],{"intervention":18420,"totalTrials":417,"cells":54816},{"EARLY_PHASE1":54817,"PHASE1":54819,"PHASE2":54821,"PHASE3":54827,"PHASE4":54829,"NA":54831},{"trials":54818,"activeCount":97},[],{"trials":54820,"activeCount":97},[],{"trials":54822,"activeCount":97},[54823],{"nctId":18415,"briefTitle":18416,"status":500,"phases":54824,"primaryCompletion":3110,"completion":503,"start":3110,"enrollment":97,"conditions":54825,"interventions":54826},[86],[18],[18345,18420],{"trials":54828,"activeCount":97},[],{"trials":54830,"activeCount":97},[],{"trials":54832,"activeCount":97},[],{"intervention":54834,"totalTrials":417,"cells":54835},"Pentamer (low)\u002FgB(low)\u002FAdjuvant vaccine",{"EARLY_PHASE1":54836,"PHASE1":54838,"PHASE2":54840,"PHASE3":54854,"PHASE4":54856,"NA":54858},{"trials":54837,"activeCount":97},[],{"trials":54839,"activeCount":97},[],{"trials":54841,"activeCount":97},[54842],{"nctId":54843,"briefTitle":54844,"status":155,"phases":54845,"primaryCompletion":54846,"completion":54846,"start":54847,"enrollment":940,"conditions":54848,"interventions":54850},"NCT05089630","A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults",[85,86],"2025-04-02","2021-10-14",[54849],"Cytomegalovirus Infections",[54834,54851,54852,54853],"Pentamer (med)\u002FgB(low)\u002FAdjuvant vaccine","Pentamer (med)\u002FgB(med)\u002FAdjuvant vaccine","Pentamer (high)\u002FgB(med)\u002FAdjuvant vaccine",{"trials":54855,"activeCount":97},[],{"trials":54857,"activeCount":97},[],{"trials":54859,"activeCount":97},[],{"intervention":54851,"totalTrials":417,"cells":54861},{"EARLY_PHASE1":54862,"PHASE1":54864,"PHASE2":54866,"PHASE3":54872,"PHASE4":54874,"NA":54876},{"trials":54863,"activeCount":97},[],{"trials":54865,"activeCount":97},[],{"trials":54867,"activeCount":97},[54868],{"nctId":54843,"briefTitle":54844,"status":155,"phases":54869,"primaryCompletion":54846,"completion":54846,"start":54847,"enrollment":940,"conditions":54870,"interventions":54871},[85,86],[54849],[54834,54851,54852,54853],{"trials":54873,"activeCount":97},[],{"trials":54875,"activeCount":97},[],{"trials":54877,"activeCount":97},[],{"intervention":54852,"totalTrials":417,"cells":54879},{"EARLY_PHASE1":54880,"PHASE1":54882,"PHASE2":54884,"PHASE3":54890,"PHASE4":54892,"NA":54894},{"trials":54881,"activeCount":97},[],{"trials":54883,"activeCount":97},[],{"trials":54885,"activeCount":97},[54886],{"nctId":54843,"briefTitle":54844,"status":155,"phases":54887,"primaryCompletion":54846,"completion":54846,"start":54847,"enrollment":940,"conditions":54888,"interventions":54889},[85,86],[54849],[54834,54851,54852,54853],{"trials":54891,"activeCount":97},[],{"trials":54893,"activeCount":97},[],{"trials":54895,"activeCount":97},[],{"intervention":54853,"totalTrials":417,"cells":54897},{"EARLY_PHASE1":54898,"PHASE1":54900,"PHASE2":54902,"PHASE3":54908,"PHASE4":54910,"NA":54912},{"trials":54899,"activeCount":97},[],{"trials":54901,"activeCount":97},[],{"trials":54903,"activeCount":97},[54904],{"nctId":54843,"briefTitle":54844,"status":155,"phases":54905,"primaryCompletion":54846,"completion":54846,"start":54847,"enrollment":940,"conditions":54906,"interventions":54907},[85,86],[54849],[54834,54851,54852,54853],{"trials":54909,"activeCount":97},[],{"trials":54911,"activeCount":97},[],{"trials":54913,"activeCount":97},[],{"intervention":18776,"totalTrials":417,"cells":54915},{"EARLY_PHASE1":54916,"PHASE1":54918,"PHASE2":54920,"PHASE3":54926,"PHASE4":54928,"NA":54930},{"trials":54917,"activeCount":97},[],{"trials":54919,"activeCount":97},[],{"trials":54921,"activeCount":97},[54922],{"nctId":18768,"briefTitle":18769,"status":155,"phases":54923,"primaryCompletion":18771,"completion":18772,"start":7505,"enrollment":18773,"conditions":54924,"interventions":54925},[86],[3637],[11470,11470,18776,18776,3639],{"trials":54927,"activeCount":97},[],{"trials":54929,"activeCount":97},[],{"trials":54931,"activeCount":97},[],{"intervention":41727,"totalTrials":417,"cells":54933},{"EARLY_PHASE1":54934,"PHASE1":54936,"PHASE2":54938,"PHASE3":54944,"PHASE4":54946,"NA":54948},{"trials":54935,"activeCount":97},[],{"trials":54937,"activeCount":97},[],{"trials":54939,"activeCount":97},[54940],{"nctId":41721,"briefTitle":41722,"status":155,"phases":54941,"primaryCompletion":3426,"completion":3426,"start":41724,"enrollment":28,"conditions":54942,"interventions":54943},[86],[23246],[41697,41727,41728,41718],{"trials":54945,"activeCount":97},[],{"trials":54947,"activeCount":97},[],{"trials":54949,"activeCount":97},[],{"intervention":41728,"totalTrials":417,"cells":54951},{"EARLY_PHASE1":54952,"PHASE1":54954,"PHASE2":54956,"PHASE3":54962,"PHASE4":54964,"NA":54966},{"trials":54953,"activeCount":97},[],{"trials":54955,"activeCount":97},[],{"trials":54957,"activeCount":97},[54958],{"nctId":41721,"briefTitle":41722,"status":155,"phases":54959,"primaryCompletion":3426,"completion":3426,"start":41724,"enrollment":28,"conditions":54960,"interventions":54961},[86],[23246],[41697,41727,41728,41718],{"trials":54963,"activeCount":97},[],{"trials":54965,"activeCount":97},[],{"trials":54967,"activeCount":97},[],{"intervention":54969,"totalTrials":417,"cells":54970},"Lapatinib, Vinorelbine",{"EARLY_PHASE1":54971,"PHASE1":54973,"PHASE2":54975,"PHASE3":54983,"PHASE4":54985,"NA":54987},{"trials":54972,"activeCount":97},[],{"trials":54974,"activeCount":97},[],{"trials":54976,"activeCount":97},[54977],{"nctId":54978,"briefTitle":54979,"status":145,"phases":54980,"primaryCompletion":11315,"completion":11315,"start":7546,"enrollment":8038,"conditions":54981,"interventions":54982},"NCT00709618","Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects",[86],[668],[54969],{"trials":54984,"activeCount":97},[],{"trials":54986,"activeCount":97},[],{"trials":54988,"activeCount":97},[],{"intervention":54990,"totalTrials":417,"cells":54991},"SB705498 400 mg",{"EARLY_PHASE1":54992,"PHASE1":54994,"PHASE2":54996,"PHASE3":55008,"PHASE4":55010,"NA":55012},{"trials":54993,"activeCount":97},[],{"trials":54995,"activeCount":97},[],{"trials":54997,"activeCount":97},[54998],{"nctId":54999,"briefTitle":55000,"status":155,"phases":55001,"primaryCompletion":10178,"completion":10178,"start":55002,"enrollment":7840,"conditions":55003,"interventions":55005},"NCT00281684","SB-705498 Dental Pain Study After Tooth Extraction",[86],"2005-12-07",[55004],"Toothache",[54990,55006,55007],"SB705498 1000 mg","Co-Codamol",{"trials":55009,"activeCount":97},[],{"trials":55011,"activeCount":97},[],{"trials":55013,"activeCount":97},[],{"intervention":55006,"totalTrials":417,"cells":55015},{"EARLY_PHASE1":55016,"PHASE1":55018,"PHASE2":55020,"PHASE3":55026,"PHASE4":55028,"NA":55030},{"trials":55017,"activeCount":97},[],{"trials":55019,"activeCount":97},[],{"trials":55021,"activeCount":97},[55022],{"nctId":54999,"briefTitle":55000,"status":155,"phases":55023,"primaryCompletion":10178,"completion":10178,"start":55002,"enrollment":7840,"conditions":55024,"interventions":55025},[86],[55004],[54990,55006,55007],{"trials":55027,"activeCount":97},[],{"trials":55029,"activeCount":97},[],{"trials":55031,"activeCount":97},[],{"intervention":55007,"totalTrials":417,"cells":55033},{"EARLY_PHASE1":55034,"PHASE1":55036,"PHASE2":55038,"PHASE3":55044,"PHASE4":55046,"NA":55048},{"trials":55035,"activeCount":97},[],{"trials":55037,"activeCount":97},[],{"trials":55039,"activeCount":97},[55040],{"nctId":54999,"briefTitle":55000,"status":155,"phases":55041,"primaryCompletion":10178,"completion":10178,"start":55002,"enrollment":7840,"conditions":55042,"interventions":55043},[86],[55004],[54990,55006,55007],{"trials":55045,"activeCount":97},[],{"trials":55047,"activeCount":97},[],{"trials":55049,"activeCount":97},[],{"intervention":55051,"totalTrials":417,"cells":55052},"GSK3117391",{"EARLY_PHASE1":55053,"PHASE1":55055,"PHASE2":55057,"PHASE3":55067,"PHASE4":55069,"NA":55071},{"trials":55054,"activeCount":97},[],{"trials":55056,"activeCount":97},[],{"trials":55058,"activeCount":97},[55059],{"nctId":55060,"briefTitle":55061,"status":145,"phases":55062,"primaryCompletion":55063,"completion":55063,"start":55064,"enrollment":593,"conditions":55065,"interventions":55066},"NCT02965599","Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis",[86],"2017-11-14","2016-12-27",[8788],[55051],{"trials":55068,"activeCount":97},[],{"trials":55070,"activeCount":97},[],{"trials":55072,"activeCount":97},[],{"intervention":1928,"totalTrials":417,"cells":55074},{"EARLY_PHASE1":55075,"PHASE1":55077,"PHASE2":55079,"PHASE3":55085,"PHASE4":55087,"NA":55089},{"trials":55076,"activeCount":97},[],{"trials":55078,"activeCount":97},[],{"trials":55080,"activeCount":97},[55081],{"nctId":1918,"briefTitle":1919,"status":155,"phases":55082,"primaryCompletion":1921,"completion":1922,"start":1923,"enrollment":1924,"conditions":55083,"interventions":55084},[86],[1926],[1928,1929,1930,1931,1932,1933,1909,1934],{"trials":55086,"activeCount":97},[],{"trials":55088,"activeCount":97},[],{"trials":55090,"activeCount":97},[],{"intervention":1929,"totalTrials":417,"cells":55092},{"EARLY_PHASE1":55093,"PHASE1":55095,"PHASE2":55097,"PHASE3":55103,"PHASE4":55105,"NA":55107},{"trials":55094,"activeCount":97},[],{"trials":55096,"activeCount":97},[],{"trials":55098,"activeCount":97},[55099],{"nctId":1918,"briefTitle":1919,"status":155,"phases":55100,"primaryCompletion":1921,"completion":1922,"start":1923,"enrollment":1924,"conditions":55101,"interventions":55102},[86],[1926],[1928,1929,1930,1931,1932,1933,1909,1934],{"trials":55104,"activeCount":97},[],{"trials":55106,"activeCount":97},[],{"trials":55108,"activeCount":97},[],{"intervention":1930,"totalTrials":417,"cells":55110},{"EARLY_PHASE1":55111,"PHASE1":55113,"PHASE2":55115,"PHASE3":55121,"PHASE4":55123,"NA":55125},{"trials":55112,"activeCount":97},[],{"trials":55114,"activeCount":97},[],{"trials":55116,"activeCount":97},[55117],{"nctId":1918,"briefTitle":1919,"status":155,"phases":55118,"primaryCompletion":1921,"completion":1922,"start":1923,"enrollment":1924,"conditions":55119,"interventions":55120},[86],[1926],[1928,1929,1930,1931,1932,1933,1909,1934],{"trials":55122,"activeCount":97},[],{"trials":55124,"activeCount":97},[],{"trials":55126,"activeCount":97},[],{"intervention":1931,"totalTrials":417,"cells":55128},{"EARLY_PHASE1":55129,"PHASE1":55131,"PHASE2":55133,"PHASE3":55139,"PHASE4":55141,"NA":55143},{"trials":55130,"activeCount":97},[],{"trials":55132,"activeCount":97},[],{"trials":55134,"activeCount":97},[55135],{"nctId":1918,"briefTitle":1919,"status":155,"phases":55136,"primaryCompletion":1921,"completion":1922,"start":1923,"enrollment":1924,"conditions":55137,"interventions":55138},[86],[1926],[1928,1929,1930,1931,1932,1933,1909,1934],{"trials":55140,"activeCount":97},[],{"trials":55142,"activeCount":97},[],{"trials":55144,"activeCount":97},[],{"intervention":1932,"totalTrials":417,"cells":55146},{"EARLY_PHASE1":55147,"PHASE1":55149,"PHASE2":55151,"PHASE3":55157,"PHASE4":55159,"NA":55161},{"trials":55148,"activeCount":97},[],{"trials":55150,"activeCount":97},[],{"trials":55152,"activeCount":97},[55153],{"nctId":1918,"briefTitle":1919,"status":155,"phases":55154,"primaryCompletion":1921,"completion":1922,"start":1923,"enrollment":1924,"conditions":55155,"interventions":55156},[86],[1926],[1928,1929,1930,1931,1932,1933,1909,1934],{"trials":55158,"activeCount":97},[],{"trials":55160,"activeCount":97},[],{"trials":55162,"activeCount":97},[],{"intervention":1934,"totalTrials":417,"cells":55164},{"EARLY_PHASE1":55165,"PHASE1":55167,"PHASE2":55169,"PHASE3":55175,"PHASE4":55177,"NA":55179},{"trials":55166,"activeCount":97},[],{"trials":55168,"activeCount":97},[],{"trials":55170,"activeCount":97},[55171],{"nctId":1918,"briefTitle":1919,"status":155,"phases":55172,"primaryCompletion":1921,"completion":1922,"start":1923,"enrollment":1924,"conditions":55173,"interventions":55174},[86],[1926],[1928,1929,1930,1931,1932,1933,1909,1934],{"trials":55176,"activeCount":97},[],{"trials":55178,"activeCount":97},[],{"trials":55180,"activeCount":97},[],{"intervention":55182,"totalTrials":417,"cells":55183},"GSK Biologicals HIV Vaccine 732462",{"EARLY_PHASE1":55184,"PHASE1":55186,"PHASE2":55188,"PHASE3":55197,"PHASE4":55199,"NA":55201},{"trials":55185,"activeCount":97},[],{"trials":55187,"activeCount":97},[],{"trials":55189,"activeCount":97},[55190],{"nctId":55191,"briefTitle":55192,"status":155,"phases":55193,"primaryCompletion":55194,"completion":55194,"start":18003,"enrollment":41647,"conditions":55195,"interventions":55196},"NCT01218113","Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons",[86],"2012-11-05",[3428],[55182],{"trials":55198,"activeCount":97},[],{"trials":55200,"activeCount":97},[],{"trials":55202,"activeCount":97},[],{"intervention":55204,"totalTrials":417,"cells":55205},"bupropion hydrochloride",{"EARLY_PHASE1":55206,"PHASE1":55208,"PHASE2":55210,"PHASE3":55220,"PHASE4":55222,"NA":55224},{"trials":55207,"activeCount":97},[],{"trials":55209,"activeCount":97},[],{"trials":55211,"activeCount":97},[55212],{"nctId":55213,"briefTitle":55214,"status":155,"phases":55215,"primaryCompletion":55216,"completion":55216,"start":35950,"enrollment":55217,"conditions":55218,"interventions":55219},"NCT00135512","Study Of 323U66 SR In Major Depressive Disorder",[86],"2007-05-28",234,[9292],[55204],{"trials":55221,"activeCount":97},[],{"trials":55223,"activeCount":97},[],{"trials":55225,"activeCount":97},[],{"intervention":8239,"totalTrials":417,"cells":55227},{"EARLY_PHASE1":55228,"PHASE1":55230,"PHASE2":55232,"PHASE3":55238,"PHASE4":55240,"NA":55242},{"trials":55229,"activeCount":97},[],{"trials":55231,"activeCount":97},[],{"trials":55233,"activeCount":97},[55234],{"nctId":8232,"briefTitle":8233,"status":155,"phases":55235,"primaryCompletion":8235,"completion":7946,"start":8217,"enrollment":8236,"conditions":55236,"interventions":55237},[86],[21],[8177,8239],{"trials":55239,"activeCount":97},[],{"trials":55241,"activeCount":97},[],{"trials":55243,"activeCount":97},[],{"intervention":45126,"totalTrials":417,"cells":55245},{"EARLY_PHASE1":55246,"PHASE1":55248,"PHASE2":55250,"PHASE3":55256,"PHASE4":55258,"NA":55260},{"trials":55247,"activeCount":97},[],{"trials":55249,"activeCount":97},[],{"trials":55251,"activeCount":97},[55252],{"nctId":45121,"briefTitle":45122,"status":155,"phases":55253,"primaryCompletion":18536,"completion":11851,"start":22592,"enrollment":463,"conditions":55254,"interventions":55255},[86],[21691],[45126,45104,45127],{"trials":55257,"activeCount":97},[],{"trials":55259,"activeCount":97},[],{"trials":55261,"activeCount":97},[],{"intervention":45127,"totalTrials":417,"cells":55263},{"EARLY_PHASE1":55264,"PHASE1":55266,"PHASE2":55268,"PHASE3":55274,"PHASE4":55276,"NA":55278},{"trials":55265,"activeCount":97},[],{"trials":55267,"activeCount":97},[],{"trials":55269,"activeCount":97},[55270],{"nctId":45121,"briefTitle":45122,"status":155,"phases":55271,"primaryCompletion":18536,"completion":11851,"start":22592,"enrollment":463,"conditions":55272,"interventions":55273},[86],[21691],[45126,45104,45127],{"trials":55275,"activeCount":97},[],{"trials":55277,"activeCount":97},[],{"trials":55279,"activeCount":97},[],{"intervention":55281,"totalTrials":417,"cells":55282},"RSV vaccine GSK3003891A",{"EARLY_PHASE1":55283,"PHASE1":55285,"PHASE2":55287,"PHASE3":55296,"PHASE4":55298,"NA":55300},{"trials":55284,"activeCount":97},[],{"trials":55286,"activeCount":97},[],{"trials":55288,"activeCount":97},[55289],{"nctId":55290,"briefTitle":55291,"status":155,"phases":55292,"primaryCompletion":55293,"completion":55293,"start":8561,"enrollment":931,"conditions":55294,"interventions":55295},"NCT02753413","Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women",[86],"2016-06-28",[2620],[55281,5329],{"trials":55297,"activeCount":97},[],{"trials":55299,"activeCount":97},[],{"trials":55301,"activeCount":97},[],{"intervention":55303,"totalTrials":417,"cells":55304},"Tiotropium + SERETIDE 50\u002F500",{"EARLY_PHASE1":55305,"PHASE1":55307,"PHASE2":55309,"PHASE3":55317,"PHASE4":55319,"NA":55321},{"trials":55306,"activeCount":97},[],{"trials":55308,"activeCount":97},[],{"trials":55310,"activeCount":97},[55311],{"nctId":55312,"briefTitle":55313,"status":155,"phases":55314,"primaryCompletion":2296,"completion":2296,"start":749,"enrollment":212,"conditions":55315,"interventions":55316},"NCT00325169","SERETIDE Plus Tiotropium Versus Individual Components",[86],[15],[55303],{"trials":55318,"activeCount":97},[],{"trials":55320,"activeCount":97},[],{"trials":55322,"activeCount":97},[],{"intervention":55324,"totalTrials":417,"cells":55325},"Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141",{"EARLY_PHASE1":55326,"PHASE1":55328,"PHASE2":55330,"PHASE3":55341,"PHASE4":55343,"NA":55345},{"trials":55327,"activeCount":97},[],{"trials":55329,"activeCount":97},[],{"trials":55331,"activeCount":97},[55332],{"nctId":55333,"briefTitle":55334,"status":155,"phases":55335,"primaryCompletion":55336,"completion":55336,"start":55337,"enrollment":11031,"conditions":55338,"interventions":55339},"NCT00698490","Humoral and Cellular Immune Response of Herpes Simplex (gD) Candidate Vaccines From 2 Different Cell Lines",[85,86],"1997-01","1995-08",[52737],[55324,55340],"Herpes simplex virus containing gD-Alum",{"trials":55342,"activeCount":97},[],{"trials":55344,"activeCount":97},[],{"trials":55346,"activeCount":97},[],{"intervention":55340,"totalTrials":417,"cells":55348},{"EARLY_PHASE1":55349,"PHASE1":55351,"PHASE2":55353,"PHASE3":55359,"PHASE4":55361,"NA":55363},{"trials":55350,"activeCount":97},[],{"trials":55352,"activeCount":97},[],{"trials":55354,"activeCount":97},[55355],{"nctId":55333,"briefTitle":55334,"status":155,"phases":55356,"primaryCompletion":55336,"completion":55336,"start":55337,"enrollment":11031,"conditions":55357,"interventions":55358},[85,86],[52737],[55324,55340],{"trials":55360,"activeCount":97},[],{"trials":55362,"activeCount":97},[],{"trials":55364,"activeCount":97},[],{"intervention":7637,"totalTrials":417,"cells":55366},{"EARLY_PHASE1":55367,"PHASE1":55369,"PHASE2":55371,"PHASE3":55377,"PHASE4":55379,"NA":55381},{"trials":55368,"activeCount":97},[],{"trials":55370,"activeCount":97},[],{"trials":55372,"activeCount":97},[55373],{"nctId":7631,"briefTitle":7632,"status":155,"phases":55374,"primaryCompletion":2442,"completion":7634,"start":4843,"enrollment":613,"conditions":55375,"interventions":55376},[86],[305],[2387,7637,7638],{"trials":55378,"activeCount":97},[],{"trials":55380,"activeCount":97},[],{"trials":55382,"activeCount":97},[],{"intervention":7638,"totalTrials":417,"cells":55384},{"EARLY_PHASE1":55385,"PHASE1":55387,"PHASE2":55389,"PHASE3":55395,"PHASE4":55397,"NA":55399},{"trials":55386,"activeCount":97},[],{"trials":55388,"activeCount":97},[],{"trials":55390,"activeCount":97},[55391],{"nctId":7631,"briefTitle":7632,"status":155,"phases":55392,"primaryCompletion":2442,"completion":7634,"start":4843,"enrollment":613,"conditions":55393,"interventions":55394},[86],[305],[2387,7637,7638],{"trials":55396,"activeCount":97},[],{"trials":55398,"activeCount":97},[],{"trials":55400,"activeCount":97},[],{"intervention":8248,"totalTrials":417,"cells":55402},{"EARLY_PHASE1":55403,"PHASE1":55405,"PHASE2":55407,"PHASE3":55413,"PHASE4":55415,"NA":55417},{"trials":55404,"activeCount":97},[],{"trials":55406,"activeCount":97},[],{"trials":55408,"activeCount":97},[55409],{"nctId":8241,"briefTitle":8242,"status":155,"phases":55410,"primaryCompletion":2373,"completion":8244,"start":8245,"enrollment":536,"conditions":55411,"interventions":55412},[86],[21],[8177,8248],{"trials":55414,"activeCount":97},[],{"trials":55416,"activeCount":97},[],{"trials":55418,"activeCount":97},[],{"intervention":55420,"totalTrials":417,"cells":55421},"SB-742457 15mg",{"EARLY_PHASE1":55422,"PHASE1":55424,"PHASE2":55426,"PHASE3":55438,"PHASE4":55440,"NA":55442},{"trials":55423,"activeCount":97},[],{"trials":55425,"activeCount":97},[],{"trials":55427,"activeCount":97},[55428],{"nctId":55429,"briefTitle":55430,"status":155,"phases":55431,"primaryCompletion":8225,"completion":55432,"start":55433,"enrollment":10191,"conditions":55434,"interventions":55435},"NCT00710684","A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's Disease",[86],"2010-11-16","2008-07-01",[4644],[55420,55436,55437],"SB-742457 35mg","donepezil 5-10mg",{"trials":55439,"activeCount":97},[],{"trials":55441,"activeCount":97},[],{"trials":55443,"activeCount":97},[],{"intervention":55436,"totalTrials":417,"cells":55445},{"EARLY_PHASE1":55446,"PHASE1":55448,"PHASE2":55450,"PHASE3":55456,"PHASE4":55458,"NA":55460},{"trials":55447,"activeCount":97},[],{"trials":55449,"activeCount":97},[],{"trials":55451,"activeCount":97},[55452],{"nctId":55429,"briefTitle":55430,"status":155,"phases":55453,"primaryCompletion":8225,"completion":55432,"start":55433,"enrollment":10191,"conditions":55454,"interventions":55455},[86],[4644],[55420,55436,55437],{"trials":55457,"activeCount":97},[],{"trials":55459,"activeCount":97},[],{"trials":55461,"activeCount":97},[],{"intervention":55437,"totalTrials":417,"cells":55463},{"EARLY_PHASE1":55464,"PHASE1":55466,"PHASE2":55468,"PHASE3":55474,"PHASE4":55476,"NA":55478},{"trials":55465,"activeCount":97},[],{"trials":55467,"activeCount":97},[],{"trials":55469,"activeCount":97},[55470],{"nctId":55429,"briefTitle":55430,"status":155,"phases":55471,"primaryCompletion":8225,"completion":55432,"start":55433,"enrollment":10191,"conditions":55472,"interventions":55473},[86],[4644],[55420,55436,55437],{"trials":55475,"activeCount":97},[],{"trials":55477,"activeCount":97},[],{"trials":55479,"activeCount":97},[],{"intervention":55481,"totalTrials":417,"cells":55482},"Batefenterol",{"EARLY_PHASE1":55483,"PHASE1":55485,"PHASE2":55487,"PHASE3":55498,"PHASE4":55500,"NA":55502},{"trials":55484,"activeCount":97},[],{"trials":55486,"activeCount":97},[],{"trials":55488,"activeCount":97},[55489],{"nctId":55490,"briefTitle":55491,"status":155,"phases":55492,"primaryCompletion":55493,"completion":55493,"start":55494,"enrollment":1314,"conditions":55495,"interventions":55496},"NCT02570165","Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[86],"2016-07-06","2015-11-06",[15],[55481,55497],"Umeclidinium\u002F Vilanterol",{"trials":55499,"activeCount":97},[],{"trials":55501,"activeCount":97},[],{"trials":55503,"activeCount":97},[],{"intervention":55497,"totalTrials":417,"cells":55505},{"EARLY_PHASE1":55506,"PHASE1":55508,"PHASE2":55510,"PHASE3":55516,"PHASE4":55518,"NA":55520},{"trials":55507,"activeCount":97},[],{"trials":55509,"activeCount":97},[],{"trials":55511,"activeCount":97},[55512],{"nctId":55490,"briefTitle":55491,"status":155,"phases":55513,"primaryCompletion":55493,"completion":55493,"start":55494,"enrollment":1314,"conditions":55514,"interventions":55515},[86],[15],[55481,55497],{"trials":55517,"activeCount":97},[],{"trials":55519,"activeCount":97},[],{"trials":55521,"activeCount":97},[],{"intervention":42241,"totalTrials":417,"cells":55523},{"EARLY_PHASE1":55524,"PHASE1":55526,"PHASE2":55528,"PHASE3":55534,"PHASE4":55536,"NA":55538},{"trials":55525,"activeCount":97},[],{"trials":55527,"activeCount":97},[],{"trials":55529,"activeCount":97},[55530],{"nctId":42234,"briefTitle":42235,"status":155,"phases":55531,"primaryCompletion":5077,"completion":42237,"start":42238,"enrollment":224,"conditions":55532,"interventions":55533},[86],[3287],[42217,42241],{"trials":55535,"activeCount":97},[],{"trials":55537,"activeCount":97},[],{"trials":55539,"activeCount":97},[],{"intervention":55541,"totalTrials":417,"cells":55542},"GW597599B",{"EARLY_PHASE1":55543,"PHASE1":55545,"PHASE2":55547,"PHASE3":55557,"PHASE4":55559,"NA":55561},{"trials":55544,"activeCount":97},[],{"trials":55546,"activeCount":97},[],{"trials":55548,"activeCount":97},[55549],{"nctId":55550,"briefTitle":55551,"status":155,"phases":55552,"primaryCompletion":29615,"completion":29615,"start":55553,"enrollment":55554,"conditions":55555,"interventions":55556},"NCT00048204","A Study Of A New Medicine (GW597599B) For The Treatment Of Major Depressive Disorder",[86],"2002-11-04",372,[10889],[55541,39238],{"trials":55558,"activeCount":97},[],{"trials":55560,"activeCount":97},[],{"trials":55562,"activeCount":97},[],{"intervention":55564,"totalTrials":417,"cells":55565},"Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab",{"EARLY_PHASE1":55566,"PHASE1":55568,"PHASE2":55570,"PHASE3":55580,"PHASE4":55582,"NA":55584},{"trials":55567,"activeCount":97},[],{"trials":55569,"activeCount":97},[],{"trials":55571,"activeCount":97},[55572],{"nctId":55573,"briefTitle":55574,"status":155,"phases":55575,"primaryCompletion":55576,"completion":7522,"start":55577,"enrollment":149,"conditions":55578,"interventions":55579},"NCT01224821","Dosimetry\u002FValidation Study of 131Iodine-Anti B1 (Murine) Radioimmunotherapy for Chemotherapy Refractory Low Grade B Cell Lymphomas and Low Grade Lymphomas That Have Transformed to Higher Grade Histologies",[86],"1997-11","1995-12",[4574],[55564],{"trials":55581,"activeCount":97},[],{"trials":55583,"activeCount":97},[],{"trials":55585,"activeCount":97},[],{"intervention":41543,"totalTrials":417,"cells":55587},{"EARLY_PHASE1":55588,"PHASE1":55590,"PHASE2":55592,"PHASE3":55598,"PHASE4":55600,"NA":55602},{"trials":55589,"activeCount":97},[],{"trials":55591,"activeCount":97},[],{"trials":55593,"activeCount":97},[55594],{"nctId":41536,"briefTitle":41537,"status":155,"phases":55595,"primaryCompletion":41539,"completion":41539,"start":41540,"enrollment":7573,"conditions":55596,"interventions":55597},[86],[19716],[41543,41514],{"trials":55599,"activeCount":97},[],{"trials":55601,"activeCount":97},[],{"trials":55603,"activeCount":97},[],{"intervention":55605,"totalTrials":417,"cells":55606},"MenACWY liquid vaccine with approximately 30% MenA FS",{"EARLY_PHASE1":55607,"PHASE1":55609,"PHASE2":55611,"PHASE3":55623,"PHASE4":55625,"NA":55627},{"trials":55608,"activeCount":97},[],{"trials":55610,"activeCount":97},[],{"trials":55612,"activeCount":97},[55613],{"nctId":55614,"briefTitle":55615,"status":155,"phases":55616,"primaryCompletion":55617,"completion":55618,"start":55619,"enrollment":21101,"conditions":55620,"interventions":55621},"NCT03652610","A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age",[86],"2019-01-17","2019-06-11","2018-09-07",[992],[55605,55622],"Licensed GSK MenACWY vaccine",{"trials":55624,"activeCount":97},[],{"trials":55626,"activeCount":97},[],{"trials":55628,"activeCount":97},[],{"intervention":55622,"totalTrials":417,"cells":55630},{"EARLY_PHASE1":55631,"PHASE1":55633,"PHASE2":55635,"PHASE3":55641,"PHASE4":55643,"NA":55645},{"trials":55632,"activeCount":97},[],{"trials":55634,"activeCount":97},[],{"trials":55636,"activeCount":97},[55637],{"nctId":55614,"briefTitle":55615,"status":155,"phases":55638,"primaryCompletion":55617,"completion":55618,"start":55619,"enrollment":21101,"conditions":55639,"interventions":55640},[86],[992],[55605,55622],{"trials":55642,"activeCount":97},[],{"trials":55644,"activeCount":97},[],{"trials":55646,"activeCount":97},[],{"intervention":40461,"totalTrials":417,"cells":55648},{"EARLY_PHASE1":55649,"PHASE1":55651,"PHASE2":55653,"PHASE3":55659,"PHASE4":55661,"NA":55663},{"trials":55650,"activeCount":97},[],{"trials":55652,"activeCount":97},[],{"trials":55654,"activeCount":97},[55655],{"nctId":40454,"briefTitle":40455,"status":155,"phases":55656,"primaryCompletion":40457,"completion":40457,"start":114,"enrollment":40458,"conditions":55657,"interventions":55658},[86],[4191],[40420,40461,40462],{"trials":55660,"activeCount":97},[],{"trials":55662,"activeCount":97},[],{"trials":55664,"activeCount":97},[],{"intervention":40462,"totalTrials":417,"cells":55666},{"EARLY_PHASE1":55667,"PHASE1":55669,"PHASE2":55671,"PHASE3":55677,"PHASE4":55679,"NA":55681},{"trials":55668,"activeCount":97},[],{"trials":55670,"activeCount":97},[],{"trials":55672,"activeCount":97},[55673],{"nctId":40454,"briefTitle":40455,"status":155,"phases":55674,"primaryCompletion":40457,"completion":40457,"start":114,"enrollment":40458,"conditions":55675,"interventions":55676},[86],[4191],[40420,40461,40462],{"trials":55678,"activeCount":97},[],{"trials":55680,"activeCount":97},[],{"trials":55682,"activeCount":97},[],{"intervention":55684,"totalTrials":417,"cells":55685},"Lapatinib in combination with weekly paclitaxel",{"EARLY_PHASE1":55686,"PHASE1":55688,"PHASE2":55690,"PHASE3":55698,"PHASE4":55700,"NA":55702},{"trials":55687,"activeCount":97},[],{"trials":55689,"activeCount":97},[],{"trials":55691,"activeCount":97},[55692],{"nctId":55693,"briefTitle":55694,"status":155,"phases":55695,"primaryCompletion":7634,"completion":7634,"start":6352,"enrollment":1459,"conditions":55696,"interventions":55697},"NCT01138046","Phase I\u002FII Study of Lapatinib in Combination With Paclitaxel as 1L Chemotherapy for ErbB2-positive MBC",[86],[668],[55684],{"trials":55699,"activeCount":97},[],{"trials":55701,"activeCount":97},[],{"trials":55703,"activeCount":97},[],{"intervention":55705,"totalTrials":417,"cells":55706},"HPV 16\u002F18 VLP AS04",{"EARLY_PHASE1":55707,"PHASE1":55709,"PHASE2":55711,"PHASE3":55719,"PHASE4":55721,"NA":55723},{"trials":55708,"activeCount":97},[],{"trials":55710,"activeCount":97},[],{"trials":55712,"activeCount":97},[55713],{"nctId":55714,"briefTitle":55715,"status":155,"phases":55716,"primaryCompletion":2428,"completion":2428,"start":20690,"enrollment":5364,"conditions":55717,"interventions":55718},"NCT00120848","Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults",[86],[8723],[55705],{"trials":55720,"activeCount":97},[],{"trials":55722,"activeCount":97},[],{"trials":55724,"activeCount":97},[],{"intervention":55726,"totalTrials":417,"cells":55727},"Dentifrice containing 5% w\u002Fw KNO3 and 0.454% w\u002Fw SnF2 (1100 ppm fluoride).",{"EARLY_PHASE1":55728,"PHASE1":55730,"PHASE2":55732,"PHASE3":55744,"PHASE4":55746,"NA":55748},{"trials":55729,"activeCount":97},[],{"trials":55731,"activeCount":97},[],{"trials":55733,"activeCount":97},[55734],{"nctId":55735,"briefTitle":55736,"status":500,"phases":55737,"primaryCompletion":55738,"completion":55738,"start":55739,"enrollment":97,"conditions":55740,"interventions":55742},"NCT03361774","A Clinical Method Development Study to Characterise The Efficacy of a Dentifrice For The Relief Of Dentin Hypersensitivity",[86],"2018-12-03","2018-10-01",[55741],"Dentin Sensitivity",[55726,55743],"Dentifrice containing 0.454% w\u002Fw SnF2 (1100 ppm fluoride).",{"trials":55745,"activeCount":97},[],{"trials":55747,"activeCount":97},[],{"trials":55749,"activeCount":97},[],{"intervention":55743,"totalTrials":417,"cells":55751},{"EARLY_PHASE1":55752,"PHASE1":55754,"PHASE2":55756,"PHASE3":55762,"PHASE4":55764,"NA":55766},{"trials":55753,"activeCount":97},[],{"trials":55755,"activeCount":97},[],{"trials":55757,"activeCount":97},[55758],{"nctId":55735,"briefTitle":55736,"status":500,"phases":55759,"primaryCompletion":55738,"completion":55738,"start":55739,"enrollment":97,"conditions":55760,"interventions":55761},[86],[55741],[55726,55743],{"trials":55763,"activeCount":97},[],{"trials":55765,"activeCount":97},[],{"trials":55767,"activeCount":97},[],{"intervention":44832,"totalTrials":417,"cells":55769},{"EARLY_PHASE1":55770,"PHASE1":55772,"PHASE2":55774,"PHASE3":55780,"PHASE4":55782,"NA":55784},{"trials":55771,"activeCount":97},[],{"trials":55773,"activeCount":97},[],{"trials":55775,"activeCount":97},[55776],{"nctId":44826,"briefTitle":44827,"status":155,"phases":55777,"primaryCompletion":10097,"completion":44829,"start":23043,"enrollment":13062,"conditions":55778,"interventions":55779},[86],[4704,4703],[23047,44832,44833,44834,44835],{"trials":55781,"activeCount":97},[],{"trials":55783,"activeCount":97},[],{"trials":55785,"activeCount":97},[],{"intervention":44833,"totalTrials":417,"cells":55787},{"EARLY_PHASE1":55788,"PHASE1":55790,"PHASE2":55792,"PHASE3":55798,"PHASE4":55800,"NA":55802},{"trials":55789,"activeCount":97},[],{"trials":55791,"activeCount":97},[],{"trials":55793,"activeCount":97},[55794],{"nctId":44826,"briefTitle":44827,"status":155,"phases":55795,"primaryCompletion":10097,"completion":44829,"start":23043,"enrollment":13062,"conditions":55796,"interventions":55797},[86],[4704,4703],[23047,44832,44833,44834,44835],{"trials":55799,"activeCount":97},[],{"trials":55801,"activeCount":97},[],{"trials":55803,"activeCount":97},[],{"intervention":44834,"totalTrials":417,"cells":55805},{"EARLY_PHASE1":55806,"PHASE1":55808,"PHASE2":55810,"PHASE3":55816,"PHASE4":55818,"NA":55820},{"trials":55807,"activeCount":97},[],{"trials":55809,"activeCount":97},[],{"trials":55811,"activeCount":97},[55812],{"nctId":44826,"briefTitle":44827,"status":155,"phases":55813,"primaryCompletion":10097,"completion":44829,"start":23043,"enrollment":13062,"conditions":55814,"interventions":55815},[86],[4704,4703],[23047,44832,44833,44834,44835],{"trials":55817,"activeCount":97},[],{"trials":55819,"activeCount":97},[],{"trials":55821,"activeCount":97},[],{"intervention":44835,"totalTrials":417,"cells":55823},{"EARLY_PHASE1":55824,"PHASE1":55826,"PHASE2":55828,"PHASE3":55834,"PHASE4":55836,"NA":55838},{"trials":55825,"activeCount":97},[],{"trials":55827,"activeCount":97},[],{"trials":55829,"activeCount":97},[55830],{"nctId":44826,"briefTitle":44827,"status":155,"phases":55831,"primaryCompletion":10097,"completion":44829,"start":23043,"enrollment":13062,"conditions":55832,"interventions":55833},[86],[4704,4703],[23047,44832,44833,44834,44835],{"trials":55835,"activeCount":97},[],{"trials":55837,"activeCount":97},[],{"trials":55839,"activeCount":97},[],{"intervention":55841,"totalTrials":417,"cells":55842},"Tositumomab and Iodine I 131 Tositumomab followed by CHOP",{"EARLY_PHASE1":55843,"PHASE1":55845,"PHASE2":55847,"PHASE3":55858,"PHASE4":55860,"NA":55862},{"trials":55844,"activeCount":97},[],{"trials":55846,"activeCount":97},[],{"trials":55848,"activeCount":97},[55849],{"nctId":55850,"briefTitle":55851,"status":155,"phases":55852,"primaryCompletion":55853,"completion":55853,"start":55854,"enrollment":463,"conditions":55855,"interventions":55857},"NCT00992992","Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma",[86],"2013-06-30","2001-06-28",[55856],"Lymphoma, Mantle-Cell",[55841],{"trials":55859,"activeCount":97},[],{"trials":55861,"activeCount":97},[],{"trials":55863,"activeCount":97},[],{"intervention":55865,"totalTrials":417,"cells":55866},"GSK malaria vaccine 257049 Vaccine",{"EARLY_PHASE1":55867,"PHASE1":55869,"PHASE2":55871,"PHASE3":55883,"PHASE4":55885,"NA":55887},{"trials":55868,"activeCount":97},[],{"trials":55870,"activeCount":97},[],{"trials":55872,"activeCount":97},[55873],{"nctId":55874,"briefTitle":55875,"status":155,"phases":55876,"primaryCompletion":55877,"completion":55878,"start":19788,"enrollment":55879,"conditions":55880,"interventions":55881},"NCT00380393","Efficacy of RTS,S\u002FAS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.",[86],"2008-08-15","2008-11-11",894,[3287],[55865,55882],"Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine",{"trials":55884,"activeCount":97},[],{"trials":55886,"activeCount":97},[],{"trials":55888,"activeCount":97},[],{"intervention":55882,"totalTrials":417,"cells":55890},{"EARLY_PHASE1":55891,"PHASE1":55893,"PHASE2":55895,"PHASE3":55901,"PHASE4":55903,"NA":55905},{"trials":55892,"activeCount":97},[],{"trials":55894,"activeCount":97},[],{"trials":55896,"activeCount":97},[55897],{"nctId":55874,"briefTitle":55875,"status":155,"phases":55898,"primaryCompletion":55877,"completion":55878,"start":19788,"enrollment":55879,"conditions":55899,"interventions":55900},[86],[3287],[55865,55882],{"trials":55902,"activeCount":97},[],{"trials":55904,"activeCount":97},[],{"trials":55906,"activeCount":97},[],{"intervention":55908,"totalTrials":417,"cells":55909},"GSK163090 1 mg",{"EARLY_PHASE1":55910,"PHASE1":55912,"PHASE2":55914,"PHASE3":55925,"PHASE4":55927,"NA":55929},{"trials":55911,"activeCount":97},[],{"trials":55913,"activeCount":97},[],{"trials":55915,"activeCount":97},[55916],{"nctId":55917,"briefTitle":55918,"status":155,"phases":55919,"primaryCompletion":43755,"completion":43755,"start":55920,"enrollment":7769,"conditions":55921,"interventions":55922},"NCT00896363","Safety and Efficacy Study in Patients With Major Depressive Disorder",[86],"2009-04-23",[9292],[55908,55923,55924],"GSK163090 Placebo","GSK163090 3 mg",{"trials":55926,"activeCount":97},[],{"trials":55928,"activeCount":97},[],{"trials":55930,"activeCount":97},[],{"intervention":55923,"totalTrials":417,"cells":55932},{"EARLY_PHASE1":55933,"PHASE1":55935,"PHASE2":55937,"PHASE3":55943,"PHASE4":55945,"NA":55947},{"trials":55934,"activeCount":97},[],{"trials":55936,"activeCount":97},[],{"trials":55938,"activeCount":97},[55939],{"nctId":55917,"briefTitle":55918,"status":155,"phases":55940,"primaryCompletion":43755,"completion":43755,"start":55920,"enrollment":7769,"conditions":55941,"interventions":55942},[86],[9292],[55908,55923,55924],{"trials":55944,"activeCount":97},[],{"trials":55946,"activeCount":97},[],{"trials":55948,"activeCount":97},[],{"intervention":55924,"totalTrials":417,"cells":55950},{"EARLY_PHASE1":55951,"PHASE1":55953,"PHASE2":55955,"PHASE3":55961,"PHASE4":55963,"NA":55965},{"trials":55952,"activeCount":97},[],{"trials":55954,"activeCount":97},[],{"trials":55956,"activeCount":97},[55957],{"nctId":55917,"briefTitle":55918,"status":155,"phases":55958,"primaryCompletion":43755,"completion":43755,"start":55920,"enrollment":7769,"conditions":55959,"interventions":55960},[86],[9292],[55908,55923,55924],{"trials":55962,"activeCount":97},[],{"trials":55964,"activeCount":97},[],{"trials":55966,"activeCount":97},[],{"intervention":55968,"totalTrials":417,"cells":55969},"Flu Pandemic mRNA_Dose level 1",{"EARLY_PHASE1":55970,"PHASE1":55972,"PHASE2":55974,"PHASE3":55991,"PHASE4":55993,"NA":55995},{"trials":55971,"activeCount":97},[],{"trials":55973,"activeCount":97},[],{"trials":55975,"activeCount":97},[55976],{"nctId":55977,"briefTitle":55978,"status":155,"phases":55979,"primaryCompletion":55980,"completion":55980,"start":55981,"enrollment":55982,"conditions":55983,"interventions":55984},"NCT06382311","A Study to Find and Confirm the Dose and Assess Safety, Reactogenicity and Immune Response of a Vaccine Against Pandemic H5N1 Influenza Virus in Healthy Younger and Older Adults",[85,86],"2026-01-13","2024-04-18",991,[5353],[55968,55985,55986,55987,55988,55989,55990],"Flu Pandemic mRNA_Dose level 2","Flu Pandemic mRNA_ Dose level 3.","Flu Pandemic mRNA_ Dose level 4","Flu Pandemic mRNA_Dose level 5","Flu Pandemic mRNA_Dose level 6","Influenza virus vaccine",{"trials":55992,"activeCount":97},[],{"trials":55994,"activeCount":97},[],{"trials":55996,"activeCount":97},[],{"intervention":55985,"totalTrials":417,"cells":55998},{"EARLY_PHASE1":55999,"PHASE1":56001,"PHASE2":56003,"PHASE3":56009,"PHASE4":56011,"NA":56013},{"trials":56000,"activeCount":97},[],{"trials":56002,"activeCount":97},[],{"trials":56004,"activeCount":97},[56005],{"nctId":55977,"briefTitle":55978,"status":155,"phases":56006,"primaryCompletion":55980,"completion":55980,"start":55981,"enrollment":55982,"conditions":56007,"interventions":56008},[85,86],[5353],[55968,55985,55986,55987,55988,55989,55990],{"trials":56010,"activeCount":97},[],{"trials":56012,"activeCount":97},[],{"trials":56014,"activeCount":97},[],{"intervention":55986,"totalTrials":417,"cells":56016},{"EARLY_PHASE1":56017,"PHASE1":56019,"PHASE2":56021,"PHASE3":56027,"PHASE4":56029,"NA":56031},{"trials":56018,"activeCount":97},[],{"trials":56020,"activeCount":97},[],{"trials":56022,"activeCount":97},[56023],{"nctId":55977,"briefTitle":55978,"status":155,"phases":56024,"primaryCompletion":55980,"completion":55980,"start":55981,"enrollment":55982,"conditions":56025,"interventions":56026},[85,86],[5353],[55968,55985,55986,55987,55988,55989,55990],{"trials":56028,"activeCount":97},[],{"trials":56030,"activeCount":97},[],{"trials":56032,"activeCount":97},[],{"intervention":55987,"totalTrials":417,"cells":56034},{"EARLY_PHASE1":56035,"PHASE1":56037,"PHASE2":56039,"PHASE3":56045,"PHASE4":56047,"NA":56049},{"trials":56036,"activeCount":97},[],{"trials":56038,"activeCount":97},[],{"trials":56040,"activeCount":97},[56041],{"nctId":55977,"briefTitle":55978,"status":155,"phases":56042,"primaryCompletion":55980,"completion":55980,"start":55981,"enrollment":55982,"conditions":56043,"interventions":56044},[85,86],[5353],[55968,55985,55986,55987,55988,55989,55990],{"trials":56046,"activeCount":97},[],{"trials":56048,"activeCount":97},[],{"trials":56050,"activeCount":97},[],{"intervention":55988,"totalTrials":417,"cells":56052},{"EARLY_PHASE1":56053,"PHASE1":56055,"PHASE2":56057,"PHASE3":56063,"PHASE4":56065,"NA":56067},{"trials":56054,"activeCount":97},[],{"trials":56056,"activeCount":97},[],{"trials":56058,"activeCount":97},[56059],{"nctId":55977,"briefTitle":55978,"status":155,"phases":56060,"primaryCompletion":55980,"completion":55980,"start":55981,"enrollment":55982,"conditions":56061,"interventions":56062},[85,86],[5353],[55968,55985,55986,55987,55988,55989,55990],{"trials":56064,"activeCount":97},[],{"trials":56066,"activeCount":97},[],{"trials":56068,"activeCount":97},[],{"intervention":55989,"totalTrials":417,"cells":56070},{"EARLY_PHASE1":56071,"PHASE1":56073,"PHASE2":56075,"PHASE3":56081,"PHASE4":56083,"NA":56085},{"trials":56072,"activeCount":97},[],{"trials":56074,"activeCount":97},[],{"trials":56076,"activeCount":97},[56077],{"nctId":55977,"briefTitle":55978,"status":155,"phases":56078,"primaryCompletion":55980,"completion":55980,"start":55981,"enrollment":55982,"conditions":56079,"interventions":56080},[85,86],[5353],[55968,55985,55986,55987,55988,55989,55990],{"trials":56082,"activeCount":97},[],{"trials":56084,"activeCount":97},[],{"trials":56086,"activeCount":97},[],{"intervention":55990,"totalTrials":417,"cells":56088},{"EARLY_PHASE1":56089,"PHASE1":56091,"PHASE2":56093,"PHASE3":56099,"PHASE4":56101,"NA":56103},{"trials":56090,"activeCount":97},[],{"trials":56092,"activeCount":97},[],{"trials":56094,"activeCount":97},[56095],{"nctId":55977,"briefTitle":55978,"status":155,"phases":56096,"primaryCompletion":55980,"completion":55980,"start":55981,"enrollment":55982,"conditions":56097,"interventions":56098},[85,86],[5353],[55968,55985,55986,55987,55988,55989,55990],{"trials":56100,"activeCount":97},[],{"trials":56102,"activeCount":97},[],{"trials":56104,"activeCount":97},[],{"intervention":42971,"totalTrials":417,"cells":56106},{"EARLY_PHASE1":56107,"PHASE1":56109,"PHASE2":56111,"PHASE3":56117,"PHASE4":56119,"NA":56121},{"trials":56108,"activeCount":97},[],{"trials":56110,"activeCount":97},[],{"trials":56112,"activeCount":97},[56113],{"nctId":42966,"briefTitle":42967,"status":155,"phases":56114,"primaryCompletion":10463,"completion":10463,"start":2442,"enrollment":361,"conditions":56115,"interventions":56116},[86],[39624],[42971,42948,42972],{"trials":56118,"activeCount":97},[],{"trials":56120,"activeCount":97},[],{"trials":56122,"activeCount":97},[],{"intervention":42972,"totalTrials":417,"cells":56124},{"EARLY_PHASE1":56125,"PHASE1":56127,"PHASE2":56129,"PHASE3":56135,"PHASE4":56137,"NA":56139},{"trials":56126,"activeCount":97},[],{"trials":56128,"activeCount":97},[],{"trials":56130,"activeCount":97},[56131],{"nctId":42966,"briefTitle":42967,"status":155,"phases":56132,"primaryCompletion":10463,"completion":10463,"start":2442,"enrollment":361,"conditions":56133,"interventions":56134},[86],[39624],[42971,42948,42972],{"trials":56136,"activeCount":97},[],{"trials":56138,"activeCount":97},[],{"trials":56140,"activeCount":97},[],{"intervention":56142,"totalTrials":417,"cells":56143},"323U66 SR",{"EARLY_PHASE1":56144,"PHASE1":56146,"PHASE2":56148,"PHASE3":56156,"PHASE4":56158,"NA":56160},{"trials":56145,"activeCount":97},[],{"trials":56147,"activeCount":97},[],{"trials":56149,"activeCount":97},[56150],{"nctId":56151,"briefTitle":56152,"status":155,"phases":56153,"primaryCompletion":3079,"completion":3079,"start":2383,"enrollment":8786,"conditions":56154,"interventions":56155},"NCT00330616","Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan",[86],[10890],[56142],{"trials":56157,"activeCount":97},[],{"trials":56159,"activeCount":97},[],{"trials":56161,"activeCount":97},[],{"intervention":56163,"totalTrials":417,"cells":56164},"tositumomab and iodine I-131 tositumomab",{"EARLY_PHASE1":56165,"PHASE1":56167,"PHASE2":56169,"PHASE3":56178,"PHASE4":56180,"NA":56182},{"trials":56166,"activeCount":97},[],{"trials":56168,"activeCount":97},[],{"trials":56170,"activeCount":97},[56171],{"nctId":56172,"briefTitle":56173,"status":155,"phases":56174,"primaryCompletion":828,"completion":828,"start":56175,"enrollment":1117,"conditions":56176,"interventions":56177},"NCT01868035","Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP",[86],"2000-05",[4574],[56163],{"trials":56179,"activeCount":97},[],{"trials":56181,"activeCount":97},[],{"trials":56183,"activeCount":97},[],{"intervention":42590,"totalTrials":417,"cells":56185},{"EARLY_PHASE1":56186,"PHASE1":56188,"PHASE2":56190,"PHASE3":56196,"PHASE4":56198,"NA":56200},{"trials":56187,"activeCount":97},[],{"trials":56189,"activeCount":97},[],{"trials":56191,"activeCount":97},[56192],{"nctId":42584,"briefTitle":42585,"status":155,"phases":56193,"primaryCompletion":4677,"completion":4677,"start":23418,"enrollment":42587,"conditions":56194,"interventions":56195},[86],[39848],[42561,42590],{"trials":56197,"activeCount":97},[],{"trials":56199,"activeCount":97},[],{"trials":56201,"activeCount":97},[],{"intervention":42252,"totalTrials":417,"cells":56203},{"EARLY_PHASE1":56204,"PHASE1":56206,"PHASE2":56208,"PHASE3":56214,"PHASE4":56216,"NA":56218},{"trials":56205,"activeCount":97},[],{"trials":56207,"activeCount":97},[],{"trials":56209,"activeCount":97},[56210],{"nctId":42243,"briefTitle":42244,"status":155,"phases":56211,"primaryCompletion":42246,"completion":42247,"start":42248,"enrollment":42249,"conditions":56212,"interventions":56213},[86],[3287],[42217,42217,42252],{"trials":56215,"activeCount":97},[],{"trials":56217,"activeCount":97},[],{"trials":56219,"activeCount":97},[],{"intervention":56221,"totalTrials":417,"cells":56222},"Influenza investigational vaccine GSK2340274A",{"EARLY_PHASE1":56223,"PHASE1":56225,"PHASE2":56227,"PHASE3":56236,"PHASE4":56238,"NA":56240},{"trials":56224,"activeCount":97},[],{"trials":56226,"activeCount":97},[],{"trials":56228,"activeCount":97},[56229],{"nctId":56230,"briefTitle":56231,"status":155,"phases":56232,"primaryCompletion":56233,"completion":56233,"start":9891,"enrollment":414,"conditions":56234,"interventions":56235},"NCT00989612","Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1)",[86],"2010-04-19",[21],[56221],{"trials":56237,"activeCount":97},[],{"trials":56239,"activeCount":97},[],{"trials":56241,"activeCount":97},[],{"intervention":8258,"totalTrials":417,"cells":56243},{"EARLY_PHASE1":56244,"PHASE1":56246,"PHASE2":56248,"PHASE3":56254,"PHASE4":56256,"NA":56258},{"trials":56245,"activeCount":97},[],{"trials":56247,"activeCount":97},[],{"trials":56249,"activeCount":97},[56250],{"nctId":8250,"briefTitle":8251,"status":155,"phases":56251,"primaryCompletion":8253,"completion":8253,"start":8254,"enrollment":8255,"conditions":56252,"interventions":56253},[86],[21],[8258,8177],{"trials":56255,"activeCount":97},[],{"trials":56257,"activeCount":97},[],{"trials":56259,"activeCount":97},[],{"intervention":56261,"totalTrials":417,"cells":56262},"AH23844",{"EARLY_PHASE1":56263,"PHASE1":56265,"PHASE2":56267,"PHASE3":56279,"PHASE4":56281,"NA":56283},{"trials":56264,"activeCount":97},[],{"trials":56266,"activeCount":97},[],{"trials":56268,"activeCount":97},[56269],{"nctId":56270,"briefTitle":56271,"status":155,"phases":56272,"primaryCompletion":748,"completion":748,"start":2383,"enrollment":2883,"conditions":56273,"interventions":56276},"NCT00405119","A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.",[86],[56274,56275],"Gastroesophageal Reflux Disease","Reflux, Gastroesophageal",[56261,56277,56278],"NEXIUM","ZANTAC",{"trials":56280,"activeCount":97},[],{"trials":56282,"activeCount":97},[],{"trials":56284,"activeCount":97},[],{"intervention":56277,"totalTrials":417,"cells":56286},{"EARLY_PHASE1":56287,"PHASE1":56289,"PHASE2":56291,"PHASE3":56297,"PHASE4":56299,"NA":56301},{"trials":56288,"activeCount":97},[],{"trials":56290,"activeCount":97},[],{"trials":56292,"activeCount":97},[56293],{"nctId":56270,"briefTitle":56271,"status":155,"phases":56294,"primaryCompletion":748,"completion":748,"start":2383,"enrollment":2883,"conditions":56295,"interventions":56296},[86],[56274,56275],[56261,56277,56278],{"trials":56298,"activeCount":97},[],{"trials":56300,"activeCount":97},[],{"trials":56302,"activeCount":97},[],{"intervention":56278,"totalTrials":417,"cells":56304},{"EARLY_PHASE1":56305,"PHASE1":56307,"PHASE2":56309,"PHASE3":56315,"PHASE4":56317,"NA":56319},{"trials":56306,"activeCount":97},[],{"trials":56308,"activeCount":97},[],{"trials":56310,"activeCount":97},[56311],{"nctId":56270,"briefTitle":56271,"status":155,"phases":56312,"primaryCompletion":748,"completion":748,"start":2383,"enrollment":2883,"conditions":56313,"interventions":56314},[86],[56274,56275],[56261,56277,56278],{"trials":56316,"activeCount":97},[],{"trials":56318,"activeCount":97},[],{"trials":56320,"activeCount":97},[],{"intervention":56322,"totalTrials":417,"cells":56323},"Vitamin-K-Antagonist",{"EARLY_PHASE1":56324,"PHASE1":56326,"PHASE2":56328,"PHASE3":56338,"PHASE4":56340,"NA":56342},{"trials":56325,"activeCount":97},[],{"trials":56327,"activeCount":97},[],{"trials":56329,"activeCount":97},[56330],{"nctId":56331,"briefTitle":56332,"status":155,"phases":56333,"primaryCompletion":3111,"completion":3111,"start":9159,"enrollment":24932,"conditions":56334,"interventions":56335},"NCT00911300","Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart Rhythm",[86],[28372],[56336,56337,56322],"fondaparinux","unfractionated heparin",{"trials":56339,"activeCount":97},[],{"trials":56341,"activeCount":97},[],{"trials":56343,"activeCount":97},[],{"intervention":56345,"totalTrials":417,"cells":56346},"GSK2190915 - 100mcg",{"EARLY_PHASE1":56347,"PHASE1":56349,"PHASE2":56351,"PHASE3":56359,"PHASE4":56361,"NA":56363},{"trials":56348,"activeCount":97},[],{"trials":56350,"activeCount":97},[],{"trials":56352,"activeCount":97},[56353],{"nctId":56354,"briefTitle":56355,"status":155,"phases":56356,"primaryCompletion":1429,"completion":1429,"start":8468,"enrollment":421,"conditions":56357,"interventions":56358},"NCT00748306","Study in Mild Asthmatic Patients",[86],[18],[56345],{"trials":56360,"activeCount":97},[],{"trials":56362,"activeCount":97},[],{"trials":56364,"activeCount":97},[],{"intervention":56366,"totalTrials":417,"cells":56367},"Tositumomab 450 mg",{"EARLY_PHASE1":56368,"PHASE1":56370,"PHASE2":56372,"PHASE3":56381,"PHASE4":56383,"NA":56385},{"trials":56369,"activeCount":97},[],{"trials":56371,"activeCount":97},[],{"trials":56373,"activeCount":97},[56374],{"nctId":56375,"briefTitle":56376,"status":155,"phases":56377,"primaryCompletion":8406,"completion":3111,"start":2775,"enrollment":7911,"conditions":56378,"interventions":56379},"NCT00240565","Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma",[86],[4574],[56366,56380],"Tositumomab 35 mg",{"trials":56382,"activeCount":97},[],{"trials":56384,"activeCount":97},[],{"trials":56386,"activeCount":97},[],{"intervention":56380,"totalTrials":417,"cells":56388},{"EARLY_PHASE1":56389,"PHASE1":56391,"PHASE2":56393,"PHASE3":56399,"PHASE4":56401,"NA":56403},{"trials":56390,"activeCount":97},[],{"trials":56392,"activeCount":97},[],{"trials":56394,"activeCount":97},[56395],{"nctId":56375,"briefTitle":56376,"status":155,"phases":56396,"primaryCompletion":8406,"completion":3111,"start":2775,"enrollment":7911,"conditions":56397,"interventions":56398},[86],[4574],[56366,56380],{"trials":56400,"activeCount":97},[],{"trials":56402,"activeCount":97},[],{"trials":56404,"activeCount":97},[],{"intervention":19211,"totalTrials":417,"cells":56406},{"EARLY_PHASE1":56407,"PHASE1":56409,"PHASE2":56411,"PHASE3":56417,"PHASE4":56419,"NA":56421},{"trials":56408,"activeCount":97},[],{"trials":56410,"activeCount":97},[],{"trials":56412,"activeCount":97},[56413],{"nctId":19206,"briefTitle":19207,"status":500,"phases":56414,"primaryCompletion":9706,"completion":9706,"start":6352,"enrollment":97,"conditions":56415,"interventions":56416},[86],[4759],[19211,19151,10348,7830],{"trials":56418,"activeCount":97},[],{"trials":56420,"activeCount":97},[],{"trials":56422,"activeCount":97},[],{"intervention":10217,"totalTrials":417,"cells":56424},{"EARLY_PHASE1":56425,"PHASE1":56427,"PHASE2":56429,"PHASE3":56435,"PHASE4":56437,"NA":56439},{"trials":56426,"activeCount":97},[],{"trials":56428,"activeCount":97},[],{"trials":56430,"activeCount":97},[56431],{"nctId":10209,"briefTitle":10210,"status":155,"phases":56432,"primaryCompletion":9737,"completion":9737,"start":10212,"enrollment":10213,"conditions":56433,"interventions":56434},[86],[992],[10216,10217,4749,10200],{"trials":56436,"activeCount":97},[],{"trials":56438,"activeCount":97},[],{"trials":56440,"activeCount":97},[],{"intervention":56442,"totalTrials":417,"cells":56443},"Ropinirole prolonged release\u002Fextended release",{"EARLY_PHASE1":56444,"PHASE1":56446,"PHASE2":56448,"PHASE3":56456,"PHASE4":56458,"NA":56460},{"trials":56445,"activeCount":97},[],{"trials":56447,"activeCount":97},[],{"trials":56449,"activeCount":97},[56450],{"nctId":56451,"briefTitle":56452,"status":155,"phases":56453,"primaryCompletion":8826,"completion":7506,"start":8287,"enrollment":234,"conditions":56454,"interventions":56455},"NCT00434304","Clinical Evaluation of Ropinirole PR\u002FXR Tablets in Monotherapy for Parkinson's Disease (PD)",[86],[15879],[56442],{"trials":56457,"activeCount":97},[],{"trials":56459,"activeCount":97},[],{"trials":56461,"activeCount":97},[],{"intervention":56463,"totalTrials":417,"cells":56464},"GW810781",{"EARLY_PHASE1":56465,"PHASE1":56467,"PHASE2":56469,"PHASE3":56478,"PHASE4":56480,"NA":56482},{"trials":56466,"activeCount":97},[],{"trials":56468,"activeCount":97},[],{"trials":56470,"activeCount":97},[56471],{"nctId":56472,"briefTitle":56473,"status":155,"phases":56474,"primaryCompletion":11599,"completion":11599,"start":56475,"enrollment":414,"conditions":56476,"interventions":56477},"NCT00046332","A Study Comparing 4 Doses Of GW810781 Versus Placebo In HIV-Infected Patients",[86],"2002-06",[10943],[56463],{"trials":56479,"activeCount":97},[],{"trials":56481,"activeCount":97},[],{"trials":56483,"activeCount":97},[],{"intervention":56485,"totalTrials":417,"cells":56486},"ChAd155-hIi-HBV low dose formulation",{"EARLY_PHASE1":56487,"PHASE1":56489,"PHASE2":56491,"PHASE3":56505,"PHASE4":56507,"NA":56509},{"trials":56488,"activeCount":97},[],{"trials":56490,"activeCount":97},[],{"trials":56492,"activeCount":97},[56493],{"nctId":56494,"briefTitle":56495,"status":145,"phases":56496,"primaryCompletion":42390,"completion":42390,"start":56497,"enrollment":8619,"conditions":56498,"interventions":56499},"NCT03866187","Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection",[85,86],"2019-03-28",[4191],[56485,56500,56501,56502,56503,56504],"ChAd155-hIi-HBV high dose formulation","HBc-HBs\u002FAS01B-4 low dose formulation","HBc-HBs\u002FAS01B-4 high dose formulation","MVA-HBV low dose formulation","MVA-HBV high dose formulation",{"trials":56506,"activeCount":97},[],{"trials":56508,"activeCount":97},[],{"trials":56510,"activeCount":97},[],{"intervention":56500,"totalTrials":417,"cells":56512},{"EARLY_PHASE1":56513,"PHASE1":56515,"PHASE2":56517,"PHASE3":56523,"PHASE4":56525,"NA":56527},{"trials":56514,"activeCount":97},[],{"trials":56516,"activeCount":97},[],{"trials":56518,"activeCount":97},[56519],{"nctId":56494,"briefTitle":56495,"status":145,"phases":56520,"primaryCompletion":42390,"completion":42390,"start":56497,"enrollment":8619,"conditions":56521,"interventions":56522},[85,86],[4191],[56485,56500,56501,56502,56503,56504],{"trials":56524,"activeCount":97},[],{"trials":56526,"activeCount":97},[],{"trials":56528,"activeCount":97},[],{"intervention":56501,"totalTrials":417,"cells":56530},{"EARLY_PHASE1":56531,"PHASE1":56533,"PHASE2":56535,"PHASE3":56541,"PHASE4":56543,"NA":56545},{"trials":56532,"activeCount":97},[],{"trials":56534,"activeCount":97},[],{"trials":56536,"activeCount":97},[56537],{"nctId":56494,"briefTitle":56495,"status":145,"phases":56538,"primaryCompletion":42390,"completion":42390,"start":56497,"enrollment":8619,"conditions":56539,"interventions":56540},[85,86],[4191],[56485,56500,56501,56502,56503,56504],{"trials":56542,"activeCount":97},[],{"trials":56544,"activeCount":97},[],{"trials":56546,"activeCount":97},[],{"intervention":56502,"totalTrials":417,"cells":56548},{"EARLY_PHASE1":56549,"PHASE1":56551,"PHASE2":56553,"PHASE3":56559,"PHASE4":56561,"NA":56563},{"trials":56550,"activeCount":97},[],{"trials":56552,"activeCount":97},[],{"trials":56554,"activeCount":97},[56555],{"nctId":56494,"briefTitle":56495,"status":145,"phases":56556,"primaryCompletion":42390,"completion":42390,"start":56497,"enrollment":8619,"conditions":56557,"interventions":56558},[85,86],[4191],[56485,56500,56501,56502,56503,56504],{"trials":56560,"activeCount":97},[],{"trials":56562,"activeCount":97},[],{"trials":56564,"activeCount":97},[],{"intervention":56503,"totalTrials":417,"cells":56566},{"EARLY_PHASE1":56567,"PHASE1":56569,"PHASE2":56571,"PHASE3":56577,"PHASE4":56579,"NA":56581},{"trials":56568,"activeCount":97},[],{"trials":56570,"activeCount":97},[],{"trials":56572,"activeCount":97},[56573],{"nctId":56494,"briefTitle":56495,"status":145,"phases":56574,"primaryCompletion":42390,"completion":42390,"start":56497,"enrollment":8619,"conditions":56575,"interventions":56576},[85,86],[4191],[56485,56500,56501,56502,56503,56504],{"trials":56578,"activeCount":97},[],{"trials":56580,"activeCount":97},[],{"trials":56582,"activeCount":97},[],{"intervention":56504,"totalTrials":417,"cells":56584},{"EARLY_PHASE1":56585,"PHASE1":56587,"PHASE2":56589,"PHASE3":56595,"PHASE4":56597,"NA":56599},{"trials":56586,"activeCount":97},[],{"trials":56588,"activeCount":97},[],{"trials":56590,"activeCount":97},[56591],{"nctId":56494,"briefTitle":56495,"status":145,"phases":56592,"primaryCompletion":42390,"completion":42390,"start":56497,"enrollment":8619,"conditions":56593,"interventions":56594},[85,86],[4191],[56485,56500,56501,56502,56503,56504],{"trials":56596,"activeCount":97},[],{"trials":56598,"activeCount":97},[],{"trials":56600,"activeCount":97},[],{"intervention":1724,"totalTrials":417,"cells":56602},{"EARLY_PHASE1":56603,"PHASE1":56605,"PHASE2":56607,"PHASE3":56613,"PHASE4":56615,"NA":56617},{"trials":56604,"activeCount":97},[],{"trials":56606,"activeCount":97},[],{"trials":56608,"activeCount":97},[56609],{"nctId":1715,"briefTitle":1716,"status":145,"phases":56610,"primaryCompletion":1718,"completion":1718,"start":1719,"enrollment":1720,"conditions":56611,"interventions":56612},[86],[1722],[1724,137],{"trials":56614,"activeCount":97},[],{"trials":56616,"activeCount":97},[],{"trials":56618,"activeCount":97},[],{"intervention":40611,"totalTrials":417,"cells":56620},{"EARLY_PHASE1":56621,"PHASE1":56623,"PHASE2":56625,"PHASE3":56631,"PHASE4":56633,"NA":56635},{"trials":56622,"activeCount":97},[],{"trials":56624,"activeCount":97},[],{"trials":56626,"activeCount":97},[56627],{"nctId":40606,"briefTitle":40607,"status":155,"phases":56628,"primaryCompletion":7590,"completion":7590,"start":7647,"enrollment":9334,"conditions":56629,"interventions":56630},[86],[18],[40611,40571,8532],{"trials":56632,"activeCount":97},[],{"trials":56634,"activeCount":97},[],{"trials":56636,"activeCount":97},[],{"intervention":41983,"totalTrials":417,"cells":56638},{"EARLY_PHASE1":56639,"PHASE1":56641,"PHASE2":56643,"PHASE3":56649,"PHASE4":56651,"NA":56653},{"trials":56640,"activeCount":97},[],{"trials":56642,"activeCount":97},[],{"trials":56644,"activeCount":97},[56645],{"nctId":41976,"briefTitle":41977,"status":155,"phases":56646,"primaryCompletion":26945,"completion":36623,"start":41979,"enrollment":41980,"conditions":56647,"interventions":56648},[86],[3287],[41983,41984,41985,41974,23250],{"trials":56650,"activeCount":97},[],{"trials":56652,"activeCount":97},[],{"trials":56654,"activeCount":97},[],{"intervention":41984,"totalTrials":417,"cells":56656},{"EARLY_PHASE1":56657,"PHASE1":56659,"PHASE2":56661,"PHASE3":56667,"PHASE4":56669,"NA":56671},{"trials":56658,"activeCount":97},[],{"trials":56660,"activeCount":97},[],{"trials":56662,"activeCount":97},[56663],{"nctId":41976,"briefTitle":41977,"status":155,"phases":56664,"primaryCompletion":26945,"completion":36623,"start":41979,"enrollment":41980,"conditions":56665,"interventions":56666},[86],[3287],[41983,41984,41985,41974,23250],{"trials":56668,"activeCount":97},[],{"trials":56670,"activeCount":97},[],{"trials":56672,"activeCount":97},[],{"intervention":41985,"totalTrials":417,"cells":56674},{"EARLY_PHASE1":56675,"PHASE1":56677,"PHASE2":56679,"PHASE3":56685,"PHASE4":56687,"NA":56689},{"trials":56676,"activeCount":97},[],{"trials":56678,"activeCount":97},[],{"trials":56680,"activeCount":97},[56681],{"nctId":41976,"briefTitle":41977,"status":155,"phases":56682,"primaryCompletion":26945,"completion":36623,"start":41979,"enrollment":41980,"conditions":56683,"interventions":56684},[86],[3287],[41983,41984,41985,41974,23250],{"trials":56686,"activeCount":97},[],{"trials":56688,"activeCount":97},[],{"trials":56690,"activeCount":97},[],{"intervention":56692,"totalTrials":417,"cells":56693},"5% KNO3 \u002F 0.2542% NaF dentifrice with 0.5% spherical silica",{"EARLY_PHASE1":56694,"PHASE1":56696,"PHASE2":56698,"PHASE3":56711,"PHASE4":56713,"NA":56715},{"trials":56695,"activeCount":97},[],{"trials":56697,"activeCount":97},[],{"trials":56699,"activeCount":97},[56700],{"nctId":56701,"briefTitle":56702,"status":155,"phases":56703,"primaryCompletion":56704,"completion":56704,"start":56705,"enrollment":1598,"conditions":56706,"interventions":56707},"NCT03267511","A Study to Investigate the Stain and Plaque Removal Capability of Two Experimental Potassium Nitrate Dentifrices",[86],"2017-12-02","2017-09-25",[15325],[56692,56708,56709,56710],"5% KNO3 \u002F 0.2542% NaF dentifrice with 1% spherical silica and 5% STP","5% KNO3 \u002F 0.2542% NaF dentifrice with 6% abrasive silica","5% KNO3 \u002F 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP",{"trials":56712,"activeCount":97},[],{"trials":56714,"activeCount":97},[],{"trials":56716,"activeCount":97},[],{"intervention":56708,"totalTrials":417,"cells":56718},{"EARLY_PHASE1":56719,"PHASE1":56721,"PHASE2":56723,"PHASE3":56729,"PHASE4":56731,"NA":56733},{"trials":56720,"activeCount":97},[],{"trials":56722,"activeCount":97},[],{"trials":56724,"activeCount":97},[56725],{"nctId":56701,"briefTitle":56702,"status":155,"phases":56726,"primaryCompletion":56704,"completion":56704,"start":56705,"enrollment":1598,"conditions":56727,"interventions":56728},[86],[15325],[56692,56708,56709,56710],{"trials":56730,"activeCount":97},[],{"trials":56732,"activeCount":97},[],{"trials":56734,"activeCount":97},[],{"intervention":56709,"totalTrials":417,"cells":56736},{"EARLY_PHASE1":56737,"PHASE1":56739,"PHASE2":56741,"PHASE3":56747,"PHASE4":56749,"NA":56751},{"trials":56738,"activeCount":97},[],{"trials":56740,"activeCount":97},[],{"trials":56742,"activeCount":97},[56743],{"nctId":56701,"briefTitle":56702,"status":155,"phases":56744,"primaryCompletion":56704,"completion":56704,"start":56705,"enrollment":1598,"conditions":56745,"interventions":56746},[86],[15325],[56692,56708,56709,56710],{"trials":56748,"activeCount":97},[],{"trials":56750,"activeCount":97},[],{"trials":56752,"activeCount":97},[],{"intervention":56710,"totalTrials":417,"cells":56754},{"EARLY_PHASE1":56755,"PHASE1":56757,"PHASE2":56759,"PHASE3":56765,"PHASE4":56767,"NA":56769},{"trials":56756,"activeCount":97},[],{"trials":56758,"activeCount":97},[],{"trials":56760,"activeCount":97},[56761],{"nctId":56701,"briefTitle":56702,"status":155,"phases":56762,"primaryCompletion":56704,"completion":56704,"start":56705,"enrollment":1598,"conditions":56763,"interventions":56764},[86],[15325],[56692,56708,56709,56710],{"trials":56766,"activeCount":97},[],{"trials":56768,"activeCount":97},[],{"trials":56770,"activeCount":97},[],{"intervention":56772,"totalTrials":417,"cells":56773},"100 mg GSK2586184",{"EARLY_PHASE1":56774,"PHASE1":56776,"PHASE2":56778,"PHASE3":56788,"PHASE4":56790,"NA":56792},{"trials":56775,"activeCount":97},[],{"trials":56777,"activeCount":97},[],{"trials":56779,"activeCount":97},[56780],{"nctId":56781,"briefTitle":56782,"status":155,"phases":56783,"primaryCompletion":50249,"completion":39386,"start":8397,"enrollment":37,"conditions":56784,"interventions":56785},"NCT01782664","A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis",[86],[22060],[56772,56786,56787],"200 mg GSK2586184","400 mg GSK2586184",{"trials":56789,"activeCount":97},[],{"trials":56791,"activeCount":97},[],{"trials":56793,"activeCount":97},[],{"intervention":56786,"totalTrials":417,"cells":56795},{"EARLY_PHASE1":56796,"PHASE1":56798,"PHASE2":56800,"PHASE3":56806,"PHASE4":56808,"NA":56810},{"trials":56797,"activeCount":97},[],{"trials":56799,"activeCount":97},[],{"trials":56801,"activeCount":97},[56802],{"nctId":56781,"briefTitle":56782,"status":155,"phases":56803,"primaryCompletion":50249,"completion":39386,"start":8397,"enrollment":37,"conditions":56804,"interventions":56805},[86],[22060],[56772,56786,56787],{"trials":56807,"activeCount":97},[],{"trials":56809,"activeCount":97},[],{"trials":56811,"activeCount":97},[],{"intervention":56787,"totalTrials":417,"cells":56813},{"EARLY_PHASE1":56814,"PHASE1":56816,"PHASE2":56818,"PHASE3":56824,"PHASE4":56826,"NA":56828},{"trials":56815,"activeCount":97},[],{"trials":56817,"activeCount":97},[],{"trials":56819,"activeCount":97},[56820],{"nctId":56781,"briefTitle":56782,"status":155,"phases":56821,"primaryCompletion":50249,"completion":39386,"start":8397,"enrollment":37,"conditions":56822,"interventions":56823},[86],[22060],[56772,56786,56787],{"trials":56825,"activeCount":97},[],{"trials":56827,"activeCount":97},[],{"trials":56829,"activeCount":97},[],{"intervention":39176,"totalTrials":417,"cells":56831},{"EARLY_PHASE1":56832,"PHASE1":56834,"PHASE2":56836,"PHASE3":56842,"PHASE4":56844,"NA":56846},{"trials":56833,"activeCount":97},[],{"trials":56835,"activeCount":97},[],{"trials":56837,"activeCount":97},[56838],{"nctId":39171,"briefTitle":39172,"status":500,"phases":56839,"primaryCompletion":8468,"completion":8468,"start":8468,"enrollment":97,"conditions":56840,"interventions":56841},[86],[39123],[39110,39176],{"trials":56843,"activeCount":97},[],{"trials":56845,"activeCount":97},[],{"trials":56847,"activeCount":97},[],{"intervention":56849,"totalTrials":417,"cells":56850},"5% Potassium nitrate",{"EARLY_PHASE1":56851,"PHASE1":56853,"PHASE2":56855,"PHASE3":56864,"PHASE4":56866,"NA":56868},{"trials":56852,"activeCount":97},[],{"trials":56854,"activeCount":97},[],{"trials":56856,"activeCount":97},[56857],{"nctId":56858,"briefTitle":56859,"status":155,"phases":56860,"primaryCompletion":11992,"completion":11992,"start":1429,"enrollment":2045,"conditions":56861,"interventions":56862},"NCT01115452","Efficacy of Potassium Nitrate Solution in Reducing Dentinal Hypersensitivity",[86],[44583],[56849,56863],"2.5% Potassium nitrate",{"trials":56865,"activeCount":97},[],{"trials":56867,"activeCount":97},[],{"trials":56869,"activeCount":97},[],{"intervention":56863,"totalTrials":417,"cells":56871},{"EARLY_PHASE1":56872,"PHASE1":56874,"PHASE2":56876,"PHASE3":56882,"PHASE4":56884,"NA":56886},{"trials":56873,"activeCount":97},[],{"trials":56875,"activeCount":97},[],{"trials":56877,"activeCount":97},[56878],{"nctId":56858,"briefTitle":56859,"status":155,"phases":56879,"primaryCompletion":11992,"completion":11992,"start":1429,"enrollment":2045,"conditions":56880,"interventions":56881},[86],[44583],[56849,56863],{"trials":56883,"activeCount":97},[],{"trials":56885,"activeCount":97},[],{"trials":56887,"activeCount":97},[],{"intervention":43893,"totalTrials":417,"cells":56889},{"EARLY_PHASE1":56890,"PHASE1":56892,"PHASE2":56894,"PHASE3":56900,"PHASE4":56902,"NA":56904},{"trials":56891,"activeCount":97},[],{"trials":56893,"activeCount":97},[],{"trials":56895,"activeCount":97},[56896],{"nctId":43888,"briefTitle":43889,"status":155,"phases":56897,"primaryCompletion":10803,"completion":10803,"start":33286,"enrollment":1237,"conditions":56898,"interventions":56899},[86],[8723],[43872,43893,43894],{"trials":56901,"activeCount":97},[],{"trials":56903,"activeCount":97},[],{"trials":56905,"activeCount":97},[],{"intervention":43894,"totalTrials":417,"cells":56907},{"EARLY_PHASE1":56908,"PHASE1":56910,"PHASE2":56912,"PHASE3":56918,"PHASE4":56920,"NA":56922},{"trials":56909,"activeCount":97},[],{"trials":56911,"activeCount":97},[],{"trials":56913,"activeCount":97},[56914],{"nctId":43888,"briefTitle":43889,"status":155,"phases":56915,"primaryCompletion":10803,"completion":10803,"start":33286,"enrollment":1237,"conditions":56916,"interventions":56917},[86],[8723],[43872,43893,43894],{"trials":56919,"activeCount":97},[],{"trials":56921,"activeCount":97},[],{"trials":56923,"activeCount":97},[],{"intervention":39389,"totalTrials":417,"cells":56925},{"EARLY_PHASE1":56926,"PHASE1":56928,"PHASE2":56930,"PHASE3":56936,"PHASE4":56938,"NA":56940},{"trials":56927,"activeCount":97},[],{"trials":56929,"activeCount":97},[],{"trials":56931,"activeCount":97},[56932],{"nctId":39382,"briefTitle":39383,"status":155,"phases":56933,"primaryCompletion":39385,"completion":39385,"start":39386,"enrollment":3157,"conditions":56934,"interventions":56935},[86],[6484],[39389,39316],{"trials":56937,"activeCount":97},[],{"trials":56939,"activeCount":97},[],{"trials":56941,"activeCount":97},[],{"intervention":507,"totalTrials":417,"cells":56943},{"EARLY_PHASE1":56944,"PHASE1":56946,"PHASE2":56948,"PHASE3":56954,"PHASE4":56956,"NA":56958},{"trials":56945,"activeCount":97},[],{"trials":56947,"activeCount":97},[],{"trials":56949,"activeCount":97},[56950],{"nctId":498,"briefTitle":499,"status":500,"phases":56951,"primaryCompletion":502,"completion":502,"start":503,"enrollment":97,"conditions":56952,"interventions":56953},[86],[505],[53,507],{"trials":56955,"activeCount":97},[],{"trials":56957,"activeCount":97},[],{"trials":56959,"activeCount":97},[],{"intervention":56961,"totalTrials":417,"cells":56962},"Sodium bicarbonate and sodium fluoride",{"EARLY_PHASE1":56963,"PHASE1":56965,"PHASE2":56967,"PHASE3":56975,"PHASE4":56977,"NA":56979},{"trials":56964,"activeCount":97},[],{"trials":56966,"activeCount":97},[],{"trials":56968,"activeCount":97},[56969],{"nctId":56970,"briefTitle":56971,"status":155,"phases":56972,"primaryCompletion":12043,"completion":3341,"start":8667,"enrollment":31710,"conditions":56973,"interventions":56974},"NCT02207400","To Evaluate Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its Effect on Opportunistic or Resistant Organisms",[86],[15325],[56961,43205],{"trials":56976,"activeCount":97},[],{"trials":56978,"activeCount":97},[],{"trials":56980,"activeCount":97},[],{"intervention":44720,"totalTrials":417,"cells":56982},{"EARLY_PHASE1":56983,"PHASE1":56985,"PHASE2":56987,"PHASE3":56993,"PHASE4":56995,"NA":56997},{"trials":56984,"activeCount":97},[],{"trials":56986,"activeCount":97},[],{"trials":56988,"activeCount":97},[56989],{"nctId":44713,"briefTitle":44714,"status":145,"phases":56990,"primaryCompletion":44716,"completion":44716,"start":44717,"enrollment":255,"conditions":56991,"interventions":56992},[85,86],[107],[1665,44720],{"trials":56994,"activeCount":97},[],{"trials":56996,"activeCount":97},[],{"trials":56998,"activeCount":97},[],{"intervention":57000,"totalTrials":417,"cells":57001},"GSK2982772 60 mg",{"EARLY_PHASE1":57002,"PHASE1":57004,"PHASE2":57006,"PHASE3":57016,"PHASE4":57018,"NA":57020},{"trials":57003,"activeCount":97},[],{"trials":57005,"activeCount":97},[],{"trials":57007,"activeCount":97},[57008],{"nctId":57009,"briefTitle":57010,"status":155,"phases":57011,"primaryCompletion":57012,"completion":57012,"start":57013,"enrollment":3025,"conditions":57014,"interventions":57015},"NCT02858492","Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)",[86],"2018-10-22","2016-10-17",[8788],[57000],{"trials":57017,"activeCount":97},[],{"trials":57019,"activeCount":97},[],{"trials":57021,"activeCount":97},[],{"intervention":57023,"totalTrials":417,"cells":57024},"Fluticasone furoate (FF) Dry Powder Inhaler",{"EARLY_PHASE1":57025,"PHASE1":57027,"PHASE2":57029,"PHASE3":57039,"PHASE4":57041,"NA":57043},{"trials":57026,"activeCount":97},[],{"trials":57028,"activeCount":97},[],{"trials":57030,"activeCount":97},[57031],{"nctId":57032,"briefTitle":57033,"status":155,"phases":57034,"primaryCompletion":19610,"completion":19610,"start":5128,"enrollment":904,"conditions":57035,"interventions":57036},"NCT02991859","Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects",[86],[18],[57023,57037,57038],"Fluticasone propionate (FP) Dry Powder Inhaler","Budesonide (BUD) Turbuhaler",{"trials":57040,"activeCount":97},[],{"trials":57042,"activeCount":97},[],{"trials":57044,"activeCount":97},[],{"intervention":57037,"totalTrials":417,"cells":57046},{"EARLY_PHASE1":57047,"PHASE1":57049,"PHASE2":57051,"PHASE3":57057,"PHASE4":57059,"NA":57061},{"trials":57048,"activeCount":97},[],{"trials":57050,"activeCount":97},[],{"trials":57052,"activeCount":97},[57053],{"nctId":57032,"briefTitle":57033,"status":155,"phases":57054,"primaryCompletion":19610,"completion":19610,"start":5128,"enrollment":904,"conditions":57055,"interventions":57056},[86],[18],[57023,57037,57038],{"trials":57058,"activeCount":97},[],{"trials":57060,"activeCount":97},[],{"trials":57062,"activeCount":97},[],{"intervention":57038,"totalTrials":417,"cells":57064},{"EARLY_PHASE1":57065,"PHASE1":57067,"PHASE2":57069,"PHASE3":57075,"PHASE4":57077,"NA":57079},{"trials":57066,"activeCount":97},[],{"trials":57068,"activeCount":97},[],{"trials":57070,"activeCount":97},[57071],{"nctId":57032,"briefTitle":57033,"status":155,"phases":57072,"primaryCompletion":19610,"completion":19610,"start":5128,"enrollment":904,"conditions":57073,"interventions":57074},[86],[18],[57023,57037,57038],{"trials":57076,"activeCount":97},[],{"trials":57078,"activeCount":97},[],{"trials":57080,"activeCount":97},[],{"intervention":57082,"totalTrials":417,"cells":57083},"NgG low dose investigational vaccine",{"EARLY_PHASE1":57084,"PHASE1":57086,"PHASE2":57088,"PHASE3":57103,"PHASE4":57105,"NA":57107},{"trials":57085,"activeCount":97},[],{"trials":57087,"activeCount":97},[],{"trials":57089,"activeCount":97},[57090],{"nctId":57091,"briefTitle":57092,"status":155,"phases":57093,"primaryCompletion":57094,"completion":57094,"start":42805,"enrollment":57095,"conditions":57096,"interventions":57098},"NCT05630859","Safety and Efficacy of GSK Neisseria Gonorrhoeae GMMA (NgG) Investigational Vaccine When Administered to Healthy Adults 18 to 50 Years of Age.",[85,86],"2025-05-22",1004,[57097],"Sexually Transmitted Diseases",[57082,57099,57100,57101,57102],"NgG medium dose investigational vaccine","NgG high dose investigational vaccine","NgG HTD investigational vaccine","NgG below HTD investigational vaccine",{"trials":57104,"activeCount":97},[],{"trials":57106,"activeCount":97},[],{"trials":57108,"activeCount":97},[],{"intervention":57099,"totalTrials":417,"cells":57110},{"EARLY_PHASE1":57111,"PHASE1":57113,"PHASE2":57115,"PHASE3":57121,"PHASE4":57123,"NA":57125},{"trials":57112,"activeCount":97},[],{"trials":57114,"activeCount":97},[],{"trials":57116,"activeCount":97},[57117],{"nctId":57091,"briefTitle":57092,"status":155,"phases":57118,"primaryCompletion":57094,"completion":57094,"start":42805,"enrollment":57095,"conditions":57119,"interventions":57120},[85,86],[57097],[57082,57099,57100,57101,57102],{"trials":57122,"activeCount":97},[],{"trials":57124,"activeCount":97},[],{"trials":57126,"activeCount":97},[],{"intervention":57100,"totalTrials":417,"cells":57128},{"EARLY_PHASE1":57129,"PHASE1":57131,"PHASE2":57133,"PHASE3":57139,"PHASE4":57141,"NA":57143},{"trials":57130,"activeCount":97},[],{"trials":57132,"activeCount":97},[],{"trials":57134,"activeCount":97},[57135],{"nctId":57091,"briefTitle":57092,"status":155,"phases":57136,"primaryCompletion":57094,"completion":57094,"start":42805,"enrollment":57095,"conditions":57137,"interventions":57138},[85,86],[57097],[57082,57099,57100,57101,57102],{"trials":57140,"activeCount":97},[],{"trials":57142,"activeCount":97},[],{"trials":57144,"activeCount":97},[],{"intervention":57101,"totalTrials":417,"cells":57146},{"EARLY_PHASE1":57147,"PHASE1":57149,"PHASE2":57151,"PHASE3":57157,"PHASE4":57159,"NA":57161},{"trials":57148,"activeCount":97},[],{"trials":57150,"activeCount":97},[],{"trials":57152,"activeCount":97},[57153],{"nctId":57091,"briefTitle":57092,"status":155,"phases":57154,"primaryCompletion":57094,"completion":57094,"start":42805,"enrollment":57095,"conditions":57155,"interventions":57156},[85,86],[57097],[57082,57099,57100,57101,57102],{"trials":57158,"activeCount":97},[],{"trials":57160,"activeCount":97},[],{"trials":57162,"activeCount":97},[],{"intervention":57102,"totalTrials":417,"cells":57164},{"EARLY_PHASE1":57165,"PHASE1":57167,"PHASE2":57169,"PHASE3":57175,"PHASE4":57177,"NA":57179},{"trials":57166,"activeCount":97},[],{"trials":57168,"activeCount":97},[],{"trials":57170,"activeCount":97},[57171],{"nctId":57091,"briefTitle":57092,"status":155,"phases":57172,"primaryCompletion":57094,"completion":57094,"start":42805,"enrollment":57095,"conditions":57173,"interventions":57174},[85,86],[57097],[57082,57099,57100,57101,57102],{"trials":57176,"activeCount":97},[],{"trials":57178,"activeCount":97},[],{"trials":57180,"activeCount":97},[],{"intervention":57182,"totalTrials":417,"cells":57183},"Potassium nitrate and sodium fluoride",{"EARLY_PHASE1":57184,"PHASE1":57186,"PHASE2":57188,"PHASE3":57199,"PHASE4":57201,"NA":57203},{"trials":57185,"activeCount":97},[],{"trials":57187,"activeCount":97},[],{"trials":57189,"activeCount":97},[57190],{"nctId":57191,"briefTitle":57192,"status":155,"phases":57193,"primaryCompletion":57194,"completion":737,"start":57195,"enrollment":41647,"conditions":57196,"interventions":57197},"NCT02226562","Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term Relief From Dentinal Hypersensitivity",[86],"2014-12-01","2014-09-02",[55741],[57182,57198],"Standard fluoride dentifrice",{"trials":57200,"activeCount":97},[],{"trials":57202,"activeCount":97},[],{"trials":57204,"activeCount":97},[],{"intervention":57198,"totalTrials":417,"cells":57206},{"EARLY_PHASE1":57207,"PHASE1":57209,"PHASE2":57211,"PHASE3":57217,"PHASE4":57219,"NA":57221},{"trials":57208,"activeCount":97},[],{"trials":57210,"activeCount":97},[],{"trials":57212,"activeCount":97},[57213],{"nctId":57191,"briefTitle":57192,"status":155,"phases":57214,"primaryCompletion":57194,"completion":737,"start":57195,"enrollment":41647,"conditions":57215,"interventions":57216},[86],[55741],[57182,57198],{"trials":57218,"activeCount":97},[],{"trials":57220,"activeCount":97},[],{"trials":57222,"activeCount":97},[],{"intervention":57224,"totalTrials":417,"cells":57225},"vestipitant\u002Fparoxetine",{"EARLY_PHASE1":57226,"PHASE1":57228,"PHASE2":57230,"PHASE3":57239,"PHASE4":57241,"NA":57243},{"trials":57227,"activeCount":97},[],{"trials":57229,"activeCount":97},[],{"trials":57231,"activeCount":97},[57232],{"nctId":57233,"briefTitle":57234,"status":155,"phases":57235,"completion":10395,"start":11097,"enrollment":57236,"conditions":57237,"interventions":57238},"NCT00403962","A Combination Therapy In Patients With Social Anxiety Disorder",[86],204,[26760],[57224],{"trials":57240,"activeCount":97},[],{"trials":57242,"activeCount":97},[],{"trials":57244,"activeCount":97},[],{"intervention":57246,"totalTrials":417,"cells":57247},"GW685698X (fluticasone furoate) 100mcg Morning",{"EARLY_PHASE1":57248,"PHASE1":57250,"PHASE2":57252,"PHASE3":57263,"PHASE4":57265,"NA":57267},{"trials":57249,"activeCount":97},[],{"trials":57251,"activeCount":97},[],{"trials":57253,"activeCount":97},[57254],{"nctId":57255,"briefTitle":57256,"status":155,"phases":57257,"primaryCompletion":7673,"completion":7673,"start":9462,"enrollment":57258,"conditions":57259,"interventions":57260},"NCT01499446","A Study of GW685698X 100mcg Administered Once Daily Either in the Morning or the Evening and GW685698X 250mcg Administered Once Daily in the Evening Via DISKHALER for 28 Days in Subjects With Persistent Bronchial Asthma.",[86],669,[18],[57246,57261,57262],"GW685698X (fluticasone furoate) 100mcg Evening","GW685698X (fluticasone furoate) 250mcg Evening",{"trials":57264,"activeCount":97},[],{"trials":57266,"activeCount":97},[],{"trials":57268,"activeCount":97},[],{"intervention":57261,"totalTrials":417,"cells":57270},{"EARLY_PHASE1":57271,"PHASE1":57273,"PHASE2":57275,"PHASE3":57281,"PHASE4":57283,"NA":57285},{"trials":57272,"activeCount":97},[],{"trials":57274,"activeCount":97},[],{"trials":57276,"activeCount":97},[57277],{"nctId":57255,"briefTitle":57256,"status":155,"phases":57278,"primaryCompletion":7673,"completion":7673,"start":9462,"enrollment":57258,"conditions":57279,"interventions":57280},[86],[18],[57246,57261,57262],{"trials":57282,"activeCount":97},[],{"trials":57284,"activeCount":97},[],{"trials":57286,"activeCount":97},[],{"intervention":57262,"totalTrials":417,"cells":57288},{"EARLY_PHASE1":57289,"PHASE1":57291,"PHASE2":57293,"PHASE3":57299,"PHASE4":57301,"NA":57303},{"trials":57290,"activeCount":97},[],{"trials":57292,"activeCount":97},[],{"trials":57294,"activeCount":97},[57295],{"nctId":57255,"briefTitle":57256,"status":155,"phases":57296,"primaryCompletion":7673,"completion":7673,"start":9462,"enrollment":57258,"conditions":57297,"interventions":57298},[86],[18],[57246,57261,57262],{"trials":57300,"activeCount":97},[],{"trials":57302,"activeCount":97},[],{"trials":57304,"activeCount":97},[],{"intervention":8267,"totalTrials":417,"cells":57306},{"EARLY_PHASE1":57307,"PHASE1":57309,"PHASE2":57311,"PHASE3":57317,"PHASE4":57319,"NA":57321},{"trials":57308,"activeCount":97},[],{"trials":57310,"activeCount":97},[],{"trials":57312,"activeCount":97},[57313],{"nctId":8260,"briefTitle":8261,"status":145,"phases":57314,"primaryCompletion":7514,"completion":7514,"start":8263,"enrollment":181,"conditions":57315,"interventions":57316},[86],[21,8265],[8267,8268,8177],{"trials":57318,"activeCount":97},[],{"trials":57320,"activeCount":97},[],{"trials":57322,"activeCount":97},[],{"intervention":8268,"totalTrials":417,"cells":57324},{"EARLY_PHASE1":57325,"PHASE1":57327,"PHASE2":57329,"PHASE3":57335,"PHASE4":57337,"NA":57339},{"trials":57326,"activeCount":97},[],{"trials":57328,"activeCount":97},[],{"trials":57330,"activeCount":97},[57331],{"nctId":8260,"briefTitle":8261,"status":145,"phases":57332,"primaryCompletion":7514,"completion":7514,"start":8263,"enrollment":181,"conditions":57333,"interventions":57334},[86],[21,8265],[8267,8268,8177],{"trials":57336,"activeCount":97},[],{"trials":57338,"activeCount":97},[],{"trials":57340,"activeCount":97},[],{"intervention":57342,"totalTrials":417,"cells":57343},"Live attenuated tetravalent dengue vaccine",{"EARLY_PHASE1":57344,"PHASE1":57346,"PHASE2":57348,"PHASE3":57357,"PHASE4":57359,"NA":57361},{"trials":57345,"activeCount":97},[],{"trials":57347,"activeCount":97},[],{"trials":57349,"activeCount":97},[57350],{"nctId":57351,"briefTitle":57352,"status":155,"phases":57353,"primaryCompletion":46387,"completion":46387,"start":46388,"enrollment":34,"conditions":57354,"interventions":57356},"NCT00239577","A Trial of a Walter Reed Army Institute of Research (WRAIR) Live Attenuated Virus Tetravalent Dengue Vaccine in Healthy US Adults",[86],[57355],"Dengue",[57342],{"trials":57358,"activeCount":97},[],{"trials":57360,"activeCount":97},[],{"trials":57362,"activeCount":97},[],{"intervention":42837,"totalTrials":417,"cells":57364},{"EARLY_PHASE1":57365,"PHASE1":57367,"PHASE2":57369,"PHASE3":57375,"PHASE4":57377,"NA":57379},{"trials":57366,"activeCount":97},[],{"trials":57368,"activeCount":97},[],{"trials":57370,"activeCount":97},[57371],{"nctId":42830,"briefTitle":42831,"status":155,"phases":57372,"primaryCompletion":443,"completion":42833,"start":11903,"enrollment":42834,"conditions":57373,"interventions":57374},[85,86],[4481],[42837,42838,42839,42840,42841,42842,42823,42824,42794],{"trials":57376,"activeCount":97},[],{"trials":57378,"activeCount":97},[],{"trials":57380,"activeCount":97},[],{"intervention":42838,"totalTrials":417,"cells":57382},{"EARLY_PHASE1":57383,"PHASE1":57385,"PHASE2":57387,"PHASE3":57393,"PHASE4":57395,"NA":57397},{"trials":57384,"activeCount":97},[],{"trials":57386,"activeCount":97},[],{"trials":57388,"activeCount":97},[57389],{"nctId":42830,"briefTitle":42831,"status":155,"phases":57390,"primaryCompletion":443,"completion":42833,"start":11903,"enrollment":42834,"conditions":57391,"interventions":57392},[85,86],[4481],[42837,42838,42839,42840,42841,42842,42823,42824,42794],{"trials":57394,"activeCount":97},[],{"trials":57396,"activeCount":97},[],{"trials":57398,"activeCount":97},[],{"intervention":42839,"totalTrials":417,"cells":57400},{"EARLY_PHASE1":57401,"PHASE1":57403,"PHASE2":57405,"PHASE3":57411,"PHASE4":57413,"NA":57415},{"trials":57402,"activeCount":97},[],{"trials":57404,"activeCount":97},[],{"trials":57406,"activeCount":97},[57407],{"nctId":42830,"briefTitle":42831,"status":155,"phases":57408,"primaryCompletion":443,"completion":42833,"start":11903,"enrollment":42834,"conditions":57409,"interventions":57410},[85,86],[4481],[42837,42838,42839,42840,42841,42842,42823,42824,42794],{"trials":57412,"activeCount":97},[],{"trials":57414,"activeCount":97},[],{"trials":57416,"activeCount":97},[],{"intervention":42840,"totalTrials":417,"cells":57418},{"EARLY_PHASE1":57419,"PHASE1":57421,"PHASE2":57423,"PHASE3":57429,"PHASE4":57431,"NA":57433},{"trials":57420,"activeCount":97},[],{"trials":57422,"activeCount":97},[],{"trials":57424,"activeCount":97},[57425],{"nctId":42830,"briefTitle":42831,"status":155,"phases":57426,"primaryCompletion":443,"completion":42833,"start":11903,"enrollment":42834,"conditions":57427,"interventions":57428},[85,86],[4481],[42837,42838,42839,42840,42841,42842,42823,42824,42794],{"trials":57430,"activeCount":97},[],{"trials":57432,"activeCount":97},[],{"trials":57434,"activeCount":97},[],{"intervention":42841,"totalTrials":417,"cells":57436},{"EARLY_PHASE1":57437,"PHASE1":57439,"PHASE2":57441,"PHASE3":57447,"PHASE4":57449,"NA":57451},{"trials":57438,"activeCount":97},[],{"trials":57440,"activeCount":97},[],{"trials":57442,"activeCount":97},[57443],{"nctId":42830,"briefTitle":42831,"status":155,"phases":57444,"primaryCompletion":443,"completion":42833,"start":11903,"enrollment":42834,"conditions":57445,"interventions":57446},[85,86],[4481],[42837,42838,42839,42840,42841,42842,42823,42824,42794],{"trials":57448,"activeCount":97},[],{"trials":57450,"activeCount":97},[],{"trials":57452,"activeCount":97},[],{"intervention":42842,"totalTrials":417,"cells":57454},{"EARLY_PHASE1":57455,"PHASE1":57457,"PHASE2":57459,"PHASE3":57465,"PHASE4":57467,"NA":57469},{"trials":57456,"activeCount":97},[],{"trials":57458,"activeCount":97},[],{"trials":57460,"activeCount":97},[57461],{"nctId":42830,"briefTitle":42831,"status":155,"phases":57462,"primaryCompletion":443,"completion":42833,"start":11903,"enrollment":42834,"conditions":57463,"interventions":57464},[85,86],[4481],[42837,42838,42839,42840,42841,42842,42823,42824,42794],{"trials":57466,"activeCount":97},[],{"trials":57468,"activeCount":97},[],{"trials":57470,"activeCount":97},[],{"intervention":57472,"totalTrials":417,"cells":57473},"RSV MAT 60 µg",{"EARLY_PHASE1":57474,"PHASE1":57476,"PHASE2":57478,"PHASE3":57488,"PHASE4":57490,"NA":57492},{"trials":57475,"activeCount":97},[],{"trials":57477,"activeCount":97},[],{"trials":57479,"activeCount":97},[57480],{"nctId":57481,"briefTitle":57482,"status":155,"phases":57483,"primaryCompletion":57484,"completion":14344,"start":50656,"enrollment":37423,"conditions":57485,"interventions":57486},"NCT04126213","Study of Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants",[86],"2020-07-23",[2620],[57472,57487],"RSV MAT 120 µg",{"trials":57489,"activeCount":97},[],{"trials":57491,"activeCount":97},[],{"trials":57493,"activeCount":97},[],{"intervention":57487,"totalTrials":417,"cells":57495},{"EARLY_PHASE1":57496,"PHASE1":57498,"PHASE2":57500,"PHASE3":57506,"PHASE4":57508,"NA":57510},{"trials":57497,"activeCount":97},[],{"trials":57499,"activeCount":97},[],{"trials":57501,"activeCount":97},[57502],{"nctId":57481,"briefTitle":57482,"status":155,"phases":57503,"primaryCompletion":57484,"completion":14344,"start":50656,"enrollment":37423,"conditions":57504,"interventions":57505},[86],[2620],[57472,57487],{"trials":57507,"activeCount":97},[],{"trials":57509,"activeCount":97},[],{"trials":57511,"activeCount":97},[],{"intervention":57513,"totalTrials":417,"cells":57514},"Investigational MMRV(H)NS vaccine",{"EARLY_PHASE1":57515,"PHASE1":57517,"PHASE2":57519,"PHASE3":57534,"PHASE4":57536,"NA":57538},{"trials":57516,"activeCount":97},[],{"trials":57518,"activeCount":97},[],{"trials":57520,"activeCount":97},[57521],{"nctId":57522,"briefTitle":57523,"status":155,"phases":57524,"primaryCompletion":57525,"completion":41177,"start":57526,"enrollment":57527,"conditions":57528,"interventions":57530},"NCT05630846","A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age",[86],"2024-06-07","2022-12-14",801,[57529,2486],"Measles; Mumps; Rubella; Chickenpox",[57513,57531,57532,57533],"Investigational MM(H)RVNS vaccine","Investigational M(L)M(L)R(L)V(L)NS vaccine","Marketed MMRV_Lot 1 and Lot 2 vaccine",{"trials":57535,"activeCount":97},[],{"trials":57537,"activeCount":97},[],{"trials":57539,"activeCount":97},[],{"intervention":57531,"totalTrials":417,"cells":57541},{"EARLY_PHASE1":57542,"PHASE1":57544,"PHASE2":57546,"PHASE3":57552,"PHASE4":57554,"NA":57556},{"trials":57543,"activeCount":97},[],{"trials":57545,"activeCount":97},[],{"trials":57547,"activeCount":97},[57548],{"nctId":57522,"briefTitle":57523,"status":155,"phases":57549,"primaryCompletion":57525,"completion":41177,"start":57526,"enrollment":57527,"conditions":57550,"interventions":57551},[86],[57529,2486],[57513,57531,57532,57533],{"trials":57553,"activeCount":97},[],{"trials":57555,"activeCount":97},[],{"trials":57557,"activeCount":97},[],{"intervention":57532,"totalTrials":417,"cells":57559},{"EARLY_PHASE1":57560,"PHASE1":57562,"PHASE2":57564,"PHASE3":57570,"PHASE4":57572,"NA":57574},{"trials":57561,"activeCount":97},[],{"trials":57563,"activeCount":97},[],{"trials":57565,"activeCount":97},[57566],{"nctId":57522,"briefTitle":57523,"status":155,"phases":57567,"primaryCompletion":57525,"completion":41177,"start":57526,"enrollment":57527,"conditions":57568,"interventions":57569},[86],[57529,2486],[57513,57531,57532,57533],{"trials":57571,"activeCount":97},[],{"trials":57573,"activeCount":97},[],{"trials":57575,"activeCount":97},[],{"intervention":57533,"totalTrials":417,"cells":57577},{"EARLY_PHASE1":57578,"PHASE1":57580,"PHASE2":57582,"PHASE3":57588,"PHASE4":57590,"NA":57592},{"trials":57579,"activeCount":97},[],{"trials":57581,"activeCount":97},[],{"trials":57583,"activeCount":97},[57584],{"nctId":57522,"briefTitle":57523,"status":155,"phases":57585,"primaryCompletion":57525,"completion":41177,"start":57526,"enrollment":57527,"conditions":57586,"interventions":57587},[86],[57529,2486],[57513,57531,57532,57533],{"trials":57589,"activeCount":97},[],{"trials":57591,"activeCount":97},[],{"trials":57593,"activeCount":97},[],{"intervention":57595,"totalTrials":417,"cells":57596},"Herpes Zoster Vaccine 1437173A",{"EARLY_PHASE1":57597,"PHASE1":57599,"PHASE2":57601,"PHASE3":57611,"PHASE4":57613,"NA":57615},{"trials":57598,"activeCount":97},[],{"trials":57600,"activeCount":97},[],{"trials":57602,"activeCount":97},[57603],{"nctId":57604,"briefTitle":57605,"status":155,"phases":57606,"primaryCompletion":14231,"completion":57607,"start":57608,"enrollment":2297,"conditions":57609,"interventions":57610},"NCT00920218","Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A",[86],"2012-03-21","2009-07-14",[1030],[57595],{"trials":57612,"activeCount":97},[],{"trials":57614,"activeCount":97},[],{"trials":57616,"activeCount":97},[],{"intervention":27327,"totalTrials":417,"cells":57618},{"EARLY_PHASE1":57619,"PHASE1":57621,"PHASE2":57623,"PHASE3":57629,"PHASE4":57631,"NA":57633},{"trials":57620,"activeCount":97},[],{"trials":57622,"activeCount":97},[],{"trials":57624,"activeCount":97},[57625],{"nctId":27319,"briefTitle":27320,"status":155,"phases":57626,"primaryCompletion":27322,"completion":27323,"start":27324,"enrollment":3230,"conditions":57627,"interventions":57628},[86],[21],[27327,27310],{"trials":57630,"activeCount":97},[],{"trials":57632,"activeCount":97},[],{"trials":57634,"activeCount":97},[],{"intervention":57636,"totalTrials":417,"cells":57637},"Alclometasone dipropionate cream",{"EARLY_PHASE1":57638,"PHASE1":57640,"PHASE2":57642,"PHASE3":57652,"PHASE4":57654,"NA":57656},{"trials":57639,"activeCount":97},[],{"trials":57641,"activeCount":97},[],{"trials":57643,"activeCount":97},[57644],{"nctId":57645,"briefTitle":57646,"status":155,"phases":57647,"primaryCompletion":4843,"completion":4843,"start":4757,"enrollment":8152,"conditions":57648,"interventions":57651},"NCT02075632","Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream",[86],[23473,57649,22060,57650],"Allergy Symptoms","Itch",[57636],{"trials":57653,"activeCount":97},[],{"trials":57655,"activeCount":97},[],{"trials":57657,"activeCount":97},[],{"intervention":57659,"totalTrials":417,"cells":57660},"RTS,S\u002FAS02A",{"EARLY_PHASE1":57661,"PHASE1":57663,"PHASE2":57665,"PHASE3":57674,"PHASE4":57676,"NA":57678},{"trials":57662,"activeCount":97},[],{"trials":57664,"activeCount":97},[],{"trials":57666,"activeCount":97},[57667],{"nctId":57668,"briefTitle":57669,"status":155,"phases":57670,"primaryCompletion":7785,"completion":7785,"start":21092,"enrollment":57671,"conditions":57672,"interventions":57673},"NCT00197041","A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Malaria Vaccine RTS,S\u002FAS02A, When Administered to Children Aged 1 to 4 Years Living in a Malaria-endemic Region of Mozambique.",[86],2022,[3287],[57659],{"trials":57675,"activeCount":97},[],{"trials":57677,"activeCount":97},[],{"trials":57679,"activeCount":97},[],{"intervention":57681,"totalTrials":417,"cells":57682},"Metformin 500mg",{"EARLY_PHASE1":57683,"PHASE1":57685,"PHASE2":57687,"PHASE3":57698,"PHASE4":57700,"NA":57702},{"trials":57684,"activeCount":97},[],{"trials":57686,"activeCount":97},[],{"trials":57688,"activeCount":97},[57689],{"nctId":57690,"briefTitle":57691,"status":155,"phases":57692,"primaryCompletion":39797,"completion":39797,"start":57693,"enrollment":2045,"conditions":57694,"interventions":57696},"NCT01710527","BE Study of Metformin GSK 500mg",[86],"2012-05-09",[57695],"Diabetic Foot",[57681,57697],"Glucophage 500mg",{"trials":57699,"activeCount":97},[],{"trials":57701,"activeCount":97},[],{"trials":57703,"activeCount":97},[],{"intervention":57697,"totalTrials":417,"cells":57705},{"EARLY_PHASE1":57706,"PHASE1":57708,"PHASE2":57710,"PHASE3":57716,"PHASE4":57718,"NA":57720},{"trials":57707,"activeCount":97},[],{"trials":57709,"activeCount":97},[],{"trials":57711,"activeCount":97},[57712],{"nctId":57690,"briefTitle":57691,"status":155,"phases":57713,"primaryCompletion":39797,"completion":39797,"start":57693,"enrollment":2045,"conditions":57714,"interventions":57715},[86],[57695],[57681,57697],{"trials":57717,"activeCount":97},[],{"trials":57719,"activeCount":97},[],{"trials":57721,"activeCount":97},[],{"intervention":57723,"totalTrials":417,"cells":57724},"16448",{"EARLY_PHASE1":57725,"PHASE1":57727,"PHASE2":57729,"PHASE3":57737,"PHASE4":57739,"NA":57741},{"trials":57726,"activeCount":97},[],{"trials":57728,"activeCount":97},[],{"trials":57730,"activeCount":97},[57731],{"nctId":57732,"briefTitle":57733,"status":155,"phases":57734,"start":7659,"enrollment":1634,"conditions":57735,"interventions":57736},"NCT00537459","A Study On Concentrations Of 16448 In Blood And The Safety Of This Compound In Healthy Males With Premature Ejaculation",[86],[45196],[57723],{"trials":57738,"activeCount":97},[],{"trials":57740,"activeCount":97},[],{"trials":57742,"activeCount":97},[],{"intervention":24872,"totalTrials":417,"cells":57744},{"EARLY_PHASE1":57745,"PHASE1":57747,"PHASE2":57749,"PHASE3":57755,"PHASE4":57757,"NA":57759},{"trials":57746,"activeCount":97},[],{"trials":57748,"activeCount":97},[],{"trials":57750,"activeCount":97},[57751],{"nctId":24865,"briefTitle":24866,"status":155,"phases":57752,"primaryCompletion":24868,"completion":24869,"start":10540,"enrollment":13031,"conditions":57753,"interventions":57754},[86],[2486,3717,2485,2484],[18293,24872],{"trials":57756,"activeCount":97},[],{"trials":57758,"activeCount":97},[],{"trials":57760,"activeCount":97},[],{"intervention":57762,"totalTrials":417,"cells":57763},"Meningococcal ABCWY",{"EARLY_PHASE1":57764,"PHASE1":57766,"PHASE2":57768,"PHASE3":57776,"PHASE4":57778,"NA":57780},{"trials":57765,"activeCount":97},[],{"trials":57767,"activeCount":97},[],{"trials":57769,"activeCount":97},[57770],{"nctId":57771,"briefTitle":57772,"status":155,"phases":57773,"primaryCompletion":13959,"completion":12873,"start":57194,"enrollment":54619,"conditions":57774,"interventions":57775},"NCT02285777","Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents",[86],[12803],[57762],{"trials":57777,"activeCount":97},[],{"trials":57779,"activeCount":97},[],{"trials":57781,"activeCount":97},[],{"intervention":57783,"totalTrials":417,"cells":57784},"Lapatinib (GW572016) oral",{"EARLY_PHASE1":57785,"PHASE1":57787,"PHASE2":57789,"PHASE3":57798,"PHASE4":57800,"NA":57802},{"trials":57786,"activeCount":97},[],{"trials":57788,"activeCount":97},[],{"trials":57790,"activeCount":97},[57791],{"nctId":57792,"briefTitle":57793,"status":155,"phases":57794,"completion":2835,"start":2844,"enrollment":1298,"conditions":57795,"interventions":57797},"NCT00259987","Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus",[86],[57796],"Adenocarcinoma",[57783],{"trials":57799,"activeCount":97},[],{"trials":57801,"activeCount":97},[],{"trials":57803,"activeCount":97},[],{"intervention":57805,"totalTrials":417,"cells":57806},"Carbon Dioxide",{"EARLY_PHASE1":57807,"PHASE1":57809,"PHASE2":57811,"PHASE3":57820,"PHASE4":57822,"NA":57824},{"trials":57808,"activeCount":97},[],{"trials":57810,"activeCount":97},[],{"trials":57812,"activeCount":97},[57813],{"nctId":57814,"briefTitle":57815,"status":155,"phases":57816,"primaryCompletion":13418,"completion":13418,"start":7701,"enrollment":22,"conditions":57817,"interventions":57819},"NCT02113449","Market Potential of Carbon Dioxide Nasal Spray",[86],[57818],"Nasal Congestion",[57805],{"trials":57821,"activeCount":97},[],{"trials":57823,"activeCount":97},[],{"trials":57825,"activeCount":97},[],{"intervention":41301,"totalTrials":417,"cells":57827},{"EARLY_PHASE1":57828,"PHASE1":57830,"PHASE2":57832,"PHASE3":57838,"PHASE4":57840,"NA":57842},{"trials":57829,"activeCount":97},[],{"trials":57831,"activeCount":97},[],{"trials":57833,"activeCount":97},[57834],{"nctId":41295,"briefTitle":41296,"status":145,"phases":57835,"primaryCompletion":39004,"completion":39004,"start":41298,"enrollment":454,"conditions":57836,"interventions":57837},[86],[14965],[41262,41301],{"trials":57839,"activeCount":97},[],{"trials":57841,"activeCount":97},[],{"trials":57843,"activeCount":97},[],{"intervention":57845,"totalTrials":417,"cells":57846},"GSK Biologicals' investigational TB vaccine",{"EARLY_PHASE1":57847,"PHASE1":57849,"PHASE2":57851,"PHASE3":57861,"PHASE4":57863,"NA":57865},{"trials":57848,"activeCount":97},[],{"trials":57850,"activeCount":97},[],{"trials":57852,"activeCount":97},[57853],{"nctId":57854,"briefTitle":57855,"status":155,"phases":57856,"primaryCompletion":1719,"completion":1719,"start":57857,"enrollment":57858,"conditions":57859,"interventions":57860},"NCT01755598","Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults",[86],"2014-08-19",3575,[23246,51199],[57845],{"trials":57862,"activeCount":97},[],{"trials":57864,"activeCount":97},[],{"trials":57866,"activeCount":97},[],{"intervention":41689,"totalTrials":417,"cells":57868},{"EARLY_PHASE1":57869,"PHASE1":57871,"PHASE2":57873,"PHASE3":57879,"PHASE4":57881,"NA":57883},{"trials":57870,"activeCount":97},[],{"trials":57872,"activeCount":97},[],{"trials":57874,"activeCount":97},[57875],{"nctId":41683,"briefTitle":41684,"status":145,"phases":57876,"primaryCompletion":708,"completion":708,"start":41686,"enrollment":1318,"conditions":57877,"interventions":57878},[85,86],[11020,2574],[41658,41689],{"trials":57880,"activeCount":97},[],{"trials":57882,"activeCount":97},[],{"trials":57884,"activeCount":97},[],{"intervention":40367,"totalTrials":417,"cells":57886},{"EARLY_PHASE1":57887,"PHASE1":57889,"PHASE2":57891,"PHASE3":57897,"PHASE4":57899,"NA":57901},{"trials":57888,"activeCount":97},[],{"trials":57890,"activeCount":97},[],{"trials":57892,"activeCount":97},[57893],{"nctId":40359,"briefTitle":40360,"status":155,"phases":57894,"primaryCompletion":40362,"completion":40362,"start":40363,"enrollment":4542,"conditions":57895,"interventions":57896},[86],[40365],[40367,40368,5282],{"trials":57898,"activeCount":97},[],{"trials":57900,"activeCount":97},[],{"trials":57902,"activeCount":97},[],{"intervention":40368,"totalTrials":417,"cells":57904},{"EARLY_PHASE1":57905,"PHASE1":57907,"PHASE2":57909,"PHASE3":57915,"PHASE4":57917,"NA":57919},{"trials":57906,"activeCount":97},[],{"trials":57908,"activeCount":97},[],{"trials":57910,"activeCount":97},[57911],{"nctId":40359,"briefTitle":40360,"status":155,"phases":57912,"primaryCompletion":40362,"completion":40362,"start":40363,"enrollment":4542,"conditions":57913,"interventions":57914},[86],[40365],[40367,40368,5282],{"trials":57916,"activeCount":97},[],{"trials":57918,"activeCount":97},[],{"trials":57920,"activeCount":97},[],{"intervention":1739,"totalTrials":417,"cells":57922},{"EARLY_PHASE1":57923,"PHASE1":57925,"PHASE2":57927,"PHASE3":57933,"PHASE4":57935,"NA":57937},{"trials":57924,"activeCount":97},[],{"trials":57926,"activeCount":97},[],{"trials":57928,"activeCount":97},[57929],{"nctId":1730,"briefTitle":1731,"status":145,"phases":57930,"primaryCompletion":1733,"completion":1734,"start":1735,"enrollment":1736,"conditions":57931,"interventions":57932},[85,86],[107],[1739,137],{"trials":57934,"activeCount":97},[],{"trials":57936,"activeCount":97},[],{"trials":57938,"activeCount":97},[],{"intervention":57940,"totalTrials":417,"cells":57941},"HPV 16\u002F18 L1 AS04",{"EARLY_PHASE1":57942,"PHASE1":57944,"PHASE2":57946,"PHASE3":57962,"PHASE4":57964,"NA":57966},{"trials":57943,"activeCount":97},[],{"trials":57945,"activeCount":97},[],{"trials":57947,"activeCount":97},[57948],{"nctId":57949,"briefTitle":57950,"status":155,"phases":57951,"primaryCompletion":57952,"completion":57952,"start":57953,"enrollment":24106,"conditions":57954,"interventions":57955},"NCT00231413","Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.",[86],"2006-03-27","2005-03-04",[8723],[57940,57956,57957,57958,57959,57960,57961],"HPV-16\u002F18\u002F31\u002F45 L1 AS04 Formulation 1","HPV-16\u002F18\u002F31\u002F45 L1 AS04 Formulation 2","HPV-16\u002F18\u002F31\u002F45 L1 AS04 Formulation 3","HPV-16\u002F18\u002F31\u002F45 L1 AS04 Formulation 4","HPV-16\u002F18\u002F31\u002F45 L1 AS04 Formulation 5","HPV-16\u002F18\u002F31\u002F45 L1 AS04 Formulation 6",{"trials":57963,"activeCount":97},[],{"trials":57965,"activeCount":97},[],{"trials":57967,"activeCount":97},[],{"intervention":57956,"totalTrials":417,"cells":57969},{"EARLY_PHASE1":57970,"PHASE1":57972,"PHASE2":57974,"PHASE3":57980,"PHASE4":57982,"NA":57984},{"trials":57971,"activeCount":97},[],{"trials":57973,"activeCount":97},[],{"trials":57975,"activeCount":97},[57976],{"nctId":57949,"briefTitle":57950,"status":155,"phases":57977,"primaryCompletion":57952,"completion":57952,"start":57953,"enrollment":24106,"conditions":57978,"interventions":57979},[86],[8723],[57940,57956,57957,57958,57959,57960,57961],{"trials":57981,"activeCount":97},[],{"trials":57983,"activeCount":97},[],{"trials":57985,"activeCount":97},[],{"intervention":57957,"totalTrials":417,"cells":57987},{"EARLY_PHASE1":57988,"PHASE1":57990,"PHASE2":57992,"PHASE3":57998,"PHASE4":58000,"NA":58002},{"trials":57989,"activeCount":97},[],{"trials":57991,"activeCount":97},[],{"trials":57993,"activeCount":97},[57994],{"nctId":57949,"briefTitle":57950,"status":155,"phases":57995,"primaryCompletion":57952,"completion":57952,"start":57953,"enrollment":24106,"conditions":57996,"interventions":57997},[86],[8723],[57940,57956,57957,57958,57959,57960,57961],{"trials":57999,"activeCount":97},[],{"trials":58001,"activeCount":97},[],{"trials":58003,"activeCount":97},[],{"intervention":57958,"totalTrials":417,"cells":58005},{"EARLY_PHASE1":58006,"PHASE1":58008,"PHASE2":58010,"PHASE3":58016,"PHASE4":58018,"NA":58020},{"trials":58007,"activeCount":97},[],{"trials":58009,"activeCount":97},[],{"trials":58011,"activeCount":97},[58012],{"nctId":57949,"briefTitle":57950,"status":155,"phases":58013,"primaryCompletion":57952,"completion":57952,"start":57953,"enrollment":24106,"conditions":58014,"interventions":58015},[86],[8723],[57940,57956,57957,57958,57959,57960,57961],{"trials":58017,"activeCount":97},[],{"trials":58019,"activeCount":97},[],{"trials":58021,"activeCount":97},[],{"intervention":57959,"totalTrials":417,"cells":58023},{"EARLY_PHASE1":58024,"PHASE1":58026,"PHASE2":58028,"PHASE3":58034,"PHASE4":58036,"NA":58038},{"trials":58025,"activeCount":97},[],{"trials":58027,"activeCount":97},[],{"trials":58029,"activeCount":97},[58030],{"nctId":57949,"briefTitle":57950,"status":155,"phases":58031,"primaryCompletion":57952,"completion":57952,"start":57953,"enrollment":24106,"conditions":58032,"interventions":58033},[86],[8723],[57940,57956,57957,57958,57959,57960,57961],{"trials":58035,"activeCount":97},[],{"trials":58037,"activeCount":97},[],{"trials":58039,"activeCount":97},[],{"intervention":57960,"totalTrials":417,"cells":58041},{"EARLY_PHASE1":58042,"PHASE1":58044,"PHASE2":58046,"PHASE3":58052,"PHASE4":58054,"NA":58056},{"trials":58043,"activeCount":97},[],{"trials":58045,"activeCount":97},[],{"trials":58047,"activeCount":97},[58048],{"nctId":57949,"briefTitle":57950,"status":155,"phases":58049,"primaryCompletion":57952,"completion":57952,"start":57953,"enrollment":24106,"conditions":58050,"interventions":58051},[86],[8723],[57940,57956,57957,57958,57959,57960,57961],{"trials":58053,"activeCount":97},[],{"trials":58055,"activeCount":97},[],{"trials":58057,"activeCount":97},[],{"intervention":57961,"totalTrials":417,"cells":58059},{"EARLY_PHASE1":58060,"PHASE1":58062,"PHASE2":58064,"PHASE3":58070,"PHASE4":58072,"NA":58074},{"trials":58061,"activeCount":97},[],{"trials":58063,"activeCount":97},[],{"trials":58065,"activeCount":97},[58066],{"nctId":57949,"briefTitle":57950,"status":155,"phases":58067,"primaryCompletion":57952,"completion":57952,"start":57953,"enrollment":24106,"conditions":58068,"interventions":58069},[86],[8723],[57940,57956,57957,57958,57959,57960,57961],{"trials":58071,"activeCount":97},[],{"trials":58073,"activeCount":97},[],{"trials":58075,"activeCount":97},[],{"intervention":58077,"totalTrials":417,"cells":58078},"Batefenterol + Fluticasone Furoate",{"EARLY_PHASE1":58079,"PHASE1":58081,"PHASE2":58083,"PHASE3":58093,"PHASE4":58095,"NA":58097},{"trials":58080,"activeCount":97},[],{"trials":58082,"activeCount":97},[],{"trials":58084,"activeCount":97},[58085],{"nctId":58086,"briefTitle":58087,"status":155,"phases":58088,"primaryCompletion":58089,"completion":58089,"start":22081,"enrollment":44739,"conditions":58090,"interventions":58091},"NCT02573870","Batefenterol\u002FFluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease",[86],"2016-07-05",[15],[58077,58092],"Albuterol",{"trials":58094,"activeCount":97},[],{"trials":58096,"activeCount":97},[],{"trials":58098,"activeCount":97},[],{"intervention":58092,"totalTrials":417,"cells":58100},{"EARLY_PHASE1":58101,"PHASE1":58103,"PHASE2":58105,"PHASE3":58111,"PHASE4":58113,"NA":58115},{"trials":58102,"activeCount":97},[],{"trials":58104,"activeCount":97},[],{"trials":58106,"activeCount":97},[58107],{"nctId":58086,"briefTitle":58087,"status":155,"phases":58108,"primaryCompletion":58089,"completion":58089,"start":22081,"enrollment":44739,"conditions":58109,"interventions":58110},[86],[15],[58077,58092],{"trials":58112,"activeCount":97},[],{"trials":58114,"activeCount":97},[],{"trials":58116,"activeCount":97},[],{"intervention":58118,"totalTrials":417,"cells":58119},"S.sonnei vaccine",{"EARLY_PHASE1":58120,"PHASE1":58122,"PHASE2":58124,"PHASE3":58136,"PHASE4":58138,"NA":58140},{"trials":58121,"activeCount":97},[],{"trials":58123,"activeCount":97},[],{"trials":58125,"activeCount":97},[58126],{"nctId":58127,"briefTitle":58128,"status":155,"phases":58129,"primaryCompletion":58130,"completion":58131,"start":29513,"enrollment":7394,"conditions":58132,"interventions":58134},"NCT03527173","A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults",[86],"2019-05-08","2019-11-11",[58133],"Dysentery, Bacillary",[58118,58135],"S. sonnei 53G challenge strain",{"trials":58137,"activeCount":97},[],{"trials":58139,"activeCount":97},[],{"trials":58141,"activeCount":97},[],{"intervention":58135,"totalTrials":417,"cells":58143},{"EARLY_PHASE1":58144,"PHASE1":58146,"PHASE2":58148,"PHASE3":58154,"PHASE4":58156,"NA":58158},{"trials":58145,"activeCount":97},[],{"trials":58147,"activeCount":97},[],{"trials":58149,"activeCount":97},[58150],{"nctId":58127,"briefTitle":58128,"status":155,"phases":58151,"primaryCompletion":58130,"completion":58131,"start":29513,"enrollment":7394,"conditions":58152,"interventions":58153},[86],[58133],[58118,58135],{"trials":58155,"activeCount":97},[],{"trials":58157,"activeCount":97},[],{"trials":58159,"activeCount":97},[],{"intervention":18725,"totalTrials":417,"cells":58161},{"EARLY_PHASE1":58162,"PHASE1":58164,"PHASE2":58166,"PHASE3":58172,"PHASE4":58174,"NA":58176},{"trials":58163,"activeCount":97},[],{"trials":58165,"activeCount":97},[],{"trials":58167,"activeCount":97},[58168],{"nctId":18720,"briefTitle":18721,"status":155,"phases":58169,"primaryCompletion":13418,"completion":13418,"start":3045,"enrollment":7394,"conditions":58170,"interventions":58171},[86],[10147],[18725,3467,18726],{"trials":58173,"activeCount":97},[],{"trials":58175,"activeCount":97},[],{"trials":58177,"activeCount":97},[],{"intervention":58179,"totalTrials":417,"cells":58180},"GW856553X",{"EARLY_PHASE1":58181,"PHASE1":58183,"PHASE2":58185,"PHASE3":58194,"PHASE4":58196,"NA":58198},{"trials":58182,"activeCount":97},[],{"trials":58184,"activeCount":97},[],{"trials":58186,"activeCount":97},[58187],{"nctId":58188,"briefTitle":58189,"status":145,"phases":58190,"primaryCompletion":10359,"completion":10359,"start":58191,"enrollment":255,"conditions":58192,"interventions":58193},"NCT00569062","A Study of GW856553X For the Treatment of Depression",[86],"2007-09-12",[10889],[58179],{"trials":58195,"activeCount":97},[],{"trials":58197,"activeCount":97},[],{"trials":58199,"activeCount":97},[],{"intervention":58201,"totalTrials":417,"cells":58202},"683699",{"EARLY_PHASE1":58203,"PHASE1":58205,"PHASE2":58207,"PHASE3":58215,"PHASE4":58217,"NA":58219},{"trials":58204,"activeCount":97},[],{"trials":58206,"activeCount":97},[],{"trials":58208,"activeCount":97},[58209],{"nctId":58210,"briefTitle":58211,"status":155,"phases":58212,"primaryCompletion":8963,"completion":8963,"start":8478,"enrollment":7438,"conditions":58213,"interventions":58214},"NCT00101946","Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease",[86],[21782],[58201],{"trials":58216,"activeCount":97},[],{"trials":58218,"activeCount":97},[],{"trials":58220,"activeCount":97},[],{"intervention":58222,"totalTrials":417,"cells":58223},"Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).",{"EARLY_PHASE1":58224,"PHASE1":58226,"PHASE2":58228,"PHASE3":58237,"PHASE4":58239,"NA":58241},{"trials":58225,"activeCount":97},[],{"trials":58227,"activeCount":97},[],{"trials":58229,"activeCount":97},[58230],{"nctId":58231,"briefTitle":58232,"status":155,"phases":58233,"primaryCompletion":47417,"completion":47417,"start":58234,"enrollment":7991,"conditions":58235,"interventions":58236},"NCT02719743","A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age",[86],"2016-07-07",[21],[58222],{"trials":58238,"activeCount":97},[],{"trials":58240,"activeCount":97},[],{"trials":58242,"activeCount":97},[],{"intervention":58244,"totalTrials":417,"cells":58245},"GW870086 2mg",{"EARLY_PHASE1":58246,"PHASE1":58248,"PHASE2":58250,"PHASE3":58262,"PHASE4":58264,"NA":58266},{"trials":58247,"activeCount":97},[],{"trials":58249,"activeCount":97},[],{"trials":58251,"activeCount":97},[58252],{"nctId":58253,"briefTitle":58254,"status":155,"phases":58255,"primaryCompletion":7545,"completion":9682,"start":2344,"enrollment":849,"conditions":58256,"interventions":58257},"NCT01245426","A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)",[86],[18],[58244,58258,58259,58260,58261],"GW870086 4mg","GW870086 Placebo","GW870086 1mg","GW870086 3mg",{"trials":58263,"activeCount":97},[],{"trials":58265,"activeCount":97},[],{"trials":58267,"activeCount":97},[],{"intervention":58258,"totalTrials":417,"cells":58269},{"EARLY_PHASE1":58270,"PHASE1":58272,"PHASE2":58274,"PHASE3":58280,"PHASE4":58282,"NA":58284},{"trials":58271,"activeCount":97},[],{"trials":58273,"activeCount":97},[],{"trials":58275,"activeCount":97},[58276],{"nctId":58253,"briefTitle":58254,"status":155,"phases":58277,"primaryCompletion":7545,"completion":9682,"start":2344,"enrollment":849,"conditions":58278,"interventions":58279},[86],[18],[58244,58258,58259,58260,58261],{"trials":58281,"activeCount":97},[],{"trials":58283,"activeCount":97},[],{"trials":58285,"activeCount":97},[],{"intervention":58259,"totalTrials":417,"cells":58287},{"EARLY_PHASE1":58288,"PHASE1":58290,"PHASE2":58292,"PHASE3":58298,"PHASE4":58300,"NA":58302},{"trials":58289,"activeCount":97},[],{"trials":58291,"activeCount":97},[],{"trials":58293,"activeCount":97},[58294],{"nctId":58253,"briefTitle":58254,"status":155,"phases":58295,"primaryCompletion":7545,"completion":9682,"start":2344,"enrollment":849,"conditions":58296,"interventions":58297},[86],[18],[58244,58258,58259,58260,58261],{"trials":58299,"activeCount":97},[],{"trials":58301,"activeCount":97},[],{"trials":58303,"activeCount":97},[],{"intervention":58260,"totalTrials":417,"cells":58305},{"EARLY_PHASE1":58306,"PHASE1":58308,"PHASE2":58310,"PHASE3":58316,"PHASE4":58318,"NA":58320},{"trials":58307,"activeCount":97},[],{"trials":58309,"activeCount":97},[],{"trials":58311,"activeCount":97},[58312],{"nctId":58253,"briefTitle":58254,"status":155,"phases":58313,"primaryCompletion":7545,"completion":9682,"start":2344,"enrollment":849,"conditions":58314,"interventions":58315},[86],[18],[58244,58258,58259,58260,58261],{"trials":58317,"activeCount":97},[],{"trials":58319,"activeCount":97},[],{"trials":58321,"activeCount":97},[],{"intervention":58261,"totalTrials":417,"cells":58323},{"EARLY_PHASE1":58324,"PHASE1":58326,"PHASE2":58328,"PHASE3":58334,"PHASE4":58336,"NA":58338},{"trials":58325,"activeCount":97},[],{"trials":58327,"activeCount":97},[],{"trials":58329,"activeCount":97},[58330],{"nctId":58253,"briefTitle":58254,"status":155,"phases":58331,"primaryCompletion":7545,"completion":9682,"start":2344,"enrollment":849,"conditions":58332,"interventions":58333},[86],[18],[58244,58258,58259,58260,58261],{"trials":58335,"activeCount":97},[],{"trials":58337,"activeCount":97},[],{"trials":58339,"activeCount":97},[],{"intervention":41440,"totalTrials":417,"cells":58341},{"EARLY_PHASE1":58342,"PHASE1":58344,"PHASE2":58346,"PHASE3":58352,"PHASE4":58354,"NA":58356},{"trials":58343,"activeCount":97},[],{"trials":58345,"activeCount":97},[],{"trials":58347,"activeCount":97},[58348],{"nctId":41434,"briefTitle":41435,"status":155,"phases":58349,"primaryCompletion":8468,"completion":8468,"start":4756,"enrollment":41437,"conditions":58350,"interventions":58351},[86],[9292],[41404,41440],{"trials":58353,"activeCount":97},[],{"trials":58355,"activeCount":97},[],{"trials":58357,"activeCount":97},[],{"intervention":41393,"totalTrials":417,"cells":58359},{"EARLY_PHASE1":58360,"PHASE1":58362,"PHASE2":58364,"PHASE3":58370,"PHASE4":58372,"NA":58374},{"trials":58361,"activeCount":97},[],{"trials":58363,"activeCount":97},[],{"trials":58365,"activeCount":97},[58366],{"nctId":41387,"briefTitle":41388,"status":155,"phases":58367,"primaryCompletion":41390,"completion":41390,"start":40993,"enrollment":11508,"conditions":58368,"interventions":58369},[86],[18],[41393,41354,41394,41395,41377,41396],{"trials":58371,"activeCount":97},[],{"trials":58373,"activeCount":97},[],{"trials":58375,"activeCount":97},[],{"intervention":41394,"totalTrials":417,"cells":58377},{"EARLY_PHASE1":58378,"PHASE1":58380,"PHASE2":58382,"PHASE3":58388,"PHASE4":58390,"NA":58392},{"trials":58379,"activeCount":97},[],{"trials":58381,"activeCount":97},[],{"trials":58383,"activeCount":97},[58384],{"nctId":41387,"briefTitle":41388,"status":155,"phases":58385,"primaryCompletion":41390,"completion":41390,"start":40993,"enrollment":11508,"conditions":58386,"interventions":58387},[86],[18],[41393,41354,41394,41395,41377,41396],{"trials":58389,"activeCount":97},[],{"trials":58391,"activeCount":97},[],{"trials":58393,"activeCount":97},[],{"intervention":41395,"totalTrials":417,"cells":58395},{"EARLY_PHASE1":58396,"PHASE1":58398,"PHASE2":58400,"PHASE3":58406,"PHASE4":58408,"NA":58410},{"trials":58397,"activeCount":97},[],{"trials":58399,"activeCount":97},[],{"trials":58401,"activeCount":97},[58402],{"nctId":41387,"briefTitle":41388,"status":155,"phases":58403,"primaryCompletion":41390,"completion":41390,"start":40993,"enrollment":11508,"conditions":58404,"interventions":58405},[86],[18],[41393,41354,41394,41395,41377,41396],{"trials":58407,"activeCount":97},[],{"trials":58409,"activeCount":97},[],{"trials":58411,"activeCount":97},[],{"intervention":41396,"totalTrials":417,"cells":58413},{"EARLY_PHASE1":58414,"PHASE1":58416,"PHASE2":58418,"PHASE3":58424,"PHASE4":58426,"NA":58428},{"trials":58415,"activeCount":97},[],{"trials":58417,"activeCount":97},[],{"trials":58419,"activeCount":97},[58420],{"nctId":41387,"briefTitle":41388,"status":155,"phases":58421,"primaryCompletion":41390,"completion":41390,"start":40993,"enrollment":11508,"conditions":58422,"interventions":58423},[86],[18],[41393,41354,41394,41395,41377,41396],{"trials":58425,"activeCount":97},[],{"trials":58427,"activeCount":97},[],{"trials":58429,"activeCount":97},[],{"intervention":58431,"totalTrials":417,"cells":58432},"GW823093 15mg",{"EARLY_PHASE1":58433,"PHASE1":58435,"PHASE2":58437,"PHASE3":58449,"PHASE4":58451,"NA":58453},{"trials":58434,"activeCount":97},[],{"trials":58436,"activeCount":97},[],{"trials":58438,"activeCount":97},[58439],{"nctId":58440,"briefTitle":58441,"status":155,"phases":58442,"primaryCompletion":58443,"completion":58443,"start":58444,"enrollment":255,"conditions":58445,"interventions":58446},"NCT00372957","Study Of GW823093 In Japanese Subjects With Type 2 Diabetes Mellitus",[86],"2006-06-28","2006-03-22",[27],[58431,58447,58448],"GW823093 placebo","GW823093 30mg",{"trials":58450,"activeCount":97},[],{"trials":58452,"activeCount":97},[],{"trials":58454,"activeCount":97},[],{"intervention":58447,"totalTrials":417,"cells":58456},{"EARLY_PHASE1":58457,"PHASE1":58459,"PHASE2":58461,"PHASE3":58467,"PHASE4":58469,"NA":58471},{"trials":58458,"activeCount":97},[],{"trials":58460,"activeCount":97},[],{"trials":58462,"activeCount":97},[58463],{"nctId":58440,"briefTitle":58441,"status":155,"phases":58464,"primaryCompletion":58443,"completion":58443,"start":58444,"enrollment":255,"conditions":58465,"interventions":58466},[86],[27],[58431,58447,58448],{"trials":58468,"activeCount":97},[],{"trials":58470,"activeCount":97},[],{"trials":58472,"activeCount":97},[],{"intervention":58448,"totalTrials":417,"cells":58474},{"EARLY_PHASE1":58475,"PHASE1":58477,"PHASE2":58479,"PHASE3":58485,"PHASE4":58487,"NA":58489},{"trials":58476,"activeCount":97},[],{"trials":58478,"activeCount":97},[],{"trials":58480,"activeCount":97},[58481],{"nctId":58440,"briefTitle":58441,"status":155,"phases":58482,"primaryCompletion":58443,"completion":58443,"start":58444,"enrollment":255,"conditions":58483,"interventions":58484},[86],[27],[58431,58447,58448],{"trials":58486,"activeCount":97},[],{"trials":58488,"activeCount":97},[],{"trials":58490,"activeCount":97},[],{"intervention":58492,"totalTrials":417,"cells":58493},"SB683699",{"EARLY_PHASE1":58494,"PHASE1":58496,"PHASE2":58498,"PHASE3":58506,"PHASE4":58508,"NA":58510},{"trials":58495,"activeCount":97},[],{"trials":58497,"activeCount":97},[],{"trials":58499,"activeCount":97},[58500],{"nctId":58501,"briefTitle":58502,"status":155,"phases":58503,"primaryCompletion":8963,"completion":8963,"start":2823,"enrollment":24418,"conditions":58504,"interventions":58505},"NCT00097331","Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis",[86],[39994],[58492],{"trials":58507,"activeCount":97},[],{"trials":58509,"activeCount":97},[],{"trials":58511,"activeCount":97},[],{"intervention":9894,"totalTrials":417,"cells":58513},{"EARLY_PHASE1":58514,"PHASE1":58516,"PHASE2":58518,"PHASE3":58524,"PHASE4":58526,"NA":58528},{"trials":58515,"activeCount":97},[],{"trials":58517,"activeCount":97},[],{"trials":58519,"activeCount":97},[58520],{"nctId":9886,"briefTitle":9887,"status":155,"phases":58521,"primaryCompletion":9889,"completion":9890,"start":9891,"enrollment":5034,"conditions":58522,"interventions":58523},[86],[21],[9883,9884,9894,9828],{"trials":58525,"activeCount":97},[],{"trials":58527,"activeCount":97},[],{"trials":58529,"activeCount":97},[],{"intervention":58531,"totalTrials":417,"cells":58532},"FP\u002FSAL 250\u002F50mcg BID",{"EARLY_PHASE1":58533,"PHASE1":58535,"PHASE2":58537,"PHASE3":58548,"PHASE4":58550,"NA":58552},{"trials":58534,"activeCount":97},[],{"trials":58536,"activeCount":97},[],{"trials":58538,"activeCount":97},[58539],{"nctId":58540,"briefTitle":58541,"status":155,"phases":58542,"primaryCompletion":2394,"completion":2394,"start":2344,"enrollment":7840,"conditions":58543,"interventions":58544},"NCT01248975","Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid\u002FLong Acting Beta Agonist Combination Treatment for Asthma",[86],[18],[58531,58545,58546,58547],"GSK2190915 200mg QD","GSK2190915 100mg QD","Montelukast 10mg QD",{"trials":58549,"activeCount":97},[],{"trials":58551,"activeCount":97},[],{"trials":58553,"activeCount":97},[],{"intervention":58545,"totalTrials":417,"cells":58555},{"EARLY_PHASE1":58556,"PHASE1":58558,"PHASE2":58560,"PHASE3":58566,"PHASE4":58568,"NA":58570},{"trials":58557,"activeCount":97},[],{"trials":58559,"activeCount":97},[],{"trials":58561,"activeCount":97},[58562],{"nctId":58540,"briefTitle":58541,"status":155,"phases":58563,"primaryCompletion":2394,"completion":2394,"start":2344,"enrollment":7840,"conditions":58564,"interventions":58565},[86],[18],[58531,58545,58546,58547],{"trials":58567,"activeCount":97},[],{"trials":58569,"activeCount":97},[],{"trials":58571,"activeCount":97},[],{"intervention":58546,"totalTrials":417,"cells":58573},{"EARLY_PHASE1":58574,"PHASE1":58576,"PHASE2":58578,"PHASE3":58584,"PHASE4":58586,"NA":58588},{"trials":58575,"activeCount":97},[],{"trials":58577,"activeCount":97},[],{"trials":58579,"activeCount":97},[58580],{"nctId":58540,"briefTitle":58541,"status":155,"phases":58581,"primaryCompletion":2394,"completion":2394,"start":2344,"enrollment":7840,"conditions":58582,"interventions":58583},[86],[18],[58531,58545,58546,58547],{"trials":58585,"activeCount":97},[],{"trials":58587,"activeCount":97},[],{"trials":58589,"activeCount":97},[],{"intervention":58547,"totalTrials":417,"cells":58591},{"EARLY_PHASE1":58592,"PHASE1":58594,"PHASE2":58596,"PHASE3":58602,"PHASE4":58604,"NA":58606},{"trials":58593,"activeCount":97},[],{"trials":58595,"activeCount":97},[],{"trials":58597,"activeCount":97},[58598],{"nctId":58540,"briefTitle":58541,"status":155,"phases":58599,"primaryCompletion":2394,"completion":2394,"start":2344,"enrollment":7840,"conditions":58600,"interventions":58601},[86],[18],[58531,58545,58546,58547],{"trials":58603,"activeCount":97},[],{"trials":58605,"activeCount":97},[],{"trials":58607,"activeCount":97},[],{"intervention":743,"totalTrials":417,"cells":58609},{"EARLY_PHASE1":58610,"PHASE1":58612,"PHASE2":58614,"PHASE3":58620,"PHASE4":58622,"NA":58624},{"trials":58611,"activeCount":97},[],{"trials":58613,"activeCount":97},[],{"trials":58615,"activeCount":97},[58616],{"nctId":734,"briefTitle":735,"status":155,"phases":58617,"primaryCompletion":737,"completion":737,"start":738,"enrollment":739,"conditions":58618,"interventions":58619},[86],[741],[694,743],{"trials":58621,"activeCount":97},[],{"trials":58623,"activeCount":97},[],{"trials":58625,"activeCount":97},[],{"intervention":58627,"totalTrials":417,"cells":58628},"GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A",{"EARLY_PHASE1":58629,"PHASE1":58631,"PHASE2":58633,"PHASE3":58642,"PHASE4":58644,"NA":58646},{"trials":58630,"activeCount":97},[],{"trials":58632,"activeCount":97},[],{"trials":58634,"activeCount":97},[58635],{"nctId":58636,"briefTitle":58637,"status":145,"phases":58638,"primaryCompletion":58639,"completion":58639,"start":39145,"enrollment":1517,"conditions":58640,"interventions":58641},"NCT00706238","MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma",[86],"2011-01-19",[325],[58627],{"trials":58643,"activeCount":97},[],{"trials":58645,"activeCount":97},[],{"trials":58647,"activeCount":97},[],{"intervention":27255,"totalTrials":417,"cells":58649},{"EARLY_PHASE1":58650,"PHASE1":58652,"PHASE2":58654,"PHASE3":58660,"PHASE4":58662,"NA":58664},{"trials":58651,"activeCount":97},[],{"trials":58653,"activeCount":97},[],{"trials":58655,"activeCount":97},[58656],{"nctId":27247,"briefTitle":27248,"status":155,"phases":58657,"primaryCompletion":12402,"completion":12402,"start":3059,"enrollment":21052,"conditions":58658,"interventions":58659},[86],[27251,27252],[27254,27255,27256,27257,27258,27259,27260],{"trials":58661,"activeCount":97},[],{"trials":58663,"activeCount":97},[],{"trials":58665,"activeCount":97},[],{"intervention":27256,"totalTrials":417,"cells":58667},{"EARLY_PHASE1":58668,"PHASE1":58670,"PHASE2":58672,"PHASE3":58678,"PHASE4":58680,"NA":58682},{"trials":58669,"activeCount":97},[],{"trials":58671,"activeCount":97},[],{"trials":58673,"activeCount":97},[58674],{"nctId":27247,"briefTitle":27248,"status":155,"phases":58675,"primaryCompletion":12402,"completion":12402,"start":3059,"enrollment":21052,"conditions":58676,"interventions":58677},[86],[27251,27252],[27254,27255,27256,27257,27258,27259,27260],{"trials":58679,"activeCount":97},[],{"trials":58681,"activeCount":97},[],{"trials":58683,"activeCount":97},[],{"intervention":27257,"totalTrials":417,"cells":58685},{"EARLY_PHASE1":58686,"PHASE1":58688,"PHASE2":58690,"PHASE3":58696,"PHASE4":58698,"NA":58700},{"trials":58687,"activeCount":97},[],{"trials":58689,"activeCount":97},[],{"trials":58691,"activeCount":97},[58692],{"nctId":27247,"briefTitle":27248,"status":155,"phases":58693,"primaryCompletion":12402,"completion":12402,"start":3059,"enrollment":21052,"conditions":58694,"interventions":58695},[86],[27251,27252],[27254,27255,27256,27257,27258,27259,27260],{"trials":58697,"activeCount":97},[],{"trials":58699,"activeCount":97},[],{"trials":58701,"activeCount":97},[],{"intervention":27258,"totalTrials":417,"cells":58703},{"EARLY_PHASE1":58704,"PHASE1":58706,"PHASE2":58708,"PHASE3":58714,"PHASE4":58716,"NA":58718},{"trials":58705,"activeCount":97},[],{"trials":58707,"activeCount":97},[],{"trials":58709,"activeCount":97},[58710],{"nctId":27247,"briefTitle":27248,"status":155,"phases":58711,"primaryCompletion":12402,"completion":12402,"start":3059,"enrollment":21052,"conditions":58712,"interventions":58713},[86],[27251,27252],[27254,27255,27256,27257,27258,27259,27260],{"trials":58715,"activeCount":97},[],{"trials":58717,"activeCount":97},[],{"trials":58719,"activeCount":97},[],{"intervention":27259,"totalTrials":417,"cells":58721},{"EARLY_PHASE1":58722,"PHASE1":58724,"PHASE2":58726,"PHASE3":58732,"PHASE4":58734,"NA":58736},{"trials":58723,"activeCount":97},[],{"trials":58725,"activeCount":97},[],{"trials":58727,"activeCount":97},[58728],{"nctId":27247,"briefTitle":27248,"status":155,"phases":58729,"primaryCompletion":12402,"completion":12402,"start":3059,"enrollment":21052,"conditions":58730,"interventions":58731},[86],[27251,27252],[27254,27255,27256,27257,27258,27259,27260],{"trials":58733,"activeCount":97},[],{"trials":58735,"activeCount":97},[],{"trials":58737,"activeCount":97},[],{"intervention":58739,"totalTrials":417,"cells":58740},"SB-497115-GR",{"EARLY_PHASE1":58741,"PHASE1":58743,"PHASE2":58745,"PHASE3":58753,"PHASE4":58755,"NA":58757},{"trials":58742,"activeCount":97},[],{"trials":58744,"activeCount":97},[],{"trials":58746,"activeCount":97},[58747],{"nctId":58748,"briefTitle":58749,"status":155,"phases":58750,"primaryCompletion":11043,"completion":2882,"start":8037,"enrollment":6369,"conditions":58751,"interventions":58752},"NCT01636778","Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients",[86],[42684],[58739],{"trials":58754,"activeCount":97},[],{"trials":58756,"activeCount":97},[],{"trials":58758,"activeCount":97},[],{"intervention":58760,"totalTrials":417,"cells":58761},"GSK364735",{"EARLY_PHASE1":58762,"PHASE1":58764,"PHASE2":58766,"PHASE3":58775,"PHASE4":58777,"NA":58779},{"trials":58763,"activeCount":97},[],{"trials":58765,"activeCount":97},[],{"trials":58767,"activeCount":97},[58768],{"nctId":58769,"briefTitle":58770,"status":155,"phases":58771,"completion":4756,"start":4843,"enrollment":255,"conditions":58772,"interventions":58774},"NCT00398125","Monotherapy Versus Placebo Over 10 Days in Integrase Naive HIV-1 Infected Adults",[86],[9343,58773],"HIV-1 Infection",[58760],{"trials":58776,"activeCount":97},[],{"trials":58778,"activeCount":97},[],{"trials":58780,"activeCount":97},[],{"intervention":10559,"totalTrials":417,"cells":58782},{"EARLY_PHASE1":58783,"PHASE1":58785,"PHASE2":58787,"PHASE3":58793,"PHASE4":58795,"NA":58797},{"trials":58784,"activeCount":97},[],{"trials":58786,"activeCount":97},[],{"trials":58788,"activeCount":97},[58789],{"nctId":10549,"briefTitle":10550,"status":155,"phases":58790,"primaryCompletion":10552,"completion":10553,"start":10554,"enrollment":10555,"conditions":58791,"interventions":58792},[86],[3717,2484,2485,2486],[10558,10559,10526,10547],{"trials":58794,"activeCount":97},[],{"trials":58796,"activeCount":97},[],{"trials":58798,"activeCount":97},[],{"intervention":45449,"totalTrials":417,"cells":58800},{"EARLY_PHASE1":58801,"PHASE1":58803,"PHASE2":58805,"PHASE3":58811,"PHASE4":58813,"NA":58815},{"trials":58802,"activeCount":97},[],{"trials":58804,"activeCount":97},[],{"trials":58806,"activeCount":97},[58807],{"nctId":45442,"briefTitle":45443,"status":155,"phases":58808,"primaryCompletion":45445,"completion":45445,"start":811,"enrollment":45446,"conditions":58809,"interventions":58810},[86],[3298],[45449,45450,45451,45452,45423,45437,45453,45449,45450,45423,45453],{"trials":58812,"activeCount":97},[],{"trials":58814,"activeCount":97},[],{"trials":58816,"activeCount":97},[],{"intervention":45450,"totalTrials":417,"cells":58818},{"EARLY_PHASE1":58819,"PHASE1":58821,"PHASE2":58823,"PHASE3":58829,"PHASE4":58831,"NA":58833},{"trials":58820,"activeCount":97},[],{"trials":58822,"activeCount":97},[],{"trials":58824,"activeCount":97},[58825],{"nctId":45442,"briefTitle":45443,"status":155,"phases":58826,"primaryCompletion":45445,"completion":45445,"start":811,"enrollment":45446,"conditions":58827,"interventions":58828},[86],[3298],[45449,45450,45451,45452,45423,45437,45453,45449,45450,45423,45453],{"trials":58830,"activeCount":97},[],{"trials":58832,"activeCount":97},[],{"trials":58834,"activeCount":97},[],{"intervention":45451,"totalTrials":417,"cells":58836},{"EARLY_PHASE1":58837,"PHASE1":58839,"PHASE2":58841,"PHASE3":58847,"PHASE4":58849,"NA":58851},{"trials":58838,"activeCount":97},[],{"trials":58840,"activeCount":97},[],{"trials":58842,"activeCount":97},[58843],{"nctId":45442,"briefTitle":45443,"status":155,"phases":58844,"primaryCompletion":45445,"completion":45445,"start":811,"enrollment":45446,"conditions":58845,"interventions":58846},[86],[3298],[45449,45450,45451,45452,45423,45437,45453,45449,45450,45423,45453],{"trials":58848,"activeCount":97},[],{"trials":58850,"activeCount":97},[],{"trials":58852,"activeCount":97},[],{"intervention":45452,"totalTrials":417,"cells":58854},{"EARLY_PHASE1":58855,"PHASE1":58857,"PHASE2":58859,"PHASE3":58865,"PHASE4":58867,"NA":58869},{"trials":58856,"activeCount":97},[],{"trials":58858,"activeCount":97},[],{"trials":58860,"activeCount":97},[58861],{"nctId":45442,"briefTitle":45443,"status":155,"phases":58862,"primaryCompletion":45445,"completion":45445,"start":811,"enrollment":45446,"conditions":58863,"interventions":58864},[86],[3298],[45449,45450,45451,45452,45423,45437,45453,45449,45450,45423,45453],{"trials":58866,"activeCount":97},[],{"trials":58868,"activeCount":97},[],{"trials":58870,"activeCount":97},[],{"intervention":45453,"totalTrials":417,"cells":58872},{"EARLY_PHASE1":58873,"PHASE1":58875,"PHASE2":58877,"PHASE3":58883,"PHASE4":58885,"NA":58887},{"trials":58874,"activeCount":97},[],{"trials":58876,"activeCount":97},[],{"trials":58878,"activeCount":97},[58879],{"nctId":45442,"briefTitle":45443,"status":155,"phases":58880,"primaryCompletion":45445,"completion":45445,"start":811,"enrollment":45446,"conditions":58881,"interventions":58882},[86],[3298],[45449,45450,45451,45452,45423,45437,45453,45449,45450,45423,45453],{"trials":58884,"activeCount":97},[],{"trials":58886,"activeCount":97},[],{"trials":58888,"activeCount":97},[],{"intervention":58890,"totalTrials":417,"cells":58891},"SB-424323",{"EARLY_PHASE1":58892,"PHASE1":58894,"PHASE2":58896,"PHASE3":58905,"PHASE4":58907,"NA":58909},{"trials":58893,"activeCount":97},[],{"trials":58895,"activeCount":97},[],{"trials":58897,"activeCount":97},[58898],{"nctId":58899,"briefTitle":58900,"status":155,"phases":58901,"primaryCompletion":8750,"completion":8750,"start":10003,"enrollment":23431,"conditions":58902,"interventions":58904},"NCT00041509","ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST)",[86],[58903],"Arthroplasty",[58890],{"trials":58906,"activeCount":97},[],{"trials":58908,"activeCount":97},[],{"trials":58910,"activeCount":97},[],{"intervention":58912,"totalTrials":417,"cells":58913},"Tucaresol tablets 25 mg",{"EARLY_PHASE1":58914,"PHASE1":58916,"PHASE2":58918,"PHASE3":58926,"PHASE4":58928,"NA":58930},{"trials":58915,"activeCount":97},[],{"trials":58917,"activeCount":97},[],{"trials":58919,"activeCount":97},[58920],{"nctId":58921,"briefTitle":58922,"status":155,"phases":58923,"start":11097,"enrollment":6369,"conditions":58924,"interventions":58925},"NCT00343941","Tucaresol As Add-On To HAART (Highly Active Antiretroviral Therapy) In Chronic HIV-1 Infected Adults",[86],[10662],[58912],{"trials":58927,"activeCount":97},[],{"trials":58929,"activeCount":97},[],{"trials":58931,"activeCount":97},[],{"intervention":22797,"totalTrials":417,"cells":58933},{"EARLY_PHASE1":58934,"PHASE1":58936,"PHASE2":58938,"PHASE3":58944,"PHASE4":58946,"NA":58948},{"trials":58935,"activeCount":97},[],{"trials":58937,"activeCount":97},[],{"trials":58939,"activeCount":97},[58940],{"nctId":22790,"briefTitle":22791,"status":155,"phases":58941,"primaryCompletion":22793,"completion":11940,"start":22794,"enrollment":414,"conditions":58942,"interventions":58943},[86],[4759],[4762,22797,12324],{"trials":58945,"activeCount":97},[],{"trials":58947,"activeCount":97},[],{"trials":58949,"activeCount":97},[],{"intervention":58951,"totalTrials":417,"cells":58952},"RSV (GSK3389245A) low dose formulation vaccine",{"EARLY_PHASE1":58953,"PHASE1":58955,"PHASE2":58957,"PHASE3":58969,"PHASE4":58971,"NA":58973},{"trials":58954,"activeCount":97},[],{"trials":58956,"activeCount":97},[],{"trials":58958,"activeCount":97},[58959],{"nctId":58960,"briefTitle":58961,"status":155,"phases":58962,"primaryCompletion":58963,"completion":58964,"start":39815,"enrollment":177,"conditions":58965,"interventions":58966},"NCT02927873","A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants",[85,86],"2019-02-19","2020-11-26",[2620],[58951,58967,58968],"RSV (GSK3389245A) middle dose formulation vaccine","RSV (GSK3389245A) high dose formulation vaccine",{"trials":58970,"activeCount":97},[],{"trials":58972,"activeCount":97},[],{"trials":58974,"activeCount":97},[],{"intervention":58967,"totalTrials":417,"cells":58976},{"EARLY_PHASE1":58977,"PHASE1":58979,"PHASE2":58981,"PHASE3":58987,"PHASE4":58989,"NA":58991},{"trials":58978,"activeCount":97},[],{"trials":58980,"activeCount":97},[],{"trials":58982,"activeCount":97},[58983],{"nctId":58960,"briefTitle":58961,"status":155,"phases":58984,"primaryCompletion":58963,"completion":58964,"start":39815,"enrollment":177,"conditions":58985,"interventions":58986},[85,86],[2620],[58951,58967,58968],{"trials":58988,"activeCount":97},[],{"trials":58990,"activeCount":97},[],{"trials":58992,"activeCount":97},[],{"intervention":58968,"totalTrials":417,"cells":58994},{"EARLY_PHASE1":58995,"PHASE1":58997,"PHASE2":58999,"PHASE3":59005,"PHASE4":59007,"NA":59009},{"trials":58996,"activeCount":97},[],{"trials":58998,"activeCount":97},[],{"trials":59000,"activeCount":97},[59001],{"nctId":58960,"briefTitle":58961,"status":155,"phases":59002,"primaryCompletion":58963,"completion":58964,"start":39815,"enrollment":177,"conditions":59003,"interventions":59004},[85,86],[2620],[58951,58967,58968],{"trials":59006,"activeCount":97},[],{"trials":59008,"activeCount":97},[],{"trials":59010,"activeCount":97},[],{"intervention":9185,"totalTrials":417,"cells":59012},{"EARLY_PHASE1":59013,"PHASE1":59015,"PHASE2":59017,"PHASE3":59023,"PHASE4":59025,"NA":59027},{"trials":59014,"activeCount":97},[],{"trials":59016,"activeCount":97},[],{"trials":59018,"activeCount":97},[59019],{"nctId":9179,"briefTitle":9180,"status":155,"phases":59020,"primaryCompletion":2344,"completion":2344,"start":2335,"enrollment":1196,"conditions":59021,"interventions":59022},[86],[9183],[9185,4763],{"trials":59024,"activeCount":97},[],{"trials":59026,"activeCount":97},[],{"trials":59028,"activeCount":97},[],{"intervention":59030,"totalTrials":417,"cells":59031},"GSK Biologicals' influenza vaccine GSK1557482A",{"EARLY_PHASE1":59032,"PHASE1":59034,"PHASE2":59036,"PHASE3":59046,"PHASE4":59048,"NA":59050},{"trials":59033,"activeCount":97},[],{"trials":59035,"activeCount":97},[],{"trials":59037,"activeCount":97},[59038],{"nctId":59039,"briefTitle":59040,"status":155,"phases":59041,"primaryCompletion":59042,"completion":59042,"start":18494,"enrollment":26758,"conditions":59043,"interventions":59044},"NCT00778895","Clinical Study in Children, 6 Months to 3 Years of Age, to Assess Two Dose Levels of an Experimental Flu Vaccine, Using a Licensed Influenza Virus Vaccine, Vaxigrip® as the Control",[86],"2009-08-19",[21],[59030,59045],"Vaxigrip",{"trials":59047,"activeCount":97},[],{"trials":59049,"activeCount":97},[],{"trials":59051,"activeCount":97},[],{"intervention":59045,"totalTrials":417,"cells":59053},{"EARLY_PHASE1":59054,"PHASE1":59056,"PHASE2":59058,"PHASE3":59064,"PHASE4":59066,"NA":59068},{"trials":59055,"activeCount":97},[],{"trials":59057,"activeCount":97},[],{"trials":59059,"activeCount":97},[59060],{"nctId":59039,"briefTitle":59040,"status":155,"phases":59061,"primaryCompletion":59042,"completion":59042,"start":18494,"enrollment":26758,"conditions":59062,"interventions":59063},[86],[21],[59030,59045],{"trials":59065,"activeCount":97},[],{"trials":59067,"activeCount":97},[],{"trials":59069,"activeCount":97},[],{"intervention":59071,"totalTrials":417,"cells":59072},"DEN 2.5 mg",{"EARLY_PHASE1":59073,"PHASE1":59075,"PHASE2":59077,"PHASE3":59091,"PHASE4":59093,"NA":59095},{"trials":59074,"activeCount":97},[],{"trials":59076,"activeCount":97},[],{"trials":59078,"activeCount":97},[59079],{"nctId":59080,"briefTitle":59081,"status":155,"phases":59082,"primaryCompletion":9754,"completion":59083,"start":59084,"enrollment":30619,"conditions":59085,"interventions":59086},"NCT00111800","A New Oral Treatment For Type II Diabetes Mellitus",[86],"2006-07-21","2005-04-28",[27],[59071,59087,59088,59089,59090],"DEN 7.5 mg","DEN 15 mg","DEN 30 mg","DEN 45 mg",{"trials":59092,"activeCount":97},[],{"trials":59094,"activeCount":97},[],{"trials":59096,"activeCount":97},[],{"intervention":59087,"totalTrials":417,"cells":59098},{"EARLY_PHASE1":59099,"PHASE1":59101,"PHASE2":59103,"PHASE3":59109,"PHASE4":59111,"NA":59113},{"trials":59100,"activeCount":97},[],{"trials":59102,"activeCount":97},[],{"trials":59104,"activeCount":97},[59105],{"nctId":59080,"briefTitle":59081,"status":155,"phases":59106,"primaryCompletion":9754,"completion":59083,"start":59084,"enrollment":30619,"conditions":59107,"interventions":59108},[86],[27],[59071,59087,59088,59089,59090],{"trials":59110,"activeCount":97},[],{"trials":59112,"activeCount":97},[],{"trials":59114,"activeCount":97},[],{"intervention":59088,"totalTrials":417,"cells":59116},{"EARLY_PHASE1":59117,"PHASE1":59119,"PHASE2":59121,"PHASE3":59127,"PHASE4":59129,"NA":59131},{"trials":59118,"activeCount":97},[],{"trials":59120,"activeCount":97},[],{"trials":59122,"activeCount":97},[59123],{"nctId":59080,"briefTitle":59081,"status":155,"phases":59124,"primaryCompletion":9754,"completion":59083,"start":59084,"enrollment":30619,"conditions":59125,"interventions":59126},[86],[27],[59071,59087,59088,59089,59090],{"trials":59128,"activeCount":97},[],{"trials":59130,"activeCount":97},[],{"trials":59132,"activeCount":97},[],{"intervention":59089,"totalTrials":417,"cells":59134},{"EARLY_PHASE1":59135,"PHASE1":59137,"PHASE2":59139,"PHASE3":59145,"PHASE4":59147,"NA":59149},{"trials":59136,"activeCount":97},[],{"trials":59138,"activeCount":97},[],{"trials":59140,"activeCount":97},[59141],{"nctId":59080,"briefTitle":59081,"status":155,"phases":59142,"primaryCompletion":9754,"completion":59083,"start":59084,"enrollment":30619,"conditions":59143,"interventions":59144},[86],[27],[59071,59087,59088,59089,59090],{"trials":59146,"activeCount":97},[],{"trials":59148,"activeCount":97},[],{"trials":59150,"activeCount":97},[],{"intervention":59090,"totalTrials":417,"cells":59152},{"EARLY_PHASE1":59153,"PHASE1":59155,"PHASE2":59157,"PHASE3":59163,"PHASE4":59165,"NA":59167},{"trials":59154,"activeCount":97},[],{"trials":59156,"activeCount":97},[],{"trials":59158,"activeCount":97},[59159],{"nctId":59080,"briefTitle":59081,"status":155,"phases":59160,"primaryCompletion":9754,"completion":59083,"start":59084,"enrollment":30619,"conditions":59161,"interventions":59162},[86],[27],[59071,59087,59088,59089,59090],{"trials":59164,"activeCount":97},[],{"trials":59166,"activeCount":97},[],{"trials":59168,"activeCount":97},[],{"intervention":59170,"totalTrials":417,"cells":59171},"intravenous ondansetron",{"EARLY_PHASE1":59172,"PHASE1":59174,"PHASE2":59176,"PHASE3":59185,"PHASE4":59187,"NA":59189},{"trials":59173,"activeCount":97},[],{"trials":59175,"activeCount":97},[],{"trials":59177,"activeCount":97},[59178],{"nctId":59179,"briefTitle":59180,"status":155,"phases":59181,"primaryCompletion":10395,"completion":10395,"start":8478,"enrollment":59182,"conditions":59183,"interventions":59184},"NCT00108095","A Study To Evaluate An NK-1 Antiemetic For The Prevention Of Post Operative Nausea And Vomiting",[86],701,[21615,21614],[59170],{"trials":59186,"activeCount":97},[],{"trials":59188,"activeCount":97},[],{"trials":59190,"activeCount":97},[],{"intervention":59192,"totalTrials":417,"cells":59193},"INTRAVENOUS GSK679586",{"EARLY_PHASE1":59194,"PHASE1":59196,"PHASE2":59198,"PHASE3":59210,"PHASE4":59212,"NA":59214},{"trials":59195,"activeCount":97},[],{"trials":59197,"activeCount":97},[],{"trials":59199,"activeCount":97},[59200],{"nctId":59201,"briefTitle":59202,"status":155,"phases":59203,"primaryCompletion":59204,"completion":59204,"start":59205,"enrollment":13317,"conditions":59206,"interventions":59207},"NCT00843193","Efficacy and Safety Study of GSK679586 in Patients With Severe Asthma",[86],"2010-07-25","2008-12-09",[18],[59192,59208,59209],"INTRAVENOUS PLACEBO","FLUTICASONE PROPIONATE",{"trials":59211,"activeCount":97},[],{"trials":59213,"activeCount":97},[],{"trials":59215,"activeCount":97},[],{"intervention":59208,"totalTrials":417,"cells":59217},{"EARLY_PHASE1":59218,"PHASE1":59220,"PHASE2":59222,"PHASE3":59228,"PHASE4":59230,"NA":59232},{"trials":59219,"activeCount":97},[],{"trials":59221,"activeCount":97},[],{"trials":59223,"activeCount":97},[59224],{"nctId":59201,"briefTitle":59202,"status":155,"phases":59225,"primaryCompletion":59204,"completion":59204,"start":59205,"enrollment":13317,"conditions":59226,"interventions":59227},[86],[18],[59192,59208,59209],{"trials":59229,"activeCount":97},[],{"trials":59231,"activeCount":97},[],{"trials":59233,"activeCount":97},[],{"intervention":59235,"totalTrials":417,"cells":59236},"pazopanib and pemetrexed",{"EARLY_PHASE1":59237,"PHASE1":59239,"PHASE2":59241,"PHASE3":59250,"PHASE4":59252,"NA":59254},{"trials":59238,"activeCount":97},[],{"trials":59240,"activeCount":97},[],{"trials":59242,"activeCount":97},[59243],{"nctId":59244,"briefTitle":59245,"status":155,"phases":59246,"primaryCompletion":8883,"completion":8883,"start":2441,"enrollment":177,"conditions":59247,"interventions":59248},"NCT00871403","Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer",[86],[267],[59235,59249],"pemetrexed and cisplatin",{"trials":59251,"activeCount":97},[],{"trials":59253,"activeCount":97},[],{"trials":59255,"activeCount":97},[],{"intervention":59249,"totalTrials":417,"cells":59257},{"EARLY_PHASE1":59258,"PHASE1":59260,"PHASE2":59262,"PHASE3":59268,"PHASE4":59270,"NA":59272},{"trials":59259,"activeCount":97},[],{"trials":59261,"activeCount":97},[],{"trials":59263,"activeCount":97},[59264],{"nctId":59244,"briefTitle":59245,"status":155,"phases":59265,"primaryCompletion":8883,"completion":8883,"start":2441,"enrollment":177,"conditions":59266,"interventions":59267},[86],[267],[59235,59249],{"trials":59269,"activeCount":97},[],{"trials":59271,"activeCount":97},[],{"trials":59273,"activeCount":97},[],{"intervention":59275,"totalTrials":417,"cells":59276},"GSK Malaria vaccine 257049",{"EARLY_PHASE1":59277,"PHASE1":59279,"PHASE2":59281,"PHASE3":59290,"PHASE4":59292,"NA":59294},{"trials":59278,"activeCount":97},[],{"trials":59280,"activeCount":97},[],{"trials":59282,"activeCount":97},[59283],{"nctId":59284,"briefTitle":59285,"status":155,"phases":59286,"primaryCompletion":39436,"completion":6750,"start":59287,"enrollment":710,"conditions":59288,"interventions":59289},"NCT00443131","Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines",[86],"2007-03-26",[3287],[59275],{"trials":59291,"activeCount":97},[],{"trials":59293,"activeCount":97},[],{"trials":59295,"activeCount":97},[],{"intervention":39825,"totalTrials":417,"cells":59297},{"EARLY_PHASE1":59298,"PHASE1":59300,"PHASE2":59302,"PHASE3":59308,"PHASE4":59310,"NA":59312},{"trials":59299,"activeCount":97},[],{"trials":59301,"activeCount":97},[],{"trials":59303,"activeCount":97},[59304],{"nctId":39819,"briefTitle":39820,"status":155,"phases":59305,"primaryCompletion":15085,"completion":15085,"start":19703,"enrollment":2836,"conditions":59306,"interventions":59307},[86],[39823],[9060,39825],{"trials":59309,"activeCount":97},[],{"trials":59311,"activeCount":97},[],{"trials":59313,"activeCount":97},[],{"intervention":9325,"totalTrials":1459,"cells":59315},{"EARLY_PHASE1":59316,"PHASE1":59318,"PHASE2":59396,"PHASE3":59398,"PHASE4":59400,"NA":59402},{"trials":59317,"activeCount":97},[],{"trials":59319,"activeCount":97},[59320,59328,59332,59336,59344,59348,59356,59360,59368,59372,59376,59388],{"nctId":59321,"briefTitle":59322,"status":155,"phases":59323,"primaryCompletion":40295,"completion":40295,"start":2665,"enrollment":1117,"conditions":59324,"interventions":59325},"NCT00404378","Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769]",[85],[1337],[38856,59326,59327],"casopitant 100 mg","Casopitant 50 mg",{"nctId":39627,"briefTitle":39628,"status":155,"phases":59329,"primaryCompletion":23420,"completion":23420,"start":23568,"enrollment":628,"conditions":59330,"interventions":59331},[85],[39624],[39613,9325],{"nctId":38851,"briefTitle":38852,"status":155,"phases":59333,"start":8406,"enrollment":2836,"conditions":59334,"interventions":59335},[85],[9036,27],[38856,9030],{"nctId":59337,"briefTitle":59338,"status":155,"phases":59339,"primaryCompletion":7531,"completion":7531,"start":59340,"enrollment":1459,"conditions":59341,"interventions":59342},"NCT00975936","Phase 0 Microdose Study",[85],"2009-09-21",[39897],[59343,9325],"[14C]-GSK706769",{"nctId":39746,"briefTitle":39747,"status":155,"phases":59345,"primaryCompletion":2336,"completion":2336,"start":4756,"enrollment":1117,"conditions":59346,"interventions":59347},[85],[12138],[39751,9325],{"nctId":59349,"briefTitle":59350,"status":155,"phases":59351,"primaryCompletion":59352,"completion":59352,"start":59353,"enrollment":710,"conditions":59354,"interventions":59355},"NCT00411866","Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812",[85],"2007-10-10","2006-10-13",[11346],[42862,9325],{"nctId":42433,"briefTitle":42434,"status":155,"phases":59357,"primaryCompletion":39677,"completion":39677,"start":11960,"enrollment":6503,"conditions":59358,"interventions":59359},[85],[36],[42422,9325,18007,42438,42439],{"nctId":59361,"briefTitle":59362,"status":155,"phases":59363,"primaryCompletion":59364,"completion":59364,"start":9452,"enrollment":1634,"conditions":59365,"interventions":59366},"NCT01165125","A Drug Interaction Study With Fluticasone Furoate\u002FGW642444 Inhalation Powder and Ketoconazole",[85],"2010-08-28",[18],[59367,38856,38856],"FF \u002F GW642444",{"nctId":39956,"briefTitle":39957,"status":155,"phases":59369,"primaryCompletion":39959,"completion":39959,"start":39960,"enrollment":2836,"conditions":59370,"interventions":59371},[85],[39962],[39949,38856],{"nctId":9313,"briefTitle":9314,"status":155,"phases":59373,"primaryCompletion":9316,"completion":9316,"start":9317,"enrollment":31,"conditions":59374,"interventions":59375},[85],[9319],[9321,9093,9273,9322,9323,6488,9324,9325,9326,9327,9093],{"nctId":59377,"briefTitle":59378,"status":155,"phases":59379,"primaryCompletion":59380,"completion":59380,"start":59381,"enrollment":4121,"conditions":59382,"interventions":59383},"NCT01627587","A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole",[85],"2012-02-09","2011-12-12",[22921],[59384,9325,59385,59386,59387],"GSK221149 750 mg","GSK221149 100 mg","GSK221149 750 mg Fasted","GSK221149 750 mg + Food",{"nctId":59389,"briefTitle":59390,"status":155,"phases":59391,"primaryCompletion":19425,"completion":19425,"start":59392,"enrollment":3672,"conditions":59393,"interventions":59394},"NCT00460707","A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults",[85],"2007-04-16",[1337],[59395,9325,59327],"Casopitant 150 mg",{"trials":59397,"activeCount":97},[],{"trials":59399,"activeCount":97},[],{"trials":59401,"activeCount":97},[],{"trials":59403,"activeCount":97},[],{"intervention":8022,"totalTrials":750,"cells":59405},{"EARLY_PHASE1":59406,"PHASE1":59408,"PHASE2":59459,"PHASE3":59461,"PHASE4":59463,"NA":59465},{"trials":59407,"activeCount":97},[],{"trials":59409,"activeCount":97},[59410,59418,59422,59426,59430,59436,59440,59444,59451,59455],{"nctId":59411,"briefTitle":59412,"status":500,"phases":59413,"primaryCompletion":34933,"completion":34933,"start":8860,"enrollment":97,"conditions":59414,"interventions":59415},"NCT01803399","A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers",[85],[6484],[59416,59417,8022],"GSK1322322 1200 mg","GSK1322322 3000 mg",{"nctId":43566,"briefTitle":43567,"status":500,"phases":59419,"primaryCompletion":3391,"completion":3391,"start":6351,"enrollment":97,"conditions":59420,"interventions":59421},[85],[6484],[43571,40743,8022],{"nctId":8013,"briefTitle":8014,"status":155,"phases":59423,"primaryCompletion":8016,"completion":8016,"start":8017,"enrollment":8018,"conditions":59424,"interventions":59425},[85],[27],[8021,8022],{"nctId":40076,"briefTitle":40077,"status":155,"phases":59427,"primaryCompletion":40079,"completion":40079,"start":18328,"enrollment":904,"conditions":59428,"interventions":59429},[85],[11827],[40069,8022,40082,40083],{"nctId":59431,"briefTitle":59432,"status":155,"phases":59433,"primaryCompletion":24688,"completion":24688,"start":22483,"enrollment":660,"conditions":59434,"interventions":59435},"NCT00861029","VEG111485: A QTc Study of Pazopanib",[85],[1877],[2273,8022],{"nctId":18366,"briefTitle":18367,"status":155,"phases":59437,"primaryCompletion":18369,"completion":18369,"start":18370,"enrollment":414,"conditions":59438,"interventions":59439},[85],[15],[8022,18373,18345,18374],{"nctId":20319,"briefTitle":20320,"status":155,"phases":59441,"primaryCompletion":18370,"completion":18370,"start":20322,"enrollment":1237,"conditions":59442,"interventions":59443},[85],[1337],[1341,20325],{"nctId":59445,"briefTitle":59446,"status":500,"phases":59447,"primaryCompletion":9159,"completion":9159,"start":2442,"enrollment":97,"conditions":59448,"interventions":59449},"NCT00884533","QTc Study of Rosi XR in Healthy Volunteers",[85],[4644],[59450,8022],"Rosi XR",{"nctId":39354,"briefTitle":39355,"status":155,"phases":59452,"primaryCompletion":39357,"completion":39357,"start":39358,"enrollment":10794,"conditions":59453,"interventions":59454},[85],[14696],[39316,39361,8022,39362],{"nctId":45430,"briefTitle":45431,"status":155,"phases":59456,"primaryCompletion":45433,"completion":45433,"start":19218,"enrollment":45434,"conditions":59457,"interventions":59458},[85],[3298],[45423,45437,45438,20325],{"trials":59460,"activeCount":97},[],{"trials":59462,"activeCount":97},[],{"trials":59464,"activeCount":97},[],{"trials":59466,"activeCount":97},[],{"intervention":39369,"totalTrials":628,"cells":59468},{"EARLY_PHASE1":59469,"PHASE1":59471,"PHASE2":59507,"PHASE3":59509,"PHASE4":59511,"NA":59513},{"trials":59470,"activeCount":97},[],{"trials":59472,"activeCount":97},[59473,59483,59487,59491,59499,59503],{"nctId":59474,"briefTitle":59475,"status":500,"phases":59476,"primaryCompletion":59477,"completion":59477,"start":59478,"enrollment":97,"conditions":59479,"interventions":59480},"NCT02130661","Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers",[85],"2018-01","2017-10",[4644],[59481,59482,39369],"Rilapladib 25 mg","Rilapladib 250 mg",{"nctId":42475,"briefTitle":42476,"status":155,"phases":59484,"primaryCompletion":2392,"completion":2392,"start":11769,"enrollment":6994,"conditions":59485,"interventions":59486},[85],[42472],[42460,39369],{"nctId":44416,"briefTitle":44417,"status":155,"phases":59488,"primaryCompletion":44419,"completion":44419,"start":44420,"enrollment":454,"conditions":59489,"interventions":59490},[85],[15],[44409,39369],{"nctId":59492,"briefTitle":59493,"status":155,"phases":59494,"primaryCompletion":1306,"completion":59495,"start":129,"enrollment":454,"conditions":59496,"interventions":59497},"NCT06597500","A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy Participants",[85],"2024-12-23",[15],[59498,39369],"GSK3923868",{"nctId":42397,"briefTitle":42398,"status":155,"phases":59500,"primaryCompletion":960,"completion":960,"start":42400,"enrollment":2282,"conditions":59501,"interventions":59502},[85],[42402,42403],[42379,42405,39369],{"nctId":39364,"briefTitle":39365,"status":155,"phases":59504,"primaryCompletion":8649,"completion":8649,"start":9578,"enrollment":4121,"conditions":59505,"interventions":59506},[85],[6484],[39316,39316,39369],{"trials":59508,"activeCount":97},[],{"trials":59510,"activeCount":97},[],{"trials":59512,"activeCount":97},[],{"trials":59514,"activeCount":97},[],{"intervention":19303,"totalTrials":628,"cells":59516},{"EARLY_PHASE1":59517,"PHASE1":59519,"PHASE2":59558,"PHASE3":59560,"PHASE4":59562,"NA":59564},{"trials":59518,"activeCount":97},[],{"trials":59520,"activeCount":97},[59521,59530,59534,59540,59546,59552],{"nctId":59522,"briefTitle":59523,"status":155,"phases":59524,"primaryCompletion":2794,"completion":2794,"start":2813,"enrollment":433,"conditions":59525,"interventions":59526},"NCT00858455","A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572",[85],[19301],[59527,59528,59529,19303],"GSK1349572 and MaaloxAdvanced Maximum Strength","GSK1349572 and Maalox Advanced Maximum Strength","GSK1349572 and One A Day",{"nctId":19297,"briefTitle":19298,"status":155,"phases":59531,"primaryCompletion":2442,"completion":2442,"start":3550,"enrollment":1298,"conditions":59532,"interventions":59533},[85],[19301],[19303,19304,19305,10675],{"nctId":59535,"briefTitle":59536,"status":155,"phases":59537,"primaryCompletion":8468,"completion":8468,"start":9133,"enrollment":433,"conditions":59538,"interventions":59539},"NCT00774111","GSK1349572 Drug Interaction Study With Etravirine",[85],[7524],[19303],{"nctId":59541,"briefTitle":59542,"status":155,"phases":59543,"primaryCompletion":1429,"completion":1429,"start":2441,"enrollment":1298,"conditions":59544,"interventions":59545},"NCT00942136","GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study",[85],[19301],[19303,19303,9322],{"nctId":59547,"briefTitle":59548,"status":155,"phases":59549,"primaryCompletion":9737,"completion":9737,"start":3079,"enrollment":454,"conditions":59550,"interventions":59551},"NCT00555035","GSK1349572 First Time in Human Study",[85],[7524],[19303],{"nctId":59553,"briefTitle":59554,"status":155,"phases":59555,"primaryCompletion":8468,"completion":8468,"start":9133,"enrollment":255,"conditions":59556,"interventions":59557},"NCT00774735","GSK1349572 Drug Interaction Study With Protease Inhibitors",[85],[7524,9343],[19303,19303],{"trials":59559,"activeCount":97},[],{"trials":59561,"activeCount":97},[],{"trials":59563,"activeCount":97},[],{"trials":59565,"activeCount":97},[],{"intervention":59567,"totalTrials":1517,"cells":59568},"Marketed paracetamol",{"EARLY_PHASE1":59569,"PHASE1":59571,"PHASE2":59605,"PHASE3":59607,"PHASE4":59609,"NA":59611},{"trials":59570,"activeCount":97},[],{"trials":59572,"activeCount":97},[59573,59580,59586,59592,59599],{"nctId":59574,"briefTitle":59575,"status":155,"phases":59576,"primaryCompletion":7658,"completion":7658,"start":7658,"enrollment":695,"conditions":59577,"interventions":59578},"NCT01540721","Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol® Extend",[85],[7524],[59567,59579],"Experimental paracetamol formulation",{"nctId":59581,"briefTitle":59582,"status":155,"phases":59583,"primaryCompletion":7658,"completion":7658,"start":7658,"enrollment":255,"conditions":59584,"interventions":59585},"NCT01592227","A Study to Compare Two Paracetamol Formulations.",[85],[9153],[59567,59579],{"nctId":59587,"briefTitle":59588,"status":500,"phases":59589,"primaryCompletion":7647,"completion":7647,"start":6352,"enrollment":97,"conditions":59590,"interventions":59591},"NCT01381640","A Study to Compare Two Paracetamol Tablets",[85],[7524],[59567,59579],{"nctId":59593,"briefTitle":59594,"status":155,"phases":59595,"primaryCompletion":7658,"completion":7658,"start":6351,"enrollment":695,"conditions":59596,"interventions":59597},"NCT01476189","A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations",[85],[7524],[59579,59567,59598],"Higher dose marketed paracetamol",{"nctId":59600,"briefTitle":59601,"status":155,"phases":59602,"primaryCompletion":7658,"completion":7658,"start":7658,"enrollment":695,"conditions":59603,"interventions":59604},"NCT01540734","Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®",[85],[7524],[59567,59579],{"trials":59606,"activeCount":97},[],{"trials":59608,"activeCount":97},[],{"trials":59610,"activeCount":97},[],{"trials":59612,"activeCount":97},[],{"intervention":59579,"totalTrials":1517,"cells":59614},{"EARLY_PHASE1":59615,"PHASE1":59617,"PHASE2":59639,"PHASE3":59641,"PHASE4":59643,"NA":59645},{"trials":59616,"activeCount":97},[],{"trials":59618,"activeCount":97},[59619,59623,59627,59631,59635],{"nctId":59574,"briefTitle":59575,"status":155,"phases":59620,"primaryCompletion":7658,"completion":7658,"start":7658,"enrollment":695,"conditions":59621,"interventions":59622},[85],[7524],[59567,59579],{"nctId":59581,"briefTitle":59582,"status":155,"phases":59624,"primaryCompletion":7658,"completion":7658,"start":7658,"enrollment":255,"conditions":59625,"interventions":59626},[85],[9153],[59567,59579],{"nctId":59587,"briefTitle":59588,"status":500,"phases":59628,"primaryCompletion":7647,"completion":7647,"start":6352,"enrollment":97,"conditions":59629,"interventions":59630},[85],[7524],[59567,59579],{"nctId":59593,"briefTitle":59594,"status":155,"phases":59632,"primaryCompletion":7658,"completion":7658,"start":6351,"enrollment":695,"conditions":59633,"interventions":59634},[85],[7524],[59579,59567,59598],{"nctId":59600,"briefTitle":59601,"status":155,"phases":59636,"primaryCompletion":7658,"completion":7658,"start":7658,"enrollment":695,"conditions":59637,"interventions":59638},[85],[7524],[59567,59579],{"trials":59640,"activeCount":97},[],{"trials":59642,"activeCount":97},[],{"trials":59644,"activeCount":97},[],{"trials":59646,"activeCount":97},[],{"intervention":59498,"totalTrials":1517,"cells":59648},{"EARLY_PHASE1":59649,"PHASE1":59651,"PHASE2":59686,"PHASE3":59688,"PHASE4":59690,"NA":59692},{"trials":59650,"activeCount":97},[],{"trials":59652,"activeCount":97},[59653,59659,59667,59675,59679],{"nctId":59654,"briefTitle":59655,"status":155,"phases":59656,"primaryCompletion":3227,"completion":3227,"start":443,"enrollment":255,"conditions":59657,"interventions":59658},"NCT06577597","Safety, Tolerability and Blood Sampling of GSK3923868 Administered Via Dry Powder Inhaler to Healthy Participants of Chinese, Japanese and European Ancestry",[85],[14697],[59498],{"nctId":59660,"briefTitle":59661,"status":155,"phases":59662,"primaryCompletion":59663,"completion":59663,"start":59664,"enrollment":6503,"conditions":59665,"interventions":59666},"NCT05398198","Efficacy and Safety of GSK3923868 Inhalation Powder, During Experimental Human Rhinovirus Infection in Participants With Mild Asthma",[85],"2024-04-09","2022-06-09",[15],[59498],{"nctId":59668,"briefTitle":59669,"status":155,"phases":59670,"primaryCompletion":59671,"completion":59671,"start":59672,"enrollment":1459,"conditions":59673,"interventions":59674},"NCT05677347","Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)",[85],"2023-07-20","2023-01-23",[15],[59498],{"nctId":59492,"briefTitle":59493,"status":155,"phases":59676,"primaryCompletion":1306,"completion":59495,"start":129,"enrollment":454,"conditions":59677,"interventions":59678},[85],[15],[59498,39369],{"nctId":59680,"briefTitle":59681,"status":155,"phases":59682,"primaryCompletion":21342,"completion":21342,"start":59683,"enrollment":904,"conditions":59684,"interventions":59685},"NCT04585009","Safety, Tolerability and Pharmacokinetics of GSK3923868 Inhalation Powder in Healthy Participants and Stable Asthmatics",[85],"2020-10-12",[15],[59498],{"trials":59687,"activeCount":97},[],{"trials":59689,"activeCount":97},[],{"trials":59691,"activeCount":97},[],{"trials":59693,"activeCount":97},[],{"intervention":9324,"totalTrials":181,"cells":59695},{"EARLY_PHASE1":59696,"PHASE1":59698,"PHASE2":59716,"PHASE3":59718,"PHASE4":59720,"NA":59722},{"trials":59697,"activeCount":97},[],{"trials":59699,"activeCount":97},[59700,59704,59708,59712],{"nctId":19700,"briefTitle":19701,"status":155,"phases":59701,"primaryCompletion":19703,"completion":19703,"start":19704,"enrollment":1335,"conditions":59702,"interventions":59703},[85],[435],[19707,19693,9324,19708],{"nctId":19727,"briefTitle":19728,"status":155,"phases":59705,"primaryCompletion":19730,"completion":19730,"start":19731,"enrollment":695,"conditions":59706,"interventions":59707},[85],[27],[19693,9324,19734],{"nctId":19736,"briefTitle":19737,"status":155,"phases":59709,"primaryCompletion":3391,"completion":3391,"start":11030,"enrollment":473,"conditions":59710,"interventions":59711},[85],[9343],[9347,19693,10390,9324],{"nctId":9313,"briefTitle":9314,"status":155,"phases":59713,"primaryCompletion":9316,"completion":9316,"start":9317,"enrollment":31,"conditions":59714,"interventions":59715},[85],[9319],[9321,9093,9273,9322,9323,6488,9324,9325,9326,9327,9093],{"trials":59717,"activeCount":97},[],{"trials":59719,"activeCount":97},[],{"trials":59721,"activeCount":97},[],{"trials":59723,"activeCount":97},[],{"intervention":59725,"totalTrials":181,"cells":59726},"GSK1278863A",{"EARLY_PHASE1":59727,"PHASE1":59729,"PHASE2":59759,"PHASE3":59761,"PHASE4":59763,"NA":59765},{"trials":59728,"activeCount":97},[],{"trials":59730,"activeCount":97},[59731,59737,59744,59750],{"nctId":59732,"briefTitle":59733,"status":155,"phases":59734,"primaryCompletion":17736,"completion":17736,"start":24180,"enrollment":255,"conditions":59735,"interventions":59736},"NCT01319006","Relative Bioavailability Study for GSK1278863A",[85],[17996],[59725,59725,59725],{"nctId":59738,"briefTitle":59739,"status":155,"phases":59740,"primaryCompletion":59741,"completion":59741,"start":8298,"enrollment":710,"conditions":59742,"interventions":59743},"NCT00750256","A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK1278863A in Healthy Subjects",[85],"2008-12-12",[17996],[59725],{"nctId":59745,"briefTitle":59746,"status":155,"phases":59747,"primaryCompletion":40152,"completion":40152,"start":3378,"enrollment":1459,"conditions":59748,"interventions":59749},"NCT00935831","Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment",[85],[6452],[59725],{"nctId":59751,"briefTitle":59752,"status":155,"phases":59753,"primaryCompletion":59754,"completion":59754,"start":59755,"enrollment":1736,"conditions":59756,"interventions":59757},"NCT02348372","Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects",[85],"2011-06-03","2011-03-31",[17996],[59758,59725],"GSK1278863A Placebo",{"trials":59760,"activeCount":97},[],{"trials":59762,"activeCount":97},[],{"trials":59764,"activeCount":97},[],{"trials":59766,"activeCount":97},[],{"intervention":9272,"totalTrials":181,"cells":59768},{"EARLY_PHASE1":59769,"PHASE1":59771,"PHASE2":59795,"PHASE3":59797,"PHASE4":59799,"NA":59801},{"trials":59770,"activeCount":97},[],{"trials":59772,"activeCount":97},[59773,59779,59785,59789],{"nctId":59774,"briefTitle":59775,"status":155,"phases":59776,"primaryCompletion":2835,"completion":2835,"start":2404,"enrollment":1264,"conditions":59777,"interventions":59778},"NCT00404963","A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects",[85],[9036],[9272],{"nctId":59780,"briefTitle":59781,"status":155,"phases":59782,"primaryCompletion":2804,"completion":2804,"start":3552,"enrollment":730,"conditions":59783,"interventions":59784},"NCT00495014","Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects",[85],[9036],[9272],{"nctId":9265,"briefTitle":9266,"status":155,"phases":59786,"primaryCompletion":9268,"completion":9268,"start":9269,"enrollment":314,"conditions":59787,"interventions":59788},[85],[27],[9272,6488,9093,9273],{"nctId":59790,"briefTitle":59791,"status":155,"phases":59792,"primaryCompletion":2382,"completion":2382,"start":7954,"enrollment":12202,"conditions":59793,"interventions":59794},"NCT00605449","A Drug Interaction Study Between Simvastatin and GSK376501",[85],[9036],[9272],{"trials":59796,"activeCount":97},[],{"trials":59798,"activeCount":97},[],{"trials":59800,"activeCount":97},[],{"trials":59802,"activeCount":97},[],{"intervention":39362,"totalTrials":181,"cells":59804},{"EARLY_PHASE1":59805,"PHASE1":59807,"PHASE2":59831,"PHASE3":59833,"PHASE4":59835,"NA":59837},{"trials":59806,"activeCount":97},[],{"trials":59808,"activeCount":97},[59809,59813,59817,59821],{"nctId":40076,"briefTitle":40077,"status":155,"phases":59810,"primaryCompletion":40079,"completion":40079,"start":18328,"enrollment":904,"conditions":59811,"interventions":59812},[85],[11827],[40069,8022,40082,40083],{"nctId":41361,"briefTitle":41362,"status":500,"phases":59814,"primaryCompletion":34933,"completion":34933,"start":3551,"enrollment":97,"conditions":59815,"interventions":59816},[85],[18],[41354,41366,41367,41368,41369],{"nctId":39354,"briefTitle":39355,"status":155,"phases":59818,"primaryCompletion":39357,"completion":39357,"start":39358,"enrollment":10794,"conditions":59819,"interventions":59820},[85],[14696],[39316,39361,8022,39362],{"nctId":59822,"briefTitle":59823,"status":155,"phases":59824,"primaryCompletion":46691,"completion":46691,"start":59825,"enrollment":3672,"conditions":59826,"interventions":59827},"NCT01209026","Corrected QT (QTc) Study With Flucticasone Furoate and GW642444",[85],"2010-06-23",[18],[59828,59829,59830,39362],"Fluticasone furoate (200 mcg)\u002FGW642444 (25mcg) combination","Fluticasone furoate (400 mcg)\u002FGW642444 (50mcg) combination","Moxifloxacin 400mg",{"trials":59832,"activeCount":97},[],{"trials":59834,"activeCount":97},[],{"trials":59836,"activeCount":97},[],{"trials":59838,"activeCount":97},[],{"intervention":23669,"totalTrials":181,"cells":59840},{"EARLY_PHASE1":59841,"PHASE1":59843,"PHASE2":59874,"PHASE3":59876,"PHASE4":59878,"NA":59880},{"trials":59842,"activeCount":97},[],{"trials":59844,"activeCount":97},[59845,59856,59860,59870],{"nctId":59846,"briefTitle":59847,"status":155,"phases":59848,"primaryCompletion":59849,"completion":59849,"start":59850,"enrollment":730,"conditions":59851,"interventions":59852},"NCT02371603","Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers",[85],"2015-08-12","2015-02-11",[17996],[59853,59854,23669,59855],"GSK1278863 25 mg","Pioglitazone 15 mg","Trimethoprim 100 mg",{"nctId":23663,"briefTitle":23664,"status":155,"phases":59857,"primaryCompletion":23666,"completion":23666,"start":18690,"enrollment":1634,"conditions":59858,"interventions":59859},[85],[9309],[23669,23648],{"nctId":59861,"briefTitle":59862,"status":155,"phases":59863,"primaryCompletion":59864,"completion":59864,"start":24504,"enrollment":1298,"conditions":59865,"interventions":59866},"NCT01489943","A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects",[85],"2011-11-10",[21782],[59867,59868,59854,59869,23669],"GSK1605786 500 mg","Midazolam 3 mg","Omeprazole 40 mg",{"nctId":41371,"briefTitle":41372,"status":155,"phases":59871,"primaryCompletion":41374,"completion":41374,"start":39708,"enrollment":695,"conditions":59872,"interventions":59873},[85],[18],[23669,41377,41354],{"trials":59875,"activeCount":97},[],{"trials":59877,"activeCount":97},[],{"trials":59879,"activeCount":97},[],{"trials":59881,"activeCount":97},[],{"intervention":59883,"totalTrials":593,"cells":59884},"Test formulation",{"EARLY_PHASE1":59885,"PHASE1":59887,"PHASE2":59912,"PHASE3":59914,"PHASE4":59916,"NA":59918},{"trials":59886,"activeCount":97},[],{"trials":59888,"activeCount":97},[59889,59898,59905],{"nctId":59890,"briefTitle":59891,"status":155,"phases":59892,"primaryCompletion":59893,"completion":59893,"start":59894,"enrollment":345,"conditions":59895,"interventions":59896},"NCT01262989","SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fast Admin",[85],"2010-01-26","2010-01-04",[12263],[59883,59897],"Reference formulation",{"nctId":59899,"briefTitle":59900,"status":155,"phases":59901,"primaryCompletion":22171,"completion":22171,"start":59902,"enrollment":1237,"conditions":59903,"interventions":59904},"NCT01316926","Paxil CR Bioequivalence Study Brazil",[85],"2009-09-09",[9292],[59883,59897],{"nctId":59906,"briefTitle":59907,"status":155,"phases":59908,"primaryCompletion":59909,"completion":59909,"start":3634,"enrollment":1335,"conditions":59910,"interventions":59911},"NCT01330303","SECOTEX® (Tamsulosin Hydrochloride) Bioequivalence Study Brazil - Fed Admin",[85],"2009-12-22",[12263],[59897,59883],{"trials":59913,"activeCount":97},[],{"trials":59915,"activeCount":97},[],{"trials":59917,"activeCount":97},[],{"trials":59919,"activeCount":97},[],{"intervention":59897,"totalTrials":593,"cells":59921},{"EARLY_PHASE1":59922,"PHASE1":59924,"PHASE2":59938,"PHASE3":59940,"PHASE4":59942,"NA":59944},{"trials":59923,"activeCount":97},[],{"trials":59925,"activeCount":97},[59926,59930,59934],{"nctId":59890,"briefTitle":59891,"status":155,"phases":59927,"primaryCompletion":59893,"completion":59893,"start":59894,"enrollment":345,"conditions":59928,"interventions":59929},[85],[12263],[59883,59897],{"nctId":59899,"briefTitle":59900,"status":155,"phases":59931,"primaryCompletion":22171,"completion":22171,"start":59902,"enrollment":1237,"conditions":59932,"interventions":59933},[85],[9292],[59883,59897],{"nctId":59906,"briefTitle":59907,"status":155,"phases":59935,"primaryCompletion":59909,"completion":59909,"start":3634,"enrollment":1335,"conditions":59936,"interventions":59937},[85],[12263],[59897,59883],{"trials":59939,"activeCount":97},[],{"trials":59941,"activeCount":97},[],{"trials":59943,"activeCount":97},[],{"trials":59945,"activeCount":97},[],{"intervention":59947,"totalTrials":593,"cells":59948},"GSK2256294",{"EARLY_PHASE1":59949,"PHASE1":59951,"PHASE2":59974,"PHASE3":59976,"PHASE4":59978,"NA":59980},{"trials":59950,"activeCount":97},[],{"trials":59952,"activeCount":97},[59953,59959,59967],{"nctId":59954,"briefTitle":59955,"status":155,"phases":59956,"primaryCompletion":42735,"completion":42735,"start":25493,"enrollment":695,"conditions":59957,"interventions":59958},"NCT02006537","A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects",[85],[15],[59947],{"nctId":59960,"briefTitle":59961,"status":155,"phases":59962,"primaryCompletion":59963,"completion":59963,"start":59964,"enrollment":255,"conditions":59965,"interventions":59966},"NCT02262689","To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions",[85],"2015-04-24","2015-01-08",[15],[59947],{"nctId":59968,"briefTitle":59969,"status":155,"phases":59970,"primaryCompletion":16912,"completion":16912,"start":59971,"enrollment":904,"conditions":59972,"interventions":59973},"NCT01762774","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers",[85],"2013-01-16",[15],[59947],{"trials":59975,"activeCount":97},[],{"trials":59977,"activeCount":97},[],{"trials":59979,"activeCount":97},[],{"trials":59981,"activeCount":97},[],{"intervention":18127,"totalTrials":593,"cells":59983},{"EARLY_PHASE1":59984,"PHASE1":59986,"PHASE2":60005,"PHASE3":60007,"PHASE4":60009,"NA":60011},{"trials":59985,"activeCount":97},[],{"trials":59987,"activeCount":97},[59988,59992,59999],{"nctId":18120,"briefTitle":18121,"status":155,"phases":59989,"primaryCompletion":18123,"completion":18123,"start":18124,"enrollment":9196,"conditions":59990,"interventions":59991},[85],[36],[3115,18127],{"nctId":59993,"briefTitle":59994,"status":155,"phases":59995,"primaryCompletion":59996,"completion":59996,"start":24664,"enrollment":624,"conditions":59997,"interventions":59998},"NCT00920257","A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795",[85],"2013-04-17",[36],[18127],{"nctId":60000,"briefTitle":60001,"status":155,"phases":60002,"primaryCompletion":24686,"completion":24686,"start":23418,"enrollment":710,"conditions":60003,"interventions":60004},"NCT01266954","An Open Label Study To Investigate the Pharmacokinetics and Pharmacodynamics of Repeat Escalating Doses of the Oral AKT Inhibitor GSK2141795 by 18F FDG PET Analysis in Subjects With Ovarian Cancer",[85],[2761],[18127],{"trials":60006,"activeCount":97},[],{"trials":60008,"activeCount":97},[],{"trials":60010,"activeCount":97},[],{"trials":60012,"activeCount":97},[],{"intervention":60014,"totalTrials":593,"cells":60015},"GSK2647544",{"EARLY_PHASE1":60016,"PHASE1":60018,"PHASE2":60045,"PHASE3":60047,"PHASE4":60049,"NA":60051},{"trials":60017,"activeCount":97},[],{"trials":60019,"activeCount":97},[60020,60028,60037],{"nctId":60021,"briefTitle":60022,"status":155,"phases":60023,"primaryCompletion":60024,"completion":60024,"start":60025,"enrollment":9334,"conditions":60026,"interventions":60027},"NCT01702467","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers",[85],"2013-05-15","2012-10-19",[4644],[60014],{"nctId":60029,"briefTitle":60030,"status":145,"phases":60031,"primaryCompletion":60032,"completion":60032,"start":60033,"enrollment":1459,"conditions":60034,"interventions":60035},"NCT01978327","GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers",[85],"2014-03-03","2013-11-22",[4644],[60014,60036],"drug-drug interaction",{"nctId":60038,"briefTitle":60039,"status":145,"phases":60040,"primaryCompletion":60032,"completion":60032,"start":60041,"enrollment":181,"conditions":60042,"interventions":60043},"NCT01924858","A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.",[85],"2013-08-19",[4644],[60014,60044],"[18F]GSK2647544 IV bolus",{"trials":60046,"activeCount":97},[],{"trials":60048,"activeCount":97},[],{"trials":60050,"activeCount":97},[],{"trials":60052,"activeCount":97},[],{"intervention":60054,"totalTrials":593,"cells":60055},"GSK1144814",{"EARLY_PHASE1":60056,"PHASE1":60058,"PHASE2":60080,"PHASE3":60082,"PHASE4":60084,"NA":60086},{"trials":60057,"activeCount":97},[],{"trials":60059,"activeCount":97},[60060,60066,60074],{"nctId":60061,"briefTitle":60062,"status":155,"phases":60063,"primaryCompletion":4700,"completion":4700,"start":18246,"enrollment":1279,"conditions":60064,"interventions":60065},"NCT01381419","First Time in Human Study (FTIH) With Positron Emission Tomography (PET)",[85],[11346],[60054,60054,60054],{"nctId":60067,"briefTitle":60068,"status":155,"phases":60069,"primaryCompletion":60070,"completion":60070,"start":60071,"enrollment":212,"conditions":60072,"interventions":60073},"NCT01209039","A Repeat Dose Positron Emission Tomography Study With GSK1144814",[85],"2009-10-25","2009-07-01",[11346],[60054,60054,60054],{"nctId":60075,"briefTitle":60076,"status":155,"phases":60077,"primaryCompletion":36622,"completion":36622,"start":52777,"enrollment":433,"conditions":60078,"interventions":60079},"NCT01090440","Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects",[85],[11346],[60054],{"trials":60081,"activeCount":97},[],{"trials":60083,"activeCount":97},[],{"trials":60085,"activeCount":97},[],{"trials":60087,"activeCount":97},[],{"intervention":9337,"totalTrials":593,"cells":60089},{"EARLY_PHASE1":60090,"PHASE1":60092,"PHASE2":60109,"PHASE3":60111,"PHASE4":60113,"NA":60115},{"trials":60091,"activeCount":97},[],{"trials":60093,"activeCount":97},[60094,60098,60105],{"nctId":21819,"briefTitle":21820,"status":155,"phases":60095,"primaryCompletion":21822,"completion":21822,"start":21823,"enrollment":1534,"conditions":60096,"interventions":60097},[85],[21825,5658],[9337,6579],{"nctId":60099,"briefTitle":60100,"status":155,"phases":60101,"primaryCompletion":14344,"completion":14344,"start":60102,"enrollment":4542,"conditions":60103,"interventions":60104},"NCT04488770","Safety, Tolerability and Pharmacokinetic Investigation of GSK3882347 in Healthy Participants.",[85],"2020-08-24",[5658],[9337],{"nctId":9329,"briefTitle":9330,"status":155,"phases":60106,"primaryCompletion":611,"completion":9332,"start":9333,"enrollment":9334,"conditions":60107,"interventions":60108},[85],[5658],[6488,9337],{"trials":60110,"activeCount":97},[],{"trials":60112,"activeCount":97},[],{"trials":60114,"activeCount":97},[],{"trials":60116,"activeCount":97},[],{"intervention":60118,"totalTrials":593,"cells":60119},"Moxifloxacin 400 mg",{"EARLY_PHASE1":60120,"PHASE1":60122,"PHASE2":60149,"PHASE3":60151,"PHASE4":60153,"NA":60155},{"trials":60121,"activeCount":97},[],{"trials":60123,"activeCount":97},[60124,60131,60141],{"nctId":60125,"briefTitle":60126,"status":155,"phases":60127,"primaryCompletion":6351,"completion":7658,"start":1429,"enrollment":656,"conditions":60128,"interventions":60129},"NCT00996021","Study to Assess Cardiac Conduction of GSK1349572",[85],[7524],[60130,60118],"GSK1349572 250 mg",{"nctId":60132,"briefTitle":60133,"status":155,"phases":60134,"primaryCompletion":60135,"completion":60135,"start":60136,"enrollment":3025,"conditions":60137,"interventions":60138},"NCT01702376","This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.",[85],"2013-01-14","2012-10-03",[22921],[60139,60140,60118],"Retosiban 100 mg","Retosiban 800 mg",{"nctId":60142,"briefTitle":60143,"status":155,"phases":60144,"primaryCompletion":19317,"completion":19317,"start":19318,"enrollment":4542,"conditions":60145,"interventions":60146},"NCT02293148","Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers",[85],[17996],[60147,60148,60118],"GSK1278863 75 mg","GSK1278863 500 mg",{"trials":60150,"activeCount":97},[],{"trials":60152,"activeCount":97},[],{"trials":60154,"activeCount":97},[],{"trials":60156,"activeCount":97},[],{"intervention":42862,"totalTrials":593,"cells":60158},{"EARLY_PHASE1":60159,"PHASE1":60161,"PHASE2":60177,"PHASE3":60179,"PHASE4":60181,"NA":60183},{"trials":60160,"activeCount":97},[],{"trials":60162,"activeCount":97},[60163,60169,60173],{"nctId":60164,"briefTitle":60165,"status":155,"phases":60166,"start":2823,"enrollment":1237,"conditions":60167,"interventions":60168},"NCT00197093","In-Patient Study In Schizophrenic Patients",[85],[11346],[42862],{"nctId":59349,"briefTitle":59350,"status":155,"phases":60170,"primaryCompletion":59352,"completion":59352,"start":59353,"enrollment":710,"conditions":60171,"interventions":60172},[85],[11346],[42862,9325],{"nctId":42856,"briefTitle":42857,"status":155,"phases":60174,"primaryCompletion":42859,"completion":42859,"start":19038,"enrollment":3647,"conditions":60175,"interventions":60176},[85],[11346],[42862,11350],{"trials":60178,"activeCount":97},[],{"trials":60180,"activeCount":97},[],{"trials":60182,"activeCount":97},[],{"trials":60184,"activeCount":97},[],{"intervention":60186,"totalTrials":593,"cells":60187},"GW842166X",{"EARLY_PHASE1":60188,"PHASE1":60190,"PHASE2":60214,"PHASE3":60216,"PHASE4":60218,"NA":60220},{"trials":60189,"activeCount":97},[],{"trials":60191,"activeCount":97},[60192,60198,60208],{"nctId":60193,"briefTitle":60194,"status":500,"phases":60195,"primaryCompletion":2382,"completion":2382,"start":3079,"enrollment":97,"conditions":60196,"interventions":60197},"NCT00554762","Dose Response and Efficacy of GW842166 in Pain",[85],[7524],[60186],{"nctId":60199,"briefTitle":60200,"status":155,"phases":60201,"primaryCompletion":60202,"completion":60202,"start":60203,"enrollment":628,"conditions":60204,"interventions":60206},"NCT00511524","An Imaging Study to Investigate the Distribution of GW842166X in the Brain.",[85],"2007-07-04","2007-06-26",[60205],"Pain, Inflammatory",[60186,60207],"[carbonyl-^11C]GW842166",{"nctId":60209,"briefTitle":60210,"status":500,"phases":60211,"start":2356,"enrollment":97,"conditions":60212,"interventions":60213},"NCT00536497","Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects.",[85],[7524],[60186],{"trials":60215,"activeCount":97},[],{"trials":60217,"activeCount":97},[],{"trials":60219,"activeCount":97},[],{"trials":60221,"activeCount":97},[],{"intervention":9273,"totalTrials":593,"cells":60223},{"EARLY_PHASE1":60224,"PHASE1":60226,"PHASE2":60240,"PHASE3":60242,"PHASE4":60244,"NA":60246},{"trials":60225,"activeCount":97},[],{"trials":60227,"activeCount":97},[60228,60232,60236],{"nctId":9265,"briefTitle":9266,"status":155,"phases":60229,"primaryCompletion":9268,"completion":9268,"start":9269,"enrollment":314,"conditions":60230,"interventions":60231},[85],[27],[9272,6488,9093,9273],{"nctId":9313,"briefTitle":9314,"status":155,"phases":60233,"primaryCompletion":9316,"completion":9316,"start":9317,"enrollment":31,"conditions":60234,"interventions":60235},[85],[9319],[9321,9093,9273,9322,9323,6488,9324,9325,9326,9327,9093],{"nctId":9339,"briefTitle":9340,"status":155,"phases":60237,"primaryCompletion":6351,"completion":6351,"start":2442,"enrollment":1298,"conditions":60238,"interventions":60239},[85],[7524,9343],[9345,9346,6488,9323,9273,9347],{"trials":60241,"activeCount":97},[],{"trials":60243,"activeCount":97},[],{"trials":60245,"activeCount":97},[],{"trials":60247,"activeCount":97},[],{"intervention":60249,"totalTrials":593,"cells":60250},"GSK356278",{"EARLY_PHASE1":60251,"PHASE1":60253,"PHASE2":60276,"PHASE3":60278,"PHASE4":60280,"NA":60282},{"trials":60252,"activeCount":97},[],{"trials":60254,"activeCount":97},[60255,60263,60270],{"nctId":60256,"briefTitle":60257,"status":155,"phases":60258,"primaryCompletion":8803,"completion":8803,"start":5289,"enrollment":1720,"conditions":60259,"interventions":60261},"NCT01602900","Healthy Volunteer Positron Emission Tomography (PET) Brain Occupancy Study of a Phosphodiesterase 4 (PDE4) Inhibitor in Huntington's Disease",[85],[60260],"Huntington Disease",[60249,60262],"Rolipram",{"nctId":60264,"briefTitle":60265,"status":155,"phases":60266,"primaryCompletion":17159,"completion":17159,"start":60267,"enrollment":710,"conditions":60268,"interventions":60269},"NCT01573819","A Repeat Dose Study in Healthy Volunteers Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK356278",[85],"2011-11-24",[60260],[60249],{"nctId":60271,"briefTitle":60272,"status":155,"phases":60273,"primaryCompletion":10496,"completion":10496,"start":20545,"enrollment":454,"conditions":60274,"interventions":60275},"NCT01031186","First Time in Human Study",[85],[41867],[60249],{"trials":60277,"activeCount":97},[],{"trials":60279,"activeCount":97},[],{"trials":60281,"activeCount":97},[],{"trials":60283,"activeCount":97},[],{"intervention":9322,"totalTrials":593,"cells":60285},{"EARLY_PHASE1":60286,"PHASE1":60288,"PHASE2":60302,"PHASE3":60304,"PHASE4":60306,"NA":60308},{"trials":60287,"activeCount":97},[],{"trials":60289,"activeCount":97},[60290,60294,60298],{"nctId":40536,"briefTitle":40537,"status":155,"phases":60291,"primaryCompletion":40539,"completion":40539,"start":4867,"enrollment":345,"conditions":60292,"interventions":60293},[85],[15],[20900,9322],{"nctId":59541,"briefTitle":59542,"status":155,"phases":60295,"primaryCompletion":1429,"completion":1429,"start":2441,"enrollment":1298,"conditions":60296,"interventions":60297},[85],[19301],[19303,19303,9322],{"nctId":9313,"briefTitle":9314,"status":155,"phases":60299,"primaryCompletion":9316,"completion":9316,"start":9317,"enrollment":31,"conditions":60300,"interventions":60301},[85],[9319],[9321,9093,9273,9322,9323,6488,9324,9325,9326,9327,9093],{"trials":60303,"activeCount":97},[],{"trials":60305,"activeCount":97},[],{"trials":60307,"activeCount":97},[],{"trials":60309,"activeCount":97},[],{"intervention":41023,"totalTrials":593,"cells":60311},{"EARLY_PHASE1":60312,"PHASE1":60314,"PHASE2":60336,"PHASE3":60338,"PHASE4":60340,"NA":60342},{"trials":60313,"activeCount":97},[],{"trials":60315,"activeCount":97},[60316,60320,60328],{"nctId":41017,"briefTitle":41018,"status":155,"phases":60317,"primaryCompletion":41020,"completion":41020,"start":24337,"enrollment":27085,"conditions":60318,"interventions":60319},[85],[3637],[11470,41023],{"nctId":60321,"briefTitle":60322,"status":155,"phases":60323,"primaryCompletion":60324,"completion":60324,"start":8795,"enrollment":8275,"conditions":60325,"interventions":60326},"NCT00756067","Evaluation of Pneumococcal Vaccine Formulations in Elderly",[85],"2009-05-28",[3637],[60327,41023],"Pneumococcal vaccine GSK2189241A",{"nctId":60329,"briefTitle":60330,"status":155,"phases":60331,"primaryCompletion":3619,"completion":41864,"start":920,"enrollment":18147,"conditions":60332,"interventions":60333},"NCT00327665","Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population",[85],[3637],[60334,41023,60335],"11-valent pneumococcal vaccine GSK513026","10-valent pneumococcal vaccine GSK513026",{"trials":60337,"activeCount":97},[],{"trials":60339,"activeCount":97},[],{"trials":60341,"activeCount":97},[],{"trials":60343,"activeCount":97},[],{"intervention":60345,"totalTrials":593,"cells":60346},"GSK1223249",{"EARLY_PHASE1":60347,"PHASE1":60349,"PHASE2":60374,"PHASE3":60376,"PHASE4":60378,"NA":60380},{"trials":60348,"activeCount":97},[],{"trials":60350,"activeCount":97},[60351,60359,60367],{"nctId":60352,"briefTitle":60353,"status":145,"phases":60354,"primaryCompletion":60355,"completion":60355,"start":60356,"enrollment":593,"conditions":60357,"interventions":60358},"NCT01435993","Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis",[85],"2012-01-23","2011-09-08",[39994],[60345],{"nctId":60360,"briefTitle":60361,"status":145,"phases":60362,"primaryCompletion":60363,"completion":60363,"start":60364,"enrollment":593,"conditions":60365,"interventions":60366},"NCT01424423","NOGO-A in Multiple Sclerosis FTIH",[85],"2010-08-26","2010-02-11",[39962],[60345],{"nctId":60368,"briefTitle":60369,"status":155,"phases":60370,"primaryCompletion":26474,"completion":26474,"start":60371,"enrollment":7955,"conditions":60372,"interventions":60373},"NCT00875446","First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis",[85],"2009-05-13",[53684],[60345],{"trials":60375,"activeCount":97},[],{"trials":60377,"activeCount":97},[],{"trials":60379,"activeCount":97},[],{"trials":60381,"activeCount":97},[],{"intervention":9323,"totalTrials":593,"cells":60383},{"EARLY_PHASE1":60384,"PHASE1":60386,"PHASE2":60406,"PHASE3":60408,"PHASE4":60410,"NA":60412},{"trials":60385,"activeCount":97},[],{"trials":60387,"activeCount":97},[60388,60392,60402],{"nctId":9313,"briefTitle":9314,"status":155,"phases":60389,"primaryCompletion":9316,"completion":9316,"start":9317,"enrollment":31,"conditions":60390,"interventions":60391},[85],[9319],[9321,9093,9273,9322,9323,6488,9324,9325,9326,9327,9093],{"nctId":60393,"briefTitle":60394,"status":155,"phases":60395,"primaryCompletion":60396,"completion":60396,"start":60397,"enrollment":6503,"conditions":60398,"interventions":60400},"NCT00950586","Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702",[85],"2009-12-24","2009-08-24",[60399],"Cognitive Disorders",[60401,9323],"GSK1043702",{"nctId":9339,"briefTitle":9340,"status":155,"phases":60403,"primaryCompletion":6351,"completion":6351,"start":2442,"enrollment":1298,"conditions":60404,"interventions":60405},[85],[7524,9343],[9345,9346,6488,9323,9273,9347],{"trials":60407,"activeCount":97},[],{"trials":60409,"activeCount":97},[],{"trials":60411,"activeCount":97},[],{"trials":60413,"activeCount":97},[],{"intervention":60415,"totalTrials":593,"cells":60416},"GSK2256098",{"EARLY_PHASE1":60417,"PHASE1":60419,"PHASE2":60443,"PHASE3":60445,"PHASE4":60447,"NA":60449},{"trials":60418,"activeCount":97},[],{"trials":60420,"activeCount":97},[60421,60429,60436],{"nctId":60422,"briefTitle":60423,"status":155,"phases":60424,"primaryCompletion":60425,"completion":60425,"start":60426,"enrollment":4158,"conditions":60427,"interventions":60428},"NCT01138033","Study of a Focal Adhesion Kinase Inhibitor in Subjects With Solid Tumors",[85],"2015-12-21","2010-07-27",[36],[60415],{"nctId":60430,"briefTitle":60431,"status":155,"phases":60432,"primaryCompletion":158,"completion":158,"start":60433,"enrollment":1736,"conditions":60434,"interventions":60435},"NCT01938443","A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors",[85],"2013-11-18",[36,107],[60415,3048],{"nctId":60437,"briefTitle":60438,"status":155,"phases":60439,"primaryCompletion":60440,"completion":60440,"start":8733,"enrollment":12044,"conditions":60441,"interventions":60442},"NCT00996671","Phase I Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of GSK2256098 in Healthy Volunteers",[85],"2010-03-17",[36],[60415],{"trials":60444,"activeCount":97},[],{"trials":60446,"activeCount":97},[],{"trials":60448,"activeCount":97},[],{"trials":60450,"activeCount":97},[],{"intervention":59327,"totalTrials":660,"cells":60452},{"EARLY_PHASE1":60453,"PHASE1":60455,"PHASE2":60465,"PHASE3":60467,"PHASE4":60469,"NA":60471},{"trials":60454,"activeCount":97},[],{"trials":60456,"activeCount":97},[60457,60461],{"nctId":59321,"briefTitle":59322,"status":155,"phases":60458,"primaryCompletion":40295,"completion":40295,"start":2665,"enrollment":1117,"conditions":60459,"interventions":60460},[85],[1337],[38856,59326,59327],{"nctId":59389,"briefTitle":59390,"status":155,"phases":60462,"primaryCompletion":19425,"completion":19425,"start":59392,"enrollment":3672,"conditions":60463,"interventions":60464},[85],[1337],[59395,9325,59327],{"trials":60466,"activeCount":97},[],{"trials":60468,"activeCount":97},[],{"trials":60470,"activeCount":97},[],{"trials":60472,"activeCount":97},[],{"intervention":60474,"totalTrials":660,"cells":60475},"GSK3039294",{"EARLY_PHASE1":60476,"PHASE1":60478,"PHASE2":60495,"PHASE3":60497,"PHASE4":60499,"NA":60501},{"trials":60477,"activeCount":97},[],{"trials":60479,"activeCount":97},[60480,60488],{"nctId":60481,"briefTitle":60482,"status":500,"phases":60483,"primaryCompletion":60484,"completion":60484,"start":60485,"enrollment":97,"conditions":60486,"interventions":60487},"NCT03567499","Pro-arrhythmic Potential of GSK3039294 in Healthy Subjects",[85],"2019-05-03","2018-07-12",[1239],[60474],{"nctId":60489,"briefTitle":60490,"status":145,"phases":60491,"primaryCompletion":17993,"completion":17993,"start":60492,"enrollment":314,"conditions":60493,"interventions":60494},"NCT02603172","A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis",[85],"2016-05-12",[1239],[60474],{"trials":60496,"activeCount":97},[],{"trials":60498,"activeCount":97},[],{"trials":60500,"activeCount":97},[],{"trials":60502,"activeCount":97},[],{"intervention":60504,"totalTrials":660,"cells":60505},"Paroxetine Controlled Release",{"EARLY_PHASE1":60506,"PHASE1":60508,"PHASE2":60526,"PHASE3":60528,"PHASE4":60530,"NA":60532},{"trials":60507,"activeCount":97},[],{"trials":60509,"activeCount":97},[60510,60518],{"nctId":60511,"briefTitle":60512,"status":155,"phases":60513,"primaryCompletion":60514,"completion":60514,"start":60515,"enrollment":1459,"conditions":60516,"interventions":60517},"NCT00406432","A Repeat Dose Pharmacokinetic Study Of Paroxetine CR Tablet In Healthy Chinese Subjects",[85],"2006-06-02","2006-05-09",[9292],[60504],{"nctId":60519,"briefTitle":60520,"status":155,"phases":60521,"primaryCompletion":47595,"completion":47595,"start":60522,"enrollment":628,"conditions":60523,"interventions":60524},"NCT00406003","Single Dose Pharmacokinetic (PK) Study Of Paroxetine CR(12.5-37.5mg) In Healthy Chinese Subjects",[85],"2006-03-24",[9292],[60525],"Paroxetine controlled release",{"trials":60527,"activeCount":97},[],{"trials":60529,"activeCount":97},[],{"trials":60531,"activeCount":97},[],{"trials":60533,"activeCount":97},[],{"intervention":60535,"totalTrials":660,"cells":60536},"GSK163090",{"EARLY_PHASE1":60537,"PHASE1":60539,"PHASE2":60553,"PHASE3":60555,"PHASE4":60557,"NA":60559},{"trials":60538,"activeCount":97},[],{"trials":60540,"activeCount":97},[60541,60547],{"nctId":60542,"briefTitle":60543,"status":155,"phases":60544,"primaryCompletion":7546,"completion":7546,"start":3079,"enrollment":454,"conditions":60545,"interventions":60546},"NCT00559299","Patient Tolerability Study of GSK163090",[85],[10889,10890],[60535],{"nctId":60548,"briefTitle":60549,"status":155,"phases":60550,"primaryCompletion":2804,"completion":2804,"start":4843,"enrollment":3131,"conditions":60551,"interventions":60552},"NCT00435695","Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males",[85],[7524,41867],[60535],{"trials":60554,"activeCount":97},[],{"trials":60556,"activeCount":97},[],{"trials":60558,"activeCount":97},[],{"trials":60560,"activeCount":97},[],{"intervention":60562,"totalTrials":660,"cells":60563},"GSK1521498 or placebo",{"EARLY_PHASE1":60564,"PHASE1":60566,"PHASE2":60582,"PHASE3":60584,"PHASE4":60586,"NA":60588},{"trials":60565,"activeCount":97},[],{"trials":60567,"activeCount":97},[60568,60575],{"nctId":60569,"briefTitle":60570,"status":155,"phases":60571,"primaryCompletion":40863,"completion":40863,"start":18379,"enrollment":2375,"conditions":60572,"interventions":60573},"NCT00976105","Effects of Repeat Dosing of GSK1521498",[85],[9048],[60574,60562],"Zolpidem or placebo - Hypnotic drug given for sleep disorders",{"nctId":60576,"briefTitle":60577,"status":155,"phases":60578,"primaryCompletion":21200,"completion":21200,"start":60579,"enrollment":904,"conditions":60580,"interventions":60581},"NCT00857883","A First-Time-In-Human Study in Healthy Subjects",[85],"2008-11-17",[9048],[60562],{"trials":60583,"activeCount":97},[],{"trials":60585,"activeCount":97},[],{"trials":60587,"activeCount":97},[],{"trials":60589,"activeCount":97},[],{"intervention":60591,"totalTrials":660,"cells":60592},"GSK2831781",{"EARLY_PHASE1":60593,"PHASE1":60595,"PHASE2":60612,"PHASE3":60614,"PHASE4":60616,"NA":60618},{"trials":60594,"activeCount":97},[],{"trials":60596,"activeCount":97},[60597,60605],{"nctId":60598,"briefTitle":60599,"status":155,"phases":60600,"primaryCompletion":60601,"completion":60601,"start":60602,"enrollment":710,"conditions":60603,"interventions":60604},"NCT03965533","Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects",[85],"2019-12-10","2019-06-10",[5280],[60591],{"nctId":60606,"briefTitle":60607,"status":155,"phases":60608,"primaryCompletion":4867,"completion":4867,"start":60609,"enrollment":613,"conditions":60610,"interventions":60611},"NCT02195349","A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis",[85],"2014-07-30",[22060],[60591],{"trials":60613,"activeCount":97},[],{"trials":60615,"activeCount":97},[],{"trials":60617,"activeCount":97},[],{"trials":60619,"activeCount":97},[],{"intervention":60621,"totalTrials":660,"cells":60622},"Rifampin oral",{"EARLY_PHASE1":60623,"PHASE1":60625,"PHASE2":60639,"PHASE3":60641,"PHASE4":60643,"NA":60645},{"trials":60624,"activeCount":97},[],{"trials":60626,"activeCount":97},[60627,60635],{"nctId":60628,"briefTitle":60629,"status":155,"phases":60630,"primaryCompletion":40295,"completion":40295,"start":60631,"enrollment":1459,"conditions":60632,"interventions":60633},"NCT00405080","A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant).",[85],"2006-11-11",[1337],[60634,60621],"GW679769 (Casopitant) oral",{"nctId":9313,"briefTitle":9314,"status":155,"phases":60636,"primaryCompletion":9316,"completion":9316,"start":9317,"enrollment":31,"conditions":60637,"interventions":60638},[85],[9319],[9321,9093,9273,9322,9323,6488,9324,9325,9326,9327,9093],{"trials":60640,"activeCount":97},[],{"trials":60642,"activeCount":97},[],{"trials":60644,"activeCount":97},[],{"trials":60646,"activeCount":97},[],{"intervention":6489,"totalTrials":660,"cells":60648},{"EARLY_PHASE1":60649,"PHASE1":60651,"PHASE2":60661,"PHASE3":60663,"PHASE4":60665,"NA":60667},{"trials":60650,"activeCount":97},[],{"trials":60652,"activeCount":97},[60653,60657],{"nctId":7433,"briefTitle":7434,"status":155,"phases":60654,"primaryCompletion":7436,"completion":7436,"start":7437,"enrollment":7438,"conditions":60655,"interventions":60656},[85],[668],[2300,6489],{"nctId":6478,"briefTitle":6479,"status":155,"phases":60658,"primaryCompletion":1287,"completion":1287,"start":6481,"enrollment":6482,"conditions":60659,"interventions":60660},[85],[6484],[6471,6486,6487,6488,6489],{"trials":60662,"activeCount":97},[],{"trials":60664,"activeCount":97},[],{"trials":60666,"activeCount":97},[],{"trials":60668,"activeCount":97},[],{"intervention":60670,"totalTrials":660,"cells":60671},"Inhaled GSK573719",{"EARLY_PHASE1":60672,"PHASE1":60674,"PHASE2":60690,"PHASE3":60692,"PHASE4":60694,"NA":60696},{"trials":60673,"activeCount":97},[],{"trials":60675,"activeCount":97},[60676,60684],{"nctId":60677,"briefTitle":60678,"status":155,"phases":60679,"primaryCompletion":10340,"completion":10340,"start":60680,"enrollment":7438,"conditions":60681,"interventions":60682},"NCT01571999","Study to Assess the Safety and PK of GSK573719 and GSK573719\u002FGW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment",[85],"2012-03-29",[15],[60670,60683],"Inhaled GSK573719\u002Fvilanterol",{"nctId":60685,"briefTitle":60686,"status":155,"phases":60687,"primaryCompletion":13096,"completion":13096,"start":41603,"enrollment":1634,"conditions":60688,"interventions":60689},"NCT01577680","A Study to Assess the Effects of GSK573719\u002FVI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers",[85],[15],[60683,60670],{"trials":60691,"activeCount":97},[],{"trials":60693,"activeCount":97},[],{"trials":60695,"activeCount":97},[],{"trials":60697,"activeCount":97},[],{"intervention":60683,"totalTrials":660,"cells":60699},{"EARLY_PHASE1":60700,"PHASE1":60702,"PHASE2":60712,"PHASE3":60714,"PHASE4":60716,"NA":60718},{"trials":60701,"activeCount":97},[],{"trials":60703,"activeCount":97},[60704,60708],{"nctId":60677,"briefTitle":60678,"status":155,"phases":60705,"primaryCompletion":10340,"completion":10340,"start":60680,"enrollment":7438,"conditions":60706,"interventions":60707},[85],[15],[60670,60683],{"nctId":60685,"briefTitle":60686,"status":155,"phases":60709,"primaryCompletion":13096,"completion":13096,"start":41603,"enrollment":1634,"conditions":60710,"interventions":60711},[85],[15],[60683,60670],{"trials":60713,"activeCount":97},[],{"trials":60715,"activeCount":97},[],{"trials":60717,"activeCount":97},[],{"trials":60719,"activeCount":97},[],{"intervention":60721,"totalTrials":660,"cells":60722},"COREG CR and lisinopril",{"EARLY_PHASE1":60723,"PHASE1":60725,"PHASE2":60739,"PHASE3":60741,"PHASE4":60743,"NA":60745},{"trials":60724,"activeCount":97},[],{"trials":60726,"activeCount":97},[60727,60733],{"nctId":60728,"briefTitle":60729,"status":155,"phases":60730,"primaryCompletion":2804,"completion":2804,"start":3079,"enrollment":1298,"conditions":60731,"interventions":60732},"NCT00557128","Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.",[85],[13024],[60721],{"nctId":60734,"briefTitle":60735,"status":155,"phases":60736,"primaryCompletion":2804,"completion":2804,"start":8426,"enrollment":1079,"conditions":60737,"interventions":60738},"NCT00549510","Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.",[85],[13024],[60721],{"trials":60740,"activeCount":97},[],{"trials":60742,"activeCount":97},[],{"trials":60744,"activeCount":97},[],{"trials":60746,"activeCount":97},[],{"intervention":44157,"totalTrials":660,"cells":60748},{"EARLY_PHASE1":60749,"PHASE1":60751,"PHASE2":60764,"PHASE3":60766,"PHASE4":60768,"NA":60770},{"trials":60750,"activeCount":97},[],{"trials":60752,"activeCount":97},[60753,60760],{"nctId":60754,"briefTitle":60755,"status":155,"phases":60756,"primaryCompletion":10566,"completion":10566,"start":60757,"enrollment":433,"conditions":60758,"interventions":60759},"NCT02727283","A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers",[85],"2015-11-26",[5609],[44157],{"nctId":44152,"briefTitle":44153,"status":155,"phases":60761,"primaryCompletion":8539,"completion":8539,"start":8540,"enrollment":4121,"conditions":60762,"interventions":60763},[85],[5609],[44157,44158],{"trials":60765,"activeCount":97},[],{"trials":60767,"activeCount":97},[],{"trials":60769,"activeCount":97},[],{"trials":60771,"activeCount":97},[],{"intervention":60773,"totalTrials":660,"cells":60774},"Formulation A",{"EARLY_PHASE1":60775,"PHASE1":60777,"PHASE2":60799,"PHASE3":60801,"PHASE4":60803,"NA":60805},{"trials":60776,"activeCount":97},[],{"trials":60778,"activeCount":97},[60779,60790],{"nctId":60780,"briefTitle":60781,"status":155,"phases":60782,"primaryCompletion":60783,"completion":60783,"start":60784,"enrollment":1335,"conditions":60785,"interventions":60786},"NCT00548769","Firategrast (SB683699) Surface Area Study in Multiple Sclerosis Patients",[85],"2007-11-26","2007-04-21",[39962],[60773,60787,60788,60789],"Formulation B","Formulation C","Formulation D",{"nctId":60791,"briefTitle":60792,"status":155,"phases":60793,"primaryCompletion":7481,"completion":7481,"start":4789,"enrollment":433,"conditions":60794,"interventions":60795},"NCT00495274","Bioequivalence and Food Effect Study in Healthy Volunteers",[85],[19716],[60773,60787,60788,60789,60796,60797,60798],"Formulation E","Formulation F","Formulation G",{"trials":60800,"activeCount":97},[],{"trials":60802,"activeCount":97},[],{"trials":60804,"activeCount":97},[],{"trials":60806,"activeCount":97},[],{"intervention":60787,"totalTrials":660,"cells":60808},{"EARLY_PHASE1":60809,"PHASE1":60811,"PHASE2":60821,"PHASE3":60823,"PHASE4":60825,"NA":60827},{"trials":60810,"activeCount":97},[],{"trials":60812,"activeCount":97},[60813,60817],{"nctId":60780,"briefTitle":60781,"status":155,"phases":60814,"primaryCompletion":60783,"completion":60783,"start":60784,"enrollment":1335,"conditions":60815,"interventions":60816},[85],[39962],[60773,60787,60788,60789],{"nctId":60791,"briefTitle":60792,"status":155,"phases":60818,"primaryCompletion":7481,"completion":7481,"start":4789,"enrollment":433,"conditions":60819,"interventions":60820},[85],[19716],[60773,60787,60788,60789,60796,60797,60798],{"trials":60822,"activeCount":97},[],{"trials":60824,"activeCount":97},[],{"trials":60826,"activeCount":97},[],{"trials":60828,"activeCount":97},[],{"intervention":60788,"totalTrials":660,"cells":60830},{"EARLY_PHASE1":60831,"PHASE1":60833,"PHASE2":60843,"PHASE3":60845,"PHASE4":60847,"NA":60849},{"trials":60832,"activeCount":97},[],{"trials":60834,"activeCount":97},[60835,60839],{"nctId":60780,"briefTitle":60781,"status":155,"phases":60836,"primaryCompletion":60783,"completion":60783,"start":60784,"enrollment":1335,"conditions":60837,"interventions":60838},[85],[39962],[60773,60787,60788,60789],{"nctId":60791,"briefTitle":60792,"status":155,"phases":60840,"primaryCompletion":7481,"completion":7481,"start":4789,"enrollment":433,"conditions":60841,"interventions":60842},[85],[19716],[60773,60787,60788,60789,60796,60797,60798],{"trials":60844,"activeCount":97},[],{"trials":60846,"activeCount":97},[],{"trials":60848,"activeCount":97},[],{"trials":60850,"activeCount":97},[],{"intervention":60789,"totalTrials":660,"cells":60852},{"EARLY_PHASE1":60853,"PHASE1":60855,"PHASE2":60865,"PHASE3":60867,"PHASE4":60869,"NA":60871},{"trials":60854,"activeCount":97},[],{"trials":60856,"activeCount":97},[60857,60861],{"nctId":60780,"briefTitle":60781,"status":155,"phases":60858,"primaryCompletion":60783,"completion":60783,"start":60784,"enrollment":1335,"conditions":60859,"interventions":60860},[85],[39962],[60773,60787,60788,60789],{"nctId":60791,"briefTitle":60792,"status":155,"phases":60862,"primaryCompletion":7481,"completion":7481,"start":4789,"enrollment":433,"conditions":60863,"interventions":60864},[85],[19716],[60773,60787,60788,60789,60796,60797,60798],{"trials":60866,"activeCount":97},[],{"trials":60868,"activeCount":97},[],{"trials":60870,"activeCount":97},[],{"trials":60872,"activeCount":97},[],{"intervention":60874,"totalTrials":660,"cells":60875},"GSK2018682",{"EARLY_PHASE1":60876,"PHASE1":60878,"PHASE2":60894,"PHASE3":60896,"PHASE4":60898,"NA":60900},{"trials":60877,"activeCount":97},[],{"trials":60879,"activeCount":97},[60880,60888],{"nctId":60881,"briefTitle":60882,"status":155,"phases":60883,"primaryCompletion":60884,"completion":60884,"start":60885,"enrollment":345,"conditions":60886,"interventions":60887},"NCT01431937","Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers",[85],"2011-03-29","2010-10-10",[39994],[60874],{"nctId":60889,"briefTitle":60890,"status":155,"phases":60891,"primaryCompletion":18002,"completion":18002,"start":8225,"enrollment":9334,"conditions":60892,"interventions":60893},"NCT01387217","GSK2018682 FTIH in Healthy Volunteers",[85],[39962],[60874],{"trials":60895,"activeCount":97},[],{"trials":60897,"activeCount":97},[],{"trials":60899,"activeCount":97},[],{"trials":60901,"activeCount":97},[],{"intervention":60903,"totalTrials":660,"cells":60904},"GSK618334",{"EARLY_PHASE1":60905,"PHASE1":60907,"PHASE2":60922,"PHASE3":60924,"PHASE4":60926,"NA":60928},{"trials":60906,"activeCount":97},[],{"trials":60908,"activeCount":97},[60909,60916],{"nctId":60910,"briefTitle":60911,"status":155,"phases":60912,"primaryCompletion":24909,"completion":24909,"start":60913,"enrollment":1459,"conditions":60914,"interventions":60915},"NCT00814957","An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand",[85],"2008-12-08",[39123],[60903],{"nctId":60917,"briefTitle":60918,"status":155,"phases":60919,"primaryCompletion":8996,"completion":8996,"start":4856,"enrollment":454,"conditions":60920,"interventions":60921},"NCT00513279","To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334",[85],[39123],[60903],{"trials":60923,"activeCount":97},[],{"trials":60925,"activeCount":97},[],{"trials":60927,"activeCount":97},[],{"trials":60929,"activeCount":97},[],{"intervention":60931,"totalTrials":660,"cells":60932},"LPS",{"EARLY_PHASE1":60933,"PHASE1":60935,"PHASE2":60954,"PHASE3":60956,"PHASE4":60958,"NA":60960},{"trials":60934,"activeCount":97},[],{"trials":60936,"activeCount":97},[60937,60947],{"nctId":60938,"briefTitle":60939,"status":145,"phases":60940,"primaryCompletion":60941,"completion":60941,"start":60942,"enrollment":6503,"conditions":60943,"interventions":60944},"NCT03426995","First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699",[85],"2019-05-02","2018-03-13",[8788],[60945,60946,60931],"GSK3358699","GM-CSF",{"nctId":60948,"briefTitle":60949,"status":155,"phases":60950,"primaryCompletion":18012,"completion":18012,"start":4877,"enrollment":8437,"conditions":60951,"interventions":60952},"NCT01587807","A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057",[85],[9855],[60953,60931],"GSK1995057",{"trials":60955,"activeCount":97},[],{"trials":60957,"activeCount":97},[],{"trials":60959,"activeCount":97},[],{"trials":60961,"activeCount":97},[],{"intervention":60963,"totalTrials":660,"cells":60964},"GSK580416 oral",{"EARLY_PHASE1":60965,"PHASE1":60967,"PHASE2":60984,"PHASE3":60986,"PHASE4":60988,"NA":60990},{"trials":60966,"activeCount":97},[],{"trials":60968,"activeCount":97},[60969,60976],{"nctId":60970,"briefTitle":60971,"status":145,"phases":60972,"primaryCompletion":8426,"completion":8426,"start":3552,"enrollment":21520,"conditions":60973,"interventions":60975},"NCT00680485","Evaluation of the Safety, Tolerability and Pharmacokinetics of Repeat Oral Doses of GSK580416",[85],[60974,6484],"Bacterial Infection",[60963],{"nctId":60977,"briefTitle":60978,"status":155,"phases":60979,"start":2404,"enrollment":6503,"conditions":60980,"interventions":60982},"NCT00427141","A Three-Part Study Of GSK580416 In Healthy Subjects",[85],[60981,6484],"Respiratory Tract Infection",[60983],"GSK580416",{"trials":60985,"activeCount":97},[],{"trials":60987,"activeCount":97},[],{"trials":60989,"activeCount":97},[],{"trials":60991,"activeCount":97},[],{"intervention":43571,"totalTrials":660,"cells":60993},{"EARLY_PHASE1":60994,"PHASE1":60996,"PHASE2":61009,"PHASE3":61011,"PHASE4":61013,"NA":61015},{"trials":60995,"activeCount":97},[],{"trials":60997,"activeCount":97},[60998,61002],{"nctId":43566,"briefTitle":43567,"status":500,"phases":60999,"primaryCompletion":3391,"completion":3391,"start":6351,"enrollment":97,"conditions":61000,"interventions":61001},[85],[6484],[43571,40743,8022],{"nctId":61003,"briefTitle":61004,"status":155,"phases":61005,"primaryCompletion":10167,"completion":10167,"start":2428,"enrollment":37,"conditions":61006,"interventions":61007},"NCT00517673","To Evaluate Safety, Tolerability, Pharmacokinetics, And Food Effect Of Single Doses Of GSK945237 In Healthy Subjects",[85],[7524,6484],[43571,61008],"Sugar Pill",{"trials":61010,"activeCount":97},[],{"trials":61012,"activeCount":97},[],{"trials":61014,"activeCount":97},[],{"trials":61016,"activeCount":97},[],{"intervention":8921,"totalTrials":660,"cells":61018},{"EARLY_PHASE1":61019,"PHASE1":61021,"PHASE2":61036,"PHASE3":61038,"PHASE4":61040,"NA":61042},{"trials":61020,"activeCount":97},[],{"trials":61022,"activeCount":97},[61023,61032],{"nctId":61024,"briefTitle":61025,"status":145,"phases":61026,"primaryCompletion":61027,"completion":61027,"start":61028,"enrollment":255,"conditions":61029,"interventions":61030},"NCT00849069","Study to Assess the Safety of a New GSK Biologicals' GSK2231395A Candidate Vaccine",[85],"2009-04-07","2009-03-12",[8919,8918],[8921,61031],"TwinrixTM",{"nctId":8911,"briefTitle":8912,"status":155,"phases":61033,"primaryCompletion":8914,"completion":8915,"start":8916,"enrollment":345,"conditions":61034,"interventions":61035},[85],[8918,8919],[8921,4808],{"trials":61037,"activeCount":97},[],{"trials":61039,"activeCount":97},[],{"trials":61041,"activeCount":97},[],{"trials":61043,"activeCount":97},[],{"intervention":61045,"totalTrials":660,"cells":61046},"0.3% GSK1940029 gel",{"EARLY_PHASE1":61047,"PHASE1":61049,"PHASE2":61068,"PHASE3":61070,"PHASE4":61072,"NA":61074},{"trials":61048,"activeCount":97},[],{"trials":61050,"activeCount":97},[61051,61060],{"nctId":61052,"briefTitle":61053,"status":155,"phases":61054,"primaryCompletion":61055,"completion":61055,"start":18032,"enrollment":10794,"conditions":61056,"interventions":61057},"NCT01938482","Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029",[85],"2015-02-17",[15087],[61045,61058,61059],"1% GSK1940029 gel","0.3%\u002F1% vehicle gel only",{"nctId":61061,"briefTitle":61062,"status":155,"phases":61063,"primaryCompletion":61064,"completion":61064,"start":61065,"enrollment":1686,"conditions":61066,"interventions":61067},"NCT01984801","Study to Investigate the Irritation Potential of GSK1940029 Gel",[85],"2015-04-10","2013-10-14",[15087],[61045,61058,61059],{"trials":61069,"activeCount":97},[],{"trials":61071,"activeCount":97},[],{"trials":61073,"activeCount":97},[],{"trials":61075,"activeCount":97},[],{"intervention":61058,"totalTrials":660,"cells":61077},{"EARLY_PHASE1":61078,"PHASE1":61080,"PHASE2":61090,"PHASE3":61092,"PHASE4":61094,"NA":61096},{"trials":61079,"activeCount":97},[],{"trials":61081,"activeCount":97},[61082,61086],{"nctId":61052,"briefTitle":61053,"status":155,"phases":61083,"primaryCompletion":61055,"completion":61055,"start":18032,"enrollment":10794,"conditions":61084,"interventions":61085},[85],[15087],[61045,61058,61059],{"nctId":61061,"briefTitle":61062,"status":155,"phases":61087,"primaryCompletion":61064,"completion":61064,"start":61065,"enrollment":1686,"conditions":61088,"interventions":61089},[85],[15087],[61045,61058,61059],{"trials":61091,"activeCount":97},[],{"trials":61093,"activeCount":97},[],{"trials":61095,"activeCount":97},[],{"trials":61097,"activeCount":97},[],{"intervention":61059,"totalTrials":660,"cells":61099},{"EARLY_PHASE1":61100,"PHASE1":61102,"PHASE2":61112,"PHASE3":61114,"PHASE4":61116,"NA":61118},{"trials":61101,"activeCount":97},[],{"trials":61103,"activeCount":97},[61104,61108],{"nctId":61052,"briefTitle":61053,"status":155,"phases":61105,"primaryCompletion":61055,"completion":61055,"start":18032,"enrollment":10794,"conditions":61106,"interventions":61107},[85],[15087],[61045,61058,61059],{"nctId":61061,"briefTitle":61062,"status":155,"phases":61109,"primaryCompletion":61064,"completion":61064,"start":61065,"enrollment":1686,"conditions":61110,"interventions":61111},[85],[15087],[61045,61058,61059],{"trials":61113,"activeCount":97},[],{"trials":61115,"activeCount":97},[],{"trials":61117,"activeCount":97},[],{"trials":61119,"activeCount":97},[],{"intervention":170,"totalTrials":660,"cells":61121},{"EARLY_PHASE1":61122,"PHASE1":61124,"PHASE2":61138,"PHASE3":61140,"PHASE4":61142,"NA":61144},{"trials":61123,"activeCount":97},[],{"trials":61125,"activeCount":97},[61126,61134],{"nctId":61127,"briefTitle":61128,"status":145,"phases":61129,"primaryCompletion":61130,"completion":61130,"start":61131,"enrollment":463,"conditions":61132,"interventions":61133},"NCT04349280","A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer",[85],"2022-08-15","2020-10-15",[107],[170],{"nctId":153,"briefTitle":154,"status":155,"phases":61135,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":61136,"interventions":61137},[85],[107],[162,163,137,164,165,166,167,168,92,169,170],{"trials":61139,"activeCount":97},[],{"trials":61141,"activeCount":97},[],{"trials":61143,"activeCount":97},[],{"trials":61145,"activeCount":97},[],{"intervention":6802,"totalTrials":660,"cells":61147},{"EARLY_PHASE1":61148,"PHASE1":61150,"PHASE2":61163,"PHASE3":61165,"PHASE4":61167,"NA":61169},{"trials":61149,"activeCount":97},[],{"trials":61151,"activeCount":97},[61152,61156],{"nctId":6795,"briefTitle":6796,"status":155,"phases":61153,"primaryCompletion":6798,"completion":6798,"start":6799,"enrollment":1335,"conditions":61154,"interventions":61155},[85],[107],[6802,1891],{"nctId":61157,"briefTitle":61158,"status":155,"phases":61159,"primaryCompletion":61160,"completion":12064,"start":59864,"enrollment":255,"conditions":61161,"interventions":61162},"NCT01458067","A Phase I\u002FIIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency",[85],"2015-11-12",[36],[6802],{"trials":61164,"activeCount":97},[],{"trials":61166,"activeCount":97},[],{"trials":61168,"activeCount":97},[],{"trials":61170,"activeCount":97},[],{"intervention":18007,"totalTrials":660,"cells":61172},{"EARLY_PHASE1":61173,"PHASE1":61175,"PHASE2":61185,"PHASE3":61187,"PHASE4":61189,"NA":61191},{"trials":61174,"activeCount":97},[],{"trials":61176,"activeCount":97},[61177,61181],{"nctId":17999,"briefTitle":18000,"status":155,"phases":61178,"primaryCompletion":18002,"completion":18002,"start":18003,"enrollment":314,"conditions":61179,"interventions":61180},[85],[17996],[17974,18006,18007],{"nctId":42433,"briefTitle":42434,"status":155,"phases":61182,"primaryCompletion":39677,"completion":39677,"start":11960,"enrollment":6503,"conditions":61183,"interventions":61184},[85],[36],[42422,9325,18007,42438,42439],{"trials":61186,"activeCount":97},[],{"trials":61188,"activeCount":97},[],{"trials":61190,"activeCount":97},[],{"trials":61192,"activeCount":97},[],{"intervention":61194,"totalTrials":660,"cells":61195},"GSK2239633",{"EARLY_PHASE1":61196,"PHASE1":61198,"PHASE2":61213,"PHASE3":61215,"PHASE4":61217,"NA":61219},{"trials":61197,"activeCount":97},[],{"trials":61199,"activeCount":97},[61200,61206],{"nctId":61201,"briefTitle":61202,"status":155,"phases":61203,"primaryCompletion":11961,"completion":11961,"start":60884,"enrollment":1298,"conditions":61204,"interventions":61205},"NCT01371812","GSK2239633 FTIH Study",[85],[18],[61194],{"nctId":61207,"briefTitle":61208,"status":155,"phases":61209,"primaryCompletion":26151,"completion":26151,"start":61210,"enrollment":628,"conditions":61211,"interventions":61212},"NCT01086462","Intravenous Microdose Pharmacokinetic (PK) Study With [14C]-GSK2239633",[85],"2010-01-21",[18],[61194],{"trials":61214,"activeCount":97},[],{"trials":61216,"activeCount":97},[],{"trials":61218,"activeCount":97},[],{"trials":61220,"activeCount":97},[],{"intervention":61222,"totalTrials":660,"cells":61223},"GSK1265744",{"EARLY_PHASE1":61224,"PHASE1":61226,"PHASE2":61240,"PHASE3":61242,"PHASE4":61244,"NA":61246},{"trials":61225,"activeCount":97},[],{"trials":61227,"activeCount":97},[61228,61234],{"nctId":61229,"briefTitle":61230,"status":155,"phases":61231,"primaryCompletion":10166,"completion":10166,"start":9737,"enrollment":7712,"conditions":61232,"interventions":61233},"NCT00659191","A Healthy Volunteer And Patient Study To Assess The Safety, Tolerability And Pharmacokinetics Of GSK1265744",[85],[10662],[61222],{"nctId":61235,"briefTitle":61236,"status":155,"phases":61237,"primaryCompletion":1429,"completion":1429,"start":2441,"enrollment":1459,"conditions":61238,"interventions":61239},"NCT00920296","DDI Study of Etravirine and GSK1265744",[85],[7524,9343],[61222],{"trials":61241,"activeCount":97},[],{"trials":61243,"activeCount":97},[],{"trials":61245,"activeCount":97},[],{"trials":61247,"activeCount":97},[],{"intervention":61249,"totalTrials":660,"cells":61250},"GSK690693",{"EARLY_PHASE1":61251,"PHASE1":61253,"PHASE2":61267,"PHASE3":61269,"PHASE4":61271,"NA":61273},{"trials":61252,"activeCount":97},[],{"trials":61254,"activeCount":97},[61255,61261],{"nctId":61256,"briefTitle":61257,"status":145,"phases":61258,"primaryCompletion":7546,"completion":7546,"start":4756,"enrollment":730,"conditions":61259,"interventions":61260},"NCT00493818","Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693",[85],[36],[61249],{"nctId":61262,"briefTitle":61263,"status":500,"phases":61264,"primaryCompletion":7658,"completion":7658,"start":2355,"enrollment":97,"conditions":61265,"interventions":61266},"NCT00666081","Study to Investigate AKT Inhibitor GSK690693 in Subjects With Relapsed or Refractory Hematologic Malignancies",[85],[36],[61249],{"trials":61268,"activeCount":97},[],{"trials":61270,"activeCount":97},[],{"trials":61272,"activeCount":97},[],{"trials":61274,"activeCount":97},[],{"intervention":61276,"totalTrials":660,"cells":61277},"Nicotine Prototype Mini lozenge",{"EARLY_PHASE1":61278,"PHASE1":61280,"PHASE2":61297,"PHASE3":61299,"PHASE4":61301,"NA":61303},{"trials":61279,"activeCount":97},[],{"trials":61281,"activeCount":97},[61282,61291],{"nctId":61283,"briefTitle":61284,"status":155,"phases":61285,"primaryCompletion":61286,"completion":61286,"start":16971,"enrollment":4121,"conditions":61287,"interventions":61289},"NCT03541044","A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Healthy Smokers",[85],"2019-03-24",[61288],"Tobacco Use Disorder",[61276,61290],"Nicorette Mini Lozenge",{"nctId":61292,"briefTitle":61293,"status":155,"phases":61294,"primaryCompletion":19585,"completion":19585,"start":16971,"enrollment":1335,"conditions":61295,"interventions":61296},"NCT03543137","To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers",[85],[61288],[61276,61290],{"trials":61298,"activeCount":97},[],{"trials":61300,"activeCount":97},[],{"trials":61302,"activeCount":97},[],{"trials":61304,"activeCount":97},[],{"intervention":61290,"totalTrials":660,"cells":61306},{"EARLY_PHASE1":61307,"PHASE1":61309,"PHASE2":61319,"PHASE3":61321,"PHASE4":61323,"NA":61325},{"trials":61308,"activeCount":97},[],{"trials":61310,"activeCount":97},[61311,61315],{"nctId":61283,"briefTitle":61284,"status":155,"phases":61312,"primaryCompletion":61286,"completion":61286,"start":16971,"enrollment":4121,"conditions":61313,"interventions":61314},[85],[61288],[61276,61290],{"nctId":61292,"briefTitle":61293,"status":155,"phases":61316,"primaryCompletion":19585,"completion":19585,"start":16971,"enrollment":1335,"conditions":61317,"interventions":61318},[85],[61288],[61276,61290],{"trials":61320,"activeCount":97},[],{"trials":61322,"activeCount":97},[],{"trials":61324,"activeCount":97},[],{"trials":61326,"activeCount":97},[],{"intervention":61328,"totalTrials":660,"cells":61329},"GSK2982772 Modified Release",{"EARLY_PHASE1":61330,"PHASE1":61332,"PHASE2":61349,"PHASE3":61351,"PHASE4":61353,"NA":61355},{"trials":61331,"activeCount":97},[],{"trials":61333,"activeCount":97},[61334,61341],{"nctId":61335,"briefTitle":61336,"status":155,"phases":61337,"primaryCompletion":44366,"completion":44366,"start":39894,"enrollment":2797,"conditions":61338,"interventions":61339},"NCT03649412","A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772",[85],[39897],[61328,61340],"GSK2982772 Immediate Release",{"nctId":61342,"briefTitle":61343,"status":155,"phases":61344,"primaryCompletion":61345,"completion":61345,"start":61346,"enrollment":6369,"conditions":61347,"interventions":61348},"NCT03266172","A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses",[85],"2018-11-21","2017-09-27",[39897],[61328,61340],{"trials":61350,"activeCount":97},[],{"trials":61352,"activeCount":97},[],{"trials":61354,"activeCount":97},[],{"trials":61356,"activeCount":97},[],{"intervention":61340,"totalTrials":660,"cells":61358},{"EARLY_PHASE1":61359,"PHASE1":61361,"PHASE2":61371,"PHASE3":61373,"PHASE4":61375,"NA":61377},{"trials":61360,"activeCount":97},[],{"trials":61362,"activeCount":97},[61363,61367],{"nctId":61335,"briefTitle":61336,"status":155,"phases":61364,"primaryCompletion":44366,"completion":44366,"start":39894,"enrollment":2797,"conditions":61365,"interventions":61366},[85],[39897],[61328,61340],{"nctId":61342,"briefTitle":61343,"status":155,"phases":61368,"primaryCompletion":61345,"completion":61345,"start":61346,"enrollment":6369,"conditions":61369,"interventions":61370},[85],[39897],[61328,61340],{"trials":61372,"activeCount":97},[],{"trials":61374,"activeCount":97},[],{"trials":61376,"activeCount":97},[],{"trials":61378,"activeCount":97},[],{"intervention":18159,"totalTrials":660,"cells":61380},{"EARLY_PHASE1":61381,"PHASE1":61383,"PHASE2":61396,"PHASE3":61398,"PHASE4":61400,"NA":61402},{"trials":61382,"activeCount":97},[],{"trials":61384,"activeCount":97},[61385,61392],{"nctId":61386,"briefTitle":61387,"status":155,"phases":61388,"primaryCompletion":9056,"completion":9056,"start":61389,"enrollment":526,"conditions":61390,"interventions":61391},"NCT01725100","A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies",[85],"2013-02-05",[36],[18159,18159],{"nctId":18152,"briefTitle":18153,"status":155,"phases":61393,"primaryCompletion":18155,"completion":18155,"start":18156,"enrollment":628,"conditions":61394,"interventions":61395},[85],[36],[3115,18159],{"trials":61397,"activeCount":97},[],{"trials":61399,"activeCount":97},[],{"trials":61401,"activeCount":97},[],{"trials":61403,"activeCount":97},[],{"intervention":4056,"totalTrials":660,"cells":61405},{"EARLY_PHASE1":61406,"PHASE1":61408,"PHASE2":61418,"PHASE3":61420,"PHASE4":61422,"NA":61424},{"trials":61407,"activeCount":97},[],{"trials":61409,"activeCount":97},[61410,61414],{"nctId":4049,"briefTitle":4050,"status":155,"phases":61411,"primaryCompletion":4052,"completion":4052,"start":4053,"enrollment":3025,"conditions":61412,"interventions":61413},[85],[4045],[4056,4032],{"nctId":39786,"briefTitle":39787,"status":155,"phases":61415,"primaryCompletion":6519,"completion":6519,"start":39789,"enrollment":421,"conditions":61416,"interventions":61417},[85],[4071],[9060,4056],{"trials":61419,"activeCount":97},[],{"trials":61421,"activeCount":97},[],{"trials":61423,"activeCount":97},[],{"trials":61425,"activeCount":97},[],{"intervention":61427,"totalTrials":660,"cells":61428},"GSK256073A",{"EARLY_PHASE1":61429,"PHASE1":61431,"PHASE2":61445,"PHASE3":61447,"PHASE4":61449,"NA":61451},{"trials":61430,"activeCount":97},[],{"trials":61432,"activeCount":97},[61433,61439],{"nctId":61434,"briefTitle":61435,"status":155,"phases":61436,"primaryCompletion":2804,"completion":2804,"start":8426,"enrollment":181,"conditions":61437,"interventions":61438},"NCT00551694","A Second Study to Determine the Effect of GSK256073A on HVTs",[85],[7524,27251],[61427],{"nctId":61440,"briefTitle":61441,"status":155,"phases":61442,"primaryCompletion":3079,"completion":3079,"start":3552,"enrollment":904,"conditions":61443,"interventions":61444},"NCT00488449","Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers",[85],[7524,27251],[61427],{"trials":61446,"activeCount":97},[],{"trials":61448,"activeCount":97},[],{"trials":61450,"activeCount":97},[],{"trials":61452,"activeCount":97},[],{"intervention":59854,"totalTrials":660,"cells":61454},{"EARLY_PHASE1":61455,"PHASE1":61457,"PHASE2":61467,"PHASE3":61469,"PHASE4":61471,"NA":61473},{"trials":61456,"activeCount":97},[],{"trials":61458,"activeCount":97},[61459,61463],{"nctId":59846,"briefTitle":59847,"status":155,"phases":61460,"primaryCompletion":59849,"completion":59849,"start":59850,"enrollment":730,"conditions":61461,"interventions":61462},[85],[17996],[59853,59854,23669,59855],{"nctId":59861,"briefTitle":59862,"status":155,"phases":61464,"primaryCompletion":59864,"completion":59864,"start":24504,"enrollment":1298,"conditions":61465,"interventions":61466},[85],[21782],[59867,59868,59854,59869,23669],{"trials":61468,"activeCount":97},[],{"trials":61470,"activeCount":97},[],{"trials":61472,"activeCount":97},[],{"trials":61474,"activeCount":97},[],{"intervention":19725,"totalTrials":660,"cells":61476},{"EARLY_PHASE1":61477,"PHASE1":61479,"PHASE2":61491,"PHASE3":61493,"PHASE4":61495,"NA":61497},{"trials":61478,"activeCount":97},[],{"trials":61480,"activeCount":97},[61481,61485],{"nctId":19720,"briefTitle":19721,"status":155,"phases":61482,"primaryCompletion":14583,"completion":14583,"start":4826,"enrollment":710,"conditions":61483,"interventions":61484},[85],[15],[19725,19693],{"nctId":61486,"briefTitle":61487,"status":155,"phases":61488,"primaryCompletion":39262,"completion":39262,"start":49690,"enrollment":314,"conditions":61489,"interventions":61490},"NCT00551811","Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone",[85],[15],[19725],{"trials":61492,"activeCount":97},[],{"trials":61494,"activeCount":97},[],{"trials":61496,"activeCount":97},[],{"trials":61498,"activeCount":97},[],{"intervention":20525,"totalTrials":660,"cells":61500},{"EARLY_PHASE1":61501,"PHASE1":61503,"PHASE2":61513,"PHASE3":61515,"PHASE4":61517,"NA":61519},{"trials":61502,"activeCount":97},[],{"trials":61504,"activeCount":97},[61505,61509],{"nctId":20518,"briefTitle":20519,"status":155,"phases":61506,"primaryCompletion":20521,"completion":20521,"start":20522,"enrollment":1264,"conditions":61507,"interventions":61508},[85],[27],[20525,9061],{"nctId":39793,"briefTitle":39794,"status":155,"phases":61510,"primaryCompletion":39796,"completion":39796,"start":39797,"enrollment":904,"conditions":61511,"interventions":61512},[85],[27],[9060,20525],{"trials":61514,"activeCount":97},[],{"trials":61516,"activeCount":97},[],{"trials":61518,"activeCount":97},[],{"trials":61520,"activeCount":97},[],{"intervention":61522,"totalTrials":660,"cells":61523},"FF 400 mcg",{"EARLY_PHASE1":61524,"PHASE1":61526,"PHASE2":61545,"PHASE3":61547,"PHASE4":61549,"NA":61551},{"trials":61525,"activeCount":97},[],{"trials":61527,"activeCount":97},[61528,61537],{"nctId":61529,"briefTitle":61530,"status":155,"phases":61531,"primaryCompletion":61532,"completion":61532,"start":17206,"enrollment":1634,"conditions":61533,"interventions":61534},"NCT01725685","To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)\u002F Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)",[85],"2013-01-02",[18],[61522,61535,61536],"UMEC 500 mcg","FF\u002FUMEC 400\u002F500 mcg",{"nctId":61538,"briefTitle":61539,"status":155,"phases":61540,"primaryCompletion":22918,"completion":22918,"start":4984,"enrollment":6503,"conditions":61541,"interventions":61542},"NCT01894386","Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses",[85],[15],[61522,61535,61543,61544],"UMEC 250 mcg","VI 100 mcg",{"trials":61546,"activeCount":97},[],{"trials":61548,"activeCount":97},[],{"trials":61550,"activeCount":97},[],{"trials":61552,"activeCount":97},[],{"intervention":61535,"totalTrials":660,"cells":61554},{"EARLY_PHASE1":61555,"PHASE1":61557,"PHASE2":61567,"PHASE3":61569,"PHASE4":61571,"NA":61573},{"trials":61556,"activeCount":97},[],{"trials":61558,"activeCount":97},[61559,61563],{"nctId":61529,"briefTitle":61530,"status":155,"phases":61560,"primaryCompletion":61532,"completion":61532,"start":17206,"enrollment":1634,"conditions":61561,"interventions":61562},[85],[18],[61522,61535,61536],{"nctId":61538,"briefTitle":61539,"status":155,"phases":61564,"primaryCompletion":22918,"completion":22918,"start":4984,"enrollment":6503,"conditions":61565,"interventions":61566},[85],[15],[61522,61535,61543,61544],{"trials":61568,"activeCount":97},[],{"trials":61570,"activeCount":97},[],{"trials":61572,"activeCount":97},[],{"trials":61574,"activeCount":97},[],{"intervention":61576,"totalTrials":660,"cells":61577},"GSK1018921",{"EARLY_PHASE1":61578,"PHASE1":61580,"PHASE2":61596,"PHASE3":61598,"PHASE4":61600,"NA":61602},{"trials":61579,"activeCount":97},[],{"trials":61581,"activeCount":97},[61582,61588],{"nctId":61583,"briefTitle":61584,"status":155,"phases":61585,"primaryCompletion":19910,"completion":19910,"start":18263,"enrollment":1459,"conditions":61586,"interventions":61587},"NCT00945503","Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.",[85],[11346],[61576],{"nctId":61589,"briefTitle":61590,"status":155,"phases":61591,"primaryCompletion":21927,"completion":21927,"start":61592,"enrollment":9334,"conditions":61593,"interventions":61594},"NCT00527020","First Time in Human Study With GSK1018921",[85],"2007-08-10",[11346],[61576,61595],"Nicotine Lozenges",{"trials":61597,"activeCount":97},[],{"trials":61599,"activeCount":97},[],{"trials":61601,"activeCount":97},[],{"trials":61603,"activeCount":97},[],{"intervention":61605,"totalTrials":660,"cells":61606},"Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one",{"EARLY_PHASE1":61607,"PHASE1":61609,"PHASE2":61627,"PHASE3":61629,"PHASE4":61631,"NA":61633},{"trials":61608,"activeCount":97},[],{"trials":61610,"activeCount":97},[61611,61621],{"nctId":61612,"briefTitle":61613,"status":155,"phases":61614,"primaryCompletion":24580,"completion":24580,"start":11540,"enrollment":1298,"conditions":61615,"interventions":61617},"NCT01847417","Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fed Conditions",[85],[61616],"Ulcers, Duodenal and Gastric",[61605,61618,61619,61620],"Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two","ASA 100 mg","Pantoprazole 20 mg gastro-resistant",{"nctId":61622,"briefTitle":61623,"status":155,"phases":61624,"primaryCompletion":29759,"completion":29759,"start":18873,"enrollment":1298,"conditions":61625,"interventions":61626},"NCT01847404","Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fasting Conditions",[85],[61616],[61605,61618,61619,61620],{"trials":61628,"activeCount":97},[],{"trials":61630,"activeCount":97},[],{"trials":61632,"activeCount":97},[],{"trials":61634,"activeCount":97},[],{"intervention":61618,"totalTrials":660,"cells":61636},{"EARLY_PHASE1":61637,"PHASE1":61639,"PHASE2":61649,"PHASE3":61651,"PHASE4":61653,"NA":61655},{"trials":61638,"activeCount":97},[],{"trials":61640,"activeCount":97},[61641,61645],{"nctId":61612,"briefTitle":61613,"status":155,"phases":61642,"primaryCompletion":24580,"completion":24580,"start":11540,"enrollment":1298,"conditions":61643,"interventions":61644},[85],[61616],[61605,61618,61619,61620],{"nctId":61622,"briefTitle":61623,"status":155,"phases":61646,"primaryCompletion":29759,"completion":29759,"start":18873,"enrollment":1298,"conditions":61647,"interventions":61648},[85],[61616],[61605,61618,61619,61620],{"trials":61650,"activeCount":97},[],{"trials":61652,"activeCount":97},[],{"trials":61654,"activeCount":97},[],{"trials":61656,"activeCount":97},[],{"intervention":61619,"totalTrials":660,"cells":61658},{"EARLY_PHASE1":61659,"PHASE1":61661,"PHASE2":61671,"PHASE3":61673,"PHASE4":61675,"NA":61677},{"trials":61660,"activeCount":97},[],{"trials":61662,"activeCount":97},[61663,61667],{"nctId":61612,"briefTitle":61613,"status":155,"phases":61664,"primaryCompletion":24580,"completion":24580,"start":11540,"enrollment":1298,"conditions":61665,"interventions":61666},[85],[61616],[61605,61618,61619,61620],{"nctId":61622,"briefTitle":61623,"status":155,"phases":61668,"primaryCompletion":29759,"completion":29759,"start":18873,"enrollment":1298,"conditions":61669,"interventions":61670},[85],[61616],[61605,61618,61619,61620],{"trials":61672,"activeCount":97},[],{"trials":61674,"activeCount":97},[],{"trials":61676,"activeCount":97},[],{"trials":61678,"activeCount":97},[],{"intervention":61620,"totalTrials":660,"cells":61680},{"EARLY_PHASE1":61681,"PHASE1":61683,"PHASE2":61693,"PHASE3":61695,"PHASE4":61697,"NA":61699},{"trials":61682,"activeCount":97},[],{"trials":61684,"activeCount":97},[61685,61689],{"nctId":61612,"briefTitle":61613,"status":155,"phases":61686,"primaryCompletion":24580,"completion":24580,"start":11540,"enrollment":1298,"conditions":61687,"interventions":61688},[85],[61616],[61605,61618,61619,61620],{"nctId":61622,"briefTitle":61623,"status":155,"phases":61690,"primaryCompletion":29759,"completion":29759,"start":18873,"enrollment":1298,"conditions":61691,"interventions":61692},[85],[61616],[61605,61618,61619,61620],{"trials":61694,"activeCount":97},[],{"trials":61696,"activeCount":97},[],{"trials":61698,"activeCount":97},[],{"trials":61700,"activeCount":97},[],{"intervention":61702,"totalTrials":660,"cells":61703},"Reference Montelukast",{"EARLY_PHASE1":61704,"PHASE1":61706,"PHASE2":61726,"PHASE3":61728,"PHASE4":61730,"NA":61732},{"trials":61705,"activeCount":97},[],{"trials":61707,"activeCount":97},[61708,61718],{"nctId":61709,"briefTitle":61710,"status":155,"phases":61711,"primaryCompletion":61712,"completion":61712,"start":61713,"enrollment":1634,"conditions":61714,"interventions":61715},"NCT02322671","Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects",[85],"2015-04-20","2015-02-23",[9855],[61702,61716,61717],"Test 1 Montelukast","Test 2 Montelukast",{"nctId":61719,"briefTitle":61720,"status":155,"phases":61721,"primaryCompletion":61722,"completion":61722,"start":8696,"enrollment":2045,"conditions":61723,"interventions":61724},"NCT02658422","Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under Fasting Conditions",[85],"2015-09-21",[9855,42132],[61725,61702],"Test Montelukast",{"trials":61727,"activeCount":97},[],{"trials":61729,"activeCount":97},[],{"trials":61731,"activeCount":97},[],{"trials":61733,"activeCount":97},[],{"intervention":9163,"totalTrials":660,"cells":61735},{"EARLY_PHASE1":61736,"PHASE1":61738,"PHASE2":61751,"PHASE3":61753,"PHASE4":61755,"NA":61757},{"trials":61737,"activeCount":97},[],{"trials":61739,"activeCount":97},[61740,61744],{"nctId":9156,"briefTitle":9157,"status":155,"phases":61741,"primaryCompletion":9159,"completion":9159,"start":8468,"enrollment":473,"conditions":61742,"interventions":61743},[85],[9161],[4763,9163,9164,9165,9166],{"nctId":61745,"briefTitle":61746,"status":155,"phases":61747,"primaryCompletion":2442,"completion":2442,"start":2442,"enrollment":1459,"conditions":61748,"interventions":61749},"NCT01551836","At What Time Therapeutic Plasma Concentrations of Paracetamol Are Achieved in Two Marketed Formulations",[85],[19301],[9163,61750],"Paracetamol formulation 2",{"trials":61752,"activeCount":97},[],{"trials":61754,"activeCount":97},[],{"trials":61756,"activeCount":97},[],{"trials":61758,"activeCount":97},[],{"intervention":9164,"totalTrials":660,"cells":61760},{"EARLY_PHASE1":61761,"PHASE1":61763,"PHASE2":61773,"PHASE3":61775,"PHASE4":61777,"NA":61779},{"trials":61762,"activeCount":97},[],{"trials":61764,"activeCount":97},[61765,61769],{"nctId":9156,"briefTitle":9157,"status":155,"phases":61766,"primaryCompletion":9159,"completion":9159,"start":8468,"enrollment":473,"conditions":61767,"interventions":61768},[85],[9161],[4763,9163,9164,9165,9166],{"nctId":61745,"briefTitle":61746,"status":155,"phases":61770,"primaryCompletion":2442,"completion":2442,"start":2442,"enrollment":1459,"conditions":61771,"interventions":61772},[85],[19301],[9163,61750],{"trials":61774,"activeCount":97},[],{"trials":61776,"activeCount":97},[],{"trials":61778,"activeCount":97},[],{"trials":61780,"activeCount":97},[],{"intervention":61782,"totalTrials":660,"cells":61783},"Candesartan cilexetil",{"EARLY_PHASE1":61784,"PHASE1":61786,"PHASE2":61801,"PHASE3":61803,"PHASE4":61805,"NA":61807},{"trials":61785,"activeCount":97},[],{"trials":61787,"activeCount":97},[61788,61795],{"nctId":61789,"briefTitle":61790,"status":155,"phases":61791,"primaryCompletion":19164,"completion":19164,"start":61792,"enrollment":433,"conditions":61793,"interventions":61794},"NCT02006589","Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions",[85],"2013-12-11",[13024],[61782,61782],{"nctId":61796,"briefTitle":61797,"status":155,"phases":61798,"primaryCompletion":19164,"completion":19164,"start":39342,"enrollment":433,"conditions":61799,"interventions":61800},"NCT02006602","Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions",[85],[13024],[61782,61782],{"trials":61802,"activeCount":97},[],{"trials":61804,"activeCount":97},[],{"trials":61806,"activeCount":97},[],{"trials":61808,"activeCount":97},[],{"intervention":61810,"totalTrials":660,"cells":61811},"GSK424887",{"EARLY_PHASE1":61812,"PHASE1":61814,"PHASE2":61832,"PHASE3":61834,"PHASE4":61836,"NA":61838},{"trials":61813,"activeCount":97},[],{"trials":61815,"activeCount":97},[61816,61823],{"nctId":61817,"briefTitle":61818,"status":155,"phases":61819,"primaryCompletion":25456,"completion":25456,"start":61820,"enrollment":93,"conditions":61821,"interventions":61822},"NCT01059591","First Study in Humans With GSK424887",[85],"2006-05-25",[41867],[61810],{"nctId":61824,"briefTitle":61825,"status":155,"phases":61826,"primaryCompletion":61827,"completion":61827,"start":8795,"enrollment":1686,"conditions":61828,"interventions":61829},"NCT01424384","Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic",[85],"2009-04-30",[41867],[61830,61810,61831],"Citalopram","Plactebo To Match",{"trials":61833,"activeCount":97},[],{"trials":61835,"activeCount":97},[],{"trials":61837,"activeCount":97},[],{"trials":61839,"activeCount":97},[],{"intervention":61841,"totalTrials":660,"cells":61842},"GSK1034702",{"EARLY_PHASE1":61843,"PHASE1":61845,"PHASE2":61859,"PHASE3":61861,"PHASE4":61863,"NA":61865},{"trials":61844,"activeCount":97},[],{"trials":61846,"activeCount":97},[61847,61853],{"nctId":61848,"briefTitle":61849,"status":155,"phases":61850,"primaryCompletion":38241,"completion":38241,"start":42642,"enrollment":181,"conditions":61851,"interventions":61852},"NCT00937846","Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study",[85],[60399],[61841],{"nctId":61854,"briefTitle":61855,"status":155,"phases":61856,"primaryCompletion":39065,"completion":39065,"start":4790,"enrollment":255,"conditions":61857,"interventions":61858},"NCT00743405","Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects",[85],[60399],[61841],{"trials":61860,"activeCount":97},[],{"trials":61862,"activeCount":97},[],{"trials":61864,"activeCount":97},[],{"trials":61866,"activeCount":97},[],{"intervention":9347,"totalTrials":660,"cells":61868},{"EARLY_PHASE1":61869,"PHASE1":61871,"PHASE2":61881,"PHASE3":61883,"PHASE4":61885,"NA":61887},{"trials":61870,"activeCount":97},[],{"trials":61872,"activeCount":97},[61873,61877],{"nctId":19736,"briefTitle":19737,"status":155,"phases":61874,"primaryCompletion":3391,"completion":3391,"start":11030,"enrollment":473,"conditions":61875,"interventions":61876},[85],[9343],[9347,19693,10390,9324],{"nctId":9339,"briefTitle":9340,"status":155,"phases":61878,"primaryCompletion":6351,"completion":6351,"start":2442,"enrollment":1298,"conditions":61879,"interventions":61880},[85],[7524,9343],[9345,9346,6488,9323,9273,9347],{"trials":61882,"activeCount":97},[],{"trials":61884,"activeCount":97},[],{"trials":61886,"activeCount":97},[],{"trials":61888,"activeCount":97},[],{"intervention":39203,"totalTrials":660,"cells":61890},{"EARLY_PHASE1":61891,"PHASE1":61893,"PHASE2":61903,"PHASE3":61905,"PHASE4":61907,"NA":61909},{"trials":61892,"activeCount":97},[],{"trials":61894,"activeCount":97},[61895,61899],{"nctId":39196,"briefTitle":39197,"status":155,"phases":61896,"primaryCompletion":37724,"completion":37724,"start":39199,"enrollment":8786,"conditions":61897,"interventions":61898},[85],[26760],[39202,9302,39203],{"nctId":41861,"briefTitle":41862,"status":155,"phases":61900,"primaryCompletion":41864,"completion":41864,"start":41865,"enrollment":454,"conditions":61901,"interventions":61902},[85],[41867],[41869,39203,39202],{"trials":61904,"activeCount":97},[],{"trials":61906,"activeCount":97},[],{"trials":61908,"activeCount":97},[],{"trials":61910,"activeCount":97},[],{"intervention":6818,"totalTrials":660,"cells":61912},{"EARLY_PHASE1":61913,"PHASE1":61915,"PHASE2":61925,"PHASE3":61927,"PHASE4":61929,"NA":61931},{"trials":61914,"activeCount":97},[],{"trials":61916,"activeCount":97},[61917,61921],{"nctId":6808,"briefTitle":6809,"status":145,"phases":61918,"primaryCompletion":6811,"completion":6812,"start":6813,"enrollment":6814,"conditions":61919,"interventions":61920},[85],[2761],[6817,6818,1891,6819],{"nctId":6821,"briefTitle":6822,"status":500,"phases":61922,"primaryCompletion":6824,"completion":6824,"start":483,"enrollment":97,"conditions":61923,"interventions":61924},[85],[36],[6827,1891,6818,6819],{"trials":61926,"activeCount":97},[],{"trials":61928,"activeCount":97},[],{"trials":61930,"activeCount":97},[],{"trials":61932,"activeCount":97},[],{"intervention":21035,"totalTrials":660,"cells":61934},{"EARLY_PHASE1":61935,"PHASE1":61937,"PHASE2":61949,"PHASE3":61951,"PHASE4":61953,"NA":61955},{"trials":61936,"activeCount":97},[],{"trials":61938,"activeCount":97},[61939,61945],{"nctId":61940,"briefTitle":61941,"status":155,"phases":61942,"primaryCompletion":2804,"completion":2804,"start":8426,"enrollment":1003,"conditions":61943,"interventions":61944},"NCT00556920","Study to Demonstrate the Bioequivalence of the Fixed Dose Combination of COREG CR™ and Lisinopril to Its Components",[85],[13024],[21035],{"nctId":21030,"briefTitle":21031,"status":155,"phases":61946,"primaryCompletion":2804,"completion":2804,"start":2356,"enrollment":10794,"conditions":61947,"interventions":61948},[85],[13024],[21035,21028],{"trials":61950,"activeCount":97},[],{"trials":61952,"activeCount":97},[],{"trials":61954,"activeCount":97},[],{"trials":61956,"activeCount":97},[],{"intervention":61958,"totalTrials":660,"cells":61959},"GSK2269557 ELLIPTA DPI",{"EARLY_PHASE1":61960,"PHASE1":61962,"PHASE2":61979,"PHASE3":61981,"PHASE4":61983,"NA":61985},{"trials":61961,"activeCount":97},[],{"trials":61963,"activeCount":97},[61964,61973],{"nctId":61965,"briefTitle":61966,"status":155,"phases":61967,"primaryCompletion":61968,"completion":61968,"start":61969,"enrollment":2836,"conditions":61970,"interventions":61971},"NCT02691325","Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects",[85],"2016-06-05","2016-03-14",[15],[61958,61972],"Activated charcoal",{"nctId":61974,"briefTitle":61975,"status":155,"phases":61976,"primaryCompletion":2392,"completion":2392,"start":41085,"enrollment":710,"conditions":61977,"interventions":61978},"NCT02972905","Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects",[85],[15],[61958],{"trials":61980,"activeCount":97},[],{"trials":61982,"activeCount":97},[],{"trials":61984,"activeCount":97},[],{"trials":61986,"activeCount":97},[],{"intervention":41367,"totalTrials":660,"cells":61988},{"EARLY_PHASE1":61989,"PHASE1":61991,"PHASE2":62001,"PHASE3":62003,"PHASE4":62005,"NA":62007},{"trials":61990,"activeCount":97},[],{"trials":61992,"activeCount":97},[61993,61997],{"nctId":41361,"briefTitle":41362,"status":500,"phases":61994,"primaryCompletion":34933,"completion":34933,"start":3551,"enrollment":97,"conditions":61995,"interventions":61996},[85],[18],[41354,41366,41367,41368,41369],{"nctId":59822,"briefTitle":59823,"status":155,"phases":61998,"primaryCompletion":46691,"completion":46691,"start":59825,"enrollment":3672,"conditions":61999,"interventions":62000},[85],[18],[59828,59829,59830,39362],{"trials":62002,"activeCount":97},[],{"trials":62004,"activeCount":97},[],{"trials":62006,"activeCount":97},[],{"trials":62008,"activeCount":97},[],{"intervention":62010,"totalTrials":660,"cells":62011},"GSK1362885",{"EARLY_PHASE1":62012,"PHASE1":62014,"PHASE2":62032,"PHASE3":62034,"PHASE4":62036,"NA":62038},{"trials":62013,"activeCount":97},[],{"trials":62015,"activeCount":97},[62016,62025],{"nctId":62017,"briefTitle":62018,"status":155,"phases":62019,"primaryCompletion":40712,"completion":40712,"start":62020,"enrollment":656,"conditions":62021,"interventions":62022},"NCT00823940","A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects",[85],"2009-01-13",[27],[62010,62010,62023,62024],"Glucagon","Glucagon + GSK1362885",{"nctId":62026,"briefTitle":62027,"status":155,"phases":62028,"primaryCompletion":62029,"completion":62029,"start":19175,"enrollment":314,"conditions":62030,"interventions":62031},"NCT01013766","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics",[85],"2009-11-20",[27],[62010,62010],{"trials":62033,"activeCount":97},[],{"trials":62035,"activeCount":97},[],{"trials":62037,"activeCount":97},[],{"trials":62039,"activeCount":97},[],{"intervention":39215,"totalTrials":660,"cells":62041},{"EARLY_PHASE1":62042,"PHASE1":62044,"PHASE2":62054,"PHASE3":62056,"PHASE4":62058,"NA":62060},{"trials":62043,"activeCount":97},[],{"trials":62045,"activeCount":97},[62046,62050],{"nctId":39209,"briefTitle":39210,"status":145,"phases":62047,"primaryCompletion":19269,"completion":19269,"start":39212,"enrollment":181,"conditions":62048,"interventions":62049},[85],[26760],[9302,39215],{"nctId":42163,"briefTitle":42164,"status":145,"phases":62051,"primaryCompletion":39094,"completion":39094,"start":10014,"enrollment":1459,"conditions":62052,"interventions":62053},[85],[22321],[42148,39215],{"trials":62055,"activeCount":97},[],{"trials":62057,"activeCount":97},[],{"trials":62059,"activeCount":97},[],{"trials":62061,"activeCount":97},[],{"intervention":9294,"totalTrials":660,"cells":62063},{"EARLY_PHASE1":62064,"PHASE1":62066,"PHASE2":62078,"PHASE3":62080,"PHASE4":62082,"NA":62084},{"trials":62065,"activeCount":97},[],{"trials":62067,"activeCount":97},[62068,62074],{"nctId":62069,"briefTitle":62070,"status":155,"phases":62071,"primaryCompletion":5018,"completion":5018,"start":2355,"enrollment":255,"conditions":62072,"interventions":62073},"NCT00675116","GW823296 Repeat Dose Study In Healthy Male And Female Subjects",[85],[7524],[9294],{"nctId":9286,"briefTitle":9287,"status":155,"phases":62075,"primaryCompletion":9289,"completion":9289,"start":9290,"enrollment":710,"conditions":62076,"interventions":62077},[85],[9292],[9294,6488],{"trials":62079,"activeCount":97},[],{"trials":62081,"activeCount":97},[],{"trials":62083,"activeCount":97},[],{"trials":62085,"activeCount":97},[],{"intervention":19321,"totalTrials":660,"cells":62087},{"EARLY_PHASE1":62088,"PHASE1":62090,"PHASE2":62100,"PHASE3":62102,"PHASE4":62104,"NA":62106},{"trials":62089,"activeCount":97},[],{"trials":62091,"activeCount":97},[62092,62096],{"nctId":19314,"briefTitle":19315,"status":145,"phases":62093,"primaryCompletion":19317,"completion":19317,"start":19318,"enrollment":454,"conditions":62094,"interventions":62095},[85],[9343],[19321,19321,10675],{"nctId":19323,"briefTitle":19324,"status":155,"phases":62097,"primaryCompletion":2392,"completion":2392,"start":19326,"enrollment":234,"conditions":62098,"interventions":62099},[85],[9343],[19321,19329,19330,10675],{"trials":62101,"activeCount":97},[],{"trials":62103,"activeCount":97},[],{"trials":62105,"activeCount":97},[],{"trials":62107,"activeCount":97},[],{"intervention":62109,"totalTrials":660,"cells":62110},"GSK2126458",{"EARLY_PHASE1":62111,"PHASE1":62113,"PHASE2":62129,"PHASE3":62131,"PHASE4":62133,"NA":62135},{"trials":62112,"activeCount":97},[],{"trials":62114,"activeCount":97},[62115,62122],{"nctId":62116,"briefTitle":62117,"status":155,"phases":62118,"primaryCompletion":62119,"completion":62119,"start":18689,"enrollment":7438,"conditions":62120,"interventions":62121},"NCT01725139","A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)",[85],"2016-07-12",[42392],[62109],{"nctId":62123,"briefTitle":62124,"status":155,"phases":62125,"primaryCompletion":42736,"completion":10406,"start":62126,"enrollment":14542,"conditions":62127,"interventions":62128},"NCT00972686","Dose-Escalation Study of GSK2126458",[85],"2009-08-31",[2761],[62109],{"trials":62130,"activeCount":97},[],{"trials":62132,"activeCount":97},[],{"trials":62134,"activeCount":97},[],{"trials":62136,"activeCount":97},[],{"intervention":3039,"totalTrials":660,"cells":62138},{"EARLY_PHASE1":62139,"PHASE1":62141,"PHASE2":62151,"PHASE3":62153,"PHASE4":62155,"NA":62157},{"trials":62140,"activeCount":97},[],{"trials":62142,"activeCount":97},[62143,62147],{"nctId":4254,"briefTitle":4255,"status":155,"phases":62144,"primaryCompletion":4257,"completion":4257,"start":4258,"enrollment":255,"conditions":62145,"interventions":62146},[85],[2761],[3039,2275],{"nctId":3033,"briefTitle":3034,"status":155,"phases":62148,"start":3036,"enrollment":255,"conditions":62149,"interventions":62150},[85],[1431],[2286,3039],{"trials":62152,"activeCount":97},[],{"trials":62154,"activeCount":97},[],{"trials":62156,"activeCount":97},[],{"trials":62158,"activeCount":97},[],{"intervention":62160,"totalTrials":660,"cells":62161},"single dose",{"EARLY_PHASE1":62162,"PHASE1":62164,"PHASE2":62181,"PHASE3":62183,"PHASE4":62185,"NA":62187},{"trials":62163,"activeCount":97},[],{"trials":62165,"activeCount":97},[62166,62173],{"nctId":62167,"briefTitle":62168,"status":155,"phases":62169,"primaryCompletion":11017,"completion":11017,"start":62170,"enrollment":2836,"conditions":62171,"interventions":62172},"NCT00513565","A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy Volunteers",[85],"2007-09-13",[41867],[62160],{"nctId":62174,"briefTitle":62175,"status":155,"phases":62176,"primaryCompletion":62177,"completion":62177,"start":62178,"enrollment":1279,"conditions":62179,"interventions":62180},"NCT01181908","Alcohol Interaction Study",[85],"2009-12-30","2009-11-11",[42738],[62160],{"trials":62182,"activeCount":97},[],{"trials":62184,"activeCount":97},[],{"trials":62186,"activeCount":97},[],{"trials":62188,"activeCount":97},[],{"intervention":62190,"totalTrials":660,"cells":62191},"Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg",{"EARLY_PHASE1":62192,"PHASE1":62194,"PHASE2":62213,"PHASE3":62215,"PHASE4":62217,"NA":62219},{"trials":62193,"activeCount":97},[],{"trials":62195,"activeCount":97},[62196,62206],{"nctId":62197,"briefTitle":62198,"status":155,"phases":62199,"primaryCompletion":62200,"completion":62200,"start":62201,"enrollment":624,"conditions":62202,"interventions":62204},"NCT02058576","Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State",[85],"2015-01-02","2014-02-11",[62203],"Urologic Diseases",[62190,62205],"Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination",{"nctId":62207,"briefTitle":62208,"status":155,"phases":62209,"primaryCompletion":62210,"completion":62210,"start":41803,"enrollment":868,"conditions":62211,"interventions":62212},"NCT02052713","Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State",[85],"2014-12-29",[62203],[62190,62205],{"trials":62214,"activeCount":97},[],{"trials":62216,"activeCount":97},[],{"trials":62218,"activeCount":97},[],{"trials":62220,"activeCount":97},[],{"intervention":62205,"totalTrials":660,"cells":62222},{"EARLY_PHASE1":62223,"PHASE1":62225,"PHASE2":62235,"PHASE3":62237,"PHASE4":62239,"NA":62241},{"trials":62224,"activeCount":97},[],{"trials":62226,"activeCount":97},[62227,62231],{"nctId":62197,"briefTitle":62198,"status":155,"phases":62228,"primaryCompletion":62200,"completion":62200,"start":62201,"enrollment":624,"conditions":62229,"interventions":62230},[85],[62203],[62190,62205],{"nctId":62207,"briefTitle":62208,"status":155,"phases":62232,"primaryCompletion":62210,"completion":62210,"start":41803,"enrollment":868,"conditions":62233,"interventions":62234},[85],[62203],[62190,62205],{"trials":62236,"activeCount":97},[],{"trials":62238,"activeCount":97},[],{"trials":62240,"activeCount":97},[],{"trials":62242,"activeCount":97},[],{"intervention":62244,"totalTrials":660,"cells":62245},"GSK2878175",{"EARLY_PHASE1":62246,"PHASE1":62248,"PHASE2":62264,"PHASE3":62266,"PHASE4":62268,"NA":62270},{"trials":62247,"activeCount":97},[],{"trials":62249,"activeCount":97},[62250,62257],{"nctId":62251,"briefTitle":62252,"status":155,"phases":62253,"primaryCompletion":62254,"completion":62254,"start":41570,"enrollment":149,"conditions":62255,"interventions":62256},"NCT01879462","A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects",[85],"2014-01-10",[42684],[62244],{"nctId":62258,"briefTitle":62259,"status":155,"phases":62260,"primaryCompletion":22542,"completion":17985,"start":62261,"enrollment":1335,"conditions":62262,"interventions":62263},"NCT02014571","Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.",[85],"2013-12-26",[42684],[62244],{"trials":62265,"activeCount":97},[],{"trials":62267,"activeCount":97},[],{"trials":62269,"activeCount":97},[],{"trials":62271,"activeCount":97},[],{"intervention":9321,"totalTrials":660,"cells":62273},{"EARLY_PHASE1":62274,"PHASE1":62276,"PHASE2":62286,"PHASE3":62288,"PHASE4":62290,"NA":62292},{"trials":62275,"activeCount":97},[],{"trials":62277,"activeCount":97},[62278,62282],{"nctId":9313,"briefTitle":9314,"status":155,"phases":62279,"primaryCompletion":9316,"completion":9316,"start":9317,"enrollment":31,"conditions":62280,"interventions":62281},[85],[9319],[9321,9093,9273,9322,9323,6488,9324,9325,9326,9327,9093],{"nctId":39163,"briefTitle":39164,"status":155,"phases":62283,"primaryCompletion":21596,"completion":21596,"start":10013,"enrollment":14145,"conditions":62284,"interventions":62285},[85],[39123],[39110,9321],{"trials":62287,"activeCount":97},[],{"trials":62289,"activeCount":97},[],{"trials":62291,"activeCount":97},[],{"trials":62293,"activeCount":97},[],{"intervention":62295,"totalTrials":660,"cells":62296},"A",{"EARLY_PHASE1":62297,"PHASE1":62299,"PHASE2":62318,"PHASE3":62320,"PHASE4":62322,"NA":62324},{"trials":62298,"activeCount":97},[],{"trials":62300,"activeCount":97},[62301,62309],{"nctId":62302,"briefTitle":62303,"status":155,"phases":62304,"primaryCompletion":9208,"completion":9208,"start":62305,"enrollment":1720,"conditions":62306,"interventions":62307},"NCT01267071","A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers",[85],"2010-06-14",[39624],[62295,62308],"B",{"nctId":62310,"briefTitle":62311,"status":155,"phases":62312,"primaryCompletion":62313,"completion":62313,"start":56233,"enrollment":454,"conditions":62314,"interventions":62315},"NCT01424462","Healthy Volunteer Pilot Study Using 3 Types of Modified Release Formulations of Firategrast to Investigate How Quickly Absorption From the Digestive System Takes Place.",[85],"2010-07-06",[39994],[62295,62308,62316,62317],"C","D",{"trials":62319,"activeCount":97},[],{"trials":62321,"activeCount":97},[],{"trials":62323,"activeCount":97},[],{"trials":62325,"activeCount":97},[],{"intervention":62308,"totalTrials":660,"cells":62327},{"EARLY_PHASE1":62328,"PHASE1":62330,"PHASE2":62340,"PHASE3":62342,"PHASE4":62344,"NA":62346},{"trials":62329,"activeCount":97},[],{"trials":62331,"activeCount":97},[62332,62336],{"nctId":62302,"briefTitle":62303,"status":155,"phases":62333,"primaryCompletion":9208,"completion":9208,"start":62305,"enrollment":1720,"conditions":62334,"interventions":62335},[85],[39624],[62295,62308],{"nctId":62310,"briefTitle":62311,"status":155,"phases":62337,"primaryCompletion":62313,"completion":62313,"start":56233,"enrollment":454,"conditions":62338,"interventions":62339},[85],[39994],[62295,62308,62316,62317],{"trials":62341,"activeCount":97},[],{"trials":62343,"activeCount":97},[],{"trials":62345,"activeCount":97},[],{"trials":62347,"activeCount":97},[],{"intervention":18488,"totalTrials":660,"cells":62349},{"EARLY_PHASE1":62350,"PHASE1":62352,"PHASE2":62362,"PHASE3":62364,"PHASE4":62366,"NA":62368},{"trials":62351,"activeCount":97},[],{"trials":62353,"activeCount":97},[62354,62358],{"nctId":18482,"briefTitle":18483,"status":155,"phases":62355,"primaryCompletion":8298,"completion":8298,"start":18485,"enrollment":433,"conditions":62356,"interventions":62357},[85],[15],[9403,10797,18488],{"nctId":18490,"briefTitle":18491,"status":155,"phases":62359,"primaryCompletion":18493,"completion":18493,"start":18494,"enrollment":433,"conditions":62360,"interventions":62361},[85],[15],[18488,10797,9403],{"trials":62363,"activeCount":97},[],{"trials":62365,"activeCount":97},[],{"trials":62367,"activeCount":97},[],{"trials":62369,"activeCount":97},[],{"intervention":62371,"totalTrials":660,"cells":62372},"GSK958108",{"EARLY_PHASE1":62373,"PHASE1":62375,"PHASE2":62391,"PHASE3":62393,"PHASE4":62395,"NA":62397},{"trials":62374,"activeCount":97},[],{"trials":62376,"activeCount":97},[62377,62384],{"nctId":62378,"briefTitle":62379,"status":155,"phases":62380,"primaryCompletion":21596,"completion":21596,"start":62381,"enrollment":1279,"conditions":62382,"interventions":62383},"NCT00664365","FTIH Study With GSK958108",[85],"2008-04-12",[45196],[62371],{"nctId":62385,"briefTitle":62386,"status":155,"phases":62387,"primaryCompletion":62388,"completion":62388,"start":18255,"enrollment":2797,"conditions":62389,"interventions":62390},"NCT00861484","Proof of Mechanism in ELT",[85],"2009-12-11",[45196],[62371],{"trials":62392,"activeCount":97},[],{"trials":62394,"activeCount":97},[],{"trials":62396,"activeCount":97},[],{"trials":62398,"activeCount":97},[],{"intervention":62400,"totalTrials":660,"cells":62401},"GSK3050002",{"EARLY_PHASE1":62402,"PHASE1":62404,"PHASE2":62419,"PHASE3":62421,"PHASE4":62423,"NA":62425},{"trials":62403,"activeCount":97},[],{"trials":62405,"activeCount":97},[62406,62413],{"nctId":62407,"briefTitle":62408,"status":500,"phases":62409,"primaryCompletion":13541,"completion":13541,"start":62410,"enrollment":97,"conditions":62411,"interventions":62412},"NCT02671188","A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis",[85],"2018-06-01",[39897],[62400],{"nctId":62414,"briefTitle":62415,"status":155,"phases":62416,"primaryCompletion":61713,"completion":61713,"start":62254,"enrollment":2375,"conditions":62417,"interventions":62418},"NCT01984047","Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002",[85],[7295],[62400],{"trials":62420,"activeCount":97},[],{"trials":62422,"activeCount":97},[],{"trials":62424,"activeCount":97},[],{"trials":62426,"activeCount":97},[],{"intervention":62428,"totalTrials":660,"cells":62429},"Cephalexin 125 mg\u002F5ml",{"EARLY_PHASE1":62430,"PHASE1":62432,"PHASE2":62448,"PHASE3":62450,"PHASE4":62452,"NA":62454},{"trials":62431,"activeCount":97},[],{"trials":62433,"activeCount":97},[62434,62442],{"nctId":62435,"briefTitle":62436,"status":155,"phases":62437,"primaryCompletion":22188,"completion":22188,"start":62438,"enrollment":695,"conditions":62439,"interventions":62440},"NCT01767571","Bioequivalence Study of Cephalexin Suspension 250",[85],"2011-01-30",[14696],[62428,62441],"Cephalexin 250mg\u002F5ml",{"nctId":62443,"briefTitle":62444,"status":155,"phases":62445,"primaryCompletion":22188,"completion":22188,"start":62438,"enrollment":695,"conditions":62446,"interventions":62447},"NCT01767532","Bioequivalence Study of Cephalexin Suspension 125",[85],[14696],[62428,62428],{"trials":62449,"activeCount":97},[],{"trials":62451,"activeCount":97},[],{"trials":62453,"activeCount":97},[],{"trials":62455,"activeCount":97},[],{"intervention":1689,"totalTrials":660,"cells":62457},{"EARLY_PHASE1":62458,"PHASE1":62460,"PHASE2":62473,"PHASE3":62475,"PHASE4":62477,"NA":62479},{"trials":62459,"activeCount":97},[],{"trials":62461,"activeCount":97},[62462,62469],{"nctId":62463,"briefTitle":62464,"status":155,"phases":62465,"primaryCompletion":62466,"completion":62466,"start":21939,"enrollment":656,"conditions":62467,"interventions":62468},"NCT02798978","A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects",[85],"2017-10-13",[36,107],[1689],{"nctId":1680,"briefTitle":1681,"status":155,"phases":62470,"primaryCompletion":1683,"completion":1684,"start":1685,"enrollment":1686,"conditions":62471,"interventions":62472},[85],[107],[1689,163,1690,137],{"trials":62474,"activeCount":97},[],{"trials":62476,"activeCount":97},[],{"trials":62478,"activeCount":97},[],{"trials":62480,"activeCount":97},[],{"intervention":62482,"totalTrials":660,"cells":62483},"Treatment sequence A",{"EARLY_PHASE1":62484,"PHASE1":62486,"PHASE2":62506,"PHASE3":62508,"PHASE4":62510,"NA":62512},{"trials":62485,"activeCount":97},[],{"trials":62487,"activeCount":97},[62488,62497],{"nctId":62489,"briefTitle":62490,"status":155,"phases":62491,"primaryCompletion":61713,"completion":61713,"start":62492,"enrollment":719,"conditions":62493,"interventions":62494},"NCT02184585","Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States",[85],"2014-07-10",[12263],[62482,62495,62496],"Treatment sequence B","Treatment sequence C",{"nctId":62498,"briefTitle":62499,"status":155,"phases":62500,"primaryCompletion":62501,"completion":62501,"start":62502,"enrollment":8861,"conditions":62503,"interventions":62504},"NCT00537654","A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State",[85],"2008-02-22","2007-10-18",[12263],[62482,62495,62496,62505],"Treatment sequence D",{"trials":62507,"activeCount":97},[],{"trials":62509,"activeCount":97},[],{"trials":62511,"activeCount":97},[],{"trials":62513,"activeCount":97},[],{"intervention":62495,"totalTrials":660,"cells":62515},{"EARLY_PHASE1":62516,"PHASE1":62518,"PHASE2":62528,"PHASE3":62530,"PHASE4":62532,"NA":62534},{"trials":62517,"activeCount":97},[],{"trials":62519,"activeCount":97},[62520,62524],{"nctId":62489,"briefTitle":62490,"status":155,"phases":62521,"primaryCompletion":61713,"completion":61713,"start":62492,"enrollment":719,"conditions":62522,"interventions":62523},[85],[12263],[62482,62495,62496],{"nctId":62498,"briefTitle":62499,"status":155,"phases":62525,"primaryCompletion":62501,"completion":62501,"start":62502,"enrollment":8861,"conditions":62526,"interventions":62527},[85],[12263],[62482,62495,62496,62505],{"trials":62529,"activeCount":97},[],{"trials":62531,"activeCount":97},[],{"trials":62533,"activeCount":97},[],{"trials":62535,"activeCount":97},[],{"intervention":62496,"totalTrials":660,"cells":62537},{"EARLY_PHASE1":62538,"PHASE1":62540,"PHASE2":62550,"PHASE3":62552,"PHASE4":62554,"NA":62556},{"trials":62539,"activeCount":97},[],{"trials":62541,"activeCount":97},[62542,62546],{"nctId":62489,"briefTitle":62490,"status":155,"phases":62543,"primaryCompletion":61713,"completion":61713,"start":62492,"enrollment":719,"conditions":62544,"interventions":62545},[85],[12263],[62482,62495,62496],{"nctId":62498,"briefTitle":62499,"status":155,"phases":62547,"primaryCompletion":62501,"completion":62501,"start":62502,"enrollment":8861,"conditions":62548,"interventions":62549},[85],[12263],[62482,62495,62496,62505],{"trials":62551,"activeCount":97},[],{"trials":62553,"activeCount":97},[],{"trials":62555,"activeCount":97},[],{"trials":62557,"activeCount":97},[],{"intervention":62559,"totalTrials":660,"cells":62560},"GSK2849330",{"EARLY_PHASE1":62561,"PHASE1":62563,"PHASE2":62581,"PHASE3":62583,"PHASE4":62585,"NA":62587},{"trials":62562,"activeCount":97},[],{"trials":62564,"activeCount":97},[62565,62573],{"nctId":62566,"briefTitle":62567,"status":155,"phases":62568,"primaryCompletion":13316,"completion":13316,"start":62569,"enrollment":628,"conditions":62570,"interventions":62571},"NCT02345174","Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors",[85],"2015-03-19",[36,107],[62559,62572],"89Zr-GSK2849330",{"nctId":62574,"briefTitle":62575,"status":155,"phases":62576,"primaryCompletion":62577,"completion":62577,"start":62578,"enrollment":1079,"conditions":62579,"interventions":62580},"NCT01966445","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",[85],"2017-09-18","2013-11-26",[36,107],[62559],{"trials":62582,"activeCount":97},[],{"trials":62584,"activeCount":97},[],{"trials":62586,"activeCount":97},[],{"trials":62588,"activeCount":97},[],{"intervention":62590,"totalTrials":417,"cells":62591},"Paroxetine treatment during 8 weeks",{"EARLY_PHASE1":62592,"PHASE1":62594,"PHASE2":62604,"PHASE3":62606,"PHASE4":62608,"NA":62610},{"trials":62593,"activeCount":97},[],{"trials":62595,"activeCount":97},[62596],{"nctId":62597,"briefTitle":62598,"status":155,"phases":62599,"primaryCompletion":62600,"completion":62600,"start":62601,"enrollment":904,"conditions":62602,"interventions":62603},"NCT00470483","A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder",[85],"2009-01-07","2007-01-22",[26760],[62590],{"trials":62605,"activeCount":97},[],{"trials":62607,"activeCount":97},[],{"trials":62609,"activeCount":97},[],{"trials":62611,"activeCount":97},[],{"intervention":62613,"totalTrials":417,"cells":62614},"FluLaval® TF",{"EARLY_PHASE1":62615,"PHASE1":62617,"PHASE2":62627,"PHASE3":62629,"PHASE4":62631,"NA":62633},{"trials":62616,"activeCount":97},[],{"trials":62618,"activeCount":97},[62619],{"nctId":62620,"briefTitle":62621,"status":155,"phases":62622,"primaryCompletion":62623,"completion":18807,"start":62624,"enrollment":28,"conditions":62625,"interventions":62626},"NCT00727428","Immunogenicity and Safety of GSK Biologicals' FluLaval® TF",[85],"2008-08-29","2008-08-05",[21],[62613],{"trials":62628,"activeCount":97},[],{"trials":62630,"activeCount":97},[],{"trials":62632,"activeCount":97},[],{"trials":62634,"activeCount":97},[],{"intervention":62636,"totalTrials":417,"cells":62637},"Paroxetine CR and Paroxetine IR",{"EARLY_PHASE1":62638,"PHASE1":62640,"PHASE2":62650,"PHASE3":62652,"PHASE4":62654,"NA":62656},{"trials":62639,"activeCount":97},[],{"trials":62641,"activeCount":97},[62642],{"nctId":62643,"briefTitle":62644,"status":155,"phases":62645,"primaryCompletion":62646,"completion":62646,"start":62647,"enrollment":93,"conditions":62648,"interventions":62649},"NCT01000857","Repeat Dose Study of Controlled-Release Paroxetine Tablets and Immediate-Release Paroxetine Tablets in Healthy Japanese Male Subjects",[85],"2010-02-25","2009-11-05",[9292],[62636],{"trials":62651,"activeCount":97},[],{"trials":62653,"activeCount":97},[],{"trials":62655,"activeCount":97},[],{"trials":62657,"activeCount":97},[],{"intervention":62659,"totalTrials":417,"cells":62660},"RSV F subunit 45 μg No adjuvant",{"EARLY_PHASE1":62661,"PHASE1":62663,"PHASE2":62682,"PHASE3":62684,"PHASE4":62686,"NA":62688},{"trials":62662,"activeCount":97},[],{"trials":62664,"activeCount":97},[62665],{"nctId":62666,"briefTitle":62667,"status":155,"phases":62668,"primaryCompletion":62669,"completion":62669,"start":62670,"enrollment":12474,"conditions":62671,"interventions":62673},"NCT02298179","A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults",[85],"2017-03-27","2014-12-19",[62672],"Respiratory Syncytial Virus (RSV)",[62659,62674,62675,62676,62677,62678,62679,62680,62681],"RSV F subunit 45 μg Aluminum hydroxide adjuvant","RSV F subunit 45 μg MF59 adjuvant","RSV F subunit 90 μg No adjuvant","RSV F subunit 90 μg Aluminum hydroxide adjuvant","RSV F subunit 90 μg MF59 adjuvant","RSV F subunit 135 μg No adjuvant","RSV F subunit 135 μg Aluminum hydroxide adjuvant","RSV F subunit 135 μg MF59 adjuvant",{"trials":62683,"activeCount":97},[],{"trials":62685,"activeCount":97},[],{"trials":62687,"activeCount":97},[],{"trials":62689,"activeCount":97},[],{"intervention":62674,"totalTrials":417,"cells":62691},{"EARLY_PHASE1":62692,"PHASE1":62694,"PHASE2":62700,"PHASE3":62702,"PHASE4":62704,"NA":62706},{"trials":62693,"activeCount":97},[],{"trials":62695,"activeCount":97},[62696],{"nctId":62666,"briefTitle":62667,"status":155,"phases":62697,"primaryCompletion":62669,"completion":62669,"start":62670,"enrollment":12474,"conditions":62698,"interventions":62699},[85],[62672],[62659,62674,62675,62676,62677,62678,62679,62680,62681],{"trials":62701,"activeCount":97},[],{"trials":62703,"activeCount":97},[],{"trials":62705,"activeCount":97},[],{"trials":62707,"activeCount":97},[],{"intervention":62675,"totalTrials":417,"cells":62709},{"EARLY_PHASE1":62710,"PHASE1":62712,"PHASE2":62718,"PHASE3":62720,"PHASE4":62722,"NA":62724},{"trials":62711,"activeCount":97},[],{"trials":62713,"activeCount":97},[62714],{"nctId":62666,"briefTitle":62667,"status":155,"phases":62715,"primaryCompletion":62669,"completion":62669,"start":62670,"enrollment":12474,"conditions":62716,"interventions":62717},[85],[62672],[62659,62674,62675,62676,62677,62678,62679,62680,62681],{"trials":62719,"activeCount":97},[],{"trials":62721,"activeCount":97},[],{"trials":62723,"activeCount":97},[],{"trials":62725,"activeCount":97},[],{"intervention":62676,"totalTrials":417,"cells":62727},{"EARLY_PHASE1":62728,"PHASE1":62730,"PHASE2":62736,"PHASE3":62738,"PHASE4":62740,"NA":62742},{"trials":62729,"activeCount":97},[],{"trials":62731,"activeCount":97},[62732],{"nctId":62666,"briefTitle":62667,"status":155,"phases":62733,"primaryCompletion":62669,"completion":62669,"start":62670,"enrollment":12474,"conditions":62734,"interventions":62735},[85],[62672],[62659,62674,62675,62676,62677,62678,62679,62680,62681],{"trials":62737,"activeCount":97},[],{"trials":62739,"activeCount":97},[],{"trials":62741,"activeCount":97},[],{"trials":62743,"activeCount":97},[],{"intervention":62677,"totalTrials":417,"cells":62745},{"EARLY_PHASE1":62746,"PHASE1":62748,"PHASE2":62754,"PHASE3":62756,"PHASE4":62758,"NA":62760},{"trials":62747,"activeCount":97},[],{"trials":62749,"activeCount":97},[62750],{"nctId":62666,"briefTitle":62667,"status":155,"phases":62751,"primaryCompletion":62669,"completion":62669,"start":62670,"enrollment":12474,"conditions":62752,"interventions":62753},[85],[62672],[62659,62674,62675,62676,62677,62678,62679,62680,62681],{"trials":62755,"activeCount":97},[],{"trials":62757,"activeCount":97},[],{"trials":62759,"activeCount":97},[],{"trials":62761,"activeCount":97},[],{"intervention":62678,"totalTrials":417,"cells":62763},{"EARLY_PHASE1":62764,"PHASE1":62766,"PHASE2":62772,"PHASE3":62774,"PHASE4":62776,"NA":62778},{"trials":62765,"activeCount":97},[],{"trials":62767,"activeCount":97},[62768],{"nctId":62666,"briefTitle":62667,"status":155,"phases":62769,"primaryCompletion":62669,"completion":62669,"start":62670,"enrollment":12474,"conditions":62770,"interventions":62771},[85],[62672],[62659,62674,62675,62676,62677,62678,62679,62680,62681],{"trials":62773,"activeCount":97},[],{"trials":62775,"activeCount":97},[],{"trials":62777,"activeCount":97},[],{"trials":62779,"activeCount":97},[],{"intervention":62679,"totalTrials":417,"cells":62781},{"EARLY_PHASE1":62782,"PHASE1":62784,"PHASE2":62790,"PHASE3":62792,"PHASE4":62794,"NA":62796},{"trials":62783,"activeCount":97},[],{"trials":62785,"activeCount":97},[62786],{"nctId":62666,"briefTitle":62667,"status":155,"phases":62787,"primaryCompletion":62669,"completion":62669,"start":62670,"enrollment":12474,"conditions":62788,"interventions":62789},[85],[62672],[62659,62674,62675,62676,62677,62678,62679,62680,62681],{"trials":62791,"activeCount":97},[],{"trials":62793,"activeCount":97},[],{"trials":62795,"activeCount":97},[],{"trials":62797,"activeCount":97},[],{"intervention":62680,"totalTrials":417,"cells":62799},{"EARLY_PHASE1":62800,"PHASE1":62802,"PHASE2":62808,"PHASE3":62810,"PHASE4":62812,"NA":62814},{"trials":62801,"activeCount":97},[],{"trials":62803,"activeCount":97},[62804],{"nctId":62666,"briefTitle":62667,"status":155,"phases":62805,"primaryCompletion":62669,"completion":62669,"start":62670,"enrollment":12474,"conditions":62806,"interventions":62807},[85],[62672],[62659,62674,62675,62676,62677,62678,62679,62680,62681],{"trials":62809,"activeCount":97},[],{"trials":62811,"activeCount":97},[],{"trials":62813,"activeCount":97},[],{"trials":62815,"activeCount":97},[],{"intervention":62681,"totalTrials":417,"cells":62817},{"EARLY_PHASE1":62818,"PHASE1":62820,"PHASE2":62826,"PHASE3":62828,"PHASE4":62830,"NA":62832},{"trials":62819,"activeCount":97},[],{"trials":62821,"activeCount":97},[62822],{"nctId":62666,"briefTitle":62667,"status":155,"phases":62823,"primaryCompletion":62669,"completion":62669,"start":62670,"enrollment":12474,"conditions":62824,"interventions":62825},[85],[62672],[62659,62674,62675,62676,62677,62678,62679,62680,62681],{"trials":62827,"activeCount":97},[],{"trials":62829,"activeCount":97},[],{"trials":62831,"activeCount":97},[],{"trials":62833,"activeCount":97},[],{"intervention":18463,"totalTrials":417,"cells":62835},{"EARLY_PHASE1":62836,"PHASE1":62838,"PHASE2":62844,"PHASE3":62846,"PHASE4":62848,"NA":62850},{"trials":62837,"activeCount":97},[],{"trials":62839,"activeCount":97},[62840],{"nctId":18457,"briefTitle":18458,"status":155,"phases":62841,"primaryCompletion":18460,"completion":18460,"start":15600,"enrollment":433,"conditions":62842,"interventions":62843},[85],[18],[18463,8556,10797],{"trials":62845,"activeCount":97},[],{"trials":62847,"activeCount":97},[],{"trials":62849,"activeCount":97},[],{"trials":62851,"activeCount":97},[],{"intervention":59326,"totalTrials":417,"cells":62853},{"EARLY_PHASE1":62854,"PHASE1":62856,"PHASE2":62862,"PHASE3":62864,"PHASE4":62866,"NA":62868},{"trials":62855,"activeCount":97},[],{"trials":62857,"activeCount":97},[62858],{"nctId":59321,"briefTitle":59322,"status":155,"phases":62859,"primaryCompletion":40295,"completion":40295,"start":2665,"enrollment":1117,"conditions":62860,"interventions":62861},[85],[1337],[38856,59326,59327],{"trials":62863,"activeCount":97},[],{"trials":62865,"activeCount":97},[],{"trials":62867,"activeCount":97},[],{"trials":62869,"activeCount":97},[],{"intervention":18674,"totalTrials":417,"cells":62871},{"EARLY_PHASE1":62872,"PHASE1":62874,"PHASE2":62880,"PHASE3":62882,"PHASE4":62884,"NA":62886},{"trials":62873,"activeCount":97},[],{"trials":62875,"activeCount":97},[62876],{"nctId":18667,"briefTitle":18668,"status":155,"phases":62877,"primaryCompletion":18670,"completion":18670,"start":18671,"enrollment":6503,"conditions":62878,"interventions":62879},[85],[15],[18674,18675,3467,3467,18676],{"trials":62881,"activeCount":97},[],{"trials":62883,"activeCount":97},[],{"trials":62885,"activeCount":97},[],{"trials":62887,"activeCount":97},[],{"intervention":18675,"totalTrials":417,"cells":62889},{"EARLY_PHASE1":62890,"PHASE1":62892,"PHASE2":62898,"PHASE3":62900,"PHASE4":62902,"NA":62904},{"trials":62891,"activeCount":97},[],{"trials":62893,"activeCount":97},[62894],{"nctId":18667,"briefTitle":18668,"status":155,"phases":62895,"primaryCompletion":18670,"completion":18670,"start":18671,"enrollment":6503,"conditions":62896,"interventions":62897},[85],[15],[18674,18675,3467,3467,18676],{"trials":62899,"activeCount":97},[],{"trials":62901,"activeCount":97},[],{"trials":62903,"activeCount":97},[],{"trials":62905,"activeCount":97},[],{"intervention":62907,"totalTrials":417,"cells":62908},"Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine",{"EARLY_PHASE1":62909,"PHASE1":62911,"PHASE2":62921,"PHASE3":62923,"PHASE4":62925,"NA":62927},{"trials":62910,"activeCount":97},[],{"trials":62912,"activeCount":97},[62913],{"nctId":62914,"briefTitle":62915,"status":155,"phases":62916,"primaryCompletion":2373,"completion":62917,"start":21442,"enrollment":4388,"conditions":62918,"interventions":62919},"NCT00309647","Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age",[85],"2006-11-16",[21],[62907,62920],"Influenza Monovalent Whole virus",{"trials":62922,"activeCount":97},[],{"trials":62924,"activeCount":97},[],{"trials":62926,"activeCount":97},[],{"trials":62928,"activeCount":97},[],{"intervention":62920,"totalTrials":417,"cells":62930},{"EARLY_PHASE1":62931,"PHASE1":62933,"PHASE2":62939,"PHASE3":62941,"PHASE4":62943,"NA":62945},{"trials":62932,"activeCount":97},[],{"trials":62934,"activeCount":97},[62935],{"nctId":62914,"briefTitle":62915,"status":155,"phases":62936,"primaryCompletion":2373,"completion":62917,"start":21442,"enrollment":4388,"conditions":62937,"interventions":62938},[85],[21],[62907,62920],{"trials":62940,"activeCount":97},[],{"trials":62942,"activeCount":97},[],{"trials":62944,"activeCount":97},[],{"trials":62946,"activeCount":97},[],{"intervention":10932,"totalTrials":417,"cells":62948},{"EARLY_PHASE1":62949,"PHASE1":62951,"PHASE2":62957,"PHASE3":62959,"PHASE4":62961,"NA":62963},{"trials":62950,"activeCount":97},[],{"trials":62952,"activeCount":97},[62953],{"nctId":10926,"briefTitle":10927,"status":155,"phases":62954,"primaryCompletion":2427,"completion":2427,"start":8135,"enrollment":656,"conditions":62955,"interventions":62956},[85],[10930],[10932,10919,10933],{"trials":62958,"activeCount":97},[],{"trials":62960,"activeCount":97},[],{"trials":62962,"activeCount":97},[],{"trials":62964,"activeCount":97},[],{"intervention":10933,"totalTrials":417,"cells":62966},{"EARLY_PHASE1":62967,"PHASE1":62969,"PHASE2":62975,"PHASE3":62977,"PHASE4":62979,"NA":62981},{"trials":62968,"activeCount":97},[],{"trials":62970,"activeCount":97},[62971],{"nctId":10926,"briefTitle":10927,"status":155,"phases":62972,"primaryCompletion":2427,"completion":2427,"start":8135,"enrollment":656,"conditions":62973,"interventions":62974},[85],[10930],[10932,10919,10933],{"trials":62976,"activeCount":97},[],{"trials":62978,"activeCount":97},[],{"trials":62980,"activeCount":97},[],{"trials":62982,"activeCount":97},[],{"intervention":62984,"totalTrials":417,"cells":62985},"FF\u002FVI 100\u002F25 mcg",{"EARLY_PHASE1":62986,"PHASE1":62988,"PHASE2":62997,"PHASE3":62999,"PHASE4":63001,"NA":63003},{"trials":62987,"activeCount":97},[],{"trials":62989,"activeCount":97},[62990],{"nctId":62991,"briefTitle":62992,"status":155,"phases":62993,"primaryCompletion":62994,"completion":62994,"start":40667,"enrollment":2045,"conditions":62995,"interventions":62996},"NCT01837316","A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)\u002F Vilanterol (VI) 100\u002F25 Micrograms (mcg) Combination When Administered in Adult Patients With Asthma",[85],"2014-08-08",[18],[62984],{"trials":62998,"activeCount":97},[],{"trials":63000,"activeCount":97},[],{"trials":63002,"activeCount":97},[],{"trials":63004,"activeCount":97},[],{"intervention":63006,"totalTrials":417,"cells":63007},"Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg",{"EARLY_PHASE1":63008,"PHASE1":63010,"PHASE2":63022,"PHASE3":63024,"PHASE4":63026,"NA":63028},{"trials":63009,"activeCount":97},[],{"trials":63011,"activeCount":97},[63012],{"nctId":63013,"briefTitle":63014,"status":155,"phases":63015,"primaryCompletion":3462,"completion":3462,"start":63016,"enrollment":44739,"conditions":63017,"interventions":63018},"NCT01495026","A Study Assessing a Range of Formulations of the Fixed Dose Combination Product Containing Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) to Find a Formulation Which is Bioequivalent to Harnal-D Tablets (Tamsulosin Hydrochloride, 0.2mg) in Healthy Male Subjects From North East Asia",[85],"2011-11-06",[12263],[63019,63019,63006,63006,63006,63006,63020,63020,63021],"Dutasteride","Harnal-D Tablets with water","Harnal-D tablets without water",{"trials":63023,"activeCount":97},[],{"trials":63025,"activeCount":97},[],{"trials":63027,"activeCount":97},[],{"trials":63029,"activeCount":97},[],{"intervention":63020,"totalTrials":417,"cells":63031},{"EARLY_PHASE1":63032,"PHASE1":63034,"PHASE2":63040,"PHASE3":63042,"PHASE4":63044,"NA":63046},{"trials":63033,"activeCount":97},[],{"trials":63035,"activeCount":97},[63036],{"nctId":63013,"briefTitle":63014,"status":155,"phases":63037,"primaryCompletion":3462,"completion":3462,"start":63016,"enrollment":44739,"conditions":63038,"interventions":63039},[85],[12263],[63019,63019,63006,63006,63006,63006,63020,63020,63021],{"trials":63041,"activeCount":97},[],{"trials":63043,"activeCount":97},[],{"trials":63045,"activeCount":97},[],{"trials":63047,"activeCount":97},[],{"intervention":63021,"totalTrials":417,"cells":63049},{"EARLY_PHASE1":63050,"PHASE1":63052,"PHASE2":63058,"PHASE3":63060,"PHASE4":63062,"NA":63064},{"trials":63051,"activeCount":97},[],{"trials":63053,"activeCount":97},[63054],{"nctId":63013,"briefTitle":63014,"status":155,"phases":63055,"primaryCompletion":3462,"completion":3462,"start":63016,"enrollment":44739,"conditions":63056,"interventions":63057},[85],[12263],[63019,63019,63006,63006,63006,63006,63020,63020,63021],{"trials":63059,"activeCount":97},[],{"trials":63061,"activeCount":97},[],{"trials":63063,"activeCount":97},[],{"trials":63065,"activeCount":97},[],{"intervention":63067,"totalTrials":417,"cells":63068},"GSK Biologicals' 719125",{"EARLY_PHASE1":63069,"PHASE1":63071,"PHASE2":63080,"PHASE3":63082,"PHASE4":63084,"NA":63086},{"trials":63070,"activeCount":97},[],{"trials":63072,"activeCount":97},[63073],{"nctId":63074,"briefTitle":63075,"status":155,"phases":63076,"primaryCompletion":39145,"completion":20447,"start":63077,"enrollment":593,"conditions":63078,"interventions":63079},"NCT00140738","Safety and Immunogenicity Study of the New dHER2 Vaccine to Treat HER2-positive Metastatic Breast Cancer",[85],"2005-03-10",[668],[63067],{"trials":63081,"activeCount":97},[],{"trials":63083,"activeCount":97},[],{"trials":63085,"activeCount":97},[],{"trials":63087,"activeCount":97},[],{"intervention":63089,"totalTrials":417,"cells":63090},"Paroxetine hydrochloride",{"EARLY_PHASE1":63091,"PHASE1":63093,"PHASE2":63104,"PHASE3":63106,"PHASE4":63108,"NA":63110},{"trials":63092,"activeCount":97},[],{"trials":63094,"activeCount":97},[63095],{"nctId":63096,"briefTitle":63097,"status":155,"phases":63098,"primaryCompletion":63099,"completion":63099,"start":3156,"enrollment":12044,"conditions":63100,"interventions":63102},"NCT04311463","Bioequivalence Study of Paroxetine and PAXIL Under Fasting Conditions in Healthy Mexican Participants",[85],"2021-01-02",[63101],"Anxiety Disorders",[63089,63103],"PAXIL",{"trials":63105,"activeCount":97},[],{"trials":63107,"activeCount":97},[],{"trials":63109,"activeCount":97},[],{"trials":63111,"activeCount":97},[],{"intervention":63103,"totalTrials":417,"cells":63113},{"EARLY_PHASE1":63114,"PHASE1":63116,"PHASE2":63122,"PHASE3":63124,"PHASE4":63126,"NA":63128},{"trials":63115,"activeCount":97},[],{"trials":63117,"activeCount":97},[63118],{"nctId":63096,"briefTitle":63097,"status":155,"phases":63119,"primaryCompletion":63099,"completion":63099,"start":3156,"enrollment":12044,"conditions":63120,"interventions":63121},[85],[63101],[63089,63103],{"trials":63123,"activeCount":97},[],{"trials":63125,"activeCount":97},[],{"trials":63127,"activeCount":97},[],{"trials":63129,"activeCount":97},[],{"intervention":63131,"totalTrials":417,"cells":63132},"Ketoconazole + GW642444M",{"EARLY_PHASE1":63133,"PHASE1":63135,"PHASE2":63143,"PHASE3":63145,"PHASE4":63147,"NA":63149},{"trials":63134,"activeCount":97},[],{"trials":63136,"activeCount":97},[63137],{"nctId":63138,"briefTitle":63139,"status":155,"phases":63140,"primaryCompletion":25494,"completion":25494,"start":19910,"enrollment":454,"conditions":63141,"interventions":63142},"NCT00866515","Drug Interaction Study to Investigate Co-administration of GW642444M With Ketoconazole",[85],[15],[63131],{"trials":63144,"activeCount":97},[],{"trials":63146,"activeCount":97},[],{"trials":63148,"activeCount":97},[],{"trials":63150,"activeCount":97},[],{"intervention":63152,"totalTrials":417,"cells":63153},"GSK2838232 100 mg",{"EARLY_PHASE1":63154,"PHASE1":63156,"PHASE2":63167,"PHASE3":63169,"PHASE4":63171,"NA":63173},{"trials":63155,"activeCount":97},[],{"trials":63157,"activeCount":97},[63158],{"nctId":63159,"briefTitle":63160,"status":155,"phases":63161,"primaryCompletion":63162,"completion":63162,"start":38018,"enrollment":93,"conditions":63163,"interventions":63164},"NCT03234036","A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir",[85],"2017-11-10",[9343,10943],[63152,63165,63166],"GSK2838232 50 mg","Ritonavir 100 mg",{"trials":63168,"activeCount":97},[],{"trials":63170,"activeCount":97},[],{"trials":63172,"activeCount":97},[],{"trials":63174,"activeCount":97},[],{"intervention":63165,"totalTrials":417,"cells":63176},{"EARLY_PHASE1":63177,"PHASE1":63179,"PHASE2":63185,"PHASE3":63187,"PHASE4":63189,"NA":63191},{"trials":63178,"activeCount":97},[],{"trials":63180,"activeCount":97},[63181],{"nctId":63159,"briefTitle":63160,"status":155,"phases":63182,"primaryCompletion":63162,"completion":63162,"start":38018,"enrollment":93,"conditions":63183,"interventions":63184},[85],[9343,10943],[63152,63165,63166],{"trials":63186,"activeCount":97},[],{"trials":63188,"activeCount":97},[],{"trials":63190,"activeCount":97},[],{"trials":63192,"activeCount":97},[],{"intervention":63166,"totalTrials":417,"cells":63194},{"EARLY_PHASE1":63195,"PHASE1":63197,"PHASE2":63203,"PHASE3":63205,"PHASE4":63207,"NA":63209},{"trials":63196,"activeCount":97},[],{"trials":63198,"activeCount":97},[63199],{"nctId":63159,"briefTitle":63160,"status":155,"phases":63200,"primaryCompletion":63162,"completion":63162,"start":38018,"enrollment":93,"conditions":63201,"interventions":63202},[85],[9343,10943],[63152,63165,63166],{"trials":63204,"activeCount":97},[],{"trials":63206,"activeCount":97},[],{"trials":63208,"activeCount":97},[],{"trials":63210,"activeCount":97},[],{"intervention":63212,"totalTrials":417,"cells":63213},"GSK1322322\u002Fplacebo",{"EARLY_PHASE1":63214,"PHASE1":63216,"PHASE2":63226,"PHASE3":63228,"PHASE4":63230,"NA":63232},{"trials":63215,"activeCount":97},[],{"trials":63217,"activeCount":97},[63218],{"nctId":63219,"briefTitle":63220,"status":155,"phases":63221,"primaryCompletion":22162,"completion":22162,"start":63222,"enrollment":3025,"conditions":63223,"interventions":63224},"NCT00896558","A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects",[85],"2009-05-11",[6484],[63212,63225],"GSK1322322\u002Fplacebo and midazolam",{"trials":63227,"activeCount":97},[],{"trials":63229,"activeCount":97},[],{"trials":63231,"activeCount":97},[],{"trials":63233,"activeCount":97},[],{"intervention":63225,"totalTrials":417,"cells":63235},{"EARLY_PHASE1":63236,"PHASE1":63238,"PHASE2":63244,"PHASE3":63246,"PHASE4":63248,"NA":63250},{"trials":63237,"activeCount":97},[],{"trials":63239,"activeCount":97},[63240],{"nctId":63219,"briefTitle":63220,"status":155,"phases":63241,"primaryCompletion":22162,"completion":22162,"start":63222,"enrollment":3025,"conditions":63242,"interventions":63243},[85],[6484],[63212,63225],{"trials":63245,"activeCount":97},[],{"trials":63247,"activeCount":97},[],{"trials":63249,"activeCount":97},[],{"trials":63251,"activeCount":97},[],{"intervention":8011,"totalTrials":417,"cells":63253},{"EARLY_PHASE1":63254,"PHASE1":63256,"PHASE2":63262,"PHASE3":63264,"PHASE4":63266,"NA":63268},{"trials":63255,"activeCount":97},[],{"trials":63257,"activeCount":97},[63258],{"nctId":8004,"briefTitle":8005,"status":155,"phases":63259,"primaryCompletion":8007,"completion":8007,"start":8008,"enrollment":433,"conditions":63260,"interventions":63261},[85],[27],[7997,8011],{"trials":63263,"activeCount":97},[],{"trials":63265,"activeCount":97},[],{"trials":63267,"activeCount":97},[],{"trials":63269,"activeCount":97},[],{"intervention":63271,"totalTrials":417,"cells":63272},"Paroxetine 12.5 milligrams",{"EARLY_PHASE1":63273,"PHASE1":63275,"PHASE2":63286,"PHASE3":63288,"PHASE4":63290,"NA":63292},{"trials":63274,"activeCount":97},[],{"trials":63276,"activeCount":97},[63277],{"nctId":63278,"briefTitle":63279,"status":155,"phases":63280,"primaryCompletion":63281,"completion":63281,"start":57608,"enrollment":1634,"conditions":63282,"interventions":63283},"NCT00938184","Single Dose Study of Controlled-Release Paroxetine Tablets in Healthy Japanese Male Subjects",[85],"2009-09-02",[9292],[63271,63284,63285],"Paroxetine 25 milligrams","Paroxetine 50 milligrams",{"trials":63287,"activeCount":97},[],{"trials":63289,"activeCount":97},[],{"trials":63291,"activeCount":97},[],{"trials":63293,"activeCount":97},[],{"intervention":63284,"totalTrials":417,"cells":63295},{"EARLY_PHASE1":63296,"PHASE1":63298,"PHASE2":63304,"PHASE3":63306,"PHASE4":63308,"NA":63310},{"trials":63297,"activeCount":97},[],{"trials":63299,"activeCount":97},[63300],{"nctId":63278,"briefTitle":63279,"status":155,"phases":63301,"primaryCompletion":63281,"completion":63281,"start":57608,"enrollment":1634,"conditions":63302,"interventions":63303},[85],[9292],[63271,63284,63285],{"trials":63305,"activeCount":97},[],{"trials":63307,"activeCount":97},[],{"trials":63309,"activeCount":97},[],{"trials":63311,"activeCount":97},[],{"intervention":63285,"totalTrials":417,"cells":63313},{"EARLY_PHASE1":63314,"PHASE1":63316,"PHASE2":63322,"PHASE3":63324,"PHASE4":63326,"NA":63328},{"trials":63315,"activeCount":97},[],{"trials":63317,"activeCount":97},[63318],{"nctId":63278,"briefTitle":63279,"status":155,"phases":63319,"primaryCompletion":63281,"completion":63281,"start":57608,"enrollment":1634,"conditions":63320,"interventions":63321},[85],[9292],[63271,63284,63285],{"trials":63323,"activeCount":97},[],{"trials":63325,"activeCount":97},[],{"trials":63327,"activeCount":97},[],{"trials":63329,"activeCount":97},[],{"intervention":63331,"totalTrials":417,"cells":63332},"100 mg GSK investigational drug",{"EARLY_PHASE1":63333,"PHASE1":63335,"PHASE2":63352,"PHASE3":63354,"PHASE4":63356,"NA":63358},{"trials":63334,"activeCount":97},[],{"trials":63336,"activeCount":97},[63337],{"nctId":63338,"briefTitle":63339,"status":155,"phases":63340,"primaryCompletion":6316,"completion":6316,"start":63341,"enrollment":212,"conditions":63342,"interventions":63343},"NCT00828867","Single Dose Escalation First Time in Human PK Study",[85],"2008-11-14",[6484],[63331,63344,63345,63346,63347,63348,63349,63350,63351],"200 mg GSK investigational drug","400 mg GSK investigational drug","800 mg GSK investigational drug","2000 mg GSK investigational drug","1500 mg GSK investigational drug","800mg fed GSK investigational drug","3000mg GSK investigational drug","4000mg GSK investigational drug",{"trials":63353,"activeCount":97},[],{"trials":63355,"activeCount":97},[],{"trials":63357,"activeCount":97},[],{"trials":63359,"activeCount":97},[],{"intervention":63344,"totalTrials":417,"cells":63361},{"EARLY_PHASE1":63362,"PHASE1":63364,"PHASE2":63370,"PHASE3":63372,"PHASE4":63374,"NA":63376},{"trials":63363,"activeCount":97},[],{"trials":63365,"activeCount":97},[63366],{"nctId":63338,"briefTitle":63339,"status":155,"phases":63367,"primaryCompletion":6316,"completion":6316,"start":63341,"enrollment":212,"conditions":63368,"interventions":63369},[85],[6484],[63331,63344,63345,63346,63347,63348,63349,63350,63351],{"trials":63371,"activeCount":97},[],{"trials":63373,"activeCount":97},[],{"trials":63375,"activeCount":97},[],{"trials":63377,"activeCount":97},[],{"intervention":63345,"totalTrials":417,"cells":63379},{"EARLY_PHASE1":63380,"PHASE1":63382,"PHASE2":63388,"PHASE3":63390,"PHASE4":63392,"NA":63394},{"trials":63381,"activeCount":97},[],{"trials":63383,"activeCount":97},[63384],{"nctId":63338,"briefTitle":63339,"status":155,"phases":63385,"primaryCompletion":6316,"completion":6316,"start":63341,"enrollment":212,"conditions":63386,"interventions":63387},[85],[6484],[63331,63344,63345,63346,63347,63348,63349,63350,63351],{"trials":63389,"activeCount":97},[],{"trials":63391,"activeCount":97},[],{"trials":63393,"activeCount":97},[],{"trials":63395,"activeCount":97},[],{"intervention":63346,"totalTrials":417,"cells":63397},{"EARLY_PHASE1":63398,"PHASE1":63400,"PHASE2":63406,"PHASE3":63408,"PHASE4":63410,"NA":63412},{"trials":63399,"activeCount":97},[],{"trials":63401,"activeCount":97},[63402],{"nctId":63338,"briefTitle":63339,"status":155,"phases":63403,"primaryCompletion":6316,"completion":6316,"start":63341,"enrollment":212,"conditions":63404,"interventions":63405},[85],[6484],[63331,63344,63345,63346,63347,63348,63349,63350,63351],{"trials":63407,"activeCount":97},[],{"trials":63409,"activeCount":97},[],{"trials":63411,"activeCount":97},[],{"trials":63413,"activeCount":97},[],{"intervention":63347,"totalTrials":417,"cells":63415},{"EARLY_PHASE1":63416,"PHASE1":63418,"PHASE2":63424,"PHASE3":63426,"PHASE4":63428,"NA":63430},{"trials":63417,"activeCount":97},[],{"trials":63419,"activeCount":97},[63420],{"nctId":63338,"briefTitle":63339,"status":155,"phases":63421,"primaryCompletion":6316,"completion":6316,"start":63341,"enrollment":212,"conditions":63422,"interventions":63423},[85],[6484],[63331,63344,63345,63346,63347,63348,63349,63350,63351],{"trials":63425,"activeCount":97},[],{"trials":63427,"activeCount":97},[],{"trials":63429,"activeCount":97},[],{"trials":63431,"activeCount":97},[],{"intervention":63348,"totalTrials":417,"cells":63433},{"EARLY_PHASE1":63434,"PHASE1":63436,"PHASE2":63442,"PHASE3":63444,"PHASE4":63446,"NA":63448},{"trials":63435,"activeCount":97},[],{"trials":63437,"activeCount":97},[63438],{"nctId":63338,"briefTitle":63339,"status":155,"phases":63439,"primaryCompletion":6316,"completion":6316,"start":63341,"enrollment":212,"conditions":63440,"interventions":63441},[85],[6484],[63331,63344,63345,63346,63347,63348,63349,63350,63351],{"trials":63443,"activeCount":97},[],{"trials":63445,"activeCount":97},[],{"trials":63447,"activeCount":97},[],{"trials":63449,"activeCount":97},[],{"intervention":63349,"totalTrials":417,"cells":63451},{"EARLY_PHASE1":63452,"PHASE1":63454,"PHASE2":63460,"PHASE3":63462,"PHASE4":63464,"NA":63466},{"trials":63453,"activeCount":97},[],{"trials":63455,"activeCount":97},[63456],{"nctId":63338,"briefTitle":63339,"status":155,"phases":63457,"primaryCompletion":6316,"completion":6316,"start":63341,"enrollment":212,"conditions":63458,"interventions":63459},[85],[6484],[63331,63344,63345,63346,63347,63348,63349,63350,63351],{"trials":63461,"activeCount":97},[],{"trials":63463,"activeCount":97},[],{"trials":63465,"activeCount":97},[],{"trials":63467,"activeCount":97},[],{"intervention":63350,"totalTrials":417,"cells":63469},{"EARLY_PHASE1":63470,"PHASE1":63472,"PHASE2":63478,"PHASE3":63480,"PHASE4":63482,"NA":63484},{"trials":63471,"activeCount":97},[],{"trials":63473,"activeCount":97},[63474],{"nctId":63338,"briefTitle":63339,"status":155,"phases":63475,"primaryCompletion":6316,"completion":6316,"start":63341,"enrollment":212,"conditions":63476,"interventions":63477},[85],[6484],[63331,63344,63345,63346,63347,63348,63349,63350,63351],{"trials":63479,"activeCount":97},[],{"trials":63481,"activeCount":97},[],{"trials":63483,"activeCount":97},[],{"trials":63485,"activeCount":97},[],{"intervention":63351,"totalTrials":417,"cells":63487},{"EARLY_PHASE1":63488,"PHASE1":63490,"PHASE2":63496,"PHASE3":63498,"PHASE4":63500,"NA":63502},{"trials":63489,"activeCount":97},[],{"trials":63491,"activeCount":97},[63492],{"nctId":63338,"briefTitle":63339,"status":155,"phases":63493,"primaryCompletion":6316,"completion":6316,"start":63341,"enrollment":212,"conditions":63494,"interventions":63495},[85],[6484],[63331,63344,63345,63346,63347,63348,63349,63350,63351],{"trials":63497,"activeCount":97},[],{"trials":63499,"activeCount":97},[],{"trials":63501,"activeCount":97},[],{"trials":63503,"activeCount":97},[],{"intervention":63505,"totalTrials":417,"cells":63506},"Capoten",{"EARLY_PHASE1":63507,"PHASE1":63509,"PHASE2":63520,"PHASE3":63522,"PHASE4":63524,"NA":63526},{"trials":63508,"activeCount":97},[],{"trials":63510,"activeCount":97},[63511],{"nctId":63512,"briefTitle":63513,"status":500,"phases":63514,"primaryCompletion":63515,"completion":63515,"start":63516,"enrollment":97,"conditions":63517,"interventions":63518},"NCT04878315","Bioequivalence Study Between Capoten Versus Captopril Reference Product in Healthy Adult Participants Under Fasting Conditions",[85],"2022-03-25","2022-02-13",[5280],[63505,63519],"Captopril",{"trials":63521,"activeCount":97},[],{"trials":63523,"activeCount":97},[],{"trials":63525,"activeCount":97},[],{"trials":63527,"activeCount":97},[],{"intervention":63519,"totalTrials":417,"cells":63529},{"EARLY_PHASE1":63530,"PHASE1":63532,"PHASE2":63538,"PHASE3":63540,"PHASE4":63542,"NA":63544},{"trials":63531,"activeCount":97},[],{"trials":63533,"activeCount":97},[63534],{"nctId":63512,"briefTitle":63513,"status":500,"phases":63535,"primaryCompletion":63515,"completion":63515,"start":63516,"enrollment":97,"conditions":63536,"interventions":63537},[85],[5280],[63505,63519],{"trials":63539,"activeCount":97},[],{"trials":63541,"activeCount":97},[],{"trials":63543,"activeCount":97},[],{"trials":63545,"activeCount":97},[],{"intervention":63547,"totalTrials":417,"cells":63548},"SB751689",{"EARLY_PHASE1":63549,"PHASE1":63551,"PHASE2":63560,"PHASE3":63562,"PHASE4":63564,"NA":63566},{"trials":63550,"activeCount":97},[],{"trials":63552,"activeCount":97},[63553],{"nctId":63554,"briefTitle":63555,"status":155,"phases":63556,"completion":63557,"start":31572,"enrollment":1634,"conditions":63558,"interventions":63559},"NCT00554255","A Study of SB751689 in Japanese Postmenopausal Women",[85],"2006-12-12",[12138],[63547],{"trials":63561,"activeCount":97},[],{"trials":63563,"activeCount":97},[],{"trials":63565,"activeCount":97},[],{"trials":63567,"activeCount":97},[],{"intervention":63569,"totalTrials":417,"cells":63570},"darapladib 160mg",{"EARLY_PHASE1":63571,"PHASE1":63573,"PHASE2":63582,"PHASE3":63584,"PHASE4":63586,"NA":63588},{"trials":63572,"activeCount":97},[],{"trials":63574,"activeCount":97},[63575],{"nctId":63576,"briefTitle":63577,"status":155,"phases":63578,"primaryCompletion":63579,"completion":63579,"start":21804,"enrollment":1298,"conditions":63580,"interventions":63581},"NCT02000804","Darapladib China PK",[85],"2014-01-04",[9309],[63569],{"trials":63583,"activeCount":97},[],{"trials":63585,"activeCount":97},[],{"trials":63587,"activeCount":97},[],{"trials":63589,"activeCount":97},[],{"intervention":63591,"totalTrials":417,"cells":63592},"GSK2110183 Gelatin",{"EARLY_PHASE1":63593,"PHASE1":63595,"PHASE2":63604,"PHASE3":63606,"PHASE4":63608,"NA":63610},{"trials":63594,"activeCount":97},[],{"trials":63596,"activeCount":97},[63597],{"nctId":63598,"briefTitle":63599,"status":155,"phases":63600,"primaryCompletion":42961,"completion":42961,"start":848,"enrollment":1634,"conditions":63601,"interventions":63602},"NCT02040480","Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib",[85],[36],[63591,63603],"GSK2110183 IR",{"trials":63605,"activeCount":97},[],{"trials":63607,"activeCount":97},[],{"trials":63609,"activeCount":97},[],{"trials":63611,"activeCount":97},[],{"intervention":63603,"totalTrials":417,"cells":63613},{"EARLY_PHASE1":63614,"PHASE1":63616,"PHASE2":63622,"PHASE3":63624,"PHASE4":63626,"NA":63628},{"trials":63615,"activeCount":97},[],{"trials":63617,"activeCount":97},[63618],{"nctId":63598,"briefTitle":63599,"status":155,"phases":63619,"primaryCompletion":42961,"completion":42961,"start":848,"enrollment":1634,"conditions":63620,"interventions":63621},[85],[36],[63591,63603],{"trials":63623,"activeCount":97},[],{"trials":63625,"activeCount":97},[],{"trials":63627,"activeCount":97},[],{"trials":63629,"activeCount":97},[],{"intervention":60574,"totalTrials":417,"cells":63631},{"EARLY_PHASE1":63632,"PHASE1":63634,"PHASE2":63640,"PHASE3":63642,"PHASE4":63644,"NA":63646},{"trials":63633,"activeCount":97},[],{"trials":63635,"activeCount":97},[63636],{"nctId":60569,"briefTitle":60570,"status":155,"phases":63637,"primaryCompletion":40863,"completion":40863,"start":18379,"enrollment":2375,"conditions":63638,"interventions":63639},[85],[9048],[60574,60562],{"trials":63641,"activeCount":97},[],{"trials":63643,"activeCount":97},[],{"trials":63645,"activeCount":97},[],{"trials":63647,"activeCount":97},[],{"intervention":41565,"totalTrials":417,"cells":63649},{"EARLY_PHASE1":63650,"PHASE1":63652,"PHASE2":63658,"PHASE3":63660,"PHASE4":63662,"NA":63664},{"trials":63651,"activeCount":97},[],{"trials":63653,"activeCount":97},[63654],{"nctId":41558,"briefTitle":41559,"status":155,"phases":63655,"primaryCompletion":41561,"completion":41561,"start":41562,"enrollment":255,"conditions":63656,"interventions":63657},[85],[21782],[41551,41565],{"trials":63659,"activeCount":97},[],{"trials":63661,"activeCount":97},[],{"trials":63663,"activeCount":97},[],{"trials":63665,"activeCount":97},[],{"intervention":63667,"totalTrials":417,"cells":63668},"PhtD vaccine with\u002Fwithout adjuvant",{"EARLY_PHASE1":63669,"PHASE1":63671,"PHASE2":63681,"PHASE3":63683,"PHASE4":63685,"NA":63687},{"trials":63670,"activeCount":97},[],{"trials":63672,"activeCount":97},[63673],{"nctId":63674,"briefTitle":63675,"status":155,"phases":63676,"primaryCompletion":11097,"completion":11097,"start":7581,"enrollment":1579,"conditions":63677,"interventions":63678},"NCT01767402","Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults",[85],[51398],[63667,63679,63680],"Pneumovax 23TM","NaCl",{"trials":63682,"activeCount":97},[],{"trials":63684,"activeCount":97},[],{"trials":63686,"activeCount":97},[],{"trials":63688,"activeCount":97},[],{"intervention":63679,"totalTrials":417,"cells":63690},{"EARLY_PHASE1":63691,"PHASE1":63693,"PHASE2":63699,"PHASE3":63701,"PHASE4":63703,"NA":63705},{"trials":63692,"activeCount":97},[],{"trials":63694,"activeCount":97},[63695],{"nctId":63674,"briefTitle":63675,"status":155,"phases":63696,"primaryCompletion":11097,"completion":11097,"start":7581,"enrollment":1579,"conditions":63697,"interventions":63698},[85],[51398],[63667,63679,63680],{"trials":63700,"activeCount":97},[],{"trials":63702,"activeCount":97},[],{"trials":63704,"activeCount":97},[],{"trials":63706,"activeCount":97},[],{"intervention":63680,"totalTrials":417,"cells":63708},{"EARLY_PHASE1":63709,"PHASE1":63711,"PHASE2":63717,"PHASE3":63719,"PHASE4":63721,"NA":63723},{"trials":63710,"activeCount":97},[],{"trials":63712,"activeCount":97},[63713],{"nctId":63674,"briefTitle":63675,"status":155,"phases":63714,"primaryCompletion":11097,"completion":11097,"start":7581,"enrollment":1579,"conditions":63715,"interventions":63716},[85],[51398],[63667,63679,63680],{"trials":63718,"activeCount":97},[],{"trials":63720,"activeCount":97},[],{"trials":63722,"activeCount":97},[],{"trials":63724,"activeCount":97},[],{"intervention":63726,"totalTrials":417,"cells":63727},"Intravenous (IV) single dose",{"EARLY_PHASE1":63728,"PHASE1":63730,"PHASE2":63739,"PHASE3":63741,"PHASE4":63743,"NA":63745},{"trials":63729,"activeCount":97},[],{"trials":63731,"activeCount":97},[63732],{"nctId":63733,"briefTitle":63734,"status":155,"phases":63735,"primaryCompletion":18064,"completion":18064,"start":18428,"enrollment":1517,"conditions":63736,"interventions":63737},"NCT01563042","A Single Dose Pharmacokinetics (PK) Study of GSK2434735 in Healthy Male Volunteers",[85],[18],[63726,63738],"Subcutaneous (SC) single dose",{"trials":63740,"activeCount":97},[],{"trials":63742,"activeCount":97},[],{"trials":63744,"activeCount":97},[],{"trials":63746,"activeCount":97},[],{"intervention":63738,"totalTrials":417,"cells":63748},{"EARLY_PHASE1":63749,"PHASE1":63751,"PHASE2":63757,"PHASE3":63759,"PHASE4":63761,"NA":63763},{"trials":63750,"activeCount":97},[],{"trials":63752,"activeCount":97},[63753],{"nctId":63733,"briefTitle":63734,"status":155,"phases":63754,"primaryCompletion":18064,"completion":18064,"start":18428,"enrollment":1517,"conditions":63755,"interventions":63756},[85],[18],[63726,63738],{"trials":63758,"activeCount":97},[],{"trials":63760,"activeCount":97},[],{"trials":63762,"activeCount":97},[],{"trials":63764,"activeCount":97},[],{"intervention":63766,"totalTrials":417,"cells":63767},"Tafenoquine 150 mg",{"EARLY_PHASE1":63768,"PHASE1":63770,"PHASE2":63780,"PHASE3":63782,"PHASE4":63784,"NA":63786},{"trials":63769,"activeCount":97},[],{"trials":63771,"activeCount":97},[63772],{"nctId":63773,"briefTitle":63774,"status":155,"phases":63775,"primaryCompletion":4996,"completion":4996,"start":63776,"enrollment":23382,"conditions":63777,"interventions":63778},"NCT02658435","Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)",[85],"2016-02-02",[3298],[63766,63779],"Matched placebo 150mg",{"trials":63781,"activeCount":97},[],{"trials":63783,"activeCount":97},[],{"trials":63785,"activeCount":97},[],{"trials":63787,"activeCount":97},[],{"intervention":63779,"totalTrials":417,"cells":63789},{"EARLY_PHASE1":63790,"PHASE1":63792,"PHASE2":63798,"PHASE3":63800,"PHASE4":63802,"NA":63804},{"trials":63791,"activeCount":97},[],{"trials":63793,"activeCount":97},[63794],{"nctId":63773,"briefTitle":63774,"status":155,"phases":63795,"primaryCompletion":4996,"completion":4996,"start":63776,"enrollment":23382,"conditions":63796,"interventions":63797},[85],[3298],[63766,63779],{"trials":63799,"activeCount":97},[],{"trials":63801,"activeCount":97},[],{"trials":63803,"activeCount":97},[],{"trials":63805,"activeCount":97},[],{"intervention":19707,"totalTrials":417,"cells":63807},{"EARLY_PHASE1":63808,"PHASE1":63810,"PHASE2":63816,"PHASE3":63818,"PHASE4":63820,"NA":63822},{"trials":63809,"activeCount":97},[],{"trials":63811,"activeCount":97},[63812],{"nctId":19700,"briefTitle":19701,"status":155,"phases":63813,"primaryCompletion":19703,"completion":19703,"start":19704,"enrollment":1335,"conditions":63814,"interventions":63815},[85],[435],[19707,19693,9324,19708],{"trials":63817,"activeCount":97},[],{"trials":63819,"activeCount":97},[],{"trials":63821,"activeCount":97},[],{"trials":63823,"activeCount":97},[],{"intervention":19708,"totalTrials":417,"cells":63825},{"EARLY_PHASE1":63826,"PHASE1":63828,"PHASE2":63834,"PHASE3":63836,"PHASE4":63838,"NA":63840},{"trials":63827,"activeCount":97},[],{"trials":63829,"activeCount":97},[63830],{"nctId":19700,"briefTitle":19701,"status":155,"phases":63831,"primaryCompletion":19703,"completion":19703,"start":19704,"enrollment":1335,"conditions":63832,"interventions":63833},[85],[435],[19707,19693,9324,19708],{"trials":63835,"activeCount":97},[],{"trials":63837,"activeCount":97},[],{"trials":63839,"activeCount":97},[],{"trials":63841,"activeCount":97},[],{"intervention":59481,"totalTrials":417,"cells":63843},{"EARLY_PHASE1":63844,"PHASE1":63846,"PHASE2":63852,"PHASE3":63854,"PHASE4":63856,"NA":63858},{"trials":63845,"activeCount":97},[],{"trials":63847,"activeCount":97},[63848],{"nctId":59474,"briefTitle":59475,"status":500,"phases":63849,"primaryCompletion":59477,"completion":59477,"start":59478,"enrollment":97,"conditions":63850,"interventions":63851},[85],[4644],[59481,59482,39369],{"trials":63853,"activeCount":97},[],{"trials":63855,"activeCount":97},[],{"trials":63857,"activeCount":97},[],{"trials":63859,"activeCount":97},[],{"intervention":59482,"totalTrials":417,"cells":63861},{"EARLY_PHASE1":63862,"PHASE1":63864,"PHASE2":63870,"PHASE3":63872,"PHASE4":63874,"NA":63876},{"trials":63863,"activeCount":97},[],{"trials":63865,"activeCount":97},[63866],{"nctId":59474,"briefTitle":59475,"status":500,"phases":63867,"primaryCompletion":59477,"completion":59477,"start":59478,"enrollment":97,"conditions":63868,"interventions":63869},[85],[4644],[59481,59482,39369],{"trials":63871,"activeCount":97},[],{"trials":63873,"activeCount":97},[],{"trials":63875,"activeCount":97},[],{"trials":63877,"activeCount":97},[],{"intervention":63879,"totalTrials":417,"cells":63880},"Pazopanib eye drops and Allergen Refresh Plus eye drops",{"EARLY_PHASE1":63881,"PHASE1":63883,"PHASE2":63892,"PHASE3":63894,"PHASE4":63896,"NA":63898},{"trials":63882,"activeCount":97},[],{"trials":63884,"activeCount":97},[63885],{"nctId":63886,"briefTitle":63887,"status":155,"phases":63888,"completion":2336,"start":748,"enrollment":1079,"conditions":63889,"interventions":63891},"NCT00463320","A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.",[85],[39848,63890],"Age-related Macular Degeneration",[63879],{"trials":63893,"activeCount":97},[],{"trials":63895,"activeCount":97},[],{"trials":63897,"activeCount":97},[],{"trials":63899,"activeCount":97},[],{"intervention":63901,"totalTrials":417,"cells":63902},"Inhaled FF 200mcg\u002FGW642444M 25mcg",{"EARLY_PHASE1":63903,"PHASE1":63905,"PHASE2":63915,"PHASE3":63917,"PHASE4":63919,"NA":63921},{"trials":63904,"activeCount":97},[],{"trials":63906,"activeCount":97},[63907],{"nctId":63908,"briefTitle":63909,"status":155,"phases":63910,"primaryCompletion":63911,"completion":63911,"start":63912,"enrollment":8786,"conditions":63913,"interventions":63914},"NCT01266941","A Study to Assess the Effects of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Mild, Moderate or Severe Hepatic Impairment.",[85],"2011-07-15","2010-10-18",[18],[63901],{"trials":63916,"activeCount":97},[],{"trials":63918,"activeCount":97},[],{"trials":63920,"activeCount":97},[],{"trials":63922,"activeCount":97},[],{"intervention":60634,"totalTrials":417,"cells":63924},{"EARLY_PHASE1":63925,"PHASE1":63927,"PHASE2":63933,"PHASE3":63935,"PHASE4":63937,"NA":63939},{"trials":63926,"activeCount":97},[],{"trials":63928,"activeCount":97},[63929],{"nctId":60628,"briefTitle":60629,"status":155,"phases":63930,"primaryCompletion":40295,"completion":40295,"start":60631,"enrollment":1459,"conditions":63931,"interventions":63932},[85],[1337],[60634,60621],{"trials":63934,"activeCount":97},[],{"trials":63936,"activeCount":97},[],{"trials":63938,"activeCount":97},[],{"trials":63940,"activeCount":97},[],{"intervention":63942,"totalTrials":417,"cells":63943},"GSK2339345 (Inhaled) Single Dose",{"EARLY_PHASE1":63944,"PHASE1":63946,"PHASE2":63957,"PHASE3":63959,"PHASE4":63961,"NA":63963},{"trials":63945,"activeCount":97},[],{"trials":63947,"activeCount":97},[63948],{"nctId":63949,"briefTitle":63950,"status":155,"phases":63951,"primaryCompletion":63952,"completion":63952,"start":63953,"enrollment":710,"conditions":63954,"interventions":63955},"NCT01587716","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.",[85],"2012-07-30","2012-04-23",[40347],[63942,63956],"GSK2339345 (Inhaled) Repeat Dose",{"trials":63958,"activeCount":97},[],{"trials":63960,"activeCount":97},[],{"trials":63962,"activeCount":97},[],{"trials":63964,"activeCount":97},[],{"intervention":63956,"totalTrials":417,"cells":63966},{"EARLY_PHASE1":63967,"PHASE1":63969,"PHASE2":63975,"PHASE3":63977,"PHASE4":63979,"NA":63981},{"trials":63968,"activeCount":97},[],{"trials":63970,"activeCount":97},[63971],{"nctId":63949,"briefTitle":63950,"status":155,"phases":63972,"primaryCompletion":63952,"completion":63952,"start":63953,"enrollment":710,"conditions":63973,"interventions":63974},[85],[40347],[63942,63956],{"trials":63976,"activeCount":97},[],{"trials":63978,"activeCount":97},[],{"trials":63980,"activeCount":97},[],{"trials":63982,"activeCount":97},[],{"intervention":63984,"totalTrials":417,"cells":63985},"Rosuvastatin10 mg",{"EARLY_PHASE1":63986,"PHASE1":63988,"PHASE2":64000,"PHASE3":64002,"PHASE4":64004,"NA":64006},{"trials":63987,"activeCount":97},[],{"trials":63989,"activeCount":97},[63990],{"nctId":63991,"briefTitle":63992,"status":155,"phases":63993,"primaryCompletion":39376,"completion":63994,"start":63995,"enrollment":628,"conditions":63996,"interventions":63997},"NCT02082665","Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam",[85],"2016-08-01","2015-02-19",[36],[63984,63998,63999],"Midazolam 3 mg syrup","Dabrafenib 75 mg",{"trials":64001,"activeCount":97},[],{"trials":64003,"activeCount":97},[],{"trials":64005,"activeCount":97},[],{"trials":64007,"activeCount":97},[],{"intervention":63998,"totalTrials":417,"cells":64009},{"EARLY_PHASE1":64010,"PHASE1":64012,"PHASE2":64018,"PHASE3":64020,"PHASE4":64022,"NA":64024},{"trials":64011,"activeCount":97},[],{"trials":64013,"activeCount":97},[64014],{"nctId":63991,"briefTitle":63992,"status":155,"phases":64015,"primaryCompletion":39376,"completion":63994,"start":63995,"enrollment":628,"conditions":64016,"interventions":64017},[85],[36],[63984,63998,63999],{"trials":64019,"activeCount":97},[],{"trials":64021,"activeCount":97},[],{"trials":64023,"activeCount":97},[],{"trials":64025,"activeCount":97},[],{"intervention":63999,"totalTrials":417,"cells":64027},{"EARLY_PHASE1":64028,"PHASE1":64030,"PHASE2":64036,"PHASE3":64038,"PHASE4":64040,"NA":64042},{"trials":64029,"activeCount":97},[],{"trials":64031,"activeCount":97},[64032],{"nctId":63991,"briefTitle":63992,"status":155,"phases":64033,"primaryCompletion":39376,"completion":63994,"start":63995,"enrollment":628,"conditions":64034,"interventions":64035},[85],[36],[63984,63998,63999],{"trials":64037,"activeCount":97},[],{"trials":64039,"activeCount":97},[],{"trials":64041,"activeCount":97},[],{"trials":64043,"activeCount":97},[],{"intervention":64045,"totalTrials":417,"cells":64046},"Atovaquone\u002Fproguanil HCL",{"EARLY_PHASE1":64047,"PHASE1":64049,"PHASE2":64058,"PHASE3":64060,"PHASE4":64062,"NA":64064},{"trials":64048,"activeCount":97},[],{"trials":64050,"activeCount":97},[64051],{"nctId":64052,"briefTitle":64053,"status":155,"phases":64054,"primaryCompletion":11315,"completion":11315,"start":3389,"enrollment":255,"conditions":64055,"interventions":64056},"NCT01858831","Single Oral Dose Study of Atovaquone\u002FProguanil Hydrochloride Combination Tablets and Atovaquone Suspension",[85],[3287],[64045,64057],"Atovaquone",{"trials":64059,"activeCount":97},[],{"trials":64061,"activeCount":97},[],{"trials":64063,"activeCount":97},[],{"trials":64065,"activeCount":97},[],{"intervention":64057,"totalTrials":417,"cells":64067},{"EARLY_PHASE1":64068,"PHASE1":64070,"PHASE2":64076,"PHASE3":64078,"PHASE4":64080,"NA":64082},{"trials":64069,"activeCount":97},[],{"trials":64071,"activeCount":97},[64072],{"nctId":64052,"briefTitle":64053,"status":155,"phases":64073,"primaryCompletion":11315,"completion":11315,"start":3389,"enrollment":255,"conditions":64074,"interventions":64075},[85],[3287],[64045,64057],{"trials":64077,"activeCount":97},[],{"trials":64079,"activeCount":97},[],{"trials":64081,"activeCount":97},[],{"trials":64083,"activeCount":97},[],{"intervention":41671,"totalTrials":417,"cells":64085},{"EARLY_PHASE1":64086,"PHASE1":64088,"PHASE2":64094,"PHASE3":64096,"PHASE4":64098,"NA":64100},{"trials":64087,"activeCount":97},[],{"trials":64089,"activeCount":97},[64090],{"nctId":41665,"briefTitle":41666,"status":145,"phases":64091,"primaryCompletion":41668,"completion":41668,"start":9057,"enrollment":212,"conditions":64092,"interventions":64093},[85],[3381],[41658,41671],{"trials":64095,"activeCount":97},[],{"trials":64097,"activeCount":97},[],{"trials":64099,"activeCount":97},[],{"trials":64101,"activeCount":97},[],{"intervention":64103,"totalTrials":417,"cells":64104},"GSK2586184 800mg single and repeat dose",{"EARLY_PHASE1":64105,"PHASE1":64107,"PHASE2":64116,"PHASE3":64118,"PHASE4":64120,"NA":64122},{"trials":64106,"activeCount":97},[],{"trials":64108,"activeCount":97},[64109],{"nctId":64110,"briefTitle":64111,"status":155,"phases":64112,"primaryCompletion":38064,"completion":38064,"start":64113,"enrollment":421,"conditions":64114,"interventions":64115},"NCT01687309","A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender",[85],"2012-04-30",[435],[64103],{"trials":64117,"activeCount":97},[],{"trials":64119,"activeCount":97},[],{"trials":64121,"activeCount":97},[],{"trials":64123,"activeCount":97},[],{"intervention":64125,"totalTrials":417,"cells":64126},"GSK HIV vaccine 732462",{"EARLY_PHASE1":64127,"PHASE1":64129,"PHASE2":64140,"PHASE3":64142,"PHASE4":64144,"NA":64146},{"trials":64128,"activeCount":97},[],{"trials":64130,"activeCount":97},[64131],{"nctId":64132,"briefTitle":64133,"status":155,"phases":64134,"primaryCompletion":64135,"completion":64136,"start":64137,"enrollment":11109,"conditions":64138,"interventions":64139},"NCT01092611","Long-term Follow-up of Participants From Studies Evaluating GSK HIV Vaccine",[85],"2014-03-17","2014-05-19","2010-03-22",[3428],[64125],{"trials":64141,"activeCount":97},[],{"trials":64143,"activeCount":97},[],{"trials":64145,"activeCount":97},[],{"trials":64147,"activeCount":97},[],{"intervention":64149,"totalTrials":417,"cells":64150},"NTHI vaccine GSK2838500A",{"EARLY_PHASE1":64151,"PHASE1":64153,"PHASE2":64170,"PHASE3":64172,"PHASE4":64174,"NA":64176},{"trials":64152,"activeCount":97},[],{"trials":64154,"activeCount":97},[64155],{"nctId":64156,"briefTitle":64157,"status":155,"phases":64158,"primaryCompletion":64159,"completion":64159,"start":64160,"enrollment":11098,"conditions":64161,"interventions":64162},"NCT01678677","A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers",[85],"2014-01-30","2012-08-31",[9855],[64149,64163,64164,64165,64166,64167,64168,64169],"NTHI vaccine GSK2838501A","NTHI vaccine GSK2838502A","NTHI vaccine GSK2838503A","NTHI vaccine GSK2838504A","NTHI vaccine GSK2838505A","NTHI vaccine GSK2838508A","NTHI vaccine GSK2838509A",{"trials":64171,"activeCount":97},[],{"trials":64173,"activeCount":97},[],{"trials":64175,"activeCount":97},[],{"trials":64177,"activeCount":97},[],{"intervention":64163,"totalTrials":417,"cells":64179},{"EARLY_PHASE1":64180,"PHASE1":64182,"PHASE2":64188,"PHASE3":64190,"PHASE4":64192,"NA":64194},{"trials":64181,"activeCount":97},[],{"trials":64183,"activeCount":97},[64184],{"nctId":64156,"briefTitle":64157,"status":155,"phases":64185,"primaryCompletion":64159,"completion":64159,"start":64160,"enrollment":11098,"conditions":64186,"interventions":64187},[85],[9855],[64149,64163,64164,64165,64166,64167,64168,64169],{"trials":64189,"activeCount":97},[],{"trials":64191,"activeCount":97},[],{"trials":64193,"activeCount":97},[],{"trials":64195,"activeCount":97},[],{"intervention":64164,"totalTrials":417,"cells":64197},{"EARLY_PHASE1":64198,"PHASE1":64200,"PHASE2":64206,"PHASE3":64208,"PHASE4":64210,"NA":64212},{"trials":64199,"activeCount":97},[],{"trials":64201,"activeCount":97},[64202],{"nctId":64156,"briefTitle":64157,"status":155,"phases":64203,"primaryCompletion":64159,"completion":64159,"start":64160,"enrollment":11098,"conditions":64204,"interventions":64205},[85],[9855],[64149,64163,64164,64165,64166,64167,64168,64169],{"trials":64207,"activeCount":97},[],{"trials":64209,"activeCount":97},[],{"trials":64211,"activeCount":97},[],{"trials":64213,"activeCount":97},[],{"intervention":64165,"totalTrials":417,"cells":64215},{"EARLY_PHASE1":64216,"PHASE1":64218,"PHASE2":64224,"PHASE3":64226,"PHASE4":64228,"NA":64230},{"trials":64217,"activeCount":97},[],{"trials":64219,"activeCount":97},[64220],{"nctId":64156,"briefTitle":64157,"status":155,"phases":64221,"primaryCompletion":64159,"completion":64159,"start":64160,"enrollment":11098,"conditions":64222,"interventions":64223},[85],[9855],[64149,64163,64164,64165,64166,64167,64168,64169],{"trials":64225,"activeCount":97},[],{"trials":64227,"activeCount":97},[],{"trials":64229,"activeCount":97},[],{"trials":64231,"activeCount":97},[],{"intervention":64166,"totalTrials":417,"cells":64233},{"EARLY_PHASE1":64234,"PHASE1":64236,"PHASE2":64242,"PHASE3":64244,"PHASE4":64246,"NA":64248},{"trials":64235,"activeCount":97},[],{"trials":64237,"activeCount":97},[64238],{"nctId":64156,"briefTitle":64157,"status":155,"phases":64239,"primaryCompletion":64159,"completion":64159,"start":64160,"enrollment":11098,"conditions":64240,"interventions":64241},[85],[9855],[64149,64163,64164,64165,64166,64167,64168,64169],{"trials":64243,"activeCount":97},[],{"trials":64245,"activeCount":97},[],{"trials":64247,"activeCount":97},[],{"trials":64249,"activeCount":97},[],{"intervention":64167,"totalTrials":417,"cells":64251},{"EARLY_PHASE1":64252,"PHASE1":64254,"PHASE2":64260,"PHASE3":64262,"PHASE4":64264,"NA":64266},{"trials":64253,"activeCount":97},[],{"trials":64255,"activeCount":97},[64256],{"nctId":64156,"briefTitle":64157,"status":155,"phases":64257,"primaryCompletion":64159,"completion":64159,"start":64160,"enrollment":11098,"conditions":64258,"interventions":64259},[85],[9855],[64149,64163,64164,64165,64166,64167,64168,64169],{"trials":64261,"activeCount":97},[],{"trials":64263,"activeCount":97},[],{"trials":64265,"activeCount":97},[],{"trials":64267,"activeCount":97},[],{"intervention":64168,"totalTrials":417,"cells":64269},{"EARLY_PHASE1":64270,"PHASE1":64272,"PHASE2":64278,"PHASE3":64280,"PHASE4":64282,"NA":64284},{"trials":64271,"activeCount":97},[],{"trials":64273,"activeCount":97},[64274],{"nctId":64156,"briefTitle":64157,"status":155,"phases":64275,"primaryCompletion":64159,"completion":64159,"start":64160,"enrollment":11098,"conditions":64276,"interventions":64277},[85],[9855],[64149,64163,64164,64165,64166,64167,64168,64169],{"trials":64279,"activeCount":97},[],{"trials":64281,"activeCount":97},[],{"trials":64283,"activeCount":97},[],{"trials":64285,"activeCount":97},[],{"intervention":64169,"totalTrials":417,"cells":64287},{"EARLY_PHASE1":64288,"PHASE1":64290,"PHASE2":64296,"PHASE3":64298,"PHASE4":64300,"NA":64302},{"trials":64289,"activeCount":97},[],{"trials":64291,"activeCount":97},[64292],{"nctId":64156,"briefTitle":64157,"status":155,"phases":64293,"primaryCompletion":64159,"completion":64159,"start":64160,"enrollment":11098,"conditions":64294,"interventions":64295},[85],[9855],[64149,64163,64164,64165,64166,64167,64168,64169],{"trials":64297,"activeCount":97},[],{"trials":64299,"activeCount":97},[],{"trials":64301,"activeCount":97},[],{"trials":64303,"activeCount":97},[],{"intervention":7449,"totalTrials":417,"cells":64305},{"EARLY_PHASE1":64306,"PHASE1":64308,"PHASE2":64314,"PHASE3":64316,"PHASE4":64318,"NA":64320},{"trials":64307,"activeCount":97},[],{"trials":64309,"activeCount":97},[64310],{"nctId":7442,"briefTitle":7443,"status":155,"phases":64311,"primaryCompletion":7445,"completion":7445,"start":7446,"enrollment":750,"conditions":64312,"interventions":64313},[85],[36],[2274,7449],{"trials":64315,"activeCount":97},[],{"trials":64317,"activeCount":97},[],{"trials":64319,"activeCount":97},[],{"trials":64321,"activeCount":97},[],{"intervention":1650,"totalTrials":417,"cells":64323},{"EARLY_PHASE1":64324,"PHASE1":64326,"PHASE2":64332,"PHASE3":64334,"PHASE4":64336,"NA":64338},{"trials":64325,"activeCount":97},[],{"trials":64327,"activeCount":97},[64328],{"nctId":1641,"briefTitle":1642,"status":145,"phases":64329,"primaryCompletion":1644,"completion":1645,"start":1646,"enrollment":628,"conditions":64330,"interventions":64331},[85],[107],[1649,1650,1651,1241,137],{"trials":64333,"activeCount":97},[],{"trials":64335,"activeCount":97},[],{"trials":64337,"activeCount":97},[],{"trials":64339,"activeCount":97},[],{"intervention":17856,"totalTrials":417,"cells":64341},{"EARLY_PHASE1":64342,"PHASE1":64344,"PHASE2":64350,"PHASE3":64352,"PHASE4":64354,"NA":64356},{"trials":64343,"activeCount":97},[],{"trials":64345,"activeCount":97},[64346],{"nctId":17850,"briefTitle":17851,"status":155,"phases":64347,"primaryCompletion":8287,"completion":8287,"start":17853,"enrollment":454,"conditions":64348,"interventions":64349},[85],[18],[17843,17856],{"trials":64351,"activeCount":97},[],{"trials":64353,"activeCount":97},[],{"trials":64355,"activeCount":97},[],{"trials":64357,"activeCount":97},[],{"intervention":64359,"totalTrials":417,"cells":64360},"GSK1482160 or placebo",{"EARLY_PHASE1":64361,"PHASE1":64363,"PHASE2":64371,"PHASE3":64373,"PHASE4":64375,"NA":64377},{"trials":64362,"activeCount":97},[],{"trials":64364,"activeCount":97},[64365],{"nctId":64366,"briefTitle":64367,"status":155,"phases":64368,"primaryCompletion":19001,"completion":19001,"start":60579,"enrollment":463,"conditions":64369,"interventions":64370},"NCT00849134","First Time in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Effect of Food of Single Assending Doses of GSK1482160.",[85],[60205],[64359],{"trials":64372,"activeCount":97},[],{"trials":64374,"activeCount":97},[],{"trials":64376,"activeCount":97},[],{"trials":64378,"activeCount":97},[],{"intervention":64380,"totalTrials":417,"cells":64381},"flucloxacillin 250 mg",{"EARLY_PHASE1":64382,"PHASE1":64384,"PHASE2":64394,"PHASE3":64396,"PHASE4":64398,"NA":64400},{"trials":64383,"activeCount":97},[],{"trials":64385,"activeCount":97},[64386],{"nctId":64387,"briefTitle":64388,"status":155,"phases":64389,"primaryCompletion":64390,"completion":64390,"start":19409,"enrollment":1298,"conditions":64391,"interventions":64392},"NCT00358371","Bioavailability Of Flucloxacillin Capsules (250 mg and 500 mg)",[85],"2005-02-08",[6484],[64380,64393],"flucloxacillin 500 mg",{"trials":64395,"activeCount":97},[],{"trials":64397,"activeCount":97},[],{"trials":64399,"activeCount":97},[],{"trials":64401,"activeCount":97},[],{"intervention":64393,"totalTrials":417,"cells":64403},{"EARLY_PHASE1":64404,"PHASE1":64406,"PHASE2":64412,"PHASE3":64414,"PHASE4":64416,"NA":64418},{"trials":64405,"activeCount":97},[],{"trials":64407,"activeCount":97},[64408],{"nctId":64387,"briefTitle":64388,"status":155,"phases":64409,"primaryCompletion":64390,"completion":64390,"start":19409,"enrollment":1298,"conditions":64410,"interventions":64411},[85],[6484],[64380,64393],{"trials":64413,"activeCount":97},[],{"trials":64415,"activeCount":97},[],{"trials":64417,"activeCount":97},[],{"trials":64419,"activeCount":97},[],{"intervention":64421,"totalTrials":417,"cells":64422},"GSK2849466",{"EARLY_PHASE1":64423,"PHASE1":64425,"PHASE2":64434,"PHASE3":64436,"PHASE4":64438,"NA":64440},{"trials":64424,"activeCount":97},[],{"trials":64426,"activeCount":97},[64427],{"nctId":64428,"briefTitle":64429,"status":155,"phases":64430,"primaryCompletion":31366,"completion":31366,"start":64431,"enrollment":7438,"conditions":64432,"interventions":64433},"NCT01696604","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects",[85],"2012-09-26",[42472],[64421],{"trials":64435,"activeCount":97},[],{"trials":64437,"activeCount":97},[],{"trials":64439,"activeCount":97},[],{"trials":64441,"activeCount":97},[],{"intervention":18987,"totalTrials":417,"cells":64443},{"EARLY_PHASE1":64444,"PHASE1":64446,"PHASE2":64452,"PHASE3":64454,"PHASE4":64456,"NA":64458},{"trials":64445,"activeCount":97},[],{"trials":64447,"activeCount":97},[64448],{"nctId":18979,"briefTitle":18980,"status":155,"phases":64449,"primaryCompletion":18982,"completion":18982,"start":18983,"enrollment":345,"conditions":64450,"interventions":64451},[85],[18985],[18987,18988,915],{"trials":64453,"activeCount":97},[],{"trials":64455,"activeCount":97},[],{"trials":64457,"activeCount":97},[],{"trials":64459,"activeCount":97},[],{"intervention":18988,"totalTrials":417,"cells":64461},{"EARLY_PHASE1":64462,"PHASE1":64464,"PHASE2":64470,"PHASE3":64472,"PHASE4":64474,"NA":64476},{"trials":64463,"activeCount":97},[],{"trials":64465,"activeCount":97},[64466],{"nctId":18979,"briefTitle":18980,"status":155,"phases":64467,"primaryCompletion":18982,"completion":18982,"start":18983,"enrollment":345,"conditions":64468,"interventions":64469},[85],[18985],[18987,18988,915],{"trials":64471,"activeCount":97},[],{"trials":64473,"activeCount":97},[],{"trials":64475,"activeCount":97},[],{"trials":64477,"activeCount":97},[],{"intervention":64479,"totalTrials":417,"cells":64480},"Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico",{"EARLY_PHASE1":64481,"PHASE1":64483,"PHASE2":64492,"PHASE3":64494,"PHASE4":64496,"NA":64498},{"trials":64482,"activeCount":97},[],{"trials":64484,"activeCount":97},[64485],{"nctId":64486,"briefTitle":64487,"status":155,"phases":64488,"primaryCompletion":8316,"completion":8316,"start":21276,"enrollment":1237,"conditions":64489,"interventions":64490},"NCT01339247","Paxil CR Bioequivalence Study Brazil - Fed Administration",[85],[9292],[64479,64491],"Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada",{"trials":64493,"activeCount":97},[],{"trials":64495,"activeCount":97},[],{"trials":64497,"activeCount":97},[],{"trials":64499,"activeCount":97},[],{"intervention":64491,"totalTrials":417,"cells":64501},{"EARLY_PHASE1":64502,"PHASE1":64504,"PHASE2":64510,"PHASE3":64512,"PHASE4":64514,"NA":64516},{"trials":64503,"activeCount":97},[],{"trials":64505,"activeCount":97},[64506],{"nctId":64486,"briefTitle":64487,"status":155,"phases":64507,"primaryCompletion":8316,"completion":8316,"start":21276,"enrollment":1237,"conditions":64508,"interventions":64509},[85],[9292],[64479,64491],{"trials":64511,"activeCount":97},[],{"trials":64513,"activeCount":97},[],{"trials":64515,"activeCount":97},[],{"trials":64517,"activeCount":97},[],{"intervention":64519,"totalTrials":417,"cells":64520},"Aripiprazole",{"EARLY_PHASE1":64521,"PHASE1":64523,"PHASE2":64531,"PHASE3":64533,"PHASE4":64535,"NA":64537},{"trials":64522,"activeCount":97},[],{"trials":64524,"activeCount":97},[64525],{"nctId":64526,"briefTitle":64527,"status":155,"phases":64528,"primaryCompletion":1428,"completion":1428,"start":26336,"enrollment":1318,"conditions":64529,"interventions":64530},"NCT01424449","A PET Study in Healthy Volunteers",[85],[9292],[64519],{"trials":64532,"activeCount":97},[],{"trials":64534,"activeCount":97},[],{"trials":64536,"activeCount":97},[],{"trials":64538,"activeCount":97},[],{"intervention":64540,"totalTrials":417,"cells":64541},"Dutasteride-Test product",{"EARLY_PHASE1":64542,"PHASE1":64544,"PHASE2":64554,"PHASE3":64556,"PHASE4":64558,"NA":64560},{"trials":64543,"activeCount":97},[],{"trials":64545,"activeCount":97},[64546],{"nctId":64547,"briefTitle":64548,"status":155,"phases":64549,"primaryCompletion":25262,"completion":25262,"start":64550,"enrollment":710,"conditions":64551,"interventions":64552},"NCT02578953","Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects",[85],"2015-09-09",[12263],[64540,64553],"Dutasteride-Reference product",{"trials":64555,"activeCount":97},[],{"trials":64557,"activeCount":97},[],{"trials":64559,"activeCount":97},[],{"trials":64561,"activeCount":97},[],{"intervention":64553,"totalTrials":417,"cells":64563},{"EARLY_PHASE1":64564,"PHASE1":64566,"PHASE2":64572,"PHASE3":64574,"PHASE4":64576,"NA":64578},{"trials":64565,"activeCount":97},[],{"trials":64567,"activeCount":97},[64568],{"nctId":64547,"briefTitle":64548,"status":155,"phases":64569,"primaryCompletion":25262,"completion":25262,"start":64550,"enrollment":710,"conditions":64570,"interventions":64571},[85],[12263],[64540,64553],{"trials":64573,"activeCount":97},[],{"trials":64575,"activeCount":97},[],{"trials":64577,"activeCount":97},[],{"trials":64579,"activeCount":97},[],{"intervention":64581,"totalTrials":417,"cells":64582},"GW784568X",{"EARLY_PHASE1":64583,"PHASE1":64585,"PHASE2":64594,"PHASE3":64596,"PHASE4":64598,"NA":64600},{"trials":64584,"activeCount":97},[],{"trials":64586,"activeCount":97},[64587],{"nctId":64588,"briefTitle":64589,"status":155,"phases":64590,"primaryCompletion":64591,"completion":64591,"start":718,"enrollment":6369,"conditions":64592,"interventions":64593},"NCT00404586","Effects Of Single Doses Of GW784568X On Allergic Rhinitis Symptoms In Male Subjects Whilst In An Environmental Chamber",[85],"2007-01-16",[10182],[64581,8381],{"trials":64595,"activeCount":97},[],{"trials":64597,"activeCount":97},[],{"trials":64599,"activeCount":97},[],{"trials":64601,"activeCount":97},[],{"intervention":64603,"totalTrials":417,"cells":64604},"WellbutrinXL",{"EARLY_PHASE1":64605,"PHASE1":64607,"PHASE2":64616,"PHASE3":64618,"PHASE4":64620,"NA":64622},{"trials":64606,"activeCount":97},[],{"trials":64608,"activeCount":97},[64609],{"nctId":64610,"briefTitle":64611,"status":155,"phases":64612,"primaryCompletion":39212,"completion":39212,"start":64613,"enrollment":2797,"conditions":64614,"interventions":64615},"NCT00439868","A Study To Evaluate The Effect Of WELLBUTRIN XL On Intraocular Pressure",[85],"2007-02-16",[9292],[64603],{"trials":64617,"activeCount":97},[],{"trials":64619,"activeCount":97},[],{"trials":64621,"activeCount":97},[],{"trials":64623,"activeCount":97},[],{"intervention":64625,"totalTrials":417,"cells":64626},"GW786034,",{"EARLY_PHASE1":64627,"PHASE1":64629,"PHASE2":64640,"PHASE3":64642,"PHASE4":64644,"NA":64646},{"trials":64628,"activeCount":97},[],{"trials":64630,"activeCount":97},[64631],{"nctId":64632,"briefTitle":64633,"status":155,"phases":64634,"primaryCompletion":55433,"completion":55433,"start":64635,"enrollment":750,"conditions":64636,"interventions":64637},"NCT00478725","Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034",[85],"2007-07-18",[1877],[64625,64638,64639],"GW786034, IV","GW786034, radiolabeled",{"trials":64641,"activeCount":97},[],{"trials":64643,"activeCount":97},[],{"trials":64645,"activeCount":97},[],{"trials":64647,"activeCount":97},[],{"intervention":64638,"totalTrials":417,"cells":64649},{"EARLY_PHASE1":64650,"PHASE1":64652,"PHASE2":64658,"PHASE3":64660,"PHASE4":64662,"NA":64664},{"trials":64651,"activeCount":97},[],{"trials":64653,"activeCount":97},[64654],{"nctId":64632,"briefTitle":64633,"status":155,"phases":64655,"primaryCompletion":55433,"completion":55433,"start":64635,"enrollment":750,"conditions":64656,"interventions":64657},[85],[1877],[64625,64638,64639],{"trials":64659,"activeCount":97},[],{"trials":64661,"activeCount":97},[],{"trials":64663,"activeCount":97},[],{"trials":64665,"activeCount":97},[],{"intervention":64639,"totalTrials":417,"cells":64667},{"EARLY_PHASE1":64668,"PHASE1":64670,"PHASE2":64676,"PHASE3":64678,"PHASE4":64680,"NA":64682},{"trials":64669,"activeCount":97},[],{"trials":64671,"activeCount":97},[64672],{"nctId":64632,"briefTitle":64633,"status":155,"phases":64673,"primaryCompletion":55433,"completion":55433,"start":64635,"enrollment":750,"conditions":64674,"interventions":64675},[85],[1877],[64625,64638,64639],{"trials":64677,"activeCount":97},[],{"trials":64679,"activeCount":97},[],{"trials":64681,"activeCount":97},[],{"trials":64683,"activeCount":97},[],{"intervention":25164,"totalTrials":417,"cells":64685},{"EARLY_PHASE1":64686,"PHASE1":64688,"PHASE2":64694,"PHASE3":64696,"PHASE4":64698,"NA":64700},{"trials":64687,"activeCount":97},[],{"trials":64689,"activeCount":97},[64690],{"nctId":25158,"briefTitle":25159,"status":155,"phases":64691,"primaryCompletion":9159,"completion":9159,"start":2441,"enrollment":255,"conditions":64692,"interventions":64693},[85],[25162],[25164,25151],{"trials":64695,"activeCount":97},[],{"trials":64697,"activeCount":97},[],{"trials":64699,"activeCount":97},[],{"trials":64701,"activeCount":97},[],{"intervention":64703,"totalTrials":417,"cells":64704},"TREXIMA™",{"EARLY_PHASE1":64705,"PHASE1":64707,"PHASE2":64717,"PHASE3":64719,"PHASE4":64721,"NA":64723},{"trials":64706,"activeCount":97},[],{"trials":64708,"activeCount":97},[64709],{"nctId":64710,"briefTitle":64711,"status":155,"phases":64712,"primaryCompletion":4738,"completion":4738,"start":9486,"enrollment":255,"conditions":64713,"interventions":64714},"NCT00875784","An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate \u002F Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate)",[85],[14168],[64703,64715,64715,64716],"IMITREX®","IMITREX Tablet 100mg",{"trials":64718,"activeCount":97},[],{"trials":64720,"activeCount":97},[],{"trials":64722,"activeCount":97},[],{"trials":64724,"activeCount":97},[],{"intervention":64715,"totalTrials":417,"cells":64726},{"EARLY_PHASE1":64727,"PHASE1":64729,"PHASE2":64735,"PHASE3":64737,"PHASE4":64739,"NA":64741},{"trials":64728,"activeCount":97},[],{"trials":64730,"activeCount":97},[64731],{"nctId":64710,"briefTitle":64711,"status":155,"phases":64732,"primaryCompletion":4738,"completion":4738,"start":9486,"enrollment":255,"conditions":64733,"interventions":64734},[85],[14168],[64703,64715,64715,64716],{"trials":64736,"activeCount":97},[],{"trials":64738,"activeCount":97},[],{"trials":64740,"activeCount":97},[],{"trials":64742,"activeCount":97},[],{"intervention":64716,"totalTrials":417,"cells":64744},{"EARLY_PHASE1":64745,"PHASE1":64747,"PHASE2":64753,"PHASE3":64755,"PHASE4":64757,"NA":64759},{"trials":64746,"activeCount":97},[],{"trials":64748,"activeCount":97},[64749],{"nctId":64710,"briefTitle":64711,"status":155,"phases":64750,"primaryCompletion":4738,"completion":4738,"start":9486,"enrollment":255,"conditions":64751,"interventions":64752},[85],[14168],[64703,64715,64715,64716],{"trials":64754,"activeCount":97},[],{"trials":64756,"activeCount":97},[],{"trials":64758,"activeCount":97},[],{"trials":64760,"activeCount":97},[],{"intervention":64762,"totalTrials":417,"cells":64763},"GSK2798745 Micronized API without SLS and hypermellose",{"EARLY_PHASE1":64764,"PHASE1":64766,"PHASE2":64776,"PHASE3":64778,"PHASE4":64780,"NA":64782},{"trials":64765,"activeCount":97},[],{"trials":64767,"activeCount":97},[64768],{"nctId":64769,"briefTitle":64770,"status":155,"phases":64771,"primaryCompletion":2392,"completion":2392,"start":41085,"enrollment":1634,"conditions":64772,"interventions":64773},"NCT02925546","A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets",[85],[17253],[64762,64774,64775],"GSK2798745 Micronized API with SLS and hypermellose","GSK2798745 milled API without SLS and hypermellose",{"trials":64777,"activeCount":97},[],{"trials":64779,"activeCount":97},[],{"trials":64781,"activeCount":97},[],{"trials":64783,"activeCount":97},[],{"intervention":64774,"totalTrials":417,"cells":64785},{"EARLY_PHASE1":64786,"PHASE1":64788,"PHASE2":64794,"PHASE3":64796,"PHASE4":64798,"NA":64800},{"trials":64787,"activeCount":97},[],{"trials":64789,"activeCount":97},[64790],{"nctId":64769,"briefTitle":64770,"status":155,"phases":64791,"primaryCompletion":2392,"completion":2392,"start":41085,"enrollment":1634,"conditions":64792,"interventions":64793},[85],[17253],[64762,64774,64775],{"trials":64795,"activeCount":97},[],{"trials":64797,"activeCount":97},[],{"trials":64799,"activeCount":97},[],{"trials":64801,"activeCount":97},[],{"intervention":64775,"totalTrials":417,"cells":64803},{"EARLY_PHASE1":64804,"PHASE1":64806,"PHASE2":64812,"PHASE3":64814,"PHASE4":64816,"NA":64818},{"trials":64805,"activeCount":97},[],{"trials":64807,"activeCount":97},[64808],{"nctId":64769,"briefTitle":64770,"status":155,"phases":64809,"primaryCompletion":2392,"completion":2392,"start":41085,"enrollment":1634,"conditions":64810,"interventions":64811},[85],[17253],[64762,64774,64775],{"trials":64813,"activeCount":97},[],{"trials":64815,"activeCount":97},[],{"trials":64817,"activeCount":97},[],{"trials":64819,"activeCount":97},[],{"intervention":64821,"totalTrials":417,"cells":64822},"Pneumococcal vaccine GSK2830930A",{"EARLY_PHASE1":64823,"PHASE1":64825,"PHASE2":64833,"PHASE3":64835,"PHASE4":64837,"NA":64839},{"trials":64824,"activeCount":97},[],{"trials":64826,"activeCount":97},[64827],{"nctId":64828,"briefTitle":64829,"status":155,"phases":64830,"primaryCompletion":45551,"completion":45551,"start":59381,"enrollment":4542,"conditions":64831,"interventions":64832},"NCT01485406","Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers",[85],[3637],[64821,10348],{"trials":64834,"activeCount":97},[],{"trials":64836,"activeCount":97},[],{"trials":64838,"activeCount":97},[],{"trials":64840,"activeCount":97},[],{"intervention":59416,"totalTrials":417,"cells":64842},{"EARLY_PHASE1":64843,"PHASE1":64845,"PHASE2":64851,"PHASE3":64853,"PHASE4":64855,"NA":64857},{"trials":64844,"activeCount":97},[],{"trials":64846,"activeCount":97},[64847],{"nctId":59411,"briefTitle":59412,"status":500,"phases":64848,"primaryCompletion":34933,"completion":34933,"start":8860,"enrollment":97,"conditions":64849,"interventions":64850},[85],[6484],[59416,59417,8022],{"trials":64852,"activeCount":97},[],{"trials":64854,"activeCount":97},[],{"trials":64856,"activeCount":97},[],{"trials":64858,"activeCount":97},[],{"intervention":59417,"totalTrials":417,"cells":64860},{"EARLY_PHASE1":64861,"PHASE1":64863,"PHASE2":64869,"PHASE3":64871,"PHASE4":64873,"NA":64875},{"trials":64862,"activeCount":97},[],{"trials":64864,"activeCount":97},[64865],{"nctId":59411,"briefTitle":59412,"status":500,"phases":64866,"primaryCompletion":34933,"completion":34933,"start":8860,"enrollment":97,"conditions":64867,"interventions":64868},[85],[6484],[59416,59417,8022],{"trials":64870,"activeCount":97},[],{"trials":64872,"activeCount":97},[],{"trials":64874,"activeCount":97},[],{"trials":64876,"activeCount":97},[],{"intervention":64878,"totalTrials":417,"cells":64879},"Retosiban solution for",{"EARLY_PHASE1":64880,"PHASE1":64882,"PHASE2":64891,"PHASE3":64893,"PHASE4":64895,"NA":64897},{"trials":64881,"activeCount":97},[],{"trials":64883,"activeCount":97},[64884],{"nctId":64885,"briefTitle":64886,"status":155,"phases":64887,"primaryCompletion":64888,"completion":64888,"start":39357,"enrollment":2045,"conditions":64889,"interventions":64890},"NCT02377414","Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women",[85],"2015-04-17",[22921],[64878],{"trials":64892,"activeCount":97},[],{"trials":64894,"activeCount":97},[],{"trials":64896,"activeCount":97},[],{"trials":64898,"activeCount":97},[],{"intervention":60945,"totalTrials":417,"cells":64900},{"EARLY_PHASE1":64901,"PHASE1":64903,"PHASE2":64909,"PHASE3":64911,"PHASE4":64913,"NA":64915},{"trials":64902,"activeCount":97},[],{"trials":64904,"activeCount":97},[64905],{"nctId":60938,"briefTitle":60939,"status":145,"phases":64906,"primaryCompletion":60941,"completion":60941,"start":60942,"enrollment":6503,"conditions":64907,"interventions":64908},[85],[8788],[60945,60946,60931],{"trials":64910,"activeCount":97},[],{"trials":64912,"activeCount":97},[],{"trials":64914,"activeCount":97},[],{"trials":64916,"activeCount":97},[],{"intervention":60946,"totalTrials":417,"cells":64918},{"EARLY_PHASE1":64919,"PHASE1":64921,"PHASE2":64927,"PHASE3":64929,"PHASE4":64931,"NA":64933},{"trials":64920,"activeCount":97},[],{"trials":64922,"activeCount":97},[64923],{"nctId":60938,"briefTitle":60939,"status":145,"phases":64924,"primaryCompletion":60941,"completion":60941,"start":60942,"enrollment":6503,"conditions":64925,"interventions":64926},[85],[8788],[60945,60946,60931],{"trials":64928,"activeCount":97},[],{"trials":64930,"activeCount":97},[],{"trials":64932,"activeCount":97},[],{"trials":64934,"activeCount":97},[],{"intervention":64936,"totalTrials":417,"cells":64937},"MT400",{"EARLY_PHASE1":64938,"PHASE1":64940,"PHASE2":64949,"PHASE3":64951,"PHASE4":64953,"NA":64955},{"trials":64939,"activeCount":97},[],{"trials":64941,"activeCount":97},[64942],{"nctId":64943,"briefTitle":64944,"status":155,"phases":64945,"primaryCompletion":2804,"completion":2804,"start":8426,"enrollment":656,"conditions":64946,"interventions":64948},"NCT00596245","Open-Label, Placebo-Controlled, Parallel Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT 400 or Naproxen Sodium Tablets",[85],[64947],"Healthy",[64936],{"trials":64950,"activeCount":97},[],{"trials":64952,"activeCount":97},[],{"trials":64954,"activeCount":97},[],{"trials":64956,"activeCount":97},[],{"intervention":3018,"totalTrials":417,"cells":64958},{"EARLY_PHASE1":64959,"PHASE1":64961,"PHASE2":64967,"PHASE3":64969,"PHASE4":64971,"NA":64973},{"trials":64960,"activeCount":97},[],{"trials":64962,"activeCount":97},[64963],{"nctId":3011,"briefTitle":3012,"status":155,"phases":64964,"primaryCompletion":3014,"completion":3014,"start":3015,"enrollment":1459,"conditions":64965,"interventions":64966},[85],[1337],[164,3018],{"trials":64968,"activeCount":97},[],{"trials":64970,"activeCount":97},[],{"trials":64972,"activeCount":97},[],{"trials":64974,"activeCount":97},[],{"intervention":21027,"totalTrials":417,"cells":64976},{"EARLY_PHASE1":64977,"PHASE1":64979,"PHASE2":64985,"PHASE3":64987,"PHASE4":64989,"NA":64991},{"trials":64978,"activeCount":97},[],{"trials":64980,"activeCount":97},[64981],{"nctId":21020,"briefTitle":21021,"status":155,"phases":64982,"primaryCompletion":21023,"completion":21023,"start":21024,"enrollment":234,"conditions":64983,"interventions":64984},[85],[13024],[21027,21028],{"trials":64986,"activeCount":97},[],{"trials":64988,"activeCount":97},[],{"trials":64990,"activeCount":97},[],{"trials":64992,"activeCount":97},[],{"intervention":64994,"totalTrials":417,"cells":64995},"Alprazolam 0.5 mg",{"EARLY_PHASE1":64996,"PHASE1":64998,"PHASE2":65008,"PHASE3":65010,"PHASE4":65012,"NA":65014},{"trials":64997,"activeCount":97},[],{"trials":64999,"activeCount":97},[65000],{"nctId":65001,"briefTitle":65002,"status":155,"phases":65003,"primaryCompletion":65004,"completion":65004,"start":65005,"enrollment":695,"conditions":65006,"interventions":65007},"NCT01745562","Bioequivalence Trial of Alprazolam 0.5 mg Tablets",[85],"2010-12-17","2010-12-07",[63101],[64994,64994],{"trials":65009,"activeCount":97},[],{"trials":65011,"activeCount":97},[],{"trials":65013,"activeCount":97},[],{"trials":65015,"activeCount":97},[],{"intervention":43488,"totalTrials":417,"cells":65017},{"EARLY_PHASE1":65018,"PHASE1":65020,"PHASE2":65026,"PHASE3":65028,"PHASE4":65030,"NA":65032},{"trials":65019,"activeCount":97},[],{"trials":65021,"activeCount":97},[65022],{"nctId":43480,"briefTitle":43481,"status":155,"phases":65023,"primaryCompletion":43483,"completion":43483,"start":43484,"enrollment":3025,"conditions":65024,"interventions":65025},[85],[43486],[43473,43488],{"trials":65027,"activeCount":97},[],{"trials":65029,"activeCount":97},[],{"trials":65031,"activeCount":97},[],{"trials":65033,"activeCount":97},[],{"intervention":65035,"totalTrials":417,"cells":65036},"GSK2894512 Topical Cream",{"EARLY_PHASE1":65037,"PHASE1":65039,"PHASE2":65048,"PHASE3":65050,"PHASE4":65052,"NA":65054},{"trials":65038,"activeCount":97},[],{"trials":65040,"activeCount":97},[65041],{"nctId":65042,"briefTitle":65043,"status":155,"phases":65044,"primaryCompletion":22238,"completion":22238,"start":65045,"enrollment":361,"conditions":65046,"interventions":65047},"NCT02466152","Pharmacokinetic Study of Topical GSK2894512 Cream",[85],"2015-05-28",[21691],[65035],{"trials":65049,"activeCount":97},[],{"trials":65051,"activeCount":97},[],{"trials":65053,"activeCount":97},[],{"trials":65055,"activeCount":97},[],{"intervention":65057,"totalTrials":417,"cells":65058},"GSK729327",{"EARLY_PHASE1":65059,"PHASE1":65061,"PHASE2":65069,"PHASE3":65071,"PHASE4":65073,"NA":65075},{"trials":65060,"activeCount":97},[],{"trials":65062,"activeCount":97},[65063],{"nctId":65064,"briefTitle":65065,"status":155,"phases":65066,"primaryCompletion":8468,"completion":2813,"start":4843,"enrollment":14542,"conditions":65067,"interventions":65068},"NCT00448890","Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers",[85],[11346],[65057],{"trials":65070,"activeCount":97},[],{"trials":65072,"activeCount":97},[],{"trials":65074,"activeCount":97},[],{"trials":65076,"activeCount":97},[],{"intervention":61031,"totalTrials":417,"cells":65078},{"EARLY_PHASE1":65079,"PHASE1":65081,"PHASE2":65087,"PHASE3":65089,"PHASE4":65091,"NA":65093},{"trials":65080,"activeCount":97},[],{"trials":65082,"activeCount":97},[65083],{"nctId":61024,"briefTitle":61025,"status":145,"phases":65084,"primaryCompletion":61027,"completion":61027,"start":61028,"enrollment":255,"conditions":65085,"interventions":65086},[85],[8919,8918],[8921,61031],{"trials":65088,"activeCount":97},[],{"trials":65090,"activeCount":97},[],{"trials":65092,"activeCount":97},[],{"trials":65094,"activeCount":97},[],{"intervention":65096,"totalTrials":417,"cells":65097},"Paroxetine IR tablets A",{"EARLY_PHASE1":65098,"PHASE1":65100,"PHASE2":65110,"PHASE3":65112,"PHASE4":65114,"NA":65116},{"trials":65099,"activeCount":97},[],{"trials":65101,"activeCount":97},[65102],{"nctId":65103,"briefTitle":65104,"status":155,"phases":65105,"primaryCompletion":65106,"completion":65106,"start":8527,"enrollment":3672,"conditions":65107,"interventions":65108},"NCT03329573","Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects",[85],"2018-08-03",[63101],[65096,65109],"Paroxetine IR tablets B",{"trials":65111,"activeCount":97},[],{"trials":65113,"activeCount":97},[],{"trials":65115,"activeCount":97},[],{"trials":65117,"activeCount":97},[],{"intervention":65109,"totalTrials":417,"cells":65119},{"EARLY_PHASE1":65120,"PHASE1":65122,"PHASE2":65128,"PHASE3":65130,"PHASE4":65132,"NA":65134},{"trials":65121,"activeCount":97},[],{"trials":65123,"activeCount":97},[65124],{"nctId":65103,"briefTitle":65104,"status":155,"phases":65125,"primaryCompletion":65106,"completion":65106,"start":8527,"enrollment":3672,"conditions":65126,"interventions":65127},[85],[63101],[65096,65109],{"trials":65129,"activeCount":97},[],{"trials":65131,"activeCount":97},[],{"trials":65133,"activeCount":97},[],{"trials":65135,"activeCount":97},[],{"intervention":65137,"totalTrials":417,"cells":65138},"GI198745",{"EARLY_PHASE1":65139,"PHASE1":65141,"PHASE2":65149,"PHASE3":65151,"PHASE4":65153,"NA":65155},{"trials":65140,"activeCount":97},[],{"trials":65142,"activeCount":97},[65143],{"nctId":65144,"briefTitle":65145,"status":155,"phases":65146,"primaryCompletion":7437,"completion":7437,"start":18288,"enrollment":1298,"conditions":65147,"interventions":65148},"NCT00609596","A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.",[85],[12263],[65137],{"trials":65150,"activeCount":97},[],{"trials":65152,"activeCount":97},[],{"trials":65154,"activeCount":97},[],{"trials":65156,"activeCount":97},[],{"intervention":65158,"totalTrials":417,"cells":65159},"GSK2981710",{"EARLY_PHASE1":65160,"PHASE1":65162,"PHASE2":65171,"PHASE3":65173,"PHASE4":65175,"NA":65177},{"trials":65161,"activeCount":97},[],{"trials":65163,"activeCount":97},[65164],{"nctId":65165,"briefTitle":65166,"status":155,"phases":65167,"primaryCompletion":65168,"completion":65168,"start":55194,"enrollment":7891,"conditions":65169,"interventions":65170},"NCT01702480","Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects",[85],"2015-07-03",[4644],[65158],{"trials":65172,"activeCount":97},[],{"trials":65174,"activeCount":97},[],{"trials":65176,"activeCount":97},[],{"trials":65178,"activeCount":97},[],{"intervention":65180,"totalTrials":417,"cells":65181},"Montelukast 5 mg chewable",{"EARLY_PHASE1":65182,"PHASE1":65184,"PHASE2":65194,"PHASE3":65196,"PHASE4":65198,"NA":65200},{"trials":65183,"activeCount":97},[],{"trials":65185,"activeCount":97},[65186],{"nctId":65187,"briefTitle":65188,"status":155,"phases":65189,"primaryCompletion":65190,"completion":65190,"start":65191,"enrollment":2045,"conditions":65192,"interventions":65193},"NCT01863654","Bioequivalence Study of Montelukast 5 mg Chewable",[85],"2010-05-26","2010-05-16",[18],[65180,65180],{"trials":65195,"activeCount":97},[],{"trials":65197,"activeCount":97},[],{"trials":65199,"activeCount":97},[],{"trials":65201,"activeCount":97},[],{"intervention":65203,"totalTrials":417,"cells":65204},"GSK615915A",{"EARLY_PHASE1":65205,"PHASE1":65207,"PHASE2":65217,"PHASE3":65219,"PHASE4":65221,"NA":65223},{"trials":65206,"activeCount":97},[],{"trials":65208,"activeCount":97},[65209],{"nctId":65210,"briefTitle":65211,"status":155,"phases":65212,"primaryCompletion":65213,"completion":65213,"start":65214,"enrollment":4121,"conditions":65215,"interventions":65216},"NCT00400660","A First Time In Human Study To Assess The Compound GSK615915",[85],"2006-07-03","2005-11-23",[8451],[65203],{"trials":65218,"activeCount":97},[],{"trials":65220,"activeCount":97},[],{"trials":65222,"activeCount":97},[],{"trials":65224,"activeCount":97},[],{"intervention":65226,"totalTrials":417,"cells":65227},"SB756050",{"EARLY_PHASE1":65228,"PHASE1":65230,"PHASE2":65239,"PHASE3":65241,"PHASE4":65243,"NA":65245},{"trials":65229,"activeCount":97},[],{"trials":65231,"activeCount":97},[65232],{"nctId":65233,"briefTitle":65234,"status":155,"phases":65235,"primaryCompletion":65236,"completion":65236,"start":40241,"enrollment":6503,"conditions":65237,"interventions":65238},"NCT00733577","A Study to Test How SB756050 Affects Subjects With Type 2 Diabetes Mellitus After 6 Days of Dosing.",[85],"2009-03-03",[27],[65226],{"trials":65240,"activeCount":97},[],{"trials":65242,"activeCount":97},[],{"trials":65244,"activeCount":97},[],{"trials":65246,"activeCount":97},[],{"intervention":60036,"totalTrials":417,"cells":65248},{"EARLY_PHASE1":65249,"PHASE1":65251,"PHASE2":65257,"PHASE3":65259,"PHASE4":65261,"NA":65263},{"trials":65250,"activeCount":97},[],{"trials":65252,"activeCount":97},[65253],{"nctId":60029,"briefTitle":60030,"status":145,"phases":65254,"primaryCompletion":60032,"completion":60032,"start":60033,"enrollment":1459,"conditions":65255,"interventions":65256},[85],[4644],[60014,60036],{"trials":65258,"activeCount":97},[],{"trials":65260,"activeCount":97},[],{"trials":65262,"activeCount":97},[],{"trials":65264,"activeCount":97},[],{"intervention":65266,"totalTrials":417,"cells":65267},"SB705498",{"EARLY_PHASE1":65268,"PHASE1":65270,"PHASE2":65279,"PHASE3":65281,"PHASE4":65283,"NA":65285},{"trials":65269,"activeCount":97},[],{"trials":65271,"activeCount":97},[65272],{"nctId":65273,"briefTitle":65274,"status":155,"phases":65275,"primaryCompletion":65276,"completion":65276,"start":41933,"enrollment":433,"conditions":65277,"interventions":65278},"NCT01673529","Investigation of Topical SB705498 on Healthy Volunteers",[85],"2012-10-04",[21691],[65266],{"trials":65280,"activeCount":97},[],{"trials":65282,"activeCount":97},[],{"trials":65284,"activeCount":97},[],{"trials":65286,"activeCount":97},[],{"intervention":65288,"totalTrials":417,"cells":65289},"AMB new formulation",{"EARLY_PHASE1":65290,"PHASE1":65292,"PHASE2":65302,"PHASE3":65304,"PHASE4":65306,"NA":65308},{"trials":65291,"activeCount":97},[],{"trials":65293,"activeCount":97},[65294],{"nctId":65295,"briefTitle":65296,"status":155,"phases":65297,"primaryCompletion":4910,"completion":4910,"start":65298,"enrollment":1079,"conditions":65299,"interventions":65300},"NCT04095286","Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants",[85],"2019-09-30",[17209],[65288,65301],"Reference AMB",{"trials":65303,"activeCount":97},[],{"trials":65305,"activeCount":97},[],{"trials":65307,"activeCount":97},[],{"trials":65309,"activeCount":97},[],{"intervention":65301,"totalTrials":417,"cells":65311},{"EARLY_PHASE1":65312,"PHASE1":65314,"PHASE2":65320,"PHASE3":65322,"PHASE4":65324,"NA":65326},{"trials":65313,"activeCount":97},[],{"trials":65315,"activeCount":97},[65316],{"nctId":65295,"briefTitle":65296,"status":155,"phases":65317,"primaryCompletion":4910,"completion":4910,"start":65298,"enrollment":1079,"conditions":65318,"interventions":65319},[85],[17209],[65288,65301],{"trials":65321,"activeCount":97},[],{"trials":65323,"activeCount":97},[],{"trials":65325,"activeCount":97},[],{"trials":65327,"activeCount":97},[],{"intervention":65329,"totalTrials":417,"cells":65330},"Pramipexole, Amisulpride",{"EARLY_PHASE1":65331,"PHASE1":65333,"PHASE2":65342,"PHASE3":65344,"PHASE4":65346,"NA":65348},{"trials":65332,"activeCount":97},[],{"trials":65334,"activeCount":97},[65335],{"nctId":65336,"briefTitle":65337,"status":155,"phases":65338,"primaryCompletion":2804,"completion":2804,"start":2296,"enrollment":3025,"conditions":65339,"interventions":65341},"NCT00471588","Characterize The Modulatory Effects Of Dopamine D2\u002FD3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors",[85],[65340],"Obsessive-Compulsive Disorder",[65329],{"trials":65343,"activeCount":97},[],{"trials":65345,"activeCount":97},[],{"trials":65347,"activeCount":97},[],{"trials":65349,"activeCount":97},[],{"intervention":65351,"totalTrials":417,"cells":65352},"GSK461364",{"EARLY_PHASE1":65353,"PHASE1":65355,"PHASE2":65364,"PHASE3":65366,"PHASE4":65368,"NA":65370},{"trials":65354,"activeCount":97},[],{"trials":65356,"activeCount":97},[65357],{"nctId":65358,"briefTitle":65359,"status":155,"phases":65360,"primaryCompletion":20447,"completion":20447,"start":65361,"enrollment":212,"conditions":65362,"interventions":65363},"NCT00536835","Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma",[85],"2007-08-16",[4574],[65351],{"trials":65365,"activeCount":97},[],{"trials":65367,"activeCount":97},[],{"trials":65369,"activeCount":97},[],{"trials":65371,"activeCount":97},[],{"intervention":65373,"totalTrials":417,"cells":65374},"SB659032",{"EARLY_PHASE1":65375,"PHASE1":65377,"PHASE2":65385,"PHASE3":65387,"PHASE4":65389,"NA":65391},{"trials":65376,"activeCount":97},[],{"trials":65378,"activeCount":97},[65379],{"nctId":65380,"briefTitle":65381,"status":155,"phases":65382,"primaryCompletion":11097,"completion":11097,"start":2823,"enrollment":473,"conditions":65383,"interventions":65384},"NCT01750827","A Study to Assess the Effect of SB 659032 on Platelet Function",[85],[9309],[65373],{"trials":65386,"activeCount":97},[],{"trials":65388,"activeCount":97},[],{"trials":65390,"activeCount":97},[],{"trials":65392,"activeCount":97},[],{"intervention":65394,"totalTrials":417,"cells":65395},"SB-743921",{"EARLY_PHASE1":65396,"PHASE1":65398,"PHASE2":65406,"PHASE3":65408,"PHASE4":65410,"NA":65412},{"trials":65397,"activeCount":97},[],{"trials":65399,"activeCount":97},[65400],{"nctId":65401,"briefTitle":65402,"status":155,"phases":65403,"start":2775,"enrollment":255,"conditions":65404,"interventions":65405},"NCT00136513","SB-743921 In Patients With Solid Tumors",[85],[1431],[65394],{"trials":65407,"activeCount":97},[],{"trials":65409,"activeCount":97},[],{"trials":65411,"activeCount":97},[],{"trials":65413,"activeCount":97},[],{"intervention":65415,"totalTrials":417,"cells":65416},"Belimumab 200 mg\u002FmL",{"EARLY_PHASE1":65417,"PHASE1":65419,"PHASE2":65427,"PHASE3":65429,"PHASE4":65431,"NA":65433},{"trials":65418,"activeCount":97},[],{"trials":65420,"activeCount":97},[65421],{"nctId":65422,"briefTitle":65423,"status":155,"phases":65424,"primaryCompletion":525,"completion":525,"start":61065,"enrollment":8861,"conditions":65425,"interventions":65426},"NCT01894360","A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects",[85],[435],[65415],{"trials":65428,"activeCount":97},[],{"trials":65430,"activeCount":97},[],{"trials":65432,"activeCount":97},[],{"trials":65434,"activeCount":97},[],{"intervention":65436,"totalTrials":417,"cells":65437},"Dutasteride and Tamsulosin",{"EARLY_PHASE1":65438,"PHASE1":65440,"PHASE2":65448,"PHASE3":65450,"PHASE4":65452,"NA":65454},{"trials":65439,"activeCount":97},[],{"trials":65441,"activeCount":97},[65442],{"nctId":65443,"briefTitle":65444,"status":155,"phases":65445,"primaryCompletion":19164,"completion":19164,"start":8396,"enrollment":1298,"conditions":65446,"interventions":65447},"NCT01957189","This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples",[85],[12263],[65436],{"trials":65449,"activeCount":97},[],{"trials":65451,"activeCount":97},[],{"trials":65453,"activeCount":97},[],{"trials":65455,"activeCount":97},[],{"intervention":65457,"totalTrials":417,"cells":65458},"GSK1827771",{"EARLY_PHASE1":65459,"PHASE1":65461,"PHASE2":65470,"PHASE3":65472,"PHASE4":65474,"NA":65476},{"trials":65460,"activeCount":97},[],{"trials":65462,"activeCount":97},[65463],{"nctId":65464,"briefTitle":65465,"status":155,"phases":65466,"primaryCompletion":65467,"completion":65467,"start":39233,"enrollment":6369,"conditions":65468,"interventions":65469},"NCT00539760","A Phase I Rheumatoid Arthritis Study in Healthy Volunteers",[85],"2008-04-05",[8788],[65457],{"trials":65471,"activeCount":97},[],{"trials":65473,"activeCount":97},[],{"trials":65475,"activeCount":97},[],{"trials":65477,"activeCount":97},[],{"intervention":65479,"totalTrials":417,"cells":65480},"120 mg orlistat",{"EARLY_PHASE1":65481,"PHASE1":65483,"PHASE2":65494,"PHASE3":65496,"PHASE4":65498,"NA":65500},{"trials":65482,"activeCount":97},[],{"trials":65484,"activeCount":97},[65485],{"nctId":65486,"briefTitle":65487,"status":155,"phases":65488,"primaryCompletion":2794,"completion":2794,"start":8116,"enrollment":6503,"conditions":65489,"interventions":65491},"NCT01550926","A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms",[85],[65490],"Overweight",[65479,65492,65493],"60 mg orlistat","orlistat experimental dose",{"trials":65495,"activeCount":97},[],{"trials":65497,"activeCount":97},[],{"trials":65499,"activeCount":97},[],{"trials":65501,"activeCount":97},[],{"intervention":65492,"totalTrials":417,"cells":65503},{"EARLY_PHASE1":65504,"PHASE1":65506,"PHASE2":65512,"PHASE3":65514,"PHASE4":65516,"NA":65518},{"trials":65505,"activeCount":97},[],{"trials":65507,"activeCount":97},[65508],{"nctId":65486,"briefTitle":65487,"status":155,"phases":65509,"primaryCompletion":2794,"completion":2794,"start":8116,"enrollment":6503,"conditions":65510,"interventions":65511},[85],[65490],[65479,65492,65493],{"trials":65513,"activeCount":97},[],{"trials":65515,"activeCount":97},[],{"trials":65517,"activeCount":97},[],{"trials":65519,"activeCount":97},[],{"intervention":65493,"totalTrials":417,"cells":65521},{"EARLY_PHASE1":65522,"PHASE1":65524,"PHASE2":65530,"PHASE3":65532,"PHASE4":65534,"NA":65536},{"trials":65523,"activeCount":97},[],{"trials":65525,"activeCount":97},[65526],{"nctId":65486,"briefTitle":65487,"status":155,"phases":65527,"primaryCompletion":2794,"completion":2794,"start":8116,"enrollment":6503,"conditions":65528,"interventions":65529},[85],[65490],[65479,65492,65493],{"trials":65531,"activeCount":97},[],{"trials":65533,"activeCount":97},[],{"trials":65535,"activeCount":97},[],{"trials":65537,"activeCount":97},[],{"intervention":12549,"totalTrials":417,"cells":65539},{"EARLY_PHASE1":65540,"PHASE1":65542,"PHASE2":65548,"PHASE3":65550,"PHASE4":65552,"NA":65554},{"trials":65541,"activeCount":97},[],{"trials":65543,"activeCount":97},[65544],{"nctId":12542,"briefTitle":12543,"status":500,"phases":65545,"primaryCompletion":12545,"completion":12545,"start":12546,"enrollment":97,"conditions":65546,"interventions":65547},[85],[7295],[12549,12535],{"trials":65549,"activeCount":97},[],{"trials":65551,"activeCount":97},[],{"trials":65553,"activeCount":97},[],{"trials":65555,"activeCount":97},[],{"intervention":65557,"totalTrials":417,"cells":65558},"GSK3008356",{"EARLY_PHASE1":65559,"PHASE1":65561,"PHASE2":65569,"PHASE3":65571,"PHASE4":65573,"NA":65575},{"trials":65560,"activeCount":97},[],{"trials":65562,"activeCount":97},[65563],{"nctId":65564,"briefTitle":65565,"status":155,"phases":65566,"primaryCompletion":16972,"completion":16972,"start":61969,"enrollment":14145,"conditions":65567,"interventions":65568},"NCT02742766","Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects",[85],[5280],[65557],{"trials":65570,"activeCount":97},[],{"trials":65572,"activeCount":97},[],{"trials":65574,"activeCount":97},[],{"trials":65576,"activeCount":97},[],{"intervention":65578,"totalTrials":417,"cells":65579},"A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323",{"EARLY_PHASE1":65580,"PHASE1":65582,"PHASE2":65590,"PHASE3":65592,"PHASE4":65594,"NA":65596},{"trials":65581,"activeCount":97},[],{"trials":65583,"activeCount":97},[65584],{"nctId":65585,"briefTitle":65586,"status":155,"phases":65587,"primaryCompletion":11714,"completion":11714,"start":7473,"enrollment":181,"conditions":65588,"interventions":65589},"NCT00564746","To Assess the Excretion Balance and Pharmacokinetics of a Single Oral Dose of [14C]SB-681323 in Healthy Adult Males",[85],[15],[65578],{"trials":65591,"activeCount":97},[],{"trials":65593,"activeCount":97},[],{"trials":65595,"activeCount":97},[],{"trials":65597,"activeCount":97},[],{"intervention":65599,"totalTrials":417,"cells":65600},"Cherry lamotrigine ODT",{"EARLY_PHASE1":65601,"PHASE1":65603,"PHASE2":65613,"PHASE3":65615,"PHASE4":65617,"NA":65619},{"trials":65602,"activeCount":97},[],{"trials":65604,"activeCount":97},[65605],{"nctId":65606,"briefTitle":65607,"status":155,"phases":65608,"primaryCompletion":21171,"completion":21171,"start":27324,"enrollment":1298,"conditions":65609,"interventions":65611},"NCT01607086","Compare the Properties and Characteristics of an Investigational Formulation of Lamotrigine With Placebo",[85],[65610],"Mental Disorders",[65599,65612],"Cherry Placebo",{"trials":65614,"activeCount":97},[],{"trials":65616,"activeCount":97},[],{"trials":65618,"activeCount":97},[],{"trials":65620,"activeCount":97},[],{"intervention":65612,"totalTrials":417,"cells":65622},{"EARLY_PHASE1":65623,"PHASE1":65625,"PHASE2":65631,"PHASE3":65633,"PHASE4":65635,"NA":65637},{"trials":65624,"activeCount":97},[],{"trials":65626,"activeCount":97},[65627],{"nctId":65606,"briefTitle":65607,"status":155,"phases":65628,"primaryCompletion":21171,"completion":21171,"start":27324,"enrollment":1298,"conditions":65629,"interventions":65630},[85],[65610],[65599,65612],{"trials":65632,"activeCount":97},[],{"trials":65634,"activeCount":97},[],{"trials":65636,"activeCount":97},[],{"trials":65638,"activeCount":97},[],{"intervention":65640,"totalTrials":417,"cells":65641},"GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide",{"EARLY_PHASE1":65642,"PHASE1":65644,"PHASE2":65657,"PHASE3":65659,"PHASE4":65661,"NA":65663},{"trials":65643,"activeCount":97},[],{"trials":65645,"activeCount":97},[65646],{"nctId":65647,"briefTitle":65648,"status":155,"phases":65649,"primaryCompletion":65650,"completion":65650,"start":65651,"enrollment":25604,"conditions":65652,"interventions":65653},"NCT05561673","A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years",[85],"2024-11-29","2022-10-04",[24],[65640,65654,65655,65656,65656],"GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system","GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system","GSK's HBsAg",{"trials":65658,"activeCount":97},[],{"trials":65660,"activeCount":97},[],{"trials":65662,"activeCount":97},[],{"trials":65664,"activeCount":97},[],{"intervention":65654,"totalTrials":417,"cells":65666},{"EARLY_PHASE1":65667,"PHASE1":65669,"PHASE2":65675,"PHASE3":65677,"PHASE4":65679,"NA":65681},{"trials":65668,"activeCount":97},[],{"trials":65670,"activeCount":97},[65671],{"nctId":65647,"briefTitle":65648,"status":155,"phases":65672,"primaryCompletion":65650,"completion":65650,"start":65651,"enrollment":25604,"conditions":65673,"interventions":65674},[85],[24],[65640,65654,65655,65656,65656],{"trials":65676,"activeCount":97},[],{"trials":65678,"activeCount":97},[],{"trials":65680,"activeCount":97},[],{"trials":65682,"activeCount":97},[],{"intervention":65655,"totalTrials":417,"cells":65684},{"EARLY_PHASE1":65685,"PHASE1":65687,"PHASE2":65693,"PHASE3":65695,"PHASE4":65697,"NA":65699},{"trials":65686,"activeCount":97},[],{"trials":65688,"activeCount":97},[65689],{"nctId":65647,"briefTitle":65648,"status":155,"phases":65690,"primaryCompletion":65650,"completion":65650,"start":65651,"enrollment":25604,"conditions":65691,"interventions":65692},[85],[24],[65640,65654,65655,65656,65656],{"trials":65694,"activeCount":97},[],{"trials":65696,"activeCount":97},[],{"trials":65698,"activeCount":97},[],{"trials":65700,"activeCount":97},[],{"intervention":65656,"totalTrials":417,"cells":65702},{"EARLY_PHASE1":65703,"PHASE1":65705,"PHASE2":65711,"PHASE3":65713,"PHASE4":65715,"NA":65717},{"trials":65704,"activeCount":97},[],{"trials":65706,"activeCount":97},[65707],{"nctId":65647,"briefTitle":65648,"status":155,"phases":65708,"primaryCompletion":65650,"completion":65650,"start":65651,"enrollment":25604,"conditions":65709,"interventions":65710},[85],[24],[65640,65654,65655,65656,65656],{"trials":65712,"activeCount":97},[],{"trials":65714,"activeCount":97},[],{"trials":65716,"activeCount":97},[],{"trials":65718,"activeCount":97},[],{"intervention":18006,"totalTrials":417,"cells":65720},{"EARLY_PHASE1":65721,"PHASE1":65723,"PHASE2":65729,"PHASE3":65731,"PHASE4":65733,"NA":65735},{"trials":65722,"activeCount":97},[],{"trials":65724,"activeCount":97},[65725],{"nctId":17999,"briefTitle":18000,"status":155,"phases":65726,"primaryCompletion":18002,"completion":18002,"start":18003,"enrollment":314,"conditions":65727,"interventions":65728},[85],[17996],[17974,18006,18007],{"trials":65730,"activeCount":97},[],{"trials":65732,"activeCount":97},[],{"trials":65734,"activeCount":97},[],{"trials":65736,"activeCount":97},[],{"intervention":65738,"totalTrials":417,"cells":65739},"Ciprofloxacin",{"EARLY_PHASE1":65740,"PHASE1":65742,"PHASE2":65750,"PHASE3":65752,"PHASE4":65754,"NA":65756},{"trials":65741,"activeCount":97},[],{"trials":65743,"activeCount":97},[65744],{"nctId":65745,"briefTitle":65746,"status":155,"phases":65747,"primaryCompletion":44327,"completion":44327,"start":4778,"enrollment":710,"conditions":65748,"interventions":65749},"NCT00688272","Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of Eltrombopag",[85],[505],[65738,23772],{"trials":65751,"activeCount":97},[],{"trials":65753,"activeCount":97},[],{"trials":65755,"activeCount":97},[],{"trials":65757,"activeCount":97},[],{"intervention":65759,"totalTrials":417,"cells":65760},"Alprazolam 2mg",{"EARLY_PHASE1":65761,"PHASE1":65763,"PHASE2":65774,"PHASE3":65776,"PHASE4":65778,"NA":65780},{"trials":65762,"activeCount":97},[],{"trials":65764,"activeCount":97},[65765],{"nctId":65766,"briefTitle":65767,"status":155,"phases":65768,"primaryCompletion":65769,"completion":65769,"start":65770,"enrollment":93,"conditions":65771,"interventions":65772},"NCT01745575","Bioequivalence Trial of Alprazolam 2 mg Tablets",[85],"2010-04-05","2010-03-28",[63101],[65759,65773],"Alprazolam 2 mg",{"trials":65775,"activeCount":97},[],{"trials":65777,"activeCount":97},[],{"trials":65779,"activeCount":97},[],{"trials":65781,"activeCount":97},[],{"intervention":65773,"totalTrials":417,"cells":65783},{"EARLY_PHASE1":65784,"PHASE1":65786,"PHASE2":65792,"PHASE3":65794,"PHASE4":65796,"NA":65798},{"trials":65785,"activeCount":97},[],{"trials":65787,"activeCount":97},[65788],{"nctId":65766,"briefTitle":65767,"status":155,"phases":65789,"primaryCompletion":65769,"completion":65769,"start":65770,"enrollment":93,"conditions":65790,"interventions":65791},[85],[63101],[65759,65773],{"trials":65793,"activeCount":97},[],{"trials":65795,"activeCount":97},[],{"trials":65797,"activeCount":97},[],{"trials":65799,"activeCount":97},[],{"intervention":65801,"totalTrials":417,"cells":65802},"Amlodipine+Rosuvastatin",{"EARLY_PHASE1":65803,"PHASE1":65805,"PHASE2":65816,"PHASE3":65818,"PHASE4":65820,"NA":65822},{"trials":65804,"activeCount":97},[],{"trials":65806,"activeCount":97},[65807],{"nctId":65808,"briefTitle":65809,"status":155,"phases":65810,"primaryCompletion":65811,"completion":65811,"start":39386,"enrollment":1298,"conditions":65812,"interventions":65813},"NCT02075619","Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions",[85],"2014-07-11",[13024],[65801,65814,65815],"GSK3074477 FDC - 1","GSK3074477 FDC - 2",{"trials":65817,"activeCount":97},[],{"trials":65819,"activeCount":97},[],{"trials":65821,"activeCount":97},[],{"trials":65823,"activeCount":97},[],{"intervention":65814,"totalTrials":417,"cells":65825},{"EARLY_PHASE1":65826,"PHASE1":65828,"PHASE2":65834,"PHASE3":65836,"PHASE4":65838,"NA":65840},{"trials":65827,"activeCount":97},[],{"trials":65829,"activeCount":97},[65830],{"nctId":65808,"briefTitle":65809,"status":155,"phases":65831,"primaryCompletion":65811,"completion":65811,"start":39386,"enrollment":1298,"conditions":65832,"interventions":65833},[85],[13024],[65801,65814,65815],{"trials":65835,"activeCount":97},[],{"trials":65837,"activeCount":97},[],{"trials":65839,"activeCount":97},[],{"trials":65841,"activeCount":97},[],{"intervention":65815,"totalTrials":417,"cells":65843},{"EARLY_PHASE1":65844,"PHASE1":65846,"PHASE2":65852,"PHASE3":65854,"PHASE4":65856,"NA":65858},{"trials":65845,"activeCount":97},[],{"trials":65847,"activeCount":97},[65848],{"nctId":65808,"briefTitle":65809,"status":155,"phases":65849,"primaryCompletion":65811,"completion":65811,"start":39386,"enrollment":1298,"conditions":65850,"interventions":65851},[85],[13024],[65801,65814,65815],{"trials":65853,"activeCount":97},[],{"trials":65855,"activeCount":97},[],{"trials":65857,"activeCount":97},[],{"trials":65859,"activeCount":97},[],{"intervention":65861,"totalTrials":417,"cells":65862},"GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic",{"EARLY_PHASE1":65863,"PHASE1":65865,"PHASE2":65874,"PHASE3":65876,"PHASE4":65878,"NA":65880},{"trials":65864,"activeCount":97},[],{"trials":65866,"activeCount":97},[65867],{"nctId":65868,"briefTitle":65869,"status":155,"phases":65870,"primaryCompletion":65871,"completion":65871,"start":48966,"enrollment":2797,"conditions":65872,"interventions":65873},"NCT01213472","Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma",[85],"2018-04-17",[325],[65861],{"trials":65875,"activeCount":97},[],{"trials":65877,"activeCount":97},[],{"trials":65879,"activeCount":97},[],{"trials":65881,"activeCount":97},[],{"intervention":5273,"totalTrials":417,"cells":65883},{"EARLY_PHASE1":65884,"PHASE1":65886,"PHASE2":65892,"PHASE3":65894,"PHASE4":65896,"NA":65898},{"trials":65885,"activeCount":97},[],{"trials":65887,"activeCount":97},[65888],{"nctId":5265,"briefTitle":5266,"status":155,"phases":65889,"primaryCompletion":5268,"completion":5268,"start":5269,"enrollment":2836,"conditions":65890,"interventions":65891},[85],[5271],[5273,4487],{"trials":65893,"activeCount":97},[],{"trials":65895,"activeCount":97},[],{"trials":65897,"activeCount":97},[],{"trials":65899,"activeCount":97},[],{"intervention":65901,"totalTrials":417,"cells":65902},"New formulation",{"EARLY_PHASE1":65903,"PHASE1":65905,"PHASE2":65915,"PHASE3":65917,"PHASE4":65919,"NA":65921},{"trials":65904,"activeCount":97},[],{"trials":65906,"activeCount":97},[65907],{"nctId":65908,"briefTitle":65909,"status":155,"phases":65910,"primaryCompletion":65911,"completion":65911,"start":38873,"enrollment":9334,"conditions":65912,"interventions":65913},"NCT00711776","Bioequivalence Study of Aciclovir 5% Cream in Japanese Healthy Volunteers",[85],"2008-08-17",[14521],[65901,65914],"Current formulation",{"trials":65916,"activeCount":97},[],{"trials":65918,"activeCount":97},[],{"trials":65920,"activeCount":97},[],{"trials":65922,"activeCount":97},[],{"intervention":65914,"totalTrials":417,"cells":65924},{"EARLY_PHASE1":65925,"PHASE1":65927,"PHASE2":65933,"PHASE3":65935,"PHASE4":65937,"NA":65939},{"trials":65926,"activeCount":97},[],{"trials":65928,"activeCount":97},[65929],{"nctId":65908,"briefTitle":65909,"status":155,"phases":65930,"primaryCompletion":65911,"completion":65911,"start":38873,"enrollment":9334,"conditions":65931,"interventions":65932},[85],[14521],[65901,65914],{"trials":65934,"activeCount":97},[],{"trials":65936,"activeCount":97},[],{"trials":65938,"activeCount":97},[],{"trials":65940,"activeCount":97},[],{"intervention":65942,"totalTrials":417,"cells":65943},"5 mg GSK1278863",{"EARLY_PHASE1":65944,"PHASE1":65946,"PHASE2":65956,"PHASE3":65958,"PHASE4":65960,"NA":65962},{"trials":65945,"activeCount":97},[],{"trials":65947,"activeCount":97},[65948],{"nctId":65949,"briefTitle":65950,"status":145,"phases":65951,"primaryCompletion":65952,"completion":65952,"start":65953,"enrollment":2836,"conditions":65954,"interventions":65955},"NCT01406340","Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment",[85],"2013-08-31","2011-08-30",[17996],[65942],{"trials":65957,"activeCount":97},[],{"trials":65959,"activeCount":97},[],{"trials":65961,"activeCount":97},[],{"trials":65963,"activeCount":97},[],{"intervention":65965,"totalTrials":417,"cells":65966},"Reference Treatment: 5 mg amlodipine + 50 mg losartan",{"EARLY_PHASE1":65967,"PHASE1":65969,"PHASE2":65981,"PHASE3":65983,"PHASE4":65985,"NA":65987},{"trials":65968,"activeCount":97},[],{"trials":65970,"activeCount":97},[65971],{"nctId":65972,"briefTitle":65973,"status":155,"phases":65974,"primaryCompletion":65975,"completion":65975,"start":12320,"enrollment":931,"conditions":65976,"interventions":65977},"NCT01797926","Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5\u002F50 and FDC5\u002F100 Under Fasting Conditions",[85],"2013-07-25",[13024],[65965,65978,65979,65980],"Reference Treatment:5 mg amlodipine + 100 mg losartan","FDC 5\u002F50 amlodipine\u002F losartan","FDC 5\u002F100 amlodipine \u002Flosartan",{"trials":65982,"activeCount":97},[],{"trials":65984,"activeCount":97},[],{"trials":65986,"activeCount":97},[],{"trials":65988,"activeCount":97},[],{"intervention":65978,"totalTrials":417,"cells":65990},{"EARLY_PHASE1":65991,"PHASE1":65993,"PHASE2":65999,"PHASE3":66001,"PHASE4":66003,"NA":66005},{"trials":65992,"activeCount":97},[],{"trials":65994,"activeCount":97},[65995],{"nctId":65972,"briefTitle":65973,"status":155,"phases":65996,"primaryCompletion":65975,"completion":65975,"start":12320,"enrollment":931,"conditions":65997,"interventions":65998},[85],[13024],[65965,65978,65979,65980],{"trials":66000,"activeCount":97},[],{"trials":66002,"activeCount":97},[],{"trials":66004,"activeCount":97},[],{"trials":66006,"activeCount":97},[],{"intervention":65979,"totalTrials":417,"cells":66008},{"EARLY_PHASE1":66009,"PHASE1":66011,"PHASE2":66017,"PHASE3":66019,"PHASE4":66021,"NA":66023},{"trials":66010,"activeCount":97},[],{"trials":66012,"activeCount":97},[66013],{"nctId":65972,"briefTitle":65973,"status":155,"phases":66014,"primaryCompletion":65975,"completion":65975,"start":12320,"enrollment":931,"conditions":66015,"interventions":66016},[85],[13024],[65965,65978,65979,65980],{"trials":66018,"activeCount":97},[],{"trials":66020,"activeCount":97},[],{"trials":66022,"activeCount":97},[],{"trials":66024,"activeCount":97},[],{"intervention":65980,"totalTrials":417,"cells":66026},{"EARLY_PHASE1":66027,"PHASE1":66029,"PHASE2":66035,"PHASE3":66037,"PHASE4":66039,"NA":66041},{"trials":66028,"activeCount":97},[],{"trials":66030,"activeCount":97},[66031],{"nctId":65972,"briefTitle":65973,"status":155,"phases":66032,"primaryCompletion":65975,"completion":65975,"start":12320,"enrollment":931,"conditions":66033,"interventions":66034},[85],[13024],[65965,65978,65979,65980],{"trials":66036,"activeCount":97},[],{"trials":66038,"activeCount":97},[],{"trials":66040,"activeCount":97},[],{"trials":66042,"activeCount":97},[],{"intervention":39330,"totalTrials":417,"cells":66044},{"EARLY_PHASE1":66045,"PHASE1":66047,"PHASE2":66053,"PHASE3":66055,"PHASE4":66057,"NA":66059},{"trials":66046,"activeCount":97},[],{"trials":66048,"activeCount":97},[66049],{"nctId":39323,"briefTitle":39324,"status":155,"phases":66050,"primaryCompletion":39326,"completion":39326,"start":39327,"enrollment":628,"conditions":66051,"interventions":66052},[85],[14696],[39330,39316],{"trials":66054,"activeCount":97},[],{"trials":66056,"activeCount":97},[],{"trials":66058,"activeCount":97},[],{"trials":66060,"activeCount":97},[],{"intervention":66062,"totalTrials":417,"cells":66063},"Nimesulide 100 mg",{"EARLY_PHASE1":66064,"PHASE1":66066,"PHASE2":66075,"PHASE3":66077,"PHASE4":66079,"NA":66081},{"trials":66065,"activeCount":97},[],{"trials":66067,"activeCount":97},[66068],{"nctId":66069,"briefTitle":66070,"status":155,"phases":66071,"primaryCompletion":18835,"completion":18835,"start":66072,"enrollment":695,"conditions":66073,"interventions":66074},"NCT01745614","Bioequivalence Study of Nimesulide 100 mg Tablets",[85],"2010-07-18",[9153],[66062,66062],{"trials":66076,"activeCount":97},[],{"trials":66078,"activeCount":97},[],{"trials":66080,"activeCount":97},[],{"trials":66082,"activeCount":97},[],{"intervention":66084,"totalTrials":417,"cells":66085},"FDC capsule of dutasteride and tamsulosin",{"EARLY_PHASE1":66086,"PHASE1":66088,"PHASE2":66099,"PHASE3":66101,"PHASE4":66103,"NA":66105},{"trials":66087,"activeCount":97},[],{"trials":66089,"activeCount":97},[66090],{"nctId":66091,"briefTitle":66092,"status":155,"phases":66093,"primaryCompletion":66094,"completion":66094,"start":66095,"enrollment":904,"conditions":66096,"interventions":66097},"NCT02509104","Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects",[85],"2015-10-10","2015-07-30",[12263],[66084,66098],"Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating",{"trials":66100,"activeCount":97},[],{"trials":66102,"activeCount":97},[],{"trials":66104,"activeCount":97},[],{"trials":66106,"activeCount":97},[],{"intervention":66098,"totalTrials":417,"cells":66108},{"EARLY_PHASE1":66109,"PHASE1":66111,"PHASE2":66117,"PHASE3":66119,"PHASE4":66121,"NA":66123},{"trials":66110,"activeCount":97},[],{"trials":66112,"activeCount":97},[66113],{"nctId":66091,"briefTitle":66092,"status":155,"phases":66114,"primaryCompletion":66094,"completion":66094,"start":66095,"enrollment":904,"conditions":66115,"interventions":66116},[85],[12263],[66084,66098],{"trials":66118,"activeCount":97},[],{"trials":66120,"activeCount":97},[],{"trials":66122,"activeCount":97},[],{"trials":66124,"activeCount":97},[],{"intervention":66126,"totalTrials":417,"cells":66127},"FLOVENT (fluticasone propionate) HFA",{"EARLY_PHASE1":66128,"PHASE1":66130,"PHASE2":66138,"PHASE3":66140,"PHASE4":66142,"NA":66144},{"trials":66129,"activeCount":97},[],{"trials":66131,"activeCount":97},[66132],{"nctId":66133,"briefTitle":66134,"status":155,"phases":66135,"primaryCompletion":17676,"completion":17676,"start":10977,"enrollment":433,"conditions":66136,"interventions":66137},"NCT00370097","FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects",[85],[18],[66126],{"trials":66139,"activeCount":97},[],{"trials":66141,"activeCount":97},[],{"trials":66143,"activeCount":97},[],{"trials":66145,"activeCount":97},[],{"intervention":66147,"totalTrials":417,"cells":66148},"Lavoltidine",{"EARLY_PHASE1":66149,"PHASE1":66151,"PHASE2":66159,"PHASE3":66161,"PHASE4":66163,"NA":66165},{"trials":66150,"activeCount":97},[],{"trials":66152,"activeCount":97},[66153],{"nctId":66154,"briefTitle":66155,"status":155,"phases":66156,"start":2835,"enrollment":1634,"conditions":66157,"interventions":66158},"NCT00551473","Open-label Comparison of 24hr Gastric pH on Days 1, 2, 7 With Once-daily Administration of Lavoltidine 40 mg.",[85],[56274,56275],[66147],{"trials":66160,"activeCount":97},[],{"trials":66162,"activeCount":97},[],{"trials":66164,"activeCount":97},[],{"trials":66166,"activeCount":97},[],{"intervention":66168,"totalTrials":417,"cells":66169},"GSK932121; Rosiglitazone; Rosuvastatin",{"EARLY_PHASE1":66170,"PHASE1":66172,"PHASE2":66181,"PHASE3":66183,"PHASE4":66185,"NA":66187},{"trials":66171,"activeCount":97},[],{"trials":66173,"activeCount":97},[66174],{"nctId":66175,"briefTitle":66176,"status":145,"phases":66177,"primaryCompletion":24042,"completion":24042,"start":66178,"enrollment":1459,"conditions":66179,"interventions":66180},"NCT00811356","A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria",[85],"2008-12-11",[3287],[66168],{"trials":66182,"activeCount":97},[],{"trials":66184,"activeCount":97},[],{"trials":66186,"activeCount":97},[],{"trials":66188,"activeCount":97},[],{"intervention":66190,"totalTrials":417,"cells":66191},"GSK3888550A RSV Maternal vaccine formulation 1",{"EARLY_PHASE1":66192,"PHASE1":66194,"PHASE2":66207,"PHASE3":66209,"PHASE4":66211,"NA":66213},{"trials":66193,"activeCount":97},[],{"trials":66195,"activeCount":97},[66196],{"nctId":66197,"briefTitle":66198,"status":155,"phases":66199,"primaryCompletion":66200,"completion":22941,"start":66201,"enrollment":66202,"conditions":66203,"interventions":66204},"NCT03674177","A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women",[85],"2019-04-16","2018-10-30",502,[2620],[66190,66205,66206],"GSK3888550A RSV Maternal vaccine formulation 2","GSK3888550A RSV Maternal vaccine formulation 3",{"trials":66208,"activeCount":97},[],{"trials":66210,"activeCount":97},[],{"trials":66212,"activeCount":97},[],{"trials":66214,"activeCount":97},[],{"intervention":66205,"totalTrials":417,"cells":66216},{"EARLY_PHASE1":66217,"PHASE1":66219,"PHASE2":66225,"PHASE3":66227,"PHASE4":66229,"NA":66231},{"trials":66218,"activeCount":97},[],{"trials":66220,"activeCount":97},[66221],{"nctId":66197,"briefTitle":66198,"status":155,"phases":66222,"primaryCompletion":66200,"completion":22941,"start":66201,"enrollment":66202,"conditions":66223,"interventions":66224},[85],[2620],[66190,66205,66206],{"trials":66226,"activeCount":97},[],{"trials":66228,"activeCount":97},[],{"trials":66230,"activeCount":97},[],{"trials":66232,"activeCount":97},[],{"intervention":66206,"totalTrials":417,"cells":66234},{"EARLY_PHASE1":66235,"PHASE1":66237,"PHASE2":66243,"PHASE3":66245,"PHASE4":66247,"NA":66249},{"trials":66236,"activeCount":97},[],{"trials":66238,"activeCount":97},[66239],{"nctId":66197,"briefTitle":66198,"status":155,"phases":66240,"primaryCompletion":66200,"completion":22941,"start":66201,"enrollment":66202,"conditions":66241,"interventions":66242},[85],[2620],[66190,66205,66206],{"trials":66244,"activeCount":97},[],{"trials":66246,"activeCount":97},[],{"trials":66248,"activeCount":97},[],{"trials":66250,"activeCount":97},[],{"intervention":66252,"totalTrials":417,"cells":66253},"UMEC\u002FVI 125\u002F25 mcg",{"EARLY_PHASE1":66254,"PHASE1":66256,"PHASE2":66268,"PHASE3":66270,"PHASE4":66272,"NA":66274},{"trials":66255,"activeCount":97},[],{"trials":66257,"activeCount":97},[66258],{"nctId":66259,"briefTitle":66260,"status":155,"phases":66261,"primaryCompletion":65975,"completion":65975,"start":49263,"enrollment":454,"conditions":66262,"interventions":66263},"NCT01899638","Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.",[85],[15],[66252,66264,66265,66266,66267],"UMEC\u002FVI 62.5\u002F25 mcg","UMEC 125 mcg","UMEC 62.5 mcg","VI 25 mcg",{"trials":66269,"activeCount":97},[],{"trials":66271,"activeCount":97},[],{"trials":66273,"activeCount":97},[],{"trials":66275,"activeCount":97},[],{"intervention":66264,"totalTrials":417,"cells":66277},{"EARLY_PHASE1":66278,"PHASE1":66280,"PHASE2":66286,"PHASE3":66288,"PHASE4":66290,"NA":66292},{"trials":66279,"activeCount":97},[],{"trials":66281,"activeCount":97},[66282],{"nctId":66259,"briefTitle":66260,"status":155,"phases":66283,"primaryCompletion":65975,"completion":65975,"start":49263,"enrollment":454,"conditions":66284,"interventions":66285},[85],[15],[66252,66264,66265,66266,66267],{"trials":66287,"activeCount":97},[],{"trials":66289,"activeCount":97},[],{"trials":66291,"activeCount":97},[],{"trials":66293,"activeCount":97},[],{"intervention":66265,"totalTrials":417,"cells":66295},{"EARLY_PHASE1":66296,"PHASE1":66298,"PHASE2":66304,"PHASE3":66306,"PHASE4":66308,"NA":66310},{"trials":66297,"activeCount":97},[],{"trials":66299,"activeCount":97},[66300],{"nctId":66259,"briefTitle":66260,"status":155,"phases":66301,"primaryCompletion":65975,"completion":65975,"start":49263,"enrollment":454,"conditions":66302,"interventions":66303},[85],[15],[66252,66264,66265,66266,66267],{"trials":66305,"activeCount":97},[],{"trials":66307,"activeCount":97},[],{"trials":66309,"activeCount":97},[],{"trials":66311,"activeCount":97},[],{"intervention":66266,"totalTrials":417,"cells":66313},{"EARLY_PHASE1":66314,"PHASE1":66316,"PHASE2":66322,"PHASE3":66324,"PHASE4":66326,"NA":66328},{"trials":66315,"activeCount":97},[],{"trials":66317,"activeCount":97},[66318],{"nctId":66259,"briefTitle":66260,"status":155,"phases":66319,"primaryCompletion":65975,"completion":65975,"start":49263,"enrollment":454,"conditions":66320,"interventions":66321},[85],[15],[66252,66264,66265,66266,66267],{"trials":66323,"activeCount":97},[],{"trials":66325,"activeCount":97},[],{"trials":66327,"activeCount":97},[],{"trials":66329,"activeCount":97},[],{"intervention":66267,"totalTrials":417,"cells":66331},{"EARLY_PHASE1":66332,"PHASE1":66334,"PHASE2":66340,"PHASE3":66342,"PHASE4":66344,"NA":66346},{"trials":66333,"activeCount":97},[],{"trials":66335,"activeCount":97},[66336],{"nctId":66259,"briefTitle":66260,"status":155,"phases":66337,"primaryCompletion":65975,"completion":65975,"start":49263,"enrollment":454,"conditions":66338,"interventions":66339},[85],[15],[66252,66264,66265,66266,66267],{"trials":66341,"activeCount":97},[],{"trials":66343,"activeCount":97},[],{"trials":66345,"activeCount":97},[],{"trials":66347,"activeCount":97},[],{"intervention":66349,"totalTrials":417,"cells":66350},"GW805858",{"EARLY_PHASE1":66351,"PHASE1":66353,"PHASE2":66362,"PHASE3":66364,"PHASE4":66366,"NA":66368},{"trials":66352,"activeCount":97},[],{"trials":66354,"activeCount":97},[66355],{"nctId":66356,"briefTitle":66357,"status":145,"phases":66358,"primaryCompletion":66359,"completion":66359,"start":18741,"enrollment":3379,"conditions":66360,"interventions":66361},"NCT00453791","The Safety and Tolerability of GW805858 in Healthy Volunteers and Mild Asthmatics",[85],"2006-04-10",[18],[66349],{"trials":66363,"activeCount":97},[],{"trials":66365,"activeCount":97},[],{"trials":66367,"activeCount":97},[],{"trials":66369,"activeCount":97},[],{"intervention":66371,"totalTrials":417,"cells":66372},"50mg Ezogabine\u002Fretigabine",{"EARLY_PHASE1":66373,"PHASE1":66375,"PHASE2":66387,"PHASE3":66389,"PHASE4":66391,"NA":66393},{"trials":66374,"activeCount":97},[],{"trials":66376,"activeCount":97},[66377],{"nctId":66378,"briefTitle":66379,"status":155,"phases":66380,"primaryCompletion":18806,"completion":18806,"start":66381,"enrollment":417,"conditions":66382,"interventions":66383},"NCT01462669","Crossover Study to Evaluate the Pharmacokinetics of Ezogabine\u002FRetigabine in Taiwanese Subjects",[85],"2012-04-10",[12518],[66371,66384,66385,66386],"100mg Ezogabine\u002Fretigabine","200mg Ezogabine\u002Fretigabine","400mg Ezogabine\u002Fretigabine",{"trials":66388,"activeCount":97},[],{"trials":66390,"activeCount":97},[],{"trials":66392,"activeCount":97},[],{"trials":66394,"activeCount":97},[],{"intervention":66384,"totalTrials":417,"cells":66396},{"EARLY_PHASE1":66397,"PHASE1":66399,"PHASE2":66405,"PHASE3":66407,"PHASE4":66409,"NA":66411},{"trials":66398,"activeCount":97},[],{"trials":66400,"activeCount":97},[66401],{"nctId":66378,"briefTitle":66379,"status":155,"phases":66402,"primaryCompletion":18806,"completion":18806,"start":66381,"enrollment":417,"conditions":66403,"interventions":66404},[85],[12518],[66371,66384,66385,66386],{"trials":66406,"activeCount":97},[],{"trials":66408,"activeCount":97},[],{"trials":66410,"activeCount":97},[],{"trials":66412,"activeCount":97},[],{"intervention":66385,"totalTrials":417,"cells":66414},{"EARLY_PHASE1":66415,"PHASE1":66417,"PHASE2":66423,"PHASE3":66425,"PHASE4":66427,"NA":66429},{"trials":66416,"activeCount":97},[],{"trials":66418,"activeCount":97},[66419],{"nctId":66378,"briefTitle":66379,"status":155,"phases":66420,"primaryCompletion":18806,"completion":18806,"start":66381,"enrollment":417,"conditions":66421,"interventions":66422},[85],[12518],[66371,66384,66385,66386],{"trials":66424,"activeCount":97},[],{"trials":66426,"activeCount":97},[],{"trials":66428,"activeCount":97},[],{"trials":66430,"activeCount":97},[],{"intervention":66386,"totalTrials":417,"cells":66432},{"EARLY_PHASE1":66433,"PHASE1":66435,"PHASE2":66441,"PHASE3":66443,"PHASE4":66445,"NA":66447},{"trials":66434,"activeCount":97},[],{"trials":66436,"activeCount":97},[66437],{"nctId":66378,"briefTitle":66379,"status":155,"phases":66438,"primaryCompletion":18806,"completion":18806,"start":66381,"enrollment":417,"conditions":66439,"interventions":66440},[85],[12518],[66371,66384,66385,66386],{"trials":66442,"activeCount":97},[],{"trials":66444,"activeCount":97},[],{"trials":66446,"activeCount":97},[],{"trials":66448,"activeCount":97},[],{"intervention":66450,"totalTrials":417,"cells":66451},"GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state",{"EARLY_PHASE1":66452,"PHASE1":66454,"PHASE2":66462,"PHASE3":66464,"PHASE4":66466,"NA":66468},{"trials":66453,"activeCount":97},[],{"trials":66455,"activeCount":97},[66456],{"nctId":66457,"briefTitle":66458,"status":155,"phases":66459,"primaryCompletion":18183,"completion":18183,"start":12269,"enrollment":433,"conditions":66460,"interventions":66461},"NCT01466322","A Study to Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.",[85],[39994],[66450],{"trials":66463,"activeCount":97},[],{"trials":66465,"activeCount":97},[],{"trials":66467,"activeCount":97},[],{"trials":66469,"activeCount":97},[],{"intervention":66471,"totalTrials":417,"cells":66472},"GSK2793660 solution",{"EARLY_PHASE1":66473,"PHASE1":66475,"PHASE2":66484,"PHASE3":66486,"PHASE4":66488,"NA":66490},{"trials":66474,"activeCount":97},[],{"trials":66476,"activeCount":97},[66477],{"nctId":66478,"briefTitle":66479,"status":145,"phases":66480,"primaryCompletion":4971,"completion":4971,"start":9578,"enrollment":2797,"conditions":66481,"interventions":66482},"NCT02058407","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects",[85],[4390],[66471,66483],"GSK2793660",{"trials":66485,"activeCount":97},[],{"trials":66487,"activeCount":97},[],{"trials":66489,"activeCount":97},[],{"trials":66491,"activeCount":97},[],{"intervention":66483,"totalTrials":417,"cells":66493},{"EARLY_PHASE1":66494,"PHASE1":66496,"PHASE2":66502,"PHASE3":66504,"PHASE4":66506,"NA":66508},{"trials":66495,"activeCount":97},[],{"trials":66497,"activeCount":97},[66498],{"nctId":66478,"briefTitle":66479,"status":145,"phases":66499,"primaryCompletion":4971,"completion":4971,"start":9578,"enrollment":2797,"conditions":66500,"interventions":66501},[85],[4390],[66471,66483],{"trials":66503,"activeCount":97},[],{"trials":66505,"activeCount":97},[],{"trials":66507,"activeCount":97},[],{"trials":66509,"activeCount":97},[],{"intervention":40082,"totalTrials":417,"cells":66511},{"EARLY_PHASE1":66512,"PHASE1":66514,"PHASE2":66520,"PHASE3":66522,"PHASE4":66524,"NA":66526},{"trials":66513,"activeCount":97},[],{"trials":66515,"activeCount":97},[66516],{"nctId":40076,"briefTitle":40077,"status":155,"phases":66517,"primaryCompletion":40079,"completion":40079,"start":18328,"enrollment":904,"conditions":66518,"interventions":66519},[85],[11827],[40069,8022,40082,40083],{"trials":66521,"activeCount":97},[],{"trials":66523,"activeCount":97},[],{"trials":66525,"activeCount":97},[],{"trials":66527,"activeCount":97},[],{"intervention":6486,"totalTrials":417,"cells":66529},{"EARLY_PHASE1":66530,"PHASE1":66532,"PHASE2":66538,"PHASE3":66540,"PHASE4":66542,"NA":66544},{"trials":66531,"activeCount":97},[],{"trials":66533,"activeCount":97},[66534],{"nctId":6478,"briefTitle":6479,"status":155,"phases":66535,"primaryCompletion":1287,"completion":1287,"start":6481,"enrollment":6482,"conditions":66536,"interventions":66537},[85],[6484],[6471,6486,6487,6488,6489],{"trials":66539,"activeCount":97},[],{"trials":66541,"activeCount":97},[],{"trials":66543,"activeCount":97},[],{"trials":66545,"activeCount":97},[],{"intervention":6487,"totalTrials":417,"cells":66547},{"EARLY_PHASE1":66548,"PHASE1":66550,"PHASE2":66556,"PHASE3":66558,"PHASE4":66560,"NA":66562},{"trials":66549,"activeCount":97},[],{"trials":66551,"activeCount":97},[66552],{"nctId":6478,"briefTitle":6479,"status":155,"phases":66553,"primaryCompletion":1287,"completion":1287,"start":6481,"enrollment":6482,"conditions":66554,"interventions":66555},[85],[6484],[6471,6486,6487,6488,6489],{"trials":66557,"activeCount":97},[],{"trials":66559,"activeCount":97},[],{"trials":66561,"activeCount":97},[],{"trials":66563,"activeCount":97},[],{"intervention":66565,"totalTrials":417,"cells":66566},"GSK364735 oral solution and oral",{"EARLY_PHASE1":66567,"PHASE1":66569,"PHASE2":66577,"PHASE3":66579,"PHASE4":66581,"NA":66583},{"trials":66568,"activeCount":97},[],{"trials":66570,"activeCount":97},[66571],{"nctId":66572,"briefTitle":66573,"status":155,"phases":66574,"start":2404,"enrollment":904,"conditions":66575,"interventions":66576},"NCT00386347","A Study To Evaluate Formulations And Food Effect On GSK364735 In Healthy Subjects.",[85],[10662,9343],[66565],{"trials":66578,"activeCount":97},[],{"trials":66580,"activeCount":97},[],{"trials":66582,"activeCount":97},[],{"trials":66584,"activeCount":97},[],{"intervention":66586,"totalTrials":417,"cells":66587},"Azithromycin - 250 mg",{"EARLY_PHASE1":66588,"PHASE1":66590,"PHASE2":66600,"PHASE3":66602,"PHASE4":66604,"NA":66606},{"trials":66589,"activeCount":97},[],{"trials":66591,"activeCount":97},[66592],{"nctId":66593,"briefTitle":66594,"status":155,"phases":66595,"primaryCompletion":26159,"completion":26159,"start":10836,"enrollment":454,"conditions":66596,"interventions":66597},"NCT01416350","A Single and Repeat Dose PK\u002FPD Study to Characterise Biomarker Response in Healthy Subjects Treated With Azithromycin",[85],[39897],[66586,66598,66599],"Azithromycin - 1000 mg","Azithromycin - 250 mg every other day for 3 weeks",{"trials":66601,"activeCount":97},[],{"trials":66603,"activeCount":97},[],{"trials":66605,"activeCount":97},[],{"trials":66607,"activeCount":97},[],{"intervention":66598,"totalTrials":417,"cells":66609},{"EARLY_PHASE1":66610,"PHASE1":66612,"PHASE2":66618,"PHASE3":66620,"PHASE4":66622,"NA":66624},{"trials":66611,"activeCount":97},[],{"trials":66613,"activeCount":97},[66614],{"nctId":66593,"briefTitle":66594,"status":155,"phases":66615,"primaryCompletion":26159,"completion":26159,"start":10836,"enrollment":454,"conditions":66616,"interventions":66617},[85],[39897],[66586,66598,66599],{"trials":66619,"activeCount":97},[],{"trials":66621,"activeCount":97},[],{"trials":66623,"activeCount":97},[],{"trials":66625,"activeCount":97},[],{"intervention":66599,"totalTrials":417,"cells":66627},{"EARLY_PHASE1":66628,"PHASE1":66630,"PHASE2":66636,"PHASE3":66638,"PHASE4":66640,"NA":66642},{"trials":66629,"activeCount":97},[],{"trials":66631,"activeCount":97},[66632],{"nctId":66593,"briefTitle":66594,"status":155,"phases":66633,"primaryCompletion":26159,"completion":26159,"start":10836,"enrollment":454,"conditions":66634,"interventions":66635},[85],[39897],[66586,66598,66599],{"trials":66637,"activeCount":97},[],{"trials":66639,"activeCount":97},[],{"trials":66641,"activeCount":97},[],{"trials":66643,"activeCount":97},[],{"intervention":66645,"totalTrials":417,"cells":66646},"GSK Biologicals' human rotavirus vaccine 444563",{"EARLY_PHASE1":66647,"PHASE1":66649,"PHASE2":66658,"PHASE3":66660,"PHASE4":66662,"NA":66664},{"trials":66648,"activeCount":97},[],{"trials":66650,"activeCount":97},[66651],{"nctId":66652,"briefTitle":66653,"status":155,"phases":66654,"primaryCompletion":40993,"completion":40993,"start":66655,"enrollment":1003,"conditions":66656,"interventions":66657},"NCT01107587","Study to Assess the Safety of GSK Biologicals' Liquid Human Rotavirus Vaccine in Healthy Infants",[85],"2010-04-13",[4759],[66645],{"trials":66659,"activeCount":97},[],{"trials":66661,"activeCount":97},[],{"trials":66663,"activeCount":97},[],{"trials":66665,"activeCount":97},[],{"intervention":66667,"totalTrials":417,"cells":66668},"IH Oxytocin",{"EARLY_PHASE1":66669,"PHASE1":66671,"PHASE2":66684,"PHASE3":66686,"PHASE4":66688,"NA":66690},{"trials":66670,"activeCount":97},[],{"trials":66672,"activeCount":97},[66673],{"nctId":66674,"briefTitle":66675,"status":145,"phases":66676,"primaryCompletion":4995,"completion":66677,"start":66678,"enrollment":3379,"conditions":66679,"interventions":66681},"NCT02999100","Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnant Women and With Intravenous (IV) Oxytocin in Healthy Non-pregnant Women",[85],"2019-03-04","2016-11-23",[66680],"Postpartum Hemorrhage",[66667,66682,66683],"IM Oxytocin","IV Oxytocin",{"trials":66685,"activeCount":97},[],{"trials":66687,"activeCount":97},[],{"trials":66689,"activeCount":97},[],{"trials":66691,"activeCount":97},[],{"intervention":66682,"totalTrials":417,"cells":66693},{"EARLY_PHASE1":66694,"PHASE1":66696,"PHASE2":66702,"PHASE3":66704,"PHASE4":66706,"NA":66708},{"trials":66695,"activeCount":97},[],{"trials":66697,"activeCount":97},[66698],{"nctId":66674,"briefTitle":66675,"status":145,"phases":66699,"primaryCompletion":4995,"completion":66677,"start":66678,"enrollment":3379,"conditions":66700,"interventions":66701},[85],[66680],[66667,66682,66683],{"trials":66703,"activeCount":97},[],{"trials":66705,"activeCount":97},[],{"trials":66707,"activeCount":97},[],{"trials":66709,"activeCount":97},[],{"intervention":66683,"totalTrials":417,"cells":66711},{"EARLY_PHASE1":66712,"PHASE1":66714,"PHASE2":66720,"PHASE3":66722,"PHASE4":66724,"NA":66726},{"trials":66713,"activeCount":97},[],{"trials":66715,"activeCount":97},[66716],{"nctId":66674,"briefTitle":66675,"status":145,"phases":66717,"primaryCompletion":4995,"completion":66677,"start":66678,"enrollment":3379,"conditions":66718,"interventions":66719},[85],[66680],[66667,66682,66683],{"trials":66721,"activeCount":97},[],{"trials":66723,"activeCount":97},[],{"trials":66725,"activeCount":97},[],{"trials":66727,"activeCount":97},[],{"intervention":66729,"totalTrials":417,"cells":66730},"GSK2230672",{"EARLY_PHASE1":66731,"PHASE1":66733,"PHASE2":66741,"PHASE3":66743,"PHASE4":66745,"NA":66747},{"trials":66732,"activeCount":97},[],{"trials":66734,"activeCount":97},[66735],{"nctId":66736,"briefTitle":66737,"status":155,"phases":66738,"primaryCompletion":26113,"completion":26113,"start":8540,"enrollment":433,"conditions":66739,"interventions":66740},"NCT02801981","Dose-escalation Study of GSK2330672 in Japanese Healthy Male Volunteers",[85],[4071],[66729],{"trials":66742,"activeCount":97},[],{"trials":66744,"activeCount":97},[],{"trials":66746,"activeCount":97},[],{"trials":66748,"activeCount":97},[],{"intervention":66750,"totalTrials":417,"cells":66751},"Ronacaleret 100 mg",{"EARLY_PHASE1":66752,"PHASE1":66754,"PHASE2":66766,"PHASE3":66768,"PHASE4":66770,"NA":66772},{"trials":66753,"activeCount":97},[],{"trials":66755,"activeCount":97},[66756],{"nctId":66757,"briefTitle":66758,"status":155,"phases":66759,"primaryCompletion":66760,"completion":66760,"start":54092,"enrollment":1298,"conditions":66761,"interventions":66763},"NCT01802892","Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)",[85],"2013-04-02",[66762],"Transplantation, Stem Cell",[66750,66764,66765],"Ronacaleret 400 mg","Plerixafor",{"trials":66767,"activeCount":97},[],{"trials":66769,"activeCount":97},[],{"trials":66771,"activeCount":97},[],{"trials":66773,"activeCount":97},[],{"intervention":66764,"totalTrials":417,"cells":66775},{"EARLY_PHASE1":66776,"PHASE1":66778,"PHASE2":66784,"PHASE3":66786,"PHASE4":66788,"NA":66790},{"trials":66777,"activeCount":97},[],{"trials":66779,"activeCount":97},[66780],{"nctId":66757,"briefTitle":66758,"status":155,"phases":66781,"primaryCompletion":66760,"completion":66760,"start":54092,"enrollment":1298,"conditions":66782,"interventions":66783},[85],[66762],[66750,66764,66765],{"trials":66785,"activeCount":97},[],{"trials":66787,"activeCount":97},[],{"trials":66789,"activeCount":97},[],{"trials":66791,"activeCount":97},[],{"intervention":66765,"totalTrials":417,"cells":66793},{"EARLY_PHASE1":66794,"PHASE1":66796,"PHASE2":66802,"PHASE3":66804,"PHASE4":66806,"NA":66808},{"trials":66795,"activeCount":97},[],{"trials":66797,"activeCount":97},[66798],{"nctId":66757,"briefTitle":66758,"status":155,"phases":66799,"primaryCompletion":66760,"completion":66760,"start":54092,"enrollment":1298,"conditions":66800,"interventions":66801},[85],[66762],[66750,66764,66765],{"trials":66803,"activeCount":97},[],{"trials":66805,"activeCount":97},[],{"trials":66807,"activeCount":97},[],{"trials":66809,"activeCount":97},[],{"intervention":66811,"totalTrials":417,"cells":66812},"CHR-5154",{"EARLY_PHASE1":66813,"PHASE1":66815,"PHASE2":66825,"PHASE3":66827,"PHASE4":66829,"NA":66831},{"trials":66814,"activeCount":97},[],{"trials":66816,"activeCount":97},[66817],{"nctId":66818,"briefTitle":66819,"status":145,"phases":66820,"primaryCompletion":66821,"completion":66821,"start":66822,"enrollment":6482,"conditions":66823,"interventions":66824},"NCT01934101","Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers",[85],"2014-05-28","2013-08-12",[8788],[66811],{"trials":66826,"activeCount":97},[],{"trials":66828,"activeCount":97},[],{"trials":66830,"activeCount":97},[],{"trials":66832,"activeCount":97},[],{"intervention":25652,"totalTrials":417,"cells":66834},{"EARLY_PHASE1":66835,"PHASE1":66837,"PHASE2":66843,"PHASE3":66845,"PHASE4":66847,"NA":66849},{"trials":66836,"activeCount":97},[],{"trials":66838,"activeCount":97},[66839],{"nctId":25645,"briefTitle":25646,"status":155,"phases":66840,"primaryCompletion":25648,"completion":25648,"start":452,"enrollment":25649,"conditions":66841,"interventions":66842},[85],[5353],[25652,25653,25654,25655,25656,25657,25658,25659,25660,25638],{"trials":66844,"activeCount":97},[],{"trials":66846,"activeCount":97},[],{"trials":66848,"activeCount":97},[],{"trials":66850,"activeCount":97},[],{"intervention":25653,"totalTrials":417,"cells":66852},{"EARLY_PHASE1":66853,"PHASE1":66855,"PHASE2":66861,"PHASE3":66863,"PHASE4":66865,"NA":66867},{"trials":66854,"activeCount":97},[],{"trials":66856,"activeCount":97},[66857],{"nctId":25645,"briefTitle":25646,"status":155,"phases":66858,"primaryCompletion":25648,"completion":25648,"start":452,"enrollment":25649,"conditions":66859,"interventions":66860},[85],[5353],[25652,25653,25654,25655,25656,25657,25658,25659,25660,25638],{"trials":66862,"activeCount":97},[],{"trials":66864,"activeCount":97},[],{"trials":66866,"activeCount":97},[],{"trials":66868,"activeCount":97},[],{"intervention":25654,"totalTrials":417,"cells":66870},{"EARLY_PHASE1":66871,"PHASE1":66873,"PHASE2":66879,"PHASE3":66881,"PHASE4":66883,"NA":66885},{"trials":66872,"activeCount":97},[],{"trials":66874,"activeCount":97},[66875],{"nctId":25645,"briefTitle":25646,"status":155,"phases":66876,"primaryCompletion":25648,"completion":25648,"start":452,"enrollment":25649,"conditions":66877,"interventions":66878},[85],[5353],[25652,25653,25654,25655,25656,25657,25658,25659,25660,25638],{"trials":66880,"activeCount":97},[],{"trials":66882,"activeCount":97},[],{"trials":66884,"activeCount":97},[],{"trials":66886,"activeCount":97},[],{"intervention":25655,"totalTrials":417,"cells":66888},{"EARLY_PHASE1":66889,"PHASE1":66891,"PHASE2":66897,"PHASE3":66899,"PHASE4":66901,"NA":66903},{"trials":66890,"activeCount":97},[],{"trials":66892,"activeCount":97},[66893],{"nctId":25645,"briefTitle":25646,"status":155,"phases":66894,"primaryCompletion":25648,"completion":25648,"start":452,"enrollment":25649,"conditions":66895,"interventions":66896},[85],[5353],[25652,25653,25654,25655,25656,25657,25658,25659,25660,25638],{"trials":66898,"activeCount":97},[],{"trials":66900,"activeCount":97},[],{"trials":66902,"activeCount":97},[],{"trials":66904,"activeCount":97},[],{"intervention":25656,"totalTrials":417,"cells":66906},{"EARLY_PHASE1":66907,"PHASE1":66909,"PHASE2":66915,"PHASE3":66917,"PHASE4":66919,"NA":66921},{"trials":66908,"activeCount":97},[],{"trials":66910,"activeCount":97},[66911],{"nctId":25645,"briefTitle":25646,"status":155,"phases":66912,"primaryCompletion":25648,"completion":25648,"start":452,"enrollment":25649,"conditions":66913,"interventions":66914},[85],[5353],[25652,25653,25654,25655,25656,25657,25658,25659,25660,25638],{"trials":66916,"activeCount":97},[],{"trials":66918,"activeCount":97},[],{"trials":66920,"activeCount":97},[],{"trials":66922,"activeCount":97},[],{"intervention":25657,"totalTrials":417,"cells":66924},{"EARLY_PHASE1":66925,"PHASE1":66927,"PHASE2":66933,"PHASE3":66935,"PHASE4":66937,"NA":66939},{"trials":66926,"activeCount":97},[],{"trials":66928,"activeCount":97},[66929],{"nctId":25645,"briefTitle":25646,"status":155,"phases":66930,"primaryCompletion":25648,"completion":25648,"start":452,"enrollment":25649,"conditions":66931,"interventions":66932},[85],[5353],[25652,25653,25654,25655,25656,25657,25658,25659,25660,25638],{"trials":66934,"activeCount":97},[],{"trials":66936,"activeCount":97},[],{"trials":66938,"activeCount":97},[],{"trials":66940,"activeCount":97},[],{"intervention":25658,"totalTrials":417,"cells":66942},{"EARLY_PHASE1":66943,"PHASE1":66945,"PHASE2":66951,"PHASE3":66953,"PHASE4":66955,"NA":66957},{"trials":66944,"activeCount":97},[],{"trials":66946,"activeCount":97},[66947],{"nctId":25645,"briefTitle":25646,"status":155,"phases":66948,"primaryCompletion":25648,"completion":25648,"start":452,"enrollment":25649,"conditions":66949,"interventions":66950},[85],[5353],[25652,25653,25654,25655,25656,25657,25658,25659,25660,25638],{"trials":66952,"activeCount":97},[],{"trials":66954,"activeCount":97},[],{"trials":66956,"activeCount":97},[],{"trials":66958,"activeCount":97},[],{"intervention":25659,"totalTrials":417,"cells":66960},{"EARLY_PHASE1":66961,"PHASE1":66963,"PHASE2":66969,"PHASE3":66971,"PHASE4":66973,"NA":66975},{"trials":66962,"activeCount":97},[],{"trials":66964,"activeCount":97},[66965],{"nctId":25645,"briefTitle":25646,"status":155,"phases":66966,"primaryCompletion":25648,"completion":25648,"start":452,"enrollment":25649,"conditions":66967,"interventions":66968},[85],[5353],[25652,25653,25654,25655,25656,25657,25658,25659,25660,25638],{"trials":66970,"activeCount":97},[],{"trials":66972,"activeCount":97},[],{"trials":66974,"activeCount":97},[],{"trials":66976,"activeCount":97},[],{"intervention":25660,"totalTrials":417,"cells":66978},{"EARLY_PHASE1":66979,"PHASE1":66981,"PHASE2":66987,"PHASE3":66989,"PHASE4":66991,"NA":66993},{"trials":66980,"activeCount":97},[],{"trials":66982,"activeCount":97},[66983],{"nctId":25645,"briefTitle":25646,"status":155,"phases":66984,"primaryCompletion":25648,"completion":25648,"start":452,"enrollment":25649,"conditions":66985,"interventions":66986},[85],[5353],[25652,25653,25654,25655,25656,25657,25658,25659,25660,25638],{"trials":66988,"activeCount":97},[],{"trials":66990,"activeCount":97},[],{"trials":66992,"activeCount":97},[],{"trials":66994,"activeCount":97},[],{"intervention":66996,"totalTrials":417,"cells":66997},"SB-659032",{"EARLY_PHASE1":66998,"PHASE1":67000,"PHASE2":67008,"PHASE3":67010,"PHASE4":67012,"NA":67014},{"trials":66999,"activeCount":97},[],{"trials":67001,"activeCount":97},[67002],{"nctId":67003,"briefTitle":67004,"status":155,"phases":67005,"primaryCompletion":749,"completion":749,"start":10212,"enrollment":93,"conditions":67006,"interventions":67007},"NCT01745458","SB-659032 Platelet Aggregation Study",[85],[9309],[66996],{"trials":67009,"activeCount":97},[],{"trials":67011,"activeCount":97},[],{"trials":67013,"activeCount":97},[],{"trials":67015,"activeCount":97},[],{"intervention":67017,"totalTrials":417,"cells":67018},"GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A",{"EARLY_PHASE1":67019,"PHASE1":67021,"PHASE2":67030,"PHASE3":67032,"PHASE4":67034,"NA":67036},{"trials":67020,"activeCount":97},[],{"trials":67022,"activeCount":97},[67023],{"nctId":67024,"briefTitle":67025,"status":155,"phases":67026,"primaryCompletion":67027,"completion":67027,"start":40144,"enrollment":7438,"conditions":67028,"interventions":67029},"NCT01051063","Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy",[85],"2016-04-26",[3381],[67017],{"trials":67031,"activeCount":97},[],{"trials":67033,"activeCount":97},[],{"trials":67035,"activeCount":97},[],{"trials":67037,"activeCount":97},[],{"intervention":67039,"totalTrials":417,"cells":67040},"SB797620",{"EARLY_PHASE1":67041,"PHASE1":67043,"PHASE2":67051,"PHASE3":67053,"PHASE4":67055,"NA":67057},{"trials":67042,"activeCount":97},[],{"trials":67044,"activeCount":97},[67045],{"nctId":67046,"briefTitle":67047,"status":500,"phases":67048,"start":9737,"enrollment":97,"conditions":67049,"interventions":67050},"NCT00549263","Bioequivalence Study of SB797620 in Healthy Japanese Volunteers",[85],[7524],[67039],{"trials":67052,"activeCount":97},[],{"trials":67054,"activeCount":97},[],{"trials":67056,"activeCount":97},[],{"trials":67058,"activeCount":97},[],{"intervention":67060,"totalTrials":417,"cells":67061},"GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin",{"EARLY_PHASE1":67062,"PHASE1":67064,"PHASE2":67072,"PHASE3":67074,"PHASE4":67076,"NA":67078},{"trials":67063,"activeCount":97},[],{"trials":67065,"activeCount":97},[67066],{"nctId":67067,"briefTitle":67068,"status":155,"phases":67069,"primaryCompletion":6317,"completion":6317,"start":49993,"enrollment":1459,"conditions":67070,"interventions":67071},"NCT01153802","An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands",[85],[9292],[67060],{"trials":67073,"activeCount":97},[],{"trials":67075,"activeCount":97},[],{"trials":67077,"activeCount":97},[],{"trials":67079,"activeCount":97},[],{"intervention":67081,"totalTrials":417,"cells":67082},"Pyrimethamine",{"EARLY_PHASE1":67083,"PHASE1":67085,"PHASE2":67096,"PHASE3":67098,"PHASE4":67100,"NA":67102},{"trials":67084,"activeCount":97},[],{"trials":67086,"activeCount":97},[67087],{"nctId":67088,"briefTitle":67089,"status":155,"phases":67090,"primaryCompletion":67091,"completion":67091,"start":56705,"enrollment":473,"conditions":67092,"interventions":67094},"NCT03258762","Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects",[85],"2017-11-19",[67093],"Toxoplasmosis",[67081,67095],"Calcium folinate",{"trials":67097,"activeCount":97},[],{"trials":67099,"activeCount":97},[],{"trials":67101,"activeCount":97},[],{"trials":67103,"activeCount":97},[],{"intervention":67095,"totalTrials":417,"cells":67105},{"EARLY_PHASE1":67106,"PHASE1":67108,"PHASE2":67114,"PHASE3":67116,"PHASE4":67118,"NA":67120},{"trials":67107,"activeCount":97},[],{"trials":67109,"activeCount":97},[67110],{"nctId":67088,"briefTitle":67089,"status":155,"phases":67111,"primaryCompletion":67091,"completion":67091,"start":56705,"enrollment":473,"conditions":67112,"interventions":67113},[85],[67093],[67081,67095],{"trials":67115,"activeCount":97},[],{"trials":67117,"activeCount":97},[],{"trials":67119,"activeCount":97},[],{"trials":67121,"activeCount":97},[],{"intervention":67123,"totalTrials":417,"cells":67124},"Herpes simplex candidate (gD) vaccine GSK208141",{"EARLY_PHASE1":67125,"PHASE1":67127,"PHASE2":67137,"PHASE3":67139,"PHASE4":67141,"NA":67143},{"trials":67126,"activeCount":97},[],{"trials":67128,"activeCount":97},[67129],{"nctId":67130,"briefTitle":67131,"status":155,"phases":67132,"primaryCompletion":67133,"completion":67133,"start":67134,"enrollment":433,"conditions":67135,"interventions":67136},"NCT00698893","Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults",[85],"1992-07-01","1992-05-01",[8709],[67123],{"trials":67138,"activeCount":97},[],{"trials":67140,"activeCount":97},[],{"trials":67142,"activeCount":97},[],{"trials":67144,"activeCount":97},[],{"intervention":67146,"totalTrials":417,"cells":67147},"FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose",{"EARLY_PHASE1":67148,"PHASE1":67150,"PHASE2":67159,"PHASE3":67161,"PHASE4":67163,"NA":67165},{"trials":67149,"activeCount":97},[],{"trials":67151,"activeCount":97},[67152],{"nctId":67153,"briefTitle":67154,"status":155,"phases":67155,"primaryCompletion":41106,"completion":41106,"start":10566,"enrollment":22557,"conditions":67156,"interventions":67157},"NCT02688387","A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects",[85],[17209],[67146,67158],"Reference",{"trials":67160,"activeCount":97},[],{"trials":67162,"activeCount":97},[],{"trials":67164,"activeCount":97},[],{"trials":67166,"activeCount":97},[],{"intervention":67158,"totalTrials":417,"cells":67168},{"EARLY_PHASE1":67169,"PHASE1":67171,"PHASE2":67177,"PHASE3":67179,"PHASE4":67181,"NA":67183},{"trials":67170,"activeCount":97},[],{"trials":67172,"activeCount":97},[67173],{"nctId":67153,"briefTitle":67154,"status":155,"phases":67174,"primaryCompletion":41106,"completion":41106,"start":10566,"enrollment":22557,"conditions":67175,"interventions":67176},[85],[17209],[67146,67158],{"trials":67178,"activeCount":97},[],{"trials":67180,"activeCount":97},[],{"trials":67182,"activeCount":97},[],{"trials":67184,"activeCount":97},[],{"intervention":67186,"totalTrials":417,"cells":67187},"GSK256073A tablets + IR niacin",{"EARLY_PHASE1":67188,"PHASE1":67190,"PHASE2":67198,"PHASE3":67200,"PHASE4":67202,"NA":67204},{"trials":67189,"activeCount":97},[],{"trials":67191,"activeCount":97},[67192],{"nctId":67193,"briefTitle":67194,"status":155,"phases":67195,"primaryCompletion":2355,"completion":2355,"start":2804,"enrollment":1298,"conditions":67196,"interventions":67197},"NCT00608699","A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers",[85],[7524,27251],[67186],{"trials":67199,"activeCount":97},[],{"trials":67201,"activeCount":97},[],{"trials":67203,"activeCount":97},[],{"trials":67205,"activeCount":97},[],{"intervention":67207,"totalTrials":417,"cells":67208},"GSK1550188 1mg\u002Fkg or 10mg\u002Fkg",{"EARLY_PHASE1":67209,"PHASE1":67211,"PHASE2":67220,"PHASE3":67222,"PHASE4":67224,"NA":67226},{"trials":67210,"activeCount":97},[],{"trials":67212,"activeCount":97},[67213],{"nctId":67214,"briefTitle":67215,"status":155,"phases":67216,"primaryCompletion":27094,"completion":27094,"start":67217,"enrollment":1459,"conditions":67218,"interventions":67219},"NCT01381536","Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)",[85],"2010-07-20",[435],[67207],{"trials":67221,"activeCount":97},[],{"trials":67223,"activeCount":97},[],{"trials":67225,"activeCount":97},[],{"trials":67227,"activeCount":97},[],{"intervention":59527,"totalTrials":417,"cells":67229},{"EARLY_PHASE1":67230,"PHASE1":67232,"PHASE2":67238,"PHASE3":67240,"PHASE4":67242,"NA":67244},{"trials":67231,"activeCount":97},[],{"trials":67233,"activeCount":97},[67234],{"nctId":59522,"briefTitle":59523,"status":155,"phases":67235,"primaryCompletion":2794,"completion":2794,"start":2813,"enrollment":433,"conditions":67236,"interventions":67237},[85],[19301],[59527,59528,59529,19303],{"trials":67239,"activeCount":97},[],{"trials":67241,"activeCount":97},[],{"trials":67243,"activeCount":97},[],{"trials":67245,"activeCount":97},[],{"intervention":59528,"totalTrials":417,"cells":67247},{"EARLY_PHASE1":67248,"PHASE1":67250,"PHASE2":67256,"PHASE3":67258,"PHASE4":67260,"NA":67262},{"trials":67249,"activeCount":97},[],{"trials":67251,"activeCount":97},[67252],{"nctId":59522,"briefTitle":59523,"status":155,"phases":67253,"primaryCompletion":2794,"completion":2794,"start":2813,"enrollment":433,"conditions":67254,"interventions":67255},[85],[19301],[59527,59528,59529,19303],{"trials":67257,"activeCount":97},[],{"trials":67259,"activeCount":97},[],{"trials":67261,"activeCount":97},[],{"trials":67263,"activeCount":97},[],{"intervention":59529,"totalTrials":417,"cells":67265},{"EARLY_PHASE1":67266,"PHASE1":67268,"PHASE2":67274,"PHASE3":67276,"PHASE4":67278,"NA":67280},{"trials":67267,"activeCount":97},[],{"trials":67269,"activeCount":97},[67270],{"nctId":59522,"briefTitle":59523,"status":155,"phases":67271,"primaryCompletion":2794,"completion":2794,"start":2813,"enrollment":433,"conditions":67272,"interventions":67273},[85],[19301],[59527,59528,59529,19303],{"trials":67275,"activeCount":97},[],{"trials":67277,"activeCount":97},[],{"trials":67279,"activeCount":97},[],{"trials":67281,"activeCount":97},[],{"intervention":67283,"totalTrials":417,"cells":67284},"GSK2800528, solution for",{"EARLY_PHASE1":67285,"PHASE1":67287,"PHASE2":67298,"PHASE3":67300,"PHASE4":67302,"NA":67304},{"trials":67286,"activeCount":97},[],{"trials":67288,"activeCount":97},[67289],{"nctId":67290,"briefTitle":67291,"status":155,"phases":67292,"primaryCompletion":67293,"completion":67293,"start":67294,"enrollment":6369,"conditions":67295,"interventions":67296},"NCT01899755","A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.",[85],"2014-04-03","2013-07-10",[22060],[67283,67297],"Adalimumab, solution for",{"trials":67299,"activeCount":97},[],{"trials":67301,"activeCount":97},[],{"trials":67303,"activeCount":97},[],{"trials":67305,"activeCount":97},[],{"intervention":67297,"totalTrials":417,"cells":67307},{"EARLY_PHASE1":67308,"PHASE1":67310,"PHASE2":67316,"PHASE3":67318,"PHASE4":67320,"NA":67322},{"trials":67309,"activeCount":97},[],{"trials":67311,"activeCount":97},[67312],{"nctId":67290,"briefTitle":67291,"status":155,"phases":67313,"primaryCompletion":67293,"completion":67293,"start":67294,"enrollment":6369,"conditions":67314,"interventions":67315},[85],[22060],[67283,67297],{"trials":67317,"activeCount":97},[],{"trials":67319,"activeCount":97},[],{"trials":67321,"activeCount":97},[],{"trials":67323,"activeCount":97},[],{"intervention":60796,"totalTrials":417,"cells":67325},{"EARLY_PHASE1":67326,"PHASE1":67328,"PHASE2":67334,"PHASE3":67336,"PHASE4":67338,"NA":67340},{"trials":67327,"activeCount":97},[],{"trials":67329,"activeCount":97},[67330],{"nctId":60791,"briefTitle":60792,"status":155,"phases":67331,"primaryCompletion":7481,"completion":7481,"start":4789,"enrollment":433,"conditions":67332,"interventions":67333},[85],[19716],[60773,60787,60788,60789,60796,60797,60798],{"trials":67335,"activeCount":97},[],{"trials":67337,"activeCount":97},[],{"trials":67339,"activeCount":97},[],{"trials":67341,"activeCount":97},[],{"intervention":60797,"totalTrials":417,"cells":67343},{"EARLY_PHASE1":67344,"PHASE1":67346,"PHASE2":67352,"PHASE3":67354,"PHASE4":67356,"NA":67358},{"trials":67345,"activeCount":97},[],{"trials":67347,"activeCount":97},[67348],{"nctId":60791,"briefTitle":60792,"status":155,"phases":67349,"primaryCompletion":7481,"completion":7481,"start":4789,"enrollment":433,"conditions":67350,"interventions":67351},[85],[19716],[60773,60787,60788,60789,60796,60797,60798],{"trials":67353,"activeCount":97},[],{"trials":67355,"activeCount":97},[],{"trials":67357,"activeCount":97},[],{"trials":67359,"activeCount":97},[],{"intervention":60798,"totalTrials":417,"cells":67361},{"EARLY_PHASE1":67362,"PHASE1":67364,"PHASE2":67370,"PHASE3":67372,"PHASE4":67374,"NA":67376},{"trials":67363,"activeCount":97},[],{"trials":67365,"activeCount":97},[67366],{"nctId":60791,"briefTitle":60792,"status":155,"phases":67367,"primaryCompletion":7481,"completion":7481,"start":4789,"enrollment":433,"conditions":67368,"interventions":67369},[85],[19716],[60773,60787,60788,60789,60796,60797,60798],{"trials":67371,"activeCount":97},[],{"trials":67373,"activeCount":97},[],{"trials":67375,"activeCount":97},[],{"trials":67377,"activeCount":97},[],{"intervention":67379,"totalTrials":417,"cells":67380},"CCI15106 7.5 mg",{"EARLY_PHASE1":67381,"PHASE1":67383,"PHASE2":67394,"PHASE3":67396,"PHASE4":67398,"NA":67400},{"trials":67382,"activeCount":97},[],{"trials":67384,"activeCount":97},[67385],{"nctId":67386,"briefTitle":67387,"status":145,"phases":67388,"primaryCompletion":67389,"completion":67390,"start":67391,"enrollment":1237,"conditions":67392,"interventions":67393},"NCT03243760","Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients",[85],"2016-07-20","2016-08-20","2016-02-10",[15],[67379],{"trials":67395,"activeCount":97},[],{"trials":67397,"activeCount":97},[],{"trials":67399,"activeCount":97},[],{"trials":67401,"activeCount":97},[],{"intervention":67403,"totalTrials":417,"cells":67404},"fosamprenavir + ritonavir + methadone",{"EARLY_PHASE1":67405,"PHASE1":67407,"PHASE2":67415,"PHASE3":67417,"PHASE4":67419,"NA":67421},{"trials":67406,"activeCount":97},[],{"trials":67408,"activeCount":97},[67409],{"nctId":67410,"briefTitle":67411,"status":155,"phases":67412,"start":1380,"enrollment":454,"conditions":67413,"interventions":67414},"NCT00481182","Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.",[85],[7524],[67403],{"trials":67416,"activeCount":97},[],{"trials":67418,"activeCount":97},[],{"trials":67420,"activeCount":97},[],{"trials":67422,"activeCount":97},[],{"intervention":60044,"totalTrials":417,"cells":67424},{"EARLY_PHASE1":67425,"PHASE1":67427,"PHASE2":67433,"PHASE3":67435,"PHASE4":67437,"NA":67439},{"trials":67426,"activeCount":97},[],{"trials":67428,"activeCount":97},[67429],{"nctId":60038,"briefTitle":60039,"status":145,"phases":67430,"primaryCompletion":60032,"completion":60032,"start":60041,"enrollment":181,"conditions":67431,"interventions":67432},[85],[4644],[60014,60044],{"trials":67434,"activeCount":97},[],{"trials":67436,"activeCount":97},[],{"trials":67438,"activeCount":97},[],{"trials":67440,"activeCount":97},[],{"intervention":67442,"totalTrials":417,"cells":67443},"100mcg",{"EARLY_PHASE1":67444,"PHASE1":67446,"PHASE2":67457,"PHASE3":67459,"PHASE4":67461,"NA":67463},{"trials":67445,"activeCount":97},[],{"trials":67447,"activeCount":97},[67448],{"nctId":67449,"briefTitle":67450,"status":155,"phases":67451,"primaryCompletion":30466,"completion":30466,"start":67452,"enrollment":710,"conditions":67453,"interventions":67454},"NCT00803673","A Healthy Volunteer Study With Inhaled GSK573719 and Placebo",[85],"2008-05-05",[15],[67442,67455,67456],"500mcg","1000mcg",{"trials":67458,"activeCount":97},[],{"trials":67460,"activeCount":97},[],{"trials":67462,"activeCount":97},[],{"trials":67464,"activeCount":97},[],{"intervention":67455,"totalTrials":417,"cells":67466},{"EARLY_PHASE1":67467,"PHASE1":67469,"PHASE2":67475,"PHASE3":67477,"PHASE4":67479,"NA":67481},{"trials":67468,"activeCount":97},[],{"trials":67470,"activeCount":97},[67471],{"nctId":67449,"briefTitle":67450,"status":155,"phases":67472,"primaryCompletion":30466,"completion":30466,"start":67452,"enrollment":710,"conditions":67473,"interventions":67474},[85],[15],[67442,67455,67456],{"trials":67476,"activeCount":97},[],{"trials":67478,"activeCount":97},[],{"trials":67480,"activeCount":97},[],{"trials":67482,"activeCount":97},[],{"intervention":67456,"totalTrials":417,"cells":67484},{"EARLY_PHASE1":67485,"PHASE1":67487,"PHASE2":67493,"PHASE3":67495,"PHASE4":67497,"NA":67499},{"trials":67486,"activeCount":97},[],{"trials":67488,"activeCount":97},[67489],{"nctId":67449,"briefTitle":67450,"status":155,"phases":67490,"primaryCompletion":30466,"completion":30466,"start":67452,"enrollment":710,"conditions":67491,"interventions":67492},[85],[15],[67442,67455,67456],{"trials":67494,"activeCount":97},[],{"trials":67496,"activeCount":97},[],{"trials":67498,"activeCount":97},[],{"trials":67500,"activeCount":97},[],{"intervention":67502,"totalTrials":417,"cells":67503},"[14C]GW642444",{"EARLY_PHASE1":67504,"PHASE1":67506,"PHASE2":67515,"PHASE3":67517,"PHASE4":67519,"NA":67521},{"trials":67505,"activeCount":97},[],{"trials":67507,"activeCount":97},[67508],{"nctId":67509,"briefTitle":67510,"status":155,"phases":67511,"primaryCompletion":21187,"completion":21187,"start":67512,"enrollment":628,"conditions":67513,"interventions":67514},"NCT01286831","A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.",[85],"2010-05-18",[15],[67502],{"trials":67516,"activeCount":97},[],{"trials":67518,"activeCount":97},[],{"trials":67520,"activeCount":97},[],{"trials":67522,"activeCount":97},[],{"intervention":67524,"totalTrials":417,"cells":67525},"Capozide",{"EARLY_PHASE1":67526,"PHASE1":67528,"PHASE2":67539,"PHASE3":67541,"PHASE4":67543,"NA":67545},{"trials":67527,"activeCount":97},[],{"trials":67529,"activeCount":97},[67530],{"nctId":67531,"briefTitle":67532,"status":500,"phases":67533,"primaryCompletion":67534,"completion":67534,"start":67535,"enrollment":97,"conditions":67536,"interventions":67537},"NCT04964050","A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions",[85],"2022-05-26","2022-04-21",[5280],[67524,67538],"ACE-Hemmer-Ratiopharm",{"trials":67540,"activeCount":97},[],{"trials":67542,"activeCount":97},[],{"trials":67544,"activeCount":97},[],{"trials":67546,"activeCount":97},[],{"intervention":67538,"totalTrials":417,"cells":67548},{"EARLY_PHASE1":67549,"PHASE1":67551,"PHASE2":67557,"PHASE3":67559,"PHASE4":67561,"NA":67563},{"trials":67550,"activeCount":97},[],{"trials":67552,"activeCount":97},[67553],{"nctId":67531,"briefTitle":67532,"status":500,"phases":67554,"primaryCompletion":67534,"completion":67534,"start":67535,"enrollment":97,"conditions":67555,"interventions":67556},[85],[5280],[67524,67538],{"trials":67558,"activeCount":97},[],{"trials":67560,"activeCount":97},[],{"trials":67562,"activeCount":97},[],{"trials":67564,"activeCount":97},[],{"intervention":67566,"totalTrials":417,"cells":67567},"GSK1059615",{"EARLY_PHASE1":67568,"PHASE1":67570,"PHASE2":67579,"PHASE3":67581,"PHASE4":67583,"NA":67585},{"trials":67569,"activeCount":97},[],{"trials":67571,"activeCount":97},[67572],{"nctId":67573,"briefTitle":67574,"status":145,"phases":67575,"primaryCompletion":33172,"completion":33172,"start":67576,"enrollment":361,"conditions":67577,"interventions":67578},"NCT00695448","Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma",[85],"2008-06-24",[2761],[67566],{"trials":67580,"activeCount":97},[],{"trials":67582,"activeCount":97},[],{"trials":67584,"activeCount":97},[],{"trials":67586,"activeCount":97},[],{"intervention":7484,"totalTrials":417,"cells":67588},{"EARLY_PHASE1":67589,"PHASE1":67591,"PHASE2":67597,"PHASE3":67599,"PHASE4":67601,"NA":67603},{"trials":67590,"activeCount":97},[],{"trials":67592,"activeCount":97},[67593],{"nctId":7477,"briefTitle":7478,"status":155,"phases":67594,"primaryCompletion":7480,"completion":7480,"start":7481,"enrollment":1459,"conditions":67595,"interventions":67596},[85],[2667],[2300,7484,2839],{"trials":67598,"activeCount":97},[],{"trials":67600,"activeCount":97},[],{"trials":67602,"activeCount":97},[],{"trials":67604,"activeCount":97},[],{"intervention":19004,"totalTrials":417,"cells":67606},{"EARLY_PHASE1":67607,"PHASE1":67609,"PHASE2":67615,"PHASE3":67617,"PHASE4":67619,"NA":67621},{"trials":67608,"activeCount":97},[],{"trials":67610,"activeCount":97},[67611],{"nctId":18997,"briefTitle":18998,"status":155,"phases":67612,"primaryCompletion":19000,"completion":19000,"start":19001,"enrollment":454,"conditions":67613,"interventions":67614},[85],[15],[19004,915,19005,19006,19007],{"trials":67616,"activeCount":97},[],{"trials":67618,"activeCount":97},[],{"trials":67620,"activeCount":97},[],{"trials":67622,"activeCount":97},[],{"intervention":19005,"totalTrials":417,"cells":67624},{"EARLY_PHASE1":67625,"PHASE1":67627,"PHASE2":67633,"PHASE3":67635,"PHASE4":67637,"NA":67639},{"trials":67626,"activeCount":97},[],{"trials":67628,"activeCount":97},[67629],{"nctId":18997,"briefTitle":18998,"status":155,"phases":67630,"primaryCompletion":19000,"completion":19000,"start":19001,"enrollment":454,"conditions":67631,"interventions":67632},[85],[15],[19004,915,19005,19006,19007],{"trials":67634,"activeCount":97},[],{"trials":67636,"activeCount":97},[],{"trials":67638,"activeCount":97},[],{"trials":67640,"activeCount":97},[],{"intervention":19006,"totalTrials":417,"cells":67642},{"EARLY_PHASE1":67643,"PHASE1":67645,"PHASE2":67651,"PHASE3":67653,"PHASE4":67655,"NA":67657},{"trials":67644,"activeCount":97},[],{"trials":67646,"activeCount":97},[67647],{"nctId":18997,"briefTitle":18998,"status":155,"phases":67648,"primaryCompletion":19000,"completion":19000,"start":19001,"enrollment":454,"conditions":67649,"interventions":67650},[85],[15],[19004,915,19005,19006,19007],{"trials":67652,"activeCount":97},[],{"trials":67654,"activeCount":97},[],{"trials":67656,"activeCount":97},[],{"trials":67658,"activeCount":97},[],{"intervention":19007,"totalTrials":417,"cells":67660},{"EARLY_PHASE1":67661,"PHASE1":67663,"PHASE2":67669,"PHASE3":67671,"PHASE4":67673,"NA":67675},{"trials":67662,"activeCount":97},[],{"trials":67664,"activeCount":97},[67665],{"nctId":18997,"briefTitle":18998,"status":155,"phases":67666,"primaryCompletion":19000,"completion":19000,"start":19001,"enrollment":454,"conditions":67667,"interventions":67668},[85],[15],[19004,915,19005,19006,19007],{"trials":67670,"activeCount":97},[],{"trials":67672,"activeCount":97},[],{"trials":67674,"activeCount":97},[],{"trials":67676,"activeCount":97},[],{"intervention":67678,"totalTrials":417,"cells":67679},"GSK369796",{"EARLY_PHASE1":67680,"PHASE1":67682,"PHASE2":67691,"PHASE3":67693,"PHASE4":67695,"NA":67697},{"trials":67681,"activeCount":97},[],{"trials":67683,"activeCount":97},[67684],{"nctId":67685,"briefTitle":67686,"status":155,"phases":67687,"primaryCompletion":67688,"completion":67688,"start":4790,"enrollment":212,"conditions":67689,"interventions":67690},"NCT00675064","Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects",[85],"2008-10-12",[3287],[67678],{"trials":67692,"activeCount":97},[],{"trials":67694,"activeCount":97},[],{"trials":67696,"activeCount":97},[],{"trials":67698,"activeCount":97},[],{"intervention":23773,"totalTrials":417,"cells":67700},{"EARLY_PHASE1":67701,"PHASE1":67703,"PHASE2":67709,"PHASE3":67711,"PHASE4":67713,"NA":67715},{"trials":67702,"activeCount":97},[],{"trials":67704,"activeCount":97},[67705],{"nctId":23764,"briefTitle":23765,"status":155,"phases":67706,"primaryCompletion":23767,"completion":23767,"start":23768,"enrollment":345,"conditions":67707,"interventions":67708},[85],[23770],[23772,19353,23773],{"trials":67710,"activeCount":97},[],{"trials":67712,"activeCount":97},[],{"trials":67714,"activeCount":97},[],{"trials":67716,"activeCount":97},[],{"intervention":67718,"totalTrials":417,"cells":67719},"FDC product of dutasteride",{"EARLY_PHASE1":67720,"PHASE1":67722,"PHASE2":67732,"PHASE3":67734,"PHASE4":67736,"NA":67738},{"trials":67721,"activeCount":97},[],{"trials":67723,"activeCount":97},[67724],{"nctId":67725,"briefTitle":67726,"status":155,"phases":67727,"primaryCompletion":67728,"completion":67728,"start":3369,"enrollment":9334,"conditions":67729,"interventions":67730},"NCT01471678","Bioavailability of Two Combination Products of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) in Asian Males.",[85],"2011-09-07",[12263],[63019,67718,67731],"Harnal D Tablets and Harnal",{"trials":67733,"activeCount":97},[],{"trials":67735,"activeCount":97},[],{"trials":67737,"activeCount":97},[],{"trials":67739,"activeCount":97},[],{"intervention":67731,"totalTrials":417,"cells":67741},{"EARLY_PHASE1":67742,"PHASE1":67744,"PHASE2":67750,"PHASE3":67752,"PHASE4":67754,"NA":67756},{"trials":67743,"activeCount":97},[],{"trials":67745,"activeCount":97},[67746],{"nctId":67725,"briefTitle":67726,"status":155,"phases":67747,"primaryCompletion":67728,"completion":67728,"start":3369,"enrollment":9334,"conditions":67748,"interventions":67749},[85],[12263],[63019,67718,67731],{"trials":67751,"activeCount":97},[],{"trials":67753,"activeCount":97},[],{"trials":67755,"activeCount":97},[],{"trials":67757,"activeCount":97},[],{"intervention":67759,"totalTrials":417,"cells":67760},"Pazopanib vehicle",{"EARLY_PHASE1":67761,"PHASE1":67763,"PHASE2":67775,"PHASE3":67777,"PHASE4":67779,"NA":67781},{"trials":67762,"activeCount":97},[],{"trials":67764,"activeCount":97},[67765],{"nctId":67766,"briefTitle":67767,"status":155,"phases":67768,"primaryCompletion":67769,"completion":67769,"start":67770,"enrollment":750,"conditions":67771,"interventions":67772},"NCT00358384","Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034",[85],"2006-02-24","2005-09-26",[22060],[2273,67759,67773,67774],"Betamethasone valerate","Calcipotriol",{"trials":67776,"activeCount":97},[],{"trials":67778,"activeCount":97},[],{"trials":67780,"activeCount":97},[],{"trials":67782,"activeCount":97},[],{"intervention":67773,"totalTrials":417,"cells":67784},{"EARLY_PHASE1":67785,"PHASE1":67787,"PHASE2":67793,"PHASE3":67795,"PHASE4":67797,"NA":67799},{"trials":67786,"activeCount":97},[],{"trials":67788,"activeCount":97},[67789],{"nctId":67766,"briefTitle":67767,"status":155,"phases":67790,"primaryCompletion":67769,"completion":67769,"start":67770,"enrollment":750,"conditions":67791,"interventions":67792},[85],[22060],[2273,67759,67773,67774],{"trials":67794,"activeCount":97},[],{"trials":67796,"activeCount":97},[],{"trials":67798,"activeCount":97},[],{"trials":67800,"activeCount":97},[],{"intervention":67774,"totalTrials":417,"cells":67802},{"EARLY_PHASE1":67803,"PHASE1":67805,"PHASE2":67811,"PHASE3":67813,"PHASE4":67815,"NA":67817},{"trials":67804,"activeCount":97},[],{"trials":67806,"activeCount":97},[67807],{"nctId":67766,"briefTitle":67767,"status":155,"phases":67808,"primaryCompletion":67769,"completion":67769,"start":67770,"enrollment":750,"conditions":67809,"interventions":67810},[85],[22060],[2273,67759,67773,67774],{"trials":67812,"activeCount":97},[],{"trials":67814,"activeCount":97},[],{"trials":67816,"activeCount":97},[],{"trials":67818,"activeCount":97},[],{"intervention":67820,"totalTrials":417,"cells":67821},"Triamcinolone acetonide",{"EARLY_PHASE1":67822,"PHASE1":67824,"PHASE2":67834,"PHASE3":67836,"PHASE4":67838,"NA":67840},{"trials":67823,"activeCount":97},[],{"trials":67825,"activeCount":97},[67826],{"nctId":67827,"briefTitle":67828,"status":145,"phases":67829,"primaryCompletion":67830,"completion":67830,"start":885,"enrollment":1165,"conditions":67831,"interventions":67833},"NCT01978301","Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars",[85],"2015-02-05",[67832],"Fibrosis",[67820],{"trials":67835,"activeCount":97},[],{"trials":67837,"activeCount":97},[],{"trials":67839,"activeCount":97},[],{"trials":67841,"activeCount":97},[],{"intervention":67843,"totalTrials":417,"cells":67844},"[11C]-GSK2256098 500 MBq",{"EARLY_PHASE1":67845,"PHASE1":67847,"PHASE2":67856,"PHASE3":67858,"PHASE4":67860,"NA":67862},{"trials":67846,"activeCount":97},[],{"trials":67848,"activeCount":97},[67849],{"nctId":67850,"briefTitle":67851,"status":155,"phases":67852,"primaryCompletion":67853,"completion":67853,"start":989,"enrollment":750,"conditions":67854,"interventions":67855},"NCT02551653","Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients",[85],"2017-03-14",[17209],[67843],{"trials":67857,"activeCount":97},[],{"trials":67859,"activeCount":97},[],{"trials":67861,"activeCount":97},[],{"trials":67863,"activeCount":97},[],{"intervention":67865,"totalTrials":417,"cells":67866},"GSK1322322 Initial fit for purpose",{"EARLY_PHASE1":67867,"PHASE1":67869,"PHASE2":67883,"PHASE3":67885,"PHASE4":67887,"NA":67889},{"trials":67868,"activeCount":97},[],{"trials":67870,"activeCount":97},[67871],{"nctId":67872,"briefTitle":67873,"status":145,"phases":67874,"primaryCompletion":67875,"completion":67875,"start":67876,"enrollment":1459,"conditions":67877,"interventions":67878},"NCT01818011","A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects",[85],"2013-10-18","2013-08-07",[6484],[67865,67879,67880,67881,67882],"GSK1322322 over granulated","GSK1322322 intended commercial","13C-GSK1322322 stable isotope powder","GSK1322322 for",{"trials":67884,"activeCount":97},[],{"trials":67886,"activeCount":97},[],{"trials":67888,"activeCount":97},[],{"trials":67890,"activeCount":97},[],{"intervention":67879,"totalTrials":417,"cells":67892},{"EARLY_PHASE1":67893,"PHASE1":67895,"PHASE2":67901,"PHASE3":67903,"PHASE4":67905,"NA":67907},{"trials":67894,"activeCount":97},[],{"trials":67896,"activeCount":97},[67897],{"nctId":67872,"briefTitle":67873,"status":145,"phases":67898,"primaryCompletion":67875,"completion":67875,"start":67876,"enrollment":1459,"conditions":67899,"interventions":67900},[85],[6484],[67865,67879,67880,67881,67882],{"trials":67902,"activeCount":97},[],{"trials":67904,"activeCount":97},[],{"trials":67906,"activeCount":97},[],{"trials":67908,"activeCount":97},[],{"intervention":67880,"totalTrials":417,"cells":67910},{"EARLY_PHASE1":67911,"PHASE1":67913,"PHASE2":67919,"PHASE3":67921,"PHASE4":67923,"NA":67925},{"trials":67912,"activeCount":97},[],{"trials":67914,"activeCount":97},[67915],{"nctId":67872,"briefTitle":67873,"status":145,"phases":67916,"primaryCompletion":67875,"completion":67875,"start":67876,"enrollment":1459,"conditions":67917,"interventions":67918},[85],[6484],[67865,67879,67880,67881,67882],{"trials":67920,"activeCount":97},[],{"trials":67922,"activeCount":97},[],{"trials":67924,"activeCount":97},[],{"trials":67926,"activeCount":97},[],{"intervention":67881,"totalTrials":417,"cells":67928},{"EARLY_PHASE1":67929,"PHASE1":67931,"PHASE2":67937,"PHASE3":67939,"PHASE4":67941,"NA":67943},{"trials":67930,"activeCount":97},[],{"trials":67932,"activeCount":97},[67933],{"nctId":67872,"briefTitle":67873,"status":145,"phases":67934,"primaryCompletion":67875,"completion":67875,"start":67876,"enrollment":1459,"conditions":67935,"interventions":67936},[85],[6484],[67865,67879,67880,67881,67882],{"trials":67938,"activeCount":97},[],{"trials":67940,"activeCount":97},[],{"trials":67942,"activeCount":97},[],{"trials":67944,"activeCount":97},[],{"intervention":67882,"totalTrials":417,"cells":67946},{"EARLY_PHASE1":67947,"PHASE1":67949,"PHASE2":67955,"PHASE3":67957,"PHASE4":67959,"NA":67961},{"trials":67948,"activeCount":97},[],{"trials":67950,"activeCount":97},[67951],{"nctId":67872,"briefTitle":67873,"status":145,"phases":67952,"primaryCompletion":67875,"completion":67875,"start":67876,"enrollment":1459,"conditions":67953,"interventions":67954},[85],[6484],[67865,67879,67880,67881,67882],{"trials":67956,"activeCount":97},[],{"trials":67958,"activeCount":97},[],{"trials":67960,"activeCount":97},[],{"trials":67962,"activeCount":97},[],{"intervention":67964,"totalTrials":417,"cells":67965},"GSK1322322 1000 mg containing radioactive 14C-GSK1322322",{"EARLY_PHASE1":67966,"PHASE1":67968,"PHASE2":67977,"PHASE3":67979,"PHASE4":67981,"NA":67983},{"trials":67967,"activeCount":97},[],{"trials":67969,"activeCount":97},[67970],{"nctId":67971,"briefTitle":67972,"status":155,"phases":67973,"primaryCompletion":9953,"completion":9953,"start":21178,"enrollment":1517,"conditions":67974,"interventions":67975},"NCT01663389","A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose",[85],[6484],[67964,67976],"GSK1322322 1200 mg containing radioactive 14C-GSK1322322",{"trials":67978,"activeCount":97},[],{"trials":67980,"activeCount":97},[],{"trials":67982,"activeCount":97},[],{"trials":67984,"activeCount":97},[],{"intervention":67976,"totalTrials":417,"cells":67986},{"EARLY_PHASE1":67987,"PHASE1":67989,"PHASE2":67995,"PHASE3":67997,"PHASE4":67999,"NA":68001},{"trials":67988,"activeCount":97},[],{"trials":67990,"activeCount":97},[67991],{"nctId":67971,"briefTitle":67972,"status":155,"phases":67992,"primaryCompletion":9953,"completion":9953,"start":21178,"enrollment":1517,"conditions":67993,"interventions":67994},[85],[6484],[67964,67976],{"trials":67996,"activeCount":97},[],{"trials":67998,"activeCount":97},[],{"trials":68000,"activeCount":97},[],{"trials":68002,"activeCount":97},[],{"intervention":68004,"totalTrials":417,"cells":68005},"4 adjuvanted pandemic influenza candidate vaccines",{"EARLY_PHASE1":68006,"PHASE1":68008,"PHASE2":68018,"PHASE3":68020,"PHASE4":68022,"NA":68024},{"trials":68007,"activeCount":97},[],{"trials":68009,"activeCount":97},[68010],{"nctId":68011,"briefTitle":68012,"status":155,"phases":68013,"primaryCompletion":68014,"completion":68014,"start":57952,"enrollment":4388,"conditions":68015,"interventions":68016},"NCT00309634","Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years",[85],"2006-10-28",[21],[68004,68017],"4 non-adjuvanted pandemic influenza candidate vaccines",{"trials":68019,"activeCount":97},[],{"trials":68021,"activeCount":97},[],{"trials":68023,"activeCount":97},[],{"trials":68025,"activeCount":97},[],{"intervention":68017,"totalTrials":417,"cells":68027},{"EARLY_PHASE1":68028,"PHASE1":68030,"PHASE2":68036,"PHASE3":68038,"PHASE4":68040,"NA":68042},{"trials":68029,"activeCount":97},[],{"trials":68031,"activeCount":97},[68032],{"nctId":68011,"briefTitle":68012,"status":155,"phases":68033,"primaryCompletion":68014,"completion":68014,"start":57952,"enrollment":4388,"conditions":68034,"interventions":68035},[85],[21],[68004,68017],{"trials":68037,"activeCount":97},[],{"trials":68039,"activeCount":97},[],{"trials":68041,"activeCount":97},[],{"trials":68043,"activeCount":97},[],{"intervention":68045,"totalTrials":417,"cells":68046},"GSK221149",{"EARLY_PHASE1":68047,"PHASE1":68049,"PHASE2":68057,"PHASE3":68059,"PHASE4":68061,"NA":68063},{"trials":68048,"activeCount":97},[],{"trials":68050,"activeCount":97},[68051],{"nctId":68052,"briefTitle":68053,"status":145,"phases":68054,"start":748,"enrollment":710,"conditions":68055,"interventions":68056},"NCT00449709","A Study To Assess The Pharmacokinetics Of Different Modified Release Formulations Of GSK221149 In Healthy Adult Subjects",[85],[22921,45196],[68045],{"trials":68058,"activeCount":97},[],{"trials":68060,"activeCount":97},[],{"trials":68062,"activeCount":97},[],{"trials":68064,"activeCount":97},[],{"intervention":68066,"totalTrials":417,"cells":68067},"GW824575",{"EARLY_PHASE1":68068,"PHASE1":68070,"PHASE2":68080,"PHASE3":68082,"PHASE4":68084,"NA":68086},{"trials":68069,"activeCount":97},[],{"trials":68071,"activeCount":97},[68072],{"nctId":68073,"briefTitle":68074,"status":145,"phases":68075,"primaryCompletion":8803,"completion":8803,"start":18427,"enrollment":433,"conditions":68076,"interventions":68078},"NCT01551771","GW824575 First Time in Human",[85],[68077],"Retinal Diseases",[68066,68079],"GW824575 matched-placebo",{"trials":68081,"activeCount":97},[],{"trials":68083,"activeCount":97},[],{"trials":68085,"activeCount":97},[],{"trials":68087,"activeCount":97},[],{"intervention":68079,"totalTrials":417,"cells":68089},{"EARLY_PHASE1":68090,"PHASE1":68092,"PHASE2":68098,"PHASE3":68100,"PHASE4":68102,"NA":68104},{"trials":68091,"activeCount":97},[],{"trials":68093,"activeCount":97},[68094],{"nctId":68073,"briefTitle":68074,"status":145,"phases":68095,"primaryCompletion":8803,"completion":8803,"start":18427,"enrollment":433,"conditions":68096,"interventions":68097},[85],[68077],[68066,68079],{"trials":68099,"activeCount":97},[],{"trials":68101,"activeCount":97},[],{"trials":68103,"activeCount":97},[],{"trials":68105,"activeCount":97},[],{"intervention":68107,"totalTrials":417,"cells":68108},"Trametinib 0.5 mg",{"EARLY_PHASE1":68109,"PHASE1":68111,"PHASE2":68121,"PHASE3":68123,"PHASE4":68125,"NA":68127},{"trials":68110,"activeCount":97},[],{"trials":68112,"activeCount":97},[68113],{"nctId":68114,"briefTitle":68115,"status":500,"phases":68116,"primaryCompletion":6824,"completion":6824,"start":492,"enrollment":97,"conditions":68117,"interventions":68118},"NCT02292732","A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors",[85],[36],[68107,68119,68120],"Trametinib 2 mg","ORTHO-NOVUM® tablet 1\u002F35",{"trials":68122,"activeCount":97},[],{"trials":68124,"activeCount":97},[],{"trials":68126,"activeCount":97},[],{"trials":68128,"activeCount":97},[],{"intervention":68119,"totalTrials":417,"cells":68130},{"EARLY_PHASE1":68131,"PHASE1":68133,"PHASE2":68139,"PHASE3":68141,"PHASE4":68143,"NA":68145},{"trials":68132,"activeCount":97},[],{"trials":68134,"activeCount":97},[68135],{"nctId":68114,"briefTitle":68115,"status":500,"phases":68136,"primaryCompletion":6824,"completion":6824,"start":492,"enrollment":97,"conditions":68137,"interventions":68138},[85],[36],[68107,68119,68120],{"trials":68140,"activeCount":97},[],{"trials":68142,"activeCount":97},[],{"trials":68144,"activeCount":97},[],{"trials":68146,"activeCount":97},[],{"intervention":68120,"totalTrials":417,"cells":68148},{"EARLY_PHASE1":68149,"PHASE1":68151,"PHASE2":68157,"PHASE3":68159,"PHASE4":68161,"NA":68163},{"trials":68150,"activeCount":97},[],{"trials":68152,"activeCount":97},[68153],{"nctId":68114,"briefTitle":68115,"status":500,"phases":68154,"primaryCompletion":6824,"completion":6824,"start":492,"enrollment":97,"conditions":68155,"interventions":68156},[85],[36],[68107,68119,68120],{"trials":68158,"activeCount":97},[],{"trials":68160,"activeCount":97},[],{"trials":68162,"activeCount":97},[],{"trials":68164,"activeCount":97},[],{"intervention":3300,"totalTrials":417,"cells":68166},{"EARLY_PHASE1":68167,"PHASE1":68169,"PHASE2":68175,"PHASE3":68177,"PHASE4":68179,"NA":68181},{"trials":68168,"activeCount":97},[],{"trials":68170,"activeCount":97},[68171],{"nctId":3292,"briefTitle":3293,"status":155,"phases":68172,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":201,"conditions":68173,"interventions":68174},[85],[3298],[3273,3300,3301],{"trials":68176,"activeCount":97},[],{"trials":68178,"activeCount":97},[],{"trials":68180,"activeCount":97},[],{"trials":68182,"activeCount":97},[],{"intervention":3301,"totalTrials":417,"cells":68184},{"EARLY_PHASE1":68185,"PHASE1":68187,"PHASE2":68193,"PHASE3":68195,"PHASE4":68197,"NA":68199},{"trials":68186,"activeCount":97},[],{"trials":68188,"activeCount":97},[68189],{"nctId":3292,"briefTitle":3293,"status":155,"phases":68190,"primaryCompletion":3295,"completion":3295,"start":3296,"enrollment":201,"conditions":68191,"interventions":68192},[85],[3298],[3273,3300,3301],{"trials":68194,"activeCount":97},[],{"trials":68196,"activeCount":97},[],{"trials":68198,"activeCount":97},[],{"trials":68200,"activeCount":97},[],{"intervention":68202,"totalTrials":417,"cells":68203},"400 mg Amoxicillin + 57 mg Clavulanic Acid\u002F 5 ml",{"EARLY_PHASE1":68204,"PHASE1":68206,"PHASE2":68214,"PHASE3":68216,"PHASE4":68218,"NA":68220},{"trials":68205,"activeCount":97},[],{"trials":68207,"activeCount":97},[68208],{"nctId":68209,"briefTitle":68210,"status":155,"phases":68211,"primaryCompletion":10836,"completion":10836,"start":7514,"enrollment":8786,"conditions":68212,"interventions":68213},"NCT01772238","Bioequivalence Study of an Amoxicillin-Clavulanic",[85],[14696],[68202,68202],{"trials":68215,"activeCount":97},[],{"trials":68217,"activeCount":97},[],{"trials":68219,"activeCount":97},[],{"trials":68221,"activeCount":97},[],{"intervention":68223,"totalTrials":417,"cells":68224},"Cephalexin 1g",{"EARLY_PHASE1":68225,"PHASE1":68227,"PHASE2":68236,"PHASE3":68238,"PHASE4":68240,"NA":68242},{"trials":68226,"activeCount":97},[],{"trials":68228,"activeCount":97},[68229],{"nctId":68230,"briefTitle":68231,"status":155,"phases":68232,"primaryCompletion":68233,"completion":68233,"start":19001,"enrollment":93,"conditions":68234,"interventions":68235},"NCT01767584","Bioequivalence Study of Cephalexin Tablets 1g",[85],"2009-04-14",[14696],[68223,68223],{"trials":68237,"activeCount":97},[],{"trials":68239,"activeCount":97},[],{"trials":68241,"activeCount":97},[],{"trials":68243,"activeCount":97},[],{"intervention":68245,"totalTrials":417,"cells":68246},"Minocycline",{"EARLY_PHASE1":68247,"PHASE1":68249,"PHASE2":68257,"PHASE3":68259,"PHASE4":68261,"NA":68263},{"trials":68248,"activeCount":97},[],{"trials":68250,"activeCount":97},[68251],{"nctId":68252,"briefTitle":68253,"status":155,"phases":68254,"primaryCompletion":9697,"completion":9697,"start":5195,"enrollment":695,"conditions":68255,"interventions":68256},"NCT01938508","Minocycline Bioequivalence Study",[85],[13421],[68245],{"trials":68258,"activeCount":97},[],{"trials":68260,"activeCount":97},[],{"trials":68262,"activeCount":97},[],{"trials":68264,"activeCount":97},[],{"intervention":59853,"totalTrials":417,"cells":68266},{"EARLY_PHASE1":68267,"PHASE1":68269,"PHASE2":68275,"PHASE3":68277,"PHASE4":68279,"NA":68281},{"trials":68268,"activeCount":97},[],{"trials":68270,"activeCount":97},[68271],{"nctId":59846,"briefTitle":59847,"status":155,"phases":68272,"primaryCompletion":59849,"completion":59849,"start":59850,"enrollment":730,"conditions":68273,"interventions":68274},[85],[17996],[59853,59854,23669,59855],{"trials":68276,"activeCount":97},[],{"trials":68278,"activeCount":97},[],{"trials":68280,"activeCount":97},[],{"trials":68282,"activeCount":97},[],{"intervention":59855,"totalTrials":417,"cells":68284},{"EARLY_PHASE1":68285,"PHASE1":68287,"PHASE2":68293,"PHASE3":68295,"PHASE4":68297,"NA":68299},{"trials":68286,"activeCount":97},[],{"trials":68288,"activeCount":97},[68289],{"nctId":59846,"briefTitle":59847,"status":155,"phases":68290,"primaryCompletion":59849,"completion":59849,"start":59850,"enrollment":730,"conditions":68291,"interventions":68292},[85],[17996],[59853,59854,23669,59855],{"trials":68294,"activeCount":97},[],{"trials":68296,"activeCount":97},[],{"trials":68298,"activeCount":97},[],{"trials":68300,"activeCount":97},[],{"intervention":68302,"totalTrials":417,"cells":68303},"Montelukast 10 mg",{"EARLY_PHASE1":68304,"PHASE1":68306,"PHASE2":68314,"PHASE3":68316,"PHASE4":68318,"NA":68320},{"trials":68305,"activeCount":97},[],{"trials":68307,"activeCount":97},[68308],{"nctId":68309,"briefTitle":68310,"status":155,"phases":68311,"primaryCompletion":65190,"completion":65190,"start":65191,"enrollment":2045,"conditions":68312,"interventions":68313},"NCT01943942","Bioequivalence Study of Montelukast 10 mg Tablets",[85],[18],[68302,68302],{"trials":68315,"activeCount":97},[],{"trials":68317,"activeCount":97},[],{"trials":68319,"activeCount":97},[],{"trials":68321,"activeCount":97},[],{"intervention":68323,"totalTrials":417,"cells":68324},"GSK618334 Low Dose",{"EARLY_PHASE1":68325,"PHASE1":68327,"PHASE2":68339,"PHASE3":68341,"PHASE4":68343,"NA":68345},{"trials":68326,"activeCount":97},[],{"trials":68328,"activeCount":97},[68329],{"nctId":68330,"briefTitle":68331,"status":155,"phases":68332,"primaryCompletion":68333,"completion":68333,"start":37358,"enrollment":4121,"conditions":68334,"interventions":68335},"NCT01036061","GSK618334 Repeat Dose Study",[85],"2010-02-17",[39123],[68323,68336,68337,68338],"GSK618334 PET subjects","GSK618334 Medium Dose","GSK618334 High Dose",{"trials":68340,"activeCount":97},[],{"trials":68342,"activeCount":97},[],{"trials":68344,"activeCount":97},[],{"trials":68346,"activeCount":97},[],{"intervention":68336,"totalTrials":417,"cells":68348},{"EARLY_PHASE1":68349,"PHASE1":68351,"PHASE2":68357,"PHASE3":68359,"PHASE4":68361,"NA":68363},{"trials":68350,"activeCount":97},[],{"trials":68352,"activeCount":97},[68353],{"nctId":68330,"briefTitle":68331,"status":155,"phases":68354,"primaryCompletion":68333,"completion":68333,"start":37358,"enrollment":4121,"conditions":68355,"interventions":68356},[85],[39123],[68323,68336,68337,68338],{"trials":68358,"activeCount":97},[],{"trials":68360,"activeCount":97},[],{"trials":68362,"activeCount":97},[],{"trials":68364,"activeCount":97},[],{"intervention":68337,"totalTrials":417,"cells":68366},{"EARLY_PHASE1":68367,"PHASE1":68369,"PHASE2":68375,"PHASE3":68377,"PHASE4":68379,"NA":68381},{"trials":68368,"activeCount":97},[],{"trials":68370,"activeCount":97},[68371],{"nctId":68330,"briefTitle":68331,"status":155,"phases":68372,"primaryCompletion":68333,"completion":68333,"start":37358,"enrollment":4121,"conditions":68373,"interventions":68374},[85],[39123],[68323,68336,68337,68338],{"trials":68376,"activeCount":97},[],{"trials":68378,"activeCount":97},[],{"trials":68380,"activeCount":97},[],{"trials":68382,"activeCount":97},[],{"intervention":68338,"totalTrials":417,"cells":68384},{"EARLY_PHASE1":68385,"PHASE1":68387,"PHASE2":68393,"PHASE3":68395,"PHASE4":68397,"NA":68399},{"trials":68386,"activeCount":97},[],{"trials":68388,"activeCount":97},[68389],{"nctId":68330,"briefTitle":68331,"status":155,"phases":68390,"primaryCompletion":68333,"completion":68333,"start":37358,"enrollment":4121,"conditions":68391,"interventions":68392},[85],[39123],[68323,68336,68337,68338],{"trials":68394,"activeCount":97},[],{"trials":68396,"activeCount":97},[],{"trials":68398,"activeCount":97},[],{"trials":68400,"activeCount":97},[],{"intervention":68402,"totalTrials":417,"cells":68403},"Tab carvedilol 25 mg",{"EARLY_PHASE1":68404,"PHASE1":68406,"PHASE2":68418,"PHASE3":68420,"PHASE4":68422,"NA":68424},{"trials":68405,"activeCount":97},[],{"trials":68407,"activeCount":97},[68408],{"nctId":68409,"briefTitle":68410,"status":155,"phases":68411,"primaryCompletion":18021,"completion":18021,"start":68412,"enrollment":7438,"conditions":68413,"interventions":68415},"NCT01793870","A Study in Healthy Volunteers to Evaluate the Application of Stable Isotope Approach to Reduce Number of Subjects Needed for PK Studies",[85],"2013-01-15",[68414],"Metabolic, Cardiovascular",[68402,68416,68417],"Tab carvedilol 6.25 mg","Powder carvedilol up to 2.5 mg",{"trials":68419,"activeCount":97},[],{"trials":68421,"activeCount":97},[],{"trials":68423,"activeCount":97},[],{"trials":68425,"activeCount":97},[],{"intervention":68416,"totalTrials":417,"cells":68427},{"EARLY_PHASE1":68428,"PHASE1":68430,"PHASE2":68436,"PHASE3":68438,"PHASE4":68440,"NA":68442},{"trials":68429,"activeCount":97},[],{"trials":68431,"activeCount":97},[68432],{"nctId":68409,"briefTitle":68410,"status":155,"phases":68433,"primaryCompletion":18021,"completion":18021,"start":68412,"enrollment":7438,"conditions":68434,"interventions":68435},[85],[68414],[68402,68416,68417],{"trials":68437,"activeCount":97},[],{"trials":68439,"activeCount":97},[],{"trials":68441,"activeCount":97},[],{"trials":68443,"activeCount":97},[],{"intervention":68417,"totalTrials":417,"cells":68445},{"EARLY_PHASE1":68446,"PHASE1":68448,"PHASE2":68454,"PHASE3":68456,"PHASE4":68458,"NA":68460},{"trials":68447,"activeCount":97},[],{"trials":68449,"activeCount":97},[68450],{"nctId":68409,"briefTitle":68410,"status":155,"phases":68451,"primaryCompletion":18021,"completion":18021,"start":68412,"enrollment":7438,"conditions":68452,"interventions":68453},[85],[68414],[68402,68416,68417],{"trials":68455,"activeCount":97},[],{"trials":68457,"activeCount":97},[],{"trials":68459,"activeCount":97},[],{"trials":68461,"activeCount":97},[],{"intervention":68463,"totalTrials":417,"cells":68464},"Tykerb",{"EARLY_PHASE1":68465,"PHASE1":68467,"PHASE2":68475,"PHASE3":68477,"PHASE4":68479,"NA":68481},{"trials":68466,"activeCount":97},[],{"trials":68468,"activeCount":97},[68469],{"nctId":68470,"briefTitle":68471,"status":155,"phases":68472,"primaryCompletion":15622,"completion":15622,"start":36319,"enrollment":2759,"conditions":68473,"interventions":68474},"NCT00462956","GW572016 In Patients With Advanced Or Metastatic Breast Cancer",[85],[668],[68463],{"trials":68476,"activeCount":97},[],{"trials":68478,"activeCount":97},[],{"trials":68480,"activeCount":97},[],{"trials":68482,"activeCount":97},[],{"intervention":22923,"totalTrials":417,"cells":68484},{"EARLY_PHASE1":68485,"PHASE1":68487,"PHASE2":68493,"PHASE3":68495,"PHASE4":68497,"NA":68499},{"trials":68486,"activeCount":97},[],{"trials":68488,"activeCount":97},[68489],{"nctId":22915,"briefTitle":22916,"status":155,"phases":68490,"primaryCompletion":22918,"completion":22918,"start":22919,"enrollment":1634,"conditions":68491,"interventions":68492},[85],[22921],[22908,22923],{"trials":68494,"activeCount":97},[],{"trials":68496,"activeCount":97},[],{"trials":68498,"activeCount":97},[],{"trials":68500,"activeCount":97},[],{"intervention":68502,"totalTrials":417,"cells":68503},"0.1 mg GSK2330672",{"EARLY_PHASE1":68504,"PHASE1":68506,"PHASE2":68520,"PHASE3":68522,"PHASE4":68524,"NA":68526},{"trials":68505,"activeCount":97},[],{"trials":68507,"activeCount":97},[68508],{"nctId":68509,"briefTitle":68510,"status":155,"phases":68511,"primaryCompletion":26474,"completion":26474,"start":9776,"enrollment":7438,"conditions":68512,"interventions":68513},"NCT01416324","First Time in Human Study Using GSK2330672",[85],[27],[68502,68514,68515,68516,68517,68518,68519],"0.3 mg GSK2330672","1 mg GSK2330672","3 mg GSK2330672","10 mg GSK2330672","30 mg GSK2330672","60 mg GSK2330672",{"trials":68521,"activeCount":97},[],{"trials":68523,"activeCount":97},[],{"trials":68525,"activeCount":97},[],{"trials":68527,"activeCount":97},[],{"intervention":68514,"totalTrials":417,"cells":68529},{"EARLY_PHASE1":68530,"PHASE1":68532,"PHASE2":68538,"PHASE3":68540,"PHASE4":68542,"NA":68544},{"trials":68531,"activeCount":97},[],{"trials":68533,"activeCount":97},[68534],{"nctId":68509,"briefTitle":68510,"status":155,"phases":68535,"primaryCompletion":26474,"completion":26474,"start":9776,"enrollment":7438,"conditions":68536,"interventions":68537},[85],[27],[68502,68514,68515,68516,68517,68518,68519],{"trials":68539,"activeCount":97},[],{"trials":68541,"activeCount":97},[],{"trials":68543,"activeCount":97},[],{"trials":68545,"activeCount":97},[],{"intervention":68515,"totalTrials":417,"cells":68547},{"EARLY_PHASE1":68548,"PHASE1":68550,"PHASE2":68556,"PHASE3":68558,"PHASE4":68560,"NA":68562},{"trials":68549,"activeCount":97},[],{"trials":68551,"activeCount":97},[68552],{"nctId":68509,"briefTitle":68510,"status":155,"phases":68553,"primaryCompletion":26474,"completion":26474,"start":9776,"enrollment":7438,"conditions":68554,"interventions":68555},[85],[27],[68502,68514,68515,68516,68517,68518,68519],{"trials":68557,"activeCount":97},[],{"trials":68559,"activeCount":97},[],{"trials":68561,"activeCount":97},[],{"trials":68563,"activeCount":97},[],{"intervention":68516,"totalTrials":417,"cells":68565},{"EARLY_PHASE1":68566,"PHASE1":68568,"PHASE2":68574,"PHASE3":68576,"PHASE4":68578,"NA":68580},{"trials":68567,"activeCount":97},[],{"trials":68569,"activeCount":97},[68570],{"nctId":68509,"briefTitle":68510,"status":155,"phases":68571,"primaryCompletion":26474,"completion":26474,"start":9776,"enrollment":7438,"conditions":68572,"interventions":68573},[85],[27],[68502,68514,68515,68516,68517,68518,68519],{"trials":68575,"activeCount":97},[],{"trials":68577,"activeCount":97},[],{"trials":68579,"activeCount":97},[],{"trials":68581,"activeCount":97},[],{"intervention":68517,"totalTrials":417,"cells":68583},{"EARLY_PHASE1":68584,"PHASE1":68586,"PHASE2":68592,"PHASE3":68594,"PHASE4":68596,"NA":68598},{"trials":68585,"activeCount":97},[],{"trials":68587,"activeCount":97},[68588],{"nctId":68509,"briefTitle":68510,"status":155,"phases":68589,"primaryCompletion":26474,"completion":26474,"start":9776,"enrollment":7438,"conditions":68590,"interventions":68591},[85],[27],[68502,68514,68515,68516,68517,68518,68519],{"trials":68593,"activeCount":97},[],{"trials":68595,"activeCount":97},[],{"trials":68597,"activeCount":97},[],{"trials":68599,"activeCount":97},[],{"intervention":68518,"totalTrials":417,"cells":68601},{"EARLY_PHASE1":68602,"PHASE1":68604,"PHASE2":68610,"PHASE3":68612,"PHASE4":68614,"NA":68616},{"trials":68603,"activeCount":97},[],{"trials":68605,"activeCount":97},[68606],{"nctId":68509,"briefTitle":68510,"status":155,"phases":68607,"primaryCompletion":26474,"completion":26474,"start":9776,"enrollment":7438,"conditions":68608,"interventions":68609},[85],[27],[68502,68514,68515,68516,68517,68518,68519],{"trials":68611,"activeCount":97},[],{"trials":68613,"activeCount":97},[],{"trials":68615,"activeCount":97},[],{"trials":68617,"activeCount":97},[],{"intervention":68519,"totalTrials":417,"cells":68619},{"EARLY_PHASE1":68620,"PHASE1":68622,"PHASE2":68628,"PHASE3":68630,"PHASE4":68632,"NA":68634},{"trials":68621,"activeCount":97},[],{"trials":68623,"activeCount":97},[68624],{"nctId":68509,"briefTitle":68510,"status":155,"phases":68625,"primaryCompletion":26474,"completion":26474,"start":9776,"enrollment":7438,"conditions":68626,"interventions":68627},[85],[27],[68502,68514,68515,68516,68517,68518,68519],{"trials":68629,"activeCount":97},[],{"trials":68631,"activeCount":97},[],{"trials":68633,"activeCount":97},[],{"trials":68635,"activeCount":97},[],{"intervention":68637,"totalTrials":417,"cells":68638},"GSK163090 capsule, fasted",{"EARLY_PHASE1":68639,"PHASE1":68641,"PHASE2":68651,"PHASE3":68653,"PHASE4":68655,"NA":68657},{"trials":68640,"activeCount":97},[],{"trials":68642,"activeCount":97},[68643],{"nctId":68644,"briefTitle":68645,"status":155,"phases":68646,"primaryCompletion":10048,"completion":10048,"start":7473,"enrollment":433,"conditions":68647,"interventions":68648},"NCT00536679","Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers",[85],[41867],[68637,68649,68650],"GSK163090 Tablet, fasted","GSK163090 Tablet, fed",{"trials":68652,"activeCount":97},[],{"trials":68654,"activeCount":97},[],{"trials":68656,"activeCount":97},[],{"trials":68658,"activeCount":97},[],{"intervention":68649,"totalTrials":417,"cells":68660},{"EARLY_PHASE1":68661,"PHASE1":68663,"PHASE2":68669,"PHASE3":68671,"PHASE4":68673,"NA":68675},{"trials":68662,"activeCount":97},[],{"trials":68664,"activeCount":97},[68665],{"nctId":68644,"briefTitle":68645,"status":155,"phases":68666,"primaryCompletion":10048,"completion":10048,"start":7473,"enrollment":433,"conditions":68667,"interventions":68668},[85],[41867],[68637,68649,68650],{"trials":68670,"activeCount":97},[],{"trials":68672,"activeCount":97},[],{"trials":68674,"activeCount":97},[],{"trials":68676,"activeCount":97},[],{"intervention":68650,"totalTrials":417,"cells":68678},{"EARLY_PHASE1":68679,"PHASE1":68681,"PHASE2":68687,"PHASE3":68689,"PHASE4":68691,"NA":68693},{"trials":68680,"activeCount":97},[],{"trials":68682,"activeCount":97},[68683],{"nctId":68644,"briefTitle":68645,"status":155,"phases":68684,"primaryCompletion":10048,"completion":10048,"start":7473,"enrollment":433,"conditions":68685,"interventions":68686},[85],[41867],[68637,68649,68650],{"trials":68688,"activeCount":97},[],{"trials":68690,"activeCount":97},[],{"trials":68692,"activeCount":97},[],{"trials":68694,"activeCount":97},[],{"intervention":9842,"totalTrials":417,"cells":68696},{"EARLY_PHASE1":68697,"PHASE1":68699,"PHASE2":68705,"PHASE3":68707,"PHASE4":68709,"NA":68711},{"trials":68698,"activeCount":97},[],{"trials":68700,"activeCount":97},[68701],{"nctId":9835,"briefTitle":9836,"status":155,"phases":68702,"primaryCompletion":1263,"completion":9838,"start":1718,"enrollment":3392,"conditions":68703,"interventions":68704},[85],[9840],[9842,9843,9844,9845,9846,9847],{"trials":68706,"activeCount":97},[],{"trials":68708,"activeCount":97},[],{"trials":68710,"activeCount":97},[],{"trials":68712,"activeCount":97},[],{"intervention":9843,"totalTrials":417,"cells":68714},{"EARLY_PHASE1":68715,"PHASE1":68717,"PHASE2":68723,"PHASE3":68725,"PHASE4":68727,"NA":68729},{"trials":68716,"activeCount":97},[],{"trials":68718,"activeCount":97},[68719],{"nctId":9835,"briefTitle":9836,"status":155,"phases":68720,"primaryCompletion":1263,"completion":9838,"start":1718,"enrollment":3392,"conditions":68721,"interventions":68722},[85],[9840],[9842,9843,9844,9845,9846,9847],{"trials":68724,"activeCount":97},[],{"trials":68726,"activeCount":97},[],{"trials":68728,"activeCount":97},[],{"trials":68730,"activeCount":97},[],{"intervention":9844,"totalTrials":417,"cells":68732},{"EARLY_PHASE1":68733,"PHASE1":68735,"PHASE2":68741,"PHASE3":68743,"PHASE4":68745,"NA":68747},{"trials":68734,"activeCount":97},[],{"trials":68736,"activeCount":97},[68737],{"nctId":9835,"briefTitle":9836,"status":155,"phases":68738,"primaryCompletion":1263,"completion":9838,"start":1718,"enrollment":3392,"conditions":68739,"interventions":68740},[85],[9840],[9842,9843,9844,9845,9846,9847],{"trials":68742,"activeCount":97},[],{"trials":68744,"activeCount":97},[],{"trials":68746,"activeCount":97},[],{"trials":68748,"activeCount":97},[],{"intervention":9845,"totalTrials":417,"cells":68750},{"EARLY_PHASE1":68751,"PHASE1":68753,"PHASE2":68759,"PHASE3":68761,"PHASE4":68763,"NA":68765},{"trials":68752,"activeCount":97},[],{"trials":68754,"activeCount":97},[68755],{"nctId":9835,"briefTitle":9836,"status":155,"phases":68756,"primaryCompletion":1263,"completion":9838,"start":1718,"enrollment":3392,"conditions":68757,"interventions":68758},[85],[9840],[9842,9843,9844,9845,9846,9847],{"trials":68760,"activeCount":97},[],{"trials":68762,"activeCount":97},[],{"trials":68764,"activeCount":97},[],{"trials":68766,"activeCount":97},[],{"intervention":9847,"totalTrials":417,"cells":68768},{"EARLY_PHASE1":68769,"PHASE1":68771,"PHASE2":68777,"PHASE3":68779,"PHASE4":68781,"NA":68783},{"trials":68770,"activeCount":97},[],{"trials":68772,"activeCount":97},[68773],{"nctId":9835,"briefTitle":9836,"status":155,"phases":68774,"primaryCompletion":1263,"completion":9838,"start":1718,"enrollment":3392,"conditions":68775,"interventions":68776},[85],[9840],[9842,9843,9844,9845,9846,9847],{"trials":68778,"activeCount":97},[],{"trials":68780,"activeCount":97},[],{"trials":68782,"activeCount":97},[],{"trials":68784,"activeCount":97},[],{"intervention":68786,"totalTrials":417,"cells":68787},"Alprazolam 0.25 mg",{"EARLY_PHASE1":68788,"PHASE1":68790,"PHASE2":68799,"PHASE3":68801,"PHASE4":68803,"NA":68805},{"trials":68789,"activeCount":97},[],{"trials":68791,"activeCount":97},[68792],{"nctId":68793,"briefTitle":68794,"status":155,"phases":68795,"primaryCompletion":68796,"completion":68796,"start":29760,"enrollment":695,"conditions":68797,"interventions":68798},"NCT01853956","Bioequivalence Trial of Alprazolam 0.25 mg Tablets",[85],"2010-12-10",[63101],[68786,68786],{"trials":68800,"activeCount":97},[],{"trials":68802,"activeCount":97},[],{"trials":68804,"activeCount":97},[],{"trials":68806,"activeCount":97},[],{"intervention":44391,"totalTrials":417,"cells":68808},{"EARLY_PHASE1":68809,"PHASE1":68811,"PHASE2":68817,"PHASE3":68819,"PHASE4":68821,"NA":68823},{"trials":68810,"activeCount":97},[],{"trials":68812,"activeCount":97},[68813],{"nctId":44384,"briefTitle":44385,"status":155,"phases":68814,"primaryCompletion":1874,"completion":44387,"start":44388,"enrollment":27267,"conditions":68815,"interventions":68816},[85],[21],[44377,44391],{"trials":68818,"activeCount":97},[],{"trials":68820,"activeCount":97},[],{"trials":68822,"activeCount":97},[],{"trials":68824,"activeCount":97},[],{"intervention":68826,"totalTrials":417,"cells":68827},"GSK3352589",{"EARLY_PHASE1":68828,"PHASE1":68830,"PHASE2":68838,"PHASE3":68840,"PHASE4":68842,"NA":68844},{"trials":68829,"activeCount":97},[],{"trials":68831,"activeCount":97},[68832],{"nctId":68833,"briefTitle":68834,"status":155,"phases":68835,"primaryCompletion":18652,"completion":18652,"start":44357,"enrollment":37,"conditions":68836,"interventions":68837},"NCT03154086","A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers",[85],[5609],[68826],{"trials":68839,"activeCount":97},[],{"trials":68841,"activeCount":97},[],{"trials":68843,"activeCount":97},[],{"trials":68845,"activeCount":97},[],{"intervention":68847,"totalTrials":417,"cells":68848},"Firategrast immediate release",{"EARLY_PHASE1":68849,"PHASE1":68851,"PHASE2":68862,"PHASE3":68864,"PHASE4":68866,"NA":68868},{"trials":68850,"activeCount":97},[],{"trials":68852,"activeCount":97},[68853],{"nctId":68854,"briefTitle":68855,"status":155,"phases":68856,"primaryCompletion":3633,"completion":3633,"start":68857,"enrollment":12044,"conditions":68858,"interventions":68859},"NCT01416363","Healthy Volunteer Study Using 3 Different Formulations of Firategrast",[85],"2011-05-20",[39994],[68847,68860,68861],"Firategrast modified release","Firategrast gastro-retentive solution",{"trials":68863,"activeCount":97},[],{"trials":68865,"activeCount":97},[],{"trials":68867,"activeCount":97},[],{"trials":68869,"activeCount":97},[],{"intervention":68860,"totalTrials":417,"cells":68871},{"EARLY_PHASE1":68872,"PHASE1":68874,"PHASE2":68880,"PHASE3":68882,"PHASE4":68884,"NA":68886},{"trials":68873,"activeCount":97},[],{"trials":68875,"activeCount":97},[68876],{"nctId":68854,"briefTitle":68855,"status":155,"phases":68877,"primaryCompletion":3633,"completion":3633,"start":68857,"enrollment":12044,"conditions":68878,"interventions":68879},[85],[39994],[68847,68860,68861],{"trials":68881,"activeCount":97},[],{"trials":68883,"activeCount":97},[],{"trials":68885,"activeCount":97},[],{"trials":68887,"activeCount":97},[],{"intervention":68861,"totalTrials":417,"cells":68889},{"EARLY_PHASE1":68890,"PHASE1":68892,"PHASE2":68898,"PHASE3":68900,"PHASE4":68902,"NA":68904},{"trials":68891,"activeCount":97},[],{"trials":68893,"activeCount":97},[68894],{"nctId":68854,"briefTitle":68855,"status":155,"phases":68895,"primaryCompletion":3633,"completion":3633,"start":68857,"enrollment":12044,"conditions":68896,"interventions":68897},[85],[39994],[68847,68860,68861],{"trials":68899,"activeCount":97},[],{"trials":68901,"activeCount":97},[],{"trials":68903,"activeCount":97},[],{"trials":68905,"activeCount":97},[],{"intervention":61536,"totalTrials":417,"cells":68907},{"EARLY_PHASE1":68908,"PHASE1":68910,"PHASE2":68916,"PHASE3":68918,"PHASE4":68920,"NA":68922},{"trials":68909,"activeCount":97},[],{"trials":68911,"activeCount":97},[68912],{"nctId":61529,"briefTitle":61530,"status":155,"phases":68913,"primaryCompletion":61532,"completion":61532,"start":17206,"enrollment":1634,"conditions":68914,"interventions":68915},[85],[18],[61522,61535,61536],{"trials":68917,"activeCount":97},[],{"trials":68919,"activeCount":97},[],{"trials":68921,"activeCount":97},[],{"trials":68923,"activeCount":97},[],{"intervention":22063,"totalTrials":417,"cells":68925},{"EARLY_PHASE1":68926,"PHASE1":68928,"PHASE2":68934,"PHASE3":68936,"PHASE4":68938,"NA":68940},{"trials":68927,"activeCount":97},[],{"trials":68929,"activeCount":97},[68930],{"nctId":22054,"briefTitle":22055,"status":500,"phases":68931,"primaryCompletion":22057,"completion":22057,"start":22058,"enrollment":97,"conditions":68932,"interventions":68933},[85],[22060],[22062,22063],{"trials":68935,"activeCount":97},[],{"trials":68937,"activeCount":97},[],{"trials":68939,"activeCount":97},[],{"trials":68941,"activeCount":97},[],{"intervention":59343,"totalTrials":417,"cells":68943},{"EARLY_PHASE1":68944,"PHASE1":68946,"PHASE2":68952,"PHASE3":68954,"PHASE4":68956,"NA":68958},{"trials":68945,"activeCount":97},[],{"trials":68947,"activeCount":97},[68948],{"nctId":59337,"briefTitle":59338,"status":155,"phases":68949,"primaryCompletion":7531,"completion":7531,"start":59340,"enrollment":1459,"conditions":68950,"interventions":68951},[85],[39897],[59343,9325],{"trials":68953,"activeCount":97},[],{"trials":68955,"activeCount":97},[],{"trials":68957,"activeCount":97},[],{"trials":68959,"activeCount":97},[],{"intervention":1879,"totalTrials":417,"cells":68961},{"EARLY_PHASE1":68962,"PHASE1":68964,"PHASE2":68970,"PHASE3":68972,"PHASE4":68974,"NA":68976},{"trials":68963,"activeCount":97},[],{"trials":68965,"activeCount":97},[68966],{"nctId":1871,"briefTitle":1872,"status":155,"phases":68967,"primaryCompletion":1874,"completion":1874,"start":1875,"enrollment":361,"conditions":68968,"interventions":68969},[85],[1877],[140,1879,1880],{"trials":68971,"activeCount":97},[],{"trials":68973,"activeCount":97},[],{"trials":68975,"activeCount":97},[],{"trials":68977,"activeCount":97},[],{"intervention":1880,"totalTrials":417,"cells":68979},{"EARLY_PHASE1":68980,"PHASE1":68982,"PHASE2":68988,"PHASE3":68990,"PHASE4":68992,"NA":68994},{"trials":68981,"activeCount":97},[],{"trials":68983,"activeCount":97},[68984],{"nctId":1871,"briefTitle":1872,"status":155,"phases":68985,"primaryCompletion":1874,"completion":1874,"start":1875,"enrollment":361,"conditions":68986,"interventions":68987},[85],[1877],[140,1879,1880],{"trials":68989,"activeCount":97},[],{"trials":68991,"activeCount":97},[],{"trials":68993,"activeCount":97},[],{"trials":68995,"activeCount":97},[],{"intervention":68997,"totalTrials":417,"cells":68998},"Retigabine \u002F Ezogabine",{"EARLY_PHASE1":68999,"PHASE1":69001,"PHASE2":69010,"PHASE3":69012,"PHASE4":69014,"NA":69016},{"trials":69000,"activeCount":97},[],{"trials":69002,"activeCount":97},[69003],{"nctId":69004,"briefTitle":69005,"status":155,"phases":69006,"primaryCompletion":18535,"completion":18535,"start":69007,"enrollment":1720,"conditions":69008,"interventions":69009},"NCT01480609","Effect of Haemodialysis on the Pharmacokinetics of Ezogabine\u002FRetigabine and Its N-acetyl Metabolite",[85],"2011-11-30",[12518],[68997],{"trials":69011,"activeCount":97},[],{"trials":69013,"activeCount":97},[],{"trials":69015,"activeCount":97},[],{"trials":69017,"activeCount":97},[],{"intervention":69019,"totalTrials":417,"cells":69020},"HIV Vaccine 732462",{"EARLY_PHASE1":69021,"PHASE1":69023,"PHASE2":69032,"PHASE3":69034,"PHASE4":69036,"NA":69038},{"trials":69022,"activeCount":97},[],{"trials":69024,"activeCount":97},[69025],{"nctId":69026,"briefTitle":69027,"status":155,"phases":69028,"primaryCompletion":19192,"completion":19192,"start":69029,"enrollment":212,"conditions":69030,"interventions":69031},"NCT00814762","Safety of the HIV Vaccine 732462 in HIV Infected Subjects Aged 18 to 55 Years Old",[85],"2009-02-03",[3428],[69019],{"trials":69033,"activeCount":97},[],{"trials":69035,"activeCount":97},[],{"trials":69037,"activeCount":97},[],{"trials":69039,"activeCount":97},[],{"intervention":69041,"totalTrials":417,"cells":69042},"Daprodustat 2 mg",{"EARLY_PHASE1":69043,"PHASE1":69045,"PHASE2":69056,"PHASE3":69058,"PHASE4":69060,"NA":69062},{"trials":69044,"activeCount":97},[],{"trials":69046,"activeCount":97},[69047],{"nctId":69048,"briefTitle":69049,"status":155,"phases":69050,"primaryCompletion":69051,"completion":69051,"start":69052,"enrollment":6482,"conditions":69053,"interventions":69054},"NCT03493386","Daprodustat Bioequivalence and Food Effect Study",[85],"2018-06-09","2018-04-24",[17996],[69041,69055],"Daprodustat 4 mg",{"trials":69057,"activeCount":97},[],{"trials":69059,"activeCount":97},[],{"trials":69061,"activeCount":97},[],{"trials":69063,"activeCount":97},[],{"intervention":69055,"totalTrials":417,"cells":69065},{"EARLY_PHASE1":69066,"PHASE1":69068,"PHASE2":69074,"PHASE3":69076,"PHASE4":69078,"NA":69080},{"trials":69067,"activeCount":97},[],{"trials":69069,"activeCount":97},[69070],{"nctId":69048,"briefTitle":69049,"status":155,"phases":69071,"primaryCompletion":69051,"completion":69051,"start":69052,"enrollment":6482,"conditions":69072,"interventions":69073},[85],[17996],[69041,69055],{"trials":69075,"activeCount":97},[],{"trials":69077,"activeCount":97},[],{"trials":69079,"activeCount":97},[],{"trials":69081,"activeCount":97},[],{"intervention":69083,"totalTrials":417,"cells":69084},"Fluticasone Propionate\u002FSalmeterol Xinafoate DISKUS",{"EARLY_PHASE1":69085,"PHASE1":69087,"PHASE2":69096,"PHASE3":69098,"PHASE4":69100,"NA":69102},{"trials":69086,"activeCount":97},[],{"trials":69088,"activeCount":97},[69089],{"nctId":69090,"briefTitle":69091,"status":500,"phases":69092,"primaryCompletion":13584,"completion":13584,"start":22334,"enrollment":97,"conditions":69093,"interventions":69094},"NCT02218762","A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler",[85],[18],[69083,69095],"Fluticasone Propionate\u002FSalmeterol Xinafoate ROTACAPS",{"trials":69097,"activeCount":97},[],{"trials":69099,"activeCount":97},[],{"trials":69101,"activeCount":97},[],{"trials":69103,"activeCount":97},[],{"intervention":69095,"totalTrials":417,"cells":69105},{"EARLY_PHASE1":69106,"PHASE1":69108,"PHASE2":69114,"PHASE3":69116,"PHASE4":69118,"NA":69120},{"trials":69107,"activeCount":97},[],{"trials":69109,"activeCount":97},[69110],{"nctId":69090,"briefTitle":69091,"status":500,"phases":69111,"primaryCompletion":13584,"completion":13584,"start":22334,"enrollment":97,"conditions":69112,"interventions":69113},[85],[18],[69083,69095],{"trials":69115,"activeCount":97},[],{"trials":69117,"activeCount":97},[],{"trials":69119,"activeCount":97},[],{"trials":69121,"activeCount":97},[],{"intervention":60130,"totalTrials":417,"cells":69123},{"EARLY_PHASE1":69124,"PHASE1":69126,"PHASE2":69132,"PHASE3":69134,"PHASE4":69136,"NA":69138},{"trials":69125,"activeCount":97},[],{"trials":69127,"activeCount":97},[69128],{"nctId":60125,"briefTitle":60126,"status":155,"phases":69129,"primaryCompletion":6351,"completion":7658,"start":1429,"enrollment":656,"conditions":69130,"interventions":69131},[85],[7524],[60130,60118],{"trials":69133,"activeCount":97},[],{"trials":69135,"activeCount":97},[],{"trials":69137,"activeCount":97},[],{"trials":69139,"activeCount":97},[],{"intervention":69141,"totalTrials":417,"cells":69142},"Cefixime test",{"EARLY_PHASE1":69143,"PHASE1":69145,"PHASE2":69156,"PHASE3":69158,"PHASE4":69160,"NA":69162},{"trials":69144,"activeCount":97},[],{"trials":69146,"activeCount":97},[69147],{"nctId":69148,"briefTitle":69149,"status":500,"phases":69150,"primaryCompletion":69151,"completion":69151,"start":69152,"enrollment":97,"conditions":69153,"interventions":69154},"NCT03329547","A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulation in Healthy Adults Under Fasting Conditions",[85],"2018-02-02","2018-01-11",[6484],[69141,69155],"Cefixime reference",{"trials":69157,"activeCount":97},[],{"trials":69159,"activeCount":97},[],{"trials":69161,"activeCount":97},[],{"trials":69163,"activeCount":97},[],{"intervention":69155,"totalTrials":417,"cells":69165},{"EARLY_PHASE1":69166,"PHASE1":69168,"PHASE2":69174,"PHASE3":69176,"PHASE4":69178,"NA":69180},{"trials":69167,"activeCount":97},[],{"trials":69169,"activeCount":97},[69170],{"nctId":69148,"briefTitle":69149,"status":500,"phases":69171,"primaryCompletion":69151,"completion":69151,"start":69152,"enrollment":97,"conditions":69172,"interventions":69173},[85],[6484],[69141,69155],{"trials":69175,"activeCount":97},[],{"trials":69177,"activeCount":97},[],{"trials":69179,"activeCount":97},[],{"trials":69181,"activeCount":97},[],{"intervention":6506,"totalTrials":417,"cells":69183},{"EARLY_PHASE1":69184,"PHASE1":69186,"PHASE2":69192,"PHASE3":69194,"PHASE4":69196,"NA":69198},{"trials":69185,"activeCount":97},[],{"trials":69187,"activeCount":97},[69188],{"nctId":6498,"briefTitle":6499,"status":155,"phases":69189,"primaryCompletion":6501,"completion":6501,"start":6502,"enrollment":6503,"conditions":69190,"interventions":69191},[85],[6484],[6506,6507,6471],{"trials":69193,"activeCount":97},[],{"trials":69195,"activeCount":97},[],{"trials":69197,"activeCount":97},[],{"trials":69199,"activeCount":97},[],{"intervention":6507,"totalTrials":417,"cells":69201},{"EARLY_PHASE1":69202,"PHASE1":69204,"PHASE2":69210,"PHASE3":69212,"PHASE4":69214,"NA":69216},{"trials":69203,"activeCount":97},[],{"trials":69205,"activeCount":97},[69206],{"nctId":6498,"briefTitle":6499,"status":155,"phases":69207,"primaryCompletion":6501,"completion":6501,"start":6502,"enrollment":6503,"conditions":69208,"interventions":69209},[85],[6484],[6506,6507,6471],{"trials":69211,"activeCount":97},[],{"trials":69213,"activeCount":97},[],{"trials":69215,"activeCount":97},[],{"trials":69217,"activeCount":97},[],{"intervention":69219,"totalTrials":417,"cells":69220},"Candesartan Cilexetil in formulation 1",{"EARLY_PHASE1":69221,"PHASE1":69223,"PHASE2":69234,"PHASE3":69236,"PHASE4":69238,"NA":69240},{"trials":69222,"activeCount":97},[],{"trials":69224,"activeCount":97},[69225],{"nctId":69226,"briefTitle":69227,"status":155,"phases":69228,"primaryCompletion":59964,"completion":59964,"start":69229,"enrollment":1634,"conditions":69230,"interventions":69231},"NCT02254447","Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions",[85],"2014-12-02",[14279],[69219,69232,69233],"Candesartan Cilexetil in formulation 2","ATACAND",{"trials":69235,"activeCount":97},[],{"trials":69237,"activeCount":97},[],{"trials":69239,"activeCount":97},[],{"trials":69241,"activeCount":97},[],{"intervention":69232,"totalTrials":417,"cells":69243},{"EARLY_PHASE1":69244,"PHASE1":69246,"PHASE2":69252,"PHASE3":69254,"PHASE4":69256,"NA":69258},{"trials":69245,"activeCount":97},[],{"trials":69247,"activeCount":97},[69248],{"nctId":69226,"briefTitle":69227,"status":155,"phases":69249,"primaryCompletion":59964,"completion":59964,"start":69229,"enrollment":1634,"conditions":69250,"interventions":69251},[85],[14279],[69219,69232,69233],{"trials":69253,"activeCount":97},[],{"trials":69255,"activeCount":97},[],{"trials":69257,"activeCount":97},[],{"trials":69259,"activeCount":97},[],{"intervention":69233,"totalTrials":417,"cells":69261},{"EARLY_PHASE1":69262,"PHASE1":69264,"PHASE2":69270,"PHASE3":69272,"PHASE4":69274,"NA":69276},{"trials":69263,"activeCount":97},[],{"trials":69265,"activeCount":97},[69266],{"nctId":69226,"briefTitle":69227,"status":155,"phases":69267,"primaryCompletion":59964,"completion":59964,"start":69229,"enrollment":1634,"conditions":69268,"interventions":69269},[85],[14279],[69219,69232,69233],{"trials":69271,"activeCount":97},[],{"trials":69273,"activeCount":97},[],{"trials":69275,"activeCount":97},[],{"trials":69277,"activeCount":97},[],{"intervention":69279,"totalTrials":417,"cells":69280},"Investigational Medicinal Product",{"EARLY_PHASE1":69281,"PHASE1":69283,"PHASE2":69292,"PHASE3":69294,"PHASE4":69296,"NA":69298},{"trials":69282,"activeCount":97},[],{"trials":69284,"activeCount":97},[69285],{"nctId":69286,"briefTitle":69287,"status":155,"phases":69288,"primaryCompletion":589,"completion":589,"start":69289,"enrollment":710,"conditions":69290,"interventions":69291},"NCT01332513","An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine\u002FRetigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.",[85],"2011-02-10",[12518],[69279,69279,69279,69279,69279,69279],{"trials":69293,"activeCount":97},[],{"trials":69295,"activeCount":97},[],{"trials":69297,"activeCount":97},[],{"trials":69299,"activeCount":97},[],{"intervention":18472,"totalTrials":417,"cells":69301},{"EARLY_PHASE1":69302,"PHASE1":69304,"PHASE2":69310,"PHASE3":69312,"PHASE4":69314,"NA":69316},{"trials":69303,"activeCount":97},[],{"trials":69305,"activeCount":97},[69306],{"nctId":18465,"briefTitle":18466,"status":155,"phases":69307,"primaryCompletion":18468,"completion":18468,"start":18469,"enrollment":1298,"conditions":69308,"interventions":69309},[85],[15],[10797,18472],{"trials":69311,"activeCount":97},[],{"trials":69313,"activeCount":97},[],{"trials":69315,"activeCount":97},[],{"trials":69317,"activeCount":97},[],{"intervention":69319,"totalTrials":417,"cells":69320},"Paxil CR",{"EARLY_PHASE1":69321,"PHASE1":69323,"PHASE2":69332,"PHASE3":69334,"PHASE4":69336,"NA":69338},{"trials":69322,"activeCount":97},[],{"trials":69324,"activeCount":97},[69325],{"nctId":69326,"briefTitle":69327,"status":155,"phases":69328,"primaryCompletion":69329,"completion":69329,"start":8298,"enrollment":27223,"conditions":69330,"interventions":69331},"NCT00749359","PAXIL CR Bioequivalence Study",[85],"2008-09-16",[9292],[69319],{"trials":69333,"activeCount":97},[],{"trials":69335,"activeCount":97},[],{"trials":69337,"activeCount":97},[],{"trials":69339,"activeCount":97},[],{"intervention":69341,"totalTrials":417,"cells":69342},"1278863",{"EARLY_PHASE1":69343,"PHASE1":69345,"PHASE2":69354,"PHASE3":69356,"PHASE4":69358,"NA":69360},{"trials":69344,"activeCount":97},[],{"trials":69346,"activeCount":97},[69347],{"nctId":69348,"briefTitle":69349,"status":155,"phases":69350,"primaryCompletion":63281,"completion":63281,"start":69351,"enrollment":1298,"conditions":69352,"interventions":69353},"NCT00840320","Repeat Dose Safety Study for Compound to Treat Anemia",[85],"2009-03-13",[6452],[69341],{"trials":69355,"activeCount":97},[],{"trials":69357,"activeCount":97},[],{"trials":69359,"activeCount":97},[],{"trials":69361,"activeCount":97},[],{"intervention":44661,"totalTrials":417,"cells":69363},{"EARLY_PHASE1":69364,"PHASE1":69366,"PHASE2":69372,"PHASE3":69374,"PHASE4":69376,"NA":69378},{"trials":69365,"activeCount":97},[],{"trials":69367,"activeCount":97},[69368],{"nctId":44655,"briefTitle":44656,"status":155,"phases":69369,"primaryCompletion":23222,"completion":23222,"start":44658,"enrollment":1079,"conditions":69370,"interventions":69371},[85],[9319,107],[44648,44661,44662],{"trials":69373,"activeCount":97},[],{"trials":69375,"activeCount":97},[],{"trials":69377,"activeCount":97},[],{"trials":69379,"activeCount":97},[],{"intervention":44662,"totalTrials":417,"cells":69381},{"EARLY_PHASE1":69382,"PHASE1":69384,"PHASE2":69390,"PHASE3":69392,"PHASE4":69394,"NA":69396},{"trials":69383,"activeCount":97},[],{"trials":69385,"activeCount":97},[69386],{"nctId":44655,"briefTitle":44656,"status":155,"phases":69387,"primaryCompletion":23222,"completion":23222,"start":44658,"enrollment":1079,"conditions":69388,"interventions":69389},[85],[9319,107],[44648,44661,44662],{"trials":69391,"activeCount":97},[],{"trials":69393,"activeCount":97},[],{"trials":69395,"activeCount":97},[],{"trials":69397,"activeCount":97},[],{"intervention":69399,"totalTrials":417,"cells":69400},"CCI15106",{"EARLY_PHASE1":69401,"PHASE1":69403,"PHASE2":69413,"PHASE3":69415,"PHASE4":69417,"NA":69419},{"trials":69402,"activeCount":97},[],{"trials":69404,"activeCount":97},[69405],{"nctId":69406,"briefTitle":69407,"status":155,"phases":69408,"primaryCompletion":69409,"completion":69409,"start":69410,"enrollment":3025,"conditions":69411,"interventions":69412},"NCT03235726","Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug",[85],"2018-06-19","2017-07-13",[15],[69399],{"trials":69414,"activeCount":97},[],{"trials":69416,"activeCount":97},[],{"trials":69418,"activeCount":97},[],{"trials":69420,"activeCount":97},[],{"intervention":69422,"totalTrials":417,"cells":69423},"Formulation 1 (plain): NTHi\u002FMcat vaccine GSK3277513A",{"EARLY_PHASE1":69424,"PHASE1":69426,"PHASE2":69437,"PHASE3":69439,"PHASE4":69441,"NA":69443},{"trials":69425,"activeCount":97},[],{"trials":69427,"activeCount":97},[69428],{"nctId":69429,"briefTitle":69430,"status":155,"phases":69431,"primaryCompletion":39510,"completion":39510,"start":69432,"enrollment":201,"conditions":69433,"interventions":69434},"NCT02547974","A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.",[85],"2015-08-31",[9855],[69422,69435,69436],"Formulation 2 (adjuvanted): NTHi\u002FMcat vaccine GSK3277513A","Formulation 3 (adjuvanted): NTHi\u002FMcat vaccine GSK3339036A",{"trials":69438,"activeCount":97},[],{"trials":69440,"activeCount":97},[],{"trials":69442,"activeCount":97},[],{"trials":69444,"activeCount":97},[],{"intervention":69435,"totalTrials":417,"cells":69446},{"EARLY_PHASE1":69447,"PHASE1":69449,"PHASE2":69455,"PHASE3":69457,"PHASE4":69459,"NA":69461},{"trials":69448,"activeCount":97},[],{"trials":69450,"activeCount":97},[69451],{"nctId":69429,"briefTitle":69430,"status":155,"phases":69452,"primaryCompletion":39510,"completion":39510,"start":69432,"enrollment":201,"conditions":69453,"interventions":69454},[85],[9855],[69422,69435,69436],{"trials":69456,"activeCount":97},[],{"trials":69458,"activeCount":97},[],{"trials":69460,"activeCount":97},[],{"trials":69462,"activeCount":97},[],{"intervention":69436,"totalTrials":417,"cells":69464},{"EARLY_PHASE1":69465,"PHASE1":69467,"PHASE2":69473,"PHASE3":69475,"PHASE4":69477,"NA":69479},{"trials":69466,"activeCount":97},[],{"trials":69468,"activeCount":97},[69469],{"nctId":69429,"briefTitle":69430,"status":155,"phases":69470,"primaryCompletion":39510,"completion":39510,"start":69432,"enrollment":201,"conditions":69471,"interventions":69472},[85],[9855],[69422,69435,69436],{"trials":69474,"activeCount":97},[],{"trials":69476,"activeCount":97},[],{"trials":69478,"activeCount":97},[],{"trials":69480,"activeCount":97},[],{"intervention":69482,"totalTrials":417,"cells":69483},"GSK3342830",{"EARLY_PHASE1":69484,"PHASE1":69486,"PHASE2":69496,"PHASE3":69498,"PHASE4":69500,"NA":69502},{"trials":69485,"activeCount":97},[],{"trials":69487,"activeCount":97},[69488],{"nctId":69489,"briefTitle":69490,"status":145,"phases":69491,"primaryCompletion":69492,"completion":69492,"start":69493,"enrollment":234,"conditions":69494,"interventions":69495},"NCT02751424","A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830",[85],"2017-02-02","2016-06-13",[6484],[69482],{"trials":69497,"activeCount":97},[],{"trials":69499,"activeCount":97},[],{"trials":69501,"activeCount":97},[],{"trials":69503,"activeCount":97},[],{"intervention":69505,"totalTrials":417,"cells":69506},"GSK1550188 IV",{"EARLY_PHASE1":69507,"PHASE1":69509,"PHASE2":69520,"PHASE3":69522,"PHASE4":69524,"NA":69526},{"trials":69508,"activeCount":97},[],{"trials":69510,"activeCount":97},[69511],{"nctId":69512,"briefTitle":69513,"status":155,"phases":69514,"primaryCompletion":69515,"completion":69515,"start":69516,"enrollment":433,"conditions":69517,"interventions":69518},"NCT01516450","Japanese phase1 Study of Belimumab (IV vs SC)",[85],"2012-04-11","2011-12-26",[435],[69505,69519],"GSK1550188 SC",{"trials":69521,"activeCount":97},[],{"trials":69523,"activeCount":97},[],{"trials":69525,"activeCount":97},[],{"trials":69527,"activeCount":97},[],{"intervention":69519,"totalTrials":417,"cells":69529},{"EARLY_PHASE1":69530,"PHASE1":69532,"PHASE2":69538,"PHASE3":69540,"PHASE4":69542,"NA":69544},{"trials":69531,"activeCount":97},[],{"trials":69533,"activeCount":97},[69534],{"nctId":69512,"briefTitle":69513,"status":155,"phases":69535,"primaryCompletion":69515,"completion":69515,"start":69516,"enrollment":433,"conditions":69536,"interventions":69537},[85],[435],[69505,69519],{"trials":69539,"activeCount":97},[],{"trials":69541,"activeCount":97},[],{"trials":69543,"activeCount":97},[],{"trials":69545,"activeCount":97},[],{"intervention":69547,"totalTrials":417,"cells":69548},"Minocycline 100mg",{"EARLY_PHASE1":69549,"PHASE1":69551,"PHASE2":69562,"PHASE3":69564,"PHASE4":69566,"NA":69568},{"trials":69550,"activeCount":97},[],{"trials":69552,"activeCount":97},[69553],{"nctId":69554,"briefTitle":69555,"status":155,"phases":69556,"primaryCompletion":69557,"completion":69557,"start":69558,"enrollment":463,"conditions":69559,"interventions":69561},"NCT01755611","Bioequivalence Minocycline Bioequivalence",[85],"2011-06-25","2011-06-17",[69560],"Skin Infections (Acne)",[69547,69547],{"trials":69563,"activeCount":97},[],{"trials":69565,"activeCount":97},[],{"trials":69567,"activeCount":97},[],{"trials":69569,"activeCount":97},[],{"intervention":69571,"totalTrials":417,"cells":69572},"Trametinib pediatric formulation",{"EARLY_PHASE1":69573,"PHASE1":69575,"PHASE2":69583,"PHASE3":69585,"PHASE4":69587,"NA":69589},{"trials":69574,"activeCount":97},[],{"trials":69576,"activeCount":97},[69577],{"nctId":69578,"briefTitle":69579,"status":155,"phases":69580,"primaryCompletion":4721,"completion":4721,"start":63952,"enrollment":1634,"conditions":69581,"interventions":69582},"NCT01647659","Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation",[85],[36],[3048,69571],{"trials":69584,"activeCount":97},[],{"trials":69586,"activeCount":97},[],{"trials":69588,"activeCount":97},[],{"trials":69590,"activeCount":97},[],{"intervention":69592,"totalTrials":417,"cells":69593},"GR121167 Solution",{"EARLY_PHASE1":69594,"PHASE1":69596,"PHASE2":69606,"PHASE3":69608,"PHASE4":69610,"NA":69612},{"trials":69595,"activeCount":97},[],{"trials":69597,"activeCount":97},[69598],{"nctId":69599,"briefTitle":69600,"status":155,"phases":69601,"primaryCompletion":69602,"completion":69602,"start":69603,"enrollment":1634,"conditions":69604,"interventions":69605},"NCT01428479","Phase1 Study of GR121167, Single and Multiple Dose Study in Healthy Japanese Males",[85],"2011-04-04","2011-01-07",[5353],[69592],{"trials":69607,"activeCount":97},[],{"trials":69609,"activeCount":97},[],{"trials":69611,"activeCount":97},[],{"trials":69613,"activeCount":97},[],{"intervention":26279,"totalTrials":417,"cells":69615},{"EARLY_PHASE1":69616,"PHASE1":69618,"PHASE2":69624,"PHASE3":69626,"PHASE4":69628,"NA":69630},{"trials":69617,"activeCount":97},[],{"trials":69619,"activeCount":97},[69620],{"nctId":26272,"briefTitle":26273,"status":155,"phases":69621,"primaryCompletion":26275,"completion":26275,"start":26276,"enrollment":6482,"conditions":69622,"interventions":69623},[85],[15087],[26279,26265],{"trials":69625,"activeCount":97},[],{"trials":69627,"activeCount":97},[],{"trials":69629,"activeCount":97},[],{"trials":69631,"activeCount":97},[],{"intervention":69633,"totalTrials":417,"cells":69634},"GSK2376497",{"EARLY_PHASE1":69635,"PHASE1":69637,"PHASE2":69648,"PHASE3":69650,"PHASE4":69652,"NA":69654},{"trials":69636,"activeCount":97},[],{"trials":69638,"activeCount":97},[69639],{"nctId":69640,"briefTitle":69641,"status":155,"phases":69642,"primaryCompletion":69643,"completion":69643,"start":69644,"enrollment":11953,"conditions":69645,"interventions":69646},"NCT01545570","A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers",[85],"2012-12-23","2011-11-07",[27],[69633,69647],"0.9% sodium chloride",{"trials":69649,"activeCount":97},[],{"trials":69651,"activeCount":97},[],{"trials":69653,"activeCount":97},[],{"trials":69655,"activeCount":97},[],{"intervention":69647,"totalTrials":417,"cells":69657},{"EARLY_PHASE1":69658,"PHASE1":69660,"PHASE2":69666,"PHASE3":69668,"PHASE4":69670,"NA":69672},{"trials":69659,"activeCount":97},[],{"trials":69661,"activeCount":97},[69662],{"nctId":69640,"briefTitle":69641,"status":155,"phases":69663,"primaryCompletion":69643,"completion":69643,"start":69644,"enrollment":11953,"conditions":69664,"interventions":69665},[85],[27],[69633,69647],{"trials":69667,"activeCount":97},[],{"trials":69669,"activeCount":97},[],{"trials":69671,"activeCount":97},[],{"trials":69673,"activeCount":97},[],{"intervention":69675,"totalTrials":417,"cells":69676},"GSK3858279 IV",{"EARLY_PHASE1":69677,"PHASE1":69679,"PHASE2":69689,"PHASE3":69691,"PHASE4":69693,"NA":69695},{"trials":69678,"activeCount":97},[],{"trials":69680,"activeCount":97},[69681],{"nctId":69682,"briefTitle":69683,"status":155,"phases":69684,"primaryCompletion":47,"completion":47,"start":69685,"enrollment":105,"conditions":69686,"interventions":69687},"NCT03485365","A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement (TE) Study of GSK3858279 in Healthy Participants and Evaluation of the Efficacy of Repeat Doses in Participants With Osteoarthritis (OA)",[85],"2018-05-17",[60205],[69675,69688],"GSK3858279 SC",{"trials":69690,"activeCount":97},[],{"trials":69692,"activeCount":97},[],{"trials":69694,"activeCount":97},[],{"trials":69696,"activeCount":97},[],{"intervention":69688,"totalTrials":417,"cells":69698},{"EARLY_PHASE1":69699,"PHASE1":69701,"PHASE2":69707,"PHASE3":69709,"PHASE4":69711,"NA":69713},{"trials":69700,"activeCount":97},[],{"trials":69702,"activeCount":97},[69703],{"nctId":69682,"briefTitle":69683,"status":155,"phases":69704,"primaryCompletion":47,"completion":47,"start":69685,"enrollment":105,"conditions":69705,"interventions":69706},[85],[60205],[69675,69688],{"trials":69708,"activeCount":97},[],{"trials":69710,"activeCount":97},[],{"trials":69712,"activeCount":97},[],{"trials":69714,"activeCount":97},[],{"intervention":61716,"totalTrials":417,"cells":69716},{"EARLY_PHASE1":69717,"PHASE1":69719,"PHASE2":69725,"PHASE3":69727,"PHASE4":69729,"NA":69731},{"trials":69718,"activeCount":97},[],{"trials":69720,"activeCount":97},[69721],{"nctId":61709,"briefTitle":61710,"status":155,"phases":69722,"primaryCompletion":61712,"completion":61712,"start":61713,"enrollment":1634,"conditions":69723,"interventions":69724},[85],[9855],[61702,61716,61717],{"trials":69726,"activeCount":97},[],{"trials":69728,"activeCount":97},[],{"trials":69730,"activeCount":97},[],{"trials":69732,"activeCount":97},[],{"intervention":61717,"totalTrials":417,"cells":69734},{"EARLY_PHASE1":69735,"PHASE1":69737,"PHASE2":69743,"PHASE3":69745,"PHASE4":69747,"NA":69749},{"trials":69736,"activeCount":97},[],{"trials":69738,"activeCount":97},[69739],{"nctId":61709,"briefTitle":61710,"status":155,"phases":69740,"primaryCompletion":61712,"completion":61712,"start":61713,"enrollment":1634,"conditions":69741,"interventions":69742},[85],[9855],[61702,61716,61717],{"trials":69744,"activeCount":97},[],{"trials":69746,"activeCount":97},[],{"trials":69748,"activeCount":97},[],{"trials":69750,"activeCount":97},[],{"intervention":69752,"totalTrials":417,"cells":69753},"GSK716155 for",{"EARLY_PHASE1":69754,"PHASE1":69756,"PHASE2":69765,"PHASE3":69767,"PHASE4":69769,"NA":69771},{"trials":69755,"activeCount":97},[],{"trials":69757,"activeCount":97},[69758],{"nctId":69759,"briefTitle":69760,"status":155,"phases":69761,"primaryCompletion":69762,"completion":69762,"start":10332,"enrollment":345,"conditions":69763,"interventions":69764},"NCT00530309","Clinical Assessment of GSK716155 for Type 2 Diabetes Mellitus",[85],"2008-04-17",[27],[69752],{"trials":69766,"activeCount":97},[],{"trials":69768,"activeCount":97},[],{"trials":69770,"activeCount":97},[],{"trials":69772,"activeCount":97},[],{"intervention":40721,"totalTrials":417,"cells":69774},{"EARLY_PHASE1":69775,"PHASE1":69777,"PHASE2":69783,"PHASE3":69785,"PHASE4":69787,"NA":69789},{"trials":69776,"activeCount":97},[],{"trials":69778,"activeCount":97},[69779],{"nctId":40716,"briefTitle":40717,"status":500,"phases":69780,"primaryCompletion":7711,"completion":7711,"start":8860,"enrollment":97,"conditions":69781,"interventions":69782},[85],[6484],[40702,40721,40722,40723],{"trials":69784,"activeCount":97},[],{"trials":69786,"activeCount":97},[],{"trials":69788,"activeCount":97},[],{"trials":69790,"activeCount":97},[],{"intervention":40723,"totalTrials":417,"cells":69792},{"EARLY_PHASE1":69793,"PHASE1":69795,"PHASE2":69801,"PHASE3":69803,"PHASE4":69805,"NA":69807},{"trials":69794,"activeCount":97},[],{"trials":69796,"activeCount":97},[69797],{"nctId":40716,"briefTitle":40717,"status":500,"phases":69798,"primaryCompletion":7711,"completion":7711,"start":8860,"enrollment":97,"conditions":69799,"interventions":69800},[85],[6484],[40702,40721,40722,40723],{"trials":69802,"activeCount":97},[],{"trials":69804,"activeCount":97},[],{"trials":69806,"activeCount":97},[],{"trials":69808,"activeCount":97},[],{"intervention":69810,"totalTrials":417,"cells":69811},"Fluticasone Propionate \u002F Salmeterol Xinafoate DISKUS",{"EARLY_PHASE1":69812,"PHASE1":69814,"PHASE2":69824,"PHASE3":69826,"PHASE4":69828,"NA":69830},{"trials":69813,"activeCount":97},[],{"trials":69815,"activeCount":97},[69816],{"nctId":69817,"briefTitle":69818,"status":155,"phases":69819,"primaryCompletion":69820,"completion":69820,"start":33790,"enrollment":710,"conditions":69821,"interventions":69822},"NCT01890863","ROTAHALER Device Optimization Study",[85],"2013-09-30",[18],[69810,69823],"Fluticasone Propionate \u002F Salmeterol Xinafoate ROTACAP",{"trials":69825,"activeCount":97},[],{"trials":69827,"activeCount":97},[],{"trials":69829,"activeCount":97},[],{"trials":69831,"activeCount":97},[],{"intervention":69823,"totalTrials":417,"cells":69833},{"EARLY_PHASE1":69834,"PHASE1":69836,"PHASE2":69842,"PHASE3":69844,"PHASE4":69846,"NA":69848},{"trials":69835,"activeCount":97},[],{"trials":69837,"activeCount":97},[69838],{"nctId":69817,"briefTitle":69818,"status":155,"phases":69839,"primaryCompletion":69820,"completion":69820,"start":33790,"enrollment":710,"conditions":69840,"interventions":69841},[85],[18],[69810,69823],{"trials":69843,"activeCount":97},[],{"trials":69845,"activeCount":97},[],{"trials":69847,"activeCount":97},[],{"trials":69849,"activeCount":97},[],{"intervention":9165,"totalTrials":417,"cells":69851},{"EARLY_PHASE1":69852,"PHASE1":69854,"PHASE2":69860,"PHASE3":69862,"PHASE4":69864,"NA":69866},{"trials":69853,"activeCount":97},[],{"trials":69855,"activeCount":97},[69856],{"nctId":9156,"briefTitle":9157,"status":155,"phases":69857,"primaryCompletion":9159,"completion":9159,"start":8468,"enrollment":473,"conditions":69858,"interventions":69859},[85],[9161],[4763,9163,9164,9165,9166],{"trials":69861,"activeCount":97},[],{"trials":69863,"activeCount":97},[],{"trials":69865,"activeCount":97},[],{"trials":69867,"activeCount":97},[],{"intervention":9166,"totalTrials":417,"cells":69869},{"EARLY_PHASE1":69870,"PHASE1":69872,"PHASE2":69878,"PHASE3":69880,"PHASE4":69882,"NA":69884},{"trials":69871,"activeCount":97},[],{"trials":69873,"activeCount":97},[69874],{"nctId":9156,"briefTitle":9157,"status":155,"phases":69875,"primaryCompletion":9159,"completion":9159,"start":8468,"enrollment":473,"conditions":69876,"interventions":69877},[85],[9161],[4763,9163,9164,9165,9166],{"trials":69879,"activeCount":97},[],{"trials":69881,"activeCount":97},[],{"trials":69883,"activeCount":97},[],{"trials":69885,"activeCount":97},[],{"intervention":69887,"totalTrials":417,"cells":69888},"GSK610677",{"EARLY_PHASE1":69889,"PHASE1":69891,"PHASE2":69899,"PHASE3":69901,"PHASE4":69903,"NA":69905},{"trials":69890,"activeCount":97},[],{"trials":69892,"activeCount":97},[69893],{"nctId":69894,"briefTitle":69895,"status":155,"phases":69896,"primaryCompletion":10368,"completion":10368,"start":8741,"enrollment":1298,"conditions":69897,"interventions":69898},"NCT00694902","Single Dose Escalation Study FTIM in Order to Assess Safety and Tolerability of GSK610677",[85],[15],[69887],{"trials":69900,"activeCount":97},[],{"trials":69902,"activeCount":97},[],{"trials":69904,"activeCount":97},[],{"trials":69906,"activeCount":97},[],{"intervention":69908,"totalTrials":417,"cells":69909},"GSK587323",{"EARLY_PHASE1":69910,"PHASE1":69912,"PHASE2":69923,"PHASE3":69925,"PHASE4":69927,"NA":69929},{"trials":69911,"activeCount":97},[],{"trials":69913,"activeCount":97},[69914],{"nctId":69915,"briefTitle":69916,"status":155,"phases":69917,"primaryCompletion":69918,"completion":69918,"start":69919,"enrollment":433,"conditions":69920,"interventions":69921},"NCT02094924","A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323",[85],"2014-05-23","2014-04-17",[13024],[69908,69922],"FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg",{"trials":69924,"activeCount":97},[],{"trials":69926,"activeCount":97},[],{"trials":69928,"activeCount":97},[],{"trials":69930,"activeCount":97},[],{"intervention":69922,"totalTrials":417,"cells":69932},{"EARLY_PHASE1":69933,"PHASE1":69935,"PHASE2":69941,"PHASE3":69943,"PHASE4":69945,"NA":69947},{"trials":69934,"activeCount":97},[],{"trials":69936,"activeCount":97},[69937],{"nctId":69915,"briefTitle":69916,"status":155,"phases":69938,"primaryCompletion":69918,"completion":69918,"start":69919,"enrollment":433,"conditions":69939,"interventions":69940},[85],[13024],[69908,69922],{"trials":69942,"activeCount":97},[],{"trials":69944,"activeCount":97},[],{"trials":69946,"activeCount":97},[],{"trials":69948,"activeCount":97},[],{"intervention":69950,"totalTrials":417,"cells":69951},"IM oxytocin 10 IU",{"EARLY_PHASE1":69952,"PHASE1":69954,"PHASE2":69968,"PHASE3":69970,"PHASE4":69972,"NA":69974},{"trials":69953,"activeCount":97},[],{"trials":69955,"activeCount":97},[69956],{"nctId":69957,"briefTitle":69958,"status":155,"phases":69959,"primaryCompletion":69960,"completion":69960,"start":69961,"enrollment":433,"conditions":69962,"interventions":69963},"NCT02542813","Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers",[85],"2015-12-16","2015-09-14",[66680],[69950,69964,69965,69966,69967],"IH oxytocin 50 mcg","IH oxytocin 200 mcg","IH oxytocin 400 mcg","IH oxytocin 600 mcg",{"trials":69969,"activeCount":97},[],{"trials":69971,"activeCount":97},[],{"trials":69973,"activeCount":97},[],{"trials":69975,"activeCount":97},[],{"intervention":69964,"totalTrials":417,"cells":69977},{"EARLY_PHASE1":69978,"PHASE1":69980,"PHASE2":69986,"PHASE3":69988,"PHASE4":69990,"NA":69992},{"trials":69979,"activeCount":97},[],{"trials":69981,"activeCount":97},[69982],{"nctId":69957,"briefTitle":69958,"status":155,"phases":69983,"primaryCompletion":69960,"completion":69960,"start":69961,"enrollment":433,"conditions":69984,"interventions":69985},[85],[66680],[69950,69964,69965,69966,69967],{"trials":69987,"activeCount":97},[],{"trials":69989,"activeCount":97},[],{"trials":69991,"activeCount":97},[],{"trials":69993,"activeCount":97},[],{"intervention":69965,"totalTrials":417,"cells":69995},{"EARLY_PHASE1":69996,"PHASE1":69998,"PHASE2":70004,"PHASE3":70006,"PHASE4":70008,"NA":70010},{"trials":69997,"activeCount":97},[],{"trials":69999,"activeCount":97},[70000],{"nctId":69957,"briefTitle":69958,"status":155,"phases":70001,"primaryCompletion":69960,"completion":69960,"start":69961,"enrollment":433,"conditions":70002,"interventions":70003},[85],[66680],[69950,69964,69965,69966,69967],{"trials":70005,"activeCount":97},[],{"trials":70007,"activeCount":97},[],{"trials":70009,"activeCount":97},[],{"trials":70011,"activeCount":97},[],{"intervention":69966,"totalTrials":417,"cells":70013},{"EARLY_PHASE1":70014,"PHASE1":70016,"PHASE2":70022,"PHASE3":70024,"PHASE4":70026,"NA":70028},{"trials":70015,"activeCount":97},[],{"trials":70017,"activeCount":97},[70018],{"nctId":69957,"briefTitle":69958,"status":155,"phases":70019,"primaryCompletion":69960,"completion":69960,"start":69961,"enrollment":433,"conditions":70020,"interventions":70021},[85],[66680],[69950,69964,69965,69966,69967],{"trials":70023,"activeCount":97},[],{"trials":70025,"activeCount":97},[],{"trials":70027,"activeCount":97},[],{"trials":70029,"activeCount":97},[],{"intervention":69967,"totalTrials":417,"cells":70031},{"EARLY_PHASE1":70032,"PHASE1":70034,"PHASE2":70040,"PHASE3":70042,"PHASE4":70044,"NA":70046},{"trials":70033,"activeCount":97},[],{"trials":70035,"activeCount":97},[70036],{"nctId":69957,"briefTitle":69958,"status":155,"phases":70037,"primaryCompletion":69960,"completion":69960,"start":69961,"enrollment":433,"conditions":70038,"interventions":70039},[85],[66680],[69950,69964,69965,69966,69967],{"trials":70041,"activeCount":97},[],{"trials":70043,"activeCount":97},[],{"trials":70045,"activeCount":97},[],{"trials":70047,"activeCount":97},[],{"intervention":70049,"totalTrials":417,"cells":70050},"GSK189075A",{"EARLY_PHASE1":70051,"PHASE1":70053,"PHASE2":70061,"PHASE3":70063,"PHASE4":70065,"NA":70067},{"trials":70052,"activeCount":97},[],{"trials":70054,"activeCount":97},[70055],{"nctId":70056,"briefTitle":70057,"status":155,"phases":70058,"primaryCompletion":10803,"completion":10803,"start":2823,"enrollment":433,"conditions":70059,"interventions":70060},"NCT01571661","A First-time-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of GSK189075A in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus",[85],[27],[70049],{"trials":70062,"activeCount":97},[],{"trials":70064,"activeCount":97},[],{"trials":70066,"activeCount":97},[],{"trials":70068,"activeCount":97},[],{"intervention":70070,"totalTrials":417,"cells":70071},"Isotretinoin: Reference Medication 1",{"EARLY_PHASE1":70072,"PHASE1":70074,"PHASE2":70085,"PHASE3":70087,"PHASE4":70089,"NA":70091},{"trials":70073,"activeCount":97},[],{"trials":70075,"activeCount":97},[70076],{"nctId":70077,"briefTitle":70078,"status":155,"phases":70079,"primaryCompletion":4984,"completion":4984,"start":70080,"enrollment":710,"conditions":70081,"interventions":70082},"NCT02498288","A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition",[85],"2013-05-31",[15087],[70070,70083,70084],"Isotretinoin: Reference Medication 2","Isotretinoin: Test Medication",{"trials":70086,"activeCount":97},[],{"trials":70088,"activeCount":97},[],{"trials":70090,"activeCount":97},[],{"trials":70092,"activeCount":97},[],{"intervention":70083,"totalTrials":417,"cells":70094},{"EARLY_PHASE1":70095,"PHASE1":70097,"PHASE2":70103,"PHASE3":70105,"PHASE4":70107,"NA":70109},{"trials":70096,"activeCount":97},[],{"trials":70098,"activeCount":97},[70099],{"nctId":70077,"briefTitle":70078,"status":155,"phases":70100,"primaryCompletion":4984,"completion":4984,"start":70080,"enrollment":710,"conditions":70101,"interventions":70102},[85],[15087],[70070,70083,70084],{"trials":70104,"activeCount":97},[],{"trials":70106,"activeCount":97},[],{"trials":70108,"activeCount":97},[],{"trials":70110,"activeCount":97},[],{"intervention":70084,"totalTrials":417,"cells":70112},{"EARLY_PHASE1":70113,"PHASE1":70115,"PHASE2":70121,"PHASE3":70123,"PHASE4":70125,"NA":70127},{"trials":70114,"activeCount":97},[],{"trials":70116,"activeCount":97},[70117],{"nctId":70077,"briefTitle":70078,"status":155,"phases":70118,"primaryCompletion":4984,"completion":4984,"start":70080,"enrollment":710,"conditions":70119,"interventions":70120},[85],[15087],[70070,70083,70084],{"trials":70122,"activeCount":97},[],{"trials":70124,"activeCount":97},[],{"trials":70126,"activeCount":97},[],{"trials":70128,"activeCount":97},[],{"intervention":70130,"totalTrials":417,"cells":70131},"GSK2618960",{"EARLY_PHASE1":70132,"PHASE1":70134,"PHASE2":70143,"PHASE3":70145,"PHASE4":70147,"NA":70149},{"trials":70133,"activeCount":97},[],{"trials":70135,"activeCount":97},[70136],{"nctId":70137,"briefTitle":70138,"status":155,"phases":70139,"primaryCompletion":70140,"completion":70140,"start":18911,"enrollment":1634,"conditions":70141,"interventions":70142},"NCT02293161","Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers",[85],"2015-09-01",[39897],[70130],{"trials":70144,"activeCount":97},[],{"trials":70146,"activeCount":97},[],{"trials":70148,"activeCount":97},[],{"trials":70150,"activeCount":97},[],{"intervention":70152,"totalTrials":417,"cells":70153},"Bupropion HCl XL tablet 150mg",{"EARLY_PHASE1":70154,"PHASE1":70156,"PHASE2":70166,"PHASE3":70168,"PHASE4":70170,"NA":70172},{"trials":70155,"activeCount":97},[],{"trials":70157,"activeCount":97},[70158],{"nctId":70159,"briefTitle":70160,"status":155,"phases":70161,"primaryCompletion":2910,"completion":2910,"start":70162,"enrollment":433,"conditions":70163,"interventions":70164},"NCT02698553","A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers",[85],"2016-05-23",[10889],[70152,70165],"Bupropion HCl XL tablet 300mg",{"trials":70167,"activeCount":97},[],{"trials":70169,"activeCount":97},[],{"trials":70171,"activeCount":97},[],{"trials":70173,"activeCount":97},[],{"intervention":70165,"totalTrials":417,"cells":70175},{"EARLY_PHASE1":70176,"PHASE1":70178,"PHASE2":70184,"PHASE3":70186,"PHASE4":70188,"NA":70190},{"trials":70177,"activeCount":97},[],{"trials":70179,"activeCount":97},[70180],{"nctId":70159,"briefTitle":70160,"status":155,"phases":70181,"primaryCompletion":2910,"completion":2910,"start":70162,"enrollment":433,"conditions":70182,"interventions":70183},[85],[10889],[70152,70165],{"trials":70185,"activeCount":97},[],{"trials":70187,"activeCount":97},[],{"trials":70189,"activeCount":97},[],{"trials":70191,"activeCount":97},[],{"intervention":70193,"totalTrials":417,"cells":70194},"FF, 50 mcg",{"EARLY_PHASE1":70195,"PHASE1":70197,"PHASE2":70210,"PHASE3":70212,"PHASE4":70214,"NA":70216},{"trials":70196,"activeCount":97},[],{"trials":70198,"activeCount":97},[70199],{"nctId":70200,"briefTitle":70201,"status":155,"phases":70202,"primaryCompletion":70203,"completion":70203,"start":70204,"enrollment":710,"conditions":70205,"interventions":70206},"NCT01669070","A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)",[85],"2012-11-16","2012-08-15",[18],[70193,70207,70208,70209],"FF, 100 mcg","FF, 200 mcg","FF, 250 mcg",{"trials":70211,"activeCount":97},[],{"trials":70213,"activeCount":97},[],{"trials":70215,"activeCount":97},[],{"trials":70217,"activeCount":97},[],{"intervention":70207,"totalTrials":417,"cells":70219},{"EARLY_PHASE1":70220,"PHASE1":70222,"PHASE2":70228,"PHASE3":70230,"PHASE4":70232,"NA":70234},{"trials":70221,"activeCount":97},[],{"trials":70223,"activeCount":97},[70224],{"nctId":70200,"briefTitle":70201,"status":155,"phases":70225,"primaryCompletion":70203,"completion":70203,"start":70204,"enrollment":710,"conditions":70226,"interventions":70227},[85],[18],[70193,70207,70208,70209],{"trials":70229,"activeCount":97},[],{"trials":70231,"activeCount":97},[],{"trials":70233,"activeCount":97},[],{"trials":70235,"activeCount":97},[],{"intervention":70208,"totalTrials":417,"cells":70237},{"EARLY_PHASE1":70238,"PHASE1":70240,"PHASE2":70246,"PHASE3":70248,"PHASE4":70250,"NA":70252},{"trials":70239,"activeCount":97},[],{"trials":70241,"activeCount":97},[70242],{"nctId":70200,"briefTitle":70201,"status":155,"phases":70243,"primaryCompletion":70203,"completion":70203,"start":70204,"enrollment":710,"conditions":70244,"interventions":70245},[85],[18],[70193,70207,70208,70209],{"trials":70247,"activeCount":97},[],{"trials":70249,"activeCount":97},[],{"trials":70251,"activeCount":97},[],{"trials":70253,"activeCount":97},[],{"intervention":70209,"totalTrials":417,"cells":70255},{"EARLY_PHASE1":70256,"PHASE1":70258,"PHASE2":70264,"PHASE3":70266,"PHASE4":70268,"NA":70270},{"trials":70257,"activeCount":97},[],{"trials":70259,"activeCount":97},[70260],{"nctId":70200,"briefTitle":70201,"status":155,"phases":70261,"primaryCompletion":70203,"completion":70203,"start":70204,"enrollment":710,"conditions":70262,"interventions":70263},[85],[18],[70193,70207,70208,70209],{"trials":70265,"activeCount":97},[],{"trials":70267,"activeCount":97},[],{"trials":70269,"activeCount":97},[],{"trials":70271,"activeCount":97},[],{"intervention":70273,"totalTrials":417,"cells":70274},"GSK2820151",{"EARLY_PHASE1":70275,"PHASE1":70277,"PHASE2":70286,"PHASE3":70288,"PHASE4":70290,"NA":70292},{"trials":70276,"activeCount":97},[],{"trials":70278,"activeCount":97},[70279],{"nctId":70280,"briefTitle":70281,"status":145,"phases":70282,"primaryCompletion":70283,"completion":70283,"start":23213,"enrollment":1517,"conditions":70284,"interventions":70285},"NCT02630251","Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors",[85],"2018-12-13",[36,107],[70273],{"trials":70287,"activeCount":97},[],{"trials":70289,"activeCount":97},[],{"trials":70291,"activeCount":97},[],{"trials":70293,"activeCount":97},[],{"intervention":70295,"totalTrials":417,"cells":70296},"ropinirole dosing for up to 28 days",{"EARLY_PHASE1":70297,"PHASE1":70299,"PHASE2":70307,"PHASE3":70309,"PHASE4":70311,"NA":70313},{"trials":70298,"activeCount":97},[],{"trials":70300,"activeCount":97},[70301],{"nctId":70302,"briefTitle":70303,"status":155,"phases":70304,"primaryCompletion":7659,"completion":7659,"start":4844,"enrollment":6503,"conditions":70305,"interventions":70306},"NCT00422994","A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole",[85],[14255],[70295],{"trials":70308,"activeCount":97},[],{"trials":70310,"activeCount":97},[],{"trials":70312,"activeCount":97},[],{"trials":70314,"activeCount":97},[],{"intervention":70316,"totalTrials":417,"cells":70317},"HSVTI Formulation 1",{"EARLY_PHASE1":70318,"PHASE1":70320,"PHASE2":70332,"PHASE3":70334,"PHASE4":70336,"NA":70338},{"trials":70319,"activeCount":97},[],{"trials":70321,"activeCount":97},[70322],{"nctId":70323,"briefTitle":70324,"status":155,"phases":70325,"primaryCompletion":70326,"completion":70327,"start":70328,"enrollment":1003,"conditions":70329,"interventions":70330},"NCT05989672","A Study on the Reactogenicity, Safety and Immune Response of a Targeted Immunotherapy Against HSV in Healthy Japanese Participants Aged 18-40 Years",[85],"2023-11-29","2024-04-24","2023-08-08",[8709],[70316,70331],"HSVTI Formulation 2",{"trials":70333,"activeCount":97},[],{"trials":70335,"activeCount":97},[],{"trials":70337,"activeCount":97},[],{"trials":70339,"activeCount":97},[],{"intervention":70331,"totalTrials":417,"cells":70341},{"EARLY_PHASE1":70342,"PHASE1":70344,"PHASE2":70350,"PHASE3":70352,"PHASE4":70354,"NA":70356},{"trials":70343,"activeCount":97},[],{"trials":70345,"activeCount":97},[70346],{"nctId":70323,"briefTitle":70324,"status":155,"phases":70347,"primaryCompletion":70326,"completion":70327,"start":70328,"enrollment":1003,"conditions":70348,"interventions":70349},[85],[8709],[70316,70331],{"trials":70351,"activeCount":97},[],{"trials":70353,"activeCount":97},[],{"trials":70355,"activeCount":97},[],{"trials":70357,"activeCount":97},[],{"intervention":70359,"totalTrials":417,"cells":70360},"escitalopram 10 mg",{"EARLY_PHASE1":70361,"PHASE1":70363,"PHASE2":70371,"PHASE3":70373,"PHASE4":70375,"NA":70377},{"trials":70362,"activeCount":97},[],{"trials":70364,"activeCount":97},[70365],{"nctId":70366,"briefTitle":70367,"status":155,"phases":70368,"primaryCompletion":41638,"completion":41638,"start":18124,"enrollment":93,"conditions":70369,"interventions":70370},"NCT01745601","Bioequivalence Study of Escitalopram Tablets 10 mg",[85],[63101],[70359,70359],{"trials":70372,"activeCount":97},[],{"trials":70374,"activeCount":97},[],{"trials":70376,"activeCount":97},[],{"trials":70378,"activeCount":97},[],{"intervention":70380,"totalTrials":417,"cells":70381},"GSK2292767 50 μg",{"EARLY_PHASE1":70382,"PHASE1":70384,"PHASE2":70394,"PHASE3":70396,"PHASE4":70398,"NA":70400},{"trials":70383,"activeCount":97},[],{"trials":70385,"activeCount":97},[70386],{"nctId":70387,"briefTitle":70388,"status":155,"phases":70389,"primaryCompletion":31709,"completion":70390,"start":3310,"enrollment":12044,"conditions":70391,"interventions":70392},"NCT03045887","Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes",[85],"2017-08-16",[18],[70380,70393],"GSK2292767 500 μg",{"trials":70395,"activeCount":97},[],{"trials":70397,"activeCount":97},[],{"trials":70399,"activeCount":97},[],{"trials":70401,"activeCount":97},[],{"intervention":70393,"totalTrials":417,"cells":70403},{"EARLY_PHASE1":70404,"PHASE1":70406,"PHASE2":70412,"PHASE3":70414,"PHASE4":70416,"NA":70418},{"trials":70405,"activeCount":97},[],{"trials":70407,"activeCount":97},[70408],{"nctId":70387,"briefTitle":70388,"status":155,"phases":70409,"primaryCompletion":31709,"completion":70390,"start":3310,"enrollment":12044,"conditions":70410,"interventions":70411},[85],[18],[70380,70393],{"trials":70413,"activeCount":97},[],{"trials":70415,"activeCount":97},[],{"trials":70417,"activeCount":97},[],{"trials":70419,"activeCount":97},[],{"intervention":18373,"totalTrials":417,"cells":70421},{"EARLY_PHASE1":70422,"PHASE1":70424,"PHASE2":70430,"PHASE3":70432,"PHASE4":70434,"NA":70436},{"trials":70423,"activeCount":97},[],{"trials":70425,"activeCount":97},[70426],{"nctId":18366,"briefTitle":18367,"status":155,"phases":70427,"primaryCompletion":18369,"completion":18369,"start":18370,"enrollment":414,"conditions":70428,"interventions":70429},[85],[15],[8022,18373,18345,18374],{"trials":70431,"activeCount":97},[],{"trials":70433,"activeCount":97},[],{"trials":70435,"activeCount":97},[],{"trials":70437,"activeCount":97},[],{"intervention":18374,"totalTrials":417,"cells":70439},{"EARLY_PHASE1":70440,"PHASE1":70442,"PHASE2":70448,"PHASE3":70450,"PHASE4":70452,"NA":70454},{"trials":70441,"activeCount":97},[],{"trials":70443,"activeCount":97},[70444],{"nctId":18366,"briefTitle":18367,"status":155,"phases":70445,"primaryCompletion":18369,"completion":18369,"start":18370,"enrollment":414,"conditions":70446,"interventions":70447},[85],[15],[8022,18373,18345,18374],{"trials":70449,"activeCount":97},[],{"trials":70451,"activeCount":97},[],{"trials":70453,"activeCount":97},[],{"trials":70455,"activeCount":97},[],{"intervention":22737,"totalTrials":417,"cells":70457},{"EARLY_PHASE1":70458,"PHASE1":70460,"PHASE2":70466,"PHASE3":70468,"PHASE4":70470,"NA":70472},{"trials":70459,"activeCount":97},[],{"trials":70461,"activeCount":97},[70462],{"nctId":22729,"briefTitle":22730,"status":155,"phases":70463,"primaryCompletion":22732,"completion":22733,"start":20266,"enrollment":6814,"conditions":70464,"interventions":70465},[85],[22735],[22737,22738,8653],{"trials":70467,"activeCount":97},[],{"trials":70469,"activeCount":97},[],{"trials":70471,"activeCount":97},[],{"trials":70473,"activeCount":97},[],{"intervention":22738,"totalTrials":417,"cells":70475},{"EARLY_PHASE1":70476,"PHASE1":70478,"PHASE2":70484,"PHASE3":70486,"PHASE4":70488,"NA":70490},{"trials":70477,"activeCount":97},[],{"trials":70479,"activeCount":97},[70480],{"nctId":22729,"briefTitle":22730,"status":155,"phases":70481,"primaryCompletion":22732,"completion":22733,"start":20266,"enrollment":6814,"conditions":70482,"interventions":70483},[85],[22735],[22737,22738,8653],{"trials":70485,"activeCount":97},[],{"trials":70487,"activeCount":97},[],{"trials":70489,"activeCount":97},[],{"trials":70491,"activeCount":97},[],{"intervention":23454,"totalTrials":417,"cells":70493},{"EARLY_PHASE1":70494,"PHASE1":70496,"PHASE2":70502,"PHASE3":70504,"PHASE4":70506,"NA":70508},{"trials":70495,"activeCount":97},[],{"trials":70497,"activeCount":97},[70498],{"nctId":23447,"briefTitle":23448,"status":155,"phases":70499,"primaryCompletion":23450,"completion":23450,"start":23451,"enrollment":1117,"conditions":70500,"interventions":70501},[85],[22060],[23454,23455,23456,23457,12069,23458],{"trials":70503,"activeCount":97},[],{"trials":70505,"activeCount":97},[],{"trials":70507,"activeCount":97},[],{"trials":70509,"activeCount":97},[],{"intervention":23455,"totalTrials":417,"cells":70511},{"EARLY_PHASE1":70512,"PHASE1":70514,"PHASE2":70520,"PHASE3":70522,"PHASE4":70524,"NA":70526},{"trials":70513,"activeCount":97},[],{"trials":70515,"activeCount":97},[70516],{"nctId":23447,"briefTitle":23448,"status":155,"phases":70517,"primaryCompletion":23450,"completion":23450,"start":23451,"enrollment":1117,"conditions":70518,"interventions":70519},[85],[22060],[23454,23455,23456,23457,12069,23458],{"trials":70521,"activeCount":97},[],{"trials":70523,"activeCount":97},[],{"trials":70525,"activeCount":97},[],{"trials":70527,"activeCount":97},[],{"intervention":23456,"totalTrials":417,"cells":70529},{"EARLY_PHASE1":70530,"PHASE1":70532,"PHASE2":70538,"PHASE3":70540,"PHASE4":70542,"NA":70544},{"trials":70531,"activeCount":97},[],{"trials":70533,"activeCount":97},[70534],{"nctId":23447,"briefTitle":23448,"status":155,"phases":70535,"primaryCompletion":23450,"completion":23450,"start":23451,"enrollment":1117,"conditions":70536,"interventions":70537},[85],[22060],[23454,23455,23456,23457,12069,23458],{"trials":70539,"activeCount":97},[],{"trials":70541,"activeCount":97},[],{"trials":70543,"activeCount":97},[],{"trials":70545,"activeCount":97},[],{"intervention":23457,"totalTrials":417,"cells":70547},{"EARLY_PHASE1":70548,"PHASE1":70550,"PHASE2":70556,"PHASE3":70558,"PHASE4":70560,"NA":70562},{"trials":70549,"activeCount":97},[],{"trials":70551,"activeCount":97},[70552],{"nctId":23447,"briefTitle":23448,"status":155,"phases":70553,"primaryCompletion":23450,"completion":23450,"start":23451,"enrollment":1117,"conditions":70554,"interventions":70555},[85],[22060],[23454,23455,23456,23457,12069,23458],{"trials":70557,"activeCount":97},[],{"trials":70559,"activeCount":97},[],{"trials":70561,"activeCount":97},[],{"trials":70563,"activeCount":97},[],{"intervention":23458,"totalTrials":417,"cells":70565},{"EARLY_PHASE1":70566,"PHASE1":70568,"PHASE2":70574,"PHASE3":70576,"PHASE4":70578,"NA":70580},{"trials":70567,"activeCount":97},[],{"trials":70569,"activeCount":97},[70570],{"nctId":23447,"briefTitle":23448,"status":155,"phases":70571,"primaryCompletion":23450,"completion":23450,"start":23451,"enrollment":1117,"conditions":70572,"interventions":70573},[85],[22060],[23454,23455,23456,23457,12069,23458],{"trials":70575,"activeCount":97},[],{"trials":70577,"activeCount":97},[],{"trials":70579,"activeCount":97},[],{"trials":70581,"activeCount":97},[],{"intervention":70583,"totalTrials":417,"cells":70584},"SB 480848,",{"EARLY_PHASE1":70585,"PHASE1":70587,"PHASE2":70595,"PHASE3":70597,"PHASE4":70599,"NA":70601},{"trials":70586,"activeCount":97},[],{"trials":70588,"activeCount":97},[70589],{"nctId":70590,"briefTitle":70591,"status":155,"phases":70592,"primaryCompletion":8426,"completion":8426,"start":2296,"enrollment":613,"conditions":70593,"interventions":70594},"NCT00368576","A Study To Determine The Effect Of SB-480848 On Asthma",[85],[9309],[70583],{"trials":70596,"activeCount":97},[],{"trials":70598,"activeCount":97},[],{"trials":70600,"activeCount":97},[],{"trials":70602,"activeCount":97},[],{"intervention":42574,"totalTrials":417,"cells":70604},{"EARLY_PHASE1":70605,"PHASE1":70607,"PHASE2":70613,"PHASE3":70615,"PHASE4":70617,"NA":70619},{"trials":70606,"activeCount":97},[],{"trials":70608,"activeCount":97},[70609],{"nctId":42568,"briefTitle":42569,"status":155,"phases":70610,"primaryCompletion":19267,"completion":19267,"start":42571,"enrollment":1298,"conditions":70611,"interventions":70612},[85],[39848],[42561,42574],{"trials":70614,"activeCount":97},[],{"trials":70616,"activeCount":97},[],{"trials":70618,"activeCount":97},[],{"trials":70620,"activeCount":97},[],{"intervention":70622,"totalTrials":417,"cells":70623},"3 mg\u002Fkg GSK2402968",{"EARLY_PHASE1":70624,"PHASE1":70626,"PHASE2":70638,"PHASE3":70640,"PHASE4":70642,"NA":70644},{"trials":70625,"activeCount":97},[],{"trials":70627,"activeCount":97},[70628],{"nctId":70629,"briefTitle":70630,"status":155,"phases":70631,"primaryCompletion":70632,"completion":70632,"start":10633,"enrollment":454,"conditions":70633,"interventions":70634},"NCT01128855","A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects",[85],"2011-10-25",[25854],[70622,70635,70636,70637],"6 mg\u002Fkg GSK2402968","9 mg\u002Fkg GSK2402968","12 mg\u002Fkg GSK2402968",{"trials":70639,"activeCount":97},[],{"trials":70641,"activeCount":97},[],{"trials":70643,"activeCount":97},[],{"trials":70645,"activeCount":97},[],{"intervention":70635,"totalTrials":417,"cells":70647},{"EARLY_PHASE1":70648,"PHASE1":70650,"PHASE2":70656,"PHASE3":70658,"PHASE4":70660,"NA":70662},{"trials":70649,"activeCount":97},[],{"trials":70651,"activeCount":97},[70652],{"nctId":70629,"briefTitle":70630,"status":155,"phases":70653,"primaryCompletion":70632,"completion":70632,"start":10633,"enrollment":454,"conditions":70654,"interventions":70655},[85],[25854],[70622,70635,70636,70637],{"trials":70657,"activeCount":97},[],{"trials":70659,"activeCount":97},[],{"trials":70661,"activeCount":97},[],{"trials":70663,"activeCount":97},[],{"intervention":70636,"totalTrials":417,"cells":70665},{"EARLY_PHASE1":70666,"PHASE1":70668,"PHASE2":70674,"PHASE3":70676,"PHASE4":70678,"NA":70680},{"trials":70667,"activeCount":97},[],{"trials":70669,"activeCount":97},[70670],{"nctId":70629,"briefTitle":70630,"status":155,"phases":70671,"primaryCompletion":70632,"completion":70632,"start":10633,"enrollment":454,"conditions":70672,"interventions":70673},[85],[25854],[70622,70635,70636,70637],{"trials":70675,"activeCount":97},[],{"trials":70677,"activeCount":97},[],{"trials":70679,"activeCount":97},[],{"trials":70681,"activeCount":97},[],{"intervention":70637,"totalTrials":417,"cells":70683},{"EARLY_PHASE1":70684,"PHASE1":70686,"PHASE2":70692,"PHASE3":70694,"PHASE4":70696,"NA":70698},{"trials":70685,"activeCount":97},[],{"trials":70687,"activeCount":97},[70688],{"nctId":70629,"briefTitle":70630,"status":155,"phases":70689,"primaryCompletion":70632,"completion":70632,"start":10633,"enrollment":454,"conditions":70690,"interventions":70691},[85],[25854],[70622,70635,70636,70637],{"trials":70693,"activeCount":97},[],{"trials":70695,"activeCount":97},[],{"trials":70697,"activeCount":97},[],{"trials":70699,"activeCount":97},[],{"intervention":61972,"totalTrials":417,"cells":70701},{"EARLY_PHASE1":70702,"PHASE1":70704,"PHASE2":70710,"PHASE3":70712,"PHASE4":70714,"NA":70716},{"trials":70703,"activeCount":97},[],{"trials":70705,"activeCount":97},[70706],{"nctId":61965,"briefTitle":61966,"status":155,"phases":70707,"primaryCompletion":61968,"completion":61968,"start":61969,"enrollment":2836,"conditions":70708,"interventions":70709},[85],[15],[61958,61972],{"trials":70711,"activeCount":97},[],{"trials":70713,"activeCount":97},[],{"trials":70715,"activeCount":97},[],{"trials":70717,"activeCount":97},[],{"intervention":61595,"totalTrials":417,"cells":70719},{"EARLY_PHASE1":70720,"PHASE1":70722,"PHASE2":70728,"PHASE3":70730,"PHASE4":70732,"NA":70734},{"trials":70721,"activeCount":97},[],{"trials":70723,"activeCount":97},[70724],{"nctId":61589,"briefTitle":61590,"status":155,"phases":70725,"primaryCompletion":21927,"completion":21927,"start":61592,"enrollment":9334,"conditions":70726,"interventions":70727},[85],[11346],[61576,61595],{"trials":70729,"activeCount":97},[],{"trials":70731,"activeCount":97},[],{"trials":70733,"activeCount":97},[],{"trials":70735,"activeCount":97},[],{"intervention":26462,"totalTrials":417,"cells":70737},{"EARLY_PHASE1":70738,"PHASE1":70740,"PHASE2":70746,"PHASE3":70748,"PHASE4":70750,"NA":70752},{"trials":70739,"activeCount":97},[],{"trials":70741,"activeCount":97},[70742],{"nctId":26454,"briefTitle":26455,"status":155,"phases":70743,"primaryCompletion":26457,"completion":26458,"start":26459,"enrollment":23263,"conditions":70744,"interventions":70745},[85],[21],[26462,26463,26447,26464],{"trials":70747,"activeCount":97},[],{"trials":70749,"activeCount":97},[],{"trials":70751,"activeCount":97},[],{"trials":70753,"activeCount":97},[],{"intervention":26463,"totalTrials":417,"cells":70755},{"EARLY_PHASE1":70756,"PHASE1":70758,"PHASE2":70764,"PHASE3":70766,"PHASE4":70768,"NA":70770},{"trials":70757,"activeCount":97},[],{"trials":70759,"activeCount":97},[70760],{"nctId":26454,"briefTitle":26455,"status":155,"phases":70761,"primaryCompletion":26457,"completion":26458,"start":26459,"enrollment":23263,"conditions":70762,"interventions":70763},[85],[21],[26462,26463,26447,26464],{"trials":70765,"activeCount":97},[],{"trials":70767,"activeCount":97},[],{"trials":70769,"activeCount":97},[],{"trials":70771,"activeCount":97},[],{"intervention":70773,"totalTrials":417,"cells":70774},"GSK573719 62.5 mcg",{"EARLY_PHASE1":70775,"PHASE1":70777,"PHASE2":70787,"PHASE3":70789,"PHASE4":70791,"NA":70793},{"trials":70776,"activeCount":97},[],{"trials":70778,"activeCount":97},[70779],{"nctId":70780,"briefTitle":70781,"status":155,"phases":70782,"primaryCompletion":70783,"completion":70783,"start":40034,"enrollment":1117,"conditions":70784,"interventions":70785},"NCT01521390","Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.",[85],"2011-12-16",[15],[70773,70773,70786,70786],"GSK573719 125 mcg",{"trials":70788,"activeCount":97},[],{"trials":70790,"activeCount":97},[],{"trials":70792,"activeCount":97},[],{"trials":70794,"activeCount":97},[],{"intervention":70786,"totalTrials":417,"cells":70796},{"EARLY_PHASE1":70797,"PHASE1":70799,"PHASE2":70805,"PHASE3":70807,"PHASE4":70809,"NA":70811},{"trials":70798,"activeCount":97},[],{"trials":70800,"activeCount":97},[70801],{"nctId":70780,"briefTitle":70781,"status":155,"phases":70802,"primaryCompletion":70783,"completion":70783,"start":40034,"enrollment":1117,"conditions":70803,"interventions":70804},[85],[15],[70773,70773,70786,70786],{"trials":70806,"activeCount":97},[],{"trials":70808,"activeCount":97},[],{"trials":70810,"activeCount":97},[],{"trials":70812,"activeCount":97},[],{"intervention":70814,"totalTrials":417,"cells":70815},"Lamotrigine Dispersible\u002FChewable tablets 5mg*5",{"EARLY_PHASE1":70816,"PHASE1":70818,"PHASE2":70829,"PHASE3":70831,"PHASE4":70833,"NA":70835},{"trials":70817,"activeCount":97},[],{"trials":70819,"activeCount":97},[70820],{"nctId":70821,"briefTitle":70822,"status":155,"phases":70823,"primaryCompletion":70824,"completion":70824,"start":70825,"enrollment":1298,"conditions":70826,"interventions":70827},"NCT01879423","The Bioequivalence Study of Lamotrigine Dispersible\u002FChewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects",[85],"2013-06-06","2013-04-28",[12518],[70814,70828],"Lamotrigine Compressed tablet 25mg",{"trials":70830,"activeCount":97},[],{"trials":70832,"activeCount":97},[],{"trials":70834,"activeCount":97},[],{"trials":70836,"activeCount":97},[],{"intervention":70828,"totalTrials":417,"cells":70838},{"EARLY_PHASE1":70839,"PHASE1":70841,"PHASE2":70847,"PHASE3":70849,"PHASE4":70851,"NA":70853},{"trials":70840,"activeCount":97},[],{"trials":70842,"activeCount":97},[70843],{"nctId":70821,"briefTitle":70822,"status":155,"phases":70844,"primaryCompletion":70824,"completion":70824,"start":70825,"enrollment":1298,"conditions":70845,"interventions":70846},[85],[12518],[70814,70828],{"trials":70848,"activeCount":97},[],{"trials":70850,"activeCount":97},[],{"trials":70852,"activeCount":97},[],{"trials":70854,"activeCount":97},[],{"intervention":41366,"totalTrials":417,"cells":70856},{"EARLY_PHASE1":70857,"PHASE1":70859,"PHASE2":70865,"PHASE3":70867,"PHASE4":70869,"NA":70871},{"trials":70858,"activeCount":97},[],{"trials":70860,"activeCount":97},[70861],{"nctId":41361,"briefTitle":41362,"status":500,"phases":70862,"primaryCompletion":34933,"completion":34933,"start":3551,"enrollment":97,"conditions":70863,"interventions":70864},[85],[18],[41354,41366,41367,41368,41369],{"trials":70866,"activeCount":97},[],{"trials":70868,"activeCount":97},[],{"trials":70870,"activeCount":97},[],{"trials":70872,"activeCount":97},[],{"intervention":41369,"totalTrials":417,"cells":70874},{"EARLY_PHASE1":70875,"PHASE1":70877,"PHASE2":70883,"PHASE3":70885,"PHASE4":70887,"NA":70889},{"trials":70876,"activeCount":97},[],{"trials":70878,"activeCount":97},[70879],{"nctId":41361,"briefTitle":41362,"status":500,"phases":70880,"primaryCompletion":34933,"completion":34933,"start":3551,"enrollment":97,"conditions":70881,"interventions":70882},[85],[18],[41354,41366,41367,41368,41369],{"trials":70884,"activeCount":97},[],{"trials":70886,"activeCount":97},[],{"trials":70888,"activeCount":97},[],{"trials":70890,"activeCount":97},[],{"intervention":70892,"totalTrials":417,"cells":70893},"digoxin plus albiglutide",{"EARLY_PHASE1":70894,"PHASE1":70896,"PHASE2":70905,"PHASE3":70907,"PHASE4":70909,"NA":70911},{"trials":70895,"activeCount":97},[],{"trials":70897,"activeCount":97},[70898],{"nctId":70899,"briefTitle":70900,"status":155,"phases":70901,"primaryCompletion":26459,"completion":26459,"start":70902,"enrollment":255,"conditions":70903,"interventions":70904},"NCT01147718","A Drug Interaction Study of Albiglutide and Digoxin",[85],"2010-06-11",[27],[70892],{"trials":70906,"activeCount":97},[],{"trials":70908,"activeCount":97},[],{"trials":70910,"activeCount":97},[],{"trials":70912,"activeCount":97},[],{"intervention":62023,"totalTrials":417,"cells":70914},{"EARLY_PHASE1":70915,"PHASE1":70917,"PHASE2":70923,"PHASE3":70925,"PHASE4":70927,"NA":70929},{"trials":70916,"activeCount":97},[],{"trials":70918,"activeCount":97},[70919],{"nctId":62017,"briefTitle":62018,"status":155,"phases":70920,"primaryCompletion":40712,"completion":40712,"start":62020,"enrollment":656,"conditions":70921,"interventions":70922},[85],[27],[62010,62010,62023,62024],{"trials":70924,"activeCount":97},[],{"trials":70926,"activeCount":97},[],{"trials":70928,"activeCount":97},[],{"trials":70930,"activeCount":97},[],{"intervention":62024,"totalTrials":417,"cells":70932},{"EARLY_PHASE1":70933,"PHASE1":70935,"PHASE2":70941,"PHASE3":70943,"PHASE4":70945,"NA":70947},{"trials":70934,"activeCount":97},[],{"trials":70936,"activeCount":97},[70937],{"nctId":62017,"briefTitle":62018,"status":155,"phases":70938,"primaryCompletion":40712,"completion":40712,"start":62020,"enrollment":656,"conditions":70939,"interventions":70940},[85],[27],[62010,62010,62023,62024],{"trials":70942,"activeCount":97},[],{"trials":70944,"activeCount":97},[],{"trials":70946,"activeCount":97},[],{"trials":70948,"activeCount":97},[],{"intervention":70950,"totalTrials":417,"cells":70951},"CV0501",{"EARLY_PHASE1":70952,"PHASE1":70954,"PHASE2":70963,"PHASE3":70965,"PHASE4":70967,"NA":70969},{"trials":70953,"activeCount":97},[],{"trials":70955,"activeCount":97},[70956],{"nctId":70957,"briefTitle":70958,"status":155,"phases":70959,"primaryCompletion":70960,"completion":70960,"start":3587,"enrollment":7991,"conditions":70961,"interventions":70962},"NCT05477186","Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old",[85],"2023-08-18",[12437,54443],[70950,70950,70950,70950,70950,70950,70950],{"trials":70964,"activeCount":97},[],{"trials":70966,"activeCount":97},[],{"trials":70968,"activeCount":97},[],{"trials":70970,"activeCount":97},[],{"intervention":70972,"totalTrials":417,"cells":70973},"GSK3368715",{"EARLY_PHASE1":70974,"PHASE1":70976,"PHASE2":70984,"PHASE3":70986,"PHASE4":70988,"NA":70990},{"trials":70975,"activeCount":97},[],{"trials":70977,"activeCount":97},[70978],{"nctId":70979,"briefTitle":70980,"status":145,"phases":70981,"primaryCompletion":4418,"completion":4418,"start":57012,"enrollment":3379,"conditions":70982,"interventions":70983},"NCT03666988","First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)",[85],[107],[70972,70972],{"trials":70985,"activeCount":97},[],{"trials":70987,"activeCount":97},[],{"trials":70989,"activeCount":97},[],{"trials":70991,"activeCount":97},[],{"intervention":7509,"totalTrials":417,"cells":70993},{"EARLY_PHASE1":70994,"PHASE1":70996,"PHASE2":71002,"PHASE3":71004,"PHASE4":71006,"NA":71008},{"trials":70995,"activeCount":97},[],{"trials":70997,"activeCount":97},[70998],{"nctId":7502,"briefTitle":7503,"status":155,"phases":70999,"primaryCompletion":7505,"completion":7505,"start":7506,"enrollment":1459,"conditions":71000,"interventions":71001},[85],[668],[2300,7509],{"trials":71003,"activeCount":97},[],{"trials":71005,"activeCount":97},[],{"trials":71007,"activeCount":97},[],{"trials":71009,"activeCount":97},[],{"intervention":71011,"totalTrials":417,"cells":71012},"Diltiazem",{"EARLY_PHASE1":71013,"PHASE1":71015,"PHASE2":71023,"PHASE3":71025,"PHASE4":71027,"NA":71029},{"trials":71014,"activeCount":97},[],{"trials":71016,"activeCount":97},[71017],{"nctId":71018,"briefTitle":71019,"status":155,"phases":71020,"primaryCompletion":69820,"completion":69820,"start":18873,"enrollment":710,"conditions":71021,"interventions":71022},"NCT01852565","Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).",[85],[9309],[9311,71011],{"trials":71024,"activeCount":97},[],{"trials":71026,"activeCount":97},[],{"trials":71028,"activeCount":97},[],{"trials":71030,"activeCount":97},[],{"intervention":71032,"totalTrials":417,"cells":71033},"Follicular Lymphoma",{"EARLY_PHASE1":71034,"PHASE1":71036,"PHASE2":71045,"PHASE3":71047,"PHASE4":71049,"NA":71051},{"trials":71035,"activeCount":97},[],{"trials":71037,"activeCount":97},[71038],{"nctId":71039,"briefTitle":71040,"status":155,"phases":71041,"primaryCompletion":19408,"completion":55853,"start":71042,"enrollment":1117,"conditions":71043,"interventions":71044},"NCT00315731","A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma",[85],"2003-03-31",[3554],[71032],{"trials":71046,"activeCount":97},[],{"trials":71048,"activeCount":97},[],{"trials":71050,"activeCount":97},[],{"trials":71052,"activeCount":97},[],{"intervention":45116,"totalTrials":417,"cells":71054},{"EARLY_PHASE1":71055,"PHASE1":71057,"PHASE2":71063,"PHASE3":71065,"PHASE4":71067,"NA":71069},{"trials":71056,"activeCount":97},[],{"trials":71058,"activeCount":97},[71059],{"nctId":45111,"briefTitle":45112,"status":155,"phases":71060,"primaryCompletion":9812,"completion":9812,"start":11851,"enrollment":454,"conditions":71061,"interventions":71062},[85],[21691],[45104,45116,45117],{"trials":71064,"activeCount":97},[],{"trials":71066,"activeCount":97},[],{"trials":71068,"activeCount":97},[],{"trials":71070,"activeCount":97},[],{"intervention":45117,"totalTrials":417,"cells":71072},{"EARLY_PHASE1":71073,"PHASE1":71075,"PHASE2":71081,"PHASE3":71083,"PHASE4":71085,"NA":71087},{"trials":71074,"activeCount":97},[],{"trials":71076,"activeCount":97},[71077],{"nctId":45111,"briefTitle":45112,"status":155,"phases":71078,"primaryCompletion":9812,"completion":9812,"start":11851,"enrollment":454,"conditions":71079,"interventions":71080},[85],[21691],[45104,45116,45117],{"trials":71082,"activeCount":97},[],{"trials":71084,"activeCount":97},[],{"trials":71086,"activeCount":97},[],{"trials":71088,"activeCount":97},[],{"intervention":71090,"totalTrials":417,"cells":71091},"Investigational H7N9 vaccine GSK3277510A",{"EARLY_PHASE1":71092,"PHASE1":71094,"PHASE2":71103,"PHASE3":71105,"PHASE4":71107,"NA":71109},{"trials":71093,"activeCount":97},[],{"trials":71095,"activeCount":97},[71096],{"nctId":71097,"briefTitle":71098,"status":500,"phases":71099,"primaryCompletion":8540,"completion":6824,"start":19326,"enrollment":97,"conditions":71100,"interventions":71101},"NCT02177734","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age",[85],[21],[71090,71102],"Investigational H7N9 vaccine GSK3277509A",{"trials":71104,"activeCount":97},[],{"trials":71106,"activeCount":97},[],{"trials":71108,"activeCount":97},[],{"trials":71110,"activeCount":97},[],{"intervention":71102,"totalTrials":417,"cells":71112},{"EARLY_PHASE1":71113,"PHASE1":71115,"PHASE2":71121,"PHASE3":71123,"PHASE4":71125,"NA":71127},{"trials":71114,"activeCount":97},[],{"trials":71116,"activeCount":97},[71117],{"nctId":71097,"briefTitle":71098,"status":500,"phases":71118,"primaryCompletion":8540,"completion":6824,"start":19326,"enrollment":97,"conditions":71119,"interventions":71120},[85],[21],[71090,71102],{"trials":71122,"activeCount":97},[],{"trials":71124,"activeCount":97},[],{"trials":71126,"activeCount":97},[],{"trials":71128,"activeCount":97},[],{"intervention":71130,"totalTrials":417,"cells":71131},"GSK961081 800 microgram dose",{"EARLY_PHASE1":71132,"PHASE1":71134,"PHASE2":71146,"PHASE3":71148,"PHASE4":71150,"NA":71152},{"trials":71133,"activeCount":97},[],{"trials":71135,"activeCount":97},[71136],{"nctId":71137,"briefTitle":71138,"status":155,"phases":71139,"primaryCompletion":71140,"completion":71140,"start":51846,"enrollment":1298,"conditions":71141,"interventions":71142},"NCT01449799","An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers",[85],"2011-09-21",[15],[71130,71143,71144,71145],"Fluticasone Propionate 500 microgram dose","GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately","GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend",{"trials":71147,"activeCount":97},[],{"trials":71149,"activeCount":97},[],{"trials":71151,"activeCount":97},[],{"trials":71153,"activeCount":97},[],{"intervention":71143,"totalTrials":417,"cells":71155},{"EARLY_PHASE1":71156,"PHASE1":71158,"PHASE2":71164,"PHASE3":71166,"PHASE4":71168,"NA":71170},{"trials":71157,"activeCount":97},[],{"trials":71159,"activeCount":97},[71160],{"nctId":71137,"briefTitle":71138,"status":155,"phases":71161,"primaryCompletion":71140,"completion":71140,"start":51846,"enrollment":1298,"conditions":71162,"interventions":71163},[85],[15],[71130,71143,71144,71145],{"trials":71165,"activeCount":97},[],{"trials":71167,"activeCount":97},[],{"trials":71169,"activeCount":97},[],{"trials":71171,"activeCount":97},[],{"intervention":71144,"totalTrials":417,"cells":71173},{"EARLY_PHASE1":71174,"PHASE1":71176,"PHASE2":71182,"PHASE3":71184,"PHASE4":71186,"NA":71188},{"trials":71175,"activeCount":97},[],{"trials":71177,"activeCount":97},[71178],{"nctId":71137,"briefTitle":71138,"status":155,"phases":71179,"primaryCompletion":71140,"completion":71140,"start":51846,"enrollment":1298,"conditions":71180,"interventions":71181},[85],[15],[71130,71143,71144,71145],{"trials":71183,"activeCount":97},[],{"trials":71185,"activeCount":97},[],{"trials":71187,"activeCount":97},[],{"trials":71189,"activeCount":97},[],{"intervention":71145,"totalTrials":417,"cells":71191},{"EARLY_PHASE1":71192,"PHASE1":71194,"PHASE2":71200,"PHASE3":71202,"PHASE4":71204,"NA":71206},{"trials":71193,"activeCount":97},[],{"trials":71195,"activeCount":97},[71196],{"nctId":71137,"briefTitle":71138,"status":155,"phases":71197,"primaryCompletion":71140,"completion":71140,"start":51846,"enrollment":1298,"conditions":71198,"interventions":71199},[85],[15],[71130,71143,71144,71145],{"trials":71201,"activeCount":97},[],{"trials":71203,"activeCount":97},[],{"trials":71205,"activeCount":97},[],{"trials":71207,"activeCount":97},[],{"intervention":71209,"totalTrials":417,"cells":71210},"Afuresertib GC - Fasted State",{"EARLY_PHASE1":71211,"PHASE1":71213,"PHASE2":71228,"PHASE3":71230,"PHASE4":71232,"NA":71234},{"trials":71212,"activeCount":97},[],{"trials":71214,"activeCount":97},[71215],{"nctId":71216,"briefTitle":71217,"status":155,"phases":71218,"primaryCompletion":71219,"completion":71219,"start":71220,"enrollment":710,"conditions":71221,"interventions":71222},"NCT01827644","Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers",[85],"2013-07-12","2013-04-24",[36],[71209,71223,71224,71225,71226,71227],"Afuresertib HPMC capsule - Fasted State","Afuresertib ECT - Fasted State","Afuresertib GC - Fed State","Afuresertib HPMC capsule - Fed State","Afuresertib ECT - Fed State",{"trials":71229,"activeCount":97},[],{"trials":71231,"activeCount":97},[],{"trials":71233,"activeCount":97},[],{"trials":71235,"activeCount":97},[],{"intervention":71223,"totalTrials":417,"cells":71237},{"EARLY_PHASE1":71238,"PHASE1":71240,"PHASE2":71246,"PHASE3":71248,"PHASE4":71250,"NA":71252},{"trials":71239,"activeCount":97},[],{"trials":71241,"activeCount":97},[71242],{"nctId":71216,"briefTitle":71217,"status":155,"phases":71243,"primaryCompletion":71219,"completion":71219,"start":71220,"enrollment":710,"conditions":71244,"interventions":71245},[85],[36],[71209,71223,71224,71225,71226,71227],{"trials":71247,"activeCount":97},[],{"trials":71249,"activeCount":97},[],{"trials":71251,"activeCount":97},[],{"trials":71253,"activeCount":97},[],{"intervention":71224,"totalTrials":417,"cells":71255},{"EARLY_PHASE1":71256,"PHASE1":71258,"PHASE2":71264,"PHASE3":71266,"PHASE4":71268,"NA":71270},{"trials":71257,"activeCount":97},[],{"trials":71259,"activeCount":97},[71260],{"nctId":71216,"briefTitle":71217,"status":155,"phases":71261,"primaryCompletion":71219,"completion":71219,"start":71220,"enrollment":710,"conditions":71262,"interventions":71263},[85],[36],[71209,71223,71224,71225,71226,71227],{"trials":71265,"activeCount":97},[],{"trials":71267,"activeCount":97},[],{"trials":71269,"activeCount":97},[],{"trials":71271,"activeCount":97},[],{"intervention":71225,"totalTrials":417,"cells":71273},{"EARLY_PHASE1":71274,"PHASE1":71276,"PHASE2":71282,"PHASE3":71284,"PHASE4":71286,"NA":71288},{"trials":71275,"activeCount":97},[],{"trials":71277,"activeCount":97},[71278],{"nctId":71216,"briefTitle":71217,"status":155,"phases":71279,"primaryCompletion":71219,"completion":71219,"start":71220,"enrollment":710,"conditions":71280,"interventions":71281},[85],[36],[71209,71223,71224,71225,71226,71227],{"trials":71283,"activeCount":97},[],{"trials":71285,"activeCount":97},[],{"trials":71287,"activeCount":97},[],{"trials":71289,"activeCount":97},[],{"intervention":71226,"totalTrials":417,"cells":71291},{"EARLY_PHASE1":71292,"PHASE1":71294,"PHASE2":71300,"PHASE3":71302,"PHASE4":71304,"NA":71306},{"trials":71293,"activeCount":97},[],{"trials":71295,"activeCount":97},[71296],{"nctId":71216,"briefTitle":71217,"status":155,"phases":71297,"primaryCompletion":71219,"completion":71219,"start":71220,"enrollment":710,"conditions":71298,"interventions":71299},[85],[36],[71209,71223,71224,71225,71226,71227],{"trials":71301,"activeCount":97},[],{"trials":71303,"activeCount":97},[],{"trials":71305,"activeCount":97},[],{"trials":71307,"activeCount":97},[],{"intervention":71227,"totalTrials":417,"cells":71309},{"EARLY_PHASE1":71310,"PHASE1":71312,"PHASE2":71318,"PHASE3":71320,"PHASE4":71322,"NA":71324},{"trials":71311,"activeCount":97},[],{"trials":71313,"activeCount":97},[71314],{"nctId":71216,"briefTitle":71217,"status":155,"phases":71315,"primaryCompletion":71219,"completion":71219,"start":71220,"enrollment":710,"conditions":71316,"interventions":71317},[85],[36],[71209,71223,71224,71225,71226,71227],{"trials":71319,"activeCount":97},[],{"trials":71321,"activeCount":97},[],{"trials":71323,"activeCount":97},[],{"trials":71325,"activeCount":97},[],{"intervention":71327,"totalTrials":417,"cells":71328},"GSK2816126",{"EARLY_PHASE1":71329,"PHASE1":71331,"PHASE2":71339,"PHASE3":71341,"PHASE4":71343,"NA":71345},{"trials":71330,"activeCount":97},[],{"trials":71332,"activeCount":97},[71333],{"nctId":71334,"briefTitle":71335,"status":145,"phases":71336,"primaryCompletion":6535,"completion":6535,"start":811,"enrollment":212,"conditions":71337,"interventions":71338},"NCT02082977","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed\u002FRefractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma",[85],[36,107],[71327],{"trials":71340,"activeCount":97},[],{"trials":71342,"activeCount":97},[],{"trials":71344,"activeCount":97},[],{"trials":71346,"activeCount":97},[],{"intervention":71348,"totalTrials":417,"cells":71349},"Creatine",{"EARLY_PHASE1":71350,"PHASE1":71352,"PHASE2":71361,"PHASE3":71363,"PHASE4":71365,"NA":71367},{"trials":71351,"activeCount":97},[],{"trials":71353,"activeCount":97},[71354],{"nctId":71355,"briefTitle":71356,"status":155,"phases":71357,"primaryCompletion":18087,"completion":71358,"start":30950,"enrollment":255,"conditions":71359,"interventions":71360},"NCT02058654","A Clinical Study to Investigate the Effects of Creatine Supplementation on Muscle Energetics and Cognitive Function in Young Healthy Male Athletes and an Ageing Population",[85],"2014-06-24",[40022],[71348],{"trials":71362,"activeCount":97},[],{"trials":71364,"activeCount":97},[],{"trials":71366,"activeCount":97},[],{"trials":71368,"activeCount":97},[],{"intervention":61725,"totalTrials":417,"cells":71370},{"EARLY_PHASE1":71371,"PHASE1":71373,"PHASE2":71379,"PHASE3":71381,"PHASE4":71383,"NA":71385},{"trials":71372,"activeCount":97},[],{"trials":71374,"activeCount":97},[71375],{"nctId":61719,"briefTitle":61720,"status":155,"phases":71376,"primaryCompletion":61722,"completion":61722,"start":8696,"enrollment":2045,"conditions":71377,"interventions":71378},[85],[9855,42132],[61725,61702],{"trials":71380,"activeCount":97},[],{"trials":71382,"activeCount":97},[],{"trials":71384,"activeCount":97},[],{"trials":71386,"activeCount":97},[],{"intervention":18684,"totalTrials":417,"cells":71388},{"EARLY_PHASE1":71389,"PHASE1":71391,"PHASE2":71397,"PHASE3":71399,"PHASE4":71401,"NA":71403},{"trials":71390,"activeCount":97},[],{"trials":71392,"activeCount":97},[71393],{"nctId":18678,"briefTitle":18679,"status":155,"phases":71394,"primaryCompletion":8539,"completion":8539,"start":18681,"enrollment":433,"conditions":71395,"interventions":71396},[85],[15],[3467,18684],{"trials":71398,"activeCount":97},[],{"trials":71400,"activeCount":97},[],{"trials":71402,"activeCount":97},[],{"trials":71404,"activeCount":97},[],{"intervention":41118,"totalTrials":417,"cells":71406},{"EARLY_PHASE1":71407,"PHASE1":71409,"PHASE2":71415,"PHASE3":71417,"PHASE4":71419,"NA":71421},{"trials":71408,"activeCount":97},[],{"trials":71410,"activeCount":97},[71411],{"nctId":41111,"briefTitle":41112,"status":155,"phases":71412,"primaryCompletion":41114,"completion":41114,"start":41115,"enrollment":454,"conditions":71413,"interventions":71414},[85],[23246],[41118,41096],{"trials":71416,"activeCount":97},[],{"trials":71418,"activeCount":97},[],{"trials":71420,"activeCount":97},[],{"trials":71422,"activeCount":97},[],{"intervention":71424,"totalTrials":417,"cells":71425},"GSK3335065",{"EARLY_PHASE1":71426,"PHASE1":71428,"PHASE2":71439,"PHASE3":71441,"PHASE4":71443,"NA":71445},{"trials":71427,"activeCount":97},[],{"trials":71429,"activeCount":97},[71430],{"nctId":71431,"briefTitle":71432,"status":145,"phases":71433,"primaryCompletion":71434,"completion":71434,"start":71435,"enrollment":1634,"conditions":71436,"interventions":71438},"NCT03245619","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults",[85],"2018-05-19","2017-08-22",[71437],"Pancreatitis, Acute Necrotizing",[71424],{"trials":71440,"activeCount":97},[],{"trials":71442,"activeCount":97},[],{"trials":71444,"activeCount":97},[],{"trials":71446,"activeCount":97},[],{"intervention":43758,"totalTrials":417,"cells":71448},{"EARLY_PHASE1":71449,"PHASE1":71451,"PHASE2":71457,"PHASE3":71459,"PHASE4":71461,"NA":71463},{"trials":71450,"activeCount":97},[],{"trials":71452,"activeCount":97},[71453],{"nctId":43752,"briefTitle":43753,"status":155,"phases":71454,"primaryCompletion":18982,"completion":41281,"start":43755,"enrollment":8236,"conditions":71455,"interventions":71456},[85],[21],[43758,43745,43759],{"trials":71458,"activeCount":97},[],{"trials":71460,"activeCount":97},[],{"trials":71462,"activeCount":97},[],{"trials":71464,"activeCount":97},[],{"intervention":43759,"totalTrials":417,"cells":71466},{"EARLY_PHASE1":71467,"PHASE1":71469,"PHASE2":71475,"PHASE3":71477,"PHASE4":71479,"NA":71481},{"trials":71468,"activeCount":97},[],{"trials":71470,"activeCount":97},[71471],{"nctId":43752,"briefTitle":43753,"status":155,"phases":71472,"primaryCompletion":18982,"completion":41281,"start":43755,"enrollment":8236,"conditions":71473,"interventions":71474},[85],[21],[43758,43745,43759],{"trials":71476,"activeCount":97},[],{"trials":71478,"activeCount":97},[],{"trials":71480,"activeCount":97},[],{"trials":71482,"activeCount":97},[],{"intervention":71484,"totalTrials":417,"cells":71485},"Inhaled FF\u002F GW642444M",{"EARLY_PHASE1":71486,"PHASE1":71488,"PHASE2":71496,"PHASE3":71498,"PHASE4":71500,"NA":71502},{"trials":71487,"activeCount":97},[],{"trials":71489,"activeCount":97},[71490],{"nctId":71491,"briefTitle":71492,"status":155,"phases":71493,"primaryCompletion":7514,"completion":7514,"start":22664,"enrollment":1634,"conditions":71494,"interventions":71495},"NCT01266980","A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment.",[85],[15],[71484],{"trials":71497,"activeCount":97},[],{"trials":71499,"activeCount":97},[],{"trials":71501,"activeCount":97},[],{"trials":71503,"activeCount":97},[],{"intervention":71505,"totalTrials":417,"cells":71506},"oral topotecan",{"EARLY_PHASE1":71507,"PHASE1":71509,"PHASE2":71518,"PHASE3":71520,"PHASE4":71522,"NA":71524},{"trials":71508,"activeCount":97},[],{"trials":71510,"activeCount":97},[71511],{"nctId":71512,"briefTitle":71513,"status":500,"phases":71514,"primaryCompletion":8883,"completion":8883,"start":10167,"enrollment":97,"conditions":71515,"interventions":71517},"NCT00682279","A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors",[85],[71516],"Advanced Solid Tumors",[71505],{"trials":71519,"activeCount":97},[],{"trials":71521,"activeCount":97},[],{"trials":71523,"activeCount":97},[],{"trials":71525,"activeCount":97},[],{"intervention":19304,"totalTrials":417,"cells":71527},{"EARLY_PHASE1":71528,"PHASE1":71530,"PHASE2":71536,"PHASE3":71538,"PHASE4":71540,"NA":71542},{"trials":71529,"activeCount":97},[],{"trials":71531,"activeCount":97},[71532],{"nctId":19297,"briefTitle":19298,"status":155,"phases":71533,"primaryCompletion":2442,"completion":2442,"start":3550,"enrollment":1298,"conditions":71534,"interventions":71535},[85],[19301],[19303,19304,19305,10675],{"trials":71537,"activeCount":97},[],{"trials":71539,"activeCount":97},[],{"trials":71541,"activeCount":97},[],{"trials":71543,"activeCount":97},[],{"intervention":19305,"totalTrials":417,"cells":71545},{"EARLY_PHASE1":71546,"PHASE1":71548,"PHASE2":71554,"PHASE3":71556,"PHASE4":71558,"NA":71560},{"trials":71547,"activeCount":97},[],{"trials":71549,"activeCount":97},[71550],{"nctId":19297,"briefTitle":19298,"status":155,"phases":71551,"primaryCompletion":2442,"completion":2442,"start":3550,"enrollment":1298,"conditions":71552,"interventions":71553},[85],[19301],[19303,19304,19305,10675],{"trials":71555,"activeCount":97},[],{"trials":71557,"activeCount":97},[],{"trials":71559,"activeCount":97},[],{"trials":71561,"activeCount":97},[],{"intervention":71563,"totalTrials":417,"cells":71564},"FF UD-DPI",{"EARLY_PHASE1":71565,"PHASE1":71567,"PHASE2":71577,"PHASE3":71579,"PHASE4":71581,"NA":71583},{"trials":71566,"activeCount":97},[],{"trials":71568,"activeCount":97},[71569],{"nctId":71570,"briefTitle":71571,"status":155,"phases":71572,"primaryCompletion":62670,"completion":62670,"start":71573,"enrollment":255,"conditions":71574,"interventions":71575},"NCT02218723","Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation",[85],"2014-10-28",[18],[71563,71576],"FF ELLIPTA DPI",{"trials":71578,"activeCount":97},[],{"trials":71580,"activeCount":97},[],{"trials":71582,"activeCount":97},[],{"trials":71584,"activeCount":97},[],{"intervention":71576,"totalTrials":417,"cells":71586},{"EARLY_PHASE1":71587,"PHASE1":71589,"PHASE2":71595,"PHASE3":71597,"PHASE4":71599,"NA":71601},{"trials":71588,"activeCount":97},[],{"trials":71590,"activeCount":97},[71591],{"nctId":71570,"briefTitle":71571,"status":155,"phases":71592,"primaryCompletion":62670,"completion":62670,"start":71573,"enrollment":255,"conditions":71593,"interventions":71594},[85],[18],[71563,71576],{"trials":71596,"activeCount":97},[],{"trials":71598,"activeCount":97},[],{"trials":71600,"activeCount":97},[],{"trials":71602,"activeCount":97},[],{"intervention":61008,"totalTrials":417,"cells":71604},{"EARLY_PHASE1":71605,"PHASE1":71607,"PHASE2":71613,"PHASE3":71615,"PHASE4":71617,"NA":71619},{"trials":71606,"activeCount":97},[],{"trials":71608,"activeCount":97},[71609],{"nctId":61003,"briefTitle":61004,"status":155,"phases":71610,"primaryCompletion":10167,"completion":10167,"start":2428,"enrollment":37,"conditions":71611,"interventions":71612},[85],[7524,6484],[43571,61008],{"trials":71614,"activeCount":97},[],{"trials":71616,"activeCount":97},[],{"trials":71618,"activeCount":97},[],{"trials":71620,"activeCount":97},[],{"intervention":71622,"totalTrials":417,"cells":71623},"Influenza vaccine GSK2186877A formulation 1",{"EARLY_PHASE1":71624,"PHASE1":71626,"PHASE2":71635,"PHASE3":71637,"PHASE4":71639,"NA":71641},{"trials":71625,"activeCount":97},[],{"trials":71627,"activeCount":97},[71628],{"nctId":71629,"briefTitle":71630,"status":155,"phases":71631,"primaryCompletion":24869,"completion":24869,"start":65769,"enrollment":345,"conditions":71632,"interventions":71633},"NCT01096056","Trial to Evaluate the Safety and the Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Healthy Children",[85],[21],[71622,71634,25702],"Influenza vaccine GSK2186877A formulation 2",{"trials":71636,"activeCount":97},[],{"trials":71638,"activeCount":97},[],{"trials":71640,"activeCount":97},[],{"trials":71642,"activeCount":97},[],{"intervention":71634,"totalTrials":417,"cells":71644},{"EARLY_PHASE1":71645,"PHASE1":71647,"PHASE2":71653,"PHASE3":71655,"PHASE4":71657,"NA":71659},{"trials":71646,"activeCount":97},[],{"trials":71648,"activeCount":97},[71649],{"nctId":71629,"briefTitle":71630,"status":155,"phases":71650,"primaryCompletion":24869,"completion":24869,"start":65769,"enrollment":345,"conditions":71651,"interventions":71652},[85],[21],[71622,71634,25702],{"trials":71654,"activeCount":97},[],{"trials":71656,"activeCount":97},[],{"trials":71658,"activeCount":97},[],{"trials":71660,"activeCount":97},[],{"intervention":71662,"totalTrials":417,"cells":71663},"600 mg zanamivir + moxifloxacin placebo",{"EARLY_PHASE1":71664,"PHASE1":71666,"PHASE2":71678,"PHASE3":71680,"PHASE4":71682,"NA":71684},{"trials":71665,"activeCount":97},[],{"trials":71667,"activeCount":97},[71668],{"nctId":71669,"briefTitle":71670,"status":155,"phases":71671,"primaryCompletion":71672,"completion":71672,"start":19513,"enrollment":345,"conditions":71673,"interventions":71674},"NCT01353729","A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers",[85],"2011-08-02",[5353],[71662,71675,71676,71677],"1200 mg zanamivir + moxifloxacin placebo","zanamivir placebo + moxifloxacin placebo","zanamivir placebo + 400 mg moxifloxacin",{"trials":71679,"activeCount":97},[],{"trials":71681,"activeCount":97},[],{"trials":71683,"activeCount":97},[],{"trials":71685,"activeCount":97},[],{"intervention":71675,"totalTrials":417,"cells":71687},{"EARLY_PHASE1":71688,"PHASE1":71690,"PHASE2":71696,"PHASE3":71698,"PHASE4":71700,"NA":71702},{"trials":71689,"activeCount":97},[],{"trials":71691,"activeCount":97},[71692],{"nctId":71669,"briefTitle":71670,"status":155,"phases":71693,"primaryCompletion":71672,"completion":71672,"start":19513,"enrollment":345,"conditions":71694,"interventions":71695},[85],[5353],[71662,71675,71676,71677],{"trials":71697,"activeCount":97},[],{"trials":71699,"activeCount":97},[],{"trials":71701,"activeCount":97},[],{"trials":71703,"activeCount":97},[],{"intervention":71676,"totalTrials":417,"cells":71705},{"EARLY_PHASE1":71706,"PHASE1":71708,"PHASE2":71714,"PHASE3":71716,"PHASE4":71718,"NA":71720},{"trials":71707,"activeCount":97},[],{"trials":71709,"activeCount":97},[71710],{"nctId":71669,"briefTitle":71670,"status":155,"phases":71711,"primaryCompletion":71672,"completion":71672,"start":19513,"enrollment":345,"conditions":71712,"interventions":71713},[85],[5353],[71662,71675,71676,71677],{"trials":71715,"activeCount":97},[],{"trials":71717,"activeCount":97},[],{"trials":71719,"activeCount":97},[],{"trials":71721,"activeCount":97},[],{"intervention":71677,"totalTrials":417,"cells":71723},{"EARLY_PHASE1":71724,"PHASE1":71726,"PHASE2":71732,"PHASE3":71734,"PHASE4":71736,"NA":71738},{"trials":71725,"activeCount":97},[],{"trials":71727,"activeCount":97},[71728],{"nctId":71669,"briefTitle":71670,"status":155,"phases":71729,"primaryCompletion":71672,"completion":71672,"start":19513,"enrollment":345,"conditions":71730,"interventions":71731},[85],[5353],[71662,71675,71676,71677],{"trials":71733,"activeCount":97},[],{"trials":71735,"activeCount":97},[],{"trials":71737,"activeCount":97},[],{"trials":71739,"activeCount":97},[],{"intervention":64947,"totalTrials":417,"cells":71741},{"EARLY_PHASE1":71742,"PHASE1":71744,"PHASE2":71755,"PHASE3":71757,"PHASE4":71759,"NA":71761},{"trials":71743,"activeCount":97},[],{"trials":71745,"activeCount":97},[71746],{"nctId":71747,"briefTitle":71748,"status":145,"phases":71749,"primaryCompletion":71750,"completion":71750,"start":71751,"enrollment":1517,"conditions":71752,"interventions":71753},"NCT01424475","LRRK2 Mutation and Parkinson's Disease",[85],"2015-01-12","2011-08-11",[15879],[64947,71754],"PKD Patients",{"trials":71756,"activeCount":97},[],{"trials":71758,"activeCount":97},[],{"trials":71760,"activeCount":97},[],{"trials":71762,"activeCount":97},[],{"intervention":71754,"totalTrials":417,"cells":71764},{"EARLY_PHASE1":71765,"PHASE1":71767,"PHASE2":71773,"PHASE3":71775,"PHASE4":71777,"NA":71779},{"trials":71766,"activeCount":97},[],{"trials":71768,"activeCount":97},[71769],{"nctId":71747,"briefTitle":71748,"status":145,"phases":71770,"primaryCompletion":71750,"completion":71750,"start":71751,"enrollment":1517,"conditions":71771,"interventions":71772},[85],[15879],[64947,71754],{"trials":71774,"activeCount":97},[],{"trials":71776,"activeCount":97},[],{"trials":71778,"activeCount":97},[],{"trials":71780,"activeCount":97},[],{"intervention":71782,"totalTrials":417,"cells":71783},"SB-568859",{"EARLY_PHASE1":71784,"PHASE1":71786,"PHASE2":71794,"PHASE3":71796,"PHASE4":71798,"NA":71800},{"trials":71785,"activeCount":97},[],{"trials":71787,"activeCount":97},[71788],{"nctId":71789,"briefTitle":71790,"status":155,"phases":71791,"completion":2428,"start":4756,"enrollment":695,"conditions":71792,"interventions":71793},"NCT00470145","Comparison Of Two Tablet Formulations Of SB-568859",[85],[9309],[71782],{"trials":71795,"activeCount":97},[],{"trials":71797,"activeCount":97},[],{"trials":71799,"activeCount":97},[],{"trials":71801,"activeCount":97},[],{"intervention":71803,"totalTrials":417,"cells":71804},"500mg IV GSK1322322\u002Fplacebo",{"EARLY_PHASE1":71805,"PHASE1":71807,"PHASE2":71824,"PHASE3":71826,"PHASE4":71828,"NA":71830},{"trials":71806,"activeCount":97},[],{"trials":71808,"activeCount":97},[71809],{"nctId":71810,"briefTitle":71811,"status":155,"phases":71812,"primaryCompletion":71813,"completion":71813,"start":71814,"enrollment":4542,"conditions":71815,"interventions":71816},"NCT01610388","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects",[85],"2012-01-26","2011-09-13",[6484],[71803,71817,71818,71819,71820,71821,71822,71823],"1000mg oral GSK1322322\u002Fplacebo","1000mg IV GSK1322322\u002Fplacebo","1500mg oral GSK1322322\u002Fplacebo dose","1500mg IV GSK1322322\u002Fplacebo","2000mg IV GSK1322322J\u002Fplacebo","3000mg IV GSK1322322J\u002Fplacebo","1000mg IV GSK1322322J\u002Fplacebo",{"trials":71825,"activeCount":97},[],{"trials":71827,"activeCount":97},[],{"trials":71829,"activeCount":97},[],{"trials":71831,"activeCount":97},[],{"intervention":71817,"totalTrials":417,"cells":71833},{"EARLY_PHASE1":71834,"PHASE1":71836,"PHASE2":71842,"PHASE3":71844,"PHASE4":71846,"NA":71848},{"trials":71835,"activeCount":97},[],{"trials":71837,"activeCount":97},[71838],{"nctId":71810,"briefTitle":71811,"status":155,"phases":71839,"primaryCompletion":71813,"completion":71813,"start":71814,"enrollment":4542,"conditions":71840,"interventions":71841},[85],[6484],[71803,71817,71818,71819,71820,71821,71822,71823],{"trials":71843,"activeCount":97},[],{"trials":71845,"activeCount":97},[],{"trials":71847,"activeCount":97},[],{"trials":71849,"activeCount":97},[],{"intervention":71818,"totalTrials":417,"cells":71851},{"EARLY_PHASE1":71852,"PHASE1":71854,"PHASE2":71860,"PHASE3":71862,"PHASE4":71864,"NA":71866},{"trials":71853,"activeCount":97},[],{"trials":71855,"activeCount":97},[71856],{"nctId":71810,"briefTitle":71811,"status":155,"phases":71857,"primaryCompletion":71813,"completion":71813,"start":71814,"enrollment":4542,"conditions":71858,"interventions":71859},[85],[6484],[71803,71817,71818,71819,71820,71821,71822,71823],{"trials":71861,"activeCount":97},[],{"trials":71863,"activeCount":97},[],{"trials":71865,"activeCount":97},[],{"trials":71867,"activeCount":97},[],{"intervention":71819,"totalTrials":417,"cells":71869},{"EARLY_PHASE1":71870,"PHASE1":71872,"PHASE2":71878,"PHASE3":71880,"PHASE4":71882,"NA":71884},{"trials":71871,"activeCount":97},[],{"trials":71873,"activeCount":97},[71874],{"nctId":71810,"briefTitle":71811,"status":155,"phases":71875,"primaryCompletion":71813,"completion":71813,"start":71814,"enrollment":4542,"conditions":71876,"interventions":71877},[85],[6484],[71803,71817,71818,71819,71820,71821,71822,71823],{"trials":71879,"activeCount":97},[],{"trials":71881,"activeCount":97},[],{"trials":71883,"activeCount":97},[],{"trials":71885,"activeCount":97},[],{"intervention":71820,"totalTrials":417,"cells":71887},{"EARLY_PHASE1":71888,"PHASE1":71890,"PHASE2":71896,"PHASE3":71898,"PHASE4":71900,"NA":71902},{"trials":71889,"activeCount":97},[],{"trials":71891,"activeCount":97},[71892],{"nctId":71810,"briefTitle":71811,"status":155,"phases":71893,"primaryCompletion":71813,"completion":71813,"start":71814,"enrollment":4542,"conditions":71894,"interventions":71895},[85],[6484],[71803,71817,71818,71819,71820,71821,71822,71823],{"trials":71897,"activeCount":97},[],{"trials":71899,"activeCount":97},[],{"trials":71901,"activeCount":97},[],{"trials":71903,"activeCount":97},[],{"intervention":71821,"totalTrials":417,"cells":71905},{"EARLY_PHASE1":71906,"PHASE1":71908,"PHASE2":71914,"PHASE3":71916,"PHASE4":71918,"NA":71920},{"trials":71907,"activeCount":97},[],{"trials":71909,"activeCount":97},[71910],{"nctId":71810,"briefTitle":71811,"status":155,"phases":71911,"primaryCompletion":71813,"completion":71813,"start":71814,"enrollment":4542,"conditions":71912,"interventions":71913},[85],[6484],[71803,71817,71818,71819,71820,71821,71822,71823],{"trials":71915,"activeCount":97},[],{"trials":71917,"activeCount":97},[],{"trials":71919,"activeCount":97},[],{"trials":71921,"activeCount":97},[],{"intervention":71822,"totalTrials":417,"cells":71923},{"EARLY_PHASE1":71924,"PHASE1":71926,"PHASE2":71932,"PHASE3":71934,"PHASE4":71936,"NA":71938},{"trials":71925,"activeCount":97},[],{"trials":71927,"activeCount":97},[71928],{"nctId":71810,"briefTitle":71811,"status":155,"phases":71929,"primaryCompletion":71813,"completion":71813,"start":71814,"enrollment":4542,"conditions":71930,"interventions":71931},[85],[6484],[71803,71817,71818,71819,71820,71821,71822,71823],{"trials":71933,"activeCount":97},[],{"trials":71935,"activeCount":97},[],{"trials":71937,"activeCount":97},[],{"trials":71939,"activeCount":97},[],{"intervention":71823,"totalTrials":417,"cells":71941},{"EARLY_PHASE1":71942,"PHASE1":71944,"PHASE2":71950,"PHASE3":71952,"PHASE4":71954,"NA":71956},{"trials":71943,"activeCount":97},[],{"trials":71945,"activeCount":97},[71946],{"nctId":71810,"briefTitle":71811,"status":155,"phases":71947,"primaryCompletion":71813,"completion":71813,"start":71814,"enrollment":4542,"conditions":71948,"interventions":71949},[85],[6484],[71803,71817,71818,71819,71820,71821,71822,71823],{"trials":71951,"activeCount":97},[],{"trials":71953,"activeCount":97},[],{"trials":71955,"activeCount":97},[],{"trials":71957,"activeCount":97},[],{"intervention":9385,"totalTrials":417,"cells":71959},{"EARLY_PHASE1":71960,"PHASE1":71962,"PHASE2":71968,"PHASE3":71970,"PHASE4":71972,"NA":71974},{"trials":71961,"activeCount":97},[],{"trials":71963,"activeCount":97},[71964],{"nctId":9377,"briefTitle":9378,"status":155,"phases":71965,"primaryCompletion":9380,"completion":9380,"start":9381,"enrollment":9382,"conditions":71966,"interventions":71967},[85],[15],[9385,9370],{"trials":71969,"activeCount":97},[],{"trials":71971,"activeCount":97},[],{"trials":71973,"activeCount":97},[],{"trials":71975,"activeCount":97},[],{"intervention":71977,"totalTrials":417,"cells":71978},"GSK923295",{"EARLY_PHASE1":71979,"PHASE1":71981,"PHASE2":71989,"PHASE3":71991,"PHASE4":71993,"NA":71995},{"trials":71980,"activeCount":97},[],{"trials":71982,"activeCount":97},[71983],{"nctId":71984,"briefTitle":71985,"status":155,"phases":71986,"primaryCompletion":36114,"completion":10038,"start":19787,"enrollment":12202,"conditions":71987,"interventions":71988},"NCT00504790","Phase I Study to Assess the Safety, Pharmacokinetics, & Pharmacodynamics of GSK923295 in Subjects w\u002F Refractory Cancer",[85],[36],[71977],{"trials":71990,"activeCount":97},[],{"trials":71992,"activeCount":97},[],{"trials":71994,"activeCount":97},[],{"trials":71996,"activeCount":97},[],{"intervention":42993,"totalTrials":417,"cells":71998},{"EARLY_PHASE1":71999,"PHASE1":72001,"PHASE2":72007,"PHASE3":72009,"PHASE4":72011,"NA":72013},{"trials":72000,"activeCount":97},[],{"trials":72002,"activeCount":97},[72003],{"nctId":42987,"briefTitle":42988,"status":155,"phases":72004,"primaryCompletion":42990,"completion":42990,"start":8199,"enrollment":345,"conditions":72005,"interventions":72006},[85],[20928],[42993,42980,42994,42995],{"trials":72008,"activeCount":97},[],{"trials":72010,"activeCount":97},[],{"trials":72012,"activeCount":97},[],{"trials":72014,"activeCount":97},[],{"intervention":42994,"totalTrials":417,"cells":72016},{"EARLY_PHASE1":72017,"PHASE1":72019,"PHASE2":72025,"PHASE3":72027,"PHASE4":72029,"NA":72031},{"trials":72018,"activeCount":97},[],{"trials":72020,"activeCount":97},[72021],{"nctId":42987,"briefTitle":42988,"status":155,"phases":72022,"primaryCompletion":42990,"completion":42990,"start":8199,"enrollment":345,"conditions":72023,"interventions":72024},[85],[20928],[42993,42980,42994,42995],{"trials":72026,"activeCount":97},[],{"trials":72028,"activeCount":97},[],{"trials":72030,"activeCount":97},[],{"trials":72032,"activeCount":97},[],{"intervention":42995,"totalTrials":417,"cells":72034},{"EARLY_PHASE1":72035,"PHASE1":72037,"PHASE2":72043,"PHASE3":72045,"PHASE4":72047,"NA":72049},{"trials":72036,"activeCount":97},[],{"trials":72038,"activeCount":97},[72039],{"nctId":42987,"briefTitle":42988,"status":155,"phases":72040,"primaryCompletion":42990,"completion":42990,"start":8199,"enrollment":345,"conditions":72041,"interventions":72042},[85],[20928],[42993,42980,42994,42995],{"trials":72044,"activeCount":97},[],{"trials":72046,"activeCount":97},[],{"trials":72048,"activeCount":97},[],{"trials":72050,"activeCount":97},[],{"intervention":60262,"totalTrials":417,"cells":72052},{"EARLY_PHASE1":72053,"PHASE1":72055,"PHASE2":72061,"PHASE3":72063,"PHASE4":72065,"NA":72067},{"trials":72054,"activeCount":97},[],{"trials":72056,"activeCount":97},[72057],{"nctId":60256,"briefTitle":60257,"status":155,"phases":72058,"primaryCompletion":8803,"completion":8803,"start":5289,"enrollment":1720,"conditions":72059,"interventions":72060},[85],[60260],[60249,60262],{"trials":72062,"activeCount":97},[],{"trials":72064,"activeCount":97},[],{"trials":72066,"activeCount":97},[],{"trials":72068,"activeCount":97},[],{"intervention":72070,"totalTrials":417,"cells":72071},"GSK3008348",{"EARLY_PHASE1":72072,"PHASE1":72074,"PHASE2":72086,"PHASE3":72088,"PHASE4":72090,"NA":72092},{"trials":72073,"activeCount":97},[],{"trials":72075,"activeCount":97},[72076],{"nctId":72077,"briefTitle":72078,"status":145,"phases":72079,"primaryCompletion":72080,"completion":72081,"start":72082,"enrollment":1720,"conditions":72083,"interventions":72084},"NCT03069989","Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging",[85],"2018-07-04","2018-07-18","2017-06-13",[42392],[72070,72085],"[18F]-FBA-A20FMDV2",{"trials":72087,"activeCount":97},[],{"trials":72089,"activeCount":97},[],{"trials":72091,"activeCount":97},[],{"trials":72093,"activeCount":97},[],{"intervention":72085,"totalTrials":417,"cells":72095},{"EARLY_PHASE1":72096,"PHASE1":72098,"PHASE2":72104,"PHASE3":72106,"PHASE4":72108,"NA":72110},{"trials":72097,"activeCount":97},[],{"trials":72099,"activeCount":97},[72100],{"nctId":72077,"briefTitle":72078,"status":145,"phases":72101,"primaryCompletion":72080,"completion":72081,"start":72082,"enrollment":1720,"conditions":72102,"interventions":72103},[85],[42392],[72070,72085],{"trials":72105,"activeCount":97},[],{"trials":72107,"activeCount":97},[],{"trials":72109,"activeCount":97},[],{"trials":72111,"activeCount":97},[],{"intervention":72113,"totalTrials":417,"cells":72114},"This is a pharmacokinetic study",{"EARLY_PHASE1":72115,"PHASE1":72117,"PHASE2":72126,"PHASE3":72128,"PHASE4":72130,"NA":72132},{"trials":72116,"activeCount":97},[],{"trials":72118,"activeCount":97},[72119],{"nctId":72120,"briefTitle":72121,"status":155,"phases":72122,"primaryCompletion":27084,"completion":27084,"start":72123,"enrollment":1003,"conditions":72124,"interventions":72125},"NCT00989625","A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.",[85],"2008-11-04",[14168],[72113,72113,72113],{"trials":72127,"activeCount":97},[],{"trials":72129,"activeCount":97},[],{"trials":72131,"activeCount":97},[],{"trials":72133,"activeCount":97},[],{"intervention":72135,"totalTrials":417,"cells":72136},"Reference mosapride citrate",{"EARLY_PHASE1":72137,"PHASE1":72139,"PHASE2":72150,"PHASE3":72152,"PHASE4":72154,"NA":72156},{"trials":72138,"activeCount":97},[],{"trials":72140,"activeCount":97},[72141],{"nctId":72142,"briefTitle":72143,"status":155,"phases":72144,"primaryCompletion":45529,"completion":45529,"start":72145,"enrollment":1634,"conditions":72146,"interventions":72148},"NCT02201316","A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions",[85],"2014-02-03",[72147],"Gastritis",[72135,72149,72149],"GR107719B",{"trials":72151,"activeCount":97},[],{"trials":72153,"activeCount":97},[],{"trials":72155,"activeCount":97},[],{"trials":72157,"activeCount":97},[],{"intervention":72149,"totalTrials":417,"cells":72159},{"EARLY_PHASE1":72160,"PHASE1":72162,"PHASE2":72168,"PHASE3":72170,"PHASE4":72172,"NA":72174},{"trials":72161,"activeCount":97},[],{"trials":72163,"activeCount":97},[72164],{"nctId":72142,"briefTitle":72143,"status":155,"phases":72165,"primaryCompletion":45529,"completion":45529,"start":72145,"enrollment":1634,"conditions":72166,"interventions":72167},[85],[72147],[72135,72149,72149],{"trials":72169,"activeCount":97},[],{"trials":72171,"activeCount":97},[],{"trials":72173,"activeCount":97},[],{"trials":72175,"activeCount":97},[],{"intervention":72177,"totalTrials":417,"cells":72178},"SB-756050 immediate release",{"EARLY_PHASE1":72179,"PHASE1":72181,"PHASE2":72190,"PHASE3":72192,"PHASE4":72194,"NA":72196},{"trials":72180,"activeCount":97},[],{"trials":72182,"activeCount":97},[72183],{"nctId":72184,"briefTitle":72185,"status":155,"phases":72186,"primaryCompletion":1415,"completion":1415,"start":39094,"enrollment":710,"conditions":72187,"interventions":72188},"NCT00607906","First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050",[85],[27],[72177,72189],"SB-756050 modified release",{"trials":72191,"activeCount":97},[],{"trials":72193,"activeCount":97},[],{"trials":72195,"activeCount":97},[],{"trials":72197,"activeCount":97},[],{"intervention":72189,"totalTrials":417,"cells":72199},{"EARLY_PHASE1":72200,"PHASE1":72202,"PHASE2":72208,"PHASE3":72210,"PHASE4":72212,"NA":72214},{"trials":72201,"activeCount":97},[],{"trials":72203,"activeCount":97},[72204],{"nctId":72184,"briefTitle":72185,"status":155,"phases":72205,"primaryCompletion":1415,"completion":1415,"start":39094,"enrollment":710,"conditions":72206,"interventions":72207},[85],[27],[72177,72189],{"trials":72209,"activeCount":97},[],{"trials":72211,"activeCount":97},[],{"trials":72213,"activeCount":97},[],{"trials":72215,"activeCount":97},[],{"intervention":72217,"totalTrials":417,"cells":72218},"GSK2336805 150mg",{"EARLY_PHASE1":72219,"PHASE1":72221,"PHASE2":72229,"PHASE3":72231,"PHASE4":72233,"NA":72235},{"trials":72220,"activeCount":97},[],{"trials":72222,"activeCount":97},[72223],{"nctId":72224,"briefTitle":72225,"status":155,"phases":72226,"primaryCompletion":53417,"completion":53417,"start":24686,"enrollment":454,"conditions":72227,"interventions":72228},"NCT01424540","Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805",[85],[23770],[72217],{"trials":72230,"activeCount":97},[],{"trials":72232,"activeCount":97},[],{"trials":72234,"activeCount":97},[],{"trials":72236,"activeCount":97},[],{"intervention":72238,"totalTrials":417,"cells":72239},"Iodine-131 Anti-B1 Antibody",{"EARLY_PHASE1":72240,"PHASE1":72242,"PHASE2":72252,"PHASE3":72254,"PHASE4":72256,"NA":72258},{"trials":72241,"activeCount":97},[],{"trials":72243,"activeCount":97},[72244],{"nctId":72245,"briefTitle":72246,"status":155,"phases":72247,"primaryCompletion":72248,"completion":72248,"start":72249,"enrollment":361,"conditions":72250,"interventions":72251},"NCT00992758","Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement",[85],"2012-06-07","1999-05-28",[4574],[72238],{"trials":72253,"activeCount":97},[],{"trials":72255,"activeCount":97},[],{"trials":72257,"activeCount":97},[],{"trials":72259,"activeCount":97},[],{"intervention":72261,"totalTrials":417,"cells":72262},"RTS,S\u002FAS02D and RTS,S\u002FAS02A",{"EARLY_PHASE1":72263,"PHASE1":72265,"PHASE2":72275,"PHASE3":72277,"PHASE4":72279,"NA":72281},{"trials":72264,"activeCount":97},[],{"trials":72266,"activeCount":97},[72267],{"nctId":72268,"briefTitle":72269,"status":155,"phases":72270,"primaryCompletion":72271,"completion":72271,"start":72272,"enrollment":1196,"conditions":72273,"interventions":72274},"NCT00197067","A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S\u002FAS02D (0.5 mL Dose) and RTS,S\u002FAS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.",[85],"2005-04-26","2004-03-15",[3287],[72261],{"trials":72276,"activeCount":97},[],{"trials":72278,"activeCount":97},[],{"trials":72280,"activeCount":97},[],{"trials":72282,"activeCount":97},[],{"intervention":72284,"totalTrials":417,"cells":72285},"Salbutamol Sulphate 150mcg UD-DPI Blister",{"EARLY_PHASE1":72286,"PHASE1":72288,"PHASE2":72306,"PHASE3":72308,"PHASE4":72310,"NA":72312},{"trials":72287,"activeCount":97},[],{"trials":72289,"activeCount":97},[72290],{"nctId":72291,"briefTitle":72292,"status":155,"phases":72293,"primaryCompletion":72294,"completion":72294,"start":40667,"enrollment":1237,"conditions":72295,"interventions":72296},"NCT01984086","Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.",[85],"2014-05-26",[18],[72284,72297,72298,72297,72299,72300,72301,72298,72302,72303,72304,72305],"Salbutamol Sulphate 200mcg UD-DPI Blister","Salbutamol Sulphate 250mcg UD-DPI Blister","Salbutamol Diskus 200mcg Blister","Salbutamol MDI 100mcg","Salbutamol Sulphate UD-DPI Blister","Salbutamol Diskus 200mcg Blister without activated charcoal","Salbutamol Diskus 200mcg Blister with activated charcoal","Salbutamol MDI 100mcg without activated charcoal","Salbutamol MDI 100mcg with activated charcoal",{"trials":72307,"activeCount":97},[],{"trials":72309,"activeCount":97},[],{"trials":72311,"activeCount":97},[],{"trials":72313,"activeCount":97},[],{"intervention":72297,"totalTrials":417,"cells":72315},{"EARLY_PHASE1":72316,"PHASE1":72318,"PHASE2":72324,"PHASE3":72326,"PHASE4":72328,"NA":72330},{"trials":72317,"activeCount":97},[],{"trials":72319,"activeCount":97},[72320],{"nctId":72291,"briefTitle":72292,"status":155,"phases":72321,"primaryCompletion":72294,"completion":72294,"start":40667,"enrollment":1237,"conditions":72322,"interventions":72323},[85],[18],[72284,72297,72298,72297,72299,72300,72301,72298,72302,72303,72304,72305],{"trials":72325,"activeCount":97},[],{"trials":72327,"activeCount":97},[],{"trials":72329,"activeCount":97},[],{"trials":72331,"activeCount":97},[],{"intervention":72298,"totalTrials":417,"cells":72333},{"EARLY_PHASE1":72334,"PHASE1":72336,"PHASE2":72342,"PHASE3":72344,"PHASE4":72346,"NA":72348},{"trials":72335,"activeCount":97},[],{"trials":72337,"activeCount":97},[72338],{"nctId":72291,"briefTitle":72292,"status":155,"phases":72339,"primaryCompletion":72294,"completion":72294,"start":40667,"enrollment":1237,"conditions":72340,"interventions":72341},[85],[18],[72284,72297,72298,72297,72299,72300,72301,72298,72302,72303,72304,72305],{"trials":72343,"activeCount":97},[],{"trials":72345,"activeCount":97},[],{"trials":72347,"activeCount":97},[],{"trials":72349,"activeCount":97},[],{"intervention":72299,"totalTrials":417,"cells":72351},{"EARLY_PHASE1":72352,"PHASE1":72354,"PHASE2":72360,"PHASE3":72362,"PHASE4":72364,"NA":72366},{"trials":72353,"activeCount":97},[],{"trials":72355,"activeCount":97},[72356],{"nctId":72291,"briefTitle":72292,"status":155,"phases":72357,"primaryCompletion":72294,"completion":72294,"start":40667,"enrollment":1237,"conditions":72358,"interventions":72359},[85],[18],[72284,72297,72298,72297,72299,72300,72301,72298,72302,72303,72304,72305],{"trials":72361,"activeCount":97},[],{"trials":72363,"activeCount":97},[],{"trials":72365,"activeCount":97},[],{"trials":72367,"activeCount":97},[],{"intervention":72300,"totalTrials":417,"cells":72369},{"EARLY_PHASE1":72370,"PHASE1":72372,"PHASE2":72378,"PHASE3":72380,"PHASE4":72382,"NA":72384},{"trials":72371,"activeCount":97},[],{"trials":72373,"activeCount":97},[72374],{"nctId":72291,"briefTitle":72292,"status":155,"phases":72375,"primaryCompletion":72294,"completion":72294,"start":40667,"enrollment":1237,"conditions":72376,"interventions":72377},[85],[18],[72284,72297,72298,72297,72299,72300,72301,72298,72302,72303,72304,72305],{"trials":72379,"activeCount":97},[],{"trials":72381,"activeCount":97},[],{"trials":72383,"activeCount":97},[],{"trials":72385,"activeCount":97},[],{"intervention":72301,"totalTrials":417,"cells":72387},{"EARLY_PHASE1":72388,"PHASE1":72390,"PHASE2":72396,"PHASE3":72398,"PHASE4":72400,"NA":72402},{"trials":72389,"activeCount":97},[],{"trials":72391,"activeCount":97},[72392],{"nctId":72291,"briefTitle":72292,"status":155,"phases":72393,"primaryCompletion":72294,"completion":72294,"start":40667,"enrollment":1237,"conditions":72394,"interventions":72395},[85],[18],[72284,72297,72298,72297,72299,72300,72301,72298,72302,72303,72304,72305],{"trials":72397,"activeCount":97},[],{"trials":72399,"activeCount":97},[],{"trials":72401,"activeCount":97},[],{"trials":72403,"activeCount":97},[],{"intervention":72302,"totalTrials":417,"cells":72405},{"EARLY_PHASE1":72406,"PHASE1":72408,"PHASE2":72414,"PHASE3":72416,"PHASE4":72418,"NA":72420},{"trials":72407,"activeCount":97},[],{"trials":72409,"activeCount":97},[72410],{"nctId":72291,"briefTitle":72292,"status":155,"phases":72411,"primaryCompletion":72294,"completion":72294,"start":40667,"enrollment":1237,"conditions":72412,"interventions":72413},[85],[18],[72284,72297,72298,72297,72299,72300,72301,72298,72302,72303,72304,72305],{"trials":72415,"activeCount":97},[],{"trials":72417,"activeCount":97},[],{"trials":72419,"activeCount":97},[],{"trials":72421,"activeCount":97},[],{"intervention":72303,"totalTrials":417,"cells":72423},{"EARLY_PHASE1":72424,"PHASE1":72426,"PHASE2":72432,"PHASE3":72434,"PHASE4":72436,"NA":72438},{"trials":72425,"activeCount":97},[],{"trials":72427,"activeCount":97},[72428],{"nctId":72291,"briefTitle":72292,"status":155,"phases":72429,"primaryCompletion":72294,"completion":72294,"start":40667,"enrollment":1237,"conditions":72430,"interventions":72431},[85],[18],[72284,72297,72298,72297,72299,72300,72301,72298,72302,72303,72304,72305],{"trials":72433,"activeCount":97},[],{"trials":72435,"activeCount":97},[],{"trials":72437,"activeCount":97},[],{"trials":72439,"activeCount":97},[],{"intervention":72304,"totalTrials":417,"cells":72441},{"EARLY_PHASE1":72442,"PHASE1":72444,"PHASE2":72450,"PHASE3":72452,"PHASE4":72454,"NA":72456},{"trials":72443,"activeCount":97},[],{"trials":72445,"activeCount":97},[72446],{"nctId":72291,"briefTitle":72292,"status":155,"phases":72447,"primaryCompletion":72294,"completion":72294,"start":40667,"enrollment":1237,"conditions":72448,"interventions":72449},[85],[18],[72284,72297,72298,72297,72299,72300,72301,72298,72302,72303,72304,72305],{"trials":72451,"activeCount":97},[],{"trials":72453,"activeCount":97},[],{"trials":72455,"activeCount":97},[],{"trials":72457,"activeCount":97},[],{"intervention":72305,"totalTrials":417,"cells":72459},{"EARLY_PHASE1":72460,"PHASE1":72462,"PHASE2":72468,"PHASE3":72470,"PHASE4":72472,"NA":72474},{"trials":72461,"activeCount":97},[],{"trials":72463,"activeCount":97},[72464],{"nctId":72291,"briefTitle":72292,"status":155,"phases":72465,"primaryCompletion":72294,"completion":72294,"start":40667,"enrollment":1237,"conditions":72466,"interventions":72467},[85],[18],[72284,72297,72298,72297,72299,72300,72301,72298,72302,72303,72304,72305],{"trials":72469,"activeCount":97},[],{"trials":72471,"activeCount":97},[],{"trials":72473,"activeCount":97},[],{"trials":72475,"activeCount":97},[],{"intervention":72477,"totalTrials":417,"cells":72478},"Cantharidin",{"EARLY_PHASE1":72479,"PHASE1":72481,"PHASE2":72494,"PHASE3":72496,"PHASE4":72498,"NA":72500},{"trials":72480,"activeCount":97},[],{"trials":72482,"activeCount":97},[72483],{"nctId":72484,"briefTitle":72485,"status":155,"phases":72486,"primaryCompletion":72487,"completion":72488,"start":31709,"enrollment":1459,"conditions":72489,"interventions":72490},"NCT03306589","Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects",[85],"2018-01-03","2018-06-20",[8788],[72477,72491,72492,72493],"Lipopolysaccharide","Granulocyte-Macrophage Colony-Stimulating Factor","Saline Solution",{"trials":72495,"activeCount":97},[],{"trials":72497,"activeCount":97},[],{"trials":72499,"activeCount":97},[],{"trials":72501,"activeCount":97},[],{"intervention":72491,"totalTrials":417,"cells":72503},{"EARLY_PHASE1":72504,"PHASE1":72506,"PHASE2":72512,"PHASE3":72514,"PHASE4":72516,"NA":72518},{"trials":72505,"activeCount":97},[],{"trials":72507,"activeCount":97},[72508],{"nctId":72484,"briefTitle":72485,"status":155,"phases":72509,"primaryCompletion":72487,"completion":72488,"start":31709,"enrollment":1459,"conditions":72510,"interventions":72511},[85],[8788],[72477,72491,72492,72493],{"trials":72513,"activeCount":97},[],{"trials":72515,"activeCount":97},[],{"trials":72517,"activeCount":97},[],{"trials":72519,"activeCount":97},[],{"intervention":72492,"totalTrials":417,"cells":72521},{"EARLY_PHASE1":72522,"PHASE1":72524,"PHASE2":72530,"PHASE3":72532,"PHASE4":72534,"NA":72536},{"trials":72523,"activeCount":97},[],{"trials":72525,"activeCount":97},[72526],{"nctId":72484,"briefTitle":72485,"status":155,"phases":72527,"primaryCompletion":72487,"completion":72488,"start":31709,"enrollment":1459,"conditions":72528,"interventions":72529},[85],[8788],[72477,72491,72492,72493],{"trials":72531,"activeCount":97},[],{"trials":72533,"activeCount":97},[],{"trials":72535,"activeCount":97},[],{"trials":72537,"activeCount":97},[],{"intervention":72493,"totalTrials":417,"cells":72539},{"EARLY_PHASE1":72540,"PHASE1":72542,"PHASE2":72548,"PHASE3":72550,"PHASE4":72552,"NA":72554},{"trials":72541,"activeCount":97},[],{"trials":72543,"activeCount":97},[72544],{"nctId":72484,"briefTitle":72485,"status":155,"phases":72545,"primaryCompletion":72487,"completion":72488,"start":31709,"enrollment":1459,"conditions":72546,"interventions":72547},[85],[8788],[72477,72491,72492,72493],{"trials":72549,"activeCount":97},[],{"trials":72551,"activeCount":97},[],{"trials":72553,"activeCount":97},[],{"trials":72555,"activeCount":97},[],{"intervention":72557,"totalTrials":417,"cells":72558},"Active",{"EARLY_PHASE1":72559,"PHASE1":72561,"PHASE2":72571,"PHASE3":72573,"PHASE4":72575,"NA":72577},{"trials":72560,"activeCount":97},[],{"trials":72562,"activeCount":97},[72563],{"nctId":72564,"briefTitle":72565,"status":155,"phases":72566,"primaryCompletion":72567,"completion":72567,"start":4854,"enrollment":473,"conditions":72568,"interventions":72570},"NCT01366560","Effect of GSK962040 on Oesophageal Function",[85],"2010-10-22",[72569],"Gastrointestinal Motility",[72557],{"trials":72572,"activeCount":97},[],{"trials":72574,"activeCount":97},[],{"trials":72576,"activeCount":97},[],{"trials":72578,"activeCount":97},[],{"intervention":72580,"totalTrials":417,"cells":72581},"GSK3494245",{"EARLY_PHASE1":72582,"PHASE1":72584,"PHASE2":72594,"PHASE3":72596,"PHASE4":72598,"NA":72600},{"trials":72583,"activeCount":97},[],{"trials":72585,"activeCount":97},[72586],{"nctId":72587,"briefTitle":72588,"status":145,"phases":72589,"primaryCompletion":72590,"completion":72590,"start":41322,"enrollment":2759,"conditions":72591,"interventions":72593},"NCT04504435","Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants",[85],"2024-01-14",[72592],"Leishmaniasis",[72580],{"trials":72595,"activeCount":97},[],{"trials":72597,"activeCount":97},[],{"trials":72599,"activeCount":97},[],{"trials":72601,"activeCount":97},[],{"intervention":72603,"totalTrials":417,"cells":72604},"RSG XR",{"EARLY_PHASE1":72605,"PHASE1":72607,"PHASE2":72616,"PHASE3":72618,"PHASE4":72620,"NA":72622},{"trials":72606,"activeCount":97},[],{"trials":72608,"activeCount":97},[72609],{"nctId":72610,"briefTitle":72611,"status":155,"phases":72612,"primaryCompletion":18308,"completion":18308,"start":72613,"enrollment":1003,"conditions":72614,"interventions":72615},"NCT00468897","A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.",[85],"2007-03-21",[4644],[72603],{"trials":72617,"activeCount":97},[],{"trials":72619,"activeCount":97},[],{"trials":72621,"activeCount":97},[],{"trials":72623,"activeCount":97},[],{"intervention":72625,"totalTrials":417,"cells":72626},"SK&F-105517",{"EARLY_PHASE1":72627,"PHASE1":72629,"PHASE2":72637,"PHASE3":72639,"PHASE4":72641,"NA":72643},{"trials":72628,"activeCount":97},[],{"trials":72630,"activeCount":97},[72631],{"nctId":72632,"briefTitle":72633,"status":155,"phases":72634,"primaryCompletion":7954,"completion":7954,"start":8426,"enrollment":1298,"conditions":72635,"interventions":72636},"NCT00537043","A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure",[85],[13024],[72625],{"trials":72638,"activeCount":97},[],{"trials":72640,"activeCount":97},[],{"trials":72642,"activeCount":97},[],{"trials":72644,"activeCount":97},[],{"intervention":72646,"totalTrials":417,"cells":72647},"isopropylmethylphenol and Fluoride",{"EARLY_PHASE1":72648,"PHASE1":72650,"PHASE2":72659,"PHASE3":72661,"PHASE4":72663,"NA":72665},{"trials":72649,"activeCount":97},[],{"trials":72651,"activeCount":97},[72652],{"nctId":72653,"briefTitle":72654,"status":500,"phases":72655,"primaryCompletion":24898,"completion":24898,"start":40144,"enrollment":97,"conditions":72656,"interventions":72657},"NCT01079910","To Investigate the Clinical Efficacy of an Experimental Toothpaste",[85],[15173],[72646,72658],"Fluoride and Silica",{"trials":72660,"activeCount":97},[],{"trials":72662,"activeCount":97},[],{"trials":72664,"activeCount":97},[],{"trials":72666,"activeCount":97},[],{"intervention":72658,"totalTrials":417,"cells":72668},{"EARLY_PHASE1":72669,"PHASE1":72671,"PHASE2":72677,"PHASE3":72679,"PHASE4":72681,"NA":72683},{"trials":72670,"activeCount":97},[],{"trials":72672,"activeCount":97},[72673],{"nctId":72653,"briefTitle":72654,"status":500,"phases":72674,"primaryCompletion":24898,"completion":24898,"start":40144,"enrollment":97,"conditions":72675,"interventions":72676},[85],[15173],[72646,72658],{"trials":72678,"activeCount":97},[],{"trials":72680,"activeCount":97},[],{"trials":72682,"activeCount":97},[],{"trials":72684,"activeCount":97},[],{"intervention":18693,"totalTrials":417,"cells":72686},{"EARLY_PHASE1":72687,"PHASE1":72689,"PHASE2":72695,"PHASE3":72697,"PHASE4":72699,"NA":72701},{"trials":72688,"activeCount":97},[],{"trials":72690,"activeCount":97},[72691],{"nctId":18686,"briefTitle":18687,"status":155,"phases":72692,"primaryCompletion":18689,"completion":18689,"start":18690,"enrollment":8038,"conditions":72693,"interventions":72694},[85],[15],[18693,2915,18694,3467],{"trials":72696,"activeCount":97},[],{"trials":72698,"activeCount":97},[],{"trials":72700,"activeCount":97},[],{"trials":72702,"activeCount":97},[],{"intervention":72704,"totalTrials":417,"cells":72705},"GSK4172239D",{"EARLY_PHASE1":72706,"PHASE1":72708,"PHASE2":72720,"PHASE3":72722,"PHASE4":72724,"NA":72726},{"trials":72707,"activeCount":97},[],{"trials":72709,"activeCount":97},[72710],{"nctId":72711,"briefTitle":72712,"status":145,"phases":72713,"primaryCompletion":72714,"completion":72714,"start":72715,"enrollment":361,"conditions":72716,"interventions":72719},"NCT05660265","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Oral GSK4172239D Compared With Placebo in Sickle Cell Disease Participants Aged 18 to 50 Years",[85],"2025-09-22","2023-08-26",[72717,72718],"Hematologic Diseases","Anaemia, Sickle Cell",[72704],{"trials":72721,"activeCount":97},[],{"trials":72723,"activeCount":97},[],{"trials":72725,"activeCount":97},[],{"trials":72727,"activeCount":97},[],{"intervention":72729,"totalTrials":417,"cells":72730},"Belimumab for IV",{"EARLY_PHASE1":72731,"PHASE1":72733,"PHASE2":72744,"PHASE3":72746,"PHASE4":72748,"NA":72750},{"trials":72732,"activeCount":97},[],{"trials":72734,"activeCount":97},[72735],{"nctId":72736,"briefTitle":72737,"status":155,"phases":72738,"primaryCompletion":72739,"completion":72739,"start":72740,"enrollment":710,"conditions":72741,"interventions":72742},"NCT04136145","Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects",[85],"2020-01-14","2019-10-28",[435],[72729,72743],"Belimumab for SC",{"trials":72745,"activeCount":97},[],{"trials":72747,"activeCount":97},[],{"trials":72749,"activeCount":97},[],{"trials":72751,"activeCount":97},[],{"intervention":72743,"totalTrials":417,"cells":72753},{"EARLY_PHASE1":72754,"PHASE1":72756,"PHASE2":72762,"PHASE3":72764,"PHASE4":72766,"NA":72768},{"trials":72755,"activeCount":97},[],{"trials":72757,"activeCount":97},[72758],{"nctId":72736,"briefTitle":72737,"status":155,"phases":72759,"primaryCompletion":72739,"completion":72739,"start":72740,"enrollment":710,"conditions":72760,"interventions":72761},[85],[435],[72729,72743],{"trials":72763,"activeCount":97},[],{"trials":72765,"activeCount":97},[],{"trials":72767,"activeCount":97},[],{"trials":72769,"activeCount":97},[],{"intervention":60953,"totalTrials":417,"cells":72771},{"EARLY_PHASE1":72772,"PHASE1":72774,"PHASE2":72780,"PHASE3":72782,"PHASE4":72784,"NA":72786},{"trials":72773,"activeCount":97},[],{"trials":72775,"activeCount":97},[72776],{"nctId":60948,"briefTitle":60949,"status":155,"phases":72777,"primaryCompletion":18012,"completion":18012,"start":4877,"enrollment":8437,"conditions":72778,"interventions":72779},[85],[9855],[60953,60931],{"trials":72781,"activeCount":97},[],{"trials":72783,"activeCount":97},[],{"trials":72785,"activeCount":97},[],{"trials":72787,"activeCount":97},[],{"intervention":72789,"totalTrials":417,"cells":72790},"Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state",{"EARLY_PHASE1":72791,"PHASE1":72793,"PHASE2":72805,"PHASE3":72807,"PHASE4":72809,"NA":72811},{"trials":72792,"activeCount":97},[],{"trials":72794,"activeCount":97},[72795],{"nctId":72796,"briefTitle":72797,"status":155,"phases":72798,"primaryCompletion":72799,"completion":72799,"start":72800,"enrollment":314,"conditions":72801,"interventions":72802},"NCT01648231","Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health Volunteers",[85],"2012-09-25","2012-08-06",[13024],[72789,72803,72804],"Fixed Dose Combination 1: 1 x 5mg amlodipine \u002F 100mg losartan tablet administered in fasted state","Fixed Dose Combination 2: 1 x 5mg amlodipine \u002F 100mg losartan tablet administered in fasted state",{"trials":72806,"activeCount":97},[],{"trials":72808,"activeCount":97},[],{"trials":72810,"activeCount":97},[],{"trials":72812,"activeCount":97},[],{"intervention":72803,"totalTrials":417,"cells":72814},{"EARLY_PHASE1":72815,"PHASE1":72817,"PHASE2":72823,"PHASE3":72825,"PHASE4":72827,"NA":72829},{"trials":72816,"activeCount":97},[],{"trials":72818,"activeCount":97},[72819],{"nctId":72796,"briefTitle":72797,"status":155,"phases":72820,"primaryCompletion":72799,"completion":72799,"start":72800,"enrollment":314,"conditions":72821,"interventions":72822},[85],[13024],[72789,72803,72804],{"trials":72824,"activeCount":97},[],{"trials":72826,"activeCount":97},[],{"trials":72828,"activeCount":97},[],{"trials":72830,"activeCount":97},[],{"intervention":72804,"totalTrials":417,"cells":72832},{"EARLY_PHASE1":72833,"PHASE1":72835,"PHASE2":72841,"PHASE3":72843,"PHASE4":72845,"NA":72847},{"trials":72834,"activeCount":97},[],{"trials":72836,"activeCount":97},[72837],{"nctId":72796,"briefTitle":72797,"status":155,"phases":72838,"primaryCompletion":72799,"completion":72799,"start":72800,"enrollment":314,"conditions":72839,"interventions":72840},[85],[13024],[72789,72803,72804],{"trials":72842,"activeCount":97},[],{"trials":72844,"activeCount":97},[],{"trials":72846,"activeCount":97},[],{"trials":72848,"activeCount":97},[],{"intervention":72850,"totalTrials":417,"cells":72851},"subcutanious administration",{"EARLY_PHASE1":72852,"PHASE1":72854,"PHASE2":72864,"PHASE3":72866,"PHASE4":72868,"NA":72870},{"trials":72853,"activeCount":97},[],{"trials":72855,"activeCount":97},[72856],{"nctId":72857,"briefTitle":72858,"status":155,"phases":72859,"primaryCompletion":42745,"completion":72860,"start":72861,"enrollment":695,"conditions":72862,"interventions":72863},"NCT01101555","Repeat Dose Subcutaneous Rhumatoid Arthritis Efficacy Study",[85],"2012-11-29","2010-05-12",[8788],[72850],{"trials":72865,"activeCount":97},[],{"trials":72867,"activeCount":97},[],{"trials":72869,"activeCount":97},[],{"trials":72871,"activeCount":97},[],{"intervention":72873,"totalTrials":417,"cells":72874},"Reformulated scopolamine patch",{"EARLY_PHASE1":72875,"PHASE1":72877,"PHASE2":72888,"PHASE3":72890,"PHASE4":72892,"NA":72894},{"trials":72876,"activeCount":97},[],{"trials":72878,"activeCount":97},[72879],{"nctId":72880,"briefTitle":72881,"status":155,"phases":72882,"primaryCompletion":63994,"completion":19586,"start":72883,"enrollment":4940,"conditions":72884,"interventions":72886},"NCT02839135","A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.",[85],"2016-05-13",[72885],"Motion Sickness",[72873,72887],"Marketed scopolamine patch",{"trials":72889,"activeCount":97},[],{"trials":72891,"activeCount":97},[],{"trials":72893,"activeCount":97},[],{"trials":72895,"activeCount":97},[],{"intervention":72887,"totalTrials":417,"cells":72897},{"EARLY_PHASE1":72898,"PHASE1":72900,"PHASE2":72906,"PHASE3":72908,"PHASE4":72910,"NA":72912},{"trials":72899,"activeCount":97},[],{"trials":72901,"activeCount":97},[72902],{"nctId":72880,"briefTitle":72881,"status":155,"phases":72903,"primaryCompletion":63994,"completion":19586,"start":72883,"enrollment":4940,"conditions":72904,"interventions":72905},[85],[72885],[72873,72887],{"trials":72907,"activeCount":97},[],{"trials":72909,"activeCount":97},[],{"trials":72911,"activeCount":97},[],{"trials":72913,"activeCount":97},[],{"intervention":72915,"totalTrials":417,"cells":72916},"SK&F-105517-D 10 mg",{"EARLY_PHASE1":72917,"PHASE1":72919,"PHASE2":72932,"PHASE3":72934,"PHASE4":72936,"NA":72938},{"trials":72918,"activeCount":97},[],{"trials":72920,"activeCount":97},[72921],{"nctId":72922,"briefTitle":72923,"status":155,"phases":72924,"primaryCompletion":72925,"completion":72925,"start":4690,"enrollment":212,"conditions":72926,"interventions":72927},"NCT00742508","A Phase I\u002FII Clinical Study of SK&F-105517-D in Japanese Patients With Chronic Heart Failure",[85],"2009-08-21",[17253],[72915,72928,72929,72930,72931],"Carvedilol-immediate release (IR) 2.5 mg","SK&F-105517-D 20 mg","SK&F-105517-D 40 mg","Carvedilol-IR 10 mg",{"trials":72933,"activeCount":97},[],{"trials":72935,"activeCount":97},[],{"trials":72937,"activeCount":97},[],{"trials":72939,"activeCount":97},[],{"intervention":72928,"totalTrials":417,"cells":72941},{"EARLY_PHASE1":72942,"PHASE1":72944,"PHASE2":72950,"PHASE3":72952,"PHASE4":72954,"NA":72956},{"trials":72943,"activeCount":97},[],{"trials":72945,"activeCount":97},[72946],{"nctId":72922,"briefTitle":72923,"status":155,"phases":72947,"primaryCompletion":72925,"completion":72925,"start":4690,"enrollment":212,"conditions":72948,"interventions":72949},[85],[17253],[72915,72928,72929,72930,72931],{"trials":72951,"activeCount":97},[],{"trials":72953,"activeCount":97},[],{"trials":72955,"activeCount":97},[],{"trials":72957,"activeCount":97},[],{"intervention":72929,"totalTrials":417,"cells":72959},{"EARLY_PHASE1":72960,"PHASE1":72962,"PHASE2":72968,"PHASE3":72970,"PHASE4":72972,"NA":72974},{"trials":72961,"activeCount":97},[],{"trials":72963,"activeCount":97},[72964],{"nctId":72922,"briefTitle":72923,"status":155,"phases":72965,"primaryCompletion":72925,"completion":72925,"start":4690,"enrollment":212,"conditions":72966,"interventions":72967},[85],[17253],[72915,72928,72929,72930,72931],{"trials":72969,"activeCount":97},[],{"trials":72971,"activeCount":97},[],{"trials":72973,"activeCount":97},[],{"trials":72975,"activeCount":97},[],{"intervention":72930,"totalTrials":417,"cells":72977},{"EARLY_PHASE1":72978,"PHASE1":72980,"PHASE2":72986,"PHASE3":72988,"PHASE4":72990,"NA":72992},{"trials":72979,"activeCount":97},[],{"trials":72981,"activeCount":97},[72982],{"nctId":72922,"briefTitle":72923,"status":155,"phases":72983,"primaryCompletion":72925,"completion":72925,"start":4690,"enrollment":212,"conditions":72984,"interventions":72985},[85],[17253],[72915,72928,72929,72930,72931],{"trials":72987,"activeCount":97},[],{"trials":72989,"activeCount":97},[],{"trials":72991,"activeCount":97},[],{"trials":72993,"activeCount":97},[],{"intervention":72931,"totalTrials":417,"cells":72995},{"EARLY_PHASE1":72996,"PHASE1":72998,"PHASE2":73004,"PHASE3":73006,"PHASE4":73008,"NA":73010},{"trials":72997,"activeCount":97},[],{"trials":72999,"activeCount":97},[73000],{"nctId":72922,"briefTitle":72923,"status":155,"phases":73001,"primaryCompletion":72925,"completion":72925,"start":4690,"enrollment":212,"conditions":73002,"interventions":73003},[85],[17253],[72915,72928,72929,72930,72931],{"trials":73005,"activeCount":97},[],{"trials":73007,"activeCount":97},[],{"trials":73009,"activeCount":97},[],{"trials":73011,"activeCount":97},[],{"intervention":73013,"totalTrials":417,"cells":73014},"Diclofenac sodium",{"EARLY_PHASE1":73015,"PHASE1":73017,"PHASE2":73026,"PHASE3":73028,"PHASE4":73030,"NA":73032},{"trials":73016,"activeCount":97},[],{"trials":73018,"activeCount":97},[73019],{"nctId":73020,"briefTitle":73021,"status":155,"phases":73022,"primaryCompletion":8107,"completion":8107,"start":32586,"enrollment":1634,"conditions":73023,"interventions":73024},"NCT02201238","Pharmacokinetics Study Comparing Topical Diclofenac\u002FMenthol Gels With Voltaren Gel and Oral Diclofenac Sodium",[85],[9153],[73013,73025],"Menthol",{"trials":73027,"activeCount":97},[],{"trials":73029,"activeCount":97},[],{"trials":73031,"activeCount":97},[],{"trials":73033,"activeCount":97},[],{"intervention":73025,"totalTrials":417,"cells":73035},{"EARLY_PHASE1":73036,"PHASE1":73038,"PHASE2":73044,"PHASE3":73046,"PHASE4":73048,"NA":73050},{"trials":73037,"activeCount":97},[],{"trials":73039,"activeCount":97},[73040],{"nctId":73020,"briefTitle":73021,"status":155,"phases":73041,"primaryCompletion":8107,"completion":8107,"start":32586,"enrollment":1634,"conditions":73042,"interventions":73043},[85],[9153],[73013,73025],{"trials":73045,"activeCount":97},[],{"trials":73047,"activeCount":97},[],{"trials":73049,"activeCount":97},[],{"trials":73051,"activeCount":97},[],{"intervention":9173,"totalTrials":417,"cells":73053},{"EARLY_PHASE1":73054,"PHASE1":73056,"PHASE2":73062,"PHASE3":73064,"PHASE4":73066,"NA":73068},{"trials":73055,"activeCount":97},[],{"trials":73057,"activeCount":97},[73058],{"nctId":9168,"briefTitle":9169,"status":155,"phases":73059,"primaryCompletion":6351,"completion":6351,"start":6351,"enrollment":1634,"conditions":73060,"interventions":73061},[85],[7524],[9173,9174,9175,4763],{"trials":73063,"activeCount":97},[],{"trials":73065,"activeCount":97},[],{"trials":73067,"activeCount":97},[],{"trials":73069,"activeCount":97},[],{"intervention":9174,"totalTrials":417,"cells":73071},{"EARLY_PHASE1":73072,"PHASE1":73074,"PHASE2":73080,"PHASE3":73082,"PHASE4":73084,"NA":73086},{"trials":73073,"activeCount":97},[],{"trials":73075,"activeCount":97},[73076],{"nctId":9168,"briefTitle":9169,"status":155,"phases":73077,"primaryCompletion":6351,"completion":6351,"start":6351,"enrollment":1634,"conditions":73078,"interventions":73079},[85],[7524],[9173,9174,9175,4763],{"trials":73081,"activeCount":97},[],{"trials":73083,"activeCount":97},[],{"trials":73085,"activeCount":97},[],{"trials":73087,"activeCount":97},[],{"intervention":9175,"totalTrials":417,"cells":73089},{"EARLY_PHASE1":73090,"PHASE1":73092,"PHASE2":73098,"PHASE3":73100,"PHASE4":73102,"NA":73104},{"trials":73091,"activeCount":97},[],{"trials":73093,"activeCount":97},[73094],{"nctId":9168,"briefTitle":9169,"status":155,"phases":73095,"primaryCompletion":6351,"completion":6351,"start":6351,"enrollment":1634,"conditions":73096,"interventions":73097},[85],[7524],[9173,9174,9175,4763],{"trials":73099,"activeCount":97},[],{"trials":73101,"activeCount":97},[],{"trials":73103,"activeCount":97},[],{"trials":73105,"activeCount":97},[],{"intervention":13049,"totalTrials":417,"cells":73107},{"EARLY_PHASE1":73108,"PHASE1":73110,"PHASE2":73116,"PHASE3":73118,"PHASE4":73120,"NA":73122},{"trials":73109,"activeCount":97},[],{"trials":73111,"activeCount":97},[73112],{"nctId":13044,"briefTitle":13045,"status":155,"phases":73113,"primaryCompletion":7522,"completion":7522,"start":2382,"enrollment":6503,"conditions":73114,"interventions":73115},[85],[9036,27],[13037,13049,13050],{"trials":73117,"activeCount":97},[],{"trials":73119,"activeCount":97},[],{"trials":73121,"activeCount":97},[],{"trials":73123,"activeCount":97},[],{"intervention":13050,"totalTrials":417,"cells":73125},{"EARLY_PHASE1":73126,"PHASE1":73128,"PHASE2":73134,"PHASE3":73136,"PHASE4":73138,"NA":73140},{"trials":73127,"activeCount":97},[],{"trials":73129,"activeCount":97},[73130],{"nctId":13044,"briefTitle":13045,"status":155,"phases":73131,"primaryCompletion":7522,"completion":7522,"start":2382,"enrollment":6503,"conditions":73132,"interventions":73133},[85],[9036,27],[13037,13049,13050],{"trials":73135,"activeCount":97},[],{"trials":73137,"activeCount":97},[],{"trials":73139,"activeCount":97},[],{"trials":73141,"activeCount":97},[],{"intervention":21590,"totalTrials":417,"cells":73143},{"EARLY_PHASE1":73144,"PHASE1":73146,"PHASE2":73152,"PHASE3":73154,"PHASE4":73156,"NA":73158},{"trials":73145,"activeCount":97},[],{"trials":73147,"activeCount":97},[73148],{"nctId":21583,"briefTitle":21584,"status":155,"phases":73149,"primaryCompletion":21586,"completion":21586,"start":8190,"enrollment":433,"conditions":73150,"interventions":73151},[85],[1337],[21589,21590,21591,10467],{"trials":73153,"activeCount":97},[],{"trials":73155,"activeCount":97},[],{"trials":73157,"activeCount":97},[],{"trials":73159,"activeCount":97},[],{"intervention":21591,"totalTrials":417,"cells":73161},{"EARLY_PHASE1":73162,"PHASE1":73164,"PHASE2":73170,"PHASE3":73172,"PHASE4":73174,"NA":73176},{"trials":73163,"activeCount":97},[],{"trials":73165,"activeCount":97},[73166],{"nctId":21583,"briefTitle":21584,"status":155,"phases":73167,"primaryCompletion":21586,"completion":21586,"start":8190,"enrollment":433,"conditions":73168,"interventions":73169},[85],[1337],[21589,21590,21591,10467],{"trials":73171,"activeCount":97},[],{"trials":73173,"activeCount":97},[],{"trials":73175,"activeCount":97},[],{"trials":73177,"activeCount":97},[],{"intervention":73179,"totalTrials":417,"cells":73180},"Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined",{"EARLY_PHASE1":73181,"PHASE1":73183,"PHASE2":73192,"PHASE3":73194,"PHASE4":73196,"NA":73198},{"trials":73182,"activeCount":97},[],{"trials":73184,"activeCount":97},[73185],{"nctId":73186,"briefTitle":73187,"status":155,"phases":73188,"primaryCompletion":10518,"completion":10518,"start":45433,"enrollment":34,"conditions":73189,"interventions":73190},"NCT01615796","Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses",[85],[14696],[73179,73191],"Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined",{"trials":73193,"activeCount":97},[],{"trials":73195,"activeCount":97},[],{"trials":73197,"activeCount":97},[],{"trials":73199,"activeCount":97},[],{"intervention":73191,"totalTrials":417,"cells":73201},{"EARLY_PHASE1":73202,"PHASE1":73204,"PHASE2":73210,"PHASE3":73212,"PHASE4":73214,"NA":73216},{"trials":73203,"activeCount":97},[],{"trials":73205,"activeCount":97},[73206],{"nctId":73186,"briefTitle":73187,"status":155,"phases":73207,"primaryCompletion":10518,"completion":10518,"start":45433,"enrollment":34,"conditions":73208,"interventions":73209},[85],[14696],[73179,73191],{"trials":73211,"activeCount":97},[],{"trials":73213,"activeCount":97},[],{"trials":73215,"activeCount":97},[],{"trials":73217,"activeCount":97},[],{"intervention":60207,"totalTrials":417,"cells":73219},{"EARLY_PHASE1":73220,"PHASE1":73222,"PHASE2":73228,"PHASE3":73230,"PHASE4":73232,"NA":73234},{"trials":73221,"activeCount":97},[],{"trials":73223,"activeCount":97},[73224],{"nctId":60199,"briefTitle":60200,"status":155,"phases":73225,"primaryCompletion":60202,"completion":60202,"start":60203,"enrollment":628,"conditions":73226,"interventions":73227},[85],[60205],[60186,60207],{"trials":73229,"activeCount":97},[],{"trials":73231,"activeCount":97},[],{"trials":73233,"activeCount":97},[],{"trials":73235,"activeCount":97},[],{"intervention":73237,"totalTrials":417,"cells":73238},"[14C]-GSK2269557 IV",{"EARLY_PHASE1":73239,"PHASE1":73241,"PHASE2":73251,"PHASE3":73253,"PHASE4":73255,"NA":73257},{"trials":73240,"activeCount":97},[],{"trials":73242,"activeCount":97},[73243],{"nctId":73244,"briefTitle":73245,"status":155,"phases":73246,"primaryCompletion":20264,"completion":20264,"start":55063,"enrollment":628,"conditions":73247,"interventions":73248},"NCT03315559","Absorption & Elimination of Radiolabelled GSK2269557",[85],[15],[73237,73249,73250],"GSK2269557 via DPI","[14C]-GSK2269557 oral solution",{"trials":73252,"activeCount":97},[],{"trials":73254,"activeCount":97},[],{"trials":73256,"activeCount":97},[],{"trials":73258,"activeCount":97},[],{"intervention":73249,"totalTrials":417,"cells":73260},{"EARLY_PHASE1":73261,"PHASE1":73263,"PHASE2":73269,"PHASE3":73271,"PHASE4":73273,"NA":73275},{"trials":73262,"activeCount":97},[],{"trials":73264,"activeCount":97},[73265],{"nctId":73244,"briefTitle":73245,"status":155,"phases":73266,"primaryCompletion":20264,"completion":20264,"start":55063,"enrollment":628,"conditions":73267,"interventions":73268},[85],[15],[73237,73249,73250],{"trials":73270,"activeCount":97},[],{"trials":73272,"activeCount":97},[],{"trials":73274,"activeCount":97},[],{"trials":73276,"activeCount":97},[],{"intervention":73250,"totalTrials":417,"cells":73278},{"EARLY_PHASE1":73279,"PHASE1":73281,"PHASE2":73287,"PHASE3":73289,"PHASE4":73291,"NA":73293},{"trials":73280,"activeCount":97},[],{"trials":73282,"activeCount":97},[73283],{"nctId":73244,"briefTitle":73245,"status":155,"phases":73284,"primaryCompletion":20264,"completion":20264,"start":55063,"enrollment":628,"conditions":73285,"interventions":73286},[85],[15],[73237,73249,73250],{"trials":73288,"activeCount":97},[],{"trials":73290,"activeCount":97},[],{"trials":73292,"activeCount":97},[],{"trials":73294,"activeCount":97},[],{"intervention":42438,"totalTrials":417,"cells":73296},{"EARLY_PHASE1":73297,"PHASE1":73299,"PHASE2":73305,"PHASE3":73307,"PHASE4":73309,"NA":73311},{"trials":73298,"activeCount":97},[],{"trials":73300,"activeCount":97},[73301],{"nctId":42433,"briefTitle":42434,"status":155,"phases":73302,"primaryCompletion":39677,"completion":39677,"start":11960,"enrollment":6503,"conditions":73303,"interventions":73304},[85],[36],[42422,9325,18007,42438,42439],{"trials":73306,"activeCount":97},[],{"trials":73308,"activeCount":97},[],{"trials":73310,"activeCount":97},[],{"trials":73312,"activeCount":97},[],{"intervention":42439,"totalTrials":417,"cells":73314},{"EARLY_PHASE1":73315,"PHASE1":73317,"PHASE2":73323,"PHASE3":73325,"PHASE4":73327,"NA":73329},{"trials":73316,"activeCount":97},[],{"trials":73318,"activeCount":97},[73319],{"nctId":42433,"briefTitle":42434,"status":155,"phases":73320,"primaryCompletion":39677,"completion":39677,"start":11960,"enrollment":6503,"conditions":73321,"interventions":73322},[85],[36],[42422,9325,18007,42438,42439],{"trials":73324,"activeCount":97},[],{"trials":73326,"activeCount":97},[],{"trials":73328,"activeCount":97},[],{"trials":73330,"activeCount":97},[],{"intervention":61543,"totalTrials":417,"cells":73332},{"EARLY_PHASE1":73333,"PHASE1":73335,"PHASE2":73341,"PHASE3":73343,"PHASE4":73345,"NA":73347},{"trials":73334,"activeCount":97},[],{"trials":73336,"activeCount":97},[73337],{"nctId":61538,"briefTitle":61539,"status":155,"phases":73338,"primaryCompletion":22918,"completion":22918,"start":4984,"enrollment":6503,"conditions":73339,"interventions":73340},[85],[15],[61522,61535,61543,61544],{"trials":73342,"activeCount":97},[],{"trials":73344,"activeCount":97},[],{"trials":73346,"activeCount":97},[],{"trials":73348,"activeCount":97},[],{"intervention":61544,"totalTrials":417,"cells":73350},{"EARLY_PHASE1":73351,"PHASE1":73353,"PHASE2":73359,"PHASE3":73361,"PHASE4":73363,"NA":73365},{"trials":73352,"activeCount":97},[],{"trials":73354,"activeCount":97},[73355],{"nctId":61538,"briefTitle":61539,"status":155,"phases":73356,"primaryCompletion":22918,"completion":22918,"start":4984,"enrollment":6503,"conditions":73357,"interventions":73358},[85],[15],[61522,61535,61543,61544],{"trials":73360,"activeCount":97},[],{"trials":73362,"activeCount":97},[],{"trials":73364,"activeCount":97},[],{"trials":73366,"activeCount":97},[],{"intervention":40298,"totalTrials":417,"cells":73368},{"EARLY_PHASE1":73369,"PHASE1":73371,"PHASE2":73377,"PHASE3":73379,"PHASE4":73381,"NA":73383},{"trials":73370,"activeCount":97},[],{"trials":73372,"activeCount":97},[73373],{"nctId":40292,"briefTitle":40293,"status":155,"phases":73374,"primaryCompletion":4836,"completion":4836,"start":40295,"enrollment":3025,"conditions":73375,"interventions":73376},[85],[19716],[19718,40298],{"trials":73378,"activeCount":97},[],{"trials":73380,"activeCount":97},[],{"trials":73382,"activeCount":97},[],{"trials":73384,"activeCount":97},[],{"intervention":73386,"totalTrials":417,"cells":73387},"Fluimucil® 2% solution",{"EARLY_PHASE1":73388,"PHASE1":73390,"PHASE2":73400,"PHASE3":73402,"PHASE4":73404,"NA":73406},{"trials":73389,"activeCount":97},[],{"trials":73391,"activeCount":97},[73392],{"nctId":73393,"briefTitle":73394,"status":155,"phases":73395,"primaryCompletion":40354,"completion":40354,"start":73396,"enrollment":4121,"conditions":73397,"interventions":73398},"NCT02688361","A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution",[85],"2016-02-22",[14696],[73386,73399],"Acetylcysteine 2% solution",{"trials":73401,"activeCount":97},[],{"trials":73403,"activeCount":97},[],{"trials":73405,"activeCount":97},[],{"trials":73407,"activeCount":97},[],{"intervention":73399,"totalTrials":417,"cells":73409},{"EARLY_PHASE1":73410,"PHASE1":73412,"PHASE2":73418,"PHASE3":73420,"PHASE4":73422,"NA":73424},{"trials":73411,"activeCount":97},[],{"trials":73413,"activeCount":97},[73414],{"nctId":73393,"briefTitle":73394,"status":155,"phases":73415,"primaryCompletion":40354,"completion":40354,"start":73396,"enrollment":4121,"conditions":73416,"interventions":73417},[85],[14696],[73386,73399],{"trials":73419,"activeCount":97},[],{"trials":73421,"activeCount":97},[],{"trials":73423,"activeCount":97},[],{"trials":73425,"activeCount":97},[],{"intervention":73427,"totalTrials":417,"cells":73428},"Crestor®",{"EARLY_PHASE1":73429,"PHASE1":73431,"PHASE2":73440,"PHASE3":73442,"PHASE4":73444,"NA":73446},{"trials":73430,"activeCount":97},[],{"trials":73432,"activeCount":97},[73433],{"nctId":73434,"briefTitle":73435,"status":155,"phases":73436,"primaryCompletion":9126,"completion":9126,"start":11235,"enrollment":1237,"conditions":73437,"interventions":73438},"NCT01711749","Rosuvastatin Calcium Bioequivalence Study - Fast",[85],[43486],[73427,73439],"rosuvastatin calcium",{"trials":73441,"activeCount":97},[],{"trials":73443,"activeCount":97},[],{"trials":73445,"activeCount":97},[],{"trials":73447,"activeCount":97},[],{"intervention":73439,"totalTrials":417,"cells":73449},{"EARLY_PHASE1":73450,"PHASE1":73452,"PHASE2":73458,"PHASE3":73460,"PHASE4":73462,"NA":73464},{"trials":73451,"activeCount":97},[],{"trials":73453,"activeCount":97},[73454],{"nctId":73434,"briefTitle":73435,"status":155,"phases":73455,"primaryCompletion":9126,"completion":9126,"start":11235,"enrollment":1237,"conditions":73456,"interventions":73457},[85],[43486],[73427,73439],{"trials":73459,"activeCount":97},[],{"trials":73461,"activeCount":97},[],{"trials":73463,"activeCount":97},[],{"trials":73465,"activeCount":97},[],{"intervention":61830,"totalTrials":417,"cells":73467},{"EARLY_PHASE1":73468,"PHASE1":73470,"PHASE2":73476,"PHASE3":73478,"PHASE4":73480,"NA":73482},{"trials":73469,"activeCount":97},[],{"trials":73471,"activeCount":97},[73472],{"nctId":61824,"briefTitle":61825,"status":155,"phases":73473,"primaryCompletion":61827,"completion":61827,"start":8795,"enrollment":1686,"conditions":73474,"interventions":73475},[85],[41867],[61830,61810,61831],{"trials":73477,"activeCount":97},[],{"trials":73479,"activeCount":97},[],{"trials":73481,"activeCount":97},[],{"trials":73483,"activeCount":97},[],{"intervention":61831,"totalTrials":417,"cells":73485},{"EARLY_PHASE1":73486,"PHASE1":73488,"PHASE2":73494,"PHASE3":73496,"PHASE4":73498,"NA":73500},{"trials":73487,"activeCount":97},[],{"trials":73489,"activeCount":97},[73490],{"nctId":61824,"briefTitle":61825,"status":155,"phases":73491,"primaryCompletion":61827,"completion":61827,"start":8795,"enrollment":1686,"conditions":73492,"interventions":73493},[85],[41867],[61830,61810,61831],{"trials":73495,"activeCount":97},[],{"trials":73497,"activeCount":97},[],{"trials":73499,"activeCount":97},[],{"trials":73501,"activeCount":97},[],{"intervention":73503,"totalTrials":417,"cells":73504},"Treatment Period 1 - IV dose of GSK573719",{"EARLY_PHASE1":73505,"PHASE1":73507,"PHASE2":73518,"PHASE3":73520,"PHASE4":73522,"NA":73524},{"trials":73506,"activeCount":97},[],{"trials":73508,"activeCount":97},[73509],{"nctId":73510,"briefTitle":73511,"status":155,"phases":73512,"primaryCompletion":73513,"completion":73513,"start":73514,"enrollment":628,"conditions":73515,"interventions":73516},"NCT01362257","A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719",[85],"2011-06-22","2011-04-29",[15],[73503,73517],"Treatment Period 2 - Oral dose of GSK573719",{"trials":73519,"activeCount":97},[],{"trials":73521,"activeCount":97},[],{"trials":73523,"activeCount":97},[],{"trials":73525,"activeCount":97},[],{"intervention":73517,"totalTrials":417,"cells":73527},{"EARLY_PHASE1":73528,"PHASE1":73530,"PHASE2":73536,"PHASE3":73538,"PHASE4":73540,"NA":73542},{"trials":73529,"activeCount":97},[],{"trials":73531,"activeCount":97},[73532],{"nctId":73510,"briefTitle":73511,"status":155,"phases":73533,"primaryCompletion":73513,"completion":73513,"start":73514,"enrollment":628,"conditions":73534,"interventions":73535},[85],[15],[73503,73517],{"trials":73537,"activeCount":97},[],{"trials":73539,"activeCount":97},[],{"trials":73541,"activeCount":97},[],{"trials":73543,"activeCount":97},[],{"intervention":59450,"totalTrials":417,"cells":73545},{"EARLY_PHASE1":73546,"PHASE1":73548,"PHASE2":73554,"PHASE3":73556,"PHASE4":73558,"NA":73560},{"trials":73547,"activeCount":97},[],{"trials":73549,"activeCount":97},[73550],{"nctId":59445,"briefTitle":59446,"status":500,"phases":73551,"primaryCompletion":9159,"completion":9159,"start":2442,"enrollment":97,"conditions":73552,"interventions":73553},[85],[4644],[59450,8022],{"trials":73555,"activeCount":97},[],{"trials":73557,"activeCount":97},[],{"trials":73559,"activeCount":97},[],{"trials":73561,"activeCount":97},[],{"intervention":42740,"totalTrials":417,"cells":73563},{"EARLY_PHASE1":73564,"PHASE1":73566,"PHASE2":73572,"PHASE3":73574,"PHASE4":73576,"NA":73578},{"trials":73565,"activeCount":97},[],{"trials":73567,"activeCount":97},[73568],{"nctId":42732,"briefTitle":42733,"status":155,"phases":73569,"primaryCompletion":42735,"completion":42735,"start":42736,"enrollment":904,"conditions":73570,"interventions":73571},[85],[42738],[42725,42740],{"trials":73573,"activeCount":97},[],{"trials":73575,"activeCount":97},[],{"trials":73577,"activeCount":97},[],{"trials":73579,"activeCount":97},[],{"intervention":73581,"totalTrials":417,"cells":73582},"GI198745 0.1 mg",{"EARLY_PHASE1":73583,"PHASE1":73585,"PHASE2":73595,"PHASE3":73597,"PHASE4":73599,"NA":73601},{"trials":73584,"activeCount":97},[],{"trials":73586,"activeCount":97},[73587],{"nctId":73588,"briefTitle":73589,"status":155,"phases":73590,"primaryCompletion":31972,"completion":31972,"start":73591,"enrollment":710,"conditions":73592,"interventions":73593},"NCT01929330","Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers",[85],"2013-09-23",[22627],[73581,73594],"GI198745 0.5 mg",{"trials":73596,"activeCount":97},[],{"trials":73598,"activeCount":97},[],{"trials":73600,"activeCount":97},[],{"trials":73602,"activeCount":97},[],{"intervention":73594,"totalTrials":417,"cells":73604},{"EARLY_PHASE1":73605,"PHASE1":73607,"PHASE2":73613,"PHASE3":73615,"PHASE4":73617,"NA":73619},{"trials":73606,"activeCount":97},[],{"trials":73608,"activeCount":97},[73609],{"nctId":73588,"briefTitle":73589,"status":155,"phases":73610,"primaryCompletion":31972,"completion":31972,"start":73591,"enrollment":710,"conditions":73611,"interventions":73612},[85],[22627],[73581,73594],{"trials":73614,"activeCount":97},[],{"trials":73616,"activeCount":97},[],{"trials":73618,"activeCount":97},[],{"trials":73620,"activeCount":97},[],{"intervention":2285,"totalTrials":417,"cells":73622},{"EARLY_PHASE1":73623,"PHASE1":73625,"PHASE2":73631,"PHASE3":73633,"PHASE4":73635,"NA":73637},{"trials":73624,"activeCount":97},[],{"trials":73626,"activeCount":97},[73627],{"nctId":2277,"briefTitle":2278,"status":155,"phases":73628,"primaryCompletion":2280,"completion":2280,"start":2281,"enrollment":2282,"conditions":73629,"interventions":73630},[85],[107],[2285,2264,2275,2286,2287,2288],{"trials":73632,"activeCount":97},[],{"trials":73634,"activeCount":97},[],{"trials":73636,"activeCount":97},[],{"trials":73638,"activeCount":97},[],{"intervention":73640,"totalTrials":417,"cells":73641},"Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg",{"EARLY_PHASE1":73642,"PHASE1":73644,"PHASE2":73653,"PHASE3":73655,"PHASE4":73657,"NA":73659},{"trials":73643,"activeCount":97},[],{"trials":73645,"activeCount":97},[73646],{"nctId":73647,"briefTitle":73648,"status":155,"phases":73649,"primaryCompletion":2967,"completion":2967,"start":555,"enrollment":695,"conditions":73650,"interventions":73651},"NCT03415243","To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers",[85],[9183],[73640,73652],"Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg",{"trials":73654,"activeCount":97},[],{"trials":73656,"activeCount":97},[],{"trials":73658,"activeCount":97},[],{"trials":73660,"activeCount":97},[],{"intervention":73652,"totalTrials":417,"cells":73662},{"EARLY_PHASE1":73663,"PHASE1":73665,"PHASE2":73671,"PHASE3":73673,"PHASE4":73675,"NA":73677},{"trials":73664,"activeCount":97},[],{"trials":73666,"activeCount":97},[73667],{"nctId":73647,"briefTitle":73648,"status":155,"phases":73668,"primaryCompletion":2967,"completion":2967,"start":555,"enrollment":695,"conditions":73669,"interventions":73670},[85],[9183],[73640,73652],{"trials":73672,"activeCount":97},[],{"trials":73674,"activeCount":97},[],{"trials":73676,"activeCount":97},[],{"trials":73678,"activeCount":97},[],{"intervention":73680,"totalTrials":417,"cells":73681},"GSK598809, using [11C]-(+)-PHNO",{"EARLY_PHASE1":73682,"PHASE1":73684,"PHASE2":73692,"PHASE3":73694,"PHASE4":73696,"NA":73698},{"trials":73683,"activeCount":97},[],{"trials":73685,"activeCount":97},[73686],{"nctId":73687,"briefTitle":73688,"status":155,"phases":73689,"primaryCompletion":7522,"completion":7522,"start":4756,"enrollment":463,"conditions":73690,"interventions":73691},"NCT00468806","Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males.",[85],[7524],[73680],{"trials":73693,"activeCount":97},[],{"trials":73695,"activeCount":97},[],{"trials":73697,"activeCount":97},[],{"trials":73699,"activeCount":97},[],{"intervention":73701,"totalTrials":417,"cells":73702},"GSK2485852 70 mg",{"EARLY_PHASE1":73703,"PHASE1":73705,"PHASE2":73719,"PHASE3":73721,"PHASE4":73723,"NA":73725},{"trials":73704,"activeCount":97},[],{"trials":73706,"activeCount":97},[73707],{"nctId":73708,"briefTitle":73709,"status":145,"phases":73710,"primaryCompletion":73711,"completion":73711,"start":18982,"enrollment":9334,"conditions":73712,"interventions":73713},"NCT01332552","A First Time in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of GSK2485852 in Chronically Infected Hepatitis C Subjects",[85],"2011-04-06",[23770],[73701,73714,73714,73714,73715,73716,73717,73718],"GSK2485852 420 mg","GSK2485852 630 mg","GSK2485852 70 mg + Ritonavir 100mg","GSK2485852 210 mg + Ritonavir 100mg","GSK2485852 210 mg +Ritonavir 100mg",{"trials":73720,"activeCount":97},[],{"trials":73722,"activeCount":97},[],{"trials":73724,"activeCount":97},[],{"trials":73726,"activeCount":97},[],{"intervention":73714,"totalTrials":417,"cells":73728},{"EARLY_PHASE1":73729,"PHASE1":73731,"PHASE2":73737,"PHASE3":73739,"PHASE4":73741,"NA":73743},{"trials":73730,"activeCount":97},[],{"trials":73732,"activeCount":97},[73733],{"nctId":73708,"briefTitle":73709,"status":145,"phases":73734,"primaryCompletion":73711,"completion":73711,"start":18982,"enrollment":9334,"conditions":73735,"interventions":73736},[85],[23770],[73701,73714,73714,73714,73715,73716,73717,73718],{"trials":73738,"activeCount":97},[],{"trials":73740,"activeCount":97},[],{"trials":73742,"activeCount":97},[],{"trials":73744,"activeCount":97},[],{"intervention":73715,"totalTrials":417,"cells":73746},{"EARLY_PHASE1":73747,"PHASE1":73749,"PHASE2":73755,"PHASE3":73757,"PHASE4":73759,"NA":73761},{"trials":73748,"activeCount":97},[],{"trials":73750,"activeCount":97},[73751],{"nctId":73708,"briefTitle":73709,"status":145,"phases":73752,"primaryCompletion":73711,"completion":73711,"start":18982,"enrollment":9334,"conditions":73753,"interventions":73754},[85],[23770],[73701,73714,73714,73714,73715,73716,73717,73718],{"trials":73756,"activeCount":97},[],{"trials":73758,"activeCount":97},[],{"trials":73760,"activeCount":97},[],{"trials":73762,"activeCount":97},[],{"intervention":73716,"totalTrials":417,"cells":73764},{"EARLY_PHASE1":73765,"PHASE1":73767,"PHASE2":73773,"PHASE3":73775,"PHASE4":73777,"NA":73779},{"trials":73766,"activeCount":97},[],{"trials":73768,"activeCount":97},[73769],{"nctId":73708,"briefTitle":73709,"status":145,"phases":73770,"primaryCompletion":73711,"completion":73711,"start":18982,"enrollment":9334,"conditions":73771,"interventions":73772},[85],[23770],[73701,73714,73714,73714,73715,73716,73717,73718],{"trials":73774,"activeCount":97},[],{"trials":73776,"activeCount":97},[],{"trials":73778,"activeCount":97},[],{"trials":73780,"activeCount":97},[],{"intervention":73717,"totalTrials":417,"cells":73782},{"EARLY_PHASE1":73783,"PHASE1":73785,"PHASE2":73791,"PHASE3":73793,"PHASE4":73795,"NA":73797},{"trials":73784,"activeCount":97},[],{"trials":73786,"activeCount":97},[73787],{"nctId":73708,"briefTitle":73709,"status":145,"phases":73788,"primaryCompletion":73711,"completion":73711,"start":18982,"enrollment":9334,"conditions":73789,"interventions":73790},[85],[23770],[73701,73714,73714,73714,73715,73716,73717,73718],{"trials":73792,"activeCount":97},[],{"trials":73794,"activeCount":97},[],{"trials":73796,"activeCount":97},[],{"trials":73798,"activeCount":97},[],{"intervention":73718,"totalTrials":417,"cells":73800},{"EARLY_PHASE1":73801,"PHASE1":73803,"PHASE2":73809,"PHASE3":73811,"PHASE4":73813,"NA":73815},{"trials":73802,"activeCount":97},[],{"trials":73804,"activeCount":97},[73805],{"nctId":73708,"briefTitle":73709,"status":145,"phases":73806,"primaryCompletion":73711,"completion":73711,"start":18982,"enrollment":9334,"conditions":73807,"interventions":73808},[85],[23770],[73701,73714,73714,73714,73715,73716,73717,73718],{"trials":73810,"activeCount":97},[],{"trials":73812,"activeCount":97},[],{"trials":73814,"activeCount":97},[],{"trials":73816,"activeCount":97},[],{"intervention":73818,"totalTrials":417,"cells":73819},"GSK1605786 ChemoCentryx: formulation A",{"EARLY_PHASE1":73820,"PHASE1":73822,"PHASE2":73835,"PHASE3":73837,"PHASE4":73839,"NA":73841},{"trials":73821,"activeCount":97},[],{"trials":73823,"activeCount":97},[73824],{"nctId":73825,"briefTitle":73826,"status":155,"phases":73827,"primaryCompletion":23419,"completion":23419,"start":73828,"enrollment":1298,"conditions":73829,"interventions":73830},"NCT01114607","A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects",[85],"2010-05-05",[21782],[73818,73831,73832,73833,73834],"GSK1605786 GSK: formulation B","GSK1605786 GSK direct-fill: formulation C","GSK1605786 GSK modified-process: formulation D","GSK1605786 GSK tablet: formulation E",{"trials":73836,"activeCount":97},[],{"trials":73838,"activeCount":97},[],{"trials":73840,"activeCount":97},[],{"trials":73842,"activeCount":97},[],{"intervention":73831,"totalTrials":417,"cells":73844},{"EARLY_PHASE1":73845,"PHASE1":73847,"PHASE2":73853,"PHASE3":73855,"PHASE4":73857,"NA":73859},{"trials":73846,"activeCount":97},[],{"trials":73848,"activeCount":97},[73849],{"nctId":73825,"briefTitle":73826,"status":155,"phases":73850,"primaryCompletion":23419,"completion":23419,"start":73828,"enrollment":1298,"conditions":73851,"interventions":73852},[85],[21782],[73818,73831,73832,73833,73834],{"trials":73854,"activeCount":97},[],{"trials":73856,"activeCount":97},[],{"trials":73858,"activeCount":97},[],{"trials":73860,"activeCount":97},[],{"intervention":73832,"totalTrials":417,"cells":73862},{"EARLY_PHASE1":73863,"PHASE1":73865,"PHASE2":73871,"PHASE3":73873,"PHASE4":73875,"NA":73877},{"trials":73864,"activeCount":97},[],{"trials":73866,"activeCount":97},[73867],{"nctId":73825,"briefTitle":73826,"status":155,"phases":73868,"primaryCompletion":23419,"completion":23419,"start":73828,"enrollment":1298,"conditions":73869,"interventions":73870},[85],[21782],[73818,73831,73832,73833,73834],{"trials":73872,"activeCount":97},[],{"trials":73874,"activeCount":97},[],{"trials":73876,"activeCount":97},[],{"trials":73878,"activeCount":97},[],{"intervention":73833,"totalTrials":417,"cells":73880},{"EARLY_PHASE1":73881,"PHASE1":73883,"PHASE2":73889,"PHASE3":73891,"PHASE4":73893,"NA":73895},{"trials":73882,"activeCount":97},[],{"trials":73884,"activeCount":97},[73885],{"nctId":73825,"briefTitle":73826,"status":155,"phases":73886,"primaryCompletion":23419,"completion":23419,"start":73828,"enrollment":1298,"conditions":73887,"interventions":73888},[85],[21782],[73818,73831,73832,73833,73834],{"trials":73890,"activeCount":97},[],{"trials":73892,"activeCount":97},[],{"trials":73894,"activeCount":97},[],{"trials":73896,"activeCount":97},[],{"intervention":73834,"totalTrials":417,"cells":73898},{"EARLY_PHASE1":73899,"PHASE1":73901,"PHASE2":73907,"PHASE3":73909,"PHASE4":73911,"NA":73913},{"trials":73900,"activeCount":97},[],{"trials":73902,"activeCount":97},[73903],{"nctId":73825,"briefTitle":73826,"status":155,"phases":73904,"primaryCompletion":23419,"completion":23419,"start":73828,"enrollment":1298,"conditions":73905,"interventions":73906},[85],[21782],[73818,73831,73832,73833,73834],{"trials":73908,"activeCount":97},[],{"trials":73910,"activeCount":97},[],{"trials":73912,"activeCount":97},[],{"trials":73914,"activeCount":97},[],{"intervention":26117,"totalTrials":417,"cells":73916},{"EARLY_PHASE1":73917,"PHASE1":73919,"PHASE2":73925,"PHASE3":73927,"PHASE4":73929,"NA":73931},{"trials":73918,"activeCount":97},[],{"trials":73920,"activeCount":97},[73921],{"nctId":26110,"briefTitle":26111,"status":155,"phases":73922,"primaryCompletion":26113,"completion":26113,"start":492,"enrollment":2759,"conditions":73923,"interventions":73924},[85],[27],[26116,26117],{"trials":73926,"activeCount":97},[],{"trials":73928,"activeCount":97},[],{"trials":73930,"activeCount":97},[],{"trials":73932,"activeCount":97},[],{"intervention":60139,"totalTrials":417,"cells":73934},{"EARLY_PHASE1":73935,"PHASE1":73937,"PHASE2":73943,"PHASE3":73945,"PHASE4":73947,"NA":73949},{"trials":73936,"activeCount":97},[],{"trials":73938,"activeCount":97},[73939],{"nctId":60132,"briefTitle":60133,"status":155,"phases":73940,"primaryCompletion":60135,"completion":60135,"start":60136,"enrollment":3025,"conditions":73941,"interventions":73942},[85],[22921],[60139,60140,60118],{"trials":73944,"activeCount":97},[],{"trials":73946,"activeCount":97},[],{"trials":73948,"activeCount":97},[],{"trials":73950,"activeCount":97},[],{"intervention":60140,"totalTrials":417,"cells":73952},{"EARLY_PHASE1":73953,"PHASE1":73955,"PHASE2":73961,"PHASE3":73963,"PHASE4":73965,"NA":73967},{"trials":73954,"activeCount":97},[],{"trials":73956,"activeCount":97},[73957],{"nctId":60132,"briefTitle":60133,"status":155,"phases":73958,"primaryCompletion":60135,"completion":60135,"start":60136,"enrollment":3025,"conditions":73959,"interventions":73960},[85],[22921],[60139,60140,60118],{"trials":73962,"activeCount":97},[],{"trials":73964,"activeCount":97},[],{"trials":73966,"activeCount":97},[],{"trials":73968,"activeCount":97},[],{"intervention":73970,"totalTrials":417,"cells":73971},"RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B",{"EARLY_PHASE1":73972,"PHASE1":73974,"PHASE2":73985,"PHASE3":73987,"PHASE4":73989,"NA":73991},{"trials":73973,"activeCount":97},[],{"trials":73975,"activeCount":97},[73976],{"nctId":73977,"briefTitle":73978,"status":155,"phases":73979,"primaryCompletion":73980,"completion":73981,"start":73982,"enrollment":345,"conditions":73983,"interventions":73984},"NCT04090658","A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults",[85],"2020-01-10","2020-12-11","2019-09-25",[2620],[73970],{"trials":73986,"activeCount":97},[],{"trials":73988,"activeCount":97},[],{"trials":73990,"activeCount":97},[],{"trials":73992,"activeCount":97},[],{"intervention":73994,"totalTrials":417,"cells":73995},"Diclofenac + Menthol Gel",{"EARLY_PHASE1":73996,"PHASE1":73998,"PHASE2":74009,"PHASE3":74011,"PHASE4":74013,"NA":74015},{"trials":73997,"activeCount":97},[],{"trials":73999,"activeCount":97},[74000],{"nctId":74001,"briefTitle":74002,"status":155,"phases":74003,"primaryCompletion":74004,"completion":74004,"start":11484,"enrollment":8493,"conditions":74005,"interventions":74006},"NCT02192203","A Safety Study to Investigate the Skin Sensitization Potential of MFC51123",[85],"2014-07-15",[9153],[73994,74007,74008],"Diclofenac Only Gel","Menthol Only Gel",{"trials":74010,"activeCount":97},[],{"trials":74012,"activeCount":97},[],{"trials":74014,"activeCount":97},[],{"trials":74016,"activeCount":97},[],{"intervention":74007,"totalTrials":417,"cells":74018},{"EARLY_PHASE1":74019,"PHASE1":74021,"PHASE2":74027,"PHASE3":74029,"PHASE4":74031,"NA":74033},{"trials":74020,"activeCount":97},[],{"trials":74022,"activeCount":97},[74023],{"nctId":74001,"briefTitle":74002,"status":155,"phases":74024,"primaryCompletion":74004,"completion":74004,"start":11484,"enrollment":8493,"conditions":74025,"interventions":74026},[85],[9153],[73994,74007,74008],{"trials":74028,"activeCount":97},[],{"trials":74030,"activeCount":97},[],{"trials":74032,"activeCount":97},[],{"trials":74034,"activeCount":97},[],{"intervention":74008,"totalTrials":417,"cells":74036},{"EARLY_PHASE1":74037,"PHASE1":74039,"PHASE2":74045,"PHASE3":74047,"PHASE4":74049,"NA":74051},{"trials":74038,"activeCount":97},[],{"trials":74040,"activeCount":97},[74041],{"nctId":74001,"briefTitle":74002,"status":155,"phases":74042,"primaryCompletion":74004,"completion":74004,"start":11484,"enrollment":8493,"conditions":74043,"interventions":74044},[85],[9153],[73994,74007,74008],{"trials":74046,"activeCount":97},[],{"trials":74048,"activeCount":97},[],{"trials":74050,"activeCount":97},[],{"trials":74052,"activeCount":97},[],{"intervention":74054,"totalTrials":417,"cells":74055},"TDF",{"EARLY_PHASE1":74056,"PHASE1":74058,"PHASE2":74067,"PHASE3":74069,"PHASE4":74071,"NA":74073},{"trials":74057,"activeCount":97},[],{"trials":74059,"activeCount":97},[74060],{"nctId":74061,"briefTitle":74062,"status":155,"phases":74063,"primaryCompletion":74064,"completion":74064,"start":43604,"enrollment":473,"conditions":74065,"interventions":74066},"NCT01480622","Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects",[85],"2011-12-30",[4191],[74054],{"trials":74068,"activeCount":97},[],{"trials":74070,"activeCount":97},[],{"trials":74072,"activeCount":97},[],{"trials":74074,"activeCount":97},[],{"intervention":74076,"totalTrials":417,"cells":74077},"Deuterated Water",{"EARLY_PHASE1":74078,"PHASE1":74080,"PHASE2":74090,"PHASE3":74092,"PHASE4":74094,"NA":74096},{"trials":74079,"activeCount":97},[],{"trials":74081,"activeCount":97},[74082],{"nctId":74083,"briefTitle":74084,"status":155,"phases":74085,"primaryCompletion":13095,"completion":13095,"start":74086,"enrollment":454,"conditions":74087,"interventions":74088},"NCT01962454","A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers",[85],"2014-05-05",[42472],[74076,74089],"Testosterone enanthate",{"trials":74091,"activeCount":97},[],{"trials":74093,"activeCount":97},[],{"trials":74095,"activeCount":97},[],{"trials":74097,"activeCount":97},[],{"intervention":74089,"totalTrials":417,"cells":74099},{"EARLY_PHASE1":74100,"PHASE1":74102,"PHASE2":74108,"PHASE3":74110,"PHASE4":74112,"NA":74114},{"trials":74101,"activeCount":97},[],{"trials":74103,"activeCount":97},[74104],{"nctId":74083,"briefTitle":74084,"status":155,"phases":74105,"primaryCompletion":13095,"completion":13095,"start":74086,"enrollment":454,"conditions":74106,"interventions":74107},[85],[42472],[74076,74089],{"trials":74109,"activeCount":97},[],{"trials":74111,"activeCount":97},[],{"trials":74113,"activeCount":97},[],{"trials":74115,"activeCount":97},[],{"intervention":74117,"totalTrials":417,"cells":74118},"GSK625433\u002Fplacebo",{"EARLY_PHASE1":74119,"PHASE1":74121,"PHASE2":74129,"PHASE3":74131,"PHASE4":74133,"NA":74135},{"trials":74120,"activeCount":97},[],{"trials":74122,"activeCount":97},[74123],{"nctId":74124,"briefTitle":74125,"status":145,"phases":74126,"primaryCompletion":748,"completion":748,"start":2404,"enrollment":6503,"conditions":74127,"interventions":74128},"NCT00439959","Monotherapy Versus Placebo Over 14 or 17 Days in Healthy and Hepatitis C Infected Adults",[85],[42684,23770],[74117],{"trials":74130,"activeCount":97},[],{"trials":74132,"activeCount":97},[],{"trials":74134,"activeCount":97},[],{"trials":74136,"activeCount":97},[],{"intervention":74138,"totalTrials":417,"cells":74139},"GR37547",{"EARLY_PHASE1":74140,"PHASE1":74142,"PHASE2":74151,"PHASE3":74153,"PHASE4":74155,"NA":74157},{"trials":74141,"activeCount":97},[],{"trials":74143,"activeCount":97},[74144],{"nctId":74145,"briefTitle":74146,"status":155,"phases":74147,"primaryCompletion":18918,"completion":18918,"start":25261,"enrollment":93,"conditions":74148,"interventions":74149},"NCT03150082","Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects",[85],[6484],[74138,74150],"Ciprofloxacin reference",{"trials":74152,"activeCount":97},[],{"trials":74154,"activeCount":97},[],{"trials":74156,"activeCount":97},[],{"trials":74158,"activeCount":97},[],{"intervention":74150,"totalTrials":417,"cells":74160},{"EARLY_PHASE1":74161,"PHASE1":74163,"PHASE2":74169,"PHASE3":74171,"PHASE4":74173,"NA":74175},{"trials":74162,"activeCount":97},[],{"trials":74164,"activeCount":97},[74165],{"nctId":74145,"briefTitle":74146,"status":155,"phases":74166,"primaryCompletion":18918,"completion":18918,"start":25261,"enrollment":93,"conditions":74167,"interventions":74168},[85],[6484],[74138,74150],{"trials":74170,"activeCount":97},[],{"trials":74172,"activeCount":97},[],{"trials":74174,"activeCount":97},[],{"trials":74176,"activeCount":97},[],{"intervention":74178,"totalTrials":417,"cells":74179},"GW876008 200mcg",{"EARLY_PHASE1":74180,"PHASE1":74182,"PHASE2":74191,"PHASE3":74193,"PHASE4":74195,"NA":74197},{"trials":74181,"activeCount":97},[],{"trials":74183,"activeCount":97},[74184],{"nctId":74185,"briefTitle":74186,"status":155,"phases":74187,"primaryCompletion":9133,"completion":9133,"start":4843,"enrollment":463,"conditions":74188,"interventions":74189},"NCT00376896","Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers",[85],[11510,11511],[74178,74190],"GW876008 20mcg",{"trials":74192,"activeCount":97},[],{"trials":74194,"activeCount":97},[],{"trials":74196,"activeCount":97},[],{"trials":74198,"activeCount":97},[],{"intervention":74190,"totalTrials":417,"cells":74200},{"EARLY_PHASE1":74201,"PHASE1":74203,"PHASE2":74209,"PHASE3":74211,"PHASE4":74213,"NA":74215},{"trials":74202,"activeCount":97},[],{"trials":74204,"activeCount":97},[74205],{"nctId":74185,"briefTitle":74186,"status":155,"phases":74206,"primaryCompletion":9133,"completion":9133,"start":4843,"enrollment":463,"conditions":74207,"interventions":74208},[85],[11510,11511],[74178,74190],{"trials":74210,"activeCount":97},[],{"trials":74212,"activeCount":97},[],{"trials":74214,"activeCount":97},[],{"trials":74216,"activeCount":97},[],{"intervention":43127,"totalTrials":417,"cells":74218},{"EARLY_PHASE1":74219,"PHASE1":74221,"PHASE2":74227,"PHASE3":74229,"PHASE4":74231,"NA":74233},{"trials":74220,"activeCount":97},[],{"trials":74222,"activeCount":97},[74223],{"nctId":43121,"briefTitle":43122,"status":155,"phases":74224,"primaryCompletion":43124,"completion":22933,"start":24581,"enrollment":4940,"conditions":74225,"interventions":74226},[85],[40533],[43127,43128,43114,43129,43130,43131],{"trials":74228,"activeCount":97},[],{"trials":74230,"activeCount":97},[],{"trials":74232,"activeCount":97},[],{"trials":74234,"activeCount":97},[],{"intervention":43128,"totalTrials":417,"cells":74236},{"EARLY_PHASE1":74237,"PHASE1":74239,"PHASE2":74245,"PHASE3":74247,"PHASE4":74249,"NA":74251},{"trials":74238,"activeCount":97},[],{"trials":74240,"activeCount":97},[74241],{"nctId":43121,"briefTitle":43122,"status":155,"phases":74242,"primaryCompletion":43124,"completion":22933,"start":24581,"enrollment":4940,"conditions":74243,"interventions":74244},[85],[40533],[43127,43128,43114,43129,43130,43131],{"trials":74246,"activeCount":97},[],{"trials":74248,"activeCount":97},[],{"trials":74250,"activeCount":97},[],{"trials":74252,"activeCount":97},[],{"intervention":43129,"totalTrials":417,"cells":74254},{"EARLY_PHASE1":74255,"PHASE1":74257,"PHASE2":74263,"PHASE3":74265,"PHASE4":74267,"NA":74269},{"trials":74256,"activeCount":97},[],{"trials":74258,"activeCount":97},[74259],{"nctId":43121,"briefTitle":43122,"status":155,"phases":74260,"primaryCompletion":43124,"completion":22933,"start":24581,"enrollment":4940,"conditions":74261,"interventions":74262},[85],[40533],[43127,43128,43114,43129,43130,43131],{"trials":74264,"activeCount":97},[],{"trials":74266,"activeCount":97},[],{"trials":74268,"activeCount":97},[],{"trials":74270,"activeCount":97},[],{"intervention":59598,"totalTrials":417,"cells":74272},{"EARLY_PHASE1":74273,"PHASE1":74275,"PHASE2":74281,"PHASE3":74283,"PHASE4":74285,"NA":74287},{"trials":74274,"activeCount":97},[],{"trials":74276,"activeCount":97},[74277],{"nctId":59593,"briefTitle":59594,"status":155,"phases":74278,"primaryCompletion":7658,"completion":7658,"start":6351,"enrollment":695,"conditions":74279,"interventions":74280},[85],[7524],[59579,59567,59598],{"trials":74282,"activeCount":97},[],{"trials":74284,"activeCount":97},[],{"trials":74286,"activeCount":97},[],{"trials":74288,"activeCount":97},[],{"intervention":11981,"totalTrials":417,"cells":74290},{"EARLY_PHASE1":74291,"PHASE1":74293,"PHASE2":74299,"PHASE3":74301,"PHASE4":74303,"NA":74305},{"trials":74292,"activeCount":97},[],{"trials":74294,"activeCount":97},[74295],{"nctId":11975,"briefTitle":11976,"status":155,"phases":74296,"primaryCompletion":2335,"completion":2335,"start":7647,"enrollment":473,"conditions":74297,"interventions":74298},[85],[9153],[11980,11968,11981],{"trials":74300,"activeCount":97},[],{"trials":74302,"activeCount":97},[],{"trials":74304,"activeCount":97},[],{"trials":74306,"activeCount":97},[],{"intervention":74308,"totalTrials":417,"cells":74309},"Oral GW679769",{"EARLY_PHASE1":74310,"PHASE1":74312,"PHASE2":74322,"PHASE3":74324,"PHASE4":74326,"NA":74328},{"trials":74311,"activeCount":97},[],{"trials":74313,"activeCount":97},[74314],{"nctId":74315,"briefTitle":74316,"status":145,"phases":74317,"primaryCompletion":20440,"completion":20440,"start":74318,"enrollment":463,"conditions":74319,"interventions":74320},"NCT00334646","Cyclophosphamide Drug Interaction Study In Cancer Patients",[85],"2005-08-10",[1337],[74308,74321],"IV Cyclophosphamide 500-700mg\u002Fm2",{"trials":74323,"activeCount":97},[],{"trials":74325,"activeCount":97},[],{"trials":74327,"activeCount":97},[],{"trials":74329,"activeCount":97},[],{"intervention":74321,"totalTrials":417,"cells":74331},{"EARLY_PHASE1":74332,"PHASE1":74334,"PHASE2":74340,"PHASE3":74342,"PHASE4":74344,"NA":74346},{"trials":74333,"activeCount":97},[],{"trials":74335,"activeCount":97},[74336],{"nctId":74315,"briefTitle":74316,"status":145,"phases":74337,"primaryCompletion":20440,"completion":20440,"start":74318,"enrollment":463,"conditions":74338,"interventions":74339},[85],[1337],[74308,74321],{"trials":74341,"activeCount":97},[],{"trials":74343,"activeCount":97},[],{"trials":74345,"activeCount":97},[],{"trials":74347,"activeCount":97},[],{"intervention":74349,"totalTrials":417,"cells":74350},"HFA-152A propellant",{"EARLY_PHASE1":74351,"PHASE1":74353,"PHASE2":74363,"PHASE3":74365,"PHASE4":74367,"NA":74369},{"trials":74352,"activeCount":97},[],{"trials":74354,"activeCount":97},[74355],{"nctId":74356,"briefTitle":74357,"status":155,"phases":74358,"primaryCompletion":54114,"completion":54114,"start":74359,"enrollment":454,"conditions":74360,"interventions":74361},"NCT06702462","A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma",[85],"2025-03-11",[18],[74349,74362],"HFA-134A propellant",{"trials":74364,"activeCount":97},[],{"trials":74366,"activeCount":97},[],{"trials":74368,"activeCount":97},[],{"trials":74370,"activeCount":97},[],{"intervention":74362,"totalTrials":417,"cells":74372},{"EARLY_PHASE1":74373,"PHASE1":74375,"PHASE2":74381,"PHASE3":74383,"PHASE4":74385,"NA":74387},{"trials":74374,"activeCount":97},[],{"trials":74376,"activeCount":97},[74377],{"nctId":74356,"briefTitle":74357,"status":155,"phases":74378,"primaryCompletion":54114,"completion":54114,"start":74359,"enrollment":454,"conditions":74379,"interventions":74380},[85],[18],[74349,74362],{"trials":74382,"activeCount":97},[],{"trials":74384,"activeCount":97},[],{"trials":74386,"activeCount":97},[],{"trials":74388,"activeCount":97},[],{"intervention":19329,"totalTrials":417,"cells":74390},{"EARLY_PHASE1":74391,"PHASE1":74393,"PHASE2":74399,"PHASE3":74401,"PHASE4":74403,"NA":74405},{"trials":74392,"activeCount":97},[],{"trials":74394,"activeCount":97},[74395],{"nctId":19323,"briefTitle":19324,"status":155,"phases":74396,"primaryCompletion":2392,"completion":2392,"start":19326,"enrollment":234,"conditions":74397,"interventions":74398},[85],[9343],[19321,19329,19330,10675],{"trials":74400,"activeCount":97},[],{"trials":74402,"activeCount":97},[],{"trials":74404,"activeCount":97},[],{"trials":74406,"activeCount":97},[],{"intervention":19330,"totalTrials":417,"cells":74408},{"EARLY_PHASE1":74409,"PHASE1":74411,"PHASE2":74417,"PHASE3":74419,"PHASE4":74421,"NA":74423},{"trials":74410,"activeCount":97},[],{"trials":74412,"activeCount":97},[74413],{"nctId":19323,"briefTitle":19324,"status":155,"phases":74414,"primaryCompletion":2392,"completion":2392,"start":19326,"enrollment":234,"conditions":74415,"interventions":74416},[85],[9343],[19321,19329,19330,10675],{"trials":74418,"activeCount":97},[],{"trials":74420,"activeCount":97},[],{"trials":74422,"activeCount":97},[],{"trials":74424,"activeCount":97},[],{"intervention":39703,"totalTrials":417,"cells":74426},{"EARLY_PHASE1":74427,"PHASE1":74429,"PHASE2":74435,"PHASE3":74437,"PHASE4":74439,"NA":74441},{"trials":74428,"activeCount":97},[],{"trials":74430,"activeCount":97},[74431],{"nctId":39696,"briefTitle":39697,"status":145,"phases":74432,"primaryCompletion":39699,"completion":39699,"start":39700,"enrollment":660,"conditions":74433,"interventions":74434},[85],[1239],[39667,39688,39703],{"trials":74436,"activeCount":97},[],{"trials":74438,"activeCount":97},[],{"trials":74440,"activeCount":97},[],{"trials":74442,"activeCount":97},[],{"intervention":74444,"totalTrials":417,"cells":74445},"amoxicillin\u002Fclavulanate potassium",{"EARLY_PHASE1":74446,"PHASE1":74448,"PHASE2":74456,"PHASE3":74458,"PHASE4":74460,"NA":74462},{"trials":74447,"activeCount":97},[],{"trials":74449,"activeCount":97},[74450],{"nctId":74451,"briefTitle":74452,"status":155,"phases":74453,"primaryCompletion":40581,"completion":40581,"start":35276,"enrollment":3025,"conditions":74454,"interventions":74455},"NCT00354965","Pharmacokinetic Profiles Of Amoxicillin 2000 mg And Clavulanate 125 mg In Adolescent Patients",[85],[14696],[74444],{"trials":74457,"activeCount":97},[],{"trials":74459,"activeCount":97},[],{"trials":74461,"activeCount":97},[],{"trials":74463,"activeCount":97},[],{"intervention":74465,"totalTrials":417,"cells":74466},"Fixed dose combination",{"EARLY_PHASE1":74467,"PHASE1":74469,"PHASE2":74478,"PHASE3":74480,"PHASE4":74482,"NA":74484},{"trials":74468,"activeCount":97},[],{"trials":74470,"activeCount":97},[74471],{"nctId":74472,"briefTitle":74473,"status":155,"phases":74474,"primaryCompletion":8027,"completion":8027,"start":23146,"enrollment":345,"conditions":74475,"interventions":74476},"NCT01353742","Lamivudine and Adefovir Dipivoxil Fixed Dose Combination",[85],[4191],[37770,74477,74465],"Adefovir dipivoxil",{"trials":74479,"activeCount":97},[],{"trials":74481,"activeCount":97},[],{"trials":74483,"activeCount":97},[],{"trials":74485,"activeCount":97},[],{"intervention":74487,"totalTrials":417,"cells":74488},"GSK3008348 Nebuliser solution",{"EARLY_PHASE1":74489,"PHASE1":74491,"PHASE2":74500,"PHASE3":74502,"PHASE4":74504,"NA":74506},{"trials":74490,"activeCount":97},[],{"trials":74492,"activeCount":97},[74493],{"nctId":74494,"briefTitle":74495,"status":155,"phases":74496,"primaryCompletion":13316,"completion":13316,"start":74497,"enrollment":345,"conditions":74498,"interventions":74499},"NCT02612051","First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients",[85],"2015-12-04",[42392],[74487],{"trials":74501,"activeCount":97},[],{"trials":74503,"activeCount":97},[],{"trials":74505,"activeCount":97},[],{"trials":74507,"activeCount":97},[],{"intervention":40092,"totalTrials":417,"cells":74509},{"EARLY_PHASE1":74510,"PHASE1":74512,"PHASE2":74518,"PHASE3":74520,"PHASE4":74522,"NA":74524},{"trials":74511,"activeCount":97},[],{"trials":74513,"activeCount":97},[74514],{"nctId":40085,"briefTitle":40086,"status":155,"phases":74515,"primaryCompletion":40088,"completion":40088,"start":40089,"enrollment":433,"conditions":74516,"interventions":74517},[85],[14279],[40092,40093,40094],{"trials":74519,"activeCount":97},[],{"trials":74521,"activeCount":97},[],{"trials":74523,"activeCount":97},[],{"trials":74525,"activeCount":97},[],{"intervention":40094,"totalTrials":417,"cells":74527},{"EARLY_PHASE1":74528,"PHASE1":74530,"PHASE2":74536,"PHASE3":74538,"PHASE4":74540,"NA":74542},{"trials":74529,"activeCount":97},[],{"trials":74531,"activeCount":97},[74532],{"nctId":40085,"briefTitle":40086,"status":155,"phases":74533,"primaryCompletion":40088,"completion":40088,"start":40089,"enrollment":433,"conditions":74534,"interventions":74535},[85],[14279],[40092,40093,40094],{"trials":74537,"activeCount":97},[],{"trials":74539,"activeCount":97},[],{"trials":74541,"activeCount":97},[],{"trials":74543,"activeCount":97},[],{"intervention":42809,"totalTrials":417,"cells":74545},{"EARLY_PHASE1":74546,"PHASE1":74548,"PHASE2":74554,"PHASE3":74556,"PHASE4":74558,"NA":74560},{"trials":74547,"activeCount":97},[],{"trials":74549,"activeCount":97},[74550],{"nctId":42801,"briefTitle":42802,"status":155,"phases":74551,"primaryCompletion":3177,"completion":42804,"start":42805,"enrollment":105,"conditions":74552,"interventions":74553},[85],[42807],[42809,42810,42811,42812,42794,42813],{"trials":74555,"activeCount":97},[],{"trials":74557,"activeCount":97},[],{"trials":74559,"activeCount":97},[],{"trials":74561,"activeCount":97},[],{"intervention":42810,"totalTrials":417,"cells":74563},{"EARLY_PHASE1":74564,"PHASE1":74566,"PHASE2":74572,"PHASE3":74574,"PHASE4":74576,"NA":74578},{"trials":74565,"activeCount":97},[],{"trials":74567,"activeCount":97},[74568],{"nctId":42801,"briefTitle":42802,"status":155,"phases":74569,"primaryCompletion":3177,"completion":42804,"start":42805,"enrollment":105,"conditions":74570,"interventions":74571},[85],[42807],[42809,42810,42811,42812,42794,42813],{"trials":74573,"activeCount":97},[],{"trials":74575,"activeCount":97},[],{"trials":74577,"activeCount":97},[],{"trials":74579,"activeCount":97},[],{"intervention":42811,"totalTrials":417,"cells":74581},{"EARLY_PHASE1":74582,"PHASE1":74584,"PHASE2":74590,"PHASE3":74592,"PHASE4":74594,"NA":74596},{"trials":74583,"activeCount":97},[],{"trials":74585,"activeCount":97},[74586],{"nctId":42801,"briefTitle":42802,"status":155,"phases":74587,"primaryCompletion":3177,"completion":42804,"start":42805,"enrollment":105,"conditions":74588,"interventions":74589},[85],[42807],[42809,42810,42811,42812,42794,42813],{"trials":74591,"activeCount":97},[],{"trials":74593,"activeCount":97},[],{"trials":74595,"activeCount":97},[],{"trials":74597,"activeCount":97},[],{"intervention":42812,"totalTrials":417,"cells":74599},{"EARLY_PHASE1":74600,"PHASE1":74602,"PHASE2":74608,"PHASE3":74610,"PHASE4":74612,"NA":74614},{"trials":74601,"activeCount":97},[],{"trials":74603,"activeCount":97},[74604],{"nctId":42801,"briefTitle":42802,"status":155,"phases":74605,"primaryCompletion":3177,"completion":42804,"start":42805,"enrollment":105,"conditions":74606,"interventions":74607},[85],[42807],[42809,42810,42811,42812,42794,42813],{"trials":74609,"activeCount":97},[],{"trials":74611,"activeCount":97},[],{"trials":74613,"activeCount":97},[],{"trials":74615,"activeCount":97},[],{"intervention":42813,"totalTrials":417,"cells":74617},{"EARLY_PHASE1":74618,"PHASE1":74620,"PHASE2":74626,"PHASE3":74628,"PHASE4":74630,"NA":74632},{"trials":74619,"activeCount":97},[],{"trials":74621,"activeCount":97},[74622],{"nctId":42801,"briefTitle":42802,"status":155,"phases":74623,"primaryCompletion":3177,"completion":42804,"start":42805,"enrollment":105,"conditions":74624,"interventions":74625},[85],[42807],[42809,42810,42811,42812,42794,42813],{"trials":74627,"activeCount":97},[],{"trials":74629,"activeCount":97},[],{"trials":74631,"activeCount":97},[],{"trials":74633,"activeCount":97},[],{"intervention":59867,"totalTrials":417,"cells":74635},{"EARLY_PHASE1":74636,"PHASE1":74638,"PHASE2":74644,"PHASE3":74646,"PHASE4":74648,"NA":74650},{"trials":74637,"activeCount":97},[],{"trials":74639,"activeCount":97},[74640],{"nctId":59861,"briefTitle":59862,"status":155,"phases":74641,"primaryCompletion":59864,"completion":59864,"start":24504,"enrollment":1298,"conditions":74642,"interventions":74643},[85],[21782],[59867,59868,59854,59869,23669],{"trials":74645,"activeCount":97},[],{"trials":74647,"activeCount":97},[],{"trials":74649,"activeCount":97},[],{"trials":74651,"activeCount":97},[],{"intervention":59868,"totalTrials":417,"cells":74653},{"EARLY_PHASE1":74654,"PHASE1":74656,"PHASE2":74662,"PHASE3":74664,"PHASE4":74666,"NA":74668},{"trials":74655,"activeCount":97},[],{"trials":74657,"activeCount":97},[74658],{"nctId":59861,"briefTitle":59862,"status":155,"phases":74659,"primaryCompletion":59864,"completion":59864,"start":24504,"enrollment":1298,"conditions":74660,"interventions":74661},[85],[21782],[59867,59868,59854,59869,23669],{"trials":74663,"activeCount":97},[],{"trials":74665,"activeCount":97},[],{"trials":74667,"activeCount":97},[],{"trials":74669,"activeCount":97},[],{"intervention":59869,"totalTrials":417,"cells":74671},{"EARLY_PHASE1":74672,"PHASE1":74674,"PHASE2":74680,"PHASE3":74682,"PHASE4":74684,"NA":74686},{"trials":74673,"activeCount":97},[],{"trials":74675,"activeCount":97},[74676],{"nctId":59861,"briefTitle":59862,"status":155,"phases":74677,"primaryCompletion":59864,"completion":59864,"start":24504,"enrollment":1298,"conditions":74678,"interventions":74679},[85],[21782],[59867,59868,59854,59869,23669],{"trials":74681,"activeCount":97},[],{"trials":74683,"activeCount":97},[],{"trials":74685,"activeCount":97},[],{"trials":74687,"activeCount":97},[],{"intervention":74689,"totalTrials":417,"cells":74690},"GSK573719 250 μg",{"EARLY_PHASE1":74691,"PHASE1":74693,"PHASE2":74704,"PHASE3":74706,"PHASE4":74708,"NA":74710},{"trials":74692,"activeCount":97},[],{"trials":74694,"activeCount":97},[74695],{"nctId":74696,"briefTitle":74697,"status":155,"phases":74698,"primaryCompletion":74699,"completion":74699,"start":22171,"enrollment":6503,"conditions":74700,"interventions":74701},"NCT01013974","A Study of GSK573719 in Healthy Japanese Male Subjects",[85],"2009-12-18",[15],[74689,74702,74703],"GSK573719 500 μg","GSK573719 1000 μg",{"trials":74705,"activeCount":97},[],{"trials":74707,"activeCount":97},[],{"trials":74709,"activeCount":97},[],{"trials":74711,"activeCount":97},[],{"intervention":74702,"totalTrials":417,"cells":74713},{"EARLY_PHASE1":74714,"PHASE1":74716,"PHASE2":74722,"PHASE3":74724,"PHASE4":74726,"NA":74728},{"trials":74715,"activeCount":97},[],{"trials":74717,"activeCount":97},[74718],{"nctId":74696,"briefTitle":74697,"status":155,"phases":74719,"primaryCompletion":74699,"completion":74699,"start":22171,"enrollment":6503,"conditions":74720,"interventions":74721},[85],[15],[74689,74702,74703],{"trials":74723,"activeCount":97},[],{"trials":74725,"activeCount":97},[],{"trials":74727,"activeCount":97},[],{"trials":74729,"activeCount":97},[],{"intervention":74703,"totalTrials":417,"cells":74731},{"EARLY_PHASE1":74732,"PHASE1":74734,"PHASE2":74740,"PHASE3":74742,"PHASE4":74744,"NA":74746},{"trials":74733,"activeCount":97},[],{"trials":74735,"activeCount":97},[74736],{"nctId":74696,"briefTitle":74697,"status":155,"phases":74737,"primaryCompletion":74699,"completion":74699,"start":22171,"enrollment":6503,"conditions":74738,"interventions":74739},[85],[15],[74689,74702,74703],{"trials":74741,"activeCount":97},[],{"trials":74743,"activeCount":97},[],{"trials":74745,"activeCount":97},[],{"trials":74747,"activeCount":97},[],{"intervention":19750,"totalTrials":417,"cells":74749},{"EARLY_PHASE1":74750,"PHASE1":74752,"PHASE2":74758,"PHASE3":74760,"PHASE4":74762,"NA":74764},{"trials":74751,"activeCount":97},[],{"trials":74753,"activeCount":97},[74754],{"nctId":19742,"briefTitle":19743,"status":155,"phases":74755,"primaryCompletion":19745,"completion":19745,"start":19746,"enrollment":255,"conditions":74756,"interventions":74757},[85],[19748],[10390,19693,19750],{"trials":74759,"activeCount":97},[],{"trials":74761,"activeCount":97},[],{"trials":74763,"activeCount":97},[],{"trials":74765,"activeCount":97},[],{"intervention":6753,"totalTrials":417,"cells":74767},{"EARLY_PHASE1":74768,"PHASE1":74770,"PHASE2":74776,"PHASE3":74778,"PHASE4":74780,"NA":74782},{"trials":74769,"activeCount":97},[],{"trials":74771,"activeCount":97},[74772],{"nctId":6746,"briefTitle":6747,"status":155,"phases":74773,"primaryCompletion":6749,"completion":6749,"start":6750,"enrollment":463,"conditions":74774,"interventions":74775},[85],[2667],[2273,139,6753],{"trials":74777,"activeCount":97},[],{"trials":74779,"activeCount":97},[],{"trials":74781,"activeCount":97},[],{"trials":74783,"activeCount":97},[],{"intervention":74785,"totalTrials":417,"cells":74786},"SB-485232 (interleukin 18), pegylated liposomal doxorubicin",{"EARLY_PHASE1":74787,"PHASE1":74789,"PHASE2":74797,"PHASE3":74799,"PHASE4":74801,"NA":74803},{"trials":74788,"activeCount":97},[],{"trials":74790,"activeCount":97},[74791],{"nctId":74792,"briefTitle":74793,"status":155,"phases":74794,"primaryCompletion":27323,"completion":27323,"start":24899,"enrollment":1117,"conditions":74795,"interventions":74796},"NCT00659178","Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer",[85],[2363],[74785],{"trials":74798,"activeCount":97},[],{"trials":74800,"activeCount":97},[],{"trials":74802,"activeCount":97},[],{"trials":74804,"activeCount":97},[],{"intervention":74806,"totalTrials":417,"cells":74807},"GSK249320A",{"EARLY_PHASE1":74808,"PHASE1":74810,"PHASE2":74819,"PHASE3":74821,"PHASE4":74823,"NA":74825},{"trials":74809,"activeCount":97},[],{"trials":74811,"activeCount":97},[74812],{"nctId":74813,"briefTitle":74814,"status":155,"phases":74815,"primaryCompletion":74816,"completion":74816,"start":10332,"enrollment":4121,"conditions":74817,"interventions":74818},"NCT00622609","Anti-MAG First Administration to Human",[85],"2009-04-09",[19596],[74806],{"trials":74820,"activeCount":97},[],{"trials":74822,"activeCount":97},[],{"trials":74824,"activeCount":97},[],{"trials":74826,"activeCount":97},[],{"intervention":74828,"totalTrials":417,"cells":74829},"GSK2944404 FDC",{"EARLY_PHASE1":74830,"PHASE1":74832,"PHASE2":74843,"PHASE3":74845,"PHASE4":74847,"NA":74849},{"trials":74831,"activeCount":97},[],{"trials":74833,"activeCount":97},[74834],{"nctId":74835,"briefTitle":74836,"status":155,"phases":74837,"primaryCompletion":26392,"completion":26392,"start":74838,"enrollment":1117,"conditions":74839,"interventions":74840},"NCT01822639","A Fixed Dose Combination Amlodipine + Enalapril Bioavailability Study",[85],"2013-04-03",[13024],[74828,74841,74842],"Amlodipine 5 mg","Enalapril Maleate 20 mg",{"trials":74844,"activeCount":97},[],{"trials":74846,"activeCount":97},[],{"trials":74848,"activeCount":97},[],{"trials":74850,"activeCount":97},[],{"intervention":74841,"totalTrials":417,"cells":74852},{"EARLY_PHASE1":74853,"PHASE1":74855,"PHASE2":74861,"PHASE3":74863,"PHASE4":74865,"NA":74867},{"trials":74854,"activeCount":97},[],{"trials":74856,"activeCount":97},[74857],{"nctId":74835,"briefTitle":74836,"status":155,"phases":74858,"primaryCompletion":26392,"completion":26392,"start":74838,"enrollment":1117,"conditions":74859,"interventions":74860},[85],[13024],[74828,74841,74842],{"trials":74862,"activeCount":97},[],{"trials":74864,"activeCount":97},[],{"trials":74866,"activeCount":97},[],{"trials":74868,"activeCount":97},[],{"intervention":74842,"totalTrials":417,"cells":74870},{"EARLY_PHASE1":74871,"PHASE1":74873,"PHASE2":74879,"PHASE3":74881,"PHASE4":74883,"NA":74885},{"trials":74872,"activeCount":97},[],{"trials":74874,"activeCount":97},[74875],{"nctId":74835,"briefTitle":74836,"status":155,"phases":74876,"primaryCompletion":26392,"completion":26392,"start":74838,"enrollment":1117,"conditions":74877,"interventions":74878},[85],[13024],[74828,74841,74842],{"trials":74880,"activeCount":97},[],{"trials":74882,"activeCount":97},[],{"trials":74884,"activeCount":97},[],{"trials":74886,"activeCount":97},[],{"intervention":74888,"totalTrials":417,"cells":74889},"Metformin, 500 mg extended release",{"EARLY_PHASE1":74890,"PHASE1":74892,"PHASE2":74908,"PHASE3":74910,"PHASE4":74912,"NA":74914},{"trials":74891,"activeCount":97},[],{"trials":74893,"activeCount":97},[74894],{"nctId":74895,"briefTitle":74896,"status":145,"phases":74897,"primaryCompletion":74898,"completion":74898,"start":5169,"enrollment":454,"conditions":74899,"interventions":74900},"NCT01725672","Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers",[85],"2013-08-21",[27],[74888,74901,74902,74903,74904,74905,74906,74907],"Metformin, 1000 mg extended release","Glimepiride, 1 mg immediate release","Glimepiride, 2 mg immediate release","Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers","Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers","Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers","Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers",{"trials":74909,"activeCount":97},[],{"trials":74911,"activeCount":97},[],{"trials":74913,"activeCount":97},[],{"trials":74915,"activeCount":97},[],{"intervention":74901,"totalTrials":417,"cells":74917},{"EARLY_PHASE1":74918,"PHASE1":74920,"PHASE2":74926,"PHASE3":74928,"PHASE4":74930,"NA":74932},{"trials":74919,"activeCount":97},[],{"trials":74921,"activeCount":97},[74922],{"nctId":74895,"briefTitle":74896,"status":145,"phases":74923,"primaryCompletion":74898,"completion":74898,"start":5169,"enrollment":454,"conditions":74924,"interventions":74925},[85],[27],[74888,74901,74902,74903,74904,74905,74906,74907],{"trials":74927,"activeCount":97},[],{"trials":74929,"activeCount":97},[],{"trials":74931,"activeCount":97},[],{"trials":74933,"activeCount":97},[],{"intervention":74902,"totalTrials":417,"cells":74935},{"EARLY_PHASE1":74936,"PHASE1":74938,"PHASE2":74944,"PHASE3":74946,"PHASE4":74948,"NA":74950},{"trials":74937,"activeCount":97},[],{"trials":74939,"activeCount":97},[74940],{"nctId":74895,"briefTitle":74896,"status":145,"phases":74941,"primaryCompletion":74898,"completion":74898,"start":5169,"enrollment":454,"conditions":74942,"interventions":74943},[85],[27],[74888,74901,74902,74903,74904,74905,74906,74907],{"trials":74945,"activeCount":97},[],{"trials":74947,"activeCount":97},[],{"trials":74949,"activeCount":97},[],{"trials":74951,"activeCount":97},[],{"intervention":74903,"totalTrials":417,"cells":74953},{"EARLY_PHASE1":74954,"PHASE1":74956,"PHASE2":74962,"PHASE3":74964,"PHASE4":74966,"NA":74968},{"trials":74955,"activeCount":97},[],{"trials":74957,"activeCount":97},[74958],{"nctId":74895,"briefTitle":74896,"status":145,"phases":74959,"primaryCompletion":74898,"completion":74898,"start":5169,"enrollment":454,"conditions":74960,"interventions":74961},[85],[27],[74888,74901,74902,74903,74904,74905,74906,74907],{"trials":74963,"activeCount":97},[],{"trials":74965,"activeCount":97},[],{"trials":74967,"activeCount":97},[],{"trials":74969,"activeCount":97},[],{"intervention":74904,"totalTrials":417,"cells":74971},{"EARLY_PHASE1":74972,"PHASE1":74974,"PHASE2":74980,"PHASE3":74982,"PHASE4":74984,"NA":74986},{"trials":74973,"activeCount":97},[],{"trials":74975,"activeCount":97},[74976],{"nctId":74895,"briefTitle":74896,"status":145,"phases":74977,"primaryCompletion":74898,"completion":74898,"start":5169,"enrollment":454,"conditions":74978,"interventions":74979},[85],[27],[74888,74901,74902,74903,74904,74905,74906,74907],{"trials":74981,"activeCount":97},[],{"trials":74983,"activeCount":97},[],{"trials":74985,"activeCount":97},[],{"trials":74987,"activeCount":97},[],{"intervention":74905,"totalTrials":417,"cells":74989},{"EARLY_PHASE1":74990,"PHASE1":74992,"PHASE2":74998,"PHASE3":75000,"PHASE4":75002,"NA":75004},{"trials":74991,"activeCount":97},[],{"trials":74993,"activeCount":97},[74994],{"nctId":74895,"briefTitle":74896,"status":145,"phases":74995,"primaryCompletion":74898,"completion":74898,"start":5169,"enrollment":454,"conditions":74996,"interventions":74997},[85],[27],[74888,74901,74902,74903,74904,74905,74906,74907],{"trials":74999,"activeCount":97},[],{"trials":75001,"activeCount":97},[],{"trials":75003,"activeCount":97},[],{"trials":75005,"activeCount":97},[],{"intervention":74906,"totalTrials":417,"cells":75007},{"EARLY_PHASE1":75008,"PHASE1":75010,"PHASE2":75016,"PHASE3":75018,"PHASE4":75020,"NA":75022},{"trials":75009,"activeCount":97},[],{"trials":75011,"activeCount":97},[75012],{"nctId":74895,"briefTitle":74896,"status":145,"phases":75013,"primaryCompletion":74898,"completion":74898,"start":5169,"enrollment":454,"conditions":75014,"interventions":75015},[85],[27],[74888,74901,74902,74903,74904,74905,74906,74907],{"trials":75017,"activeCount":97},[],{"trials":75019,"activeCount":97},[],{"trials":75021,"activeCount":97},[],{"trials":75023,"activeCount":97},[],{"intervention":74907,"totalTrials":417,"cells":75025},{"EARLY_PHASE1":75026,"PHASE1":75028,"PHASE2":75034,"PHASE3":75036,"PHASE4":75038,"NA":75040},{"trials":75027,"activeCount":97},[],{"trials":75029,"activeCount":97},[75030],{"nctId":74895,"briefTitle":74896,"status":145,"phases":75031,"primaryCompletion":74898,"completion":74898,"start":5169,"enrollment":454,"conditions":75032,"interventions":75033},[85],[27],[74888,74901,74902,74903,74904,74905,74906,74907],{"trials":75035,"activeCount":97},[],{"trials":75037,"activeCount":97},[],{"trials":75039,"activeCount":97},[],{"trials":75041,"activeCount":97},[],{"intervention":75043,"totalTrials":417,"cells":75044},"GSK2646264 1%",{"EARLY_PHASE1":75045,"PHASE1":75047,"PHASE2":75058,"PHASE3":75060,"PHASE4":75062,"NA":75064},{"trials":75046,"activeCount":97},[],{"trials":75048,"activeCount":97},[75049],{"nctId":75050,"briefTitle":75051,"status":155,"phases":75052,"primaryCompletion":75053,"completion":75053,"start":75054,"enrollment":361,"conditions":75055,"interventions":75057},"NCT02927457","Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects",[85],"2018-06-12","2017-01-13",[75056],"Lupus Erythematosus, Cutaneous",[75043],{"trials":75059,"activeCount":97},[],{"trials":75061,"activeCount":97},[],{"trials":75063,"activeCount":97},[],{"trials":75065,"activeCount":97},[],{"intervention":40045,"totalTrials":417,"cells":75067},{"EARLY_PHASE1":75068,"PHASE1":75070,"PHASE2":75076,"PHASE3":75078,"PHASE4":75080,"NA":75082},{"trials":75069,"activeCount":97},[],{"trials":75071,"activeCount":97},[75072],{"nctId":40038,"briefTitle":40039,"status":155,"phases":75073,"primaryCompletion":40041,"completion":40041,"start":40042,"enrollment":1298,"conditions":75074,"interventions":75075},[85],[14696],[40045,40010],{"trials":75077,"activeCount":97},[],{"trials":75079,"activeCount":97},[],{"trials":75081,"activeCount":97},[],{"trials":75083,"activeCount":97},[],{"intervention":75085,"totalTrials":417,"cells":75086},"Investigational H7N9 vaccine GSK3206641A",{"EARLY_PHASE1":75087,"PHASE1":75089,"PHASE2":75099,"PHASE3":75101,"PHASE4":75103,"NA":75105},{"trials":75088,"activeCount":97},[],{"trials":75090,"activeCount":97},[75091],{"nctId":75092,"briefTitle":75093,"status":155,"phases":75094,"primaryCompletion":8825,"completion":75095,"start":9852,"enrollment":14772,"conditions":75096,"interventions":75097},"NCT01999842","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age",[85],"2015-01-19",[21],[75085,75098],"Investigational H7N9 vaccine GSK3206640A",{"trials":75100,"activeCount":97},[],{"trials":75102,"activeCount":97},[],{"trials":75104,"activeCount":97},[],{"trials":75106,"activeCount":97},[],{"intervention":75098,"totalTrials":417,"cells":75108},{"EARLY_PHASE1":75109,"PHASE1":75111,"PHASE2":75117,"PHASE3":75119,"PHASE4":75121,"NA":75123},{"trials":75110,"activeCount":97},[],{"trials":75112,"activeCount":97},[75113],{"nctId":75092,"briefTitle":75093,"status":155,"phases":75114,"primaryCompletion":8825,"completion":75095,"start":9852,"enrollment":14772,"conditions":75115,"interventions":75116},[85],[21],[75085,75098],{"trials":75118,"activeCount":97},[],{"trials":75120,"activeCount":97},[],{"trials":75122,"activeCount":97},[],{"trials":75124,"activeCount":97},[],{"intervention":3049,"totalTrials":417,"cells":75126},{"EARLY_PHASE1":75127,"PHASE1":75129,"PHASE2":75135,"PHASE3":75137,"PHASE4":75139,"NA":75141},{"trials":75128,"activeCount":97},[],{"trials":75130,"activeCount":97},[75131],{"nctId":3041,"briefTitle":3042,"status":500,"phases":75132,"primaryCompletion":3044,"completion":3044,"start":3045,"enrollment":97,"conditions":75133,"interventions":75134},[85],[267],[3048,164,3049],{"trials":75136,"activeCount":97},[],{"trials":75138,"activeCount":97},[],{"trials":75140,"activeCount":97},[],{"trials":75142,"activeCount":97},[],{"intervention":75144,"totalTrials":417,"cells":75145},"GW695634",{"EARLY_PHASE1":75146,"PHASE1":75148,"PHASE2":75156,"PHASE3":75158,"PHASE4":75160,"NA":75162},{"trials":75147,"activeCount":97},[],{"trials":75149,"activeCount":97},[75150],{"nctId":75151,"briefTitle":75152,"status":155,"phases":75153,"start":2775,"enrollment":1003,"conditions":75154,"interventions":75155},"NCT00090077","Monotherapy Versus Placebo Over 7 Days-Non-Nucleoside Reverse Transcriptase Inhibitor-Experienced HIV1 Infected Adults",[85],[10943],[75144],{"trials":75157,"activeCount":97},[],{"trials":75159,"activeCount":97},[],{"trials":75161,"activeCount":97},[],{"trials":75163,"activeCount":97},[],{"intervention":75165,"totalTrials":417,"cells":75166},"Danirixin HBr 50 mg IR",{"EARLY_PHASE1":75167,"PHASE1":75169,"PHASE2":75181,"PHASE3":75183,"PHASE4":75185,"NA":75187},{"trials":75168,"activeCount":97},[],{"trials":75170,"activeCount":97},[75171],{"nctId":75172,"briefTitle":75173,"status":155,"phases":75174,"primaryCompletion":75175,"completion":75175,"start":75176,"enrollment":1634,"conditions":75177,"interventions":75178},"NCT02453022","A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole",[85],"2015-07-31","2015-05-18",[15],[75165,75179,75180],"Danirixin FB 50 mg IR","Prilosec (omeprazole) 40mg Delayed-Release",{"trials":75182,"activeCount":97},[],{"trials":75184,"activeCount":97},[],{"trials":75186,"activeCount":97},[],{"trials":75188,"activeCount":97},[],{"intervention":75179,"totalTrials":417,"cells":75190},{"EARLY_PHASE1":75191,"PHASE1":75193,"PHASE2":75199,"PHASE3":75201,"PHASE4":75203,"NA":75205},{"trials":75192,"activeCount":97},[],{"trials":75194,"activeCount":97},[75195],{"nctId":75172,"briefTitle":75173,"status":155,"phases":75196,"primaryCompletion":75175,"completion":75175,"start":75176,"enrollment":1634,"conditions":75197,"interventions":75198},[85],[15],[75165,75179,75180],{"trials":75200,"activeCount":97},[],{"trials":75202,"activeCount":97},[],{"trials":75204,"activeCount":97},[],{"trials":75206,"activeCount":97},[],{"intervention":75180,"totalTrials":417,"cells":75208},{"EARLY_PHASE1":75209,"PHASE1":75211,"PHASE2":75217,"PHASE3":75219,"PHASE4":75221,"NA":75223},{"trials":75210,"activeCount":97},[],{"trials":75212,"activeCount":97},[75213],{"nctId":75172,"briefTitle":75173,"status":155,"phases":75214,"primaryCompletion":75175,"completion":75175,"start":75176,"enrollment":1634,"conditions":75215,"interventions":75216},[85],[15],[75165,75179,75180],{"trials":75218,"activeCount":97},[],{"trials":75220,"activeCount":97},[],{"trials":75222,"activeCount":97},[],{"trials":75224,"activeCount":97},[],{"intervention":75226,"totalTrials":417,"cells":75227},"Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas",{"EARLY_PHASE1":75228,"PHASE1":75230,"PHASE2":75240,"PHASE3":75242,"PHASE4":75244,"NA":75246},{"trials":75229,"activeCount":97},[],{"trials":75231,"activeCount":97},[75232],{"nctId":75233,"briefTitle":75234,"status":155,"phases":75235,"primaryCompletion":75236,"completion":46590,"start":75237,"enrollment":2759,"conditions":75238,"interventions":75239},"NCT01536561","Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma",[85],"1997-07-02","1990-04-24",[4574],[75226],{"trials":75241,"activeCount":97},[],{"trials":75243,"activeCount":97},[],{"trials":75245,"activeCount":97},[],{"trials":75247,"activeCount":97},[],{"intervention":75249,"totalTrials":417,"cells":75250},"Tafenoquine Control",{"EARLY_PHASE1":75251,"PHASE1":75253,"PHASE2":75263,"PHASE3":75265,"PHASE4":75267,"NA":75269},{"trials":75252,"activeCount":97},[],{"trials":75254,"activeCount":97},[75255],{"nctId":75256,"briefTitle":75257,"status":155,"phases":75258,"primaryCompletion":26113,"completion":26113,"start":14277,"enrollment":473,"conditions":75259,"interventions":75260},"NCT02751294","A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution",[85],[3298],[75249,75261,75262],"Tafenoquine dissolution profile X","Tafenoquine SIL",{"trials":75264,"activeCount":97},[],{"trials":75266,"activeCount":97},[],{"trials":75268,"activeCount":97},[],{"trials":75270,"activeCount":97},[],{"intervention":75261,"totalTrials":417,"cells":75272},{"EARLY_PHASE1":75273,"PHASE1":75275,"PHASE2":75281,"PHASE3":75283,"PHASE4":75285,"NA":75287},{"trials":75274,"activeCount":97},[],{"trials":75276,"activeCount":97},[75277],{"nctId":75256,"briefTitle":75257,"status":155,"phases":75278,"primaryCompletion":26113,"completion":26113,"start":14277,"enrollment":473,"conditions":75279,"interventions":75280},[85],[3298],[75249,75261,75262],{"trials":75282,"activeCount":97},[],{"trials":75284,"activeCount":97},[],{"trials":75286,"activeCount":97},[],{"trials":75288,"activeCount":97},[],{"intervention":75262,"totalTrials":417,"cells":75290},{"EARLY_PHASE1":75291,"PHASE1":75293,"PHASE2":75299,"PHASE3":75301,"PHASE4":75303,"NA":75305},{"trials":75292,"activeCount":97},[],{"trials":75294,"activeCount":97},[75295],{"nctId":75256,"briefTitle":75257,"status":155,"phases":75296,"primaryCompletion":26113,"completion":26113,"start":14277,"enrollment":473,"conditions":75297,"interventions":75298},[85],[3298],[75249,75261,75262],{"trials":75300,"activeCount":97},[],{"trials":75302,"activeCount":97},[],{"trials":75304,"activeCount":97},[],{"trials":75306,"activeCount":97},[],{"intervention":42822,"totalTrials":417,"cells":75308},{"EARLY_PHASE1":75309,"PHASE1":75311,"PHASE2":75317,"PHASE3":75319,"PHASE4":75321,"NA":75323},{"trials":75310,"activeCount":97},[],{"trials":75312,"activeCount":97},[75313],{"nctId":42815,"briefTitle":42816,"status":155,"phases":75314,"primaryCompletion":42818,"completion":42818,"start":42819,"enrollment":4891,"conditions":75315,"interventions":75316},[85],[4468],[42822,4497,4496,4495,42823,42824,42825,42794,42826],{"trials":75318,"activeCount":97},[],{"trials":75320,"activeCount":97},[],{"trials":75322,"activeCount":97},[],{"trials":75324,"activeCount":97},[],{"intervention":42825,"totalTrials":417,"cells":75326},{"EARLY_PHASE1":75327,"PHASE1":75329,"PHASE2":75335,"PHASE3":75337,"PHASE4":75339,"NA":75341},{"trials":75328,"activeCount":97},[],{"trials":75330,"activeCount":97},[75331],{"nctId":42815,"briefTitle":42816,"status":155,"phases":75332,"primaryCompletion":42818,"completion":42818,"start":42819,"enrollment":4891,"conditions":75333,"interventions":75334},[85],[4468],[42822,4497,4496,4495,42823,42824,42825,42794,42826],{"trials":75336,"activeCount":97},[],{"trials":75338,"activeCount":97},[],{"trials":75340,"activeCount":97},[],{"trials":75342,"activeCount":97},[],{"intervention":42826,"totalTrials":417,"cells":75344},{"EARLY_PHASE1":75345,"PHASE1":75347,"PHASE2":75353,"PHASE3":75355,"PHASE4":75357,"NA":75359},{"trials":75346,"activeCount":97},[],{"trials":75348,"activeCount":97},[75349],{"nctId":42815,"briefTitle":42816,"status":155,"phases":75350,"primaryCompletion":42818,"completion":42818,"start":42819,"enrollment":4891,"conditions":75351,"interventions":75352},[85],[4468],[42822,4497,4496,4495,42823,42824,42825,42794,42826],{"trials":75354,"activeCount":97},[],{"trials":75356,"activeCount":97},[],{"trials":75358,"activeCount":97},[],{"trials":75360,"activeCount":97},[],{"intervention":75362,"totalTrials":417,"cells":75363},"Intravenous GR270773 - Phospholipid emulsion",{"EARLY_PHASE1":75364,"PHASE1":75366,"PHASE2":75376,"PHASE3":75378,"PHASE4":75380,"NA":75382},{"trials":75365,"activeCount":97},[],{"trials":75367,"activeCount":97},[75368],{"nctId":75369,"briefTitle":75370,"status":155,"phases":75371,"primaryCompletion":75372,"completion":75372,"start":75373,"enrollment":433,"conditions":75374,"interventions":75375},"NCT00158769","A Study To Compare The Effects Of The Infusion Of A Sepsis Drug Between Healthy Adults And Adults With Damaged Livers",[85],"2005-10-26","2005-03-31",[40146],[75362],{"trials":75377,"activeCount":97},[],{"trials":75379,"activeCount":97},[],{"trials":75381,"activeCount":97},[],{"trials":75383,"activeCount":97},[],{"intervention":75385,"totalTrials":417,"cells":75386},"Mtb72F\u002FAS02.",{"EARLY_PHASE1":75387,"PHASE1":75389,"PHASE2":75397,"PHASE3":75399,"PHASE4":75401,"NA":75403},{"trials":75388,"activeCount":97},[],{"trials":75390,"activeCount":97},[75391],{"nctId":75392,"briefTitle":75393,"status":155,"phases":75394,"primaryCompletion":8386,"completion":8386,"start":3714,"enrollment":1003,"conditions":75395,"interventions":75396},"NCT00291889","Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F\u002FAS02 in Healthy PPD-negative Adults.",[85],[41708],[75385],{"trials":75398,"activeCount":97},[],{"trials":75400,"activeCount":97},[],{"trials":75402,"activeCount":97},[],{"trials":75404,"activeCount":97},[],{"intervention":59367,"totalTrials":417,"cells":75406},{"EARLY_PHASE1":75407,"PHASE1":75409,"PHASE2":75415,"PHASE3":75417,"PHASE4":75419,"NA":75421},{"trials":75408,"activeCount":97},[],{"trials":75410,"activeCount":97},[75411],{"nctId":59361,"briefTitle":59362,"status":155,"phases":75412,"primaryCompletion":59364,"completion":59364,"start":9452,"enrollment":1634,"conditions":75413,"interventions":75414},[85],[18],[59367,38856,38856],{"trials":75416,"activeCount":97},[],{"trials":75418,"activeCount":97},[],{"trials":75420,"activeCount":97},[],{"trials":75422,"activeCount":97},[],{"intervention":42706,"totalTrials":417,"cells":75424},{"EARLY_PHASE1":75425,"PHASE1":75427,"PHASE2":75433,"PHASE3":75435,"PHASE4":75437,"NA":75439},{"trials":75426,"activeCount":97},[],{"trials":75428,"activeCount":97},[75429],{"nctId":42700,"briefTitle":42701,"status":155,"phases":75430,"primaryCompletion":42703,"completion":42703,"start":19184,"enrollment":6503,"conditions":75431,"interventions":75432},[85],[38980],[42706,40867,42707],{"trials":75434,"activeCount":97},[],{"trials":75436,"activeCount":97},[],{"trials":75438,"activeCount":97},[],{"trials":75440,"activeCount":97},[],{"intervention":42707,"totalTrials":417,"cells":75442},{"EARLY_PHASE1":75443,"PHASE1":75445,"PHASE2":75451,"PHASE3":75453,"PHASE4":75455,"NA":75457},{"trials":75444,"activeCount":97},[],{"trials":75446,"activeCount":97},[75447],{"nctId":42700,"briefTitle":42701,"status":155,"phases":75448,"primaryCompletion":42703,"completion":42703,"start":19184,"enrollment":6503,"conditions":75449,"interventions":75450},[85],[38980],[42706,40867,42707],{"trials":75452,"activeCount":97},[],{"trials":75454,"activeCount":97},[],{"trials":75456,"activeCount":97},[],{"trials":75458,"activeCount":97},[],{"intervention":38886,"totalTrials":417,"cells":75460},{"EARLY_PHASE1":75461,"PHASE1":75463,"PHASE2":75469,"PHASE3":75471,"PHASE4":75473,"NA":75475},{"trials":75462,"activeCount":97},[],{"trials":75464,"activeCount":97},[75465],{"nctId":38878,"briefTitle":38879,"status":155,"phases":75466,"primaryCompletion":38881,"completion":38881,"start":38882,"enrollment":9334,"conditions":75467,"interventions":75468},[85],[27,9048],[38885,9030,38886,38887],{"trials":75470,"activeCount":97},[],{"trials":75472,"activeCount":97},[],{"trials":75474,"activeCount":97},[],{"trials":75476,"activeCount":97},[],{"intervention":38887,"totalTrials":417,"cells":75478},{"EARLY_PHASE1":75479,"PHASE1":75481,"PHASE2":75487,"PHASE3":75489,"PHASE4":75491,"NA":75493},{"trials":75480,"activeCount":97},[],{"trials":75482,"activeCount":97},[75483],{"nctId":38878,"briefTitle":38879,"status":155,"phases":75484,"primaryCompletion":38881,"completion":38881,"start":38882,"enrollment":9334,"conditions":75485,"interventions":75486},[85],[27,9048],[38885,9030,38886,38887],{"trials":75488,"activeCount":97},[],{"trials":75490,"activeCount":97},[],{"trials":75492,"activeCount":97},[],{"trials":75494,"activeCount":97},[],{"intervention":75496,"totalTrials":417,"cells":75497},"GSK971086",{"EARLY_PHASE1":75498,"PHASE1":75500,"PHASE2":75509,"PHASE3":75511,"PHASE4":75513,"NA":75515},{"trials":75499,"activeCount":97},[],{"trials":75501,"activeCount":97},[75502],{"nctId":75503,"briefTitle":75504,"status":155,"phases":75505,"primaryCompletion":2355,"completion":2355,"start":2336,"enrollment":3157,"conditions":75506,"interventions":75508},"NCT00540553","Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult Males",[85],[7524,75507],"Androgen Deficiency",[75496],{"trials":75510,"activeCount":97},[],{"trials":75512,"activeCount":97},[],{"trials":75514,"activeCount":97},[],{"trials":75516,"activeCount":97},[],{"intervention":75518,"totalTrials":417,"cells":75519},"GSK4347859",{"EARLY_PHASE1":75520,"PHASE1":75522,"PHASE2":75532,"PHASE3":75534,"PHASE4":75536,"NA":75538},{"trials":75521,"activeCount":97},[],{"trials":75523,"activeCount":97},[75524],{"nctId":75525,"briefTitle":75526,"status":75527,"phases":75528,"primaryCompletion":2106,"completion":2106,"start":75529,"enrollment":2282,"conditions":75530,"interventions":75531},"NCT06188507","A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants","SUSPENDED",[85],"2024-01-12",[435],[75518],{"trials":75533,"activeCount":97},[],{"trials":75535,"activeCount":97},[],{"trials":75537,"activeCount":97},[],{"trials":75539,"activeCount":97},[],{"intervention":9857,"totalTrials":417,"cells":75541},{"EARLY_PHASE1":75542,"PHASE1":75544,"PHASE2":75550,"PHASE3":75552,"PHASE4":75554,"NA":75556},{"trials":75543,"activeCount":97},[],{"trials":75545,"activeCount":97},[75546],{"nctId":9849,"briefTitle":9850,"status":155,"phases":75547,"primaryCompletion":9852,"completion":9852,"start":9853,"enrollment":6503,"conditions":75548,"interventions":75549},[85],[9855],[9857,9857,9828],{"trials":75551,"activeCount":97},[],{"trials":75553,"activeCount":97},[],{"trials":75555,"activeCount":97},[],{"trials":75557,"activeCount":97},[],{"intervention":5172,"totalTrials":417,"cells":75559},{"EARLY_PHASE1":75560,"PHASE1":75562,"PHASE2":75568,"PHASE3":75570,"PHASE4":75572,"NA":75574},{"trials":75561,"activeCount":97},[],{"trials":75563,"activeCount":97},[75564],{"nctId":5165,"briefTitle":5166,"status":155,"phases":75565,"primaryCompletion":5168,"completion":5168,"start":5169,"enrollment":1003,"conditions":75566,"interventions":75567},[85],[107],[5172,1651,1241],{"trials":75569,"activeCount":97},[],{"trials":75571,"activeCount":97},[],{"trials":75573,"activeCount":97},[],{"trials":75575,"activeCount":97},[],{"intervention":75577,"totalTrials":417,"cells":75578},"GVGH Shigella sonnei 1790GAHB vaccine",{"EARLY_PHASE1":75579,"PHASE1":75581,"PHASE2":75590,"PHASE3":75592,"PHASE4":75594,"NA":75596},{"trials":75580,"activeCount":97},[],{"trials":75582,"activeCount":97},[75583],{"nctId":75584,"briefTitle":75585,"status":155,"phases":75586,"primaryCompletion":75587,"completion":75587,"start":8161,"enrollment":8786,"conditions":75588,"interventions":75589},"NCT03089879","A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study",[85],"2017-08-31",[58133],[75577],{"trials":75591,"activeCount":97},[],{"trials":75593,"activeCount":97},[],{"trials":75595,"activeCount":97},[],{"trials":75597,"activeCount":97},[],{"intervention":75599,"totalTrials":417,"cells":75600},"Levocetirizine IRT 5 mg",{"EARLY_PHASE1":75601,"PHASE1":75603,"PHASE2":75614,"PHASE3":75616,"PHASE4":75618,"NA":75620},{"trials":75602,"activeCount":97},[],{"trials":75604,"activeCount":97},[75605],{"nctId":75606,"briefTitle":75607,"status":155,"phases":75608,"primaryCompletion":75609,"completion":75609,"start":75610,"enrollment":1264,"conditions":75611,"interventions":75612},"NCT03555890","Bioequivalence Study Between Levocetirizine Oral Disintegrating Tablet (ODT) and Levocetirizine Immediate Release Tablet (IRT)",[85],"2018-09-17","2018-05-18",[11853],[75599,75613],"Levocetirizine ODT 5 mg",{"trials":75615,"activeCount":97},[],{"trials":75617,"activeCount":97},[],{"trials":75619,"activeCount":97},[],{"trials":75621,"activeCount":97},[],{"intervention":75613,"totalTrials":417,"cells":75623},{"EARLY_PHASE1":75624,"PHASE1":75626,"PHASE2":75632,"PHASE3":75634,"PHASE4":75636,"NA":75638},{"trials":75625,"activeCount":97},[],{"trials":75627,"activeCount":97},[75628],{"nctId":75606,"briefTitle":75607,"status":155,"phases":75629,"primaryCompletion":75609,"completion":75609,"start":75610,"enrollment":1264,"conditions":75630,"interventions":75631},[85],[11853],[75599,75613],{"trials":75633,"activeCount":97},[],{"trials":75635,"activeCount":97},[],{"trials":75637,"activeCount":97},[],{"trials":75639,"activeCount":97},[],{"intervention":75641,"totalTrials":417,"cells":75642},"GSK Biologicals' quadrivalent influenza vaccine",{"EARLY_PHASE1":75643,"PHASE1":75645,"PHASE2":75656,"PHASE3":75658,"PHASE4":75660,"NA":75662},{"trials":75644,"activeCount":97},[],{"trials":75646,"activeCount":97},[75647],{"nctId":75648,"briefTitle":75649,"status":155,"phases":75650,"primaryCompletion":75651,"completion":75651,"start":75652,"enrollment":2121,"conditions":75653,"interventions":75654},"NCT00714285","Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults.",[85],"2009-01-28","2008-07-14",[21],[75641,75655],"GSK Biologicals' trivalent influenza vaccine",{"trials":75657,"activeCount":97},[],{"trials":75659,"activeCount":97},[],{"trials":75661,"activeCount":97},[],{"trials":75663,"activeCount":97},[],{"intervention":75655,"totalTrials":417,"cells":75665},{"EARLY_PHASE1":75666,"PHASE1":75668,"PHASE2":75674,"PHASE3":75676,"PHASE4":75678,"NA":75680},{"trials":75667,"activeCount":97},[],{"trials":75669,"activeCount":97},[75670],{"nctId":75648,"briefTitle":75649,"status":155,"phases":75671,"primaryCompletion":75651,"completion":75651,"start":75652,"enrollment":2121,"conditions":75672,"interventions":75673},[85],[21],[75641,75655],{"trials":75675,"activeCount":97},[],{"trials":75677,"activeCount":97},[],{"trials":75679,"activeCount":97},[],{"trials":75681,"activeCount":97},[],{"intervention":75683,"totalTrials":417,"cells":75684},"Single IV dose of GSK2862277",{"EARLY_PHASE1":75685,"PHASE1":75687,"PHASE2":75699,"PHASE3":75701,"PHASE4":75703,"NA":75705},{"trials":75686,"activeCount":97},[],{"trials":75688,"activeCount":97},[75689],{"nctId":75690,"briefTitle":75691,"status":155,"phases":75692,"primaryCompletion":8396,"completion":8396,"start":75693,"enrollment":1686,"conditions":75694,"interventions":75695},"NCT01818024","A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers",[85],"2013-02-22",[9855],[75683,75696,75697,75698],"Single IH dose of GSK2862277","Repeat IV dose of GSK2862277","Repeat IH dose selected of GSK2862277 from Part 2",{"trials":75700,"activeCount":97},[],{"trials":75702,"activeCount":97},[],{"trials":75704,"activeCount":97},[],{"trials":75706,"activeCount":97},[],{"intervention":75696,"totalTrials":417,"cells":75708},{"EARLY_PHASE1":75709,"PHASE1":75711,"PHASE2":75717,"PHASE3":75719,"PHASE4":75721,"NA":75723},{"trials":75710,"activeCount":97},[],{"trials":75712,"activeCount":97},[75713],{"nctId":75690,"briefTitle":75691,"status":155,"phases":75714,"primaryCompletion":8396,"completion":8396,"start":75693,"enrollment":1686,"conditions":75715,"interventions":75716},[85],[9855],[75683,75696,75697,75698],{"trials":75718,"activeCount":97},[],{"trials":75720,"activeCount":97},[],{"trials":75722,"activeCount":97},[],{"trials":75724,"activeCount":97},[],{"intervention":75697,"totalTrials":417,"cells":75726},{"EARLY_PHASE1":75727,"PHASE1":75729,"PHASE2":75735,"PHASE3":75737,"PHASE4":75739,"NA":75741},{"trials":75728,"activeCount":97},[],{"trials":75730,"activeCount":97},[75731],{"nctId":75690,"briefTitle":75691,"status":155,"phases":75732,"primaryCompletion":8396,"completion":8396,"start":75693,"enrollment":1686,"conditions":75733,"interventions":75734},[85],[9855],[75683,75696,75697,75698],{"trials":75736,"activeCount":97},[],{"trials":75738,"activeCount":97},[],{"trials":75740,"activeCount":97},[],{"trials":75742,"activeCount":97},[],{"intervention":75698,"totalTrials":417,"cells":75744},{"EARLY_PHASE1":75745,"PHASE1":75747,"PHASE2":75753,"PHASE3":75755,"PHASE4":75757,"NA":75759},{"trials":75746,"activeCount":97},[],{"trials":75748,"activeCount":97},[75749],{"nctId":75690,"briefTitle":75691,"status":155,"phases":75750,"primaryCompletion":8396,"completion":8396,"start":75693,"enrollment":1686,"conditions":75751,"interventions":75752},[85],[9855],[75683,75696,75697,75698],{"trials":75754,"activeCount":97},[],{"trials":75756,"activeCount":97},[],{"trials":75758,"activeCount":97},[],{"trials":75760,"activeCount":97},[],{"intervention":75762,"totalTrials":417,"cells":75763},"Cohort 1",{"EARLY_PHASE1":75764,"PHASE1":75766,"PHASE2":75776,"PHASE3":75778,"PHASE4":75780,"NA":75782},{"trials":75765,"activeCount":97},[],{"trials":75767,"activeCount":97},[75768],{"nctId":75769,"briefTitle":75770,"status":155,"phases":75771,"primaryCompletion":75772,"completion":75772,"start":22677,"enrollment":695,"conditions":75773,"interventions":75774},"NCT01458054","Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults",[85],"2011-11-28",[23770],[75762,75775],"Cohort 2",{"trials":75777,"activeCount":97},[],{"trials":75779,"activeCount":97},[],{"trials":75781,"activeCount":97},[],{"trials":75783,"activeCount":97},[],{"intervention":75775,"totalTrials":417,"cells":75785},{"EARLY_PHASE1":75786,"PHASE1":75788,"PHASE2":75794,"PHASE3":75796,"PHASE4":75798,"NA":75800},{"trials":75787,"activeCount":97},[],{"trials":75789,"activeCount":97},[75790],{"nctId":75769,"briefTitle":75770,"status":155,"phases":75791,"primaryCompletion":75772,"completion":75772,"start":22677,"enrollment":695,"conditions":75792,"interventions":75793},[85],[23770],[75762,75775],{"trials":75795,"activeCount":97},[],{"trials":75797,"activeCount":97},[],{"trials":75799,"activeCount":97},[],{"trials":75801,"activeCount":97},[],{"intervention":75803,"totalTrials":417,"cells":75804},"phenytoin",{"EARLY_PHASE1":75805,"PHASE1":75807,"PHASE2":75817,"PHASE3":75819,"PHASE4":75821,"NA":75823},{"trials":75806,"activeCount":97},[],{"trials":75808,"activeCount":97},[75809],{"nctId":75810,"briefTitle":75811,"status":155,"phases":75812,"primaryCompletion":41493,"completion":41493,"start":75813,"enrollment":35629,"conditions":75814,"interventions":75815},"NCT00627575","AED\u002FStatin Interaction Study",[85],"2008-02-04",[12518],[75816,28454,75803],"lamotrigine",{"trials":75818,"activeCount":97},[],{"trials":75820,"activeCount":97},[],{"trials":75822,"activeCount":97},[],{"trials":75824,"activeCount":97},[],{"intervention":75826,"totalTrials":417,"cells":75827},"Drug",{"EARLY_PHASE1":75828,"PHASE1":75830,"PHASE2":75839,"PHASE3":75841,"PHASE4":75843,"NA":75845},{"trials":75829,"activeCount":97},[],{"trials":75831,"activeCount":97},[75832],{"nctId":75833,"briefTitle":75834,"status":155,"phases":75835,"primaryCompletion":7867,"completion":7867,"start":75836,"enrollment":1165,"conditions":75837,"interventions":75838},"NCT01371799","A Study to Examine the Pharmacodynamic Effects of GSK1034702 on Neurophysiological Biomarkers of Cognition in Nicotine Abstained Otherwise Healthy Smokers",[85],"2009-12-17",[65610],[75826,75826],{"trials":75840,"activeCount":97},[],{"trials":75842,"activeCount":97},[],{"trials":75844,"activeCount":97},[],{"trials":75846,"activeCount":97},[],{"intervention":10388,"totalTrials":417,"cells":75848},{"EARLY_PHASE1":75849,"PHASE1":75851,"PHASE2":75857,"PHASE3":75859,"PHASE4":75861,"NA":75863},{"trials":75850,"activeCount":97},[],{"trials":75852,"activeCount":97},[75853],{"nctId":10380,"briefTitle":10381,"status":155,"phases":75854,"primaryCompletion":10383,"completion":10383,"start":10384,"enrollment":2045,"conditions":75855,"interventions":75856},[85],[10386],[10388,10389,4884,10390],{"trials":75858,"activeCount":97},[],{"trials":75860,"activeCount":97},[],{"trials":75862,"activeCount":97},[],{"trials":75864,"activeCount":97},[],{"intervention":10389,"totalTrials":417,"cells":75866},{"EARLY_PHASE1":75867,"PHASE1":75869,"PHASE2":75875,"PHASE3":75877,"PHASE4":75879,"NA":75881},{"trials":75868,"activeCount":97},[],{"trials":75870,"activeCount":97},[75871],{"nctId":10380,"briefTitle":10381,"status":155,"phases":75872,"primaryCompletion":10383,"completion":10383,"start":10384,"enrollment":2045,"conditions":75873,"interventions":75874},[85],[10386],[10388,10389,4884,10390],{"trials":75876,"activeCount":97},[],{"trials":75878,"activeCount":97},[],{"trials":75880,"activeCount":97},[],{"trials":75882,"activeCount":97},[],{"intervention":75884,"totalTrials":417,"cells":75885},"Part A: 100 mg\u002FmL GSK2618960",{"EARLY_PHASE1":75886,"PHASE1":75888,"PHASE2":75899,"PHASE3":75901,"PHASE4":75903,"NA":75905},{"trials":75887,"activeCount":97},[],{"trials":75889,"activeCount":97},[75890],{"nctId":75891,"briefTitle":75892,"status":145,"phases":75893,"primaryCompletion":75894,"completion":75894,"start":9126,"enrollment":433,"conditions":75895,"interventions":75896},"NCT01808482","A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)",[85],"2013-08-06",[39994],[75884,75897,75898],"Part B: Dose of GSK2618960 decided from Part A","Part C: Dose of GSK2618960 decided from Part A and B",{"trials":75900,"activeCount":97},[],{"trials":75902,"activeCount":97},[],{"trials":75904,"activeCount":97},[],{"trials":75906,"activeCount":97},[],{"intervention":75897,"totalTrials":417,"cells":75908},{"EARLY_PHASE1":75909,"PHASE1":75911,"PHASE2":75917,"PHASE3":75919,"PHASE4":75921,"NA":75923},{"trials":75910,"activeCount":97},[],{"trials":75912,"activeCount":97},[75913],{"nctId":75891,"briefTitle":75892,"status":145,"phases":75914,"primaryCompletion":75894,"completion":75894,"start":9126,"enrollment":433,"conditions":75915,"interventions":75916},[85],[39994],[75884,75897,75898],{"trials":75918,"activeCount":97},[],{"trials":75920,"activeCount":97},[],{"trials":75922,"activeCount":97},[],{"trials":75924,"activeCount":97},[],{"intervention":75898,"totalTrials":417,"cells":75926},{"EARLY_PHASE1":75927,"PHASE1":75929,"PHASE2":75935,"PHASE3":75937,"PHASE4":75939,"NA":75941},{"trials":75928,"activeCount":97},[],{"trials":75930,"activeCount":97},[75931],{"nctId":75891,"briefTitle":75892,"status":145,"phases":75932,"primaryCompletion":75894,"completion":75894,"start":9126,"enrollment":433,"conditions":75933,"interventions":75934},[85],[39994],[75884,75897,75898],{"trials":75936,"activeCount":97},[],{"trials":75938,"activeCount":97},[],{"trials":75940,"activeCount":97},[],{"trials":75942,"activeCount":97},[],{"intervention":9490,"totalTrials":417,"cells":75944},{"EARLY_PHASE1":75945,"PHASE1":75947,"PHASE2":75953,"PHASE3":75955,"PHASE4":75957,"NA":75959},{"trials":75946,"activeCount":97},[],{"trials":75948,"activeCount":97},[75949],{"nctId":9483,"briefTitle":9484,"status":155,"phases":75950,"primaryCompletion":9486,"completion":9486,"start":9487,"enrollment":433,"conditions":75951,"interventions":75952},[85],[18],[9490,9491,9415],{"trials":75954,"activeCount":97},[],{"trials":75956,"activeCount":97},[],{"trials":75958,"activeCount":97},[],{"trials":75960,"activeCount":97},[],{"intervention":9491,"totalTrials":417,"cells":75962},{"EARLY_PHASE1":75963,"PHASE1":75965,"PHASE2":75971,"PHASE3":75973,"PHASE4":75975,"NA":75977},{"trials":75964,"activeCount":97},[],{"trials":75966,"activeCount":97},[75967],{"nctId":9483,"briefTitle":9484,"status":155,"phases":75968,"primaryCompletion":9486,"completion":9486,"start":9487,"enrollment":433,"conditions":75969,"interventions":75970},[85],[18],[9490,9491,9415],{"trials":75972,"activeCount":97},[],{"trials":75974,"activeCount":97},[],{"trials":75976,"activeCount":97},[],{"trials":75978,"activeCount":97},[],{"intervention":75980,"totalTrials":417,"cells":75981},"[14C]Umeclidinium 18.5 mg",{"EARLY_PHASE1":75982,"PHASE1":75984,"PHASE2":75993,"PHASE3":75995,"PHASE4":75997,"NA":75999},{"trials":75983,"activeCount":97},[],{"trials":75985,"activeCount":97},[75986],{"nctId":75987,"briefTitle":75988,"status":155,"phases":75989,"primaryCompletion":41803,"completion":41803,"start":75990,"enrollment":1634,"conditions":75991,"interventions":75992},"NCT01934153","Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects",[85],"2013-09-02",[12067],[75980],{"trials":75994,"activeCount":97},[],{"trials":75996,"activeCount":97},[],{"trials":75998,"activeCount":97},[],{"trials":76000,"activeCount":97},[],{"intervention":76002,"totalTrials":417,"cells":76003},"GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic",{"EARLY_PHASE1":76004,"PHASE1":76006,"PHASE2":76015,"PHASE3":76017,"PHASE4":76019,"NA":76021},{"trials":76005,"activeCount":97},[],{"trials":76007,"activeCount":97},[76008],{"nctId":76009,"briefTitle":76010,"status":155,"phases":76011,"primaryCompletion":76012,"completion":76012,"start":17894,"enrollment":1736,"conditions":76013,"interventions":76014},"NCT00725283","Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML)",[85],"2016-06-22",[3381],[76002],{"trials":76016,"activeCount":97},[],{"trials":76018,"activeCount":97},[],{"trials":76020,"activeCount":97},[],{"trials":76022,"activeCount":97},[],{"intervention":76024,"totalTrials":417,"cells":76025},"GSK933776 for SQ administration",{"EARLY_PHASE1":76026,"PHASE1":76028,"PHASE2":76038,"PHASE3":76040,"PHASE4":76042,"NA":76044},{"trials":76027,"activeCount":97},[],{"trials":76029,"activeCount":97},[76030],{"nctId":76031,"briefTitle":76032,"status":155,"phases":76033,"primaryCompletion":74004,"completion":74004,"start":19164,"enrollment":710,"conditions":76034,"interventions":76035},"NCT02033668","Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers",[85],[41649],[76024,76036,76037],"GSK933776 for IM administration","GSK933776 for IV administration",{"trials":76039,"activeCount":97},[],{"trials":76041,"activeCount":97},[],{"trials":76043,"activeCount":97},[],{"trials":76045,"activeCount":97},[],{"intervention":76036,"totalTrials":417,"cells":76047},{"EARLY_PHASE1":76048,"PHASE1":76050,"PHASE2":76056,"PHASE3":76058,"PHASE4":76060,"NA":76062},{"trials":76049,"activeCount":97},[],{"trials":76051,"activeCount":97},[76052],{"nctId":76031,"briefTitle":76032,"status":155,"phases":76053,"primaryCompletion":74004,"completion":74004,"start":19164,"enrollment":710,"conditions":76054,"interventions":76055},[85],[41649],[76024,76036,76037],{"trials":76057,"activeCount":97},[],{"trials":76059,"activeCount":97},[],{"trials":76061,"activeCount":97},[],{"trials":76063,"activeCount":97},[],{"intervention":76037,"totalTrials":417,"cells":76065},{"EARLY_PHASE1":76066,"PHASE1":76068,"PHASE2":76074,"PHASE3":76076,"PHASE4":76078,"NA":76080},{"trials":76067,"activeCount":97},[],{"trials":76069,"activeCount":97},[76070],{"nctId":76031,"briefTitle":76032,"status":155,"phases":76071,"primaryCompletion":74004,"completion":74004,"start":19164,"enrollment":710,"conditions":76072,"interventions":76073},[85],[41649],[76024,76036,76037],{"trials":76075,"activeCount":97},[],{"trials":76077,"activeCount":97},[],{"trials":76079,"activeCount":97},[],{"trials":76081,"activeCount":97},[],{"intervention":76083,"totalTrials":417,"cells":76084},"Test formulation A",{"EARLY_PHASE1":76085,"PHASE1":76087,"PHASE2":76097,"PHASE3":76099,"PHASE4":76101,"NA":76103},{"trials":76086,"activeCount":97},[],{"trials":76088,"activeCount":97},[76089],{"nctId":76090,"briefTitle":76091,"status":155,"phases":76092,"primaryCompletion":60942,"completion":60942,"start":76093,"enrollment":695,"conditions":76094,"interventions":76095},"NCT03408392","Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)\u002F5 Milliliter (mL) Suspension Versus Cefixime 200 mg\u002F5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions",[85],"2018-02-06",[6484],[76083,76096],"Reference formulation B",{"trials":76098,"activeCount":97},[],{"trials":76100,"activeCount":97},[],{"trials":76102,"activeCount":97},[],{"trials":76104,"activeCount":97},[],{"intervention":76096,"totalTrials":417,"cells":76106},{"EARLY_PHASE1":76107,"PHASE1":76109,"PHASE2":76115,"PHASE3":76117,"PHASE4":76119,"NA":76121},{"trials":76108,"activeCount":97},[],{"trials":76110,"activeCount":97},[76111],{"nctId":76090,"briefTitle":76091,"status":155,"phases":76112,"primaryCompletion":60942,"completion":60942,"start":76093,"enrollment":695,"conditions":76113,"interventions":76114},[85],[6484],[76083,76096],{"trials":76116,"activeCount":97},[],{"trials":76118,"activeCount":97},[],{"trials":76120,"activeCount":97},[],{"trials":76122,"activeCount":97},[],{"intervention":76124,"totalTrials":417,"cells":76125},"sibutramine",{"EARLY_PHASE1":76126,"PHASE1":76128,"PHASE2":76137,"PHASE3":76139,"PHASE4":76141,"NA":76143},{"trials":76127,"activeCount":97},[],{"trials":76129,"activeCount":97},[76130],{"nctId":76131,"briefTitle":76132,"status":155,"phases":76133,"primaryCompletion":18388,"completion":18388,"start":76134,"enrollment":1237,"conditions":76135,"interventions":76136},"NCT01597609","A Study to Characterise the Physiology of Weight Loss and Regain Under Dietary, Behavioural and Pharmacological Interventions in Healthy Obese Subjects",[85],"2008-05-22",[9048],[76124],{"trials":76138,"activeCount":97},[],{"trials":76140,"activeCount":97},[],{"trials":76142,"activeCount":97},[],{"trials":76144,"activeCount":97},[],{"intervention":9326,"totalTrials":417,"cells":76146},{"EARLY_PHASE1":76147,"PHASE1":76149,"PHASE2":76155,"PHASE3":76157,"PHASE4":76159,"NA":76161},{"trials":76148,"activeCount":97},[],{"trials":76150,"activeCount":97},[76151],{"nctId":9313,"briefTitle":9314,"status":155,"phases":76152,"primaryCompletion":9316,"completion":9316,"start":9317,"enrollment":31,"conditions":76153,"interventions":76154},[85],[9319],[9321,9093,9273,9322,9323,6488,9324,9325,9326,9327,9093],{"trials":76156,"activeCount":97},[],{"trials":76158,"activeCount":97},[],{"trials":76160,"activeCount":97},[],{"trials":76162,"activeCount":97},[],{"intervention":18391,"totalTrials":417,"cells":76164},{"EARLY_PHASE1":76165,"PHASE1":76167,"PHASE2":76173,"PHASE3":76175,"PHASE4":76177,"NA":76179},{"trials":76166,"activeCount":97},[],{"trials":76168,"activeCount":97},[76169],{"nctId":18384,"briefTitle":18385,"status":155,"phases":76170,"primaryCompletion":18387,"completion":18387,"start":18388,"enrollment":2045,"conditions":76171,"interventions":76172},[85],[15],[18345,18391],{"trials":76174,"activeCount":97},[],{"trials":76176,"activeCount":97},[],{"trials":76178,"activeCount":97},[],{"trials":76180,"activeCount":97},[],{"intervention":76182,"totalTrials":417,"cells":76183},"GSK206136",{"EARLY_PHASE1":76184,"PHASE1":76186,"PHASE2":76195,"PHASE3":76197,"PHASE4":76199,"NA":76201},{"trials":76185,"activeCount":97},[],{"trials":76187,"activeCount":97},[76188],{"nctId":76189,"briefTitle":76190,"status":155,"phases":76191,"primaryCompletion":76192,"completion":76192,"start":10793,"enrollment":2797,"conditions":76193,"interventions":76194},"NCT01059578","First Study in Humans With GSK206136",[85],"2006-12-18",[41867],[76182],{"trials":76196,"activeCount":97},[],{"trials":76198,"activeCount":97},[],{"trials":76200,"activeCount":97},[],{"trials":76202,"activeCount":97},[],{"intervention":76204,"totalTrials":417,"cells":76205},"Retapamulin Microdialysis",{"EARLY_PHASE1":76206,"PHASE1":76208,"PHASE2":76217,"PHASE3":76219,"PHASE4":76221,"NA":76223},{"trials":76207,"activeCount":97},[],{"trials":76209,"activeCount":97},[76210],{"nctId":76211,"briefTitle":76212,"status":155,"phases":76213,"primaryCompletion":42735,"completion":42735,"start":76214,"enrollment":593,"conditions":76215,"interventions":76216},"NCT01812382","Retapamulin Microdialysis Feasibility Study",[85],"2014-04-02",[12727],[76204],{"trials":76218,"activeCount":97},[],{"trials":76220,"activeCount":97},[],{"trials":76222,"activeCount":97},[],{"trials":76224,"activeCount":97},[],{"intervention":76226,"totalTrials":417,"cells":76227},"GSK2556286",{"EARLY_PHASE1":76228,"PHASE1":76230,"PHASE2":76240,"PHASE3":76242,"PHASE4":76244,"NA":76246},{"trials":76229,"activeCount":97},[],{"trials":76231,"activeCount":97},[76232],{"nctId":76233,"briefTitle":76234,"status":145,"phases":76235,"primaryCompletion":76236,"completion":76236,"start":76237,"enrollment":2883,"conditions":76238,"interventions":76239},"NCT04472897","A Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2556286 in Healthy Adult Participants",[85],"2024-11-06","2020-10-30",[23246],[76226],{"trials":76241,"activeCount":97},[],{"trials":76243,"activeCount":97},[],{"trials":76245,"activeCount":97},[],{"trials":76247,"activeCount":97},[],{"intervention":76249,"totalTrials":417,"cells":76250},"GSK2269557 500 µg",{"EARLY_PHASE1":76251,"PHASE1":76253,"PHASE2":76263,"PHASE3":76265,"PHASE4":76267,"NA":76269},{"trials":76252,"activeCount":97},[],{"trials":76254,"activeCount":97},[76255],{"nctId":76256,"briefTitle":76257,"status":155,"phases":76258,"primaryCompletion":8106,"completion":8106,"start":76259,"enrollment":1459,"conditions":76260,"interventions":76261},"NCT03189589","Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects",[85],"2017-06-15",[15],[76249,76262],"GSK2269557 750 µg",{"trials":76264,"activeCount":97},[],{"trials":76266,"activeCount":97},[],{"trials":76268,"activeCount":97},[],{"trials":76270,"activeCount":97},[],{"intervention":76262,"totalTrials":417,"cells":76272},{"EARLY_PHASE1":76273,"PHASE1":76275,"PHASE2":76281,"PHASE3":76283,"PHASE4":76285,"NA":76287},{"trials":76274,"activeCount":97},[],{"trials":76276,"activeCount":97},[76277],{"nctId":76256,"briefTitle":76257,"status":155,"phases":76278,"primaryCompletion":8106,"completion":8106,"start":76259,"enrollment":1459,"conditions":76279,"interventions":76280},[85],[15],[76249,76262],{"trials":76282,"activeCount":97},[],{"trials":76284,"activeCount":97},[],{"trials":76286,"activeCount":97},[],{"trials":76288,"activeCount":97},[],{"intervention":76290,"totalTrials":417,"cells":76291},"Regimen A",{"EARLY_PHASE1":76292,"PHASE1":76294,"PHASE2":76306,"PHASE3":76308,"PHASE4":76310,"NA":76312},{"trials":76293,"activeCount":97},[],{"trials":76295,"activeCount":97},[76296],{"nctId":76297,"briefTitle":76298,"status":155,"phases":76299,"primaryCompletion":42746,"completion":42746,"start":76300,"enrollment":695,"conditions":76301,"interventions":76302},"NCT01231568","An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor",[85],"2010-10-21",[36],[76290,76303,76304,76305],"Regimen B","Regimen C","Regimen D",{"trials":76307,"activeCount":97},[],{"trials":76309,"activeCount":97},[],{"trials":76311,"activeCount":97},[],{"trials":76313,"activeCount":97},[],{"intervention":76303,"totalTrials":417,"cells":76315},{"EARLY_PHASE1":76316,"PHASE1":76318,"PHASE2":76324,"PHASE3":76326,"PHASE4":76328,"NA":76330},{"trials":76317,"activeCount":97},[],{"trials":76319,"activeCount":97},[76320],{"nctId":76297,"briefTitle":76298,"status":155,"phases":76321,"primaryCompletion":42746,"completion":42746,"start":76300,"enrollment":695,"conditions":76322,"interventions":76323},[85],[36],[76290,76303,76304,76305],{"trials":76325,"activeCount":97},[],{"trials":76327,"activeCount":97},[],{"trials":76329,"activeCount":97},[],{"trials":76331,"activeCount":97},[],{"intervention":76304,"totalTrials":417,"cells":76333},{"EARLY_PHASE1":76334,"PHASE1":76336,"PHASE2":76342,"PHASE3":76344,"PHASE4":76346,"NA":76348},{"trials":76335,"activeCount":97},[],{"trials":76337,"activeCount":97},[76338],{"nctId":76297,"briefTitle":76298,"status":155,"phases":76339,"primaryCompletion":42746,"completion":42746,"start":76300,"enrollment":695,"conditions":76340,"interventions":76341},[85],[36],[76290,76303,76304,76305],{"trials":76343,"activeCount":97},[],{"trials":76345,"activeCount":97},[],{"trials":76347,"activeCount":97},[],{"trials":76349,"activeCount":97},[],{"intervention":76305,"totalTrials":417,"cells":76351},{"EARLY_PHASE1":76352,"PHASE1":76354,"PHASE2":76360,"PHASE3":76362,"PHASE4":76364,"NA":76366},{"trials":76353,"activeCount":97},[],{"trials":76355,"activeCount":97},[76356],{"nctId":76297,"briefTitle":76298,"status":155,"phases":76357,"primaryCompletion":42746,"completion":42746,"start":76300,"enrollment":695,"conditions":76358,"interventions":76359},[85],[36],[76290,76303,76304,76305],{"trials":76361,"activeCount":97},[],{"trials":76363,"activeCount":97},[],{"trials":76365,"activeCount":97},[],{"trials":76367,"activeCount":97},[],{"intervention":76369,"totalTrials":417,"cells":76370},"Belantamab",{"EARLY_PHASE1":76371,"PHASE1":76373,"PHASE2":76383,"PHASE3":76385,"PHASE4":76387,"NA":76389},{"trials":76372,"activeCount":97},[],{"trials":76374,"activeCount":97},[76375],{"nctId":76376,"briefTitle":76377,"status":500,"phases":76378,"primaryCompletion":76379,"completion":76379,"start":76380,"enrollment":97,"conditions":76381,"interventions":76382},"NCT06413511","A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease",[85],"2025-07-08","2024-06-03",[39897],[76369],{"trials":76384,"activeCount":97},[],{"trials":76386,"activeCount":97},[],{"trials":76388,"activeCount":97},[],{"trials":76390,"activeCount":97},[],{"intervention":76392,"totalTrials":417,"cells":76393},"[14C]-GSK3191607",{"EARLY_PHASE1":76394,"PHASE1":76396,"PHASE2":76405,"PHASE3":76407,"PHASE4":76409,"NA":76411},{"trials":76395,"activeCount":97},[],{"trials":76397,"activeCount":97},[76398],{"nctId":76399,"briefTitle":76400,"status":155,"phases":76401,"primaryCompletion":60492,"completion":60492,"start":76402,"enrollment":628,"conditions":76403,"interventions":76404},"NCT02737007","A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics of GSK3191607",[85],"2016-04-18",[5943],[76392],{"trials":76406,"activeCount":97},[],{"trials":76408,"activeCount":97},[],{"trials":76410,"activeCount":97},[],{"trials":76412,"activeCount":97},[],{"intervention":76414,"totalTrials":417,"cells":76415},"89Zr-GSK3128349 1 mg",{"EARLY_PHASE1":76416,"PHASE1":76418,"PHASE2":76428,"PHASE3":76430,"PHASE4":76432,"NA":76434},{"trials":76417,"activeCount":97},[],{"trials":76419,"activeCount":97},[76420],{"nctId":76421,"briefTitle":76422,"status":155,"phases":76423,"primaryCompletion":76424,"completion":76424,"start":14024,"enrollment":1720,"conditions":76425,"interventions":76427},"NCT02829307","A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male Subjects",[85],"2017-01-27",[76426],"Drug-Related Side Effects and Adverse Reactions",[76414],{"trials":76429,"activeCount":97},[],{"trials":76431,"activeCount":97},[],{"trials":76433,"activeCount":97},[],{"trials":76435,"activeCount":97},[],{"intervention":76437,"totalTrials":417,"cells":76438},"14C-SB649868",{"EARLY_PHASE1":76439,"PHASE1":76441,"PHASE2":76449,"PHASE3":76451,"PHASE4":76453,"NA":76455},{"trials":76440,"activeCount":97},[],{"trials":76442,"activeCount":97},[76443],{"nctId":76444,"briefTitle":76445,"status":155,"phases":76446,"primaryCompletion":61592,"completion":61592,"start":39212,"enrollment":1720,"conditions":76447,"interventions":76448},"NCT00520663","Radiolabel Study In Healthy Volunteers For Insomnia-Targeting Drug",[85],[19716],[76437],{"trials":76450,"activeCount":97},[],{"trials":76452,"activeCount":97},[],{"trials":76454,"activeCount":97},[],{"trials":76456,"activeCount":97},[],{"intervention":76458,"totalTrials":417,"cells":76459},"Propafenone",{"EARLY_PHASE1":76460,"PHASE1":76462,"PHASE2":76471,"PHASE3":76473,"PHASE4":76475,"NA":76477},{"trials":76461,"activeCount":97},[],{"trials":76463,"activeCount":97},[76464],{"nctId":76465,"briefTitle":76466,"status":155,"phases":76467,"primaryCompletion":18806,"completion":18806,"start":69515,"enrollment":12044,"conditions":76468,"interventions":76470},"NCT01956487","Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites",[85],[76469],"Arrhythmia, Cardiac",[76458],{"trials":76472,"activeCount":97},[],{"trials":76474,"activeCount":97},[],{"trials":76476,"activeCount":97},[],{"trials":76478,"activeCount":97},[],{"intervention":76480,"totalTrials":417,"cells":76481},"GSK2983559",{"EARLY_PHASE1":76482,"PHASE1":76484,"PHASE2":76492,"PHASE3":76494,"PHASE4":76496,"NA":76498},{"trials":76483,"activeCount":97},[],{"trials":76485,"activeCount":97},[76486],{"nctId":76487,"briefTitle":76488,"status":145,"phases":76489,"primaryCompletion":58963,"completion":58963,"start":69152,"enrollment":3379,"conditions":76490,"interventions":76491},"NCT03358407","GSK2983559 First Time in Human Study",[85],[39481],[76480],{"trials":76493,"activeCount":97},[],{"trials":76495,"activeCount":97},[],{"trials":76497,"activeCount":97},[],{"trials":76499,"activeCount":97},[],{"intervention":76501,"totalTrials":417,"cells":76502},"mRNA-CR-04 vaccine 10μg",{"EARLY_PHASE1":76503,"PHASE1":76505,"PHASE2":76518,"PHASE3":76520,"PHASE4":76522,"NA":76524},{"trials":76504,"activeCount":97},[],{"trials":76506,"activeCount":97},[76507],{"nctId":76508,"briefTitle":76509,"status":155,"phases":76510,"primaryCompletion":76511,"completion":41177,"start":76512,"enrollment":24657,"conditions":76513,"interventions":76514},"NCT05972993","A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults",[85],"2024-05-09","2023-08-07",[12437],[76501,76515,76516,76517],"mRNA-CR-04 vaccine 30μg","mRNA-CR-04 vaccine 100μg","mRNA-CR-04 vaccine 3μg",{"trials":76519,"activeCount":97},[],{"trials":76521,"activeCount":97},[],{"trials":76523,"activeCount":97},[],{"trials":76525,"activeCount":97},[],{"intervention":76515,"totalTrials":417,"cells":76527},{"EARLY_PHASE1":76528,"PHASE1":76530,"PHASE2":76536,"PHASE3":76538,"PHASE4":76540,"NA":76542},{"trials":76529,"activeCount":97},[],{"trials":76531,"activeCount":97},[76532],{"nctId":76508,"briefTitle":76509,"status":155,"phases":76533,"primaryCompletion":76511,"completion":41177,"start":76512,"enrollment":24657,"conditions":76534,"interventions":76535},[85],[12437],[76501,76515,76516,76517],{"trials":76537,"activeCount":97},[],{"trials":76539,"activeCount":97},[],{"trials":76541,"activeCount":97},[],{"trials":76543,"activeCount":97},[],{"intervention":76516,"totalTrials":417,"cells":76545},{"EARLY_PHASE1":76546,"PHASE1":76548,"PHASE2":76554,"PHASE3":76556,"PHASE4":76558,"NA":76560},{"trials":76547,"activeCount":97},[],{"trials":76549,"activeCount":97},[76550],{"nctId":76508,"briefTitle":76509,"status":155,"phases":76551,"primaryCompletion":76511,"completion":41177,"start":76512,"enrollment":24657,"conditions":76552,"interventions":76553},[85],[12437],[76501,76515,76516,76517],{"trials":76555,"activeCount":97},[],{"trials":76557,"activeCount":97},[],{"trials":76559,"activeCount":97},[],{"trials":76561,"activeCount":97},[],{"intervention":76517,"totalTrials":417,"cells":76563},{"EARLY_PHASE1":76564,"PHASE1":76566,"PHASE2":76572,"PHASE3":76574,"PHASE4":76576,"NA":76578},{"trials":76565,"activeCount":97},[],{"trials":76567,"activeCount":97},[76568],{"nctId":76508,"briefTitle":76509,"status":155,"phases":76569,"primaryCompletion":76511,"completion":41177,"start":76512,"enrollment":24657,"conditions":76570,"interventions":76571},[85],[12437],[76501,76515,76516,76517],{"trials":76573,"activeCount":97},[],{"trials":76575,"activeCount":97},[],{"trials":76577,"activeCount":97},[],{"trials":76579,"activeCount":97},[],{"intervention":76581,"totalTrials":417,"cells":76582},"GI267119",{"EARLY_PHASE1":76583,"PHASE1":76585,"PHASE2":76595,"PHASE3":76597,"PHASE4":76599,"NA":76601},{"trials":76584,"activeCount":97},[],{"trials":76586,"activeCount":97},[76587],{"nctId":76588,"briefTitle":76589,"status":155,"phases":76590,"primaryCompletion":25456,"completion":25456,"start":76591,"enrollment":21520,"conditions":76592,"interventions":76593},"NCT00410371","Study to Compare Two Formulations of Lamotrigine in Healthy Subjects",[85],"2006-12-28",[65610],[76594,76581],"Lamotrigine",{"trials":76596,"activeCount":97},[],{"trials":76598,"activeCount":97},[],{"trials":76600,"activeCount":97},[],{"trials":76602,"activeCount":97},[],{"intervention":59384,"totalTrials":417,"cells":76604},{"EARLY_PHASE1":76605,"PHASE1":76607,"PHASE2":76613,"PHASE3":76615,"PHASE4":76617,"NA":76619},{"trials":76606,"activeCount":97},[],{"trials":76608,"activeCount":97},[76609],{"nctId":59377,"briefTitle":59378,"status":155,"phases":76610,"primaryCompletion":59380,"completion":59380,"start":59381,"enrollment":4121,"conditions":76611,"interventions":76612},[85],[22921],[59384,9325,59385,59386,59387],{"trials":76614,"activeCount":97},[],{"trials":76616,"activeCount":97},[],{"trials":76618,"activeCount":97},[],{"trials":76620,"activeCount":97},[],{"intervention":59385,"totalTrials":417,"cells":76622},{"EARLY_PHASE1":76623,"PHASE1":76625,"PHASE2":76631,"PHASE3":76633,"PHASE4":76635,"NA":76637},{"trials":76624,"activeCount":97},[],{"trials":76626,"activeCount":97},[76627],{"nctId":59377,"briefTitle":59378,"status":155,"phases":76628,"primaryCompletion":59380,"completion":59380,"start":59381,"enrollment":4121,"conditions":76629,"interventions":76630},[85],[22921],[59384,9325,59385,59386,59387],{"trials":76632,"activeCount":97},[],{"trials":76634,"activeCount":97},[],{"trials":76636,"activeCount":97},[],{"trials":76638,"activeCount":97},[],{"intervention":59386,"totalTrials":417,"cells":76640},{"EARLY_PHASE1":76641,"PHASE1":76643,"PHASE2":76649,"PHASE3":76651,"PHASE4":76653,"NA":76655},{"trials":76642,"activeCount":97},[],{"trials":76644,"activeCount":97},[76645],{"nctId":59377,"briefTitle":59378,"status":155,"phases":76646,"primaryCompletion":59380,"completion":59380,"start":59381,"enrollment":4121,"conditions":76647,"interventions":76648},[85],[22921],[59384,9325,59385,59386,59387],{"trials":76650,"activeCount":97},[],{"trials":76652,"activeCount":97},[],{"trials":76654,"activeCount":97},[],{"trials":76656,"activeCount":97},[],{"intervention":59387,"totalTrials":417,"cells":76658},{"EARLY_PHASE1":76659,"PHASE1":76661,"PHASE2":76667,"PHASE3":76669,"PHASE4":76671,"NA":76673},{"trials":76660,"activeCount":97},[],{"trials":76662,"activeCount":97},[76663],{"nctId":59377,"briefTitle":59378,"status":155,"phases":76664,"primaryCompletion":59380,"completion":59380,"start":59381,"enrollment":4121,"conditions":76665,"interventions":76666},[85],[22921],[59384,9325,59385,59386,59387],{"trials":76668,"activeCount":97},[],{"trials":76670,"activeCount":97},[],{"trials":76672,"activeCount":97},[],{"trials":76674,"activeCount":97},[],{"intervention":76676,"totalTrials":417,"cells":76677},"GSK3186899",{"EARLY_PHASE1":76678,"PHASE1":76680,"PHASE2":76688,"PHASE3":76690,"PHASE4":76692,"NA":76694},{"trials":76679,"activeCount":97},[],{"trials":76681,"activeCount":97},[76682],{"nctId":76683,"briefTitle":76684,"status":145,"phases":76685,"primaryCompletion":6585,"completion":6585,"start":42229,"enrollment":463,"conditions":76686,"interventions":76687},"NCT03874234","Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects",[85],[72592],[76676],{"trials":76689,"activeCount":97},[],{"trials":76691,"activeCount":97},[],{"trials":76693,"activeCount":97},[],{"trials":76695,"activeCount":97},[],{"intervention":76697,"totalTrials":417,"cells":76698},"Diclofenac Diethylamine (DDEA) gel",{"EARLY_PHASE1":76699,"PHASE1":76701,"PHASE2":76709,"PHASE3":76711,"PHASE4":76713,"NA":76715},{"trials":76700,"activeCount":97},[],{"trials":76702,"activeCount":97},[76703],{"nctId":76704,"briefTitle":76705,"status":155,"phases":76706,"primaryCompletion":4995,"completion":4995,"start":39895,"enrollment":149,"conditions":76707,"interventions":76708},"NCT03497039","A Study to Characterize Diclofenac's Plasma and Knee Exposure After Application of Diclofenac Gel to the Knee of Subjects With Osteoarthritis That Have a Scheduled Arthroplasty",[85],[9153],[76697],{"trials":76710,"activeCount":97},[],{"trials":76712,"activeCount":97},[],{"trials":76714,"activeCount":97},[],{"trials":76716,"activeCount":97},[],{"intervention":76718,"totalTrials":417,"cells":76719},"Immunotherapeutic GSK2302025A, different formulations",{"EARLY_PHASE1":76720,"PHASE1":76722,"PHASE2":76731,"PHASE3":76733,"PHASE4":76735,"NA":76737},{"trials":76721,"activeCount":97},[],{"trials":76723,"activeCount":97},[76724],{"nctId":76725,"briefTitle":76726,"status":155,"phases":76727,"primaryCompletion":62201,"completion":76728,"start":18880,"enrollment":177,"conditions":76729,"interventions":76730},"NCT01149343","Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer",[85],"2016-12-19",[325],[76718],{"trials":76732,"activeCount":97},[],{"trials":76734,"activeCount":97},[],{"trials":76736,"activeCount":97},[],{"trials":76738,"activeCount":97},[],{"intervention":76740,"totalTrials":417,"cells":76741},"GSK4382276A Dose level 1",{"EARLY_PHASE1":76742,"PHASE1":76744,"PHASE2":76765,"PHASE3":76767,"PHASE4":76769,"NA":76771},{"trials":76743,"activeCount":97},[],{"trials":76745,"activeCount":97},[76746],{"nctId":76747,"briefTitle":76748,"status":155,"phases":76749,"primaryCompletion":76750,"completion":76750,"start":76751,"enrollment":10257,"conditions":76752,"interventions":76753},"NCT05446740","A Study on the Safety, Reactogenicity and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults",[85],"2024-03-26","2022-08-09",[5353],[76740,76754,76755,76756,76757,76758,76759,76760,76761,76762,76763,76764],"GSK4382276A Dose level 2","GSK4382276A Dose level 3","GSK4382276A Dose level 4","GSK4382276A Dose level 5","GSK4382276A Dose level 6","GSK4382276A Dose level 7","GSK4382276A Dose level 8","GSK4382276A Dose level 9","GSK4382276A Dose level 10","FDQ21A-NH","FDQ22A-NH",{"trials":76766,"activeCount":97},[],{"trials":76768,"activeCount":97},[],{"trials":76770,"activeCount":97},[],{"trials":76772,"activeCount":97},[],{"intervention":76754,"totalTrials":417,"cells":76774},{"EARLY_PHASE1":76775,"PHASE1":76777,"PHASE2":76783,"PHASE3":76785,"PHASE4":76787,"NA":76789},{"trials":76776,"activeCount":97},[],{"trials":76778,"activeCount":97},[76779],{"nctId":76747,"briefTitle":76748,"status":155,"phases":76780,"primaryCompletion":76750,"completion":76750,"start":76751,"enrollment":10257,"conditions":76781,"interventions":76782},[85],[5353],[76740,76754,76755,76756,76757,76758,76759,76760,76761,76762,76763,76764],{"trials":76784,"activeCount":97},[],{"trials":76786,"activeCount":97},[],{"trials":76788,"activeCount":97},[],{"trials":76790,"activeCount":97},[],{"intervention":76755,"totalTrials":417,"cells":76792},{"EARLY_PHASE1":76793,"PHASE1":76795,"PHASE2":76801,"PHASE3":76803,"PHASE4":76805,"NA":76807},{"trials":76794,"activeCount":97},[],{"trials":76796,"activeCount":97},[76797],{"nctId":76747,"briefTitle":76748,"status":155,"phases":76798,"primaryCompletion":76750,"completion":76750,"start":76751,"enrollment":10257,"conditions":76799,"interventions":76800},[85],[5353],[76740,76754,76755,76756,76757,76758,76759,76760,76761,76762,76763,76764],{"trials":76802,"activeCount":97},[],{"trials":76804,"activeCount":97},[],{"trials":76806,"activeCount":97},[],{"trials":76808,"activeCount":97},[],{"intervention":76756,"totalTrials":417,"cells":76810},{"EARLY_PHASE1":76811,"PHASE1":76813,"PHASE2":76819,"PHASE3":76821,"PHASE4":76823,"NA":76825},{"trials":76812,"activeCount":97},[],{"trials":76814,"activeCount":97},[76815],{"nctId":76747,"briefTitle":76748,"status":155,"phases":76816,"primaryCompletion":76750,"completion":76750,"start":76751,"enrollment":10257,"conditions":76817,"interventions":76818},[85],[5353],[76740,76754,76755,76756,76757,76758,76759,76760,76761,76762,76763,76764],{"trials":76820,"activeCount":97},[],{"trials":76822,"activeCount":97},[],{"trials":76824,"activeCount":97},[],{"trials":76826,"activeCount":97},[],{"intervention":76757,"totalTrials":417,"cells":76828},{"EARLY_PHASE1":76829,"PHASE1":76831,"PHASE2":76837,"PHASE3":76839,"PHASE4":76841,"NA":76843},{"trials":76830,"activeCount":97},[],{"trials":76832,"activeCount":97},[76833],{"nctId":76747,"briefTitle":76748,"status":155,"phases":76834,"primaryCompletion":76750,"completion":76750,"start":76751,"enrollment":10257,"conditions":76835,"interventions":76836},[85],[5353],[76740,76754,76755,76756,76757,76758,76759,76760,76761,76762,76763,76764],{"trials":76838,"activeCount":97},[],{"trials":76840,"activeCount":97},[],{"trials":76842,"activeCount":97},[],{"trials":76844,"activeCount":97},[],{"intervention":76758,"totalTrials":417,"cells":76846},{"EARLY_PHASE1":76847,"PHASE1":76849,"PHASE2":76855,"PHASE3":76857,"PHASE4":76859,"NA":76861},{"trials":76848,"activeCount":97},[],{"trials":76850,"activeCount":97},[76851],{"nctId":76747,"briefTitle":76748,"status":155,"phases":76852,"primaryCompletion":76750,"completion":76750,"start":76751,"enrollment":10257,"conditions":76853,"interventions":76854},[85],[5353],[76740,76754,76755,76756,76757,76758,76759,76760,76761,76762,76763,76764],{"trials":76856,"activeCount":97},[],{"trials":76858,"activeCount":97},[],{"trials":76860,"activeCount":97},[],{"trials":76862,"activeCount":97},[],{"intervention":76759,"totalTrials":417,"cells":76864},{"EARLY_PHASE1":76865,"PHASE1":76867,"PHASE2":76873,"PHASE3":76875,"PHASE4":76877,"NA":76879},{"trials":76866,"activeCount":97},[],{"trials":76868,"activeCount":97},[76869],{"nctId":76747,"briefTitle":76748,"status":155,"phases":76870,"primaryCompletion":76750,"completion":76750,"start":76751,"enrollment":10257,"conditions":76871,"interventions":76872},[85],[5353],[76740,76754,76755,76756,76757,76758,76759,76760,76761,76762,76763,76764],{"trials":76874,"activeCount":97},[],{"trials":76876,"activeCount":97},[],{"trials":76878,"activeCount":97},[],{"trials":76880,"activeCount":97},[],{"intervention":76760,"totalTrials":417,"cells":76882},{"EARLY_PHASE1":76883,"PHASE1":76885,"PHASE2":76891,"PHASE3":76893,"PHASE4":76895,"NA":76897},{"trials":76884,"activeCount":97},[],{"trials":76886,"activeCount":97},[76887],{"nctId":76747,"briefTitle":76748,"status":155,"phases":76888,"primaryCompletion":76750,"completion":76750,"start":76751,"enrollment":10257,"conditions":76889,"interventions":76890},[85],[5353],[76740,76754,76755,76756,76757,76758,76759,76760,76761,76762,76763,76764],{"trials":76892,"activeCount":97},[],{"trials":76894,"activeCount":97},[],{"trials":76896,"activeCount":97},[],{"trials":76898,"activeCount":97},[],{"intervention":76761,"totalTrials":417,"cells":76900},{"EARLY_PHASE1":76901,"PHASE1":76903,"PHASE2":76909,"PHASE3":76911,"PHASE4":76913,"NA":76915},{"trials":76902,"activeCount":97},[],{"trials":76904,"activeCount":97},[76905],{"nctId":76747,"briefTitle":76748,"status":155,"phases":76906,"primaryCompletion":76750,"completion":76750,"start":76751,"enrollment":10257,"conditions":76907,"interventions":76908},[85],[5353],[76740,76754,76755,76756,76757,76758,76759,76760,76761,76762,76763,76764],{"trials":76910,"activeCount":97},[],{"trials":76912,"activeCount":97},[],{"trials":76914,"activeCount":97},[],{"trials":76916,"activeCount":97},[],{"intervention":76762,"totalTrials":417,"cells":76918},{"EARLY_PHASE1":76919,"PHASE1":76921,"PHASE2":76927,"PHASE3":76929,"PHASE4":76931,"NA":76933},{"trials":76920,"activeCount":97},[],{"trials":76922,"activeCount":97},[76923],{"nctId":76747,"briefTitle":76748,"status":155,"phases":76924,"primaryCompletion":76750,"completion":76750,"start":76751,"enrollment":10257,"conditions":76925,"interventions":76926},[85],[5353],[76740,76754,76755,76756,76757,76758,76759,76760,76761,76762,76763,76764],{"trials":76928,"activeCount":97},[],{"trials":76930,"activeCount":97},[],{"trials":76932,"activeCount":97},[],{"trials":76934,"activeCount":97},[],{"intervention":76763,"totalTrials":417,"cells":76936},{"EARLY_PHASE1":76937,"PHASE1":76939,"PHASE2":76945,"PHASE3":76947,"PHASE4":76949,"NA":76951},{"trials":76938,"activeCount":97},[],{"trials":76940,"activeCount":97},[76941],{"nctId":76747,"briefTitle":76748,"status":155,"phases":76942,"primaryCompletion":76750,"completion":76750,"start":76751,"enrollment":10257,"conditions":76943,"interventions":76944},[85],[5353],[76740,76754,76755,76756,76757,76758,76759,76760,76761,76762,76763,76764],{"trials":76946,"activeCount":97},[],{"trials":76948,"activeCount":97},[],{"trials":76950,"activeCount":97},[],{"trials":76952,"activeCount":97},[],{"intervention":76764,"totalTrials":417,"cells":76954},{"EARLY_PHASE1":76955,"PHASE1":76957,"PHASE2":76963,"PHASE3":76965,"PHASE4":76967,"NA":76969},{"trials":76956,"activeCount":97},[],{"trials":76958,"activeCount":97},[76959],{"nctId":76747,"briefTitle":76748,"status":155,"phases":76960,"primaryCompletion":76750,"completion":76750,"start":76751,"enrollment":10257,"conditions":76961,"interventions":76962},[85],[5353],[76740,76754,76755,76756,76757,76758,76759,76760,76761,76762,76763,76764],{"trials":76964,"activeCount":97},[],{"trials":76966,"activeCount":97},[],{"trials":76968,"activeCount":97},[],{"trials":76970,"activeCount":97},[],{"intervention":6827,"totalTrials":417,"cells":76972},{"EARLY_PHASE1":76973,"PHASE1":76975,"PHASE2":76981,"PHASE3":76983,"PHASE4":76985,"NA":76987},{"trials":76974,"activeCount":97},[],{"trials":76976,"activeCount":97},[76977],{"nctId":6821,"briefTitle":6822,"status":500,"phases":76978,"primaryCompletion":6824,"completion":6824,"start":483,"enrollment":97,"conditions":76979,"interventions":76980},[85],[36],[6827,1891,6818,6819],{"trials":76982,"activeCount":97},[],{"trials":76984,"activeCount":97},[],{"trials":76986,"activeCount":97},[],{"trials":76988,"activeCount":97},[],{"intervention":24342,"totalTrials":417,"cells":76990},{"EARLY_PHASE1":76991,"PHASE1":76993,"PHASE2":76999,"PHASE3":77001,"PHASE4":77003,"NA":77005},{"trials":76992,"activeCount":97},[],{"trials":76994,"activeCount":97},[76995],{"nctId":24334,"briefTitle":24335,"status":155,"phases":76996,"primaryCompletion":24337,"completion":24338,"start":24339,"enrollment":10978,"conditions":76997,"interventions":76998},[85],[8723],[24342,24327],{"trials":77000,"activeCount":97},[],{"trials":77002,"activeCount":97},[],{"trials":77004,"activeCount":97},[],{"trials":77006,"activeCount":97},[],{"intervention":77008,"totalTrials":417,"cells":77009},"GSK3888130B",{"EARLY_PHASE1":77010,"PHASE1":77012,"PHASE2":77021,"PHASE3":77023,"PHASE4":77025,"NA":77027},{"trials":77011,"activeCount":97},[],{"trials":77013,"activeCount":97},[77014],{"nctId":77015,"briefTitle":77016,"status":155,"phases":77017,"primaryCompletion":77018,"completion":77018,"start":5206,"enrollment":1686,"conditions":77019,"interventions":77020},"NCT05131971","A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants",[85],"2023-10-12",[39962,7295],[77008],{"trials":77022,"activeCount":97},[],{"trials":77024,"activeCount":97},[],{"trials":77026,"activeCount":97},[],{"trials":77028,"activeCount":97},[],{"intervention":40388,"totalTrials":417,"cells":77030},{"EARLY_PHASE1":77031,"PHASE1":77033,"PHASE2":77039,"PHASE3":77041,"PHASE4":77043,"NA":77045},{"trials":77032,"activeCount":97},[],{"trials":77034,"activeCount":97},[77035],{"nctId":40382,"briefTitle":40383,"status":155,"phases":77036,"primaryCompletion":19929,"completion":19929,"start":40385,"enrollment":695,"conditions":77037,"interventions":77038},[85],[18],[19048,40388],{"trials":77040,"activeCount":97},[],{"trials":77042,"activeCount":97},[],{"trials":77044,"activeCount":97},[],{"trials":77046,"activeCount":97},[],{"intervention":77048,"totalTrials":417,"cells":77049},"GSK2212836",{"EARLY_PHASE1":77050,"PHASE1":77052,"PHASE2":77060,"PHASE3":77062,"PHASE4":77064,"NA":77066},{"trials":77051,"activeCount":97},[],{"trials":77053,"activeCount":97},[77054],{"nctId":77055,"briefTitle":77056,"status":155,"phases":77057,"primaryCompletion":59894,"completion":59894,"start":9793,"enrollment":4121,"conditions":77058,"interventions":77059},"NCT00996268","An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.",[85],[14279],[77048,77048],{"trials":77061,"activeCount":97},[],{"trials":77063,"activeCount":97},[],{"trials":77065,"activeCount":97},[],{"trials":77067,"activeCount":97},[],{"intervention":77069,"totalTrials":417,"cells":77070},"Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg",{"EARLY_PHASE1":77071,"PHASE1":77073,"PHASE2":77083,"PHASE3":77085,"PHASE4":77087,"NA":77089},{"trials":77072,"activeCount":97},[],{"trials":77074,"activeCount":97},[77075],{"nctId":77076,"briefTitle":77077,"status":155,"phases":77078,"primaryCompletion":77079,"completion":77079,"start":7505,"enrollment":93,"conditions":77080,"interventions":77081},"NCT01332071","Avandamet Bioequivalence Study Brazil - Fed Administration",[85],"2009-12-06",[27],[77069,77082],"Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg",{"trials":77084,"activeCount":97},[],{"trials":77086,"activeCount":97},[],{"trials":77088,"activeCount":97},[],{"trials":77090,"activeCount":97},[],{"intervention":77082,"totalTrials":417,"cells":77092},{"EARLY_PHASE1":77093,"PHASE1":77095,"PHASE2":77101,"PHASE3":77103,"PHASE4":77105,"NA":77107},{"trials":77094,"activeCount":97},[],{"trials":77096,"activeCount":97},[77097],{"nctId":77076,"briefTitle":77077,"status":155,"phases":77098,"primaryCompletion":77079,"completion":77079,"start":7505,"enrollment":93,"conditions":77099,"interventions":77100},[85],[27],[77069,77082],{"trials":77102,"activeCount":97},[],{"trials":77104,"activeCount":97},[],{"trials":77106,"activeCount":97},[],{"trials":77108,"activeCount":97},[],{"intervention":77110,"totalTrials":417,"cells":77111},"solabegron and oxybutynin",{"EARLY_PHASE1":77112,"PHASE1":77114,"PHASE2":77122,"PHASE3":77124,"PHASE4":77126,"NA":77128},{"trials":77113,"activeCount":97},[],{"trials":77115,"activeCount":97},[77116],{"nctId":77117,"briefTitle":77118,"status":155,"phases":77119,"primaryCompletion":2336,"completion":2336,"start":3552,"enrollment":1298,"conditions":77120,"interventions":77121},"NCT00501267","A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder",[85],[42302],[77110],{"trials":77123,"activeCount":97},[],{"trials":77125,"activeCount":97},[],{"trials":77127,"activeCount":97},[],{"trials":77129,"activeCount":97},[],{"intervention":77131,"totalTrials":417,"cells":77132},"Losmapimod for single dose",{"EARLY_PHASE1":77133,"PHASE1":77135,"PHASE2":77144,"PHASE3":77146,"PHASE4":77148,"NA":77150},{"trials":77134,"activeCount":97},[],{"trials":77136,"activeCount":97},[77137],{"nctId":77138,"briefTitle":77139,"status":155,"phases":77140,"primaryCompletion":43706,"completion":43706,"start":15725,"enrollment":454,"conditions":77141,"interventions":77142},"NCT01648192","Phase I Study of GW856553 (Losmapimod)",[85],[11827],[77131,77143],"Losmapimod for repeat dose",{"trials":77145,"activeCount":97},[],{"trials":77147,"activeCount":97},[],{"trials":77149,"activeCount":97},[],{"trials":77151,"activeCount":97},[],{"intervention":77143,"totalTrials":417,"cells":77153},{"EARLY_PHASE1":77154,"PHASE1":77156,"PHASE2":77162,"PHASE3":77164,"PHASE4":77166,"NA":77168},{"trials":77155,"activeCount":97},[],{"trials":77157,"activeCount":97},[77158],{"nctId":77138,"briefTitle":77139,"status":155,"phases":77159,"primaryCompletion":43706,"completion":43706,"start":15725,"enrollment":454,"conditions":77160,"interventions":77161},[85],[11827],[77131,77143],{"trials":77163,"activeCount":97},[],{"trials":77165,"activeCount":97},[],{"trials":77167,"activeCount":97},[],{"trials":77169,"activeCount":97},[],{"intervention":77171,"totalTrials":417,"cells":77172},"Digoxin Alone",{"EARLY_PHASE1":77173,"PHASE1":77175,"PHASE2":77185,"PHASE3":77187,"PHASE4":77189,"NA":77191},{"trials":77174,"activeCount":97},[],{"trials":77176,"activeCount":97},[77177],{"nctId":77178,"briefTitle":77179,"status":155,"phases":77180,"primaryCompletion":77181,"completion":77181,"start":21411,"enrollment":255,"conditions":77182,"interventions":77183},"NCT01583036","An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine\u002FRetigabine in Healthy Adults. The Pharmacokinetics of Ezogabine\u002FRetigabine and the N-acetyl Metabolite of Ezogabine\u002FRetigabine (NAMR) Will Also be Assessed",[85],"2012-04-17",[12518],[77171,77184],"Digoxin + Retigabine",{"trials":77186,"activeCount":97},[],{"trials":77188,"activeCount":97},[],{"trials":77190,"activeCount":97},[],{"trials":77192,"activeCount":97},[],{"intervention":77184,"totalTrials":417,"cells":77194},{"EARLY_PHASE1":77195,"PHASE1":77197,"PHASE2":77203,"PHASE3":77205,"PHASE4":77207,"NA":77209},{"trials":77196,"activeCount":97},[],{"trials":77198,"activeCount":97},[77199],{"nctId":77178,"briefTitle":77179,"status":155,"phases":77200,"primaryCompletion":77181,"completion":77181,"start":21411,"enrollment":255,"conditions":77201,"interventions":77202},[85],[12518],[77171,77184],{"trials":77204,"activeCount":97},[],{"trials":77206,"activeCount":97},[],{"trials":77208,"activeCount":97},[],{"trials":77210,"activeCount":97},[],{"intervention":5283,"totalTrials":417,"cells":77212},{"EARLY_PHASE1":77213,"PHASE1":77215,"PHASE2":77221,"PHASE3":77223,"PHASE4":77225,"NA":77227},{"trials":77214,"activeCount":97},[],{"trials":77216,"activeCount":97},[77217],{"nctId":5275,"briefTitle":5276,"status":145,"phases":77218,"primaryCompletion":5278,"completion":5278,"start":2974,"enrollment":149,"conditions":77219,"interventions":77220},[85],[5280],[5282,5283,4487],{"trials":77222,"activeCount":97},[],{"trials":77224,"activeCount":97},[],{"trials":77226,"activeCount":97},[],{"trials":77228,"activeCount":97},[],{"intervention":60327,"totalTrials":417,"cells":77230},{"EARLY_PHASE1":77231,"PHASE1":77233,"PHASE2":77239,"PHASE3":77241,"PHASE4":77243,"NA":77245},{"trials":77232,"activeCount":97},[],{"trials":77234,"activeCount":97},[77235],{"nctId":60321,"briefTitle":60322,"status":155,"phases":77236,"primaryCompletion":60324,"completion":60324,"start":8795,"enrollment":8275,"conditions":77237,"interventions":77238},[85],[3637],[60327,41023],{"trials":77240,"activeCount":97},[],{"trials":77242,"activeCount":97},[],{"trials":77244,"activeCount":97},[],{"trials":77246,"activeCount":97},[],{"intervention":77248,"totalTrials":417,"cells":77249},"simvastatin plus albiglutide",{"EARLY_PHASE1":77250,"PHASE1":77252,"PHASE2":77260,"PHASE3":77262,"PHASE4":77264,"NA":77266},{"trials":77251,"activeCount":97},[],{"trials":77253,"activeCount":97},[77254],{"nctId":77255,"briefTitle":77256,"status":155,"phases":77257,"primaryCompletion":10237,"completion":10237,"start":41638,"enrollment":345,"conditions":77258,"interventions":77259},"NCT01147692","A Drug Interaction Study of Simvastatin and Albiglutide",[85],[27],[77248],{"trials":77261,"activeCount":97},[],{"trials":77263,"activeCount":97},[],{"trials":77265,"activeCount":97},[],{"trials":77267,"activeCount":97},[],{"intervention":77269,"totalTrials":417,"cells":77270},"2 ng GSK2445053",{"EARLY_PHASE1":77271,"PHASE1":77273,"PHASE2":77288,"PHASE3":77290,"PHASE4":77292,"NA":77294},{"trials":77272,"activeCount":97},[],{"trials":77274,"activeCount":97},[77275],{"nctId":77276,"briefTitle":77277,"status":155,"phases":77278,"primaryCompletion":18172,"completion":18172,"start":41630,"enrollment":4542,"conditions":77279,"interventions":77280},"NCT01480271","An Investigation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2245035 in Healthy Volunteers and Allergic Rhinitics.",[85],[10169],[77269,77281,77282,77283,77284,77285,77286,77287],"20ng GSK2445053","100ng GSK2445053","200ng GSK2445053","400ng GSK2445053","1000ng GSK2445053","2000ng GSK2445053","4000ng GSK2445053",{"trials":77289,"activeCount":97},[],{"trials":77291,"activeCount":97},[],{"trials":77293,"activeCount":97},[],{"trials":77295,"activeCount":97},[],{"intervention":77281,"totalTrials":417,"cells":77297},{"EARLY_PHASE1":77298,"PHASE1":77300,"PHASE2":77306,"PHASE3":77308,"PHASE4":77310,"NA":77312},{"trials":77299,"activeCount":97},[],{"trials":77301,"activeCount":97},[77302],{"nctId":77276,"briefTitle":77277,"status":155,"phases":77303,"primaryCompletion":18172,"completion":18172,"start":41630,"enrollment":4542,"conditions":77304,"interventions":77305},[85],[10169],[77269,77281,77282,77283,77284,77285,77286,77287],{"trials":77307,"activeCount":97},[],{"trials":77309,"activeCount":97},[],{"trials":77311,"activeCount":97},[],{"trials":77313,"activeCount":97},[],{"intervention":77282,"totalTrials":417,"cells":77315},{"EARLY_PHASE1":77316,"PHASE1":77318,"PHASE2":77324,"PHASE3":77326,"PHASE4":77328,"NA":77330},{"trials":77317,"activeCount":97},[],{"trials":77319,"activeCount":97},[77320],{"nctId":77276,"briefTitle":77277,"status":155,"phases":77321,"primaryCompletion":18172,"completion":18172,"start":41630,"enrollment":4542,"conditions":77322,"interventions":77323},[85],[10169],[77269,77281,77282,77283,77284,77285,77286,77287],{"trials":77325,"activeCount":97},[],{"trials":77327,"activeCount":97},[],{"trials":77329,"activeCount":97},[],{"trials":77331,"activeCount":97},[],{"intervention":77283,"totalTrials":417,"cells":77333},{"EARLY_PHASE1":77334,"PHASE1":77336,"PHASE2":77342,"PHASE3":77344,"PHASE4":77346,"NA":77348},{"trials":77335,"activeCount":97},[],{"trials":77337,"activeCount":97},[77338],{"nctId":77276,"briefTitle":77277,"status":155,"phases":77339,"primaryCompletion":18172,"completion":18172,"start":41630,"enrollment":4542,"conditions":77340,"interventions":77341},[85],[10169],[77269,77281,77282,77283,77284,77285,77286,77287],{"trials":77343,"activeCount":97},[],{"trials":77345,"activeCount":97},[],{"trials":77347,"activeCount":97},[],{"trials":77349,"activeCount":97},[],{"intervention":77284,"totalTrials":417,"cells":77351},{"EARLY_PHASE1":77352,"PHASE1":77354,"PHASE2":77360,"PHASE3":77362,"PHASE4":77364,"NA":77366},{"trials":77353,"activeCount":97},[],{"trials":77355,"activeCount":97},[77356],{"nctId":77276,"briefTitle":77277,"status":155,"phases":77357,"primaryCompletion":18172,"completion":18172,"start":41630,"enrollment":4542,"conditions":77358,"interventions":77359},[85],[10169],[77269,77281,77282,77283,77284,77285,77286,77287],{"trials":77361,"activeCount":97},[],{"trials":77363,"activeCount":97},[],{"trials":77365,"activeCount":97},[],{"trials":77367,"activeCount":97},[],{"intervention":77285,"totalTrials":417,"cells":77369},{"EARLY_PHASE1":77370,"PHASE1":77372,"PHASE2":77378,"PHASE3":77380,"PHASE4":77382,"NA":77384},{"trials":77371,"activeCount":97},[],{"trials":77373,"activeCount":97},[77374],{"nctId":77276,"briefTitle":77277,"status":155,"phases":77375,"primaryCompletion":18172,"completion":18172,"start":41630,"enrollment":4542,"conditions":77376,"interventions":77377},[85],[10169],[77269,77281,77282,77283,77284,77285,77286,77287],{"trials":77379,"activeCount":97},[],{"trials":77381,"activeCount":97},[],{"trials":77383,"activeCount":97},[],{"trials":77385,"activeCount":97},[],{"intervention":77286,"totalTrials":417,"cells":77387},{"EARLY_PHASE1":77388,"PHASE1":77390,"PHASE2":77396,"PHASE3":77398,"PHASE4":77400,"NA":77402},{"trials":77389,"activeCount":97},[],{"trials":77391,"activeCount":97},[77392],{"nctId":77276,"briefTitle":77277,"status":155,"phases":77393,"primaryCompletion":18172,"completion":18172,"start":41630,"enrollment":4542,"conditions":77394,"interventions":77395},[85],[10169],[77269,77281,77282,77283,77284,77285,77286,77287],{"trials":77397,"activeCount":97},[],{"trials":77399,"activeCount":97},[],{"trials":77401,"activeCount":97},[],{"trials":77403,"activeCount":97},[],{"intervention":77287,"totalTrials":417,"cells":77405},{"EARLY_PHASE1":77406,"PHASE1":77408,"PHASE2":77414,"PHASE3":77416,"PHASE4":77418,"NA":77420},{"trials":77407,"activeCount":97},[],{"trials":77409,"activeCount":97},[77410],{"nctId":77276,"briefTitle":77277,"status":155,"phases":77411,"primaryCompletion":18172,"completion":18172,"start":41630,"enrollment":4542,"conditions":77412,"interventions":77413},[85],[10169],[77269,77281,77282,77283,77284,77285,77286,77287],{"trials":77415,"activeCount":97},[],{"trials":77417,"activeCount":97},[],{"trials":77419,"activeCount":97},[],{"trials":77421,"activeCount":97},[],{"intervention":59395,"totalTrials":417,"cells":77423},{"EARLY_PHASE1":77424,"PHASE1":77426,"PHASE2":77432,"PHASE3":77434,"PHASE4":77436,"NA":77438},{"trials":77425,"activeCount":97},[],{"trials":77427,"activeCount":97},[77428],{"nctId":59389,"briefTitle":59390,"status":155,"phases":77429,"primaryCompletion":19425,"completion":19425,"start":59392,"enrollment":3672,"conditions":77430,"interventions":77431},[85],[1337],[59395,9325,59327],{"trials":77433,"activeCount":97},[],{"trials":77435,"activeCount":97},[],{"trials":77437,"activeCount":97},[],{"trials":77439,"activeCount":97},[],{"intervention":18703,"totalTrials":417,"cells":77441},{"EARLY_PHASE1":77442,"PHASE1":77444,"PHASE2":77450,"PHASE3":77452,"PHASE4":77454,"NA":77456},{"trials":77443,"activeCount":97},[],{"trials":77445,"activeCount":97},[77446],{"nctId":18696,"briefTitle":18697,"status":155,"phases":77447,"primaryCompletion":18699,"completion":18699,"start":18700,"enrollment":255,"conditions":77448,"interventions":77449},[85],[10147],[18703,3467,18704],{"trials":77451,"activeCount":97},[],{"trials":77453,"activeCount":97},[],{"trials":77455,"activeCount":97},[],{"trials":77457,"activeCount":97},[],{"intervention":18704,"totalTrials":417,"cells":77459},{"EARLY_PHASE1":77460,"PHASE1":77462,"PHASE2":77468,"PHASE3":77470,"PHASE4":77472,"NA":77474},{"trials":77461,"activeCount":97},[],{"trials":77463,"activeCount":97},[77464],{"nctId":18696,"briefTitle":18697,"status":155,"phases":77465,"primaryCompletion":18699,"completion":18699,"start":18700,"enrollment":255,"conditions":77466,"interventions":77467},[85],[10147],[18703,3467,18704],{"trials":77469,"activeCount":97},[],{"trials":77471,"activeCount":97},[],{"trials":77473,"activeCount":97},[],{"trials":77475,"activeCount":97},[],{"intervention":77477,"totalTrials":417,"cells":77478},"GSK2646264 0.5% topical cream",{"EARLY_PHASE1":77479,"PHASE1":77481,"PHASE2":77491,"PHASE3":77493,"PHASE4":77495,"NA":77497},{"trials":77480,"activeCount":97},[],{"trials":77482,"activeCount":97},[77483],{"nctId":77484,"briefTitle":77485,"status":155,"phases":77486,"primaryCompletion":63162,"completion":63162,"start":19318,"enrollment":1736,"conditions":77487,"interventions":77489},"NCT02424799","Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264",[85],[77488],"Urticaria",[77477,77490],"GSK2646264 1% topical cream",{"trials":77492,"activeCount":97},[],{"trials":77494,"activeCount":97},[],{"trials":77496,"activeCount":97},[],{"trials":77498,"activeCount":97},[],{"intervention":77490,"totalTrials":417,"cells":77500},{"EARLY_PHASE1":77501,"PHASE1":77503,"PHASE2":77509,"PHASE3":77511,"PHASE4":77513,"NA":77515},{"trials":77502,"activeCount":97},[],{"trials":77504,"activeCount":97},[77505],{"nctId":77484,"briefTitle":77485,"status":155,"phases":77506,"primaryCompletion":63162,"completion":63162,"start":19318,"enrollment":1736,"conditions":77507,"interventions":77508},[85],[77488],[77477,77490],{"trials":77510,"activeCount":97},[],{"trials":77512,"activeCount":97},[],{"trials":77514,"activeCount":97},[],{"trials":77516,"activeCount":97},[],{"intervention":2669,"totalTrials":417,"cells":77518},{"EARLY_PHASE1":77519,"PHASE1":77521,"PHASE2":77527,"PHASE3":77529,"PHASE4":77531,"NA":77533},{"trials":77520,"activeCount":97},[],{"trials":77522,"activeCount":97},[77523],{"nctId":2661,"briefTitle":2662,"status":155,"phases":77524,"primaryCompletion":2664,"completion":2664,"start":2665,"enrollment":1003,"conditions":77525,"interventions":77526},[85],[2667],[2273,2669,2670],{"trials":77528,"activeCount":97},[],{"trials":77530,"activeCount":97},[],{"trials":77532,"activeCount":97},[],{"trials":77534,"activeCount":97},[],{"intervention":43709,"totalTrials":417,"cells":77536},{"EARLY_PHASE1":77537,"PHASE1":77539,"PHASE2":77545,"PHASE3":77547,"PHASE4":77549,"NA":77551},{"trials":77538,"activeCount":97},[],{"trials":77540,"activeCount":97},[77541],{"nctId":43703,"briefTitle":43704,"status":155,"phases":77542,"primaryCompletion":43706,"completion":43706,"start":30042,"enrollment":904,"conditions":77543,"interventions":77544},[85],[11033],[23772,43709,43637],{"trials":77546,"activeCount":97},[],{"trials":77548,"activeCount":97},[],{"trials":77550,"activeCount":97},[],{"trials":77552,"activeCount":97},[],{"intervention":77554,"totalTrials":417,"cells":77555},"Dabrafenib 150 mg twice a day",{"EARLY_PHASE1":77556,"PHASE1":77558,"PHASE2":77569,"PHASE3":77571,"PHASE4":77573,"NA":77575},{"trials":77557,"activeCount":97},[],{"trials":77559,"activeCount":97},[77560],{"nctId":77561,"briefTitle":77562,"status":155,"phases":77563,"primaryCompletion":12042,"completion":12042,"start":77564,"enrollment":314,"conditions":77565,"interventions":77566},"NCT01954043","A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors",[85],"2013-12-20",[36],[77554,77567,77568],"Rabeprazole 40 mg once daily","Rifampin 600 mg OD",{"trials":77570,"activeCount":97},[],{"trials":77572,"activeCount":97},[],{"trials":77574,"activeCount":97},[],{"trials":77576,"activeCount":97},[],{"intervention":77567,"totalTrials":417,"cells":77578},{"EARLY_PHASE1":77579,"PHASE1":77581,"PHASE2":77587,"PHASE3":77589,"PHASE4":77591,"NA":77593},{"trials":77580,"activeCount":97},[],{"trials":77582,"activeCount":97},[77583],{"nctId":77561,"briefTitle":77562,"status":155,"phases":77584,"primaryCompletion":12042,"completion":12042,"start":77564,"enrollment":314,"conditions":77585,"interventions":77586},[85],[36],[77554,77567,77568],{"trials":77588,"activeCount":97},[],{"trials":77590,"activeCount":97},[],{"trials":77592,"activeCount":97},[],{"trials":77594,"activeCount":97},[],{"intervention":77568,"totalTrials":417,"cells":77596},{"EARLY_PHASE1":77597,"PHASE1":77599,"PHASE2":77605,"PHASE3":77607,"PHASE4":77609,"NA":77611},{"trials":77598,"activeCount":97},[],{"trials":77600,"activeCount":97},[77601],{"nctId":77561,"briefTitle":77562,"status":155,"phases":77602,"primaryCompletion":12042,"completion":12042,"start":77564,"enrollment":314,"conditions":77603,"interventions":77604},[85],[36],[77554,77567,77568],{"trials":77606,"activeCount":97},[],{"trials":77608,"activeCount":97},[],{"trials":77610,"activeCount":97},[],{"trials":77612,"activeCount":97},[],{"intervention":77614,"totalTrials":417,"cells":77615},"Albendazole IP 400 mg",{"EARLY_PHASE1":77616,"PHASE1":77618,"PHASE2":77630,"PHASE3":77632,"PHASE4":77634,"NA":77636},{"trials":77617,"activeCount":97},[],{"trials":77619,"activeCount":97},[77620],{"nctId":77621,"briefTitle":77622,"status":155,"phases":77623,"primaryCompletion":77624,"completion":77624,"start":77625,"enrollment":730,"conditions":77626,"interventions":77628},"NCT06201559","Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions",[85],"2023-09-12","2023-08-21",[77627],"Intestinal Diseases",[77614,77629],"Albendazole 400 mg",{"trials":77631,"activeCount":97},[],{"trials":77633,"activeCount":97},[],{"trials":77635,"activeCount":97},[],{"trials":77637,"activeCount":97},[],{"intervention":77629,"totalTrials":417,"cells":77639},{"EARLY_PHASE1":77640,"PHASE1":77642,"PHASE2":77648,"PHASE3":77650,"PHASE4":77652,"NA":77654},{"trials":77641,"activeCount":97},[],{"trials":77643,"activeCount":97},[77644],{"nctId":77621,"briefTitle":77622,"status":155,"phases":77645,"primaryCompletion":77624,"completion":77624,"start":77625,"enrollment":730,"conditions":77646,"interventions":77647},[85],[77627],[77614,77629],{"trials":77649,"activeCount":97},[],{"trials":77651,"activeCount":97},[],{"trials":77653,"activeCount":97},[],{"trials":77655,"activeCount":97},[],{"intervention":77657,"totalTrials":417,"cells":77658},"GSK1325756H",{"EARLY_PHASE1":77659,"PHASE1":77661,"PHASE2":77669,"PHASE3":77671,"PHASE4":77673,"NA":77675},{"trials":77660,"activeCount":97},[],{"trials":77662,"activeCount":97},[77663],{"nctId":77664,"briefTitle":77665,"status":155,"phases":77666,"primaryCompletion":41686,"completion":41686,"start":17993,"enrollment":1736,"conditions":77667,"interventions":77668},"NCT03136380","Study of Danirixin in Japanese Healthy Elderly Male Subjects",[85],[15],[77657],{"trials":77670,"activeCount":97},[],{"trials":77672,"activeCount":97},[],{"trials":77674,"activeCount":97},[],{"trials":77676,"activeCount":97},[],{"intervention":22880,"totalTrials":417,"cells":77678},{"EARLY_PHASE1":77679,"PHASE1":77681,"PHASE2":77687,"PHASE3":77689,"PHASE4":77691,"NA":77693},{"trials":77680,"activeCount":97},[],{"trials":77682,"activeCount":97},[77683],{"nctId":22875,"briefTitle":22876,"status":155,"phases":77684,"primaryCompletion":19976,"completion":19976,"start":3425,"enrollment":1298,"conditions":77685,"interventions":77686},[85],[18],[22880,22881,22882,22883],{"trials":77688,"activeCount":97},[],{"trials":77690,"activeCount":97},[],{"trials":77692,"activeCount":97},[],{"trials":77694,"activeCount":97},[],{"intervention":22882,"totalTrials":417,"cells":77696},{"EARLY_PHASE1":77697,"PHASE1":77699,"PHASE2":77705,"PHASE3":77707,"PHASE4":77709,"NA":77711},{"trials":77698,"activeCount":97},[],{"trials":77700,"activeCount":97},[77701],{"nctId":22875,"briefTitle":22876,"status":155,"phases":77702,"primaryCompletion":19976,"completion":19976,"start":3425,"enrollment":1298,"conditions":77703,"interventions":77704},[85],[18],[22880,22881,22882,22883],{"trials":77706,"activeCount":97},[],{"trials":77708,"activeCount":97},[],{"trials":77710,"activeCount":97},[],{"trials":77712,"activeCount":97},[],{"intervention":22883,"totalTrials":417,"cells":77714},{"EARLY_PHASE1":77715,"PHASE1":77717,"PHASE2":77723,"PHASE3":77725,"PHASE4":77727,"NA":77729},{"trials":77716,"activeCount":97},[],{"trials":77718,"activeCount":97},[77719],{"nctId":22875,"briefTitle":22876,"status":155,"phases":77720,"primaryCompletion":19976,"completion":19976,"start":3425,"enrollment":1298,"conditions":77721,"interventions":77722},[85],[18],[22880,22881,22882,22883],{"trials":77724,"activeCount":97},[],{"trials":77726,"activeCount":97},[],{"trials":77728,"activeCount":97},[],{"trials":77730,"activeCount":97},[],{"intervention":77732,"totalTrials":417,"cells":77733},"Nelarabine injection 400mg\u002Fm2",{"EARLY_PHASE1":77734,"PHASE1":77736,"PHASE2":77748,"PHASE3":77750,"PHASE4":77752,"NA":77754},{"trials":77735,"activeCount":97},[],{"trials":77737,"activeCount":97},[77738],{"nctId":77739,"briefTitle":77740,"status":155,"phases":77741,"primaryCompletion":42642,"completion":42642,"start":10977,"enrollment":3131,"conditions":77742,"interventions":77744},"NCT00406757","Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma",[85],[77743],"Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic",[77732,77745,77746,77747],"Nelarabine injection 650mg\u002Fm2","Nelarabine injection 1000mg\u002Fm2","Nelarabine injection 1500mg\u002Fm2",{"trials":77749,"activeCount":97},[],{"trials":77751,"activeCount":97},[],{"trials":77753,"activeCount":97},[],{"trials":77755,"activeCount":97},[],{"intervention":77745,"totalTrials":417,"cells":77757},{"EARLY_PHASE1":77758,"PHASE1":77760,"PHASE2":77766,"PHASE3":77768,"PHASE4":77770,"NA":77772},{"trials":77759,"activeCount":97},[],{"trials":77761,"activeCount":97},[77762],{"nctId":77739,"briefTitle":77740,"status":155,"phases":77763,"primaryCompletion":42642,"completion":42642,"start":10977,"enrollment":3131,"conditions":77764,"interventions":77765},[85],[77743],[77732,77745,77746,77747],{"trials":77767,"activeCount":97},[],{"trials":77769,"activeCount":97},[],{"trials":77771,"activeCount":97},[],{"trials":77773,"activeCount":97},[],{"intervention":77746,"totalTrials":417,"cells":77775},{"EARLY_PHASE1":77776,"PHASE1":77778,"PHASE2":77784,"PHASE3":77786,"PHASE4":77788,"NA":77790},{"trials":77777,"activeCount":97},[],{"trials":77779,"activeCount":97},[77780],{"nctId":77739,"briefTitle":77740,"status":155,"phases":77781,"primaryCompletion":42642,"completion":42642,"start":10977,"enrollment":3131,"conditions":77782,"interventions":77783},[85],[77743],[77732,77745,77746,77747],{"trials":77785,"activeCount":97},[],{"trials":77787,"activeCount":97},[],{"trials":77789,"activeCount":97},[],{"trials":77791,"activeCount":97},[],{"intervention":77747,"totalTrials":417,"cells":77793},{"EARLY_PHASE1":77794,"PHASE1":77796,"PHASE2":77802,"PHASE3":77804,"PHASE4":77806,"NA":77808},{"trials":77795,"activeCount":97},[],{"trials":77797,"activeCount":97},[77798],{"nctId":77739,"briefTitle":77740,"status":155,"phases":77799,"primaryCompletion":42642,"completion":42642,"start":10977,"enrollment":3131,"conditions":77800,"interventions":77801},[85],[77743],[77732,77745,77746,77747],{"trials":77803,"activeCount":97},[],{"trials":77805,"activeCount":97},[],{"trials":77807,"activeCount":97},[],{"trials":77809,"activeCount":97},[],{"intervention":77811,"totalTrials":417,"cells":77812},"Trivalent influenza vaccine GSK 138842A",{"EARLY_PHASE1":77813,"PHASE1":77815,"PHASE2":77823,"PHASE3":77825,"PHASE4":77827,"NA":77829},{"trials":77814,"activeCount":97},[],{"trials":77816,"activeCount":97},[77817],{"nctId":77818,"briefTitle":77819,"status":155,"phases":77820,"primaryCompletion":8826,"completion":22341,"start":4778,"enrollment":1196,"conditions":77821,"interventions":77822},"NCT00693706","Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix",[85],[21],[77811,25702],{"trials":77824,"activeCount":97},[],{"trials":77826,"activeCount":97},[],{"trials":77828,"activeCount":97},[],{"trials":77830,"activeCount":97},[],{"intervention":41869,"totalTrials":417,"cells":77832},{"EARLY_PHASE1":77833,"PHASE1":77835,"PHASE2":77841,"PHASE3":77843,"PHASE4":77845,"NA":77847},{"trials":77834,"activeCount":97},[],{"trials":77836,"activeCount":97},[77837],{"nctId":41861,"briefTitle":41862,"status":155,"phases":77838,"primaryCompletion":41864,"completion":41864,"start":41865,"enrollment":454,"conditions":77839,"interventions":77840},[85],[41867],[41869,39203,39202],{"trials":77842,"activeCount":97},[],{"trials":77844,"activeCount":97},[],{"trials":77846,"activeCount":97},[],{"trials":77848,"activeCount":97},[],{"intervention":77850,"totalTrials":417,"cells":77851},"Lamotrigine Dispersible\u002FChewable",{"EARLY_PHASE1":77852,"PHASE1":77854,"PHASE2":77864,"PHASE3":77866,"PHASE4":77868,"NA":77870},{"trials":77853,"activeCount":97},[],{"trials":77855,"activeCount":97},[77856],{"nctId":77857,"briefTitle":77858,"status":155,"phases":77859,"primaryCompletion":52003,"completion":52003,"start":77860,"enrollment":7554,"conditions":77861,"interventions":77862},"NCT02064465","The Bioequivalence Study of Lamotrigine Dispersible\u002FChewable Tablets 100mg Compared With Compressed Tablet 100 mg",[85],"2014-03-15",[12518],[77850,77863],"Lamotrigine Compressed",{"trials":77865,"activeCount":97},[],{"trials":77867,"activeCount":97},[],{"trials":77869,"activeCount":97},[],{"trials":77871,"activeCount":97},[],{"intervention":77863,"totalTrials":417,"cells":77873},{"EARLY_PHASE1":77874,"PHASE1":77876,"PHASE2":77882,"PHASE3":77884,"PHASE4":77886,"NA":77888},{"trials":77875,"activeCount":97},[],{"trials":77877,"activeCount":97},[77878],{"nctId":77857,"briefTitle":77858,"status":155,"phases":77879,"primaryCompletion":52003,"completion":52003,"start":77860,"enrollment":7554,"conditions":77880,"interventions":77881},[85],[12518],[77850,77863],{"trials":77883,"activeCount":97},[],{"trials":77885,"activeCount":97},[],{"trials":77887,"activeCount":97},[],{"trials":77889,"activeCount":97},[],{"intervention":77891,"totalTrials":417,"cells":77892},"GSK1247303",{"EARLY_PHASE1":77893,"PHASE1":77895,"PHASE2":77903,"PHASE3":77905,"PHASE4":77907,"NA":77909},{"trials":77894,"activeCount":97},[],{"trials":77896,"activeCount":97},[77897],{"nctId":77898,"briefTitle":77899,"status":145,"phases":77900,"primaryCompletion":7522,"completion":7522,"start":9737,"enrollment":7712,"conditions":77901,"interventions":77902},"NCT00651079","GSK1247303 First Time in Human Study",[85],[7524],[77891],{"trials":77904,"activeCount":97},[],{"trials":77906,"activeCount":97},[],{"trials":77908,"activeCount":97},[],{"trials":77910,"activeCount":97},[],{"intervention":77912,"totalTrials":417,"cells":77913},"GSK3542503",{"EARLY_PHASE1":77914,"PHASE1":77916,"PHASE2":77926,"PHASE3":77928,"PHASE4":77930,"NA":77932},{"trials":77915,"activeCount":97},[],{"trials":77917,"activeCount":97},[77918],{"nctId":77919,"briefTitle":77920,"status":155,"phases":77921,"primaryCompletion":77922,"completion":77922,"start":42280,"enrollment":656,"conditions":77923,"interventions":77924},"NCT03031496","Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions",[85],"2017-04-10",[13024],[77912,77925],"Moduretic",{"trials":77927,"activeCount":97},[],{"trials":77929,"activeCount":97},[],{"trials":77931,"activeCount":97},[],{"trials":77933,"activeCount":97},[],{"intervention":77925,"totalTrials":417,"cells":77935},{"EARLY_PHASE1":77936,"PHASE1":77938,"PHASE2":77944,"PHASE3":77946,"PHASE4":77948,"NA":77950},{"trials":77937,"activeCount":97},[],{"trials":77939,"activeCount":97},[77940],{"nctId":77919,"briefTitle":77920,"status":155,"phases":77941,"primaryCompletion":77922,"completion":77922,"start":42280,"enrollment":656,"conditions":77942,"interventions":77943},[85],[13024],[77912,77925],{"trials":77945,"activeCount":97},[],{"trials":77947,"activeCount":97},[],{"trials":77949,"activeCount":97},[],{"trials":77951,"activeCount":97},[],{"intervention":77953,"totalTrials":417,"cells":77954},"GSK557296 10 mg",{"EARLY_PHASE1":77955,"PHASE1":77957,"PHASE2":77970,"PHASE3":77972,"PHASE4":77974,"NA":77976},{"trials":77956,"activeCount":97},[],{"trials":77958,"activeCount":97},[77959],{"nctId":77960,"briefTitle":77961,"status":155,"phases":77962,"primaryCompletion":77963,"completion":77963,"start":77964,"enrollment":710,"conditions":77965,"interventions":77966},"NCT01669083","Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing",[85],"2013-03-09","2012-08-16",[41061],[77953,77967,77968,77969],"GSK557296 150 mg","GSK557296 dose 3","GSK557296 dose 4",{"trials":77971,"activeCount":97},[],{"trials":77973,"activeCount":97},[],{"trials":77975,"activeCount":97},[],{"trials":77977,"activeCount":97},[],{"intervention":77967,"totalTrials":417,"cells":77979},{"EARLY_PHASE1":77980,"PHASE1":77982,"PHASE2":77988,"PHASE3":77990,"PHASE4":77992,"NA":77994},{"trials":77981,"activeCount":97},[],{"trials":77983,"activeCount":97},[77984],{"nctId":77960,"briefTitle":77961,"status":155,"phases":77985,"primaryCompletion":77963,"completion":77963,"start":77964,"enrollment":710,"conditions":77986,"interventions":77987},[85],[41061],[77953,77967,77968,77969],{"trials":77989,"activeCount":97},[],{"trials":77991,"activeCount":97},[],{"trials":77993,"activeCount":97},[],{"trials":77995,"activeCount":97},[],{"intervention":77968,"totalTrials":417,"cells":77997},{"EARLY_PHASE1":77998,"PHASE1":78000,"PHASE2":78006,"PHASE3":78008,"PHASE4":78010,"NA":78012},{"trials":77999,"activeCount":97},[],{"trials":78001,"activeCount":97},[78002],{"nctId":77960,"briefTitle":77961,"status":155,"phases":78003,"primaryCompletion":77963,"completion":77963,"start":77964,"enrollment":710,"conditions":78004,"interventions":78005},[85],[41061],[77953,77967,77968,77969],{"trials":78007,"activeCount":97},[],{"trials":78009,"activeCount":97},[],{"trials":78011,"activeCount":97},[],{"trials":78013,"activeCount":97},[],{"intervention":77969,"totalTrials":417,"cells":78015},{"EARLY_PHASE1":78016,"PHASE1":78018,"PHASE2":78024,"PHASE3":78026,"PHASE4":78028,"NA":78030},{"trials":78017,"activeCount":97},[],{"trials":78019,"activeCount":97},[78020],{"nctId":77960,"briefTitle":77961,"status":155,"phases":78021,"primaryCompletion":77963,"completion":77963,"start":77964,"enrollment":710,"conditions":78022,"interventions":78023},[85],[41061],[77953,77967,77968,77969],{"trials":78025,"activeCount":97},[],{"trials":78027,"activeCount":97},[],{"trials":78029,"activeCount":97},[],{"trials":78031,"activeCount":97},[],{"intervention":78033,"totalTrials":417,"cells":78034},"GSK2118436 75 mg",{"EARLY_PHASE1":78035,"PHASE1":78037,"PHASE2":78047,"PHASE3":78049,"PHASE4":78051,"NA":78053},{"trials":78036,"activeCount":97},[],{"trials":78038,"activeCount":97},[78039],{"nctId":78040,"briefTitle":78041,"status":155,"phases":78042,"primaryCompletion":78043,"completion":78043,"start":78044,"enrollment":1003,"conditions":78045,"interventions":78046},"NCT01738451","A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors",[85],"2014-11-28","2013-01-22",[36],[78033],{"trials":78048,"activeCount":97},[],{"trials":78050,"activeCount":97},[],{"trials":78052,"activeCount":97},[],{"trials":78054,"activeCount":97},[],{"intervention":78056,"totalTrials":417,"cells":78057},"GW685698X & GW642444M",{"EARLY_PHASE1":78058,"PHASE1":78060,"PHASE2":78069,"PHASE3":78071,"PHASE4":78073,"NA":78075},{"trials":78059,"activeCount":97},[],{"trials":78061,"activeCount":97},[78062],{"nctId":78063,"briefTitle":78064,"status":155,"phases":78065,"primaryCompletion":8207,"completion":8207,"start":78066,"enrollment":433,"conditions":78067,"interventions":78068},"NCT00538057","Comparing Two Respiratory Drugs When Used In Combination And Separately From A Novel Inhaler Device In Healthy Subjects",[85],"2007-10-02",[18],[78056],{"trials":78070,"activeCount":97},[],{"trials":78072,"activeCount":97},[],{"trials":78074,"activeCount":97},[],{"trials":78076,"activeCount":97},[],{"intervention":41327,"totalTrials":417,"cells":78078},{"EARLY_PHASE1":78079,"PHASE1":78081,"PHASE2":78087,"PHASE3":78089,"PHASE4":78091,"NA":78093},{"trials":78080,"activeCount":97},[],{"trials":78082,"activeCount":97},[78083],{"nctId":41319,"briefTitle":41320,"status":145,"phases":78084,"primaryCompletion":41322,"completion":41323,"start":41324,"enrollment":8817,"conditions":78085,"interventions":78086},[85],[107],[6817,41327],{"trials":78088,"activeCount":97},[],{"trials":78090,"activeCount":97},[],{"trials":78092,"activeCount":97},[],{"trials":78094,"activeCount":97},[],{"intervention":78096,"totalTrials":417,"cells":78097},"GSK2190915 100mg milled",{"EARLY_PHASE1":78098,"PHASE1":78100,"PHASE2":78112,"PHASE3":78114,"PHASE4":78116,"NA":78118},{"trials":78099,"activeCount":97},[],{"trials":78101,"activeCount":97},[78102],{"nctId":78103,"briefTitle":78104,"status":155,"phases":78105,"primaryCompletion":8783,"completion":8783,"start":8263,"enrollment":473,"conditions":78106,"interventions":78107},"NCT01318980","A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A",[85],[18],[78096,78108,78109,78110,78111],"[14C] radiolabelled GSK2190915 solution","GSK2190915 100mg milled tablet administered to the proximal small bowel.","GSK2190915 100mg milled tablet administered to the distal small bowel.","GSK2190915 100mg enteric-coated tablet.",{"trials":78113,"activeCount":97},[],{"trials":78115,"activeCount":97},[],{"trials":78117,"activeCount":97},[],{"trials":78119,"activeCount":97},[],{"intervention":78108,"totalTrials":417,"cells":78121},{"EARLY_PHASE1":78122,"PHASE1":78124,"PHASE2":78130,"PHASE3":78132,"PHASE4":78134,"NA":78136},{"trials":78123,"activeCount":97},[],{"trials":78125,"activeCount":97},[78126],{"nctId":78103,"briefTitle":78104,"status":155,"phases":78127,"primaryCompletion":8783,"completion":8783,"start":8263,"enrollment":473,"conditions":78128,"interventions":78129},[85],[18],[78096,78108,78109,78110,78111],{"trials":78131,"activeCount":97},[],{"trials":78133,"activeCount":97},[],{"trials":78135,"activeCount":97},[],{"trials":78137,"activeCount":97},[],{"intervention":78109,"totalTrials":417,"cells":78139},{"EARLY_PHASE1":78140,"PHASE1":78142,"PHASE2":78148,"PHASE3":78150,"PHASE4":78152,"NA":78154},{"trials":78141,"activeCount":97},[],{"trials":78143,"activeCount":97},[78144],{"nctId":78103,"briefTitle":78104,"status":155,"phases":78145,"primaryCompletion":8783,"completion":8783,"start":8263,"enrollment":473,"conditions":78146,"interventions":78147},[85],[18],[78096,78108,78109,78110,78111],{"trials":78149,"activeCount":97},[],{"trials":78151,"activeCount":97},[],{"trials":78153,"activeCount":97},[],{"trials":78155,"activeCount":97},[],{"intervention":78110,"totalTrials":417,"cells":78157},{"EARLY_PHASE1":78158,"PHASE1":78160,"PHASE2":78166,"PHASE3":78168,"PHASE4":78170,"NA":78172},{"trials":78159,"activeCount":97},[],{"trials":78161,"activeCount":97},[78162],{"nctId":78103,"briefTitle":78104,"status":155,"phases":78163,"primaryCompletion":8783,"completion":8783,"start":8263,"enrollment":473,"conditions":78164,"interventions":78165},[85],[18],[78096,78108,78109,78110,78111],{"trials":78167,"activeCount":97},[],{"trials":78169,"activeCount":97},[],{"trials":78171,"activeCount":97},[],{"trials":78173,"activeCount":97},[],{"intervention":78111,"totalTrials":417,"cells":78175},{"EARLY_PHASE1":78176,"PHASE1":78178,"PHASE2":78184,"PHASE3":78186,"PHASE4":78188,"NA":78190},{"trials":78177,"activeCount":97},[],{"trials":78179,"activeCount":97},[78180],{"nctId":78103,"briefTitle":78104,"status":155,"phases":78181,"primaryCompletion":8783,"completion":8783,"start":8263,"enrollment":473,"conditions":78182,"interventions":78183},[85],[18],[78096,78108,78109,78110,78111],{"trials":78185,"activeCount":97},[],{"trials":78187,"activeCount":97},[],{"trials":78189,"activeCount":97},[],{"trials":78191,"activeCount":97},[],{"intervention":78193,"totalTrials":417,"cells":78194},"GW597901X",{"EARLY_PHASE1":78195,"PHASE1":78197,"PHASE2":78205,"PHASE3":78207,"PHASE4":78209,"NA":78211},{"trials":78196,"activeCount":97},[],{"trials":78198,"activeCount":97},[78199],{"nctId":78200,"briefTitle":78201,"status":155,"phases":78202,"start":19830,"enrollment":1298,"conditions":78203,"interventions":78204},"NCT00354042","Effects Of Repeat Inhaled Doses Of GW597901X On Patient Safety And Lung Function In Asthmatic Subjects",[85],[18],[78193],{"trials":78206,"activeCount":97},[],{"trials":78208,"activeCount":97},[],{"trials":78210,"activeCount":97},[],{"trials":78212,"activeCount":97},[],{"intervention":39856,"totalTrials":417,"cells":78214},{"EARLY_PHASE1":78215,"PHASE1":78217,"PHASE2":78223,"PHASE3":78225,"PHASE4":78227,"NA":78229},{"trials":78216,"activeCount":97},[],{"trials":78218,"activeCount":97},[78219],{"nctId":39851,"briefTitle":39852,"status":155,"phases":78220,"primaryCompletion":4689,"completion":4689,"start":26622,"enrollment":1298,"conditions":78221,"interventions":78222},[85],[1877],[7458,39856],{"trials":78224,"activeCount":97},[],{"trials":78226,"activeCount":97},[],{"trials":78228,"activeCount":97},[],{"trials":78230,"activeCount":97},[],{"intervention":22667,"totalTrials":417,"cells":78232},{"EARLY_PHASE1":78233,"PHASE1":78235,"PHASE2":78241,"PHASE3":78243,"PHASE4":78245,"NA":78247},{"trials":78234,"activeCount":97},[],{"trials":78236,"activeCount":97},[78237],{"nctId":22661,"briefTitle":22662,"status":155,"phases":78238,"primaryCompletion":18183,"completion":18183,"start":22664,"enrollment":454,"conditions":78239,"interventions":78240},[85],[15087],[22647,22667,22668],{"trials":78242,"activeCount":97},[],{"trials":78244,"activeCount":97},[],{"trials":78246,"activeCount":97},[],{"trials":78248,"activeCount":97},[],{"intervention":22668,"totalTrials":417,"cells":78250},{"EARLY_PHASE1":78251,"PHASE1":78253,"PHASE2":78259,"PHASE3":78261,"PHASE4":78263,"NA":78265},{"trials":78252,"activeCount":97},[],{"trials":78254,"activeCount":97},[78255],{"nctId":22661,"briefTitle":22662,"status":155,"phases":78256,"primaryCompletion":18183,"completion":18183,"start":22664,"enrollment":454,"conditions":78257,"interventions":78258},[85],[15087],[22647,22667,22668],{"trials":78260,"activeCount":97},[],{"trials":78262,"activeCount":97},[],{"trials":78264,"activeCount":97},[],{"trials":78266,"activeCount":97},[],{"intervention":78268,"totalTrials":417,"cells":78269},"CV2CoV",{"EARLY_PHASE1":78270,"PHASE1":78272,"PHASE2":78281,"PHASE3":78283,"PHASE4":78285,"NA":78287},{"trials":78271,"activeCount":97},[],{"trials":78273,"activeCount":97},[78274],{"nctId":78275,"briefTitle":78276,"status":155,"phases":78277,"primaryCompletion":3207,"completion":3207,"start":78278,"enrollment":7769,"conditions":78279,"interventions":78280},"NCT05260437","Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants",[85],"2022-03-24",[12437,54443],[78268,78268,78268,78268,78268,78268],{"trials":78282,"activeCount":97},[],{"trials":78284,"activeCount":97},[],{"trials":78286,"activeCount":97},[],{"trials":78288,"activeCount":97},[],{"intervention":78290,"totalTrials":417,"cells":78291},"Investigational H9N2 vaccine GSK2654911A",{"EARLY_PHASE1":78292,"PHASE1":78294,"PHASE2":78305,"PHASE3":78307,"PHASE4":78309,"NA":78311},{"trials":78293,"activeCount":97},[],{"trials":78295,"activeCount":97},[78296],{"nctId":78297,"briefTitle":78298,"status":155,"phases":78299,"primaryCompletion":43706,"completion":12966,"start":78300,"enrollment":78301,"conditions":78302,"interventions":78303},"NCT01659086","Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age",[85],"2012-08-22",422,[21],[78290,78304],"Investigational H9N2 vaccine GSK2654909A",{"trials":78306,"activeCount":97},[],{"trials":78308,"activeCount":97},[],{"trials":78310,"activeCount":97},[],{"trials":78312,"activeCount":97},[],{"intervention":78304,"totalTrials":417,"cells":78314},{"EARLY_PHASE1":78315,"PHASE1":78317,"PHASE2":78323,"PHASE3":78325,"PHASE4":78327,"NA":78329},{"trials":78316,"activeCount":97},[],{"trials":78318,"activeCount":97},[78319],{"nctId":78297,"briefTitle":78298,"status":155,"phases":78320,"primaryCompletion":43706,"completion":12966,"start":78300,"enrollment":78301,"conditions":78321,"interventions":78322},[85],[21],[78290,78304],{"trials":78324,"activeCount":97},[],{"trials":78326,"activeCount":97},[],{"trials":78328,"activeCount":97},[],{"trials":78330,"activeCount":97},[],{"intervention":40730,"totalTrials":417,"cells":78332},{"EARLY_PHASE1":78333,"PHASE1":78335,"PHASE2":78341,"PHASE3":78343,"PHASE4":78345,"NA":78347},{"trials":78334,"activeCount":97},[],{"trials":78336,"activeCount":97},[78337],{"nctId":40725,"briefTitle":40726,"status":155,"phases":78338,"primaryCompletion":11315,"completion":11315,"start":728,"enrollment":1298,"conditions":78339,"interventions":78340},[85],[6484],[40730,40731,40732,40733],{"trials":78342,"activeCount":97},[],{"trials":78344,"activeCount":97},[],{"trials":78346,"activeCount":97},[],{"trials":78348,"activeCount":97},[],{"intervention":40732,"totalTrials":417,"cells":78350},{"EARLY_PHASE1":78351,"PHASE1":78353,"PHASE2":78359,"PHASE3":78361,"PHASE4":78363,"NA":78365},{"trials":78352,"activeCount":97},[],{"trials":78354,"activeCount":97},[78355],{"nctId":40725,"briefTitle":40726,"status":155,"phases":78356,"primaryCompletion":11315,"completion":11315,"start":728,"enrollment":1298,"conditions":78357,"interventions":78358},[85],[6484],[40730,40731,40732,40733],{"trials":78360,"activeCount":97},[],{"trials":78362,"activeCount":97},[],{"trials":78364,"activeCount":97},[],{"trials":78366,"activeCount":97},[],{"intervention":40733,"totalTrials":417,"cells":78368},{"EARLY_PHASE1":78369,"PHASE1":78371,"PHASE2":78377,"PHASE3":78379,"PHASE4":78381,"NA":78383},{"trials":78370,"activeCount":97},[],{"trials":78372,"activeCount":97},[78373],{"nctId":40725,"briefTitle":40726,"status":155,"phases":78374,"primaryCompletion":11315,"completion":11315,"start":728,"enrollment":1298,"conditions":78375,"interventions":78376},[85],[6484],[40730,40731,40732,40733],{"trials":78378,"activeCount":97},[],{"trials":78380,"activeCount":97},[],{"trials":78382,"activeCount":97},[],{"trials":78384,"activeCount":97},[],{"intervention":39154,"totalTrials":417,"cells":78386},{"EARLY_PHASE1":78387,"PHASE1":78389,"PHASE2":78395,"PHASE3":78397,"PHASE4":78399,"NA":78401},{"trials":78388,"activeCount":97},[],{"trials":78390,"activeCount":97},[78391],{"nctId":39149,"briefTitle":39150,"status":155,"phases":78392,"primaryCompletion":18387,"completion":18387,"start":38925,"enrollment":1298,"conditions":78393,"interventions":78394},[85],[39123],[39110,39154],{"trials":78396,"activeCount":97},[],{"trials":78398,"activeCount":97},[],{"trials":78400,"activeCount":97},[],{"trials":78402,"activeCount":97},[],{"intervention":78404,"totalTrials":417,"cells":78405},"Lamotrigine IR",{"EARLY_PHASE1":78406,"PHASE1":78408,"PHASE2":78418,"PHASE3":78420,"PHASE4":78422,"NA":78424},{"trials":78407,"activeCount":97},[],{"trials":78409,"activeCount":97},[78410],{"nctId":78411,"briefTitle":78412,"status":155,"phases":78413,"primaryCompletion":46387,"completion":46387,"start":78414,"enrollment":4642,"conditions":78415,"interventions":78416},"NCT00449774","Bioequivalence And Effect Of Food And Water On Lamotrigine in Healthy Volunteers",[85],"2007-05-07",[65610],[78404,78417],"Lamotrigine ODT",{"trials":78419,"activeCount":97},[],{"trials":78421,"activeCount":97},[],{"trials":78423,"activeCount":97},[],{"trials":78425,"activeCount":97},[],{"intervention":78417,"totalTrials":417,"cells":78427},{"EARLY_PHASE1":78428,"PHASE1":78430,"PHASE2":78436,"PHASE3":78438,"PHASE4":78440,"NA":78442},{"trials":78429,"activeCount":97},[],{"trials":78431,"activeCount":97},[78432],{"nctId":78411,"briefTitle":78412,"status":155,"phases":78433,"primaryCompletion":46387,"completion":46387,"start":78414,"enrollment":4642,"conditions":78434,"interventions":78435},[85],[65610],[78404,78417],{"trials":78437,"activeCount":97},[],{"trials":78439,"activeCount":97},[],{"trials":78441,"activeCount":97},[],{"trials":78443,"activeCount":97},[],{"intervention":11718,"totalTrials":417,"cells":78445},{"EARLY_PHASE1":78446,"PHASE1":78448,"PHASE2":78454,"PHASE3":78456,"PHASE4":78458,"NA":78460},{"trials":78447,"activeCount":97},[],{"trials":78449,"activeCount":97},[78450],{"nctId":11711,"briefTitle":11712,"status":155,"phases":78451,"primaryCompletion":11714,"completion":11714,"start":11715,"enrollment":1634,"conditions":78452,"interventions":78453},[85],[15],[11718,963,8632],{"trials":78455,"activeCount":97},[],{"trials":78457,"activeCount":97},[],{"trials":78459,"activeCount":97},[],{"trials":78461,"activeCount":97},[],{"intervention":42394,"totalTrials":417,"cells":78463},{"EARLY_PHASE1":78464,"PHASE1":78466,"PHASE2":78472,"PHASE3":78474,"PHASE4":78476,"NA":78478},{"trials":78465,"activeCount":97},[],{"trials":78467,"activeCount":97},[78468],{"nctId":42386,"briefTitle":42387,"status":155,"phases":78469,"primaryCompletion":42389,"completion":42389,"start":42390,"enrollment":1003,"conditions":78470,"interventions":78471},[85],[42392],[42394,42395,42379],{"trials":78473,"activeCount":97},[],{"trials":78475,"activeCount":97},[],{"trials":78477,"activeCount":97},[],{"trials":78479,"activeCount":97},[],{"intervention":42395,"totalTrials":417,"cells":78481},{"EARLY_PHASE1":78482,"PHASE1":78484,"PHASE2":78490,"PHASE3":78492,"PHASE4":78494,"NA":78496},{"trials":78483,"activeCount":97},[],{"trials":78485,"activeCount":97},[78486],{"nctId":42386,"briefTitle":42387,"status":155,"phases":78487,"primaryCompletion":42389,"completion":42389,"start":42390,"enrollment":1003,"conditions":78488,"interventions":78489},[85],[42392],[42394,42395,42379],{"trials":78491,"activeCount":97},[],{"trials":78493,"activeCount":97},[],{"trials":78495,"activeCount":97},[],{"trials":78497,"activeCount":97},[],{"intervention":78499,"totalTrials":417,"cells":78500},"Lower dose formulation of HSV vaccine",{"EARLY_PHASE1":78501,"PHASE1":78503,"PHASE2":78515,"PHASE3":78517,"PHASE4":78519,"NA":78521},{"trials":78502,"activeCount":97},[],{"trials":78504,"activeCount":97},[78505],{"nctId":78506,"briefTitle":78507,"status":145,"phases":78508,"primaryCompletion":10125,"completion":10125,"start":78509,"enrollment":7438,"conditions":78510,"interventions":78511},"NCT04762511","A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years",[85],"2021-03-02",[8709],[78499,78512,78513,78514],"Low dose formulation of HSV vaccine","Medium dose formulation of HSV vaccine","High dose formulation of HSV vaccine",{"trials":78516,"activeCount":97},[],{"trials":78518,"activeCount":97},[],{"trials":78520,"activeCount":97},[],{"trials":78522,"activeCount":97},[],{"intervention":78512,"totalTrials":417,"cells":78524},{"EARLY_PHASE1":78525,"PHASE1":78527,"PHASE2":78533,"PHASE3":78535,"PHASE4":78537,"NA":78539},{"trials":78526,"activeCount":97},[],{"trials":78528,"activeCount":97},[78529],{"nctId":78506,"briefTitle":78507,"status":145,"phases":78530,"primaryCompletion":10125,"completion":10125,"start":78509,"enrollment":7438,"conditions":78531,"interventions":78532},[85],[8709],[78499,78512,78513,78514],{"trials":78534,"activeCount":97},[],{"trials":78536,"activeCount":97},[],{"trials":78538,"activeCount":97},[],{"trials":78540,"activeCount":97},[],{"intervention":78513,"totalTrials":417,"cells":78542},{"EARLY_PHASE1":78543,"PHASE1":78545,"PHASE2":78551,"PHASE3":78553,"PHASE4":78555,"NA":78557},{"trials":78544,"activeCount":97},[],{"trials":78546,"activeCount":97},[78547],{"nctId":78506,"briefTitle":78507,"status":145,"phases":78548,"primaryCompletion":10125,"completion":10125,"start":78509,"enrollment":7438,"conditions":78549,"interventions":78550},[85],[8709],[78499,78512,78513,78514],{"trials":78552,"activeCount":97},[],{"trials":78554,"activeCount":97},[],{"trials":78556,"activeCount":97},[],{"trials":78558,"activeCount":97},[],{"intervention":78514,"totalTrials":417,"cells":78560},{"EARLY_PHASE1":78561,"PHASE1":78563,"PHASE2":78569,"PHASE3":78571,"PHASE4":78573,"NA":78575},{"trials":78562,"activeCount":97},[],{"trials":78564,"activeCount":97},[78565],{"nctId":78506,"briefTitle":78507,"status":145,"phases":78566,"primaryCompletion":10125,"completion":10125,"start":78509,"enrollment":7438,"conditions":78567,"interventions":78568},[85],[8709],[78499,78512,78513,78514],{"trials":78570,"activeCount":97},[],{"trials":78572,"activeCount":97},[],{"trials":78574,"activeCount":97},[],{"trials":78576,"activeCount":97},[],{"intervention":78578,"totalTrials":417,"cells":78579},"DETROL LA",{"EARLY_PHASE1":78580,"PHASE1":78582,"PHASE2":78590,"PHASE3":78592,"PHASE4":78594,"NA":78596},{"trials":78581,"activeCount":97},[],{"trials":78583,"activeCount":97},[78584],{"nctId":78585,"briefTitle":78586,"status":155,"phases":78587,"primaryCompletion":7954,"completion":7954,"start":2336,"enrollment":10794,"conditions":78588,"interventions":78589},"NCT00553657","The Study To Test The Effect of Standardization Of Fluid Intake In Female Patients With Overactive Bladder",[85],[42302],[78578],{"trials":78591,"activeCount":97},[],{"trials":78593,"activeCount":97},[],{"trials":78595,"activeCount":97},[],{"trials":78597,"activeCount":97},[],{"intervention":78599,"totalTrials":417,"cells":78600},"Part A Assessing GSK1521498",{"EARLY_PHASE1":78601,"PHASE1":78603,"PHASE2":78613,"PHASE3":78615,"PHASE4":78617,"NA":78619},{"trials":78602,"activeCount":97},[],{"trials":78604,"activeCount":97},[78605],{"nctId":78606,"briefTitle":78607,"status":155,"phases":78608,"primaryCompletion":6316,"completion":6316,"start":42550,"enrollment":93,"conditions":78609,"interventions":78610},"NCT00976066","[11C]Carfentanil PET Study of GSK1521498",[85],[9048],[78599,78611,78612],"Part B Assessing GSK1521498","Part C Assessing Naltrexone",{"trials":78614,"activeCount":97},[],{"trials":78616,"activeCount":97},[],{"trials":78618,"activeCount":97},[],{"trials":78620,"activeCount":97},[],{"intervention":78611,"totalTrials":417,"cells":78622},{"EARLY_PHASE1":78623,"PHASE1":78625,"PHASE2":78631,"PHASE3":78633,"PHASE4":78635,"NA":78637},{"trials":78624,"activeCount":97},[],{"trials":78626,"activeCount":97},[78627],{"nctId":78606,"briefTitle":78607,"status":155,"phases":78628,"primaryCompletion":6316,"completion":6316,"start":42550,"enrollment":93,"conditions":78629,"interventions":78630},[85],[9048],[78599,78611,78612],{"trials":78632,"activeCount":97},[],{"trials":78634,"activeCount":97},[],{"trials":78636,"activeCount":97},[],{"trials":78638,"activeCount":97},[],{"intervention":78612,"totalTrials":417,"cells":78640},{"EARLY_PHASE1":78641,"PHASE1":78643,"PHASE2":78649,"PHASE3":78651,"PHASE4":78653,"NA":78655},{"trials":78642,"activeCount":97},[],{"trials":78644,"activeCount":97},[78645],{"nctId":78606,"briefTitle":78607,"status":155,"phases":78646,"primaryCompletion":6316,"completion":6316,"start":42550,"enrollment":93,"conditions":78647,"interventions":78648},[85],[9048],[78599,78611,78612],{"trials":78650,"activeCount":97},[],{"trials":78652,"activeCount":97},[],{"trials":78654,"activeCount":97},[],{"trials":78656,"activeCount":97},[],{"intervention":60334,"totalTrials":417,"cells":78658},{"EARLY_PHASE1":78659,"PHASE1":78661,"PHASE2":78667,"PHASE3":78669,"PHASE4":78671,"NA":78673},{"trials":78660,"activeCount":97},[],{"trials":78662,"activeCount":97},[78663],{"nctId":60329,"briefTitle":60330,"status":155,"phases":78664,"primaryCompletion":3619,"completion":41864,"start":920,"enrollment":18147,"conditions":78665,"interventions":78666},[85],[3637],[60334,41023,60335],{"trials":78668,"activeCount":97},[],{"trials":78670,"activeCount":97},[],{"trials":78672,"activeCount":97},[],{"trials":78674,"activeCount":97},[],{"intervention":60335,"totalTrials":417,"cells":78676},{"EARLY_PHASE1":78677,"PHASE1":78679,"PHASE2":78685,"PHASE3":78687,"PHASE4":78689,"NA":78691},{"trials":78678,"activeCount":97},[],{"trials":78680,"activeCount":97},[78681],{"nctId":60329,"briefTitle":60330,"status":155,"phases":78682,"primaryCompletion":3619,"completion":41864,"start":920,"enrollment":18147,"conditions":78683,"interventions":78684},[85],[3637],[60334,41023,60335],{"trials":78686,"activeCount":97},[],{"trials":78688,"activeCount":97},[],{"trials":78690,"activeCount":97},[],{"trials":78692,"activeCount":97},[],{"intervention":78694,"totalTrials":417,"cells":78695},"GSK704838",{"EARLY_PHASE1":78696,"PHASE1":78698,"PHASE2":78706,"PHASE3":78708,"PHASE4":78710,"NA":78712},{"trials":78697,"activeCount":97},[],{"trials":78699,"activeCount":97},[78700],{"nctId":78701,"briefTitle":78702,"status":155,"phases":78703,"primaryCompletion":9737,"completion":9737,"start":2356,"enrollment":454,"conditions":78704,"interventions":78705},"NCT00539825","Effect of GSK704838 In Healthy Volunteers",[85],[15],[78694],{"trials":78707,"activeCount":97},[],{"trials":78709,"activeCount":97},[],{"trials":78711,"activeCount":97},[],{"trials":78713,"activeCount":97},[],{"intervention":78715,"totalTrials":417,"cells":78716},"Isotretinoin 40 mg",{"EARLY_PHASE1":78717,"PHASE1":78719,"PHASE2":78728,"PHASE3":78730,"PHASE4":78732,"NA":78734},{"trials":78718,"activeCount":97},[],{"trials":78720,"activeCount":97},[78721],{"nctId":78722,"briefTitle":78723,"status":155,"phases":78724,"primaryCompletion":78725,"completion":78725,"start":9517,"enrollment":710,"conditions":78726,"interventions":78727},"NCT01863615","Bioequivalence Study for an Isotretinoin",[85],"2011-09-23",[69560],[78715,78715],{"trials":78729,"activeCount":97},[],{"trials":78731,"activeCount":97},[],{"trials":78733,"activeCount":97},[],{"trials":78735,"activeCount":97},[],{"intervention":62441,"totalTrials":417,"cells":78737},{"EARLY_PHASE1":78738,"PHASE1":78740,"PHASE2":78746,"PHASE3":78748,"PHASE4":78750,"NA":78752},{"trials":78739,"activeCount":97},[],{"trials":78741,"activeCount":97},[78742],{"nctId":62435,"briefTitle":62436,"status":155,"phases":78743,"primaryCompletion":22188,"completion":22188,"start":62438,"enrollment":695,"conditions":78744,"interventions":78745},[85],[14696],[62428,62441],{"trials":78747,"activeCount":97},[],{"trials":78749,"activeCount":97},[],{"trials":78751,"activeCount":97},[],{"trials":78753,"activeCount":97},[],{"intervention":39361,"totalTrials":417,"cells":78755},{"EARLY_PHASE1":78756,"PHASE1":78758,"PHASE2":78764,"PHASE3":78766,"PHASE4":78768,"NA":78770},{"trials":78757,"activeCount":97},[],{"trials":78759,"activeCount":97},[78760],{"nctId":39354,"briefTitle":39355,"status":155,"phases":78761,"primaryCompletion":39357,"completion":39357,"start":39358,"enrollment":10794,"conditions":78762,"interventions":78763},[85],[14696],[39316,39361,8022,39362],{"trials":78765,"activeCount":97},[],{"trials":78767,"activeCount":97},[],{"trials":78769,"activeCount":97},[],{"trials":78771,"activeCount":97},[],{"intervention":78773,"totalTrials":417,"cells":78774},"C. difficile investigational vaccine based on the F2 antigen",{"EARLY_PHASE1":78775,"PHASE1":78777,"PHASE2":78789,"PHASE3":78791,"PHASE4":78793,"NA":78795},{"trials":78776,"activeCount":97},[],{"trials":78778,"activeCount":97},[78779],{"nctId":78780,"briefTitle":78781,"status":155,"phases":78782,"primaryCompletion":78783,"completion":78783,"start":78784,"enrollment":1534,"conditions":78785,"interventions":78787},"NCT04026009","Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years",[85],"2022-05-10","2019-08-05",[78786],"Clostridium Infections",[78773,78788],"C. difficile investigational vaccine based on the F2 antigen (GSK2904545A) adjuvanted with AS01B",{"trials":78790,"activeCount":97},[],{"trials":78792,"activeCount":97},[],{"trials":78794,"activeCount":97},[],{"trials":78796,"activeCount":97},[],{"intervention":78788,"totalTrials":417,"cells":78798},{"EARLY_PHASE1":78799,"PHASE1":78801,"PHASE2":78807,"PHASE3":78809,"PHASE4":78811,"NA":78813},{"trials":78800,"activeCount":97},[],{"trials":78802,"activeCount":97},[78803],{"nctId":78780,"briefTitle":78781,"status":155,"phases":78804,"primaryCompletion":78783,"completion":78783,"start":78784,"enrollment":1534,"conditions":78805,"interventions":78806},[85],[78786],[78773,78788],{"trials":78808,"activeCount":97},[],{"trials":78810,"activeCount":97},[],{"trials":78812,"activeCount":97},[],{"trials":78814,"activeCount":97},[],{"intervention":78816,"totalTrials":417,"cells":78817},"Clop F1",{"EARLY_PHASE1":78818,"PHASE1":78820,"PHASE2":78831,"PHASE3":78833,"PHASE4":78835,"NA":78837},{"trials":78819,"activeCount":97},[],{"trials":78821,"activeCount":97},[78822],{"nctId":78823,"briefTitle":78824,"status":155,"phases":78825,"primaryCompletion":78826,"completion":78826,"start":41771,"enrollment":1634,"conditions":78827,"interventions":78828},"NCT02502812","Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects",[85],"2015-09-24",[14279],[78816,78829,78830],"Clop F2","Innovator",{"trials":78832,"activeCount":97},[],{"trials":78834,"activeCount":97},[],{"trials":78836,"activeCount":97},[],{"trials":78838,"activeCount":97},[],{"intervention":78829,"totalTrials":417,"cells":78840},{"EARLY_PHASE1":78841,"PHASE1":78843,"PHASE2":78849,"PHASE3":78851,"PHASE4":78853,"NA":78855},{"trials":78842,"activeCount":97},[],{"trials":78844,"activeCount":97},[78845],{"nctId":78823,"briefTitle":78824,"status":155,"phases":78846,"primaryCompletion":78826,"completion":78826,"start":41771,"enrollment":1634,"conditions":78847,"interventions":78848},[85],[14279],[78816,78829,78830],{"trials":78850,"activeCount":97},[],{"trials":78852,"activeCount":97},[],{"trials":78854,"activeCount":97},[],{"trials":78856,"activeCount":97},[],{"intervention":78830,"totalTrials":417,"cells":78858},{"EARLY_PHASE1":78859,"PHASE1":78861,"PHASE2":78867,"PHASE3":78869,"PHASE4":78871,"NA":78873},{"trials":78860,"activeCount":97},[],{"trials":78862,"activeCount":97},[78863],{"nctId":78823,"briefTitle":78824,"status":155,"phases":78864,"primaryCompletion":78826,"completion":78826,"start":41771,"enrollment":1634,"conditions":78865,"interventions":78866},[85],[14279],[78816,78829,78830],{"trials":78868,"activeCount":97},[],{"trials":78870,"activeCount":97},[],{"trials":78872,"activeCount":97},[],{"trials":78874,"activeCount":97},[],{"intervention":78876,"totalTrials":417,"cells":78877},"GSK2251052 750 mg",{"EARLY_PHASE1":78878,"PHASE1":78880,"PHASE2":78894,"PHASE3":78896,"PHASE4":78898,"NA":78900},{"trials":78879,"activeCount":97},[],{"trials":78881,"activeCount":97},[78882],{"nctId":78883,"briefTitle":78884,"status":145,"phases":78885,"primaryCompletion":78886,"completion":78886,"start":18370,"enrollment":1720,"conditions":78887,"interventions":78888},"NCT01495065","A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers",[85],"2012-02-17",[41283],[78876,78889,78890,78891,78892,78893],"GSK2251052 1500 mg","GSK2251052 1500 mg BID","GSK2251052 2250 mg","GSK2251052 3000 mg","GSK2251052 0.9% saline",{"trials":78895,"activeCount":97},[],{"trials":78897,"activeCount":97},[],{"trials":78899,"activeCount":97},[],{"trials":78901,"activeCount":97},[],{"intervention":78889,"totalTrials":417,"cells":78903},{"EARLY_PHASE1":78904,"PHASE1":78906,"PHASE2":78912,"PHASE3":78914,"PHASE4":78916,"NA":78918},{"trials":78905,"activeCount":97},[],{"trials":78907,"activeCount":97},[78908],{"nctId":78883,"briefTitle":78884,"status":145,"phases":78909,"primaryCompletion":78886,"completion":78886,"start":18370,"enrollment":1720,"conditions":78910,"interventions":78911},[85],[41283],[78876,78889,78890,78891,78892,78893],{"trials":78913,"activeCount":97},[],{"trials":78915,"activeCount":97},[],{"trials":78917,"activeCount":97},[],{"trials":78919,"activeCount":97},[],{"intervention":78890,"totalTrials":417,"cells":78921},{"EARLY_PHASE1":78922,"PHASE1":78924,"PHASE2":78930,"PHASE3":78932,"PHASE4":78934,"NA":78936},{"trials":78923,"activeCount":97},[],{"trials":78925,"activeCount":97},[78926],{"nctId":78883,"briefTitle":78884,"status":145,"phases":78927,"primaryCompletion":78886,"completion":78886,"start":18370,"enrollment":1720,"conditions":78928,"interventions":78929},[85],[41283],[78876,78889,78890,78891,78892,78893],{"trials":78931,"activeCount":97},[],{"trials":78933,"activeCount":97},[],{"trials":78935,"activeCount":97},[],{"trials":78937,"activeCount":97},[],{"intervention":78891,"totalTrials":417,"cells":78939},{"EARLY_PHASE1":78940,"PHASE1":78942,"PHASE2":78948,"PHASE3":78950,"PHASE4":78952,"NA":78954},{"trials":78941,"activeCount":97},[],{"trials":78943,"activeCount":97},[78944],{"nctId":78883,"briefTitle":78884,"status":145,"phases":78945,"primaryCompletion":78886,"completion":78886,"start":18370,"enrollment":1720,"conditions":78946,"interventions":78947},[85],[41283],[78876,78889,78890,78891,78892,78893],{"trials":78949,"activeCount":97},[],{"trials":78951,"activeCount":97},[],{"trials":78953,"activeCount":97},[],{"trials":78955,"activeCount":97},[],{"intervention":78892,"totalTrials":417,"cells":78957},{"EARLY_PHASE1":78958,"PHASE1":78960,"PHASE2":78966,"PHASE3":78968,"PHASE4":78970,"NA":78972},{"trials":78959,"activeCount":97},[],{"trials":78961,"activeCount":97},[78962],{"nctId":78883,"briefTitle":78884,"status":145,"phases":78963,"primaryCompletion":78886,"completion":78886,"start":18370,"enrollment":1720,"conditions":78964,"interventions":78965},[85],[41283],[78876,78889,78890,78891,78892,78893],{"trials":78967,"activeCount":97},[],{"trials":78969,"activeCount":97},[],{"trials":78971,"activeCount":97},[],{"trials":78973,"activeCount":97},[],{"intervention":78893,"totalTrials":417,"cells":78975},{"EARLY_PHASE1":78976,"PHASE1":78978,"PHASE2":78984,"PHASE3":78986,"PHASE4":78988,"NA":78990},{"trials":78977,"activeCount":97},[],{"trials":78979,"activeCount":97},[78980],{"nctId":78883,"briefTitle":78884,"status":145,"phases":78981,"primaryCompletion":78886,"completion":78886,"start":18370,"enrollment":1720,"conditions":78982,"interventions":78983},[85],[41283],[78876,78889,78890,78891,78892,78893],{"trials":78985,"activeCount":97},[],{"trials":78987,"activeCount":97},[],{"trials":78989,"activeCount":97},[],{"trials":78991,"activeCount":97},[],{"intervention":78993,"totalTrials":417,"cells":78994},"Glycine Transporter-1 inhibitor",{"EARLY_PHASE1":78995,"PHASE1":78997,"PHASE2":79005,"PHASE3":79007,"PHASE4":79009,"NA":79011},{"trials":78996,"activeCount":97},[],{"trials":78998,"activeCount":97},[78999],{"nctId":79000,"briefTitle":79001,"status":145,"phases":79002,"primaryCompletion":9133,"completion":2794,"start":5018,"enrollment":1736,"conditions":79003,"interventions":79004},"NCT00929370","A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.",[85],[11346],[78993],{"trials":79006,"activeCount":97},[],{"trials":79008,"activeCount":97},[],{"trials":79010,"activeCount":97},[],{"trials":79012,"activeCount":97},[],{"intervention":41077,"totalTrials":417,"cells":79014},{"EARLY_PHASE1":79015,"PHASE1":79017,"PHASE2":79023,"PHASE3":79025,"PHASE4":79027,"NA":79029},{"trials":79016,"activeCount":97},[],{"trials":79018,"activeCount":97},[79019],{"nctId":41071,"briefTitle":41072,"status":145,"phases":79020,"primaryCompletion":41074,"completion":41074,"start":40041,"enrollment":2797,"conditions":79021,"interventions":79022},[85],[41061],[41048,41077,41078],{"trials":79024,"activeCount":97},[],{"trials":79026,"activeCount":97},[],{"trials":79028,"activeCount":97},[],{"trials":79030,"activeCount":97},[],{"intervention":41078,"totalTrials":417,"cells":79032},{"EARLY_PHASE1":79033,"PHASE1":79035,"PHASE2":79041,"PHASE3":79043,"PHASE4":79045,"NA":79047},{"trials":79034,"activeCount":97},[],{"trials":79036,"activeCount":97},[79037],{"nctId":41071,"briefTitle":41072,"status":145,"phases":79038,"primaryCompletion":41074,"completion":41074,"start":40041,"enrollment":2797,"conditions":79039,"interventions":79040},[85],[41061],[41048,41077,41078],{"trials":79042,"activeCount":97},[],{"trials":79044,"activeCount":97},[],{"trials":79046,"activeCount":97},[],{"trials":79048,"activeCount":97},[],{"intervention":59828,"totalTrials":417,"cells":79050},{"EARLY_PHASE1":79051,"PHASE1":79053,"PHASE2":79059,"PHASE3":79061,"PHASE4":79063,"NA":79065},{"trials":79052,"activeCount":97},[],{"trials":79054,"activeCount":97},[79055],{"nctId":59822,"briefTitle":59823,"status":155,"phases":79056,"primaryCompletion":46691,"completion":46691,"start":59825,"enrollment":3672,"conditions":79057,"interventions":79058},[85],[18],[59828,59829,59830,39362],{"trials":79060,"activeCount":97},[],{"trials":79062,"activeCount":97},[],{"trials":79064,"activeCount":97},[],{"trials":79066,"activeCount":97},[],{"intervention":59829,"totalTrials":417,"cells":79068},{"EARLY_PHASE1":79069,"PHASE1":79071,"PHASE2":79077,"PHASE3":79079,"PHASE4":79081,"NA":79083},{"trials":79070,"activeCount":97},[],{"trials":79072,"activeCount":97},[79073],{"nctId":59822,"briefTitle":59823,"status":155,"phases":79074,"primaryCompletion":46691,"completion":46691,"start":59825,"enrollment":3672,"conditions":79075,"interventions":79076},[85],[18],[59828,59829,59830,39362],{"trials":79078,"activeCount":97},[],{"trials":79080,"activeCount":97},[],{"trials":79082,"activeCount":97},[],{"trials":79084,"activeCount":97},[],{"intervention":79086,"totalTrials":417,"cells":79087},"GW642444M for 14 days",{"EARLY_PHASE1":79088,"PHASE1":79090,"PHASE2":79098,"PHASE3":79100,"PHASE4":79102,"NA":79104},{"trials":79089,"activeCount":97},[],{"trials":79091,"activeCount":97},[79092],{"nctId":79093,"briefTitle":79094,"status":155,"phases":79095,"primaryCompletion":59392,"completion":59392,"start":15621,"enrollment":710,"conditions":79096,"interventions":79097},"NCT00469040","Safety, Blood Levels and Effects of GW642444",[85],[15],[79086],{"trials":79099,"activeCount":97},[],{"trials":79101,"activeCount":97},[],{"trials":79103,"activeCount":97},[],{"trials":79105,"activeCount":97},[],{"intervention":79107,"totalTrials":417,"cells":79108},"GSK2190915 Solution.",{"EARLY_PHASE1":79109,"PHASE1":79111,"PHASE2":79126,"PHASE3":79128,"PHASE4":79130,"NA":79132},{"trials":79110,"activeCount":97},[],{"trials":79112,"activeCount":97},[79113],{"nctId":79114,"briefTitle":79115,"status":155,"phases":79116,"primaryCompletion":79117,"completion":79117,"start":79118,"enrollment":613,"conditions":79119,"interventions":79120},"NCT02224521","GSK2190915A - Bioavailability Study",[85],"2010-06-08","2009-04-20",[18],[79107,79121,79122,79123,79124,79125],"GSK2190915 Granule","GSK2190915 Semi-solid Lipid","GSK2190915 Liquid Lipid","GSK2190915 Milled","GSK2190915 Micronised",{"trials":79127,"activeCount":97},[],{"trials":79129,"activeCount":97},[],{"trials":79131,"activeCount":97},[],{"trials":79133,"activeCount":97},[],{"intervention":79121,"totalTrials":417,"cells":79135},{"EARLY_PHASE1":79136,"PHASE1":79138,"PHASE2":79144,"PHASE3":79146,"PHASE4":79148,"NA":79150},{"trials":79137,"activeCount":97},[],{"trials":79139,"activeCount":97},[79140],{"nctId":79114,"briefTitle":79115,"status":155,"phases":79141,"primaryCompletion":79117,"completion":79117,"start":79118,"enrollment":613,"conditions":79142,"interventions":79143},[85],[18],[79107,79121,79122,79123,79124,79125],{"trials":79145,"activeCount":97},[],{"trials":79147,"activeCount":97},[],{"trials":79149,"activeCount":97},[],{"trials":79151,"activeCount":97},[],{"intervention":79122,"totalTrials":417,"cells":79153},{"EARLY_PHASE1":79154,"PHASE1":79156,"PHASE2":79162,"PHASE3":79164,"PHASE4":79166,"NA":79168},{"trials":79155,"activeCount":97},[],{"trials":79157,"activeCount":97},[79158],{"nctId":79114,"briefTitle":79115,"status":155,"phases":79159,"primaryCompletion":79117,"completion":79117,"start":79118,"enrollment":613,"conditions":79160,"interventions":79161},[85],[18],[79107,79121,79122,79123,79124,79125],{"trials":79163,"activeCount":97},[],{"trials":79165,"activeCount":97},[],{"trials":79167,"activeCount":97},[],{"trials":79169,"activeCount":97},[],{"intervention":79123,"totalTrials":417,"cells":79171},{"EARLY_PHASE1":79172,"PHASE1":79174,"PHASE2":79180,"PHASE3":79182,"PHASE4":79184,"NA":79186},{"trials":79173,"activeCount":97},[],{"trials":79175,"activeCount":97},[79176],{"nctId":79114,"briefTitle":79115,"status":155,"phases":79177,"primaryCompletion":79117,"completion":79117,"start":79118,"enrollment":613,"conditions":79178,"interventions":79179},[85],[18],[79107,79121,79122,79123,79124,79125],{"trials":79181,"activeCount":97},[],{"trials":79183,"activeCount":97},[],{"trials":79185,"activeCount":97},[],{"trials":79187,"activeCount":97},[],{"intervention":79124,"totalTrials":417,"cells":79189},{"EARLY_PHASE1":79190,"PHASE1":79192,"PHASE2":79198,"PHASE3":79200,"PHASE4":79202,"NA":79204},{"trials":79191,"activeCount":97},[],{"trials":79193,"activeCount":97},[79194],{"nctId":79114,"briefTitle":79115,"status":155,"phases":79195,"primaryCompletion":79117,"completion":79117,"start":79118,"enrollment":613,"conditions":79196,"interventions":79197},[85],[18],[79107,79121,79122,79123,79124,79125],{"trials":79199,"activeCount":97},[],{"trials":79201,"activeCount":97},[],{"trials":79203,"activeCount":97},[],{"trials":79205,"activeCount":97},[],{"intervention":79125,"totalTrials":417,"cells":79207},{"EARLY_PHASE1":79208,"PHASE1":79210,"PHASE2":79216,"PHASE3":79218,"PHASE4":79220,"NA":79222},{"trials":79209,"activeCount":97},[],{"trials":79211,"activeCount":97},[79212],{"nctId":79114,"briefTitle":79115,"status":155,"phases":79213,"primaryCompletion":79117,"completion":79117,"start":79118,"enrollment":613,"conditions":79214,"interventions":79215},[85],[18],[79107,79121,79122,79123,79124,79125],{"trials":79217,"activeCount":97},[],{"trials":79219,"activeCount":97},[],{"trials":79221,"activeCount":97},[],{"trials":79223,"activeCount":97},[],{"intervention":79225,"totalTrials":417,"cells":79226},"Palbociclib",{"EARLY_PHASE1":79227,"PHASE1":79229,"PHASE2":79238,"PHASE3":79240,"PHASE4":79242,"NA":79244},{"trials":79228,"activeCount":97},[],{"trials":79230,"activeCount":97},[79231],{"nctId":79232,"briefTitle":79233,"status":155,"phases":79234,"primaryCompletion":158,"completion":158,"start":79235,"enrollment":695,"conditions":79236,"interventions":79237},"NCT02065063","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors",[85],"2014-04-22",[36],[3048,79225],{"trials":79239,"activeCount":97},[],{"trials":79241,"activeCount":97},[],{"trials":79243,"activeCount":97},[],{"trials":79245,"activeCount":97},[],{"intervention":79247,"totalTrials":417,"cells":79248},"GSK679586",{"EARLY_PHASE1":79249,"PHASE1":79251,"PHASE2":79259,"PHASE3":79261,"PHASE4":79263,"NA":79265},{"trials":79250,"activeCount":97},[],{"trials":79252,"activeCount":97},[79253],{"nctId":79254,"briefTitle":79255,"status":155,"phases":79256,"primaryCompletion":9737,"completion":9737,"start":4843,"enrollment":904,"conditions":79257,"interventions":79258},"NCT00411814","A Study Of GSK679586A When Infused Into Healthy And Mild Asthmatic Volunteers",[85],[18],[79247],{"trials":79260,"activeCount":97},[],{"trials":79262,"activeCount":97},[],{"trials":79264,"activeCount":97},[],{"trials":79266,"activeCount":97},[],{"intervention":45438,"totalTrials":417,"cells":79268},{"EARLY_PHASE1":79269,"PHASE1":79271,"PHASE2":79277,"PHASE3":79279,"PHASE4":79281,"NA":79283},{"trials":79270,"activeCount":97},[],{"trials":79272,"activeCount":97},[79273],{"nctId":45430,"briefTitle":45431,"status":155,"phases":79274,"primaryCompletion":45433,"completion":45433,"start":19218,"enrollment":45434,"conditions":79275,"interventions":79276},[85],[3298],[45423,45437,45438,20325],{"trials":79278,"activeCount":97},[],{"trials":79280,"activeCount":97},[],{"trials":79282,"activeCount":97},[],{"trials":79284,"activeCount":97},[],{"intervention":22241,"totalTrials":417,"cells":79286},{"EARLY_PHASE1":79287,"PHASE1":79289,"PHASE2":79295,"PHASE3":79297,"PHASE4":79299,"NA":79301},{"trials":79288,"activeCount":97},[],{"trials":79290,"activeCount":97},[79291],{"nctId":22234,"briefTitle":22235,"status":155,"phases":79292,"primaryCompletion":22237,"completion":22237,"start":22238,"enrollment":93,"conditions":79293,"interventions":79294},[85],[21691],[22241,22242,22243],{"trials":79296,"activeCount":97},[],{"trials":79298,"activeCount":97},[],{"trials":79300,"activeCount":97},[],{"trials":79302,"activeCount":97},[],{"intervention":22243,"totalTrials":417,"cells":79304},{"EARLY_PHASE1":79305,"PHASE1":79307,"PHASE2":79313,"PHASE3":79315,"PHASE4":79317,"NA":79319},{"trials":79306,"activeCount":97},[],{"trials":79308,"activeCount":97},[79309],{"nctId":22234,"briefTitle":22235,"status":155,"phases":79310,"primaryCompletion":22237,"completion":22237,"start":22238,"enrollment":93,"conditions":79311,"interventions":79312},[85],[21691],[22241,22242,22243],{"trials":79314,"activeCount":97},[],{"trials":79316,"activeCount":97},[],{"trials":79318,"activeCount":97},[],{"trials":79320,"activeCount":97},[],{"intervention":79322,"totalTrials":417,"cells":79323},"Terbinafine 250 mg",{"EARLY_PHASE1":79324,"PHASE1":79326,"PHASE2":79337,"PHASE3":79339,"PHASE4":79341,"NA":79343},{"trials":79325,"activeCount":97},[],{"trials":79327,"activeCount":97},[79328],{"nctId":79329,"briefTitle":79330,"status":155,"phases":79331,"primaryCompletion":79332,"completion":79332,"start":79333,"enrollment":255,"conditions":79334,"interventions":79336},"NCT01772212","Bioequivalence Study for Terbinafine 250 mg",[85],"2011-03-15","2011-02-24",[79335],"Mycoses",[79322,79322],{"trials":79338,"activeCount":97},[],{"trials":79340,"activeCount":97},[],{"trials":79342,"activeCount":97},[],{"trials":79344,"activeCount":97},[],{"intervention":79346,"totalTrials":417,"cells":79347},"SB- 773812 60 mg",{"EARLY_PHASE1":79348,"PHASE1":79350,"PHASE2":79360,"PHASE3":79362,"PHASE4":79364,"NA":79366},{"trials":79349,"activeCount":97},[],{"trials":79351,"activeCount":97},[79352],{"nctId":79353,"briefTitle":79354,"status":155,"phases":79355,"primaryCompletion":39437,"completion":39437,"start":79356,"enrollment":1634,"conditions":79357,"interventions":79358},"NCT00500201","A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets.",[85],"2007-05-24",[11346],[79346,79359],"SB- 773812 120 mg",{"trials":79361,"activeCount":97},[],{"trials":79363,"activeCount":97},[],{"trials":79365,"activeCount":97},[],{"trials":79367,"activeCount":97},[],{"intervention":79359,"totalTrials":417,"cells":79369},{"EARLY_PHASE1":79370,"PHASE1":79372,"PHASE2":79378,"PHASE3":79380,"PHASE4":79382,"NA":79384},{"trials":79371,"activeCount":97},[],{"trials":79373,"activeCount":97},[79374],{"nctId":79353,"briefTitle":79354,"status":155,"phases":79375,"primaryCompletion":39437,"completion":39437,"start":79356,"enrollment":1634,"conditions":79376,"interventions":79377},[85],[11346],[79346,79359],{"trials":79379,"activeCount":97},[],{"trials":79381,"activeCount":97},[],{"trials":79383,"activeCount":97},[],{"trials":79385,"activeCount":97},[],{"intervention":79387,"totalTrials":417,"cells":79388},"Albendazole",{"EARLY_PHASE1":79389,"PHASE1":79391,"PHASE2":79400,"PHASE3":79402,"PHASE4":79404,"NA":79406},{"trials":79390,"activeCount":97},[],{"trials":79392,"activeCount":97},[79393],{"nctId":79394,"briefTitle":79395,"status":155,"phases":79396,"primaryCompletion":3389,"completion":2295,"start":3389,"enrollment":904,"conditions":79397,"interventions":79399},"NCT01755637","Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population",[85],[79398],"Helminthiasis",[79387],{"trials":79401,"activeCount":97},[],{"trials":79403,"activeCount":97},[],{"trials":79405,"activeCount":97},[],{"trials":79407,"activeCount":97},[],{"intervention":9867,"totalTrials":417,"cells":79409},{"EARLY_PHASE1":79410,"PHASE1":79412,"PHASE2":79418,"PHASE3":79420,"PHASE4":79422,"NA":79424},{"trials":79411,"activeCount":97},[],{"trials":79413,"activeCount":97},[79414],{"nctId":9859,"briefTitle":9860,"status":155,"phases":79415,"primaryCompletion":9862,"completion":9862,"start":9863,"enrollment":370,"conditions":79416,"interventions":79417},[85],[9865],[9867,9868,9869,9870,9828],{"trials":79419,"activeCount":97},[],{"trials":79421,"activeCount":97},[],{"trials":79423,"activeCount":97},[],{"trials":79425,"activeCount":97},[],{"intervention":9868,"totalTrials":417,"cells":79427},{"EARLY_PHASE1":79428,"PHASE1":79430,"PHASE2":79436,"PHASE3":79438,"PHASE4":79440,"NA":79442},{"trials":79429,"activeCount":97},[],{"trials":79431,"activeCount":97},[79432],{"nctId":9859,"briefTitle":9860,"status":155,"phases":79433,"primaryCompletion":9862,"completion":9862,"start":9863,"enrollment":370,"conditions":79434,"interventions":79435},[85],[9865],[9867,9868,9869,9870,9828],{"trials":79437,"activeCount":97},[],{"trials":79439,"activeCount":97},[],{"trials":79441,"activeCount":97},[],{"trials":79443,"activeCount":97},[],{"intervention":9869,"totalTrials":417,"cells":79445},{"EARLY_PHASE1":79446,"PHASE1":79448,"PHASE2":79454,"PHASE3":79456,"PHASE4":79458,"NA":79460},{"trials":79447,"activeCount":97},[],{"trials":79449,"activeCount":97},[79450],{"nctId":9859,"briefTitle":9860,"status":155,"phases":79451,"primaryCompletion":9862,"completion":9862,"start":9863,"enrollment":370,"conditions":79452,"interventions":79453},[85],[9865],[9867,9868,9869,9870,9828],{"trials":79455,"activeCount":97},[],{"trials":79457,"activeCount":97},[],{"trials":79459,"activeCount":97},[],{"trials":79461,"activeCount":97},[],{"intervention":9870,"totalTrials":417,"cells":79463},{"EARLY_PHASE1":79464,"PHASE1":79466,"PHASE2":79472,"PHASE3":79474,"PHASE4":79476,"NA":79478},{"trials":79465,"activeCount":97},[],{"trials":79467,"activeCount":97},[79468],{"nctId":9859,"briefTitle":9860,"status":155,"phases":79469,"primaryCompletion":9862,"completion":9862,"start":9863,"enrollment":370,"conditions":79470,"interventions":79471},[85],[9865],[9867,9868,9869,9870,9828],{"trials":79473,"activeCount":97},[],{"trials":79475,"activeCount":97},[],{"trials":79477,"activeCount":97},[],{"trials":79479,"activeCount":97},[],{"intervention":59758,"totalTrials":417,"cells":79481},{"EARLY_PHASE1":79482,"PHASE1":79484,"PHASE2":79490,"PHASE3":79492,"PHASE4":79494,"NA":79496},{"trials":79483,"activeCount":97},[],{"trials":79485,"activeCount":97},[79486],{"nctId":59751,"briefTitle":59752,"status":155,"phases":79487,"primaryCompletion":59754,"completion":59754,"start":59755,"enrollment":1736,"conditions":79488,"interventions":79489},[85],[17996],[59758,59725],{"trials":79491,"activeCount":97},[],{"trials":79493,"activeCount":97},[],{"trials":79495,"activeCount":97},[],{"trials":79497,"activeCount":97},[],{"intervention":7397,"totalTrials":417,"cells":79499},{"EARLY_PHASE1":79500,"PHASE1":79502,"PHASE2":79508,"PHASE3":79510,"PHASE4":79512,"NA":79514},{"trials":79501,"activeCount":97},[],{"trials":79503,"activeCount":97},[79504],{"nctId":7388,"briefTitle":7389,"status":145,"phases":79505,"primaryCompletion":7391,"completion":7392,"start":7393,"enrollment":7394,"conditions":79506,"interventions":79507},[85],[267],[7397,134,2397],{"trials":79509,"activeCount":97},[],{"trials":79511,"activeCount":97},[],{"trials":79513,"activeCount":97},[],{"trials":79515,"activeCount":97},[],{"intervention":42405,"totalTrials":417,"cells":79517},{"EARLY_PHASE1":79518,"PHASE1":79520,"PHASE2":79526,"PHASE3":79528,"PHASE4":79530,"NA":79532},{"trials":79519,"activeCount":97},[],{"trials":79521,"activeCount":97},[79522],{"nctId":42397,"briefTitle":42398,"status":155,"phases":79523,"primaryCompletion":960,"completion":960,"start":42400,"enrollment":2282,"conditions":79524,"interventions":79525},[85],[42402,42403],[42379,42405,39369],{"trials":79527,"activeCount":97},[],{"trials":79529,"activeCount":97},[],{"trials":79531,"activeCount":97},[],{"trials":79533,"activeCount":97},[],{"intervention":166,"totalTrials":417,"cells":79535},{"EARLY_PHASE1":79536,"PHASE1":79538,"PHASE2":79544,"PHASE3":79546,"PHASE4":79548,"NA":79550},{"trials":79537,"activeCount":97},[],{"trials":79539,"activeCount":97},[79540],{"nctId":153,"briefTitle":154,"status":155,"phases":79541,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":79542,"interventions":79543},[85],[107],[162,163,137,164,165,166,167,168,92,169,170],{"trials":79545,"activeCount":97},[],{"trials":79547,"activeCount":97},[],{"trials":79549,"activeCount":97},[],{"trials":79551,"activeCount":97},[],{"intervention":167,"totalTrials":417,"cells":79553},{"EARLY_PHASE1":79554,"PHASE1":79556,"PHASE2":79562,"PHASE3":79564,"PHASE4":79566,"NA":79568},{"trials":79555,"activeCount":97},[],{"trials":79557,"activeCount":97},[79558],{"nctId":153,"briefTitle":154,"status":155,"phases":79559,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":79560,"interventions":79561},[85],[107],[162,163,137,164,165,166,167,168,92,169,170],{"trials":79563,"activeCount":97},[],{"trials":79565,"activeCount":97},[],{"trials":79567,"activeCount":97},[],{"trials":79569,"activeCount":97},[],{"intervention":168,"totalTrials":417,"cells":79571},{"EARLY_PHASE1":79572,"PHASE1":79574,"PHASE2":79580,"PHASE3":79582,"PHASE4":79584,"NA":79586},{"trials":79573,"activeCount":97},[],{"trials":79575,"activeCount":97},[79576],{"nctId":153,"briefTitle":154,"status":155,"phases":79577,"primaryCompletion":157,"completion":157,"start":158,"enrollment":159,"conditions":79578,"interventions":79579},[85],[107],[162,163,137,164,165,166,167,168,92,169,170],{"trials":79581,"activeCount":97},[],{"trials":79583,"activeCount":97},[],{"trials":79585,"activeCount":97},[],{"trials":79587,"activeCount":97},[],{"intervention":79589,"totalTrials":417,"cells":79590},"Topiramate coated",{"EARLY_PHASE1":79591,"PHASE1":79593,"PHASE2":79604,"PHASE3":79606,"PHASE4":79608,"NA":79610},{"trials":79592,"activeCount":97},[],{"trials":79594,"activeCount":97},[79595],{"nctId":79596,"briefTitle":79597,"status":155,"phases":79598,"primaryCompletion":79599,"completion":79599,"start":79600,"enrollment":93,"conditions":79601,"interventions":79602},"NCT01439438","Topiramate Bioequivalence Study Brazil - Fast",[85],"2011-09-11","2011-07-22",[38346],[79589,79603],"Topamax® coated",{"trials":79605,"activeCount":97},[],{"trials":79607,"activeCount":97},[],{"trials":79609,"activeCount":97},[],{"trials":79611,"activeCount":97},[],{"intervention":79603,"totalTrials":417,"cells":79613},{"EARLY_PHASE1":79614,"PHASE1":79616,"PHASE2":79622,"PHASE3":79624,"PHASE4":79626,"NA":79628},{"trials":79615,"activeCount":97},[],{"trials":79617,"activeCount":97},[79618],{"nctId":79596,"briefTitle":79597,"status":155,"phases":79619,"primaryCompletion":79599,"completion":79599,"start":79600,"enrollment":93,"conditions":79620,"interventions":79621},[85],[38346],[79589,79603],{"trials":79623,"activeCount":97},[],{"trials":79625,"activeCount":97},[],{"trials":79627,"activeCount":97},[],{"trials":79629,"activeCount":97},[],{"intervention":4073,"totalTrials":417,"cells":79631},{"EARLY_PHASE1":79632,"PHASE1":79634,"PHASE2":79640,"PHASE3":79642,"PHASE4":79644,"NA":79646},{"trials":79633,"activeCount":97},[],{"trials":79635,"activeCount":97},[79636],{"nctId":4065,"briefTitle":4066,"status":155,"phases":79637,"primaryCompletion":4068,"completion":4068,"start":4069,"enrollment":628,"conditions":79638,"interventions":79639},[85],[4071],[4032,4073,4074],{"trials":79641,"activeCount":97},[],{"trials":79643,"activeCount":97},[],{"trials":79645,"activeCount":97},[],{"trials":79647,"activeCount":97},[],{"intervention":4074,"totalTrials":417,"cells":79649},{"EARLY_PHASE1":79650,"PHASE1":79652,"PHASE2":79658,"PHASE3":79660,"PHASE4":79662,"NA":79664},{"trials":79651,"activeCount":97},[],{"trials":79653,"activeCount":97},[79654],{"nctId":4065,"briefTitle":4066,"status":155,"phases":79655,"primaryCompletion":4068,"completion":4068,"start":4069,"enrollment":628,"conditions":79656,"interventions":79657},[85],[4071],[4032,4073,4074],{"trials":79659,"activeCount":97},[],{"trials":79661,"activeCount":97},[],{"trials":79663,"activeCount":97},[],{"trials":79665,"activeCount":97},[],{"intervention":79667,"totalTrials":417,"cells":79668},"GSK2857916",{"EARLY_PHASE1":79669,"PHASE1":79671,"PHASE2":79682,"PHASE3":79684,"PHASE4":79686,"NA":79688},{"trials":79670,"activeCount":97},[],{"trials":79672,"activeCount":97},[79673],{"nctId":79674,"briefTitle":79675,"status":155,"phases":79676,"primaryCompletion":79677,"completion":79678,"start":79679,"enrollment":14542,"conditions":79680,"interventions":79681},"NCT02064387","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916",[85],"2018-08-31","2019-08-01","2014-07-29",[278],[79667],{"trials":79683,"activeCount":97},[],{"trials":79685,"activeCount":97},[],{"trials":79687,"activeCount":97},[],{"trials":79689,"activeCount":97},[],{"intervention":39924,"totalTrials":417,"cells":79691},{"EARLY_PHASE1":79692,"PHASE1":79694,"PHASE2":79700,"PHASE3":79702,"PHASE4":79704,"NA":79706},{"trials":79693,"activeCount":97},[],{"trials":79695,"activeCount":97},[79696],{"nctId":39917,"briefTitle":39918,"status":155,"phases":79697,"primaryCompletion":39920,"completion":39920,"start":39921,"enrollment":14542,"conditions":79698,"interventions":79699},[85],[39481],[39924,39884],{"trials":79701,"activeCount":97},[],{"trials":79703,"activeCount":97},[],{"trials":79705,"activeCount":97},[],{"trials":79707,"activeCount":97},[],{"intervention":79709,"totalTrials":417,"cells":79710},"SRT2379",{"EARLY_PHASE1":79711,"PHASE1":79713,"PHASE2":79722,"PHASE3":79724,"PHASE4":79726,"NA":79728},{"trials":79712,"activeCount":97},[],{"trials":79714,"activeCount":97},[79715],{"nctId":79716,"briefTitle":79717,"status":155,"phases":79718,"primaryCompletion":79719,"completion":79719,"start":6316,"enrollment":6482,"conditions":79720,"interventions":79721},"NCT01018628","A Clinical Study to Assess the Safety and Pharmacokinetics of SRT2379 in Normal Healthy Male Volunteers",[85],"2010-08-06",[27],[79709],{"trials":79723,"activeCount":97},[],{"trials":79725,"activeCount":97},[],{"trials":79727,"activeCount":97},[],{"trials":79729,"activeCount":97},[],{"intervention":79731,"totalTrials":417,"cells":79732},"Griseofulvin 500 mg",{"EARLY_PHASE1":79733,"PHASE1":79735,"PHASE2":79748,"PHASE3":79750,"PHASE4":79752,"NA":79754},{"trials":79734,"activeCount":97},[],{"trials":79736,"activeCount":97},[79737],{"nctId":79738,"briefTitle":79739,"status":155,"phases":79740,"primaryCompletion":79741,"completion":79742,"start":79741,"enrollment":710,"conditions":79743,"interventions":79745},"NCT04318535","Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions",[85],"2020-01-13","2020-02-06",[79744],"Antifungal Agents",[79731,79746,79747],"Griseofulvin 250 mg","Reference Griseofulvin 500 mg",{"trials":79749,"activeCount":97},[],{"trials":79751,"activeCount":97},[],{"trials":79753,"activeCount":97},[],{"trials":79755,"activeCount":97},[],{"intervention":79746,"totalTrials":417,"cells":79757},{"EARLY_PHASE1":79758,"PHASE1":79760,"PHASE2":79766,"PHASE3":79768,"PHASE4":79770,"NA":79772},{"trials":79759,"activeCount":97},[],{"trials":79761,"activeCount":97},[79762],{"nctId":79738,"briefTitle":79739,"status":155,"phases":79763,"primaryCompletion":79741,"completion":79742,"start":79741,"enrollment":710,"conditions":79764,"interventions":79765},[85],[79744],[79731,79746,79747],{"trials":79767,"activeCount":97},[],{"trials":79769,"activeCount":97},[],{"trials":79771,"activeCount":97},[],{"trials":79773,"activeCount":97},[],{"intervention":79747,"totalTrials":417,"cells":79775},{"EARLY_PHASE1":79776,"PHASE1":79778,"PHASE2":79784,"PHASE3":79786,"PHASE4":79788,"NA":79790},{"trials":79777,"activeCount":97},[],{"trials":79779,"activeCount":97},[79780],{"nctId":79738,"briefTitle":79739,"status":155,"phases":79781,"primaryCompletion":79741,"completion":79742,"start":79741,"enrollment":710,"conditions":79782,"interventions":79783},[85],[79744],[79731,79746,79747],{"trials":79785,"activeCount":97},[],{"trials":79787,"activeCount":97},[],{"trials":79789,"activeCount":97},[],{"trials":79791,"activeCount":97},[],{"intervention":79793,"totalTrials":417,"cells":79794},"GSK1995057 single dose",{"EARLY_PHASE1":79795,"PHASE1":79797,"PHASE2":79807,"PHASE3":79809,"PHASE4":79811,"NA":79813},{"trials":79796,"activeCount":97},[],{"trials":79798,"activeCount":97},[79799],{"nctId":79800,"briefTitle":79801,"status":155,"phases":79802,"primaryCompletion":79803,"completion":79803,"start":79804,"enrollment":904,"conditions":79805,"interventions":79806},"NCT01476046","Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.",[85],"2012-06-17","2011-03-08",[9855],[79793],{"trials":79808,"activeCount":97},[],{"trials":79810,"activeCount":97},[],{"trials":79812,"activeCount":97},[],{"trials":79814,"activeCount":97},[],{"intervention":79816,"totalTrials":417,"cells":79817},"GSK3439171A",{"EARLY_PHASE1":79818,"PHASE1":79820,"PHASE2":79828,"PHASE3":79830,"PHASE4":79832,"NA":79834},{"trials":79819,"activeCount":97},[],{"trials":79821,"activeCount":97},[79822],{"nctId":79823,"briefTitle":79824,"status":155,"phases":79825,"primaryCompletion":4068,"completion":4068,"start":4911,"enrollment":2321,"conditions":79826,"interventions":79827},"NCT03627494","First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect",[85],[25854],[79816],{"trials":79829,"activeCount":97},[],{"trials":79831,"activeCount":97},[],{"trials":79833,"activeCount":97},[],{"trials":79835,"activeCount":97},[],{"intervention":79837,"totalTrials":417,"cells":79838},"Radiolabelled GSK189075",{"EARLY_PHASE1":79839,"PHASE1":79841,"PHASE2":79849,"PHASE3":79851,"PHASE4":79853,"NA":79855},{"trials":79840,"activeCount":97},[],{"trials":79842,"activeCount":97},[79843],{"nctId":79844,"briefTitle":79845,"status":155,"phases":79846,"start":4843,"enrollment":1720,"conditions":79847,"interventions":79848},"NCT00501683","A Single Dose Of GSK189075 Taken By Mouth Containing Small Amounts Of Radioactivity Studied In Healthy Male Volunteers",[85],[9036,27],[79837],{"trials":79850,"activeCount":97},[],{"trials":79852,"activeCount":97},[],{"trials":79854,"activeCount":97},[],{"trials":79856,"activeCount":97},[],{"intervention":79858,"totalTrials":417,"cells":79859},"warfarin plus albiglutide",{"EARLY_PHASE1":79860,"PHASE1":79862,"PHASE2":79872,"PHASE3":79874,"PHASE4":79876,"NA":79878},{"trials":79861,"activeCount":97},[],{"trials":79863,"activeCount":97},[79864],{"nctId":79865,"briefTitle":79866,"status":155,"phases":79867,"primaryCompletion":79868,"completion":79868,"start":79869,"enrollment":433,"conditions":79870,"interventions":79871},"NCT01147731","A Drug Interaction Study With Albiglutide and Warfarin",[85],"2010-09-09","2010-06-04",[27],[79858],{"trials":79873,"activeCount":97},[],{"trials":79875,"activeCount":97},[],{"trials":79877,"activeCount":97},[],{"trials":79879,"activeCount":97},[],{"intervention":79881,"totalTrials":417,"cells":79882},"GSK706769 & KALETRA",{"EARLY_PHASE1":79883,"PHASE1":79885,"PHASE2":79894,"PHASE3":79896,"PHASE4":79898,"NA":79900},{"trials":79884,"activeCount":97},[],{"trials":79886,"activeCount":97},[79887],{"nctId":79888,"briefTitle":79889,"status":155,"phases":79890,"primaryCompletion":79891,"completion":79891,"start":44528,"enrollment":7438,"conditions":79892,"interventions":79893},"NCT00723775","GSK706769\u002FKALETRA Drug-drug Interaction Study",[85],"2008-11-08",[9343],[79881],{"trials":79895,"activeCount":97},[],{"trials":79897,"activeCount":97},[],{"trials":79899,"activeCount":97},[],{"trials":79901,"activeCount":97},[],{"intervention":62316,"totalTrials":417,"cells":79903},{"EARLY_PHASE1":79904,"PHASE1":79906,"PHASE2":79912,"PHASE3":79914,"PHASE4":79916,"NA":79918},{"trials":79905,"activeCount":97},[],{"trials":79907,"activeCount":97},[79908],{"nctId":62310,"briefTitle":62311,"status":155,"phases":79909,"primaryCompletion":62313,"completion":62313,"start":56233,"enrollment":454,"conditions":79910,"interventions":79911},[85],[39994],[62295,62308,62316,62317],{"trials":79913,"activeCount":97},[],{"trials":79915,"activeCount":97},[],{"trials":79917,"activeCount":97},[],{"trials":79919,"activeCount":97},[],{"intervention":62317,"totalTrials":417,"cells":79921},{"EARLY_PHASE1":79922,"PHASE1":79924,"PHASE2":79930,"PHASE3":79932,"PHASE4":79934,"NA":79936},{"trials":79923,"activeCount":97},[],{"trials":79925,"activeCount":97},[79926],{"nctId":62310,"briefTitle":62311,"status":155,"phases":79927,"primaryCompletion":62313,"completion":62313,"start":56233,"enrollment":454,"conditions":79928,"interventions":79929},[85],[39994],[62295,62308,62316,62317],{"trials":79931,"activeCount":97},[],{"trials":79933,"activeCount":97},[],{"trials":79935,"activeCount":97},[],{"trials":79937,"activeCount":97},[],{"intervention":79939,"totalTrials":417,"cells":79940},"melrilimab",{"EARLY_PHASE1":79941,"PHASE1":79943,"PHASE2":79952,"PHASE3":79954,"PHASE4":79956,"NA":79958},{"trials":79942,"activeCount":97},[],{"trials":79944,"activeCount":97},[79945],{"nctId":79946,"briefTitle":79947,"status":155,"phases":79948,"primaryCompletion":1287,"completion":1287,"start":79949,"enrollment":2282,"conditions":79950,"interventions":79951},"NCT04366349","A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants",[85],"2020-07-21",[5280,18],[79939,79939],{"trials":79953,"activeCount":97},[],{"trials":79955,"activeCount":97},[],{"trials":79957,"activeCount":97},[],{"trials":79959,"activeCount":97},[],{"intervention":5293,"totalTrials":417,"cells":79961},{"EARLY_PHASE1":79962,"PHASE1":79964,"PHASE2":79970,"PHASE3":79972,"PHASE4":79974,"NA":79976},{"trials":79963,"activeCount":97},[],{"trials":79965,"activeCount":97},[79966],{"nctId":5285,"briefTitle":5286,"status":155,"phases":79967,"primaryCompletion":5288,"completion":5288,"start":5289,"enrollment":593,"conditions":79968,"interventions":79969},[85],[5291],[4487,5293,5293],{"trials":79971,"activeCount":97},[],{"trials":79973,"activeCount":97},[],{"trials":79975,"activeCount":97},[],{"trials":79977,"activeCount":97},[],{"intervention":79979,"totalTrials":417,"cells":79980},"GW842470X",{"EARLY_PHASE1":79981,"PHASE1":79983,"PHASE2":79992,"PHASE3":79994,"PHASE4":79996,"NA":79998},{"trials":79982,"activeCount":97},[],{"trials":79984,"activeCount":97},[79985],{"nctId":79986,"briefTitle":79987,"status":155,"phases":79988,"primaryCompletion":79989,"completion":79989,"start":23408,"enrollment":6369,"conditions":79990,"interventions":79991},"NCT00356642","Study Of Single And Ten Day Repeat Atopical Applications Of GW842470X Cream On The Skin Of Patients With Atopic Dermatitis",[85],"2005-12-21",[21691],[79979],{"trials":79993,"activeCount":97},[],{"trials":79995,"activeCount":97},[],{"trials":79997,"activeCount":97},[],{"trials":79999,"activeCount":97},[],{"intervention":80001,"totalTrials":417,"cells":80002},"Chloroquine, Tafenoquine",{"EARLY_PHASE1":80003,"PHASE1":80005,"PHASE2":80014,"PHASE3":80016,"PHASE4":80018,"NA":80020},{"trials":80004,"activeCount":97},[],{"trials":80006,"activeCount":97},[80007],{"nctId":80008,"briefTitle":80009,"status":155,"phases":80010,"primaryCompletion":9317,"completion":9317,"start":80011,"enrollment":37,"conditions":80012,"interventions":80013},"NCT00871156","Tafenoquine\u002FChloroquine DDI Study",[85],"2009-03-24",[3287],[80001],{"trials":80015,"activeCount":97},[],{"trials":80017,"activeCount":97},[],{"trials":80019,"activeCount":97},[],{"trials":80021,"activeCount":97},[],{"intervention":80023,"totalTrials":417,"cells":80024},"1 µg CoV2 SAM",{"EARLY_PHASE1":80025,"PHASE1":80027,"PHASE2":80036,"PHASE3":80038,"PHASE4":80040,"NA":80042},{"trials":80026,"activeCount":97},[],{"trials":80028,"activeCount":97},[80029],{"nctId":80030,"briefTitle":80031,"status":155,"phases":80032,"primaryCompletion":14320,"completion":80033,"start":3256,"enrollment":345,"conditions":80034,"interventions":80035},"NCT04758962","A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults",[85],"2022-04-19",[9840],[80023],{"trials":80037,"activeCount":97},[],{"trials":80039,"activeCount":97},[],{"trials":80041,"activeCount":97},[],{"trials":80043,"activeCount":97},[],{"intervention":80045,"totalTrials":417,"cells":80046},"GSK1120212 plus everolimus",{"EARLY_PHASE1":80047,"PHASE1":80049,"PHASE2":80058,"PHASE3":80060,"PHASE4":80062,"NA":80064},{"trials":80048,"activeCount":97},[],{"trials":80050,"activeCount":97},[80051],{"nctId":80052,"briefTitle":80053,"status":155,"phases":80054,"primaryCompletion":18133,"completion":18133,"start":80055,"enrollment":6482,"conditions":80056,"interventions":80057},"NCT00955773","A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects",[85],"2009-08-17",[36],[80045],{"trials":80059,"activeCount":97},[],{"trials":80061,"activeCount":97},[],{"trials":80063,"activeCount":97},[],{"trials":80065,"activeCount":97},[],{"intervention":80067,"totalTrials":417,"cells":80068},"denosumab 60mg",{"EARLY_PHASE1":80069,"PHASE1":80071,"PHASE2":80081,"PHASE3":80083,"PHASE4":80085,"NA":80087},{"trials":80070,"activeCount":97},[],{"trials":80072,"activeCount":97},[80073],{"nctId":80074,"briefTitle":80075,"status":155,"phases":80076,"primaryCompletion":61055,"completion":61055,"start":80077,"enrollment":6482,"conditions":80078,"interventions":80079},"NCT02135640","China HVT Safety, PK, PD",[85],"2014-07-17",[12138],[80067,80080],"denosumab 120 mg",{"trials":80082,"activeCount":97},[],{"trials":80084,"activeCount":97},[],{"trials":80086,"activeCount":97},[],{"trials":80088,"activeCount":97},[],{"intervention":80080,"totalTrials":417,"cells":80090},{"EARLY_PHASE1":80091,"PHASE1":80093,"PHASE2":80099,"PHASE3":80101,"PHASE4":80103,"NA":80105},{"trials":80092,"activeCount":97},[],{"trials":80094,"activeCount":97},[80095],{"nctId":80074,"briefTitle":80075,"status":155,"phases":80096,"primaryCompletion":61055,"completion":61055,"start":80077,"enrollment":6482,"conditions":80097,"interventions":80098},[85],[12138],[80067,80080],{"trials":80100,"activeCount":97},[],{"trials":80102,"activeCount":97},[],{"trials":80104,"activeCount":97},[],{"trials":80106,"activeCount":97},[],{"intervention":80108,"totalTrials":417,"cells":80109},"Amoxicillin powder for oral suspension (Clamoxyl®) 500mg\u002F5mL",{"EARLY_PHASE1":80110,"PHASE1":80112,"PHASE2":80123,"PHASE3":80125,"PHASE4":80127,"NA":80129},{"trials":80111,"activeCount":97},[],{"trials":80113,"activeCount":97},[80114],{"nctId":80115,"briefTitle":80116,"status":155,"phases":80117,"primaryCompletion":80118,"completion":80118,"start":80119,"enrollment":695,"conditions":80120,"interventions":80121},"NCT01431989","Amoxicillin Bioequivalence Study Brazil - Fast",[85],"2011-06-11","2011-05-27",[6484],[80108,80122],"Amoxil® 500mg\u002F5mL powder for oral suspension",{"trials":80124,"activeCount":97},[],{"trials":80126,"activeCount":97},[],{"trials":80128,"activeCount":97},[],{"trials":80130,"activeCount":97},[],{"intervention":80122,"totalTrials":417,"cells":80132},{"EARLY_PHASE1":80133,"PHASE1":80135,"PHASE2":80141,"PHASE3":80143,"PHASE4":80145,"NA":80147},{"trials":80134,"activeCount":97},[],{"trials":80136,"activeCount":97},[80137],{"nctId":80115,"briefTitle":80116,"status":155,"phases":80138,"primaryCompletion":80118,"completion":80118,"start":80119,"enrollment":695,"conditions":80139,"interventions":80140},[85],[6484],[80108,80122],{"trials":80142,"activeCount":97},[],{"trials":80144,"activeCount":97},[],{"trials":80146,"activeCount":97},[],{"trials":80148,"activeCount":97},[],{"intervention":80150,"totalTrials":417,"cells":80151},"Pumarix™",{"EARLY_PHASE1":80152,"PHASE1":80154,"PHASE2":80166,"PHASE3":80168,"PHASE4":80170,"NA":80172},{"trials":80153,"activeCount":97},[],{"trials":80155,"activeCount":97},[80156],{"nctId":80157,"briefTitle":80158,"status":155,"phases":80159,"primaryCompletion":80160,"completion":80161,"start":80162,"enrollment":22593,"conditions":80163,"interventions":80164},"NCT00510874","Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults",[85],"2008-06-17","2008-10-24","2007-07-28",[21],[80150,80165],"Pandemrix ™",{"trials":80167,"activeCount":97},[],{"trials":80169,"activeCount":97},[],{"trials":80171,"activeCount":97},[],{"trials":80173,"activeCount":97},[],{"intervention":80165,"totalTrials":417,"cells":80175},{"EARLY_PHASE1":80176,"PHASE1":80178,"PHASE2":80184,"PHASE3":80186,"PHASE4":80188,"NA":80190},{"trials":80177,"activeCount":97},[],{"trials":80179,"activeCount":97},[80180],{"nctId":80157,"briefTitle":80158,"status":155,"phases":80181,"primaryCompletion":80160,"completion":80161,"start":80162,"enrollment":22593,"conditions":80182,"interventions":80183},[85],[21],[80150,80165],{"trials":80185,"activeCount":97},[],{"trials":80187,"activeCount":97},[],{"trials":80189,"activeCount":97},[],{"trials":80191,"activeCount":97},[],{"intervention":80193,"totalTrials":417,"cells":80194},"GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A",{"EARLY_PHASE1":80195,"PHASE1":80197,"PHASE2":80207,"PHASE3":80209,"PHASE4":80211,"NA":80213},{"trials":80196,"activeCount":97},[],{"trials":80198,"activeCount":97},[80199],{"nctId":80200,"briefTitle":80201,"status":155,"phases":80202,"primaryCompletion":39093,"completion":39093,"start":80203,"enrollment":345,"conditions":80204,"interventions":80206},"NCT00435396","Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects",[85],"2007-02-22",[80205],"Infections, Cytomegalovirus",[80193],{"trials":80208,"activeCount":97},[],{"trials":80210,"activeCount":97},[],{"trials":80212,"activeCount":97},[],{"trials":80214,"activeCount":97},[],{"intervention":80216,"totalTrials":417,"cells":80217},"Cyclosporine",{"EARLY_PHASE1":80218,"PHASE1":80220,"PHASE2":80230,"PHASE3":80232,"PHASE4":80234,"NA":80236},{"trials":80219,"activeCount":97},[],{"trials":80221,"activeCount":97},[80222],{"nctId":80223,"briefTitle":80224,"status":155,"phases":80225,"primaryCompletion":80226,"completion":80226,"start":80227,"enrollment":12202,"conditions":80228,"interventions":80229},"NCT02281370","Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects",[85],"2014-12-24","2014-11-05",[33672],[23772,80216],{"trials":80231,"activeCount":97},[],{"trials":80233,"activeCount":97},[],{"trials":80235,"activeCount":97},[],{"trials":80237,"activeCount":97},[],{"intervention":80239,"totalTrials":417,"cells":80240},"GSK598809 new formulation",{"EARLY_PHASE1":80241,"PHASE1":80243,"PHASE2":80253,"PHASE3":80255,"PHASE4":80257,"NA":80259},{"trials":80242,"activeCount":97},[],{"trials":80244,"activeCount":97},[80245],{"nctId":80246,"briefTitle":80247,"status":155,"phases":80248,"primaryCompletion":32283,"completion":32283,"start":80249,"enrollment":433,"conditions":80250,"interventions":80251},"NCT00728897","A Healthy Volunteer Study to Investigate the Relative Bioavailability of Two Forms of GSK598809 Capsules.",[85],"2008-07-02",[39123],[80239,80252],"GSK598809 old formulation",{"trials":80254,"activeCount":97},[],{"trials":80256,"activeCount":97},[],{"trials":80258,"activeCount":97},[],{"trials":80260,"activeCount":97},[],{"intervention":80252,"totalTrials":417,"cells":80262},{"EARLY_PHASE1":80263,"PHASE1":80265,"PHASE2":80271,"PHASE3":80273,"PHASE4":80275,"NA":80277},{"trials":80264,"activeCount":97},[],{"trials":80266,"activeCount":97},[80267],{"nctId":80246,"briefTitle":80247,"status":155,"phases":80268,"primaryCompletion":32283,"completion":32283,"start":80249,"enrollment":433,"conditions":80269,"interventions":80270},[85],[39123],[80239,80252],{"trials":80272,"activeCount":97},[],{"trials":80274,"activeCount":97},[],{"trials":80276,"activeCount":97},[],{"trials":80278,"activeCount":97},[],{"intervention":80280,"totalTrials":417,"cells":80281},"SB-240563",{"EARLY_PHASE1":80282,"PHASE1":80284,"PHASE2":80294,"PHASE3":80296,"PHASE4":80298,"NA":80300},{"trials":80283,"activeCount":97},[],{"trials":80285,"activeCount":97},[80286],{"nctId":80287,"briefTitle":80288,"status":155,"phases":80289,"primaryCompletion":80290,"completion":80290,"start":80291,"enrollment":8786,"conditions":80292,"interventions":80293},"NCT01471327","Japanese Phase 1 Study of Mepolizumab",[85],"2012-04-27","2011-08-09",[18],[80280],{"trials":80295,"activeCount":97},[],{"trials":80297,"activeCount":97},[],{"trials":80299,"activeCount":97},[],{"trials":80301,"activeCount":97},[],{"intervention":80303,"totalTrials":417,"cells":80304},"[14c}-GSK1349572",{"EARLY_PHASE1":80305,"PHASE1":80307,"PHASE2":80315,"PHASE3":80317,"PHASE4":80319,"NA":80321},{"trials":80306,"activeCount":97},[],{"trials":80308,"activeCount":97},[80309],{"nctId":80310,"briefTitle":80311,"status":155,"phases":80312,"primaryCompletion":2794,"completion":2794,"start":8116,"enrollment":628,"conditions":80313,"interventions":80314},"NCT00828763","GSK1349572 Mass Balance Study",[85],[19301],[80303],{"trials":80316,"activeCount":97},[],{"trials":80318,"activeCount":97},[],{"trials":80320,"activeCount":97},[],{"trials":80322,"activeCount":97},[],{"intervention":80324,"totalTrials":417,"cells":80325},"influenza vaccine Fluarix, Adjuvanted Fluarix",{"EARLY_PHASE1":80326,"PHASE1":80328,"PHASE2":80338,"PHASE3":80340,"PHASE4":80342,"NA":80344},{"trials":80327,"activeCount":97},[],{"trials":80329,"activeCount":97},[80330],{"nctId":80331,"briefTitle":80332,"status":155,"phases":80333,"primaryCompletion":19759,"completion":80334,"start":80335,"enrollment":719,"conditions":80336,"interventions":80337},"NCT00318058","Safety Study of an Adjuvanted Candidate Influenza Vaccine to Prevent Influenza Disease in the Elderly Population",[85],"2005-11-04","2005-10-03",[21],[80324],{"trials":80339,"activeCount":97},[],{"trials":80341,"activeCount":97},[],{"trials":80343,"activeCount":97},[],{"trials":80345,"activeCount":97},[],{"intervention":80347,"totalTrials":417,"cells":80348},"Investigational MenC-CRM adjuavnted with 12.5 ug of LHD153R",{"EARLY_PHASE1":80349,"PHASE1":80351,"PHASE2":80363,"PHASE3":80365,"PHASE4":80367,"NA":80369},{"trials":80350,"activeCount":97},[],{"trials":80352,"activeCount":97},[80353],{"nctId":80354,"briefTitle":80355,"status":155,"phases":80356,"primaryCompletion":75587,"completion":75587,"start":16102,"enrollment":526,"conditions":80357,"interventions":80358},"NCT02639351","Safety and Immunogenicity of an Aluminium Hydroxide\u002FLHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine",[85],[992],[80347,80359,80360,80361,80362],"Investigational MenC-CRM adjuavnted with 25 ug of LHD153R","Investigational MenC-CRM adjuavnted with 50 ug of LHD153R","Investigational MenC-CRM adjuavnted with 100 ug of LHD153R","Meningococcal C-CRM Conjugate Vaccine",{"trials":80364,"activeCount":97},[],{"trials":80366,"activeCount":97},[],{"trials":80368,"activeCount":97},[],{"trials":80370,"activeCount":97},[],{"intervention":80359,"totalTrials":417,"cells":80372},{"EARLY_PHASE1":80373,"PHASE1":80375,"PHASE2":80381,"PHASE3":80383,"PHASE4":80385,"NA":80387},{"trials":80374,"activeCount":97},[],{"trials":80376,"activeCount":97},[80377],{"nctId":80354,"briefTitle":80355,"status":155,"phases":80378,"primaryCompletion":75587,"completion":75587,"start":16102,"enrollment":526,"conditions":80379,"interventions":80380},[85],[992],[80347,80359,80360,80361,80362],{"trials":80382,"activeCount":97},[],{"trials":80384,"activeCount":97},[],{"trials":80386,"activeCount":97},[],{"trials":80388,"activeCount":97},[],{"intervention":80360,"totalTrials":417,"cells":80390},{"EARLY_PHASE1":80391,"PHASE1":80393,"PHASE2":80399,"PHASE3":80401,"PHASE4":80403,"NA":80405},{"trials":80392,"activeCount":97},[],{"trials":80394,"activeCount":97},[80395],{"nctId":80354,"briefTitle":80355,"status":155,"phases":80396,"primaryCompletion":75587,"completion":75587,"start":16102,"enrollment":526,"conditions":80397,"interventions":80398},[85],[992],[80347,80359,80360,80361,80362],{"trials":80400,"activeCount":97},[],{"trials":80402,"activeCount":97},[],{"trials":80404,"activeCount":97},[],{"trials":80406,"activeCount":97},[],{"intervention":80361,"totalTrials":417,"cells":80408},{"EARLY_PHASE1":80409,"PHASE1":80411,"PHASE2":80417,"PHASE3":80419,"PHASE4":80421,"NA":80423},{"trials":80410,"activeCount":97},[],{"trials":80412,"activeCount":97},[80413],{"nctId":80354,"briefTitle":80355,"status":155,"phases":80414,"primaryCompletion":75587,"completion":75587,"start":16102,"enrollment":526,"conditions":80415,"interventions":80416},[85],[992],[80347,80359,80360,80361,80362],{"trials":80418,"activeCount":97},[],{"trials":80420,"activeCount":97},[],{"trials":80422,"activeCount":97},[],{"trials":80424,"activeCount":97},[],{"intervention":80362,"totalTrials":417,"cells":80426},{"EARLY_PHASE1":80427,"PHASE1":80429,"PHASE2":80435,"PHASE3":80437,"PHASE4":80439,"NA":80441},{"trials":80428,"activeCount":97},[],{"trials":80430,"activeCount":97},[80431],{"nctId":80354,"briefTitle":80355,"status":155,"phases":80432,"primaryCompletion":75587,"completion":75587,"start":16102,"enrollment":526,"conditions":80433,"interventions":80434},[85],[992],[80347,80359,80360,80361,80362],{"trials":80436,"activeCount":97},[],{"trials":80438,"activeCount":97},[],{"trials":80440,"activeCount":97},[],{"trials":80442,"activeCount":97},[],{"intervention":80444,"totalTrials":417,"cells":80445},"Oseltamivir and Intravenous Zanamivir",{"EARLY_PHASE1":80446,"PHASE1":80448,"PHASE2":80456,"PHASE3":80458,"PHASE4":80460,"NA":80462},{"trials":80447,"activeCount":97},[],{"trials":80449,"activeCount":97},[80450],{"nctId":80451,"briefTitle":80452,"status":500,"phases":80453,"primaryCompletion":8426,"completion":8426,"start":8426,"enrollment":97,"conditions":80454,"interventions":80455},"NCT00540501","A Study to Evaluate Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Subjects",[85],[7524],[80444],{"trials":80457,"activeCount":97},[],{"trials":80459,"activeCount":97},[],{"trials":80461,"activeCount":97},[],{"trials":80463,"activeCount":97},[],{"intervention":80465,"totalTrials":417,"cells":80466},"GI-270384",{"EARLY_PHASE1":80467,"PHASE1":80469,"PHASE2":80478,"PHASE3":80480,"PHASE4":80482,"NA":80484},{"trials":80468,"activeCount":97},[],{"trials":80470,"activeCount":97},[80471],{"nctId":80472,"briefTitle":80473,"status":145,"phases":80474,"start":1361,"enrollment":433,"conditions":80475,"interventions":80477},"NCT00457171","GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis",[85],[80476],"Ulcerative Colitis",[80465],{"trials":80479,"activeCount":97},[],{"trials":80481,"activeCount":97},[],{"trials":80483,"activeCount":97},[],{"trials":80485,"activeCount":97},[],{"intervention":80487,"totalTrials":417,"cells":80488},"an undetermined dose of GSK1292263",{"EARLY_PHASE1":80489,"PHASE1":80491,"PHASE2":80501,"PHASE3":80503,"PHASE4":80505,"NA":80507},{"trials":80490,"activeCount":97},[],{"trials":80492,"activeCount":97},[80493],{"nctId":80494,"briefTitle":80495,"status":155,"phases":80496,"primaryCompletion":33172,"completion":33172,"start":80497,"enrollment":7955,"conditions":80498,"interventions":80499},"NCT00783549","A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs.",[85],"2008-09-04",[27251],[80487,80500,80500,80500,80500],"ascending dose of GSK1292263",{"trials":80502,"activeCount":97},[],{"trials":80504,"activeCount":97},[],{"trials":80506,"activeCount":97},[],{"trials":80508,"activeCount":97},[],{"intervention":80500,"totalTrials":417,"cells":80510},{"EARLY_PHASE1":80511,"PHASE1":80513,"PHASE2":80519,"PHASE3":80521,"PHASE4":80523,"NA":80525},{"trials":80512,"activeCount":97},[],{"trials":80514,"activeCount":97},[80515],{"nctId":80494,"briefTitle":80495,"status":155,"phases":80516,"primaryCompletion":33172,"completion":33172,"start":80497,"enrollment":7955,"conditions":80517,"interventions":80518},[85],[27251],[80487,80500,80500,80500,80500],{"trials":80520,"activeCount":97},[],{"trials":80522,"activeCount":97},[],{"trials":80524,"activeCount":97},[],{"trials":80526,"activeCount":97},[],{"intervention":80528,"totalTrials":417,"cells":80529},"Immunotherapeutic SB719125",{"EARLY_PHASE1":80530,"PHASE1":80532,"PHASE2":80542,"PHASE3":80544,"PHASE4":80546,"NA":80548},{"trials":80531,"activeCount":97},[],{"trials":80533,"activeCount":97},[80534],{"nctId":80535,"briefTitle":80536,"status":155,"phases":80537,"primaryCompletion":80538,"completion":80538,"start":80539,"enrollment":4542,"conditions":80540,"interventions":80541},"NCT00058526","A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer",[85],"2006-09-06","2003-03-20",[668],[80528],{"trials":80543,"activeCount":97},[],{"trials":80545,"activeCount":97},[],{"trials":80547,"activeCount":97},[],{"trials":80549,"activeCount":97},[],{"intervention":80551,"totalTrials":417,"cells":80552},"GSK2586184 400mg",{"EARLY_PHASE1":80553,"PHASE1":80555,"PHASE2":80563,"PHASE3":80565,"PHASE4":80567,"NA":80569},{"trials":80554,"activeCount":97},[],{"trials":80556,"activeCount":97},[80557],{"nctId":80558,"briefTitle":80559,"status":145,"phases":80560,"primaryCompletion":62994,"completion":62994,"start":77564,"enrollment":660,"conditions":80561,"interventions":80562},"NCT02000453","Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.",[85],[7295],[80551],{"trials":80564,"activeCount":97},[],{"trials":80566,"activeCount":97},[],{"trials":80568,"activeCount":97},[],{"trials":80570,"activeCount":97},[],{"intervention":80572,"totalTrials":417,"cells":80573},"rhPTH",{"EARLY_PHASE1":80574,"PHASE1":80576,"PHASE2":80586,"PHASE3":80588,"PHASE4":80590,"NA":80592},{"trials":80575,"activeCount":97},[],{"trials":80577,"activeCount":97},[80578],{"nctId":80579,"briefTitle":80580,"status":155,"phases":80581,"primaryCompletion":7954,"completion":7954,"start":2336,"enrollment":345,"conditions":80582,"interventions":80583},"NCT00532077","A Study to Evaluate the Effects of SB-751689 or rhPTH(1-34) on Excretion of Calcium and Phosphate in Women",[85],[12138],[80572,80584,80585],"SB-751689 100 mg","SB-751689 400 mg",{"trials":80587,"activeCount":97},[],{"trials":80589,"activeCount":97},[],{"trials":80591,"activeCount":97},[],{"trials":80593,"activeCount":97},[],{"intervention":80584,"totalTrials":417,"cells":80595},{"EARLY_PHASE1":80596,"PHASE1":80598,"PHASE2":80604,"PHASE3":80606,"PHASE4":80608,"NA":80610},{"trials":80597,"activeCount":97},[],{"trials":80599,"activeCount":97},[80600],{"nctId":80579,"briefTitle":80580,"status":155,"phases":80601,"primaryCompletion":7954,"completion":7954,"start":2336,"enrollment":345,"conditions":80602,"interventions":80603},[85],[12138],[80572,80584,80585],{"trials":80605,"activeCount":97},[],{"trials":80607,"activeCount":97},[],{"trials":80609,"activeCount":97},[],{"trials":80611,"activeCount":97},[],{"intervention":80585,"totalTrials":417,"cells":80613},{"EARLY_PHASE1":80614,"PHASE1":80616,"PHASE2":80622,"PHASE3":80624,"PHASE4":80626,"NA":80628},{"trials":80615,"activeCount":97},[],{"trials":80617,"activeCount":97},[80618],{"nctId":80579,"briefTitle":80580,"status":155,"phases":80619,"primaryCompletion":7954,"completion":7954,"start":2336,"enrollment":345,"conditions":80620,"interventions":80621},[85],[12138],[80572,80584,80585],{"trials":80623,"activeCount":97},[],{"trials":80625,"activeCount":97},[],{"trials":80627,"activeCount":97},[],{"trials":80629,"activeCount":97},[],{"intervention":26179,"totalTrials":417,"cells":80631},{"EARLY_PHASE1":80632,"PHASE1":80634,"PHASE2":80640,"PHASE3":80642,"PHASE4":80644,"NA":80646},{"trials":80633,"activeCount":97},[],{"trials":80635,"activeCount":97},[80636],{"nctId":26173,"briefTitle":26174,"status":155,"phases":80637,"primaryCompletion":26176,"completion":26176,"start":18002,"enrollment":695,"conditions":80638,"interventions":80639},[85],[5353],[26179,26180],{"trials":80641,"activeCount":97},[],{"trials":80643,"activeCount":97},[],{"trials":80645,"activeCount":97},[],{"trials":80647,"activeCount":97},[],{"intervention":80649,"totalTrials":417,"cells":80650},"GSK561679 tablet or solution",{"EARLY_PHASE1":80651,"PHASE1":80653,"PHASE2":80661,"PHASE3":80663,"PHASE4":80665,"NA":80667},{"trials":80652,"activeCount":97},[],{"trials":80654,"activeCount":97},[80655],{"nctId":80656,"briefTitle":80657,"status":155,"phases":80658,"primaryCompletion":2382,"completion":2382,"start":8426,"enrollment":1459,"conditions":80659,"interventions":80660},"NCT00539136","A Study to Examine the Absorption of GSK561679 in Healthy Male Volunteers",[85],[7524],[80649],{"trials":80662,"activeCount":97},[],{"trials":80664,"activeCount":97},[],{"trials":80666,"activeCount":97},[],{"trials":80668,"activeCount":97},[],{"intervention":80670,"totalTrials":417,"cells":80671},"Lamotrigine caplet",{"EARLY_PHASE1":80672,"PHASE1":80674,"PHASE2":80684,"PHASE3":80686,"PHASE4":80688,"NA":80690},{"trials":80673,"activeCount":97},[],{"trials":80675,"activeCount":97},[80676],{"nctId":80677,"briefTitle":80678,"status":155,"phases":80679,"primaryCompletion":80680,"completion":80680,"start":80681,"enrollment":29099,"conditions":80682,"interventions":80683},"NCT00605371","Bioequivalence and Food Effect of 250mg of Lamotrigine XR",[85],"2008-03-06","2008-01-15",[12518],[76594,80670],{"trials":80685,"activeCount":97},[],{"trials":80687,"activeCount":97},[],{"trials":80689,"activeCount":97},[],{"trials":80691,"activeCount":97},[],{"intervention":80693,"totalTrials":417,"cells":80694},"Gabapentin 300 mg",{"EARLY_PHASE1":80695,"PHASE1":80697,"PHASE2":80706,"PHASE3":80708,"PHASE4":80710,"NA":80712},{"trials":80696,"activeCount":97},[],{"trials":80698,"activeCount":97},[80699],{"nctId":80700,"briefTitle":80701,"status":155,"phases":80702,"primaryCompletion":80703,"completion":80703,"start":18982,"enrollment":93,"conditions":80704,"interventions":80705},"NCT01738893","Bioequivalence Study of 300 mg Gabapentin",[85],"2011-01-22",[12518],[80693,80693],{"trials":80707,"activeCount":97},[],{"trials":80709,"activeCount":97},[],{"trials":80711,"activeCount":97},[],{"trials":80713,"activeCount":97},[],{"intervention":80715,"totalTrials":417,"cells":80716},"GSK586529",{"EARLY_PHASE1":80717,"PHASE1":80719,"PHASE2":80728,"PHASE3":80730,"PHASE4":80732,"NA":80734},{"trials":80718,"activeCount":97},[],{"trials":80720,"activeCount":97},[80721],{"nctId":80722,"briefTitle":80723,"status":155,"phases":80724,"primaryCompletion":43462,"completion":43462,"start":80725,"enrollment":1279,"conditions":80726,"interventions":80727},"NCT00703547","A First Time in Human Study of GSK586529 in Healthy Volunteers",[85],"2008-01-28",[41867],[80715,80715],{"trials":80729,"activeCount":97},[],{"trials":80731,"activeCount":97},[],{"trials":80733,"activeCount":97},[],{"trials":80735,"activeCount":97},[],{"intervention":80737,"totalTrials":417,"cells":80738},"4 mg nicotine lozenge",{"EARLY_PHASE1":80739,"PHASE1":80741,"PHASE2":80752,"PHASE3":80754,"PHASE4":80756,"NA":80758},{"trials":80740,"activeCount":97},[],{"trials":80742,"activeCount":97},[80743],{"nctId":80744,"briefTitle":80745,"status":155,"phases":80746,"primaryCompletion":2382,"completion":2382,"start":9737,"enrollment":2045,"conditions":80747,"interventions":80748},"NCT00651352","A Single Dose Bioequivalence Study OfTwo Formulations Of Nicotine Lozenges",[85],[9691],[80737,80749,80750,80751],"2 mg nicotine lozenge","2 mg nicotine prototype","4 mg nicotine prototype",{"trials":80753,"activeCount":97},[],{"trials":80755,"activeCount":97},[],{"trials":80757,"activeCount":97},[],{"trials":80759,"activeCount":97},[],{"intervention":80749,"totalTrials":417,"cells":80761},{"EARLY_PHASE1":80762,"PHASE1":80764,"PHASE2":80770,"PHASE3":80772,"PHASE4":80774,"NA":80776},{"trials":80763,"activeCount":97},[],{"trials":80765,"activeCount":97},[80766],{"nctId":80744,"briefTitle":80745,"status":155,"phases":80767,"primaryCompletion":2382,"completion":2382,"start":9737,"enrollment":2045,"conditions":80768,"interventions":80769},[85],[9691],[80737,80749,80750,80751],{"trials":80771,"activeCount":97},[],{"trials":80773,"activeCount":97},[],{"trials":80775,"activeCount":97},[],{"trials":80777,"activeCount":97},[],{"intervention":80750,"totalTrials":417,"cells":80779},{"EARLY_PHASE1":80780,"PHASE1":80782,"PHASE2":80788,"PHASE3":80790,"PHASE4":80792,"NA":80794},{"trials":80781,"activeCount":97},[],{"trials":80783,"activeCount":97},[80784],{"nctId":80744,"briefTitle":80745,"status":155,"phases":80785,"primaryCompletion":2382,"completion":2382,"start":9737,"enrollment":2045,"conditions":80786,"interventions":80787},[85],[9691],[80737,80749,80750,80751],{"trials":80789,"activeCount":97},[],{"trials":80791,"activeCount":97},[],{"trials":80793,"activeCount":97},[],{"trials":80795,"activeCount":97},[],{"intervention":80751,"totalTrials":417,"cells":80797},{"EARLY_PHASE1":80798,"PHASE1":80800,"PHASE2":80806,"PHASE3":80808,"PHASE4":80810,"NA":80812},{"trials":80799,"activeCount":97},[],{"trials":80801,"activeCount":97},[80802],{"nctId":80744,"briefTitle":80745,"status":155,"phases":80803,"primaryCompletion":2382,"completion":2382,"start":9737,"enrollment":2045,"conditions":80804,"interventions":80805},[85],[9691],[80737,80749,80750,80751],{"trials":80807,"activeCount":97},[],{"trials":80809,"activeCount":97},[],{"trials":80811,"activeCount":97},[],{"trials":80813,"activeCount":97},[],{"intervention":80815,"totalTrials":417,"cells":80816},"GSK2126458 and GSK1120212",{"EARLY_PHASE1":80817,"PHASE1":80819,"PHASE2":80827,"PHASE3":80829,"PHASE4":80831,"NA":80833},{"trials":80818,"activeCount":97},[],{"trials":80820,"activeCount":97},[80821],{"nctId":80822,"briefTitle":80823,"status":145,"phases":80824,"primaryCompletion":64159,"completion":45622,"start":16834,"enrollment":43002,"conditions":80825,"interventions":80826},"NCT01248858","Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.",[85],[36],[80815],{"trials":80828,"activeCount":97},[],{"trials":80830,"activeCount":97},[],{"trials":80832,"activeCount":97},[],{"trials":80834,"activeCount":97},[],{"intervention":60147,"totalTrials":417,"cells":80836},{"EARLY_PHASE1":80837,"PHASE1":80839,"PHASE2":80845,"PHASE3":80847,"PHASE4":80849,"NA":80851},{"trials":80838,"activeCount":97},[],{"trials":80840,"activeCount":97},[80841],{"nctId":60142,"briefTitle":60143,"status":155,"phases":80842,"primaryCompletion":19317,"completion":19317,"start":19318,"enrollment":4542,"conditions":80843,"interventions":80844},[85],[17996],[60147,60148,60118],{"trials":80846,"activeCount":97},[],{"trials":80848,"activeCount":97},[],{"trials":80850,"activeCount":97},[],{"trials":80852,"activeCount":97},[],{"intervention":60148,"totalTrials":417,"cells":80854},{"EARLY_PHASE1":80855,"PHASE1":80857,"PHASE2":80863,"PHASE3":80865,"PHASE4":80867,"NA":80869},{"trials":80856,"activeCount":97},[],{"trials":80858,"activeCount":97},[80859],{"nctId":60142,"briefTitle":60143,"status":155,"phases":80860,"primaryCompletion":19317,"completion":19317,"start":19318,"enrollment":4542,"conditions":80861,"interventions":80862},[85],[17996],[60147,60148,60118],{"trials":80864,"activeCount":97},[],{"trials":80866,"activeCount":97},[],{"trials":80868,"activeCount":97},[],{"trials":80870,"activeCount":97},[],{"intervention":62572,"totalTrials":417,"cells":80872},{"EARLY_PHASE1":80873,"PHASE1":80875,"PHASE2":80881,"PHASE3":80883,"PHASE4":80885,"NA":80887},{"trials":80874,"activeCount":97},[],{"trials":80876,"activeCount":97},[80877],{"nctId":62566,"briefTitle":62567,"status":155,"phases":80878,"primaryCompletion":13316,"completion":13316,"start":62569,"enrollment":628,"conditions":80879,"interventions":80880},[85],[36,107],[62559,62572],{"trials":80882,"activeCount":97},[],{"trials":80884,"activeCount":97},[],{"trials":80886,"activeCount":97},[],{"trials":80888,"activeCount":97},[],{"intervention":80890,"totalTrials":417,"cells":80891},"GSK3884464",{"EARLY_PHASE1":80892,"PHASE1":80894,"PHASE2":80904,"PHASE3":80906,"PHASE4":80908,"NA":80910},{"trials":80893,"activeCount":97},[],{"trials":80895,"activeCount":97},[80896],{"nctId":80897,"briefTitle":80898,"status":145,"phases":80899,"primaryCompletion":80900,"completion":80900,"start":80901,"enrollment":9334,"conditions":80902,"interventions":80903},"NCT05044325","A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants",[85],"2022-08-05","2021-09-20",[40356],[80890],{"trials":80905,"activeCount":97},[],{"trials":80907,"activeCount":97},[],{"trials":80909,"activeCount":97},[],{"trials":80911,"activeCount":97},[],{"intervention":62505,"totalTrials":417,"cells":80913},{"EARLY_PHASE1":80914,"PHASE1":80916,"PHASE2":80922,"PHASE3":80924,"PHASE4":80926,"NA":80928},{"trials":80915,"activeCount":97},[],{"trials":80917,"activeCount":97},[80918],{"nctId":62498,"briefTitle":62499,"status":155,"phases":80919,"primaryCompletion":62501,"completion":62501,"start":62502,"enrollment":8861,"conditions":80920,"interventions":80921},[85],[12263],[62482,62495,62496,62505],{"trials":80923,"activeCount":97},[],{"trials":80925,"activeCount":97},[],{"trials":80927,"activeCount":97},[],{"trials":80929,"activeCount":97},[],{"intervention":60401,"totalTrials":417,"cells":80931},{"EARLY_PHASE1":80932,"PHASE1":80934,"PHASE2":80940,"PHASE3":80942,"PHASE4":80944,"NA":80946},{"trials":80933,"activeCount":97},[],{"trials":80935,"activeCount":97},[80936],{"nctId":60393,"briefTitle":60394,"status":155,"phases":80937,"primaryCompletion":60396,"completion":60396,"start":60397,"enrollment":6503,"conditions":80938,"interventions":80939},[85],[60399],[60401,9323],{"trials":80941,"activeCount":97},[],{"trials":80943,"activeCount":97},[],{"trials":80945,"activeCount":97},[],{"trials":80947,"activeCount":97},[],{"intervention":80949,"totalTrials":417,"cells":80950},"GSK1322888",{"EARLY_PHASE1":80951,"PHASE1":80953,"PHASE2":80962,"PHASE3":80964,"PHASE4":80966,"NA":80968},{"trials":80952,"activeCount":97},[],{"trials":80954,"activeCount":97},[80955],{"nctId":80956,"briefTitle":80957,"status":155,"phases":80958,"primaryCompletion":80959,"completion":80959,"start":26459,"enrollment":7438,"conditions":80960,"interventions":80961},"NCT01294566","FTIH to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses of GSK1322888 in Healthy Caucasian and Japanese Volunteers",[85],"2011-03-23",[39624],[80949],{"trials":80963,"activeCount":97},[],{"trials":80965,"activeCount":97},[],{"trials":80967,"activeCount":97},[],{"trials":80969,"activeCount":97},[],{"intervention":26643,"totalTrials":417,"cells":80971},{"EARLY_PHASE1":80972,"PHASE1":80974,"PHASE2":80980,"PHASE3":80982,"PHASE4":80984,"NA":80986},{"trials":80973,"activeCount":97},[],{"trials":80975,"activeCount":97},[80976],{"nctId":26638,"briefTitle":26639,"status":155,"phases":80977,"primaryCompletion":17134,"completion":17134,"start":18087,"enrollment":710,"conditions":80978,"interventions":80979},[85],[9153],[26643,26644,26645,26646,26647],{"trials":80981,"activeCount":97},[],{"trials":80983,"activeCount":97},[],{"trials":80985,"activeCount":97},[],{"trials":80987,"activeCount":97},[],{"intervention":26645,"totalTrials":417,"cells":80989},{"EARLY_PHASE1":80990,"PHASE1":80992,"PHASE2":80998,"PHASE3":81000,"PHASE4":81002,"NA":81004},{"trials":80991,"activeCount":97},[],{"trials":80993,"activeCount":97},[80994],{"nctId":26638,"briefTitle":26639,"status":155,"phases":80995,"primaryCompletion":17134,"completion":17134,"start":18087,"enrollment":710,"conditions":80996,"interventions":80997},[85],[9153],[26643,26644,26645,26646,26647],{"trials":80999,"activeCount":97},[],{"trials":81001,"activeCount":97},[],{"trials":81003,"activeCount":97},[],{"trials":81005,"activeCount":97},[],{"intervention":26646,"totalTrials":417,"cells":81007},{"EARLY_PHASE1":81008,"PHASE1":81010,"PHASE2":81016,"PHASE3":81018,"PHASE4":81020,"NA":81022},{"trials":81009,"activeCount":97},[],{"trials":81011,"activeCount":97},[81012],{"nctId":26638,"briefTitle":26639,"status":155,"phases":81013,"primaryCompletion":17134,"completion":17134,"start":18087,"enrollment":710,"conditions":81014,"interventions":81015},[85],[9153],[26643,26644,26645,26646,26647],{"trials":81017,"activeCount":97},[],{"trials":81019,"activeCount":97},[],{"trials":81021,"activeCount":97},[],{"trials":81023,"activeCount":97},[],{"intervention":26647,"totalTrials":417,"cells":81025},{"EARLY_PHASE1":81026,"PHASE1":81028,"PHASE2":81034,"PHASE3":81036,"PHASE4":81038,"NA":81040},{"trials":81027,"activeCount":97},[],{"trials":81029,"activeCount":97},[81030],{"nctId":26638,"briefTitle":26639,"status":155,"phases":81031,"primaryCompletion":17134,"completion":17134,"start":18087,"enrollment":710,"conditions":81032,"interventions":81033},[85],[9153],[26643,26644,26645,26646,26647],{"trials":81035,"activeCount":97},[],{"trials":81037,"activeCount":97},[],{"trials":81039,"activeCount":97},[],{"trials":81041,"activeCount":97},[],{"intervention":9345,"totalTrials":417,"cells":81043},{"EARLY_PHASE1":81044,"PHASE1":81046,"PHASE2":81052,"PHASE3":81054,"PHASE4":81056,"NA":81058},{"trials":81045,"activeCount":97},[],{"trials":81047,"activeCount":97},[81048],{"nctId":9339,"briefTitle":9340,"status":155,"phases":81049,"primaryCompletion":6351,"completion":6351,"start":2442,"enrollment":1298,"conditions":81050,"interventions":81051},[85],[7524,9343],[9345,9346,6488,9323,9273,9347],{"trials":81053,"activeCount":97},[],{"trials":81055,"activeCount":97},[],{"trials":81057,"activeCount":97},[],{"trials":81059,"activeCount":97},[],{"intervention":1690,"totalTrials":417,"cells":81061},{"EARLY_PHASE1":81062,"PHASE1":81064,"PHASE2":81070,"PHASE3":81072,"PHASE4":81074,"NA":81076},{"trials":81063,"activeCount":97},[],{"trials":81065,"activeCount":97},[81066],{"nctId":1680,"briefTitle":1681,"status":155,"phases":81067,"primaryCompletion":1683,"completion":1684,"start":1685,"enrollment":1686,"conditions":81068,"interventions":81069},[85],[107],[1689,163,1690,137],{"trials":81071,"activeCount":97},[],{"trials":81073,"activeCount":97},[],{"trials":81075,"activeCount":97},[],{"trials":81077,"activeCount":97},[],{"intervention":81079,"totalTrials":417,"cells":81080},"Vofopitant",{"EARLY_PHASE1":81081,"PHASE1":81083,"PHASE2":81091,"PHASE3":81093,"PHASE4":81095,"NA":81097},{"trials":81082,"activeCount":97},[],{"trials":81084,"activeCount":97},[81085],{"nctId":81086,"briefTitle":81087,"status":145,"phases":81088,"primaryCompletion":8915,"completion":8915,"start":27022,"enrollment":1459,"conditions":81089,"interventions":81090},"NCT00907985","A Study to Evaluate the Effect of Single Doses of Drug A (Lamotrigine) and Drug B (Vofopitant) Alone and in Combination on Resting Motor Threshold in Healthy Subjects",[85],[22321],[81079,76594],{"trials":81092,"activeCount":97},[],{"trials":81094,"activeCount":97},[],{"trials":81096,"activeCount":97},[],{"trials":81098,"activeCount":97},[],{"intervention":81100,"totalTrials":417,"cells":81101},"Blood sampling",{"EARLY_PHASE1":81102,"PHASE1":81104,"PHASE2":81115,"PHASE3":81117,"PHASE4":81119,"NA":81121},{"trials":81103,"activeCount":97},[],{"trials":81105,"activeCount":97},[81106],{"nctId":81107,"briefTitle":81108,"status":155,"phases":81109,"primaryCompletion":81110,"completion":81110,"start":38714,"enrollment":8861,"conditions":81111,"interventions":81112},"NCT03201211","A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults",[85],"2020-03-19",[9855],[81100,81113,81114],"GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, PE-PilA and UspA2.","GSK biologicals investigational NTHi Mcat vaccine containing 10µg of PD, 10µg of PE-PilA, and 3.3µg of UspA2.",{"trials":81116,"activeCount":97},[],{"trials":81118,"activeCount":97},[],{"trials":81120,"activeCount":97},[],{"trials":81122,"activeCount":97},[],{"intervention":81113,"totalTrials":417,"cells":81124},{"EARLY_PHASE1":81125,"PHASE1":81127,"PHASE2":81133,"PHASE3":81135,"PHASE4":81137,"NA":81139},{"trials":81126,"activeCount":97},[],{"trials":81128,"activeCount":97},[81129],{"nctId":81107,"briefTitle":81108,"status":155,"phases":81130,"primaryCompletion":81110,"completion":81110,"start":38714,"enrollment":8861,"conditions":81131,"interventions":81132},[85],[9855],[81100,81113,81114],{"trials":81134,"activeCount":97},[],{"trials":81136,"activeCount":97},[],{"trials":81138,"activeCount":97},[],{"trials":81140,"activeCount":97},[],{"intervention":81114,"totalTrials":417,"cells":81142},{"EARLY_PHASE1":81143,"PHASE1":81145,"PHASE2":81151,"PHASE3":81153,"PHASE4":81155,"NA":81157},{"trials":81144,"activeCount":97},[],{"trials":81146,"activeCount":97},[81147],{"nctId":81107,"briefTitle":81108,"status":155,"phases":81148,"primaryCompletion":81110,"completion":81110,"start":38714,"enrollment":8861,"conditions":81149,"interventions":81150},[85],[9855],[81100,81113,81114],{"trials":81152,"activeCount":97},[],{"trials":81154,"activeCount":97},[],{"trials":81156,"activeCount":97},[],{"trials":81158,"activeCount":97},[],{"intervention":81160,"totalTrials":417,"cells":81161},"GSK2336805 10mg",{"EARLY_PHASE1":81162,"PHASE1":81164,"PHASE2":81180,"PHASE3":81182,"PHASE4":81184,"NA":81186},{"trials":81163,"activeCount":97},[],{"trials":81165,"activeCount":97},[81166],{"nctId":81167,"briefTitle":81168,"status":155,"phases":81169,"primaryCompletion":21805,"completion":21805,"start":81170,"enrollment":7712,"conditions":81171,"interventions":81172},"NCT01277692","A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.",[85],"2010-11-03",[23770],[81160,81173,81174,81175,81176,81177,81178,81179,81174],"GSK2336805 30mg","GSK2236805 100mg","GSK2236805 200mg","GSK2236805 10mg","GSK2236805 dose to be determined up to 100mg","GSK2236805 5mg","GSK2236805 30mg",{"trials":81181,"activeCount":97},[],{"trials":81183,"activeCount":97},[],{"trials":81185,"activeCount":97},[],{"trials":81187,"activeCount":97},[],{"intervention":81173,"totalTrials":417,"cells":81189},{"EARLY_PHASE1":81190,"PHASE1":81192,"PHASE2":81198,"PHASE3":81200,"PHASE4":81202,"NA":81204},{"trials":81191,"activeCount":97},[],{"trials":81193,"activeCount":97},[81194],{"nctId":81167,"briefTitle":81168,"status":155,"phases":81195,"primaryCompletion":21805,"completion":21805,"start":81170,"enrollment":7712,"conditions":81196,"interventions":81197},[85],[23770],[81160,81173,81174,81175,81176,81177,81178,81179,81174],{"trials":81199,"activeCount":97},[],{"trials":81201,"activeCount":97},[],{"trials":81203,"activeCount":97},[],{"trials":81205,"activeCount":97},[],{"intervention":81174,"totalTrials":417,"cells":81207},{"EARLY_PHASE1":81208,"PHASE1":81210,"PHASE2":81216,"PHASE3":81218,"PHASE4":81220,"NA":81222},{"trials":81209,"activeCount":97},[],{"trials":81211,"activeCount":97},[81212],{"nctId":81167,"briefTitle":81168,"status":155,"phases":81213,"primaryCompletion":21805,"completion":21805,"start":81170,"enrollment":7712,"conditions":81214,"interventions":81215},[85],[23770],[81160,81173,81174,81175,81176,81177,81178,81179,81174],{"trials":81217,"activeCount":97},[],{"trials":81219,"activeCount":97},[],{"trials":81221,"activeCount":97},[],{"trials":81223,"activeCount":97},[],{"intervention":81175,"totalTrials":417,"cells":81225},{"EARLY_PHASE1":81226,"PHASE1":81228,"PHASE2":81234,"PHASE3":81236,"PHASE4":81238,"NA":81240},{"trials":81227,"activeCount":97},[],{"trials":81229,"activeCount":97},[81230],{"nctId":81167,"briefTitle":81168,"status":155,"phases":81231,"primaryCompletion":21805,"completion":21805,"start":81170,"enrollment":7712,"conditions":81232,"interventions":81233},[85],[23770],[81160,81173,81174,81175,81176,81177,81178,81179,81174],{"trials":81235,"activeCount":97},[],{"trials":81237,"activeCount":97},[],{"trials":81239,"activeCount":97},[],{"trials":81241,"activeCount":97},[],{"intervention":81176,"totalTrials":417,"cells":81243},{"EARLY_PHASE1":81244,"PHASE1":81246,"PHASE2":81252,"PHASE3":81254,"PHASE4":81256,"NA":81258},{"trials":81245,"activeCount":97},[],{"trials":81247,"activeCount":97},[81248],{"nctId":81167,"briefTitle":81168,"status":155,"phases":81249,"primaryCompletion":21805,"completion":21805,"start":81170,"enrollment":7712,"conditions":81250,"interventions":81251},[85],[23770],[81160,81173,81174,81175,81176,81177,81178,81179,81174],{"trials":81253,"activeCount":97},[],{"trials":81255,"activeCount":97},[],{"trials":81257,"activeCount":97},[],{"trials":81259,"activeCount":97},[],{"intervention":81177,"totalTrials":417,"cells":81261},{"EARLY_PHASE1":81262,"PHASE1":81264,"PHASE2":81270,"PHASE3":81272,"PHASE4":81274,"NA":81276},{"trials":81263,"activeCount":97},[],{"trials":81265,"activeCount":97},[81266],{"nctId":81167,"briefTitle":81168,"status":155,"phases":81267,"primaryCompletion":21805,"completion":21805,"start":81170,"enrollment":7712,"conditions":81268,"interventions":81269},[85],[23770],[81160,81173,81174,81175,81176,81177,81178,81179,81174],{"trials":81271,"activeCount":97},[],{"trials":81273,"activeCount":97},[],{"trials":81275,"activeCount":97},[],{"trials":81277,"activeCount":97},[],{"intervention":81178,"totalTrials":417,"cells":81279},{"EARLY_PHASE1":81280,"PHASE1":81282,"PHASE2":81288,"PHASE3":81290,"PHASE4":81292,"NA":81294},{"trials":81281,"activeCount":97},[],{"trials":81283,"activeCount":97},[81284],{"nctId":81167,"briefTitle":81168,"status":155,"phases":81285,"primaryCompletion":21805,"completion":21805,"start":81170,"enrollment":7712,"conditions":81286,"interventions":81287},[85],[23770],[81160,81173,81174,81175,81176,81177,81178,81179,81174],{"trials":81289,"activeCount":97},[],{"trials":81291,"activeCount":97},[],{"trials":81293,"activeCount":97},[],{"trials":81295,"activeCount":97},[],{"intervention":81179,"totalTrials":417,"cells":81297},{"EARLY_PHASE1":81298,"PHASE1":81300,"PHASE2":81306,"PHASE3":81308,"PHASE4":81310,"NA":81312},{"trials":81299,"activeCount":97},[],{"trials":81301,"activeCount":97},[81302],{"nctId":81167,"briefTitle":81168,"status":155,"phases":81303,"primaryCompletion":21805,"completion":21805,"start":81170,"enrollment":7712,"conditions":81304,"interventions":81305},[85],[23770],[81160,81173,81174,81175,81176,81177,81178,81179,81174],{"trials":81307,"activeCount":97},[],{"trials":81309,"activeCount":97},[],{"trials":81311,"activeCount":97},[],{"trials":81313,"activeCount":97},[],{"intervention":81315,"totalTrials":417,"cells":81316},"Immunotherapeutic GSK2302032A, different formulations",{"EARLY_PHASE1":81317,"PHASE1":81319,"PHASE2":81328,"PHASE3":81330,"PHASE4":81332,"NA":81334},{"trials":81318,"activeCount":97},[],{"trials":81320,"activeCount":97},[81321],{"nctId":81322,"briefTitle":81323,"status":145,"phases":81324,"primaryCompletion":22113,"completion":81325,"start":67217,"enrollment":1237,"conditions":81326,"interventions":81327},"NCT01159964","Evaluation of a New Anti-cancer Vaccine for Patients With Non-small Cell Lung Cancer, After Tumor Removal by Surgery",[85],"2014-09-10",[267],[81315],{"trials":81329,"activeCount":97},[],{"trials":81331,"activeCount":97},[],{"trials":81333,"activeCount":97},[],{"trials":81335,"activeCount":97},[],{"intervention":45554,"totalTrials":417,"cells":81337},{"EARLY_PHASE1":81338,"PHASE1":81340,"PHASE2":81346,"PHASE3":81348,"PHASE4":81350,"NA":81352},{"trials":81339,"activeCount":97},[],{"trials":81341,"activeCount":97},[81342],{"nctId":45548,"briefTitle":45549,"status":155,"phases":81343,"primaryCompletion":45551,"completion":45551,"start":22180,"enrollment":3379,"conditions":81344,"interventions":81345},[85],[40347],[45541,45541,45554],{"trials":81347,"activeCount":97},[],{"trials":81349,"activeCount":97},[],{"trials":81351,"activeCount":97},[],{"trials":81353,"activeCount":97},[],{"intervention":81355,"totalTrials":417,"cells":81356},"GSK1349572 and tenofovir",{"EARLY_PHASE1":81357,"PHASE1":81359,"PHASE2":81367,"PHASE3":81369,"PHASE4":81371,"NA":81373},{"trials":81358,"activeCount":97},[],{"trials":81360,"activeCount":97},[81361],{"nctId":81362,"briefTitle":81363,"status":155,"phases":81364,"primaryCompletion":9133,"start":7976,"enrollment":433,"conditions":81365,"interventions":81366},"NCT00726336","GSK1349572 Drug Interaction With Tenofovir",[85],[7524],[81355],{"trials":81368,"activeCount":97},[],{"trials":81370,"activeCount":97},[],{"trials":81372,"activeCount":97},[],{"trials":81374,"activeCount":97},[],{"intervention":81376,"totalTrials":417,"cells":81377},"14C GSK2251052",{"EARLY_PHASE1":81378,"PHASE1":81380,"PHASE2":81389,"PHASE3":81391,"PHASE4":81393,"NA":81395},{"trials":81379,"activeCount":97},[],{"trials":81381,"activeCount":97},[81382],{"nctId":81383,"briefTitle":81384,"status":155,"phases":81385,"primaryCompletion":19513,"completion":19513,"start":81386,"enrollment":628,"conditions":81387,"interventions":81388},"NCT01475695","GSK2251052 Mass Balance in Healthy Adult Subjects",[85],"2011-04-21",[41283],[81376],{"trials":81390,"activeCount":97},[],{"trials":81392,"activeCount":97},[],{"trials":81394,"activeCount":97},[],{"trials":81396,"activeCount":97},[],{"intervention":38907,"totalTrials":417,"cells":81398},{"EARLY_PHASE1":81399,"PHASE1":81401,"PHASE2":81407,"PHASE3":81409,"PHASE4":81411,"NA":81413},{"trials":81400,"activeCount":97},[],{"trials":81402,"activeCount":97},[81403],{"nctId":38902,"briefTitle":38903,"status":155,"phases":81404,"primaryCompletion":7954,"completion":2355,"start":4756,"enrollment":2836,"conditions":81405,"interventions":81406},[85],[9036,27],[9030,38907],{"trials":81408,"activeCount":97},[],{"trials":81410,"activeCount":97},[],{"trials":81412,"activeCount":97},[],{"trials":81414,"activeCount":97},[],{"intervention":81416,"totalTrials":417,"cells":81417},"P501-AS15 vaccine",{"EARLY_PHASE1":81418,"PHASE1":81420,"PHASE2":81430,"PHASE3":81432,"PHASE4":81434,"NA":81436},{"trials":81419,"activeCount":97},[],{"trials":81421,"activeCount":97},[81422],{"nctId":81423,"briefTitle":81424,"status":155,"phases":81425,"primaryCompletion":81426,"completion":81426,"start":81427,"enrollment":463,"conditions":81428,"interventions":81429},"NCT00148928","Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA",[85],"2006-11-07","2005-03-01",[5634],[81416],{"trials":81431,"activeCount":97},[],{"trials":81433,"activeCount":97},[],{"trials":81435,"activeCount":97},[],{"trials":81437,"activeCount":97},[],{"intervention":11348,"totalTrials":417,"cells":81439},{"EARLY_PHASE1":81440,"PHASE1":81442,"PHASE2":81448,"PHASE3":81450,"PHASE4":81452,"NA":81454},{"trials":81441,"activeCount":97},[],{"trials":81443,"activeCount":97},[81444],{"nctId":11342,"briefTitle":11343,"status":145,"phases":81445,"primaryCompletion":10212,"completion":10212,"start":10212,"enrollment":10794,"conditions":81446,"interventions":81447},[85],[11346],[11348,11349,11350],{"trials":81449,"activeCount":97},[],{"trials":81451,"activeCount":97},[],{"trials":81453,"activeCount":97},[],{"trials":81455,"activeCount":97},[],{"intervention":81457,"totalTrials":417,"cells":81458},"GSK1160724",{"EARLY_PHASE1":81459,"PHASE1":81461,"PHASE2":81471,"PHASE3":81473,"PHASE4":81475,"NA":81477},{"trials":81460,"activeCount":97},[],{"trials":81462,"activeCount":97},[81463],{"nctId":81464,"briefTitle":81465,"status":155,"phases":81466,"primaryCompletion":81467,"completion":81467,"start":8208,"enrollment":1279,"conditions":81468,"interventions":81469},"NCT00555022","Effect of GSK1160724 In Healthy Volunteers",[85],"2008-04-07",[15],[81457,81470],"Tiotropium bromide",{"trials":81472,"activeCount":97},[],{"trials":81474,"activeCount":97},[],{"trials":81476,"activeCount":97},[],{"trials":81478,"activeCount":97},[],{"intervention":81480,"totalTrials":417,"cells":81481},"GSK626616, placebo, midazolam",{"EARLY_PHASE1":81482,"PHASE1":81484,"PHASE2":81493,"PHASE3":81495,"PHASE4":81497,"NA":81499},{"trials":81483,"activeCount":97},[],{"trials":81485,"activeCount":97},[81486],{"nctId":81487,"briefTitle":81488,"status":155,"phases":81489,"start":4843,"enrollment":13419,"conditions":81490,"interventions":81491},"NCT00443170","A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects",[85],[7524,17996],[81480,81492],"omeprazole, caffeine, flurbiprofen, rosiglitazone",{"trials":81494,"activeCount":97},[],{"trials":81496,"activeCount":97},[],{"trials":81498,"activeCount":97},[],{"trials":81500,"activeCount":97},[],{"intervention":81492,"totalTrials":417,"cells":81502},{"EARLY_PHASE1":81503,"PHASE1":81505,"PHASE2":81511,"PHASE3":81513,"PHASE4":81515,"NA":81517},{"trials":81504,"activeCount":97},[],{"trials":81506,"activeCount":97},[81507],{"nctId":81487,"briefTitle":81488,"status":155,"phases":81508,"start":4843,"enrollment":13419,"conditions":81509,"interventions":81510},[85],[7524,17996],[81480,81492],{"trials":81512,"activeCount":97},[],{"trials":81514,"activeCount":97},[],{"trials":81516,"activeCount":97},[],{"trials":81518,"activeCount":97},[],{"intervention":81520,"totalTrials":417,"cells":81521},"[14C]-GSK1278863 solution for IV",{"EARLY_PHASE1":81522,"PHASE1":81524,"PHASE2":81535,"PHASE3":81537,"PHASE4":81539,"NA":81541},{"trials":81523,"activeCount":97},[],{"trials":81525,"activeCount":97},[81526],{"nctId":81527,"briefTitle":81528,"status":155,"phases":81529,"primaryCompletion":51457,"completion":51457,"start":81530,"enrollment":628,"conditions":81531,"interventions":81532},"NCT03239522","Absorption and Elimination of Radiolabeled Daprodustat",[85],"2017-10-10",[17996],[81520,81533,81534],"[14C]-GSK1278863 oral solution","Daprodustat 6 mg oral",{"trials":81536,"activeCount":97},[],{"trials":81538,"activeCount":97},[],{"trials":81540,"activeCount":97},[],{"trials":81542,"activeCount":97},[],{"intervention":81533,"totalTrials":417,"cells":81544},{"EARLY_PHASE1":81545,"PHASE1":81547,"PHASE2":81553,"PHASE3":81555,"PHASE4":81557,"NA":81559},{"trials":81546,"activeCount":97},[],{"trials":81548,"activeCount":97},[81549],{"nctId":81527,"briefTitle":81528,"status":155,"phases":81550,"primaryCompletion":51457,"completion":51457,"start":81530,"enrollment":628,"conditions":81551,"interventions":81552},[85],[17996],[81520,81533,81534],{"trials":81554,"activeCount":97},[],{"trials":81556,"activeCount":97},[],{"trials":81558,"activeCount":97},[],{"trials":81560,"activeCount":97},[],{"intervention":81534,"totalTrials":417,"cells":81562},{"EARLY_PHASE1":81563,"PHASE1":81565,"PHASE2":81571,"PHASE3":81573,"PHASE4":81575,"NA":81577},{"trials":81564,"activeCount":97},[],{"trials":81566,"activeCount":97},[81567],{"nctId":81527,"briefTitle":81528,"status":155,"phases":81568,"primaryCompletion":51457,"completion":51457,"start":81530,"enrollment":628,"conditions":81569,"interventions":81570},[85],[17996],[81520,81533,81534],{"trials":81572,"activeCount":97},[],{"trials":81574,"activeCount":97},[],{"trials":81576,"activeCount":97},[],{"trials":81578,"activeCount":97},[],{"intervention":81580,"totalTrials":417,"cells":81581},"Flu Seasonal \u002FSARS-CoV-2 mRNA Dose 1",{"EARLY_PHASE1":81582,"PHASE1":81584,"PHASE2":81599,"PHASE3":81601,"PHASE4":81603,"NA":81605},{"trials":81583,"activeCount":97},[],{"trials":81585,"activeCount":97},[81586],{"nctId":81587,"briefTitle":81588,"status":155,"phases":81589,"primaryCompletion":81590,"completion":81590,"start":4174,"enrollment":1229,"conditions":81591,"interventions":81592},"NCT06680375","A Study of an Investigational Flu Seasonal\u002FSARS-CoV-2 Combination Vaccine in Adults",[85],"2025-06-09",[12437],[81580,81593,81594,81595,81596,81597,81598],"Flu Seasonal \u002FSARS-CoV-2 mRNA Dose 2","Flu Seasonal mRNA","SARS-CoV-2 mRNA Dose 1","SARS-CoV-2 mRNA Dose 2","Licensed Flu Seasonal","Licensed COVID-19 mRNA",{"trials":81600,"activeCount":97},[],{"trials":81602,"activeCount":97},[],{"trials":81604,"activeCount":97},[],{"trials":81606,"activeCount":97},[],{"intervention":81593,"totalTrials":417,"cells":81608},{"EARLY_PHASE1":81609,"PHASE1":81611,"PHASE2":81617,"PHASE3":81619,"PHASE4":81621,"NA":81623},{"trials":81610,"activeCount":97},[],{"trials":81612,"activeCount":97},[81613],{"nctId":81587,"briefTitle":81588,"status":155,"phases":81614,"primaryCompletion":81590,"completion":81590,"start":4174,"enrollment":1229,"conditions":81615,"interventions":81616},[85],[12437],[81580,81593,81594,81595,81596,81597,81598],{"trials":81618,"activeCount":97},[],{"trials":81620,"activeCount":97},[],{"trials":81622,"activeCount":97},[],{"trials":81624,"activeCount":97},[],{"intervention":81594,"totalTrials":417,"cells":81626},{"EARLY_PHASE1":81627,"PHASE1":81629,"PHASE2":81635,"PHASE3":81637,"PHASE4":81639,"NA":81641},{"trials":81628,"activeCount":97},[],{"trials":81630,"activeCount":97},[81631],{"nctId":81587,"briefTitle":81588,"status":155,"phases":81632,"primaryCompletion":81590,"completion":81590,"start":4174,"enrollment":1229,"conditions":81633,"interventions":81634},[85],[12437],[81580,81593,81594,81595,81596,81597,81598],{"trials":81636,"activeCount":97},[],{"trials":81638,"activeCount":97},[],{"trials":81640,"activeCount":97},[],{"trials":81642,"activeCount":97},[],{"intervention":81595,"totalTrials":417,"cells":81644},{"EARLY_PHASE1":81645,"PHASE1":81647,"PHASE2":81653,"PHASE3":81655,"PHASE4":81657,"NA":81659},{"trials":81646,"activeCount":97},[],{"trials":81648,"activeCount":97},[81649],{"nctId":81587,"briefTitle":81588,"status":155,"phases":81650,"primaryCompletion":81590,"completion":81590,"start":4174,"enrollment":1229,"conditions":81651,"interventions":81652},[85],[12437],[81580,81593,81594,81595,81596,81597,81598],{"trials":81654,"activeCount":97},[],{"trials":81656,"activeCount":97},[],{"trials":81658,"activeCount":97},[],{"trials":81660,"activeCount":97},[],{"intervention":81596,"totalTrials":417,"cells":81662},{"EARLY_PHASE1":81663,"PHASE1":81665,"PHASE2":81671,"PHASE3":81673,"PHASE4":81675,"NA":81677},{"trials":81664,"activeCount":97},[],{"trials":81666,"activeCount":97},[81667],{"nctId":81587,"briefTitle":81588,"status":155,"phases":81668,"primaryCompletion":81590,"completion":81590,"start":4174,"enrollment":1229,"conditions":81669,"interventions":81670},[85],[12437],[81580,81593,81594,81595,81596,81597,81598],{"trials":81672,"activeCount":97},[],{"trials":81674,"activeCount":97},[],{"trials":81676,"activeCount":97},[],{"trials":81678,"activeCount":97},[],{"intervention":81597,"totalTrials":417,"cells":81680},{"EARLY_PHASE1":81681,"PHASE1":81683,"PHASE2":81689,"PHASE3":81691,"PHASE4":81693,"NA":81695},{"trials":81682,"activeCount":97},[],{"trials":81684,"activeCount":97},[81685],{"nctId":81587,"briefTitle":81588,"status":155,"phases":81686,"primaryCompletion":81590,"completion":81590,"start":4174,"enrollment":1229,"conditions":81687,"interventions":81688},[85],[12437],[81580,81593,81594,81595,81596,81597,81598],{"trials":81690,"activeCount":97},[],{"trials":81692,"activeCount":97},[],{"trials":81694,"activeCount":97},[],{"trials":81696,"activeCount":97},[],{"intervention":81598,"totalTrials":417,"cells":81698},{"EARLY_PHASE1":81699,"PHASE1":81701,"PHASE2":81707,"PHASE3":81709,"PHASE4":81711,"NA":81713},{"trials":81700,"activeCount":97},[],{"trials":81702,"activeCount":97},[81703],{"nctId":81587,"briefTitle":81588,"status":155,"phases":81704,"primaryCompletion":81590,"completion":81590,"start":4174,"enrollment":1229,"conditions":81705,"interventions":81706},[85],[12437],[81580,81593,81594,81595,81596,81597,81598],{"trials":81708,"activeCount":97},[],{"trials":81710,"activeCount":97},[],{"trials":81712,"activeCount":97},[],{"trials":81714,"activeCount":97},[],{"intervention":2273,"totalTrials":2045,"cells":81716},{"EARLY_PHASE1":81717,"PHASE1":81719,"PHASE2":81793,"PHASE3":81861,"PHASE4":81883,"NA":81891},{"trials":81718,"activeCount":97},[],{"trials":81720,"activeCount":97},[81721,81729,81733,81737,81743,81747,81751,81755,81759,81766,81770,81777,81781,81785,81789],{"nctId":81722,"briefTitle":81723,"status":155,"phases":81724,"primaryCompletion":81725,"completion":81725,"start":81726,"enrollment":695,"conditions":81727,"interventions":81728},"NCT00370513","A Phase I Study of Pazopanib in Adult Patients With Liver Cancer",[85],"2009-04-08","2006-12-06",[42065],[2263],{"nctId":2256,"briefTitle":2257,"status":155,"phases":81730,"primaryCompletion":2259,"completion":2259,"start":2260,"enrollment":255,"conditions":81731,"interventions":81732},[85],[267],[2263,2264],{"nctId":39537,"briefTitle":39538,"status":155,"phases":81734,"primaryCompletion":39540,"completion":39540,"start":19254,"enrollment":7712,"conditions":81735,"interventions":81736},[85],[267],[2263,39543,2287],{"nctId":81738,"briefTitle":81739,"status":155,"phases":81740,"primaryCompletion":40993,"completion":40993,"start":40863,"enrollment":1335,"conditions":81741,"interventions":81742},"NCT01072214","A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers",[85],[39848],[2263,2263,2263],{"nctId":7460,"briefTitle":7461,"status":155,"phases":81744,"primaryCompletion":7463,"completion":7464,"start":7465,"enrollment":255,"conditions":81745,"interventions":81746},[85],[1877],[2263,2274],{"nctId":59431,"briefTitle":59432,"status":155,"phases":81748,"primaryCompletion":24688,"completion":24688,"start":22483,"enrollment":660,"conditions":81749,"interventions":81750},[85],[1877],[2273,8022],{"nctId":67766,"briefTitle":67767,"status":155,"phases":81752,"primaryCompletion":67769,"completion":67769,"start":67770,"enrollment":750,"conditions":81753,"interventions":81754},[85],[22060],[2273,67759,67773,67774],{"nctId":2266,"briefTitle":2267,"status":155,"phases":81756,"primaryCompletion":2269,"completion":2269,"start":2270,"enrollment":34,"conditions":81757,"interventions":81758},[85],[668],[2273,2274,2264,2275],{"nctId":81760,"briefTitle":81761,"status":155,"phases":81762,"primaryCompletion":73514,"completion":73514,"start":81763,"enrollment":1117,"conditions":81764,"interventions":81765},"NCT01154062","A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration",[85],"2010-08-16",[39848],[2273],{"nctId":2764,"briefTitle":2765,"status":155,"phases":81767,"primaryCompletion":2767,"completion":2767,"start":2768,"enrollment":37,"conditions":81768,"interventions":81769},[85],[2761],[2446,2263],{"nctId":81771,"briefTitle":81772,"status":155,"phases":81773,"primaryCompletion":81774,"completion":81774,"start":38367,"enrollment":695,"conditions":81775,"interventions":81776},"NCT00363194","A Two-way Crossover Study Of The Effect Of Food On The Pharmacokinetics Of Pazopanib In Cancer Patients",[85],"2009-06-19",[1877],[2273],{"nctId":3365,"briefTitle":3366,"status":155,"phases":81778,"primaryCompletion":3368,"completion":3369,"start":3370,"enrollment":2836,"conditions":81779,"interventions":81780},[85],[267],[2273,1758,134],{"nctId":6746,"briefTitle":6747,"status":155,"phases":81782,"primaryCompletion":6749,"completion":6749,"start":6750,"enrollment":463,"conditions":81783,"interventions":81784},[85],[2667],[2273,139,6753],{"nctId":2661,"briefTitle":2662,"status":155,"phases":81786,"primaryCompletion":2664,"completion":2664,"start":2665,"enrollment":1003,"conditions":81787,"interventions":81788},[85],[2667],[2273,2669,2670],{"nctId":3532,"briefTitle":3533,"status":155,"phases":81790,"primaryCompletion":546,"completion":3535,"start":3536,"enrollment":3537,"conditions":81791,"interventions":81792},[85],[668],[2328,2273,2329],{"trials":81794,"activeCount":97},[81795,81799,81806,81812,81819,81825,81829,81833,81837,81843,81849,81853],{"nctId":39563,"briefTitle":39564,"status":145,"phases":81796,"primaryCompletion":8037,"completion":8037,"start":729,"enrollment":454,"conditions":81797,"interventions":81798},[86],[2778],[2263,2287],{"nctId":81800,"briefTitle":81801,"status":145,"phases":81802,"primaryCompletion":67391,"completion":67391,"start":27334,"enrollment":1318,"conditions":81803,"interventions":81805},"NCT02204371","Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia",[86],[81804],"Telangiectasia, Hereditary Hemorrhagic",[2273],{"nctId":81807,"briefTitle":81808,"status":155,"phases":81809,"primaryCompletion":59902,"completion":59902,"start":10359,"enrollment":656,"conditions":81810,"interventions":81811},"NCT00733304","An Extension to Study MD7108240",[86],[39848],[2273],{"nctId":81813,"briefTitle":81814,"status":155,"phases":81815,"primaryCompletion":2355,"completion":2355,"start":4843,"enrollment":8786,"conditions":81816,"interventions":81818},"NCT00367679","Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer",[86],[81817,267],"Non-Small Cell Lung Cancer",[2273],{"nctId":81820,"briefTitle":81821,"status":155,"phases":81822,"primaryCompletion":13418,"completion":13418,"start":2844,"enrollment":20814,"conditions":81823,"interventions":81824},"NCT00297258","Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma",[86],[46078],[2263],{"nctId":7587,"briefTitle":7588,"status":155,"phases":81826,"primaryCompletion":7590,"completion":7591,"start":2804,"enrollment":781,"conditions":81827,"interventions":81828},[86],[668],[2300,2273],{"nctId":2352,"briefTitle":2353,"status":155,"phases":81830,"primaryCompletion":2355,"completion":2355,"start":2356,"enrollment":1459,"conditions":81831,"interventions":81832},[86],[2358,2359,2360,2361,2362,2363,36],[2263,2275,2264],{"nctId":7618,"briefTitle":7619,"status":155,"phases":81834,"primaryCompletion":5018,"completion":7545,"start":4843,"enrollment":7621,"conditions":81835,"interventions":81836},[86],[7623,7624],[2263,2300],{"nctId":81838,"briefTitle":81839,"status":145,"phases":81840,"primaryCompletion":3550,"completion":3550,"start":9737,"enrollment":473,"conditions":81841,"interventions":81842},"NCT00549328","Monotherapy Pazopanib in Subjects With Advanced Non-Small Cell Lung Cancer",[86],[267],[2273],{"nctId":81844,"briefTitle":81845,"status":155,"phases":81846,"primaryCompletion":828,"completion":7634,"start":3551,"enrollment":7840,"conditions":81847,"interventions":81848},"NCT01227928","Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women",[86],[2363],[2273],{"nctId":7655,"briefTitle":7656,"status":155,"phases":81850,"primaryCompletion":7658,"completion":7658,"start":7659,"enrollment":2825,"conditions":81851,"interventions":81852},[86],[7661],[2263,2300],{"nctId":81854,"briefTitle":81855,"status":155,"phases":81856,"primaryCompletion":16323,"completion":81857,"start":81858,"enrollment":730,"conditions":81859,"interventions":81860},"NCT00612456","To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD",[86],"2009-06-17","2008-03-05",[39848],[2273],{"trials":81862,"activeCount":97},[81863,81870,81877],{"nctId":81864,"briefTitle":81865,"status":155,"phases":81866,"primaryCompletion":7522,"completion":34933,"start":4844,"enrollment":81867,"conditions":81868,"interventions":81869},"NCT00334282","Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma",[87],435,[1877],[2273],{"nctId":81871,"briefTitle":81872,"status":155,"phases":81873,"primaryCompletion":10463,"completion":9728,"start":9133,"enrollment":35404,"conditions":81874,"interventions":81875},"NCT00753688","Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy",[87],[46078],[81876],"PAZOPANIB",{"nctId":81878,"briefTitle":81879,"status":155,"phases":81880,"primaryCompletion":7658,"completion":828,"start":4757,"enrollment":526,"conditions":81881,"interventions":81882},"NCT00387764","Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced\u002FMetastatic Renal Cell Cancer",[87],[1877],[2263],{"trials":81884,"activeCount":97},[81885],{"nctId":81886,"briefTitle":81887,"status":155,"phases":81888,"primaryCompletion":9682,"completion":9682,"start":3551,"enrollment":1736,"conditions":81889,"interventions":81890},"NCT01205230","VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK",[88],[36],[2263],{"trials":81892,"activeCount":97},[81893],{"nctId":81894,"briefTitle":81895,"status":155,"phases":81896,"primaryCompletion":827,"completion":827,"start":2344,"enrollment":417,"conditions":81897,"interventions":81898},"NCT01446224","Cardiovascular and Torsades de Pointes Monitoring for Pazopanib",[],[1877],[2273,81899],"Other anti-VEGFs",{"intervention":75816,"totalTrials":1079,"cells":81901},{"EARLY_PHASE1":81902,"PHASE1":81904,"PHASE2":81951,"PHASE3":81965,"PHASE4":82026,"NA":82055},{"trials":81903,"activeCount":97},[],{"trials":81905,"activeCount":97},[81906,81910,81914,81921,81929,81937,81941,81945],{"nctId":75810,"briefTitle":75811,"status":155,"phases":81907,"primaryCompletion":41493,"completion":41493,"start":75813,"enrollment":35629,"conditions":81908,"interventions":81909},[85],[12518],[75816,28454,75803],{"nctId":76588,"briefTitle":76589,"status":155,"phases":81911,"primaryCompletion":25456,"completion":25456,"start":76591,"enrollment":21520,"conditions":81912,"interventions":81913},[85],[65610],[76594,76581],{"nctId":81915,"briefTitle":81916,"status":155,"phases":81917,"primaryCompletion":19093,"completion":19093,"start":81918,"enrollment":9445,"conditions":81919,"interventions":81920},"NCT00412191","Bioequivalence And Lack Of Food Effects Of 300mg Lamotrigine XR",[85],"2007-02-06",[12518],[76594],{"nctId":81922,"briefTitle":81923,"status":155,"phases":81924,"primaryCompletion":81925,"completion":81925,"start":81926,"enrollment":433,"conditions":81927,"interventions":81928},"NCT02513654","Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects",[85],"2015-11-11","2015-09-06",[22321],[76594],{"nctId":81930,"briefTitle":81931,"status":155,"phases":81932,"primaryCompletion":81933,"completion":81933,"start":11106,"enrollment":1686,"conditions":81934,"interventions":81936},"NCT00144872","LAMICTAL (Lamotrigine) For The Treatment Of Absence Seizures",[85],"2006-04-22",[81935],"Seizure, Absence",[76594],{"nctId":80677,"briefTitle":80678,"status":155,"phases":81938,"primaryCompletion":80680,"completion":80680,"start":80681,"enrollment":29099,"conditions":81939,"interventions":81940},[85],[12518],[76594,80670],{"nctId":81086,"briefTitle":81087,"status":145,"phases":81942,"primaryCompletion":8915,"completion":8915,"start":27022,"enrollment":1459,"conditions":81943,"interventions":81944},[85],[22321],[81079,76594],{"nctId":81946,"briefTitle":81947,"status":155,"phases":81948,"primaryCompletion":589,"completion":589,"start":17736,"enrollment":1298,"conditions":81949,"interventions":81950},"NCT01357902","Lamotrigine Bioequivalence Study to Compare Dispersible Tables With Compressed Tablets in China",[85],[12518],[76594],{"trials":81952,"activeCount":97},[81953,81959],{"nctId":81954,"briefTitle":81955,"status":155,"phases":81956,"primaryCompletion":20690,"completion":20690,"start":56175,"enrollment":1214,"conditions":81957,"interventions":81958},"NCT00043875","Pediatric Epilepsy Trial in Subjects 1-24 Months",[86],[12518],[75816],{"nctId":81960,"briefTitle":81961,"status":155,"phases":81962,"primaryCompletion":8852,"completion":8852,"start":7837,"enrollment":10850,"conditions":81963,"interventions":81964},"NCT00044278","Pediatric Epilepsy Study in Subjects 1-24 Months",[86],[12518],[75816],{"trials":81966,"activeCount":97},[81967,81973,81980,81986,81992,81999,82008,82014,82020],{"nctId":81968,"briefTitle":81969,"status":155,"phases":81970,"primaryCompletion":10212,"completion":10212,"start":10670,"enrollment":29099,"conditions":81971,"interventions":81972},"NCT00086593","Study Of An FDA-approved Drug As Additional Therapy In Patients With Schizophrenia",[87],[11346],[75816],{"nctId":81974,"briefTitle":81975,"status":155,"phases":81976,"primaryCompletion":4757,"completion":4757,"start":2845,"enrollment":201,"conditions":81977,"interventions":81979},"NCT00224510","A Study To Investigate The Antidepressant Effect Of Lamotrigine In Patients With Bipolar Disorder Using Lithium",[87],[22321,81978],"Bipolar Depression",[75816],{"nctId":81981,"briefTitle":81982,"status":155,"phases":81983,"completion":10803,"start":19831,"enrollment":17033,"conditions":81984,"interventions":81985},"NCT00071747","Clinical Study Of Schizophrenia in Both Men and Women",[87],[11346],[75816],{"nctId":81987,"briefTitle":81988,"status":155,"phases":81989,"primaryCompletion":10395,"completion":10395,"start":20690,"enrollment":15283,"conditions":81990,"interventions":81991},"NCT00274677","Depression And Bipolar Disorder",[87],[22321],[75816],{"nctId":81993,"briefTitle":81994,"status":155,"phases":81995,"primaryCompletion":9737,"completion":9737,"start":7954,"enrollment":105,"conditions":81996,"interventions":81998},"NCT00579982","An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder",[87],[81997],"Mood Disorders",[76594],{"nctId":82000,"briefTitle":82001,"status":155,"phases":82002,"primaryCompletion":82003,"completion":82004,"start":82005,"enrollment":1579,"conditions":82006,"interventions":82007},"NCT00056277","Bipolar Disorder Study for Men and Women",[87],"2005-08-01","2005-12-14","2003-02-27",[22321],[75816],{"nctId":82009,"briefTitle":82010,"status":155,"phases":82011,"primaryCompletion":1428,"completion":1428,"start":2336,"enrollment":25604,"conditions":82012,"interventions":82013},"NCT00516139","Lamotrigine Extended-Release In Elderly Patients With Epilepsy",[87],[12518],[76594],{"nctId":82015,"briefTitle":82016,"status":155,"phases":82017,"primaryCompletion":11992,"completion":11992,"start":3079,"enrollment":4921,"conditions":82018,"interventions":82019},"NCT00550407","An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients",[87],[22321],[75816],{"nctId":82021,"briefTitle":82022,"status":155,"phases":82023,"primaryCompletion":8098,"completion":8098,"start":9706,"enrollment":8891,"conditions":82024,"interventions":82025},"NCT01602510","Lamotrigine Phase III Study in Bipolar I Disorder",[87],[22321],[76594],{"trials":82027,"activeCount":97},[82028,82036,82042,82048],{"nctId":82029,"briefTitle":82030,"status":155,"phases":82031,"primaryCompletion":82032,"completion":82032,"start":82033,"enrollment":1264,"conditions":82034,"interventions":82035},"NCT00043914","Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy",[88],"2003-01-29","2002-01-14",[12518],[75816],{"nctId":82037,"briefTitle":82038,"status":155,"phases":82039,"primaryCompletion":8406,"completion":8406,"start":2805,"enrollment":361,"conditions":82040,"interventions":82041},"NCT00360126","An Open-Label Extension Study Of Lamotrigine In Subjects With Bipolar Disorder",[88],[22321],[75816],{"nctId":82043,"briefTitle":82044,"status":155,"phases":82045,"primaryCompletion":19830,"completion":19830,"start":19831,"enrollment":2069,"conditions":82046,"interventions":82047},"NCT00067938","Bipolar Study in Adults at Least 18 Years of Age",[88],[22321],[75816],{"nctId":82049,"briefTitle":82050,"status":155,"phases":82051,"primaryCompletion":21731,"completion":81427,"start":82052,"enrollment":1672,"conditions":82053,"interventions":82054},"NCT00043901","Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug",[88],"2000-12-01",[38346],[75816],{"trials":82056,"activeCount":97},[82057,82064,82073,82079,82085,82092],{"nctId":82058,"briefTitle":82059,"status":155,"phases":82060,"primaryCompletion":82061,"completion":82061,"start":8135,"enrollment":12088,"conditions":82062,"interventions":82063},"NCT01428518","Special Drug Use Investigation for LAMICTAL Bipolar",[],"2016-01",[22321],[76594],{"nctId":82065,"briefTitle":82066,"status":155,"phases":82067,"primaryCompletion":10275,"completion":10275,"start":82068,"enrollment":82069,"conditions":82070,"interventions":82071},"NCT00264680","Spanish Validation Of Quality of Life Questionnaire (QOLIE-10) For Epilepsy",[],"2003-10-01",333,[12518],[75816,82072],"valproic acid",{"nctId":82074,"briefTitle":82075,"status":155,"phases":82076,"primaryCompletion":2804,"completion":2804,"start":748,"enrollment":4086,"conditions":82077,"interventions":82078},"NCT00460226","Lamictal Bipolar Observational Study",[],[22321],[75816],{"nctId":82080,"briefTitle":82081,"status":155,"phases":82082,"primaryCompletion":8037,"completion":8037,"start":11315,"enrollment":417,"conditions":82083,"interventions":82084},"NCT01657864","WEUSKOP6166: Lamotrigine and Aseptic Meningitis",[],[12518],[76594],{"nctId":82086,"briefTitle":82087,"status":155,"phases":82088,"primaryCompletion":26113,"completion":26113,"start":8468,"enrollment":82089,"conditions":82090,"interventions":82091},"NCT01376180","Drug Use Investigation for LAMICTAL",[],3000,[12518],[76594],{"nctId":82093,"briefTitle":82094,"status":155,"phases":82095,"primaryCompletion":14276,"completion":14276,"start":3550,"enrollment":4880,"conditions":82096,"interventions":82097},"NCT01863602","Special Drug Use Investigation for LAMICTAL® (Long Term)",[],[12518],[76594],{"intervention":8381,"totalTrials":695,"cells":82099},{"EARLY_PHASE1":82100,"PHASE1":82102,"PHASE2":82114,"PHASE3":82141,"PHASE4":82179,"NA":82229},{"trials":82101,"activeCount":97},[],{"trials":82103,"activeCount":97},[82104,82108],{"nctId":64588,"briefTitle":64589,"status":155,"phases":82105,"primaryCompletion":64591,"completion":64591,"start":718,"enrollment":6369,"conditions":82106,"interventions":82107},[85],[10182],[64581,8381],{"nctId":82109,"briefTitle":82110,"status":155,"phases":82111,"start":7785,"enrollment":6503,"conditions":82112,"interventions":82113},"NCT00348361","Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever)",[85],[39086],[8454],{"trials":82115,"activeCount":97},[82116,82120,82126,82130,82137],{"nctId":8371,"briefTitle":8372,"status":155,"phases":82117,"primaryCompletion":8374,"completion":8375,"start":4996,"enrollment":8376,"conditions":82118,"interventions":82119},[86],[18],[8379,8380,8381],{"nctId":82121,"briefTitle":82122,"status":155,"phases":82123,"primaryCompletion":10395,"completion":10395,"start":10803,"enrollment":2375,"conditions":82124,"interventions":82125},"NCT00400855","Study on the Effects of an AMP Challenge on Asthmatic Patients Following Treatment With Fluticasone Propionate",[86],[18],[8381],{"nctId":39098,"briefTitle":39099,"status":155,"phases":82127,"primaryCompletion":7522,"completion":7522,"start":7954,"enrollment":10794,"conditions":82128,"interventions":82129},[86],[10169],[39027,8409],{"nctId":82131,"briefTitle":82132,"status":155,"phases":82133,"primaryCompletion":470,"completion":470,"start":4877,"enrollment":82134,"conditions":82135,"interventions":82136},"NCT01563029","A Dose-ranging Study of Fluticasone Furoate (FF)",[86],597,[18],[8532,8454],{"nctId":59201,"briefTitle":59202,"status":155,"phases":82138,"primaryCompletion":59204,"completion":59204,"start":59205,"enrollment":13317,"conditions":82139,"interventions":82140},[86],[18],[59192,59208,59209],{"trials":82142,"activeCount":97},[82143,82150,82154,82158,82162,82168,82175],{"nctId":82144,"briefTitle":82145,"status":155,"phases":82146,"primaryCompletion":19408,"completion":19408,"start":82147,"enrollment":4377,"conditions":82148,"interventions":82149},"NCT00398476","Fluticasone Nasal Spray Patient Preference Study",[87],"2006-12-01",[10182],[8409,8556],{"nctId":9407,"briefTitle":9408,"status":155,"phases":82151,"primaryCompletion":9410,"completion":9410,"start":9411,"enrollment":9412,"conditions":82152,"interventions":82153},[87],[18],[8532,9415,8381,9370,9416,9417],{"nctId":8403,"briefTitle":8404,"status":155,"phases":82155,"primaryCompletion":7954,"completion":7954,"start":8406,"enrollment":265,"conditions":82156,"interventions":82157},[87],[18],[8409,8354],{"nctId":26156,"briefTitle":26157,"status":155,"phases":82159,"primaryCompletion":13358,"completion":26159,"start":22189,"enrollment":18826,"conditions":82160,"interventions":82161},[87],[18],[26136,8381],{"nctId":82163,"briefTitle":82164,"status":155,"phases":82165,"primaryCompletion":3390,"completion":3390,"start":9728,"enrollment":6339,"conditions":82166,"interventions":82167},"NCT01817790","Assessment of Fluticasone Propionate on Ocular Allergy Symptoms",[87],[39086,39059],[8381],{"nctId":82169,"briefTitle":82170,"status":155,"phases":82171,"primaryCompletion":27059,"completion":21411,"start":82172,"enrollment":603,"conditions":82173,"interventions":82174},"NCT01159912","Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents",[87],"2010-06-30",[18],[8381,9502],{"nctId":38541,"briefTitle":38542,"status":155,"phases":82176,"start":7839,"enrollment":1196,"conditions":82177,"interventions":82178},[87],[18],[38530,8381],{"trials":82180,"activeCount":97},[82181,82188,82192,82196,82200,82204,82208,82215,82219,82223],{"nctId":82182,"briefTitle":82183,"status":155,"phases":82184,"primaryCompletion":82185,"completion":82185,"start":30951,"enrollment":177,"conditions":82186,"interventions":82187},"NCT01915914","A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis",[88],"2015-02-15",[13421],[8381],{"nctId":8423,"briefTitle":8424,"status":155,"phases":82189,"primaryCompletion":8426,"completion":8426,"start":8427,"enrollment":8428,"conditions":82190,"interventions":82191},[88],[18],[8354,8431,8409,8432],{"nctId":8443,"briefTitle":8444,"status":155,"phases":82193,"primaryCompletion":8446,"completion":8447,"start":8448,"enrollment":8449,"conditions":82194,"interventions":82195},[88],[8451,8452],[8380,8454],{"nctId":8456,"briefTitle":8457,"status":155,"phases":82197,"primaryCompletion":8459,"completion":8459,"start":8460,"enrollment":8461,"conditions":82198,"interventions":82199},[88],[18],[8381,8380],{"nctId":15745,"briefTitle":15746,"status":155,"phases":82201,"primaryCompletion":2804,"completion":2804,"start":748,"enrollment":8861,"conditions":82202,"interventions":82203},[88],[18],[15732,8381],{"nctId":8484,"briefTitle":8485,"status":155,"phases":82205,"primaryCompletion":2428,"completion":2428,"start":8427,"enrollment":1944,"conditions":82206,"interventions":82207},[88],[18],[8354,8409,8431],{"nctId":82209,"briefTitle":82210,"status":155,"phases":82211,"primaryCompletion":749,"completion":749,"start":11599,"enrollment":6482,"conditions":82212,"interventions":82213},"NCT00169546","Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.",[88],[18],[82214,8381],"Salmeterol\u002Ffluticasone propionate",{"nctId":8497,"briefTitle":8498,"status":145,"phases":82216,"primaryCompletion":5018,"completion":5018,"start":8426,"enrollment":433,"conditions":82217,"interventions":82218},[88],[18],[8354,8409],{"nctId":17673,"briefTitle":17674,"status":155,"phases":82220,"primaryCompletion":17676,"completion":17676,"start":17677,"enrollment":17678,"conditions":82221,"interventions":82222},[88],[18],[17660,8381,963],{"nctId":82224,"briefTitle":82225,"status":155,"phases":82226,"primaryCompletion":7954,"completion":7954,"start":8426,"enrollment":2759,"conditions":82227,"interventions":82228},"NCT00848965","A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber",[88],[10182,39086],[8381],{"trials":82230,"activeCount":97},[82231,82238,82245,82251],{"nctId":82232,"briefTitle":82233,"status":155,"phases":82234,"primaryCompletion":19521,"completion":19521,"start":82235,"enrollment":7532,"conditions":82236,"interventions":82237},"NCT03273946","Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to \u003C4 Years",[],"2018-01-09",[18],[8381],{"nctId":82239,"briefTitle":82240,"status":155,"phases":82241,"primaryCompletion":7647,"completion":7647,"start":2442,"enrollment":82242,"conditions":82243,"interventions":82244},"NCT01328964","Comparison of Asthma-related Outcomes and Costs in Pediatric Subjects That Received Fluticasone Propionate, Budesonide or Montelukast in a Large Managed Care Population",[],9906,[18],[8381,9416,8578],{"nctId":82246,"briefTitle":82247,"status":155,"phases":82248,"primaryCompletion":22319,"completion":22319,"start":8037,"enrollment":417,"conditions":82249,"interventions":82250},"NCT01681979","WEUSRTP4850: Phase II: ICS\u002FLABA Use in Pregnancy and Outcomes",[],[18],[8381],{"nctId":82252,"briefTitle":82253,"status":155,"phases":82254,"primaryCompletion":21200,"completion":21200,"start":7436,"enrollment":10978,"conditions":82255,"interventions":82256},"NCT01199757","A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures",[],[10182],[9502,17968,8409],{"intervention":9502,"totalTrials":695,"cells":82258},{"EARLY_PHASE1":82259,"PHASE1":82261,"PHASE2":82281,"PHASE3":82319,"PHASE4":82385,"NA":82395},{"trials":82260,"activeCount":97},[],{"trials":82262,"activeCount":97},[82263,82267,82271,82277],{"nctId":18457,"briefTitle":18458,"status":155,"phases":82264,"primaryCompletion":18460,"completion":18460,"start":15600,"enrollment":433,"conditions":82265,"interventions":82266},[85],[18],[18463,8556,10797],{"nctId":9590,"briefTitle":9591,"status":155,"phases":82268,"primaryCompletion":9593,"completion":9593,"start":9594,"enrollment":255,"conditions":82269,"interventions":82270},[85],[18],[8532,9546],{"nctId":82272,"briefTitle":82273,"status":155,"phases":82274,"primaryCompletion":45205,"completion":45205,"start":23057,"enrollment":526,"conditions":82275,"interventions":82276},"NCT01000597","Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese Subjects",[85],[18],[8556],{"nctId":41799,"briefTitle":41800,"status":155,"phases":82278,"primaryCompletion":41802,"completion":41802,"start":41803,"enrollment":6503,"conditions":82279,"interventions":82280},[85],[15],[9395,9502],{"trials":82282,"activeCount":97},[82283,82287,82293,82297,82301,82305,82311,82315],{"nctId":9607,"briefTitle":9608,"status":155,"phases":82284,"primaryCompletion":2295,"completion":2295,"start":2394,"enrollment":93,"conditions":82285,"interventions":82286},[86],[18],[8532,9546],{"nctId":82288,"briefTitle":82289,"status":155,"phases":82290,"primaryCompletion":25863,"completion":25863,"start":503,"enrollment":695,"conditions":82291,"interventions":82292},"NCT01808339","To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma",[86],[18],[8532],{"nctId":9495,"briefTitle":9496,"status":155,"phases":82294,"primaryCompletion":9498,"completion":9498,"start":9499,"enrollment":695,"conditions":82295,"interventions":82296},[86],[18],[9502,9415],{"nctId":8524,"briefTitle":8525,"status":155,"phases":82298,"primaryCompletion":8527,"completion":8527,"start":8528,"enrollment":8529,"conditions":82299,"interventions":82300},[86],[18],[2915,8532,2916],{"nctId":40606,"briefTitle":40607,"status":155,"phases":82302,"primaryCompletion":7590,"completion":7590,"start":7647,"enrollment":9334,"conditions":82303,"interventions":82304},[86],[18],[40611,40571,8532],{"nctId":82306,"briefTitle":82307,"status":155,"phases":82308,"primaryCompletion":22445,"completion":22445,"start":7647,"enrollment":9334,"conditions":82309,"interventions":82310},"NCT01332292","Pharmacokinetics and PharmacoDynamics of GW685698 in Paedeatric Asthmatic Patients",[86],[18],[9502],{"nctId":82131,"briefTitle":82132,"status":155,"phases":82312,"primaryCompletion":470,"completion":470,"start":4877,"enrollment":82134,"conditions":82313,"interventions":82314},[86],[18],[8532,8454],{"nctId":42892,"briefTitle":42893,"status":155,"phases":82316,"primaryCompletion":2335,"completion":2335,"start":26336,"enrollment":3025,"conditions":82317,"interventions":82318},[86],[18],[8532,18676],{"trials":82320,"activeCount":97},[82321,82325,82331,82335,82341,82345,82349,82353,82359,82363,82367,82374,82381],{"nctId":82144,"briefTitle":82145,"status":155,"phases":82322,"primaryCompletion":19408,"completion":19408,"start":82147,"enrollment":4377,"conditions":82323,"interventions":82324},[87],[10182],[8409,8556],{"nctId":82326,"briefTitle":82327,"status":155,"phases":82328,"primaryCompletion":8089,"completion":8089,"start":2295,"enrollment":4542,"conditions":82329,"interventions":82330},"NCT01622231","Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis",[87],[11853],[9502],{"nctId":9523,"briefTitle":9524,"status":155,"phases":82332,"primaryCompletion":9526,"completion":9526,"start":9527,"enrollment":9528,"conditions":82333,"interventions":82334},[87],[15],[8556,9531,9532],{"nctId":82336,"briefTitle":82337,"status":155,"phases":82338,"primaryCompletion":9706,"completion":9706,"start":2295,"enrollment":24418,"conditions":82339,"interventions":82340},"NCT01630135","Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis",[87],[10182],[9502],{"nctId":9407,"briefTitle":9408,"status":155,"phases":82342,"primaryCompletion":9410,"completion":9410,"start":9411,"enrollment":9412,"conditions":82343,"interventions":82344},[87],[18],[8532,9415,8381,9370,9416,9417],{"nctId":26147,"briefTitle":26148,"status":155,"phases":82346,"primaryCompletion":24686,"completion":26150,"start":26151,"enrollment":26152,"conditions":82347,"interventions":82348},[87],[18],[26136,9502],{"nctId":8551,"briefTitle":8552,"status":155,"phases":82350,"primaryCompletion":828,"completion":828,"start":3111,"enrollment":4086,"conditions":82351,"interventions":82352},[87],[18],[8556,2979],{"nctId":82354,"briefTitle":82355,"status":155,"phases":82356,"primaryCompletion":30042,"completion":72800,"start":3369,"enrollment":45434,"conditions":82357,"interventions":82358},"NCT01395888","A Study to Compare the Impact of Fulticasone Furoate\u002FVilanterol vs. Tiotropium on Arterial Stiffness in COPD",[87],[15],[8556,2934],{"nctId":9548,"briefTitle":9549,"status":155,"phases":82360,"primaryCompletion":9551,"completion":9551,"start":9552,"enrollment":9553,"conditions":82361,"interventions":82362},[87],[15],[9556,8556,9531],{"nctId":9558,"briefTitle":9559,"status":155,"phases":82364,"primaryCompletion":3044,"completion":8860,"start":8089,"enrollment":6369,"conditions":82365,"interventions":82366},[87],[15],[8532,9415],{"nctId":82368,"briefTitle":82369,"status":155,"phases":82370,"primaryCompletion":60425,"completion":60425,"start":82371,"enrollment":1237,"conditions":82372,"interventions":82373},"NCT02502734","Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma",[87],"2015-09-07",[18],[9502,963],{"nctId":82375,"briefTitle":82376,"status":155,"phases":82377,"primaryCompletion":10803,"completion":10803,"start":1361,"enrollment":53682,"conditions":82378,"interventions":82380},"NCT00115622","Study In Adults And Adolescents With Seasonal Allergic Rhinitis",[87],[82379,10169,39059],"Hayfever",[8556],{"nctId":82169,"briefTitle":82170,"status":155,"phases":82382,"primaryCompletion":27059,"completion":21411,"start":82172,"enrollment":603,"conditions":82383,"interventions":82384},[87],[18],[8381,9502],{"trials":82386,"activeCount":97},[82387,82391],{"nctId":9650,"briefTitle":9651,"status":500,"phases":82388,"primaryCompletion":9653,"completion":9653,"start":4867,"enrollment":97,"conditions":82389,"interventions":82390},[88],[18],[9546,8532,9656],{"nctId":14316,"briefTitle":14317,"status":155,"phases":82392,"primaryCompletion":14319,"completion":14320,"start":14321,"enrollment":6646,"conditions":82393,"interventions":82394},[88],[18],[9502,8578,14303],{"trials":82396,"activeCount":97},[82397],{"nctId":82252,"briefTitle":82253,"status":155,"phases":82398,"primaryCompletion":21200,"completion":21200,"start":7436,"enrollment":10978,"conditions":82399,"interventions":82400},[],[10182],[9502,17968,8409],{"intervention":23772,"totalTrials":93,"cells":82402},{"EARLY_PHASE1":82403,"PHASE1":82405,"PHASE2":82462,"PHASE3":82477,"PHASE4":82530,"NA":82538},{"trials":82404,"activeCount":97},[],{"trials":82406,"activeCount":97},[82407,82415,82421,82425,82431,82438,82444,82448,82452,82458],{"nctId":82408,"briefTitle":82409,"status":155,"phases":82410,"primaryCompletion":24043,"completion":24043,"start":82411,"enrollment":1079,"conditions":82412,"interventions":82413},"NCT00442871","Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment",[85],"2006-09-28",[505],[82414],"eltrombopag",{"nctId":82416,"briefTitle":82417,"status":155,"phases":82418,"primaryCompletion":72567,"completion":72567,"start":9087,"enrollment":1634,"conditions":82419,"interventions":82420},"NCT00358540","Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And Ifosfamide",[85],[11033],[82414],{"nctId":65745,"briefTitle":65746,"status":155,"phases":82422,"primaryCompletion":44327,"completion":44327,"start":4778,"enrollment":710,"conditions":82423,"interventions":82424},[85],[505],[65738,23772],{"nctId":82426,"briefTitle":82427,"status":155,"phases":82428,"start":2835,"enrollment":1459,"conditions":82429,"interventions":82430},"NCT00487968","Eltrombopag Taste Testing in Healthy Adult Volunteers",[85],[7524,33672],[82414],{"nctId":82432,"briefTitle":82433,"status":155,"phases":82434,"primaryCompletion":10014,"completion":10014,"start":82435,"enrollment":2797,"conditions":82436,"interventions":82437},"NCT00359463","Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment",[85],"2006-04-18",[505],[82414],{"nctId":82439,"briefTitle":82440,"status":155,"phases":82441,"primaryCompletion":17526,"completion":17526,"start":40041,"enrollment":93,"conditions":82442,"interventions":82443},"NCT02254434","A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions",[85],[48762],[23772],{"nctId":23764,"briefTitle":23765,"status":155,"phases":82445,"primaryCompletion":23767,"completion":23767,"start":23768,"enrollment":345,"conditions":82446,"interventions":82447},[85],[23770],[23772,19353,23773],{"nctId":43703,"briefTitle":43704,"status":155,"phases":82449,"primaryCompletion":43706,"completion":43706,"start":30042,"enrollment":904,"conditions":82450,"interventions":82451},[85],[11033],[23772,43709,43637],{"nctId":82453,"briefTitle":82454,"status":155,"phases":82455,"primaryCompletion":10496,"completion":10496,"start":39846,"enrollment":345,"conditions":82456,"interventions":82457},"NCT01072162","Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect",[85],[505],[23772,23772],{"nctId":80223,"briefTitle":80224,"status":155,"phases":82459,"primaryCompletion":80226,"completion":80226,"start":80227,"enrollment":12202,"conditions":82460,"interventions":82461},[85],[33672],[23772,80216],{"trials":82463,"activeCount":97},[82464,82471],{"nctId":82465,"briefTitle":82466,"status":155,"phases":82467,"primaryCompletion":8825,"completion":8825,"start":82468,"enrollment":11953,"conditions":82469,"interventions":82470},"NCT00908037","Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)",[86],"2009-09-30",[505],[82414],{"nctId":82472,"briefTitle":82473,"status":155,"phases":82474,"primaryCompletion":7976,"completion":10166,"start":748,"enrollment":2321,"conditions":82475,"interventions":82476},"NCT00424177","Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)",[86],[505],[82414],{"trials":82478,"activeCount":97},[82479,82492,82499,82506,82513,82520,82524],{"nctId":82480,"briefTitle":82481,"status":145,"phases":82482,"primaryCompletion":11992,"completion":11992,"start":7546,"enrollment":556,"conditions":82483,"interventions":82491},"NCT00678587","Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures",[87],[82484,82485,82486,82487,10662,42685,82488,10090,82489,47886,82490],"Non-alcoholic Steatohepatitis","Chronic Liver Disease","HCV","NASH - Nonalcoholic Steatohepatitis","Hepatitis C Virus","Human Immunodeficiency Virus","Hepatitis B Virus",[23772],{"nctId":82493,"briefTitle":82494,"status":155,"phases":82495,"primaryCompletion":9682,"completion":9682,"start":8426,"enrollment":82496,"conditions":82497,"interventions":82498},"NCT00529568","Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease",[87],759,[42684],[82414],{"nctId":82500,"briefTitle":82501,"status":155,"phases":82502,"primaryCompletion":7598,"completion":7590,"start":8426,"enrollment":82503,"conditions":82504,"interventions":82505},"NCT00516321","Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease",[87],687,[42684],[82414],{"nctId":82507,"briefTitle":82508,"status":155,"phases":82509,"primaryCompletion":7634,"completion":7634,"start":728,"enrollment":2883,"conditions":82510,"interventions":82512},"NCT01520909","Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and\u002For Bleeding Inside the Body.",[87],[82511],"Idiopathic Thrombocytopenic Purpura",[23772],{"nctId":82514,"briefTitle":82515,"status":155,"phases":82516,"primaryCompletion":729,"completion":729,"start":7522,"enrollment":421,"conditions":82517,"interventions":82518},"NCT00828750","Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)",[87],[82511,33672],[82519],"Eltrombopag oral",{"nctId":37859,"briefTitle":37860,"status":155,"phases":82521,"primaryCompletion":3390,"completion":3390,"start":1429,"enrollment":9334,"conditions":82522,"interventions":82523},[87],[23770],[23772,37848],{"nctId":82525,"briefTitle":82526,"status":155,"phases":82527,"primaryCompletion":5018,"completion":5018,"start":4843,"enrollment":10850,"conditions":82528,"interventions":82529},"NCT00370331","RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag",[87],[505],[82414],{"trials":82531,"activeCount":97},[82532],{"nctId":82533,"briefTitle":82534,"status":500,"phases":82535,"primaryCompletion":3044,"completion":3044,"start":503,"enrollment":97,"conditions":82536,"interventions":82537},"NCT01055600","Milk-only Lactation Study for Patients on Eltrombopag",[88],[11033],[82414],{"trials":82539,"activeCount":97},[82540,82546,82552,82558,82564,82571],{"nctId":82541,"briefTitle":82542,"status":155,"phases":82543,"primaryCompletion":503,"completion":503,"start":8406,"enrollment":15259,"conditions":82544,"interventions":82545},"NCT00643929","LENS - Long-term Eltrombopag Observational Study",[],[505],[23772],{"nctId":82547,"briefTitle":82548,"status":155,"phases":82549,"primaryCompletion":11992,"completion":11992,"start":9159,"enrollment":417,"conditions":82550,"interventions":82551},"NCT01235988","Meta-analysis - Eltrombopag",[],[11033],[23772],{"nctId":82553,"briefTitle":82554,"status":155,"phases":82555,"primaryCompletion":3044,"completion":3044,"start":3078,"enrollment":417,"conditions":82556,"interventions":82557},"NCT01064336","Promacta Pregnancy Registry",[],[505],[23772],{"nctId":82559,"briefTitle":82560,"status":155,"phases":82561,"primaryCompletion":7701,"completion":7701,"start":7590,"enrollment":417,"conditions":82562,"interventions":82563},"NCT01458080","WEUSKOP5410: Observational Study in ENABLE Clinical Trials",[],[23770],[82414],{"nctId":82565,"briefTitle":82566,"status":155,"phases":82567,"primaryCompletion":11992,"completion":11992,"start":9159,"enrollment":417,"conditions":82568,"interventions":82569},"NCT01236014","Indirect Comparison Between Eltrombopag & Romiplostim",[],[11033],[23772,82570],"Romiplostim",{"nctId":82572,"briefTitle":82573,"status":155,"phases":82574,"primaryCompletion":9224,"completion":9224,"start":10463,"enrollment":10716,"conditions":82575,"interventions":82576},"NCT01439321","Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim",[],[53822],[23772,82570],{"intervention":9093,"totalTrials":463,"cells":82578},{"EARLY_PHASE1":82579,"PHASE1":82581,"PHASE2":82608,"PHASE3":82625,"PHASE4":82685,"NA":82734},{"trials":82580,"activeCount":97},[],{"trials":82582,"activeCount":97},[82583,82589,82593,82597,82604],{"nctId":82584,"briefTitle":82585,"status":155,"phases":82586,"primaryCompletion":10167,"completion":10167,"start":2355,"enrollment":473,"conditions":82587,"interventions":82588},"NCT00688207","Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)",[85],[4644],[9093],{"nctId":9265,"briefTitle":9266,"status":155,"phases":82590,"primaryCompletion":9268,"completion":9268,"start":9269,"enrollment":314,"conditions":82591,"interventions":82592},[85],[27],[9272,6488,9093,9273],{"nctId":21583,"briefTitle":21584,"status":155,"phases":82594,"primaryCompletion":21586,"completion":21586,"start":8190,"enrollment":433,"conditions":82595,"interventions":82596},[85],[1337],[21589,21590,21591,10467],{"nctId":82598,"briefTitle":82599,"status":155,"phases":82600,"primaryCompletion":42079,"completion":42079,"start":82601,"enrollment":93,"conditions":82602,"interventions":82603},"NCT00318630","The Effect Of AVANDIA On The Late Asthmatic Response",[85],"2005-07-22",[18],[9093],{"nctId":9313,"briefTitle":9314,"status":155,"phases":82605,"primaryCompletion":9316,"completion":9316,"start":9317,"enrollment":31,"conditions":82606,"interventions":82607},[85],[9319],[9321,9093,9273,9322,9323,6488,9324,9325,9326,9327,9093],{"trials":82609,"activeCount":97},[82610,82617],{"nctId":82611,"briefTitle":82612,"status":155,"phases":82613,"primaryCompletion":82614,"completion":69029,"start":23430,"enrollment":2797,"conditions":82615,"interventions":82616},"NCT00381238","Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's Disease",[86],"2009-02-01",[4644],[10467],{"nctId":82618,"briefTitle":82619,"status":155,"phases":82620,"primaryCompletion":82621,"completion":82621,"start":82622,"enrollment":526,"conditions":82623,"interventions":82624},"NCT00265148","Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's Disease",[86],"2008-07-10","2004-05-18",[4644],[9093],{"trials":82626,"activeCount":97},[82627,82634,82640,82646,82653,82662,82666,82673,82677],{"nctId":82628,"briefTitle":82629,"status":155,"phases":82630,"primaryCompletion":42990,"completion":42990,"start":82631,"enrollment":603,"conditions":82632,"interventions":82633},"NCT00297063","BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-",[87],"2006-01-11",[27],[9093],{"nctId":82635,"briefTitle":82636,"status":155,"phases":82637,"completion":4756,"start":2844,"enrollment":730,"conditions":82638,"interventions":82639},"NCT00523913","A Study Of BRL49653C For The Treatment Of Type 2 Diabetes",[87],[27],[10467],{"nctId":82641,"briefTitle":82642,"status":155,"phases":82643,"completion":3036,"start":37767,"enrollment":952,"conditions":82644,"interventions":82645},"NCT00500955","Rosiglitazone on Microalbuminuria in Type 2 Diabetics",[87],[27],[9093],{"nctId":82647,"briefTitle":82648,"status":155,"phases":82649,"primaryCompletion":8386,"completion":8386,"start":7582,"enrollment":1237,"conditions":82650,"interventions":82652},"NCT00231387","Rosiglitazone And Plaque Study for Type 2 Diabetes Mellitus",[87],[82651],"Non-insulin-dependent Diabetes Mellitus",[10467],{"nctId":82654,"briefTitle":82655,"status":155,"phases":82656,"primaryCompletion":17885,"completion":82657,"start":82658,"enrollment":82659,"conditions":82660,"interventions":82661},"NCT00428090","Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease",[87],"2008-09-05","2007-02-27",862,[4644],[9093],{"nctId":9084,"briefTitle":9085,"status":155,"phases":82663,"primaryCompletion":9087,"completion":9088,"start":9089,"enrollment":9090,"conditions":82664,"interventions":82665},[87],[27],[9093,9094,8128],{"nctId":82667,"briefTitle":82668,"status":155,"phases":82669,"primaryCompletion":2805,"completion":2805,"start":20690,"enrollment":710,"conditions":82670,"interventions":82672},"NCT00422955","Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.",[87],[82671],"Neuropathy, Diabetic",[10467],{"nctId":9096,"briefTitle":9097,"status":155,"phases":82674,"primaryCompletion":8468,"completion":8468,"start":2481,"enrollment":9099,"conditions":82675,"interventions":82676},[87],[27],[9093,8065,9016],{"nctId":82678,"briefTitle":82679,"status":155,"phases":82680,"primaryCompletion":39078,"completion":39078,"start":82681,"enrollment":82682,"conditions":82683,"interventions":82684},"NCT00432679","A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study",[87],"2006-05-24",149,[27],[9093],{"trials":82686,"activeCount":97},[82687,82695,82699,82707,82713,82719,82726,82730],{"nctId":82688,"briefTitle":82689,"status":155,"phases":82690,"primaryCompletion":82691,"completion":82691,"start":82692,"enrollment":1982,"conditions":82693,"interventions":82694},"NCT00501020","Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin",[88],"2003-02-13","2001-06-05",[27],[9093],{"nctId":9113,"briefTitle":9114,"status":155,"phases":82696,"primaryCompletion":9116,"completion":9116,"start":9117,"enrollment":9118,"conditions":82697,"interventions":82698},[88],[27],[9093,9016],{"nctId":82700,"briefTitle":82701,"status":155,"phases":82702,"primaryCompletion":82703,"completion":82703,"start":82704,"enrollment":20448,"conditions":82705,"interventions":82706},"NCT00333723","AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone",[88],"2003-01-06","2000-07-28",[27],[9093],{"nctId":82708,"briefTitle":82709,"status":155,"phases":82710,"primaryCompletion":11097,"completion":11097,"start":7909,"enrollment":839,"conditions":82711,"interventions":82712},"NCT00306644","Effect Of Rosiglitazone On Carotid Intima Media Thickness In Patients With Insulin Resistance Syndrome And\u002FOr Type 2 Diabetes",[88],[27],[9093],{"nctId":82714,"briefTitle":82715,"status":155,"phases":82716,"primaryCompletion":2775,"completion":2775,"start":7582,"enrollment":51396,"conditions":82717,"interventions":82718},"NCT00329225","Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin",[88],[27],[10467],{"nctId":82720,"briefTitle":82721,"status":155,"phases":82722,"primaryCompletion":82723,"completion":82723,"start":7909,"enrollment":444,"conditions":82724,"interventions":82725},"NCT00044460","Efficacy and Safety In Poorly Controlled Type 2 Diabetics",[88],"2003-04-10",[27],[10467],{"nctId":10460,"briefTitle":10461,"status":145,"phases":82727,"primaryCompletion":10463,"completion":10463,"start":2795,"enrollment":10464,"conditions":82728,"interventions":82729},[88],[27],[8130,10467],{"nctId":13058,"briefTitle":13059,"status":155,"phases":82731,"completion":2405,"start":13061,"enrollment":13062,"conditions":82732,"interventions":82733},[88],[8063],[9093,13065,13066,13067],{"trials":82735,"activeCount":97},[82736],{"nctId":82737,"briefTitle":82738,"status":155,"phases":82739,"primaryCompletion":2813,"completion":8116,"start":9133,"enrollment":82740,"conditions":82741,"interventions":82742},"NCT00995995","Evaluation of the Duration of Oral Combination Therapy in Type 2 Diabetes, Prior to the Initiation of Insulin in the UK",[],7641,[27],[9093],{"intervention":4762,"totalTrials":1634,"cells":82744},{"EARLY_PHASE1":82745,"PHASE1":82747,"PHASE2":82749,"PHASE3":82770,"PHASE4":82836,"NA":82842},{"trials":82746,"activeCount":97},[],{"trials":82748,"activeCount":97},[],{"trials":82750,"activeCount":97},[82751,82759,82766],{"nctId":82752,"briefTitle":82753,"status":155,"phases":82754,"primaryCompletion":82755,"completion":82755,"start":7848,"enrollment":82756,"conditions":82757,"interventions":82758},"NCT00425737","Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine in Healthy Infants",[86],"2001-07",405,[4759],[4762],{"nctId":82760,"briefTitle":82761,"status":155,"phases":82762,"primaryCompletion":10056,"completion":10056,"start":10288,"enrollment":82763,"conditions":82764,"interventions":82765},"NCT00429481","Assess Efficacy, Immune Response & Safety of 2 Doses of Oral Live Attenuated HRV Vaccine at Different Viral Concentrations in Healthy Infants",[86],2464,[24],[4762],{"nctId":22790,"briefTitle":22791,"status":155,"phases":82767,"primaryCompletion":22793,"completion":11940,"start":22794,"enrollment":414,"conditions":82768,"interventions":82769},[86],[4759],[4762,22797,12324],{"trials":82771,"activeCount":97},[82772,82778,82782,82786,82794,82798,82802,82809,82813,82820,82824,82828,82832],{"nctId":82773,"briefTitle":82774,"status":155,"phases":82775,"primaryCompletion":22484,"completion":11940,"start":3620,"enrollment":1196,"conditions":82776,"interventions":82777},"NCT00396630","A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.",[87],[4759],[4762],{"nctId":11168,"briefTitle":11169,"status":155,"phases":82779,"primaryCompletion":11171,"completion":11171,"start":11172,"enrollment":1608,"conditions":82780,"interventions":82781},[87],[992],[8653,4811,4805,4810,4762,8674,8675,11175],{"nctId":4753,"briefTitle":4754,"status":155,"phases":82783,"completion":4756,"start":4757,"enrollment":4388,"conditions":82784,"interventions":82785},[87],[4759],[4761,4684,4762,4763],{"nctId":82787,"briefTitle":82788,"status":155,"phases":82789,"primaryCompletion":21530,"completion":21530,"start":82790,"enrollment":82791,"conditions":82792,"interventions":82793},"NCT00420316","Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.",[87],"2007-02-12",1613,[4759],[4762],{"nctId":4765,"briefTitle":4766,"status":155,"phases":82795,"primaryCompletion":4768,"completion":4769,"start":4770,"enrollment":4771,"conditions":82796,"interventions":82797},[87],[4759],[4683,4472,4762],{"nctId":32342,"briefTitle":32343,"status":155,"phases":82799,"primaryCompletion":32345,"completion":2311,"start":32346,"enrollment":32347,"conditions":82800,"interventions":82801},[87],[4759,5000],[32331,4762],{"nctId":82803,"briefTitle":82804,"status":155,"phases":82805,"primaryCompletion":33172,"completion":82806,"start":46387,"enrollment":51710,"conditions":82807,"interventions":82808},"NCT00480324","Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants",[87],"2009-11-21",[4759,5000],[4762],{"nctId":18802,"briefTitle":18803,"status":155,"phases":82810,"primaryCompletion":18805,"completion":18806,"start":18807,"enrollment":12261,"conditions":82811,"interventions":82812},[87],[3637],[3639,12323,18810,4762,18811],{"nctId":82814,"briefTitle":82815,"status":155,"phases":82816,"primaryCompletion":2405,"completion":2405,"start":19831,"enrollment":82817,"conditions":82818,"interventions":82819},"NCT00757770","Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals' HRV Vaccine",[87],854,[4759],[4762],{"nctId":4796,"briefTitle":4797,"status":155,"phases":82821,"primaryCompletion":4799,"completion":4800,"start":4801,"enrollment":4802,"conditions":82822,"interventions":82823},[87],[4702,30,4704,33,3624,24],[4472,4805,4806,4807,4808,4809,4810,4811,4762],{"nctId":4813,"briefTitle":4814,"status":155,"phases":82825,"primaryCompletion":4816,"completion":4816,"start":4817,"enrollment":4818,"conditions":82826,"interventions":82827},[87],[3637],[4744,4472,4821,4762],{"nctId":4832,"briefTitle":4833,"status":155,"phases":82829,"primaryCompletion":4835,"completion":4835,"start":4836,"enrollment":4771,"conditions":82830,"interventions":82831},[87],[3637,4742],[4683,4472,4762],{"nctId":4991,"briefTitle":4992,"status":155,"phases":82833,"primaryCompletion":4994,"completion":4995,"start":4996,"enrollment":4997,"conditions":82834,"interventions":82835},[87],[4999,5000],[4762,4805,4810,4485],{"trials":82837,"activeCount":97},[82838],{"nctId":16141,"briefTitle":16142,"status":155,"phases":82839,"primaryCompletion":16144,"completion":16144,"start":16145,"enrollment":556,"conditions":82840,"interventions":82841},[88],[16147],[16128,4762],{"trials":82843,"activeCount":97},[82844],{"nctId":82845,"briefTitle":82846,"status":155,"phases":82847,"primaryCompletion":11274,"completion":82848,"start":62917,"enrollment":11217,"conditions":82849,"interventions":82850},"NCT00353366","To Evaluate Safety & Reactogenicity of GSK Bio's Human Rotavirus (HRV) Vaccine in Filipino Infants at Least 6 Weeks of Age at First Vaccination",[],"2010-07-17",[4759,5000],[4762],{"intervention":63019,"totalTrials":7438,"cells":82852},{"EARLY_PHASE1":82853,"PHASE1":82855,"PHASE2":82883,"PHASE3":82885,"PHASE4":82903,"NA":82934},{"trials":82854,"activeCount":97},[],{"trials":82856,"activeCount":97},[82857,82861,82867,82875,82879],{"nctId":63013,"briefTitle":63014,"status":155,"phases":82858,"primaryCompletion":3462,"completion":3462,"start":63016,"enrollment":44739,"conditions":82859,"interventions":82860},[85],[12263],[63019,63019,63006,63006,63006,63006,63020,63020,63021],{"nctId":82862,"briefTitle":82863,"status":155,"phases":82864,"primaryCompletion":26473,"completion":26473,"start":26159,"enrollment":8786,"conditions":82865,"interventions":82866},"NCT01577693","Study to Compare the Bioavailability of Dutasteride Novel Formulation Form to the Soft Gel Capsule Form in Healthy Male Subjects",[85],[12263],[13084,13084],{"nctId":82868,"briefTitle":82869,"status":155,"phases":82870,"primaryCompletion":82871,"completion":82871,"start":82872,"enrollment":34,"conditions":82873,"interventions":82874},"NCT01254071","A Study to Determine the Bioavailability of a Fixed Dose Combination Product of Dutasteride (0.5mg) and Tamsulosin Hydrochloride (0.2mg) Relative to Co-administration of the Individual Components in Healthy Male Subjects of North East Asian and Non-Asian Ancestry.",[85],"2010-12-21","2010-09-10",[12263],[63019],{"nctId":67725,"briefTitle":67726,"status":155,"phases":82876,"primaryCompletion":67728,"completion":67728,"start":3369,"enrollment":9334,"conditions":82877,"interventions":82878},[85],[12263],[63019,67718,67731],{"nctId":13078,"briefTitle":13079,"status":155,"phases":82880,"primaryCompletion":8336,"completion":8336,"start":9862,"enrollment":8786,"conditions":82881,"interventions":82882},[85],[12263],[13083,13084,12273],{"trials":82884,"activeCount":97},[],{"trials":82886,"activeCount":97},[82887,82896],{"nctId":82888,"briefTitle":82889,"status":155,"phases":82890,"primaryCompletion":8207,"completion":82891,"start":82892,"enrollment":82893,"conditions":82894,"interventions":82895},"NCT00368979","Dutasteride (GI198745) In Benign Prostatic Hyperplasia Subjects",[87],"2007-12-06","2006-02-17",378,[12263],[63019],{"nctId":82897,"briefTitle":82898,"status":155,"phases":82899,"primaryCompletion":2813,"completion":3550,"start":21220,"enrollment":82900,"conditions":82901,"interventions":82902},"NCT00056407","\"REDUCE\" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk",[87],8231,[5634],[63019],{"trials":82904,"activeCount":97},[82905,82911,82915,82921,82928],{"nctId":82906,"briefTitle":82907,"status":145,"phases":82908,"start":748,"enrollment":1589,"conditions":82909,"interventions":82910},"NCT00421421","Effects Of Dutasteride On Risk Reduction Of Acute Urinary Retention Relapse Following Trial Without Catheter",[88],[22619],[63019],{"nctId":17335,"briefTitle":17336,"status":155,"phases":82912,"primaryCompletion":3390,"completion":3390,"start":2835,"enrollment":4377,"conditions":82913,"interventions":82914},[88],[5634],[13084,17322],{"nctId":82916,"briefTitle":82917,"status":155,"phases":82918,"completion":10212,"start":7581,"enrollment":1003,"conditions":82919,"interventions":82920},"NCT00062790","Effect Of Dutasteride On Intraprostatic Dihydrotestosterone (DHT) Levels",[88],[12263],[63019],{"nctId":82922,"briefTitle":82923,"status":155,"phases":82924,"primaryCompletion":2428,"completion":2428,"start":7785,"enrollment":345,"conditions":82925,"interventions":82927},"NCT00375765","Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer",[88],[22619,82926],"Prostate Cancer",[63019],{"nctId":82929,"briefTitle":82930,"status":155,"phases":82931,"primaryCompletion":3078,"completion":1428,"start":8963,"enrollment":1272,"conditions":82932,"interventions":82933},"NCT00363311","Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men",[88],[5634],[63019],{"trials":82935,"activeCount":97},[82936,82943,82951,82957,82963],{"nctId":82937,"briefTitle":82938,"status":155,"phases":82939,"primaryCompletion":1428,"completion":1428,"start":1361,"enrollment":82940,"conditions":82941,"interventions":82942},"NCT01299571","AVODART(Dutasteride) Post-marketing Surveillance(PMS)",[],3977,[22619,12263],[63019],{"nctId":82944,"briefTitle":82945,"status":155,"phases":82946,"primaryCompletion":11746,"completion":11747,"start":82947,"enrollment":82948,"conditions":82949,"interventions":82950},"NCT01004809","AVODART® Alopecia Post-marketing Surveillance (PMS)",[],"2010-04-29",712,[22627],[63019],{"nctId":82952,"briefTitle":82953,"status":155,"phases":82954,"primaryCompletion":1428,"completion":1428,"start":26336,"enrollment":417,"conditions":82955,"interventions":82956},"NCT01337258","Economic Analyses of the REDUCE Trial",[],[5634,22619,36],[63019],{"nctId":82958,"briefTitle":82959,"status":155,"phases":82960,"primaryCompletion":3045,"completion":19576,"start":2344,"enrollment":15623,"conditions":82961,"interventions":82962},"NCT01376284","Drug Use Investigation for AVOLVE(BPH)",[],[12263],[63019],{"nctId":82964,"briefTitle":82965,"status":155,"phases":82966,"primaryCompletion":22592,"completion":9890,"start":74816,"enrollment":82967,"conditions":82968,"interventions":82969},"NCT00883909","ARI103094-Follow-Up Study for REDUCE Study Subjects",[],2795,[5634],[13084],{"intervention":41432,"totalTrials":433,"cells":82971},{"EARLY_PHASE1":82972,"PHASE1":82974,"PHASE2":82983,"PHASE3":83023,"PHASE4":83031,"NA":83039},{"trials":82973,"activeCount":97},[],{"trials":82975,"activeCount":97},[82976],{"nctId":82977,"briefTitle":82978,"status":155,"phases":82979,"primaryCompletion":82980,"completion":82980,"start":57,"enrollment":12044,"conditions":82981,"interventions":82982},"NCT06065735","Concentration-QT Study of Paroxetine in Healthy Adults",[85],"2024-01-08",[63101],[41432],{"trials":82984,"activeCount":97},[82985,82989,82996,83004,83008,83012,83016],{"nctId":39230,"briefTitle":39231,"status":155,"phases":82986,"primaryCompletion":39233,"completion":39233,"start":39234,"enrollment":39235,"conditions":82987,"interventions":82988},[86],[26760],[9302,39238],{"nctId":82990,"briefTitle":82991,"status":155,"phases":82992,"primaryCompletion":2805,"completion":2383,"start":8750,"conditions":82993,"interventions":82995},"NCT00135525","Study Of Generalized Anxiety Disorder",[86],[82994,63101],"Anxiety Disorder",[41432],{"nctId":82997,"briefTitle":82998,"status":145,"phases":82999,"primaryCompletion":66178,"completion":66178,"start":83000,"enrollment":1517,"conditions":83001,"interventions":83003},"NCT00557622","Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)",[86],"2008-01-25",[40995,83002],"Stress Disorders, Post-Traumatic",[39238],{"nctId":44203,"briefTitle":44204,"status":155,"phases":83005,"primaryCompletion":2844,"completion":2844,"start":11097,"enrollment":1264,"conditions":83006,"interventions":83007},[86],[41867],[44194,39238],{"nctId":55550,"briefTitle":55551,"status":155,"phases":83009,"primaryCompletion":29615,"completion":29615,"start":55553,"enrollment":55554,"conditions":83010,"interventions":83011},[86],[10889],[55541,39238],{"nctId":41426,"briefTitle":41427,"status":155,"phases":83013,"primaryCompletion":4768,"completion":22482,"start":41429,"enrollment":1381,"conditions":83014,"interventions":83015},[86],[9292],[41404,41432],{"nctId":83017,"briefTitle":83018,"status":155,"phases":83019,"primaryCompletion":4757,"completion":4757,"start":10395,"enrollment":4094,"conditions":83020,"interventions":83022},"NCT00273039","A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder",[86],[83021,63101],"Social Anxiety Disorder",[39238],{"trials":83024,"activeCount":97},[83025],{"nctId":83026,"briefTitle":83027,"status":155,"phases":83028,"primaryCompletion":11097,"completion":2796,"start":7909,"enrollment":3025,"conditions":83029,"interventions":83030},"NCT00839397","BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder",[87],[40995],[41432],{"trials":83032,"activeCount":97},[83033],{"nctId":83034,"briefTitle":83035,"status":155,"phases":83036,"primaryCompletion":11759,"completion":11759,"start":2796,"enrollment":1579,"conditions":83037,"interventions":83038},"NCT00259883","Combination Of PAXIL Tablet And Benzodiazepines",[88],[65610],[39238],{"trials":83040,"activeCount":97},[83041,83048,83054,83061,83067,83073],{"nctId":83042,"briefTitle":83043,"status":155,"phases":83044,"primaryCompletion":8116,"completion":2795,"start":2382,"enrollment":21520,"conditions":83045,"interventions":83047},"NCT01376128","Special Drug Use Investigation for PAXIL Tablet (Pediatric Panic Disorder)",[],[83046],"Panic Disorder",[41432],{"nctId":83049,"briefTitle":83050,"status":155,"phases":83051,"primaryCompletion":493,"completion":493,"start":26336,"enrollment":1944,"conditions":83052,"interventions":83053},"NCT01376271","Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)",[],[26760],[41432],{"nctId":83055,"briefTitle":83056,"status":155,"phases":83057,"primaryCompletion":2382,"completion":7546,"start":4844,"enrollment":83058,"conditions":83059,"interventions":83060},"NCT01371474","Special Drug Use Investigation for PAXIL Tablet (Investigation in Case of Administered From 20mg\u002FDay)",[],1483,[83046],[41432],{"nctId":83062,"briefTitle":83063,"status":155,"phases":83064,"primaryCompletion":3714,"completion":8478,"start":2405,"enrollment":26758,"conditions":83065,"interventions":83066},"NCT01371461","Special Drug Use Investigation for PAXIL Tablet (20mg-Clinical Symptom Progression)",[],[65610],[41432],{"nctId":83068,"briefTitle":83069,"status":155,"phases":83070,"primaryCompletion":2823,"completion":8427,"start":7838,"enrollment":940,"conditions":83071,"interventions":83072},"NCT01371448","Special Drug Use Investigation for PAXIL Tablet (Long-term)",[],[65610],[41432],{"nctId":83074,"briefTitle":83075,"status":155,"phases":83076,"primaryCompletion":8427,"completion":749,"start":2481,"enrollment":83077,"conditions":83078,"interventions":83079},"NCT01371435","Drug Use Investigation for PAXIL Tablet",[],3708,[65610],[41432],{"intervention":1366,"totalTrials":433,"cells":83081},{"EARLY_PHASE1":83082,"PHASE1":83084,"PHASE2":83098,"PHASE3":83173,"PHASE4":83182,"NA":83184},{"trials":83083,"activeCount":97},[],{"trials":83085,"activeCount":97},[83086,83092],{"nctId":83087,"briefTitle":83088,"status":155,"phases":83089,"start":1360,"enrollment":2384,"conditions":83090,"interventions":83091},"NCT00332046","fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder",[85],[83021],[1366],{"nctId":83093,"briefTitle":83094,"status":155,"phases":83095,"primaryCompletion":23134,"completion":23134,"start":11118,"enrollment":1298,"conditions":83096,"interventions":83097},"NCT00359177","Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment",[85],[20347],[1366],{"trials":83099,"activeCount":97},[83100,83106,83110,83116,83122,83130,83136,83143,83149,83153,83161,83167],{"nctId":83101,"briefTitle":83102,"status":155,"phases":83103,"primaryCompletion":8406,"completion":8406,"start":1360,"enrollment":8469,"conditions":83104,"interventions":83105},"NCT00280423","Effects Of GW679769 On Sleep Onset And Maintenance And Next Day Functioning In Subjects With Primary Insomnia",[86],[19716,40289],[1366],{"nctId":1357,"briefTitle":1358,"status":155,"phases":83107,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1362,"conditions":83108,"interventions":83109},[86],[1337,1364],[1366,283,1367],{"nctId":83111,"briefTitle":83112,"status":155,"phases":83113,"primaryCompletion":4757,"completion":4757,"start":2796,"enrollment":9518,"conditions":83114,"interventions":83115},"NCT00413023","Study Of The Effects Of A New Antidepressant Therapy In Patients With Major Depressive Disorder (MDD)",[86],[10889],[1366],{"nctId":83117,"briefTitle":83118,"status":155,"phases":83119,"primaryCompletion":4757,"completion":4757,"start":8478,"enrollment":46944,"conditions":83120,"interventions":83121},"NCT00102492","Study Of GW679769 In Major Depressive Disorder",[86],[10889,10890],[1366],{"nctId":83123,"briefTitle":83124,"status":155,"phases":83125,"primaryCompletion":2296,"completion":2296,"start":1360,"enrollment":3131,"conditions":83126,"interventions":83128},"NCT00358410","An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia",[86],[83127],"Nonulcer Dyspepsia",[83129],"GW679769 oral",{"nctId":83131,"briefTitle":83132,"status":155,"phases":83133,"primaryCompletion":10395,"completion":10395,"start":1380,"enrollment":81867,"conditions":83134,"interventions":83135},"NCT00274690","Post-Operative Nausea And Vomiting Study In Female Patients",[86],[21615,21614],[1366],{"nctId":83137,"briefTitle":83138,"status":145,"phases":83139,"primaryCompletion":8406,"completion":8406,"start":1360,"enrollment":417,"conditions":83140,"interventions":83142},"NCT00332319","Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients",[86],[83141,42302],"Incontinence, Urinary and Urinary Bladder, Overactive",[1366],{"nctId":83144,"briefTitle":83145,"status":155,"phases":83146,"primaryCompletion":2428,"completion":2428,"start":2383,"enrollment":37,"conditions":83147,"interventions":83148},"NCT00354809","Evaluation of A Morning Dosing Of A New Medicine And Its Effects On Sleep At Bedtime In Subjects With Primary Insomnia",[86],[19716,40289],[1366],{"nctId":1377,"briefTitle":1378,"status":155,"phases":83150,"start":1380,"enrollment":1381,"conditions":83151,"interventions":83152},[86],[1383,1384],[1386,1387,1366,283],{"nctId":83154,"briefTitle":83155,"status":155,"phases":83156,"primaryCompletion":83157,"completion":83157,"start":83158,"enrollment":6503,"conditions":83159,"interventions":83160},"NCT00650871","A Study to Evaluate the Effects of GW679769 on Sleep and Cognitive Function in Subjects With Primary Insomnia",[86],"2005-08-30","2004-07-30",[19716],[1366],{"nctId":83162,"briefTitle":83163,"status":155,"phases":83164,"primaryCompletion":748,"completion":748,"start":1360,"enrollment":25604,"conditions":83165,"interventions":83166},"NCT00280436","Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia",[86],[19716,40289],[1366],{"nctId":83168,"briefTitle":83169,"status":155,"phases":83170,"primaryCompletion":8406,"completion":8406,"start":749,"enrollment":3392,"conditions":83171,"interventions":83172},"NCT00321477","A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder",[86],[83141,42302],[83129],{"trials":83174,"activeCount":97},[83175],{"nctId":83176,"briefTitle":83177,"status":155,"phases":83178,"primaryCompletion":8963,"completion":8963,"start":7613,"enrollment":83179,"conditions":83180,"interventions":83181},"NCT00326248","Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women",[87],482,[21614],[1366],{"trials":83183,"activeCount":97},[],{"trials":83185,"activeCount":97},[83186],{"nctId":83187,"briefTitle":83188,"status":155,"phases":83189,"primaryCompletion":4757,"completion":4757,"start":2805,"enrollment":1720,"conditions":83190,"interventions":83193},"NCT00264628","GW679769 In Fibromyalgia",[],[9292,83191,83192],"Depression","Fibromyalgia",[1366],{"intervention":9000,"totalTrials":1117,"cells":83195},{"EARLY_PHASE1":83196,"PHASE1":83198,"PHASE2":83206,"PHASE3":83226,"PHASE4":83274,"NA":83289},{"trials":83197,"activeCount":97},[],{"trials":83199,"activeCount":97},[83200],{"nctId":83201,"briefTitle":83202,"status":155,"phases":83203,"primaryCompletion":7445,"completion":7445,"start":19094,"enrollment":42446,"conditions":83204,"interventions":83205},"NCT00541970","Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs",[85],[8723],[9000],{"trials":83207,"activeCount":97},[83208,83214,83220],{"nctId":83209,"briefTitle":83210,"status":155,"phases":83211,"primaryCompletion":5018,"completion":3551,"start":3079,"enrollment":19873,"conditions":83212,"interventions":83213},"NCT00518336","Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil",[86],[8723],[9000],{"nctId":83215,"briefTitle":83216,"status":155,"phases":83217,"primaryCompletion":10056,"completion":10056,"start":10288,"enrollment":3179,"conditions":83218,"interventions":83219},"NCT00689741","Efficacy Study of HPV-16\u002F18 Vaccine (GSK 580299) to Prevent HPV-16 and\u002For -18 Cervical Infection in Young Healthy Women",[86],[8723],[9000],{"nctId":83221,"briefTitle":83222,"status":155,"phases":83223,"primaryCompletion":3377,"completion":3377,"start":38966,"enrollment":1579,"conditions":83224,"interventions":83225},"NCT00586339","Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females",[86],[8723],[9000],{"trials":83227,"activeCount":97},[83228,83236,83245,83249,83257,83264,83268],{"nctId":83229,"briefTitle":83230,"status":155,"phases":83231,"primaryCompletion":62646,"completion":18835,"start":8305,"enrollment":83232,"conditions":83233,"interventions":83235},"NCT00481767","Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.",[87],676,[83234],"Human Papillomavirus (HPV) Infection",[9000],{"nctId":83237,"briefTitle":83238,"status":155,"phases":83239,"primaryCompletion":83240,"completion":83240,"start":83241,"enrollment":83242,"conditions":83243,"interventions":83244},"NCT00294047","Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older",[87],"2014-01-29","2006-02-16",5752,[8723,12417],[9000],{"nctId":20808,"briefTitle":20809,"status":155,"phases":83246,"primaryCompletion":20811,"completion":20812,"start":20813,"enrollment":20814,"conditions":83247,"interventions":83248},[87],[8723],[9000,8673,4809],{"nctId":83250,"briefTitle":83251,"status":155,"phases":83252,"primaryCompletion":83253,"completion":83253,"start":83254,"enrollment":15726,"conditions":83255,"interventions":83256},"NCT00196937","Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16\u002F18",[87],"2005-12-15","2004-10-07",[8723],[9000],{"nctId":83258,"briefTitle":83259,"status":155,"phases":83260,"primaryCompletion":83261,"completion":83261,"start":7446,"enrollment":1736,"conditions":83262,"interventions":83263},"NCT01190176","Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects",[87],"2017-09-20",[8723],[9000],{"nctId":38038,"briefTitle":38039,"status":155,"phases":83265,"primaryCompletion":22238,"completion":22238,"start":38041,"enrollment":38042,"conditions":83266,"interventions":83267},[87],[8723],[9000,38027],{"nctId":83269,"briefTitle":83270,"status":155,"phases":83271,"primaryCompletion":3551,"completion":3551,"start":2795,"enrollment":2883,"conditions":83272,"interventions":83273},"NCT00811798","Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.",[87],[8723],[9000],{"trials":83275,"activeCount":97},[83276,83280],{"nctId":8992,"briefTitle":8993,"status":155,"phases":83277,"primaryCompletion":8995,"completion":8995,"start":8996,"enrollment":8997,"conditions":83278,"interventions":83279},[88],[8723],[9000,4808],{"nctId":83281,"briefTitle":83282,"status":145,"phases":83283,"primaryCompletion":21411,"completion":21411,"start":83284,"enrollment":83285,"conditions":83286,"interventions":83288},"NCT00730847","A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards.",[88],"2008-09-17",743,[83287],"Human Papillomavirus Infection Leading to Cervical Cancer",[9000],{"trials":83290,"activeCount":97},[83291,83298],{"nctId":83292,"briefTitle":83293,"status":155,"phases":83294,"primaryCompletion":34933,"completion":34933,"start":7976,"enrollment":83295,"conditions":83296,"interventions":83297},"NCT01498627","Cervarix Long-term Safety Surveillance",[],2945,[8723],[9000],{"nctId":83299,"briefTitle":83300,"status":155,"phases":83301,"primaryCompletion":22319,"completion":22319,"start":8089,"enrollment":47596,"conditions":83302,"interventions":83303},"NCT01905462","Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK",[],[8723],[9000],{"intervention":25702,"totalTrials":1117,"cells":83305},{"EARLY_PHASE1":83306,"PHASE1":83308,"PHASE2":83318,"PHASE3":83340,"PHASE4":83372,"NA":83374},{"trials":83307,"activeCount":97},[],{"trials":83309,"activeCount":97},[83310,83314],{"nctId":71629,"briefTitle":71630,"status":155,"phases":83311,"primaryCompletion":24869,"completion":24869,"start":65769,"enrollment":345,"conditions":83312,"interventions":83313},[85],[21],[71622,71634,25702],{"nctId":77818,"briefTitle":77819,"status":155,"phases":83315,"primaryCompletion":8826,"completion":22341,"start":4778,"enrollment":1196,"conditions":83316,"interventions":83317},[85],[21],[77811,25702],{"trials":83319,"activeCount":97},[83320,83324,83328,83332,83336],{"nctId":46859,"briefTitle":46860,"status":155,"phases":83321,"primaryCompletion":46862,"completion":46862,"start":46863,"enrollment":8529,"conditions":83322,"interventions":83323},[86],[21],[25702,46850,46866,46867,46868],{"nctId":49687,"briefTitle":49688,"status":155,"phases":83325,"primaryCompletion":18825,"completion":18825,"start":49690,"enrollment":49691,"conditions":83326,"interventions":83327},[86],[21],[49678,25702],{"nctId":45334,"briefTitle":45335,"status":155,"phases":83329,"completion":24105,"start":45337,"enrollment":45338,"conditions":83330,"interventions":83331},[86],[21],[25702,45325],{"nctId":43050,"briefTitle":43051,"status":155,"phases":83333,"primaryCompletion":20425,"completion":20425,"start":8198,"enrollment":9392,"conditions":83334,"interventions":83335},[86],[21],[43055,25702],{"nctId":45342,"briefTitle":45343,"status":155,"phases":83337,"completion":7659,"start":2404,"enrollment":1196,"conditions":83338,"interventions":83339},[86],[21],[25702,45325],{"trials":83341,"activeCount":97},[83342,83346,83350,83354,83360,83364,83368],{"nctId":25697,"briefTitle":25698,"status":155,"phases":83343,"completion":4843,"start":4757,"enrollment":19789,"conditions":83344,"interventions":83345},[87],[21],[25679,25702],{"nctId":26993,"briefTitle":26994,"status":155,"phases":83347,"primaryCompletion":26996,"completion":16322,"start":17894,"enrollment":26997,"conditions":83348,"interventions":83349},[87],[21],[25702,8311],{"nctId":27019,"briefTitle":27020,"status":155,"phases":83351,"primaryCompletion":27022,"completion":27022,"start":27023,"enrollment":27024,"conditions":83352,"interventions":83353},[87],[21],[26949,25702],{"nctId":83355,"briefTitle":83356,"status":155,"phases":83357,"completion":2296,"start":8963,"enrollment":201,"conditions":83358,"interventions":83359},"NCT00345904","Study to Evaluate the Safety and Immunogenicity of Fluarix™ 2006\u002F2007 in Adults Aged 18 Years or Above",[87],[21],[25702],{"nctId":36033,"briefTitle":36034,"status":155,"phases":83361,"primaryCompletion":25728,"completion":36036,"start":8217,"enrollment":36037,"conditions":83362,"interventions":83363},[87],[21],[25702,36022],{"nctId":36661,"briefTitle":36662,"status":155,"phases":83365,"primaryCompletion":36664,"completion":9307,"start":36665,"enrollment":36666,"conditions":83366,"interventions":83367},[87],[21],[36650,25702],{"nctId":38688,"briefTitle":38689,"status":155,"phases":83369,"primaryCompletion":3619,"completion":12180,"start":920,"enrollment":38691,"conditions":83370,"interventions":83371},[87],[21],[38677,25702],{"trials":83373,"activeCount":97},[],{"trials":83375,"activeCount":97},[83376],{"nctId":83377,"briefTitle":83378,"status":155,"phases":83379,"primaryCompletion":7659,"completion":7659,"start":7613,"enrollment":83380,"conditions":83381,"interventions":83382},"NCT00306982","Incidence of Influenza, Downstream Complications of Influenza & Hospitalizations in Elderly Vaccinated With Fluarix™",[],1524,[21],[25702],{"intervention":2934,"totalTrials":3131,"cells":83384},{"EARLY_PHASE1":83385,"PHASE1":83387,"PHASE2":83393,"PHASE3":83411,"PHASE4":83429,"NA":83443},{"trials":83386,"activeCount":97},[],{"trials":83388,"activeCount":97},[83389],{"nctId":39403,"briefTitle":39404,"status":155,"phases":83390,"primaryCompletion":39406,"completion":39406,"start":39407,"enrollment":3379,"conditions":83391,"interventions":83392},[85],[15],[9403,2934],{"trials":83394,"activeCount":97},[83395,83399,83403,83407],{"nctId":18401,"briefTitle":18402,"status":155,"phases":83396,"primaryCompletion":4973,"completion":18404,"start":11961,"enrollment":781,"conditions":83397,"interventions":83398},[86],[15],[18345,18345,18345,18345,18345,18345,2934],{"nctId":18408,"briefTitle":18409,"status":155,"phases":83400,"primaryCompletion":4827,"completion":4827,"start":18411,"enrollment":1298,"conditions":83401,"interventions":83402},[86],[15],[18345,2934],{"nctId":52774,"briefTitle":52775,"status":155,"phases":83404,"primaryCompletion":11275,"completion":8008,"start":52777,"enrollment":17033,"conditions":83405,"interventions":83406},[86],[15],[2934,52765],{"nctId":9397,"briefTitle":9398,"status":155,"phases":83408,"primaryCompletion":2835,"completion":2835,"start":2404,"enrollment":1237,"conditions":83409,"interventions":83410},[86],[15],[9402,2980,9403],{"trials":83412,"activeCount":97},[83413,83417,83421,83425],{"nctId":11642,"briefTitle":11643,"status":155,"phases":83414,"primaryCompletion":11645,"completion":11645,"start":11646,"enrollment":11647,"conditions":83415,"interventions":83416},[87],[15],[8622,2934,11650,11651],{"nctId":82354,"briefTitle":82355,"status":155,"phases":83418,"primaryCompletion":30042,"completion":72800,"start":3369,"enrollment":45434,"conditions":83419,"interventions":83420},[87],[15],[8556,2934],{"nctId":2926,"briefTitle":2927,"status":500,"phases":83422,"primaryCompletion":2929,"completion":2929,"start":2930,"enrollment":97,"conditions":83423,"interventions":83424},[87],[18],[2895,2933,2934,2916],{"nctId":12073,"briefTitle":12074,"status":155,"phases":83426,"primaryCompletion":12076,"completion":12077,"start":11658,"enrollment":12078,"conditions":83427,"interventions":83428},[87],[15],[12052,2934],{"trials":83430,"activeCount":97},[83431,83435,83439],{"nctId":2963,"briefTitle":2964,"status":155,"phases":83432,"primaryCompletion":2966,"completion":2966,"start":2967,"enrollment":1924,"conditions":83433,"interventions":83434},[88],[15],[2895,2934,2916],{"nctId":2971,"briefTitle":2972,"status":155,"phases":83436,"primaryCompletion":1116,"completion":1116,"start":2974,"enrollment":2975,"conditions":83437,"interventions":83438},[88],[15],[2978,2979,2895,2980],{"nctId":2982,"briefTitle":2983,"status":155,"phases":83440,"primaryCompletion":2985,"completion":2985,"start":2974,"enrollment":2986,"conditions":83441,"interventions":83442},[88],[15],[2978,2979,2895,2980],{"trials":83444,"activeCount":97},[83445],{"nctId":83446,"briefTitle":83447,"status":155,"phases":83448,"primaryCompletion":7647,"completion":7647,"start":2441,"enrollment":83449,"conditions":83450,"interventions":83451},"NCT01331694","Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg\u002FSalmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[],76130,[15],[83452,2980,83453],"fluticasone\u002Fsalmeterol combination (FSC) 250\u002F50mcg","ipratropium bromide alone or in fixed dose combination with albuterol",{"intervention":3048,"totalTrials":3131,"cells":83455},{"EARLY_PHASE1":83456,"PHASE1":83458,"PHASE2":83499,"PHASE3":83528,"PHASE4":83530,"NA":83532},{"trials":83457,"activeCount":97},[],{"trials":83459,"activeCount":97},[83460,83464,83468,83476,83483,83487,83491,83495],{"nctId":41768,"briefTitle":41769,"status":155,"phases":83461,"primaryCompletion":41771,"completion":41771,"start":41772,"enrollment":12044,"conditions":83462,"interventions":83463},[85],[2761],[41775,3048,247],{"nctId":69578,"briefTitle":69579,"status":155,"phases":83465,"primaryCompletion":4721,"completion":4721,"start":63952,"enrollment":1634,"conditions":83466,"interventions":83467},[85],[36],[3048,69571],{"nctId":83469,"briefTitle":83470,"status":500,"phases":83471,"primaryCompletion":83472,"completion":83473,"start":6824,"enrollment":97,"conditions":83474,"interventions":83475},"NCT02447939","Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma",[85],"2018-10","2018-12",[325],[41775,3048],{"nctId":83477,"briefTitle":83478,"status":500,"phases":83479,"primaryCompletion":83480,"completion":83473,"start":6824,"enrollment":97,"conditions":83481,"interventions":83482},"NCT02939846","Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours",[85],"2018-08",[36],[3048],{"nctId":3041,"briefTitle":3042,"status":500,"phases":83484,"primaryCompletion":3044,"completion":3044,"start":3045,"enrollment":97,"conditions":83485,"interventions":83486},[85],[267],[3048,164,3049],{"nctId":60430,"briefTitle":60431,"status":155,"phases":83488,"primaryCompletion":158,"completion":158,"start":60433,"enrollment":1736,"conditions":83489,"interventions":83490},[85],[36,107],[60415,3048],{"nctId":79232,"briefTitle":79233,"status":155,"phases":83492,"primaryCompletion":158,"completion":158,"start":79235,"enrollment":695,"conditions":83493,"interventions":83494},[85],[36],[3048,79225],{"nctId":3055,"briefTitle":3056,"status":155,"phases":83496,"primaryCompletion":3058,"completion":3058,"start":3059,"enrollment":803,"conditions":83497,"interventions":83498},[85],[36],[3048,164,3062,165,135,3063,134],{"trials":83500,"activeCount":97},[83501,83508,83512,83518],{"nctId":83502,"briefTitle":83503,"status":155,"phases":83504,"primaryCompletion":17134,"completion":5160,"start":83505,"enrollment":454,"conditions":83506,"interventions":83507},"NCT01943864","A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers",[86],"2013-09-19",[36],[3048,3048],{"nctId":44666,"briefTitle":44667,"status":500,"phases":83509,"primaryCompletion":44669,"completion":44669,"start":43679,"enrollment":97,"conditions":83510,"interventions":83511},[86],[2761],[44648,3048],{"nctId":83513,"briefTitle":83514,"status":145,"phases":83515,"primaryCompletion":46099,"completion":46099,"start":18244,"enrollment":6503,"conditions":83516,"interventions":83517},"NCT02314143","Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib",[86],[325],[41775,3048],{"nctId":83519,"briefTitle":83520,"status":155,"phases":83521,"primaryCompletion":25481,"completion":83522,"start":83523,"enrollment":1459,"conditions":83524,"interventions":83525},"NCT01928940","Japan PhI\u002FII of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E\u002FK Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)",[86],"2016-07-04","2013-08-15",[2761],[83526,83527],"dabrafenib","trametinib",{"trials":83529,"activeCount":97},[],{"trials":83531,"activeCount":97},[],{"trials":83533,"activeCount":97},[83534],{"nctId":83535,"briefTitle":83536,"status":969,"phases":83537,"conditions":83538,"interventions":83539},"NCT02416232","Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E\u002FK Mutation Positive Cutaneous Melanoma",[],[325],[3048,41775],{"intervention":963,"totalTrials":361,"cells":83541},{"EARLY_PHASE1":83542,"PHASE1":83544,"PHASE2":83554,"PHASE3":83560,"PHASE4":83578,"NA":83592},{"trials":83543,"activeCount":97},[],{"trials":83545,"activeCount":97},[83546,83550],{"nctId":11703,"briefTitle":11704,"status":155,"phases":83547,"primaryCompletion":11706,"completion":11706,"start":11707,"enrollment":361,"conditions":83548,"interventions":83549},[85],[15],[963,8632],{"nctId":11711,"briefTitle":11712,"status":155,"phases":83551,"primaryCompletion":11714,"completion":11714,"start":11715,"enrollment":1634,"conditions":83552,"interventions":83553},[85],[15],[11718,963,8632],{"trials":83555,"activeCount":97},[83556],{"nctId":10781,"briefTitle":10782,"status":155,"phases":83557,"primaryCompletion":5196,"completion":5196,"start":4844,"enrollment":1686,"conditions":83558,"interventions":83559},[86],[15],[10786,10787,10772],{"trials":83561,"activeCount":97},[83562,83566,83570,83574],{"nctId":24413,"briefTitle":24414,"status":155,"phases":83563,"primaryCompletion":24416,"completion":24417,"start":4721,"enrollment":24418,"conditions":83564,"interventions":83565},[87],[18],[24402,24421,10787],{"nctId":29509,"briefTitle":29510,"status":155,"phases":83567,"primaryCompletion":29512,"completion":29512,"start":29513,"enrollment":536,"conditions":83568,"interventions":83569},[87],[18],[29498,963],{"nctId":82368,"briefTitle":82369,"status":155,"phases":83571,"primaryCompletion":60425,"completion":60425,"start":82371,"enrollment":1237,"conditions":83572,"interventions":83573},[87],[18],[9502,963],{"nctId":38710,"briefTitle":38711,"status":155,"phases":83575,"primaryCompletion":38713,"completion":38713,"start":38714,"enrollment":3537,"conditions":83576,"interventions":83577},[87],[18],[38699,38717,963],{"trials":83579,"activeCount":97},[83580,83584,83588],{"nctId":956,"briefTitle":957,"status":155,"phases":83581,"primaryCompletion":959,"completion":959,"start":960,"enrollment":414,"conditions":83582,"interventions":83583},[88],[18],[694,963],{"nctId":15766,"briefTitle":15767,"status":155,"phases":83585,"primaryCompletion":242,"completion":242,"start":708,"enrollment":9392,"conditions":83586,"interventions":83587},[88],[18],[15753,963],{"nctId":17673,"briefTitle":17674,"status":155,"phases":83589,"primaryCompletion":17676,"completion":17676,"start":17677,"enrollment":17678,"conditions":83590,"interventions":83591},[88],[18],[17660,8381,963],{"trials":83593,"activeCount":97},[83594],{"nctId":83595,"briefTitle":83596,"status":155,"phases":83597,"primaryCompletion":83598,"completion":83598,"start":6545,"enrollment":13480,"conditions":83599,"interventions":83600},"NCT03357341","Sensor and Electronic Health Records (EHR) Integration Pilot Study",[],"2019-09-27",[15],[963],{"intervention":5329,"totalTrials":361,"cells":83602},{"EARLY_PHASE1":83603,"PHASE1":83605,"PHASE2":83607,"PHASE3":83621,"PHASE4":83655,"NA":83661},{"trials":83604,"activeCount":97},[],{"trials":83606,"activeCount":97},[],{"trials":83608,"activeCount":97},[83609,83613,83617],{"nctId":43135,"briefTitle":43136,"status":155,"phases":83610,"primaryCompletion":21663,"completion":8574,"start":13095,"enrollment":8090,"conditions":83611,"interventions":83612},[86],[2620],[43114,43130,43131,5329],{"nctId":5319,"briefTitle":5320,"status":155,"phases":83614,"primaryCompletion":5322,"completion":5322,"start":5323,"enrollment":4158,"conditions":83615,"interventions":83616},[86],[5325],[5327,5328,4471,5329],{"nctId":55290,"briefTitle":55291,"status":155,"phases":83618,"primaryCompletion":55293,"completion":55293,"start":8561,"enrollment":931,"conditions":83619,"interventions":83620},[86],[2620],[55281,5329],{"trials":83622,"activeCount":97},[83623,83627,83634,83638,83644,83648],{"nctId":21641,"briefTitle":21642,"status":155,"phases":83624,"primaryCompletion":21644,"completion":21645,"start":21646,"enrollment":21647,"conditions":83625,"interventions":83626},[87],[1030],[21622,5329],{"nctId":83628,"briefTitle":83629,"status":155,"phases":83630,"primaryCompletion":76214,"completion":76214,"start":83631,"enrollment":8376,"conditions":83632,"interventions":83633},"NCT01738477","Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults",[87],"2013-01-31",[33,3624,30],[5329],{"nctId":31807,"briefTitle":31808,"status":155,"phases":83635,"primaryCompletion":24686,"completion":16102,"start":19786,"enrollment":31810,"conditions":83636,"interventions":83637},[87],[3624,33,30],[5329,31796],{"nctId":83639,"briefTitle":83640,"status":155,"phases":83641,"completion":8406,"start":5196,"enrollment":255,"conditions":83642,"interventions":83643},"NCT00406562","Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.",[87],[33,30,3624],[5329],{"nctId":33378,"briefTitle":33379,"status":155,"phases":83645,"completion":2835,"start":748,"enrollment":19789,"conditions":83646,"interventions":83647},[87],[30,3624,33],[5329,33367],{"nctId":83649,"briefTitle":83650,"status":155,"phases":83651,"primaryCompletion":79677,"completion":79677,"start":83652,"enrollment":5656,"conditions":83653,"interventions":83654},"NCT03311659","Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects",[87],"2018-01-26",[3649],[5329],{"trials":83656,"activeCount":97},[83657],{"nctId":8747,"briefTitle":8748,"status":145,"phases":83658,"completion":2405,"start":8750,"enrollment":8751,"conditions":83659,"interventions":83660},[88],[3624,33,30],[8754,8755,8756],{"trials":83662,"activeCount":97},[83663],{"nctId":83664,"briefTitle":83665,"status":155,"phases":83666,"primaryCompletion":83667,"completion":83667,"start":73591,"enrollment":10191,"conditions":83668,"interventions":83669},"NCT01929291","Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea",[],"2016-01-11",[3649],[5329],{"intervention":7830,"totalTrials":361,"cells":83671},{"EARLY_PHASE1":83672,"PHASE1":83674,"PHASE2":83676,"PHASE3":83693,"PHASE4":83728,"NA":83730},{"trials":83673,"activeCount":97},[],{"trials":83675,"activeCount":97},[],{"trials":83677,"activeCount":97},[83678,83682,83686],{"nctId":19181,"briefTitle":19182,"status":155,"phases":83679,"primaryCompletion":19184,"completion":19184,"start":15600,"enrollment":8931,"conditions":83680,"interventions":83681},[86],[33,24,4704,4702,3624,30,4703],[4706,19187,19151,10346,7830],{"nctId":19206,"briefTitle":19207,"status":500,"phases":83683,"primaryCompletion":9706,"completion":9706,"start":6352,"enrollment":97,"conditions":83684,"interventions":83685},[86],[4759],[19211,19151,10348,7830],{"nctId":83687,"briefTitle":83688,"status":155,"phases":83689,"primaryCompletion":83690,"completion":83690,"start":39421,"enrollment":30619,"conditions":83691,"interventions":83692},"NCT00432380","A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.",[86],"2007-09-04",[4759,5000],[7830],{"trials":83694,"activeCount":97},[83695,83699,83703,83710,83716,83720],{"nctId":7821,"briefTitle":7822,"status":155,"phases":83696,"primaryCompletion":2373,"completion":7824,"start":7825,"enrollment":7826,"conditions":83697,"interventions":83698},[87],[24],[7829,7830,7831,7832,7718],{"nctId":7862,"briefTitle":7863,"status":155,"phases":83700,"primaryCompletion":7865,"completion":7866,"start":7867,"enrollment":7868,"conditions":83701,"interventions":83702},[87],[4704],[7871,7872,7873,7874,7875,7830,7718,7876],{"nctId":83704,"briefTitle":83705,"status":155,"phases":83706,"primaryCompletion":7546,"completion":7546,"start":2805,"enrollment":83707,"conditions":83708,"interventions":83709},"NCT00241644","Vaccine Efficacy Against Rotavirus Diarrhea; Vaccine Given With Routine Childhood Vaccinations in Healthy African Infants",[87],2089,[4759],[7830],{"nctId":83711,"briefTitle":83712,"status":155,"phases":83713,"primaryCompletion":5018,"completion":5018,"start":5196,"enrollment":18893,"conditions":83714,"interventions":83715},"NCT00329745","Year 3 Extension for Efficacy Follow-up in Subjects Vaccinated in Studies Rota-028, 029 or 030 (NCT00197210)",[87],[4759],[7830],{"nctId":19887,"briefTitle":19888,"status":155,"phases":83717,"primaryCompletion":19890,"completion":19890,"start":9568,"enrollment":15576,"conditions":83718,"interventions":83719},[87],[4702,33,3624,30,4704],[19893,11069,19818,10348,7830],{"nctId":83721,"briefTitle":83722,"status":155,"phases":83723,"primaryCompletion":83724,"completion":25446,"start":25456,"enrollment":83725,"conditions":83726,"interventions":83727},"NCT00420745","To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term Infants",[87],"2008-03-01",1009,[4759],[7830],{"trials":83729,"activeCount":97},[],{"trials":83731,"activeCount":97},[83732,83741],{"nctId":83733,"briefTitle":83734,"status":155,"phases":83735,"primaryCompletion":83736,"completion":83737,"start":24514,"enrollment":83738,"conditions":83739,"interventions":83740},"NCT00938327","Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian Infants",[],"2010-02-20","2010-04-23",332,[4759],[7830],{"nctId":83742,"briefTitle":83743,"status":155,"phases":83744,"primaryCompletion":83745,"completion":9317,"start":83746,"enrollment":83747,"conditions":83748,"interventions":83749},"NCT00779779","Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Infants",[],"2009-05-25","2008-11-22",522,[4759],[7830],{"intervention":10348,"totalTrials":750,"cells":83751},{"EARLY_PHASE1":83752,"PHASE1":83754,"PHASE2":83760,"PHASE3":83778,"PHASE4":83799,"NA":83801},{"trials":83753,"activeCount":97},[],{"trials":83755,"activeCount":97},[83756],{"nctId":64828,"briefTitle":64829,"status":155,"phases":83757,"primaryCompletion":45551,"completion":45551,"start":59381,"enrollment":4542,"conditions":83758,"interventions":83759},[85],[3637],[64821,10348],{"trials":83761,"activeCount":97},[83762,83766,83770,83774],{"nctId":19160,"briefTitle":19161,"status":155,"phases":83763,"primaryCompletion":19163,"completion":19164,"start":19165,"enrollment":19166,"conditions":83764,"interventions":83765},[86],[3637],[19169,19170,10348,7875,19151],{"nctId":41964,"briefTitle":41965,"status":155,"phases":83767,"primaryCompletion":7445,"completion":7445,"start":41967,"enrollment":41968,"conditions":83768,"interventions":83769},[86],[3637],[4682,4682,10348,41971,41972,23250,41973,41974],{"nctId":19189,"briefTitle":19190,"status":155,"phases":83771,"primaryCompletion":16834,"completion":16834,"start":19192,"enrollment":19193,"conditions":83772,"interventions":83773},[86],[33,30,4704,24,4702,3624,19177],[4706,19151,19196,8969,10348],{"nctId":19206,"briefTitle":19207,"status":500,"phases":83775,"primaryCompletion":9706,"completion":9706,"start":6352,"enrollment":97,"conditions":83776,"interventions":83777},[86],[4759],[19211,19151,10348,7830],{"trials":83779,"activeCount":97},[83780,83784,83791,83795],{"nctId":19215,"briefTitle":19216,"status":155,"phases":83781,"primaryCompletion":19218,"completion":19218,"start":10632,"enrollment":536,"conditions":83782,"interventions":83783},[87],[3637,4742],[10348,19151],{"nctId":83785,"briefTitle":83786,"status":155,"phases":83787,"primaryCompletion":39385,"completion":39385,"start":83788,"enrollment":3025,"conditions":83789,"interventions":83790},"NCT01746108","Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection",[87],"2013-06-18",[3637,4742],[10348],{"nctId":10337,"briefTitle":10338,"status":155,"phases":83792,"primaryCompletion":10340,"completion":10341,"start":9452,"enrollment":10342,"conditions":83793,"interventions":83794},[87],[992,5046],[10345,10346,10347,8968,10348],{"nctId":19887,"briefTitle":19888,"status":155,"phases":83796,"primaryCompletion":19890,"completion":19890,"start":9568,"enrollment":15576,"conditions":83797,"interventions":83798},[87],[4702,33,3624,30,4704],[19893,11069,19818,10348,7830],{"trials":83800,"activeCount":97},[],{"trials":83802,"activeCount":97},[83803],{"nctId":83804,"briefTitle":83805,"status":145,"phases":83806,"primaryCompletion":7682,"completion":7682,"start":7647,"enrollment":695,"conditions":83807,"interventions":83808},"NCT01046097","Post-marketing Surveillance Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Philippines",[],[3637],[10348],{"intervention":26341,"totalTrials":750,"cells":83810},{"EARLY_PHASE1":83811,"PHASE1":83813,"PHASE2":83815,"PHASE3":83817,"PHASE4":83848,"NA":83850},{"trials":83812,"activeCount":97},[],{"trials":83814,"activeCount":97},[],{"trials":83816,"activeCount":97},[],{"trials":83818,"activeCount":97},[83819,83826,83832,83836,83844],{"nctId":83820,"briefTitle":83821,"status":155,"phases":83822,"primaryCompletion":8468,"completion":8468,"start":2428,"enrollment":212,"conditions":83823,"interventions":83825},"NCT00981409","The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients",[87],[83824],"Embolism, Pulmonary",[26341,56337],{"nctId":83827,"briefTitle":83828,"status":155,"phases":83829,"primaryCompletion":6351,"completion":6351,"start":7546,"enrollment":12202,"conditions":83830,"interventions":83831},"NCT00911157","The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients",[87],[26339],[26341,56337],{"nctId":26333,"briefTitle":26334,"status":155,"phases":83833,"primaryCompletion":26336,"completion":11030,"start":8468,"enrollment":26337,"conditions":83834,"interventions":83835},[87],[26339],[26341,26322],{"nctId":83837,"briefTitle":83838,"status":155,"phases":83839,"primaryCompletion":8478,"completion":8478,"start":11577,"enrollment":83840,"conditions":83841,"interventions":83842},"NCT00038961","A Study to Evaluate the Efficacy and Safety of Fondaparinux Sodium When Used With Intermittent Pneumatic Compression to Prevent Venous Thromboembolic (IPC) Versus IPC Alone for the Prevention of Venous Thromboembolic Events in Subjects at Increased Risk Undergoing Major Abdominal Surgery (APOLLO).",[87],1309,[35338],[83843],"fondaparinux sodium",{"nctId":36576,"briefTitle":36577,"status":155,"phases":83845,"completion":8406,"start":2383,"enrollment":4377,"conditions":83846,"interventions":83847},[87],[36580],[26341,36565],{"trials":83849,"activeCount":97},[],{"trials":83851,"activeCount":97},[83852,83859,83866,83872,83880],{"nctId":83853,"briefTitle":83854,"status":155,"phases":83855,"primaryCompletion":3045,"completion":3045,"start":8468,"enrollment":24458,"conditions":83856,"interventions":83857},"NCT01390883","Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal (Urology,Obstetrics,Gynecology)",[],[14279],[83858],"Fondaparinux Sodium",{"nctId":83860,"briefTitle":83861,"status":155,"phases":83862,"primaryCompletion":13584,"completion":13584,"start":728,"enrollment":1517,"conditions":83863,"interventions":83865},"NCT01428544","Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg)",[],[83864],"Ataxia",[26341],{"nctId":83867,"briefTitle":83868,"status":155,"phases":83869,"primaryCompletion":13584,"completion":13584,"start":2427,"enrollment":1196,"conditions":83870,"interventions":83871},"NCT01428531","Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment",[],[83864],[83858],{"nctId":83873,"briefTitle":83874,"status":155,"phases":83875,"primaryCompletion":11030,"completion":11030,"start":26336,"enrollment":83876,"conditions":83877,"interventions":83878},"NCT01064362","Hemorrhage Risk Prescribed Arixtra",[],13442,[26339],[26341,83879],"Low molecular weight heparin",{"nctId":83881,"briefTitle":83882,"status":155,"phases":83883,"primaryCompletion":8151,"completion":8151,"start":1429,"enrollment":83884,"conditions":83885,"interventions":83886},"NCT01390896","Special Drug Use Investigation for ARIXTRA (Fondaparinux) Abdominal General Surgery",[],329,[14279],[83858],{"intervention":9311,"totalTrials":750,"cells":83888},{"EARLY_PHASE1":83889,"PHASE1":83891,"PHASE2":83933,"PHASE3":83942,"PHASE4":83951,"NA":83953},{"trials":83890,"activeCount":97},[],{"trials":83892,"activeCount":97},[83893,83900,83906,83910,83916,83923,83927],{"nctId":83894,"briefTitle":83895,"status":155,"phases":83896,"primaryCompletion":34584,"completion":34584,"start":83897,"enrollment":1165,"conditions":83898,"interventions":83899},"NCT02058641","Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)",[85],"2014-02-26",[9309],[9311],{"nctId":83901,"briefTitle":83902,"status":155,"phases":83903,"primaryCompletion":2356,"completion":2356,"start":2428,"enrollment":1634,"conditions":83904,"interventions":83905},"NCT00551317","A Study Investigating the Concentrations of Darapladib in Blood and the Safety of This Compound in Healthy Japanese Men",[85],[9309],[9311],{"nctId":71018,"briefTitle":71019,"status":155,"phases":83907,"primaryCompletion":69820,"completion":69820,"start":18873,"enrollment":710,"conditions":83908,"interventions":83909},[85],[9309],[9311,71011],{"nctId":83911,"briefTitle":83912,"status":155,"phases":83913,"start":7659,"enrollment":1264,"conditions":83914,"interventions":83915},"NCT00411073","Study Of The Effects Of SB 480848 (Darapladib) On The Electrical Conduction Of The Heart",[85],[9309],[9311],{"nctId":83917,"briefTitle":83918,"status":155,"phases":83919,"primaryCompletion":8468,"completion":8468,"start":10167,"enrollment":454,"conditions":83920,"interventions":83921},"NCT00743860","A Healthy Volunteer Pharmacokinetic Study of Single and Repeat Doses of SB-480848",[85],[9309],[83922],"darapladib",{"nctId":9304,"briefTitle":9305,"status":155,"phases":83924,"primaryCompletion":9045,"completion":9045,"start":9307,"enrollment":93,"conditions":83925,"interventions":83926},[85],[9309],[9311,6488],{"nctId":83928,"briefTitle":83929,"status":155,"phases":83930,"primaryCompletion":18056,"completion":18056,"start":9452,"enrollment":1298,"conditions":83931,"interventions":83932},"NCT01154114","Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects",[85],[9309],[83922],{"trials":83934,"activeCount":97},[83935],{"nctId":83936,"briefTitle":83937,"status":155,"phases":83938,"primaryCompletion":3390,"completion":3390,"start":9233,"enrollment":1686,"conditions":83939,"interventions":83941},"NCT01506895","A Phase 2 Clinical Study to Investigate Effects of Darapladib in Subjects With Diabetic Macular Edema",[86],[83940],"Retinopathy, Diabetic",[83922],{"trials":83943,"activeCount":97},[83944],{"nctId":83945,"briefTitle":83946,"status":155,"phases":83947,"primaryCompletion":8395,"completion":10190,"start":18501,"enrollment":83948,"conditions":83949,"interventions":83950},"NCT00799903","The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial",[87],15828,[9309],[9311],{"trials":83952,"activeCount":97},[],{"trials":83954,"activeCount":97},[83955],{"nctId":83956,"briefTitle":83957,"status":155,"phases":83958,"primaryCompletion":9507,"completion":9507,"start":2394,"enrollment":83959,"conditions":83960,"interventions":83961},"NCT01636271","SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848\u002F033)",[],28855,[40204],[83922],{"intervention":83963,"totalTrials":750,"cells":83964},"Ropinirole",{"EARLY_PHASE1":83965,"PHASE1":83967,"PHASE2":83982,"PHASE3":83998,"PHASE4":84025,"NA":84033},{"trials":83966,"activeCount":97},[],{"trials":83968,"activeCount":97},[83969,83976],{"nctId":83970,"briefTitle":83971,"status":155,"phases":83972,"primaryCompletion":63557,"completion":63557,"start":83973,"enrollment":2045,"conditions":83974,"interventions":83975},"NCT00419692","Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food",[85],"2006-08-24",[14255],[83963],{"nctId":83977,"briefTitle":83978,"status":155,"phases":83979,"primaryCompletion":11707,"completion":11707,"start":40993,"enrollment":1298,"conditions":83980,"interventions":83981},"NCT01435915","Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects",[85],[15879],[83963],{"trials":83983,"activeCount":97},[83984,83990],{"nctId":83985,"briefTitle":83986,"status":155,"phases":83987,"completion":2336,"start":4756,"enrollment":695,"conditions":83988,"interventions":83989},"NCT00460148","Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole",[86],[15879],[83963],{"nctId":83991,"briefTitle":83992,"status":155,"phases":83993,"completion":10212,"start":11097,"enrollment":15259,"conditions":83994,"interventions":83996},"NCT00256893","Fibromyalgia Study In Adults",[86],[83995],"Fibromyalgia Syndrome, Primary",[83997],"ropinirole",{"trials":83999,"activeCount":97},[84000,84007,84013,84019],{"nctId":84001,"briefTitle":84002,"status":155,"phases":84003,"primaryCompletion":2804,"completion":2804,"start":8852,"enrollment":9196,"conditions":84004,"interventions":84006},"NCT00357097","The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome",[87],[14255,84005],"Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)",[83963],{"nctId":84008,"briefTitle":84009,"status":155,"phases":84010,"completion":1361,"start":10886,"enrollment":4532,"conditions":84011,"interventions":84012},"NCT00381472","Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa",[87],[15879],[83963],{"nctId":84014,"briefTitle":84015,"status":155,"phases":84016,"primaryCompletion":10670,"completion":10670,"start":19831,"enrollment":3635,"conditions":84017,"interventions":84018},"NCT00363857","A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome",[87],[14254,14255],[83963],{"nctId":84020,"briefTitle":84021,"status":155,"phases":84022,"completion":749,"start":10803,"enrollment":1534,"conditions":84023,"interventions":84024},"NCT00225862","A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)",[87],[14255],[83997],{"trials":84026,"activeCount":97},[84027],{"nctId":84028,"briefTitle":84029,"status":155,"phases":84030,"primaryCompletion":10167,"completion":10167,"start":7613,"enrollment":25254,"conditions":84031,"interventions":84032},"NCT00329602","Long-term Study Of Ropinirole In Restless Legs Syndrome",[88],[14255],[83963],{"trials":84034,"activeCount":97},[84035],{"nctId":84036,"briefTitle":84037,"status":155,"phases":84038,"primaryCompletion":23420,"completion":23420,"start":8446,"enrollment":84039,"conditions":84040,"interventions":84041},"NCT01327339","REQUIP RLS Post Marketing Surveillance",[],755,[14255],[83963],{"intervention":56336,"totalTrials":1165,"cells":84043},{"EARLY_PHASE1":84044,"PHASE1":84046,"PHASE2":84048,"PHASE3":84054,"PHASE4":84078,"NA":84080},{"trials":84045,"activeCount":97},[],{"trials":84047,"activeCount":97},[],{"trials":84049,"activeCount":97},[84050],{"nctId":56331,"briefTitle":56332,"status":155,"phases":84051,"primaryCompletion":3111,"completion":3111,"start":9159,"enrollment":24932,"conditions":84052,"interventions":84053},[86],[28372],[56336,56337,56322],{"trials":84055,"activeCount":97},[84056,84064,84070],{"nctId":84057,"briefTitle":84058,"status":155,"phases":84059,"primaryCompletion":9755,"completion":9755,"start":84060,"enrollment":24657,"conditions":84061,"interventions":84062},"NCT00320398","Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)",[87],"2006-01-30",[26339],[84063],"Fondaparinux",{"nctId":84065,"briefTitle":84066,"status":155,"phases":84067,"primaryCompletion":8459,"completion":8459,"start":83241,"enrollment":6503,"conditions":84068,"interventions":84069},"NCT00320424","Hip Fracture Study of GSK576428 (Fondaparinux Sodium)",[87],[35338],[84063],{"nctId":84071,"briefTitle":84072,"status":155,"phases":84073,"primaryCompletion":749,"completion":749,"start":10056,"enrollment":84074,"conditions":84075,"interventions":84076},"NCT00139815","Michelangelo - Oasis 5",[87],20078,[35338],[84063,84077],"enoxaparin",{"trials":84079,"activeCount":97},[],{"trials":84081,"activeCount":97},[84082,84088,84098,84106,84112],{"nctId":84083,"briefTitle":84084,"status":155,"phases":84085,"primaryCompletion":8860,"completion":8860,"start":828,"enrollment":417,"conditions":84086,"interventions":84087},"NCT01691495","ARIXTRA® Adherence in SVT Patients.",[],[26339],[84063],{"nctId":84089,"briefTitle":84090,"status":155,"phases":84091,"primaryCompletion":26336,"completion":26336,"start":8116,"enrollment":14367,"conditions":84092,"interventions":84094},"NCT01304238","Retrospective Registry of Patients With Acute Heparin-induced Thrombocytopenia Type II",[],[84093],"Acute HIT II (Heparin-induced Thrombocytopenia Type II)",[84095,84096,84097,56336],"lepirudin","danaparoid","argatroban",{"nctId":84099,"briefTitle":84100,"status":155,"phases":84101,"primaryCompletion":2335,"completion":10463,"start":2834,"enrollment":84102,"conditions":84103,"interventions":84104},"NCT01444612","Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery",[],4068,[26339],[84105,84077,56336,56337],"dalteparin",{"nctId":84107,"briefTitle":84108,"status":155,"phases":84109,"primaryCompletion":7545,"completion":7545,"start":2382,"enrollment":417,"conditions":84110,"interventions":84111},"NCT01406301","Fondaparinux EU-RMP (Adherence)",[],[11827],[56336],{"nctId":84113,"briefTitle":84114,"status":155,"phases":84115,"primaryCompletion":1428,"completion":1428,"start":3078,"enrollment":201,"conditions":84116,"interventions":84117},"NCT01004939","Retrospective Study of Patients Who Were Treated With Fondaparinux Pre-, Peri- and\u002For Postpartum for Prophylaxis or Treatment of Venous Thromboembolism",[],[35338,36580],[56336],{"intervention":43205,"totalTrials":1720,"cells":84119},{"EARLY_PHASE1":84120,"PHASE1":84122,"PHASE2":84124,"PHASE3":84147,"PHASE4":84160,"NA":84162},{"trials":84121,"activeCount":97},[],{"trials":84123,"activeCount":97},[],{"trials":84125,"activeCount":97},[84126,84130,84134,84143],{"nctId":43200,"briefTitle":43201,"status":155,"phases":84127,"primaryCompletion":11992,"completion":11992,"start":9159,"enrollment":710,"conditions":84128,"interventions":84129},[86],[32730],[43205,43191,43206],{"nctId":51173,"briefTitle":51174,"status":155,"phases":84131,"primaryCompletion":8721,"completion":7711,"start":8860,"enrollment":14391,"conditions":84132,"interventions":84133},[86],[15325],[51164,43205],{"nctId":84135,"briefTitle":84136,"status":155,"phases":84137,"primaryCompletion":84138,"completion":84138,"start":84139,"enrollment":84140,"conditions":84141,"interventions":84142},"NCT03238352","A Study to Assess Efficacy of an Experimental Oral Rinse in Providing Long Term Relief From Dentinal Hypersensitivity",[86],"2017-10-27","2017-08-07",89,[55741],[43205],{"nctId":56970,"briefTitle":56971,"status":155,"phases":84144,"primaryCompletion":12043,"completion":3341,"start":8667,"enrollment":31710,"conditions":84145,"interventions":84146},[86],[15325],[56961,43205],{"trials":84148,"activeCount":97},[84149,84153],{"nctId":28891,"briefTitle":28892,"status":155,"phases":84150,"primaryCompletion":11315,"completion":11315,"start":728,"enrollment":1264,"conditions":84151,"interventions":84152},[87],[28895],[28897,28880],{"nctId":84154,"briefTitle":84155,"status":155,"phases":84156,"primaryCompletion":9133,"completion":9133,"start":7546,"enrollment":2282,"conditions":84157,"interventions":84158},"NCT00708305","Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes",[87],[13126],[84159],"Sodium Fluoride",{"trials":84161,"activeCount":97},[],{"trials":84163,"activeCount":97},[84164,84173],{"nctId":84165,"briefTitle":84166,"status":155,"phases":84167,"primaryCompletion":8860,"completion":8860,"start":19576,"enrollment":234,"conditions":84168,"interventions":84169},"NCT02195583","The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ",[89],[15325],[43205,43205,43205,84170,84171,84172],"Sodium fluoride (1426 ppm) + zinc base A","Sodium fluoride (1426 ppm) + zinc base B","Fluoride",{"nctId":84174,"briefTitle":84175,"status":155,"phases":84176,"primaryCompletion":9233,"completion":9233,"start":8135,"enrollment":904,"conditions":84177,"interventions":84179},"NCT01657903","Evaluation of Efficacy of Experimental Gel to Foam Dentifrices in Dental Erosion",[89],[53481,84178],"Acid Wear",[84159,84180],"Potassium nitrate",{"intervention":84182,"totalTrials":1720,"cells":84183},"Stannous Fluoride",{"EARLY_PHASE1":84184,"PHASE1":84186,"PHASE2":84188,"PHASE3":84190,"PHASE4":84235,"NA":84237},{"trials":84185,"activeCount":97},[],{"trials":84187,"activeCount":97},[],{"trials":84189,"activeCount":97},[],{"trials":84191,"activeCount":97},[84192,84200,84206,84213,84219,84228],{"nctId":84193,"briefTitle":84194,"status":155,"phases":84195,"primaryCompletion":61792,"completion":61792,"start":43595,"enrollment":11018,"conditions":84196,"interventions":84197},"NCT04123665","A Phase 3 Clinical Study Investigating the Gingivitis Efficacy of a Test Dentifrice Containing Stannous Fluoride",[87],[15173],[84198,84199],"Stannous fluoride","Sodium monofluorophosphate",{"nctId":84201,"briefTitle":84202,"status":155,"phases":84203,"primaryCompletion":5195,"completion":5195,"start":3390,"enrollment":35629,"conditions":84204,"interventions":84205},"NCT01827670","Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity",[87],[44583],[84198,84199],{"nctId":84207,"briefTitle":84208,"status":155,"phases":84209,"primaryCompletion":11315,"completion":11315,"start":3389,"enrollment":2107,"conditions":84210,"interventions":84211},"NCT01592851","Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity",[87],[44583],[84182,84212],"Sodium Monofluorophosphate",{"nctId":84214,"briefTitle":84215,"status":155,"phases":84216,"primaryCompletion":11315,"completion":11315,"start":728,"enrollment":201,"conditions":84217,"interventions":84218},"NCT01592864","The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity",[87],[44583],[84182,84212],{"nctId":84220,"briefTitle":84221,"status":155,"phases":84222,"primaryCompletion":84223,"completion":60492,"start":16102,"enrollment":4094,"conditions":84224,"interventions":84225},"NCT02832375","Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity",[87],"2016-05-01",[55741],[84226,84227],"stannous fluoride","sodium monofluorophosphate",{"nctId":84229,"briefTitle":84230,"status":155,"phases":84231,"primaryCompletion":22657,"completion":84232,"start":15213,"enrollment":201,"conditions":84233,"interventions":84234},"NCT03072719","The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal Hypersensitivity",[87],"2012-06-12",[44583],[84182,84212],{"trials":84236,"activeCount":97},[],{"trials":84238,"activeCount":97},[84239,84246],{"nctId":84240,"briefTitle":84241,"status":155,"phases":84242,"primaryCompletion":16102,"completion":84243,"start":13183,"enrollment":22617,"conditions":84244,"interventions":84245},"NCT02750943","Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease",[89],"2016-03-04",[15173],[84182,84212],{"nctId":84247,"briefTitle":84248,"status":155,"phases":84249,"primaryCompletion":903,"completion":12378,"start":70162,"enrollment":2825,"conditions":84250,"interventions":84251},"NCT02752958","Impact of Long Term Management of Dentine Hypersensitivity (DH) With a Daily Use Anti-sensitivity Toothpaste on the Quality of Life Related to Oral Health",[89],[55741],[84226],{"intervention":4805,"totalTrials":1318,"cells":84253},{"EARLY_PHASE1":84254,"PHASE1":84256,"PHASE2":84258,"PHASE3":84264,"PHASE4":84282,"NA":84284},{"trials":84255,"activeCount":97},[],{"trials":84257,"activeCount":97},[],{"trials":84259,"activeCount":97},[84260],{"nctId":21438,"briefTitle":21439,"status":155,"phases":84261,"primaryCompletion":21441,"completion":21442,"start":21443,"enrollment":19270,"conditions":84262,"interventions":84263},[86],[4704,4703],[21446,4806,4805,19386,21447],{"trials":84265,"activeCount":97},[84266,84270,84274,84278],{"nctId":11168,"briefTitle":11169,"status":155,"phases":84267,"primaryCompletion":11171,"completion":11171,"start":11172,"enrollment":1608,"conditions":84268,"interventions":84269},[87],[992],[8653,4811,4805,4810,4762,8674,8675,11175],{"nctId":19422,"briefTitle":19423,"status":155,"phases":84271,"primaryCompletion":19425,"completion":18288,"start":19426,"enrollment":19427,"conditions":84272,"interventions":84273},[87],[4704,4703],[19430,4806,19385,4805,19386,8674,8675],{"nctId":4796,"briefTitle":4797,"status":155,"phases":84275,"primaryCompletion":4799,"completion":4800,"start":4801,"enrollment":4802,"conditions":84276,"interventions":84277},[87],[4702,30,4704,33,3624,24],[4472,4805,4806,4807,4808,4809,4810,4811,4762],{"nctId":4991,"briefTitle":4992,"status":155,"phases":84279,"primaryCompletion":4994,"completion":4995,"start":4996,"enrollment":4997,"conditions":84280,"interventions":84281},[87],[4999,5000],[4762,4805,4810,4485],{"trials":84283,"activeCount":97},[],{"trials":84285,"activeCount":97},[84286,84292],{"nctId":84287,"briefTitle":84288,"status":155,"phases":84289,"primaryCompletion":13584,"completion":13584,"start":8721,"enrollment":417,"conditions":84290,"interventions":84291},"NCT02447978","Duration of Protection: GSK DTaP Vaccines",[],[30,3624,33],[4809,4805,19402],{"nctId":84293,"briefTitle":84294,"status":155,"phases":84295,"primaryCompletion":8852,"completion":8852,"start":10056,"enrollment":84296,"conditions":84297,"interventions":84298},"NCT00146835","Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine",[],120794,[24,4702,30,33,3624],[4805,84299,84300],"Licensed DTPa containing vaccine","Prevnar®:",{"intervention":8431,"totalTrials":1318,"cells":84302},{"EARLY_PHASE1":84303,"PHASE1":84305,"PHASE2":84307,"PHASE3":84313,"PHASE4":84323,"NA":84337},{"trials":84304,"activeCount":97},[],{"trials":84306,"activeCount":97},[],{"trials":84308,"activeCount":97},[84309],{"nctId":52453,"briefTitle":52454,"status":155,"phases":84310,"primaryCompletion":2394,"completion":2394,"start":3551,"enrollment":8347,"conditions":84311,"interventions":84312},[86],[18],[52444,52458,52459,8431,52460],{"trials":84314,"activeCount":97},[84315,84319],{"nctId":36478,"briefTitle":36479,"status":155,"phases":84316,"primaryCompletion":4756,"completion":4756,"start":2805,"enrollment":27024,"conditions":84317,"interventions":84318},[87],[18],[8431,36467],{"nctId":8570,"briefTitle":8571,"status":155,"phases":84320,"primaryCompletion":8573,"completion":8574,"start":8575,"enrollment":3537,"conditions":84321,"interventions":84322},[87],[18],[3467,8578,8522],{"trials":84324,"activeCount":97},[84325,84329,84333],{"nctId":8423,"briefTitle":8424,"status":155,"phases":84326,"primaryCompletion":8426,"completion":8426,"start":8427,"enrollment":8428,"conditions":84327,"interventions":84328},[88],[18],[8354,8431,8409,8432],{"nctId":14316,"briefTitle":14317,"status":155,"phases":84330,"primaryCompletion":14319,"completion":14320,"start":14321,"enrollment":6646,"conditions":84331,"interventions":84332},[88],[18],[9502,8578,14303],{"nctId":8484,"briefTitle":8485,"status":155,"phases":84334,"primaryCompletion":2428,"completion":2428,"start":8427,"enrollment":1944,"conditions":84335,"interventions":84336},[88],[18],[8354,8409,8431],{"trials":84338,"activeCount":97},[84339],{"nctId":82239,"briefTitle":82240,"status":155,"phases":84340,"primaryCompletion":7647,"completion":7647,"start":2442,"enrollment":82242,"conditions":84341,"interventions":84342},[],[18],[8381,9416,8578],{"intervention":84212,"totalTrials":1318,"cells":84344},{"EARLY_PHASE1":84345,"PHASE1":84347,"PHASE2":84349,"PHASE3":84351,"PHASE4":84377,"NA":84379},{"trials":84346,"activeCount":97},[],{"trials":84348,"activeCount":97},[],{"trials":84350,"activeCount":97},[],{"trials":84352,"activeCount":97},[84353,84357,84361,84365,84369,84373],{"nctId":84193,"briefTitle":84194,"status":155,"phases":84354,"primaryCompletion":61792,"completion":61792,"start":43595,"enrollment":11018,"conditions":84355,"interventions":84356},[87],[15173],[84198,84199],{"nctId":84201,"briefTitle":84202,"status":155,"phases":84358,"primaryCompletion":5195,"completion":5195,"start":3390,"enrollment":35629,"conditions":84359,"interventions":84360},[87],[44583],[84198,84199],{"nctId":84207,"briefTitle":84208,"status":155,"phases":84362,"primaryCompletion":11315,"completion":11315,"start":3389,"enrollment":2107,"conditions":84363,"interventions":84364},[87],[44583],[84182,84212],{"nctId":84214,"briefTitle":84215,"status":155,"phases":84366,"primaryCompletion":11315,"completion":11315,"start":728,"enrollment":201,"conditions":84367,"interventions":84368},[87],[44583],[84182,84212],{"nctId":84220,"briefTitle":84221,"status":155,"phases":84370,"primaryCompletion":84223,"completion":60492,"start":16102,"enrollment":4094,"conditions":84371,"interventions":84372},[87],[55741],[84226,84227],{"nctId":84229,"briefTitle":84230,"status":155,"phases":84374,"primaryCompletion":22657,"completion":84232,"start":15213,"enrollment":201,"conditions":84375,"interventions":84376},[87],[44583],[84182,84212],{"trials":84378,"activeCount":97},[],{"trials":84380,"activeCount":97},[84381],{"nctId":84240,"briefTitle":84241,"status":155,"phases":84382,"primaryCompletion":16102,"completion":84243,"start":13183,"enrollment":22617,"conditions":84383,"interventions":84384},[89],[15173],[84182,84212],{"intervention":11489,"totalTrials":1318,"cells":84386},{"EARLY_PHASE1":84387,"PHASE1":84389,"PHASE2":84391,"PHASE3":84393,"PHASE4":84411,"NA":84421},{"trials":84388,"activeCount":97},[],{"trials":84390,"activeCount":97},[],{"trials":84392,"activeCount":97},[],{"trials":84394,"activeCount":97},[84395,84399,84403,84407],{"nctId":18314,"briefTitle":18315,"status":155,"phases":84396,"primaryCompletion":18317,"completion":18317,"start":18318,"enrollment":18319,"conditions":84397,"interventions":84398},[87],[992],[8291,18322,11489],{"nctId":18324,"briefTitle":18325,"status":155,"phases":84400,"primaryCompletion":18327,"completion":18327,"start":18328,"enrollment":18329,"conditions":84401,"interventions":84402},[87],[992],[8291,11489],{"nctId":31569,"briefTitle":31570,"status":155,"phases":84404,"primaryCompletion":15621,"completion":15621,"start":31572,"enrollment":31573,"conditions":84405,"interventions":84406},[87],[3624,30,33],[31558,11489],{"nctId":32302,"briefTitle":32303,"status":155,"phases":84408,"primaryCompletion":32305,"completion":9793,"start":18807,"enrollment":10464,"conditions":84409,"interventions":84410},[87],[33,3624,30,3649],[11489,32291],{"trials":84412,"activeCount":97},[84413,84417],{"nctId":11480,"briefTitle":11481,"status":155,"phases":84414,"primaryCompletion":11483,"completion":11483,"start":11484,"enrollment":2922,"conditions":84415,"interventions":84416},[88],[11486],[11488,11489,11490,10572],{"nctId":17463,"briefTitle":17464,"status":155,"phases":84418,"primaryCompletion":17466,"completion":17466,"start":17467,"enrollment":17468,"conditions":84419,"interventions":84420},[88],[3624,33,30],[11489,17450],{"trials":84422,"activeCount":97},[84423],{"nctId":84424,"briefTitle":84425,"status":155,"phases":84426,"primaryCompletion":7659,"completion":7659,"start":7613,"enrollment":84427,"conditions":84428,"interventions":84429},"NCT00297856","Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine",[],10000,[30,33,3624],[11489,84430],"Td (Tetanus diphtheria) vaccine",{"intervention":4809,"totalTrials":1318,"cells":84432},{"EARLY_PHASE1":84433,"PHASE1":84435,"PHASE2":84437,"PHASE3":84443,"PHASE4":84461,"NA":84467},{"trials":84434,"activeCount":97},[],{"trials":84436,"activeCount":97},[],{"trials":84438,"activeCount":97},[84439],{"nctId":21429,"briefTitle":21430,"status":155,"phases":84440,"primaryCompletion":7582,"completion":7582,"start":2482,"enrollment":21432,"conditions":84441,"interventions":84442},[86],[4759],[21435,19386,19416,4809,21436,4807],{"trials":84444,"activeCount":97},[84445,84449,84453,84457],{"nctId":19783,"briefTitle":19784,"status":155,"phases":84446,"primaryCompletion":19786,"completion":19787,"start":19788,"enrollment":19789,"conditions":84447,"interventions":84448},[87],[33,30,3624],[19792,4809,4810],{"nctId":20808,"briefTitle":20809,"status":155,"phases":84450,"primaryCompletion":20811,"completion":20812,"start":20813,"enrollment":20814,"conditions":84451,"interventions":84452},[87],[8723],[9000,8673,4809],{"nctId":19405,"briefTitle":19406,"status":155,"phases":84454,"primaryCompletion":2373,"completion":19408,"start":19409,"enrollment":19410,"conditions":84455,"interventions":84456},[87],[33,3624,30],[19413,19414,19415,4809,19416,8674],{"nctId":4796,"briefTitle":4797,"status":155,"phases":84458,"primaryCompletion":4799,"completion":4800,"start":4801,"enrollment":4802,"conditions":84459,"interventions":84460},[87],[4702,30,4704,33,3624,24],[4472,4805,4806,4807,4808,4809,4810,4811,4762],{"trials":84462,"activeCount":97},[84463],{"nctId":8747,"briefTitle":8748,"status":145,"phases":84464,"completion":2405,"start":8750,"enrollment":8751,"conditions":84465,"interventions":84466},[88],[3624,33,30],[8754,8755,8756],{"trials":84468,"activeCount":97},[84469],{"nctId":84287,"briefTitle":84288,"status":155,"phases":84470,"primaryCompletion":13584,"completion":13584,"start":8721,"enrollment":417,"conditions":84471,"interventions":84472},[],[30,3624,33],[4809,4805,19402],{"intervention":28454,"totalTrials":628,"cells":84474},{"EARLY_PHASE1":84475,"PHASE1":84477,"PHASE2":84495,"PHASE3":84497,"PHASE4":84503,"NA":84505},{"trials":84476,"activeCount":97},[],{"trials":84478,"activeCount":97},[84479,84483,84487,84491],{"nctId":19736,"briefTitle":19737,"status":155,"phases":84480,"primaryCompletion":3391,"completion":3391,"start":11030,"enrollment":473,"conditions":84481,"interventions":84482},[85],[9343],[9347,19693,10390,9324],{"nctId":19742,"briefTitle":19743,"status":155,"phases":84484,"primaryCompletion":19745,"completion":19745,"start":19746,"enrollment":255,"conditions":84485,"interventions":84486},[85],[19748],[10390,19693,19750],{"nctId":75810,"briefTitle":75811,"status":155,"phases":84488,"primaryCompletion":41493,"completion":41493,"start":75813,"enrollment":35629,"conditions":84489,"interventions":84490},[85],[12518],[75816,28454,75803],{"nctId":10380,"briefTitle":10381,"status":155,"phases":84492,"primaryCompletion":10383,"completion":10383,"start":10384,"enrollment":2045,"conditions":84493,"interventions":84494},[85],[10386],[10388,10389,4884,10390],{"trials":84496,"activeCount":97},[],{"trials":84498,"activeCount":97},[84499],{"nctId":28449,"briefTitle":28450,"status":155,"phases":84500,"primaryCompletion":8426,"completion":8426,"start":8406,"enrollment":20448,"conditions":84501,"interventions":84502},[87],[12294],[28438,28454],{"trials":84504,"activeCount":97},[],{"trials":84506,"activeCount":97},[84507],{"nctId":84508,"briefTitle":84509,"status":155,"phases":84510,"primaryCompletion":2336,"completion":2336,"start":8963,"enrollment":149,"conditions":84511,"interventions":84514},"NCT00368589","Effects Of Atorvastatin On Macrophage Activity And Plaque Inflammation Using Magnetic Resonance Imaging",[],[84512,84513,9309],"Atherosclerotic Carotid Disease","Atheroma",[28454],{"intervention":84516,"totalTrials":628,"cells":84517},"Fluticasone furoate nasal spray",{"EARLY_PHASE1":84518,"PHASE1":84520,"PHASE2":84522,"PHASE3":84531,"PHASE4":84539,"NA":84559},{"trials":84519,"activeCount":97},[],{"trials":84521,"activeCount":97},[],{"trials":84523,"activeCount":97},[84524],{"nctId":84525,"briefTitle":84526,"status":155,"phases":84527,"primaryCompletion":8116,"completion":8116,"start":2382,"enrollment":931,"conditions":84528,"interventions":84529},"NCT00730756","A Pilot Study In Adults And Adolescents With Irritant (Non-Allergic) Rhinitis",[86],[10182],[84530],"Fluticasone Furoate Nasal Spray",{"trials":84532,"activeCount":97},[84533],{"nctId":84534,"briefTitle":84535,"status":155,"phases":84536,"primaryCompletion":7647,"completion":1428,"start":1429,"enrollment":10407,"conditions":84537,"interventions":84538},"NCT01231464","A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Nasal Spray for 2 Weeks in Chinese Adult and Adolescent Subjects With Allergic Rhinitis",[87],[10182,39086],[13914],{"trials":84540,"activeCount":97},[84541,84545,84551],{"nctId":13908,"briefTitle":13909,"status":155,"phases":84542,"primaryCompletion":729,"completion":729,"start":7546,"enrollment":13911,"conditions":84543,"interventions":84544},[88],[10182],[13914,13895],{"nctId":84546,"briefTitle":84547,"status":155,"phases":84548,"primaryCompletion":7546,"completion":7546,"start":7954,"enrollment":1781,"conditions":84549,"interventions":84550},"NCT00609674","A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis",[88],[10182],[84516],{"nctId":84552,"briefTitle":84553,"status":155,"phases":84554,"primaryCompletion":18536,"completion":84555,"start":60783,"enrollment":84556,"conditions":84557,"interventions":84558},"NCT00570492","Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.",[88],"2011-03-17",474,[10182],[84516],{"trials":84560,"activeCount":97},[84561],{"nctId":84562,"briefTitle":84563,"status":145,"phases":84564,"primaryCompletion":3111,"completion":3111,"start":3551,"enrollment":593,"conditions":84565,"interventions":84566},"NCT01337323","Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting",[],[10169,39059],[84516],{"intervention":8440,"totalTrials":628,"cells":84568},{"EARLY_PHASE1":84569,"PHASE1":84571,"PHASE2":84577,"PHASE3":84579,"PHASE4":84589,"NA":84599},{"trials":84570,"activeCount":97},[],{"trials":84572,"activeCount":97},[84573],{"nctId":81464,"briefTitle":81465,"status":155,"phases":84574,"primaryCompletion":81467,"completion":81467,"start":8208,"enrollment":1279,"conditions":84575,"interventions":84576},[85],[15],[81457,81470],{"trials":84578,"activeCount":97},[],{"trials":84580,"activeCount":97},[84581,84585],{"nctId":18532,"briefTitle":18533,"status":155,"phases":84582,"primaryCompletion":11748,"completion":18535,"start":18536,"enrollment":18537,"conditions":84583,"interventions":84584},[87],[15],[18444,18445,10797,8440],{"nctId":18438,"briefTitle":18439,"status":155,"phases":84586,"primaryCompletion":3389,"completion":3389,"start":8883,"enrollment":18441,"conditions":84587,"interventions":84588},[87],[15],[18444,18445,18345,8440],{"trials":84590,"activeCount":97},[84591,84595],{"nctId":8434,"briefTitle":8435,"status":155,"phases":84592,"primaryCompletion":7701,"completion":7701,"start":3390,"enrollment":8437,"conditions":84593,"interventions":84594},[88],[15],[8354,8440,8441],{"nctId":8465,"briefTitle":8466,"status":155,"phases":84596,"primaryCompletion":7658,"completion":7658,"start":8468,"enrollment":8469,"conditions":84597,"interventions":84598},[88],[15],[8472,8473],{"trials":84600,"activeCount":97},[84601],{"nctId":84602,"briefTitle":84603,"status":155,"phases":84604,"primaryCompletion":2834,"completion":2834,"start":5018,"enrollment":84605,"conditions":84606,"interventions":84607},"NCT01387178","Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250\u002FSalmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease",[],22223,[15],[84608,8440],"fluticasone propionate\u002Fsalmeterol 250µg\u002F50µg",{"intervention":84610,"totalTrials":628,"cells":84611},"adefovir dipivoxil",{"EARLY_PHASE1":84612,"PHASE1":84614,"PHASE2":84620,"PHASE3":84622,"PHASE4":84628,"NA":84651},{"trials":84613,"activeCount":97},[],{"trials":84615,"activeCount":97},[84616],{"nctId":74472,"briefTitle":74473,"status":155,"phases":84617,"primaryCompletion":8027,"completion":8027,"start":23146,"enrollment":345,"conditions":84618,"interventions":84619},[85],[4191],[37770,74477,74465],{"trials":84621,"activeCount":97},[],{"trials":84623,"activeCount":97},[84624],{"nctId":10832,"briefTitle":10833,"status":155,"phases":84625,"primaryCompletion":10835,"completion":5207,"start":10836,"enrollment":10837,"conditions":84626,"interventions":84627},[87],[24],[10840,10841],{"trials":84629,"activeCount":97},[84630,84637,84644],{"nctId":84631,"briefTitle":84632,"status":155,"phases":84633,"primaryCompletion":10167,"completion":10167,"start":7659,"enrollment":84634,"conditions":84635,"interventions":84636},"NCT00441974","Adefovir Dipivoxil For The Treatment Of Chinese Compensated Chronic Hepatitis B(CHB)Patients",[88],1470,[4190],[84610],{"nctId":84638,"briefTitle":84639,"status":155,"phases":84640,"primaryCompletion":2813,"completion":2813,"start":1360,"enrollment":84641,"conditions":84642,"interventions":84643},"NCT00324961","Adefovir Dipivoxil Tablets (10mg) In Chinese Subjects With HBe Antigen Negative Chronic Hepatitis B",[88],533,[4190],[84610],{"nctId":84645,"briefTitle":84646,"status":155,"phases":84647,"primaryCompletion":1429,"completion":1429,"start":8386,"enrollment":42834,"conditions":84648,"interventions":84650},"NCT00347009","Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis",[88],[4191,84649,67832,4190],"Cirrhosis",[84610],{"trials":84652,"activeCount":97},[84653],{"nctId":84654,"briefTitle":84655,"status":155,"phases":84656,"primaryCompletion":2834,"completion":2834,"start":19830,"enrollment":84657,"conditions":84658,"interventions":84659},"NCT01329419","HEPSERA Post Marketing Surveillance",[],4393,[24],[84610],{"intervention":12205,"totalTrials":1517,"cells":84661},{"EARLY_PHASE1":84662,"PHASE1":84664,"PHASE2":84672,"PHASE3":84674,"PHASE4":84680,"NA":84690},{"trials":84663,"activeCount":97},[],{"trials":84665,"activeCount":97},[84666],{"nctId":84667,"briefTitle":84668,"status":155,"phases":84669,"primaryCompletion":7546,"completion":7546,"start":2355,"enrollment":454,"conditions":84670,"interventions":84671},"NCT02602002","Experimental Medicine Study to Validate Pharmacodynamic Pain Assessments in Healthy Volunteers With an Opioid Analgesic (Remifentanil)",[85],[9153],[12205],{"trials":84673,"activeCount":97},[],{"trials":84675,"activeCount":97},[84676],{"nctId":12199,"briefTitle":12200,"status":145,"phases":84677,"primaryCompletion":7976,"completion":10167,"start":3079,"enrollment":12202,"conditions":84678,"interventions":84679},[87],[9161],[12205,12188],{"trials":84681,"activeCount":97},[84682,84686],{"nctId":9355,"briefTitle":9356,"status":155,"phases":84683,"start":2823,"enrollment":9358,"conditions":84684,"interventions":84685},[88],[9360],[9301,9362,9363,9364,9365,9366],{"nctId":15256,"briefTitle":15257,"status":145,"phases":84687,"start":5196,"enrollment":15259,"conditions":84688,"interventions":84689},[88],[9161,9360],[15243,12205],{"trials":84691,"activeCount":97},[84692],{"nctId":84693,"briefTitle":84694,"status":155,"phases":84695,"primaryCompletion":6352,"completion":6352,"start":8427,"enrollment":84696,"conditions":84697,"interventions":84698},"NCT01299584","ULTIVA Post Marketing Surveillance",[],775,[9161],[12205],{"intervention":41775,"totalTrials":1517,"cells":84700},{"EARLY_PHASE1":84701,"PHASE1":84703,"PHASE2":84713,"PHASE3":84723,"PHASE4":84725,"NA":84727},{"trials":84702,"activeCount":97},[],{"trials":84704,"activeCount":97},[84705,84709],{"nctId":41768,"briefTitle":41769,"status":155,"phases":84706,"primaryCompletion":41771,"completion":41771,"start":41772,"enrollment":12044,"conditions":84707,"interventions":84708},[85],[2761],[41775,3048,247],{"nctId":83469,"briefTitle":83470,"status":500,"phases":84710,"primaryCompletion":83472,"completion":83473,"start":6824,"enrollment":97,"conditions":84711,"interventions":84712},[85],[325],[41775,3048],{"trials":84714,"activeCount":97},[84715,84719],{"nctId":83513,"briefTitle":83514,"status":145,"phases":84716,"primaryCompletion":46099,"completion":46099,"start":18244,"enrollment":6503,"conditions":84717,"interventions":84718},[86],[325],[41775,3048],{"nctId":83519,"briefTitle":83520,"status":155,"phases":84720,"primaryCompletion":25481,"completion":83522,"start":83523,"enrollment":1459,"conditions":84721,"interventions":84722},[86],[2761],[83526,83527],{"trials":84724,"activeCount":97},[],{"trials":84726,"activeCount":97},[],{"trials":84728,"activeCount":97},[84729],{"nctId":83535,"briefTitle":83536,"status":969,"phases":84730,"conditions":84731,"interventions":84732},[],[325],[3048,41775],{"intervention":32209,"totalTrials":1517,"cells":84734},{"EARLY_PHASE1":84735,"PHASE1":84737,"PHASE2":84739,"PHASE3":84749,"PHASE4":84763,"NA":84765},{"trials":84736,"activeCount":97},[],{"trials":84738,"activeCount":97},[],{"trials":84740,"activeCount":97},[84741],{"nctId":84742,"briefTitle":84743,"status":155,"phases":84744,"primaryCompletion":59664,"completion":59664,"start":84745,"enrollment":12044,"conditions":84746,"interventions":84747},"NCT01342952","Long-term Ambrisentan Extension Study for Pediatric Patients Who Participated in AMB112529",[86],"2011-06-21",[17209],[84748],"Ambrisentan",{"trials":84750,"activeCount":97},[84751,84755],{"nctId":32203,"briefTitle":32204,"status":155,"phases":84752,"primaryCompletion":3296,"completion":3296,"start":25962,"enrollment":32206,"conditions":84753,"interventions":84754},[87],[17209],[32209,32192],{"nctId":84756,"briefTitle":84757,"status":155,"phases":84758,"primaryCompletion":84759,"completion":84759,"start":11746,"enrollment":3112,"conditions":84760,"interventions":84762},"NCT01808313","Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)",[87],"2014-08-15",[84761],"Vascular Disease",[32209],{"trials":84764,"activeCount":97},[],{"trials":84766,"activeCount":97},[84767,84773],{"nctId":84768,"briefTitle":84769,"status":155,"phases":84770,"primaryCompletion":7682,"completion":7682,"start":7546,"enrollment":1924,"conditions":84771,"interventions":84772},"NCT00679224","An Observational Study For Ambrisentan",[],[17209],[32209],{"nctId":84774,"briefTitle":84775,"status":155,"phases":84776,"primaryCompletion":15854,"completion":15854,"start":84777,"enrollment":10685,"conditions":84778,"interventions":84779},"NCT01406327","Drug Use Investigation for VOLIBRIS® (Ambrisentan) (Pulmonary Arterial Hypertension)",[],"2010-12-14",[17209],[84748],{"intervention":12152,"totalTrials":181,"cells":84781},{"EARLY_PHASE1":84782,"PHASE1":84784,"PHASE2":84786,"PHASE3":84788,"PHASE4":84790,"NA":84811},{"trials":84783,"activeCount":97},[],{"trials":84785,"activeCount":97},[],{"trials":84787,"activeCount":97},[],{"trials":84789,"activeCount":97},[],{"trials":84791,"activeCount":97},[84792,84796,84803],{"nctId":12147,"briefTitle":12148,"status":155,"phases":84793,"primaryCompletion":7659,"completion":7659,"start":7785,"enrollment":536,"conditions":84794,"interventions":84795},[88],[12138],[12152,12122],{"nctId":84797,"briefTitle":84798,"status":155,"phases":84799,"primaryCompletion":2428,"completion":2428,"start":10395,"enrollment":414,"conditions":84800,"interventions":84801},"NCT02948881","A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo",[88],[12138],[84802],"ibandronate",{"nctId":84804,"briefTitle":84805,"status":155,"phases":84806,"primaryCompletion":84807,"completion":84807,"start":84808,"enrollment":10407,"conditions":84809,"interventions":84810},"NCT00405392","Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis",[88],"2008-05-27","2007-03-22",[23376],[12152],{"trials":84812,"activeCount":97},[84813],{"nctId":84814,"briefTitle":84815,"status":155,"phases":84816,"primaryCompletion":728,"completion":728,"start":3552,"enrollment":84817,"conditions":84818,"interventions":84819},"NCT01381393","BONVIVA(Ibandronate) PMS(Post-marketing Surveillance )",[],659,[12138],[12152],{"intervention":56337,"totalTrials":181,"cells":84821},{"EARLY_PHASE1":84822,"PHASE1":84824,"PHASE2":84826,"PHASE3":84832,"PHASE4":84842,"NA":84844},{"trials":84823,"activeCount":97},[],{"trials":84825,"activeCount":97},[],{"trials":84827,"activeCount":97},[84828],{"nctId":56331,"briefTitle":56332,"status":155,"phases":84829,"primaryCompletion":3111,"completion":3111,"start":9159,"enrollment":24932,"conditions":84830,"interventions":84831},[86],[28372],[56336,56337,56322],{"trials":84833,"activeCount":97},[84834,84838],{"nctId":83820,"briefTitle":83821,"status":155,"phases":84835,"primaryCompletion":8468,"completion":8468,"start":2428,"enrollment":212,"conditions":84836,"interventions":84837},[87],[83824],[26341,56337],{"nctId":83827,"briefTitle":83828,"status":155,"phases":84839,"primaryCompletion":6351,"completion":6351,"start":7546,"enrollment":12202,"conditions":84840,"interventions":84841},[87],[26339],[26341,56337],{"trials":84843,"activeCount":97},[],{"trials":84845,"activeCount":97},[84846],{"nctId":84099,"briefTitle":84100,"status":155,"phases":84847,"primaryCompletion":2335,"completion":10463,"start":2834,"enrollment":84102,"conditions":84848,"interventions":84849},[],[26339],[84105,84077,56336,56337],{"intervention":10149,"totalTrials":181,"cells":84851},{"EARLY_PHASE1":84852,"PHASE1":84854,"PHASE2":84864,"PHASE3":84866,"PHASE4":84874,"NA":84876},{"trials":84853,"activeCount":97},[],{"trials":84855,"activeCount":97},[84856,84860],{"nctId":10141,"briefTitle":10142,"status":155,"phases":84857,"primaryCompletion":10144,"completion":10144,"start":10145,"enrollment":454,"conditions":84858,"interventions":84859},[85],[10147],[10149,10134],{"nctId":10151,"briefTitle":10152,"status":155,"phases":84861,"primaryCompletion":10047,"completion":10047,"start":10154,"enrollment":454,"conditions":84862,"interventions":84863},[85],[10156],[10158,10159],{"trials":84865,"activeCount":97},[],{"trials":84867,"activeCount":97},[84868],{"nctId":84869,"briefTitle":84870,"status":155,"phases":84871,"primaryCompletion":9706,"completion":9706,"start":3389,"enrollment":1237,"conditions":84872,"interventions":84873},"NCT01563081","Safety Study of Levocetirizine Oral Solution for Japanese Pediatrics",[87],[11853],[10149,10149],{"trials":84875,"activeCount":97},[],{"trials":84877,"activeCount":97},[84878],{"nctId":84879,"briefTitle":84880,"status":155,"phases":84881,"primaryCompletion":827,"completion":827,"start":729,"enrollment":84882,"conditions":84883,"interventions":84884},"NCT01445262","Drug Use Investigation for XYZAL®",[],10728,[10147],[10149],{"intervention":84886,"totalTrials":181,"cells":84887},"Salmeterol and Fluticasone",{"EARLY_PHASE1":84888,"PHASE1":84890,"PHASE2":84892,"PHASE3":84894,"PHASE4":84896,"NA":84898},{"trials":84889,"activeCount":97},[],{"trials":84891,"activeCount":97},[],{"trials":84893,"activeCount":97},[],{"trials":84895,"activeCount":97},[],{"trials":84897,"activeCount":97},[],{"trials":84899,"activeCount":97},[84900,84906,84912,84918],{"nctId":84901,"briefTitle":84902,"status":155,"phases":84903,"primaryCompletion":3389,"completion":8151,"start":9159,"enrollment":30275,"conditions":84904,"interventions":84905},"NCT01332409","Special Drug Use Investigation for ADOAIR DISKUS COPD (Salmeterol and Fluticasone)",[],[15],[84886],{"nctId":84907,"briefTitle":84908,"status":155,"phases":84909,"primaryCompletion":1429,"completion":8883,"start":8426,"enrollment":23749,"conditions":84910,"interventions":84911},"NCT01395849","Drug Use Investigation for ADOAIR (Fluticasone\u002FSalmeterol)",[],[9855],[84886],{"nctId":84913,"briefTitle":84914,"status":155,"phases":84915,"primaryCompletion":8089,"completion":8089,"start":6351,"enrollment":536,"conditions":84916,"interventions":84917},"NCT01332422","Special Drug Use Investigation for ADOAIR Metered-dose Inhaler (Pediatric)",[],[18],[84886],{"nctId":84919,"briefTitle":84920,"status":155,"phases":84921,"primaryCompletion":3110,"completion":3110,"start":3079,"enrollment":84922,"conditions":84923,"interventions":84924},"NCT01395862","Special Drug Use Investigation for ADOAIR (Fluticasone\u002FSalmeterol)",[],1001,[9855],[84886],{"intervention":84926,"totalTrials":181,"cells":84927},"Valaciclovir",{"EARLY_PHASE1":84928,"PHASE1":84930,"PHASE2":84939,"PHASE3":84941,"PHASE4":84943,"NA":84962},{"trials":84929,"activeCount":97},[],{"trials":84931,"activeCount":97},[84932],{"nctId":84933,"briefTitle":84934,"status":155,"phases":84935,"primaryCompletion":15621,"completion":15621,"start":84936,"enrollment":710,"conditions":84937,"interventions":84938},"NCT00297206","A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children",[85],"2003-01-25",[8709],[84926],{"trials":84940,"activeCount":97},[],{"trials":84942,"activeCount":97},[],{"trials":84944,"activeCount":97},[84945,84954],{"nctId":84946,"briefTitle":84947,"status":155,"phases":84948,"primaryCompletion":84949,"completion":84949,"start":84950,"enrollment":6814,"conditions":84951,"interventions":84953},"NCT00116844","VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.",[88],"2006-01-10","2005-03-29",[84952],"Infections, Herpesviridae",[84926],{"nctId":84955,"briefTitle":84956,"status":155,"phases":84957,"primaryCompletion":84958,"completion":84958,"start":84959,"enrollment":24284,"conditions":84960,"interventions":84961},"NCT00158860","A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.",[88],"2006-07-26","2004-06-21",[13937],[84926],{"trials":84963,"activeCount":97},[84964],{"nctId":84965,"briefTitle":84966,"status":155,"phases":84967,"primaryCompletion":10167,"completion":7647,"start":3079,"enrollment":84968,"conditions":84969,"interventions":84970},"NCT01390857","Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)",[],379,[3717],[84926],{"intervention":17968,"totalTrials":593,"cells":84972},{"EARLY_PHASE1":84973,"PHASE1":84975,"PHASE2":84977,"PHASE3":84979,"PHASE4":84989,"NA":84991},{"trials":84974,"activeCount":97},[],{"trials":84976,"activeCount":97},[],{"trials":84978,"activeCount":97},[],{"trials":84980,"activeCount":97},[84981,84985],{"nctId":765,"briefTitle":766,"status":155,"phases":84982,"primaryCompletion":768,"completion":768,"start":769,"enrollment":770,"conditions":84983,"interventions":84984},[87],[741],[694,773],{"nctId":17963,"briefTitle":17964,"status":155,"phases":84986,"primaryCompletion":8406,"completion":8406,"start":8427,"enrollment":25,"conditions":84987,"interventions":84988},[87],[10182],[17843,17968],{"trials":84990,"activeCount":97},[],{"trials":84992,"activeCount":97},[84993],{"nctId":82252,"briefTitle":82253,"status":155,"phases":84994,"primaryCompletion":21200,"completion":21200,"start":7436,"enrollment":10978,"conditions":84995,"interventions":84996},[],[10182],[9502,17968,8409],{"intervention":84998,"totalTrials":593,"cells":84999},"Retapamulin",{"EARLY_PHASE1":85000,"PHASE1":85002,"PHASE2":85004,"PHASE3":85013,"PHASE4":85015,"NA":85017},{"trials":85001,"activeCount":97},[],{"trials":85003,"activeCount":97},[],{"trials":85005,"activeCount":97},[85006],{"nctId":85007,"briefTitle":85008,"status":155,"phases":85009,"primaryCompletion":7954,"completion":7954,"start":2356,"enrollment":2384,"conditions":85010,"interventions":85011},"NCT00539994","Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus",[86],[6484],[85012,84998],"retapamulin",{"trials":85014,"activeCount":97},[],{"trials":85016,"activeCount":97},[],{"trials":85018,"activeCount":97},[85019,85026],{"nctId":85020,"briefTitle":85021,"status":155,"phases":85022,"primaryCompletion":9706,"completion":9706,"start":8468,"enrollment":417,"conditions":85023,"interventions":85024},"NCT01153880","United States Pharmacovigilence Retapamulin-Prescribing",[],[12727],[84998,85025],"Co-prescription of retapamulin and topical mupirocin",{"nctId":85027,"briefTitle":85028,"status":155,"phases":85029,"primaryCompletion":9706,"completion":9706,"start":10166,"enrollment":417,"conditions":85030,"interventions":85031},"NCT01153828","EU PV for Retapamulin-Prescribing",[],[26970],[84998,85025,85032],"Co-prescription of retapamulin and topical fusidic acid",{"intervention":85034,"totalTrials":593,"cells":85035},"retigabine\u002Fezogabine",{"EARLY_PHASE1":85036,"PHASE1":85038,"PHASE2":85040,"PHASE3":85042,"PHASE4":85050,"NA":85052},{"trials":85037,"activeCount":97},[],{"trials":85039,"activeCount":97},[],{"trials":85041,"activeCount":97},[],{"trials":85043,"activeCount":97},[85044],{"nctId":85045,"briefTitle":85046,"status":145,"phases":85047,"primaryCompletion":83788,"completion":83788,"start":4986,"enrollment":181,"conditions":85048,"interventions":85049},"NCT01668654","Long-term, Open-label Safety Extension Study of Retigabine\u002FEzogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS",[87],[12518],[85034],{"trials":85051,"activeCount":97},[],{"trials":85053,"activeCount":97},[85054,85065],{"nctId":85055,"briefTitle":85056,"status":155,"phases":85057,"primaryCompletion":8883,"completion":7545,"start":3551,"enrollment":85058,"conditions":85059,"interventions":85060},"NCT01587339","Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy",[],6498,[12518],[85034,85061,85062,85063,85064],"lacosamide","zonisamide","pregabalin","eslicarbazepine",{"nctId":85066,"briefTitle":85067,"status":155,"phases":85068,"primaryCompletion":9682,"completion":9682,"start":9682,"enrollment":417,"conditions":85069,"interventions":85070},"NCT01457989","Meta-Analysis Plan for Pooled Data for Studies VRX-RET-E22-303 and VRX-RET-E22-304",[],[21978],[85034],{"intervention":10558,"totalTrials":593,"cells":85072},{"EARLY_PHASE1":85073,"PHASE1":85075,"PHASE2":85077,"PHASE3":85083,"PHASE4":85089,"NA":85091},{"trials":85074,"activeCount":97},[],{"trials":85076,"activeCount":97},[],{"trials":85078,"activeCount":97},[85079],{"nctId":10549,"briefTitle":10550,"status":155,"phases":85080,"primaryCompletion":10552,"completion":10553,"start":10554,"enrollment":10555,"conditions":85081,"interventions":85082},[86],[3717,2484,2485,2486],[10558,10559,10526,10547],{"trials":85084,"activeCount":97},[85085],{"nctId":23131,"briefTitle":23132,"status":155,"phases":85086,"primaryCompletion":23134,"completion":23134,"start":23135,"enrollment":23136,"conditions":85087,"interventions":85088},[87],[3717,23138],[23140,19877,23141],{"trials":85090,"activeCount":97},[],{"trials":85092,"activeCount":97},[85093],{"nctId":85094,"briefTitle":85095,"status":500,"phases":85096,"primaryCompletion":19326,"completion":19326,"start":22319,"enrollment":97,"conditions":85097,"interventions":85098},"NCT01738841","Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines",[],[2485,2484,2486,3717],[10558],{"intervention":11980,"totalTrials":593,"cells":85100},{"EARLY_PHASE1":85101,"PHASE1":85103,"PHASE2":85109,"PHASE3":85111,"PHASE4":85113,"NA":85119},{"trials":85102,"activeCount":97},[],{"trials":85104,"activeCount":97},[85105],{"nctId":11975,"briefTitle":11976,"status":155,"phases":85106,"primaryCompletion":2335,"completion":2335,"start":7647,"enrollment":473,"conditions":85107,"interventions":85108},[85],[9153],[11980,11968,11981],{"trials":85110,"activeCount":97},[],{"trials":85112,"activeCount":97},[],{"trials":85114,"activeCount":97},[85115],{"nctId":11989,"briefTitle":11990,"status":155,"phases":85116,"primaryCompletion":3078,"completion":3078,"start":11992,"enrollment":536,"conditions":85117,"interventions":85118},[88],[11994],[11968,11980],{"trials":85120,"activeCount":97},[85121],{"nctId":85122,"briefTitle":85123,"status":500,"phases":85124,"primaryCompletion":8151,"completion":8151,"start":8151,"enrollment":97,"conditions":85125,"interventions":85126},"NCT02262702","Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study",[],[10386],[85127,11980],"Paracetamol 665 mg",{"intervention":85129,"totalTrials":593,"cells":85130},"FSC",{"EARLY_PHASE1":85131,"PHASE1":85133,"PHASE2":85135,"PHASE3":85137,"PHASE4":85155,"NA":85157},{"trials":85132,"activeCount":97},[],{"trials":85134,"activeCount":97},[],{"trials":85136,"activeCount":97},[],{"trials":85138,"activeCount":97},[85139,85147],{"nctId":85140,"briefTitle":85141,"status":155,"phases":85142,"primaryCompletion":85143,"completion":85143,"start":85144,"enrollment":8817,"conditions":85145,"interventions":85146},"NCT01978119","A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250\u002F50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma",[87],"2015-01-28","2013-11-06",[18],[85129],{"nctId":85148,"briefTitle":85149,"status":155,"phases":85150,"primaryCompletion":8682,"completion":8682,"start":85151,"enrollment":85152,"conditions":85153,"interventions":85154},"NCT01978145","A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate\u002FSalmeterol (FSC) 250\u002F50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)",[87],"2013-11-14",665,[15],[85129],{"trials":85156,"activeCount":97},[],{"trials":85158,"activeCount":97},[85159],{"nctId":85160,"briefTitle":85161,"status":155,"phases":85162,"primaryCompletion":2335,"completion":8883,"start":3551,"enrollment":85163,"conditions":85164,"interventions":85165},"NCT01381458","Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation",[],1936,[15],[85129,85166],"ACs",{"intervention":30719,"totalTrials":593,"cells":85168},{"EARLY_PHASE1":85169,"PHASE1":85171,"PHASE2":85173,"PHASE3":85175,"PHASE4":85188,"NA":85190},{"trials":85170,"activeCount":97},[],{"trials":85172,"activeCount":97},[],{"trials":85174,"activeCount":97},[],{"trials":85176,"activeCount":97},[85177,85184],{"nctId":85178,"briefTitle":85179,"status":155,"phases":85180,"primaryCompletion":7591,"completion":728,"start":3551,"enrollment":739,"conditions":85181,"interventions":85182},"NCT01205451","A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity",[87],[38020],[85183],"Botulinum toxin type A",{"nctId":30712,"briefTitle":30713,"status":155,"phases":85185,"primaryCompletion":30715,"completion":30715,"start":2373,"enrollment":19760,"conditions":85186,"interventions":85187},[87],[30717],[30719,30701],{"trials":85189,"activeCount":97},[],{"trials":85191,"activeCount":97},[85192],{"nctId":85193,"briefTitle":85194,"status":155,"phases":85195,"primaryCompletion":22334,"completion":22334,"start":9682,"enrollment":85196,"conditions":85197,"interventions":85198},"NCT01390922","Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.)",[],1038,[2485],[30719],{"intervention":85200,"totalTrials":593,"cells":85201},"fluticasone propionate\u002Fsalmeterol xinafoate combination",{"EARLY_PHASE1":85202,"PHASE1":85204,"PHASE2":85206,"PHASE3":85208,"PHASE4":85210,"NA":85212},{"trials":85203,"activeCount":97},[],{"trials":85205,"activeCount":97},[],{"trials":85207,"activeCount":97},[],{"trials":85209,"activeCount":97},[],{"trials":85211,"activeCount":97},[],{"trials":85213,"activeCount":97},[85214,85222,85229],{"nctId":85215,"briefTitle":85216,"status":155,"phases":85217,"primaryCompletion":6352,"completion":6352,"start":2441,"enrollment":85218,"conditions":85219,"interventions":85220},"NCT01347060","Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate\u002FSalmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy",[],17448,[18],[85200,85221],"inhaled corticosteroids",{"nctId":85223,"briefTitle":85224,"status":155,"phases":85225,"primaryCompletion":7647,"completion":7647,"start":9159,"enrollment":85226,"conditions":85227,"interventions":85228},"NCT01381471","Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)",[],11060,[15],[85200],{"nctId":85230,"briefTitle":85231,"status":155,"phases":85232,"primaryCompletion":7647,"completion":7647,"start":6351,"enrollment":85233,"conditions":85234,"interventions":85235},"NCT01332461","Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies",[],5677,[15],[85200,85236],"Other maintenance Treatments",{"intervention":85238,"totalTrials":593,"cells":85239},"5ARI",{"EARLY_PHASE1":85240,"PHASE1":85242,"PHASE2":85244,"PHASE3":85246,"PHASE4":85248,"NA":85250},{"trials":85241,"activeCount":97},[],{"trials":85243,"activeCount":97},[],{"trials":85245,"activeCount":97},[],{"trials":85247,"activeCount":97},[],{"trials":85249,"activeCount":97},[],{"trials":85251,"activeCount":97},[85252,85259,85266],{"nctId":85253,"briefTitle":85254,"status":155,"phases":85255,"primaryCompletion":2344,"completion":2344,"start":2335,"enrollment":85256,"conditions":85257,"interventions":85258},"NCT01376258","Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database",[],28903,[12263],[85238],{"nctId":85260,"briefTitle":85261,"status":155,"phases":85262,"primaryCompletion":11030,"completion":11030,"start":2794,"enrollment":83738,"conditions":85263,"interventions":85264},"NCT01386983","Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment",[],[12263],[85238,85265],"5ARI + AB",{"nctId":85267,"briefTitle":85268,"status":155,"phases":85269,"primaryCompletion":11030,"completion":11030,"start":6352,"enrollment":85270,"conditions":85271,"interventions":85272},"NCT01323998","Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan",[],35032,[12263],[85238,85273],"AB",{"intervention":85275,"totalTrials":593,"cells":85276},"Naratriptan",{"EARLY_PHASE1":85277,"PHASE1":85279,"PHASE2":85281,"PHASE3":85283,"PHASE4":85285,"NA":85287},{"trials":85278,"activeCount":97},[],{"trials":85280,"activeCount":97},[],{"trials":85282,"activeCount":97},[],{"trials":85284,"activeCount":97},[],{"trials":85286,"activeCount":97},[],{"trials":85288,"activeCount":97},[85289,85295,85301],{"nctId":85290,"briefTitle":85291,"status":155,"phases":85292,"primaryCompletion":2394,"completion":2394,"start":3550,"enrollment":10126,"conditions":85293,"interventions":85294},"NCT01376193","Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet",[],[14168],[85275],{"nctId":85296,"briefTitle":85297,"status":155,"phases":85298,"primaryCompletion":3045,"completion":3045,"start":2795,"enrollment":536,"conditions":85299,"interventions":85300},"NCT01332383","Special Drug Use Investigation for AMERGE® Tablet (Long-term)",[],[14168],[85275],{"nctId":85302,"briefTitle":85303,"status":155,"phases":85304,"primaryCompletion":484,"completion":484,"start":85305,"enrollment":85306,"conditions":85307,"interventions":85308},"NCT01059604","Sumatriptan and Naratriptan Pregnancy Registry",[],"2001-12",868,[14168],[85309,85275,85310],"Sumatriptan","Sumatriptan-naproxen combination",{"intervention":85309,"totalTrials":593,"cells":85312},{"EARLY_PHASE1":85313,"PHASE1":85315,"PHASE2":85317,"PHASE3":85319,"PHASE4":85321,"NA":85327},{"trials":85314,"activeCount":97},[],{"trials":85316,"activeCount":97},[],{"trials":85318,"activeCount":97},[],{"trials":85320,"activeCount":97},[],{"trials":85322,"activeCount":97},[85323],{"nctId":14164,"briefTitle":14165,"status":155,"phases":85324,"primaryCompletion":6351,"completion":6351,"start":10166,"enrollment":11770,"conditions":85325,"interventions":85326},[88],[14168],[14151,14170,14171],{"trials":85328,"activeCount":97},[85329,85336],{"nctId":85330,"briefTitle":85331,"status":155,"phases":85332,"primaryCompletion":1380,"completion":2844,"start":2776,"enrollment":85333,"conditions":85334,"interventions":85335},"NCT01376141","Drug Use Investigation for IMIGRAN Tablet",[],3571,[14168],[85309],{"nctId":85302,"briefTitle":85303,"status":155,"phases":85337,"primaryCompletion":484,"completion":484,"start":85305,"enrollment":85306,"conditions":85338,"interventions":85339},[],[14168],[85309,85275,85310],{"intervention":37770,"totalTrials":593,"cells":85341},{"EARLY_PHASE1":85342,"PHASE1":85344,"PHASE2":85350,"PHASE3":85352,"PHASE4":85358,"NA":85360},{"trials":85343,"activeCount":97},[],{"trials":85345,"activeCount":97},[85346],{"nctId":74472,"briefTitle":74473,"status":155,"phases":85347,"primaryCompletion":8027,"completion":8027,"start":23146,"enrollment":345,"conditions":85348,"interventions":85349},[85],[4191],[37770,74477,74465],{"trials":85351,"activeCount":97},[],{"trials":85353,"activeCount":97},[85354],{"nctId":37764,"briefTitle":37765,"status":155,"phases":85355,"start":37767,"enrollment":3392,"conditions":85356,"interventions":85357},[87],[4190],[37753,37770],{"trials":85359,"activeCount":97},[],{"trials":85361,"activeCount":97},[85362],{"nctId":85363,"briefTitle":85364,"status":155,"phases":85365,"primaryCompletion":7658,"completion":729,"start":8852,"enrollment":8469,"conditions":85366,"interventions":85367},"NCT01376154","Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)",[],[4191],[37770],{"intervention":37426,"totalTrials":593,"cells":85369},{"EARLY_PHASE1":85370,"PHASE1":85372,"PHASE2":85378,"PHASE3":85380,"PHASE4":85386,"NA":85388},{"trials":85371,"activeCount":97},[],{"trials":85373,"activeCount":97},[85374],{"nctId":38870,"briefTitle":38871,"status":155,"phases":85375,"primaryCompletion":38873,"completion":38873,"start":38874,"enrollment":9334,"conditions":85376,"interventions":85377},[85],[27],[9030,37426],{"trials":85379,"activeCount":97},[],{"trials":85381,"activeCount":97},[85382],{"nctId":37418,"briefTitle":37419,"status":155,"phases":85383,"primaryCompletion":37421,"completion":23180,"start":37422,"enrollment":37423,"conditions":85384,"interventions":85385},[87],[10889],[37426,37407],{"trials":85387,"activeCount":97},[],{"trials":85389,"activeCount":97},[85390],{"nctId":85391,"briefTitle":85392,"status":155,"phases":85393,"primaryCompletion":7634,"completion":7634,"start":7701,"enrollment":417,"conditions":85394,"interventions":85395},"NCT02039960","PRJ2215: Assessment of Buproprion Misuse\u002FAbuse 2004-2011",[],[10889],[37426],{"intervention":13026,"totalTrials":593,"cells":85397},{"EARLY_PHASE1":85398,"PHASE1":85400,"PHASE2":85402,"PHASE3":85404,"PHASE4":85406,"NA":85416},{"trials":85399,"activeCount":97},[],{"trials":85401,"activeCount":97},[],{"trials":85403,"activeCount":97},[],{"trials":85405,"activeCount":97},[],{"trials":85407,"activeCount":97},[85408,85412],{"nctId":13018,"briefTitle":13019,"status":155,"phases":85409,"primaryCompletion":2775,"completion":2775,"start":13021,"enrollment":13022,"conditions":85410,"interventions":85411},[88],[13024],[13026,13005],{"nctId":13028,"briefTitle":13029,"status":155,"phases":85413,"primaryCompletion":2775,"completion":2775,"start":13021,"enrollment":13031,"conditions":85414,"interventions":85415},[88],[13024],[13026,13005],{"trials":85417,"activeCount":97},[85418],{"nctId":85419,"briefTitle":85420,"status":155,"phases":85421,"primaryCompletion":7658,"completion":7658,"start":3550,"enrollment":85422,"conditions":85423,"interventions":85424},"NCT01587638","Use of Beta-blockers and Risk of New Onset Diabetes",[],12336,[13024],[13026,85425],"cardio selective betablocker",{"intervention":85265,"totalTrials":593,"cells":85427},{"EARLY_PHASE1":85428,"PHASE1":85430,"PHASE2":85432,"PHASE3":85434,"PHASE4":85436,"NA":85438},{"trials":85429,"activeCount":97},[],{"trials":85431,"activeCount":97},[],{"trials":85433,"activeCount":97},[],{"trials":85435,"activeCount":97},[],{"trials":85437,"activeCount":97},[],{"trials":85439,"activeCount":97},[85440,85444,85451],{"nctId":85260,"briefTitle":85261,"status":155,"phases":85441,"primaryCompletion":11030,"completion":11030,"start":2794,"enrollment":83738,"conditions":85442,"interventions":85443},[],[12263],[85238,85265],{"nctId":85445,"briefTitle":85446,"status":155,"phases":85447,"primaryCompletion":26336,"completion":26336,"start":6351,"enrollment":85448,"conditions":85449,"interventions":85450},"NCT01332435","Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use",[],6896,[12263],[85265],{"nctId":85452,"briefTitle":85453,"status":155,"phases":85454,"primaryCompletion":3391,"completion":3391,"start":3391,"enrollment":84102,"conditions":85455,"interventions":85456},"NCT01332487","Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia",[],[12263],[85265],{"intervention":85458,"totalTrials":660,"cells":85459},"NUCALA",{"EARLY_PHASE1":85460,"PHASE1":85462,"PHASE2":85464,"PHASE3":85466,"PHASE4":85468,"NA":85470},{"trials":85461,"activeCount":97},[],{"trials":85463,"activeCount":97},[],{"trials":85465,"activeCount":97},[],{"trials":85467,"activeCount":97},[],{"trials":85469,"activeCount":97},[],{"trials":85471,"activeCount":97},[85472,85480],{"nctId":85473,"briefTitle":85474,"status":155,"phases":85475,"primaryCompletion":85476,"completion":85476,"start":39815,"enrollment":85477,"conditions":85478,"interventions":85479},"NCT03028480","Long Term Special Drug Use Investigation of Mepolizumab",[],"2023-11-22",1061,[18],[85458],{"nctId":85481,"briefTitle":85482,"status":155,"phases":85483,"primaryCompletion":85484,"completion":85484,"start":2974,"enrollment":85485,"conditions":85486,"interventions":85487},"NCT03557060","NUCALA® Special Drug Use Investigation (EGPA, Long-term)",[],"2025-07-30",4115,[851,783],[85488],"Nucala",{"intervention":85490,"totalTrials":660,"cells":85491},"Potassium Nitrate",{"EARLY_PHASE1":85492,"PHASE1":85494,"PHASE2":85502,"PHASE3":85504,"PHASE4":85506,"NA":85508},{"trials":85493,"activeCount":97},[],{"trials":85495,"activeCount":97},[85496],{"nctId":85497,"briefTitle":85498,"status":155,"phases":85499,"primaryCompletion":3550,"completion":3550,"start":8116,"enrollment":1459,"conditions":85500,"interventions":85501},"NCT01587950","The Effects of Potassium Nitrate in Reducing Dentinal Hypersensitivity",[85],[44593,20948],[85490],{"trials":85503,"activeCount":97},[],{"trials":85505,"activeCount":97},[],{"trials":85507,"activeCount":97},[],{"trials":85509,"activeCount":97},[85510],{"nctId":84174,"briefTitle":84175,"status":155,"phases":85511,"primaryCompletion":9233,"completion":9233,"start":8135,"enrollment":904,"conditions":85512,"interventions":85513},[89],[53481,84178],[84159,84180],{"intervention":85515,"totalTrials":660,"cells":85516},"nelarabine",{"EARLY_PHASE1":85517,"PHASE1":85519,"PHASE2":85521,"PHASE3":85530,"PHASE4":85532,"NA":85534},{"trials":85518,"activeCount":97},[],{"trials":85520,"activeCount":97},[],{"trials":85522,"activeCount":97},[85523],{"nctId":85524,"briefTitle":85525,"status":155,"phases":85526,"completion":7673,"start":10107,"conditions":85527,"interventions":85529},"NCT00003635","506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents",[86],[85528],"Leukemia",[85515],{"trials":85531,"activeCount":97},[],{"trials":85533,"activeCount":97},[],{"trials":85535,"activeCount":97},[85536],{"nctId":85537,"briefTitle":85538,"status":155,"phases":85539,"primaryCompletion":10905,"completion":10905,"start":8116,"enrollment":695,"conditions":85540,"interventions":85542},"NCT00866671","Observational Study of Nelarabine in Children and Young Adults",[],[85541],"Leukaemia, Lymphoblastic, Acute",[85515],{"intervention":85544,"totalTrials":660,"cells":85545},"Treatment",{"EARLY_PHASE1":85546,"PHASE1":85548,"PHASE2":85550,"PHASE3":85552,"PHASE4":85554,"NA":85556},{"trials":85547,"activeCount":97},[],{"trials":85549,"activeCount":97},[],{"trials":85551,"activeCount":97},[],{"trials":85553,"activeCount":97},[],{"trials":85555,"activeCount":97},[],{"trials":85557,"activeCount":97},[85558,85564],{"nctId":85559,"briefTitle":85560,"status":145,"phases":85561,"primaryCompletion":24869,"completion":24869,"start":18460,"enrollment":593,"conditions":85562,"interventions":85563},"NCT01357863","Role of Early Versus Late Switch to Lapatinib-Capecitabine",[],[36],[85544],{"nctId":85565,"briefTitle":85566,"status":155,"phases":85567,"primaryCompletion":2805,"completion":2805,"start":8478,"enrollment":85568,"conditions":85569,"interventions":85570},"NCT01387165","Epidemiologic Survey to Describe the Current Medical Practice of General Practitioners Treating Subjects With Type 2 Diabetes Mellitus in Latina",[],3592,[27],[85544],{"intervention":85572,"totalTrials":660,"cells":85573},"Meningococcal quadrivalent CRM-197 conjugate vaccine",{"EARLY_PHASE1":85574,"PHASE1":85576,"PHASE2":85578,"PHASE3":85580,"PHASE4":85582,"NA":85584},{"trials":85575,"activeCount":97},[],{"trials":85577,"activeCount":97},[],{"trials":85579,"activeCount":97},[],{"trials":85581,"activeCount":97},[],{"trials":85583,"activeCount":97},[],{"trials":85585,"activeCount":97},[85586,85592],{"nctId":85587,"briefTitle":85588,"status":155,"phases":85589,"primaryCompletion":20257,"completion":20257,"start":57194,"enrollment":7947,"conditions":85590,"interventions":85591},"NCT02287688","Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study",[],[12803,992],[85572],{"nctId":85593,"briefTitle":85594,"status":155,"phases":85595,"primaryCompletion":41668,"completion":41668,"start":12653,"enrollment":7911,"conditions":85596,"interventions":85598},"NCT02223637","Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry",[],[12803,85597,992],"Pregnancy",[85572],{"intervention":85600,"totalTrials":660,"cells":85601},"Fluticasone",{"EARLY_PHASE1":85602,"PHASE1":85604,"PHASE2":85606,"PHASE3":85608,"PHASE4":85610,"NA":85612},{"trials":85603,"activeCount":97},[],{"trials":85605,"activeCount":97},[],{"trials":85607,"activeCount":97},[],{"trials":85609,"activeCount":97},[],{"trials":85611,"activeCount":97},[],{"trials":85613,"activeCount":97},[85614,85620],{"nctId":85615,"briefTitle":85616,"status":155,"phases":85617,"primaryCompletion":8860,"completion":8860,"start":2344,"enrollment":10126,"conditions":85618,"interventions":85619},"NCT01420822","Special Drug Use Investigation for ALLERMIST (Long Term)",[],[11853],[85600],{"nctId":85621,"briefTitle":85622,"status":155,"phases":85623,"primaryCompletion":3551,"completion":7590,"start":7658,"enrollment":30275,"conditions":85624,"interventions":85625},"NCT01376206","Drug Use Investigation for ALLERMIST",[],[11853],[85600],{"intervention":85221,"totalTrials":660,"cells":85627},{"EARLY_PHASE1":85628,"PHASE1":85630,"PHASE2":85632,"PHASE3":85634,"PHASE4":85636,"NA":85638},{"trials":85629,"activeCount":97},[],{"trials":85631,"activeCount":97},[],{"trials":85633,"activeCount":97},[],{"trials":85635,"activeCount":97},[],{"trials":85637,"activeCount":97},[],{"trials":85639,"activeCount":97},[85640,85644],{"nctId":85215,"briefTitle":85216,"status":155,"phases":85641,"primaryCompletion":6352,"completion":6352,"start":2441,"enrollment":85218,"conditions":85642,"interventions":85643},[],[18],[85200,85221],{"nctId":85645,"briefTitle":85646,"status":155,"phases":85647,"primaryCompletion":11030,"completion":11030,"start":2442,"enrollment":85648,"conditions":85649,"interventions":85650},"NCT01332344","Outcomes in Patients Taking Fluticasone Propionate\u002FSalmeterol Combination or Other Inhaled Corticosteroids",[],5180,[18],[85651,85652],"Fluticasone propionate\u002Fsalmeterol combination","Inhaled corticosteroids",{"intervention":85654,"totalTrials":660,"cells":85655},"Targeted agents indicated in management of advanced\u002Fmetastatic RCC",{"EARLY_PHASE1":85656,"PHASE1":85658,"PHASE2":85660,"PHASE3":85662,"PHASE4":85664,"NA":85666},{"trials":85657,"activeCount":97},[],{"trials":85659,"activeCount":97},[],{"trials":85661,"activeCount":97},[],{"trials":85663,"activeCount":97},[],{"trials":85665,"activeCount":97},[],{"trials":85667,"activeCount":97},[85668,85674],{"nctId":85669,"briefTitle":85670,"status":155,"phases":85671,"primaryCompletion":2394,"completion":2394,"start":8883,"enrollment":417,"conditions":85672,"interventions":85673},"NCT01381601","Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)",[],[1877],[85654],{"nctId":85675,"briefTitle":85676,"status":155,"phases":85677,"primaryCompletion":7591,"completion":7591,"start":8883,"enrollment":417,"conditions":85678,"interventions":85679},"NCT01381614","Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)",[],[1877],[85654],{"intervention":85681,"totalTrials":660,"cells":85682},"BOTOX",{"EARLY_PHASE1":85683,"PHASE1":85685,"PHASE2":85687,"PHASE3":85689,"PHASE4":85691,"NA":85693},{"trials":85684,"activeCount":97},[],{"trials":85686,"activeCount":97},[],{"trials":85688,"activeCount":97},[],{"trials":85690,"activeCount":97},[],{"trials":85692,"activeCount":97},[],{"trials":85694,"activeCount":97},[85695,85702],{"nctId":85696,"briefTitle":85697,"status":155,"phases":85698,"primaryCompletion":3391,"completion":3391,"start":7647,"enrollment":85699,"conditions":85700,"interventions":85701},"NCT01332474","JCP Study of Investigation of Patient Background Characteristics",[],326,[38020],[85681],{"nctId":85703,"briefTitle":85704,"status":12113,"phases":85705,"primaryCompletion":85706,"completion":85706,"start":39699,"enrollment":4388,"conditions":85707,"interventions":85709},"NCT03543150","BOTOX® Drug Use Investigation (Spasmodic Dysphonia)",[],"2022-02-28",[85708],"Dysphonia",[85681],{"intervention":18322,"totalTrials":660,"cells":85711},{"EARLY_PHASE1":85712,"PHASE1":85714,"PHASE2":85716,"PHASE3":85718,"PHASE4":85724,"NA":85726},{"trials":85713,"activeCount":97},[],{"trials":85715,"activeCount":97},[],{"trials":85717,"activeCount":97},[],{"trials":85719,"activeCount":97},[85720],{"nctId":18314,"briefTitle":18315,"status":155,"phases":85721,"primaryCompletion":18317,"completion":18317,"start":18318,"enrollment":18319,"conditions":85722,"interventions":85723},[87],[992],[8291,18322,11489],{"trials":85725,"activeCount":97},[],{"trials":85727,"activeCount":97},[85728],{"nctId":85729,"briefTitle":85730,"status":155,"phases":85731,"primaryCompletion":7634,"completion":7634,"start":3551,"enrollment":85732,"conditions":85733,"interventions":85734},"NCT01187927","Drug Use Investigation for Cervarix®",[],1230,[8723],[18322],{"intervention":85736,"totalTrials":660,"cells":85737},"Belimumab 10 mg\u002Fkg",{"EARLY_PHASE1":85738,"PHASE1":85740,"PHASE2":85742,"PHASE3":85753,"PHASE4":85755,"NA":85757},{"trials":85739,"activeCount":97},[],{"trials":85741,"activeCount":97},[],{"trials":85743,"activeCount":97},[85744],{"nctId":85745,"briefTitle":85746,"status":155,"phases":85747,"primaryCompletion":85748,"completion":85749,"start":85750,"enrollment":7911,"conditions":85751,"interventions":85752},"NCT01649765","Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy",[86],"2018-01-24","2025-09-30","2012-09-07",[435],[85736],{"trials":85754,"activeCount":97},[],{"trials":85756,"activeCount":97},[],{"trials":85758,"activeCount":97},[85759],{"nctId":85760,"briefTitle":85761,"status":155,"phases":85762,"primaryCompletion":10463,"completion":10463,"start":2441,"enrollment":85763,"conditions":85764,"interventions":85765},"NCT01914770","Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76",[],1016,[435],[85766,85736],"Belimumab 1 mg\u002Fkg",{"intervention":85768,"totalTrials":660,"cells":85769},"GW501516",{"EARLY_PHASE1":85770,"PHASE1":85772,"PHASE2":85774,"PHASE3":85783,"PHASE4":85785,"NA":85787},{"trials":85771,"activeCount":97},[],{"trials":85773,"activeCount":97},[],{"trials":85775,"activeCount":97},[85776],{"nctId":85777,"briefTitle":85778,"status":155,"phases":85779,"primaryCompletion":8852,"completion":8852,"start":19830,"enrollment":14772,"conditions":85780,"interventions":85781},"NCT00158899","GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol",[86],[27251,39018],[85782],"GW501516 oral",{"trials":85784,"activeCount":97},[],{"trials":85786,"activeCount":97},[],{"trials":85788,"activeCount":97},[85789],{"nctId":85790,"briefTitle":85791,"status":155,"phases":85792,"start":1361,"enrollment":7394,"conditions":85793,"interventions":85795},"NCT00388180","An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation",[],[85794,27251,9048],"Hypercholesterolemia",[85768,53397],{"intervention":53397,"totalTrials":660,"cells":85797},{"EARLY_PHASE1":85798,"PHASE1":85800,"PHASE2":85802,"PHASE3":85808,"PHASE4":85810,"NA":85812},{"trials":85799,"activeCount":97},[],{"trials":85801,"activeCount":97},[],{"trials":85803,"activeCount":97},[85804],{"nctId":53392,"briefTitle":53393,"status":155,"phases":85805,"primaryCompletion":7785,"completion":7785,"start":20690,"enrollment":17295,"conditions":85806,"interventions":85807},[86],[27251],[53397,53383],{"trials":85809,"activeCount":97},[],{"trials":85811,"activeCount":97},[],{"trials":85813,"activeCount":97},[85814],{"nctId":85790,"briefTitle":85791,"status":155,"phases":85815,"start":1361,"enrollment":7394,"conditions":85816,"interventions":85817},[],[85794,27251,9048],[85768,53397],{"intervention":19402,"totalTrials":660,"cells":85819},{"EARLY_PHASE1":85820,"PHASE1":85822,"PHASE2":85824,"PHASE3":85826,"PHASE4":85832,"NA":85834},{"trials":85821,"activeCount":97},[],{"trials":85823,"activeCount":97},[],{"trials":85825,"activeCount":97},[],{"trials":85827,"activeCount":97},[85828],{"nctId":19392,"briefTitle":19393,"status":155,"phases":85829,"primaryCompletion":19395,"completion":19396,"start":19397,"enrollment":19398,"conditions":85830,"interventions":85831},[87],[19400],[8673,8674,19402,19403],{"trials":85833,"activeCount":97},[],{"trials":85835,"activeCount":97},[85836],{"nctId":84287,"briefTitle":84288,"status":155,"phases":85837,"primaryCompletion":13584,"completion":13584,"start":8721,"enrollment":417,"conditions":85838,"interventions":85839},[],[30,3624,33],[4809,4805,19402],{"intervention":9416,"totalTrials":660,"cells":85841},{"EARLY_PHASE1":85842,"PHASE1":85844,"PHASE2":85846,"PHASE3":85848,"PHASE4":85854,"NA":85856},{"trials":85843,"activeCount":97},[],{"trials":85845,"activeCount":97},[],{"trials":85847,"activeCount":97},[],{"trials":85849,"activeCount":97},[85850],{"nctId":9407,"briefTitle":9408,"status":155,"phases":85851,"primaryCompletion":9410,"completion":9410,"start":9411,"enrollment":9412,"conditions":85852,"interventions":85853},[87],[18],[8532,9415,8381,9370,9416,9417],{"trials":85855,"activeCount":97},[],{"trials":85857,"activeCount":97},[85858],{"nctId":82239,"briefTitle":82240,"status":155,"phases":85859,"primaryCompletion":7647,"completion":7647,"start":2442,"enrollment":82242,"conditions":85860,"interventions":85861},[],[18],[8381,9416,8578],{"intervention":84172,"totalTrials":660,"cells":85863},{"EARLY_PHASE1":85864,"PHASE1":85866,"PHASE2":85868,"PHASE3":85870,"PHASE4":85878,"NA":85880},{"trials":85865,"activeCount":97},[],{"trials":85867,"activeCount":97},[],{"trials":85869,"activeCount":97},[],{"trials":85871,"activeCount":97},[85872],{"nctId":85873,"briefTitle":85874,"status":155,"phases":85875,"primaryCompletion":11315,"completion":11315,"start":9233,"enrollment":10794,"conditions":85876,"interventions":85877},"NCT01607411","A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model",[87],[13126],[84172],{"trials":85879,"activeCount":97},[],{"trials":85881,"activeCount":97},[85882],{"nctId":84165,"briefTitle":84166,"status":155,"phases":85883,"primaryCompletion":8860,"completion":8860,"start":19576,"enrollment":234,"conditions":85884,"interventions":85885},[89],[15325],[43205,43205,43205,84170,84171,84172],{"intervention":85887,"totalTrials":660,"cells":85888},"Lamotrigine monotherapy",{"EARLY_PHASE1":85889,"PHASE1":85891,"PHASE2":85893,"PHASE3":85895,"PHASE4":85897,"NA":85899},{"trials":85890,"activeCount":97},[],{"trials":85892,"activeCount":97},[],{"trials":85894,"activeCount":97},[],{"trials":85896,"activeCount":97},[],{"trials":85898,"activeCount":97},[],{"trials":85900,"activeCount":97},[85901,85910],{"nctId":85902,"briefTitle":85903,"status":155,"phases":85904,"primaryCompletion":1428,"completion":1428,"start":11577,"enrollment":85905,"conditions":85906,"interventions":85907},"NCT01064297","Lamotrigine Pregnancy Registry (LAM05)",[],3416,[12518,22321],[85887,85908,85909],"Lamotrigine polytherapy including valproate","Lamotrigine polytherapy without valproate",{"nctId":85911,"briefTitle":85912,"status":155,"phases":85913,"primaryCompletion":827,"completion":827,"start":2795,"enrollment":417,"conditions":85914,"interventions":85915},"NCT01055327","Birth Defects Associated With Exposure to Lamotrigine in Pregnancy (EUROCAT)",[],[12518],[85887,85916,85917],"No anti-epileptic drug exposure","Non lamotrigine anti-epileptic drug monotherapy",{"intervention":85919,"totalTrials":660,"cells":85920},"Salmeterol\u002FFluticasone propionate",{"EARLY_PHASE1":85921,"PHASE1":85923,"PHASE2":85925,"PHASE3":85927,"PHASE4":85929,"NA":85935},{"trials":85922,"activeCount":97},[],{"trials":85924,"activeCount":97},[],{"trials":85926,"activeCount":97},[],{"trials":85928,"activeCount":97},[],{"trials":85930,"activeCount":97},[85931],{"nctId":82209,"briefTitle":82210,"status":155,"phases":85932,"primaryCompletion":749,"completion":749,"start":11599,"enrollment":6482,"conditions":85933,"interventions":85934},[88],[18],[82214,8381],{"trials":85936,"activeCount":97},[85937],{"nctId":85938,"briefTitle":85939,"status":155,"phases":85940,"primaryCompletion":10167,"completion":10167,"start":3036,"enrollment":85941,"conditions":85942,"interventions":85943},"NCT00662805","Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)",[],762,[15],[85919],{"intervention":85945,"totalTrials":660,"cells":85946},"Azathioprine",{"EARLY_PHASE1":85947,"PHASE1":85949,"PHASE2":85951,"PHASE3":85953,"PHASE4":85955,"NA":85957},{"trials":85948,"activeCount":97},[],{"trials":85950,"activeCount":97},[],{"trials":85952,"activeCount":97},[],{"trials":85954,"activeCount":97},[],{"trials":85956,"activeCount":97},[],{"trials":85958,"activeCount":97},[85959,85965],{"nctId":85960,"briefTitle":85961,"status":155,"phases":85962,"primaryCompletion":7590,"completion":7590,"start":1361,"enrollment":12202,"conditions":85963,"interventions":85964},"NCT01381432","Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)",[],[47886],[85945],{"nctId":85966,"briefTitle":85967,"status":155,"phases":85968,"primaryCompletion":7590,"completion":7590,"start":2845,"enrollment":212,"conditions":85969,"interventions":85970},"NCT01390766","Drug Use Investigation for IMURAN (Azathioprine) Tablet (Hepatic Transplantation)",[],[47886],[85945],{"intervention":85972,"totalTrials":660,"cells":85973},"Anticholinergics",{"EARLY_PHASE1":85974,"PHASE1":85976,"PHASE2":85978,"PHASE3":85980,"PHASE4":85982,"NA":85984},{"trials":85975,"activeCount":97},[],{"trials":85977,"activeCount":97},[],{"trials":85979,"activeCount":97},[],{"trials":85981,"activeCount":97},[],{"trials":85983,"activeCount":97},[],{"trials":85985,"activeCount":97},[85986,85994],{"nctId":85987,"briefTitle":85988,"status":155,"phases":85989,"primaryCompletion":7598,"completion":9224,"start":8883,"enrollment":85990,"conditions":85991,"interventions":85992},"NCT01395875","Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment",[],2849,[15],[85993,85972],"Fluticasone Propionate \u002F Salmeterol Xinafoate Combination",{"nctId":85995,"briefTitle":85996,"status":155,"phases":85997,"primaryCompletion":10463,"completion":8883,"start":2335,"enrollment":417,"conditions":85998,"interventions":85999},"NCT01337336","Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250\u002F50mcg Versus Anticholinergics in a COPD-Comorbid Depression\u002FAnxiety Population",[],[15],[86000,85972],"fluticasone propionate\u002Fsalmeterol xinafoate",{"intervention":85025,"totalTrials":660,"cells":86002},{"EARLY_PHASE1":86003,"PHASE1":86005,"PHASE2":86007,"PHASE3":86009,"PHASE4":86011,"NA":86013},{"trials":86004,"activeCount":97},[],{"trials":86006,"activeCount":97},[],{"trials":86008,"activeCount":97},[],{"trials":86010,"activeCount":97},[],{"trials":86012,"activeCount":97},[],{"trials":86014,"activeCount":97},[86015,86019],{"nctId":85020,"briefTitle":85021,"status":155,"phases":86016,"primaryCompletion":9706,"completion":9706,"start":8468,"enrollment":417,"conditions":86017,"interventions":86018},[],[12727],[84998,85025],{"nctId":85027,"briefTitle":85028,"status":155,"phases":86020,"primaryCompletion":9706,"completion":9706,"start":10166,"enrollment":417,"conditions":86021,"interventions":86022},[],[26970],[84998,85025,85032],{"intervention":86024,"totalTrials":660,"cells":86025},"Gabapentin prescriptions",{"EARLY_PHASE1":86026,"PHASE1":86028,"PHASE2":86030,"PHASE3":86032,"PHASE4":86034,"NA":86036},{"trials":86027,"activeCount":97},[],{"trials":86029,"activeCount":97},[],{"trials":86031,"activeCount":97},[],{"trials":86033,"activeCount":97},[],{"trials":86035,"activeCount":97},[],{"trials":86037,"activeCount":97},[86038,86051],{"nctId":86039,"briefTitle":86040,"status":155,"phases":86041,"primaryCompletion":3391,"completion":3391,"start":3078,"enrollment":86042,"conditions":86043,"interventions":86050},"NCT01138124","Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD)",[],54202,[86044,14255,12518,50210,86045,13024,86046,86047,86048,86049],"Renal Pelvis Cancer","Chronic Pancreatitis","Pancreatic Cancer","Diabetes","Renal Cancer","Renal Cell Carcinoma",[86024],{"nctId":86052,"briefTitle":86053,"status":155,"phases":86054,"primaryCompletion":3551,"completion":3551,"start":11030,"enrollment":86055,"conditions":86056,"interventions":86063},"NCT01236053","Cancer in Patients With Gabapentin (GPRD)",[],2323608,[38980,12518,86044,86046,7676,86057,86045,86058,86049,86047,86059,86060,86061,86062,36,86048],"Nervous System Cancer","Stomach Cancer","Bladder Cancer","Bone and Joint Cancer","Penis Cancer","Anal Cancer",[86024],{"intervention":86065,"totalTrials":660,"cells":86066},"Orlistat",{"EARLY_PHASE1":86067,"PHASE1":86069,"PHASE2":86071,"PHASE3":86073,"PHASE4":86075,"NA":86083},{"trials":86068,"activeCount":97},[],{"trials":86070,"activeCount":97},[],{"trials":86072,"activeCount":97},[],{"trials":86074,"activeCount":97},[],{"trials":86076,"activeCount":97},[86077],{"nctId":86078,"briefTitle":86079,"status":155,"phases":86080,"primaryCompletion":2441,"completion":2441,"start":10167,"enrollment":8337,"conditions":86081,"interventions":86082},"NCT00752726","Effect of Orlistat in Body Composition",[88],[9048,65490],[86065],{"trials":86084,"activeCount":97},[86085],{"nctId":86086,"briefTitle":86087,"status":155,"phases":86088,"primaryCompletion":2344,"completion":2344,"start":26336,"enrollment":526,"conditions":86089,"interventions":86090},"NCT01387243","Survey on the Pharmacy Follow-up of Alli Purchasers",[],[65490],[86065],{"intervention":86092,"totalTrials":660,"cells":86093},"Oral Rotarix®",{"EARLY_PHASE1":86094,"PHASE1":86096,"PHASE2":86098,"PHASE3":86100,"PHASE4":86102,"NA":86104},{"trials":86095,"activeCount":97},[],{"trials":86097,"activeCount":97},[],{"trials":86099,"activeCount":97},[],{"trials":86101,"activeCount":97},[],{"trials":86103,"activeCount":97},[],{"trials":86105,"activeCount":97},[86106,86113],{"nctId":86107,"briefTitle":86108,"status":155,"phases":86109,"primaryCompletion":482,"completion":482,"start":8037,"enrollment":86110,"conditions":86111,"interventions":86112},"NCT01636739","Special Drug Use Investigation for ROTARIX®",[],10982,[4759],[86092],{"nctId":86114,"briefTitle":86115,"status":155,"phases":86116,"primaryCompletion":10905,"completion":10905,"start":2295,"enrollment":86117,"conditions":86118,"interventions":86119},"NCT01636193","Drug Use Investigation for ROTARIX®",[],1607,[4759],[86092],{"intervention":84077,"totalTrials":660,"cells":86121},{"EARLY_PHASE1":86122,"PHASE1":86124,"PHASE2":86126,"PHASE3":86128,"PHASE4":86134,"NA":86136},{"trials":86123,"activeCount":97},[],{"trials":86125,"activeCount":97},[],{"trials":86127,"activeCount":97},[],{"trials":86129,"activeCount":97},[86130],{"nctId":84071,"briefTitle":84072,"status":155,"phases":86131,"primaryCompletion":749,"completion":749,"start":10056,"enrollment":84074,"conditions":86132,"interventions":86133},[87],[35338],[84063,84077],{"trials":86135,"activeCount":97},[],{"trials":86137,"activeCount":97},[86138],{"nctId":84099,"briefTitle":84100,"status":155,"phases":86139,"primaryCompletion":2335,"completion":10463,"start":2834,"enrollment":84102,"conditions":86140,"interventions":86141},[],[26339],[84105,84077,56336,56337],{"intervention":86143,"totalTrials":660,"cells":86144},"Fluoride toothpaste",{"EARLY_PHASE1":86145,"PHASE1":86147,"PHASE2":86149,"PHASE3":86151,"PHASE4":86153,"NA":86155},{"trials":86146,"activeCount":97},[],{"trials":86148,"activeCount":97},[],{"trials":86150,"activeCount":97},[],{"trials":86152,"activeCount":97},[],{"trials":86154,"activeCount":97},[],{"trials":86156,"activeCount":97},[86157,86165],{"nctId":86158,"briefTitle":86159,"status":155,"phases":86160,"primaryCompletion":22081,"completion":86161,"start":86162,"enrollment":9196,"conditions":86163,"interventions":86164},"NCT02753075","A Study in Dentinal Hypersensitivity (DH) Participants to Assess the Efficacy of an Occluding Dentifrice.",[89],"2015-12-18","2015-09-08",[55741],[86143],{"nctId":86166,"briefTitle":86167,"status":155,"phases":86168,"primaryCompletion":35747,"completion":482,"start":502,"enrollment":526,"conditions":86169,"interventions":86170},"NCT02399163","Evaluation of Oral Hygiene Products in an In Situ Caries Model",[89],[13126],[86171,86143,86172],"Fluoride free toothpaste","Fluoride mouthwash",{"intervention":86174,"totalTrials":660,"cells":86175},"Rosiglitazone Extended Release 2mg",{"EARLY_PHASE1":86176,"PHASE1":86178,"PHASE2":86180,"PHASE3":86182,"PHASE4":86193,"NA":86195},{"trials":86177,"activeCount":97},[],{"trials":86179,"activeCount":97},[],{"trials":86181,"activeCount":97},[],{"trials":86183,"activeCount":97},[86184],{"nctId":86185,"briefTitle":86186,"status":155,"phases":86187,"primaryCompletion":39129,"completion":39129,"start":86188,"enrollment":86189,"conditions":86190,"interventions":86191},"NCT00348140","Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease",[87],"2006-07-12",1468,[4644],[86174,86192],"Rosiglitazone Extended Release 8mg",{"trials":86194,"activeCount":97},[],{"trials":86196,"activeCount":97},[86197],{"nctId":86198,"briefTitle":86199,"status":155,"phases":86200,"primaryCompletion":16323,"completion":75651,"start":9380,"enrollment":86201,"conditions":86202,"interventions":86203},"NCT00348309","Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease",[89],1496,[4644],[86174,86192],{"intervention":86192,"totalTrials":660,"cells":86205},{"EARLY_PHASE1":86206,"PHASE1":86208,"PHASE2":86210,"PHASE3":86212,"PHASE4":86218,"NA":86220},{"trials":86207,"activeCount":97},[],{"trials":86209,"activeCount":97},[],{"trials":86211,"activeCount":97},[],{"trials":86213,"activeCount":97},[86214],{"nctId":86185,"briefTitle":86186,"status":155,"phases":86215,"primaryCompletion":39129,"completion":39129,"start":86188,"enrollment":86189,"conditions":86216,"interventions":86217},[87],[4644],[86174,86192],{"trials":86219,"activeCount":97},[],{"trials":86221,"activeCount":97},[86222],{"nctId":86198,"briefTitle":86199,"status":155,"phases":86223,"primaryCompletion":16323,"completion":75651,"start":9380,"enrollment":86201,"conditions":86224,"interventions":86225},[89],[4644],[86174,86192],{"intervention":86227,"totalTrials":660,"cells":86228},"Benlysta",{"EARLY_PHASE1":86229,"PHASE1":86231,"PHASE2":86233,"PHASE3":86235,"PHASE4":86237,"NA":86239},{"trials":86230,"activeCount":97},[],{"trials":86232,"activeCount":97},[],{"trials":86234,"activeCount":97},[],{"trials":86236,"activeCount":97},[],{"trials":86238,"activeCount":97},[],{"trials":86240,"activeCount":97},[86241,86248],{"nctId":86242,"briefTitle":86243,"status":155,"phases":86244,"primaryCompletion":2561,"completion":2561,"start":36664,"enrollment":86245,"conditions":86246,"interventions":86247},"NCT01729455","Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry",[],3138,[435],[86227],{"nctId":86249,"briefTitle":86250,"status":155,"phases":86251,"primaryCompletion":6993,"completion":6993,"start":86252,"enrollment":86253,"conditions":86254,"interventions":86255},"NCT03370263","BENLYSTA® Special Drug Use Investigation",[],"2018-01-15",1514,[435],[86227],{"intervention":82570,"totalTrials":660,"cells":86257},{"EARLY_PHASE1":86258,"PHASE1":86260,"PHASE2":86262,"PHASE3":86264,"PHASE4":86266,"NA":86268},{"trials":86259,"activeCount":97},[],{"trials":86261,"activeCount":97},[],{"trials":86263,"activeCount":97},[],{"trials":86265,"activeCount":97},[],{"trials":86267,"activeCount":97},[],{"trials":86269,"activeCount":97},[86270,86274],{"nctId":82565,"briefTitle":82566,"status":155,"phases":86271,"primaryCompletion":11992,"completion":11992,"start":9159,"enrollment":417,"conditions":86272,"interventions":86273},[],[11033],[23772,82570],{"nctId":82572,"briefTitle":82573,"status":155,"phases":86275,"primaryCompletion":9224,"completion":9224,"start":10463,"enrollment":10716,"conditions":86276,"interventions":86277},[],[53822],[23772,82570],{"intervention":86279,"totalTrials":417,"cells":86280},"Pirinase Hayfever Relief for Adults 0.05% Nasal Spray",{"EARLY_PHASE1":86281,"PHASE1":86283,"PHASE2":86285,"PHASE3":86287,"PHASE4":86289,"NA":86291},{"trials":86282,"activeCount":97},[],{"trials":86284,"activeCount":97},[],{"trials":86286,"activeCount":97},[],{"trials":86288,"activeCount":97},[],{"trials":86290,"activeCount":97},[],{"trials":86292,"activeCount":97},[86293],{"nctId":86294,"briefTitle":86295,"status":155,"phases":86296,"primaryCompletion":86297,"completion":86297,"start":86298,"enrollment":4121,"conditions":86299,"interventions":86300},"NCT02856282","Drug Utilization Study for Pirinase Hayfever Relief",[],"2018-03-31","2016-02-15",[10169],[86279],{"intervention":86302,"totalTrials":417,"cells":86303},"Metformin hydrochloride prolonged release",{"EARLY_PHASE1":86304,"PHASE1":86306,"PHASE2":86308,"PHASE3":86310,"PHASE4":86312,"NA":86314},{"trials":86305,"activeCount":97},[],{"trials":86307,"activeCount":97},[],{"trials":86309,"activeCount":97},[],{"trials":86311,"activeCount":97},[],{"trials":86313,"activeCount":97},[],{"trials":86315,"activeCount":97},[86316],{"nctId":86317,"briefTitle":86318,"status":155,"phases":86319,"primaryCompletion":86320,"completion":86320,"start":43483,"enrollment":255,"conditions":86321,"interventions":86322},"NCT01561976","Evaluation of Food Effect on the Pharmacokinetics of Sustained Release Metformin in Healthy Indian Volunteers",[89],"2012-02-21",[27],[86302,86323,86324],"metformin hydrochloride prolonged release","Metformin hydrochloride sustained release\u002FGlimepiride",{"intervention":86324,"totalTrials":417,"cells":86326},{"EARLY_PHASE1":86327,"PHASE1":86329,"PHASE2":86331,"PHASE3":86333,"PHASE4":86335,"NA":86337},{"trials":86328,"activeCount":97},[],{"trials":86330,"activeCount":97},[],{"trials":86332,"activeCount":97},[],{"trials":86334,"activeCount":97},[],{"trials":86336,"activeCount":97},[],{"trials":86338,"activeCount":97},[86339],{"nctId":86317,"briefTitle":86318,"status":155,"phases":86340,"primaryCompletion":86320,"completion":86320,"start":43483,"enrollment":255,"conditions":86341,"interventions":86342},[89],[27],[86302,86323,86324],{"intervention":86344,"totalTrials":417,"cells":86345},"Fluticasone propionate\u002Fsalmeterol combination ED MD",{"EARLY_PHASE1":86346,"PHASE1":86348,"PHASE2":86350,"PHASE3":86352,"PHASE4":86354,"NA":86356},{"trials":86347,"activeCount":97},[],{"trials":86349,"activeCount":97},[],{"trials":86351,"activeCount":97},[],{"trials":86353,"activeCount":97},[],{"trials":86355,"activeCount":97},[],{"trials":86357,"activeCount":97},[86358],{"nctId":86359,"briefTitle":86360,"status":155,"phases":86361,"primaryCompletion":1428,"completion":1428,"start":2442,"enrollment":86362,"conditions":86363,"interventions":86364},"NCT01332357","Use of Fluticasone Propionate\u002FSalmeterol Combination Post Emergency Department Visit",[],6139,[18],[86344,86365],"Fluticasone propionate\u002Fsalmeterol combination OP MD",{"intervention":86365,"totalTrials":417,"cells":86367},{"EARLY_PHASE1":86368,"PHASE1":86370,"PHASE2":86372,"PHASE3":86374,"PHASE4":86376,"NA":86378},{"trials":86369,"activeCount":97},[],{"trials":86371,"activeCount":97},[],{"trials":86373,"activeCount":97},[],{"trials":86375,"activeCount":97},[],{"trials":86377,"activeCount":97},[],{"trials":86379,"activeCount":97},[86380],{"nctId":86359,"briefTitle":86360,"status":155,"phases":86381,"primaryCompletion":1428,"completion":1428,"start":2442,"enrollment":86362,"conditions":86382,"interventions":86383},[],[18],[86344,86365],{"intervention":86385,"totalTrials":417,"cells":86386},"pseudoephedrine hydrochloride",{"EARLY_PHASE1":86387,"PHASE1":86389,"PHASE2":86391,"PHASE3":86393,"PHASE4":86395,"NA":86397},{"trials":86388,"activeCount":97},[],{"trials":86390,"activeCount":97},[],{"trials":86392,"activeCount":97},[],{"trials":86394,"activeCount":97},[],{"trials":86396,"activeCount":97},[],{"trials":86398,"activeCount":97},[86399],{"nctId":86400,"briefTitle":86401,"status":155,"phases":86402,"primaryCompletion":4756,"completion":4756,"start":748,"enrollment":1279,"conditions":86403,"interventions":86405},"NCT00517946","A Study To Investigate If MRI Scanning Is Effective At Seeing What Hayfever Drugs Do In Nasal Passage.",[],[39059,86404],"Sinusitis",[86385,86406],"cetirizine hydrochloride",{"intervention":86406,"totalTrials":417,"cells":86408},{"EARLY_PHASE1":86409,"PHASE1":86411,"PHASE2":86413,"PHASE3":86415,"PHASE4":86417,"NA":86419},{"trials":86410,"activeCount":97},[],{"trials":86412,"activeCount":97},[],{"trials":86414,"activeCount":97},[],{"trials":86416,"activeCount":97},[],{"trials":86418,"activeCount":97},[],{"trials":86420,"activeCount":97},[86421],{"nctId":86400,"briefTitle":86401,"status":155,"phases":86422,"primaryCompletion":4756,"completion":4756,"start":748,"enrollment":1279,"conditions":86423,"interventions":86424},[],[39059,86404],[86385,86406],{"intervention":86426,"totalTrials":417,"cells":86427},"levodopa",{"EARLY_PHASE1":86428,"PHASE1":86430,"PHASE2":86432,"PHASE3":86434,"PHASE4":86436,"NA":86438},{"trials":86429,"activeCount":97},[],{"trials":86431,"activeCount":97},[],{"trials":86433,"activeCount":97},[],{"trials":86435,"activeCount":97},[],{"trials":86437,"activeCount":97},[],{"trials":86439,"activeCount":97},[86440],{"nctId":86441,"briefTitle":86442,"status":155,"phases":86443,"primaryCompletion":8135,"completion":8135,"start":3111,"enrollment":417,"conditions":86444,"interventions":86446},"NCT01545856","Cardiovascular Events in Parkinson's Disease Patients",[],[86445,15879],"Cardiovascular Event",[86426],{"intervention":86448,"totalTrials":417,"cells":86449},"Developmental moisturizing cream 1",{"EARLY_PHASE1":86450,"PHASE1":86452,"PHASE2":86454,"PHASE3":86456,"PHASE4":86458,"NA":86460},{"trials":86451,"activeCount":97},[],{"trials":86453,"activeCount":97},[],{"trials":86455,"activeCount":97},[],{"trials":86457,"activeCount":97},[],{"trials":86459,"activeCount":97},[],{"trials":86461,"activeCount":97},[86462],{"nctId":86463,"briefTitle":86464,"status":155,"phases":86465,"primaryCompletion":66200,"completion":66200,"start":86466,"enrollment":7532,"conditions":86467,"interventions":86470},"NCT03804710","To Evaluate the Effect of Moisturizing Creams on Skin Barrier Function",[89],"2019-01-22",[86468,86469],"Dry Skin","Skin Care",[86448,86471],"Developmental moisturizing cream 2",{"intervention":86471,"totalTrials":417,"cells":86473},{"EARLY_PHASE1":86474,"PHASE1":86476,"PHASE2":86478,"PHASE3":86480,"PHASE4":86482,"NA":86484},{"trials":86475,"activeCount":97},[],{"trials":86477,"activeCount":97},[],{"trials":86479,"activeCount":97},[],{"trials":86481,"activeCount":97},[],{"trials":86483,"activeCount":97},[],{"trials":86485,"activeCount":97},[86486],{"nctId":86463,"briefTitle":86464,"status":155,"phases":86487,"primaryCompletion":66200,"completion":66200,"start":86466,"enrollment":7532,"conditions":86488,"interventions":86489},[89],[86468,86469],[86448,86471],{"intervention":86491,"totalTrials":417,"cells":86492},"Meloxicam GSK 15mg",{"EARLY_PHASE1":86493,"PHASE1":86495,"PHASE2":86497,"PHASE3":86499,"PHASE4":86501,"NA":86503},{"trials":86494,"activeCount":97},[],{"trials":86496,"activeCount":97},[],{"trials":86498,"activeCount":97},[],{"trials":86500,"activeCount":97},[],{"trials":86502,"activeCount":97},[],{"trials":86504,"activeCount":97},[86505],{"nctId":86506,"briefTitle":86507,"status":155,"phases":86508,"primaryCompletion":8395,"completion":8395,"start":9045,"enrollment":695,"conditions":86509,"interventions":86510},"NCT01750931","This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.",[89],[8788],[86491,86511],"Mobic 15mg",{"intervention":86511,"totalTrials":417,"cells":86513},{"EARLY_PHASE1":86514,"PHASE1":86516,"PHASE2":86518,"PHASE3":86520,"PHASE4":86522,"NA":86524},{"trials":86515,"activeCount":97},[],{"trials":86517,"activeCount":97},[],{"trials":86519,"activeCount":97},[],{"trials":86521,"activeCount":97},[],{"trials":86523,"activeCount":97},[],{"trials":86525,"activeCount":97},[86526],{"nctId":86506,"briefTitle":86507,"status":155,"phases":86527,"primaryCompletion":8395,"completion":8395,"start":9045,"enrollment":695,"conditions":86528,"interventions":86529},[89],[8788],[86491,86511],{"intervention":86531,"totalTrials":417,"cells":86532},"Amoxicillin and clavulanate",{"EARLY_PHASE1":86533,"PHASE1":86535,"PHASE2":86537,"PHASE3":86539,"PHASE4":86541,"NA":86543},{"trials":86534,"activeCount":97},[],{"trials":86536,"activeCount":97},[],{"trials":86538,"activeCount":97},[],{"trials":86540,"activeCount":97},[],{"trials":86542,"activeCount":97},[],{"trials":86544,"activeCount":97},[86545],{"nctId":86546,"briefTitle":86547,"status":155,"phases":86548,"primaryCompletion":8468,"completion":8468,"start":7954,"enrollment":12,"conditions":86549,"interventions":86551},"NCT01406275","Special Drug Use Investigation for CLAVAMOX® (Amoxicillin\u002FClavulanate) Pediatrics Dry Syrup (Every Indication Excluded Otitis Media)",[],[86550],"Otitis Maedia",[86531],{"intervention":86553,"totalTrials":417,"cells":86554},"Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009",{"EARLY_PHASE1":86555,"PHASE1":86557,"PHASE2":86559,"PHASE3":86561,"PHASE4":86563,"NA":86565},{"trials":86556,"activeCount":97},[],{"trials":86558,"activeCount":97},[],{"trials":86560,"activeCount":97},[],{"trials":86562,"activeCount":97},[],{"trials":86564,"activeCount":97},[],{"trials":86566,"activeCount":97},[86567],{"nctId":86568,"briefTitle":86569,"status":155,"phases":86570,"primaryCompletion":3044,"completion":3044,"start":8135,"enrollment":417,"conditions":86571,"interventions":86572},"NCT01587768","WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics",[],[6484],[86553],{"intervention":85127,"totalTrials":417,"cells":86574},{"EARLY_PHASE1":86575,"PHASE1":86577,"PHASE2":86579,"PHASE3":86581,"PHASE4":86583,"NA":86585},{"trials":86576,"activeCount":97},[],{"trials":86578,"activeCount":97},[],{"trials":86580,"activeCount":97},[],{"trials":86582,"activeCount":97},[],{"trials":86584,"activeCount":97},[],{"trials":86586,"activeCount":97},[86587],{"nctId":85122,"briefTitle":85123,"status":500,"phases":86588,"primaryCompletion":8151,"completion":8151,"start":8151,"enrollment":97,"conditions":86589,"interventions":86590},[],[10386],[85127,11980],{"intervention":85061,"totalTrials":417,"cells":86592},{"EARLY_PHASE1":86593,"PHASE1":86595,"PHASE2":86597,"PHASE3":86599,"PHASE4":86601,"NA":86603},{"trials":86594,"activeCount":97},[],{"trials":86596,"activeCount":97},[],{"trials":86598,"activeCount":97},[],{"trials":86600,"activeCount":97},[],{"trials":86602,"activeCount":97},[],{"trials":86604,"activeCount":97},[86605],{"nctId":85055,"briefTitle":85056,"status":155,"phases":86606,"primaryCompletion":8883,"completion":7545,"start":3551,"enrollment":85058,"conditions":86607,"interventions":86608},[],[12518],[85034,85061,85062,85063,85064],{"intervention":85062,"totalTrials":417,"cells":86610},{"EARLY_PHASE1":86611,"PHASE1":86613,"PHASE2":86615,"PHASE3":86617,"PHASE4":86619,"NA":86621},{"trials":86612,"activeCount":97},[],{"trials":86614,"activeCount":97},[],{"trials":86616,"activeCount":97},[],{"trials":86618,"activeCount":97},[],{"trials":86620,"activeCount":97},[],{"trials":86622,"activeCount":97},[86623],{"nctId":85055,"briefTitle":85056,"status":155,"phases":86624,"primaryCompletion":8883,"completion":7545,"start":3551,"enrollment":85058,"conditions":86625,"interventions":86626},[],[12518],[85034,85061,85062,85063,85064],{"intervention":85063,"totalTrials":417,"cells":86628},{"EARLY_PHASE1":86629,"PHASE1":86631,"PHASE2":86633,"PHASE3":86635,"PHASE4":86637,"NA":86639},{"trials":86630,"activeCount":97},[],{"trials":86632,"activeCount":97},[],{"trials":86634,"activeCount":97},[],{"trials":86636,"activeCount":97},[],{"trials":86638,"activeCount":97},[],{"trials":86640,"activeCount":97},[86641],{"nctId":85055,"briefTitle":85056,"status":155,"phases":86642,"primaryCompletion":8883,"completion":7545,"start":3551,"enrollment":85058,"conditions":86643,"interventions":86644},[],[12518],[85034,85061,85062,85063,85064],{"intervention":85064,"totalTrials":417,"cells":86646},{"EARLY_PHASE1":86647,"PHASE1":86649,"PHASE2":86651,"PHASE3":86653,"PHASE4":86655,"NA":86657},{"trials":86648,"activeCount":97},[],{"trials":86650,"activeCount":97},[],{"trials":86652,"activeCount":97},[],{"trials":86654,"activeCount":97},[],{"trials":86656,"activeCount":97},[],{"trials":86658,"activeCount":97},[86659],{"nctId":85055,"briefTitle":85056,"status":155,"phases":86660,"primaryCompletion":8883,"completion":7545,"start":3551,"enrollment":85058,"conditions":86661,"interventions":86662},[],[12518],[85034,85061,85062,85063,85064],{"intervention":81899,"totalTrials":417,"cells":86664},{"EARLY_PHASE1":86665,"PHASE1":86667,"PHASE2":86669,"PHASE3":86671,"PHASE4":86673,"NA":86675},{"trials":86666,"activeCount":97},[],{"trials":86668,"activeCount":97},[],{"trials":86670,"activeCount":97},[],{"trials":86672,"activeCount":97},[],{"trials":86674,"activeCount":97},[],{"trials":86676,"activeCount":97},[86677],{"nctId":81894,"briefTitle":81895,"status":155,"phases":86678,"primaryCompletion":827,"completion":827,"start":2344,"enrollment":417,"conditions":86679,"interventions":86680},[],[1877],[2273,81899],{"intervention":86682,"totalTrials":417,"cells":86683},"Higher-dose inhaled corticosteroids",{"EARLY_PHASE1":86684,"PHASE1":86686,"PHASE2":86688,"PHASE3":86690,"PHASE4":86692,"NA":86694},{"trials":86685,"activeCount":97},[],{"trials":86687,"activeCount":97},[],{"trials":86689,"activeCount":97},[],{"trials":86691,"activeCount":97},[],{"trials":86693,"activeCount":97},[],{"trials":86695,"activeCount":97},[86696],{"nctId":86697,"briefTitle":86698,"status":155,"phases":86699,"primaryCompletion":2427,"completion":2427,"start":2335,"enrollment":86700,"conditions":86701,"interventions":86702},"NCT01431924","Observed Outcomes Associated With Fluticasone Propionate\u002FSalmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients",[],7779,[18],[86682,86703],"Low-dose fixed dose fluticasone propionate\u002Fsalmeterol xinafoate combination",{"intervention":86703,"totalTrials":417,"cells":86705},{"EARLY_PHASE1":86706,"PHASE1":86708,"PHASE2":86710,"PHASE3":86712,"PHASE4":86714,"NA":86716},{"trials":86707,"activeCount":97},[],{"trials":86709,"activeCount":97},[],{"trials":86711,"activeCount":97},[],{"trials":86713,"activeCount":97},[],{"trials":86715,"activeCount":97},[],{"trials":86717,"activeCount":97},[86718],{"nctId":86697,"briefTitle":86698,"status":155,"phases":86719,"primaryCompletion":2427,"completion":2427,"start":2335,"enrollment":86700,"conditions":86720,"interventions":86721},[],[18],[86682,86703],{"intervention":86723,"totalTrials":417,"cells":86724},"Non-steroidal anti-inflammatory drug",{"EARLY_PHASE1":86725,"PHASE1":86727,"PHASE2":86729,"PHASE3":86731,"PHASE4":86733,"NA":86735},{"trials":86726,"activeCount":97},[],{"trials":86728,"activeCount":97},[],{"trials":86730,"activeCount":97},[],{"trials":86732,"activeCount":97},[],{"trials":86734,"activeCount":97},[],{"trials":86736,"activeCount":97},[86737],{"nctId":86738,"briefTitle":86739,"status":155,"phases":86740,"primaryCompletion":729,"completion":729,"start":1429,"enrollment":86741,"conditions":86742,"interventions":86743},"NCT01435941","Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine",[],11249,[14168],[86723,86744],"Triptan",{"intervention":86744,"totalTrials":417,"cells":86746},{"EARLY_PHASE1":86747,"PHASE1":86749,"PHASE2":86751,"PHASE3":86753,"PHASE4":86755,"NA":86757},{"trials":86748,"activeCount":97},[],{"trials":86750,"activeCount":97},[],{"trials":86752,"activeCount":97},[],{"trials":86754,"activeCount":97},[],{"trials":86756,"activeCount":97},[],{"trials":86758,"activeCount":97},[86759],{"nctId":86738,"briefTitle":86739,"status":155,"phases":86760,"primaryCompletion":729,"completion":729,"start":1429,"enrollment":86741,"conditions":86761,"interventions":86762},[],[14168],[86723,86744],{"intervention":86764,"totalTrials":417,"cells":86765},"Inhaled LABA use",{"EARLY_PHASE1":86766,"PHASE1":86768,"PHASE2":86770,"PHASE3":86772,"PHASE4":86774,"NA":86776},{"trials":86767,"activeCount":97},[],{"trials":86769,"activeCount":97},[],{"trials":86771,"activeCount":97},[],{"trials":86773,"activeCount":97},[],{"trials":86775,"activeCount":97},[],{"trials":86777,"activeCount":97},[86778],{"nctId":86779,"briefTitle":86780,"status":155,"phases":86781,"primaryCompletion":3044,"completion":3044,"start":728,"enrollment":417,"conditions":86782,"interventions":86783},"NCT01636726","WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial Infarction",[],[18],[86764],{"intervention":86785,"totalTrials":417,"cells":86786},"Combination therapy of sumatriptan and naproxen sodium",{"EARLY_PHASE1":86787,"PHASE1":86789,"PHASE2":86791,"PHASE3":86793,"PHASE4":86795,"NA":86797},{"trials":86788,"activeCount":97},[],{"trials":86790,"activeCount":97},[],{"trials":86792,"activeCount":97},[],{"trials":86794,"activeCount":97},[],{"trials":86796,"activeCount":97},[],{"trials":86798,"activeCount":97},[86799],{"nctId":86800,"briefTitle":86801,"status":155,"phases":86802,"primaryCompletion":2394,"completion":2394,"start":3078,"enrollment":417,"conditions":86803,"interventions":86804},"NCT01381497","Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy",[],[14168],[86785,86805],"Triptan monotherapy",{"intervention":86805,"totalTrials":417,"cells":86807},{"EARLY_PHASE1":86808,"PHASE1":86810,"PHASE2":86812,"PHASE3":86814,"PHASE4":86816,"NA":86818},{"trials":86809,"activeCount":97},[],{"trials":86811,"activeCount":97},[],{"trials":86813,"activeCount":97},[],{"trials":86815,"activeCount":97},[],{"trials":86817,"activeCount":97},[],{"trials":86819,"activeCount":97},[86820],{"nctId":86800,"briefTitle":86801,"status":155,"phases":86821,"primaryCompletion":2394,"completion":2394,"start":3078,"enrollment":417,"conditions":86822,"interventions":86823},[],[14168],[86785,86805],{"intervention":86825,"totalTrials":417,"cells":86826},"Adefovir",{"EARLY_PHASE1":86827,"PHASE1":86829,"PHASE2":86831,"PHASE3":86833,"PHASE4":86835,"NA":86837},{"trials":86828,"activeCount":97},[],{"trials":86830,"activeCount":97},[],{"trials":86832,"activeCount":97},[],{"trials":86834,"activeCount":97},[],{"trials":86836,"activeCount":97},[],{"trials":86838,"activeCount":97},[86839],{"nctId":86840,"briefTitle":86841,"status":155,"phases":86842,"primaryCompletion":3552,"completion":8037,"start":1380,"enrollment":86843,"conditions":86844,"interventions":86845},"NCT01863589","Drug Use Investigation for HEPSERA (Adefovir) Tablet",[],436,[24],[86825],{"intervention":86847,"totalTrials":417,"cells":86848},"Test Toothpaste",{"EARLY_PHASE1":86849,"PHASE1":86851,"PHASE2":86853,"PHASE3":86855,"PHASE4":86857,"NA":86859},{"trials":86850,"activeCount":97},[],{"trials":86852,"activeCount":97},[],{"trials":86854,"activeCount":97},[],{"trials":86856,"activeCount":97},[],{"trials":86858,"activeCount":97},[],{"trials":86860,"activeCount":97},[86861],{"nctId":86862,"briefTitle":86863,"status":155,"phases":86864,"primaryCompletion":3111,"completion":3111,"start":3111,"enrollment":1134,"conditions":86865,"interventions":86868},"NCT01494649","Pilot Study to Investigate the Efficacy of a Toothpaste in Providing Relief From Dentinal Hypersensitivity",[89],[86866,86867],"Dentinal Sensitivity","Hypersensitivity",[86847,86869],"Negative Control Toothpaste",{"intervention":86869,"totalTrials":417,"cells":86871},{"EARLY_PHASE1":86872,"PHASE1":86874,"PHASE2":86876,"PHASE3":86878,"PHASE4":86880,"NA":86882},{"trials":86873,"activeCount":97},[],{"trials":86875,"activeCount":97},[],{"trials":86877,"activeCount":97},[],{"trials":86879,"activeCount":97},[],{"trials":86881,"activeCount":97},[],{"trials":86883,"activeCount":97},[86884],{"nctId":86862,"briefTitle":86863,"status":155,"phases":86885,"primaryCompletion":3111,"completion":3111,"start":3111,"enrollment":1134,"conditions":86886,"interventions":86887},[89],[86866,86867],[86847,86869],{"intervention":84608,"totalTrials":417,"cells":86889},{"EARLY_PHASE1":86890,"PHASE1":86892,"PHASE2":86894,"PHASE3":86896,"PHASE4":86898,"NA":86900},{"trials":86891,"activeCount":97},[],{"trials":86893,"activeCount":97},[],{"trials":86895,"activeCount":97},[],{"trials":86897,"activeCount":97},[],{"trials":86899,"activeCount":97},[],{"trials":86901,"activeCount":97},[86902],{"nctId":84602,"briefTitle":84603,"status":155,"phases":86903,"primaryCompletion":2834,"completion":2834,"start":5018,"enrollment":84605,"conditions":86904,"interventions":86905},[],[15],[84608,8440],{"intervention":86907,"totalTrials":417,"cells":86908},"ALTARGO",{"EARLY_PHASE1":86909,"PHASE1":86911,"PHASE2":86913,"PHASE3":86915,"PHASE4":86917,"NA":86919},{"trials":86910,"activeCount":97},[],{"trials":86912,"activeCount":97},[],{"trials":86914,"activeCount":97},[],{"trials":86916,"activeCount":97},[],{"trials":86918,"activeCount":97},[],{"trials":86920,"activeCount":97},[86921],{"nctId":86922,"briefTitle":86923,"status":155,"phases":86924,"primaryCompletion":482,"completion":482,"start":8089,"enrollment":86925,"conditions":86926,"interventions":86927},"NCT01445600","ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)",[],3612,[12727],[86907],{"intervention":7966,"totalTrials":417,"cells":86929},{"EARLY_PHASE1":86930,"PHASE1":86932,"PHASE2":86934,"PHASE3":86936,"PHASE4":86938,"NA":86940},{"trials":86931,"activeCount":97},[],{"trials":86933,"activeCount":97},[],{"trials":86935,"activeCount":97},[],{"trials":86937,"activeCount":97},[],{"trials":86939,"activeCount":97},[],{"trials":86941,"activeCount":97},[86942],{"nctId":86943,"briefTitle":86944,"status":155,"phases":86945,"start":2796,"enrollment":1944,"conditions":86946,"interventions":86947},"NCT00237991","Safety of GlaxoSmithKline (GSK) Biologicals Hepatitis A Vaccine in Korean Population",[],[7966],[7966],{"intervention":86949,"totalTrials":417,"cells":86950},"No intervention",{"EARLY_PHASE1":86951,"PHASE1":86953,"PHASE2":86955,"PHASE3":86957,"PHASE4":86959,"NA":86961},{"trials":86952,"activeCount":97},[],{"trials":86954,"activeCount":97},[],{"trials":86956,"activeCount":97},[],{"trials":86958,"activeCount":97},[],{"trials":86960,"activeCount":97},[],{"trials":86962,"activeCount":97},[86963],{"nctId":86964,"briefTitle":86965,"status":155,"phases":86966,"primaryCompletion":2795,"completion":2795,"start":8468,"enrollment":86967,"conditions":86968,"interventions":86969},"NCT00791518","Evaluation of Lung Function and Symptoms in Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD) on Long-Acting Bronchodilator Monotherapy",[],1084,[15],[86949],{"intervention":84430,"totalTrials":417,"cells":86971},{"EARLY_PHASE1":86972,"PHASE1":86974,"PHASE2":86976,"PHASE3":86978,"PHASE4":86980,"NA":86982},{"trials":86973,"activeCount":97},[],{"trials":86975,"activeCount":97},[],{"trials":86977,"activeCount":97},[],{"trials":86979,"activeCount":97},[],{"trials":86981,"activeCount":97},[],{"trials":86983,"activeCount":97},[86984],{"nctId":84424,"briefTitle":84425,"status":155,"phases":86985,"primaryCompletion":7659,"completion":7659,"start":7613,"enrollment":84427,"conditions":86986,"interventions":86987},[],[30,33,3624],[11489,84430],{"intervention":86989,"totalTrials":417,"cells":86990},"Zanamivir hydrate",{"EARLY_PHASE1":86991,"PHASE1":86993,"PHASE2":86995,"PHASE3":86997,"PHASE4":86999,"NA":87001},{"trials":86992,"activeCount":97},[],{"trials":86994,"activeCount":97},[],{"trials":86996,"activeCount":97},[],{"trials":86998,"activeCount":97},[],{"trials":87000,"activeCount":97},[],{"trials":87002,"activeCount":97},[87003],{"nctId":87004,"briefTitle":87005,"status":155,"phases":87006,"primaryCompletion":8116,"completion":2795,"start":5196,"enrollment":17908,"conditions":87007,"interventions":87008},"NCT01390792","Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)",[],[5353],[86989],{"intervention":87010,"totalTrials":417,"cells":87011},"Ipratropium Bromide",{"EARLY_PHASE1":87012,"PHASE1":87014,"PHASE2":87016,"PHASE3":87018,"PHASE4":87020,"NA":87022},{"trials":87013,"activeCount":97},[],{"trials":87015,"activeCount":97},[],{"trials":87017,"activeCount":97},[],{"trials":87019,"activeCount":97},[],{"trials":87021,"activeCount":97},[],{"trials":87023,"activeCount":97},[87024],{"nctId":87025,"briefTitle":87026,"status":155,"phases":87027,"primaryCompletion":10611,"completion":10611,"start":87028,"enrollment":1720,"conditions":87029,"interventions":87030},"NCT03136120","Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease",[],"2017-11-21",[571],[87010],{"intervention":87032,"totalTrials":417,"cells":87033},"Administration of rosiglitazone\u002Fmetformin",{"EARLY_PHASE1":87034,"PHASE1":87036,"PHASE2":87038,"PHASE3":87040,"PHASE4":87042,"NA":87044},{"trials":87035,"activeCount":97},[],{"trials":87037,"activeCount":97},[],{"trials":87039,"activeCount":97},[],{"trials":87041,"activeCount":97},[],{"trials":87043,"activeCount":97},[],{"trials":87045,"activeCount":97},[87046],{"nctId":87047,"briefTitle":87048,"status":155,"phases":87049,"primaryCompletion":26336,"completion":26336,"start":3036,"enrollment":8415,"conditions":87050,"interventions":87051},"NCT01294553","An Open Label, Multi-centre, Non-interventional Post-marketing Surveillance to Monitor the Safety and\u002For Efficacy of AVANDAMET Between June 2004 and January 2010",[],[27],[87032],{"intervention":87053,"totalTrials":417,"cells":87054},"Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants",{"EARLY_PHASE1":87055,"PHASE1":87057,"PHASE2":87059,"PHASE3":87061,"PHASE4":87063,"NA":87065},{"trials":87056,"activeCount":97},[],{"trials":87058,"activeCount":97},[],{"trials":87060,"activeCount":97},[],{"trials":87062,"activeCount":97},[],{"trials":87064,"activeCount":97},[],{"trials":87066,"activeCount":97},[87067],{"nctId":87068,"briefTitle":87069,"status":155,"phases":87070,"primaryCompletion":3044,"completion":3044,"start":8135,"enrollment":417,"conditions":87071,"interventions":87073},"NCT01587729","IMI PROTECT(WP2): Antidepressants & Fractures",[],[87072],"Depression, Postpartum",[87053],{"intervention":87075,"totalTrials":417,"cells":87076},"Early maintenance treatment",{"EARLY_PHASE1":87077,"PHASE1":87079,"PHASE2":87081,"PHASE3":87083,"PHASE4":87085,"NA":87087},{"trials":87078,"activeCount":97},[],{"trials":87080,"activeCount":97},[],{"trials":87082,"activeCount":97},[],{"trials":87084,"activeCount":97},[],{"trials":87086,"activeCount":97},[],{"trials":87088,"activeCount":97},[87089],{"nctId":87090,"briefTitle":87091,"status":155,"phases":87092,"primaryCompletion":2344,"completion":8883,"start":2335,"enrollment":87093,"conditions":87094,"interventions":87095},"NCT01431911","Outcomes Associated With Early or Delayed Maintenance Treatment Post-Chronic Obstructive Pulmonary Disease Exacerbation",[],3806,[15],[87075,87096],"Delayed Maintenance treatment",{"intervention":87096,"totalTrials":417,"cells":87098},{"EARLY_PHASE1":87099,"PHASE1":87101,"PHASE2":87103,"PHASE3":87105,"PHASE4":87107,"NA":87109},{"trials":87100,"activeCount":97},[],{"trials":87102,"activeCount":97},[],{"trials":87104,"activeCount":97},[],{"trials":87106,"activeCount":97},[],{"trials":87108,"activeCount":97},[],{"trials":87110,"activeCount":97},[87111],{"nctId":87090,"briefTitle":87091,"status":155,"phases":87112,"primaryCompletion":2344,"completion":8883,"start":2335,"enrollment":87093,"conditions":87113,"interventions":87114},[],[15],[87075,87096],{"intervention":87116,"totalTrials":417,"cells":87117},"Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]",{"EARLY_PHASE1":87118,"PHASE1":87120,"PHASE2":87122,"PHASE3":87124,"PHASE4":87126,"NA":87128},{"trials":87119,"activeCount":97},[],{"trials":87121,"activeCount":97},[],{"trials":87123,"activeCount":97},[],{"trials":87125,"activeCount":97},[],{"trials":87127,"activeCount":97},[],{"trials":87129,"activeCount":97},[87130],{"nctId":87131,"briefTitle":87132,"status":155,"phases":87133,"primaryCompletion":875,"completion":875,"start":8618,"enrollment":87134,"conditions":87135,"interventions":87136},"NCT02757950","A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.",[],2462,[30],[87116],{"intervention":82072,"totalTrials":417,"cells":87138},{"EARLY_PHASE1":87139,"PHASE1":87141,"PHASE2":87143,"PHASE3":87145,"PHASE4":87147,"NA":87149},{"trials":87140,"activeCount":97},[],{"trials":87142,"activeCount":97},[],{"trials":87144,"activeCount":97},[],{"trials":87146,"activeCount":97},[],{"trials":87148,"activeCount":97},[],{"trials":87150,"activeCount":97},[87151],{"nctId":82065,"briefTitle":82066,"status":155,"phases":87152,"primaryCompletion":10275,"completion":10275,"start":82068,"enrollment":82069,"conditions":87153,"interventions":87154},[],[12518],[75816,82072],{"intervention":87156,"totalTrials":417,"cells":87157},"Alli® 60 mg",{"EARLY_PHASE1":87158,"PHASE1":87160,"PHASE2":87162,"PHASE3":87164,"PHASE4":87166,"NA":87168},{"trials":87159,"activeCount":97},[],{"trials":87161,"activeCount":97},[],{"trials":87163,"activeCount":97},[],{"trials":87165,"activeCount":97},[],{"trials":87167,"activeCount":97},[],{"trials":87169,"activeCount":97},[87170],{"nctId":87171,"briefTitle":87172,"status":500,"phases":87173,"primaryCompletion":492,"completion":492,"start":8098,"enrollment":97,"conditions":87174,"interventions":87176},"NCT02141230","Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.",[89],[87175],"Weight Loss",[87156],{"intervention":87178,"totalTrials":417,"cells":87179},"New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications",{"EARLY_PHASE1":87180,"PHASE1":87182,"PHASE2":87184,"PHASE3":87186,"PHASE4":87188,"NA":87190},{"trials":87181,"activeCount":97},[],{"trials":87183,"activeCount":97},[],{"trials":87185,"activeCount":97},[],{"trials":87187,"activeCount":97},[],{"trials":87189,"activeCount":97},[],{"trials":87191,"activeCount":97},[87192],{"nctId":87193,"briefTitle":87194,"status":155,"phases":87195,"primaryCompletion":5195,"completion":5195,"start":8037,"enrollment":417,"conditions":87196,"interventions":87197},"NCT01763463","WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects",[],[15],[87178,87198],"New users of FLOVENT DISKUS, FLVENT HFA",{"intervention":87198,"totalTrials":417,"cells":87200},{"EARLY_PHASE1":87201,"PHASE1":87203,"PHASE2":87205,"PHASE3":87207,"PHASE4":87209,"NA":87211},{"trials":87202,"activeCount":97},[],{"trials":87204,"activeCount":97},[],{"trials":87206,"activeCount":97},[],{"trials":87208,"activeCount":97},[],{"trials":87210,"activeCount":97},[],{"trials":87212,"activeCount":97},[87213],{"nctId":87193,"briefTitle":87194,"status":155,"phases":87214,"primaryCompletion":5195,"completion":5195,"start":8037,"enrollment":417,"conditions":87215,"interventions":87216},[],[15],[87178,87198],{"intervention":87218,"totalTrials":417,"cells":87219},"No Intervention -- Observational study",{"EARLY_PHASE1":87220,"PHASE1":87222,"PHASE2":87224,"PHASE3":87226,"PHASE4":87228,"NA":87230},{"trials":87221,"activeCount":97},[],{"trials":87223,"activeCount":97},[],{"trials":87225,"activeCount":97},[],{"trials":87227,"activeCount":97},[],{"trials":87229,"activeCount":97},[],{"trials":87231,"activeCount":97},[87232],{"nctId":87233,"briefTitle":87234,"status":155,"phases":87235,"start":748,"enrollment":8786,"conditions":87236,"interventions":87237},"NCT00435838","A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701",[],[10662],[87218],{"intervention":84299,"totalTrials":417,"cells":87239},{"EARLY_PHASE1":87240,"PHASE1":87242,"PHASE2":87244,"PHASE3":87246,"PHASE4":87248,"NA":87250},{"trials":87241,"activeCount":97},[],{"trials":87243,"activeCount":97},[],{"trials":87245,"activeCount":97},[],{"trials":87247,"activeCount":97},[],{"trials":87249,"activeCount":97},[],{"trials":87251,"activeCount":97},[87252],{"nctId":84293,"briefTitle":84294,"status":155,"phases":87253,"primaryCompletion":8852,"completion":8852,"start":10056,"enrollment":84296,"conditions":87254,"interventions":87255},[],[24,4702,30,33,3624],[4805,84299,84300],{"intervention":84300,"totalTrials":417,"cells":87257},{"EARLY_PHASE1":87258,"PHASE1":87260,"PHASE2":87262,"PHASE3":87264,"PHASE4":87266,"NA":87268},{"trials":87259,"activeCount":97},[],{"trials":87261,"activeCount":97},[],{"trials":87263,"activeCount":97},[],{"trials":87265,"activeCount":97},[],{"trials":87267,"activeCount":97},[],{"trials":87269,"activeCount":97},[87270],{"nctId":84293,"briefTitle":84294,"status":155,"phases":87271,"primaryCompletion":8852,"completion":8852,"start":10056,"enrollment":84296,"conditions":87272,"interventions":87273},[],[24,4702,30,33,3624],[4805,84299,84300],{"intervention":87275,"totalTrials":417,"cells":87276},"Lapatinib plus capecitabine",{"EARLY_PHASE1":87277,"PHASE1":87279,"PHASE2":87281,"PHASE3":87283,"PHASE4":87285,"NA":87287},{"trials":87278,"activeCount":97},[],{"trials":87280,"activeCount":97},[],{"trials":87282,"activeCount":97},[],{"trials":87284,"activeCount":97},[],{"trials":87286,"activeCount":97},[],{"trials":87288,"activeCount":97},[87289],{"nctId":87290,"briefTitle":87291,"status":155,"phases":87292,"primaryCompletion":35747,"completion":35747,"start":8860,"enrollment":417,"conditions":87293,"interventions":87294},"NCT01782651","Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients",[],[668],[87275],{"intervention":87296,"totalTrials":417,"cells":87297},"Intervention A Standard dose",{"EARLY_PHASE1":87298,"PHASE1":87300,"PHASE2":87302,"PHASE3":87304,"PHASE4":87306,"NA":87308},{"trials":87299,"activeCount":97},[],{"trials":87301,"activeCount":97},[],{"trials":87303,"activeCount":97},[],{"trials":87305,"activeCount":97},[],{"trials":87307,"activeCount":97},[],{"trials":87309,"activeCount":97},[87310],{"nctId":87311,"briefTitle":87312,"status":155,"phases":87313,"primaryCompletion":728,"completion":728,"start":2813,"enrollment":11044,"conditions":87314,"interventions":87315},"NCT01054586","Fosamprenavir in Pts With Hepatic Impairment",[],[9343],[87296,87316,87317,87318,87319],"Intervention B Reduced Dose","Intervention C","Intervention D","Intervention E",{"intervention":87316,"totalTrials":417,"cells":87321},{"EARLY_PHASE1":87322,"PHASE1":87324,"PHASE2":87326,"PHASE3":87328,"PHASE4":87330,"NA":87332},{"trials":87323,"activeCount":97},[],{"trials":87325,"activeCount":97},[],{"trials":87327,"activeCount":97},[],{"trials":87329,"activeCount":97},[],{"trials":87331,"activeCount":97},[],{"trials":87333,"activeCount":97},[87334],{"nctId":87311,"briefTitle":87312,"status":155,"phases":87335,"primaryCompletion":728,"completion":728,"start":2813,"enrollment":11044,"conditions":87336,"interventions":87337},[],[9343],[87296,87316,87317,87318,87319],{"intervention":87317,"totalTrials":417,"cells":87339},{"EARLY_PHASE1":87340,"PHASE1":87342,"PHASE2":87344,"PHASE3":87346,"PHASE4":87348,"NA":87350},{"trials":87341,"activeCount":97},[],{"trials":87343,"activeCount":97},[],{"trials":87345,"activeCount":97},[],{"trials":87347,"activeCount":97},[],{"trials":87349,"activeCount":97},[],{"trials":87351,"activeCount":97},[87352],{"nctId":87311,"briefTitle":87312,"status":155,"phases":87353,"primaryCompletion":728,"completion":728,"start":2813,"enrollment":11044,"conditions":87354,"interventions":87355},[],[9343],[87296,87316,87317,87318,87319],{"intervention":87318,"totalTrials":417,"cells":87357},{"EARLY_PHASE1":87358,"PHASE1":87360,"PHASE2":87362,"PHASE3":87364,"PHASE4":87366,"NA":87368},{"trials":87359,"activeCount":97},[],{"trials":87361,"activeCount":97},[],{"trials":87363,"activeCount":97},[],{"trials":87365,"activeCount":97},[],{"trials":87367,"activeCount":97},[],{"trials":87369,"activeCount":97},[87370],{"nctId":87311,"briefTitle":87312,"status":155,"phases":87371,"primaryCompletion":728,"completion":728,"start":2813,"enrollment":11044,"conditions":87372,"interventions":87373},[],[9343],[87296,87316,87317,87318,87319],{"intervention":87319,"totalTrials":417,"cells":87375},{"EARLY_PHASE1":87376,"PHASE1":87378,"PHASE2":87380,"PHASE3":87382,"PHASE4":87384,"NA":87386},{"trials":87377,"activeCount":97},[],{"trials":87379,"activeCount":97},[],{"trials":87381,"activeCount":97},[],{"trials":87383,"activeCount":97},[],{"trials":87385,"activeCount":97},[],{"trials":87387,"activeCount":97},[87388],{"nctId":87311,"briefTitle":87312,"status":155,"phases":87389,"primaryCompletion":728,"completion":728,"start":2813,"enrollment":11044,"conditions":87390,"interventions":87391},[],[9343],[87296,87316,87317,87318,87319],{"intervention":87393,"totalTrials":417,"cells":87394},"Local standard of care",{"EARLY_PHASE1":87395,"PHASE1":87397,"PHASE2":87399,"PHASE3":87401,"PHASE4":87403,"NA":87405},{"trials":87396,"activeCount":97},[],{"trials":87398,"activeCount":97},[],{"trials":87400,"activeCount":97},[],{"trials":87402,"activeCount":97},[],{"trials":87404,"activeCount":97},[],{"trials":87406,"activeCount":97},[87407],{"nctId":87408,"briefTitle":87409,"status":145,"phases":87410,"primaryCompletion":4069,"completion":4069,"start":87411,"enrollment":2384,"conditions":87412,"interventions":87414},"NCT03212690","Study of Renin-angiotensin System in Mechanically Ventilated Subjects",[89],"2018-06-11",[87413],"Acute Lung Injury",[87393],{"intervention":87416,"totalTrials":417,"cells":87417},"HEC or MEC",{"EARLY_PHASE1":87418,"PHASE1":87420,"PHASE2":87422,"PHASE3":87424,"PHASE4":87426,"NA":87428},{"trials":87419,"activeCount":97},[],{"trials":87421,"activeCount":97},[],{"trials":87423,"activeCount":97},[],{"trials":87425,"activeCount":97},[],{"trials":87427,"activeCount":97},[],{"trials":87429,"activeCount":97},[87430],{"nctId":87431,"briefTitle":87432,"status":155,"phases":87433,"primaryCompletion":2441,"completion":2441,"start":2795,"enrollment":87434,"conditions":87435,"interventions":87437},"NCT01366599","CV Events in Emetogenic Chemotherapy",[],12058,[20347,86445,87436],"Arterial Thromboembolic Event",[87416],{"intervention":87439,"totalTrials":417,"cells":87440},"Treatment with zanamivir",{"EARLY_PHASE1":87441,"PHASE1":87443,"PHASE2":87445,"PHASE3":87447,"PHASE4":87449,"NA":87451},{"trials":87442,"activeCount":97},[],{"trials":87444,"activeCount":97},[],{"trials":87446,"activeCount":97},[],{"trials":87448,"activeCount":97},[],{"trials":87450,"activeCount":97},[],{"trials":87452,"activeCount":97},[87453],{"nctId":87454,"briefTitle":87455,"status":155,"phases":87456,"primaryCompletion":9706,"completion":9706,"start":7545,"enrollment":417,"conditions":87457,"interventions":87458},"NCT01462487","Safety of Inhaled Zanamivir in Pregnancy",[],[5353],[87439],{"intervention":84170,"totalTrials":417,"cells":87460},{"EARLY_PHASE1":87461,"PHASE1":87463,"PHASE2":87465,"PHASE3":87467,"PHASE4":87469,"NA":87471},{"trials":87462,"activeCount":97},[],{"trials":87464,"activeCount":97},[],{"trials":87466,"activeCount":97},[],{"trials":87468,"activeCount":97},[],{"trials":87470,"activeCount":97},[],{"trials":87472,"activeCount":97},[87473],{"nctId":84165,"briefTitle":84166,"status":155,"phases":87474,"primaryCompletion":8860,"completion":8860,"start":19576,"enrollment":234,"conditions":87475,"interventions":87476},[89],[15325],[43205,43205,43205,84170,84171,84172],{"intervention":84171,"totalTrials":417,"cells":87478},{"EARLY_PHASE1":87479,"PHASE1":87481,"PHASE2":87483,"PHASE3":87485,"PHASE4":87487,"NA":87489},{"trials":87480,"activeCount":97},[],{"trials":87482,"activeCount":97},[],{"trials":87484,"activeCount":97},[],{"trials":87486,"activeCount":97},[],{"trials":87488,"activeCount":97},[],{"trials":87490,"activeCount":97},[87491],{"nctId":84165,"briefTitle":84166,"status":155,"phases":87492,"primaryCompletion":8860,"completion":8860,"start":19576,"enrollment":234,"conditions":87493,"interventions":87494},[89],[15325],[43205,43205,43205,84170,84171,84172],{"intervention":87496,"totalTrials":417,"cells":87497},"Non-EZG containing AED polytherapy",{"EARLY_PHASE1":87498,"PHASE1":87500,"PHASE2":87502,"PHASE3":87504,"PHASE4":87506,"NA":87508},{"trials":87499,"activeCount":97},[],{"trials":87501,"activeCount":97},[],{"trials":87503,"activeCount":97},[],{"trials":87505,"activeCount":97},[],{"trials":87507,"activeCount":97},[],{"trials":87509,"activeCount":97},[87510],{"nctId":87511,"briefTitle":87512,"status":145,"phases":87513,"primaryCompletion":26113,"completion":26113,"start":729,"enrollment":417,"conditions":87514,"interventions":87515},"NCT01462656","Risk of Urinary Retention With Retigabine",[],[12518],[87496,87516,87517,87518],"EZG containing AED polytherapy","Non-EZG AED monotherapy","EZG AED monotherapy",{"intervention":87516,"totalTrials":417,"cells":87520},{"EARLY_PHASE1":87521,"PHASE1":87523,"PHASE2":87525,"PHASE3":87527,"PHASE4":87529,"NA":87531},{"trials":87522,"activeCount":97},[],{"trials":87524,"activeCount":97},[],{"trials":87526,"activeCount":97},[],{"trials":87528,"activeCount":97},[],{"trials":87530,"activeCount":97},[],{"trials":87532,"activeCount":97},[87533],{"nctId":87511,"briefTitle":87512,"status":145,"phases":87534,"primaryCompletion":26113,"completion":26113,"start":729,"enrollment":417,"conditions":87535,"interventions":87536},[],[12518],[87496,87516,87517,87518],{"intervention":87517,"totalTrials":417,"cells":87538},{"EARLY_PHASE1":87539,"PHASE1":87541,"PHASE2":87543,"PHASE3":87545,"PHASE4":87547,"NA":87549},{"trials":87540,"activeCount":97},[],{"trials":87542,"activeCount":97},[],{"trials":87544,"activeCount":97},[],{"trials":87546,"activeCount":97},[],{"trials":87548,"activeCount":97},[],{"trials":87550,"activeCount":97},[87551],{"nctId":87511,"briefTitle":87512,"status":145,"phases":87552,"primaryCompletion":26113,"completion":26113,"start":729,"enrollment":417,"conditions":87553,"interventions":87554},[],[12518],[87496,87516,87517,87518],{"intervention":87518,"totalTrials":417,"cells":87556},{"EARLY_PHASE1":87557,"PHASE1":87559,"PHASE2":87561,"PHASE3":87563,"PHASE4":87565,"NA":87567},{"trials":87558,"activeCount":97},[],{"trials":87560,"activeCount":97},[],{"trials":87562,"activeCount":97},[],{"trials":87564,"activeCount":97},[],{"trials":87566,"activeCount":97},[],{"trials":87568,"activeCount":97},[87569],{"nctId":87511,"briefTitle":87512,"status":145,"phases":87570,"primaryCompletion":26113,"completion":26113,"start":729,"enrollment":417,"conditions":87571,"interventions":87572},[],[12518],[87496,87516,87517,87518],{"intervention":87574,"totalTrials":417,"cells":87575},"0.425 % w\u002Fw phytate,1150ppm F",{"EARLY_PHASE1":87576,"PHASE1":87578,"PHASE2":87580,"PHASE3":87582,"PHASE4":87584,"NA":87586},{"trials":87577,"activeCount":97},[],{"trials":87579,"activeCount":97},[],{"trials":87581,"activeCount":97},[],{"trials":87583,"activeCount":97},[],{"trials":87585,"activeCount":97},[],{"trials":87587,"activeCount":97},[87588],{"nctId":87589,"briefTitle":87590,"status":155,"phases":87591,"primaryCompletion":39376,"completion":87592,"start":5160,"enrollment":7712,"conditions":87593,"interventions":87594},"NCT02751320","Efficacy of Three Toothpastes Using an in Situ Caries Model",[89],"2016-08-11",[13126],[87574,87595,87596,87597,87598],"0.85 % w\u002Fw phytate,1150ppm F","0.85 % w\u002Fw phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F","1150ppm F","0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F",{"intervention":87595,"totalTrials":417,"cells":87600},{"EARLY_PHASE1":87601,"PHASE1":87603,"PHASE2":87605,"PHASE3":87607,"PHASE4":87609,"NA":87611},{"trials":87602,"activeCount":97},[],{"trials":87604,"activeCount":97},[],{"trials":87606,"activeCount":97},[],{"trials":87608,"activeCount":97},[],{"trials":87610,"activeCount":97},[],{"trials":87612,"activeCount":97},[87613],{"nctId":87589,"briefTitle":87590,"status":155,"phases":87614,"primaryCompletion":39376,"completion":87592,"start":5160,"enrollment":7712,"conditions":87615,"interventions":87616},[89],[13126],[87574,87595,87596,87597,87598],{"intervention":87596,"totalTrials":417,"cells":87618},{"EARLY_PHASE1":87619,"PHASE1":87621,"PHASE2":87623,"PHASE3":87625,"PHASE4":87627,"NA":87629},{"trials":87620,"activeCount":97},[],{"trials":87622,"activeCount":97},[],{"trials":87624,"activeCount":97},[],{"trials":87626,"activeCount":97},[],{"trials":87628,"activeCount":97},[],{"trials":87630,"activeCount":97},[87631],{"nctId":87589,"briefTitle":87590,"status":155,"phases":87632,"primaryCompletion":39376,"completion":87592,"start":5160,"enrollment":7712,"conditions":87633,"interventions":87634},[89],[13126],[87574,87595,87596,87597,87598],{"intervention":87597,"totalTrials":417,"cells":87636},{"EARLY_PHASE1":87637,"PHASE1":87639,"PHASE2":87641,"PHASE3":87643,"PHASE4":87645,"NA":87647},{"trials":87638,"activeCount":97},[],{"trials":87640,"activeCount":97},[],{"trials":87642,"activeCount":97},[],{"trials":87644,"activeCount":97},[],{"trials":87646,"activeCount":97},[],{"trials":87648,"activeCount":97},[87649],{"nctId":87589,"briefTitle":87590,"status":155,"phases":87650,"primaryCompletion":39376,"completion":87592,"start":5160,"enrollment":7712,"conditions":87651,"interventions":87652},[89],[13126],[87574,87595,87596,87597,87598],{"intervention":87598,"totalTrials":417,"cells":87654},{"EARLY_PHASE1":87655,"PHASE1":87657,"PHASE2":87659,"PHASE3":87661,"PHASE4":87663,"NA":87665},{"trials":87656,"activeCount":97},[],{"trials":87658,"activeCount":97},[],{"trials":87660,"activeCount":97},[],{"trials":87662,"activeCount":97},[],{"trials":87664,"activeCount":97},[],{"trials":87666,"activeCount":97},[87667],{"nctId":87589,"briefTitle":87590,"status":155,"phases":87668,"primaryCompletion":39376,"completion":87592,"start":5160,"enrollment":7712,"conditions":87669,"interventions":87670},[89],[13126],[87574,87595,87596,87597,87598],{"intervention":85908,"totalTrials":417,"cells":87672},{"EARLY_PHASE1":87673,"PHASE1":87675,"PHASE2":87677,"PHASE3":87679,"PHASE4":87681,"NA":87683},{"trials":87674,"activeCount":97},[],{"trials":87676,"activeCount":97},[],{"trials":87678,"activeCount":97},[],{"trials":87680,"activeCount":97},[],{"trials":87682,"activeCount":97},[],{"trials":87684,"activeCount":97},[87685],{"nctId":85902,"briefTitle":85903,"status":155,"phases":87686,"primaryCompletion":1428,"completion":1428,"start":11577,"enrollment":85905,"conditions":87687,"interventions":87688},[],[12518,22321],[85887,85908,85909],{"intervention":85909,"totalTrials":417,"cells":87690},{"EARLY_PHASE1":87691,"PHASE1":87693,"PHASE2":87695,"PHASE3":87697,"PHASE4":87699,"NA":87701},{"trials":87692,"activeCount":97},[],{"trials":87694,"activeCount":97},[],{"trials":87696,"activeCount":97},[],{"trials":87698,"activeCount":97},[],{"trials":87700,"activeCount":97},[],{"trials":87702,"activeCount":97},[87703],{"nctId":85902,"briefTitle":85903,"status":155,"phases":87704,"primaryCompletion":1428,"completion":1428,"start":11577,"enrollment":85905,"conditions":87705,"interventions":87706},[],[12518,22321],[85887,85908,85909],{"intervention":87708,"totalTrials":417,"cells":87709},"0.13% Benzalkonium Chloride",{"EARLY_PHASE1":87710,"PHASE1":87712,"PHASE2":87714,"PHASE3":87716,"PHASE4":87718,"NA":87720},{"trials":87711,"activeCount":97},[],{"trials":87713,"activeCount":97},[],{"trials":87715,"activeCount":97},[],{"trials":87717,"activeCount":97},[],{"trials":87719,"activeCount":97},[],{"trials":87721,"activeCount":97},[87722],{"nctId":87723,"briefTitle":87724,"status":155,"phases":87725,"primaryCompletion":9233,"completion":9233,"start":9233,"enrollment":710,"conditions":87726,"interventions":87727},"NCT01762982","Patch Test of Benzalkonium Chloride Disinfectant Spray",[89],[18023],[87708,87728,87729],"SLS Solution","Normal Saline Water",{"intervention":87728,"totalTrials":417,"cells":87731},{"EARLY_PHASE1":87732,"PHASE1":87734,"PHASE2":87736,"PHASE3":87738,"PHASE4":87740,"NA":87742},{"trials":87733,"activeCount":97},[],{"trials":87735,"activeCount":97},[],{"trials":87737,"activeCount":97},[],{"trials":87739,"activeCount":97},[],{"trials":87741,"activeCount":97},[],{"trials":87743,"activeCount":97},[87744],{"nctId":87723,"briefTitle":87724,"status":155,"phases":87745,"primaryCompletion":9233,"completion":9233,"start":9233,"enrollment":710,"conditions":87746,"interventions":87747},[89],[18023],[87708,87728,87729],{"intervention":87729,"totalTrials":417,"cells":87749},{"EARLY_PHASE1":87750,"PHASE1":87752,"PHASE2":87754,"PHASE3":87756,"PHASE4":87758,"NA":87760},{"trials":87751,"activeCount":97},[],{"trials":87753,"activeCount":97},[],{"trials":87755,"activeCount":97},[],{"trials":87757,"activeCount":97},[],{"trials":87759,"activeCount":97},[],{"trials":87761,"activeCount":97},[87762],{"nctId":87723,"briefTitle":87724,"status":155,"phases":87763,"primaryCompletion":9233,"completion":9233,"start":9233,"enrollment":710,"conditions":87764,"interventions":87765},[89],[18023],[87708,87728,87729],{"intervention":87767,"totalTrials":417,"cells":87768},"TZD only",{"EARLY_PHASE1":87769,"PHASE1":87771,"PHASE2":87773,"PHASE3":87775,"PHASE4":87777,"NA":87779},{"trials":87770,"activeCount":97},[],{"trials":87772,"activeCount":97},[],{"trials":87774,"activeCount":97},[],{"trials":87776,"activeCount":97},[],{"trials":87778,"activeCount":97},[],{"trials":87780,"activeCount":97},[87781],{"nctId":87782,"briefTitle":87783,"status":155,"phases":87784,"primaryCompletion":3078,"completion":3078,"start":2795,"enrollment":87785,"conditions":87786,"interventions":87788},"NCT01055223","Fracture Risk With Thiazolidinediones",[],98483,[35214,87787],"Type II Diabetes",[87767,87789,87790],"TZD + spironolactone","TZD + amiloride",{"intervention":87789,"totalTrials":417,"cells":87792},{"EARLY_PHASE1":87793,"PHASE1":87795,"PHASE2":87797,"PHASE3":87799,"PHASE4":87801,"NA":87803},{"trials":87794,"activeCount":97},[],{"trials":87796,"activeCount":97},[],{"trials":87798,"activeCount":97},[],{"trials":87800,"activeCount":97},[],{"trials":87802,"activeCount":97},[],{"trials":87804,"activeCount":97},[87805],{"nctId":87782,"briefTitle":87783,"status":155,"phases":87806,"primaryCompletion":3078,"completion":3078,"start":2795,"enrollment":87785,"conditions":87807,"interventions":87808},[],[35214,87787],[87767,87789,87790],{"intervention":87790,"totalTrials":417,"cells":87810},{"EARLY_PHASE1":87811,"PHASE1":87813,"PHASE2":87815,"PHASE3":87817,"PHASE4":87819,"NA":87821},{"trials":87812,"activeCount":97},[],{"trials":87814,"activeCount":97},[],{"trials":87816,"activeCount":97},[],{"trials":87818,"activeCount":97},[],{"trials":87820,"activeCount":97},[],{"trials":87822,"activeCount":97},[87823],{"nctId":87782,"briefTitle":87783,"status":155,"phases":87824,"primaryCompletion":3078,"completion":3078,"start":2795,"enrollment":87785,"conditions":87825,"interventions":87826},[],[35214,87787],[87767,87789,87790],{"intervention":87828,"totalTrials":417,"cells":87829},"BONVIVA(ibandronate)",{"EARLY_PHASE1":87830,"PHASE1":87832,"PHASE2":87834,"PHASE3":87836,"PHASE4":87838,"NA":87840},{"trials":87831,"activeCount":97},[],{"trials":87833,"activeCount":97},[],{"trials":87835,"activeCount":97},[],{"trials":87837,"activeCount":97},[],{"trials":87839,"activeCount":97},[],{"trials":87841,"activeCount":97},[87842],{"nctId":87843,"briefTitle":87844,"status":155,"phases":87845,"primaryCompletion":3390,"completion":3390,"start":3079,"enrollment":4723,"conditions":87846,"interventions":87847},"NCT01376102","BONVIVA(Ibandronate) Injection PMS(Post-marketing Surveillance)",[],[12138],[87828],{"intervention":87849,"totalTrials":417,"cells":87850},"Arzerra",{"EARLY_PHASE1":87851,"PHASE1":87853,"PHASE2":87855,"PHASE3":87857,"PHASE4":87859,"NA":87861},{"trials":87852,"activeCount":97},[],{"trials":87854,"activeCount":97},[],{"trials":87856,"activeCount":97},[],{"trials":87858,"activeCount":97},[],{"trials":87860,"activeCount":97},[],{"trials":87862,"activeCount":97},[87863],{"nctId":87864,"briefTitle":87865,"status":155,"phases":87866,"primaryCompletion":8089,"completion":8089,"start":3111,"enrollment":417,"conditions":87867,"interventions":87868},"NCT01453062","Phase IV Observational Study in Chronic Lymphocytic Leukemia",[],[5198],[87849],{"intervention":87870,"totalTrials":417,"cells":87871},"Trobalt™",{"EARLY_PHASE1":87872,"PHASE1":87874,"PHASE2":87876,"PHASE3":87878,"PHASE4":87880,"NA":87882},{"trials":87873,"activeCount":97},[],{"trials":87875,"activeCount":97},[],{"trials":87877,"activeCount":97},[],{"trials":87879,"activeCount":97},[],{"trials":87881,"activeCount":97},[],{"trials":87883,"activeCount":97},[87884],{"nctId":87885,"briefTitle":87886,"status":155,"phases":87887,"primaryCompletion":827,"completion":827,"start":3110,"enrollment":417,"conditions":87888,"interventions":87889},"NCT01721213","Trobalt™ Products Risk Survey",[],[12518],[87870],{"intervention":87891,"totalTrials":417,"cells":87892},"Valaciclovir Hydrochloride.",{"EARLY_PHASE1":87893,"PHASE1":87895,"PHASE2":87897,"PHASE3":87899,"PHASE4":87901,"NA":87903},{"trials":87894,"activeCount":97},[],{"trials":87896,"activeCount":97},[],{"trials":87898,"activeCount":97},[],{"trials":87900,"activeCount":97},[],{"trials":87902,"activeCount":97},[],{"trials":87904,"activeCount":97},[87905],{"nctId":87906,"briefTitle":87907,"status":155,"phases":87908,"primaryCompletion":3550,"completion":8883,"start":4843,"enrollment":87909,"conditions":87910,"interventions":87912},"NCT01390805","Special Drug Use Investigation for VALTREX (Valaciclovir) (Suppression Prophylaxis)",[],462,[87911],"Genital Herpes",[87891],{"intervention":87914,"totalTrials":417,"cells":87915},"Belantamab mafodotin 2.5 mg\u002Fkg IV Q3Weeks + Vd",{"EARLY_PHASE1":87916,"PHASE1":87918,"PHASE2":87920,"PHASE3":87922,"PHASE4":87924,"NA":87926},{"trials":87917,"activeCount":97},[],{"trials":87919,"activeCount":97},[],{"trials":87921,"activeCount":97},[],{"trials":87923,"activeCount":97},[],{"trials":87925,"activeCount":97},[],{"trials":87927,"activeCount":97},[87928],{"nctId":87929,"briefTitle":87930,"status":4104,"phases":87931,"conditions":87932,"interventions":87933},"NCT03763370","Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma",[],[278],[87914,87934],"Belantamab mafodotin 2.5\u002F1.9 mg\u002Fkg IV Q4Weeks + Pd",{"intervention":87934,"totalTrials":417,"cells":87936},{"EARLY_PHASE1":87937,"PHASE1":87939,"PHASE2":87941,"PHASE3":87943,"PHASE4":87945,"NA":87947},{"trials":87938,"activeCount":97},[],{"trials":87940,"activeCount":97},[],{"trials":87942,"activeCount":97},[],{"trials":87944,"activeCount":97},[],{"trials":87946,"activeCount":97},[],{"trials":87948,"activeCount":97},[87949],{"nctId":87929,"briefTitle":87930,"status":4104,"phases":87950,"conditions":87951,"interventions":87952},[],[278],[87914,87934],{"intervention":85993,"totalTrials":417,"cells":87954},{"EARLY_PHASE1":87955,"PHASE1":87957,"PHASE2":87959,"PHASE3":87961,"PHASE4":87963,"NA":87965},{"trials":87956,"activeCount":97},[],{"trials":87958,"activeCount":97},[],{"trials":87960,"activeCount":97},[],{"trials":87962,"activeCount":97},[],{"trials":87964,"activeCount":97},[],{"trials":87966,"activeCount":97},[87967],{"nctId":85987,"briefTitle":85988,"status":155,"phases":87968,"primaryCompletion":7598,"completion":9224,"start":8883,"enrollment":85990,"conditions":87969,"interventions":87970},[],[15],[85993,85972],{"intervention":83879,"totalTrials":417,"cells":87972},{"EARLY_PHASE1":87973,"PHASE1":87975,"PHASE2":87977,"PHASE3":87979,"PHASE4":87981,"NA":87983},{"trials":87974,"activeCount":97},[],{"trials":87976,"activeCount":97},[],{"trials":87978,"activeCount":97},[],{"trials":87980,"activeCount":97},[],{"trials":87982,"activeCount":97},[],{"trials":87984,"activeCount":97},[87985],{"nctId":83873,"briefTitle":83874,"status":155,"phases":87986,"primaryCompletion":11030,"completion":11030,"start":26336,"enrollment":83876,"conditions":87987,"interventions":87988},[],[26339],[26341,83879],{"intervention":87990,"totalTrials":417,"cells":87991},"Arnuity",{"EARLY_PHASE1":87992,"PHASE1":87994,"PHASE2":87996,"PHASE3":87998,"PHASE4":88000,"NA":88002},{"trials":87993,"activeCount":97},[],{"trials":87995,"activeCount":97},[],{"trials":87997,"activeCount":97},[],{"trials":87999,"activeCount":97},[],{"trials":88001,"activeCount":97},[],{"trials":88003,"activeCount":97},[88004],{"nctId":88005,"briefTitle":88006,"status":155,"phases":88007,"primaryCompletion":88008,"completion":88008,"start":588,"enrollment":88009,"conditions":88010,"interventions":88011},"NCT03595930","Post-marketing Surveillance (PMS) Study to Observe the Safety and Effectiveness of ARNUITY in Asthma Subjects in a Real World Setting",[],"2020-07-22",668,[18],[87990],{"intervention":88013,"totalTrials":417,"cells":88014},"Intermittent, sub-chronic and chronic Flixonase use",{"EARLY_PHASE1":88015,"PHASE1":88017,"PHASE2":88019,"PHASE3":88021,"PHASE4":88023,"NA":88025},{"trials":88016,"activeCount":97},[],{"trials":88018,"activeCount":97},[],{"trials":88020,"activeCount":97},[],{"trials":88022,"activeCount":97},[],{"trials":88024,"activeCount":97},[],{"trials":88026,"activeCount":97},[88027],{"nctId":88028,"briefTitle":88029,"status":155,"phases":88030,"primaryCompletion":6352,"completion":6352,"start":7954,"enrollment":417,"conditions":88031,"interventions":88032},"NCT01077609","Flixonase Safety in Patients With Allergic Rhinitis (AR)",[],[10182],[88013,88033],"Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase",{"intervention":88033,"totalTrials":417,"cells":88035},{"EARLY_PHASE1":88036,"PHASE1":88038,"PHASE2":88040,"PHASE3":88042,"PHASE4":88044,"NA":88046},{"trials":88037,"activeCount":97},[],{"trials":88039,"activeCount":97},[],{"trials":88041,"activeCount":97},[],{"trials":88043,"activeCount":97},[],{"trials":88045,"activeCount":97},[],{"trials":88047,"activeCount":97},[88048],{"nctId":88028,"briefTitle":88029,"status":155,"phases":88049,"primaryCompletion":6352,"completion":6352,"start":7954,"enrollment":417,"conditions":88050,"interventions":88051},[],[10182],[88013,88033],{"intervention":88053,"totalTrials":417,"cells":88054},"Rotarix or Rotarix liquid formulation",{"EARLY_PHASE1":88055,"PHASE1":88057,"PHASE2":88059,"PHASE3":88061,"PHASE4":88063,"NA":88065},{"trials":88056,"activeCount":97},[],{"trials":88058,"activeCount":97},[],{"trials":88060,"activeCount":97},[],{"trials":88062,"activeCount":97},[],{"trials":88064,"activeCount":97},[],{"trials":88066,"activeCount":97},[88067],{"nctId":88068,"briefTitle":88069,"status":155,"phases":88070,"primaryCompletion":88071,"completion":88071,"start":22966,"enrollment":88072,"conditions":88073,"interventions":88074},"NCT00750893","Evaluation of Reactogenicity and Safety of GSK Biologicals' Rotarix (Human Rotavirus Vaccine) in Infants",[],"2013-06-15",3111,[4759],[88053],{"intervention":88076,"totalTrials":417,"cells":88077},"Prescription drugs with known hepatotoxicity",{"EARLY_PHASE1":88078,"PHASE1":88080,"PHASE2":88082,"PHASE3":88084,"PHASE4":88086,"NA":88088},{"trials":88079,"activeCount":97},[],{"trials":88081,"activeCount":97},[],{"trials":88083,"activeCount":97},[],{"trials":88085,"activeCount":97},[],{"trials":88087,"activeCount":97},[],{"trials":88089,"activeCount":97},[88090],{"nctId":88091,"briefTitle":88092,"status":155,"phases":88093,"primaryCompletion":484,"completion":484,"start":9233,"enrollment":417,"conditions":88094,"interventions":88096},"NCT01584765","Rechallenge, Potential Drug Induced Liver Injury (Kaiser)",[],[88095],"Drug-induced Liver Injury",[88076],{"intervention":88098,"totalTrials":417,"cells":88099},"Sumatriptan\u002FNaproxen combination",{"EARLY_PHASE1":88100,"PHASE1":88102,"PHASE2":88104,"PHASE3":88106,"PHASE4":88108,"NA":88110},{"trials":88101,"activeCount":97},[],{"trials":88103,"activeCount":97},[],{"trials":88105,"activeCount":97},[],{"trials":88107,"activeCount":97},[],{"trials":88109,"activeCount":97},[],{"trials":88111,"activeCount":97},[88112],{"nctId":88113,"briefTitle":88114,"status":155,"phases":88115,"primaryCompletion":3078,"completion":3078,"start":2441,"enrollment":88116,"conditions":88117,"interventions":88118},"NCT01332500","Treximet ™ Pharmacy Budget Impact Model Database Validation Study",[],61737,[14168],[88098,88119],"other oral triptans",{"intervention":88119,"totalTrials":417,"cells":88121},{"EARLY_PHASE1":88122,"PHASE1":88124,"PHASE2":88126,"PHASE3":88128,"PHASE4":88130,"NA":88132},{"trials":88123,"activeCount":97},[],{"trials":88125,"activeCount":97},[],{"trials":88127,"activeCount":97},[],{"trials":88129,"activeCount":97},[],{"trials":88131,"activeCount":97},[],{"trials":88133,"activeCount":97},[88134],{"nctId":88113,"briefTitle":88114,"status":155,"phases":88135,"primaryCompletion":3078,"completion":3078,"start":2441,"enrollment":88116,"conditions":88136,"interventions":88137},[],[14168],[88098,88119],{"intervention":88139,"totalTrials":417,"cells":88140},"Orlistat 120",{"EARLY_PHASE1":88141,"PHASE1":88143,"PHASE2":88145,"PHASE3":88147,"PHASE4":88149,"NA":88151},{"trials":88142,"activeCount":97},[],{"trials":88144,"activeCount":97},[],{"trials":88146,"activeCount":97},[],{"trials":88148,"activeCount":97},[],{"trials":88150,"activeCount":97},[],{"trials":88152,"activeCount":97},[88153],{"nctId":88154,"briefTitle":88155,"status":155,"phases":88156,"primaryCompletion":3391,"completion":3391,"start":2834,"enrollment":417,"conditions":88157,"interventions":88158},"NCT01332448","Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials",[],[9048],[88139,88159],"Orlistat 60",{"intervention":88159,"totalTrials":417,"cells":88161},{"EARLY_PHASE1":88162,"PHASE1":88164,"PHASE2":88166,"PHASE3":88168,"PHASE4":88170,"NA":88172},{"trials":88163,"activeCount":97},[],{"trials":88165,"activeCount":97},[],{"trials":88167,"activeCount":97},[],{"trials":88169,"activeCount":97},[],{"trials":88171,"activeCount":97},[],{"trials":88173,"activeCount":97},[88174],{"nctId":88154,"briefTitle":88155,"status":155,"phases":88175,"primaryCompletion":3391,"completion":3391,"start":2834,"enrollment":417,"conditions":88176,"interventions":88177},[],[9048],[88139,88159],{"intervention":88179,"totalTrials":417,"cells":88180},"GW510516X",{"EARLY_PHASE1":88181,"PHASE1":88183,"PHASE2":88185,"PHASE3":88187,"PHASE4":88189,"NA":88191},{"trials":88182,"activeCount":97},[],{"trials":88184,"activeCount":97},[],{"trials":88186,"activeCount":97},[],{"trials":88188,"activeCount":97},[],{"trials":88190,"activeCount":97},[],{"trials":88192,"activeCount":97},[88193],{"nctId":88194,"briefTitle":88195,"status":145,"phases":88196,"start":749,"enrollment":255,"conditions":88197,"interventions":88198},"NCT00318617","Effect Of GW501516X On How The Heart Obtains And Uses Energy",[],[27251,40356],[88179],{"intervention":88200,"totalTrials":417,"cells":88201},"Nebivolol",{"EARLY_PHASE1":88202,"PHASE1":88204,"PHASE2":88206,"PHASE3":88208,"PHASE4":88210,"NA":88212},{"trials":88203,"activeCount":97},[],{"trials":88205,"activeCount":97},[],{"trials":88207,"activeCount":97},[],{"trials":88209,"activeCount":97},[],{"trials":88211,"activeCount":97},[],{"trials":88213,"activeCount":97},[88214],{"nctId":88215,"briefTitle":88216,"status":155,"phases":88217,"primaryCompletion":2344,"completion":22445,"start":11992,"enrollment":83285,"conditions":88218,"interventions":88219},"NCT01077661","Regulatory Nebilet PMS",[],[13024,40356],[88200],{"intervention":88221,"totalTrials":417,"cells":88222},"SC belimumab 200 mg",{"EARLY_PHASE1":88223,"PHASE1":88225,"PHASE2":88227,"PHASE3":88229,"PHASE4":88231,"NA":88233},{"trials":88224,"activeCount":97},[],{"trials":88226,"activeCount":97},[],{"trials":88228,"activeCount":97},[],{"trials":88230,"activeCount":97},[],{"trials":88232,"activeCount":97},[],{"trials":88234,"activeCount":97},[88235],{"nctId":88236,"briefTitle":88237,"status":969,"phases":88238,"conditions":88239,"interventions":88240},"NCT03125486","Compassionate Use for Subcutaneous (SC) Belimumab",[],[435],[88221],{"intervention":88242,"totalTrials":417,"cells":88243},"GSK Biologicals' Infanrix™",{"EARLY_PHASE1":88244,"PHASE1":88246,"PHASE2":88248,"PHASE3":88250,"PHASE4":88252,"NA":88254},{"trials":88245,"activeCount":97},[],{"trials":88247,"activeCount":97},[],{"trials":88249,"activeCount":97},[],{"trials":88251,"activeCount":97},[],{"trials":88253,"activeCount":97},[],{"trials":88255,"activeCount":97},[88256],{"nctId":88257,"briefTitle":88258,"status":155,"phases":88259,"primaryCompletion":88260,"completion":88260,"start":88261,"enrollment":88262,"conditions":88263,"interventions":88264},"NCT00908115","Post Market Surveillance for Infanrix™",[],"2008-06-23","2003-08-01",1258,[30,3624,33],[88242],{"intervention":88266,"totalTrials":417,"cells":88267},"Tyrosine kinase inhibitors",{"EARLY_PHASE1":88268,"PHASE1":88270,"PHASE2":88272,"PHASE3":88274,"PHASE4":88276,"NA":88278},{"trials":88269,"activeCount":97},[],{"trials":88271,"activeCount":97},[],{"trials":88273,"activeCount":97},[],{"trials":88275,"activeCount":97},[],{"trials":88277,"activeCount":97},[],{"trials":88279,"activeCount":97},[88280],{"nctId":88281,"briefTitle":88282,"status":155,"phases":88283,"primaryCompletion":2335,"completion":2335,"start":8116,"enrollment":88284,"conditions":88285,"interventions":88286},"NCT01098500","Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs",[],3800,[36],[88266],{"intervention":88288,"totalTrials":417,"cells":88289},"Cumulative corticosteroid exposure",{"EARLY_PHASE1":88290,"PHASE1":88292,"PHASE2":88294,"PHASE3":88296,"PHASE4":88298,"NA":88300},{"trials":88291,"activeCount":97},[],{"trials":88293,"activeCount":97},[],{"trials":88295,"activeCount":97},[],{"trials":88297,"activeCount":97},[],{"trials":88299,"activeCount":97},[],{"trials":88301,"activeCount":97},[88302],{"nctId":88303,"briefTitle":88304,"status":155,"phases":88305,"primaryCompletion":82061,"completion":82061,"start":3389,"enrollment":417,"conditions":88306,"interventions":88307},"NCT01616472","WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins)",[],[435],[88288],{"intervention":85166,"totalTrials":417,"cells":88309},{"EARLY_PHASE1":88310,"PHASE1":88312,"PHASE2":88314,"PHASE3":88316,"PHASE4":88318,"NA":88320},{"trials":88311,"activeCount":97},[],{"trials":88313,"activeCount":97},[],{"trials":88315,"activeCount":97},[],{"trials":88317,"activeCount":97},[],{"trials":88319,"activeCount":97},[],{"trials":88321,"activeCount":97},[88322],{"nctId":85160,"briefTitle":85161,"status":155,"phases":88323,"primaryCompletion":2335,"completion":8883,"start":3551,"enrollment":85163,"conditions":88324,"interventions":88325},[],[15],[85129,85166],{"intervention":85916,"totalTrials":417,"cells":88327},{"EARLY_PHASE1":88328,"PHASE1":88330,"PHASE2":88332,"PHASE3":88334,"PHASE4":88336,"NA":88338},{"trials":88329,"activeCount":97},[],{"trials":88331,"activeCount":97},[],{"trials":88333,"activeCount":97},[],{"trials":88335,"activeCount":97},[],{"trials":88337,"activeCount":97},[],{"trials":88339,"activeCount":97},[88340],{"nctId":85911,"briefTitle":85912,"status":155,"phases":88341,"primaryCompletion":827,"completion":827,"start":2795,"enrollment":417,"conditions":88342,"interventions":88343},[],[12518],[85887,85916,85917],{"intervention":85917,"totalTrials":417,"cells":88345},{"EARLY_PHASE1":88346,"PHASE1":88348,"PHASE2":88350,"PHASE3":88352,"PHASE4":88354,"NA":88356},{"trials":88347,"activeCount":97},[],{"trials":88349,"activeCount":97},[],{"trials":88351,"activeCount":97},[],{"trials":88353,"activeCount":97},[],{"trials":88355,"activeCount":97},[],{"trials":88357,"activeCount":97},[88358],{"nctId":85911,"briefTitle":85912,"status":155,"phases":88359,"primaryCompletion":827,"completion":827,"start":2795,"enrollment":417,"conditions":88360,"interventions":88361},[],[12518],[85887,85916,85917],{"intervention":88363,"totalTrials":417,"cells":88364},"Observational Study",{"EARLY_PHASE1":88365,"PHASE1":88367,"PHASE2":88369,"PHASE3":88371,"PHASE4":88373,"NA":88375},{"trials":88366,"activeCount":97},[],{"trials":88368,"activeCount":97},[],{"trials":88370,"activeCount":97},[],{"trials":88372,"activeCount":97},[],{"trials":88374,"activeCount":97},[],{"trials":88376,"activeCount":97},[88377],{"nctId":88378,"briefTitle":88379,"status":155,"phases":88380,"completion":2336,"start":2296,"enrollment":10716,"conditions":88381,"interventions":88382},"NCT00373945","HLA-B*5701 And Hypersensitivity To Abacavir",[],[10662],[88363],{"intervention":85236,"totalTrials":417,"cells":88384},{"EARLY_PHASE1":88385,"PHASE1":88387,"PHASE2":88389,"PHASE3":88391,"PHASE4":88393,"NA":88395},{"trials":88386,"activeCount":97},[],{"trials":88388,"activeCount":97},[],{"trials":88390,"activeCount":97},[],{"trials":88392,"activeCount":97},[],{"trials":88394,"activeCount":97},[],{"trials":88396,"activeCount":97},[88397],{"nctId":85230,"briefTitle":85231,"status":155,"phases":88398,"primaryCompletion":7647,"completion":7647,"start":6351,"enrollment":85233,"conditions":88399,"interventions":88400},[],[15],[85200,85236],{"intervention":88402,"totalTrials":417,"cells":88403},"Vaccines",{"EARLY_PHASE1":88404,"PHASE1":88406,"PHASE2":88408,"PHASE3":88410,"PHASE4":88412,"NA":88414},{"trials":88405,"activeCount":97},[],{"trials":88407,"activeCount":97},[],{"trials":88409,"activeCount":97},[],{"trials":88411,"activeCount":97},[],{"trials":88413,"activeCount":97},[],{"trials":88415,"activeCount":97},[88416],{"nctId":88417,"briefTitle":88418,"status":155,"phases":88419,"primaryCompletion":7591,"completion":7591,"start":9682,"enrollment":417,"conditions":88420,"interventions":88421},"NCT01416597","A Systematic Review of Studies of the Effect of Influenza Vaccine Against Mismatched Strains",[],[21],[88402],{"intervention":88423,"totalTrials":417,"cells":88424},"Adherent with 5-alpha-reductase inhibitor (5ARI) therapy",{"EARLY_PHASE1":88425,"PHASE1":88427,"PHASE2":88429,"PHASE3":88431,"PHASE4":88433,"NA":88435},{"trials":88426,"activeCount":97},[],{"trials":88428,"activeCount":97},[],{"trials":88430,"activeCount":97},[],{"trials":88432,"activeCount":97},[],{"trials":88434,"activeCount":97},[],{"trials":88436,"activeCount":97},[88437],{"nctId":88438,"briefTitle":88439,"status":155,"phases":88440,"primaryCompletion":6352,"completion":11030,"start":6352,"enrollment":85270,"conditions":88441,"interventions":88442},"NCT01334723","Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia",[],[12263],[88423,88443],"Non-adherent to 5ARI therapy",{"intervention":88443,"totalTrials":417,"cells":88445},{"EARLY_PHASE1":88446,"PHASE1":88448,"PHASE2":88450,"PHASE3":88452,"PHASE4":88454,"NA":88456},{"trials":88447,"activeCount":97},[],{"trials":88449,"activeCount":97},[],{"trials":88451,"activeCount":97},[],{"trials":88453,"activeCount":97},[],{"trials":88455,"activeCount":97},[],{"trials":88457,"activeCount":97},[88458],{"nctId":88438,"briefTitle":88439,"status":155,"phases":88459,"primaryCompletion":6352,"completion":11030,"start":6352,"enrollment":85270,"conditions":88460,"interventions":88461},[],[12263],[88423,88443],{"intervention":88463,"totalTrials":417,"cells":88464},"Epoprostenol",{"EARLY_PHASE1":88465,"PHASE1":88467,"PHASE2":88469,"PHASE3":88471,"PHASE4":88473,"NA":88475},{"trials":88466,"activeCount":97},[],{"trials":88468,"activeCount":97},[],{"trials":88470,"activeCount":97},[],{"trials":88472,"activeCount":97},[],{"trials":88474,"activeCount":97},[],{"trials":88476,"activeCount":97},[88477],{"nctId":88478,"briefTitle":88479,"status":155,"phases":88480,"primaryCompletion":3550,"completion":2441,"start":88481,"enrollment":88482,"conditions":88483,"interventions":88484},"NCT01387191","Drug Use Investigation for FLOLAN (Epoprostenol) Injection 0.5mg・1.5mg",[],"1999-08",748,[14279],[88463],{"intervention":88486,"totalTrials":417,"cells":88487},"Pravastatin alone",{"EARLY_PHASE1":88488,"PHASE1":88490,"PHASE2":88492,"PHASE3":88494,"PHASE4":88496,"NA":88498},{"trials":88489,"activeCount":97},[],{"trials":88491,"activeCount":97},[],{"trials":88493,"activeCount":97},[],{"trials":88495,"activeCount":97},[],{"trials":88497,"activeCount":97},[],{"trials":88499,"activeCount":97},[88500],{"nctId":88501,"briefTitle":88502,"status":155,"phases":88503,"primaryCompletion":11315,"completion":11315,"start":7591,"enrollment":417,"conditions":88504,"interventions":88505},"NCT01602913","Type II Diabetes Mellitus in Patients Exposed to Pravastatin and Paroxetine",[],[87072],[88486,88506,88507],"Paroxetine alone","Pravastatin and paroxetine combined",{"intervention":88506,"totalTrials":417,"cells":88509},{"EARLY_PHASE1":88510,"PHASE1":88512,"PHASE2":88514,"PHASE3":88516,"PHASE4":88518,"NA":88520},{"trials":88511,"activeCount":97},[],{"trials":88513,"activeCount":97},[],{"trials":88515,"activeCount":97},[],{"trials":88517,"activeCount":97},[],{"trials":88519,"activeCount":97},[],{"trials":88521,"activeCount":97},[88522],{"nctId":88501,"briefTitle":88502,"status":155,"phases":88523,"primaryCompletion":11315,"completion":11315,"start":7591,"enrollment":417,"conditions":88524,"interventions":88525},[],[87072],[88486,88506,88507],{"intervention":88507,"totalTrials":417,"cells":88527},{"EARLY_PHASE1":88528,"PHASE1":88530,"PHASE2":88532,"PHASE3":88534,"PHASE4":88536,"NA":88538},{"trials":88529,"activeCount":97},[],{"trials":88531,"activeCount":97},[],{"trials":88533,"activeCount":97},[],{"trials":88535,"activeCount":97},[],{"trials":88537,"activeCount":97},[],{"trials":88539,"activeCount":97},[88540],{"nctId":88501,"briefTitle":88502,"status":155,"phases":88541,"primaryCompletion":11315,"completion":11315,"start":7591,"enrollment":417,"conditions":88542,"interventions":88543},[],[87072],[88486,88506,88507],{"intervention":88545,"totalTrials":417,"cells":88546},"Combination therapy with sumatriptan and naproxen sodium",{"EARLY_PHASE1":88547,"PHASE1":88549,"PHASE2":88551,"PHASE3":88553,"PHASE4":88555,"NA":88557},{"trials":88548,"activeCount":97},[],{"trials":88550,"activeCount":97},[],{"trials":88552,"activeCount":97},[],{"trials":88554,"activeCount":97},[],{"trials":88556,"activeCount":97},[],{"trials":88558,"activeCount":97},[88559],{"nctId":88560,"briefTitle":88561,"status":155,"phases":88562,"primaryCompletion":9224,"completion":9224,"start":10463,"enrollment":417,"conditions":88563,"interventions":88564},"NCT01381523","A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data",[],[14168],[88545,88565],"Single-entity oral triptans",{"intervention":88565,"totalTrials":417,"cells":88567},{"EARLY_PHASE1":88568,"PHASE1":88570,"PHASE2":88572,"PHASE3":88574,"PHASE4":88576,"NA":88578},{"trials":88569,"activeCount":97},[],{"trials":88571,"activeCount":97},[],{"trials":88573,"activeCount":97},[],{"trials":88575,"activeCount":97},[],{"trials":88577,"activeCount":97},[],{"trials":88579,"activeCount":97},[88580],{"nctId":88560,"briefTitle":88561,"status":155,"phases":88581,"primaryCompletion":9224,"completion":9224,"start":10463,"enrollment":417,"conditions":88582,"interventions":88583},[],[14168],[88545,88565],{"intervention":88585,"totalTrials":417,"cells":88586},"allocation of treatment with metformin or rosiglitazone",{"EARLY_PHASE1":88587,"PHASE1":88589,"PHASE2":88591,"PHASE3":88593,"PHASE4":88595,"NA":88597},{"trials":88588,"activeCount":97},[],{"trials":88590,"activeCount":97},[],{"trials":88592,"activeCount":97},[],{"trials":88594,"activeCount":97},[],{"trials":88596,"activeCount":97},[],{"trials":88598,"activeCount":97},[88599],{"nctId":88600,"briefTitle":88601,"status":155,"phases":88602,"primaryCompletion":26336,"completion":26336,"start":11992,"enrollment":417,"conditions":88603,"interventions":88604},"NCT01195259","Malignancy Meta Analysis for BRL49653",[],[27],[88585],{"intervention":84095,"totalTrials":417,"cells":88606},{"EARLY_PHASE1":88607,"PHASE1":88609,"PHASE2":88611,"PHASE3":88613,"PHASE4":88615,"NA":88617},{"trials":88608,"activeCount":97},[],{"trials":88610,"activeCount":97},[],{"trials":88612,"activeCount":97},[],{"trials":88614,"activeCount":97},[],{"trials":88616,"activeCount":97},[],{"trials":88618,"activeCount":97},[88619],{"nctId":84089,"briefTitle":84090,"status":155,"phases":88620,"primaryCompletion":26336,"completion":26336,"start":8116,"enrollment":14367,"conditions":88621,"interventions":88622},[],[84093],[84095,84096,84097,56336],{"intervention":84096,"totalTrials":417,"cells":88624},{"EARLY_PHASE1":88625,"PHASE1":88627,"PHASE2":88629,"PHASE3":88631,"PHASE4":88633,"NA":88635},{"trials":88626,"activeCount":97},[],{"trials":88628,"activeCount":97},[],{"trials":88630,"activeCount":97},[],{"trials":88632,"activeCount":97},[],{"trials":88634,"activeCount":97},[],{"trials":88636,"activeCount":97},[88637],{"nctId":84089,"briefTitle":84090,"status":155,"phases":88638,"primaryCompletion":26336,"completion":26336,"start":8116,"enrollment":14367,"conditions":88639,"interventions":88640},[],[84093],[84095,84096,84097,56336],{"intervention":84097,"totalTrials":417,"cells":88642},{"EARLY_PHASE1":88643,"PHASE1":88645,"PHASE2":88647,"PHASE3":88649,"PHASE4":88651,"NA":88653},{"trials":88644,"activeCount":97},[],{"trials":88646,"activeCount":97},[],{"trials":88648,"activeCount":97},[],{"trials":88650,"activeCount":97},[],{"trials":88652,"activeCount":97},[],{"trials":88654,"activeCount":97},[88655],{"nctId":84089,"briefTitle":84090,"status":155,"phases":88656,"primaryCompletion":26336,"completion":26336,"start":8116,"enrollment":14367,"conditions":88657,"interventions":88658},[],[84093],[84095,84096,84097,56336],{"intervention":88660,"totalTrials":417,"cells":88661},"Anti-epileptic drug",{"EARLY_PHASE1":88662,"PHASE1":88664,"PHASE2":88666,"PHASE3":88668,"PHASE4":88670,"NA":88672},{"trials":88663,"activeCount":97},[],{"trials":88665,"activeCount":97},[],{"trials":88667,"activeCount":97},[],{"trials":88669,"activeCount":97},[],{"trials":88671,"activeCount":97},[],{"trials":88673,"activeCount":97},[88674],{"nctId":88675,"briefTitle":88676,"status":155,"phases":88677,"primaryCompletion":22445,"completion":22445,"start":7647,"enrollment":88678,"conditions":88679,"interventions":88680},"NCT01390909","Clinical and Economic Burden of Uncontrolled Epilepsy: Analyses From a Medicaid Database and a Private Health Plan Database",[],12386,[12518],[88660],{"intervention":88682,"totalTrials":417,"cells":88683},"ChapStick Moisturizer, Strawberry Flavor",{"EARLY_PHASE1":88684,"PHASE1":88686,"PHASE2":88688,"PHASE3":88690,"PHASE4":88692,"NA":88694},{"trials":88685,"activeCount":97},[],{"trials":88687,"activeCount":97},[],{"trials":88689,"activeCount":97},[],{"trials":88691,"activeCount":97},[],{"trials":88693,"activeCount":97},[],{"trials":88695,"activeCount":97},[88696],{"nctId":88697,"briefTitle":88698,"status":155,"phases":88699,"primaryCompletion":88700,"completion":88700,"start":88701,"enrollment":473,"conditions":88702,"interventions":88704},"NCT04749459","Sun Protection Factor (SPF) Determination of Two Sunscreen-Containing Lip Balms",[89],"2021-03-31","2021-03-03",[88703],"Sunscreening Agents",[88682,88705,88706],"ChapStick Moisturizer, Classic Flavor","ISO 24444:2010 P2 Standard Reference Sunscreen",{"intervention":88705,"totalTrials":417,"cells":88708},{"EARLY_PHASE1":88709,"PHASE1":88711,"PHASE2":88713,"PHASE3":88715,"PHASE4":88717,"NA":88719},{"trials":88710,"activeCount":97},[],{"trials":88712,"activeCount":97},[],{"trials":88714,"activeCount":97},[],{"trials":88716,"activeCount":97},[],{"trials":88718,"activeCount":97},[],{"trials":88720,"activeCount":97},[88721],{"nctId":88697,"briefTitle":88698,"status":155,"phases":88722,"primaryCompletion":88700,"completion":88700,"start":88701,"enrollment":473,"conditions":88723,"interventions":88724},[89],[88703],[88682,88705,88706],{"intervention":88706,"totalTrials":417,"cells":88726},{"EARLY_PHASE1":88727,"PHASE1":88729,"PHASE2":88731,"PHASE3":88733,"PHASE4":88735,"NA":88737},{"trials":88728,"activeCount":97},[],{"trials":88730,"activeCount":97},[],{"trials":88732,"activeCount":97},[],{"trials":88734,"activeCount":97},[],{"trials":88736,"activeCount":97},[],{"trials":88738,"activeCount":97},[88739],{"nctId":88697,"briefTitle":88698,"status":155,"phases":88740,"primaryCompletion":88700,"completion":88700,"start":88701,"enrollment":473,"conditions":88741,"interventions":88742},[89],[88703],[88682,88705,88706],{"intervention":84105,"totalTrials":417,"cells":88744},{"EARLY_PHASE1":88745,"PHASE1":88747,"PHASE2":88749,"PHASE3":88751,"PHASE4":88753,"NA":88755},{"trials":88746,"activeCount":97},[],{"trials":88748,"activeCount":97},[],{"trials":88750,"activeCount":97},[],{"trials":88752,"activeCount":97},[],{"trials":88754,"activeCount":97},[],{"trials":88756,"activeCount":97},[88757],{"nctId":84099,"briefTitle":84100,"status":155,"phases":88758,"primaryCompletion":2335,"completion":10463,"start":2834,"enrollment":84102,"conditions":88759,"interventions":88760},[],[26339],[84105,84077,56336,56337],{"intervention":88762,"totalTrials":417,"cells":88763},"Mejoral® 500",{"EARLY_PHASE1":88764,"PHASE1":88766,"PHASE2":88768,"PHASE3":88770,"PHASE4":88772,"NA":88774},{"trials":88765,"activeCount":97},[],{"trials":88767,"activeCount":97},[],{"trials":88769,"activeCount":97},[],{"trials":88771,"activeCount":97},[],{"trials":88773,"activeCount":97},[],{"trials":88775,"activeCount":97},[88776],{"nctId":88777,"briefTitle":88778,"status":155,"phases":88779,"primaryCompletion":88780,"completion":88781,"start":88780,"enrollment":695,"conditions":88782,"interventions":88783},"NCT02504775","Bioequivalence Study for Mejoral 500 Product",[89],"2015-08-01","2015-08-19",[9153],[88762,88784],"Tylenol® Caplets",{"intervention":88784,"totalTrials":417,"cells":88786},{"EARLY_PHASE1":88787,"PHASE1":88789,"PHASE2":88791,"PHASE3":88793,"PHASE4":88795,"NA":88797},{"trials":88788,"activeCount":97},[],{"trials":88790,"activeCount":97},[],{"trials":88792,"activeCount":97},[],{"trials":88794,"activeCount":97},[],{"trials":88796,"activeCount":97},[],{"trials":88798,"activeCount":97},[88799],{"nctId":88777,"briefTitle":88778,"status":155,"phases":88800,"primaryCompletion":88780,"completion":88781,"start":88780,"enrollment":695,"conditions":88801,"interventions":88802},[89],[9153],[88762,88784],{"intervention":88804,"totalTrials":417,"cells":88805},"molibresib",{"EARLY_PHASE1":88806,"PHASE1":88808,"PHASE2":88810,"PHASE3":88812,"PHASE4":88814,"NA":88816},{"trials":88807,"activeCount":97},[],{"trials":88809,"activeCount":97},[],{"trials":88811,"activeCount":97},[],{"trials":88813,"activeCount":97},[],{"trials":88815,"activeCount":97},[],{"trials":88817,"activeCount":97},[88818],{"nctId":88819,"briefTitle":88820,"status":969,"phases":88821,"conditions":88822,"interventions":88823},"NCT03702036","Compassionate Use Individual Request Program for GSK525762 in NUT Midline Carcinoma",[],[2761],[88804],{"intervention":88825,"totalTrials":417,"cells":88826},"Pazopanib use",{"EARLY_PHASE1":88827,"PHASE1":88829,"PHASE2":88831,"PHASE3":88833,"PHASE4":88835,"NA":88837},{"trials":88828,"activeCount":97},[],{"trials":88830,"activeCount":97},[],{"trials":88832,"activeCount":97},[],{"trials":88834,"activeCount":97},[],{"trials":88836,"activeCount":97},[],{"trials":88838,"activeCount":97},[88839],{"nctId":88840,"briefTitle":88841,"status":155,"phases":88842,"primaryCompletion":827,"completion":827,"start":2344,"enrollment":417,"conditions":88843,"interventions":88844},"NCT01449825","Hepatic Monitoring for Pazopanib",[],[1877],[88825,88845],"Use of sunitinib, bevacizumab, or sorafenib",{"intervention":88845,"totalTrials":417,"cells":88847},{"EARLY_PHASE1":88848,"PHASE1":88850,"PHASE2":88852,"PHASE3":88854,"PHASE4":88856,"NA":88858},{"trials":88849,"activeCount":97},[],{"trials":88851,"activeCount":97},[],{"trials":88853,"activeCount":97},[],{"trials":88855,"activeCount":97},[],{"trials":88857,"activeCount":97},[],{"trials":88859,"activeCount":97},[88860],{"nctId":88840,"briefTitle":88841,"status":155,"phases":88861,"primaryCompletion":827,"completion":827,"start":2344,"enrollment":417,"conditions":88862,"interventions":88863},[],[1877],[88825,88845],{"intervention":88865,"totalTrials":417,"cells":88866},"5ARI or AB or Combination Therapy",{"EARLY_PHASE1":88867,"PHASE1":88869,"PHASE2":88871,"PHASE3":88873,"PHASE4":88875,"NA":88877},{"trials":88868,"activeCount":97},[],{"trials":88870,"activeCount":97},[],{"trials":88872,"activeCount":97},[],{"trials":88874,"activeCount":97},[],{"trials":88876,"activeCount":97},[],{"trials":88878,"activeCount":97},[88879],{"nctId":88880,"briefTitle":88881,"status":155,"phases":88882,"primaryCompletion":3551,"completion":3551,"start":2795,"enrollment":4388,"conditions":88883,"interventions":88884},"NCT01390870","Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence",[],[12263],[88865],{"intervention":88886,"totalTrials":417,"cells":88887},"5-alpha Reductase Inhibitor",{"EARLY_PHASE1":88888,"PHASE1":88890,"PHASE2":88892,"PHASE3":88894,"PHASE4":88896,"NA":88898},{"trials":88889,"activeCount":97},[],{"trials":88891,"activeCount":97},[],{"trials":88893,"activeCount":97},[],{"trials":88895,"activeCount":97},[],{"trials":88897,"activeCount":97},[],{"trials":88899,"activeCount":97},[88900],{"nctId":88901,"briefTitle":88902,"status":155,"phases":88903,"primaryCompletion":3391,"completion":3391,"start":11030,"enrollment":88904,"conditions":88905,"interventions":88906},"NCT01381510","Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database",[],54459,[12263],[88886],{"intervention":88908,"totalTrials":417,"cells":88909},"Early combination therapy",{"EARLY_PHASE1":88910,"PHASE1":88912,"PHASE2":88914,"PHASE3":88916,"PHASE4":88918,"NA":88920},{"trials":88911,"activeCount":97},[],{"trials":88913,"activeCount":97},[],{"trials":88915,"activeCount":97},[],{"trials":88917,"activeCount":97},[],{"trials":88919,"activeCount":97},[],{"trials":88921,"activeCount":97},[88922],{"nctId":88923,"briefTitle":88924,"status":155,"phases":88925,"primaryCompletion":8883,"completion":8883,"start":3391,"enrollment":88926,"conditions":88927,"interventions":88928},"NCT01435954","Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy",[],13551,[22619],[88908,88929],"Delayed combination therapy",{"intervention":88929,"totalTrials":417,"cells":88931},{"EARLY_PHASE1":88932,"PHASE1":88934,"PHASE2":88936,"PHASE3":88938,"PHASE4":88940,"NA":88942},{"trials":88933,"activeCount":97},[],{"trials":88935,"activeCount":97},[],{"trials":88937,"activeCount":97},[],{"trials":88939,"activeCount":97},[],{"trials":88941,"activeCount":97},[],{"trials":88943,"activeCount":97},[88944],{"nctId":88923,"briefTitle":88924,"status":155,"phases":88945,"primaryCompletion":8883,"completion":8883,"start":3391,"enrollment":88926,"conditions":88946,"interventions":88947},[],[22619],[88908,88929],{"intervention":88949,"totalTrials":417,"cells":88950},"4CMenB",{"EARLY_PHASE1":88951,"PHASE1":88953,"PHASE2":88955,"PHASE3":88957,"PHASE4":88959,"NA":88961},{"trials":88952,"activeCount":97},[],{"trials":88954,"activeCount":97},[],{"trials":88956,"activeCount":97},[],{"trials":88958,"activeCount":97},[],{"trials":88960,"activeCount":97},[],{"trials":88962,"activeCount":97},[88963],{"nctId":88964,"briefTitle":88965,"status":155,"phases":88966,"primaryCompletion":88967,"completion":88967,"start":88968,"enrollment":660,"conditions":88969,"interventions":88970},"NCT02640677","Safety of 4CMenB Exposure During Pregnancy",[],"2019-11-30","2016-01-31",[992],[88949],{"intervention":88972,"totalTrials":417,"cells":88973},"Standard fluoride toothpaste",{"EARLY_PHASE1":88974,"PHASE1":88976,"PHASE2":88978,"PHASE3":88980,"PHASE4":88982,"NA":88984},{"trials":88975,"activeCount":97},[],{"trials":88977,"activeCount":97},[],{"trials":88979,"activeCount":97},[],{"trials":88981,"activeCount":97},[],{"trials":88983,"activeCount":97},[],{"trials":88985,"activeCount":97},[88986],{"nctId":88987,"briefTitle":88988,"status":155,"phases":88989,"primaryCompletion":8098,"completion":8098,"start":11769,"enrollment":9196,"conditions":88990,"interventions":88991},"NCT02542943","Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity",[89],[55741],[88972],{"intervention":88993,"totalTrials":417,"cells":88994},"GSK149203A",{"EARLY_PHASE1":88995,"PHASE1":88997,"PHASE2":88999,"PHASE3":89001,"PHASE4":89003,"NA":89005},{"trials":88996,"activeCount":97},[],{"trials":88998,"activeCount":97},[],{"trials":89000,"activeCount":97},[],{"trials":89002,"activeCount":97},[],{"trials":89004,"activeCount":97},[],{"trials":89006,"activeCount":97},[89007],{"nctId":89008,"briefTitle":89009,"status":155,"phases":89010,"primaryCompletion":89011,"completion":89011,"start":25970,"enrollment":149,"conditions":89012,"interventions":89013},"NCT01357915","Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine",[89],"2012-09-13",[80205],[88993],{"intervention":89015,"totalTrials":417,"cells":89016},"Exposure to any bupropion during the first trimester",{"EARLY_PHASE1":89017,"PHASE1":89019,"PHASE2":89021,"PHASE3":89023,"PHASE4":89025,"NA":89027},{"trials":89018,"activeCount":97},[],{"trials":89020,"activeCount":97},[],{"trials":89022,"activeCount":97},[],{"trials":89024,"activeCount":97},[],{"trials":89026,"activeCount":97},[],{"trials":89028,"activeCount":97},[89029],{"nctId":89030,"briefTitle":89031,"status":155,"phases":89032,"primaryCompletion":9706,"completion":9706,"start":3111,"enrollment":417,"conditions":89033,"interventions":89034},"NCT01597661","Bupropion & Cardio Birth Defect (Slone)",[],[9292],[89015,89035],"Exposure to bupropion alone during the first trimester",{"intervention":89035,"totalTrials":417,"cells":89037},{"EARLY_PHASE1":89038,"PHASE1":89040,"PHASE2":89042,"PHASE3":89044,"PHASE4":89046,"NA":89048},{"trials":89039,"activeCount":97},[],{"trials":89041,"activeCount":97},[],{"trials":89043,"activeCount":97},[],{"trials":89045,"activeCount":97},[],{"trials":89047,"activeCount":97},[],{"trials":89049,"activeCount":97},[89050],{"nctId":89030,"briefTitle":89031,"status":155,"phases":89051,"primaryCompletion":9706,"completion":9706,"start":3111,"enrollment":417,"conditions":89052,"interventions":89053},[],[9292],[89015,89035],{"intervention":89055,"totalTrials":417,"cells":89056},"Zinc-A toothpaste",{"EARLY_PHASE1":89057,"PHASE1":89059,"PHASE2":89061,"PHASE3":89063,"PHASE4":89065,"NA":89067},{"trials":89058,"activeCount":97},[],{"trials":89060,"activeCount":97},[],{"trials":89062,"activeCount":97},[],{"trials":89064,"activeCount":97},[],{"trials":89066,"activeCount":97},[],{"trials":89068,"activeCount":97},[89069],{"nctId":89070,"briefTitle":89071,"status":155,"phases":89072,"primaryCompletion":89073,"completion":89073,"start":9567,"enrollment":1117,"conditions":89074,"interventions":89076},"NCT03587428","Effect of Two Toothpastes on Bacteria in Saliva",[89],"2014-11-27",[89075],"Oral Health",[89055,89077],"Zinc-B toothpaste",{"intervention":89077,"totalTrials":417,"cells":89079},{"EARLY_PHASE1":89080,"PHASE1":89082,"PHASE2":89084,"PHASE3":89086,"PHASE4":89088,"NA":89090},{"trials":89081,"activeCount":97},[],{"trials":89083,"activeCount":97},[],{"trials":89085,"activeCount":97},[],{"trials":89087,"activeCount":97},[],{"trials":89089,"activeCount":97},[],{"trials":89091,"activeCount":97},[89092],{"nctId":89070,"briefTitle":89071,"status":155,"phases":89093,"primaryCompletion":89073,"completion":89073,"start":9567,"enrollment":1117,"conditions":89094,"interventions":89095},[89],[89075],[89055,89077],{"intervention":89097,"totalTrials":417,"cells":89098},"Benzodiazepine (BZD) use, defined by ATC codes",{"EARLY_PHASE1":89099,"PHASE1":89101,"PHASE2":89103,"PHASE3":89105,"PHASE4":89107,"NA":89109},{"trials":89100,"activeCount":97},[],{"trials":89102,"activeCount":97},[],{"trials":89104,"activeCount":97},[],{"trials":89106,"activeCount":97},[],{"trials":89108,"activeCount":97},[],{"trials":89110,"activeCount":97},[89111],{"nctId":89112,"briefTitle":89113,"status":155,"phases":89114,"primaryCompletion":9507,"completion":9507,"start":8135,"enrollment":417,"conditions":89115,"interventions":89116},"NCT01587833","WEUKBRE5559: IMI PROTECT: Benzodiazepines & Fracture",[],[63101],[89097],{"intervention":89118,"totalTrials":417,"cells":89119},"Asthma treatment with an asthma-related medication and at least one asthma controller medication",{"EARLY_PHASE1":89120,"PHASE1":89122,"PHASE2":89124,"PHASE3":89126,"PHASE4":89128,"NA":89130},{"trials":89121,"activeCount":97},[],{"trials":89123,"activeCount":97},[],{"trials":89125,"activeCount":97},[],{"trials":89127,"activeCount":97},[],{"trials":89129,"activeCount":97},[],{"trials":89131,"activeCount":97},[89132],{"nctId":89133,"briefTitle":89134,"status":155,"phases":89135,"primaryCompletion":6352,"completion":6352,"start":2441,"enrollment":89136,"conditions":89137,"interventions":89138},"NCT01346852","Predictive Ability of Therapeutic Risk Factors in Pediatric and Adult Asthma Patients",[],101437,[18],[89118],{"intervention":89140,"totalTrials":417,"cells":89141},"Carvedilol immediate release only",{"EARLY_PHASE1":89142,"PHASE1":89144,"PHASE2":89146,"PHASE3":89148,"PHASE4":89150,"NA":89152},{"trials":89143,"activeCount":97},[],{"trials":89145,"activeCount":97},[],{"trials":89147,"activeCount":97},[],{"trials":89149,"activeCount":97},[],{"trials":89151,"activeCount":97},[],{"trials":89153,"activeCount":97},[89154],{"nctId":89155,"briefTitle":89156,"status":155,"phases":89157,"primaryCompletion":8883,"completion":8883,"start":11030,"enrollment":417,"conditions":89158,"interventions":89159},"NCT01316952","Coreg and HSRs-Updated Analysis",[],[86867],[89140,89160,89161,89162,89163],"Carvedilol extended release only","Long acting β-blockers","Other α1\u002Fβ-adrenergic antagonists","Short acting Non-selective β-blockers and short acting β1-Selective agents",{"intervention":89160,"totalTrials":417,"cells":89165},{"EARLY_PHASE1":89166,"PHASE1":89168,"PHASE2":89170,"PHASE3":89172,"PHASE4":89174,"NA":89176},{"trials":89167,"activeCount":97},[],{"trials":89169,"activeCount":97},[],{"trials":89171,"activeCount":97},[],{"trials":89173,"activeCount":97},[],{"trials":89175,"activeCount":97},[],{"trials":89177,"activeCount":97},[89178],{"nctId":89155,"briefTitle":89156,"status":155,"phases":89179,"primaryCompletion":8883,"completion":8883,"start":11030,"enrollment":417,"conditions":89180,"interventions":89181},[],[86867],[89140,89160,89161,89162,89163],{"intervention":89161,"totalTrials":417,"cells":89183},{"EARLY_PHASE1":89184,"PHASE1":89186,"PHASE2":89188,"PHASE3":89190,"PHASE4":89192,"NA":89194},{"trials":89185,"activeCount":97},[],{"trials":89187,"activeCount":97},[],{"trials":89189,"activeCount":97},[],{"trials":89191,"activeCount":97},[],{"trials":89193,"activeCount":97},[],{"trials":89195,"activeCount":97},[89196],{"nctId":89155,"briefTitle":89156,"status":155,"phases":89197,"primaryCompletion":8883,"completion":8883,"start":11030,"enrollment":417,"conditions":89198,"interventions":89199},[],[86867],[89140,89160,89161,89162,89163],{"intervention":89162,"totalTrials":417,"cells":89201},{"EARLY_PHASE1":89202,"PHASE1":89204,"PHASE2":89206,"PHASE3":89208,"PHASE4":89210,"NA":89212},{"trials":89203,"activeCount":97},[],{"trials":89205,"activeCount":97},[],{"trials":89207,"activeCount":97},[],{"trials":89209,"activeCount":97},[],{"trials":89211,"activeCount":97},[],{"trials":89213,"activeCount":97},[89214],{"nctId":89155,"briefTitle":89156,"status":155,"phases":89215,"primaryCompletion":8883,"completion":8883,"start":11030,"enrollment":417,"conditions":89216,"interventions":89217},[],[86867],[89140,89160,89161,89162,89163],{"intervention":89163,"totalTrials":417,"cells":89219},{"EARLY_PHASE1":89220,"PHASE1":89222,"PHASE2":89224,"PHASE3":89226,"PHASE4":89228,"NA":89230},{"trials":89221,"activeCount":97},[],{"trials":89223,"activeCount":97},[],{"trials":89225,"activeCount":97},[],{"trials":89227,"activeCount":97},[],{"trials":89229,"activeCount":97},[],{"trials":89231,"activeCount":97},[89232],{"nctId":89155,"briefTitle":89156,"status":155,"phases":89233,"primaryCompletion":8883,"completion":8883,"start":11030,"enrollment":417,"conditions":89234,"interventions":89235},[],[86867],[89140,89160,89161,89162,89163],{"intervention":89237,"totalTrials":417,"cells":89238},"Regular bupropion use",{"EARLY_PHASE1":89239,"PHASE1":89241,"PHASE2":89243,"PHASE3":89245,"PHASE4":89247,"NA":89249},{"trials":89240,"activeCount":97},[],{"trials":89242,"activeCount":97},[],{"trials":89244,"activeCount":97},[],{"trials":89246,"activeCount":97},[],{"trials":89248,"activeCount":97},[],{"trials":89250,"activeCount":97},[89251],{"nctId":89252,"briefTitle":89253,"status":155,"phases":89254,"primaryCompletion":3078,"completion":3078,"start":7546,"enrollment":89255,"conditions":89256,"interventions":89257},"NCT01077596","Carcinogenicity Study of Bupropion",[],50430,[9292,36],[89237,89258,89259,89260],"Regular SSRI (Selective serotonin reuptake inhibitors) use","Regular TCA (Tricyclic antidepressants) use","Regular use of any other antidepressant",{"intervention":89258,"totalTrials":417,"cells":89262},{"EARLY_PHASE1":89263,"PHASE1":89265,"PHASE2":89267,"PHASE3":89269,"PHASE4":89271,"NA":89273},{"trials":89264,"activeCount":97},[],{"trials":89266,"activeCount":97},[],{"trials":89268,"activeCount":97},[],{"trials":89270,"activeCount":97},[],{"trials":89272,"activeCount":97},[],{"trials":89274,"activeCount":97},[89275],{"nctId":89252,"briefTitle":89253,"status":155,"phases":89276,"primaryCompletion":3078,"completion":3078,"start":7546,"enrollment":89255,"conditions":89277,"interventions":89278},[],[9292,36],[89237,89258,89259,89260],{"intervention":89259,"totalTrials":417,"cells":89280},{"EARLY_PHASE1":89281,"PHASE1":89283,"PHASE2":89285,"PHASE3":89287,"PHASE4":89289,"NA":89291},{"trials":89282,"activeCount":97},[],{"trials":89284,"activeCount":97},[],{"trials":89286,"activeCount":97},[],{"trials":89288,"activeCount":97},[],{"trials":89290,"activeCount":97},[],{"trials":89292,"activeCount":97},[89293],{"nctId":89252,"briefTitle":89253,"status":155,"phases":89294,"primaryCompletion":3078,"completion":3078,"start":7546,"enrollment":89255,"conditions":89295,"interventions":89296},[],[9292,36],[89237,89258,89259,89260],{"intervention":89260,"totalTrials":417,"cells":89298},{"EARLY_PHASE1":89299,"PHASE1":89301,"PHASE2":89303,"PHASE3":89305,"PHASE4":89307,"NA":89309},{"trials":89300,"activeCount":97},[],{"trials":89302,"activeCount":97},[],{"trials":89304,"activeCount":97},[],{"trials":89306,"activeCount":97},[],{"trials":89308,"activeCount":97},[],{"trials":89310,"activeCount":97},[89311],{"nctId":89252,"briefTitle":89253,"status":155,"phases":89312,"primaryCompletion":3078,"completion":3078,"start":7546,"enrollment":89255,"conditions":89313,"interventions":89314},[],[9292,36],[89237,89258,89259,89260],{"intervention":89316,"totalTrials":417,"cells":89317},"Receiving a prescription of Relenza for prophylaxis",{"EARLY_PHASE1":89318,"PHASE1":89320,"PHASE2":89322,"PHASE3":89324,"PHASE4":89326,"NA":89328},{"trials":89319,"activeCount":97},[],{"trials":89321,"activeCount":97},[],{"trials":89323,"activeCount":97},[],{"trials":89325,"activeCount":97},[],{"trials":89327,"activeCount":97},[],{"trials":89329,"activeCount":97},[89330],{"nctId":89331,"briefTitle":89332,"status":155,"phases":89333,"primaryCompletion":7647,"completion":7647,"start":2441,"enrollment":89334,"conditions":89335,"interventions":89340},"NCT01156701","Prophylactic Efficacy of Relenza Against Influenza A and B",[],171705,[15,8451,5353,18,89336,89337,89338,86550,89339,86404],"Respiratory Disease","Exacerbation of COPD","Bronchitis","Pneumonia",[89316],{"intervention":89342,"totalTrials":417,"cells":89343},"Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer",{"EARLY_PHASE1":89344,"PHASE1":89346,"PHASE2":89348,"PHASE3":89350,"PHASE4":89352,"NA":89354},{"trials":89345,"activeCount":97},[],{"trials":89347,"activeCount":97},[],{"trials":89349,"activeCount":97},[],{"trials":89351,"activeCount":97},[],{"trials":89353,"activeCount":97},[],{"trials":89355,"activeCount":97},[89356],{"nctId":89357,"briefTitle":89358,"status":155,"phases":89359,"primaryCompletion":59754,"completion":59754,"start":89360,"enrollment":7947,"conditions":89361,"interventions":89362},"NCT01064349","Breast Cancer With Over-expression of erbB2-BRAINSTORM",[],"2009-05-06",[36],[89342],{"intervention":89364,"totalTrials":417,"cells":89365},"RELVAR 100 ELLIPTA",{"EARLY_PHASE1":89366,"PHASE1":89368,"PHASE2":89370,"PHASE3":89372,"PHASE4":89374,"NA":89376},{"trials":89367,"activeCount":97},[],{"trials":89369,"activeCount":97},[],{"trials":89371,"activeCount":97},[],{"trials":89373,"activeCount":97},[],{"trials":89375,"activeCount":97},[],{"trials":89377,"activeCount":97},[89378],{"nctId":89379,"briefTitle":89380,"status":155,"phases":89381,"primaryCompletion":89382,"completion":89382,"start":45045,"enrollment":89383,"conditions":89384,"interventions":89385},"NCT03219255","RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term)",[],"2021-03-30",1047,[15],[89364],{"intervention":89387,"totalTrials":417,"cells":89388},"Lamotrigine use",{"EARLY_PHASE1":89389,"PHASE1":89391,"PHASE2":89393,"PHASE3":89395,"PHASE4":89397,"NA":89399},{"trials":89390,"activeCount":97},[],{"trials":89392,"activeCount":97},[],{"trials":89394,"activeCount":97},[],{"trials":89396,"activeCount":97},[],{"trials":89398,"activeCount":97},[],{"trials":89400,"activeCount":97},[89401],{"nctId":89402,"briefTitle":89403,"status":155,"phases":89404,"primaryCompletion":3044,"completion":3044,"start":7591,"enrollment":417,"conditions":89405,"interventions":89406},"NCT01607333","WEUKBRE5557: IMI PROTECT(Work Package 2): Antiepileptics & Suicide",[],[12518],[89387],{"intervention":89408,"totalTrials":417,"cells":89409},"Poliomyelitis vaccine (inactivated) -PoliorixTM",{"EARLY_PHASE1":89410,"PHASE1":89412,"PHASE2":89414,"PHASE3":89416,"PHASE4":89418,"NA":89420},{"trials":89411,"activeCount":97},[],{"trials":89413,"activeCount":97},[],{"trials":89415,"activeCount":97},[],{"trials":89417,"activeCount":97},[],{"trials":89419,"activeCount":97},[],{"trials":89421,"activeCount":97},[89422],{"nctId":89423,"briefTitle":89424,"status":155,"phases":89425,"primaryCompletion":7545,"completion":7545,"start":2428,"enrollment":24932,"conditions":89426,"interventions":89427},"NCT00514033","A Post-marketing Safety Study of GSK Bio IPV Vaccine (PoliorixTM) in Korean Children",[],[4702],[89408],{"intervention":89429,"totalTrials":417,"cells":89430},"Cervarix.",{"EARLY_PHASE1":89431,"PHASE1":89433,"PHASE2":89435,"PHASE3":89437,"PHASE4":89439,"NA":89441},{"trials":89432,"activeCount":97},[],{"trials":89434,"activeCount":97},[],{"trials":89436,"activeCount":97},[],{"trials":89438,"activeCount":97},[],{"trials":89440,"activeCount":97},[],{"trials":89442,"activeCount":97},[89443],{"nctId":89444,"briefTitle":89445,"status":155,"phases":89446,"primaryCompletion":89447,"completion":89447,"start":9452,"enrollment":89448,"conditions":89449,"interventions":89450},"NCT01101542","Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females",[],"2014-02-20",3091,[8723],[89429],{"intervention":89452,"totalTrials":417,"cells":89453},"Idursulfase",{"EARLY_PHASE1":89454,"PHASE1":89456,"PHASE2":89458,"PHASE3":89460,"PHASE4":89462,"NA":89464},{"trials":89455,"activeCount":97},[],{"trials":89457,"activeCount":97},[],{"trials":89459,"activeCount":97},[],{"trials":89461,"activeCount":97},[],{"trials":89463,"activeCount":97},[],{"trials":89465,"activeCount":97},[89466],{"nctId":89467,"briefTitle":89468,"status":155,"phases":89469,"primaryCompletion":546,"completion":546,"start":89470,"enrollment":750,"conditions":89471,"interventions":89473},"NCT01602601","A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723",[],"2012-04-09",[89472],"Mucopolysaccharidosis II",[89452,89474],"GSK2788723",{"intervention":89474,"totalTrials":417,"cells":89476},{"EARLY_PHASE1":89477,"PHASE1":89479,"PHASE2":89481,"PHASE3":89483,"PHASE4":89485,"NA":89487},{"trials":89478,"activeCount":97},[],{"trials":89480,"activeCount":97},[],{"trials":89482,"activeCount":97},[],{"trials":89484,"activeCount":97},[],{"trials":89486,"activeCount":97},[],{"trials":89488,"activeCount":97},[89489],{"nctId":89467,"briefTitle":89468,"status":155,"phases":89490,"primaryCompletion":546,"completion":546,"start":89470,"enrollment":750,"conditions":89491,"interventions":89492},[],[89472],[89452,89474],{"intervention":85032,"totalTrials":417,"cells":89494},{"EARLY_PHASE1":89495,"PHASE1":89497,"PHASE2":89499,"PHASE3":89501,"PHASE4":89503,"NA":89505},{"trials":89496,"activeCount":97},[],{"trials":89498,"activeCount":97},[],{"trials":89500,"activeCount":97},[],{"trials":89502,"activeCount":97},[],{"trials":89504,"activeCount":97},[],{"trials":89506,"activeCount":97},[89507],{"nctId":85027,"briefTitle":85028,"status":155,"phases":89508,"primaryCompletion":9706,"completion":9706,"start":10166,"enrollment":417,"conditions":89509,"interventions":89510},[],[26970],[84998,85025,85032],{"intervention":89512,"totalTrials":417,"cells":89513},"fluticasone furoate group",{"EARLY_PHASE1":89514,"PHASE1":89516,"PHASE2":89518,"PHASE3":89520,"PHASE4":89522,"NA":89524},{"trials":89515,"activeCount":97},[],{"trials":89517,"activeCount":97},[],{"trials":89519,"activeCount":97},[],{"trials":89521,"activeCount":97},[],{"trials":89523,"activeCount":97},[],{"trials":89525,"activeCount":97},[89526],{"nctId":89527,"briefTitle":89528,"status":155,"phases":89529,"primaryCompletion":11043,"completion":11043,"start":7647,"enrollment":89530,"conditions":89531,"interventions":89532},"NCT01001130","Regulatory AVAMYS Nasal Spray PMS",[],3244,[10147],[89512],{"intervention":89534,"totalTrials":417,"cells":89535},"TYKERB®",{"EARLY_PHASE1":89536,"PHASE1":89538,"PHASE2":89540,"PHASE3":89542,"PHASE4":89544,"NA":89546},{"trials":89537,"activeCount":97},[],{"trials":89539,"activeCount":97},[],{"trials":89541,"activeCount":97},[],{"trials":89543,"activeCount":97},[],{"trials":89545,"activeCount":97},[],{"trials":89547,"activeCount":97},[89548],{"nctId":89549,"briefTitle":89550,"status":155,"phases":89551,"primaryCompletion":3044,"completion":3044,"start":26336,"enrollment":1982,"conditions":89552,"interventions":89553},"NCT00975988","Regulatory TYKERB® Tablets PMS",[],[36],[89534],{"intervention":89555,"totalTrials":417,"cells":89556},"Guaifenesin",{"EARLY_PHASE1":89557,"PHASE1":89559,"PHASE2":89561,"PHASE3":89563,"PHASE4":89565,"NA":89567},{"trials":89558,"activeCount":97},[],{"trials":89560,"activeCount":97},[],{"trials":89562,"activeCount":97},[],{"trials":89564,"activeCount":97},[],{"trials":89566,"activeCount":97},[],{"trials":89568,"activeCount":97},[89569],{"nctId":89570,"briefTitle":89571,"status":155,"phases":89572,"primaryCompletion":5195,"completion":5195,"start":9233,"enrollment":868,"conditions":89573,"interventions":89575},"NCT01562548","Exploratory Efficacy Study of Guaifenesin in Upper Back Pain",[89],[89574],"Upper Back Pain",[89555],{"intervention":85651,"totalTrials":417,"cells":89577},{"EARLY_PHASE1":89578,"PHASE1":89580,"PHASE2":89582,"PHASE3":89584,"PHASE4":89586,"NA":89588},{"trials":89579,"activeCount":97},[],{"trials":89581,"activeCount":97},[],{"trials":89583,"activeCount":97},[],{"trials":89585,"activeCount":97},[],{"trials":89587,"activeCount":97},[],{"trials":89589,"activeCount":97},[89590],{"nctId":85645,"briefTitle":85646,"status":155,"phases":89591,"primaryCompletion":11030,"completion":11030,"start":2442,"enrollment":85648,"conditions":89592,"interventions":89593},[],[18],[85651,85652],{"intervention":89595,"totalTrials":417,"cells":89596},"3. Exposure to other antidepressants during the first trimester comparison cohort",{"EARLY_PHASE1":89597,"PHASE1":89599,"PHASE2":89601,"PHASE3":89603,"PHASE4":89605,"NA":89607},{"trials":89598,"activeCount":97},[],{"trials":89600,"activeCount":97},[],{"trials":89602,"activeCount":97},[],{"trials":89604,"activeCount":97},[],{"trials":89606,"activeCount":97},[],{"trials":89608,"activeCount":97},[89609],{"nctId":89610,"briefTitle":89611,"status":155,"phases":89612,"primaryCompletion":2344,"completion":2344,"start":11030,"enrollment":89613,"conditions":89614,"interventions":89615},"NCT01165255","Bupropion and Specific Cardiovascular Malformations",[],7005,[9292,85597,9684],[89595,89616,89617],"2. Exposure to bupropion outside the first trimester comparison cohort","1. Exposure to bupropion during the first trimester",{"intervention":89616,"totalTrials":417,"cells":89619},{"EARLY_PHASE1":89620,"PHASE1":89622,"PHASE2":89624,"PHASE3":89626,"PHASE4":89628,"NA":89630},{"trials":89621,"activeCount":97},[],{"trials":89623,"activeCount":97},[],{"trials":89625,"activeCount":97},[],{"trials":89627,"activeCount":97},[],{"trials":89629,"activeCount":97},[],{"trials":89631,"activeCount":97},[89632],{"nctId":89610,"briefTitle":89611,"status":155,"phases":89633,"primaryCompletion":2344,"completion":2344,"start":11030,"enrollment":89613,"conditions":89634,"interventions":89635},[],[9292,85597,9684],[89595,89616,89617],{"intervention":89617,"totalTrials":417,"cells":89637},{"EARLY_PHASE1":89638,"PHASE1":89640,"PHASE2":89642,"PHASE3":89644,"PHASE4":89646,"NA":89648},{"trials":89639,"activeCount":97},[],{"trials":89641,"activeCount":97},[],{"trials":89643,"activeCount":97},[],{"trials":89645,"activeCount":97},[],{"trials":89647,"activeCount":97},[],{"trials":89649,"activeCount":97},[89650],{"nctId":89610,"briefTitle":89611,"status":155,"phases":89651,"primaryCompletion":2344,"completion":2344,"start":11030,"enrollment":89613,"conditions":89652,"interventions":89653},[],[9292,85597,9684],[89595,89616,89617],{"intervention":86171,"totalTrials":417,"cells":89655},{"EARLY_PHASE1":89656,"PHASE1":89658,"PHASE2":89660,"PHASE3":89662,"PHASE4":89664,"NA":89666},{"trials":89657,"activeCount":97},[],{"trials":89659,"activeCount":97},[],{"trials":89661,"activeCount":97},[],{"trials":89663,"activeCount":97},[],{"trials":89665,"activeCount":97},[],{"trials":89667,"activeCount":97},[89668],{"nctId":86166,"briefTitle":86167,"status":155,"phases":89669,"primaryCompletion":35747,"completion":482,"start":502,"enrollment":526,"conditions":89670,"interventions":89671},[89],[13126],[86171,86143,86172],{"intervention":86172,"totalTrials":417,"cells":89673},{"EARLY_PHASE1":89674,"PHASE1":89676,"PHASE2":89678,"PHASE3":89680,"PHASE4":89682,"NA":89684},{"trials":89675,"activeCount":97},[],{"trials":89677,"activeCount":97},[],{"trials":89679,"activeCount":97},[],{"trials":89681,"activeCount":97},[],{"trials":89683,"activeCount":97},[],{"trials":89685,"activeCount":97},[89686],{"nctId":86166,"briefTitle":86167,"status":155,"phases":89687,"primaryCompletion":35747,"completion":482,"start":502,"enrollment":526,"conditions":89688,"interventions":89689},[89],[13126],[86171,86143,86172],{"intervention":85310,"totalTrials":417,"cells":89691},{"EARLY_PHASE1":89692,"PHASE1":89694,"PHASE2":89696,"PHASE3":89698,"PHASE4":89700,"NA":89702},{"trials":89693,"activeCount":97},[],{"trials":89695,"activeCount":97},[],{"trials":89697,"activeCount":97},[],{"trials":89699,"activeCount":97},[],{"trials":89701,"activeCount":97},[],{"trials":89703,"activeCount":97},[89704],{"nctId":85302,"briefTitle":85303,"status":155,"phases":89705,"primaryCompletion":484,"completion":484,"start":85305,"enrollment":85306,"conditions":89706,"interventions":89707},[],[14168],[85309,85275,85310],{"intervention":89709,"totalTrials":417,"cells":89710},"HYCAMTIN",{"EARLY_PHASE1":89711,"PHASE1":89713,"PHASE2":89715,"PHASE3":89717,"PHASE4":89719,"NA":89721},{"trials":89712,"activeCount":97},[],{"trials":89714,"activeCount":97},[],{"trials":89716,"activeCount":97},[],{"trials":89718,"activeCount":97},[],{"trials":89720,"activeCount":97},[],{"trials":89722,"activeCount":97},[89723],{"nctId":89724,"briefTitle":89725,"status":155,"phases":89726,"primaryCompletion":9233,"completion":9233,"start":6351,"enrollment":10126,"conditions":89727,"interventions":89728},"NCT00997061","SCOT Registry: Small Cell Lung Cancer Treatment and Outcome",[],[2778],[89709],{"intervention":89730,"totalTrials":417,"cells":89731},"Arnuity Ellipta",{"EARLY_PHASE1":89732,"PHASE1":89734,"PHASE2":89736,"PHASE3":89738,"PHASE4":89740,"NA":89742},{"trials":89733,"activeCount":97},[],{"trials":89735,"activeCount":97},[],{"trials":89737,"activeCount":97},[],{"trials":89739,"activeCount":97},[],{"trials":89741,"activeCount":97},[],{"trials":89743,"activeCount":97},[89744],{"nctId":89745,"briefTitle":89746,"status":155,"phases":89747,"primaryCompletion":20735,"completion":20735,"start":89748,"enrollment":952,"conditions":89749,"interventions":89750},"NCT03184480","Arnuity® Ellipta® Drug Use Investigation",[],"2017-08-19",[18],[89730],{"intervention":89752,"totalTrials":417,"cells":89753},"Toothpaste containing 1150ppm F",{"EARLY_PHASE1":89754,"PHASE1":89756,"PHASE2":89758,"PHASE3":89760,"PHASE4":89762,"NA":89764},{"trials":89755,"activeCount":97},[],{"trials":89757,"activeCount":97},[],{"trials":89759,"activeCount":97},[],{"trials":89761,"activeCount":97},[],{"trials":89763,"activeCount":97},[],{"trials":89765,"activeCount":97},[89766],{"nctId":89767,"briefTitle":89768,"status":500,"phases":89769,"primaryCompletion":8539,"completion":8539,"start":8098,"enrollment":97,"conditions":89770,"interventions":89771},"NCT02436473","Clinical Efficacy of Fluoride Toothpastes Using an In Situ Caries Model",[89],[13126],[89752,89772,89752],"Toothpaste containing 250ppm F",{"intervention":89772,"totalTrials":417,"cells":89774},{"EARLY_PHASE1":89775,"PHASE1":89777,"PHASE2":89779,"PHASE3":89781,"PHASE4":89783,"NA":89785},{"trials":89776,"activeCount":97},[],{"trials":89778,"activeCount":97},[],{"trials":89780,"activeCount":97},[],{"trials":89782,"activeCount":97},[],{"trials":89784,"activeCount":97},[],{"trials":89786,"activeCount":97},[89787],{"nctId":89767,"briefTitle":89768,"status":500,"phases":89788,"primaryCompletion":8539,"completion":8539,"start":8098,"enrollment":97,"conditions":89789,"interventions":89790},[89],[13126],[89752,89772,89752],{"intervention":89792,"totalTrials":417,"cells":89793},"CCB use",{"EARLY_PHASE1":89794,"PHASE1":89796,"PHASE2":89798,"PHASE3":89800,"PHASE4":89802,"NA":89804},{"trials":89795,"activeCount":97},[],{"trials":89797,"activeCount":97},[],{"trials":89799,"activeCount":97},[],{"trials":89801,"activeCount":97},[],{"trials":89803,"activeCount":97},[],{"trials":89805,"activeCount":97},[89806],{"nctId":89807,"briefTitle":89808,"status":155,"phases":89809,"primaryCompletion":13418,"completion":8860,"start":8135,"enrollment":417,"conditions":89810,"interventions":89811},"NCT01587742","IMI PROTECT (Work Package 2): Calcium Channel Blockers and Cancer",[],[13024],[89792],{"intervention":89813,"totalTrials":417,"cells":89814},"Arepanrix®",{"EARLY_PHASE1":89815,"PHASE1":89817,"PHASE2":89819,"PHASE3":89821,"PHASE4":89823,"NA":89825},{"trials":89816,"activeCount":97},[],{"trials":89818,"activeCount":97},[],{"trials":89820,"activeCount":97},[],{"trials":89822,"activeCount":97},[],{"trials":89824,"activeCount":97},[],{"trials":89826,"activeCount":97},[89827],{"nctId":89828,"briefTitle":89829,"status":155,"phases":89830,"primaryCompletion":1428,"completion":2335,"start":2834,"enrollment":89831,"conditions":89832,"interventions":89833},"NCT02069496","Drug Use Investigation for Arepanrix® (H1N1)",[],3405,[21],[89813],{"intervention":89835,"totalTrials":417,"cells":89836},"Rosiglitazone + Metformin",{"EARLY_PHASE1":89837,"PHASE1":89839,"PHASE2":89841,"PHASE3":89843,"PHASE4":89845,"NA":89847},{"trials":89838,"activeCount":97},[],{"trials":89840,"activeCount":97},[],{"trials":89842,"activeCount":97},[],{"trials":89844,"activeCount":97},[],{"trials":89846,"activeCount":97},[],{"trials":89848,"activeCount":97},[89849],{"nctId":89850,"briefTitle":89851,"status":155,"phases":89852,"primaryCompletion":2344,"completion":2344,"start":7658,"enrollment":89853,"conditions":89854,"interventions":89855},"NCT01332370","Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone",[],5391,[27],[89835,89856],"Sitagliptin + Metformin",{"intervention":89856,"totalTrials":417,"cells":89858},{"EARLY_PHASE1":89859,"PHASE1":89861,"PHASE2":89863,"PHASE3":89865,"PHASE4":89867,"NA":89869},{"trials":89860,"activeCount":97},[],{"trials":89862,"activeCount":97},[],{"trials":89864,"activeCount":97},[],{"trials":89866,"activeCount":97},[],{"trials":89868,"activeCount":97},[],{"trials":89870,"activeCount":97},[89871],{"nctId":89850,"briefTitle":89851,"status":155,"phases":89872,"primaryCompletion":2344,"completion":2344,"start":7658,"enrollment":89853,"conditions":89873,"interventions":89874},[],[27],[89835,89856],{"intervention":85273,"totalTrials":417,"cells":89876},{"EARLY_PHASE1":89877,"PHASE1":89879,"PHASE2":89881,"PHASE3":89883,"PHASE4":89885,"NA":89887},{"trials":89878,"activeCount":97},[],{"trials":89880,"activeCount":97},[],{"trials":89882,"activeCount":97},[],{"trials":89884,"activeCount":97},[],{"trials":89886,"activeCount":97},[],{"trials":89888,"activeCount":97},[89889],{"nctId":85267,"briefTitle":85268,"status":155,"phases":89890,"primaryCompletion":11030,"completion":11030,"start":6352,"enrollment":85270,"conditions":89891,"interventions":89892},[],[12263],[85238,85273],{"intervention":85425,"totalTrials":417,"cells":89894},{"EARLY_PHASE1":89895,"PHASE1":89897,"PHASE2":89899,"PHASE3":89901,"PHASE4":89903,"NA":89905},{"trials":89896,"activeCount":97},[],{"trials":89898,"activeCount":97},[],{"trials":89900,"activeCount":97},[],{"trials":89902,"activeCount":97},[],{"trials":89904,"activeCount":97},[],{"trials":89906,"activeCount":97},[89907],{"nctId":85419,"briefTitle":85420,"status":155,"phases":89908,"primaryCompletion":7658,"completion":7658,"start":3550,"enrollment":85422,"conditions":89909,"interventions":89910},[],[13024],[13026,85425],{"intervention":85766,"totalTrials":417,"cells":89912},{"EARLY_PHASE1":89913,"PHASE1":89915,"PHASE2":89917,"PHASE3":89919,"PHASE4":89921,"NA":89923},{"trials":89914,"activeCount":97},[],{"trials":89916,"activeCount":97},[],{"trials":89918,"activeCount":97},[],{"trials":89920,"activeCount":97},[],{"trials":89922,"activeCount":97},[],{"trials":89924,"activeCount":97},[89925],{"nctId":85760,"briefTitle":85761,"status":155,"phases":89926,"primaryCompletion":10463,"completion":10463,"start":2441,"enrollment":85763,"conditions":89927,"interventions":89928},[],[435],[85766,85736],{"intervention":86000,"totalTrials":417,"cells":89930},{"EARLY_PHASE1":89931,"PHASE1":89933,"PHASE2":89935,"PHASE3":89937,"PHASE4":89939,"NA":89941},{"trials":89932,"activeCount":97},[],{"trials":89934,"activeCount":97},[],{"trials":89936,"activeCount":97},[],{"trials":89938,"activeCount":97},[],{"trials":89940,"activeCount":97},[],{"trials":89942,"activeCount":97},[89943],{"nctId":85995,"briefTitle":85996,"status":155,"phases":89944,"primaryCompletion":10463,"completion":8883,"start":2335,"enrollment":417,"conditions":89945,"interventions":89946},[],[15],[86000,85972],{"intervention":89948,"totalTrials":417,"cells":89949},"TIO",{"EARLY_PHASE1":89950,"PHASE1":89952,"PHASE2":89954,"PHASE3":89956,"PHASE4":89958,"NA":89960},{"trials":89951,"activeCount":97},[],{"trials":89953,"activeCount":97},[],{"trials":89955,"activeCount":97},[],{"trials":89957,"activeCount":97},[],{"trials":89959,"activeCount":97},[],{"trials":89961,"activeCount":97},[89962],{"nctId":89963,"briefTitle":89964,"status":155,"phases":89965,"primaryCompletion":11030,"completion":3551,"start":5018,"enrollment":89966,"conditions":89967,"interventions":89968},"NCT01381406","Impact of Initiating Tiotropium Alone Versus Initiating Tiotropium in Combination With Fluticasone Propionate\u002FSalmeterol Xinafoate Combination (FSC) on Chronic Obstructive Pulmonary Disease-related Outcomes in Patients With Pre-existing Exacerbations",[],3333,[15],[89948,89969],"TIO+FSC",{"intervention":89969,"totalTrials":417,"cells":89971},{"EARLY_PHASE1":89972,"PHASE1":89974,"PHASE2":89976,"PHASE3":89978,"PHASE4":89980,"NA":89982},{"trials":89973,"activeCount":97},[],{"trials":89975,"activeCount":97},[],{"trials":89977,"activeCount":97},[],{"trials":89979,"activeCount":97},[],{"trials":89981,"activeCount":97},[],{"trials":89983,"activeCount":97},[89984],{"nctId":89963,"briefTitle":89964,"status":155,"phases":89985,"primaryCompletion":11030,"completion":3551,"start":5018,"enrollment":89966,"conditions":89986,"interventions":89987},[],[15],[89948,89969],{"intervention":89989,"totalTrials":417,"cells":89990},"20% w\u002Fw sodium bicarbonate",{"EARLY_PHASE1":89991,"PHASE1":89993,"PHASE2":89995,"PHASE3":89997,"PHASE4":89999,"NA":90001},{"trials":89992,"activeCount":97},[],{"trials":89994,"activeCount":97},[],{"trials":89996,"activeCount":97},[],{"trials":89998,"activeCount":97},[],{"trials":90000,"activeCount":97},[],{"trials":90002,"activeCount":97},[90003],{"nctId":90004,"briefTitle":90005,"status":155,"phases":90006,"primaryCompletion":69492,"completion":69492,"start":76728,"enrollment":2825,"conditions":90007,"interventions":90009},"NCT02992691","Efficacy of Three Experimental Toothpastes to Remove Plaque",[89],[90008],"Dental Plaque",[89989,90010,90011,90012,90013],"35% w\u002Fw sodium bicarbonate","50% w\u002Fw sodium bicarbonate","67% w\u002Fw sodium bicarbonate","0% w\u002Fw sodium bicarbonate",{"intervention":90010,"totalTrials":417,"cells":90015},{"EARLY_PHASE1":90016,"PHASE1":90018,"PHASE2":90020,"PHASE3":90022,"PHASE4":90024,"NA":90026},{"trials":90017,"activeCount":97},[],{"trials":90019,"activeCount":97},[],{"trials":90021,"activeCount":97},[],{"trials":90023,"activeCount":97},[],{"trials":90025,"activeCount":97},[],{"trials":90027,"activeCount":97},[90028],{"nctId":90004,"briefTitle":90005,"status":155,"phases":90029,"primaryCompletion":69492,"completion":69492,"start":76728,"enrollment":2825,"conditions":90030,"interventions":90031},[89],[90008],[89989,90010,90011,90012,90013],{"intervention":90011,"totalTrials":417,"cells":90033},{"EARLY_PHASE1":90034,"PHASE1":90036,"PHASE2":90038,"PHASE3":90040,"PHASE4":90042,"NA":90044},{"trials":90035,"activeCount":97},[],{"trials":90037,"activeCount":97},[],{"trials":90039,"activeCount":97},[],{"trials":90041,"activeCount":97},[],{"trials":90043,"activeCount":97},[],{"trials":90045,"activeCount":97},[90046],{"nctId":90004,"briefTitle":90005,"status":155,"phases":90047,"primaryCompletion":69492,"completion":69492,"start":76728,"enrollment":2825,"conditions":90048,"interventions":90049},[89],[90008],[89989,90010,90011,90012,90013],{"intervention":90012,"totalTrials":417,"cells":90051},{"EARLY_PHASE1":90052,"PHASE1":90054,"PHASE2":90056,"PHASE3":90058,"PHASE4":90060,"NA":90062},{"trials":90053,"activeCount":97},[],{"trials":90055,"activeCount":97},[],{"trials":90057,"activeCount":97},[],{"trials":90059,"activeCount":97},[],{"trials":90061,"activeCount":97},[],{"trials":90063,"activeCount":97},[90064],{"nctId":90004,"briefTitle":90005,"status":155,"phases":90065,"primaryCompletion":69492,"completion":69492,"start":76728,"enrollment":2825,"conditions":90066,"interventions":90067},[89],[90008],[89989,90010,90011,90012,90013],{"intervention":90013,"totalTrials":417,"cells":90069},{"EARLY_PHASE1":90070,"PHASE1":90072,"PHASE2":90074,"PHASE3":90076,"PHASE4":90078,"NA":90080},{"trials":90071,"activeCount":97},[],{"trials":90073,"activeCount":97},[],{"trials":90075,"activeCount":97},[],{"trials":90077,"activeCount":97},[],{"trials":90079,"activeCount":97},[],{"trials":90081,"activeCount":97},[90082],{"nctId":90004,"briefTitle":90005,"status":155,"phases":90083,"primaryCompletion":69492,"completion":69492,"start":76728,"enrollment":2825,"conditions":90084,"interventions":90085},[89],[90008],[89989,90010,90011,90012,90013],{"intervention":83452,"totalTrials":417,"cells":90087},{"EARLY_PHASE1":90088,"PHASE1":90090,"PHASE2":90092,"PHASE3":90094,"PHASE4":90096,"NA":90098},{"trials":90089,"activeCount":97},[],{"trials":90091,"activeCount":97},[],{"trials":90093,"activeCount":97},[],{"trials":90095,"activeCount":97},[],{"trials":90097,"activeCount":97},[],{"trials":90099,"activeCount":97},[90100],{"nctId":83446,"briefTitle":83447,"status":155,"phases":90101,"primaryCompletion":7647,"completion":7647,"start":2441,"enrollment":83449,"conditions":90102,"interventions":90103},[],[15],[83452,2980,83453],{"intervention":83453,"totalTrials":417,"cells":90105},{"EARLY_PHASE1":90106,"PHASE1":90108,"PHASE2":90110,"PHASE3":90112,"PHASE4":90114,"NA":90116},{"trials":90107,"activeCount":97},[],{"trials":90109,"activeCount":97},[],{"trials":90111,"activeCount":97},[],{"trials":90113,"activeCount":97},[],{"trials":90115,"activeCount":97},[],{"trials":90117,"activeCount":97},[90118],{"nctId":83446,"briefTitle":83447,"status":155,"phases":90119,"primaryCompletion":7647,"completion":7647,"start":2441,"enrollment":83449,"conditions":90120,"interventions":90121},[],[15],[83452,2980,83453],{"intervention":90123,"totalTrials":417,"cells":90124},"Lapatanib",{"EARLY_PHASE1":90125,"PHASE1":90127,"PHASE2":90129,"PHASE3":90131,"PHASE4":90133,"NA":90135},{"trials":90126,"activeCount":97},[],{"trials":90128,"activeCount":97},[],{"trials":90130,"activeCount":97},[],{"trials":90132,"activeCount":97},[],{"trials":90134,"activeCount":97},[],{"trials":90136,"activeCount":97},[90137],{"nctId":90138,"briefTitle":90139,"status":155,"phases":90140,"primaryCompletion":9682,"completion":9682,"start":2344,"enrollment":417,"conditions":90141,"interventions":90142},"NCT01462552","Physician Liver Function Test (LFT) Monitoring for Tykerb Pts",[],[36],[90123],{"intervention":90144,"totalTrials":417,"cells":90145},"Substance P",{"EARLY_PHASE1":90146,"PHASE1":90148,"PHASE2":90150,"PHASE3":90152,"PHASE4":90154,"NA":90156},{"trials":90147,"activeCount":97},[],{"trials":90149,"activeCount":97},[],{"trials":90151,"activeCount":97},[],{"trials":90153,"activeCount":97},[],{"trials":90155,"activeCount":97},[],{"trials":90157,"activeCount":97},[90158],{"nctId":90159,"briefTitle":90160,"status":155,"phases":90161,"primaryCompletion":90162,"completion":90162,"start":78509,"enrollment":2045,"conditions":90163,"interventions":90164},"NCT04676763","Substance P Challenge in Healthy Participants",[89],"2021-07-21",[13421],[90144,90165,90166],"Normal Saline","Histamine",{"intervention":90165,"totalTrials":417,"cells":90168},{"EARLY_PHASE1":90169,"PHASE1":90171,"PHASE2":90173,"PHASE3":90175,"PHASE4":90177,"NA":90179},{"trials":90170,"activeCount":97},[],{"trials":90172,"activeCount":97},[],{"trials":90174,"activeCount":97},[],{"trials":90176,"activeCount":97},[],{"trials":90178,"activeCount":97},[],{"trials":90180,"activeCount":97},[90181],{"nctId":90159,"briefTitle":90160,"status":155,"phases":90182,"primaryCompletion":90162,"completion":90162,"start":78509,"enrollment":2045,"conditions":90183,"interventions":90184},[89],[13421],[90144,90165,90166],{"intervention":90166,"totalTrials":417,"cells":90186},{"EARLY_PHASE1":90187,"PHASE1":90189,"PHASE2":90191,"PHASE3":90193,"PHASE4":90195,"NA":90197},{"trials":90188,"activeCount":97},[],{"trials":90190,"activeCount":97},[],{"trials":90192,"activeCount":97},[],{"trials":90194,"activeCount":97},[],{"trials":90196,"activeCount":97},[],{"trials":90198,"activeCount":97},[90199],{"nctId":90159,"briefTitle":90160,"status":155,"phases":90200,"primaryCompletion":90162,"completion":90162,"start":78509,"enrollment":2045,"conditions":90201,"interventions":90202},[89],[13421],[90144,90165,90166],{"intervention":90204,"totalTrials":417,"cells":90205},"Trastuzumab or Lapatinib",{"EARLY_PHASE1":90206,"PHASE1":90208,"PHASE2":90210,"PHASE3":90212,"PHASE4":90214,"NA":90216},{"trials":90207,"activeCount":97},[],{"trials":90209,"activeCount":97},[],{"trials":90211,"activeCount":97},[],{"trials":90213,"activeCount":97},[],{"trials":90215,"activeCount":97},[],{"trials":90217,"activeCount":97},[90218],{"nctId":90219,"briefTitle":90220,"status":155,"phases":90221,"primaryCompletion":22319,"completion":22319,"start":2834,"enrollment":417,"conditions":90222,"interventions":90223},"NCT01077648","Brain Metastasis in Breast Cancer Patients",[],[36],[90204]]